<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en"><head>

<meta charset="utf-8">
<meta name="generator" content="quarto-1.5.16">

<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes">


<title>Differences in care for patients with left vs.&nbsp;right hemisphere intracerebral hemorrhage</title>
<style>
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
div.columns{display: flex; gap: min(4vw, 1.5em);}
div.column{flex: auto; overflow-x: auto;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
ul.task-list li input[type="checkbox"] {
  width: 0.8em;
  margin: 0 0.8em 0.2em -1em; /* quarto-specific, see https://github.com/quarto-dev/quarto-cli/issues/4556 */ 
  vertical-align: middle;
}
/* CSS for citations */
div.csl-bib-body { }
div.csl-entry {
  clear: both;
  margin-bottom: 0em;
}
.hanging-indent div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}</style>


<script src="site_libs/clipboard/clipboard.min.js"></script>
<script src="site_libs/quarto-html/quarto.js"></script>
<script src="site_libs/quarto-html/popper.min.js"></script>
<script src="site_libs/quarto-html/tippy.umd.min.js"></script>
<script src="site_libs/quarto-html/anchor.min.js"></script>
<link href="site_libs/quarto-html/tippy.css" rel="stylesheet">
<link href="site_libs/quarto-html/quarto-syntax-highlighting.css" rel="stylesheet" id="quarto-text-highlighting-styles">
<script src="site_libs/bootstrap/bootstrap.min.js"></script>
<link href="site_libs/bootstrap/bootstrap-icons.css" rel="stylesheet">
<link href="site_libs/bootstrap/bootstrap.min.css" rel="stylesheet" id="quarto-bootstrap" data-mode="light">
<script async="" src="https://hypothes.is/embed.js"></script>
<script>
  window.document.addEventListener("DOMContentLoaded", function (_event) {
    document.body.classList.add('hypothesis-enabled');
  });
</script>


<meta name="citation_title" content="Differences in care for patients with left vs. right hemisphere intracerebral hemorrhage">
<meta name="citation_author" content="Nikhil Patel">
<meta name="citation_author" content="Rahul Karamchandani">
<meta name="citation_language" content="en">
<meta name="citation_reference" content="citation_title=Mastering the Art of Cookbook Medicine: Machine Learning, Randomized Trials, and Misallocation;,citation_abstract=The application of machine learning (ML) to randomized controlled trials (RCTs) can quantify and improve misallocation in healthcare. We study the decision to prescribe anticoagulants for atrial fibrillation patients; anticoagulation reduces stroke risk but increases hemorrhage risk. We combine observational data on treatment choice and guideline use with ML estimates of heterogeneous treatment effects from eight RCTs. When physicians adopt a clinical guideline, treatment decisions shift towards the recommendation but adherence remains far from perfect. Improving guideline adherence would produce larger gains than informing physicians about guidelines. Adherence to an optimal rule would prevent 47% more strokes without increasing hemorrhages.;,citation_author=Jason Abaluck;,citation_author=Leila Agha;,citation_author=David Chan;,citation_author=Daniel Singer;,citation_author=Diana Zhu;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial;,citation_abstract=Background Casirivimab and imdevimab are non-competing monoclonal antibodies that bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike glycoprotein, blocking viral entry into host cells. We aimed to evaluate the efficacy and safety of casirivimab and imdevimab administered in combination in patients admitted to hospital with COVID-19.;,citation_author=Obbina Abani;,citation_author=Ali Abbas;,citation_author=Fatima Abbas;,citation_author=Mustafa Abbas;,citation_author=Sadia Abbasi;,citation_author=Hakam Abbass;,citation_author=Alfie Abbott;,citation_author=Nabeel Abdallah;,citation_author=Ashraf Abdelaziz;,citation_author=Mohamed Abdelfattah;,citation_author=Bushra Abdelqader;,citation_author=Basir Abdul;,citation_author=Althaf Abdul Rasheed;,citation_author=Ajibode Abdulakeem;,citation_author=Rezan Abdul-Kadir;,citation_author=Abdullah Abdullah;,citation_author=Abdulfatahi Abdulmumeen;,citation_author=Rasheed Abdul-Raheem;,citation_author=Niyaz Abdulshukkoor;,citation_author=Kula Abdusamad;,citation_author=Yazeed Abed El Khaleq;,citation_author=Mai Abedalla;,citation_author=Abeer Ul-Amna;,citation_author=Katrina Abernethy;,citation_author=Adebanke Aboaba;,citation_author=Hani Abo-Leyah;,citation_author=Ahmed Abou-Haggar;,citation_author=Mahmoud Abouibrahim;,citation_author=Miriam Abraham;,citation_author=Tizzy Abraham;,citation_author=Abraheem Abraheem;,citation_author=Judith Abrams;,citation_author=Hyacinth-John Abu;,citation_author=Ahmed Abu-Arafeh;,citation_author=Syed M Abubacker;,citation_author=Akata Abung;,citation_author=Yaa Aceampong;,citation_author=Amaka Achara;,citation_author=Devikumar Acharya;,citation_author=Sarah Acheampong;,citation_author=Janet Acheson;,citation_author=Andres Acosta;,citation_author=Catherine Acton;,citation_author=Jacqueline Adabie-Ankrah;,citation_author=Fiona Adam;,citation_author=Matthew Adam;,citation_author=Huzaifa Adamali;,citation_author=Carol Adams;,citation_author=Charlotte Adams;,citation_author=Kate Adams;,citation_author=Richard Adams;,citation_author=Tim Adams;,citation_author=Krishma Adatia;,citation_author=Kirsty Adcock;,citation_author=Ade Adebiyi;,citation_author=Ken Adegoke;,citation_author=Vicki Adell;,citation_author=Sherna Adenwalla;,citation_author=Oluwasegun A Adesemoye;,citation_author=Emmanuel O Adewunmi;,citation_author=Joyce Adeyemi;,citation_author=Binay Adhikari;,citation_author=Rina Adhikary;,citation_author=Gabrielle Adkins;,citation_author=Adnan Adnan;,citation_author=John Aeron-Thomas;,citation_author=Debbie Affleck;,citation_author=Carmel Afnan;,citation_author=Muhammad Afridi;,citation_author=Zainab A Aftab;,citation_author=Meenakshi Agarwal;,citation_author=Rachel Agbeko;,citation_author=Chris Agbo;,citation_author=Sunil Aggarwal;,citation_author=Arameh Aghababaie;,citation_author=Shafana Ahamed Sadiq;,citation_author=Mohamed H Ahammed Nazeer;,citation_author=Mohammad Ahmad;,citation_author=Syed Ahmad;,citation_author=Asim Ahmed;,citation_author=Bilal Ahmed;,citation_author=Forizuddin Ahmed;,citation_author=Hamze Ahmed;,citation_author=Irshad Ahmed;,citation_author=Khaled Ahmed;,citation_author=Liban Ahmed;,citation_author=Mahin Ahmed;,citation_author=Maria C Ahmed;,citation_author=Muhammad S Ahmed;,citation_author=Naseer Ahmed;,citation_author=Nausheen Ahmed;,citation_author=Osama Ahmed;,citation_author=Rajia A Ahmed;,citation_author=Rizwan Ahmed;,citation_author=Saif Ahmed;,citation_author=Sammiya Ahmed;,citation_author=Syed Ahmed;,citation_author=Syed Haris Ahmed;,citation_author=Roa Ahmed Ali;,citation_author=Sana Ahmed;,citation_author=Sana Ahmer;,citation_author=Dhiraj Ail;,citation_author=Mark Ainsworth;,citation_author=Myriam Aissa;,citation_author=Lindianne Aitken;,citation_author=Bini Ajay;,citation_author=Abdulakeem Ajibode;,citation_author=Ayesha Ajmi;,citation_author=Nasim Akhtar;,citation_author=Nauman Akhtar;,citation_author=Suha Akili;,citation_author=Oludoyinsola Akindolie;,citation_author=Yinka Akinfenwa;,citation_author=Olugbenga Akinkugbe;,citation_author=Ibrahim Akinpelu;,citation_author=Olugbenro Aktinade;,citation_author=Ahmad S A R Al Aaraj;,citation_author=Asma Al Balushi;,citation_author=Majd Al Dakhola;,citation_author=Aladdin Al Swaifi;,citation_author=Eslam Al-Abadi;,citation_author=Narendra Aladangady;,citation_author=Ayaz Alam;,citation_author=Sajid Alam;,citation_author=Abbas Al-Asadi;,citation_author=Kyriaki Alatzoglou;,citation_author=Paul Albert;,citation_author=Lorraine Albon;,citation_author=Gemma Alcorn;,citation_author=Stephen Alcorn;,citation_author=Aggie Aldana;,citation_author=David Alderdice;,citation_author=Rayan Aldouri;,citation_author=Jonathan Aldridge;,citation_author=Nicolas Aldridge;,citation_author=Ana Alegria;,citation_author=Alison Alexander;,citation_author=John Alexander;,citation_author=Peter D G Alexander;,citation_author=Julyan Al-Fori;,citation_author=Laith Alghazawi;,citation_author=Bahij Al-Hakim;,citation_author=Shams Al-Hity;,citation_author=Ali Ali;,citation_author=Asad Ali;,citation_author=Fawzia R Ali;,citation_author=Jawad Ali;,citation_author=Mariam Ali;,citation_author=Mohammad Ali;,citation_author=Nayab Ali;,citation_author=Oudai Ali;,citation_author=Sakina Ali;,citation_author=Syed Ali;,citation_author=Abid Alina;,citation_author=Fine Aliyuda;,citation_author=Katrin Alizadeh;,citation_author=Maithem Al-Jibury;,citation_author=Saba Al-Juboori;,citation_author=Majid Al-Khalil;,citation_author=Moutaz Alkhusheh;,citation_author=Fiona Allan;,citation_author=Alison Allanson;,citation_author=Robert Allcock;,citation_author=Eireann Allen;,citation_author=Kerry Allen;,citation_author=Louise Allen;,citation_author=Poppy Allen;,citation_author=Rebecca Allen;,citation_author=Sam Allen;,citation_author=Sharon Allen;,citation_author=Simon Allen;,citation_author=Kathryn Allison;,citation_author=Bethan Allman;,citation_author=Lynne Allsop;,citation_author=Hassan Al-Moasseb;,citation_author=Magda Al-Obaidi;,citation_author=Lina Alomari;,citation_author=Akram Al-Rabahi;,citation_author=Bahar Al-Ramadhani;,citation_author=Zayneb Al-Saadi;,citation_author=Inji Alshaer;,citation_author=Rustam Al-Shahi Salman;,citation_author=Warkaq Al-Shamkhani;,citation_author=Bashar Al-Sheklly;,citation_author=Sara Altaf;,citation_author=Mary Alvarez;,citation_author=Maysaa Alzetani;,citation_author=Susan Amamou;,citation_author=Noor Amar;,citation_author=Sakkarai Ambalavanan;,citation_author=Robert Ambrogetti;,citation_author=Chris Ambrose;,citation_author=Amir Ameen;,citation_author=Maria R Amezaga;,citation_author=Allison Amin;,citation_author=Amina Amin;,citation_author=Kanish Amin;,citation_author=Syed Amin;,citation_author=Tara Amin;,citation_author=Amjad Amjad;,citation_author=Neelma Amjad;,citation_author=Victoria Amosun;,citation_author=Khaled Amsha;,citation_author=Pugh Amy;,citation_author=Atul Anand;,citation_author=Samantha Anandappa;,citation_author=Julie Anderson;,citation_author=Laura Anderson;,citation_author=Michelle Anderson;,citation_author=Nicola Anderson;,citation_author=Rachel Anderson;,citation_author=Rory Anderson;,citation_author=Wendy Anderson;,citation_author=Prematie Andreou;,citation_author=Angela Andrews;,citation_author=Antonette Andrews;,citation_author=Jill Andrews;,citation_author=Kanayochukwu Aneke;,citation_author=Andrew Ang;,citation_author=Wan Wei Ang;,citation_author=Tammy Angel;,citation_author=Aramburo Angela;,citation_author=Paola Angelini;,citation_author=Lazarus Anguvaa;,citation_author=Oleg Anichtchik;,citation_author=Millicent Anim-Somuah;,citation_author=Krishnan Aniruddhan;,citation_author=Jessica Annett;,citation_author=Louise Anning;,citation_author=Patrick J Anstey;,citation_author=Rebekah Anstey;,citation_author=Alpha Anthony;,citation_author=Aaron Anthony-Pillai;,citation_author=Philip Antill;,citation_author=Zhelyazkova Antonina;,citation_author=Varghese Anu;,citation_author=Muhammad Anwar;,citation_author=Aristeidis Apostolopoulos;,citation_author=Sarah Appleby;,citation_author=Diane Appleyard;,citation_author=Maia Far Aquino;,citation_author=Bianca Araba;,citation_author=Samuel Aransiola;,citation_author=Mariana Araujo;,citation_author=Ann Archer;,citation_author=Denise Archer;,citation_author=Simon Archer;,citation_author=Christian Ardley;,citation_author=Ana-Maria Arias;,citation_author=Ryoki Arimoto;,citation_author=Charlotte Arkley;,citation_author=Charlotte Armah;,citation_author=Ilianna Armata;,citation_author=Adam Armitage;,citation_author=Ceri Armstrong;,citation_author=Maureen Armstrong;,citation_author=Sonia Armstrong;,citation_author=Philippa Armtrong;,citation_author=Heike Arndt;,citation_author=Clare Arnison-Newgass;,citation_author=David Arnold;,citation_author=Rachael Arnold;,citation_author=Dhawal Arora;,citation_author=Kavan Arora;,citation_author=Pardeep Arora;,citation_author=Rishi Arora;,citation_author=Arslam Arter;,citation_author=Ayush Arya;,citation_author=Rita Arya;,citation_author=Denisa Asandei;,citation_author=Adeeba Asghar;,citation_author=Catherine Ashbrook-Raby;,citation_author=Helen Ashby;,citation_author=Jan Ashcroft;,citation_author=John Ashcroft;,citation_author=Samuel Ashcroft;,citation_author=Georgia Asher;,citation_author=Ayesha Ashfaq;,citation_author=Abdul Ashish;,citation_author=Sally Ashman-Flavell;,citation_author=Sundar Ashok;,citation_author=Abd-El-Aziz Ashour;,citation_author=Muhammad Z Ashraf;,citation_author=Saima Ashraf;,citation_author=Mohammad B Ashraq;,citation_author=Deborah Ashton;,citation_author=Susan Ashton;,citation_author=Andrew Ashworth;,citation_author=Rebecca Ashworth;,citation_author=Arshia Aslam;,citation_author=Harshini Asogan;,citation_author=Atif Asrar;,citation_author=Omar Assaf;,citation_author=Raine Astin-Chamberlain;,citation_author=Deborah Athorne;,citation_author=Billie Atkins;,citation_author=Christopher Atkins;,citation_author=Stacey Atkins;,citation_author=John Atkinson;,citation_author=Vicki Atkinson;,citation_author=Brygitta Atraskiewicz;,citation_author=Abdul A Attia;,citation_author=Paula Aubrey;,citation_author=Avinash Aujayeb;,citation_author=Aye CT Aung;,citation_author=Hnin Aung;,citation_author=Kyaw T Aung;,citation_author=Yin Aung;,citation_author=Zaw M Aung;,citation_author=Emily Austin;,citation_author=Karen Austin;,citation_author=Abdusshakur Auwal;,citation_author=Miriam Avery;,citation_author=Nicholas Aveyard;,citation_author=Joanne Avis;,citation_author=Georgina Aviss;,citation_author=Cristina Avram;,citation_author=Paula Avram;,citation_author=Gabriel Awadzi;,citation_author=Atia Awan;,citation_author=Aszad Aya;,citation_author=Eman Ayaz;,citation_author=Amanda Ayers;,citation_author=Jawwad Azam;,citation_author=Mohammed Azharuddin;,citation_author=Ghazala Aziz;,citation_author=N Aziz;,citation_author=Ali Azkoul;,citation_author=Ashaari Azman Shah;,citation_author=Giada Azzopardi;,citation_author=Hocine Azzoug;,citation_author=Fiyinfoluwa Babatunde;,citation_author=Melvin Babi;,citation_author=Babiker Babiker;,citation_author=Gayna Babington;,citation_author=Matthew Babirecki;,citation_author=Marta Babores;,citation_author=Adetona O Babs-Osibodu;,citation_author=Sammy Bacciarelli;,citation_author=Roudi Bachar;,citation_author=Gina Bacon;,citation_author=Jenny Bacon;,citation_author=Bibi Badal;,citation_author=Gurpreet R Badhan;,citation_author=Shreya Badhrinarayanan;,citation_author=Joseph P Bae;,citation_author=Alice Baggaley;,citation_author=Amy Baggott;,citation_author=Graham Bagley;,citation_author=Dinesh Bagmane;,citation_author=Lynsey Bagshaw;,citation_author=Kasra Bahadori;,citation_author=James Bailey;,citation_author=Katie Bailey;,citation_author=Lindsey Bailey;,citation_author=Liz Bailey;,citation_author=Morgan Bailey;,citation_author=Pippa Bailey;,citation_author=Sarah Bailey;,citation_author=Hamish Baillie;,citation_author=J Kenneth Baillie;,citation_author=Jennifer Bain;,citation_author=Vikram Bains;,citation_author=David Baird;,citation_author=Kevin Baird;,citation_author=Susan Baird;,citation_author=Tracy Baird;,citation_author=Yolanda Baird;,citation_author=Aiysha Bajandouh;,citation_author=Evelyn Baker;,citation_author=Johanne Baker;,citation_author=Josephine Baker;,citation_author=Kenneth Baker;,citation_author=Rebecca Baker;,citation_author=Terri-Anne Baker;,citation_author=Victoria Baker;,citation_author=Hugh Bakere;,citation_author=Nawar Bakerly;,citation_author=Michelle Baker-Moffatt;,citation_author=Nauman Bakhtiar;,citation_author=Panos Bakoulas;,citation_author=Niranjan Balachandran;,citation_author=Andrea Balan;,citation_author=Theodosios Balaskas;,citation_author=Madhu Balasubramaniam;,citation_author=Alison Balcombe;,citation_author=Alexander Baldwin;,citation_author=Ashley Baldwin;,citation_author=Caron Baldwin;,citation_author=Danielle Baldwin;,citation_author=Rebekah Baldwin-Jones;,citation_author=James Balfour;,citation_author=Matthew Ball;,citation_author=K Ballard;,citation_author=Ismael Balluz;,citation_author=Craig Balmforth;,citation_author=Emese Balogh;,citation_author=Amir Baluwala;,citation_author=Gabby Bambridge;,citation_author=Alasdair Bamford;,citation_author=Amy Bamford;,citation_author=Peter Bamford;,citation_author=Adefunke Bamgboye;,citation_author=Elizabeth Bancroft;,citation_author=Hollie Bancroft;,citation_author=Joyce Banda;,citation_author=Krishna Bandaru;,citation_author=Srini Bandi;,citation_author=Nageswar Bandla;,citation_author=Somaditya Bandyopadhyam;,citation_author=Amit Banerjee;,citation_author=Ritwik Banerjee;,citation_author=Harrison Banks;,citation_author=Luke Banks;,citation_author=Paul Banks;,citation_author=Oliver Bannister;,citation_author=Laura Banton;,citation_author=Tran Bao;,citation_author=Mariamma Baptist;,citation_author=Tanya Baqai;,citation_author=Ananya M Baral;,citation_author=Desislava Baramova;,citation_author=Russel Barber;,citation_author=Emma Barbon;,citation_author=Miriam Barbosa;,citation_author=Monica Barbosa;,citation_author=Jamie Barbour;,citation_author=Alexander Barclay;,citation_author=Claire Barclay;,citation_author=George Bardsley;,citation_author=Stephanie Bareford;,citation_author=Shahedal Bari;,citation_author=Morris Barimbing;,citation_author=Amy Barker;,citation_author=Debbie Barker;,citation_author=Helen Barker;,citation_author=Joseph Barker;,citation_author=Leon Barker;,citation_author=Oliver Barker;,citation_author=Kerry Barker-Williams;,citation_author=Sinha Barkha;,citation_author=Juliana Barla;,citation_author=Gavin Barlow;,citation_author=Richard Barlow;,citation_author=Valerie Barlow;,citation_author=James Barnacle;,citation_author=Alex Barnard;,citation_author=Debi Barnes;,citation_author=Nicky Barnes;,citation_author=Theresa Barnes;,citation_author=Calum Barnetson;,citation_author=Amy Barnett;,citation_author=Ashton Barnett-Vanes;,citation_author=William Barnsley;,citation_author=Andrew Barr;,citation_author=David Barr;,citation_author=Shaney Barratt;,citation_author=Manuella Barrera;,citation_author=Amy Barrett;,citation_author=Fiona Barrett;,citation_author=Jessica Barrett;,citation_author=Jazz Bartholomew;,citation_author=Claire Bartlett;,citation_author=Georgina Bartlett;,citation_author=Greg Barton;,citation_author=Jill Barton;,citation_author=Lorna Barton;,citation_author=Rachael Barton;,citation_author=Rosaleen Baruah;,citation_author=Sonia Baryschpolec;,citation_author=Archana Bashyal;,citation_author=Betsy Basker;,citation_author=Buddha Basnyat;,citation_author=Ayten Basoglu;,citation_author=John Bassett;,citation_author=G Bassett;,citation_author=Chris Bassford;,citation_author=Bengisu Bassoy;,citation_author=Victoria Bastion;,citation_author=Anup Bastola;,citation_author=Anupam Basumatary;,citation_author=Tristan Bate;,citation_author=Harry J Bateman;,citation_author=Kathryn Bateman;,citation_author=Vhairi Bateman;,citation_author=Eleanor Bates;,citation_author=Hayley Bates;,citation_author=Michelle Bates;,citation_author=Simon Bates;,citation_author=Sally Batham;,citation_author=Ana Batista;,citation_author=Amit Batla;,citation_author=Dushyant Batra;,citation_author=Harry Batty;,citation_author=Thomas Batty;,citation_author=Miranda Baum;,citation_author=Rachel Baumber;,citation_author=Carina Bautista;,citation_author=Fareha Bawa;,citation_author=Fatima S Bawani;,citation_author=Simon Bax;,citation_author=Matt Baxter;,citation_author=Nicola Baxter;,citation_author=Zachary Baxter;,citation_author=Hannah Bayes;,citation_author=Farid Bazari;,citation_author=Rohit Bazaz;,citation_author=Ahmad Bazli;,citation_author=Laura Beacham;,citation_author=Wendy Beadles;,citation_author=Philip Beak;,citation_author=Andy Beale;,citation_author=Jack Bearpark;,citation_author=Karen Beaumont;,citation_author=Dawn Beaumont-Jewell;,citation_author=Theresa Beaver;,citation_author=Sarah Beavis;,citation_author=Christy Beazley;,citation_author=Sarah Beck;,citation_author=Virginia Beckett;,citation_author=Rosie Beckitt;,citation_author=Heidi Beddall;,citation_author=Seonaid Beddows;,citation_author=Deborah Beeby;,citation_author=Gail Beech;,citation_author=Michelle Beecroft;,citation_author=Sally Beer;,citation_author=Jane Beety;,citation_author=Gabriela Bega;,citation_author=Alison Begg;,citation_author=Susan Begg;,citation_author=Sara Beghini;,citation_author=Ayesha Begum;,citation_author=Salman Begum;,citation_author=Selina Begum;,citation_author=Teresa Behan;,citation_author=Roya Behrouzi;,citation_author=Jon Beishon;,citation_author=Claire Beith;,citation_author=James Belcher;,citation_author=Holly Belfield;,citation_author=Katherine Belfield;,citation_author=Ajay Belgaumkar;,citation_author=Dina Bell;,citation_author=Gareth Bell;,citation_author=Gillian Bell;,citation_author=Lauren Bell;,citation_author=Louise Bell;,citation_author=Nicholas Bell;,citation_author=Pippa Bell;,citation_author=Stephanie Bell;,citation_author=Jennifer L Bell;,citation_author=Jennifer Bellamu;,citation_author=Mary Bellamy;,citation_author=Arianna Bellini;,citation_author=Amanda Bellis;,citation_author=Fionn Bellis;,citation_author=Lesley Bendall;,citation_author=Naveena Benesh;,citation_author=Nicola Benetti;,citation_author=Leonie Benham;,citation_author=Guy Benison-Horner;,citation_author=Ann Bennett;,citation_author=Caroline Bennett;,citation_author=Gillian Bennett;,citation_author=Kristopher Bennett;,citation_author=Lorraine Bennett;,citation_author=Sara Bennett;,citation_author=Karen Bennion;,citation_author=Vivienne Benson;,citation_author=Andrew Bentley;,citation_author=James Bentley;,citation_author=Ian Benton;,citation_author=Eva Beranova;,citation_author=Matthew Beresford;,citation_author=Colin Bergin;,citation_author=Malin Bergstrom;,citation_author=Jolanta Bernatoniene;,citation_author=Thomas Berriman;,citation_author=Zoe Berry;,citation_author=Kimberley Best;,citation_author=Ans-Mari Bester;,citation_author=Yvonne Beuvink;,citation_author=Emily Bevan;,citation_author=Sarah Bevins;,citation_author=Tom Bewick;,citation_author=Andrew Bexley;,citation_author=Sonay Beyatli;,citation_author=Fenella Beynon;,citation_author=Arjun Bhadi;,citation_author=Sanjay Bhagani;,citation_author=Shiv Bhakta;,citation_author=Rekha Bhalla;,citation_author=Khushpreet Bhandal;,citation_author=Kulbinder Bhandal;,citation_author=Ashwin Bhandari;,citation_author=Sangam Bhandari;,citation_author=Aashutosh Bhanot;,citation_author=Ravina Bhanot;,citation_author=Prashanth Bhat;,citation_author=Rahul Bhatnagar;,citation_author=Karan Bhatt;,citation_author=Janki Bhayani;,citation_author=Deepika Bhojwani;,citation_author=Salimuzzaman Bhuiyan;,citation_author=Anna Bibby;,citation_author=Fatima Bibi;,citation_author=Naheeda Bibi;,citation_author=Salma Bibi;,citation_author=Tihana Bicanic;,citation_author=Sarah Bidgood;,citation_author=Julie Bigg;,citation_author=Sarah Biggs;,citation_author=Alphonsa Biju;,citation_author=Andras Bikov;,citation_author=Sophie Billingham;,citation_author=Jessica Billings;,citation_author=Alice Binns;,citation_author=Muhammad BinRofaie;,citation_author=Oliver Bintcliffe;,citation_author=Catherine Birch;,citation_author=Jenny Birch;,citation_author=Katherine Birchall;,citation_author=Sam Bird;,citation_author=Sumedha Bird;,citation_author=Mark Birt;,citation_author=Kilanalei Bishop;,citation_author=Linda Bishop;,citation_author=Lisa Bishop;,citation_author=Karen Bisnauthsing;,citation_author=Nibedan Biswas;,citation_author=Sahar Biuk;,citation_author=Karen Blachford;,citation_author=Ethel Black;,citation_author=Helen Black;,citation_author=Karen Black;,citation_author=Mairead Black;,citation_author=Polly Black;,citation_author=Hayley Blackgrove;,citation_author=Bethan Blackledge;,citation_author=Joanne Blackler;,citation_author=Samantha Blackley;,citation_author=Helen Blackman;,citation_author=Caroline Blackstock;,citation_author=Francesca Blakemore;,citation_author=Helen Blamey;,citation_author=Alison Bland;,citation_author=Sujata Blane;,citation_author=Simon Blankley;,citation_author=Parry Blaxill;,citation_author=Katie Blaylock;,citation_author=Jane Blazeby;,citation_author=Natalie Blencowe;,citation_author=Ben Bloom;,citation_author=Jack Bloomfield;,citation_author=Angela Bloss;,citation_author=Hannah Bloxham;,citation_author=Louise Blundell;,citation_author=Andrew Blunsum;,citation_author=Mark Blunt;,citation_author=Ian Blyth;,citation_author=Kevin Blyth;,citation_author=Andrew Blythe;,citation_author=Karen Blythe;,citation_author=Marilyn Boampoaa;,citation_author=Boniface Bobie;,citation_author=Karen Bobruk;,citation_author=Pritesh N Bodalia;,citation_author=Neena Bodasing;,citation_author=Tanya Bodenham;,citation_author=Gabriele Boehmer;,citation_author=Marta Boffito;,citation_author=Kristyna Bohmova;,citation_author=Niamh Bohnacker;,citation_author=Sumit Bokhandi;,citation_author=Maria Bokhar;,citation_author=Saba Bokhari;,citation_author=Sakina Bokhari;,citation_author=Syed O Bokhari;,citation_author=Ambrose Boles;,citation_author=Charlotte Bond;,citation_author=Helena Bond;,citation_author=Stuart Bond;,citation_author=Thomas Bond;,citation_author=Alice Bone;,citation_author=Georgia Boniface;,citation_author=Lizzy Bonney;,citation_author=Sarah Boot;,citation_author=Joanne Borbone;,citation_author=Naomi Borman;,citation_author=Mamu Boshir;,citation_author=Fiona Bottrill;,citation_author=Laura Bough;,citation_author=Hayley Boughton;,citation_author=Zoe Boult;,citation_author=Miriam Bourke;,citation_author=Stephen Bourke;,citation_author=Michelle Bourne;,citation_author=Rachel Bousfield;,citation_author=Lucy Boustred;,citation_author=Alexandra Bowes;,citation_author=Amy Bowes;,citation_author=Philip Bowker;,citation_author=Louise Bowman;,citation_author=Simon Bowman;,citation_author=Rachel Bowmer;,citation_author=Angie Bowring;,citation_author=Helen Bowyer;,citation_author=Aileen Boyd;,citation_author=Jenny Boyd;,citation_author=Laura Boyd;,citation_author=Namoi Boyle;,citation_author=Pauline Boyle;,citation_author=Rosalind Boyle;,citation_author=Louise Boyles;,citation_author=Leanna Brace;,citation_author=Jodie Bradder;,citation_author=Clare J Bradley;,citation_author=Pamela Bradley;,citation_author=Patrick Bradley;,citation_author=Paul Bradley;,citation_author=Joanne Bradley-Potts;,citation_author=Lynne Bradshaw;,citation_author=Zena Bradshaw;,citation_author=Rebecca Brady;,citation_author=Shirin Brady;,citation_author=Denise Braganza;,citation_author=Marie Branch;,citation_author=Thomas Brankin-Frisby;,citation_author=Jamie Brannigan;,citation_author=Sophie Brattan;,citation_author=Fiona Bray;,citation_author=Nancy Bray;,citation_author=Manny Brazil;,citation_author=Lucy Brear;,citation_author=Tracy Brear;,citation_author=Stephen Brearey;,citation_author=Laura Bremner;,citation_author=Morwenna Brend;,citation_author=Giovanna Bretland;,citation_author=Chris Brewer;,citation_author=Gavin Bridgwood;,citation_author=Sara Brigham;,citation_author=John Bright;,citation_author=Chris Brightling;,citation_author=Lutece Brimfield;,citation_author=Elaine Brinkworth;,citation_author=Robin Brittain-Long;,citation_author=Vianne Britten;,citation_author=Lauren Broad;,citation_author=Sarah Broad;,citation_author=Rosie Broadhurst;,citation_author=Andrew Broadley;,citation_author=Marie Broadway;,citation_author=Christopher Brockelsby;,citation_author=Megan Brocken;,citation_author=Tomos Brockley;,citation_author=Mary Brodsky;,citation_author=Fiona Brogan;,citation_author=Liz Brohan;,citation_author=Felicity Brokke;,citation_author=Jacob Brolly;,citation_author=David Bromley;,citation_author=Hannah Brooke-Ball;,citation_author=Verity Brooker;,citation_author=Matthew Brookes;,citation_author=Deirdre Brooking;,citation_author=Alison Brooks;,citation_author=Karen Brooks;,citation_author=Nicole Brooks;,citation_author=Philip Brooks;,citation_author=Rachel Brooks;,citation_author=Sophie Brooks;,citation_author=Tim Brooks;,citation_author=Natalie Broomhead;,citation_author=Chloe Broughton;,citation_author=Nathaniel Broughton;,citation_author=Matt Brouns;,citation_author=Alison Brown;,citation_author=Ammani Brown;,citation_author=Carly Brown;,citation_author=Catrin Brown;,citation_author=Ellen Brown;,citation_author=Heather Brown;,citation_author=Janet Brown;,citation_author=Louise Brown;,citation_author=Niall Brown;,citation_author=Pauline Brown;,citation_author=Rachel Brown;,citation_author=Richard Brown;,citation_author=Robert Brown;,citation_author=Steven Brown;,citation_author=Thomas Brown;,citation_author=Tom Brown;,citation_author=Bria Browne;,citation_author=Charlotte Browne;,citation_author=Duncan Browne;,citation_author=Mitchell Browne;,citation_author=Stephen Brownlee;,citation_author=Alba Brraka;,citation_author=Johanna Bruce;,citation_author=Michelle Bruce;,citation_author=Wojciech Brudlo;,citation_author=Nigel Brunskill;,citation_author=Alan Brunton;,citation_author=Margaret Brunton;,citation_author=Meera Bryant;,citation_author=April Buazon;,citation_author=Maya H Buch;,citation_author=Ruaridh Buchan;,citation_author=Ruaridh Buchanan;,citation_author=Danielle Buche;,citation_author=Amanda Buck;,citation_author=Matthew Buckland;,citation_author=Laura Buckley;,citation_author=Philip Buckley;,citation_author=Sarah Buckley;,citation_author=Carol Buckman;,citation_author=George Bugg;,citation_author=Ramadan Bujazia;,citation_author=Marwan Bukhari;,citation_author=Shanze Bukhari;,citation_author=Richard Bulbulia;,citation_author=Alex Bull;,citation_author=Damian Bull;,citation_author=Rhian Bull;,citation_author=Thomas Bull;,citation_author=Naomi Bulteel;,citation_author=Kasun Bumunarachchi;,citation_author=Roneleeh Bungue-Tuble;,citation_author=Caroline Burchett;,citation_author=Dorota Burda;,citation_author=Christy Burden;,citation_author=Thomas G Burden;,citation_author=Mika Burgess;,citation_author=Richard Burgess;,citation_author=Sophia Burgess;,citation_author=Adrian Burman;,citation_author=Sara Burnard;,citation_author=Caroline Burnett;,citation_author=Amy Burns;,citation_author=Collette Burns;,citation_author=James Burns;,citation_author=Karen Burns;,citation_author=Daniel Burrage;,citation_author=Kate Burrows;,citation_author=Claire Burston;,citation_author=Ben Burton;,citation_author=Fiona Burton;,citation_author=Matthew Burton;,citation_author=Deborah Butcher;,citation_author=Aaron Butler;,citation_author=Jessica Butler;,citation_author=Joanne Butler;,citation_author=Joshua Butler;,citation_author=Peter Butler;,citation_author=Susan Butler;,citation_author=Al-Tahoor Butt;,citation_author=Mohammad M Butt;,citation_author=Caryl Butterworth;,citation_author=Nicola Butterworth-Cowin;,citation_author=Robert Buttery;,citation_author=Tom Buttle;,citation_author=Heather Button;,citation_author=Daniel Buttress;,citation_author=Jane Byrne;,citation_author=Wendy Byrne;,citation_author=Victoria Byrne-Watts;,citation_author=Amanda Cabandugama;,citation_author=Ruth Cade;,citation_author=Anthony Cadwgan;,citation_author=Ajeng Cahyareny;,citation_author=Donna Cairney;,citation_author=James Calderwood;,citation_author=Darren Caldow;,citation_author=Giorgio Calisti;,citation_author=Debbie Callaghan;,citation_author=Jennifer Callaghan;,citation_author=Claire Callens;,citation_author=Donaldson Callum;,citation_author=Caroline Calver;,citation_author=Melissa Cambell-Kelly;,citation_author=Tracey Camburn;,citation_author=David R Cameron;,citation_author=Eleanor Cameron;,citation_author=Fraser Cameron;,citation_author=Sarah Cameron;,citation_author=Sheena Cameron;,citation_author=Christian Camm;,citation_author=Renee F D Cammack;,citation_author=Alison Campbell;,citation_author=Amy Campbell;,citation_author=Barbara Campbell;,citation_author=Bridget Campbell;,citation_author=Debbie Campbell;,citation_author=Helen Campbell;,citation_author=Hilary Campbell;,citation_author=Jonathan Campbell;,citation_author=Mark Campbell;,citation_author=Robyn Campbell;,citation_author=Wynny Campbell;,citation_author=Quentin Campbell Hewson;,citation_author=Julie Camsooksai;,citation_author=Lisa Canclini;,citation_author=Shaula M Candido;,citation_author=Janie Candlish;,citation_author=Cielito Caneja;,citation_author=Alexandra Cann;,citation_author=Johnathon Cann;,citation_author=Ruby Cannan;,citation_author=Emma Cannon;,citation_author=Michael Cannon;,citation_author=Petra Cannon;,citation_author=Vivienne Cannons;,citation_author=Jane Cantliff;,citation_author=Ben Caplin;,citation_author=Santino Capocci;,citation_author=Noemi Caponi;,citation_author=Angelika Capp;,citation_author=Thomas Capstick;,citation_author=Mary Cardwell;,citation_author=Rachel Carey;,citation_author=Simon Carley;,citation_author=Tammy Carlin;,citation_author=Samantha Carmichael;,citation_author=Mandy Carnahan;,citation_author=Charlotte Caroline;,citation_author=Jodi Carpenter;,citation_author=Sharon Carr;,citation_author=Anna Carrasco;,citation_author=Zoe Carrington;,citation_author=Amy Carroll;,citation_author=Paul Carroll;,citation_author=Jonathan Carter;,citation_author=Michael Carter;,citation_author=Paul Carter;,citation_author=Penny Carter;,citation_author=Douglas Cartwright;,citation_author=Jo-Anne Cartwright;,citation_author=Claire Carty;,citation_author=Jaime Carungcong;,citation_author=Susan Casey;,citation_author=Annie Cassells;,citation_author=Teresa Castiello;,citation_author=Gail Castle;,citation_author=Bridget Castles;,citation_author=Melanie Caswell;,citation_author=Ana Maria Catana;,citation_author=Heidi Cate;,citation_author=Susanne Cathcart;,citation_author=Katrina Cathie;,citation_author=Christine Catley;,citation_author=Laura Catlow;,citation_author=Matthew Caudwell;,citation_author=Anna Cavazza;,citation_author=Luke Cave;,citation_author=Simon Cavinato;,citation_author=Frianne Cawa;,citation_author=Kathryn Cawley;,citation_author=Chloe Caws;,citation_author=Hankins Cendl;,citation_author=Hannah Century;,citation_author=Jeva Cernova;,citation_author=Mansur Cesay;,citation_author=Ed Cetti;,citation_author=Stephanie Chabane;,citation_author=Manish Chablani;,citation_author=Cathleen Chabo;,citation_author=David Chadwick;,citation_author=Julie Chadwick;,citation_author=Robert Chadwick;,citation_author=Ela Chakkarapani;,citation_author=Arup Chakraborty;,citation_author=Mallinath Chakraborty;,citation_author=Mollika Chakravorty;,citation_author=Bimal Chalise;,citation_author=James Chalmers;,citation_author=Richard Chalmers;,citation_author=Georgina Chamberlain;,citation_author=Sarah Chamberlain;,citation_author=Emma Chambers;,citation_author=Jonathan Chambers;,citation_author=Lucy Chambers;,citation_author=Naomi Chambers;,citation_author=Alex Chan;,citation_author=Carmen Chan;,citation_author=Cheuk Chan;,citation_author=Evelyn Chan;,citation_author=Kayen Chan;,citation_author=Kimberley Chan;,citation_author=Ping Chan;,citation_author=Rebekah (Pui-Ching) Chan;,citation_author=Xin Hui S Chan;,citation_author=Chris Chandler;,citation_author=Heidi Chandler;,citation_author=Kim J Chandler;,citation_author=Stuart Chandler;,citation_author=Zoe Chandler;,citation_author=Sumit Chandra;,citation_author=Navin Chandran;,citation_author=Badrinathan Chandrasekaran;,citation_author=Yvonne Chang;,citation_author=Josephine Chaplin;,citation_author=Graeme Chapman;,citation_author=John Chapman;,citation_author=Katie Chapman;,citation_author=Laura Chapman;,citation_author=Lianne Chapman;,citation_author=Polly Chapman;,citation_author=Timothy Chapman;,citation_author=Lucy C Chappell;,citation_author=Lucy Chappell;,citation_author=Amanda Charalambou;,citation_author=Bethan Charles;,citation_author=Dianne Charlton;,citation_author=Kevin Chatar;,citation_author=Calvin Chatha;,citation_author=Ritesh Chaube;,citation_author=Muhammad Y N Chaudhary;,citation_author=Iram Chaudhry;,citation_author=Nazia Chaudhuri;,citation_author=Muhammad Chaudhury;,citation_author=Anoop Chauhan;,citation_author=Ruchi Singh Chauhan;,citation_author=Nicola Chavasse;,citation_author=Vipal Chawla;,citation_author=Lindsay Cheater;,citation_author=James Cheaveau;,citation_author=Charlotte Cheeld;,citation_author=Michelle Cheeseman;,citation_author=Fang Chen;,citation_author=Hui Min Chen;,citation_author=Terence Chen;,citation_author=Floria Cheng;,citation_author=Lok Yin Cheng;,citation_author=Zhihang Cheng;,citation_author=Helen Chenoweth;,citation_author=Chun How Cheong;,citation_author=Shiney Cherian;,citation_author=Mary Cherrie;,citation_author=Helen Cheshire;,citation_author=Chee Kay Cheung;,citation_author=Elaine Cheung;,citation_author=Michelle Cheung;,citation_author=Claire Cheyne;,citation_author=Swati Chhabra;,citation_author=Wei Ling Chia;,citation_author=Eric Chiang;,citation_author=Angela Chiapparino;,citation_author=Rosavic Chicano;,citation_author=Zviedzo A Chikwanha;,citation_author=Sam Chilcott;,citation_author=Phillipa Chimbo;,citation_author=KokWai Chin;,citation_author=Wen Jie Chin;,citation_author=Rumbidzai Chineka;,citation_author=Amol Chingale;,citation_author=Heather Chisem;,citation_author=Claire Chisenga;,citation_author=Ben Chisnall;,citation_author=Carolyn Chiswick;,citation_author=Sunder Chita;,citation_author=Nihil Chitalia;,citation_author=Matthew Chiu;,citation_author=Brenda Chivima;,citation_author=Catherine Chmiel;,citation_author=Soha Choi;,citation_author=Willy Choon Kon Yune;,citation_author=Vandana Choudhary;,citation_author=Sarah Choudhury;,citation_author=Bing-Lun Chow;,citation_author=Mahibbur Chowdhury;,citation_author=Shahid Chowdhury;,citation_author=Victoria Christenssen;,citation_author=Peter Christian;,citation_author=Alexander Christides;,citation_author=Fiona Christie;,citation_author=Daniel Christmas;,citation_author=Thereza Christopherson;,citation_author=Mark Christy;,citation_author=Paris Chrysostomou;,citation_author=Yunli Chua;,citation_author=Dip Chudgar;,citation_author=Richard Chudleigh;,citation_author=Srikanth Chukkambotla;,citation_author=Michael Eze Chukwu;,citation_author=Izu Chukwulobelu;,citation_author=Chi Yee Chung;,citation_author=Elaine Church;,citation_author=Sara R Church;,citation_author=David Churchill;,citation_author=Nicole Cianci;,citation_author=Nick Ciccone;,citation_author=Paola Cicconi;,citation_author=Paola Cinardo;,citation_author=Zdenka Cipinova;,citation_author=Bessie Cipriano;,citation_author=Sarah Clamp;,citation_author=Melanie Clapham;,citation_author=Edel Clare;,citation_author=Sarbjit Clare;,citation_author=Andrew Clark;,citation_author=Charlotte Clark;,citation_author=Diane Clark;,citation_author=Felicity Clark;,citation_author=Gabrielle Clark;,citation_author=James Clark;,citation_author=Katherine Clark;,citation_author=Kaylea Clark;,citation_author=Louise Clark;,citation_author=Lucy Clark;,citation_author=Matthew Clark;,citation_author=Patricia Clark;,citation_author=Richard Clark;,citation_author=Thomas Clark;,citation_author=Zoe Clark;,citation_author=Andrea Clarke;,citation_author=Paul Clarke;,citation_author=Robert Clarke;,citation_author=Roseanne Clarke;,citation_author=Samantha Clarke;,citation_author=Sheron Clarke;,citation_author=Alleyna Claxton;,citation_author=Kate Clay;,citation_author=Elizabeth Clayton;,citation_author=Olivia Clayton;,citation_author=Jill Clayton-Smith;,citation_author=Chris Cleaver;,citation_author=Carlota Clemente de la Torre;,citation_author=Jayne Clements;,citation_author=Suzanne Clements;,citation_author=Francesca Clemons;,citation_author=Rachael Clifford;,citation_author=Sarah Clifford;,citation_author=Amelia Clive;,citation_author=Jonathan Clouston;,citation_author=Samantha Clueit;,citation_author=Andrea Clyne;,citation_author=Michelle Coakley;,citation_author=Peter G L Coakley;,citation_author=Kathryn Cobain;,citation_author=Alexandra Cochrane;,citation_author=Patricia Cochrane;,citation_author=Maeve Cockerell;,citation_author=Helen Cockerill;,citation_author=Shirley Cocks;,citation_author=Rachel Codling;,citation_author=Adam Coe;,citation_author=Samantha Coetzee;,citation_author=David Coey;,citation_author=Danielle Cohen;,citation_author=Jonathan Cohen;,citation_author=Oliver Cohen;,citation_author=David Cohen;,citation_author=Mike Cohn;,citation_author=Louise Coke;,citation_author=Olutoyin Coker;,citation_author=Nicholas Colbeck;,citation_author=Roghan Colbert;,citation_author=Esther Cole;,citation_author=Jade Cole;,citation_author=Joby Cole;,citation_author=Garry Coleman;,citation_author=Matt Coleman;,citation_author=Tom Coleman;,citation_author=Holly Coles;,citation_author=Macleod Colin;,citation_author=Alicia Colino-Acevedo;,citation_author=Julie Colley;,citation_author=Dawn Collier;,citation_author=Heather Collier;,citation_author=Paul Collini;,citation_author=Emma Collins;,citation_author=Jaimie Collins;,citation_author=Joanne Collins;,citation_author=Nicola Collins;,citation_author=Sally Collins;,citation_author=Vicky Collins;,citation_author=Andrew Collinson;,citation_author=Bernadette Collinson;,citation_author=Jennifer Collinson;,citation_author=Matthew Collis;,citation_author=Madeleine Colmar;,citation_author=Hayley E Colton;,citation_author=James Colton;,citation_author=Katie Colville;,citation_author=Carolyn Colvin;,citation_author=Edward Combes;,citation_author=David Comer;,citation_author=Alison Comerford;,citation_author=Dónal Concannon;,citation_author=Robin Condliffe;,citation_author=Lynne Connell;,citation_author=Natalie Connell;,citation_author=Karen Connelly;,citation_author=Gavin Connolly;,citation_author=Emma Connor;,citation_author=Antonia Conroy;,citation_author=Veronica Conteh;,citation_author=Rory Convery;,citation_author=Francesca Conway;,citation_author=Grainne Conway;,citation_author=Rhiannon Conway;,citation_author=Jo-Anna Conyngham;,citation_author=Colette Cook;,citation_author=Eloise Cook;,citation_author=Gemma Cook;,citation_author=Helen Cook;,citation_author=Julie Cook;,citation_author=Danielle Cooke;,citation_author=Graham Cooke;,citation_author=Katrina Cooke;,citation_author=Tim Cooke;,citation_author=Adele Cooper;,citation_author=Chris Cooper;,citation_author=David Cooper;,citation_author=Helen Cooper;,citation_author=Jamie Cooper;,citation_author=Lauren Cooper;,citation_author=Nick Cooper;,citation_author=Rowena Cooper;,citation_author=Thomas Cope;,citation_author=Sinead Corbet;,citation_author=Carolyn Corbett;,citation_author=John Corcoran;,citation_author=Chris Cordell;,citation_author=Jessica Cordle;,citation_author=Alasdair Corfield;,citation_author=John Corless;,citation_author=Alison Corlett;,citation_author=Joe Cornwell;,citation_author=Michael Cornwell;,citation_author=Diana Corogeanu;,citation_author=Mirella Corredera;,citation_author=Ruth Corrigan;,citation_author=P Corry;,citation_author=Rita Corser;,citation_author=Denise Cosgrove;,citation_author=Tracey Cosier;,citation_author=Patricia Costa;,citation_author=Charlie Coston;,citation_author=Susannah Cotgrove;,citation_author=Zoe Coton;,citation_author=Lisa-Jayne Cottam;,citation_author=Rhiannon Cotter;,citation_author=Donna Cotterill;,citation_author=Caroline Cotton;,citation_author=Andrew Coull;,citation_author=James Coulson;,citation_author=David Counsell;,citation_author=David Counter;,citation_author=Cherry Coupland;,citation_author=Ellie Courtney;,citation_author=Julia Courtney;,citation_author=Rebecca Cousins;,citation_author=Alexander Cowan;,citation_author=Elena Cowan;,citation_author=Richard Cowell;,citation_author=Louise Cowen;,citation_author=Steve Cowman;,citation_author=Amanda Cowton;,citation_author=Ellie Cox;,citation_author=Giles Cox;,citation_author=Karina Cox;,citation_author=Miriam Cox;,citation_author=Karen Coy;,citation_author=Andrea Cradduck-Bamford;,citation_author=Victoria Craig;,citation_author=Felicity Craighead;,citation_author=Matthew Cramp;,citation_author=Jacolene Crause;,citation_author=Angie Crawford;,citation_author=Emma Crawford;,citation_author=Isobel Crawford;,citation_author=Sarah Crawshaw;,citation_author=Ben Creagh-Brown;,citation_author=Andrew Creamer;,citation_author=Joanne Cremona;,citation_author=Saveria Cremona;,citation_author=Janet Cresswell;,citation_author=Mark Cribb;,citation_author=Charles Crichton;,citation_author=Declan Crilly;,citation_author=Lauren Crisp;,citation_author=Nikki Crisp;,citation_author=Dominic Crocombe;,citation_author=Maria Croft;,citation_author=Derrick Crook;,citation_author=Jennifer Crooks;,citation_author=Harriet Crosby;,citation_author=Elizabeth Cross;,citation_author=Ellie Cross;,citation_author=Sarah Cross;,citation_author=Tim Cross;,citation_author=Amy Crothers;,citation_author=Stephen Crotty;,citation_author=Susan Crouch;,citation_author=Madeleine Crow;,citation_author=Amanda Crowder;,citation_author=Kate Crowley;,citation_author=Teresa Crowley;,citation_author=Rebecca Croysdill;,citation_author=Callum Cruickshank;,citation_author=Conor Cruickshank;,citation_author=Irena Cruickshank;,citation_author=James Cruise;,citation_author=Carina Cruz;,citation_author=Trino Cruz Cervera;,citation_author=Dominic Cryans;,citation_author=Guanguo Cui;,citation_author=Helen Cui;,citation_author=Lorraine Cullen;,citation_author=Gillian Cummings-Fosong;,citation_author=Victoria Cunliffe;,citation_author=Neil Cunningham;,citation_author=Nicola Cunningham;,citation_author=Jason Cupitt;,citation_author=Hollie Curgenven;,citation_author=Gerens Curnow;,citation_author=David Curran;,citation_author=Simon Curran;,citation_author=Craig Currie;,citation_author=Jacqueline Currie;,citation_author=Scarlett Currie;,citation_author=Jonathan Curtis;,citation_author=Katrina Curtis;,citation_author=Olivia Curtis;,citation_author=Thomas Curtis;,citation_author=Rebecca Cuthbertson;,citation_author=Sean Cutler;,citation_author=Marta Czekaj;,citation_author=Patrycja Czylok;,citation_author=Silvia D’Arcangelo;,citation_author=Joana Rocha;,citation_author=Andrew Dagens;,citation_author=Helen Daggett;,citation_author=Jacqui Daglish;,citation_author=Sandeep Dahiya;,citation_author=Anne Dale;,citation_author=Katie Dale;,citation_author=Michaela Dale;,citation_author=Sam Dale;,citation_author=Jolyon Dales;,citation_author=Helen Dalgleish;,citation_author=Helen Dallow;,citation_author=Dermot Dalton;,citation_author=Zoe Daly;,citation_author=Eleanor Damm;,citation_author=Akila Danga;,citation_author=Amelia Daniel;,citation_author=Priya Daniel;,citation_author=Allison Daniels;,citation_author=Adela Dann;,citation_author=Sandra Danso-Bamfo;,citation_author=Alex Darbyshire;,citation_author=Janet Darbyshire;,citation_author=Paul Dargan;,citation_author=Paul Dark;,citation_author=Kate Darlington;,citation_author=Sarah Darnell;,citation_author=Tom Darton;,citation_author=Guledew Darylile;,citation_author=Manjusha Das;,citation_author=Sukamal Das;,citation_author=Martin Daschel;,citation_author=Joanne Dasgin;,citation_author=Dibyendu Datta;,citation_author=Anna Daunt;,citation_author=Vaishali Dave;,citation_author=Emily Davenport;,citation_author=Mark Davey;,citation_author=Miriam Davey;,citation_author=Molly Davey;,citation_author=Mini David;,citation_author=Alexander Davidson;,citation_author=Laura Davidson;,citation_author=Neil Davidson;,citation_author=Richard Davidson;,citation_author=Albert Davies;,citation_author=Amanda Davies;,citation_author=Amy Davies;,citation_author=Angela Davies;,citation_author=Carolyn Davies;,citation_author=Catrin Davies;,citation_author=Drew Davies;,citation_author=Elaine Davies;,citation_author=Ffyon Davies;,citation_author=Helen Davies;,citation_author=Jim Davies;,citation_author=Karen Davies;,citation_author=Kelly Davies;,citation_author=Kim Davies;,citation_author=Louisa Davies;,citation_author=Matthew Davies;,citation_author=Michelle Davies;,citation_author=Nina Davies;,citation_author=Owen Davies;,citation_author=Patrick Davies;,citation_author=Rachel Davies;,citation_author=Rhys Davies;,citation_author=Ruth Davies;,citation_author=Sarah Davies;,citation_author=Simon Davies;,citation_author=Alison Davis;,citation_author=Gwyneth Davis;,citation_author=Illinos Davis;,citation_author=Julie-Ann Davis;,citation_author=Katherine Davis;,citation_author=Peter Davis;,citation_author=Alexander Davison;,citation_author=Christine Dawe;,citation_author=H Dawe;,citation_author=Mark Dawkins;,citation_author=Danielle Dawson;,citation_author=Elizabeth Dawson;,citation_author=Joy Dawson;,citation_author=Susan Dawson;,citation_author=Tom Dawson;,citation_author=Andrew Daxter;,citation_author=Andrew Day;,citation_author=Jacob Day;,citation_author=Jeremy N Day;,citation_author=Jamie D’Costa;,citation_author=Parijat De;,citation_author=Duneesha Fonseka;,citation_author=Toni Freitas;,citation_author=Frederico De Santana Miranda;,citation_author=Eleanor Sausmarez;,citation_author=Shanika Silva;,citation_author=Thushan Silva;,citation_author=Jessica De Sousa;,citation_author=Paulo De Sousa;,citation_author=James Souza;,citation_author=Anthony De Soyza;,citation_author=Natasha Vere;,citation_author=Johannes Vos;,citation_author=Bethan Deacon;,citation_author=Sharon Dealing;,citation_author=Anna Dean;,citation_author=Julie Dean;,citation_author=Katrina Dean;,citation_author=Stephen Dean;,citation_author=Tessa Dean;,citation_author=Jill Deane;,citation_author=James Dear;,citation_author=Effie Dearden;,citation_author=Alison Deary;,citation_author=Catherine Deas;,citation_author=Samuel Debbie;,citation_author=Gabor Debreceni;,citation_author=Vashist Deelchand;,citation_author=Matthew Deeley;,citation_author=Joanne Deery;,citation_author=Emmanuel Defever;,citation_author=Manuela Del Forno;,citation_author=Arnold Dela Rosa;,citation_author=Amanda Dell;,citation_author=Carrie Demetriou;,citation_author=David DeMets;,citation_author=Jane Democratis;,citation_author=Jacqueline Denham;,citation_author=Emmanuelle Denis;,citation_author=Laura Denley;,citation_author=Craig Denmade;,citation_author=Kathy Dent;,citation_author=Martin Dent;,citation_author=Elise Denton;,citation_author=Tom Denwood;,citation_author=Nishigandh Deole;,citation_author=Darshita Depala;,citation_author=Maria Depante;,citation_author=Susan Dermody;,citation_author=Amisha Desai;,citation_author=Asmita Desai;,citation_author=Purav Desai;,citation_author=Sanjeev Deshpande;,citation_author=Vai Deshpande;,citation_author=Sirjana Devkota;,citation_author=Usha Devkota;,citation_author=Prakash Dey;,citation_author=Vishal Dey;,citation_author=Rogin Deylami;,citation_author=Kevin Dhaliwal;,citation_author=Sundip Dhani;,citation_author=Amandeep Dhanoa;,citation_author=Mili Dhar;,citation_author=Devesh Dhasmana;,citation_author=Ekanjali Dhillon;,citation_author=Reiss Dhillon;,citation_author=Meghnath Dhimal;,citation_author=Priya Dias;,citation_author=Stephanie Diaz;,citation_author=Kayleigh Diaz-Pratt;,citation_author=Debbie Dickerson;,citation_author=Pamela Dicks;,citation_author=Stuart Dickson;,citation_author=J Digby;,citation_author=Sean Dillane;,citation_author=Sarah Diment;,citation_author=Paul Dimitri;,citation_author=Thai Ha Dinh;,citation_author=Alex Dipper;,citation_author=Laura Dirmantaite;,citation_author=Lisa Ditchfield;,citation_author=Sarah Diver;,citation_author=Lavanya Diwakar;,citation_author=Caroline Dixon;,citation_author=Giles Dixon;,citation_author=Brice Djeugam;,citation_author=Petr Dlouhy;,citation_author=Andrea D’Mello;,citation_author=Paul Dmitri;,citation_author=Laurence Dobbie;,citation_author=Marinela Dobranszky Oroian;,citation_author=Charlotte Dobson;,citation_author=Lee Dobson;,citation_author=Marie Docherty;,citation_author=David Dockrell;,citation_author=James Dodd;,citation_author=Jackie Dodds;,citation_author=Rebecca Dodds;,citation_author=Steve Dodds;,citation_author=Richi Dogra;,citation_author=Erin Doherty;,citation_author=Warren Doherty;,citation_author=Yumiko Doi;,citation_author=Iain Doig;,citation_author=Eleanor Doke;,citation_author=Daniel Dolan;,citation_author=Mark Dolman;,citation_author=Rozzie Dolman;,citation_author=Lisa Donald;,citation_author=Callum Donaldson;,citation_author=Christopher Donaldson;,citation_author=Denise Donaldson;,citation_author=Gillian Donaldson;,citation_author=Kate Donaldson;,citation_author=Joanne Donnachie;,citation_author=Eilish Donnelly;,citation_author=Ronan Donnelly;,citation_author=Aravindhan Donohoe;,citation_author=Gemma Donohoe;,citation_author=Bryan Donohue;,citation_author=Sinead Donton;,citation_author=Emma Dooks;,citation_author=Grainne Doran;,citation_author=Kane Dorey;,citation_author=Sharon Dorgan;,citation_author=Moonira Dosani;,citation_author=Davinder Dosanjh;,citation_author=Paula Dospinescu;,citation_author=Katie Douglas;,citation_author=Jonathan Douse;,citation_author=Lucy Dowden;,citation_author=Michelle Dower;,citation_author=Sud Dowling;,citation_author=Nicola Downer;,citation_author=Charlotte Downes;,citation_author=Rob Downes;,citation_author=Thomas Downes;,citation_author=Damian Downey;,citation_author=Robert Downey;,citation_author=Louise Downs;,citation_author=Simon Dowson;,citation_author=Cornel Dragan;,citation_author=Cristina Dragos;,citation_author=Maire Drain;,citation_author=Chelsea Drake;,citation_author=Victoria Drew;,citation_author=Olivia Drewett;,citation_author=Celine Driscoll;,citation_author=Helena Drogan;,citation_author=Graham Drummond;,citation_author=Katie Drury;,citation_author=Ronald Druyeh;,citation_author=Jack Dryburgh-Jones;,citation_author=Simon Drysdale;,citation_author=An Du Thinh;,citation_author=Hazel Dube;,citation_author=Judith Dube;,citation_author=Stephen Duberley;,citation_author=Hayley Duckles-Leech;,citation_author=Nicola Duff;,citation_author=Emma Duffield;,citation_author=Helen Duffy;,citation_author=Lionel Dufour;,citation_author=Annette Duggan;,citation_author=Parveen Dugh;,citation_author=Janice Duignan;,citation_author=Simon Dummer;,citation_author=Andrew Duncan;,citation_author=Christopher Duncan;,citation_author=Fullerton Duncan;,citation_author=Gregory Duncan;,citation_author=Stephanie Dundas;,citation_author=Alessia Dunn;,citation_author=Charlotte Dunn;,citation_author=Damian Dunn;,citation_author=Laura Dunn;,citation_author=Paul Dunn;,citation_author=Charlene Dunne;,citation_author=Karen Dunne;,citation_author=Fiona Dunning;,citation_author=Aidan Dunphy;,citation_author=Venkat Duraiswamy;,citation_author=Beatriz Duran;,citation_author=Ingrid DuRand;,citation_author=Natalie Duric;,citation_author=Alison Durie;,citation_author=Emily Durie;,citation_author=Hannah Durrington;,citation_author=Haris Duvnjak;,citation_author=Akshay Dwarakanath;,citation_author=Laasya Dwarakanath;,citation_author=Ellen Dwyer;,citation_author=Claudia Dyball;,citation_author=Kristyn Dyer;,citation_author=Harvey Dymond;,citation_author=Tom Dymond;,citation_author=Chris Eades;,citation_author=Laura Eagles;,citation_author=Joanne Early;,citation_author=Melissa Earwaker;,citation_author=Nicholas Easom;,citation_author=Clare East;,citation_author=Amy Easthope;,citation_author=Fraser Easton;,citation_author=Ruth Eatough;,citation_author=Oluwadamilola Ebigbola;,citation_author=Daniel Ebner;,citation_author=Martin Ebon;,citation_author=Sinan Eccles;,citation_author=Chloe Eddings;,citation_author=Michael Eddleston;,citation_author=Maureen Edgar;,citation_author=Katharine Edgerley;,citation_author=Nicholas Edmond;,citation_author=Mary Edmondson;,citation_author=Tracy Edmunds;,citation_author=Alexandra Edwards;,citation_author=Catherine Edwards;,citation_author=Joy Edwards;,citation_author=Kennedy Edwards;,citation_author=Mandy Edwards;,citation_author=Jenny Eedle;,citation_author=Dawn Egginton;,citation_author=Loveth Ehiorobo;,citation_author=Sarah Eisen;,citation_author=Ugochukwu Ekeowa;,citation_author=Mohamed Ekoi;,citation_author=Ayomide Ekunola;,citation_author=Soha El Behery;,citation_author=Mohamed Elbeshy;,citation_author=Kate El-Bouzidi;,citation_author=Jennifer Elder;,citation_author=Mohammed El-Din;,citation_author=Diana Eleanor;,citation_author=Ibrahim Eletu;,citation_author=Eman Elfar;,citation_author=Mayy M Elgamal;,citation_author=Amr Elgohary;,citation_author=Stellios Elia;,citation_author=Jennifer Elias;,citation_author=Tania Elias;,citation_author=Nadia Elkaram;,citation_author=Andrew V Elkins;,citation_author=Julie Ellam;,citation_author=Nikki Ellard;,citation_author=Laura N Ellerton;,citation_author=Lucy Elliot;,citation_author=Amy Elliott;,citation_author=Fiona Elliott;,citation_author=Kerry Elliott;,citation_author=Scott Elliott;,citation_author=Annie Ellis;,citation_author=Christine Ellis;,citation_author=Kaytie Ellis;,citation_author=Tak-Yan Ellis;,citation_author=Yvette Ellis;,citation_author=Rahma Elmahdi;,citation_author=Einas Elmahi;,citation_author=Hannah-May Elmasry;,citation_author=Najla Elndari;,citation_author=Omer Elneima;,citation_author=Mohamed Elokl;,citation_author=Ahmed Elradi;,citation_author=Mohamed Elsaadany;,citation_author=Sally El-Sayeh;,citation_author=Hana El-Sbahi;,citation_author=Tarek Elsefi;,citation_author=Karim El-Shakankery;,citation_author=Hosni El-Taweel;,citation_author=Sarah Elyoussfi;,citation_author=Jonathan Emberey;,citation_author=Jonathan R Emberson;,citation_author=John Emberton;,citation_author=Julian Emmanuel;,citation_author=Ingrid Emmerson;,citation_author=Michael Emms;,citation_author=Florence Emond;,citation_author=Marieke Emonts;,citation_author=Nicu Enachi;,citation_author=Angila Engden;,citation_author=Katy English;,citation_author=Emma Entwistle;,citation_author=Hene Enyi;,citation_author=Marios Erotocritou;,citation_author=Peter Eskander;,citation_author=Hanif Esmail;,citation_author=Lise Estcourt;,citation_author=Brynach Evans;,citation_author=Chris Evans;,citation_author=Debra Evans;,citation_author=Gail Evans;,citation_author=Gareth Evans;,citation_author=Jennifer Evans;,citation_author=Jolanta Evans;,citation_author=Lisa Evans;,citation_author=Lynn Evans;,citation_author=Mim Evans;,citation_author=Morgan Evans;,citation_author=Ranoromanana Evans;,citation_author=Teriann Evans;,citation_author=Terry J Evans;,citation_author=Caroline Everden;,citation_author=Serenydd Everden;,citation_author=Hayley Evison;,citation_author=Lynsey Evison;,citation_author=David Eyre;,citation_author=Jacqueline Faccenda;,citation_author=Leila Fahel;,citation_author=Youstina Fahmay;,citation_author=Sara Fairbairn;,citation_author=Terry Fairbairn;,citation_author=Andy Fairclough;,citation_author=Louise Fairlie;,citation_author=Mark Fairweather;,citation_author=Anne Fajardo;,citation_author=Naomi Falcone;,citation_author=Euan Falconer;,citation_author=John Fallon;,citation_author=Andrea Fallow;,citation_author=David Faluyi;,citation_author=Victoria Fancois;,citation_author=Qayyum Farah;,citation_author=Nowin Z Fard;,citation_author=Leila Fares;,citation_author=Amr Farg;,citation_author=Adam Farmer;,citation_author=Katie Farmer;,citation_author=Toni Farmery;,citation_author=Samantha Farnworth;,citation_author=Faiyaz Farook;,citation_author=Hadia Farooq;,citation_author=Sidrah Farooq;,citation_author=Fiona Farquhar;,citation_author=Aaron Farrell;,citation_author=Barbara Farrell;,citation_author=James Farthing;,citation_author=Syeda Farzana;,citation_author=Rahmatu Fasina;,citation_author=Azam Fatemi;,citation_author=Mina Fatemi;,citation_author=Nibah Fatimah;,citation_author=Maria Faulkner;,citation_author=Saul N Faust;,citation_author=Joe Fawke;,citation_author=Sinmidele Fawohunre;,citation_author=Abul Fazal;,citation_author=Simon Fearby;,citation_author=Alex Feben;,citation_author=Federico Fedel;,citation_author=Daria Fedorova;,citation_author=Christopher Fegan;,citation_author=Mae Felongco;,citation_author=Lynsey Felton;,citation_author=Tim Felton;,citation_author=Kate Fenlon;,citation_author=Andrea Fenn;,citation_author=Isabelle Fenner;,citation_author=Ciara Fenton;,citation_author=Melisa Fenton;,citation_author=Cameron Ferguson;,citation_author=Jenny Ferguson;,citation_author=Kathryn Ferguson;,citation_author=Katie Ferguson;,citation_author=Susan Ferguson;,citation_author=Susie Ferguson;,citation_author=Victoria Ferguson;,citation_author=Denzil Fernandes;,citation_author=Candida Fernandez;,citation_author=Eduardo Fernandez;,citation_author=Maria Fernandez;,citation_author=Sonia Fernandez Lopez;,citation_author=Callum J Fernando;,citation_author=Ahmed Feroz;,citation_author=Pietro Ferranti;,citation_author=Thais Ferrari;,citation_author=Eleanor Ferrelly;,citation_author=Alexandra Ferrera;,citation_author=Emma Ferriman;,citation_author=Nicholas Fethers;,citation_author=Ben Field;,citation_author=Janet Field;,citation_author=Rebecca Field;,citation_author=Karen Fielder;,citation_author=Lindsey Fieldhouse;,citation_author=Andra Fielding;,citation_author=Julie Fielding;,citation_author=Sarah Fielding;,citation_author=Asma Fikree;,citation_author=Sarah A Filson;,citation_author=Sarah Finbow;,citation_author=Debbie Finch;,citation_author=Joanne Finch;,citation_author=Laurie Finch;,citation_author=Natalie Fineman;,citation_author=Lauren Finlayson;,citation_author=Adam Finn;,citation_author=Joanne Finn;,citation_author=Clare Finney;,citation_author=Sofia Fiouni;,citation_author=Jo Fiquet;,citation_author=James Fisher;,citation_author=Neil Fisher;,citation_author=Daniel Fishman;,citation_author=Krystofer Fishwick;,citation_author=Fiona Fitzgerald;,citation_author=Chloe Fitzpatrick-Creamer;,citation_author=Jan Flaherty;,citation_author=Michael Flanagan;,citation_author=Charles Flanders;,citation_author=Julie Fleming;,citation_author=Lucy Fleming;,citation_author=Paul Fleming;,citation_author=William Flesher;,citation_author=Alison Fletcher;,citation_author=Jonathan Fletcher;,citation_author=Lucy Fletcher;,citation_author=Simon Fletcher;,citation_author=Sophie Fletcher;,citation_author=Karen Flewitt;,citation_author=Christopher Flood;,citation_author=Ian Floodgate;,citation_author=Vincent Florence;,citation_author=Sharon Floyd;,citation_author=Rachel Flynn;,citation_author=Claire Foden;,citation_author=Adama Fofana;,citation_author=Georgina Fogarty;,citation_author=Claire Foley;,citation_author=Paul Foley;,citation_author=Linda Folkes;,citation_author=Daniela M Font;,citation_author=Aiwyne Foo;,citation_author=Jane Foo;,citation_author=Andrew Foot;,citation_author=Jayne Foot;,citation_author=Jane Forbes;,citation_author=Jamie Ford;,citation_author=Jennifer Foreman;,citation_author=Caroline Fornolles;,citation_author=Adam Forrest;,citation_author=Ellie Forsey;,citation_author=Miranda Forsey;,citation_author=Thomas Forshall;,citation_author=Elliot Forster;,citation_author=Julian Forton;,citation_author=Emily Foster;,citation_author=Joseph Foster;,citation_author=Rachel A Foster;,citation_author=Tracy Foster;,citation_author=Angela Foulds;,citation_author=Ian Foulds;,citation_author=Folakemi Fowe;,citation_author=Emily Fowler;,citation_author=Robert Fowler;,citation_author=Stephen Fowler;,citation_author=Claire Fox;,citation_author=Heather Fox;,citation_author=Jonathan Fox;,citation_author=Lauren Fox;,citation_author=Natalie Fox;,citation_author=Olivia Fox;,citation_author=Simon Fox;,citation_author=Sarah-Jane Foxton;,citation_author=Rebecca Frake;,citation_author=Alex Francioni;,citation_author=Olesya Francis;,citation_author=Rebecca Francis;,citation_author=Sarah Francis;,citation_author=Sasha Francis;,citation_author=Theodora Francis-Bacon;,citation_author=Helen Frankland;,citation_author=Jessica Franklin;,citation_author=Catherine Fraser;,citation_author=Sharon Frayling;,citation_author=Martyn Fredlund;,citation_author=Carol Freeman;,citation_author=Elaine Freeman;,citation_author=Hannah Freeman;,citation_author=Nicola Freeman;,citation_author=Clare Freer;,citation_author=Eleanor French;,citation_author=Matthew Frise;,citation_author=Renate Fromson;,citation_author=Adam Frosh;,citation_author=John Frost;,citation_author=Victoria Frost;,citation_author=Oliver Froud;,citation_author=Rachel Frowd;,citation_author=Arun Fryatt;,citation_author=Bridget Fuller;,citation_author=Liz Fuller;,citation_author=Tracy Fuller;,citation_author=Duncan Fullerton;,citation_author=Carrie Fung;,citation_author=Gayle Fung;,citation_author=Sarah Funnell;,citation_author=John Furness;,citation_author=Andrew Fyfe;,citation_author=Nytianandan G;,citation_author=Elizabeth Gabbitas;,citation_author=Claire Gabriel;,citation_author=Zoë Gabriel;,citation_author=Hadiza Gachi;,citation_author=Joshua Gahir;,citation_author=Sarveen Gajebasia;,citation_author=Katarzyna Gajewska-Knapik;,citation_author=Christopher Gale;,citation_author=Hugo Gale;,citation_author=Rebecca Gale;,citation_author=Swetha Gali;,citation_author=Bernadette Gallagher;,citation_author=Jude Gallagher;,citation_author=Rosie Gallagher;,citation_author=William Gallagher;,citation_author=Joanne Galliford;,citation_author=Catherine Galloway;,citation_author=Chris Galloway;,citation_author=Emma Galloway;,citation_author=Jacqui Galloway;,citation_author=James Galloway;,citation_author=Laura Gamble;,citation_author=Liz Gamble;,citation_author=Brian Gammon;,citation_author=Jaikumar Ganapathi;,citation_author=Ramesh Ganapathy;,citation_author=Kaminiben Gandhi;,citation_author=Sarah Gandhi;,citation_author=Usha Ganesh;,citation_author=Abrar Gani;,citation_author=Emma-James Garden;,citation_author=Antoni D Gardener;,citation_author=Emma Gardiner;,citation_author=Michael Gardiner;,citation_author=Phil Gardiner;,citation_author=Siobhan Gardiner;,citation_author=Caroline Gardiner-Hill;,citation_author=Jonathan Gardner;,citation_author=Mark Garfield;,citation_author=Atul Garg;,citation_author=Nathan Garlick;,citation_author=Justin Garner;,citation_author=Lucie Garner;,citation_author=Zoe Garner;,citation_author=Rosaline Garr;,citation_author=Florence Garty;,citation_author=Rachel Gascoyne;,citation_author=Hyeriju Gashau;,citation_author=Aoife Gatenby;,citation_author=Erin Gaughan;,citation_author=Alok Gaurav;,citation_author=Mariana Gavrila;,citation_author=Jane Gaylard;,citation_author=Emma Gaywood;,citation_author=Catherine Geddie;,citation_author=Ian Gedge;,citation_author=Sarah Gee;,citation_author=Minerva Gellamucho;,citation_author=Karzan Gelly;,citation_author=Leila Gelmon;,citation_author=Sandra Gelves-Zapata;,citation_author=Gemma Genato;,citation_author=Susan Gent;,citation_author=Natalie Geoghegan;,citation_author=Sam George;,citation_author=Tina George;,citation_author=Simon Georges;,citation_author=Domonique Georgiou;,citation_author=Peter Gerard;,citation_author=Leigh Gerdes;,citation_author=Louise Germain;,citation_author=Helen Gerrish;,citation_author=Abel Getachew;,citation_author=Louise Gethin;,citation_author=Hisham Ghanayem;,citation_author=Anca Gherman;,citation_author=Alison Ghosh;,citation_author=Justin Ghosh;,citation_author=Sudhamay Ghosh;,citation_author=Sarra Giannopoulou;,citation_author=Malick Gibani;,citation_author=Ben Gibbison;,citation_author=Kerry Gibbons;,citation_author=Alex Gibson;,citation_author=Bethan Gibson;,citation_author=Kimberley Gibson;,citation_author=Kirsty Gibson;,citation_author=Sian Gibson;,citation_author=Cat Gilbert;,citation_author=Jeanette Gilbert;,citation_author=Kayleigh Gilbert;,citation_author=Benjamin Giles;,citation_author=Mandy Gill;,citation_author=Lynne Gill;,citation_author=Paul Gillen;,citation_author=Annelies Gillesen;,citation_author=Katherine Gillespie;,citation_author=Elizabeth Gillham;,citation_author=Andrew Gillian;,citation_author=Deborah Gilliland;,citation_author=Robert Gillott;,citation_author=Danielle Gilmour;,citation_author=Kate Gilmour;,citation_author=Franciscus Ginting;,citation_author=Theodora Giokanini-Royal;,citation_author=Anna Gipson;,citation_author=Joanna Girling;,citation_author=Rhian Gisby;,citation_author=Angelena Gkioni;,citation_author=Aikaterini Gkoritsa;,citation_author=Effrossyni Gkrania-Klotsas;,citation_author=Amy Gladwell;,citation_author=James Glanville;,citation_author=Jessica Glasgow;,citation_author=Susannah Glasgow;,citation_author=Jon Glass;,citation_author=Lynn Glass;,citation_author=Sharon Glaysher;,citation_author=Lisa Gledhill;,citation_author=Ana Glennon;,citation_author=John Glover;,citation_author=Kyle Glover;,citation_author=Jan Glover Bengtsson;,citation_author=Deborah Glowski;,citation_author=Chevanthy Gnanalingam;,citation_author=Julie Goddard;,citation_author=Wendy Goddard;,citation_author=Emily Godden;,citation_author=Jo Godden;,citation_author=Emma Godson;,citation_author=Sukanya Gogoi;,citation_author=Aiky Goh;,citation_author=Rebeca Goiriz;,citation_author=Sriya Gokaraju;,citation_author=Raphael Goldacre;,citation_author=Arthur Goldsmith;,citation_author=Portia Goldsmith;,citation_author=Darren Gomersall;,citation_author=Lucia Gomez;,citation_author=Raquel Gomez-Marcos;,citation_author=Ali Gondal;,citation_author=Celia Gonzalez;,citation_author=Jack Goodall;,citation_author=Bob Goodenough;,citation_author=Laura Goodfellow;,citation_author=James Goodlife;,citation_author=Camelia Goodwin;,citation_author=Elizabeth Goodwin;,citation_author=Jayne Goodwin;,citation_author=Paula Goodyear;,citation_author=Rajiv Gooentilleke;,citation_author=Michelle Goonasekara;,citation_author=Sheila Gooseman;,citation_author=Shameer Gopal;,citation_author=Sally Gordon;,citation_author=Robin Gore;,citation_author=Hugh Gorick;,citation_author=Caitlin Gorman;,citation_author=Claire Gorman;,citation_author=Stuart Gormely;,citation_author=Diana Gorog;,citation_author=Michelle Gorst;,citation_author=Thomas Gorsuch;,citation_author=Jayshreebahen Gosai;,citation_author=Rebecca Gosling;,citation_author=Sally Gosling;,citation_author=Georgina Gosney;,citation_author=Vanessa Goss;,citation_author=Dzintars Gotham;,citation_author=Naomi Gott;,citation_author=Elizabeth Goudie;,citation_author=Susan Gould;,citation_author=Lysander Gourbault;,citation_author=Abha Govind;,citation_author=Sharon Gowans;,citation_author=Girish Gowda;,citation_author=Rohit Gowda;,citation_author=Hannah Gower;,citation_author=Pankaj Goyal;,citation_author=Sunil Goyal;,citation_author=Sushant Goyal;,citation_author=Clive Graham;,citation_author=Jonathan Graham;,citation_author=Justin Graham;,citation_author=Libby Graham;,citation_author=Sharon Graham;,citation_author=Matthew Graham-Brown;,citation_author=Julia Grahamslaw;,citation_author=Gianluca Grana;,citation_author=Tracyanne Grandison;,citation_author=Louis Grandjean;,citation_author=Alison Grant;,citation_author=Ann Grant;,citation_author=David Grant;,citation_author=Matthew Grant;,citation_author=Pauleen Grant;,citation_author=Rhys Gravell;,citation_author=Jenny Graves;,citation_author=Alasdair Gray;,citation_author=Catherine Gray;,citation_author=Georgina Gray;,citation_author=Jackie Gray;,citation_author=Karen Gray;,citation_author=Nicola Gray;,citation_author=Sebastian Gray;,citation_author=Alan Grayson;,citation_author=Fiona Greaves;,citation_author=Paul Greaves;,citation_author=Alastair Green;,citation_author=Charlotte Green;,citation_author=Christopher A Green;,citation_author=David Green;,citation_author=Frederick Green;,citation_author=Joel Green;,citation_author=Marie Green;,citation_author=Nicola Green;,citation_author=Stacey Green;,citation_author=Diarra Greene;,citation_author=Philippa Greenfield;,citation_author=Alan Greenhalgh;,citation_author=Daniel Greenwood;,citation_author=Sandra Greer;,citation_author=James Gregory;,citation_author=Jane Gregory;,citation_author=Katie Gregory;,citation_author=Tamsin Gregory;,citation_author=Jill Greig;,citation_author=Julia Greig;,citation_author=Rebecca Grenfell;,citation_author=Teena Grenier;,citation_author=Susan Grevatt;,citation_author=Glaxy Grey;,citation_author=Andrew Gribbin;,citation_author=Amy Gribble;,citation_author=Natasha Grieg;,citation_author=Douglas Grieve;,citation_author=Ben Griffin;,citation_author=Denise Griffin;,citation_author=Mel Griffin;,citation_author=Sian Griffith;,citation_author=Andrew Griffiths;,citation_author=Daniel Griffiths;,citation_author=David Griffiths;,citation_author=Donna Griffiths;,citation_author=Isabel Griffiths;,citation_author=Mark Griffiths;,citation_author=Nicola Griffiths;,citation_author=Oliver Griffiths;,citation_author=Sarah Griffiths;,citation_author=Yvonne Griffiths;,citation_author=Sofia Grigoriadou;,citation_author=Steph Grigsby;,citation_author=Evelina Grobovaite;,citation_author=Clarissa Grondin;,citation_author=Rachel Groome;,citation_author=Liliana Grosu;,citation_author=Jenny Grounds;,citation_author=Margaret Grout;,citation_author=Helen Grover;,citation_author=Helen Grover;,citation_author=Jayne Groves;,citation_author=Neil Grubb;,citation_author=Julie Grundy;,citation_author=Francesca Guarino;,citation_author=Sharada Gudur;,citation_author=Sharazeq Guettari;,citation_author=Shivang Gulati;,citation_author=Vikas Gulia;,citation_author=Pumali Gunasekera;,citation_author=Malin Gunawardena;,citation_author=Kirun Gunganah;,citation_author=Jessica Gunn;,citation_author=Emma Gunter;,citation_author=Alok Gupta;,citation_author=Atul Gupta;,citation_author=Rajeev Gupta;,citation_author=Richa Gupta;,citation_author=Rishi Gupta;,citation_author=Tarun Gupta;,citation_author=Vineet Gupta;,citation_author=Ankur Gupta-Wright;,citation_author=Victoria Guratsky;,citation_author=Alvyda Gureviciute;,citation_author=Sambasivarao Gurram;,citation_author=Anju Gurung;,citation_author=Bhawana Gurung;,citation_author=Shraddha Gurung;,citation_author=Hazel Guth;,citation_author=Pradip Gyanwali;,citation_author=Ruth Habibi;,citation_author=Berkin Hack;,citation_author=Pamela Hackney;,citation_author=Christian Hacon;,citation_author=Aiman Haddad;,citation_author=Denise Hadfield;,citation_author=Michalis Hadjiandreou;,citation_author=Nikolaos Hadjisavvas;,citation_author=Anna Haestier;,citation_author=Nauman Hafiz;,citation_author=Rana Hafiz-Ur-Rehman;,citation_author=Javed Hafsa;,citation_author=Samantha Hagan;,citation_author=Jack W Hague;,citation_author=Rosemary Hague;,citation_author=Kate Haigh;,citation_author=Christina Haines;,citation_author=Scott Hainey;,citation_author=Morton Hair;,citation_author=Brigid Hairsine;,citation_author=Juraj Hajnik;,citation_author=Anne Haldeos;,citation_author=Writaja Halder;,citation_author=Jennie Hale;,citation_author=Carmel Halevy;,citation_author=Paul Halford;,citation_author=William Halford;,citation_author=Alistair Hall;,citation_author=Anthony Hall;,citation_author=Claire Hall;,citation_author=Elizabeth Hall;,citation_author=Fiona Hall;,citation_author=Helen Hall;,citation_author=Jennifer Hall;,citation_author=Kathryn Hall;,citation_author=Jan Hallas;,citation_author=Kyle Hallas;,citation_author=Charles Hallett;,citation_author=Heather Halls;,citation_author=Maryam Hamdollah-Zadeh;,citation_author=Bilal Hameed;,citation_author=Raph Hamers;,citation_author=Imran Hamid;,citation_author=Mohamad Hamie;,citation_author=Bethany Hamilton;,citation_author=Fergus Hamilton;,citation_author=Leigh Hamilton;,citation_author=Nicola Hamilton;,citation_author=Sara Hamilton;,citation_author=Ruth Hamlin;,citation_author=Eleanor Hamlyn;,citation_author=Beatrice Hammans;,citation_author=Shirley Hammersley;,citation_author=Kate Hammerton;,citation_author=Bev Hammond;,citation_author=Leah Hammond;,citation_author=Fiona Hammonds;,citation_author=Ibrahim Hamoodi;,citation_author=Karen Hampshire;,citation_author=Jude Hampson;,citation_author=Lucy Hampson;,citation_author=Ozan Hanci;,citation_author=Sadiyah Hand;,citation_author=Jasmine Handford;,citation_author=Soran Handrean;,citation_author=Sarah Haney;,citation_author=Sheharyar Hanif;,citation_author=E Hanison;,citation_author=Esther Hanison;,citation_author=Jennifer Hannah;,citation_author=Amy Hannington;,citation_author=Merhej Hannun;,citation_author=Aidan Hanrath;,citation_author=Anita Hanson;,citation_author=Jane Hanson;,citation_author=Kathryn Hanson;,citation_author=Steve Hanson;,citation_author=Mazhar Ul Haq;,citation_author=Ala Haqiqi;,citation_author=Monjurul Haque;,citation_author=Lesley Harden;,citation_author=Zoe Harding;,citation_author=Simon Hardman;,citation_author=Joanna Hardy;,citation_author=Kumar Haresh;,citation_author=Rachel Harford;,citation_author=Beverley Hargadon;,citation_author=Carolyn Hargreaves;,citation_author=James Hargreaves;,citation_author=Alice Harin;,citation_author=Mohammed Haris;,citation_author=Edward Harlock;,citation_author=Paula Harman;,citation_author=Tracy Harman;,citation_author=Mark Harmer;,citation_author=Muhammad A Haroon;,citation_author=Charlie Harper;,citation_author=Heather Harper;,citation_author=Peter Harper;,citation_author=Rosemary Harper;,citation_author=Sarah Harrhy;,citation_author=Sian Harrington;,citation_author=Yasmin Harrington-Davies;,citation_author=Jade Harris;,citation_author=Jess Harris;,citation_author=John Harris;,citation_author=Laura Harris;,citation_author=Marie-Clare Harris;,citation_author=Nichola Harris;,citation_author=Sophie Harris;,citation_author=David Harrison;,citation_author=Laura Harrison;,citation_author=Melanie Harrison;,citation_author=Rowan Harrison;,citation_author=Susie Harrison;,citation_author=Thomas Harrison;,citation_author=Wendy Harrison;,citation_author=Elizabeth Harrod;,citation_author=Ciaran Hart;,citation_author=Dominic Hart;,citation_author=Lisa Hartley;,citation_author=Rosemary Hartley;,citation_author=Ruth Hartley;,citation_author=Tom Hartley;,citation_author=William Hartrey;,citation_author=Phillipa Hartridge;,citation_author=Stuart Hartshorn;,citation_author=Heli Harvala;,citation_author=Alice Harvey;,citation_author=Angela Harvey;,citation_author=Max Harvey;,citation_author=Catherine Harwood;,citation_author=Helen Harwood;,citation_author=Brigitte Haselden;,citation_author=K Hashem;,citation_author=Mohammed Hashimm;,citation_author=Tadaaki Hashimoto;,citation_author=Imranullah Hashmi;,citation_author=Zena Haslam;,citation_author=Adil Hassan;,citation_author=Ali Hassan;,citation_author=Sapna Hassasing;,citation_author=Jane Hassell;,citation_author=Philip Hassell;,citation_author=Alex Hastings;,citation_author=Bethany Hastings;,citation_author=Janice Hastings;,citation_author=Stephanie Hatch;,citation_author=Jonathan Hatton;,citation_author=May Havinden-Williams;,citation_author=Stefan Havlik;,citation_author=Daniel B Hawcutt;,citation_author=Kadean Hawes;,citation_author=Liz Hawes;,citation_author=Nicola Hawes;,citation_author=Annie Hawkins;,citation_author=Nancy Hawkins;,citation_author=Dan Hawley;,citation_author=Ed Hawley-Jones;,citation_author=Edward Haworth;,citation_author=Alasdair Hay;,citation_author=Cathy Hay;,citation_author=Amna Hayat;,citation_author=Jamal Hayat;,citation_author=Mohamed-Riyal Hayathu;,citation_author=A Hayder;,citation_author=Anne Hayes;,citation_author=Jonas Hayes;,citation_author=Kate Hayes;,citation_author=Melony Hayes;,citation_author=Fiona Hayes;,citation_author=Patrick Hayle;,citation_author=Chloe Haylett;,citation_author=Antara Hayman;,citation_author=Melanie Hayman;,citation_author=Matthew Haynes;,citation_author=Richard Haynes;,citation_author=Rachel Hayre;,citation_author=Sarah Haysom;,citation_author=James Hayward;,citation_author=Patrick Haywood;,citation_author=Tracy Hazelton;,citation_author=Phoebe Hazenberg;,citation_author=Zhengmai He;,citation_author=Elizabeth Headon;,citation_author=Carrie Heal;,citation_author=Brendan Healy;,citation_author=Amy Hearn;,citation_author=Angela Heath;,citation_author=Rowan Heath;,citation_author=Diane Heaton;,citation_author=Kerry Hebbron;,citation_author=Gemma Hector;,citation_author=Andy Hedges;,citation_author=Katrine Hedges;,citation_author=Cheryl Heeley;,citation_author=Elaine Heeney;,citation_author=Rajdeep Heire;,citation_author=Georgia Hemingway;,citation_author=Ulla Hemmila;,citation_author=Scott Hemphill;,citation_author=Deborah Hemsley;,citation_author=Abigail Henderson;,citation_author=Eilidh Henderson;,citation_author=Jennifer Henderson;,citation_author=Steven Henderson;,citation_author=Joanne Henry;,citation_author=Karol Henry;,citation_author=Lavinia Henry;,citation_author=Margo Henry;,citation_author=Natalie Henry;,citation_author=David Henshall;,citation_author=Gillian Herdman;,citation_author=Rosaleen Herdman-Grant;,citation_author=Morag Herkes;,citation_author=Emma Heron;,citation_author=William Herrington;,citation_author=Emilia Heselden;,citation_author=Peta Heslop;,citation_author=Simon Hester;,citation_author=Emily Hetherington;,citation_author=Joseph Hetherington;,citation_author=Chamila Hettiarachchi;,citation_author=Pramodh Hettiarachchi;,citation_author=Hayley Hewer;,citation_author=John Hewertson;,citation_author=Anna Hewetson;,citation_author=Sue Hewins;,citation_author=Claire Hewitt;,citation_author=Davina Hewitt;,citation_author=Richard Hewitt;,citation_author=Jacqueline Hewson;,citation_author=Samuel Hey;,citation_author=Robert S Heyderman;,citation_author=Mathis Heydtmann;,citation_author=Joseph Heys;,citation_author=Jonathan Heywood;,citation_author=Meg Hibbert;,citation_author=John Hickey;,citation_author=Naomi Hickey;,citation_author=Peter Hickey;,citation_author=Alex Hicks;,citation_author=Bethany Hicks;,citation_author=Jenny Hicks;,citation_author=Scott R Hicks;,citation_author=Daniel Higbee;,citation_author=Lucy Higgins;,citation_author=Andrew Higham;,citation_author=Martin Highcock;,citation_author=Judith Highgate;,citation_author=Mondy Hikmat;,citation_author=Amanda Hill;,citation_author=Helen Hill;,citation_author=Joanne Hill;,citation_author=Lisa Hill;,citation_author=Phoebe Hill;,citation_author=Uta Hill;,citation_author=Annette Hilldrith;,citation_author=Catherine Hillman-Cooper;,citation_author=Zoe Hilton;,citation_author=Sarah Hinch;,citation_author=Andrew Hindle;,citation_author=Alice Hindmarsh;,citation_author=Paul Hine;,citation_author=Kim Hinshaw;,citation_author=Clare Hird;,citation_author=Jemma Hives;,citation_author=Benson Ho;,citation_author=Michaela Hoare;,citation_author=David Hobden;,citation_author=Gill Hobden;,citation_author=Maria Hobrok;,citation_author=Simon Hobson;,citation_author=Simon Hodge;,citation_author=Lesley Hodgen;,citation_author=Holly Hodgkins;,citation_author=Sally Hodgkinson;,citation_author=David Hodgson;,citation_author=Helen Hodgson;,citation_author=Luke Hodgson;,citation_author=Sheila Hodgson;,citation_author=Gemma Hodkinson;,citation_author=Kenneth Hodson;,citation_author=Matthew Hogben;,citation_author=Lucy Hogg;,citation_author=Lee Hoggett;,citation_author=Abigail Holborow;,citation_author=Catherine Holbrook;,citation_author=Catherine Holden;,citation_author=Melinda Holden;,citation_author=Thomas Holder;,citation_author=Niels Holdhof;,citation_author=Hannah Holdsworth;,citation_author=Lisa Holland;,citation_author=Nicky Holland;,citation_author=Marie Hollands;,citation_author=Elizabeth Holliday;,citation_author=Nina Holling;,citation_author=Laszlo Hollos;,citation_author=Simon Holloway;,citation_author=Marcus Hollyer;,citation_author=Amy Holman;,citation_author=Ann Holmes;,citation_author=Megan Holmes;,citation_author=Raphael Holmes;,citation_author=Rebecca Holmes;,citation_author=Kelly Holroyd;,citation_author=Lyndsey Holt;,citation_author=Siobhan Holt;,citation_author=Susie Holt;,citation_author=Alexandra Holyome;,citation_author=Marie Home;,citation_author=Renate Homewood;,citation_author=Kate Hong;,citation_author=Clare Hooper;,citation_author=Sarah Hoosdally;,citation_author=Samantha Hope;,citation_author=Susan Hope;,citation_author=Bridget Hopkins;,citation_author=Peter W Horby;,citation_author=Stephanie Horler;,citation_author=Anil Hormis;,citation_author=Daniel Hornan;,citation_author=Nicola Hornby;,citation_author=Zoey Horne;,citation_author=Rebecca Horner;,citation_author=Latoya Horsford;,citation_author=Megan Horsford;,citation_author=Mark Horsford;,citation_author=Valana Horsham;,citation_author=Alexander Horsley;,citation_author=Ashley Horsley;,citation_author=Elizabeth Horsley;,citation_author=Sarah Horton;,citation_author=Jane Hosea;,citation_author=Toby Hoskins;,citation_author=Muhammad S Hossain;,citation_author=Rashed Hossain;,citation_author=Maxine Hough;,citation_author=Sarah Hough;,citation_author=Catherine Houghton;,citation_author=Kathryn Houghton;,citation_author=Rebecca Houlihan;,citation_author=Kay Housely;,citation_author=Hamish Houston;,citation_author=Roseanna Hovvels;,citation_author=Lee How;,citation_author=Laura Howaniec;,citation_author=Laura Howard;,citation_author=Linda Howard;,citation_author=Lucy Howard;,citation_author=Sarah Howard;,citation_author=Stuart Howard;,citation_author=Richard Howard-Griffin;,citation_author=Alison Howarth;,citation_author=Serena Howe;,citation_author=Mark Howells;,citation_author=Lyn Howie;,citation_author=Kerry Howlett;,citation_author=Sophie Howlett;,citation_author=Josh Hrycaiczuk;,citation_author=Naing Zaya Htoon;,citation_author=Su Htwe;,citation_author=Ying Hu;,citation_author=Chiang Ooi Huah;,citation_author=Abby Huckle;,citation_author=Shahzya Huda;,citation_author=Alison Hudak;,citation_author=Lisa Hudig;,citation_author=Heather Hudson;,citation_author=Oli Hudson;,citation_author=Alison Hufton;,citation_author=Connor Huggins;,citation_author=Alistair Hughes;,citation_author=Emma Hughes;,citation_author=Gareth Hughes;,citation_author=Heather Hughes;,citation_author=Luke Hughes;,citation_author=Rachel Hughes;,citation_author=Rebecca Hughes;,citation_author=Samantha Hughes;,citation_author=Stephen Hughes;,citation_author=Vikki Hughes;,citation_author=Wesley Hughes;,citation_author=Lukas Huhn;,citation_author=Ching Hui;,citation_author=Ruth Hulbert;,citation_author=Diana Hull;,citation_author=Grace Hull;,citation_author=Robert Hull;,citation_author=Amanda Hulme;,citation_author=Peter Hulme;,citation_author=Wendy Hulse;,citation_author=George Hulston;,citation_author=Ryan Hum;,citation_author=Megan Hume;,citation_author=Charlotte Humphrey;,citation_author=Alasdair Humphries;,citation_author=Joanne Humphries;,citation_author=Fiona Hunt;,citation_author=Jonquil Hunt;,citation_author=Kristen Hunt;,citation_author=Luke Hunt;,citation_author=Sophie Hunt;,citation_author=Alexandra Hunter;,citation_author=Ewan Hunter;,citation_author=Karl Hunter;,citation_author=Neil Hunter;,citation_author=Sophie Hunter;,citation_author=George Huntington;,citation_author=Elizabeth Hurditch;,citation_author=Cian Hurley;,citation_author=Katrina Hurley;,citation_author=Mohammed A Husain;,citation_author=Syeda Y Husaini;,citation_author=Coralie Huson;,citation_author=Afreen Hussain;,citation_author=Ibraar Hussain;,citation_author=Ifza Hussain;,citation_author=Mohammad Hussain;,citation_author=Muhammad Hussain;,citation_author=Reda Hussain;,citation_author=Samia Hussain;,citation_author=Sanniah Hussain;,citation_author=Yasmin Hussain;,citation_author=Mohammed Hussam El-Din;,citation_author=Rebecca Hussey;,citation_author=Adiel H Hussien;,citation_author=Anja Hutchinson;,citation_author=Camille Hutchinson;,citation_author=Dorothy Hutchinson;,citation_author=Elizabeth Hutchinson;,citation_author=John Hutchinson;,citation_author=Claire Hutsby;,citation_author=Paula Hutton;,citation_author=Thuong Huyen;,citation_author=Daniella Hydes;,citation_author=Jamie Hyde-Wyatt;,citation_author=Niamh Hynes;,citation_author=Megan Hyslop;,citation_author=Mazen Ibraheim;,citation_author=Abdalla Ibrahim;,citation_author=Ahmed Ibrahim;,citation_author=Asil Ibrahim;,citation_author=Mohamed Ibrahim;,citation_author=Wadah Ibrahim;,citation_author=Adetokunbo I Idowu;,citation_author=Muhammad Idrees;,citation_author=Nauman Idrees;,citation_author=Hina Iftikhar;,citation_author=Mawara Iftikhar;,citation_author=Chukwuemeka Igwe;,citation_author=Mohammad Ijaz;,citation_author=Amaju Ikomi;,citation_author=Clare Iles;,citation_author=Stamatina Iliodromiti;,citation_author=Mary Ilsley;,citation_author=Lorna Ilves;,citation_author=La’ali Imam-Gutierrez;,citation_author=Christopher Imray;,citation_author=Haider Imtiaz;,citation_author=Jack Ingham;,citation_author=Julie Ingham;,citation_author=Rory Ingham;,citation_author=Tejas Ingle;,citation_author=Jennifer Inglis;,citation_author=Anne Ingram;,citation_author=Luke Ingram;,citation_author=Peter Inns;,citation_author=Ken Inweregbu;,citation_author=Andreea A Ionescu;,citation_author=Ana Ionita;,citation_author=Ilian P Iordanov;,citation_author=Anil Ipe;,citation_author=Madiha Iqbal;,citation_author=Mohammed Iqbal;,citation_author=Faisal Iqbal Sait;,citation_author=Jane Ireland;,citation_author=Robert Irons;,citation_author=Mohannad Irshad;,citation_author=Muhammad S Irshad;,citation_author=Janice Irvine;,citation_author=Val Irvine;,citation_author=Robert Irving;,citation_author=Mina Ishak;,citation_author=Erica Isherwood;,citation_author=Aminul Islam;,citation_author=Samsul Islam;,citation_author=Abdurrahman Islim;,citation_author=Ali Ismail;,citation_author=Omar Ismail;,citation_author=Caroline Ison;,citation_author=M’hamedi Israa;,citation_author=Sharon Isralls;,citation_author=Monica Ivan;,citation_author=Chineze Ivenso;,citation_author=Ashleigh Ivy;,citation_author=Sophie Iwanikiw;,citation_author=Karen Ixer;,citation_author=Menaka Iyer;,citation_author=Mia Iyer;,citation_author=Calum Jack;,citation_author=Amanda Jackson;,citation_author=Ben Jackson;,citation_author=Beth Jackson;,citation_author=Ella Jackson;,citation_author=Helen Jackson;,citation_author=Lauren Jackson;,citation_author=Melanie Jackson;,citation_author=Nicola Jackson;,citation_author=Shane Jackson;,citation_author=Patricia Jacob;,citation_author=Reni Jacob;,citation_author=Nicola Jacques;,citation_author=Anisa Jafar;,citation_author=Daniel Jafferji;,citation_author=Ali Jaffery;,citation_author=Chandrashekar Jagadish;,citation_author=Vijay Jagannathan;,citation_author=Mandeep Jagpal;,citation_author=Fernandez R Jaime;,citation_author=Neemisha Jain;,citation_author=Seema Jain;,citation_author=Susan Jain;,citation_author=Sanjay Jaiswal;,citation_author=Danyal Jajbhay;,citation_author=Thomas Jaki;,citation_author=Bintou Jallow;,citation_author=Yusuf Jaly;,citation_author=Sabine Jamal;,citation_author=Zeba Jamal;,citation_author=Yasmin Jameel;,citation_author=Albie James;,citation_author=Christie James;,citation_author=Kate James;,citation_author=Lee James;,citation_author=Linda James;,citation_author=Mark James;,citation_author=Nicholas James;,citation_author=Olivia James;,citation_author=Rebecca James;,citation_author=Ruth James;,citation_author=Tracy James;,citation_author=Jack Jameson;,citation_author=Aaron Jamison;,citation_author=Phoebe Jane;,citation_author=Azara Janmohamed;,citation_author=Deepa Japp;,citation_author=Victor Jardim;,citation_author=Catherine Jardine;,citation_author=Emma Jarnell;,citation_author=Ellie Jarvie;,citation_author=Claire Jarvis;,citation_author=Rosina Jarvis;,citation_author=Patrycja Jastrzebska;,citation_author=Hafsa Javed;,citation_author=Mays Jawad;,citation_author=Lona Jawaheer;,citation_author=Anu Jayachandran;,citation_author=D Jayachandran;,citation_author=Angelina Jayakumar;,citation_author=Deepak Jayaram;,citation_author=Ravi Jayaram;,citation_author=Geeshath Jayasekera;,citation_author=Thilina Jayatilleke;,citation_author=Abi Jayebalan;,citation_author=Saman Jeddi;,citation_author=Mohammad S Jeelani;,citation_author=Katie Jeffery;,citation_author=Helen Jeffrey;,citation_author=Rachel Jeffrey;,citation_author=Nathan Jeffreys;,citation_author=Benjamin Jeffs;,citation_author=Debbie Jegede;,citation_author=Taylor Jemima;,citation_author=Ifan Jenkin;,citation_author=Alison Jenkins;,citation_author=Christopher Jenkins;,citation_author=David Jenkins;,citation_author=Elinor Jenkins;,citation_author=Sarah Jenkins;,citation_author=Sian Jenkins;,citation_author=Stephen Jenkins;,citation_author=Jacqui Jennings;,citation_author=Louise Jennings;,citation_author=Virginia Jennings;,citation_author=Ellen Jerome;,citation_author=Douglas Jerry;,citation_author=Ellen Jessup-Dunton;,citation_author=Jorge A Jesus Silva;,citation_author=Champa Jetha;,citation_author=Kishan Jethwa;,citation_author=Roshan Jha;,citation_author=Shaman Jhanji;,citation_author=Khoo Jian;,citation_author=Zhixin Jiao;,citation_author=Laura Jimenez;,citation_author=Ana Jimenez Gil;,citation_author=Jithin Jith;,citation_author=Teishel Joefield;,citation_author=Navraj Johal;,citation_author=Karine Johannessen;,citation_author=Aisyah Johari;,citation_author=Annie John;,citation_author=Anu John;,citation_author=Navin John;,citation_author=Emma Johns;,citation_author=Margaret Johns;,citation_author=Antoinette Johnson;,citation_author=Emma Johnson;,citation_author=Gillian Johnson;,citation_author=Kathryn Johnson;,citation_author=Katie Johnson;,citation_author=Luke Johnson;,citation_author=Mark Johnson;,citation_author=Nelsonseelan Johnson;,citation_author=Oliver Johnson;,citation_author=Claire Johnston;,citation_author=Janet Johnston;,citation_author=Susan Johnston;,citation_author=Victoria Johnston;,citation_author=Dawn Johnstone;,citation_author=Ed Johnstone;,citation_author=Janet Johnstone;,citation_author=Manohar Joishy;,citation_author=Adam Jones;,citation_author=Alistair Jones;,citation_author=Annabel Jones;,citation_author=Ben Jones;,citation_author=Bryony Jones;,citation_author=Carys Jones;,citation_author=Ceri Jones;,citation_author=Charlotte Jones;,citation_author=Christine E Jones;,citation_author=Debra Jones;,citation_author=Emily Jones;,citation_author=Gareth Jones;,citation_author=Geraldine Jones;,citation_author=Jac Jones;,citation_author=James Jones;,citation_author=Jonathon Jones;,citation_author=Julie Jones;,citation_author=Kate E Jones;,citation_author=Laura Jones;,citation_author=Laura M Jones;,citation_author=Louise Jones;,citation_author=Mathew Jones;,citation_author=Nicola Jones;,citation_author=Paul Jones;,citation_author=Rhianna Jones;,citation_author=Ruth E Jones;,citation_author=Samantha Jones;,citation_author=Sophie Jones;,citation_author=Stefanie Jones;,citation_author=Steve Jones;,citation_author=Taya Jones;,citation_author=Tim Jones;,citation_author=Tracey Jones;,citation_author=Ramya Jonnalagadda;,citation_author=Rebecca Jordache;,citation_author=Sanal Jose;,citation_author=Anna Joseph;,citation_author=P Aiden Joseph;,citation_author=Rosane Joseph;,citation_author=Sibet Joseph;,citation_author=Dhaara Joshi;,citation_author=Mehul Joshi;,citation_author=Pratichi Joshi;,citation_author=Benz Josiah;,citation_author=Tiffany Joyce;,citation_author=Adriel Ju Wen Kwek;,citation_author=Edward Jude;,citation_author=Parminder Judge;,citation_author=Jessica Juhl;,citation_author=Sirisha Jujjavarapu;,citation_author=Mark Juniper;,citation_author=Edmund Juszczak;,citation_author=Deepthi Jyothish;,citation_author=Kasamu Kabiru Dawa;,citation_author=Mark Kacar;,citation_author=Nikhil Kadam;,citation_author=Gail Kakoullis;,citation_author=Azad Kala Bhushan;,citation_author=Richard J K Kalayi;,citation_author=Roobala Kaliannan Periyasami;,citation_author=Efthymia Kallistrou;,citation_author=Seika Kalsoom;,citation_author=Elisa Kam;,citation_author=John Kamara;,citation_author=Ajay Kamath;,citation_author=Prakash Kamath;,citation_author=Ravindra Kamath;,citation_author=Siddharth A Kamerkar;,citation_author=Nick Kametas;,citation_author=Musaiwale Kamfose;,citation_author=Leia Kane;,citation_author=Osei Kankam;,citation_author=Thogulava Kannan;,citation_author=Abhinav Kant;,citation_author=Vikas Kapil;,citation_author=Ritoo Kapoor;,citation_author=Sonal Kapoor;,citation_author=Sourjya Kar;,citation_author=Janaka Kara;,citation_author=Rona Kark;,citation_author=Abhilasha Karkey;,citation_author=Nicholas Karunaratne;,citation_author=Natashja Kasianczuk;,citation_author=Vidya Kasipandian;,citation_author=Rizwan Kassam;,citation_author=Janarth Kathirgamachelvam;,citation_author=Victoria Katsande;,citation_author=Kulbinder Kaul;,citation_author=Daljit Kaur;,citation_author=Dervinder Kaur;,citation_author=Jasmin Kaur;,citation_author=Jaspreet Kaur;,citation_author=Zunaira Kausar;,citation_author=Mohammad A A Kawser;,citation_author=Andrea Kay;,citation_author=Sarah Kay;,citation_author=Jossy N Kayappurathu;,citation_author=Callum Kaye;,citation_author=Ahemd Kazeem;,citation_author=Rachel Kearns;,citation_author=Nichola Kearsley;,citation_author=Joanne Keating;,citation_author=John Keating;,citation_author=Liza Keating;,citation_author=Elizabeth Keddie-Gray;,citation_author=Breffni Keegan;,citation_author=Natalie Keenan;,citation_author=Jonathan Kefas;,citation_author=Stephen Kegg;,citation_author=Laura Keith;,citation_author=Uzoamaka Keke;,citation_author=Joanne Kellett;,citation_author=Alison Kelly;,citation_author=David Kelly;,citation_author=Diane Kelly;,citation_author=Dominic Kelly;,citation_author=Emma Kelly;,citation_author=Laura Kelly;,citation_author=Martin Kelly;,citation_author=Michael Kelly;,citation_author=Rosalind Kelly;,citation_author=Sinead Kelly;,citation_author=Stephen Kelly;,citation_author=Mary Kelly-Baxter;,citation_author=Marketa Keltos;,citation_author=Timothy Kemp;,citation_author=Alexandra Kendall-Smith;,citation_author=Sarah Kennard;,citation_author=Ann Kennedy;,citation_author=James Kennedy;,citation_author=Sophie Kennedy-Hay;,citation_author=Julia Kenny;,citation_author=Melanie Kent;,citation_author=Lynne Keogan;,citation_author=Alexander Keough;,citation_author=A Kerr;,citation_author=Andrew Kerr;,citation_author=Caroline Kerrison;,citation_author=Anthony Kerry;,citation_author=Helen Kerslake;,citation_author=Ian Kerslake;,citation_author=Helen Kerss;,citation_author=Jocelyn Keshet-Price;,citation_author=Evelyne Kestelyn;,citation_author=Georgina Keyte;,citation_author=Abdul Khadar;,citation_author=Ali Khalid;,citation_author=Muhammad U Khalid;,citation_author=Syed Khalid;,citation_author=Amir Khalil;,citation_author=Asma Khalil;,citation_author=Sijjad Khalil;,citation_author=Abubakar Khan;,citation_author=Ali Khan;,citation_author=Al-Imran Khan;,citation_author=Arham Khan;,citation_author=Asad Khan;,citation_author=Aurangzeb Khan;,citation_author=Burhan Khan;,citation_author=Fatimah Khan;,citation_author=Kausik Khan;,citation_author=Malik A Khan;,citation_author=Marria Khan;,citation_author=Mehrunnisha Khan;,citation_author=Mohammad Khan;,citation_author=Nayeem Khan;,citation_author=Omar Khan;,citation_author=Rahila Khan;,citation_author=Shabana Khan;,citation_author=Shahul Khan;,citation_author=Shoaib Khan;,citation_author=Tasaduksultan Khan;,citation_author=Waseem Khan;,citation_author=Usman F Khatana;,citation_author=Jibran Khatri;,citation_author=Jyoti Khatri;,citation_author=Hafiza Khatun;,citation_author=Taslima Khatun;,citation_author=Mena Kheia;,citation_author=Jacyntha Khera;,citation_author=Htet Htet Ei Khin;,citation_author=Najaf Khoja;,citation_author=Kiran Khokhar;,citation_author=Chloe Khurana;,citation_author=Faith Kibutu;,citation_author=Andrew Kidd;,citation_author=Michelle Kidd;,citation_author=Joe Kidney;,citation_author=Shane Kidney;,citation_author=Will Kieffer;,citation_author=James Kilbane;,citation_author=Caroline Kilby;,citation_author=Eliz Kilich;,citation_author=Eileen Killen;,citation_author=Susan Kilroy;,citation_author=Bomee Kim;,citation_author=Jee W Kim;,citation_author=Sarah Kimber;,citation_author=Andy King;,citation_author=Barbara King;,citation_author=J King;,citation_author=Jennifer King;,citation_author=Kirsten King;,citation_author=Rachel King;,citation_author=Sarah King;,citation_author=Victoria King;,citation_author=Emily King-Oakley;,citation_author=Laura Kingsmore;,citation_author=Fiona Kinney;,citation_author=Sidra Kiran;,citation_author=Jeremy Kirk;,citation_author=Jodie Kirk;,citation_author=Amy Kirkby;,citation_author=Emily Kirkham;,citation_author=Gemma Kirkman;,citation_author=Ursula Kirwan;,citation_author=Toby Kitching;,citation_author=Laura Kitto;,citation_author=Lauren Kittridge;,citation_author=Sarah Klaczek;,citation_author=Frieder Kleemann;,citation_author=Susan Kmachia;,citation_author=Christopher P Knapp;,citation_author=Lucy Knibbs;,citation_author=Alicia Knight;,citation_author=Fraser Knight;,citation_author=Marian Knight;,citation_author=Sarah Knight;,citation_author=Steven Knight;,citation_author=Tom Knight;,citation_author=Ellen Knights;,citation_author=Jane Knights;,citation_author=Martin Knolle;,citation_author=Carol Knott;,citation_author=Charlotte Knowles;,citation_author=Karen Knowles;,citation_author=Laurence Knowles;,citation_author=Emily Knox;,citation_author=Lucy Knox;,citation_author=Oliver Koch;,citation_author=Ronan Kodituwakku;,citation_author=Gouri Koduri;,citation_author=Aisha Koirata;,citation_author=Eirene Kolakaluri;,citation_author=Magdalena Kolodziej;,citation_author=Eirini Kolokouri;,citation_author=Samantha Kon;,citation_author=Niladri Konar;,citation_author=Mari Kononen;,citation_author=Athanasios Konstantinidis;,citation_author=Hui Fen Koo;,citation_author=Imogen Koopmans;,citation_author=Emmanuela Kopyj;,citation_author=Laura Korcierz;,citation_author=James Korolewicz;,citation_author=George Koshy;,citation_author=Chris Kosmidis;,citation_author=Jalpa Kotecha;,citation_author=Easwari Kothandaraman;,citation_author=Leonidas Koukouflis;,citation_author=Koushan Kouranloo;,citation_author=Rukhsana Kousar;,citation_author=Margarita Kousteni;,citation_author=Maja Kovac;,citation_author=Alex Kozak Eskenazia;,citation_author=Kestutis Krasauskas;,citation_author=Raghu Krishnamurthy;,citation_author=Vinodh Krishnamurthy;,citation_author=Manju Krishnan;,citation_author=Hari Krishnan;,citation_author=Suzanne Krizak;,citation_author=Sean Krupej;,citation_author=Agnieszka Kubisz-Pudelko;,citation_author=Soren Kudsk-Iversen;,citation_author=Aurimas Kudzinskas;,citation_author=Chirag Kukadiya;,citation_author=Nainesha Kulkarni;,citation_author=Aditi Kumar;,citation_author=Mayur Kumar;,citation_author=Ramesh Kumar;,citation_author=Ravi Kumar;,citation_author=Rita Kumar;,citation_author=Rupa Kumar;,citation_author=Satish Kumar;,citation_author=Vimal Kumar;,citation_author=Arun Kundu;,citation_author=Heinke Kunst;,citation_author=Amit Kurani;,citation_author=Mohammed Kurdy;,citation_author=Rincy Kurian;,citation_author=Vimal Kurmars;,citation_author=Cameron Kuronen-Stewart;,citation_author=Ranganai S Kusangaya;,citation_author=Vlad Kushakovsky;,citation_author=Apexa Kuverji;,citation_author=Amma Kyei-Mensah;,citation_author=Thyra Kyere-Diabour;,citation_author=Moe Kyi;,citation_author=Nyan May Kyi;,citation_author=Laura Kyle;,citation_author=Karali-Tsilimpari Kyriaki;,citation_author=Julius Labao;,citation_author=Louise Lacey;,citation_author=Nikki Lack;,citation_author=Emma Ladlow;,citation_author=Heather Lafferty;,citation_author=Shondipon Laha;,citation_author=Sushil Lahane;,citation_author=Clement Lai;,citation_author=James Lai;,citation_author=Robert Laing;,citation_author=Inez Laing-Faiers;,citation_author=Emily Laity;,citation_author=Nicki Lakeman;,citation_author=David Lalloo;,citation_author=Fiona Lalloo;,citation_author=Alison Lam;,citation_author=Fiona Lamb;,citation_author=Lucy Lamb;,citation_author=Thomas Lamb;,citation_author=Pauline Lambert;,citation_author=Claudia Lameirinhas;,citation_author=Mohammed K G Lami;,citation_author=Abigail Lamikanra;,citation_author=Holly Lamont;,citation_author=Michal Lamparski;,citation_author=Djillali Lamrani;,citation_author=Christine Lanaghan;,citation_author=Ivone Lancona-Malcolm;,citation_author=Geraldine Landers;,citation_author=Martin J Landray;,citation_author=Matthew Lane;,citation_author=Nicholas Lane;,citation_author=Alidih Lang;,citation_author=Stephen Lang;,citation_author=Daniel Langer;,citation_author=Margaret Langley;,citation_author=Charles Langoya;,citation_author=Emily Langthorne;,citation_author=Taiya Large;,citation_author=Wojciech Lason;,citation_author=Anna Last;,citation_author=Scott Latham;,citation_author=Victoria Latham;,citation_author=John Latham-Mollart;,citation_author=Afzal Latheef;,citation_author=Nang Latt;,citation_author=Dawn Lau;,citation_author=Eva Lau;,citation_author=Myra Laurenson;,citation_author=Hou Law;,citation_author=Jessica Law;,citation_author=Penny Law;,citation_author=Richard Law;,citation_author=Emma Lawrence;,citation_author=Neil Lawrence;,citation_author=Ryan Lawrie;,citation_author=Louise Lawson;,citation_author=Michael Lay;,citation_author=Christine Laycock;,citation_author=Reina Layug;,citation_author=Maria Lazo;,citation_author=Vietland Le;,citation_author=Amelia Lea;,citation_author=William Lea;,citation_author=Ian Leadbitter;,citation_author=Thomas Leahy;,citation_author=Richard Lean;,citation_author=Lorna Leandro;,citation_author=Darren Leaning;,citation_author=Sandra Leason;,citation_author=Marie A Ledingham;,citation_author=Emma Lee;,citation_author=Hannah Lee;,citation_author=Irish Lee;,citation_author=Judith Lee;,citation_author=Sam Lee;,citation_author=Shi Han Lee;,citation_author=Simon Lee;,citation_author=Sindy Lee;,citation_author=Stephanie Lee;,citation_author=Tracey Lee;,citation_author=Xiang Lee;,citation_author=Robyn Lee;,citation_author=Diana Lees;,citation_author=Jennifer Lees;,citation_author=Helen Legge;,citation_author=Julian Leggett;,citation_author=Katie Leigh-Ellis;,citation_author=Nicky Leitch;,citation_author=Eleni Lekoudis;,citation_author=Petula Lemessy;,citation_author=Nicholas Lemoine;,citation_author=Katy Leng;,citation_author=Katrina Lennon;,citation_author=Liz Lennon;,citation_author=Kelly Leonard;,citation_author=Wen Leong;,citation_author=Nicky Leopold;,citation_author=Oskar Lepiarczyk;,citation_author=Isla Leslie;,citation_author=Eleni Lester;,citation_author=Ullrich Leuschner;,citation_author=Emma Levell;,citation_author=Chris Levett;,citation_author=Alice Lewin;,citation_author=Alison Lewis;,citation_author=David Lewis;,citation_author=Dee Lewis;,citation_author=Joanne Lewis;,citation_author=Joseph Lewis;,citation_author=Kathryn Lewis;,citation_author=Keir Lewis;,citation_author=Leon Lewis;,citation_author=Marissa Lewis;,citation_author=Rob Lewis;,citation_author=Robert Lewis;,citation_author=Catherine Lewis-Clarke;,citation_author=Adam Lewszuk;,citation_author=Penny Lewthwaite;,citation_author=Samantha Ley;,citation_author=Angela Liao;,citation_author=Victoria Licence;,citation_author=David Lieberman;,citation_author=Susan Liebeschuetz;,citation_author=Nicky Lightfoot;,citation_author=Patrick Lillie;,citation_author=Ben Lim;,citation_author=Carys Lim;,citation_author=Ee Thong Lim;,citation_author=Ivy Lim;,citation_author=Terence Lim;,citation_author=Wei Shen Lim;,citation_author=Wilson Lim;,citation_author=James Limb;,citation_author=Usha Limbu;,citation_author=Christian Linares;,citation_author=Dermot Linden;,citation_author=Gabriella Lindergard;,citation_author=Kate Lindley;,citation_author=Charlotte Lindsay;,citation_author=Emily Lindsay;,citation_author=Max Lindsay;,citation_author=Helen Lindsay- Clarke;,citation_author=Mirella Ling;,citation_author=Claire Lingam;,citation_author=Linette Linkson;,citation_author=Mike Linney;,citation_author=Louise Linsell;,citation_author=Conrad Lippold;,citation_author=George Lipscomb;,citation_author=Karen Lipscomb;,citation_author=Laura Lipskis;,citation_author=Ana Lisboa;,citation_author=Evangeline Lister;,citation_author=Jeff Little;,citation_author=Sam Little;,citation_author=Xuedi Liu;,citation_author=Daniel K Llanera;,citation_author=Rhiannon Llewellyn;,citation_author=Martin Llewelyn;,citation_author=Aaron Lloyd;,citation_author=Adam Lloyd;,citation_author=Aimee Lloyd;,citation_author=Arwel Lloyd;,citation_author=Oliver Lloyd;,citation_author=Richard Lloyd;,citation_author=Su Lo;,citation_author=David Loader;,citation_author=Lydianne Lock;,citation_author=Sara Lock;,citation_author=Stephen Lock;,citation_author=Angela Locke;,citation_author=Jacqueline Locke;,citation_author=Thomas Locke;,citation_author=Teresa Lockett;,citation_author=Jeorghino Lodge;,citation_author=Martina Lofthouse;,citation_author=Heather Loftus;,citation_author=Meg Logan;,citation_author=Chloe A Logue;,citation_author=Sook Yin Loh;,citation_author=Siddharth Lokanathan;,citation_author=Kaatje Lomme;,citation_author=Emily London;,citation_author=Gabriella Long;,citation_author=Natalie Long;,citation_author=Bev Longhurst;,citation_author=Mark Longshaw;,citation_author=Jennifer Lonnen;,citation_author=Caroline Lonsdale;,citation_author=Laura Looby;,citation_author=Ronda Loosley;,citation_author=Paola Lopez;,citation_author=Paula Lopez;,citation_author=Robert Lord;,citation_author=Claire Lorimer;,citation_author=Francesco Loro;,citation_author=Rachel Lorusso;,citation_author=Robert Loveless;,citation_author=Maxine Lovell;,citation_author=Angeliki Loverdou;,citation_author=Andrew Low;,citation_author=Jen Mae Low;,citation_author=Alastair Lowe;,citation_author=Catherine Lowe;,citation_author=Emily Lowe;,citation_author=Faye Lowe;,citation_author=Michael Lowe;,citation_author=Richard Lowsby;,citation_author=Vicki Lowthorpe;,citation_author=Gamu Lubimbi;,citation_author=Alexandra Lubina Solomon;,citation_author=Georgia Lucas;,citation_author=Jacob Lucas;,citation_author=Alice Lucey;,citation_author=Olivia Lucey;,citation_author=Suzanne Luck;,citation_author=Akish Luintel;,citation_author=H Luke;,citation_author=Jane Luke;,citation_author=Naomi Lungu;,citation_author=Apurva Lunia;,citation_author=Muriel Lunn;,citation_author=Ji Luo;,citation_author=Cindy N Luximon;,citation_author=Barrie Lyell;,citation_author=Elisavet Lyka;,citation_author=Audrey Lynas;,citation_author=Ceri Lynch;,citation_author=Daniel Lynch;,citation_author=Daniella Lynch;,citation_author=Stephen Lynch;,citation_author=Rea-Grace Maamari;,citation_author=Hannah Mabb;,citation_author=Louies Mabelin;,citation_author=Jessica Macaro;,citation_author=Kateryna Macconaill;,citation_author=Chloe Macdonald;,citation_author=Claire Macfadyen;,citation_author=James G Macfarlane;,citation_author=Jill Macfarlane;,citation_author=Laura Macfarlane;,citation_author=Lisa MacInnes;,citation_author=Iain MacIntyre;,citation_author=Jill MacIntyre;,citation_author=Kirsten Mack;,citation_author=Callum Mackay;,citation_author=Euan Mackay;,citation_author=Laura Mackay;,citation_author=Alexander Mackenzie;,citation_author=Matt Mackenzie;,citation_author=Robert MacKenzie Ross;,citation_author=Ami Mackey;,citation_author=Fiona Mackie;,citation_author=Robert Mackie;,citation_author=Carolyn Mackinlay;,citation_author=Claire Mackintosh;,citation_author=Katherine Mackintosh;,citation_author=Mary J MacLeod;,citation_author=Michael Macmahon;,citation_author=Andrew MacNair;,citation_author=Catherine Macphee;,citation_author=Iain Macpherson;,citation_author=Catriona Macrae;,citation_author=Allan MacRaild;,citation_author=Alannah Madden;,citation_author=Mary Madden;,citation_author=Norman Madeja;,citation_author=Pradeep Madhivathanan;,citation_author=Madhavi Madhusudhana;,citation_author=Alpha Madu;,citation_author=Lorraine Madziva;,citation_author=Marion Mafham;,citation_author=Nick Magee;,citation_author=Frederick Magezi;,citation_author=Negar Maghsoodi;,citation_author=Christopher Magier;,citation_author=Marios Magriplis;,citation_author=Natasha Mahabir;,citation_author=Subramanian Mahadevan-Bava;,citation_author=Anjanie Maharajh;,citation_author=Kijan Maharjan;,citation_author=Ajit Mahaveer;,citation_author=Bal Mahay;,citation_author=Kanta Mahay;,citation_author=Hibo Mahdi;,citation_author=Thushika Mahendiran;,citation_author=Siva Mahendran;,citation_author=Sarah Maher;,citation_author=Anistta Maheswaran;,citation_author=Shameera Maheswaran;,citation_author=Tina Maheswaran;,citation_author=Parisa Mahjoob-Afag;,citation_author=Ahmed Mahmood;,citation_author=Farhana Mahmood;,citation_author=Waheed Mahmood;,citation_author=Zahra Mahmood;,citation_author=Hager Mahmoud;,citation_author=Ewan Mahony;,citation_author=Luke Mair;,citation_author=Toluwani Majekdunmi;,citation_author=Kesson Majid;,citation_author=Rupert Major;,citation_author=J Majumdar;,citation_author=Jaydip Majumdar;,citation_author=Mohammad K H Majumder;,citation_author=Stephen Makin;,citation_author=Marius Malanca;,citation_author=Hannah Malcolm;,citation_author=Flora Malein;,citation_author=Neeraj Malhan;,citation_author=Ayesha Malik;,citation_author=Gulshan Malik;,citation_author=Mohammed Maljk;,citation_author=Paul Mallett;,citation_author=Petrina Mallinder;,citation_author=Georgia Mallison;,citation_author=Louise Mallon;,citation_author=Edward Malone;,citation_author=Gracie Maloney;,citation_author=Madhu Mamman;,citation_author=Irene Man;,citation_author=Kathy Man;,citation_author=Rossana Mancinelli;,citation_author=Marco Mancuso-Marcello;,citation_author=Tracy Manders;,citation_author=Lauren Manderson;,citation_author=Justin Mandeville;,citation_author=Roope Manhas;,citation_author=Carmen Maniero;,citation_author=Ravi Manikonda;,citation_author=Bobby Mann;,citation_author=Jonathan Manning;,citation_author=Pascoe Mannion;,citation_author=Katherine Mansi;,citation_author=Katarina Manso;,citation_author=Dina Mansour;,citation_author=Isheunesu T Mapfunde;,citation_author=Predeesh Mappa;,citation_author=Hemant Maraj;,citation_author=Clare Marchand;,citation_author=Neil Marcus;,citation_author=Maria Marecka;,citation_author=Gomathi Margabanthu;,citation_author=Jordi Margalef;,citation_author=Lavinia Margarit;,citation_author=Georgios Margaritopoulos;,citation_author=Mike Margarson;,citation_author=Fernandez M Maria del Rocio;,citation_author=Teresa Maria Pfyl;,citation_author=Victor Mariano;,citation_author=Ashleigh Maric;,citation_author=Grace Markham;,citation_author=Maria Marks;,citation_author=P Marks;,citation_author=Elisabeth Marouzet;,citation_author=Arran Marriott;,citation_author=Cheryl Marriott;,citation_author=Nemonie Marriott;,citation_author=Brian Marsden;,citation_author=Christopher Marsden;,citation_author=Karen Marsden;,citation_author=Paul Marsden;,citation_author=Sarah Marsden;,citation_author=Tracy Marsden;,citation_author=Robyn Marsh;,citation_author=Adam Marshall;,citation_author=Andrew Marshall;,citation_author=Gail Marshall;,citation_author=Henry Marshall;,citation_author=Jaimie Marshall;,citation_author=Jenna Marshall;,citation_author=Nicola Marshall;,citation_author=Riley Marshall;,citation_author=Jennifer Marshall;,citation_author=Emmeline Martin;,citation_author=Hayley Martin;,citation_author=Hope Martin;,citation_author=Jane Martin;,citation_author=Karen Martin;,citation_author=Kate Martin;,citation_author=Laila Martin;,citation_author=Michael Martin;,citation_author=Noelia Martin;,citation_author=Tim Martin;,citation_author=Winston Martin;,citation_author=Sarah Martin;,citation_author=Tim Martindale;,citation_author=Marcus Martineau;,citation_author=Lauren Martinez;,citation_author=Jose C Martinez Garrido;,citation_author=Juan Martin-Lazaro;,citation_author=Lucas Martins Ferreira;,citation_author=Vijay K Maruthamuthu;,citation_author=Gemma Maryan;,citation_author=Roman Mary-Genetu;,citation_author=Sam Maryosh;,citation_author=Vidan Masani;,citation_author=Diego Maseda;,citation_author=Sheila Mashate;,citation_author=Yasaman Mashhoudi;,citation_author=Al Mashta;,citation_author=Izhaq Masih;,citation_author=Sanna Masih;,citation_author=Nick Maskell;,citation_author=Perry Maskell;,citation_author=Matthew Masoli;,citation_author=Rebecca Mason;,citation_author=Richard Mason;,citation_author=Ruth Mason;,citation_author=Claire Mason;,citation_author=Mohammad Masood;,citation_author=Mohammad T Masood;,citation_author=Syed S M E Masood;,citation_author=Aaqib Masud;,citation_author=Lear Matapure;,citation_author=Cristina Matei;,citation_author=Ropafadzo Matewe;,citation_author=Manraj Matharu;,citation_author=Stephy Mathen;,citation_author=Alex Mather;,citation_author=Nicole Mather;,citation_author=Jonathan Mathers;,citation_author=Joanna Matheson;,citation_author=Amal Mathew;,citation_author=Anna Mathew;,citation_author=Moncy Mathew;,citation_author=Verghese Mathew;,citation_author=Jesha Mathews;,citation_author=Kate Mathias;,citation_author=Alexander Mathioudakis;,citation_author=Darwin Matila;,citation_author=Wadzanai Matimba-Mupaya;,citation_author=Nashaba Matin;,citation_author=Elina Matisa;,citation_author=Max Matonhodze;,citation_author=Elijah Matovu;,citation_author=Jaysankar Mattappillil;,citation_author=Alison J Matthews;,citation_author=Heather Matthews;,citation_author=Helen Matthews;,citation_author=Fiona Maxton;,citation_author=Adam Maxwell;,citation_author=Veronica Maxwell;,citation_author=James May;,citation_author=Joanne May;,citation_author=Philippa May;,citation_author=Irving Mayanagao;,citation_author=Matthew Maycock;,citation_author=Graham Mayers;,citation_author=Victoria Maynard;,citation_author=Shelley Mayor;,citation_author=Ibreaheim Mazen;,citation_author=Andrea Mazzella;,citation_author=Nyambura Mburu;,citation_author=Eleanor McAleese;,citation_author=Paul McAlinden;,citation_author=Audrey McAlpine;,citation_author=Graeme McAlpine;,citation_author=Jonathan McAndrew;,citation_author=Hamish McAuley;,citation_author=Sarah McAuliffe;,citation_author=Claire McBrearty;,citation_author=Erin McBride;,citation_author=Michael McBuigan;,citation_author=James McBurney;,citation_author=Laura McCabe;,citation_author=Amanda McCairn;,citation_author=Jake McCammon;,citation_author=Nicole McCammon;,citation_author=Conor McCann;,citation_author=Erin McCann;,citation_author=Alexandra McCarrick;,citation_author=Brendan McCarron;,citation_author=Eoghan McCarthy;,citation_author=Michelle McCarthy;,citation_author=Natalie McCarthy;,citation_author=Sinead McCaughey;,citation_author=Gareth McChlery;,citation_author=Tara McClay;,citation_author=Beverley McClelland;,citation_author=Declan McClintock;,citation_author=Patricia McCormack;,citation_author=Jacqueline McCormick;,citation_author=Wendy McCormick;,citation_author=Paul McCourt;,citation_author=Jame McCrae;,citation_author=Sharon McCready;,citation_author=Gordan McCreath;,citation_author=Helen McCreedy;,citation_author=Iain J McCullagh;,citation_author=Liz McCullagh;,citation_author=Megan McCullagh;,citation_author=Conor McCullough;,citation_author=Katherine McCullough;,citation_author=Nicola McCullough;,citation_author=Sarah McCullough;,citation_author=Fiona McCurrach;,citation_author=Paula McDermott;,citation_author=Rory McDermott;,citation_author=Katharine McDevitt;,citation_author=Helen McDill;,citation_author=Basil McDonald;,citation_author=Claire McDonald;,citation_author=Debbie McDonald;,citation_author=Rob McDonald;,citation_author=Sam McDonald;,citation_author=Damhnaic McDonald;,citation_author=Rowan McDougall;,citation_author=Irene McEleavy;,citation_author=Julie McEntee;,citation_author=Evanna McEvoy;,citation_author=Ruth McEwen;,citation_author=Margaret McFadden;,citation_author=Denise McFarland;,citation_author=Margaret McFarland;,citation_author=Rachel McFarland;,citation_author=Erin McGarry;,citation_author=Lorcan McGarvey;,citation_author=Laura McGenily;,citation_author=Clodagh McGettigan;,citation_author=Michael McGettrick;,citation_author=Christopher McGhee;,citation_author=Fiona McGill;,citation_author=Sarah McGinnity;,citation_author=Hannah McGivern;,citation_author=Neil McGlinchey;,citation_author=Phil McGlone;,citation_author=Deborah McGlynn;,citation_author=Claire McGoldrick;,citation_author=Clare McGoldrick;,citation_author=Elizabeth McGough;,citation_author=Brendan McGrath;,citation_author=Amanda McGregor;,citation_author=Annemarie McGregor;,citation_author=Heather McGuinness;,citation_author=Sean McGuire;,citation_author=Tara McHugh;,citation_author=Caroline McInnes;,citation_author=Neil McInnes;,citation_author=Karen McIntyre;,citation_author=Mhairi McIntyre;,citation_author=Lorna McKay;,citation_author=Conor P McKeag;,citation_author=Madeleine McKee;,citation_author=Joseph McKeever;,citation_author=Shirley McKenna;,citation_author=Donogh McKeogh;,citation_author=Caroline McKerr;,citation_author=Anthony M McKie;,citation_author=Laura Mckie;,citation_author=Gerard McKnight;,citation_author=Heather McLachlan;,citation_author=Andrew McLaren;,citation_author=Barbara McLaren;,citation_author=Nicola McLarty;,citation_author=Maria McLaughlin;,citation_author=James McLay;,citation_author=Mary McLeish;,citation_author=Tina McLennan;,citation_author=Stewart McLure;,citation_author=Anne-Marie McMahon;,citation_author=Genevieve McMahon;,citation_author=Mike McMahon;,citation_author=Stephen McMahon;,citation_author=Terence McManus;,citation_author=Moyra McMaster;,citation_author=Paddy McMaster;,citation_author=Samuel McMeekin;,citation_author=Nicola McMillan;,citation_author=Jason McMinn;,citation_author=Liam McMorrow;,citation_author=Helen McNally;,citation_author=Fiona McNeela;,citation_author=Lynne McNeil;,citation_author=Claire McNeill;,citation_author=Shea McNeill;,citation_author=Una McNelis;,citation_author=Melanie McNulty;,citation_author=Roisin McNulty;,citation_author=Christopher McParland;,citation_author=Mark McPhail;,citation_author=Alison McQueen;,citation_author=Anna McSkeane;,citation_author=Denise McSorland;,citation_author=Gini McTaggart;,citation_author=Jacqueline McTaggart;,citation_author=Joanna Mead;,citation_author=Emma Meadows;,citation_author=Olivia Meakin;,citation_author=Ben Mearns;,citation_author=Claire Mearns;,citation_author=Kim Mears;,citation_author=William Mears;,citation_author=Manjula Meda;,citation_author=Ayren Mediana;,citation_author=Ross Medine;,citation_author=Thomas Medveczky;,citation_author=Sharon Meehan;,citation_author=Emily Meeks;,citation_author=Abbi Megan;,citation_author=Nevan Meghani;,citation_author=Salim Meghjee;,citation_author=Amina Mehar;,citation_author=Rohan Mehra;,citation_author=James Meiring;,citation_author=Rayane Mejri;,citation_author=Sabina Melander;,citation_author=Adriana-Stefania Melinte;,citation_author=Francesca Mellor;,citation_author=Samantha Mellor;,citation_author=Zoe Mellor;,citation_author=Katrina Mellows;,citation_author=Vladimir Melnic;,citation_author=Alice Melville;,citation_author=Julie Melville;,citation_author=Helen Membrey;,citation_author=Mark Mencias;,citation_author=Cheryl Mendonca;,citation_author=Alexander Mentzer;,citation_author=Dan Menzies;,citation_author=Sue Mepham;,citation_author=Oliver Mercer;,citation_author=Pauline Mercer;,citation_author=Arwa Merchant;,citation_author=Fatema Merchant;,citation_author=Mihaela Mercioniu;,citation_author=Megan Meredith;,citation_author=Marta Merida Morillas;,citation_author=Blair Merrick;,citation_author=Jack Merritt;,citation_author=Simon Merritt;,citation_author=Ekta Merwaha;,citation_author=Simon Message;,citation_author=Gabriel Metcalf-Cuenca;,citation_author=Benjamin Metcalfe;,citation_author=Kneale Metcalfe;,citation_author=Stella Metherell;,citation_author=Alexsandra Metryka;,citation_author=Louise Mew;,citation_author=Simon Meyrick;,citation_author=Nhlanhla Mguni;,citation_author=Atiqa Miah;,citation_author=Jagrul Miah;,citation_author=Nahima Miah;,citation_author=Gabriela Mic;,citation_author=Dariush Micallef;,citation_author=Alice Michael;,citation_author=Angiy Michael;,citation_author=Shery Michael;,citation_author=Natalia Michalak;,citation_author=Loredana Michalca-Mason;,citation_author=Janet Middle;,citation_author=Hayley Middleton;,citation_author=Jennifer T Middleton;,citation_author=Maeve Middleton;,citation_author=Sophie Middleton;,citation_author=Shelley Mieres;,citation_author=Loredana Mihalca-Mason;,citation_author=Theresia Mikolasch;,citation_author=Sarah Milgate;,citation_author=Colin Millar;,citation_author=Jonathan Millar;,citation_author=James Millard;,citation_author=David Miller;,citation_author=Johnathan Miller;,citation_author=Lucy Miller;,citation_author=Rachel Miller;,citation_author=Naomi Miller-Biot;,citation_author=Alex Miller-Fik;,citation_author=Louise Millett;,citation_author=Hazel Milligan;,citation_author=Iain Milligan;,citation_author=Caitlin Milliken;,citation_author=Katherine Millington;,citation_author=Samuel Millington;,citation_author=Helen Mills;,citation_author=Janet Mills;,citation_author=Helen Millward;,citation_author=Sebastian Millward;,citation_author=Rebecca Miln;,citation_author=Alice Milne;,citation_author=Charlotte Milne;,citation_author=Louise Milne;,citation_author=Joanne Milner;,citation_author=Zayar Min;,citation_author=Samuel Mindel;,citation_author=Chrissie Minnis;,citation_author=Paul Minnis;,citation_author=Jane Minton;,citation_author=Frederico Miranda;,citation_author=Taimur Mirza;,citation_author=Anjum Misbahuddin;,citation_author=Aseem Mishra;,citation_author=Biswa Mishra;,citation_author=Eleanor Mishra;,citation_author=Ritu Mishra;,citation_author=Sannidhya Misra;,citation_author=Deena Mistry;,citation_author=Heena Mistry;,citation_author=Dushyant Mital;,citation_author=Sarah Mitchard;,citation_author=Ben Mitchell;,citation_author=Piers Mitchell;,citation_author=Philip Mitchelmore;,citation_author=Andrew Mitra;,citation_author=Atideb Mitra;,citation_author=Sandip Mitra;,citation_author=Emma Moakes;,citation_author=Emma Moatt;,citation_author=Gita Modgil;,citation_author=Abdelrahman Mohamed;,citation_author=Arez Mohamed;,citation_author=Osab Mohamed;,citation_author=Waheed Mohammad;,citation_author=Aliabdulla Mohammed;,citation_author=Omer Mohammed;,citation_author=Yaser N S Mohammed;,citation_author=Bilal A Mohamud;,citation_author=Amr Moharram;,citation_author=Hoi-Ping Mok;,citation_author=Jonathan Mok;,citation_author=Christine Moller-Christensen;,citation_author=Mateus Mollet;,citation_author=Malid Molloholli;,citation_author=Aoife Molloy;,citation_author=Linda Molloy;,citation_author=Andrew Molyneux;,citation_author=Tasnim Momoniat;,citation_author=Holly Monaghan;,citation_author=Krista Monaghan;,citation_author=Shiva Mongolu;,citation_author=Tesha Monika;,citation_author=Katelyn Monsell;,citation_author=Mahmoud Montasser;,citation_author=Alan Montgomery;,citation_author=Hugh Montgomery;,citation_author=Prebashan Moodley;,citation_author=Margaret Moody;,citation_author=Nick Moody;,citation_author=Angela Moon;,citation_author=James Moon;,citation_author=Ji-Hye Moon;,citation_author=Maria Moon;,citation_author=May Moonan;,citation_author=Parvez Moondi;,citation_author=Alex Moore;,citation_author=Christopher Moore;,citation_author=David A J Moore;,citation_author=Faye Moore;,citation_author=Judith Moore;,citation_author=Laura Moore;,citation_author=Sally Moore;,citation_author=Sonia Moore;,citation_author=Rachel Moores;,citation_author=Ed Morab;,citation_author=Jose Morales;,citation_author=Nuria Moramorell;,citation_author=Louise Moran;,citation_author=Grishma Moray;,citation_author=Jeronimo Moreno-Cuesta;,citation_author=Amy Morgan;,citation_author=Caitlin Morgan;,citation_author=Christine Morgan;,citation_author=Colin Morgan;,citation_author=Lauren Morgan;,citation_author=Leila Morgan;,citation_author=Matthew Morgan;,citation_author=Patrick Morgan;,citation_author=Katie Morgan-Jones;,citation_author=Emily Morgan-Smith;,citation_author=Anna Morley;,citation_author=Thomas Morley;,citation_author=Wendy Morley;,citation_author=Anna Morris;,citation_author=Damian Morris;,citation_author=Fiona Morris;,citation_author=Helen Morris;,citation_author=Juliet Morris;,citation_author=Katie Morris;,citation_author=Laura Morris;,citation_author=Lucy Morris;,citation_author=Mary-Anne Morris;,citation_author=Niall Morris;,citation_author=Paul Morris;,citation_author=Sheila Morris;,citation_author=Susan Morris;,citation_author=Douglas Morrison;,citation_author=Moira Morrison;,citation_author=Scott Morrison;,citation_author=Mary Morrissey;,citation_author=Anna Morrow;,citation_author=Franca Morselli;,citation_author=Gordon Mortem;,citation_author=Valerie Mortland;,citation_author=Chelsea Morton;,citation_author=Gordon Morton;,citation_author=Priti Morzaria;,citation_author=Alison Moss;,citation_author=Charlotte Moss;,citation_author=Sarah Moss;,citation_author=Stuart Moss;,citation_author=Nicki Motherwell;,citation_author=Johanna Mouland;,citation_author=Caroline Moulds;,citation_author=Hilary Moulton;,citation_author=Elizabeth Mousley;,citation_author=Karen Moxham;,citation_author=Borja Moya;,citation_author=Quberkani Moyo;,citation_author=Eunice Mshengu;,citation_author=Sheila Mtuwa;,citation_author=Ali Muazzam;,citation_author=Iqtedar A Muazzam;,citation_author=Nykki Muchenje;,citation_author=Dalia Mudawi;,citation_author=Girish Muddegowda;,citation_author=Imran Mugal;,citation_author=Ahsan Mughal;,citation_author=Javaid Muglu;,citation_author=Javed Muhammad;,citation_author=Carol Muir;,citation_author=Dipak Mukherjee;,citation_author=Syed A A Mukhtar;,citation_author=Denise Mukimbiri;,citation_author=Peter Mulgrew;,citation_author=Ben Mulhearn;,citation_author=Arafat Mulla;,citation_author=Dee Mullan;,citation_author=Dileepkumar Mullasseril Kutten;,citation_author=Niall Mullen;,citation_author=Rosemary Mullett;,citation_author=Sandra Mulligan;,citation_author=Lana Mumelj;,citation_author=Andrew Mumford;,citation_author=Mohammed Munavvar;,citation_author=Henry Munby;,citation_author=Anne-Marie Munro;,citation_author=Sheila Munt;,citation_author=McDonald Mupudzi;,citation_author=Arshid Murad;,citation_author=Oluwatosin H Muraina;,citation_author=Koteshwara Muralidhara;,citation_author=Mhairi Murdoch;,citation_author=Jennifer Murira;,citation_author=Alison Murphy;,citation_author=Carl Murphy;,citation_author=Gail Murphy;,citation_author=Peter Murphy;,citation_author=Sheenagh Murphy;,citation_author=Simon Murphy;,citation_author=Clare Murray;,citation_author=David Murray;,citation_author=Eleanor Murray;,citation_author=Katie Murray;,citation_author=Kenneth Murray;,citation_author=Lisa Murray;,citation_author=Lorna Murray;,citation_author=Tracey Murray;,citation_author=Eoin Murtagh;,citation_author=Mithun Murthy;,citation_author=Catherine Murton;,citation_author=Rosie Murton;,citation_author=Neeka Muru;,citation_author=Rosemary Musanhu;,citation_author=Maimuna Mushabe;,citation_author=Omaisa Mushtaq;,citation_author=Ahmed M M Mustafa;,citation_author=Elhaytham Mustafa;,citation_author=Mustafa Mustafa;,citation_author=Ibrahim Mustapha;,citation_author=Zhain Mustufvi;,citation_author=Callum Mutch;,citation_author=Eric Mutema;,citation_author=Balakumar Muthukrishnan;,citation_author=Sheree Mutton;,citation_author=Natasha Muzengi;,citation_author=Memory Mwadeyi;,citation_author=Bettina Mwale;,citation_author=Esther Mwaura;,citation_author=Raji Myagerimath;,citation_author=Alice Myers;,citation_author=Sam Myers;,citation_author=Khin Swe Myint;,citation_author=Yadee Myint;,citation_author=Libor Myslivecek;,citation_author=Evelyn Nadar;,citation_author=Iftikhar Nadeem;,citation_author=Moosa Nadheem;,citation_author=Asma Naeem;,citation_author=Hassan Naeem;,citation_author=Salman Naeem;,citation_author=Samraiz Nafees;,citation_author=Mohamed Nafei;,citation_author=Thapas Nagarajan;,citation_author=Imrun Nagra;,citation_author=Deepak Nagra;,citation_author=Mina Naguib;,citation_author=Kirushthiga Naguleswaran;,citation_author=K Shonit Nagumantry;,citation_author=Kevin Naicker;,citation_author=Sarveshni Naidoo;,citation_author=Gireesha Naik;,citation_author=Rishi Naik;,citation_author=Samir Naik;,citation_author=Devu S Nair;,citation_author=Rajiv Nair;,citation_author=Tanushree Nair;,citation_author=Jay Naisbitt;,citation_author=Kerry Naismith;,citation_author=Sri Nallapareddy;,citation_author=Soum Nallapeta;,citation_author=Arumugan Nallasivan;,citation_author=Uttam Nanda;,citation_author=Aarti Nandani;,citation_author=Ali Raza Naqvi;,citation_author=Asadullah Naqvi;,citation_author=Sara Naqvi;,citation_author=Sophia Nasa;,citation_author=Dominic Nash;,citation_author=Nader Nasheed;,citation_author=Abdul Nasimudeen;,citation_author=Umer Nasir;,citation_author=Tahir Nasser;,citation_author=Anuja Natarajan;,citation_author=Geetha Natarajan;,citation_author=Nalin Natarajan;,citation_author=Nikhila Natarajan;,citation_author=Rajkumar Natarajan;,citation_author=Noel Nathaniel;,citation_author=Mala Nathvani;,citation_author=Priyan Nathwani;,citation_author=George Nava;,citation_author=Neena Navaneetham;,citation_author=Jeya Navaratnam;,citation_author=Helen Navarra;,citation_author=Sadaf Naveed;,citation_author=John Navin;,citation_author=Khuteja Nawaz;,citation_author=Sarfaraz Nawaz;,citation_author=Shasta Nawaz;,citation_author=Bonilla Nayar;,citation_author=Suzanne Naylor;,citation_author=Moez Nayyar;,citation_author=Farrah Naz;,citation_author=Mobeena Naz;,citation_author=Babak Nazari;,citation_author=S Nazir;,citation_author=Sehar Nazir;,citation_author=Dumisani Ncomanzi;,citation_author=Onyine Ndefo;,citation_author=Alan Neal;,citation_author=Elaine Neary;,citation_author=Mostafa Negmeldin;,citation_author=Paula Neill;,citation_author=Hector E Neils;,citation_author=Avideah Nejad;,citation_author=Louise Nel;,citation_author=Marie Nelson;,citation_author=Richard Nelson;,citation_author=Scott Nelson;,citation_author=Erni Nelwan;,citation_author=Rajesh Nemane;,citation_author=Samiksha Nepal;,citation_author=Daniel Nethercott;,citation_author=Kimberley Netherton;,citation_author=Kimberley Nettleton;,citation_author=Alison Newby;,citation_author=Angela Newby;,citation_author=David Newby;,citation_author=Tracy Newcombe;,citation_author=Diana Newman;,citation_author=Julie Newman;,citation_author=Oscar Newman;,citation_author=Tabitha Newman;,citation_author=Thomas Newman;,citation_author=Rachel Newport;,citation_author=Maria Newton;,citation_author=Anthony Y K C Ng;,citation_author=Ka Wing Ng;,citation_author=Maxine Ng;,citation_author=Sarah Ng;,citation_author=Wee Jin Ng;,citation_author=Thomas Ngan;,citation_author=Gabriel CE Ngui;,citation_author=Alice Ngumo;,citation_author=Caoimhe Nic Fhogartaigh;,citation_author=Nathalie Nicholas;,citation_author=Philip Nicholas;,citation_author=Donna Nicholls;,citation_author=Lisa Nicholls;,citation_author=Alice Nicholson;,citation_author=Anne Nicholson;,citation_author=Annette Nicholson;,citation_author=Ian Nickson;,citation_author=Eileen Nicol;,citation_author=Elizabeth Nicol;,citation_author=Rebecca Nicol;,citation_author=Pantelis Nicola;,citation_author=Antony Nicoll;,citation_author=Pantzaris Nikolaos;,citation_author=Georgii Nikonovich;,citation_author=Annette Nilsson;,citation_author=Kofi Nimako;,citation_author=Louise Nimako;,citation_author=Camus Nimmo;,citation_author=Preethy Ninan;,citation_author=Mahesh Nirmalan;,citation_author=Muhammad Nisar;,citation_author=Toby Nisbett;,citation_author=Aksinya Nisha James;,citation_author=Sabaahat Nishat;,citation_author=Tomoko Nishiyama;,citation_author=Sara Nix;,citation_author=Jennifer Nixon;,citation_author=Maxine Nixon;,citation_author=Khwaja Nizam Ud Din;,citation_author=Maria Nizami;,citation_author=Lyrics Noba;,citation_author=Harriet Noble;,citation_author=Hsu M Noe;,citation_author=Jerry Nolan;,citation_author=Zahid Noor;,citation_author=Zaid Noori;,citation_author=Louis Norman;,citation_author=Rachel Norman;,citation_author=Karen Norris;,citation_author=Lillian Norris;,citation_author=Sally Ann Nortcliffe;,citation_author=Fiona North;,citation_author=Julie North;,citation_author=Thomas North;,citation_author=John Northfield;,citation_author=Samantha Northover;,citation_author=Jurgens Nortje;,citation_author=Donna Norton;,citation_author=Rowen Norton;,citation_author=Holly Notman;,citation_author=Khalid Nourein;,citation_author=Timea Novak;,citation_author=Mohamed Nugdallah;,citation_author=Anne Marie Nugent;,citation_author=Justine Nugent;,citation_author=Kribashnie Nundlall;,citation_author=Arvind Nune;,citation_author=Kieran Nunn;,citation_author=Michelle Nunn;,citation_author=Jane Nunnick;,citation_author=Yvonne Nupa;,citation_author=Zubeir Nurgat;,citation_author=Godfrey Nyamugunduru;,citation_author=Maggie Nyirenda;,citation_author=Kerry Nyland;,citation_author=Daire O Shea;,citation_author=Chloe O’Hara;,citation_author=Kevin O’Reilly;,citation_author=William O’Rourke;,citation_author=Caroline Oakley;,citation_author=Begho Obale;,citation_author=Clements Oboh;,citation_author=Clare O’Brien;,citation_author=Julie O’Brien;,citation_author=Kirsty O’Brien;,citation_author=Linda O’Brien;,citation_author=Neale O’Brien;,citation_author=Rachel O’Brien;,citation_author=Tracey O’Brien;,citation_author=Emma O’Bryan;,citation_author=Ross Obukofe;,citation_author=Christopher O’Callaghan;,citation_author=Lorcan O’Connell;,citation_author=Tadg OConnor;,citation_author=Chris O’Connor;,citation_author=Grainne O’Connor;,citation_author=Miranda Odam;,citation_author=Sam Oddie;,citation_author=Sharon Oddy;,citation_author=Yejide Odedina;,citation_author=Krishma Odedra;,citation_author=Sven W Odelberg;,citation_author=Natasha Odell;,citation_author=Omolola Oderinde;,citation_author=Jessica Odone;,citation_author=Catherine O’Donovan;,citation_author=Stephen O’Farrell;,citation_author=Pamela Offord;,citation_author=Tanwa Ogbara;,citation_author=Catherine Ogilvie;,citation_author=Ciaran O’Gorman;,citation_author=Oluwatomilola Ogunkeye;,citation_author=Udeme Ohia;,citation_author=Shinjali Ohja;,citation_author=Ohiowele Ojo;,citation_author=Mark O’Kane;,citation_author=Tolu Okeke;,citation_author=Eleanor OKell;,citation_author=Alicia Okines;,citation_author=Iheoma Okpala;,citation_author=Ernest Okpo;,citation_author=F Okpoko;,citation_author=Maryanne Okubanjo;,citation_author=Raphael Olaiya;,citation_author=Tim Old;,citation_author=Gregory Oleszkiewicz;,citation_author=Marta Oliveira;,citation_author=Annie Oliver;,citation_author=Catherine Oliver;,citation_author=Jesse Oliver;,citation_author=Martyn Oliver;,citation_author=Zoe Oliver;,citation_author=Nurudeen O Olokoto;,citation_author=Folusho Olonipile;,citation_author=Olumide Olufuwa;,citation_author=Olatomiwa Olukoya;,citation_author=Akinlolu Oluwole-Ojo;,citation_author=Laura O’Malley;,citation_author=Maryam Omar;,citation_author=Zohra Omar;,citation_author=Nimca Omer;,citation_author=Connaire O’Neill;,citation_author=Lauran O’Neill;,citation_author=Chon Sum Ong;,citation_author=Chidera Onyeagor;,citation_author=Huah Chiang Ooi;,citation_author=Amin Oomatia;,citation_author=Maria Opena;,citation_author=Richard Oram;,citation_author=Christy Ord;,citation_author=Jonathan Ord;,citation_author=Lola Orekoya;,citation_author=Devaki O’Riordan;,citation_author=Sean O’Riordan;,citation_author=Amy Orme;,citation_author=Hannah Orme;,citation_author=Charlotte Orr;,citation_author=Sarah Orr;,citation_author=Christopher Orton;,citation_author=Anna Osadcow;,citation_author=Rawlings Osagie;,citation_author=Rostam Osanlou;,citation_author=Lynn Osborne;,citation_author=Nigel Osborne;,citation_author=Rebecca Osborne;,citation_author=Wendy Osborne;,citation_author=William Osborne;,citation_author=Charles Osbourne;,citation_author=Jennifer Osei-Bobie;,citation_author=Joseph Osman;,citation_author=Wa’el Osman;,citation_author=Bashir Osman;,citation_author=G Osoata;,citation_author=Marlies Ostermann;,citation_author=Eoin O’Sullivan;,citation_author=Susan O’Sullivan;,citation_author=Noor Otey;,citation_author=Otheroro K Otite;,citation_author=Marie O’Toole;,citation_author=Ashley David Otter;,citation_author=Rachel Owen;,citation_author=Stephanie Owen;,citation_author=Emma Owens;,citation_author=Yetunde Owoseni;,citation_author=Michael Owston;,citation_author=Ruth Oxlade;,citation_author=Feray Ozdes;,citation_author=Jamie Pack;,citation_author=Sophie Packham;,citation_author=Piotr Paczko;,citation_author=Grace Padden;,citation_author=Anand Padmakumar;,citation_author=Iain Page;,citation_author=Joseph Page;,citation_author=Valerie Page;,citation_author=Jodi Paget;,citation_author=Katherine Pagett;,citation_author=Lee Paisley;,citation_author=Susie Pajak;,citation_author=Angela Pakozdi;,citation_author=Soubhik Pal;,citation_author=Sushi Pal;,citation_author=April Palacios;,citation_author=Vishnu B Palagiri Sai;,citation_author=Vadivu Palaniappan;,citation_author=Priya Palanivelu;,citation_author=Adrian Palfreeman;,citation_author=Deepshikha Palit;,citation_author=Alistair Palmer;,citation_author=Lynne Palmer;,citation_author=Ian Pamphlett;,citation_author=Daniel Pan;,citation_author=Anmol Pandey;,citation_author=Nithya Pandian;,citation_author=Krishnaa Pandya;,citation_author=Tej Pandya;,citation_author=Alice Panes;,citation_author=Yee Wei Pang;,citation_author=Laura Pannell;,citation_author=Kanwar Pannu;,citation_author=Suman Pant;,citation_author=Sathianathan Panthakalam;,citation_author=Charles T Pantin;,citation_author=Norman Pao;,citation_author=Helen Papaconstantinou;,citation_author=Padmasayee Papineni;,citation_author=Kitty Paques;,citation_author=Kerry Paradowski;,citation_author=Vinay Parambil;,citation_author=Supathum Paranamana;,citation_author=Siddhant R Parashar;,citation_author=Ian Parberry;,citation_author=Amy Parekh;,citation_author=Dhruv Parekh;,citation_author=Louise Parfitt;,citation_author=Helen Parfrey;,citation_author=Omi Parikh;,citation_author=Gemma Parish;,citation_author=John Park;,citation_author=Angela Parker;,citation_author=Ben Parker;,citation_author=Emma Parker;,citation_author=Jacob Parker;,citation_author=Julie Parker;,citation_author=Laura Parker;,citation_author=Lucy Parker;,citation_author=Sara Parker;,citation_author=Sean Parker;,citation_author=Kirstin Parkin;,citation_author=Anna Parkinson;,citation_author=Valerie Parkinson;,citation_author=Chetan Parmar;,citation_author=Viraj Parmar;,citation_author=Victoria Parris;,citation_author=Helen C Parry;,citation_author=Siobhan Parslow-Williams;,citation_author=Maria Parsonage;,citation_author=Penny Parsons;,citation_author=Richard Partridge;,citation_author=Kevin Parvin;,citation_author=Lauren Passby;,citation_author=Samuel Passey;,citation_author=Juan Pastrana;,citation_author=Mital Patal;,citation_author=Sarah Patch;,citation_author=Aamie Patel;,citation_author=Alkesh Patel;,citation_author=Amisha Patel;,citation_author=Dakshesh Patel;,citation_author=Darshna Patel;,citation_author=Hemani Patel;,citation_author=Jaymik Patel;,citation_author=Kamal Patel;,citation_author=Kayur Patel;,citation_author=Kiran Patel;,citation_author=Krish Patel;,citation_author=Manish Patel;,citation_author=Martyn Patel;,citation_author=Mehul Patel;,citation_author=Naleem Patel;,citation_author=Nehalbhai Patel;,citation_author=Prital Patel;,citation_author=Saagar Patel;,citation_author=Soonie Patel;,citation_author=Trishna Patel;,citation_author=Vishal Patel;,citation_author=Sangeeta Pathak;,citation_author=Nazima Pathan;,citation_author=Alexandra Patience;,citation_author=Donna Patience;,citation_author=Abigail Patrick;,citation_author=Georgie Patrick;,citation_author=Jean Patrick;,citation_author=Simon Patten;,citation_author=Ben Pattenden;,citation_author=Charlotte Patterson;,citation_author=Linda Patterson;,citation_author=Molly Patterson;,citation_author=Robert Patterson;,citation_author=Suman Paul;,citation_author=Leigh Pauls;,citation_author=Stephane Paulus;,citation_author=Amelia Pavely;,citation_author=Susan Pavord;,citation_author=Brendan Payne;,citation_author=Elizabeth Payne;,citation_author=Ruth Payne;,citation_author=Linda Peacock;,citation_author=Louise Peacock;,citation_author=Sarah Peacock;,citation_author=Henry Peake;,citation_author=Jasmine Pearce;,citation_author=Rupert Pearse;,citation_author=Andrew Pearson;,citation_author=Daniel Pearson;,citation_author=Harriet Pearson;,citation_author=Karen Pearson;,citation_author=Samuel A Pearson;,citation_author=Sandra Pearson;,citation_author=Alice Peasley;,citation_author=Hilary Peddie;,citation_author=Russell Peek;,citation_author=Claire Pegg;,citation_author=Suzannah Peglar;,citation_author=Benjamin H Peirce;,citation_author=Claire Pelham;,citation_author=Abigail Pemberton;,citation_author=Melchizedek Penacerrada;,citation_author=Anthony Pender;,citation_author=Carmel Pendlebury;,citation_author=Jessica Pendlebury;,citation_author=Rachel Penfold;,citation_author=Catherine Penman;,citation_author=Julie Penman;,citation_author=Rachel Penman;,citation_author=Justin Penner;,citation_author=Kristi Penney;,citation_author=James Penny;,citation_author=Justin Pepperell;,citation_author=Adriana Pereira;,citation_author=Rita Pereira;,citation_author=Carlota Pereira Dias Alves;,citation_author=Elena Perez;,citation_author=Jane Perez;,citation_author=Tanaraj Perinpanathan;,citation_author=Lakshmi Periyasamy;,citation_author=Elizabeth Perritt;,citation_author=Alison Perry;,citation_author=Emily Perry;,citation_author=Meghan Perry;,citation_author=Thomas M Perumpral;,citation_author=Guilherme Pessoa-Amorim;,citation_author=Ruth Petch;,citation_author=Lionel Peter;,citation_author=Cecilia Peters;,citation_author=Mark Peters;,citation_author=Steve Peters;,citation_author=Tim Peters;,citation_author=Remy Petersen;,citation_author=Alexandra Peterson;,citation_author=Leon Peto;,citation_author=Iulia Petras;,citation_author=Boyanka Petrova;,citation_author=Mirela Petrova;,citation_author=Paul Pfeffer;,citation_author=Mysore Phanish;,citation_author=Paul Phelan;,citation_author=Christopher Philbey;,citation_author=Jennifer Philbin;,citation_author=Alex Phillips;,citation_author=Dylan Phillips;,citation_author=Rachael Phillips;,citation_author=Marie Phipps;,citation_author=Virach Phongsathorn;,citation_author=Mandeep Phull;,citation_author=Sara Pick;,citation_author=James Pickard;,citation_author=Charlotte Pickering;,citation_author=Gillian Pickering;,citation_author=Thomas Pickett;,citation_author=Hayleah Pickford;,citation_author=Joanna Pickles;,citation_author=Benjamin Pickwell-Smith;,citation_author=Natalia Pieniazek;,citation_author=Charlie Piercy;,citation_author=Angelo Pieris;,citation_author=Samia Pilgrim;,citation_author=Paul A Pillai;,citation_author=Zoe Pilsworth;,citation_author=Heather Pinches;,citation_author=Stacey Pinches;,citation_author=Kirsty Pine;,citation_author=Muni T Pinjala;,citation_author=Stefania Pintus;,citation_author=Graeme Piper;,citation_author=Tasneem Pirani;,citation_author=Marcus Pittman;,citation_author=Sally Pitts;,citation_author=Nicolene Plaatjies;,citation_author=Naomi Platt;,citation_author=Robert Pleass;,citation_author=Rutger Ploeg;,citation_author=Laura Plummer;,citation_author=Charles Plumptre;,citation_author=Jonathan Pobjoy;,citation_author=Tatiana Pogreban;,citation_author=Stephen Poku;,citation_author=Rachel Pollard;,citation_author=Louisa Pollock;,citation_author=Oluwamayowa Poluyi;,citation_author=Gary John Polwarth;,citation_author=Fiona Pomery;,citation_author=Ponmurugan Ponnusamy;,citation_author=Suresh Ponnusamy;,citation_author=Aravind Ponnuswamy;,citation_author=Inês Ponte Bettencourt dos Reis;,citation_author=Suman Pooboni;,citation_author=Alice Poole;,citation_author=Lynda Poole;,citation_author=Michele Poole;,citation_author=Sharon Poon;,citation_author=Tajinder Poonian;,citation_author=David Porter;,citation_author=Jo Porter;,citation_author=Linda Porter;,citation_author=Ross Porter;,citation_author=Kelly Postlethwaite;,citation_author=Narayana Pothina;,citation_author=Priyadarshan Potla;,citation_author=Dorota Potoczna;,citation_author=Jason Pott;,citation_author=Alison Potter;,citation_author=Jean Potter;,citation_author=Sarah Potter;,citation_author=Tracey Potter;,citation_author=Elspeth Potton;,citation_author=Joanne B Potts;,citation_author=Julie Potts;,citation_author=Kathryn Potts;,citation_author=Beli Poudyal;,citation_author=Una Poultney;,citation_author=Katherine Poulton;,citation_author=Vanessa Poustie;,citation_author=James Powell;,citation_author=Jordan Powell;,citation_author=Deborah Power;,citation_author=Nick Power;,citation_author=Gillian Powter;,citation_author=Joseph Poxon;,citation_author=Robin Poyner;,citation_author=Vidushi Pradhan;,citation_author=Helena Prady;,citation_author=Aalekh Prasad;,citation_author=Krishna Prasad;,citation_author=Fredy Prasanth Raj;,citation_author=Sangeetha Prasath;,citation_author=Sindhuja Pratheepkumar;,citation_author=Anezka Pratley;,citation_author=Steven Pratt;,citation_author=David Preiss;,citation_author=Claire Prendergast;,citation_author=Lynn Prentice;,citation_author=Peter Prentice;,citation_author=Verity Prescott;,citation_author=Laura Presland;,citation_author=Catharine Prest;,citation_author=Stephen Preston;,citation_author=Martha Pretorius;,citation_author=Natalie Prevatt;,citation_author=Sandra Prew;,citation_author=Ashley Price;,citation_author=Carly Price;,citation_author=Claire Price;,citation_author=David Price;,citation_author=Elizabeth Price;,citation_author=Nathan Price;,citation_author=Vivien Price;,citation_author=Anne Priest;,citation_author=Jimena Prieto;,citation_author=Lorraine Primrose;,citation_author=Clare Prince;,citation_author=Judith Prince;,citation_author=Laura Prince;,citation_author=Shirley Pringle;,citation_author=Veronika Pristopan;,citation_author=Kelly Pritchard;,citation_author=Lucy Pritchard;,citation_author=Simon Pritchard;,citation_author=Verma Priyash;,citation_author=Andrew Procter;,citation_author=Clare Proctor;,citation_author=Rebecca Proudfoot;,citation_author=Ben Prudon;,citation_author=David Pryor;,citation_author=Solomon Pudi;,citation_author=Joanne Pugh;,citation_author=Lawrence Pugh;,citation_author=Mark T Pugh;,citation_author=Nichola Pugh;,citation_author=Richard Pugh;,citation_author=Veronika Puisa;,citation_author=Kirandip Punia;,citation_author=Saleel Punnilath Abdulsamad;,citation_author=Laura Purandare;,citation_author=Daniel Purchase;,citation_author=Corrina Purdue;,citation_author=Bally Purewal;,citation_author=Molly Pursell;,citation_author=Gregory Purssord;,citation_author=Rory Purves;,citation_author=Sarah Purvis;,citation_author=Khairunnisa Puspatriani;,citation_author=Kathryn Puxty;,citation_author=Zoe Puyrigaud;,citation_author=Michael Pynn;,citation_author=Tariq Qadeer;,citation_author=Mohammad Qayum;,citation_author=Corrine Quah;,citation_author=Sheena Quaid;,citation_author=Nathaniel Quail;,citation_author=Charlotte Quamina;,citation_author=Alice Quayle;,citation_author=Eleanor Quek;,citation_author=Siobhan Quenby;,citation_author=Xinyi Qui;,citation_author=Vanessa Quick;,citation_author=Julie Quigley;,citation_author=Juan-Carlos Quijano-Campos;,citation_author=Andrew Quinn;,citation_author=James Quinn;,citation_author=Tom Quinn;,citation_author=Quratulain Quratulain;,citation_author=Danya Qureshi;,citation_author=Ehsaan Qureshi;,citation_author=Hasanain Qureshi;,citation_author=Khadija Qureshi;,citation_author=Nawaz Qureshi;,citation_author=Qurratulain Qurratulain;,citation_author=Saad Qutab;,citation_author=Muhammad S Rabbani;,citation_author=Simon Rabinowicz;,citation_author=Madalina Raceala;,citation_author=Raissa Rachman;,citation_author=Laura Rad;,citation_author=Jane Radford;,citation_author=Liz Radford;,citation_author=Jayachandran Radhakrishnan;,citation_author=Cecillia Rafique;,citation_author=Jethin Rafique;,citation_author=Muhammad Rafique;,citation_author=Ravi Ragatha;,citation_author=Aiswarya Raghunathan;,citation_author=Abigail Raguro;,citation_author=Shankho D Raha;,citation_author=Sana Rahama;,citation_author=Mutia Rahardjani;,citation_author=Karen Rahilly;,citation_author=Faisal Rahim;,citation_author=Abdul H Rahimi;,citation_author=Haseena R Rahimi;,citation_author=Muhammad Rahman;,citation_author=Salim Ur Rahman;,citation_author=Prajan Rai;,citation_author=Lenka Raisova;,citation_author=Arjun Raj;,citation_author=Pradeep Rajagopalan;,citation_author=Nithy Rajaiah;,citation_author=Kanendran Rajalingam;,citation_author=Arvind Rajasekaran;,citation_author=Aylur Rajasri;,citation_author=Sagar Rajbhandari;,citation_author=Thurkka Rajeswaran;,citation_author=Jyothi Rajeswary;,citation_author=Jeyanthy Rajkanna;,citation_author=Gayathri Rajmohan;,citation_author=Ruth Rallan;,citation_author=Katherine Ralston;,citation_author=Maximilian Ralston;,citation_author=Matsa Ram;,citation_author=Balaji Ramabhadran;,citation_author=Fathima Ramali;,citation_author=Mohamed Ramali;,citation_author=Athimalaipet Ramanan;,citation_author=Shashikira Ramanna;,citation_author=Maheshi Ramasamy;,citation_author=Irfah Rambe;,citation_author=Dhanishta Ramdin;,citation_author=Jozel Ramirez;,citation_author=Mylah Ramirez;,citation_author=Geshwin Ramnarain;,citation_author=Lidia Ramos;,citation_author=Tommy Rampling;,citation_author=Shanthi Ramraj;,citation_author=Alex Ramshaw;,citation_author=Aleem Rana;,citation_author=Ghulam F Rana;,citation_author=Rehman Rana;,citation_author=Abby Rand;,citation_author=James Rand;,citation_author=Harpal Randheva;,citation_author=Poonam Ranga;,citation_author=Manmeet Rangar;,citation_author=Harini Rangarajan;,citation_author=Sameer Ranjan;,citation_author=Hannah Rank;,citation_author=Poormina Ranka;,citation_author=Rajesh Rankhelawon;,citation_author=Anita Rao;,citation_author=Sandhya Rao;,citation_author=Sanjay Rao;,citation_author=Deepak Rao;,citation_author=Althaf A Rasheed;,citation_author=Khalid Rashid;,citation_author=Simbisai Ratcliff;,citation_author=Sam Ratcliffe;,citation_author=Sophy Ratcliffe;,citation_author=Sanjeev Rath;,citation_author=Mohmad I Rather;,citation_author=Selina Rathore;,citation_author=Aravinden Ratnakumar;,citation_author=Jonathan Ratoff;,citation_author=Deepa Rattehalli;,citation_author=Jason Raw;,citation_author=Rachael Raw;,citation_author=Hywel Rawlins;,citation_author=Gautam Ray;,citation_author=Adam Raymond-White;,citation_author=Dana Raynard;,citation_author=Nicola Rayner;,citation_author=Amy Raynsford;,citation_author=Salman Razvi;,citation_author=Zarine Razvi;,citation_author=Kerry Read;,citation_author=Sarah Read;,citation_author=Ajay Reddy;,citation_author=Anvesh Reddy;,citation_author=Harsha Reddy;,citation_author=Aine Redfern-Walsh;,citation_author=Alex Redome;,citation_author=Joan Redome;,citation_author=Anna Reed;,citation_author=John Reed;,citation_author=Andrew Rees;,citation_author=James Rees;,citation_author=Martyn Rees;,citation_author=Sarah Rees;,citation_author=Stephanie Rees;,citation_author=Tabitha Rees;,citation_author=Fiona Regan;,citation_author=Karen Regan;,citation_author=Susan Regan;,citation_author=Kanchan Rege;,citation_author=Ahmed Rehan;,citation_author=A Rehman;,citation_author=Shoib Rehman;,citation_author=Zainab Rehman;,citation_author=Ada Reid;,citation_author=Andrew Reid;,citation_author=Jennifer Reid;,citation_author=Jeremy Reid;,citation_author=Sharon Reid;,citation_author=Mkyla Reilly;,citation_author=Christina Reith;,citation_author=Alda Remegoso;,citation_author=Dinakaran Rengan;,citation_author=Stephen Renshaw;,citation_author=Remya Renu Vattekkat;,citation_author=Henrik Reschreiter;,citation_author=Mark Revels;,citation_author=Glynis Rewitzky;,citation_author=Severine Rey;,citation_author=Charles Reynard;,citation_author=Dominic Reynish;,citation_author=Peter Reynolds;,citation_author=Piero Reynolds;,citation_author=Jonathan Rhodes;,citation_author=Naghma Riaz;,citation_author=Emily Rice;,citation_author=Matthew Rice;,citation_author=Mel Rich;,citation_author=Alex Richards;,citation_author=Alison Richards;,citation_author=Liz Richards;,citation_author=Suzanne Richards;,citation_author=Celia Richardson;,citation_author=Julie Richardson;,citation_author=Neil Richardson;,citation_author=Nicky Richardson;,citation_author=Joanne Riches;,citation_author=Katie Riches;,citation_author=Leah Richmond;,citation_author=Ruth Richmond;,citation_author=William Ricketts;,citation_author=Hannah Rickman;,citation_author=Anna Riddell;,citation_author=Mohamed Ridha;,citation_author=Carrie Ridley;,citation_author=Paul Ridley;,citation_author=Gudrun Rieck;,citation_author=Linsey Rigby;,citation_author=Samita Rijal;,citation_author=Hannah Riley;,citation_author=Matthew Riley;,citation_author=Phil Riley;,citation_author=Atika Rimainar;,citation_author=Zwesty V P Rimba;,citation_author=Dominic Rimmer;,citation_author=Robert Rintoul;,citation_author=Andrew Riordan;,citation_author=David Ripley;,citation_author=Naomi Rippon;,citation_author=Chloe Rishton;,citation_author=Michael Riste;,citation_author=David Ritchie;,citation_author=Jane Ritchie;,citation_author=Andy Ritchings;,citation_author=Pilar Rivera Ortega;,citation_author=Vanessa Rivers;,citation_author=Batool Rizvi;,citation_author=Syed AS Rizvi;,citation_author=Syed H M Rizvi;,citation_author=James Robb;,citation_author=David J Roberts;,citation_author=Ian Roberts;,citation_author=Jane Roberts;,citation_author=Jean Roberts;,citation_author=Karen Roberts;,citation_author=Mark Roberts;,citation_author=Nicky Roberts;,citation_author=Philip Roberts;,citation_author=Rebecca Roberts;,citation_author=Calum Robertson;,citation_author=James Robertson;,citation_author=Jamie Robertson;,citation_author=Nichola Robertson;,citation_author=Stuart Robertson;,citation_author=Nicole Robin;,citation_author=Caroline Robinson;,citation_author=Emma Robinson;,citation_author=Gisela Robinson;,citation_author=Hannah Robinson;,citation_author=Jemima Robinson;,citation_author=Kate Robinson;,citation_author=Matthew Robinson;,citation_author=Ryan Robinson;,citation_author=Sandra Robinson;,citation_author=Alexandra Robinson;,citation_author=Steve Robson;,citation_author=Lisa Roche;,citation_author=Samantha Roche;,citation_author=Natalie Rodden;,citation_author=Alistair Roddick;,citation_author=Jack Roddy;,citation_author=Marion Roderick;,citation_author=Alison Rodger;,citation_author=Faye Rodger;,citation_author=Megan Rodger;,citation_author=Alicia Rodgers;,citation_author=Deirdre Rodgers;,citation_author=Natasha Rodgers;,citation_author=Penny Rodgers;,citation_author=Rocio Rodriguez-Belmonte;,citation_author=Nicholas Roe;,citation_author=Charles Roehr;,citation_author=Gill Rogers;,citation_author=Jason Rogers;,citation_author=Joanne Rogers;,citation_author=John Rogers;,citation_author=Leigh Rogers;,citation_author=Lindsay Rogers;,citation_author=Michaela Rogers;,citation_author=Paula Rogers;,citation_author=Susan Rogers;,citation_author=Thomas Rogers;,citation_author=Paula Rogers;,citation_author=Sakib Rokadiya;,citation_author=Lee Rollins;,citation_author=Jennifer Rollo;,citation_author=Catherine Rolls;,citation_author=Atal Roman;,citation_author=Claire Rook;,citation_author=Kevin Rooney;,citation_author=Lynsey Rooney;,citation_author=Lace P Rosaroso;,citation_author=Alastair Rose;,citation_author=Annie Rose;,citation_author=Steve Rose;,citation_author=Zoe Rose;,citation_author=Josephine Rosier;,citation_author=Jack Ross;,citation_author=Jennifer Rossdale;,citation_author=Alex Rothman;,citation_author=Joanne Rothwell;,citation_author=Lindsay Roughley;,citation_author=Kathryn Rowan;,citation_author=Neil Rowan;,citation_author=Stephen Rowan;,citation_author=Anna Rowe;,citation_author=Cathy Rowe;,citation_author=Louise Rowe-Leete;,citation_author=Benjamin Rowlands;,citation_author=Megan Rowley;,citation_author=Subarna Roy;,citation_author=Matthew Royds;,citation_author=Anna Roynon-Reed;,citation_author=Sam Rozewicz;,citation_author=Anna Rudenko;,citation_author=Senthan Rudrakumar;,citation_author=Banu Rudran;,citation_author=Shannon Ruff;,citation_author=Prita Rughani;,citation_author=Sharon Rundell;,citation_author=Jeremy Rushmer;,citation_author=Darren Rusk;,citation_author=Peter Russell;,citation_author=Richard Russell;,citation_author=Cristina Russo;,citation_author=Marieke Rutgers;,citation_author=Aidan Ryan;,citation_author=Brendan Ryan;,citation_author=Kathryn Ryan;,citation_author=Lucy Ryan;,citation_author=Matthew Ryan;,citation_author=Pat Ryan;,citation_author=Phil Ryan;,citation_author=Declan Ryan-Wakeling;,citation_author=M Saad;,citation_author=Javeson Sabale;,citation_author=Suganya Sabaretnam;,citation_author=Noman Sadiq;,citation_author=Emma Sadler;,citation_author=Ashiq Saffy;,citation_author=Beth Sage;,citation_author=Harkiran Sagoo;,citation_author=Sobia Sagrir;,citation_author=Rajnish Saha;,citation_author=Sian Saha;,citation_author=Nikhil Sahdev;,citation_author=Sarvjit Sahedra;,citation_author=Jagdeep Sahota;,citation_author=Nooria Said;,citation_author=Sreekanth Sakthi;,citation_author=Hikari Sakuri;,citation_author=Murthy Saladi;,citation_author=Abdul Salam;,citation_author=Armorel Salberg;,citation_author=Erika Salciute;,citation_author=Gina Saleeb;,citation_author=Mumtaz Saleh;,citation_author=Hizni Salih;,citation_author=Laylan Salih;,citation_author=Sarah Salisbury;,citation_author=SiteEneye Saliu;,citation_author=Rustam Salman;,citation_author=Jenny Salmon;,citation_author=Dario Salutous;,citation_author=Mfon Sam;,citation_author=Sally Sam;,citation_author=Tinashe Samakomva;,citation_author=Razan Saman;,citation_author=Sakeena Samar;,citation_author=Renaldo Samlal;,citation_author=Emily Sammons;,citation_author=David Sammut;,citation_author=Mark Sammut;,citation_author=Sunitha Sampath;,citation_author=Claire Sampson;,citation_author=Julia Sampson;,citation_author=Aashna Samson;,citation_author=Anda Samson;,citation_author=Johnson Samuel;,citation_author=Merna Samuel;,citation_author=Reena Samuel;,citation_author=Thomas D L Samuel;,citation_author=Younan Samuel;,citation_author=Theo Samuels;,citation_author=Joanna Samways;,citation_author=Manjula Samyraju;,citation_author=Ilves Sana;,citation_author=Veronica Sanchez;,citation_author=Amada Sanchez Gonzalez;,citation_author=Alina Sanda-Gomez;,citation_author=Peter Sandercock;,citation_author=Amy Sanderson;,citation_author=Tom Sanderson;,citation_author=Prabowo Sandhi;,citation_author=Kuljinder Sandhu;,citation_author=Loveleen Sandhu;,citation_author=Sam Sandow;,citation_author=Victoria Sandrey;,citation_author=Sarah Sands;,citation_author=Mirriam Sangombe;,citation_author=Mathew Sanju;,citation_author=Lakshmi Sankaran;,citation_author=Filipa Santos;,citation_author=Rojy Santosh;,citation_author=Jayanta Sanyal;,citation_author=Aureo F Sanz-Cepero;,citation_author=Dan Saragih;,citation_author=Dinesh Saralaya;,citation_author=Arun Saraswatula;,citation_author=Joshua Sarella;,citation_author=Avishay Sarfatti;,citation_author=Rebecca Sargent;,citation_author=Beatrix Sari;,citation_author=Diah Sari;,citation_author=Khatija Sarkar;,citation_author=Rahuldeb Sarkar;,citation_author=Sruthi Sarma;,citation_author=Zainab Sarwar;,citation_author=Thea Sass;,citation_author=Sonia Sathe;,citation_author=Sobitha Sathianandan;,citation_author=Abilash Sathyanarayanan;,citation_author=Lavanya S J P Sathyanarayanan;,citation_author=Thozhukat Sathyapalan;,citation_author=Prakash Satodia;,citation_author=Vera Saulite;,citation_author=Andrew Saunders;,citation_author=Rachel Saunders;,citation_author=Samantha Saunders;,citation_author=Anne Saunderson;,citation_author=Heather Savill;,citation_author=Karishma Savlani;,citation_author=Gauri Saxena;,citation_author=Matthew Saxton;,citation_author=Amrinder Sayan;,citation_author=Diane Scaletta;,citation_author=Deborah Scanlon;,citation_author=Jeremy Scanlon;,citation_author=Lyndsay Scarratt;,citation_author=Sean Scattergood;,citation_author=Alvin Schadenberg;,citation_author=Jenna Schafers;,citation_author=Wendy Schneblen;,citation_author=Rebecca Schofield;,citation_author=Samuel Schofield;,citation_author=David Scholes;,citation_author=Karen Scholes;,citation_author=Alex Schoolmeesters;,citation_author=Natasha Schumacher;,citation_author=Nicola Schunke;,citation_author=Martin Schuster Bruce;,citation_author=Karin Schwarz;,citation_author=Antonia Scobie;,citation_author=Tim Scorrer;,citation_author=A. Scott;,citation_author=Alistair Scott;,citation_author=Anne Scott;,citation_author=Catherine Scott;,citation_author=Christine Scott;,citation_author=Emily Scott;,citation_author=Kathyn Scott;,citation_author=Leanne Scott;,citation_author=Martha Scott;,citation_author=Stephen Scott;,citation_author=Timothy Scott;,citation_author=Sarah Scourfield;,citation_author=Wendy Scrase;,citation_author=Angela Scullion;,citation_author=Therese Scullion;,citation_author=Emily Seager;,citation_author=Cathy Seagrave;,citation_author=Rebecca Seaman;,citation_author=Eleanor Sear;,citation_author=Isabella Seaton;,citation_author=Anna Seckington;,citation_author=Joanna Sedano;,citation_author=Gabrielle Seddon;,citation_author=Yee Yong See;,citation_author=Muhammad A Seelarbokus;,citation_author=Christopher Sefton;,citation_author=Matias Segovia;,citation_author=Fatima Seidu;,citation_author=Gillian Sekadde;,citation_author=Faye Selby;,citation_author=Georgina Selby;,citation_author=Claire Sellar;,citation_author=Katharine Sellers;,citation_author=Joseph Selley;,citation_author=Victoria Sellick;,citation_author=Hannah Selman;,citation_author=Gobika Selvadurai;,citation_author=Brintha Selvarajah;,citation_author=Haresh Selvaskandan;,citation_author=Subothini S Selvendran;,citation_author=Jeyakumar Selwyn;,citation_author=Gary Semple;,citation_author=Nandini Sen;,citation_author=Seema Sen;,citation_author=Aditya Sengupta;,citation_author=Niladri Sengupta;,citation_author=Susana Senra;,citation_author=HoJan Senya;,citation_author=Niranjan Setty;,citation_author=Abigail Seward;,citation_author=Teswaree Sewdin;,citation_author=Jack Seymour;,citation_author=Hussam Shabbir;,citation_author=Fiona Shackley;,citation_author=Tariq Shafi;,citation_author=Aashni Shah;,citation_author=Ahmar Shah;,citation_author=Anand Shah;,citation_author=Bhavni Shah;,citation_author=Momin Shah;,citation_author=Neil Shah;,citation_author=Pallav Shah;,citation_author=Priyank Shah;,citation_author=Qasim Shah;,citation_author=Sarfaraz H Shah;,citation_author=Snehal Shah;,citation_author=Suraj Shah;,citation_author=Syed Shah;,citation_author=Wajid Shah;,citation_author=Saarma Shahad;,citation_author=Sousan Shahi;,citation_author=Sipan Shahnazari;,citation_author=Muhammad Shahzeb;,citation_author=Aisha Shaibu;,citation_author=Zara Shaida;,citation_author=Amina Y Shaikh;,citation_author=Maliha Shaikh;,citation_author=Rajit Shail;,citation_author=Mariya Shaji;,citation_author=Muhammad Shakeel;,citation_author=Korah Shalan;,citation_author=Nadia Shamim;,citation_author=Kazi Shams;,citation_author=Thomas Shanahan;,citation_author=Hamed Sharaf;,citation_author=Asir Sharif;,citation_author=Ajay Sharma;,citation_author=Ash Sharma;,citation_author=Bhawna Sharma;,citation_author=Mona Sharma;,citation_author=Ojasvi Sharma;,citation_author=Poonam Sharma;,citation_author=Rajeev Sharma;,citation_author=Sanjeev Sharma;,citation_author=Sarkhara Sharma;,citation_author=Shriv Sharma;,citation_author=Sonal Sharma;,citation_author=Alexander Sharp;,citation_author=Charles Sharp;,citation_author=Gemma Sharp;,citation_author=Paula Sharratt;,citation_author=Phoebe Sharratt;,citation_author=Katherine Sharrocks;,citation_author=Serene Shashaa;,citation_author=Christopher Shaw;,citation_author=Daisy Shaw;,citation_author=David Shaw;,citation_author=Deborah Shaw;,citation_author=Joanne Shaw;,citation_author=Jonathon Shaw;,citation_author=Lisa Shaw;,citation_author=Tomos G Shaw;,citation_author=Anna Shawcross;,citation_author=Jill Shawe;,citation_author=Lou Shayler;,citation_author=Sophy Shedwell;,citation_author=Jonathan Sheffield;,citation_author=Zak Shehata;,citation_author=Arshiya Sheik;,citation_author=Asif Sheikh;,citation_author=Noorann Sheikh;,citation_author=Benjamin Shelley;,citation_author=Sarah Shelton;,citation_author=Anil Shenoy;,citation_author=Julie Shenton;,citation_author=Amy Shepherd;,citation_author=Kate Shepherd;,citation_author=Lorna Shepherd;,citation_author=Scott Shepherd;,citation_author=Rhian Sheppeard;,citation_author=Helen Sheridan;,citation_author=Ray Sheridan;,citation_author=Samuel Sherridan;,citation_author=Leanne Sherris;,citation_author=Susanna Sherwin;,citation_author=Shaad Shibly;,citation_author=Chiaki Shioi;,citation_author=Anand Shirgaonkar;,citation_author=Kim Shirley;,citation_author=Adebusola Shonubi;,citation_author=Rob Shortman;,citation_author=Rohan Shotton;,citation_author=Sarah Shotton;,citation_author=Ervin Shpuza;,citation_author=Anil Shrestha;,citation_author=Apurba Shrestha;,citation_author=Nora Shrestha;,citation_author=Suchita Shrestha;,citation_author=Karen Shuker;,citation_author=Jack Shurmer;,citation_author=Gilbert Siame;,citation_author=Loria Siamia;,citation_author=Seshnag Siddavaram;,citation_author=Nasir Siddique;,citation_author=Sohail Siddique;,citation_author=Nyma Sikondari;,citation_author=Claudia Silva Moniz;,citation_author=Malcolm Sim;,citation_author=Theresa Simangan;,citation_author=Vimbai Simbi;,citation_author=Robert Sime;,citation_author=Oliver Simmons;,citation_author=Richard Simms;,citation_author=Merritt Simon;,citation_author=Natalie Simon;,citation_author=Angela Simpson;,citation_author=Anna Simpson;,citation_author=Danny Simpson;,citation_author=Georgina Simpson;,citation_author=Joanne Simpson;,citation_author=Kerry Simpson;,citation_author=Phillip Simpson;,citation_author=Thomas Simpson;,citation_author=Kathryn Simpson;,citation_author=Cindy Sing;,citation_author=Ankita Singh;,citation_author=Claire Singh;,citation_author=Jayaprakash Singh;,citation_author=Jyoti Singh;,citation_author=Lokeshwar Singh;,citation_author=Manjeet Singh;,citation_author=Nadira Singh;,citation_author=Pankaj Singh;,citation_author=Prabhsimran Singh;,citation_author=Salil Singh;,citation_author=Saurabh Singh;,citation_author=Parag Singhal;,citation_author=Bryan Singizi;,citation_author=Manas Sinha;,citation_author=Utkarsh Sinha;,citation_author=Guy Sisson;,citation_author=Sarah Sithiravel;,citation_author=Karthikadevi Sivakumar;,citation_author=Shanmugasundaram Sivakumar;,citation_author=Darsh Sivakumran;,citation_author=Sivanthi Sivanadarajah;,citation_author=Pasupathy-Rajah Sivasothy;,citation_author=Nicole Skehan;,citation_author=Robert Skelly;,citation_author=Orlagh Skelton;,citation_author=Imogen Skene;,citation_author=Denise Skinner;,citation_author=Tabitha Skinner;,citation_author=Victoria Skinner;,citation_author=Agnieszka Skorko;,citation_author=Iwona Skorupinska;,citation_author=Mariola Skorupinska;,citation_author=Amy Slack;,citation_author=Katie Slack;,citation_author=Wendy Slack;,citation_author=Heather Slade;,citation_author=Mark Slade;,citation_author=Lynda Slater;,citation_author=Nicola Slawson;,citation_author=Andrew Sloan;,citation_author=Brendan Sloan;,citation_author=Derek Sloan;,citation_author=Geraldine Sloane;,citation_author=Benjamin Small;,citation_author=Ellen Small;,citation_author=Samuel Small;,citation_author=Dawn Smalls;,citation_author=Karen D Smallshaw;,citation_author=Andy Smallwood;,citation_author=Carien Smit;,citation_author=Aileen Smith;,citation_author=Alex Smith;,citation_author=Amanda Smith;,citation_author=Amy Smith;,citation_author=Andrew Smith;,citation_author=Catherine Smith;,citation_author=Chris Smith;,citation_author=Christopher Smith;,citation_author=Dominic Smith;,citation_author=Eleanor Smith;,citation_author=Harriet Smith;,citation_author=Hazel Smith;,citation_author=Helen Smith;,citation_author=Jacky Smith;,citation_author=Jessica Smith;,citation_author=Kate Smith;,citation_author=Kerry Smith;,citation_author=Lara Smith;,citation_author=Linda Smith;,citation_author=Lisa Smith;,citation_author=Loren Smith;,citation_author=Maria Smith;,citation_author=Mel Smith;,citation_author=Oliver Smith;,citation_author=Rachel Smith;,citation_author=Rebecca Smith;,citation_author=Richard Smith;,citation_author=Sally Smith;,citation_author=Samantha Smith;,citation_author=Stacey Smith;,citation_author=Stephanie Smith;,citation_author=Susan Smith;,citation_author=Imogen Smith;,citation_author=John Smith;,citation_author=Sue Smolen;,citation_author=Sara Smuts;,citation_author=Naoise Smyth;,citation_author=Annette Snell;,citation_author=David Snell;,citation_author=Luke Snell;,citation_author=Beng So;,citation_author=Michelle Soan;,citation_author=Toluleyi Sobande;,citation_author=Alberto Sobrino Diaz;,citation_author=Basit Sohail;,citation_author=Bina Sohail;,citation_author=Herminder Sohal;,citation_author=Roy Soiza;,citation_author=Olajumoke Solademi;,citation_author=Babak Soleimani;,citation_author=Amanda Solesbury;,citation_author=Reanne Solly;,citation_author=Louise Solomon;,citation_author=Subash Somalanka;,citation_author=Chandrashekaraiah Somashekar;,citation_author=Raj Sonia;,citation_author=Shiu-Ching Soo;,citation_author=Pavandeep Soor;,citation_author=Germanda Soothill;,citation_author=Jennifer Soren;,citation_author=Apina Sothinathan;,citation_author=Pragalathan Sothirajah;,citation_author=Najwa Soussi;,citation_author=Donna Southam;,citation_author=David Southern;,citation_author=Iain Southern;,citation_author=Louise Southern;,citation_author=Sara M Southin;,citation_author=Jessica Southwell;,citation_author=Thomas Southworth;,citation_author=Jason Sowter;,citation_author=Claudia Spalding;,citation_author=Enti Spata;,citation_author=Katie Spears;,citation_author=Mark Spears;,citation_author=Michelle Spence;,citation_author=Branwell Spencer;,citation_author=Gisele Spencer;,citation_author=Sue Spencer;,citation_author=Tom Spencer;,citation_author=Helen Spickett;,citation_author=Jennifer Spillane;,citation_author=William Spiller;,citation_author=Kerry Spinks;,citation_author=Michelle Spinks;,citation_author=Nick Spittle;,citation_author=Janet Spriggs;,citation_author=Oliver Spring;,citation_author=Gemma Squires;,citation_author=Jack Squires;,citation_author=Rebecca Squires;,citation_author=Ram Sreenivasan;,citation_author=Shiva Sreenivasan;,citation_author=K Sri Paranthamen;,citation_author=Ramesh Srinivasan;,citation_author=Asha Srirajamadhuveeti;,citation_author=Vino Srirathan;,citation_author=Sybil Stacpoole;,citation_author=Louise Stadon;,citation_author=Jocasta Staines;,citation_author=Nikki Staines;,citation_author=Katie Stammers;,citation_author=Roxana Stanciu;,citation_author=Grazyna Stanczuk;,citation_author=Robyn Staples;,citation_author=Simon Stapley;,citation_author=Natalie Staplin;,citation_author=Adam Stark;,citation_author=Michelle Starr;,citation_author=Rached Stead;,citation_author=Conor Steele;,citation_author=John Steer;,citation_author=Vergnano Stefania;,citation_author=Paula Stefanowska;,citation_author=Caroline Stemp;,citation_author=Alison Stephens;,citation_author=David Stephensen;,citation_author=Elaine Stephenson;,citation_author=Monique Sterrenburg;,citation_author=Melanie Stevens;,citation_author=Will Stevens;,citation_author=Amy Stevenson;,citation_author=Andrew Stevenson;,citation_author=Lesley Stevenson;,citation_author=Sarah Stevenson;,citation_author=Matthew Steward;,citation_author=Claire Stewart;,citation_author=Colin Stewart;,citation_author=McKenna Stewart;,citation_author=Rachel Stewart;,citation_author=Richard Stewart;,citation_author=Jo Stickley;,citation_author=Gemma Stiller;,citation_author=Sarah Stirrup;,citation_author=Sarah Stock;,citation_author=Alexander Stockdale;,citation_author=Lynne Stockham;,citation_author=Paul Stockton;,citation_author=Emma Stoddard;,citation_author=Chris Stokes;,citation_author=Ben Stone;,citation_author=Roisin Stone;,citation_author=Sarah Stone;,citation_author=Imogen Storey;,citation_author=Kim Storton;,citation_author=Frederick Stourton;,citation_author=Angela Strachan;,citation_author=Catherine Strait;,citation_author=Emma Stratton;,citation_author=Jane Stratton;,citation_author=Sam Straw;,citation_author=Dieter Streit;,citation_author=Emma Stride;,citation_author=Sally Stringer;,citation_author=Sophia Strong-Sheldrake;,citation_author=Siske Struik;,citation_author=Carmel Stuart;,citation_author=Anna Stubbs;,citation_author=Harrison Stubbs;,citation_author=Ann Sturdy;,citation_author=Sharon Sturney;,citation_author=Matt Stuttard;,citation_author=Cristina Suarez;,citation_author=Karuna Subba;,citation_author=Christian P Subbe;,citation_author=Manjula Subramanian;,citation_author=Venkatram Subramanian;,citation_author=Chinari Subudhi;,citation_author=Rebecca Suckling;,citation_author=Srivatsan Sudershan;,citation_author=Peter Sugden;,citation_author=Rudresh Sukla;,citation_author=Ali Suliman;,citation_author=Fatimah Suliman;,citation_author=Sugrah Sultan;,citation_author=Samyukta Sundar;,citation_author=Reka Sundhar;,citation_author=Edmond Sung;,citation_author=Nadia Sunni;,citation_author=Jay Suntharalingam;,citation_author=Amitava Sur;,citation_author=Dharmic Suresh;,citation_author=Shilpa Suresh;,citation_author=Michael Surtees;,citation_author=C Susan;,citation_author=Danielle Suter;,citation_author=Helen Sutherland;,citation_author=Rachel Sutherland;,citation_author=Rebecca Sutherland;,citation_author=Dovile Sutinyte;,citation_author=Deborah Sutton;,citation_author=Sam Sutton;,citation_author=Mihaela Sutu;,citation_author=Marie-Louise Svensson;,citation_author=Sima Svirpliene;,citation_author=Andrew Swain;,citation_author=Rose Swain;,citation_author=Thomas Swaine;,citation_author=Christopher Swales;,citation_author=Tirion Swart;,citation_author=Stephen Sweetman;,citation_author=Samaher Sweity;,citation_author=Ealish Swift;,citation_author=Paul Swift;,citation_author=Pauline Swift;,citation_author=Rachael Swift;,citation_author=Rachel Swingler;,citation_author=Sophie Swinhoe;,citation_author=Katarzyna Swist-Szulik;,citation_author=Luke Swithenbank;,citation_author=Omair Syed;,citation_author=Catriona Sykes;,citation_author=Daisy Sykes;,citation_author=Eliot Sykes;,citation_author=Luke Sylvester;,citation_author=Dominic Symon;,citation_author=Andrew Syndercombe;,citation_author=Zoe Syrimi;,citation_author=Jen Syson;,citation_author=Gemma Szabo;,citation_author=Tamas Szakmany;,citation_author=Megan Szekely;,citation_author=Matthew Szeto;,citation_author=Maria Tadros;,citation_author=Amr Tageldin;,citation_author=Lucy Tague;,citation_author=Hasan Tahir;,citation_author=Muhammad Tahir;,citation_author=Abigail Takyi;,citation_author=Peter Talbot;,citation_author=Alison Talbot -Smith;,citation_author=James Talbot-Ponsonby;,citation_author=Richard Tallent;,citation_author=Bradley Tallon;,citation_author=Phoebe Tamblin-Hopper;,citation_author=Adrian Tan;,citation_author=Bee Theng Tan;,citation_author=Hock Tan;,citation_author=Huey Tan;,citation_author=Keith Tan;,citation_author=WeiTeen Tan;,citation_author=Anand Tana;,citation_author=Christina Tanney;,citation_author=Tabitha Tanqueray;,citation_author=Emma Tanton;,citation_author=Anita Tantri;,citation_author=Hayley Tarft;,citation_author=Hayley Tarft;,citation_author=Priyal Taribagil;,citation_author=Obaid Tarin;,citation_author=Syed Tariq;,citation_author=David Tarpey;,citation_author=Lisa Tarrant;,citation_author=Antonia Tasiou;,citation_author=Margaret L Tate;,citation_author=Kate Tatham;,citation_author=Vera Tavoukjian;,citation_author=Alexander Taylor;,citation_author=Beverley Taylor;,citation_author=Charlie Taylor;,citation_author=David Taylor;,citation_author=Elisabeth Taylor;,citation_author=Janet Taylor;,citation_author=Jennifer Taylor;,citation_author=Joanne Taylor;,citation_author=Julie Taylor;,citation_author=Karen Taylor;,citation_author=Leanne Taylor;,citation_author=Margaret Taylor;,citation_author=Matthew Taylor;,citation_author=Melanie Taylor;,citation_author=Natalie Taylor;,citation_author=Rachael Taylor;,citation_author=Rachel Taylor;,citation_author=Samantha Taylor;,citation_author=Suzanne Taylor;,citation_author=Tracey Taylor;,citation_author=Vicky Taylor;,citation_author=Michelle Taylor-Siddons;,citation_author=Thomas Taynton;,citation_author=Amelia Te;,citation_author=Jessica Teasdale;,citation_author=Julie Tebbutt;,citation_author=Caroline Tee;,citation_author=Rajni Tejwani;,citation_author=Adam Telfer;,citation_author=Vibha Teli;,citation_author=Jennifer Tempany;,citation_author=Julie Temple;,citation_author=Natalie Temple;,citation_author=Helen Tench;,citation_author=Yi He Teoh;,citation_author=Lynne Terrett;,citation_author=Louise Terry;,citation_author=Dariusz Tetla;,citation_author=Shirish Tewari;,citation_author=Daniel Tewkesbury;,citation_author=Joana Texeira;,citation_author=ChiaLing Tey;,citation_author=Clare Thakker;,citation_author=Manish Thakker;,citation_author=Hilary Thatcher;,citation_author=Andrew Thayanandan;,citation_author=Krishna Thazhatheyil;,citation_author=Eaint Thein;,citation_author=Lambrini Theocharidou;,citation_author=Phyu Thet;,citation_author=Kapeendran Thevarajah;,citation_author=Mayooran Thevendra;,citation_author=Nang Thiri Phoo;,citation_author=Yvette Thirlwall;,citation_author=Muthu Thirumaran;,citation_author=Alice Thomas;,citation_author=Andrew Thomas;,citation_author=Caradog Thomas;,citation_author=Emma Thomas;,citation_author=Enson Thomas;,citation_author=Esther Thomas;,citation_author=Helen Thomas;,citation_author=James Thomas;,citation_author=Karen Thomas;,citation_author=Koshy Thomas;,citation_author=Lucy Thomas;,citation_author=Rachel Thomas;,citation_author=Rebecca Thomas;,citation_author=Rhys Thomas;,citation_author=Ruth Thomas;,citation_author=Sarah Thomas;,citation_author=Sherine Thomas;,citation_author=Tessy Thomas;,citation_author=Vicky Thomas;,citation_author=Rhian Thomas-Turner;,citation_author=Catherine Thompson;,citation_author=Christopher Thompson;,citation_author=Clara Thompson;,citation_author=Fiona Thompson;,citation_author=Katharine Thompson;,citation_author=Laura Thompson;,citation_author=Liz Thompson;,citation_author=Luke Thompson;,citation_author=Michael Thompson;,citation_author=Orla Thompson;,citation_author=Rebecca Thompson;,citation_author=Roger Thompson;,citation_author=Nicola Thomson;,citation_author=Natasha Thorn;,citation_author=Charlotte Thorne;,citation_author=Nicola Thorne;,citation_author=Danielle Thornton;,citation_author=Jim Thornton;,citation_author=Richard Thornton;,citation_author=Sara Thornton;,citation_author=Susan Thornton;,citation_author=Thomas Thornton;,citation_author=Tracey Thornton;,citation_author=Christopher Thorpe;,citation_author=Sarah Thorpe;,citation_author=Paradeep Thozthumparambil;,citation_author=Laura Thrasyvoulou;,citation_author=Hannah Thraves;,citation_author=Vicky Thwaiotes;,citation_author=Guy Thwaites;,citation_author=Simon Tiberi;,citation_author=Serena Tieger;,citation_author=Carey Tierney;,citation_author=Caroline Tierney;,citation_author=Mark Tighe;,citation_author=Sorrell Tilbey;,citation_author=Amanda Tiller;,citation_author=John Timerick;,citation_author=Elizabeth Timlick;,citation_author=Alison Timmis;,citation_author=Hayley Timms;,citation_author=Anne-Marie Timoroksa;,citation_author=Samakomva Tinashe;,citation_author=Heather Tinkler;,citation_author=Marianne Tinkler;,citation_author=Myat Tin Trafford;,citation_author=Jacqui Tipper;,citation_author=Helen Tivenan;,citation_author=Helen T-Michael;,citation_author=Anne Todd;,citation_author=Jackie Todd;,citation_author=Stacy Todd;,citation_author=Mohamed Tohfa;,citation_author=Melanie Tolson;,citation_author=Ana Luisa Tomas;,citation_author=Natalia Tomasova;,citation_author=Sharon Tomlin;,citation_author=Simon Tomlins;,citation_author=Jo Tomlinson;,citation_author=James Tonkin;,citation_author=Ivan Tonna;,citation_author=Catherine Toohey;,citation_author=Kirsty Topham;,citation_author=Mathew Topping;,citation_author=Ruhaif Tousis;,citation_author=Peter Tovey;,citation_author=Gareth Towersey;,citation_author=Jill Townley;,citation_author=Alain Townsend;,citation_author=Richard Tozer;,citation_author=Helen Tranter;,citation_author=Christopher Travill;,citation_author=Sarah Traynor;,citation_author=Ascanio Tridente;,citation_author=Sanchia Triggs;,citation_author=Fiona Trim;,citation_author=Alex Trimmings;,citation_author=Tom Trinick;,citation_author=Sven Troedson;,citation_author=Emily Tropman;,citation_author=Amy Trotter;,citation_author=Madeleine Trowsdale Stannard;,citation_author=Nigel Trudgill;,citation_author=Robert Truell;,citation_author=Maria Truslove;,citation_author=Shaun Trussell;,citation_author=Tariq Trussell;,citation_author=Kyriaki Tsakiridou;,citation_author=Christine Tsang;,citation_author=Hoi Pat Tsang;,citation_author=Peter Tsang;,citation_author=Tan Tsawayo;,citation_author=Kyriaki K Tsilimpari;,citation_author=Georgios Tsinaslanidis;,citation_author=Simon Tso;,citation_author=Sally Tucker;,citation_author=Aisha Tufail;,citation_author=Redmond Tully;,citation_author=Grace Tunesi;,citation_author=Killiam Turbitt;,citation_author=Rezon Turel;,citation_author=Tolga Turgut;,citation_author=Claudia Turley;,citation_author=Alison Turnbull;,citation_author=Aine Turner;,citation_author=Ash Turner;,citation_author=Charlotte Turner;,citation_author=Gail Turner;,citation_author=Kate Turner;,citation_author=Kelly Turner;,citation_author=Lucy Turner;,citation_author=Mark Turner;,citation_author=Patricia Turner;,citation_author=Sally Turner;,citation_author=Samantha Turner;,citation_author=Victoria Turner;,citation_author=Sharon Turney;,citation_author=Jon Turvey;,citation_author=Conor Tweed;,citation_author=David Tweed;,citation_author=Rebecca Twemlow;,citation_author=Emma Twohey;,citation_author=Bhavya Tyagi;,citation_author=Vedang Tyagi;,citation_author=Abigail Tyer;,citation_author=Jayne Tyler;,citation_author=Jennifer Tyler;,citation_author=Alison Tyzack;,citation_author=Petros Tzavaras;,citation_author=Mohammad S Uddin;,citation_author=Ruhama Uddin;,citation_author=Ruzena Uddin;,citation_author=Waqar Ul Hassan;,citation_author=Salamat Ullah;,citation_author=Sana Ullah;,citation_author=Sanda Ullah;,citation_author=Ju Um;,citation_author=Athavan Umaipalan;,citation_author=Judith Umeadi;,citation_author=Akudo Umeh;,citation_author=Wilfred Umeojiako;,citation_author=Ben Ummat;,citation_author=Charlotte Underwood;,citation_author=Jonathan Underwood;,citation_author=Adam Unsworth;,citation_author=Veerpal S Uppal;,citation_author=Gerry Upson;,citation_author=Masood Ur Rasool;,citation_author=Sebastian Urruela;,citation_author=Hiromi Uru;,citation_author=Miranda Usher;,citation_author=Rebecca Usher;,citation_author=Alex UsherRea;,citation_author=Andrew Ustianowski;,citation_author=Linda C Vaccari;,citation_author=Uddhav Vaghela;,citation_author=Abhay Vaidya;,citation_author=Bernardas Valecka;,citation_author=Jennifer Valentine;,citation_author=Balan Valeria;,citation_author=Pramodh Vallabhaneni;,citation_author=Luke Vamplew;,citation_author=Ekaterini Vamvakiti;,citation_author=Joannis Vamvakopoulos;,citation_author=Maud Venne;,citation_author=Alex Meer;,citation_author=Nora Stelt;,citation_author=Joseph Vance-Daniel;,citation_author=Rama Vancheeswaran;,citation_author=Samuel I Vandeyoon;,citation_author=Padma Vankayalapati;,citation_author=Piyush Vanmali;,citation_author=Chloe Vansomeren;,citation_author=William Van’t Hoff;,citation_author=Sejal Vara;,citation_author=Stehen J Vardy;,citation_author=Anu Varghese;,citation_author=Maria Varghese;,citation_author=William Varney;,citation_author=Giulia Varnier;,citation_author=Valeria Vasadi;,citation_author=Olivia Vass;,citation_author=Vimal Vasu;,citation_author=Vasanthi Vasudevan;,citation_author=Manu Vatish;,citation_author=Heloyes Vayalaman;,citation_author=Christopher Vaz;,citation_author=Niki Veale;,citation_author=Sachuda Veerasamy;,citation_author=Swati Velankar;,citation_author=Luxmi Velauthar;,citation_author=Neyme Veli;,citation_author=Nicola Vella;,citation_author=Anitha Velusamy;,citation_author=Ian Venables;,citation_author=Mavi Venditti;,citation_author=Ramya Venkataramakrishnan;,citation_author=Richard Venn;,citation_author=Robert Venn;,citation_author=Lyn Ventilacion;,citation_author=Joanne Vere;,citation_author=Mark Veres;,citation_author=Stefania Vergnano;,citation_author=Will Verling;,citation_author=Amit Verma;,citation_author=Rachel Vernall;,citation_author=Britney Vernon;,citation_author=Mark Vertue;,citation_author=Jerik Verula;,citation_author=Natalie Vethanayagam;,citation_author=Lucy Veys;,citation_author=Carinna Vickers;,citation_author=Saji Victor;,citation_author=Celine Vidaillac;,citation_author=Jennifer Vidler;,citation_author=Bavithra Vijayakumar;,citation_author=Vinod W Vijayaraghavan Nalini;,citation_author=Brigita Vilcinskaite;,citation_author=Neringa Vilimiene;,citation_author=Lynn Vinall;,citation_author=Sylvia Vinay;,citation_author=Latha Vinayakarao;,citation_author=Rachel Vincent;,citation_author=Rosie Vincent;,citation_author=Pritpal Virdee;,citation_author=Emma Virgilio;,citation_author=Abdullah M Virk;,citation_author=Elisa Visentin;,citation_author=Karunakaran Vithian;,citation_author=Sorice Vittoria;,citation_author=Elena Vlad;,citation_author=Ben Vlies;,citation_author=Alain Vuylsteke;,citation_author=Eleftheria Vyras;,citation_author=Richard Wach;,citation_author=Beverley Wadams;,citation_author=Susan Wadd;,citation_author=Natalia Waddington;,citation_author=Phillip Wade;,citation_author=Kirsten Wadsworth;,citation_author=Syed E I Wafa;,citation_author=Daniel Wagstaff;,citation_author=Lynda Wagstaff;,citation_author=Dalia Wahab;,citation_author=Zaroug Wahbi;,citation_author=Abiodun Waheed Adigun;,citation_author=Sawan Waidyanatha;,citation_author=Rachel Wake;,citation_author=Alice Wakefield;,citation_author=William Wakeford;,citation_author=Fiona Wakinshaw;,citation_author=Andrew Walden;,citation_author=Lorna Walding;,citation_author=Alexandria Waldron;,citation_author=Gemma Walker;,citation_author=Harriet Walker;,citation_author=Ian Walker;,citation_author=Kevin Walker;,citation_author=Kim Walker;,citation_author=Linda Walker;,citation_author=Olivia Walker;,citation_author=Rachel Walker;,citation_author=Rebecca Walker;,citation_author=Susan Walker;,citation_author=Rebecca Wallbutton;,citation_author=Jessica Wallen;,citation_author=Karl Wallendszus;,citation_author=Arabella Waller;,citation_author=Rosemary Waller;,citation_author=Gabiel Wallis;,citation_author=Gabriel Wallis;,citation_author=Louise Wallis;,citation_author=Donna Walsh;,citation_author=Elizabeth Walsh;,citation_author=Livia Walsh;,citation_author=Deborah Walstow;,citation_author=Daniel Walter;,citation_author=Alex Walters;,citation_author=Holt Walters;,citation_author=James Walters;,citation_author=Jocelyn Walters;,citation_author=Eileen Walton;,citation_author=Lucy Walton;,citation_author=Olivia Walton;,citation_author=Sharon Walton;,citation_author=Susan Walton;,citation_author=Mandy Wan;,citation_author=Thin Wan;,citation_author=Junita Wanda;,citation_author=Mary Wands;,citation_author=Rachel Wane;,citation_author=Frank Wang;,citation_author=Nick Wang;,citation_author=Ran Wang;,citation_author=Deborah Warbrick;,citation_author=Samantha Warburton;,citation_author=Deborah Ward;,citation_author=Emma Ward;,citation_author=Joanna Ward;,citation_author=Luke Ward;,citation_author=Nicola Ward;,citation_author=Rachael Ward;,citation_author=Thomas Ward;,citation_author=Tom Ward;,citation_author=Scott A Warden;,citation_author=Steve Wardle;,citation_author=Hassan Wardy;,citation_author=Scott Waring;,citation_author=Jenny Warmington;,citation_author=Ben Warner;,citation_author=Christian Warner;,citation_author=Lewis Warnock;,citation_author=Sarah Warran;,citation_author=Jade Warren;,citation_author=Lisa Warren;,citation_author=Yolanda Warren;,citation_author=Hannah Warren-Miell;,citation_author=Adilia Warris;,citation_author=Gill Warwick;,citation_author=Hazel J Watchorn;,citation_author=Holly Waterfall;,citation_author=Abby Waters;,citation_author=Donald Waters;,citation_author=Mark Waterstone;,citation_author=Catherine Watkins;,citation_author=Catrin Watkins;,citation_author=Eleanor Watkins;,citation_author=Karen Watkins;,citation_author=Lynn Watkins;,citation_author=Abigail Watson;,citation_author=Adam J R Watson;,citation_author=Ekaterina Watson;,citation_author=Eleanor Watson;,citation_author=J G R Watson;,citation_author=Paul Watson;,citation_author=Rebecca Watson;,citation_author=Robert Watson;,citation_author=Malcolm Watters;,citation_author=Donna Watterson;,citation_author=Daniel Watts;,citation_author=John Watts;,citation_author=Merlin Watts;,citation_author=Victoria Waugh;,citation_author=Emma Wayman;,citation_author=Akhlaq Wazir;,citation_author=Mark Weatherhead;,citation_author=Nick Weatherly;,citation_author=Hayley Webb;,citation_author=Kathryn Webb;,citation_author=Kylie Webb;,citation_author=Stephen Webb;,citation_author=Cheryl Websdale;,citation_author=Deborah Webster;,citation_author=Ian Webster;,citation_author=Tim Webster;,citation_author=Ling Wee;,citation_author=Rebecca Weerakoon;,citation_author=Thanuja Weerasinghe;,citation_author=Janaka Weeratunga;,citation_author=Maria Weetman;,citation_author=Shuying Wei;,citation_author=Immo Weichert;,citation_author=David M Weinreich;,citation_author=Hugh Welch;,citation_author=James Welch;,citation_author=Leanne Welch;,citation_author=Steven Welch;,citation_author=A Welford;,citation_author=Samantha Weller;,citation_author=Lucy Wellings;,citation_author=Brian Wells;,citation_author=Susan Wellstead;,citation_author=Berni Welsh;,citation_author=Richard Welsh;,citation_author=Ingeborg Welters;,citation_author=Rachael Welton;,citation_author=Lauren Wentworth;,citation_author=Kate Wesseldine;,citation_author=Magdelena West;,citation_author=Raha West;,citation_author=Ruth West;,citation_author=Sophie West;,citation_author=Luke Western;,citation_author=Ruth Westhead;,citation_author=Heather Weston;,citation_author=Alice Westwood;,citation_author=Bill Wetherill;,citation_author=Sharon Wheaver;,citation_author=Helen Wheeler;,citation_author=Ben Whelan;,citation_author=Matthew Whelband;,citation_author=Amanda Whileman;,citation_author=Alison Whitcher;,citation_author=Andrew White;,citation_author=Benjamin White;,citation_author=Christopher White;,citation_author=Duncan White;,citation_author=Hannah White;,citation_author=James White;,citation_author=Jonathan White;,citation_author=Katie White;,citation_author=Marie White;,citation_author=Nick White;,citation_author=Sarah White;,citation_author=Sonia White;,citation_author=Tracey White;,citation_author=Catherine Whitehead;,citation_author=Anne Whitehouse;,citation_author=Claire Whitehouse;,citation_author=Tony Whitehouse;,citation_author=Julia Whiteley;,citation_author=Sophie Whiteley;,citation_author=Gabriel Whitlingum;,citation_author=David Whitmore;,citation_author=Elizabeth Whittaker;,citation_author=Lindsay Whittam;,citation_author=Ashley Whittington;,citation_author=Helen Whittle;,citation_author=Robert Whittle;,citation_author=Eunice Wiafe;,citation_author=Lou Wiblin;,citation_author=Olivia Wickens;,citation_author=John Widdrington;,citation_author=Jason Wieboldt;,citation_author=Hannah Wieringa;,citation_author=Cornelia Wiesender;,citation_author=Laura Wiffen;,citation_author=Andrew Wight;,citation_author=Christopher Wignall;,citation_author=Danielle Wilcock;,citation_author=Emma Wilcock;,citation_author=Louise Wilcox;,citation_author=Laura Wild;,citation_author=Stephen Wild;,citation_author=Michael Wilde;,citation_author=Peter Wilding;,citation_author=Tracey Wildsmith;,citation_author=Joe Wileman;,citation_author=Joy Wiles;,citation_author=Kate Wiles;,citation_author=Elva Wilhelmsen;,citation_author=Thomas Wiliams;,citation_author=Janet Wilkie;,citation_author=David Wilkin;,citation_author=Hannah Wilkins;,citation_author=Joy Wilkins;,citation_author=Suzanne Wilkins;,citation_author=Iain Wilkinson;,citation_author=Lesley Wilkinson;,citation_author=Nicola Wilkinson;,citation_author=Sophia Wilkinson;,citation_author=Susan Wilkinson;,citation_author=Tim Wilkinson;,citation_author=Sylvia Willetts;,citation_author=Aimee Williams;,citation_author=Alexandra Williams;,citation_author=Alison Williams;,citation_author=Angharad Williams;,citation_author=Ava Williams;,citation_author=Carl Williams;,citation_author=Caroline V Williams;,citation_author=Claire Williams;,citation_author=Dewi Williams;,citation_author=Gail Williams;,citation_author=Gemma Williams;,citation_author=Gina Williams;,citation_author=Hannah Williams;,citation_author=James Williams;,citation_author=Jennie Williams;,citation_author=John Williams;,citation_author=Joseph Williams;,citation_author=Karen Williams;,citation_author=Kathryn Williams;,citation_author=Marie Williams;,citation_author=Matthew Williams;,citation_author=Patricia Williams;,citation_author=Penny Williams;,citation_author=Rupert Williams;,citation_author=Samson Williams;,citation_author=Sarah Williams;,citation_author=Sophie Williams;,citation_author=Tamanna Williams;,citation_author=Annie Williamson;,citation_author=Cath Williamson;,citation_author=Catherine Williamson;,citation_author=Dawn Williamson;,citation_author=James D Williamson;,citation_author=Jodie Williamson;,citation_author=Rachel Williamson;,citation_author=Helen Williamson;,citation_author=Elizabeth Willis;,citation_author=Emily Willis;,citation_author=Heather Willis;,citation_author=Herika Willis;,citation_author=Joanna Willis;,citation_author=Louise Wills;,citation_author=Lucy Willsher;,citation_author=Catherine Willshire;,citation_author=Francesca Willson;,citation_author=Alison Wilson;,citation_author=Andrea Wilson;,citation_author=Antoinette Wilson;,citation_author=Billy Wilson;,citation_author=James Wilson;,citation_author=Karen Wilson;,citation_author=Kate Wilson;,citation_author=Lucinda Wilson;,citation_author=Mark Wilson;,citation_author=Toni Wilson;,citation_author=Marlar Win;,citation_author=Tin Tin Win;,citation_author=Wut Yee Win;,citation_author=Lucinda Winckworth;,citation_author=Laura Winder;,citation_author=Piers Winder;,citation_author=Helen Winmill;,citation_author=Simon Winn;,citation_author=Carmen Winpenny;,citation_author=Helen Winslow;,citation_author=Helen Winter;,citation_author=Jonathan Winter;,citation_author=Barbara Winter-Goodwin;,citation_author=Stephen Wisdom;,citation_author=Matthew Wise;,citation_author=Martin Wiselka;,citation_author=Rebecca Wiseman;,citation_author=Sophie Wiseman;,citation_author=Steven Wishart;,citation_author=Eric Witele;,citation_author=Nicholas Withers;,citation_author=Janet Wittes;,citation_author=Donna Wixted;,citation_author=Therese Wodehouse;,citation_author=Will Wolf;,citation_author=Nicola Wolff;,citation_author=Kirsten Wolffsohn;,citation_author=Rebecca Wolf-Roberts;,citation_author=Magda Wolna;,citation_author=Elena Wolodimeroff;,citation_author=Adam Wolstencroft;,citation_author=Alan Wong;,citation_author=Charlotte Wong;,citation_author=Chi-Hung Wong;,citation_author=Chi-Man Wong;,citation_author=Edwin Wong;,citation_author=Jessica Sue Yi Wong;,citation_author=Kit Y Wong;,citation_author=Mei Yin Wong;,citation_author=Nick Wong;,citation_author=Sam Wong;,citation_author=Amanda Wood;,citation_author=Caroline Wood;,citation_author=Dianne Wood;,citation_author=Fiona Wood;,citation_author=Hannah Wood;,citation_author=Jennifer Wood;,citation_author=Joe Wood;,citation_author=Lisa Wood;,citation_author=Louise Wood;,citation_author=Stephen Wood;,citation_author=Tracy Wood;,citation_author=Katharine Woodall;,citation_author=Rebecca Woodfield;,citation_author=Christopher Woodford;,citation_author=Elizabeth Woodford;,citation_author=Jill Woodford;,citation_author=Louise Woodhead;,citation_author=Timothy Woodhead;,citation_author=Philip Woodland;,citation_author=Marc Woodman;,citation_author=Jane Woods;,citation_author=Katherine Woods;,citation_author=Sarah Woods;,citation_author=Zoe Woodward;,citation_author=Megan Woolcock;,citation_author=Gemma Wooldridge;,citation_author=Rebecca Woolf;,citation_author=Chris Woollard;,citation_author=Christopher Woollard;,citation_author=Louisa Woollen;,citation_author=Emma Woolley;,citation_author=Jade Woolley;,citation_author=Daniel Woosey;,citation_author=Dan Wootton;,citation_author=Joanne Wootton;,citation_author=Daniel Worley;,citation_author=Stephy Worton;,citation_author=Jonathan Wraight;,citation_author=Maria Wray;,citation_author=Kim Wren;,citation_author=Lynn Wren;,citation_author=Caroline Wrey Brown;,citation_author=Catherine Wright;,citation_author=Demi Wright;,citation_author=Francesca Wright;,citation_author=Imogen Wright;,citation_author=Lianne Wright;,citation_author=Rachel Wright;,citation_author=Stephanie Wright;,citation_author=Tim Wright;,citation_author=Caroline Wroe;,citation_author=Hannah Wroe;,citation_author=Henry Wu;,citation_author=Peishan Wu;,citation_author=Pensee Wu;,citation_author=Jonathan Wubetu;,citation_author=Fitria Wulandari;,citation_author=Retno Wulandari;,citation_author=Craig Wyatt;,citation_author=Frederick Wyn-Griffiths;,citation_author=Inez Wynter;,citation_author=Bindhu Xavier;,citation_author=Arnold Xhikola;,citation_author=Zhongyang Xia;,citation_author=Huiyuan Xiao;,citation_author=Masseh Yakubi;,citation_author=May Yan;,citation_author=Freda Yang;,citation_author=Yingjia Yang;,citation_author=Michael Yanney;,citation_author=Woei Lin Yap;,citation_author=Nabil Yaqoob;,citation_author=Salima Yasmin;,citation_author=Bryan Yates;,citation_author=David Yates;,citation_author=Edward Yates;,citation_author=Helen Yates;,citation_author=Thomas Yates;,citation_author=Mark Yates;,citation_author=Charlotte Yearwood Martin;,citation_author=Khin Yein;,citation_author=Fiona Yelnoorkar;,citation_author=Peter Yew;,citation_author=Laura Ylquimiche;,citation_author=Laura Ylquimiche Melly;,citation_author=Inez Ynter;,citation_author=H Yong;,citation_author=Jemma Yorke;,citation_author=Jasmine Youens;,citation_author=Abdel Younes Ibrahim;,citation_author=Eoin Young;,citation_author=Gail Young;,citation_author=Louise Young;,citation_author=Asfand Yousafzar;,citation_author=Sajeda Youssouf;,citation_author=Ahmed Yousuf;,citation_author=Chrissie Yu;,citation_author=Bernard Yung;,citation_author=Daniel Yusef;,citation_author=Said Yusef;,citation_author=Intekhab Yusuf;,citation_author=Anna-Sophia Zafar;,citation_author=Silvia Zagalo;,citation_author=Su Zaher;,citation_author=Aqsa Zahoor;,citation_author=Kareem Zaki;,citation_author=Nabhan Zakir;,citation_author=Kasia Zalewska;,citation_author=Ane Zamalloa;,citation_author=Mohsin Zaman;,citation_author=Shakir Zaman;,citation_author=Julie Zamikula;,citation_author=Louise Zammit;,citation_author=Marie Zammit-Mangion;,citation_author=Esther Zebracki;,citation_author=Daniel Zehnder;,citation_author=Lisa Zeidan;,citation_author=Xiaobei Zhao;,citation_author=Dongling Zheng;,citation_author=Doreen Zhu;,citation_author=Madiha Zia;,citation_author=Omar Zibdeh;,citation_author=Rabia Zill-E-Huma;,citation_author=Ei Thankt Zin;,citation_author=Eleanor Zinkin;,citation_author=Vivian Zinyemba;,citation_author=Christos Zipitis;,citation_author=Arkadiusz Zmierczak;,citation_author=Azam Zubir;,citation_author=Naz Zuhra;,citation_author=Rasha Zulaikha;,citation_author=Sabrina Zulfikar;,citation_author=Carol Zullo;,citation_author=Ana Zuriaga-Alvaro;,citation_author=Sheba Zyengi;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_issue=10325;,citation_doi=10.1016/S0140-6736(22)00163-5;,citation_issn=01406736;,citation_volume=399;,citation_language=en-US;,citation_journal_title=The Lancet;">
<meta name="citation_reference" content="citation_title=Why RECOVERY is a milestone in medical research;,citation_author=Kamran Abbasi;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_issue=9;,citation_doi=10.1177/01410768211043972;,citation_issn=0141-0768, 1758-1095;,citation_volume=114;,citation_language=en-US;,citation_journal_title=Journal of the Royal Society of Medicine;">
<meta name="citation_reference" content="citation_title=Time to Stop Using Ineffective Covid-19 Drugs;,citation_abstract=In practicing evidence-based medicine, physicians use the best evidence currently available on safety and efficacy in making decisions on treatment choices for their patients. During the Covid-19 pandemic, some of the early treatment trials were rushed, leading to studies that were badly conducted1 or had too few patients.2 As a result, initial evidence of the efficacy of some Covid-19 treatments could not be replicated,3,4 but these drugs were already in widespread use by then, and some clinicians have been reluctant to change to proven efficacious alternatives. Ivermectin and fluvoxamine, in particular, are still widely prescribed, even though evidence has been . . .;,citation_author=Salim S. Abdool Karim;,citation_author=Nikita Devnarain;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_issue=7;,citation_doi=10.1056/NEJMe2209017;,citation_issn=0028-4793;,citation_volume=387;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Deliberate Practice at the Virtual Bedside to Improve Clinical Reasoning;,citation_author=Raja-Elie E. Abdulnour;,citation_author=Andrew S. Parsons;,citation_author=Daniel Muller;,citation_author=Jeffrey Drazen;,citation_author=Eric J. Rubin;,citation_author=Joseph Rencic;,citation_publication_date=2022-05;,citation_cover_date=2022-05;,citation_year=2022;,citation_issue=20;,citation_doi=10.1056/NEJMe2204540;,citation_issn=0028-4793, 1533-4406;,citation_volume=386;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Epidemiology and patterns of tracheostomy practice in patients with acute respiratory distress syndrome in ICUs across 50 countries;,citation_abstract=To better understand the epidemiology and patterns of tracheostomy practice for patients with acute respiratory distress syndrome (ARDS), we investigated the current usage of tracheostomy in patients with ARDS recruited into the Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure (LUNG-SAFE) study.;,citation_author=Toshikazu Abe;,citation_author=Fabiana Madotto;,citation_author=Tài Pham;,citation_author=Isao Nagata;,citation_author=Masatoshi Uchida;,citation_author=Nanako Tamiya;,citation_author=Kiyoyasu Kurahashi;,citation_author=Giacomo Bellani;,citation_author=John G. Laffey;,citation_author=Guy M. Francois;,citation_author=Francesca Rabboni;,citation_author=Fabiana Madotto;,citation_author=Sara Conti;,citation_author=John G. Laffey;,citation_author=Giacomo Bellani;,citation_author=Tai Pham;,citation_author=Eddy Fan;,citation_author=Antonio Pesenti;,citation_author=Laurent Brochard;,citation_author=Andres Esteban;,citation_author=Luciano Gattinoni;,citation_author=Frank Haren;,citation_author=Anders Larsson;,citation_author=Daniel F. McAuley;,citation_author=Marco Ranieri;,citation_author=Gordon Rubenfeld;,citation_author=B. Taylor Thompson;,citation_author=Hermann Wrigge;,citation_author=Arthur S. Slutsky;,citation_author=Fernando Rios;,citation_author=T. Sottiaux;,citation_author=P. Depuydt;,citation_author=Fredy S. Lora;,citation_author=Luciano Cesar Azevedo;,citation_author=Guillermo Bugedo;,citation_author=Haibo Qiu;,citation_author=Marcos Gonzalez;,citation_author=Juan Silesky;,citation_author=Vladimir Cerny;,citation_author=Jonas Nielsen;,citation_author=Manuel Jibaja;,citation_author=Tài Pham;,citation_author=Dimitrios Matamis;,citation_author=Jorge Luis Ranero;,citation_author=Pravin Amin;,citation_author=S. M. Hashemian;,citation_author=Kevin Clarkson;,citation_author=Kiyoyasu Kurahashi;,citation_author=Asisclo Villagomez;,citation_author=Amine Ali Zeggwagh;,citation_author=Leo M. Heunks;,citation_author=Jon Henrik Laake;,citation_author=Jose Emmanuel Palo;,citation_author=Antero Vale Fernandes;,citation_author=Dorel Sandesc;,citation_author=Yaasen Arabi;,citation_author=Vesna Bumbasierevic;,citation_author=Nicolas Nin;,citation_author=Jose A. Lorente;,citation_author=Lise Piquilloud;,citation_author=Fekri Abroug;,citation_author=Lia McNamee;,citation_author=Javier Hurtado;,citation_author=Ed Bajwa;,citation_author=Gabriel Démpair;,citation_author=Hektor Sula;,citation_author=Lordian Nunci;,citation_author=Alma Cani;,citation_author=Alan Zazu;,citation_author=Christian Dellera;,citation_author=Carolina S. Insaurralde;,citation_author=Risso V. Alejandro;,citation_author=Julio Daldin;,citation_author=Mauricio Vinzio;,citation_author=Ruben O. Fernandez;,citation_author=Luis P. Cardonnet;,citation_author=Lisandro R. Bettini;,citation_author=Mariano Carboni Bisso;,citation_author=Emilio M. Osman;,citation_author=Mariano G. Setten;,citation_author=Pablo Lovazzano;,citation_author=Javier Alvarez;,citation_author=Veronica Villar;,citation_author=Cesar Milstein;,citation_author=Norberto C. Pozo;,citation_author=Nicolas Grubissich;,citation_author=Gustavo A. Plotnikow;,citation_author=Daniela N. Vasquez;,citation_author=Santiago Ilutovich;,citation_author=Norberto Tiribelli;,citation_author=Ariel Chena;,citation_author=Carlos A. Pellegrini;,citation_author=María G. Saenz;,citation_author=Elisa Estenssoro;,citation_author=Matias Brizuela;,citation_author=Hernan Gianinetto;,citation_author=Pablo E. Gomez;,citation_author=Valeria I. Cerrato;,citation_author=Marco G. Bezzi;,citation_author=Silvina A. Borello;,citation_author=Flavia A. Loiacono;,citation_author=Adriana M. Fernandez;,citation_author=Serena Knowles;,citation_author=Claire Reynolds;,citation_author=Deborah M. Inskip;,citation_author=Jennene J. Miller;,citation_author=Jing Kong;,citation_author=Christina Whitehead;,citation_author=Shailesh Bihari;,citation_author=Aylin Seven;,citation_author=Amanda Krstevski;,citation_author=Helen J. Rodgers;,citation_author=Rebecca T. Millar;,citation_author=Toni E. Mckenna;,citation_author=Irene M. Bailey;,citation_author=Gabrielle C. Hanlon;,citation_author=Anders Aneman;,citation_author=Joan M. Lynch;,citation_author=Raman Azad;,citation_author=John Neal;,citation_author=Paul W. Woods;,citation_author=Brigit L. Roberts;,citation_author=Mark R. Kol;,citation_author=Helen S. Wong;,citation_author=Katharina C. Riss;,citation_author=Xavier Wittebole;,citation_author=Caroline Berghe;,citation_author=Pierre A. Bulpa;,citation_author=Alain M. Dive;,citation_author=Rik Verstraete;,citation_author=Herve Lebbinck;,citation_author=Pieter Depuydt;,citation_author=Joris Vermassen;,citation_author=Philippe Meersseman;,citation_author=Helga Ceunen;,citation_author=Jonas I. Rosa;,citation_author=Daniel O. Beraldo;,citation_author=Claudio Piras;,citation_author=Adenilton M. Rampinelli;,citation_author=Antonio P. Nassar;,citation_author=Sergio Mataloun;,citation_author=Marcelo Moock;,citation_author=Marlus M. Thompson;,citation_author=Claudio H. Gonçalves;,citation_author=Ana Carolina P. Antônio;,citation_author=Aline Ascoli;,citation_author=Rodrigo S. Biondi;,citation_author=Danielle C. Fontenele;,citation_author=Danielle Nobrega;,citation_author=Vanessa M. Sales;,citation_author=Suresh Shindhe;,citation_author=Dayangku Hajah Maizatul Aiman binti Pengiran Haji Ismail;,citation_author=John Laffey;,citation_author=Francois Beloncle;,citation_author=Kyle G. Davies;,citation_author=Rob Cirone;,citation_author=Venika Manoharan;,citation_author=Mehvish Ismail;,citation_author=Ewan C. Goligher;,citation_author=Mandeep Jassal;,citation_author=Erin Nishikawa;,citation_author=Areej Javeed;,citation_author=Gerard Curley;,citation_author=Nuttapol Rittayamai;,citation_author=Matteo Parotto;,citation_author=Niall D. Ferguson;,citation_author=Sangeeta Mehta;,citation_author=Jenny Knoll;,citation_author=Antoine Pronovost;,citation_author=Sergio Canestrini Chile;,citation_author=Alejandro R. Bruhn;,citation_author=Patricio H. Garcia;,citation_author=Felipe A. Aliaga;,citation_author=Pamela A. Farías;,citation_author=Jacob S. Yumha;,citation_author=Claudia A. Ortiz;,citation_author=Javier E. Salas;,citation_author=Alejandro A. Saez;,citation_author=Luis D. Vega;,citation_author=Eduardo F. Labarca;,citation_author=Felipe T. Martinez;,citation_author=Nicolás G. Carreño;,citation_author=Pilar Lora;,citation_author=Haitao Liu;,citation_author=Ling Liu;,citation_author=Rui Tang;,citation_author=Xiaoming Luo;,citation_author=Youzhong An;,citation_author=Huiying Zhao;,citation_author=Yan Gao;,citation_author=Zhe Zhai;,citation_author=Zheng L. Ye;,citation_author=Wei Wang;,citation_author=Wenwen Li;,citation_author=Qingdong Li;,citation_author=Ruiqiang Zheng;,citation_author=Wenkui Yu;,citation_author=Juanhong Shen;,citation_author=Xinyu Li;,citation_author=Tao Yu;,citation_author=Weihua Lu;,citation_author=Ya Q. Wu;,citation_author=Xiao B. Huang;,citation_author=Zhenyang He;,citation_author=Yuanhua Lu;,citation_author=Hui Han;,citation_author=Fan Zhang;,citation_author=Renhua Sun;,citation_author=Hua X. Wang;,citation_author=Shu H. Qin;,citation_author=Bao H. Zhu;,citation_author=Jun Zhao;,citation_author=Jian Liu;,citation_author=Bin Li;,citation_author=Jing L. Liu;,citation_author=Fa C. Zhou;,citation_author=Qiong J. Li;,citation_author=Xing Y. Zhang;,citation_author=Zhou Li-Xin;,citation_author=Qiang Xin-Hua;,citation_author=Liangyan Jiang;,citation_author=Yuan N. Gao;,citation_author=Xian Y. Zhao;,citation_author=Yuan Y. Li;,citation_author=Xiao L. Li;,citation_author=Chunting Wang;,citation_author=Qingchun Yao;,citation_author=Rongguo Yu;,citation_author=Kai Chen;,citation_author=Huanzhang Shao;,citation_author=Bingyu Qin;,citation_author=Qing Q. Huang;,citation_author=Wei H. Zhu;,citation_author=Ai Y. Hang;,citation_author=Ma X. Hua;,citation_author=Yimin Li;,citation_author=Yonghao Xu;,citation_author=Yu D. Di;,citation_author=Long L. Ling;,citation_author=Tie H. Qin;,citation_author=Shou H. Wang;,citation_author=Junping Qin;,citation_author=Yi Han;,citation_author=Monica P. Vargas;,citation_author=Juan I. Silesky Jimenez;,citation_author=Manuel A. González Rojas;,citation_author=Jaime E. Solis-Quesada;,citation_author=Christian M. Ramirez-Alfaro;,citation_author=Jan Máca;,citation_author=Peter Sklienka;,citation_author=Jakob Gjedsted;,citation_author=Boris G. Villamagua;,citation_author=Miguel Llano;,citation_author=Philippe Burtin;,citation_author=Gautier Buzancais;,citation_author=Pascal Beuret;,citation_author=Nicolas Pelletier;,citation_author=Satar Mortaza;,citation_author=Alain Mercat;,citation_author=Jonathan Chelly;,citation_author=Sébastien Jochmans;,citation_author=Nicolas Terzi;,citation_author=Cédric Daubin;,citation_author=Guillaume Carteaux;,citation_author=Nicolas Prost;,citation_author=Jean-Daniel Chiche;,citation_author=Fabrice Daviaud;,citation_author=Muriel Fartoukh;,citation_author=Guillaume Barberet;,citation_author=Jerome Biehler;,citation_author=Jean Dellamonica;,citation_author=Denis Doyen;,citation_author=Jean-Michel Arnal;,citation_author=Anais Briquet;,citation_author=Sami Hraiech;,citation_author=Laurent Papazian;,citation_author=Damien Roux;,citation_author=Jonathan Messika;,citation_author=Evangelos Kalaitzis;,citation_author=Réanimation Médicale;,citation_author=Laurence Dangers;,citation_author=Alain Combes;,citation_author=Siu-Ming Au;,citation_author=Gaetan Béduneau;,citation_author=Dorothée Carpentier;,citation_author=Elie H. Zogheib;,citation_author=Herve Dupont;,citation_author=Sylvie Ricome;,citation_author=Francesco L. Santoli;,citation_author=Sebastien L. Besset;,citation_author=Philippe Michel;,citation_author=Bruno Gelée;,citation_author=Pierre-Eric Danin;,citation_author=Bernard Goubaux;,citation_author=Philippe J. Crova;,citation_author=Nga T. Phan;,citation_author=Frantz Berkelmans;,citation_author=Julio C. Badie;,citation_author=Romain Tapponnier;,citation_author=for the LUNG-SAFE Investigators and the ESICM Trials Group;,citation_publication_date=2018-08;,citation_cover_date=2018-08;,citation_year=2018;,citation_issue=1;,citation_doi=10.1186/s13054-018-2126-6;,citation_issn=1364-8535;,citation_volume=22;,citation_journal_title=Critical Care;">
<meta name="citation_reference" content="citation_title=Next Chapter for Weight Control — Small-Molecule GLP-1 Receptor Agonists?;,citation_abstract=Obesity is a major risk factor for many health conditions, including cardiovascular disease, type 2 diabetes, sleep apnea, and cancer. The therapeutic armamentarium for long-term weight management is limited by side effects and contraindications.1 Two injectable incretin-based glucagon-like peptide-1 (GLP-1) receptor agonists — liraglutide (3.0 mg daily) and semaglutide (2.4 mg weekly) — have been approved by the Food and Drug Administration (FDA) for weight management, with better side-effect profiles than other treatments. An oral formulation of semaglutide (7 or 14 mg once daily) has been approved by the FDA for the treatment of type 2 diabetes but not yet . . .;,citation_author=E. Dale Abel;,citation_publication_date=2023-09;,citation_cover_date=2023-09;,citation_year=2023;,citation_issue=10;,citation_doi=10.1056/NEJMe2307285;,citation_issn=0028-4793;,citation_pmid=37672699;,citation_volume=389;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Common things are common, but what is common? Incorporating probability information into differential diagnosis;,citation_abstract=The well-known clinical axiom declaring that “common things are common” attests to the pivotal role of probability in diagnosis. Despite the popularity of this and related axioms, there is no operationalized definition of a common disease, and no practicable way of incorporating actual disease frequencies into differential diagnosis. In this essay, we aim to disambiguate the definition of a common (or rare) disease and show that incidence—not prevalence—is the proper metric of disease frequency for differential diagnosis. We explore how numerical estimates of disease frequencies based on incidence can be incorporated into differential diagnosis as well as the inherent limitations of this method. These concepts have important implications for diagnostic decision making and medical education, and hold promise as a method to improve diagnostic accuracy.;,citation_author=Scott K. Aberegg;,citation_author=Sean J. Callahan;,citation_publication_date=2022;,citation_cover_date=2022;,citation_year=2022;,citation_issue=6;,citation_doi=10.1111/jep.13636;,citation_issn=1365-2753;,citation_volume=28;,citation_language=en-US;,citation_journal_title=Journal of Evaluation in Clinical Practice;">
<meta name="citation_reference" content="citation_title=Empirical Consequences of Current Recommendations for the Design and Interpretation of Noninferiority Trials;,citation_abstract=BACKGROUND: Noninferiority trials are increasingly common, though they have less standardized designs and their interpretation is less familiar to clinicians than superiority trials. OBJECTIVE: To empirically evaluate a cohort of noninferiority trials to determine 1) their interpretation as recommended by CONSORT, 2) choice of alpha threshold and its sidedness, and 3) differences between methods of analysis such as intention-to-treat and per-protocol. DESIGN: We searched MEDLINE for parallel-group randomized controlled noninferiority trials published in the five highest-impact general medical journals between 2011 and 2016. MAIN MEASURES: Data abstracted included trial design parameters, results, and interpretation of results based on CONSORT recommendations. KEY RESULTS: One hundred sixty-three trials and 182 noninferiority comparisons were included in our analysis. Based on CONSORT-recommended interpretation, 79% of experimental therapies met criteria for noninferiority, 13% met criteria for superiority, 20% were declared inconclusive, and 2% met criteria for inferiority. However, for 12% of trials, the experimental therapy was statistically significantly worse than the active control, but CONSORT recommended an interpretation of inconclusive or noninferior. A two-sided alpha equivalent of greater than 0.05 was used in 34% of the trials, and in five of these trials, the use of a standard two-sided alpha of 0.05 led to changes in the interpretation of results that disfavored the experimental therapy. In four of the five comparisons where different methods of analysis (e.g., intention-to-treat and per-protocol) yielded different results, the intention-to-treat analysis was the more conservative. In 11% of trials, a secondary advantage of the new therapy was neither reported nor could it be inferred by reviewers. CONCLUSIONS: In this cohort, the design and interpretation of noninferiority trials led to significant and systematic bias in favor of the experimental therapy. Clinicians should exercise caution when interpreting these trials. Future trials may be more reliable if design parameters are standardized.;,citation_author=Scott K. Aberegg;,citation_author=Andrew M. Hersh;,citation_author=Matthew H. Samore;,citation_publication_date=2018-01;,citation_cover_date=2018-01;,citation_year=2018;,citation_issue=1;,citation_doi=10.1007/s11606-017-4161-4;,citation_issn=0884-8734, 1525-1497;,citation_volume=33;,citation_language=en-US;,citation_journal_title=Journal of General Internal Medicine;">
<meta name="citation_reference" content="citation_title=Do non-inferiority trials of reduced intensity therapies show reduced effects? A descriptive analysis;,citation_abstract=Objectives To identify non-inferiority trials within a cohort where the experimental therapy is the same as the active control comparator but at a reduced intensity and determine if these non-inferiority trials of reduced intensity therapies have less favourable results than other non-inferiority trials in the cohort. Such a finding would provide suggestive evidence of biocreep in these trials. Design This metaresearch study used a cohort of non-inferiority trials published in the five highest impact general medical journals during a 5-year period. Data relating to the characteristics and results of the trials were abstracted. Primary outcome measures Proportions of trials with a declaration of superiority, non-inferiority and point estimates favouring the experimental therapy and mean absolute risk differences for trials with outcomes expressed as a proportion. Results Our search yielded 163 trials reporting 182 non-inferiority comparisons; 36 comparisons from 31 trials were between the same therapy at reduced and full intensity. Compared with trials not evaluating reduced intensity therapies, fewer comparisons of reduced intensity therapies demonstrated a favourable result (non-inferiority or superiority) (58.3%vs82.2%; P=0.002) and fewer demonstrated superiority (2.8%vs18.5%; P=0.019). Likewise, point estimates for reduced intensity therapies more often favoured active control than those for other trials (77.8%vs39.7%; P&amp;amp;amp;lt;0.001) as did mean absolute risk differences (+2.5% vs -0.7%; P=0.018). Conclusions Non-inferiority trials comparing a therapy at reduced intensity to the same therapy at full intensity showed reduced effects compared with other non-inferiority trials. This suggests these trials may have a high rate of type 1 errors and biocreep, with significant implications for the design and interpretation of future non-inferiority trials.;,citation_author=Scott K. Aberegg;,citation_author=Andrew M. Hersh;,citation_author=Matthew H. Samore;,citation_publication_date=2018-03;,citation_cover_date=2018-03;,citation_year=2018;,citation_issue=3;,citation_doi=10.1136/bmjopen-2017-019494;,citation_issn=2044-6055, 2044-6055;,citation_pmid=29500210;,citation_volume=8;,citation_language=en-US;,citation_journal_title=BMJ Open;,citation_publisher=British Medical Journal Publishing Group;">
<meta name="citation_reference" content="citation_title=Reporting Noninferiority Trials;,citation_abstract=To the Editor: Dr Piaggio and colleagues presented an updated extension of the Consolidated Standards of Reporting Trials (CONSORT) statement for reporting noninferiority and equivalence trials. I believe the statement should be revised so that interpretation of noninferiority trials is not biased.Because Figure 1 in the article has a zone of inferiority that is asymmetric (it lacks a negative delta on the left to mirror the positive delta on the right), superiority of the new treatment is more likely than inferiority, and an advantage is conferred to the therapy arbitrarily designated as new. For example, if a new anticoagulant is compared with warfarin (reference treatment) and the results statistically favor the new anticoagulant by any margin, it is declared superior (scenario A in Figure 1).;,citation_author=Scott Aberegg;,citation_publication_date=2013-04;,citation_cover_date=2013-04;,citation_year=2013;,citation_issue=15;,citation_doi=10.1001/jama.2013.3086;,citation_issn=0098-7484;,citation_volume=309;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Extracorporeal Membrane Oxygenation for Adult Respiratory Failure;,citation_author=Darryl Abrams;,citation_author=Daniel Brodie;,citation_publication_date=2017-09;,citation_cover_date=2017-09;,citation_year=2017;,citation_issue=3;,citation_doi=10.1016/j.chest.2017.06.016;,citation_issn=00123692;,citation_volume=152;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Extracorporeal cardiopulmonary resuscitation in adults: Evidence and implications;,citation_abstract=Rates of survival with functional recovery for both in-hospital and out-of-hospital cardiac arrest are notably low. Extra-corporeal cardiopulmonary resuscitation (ECPR) is emerging as a modality to improve prognosis by augmenting per-fusion to vital end-organs by utilizing extracorporeal membrane oxygenation (ECMO) during conventional CPR and stabilizing the patient for interventions aimed at reversing the aetiology of the arrest. Implementing this emergent procedure requires a substantial investment in resources, and even the most successful ECPR programs may nonethe-less burden healthcare systems, clinicians, patients, and their families with unsalvageable patients supported by extra-corporeal devices. Non-randomized and observational studies have repeatedly shown an association between ECPR and improved survival, versus conventional CPR, for in-hospital cardiac arrest in select patient populations. Recently, randomized controlled trials suggest benefit for ECPR over standard resuscitation, as well as the feasibility of perform-ing such trials, in out-of-hospital cardiac arrest within highly coordinated healthcare delivery systems. Application of these data to clinical practice should be done cautiously, with outcomes likely to vary by the setting and system within which ECPR is initiated. ECPR introduces important ethical challenges, including whether it should be con-sidered an extension of CPR, at what point it becomes sustained organ replacement therapy, and how to approach patients unable to recover or be bridged to heart replacement therapy. The economic impact of ECPR varies by health system, and has the potential to outstrip resources if used indiscriminately. Ideally, studies should include economic evaluations to inform health care systems about the cost-benefits of this therapy.;,citation_author=Darryl Abrams;,citation_author=Graeme MacLaren;,citation_author=Roberto Lorusso;,citation_author=Susanna Price;,citation_author=Demetris Yannopoulos;,citation_author=Leen Vercaemst;,citation_author=Jan Bělohlávek;,citation_author=Fabio S. Taccone;,citation_author=Nadia Aissaoui;,citation_author=Kiran Shekar;,citation_author=A. Reshad Garan;,citation_author=Nir Uriel;,citation_author=Joseph E. Tonna;,citation_author=Jae Seung Jung;,citation_author=Koji Takeda;,citation_author=Yih-Sharng Chen;,citation_author=Arthur S. Slutsky;,citation_author=Alain Combes;,citation_author=Daniel Brodie;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=1;,citation_doi=10.1007/s00134-021-06514-y;,citation_issn=0342-4642, 1432-1238;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=A positive fluid balance is an independent prognostic factor in patients with sepsis;,citation_abstract=Intravenous fluid administration is an essential component of sepsis management, but a positive fluid balance has been associated with worse prognosis. We analyzed whether a positive fluid balance and its persistence over time was an independent prognostic factor in septic patients.;,citation_author=Angela Acheampong;,citation_author=Jean-Louis Vincent;,citation_publication_date=2015-12;,citation_cover_date=2015-12;,citation_year=2015;,citation_issue=1;,citation_doi=10.1186/s13054-015-0970-1;,citation_issn=1364-8535;,citation_volume=19;,citation_language=en-US;,citation_journal_title=Critical Care;">
<meta name="citation_reference" content="citation_title=Treatment of Hyponatremic Encephalopathy in the Critically Ill:;,citation_author=Steven G. Achinger;,citation_author=Juan Carlos Ayus;,citation_publication_date=2017-10;,citation_cover_date=2017-10;,citation_year=2017;,citation_issue=10;,citation_doi=10.1097/CCM.0000000000002595;,citation_issn=0090-3493;,citation_volume=45;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Cardiovascular Health Disparities in Racial and Other Underrepresented Groups: Initial Results From the All of Us Research Program;,citation_abstract=BACKGROUND: All of Us is a novel research program that aims to accelerate research in populations traditionally underrepresented in biomedical research. Our objective was to evaluate the burden of cardiovascular disease (CVD) in broadly defined underrepresented groups. METHODS AND RESULTS: We evaluated the latest data release of All of Us. We conducted a cross-sectional analysis combining survey and electronic health record data to estimate the prevalence of CVD upon enrollment in underrepresented groups defined by race, ethnicity, age (&amp;amp;amp;gt;75 years), disability (not able to carry out everyday physical activities), sexual orientation and gender identity lesbian, gay, bisexual, transgender, queer, intersex, and asexual (LGBTQIA+), income (annual household income &amp;lt;\$35 000 US dollars) and education (less than a high school degree). We used multivariate logistic regression to estimate the adjusted odds ratio (OR) and product terms to test for interaction. The latest All of Us data release includes 315 297 participants. Of these, 230 577 (73%) had information on CVD and 17 958 had CVD (overall prevalence, 7.8%; 95% CI, 7.7–). Multivariate analyses adjusted by hypertension, hyperlipidemia, type 2 diabetes mellitus, body mass index, and smoking indicated that, compared with White participants, Black participants had a higher adjusted odds of CVD (OR, 1.21; 95% CI, 1.16–). Higher adjusted odds of CVD were also observed in underrepresented groups defined by other factors, including age &amp;gt;75 years (OR, 1.90; 95% CI, 1.81–), disability (OR, 1.60; 95% CI, 1.53–), and income &amp;lt;\$35 000 US dollars (OR, 1.22; 95% CI, 1.17–). Sex significantly modified the odds of CVD in several of the evaluated groups. CONCLUSIONS: Among participants enrolled in All of Us, underrepresented groups defined based on race, ethnicity and other factors have a disproportionately high burden of CVD. The All of Us research program constitutes a powerful platform to accelerate research focused on individuals in underrepresented groups.;,citation_author=Julián N. Acosta;,citation_author=Audrey C. Leasure;,citation_author=Cameron P. Both;,citation_author=Natalia Szejko;,citation_author=Stacy Brown;,citation_author=Victor Torres-Lopez;,citation_author=Safa Abdelhakim;,citation_author=Joseph Schindler;,citation_author=Nils Petersen;,citation_author=Lauren Sansing;,citation_author=Thomas M. Gill;,citation_author=Kevin N. Sheth;,citation_author=Guido J. Falcone;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_issue=17;,citation_doi=10.1161/JAHA.121.021724;,citation_issn=2047-9980;,citation_volume=10;,citation_language=en-US;,citation_journal_title=Journal of the American Heart Association;">
<meta name="citation_reference" content="citation_title=Transparency and the Doctor–Patient Relationship — Rethinking Conflict-of-Interest Disclosures;,citation_author=Eli Y. Adashi;,citation_author=I. Glenn Cohen;,citation_author=Jacob T. Elberg;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=4;,citation_doi=10.1056/NEJMp2114495;,citation_issn=0028-4793, 1533-4406;,citation_volume=386;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Intracranial Pressure Monitoring and Management in Aneurysmal Subarachnoid Hemorrhage;,citation_abstract=Aneurysmal subarachnoid hemorrhage is a medical condition that can lead to intracranial hypertension, negatively impacting patients’ outcomes. This review article explores the underlying pathophysiology that causes increased intracranial pressure (ICP) during hospitalization. Hydrocephalus, brain swelling, and intracranial hematoma could produce an ICP rise. Although cerebrospinal fluid withdrawal via an external ventricular drain is commonly used, ICP monitoring is not always consistently practiced. Indications for ICP monitoring include neurological deterioration, hydrocephalus, brain swelling, intracranial masses, and the need for cerebrospinal fluid drainage. This review emphasizes the importance of ICP monitoring and presents findings from the Synapse-ICU study, which supports a correlation between ICP monitoring and treatment with better patient outcomes. The review also discusses various therapeutic strategies for managing increased ICP and identifies potential areas for future research.;,citation_author=Alberto Addis;,citation_author=Marta Baggiani;,citation_author=Giuseppe Citerio;,citation_publication_date=2023-06;,citation_cover_date=2023-06;,citation_year=2023;,citation_doi=10.1007/s12028-023-01752-y;,citation_issn=1556-0961;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Critical Care Management of the Patient with Clostridioides difficile;,citation_author=Max W. Adelman;,citation_author=Michael H. Woodworth;,citation_author=Virginia O. Shaffer;,citation_author=Greg S. Martin;,citation_author=Colleen S. Kraft;,citation_publication_date=2021-01;,citation_cover_date=2021-01;,citation_year=2021;,citation_issue=1;,citation_doi=10.1097/CCM.0000000000004739;,citation_issn=0090-3493;,citation_volume=49;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Trends in Surgical Management and Mortality of Intracerebral Hemorrhage in the United States Before and After the STICH Trial;,citation_abstract=Background The Surgical Trial in Intracerebral Hemorrhage (STICH) showed no overall benefit from early surgery compared with initial conservative treatment for intracerebral hemorrhage (ICH). We hypothesized that the STICH trial findings would lead to a reduction in the rates of surgery for ICH in the United States. Using a national hospital database, we determined trends in surgery for ICH before and after publication of STICH. We also determined trends in ICH mortality during the study period.;,citation_author=Opeolu Adeoye;,citation_author=Andrew Ringer;,citation_author=Richard Hornung;,citation_author=Pooja Khatri;,citation_author=Mario Zuccarello;,citation_author=Dawn Kleindorfer;,citation_publication_date=2010-08;,citation_cover_date=2010-08;,citation_year=2010;,citation_issue=1;,citation_doi=10.1007/s12028-010-9351-4;,citation_issn=1541-6933, 1556-0961;,citation_volume=13;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Beyond Confounding: Identifying Selection Bias in Observational Pulmonary and Critical Care Research;,citation_author=Andrew J Admon;,citation_author=Amy S. B. Bohnert;,citation_author=Colin R Cooke;,citation_author=Stephanie Parks Taylor;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_doi=10.1513/AnnalsATS.202110-1188PS;,citation_issn=2329-6933, 2325-6621;,citation_language=en-US;,citation_journal_title=Annals of the American Thoracic Society;">
<meta name="citation_reference" content="citation_title=Emulating a Novel Clinical Trial Using Existing Observational Data. Predicting Results of the PreVent Study;,citation_abstract=Rationale: “Target trial emulation” has been proposed as an observational method to answer comparative effectiveness questions, but it has rarely been attempted concurrently with a randomized clinical trial (RCT). Objectives: We tested the hypothesis that blinded analysts applying target trial emulation to existing observational data could predict the results of an RCT. Methods: PreVent (Preventing Hypoxemia with Manual Ventilation during Endotracheal Intubation) was a multicenter RCT examining the effects of positive-pressure ventilation during tracheal intubation on oxygen saturation and severe hypoxemia. Analysts unaware of PreVent’s results used patient-level data from three previous trials evaluating airway management interventions to emulate PreVent’s eligibility criteria, randomization procedure, and statistical analysis. After PreVent’s release, results of this blinded observational analysis were compared with those of the RCT. Difference-in-differences estimates for comparison of treatment effects between the observational analysis and the PreVent trial are reported on the absolute scale.;,citation_author=Andrew J. Admon;,citation_author=John P. Donnelly;,citation_author=Jonathan D. Casey;,citation_author=David R. Janz;,citation_author=Derek W. Russell;,citation_author=Aaron M. Joffe;,citation_author=Derek J. Vonderhaar;,citation_author=Kevin M. Dischert;,citation_author=Susan B. Stempek;,citation_author=James M. Dargin;,citation_author=Todd W. Rice;,citation_author=Theodore J. Iwashyna;,citation_author=Matthew W. Semler;,citation_publication_date=2019-08;,citation_cover_date=2019-08;,citation_year=2019;,citation_issue=8;,citation_doi=10.1513/AnnalsATS.201903-241OC;,citation_issn=2329-6933, 2325-6621;,citation_volume=16;,citation_language=en-US;,citation_journal_title=Annals of the American Thoracic Society;">
<meta name="citation_reference" content="citation_title=21st Century Evidence: Randomized Controlled Trials Versus Systematic Reviews and Meta-Analyses;,citation_author=Ankita Agarwal;,citation_author=Bram Rochwerg;,citation_author=Jonathan E. Sevransky;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_doi=10.1097/CCM.0000000000005343;,citation_issn=0090-3493;,citation_volume=Publish Ahead of Print;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Parenteral Vitamin C in Patients with Severe Infection: A Systematic Review;,citation_abstract=BACKGROUND Inflammation and oxidative damage caused by severe infections may be attenuated by vitamin C. METHODS We conducted a systematic review of randomized controlled trials (RCTs) of parenteral vitamin C as combined therapy or monotherapy versus no parenteral vitamin C administered to adults hospitalized with severe infection. The primary outcome was mortality. We performed random-effects meta-analyses and assessed certainty in effect estimates. RESULTS Of 1547 citations, 41 RCTs (n 5 4915 patients) were eligible for inclusion. Lowcertainty evidence suggested that vitamin C may reduce in-hospital mortality (21 RCTs, 2762 patients; risk ratio, 0.88 [95% confidence interval (CI), 0.73 to 1.06]), 30-day mortality (24 RCTs, 3436 patients; risk ratio, 0.83 [95% CI, 0.71 to 0.98]), and early mortality (before hospital discharge or 30 days; 34 RCTs, 4366 patients; risk ratio, 0.80 [95% CI, 0.68 to 0.93]). Effects were attenuated in sensitivity analyses limited to published blinded trials at low risk-of-bias (in-hospital mortality: risk ratio, 1.07 [95% CI, 0.92 to 1.24], moderate certainty; 30-day mortality: risk ratio, 0.88 [95% CI, 0.71 to 1.10], low certainty; and early mortality: risk ratio, 0.88 [95% CI, 0.73 to 1.06], low certainty). For 90-day mortality, all trials had low risk-of-bias; moderate-certainty evidence suggested harm (five RCTs, 1722 patients; risk ratio, 1.07 [95% CI, 0.94 to 1.21]). Moderatecertainty evidence suggested an increased risk of hypoglycemia (risk ratio, 1.20 [95% CI, 0.69 to 2.08]). Effects on other secondary outcomes were mixed and informed by lowcertainty evidence. No credible subgroup effects were observed for mortality related to cointerventions (monotherapy vs. combined therapy), dose, or type of infection (Covid-19 vs. other). CONCLUSIONS Overall, evidence from RCTs does not establish a survival benefit for vitamin C in patients with severe infection. (PROSPERO number, CRD42020209187.);,citation_author=Arnav Agarwal;,citation_author=John Basmaji;,citation_author=Shannon M. Fernando;,citation_author=Fang Zhou Ge;,citation_author=Yingqi Xiao;,citation_author=Haseeb Faisal;,citation_author=Kimia Honarmand;,citation_author=Mathieu Hylands;,citation_author=Vincent Lau;,citation_author=Kimberley Lewis;,citation_author=Rachel Couban;,citation_author=François Lamontagne;,citation_author=Neill K. J. Adhikari;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_doi=10.1056/EVIDoa2200105;,citation_issn=2766-5526;,citation_language=en-US;,citation_journal_title=NEJM Evidence;">
<meta name="citation_reference" content="citation_title=Improving Efficiency in Medical Diagnosis;,citation_author=Leila Agha;,citation_author=Jonathan Skinner;,citation_author=David Chan;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_issue=22;,citation_doi=10.1001/jama.2022.8587;,citation_issn=0098-7484;,citation_volume=327;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Psychological determinants of erectile dysfunction among middle-aged men;,citation_author=A Aghighi;,citation_author=V H Grigoryan;,citation_author=A Delavar;,citation_publication_date=2015-03;,citation_cover_date=2015-03;,citation_year=2015;,citation_issue=2;,citation_doi=10.1038/ijir.2014.34;,citation_issn=0955-9930, 1476-5489;,citation_volume=27;,citation_language=en-US;,citation_journal_title=International Journal of Impotence Research;">
<meta name="citation_reference" content="citation_title=Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer;,citation_author=Giancarlo Agnelli;,citation_author=Cecilia Becattini;,citation_author=Guy Meyer;,citation_author=Andres Muñoz;,citation_author=Menno V. Huisman;,citation_author=Jean M. Connors;,citation_author=Alexander Cohen;,citation_author=Rupert Bauersachs;,citation_author=Benjamin Brenner;,citation_author=Adam Torbicki;,citation_author=Maria R. Sueiro;,citation_author=Catherine Lambert;,citation_author=Gualberto Gussoni;,citation_author=Mauro Campanini;,citation_author=Andrea Fontanella;,citation_author=Giorgio Vescovo;,citation_author=Melina Verso;,citation_publication_date=2020-04;,citation_cover_date=2020-04;,citation_year=2020;,citation_issue=17;,citation_doi=10.1056/NEJMoa1915103;,citation_issn=0028-4793;,citation_pmid=32223112;,citation_volume=382;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Adjusted Analyses in Studies Addressing Therapy and Harm: Users’ Guides to the Medical Literature;,citation_author=Thomas Agoritsas;,citation_author=Arnaud Merglen;,citation_author=Nilay D. Shah;,citation_author=Martin O’Donnell;,citation_author=Gordon H. Guyatt;,citation_publication_date=2017-02;,citation_cover_date=2017-02;,citation_year=2017;,citation_issue=7;,citation_doi=10.1001/jama.2016.20029;,citation_issn=0098-7484;,citation_volume=317;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Does Sample Size Matter When Interpreting the Fragility Index?:;,citation_author=Wael Ahmed;,citation_author=Robert A. Fowler;,citation_author=Victoria A. McCredie;,citation_publication_date=2016-11;,citation_cover_date=2016-11;,citation_year=2016;,citation_issue=11;,citation_doi=10.1097/CCM.0000000000001976;,citation_issn=0090-3493;,citation_volume=44;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Inferior Vena Cava Filters for the Treatment of Patients With Venous Thromboembolic Disease;,citation_author=Osman Ahmed;,citation_author=Adam S. Cifu;,citation_author=Jonathan Paul;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=13;,citation_doi=10.1001/jama.2021.9262;,citation_issn=0098-7484;,citation_volume=326;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Patient-centred intensive care medicine using a holistic approach: #Zentensivist—an interview with Dr Matthew Siuba;,citation_author=Ingo Ahrens;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=7;,citation_doi=10.1093/ehjacc/zuab061;,citation_issn=2048-8726, 2048-8734;,citation_volume=10;,citation_language=en-US;,citation_journal_title=European Heart Journal. Acute Cardiovascular Care;">
<meta name="citation_reference" content="citation_title=FASTTrial Clinical Centers with No Patients;,citation_author=V Aiyagari;,citation_author=L DaSilva;,citation_author=C Gomez;,citation_author=J Hillburn;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Clinical descriptors of disease trajectories in patients with traumatic brain injury in the intensive care unit (CENTER-TBI): A multicentre observational cohort study;,citation_abstract=Background Patients with traumatic brain injury are a heterogeneous population, and the most severely injured individuals are often treated in an intensive care unit (ICU). The primary injury at impact, and the harmful secondary events that can occur during the first week of the ICU stay, will affect outcome in this vulnerable group of patients. We aimed to identify clinical variables that might distinguish disease trajectories among patients with traumatic brain injury admitted to the ICU.;,citation_author=Cecilia A I Åkerlund;,citation_author=Anders Holst;,citation_author=Shubhayu Bhattacharyay;,citation_author=Nino Stocchetti;,citation_author=Ewout Steyerberg;,citation_author=Peter Smielewski;,citation_author=David K Menon;,citation_author=Ari Ercole;,citation_author=David W Nelson;,citation_author=Cecilia Åkerlund;,citation_author=Krisztina Amrein;,citation_author=Nada Andelic;,citation_author=Lasse Andreassen;,citation_author=Audny Anke;,citation_author=Anna Antoni;,citation_author=Gérard Audibert;,citation_author=Philippe Azouvi;,citation_author=Maria Luisa Azzolini;,citation_author=Ronald Bartels;,citation_author=Pál Barzó;,citation_author=Romuald Beauvais;,citation_author=Ronny Beer;,citation_author=Bo-Michael Bellander;,citation_author=Antonio Belli;,citation_author=Habib Benali;,citation_author=Maurizio Berardino;,citation_author=Luigi Beretta;,citation_author=Morten Blaabjerg;,citation_author=Peter Bragge;,citation_author=Alexandra Brazinova;,citation_author=Vibeke Brinck;,citation_author=Joanne Brooker;,citation_author=Camilla Brorsson;,citation_author=Andras Buki;,citation_author=Monika Bullinger;,citation_author=Manuel Cabeleira;,citation_author=Alessio Caccioppola;,citation_author=Emiliana Calappi;,citation_author=Maria Rosa Calvi;,citation_author=Peter Cameron;,citation_author=Guillermo Carbayo Lozano;,citation_author=Marco Carbonara;,citation_author=Simona Cavallo;,citation_author=Giorgio Chevallard;,citation_author=Arturo Chieregato;,citation_author=Giuseppe Citerio;,citation_author=Hans Clusmann;,citation_author=Mark Coburn;,citation_author=Jonathan Coles;,citation_author=Jamie D. Cooper;,citation_author=Marta Correia;,citation_author=Amra Čović;,citation_author=Nicola Curry;,citation_author=Endre Czeiter;,citation_author=Marek Czosnyka;,citation_author=Claire DahyotFizelier;,citation_author=Paul Dark;,citation_author=Helen Dawes;,citation_author=Véronique De Keyser;,citation_author=Vincent Degos;,citation_author=Francesco Della Corte;,citation_author=Hugo Den Boogert;,citation_author=Bart Depreitere;,citation_author=ula ilvesi;,citation_author=Abhishek Dixit;,citation_author=Emma Donoghue;,citation_author=Jens Dreier;,citation_author=GuyLoup Dulière;,citation_author=Ari Ercole;,citation_author=Patrick Esser;,citation_author=Erzsébet Ezer;,citation_author=Martin Fabricius;,citation_author=Valery L. Feigin;,citation_author=Kelly Foks;,citation_author=Shirin Frisvold;,citation_author=Alex Furmanov;,citation_author=Pablo Gagliardo;,citation_author=Damien Galanaud;,citation_author=Dashiell Gantner;,citation_author=Guoyi Gao;,citation_author=Pradeep George;,citation_author=Alexandre Ghuysen;,citation_author=Lelde Giga;,citation_author=Ben Glocker;,citation_author=Jagoš Golubovic;,citation_author=Pedro A. Gomez;,citation_author=Johannes Gratz;,citation_author=Benjamin Gravesteijn;,citation_author=Francesca Grossi;,citation_author=Russell L. Gruen;,citation_author=Deepak Gupta;,citation_author=Juanita A. Haagsma;,citation_author=Iain Haitsma;,citation_author=Raimund Helbok;,citation_author=Eirik Helseth;,citation_author=Lindsay Horton;,citation_author=Jilske Huijben;,citation_author=Peter J. Hutchinson;,citation_author=Bram Jacobs;,citation_author=Stefan Jankowski;,citation_author=Mike Jarrett;,citation_author=Jiyao Jiang;,citation_author=Faye Johnson;,citation_author=Kelly Jones;,citation_author=Mladen Karan;,citation_author=Angelos G. Kolias;,citation_author=Erwin Kompanje;,citation_author=Daniel Kondziella;,citation_author=Evgenios Kornaropoulos;,citation_author=LarsOwe Koskinen;,citation_author=Noémi Kovács;,citation_author=Ana Kowark;,citation_author=Alfonso Lagares;,citation_author=Linda Lanyon;,citation_author=Steven Laureys;,citation_author=Fiona Lecky;,citation_author=Didier Ledoux;,citation_author=Rolf Lefering;,citation_author=Valerie Legrand;,citation_author=Aurelie Lejeune;,citation_author=Leon Levi;,citation_author=Roger Lightfoot;,citation_author=Hester Lingsma;,citation_author=Andrew I. R. Maas;,citation_author=Ana M. CastañoLeón;,citation_author=Marc Maegele;,citation_author=Marek Majdan;,citation_author=Alex Manara;,citation_author=Geoffrey Manley;,citation_author=Costanza Martino;,citation_author=Hugues Maréchal;,citation_author=Julia Mattern;,citation_author=Catherine McMahon;,citation_author=Béla Melegh;,citation_author=David Menon;,citation_author=Tomas Menovsky;,citation_author=Ana Mikolic;,citation_author=Benoit Misset;,citation_author=Visakh Muraleedharan;,citation_author=Lynnette Murray;,citation_author=Ancuta Negru;,citation_author=David Nelson;,citation_author=Virginia Newcombe;,citation_author=Daan Nieboer;,citation_author=József Nyirádi;,citation_author=Otesile Olubukola;,citation_author=Matej Oresic;,citation_author=Fabrizio Ortolano;,citation_author=Aarno Palotie;,citation_author=Paul M. Parizel;,citation_author=JeanFrançois Payen;,citation_author=Natascha Perera;,citation_author=Vincent Perlbarg;,citation_author=Paolo Persona;,citation_author=Wilco Peul;,citation_author=Anna Piippo-Karjalainen;,citation_author=Matti Pirinen;,citation_author=Dana Pisica;,citation_author=Horia Ples;,citation_author=Suzanne Polinder;,citation_author=Inigo Pomposo;,citation_author=Jussi P. Posti;,citation_author=Louis Puybasset;,citation_author=Andreea Radoi;,citation_author=Arminas Ragauskas;,citation_author=Rahul Raj;,citation_author=Malinka Rambadagalla;,citation_author=Isabel Retel Helmrich;,citation_author=Jonathan Rhodes;,citation_author=Sylvia Richardson;,citation_author=Sophie Richter;,citation_author=Samuli Ripatti;,citation_author=Saulius Rocka;,citation_author=Cecilie Roe;,citation_author=Olav Roise;,citation_author=Jonathan Rosand;,citation_author=Jeffrey V. Rosenfeld;,citation_author=Christina Rosenlund;,citation_author=Guy Rosenthal;,citation_author=Rolf Rossaint;,citation_author=Sandra Rossi;,citation_author=Daniel Rueckert;,citation_author=Martin Rusnák;,citation_author=Juan Sahuquillo;,citation_author=Oliver Sakowitz;,citation_author=Renan SanchezPorras;,citation_author=Janos Sandor;,citation_author=Nadine Schäfer;,citation_author=Silke Schmidt;,citation_author=Herbert Schoechl;,citation_author=Guus Schoonman;,citation_author=Rico Frederik Schou;,citation_author=Elisabeth Schwendenwein;,citation_author=Charlie Sewalt;,citation_author=Ranjit D. Singh;,citation_author=Toril Skandsen;,citation_author=Peter Smielewski;,citation_author=Abayomi Sorinola;,citation_author=Emmanuel Stamatakis;,citation_author=Simon Stanworth;,citation_author=Robert Stevens;,citation_author=William Stewart;,citation_author=Ewout W. Steyerberg;,citation_author=Nino Stocchetti;,citation_author=Nina Sundström;,citation_author=Riikka Takala;,citation_author=Viktória Tamás;,citation_author=Tomas Tamosuitis;,citation_author=Mark Steven Taylor;,citation_author=Braden Te Ao;,citation_author=Olli Tenovuo;,citation_author=Alice Theadom;,citation_author=Matt Thomas;,citation_author=Dick Tibboel;,citation_author=Marjolein Timmers;,citation_author=Christos Tolias;,citation_author=Tony Trapani;,citation_author=Cristina Maria Tudora;,citation_author=Andreas Unterberg;,citation_author=Peter Vajkoczy;,citation_author=Shirley Vallance;,citation_author=Egils Valeinis;,citation_author=Zoltán Vámos;,citation_author=Mathieu Van Der Jagt;,citation_author=Gregory Van Der Steen;,citation_author=Joukje Van Der Naalt;,citation_author=Jeroen T. J. M. Van Dijck;,citation_author=Inge A. M. Van Erp;,citation_author=Thomas A. Van Essen;,citation_author=Wim Van Hecke;,citation_author=Caroline Van Heugten;,citation_author=Dominique Van Praag;,citation_author=Ernest Van Veen;,citation_author=Thijs Vande Vyvere;,citation_author=Roel P. J. Van Wijk;,citation_author=Alessia Vargiolu;,citation_author=Emmanuel Vega;,citation_author=Kimberley Velt;,citation_author=Jan Verheyden;,citation_author=Paul M. Vespa;,citation_author=Anne Vik;,citation_author=Rimantas Vilcinis;,citation_author=Victor Volovici;,citation_author=Nicole Von Steinbüchel;,citation_author=Daphne Voormolen;,citation_author=Petar Vulekovic;,citation_author=Kevin K. W. Wang;,citation_author=Daniel Whitehouse;,citation_author=Eveline Wiegers;,citation_author=Guy Williams;,citation_author=Lindsay Wilson;,citation_author=Stefan Winzeck;,citation_author=Stefan Wolf;,citation_author=Zhihui Yang;,citation_author=Peter Ylén;,citation_author=Alexander Younsi;,citation_author=Frederick A. Zeiler;,citation_author=Veronika Zelinkova;,citation_author=Agate Ziverte;,citation_author=Tommaso Zoerle;,citation_publication_date=2024-01;,citation_cover_date=2024-01;,citation_year=2024;,citation_issue=1;,citation_doi=10.1016/S1474-4422(23)00358-7;,citation_issn=14744422;,citation_volume=23;,citation_language=en-US;,citation_journal_title=The Lancet Neurology;">
<meta name="citation_reference" content="citation_title=Impact of duration and magnitude of raised intracranial pressure on outcome after severe traumatic brain injury: A CENTER-TBI high-resolution group study;,citation_abstract=Magnitude of intracranial pressure (ICP) elevations and their duration have been associated with worse outcomes in patients with traumatic brain injuries (TBI), however published thresholds for injury vary and uncertainty about these levels has received relatively little attention. In this study, we have analyzed high-resolution ICP monitoring data in 227 adult patients in the CENTER-TBI dataset. Our aim was to identify thresholds of ICP intensity and duration associated with worse outcome, and to evaluate the uncertainty in any such thresholds. We present ICP intensity and duration plots to visualize the relationship between ICP events and outcome. We also introduced a novel bootstrap technique to evaluate uncertainty of the equipoise line. We found that an intensity threshold of 18  4 mmHg (2 standard deviations) was associated with worse outcomes in this cohort. In contrast, the uncertainty in what duration is associated with harm was larger, and safe durations were found to be population dependent. The pressure and time dose (PTD) was also calculated as area under the curve above thresholds of ICP. A relationship between PTD and mortality could be established, as well as for unfavourable outcome. This relationship remained valid for mortality but not unfavourable outcome after adjusting for IMPACT core variables and maximum therapy intensity level. Importantly, during periods of impaired autoregulation (defined as pressure reactivity index (PRx)&amp;amp;amp;gt;0.3) ICP events were associated with worse outcomes for nearly all durations and ICP levels in this cohort and there was a stronger relationship between outcome and PTD. Whilst caution should be exercised in ascribing causation in observational analyses, these results suggest intracranial hypertension is poorly tolerated in the presence of impaired autoregulation. ICP level guidelines may need to be revised in the future taking into account cerebrovascular autoregulation status considered jointly with ICP levels.;,citation_author=Cecilia AI Åkerlund;,citation_author=Joseph Donnelly;,citation_author=Frederick A. Zeiler;,citation_author=Raimund Helbok;,citation_author=Anders Holst;,citation_author=Manuel Cabeleira;,citation_author=Fabian Güiza;,citation_author=Geert Meyfroidt;,citation_author=Marek Czosnyka;,citation_author=Peter Smielewski;,citation_author=Nino Stocchetti;,citation_author=Ari Ercole;,citation_author=David W. Nelson;,citation_author=the CENTER-TBI High Resolution ICU Sub-Study Participants Investigators;,citation_publication_date=2020-12;,citation_cover_date=2020-12;,citation_year=2020;,citation_issue=12;,citation_doi=10.1371/journal.pone.0243427;,citation_issn=1932-6203;,citation_volume=15;,citation_language=en-US;,citation_journal_title=PLOS ONE;,citation_publisher=Public Library of Science;">
<meta name="citation_reference" content="citation_title=Cognitive and functional outcome after aneurysmal subarachnoid hemorrhage;,citation_abstract=BACKGROUND AND PURPOSE: Aneurysmal subarachnoid hemorrhage (aSAH) is a medical emergency characterized by the accumulation of blood in the subarachnoid space surrounding the brain. The acute treatment of aSAH is well documented but less is known about the long-term effects of aSAH on cognition and day-to-day functioning. METHODS: We reviewed all studies in the past 10 years that have focused on the effects of aSAH on cognition and day-to-day functioning. RESULTS: Sixty-one empirical studies examining cognitive and functional outcome in patients with aSAH met inclusion criteria. Survivors of aSAH commonly experience deficits in memory, executive function, and language. These cognitive impairments interact to affect patients’ day-to-day functioning, including activities of daily living, instrumental activities of daily living, return to work, and quality of life. Deficits in cognition and day-to-day functioning are further compounded by depression, anxiety, fatigue, and sleep disturbances. CONCLUSIONS: Much remains to be learned about the brain changes underlying cognitive and functional deficits, including the role of diffuse brain damage and secondary complications like vasospasm and elevated intracranial pressure. A consideration of these issues is necessary to obtain a better understanding of how aSAH affects cognition and day-to-day functioning in the long-term.;,citation_author=Timour Al-Khindi;,citation_author=R. Loch Macdonald;,citation_author=Tom A. Schweizer;,citation_publication_date=2010-08;,citation_cover_date=2010-08;,citation_year=2010;,citation_issue=8;,citation_doi=10.1161/STROKEAHA.110.581975;,citation_issn=1524-4628;,citation_pmid=20595669;,citation_volume=41;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=Varieties of Chronic Subdural Hematoma and Glucocorticoid Treatment;,citation_abstract=The good physician treats the disease; the great physician treats the patient who has the disease. Almost 50 years ago, it was bewildering to me as a young trainee to learn from the late Dr. Leonard Mallis that at his institution of Mount Sinai Hospital in New York, they were treating chronic subdural hematomas conservatively with prednisone or dexamethasone in order to avoid surgical drainage. The results in 100 patients were later reported by Bender and Christoff.1 Since then, I have continued to witness and share the disappointment in the outcomes of this common but elusive disease, particularly in our . . .;,citation_author=Ossama Al-Mefty;,citation_publication_date=2023-06;,citation_cover_date=2023-06;,citation_year=2023;,citation_issue=24;,citation_doi=10.1056/NEJMe2304797;,citation_issn=0028-4793;,citation_pmid=37314710;,citation_volume=388;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Neurocritical care management of poor-grade subarachnoid hemorrhage: Unjustified nihilism to reasonable optimism;,citation_abstract=Background and purpose: Historically, overall outcomes for patients with high-grade subarachnoid hemorrhage (SAH) have been poor. Generally, between physicians, either reluctance to treat, or selectivity in treating such patients has been the paradigm. Recent studies have shown that early and aggressive care leads to significant improvement in survival rates and favorable outcomes of grade V SAH patients. With advancements in both neurocritical care and end-of-life care, nontreatment or selective treatment of grade V SAH patients is rarely justified. Current paradigm shifts towards early and aggressive care in such cases may lead to improved outcomes for many more patients. Materials and methods: We performed a detailed review of the current literature regarding neurointensive management strategies in high-grade SAH, discussing multiple aspects. We discussed the neurointensive care management protocols for grade V SAH patients. Results: Acutely, intracranial pressure control is of utmost importance with external ventricular drain placement, sedation, optimization of cerebral perfusion pressure, osmotherapy and hyperventilation, as well as cardiopulmonary support through management of hypotension and hypertension. Conclusions: Advancements of care in SAH patients make it unethical to deny treatment to poor Hunt and Hess grade patients. Early and aggressive treatment results in a significant improvement in survival rate and favorable outcome in such patients.;,citation_author=Fawaz Al-Mufti;,citation_author=Stephan A Mayer;,citation_author=Gurmeen Kaur;,citation_author=Daniel Bassily;,citation_author=Boyi Li;,citation_author=Matthew L Holstein;,citation_author=Jood Ani;,citation_author=Nicole E Matluck;,citation_author=Haris Kamal;,citation_author=Rolla Nuoman;,citation_author=Christian A Bowers;,citation_author=Faizan S Ali;,citation_author=Hussein Al-Shammari;,citation_author=Mohammad El-Ghanem;,citation_author=Chirag Gandhi;,citation_author=Krishna Amuluru;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_doi=10.1177/19714009211024633;,citation_issn=1971-4009, 2385-1996;,citation_language=en-US;,citation_journal_title=The Neuroradiology Journal;">
<meta name="citation_reference" content="citation_title=Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: A randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial;,citation_abstract=Background Oral anticoagulation reduces the rate of systemic embolism for patients with atrial fibrillation by two-thirds, but its benefits for patients with previous intracranial haemorrhage are uncertain. In the Start or STop Anticoagulants Randomised Trial (SoSTART), we aimed to establish whether starting is non-inferior to avoiding oral anticoagulation for survivors of intracranial haemorrhage who have atrial fibrillation.;,citation_author=Rustam Al-Shahi Salman;,citation_author=Catriona Keerie;,citation_author=Jacqueline Stephen;,citation_author=Steff Lewis;,citation_author=John Norrie;,citation_author=Martin S. Dennis;,citation_author=David E. Newby;,citation_author=Joanna M. Wardlaw;,citation_author=Gregory Y. H. Lip;,citation_author=Adrian Parry-Jones;,citation_author=Philip M. White;,citation_author=Colin Baigent;,citation_author=Dan Lasserson;,citation_author=Colin Oliver;,citation_author=Fiach O’Mahony;,citation_author=Shannon Amoils;,citation_author=John Bamford;,citation_author=Jane Armitage;,citation_author=Jonathan Emberson;,citation_author=Gabriël J. R. Rinkel;,citation_author=Gordon Lowe;,citation_author=Karen Innes;,citation_author=Kasia Adamczuk;,citation_author=Lynn Dinsmore;,citation_author=Jonathan Drever;,citation_author=Garry Milne;,citation_author=Allan Walker;,citation_author=Aidan Hutchison;,citation_author=Carol Williams;,citation_author=Ruth Fraser;,citation_author=Rosemary Anderson;,citation_author=Kate Covil;,citation_author=Kelly Stewart;,citation_author=Jessica Rees;,citation_author=Peter Hall;,citation_author=Alistair Bullen;,citation_author=Andrew Stoddart;,citation_author=Tom J. Moullaali;,citation_author=Jeb Palmer;,citation_author=Eleni Sakka;,citation_author=Joanne Perthen;,citation_author=Nicola Lyttle;,citation_author=Neshika Samarasekera;,citation_author=Allan MacRaild;,citation_author=Seona Burgess;,citation_author=Jessica Teasdale;,citation_author=Michelle Coakley;,citation_author=Pat Taylor;,citation_author=Gordon Blair;,citation_author=William Whiteley;,citation_author=Susan Shenkin;,citation_author=Una Clancy;,citation_author=Malcolm Macleod;,citation_author=Rachel Sutherland;,citation_author=Tom Moullaali;,citation_author=Amanda Barugh;,citation_author=Christine Lerpiniere;,citation_author=Fiona Moreton;,citation_author=Nicholas Fethers;,citation_author=Tal Anjum;,citation_author=Manju Krishnan;,citation_author=Peter Slade;,citation_author=Sharon Storton;,citation_author=Marie Williams;,citation_author=Caroline Davies;,citation_author=Lynda Connor;,citation_author=Glyn Gainard;,citation_author=Carl Murphy;,citation_author=Mark Barber;,citation_author=Derek Esson;,citation_author=James Choulerton;,citation_author=Louise Shaw;,citation_author=Suzanne Lucas;,citation_author=Sarah Hierons;,citation_author=Joanne Avis;,citation_author=Andrew Stone;,citation_author=Lukuman Gbadamoshi;,citation_author=Telma Costa;,citation_author=Lauren Pearce;,citation_author=Kirsty Harkness;,citation_author=Emma Richards;,citation_author=Jo Howe;,citation_author=Christine Kamara;,citation_author=Ralf Lindert;,citation_author=Ali Ali;,citation_author=Jahanzeb Rehan;,citation_author=Sarah Chapman;,citation_author=Maria Edwards;,citation_author=Raj Bathula;,citation_author=David Cohen;,citation_author=Joseph Devine;,citation_author=Mushiya Mpelembue;,citation_author=Priya Yesupatham;,citation_author=Swati Chhabra;,citation_author=Gbadebo Adewetan;,citation_author=Robert Ballantine;,citation_author=Daniel Brooks;,citation_author=Gemma Smith;,citation_author=Gill Rogers;,citation_author=Stuart Marsden;,citation_author=Sarah Clark;,citation_author=Ami Wilkinson;,citation_author=Ellen Brown;,citation_author=Lynsey Stephenson;,citation_author=Khin Nyo;,citation_author=Annie Abraham;,citation_author=Yogish Pai;,citation_author=Gek Shim;,citation_author=Vidya Baliga;,citation_author=Anand Nair;,citation_author=Matthew Robinson;,citation_author=Catherine Hawksworth;,citation_author=Jill Greig;,citation_author=Irfan Alam;,citation_author=Tonicha Nortcliffe;,citation_author=Ridha Ramiz;,citation_author=Ryan Shaw;,citation_author=Adrian Parry-Jones;,citation_author=Stephanie Lee;,citation_author=Tracy Marsden;,citation_author=Jane Perez;,citation_author=Emily Birleson;,citation_author=Rajendra Yadava;,citation_author=Mirriam Sangombe;,citation_author=Sam Stafford;,citation_author=Tom Hughes;,citation_author=Lucy Knibbs;,citation_author=Bethan Morse;,citation_author=Stefan Schwarz;,citation_author=Benjamin Jelley;,citation_author=Susan White;,citation_author=Bella Richard;,citation_author=Heidi Lawson;,citation_author=Sally Moseley;,citation_author=Michelle Tayler;,citation_author=Mandy Edwards;,citation_author=Claire Triscott;,citation_author=Rebecca Wallace;,citation_author=Angela Hall;,citation_author=Amanda Dell;,citation_author=Khalid Rashed;,citation_author=Sarah Board;,citation_author=Clare Buckley;,citation_author=Alfonso Tanate;,citation_author=Tressy Pitt-Kerby;,citation_author=Kate Beesley;,citation_author=Jess Perry;,citation_author=Christine Hellyer;,citation_author=Paul Guyler;,citation_author=Nisha Menon;,citation_author=Sharon Tysoe;,citation_author=Raji Prabakaran;,citation_author=Martin Cooper;,citation_author=Anoja Rajapakse;,citation_author=Inez Wynter;,citation_author=Susan Smith;,citation_author=Nic Weir;,citation_author=Cherish Boxall;,citation_author=Hannah Yates;,citation_author=Simon Smith;,citation_author=Pamela Crawford;,citation_author=James Marigold;,citation_author=Fiona Smith;,citation_author=Jake Harvey;,citation_author=Sue Evans;,citation_author=Laura Baldwin;,citation_author=Sarah Hammond;,citation_author=Paul Mudd;,citation_author=Angela Bowring;,citation_author=Samantha Keenan;,citation_author=Kevin Thorpe;,citation_author=Mohammad Haque;,citation_author=Joanne Taaffe;,citation_author=Natalie Temple;,citation_author=Tracey Peachey;,citation_author=Kim Wells;,citation_author=Fiona Haines;,citation_author=Nicola Butterworth-Cowin;,citation_author=Zoey Horne;,citation_author=Radim Licenik;,citation_author=Hayley Boughton;,citation_author=Timothy England;,citation_author=Amanda Hedstrom;,citation_author=Brian Menezes;,citation_author=Ruth Davies;,citation_author=Venetia Johnson;,citation_author=Simon Whittingham-Jones;,citation_author=David Werring;,citation_author=Sabaa Obarey;,citation_author=Caroline Watchurst;,citation_author=Amy Ashton;,citation_author=Shez Feerick;,citation_author=Nina Francia;,citation_author=Azra Banaras;,citation_author=Daniel Epstein;,citation_author=Marilena Marinescu;,citation_author=Annick Williams;,citation_author=Anna Robinson;,citation_author=Fiona Humphries;,citation_author=Ijaz Anwar;,citation_author=Arunkumar Annamalai;,citation_author=Susan Crawford;,citation_author=Vicky Collins;,citation_author=Lorna Shepherd;,citation_author=Elaine Siddle;,citation_author=Justin Penge;,citation_author=Daniel Epstein;,citation_author=Sam Qureshi;,citation_author=Vinodh Krishnamurthy;,citation_author=Vasileios Papavasileiou;,citation_author=Dean Waugh;,citation_author=Emelda Veraque;,citation_author=Nathan Douglas;,citation_author=Numan Khan;,citation_author=Sankaranarayanan Ramachandran;,citation_author=Peter Sommerville;,citation_author=Anthony Rudd;,citation_author=Sagal Kullane;,citation_author=Ajay Bhalla;,citation_author=Jonathan Birns;,citation_author=Rowshanara Ahmed;,citation_author=Meegan Gibbons;,citation_author=Eva Klamerus;,citation_author=Benjie Cendreda;,citation_author=Keith Muir;,citation_author=Nicola Day;,citation_author=Angela Welch;,citation_author=Wilma Smith;,citation_author=Jennifer Elliot;,citation_author=Salwa Eltawil;,citation_author=Ammad Mahmood;,citation_author=Kim Hatherley;,citation_author=Shirley Mitchell;,citation_author=Harjit Bains;,citation_author=Lauren Quinn;,citation_author=Rachel Teal;,citation_author=Ivie Gbinigie;,citation_author=George Harston;,citation_author=Phil Mathieson;,citation_author=Gary Ford;,citation_author=Ursula Schulz;,citation_author=James Kennedy;,citation_author=Kirubananthan Nagaratnam;,citation_author=Kiran Bangalore;,citation_author=Neelima Bhupathiraju;,citation_author=Chris Wharton;,citation_author=Ken Fotherby;,citation_author=Ahmad Nasar;,citation_author=Angie Stevens;,citation_author=Angela Willberry;,citation_author=Rachel Evans;,citation_author=Baljinder Rai;,citation_author=Chloe Blake;,citation_author=Kamy Thavanesan;,citation_author=Gail Hann;,citation_author=Tanith Changuion;,citation_author=Sara Nix;,citation_author=Amanda Whiting;,citation_author=Michelle Dharmasiri;,citation_author=Louise Mallon;,citation_author=Marketa Keltos;,citation_author=Nigel Smyth;,citation_author=Charlotte Eglinton;,citation_author=John Duffy;,citation_author=Ela Tone;,citation_author=Lucy Sykes;,citation_author=Emily Porter;,citation_author=Carolyn Fitton;,citation_author=Nikolaos Kirkineziadis;,citation_author=Gillian Cluckie;,citation_author=Kate Kennedy;,citation_author=Sarah Trippier;,citation_author=Rebecca Williams;,citation_author=Elizabeth Hayter;,citation_author=James Rackie;,citation_author=Bhavini Patel;,citation_author=Ghatala Rita;,citation_author=Adrian Blight;,citation_author=Val Jones;,citation_author=Liqun Zhang;,citation_author=Lillian Choy;,citation_author=Anthony Pereira;,citation_author=Brian Clarke;,citation_author=Samer Al-Hussayni;,citation_author=Lynn Dixon;,citation_author=Andrew Young;,citation_author=Adrian Bergin;,citation_author=David Broughton;,citation_author=Senthil Raghunathan;,citation_author=Benjamin Jackson;,citation_author=Jason Appleton;,citation_author=Gwendoline Wilkes;,citation_author=Amanda Buck;,citation_author=Carla Richardson;,citation_author=Judith Clarke;,citation_author=Lucy Fleming;,citation_author=Gemma Squires;,citation_author=Zhe Law;,citation_author=Camille Hutchinson;,citation_author=Vera Cvoro;,citation_author=Mandy Couser;,citation_author=Amanda McGregor;,citation_author=Sean McAuley;,citation_author=Susan Pound;,citation_author=Patricia Cochrane;,citation_author=Clare Holmes;,citation_author=Peter Murphy;,citation_author=Nicola Devitt;,citation_author=Mairead Osborn;,citation_author=Amy Steele;,citation_author=Lucy Belle Guthrie;,citation_author=Elizabeth Smith;,citation_author=Jonathan Hewitt;,citation_author=Natalie Chaston;,citation_author=Min Myint;,citation_author=Andrew Smith;,citation_author=Louise Fairlie;,citation_author=Michelle Davis;,citation_author=Beth Atkinson;,citation_author=Stephen Woodward;,citation_author=Valerie Hogg;,citation_author=Michelle Fawcett;,citation_author=Louise Finlay;,citation_author=Anand Dixit;,citation_author=Eleanor Cameron;,citation_author=Breffni Keegan;,citation_author=Jim Kelly;,citation_author=Dónal Concannon;,citation_author=Dipankar Dutta;,citation_author=Deborah Ward;,citation_author=Jon Glass;,citation_author=Susan O’Connell;,citation_author=Joseph Ngeh;,citation_author=Alison O’Kelly;,citation_author=Emma Williams;,citation_author=Suzanne Ragab;,citation_author=Damian Jenkinson;,citation_author=Judith Dube;,citation_author=Laura Gleave;,citation_author=Jacqui Leggett;,citation_author=Nisha Kissoon;,citation_author=Louise Southern;,citation_author=Utpal Naghotra;,citation_author=Maria Bokhari;,citation_author=Beverley McClelland;,citation_author=Katja Adie;,citation_author=Abhijit Mate;,citation_author=Frances Harrington;,citation_author=Ali James;,citation_author=Elizabeth Swanson;,citation_author=Terri Chant;,citation_author=Miriam Naccache;,citation_author=Abbie Coutts;,citation_author=Gillian Courtauld;,citation_author=Sarah Whurr;,citation_author=Sue Webber;,citation_author=Emily Shead;,citation_author=Robert Luder;,citation_author=Maneesh Bhargava;,citation_author=Elodie Murali;,citation_author=Larissa Cuenoud;,citation_author=Kath Pasco;,citation_author=O Speirs;,citation_author=Lianne Chapman;,citation_author=Linda Inskip;,citation_author=Lisa Kavanagh;,citation_author=Meena Srinivasan;,citation_author=Nichola Motherwell;,citation_author=Indranil Mukherjee;,citation_author=Louise Tonks;,citation_author=Denise Donaldson;,citation_author=Heather Button;,citation_author=Rebecca Wilcox;,citation_author=Fran Hurford;,citation_author=Rachel Logan;,citation_author=Andy Taylor;,citation_author=Tracie Arden;,citation_author=Michael Carpenter;,citation_author=Prabal Datta;,citation_author=Tajammal Zahoor;,citation_author=Linda Jackson;,citation_author=Ann Needle;,citation_author=Andrew Stanners;,citation_author=Imran Ghouri;,citation_author=Donna Exley;,citation_author=Salman Akhtar;,citation_author=Hollie Brooke;,citation_author=Shannen Beadle;,citation_author=Eoin O’Brien;,citation_author=Jobbin Francis;,citation_author=Joanne McGee;,citation_author=Elaine Amis;,citation_author=Jennifer Mitchell;,citation_author=Sarah Finlay;,citation_author=Devesh Sinha;,citation_author=Csilla Manoczki;,citation_author=Sam King;,citation_author=James Tarka;,citation_author=Sumita Choudhary;,citation_author=Jegamalini Premaruban;,citation_author=Dorothy Sutton;,citation_author=Pradeep Kumar;,citation_author=Charlotte Culmsee;,citation_author=Caroline Winckley;,citation_author=Holly Davies;,citation_author=Hilary Thatcher;,citation_author=Evangelos Vasileiadis;,citation_author=Basaam Aweid;,citation_author=Melinda Holden;,citation_author=Cathy Mason;,citation_author=Thant Hlaing;,citation_author=Gladys Madzamba;,citation_author=Tanya Ingram;,citation_author=Michelle Linforth;,citation_author=Claire Cullen;,citation_author=Nibu Thomas;,citation_author=John France;,citation_author=Afaq Saulat;,citation_author=Biju Bhaskaran;,citation_author=Pauline Fitzell;,citation_author=Kathleen Horan;,citation_author=Catherine Manyoni;,citation_author=Josie Garfield-Smith;,citation_author=Hannah Griffin;,citation_author=Stacey Atkins;,citation_author=Joan Redome;,citation_author=Girish Muddegowda;,citation_author=Holly Maguire;,citation_author=Adrian Barry;,citation_author=Nenette Abano;,citation_author=Resti Varquez;,citation_author=Joanne Hiden;,citation_author=Susan Lyjko;,citation_author=Alda Remegoso;,citation_author=Kay Finney;,citation_author=Adrian Butler;,citation_author=Martin Strecker;,citation_author=Mary Joan MaCleod;,citation_author=Janice Irvine;,citation_author=Sandra Nelson;,citation_author=German Guzmangutierrez;,citation_author=Jacqueline Furnace;,citation_author=Vicky Taylor;,citation_author=Hawraman Ramadan;,citation_author=Kim Storton;,citation_author=Sohail Hassan;,citation_author=Eman Abdus Sami;,citation_author=Ruth Bellfield;,citation_author=Kelvin Stewart;,citation_author=Outi Quinn;,citation_author=Chris Patterson;,citation_author=Hedley Emsley;,citation_author=Bindu Gregary;,citation_author=Shakeel Ahmed;,citation_author=Shakeelah Patel;,citation_author=Sonia Raj;,citation_author=Sulaiman Sultan;,citation_author=Fiona Wright;,citation_author=Peter Langhorne;,citation_author=Ruth Graham;,citation_author=Terry Quinn;,citation_author=Kate McArthur;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=10;,citation_doi=10.1016/S1474-4422(21)00264-7;,citation_issn=14744422;,citation_volume=20;,citation_language=en-US;,citation_journal_title=The Lancet Neurology;">
<meta name="citation_reference" content="citation_title=Prone Position–induced Improvement in Gas Exchange Does Not Predict Improved Survival in the Acute Respiratory Distress Syndrome;,citation_author=Richard K. Albert;,citation_author=Angela Keniston;,citation_author=Loredana Baboi;,citation_author=Louis Ayzac;,citation_author=Claude Guérin;,citation_publication_date=2014-02;,citation_cover_date=2014-02;,citation_year=2014;,citation_issue=4;,citation_doi=10.1164/rccm.201311-2056LE;,citation_issn=1073-449X, 1535-4970;,citation_volume=189;,citation_language=en-US;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Sigh Ventilation in Patients With Trauma: The SiVent Randomized Clinical Trial;,citation_abstract=Among patients receiving mechanical ventilation, tidal volumes with each breath are often constant or similar. This may lead to ventilator-induced lung injury by altering or depleting surfactant. The role of sigh breaths in reducing ventilator-induced lung injury among trauma patients at risk of poor outcomes is unknown.To determine whether adding sigh breaths improves clinical outcomes.A pragmatic, randomized trial of sigh breaths plus usual care conducted from 2016 to 2022 with 28-day follow-up in 15 academic trauma centers in the US. Inclusion criteria were age older than 18 years, mechanical ventilation because of trauma for less than 24 hours, 1 or more of 5 risk factors for developing acute respiratory distress syndrome, expected duration of ventilation longer than 24 hours, and predicted survival longer than 48 hours.Sigh volumes producing plateau pressures of 35 cm H2O (or 40 cm H2O for inpatients with body mass indexes &amp;amp;amp;gt;35) delivered once every 6 minutes. Usual care was defined as the patient’s physician(s) treating the patient as they wished.The primary outcome was ventilator-free days. Prespecified secondary outcomes included all-cause 28-day mortality.Of 5753 patients screened, 524 were enrolled (mean [SD] age, 43.9 [19.2] years; 394 [75.2%] were male). The median ventilator-free days was 18.4 (IQR, 7.0-25.2) in patients randomized to sighs and 16.1 (IQR, 1.1-24.4) in those receiving usual care alone (P = .08). The unadjusted mean difference in ventilator-free days between groups was 1.9 days (95% CI, 0.1 to 3.6) and the prespecified adjusted mean difference was 1.4 days (95% CI, -0.2 to 3.0). For the prespecified secondary outcome, patients randomized to sighs had 28-day mortality of 11.6% (30/259) vs 17.6% (46/261) in those receiving usual care (P = .05). No differences were observed in nonfatal adverse events comparing patients with sighs (80/259 [30.9%]) vs those without (80/261 [30.7%]).In a pragmatic, randomized trial among trauma patients receiving mechanical ventilation with risk factors for developing acute respiratory distress syndrome, the addition of sigh breaths did not significantly increase ventilator-free days. Prespecified secondary outcome data suggest that sighs are well-tolerated and may improve clinical outcomes.ClinicalTrials.gov Identifier: NCT02582957;,citation_author=Richard K. Albert;,citation_author=Gregory J. Jurkovich;,citation_author=John Connett;,citation_author=Erika S. Helgeson;,citation_author=Angela Keniston;,citation_author=Helen Voelker;,citation_author=Sarah Lindberg;,citation_author=Jennifer L. Proper;,citation_author=Grant Bochicchio;,citation_author=Deborah M. Stein;,citation_author=Christian Cain;,citation_author=Ron Tesoriero;,citation_author=Carlos V. R. Brown;,citation_author=James Davis;,citation_author=Lena Napolitano;,citation_author=Thomas Carver;,citation_author=Mark Cipolle;,citation_author=Luis Cardenas;,citation_author=Joseph Minei;,citation_author=Raminder Nirula;,citation_author=Jay Doucet;,citation_author=Preston R. Miller;,citation_author=Jeffrey Johnson;,citation_author=Kenji Inaba;,citation_author=Lillian Kao;,citation_publication_date=2023-10;,citation_cover_date=2023-10;,citation_year=2023;,citation_doi=10.1001/jama.2023.21739;,citation_issn=0098-7484;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Accurately Measuring Preventable Ventilator-associated Pneumonia Deaths Using Observational Data: It’s about Time;,citation_author=Owen R. Albin;,citation_author=Andrew J. Admon;,citation_publication_date=2021-05;,citation_cover_date=2021-05;,citation_year=2021;,citation_issue=5;,citation_doi=10.1513/AnnalsATS.202102-126ED;,citation_issn=2329-6933, 2325-6621;,citation_volume=18;,citation_language=en-US;,citation_journal_title=Annals of the American Thoracic Society;">
<meta name="citation_reference" content="citation_title=Mortality Rates Among Hospitalized Patients With COVID-19 Infection Treated With Tocilizumab and Corticosteroids: A Bayesian Reanalysis of a Previous Meta-analysis;,citation_abstract=IMPORTANCE A World Health Organization (WHO) meta-analysis found that tocilizumab was associated with reduced mortality in hospitalized patients with COVID-19. However, uncertainty remains concerning the magnitude of tocilizumab’s benefits and whether its association with mortality benefit is similar across respiratory subgroups.;,citation_author=Arthur M. Albuquerque;,citation_author=Lucas Tramujas;,citation_author=Lorenzo R. Sewanan;,citation_author=Donald R. Williams;,citation_author=James M. Brophy;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_issue=2;,citation_doi=10.1001/jamanetworkopen.2022.0548;,citation_issn=2574-3805;,citation_volume=5;,citation_language=en-US;,citation_journal_title=JAMA Network Open;">
<meta name="citation_reference" content="citation_title=Nutrition support for critically ill patients;,citation_abstract=Nutrition support is an important aspect of the management of critically ill patients. This review highlights the emerging evidence on critical care nutrition and focuses on the pathophysiologic interplay between critical illness, the gastrointestinal tract, and nutrition support and the evidence on the best route, dose, and timing of nutrition. Although indirect calorimetry is recommended to measure energy expenditure, predictive equations are commonly used but are limited by their inaccuracy in individual patients. The current evidence supports early enteral nutrition (EN) in most patients, with a gradual increase in the daily dose over the first week. Delayed EN is warranted in patients with severe shock. According to recent trials, parenteral nutrition seems to be as effective as EN and may be started if adequate EN is not achieved by the first week of critical illness. A high protein dose has been recommended, but the best timing is unclear. Immuno-nutrition should not be routinely provided to critically ill patients. Patients receiving artificial nutrition should be monitored for metabolic derangements. Additional adequately powered studies are still needed to resolve many unanswered questions.;,citation_author=Hasan M. Al-Dorzi;,citation_author=Yaseen M. Arabi;,citation_publication_date=2021-11;,citation_cover_date=2021-11;,citation_year=2021;,citation_issue=S2;,citation_doi=10.1002/jpen.2228;,citation_issn=0148-6071, 1941-2444;,citation_volume=45;,citation_language=en-US;,citation_journal_title=Journal of Parenteral and Enteral Nutrition;">
<meta name="citation_reference" content="citation_title=How Well Do Standard Stroke Outcome Measures Reflect Quality of Life?;,citation_abstract=Background and Purpose— Quality of life (QoL) is important to stroke survivors yet is often recorded as a secondary measure in acute stroke randomized controlled trials. We examined whether commonly used stroke outcome measures captured aspects of QoL. Methods— We examined primary outcomes by National Institutes of Health Stroke Scale (NIHSS), Barthel Index (BI) and modified Rankin Scale (mRS), and QoL by Stroke Impact Scale (SIS) and European Quality of Life Scale (EQ-5D) from the Virtual International Stroke Trials Archive (VISTA). Using Spearman correlations and logistic regression, we described the relationships between QoL mRS, NIHSS, and BI at 3 months, stratified by respondent (patient or proxy). Using \chi2 analyses, we examined the mismatch between good primary outcome (mRS \leq1, NIHSS \leq5, or BI \geq95) but poor QoL, and poor primary outcome (mRS \geq3, NIHSS \geq20, or BI \leq60) but good QoL. Results— Patient-assessed QoL had a stronger association with mRS (EQ-5D weighted score n=2987, P&amp;amp;amp;lt;0.0001, r=-0.7, r2=0.53; SIS recovery n=2970, P&amp;lt;0.0001, r=-0.71, r2=0.52). Proxy responses had a stronger association with BI (EQ-5D weighted score n=837, P<0.0001, r=0.78, r2=0.63; SIS recovery n=867, P<0.0001, r=0.68, r2=0.48). mRS explained more of the variation in QoL (EQ-5D weighted score=53%, recovery by SIS v3.0=52%) than NIHSS or BI and resulted in fewer mismatches between good primary outcome and poor QoL (P<0.0001, EQ-5D weighted score=8.5%; SIS recovery=10%; SIS-16=4.4%). Conclusions— The mRS seemed to align closely with stroke survivors’ interests, capturing more information on QoL than either NIHSS or BI. This further supports its recommendation as a primary outcome measure in acute stroke randomized controlled trials.;,citation_author=Myzoon Ali;,citation_author=Rachael Fulton;,citation_author=Terry Quinn;,citation_author=Marian Brady;,citation_author=null null;,citation_author=null null;,citation_author=K. R. Lees;,citation_author=A. Alexandrov;,citation_author=P. M. Bath;,citation_author=E. Bluhmki;,citation_author=N. Bornstein;,citation_author=L. Claesson;,citation_author=S. M. Davis;,citation_author=G. Donnan;,citation_author=H. C. Diener;,citation_author=M. Fisher;,citation_author=B. Gregson;,citation_author=J. Grotta;,citation_author=W. Hacke;,citation_author=M. G. Hennerici;,citation_author=M. Hommel;,citation_author=M. Kaste;,citation_author=P. Lyden;,citation_author=J. Marler;,citation_author=K. Muir;,citation_author=R. Sacco;,citation_author=A. Shuaib;,citation_author=P. Teal;,citation_author=N. G. Wahlgren;,citation_author=S. Warach;,citation_author=C. Weimar;,citation_author=null null;,citation_author=M. Brady;,citation_author=M. Ali;,citation_author=A. Ashburn;,citation_author=D. Barer;,citation_author=J. Bernhardt;,citation_author=A. Bowen;,citation_author=E. Brodie;,citation_author=S. Corr;,citation_author=A. Drummond;,citation_author=J. Edmans;,citation_author=C. English;,citation_author=J. Gladman;,citation_author=E. Godecke;,citation_author=T. Hoffmann;,citation_author=L. Kalra;,citation_author=S. Kuys;,citation_author=P. Langhorne;,citation_author=A. C. Laska;,citation_author=K. R. Lees;,citation_author=N. Lincoln;,citation_author=P. Logan;,citation_author=L. Jongbloed;,citation_author=G. Mead;,citation_author=A. Pollock;,citation_author=V. Pomeroy;,citation_author=H. Rodgers;,citation_author=C. Sackley;,citation_author=L. Shaw;,citation_author=D. J. Stott;,citation_author=K. S. Sunnerhagen;,citation_author=S. Tyson;,citation_author=P. Vliet;,citation_author=M. Walker;,citation_author=W. Whiteley;,citation_author=null null;,citation_author=S. Warach;,citation_author=G. Albers;,citation_author=S. Davis;,citation_author=G. Donnan;,citation_author=M. Fisher;,citation_author=T. Furlan;,citation_author=J. Grotta;,citation_author=W. Hacke;,citation_author=C. Kidwell;,citation_author=W. Koroshetz;,citation_author=K. R. Lees;,citation_author=M. Lev;,citation_author=D. Liebeskind;,citation_author=G. Sorensen;,citation_author=V. Thijs;,citation_author=G. Thomalla;,citation_author=J. Wardlaw;,citation_author=M. Wintermark;,citation_author=null null;,citation_author=D. F. Hanley;,citation_author=B. Gregson;,citation_author=S. Davis;,citation_author=K. R. Lees;,citation_author=P. Lyden;,citation_author=K. Muir;,citation_author=T. Steiner;,citation_author=S. Mayer;,citation_author=null null;,citation_author=N. G. Wahlgren;,citation_author=C. Molina;,citation_author=H. Numminen;,citation_author=K. R. Lees;,citation_author=G. Tsivgoulis;,citation_author=C. Weimar;,citation_author=null null;,citation_author=H. -C. Diener;,citation_author=G. Hankey;,citation_author=K. R. Lees;,citation_author=B. Ovbiagele;,citation_author=C. Weir;,citation_publication_date=2013-11;,citation_cover_date=2013-11;,citation_year=2013;,citation_issue=11;,citation_doi=10.1161/STROKEAHA.113.001126;,citation_volume=44;,citation_journal_title=Stroke;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: A randomized controlled trial;,citation_abstract=Background: The role of remdesivir in the treatment of patients in hospital with COVID-19 remains ill defined in a global context. The World Health Organization Solidarity randomized controlled trial (RCT) evaluated remdesivir in patients across many countries, with Canada enrolling patients using an expanded data collection format in the Canadian Treatments for COVID-19 (CATCO) trial. We report on the Canadian findings, with additional demographics, characteristics and clinical outcomes, to explore the potential for differential effects across different health care systems.;,citation_author=Karim Ali;,citation_author=Tanweer Azher;,citation_author=Mahin Baqi;,citation_author=Alexandra Binnie;,citation_author=Sergio Borgia;,citation_author=François M. Carrier;,citation_author=Yiorgos Alexandroa Cavayas;,citation_author=Nicolas Chagnon;,citation_author=Matthew P. Cheng;,citation_author=John Conly;,citation_author=Cecilia Costiniuk;,citation_author=Peter Daley;,citation_author=Nick Daneman;,citation_author=Josh Douglas;,citation_author=Catarina Downey;,citation_author=Erick Duan;,citation_author=Emmanuelle Duceppe;,citation_author=Madeleine Durand;,citation_author=Shane English;,citation_author=George Farjou;,citation_author=Evradiki Fera;,citation_author=Patricia Fontela;,citation_author=Rob Fowler;,citation_author=Michael Fralick;,citation_author=Anna Geagea;,citation_author=Jennifer Grant;,citation_author=Luke B. Harrison;,citation_author=Thomas Havey;,citation_author=Holly Hoang;,citation_author=Lauren E. Kelly;,citation_author=Yoav Keynan;,citation_author=Kosar Khwaja;,citation_author=Gail Klein;,citation_author=Marina Klein;,citation_author=Christophe Kolan;,citation_author=Nadine Kronfli;,citation_author=Francois Lamontagne;,citation_author=Rob Lau;,citation_author=Michael Fralick;,citation_author=Todd C. Lee;,citation_author=Nelson Lee;,citation_author=Rachel Lim;,citation_author=Sarah Longo;,citation_author=Alexandra Lostun;,citation_author=Erika MacIntyre;,citation_author=Isabelle Malhamé;,citation_author=Kathryn Mangof;,citation_author=Marlee McGuinty;,citation_author=Sonya Mergler;,citation_author=Matthew P. Munan;,citation_author=Srinivas Murthy;,citation_author=Conar O’Neil;,citation_author=Daniel Ovakim;,citation_author=Jesse Papenburg;,citation_author=Ken Parhar;,citation_author=Seema Nair Parvathy;,citation_author=Chandni Patel;,citation_author=Santiago Perez-Patrigeon;,citation_author=Ruxandra Pinto;,citation_author=Subitha Rajakumaran;,citation_author=Asgar Rishu;,citation_author=Malaika Roba-Oshin;,citation_author=Moira Rushton;,citation_author=Mariam Saleem;,citation_author=Marina Salvadori;,citation_author=Kim Scherr;,citation_author=Kevin Schwartz;,citation_author=Makeda Semret;,citation_author=Michael Silverman;,citation_author=Ameeta Singh;,citation_author=Wendy Sligl;,citation_author=Stephanie Smith;,citation_author=Ranjani Somayaji;,citation_author=Darrell H. S. Tan;,citation_author=Siobhan Tobin;,citation_author=Meaghan Todd;,citation_author=Tuong-Vi Tran;,citation_author=Alain Tremblay;,citation_author=Jennifer Tsang;,citation_author=Alexis Turgeon;,citation_author=Erik Vakil;,citation_author=Jason Weatherald;,citation_author=Cedric Yansouni;,citation_author=Ryan Zarychanski;,citation_author=Canadian Treatments for COVID-19 (CATCO);,citation_author=Association of Medical Microbiology and Infectious Disease Canada (AMMI) Clinical Research Network and the Canadian Critical Care Trials Group;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_doi=10.1503/cmaj.211698;,citation_issn=0820-3946, 1488-2329;,citation_language=en-US;,citation_journal_title=Canadian Medical Association Journal;">
<meta name="citation_reference" content="citation_title=Stroke Outcome in Clinical Trial Patients Deriving From Different Countries;,citation_abstract=Background and Purpose— Stroke incidence and outcome vary widely within and across geographical locations. We examined whether differences in index stroke severity, stroke risk factors, mortality, and stroke outcome across geographical locations remain after adjusting for case mix. Methods— We analyzed 3284 patients from the Virtual International Stroke Trials Archive (VISTA). We used logistic regression to examine the incidence of mild index stroke, functional, and neurological outcomes after accounting for age, medical history, year of trial recruitment, and initial stroke severity in the functional and neurological outcome analyses. We examined mortality between geographical regions using a Cox proportional hazards model, accounting for age, initial stroke severity, medical history, and year of trial recruitment. Results— Patients enrolled in the USA and Canada had the most severe index strokes. Those recruited in Austria and Switzerland had the best functional and neurological outcomes at 90 days (P&amp;amp;amp;lt;0.05), whereas those enrolled in Germany had the worst functional outcome at 90 days (P=0.013). Patients enrolled in Austria, Switzerland, Belgium, Netherlands, Finland, Germany, Greece, Israel, Spain, and Portugal had a significantly better survival rate when compared with those enrolled in USA and Canada. Patients enrolled in trials after 1998 had more severe index strokes, with no significant difference in outcome compared with those enrolled before 1998. Conclusion— We identified regional variations in index stroke severity, outcome, and mortality for patients enrolled in ischemic stroke clinical trials over the past 13 years that were not fully explained by case mix. Index stroke severity was greater in patients enrolled after 1998, with no significant improvement in outcomes compared to those enrolled before 1998.;,citation_author=Myzoon Ali;,citation_author=Sari Atula;,citation_author=Philip M. W. Bath;,citation_author=James Grotta;,citation_author=Werner Hacke;,citation_author=Patrick Lyden;,citation_author=John R. Marler;,citation_author=Ralph L. Sacco;,citation_author=Kennedy R. Lees;,citation_publication_date=2009-01;,citation_cover_date=2009-01;,citation_year=2009;,citation_issue=1;,citation_doi=10.1161/STROKEAHA.108.518035;,citation_volume=40;,citation_journal_title=Stroke;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=Electroencephalogram in the intensive care unit: A focused look at acute brain injury;,citation_abstract=Over the past decades, electroencephalography (EEG) has become a widely applied and highly sophisticated brain monitoring tool in a variety of intensive care unit (ICU) settings. The most common indication for EEG monitoring currently is the management of refractory status epilepticus. In addition, a number of studies have associated frequent seizures, including nonconvulsive status epilepticus (NCSE), with worsening secondary brain injury and with worse outcomes. With the widespread utilization of EEG (spot and continuous EEG), rhythmic and periodic patterns that do not fulfill strict seizure criteria have been identified, epidemiologically quantified, and linked to pathophysiological events across a wide spectrum of critical and acute illnesses, including acute brain injury. Increasingly, EEG is not just qualitatively described, but also quantitatively analyzed together with other modalities to generate innovative measurements with possible clinical relevance. In this review, we discuss the current knowledge and emerging applications of EEG in the ICU, including seizure detection, ischemia monitoring, detection of cortical spreading depolarizations, assessment of consciousness and prognostication. We also review some technical aspects and challenges of using EEG in the ICU including the logistics of setting up ICU EEG monitoring in resource-limited settings.;,citation_author=Ayham Alkhachroum;,citation_author=Brian Appavu;,citation_author=Satoshi Egawa;,citation_author=Brandon Foreman;,citation_author=Nicolas Gaspard;,citation_author=Emily J. Gilmore;,citation_author=Lawrence J. Hirsch;,citation_author=Pedro Kurtz;,citation_author=Virginie Lambrecq;,citation_author=Julie Kromm;,citation_author=Paul Vespa;,citation_author=Sahar F. Zafar;,citation_author=Benjamin Rohaut;,citation_author=Jan Claassen;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_doi=10.1007/s00134-022-06854-3;,citation_issn=1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Diagnostic Performance of Computed Tomography Angiography and Computed Tomography Perfusion Tissue Time-to-Maximum in Vasospasm Following Aneurysmal Subarachnoid Hemorrhage;,citation_abstract=BACKGROUND: Vasospasm is a treatable cause of deterioration following aneurysmal subarachnoid hemorrhage. Cerebral computed tomography perfusion mean transit times have been proposed as a predictor of vasospasm but suffer from well- known technical limitations. We evaluated fully automated, thresholded time-to-maxima of the tissue residue function (Tmax) for determination of vasospasm following aneurysmal subarachnoid hemorrhage. METHODS AND RESULTS: Retrospective analysis of 540 arterial segments from 36 encounters in 31 consecutive patients with aneurysmal subarachnoid hemorrhage undergoing computed tomography angiography (CTA), computed tomography perfusion, and digital subtraction angiography (DSA) within 24 hours. Tmax at 4, 6, 8, and 10 s was generated using RAPID (iSchemaView Inc., Menlo Park, CA). Dual-reader CTA and computed tomography perfusion interpretations were compared for patients with and without vasospasm on DSA (DSA+ and DSA-). Logistic regression models were developed using CTA and Tmax as input predictors and DSA vasospasm as outcome in adjusted and unadjusted models. Imaging studies from all 31 subjects (mean age 47.311.1, 77% female, 65% with single aneurysm with mean size of 6.02.9 mm) were included. Vasospasm was identified in 42 segments on DSA and 59 segments on CTA, with significant associations across individual vessel segments (P&amp;amp;amp;lt;0.001). In adjusted analyses, DSA vasospasm was associated with CTA (odds ratio [OR], 2.43; 95% CI, 0.94–; P=0.068) as well as territory-specific Tmax&amp;gt;6 seconds delays (OR, 3.57; 95% CI, 1.36–; P=0.009). Sensitivity/ specificity for DSA vasospasm was 31%/91% for CTA, 26%/89% for Tmax&amp;gt;6 seconds, and 12%/99% for CTA+Tmax>6 seconds. CONCLUSIONS: CTA and Tmax offer high specificity for presence of vasospasm; their utility, even in combination, as screening tests is, however, limited by poor sensitivity.;,citation_author=Jason W. Allen;,citation_author=Adam Prater;,citation_author=Omar Kallas;,citation_author=Syed A. Abidi;,citation_author=Brian M. Howard;,citation_author=Frank Tong;,citation_author=Shashank Agarwal;,citation_author=Shadi Yaghi;,citation_author=Seena Dehkharghani;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=1;,citation_doi=10.1161/JAHA.121.023828;,citation_issn=2047-9980;,citation_volume=11;,citation_language=en-US;,citation_journal_title=Journal of the American Heart Association;">
<meta name="citation_reference" content="citation_title=Review and Updates on the Treatment of Refractory and Super Refractory Status Epilepticus;,citation_abstract=Refractory and super-refractory status epilepticus (RSE and SRSE) are life-threatening conditions requiring prompt initiation of appropriate treatment to avoid permanent neurological damage and reduce morbidity and mortality. RSE is defined as status epilepticus that persists despite administering at least two appropriately dosed parenteral medications, including a benzodiazepine. SRSE is status epilepticus that persists at least 24 h after adding at least one appropriately dosed continuous anesthetic (i.e., midazolam, propofol, pentobarbital, and ketamine). Other therapeutic interventions include immunotherapy, neuromodulation, ketogenic diet, or even surgical intervention in certain cases. Continuous electroencephalogram is an essential monitoring tool for diagnosis and treatment. In this review, we focus on the diagnosis and treatment of RSE and SRSE.;,citation_author=Yazeed S. Alolayan;,citation_author=Kelly McKinley;,citation_author=Ritwik Bhatia;,citation_author=Ayham Alkhachroum;,citation_publication_date=2021-07;,citation_cover_date=2021-07;,citation_year=2021;,citation_issue=14;,citation_doi=10.3390/jcm10143028;,citation_issn=2077-0383;,citation_volume=10;,citation_language=en-US;,citation_journal_title=Journal of Clinical Medicine;">
<meta name="citation_reference" content="citation_title=Adjust for Multiple Comparisons? It’s Not That Simple;,citation_author=Andrew D. Althouse;,citation_publication_date=2016-05;,citation_cover_date=2016-05;,citation_year=2016;,citation_issue=5;,citation_doi=10.1016/j.athoracsur.2015.11.024;,citation_issn=00034975;,citation_volume=101;,citation_language=en-US;,citation_journal_title=The Annals of Thoracic Surgery;">
<meta name="citation_reference" content="citation_title=Comment on “Post-hoc Power: If You Must, At Least Try to Understand”;,citation_author=Andrew D. Althouse;,citation_author=Zad R. Chow;,citation_publication_date=2019-12;,citation_cover_date=2019-12;,citation_year=2019;,citation_issue=6;,citation_doi=10.1097/SLA.0000000000003296;,citation_issn=0003-4932, 1528-1140;,citation_volume=270;,citation_language=en-US;,citation_journal_title=Annals of Surgery;">
<meta name="citation_reference" content="citation_title=Recommendations for Statistical Reporting in Cardiovascular Medicine: A Special Report From the American Heart Association;,citation_abstract=Statistical analyses are a crucial component of the biomedical research process and are necessary to draw inferences from biomedical research data. The application of sound statistical methodology is a prerequisite for publication in the American Heart Association (AHA) journal portfolio. The objective of this document is to summarize key aspects of statistical reporting that might be most relevant to the authors, reviewers, and readership of AHA journals. The AHA Scientific Publication Committee convened a task force to inventory existing statistical standards for publication in biomedical journals and to identify approaches suitable for the AHA journal portfolio. The experts on the task force were selected by the AHA Scientific Publication Committee, who identified 12 key topics that serve as the section headers for this document. For each topic, the members of the writing group identified relevant references and evaluated them as a resource to make the standards summarized herein. Each section was independently reviewed by an expert reviewer who was not part of the task force. Expert reviewers were also permitted to comment on other sections if they chose. Differences of opinion were adjudicated by consensus. The standards presented in this report are intended to serve as a guide for high-quality reporting of statistical analyses methods and results.;,citation_author=Andrew D. Althouse;,citation_author=Jennifer E. Below;,citation_author=Brian L. Claggett;,citation_author=Nancy J. Cox;,citation_author=James A. Lemos;,citation_author=Rahul C. Deo;,citation_author=Sue Duval;,citation_author=Rory Hachamovitch;,citation_author=Sanjay Kaul;,citation_author=Scott W. Keith;,citation_author=Eric Secemsky;,citation_author=Armando Teixeira-Pinto;,citation_author=Veronique L. Roger;,citation_author=on behalf of the American Heart Association Scientific Publishing Committee Statistics Task Force;,citation_publication_date=2021-07;,citation_cover_date=2021-07;,citation_year=2021;,citation_issue=4;,citation_doi=10.1161/CIRCULATIONAHA.121.055393;,citation_issn=0009-7322, 1524-4539;,citation_volume=144;,citation_language=en-US;,citation_journal_title=Circulation;">
<meta name="citation_reference" content="citation_title=The cost of dichotomising continuous variables;,citation_abstract=Measurements of continuous variables are made in all branches of medicine, aiding in the diagnosis and treatment of patients. In clinical practice it is helpful to label individuals as having or not having an attribute, such as being “hypertensive” or “obese” or having “high cholesterol,” depending on the value of a continuous variable. Categorisation of continuous variables is also common in clinical research, but here such simplicity is gained at some cost. Though grouping may help data presentation, notably in tables, categorisation is unnecessary for statistical analysis and it has some serious drawbacks. Here we consider the impact of converting continuous data to two groups (dichotomising), as this is the most common approach in clinical research.1 What are the perceived advantages of forcing all individuals into two groups? A common argument is that it greatly simplifies the statistical analysis and leads to easy interpretation and presentation of results. A …;,citation_author=Douglas G. Altman;,citation_author=Patrick Royston;,citation_publication_date=2006-05;,citation_cover_date=2006-05;,citation_year=2006;,citation_issue=7549;,citation_doi=10.1136/bmj.332.7549.1080;,citation_issn=0959-8138, 1468-5833;,citation_pmid=16675816;,citation_volume=332;,citation_language=en-US;,citation_journal_title=BMJ;,citation_publisher=British Medical Journal Publishing Group;">
<meta name="citation_reference" content="citation_title=Statistical reviewing for medical journals;,citation_abstract=This paper reviews the difficulties associated with being a statistical reviewer for a medical journal. As background, I consider first the use of statistical reviewers by medical journals, medical journals’ policies on statistical peer review, and the limited evidence of its effectiveness. The assessment of a manuscript is considered under the headings of design, methods of analysis, presentation and interpretation, with many illustrative examples of the difficulties to be overcome. I emphasize the judgemental nature of many aspects. I suggest how to present and structure the reviewer’s report to the editor. Finally, I consider wider issues, including the various other ways in which statisticians can interact with medical journals. 1998 John Wiley &amp;amp;amp; Sons, Ltd.;,citation_author=Douglas G. Altman;,citation_publication_date=1998-12;,citation_cover_date=1998-12;,citation_year=1998;,citation_issue=23;,citation_doi=10.1002/(SICI)1097-0258(19981215)17:23&amp;amp;lt;2661::AID-SIM33&amp;gt;3.0.CO;2-B;,citation_issn=0277-6715, 1097-0258;,citation_volume=17;,citation_language=en-US;,citation_journal_title=Statistics in Medicine;">
<meta name="citation_reference" content="citation_title=Statistics notes: Absence of evidence is not evidence of absence;,citation_abstract=The non-equivalence of statistical significance and clinical importance has long been recognised, but this error of interpretation remains common. Although a significant result in a large study may sometimes not be clinically important, a far greater problem arises from misinterpretation of non-significant findings. By convention a P value greater than 5% (P&amp;amp;amp;gt;0.05) is called “not significant.” Randomised controlled clinical trials that do not show a significant difference between the treatments being compared are often called “negative.” This term wrongly implies that the study has shown that there is no difference, whereas usually all that has been shown is an absence of evidence of a difference. These are quite different statements. The sample size of controlled trials is generally inadequate, with a consequent lack of power to detect real, and clinically worthwhile, differences in treatment. Freiman et al1 found that only …;,citation_author=Douglas G. Altman;,citation_author=J. Martin Bland;,citation_publication_date=1995-08;,citation_cover_date=1995-08;,citation_year=1995;,citation_issue=7003;,citation_doi=10.1136/bmj.311.7003.485;,citation_issn=0959-8138, 1468-5833;,citation_pmid=7647644;,citation_volume=311;,citation_language=en-US;,citation_journal_title=BMJ;,citation_publisher=British Medical Journal Publishing Group;">
<meta name="citation_reference" content="citation_title=A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke;,citation_author=Pierre Amarenco;,citation_author=Jong S. Kim;,citation_author=Julien Labreuche;,citation_author=Hugo Charles;,citation_author=Jérémie Abtan;,citation_author=Yannick Béjot;,citation_author=Lucie Cabrejo;,citation_author=Jae-Kwan Cha;,citation_author=Grégory Ducrocq;,citation_author=Maurice Giroud;,citation_author=Celine Guidoux;,citation_author=Cristina Hobeanu;,citation_author=Yong-Jae Kim;,citation_author=Bertrand Lapergue;,citation_author=Philippa C. Lavallée;,citation_author=Byung-Chul Lee;,citation_author=Kyung-Bok Lee;,citation_author=Didier Leys;,citation_author=Marie-Hélène Mahagne;,citation_author=Elena Meseguer;,citation_author=Norbert Nighoghossian;,citation_author=Fernando Pico;,citation_author=Yves Samson;,citation_author=Igor Sibon;,citation_author=P. Gabriel Steg;,citation_author=Sang-Min Sung;,citation_author=Pierre-Jean Touboul;,citation_author=Emmanuel Touzé;,citation_author=Olivier Varenne;,citation_author=Éric Vicaut;,citation_author=Nessima Yelles;,citation_author=Eric Bruckert;,citation_publication_date=2020-01;,citation_cover_date=2020-01;,citation_year=2020;,citation_issue=1;,citation_doi=10.1056/NEJMoa1910355;,citation_issn=0028-4793;,citation_pmid=31738483;,citation_volume=382;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Early goal-directed haemodynamic optimization of cerebral oxygenation in comatose survivors after cardiac arrest: The Neuroprotect post-cardiac arrest trial;,citation_author=Koen Ameloot;,citation_author=Cathy De Deyne;,citation_author=Ward Eertmans;,citation_author=Bert Ferdinande;,citation_author=Matthias Dupont;,citation_author=Pieter-Jan Palmers;,citation_author=Tibaut Petit;,citation_author=Philippe Nuyens;,citation_author=Joren Maeremans;,citation_author=Joris Vundelinckx;,citation_author=Maarten Vanhaverbeke;,citation_author=Ann Belmans;,citation_author=Ronald Peeters;,citation_author=Philippe Demaerel;,citation_author=Robin Lemmens;,citation_author=Jo Dens;,citation_author=Stefan Janssens;,citation_publication_date=2019-06;,citation_cover_date=2019-06;,citation_year=2019;,citation_issue=22;,citation_doi=10.1093/eurheartj/ehz120;,citation_issn=0195-668X, 1522-9645;,citation_volume=40;,citation_language=en-US;,citation_journal_title=European Heart Journal;">
<meta name="citation_reference" content="citation_title=Natural History of Hemodynamics in Vertebrobasilar Disease: Temporal Changes in the VERiTAS Study Cohort;,citation_abstract=BACKGROUND AND PURPOSE: The role of regional hypoperfusion as a contributor to stroke risk in atherosclerotic vertebrobasilar disease has recently been confirmed by the observational VERiTAS (Vertebrobasilar Flow Evaluation and Risk of Transient Ischemic Attack and Stroke) Study. We examined the stability of hemodynamic status over time and its relationship to stroke risk in patients from this prospective cohort. METHODS: VERiTAS enrolled patients with recently symptomatic \geq50% atherosclerotic stenosis/occlusion of vertebral and/or basilar arteries. Large vessel flow in the vertebrobasilar territory was assessed using quantitative magnetic resonance angiography, and patients were designated as low or normal flow based on distal territory regional flow, incorporating collateral capacity. Patients underwent standard medical management and follow-up for primary outcome event of vertebrobasilar territory stroke. Quantitative magnetic resonance angiography imaging was repeated at 6, 12, and 24 months. Flow status over time was examined relative to baseline and relative to subsequent stroke risk using a cause-specific proportional hazard model, with flow status treated as a time-varying covariate. Mean blood pressure was examined to assess for association with changes in flow status. RESULTS: Over 198 months of follow-up, 132 follow-up quantitative magnetic resonance angiography studies were performed in 58 of the 72 enrolled patients. Of the 13 patients with serial imaging who had low flow at baseline, 7 (54%) had improvement to normal flow at the last follow-up. Of the 45 patients who had normal flow at baseline, 3 (7%) converted to low flow at the last follow-up. The mean blood pressure did not differ in patients with or without changes in flow status. The time-varying flow status remained a strong predictor of subsequent stroke (hazard ratio, 10.3 [95% CI, 2.2–48.7]). CONCLUSIONS: There is potential both for improvement and worsening of hemodynamics in patients with atherosclerotic vertebrobasilar disease. Flow status, both at baseline and over time, is a risk factor for subsequent stroke, thus serving as an important prognostic marker.;,citation_author=Sepideh Amin-Hanjani;,citation_author=Alfred P. See;,citation_author=Xinjian Du;,citation_author=Linda Rose-Finnell;,citation_author=Dilip K. Pandey;,citation_author=Yi-Fan Chen;,citation_author=Mitchell S. V. Elkind;,citation_author=Gregory J. Zipfel;,citation_author=David S. Liebeskind;,citation_author=Frank L. Silver;,citation_author=Scott E. Kasner;,citation_author=Philip B. Gorelick;,citation_author=Fady T. Charbel;,citation_author=Colin P. Derdeyn;,citation_author=for the VERiTAS Study Group;,citation_publication_date=2020-11;,citation_cover_date=2020-11;,citation_year=2020;,citation_issue=11;,citation_doi=10.1161/STROKEAHA.120.029909;,citation_issn=0039-2499, 1524-4628;,citation_volume=51;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=Timing of vasoactive agents and corticosteroid initiation in septic shock;,citation_abstract=Septic shock remains a health care concern associated with significant morbidity and mortality. The Surviving Sepsis Campaign Guidelines for Management of Sepsis and Septic Shock recommend early fluid resuscitation and antimicrobials. Beyond initial management, the guidelines do not provide clear recommendations on appropriate time to initiate vasoactive therapies and corticosteroids in patients who develop shock. This review summarizes the literature regarding time of initiation of these interventions. Clinical data regarding time of initiation of these therapies in relation to shock onset, sequence of treatments with regard to each other, and clinical markers evaluated to guide initiation are summarized. Early-high vasopressor initiation within first 6&nbsp;h of shock onset is associated with lower mortality. Following norepinephrine initiation, the exact dose and timing of escalation to adjunctive vasopressor agents are not well elucidated in the literature. However, recent data indicate that timing may be an important factor in initiating vasopressors and adjunctive therapies, such as corticosteroids. Norepinephrine-equivalent dose and lactate concentration can aid in determining when to initiate vasopressin and angiotensin II in patients with septic shock. Future guidelines with clear recommendations on the time of initiation of septic shock therapies are warranted.;,citation_author=Mahmoud A. Ammar;,citation_author=Abdalla A. Ammar;,citation_author=Patrick M. Wieruszewski;,citation_author=Brittany D. Bissell;,citation_author=Micah T. Long;,citation_author=Lauren Albert;,citation_author=Ashish K. Khanna;,citation_author=Gretchen L. Sacha;,citation_publication_date=2022-05;,citation_cover_date=2022-05;,citation_year=2022;,citation_issue=1;,citation_doi=10.1186/s13613-022-01021-9;,citation_issn=2110-5820;,citation_volume=12;,citation_journal_title=Annals of Intensive Care;">
<meta name="citation_reference" content="citation_title=Discuss practical importance of results based on interval estimates and p-value functions, not only on point estimates and null p-values;,citation_abstract=It has long been argued that we need to consider much more than an observed point estimate and a p-value to understand statistical results. One of the most persistent misconceptions about p-values is that they are necessarily calculated assuming a null hypothesis of no effect is true. Instead, p-values can and should be calculated for multiple hypothesized values for the effect size. For example, a p-value function allows us to visualize results continuously by examining how the p-value varies as we move across possible effect sizes. For more focused discussions, a 95% confidence interval shows the subset of possible effect sizes that have p-values larger than 0.05 as calculated from the same data and the same background statistical assumptions. In this sense a confidence interval can be taken as showing the effect sizes that are most compatible with the data, given the assumptions, and thus may be better termed a compatibility interval. The question that should then be asked is whether any or all of the effect sizes within the interval are substantial enough to be of practical importance.;,citation_author=Valentin Amrhein;,citation_author=Sander Greenland;,citation_publication_date=2022-05;,citation_cover_date=2022-05;,citation_year=2022;,citation_doi=10.1177/02683962221105904;,citation_issn=0268-3962;,citation_language=en-US;,citation_journal_title=Journal of Information Technology;,citation_publisher=SAGE Publications Ltd;">
<meta name="citation_reference" content="citation_title=The earth is flat ( &amp;amp;amp;lt;i&amp;gt;p&amp;lt;/i&amp;gt; > 0.05): Significance thresholds and the crisis of unreplicable research;,citation_abstract=The widespread use of “statistical significance” as a license for making a claim of a scientific finding leads to considerable distortion of the scientific process (according to the American Statistical Association). We review why degrading p -values into “significant” and “nonsignificant” contributes to making studies irreproducible, or to making them seem irreproducible. A major problem is that we tend to take small p -values at face value, but mistrust results with larger p -values. In either case, p -values tell little about reliability of research, because they are hardly replicable even if an alternative hypothesis is true. Also significance ( p &nbsp;\leq~0.05) is hardly replicable: at a good statistical power of 80%, two studies will be “conflicting”, meaning that one is significant and the other is not, in one third of the cases if there is a true effect. A replication can therefore not be interpreted as having failed only because it is nonsignificant. Many apparent replication failures may thus reflect faulty judgment based on significance thresholds rather than a crisis of unreplicable research. Reliable conclusions on replicability and practical importance of a finding can only be drawn using cumulative evidence from multiple independent studies. However, applying significance thresholds makes cumulative knowledge unreliable. One reason is that with anything but ideal statistical power, significant effect sizes will be biased upwards. Interpreting inflated significant results while ignoring nonsignificant results will thus lead to wrong conclusions. But current incentives to hunt for significance lead to selective reporting and to publication bias against nonsignificant findings. Data dredging, p -hacking, and publication bias should be addressed by removing fixed significance thresholds. Consistent with the recommendations of the late Ronald Fisher, p -values should be interpreted as graded measures of the strength of evidence against the null hypothesis. Also larger p -values offer some evidence against the null hypothesis, and they cannot be interpreted as supporting the null hypothesis, falsely concluding that “there is no effect”. Information on possible true effect sizes that are compatible with the data must be obtained from the point estimate, e.g., from a sample average, and from the interval estimate, such as a confidence interval. We review how confusion about interpretation of larger p -values can be traced back to historical disputes among the founders of modern statistics. We further discuss potential arguments against removing significance thresholds, for example that decision rules should rather be more stringent, that sample sizes could decrease, or that p -values should better be completely abandoned. We conclude that whatever method of statistical inference we use, dichotomous threshold thinking must give way to non-automated informed judgment.;,citation_author=Valentin Amrhein;,citation_author=Fränzi Korner-Nievergelt;,citation_author=Tobias Roth;,citation_publication_date=2017-07;,citation_cover_date=2017-07;,citation_year=2017;,citation_doi=10.7717/peerj.3544;,citation_issn=2167-8359;,citation_volume=5;,citation_language=en-US;,citation_journal_title=PeerJ;">
<meta name="citation_reference" content="citation_title=Inferential Statistics as Descriptive Statistics: There Is No Replication Crisis if We Don’t Expect Replication;,citation_abstract=Statistical inference often fails to replicate. One reason is that many results may be selected for drawing inference because some threshold of a statistic like the P-value was crossed, leading to biased reported effect sizes. Nonetheless, considerable non-replication is to be expected even without selective reporting, and generalizations from single studies are rarely if ever warranted. Honestly reported results must vary from replication to replication because of varying assumption violations and random variation; excessive agreement itself would suggest deeper problems, such as failure to publish results in conflict with group expectations or desires. A general perception of a “replication crisis” may thus reflect failure to recognize that statistical tests not only test hypotheses, but countless assumptions and the entire environment in which research takes place. Because of all the uncertain and unknown assumptions that underpin statistical inferences, we should treat inferential statistics as highly unstable local descriptions of relations between assumptions and data, rather than as providing generalizable inferences about hypotheses or models. And that means we should treat statistical results as being much more incomplete and uncertain than is currently the norm. Acknowledging this uncertainty could help reduce the allure of selective reporting: Since a small P-value could be large in a replication study, and a large P-value could be small, there is simply no need to selectively report studies based on statistical results. Rather than focusing our study reports on uncertain conclusions, we should thus focus on describing accurately how the study was conducted, what problems occurred, what data were obtained, what analysis methods were used and why, and what output those methods produced.;,citation_author=Valentin Amrhein;,citation_author=David Trafimow;,citation_author=Sander Greenland;,citation_publication_date=2019-03;,citation_cover_date=2019-03;,citation_year=2019;,citation_issue=sup1;,citation_doi=10.1080/00031305.2018.1543137;,citation_issn=0003-1305, 1537-2731;,citation_volume=73;,citation_language=en-US;,citation_journal_title=The American Statistician;">
<meta name="citation_reference" content="citation_title=Rewriting results in the language of compatibility;,citation_author=Valentin Amrhein;,citation_author=Sander Greenland;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_doi=10.1016/j.tree.2022.02.001;,citation_issn=01695347;,citation_language=en-US;,citation_journal_title=Trends in Ecology &amp;amp;amp; Evolution;">
<meta name="citation_reference" content="citation_title=Effects of remdesivir in patients hospitalised with COVID-19: A systematic review and individual patient data meta-analysis of randomised controlled trials;,citation_abstract=Background Interpretation of the evidence from randomised controlled trials (RCTs) of remdesivir in patients treated in hospital for COVID-19 is conflicting. We aimed to assess the benefits and harms of remdesivir compared with placebo or usual care in these patients, and whether treatment effects differed between prespecified patient subgroups.;,citation_author=Alain Amstutz;,citation_author=Benjamin Speich;,citation_author=France Mentré;,citation_author=Corina Silvia Rueegg;,citation_author=Drifa Belhadi;,citation_author=Lambert Assoumou;,citation_author=Charles Burdet;,citation_author=Srinivas Murthy;,citation_author=Lori Elizabeth Dodd;,citation_author=Yeming Wang;,citation_author=Kari A O Tikkinen;,citation_author=Florence Ader;,citation_author=Maya Hites;,citation_author=Maude Bouscambert;,citation_author=Mary Anne Trabaud;,citation_author=Mike Fralick;,citation_author=Todd C Lee;,citation_author=Ruxandra Pinto;,citation_author=Andreas Barratt-Due;,citation_author=Fridtjof Lund-Johansen;,citation_author=Fredrik Müller;,citation_author=Olli P O Nevalainen;,citation_author=Bin Cao;,citation_author=Tyler Bonnett;,citation_author=Alexandra Griessbach;,citation_author=Ala Taji Heravi;,citation_author=Christof Schönenberger;,citation_author=Perrine Janiaud;,citation_author=Laura Werlen;,citation_author=Soheila Aghlmandi;,citation_author=Stefan Schandelmaier;,citation_author=Yazdan Yazdanpanah;,citation_author=Dominique Costagliola;,citation_author=Inge Christoffer Olsen;,citation_author=Matthias Briel;,citation_publication_date=2023-02;,citation_cover_date=2023-02;,citation_year=2023;,citation_doi=10.1016/S2213-2600(22)00528-8;,citation_issn=22132600;,citation_language=en-US;,citation_journal_title=The Lancet Respiratory Medicine;">
<meta name="citation_reference" content="citation_title=Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression;,citation_author=Amit Anand;,citation_author=Sanjay J. Mathew;,citation_author=Gerard Sanacora;,citation_author=James W. Murrough;,citation_author=Fernando S. Goes;,citation_author=Murat Altinay;,citation_author=Amy S. Aloysi;,citation_author=Ali A. Asghar-Ali;,citation_author=Brian S. Barnett;,citation_author=Lee C. Chang;,citation_author=Katherine A. Collins;,citation_author=Sara Costi;,citation_author=Sidra Iqbal;,citation_author=Manish K. Jha;,citation_author=Kamini Krishnan;,citation_author=Donald A. Malone;,citation_author=Sina Nikayin;,citation_author=Steven E. Nissen;,citation_author=Robert B. Ostroff;,citation_author=Irving M. Reti;,citation_author=Samuel T. Wilkinson;,citation_author=Kathy Wolski;,citation_author=Bo Hu;,citation_publication_date=2023-05;,citation_cover_date=2023-05;,citation_year=2023;,citation_issue=0;,citation_doi=10.1056/NEJMoa2302399;,citation_issn=0028-4793;,citation_volume=0;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Drugs for advanced life support;,citation_author=Lars W. Andersen;,citation_author=Jerry P. Nolan;,citation_author=Claudio Sandroni;,citation_publication_date=2022-05;,citation_cover_date=2022-05;,citation_year=2022;,citation_issue=5;,citation_doi=10.1007/s00134-022-06678-1;,citation_issn=0342-4642, 1432-1238;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Haloperidol vs. Placebo for the treatment of delirium in ICU patients: A pre-planned, secondary Bayesian analysis of the AID–ICU trial;,citation_author=Nina C. Andersen-Ranberg;,citation_author=Lone Musaeus Poulsen;,citation_author=Anders Perner;,citation_author=Johanna Hästbacka;,citation_author=Matthew Morgan;,citation_author=Giuseppe Citerio;,citation_author=Marie Oxenbøll Collet;,citation_author=Sven-Olaf Weber;,citation_author=Anne Sofie Andreasen;,citation_author=Morten Bestle;,citation_author=Bülent Uslu;,citation_author=Helle Scharling Pedersen;,citation_author=Louise Gramstrup Nielsen;,citation_author=Kjeld Damgaard;,citation_author=Troels Bek Jensen;,citation_author=Trine Sommer;,citation_author=Nilanjan Dey;,citation_author=Ole Mathiesen;,citation_author=Anders Granholm;,citation_publication_date=2023-04;,citation_cover_date=2023-04;,citation_year=2023;,citation_issue=4;,citation_doi=10.1007/s00134-023-07024-9;,citation_issn=0342-4642, 1432-1238;,citation_volume=49;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Haloperidol and delirium: What is next?;,citation_author=Nina C. Andersen-Ranberg;,citation_author=Timothy D. Girard;,citation_author=Anders Perner;,citation_publication_date=2023-10;,citation_cover_date=2023-10;,citation_year=2023;,citation_doi=10.1007/s00134-023-07232-3;,citation_issn=1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): An international, randomised, open-label, blinded-endpoint, phase 3 trial;,citation_abstract=BACKGROUND: Systolic blood pressure of more than 185 mm Hg is a contraindication to thrombolytic treatment with intravenous alteplase in patients with acute ischaemic stroke, but the target systolic blood pressure for optimal outcome is uncertain. We assessed intensive blood pressure lowering compared with guideline-recommended blood pressure lowering in patients treated with alteplase for acute ischaemic stroke. METHODS: We did an international, partial-factorial, open-label, blinded-endpoint trial of thrombolysis-eligible patients (age \geq18 years) with acute ischaemic stroke and systolic blood pressure 150 mm Hg or more, who were screened at 110 sites in 15 countries. Eligible patients were randomly assigned (1:1, by means of a central, web-based program) within 6 h of stroke onset to receive intensive (target systolic blood pressure 130-140 mm Hg within 1 h) or guideline (target systolic blood pressure &amp;amp;amp;lt;180 mm Hg) blood pressure lowering treatment over 72 h. The primary outcome was functional status at 90 days measured by shift in modified Rankin scale scores, analysed with unadjusted ordinal logistic regression. The key safety outcome was any intracranial haemorrhage. Primary and safety outcome assessments were done in a blinded manner. Analyses were done on intention-to-treat basis. This trial is registered with ClinicalTrials.gov, number NCT01422616. FINDINGS: Between March 3, 2012, and April 30, 2018, 2227 patients were randomly allocated to treatment groups. After exclusion of 31 patients because of missing consent or mistaken or duplicate randomisation, 2196 alteplase-eligible patients with acute ischaemic stroke were included: 1081 in the intensive group and 1115 in the guideline group, with 1466 (67\cdot4%) administered a standard dose among the 2175 actually given intravenous alteplase. Median time from stroke onset to randomisation was 3\cdot3 h (IQR 2\cdot6-4\cdot1). Mean systolic blood pressure over 24 h was 144\cdot3 mm Hg (SD 10\cdot2) in the intensive group and 149\cdot8 mm Hg (12\cdot0) in the guideline group (p&amp;lt;0\cdot0001). Primary outcome data were available for 1072 patients in the intensive group and 1108 in the guideline group. Functional status (mRS score distribution) at 90 days did not differ between groups (unadjusted odds ratio [OR] 1\cdot01, 95% CI 0\cdot87-1\cdot17, p=0\cdot8702). Fewer patients in the intensive group (160 [14\cdot8%] of 1081) than in the guideline group (209 [18\cdot7%] of 1115) had any intracranial haemorrhage (OR 0\cdot75, 0\cdot60-0\cdot94, p=0\cdot0137). The number of patients with any serious adverse event did not differ significantly between the intensive group (210 [19\cdot4%] of 1081) and the guideline group (245 [22\cdot0%] of 1115; OR 0\cdot86, 0\cdot70-1\cdot05, p=0\cdot1412). There was no evidence of an interaction of intensive blood pressure lowering with dose (low vs standard) of alteplase with regard to the primary outcome. INTERPRETATION: Although intensive blood pressure lowering is safe, the observed reduction in intracranial haemorrhage did not lead to improved clinical outcome compared with guideline treatment. These results might not support a major shift towards this treatment being applied in those receiving alteplase for mild-to-moderate acute ischaemic stroke. Further research is required to define the underlying mechanisms of benefit and harm resulting from early intensive blood pressure lowering in this patient group. FUNDING: National Health and Medical Research Council of Australia; UK Stroke Association; Ministry of Health and the National Council for Scientific and Technological Development of Brazil; Ministry for Health, Welfare, and Family Affairs of South Korea; Takeda.;,citation_author=Craig S. Anderson;,citation_author=Yining Huang;,citation_author=Richard I. Lindley;,citation_author=Xiaoying Chen;,citation_author=Hisatomi Arima;,citation_author=Guofang Chen;,citation_author=Qiang Li;,citation_author=Laurent Billot;,citation_author=Candice Delcourt;,citation_author=Philip M. Bath;,citation_author=Joseph P. Broderick;,citation_author=Andrew M. Demchuk;,citation_author=Geoffrey A. Donnan;,citation_author=Alice C. Durham;,citation_author=Pablo M. Lavados;,citation_author=Tsong-Hai Lee;,citation_author=Christopher Levi;,citation_author=Sheila O. Martins;,citation_author=Veronica V. Olavarria;,citation_author=Jeyaraj D. Pandian;,citation_author=Mark W. Parsons;,citation_author=Octavio M. Pontes-Neto;,citation_author=Stefano Ricci;,citation_author=Shoichiro Sato;,citation_author=Vijay K. Sharma;,citation_author=Federico Silva;,citation_author=Lili Song;,citation_author=Nguyen H. Thang;,citation_author=Joanna M. Wardlaw;,citation_author=Ji-Guang Wang;,citation_author=Xia Wang;,citation_author=Mark Woodward;,citation_author=John Chalmers;,citation_author=Thompson G. Robinson;,citation_author=ENCHANTED Investigators and Coordinators;,citation_publication_date=2019-03;,citation_cover_date=2019-03;,citation_year=2019;,citation_issue=10174;,citation_doi=10.1016/S0140-6736(19)30038-8;,citation_issn=1474-547X;,citation_pmid=30739745;,citation_volume=393;,citation_language=en-US;,citation_journal_title=Lancet (London, England);">
<meta name="citation_reference" content="citation_title=Rapid Blood-Pressure Lowering in Patients with Acute Intracerebral Hemorrhage;,citation_author=Craig S. Anderson;,citation_author=Emma Heeley;,citation_author=Yining Huang;,citation_author=Jiguang Wang;,citation_author=Christian Stapf;,citation_author=Candice Delcourt;,citation_author=Richard Lindley;,citation_author=Thompson Robinson;,citation_author=Pablo Lavados;,citation_author=Bruce Neal;,citation_author=Jun Hata;,citation_author=Hisatomi Arima;,citation_author=Mark Parsons;,citation_author=Yuechun Li;,citation_author=Jinchao Wang;,citation_author=Stephane Heritier;,citation_author=Qiang Li;,citation_author=Mark Woodward;,citation_author=R. John Simes;,citation_author=Stephen M. Davis;,citation_author=John Chalmers;,citation_publication_date=2013-06;,citation_cover_date=2013-06;,citation_year=2013;,citation_issue=25;,citation_doi=10.1056/NEJMoa1214609;,citation_issn=0028-4793;,citation_volume=368;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=IV Vitamin C in Adults With Sepsis: A Bayesian Reanalysis of a Randomized Controlled Trial*;,citation_abstract=OBJECTIVES:&nbsp; The Lessening Organ Dysfunction with Vitamin C trial showed a harmful effect of vitamin C on 28-day death or persistent organ dysfunction. To maximize interpretation, we present a post hoc Bayesian reanalysis. DESIGN:&nbsp; Bayesian reanalysis of a randomized placebo-controlled trial. SETTING:&nbsp; Thirty-five ICUs. PATIENTS:&nbsp; Adults with proven or suspected infection, vasopressor support, and no more than 24 hours of ICU admission. INTERVENTIONS:&nbsp; Patients were allocated to receive either vitamin C (50 mg/kg of body weight) or placebo every 6 hours for up to 96 hours. MEASUREMENTS AND MAIN RESULTS:&nbsp; The primary outcome was the composite of death or persistent organ dysfunction (i.e., vasopressor use, invasive mechanical ventilation, or new renal replacement therapy) at 28 days. We used Bayesian log-binomial models with random effects for hospital site and varying informative prior beliefs for the effect of vitamin C to estimate risk ratios (RRs) with 95% credible intervals (Crls) in the intention to treat population (vitamin C, 435 patients; placebo, 437 patients). Using weakly neutral priors, patients allocated to vitamin C had a higher risk of death or persistent organ dysfunction at 28 days (RR, 1.20; 95% Crl, 1.04–1.39; probability of harm, 99%). This effect was consistent when using optimistic (RR, 1.14; 95% Crl, 1.00–1.31; probability of harm, 98%) and empiric (RR, 1.09; 95% Crl, 0.97–1.22; probability of harm, 92%) priors. Patients allocated to vitamin C also had a higher risk of death at 28 days under weakly neutral (RR, 1.17; 95% Crl, 0.98–1.40; probability of harm, 96%), optimistic (RR, 1.10; 95% Crl, 0.94–1.30; probability of harm, 88%), and empiric (RR, 1.05; 95% Crl, 0.92–1.19; probability of harm, 76%) priors. CONCLUSIONS:&nbsp; The use of vitamin C in adult patients with proven or suspected infection and vasopressor support is associated with high probability of harm.;,citation_author=Federico Angriman;,citation_author=Fiona Muttalib;,citation_author=François Lamontagne;,citation_author=Neill K. J. Adhikari;,citation_author=Lovit Investigators;,citation_publication_date=2023-08;,citation_cover_date=2023-08;,citation_year=2023;,citation_issue=8;,citation_doi=10.1097/CCM.0000000000005871;,citation_issn=0090-3493;,citation_volume=51;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=The Lingering Consequences of Sepsis: A Hidden Public Health Disaster?;,citation_author=Derek C. Angus;,citation_publication_date=2010-10;,citation_cover_date=2010-10;,citation_year=2010;,citation_issue=16;,citation_doi=10.1001/jama.2010.1546;,citation_issn=0098-7484;,citation_volume=304;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Oxygen Therapy for the Critically Ill;,citation_author=Derek C. Angus;,citation_publication_date=2020-03;,citation_cover_date=2020-03;,citation_year=2020;,citation_issue=11;,citation_doi=10.1056/NEJMe2000800;,citation_issn=0028-4793, 1533-4406;,citation_volume=382;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Testing Graphical Causal Models Using the R Package “dagitty”;,citation_abstract=Causal diagrams such as directed acyclic graphs (DAGs) are used in several scientific fields to help design and analyze studies that aim to infer causal effects from observational data; for example, DAGs can help identify suitable strategies to reduce confounding bias. However, DAGs can be difficult to design, and the validity of any DAG-derived strategy hinges on the validity of the postulated DAG itself. Researchers should therefore check whether the assumptions encoded in the DAG are consistent with the data before proceeding with the analysis. Here, we explain how the R package “dagitty”, based on the web tool dagitty.net, can be used to test the statistical implications of the assumptions encoded in a given DAG. We hope that this will help researchers discover model specification errors, avoid erroneous conclusions, and build better models. © 2021 The Authors. This article was corrected on 19 July 2022. See the end of the full text for details. Basic Protocol 1: Constructing and importing DAG models from the dagitty web interface Support Protocol 1: Installing R, RStudio, and the dagitty package Basic Protocol 2: Testing DAGs against categorical data Basic Protocol 3: Testing DAGs against continuous data Support Protocol 2: Testing DAGs against continuous data with non-linearities Basic Protocol 4: Testing DAGs against a combination of categorical and continuous data;,citation_author=Ankur Ankan;,citation_author=Inge M. N. Wortel;,citation_author=Johannes Textor;,citation_publication_date=2021;,citation_cover_date=2021;,citation_year=2021;,citation_issue=2;,citation_doi=10.1002/cpz1.45;,citation_issn=2691-1299;,citation_volume=1;,citation_language=en-US;,citation_journal_title=Current Protocols;">
<meta name="citation_reference" content="citation_title=“Normal weight” is really not normal in chronic disease;,citation_author=Stefan D Anker;,citation_author=Muhammad Shariq Usman;,citation_author=Javed Butler;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_doi=10.1093/eurheartj/ehac486;,citation_issn=0195-668X, 1522-9645;,citation_language=en-US;,citation_journal_title=European Heart Journal;">
<meta name="citation_reference" content="citation_title=Cognitive decline after sepsis;,citation_author=Djillali Annane;,citation_author=Tarek Sharshar;,citation_publication_date=2015-01;,citation_cover_date=2015-01;,citation_year=2015;,citation_issue=1;,citation_doi=10.1016/S2213-2600(14)70246-2;,citation_issn=22132600;,citation_volume=3;,citation_language=en-US;,citation_journal_title=The Lancet Respiratory Medicine;">
<meta name="citation_reference" content="citation_title=Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: A phase 3, multicentre, open-label, randomised controlled trial;,citation_author=Djillali Annane;,citation_author=Sean J. Pittock;,citation_author=Hrishikesh S. Kulkarni;,citation_author=Brian W. Pickering;,citation_author=Matt R. Khoshnevis;,citation_author=Jason L. Siegel;,citation_author=Charles A. Powell;,citation_author=Pedro Castro;,citation_author=Tomoko Fujii;,citation_author=Derek Dunn;,citation_author=Keisha Smith;,citation_author=Sanjay Mitter;,citation_author=Shamsah Kazani;,citation_author=Austin Kulasekararaj;,citation_publication_date=2023-03;,citation_cover_date=2023-03;,citation_year=2023;,citation_issue=0;,citation_doi=10.1016/S2213-2600(23)00082-6;,citation_issn=2213-2600, 2213-2619;,citation_volume=0;,citation_language=en-US;,citation_journal_title=The Lancet Respiratory Medicine;,citation_publisher=Elsevier;">
<meta name="citation_reference" content="citation_title=Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge;,citation_author=Ronen Arbel;,citation_author=Yael Wolff Sagy;,citation_author=Moshe Hoshen;,citation_author=Erez Battat;,citation_author=Gil Lavie;,citation_author=Ruslan Sergienko;,citation_author=Michael Friger;,citation_author=Jacob G. Waxman;,citation_author=Noa Dagan;,citation_author=Ran Balicer;,citation_author=Yatir Ben-Shlomo;,citation_author=Alon Peretz;,citation_author=Shlomit Yaron;,citation_author=Danielle Serby;,citation_author=Ariel Hammerman;,citation_author=Doron Netzer;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_issue=0;,citation_doi=10.1056/NEJMoa2204919;,citation_issn=0028-4793;,citation_volume=0;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Evaluation of rapid changes in hemodynamic status by Point-of-Care Ultrasound: A useful tool in cardionephrology;,citation_author=Eduardo R Argaiz;,citation_author=Nestor Cruz;,citation_author=Gerardo Gamba;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=The Letter Pi : Bayesian interpretation of p-values, Reproducibility and Considerations for Replication in the Generalized Linear Model;,citation_abstract=Significance testing based on p-values has been implicated in the reproducibility crisis in scientific research, with one of the proposals being to eliminate them in favor of Bayesian analyses. Defenders of the p-values have countered that it is the improper use and errors in interpretation, rather than the p-values themselves that are to blame. Similar exchanges about the role of p-values have occurred with some regularity every 10 to 15 years since their formal introduction in statistical practice. The apparent contradiction between the repeated failures in interpretation and continuous use of p-values suggest that there is an inferential value in the computation of these values. In this work we propose to attach a radical Bayesian interpretation to the number computed and reported as a p-value for the Generalized Linear Model, which has been the workhorse of applied statistical work. We introduce a decision analytic framework for thresholding posterior tail areas (pi-values) which for any given Bayesian analysis will have a direct correspondence to p-values in non-Bayesian approaches. Pi-values are non-controversial, posterior probability summaries of treatment effects. A predictive probability argument is made to justify the exploration of the stochastic variation (replication probability) of p and pi-values and culminates into a concrete proposal for the synthesis of Likelihood and Bayesian approaches to data analyses that aim for reproducibility. We illustrate these concepts using the results of recent randomized controlled trials in cardiometabolic and kidney diseases and provide R code for the implementation of the proposed methodology.;,citation_author=Christos Argyropoulos;,citation_author=Andy P. Grieve;,citation_publication_date=2023-04;,citation_cover_date=2023-04;,citation_year=2023;,citation_fulltext_html_url=https://arxiv.org/abs/2305.00636;,citation_publisher=arXiv;">
<meta name="citation_reference" content="citation_title=Administration of methylene blue in septic shock: Pros and cons;,citation_abstract=Septic shock typically requires the administration of vasopressors. Adrenergic agents remain the first choice, namely norepinephrine. However, their use to counteract life-threatening hypotension comes with potential adverse effects, so that non-adrenergic vasopressors may also be considered. The use of agents that act through different mechanisms may also provide an advantage. Nitric oxide (NO) is the main driver of the vasodilation that leads to hypotension in septic shock, so several agents have been tested to counteract its effects. The use of non-selective NO synthase inhibitors has been of questionable benefit. Methylene blue, an inhibitor of soluble guanylate cyclase, an important enzyme involved in the NO signaling pathway in the vascular smooth muscle cell, has also been proposed. However, more than 25 years since the first clinical evaluation of MB administration in septic shock, the safety and benefits of its use are still not fully established, and it should not be used routinely in clinical practice until further evidence of its efficacy is available.;,citation_author=Julian Arias-Ortiz;,citation_author=Jean-Louis Vincent;,citation_publication_date=2024-12;,citation_cover_date=2024-12;,citation_year=2024;,citation_issue=1;,citation_doi=10.1186/s13054-024-04839-w;,citation_issn=1364-8535;,citation_volume=28;,citation_language=en-US;,citation_journal_title=Critical Care;,citation_publisher=BioMed Central;">
<meta name="citation_reference" content="citation_title=Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19;,citation_abstract=BACKGROUND Molnupiravir is an oral prodrug of b-D-N4-hydroxycytidine, active against SARS-CoV-2 in vitro and in animal models. We report data from the phase 2 component of MOVe-IN, a clinical trial evaluating molnupiravir in patients hospitalized with Covid-19. METHODS We conducted a randomized, placebo-controlled, double-blind phase 2/3 trial in patients 18 years old and older requiring in-hospital treatment for laboratoryconfirmed Covid-19 with symptom onset 10 or fewer days before randomization. Participants were randomly assigned to placebo or molnupiravir 200 mg, 400 mg, or 800 mg (1:1:1:1 ratio), twice daily for 5 days. Primary end points were safety and sustained recovery (participant alive and either not hospitalized or medically ready for discharge) through day 29. RESULTS Of 304 randomly assigned participants, 218 received at least one dose of molnupiravir and 75 of placebo. At baseline, 74.0% had at least one risk factor for severe Covid-19. Adverse events were reported in 121 of 218 (55.5%) molnupiravir-treated and 46 of 75 (61.3%) placebo-treated participants, with no apparent dose effect on adverse event rates and no evidence of hematologic toxicity based on prespecified adverse events. Of 16 confirmed deaths, most were in participants with severe Covid-19 (75.0%), with underlying comorbidities (87.5%), older than 60 years of age (81.3%), and/or symptom duration longer than 5 days (75.0%) at randomization. Median time to sustained recovery was 9 days in all groups, with similar day 29 recovery rates ranging from 81.5% to 85.2%. CONCLUSIONS In this phase 2 trial of patients hospitalized with Covid-19, a 5-day course of molnupiravir up to 800 mg twice daily was not associated with dose-limiting;,citation_author=José R. Arribas;,citation_author=Sanjay Bhagani;,citation_author=Suzana M. Lobo;,citation_author=Ilsiyar Khaertynova;,citation_author=Lourdes Mateu;,citation_author=Roman Fishchuk;,citation_author=William Y. Park;,citation_author=Khetam Hussein;,citation_author=Sei Won Kim;,citation_author=Jade Ghosn;,citation_author=Michelle L. Brown;,citation_author=Ying Zhang;,citation_author=Wei Gao;,citation_author=Christopher Assaid;,citation_author=Jay A. Grobler;,citation_author=Julie Strizki;,citation_author=Mary Vesnesky;,citation_author=Amanda Paschke;,citation_author=Joan R. Butterton;,citation_author=Carisa De Anda;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=2;,citation_doi=10.1056/EVIDoa2100044;,citation_issn=2766-5526;,citation_volume=1;,citation_language=en-US;,citation_journal_title=NEJM Evidence;">
<meta name="citation_reference" content="citation_title=Precipitating factors and 90-day outcome of acute heart failure: A report from the intercontinental &amp;amp;amp;lt;span style=&amp;quot;font-variant:small-caps;&amp;quot;&amp;gt;GREAT&amp;lt;/span&amp;gt; registry;,citation_author=Mattia Arrigo;,citation_author=Etienne Gayat;,citation_author=Jiri Parenica;,citation_author=Shiro Ishihara;,citation_author=Jian Zhang;,citation_author=Dong-Ju Choi;,citation_author=Jin Joo Park;,citation_author=Khalid F. Alhabib;,citation_author=Naoki Sato;,citation_author=Oscar Miro;,citation_author=Aldo P. Maggioni;,citation_author=Yuhui Zhang;,citation_author=Jindrich Spinar;,citation_author=Alain Cohen-Solal;,citation_author=Theodore J. Iwashyna;,citation_author=Alexandre Mebazaa;,citation_author=on behalf of the GREAT Network;,citation_publication_date=2017-02;,citation_cover_date=2017-02;,citation_year=2017;,citation_issue=2;,citation_doi=10.1002/ejhf.682;,citation_issn=1388-9842, 1879-0844;,citation_volume=19;,citation_language=en-US;,citation_journal_title=European Journal of Heart Failure;">
<meta name="citation_reference" content="citation_title=Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: A systematic review and meta-analysis;,citation_author=Charlotte JJ Asch;,citation_author=Merel JA Luitse;,citation_author=Gabriël JE Rinkel;,citation_author=Ingeborg Tweel;,citation_author=Ale Algra;,citation_author=Catharina JM Klijn;,citation_publication_date=2010-02;,citation_cover_date=2010-02;,citation_year=2010;,citation_issue=2;,citation_doi=10.1016/S1474-4422(09)70340-0;,citation_issn=1474-4422, 1474-4465;,citation_pmid=20056489;,citation_volume=9;,citation_language=en-US;,citation_journal_title=The Lancet Neurology;,citation_publisher=Elsevier;">
<meta name="citation_reference" content="citation_title=Respiratory Management in Patients with Severe Brain Injury;,citation_abstract=This article is one of ten reviews selected from the Annual Update in Intensive Care and Emergency Medicine 2018. Other selected articles can be found online at https://www-biomedcentral-com.libproxy.lib.unc.edu/collections/annualupdate2018 . Further information about the Annual Update in Intensive Care and Emergency Medicine is available from http://www.springer.com.libproxy.lib.unc.edu/series/8901 .;,citation_author=Karim Asehnoune;,citation_author=Antoine Roquilly;,citation_author=Raphaël Cinotti;,citation_publication_date=2018-12;,citation_cover_date=2018-12;,citation_year=2018;,citation_issue=1;,citation_doi=10.1186/s13054-018-1994-0;,citation_issn=1364-8535;,citation_volume=22;,citation_language=en-US;,citation_journal_title=Critical Care;,citation_publisher=BioMed Central;">
<meta name="citation_reference" content="citation_title=Thiamine, Ascorbic Acid, and Hydrocortisone As a Metabolic Resuscitation Cocktail in Sepsis: A Meta-Analysis of Randomized Controlled Trials With Trial Sequential Analysis;,citation_abstract=OBJECTIVES: Sepsis is a common condition in the ICU. Despite much research, its prognosis remains poor. In 2017, a retrospective before/after study reported promising results using a combination of thiamine, ascorbic acid, and hydrocortisone called “metabolic resuscitation cocktail” and several randomized controlled trials assessing its effectiveness were performed. DESIGN: We conducted a systematic review and meta-analysis of randomized controlled trials in septic ICU patients to assess the effects of this combination therapy. SETTING: PubMed, Embase, and the Cochrane library databases were searched from inception to March of 2021. Data were extracted independently by two authors. The main outcome was the change in Sequential Organ Failure Assessment score within 72 hours. Secondary outcomes included renal composite endpoints (acute kidney injury) Kidney Disease - Improving Global Outcome organization stage 3 or need for renal replacement therapy, vasopressor duration, and 28-day mortality. SUBJECTS: We included randomized controlled trials with patients admitted to the ICU with sepsis or septic shock. INTERVENTION: The trials compared a combination of thiamine, ascorbic acid, and hydrocortisone to standard care or placebo in patients admitted to ICU with sepsis or septic shock. MEASUREMENTS AND MAIN RESULTS: We included eight randomized controlled trials (n = 1,335 patients). Within 72 hours, the median of mean improvement was –1.8 and –3.2 in the control and intervention groups, respectively (eight randomized controlled trials, n = 1,253 patients); weighted mean difference –0.82 (95% CI, –1.15 to –0.48). Data were homogeneous and the funnel plot did not suggest any publication bias. Duration of vasopressor requirement was significantly reduced in the intervention group (six randomized controlled trials). There was no evidence of a difference regarding the ICU mortality and the renal composite outcome (acute kidney injury KDIGO 3 or need for renal replacement therapy, seven randomized controlled trials). CONCLUSIONS: Metabolic resuscitation cocktail administrated in ICU septic patients improves change in Sequential Organ Failure Assessment score within 72 hours. However, this improvement is modest and its clinical relevance is questionable. The impact on renal failure and mortality remains unclear.;,citation_author=Benjamin Assouline;,citation_author=Anna Faivre;,citation_author=Thomas Verissimo;,citation_author=Frédéric Sangla;,citation_author=Lena Berchtold;,citation_author=Raphaël Giraud;,citation_author=Karim Bendjelid;,citation_author=Sebastian Sgardello;,citation_author=Nadia Elia;,citation_author=Jérôme Pugin;,citation_author=Sophie Seigneux;,citation_author=David Legouis;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_doi=10.1097/CCM.0000000000005262;,citation_issn=0090-3493;,citation_volume=Publish Ahead of Print;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Homologous and Heterologous Covid-19 Booster Vaccinations;,citation_abstract=BACKGROUND Although the three vaccines against coronavirus disease 2019 (Covid-19) that have received emergency use authorization in the United States are highly effective, breakthrough infections are occurring. Data are needed on the serial use of homologous boosters (same as the primary vaccine) and heterologous boosters (different from the primary vaccine) in fully vaccinated recipients. METHODS In this phase 1–2, open-label clinical trial conducted at 10 sites in the United States, adults who had completed a Covid-19 vaccine regimen at least 12 weeks earlier and had no reported history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection received a booster injection with one of three vaccines: mRNA-1273 (Moderna) at a dose of 100 \mug, Ad26.COV2.S (Johnson &amp;amp;amp; Johnson–Janssen) at a dose of 51010 virus particles, or BNT162b2 (Pfizer–BioNTech) at a dose of 30 \mug. The primary end points were safety, reactogenicity, and humoral immunogenicity on trial days 15 and 29. RESULTS Of the 458 participants who were enrolled in the trial, 154 received mRNA-1273, 150 received Ad26.COV2.S, and 153 received BNT162b2 as booster vaccines; 1 participant did not receive the assigned vaccine. Reactogenicity was similar to that reported for the primary series. More than half the recipients reported having injection-site pain, malaise, headache, or myalgia. For all combinations, antibody neutralizing titers against a SARS-CoV-2 D614G pseudovirus increased by a factor of 4 to 73, and binding titers increased by a factor of 5 to 55. Homologous boosters increased neutralizing antibody titers by a factor of 4 to 20, whereas heterologous boosters increased titers by a factor of 6 to 73. Spike-specific T-cell responses increased in all but the homologous Ad26.COV2.S-boosted subgroup. CD8+ T-cell levels were more durable in the Ad26.COV2.S-primed recipients, and heterologous boosting with the Ad26.COV2.S vaccine substantially increased spike-specific CD8+ T cells in the mRNA vaccine recipients. The authors’ full names, academic degrees, and affiliations are listed in the Appendix. Dr. Atmar can be contacted at ratmar@bcm.edu or at Baylor College of Medicine, 1 Baylor Plaza, MS BCM280, Houston, TX 77030; Dr. Lyke can be contacted at klyke@som.umaryland.edu or at the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St., Baltimore, MD 21201. *The members of the DMID 21-0012 Study Group are listed in the Supplementary Appendix, available at NEJM.org. Drs. Atmar and Lyke contributed equally to this article. This article was published on January 26, 2022, at NEJM.org. DOI: 10.1056/NEJMoa2116414 Copyright © 2022 Massachusetts Medical Society. CONCLUSIONS Homologous and heterologous booster vaccines had an acceptable safety profile and were immunogenic in adults who had completed a primary Covid-19 vaccine regimen at least 12 weeks earlier. (Funded by the National Institute of Allergy and Infectious Diseases; DMID 21-0012 ClinicalTrials.gov number, NCT04889209.);,citation_author=Robert L. Atmar;,citation_author=Kirsten E. Lyke;,citation_author=Meagan E. Deming;,citation_author=Lisa A. Jackson;,citation_author=Angela R. Branche;,citation_author=Hana M. El Sahly;,citation_author=Christina A. Rostad;,citation_author=Judith M. Martin;,citation_author=Christine Johnston;,citation_author=Richard E. Rupp;,citation_author=Mark J. Mulligan;,citation_author=Rebecca C. Brady;,citation_author=Robert W. Frenck;,citation_author=Martín Bäcker;,citation_author=Angelica C. Kottkamp;,citation_author=Tara M. Babu;,citation_author=Kumaravel Rajakumar;,citation_author=Srilatha Edupuganti;,citation_author=David Dobrzynski;,citation_author=Rhea N. Coler;,citation_author=Christine M. Posavad;,citation_author=Janet I. Archer;,citation_author=Sonja Crandon;,citation_author=Seema U. Nayak;,citation_author=Daniel Szydlo;,citation_author=Jillian A. Zemanek;,citation_author=Clara P. Dominguez Islas;,citation_author=Elizabeth R. Brown;,citation_author=Mehul S. Suthar;,citation_author=M. Juliana McElrath;,citation_author=Adrian B. McDermott;,citation_author=Sarah E. O’Connell;,citation_author=David C. Montefiori;,citation_author=Amanda Eaton;,citation_author=Kathleen M. Neuzil;,citation_author=David S. Stephens;,citation_author=Paul C. Roberts;,citation_author=John H. Beigel;,citation_publication_date=2022-03;,citation_cover_date=2022-03;,citation_year=2022;,citation_issue=11;,citation_doi=10.1056/NEJMoa2116414;,citation_issn=0028-4793, 1533-4406;,citation_volume=386;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Clinical reasoning difficulties: A taxonomy for clinical teachers;,citation_abstract=Background: Clinical reasoning is the cornerstone of medical practice. To date, there is no established framework regarding clinical reasoning difficulties, how to identify them, and how to remediate them. Aim: To identify the most common clinical reasoning difficulties as they present in residents’ patient encounters, case summaries, or medical notes. To develop a guide to support medical educators’ process of educational diagnosis and management in this area. Methods: We used a participatory action research method. We carried out eight iterative reflective cycles with a group of clinical teachers. The repeated phases of experimentation and observation were conducted by participants in their own clinical teaching setting. Our findings were tested and validated on both an individual and collective basis Results: We found five categories of clinical reasoning difficulties as they present in the clinical teaching settings. We identified indicators for each. Indicators may be different depending on the type of supervision. These findings were assembled and organized to construct a guide for clinical teachers. Conclusions: The guide should assist clinical teachers in detecting clinical reasoning difficulties during clinical teaching and in providing remediation that is tailored to the specific difficulty identified. Its development furthers our understanding of clinical reasoning difficulties and provides a useful tool.;,citation_author=Marie-Claude Audétat;,citation_author=Suzanne Laurin;,citation_author=Gilbert Sanche;,citation_author=Caroline Béı̈que;,citation_author=Nathalie Caire Fon;,citation_author=Jean-Guy Blais;,citation_author=Bernard Charlin;,citation_publication_date=2013-03;,citation_cover_date=2013-03;,citation_year=2013;,citation_issue=3;,citation_doi=10.3109/0142159X.2012.733041;,citation_issn=0142-159X, 1466-187X;,citation_volume=35;,citation_language=en-US;,citation_journal_title=Medical Teacher;">
<meta name="citation_reference" content="citation_title=Diagnosis and management of clinical reasoning difficulties: Part II. Clinical reasoning difficulties: Management and remediation strategies;,citation_abstract=Part II of this AMEE Guide provides a detailed overview of the main difficulties in clinical reasoning, including the cues to look out for in clinical supervision, the root causes of each difficulty and targeted remediation strategies. Specific challenges and issues related to the management of clinical reasoning difficulties will also be discussed.;,citation_author=Marie-Claude Audétat;,citation_author=Suzanne Laurin;,citation_author=Valérie Dory;,citation_author=Bernard Charlin;,citation_author=Mathieu R. Nendaz;,citation_publication_date=2017-08;,citation_cover_date=2017-08;,citation_year=2017;,citation_issue=8;,citation_doi=10.1080/0142159X.2017.1331034;,citation_issn=0142-159X, 1466-187X;,citation_volume=39;,citation_language=en-US;,citation_journal_title=Medical Teacher;">
<meta name="citation_reference" content="citation_title=Diagnosis and management of clinical reasoning difficulties: Part I. Clinical reasoning supervision and educational diagnosis;,citation_abstract=There are many obstacles to the timely identification of clinical reasoning difficulties in health professions education. This guide aims to provide readers with a framework for supervising clinical reasoning and identifying the potential difficulties as they may occur at each step of the reasoning process.;,citation_author=Marie-Claude Audétat;,citation_author=Suzanne Laurin;,citation_author=Valérie Dory;,citation_author=Bernard Charlin;,citation_author=Mathieu R. Nendaz;,citation_publication_date=2017-08;,citation_cover_date=2017-08;,citation_year=2017;,citation_issue=8;,citation_doi=10.1080/0142159X.2017.1331033;,citation_issn=0142-159X, 1466-187X;,citation_volume=39;,citation_language=en-US;,citation_journal_title=Medical Teacher;">
<meta name="citation_reference" content="citation_title=Decompression with or without Fusion in Degenerative Lumbar Spondylolisthesis;,citation_abstract=BACKGROUND In patients with lumbar spinal stenosis and degenerative spondylolisthesis, it is uncertain whether decompression surgery alone is noninferior to decompression with instrumented fusion. METHODS We conducted an open-label, multicenter, noninferiority trial involving patients with symptomatic lumbar stenosis that had not responded to conservative management and who had single-level spondylolisthesis of 3 mm or more. Patients were randomly assigned in a 1:1 ratio to undergo decompression surgery (decompressionalone group) or decompression surgery with instrumented fusion (fusion group). The primary outcome was a reduction of at least 30% in the score on the Oswestry Disability Index (ODI; range, 0 to 100, with higher scores indicating more impairment) during the 2 years after surgery, with a noninferiority margin of -15 percentage points. Secondary outcomes included the mean change in the ODI score as well as scores on the Zurich Claudication Questionnaire, leg and back pain, the duration of surgery and length of hospital stay, and reoperation within 2 years. RESULTS The mean age of patients was approximately 66 years. Approximately 75% of the patients had leg pain for more than a year, and more than 80% had back pain for more than a year. The mean change from baseline to 2 years in the ODI score was -20.6 in the decompression-alone group and -21.3 in the fusion group (mean difference, 0.7; 95% confidence interval [CI], -2.8 to 4.3). In the modified intentionto-treat analysis, 95 of 133 patients (71.4%) in the decompression-alone group and 94 of 129 patients (72.9%) in the fusion group had a reduction of at least 30% in the ODI score (difference, -1.4 percentage points; 95% CI, -12.2 to 9.4), showing the noninferiority of decompression alone. In the per-protocol analysis, 80 of 106 patients (75.5%) and 83 of 110 patients (75.5%), respectively, had a reduction of at least 30% in the ODI score (difference, 0.0 percentage points; 95% CI, -11.4 to 11.4), showing noninferiority. The results for the secondary outcomes were generally in the same direction as those for the primary outcome. Successful fusion was achieved with certainty in 86 of 100 patients (86.0%) who had imaging available at 2 years. Reoperation was performed in 15 of 120 patients (12.5%) in the decompression-alone group and in 11 of 121 patients (9.1%) in the fusion group. CONCLUSIONS In this trial involving patients who underwent surgery for degenerative lumbar spondylolisthesis, most of whom had symptoms for more than a year, decompression alone was noninferior to decompression with instrumented fusion over a period of 2 years. Reoperation occurred somewhat more often in the decompressionalone group than in the fusion group. (NORDSTEN-DS ClinicalTrials.gov number, NCT02051374.);,citation_author=Ivar M. Austevoll;,citation_author=Erland Hermansen;,citation_author=Morten W. Fagerland;,citation_author=Kjersti Storheim;,citation_author=Jens I. Brox;,citation_author=Tore Solberg;,citation_author=Frode Rekeland;,citation_author=Eric Franssen;,citation_author=Clemens Weber;,citation_author=Helena Brisby;,citation_author=Oliver Grundnes;,citation_author=Knut R. H. Algaard;,citation_author=Tordis Böker;,citation_author=Hasan Banitalebi;,citation_author=Kari Indrekvam;,citation_author=Christian Hellum;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_issue=6;,citation_doi=10.1056/NEJMoa2100990;,citation_issn=0028-4793, 1533-4406;,citation_volume=385;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Applying Propensity Score Methods in Clinical Research in Neurology;,citation_abstract=Propensity score–based analysis is increasingly being used in observational studies to estimate the effects of treatments, interventions, and exposures. We introduce the concept of the propensity score and how it can be used in observational research. We describe 4 different ways of using the propensity score: matching on the propensity score, inverse probability of treatment weighting using the propensity score, stratification on the propensity score, and covariate adjustment on the propensity score (with a focus on the first 2). We provide recommendations for the use and reporting of propensity score methods for the conduct of observational studies in neurologic research.;,citation_author=Peter C. Austin;,citation_author=Amy Ying Xin Yu;,citation_author=Manav V. Vyas;,citation_author=Moira K. Kapral;,citation_publication_date=2021-11;,citation_cover_date=2021-11;,citation_year=2021;,citation_issue=18;,citation_doi=10.1212/WNL.0000000000012777;,citation_issn=0028-3878, 1526-632X;,citation_volume=97;,citation_language=en-US;,citation_journal_title=Neurology;">
<meta name="citation_reference" content="citation_title=The history of 0.9% saline;,citation_abstract=Background &amp;amp;amp; aims We aimed to trace the historical origins of 0.9% saline, how it came to be used so commonly today, and to consider whether its continued use can be justified. Methods We searched the Medline, Science Citation Index, ScienceDirect and Google™ databases using the key words saline, physiological, salt solution, sodium chloride, 0.9%, intravenous, injection, fluid, cholera, resuscitation, parenteral, history, historical and origins. Results The use of 0.9% saline is believed to have originated during the cholera pandemic that swept across Europe in 1831. However, an examination of the composition of the fluids used by the pioneering physicians of that era reveals solutions that bear no resemblance to 0.9% or so-called “normal” saline which appears to have very little scientific or historical basis for its routine use, except for Hamburger’s in vitro studies of red cell lysis. Conclusions The currently used 0.9% saline solution is without convincing historical basis. Given that the composition of 0.9% sodium chloride is dissimilar to most solutions used in the past, and is in no way “normal” or “physiological”, our current practice may be based on historical fallacy and misconception.;,citation_author=Sherif Awad;,citation_author=Simon P. Allison;,citation_author=Dileep N. Lobo;,citation_publication_date=2008-04;,citation_cover_date=2008-04;,citation_year=2008;,citation_issue=2;,citation_doi=10.1016/j.clnu.2008.01.008;,citation_issn=0261-5614;,citation_volume=27;,citation_language=en-US;,citation_journal_title=Clinical Nutrition;">
<meta name="citation_reference" content="citation_title=The Utility of Quantitative EEG in Detecting Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage;,citation_abstract=Summary: In this review, we discuss the utility of quantitative EEG parameters for the detection of delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage in the context of the complex pathophysiology of DCI and the limitations of current diagnostic methods. Because of the multifactorial pathophysiology of DCI, methodologies solely assessing blood vessel narrowing (vasospasm) are insufficient to detect all DCI. Quantitative EEG has facilitated the exploration of EEG as a diagnostic modality of DCI. Multiple quantitative EEG parameters such as alpha power, relative alpha variability, and alpha/delta ratio show reliable detection of DCI in multiple studies. Recent studies on epileptiform abnormalities suggest that their potential for the detection of DCI. Quantitative EEG is a promising, continuous, noninvasive, monitoring modality of DCI implementable in daily practice. Future work should validate these parameters in larger populations, facilitated by the development of automated detection algorithms and multimodal data integration.;,citation_author=Hae Young Baang;,citation_author=Hsin Yi Chen;,citation_author=Alison L. Herman;,citation_author=Emily J. Gilmore;,citation_author=Lawrence J. Hirsch;,citation_author=Kevin N. Sheth;,citation_author=Nils H. Petersen;,citation_author=Sahar F. Zafar;,citation_author=Eric S. Rosenthal;,citation_author=M. Brandon Westover;,citation_author=Jennifer A. Kim;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_doi=10.1097/WNP.0000000000000754;,citation_issn=0736-0258;,citation_volume=Publish Ahead of Print;,citation_language=en-US;,citation_journal_title=Journal of Clinical Neurophysiology;">
<meta name="citation_reference" content="citation_title=Approach to the Management of Sodium Disorders in the Neuro Critical Care Unit;,citation_abstract=To present an overview of the current diagnostic and therapeutic approaches for patients with hyponatremia and hypernatremia in the neurocritical care unit (NCCU).;,citation_author=Murad Baba;,citation_author=Diana Alsbrook;,citation_author=Stacey Williamson;,citation_author=Sandeep Soman;,citation_author=Ahmad Riad Ramadan;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_doi=10.1007/s11940-022-00723-6;,citation_issn=1534-3138;,citation_language=en-US;,citation_journal_title=Current Treatment Options in Neurology;">
<meta name="citation_reference" content="citation_title=Intracranial Pressure Monitoring Practice, Treatment, and Effect on Outcome in Aneurysmal Subarachnoid Hemorrhage;,citation_abstract=Intracranial pressure (ICP) monitoring and its management in aneurysmal subarachnoid hemorrhage (aSAH) is variable worldwide. The present study aimed to explore the practice of ICP monitoring, its variability across countries, and the association with 6-month outcomes in aSAH.;,citation_author=Marta Baggiani;,citation_author=Francesca Graziano;,citation_author=Paola Rebora;,citation_author=Chiara Robba;,citation_author=Angelo Guglielmi;,citation_author=Stefania Galimberti;,citation_author=Carlo Giussani;,citation_author=Jose I. Suarez;,citation_author=Raimund Helbok;,citation_author=Giuseppe Citerio;,citation_publication_date=2022-12;,citation_cover_date=2022-12;,citation_year=2022;,citation_doi=10.1007/s12028-022-01651-8;,citation_issn=1556-0961;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=PATCH trial: Explanatory analyses;,citation_abstract=Many patients worldwide receive platelet components (PCs) through the transfusion of diverse types of blood components. PC transfusions are essential for the treatment of central thrombocytopenia of diverse causes, and such treatment is beneficial in patients at risk of severe bleeding. PC transfusions account for almost 10% of all the blood components supplied by blood services, but they are associated with about 3.25 times as many severe reactions (attributable to transfusion) than red blood cell transfusions after stringent in-process leukoreduction to less than 106 residual cells per blood component. PCs are not homogeneous, due to the considerable differences between donors. Furthermore, the modes of PC collection and preparation, the safety precautions taken to limit either the most common (allergic-type reactions and febrile non-hemolytic reactions) or the most severe (bacterial contamination, pulmonary lesions) adverse reactions, and storage and conservation methods can all result in so-called PC “storage lesions”. Some storage lesions affect PC quality, with implications for patient outcome. Good transfusion practices should result in higher levels of platelet recovery and efficacy, and lower complication rates. These practices include a matching of tissue ABH antigens whenever possible, and of platelet HLA (and, to a lesser extent, HPA) antigens in immunization situations. This review provides an overview of all the available information relating to platelet transfusion, from donor and donation to bedside transfusion, and considers the impact of the measures applied to increase transfusion efficacy while improving safety and preventing transfusion inefficacy and refractoriness. It also considers alternatives to platelet component (PC) transfusion. Acute platelet transfusion after intracerebral hemorrhage (ICH) given in efforts to reverse antiplatelet medication effects and prevent ongoing bleeding does not appear to improve outcome and may be associated with harm. Although the underlying mechanisms are unclear, the influence of ABO-incompatible platelet transfusions on ICH outcomes has not been investigated. We hypothesized that patients with ICH who receive ABO-incompatible platelet transfusions would have worse platelet recovery (using absolute count increment [ACI]) and neurological outcomes (mortality and poor modified Rankin Scale [mRS 4-6]) than those receiving ABO-compatible transfusions. In a single-center cohort of consecutively admitted patients with ICH, we identified 125 patients receiving acute platelet transfusions, of whom 47 (38%) received an ABO-incompatible transfusion. Using quantile regression, we identified an association of ABO-incompatible platelet transfusion with lower platelet recovery (ACI, 2  103cells per \muL vs 15  103cells per \muL; adjusted coefficient \beta, -19; 95% confidence interval [CI], -35.55 to -4.44; P = .01). ABO-incompatible platelet transfusion was also associated with increased odds of mortality (adjusted odds ratio [OR], 2.59; 95% CI, 1.00-6.73; P = .05) and poor mRS (adjusted OR, 3.61; 95% CI, 0.97-13.42; P = .06); however, these estimates were imprecise. Together, these findings suggest the importance of ABO compatibility for platelet transfusions for ICH, but further investigation into the mechanism(s) underlying these observations is required.;,citation_author=M. Irem Baharoglu;,citation_author=Rustam Al-Shahi Salman;,citation_author=Charlotte Cordonnier;,citation_author=Maria M. Koopman;,citation_author=Lynn Manson;,citation_author=Sophie Susen;,citation_author=Henk A. Marquering;,citation_author=Ludo F. Beenen;,citation_author=Charles B. Majoie;,citation_author=Yvo B. Roos;,citation_publication_date=2020-04;,citation_cover_date=2020-04;,citation_year=2020;,citation_issue=16;,citation_doi=10.1182/blood.2019003298;,citation_issn=0006-4971;,citation_volume=135;,citation_language=en-US;,citation_journal_title=Blood;">
<meta name="citation_reference" content="citation_title=Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): A randomised, open-label, phase 3 trial;,citation_abstract=Background Platelet transfusion after acute spontaneous primary intracerebral haemorrhage in people taking antiplatelet therapy might reduce death or dependence by reducing the extent of the haemorrhage. We aimed to investigate whether platelet transfusion with standard care, compared with standard care alone, reduced death or dependence after intracerebral haemorrhage associated with antiplatelet therapy use.;,citation_author=M Irem Baharoglu;,citation_author=Charlotte Cordonnier;,citation_author=Rustam Al-Shahi Salman;,citation_author=Koen Gans;,citation_author=Maria M Koopman;,citation_author=Anneke Brand;,citation_author=Charles B Majoie;,citation_author=Ludo F Beenen;,citation_author=Henk A Marquering;,citation_author=Marinus Vermeulen;,citation_author=Paul J Nederkoorn;,citation_author=Rob J Haan;,citation_author=Yvo B Roos;,citation_publication_date=2016-06;,citation_cover_date=2016-06;,citation_year=2016;,citation_issue=10038;,citation_doi=10.1016/S0140-6736(16)30392-0;,citation_issn=01406736;,citation_volume=387;,citation_language=en-US;,citation_journal_title=The Lancet;">
<meta name="citation_reference" content="citation_title=Do Nonprofit Hospitals Deserve Their Tax Exemption?;,citation_author=Ge Bai;,citation_author=Sunjay Letchuman;,citation_author=David A. Hyman;,citation_publication_date=2023-07;,citation_cover_date=2023-07;,citation_year=2023;,citation_issue=0;,citation_doi=10.1056/NEJMp2303245;,citation_issn=0028-4793;,citation_volume=0;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Stewardship of global collective behavior;,citation_abstract=Collective behavior provides a framework for understanding how the actions and properties of groups emerge from the way individuals generate and share information. In humans, information flows were initially shaped by natural selection yet are increasingly structured by emerging communication technologies. Our larger, more complex social networks now transfer high-fidelity information over vast distances at low cost. The digital age and the rise of social media have accelerated changes to our social systems, with poorly understood functional consequences. This gap in our knowledge represents a principal challenge to scientific progress, democracy, and actions to address global crises. We argue that the study of collective behavior must rise to a “crisis discipline” just as medicine, conservation, and climate science have, with a focus on providing actionable insight to policymakers and regulators for the stewardship of social systems.;,citation_author=Joseph B. Bak-Coleman;,citation_author=Mark Alfano;,citation_author=Wolfram Barfuss;,citation_author=Carl T. Bergstrom;,citation_author=Miguel A. Centeno;,citation_author=Iain D. Couzin;,citation_author=Jonathan F. Donges;,citation_author=Mirta Galesic;,citation_author=Andrew S. Gersick;,citation_author=Jennifer Jacquet;,citation_author=Albert B. Kao;,citation_author=Rachel E. Moran;,citation_author=Pawel Romanczuk;,citation_author=Daniel I. Rubenstein;,citation_author=Kaia J. Tombak;,citation_author=Jay J. Van Bavel;,citation_author=Elke U. Weber;,citation_publication_date=2021-07;,citation_cover_date=2021-07;,citation_year=2021;,citation_issue=27;,citation_doi=10.1073/pnas.2025764118;,citation_issn=0027-8424, 1091-6490;,citation_volume=118;,citation_language=en-US;,citation_journal_title=Proceedings of the National Academy of Sciences;">
<meta name="citation_reference" content="citation_title=Re-envisioning paradigms of education: Towards awareness, alignment, and pluralism;,citation_abstract=In this article we introduce a synthesis of education “paradigms,” adapted from a multi-disciplinary body of literature and tailored to health professions education (HPE). Each paradigm involves a particular perspective on the purpose of education, the nature of knowledge, what knowledge is valued and included in the curriculum, what it means to learn and how learning is assessed, and the roles of teachers and learners in the learning process. We aim to foster awareness of how these different paradigms look in practice and to illustrate the importance of alignment between teaching, learning and assessment practices with paradigmatic values and assumptions. Finally, we advocate for a pluralistic approach that purposefully and meaningfully integrates paradigms of education, enhancing our ability to drive quality in HPE.;,citation_author=Lindsay R. Baker;,citation_author=Shanon Phelan;,citation_author=Nicole N. Woods;,citation_author=Victoria A. Boyd;,citation_author=Paula Rowland;,citation_author=Stella L. Ng;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_issue=3;,citation_doi=10.1007/s10459-021-10036-z;,citation_issn=1382-4996, 1573-1677;,citation_volume=26;,citation_language=en-US;,citation_journal_title=Advances in Health Sciences Education;">
<meta name="citation_reference" content="citation_title=Therapeutic hypothermia for intracerebral hemorrhage: Systematic review and meta-analysis of the experimental and clinical literature;,citation_abstract=Background Intracerebral hemorrhage remains the deadliest form of stroke worldwide, inducing neuronal death through a wide variety of pathways. Therapeutic hypothermia is a robust and well-studied neuroprotectant widely used across a variety of specialties. Aims This review summarizes results from preclinical and clinical studies to highlight the overall effectiveness of therapeutic hypothermia to improve long-term intracerebral hemorrhage outcomes while also elucidating optimal protocol regimens to maximize therapeutic effect. Summary of review A systematic review was conducted across three databases to identify trials investigating the use of therapeutic hypothermia to treat intracerebral hemorrhage. A random-effects meta-analysis was conducted on preclinical studies, looking at neurobehavioral outcomes, blood brain barrier breakdown, cerebral edema, hematoma volume, and tissue loss. Several mixed-methods meta-regression models were also performed to adjust for variance and variations in hypothermia induction procedures. Twwenty-one preclinical studies and five human studies were identified. The meta-analysis of preclinical studies demonstrated a significant benefit in behavioral scores (ES = -0.43, p = 0.02), cerebral edema (ES = 1.32, p = 0.0001), and blood brain barrier (ES = 2.73, p \leq 0.00001). Therapeutic hypothermia was not found to significantly affect hematoma expansion (ES = -0.24, p = 0.12) or tissue loss (ES = 0.06, p = 0.68). Clinical study outcome reporting was heterogeneous; however, there was recurring evidence of therapeutic hypothermia-induced edema reduction. Conclusions The combined preclinical evidence demonstrates that therapeutic hypothermia reduced multiple cell death mechanisms initiated by intracerebral hemorrhage; yet, there is no definitive evidence in clinical studies. The cooling strategies employed in both preclinical and clinical studies were highly diverse, and focused refinement of cooling protocols should be developed in future preclinical studies. The current data for therapeutic hypothermia in intracerebral hemorrhage remains questionable despite the highly promising indications in preclinical studies. Definitive randomized controlled studies are still required to answer this therapeutic question.;,citation_author=Turner S Baker;,citation_author=John Durbin;,citation_author=Zachary Troiani;,citation_author=Luis Ascanio-Cortez;,citation_author=Rebecca Baron;,citation_author=Anthony Costa;,citation_author=Fred Rincon;,citation_author=Frederick Colbourne;,citation_author=Patrick Lyden;,citation_author=Stephan A Mayer;,citation_author=Christopher P Kellner;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_doi=10.1177/17474930211044870;,citation_issn=1747-4930, 1747-4949;,citation_language=en-US;,citation_journal_title=International Journal of Stroke;">
<meta name="citation_reference" content="citation_title=Current practice and evolving concepts in septic shock resuscitation;,citation_abstract=Clinical and pathophysiological understanding of septic shock has progressed exponentially in the previous decades, translating into a steady decrease in septic shock-related morbidity and mortality. Even though large randomized, controlled trials have addressed fundamental aspects of septic shock resuscitation, many questions still exist. In this review, we will describe the current standards of septic shock resuscitation, but the emphasis will be placed on evolv-ing concepts in different domains such as clinical resuscitation targets, adequate use of fluids and vasoactive drugs, refractory shock, and the use of extracorporeal therapies. Multiple research opportunities remain open, and collabora-tive endeavors should be performed to fill in these gaps.;,citation_author=Jan Bakker;,citation_author=Eduardo Kattan;,citation_author=Djillali Annane;,citation_author=Ricardo Castro;,citation_author=Maurizio Cecconi;,citation_author=Daniel De Backer;,citation_author=Arnaldo Dubin;,citation_author=Laura Evans;,citation_author=Michelle Ng Gong;,citation_author=Olfa Hamzaoui;,citation_author=Can Ince;,citation_author=Bruno Levy;,citation_author=Xavier Monnet;,citation_author=Gustavo A. Ospina Tascón;,citation_author=Marlies Ostermann;,citation_author=Michael R. Pinsky;,citation_author=James A. Russell;,citation_author=Bernd Saugel;,citation_author=Thomas W. L. Scheeren;,citation_author=Jean-Louis Teboul;,citation_author=Antoine Vieillard Baron;,citation_author=Jean-Louis Vincent;,citation_author=Fernando G. Zampieri;,citation_author=Glenn Hernandez;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_issue=2;,citation_doi=10.1007/s00134-021-06595-9;,citation_issn=0342-4642, 1432-1238;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Minimally Invasive Surgery With Thrombolysis for Intracerebral Hemorrhage Evacuation: Bayesian Re-analysis of a Randomized Controlled Trial;,citation_abstract=Background and Objectives: Bayesian analysis of randomized controlled trials (RCTs) can extend the value of trial data beyond interpretations based on conventional p-value-based binary cutoffs. We conducted an exploratory post-hoc Bayesian re-analysis of the minimally invasive surgery with thrombolysis for intracerebral hemorrhage (ICH) evacuation (MISTIE-3) trial and derived probabilities of potential intervention effect on functional and survival outcomes. Methods: MISTIE-3 was a multicenter phase-3 RCT designed to evaluate the efficacy and safety of the MISTIE intervention. 506 adults (\geq18 years) with spontaneous, non-traumatic, supratentorial ICH of \geq30mL were randomized to receive either the MISTIE intervention (n=255) or standard medical care (n=251). We provide Bayesian-derived estimates of the effect of the MISTIE intervention on achieving a good 365-day Modified Rankin Scale score (mRS score:0-3) as relative risk (RR) and absolute risk difference (ARD), and the probabilities that these treatment effects are greater than pre-specified thresholds. We used two sets of prior distributions: 1) reference priors, including minimally informative, enthusiastic, and skeptical priors; and 2) Data-derived prior distribution, using a hierarchical random-effects model. We additionally evaluated the potential effects of the MISTIE intervention on 180-day and 30-day mRS and 365, 180, and 30-day mortality using data-derived priors. Results: The Bayesian-derived probability that MISTIE intervention has any beneficial effect (RR&amp;amp;amp;gt;1) on achieving a good 365-day mRS score was 70% using minimally informative prior, 87% with enthusiastic prior; 68% with skeptical prior; and 73% with data-derived prior. However, these probabilities were \leq 55% for RR&amp;gt;1.10, and 0% for RR>1.52 across a range of priors. The probabilities of achieving RR>1 for 180 and 30-day mRS scores are 65% and 80% respectively. Furthermore, the probabilities of achieving RR&amp;lt;1 for 365, 180, and 30-day mortality are 93%, 98%, and 99%, respectively. Conclusions: Our exploratory analyses indicate that across a range of priors, the Bayesian-derived probability of MISTIE intervention having any beneficial effect on 365-day mRS for ICH patients is between 68% to 87%. These analyses do not change the frequentist-based interpretation of the trial. However, unlike the frequentist p-values, which indirectly evaluate treatment effects and only provide an arbitrary binary cut-off (such as 0.05), the Bayesian framework directly estimates probabilities of potential treatment effects. Trial Registration: https://clinicaltrials.gov/ct2/show/NCT01827046 Classification of Evidence This study provides Class II evidence that minimally invasive surgery (MIS) + rt-PA does not significantly improve functional outcome in patients with intracerebral hemorrhage. However, The study lacks the precision to exclude a potential benefit of MIS + rt-PA.;,citation_author=Abdulaziz T. Bako;,citation_author=Thomas Potter;,citation_author=Alan P. Pan;,citation_author=Jonika Tannous;,citation_author=Gavin Britz;,citation_author=Wendy C. Ziai;,citation_author=Issam Awad;,citation_author=Daniel Hanley;,citation_author=Farhaan S. Vahidy;,citation_publication_date=2023-09;,citation_cover_date=2023-09;,citation_year=2023;,citation_doi=10.1212/WNL.0000000000207735;,citation_issn=0028-3878, 1526-632X;,citation_pmid=37684058;,citation_language=en-US;,citation_journal_title=Neurology;,citation_publisher=Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology;">
<meta name="citation_reference" content="citation_title=Scientific Autonomy, Public Accountability, and the Rise of “Peer Review” in the Cold War United States;,citation_abstract=This essay traces the history of refereeing at specialist scientific journals and at funding bodies and shows that it was only in the late twentieth century that peer review came to be seen as a process central to scientific practice. Throughout the nineteenth century and into much of the twentieth, external referee reports were considered an optional part of journal editing or grant making. The idea that refereeing is a requirement for scientific legitimacy seems to have arisen first in the Cold War United States. In the 1970s, in the wake of a series of attacks on scientific funding, American scientists faced a dilemma: there was increasing pressure for science to be accountable to those who funded it, but scientists wanted to ensure their continuing influence over funding decisions. Scientists and their supporters cast expert refereeing—or “peer review,” as it was increasingly called—as the crucial process that ensured the credibility of science as a whole. Taking funding decisions out of expert hands, they argued, would be a corruption of science itself. This public elevation of peer review both reinforced and spread the belief that only peer-reviewed science was scientifically legitimate.;,citation_author=Melinda Baldwin;,citation_publication_date=2018-09;,citation_cover_date=2018-09;,citation_year=2018;,citation_issue=3;,citation_doi=10.1086/700070;,citation_issn=0021-1753, 1545-6994;,citation_volume=109;,citation_language=en-US;,citation_journal_title=Isis;">
<meta name="citation_reference" content="citation_title=Propafenone versus amiodarone for supraventricular arrhythmias in septic shock: A randomised controlled trial;,citation_abstract=Acute onset supraventricular arrhythmias can contribute to haemodynamic compromise in septic shock. Both amiodarone and propafenone are available interventions, but their clinical effects have not yet been directly compared.;,citation_author=Martin Balik;,citation_author=Michal Maly;,citation_author=Tomas Brozek;,citation_author=Jan Rulisek;,citation_author=Michal Porizka;,citation_author=Robert Sachl;,citation_author=Michal Otahal;,citation_author=Petr Brestovansky;,citation_author=Eva Svobodova;,citation_author=Marek Flaksa;,citation_author=Zdenek Stach;,citation_author=Jan Horejsek;,citation_author=Lukas Volny;,citation_author=Ivana Jurisinova;,citation_author=Adam Novotny;,citation_author=Pavel Trachta;,citation_author=Jan Kunstyr;,citation_author=Petr Kopecky;,citation_author=Tomas Tencer;,citation_author=Jaroslav Pazout;,citation_author=Jan Belohlavek;,citation_author=Frantisek Duska;,citation_author=Adela Krajcova;,citation_author=Petr Waldauf;,citation_publication_date=2023-09;,citation_cover_date=2023-09;,citation_year=2023;,citation_doi=10.1007/s00134-023-07208-3;,citation_issn=1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Citation classics in critical care medicine;,citation_author=Anja Baltussen;,citation_author=Christoph H. Kindler;,citation_publication_date=2004-05;,citation_cover_date=2004-05;,citation_year=2004;,citation_issue=5;,citation_doi=10.1007/s00134-004-2195-7;,citation_issn=0342-4642, 1432-1238;,citation_volume=30;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Introduction to Spreading Depolarizations: Special Edition of Neurocritical Care;,citation_author=Ramani Balu;,citation_author=Brandon Foreman;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_doi=10.1007/s12028-021-01363-5;,citation_issn=1541-6933, 1556-0961;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Neurologic Improvement in Acute Cerebral Ischemia: Frequency, Magnitude, Predictors and Clinical Outcomes;,citation_abstract=BACKGROUND AND PURPOSE: Investigations of rapid neurological improvement (RNI) in patients with acute cerebral ischemia (ACI) have focused upon RNI occurring after hospital arrival. However, with stroke routing decisions and interventions increasingly migrating to the prehospital setting, there is a need to delineate the frequency, magnitude, predictors, and clinical outcomes of ACI patients with ultra-early RNI (U-RNI) in the prehospital and early post-arrival period. METHODS: We analyzed prospectively collected data of the prehospital Field Administration of Stroke Therapy-Magnesium (FAST-MAG) randomized clinical trial. Any U-RNI was defined as improvement by 2 or more points on the Los Angeles Motor Scale (LAMS) score between the prehospital and early post-Emergency Department (ED) arrival exams and classified as moderate (2-3 point) or dramatic (4-5 point) improvement. Outcomes measures included excellent recovery [modified Rankin Scale (mRS) score 0-1] and death by 90 days. RESULTS: Among the 1,245 ACI patients, mean age was 70.9 years (standard deviation 13.2); 45% were women; median prehospital-LAMS was 4 [interquartile range (IQR) 3-5]; median last known well to ED-LAMS time was 59 minutes (IQR 46-80) and median prehospital-LAMS to ED-LAMS time was 33 minutes (IQR 28-39). Overall, any U-RNI occurred in 31%, moderate U-RNI in 23%, and dramatic U-RNI in 8%. Any U-RNI was associated with improved outcomes, including excellent recovery (mRS 0-1) at 90 days 65.1% (246/378) vs 35.4% (302/852), p&amp;amp;amp;lt;0.0001; decreased mortality by 90 days 3.7% (14/378) vs 16.4% (140/852), p&amp;lt;0.0001; decreased symptomatic intracranial hemorrhage 1.6% (6/384) vs 4.6% (40/861), p=0.0112 ; increased likelihood of being discharged home 56.8% (218/384) vs. 30.2% (260/861), p <0.0001. DISCUSSION: U-RNI occurs in nearly 1 in 3 ambulance-transported patients with ACI and is associated with excellent recovery and decreased mortality at 90 days. Accounting for U-RNI may be useful for routing decisions and future prehospital interventions.;,citation_author=Clotilde Balucani;,citation_author=Steven R. Levine;,citation_author=Nerses Sanossian;,citation_author=Sidney Starkman;,citation_author=David Liebeskind;,citation_author=Jeffrey A. Gornbein;,citation_author=Kristina Shkirkova;,citation_author=Samuel Stratton;,citation_author=Marc Eckstein;,citation_author=Scott Hamilton;,citation_author=Robin Conwit;,citation_author=Latisha K. Sharma;,citation_author=Jeffrey L. Saver;,citation_publication_date=2022-12;,citation_cover_date=2022-12;,citation_year=2022;,citation_doi=10.1212/WNL.0000000000201656;,citation_issn=0028-3878, 1526-632X;,citation_language=en-US;,citation_journal_title=Neurology;,citation_publisher=Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology;">
<meta name="citation_reference" content="citation_title=From bad to worse: Collider stratification amplifies confounding bias in the “obesity paradox”;,citation_abstract=Smoking is often identified as a confounder of the obesity–mortality relationship. Selection bias can amplify the magnitude of an existing confounding bias. The objective of the present report is to demonstrate how confounding bias due to cigarette smoking is increased in the presence of collider stratification bias using an empirical example and directed acyclic graphs. The empirical example uses data from the Atherosclerosis Risk in Communities (ARIC) study, a prospective cohort study of 15,792 men and women in the United States. Poisson regression models were used to examine the confounding effect of smoking. In the total ARIC study population, smoking produced a confounding bias of \3 percentage points. This result was obtained by comparing the incidence rate ratio (IRR) for obesity from a model adjusted for smoking was 1.07 (95 % CI 1.00, 1.15) with one that did not adjust for smoking was 1.10 (95 % CI 1.03, 1.18). However, among smokers with CVD, the obesity IRR was 0.89 (95 % CI 0.81, 0.99), while among non-smokers with CVD the obesity IRR was 1.20 (95 % CI 1.03, 1.41). The empirical and graphical explanations presented suggest that the magnitude of the confounding bias induced by smoking is greater in the presence of collider stratification bias.;,citation_author=Hailey R. Banack;,citation_author=Jay S. Kaufman;,citation_publication_date=2015-10;,citation_cover_date=2015-10;,citation_year=2015;,citation_issue=10;,citation_doi=10.1007/s10654-015-0069-7;,citation_issn=0393-2990, 1573-7284;,citation_volume=30;,citation_language=en-US;,citation_journal_title=European Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=The “Obesity Paradox” Explained:;,citation_author=Hailey R. Banack;,citation_author=Jay S. Kaufman;,citation_publication_date=2013-05;,citation_cover_date=2013-05;,citation_year=2013;,citation_issue=3;,citation_doi=10.1097/EDE.0b013e31828c776c;,citation_issn=1044-3983;,citation_volume=24;,citation_language=en-US;,citation_journal_title=Epidemiology;">
<meta name="citation_reference" content="citation_title=The “obesity paradox” may not be a paradox at all;,citation_author=H R Banack;,citation_author=A Stokes;,citation_publication_date=2017-08;,citation_cover_date=2017-08;,citation_year=2017;,citation_issue=8;,citation_doi=10.1038/ijo.2017.99;,citation_issn=0307-0565, 1476-5497;,citation_volume=41;,citation_language=en-US;,citation_journal_title=International Journal of Obesity;">
<meta name="citation_reference" content="citation_title=Extracorporeal membrane oxygenation support in COVID-19: An international cohort study of the Extracorporeal Life Support Organization registry;,citation_abstract=Background Multiple major health organisations recommend the use of extracorporeal membrane oxygenation (ECMO) support for COVID-19-related acute hypoxaemic respiratory failure. However, initial reports of ECMO use in patients with COVID-19 described very high mortality and there have been no large, international cohort studies of ECMO for COVID-19 reported to date.;,citation_author=Ryan P Barbaro;,citation_author=Graeme MacLaren;,citation_author=Philip S Boonstra;,citation_author=Theodore J Iwashyna;,citation_author=Arthur S Slutsky;,citation_author=Eddy Fan;,citation_author=Robert H Bartlett;,citation_author=Joseph E Tonna;,citation_author=Robert Hyslop;,citation_author=Jeffrey J Fanning;,citation_author=Peter T Rycus;,citation_author=Steve J Hyer;,citation_author=Marc M Anders;,citation_author=Cara L Agerstrand;,citation_author=Katarzyna Hryniewicz;,citation_author=Rodrigo Diaz;,citation_author=Roberto Lorusso;,citation_author=Alain Combes;,citation_author=Daniel Brodie;,citation_author=Peta Alexander;,citation_author=Nicholas Barrett;,citation_author=Jan Bělohlávek;,citation_author=Dale Fisher;,citation_author=John Fraser;,citation_author=Ali Ait Hssain;,citation_author=Jae Sung Jung;,citation_author=Michael McMullan;,citation_author=Yatin Mehta;,citation_author=Mark T. Ogino;,citation_author=Matthew L. Paden;,citation_author=Kiran Shekar;,citation_author=Christine Stead;,citation_author=Yasir Abu-Omar;,citation_author=Vanni Agnoletti;,citation_author=Anzila Akbar;,citation_author=Huda Alfoudri;,citation_author=Carlos Alviar;,citation_author=Vladimir Aronsky;,citation_author=Erin August;,citation_author=Georg Auzinger;,citation_author=Hilda Aveja;,citation_author=Rhonda Bakken;,citation_author=Joan Balcells;,citation_author=Sripal Bangalore;,citation_author=Bernard W. Barnes;,citation_author=Alaiza Bautista;,citation_author=Lorraine L. Bellows;,citation_author=Felipe Beltran;,citation_author=Peyman Benharash;,citation_author=Marco Benni;,citation_author=Jennifer Berg;,citation_author=Pietro Bertini;,citation_author=Pablo Blanco-Schweizer;,citation_author=Melissa Brunsvold;,citation_author=Jenny Budd;,citation_author=Debra Camp;,citation_author=Mark Caridi-Scheible;,citation_author=Edmund Carton;,citation_author=Elena Casanova-Ghosh;,citation_author=Anthony Castleberry;,citation_author=Christopher T. Chipongian;,citation_author=Chang Woo Choi;,citation_author=Alessandro Circelli;,citation_author=Elliott Cohen;,citation_author=Michael Collins;,citation_author=Scott Copus;,citation_author=Jill Coy;,citation_author=Brandon Crist;,citation_author=Leonora Cruz;,citation_author=Mirosław Czuczwar;,citation_author=Mani Daneshmand;,citation_author=Daniel Davis II;,citation_author=Kim De la Cruz;,citation_author=Cyndie Devers;,citation_author=Toni Duculan;,citation_author=Lucian Durham;,citation_author=Subbarao Elapavaluru;,citation_author=Carlos V. Elzo Kraemer;,citation_author=Edmílson Cardoso Filho;,citation_author=Jillian Fitzgerald;,citation_author=Giuseppe Foti;,citation_author=Matthew Fox;,citation_author=David Fritschen;,citation_author=David Fullerton;,citation_author=Elton Gelandt;,citation_author=Stacy Gerle;,citation_author=Marco Giani;,citation_author=Si Guim Goh;,citation_author=Sara Govener;,citation_author=Julie Grone;,citation_author=Miles Guber;,citation_author=Vadim Gudzenko;,citation_author=Daniel Gutteridge;,citation_author=Jennifer Guy;,citation_author=Jonathan Haft;,citation_author=Cameron Hall;,citation_author=Ibrahim Fawzy Hassan;,citation_author=Rubén Herrán;,citation_author=Hitoshi Hirose;,citation_author=Abdulsalam Saif Ibrahim;,citation_author=Don Igielski;,citation_author=Felicia A. Ivascu;,citation_author=Jaume Izquierdo Blasco;,citation_author=Julie Jackson;,citation_author=Harsh Jain;,citation_author=Bhavini Jaiswal;,citation_author=Andrea C. Johnson;,citation_author=Jenniver A. Jurynec;,citation_author=Norma M Kellter;,citation_author=Adam Kohl;,citation_author=Zachary Kon;,citation_author=Markus Kredel;,citation_author=Karen Kriska;,citation_author=Chandra Kunavarapu;,citation_author=Oude Lansink-Hartgring;,citation_author=Jeliene LaRocque;,citation_author=Sharon Beth Larson;,citation_author=Tracie Layne;,citation_author=Stephane Ledot;,citation_author=Napolitan Lena;,citation_author=Jonathan Lillie;,citation_author=Gösta Lotz;,citation_author=Mark Lucas;,citation_author=Lee Ludwigson;,citation_author=Jacinta J. Maas;,citation_author=Joanna Maertens;,citation_author=David Mast;,citation_author=Scott McCardle;,citation_author=Bernard McDonald;,citation_author=Allison McLarty;,citation_author=Chelsea McMahon;,citation_author=Patrick Meybohm;,citation_author=Bart Meyns;,citation_author=Casey Miller;,citation_author=Fernando Moraes Neto;,citation_author=Kelly Morris;,citation_author=Ralf Muellenbach;,citation_author=Meghan Nicholson;,citation_author=Serena O’Brien;,citation_author=Kathryn O’Keefe;,citation_author=Tawnya Ogston;,citation_author=Gary Oldenburg;,citation_author=Fabiana M. Oliveira;,citation_author=Emily Oppel;,citation_author=Diego Pardo;,citation_author=Diego Pardo;,citation_author=Sara J. Parker;,citation_author=Finn M. Pedersen;,citation_author=Crescens Pellecchia;,citation_author=Jose A. S. Pelligrini;,citation_author=Thao T. N. Pham;,citation_author=Ann R. Phillips;,citation_author=Tasneem Pirani;,citation_author=Paweł Piwowarczyk;,citation_author=Robert Plambeck;,citation_author=William Pruett;,citation_author=Brittany Quandt;,citation_author=Kollengode Ramanathan;,citation_author=Alejandro Rey;,citation_author=Christian Reyher;,citation_author=Jordi Riera del Brio;,citation_author=Rachel Roberts;,citation_author=David Roe;,citation_author=Peter P. Roeleveld;,citation_author=Janet Rudy;,citation_author=Luis F. Rueda;,citation_author=Emanuele Russo;,citation_author=Jesús Sánchez Ballesteros;,citation_author=Nancy Satou;,citation_author=Mauricio Guidi Saueressig;,citation_author=Paul C. Saunders;,citation_author=Margaret Schlotterbeck;,citation_author=Patricia Schwarz;,citation_author=Nicole Scriven;,citation_author=Alexis Serra;,citation_author=Mohammad Shamsah;,citation_author=Lucy Sim;,citation_author=Alexandra Smart;,citation_author=Adam Smith;,citation_author=Deane Smith;,citation_author=Maggie Smith;,citation_author=Neel Sodha;,citation_author=Michael Sonntagbauer;,citation_author=Marc Sorenson;,citation_author=Eric B Stallkamp;,citation_author=Allison Stewart;,citation_author=Kathy Swartz;,citation_author=Koji Takeda;,citation_author=Shaun Thompson;,citation_author=Bridget Toy;,citation_author=Divina Tuazon;,citation_author=Makoto Uchiyama;,citation_author=Obiora I. Udeozo;,citation_author=Scott Poppel;,citation_author=Corey Ventetuolo;,citation_author=Leen Vercaemst;,citation_author=Nguyen V. Vinh Chau;,citation_author=I-Wen Wang;,citation_author=Carrie Williamson;,citation_author=Brock Wilson;,citation_author=Helen Winkels;,citation_publication_date=2020-10;,citation_cover_date=2020-10;,citation_year=2020;,citation_issue=10257;,citation_doi=10.1016/S0140-6736(20)32008-0;,citation_issn=01406736;,citation_volume=396;,citation_language=en-US;,citation_journal_title=The Lancet;">
<meta name="citation_reference" content="citation_title=Should we titrate mechanical ventilation based on driving pressure?—yes;,citation_abstract=Recent reports revealed that lower respiratory driving pressure is associated with better ARDS patients survival during invasive mechanical ventilation and less pulmonary complications in surgical patients and at risk ICU patients without ARDS, makes the best understanding of this subject primordial for the future application of mechanical ventilatory support.;,citation_author=Carmen Silvia Valente Barbas;,citation_author=Roberta Fittipaldi Palazzo;,citation_publication_date=2018-10;,citation_cover_date=2018-10;,citation_year=2018;,citation_issue=19;,citation_doi=10.21037/atm.2018.06.26;,citation_issn=23055839, 23055847;,citation_volume=6;,citation_language=en-US;,citation_journal_title=Annals of Translational Medicine;">
<meta name="citation_reference" content="citation_title=Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: An observational study;,citation_abstract=Background Many countries are experiencing a resurgence of COVID-19, driven predominantly by the delta (B.1.617.2) variant of SARS-CoV-2. In response, these countries are considering the administration of a third dose of mRNA COVID-19 vaccine as a booster dose to address potential waning immunity over time and reduced effectiveness against the delta variant. We aimed to use the data repositories of Israel’s largest health-care organisation to evaluate the effectiveness of a third dose of the BNT162b2 mRNA vaccine for preventing severe COVID-19 outcomes.;,citation_author=Noam Barda;,citation_author=Noa Dagan;,citation_author=Cyrille Cohen;,citation_author=Miguel A Hernán;,citation_author=Marc Lipsitch;,citation_author=Isaac S Kohane;,citation_author=Ben Y Reis;,citation_author=Ran D Balicer;,citation_publication_date=2021-12;,citation_cover_date=2021-12;,citation_year=2021;,citation_issue=10316;,citation_doi=10.1016/S0140-6736(21)02249-2;,citation_issn=01406736;,citation_volume=398;,citation_language=en-US;,citation_journal_title=The Lancet;">
<meta name="citation_reference" content="citation_title=Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting;,citation_abstract=BACKGROUND Preapproval trials showed that messenger RNA (mRNA)–based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a good safety profile, yet these trials were subject to size and patient-mix limitations. An evaluation of the safety of the BNT162b2 mRNA vaccine with respect to a broad range of potential adverse events is needed. METHODS We used data from the largest health care organization in Israel to evaluate the safety of the BNT162b2 mRNA vaccine. For each potential adverse event, in a population of persons with no previous diagnosis of that event, we individually matched vaccinated persons to unvaccinated persons according to sociodemographic and clinical variables. Risk ratios and risk differences at 42 days after vaccination were derived with the use of the Kaplan–Meier estimator. To place these results in context, we performed a similar analysis involving SARS-CoV-2–infected persons matched to uninfected persons. The same adverse events were studied in the vaccination and SARS-CoV-2 infection analyses. The authors’ affiliations are listed in the Appendix. Address reprint requests to Dr. Balicer at the Clalit Research Insti-tute, Innovation Division, Clalit Health Services, 101 Arlozorov St., Tel Aviv, Isra-el, or at rbalicer@clalit.org.il. Drs. Barda and Dagan and Drs. Reis and Balicer contributed equally to this article. This article was published on August 25, 2021, at NEJM.org. DOI: 10.1056/NEJMoa2110475 Copyright © 2021 Massachusetts Medical Society. RESULTS In the vaccination analysis, the vaccinated and control groups each included a mean of 884,828 persons. Vaccination was most strongly associated with an elevated risk of myocarditis (risk ratio, 3.24; 95% confidence interval [CI], 1.55 to 12.44; risk difference, 2.7 events per 100,000 persons; 95% CI, 1.0 to 4.6), lymphadenopathy (risk ratio, 2.43; 95% CI, 2.05 to 2.78; risk difference, 78.4 events per 100,000 persons; 95% CI, 64.1 to 89.3), appendicitis (risk ratio, 1.40; 95% CI, 1.02 to 2.01; risk difference, 5.0 events per 100,000 persons; 95% CI, 0.3 to 9.9), and herpes zoster infection (risk ratio, 1.43; 95% CI, 1.20 to 1.73; risk difference, 15.8 events per 100,000 persons; 95% CI, 8.2 to 24.2). SARS-CoV-2 infection was associated with a substantially increased risk of myocarditis (risk ratio, 18.28; 95% CI, 3.95 to 25.12; risk difference, 11.0 events per 100,000 persons; 95% CI, 5.6 to 15.8) and of additional serious adverse events, including pericarditis, arrhythmia, deep-vein thrombosis, pulmonary embolism, myocardial infarction, intracranial hemorrhage, and thrombocytopenia. CONCLUSIONS In this study in a nationwide mass vaccination setting, the BNT162b2 vaccine was not associated with an elevated risk of most of the adverse events examined. The vaccine was associated with an excess risk of myocarditis (1 to 5 events per 100,000 persons). The risk of this potentially serious adverse event and of many other serious adverse events was substantially increased after SARS-CoV-2 infection. (Funded by the Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School and Clalit Research Institute.);,citation_author=Noam Barda;,citation_author=Noa Dagan;,citation_author=Yatir Ben-Shlomo;,citation_author=Eldad Kepten;,citation_author=Jacob Waxman;,citation_author=Reut Ohana;,citation_author=Miguel A. Hernán;,citation_author=Marc Lipsitch;,citation_author=Isaac Kohane;,citation_author=Doron Netzer;,citation_author=Ben Y. Reis;,citation_author=Ran D. Balicer;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_issue=12;,citation_doi=10.1056/NEJMoa2110475;,citation_issn=0028-4793, 1533-4406;,citation_volume=385;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Best Papers 2022;,citation_abstract=BACKGROUND Single-dose human papillomavirus (HPV) vaccination, if efficacious, would be tremendously advantageous, simplifying implementation and decreasing costs.;,citation_author=Ruanne V. Barnabas;,citation_author=Elizabeth R. Brown;,citation_author=Maricianah A. Onono;,citation_author=Elizabeth A. Bukusi;,citation_author=Betty Njoroge;,citation_author=Rachel L. Winer;,citation_author=Denise A. Galloway;,citation_author=Leeya F. Pinder;,citation_author=Deborah Donnell;,citation_author=Imelda Wakhungu;,citation_author=Ouma Congo;,citation_author=Charlene Biwott;,citation_author=Syovata Kimanthi;,citation_author=Lynda Oluoch;,citation_author=Kate B. Heller;,citation_author=Hannah Leingang;,citation_author=Susan Morrison;,citation_author=Elena Rechkina;,citation_author=Stephen Cherne;,citation_author=Torin T. Schaafsma;,citation_author=R. Scott McClelland;,citation_author=Connie Celum;,citation_author=Jared M. Baeten;,citation_author=Nelly Mugo;,citation_publication_date=2022-04;,citation_cover_date=2022-04;,citation_year=2022;,citation_issue=5;,citation_doi=10.1056/EVIDoa2100056;,citation_issn=2766-5526;,citation_volume=1;,citation_language=en-US;,citation_journal_title=NEJM Evidence;">
<meta name="citation_reference" content="citation_title=Re-examining Permissive Hypercapnia in ARDS;,citation_author=Tavish Barnes;,citation_author=Vasileios Zochios;,citation_author=Ken Parhar;,citation_publication_date=2018-07;,citation_cover_date=2018-07;,citation_year=2018;,citation_issue=1;,citation_doi=10.1016/j.chest.2017.11.010;,citation_issn=00123692;,citation_volume=154;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Long-term Follow-up After Critical COVID-19: REMAP-CAP Revisited;,citation_abstract=The year 2020 was a grim and uncertain time for any clinician caring for inpatients with COVID-19, especially those with critical illness. In an era of modern medicine in which the range of options for many conditions can seem limitless, this novel viral threat was a reminder of the historical norm in medicine—a struggle to find the best available treatment.As a stark example of ambiguities and resulting divergent practices during the dark days of early 2020, one of us was an infectious diseases consultant to medical teams caring exclusively for inpatients with COVID-19. On one of the teams, all of their patients received adjunctive hydroxychloroquine as part of their admission medications. A second team, doing their daily rounds on the same floor of the hospital, chose the opposite approach—none of their patients received it. Members of both teams could mobilize logical arguments in favor of their practice, while simultaneously acknowledging that they were doing so without high-quality data from randomized clinical trials.;,citation_author=Michael L. Barnett;,citation_author=Paul E. Sax;,citation_publication_date=2022-12;,citation_cover_date=2022-12;,citation_year=2022;,citation_doi=10.1001/jama.2022.23700;,citation_issn=0098-7484;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Oral Sabizabulin for High-Risk, Hospitalized Adults with Covid-19: Interim Analysis;,citation_abstract=BACKGROUND Sabizabulin is an oral, novel microtubule disruptor that has dual antiviral and anti-inflammatory activities in preclinical models. METHODS A randomized, multicenter placebo-controlled phase 3 clinical trial was conducted with hospitalized patients with moderate to severe Covid-19 who were at high risk for acute respiratory distress syndrome (ARDS) and death. Patients were randomly assigned (2:1) to 9 mg of oral sabizabulin or placebo daily (up to 21 days). The primary end point was all-cause mortality up to day 60. Key secondary end points were days in the intensive care unit (ICU), days on mechanical ventilation, and days in the hospital. RESULTS A total of 204 patients were randomly assigned to treatment: 134 to sabizabulin and 70 to placebo. Baseline characteristics were similar. Sabizabulin superiority was demonstrated by a planned interim analysis for the first 150 randomized patients. Sabizabulin treatment resulted in a 24.9 percentage point absolute reduction and a 55.2% relative reduction in deaths compared with placebo (odds ratio, 3.23; 95% CI confidence interval, 1.45 to 7.22; P=0.0042). The mortality rate was 20.2% (19 of 94) for sabizabulin versus 45.1% (23 of 51) for placebo. For the key secondary end points, sabizabulin treatment resulted in a 43% relative reduction in ICU days (P=0.0013), a 49% relative reduction in days on mechanical ventilation (P=0.0013), and a 26% relative reduction in days in the hospital (P=0.0277) versus placebo. Adverse and serious adverse events were lower in the sabizabulin group compared with the placebo group. CONCLUSIONS Sabizabulin treatment resulted in a 24.9% absolute reduction in deaths compared with placebo in hospitalized patients with moderate to severe Covid-19 at high risk for ARDS and death, with a lower incidence of adverse and serious adverse events compared with placebo. (Funded by Veru, Inc.; ClinicalTrials.gov number, NCT04842747.);,citation_author=K. Gary Barnette;,citation_author=Michael S. Gordon;,citation_author=Domingo Rodriguez;,citation_author=T. Gary Bird;,citation_author=Alan Skolnick;,citation_author=Michael Schnaus;,citation_author=Paula K. Skarda;,citation_author=Suzana Lobo;,citation_author=Eduardo Sprinz;,citation_author=Georgi Arabadzhiev;,citation_author=Petar Kalaydzhiev;,citation_author=Mitchell Steiner;,citation_issue=0;,citation_doi=10.1056/EVIDoa2200145;,citation_volume=0;,citation_journal_title=NEJM Evidence;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Liberal or Conservative Oxygen Therapy for Acute Respiratory Distress Syndrome;,citation_abstract=BACKGROUND In patients with acute respiratory distress syndrome (ARDS), the National Heart, Lung, and Blood Institute ARDS Clinical Trials Network recommends a target partial pressure of arterial oxygen (Pao2) between 55 and 80 mm Hg. Prospective validation of this range in patients with ARDS is lacking. We hypothesized that targeting the lower limit of this range would improve outcomes in patients with ARDS. METHODS In this multicenter, randomized trial, we assigned patients with ARDS to receive either conservative oxygen therapy (target Pao2, 55 to 70 mm Hg; oxygen saturation as measured by pulse oximetry [Spo2], 88 to 92%) or liberal oxygen therapy (target Pao2, 90 to 105 mm Hg; Spo2, \geq96%) for 7 days. The same mechanical-ventilation strategies were used in both groups. The primary outcome was death from any cause at 28 days. The authors’ affiliations are listed in the Appendix. Address reprint requests to Dr. Capellier at Reanimation Medicale, Centre Hospitalier Régional Universitaire Besançon, Blvd. Fleming, 25000 Besançon, France, or at gilles.capellier@u niv-fcomte.fr. *A complete list of investigators in the LOCO2 trial is provided in the Supplementary Appendix, available at NEJM.org. N Engl J Med 2020;382:999-1008. DOI: 10.1056/NEJMoa1916431 Copyright © 2020 Massachusetts Medical Society. RESULTS After the enrollment of 205 patients, the trial was prematurely stopped by the data and safety monitoring board because of safety concerns and a low likelihood of a significant difference between the two groups in the primary outcome. Four patients who did not meet the eligibility criteria were excluded. At day 28, a total of 34 of 99 patients (34.3%) in the conservative-oxygen group and 27 of 102 patients (26.5%) in the liberal-oxygen group had died (difference, 7.8 percentage points; 95% confidence interval [CI], -4.8 to 20.6). At day 90, 44.4% of the patients in the conservative-oxygen group and 30.4% of the patients in the liberal-oxygen group had died (difference, 14.0 percentage points; 95% CI, 0.7 to 27.2). Five mesenteric ischemic events occurred in the conservative-oxygen group. CONCLUSIONS Among patients with ARDS, early exposure to a conservative-oxygenation strategy with a Pao2 between 55 and 70 mm Hg did not increase survival at 28 days. (Funded by the French Ministry of Health; LOCO2 ClinicalTrials.gov number, NCT02713451.);,citation_author=Loic Barrot;,citation_author=Pierre Asfar;,citation_author=Frederic Mauny;,citation_author=Hadrien Winiszewski;,citation_author=Florent Montini;,citation_author=Julio Badie;,citation_author=Jean-Pierre Quenot;,citation_author=Sebastien Pili-Floury;,citation_author=Belaid Bouhemad;,citation_author=Guillaume Louis;,citation_author=Bertrand Souweine;,citation_author=Olivier Collange;,citation_author=Julien Pottecher;,citation_author=Bruno Levy;,citation_author=Marc Puyraveau;,citation_author=Lucie Vettoretti;,citation_author=Jean-Michel Constantin;,citation_author=Gilles Capellier;,citation_publication_date=2020-03;,citation_cover_date=2020-03;,citation_year=2020;,citation_issue=11;,citation_doi=10.1056/NEJMoa1916431;,citation_issn=0028-4793, 1533-4406;,citation_pmid=32160661;,citation_volume=382;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Seventy-Five Trials and Eleven Systematic Reviews a Day: How Will We Ever Keep Up?;,citation_author=Hilda Bastian;,citation_author=Paul Glasziou;,citation_author=Iain Chalmers;,citation_publication_date=2010-09;,citation_cover_date=2010-09;,citation_year=2010;,citation_issue=9;,citation_doi=10.1371/journal.pmed.1000326;,citation_issn=1549-1676;,citation_volume=7;,citation_language=en-US;,citation_journal_title=PLoS Medicine;">
<meta name="citation_reference" content="citation_title=A Worse Doctor;,citation_author=Cameron Baston;,citation_publication_date=2023-08;,citation_cover_date=2023-08;,citation_year=2023;,citation_issue=2;,citation_doi=10.1016/j.chest.2023.04.025;,citation_issn=0012-3692;,citation_volume=164;,citation_language=en-US;,citation_journal_title=CHEST;">
<meta name="citation_reference" content="citation_title=Authors’ Reply: Confounding by Indication in Retrospective Studies of Intracerebral Hemorrhage: Antiepileptic Treatment and Mortality;,citation_author=Thomas W. K. Battey;,citation_author=Guido J. Falcone;,citation_author=Kevin N. Sheth;,citation_author=Joshua N. Goldstein;,citation_author=Jonathan Rosand;,citation_publication_date=2013-04;,citation_cover_date=2013-04;,citation_year=2013;,citation_issue=2;,citation_doi=10.1007/s12028-013-9820-7;,citation_issn=1541-6933, 1556-0961;,citation_volume=18;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Confounding by Indication in Retrospective Studies of Intracerebral Hemorrhage: Antiepileptic Treatment and Mortality;,citation_author=Thomas W. K. Battey;,citation_author=Guido J. Falcone;,citation_author=Alison M. Ayres;,citation_author=Kristin Schwab;,citation_author=Anand Viswanathan;,citation_author=Kristen A. McNamara;,citation_author=Zora Y. DiPucchio;,citation_author=Steven M. Greenberg;,citation_author=Kevin N. Sheth;,citation_author=Joshua N. Goldstein;,citation_author=Jonathan Rosand;,citation_publication_date=2012-12;,citation_cover_date=2012-12;,citation_year=2012;,citation_issue=3;,citation_doi=10.1007/s12028-012-9776-z;,citation_issn=1541-6933, 1556-0961;,citation_volume=17;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Funding and DSMB Membership in the VICTAS Clinical Trial;,citation_abstract=Two unusual circumstances arose in the conduct, review, and publication of the VICTAS randomized clinical trial. First, the funder reportedly withdrew financial support for the study after enrollment of only 25% of the planned study sample, resulting in early termination of the study; and second, a member of the data and safety monitoring board (DSMB) is an author of the article.The National Institutes of Health (NIH; which was not a funder of the VICTAS trial) is the largest single funder of biomedical research in the world. Clinical research is generally supported by grants or contracts, and it is very unusual for the NIH to withhold or withdraw funds for a study if appropriate documented progress is being made and no ethical or other scientific issues have arisen. However, in the past few decades, patient advocacy groups and new foundations, often with the active engagement of the individual(s) who created the foundation, have begun to fund biomedical research. It is important for investigators, and the offices of sponsored programs at the investigators’ institutions, who are usually responsible for the contractual relationship between an investigator (or institution) and the funder, to be aware of the details governing and ensuring the ongoing support of a study.;,citation_author=Howard Bauchner;,citation_author=Phil B. Fontanarosa;,citation_author=Robert M. Golub;,citation_publication_date=2021-02;,citation_cover_date=2021-02;,citation_year=2021;,citation_issue=8;,citation_doi=10.1001/jama.2020.25952;,citation_issn=0098-7484;,citation_volume=325;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Assessment of Cognitive Function in Patients After COVID-19 Infection;,citation_author=Jacqueline H. Becker;,citation_author=Jenny J. Lin;,citation_author=Molly Doernberg;,citation_author=Kimberly Stone;,citation_author=Allison Navis;,citation_author=Joanne R. Festa;,citation_author=Juan P. Wisnivesky;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=10;,citation_doi=10.1001/jamanetworkopen.2021.30645;,citation_issn=2574-3805;,citation_volume=4;,citation_language=en-US;,citation_journal_title=JAMA Network Open;">
<meta name="citation_reference" content="citation_title=Septic Cardiomyopathy:;,citation_author=Sarah J. Beesley;,citation_author=Gerhard Weber;,citation_author=Todd Sarge;,citation_author=Sara Nikravan;,citation_author=Colin K. Grissom;,citation_author=Michael J. Lanspa;,citation_author=Sajid Shahul;,citation_author=Samuel M. Brown;,citation_publication_date=2018-04;,citation_cover_date=2018-04;,citation_year=2018;,citation_issue=4;,citation_doi=10.1097/CCM.0000000000002851;,citation_issn=0090-3493;,citation_volume=46;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Remdesivir for the Treatment of Covid-19 — Final Report;,citation_abstract=BACKGROUND Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious. METHODS We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only. RESULTS A total of 1062 patients underwent randomization (with 541 assigned to remdesivir and 521 to placebo). Those who received remdesivir had a median recovery time of 10 days (95% confidence interval [CI], 9 to 11), as compared with 15 days (95% CI, 13 to 18) among those who received placebo (rate ratio for recovery, 1.29; 95% CI, 1.12 to 1.49; P&amp;amp;amp;lt;0.001, by a log-rank test). In an analysis that used a proportional-odds model with an eight-category ordinal scale, the patients who received remdesivir were found to be more likely than those who received placebo to have clinical improvement at day 15 (odds ratio, 1.5; 95% CI, 1.2 to 1.9, after adjustment for actual disease severity). The Kaplan–Meier estimates of mortality were 6.7% with remdesivir and 11.9% with placebo by day 15 and 11.4% with remdesivir and 15.2% with placebo by day 29 (hazard ratio, 0.73; 95% CI, 0.52 to 1.03). Serious adverse events were reported in 131 of the 532 patients who received remdesivir (24.6%) and in 163 of the 516 patients who received placebo (31.6%). The authors’ full names, academic degrees, and affiliations are listed in the Appendix. Address reprint requests to Dr. Beigel at the National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Ln., Rm. 7E60, MSC 9826, Rockville, MD 20892-9826, or at jbeigel@niaid.nih.gov. *A complete list of members of the ACTT-1 Study Group is provided in the Supplementary Appendix, available at NEJM.org. A preliminary version of this article was published on May 22, 2020, at NEJM.org. This article was published on October 8, 2020, and updated on October 9, 2020, at NEJM.org. N Engl J Med 2020;383:1813-26. DOI: 10.1056/NEJMoa2007764 Copyright © 2020 Massachusetts Medical Society. CONCLUSIONS Our data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACTT-1 ClinicalTrials.gov number, NCT04280705.);,citation_author=John H. Beigel;,citation_author=Kay M. Tomashek;,citation_author=Lori E. Dodd;,citation_author=Aneesh K. Mehta;,citation_author=Barry S. Zingman;,citation_author=Andre C. Kalil;,citation_author=Elizabeth Hohmann;,citation_author=Helen Y. Chu;,citation_author=Annie Luetkemeyer;,citation_author=Susan Kline;,citation_author=Diego Lopez de Castilla;,citation_author=Robert W. Finberg;,citation_author=Kerry Dierberg;,citation_author=Victor Tapson;,citation_author=Lanny Hsieh;,citation_author=Thomas F. Patterson;,citation_author=Roger Paredes;,citation_author=Daniel A. Sweeney;,citation_author=William R. Short;,citation_author=Giota Touloumi;,citation_author=David Chien Lye;,citation_author=Norio Ohmagari;,citation_author=Myoung-don Oh;,citation_author=Guillermo M. Ruiz-Palacios;,citation_author=Thomas Benfield;,citation_author=Gerd Fätkenheuer;,citation_author=Mark G. Kortepeter;,citation_author=Robert L. Atmar;,citation_author=C. Buddy Creech;,citation_author=Jens Lundgren;,citation_author=Abdel G. Babiker;,citation_author=Sarah Pett;,citation_author=James D. Neaton;,citation_author=Timothy H. Burgess;,citation_author=Tyler Bonnett;,citation_author=Michelle Green;,citation_author=Mat Makowski;,citation_author=Anu Osinusi;,citation_author=Seema Nayak;,citation_author=H. Clifford Lane;,citation_publication_date=2020-11;,citation_cover_date=2020-11;,citation_year=2020;,citation_issue=19;,citation_doi=10.1056/NEJMoa2007764;,citation_issn=0028-4793, 1533-4406;,citation_volume=383;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=What’s new in intensive care: Environmental sustainability;,citation_author=Thomas Bein;,citation_author=Susanne Koch;,citation_author=Christian Schulz;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_issue=8;,citation_doi=10.1007/s00134-021-06455-6;,citation_issn=0342-4642, 1432-1238;,citation_volume=47;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries;,citation_abstract=IMPORTANCE: Limited information exists about the epidemiology, recognition, management, and outcomes of patients with the acute respiratory distress syndrome (ARDS). OBJECTIVES: To evaluate intensive care unit (ICU) incidence and outcome of ARDS and to assess clinician recognition, ventilation management, and use of adjuncts-for example prone positioning-in routine clinical practice for patients fulfilling the ARDS Berlin Definition. DESIGN, SETTING, AND PARTICIPANTS: The Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure (LUNG SAFE) was an international, multicenter, prospective cohort study of patients undergoing invasive or noninvasive ventilation, conducted during 4 consecutive weeks in the winter of 2014 in a convenience sample of 459 ICUs from 50 countries across 5 continents. EXPOSURES: Acute respiratory distress syndrome. MAIN OUTCOMES AND MEASURES: The primary outcome was ICU incidence of ARDS. Secondary outcomes included assessment of clinician recognition of ARDS, the application of ventilatory management, the use of adjunctive interventions in routine clinical practice, and clinical outcomes from ARDS. RESULTS: Of 29,144 patients admitted to participating ICUs, 3022 (10.4%) fulfilled ARDS criteria. Of these, 2377 patients developed ARDS in the first 48 hours and whose respiratory failure was managed with invasive mechanical ventilation. The period prevalence of mild ARDS was 30.0% (95% CI, 28.2%-31.9%); of moderate ARDS, 46.6% (95% CI, 44.5%-48.6%); and of severe ARDS, 23.4% (95% CI, 21.7%-25.2%). ARDS represented 0.42 cases per ICU bed over 4 weeks and represented 10.4% (95% CI, 10.0%-10.7%) of ICU admissions and 23.4% of patients requiring mechanical ventilation. Clinical recognition of ARDS ranged from 51.3% (95% CI, 47.5%-55.0%) in mild to 78.5% (95% CI, 74.8%-81.8%) in severe ARDS. Less than two-thirds of patients with ARDS received a tidal volume 8 of mL/kg or less of predicted body weight. Plateau pressure was measured in 40.1% (95% CI, 38.2-42.1), whereas 82.6% (95% CI, 81.0%-84.1%) received a positive end-expository pressure (PEEP) of less than 12 cm H2O. Prone positioning was used in 16.3% (95% CI, 13.7%-19.2%) of patients with severe ARDS. Clinician recognition of ARDS was associated with higher PEEP, greater use of neuromuscular blockade, and prone positioning. Hospital mortality was 34.9% (95% CI, 31.4%-38.5%) for those with mild, 40.3% (95% CI, 37.4%-43.3%) for those with moderate, and 46.1% (95% CI, 41.9%-50.4%) for those with severe ARDS. CONCLUSIONS AND RELEVANCE: Among ICUs in 50 countries, the period prevalence of ARDS was 10.4% of ICU admissions. This syndrome appeared to be underrecognized and undertreated and associated with a high mortality rate. These findings indicate the potential for improvement in the management of patients with ARDS. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02010073.;,citation_author=Giacomo Bellani;,citation_author=John G. Laffey;,citation_author=Tài Pham;,citation_author=Eddy Fan;,citation_author=Laurent Brochard;,citation_author=Andres Esteban;,citation_author=Luciano Gattinoni;,citation_author=Frank Haren;,citation_author=Anders Larsson;,citation_author=Daniel F. McAuley;,citation_author=Marco Ranieri;,citation_author=Gordon Rubenfeld;,citation_author=B. Taylor Thompson;,citation_author=Hermann Wrigge;,citation_author=Arthur S. Slutsky;,citation_author=Antonio Pesenti;,citation_author=LUNG SAFE Investigators;,citation_author=ESICM Trials Group;,citation_publication_date=2016-02;,citation_cover_date=2016-02;,citation_year=2016;,citation_issue=8;,citation_doi=10.1001/jama.2016.0291;,citation_issn=1538-3598;,citation_pmid=26903337;,citation_volume=315;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Endovascular thrombectomy for acute ischaemic stroke with established large infarct: Multicentre, open-label, randomised trial;,citation_abstract=Background Recent evidence suggests a beneficial effect of endovascular thrombectomy in acute ischaemic stroke with large infarct; however, previous trials have relied on multimodal brain imaging, whereas non-contrast CT is mostly used in clinical practice.;,citation_author=Martin Bendszus;,citation_author=Jens Fiehler;,citation_author=Fabien Subtil;,citation_author=Susanne Bonekamp;,citation_author=Anne Hege Aamodt;,citation_author=Blanca Fuentes;,citation_author=Elke R Gizewski;,citation_author=Michael D Hill;,citation_author=Antonin Krajina;,citation_author=Laurent Pierot;,citation_author=Claus Z Simonsen;,citation_author=Kamil Zeleňák;,citation_author=Rolf A Blauenfeldt;,citation_author=Bastian Cheng;,citation_author=Angélique Denis;,citation_author=Hannes Deutschmann;,citation_author=Franziska Dorn;,citation_author=Fabian Flottmann;,citation_author=Susanne Gellißen;,citation_author=Johannes C Gerber;,citation_author=Mayank Goyal;,citation_author=Jozef Haring;,citation_author=Christian Herweh;,citation_author=Silke Hopf-Jensen;,citation_author=Vi Tuan Hua;,citation_author=Märit Jensen;,citation_author=Andreas Kastrup;,citation_author=Christiane Fee Keil;,citation_author=Andrej Klepanec;,citation_author=Egon Kurča;,citation_author=Ronni Mikkelsen;,citation_author=Markus Möhlenbruch;,citation_author=Stefan Müller-Hülsbeck;,citation_author=Nico Münnich;,citation_author=Paolo Pagano;,citation_author=Panagiotis Papanagiotou;,citation_author=Gabor C Petzold;,citation_author=Mirko Pham;,citation_author=Volker Puetz;,citation_author=Jan Raupach;,citation_author=Gernot Reimann;,citation_author=Peter Arthur Ringleb;,citation_author=Maximilian Schell;,citation_author=Eckhard Schlemm;,citation_author=Silvia Schönenberger;,citation_author=Bjørn Tennøe;,citation_author=Christian Ulfert;,citation_author=Kateřina Vališ;,citation_author=Eva Vítková;,citation_author=Dominik F Vollherbst;,citation_author=Wolfgang Wick;,citation_author=Götz Thomalla;,citation_author=Anne Hege Aamodt;,citation_author=Olaf Adamczewski;,citation_author=Kirill Alektoror;,citation_author=März Alexander;,citation_author=Maria Alexandrou;,citation_author=Quentin Alias;,citation_author=Fadha Elawi Al-Kuzae;,citation_author=Julien Allard;,citation_author=Rahman Al-Schameri;,citation_author=Alberto Álvarez;,citation_author=Grethe Andersen;,citation_author=Rolf AnkerlundBlaufeldt;,citation_author=Riedel Antje;,citation_author=Hannes Appelbohm;,citation_author=Maria Argren;,citation_author=Anne Assmann;,citation_author=Michael Augustin;,citation_author=Elke Bach;,citation_author=Michal Bar;,citation_author=Maria Barleben;,citation_author=Flore Baronnet;,citation_author=Andrés Barrios;,citation_author=Xénia Bavúzová;,citation_author=Rikke BayThomsen;,citation_author=Sandra Becker;,citation_author=Sylvia Beer;,citation_author=Daniel Behme;,citation_author=Maximilian Bellut;,citation_author=Martin Bendszus;,citation_author=Joachim Berkefeld;,citation_author=Maximillian Bester;,citation_author=Felix J. Bode;,citation_author=Christian Boehme;,citation_author=Ramona Boese;,citation_author=Ferdinand Bohmann;,citation_author=Susanne Bonekamp;,citation_author=Jan Borggrefe;,citation_author=Erendira Gabriela Boss;,citation_author=Maria Boutchakova;,citation_author=Elfi Boxhammer;,citation_author=Annemarie Brandhofe;,citation_author=Michael Breckwoldt;,citation_author=Casper Brekenfeld;,citation_author=Alex Brehm;,citation_author=Christian Brem;,citation_author=Stella Breuer;,citation_author=Tobias Breyer;,citation_author=Petra Brodová;,citation_author=Gabriel Broocks;,citation_author=Christoph Brosinski;,citation_author=Nele Bubel;,citation_author=Jiří Búřil;,citation_author=Martin Čábal;,citation_author=Laura Casado;,citation_author=Elena De Celis;,citation_author=Emmanuel Chabert;,citation_author=Daniel Charisse;,citation_author=Bastian Cheng;,citation_author=Vendelín Chovanec;,citation_author=Peter Cidlinsky;,citation_author=Juraj Cisár;,citation_author=Fréderic Clarençon;,citation_author=Sophie Crozier;,citation_author=Nina Čurdová;,citation_author=Michele Damaskinos;,citation_author=Dorte Damgaard;,citation_author=Martin Daniš;,citation_author=Florian Dazinger;,citation_author=Milani Deb-Chatterji;,citation_author=Asima Delalic;,citation_author=Agnieszka Delekta;,citation_author=Stephen Delorme;,citation_author=Hannes Deutschmann;,citation_author=Elie Diamandis;,citation_author=Tove Diedrichsen;,citation_author=Irena Doležalová;,citation_author=Franziska Dorn;,citation_author=Franziska Dorn;,citation_author=Richard Du Mesnil De Rochemont;,citation_author=Kristina DupontHougaard;,citation_author=Taraneh Ebrahimi;,citation_author=Florian Eff;,citation_author=Ilona Eliášová;,citation_author=Brian Enriquez;,citation_author=Mostafa Ergawy;,citation_author=Fabian Essig;,citation_author=Maiken Falkesgaard;,citation_author=Simon Fandler-Höfler;,citation_author=Andrés Fernández;,citation_author=Jean-Christophe Ferré;,citation_author=Anna Ferrier;,citation_author=Jens Fiehler;,citation_author=Krystian Figlewski;,citation_author=Sebastian Fischer;,citation_author=Urs Fischer;,citation_author=Fabian Flottmann;,citation_author=Robert Forbig;,citation_author=Christian Förch;,citation_author=Annette Fromm;,citation_author=Blanca Fuentes;,citation_author=Ines Gaedke;,citation_author=Romana Galczak;,citation_author=Malik Galijasevic;,citation_author=Bernhard Ganser;,citation_author=Thomas Gattringer;,citation_author=Matthias Gawlitza;,citation_author=Sarah Gelhard;,citation_author=Susanne Gellißen;,citation_author=Johannes Gerber;,citation_author=Michail Panagiotis Giannakakis;,citation_author=Karin Gindlhuber;,citation_author=Elke R. Gizewski;,citation_author=Bernhard Glodny;,citation_author=Tim Godel;,citation_author=Einar Goebell;,citation_author=David Goldemund;,citation_author=Michael Görtler;,citation_author=Mayank Goyal;,citation_author=Astrid E. Grams;,citation_author=Joachim Gruber;,citation_author=Katharina Gruber;,citation_author=Thomas Günthner-Lengsfeld;,citation_author=Kathrin Haase;,citation_author=Floriana Hacker-Ivan;,citation_author=Erika Hallerstig;,citation_author=Uta Hanning;,citation_author=Jozef Haring;,citation_author=Michal Haršány;,citation_author=Ján Haršány;,citation_author=Christian Hartmann;,citation_author=Eva Maria Hassler;,citation_author=Kristina Hauptmann;,citation_author=Karl Georg Häusler;,citation_author=Constantin Hecker;,citation_author=Victoria Hellstern;,citation_author=Hans Henkes;,citation_author=Victoria Hernández;,citation_author=Christian Herweh;,citation_author=Tim Hilgenfeld;,citation_author=Michael D. Hill;,citation_author=Niels Hjort;,citation_author=Nina HjortJensen;,citation_author=Maya Hoelter;,citation_author=Karl-Titus Hoffmann;,citation_author=Brigitte Holst;,citation_author=Markus Holtmannspoetter;,citation_author=Silke Hopf-Jensen;,citation_author=Julia Hoppe;,citation_author=Susanne Horner;,citation_author=Leif HougaardSoerensen;,citation_author=Vi Tuan Hua;,citation_author=Alexander Hubert;,citation_author=Eva Hurtíková;,citation_author=Stanislava Jakubíček;,citation_author=Tanja Janjic;,citation_author=Kirsten Jaramillo;,citation_author=Angela Jedlitschka;,citation_author=Schiela Jensen;,citation_author=Märit Jensen;,citation_author=Jessica Jesser;,citation_author=Leonie Jestaedt;,citation_author=Sabine Johnson;,citation_author=Tomáš Jonszta;,citation_author=Peter Kalmar;,citation_author=Sanja Karabegovic;,citation_author=Kollo Karen;,citation_author=Andreas Kastrup;,citation_author=Hopp Katja;,citation_author=Natalia Keeba;,citation_author=Petra Keese;,citation_author=Christina Kefalaykos;,citation_author=Fee Keil;,citation_author=Lars Kellert;,citation_author=Christoph Kellinghaus;,citation_author=Roxane-Isabelle Kestner;,citation_author=Stefan Kiechl;,citation_author=Monika Killer-Oberpfalzer;,citation_author=Andrej Klepanec;,citation_author=Casjupea Knispel;,citation_author=Michael Knoflach;,citation_author=Sabine Kohler;,citation_author=Konstantin Kohlhase;,citation_author=Alexander Marco Kollikowski;,citation_author=Martin Kovář;,citation_author=Antonín Krajina;,citation_author=Michael Kral;,citation_author=Georgi Krastev;,citation_author=Lars Udo Krause;,citation_author=Rudolf Kreidenhuber;,citation_author=Tomáš Křivka;,citation_author=Adam Krkoška;,citation_author=Jan Robert Kröger;,citation_author=Moritz Kronlage;,citation_author=Pawel Krukowski;,citation_author=Julia Kühn;,citation_author=Egon Kurča;,citation_author=Natalia Kurka;,citation_author=Michael Kuschnerow;,citation_author=Rita Lachmund;,citation_author=Susanne Lamprecht;,citation_author=Rüdiger Lange;,citation_author=Monika Lauer;,citation_author=Alonso De Leciñana;,citation_author=Sara Leder;,citation_author=Anne Leger;,citation_author=Nils Lehnen;,citation_author=Dominik Lehrieder;,citation_author=Maximilian Leißner;,citation_author=Markus Leitinger;,citation_author=Ursula Leitner;,citation_author=Stéphanie Lenck;,citation_author=Eva Lenzenweger;,citation_author=Thomas Liebig;,citation_author=Stephan Lowens;,citation_author=Manuel Lunzer;,citation_author=Christian Maegerlein;,citation_author=Marton Magyar;,citation_author=Leonardo Marques;,citation_author=David Matyáš;,citation_author=Gabriele Maurer;,citation_author=Matthias Mauritz;,citation_author=Thormann Maximilian;,citation_author=Lukas Mayer-Süß;,citation_author=Stephan Meckel;,citation_author=Oldřich Medek;,citation_author=Julius N. Meissner;,citation_author=Pavel Mencl;,citation_author=Andrea Merkle;,citation_author=Birte Mesche;,citation_author=Dominik Michalski;,citation_author=Robert Mikulík;,citation_author=Boris Modrau;,citation_author=Markus A. Möhlenbruch;,citation_author=Alexander Mohr;,citation_author=Christoph Mönninghoff;,citation_author=Tobias Moser;,citation_author=Ramona Mücke;,citation_author=Stefan Müller-Hülsbeck;,citation_author=Erasmia Müller-Thies-Broussalis;,citation_author=Sebastian Mutzenbach;,citation_author=Pedro Navia;,citation_author=Ulf Neuberger;,citation_author=Hermann Neugebauer;,citation_author=Jens Neumann;,citation_author=Anh Nguyên;,citation_author=Kurt Niederkorn;,citation_author=Vladimír Nosál’;,citation_author=Richard Novobilský;,citation_author=Nikos Ntoulias;,citation_author=Lukas Nussbaum;,citation_author=Joanna Oder;,citation_author=Andreas Oldag;,citation_author=Marián Ondrejkovič;,citation_author=Ferdinand Otto;,citation_author=Dagmar Otto;,citation_author=Daniel Paech;,citation_author=Paolo Pagano;,citation_author=Lars-Peder Pallesen;,citation_author=Michal Panský;,citation_author=Panagiotis Papanagiotou;,citation_author=Samp Patrick;,citation_author=Harald Paukisch;,citation_author=Johann Pelz;,citation_author=Inga Petersen;,citation_author=Martina Petersen;,citation_author=Gabor C. Petzold;,citation_author=Johannes Pfaff;,citation_author=Johannes Pfaff;,citation_author=Waltraud Pfeilschifter;,citation_author=Mirko Pham;,citation_author=Alexander Pichler;,citation_author=Laurent Pierot;,citation_author=Slaven Pikija;,citation_author=Jan PlougmannPovlsen;,citation_author=Christoph Polkowski;,citation_author=Nenad Polomac;,citation_author=Rupert Horst Portugaller;,citation_author=Marika Poulsen;,citation_author=Michael Preiß;,citation_author=Kévin Premat;,citation_author=Sjur Prestsæter;,citation_author=Rocio Prieto-Pérez;,citation_author=Marios Psychogios;,citation_author=Volker Puetz;,citation_author=Jan Purrucker;,citation_author=Heike Rai;,citation_author=Maximilian Rauch;,citation_author=Jan Raupach;,citation_author=Gernot Reimann;,citation_author=Georg Reimann;,citation_author=Sarah Reitz;,citation_author=Ondřej Renc;,citation_author=Jasmin Retzlaff;,citation_author=Ricardo Rigual;,citation_author=Peter Arthur Ringleb;,citation_author=Carlota Rivera-Bengoa;,citation_author=Jorge Rodríguez;,citation_author=Stefan Rohde;,citation_author=Siegfried Rohler;,citation_author=Charlotte Rosso;,citation_author=Christian Roth;,citation_author=Thomas Röttcher;,citation_author=Martin Roubec;,citation_author=Milada Roztočilová;,citation_author=Svetlana Rudnicka;,citation_author=Gerardo Ruiz;,citation_author=Stephen Ryan;,citation_author=Karla J. Ryckborst;,citation_author=Simen Sandvik;,citation_author=Jan-Hendrik Schäfer;,citation_author=Martin Schaller-Paule;,citation_author=Maximillian Schell;,citation_author=Peter Schellinger;,citation_author=Eckhard Schlemm;,citation_author=Florian Schmid;,citation_author=Christoph Schmidt;,citation_author=Marie Louise Schmitz;,citation_author=Claus Schneider;,citation_author=Jan-Erik Scholtz;,citation_author=Silvia Schönenberger;,citation_author=Andreas Schröter;,citation_author=Daniel Schwarz;,citation_author=Stephan Schwarz;,citation_author=Daniel Schwarzenhofer;,citation_author=Thomas Seifert-Held;,citation_author=Alexander Seiler;,citation_author=Fatih Seker;,citation_author=Eimad Shotar;,citation_author=Claus Z. Simonsen;,citation_author=Maria Theresa Simonsen;,citation_author=Jozef Sivák;,citation_author=Karolina Skagen;,citation_author=Mona Skjelland;,citation_author=Alena Šnajdrová;,citation_author=Lazlo Solymosi;,citation_author=Jesper Sømark;,citation_author=Michael Sonnberger;,citation_author=Jakub Soršák;,citation_author=Nader Sourour;,citation_author=Jogrim Søyland;,citation_author=Daniel Spitzer;,citation_author=Peter Sporns;,citation_author=Michael Städt;,citation_author=Eike Steidl;,citation_author=Anne Margrethe Kaalaas Størdal;,citation_author=Sebastian Stösser;,citation_author=Sarah Strickmann;,citation_author=Ondřej Strýček;,citation_author=Igor Suškevič;,citation_author=Jan Sýkora;,citation_author=Bjørn Tennøe;,citation_author=Daniela Thaler;,citation_author=Sara Theisen;,citation_author=Götz Thomalla;,citation_author=Petar Trendafilov;,citation_author=Johannes Trenkler;,citation_author=Christoph Trumm;,citation_author=Ioannis Tsogkas;,citation_author=Jon-Anders Tunold;,citation_author=Lars Tveit;,citation_author=Christian Ulfert;,citation_author=Kateřina Vališ;,citation_author=Jiří Vaníček;,citation_author=Christine Vassilev;,citation_author=Eva Vítková;,citation_author=Heinz-Leonhard Voit-Höhne;,citation_author=Bohuslav Vojtíšek;,citation_author=Karoline Volderauer;,citation_author=Dominik Vollherbst;,citation_author=Christoph Vollmuth;,citation_author=Kamila Volna;,citation_author=Ondřej Volný;,citation_author=Poul VonWeitzel-Mudersbach;,citation_author=Martin Vorčák;,citation_author=Marlies Wagner;,citation_author=Gaute Kjellevold Wathle;,citation_author=Werner Weber;,citation_author=Anushe Weber;,citation_author=Viktor Weiss;,citation_author=Johannes M. Weller;,citation_author=Katharina Wenger-Alakmeh;,citation_author=Cyrill Weyland;,citation_author=Friedrich Weymayr;,citation_author=Ulrike Wießpeiner;,citation_author=Johannes Willeit;,citation_author=Aymeric Wittwer;,citation_author=Frank Wollenweber;,citation_author=Ginette Wortmann;,citation_author=Silke Wunderlich;,citation_author=Yanyan Xiong;,citation_author=Se-Jong You;,citation_author=Lasse ZachoSpeiser;,citation_author=Kamil Zelenak;,citation_author=Jana Zeleňáková;,citation_author=Seraphine Zubel;,citation_publication_date=2023-11;,citation_cover_date=2023-11;,citation_year=2023;,citation_issue=10414;,citation_doi=10.1016/S0140-6736(23)02032-9;,citation_issn=01406736;,citation_volume=402;,citation_language=en-US;,citation_journal_title=The Lancet;">
<meta name="citation_reference" content="citation_title=A Gentle Introduction to the Comparison Between Null Hypothesis Testing and Bayesian Analysis: Reanalysis of Two Randomized Controlled Trials;,citation_abstract=The debate on the use and misuse of P values has risen and fallen throughout their almost century-long existence in scientific discovery. Over the past few years, the debate has again received front-page attention, particularly through the public reminder by the American Statistical Association on how P values should be used and interpreted. At the core of the issue lies a fault in the way that scientific evidence is dichotomized and research is subsequently reported, and this fault is exacerbated by researchers giving license to statistical models to do scientific inference. This paper highlights a different approach to handling the evidence collected during a randomized controlled trial, one that does not dichotomize, but rather reports the evidence collected. Through the use of a coin flipping experiment and reanalysis of real-world data, the traditional approach of testing null hypothesis significance is contrasted with a Bayesian approach. This paper is meant to be understood by those who rely on statistical models to draw conclusions from data, but are not statisticians and may therefore not be able to grasp the debate that is primarily led by statisticians.;,citation_author=Marcus Bendtsen;,citation_publication_date=2018-10;,citation_cover_date=2018-10;,citation_year=2018;,citation_issue=10;,citation_doi=10.2196/10873;,citation_issn=1438-8871;,citation_volume=20;,citation_language=en-US;,citation_journal_title=Journal of Medical Internet Research;">
<meta name="citation_reference" content="citation_title=The P Value Line Dance: When Does the Music Stop?;,citation_abstract=When should a trial stop? Such a seemingly innocent question evokes concerns of type I and II errors among those who believe that certainty can be the product of uncertainty and among researchers who have been told that they need to carefully calculate sample sizes, consider multiplicity, and not spend P values on interim analyses. However, the endeavor to dichotomize evidence into significant and nonsignificant has led to the basic driving force of science, namely uncertainty, to take a back seat. In this viewpoint we discuss that if testing the null hypothesis is the ultimate goal of science, then we need not worry about writing protocols, consider ethics, apply for funding, or run any experiments at all—all null hypotheses will be rejected at some point—everything has an effect. The job of science should be to unearth the uncertainties of the effects of treatments, not to test their difference from zero. We also show the fickleness of P values, how they may one day point to statistically significant results; and after a few more participants have been recruited, the once statistically significant effect suddenly disappears. We show plots which we hope would intuitively highlight that all assessments of evidence will fluctuate over time. Finally, we discuss the remedy in the form of Bayesian methods, where uncertainty leads; and which allows for continuous decision making to stop or continue recruitment, as new data from a trial is accumulated.;,citation_author=Marcus Bendtsen;,citation_publication_date=2020-08;,citation_cover_date=2020-08;,citation_year=2020;,citation_issue=8;,citation_doi=10.2196/21345;,citation_issn=1438-8871;,citation_volume=22;,citation_language=en-US;,citation_journal_title=Journal of Medical Internet Research;">
<meta name="citation_reference" content="citation_title=Three Recommendations for Improving the Use of &amp;amp;amp;lt;i&amp;gt;p&amp;lt;/i&amp;gt; -Values;,citation_abstract=Researchers commonly use p-values to answer the question: How strongly does the evidence favor the alternative hypothesis relative to the null hypothesis? p-Values themselves do not directly answer this question and are often misinterpreted in ways that lead to overstating the evidence against the null hypothesis. Even in the “post p &amp;amp;lt; 0.05 era,” however, it is quite possible that p-values will continue to be widely reported and used to assess the strength of evidence (if for no other reason than the widespread availability and use of statistical software that routinely produces p-values and thereby implicitly advocates for their use). If so, the potential for misinterpretation will persist. In this article, we recommend three practices that would help researchers more accurately interpret p-values. Each of the three recommended practices involves interpreting p-values in light of their corresponding “Bayes factor bound,” which is the largest odds in favor of the alternative hypothesis relative to the null hypothesis that is consistent with the observed data. The Bayes factor bound generally indicates that a given p-value provides weaker evidence against the null hypothesis than typically assumed. We therefore believe that our recommendations can guard against some of the most harmful p-value misinterpretations. In research communities that are deeply attached to reliance on “p < 0.05,” our recommendations will serve as initial steps away from this attachment. We emphasize that our recommendations are intended merely as initial, temporary steps and that many further steps will need to be taken to reach the ultimate destination: a holistic interpretation of statistical evidence that fully conforms to the principles laid out in the ASA statement on statistical significance and p-values.;,citation_author=Daniel J. Benjamin;,citation_author=James O. Berger;,citation_publication_date=2019-03;,citation_cover_date=2019-03;,citation_year=2019;,citation_issue=sup1;,citation_doi=10.1080/00031305.2018.1543135;,citation_issn=0003-1305, 1537-2731;,citation_volume=73;,citation_language=en-US;,citation_journal_title=The American Statistician;">
<meta name="citation_reference" content="citation_title=Primary brain tumours in adults;,citation_author=Martin J. Bent;,citation_author=Marjolein Geurts;,citation_author=Pim J. French;,citation_author=Marion Smits;,citation_author=David Capper;,citation_author=Jacoline E. C. Bromberg;,citation_author=Susan M. Chang;,citation_publication_date=2023-10;,citation_cover_date=2023-10;,citation_year=2023;,citation_issue=10412;,citation_doi=10.1016/S0140-6736(23)01054-1;,citation_issn=0140-6736, 1474-547X;,citation_pmid=37738997;,citation_volume=402;,citation_language=en-US;,citation_journal_title=The Lancet;,citation_publisher=Elsevier;">
<meta name="citation_reference" content="citation_title=Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non–Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial;,citation_abstract=OBJECTIVE To evaluate the benefits and risks of adding a P2Y12 inhibitor to anticoagulant therapy among non–critically ill patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS An open-label, bayesian, adaptive randomized clinical trial including 562 non–critically ill patients hospitalized for COVID-19 was conducted between February 2021 and June 2021 at 60 hospitals in Brazil, Italy, Spain, and the US. The date of final 90-day follow-up was September 15, 2021. INTERVENTIONS Patients were randomized to a therapeutic dose of heparin plus a P2Y12 inhibitor (n = 293) or a therapeutic dose of heparin only (usual care) (n = 269) in a 1:1 ratio for 14 days or until hospital discharge, whichever was sooner. Ticagrelor was the preferred P2Y12 inhibitor. MAIN OUTCOMES AND MEASURES The composite primary outcome was organ support–free days evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and, for those who survived to hospital discharge, the number of days free of respiratory or cardiovascular organ support up to day 21 of the index hospitalization (range, -1 to 21 days; higher scores indicate less organ support and better outcomes). The primary safety outcome was major bleeding by 28 days as defined by the International Society on Thrombosis and Hemostasis. RESULTS Enrollment of non–critically ill patients was discontinued when the prespecified criterion for futility was met. All 562 patients who were randomized (mean age, 52.7 [SD, 13.5] years; 41.5% women) completed the trial and 87% received a therapeutic dose of heparin by the end of study day 1. In the P2Y12 inhibitor group, ticagrelor was used in 63% of patients and clopidogrel in 37%. The median number of organ support–free days was 21 days (IQR, 20-21 days) among patients in the P2Y12 inhibitor group and was 21 days (IQR, 21-21 days) in the usual care group (adjusted odds ratio, 0.83 [95% credible interval, 0.55-1.25]; posterior probability of futility [defined as an odds ratio &amp;amp;amp;lt;1.2], 96%). Major bleeding occurred in 6 patients (2.0%) in the P2Y12 inhibitor group and in 2 patients (0.7%) in the usual care group (adjusted odds ratio, 3.31 [95% CI, 0.64-17.2]; P = .15). CONCLUSIONS AND RELEVANCE Among non–critically ill patients hospitalized for COVID-19, the use of a P2Y12 inhibitor in addition to a therapeutic dose of heparin, compared with a therapeutic dose of heparin only, did not result in an increased odds of improvement in organ support–free days within 21 days during hospitalization.;,citation_author=Jeffrey S. Berger;,citation_author=Lucy Z. Kornblith;,citation_author=Michelle N. Gong;,citation_author=Harmony R. Reynolds;,citation_author=Mary Cushman;,citation_author=Yu Cheng;,citation_author=Bryan J. McVerry;,citation_author=Keri S. Kim;,citation_author=Renato D. Lopes;,citation_author=Bassel Atassi;,citation_author=Scott Berry;,citation_author=Grant Bochicchio;,citation_author=Murillo Oliveira Antunes;,citation_author=Michael E. Farkouh;,citation_author=Yonatan Greenstein;,citation_author=Erinn M. Hade;,citation_author=Kristin Hudock;,citation_author=Robert Hyzy;,citation_author=Pooja Khatri;,citation_author=Andrei Kindzelski;,citation_author=Bridget-Anne Kirwan;,citation_author=Lisa Baumann Kreuziger;,citation_author=Patrick R. Lawler;,citation_author=Eric Leifer;,citation_author=Jose Lopez-Sendon Moreno;,citation_author=Jose Lopez-Sendon;,citation_author=James F. Luther;,citation_author=Lilia Nigro Maia;,citation_author=John Quigley;,citation_author=Robert Sherwin;,citation_author=Lana Wahid;,citation_author=Jennifer Wilson;,citation_author=Judith S. Hochman;,citation_author=Matthew D. Neal;,citation_author=ACTIV-4a Investigators;,citation_author=Jonathan Newman;,citation_author=Mark Geraci;,citation_author=Aldo Maggioni;,citation_author=Hooman Kamel;,citation_author=Ewan C. Goligher;,citation_author=Ryan Zarychanski;,citation_author=Brendan M. Everett;,citation_author=Sean Diepen;,citation_author=Gregoire Le Gal;,citation_author=Deborah M. Siegal;,citation_author=Jean-Philippe Galanaud;,citation_author=Sheila Hegde;,citation_author=Yuri Kim;,citation_author=Natalia S. Rost;,citation_author=Aneesh B. Singhal;,citation_author=Aira Contreras;,citation_author=Stephanie Mavromichalis;,citation_author=Eduardo Iturrate;,citation_author=Margaret Gilsenan;,citation_author=Anna Naumova;,citation_author=Arlene Roberts;,citation_author=Julia Levine;,citation_author=Christine M. Leeper;,citation_author=Derek C. Angus;,citation_author=Mary Martinez;,citation_author=Jake Schreiber;,citation_author=Joshua Froess;,citation_author=Caroline E. Stehle;,citation_author=Ashita Sai Vadlamudi;,citation_author=Frank Sciurba;,citation_author=Alison Morris;,citation_author=Edvin Music;,citation_author=Sophie Brouwer;,citation_author=Emilie Perrin;,citation_author=Caroline Gombault;,citation_author=Sandra Bula;,citation_author=Michael Nelson;,citation_author=Céline Daelemans;,citation_author=Laurine Paraz;,citation_author=Michelle A. Detry;,citation_author=Anna McGlothlin;,citation_author=Melanie Quintana;,citation_author=Amy Crawford;,citation_author=Danielle Sin;,citation_author=Elhaji Diene;,citation_author=Ewelina Gwiszcz;,citation_author=Isabelle Hogan;,citation_author=Alair Holden;,citation_author=Nancy Ringwood;,citation_author=Laura Fitzgerald;,citation_author=Haley Morin;,citation_author=Brenda Nunez-Garcia;,citation_author=Aaron E. Kornblith;,citation_author=Carolyn M. Hendrickson;,citation_author=Deanna Lee;,citation_author=Viet Nguyen;,citation_author=India Shelley;,citation_author=Shannon Broaddrick;,citation_author=Neha Atal;,citation_author=David T. Huang;,citation_author=Renee Wunderly;,citation_author=Meredith Buxton;,citation_author=Tracey Roberts;,citation_author=Kelsey Linstrum;,citation_author=Amanda McNamara;,citation_author=Alexandra Weissman;,citation_author=Dylan Barbee;,citation_author=Emily Berryman;,citation_author=Jamey Frasure;,citation_author=Amy Sulken;,citation_author=Jéssica Natuline Ianof;,citation_author=Lilian Mazza;,citation_author=Julia Morata;,citation_author=Carolina Martins Cafarella;,citation_author=Mayra Akimi Suiama;,citation_author=Daniele Lima Franco;,citation_author=Jorge Escobedo;,citation_author=Andrea Martinez;,citation_author=Pedro Ohara;,citation_author=Douglas Assis;,citation_author=Chiara Manzalini;,citation_author=Stefania Corsi;,citation_author=Gianluca Campo;,citation_author=Paula Prieto;,citation_author=Rocio Prieto;,citation_author=Shamila Garg;,citation_author=Ricardo Fonseco;,citation_author=Stacey Reese;,citation_author=Oluwayemisi Mohammed;,citation_author=Rowena Dolor;,citation_author=Thomas L. Ortel;,citation_author=Cameron Wolfe;,citation_author=Michael Plump;,citation_author=Rahul Nair;,citation_author=William Nkemdirim;,citation_author=Jen-Ting Chen;,citation_author=Benjamin Galen;,citation_author=Ari Moskowitz;,citation_author=Norma Keller;,citation_author=Eugene Yuriditsky;,citation_author=James Horowitz;,citation_author=Alexander Hindenburg;,citation_author=Tamta Chkhikvadze;,citation_author=Lynnie Bassoli;,citation_author=Tibério Costa;,citation_author=Jose Luis López-Sendón Moreno;,citation_author=Fernando Rodriguez Jorge;,citation_author=Sebastian García Madrona;,citation_author=Raquel Morillo Guerrero;,citation_author=Macarena Alpañes Buesa;,citation_author=Rosa Nieto Royo;,citation_author=Raquel Besse Diaz;,citation_author=Sergio Diz Fariña;,citation_author=Andres Gonzalez García;,citation_author=Osvaldo Silva Júnior;,citation_author=Cássia Pradela;,citation_author=Cláudio Jorge;,citation_author=Mariana Buka;,citation_author=Osana Costa;,citation_author=Danielli Frassatto;,citation_author=Juliana Vieira;,citation_author=Paulo Dutra;,citation_author=Larissa Moreira;,citation_author=Natalia Silva;,citation_author=Nadielly Prado;,citation_author=Ana Martins;,citation_author=Anna Centurione;,citation_author=Alexandre Matos Soeiro;,citation_author=Paulo Ricardo Avancini Caramori;,citation_author=Nicola Coppola;,citation_author=Marco Contoli;,citation_author=Esteban Lopez-de-Sa;,citation_author=Fernando Worner;,citation_author=Amparo López-Bernús;,citation_author=Jose Ramon Gonzalez Juanatey;,citation_author=Jesus Peteiro;,citation_author=Sheetal Gandotra;,citation_author=Vidya Krishnan;,citation_author=Robert Widmer;,citation_author=Lewis Satterwhite;,citation_author=Anthony Macchiavelli;,citation_author=Nicholas Hanna;,citation_author=Hemali Patel;,citation_author=Radmila Lyubarova;,citation_author=Eleonora Gashi;,citation_author=Alonso Alvaro;,citation_author=Stephen Pan;,citation_author=Srikanth Vallurupalli;,citation_author=Nicole Iovine;,citation_author=Ranjit Nair;,citation_author=Ashwin Jathavedam;,citation_author=Amish Shah;,citation_author=Abhijit Duggal;,citation_author=Akram Khan;,citation_author=Michael A. Matthay;,citation_author=Matthew E. Prekker;,citation_author=George Lim;,citation_author=Steven Moore;,citation_author=Todd W. Costantini;,citation_author=Matthew E. Kutcher;,citation_author=Bellal Joseph;,citation_author=Michael Bromberg;,citation_author=Mark B. Effron;,citation_author=Allyson Pishko;,citation_author=John P. Sheehan;,citation_author=Manila Gaddh;,citation_author=Katayoun Rezai;,citation_author=Julius Gene Latorre;,citation_author=Conrad Liang;,citation_author=Zahra Ajani;,citation_author=Stephanie Guo;,citation_author=Micah Whitson;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=3;,citation_doi=10.1001/jama.2021.23605;,citation_issn=0098-7484;,citation_volume=327;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Can Early Electroencephalography Findings Predict Survival and Functional Outcome in Patients With Severe COVID-19 Infection?;,citation_author=Adriana Bermeo-Ovalle;,citation_author=Andrew M. Naidech;,citation_publication_date=2022-03;,citation_cover_date=2022-03;,citation_year=2022;,citation_doi=10.1097/CCM.0000000000005537;,citation_issn=0090-3493;,citation_volume=Publish Ahead of Print;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Temperature Management after Cardiac Arrest — All In or Fold?;,citation_abstract=Outcomes after out-of-hospital cardiac arrest have improved over the past 20 years; however, the benefits of some methods used to treat these patients remain uncertain. In particular, the body temperature to be targeted during the first 72 hours of care after an out-of-hospital cardiac arrest remains unclear despite multiple high-quality randomized trials having been conducted to investigate the issue.1-5 Early trials of therapeutic hypothermia targeted a body temperature of 32^\circ to 34^\circC for 12 hours1 or 24 hours2 but without a specific target temperature in the control group. Subsequently, the Target Temperature Management 33^\circC versus 36^\circC after Out-of-Hospital Cardiac Arrest . . .;,citation_author=Stephen Bernard;,citation_author=Janet Bray;,citation_publication_date=2023-03;,citation_cover_date=2023-03;,citation_year=2023;,citation_issue=10;,citation_doi=10.1056/NEJMe2214973;,citation_issn=0028-4793;,citation_volume=388;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Functional Long-Term Outcome after Left- versus Right-Sided Intracerebral Hemorrhage;,citation_abstract=&amp;amp;amp;lt;b&amp;gt;&amp;lt;i&amp;gt;Background and Purpose:</i></b> Hemispheric location might influence outcome after intracerebral hemorrhage (ICH). INTERACT suggested higher short-term mortality in right hemispheric ICH, yet statistical imbalances were not addressed. This study aimed at determining the differences in long-term functional outcome in patients with right- vs. left-sided ICH with a priori-defined sub-analysis of lobar vs. deep bleedings. <b><i>Methods:</i></b> Data from a prospective hospital registry were analyzed including patients with ICH admitted between January 2006 and August 2014. Data were retrieved from institutional databases. Outcome was assessed using the modified Rankin Scale (mRS) score. Outcome measures (long-term mortality and functional outcome at 12 months) were correlated with ICH location and hemisphere, and the imbalances of baseline characteristics were addressed by propensity score matching. <b><i>Results:</i></b> A total of 831 patients with supratentorial ICH (429 left and 402 right) were analyzed. Regarding clinical baseline characteristics in the unadjusted overall cohort, there were differences in disfavor of right-sided ICH (antiplatelets: 25.2% in left ICH vs. 34.3% in right ICH; <i>p</i> < 0.01; previous ischemic stroke: 14.7% in left ICH vs. 19.7% in right ICH; <i>p</i> = 0.057; and presence/extent of intraventricular hemorrhage: 45.0% in left ICH vs. 53.0% in right ICH; <i>p</i> = 0.021; Graeb-score: 0 [0-4] in left ICH vs. 1 [0-5] in right ICH; <i>p</i> = 0.017). While there were no differences in mortality and in the proportion of patients with favorable vs. unfavorable outcome (mRS 0-3: 142/375 [37.9%] in left ICH vs. 117/362 [32.3%] in right ICH; <i>p</i> = 0.115), patients with left-sided ICH showed excellent outcome more frequently (mRS 0-1: 64/375 [17.1%] in left ICH vs. 43/362 [11.9%] in right ICH; <i>p</i> = 0.046) in the unadjusted analysis. After adjusting for confounding variables, a well-balanced group of patients (<i>n</i> = 360/hemisphere) was compared showing no differences in long-term functional outcome (mRS 0-3: 36.4% in left ICH vs. 33.9% in right ICH; <i>p</i> = 0.51). Sub-analyses of patients with deep vs. lobar ICH revealed also no differences in outcome measures (mRS 0-3: 53/151 [35.1%] in left deep ICH vs. 53/165 [32.1%] in right deep ICH; <i>p</i> = 0.58). <b><i>Conclusion:</i></b> Previously described differences in clinical end points among patients with left- vs. right-hemispheric ICH may be driven by different baseline characteristics rather than by functional deficits emerging from different hemispheric functions affected. After statistical corrections for confounding variables, there was no impact of hemispheric location on functional outcome after ICH.;,citation_author=Vanessa D. Beuscher;,citation_author=Joji B. Kuramatsu;,citation_author=Stefan T. Gerner;,citation_author=Julia Köhn;,citation_author=Hannes Lücking;,citation_author=Stephan P. Kloska;,citation_author=Hagen B. Huttner;,citation_publication_date=2017;,citation_cover_date=2017;,citation_year=2017;,citation_issue=3-4;,citation_doi=10.1159/000454775;,citation_issn=1015-9770, 1421-9786;,citation_pmid=28049189;,citation_volume=43;,citation_language=en-US;,citation_journal_title=Cerebrovascular Diseases;,citation_publisher=Karger Publishers;">
<meta name="citation_reference" content="citation_title=Challenges in HSV encephalitis: Normocellular CSF, unremarkable CCT, and atypical MRI findings;,citation_abstract=Purpose Herpes simplex virus (HSV) encephalitis continues to be the most common form of sporadic lethal encephalitis worldwide. The wide spectrum of clinical presentations and laboratory findings often poses a diagnostic challenge for physicians which might delay administration of life-saving therapy with acyclovir. Atypical presentations of HSV encephalitis have become increasingly prevalent with better diagnostic techniques and have not been well studied. Methods We retrospectively evaluated all consecutive PCR-proven HSV encephalitis cases treated at the Hospital of the Ludwig-Maximilians-University in Munich, Germany from January 1, 2013 to February 28, 2018. Results We included 18 patients with PCR-proven HSV encephalitis. The most common clinical features were altered mental status (77.8%), focal neurologic deficits (72.2%) and fever (72.2%). Remarkably, four of these patients (22.2%) had a normocellular cerebrospinal fluid (CSF) on admission. Electroencephalography and magnetic resonance imaging abnormalities were highly sensitive for HSV encephalitis independent of CSF cell count. Striking atypical findings on MRI were extensive global brain swelling and severe brainstem involvement in single patients. Of note, initial CT scans were normal in 11 out of 16 patients (68.8%). All patients were treated with acyclovir. Three patients still developed a clinical deterioration under therapy with acyclovir with one patient requiring decompressive craniotomy due to bilateral space-occupying temporal lobe hemorrhage. 94.4% of the patients survived but only 38.9% were discharged with a good clinical outcome (Glasgow Outcome Score = 5). Conclusion Atypical presentations of HSV encephalitis seem to be more common than previously thought and physicians should apply a high level of clinical suspicion and a low threshold to initiate life-saving acyclovir therapy in suspected cases.;,citation_author=Jan Philipp Bewersdorf;,citation_author=Uwe Koedel;,citation_author=Maximilian Patzig;,citation_author=Konstantinos Dimitriadis;,citation_author=Grit Paerschke;,citation_author=Hans-Walter Pfister;,citation_author=Matthias Klein;,citation_publication_date=2019-04;,citation_cover_date=2019-04;,citation_year=2019;,citation_issue=2;,citation_doi=10.1007/s15010-018-1257-7;,citation_issn=0300-8126, 1439-0973;,citation_volume=47;,citation_language=en-US;,citation_journal_title=Infection;">
<meta name="citation_reference" content="citation_title=Negative-Pressure Pulmonary Edema;,citation_author=Mallar Bhattacharya;,citation_author=Richard H. Kallet;,citation_author=Lorraine B. Ware;,citation_author=Michael A. Matthay;,citation_publication_date=2016-10;,citation_cover_date=2016-10;,citation_year=2016;,citation_issue=4;,citation_doi=10.1016/j.chest.2016.03.043;,citation_issn=00123692;,citation_volume=150;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=The leap to ordinal: Detailed functional prognosis after traumatic brain injury with a flexible modelling approach;,citation_abstract=When a patient is admitted to the intensive care unit (ICU) after a traumatic brain injury (TBI), an early prognosis is essential for baseline risk adjustment and shared decision making. TBI outcomes are commonly categorised by the Glasgow Outcome Scale–Extended (GOSE) into eight, ordered levels of functional recovery at 6 months after injury. Existing ICU prognostic models predict binary outcomes at a certain threshold of GOSE (e.g., prediction of survival [GOSE &amp;amp;amp;gt; 1]). We aimed to develop ordinal prediction models that concurrently predict probabilities of each GOSE score. From a prospective cohort (n = 1,550, 65 centres) in the ICU stratum of the Collaborative European NeuroTrauma Effectiveness Research in TBI (CENTER-TBI) patient dataset, we extracted all clinical information within 24 hours of ICU admission (1,151 predictors) and 6-month GOSE scores. We analysed the effect of two design elements on ordinal model performance: (1) the baseline predictor set, ranging from a concise set of ten validated predictors to a token-embedded representation of all possible predictors, and (2) the modelling strategy, from ordinal logistic regression to multinomial deep learning. With repeated k-fold cross-validation, we found that expanding the baseline predictor set significantly improved ordinal prediction performance while increasing analytical complexity did not. Half of these gains could be achieved with the addition of eight high-impact predictors to the concise set. At best, ordinal models achieved 0.76 (95% CI: 0.74–0.77) ordinal discrimination ability (ordinal c-index) and 57% (95% CI: 54%– 60%) explanation of ordinal variation in 6-month GOSE (Somers’ Dxy). Model performance and the effect of expanding the predictor set decreased at higher GOSE thresholds, indicating the difficulty of predicting better functional outcomes shortly after ICU admission. Our results motivate the search for informative predictors that improve confidence in prognosis of higher GOSE and the development of ordinal dynamic prediction models.;,citation_author=Shubhayu Bhattacharyay;,citation_author=Ioan Milosevic;,citation_author=Lindsay Wilson;,citation_author=David K. Menon;,citation_author=Robert D. Stevens;,citation_author=Ewout W. Steyerberg;,citation_author=David W. Nelson;,citation_author=Ari Ercole;,citation_author=the CENTER-TBI Participants;,citation_publication_date=2022-07;,citation_cover_date=2022-07;,citation_year=2022;,citation_issue=7;,citation_doi=10.1371/journal.pone.0270973;,citation_issn=1932-6203;,citation_volume=17;,citation_language=en-US;,citation_journal_title=PLOS ONE;,citation_publisher=Public Library of Science;">
<meta name="citation_reference" content="citation_title=Development and validation of novel sepsis subphenotypes using trajectories of vital signs;,citation_abstract=PURPOSE: Sepsis is a heterogeneous syndrome and identification of sub-phenotypes is essential. This study used trajectories of vital signs to develop and validate sub-phenotypes and investigated the interaction of sub-phenotypes with treatment using randomized controlled trial data. METHODS: All patients with suspected infection admitted to four academic hospitals in Emory Healthcare between 2014-2017 (training cohort) and 2018-2019 (validation cohort) were included. Group-based trajectory modeling was applied to vital signs from the first 8&nbsp;h of hospitalization to develop and validate vitals trajectory sub-phenotypes. The associations between sub-phenotypes and outcomes were evaluated in patients with sepsis. The interaction between sub-phenotype and treatment with balanced crystalloids versus saline was tested in a secondary analysis of SMART (Isotonic Solutions and Major Adverse Renal Events Trial). RESULTS: There were 12,473 patients with suspected infection in training and 8256 patients in validation cohorts, and 4 vitals trajectory sub-phenotypes were found. Group A (N = 3483, 28%) were hyperthermic, tachycardic, tachypneic, and hypotensive. Group B (N = 1578, 13%) were hyperthermic, tachycardic, tachypneic (not as pronounced as Group A) and hypertensive. Groups C (N = 4044, 32%) and D (N = 3368, 27%) had lower temperatures, heart rates, and respiratory rates, with Group C normotensive and Group D hypotensive. In the 6,919 patients with sepsis, Groups A and B were younger while Groups C and D were older. Group A had the lowest prevalence of congestive heart failure, hypertension, diabetes mellitus, and chronic kidney disease, while Group B had the highest prevalence. Groups A and D had the highest vasopressor use (p &amp;amp;amp;lt; 0.001 for all analyses above). In logistic regression, 30-day mortality was significantly higher in Groups A and D (p &amp;lt; 0.001 and p = 0.03, respectively). In the SMART trial, sub-phenotype significantly modified treatment effect (p = 0.03). Group D had significantly lower odds of mortality with balanced crystalloids compared to saline (odds ratio (OR) 0.39, 95% confidence interval (CI) 0.23-0.67, p < 0.001). CONCLUSION: Sepsis sub-phenotypes based on vital sign trajectory were consistent across cohorts, had distinct outcomes, and different responses to treatment with balanced crystalloids versus saline.;,citation_author=Sivasubramanium V. Bhavani;,citation_author=Matthew Semler;,citation_author=Edward T. Qian;,citation_author=Philip A. Verhoef;,citation_author=Chad Robichaux;,citation_author=Matthew M. Churpek;,citation_author=Craig M. Coopersmith;,citation_publication_date=2022-09;,citation_cover_date=2022-09;,citation_year=2022;,citation_doi=10.1007/s00134-022-06890-z;,citation_issn=1432-1238;,citation_pmid=36152041;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Location of Subcortical Microbleeds and Recovery of Consciousness After Severe Traumatic Brain Injury;,citation_abstract=Background In patients with severe traumatic brain injury (TBI), coma is associated with impaired subcortical arousal mechanisms. However, it is unknown which nuclei involved in arousal (arousal nuclei) are implicated in coma pathogenesis and are compatible with coma recovery. Methods We mapped an atlas of arousal nuclei in the brainstem, thalamus, hypothalamus, and basal forebrain onto 3 tesla susceptibility-weighted images (SWI) in 12 patients with acute severe TBI who presented in coma and recovered consciousness within 6 months. We assessed the spatial distribution and volume of SWI microbleeds and evaluated the association of microbleed volume with the duration of unresponsiveness and functional recovery at 6 months. Results There was no single arousal nucleus affected by microbleeds in all patients. Rather, multiple combinations of microbleeds in brainstem, thalamic, and hypothalamic arousal nuclei were associated with coma and were compatible with recovery of consciousness. Microbleeds were frequently detected in the midbrain (100%), thalamus (83%), and pons (75%). Within the brainstem, the microbleed incidence was largest within the mesopontine tegmentum (e.g., pedunculotegmental nucleus, mesencephalic reticular formation) and ventral midbrain (e.g., substantia nigra, ventral tegmental area). Brainstem arousal nuclei were partially affected by microbleeds, with microbleed volume not exceeding 35% of brainstem nucleus volume on average. Compared to microbleed volume within nonarousal brainstem regions, the microbleed volume within arousal brainstem nuclei accounted for a larger proportion of variance in the duration of unresponsiveness and 6-month Glasgow Outcome Scale–Extended scores. Conclusion These results suggest resilience of arousal mechanisms in the human brain after severe TBI.;,citation_author=Marta Bianciardi;,citation_author=Saef Izzy;,citation_author=Bruce R. Rosen;,citation_author=Lawrence L. Wald;,citation_author=Brian L. Edlow;,citation_publication_date=2021-07;,citation_cover_date=2021-07;,citation_year=2021;,citation_issue=2;,citation_doi=10.1212/WNL.0000000000012192;,citation_issn=0028-3878, 1526-632X;,citation_volume=97;,citation_language=en-US;,citation_journal_title=Neurology;">
<meta name="citation_reference" content="citation_title=Comparisons against baseline within randomised groups are often used and can be highly misleading;,citation_abstract=Background: In randomised trials, rather than comparing randomised groups directly some researchers carry out a significance test comparing a baseline with a final measurement separately in each group. Methods: We give several examples where this has been done. We use simulation to demonstrate that the procedure is invalid and also show this algebraically. Results: This approach is biased and invalid, producing conclusions which are, potentially, highly misleading. The actual alpha level of this procedure can be as high as 0.50 for two groups and 0.75 for three. Conclusions: Randomised groups should be compared directly by two-sample methods and separate tests against baseline are highly misleading.;,citation_author=J Martin Bland;,citation_author=Douglas G Altman;,citation_publication_date=2011-12;,citation_cover_date=2011-12;,citation_year=2011;,citation_issue=1;,citation_doi=10.1186/1745-6215-12-264;,citation_issn=1745-6215;,citation_volume=12;,citation_language=en-US;,citation_journal_title=Trials;">
<meta name="citation_reference" content="citation_title=Statistics Notes: The odds ratio;,citation_author=J M. Bland;,citation_publication_date=2000-05;,citation_cover_date=2000-05;,citation_year=2000;,citation_issue=7247;,citation_doi=10.1136/bmj.320.7247.1468;,citation_issn=09598138;,citation_volume=320;,citation_language=en-US;,citation_journal_title=BMJ;">
<meta name="citation_reference" content="citation_title=Effect of Hemodiafiltration or Hemodialysis on Mortality in Kidney Failure;,citation_author=Peter J. Blankestijn;,citation_author=Robin W. M. Vernooij;,citation_author=Carinna Hockham;,citation_author=Giovanni F. M. Strippoli;,citation_author=Bernard Canaud;,citation_author=Jörgen Hegbrant;,citation_author=Claudia Barth;,citation_author=Adrian Covic;,citation_author=Krister Cromm;,citation_author=Andrea Cucui;,citation_author=Andrew Davenport;,citation_author=Matthias Rose;,citation_author=Marietta Török;,citation_author=Mark Woodward;,citation_author=Michiel L. Bots;,citation_publication_date=2023-08;,citation_cover_date=2023-08;,citation_year=2023;,citation_issue=8;,citation_doi=10.1056/NEJMoa2304820;,citation_issn=0028-4793;,citation_volume=389;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Order Substitutions and Education for Balanced Crystalloid Solution Use in an Integrated Health Care System and Association With Major Adverse Kidney Events;,citation_abstract=Trials comparing balanced crystalloids with normal saline have yielded mixed results regarding reductions in kidney complications and mortality for hospitalized patients receiving intravenous fluids.To evaluate the association of a multifaceted implementation program encouraging the preferential use of lactated Ringer solution with patient outcomes and intravenous fluid–prescribing practices in a large, multilevel health care system.This type 2 hybrid implementation and comparative effectiveness study enrolled all patients 18 years or older who received 1 L or more of intravenous fluids while admitted to an emergency department and/or inpatient unit at 1 of 22 hospitals in Idaho and Utah between November 1, 2018, and February 29, 2020. An interrupted time series analysis was used to assess study outcomes before and after interventions to encourage use of lactated Ringer solution.Implementation program combining order set modification, electronic order entry alerts, and sequential clinician-targeted education to encourage prescribing of lactated Ringer solution instead of normal saline.The primary implementation outcome was the patient-level proportion of intravenous fluids that was balanced crystalloids. The primary effectiveness outcome was the incidence of major adverse kidney events (MAKE30)—a composite of new persistent kidney dysfunction, new initiation of dialysis, and death—at 30 days.Among 148 423 patients (median [IQR] age, 47 [30-67] years; 91 302 women [61%]), the proportion of total fluids received that was lactated Ringer solution increased from 28% to 75% in the first week vs the last week of the study (immediate implementation effect odds ratio [OR], 3.44; 95% CI, 2.79-4.24). The estimated MAKE30 absolute risk reduction was 2.2% (95% CI, 1.3%-3.3%) based on interrupted time series analysis showing a decrease in the week-on-week trend for MAKE30 (OR difference, 0.03; 95% CI, 0.03-0.03, P &amp;amp;amp;lt; .001). The immediate postimplementation OR for MAKE30 was 0.88 (95% CI, 0.76-1.01), with a decrease in persistent kidney dysfunction (OR, 0.80; 95% CI, 0.69-0.93) and mortality (OR, 0.78; 95% CI, 0.65-0.93) but not dialysis (OR, 1.00; 95% CI, 0.76-1.32).In this comparative effectiveness study, an implementation program was associated with an increase in the proportion of fluids administered as lactated Ringer solution compared with normal saline and was associated with a reduction in MAKE30 events among patients treated in a large integrated health care system.;,citation_author=Joseph Bledsoe;,citation_author=Ithan D. Peltan;,citation_author=R. J. Bunnell;,citation_author=Samuel M. Brown;,citation_author=Al Jephson;,citation_author=Danielle Groat;,citation_author=Nicholas M. Levin;,citation_author=Emily Wilson;,citation_author=Jon Newbold;,citation_author=Gabriel V. Fontaine;,citation_author=Joe Frandsen;,citation_author=David Hasleton;,citation_author=Paul Krakovitz;,citation_author=Kim Brunisholz;,citation_author=Todd Allen;,citation_publication_date=2022-05;,citation_cover_date=2022-05;,citation_year=2022;,citation_issue=5;,citation_doi=10.1001/jamanetworkopen.2022.10046;,citation_issn=2574-3805;,citation_volume=5;,citation_journal_title=JAMA Network Open;">
<meta name="citation_reference" content="citation_title=Association between in-ICU red blood cells transfusion and 1-year mortality in ICU survivors;,citation_abstract=Impact of in-ICU transfusion on long-term outcomes remains unknown. The purpose of this study was to assess in critical-care survivors the association between in-ICU red blood cells transfusion and 1-year mortality.;,citation_author=Alice Blet;,citation_author=Joel B. McNeil;,citation_author=Julie Josse;,citation_author=Bernard Cholley;,citation_author=Raphaël Cinotti;,citation_author=Gad Cotter;,citation_author=Agnès Dauvergne;,citation_author=Beth Davison;,citation_author=Kévin Duarte;,citation_author=Jacques Duranteau;,citation_author=Marie-Céline Fournier;,citation_author=Etienne Gayat;,citation_author=Samir Jaber;,citation_author=Sigismond Lasocki;,citation_author=Thomas Merkling;,citation_author=Katell Peoc’h;,citation_author=Imke Mayer;,citation_author=Malha Sadoune;,citation_author=Pierre-François Laterre;,citation_author=Romain Sonneville;,citation_author=Lorraine Ware;,citation_author=Alexandre Mebazaa;,citation_author=Antoine Kimmoun;,citation_publication_date=2022-10;,citation_cover_date=2022-10;,citation_year=2022;,citation_issue=1;,citation_doi=10.1186/s13054-022-04171-1;,citation_issn=1364-8535;,citation_volume=26;,citation_journal_title=Critical Care;">
<meta name="citation_reference" content="citation_title=Ventilator-Free Day Outcomes Can Be Misleading;,citation_abstract=Introduction:&nbsp; Acute respiratory distress syndrome often requires invasive mechanical ventilation, with both mortality and mechanical ventilation duration as outcomes of interest. The concept of ventilator-free days has been proposed as an outcome combining these two outcomes. Here we analyzed the construction of the ventilator-free day outcome and provided a hypothetical scenario to alert physicians that such an outcome can lead to misleading interpretations. Methods:&nbsp; We proposed the isoventilator-free day curve concept and, using an analytical development, illustrated how a median ventilator-free day value can actually result from very different combinations of death rates and mechanical ventilation durations. We also used a hypothetical example to compare the Student t test, Wilcoxon rank-sum test, and Gray test (which accounts for death as a competing event with extubation) in comparing exposition to mechanical ventilation. Results:&nbsp; A median ventilator-free day value of 10 days may mean that 10% of the patients died while survivors were ventilated during a median of 14 days or that 40% died while survivors were ventilated during a median of 5 days. Changing the time horizon affected the Student t test but not the Wilcoxon rank-sum result. The Gray test was more relevant than both the Student t test and Wilcoxon rank-sum test in identifying differences in groups showing highly different mechanical ventilation duration, despite equal median ventilator-free days. This approach was also illustrated using real data. Conclusions:&nbsp; Use of ventilator-free days as an outcome appears to have many drawbacks. Suitable methods of analyzing time to extubation should be preferred.;,citation_author=Laetitia Bodet-Contentin;,citation_author=Denis Frasca;,citation_author=Elsa Tavernier;,citation_author=Fanny Feuillet;,citation_author=Yohann Foucher;,citation_author=Bruno Giraudeau;,citation_publication_date=2018-03;,citation_cover_date=2018-03;,citation_year=2018;,citation_issue=3;,citation_doi=10.1097/CCM.0000000000002890;,citation_issn=0090-3493;,citation_volume=46;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Association Between Statin Use and Intracerebral Hemorrhage Location: A Nested Case-Control Registry Study;,citation_abstract=Background: A causal relationship between statin use and intracerebral hemorrhage (ICH) is uncertain. We hypothesized that an association between long-term statin exposure and ICH risk might vary for different ICH locations. Methods: We conducted this analysis using linked Danish nationwide registries. Within the Southern Denmark Region (population 1.2 million), we identified all first-ever cases of ICH between 2009-2018 in persons ages &amp;amp;amp;gt;55 years. Patients with medical record verified diagnoses were classified as having a lobar or non-lobar ICH and matched for age, sex, and calendar year to general population controls. We used a nationwide prescription registry to ascertain prior statin and other medication use that we classified for recency, duration, and intensity. Using conditional logistic regression adjusted for potential confounders, we calculated adjusted odds ratios (aORs) and corresponding 95% Confidence Intervals (CIs) for the risk of lobar and non-lobar ICH. Results: We identified 989 patients with lobar ICH (52.2% women, mean age 76.3-years) who we matched to 39,500 controls, and 1,175 patients with non-lobar ICH (46.5% women, mean age 75.1-years) who we matched to 46,755 controls. Current statin use was associated with a lower risk of lobar (aOR 0.83; 95%CI, 0.70-0.98) and non-lobar ICH (aOR 0.84; 95%CI, 0.72-0.98). Longer duration of statin use was also associated with lower risk of lobar (&amp;lt;1 year: aOR 0.89; 95%CI, 0.69-1.14; \geq1 year to &amp;lt;5years aOR 0.89; 95%CI 0.73-1.09; \geq5 years aOR 0.67; 95%CI, 0.51-0.87; p for trend 0.040) and non-lobar ICH (<1 year: aOR1.00; 95%CI, 0.80-1.25; \geq1 year to <5years aOR 0.88; 95%CI 0.73-1.06; \geq5 years aOR 0.62; 95%CI, 0.48-0.80; p for trend <0.001). Estimates stratified by statin intensity were similar to the main estimates for low-medium intensity therapy (lobar aOR 0.82; non-lobar aOR 0.84); the association with high intensity therapy was neutral. Discussion: We found that statin use was associated with a lower risk of ICH, particularly with longer treatment duration. This association did not vary by hematoma location.;,citation_author=Nils Jensen Boe;,citation_author=Stine Munk Hald;,citation_author=Mie Micheelsen Jensen;,citation_author=Jonas Asgaard Bojsen;,citation_author=Mohammad Talal Elhakim;,citation_author=Sandra Florisson;,citation_author=Alisa Saleh;,citation_author=Anne Clausen;,citation_author=Sören Möller;,citation_author=Frederik Severin Gråe Harbo;,citation_author=Ole Graumann;,citation_author=Jesper Hallas;,citation_author=Luis Alberto García Rodríguez;,citation_author=Rustam Al-Shahi Salman;,citation_author=Larry B. Goldstein;,citation_author=David Gaist;,citation_publication_date=2022-12;,citation_cover_date=2022-12;,citation_year=2022;,citation_doi=10.1212/WNL.0000000000201664;,citation_issn=0028-3878, 1526-632X;,citation_language=en-US;,citation_journal_title=Neurology;,citation_publisher=Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology;">
<meta name="citation_reference" content="citation_title=Individualised versus conventional glucose control in critically-ill patients: The CONTROLING study—a randomized clinical trial;,citation_abstract=Purpose: Hyperglycaemia is an adaptive response to stress commonly observed in critical illness. Its management remains debated in the intensive care unit (ICU). Individualising hyperglycaemia management, by targeting the patient’s pre-admission usual glycaemia, could improve outcome. Methods: In a multicentre, randomized, double-blind, parallel-group study, critically-ill adults were considered for inclusion. Patients underwent until ICU discharge either individualised glucose control by targeting the pre-admission usual glycaemia using the glycated haemoglobin A1c level at ICU admission (IC group), or conventional glucose control by maintaining glycaemia below 180 mg/dL (CC group). A non-commercial web application of a dynamic sliding-scale insulin protocol gave to nurses all instructions for glucose control in both groups. The primary outcome was death within 90 days. Results: Owing to a low likelihood of benefit and evidence of the possibility of harm related to hypoglycaemia, the study was stopped early. 2075 patients were randomized; 1917 received the intervention, 942 in the IC group and 975 in the CC group. Although both groups showed significant differences in terms of glycaemic control, survival proba-bility at 90-day was not significantly different (IC group: 67.2%, 95% CI [64.2%; 70.3%]; CC group: 69.6%, 95% CI [66.7%; 72.5%]). Severe hypoglycaemia (below 40 mg/dL) occurred in 3.9% of patients in the IC group and in 2.5% of patients in the CC group (p = 0.09). A post hoc analysis showed for non-diabetic patients a higher risk of 90-day mortality in the IC group compared to the CC group (HR 1.3, 95% CI [1.05; 1.59], p = 0.018).;,citation_author=Julien Bohé;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Caregiver burden and health-related quality of life amongst caregivers of out-of-hospital cardiac arrest survivors;,citation_abstract=Methods: Data were collected from the cognitive substudy of the Targeted Temperature Management-trial. Caregiver burden was assessed with the 22-item Zarit Burden Interview, with scores 20 considered as no burden. Health-related quality of life was assessed with the SF-36v2Ò, with Tscores 47–53 representing the norm. Cardiac arrest survivors were categorized based on the results from cognitive assessments as having “no cognitive impairment” or “cognitive impairment”. Results: Follow-up 6 months post event was performed for caregivers of 272 cardiac arrest survivors and 108 matched myocardial infarction controls, included at an intended ratio of 2:1. In general, caregivers of cardiac arrest survivors and controls reported similar caregiver burden. The overall scores for quality of life were within normative levels and similar for caregivers of cardiac arrest survivors and control patients. Compared to those with no cognitive impairment, caregivers of cognitively impaired cardiac arrest survivors (n = 126) reported higher levels of burden (median 18 versus 8, p &amp;amp;amp;lt; 0.001) and worse quality of life in five of eight domains, particularly “Role-Emotional” (mean 45.7 versus 49.5, p = 0.002). Conclusions: In general, caregivers of cardiac arrest survivors and myocardial infarction controls reported similar levels of burden and quality of life. Cognitive outcome and functional dependency of the cardiac arrest survivor impact burden and quality of life of the caregiver.;,citation_author=Mattias Bohm;,citation_author=Tobias Cronberg;,citation_author=Kristofer Årestedt;,citation_author=Hans Friberg;,citation_author=Christian Hassager;,citation_author=Jesper Kjaergaard;,citation_author=Michael Kuiper;,citation_author=Niklas Nielsen;,citation_author=Susann Ullén;,citation_author=Johan Undén;,citation_author=Matt P. Wise;,citation_author=Gisela Lilja;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_doi=10.1016/j.resuscitation.2021.08.025;,citation_issn=03009572;,citation_volume=167;,citation_language=en-US;,citation_journal_title=Resuscitation;">
<meta name="citation_reference" content="citation_title=Current Best Practice for Presenting Probabilities in Patient Decision Aids: Fundamental Principles;,citation_abstract=Background Shared decision making requires evidence to be conveyed to the patient in a way they can easily understand and compare. Patient decision aids facilitate this process. This article reviews the current evidence for how to present numerical probabilities within patient decision aids. Methods Following the 2013 review method, we assembled a group of 9 international experts on risk communication across Australia, Germany, the Netherlands, the United Kingdom, and the United States. We expanded the topics covered in the first review to reflect emerging areas of research. Groups of 2 to 3 authors reviewed the relevant literature based on their expertise and wrote each section before review by the full authorship team. Results Of 10 topics identified, we present 5 fundamental issues in this article. Although some topics resulted in clear guidance (presenting the chance an event will occur, addressing numerical skills), other topics (context/evaluative labels, conveying uncertainty, risk over time) continue to have evolving knowledge bases. We recommend presenting numbers over a set time period with a clear denominator, using consistent formats between outcomes and interventions to enable unbiased comparisons, and interpreting the numbers for the reader to meet the needs of varying numeracy. Discussion Understanding how different numerical formats can bias risk perception will help decision aid developers communicate risks in a balanced, comprehensible manner and avoid accidental “nudging” toward a particular option. Decisions between probability formats need to consider the available evidence and user skills. The review may be useful for other areas of science communication in which unbiased presentation of probabilities is important.;,citation_author=Carissa Bonner;,citation_author=Lyndal J. Trevena;,citation_author=Wolfgang Gaissmaier;,citation_author=Paul K. J. Han;,citation_author=Yasmina Okan;,citation_author=Elissa Ozanne;,citation_author=Ellen Peters;,citation_author=Daniëlle Timmermans;,citation_author=Brian J. Zikmund-Fisher;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=7;,citation_doi=10.1177/0272989X21996328;,citation_issn=0272-989X, 1552-681X;,citation_volume=41;,citation_language=en-US;,citation_journal_title=Medical Decision Making;">
<meta name="citation_reference" content="citation_title=Acute respiratory distress syndrome: Causes, pathophysiology, and phenotypes;,citation_author=Lieuwe D. J. Bos;,citation_author=Lorraine B. Ware;,citation_publication_date=2022-10;,citation_cover_date=2022-10;,citation_year=2022;,citation_issue=10358;,citation_doi=10.1016/S0140-6736(22)01485-4;,citation_issn=0140-6736, 1474-547X;,citation_pmid=36070787;,citation_volume=400;,citation_language=en-US;,citation_journal_title=The Lancet;">
<meta name="citation_reference" content="citation_title=Longitudinal respiratory subphenotypes in patients with COVID-19-related acute respiratory distress syndrome: Results from three observational cohorts;,citation_abstract=Introduction Patients with COVID-19-related acute respiratory distress syndrome (ARDS) have been postulated to present with distinct respiratory subphenotypes. However, most phenotyping schema have been limited by sample size, disregard for temporal dynamics, and insufficient validation. We aimed to identify respiratory subphenotypes of COVID-19-related ARDS using unbiased data-driven approaches.;,citation_author=Lieuwe D J Bos;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Atrial Fibrillation in the ICU;,citation_abstract=Atrial fibrillation (AF) is the most common arrhythmia encountered in the ICU. Preexisting AF is highly prevalent among older patients with chronic conditions who are at risk for critical illness, whereas new-onset AF can be triggered by accelerated atrial remodeling and arrhythmogenic triggers encountered during critical illness. The acute loss of atrial systole and onset of rapid ventricular rates that characterize new-onset AF often lead to decreased cardiac output and hemodynamic compromise. Thus, new-onset AF is both a marker of disease severity as well as a likely contributor to poor outcomes, similar to other manifestations of organ dysfunction during critical illness. Evaluating immediate hemodynamic effects of new-onset AF during critical illness is an important component of rapid clinical assessment aimed at identifying patients in need of urgent direct current cardioversion, treatment of reversible inciting factors, and identification of patients who may benefit from pharmacologic rate or rhythm control. In addition to acute hemodynamic effects, new-onset AF during critical illness is associated with both short- and long-term increases in the risk of stroke, heart failure, and death, with AF recurrence rates of approximately 50%&nbsp;within 1 year following hospital discharge. In the absence of a strong evidence base, there is substantial practice variation in the choice of strategies for management of new-onset AF during critical illness. We describe acute and long-term evaluation and management strategies based on current evidence and propose future avenues of investigation to fill large knowledge gaps in the management of patients with AF during critical illness.;,citation_author=Nicholas A. Bosch;,citation_author=Jonathan Cimini;,citation_author=Allan J. Walkey;,citation_publication_date=2018-12;,citation_cover_date=2018-12;,citation_year=2018;,citation_issue=6;,citation_doi=10.1016/j.chest.2018.03.040;,citation_issn=0012-3692;,citation_pmid=29627355;,citation_volume=154;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Characterization and validation of a novel measure of septic shock severity;,citation_author=Nicholas A. Bosch;,citation_author=Bijan Teja;,citation_author=Hannah Wunsch;,citation_author=Allan J. Walkey;,citation_publication_date=2020-01;,citation_cover_date=2020-01;,citation_year=2020;,citation_issue=1;,citation_doi=10.1007/s00134-019-05837-1;,citation_issn=0342-4642, 1432-1238;,citation_volume=46;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Comparative Effectiveness of Fludrocortisone and Hydrocortisone vs Hydrocortisone Alone Among Patients With Septic Shock;,citation_abstract=OBJECTIVE To compare the effectiveness of adding fludrocortisone to hydrocortisone vs hydrocortisone alone among patients with septic shock using target trial emulation. DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study from 2016 to 2020 used the enhanced claims-based Premier Healthcare Database, which included approximately 25% of US hospitalizations. Participants were adult patients hospitalized with septic shock and receiving norepinephrine who began hydrocortisone treatment. Data analysis was performed from May 2022 to December 2022. EXPOSURE Addition of fludrocortisone on the same calendar day that hydrocortisone treatment was initiated vs use of hydrocortisone alone. MAIN OUTCOME AND MEASURES Composite of hospital death or discharge to hospice. Adjusted risk differences were calculated using doubly robust targeted maximum likelihood estimation. RESULTS Analyses included 88 275 patients, 2280 who began treatment with hydrocortisone-fludrocortisone (median [IQR] age, 64 [54-73] years; 1041 female; 1239 male) and 85 995 (median [IQR] age, 67 [57-76] years; 42 136 female; 43 859 male) who began treatment with hydrocortisone alone. The primary composite outcome of death in hospital or discharge to hospice occurred among 1076 (47.2%) patients treated with hydrocortisonefludrocortisone vs 43 669 (50.8%) treated with hydrocortisone alone (adjusted absolute risk difference, -3.7%; 95% CI, -4.2% to -3.1%; P &amp;amp;amp;lt; .001). CONCLUSIONS AND RELEVANCE In this comparative effectiveness cohort study among adult patients with septic shock who began hydrocortisone treatment, the addition of fludrocortisone was superior to hydrocortisone alone.;,citation_author=Nicholas A. Bosch;,citation_author=Bijan Teja;,citation_author=Anica C. Law;,citation_author=Brandon Pang;,citation_author=S. Reza Jafarzadeh;,citation_author=Allan J. Walkey;,citation_publication_date=2023-05;,citation_cover_date=2023-05;,citation_year=2023;,citation_issue=5;,citation_doi=10.1001/jamainternmed.2023.0258;,citation_issn=2168-6106;,citation_volume=183;,citation_language=en-US;,citation_journal_title=JAMA Internal Medicine;">
<meta name="citation_reference" content="citation_title=Death due to irreversible hypoxemic respiratory failure in ARDSnet clinical trials;,citation_author=Nicholas A. Bosch;,citation_author=Ming-Ming Lee;,citation_author=Mallory N. LeSieur;,citation_author=Anica C. Law;,citation_author=Allan J. Walkey;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_doi=10.1016/j.jcrc.2021.10.017;,citation_issn=08839441;,citation_volume=67;,citation_language=en-US;,citation_journal_title=Journal of Critical Care;">
<meta name="citation_reference" content="citation_title=Implementation of a Phenobarbital-based Pathway for Severe Alcohol Withdrawal: A Mixed-Method Study;,citation_abstract=Rationale: Several institutions have implemented phenobarbital-based pathways for the treatment of alcohol withdrawal syndrome (AWS). However, little is known about the care processes, effectiveness, and safety of phenobarbital-based pathways for intensive care unit (ICU) patients.;,citation_author=Nicholas A. Bosch;,citation_author=Erika L. Crable;,citation_author=Kimberly A. Ackerbauer;,citation_author=Kristopher Clark;,citation_author=Mari-Lynn Drainoni;,citation_author=Valerie Grim;,citation_author=Michael H. Ieong;,citation_author=Allan J. Walkey;,citation_author=Jaime Murphy;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=10;,citation_doi=10.1513/AnnalsATS.202102-121OC;,citation_issn=2329-6933, 2325-6621;,citation_volume=18;,citation_language=en-US;,citation_journal_title=Annals of the American Thoracic Society;">
<meta name="citation_reference" content="citation_title=Inhaled nitric oxide versus epoprostenol during acute respiratory failure: An observational target trial emulation;,citation_abstract=Background Inhaled vasodilators nitric oxide and epoprostenol may be initiated to improve oxygenation in mechanically ventilated patients with severe acute respiratory failure; however, practice patterns and head-to-head comparisons of effectiveness are unclear. Research Question What are the practice patterns and comparative effectiveness for inhaled nitric oxide and epoprostenol in severe acute respiratory failure? Study Design and Methods Using a large United States database (Premier Healthcare Database), we identified adult patients with acute respiratory failure or acute respiratory distress syndrome who were mechanically ventilated and started on inhaled nitric oxide, epoprostenol or both. Leveraging large hospital variation in the choice of initial inhaled vasodilator, we compared the effectiveness of inhaled nitric oxide to epoprostenol by limiting analysis to patients admitted to hospitals that exclusively used either inhaled nitric oxide or epoprostenol. The primary outcome of successful extubation was modeled using multivariable Fine-Grey competing risk (death or hospice discharge) time to event models. Results Among 11,200 patients (303 hospitals), 6,366 (56.8%) received inhaled nitric oxide first, 4,720 (42.1%) received inhaled epoprostenol first, and 114 (1.0%) received both therapies on the same day. 104 hospitals (34.3%; 1,666 patients) exclusively used nitric oxide and 118 hospitals (38.9%; 1,812 patients) exclusively used epoprostenol. There were no differences in the likelihood of successful extubation between patients admitted to nitric oxide-only hospitals versus epoprostenol-only hospitals (sub-distribution hazard ratio 0.97, 95% CI 0.80-1.18). There were also no differences in total hospital costs or death. Results were robust to multiple sensitivity analyses. Interpretation There is large variation in the use of initial inhaled vasodilator for respiratory failure across United hospitals. Comparative effectiveness analyses identified no differences in outcomes based on inhaled vasodilator type.;,citation_author=Nicholas A. Bosch;,citation_author=Anica C. Law;,citation_author=Emily A. Vail;,citation_author=Kari R. Gillmeyer;,citation_author=Hayley B. Gershengorn;,citation_author=Hannah Wunsch;,citation_author=Allan J. Walkey;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_doi=10.1016/j.chest.2022.08.001;,citation_issn=0012-3692;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Practice Patterns in the Initiation of Secondary Vasopressors and Adjunctive Corticosteroids during Septic Shock in the United States;,citation_abstract=Rationale: A central component of septic shock treatment is the infusion of vasopressors, most commonly starting with norepinephrine. However, the optimal approach and practice patterns for initiating adjunctive vasopressors and corticosteroids are unknown.;,citation_author=Nicholas A. Bosch;,citation_author=Bijan Teja;,citation_author=Hannah Wunsch;,citation_author=Allan J. Walkey;,citation_publication_date=2021-12;,citation_cover_date=2021-12;,citation_year=2021;,citation_issue=12;,citation_doi=10.1513/AnnalsATS.202102-196OC;,citation_issn=2329-6933, 2325-6621;,citation_volume=18;,citation_language=en-US;,citation_journal_title=Annals of the American Thoracic Society;">
<meta name="citation_reference" content="citation_title=Predictive Validity of the Sequential Organ Failure Assessment Score versus Claims-based Scores among Critically Ill Patients;,citation_author=Nicholas A. Bosch;,citation_author=Anica C. Law;,citation_author=Justin M. Rucci;,citation_author=Daniel Peterson;,citation_author=Allan J. Walkey;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_issue=6;,citation_doi=10.1513/AnnalsATS.202111-1251RL;,citation_issn=2329-6933, 2325-6621;,citation_volume=19;,citation_language=en-US;,citation_journal_title=Annals of the American Thoracic Society;">
<meta name="citation_reference" content="citation_title=Validation of the International Classification of Diseases Code for Coronavirus Disease 2019 among Critically Ill Patients;,citation_author=Nicholas A Bosch;,citation_author=Anica C Law;,citation_author=Daniel Peterson;,citation_author=Allan J Walkey;,citation_publication_date=2021-12;,citation_cover_date=2021-12;,citation_year=2021;,citation_doi=10.1513/AnnalsATS.202110-1147RL;,citation_issn=2329-6933, 2325-6621;,citation_language=en-US;,citation_journal_title=Annals of the American Thoracic Society;">
<meta name="citation_reference" content="citation_title=Effect of Early vs Standard Approach to Tracheostomy on Functional Outcome at 6 Months Among Patients With Severe Stroke Receiving Mechanical Ventilation: The SETPOINT2 Randomized Clinical Trial;,citation_abstract=OBJECTIVE To test whether early vs standard tracheostomy improved functional outcome among patients with stroke receiving mechanical ventilation. DESIGN, SETTING, AND PARTICIPANTS In this randomized clinical trial, 382 patients with severe acute ischemic or hemorrhagic stroke receiving invasive ventilation were randomly assigned (1:1) to early tracheostomy (Յ5 days of intubation) or ongoing ventilator weaning with standard tracheostomy if needed from day 10. Patients were randomized between July 28, 2015, and January 24, 2020, at 26 US and German neurocritical care centers. The final date of follow-up was August 9, 2020. INTERVENTIONS Patients were assigned to an early tracheostomy strategy (n = 188) or to a standard tracheostomy (control group) strategy (n = 194). MAIN OUTCOMES AND MEASURES The primary outcome was functional outcome at 6 months, based on the modified Rankin Scale score (range, 0 [best] to 6 [worst]) dichotomized to a score of 0 (no disability) to 4 (moderately severe disability) vs 5 (severe disability) or 6 (death). RESULTS Among 382 patients randomized (median age, 59 years; 49.8% women), 366 (95.8%) completed the trial with available follow-up data on the primary outcome (177 patients [94.1%] in the early group; 189 patients [97.4%] in the standard group). A tracheostomy (predominantly percutaneously) was performed in 95.2% of the early tracheostomy group in a median of 4 days after intubation (IQR, 3-4 days) and in 67% of the control group in a median of 11 days after intubation (IQR, 10-12 days). The proportion without severe disability (modified Rankin Scale score, 0-4) at 6 months was not significantly different in the early tracheostomy vs the control group (43.5% vs 47.1%; difference, -3.6% [95% CI, -14.3% to 7.2%]; adjusted odds ratio, 0.93 [95% CI, 0.60-1.42]; P = .73). Of the serious adverse events, 5.0% (6 of 121 reported events) in the early tracheostomy group vs 3.4% (4 of 118 reported events) were related to tracheostomy. CONCLUSIONS AND RELEVANCE Among patients with severe stroke receiving mechanical ventilation, a strategy of early tracheostomy, compared with a standard approach to tracheostomy, did not significantly improve the rate of survival without severe disability at 6 months. However, the wide confidence intervals around the effect estimate may include a clinically important difference, so a clinically relevant benefit or harm from a strategy of early tracheostomy cannot be excluded.;,citation_author=Julian Bösel;,citation_author=Wolf-Dirk Niesen;,citation_author=Farid Salih;,citation_author=Nicholas A. Morris;,citation_author=Jeremy T. Ragland;,citation_author=Bryan Gough;,citation_author=Hauke Schneider;,citation_author=Jan-Oliver Neumann;,citation_author=David Y. Hwang;,citation_author=Phani Kantamneni;,citation_author=Michael L. James;,citation_author=William D. Freeman;,citation_author=Venkatakrishna Rajajee;,citation_author=Chethan Venkatasubba Rao;,citation_author=Deepak Nair;,citation_author=Laura Benner;,citation_author=Jan Meis;,citation_author=Christina Klose;,citation_author=Meinhard Kieser;,citation_author=José I. Suarez;,citation_author=Silvia Schönenberger;,citation_author=David B. Seder;,citation_author=SETPOINT2 and the IGNITE Study Groups;,citation_author=Ahmad Ramadan;,citation_author=Jan Claassen;,citation_author=Stephan Mayer;,citation_author=Harry Peled;,citation_author=Thomas Christianson;,citation_author=Teresa L. May;,citation_author=Richard R. Riker;,citation_author=Golschan Asgarpur;,citation_author=Henning Stetefeld;,citation_author=Stefan Kluge;,citation_publication_date=2022-05;,citation_cover_date=2022-05;,citation_year=2022;,citation_issue=19;,citation_doi=10.1001/jama.2022.4798;,citation_issn=0098-7484;,citation_volume=327;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Extubation failure in patients with acute brain injury: A major problem still awaiting a solution;,citation_author=Julian Bösel;,citation_author=Alejandro A. Rabinstein;,citation_publication_date=2022-11;,citation_cover_date=2022-11;,citation_year=2022;,citation_issue=11;,citation_doi=10.1007/s00134-022-06856-1;,citation_issn=1432-1238;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=The effectiveness of targeted temperature management following cardiac arrest may depend on bystander cardiopulmonary resuscitation rates;,citation_author=Bernd W. Böttiger;,citation_author=Martin Hellmich;,citation_author=Wolfgang A. Wetsch;,citation_publication_date=2022-04;,citation_cover_date=2022-04;,citation_year=2022;,citation_issue=4;,citation_doi=10.1097/EJA.0000000000001663;,citation_issn=0265-0215, 1365-2346;,citation_volume=39;,citation_language=en-US;,citation_journal_title=European Journal of Anaesthesiology;">
<meta name="citation_reference" content="citation_title=High-Dose Dexamethasone and Oxygen Support Strategies in Intensive Care Unit Patients With Severe COVID-19 Acute Hypoxemic Respiratory Failure: The COVIDICUS Randomized Clinical Trial;,citation_abstract=The benefit of high-dose dexamethasone and oxygenation strategies vs standard of care for patients with severe acute hypoxemic respiratory failure (AHRF) caused by COVID-19 pneumonia is debated.To assess the benefit of high-dose dexamethasone compared with standard of care dexamethasone, and to assess the benefit of high-flow nasal oxygen (HFNo2) or continuous positive airway pressure (CPAP) compared with oxygen support standard of care (o2SC).This multicenter, placebo-controlled randomized clinical trial was conducted in 19 intensive care units (ICUs) in France from April 2020 to January 2021. Eligible patients were consecutive ICU-admitted adults with COVID-19 AHRF. Randomization used a 2  3 factorial design for dexamethasone and oxygenation strategies; patients not eligible for at least 1 oxygenation strategy and/or already receiving invasive mechanical ventilation (IMV) were only randomized for dexamethasone. All patients were followed-up for 60 days. Data were analyzed from May 26 to July 31, 2021.Patients received standard dexamethasone (dexamethasone-phosphate 6 mg/d for 10 days [or placebo prior to RECOVERY trial results communication]) or high-dose dexamethasone (dexamethasone-phosphate 20 mg/d on days 1-5 then 10 mg/d on days 6-10). Those not requiring IMV were additionally randomized to o2SC, CPAP, or HFNo2.The main outcomes were time to all-cause mortality, assessed at day 60, for the dexamethasone interventions, and time to IMV requirement, assessed at day 28, for the oxygenation interventions. Differences between intervention groups were calculated using proportional Cox models and expressed as hazard ratios (HRs).Among 841 screened patients, 546 patients (median [IQR] age, 67.4 [59.3-73.1] years; 414 [75.8%] men) were randomized between standard dexamethasone (276 patients, including 37 patients who received placebo) or high-dose dexamethasone (270 patients). Of these, 333 patients were randomized among o2SC (109 patients, including 56 receiving standard dexamethasone), CPAP (109 patients, including 57 receiving standard dexamethasone), and HFNo2 (115 patients, including 56 receiving standard dexamethasone). There was no difference in 60-day mortality between standard and high-dose dexamethasone groups (HR, 0.96 [95% CI, 0.69-1.33]; P = .79). There was no significant difference for the cumulative incidence of IMV criteria at day 28 among o2 support groups (o2SC vs CPAP: HR, 1.08 [95% CI, 0.71-1.63]; o2SC vs HFNo2: HR, 1.04 [95% CI, 0.69-1.55]) or 60-day mortality (o2SC vs CPAP: HR, 0.97 [95% CI, 0.58-1.61; o2SC vs HFNo2: HR, 0.89 [95% CI, 0.53-1.47]). Interactions between interventions were not significant.In this randomized clinical trial among ICU patients with COVID-19–related AHRF, high-dose dexamethasone did not significantly improve 60-day survival. The oxygenation strategies in patients who were not initially receiving IMV did not significantly modify 28-day risk of IMV requirement.ClinicalTrials.gov Identifier: NCT04344730; EudraCT: 2020-001457-43.;,citation_author=Lila Bouadma;,citation_author=Armand Mekontso-Dessap;,citation_author=Charles Burdet;,citation_author=Hamid Merdji;,citation_author=Julien Poissy;,citation_author=Claire Dupuis;,citation_author=Christophe Guitton;,citation_author=Carole Schwebel;,citation_author=Yves Cohen;,citation_author=Cedric Bruel;,citation_author=Mehdi Marzouk;,citation_author=Guillaume Geri;,citation_author=Charles Cerf;,citation_author=Bruno Mégarbane;,citation_author=Pierre Garçon;,citation_author=Eric Kipnis;,citation_author=Benoit Visseaux;,citation_author=Naima Beldjoudi;,citation_author=Sylvie Chevret;,citation_author=Jean-François Timsit;,citation_author=COVIDICUS Study Group;,citation_publication_date=2022-07;,citation_cover_date=2022-07;,citation_year=2022;,citation_doi=10.1001/jamainternmed.2022.2168;,citation_issn=2168-6106;,citation_journal_title=JAMA Internal Medicine;">
<meta name="citation_reference" content="citation_title=Epinephrine versus norepinephrine in cardiac arrest patients with post-resuscitation shock;,citation_abstract=Purpose: Whether epinephrine or norepinephrine is preferable as the continuous intravenous vasopressor used to treat post-resuscitation shock is unclear. We assessed outcomes of patients with post-resuscitation shock after out-of-hospital cardiac arrest according to whether the continuous intravenous vasopressor used was epinephrine or norepinephrine. Methods: We conducted an observational multicenter study of consecutive patients managed in 2011–2018 for post-resuscitation shock. The primary outcome was all-cause hospital mortality, and secondary outcomes were cardiovascular hospital mortality and unfavorable neurological outcome (Cerebral Performance Category 3–5). A mul-tivariate regression analysis and a propensity score analysis were performed, as well as several sensitivity analyses. Results: Of the 766 patients included in five hospitals, 285 (37%) received epinephrine and 481 (63%) norepineph-rine. All-cause hospital mortality was significantly higher in the epinephrine group (OR 2.6; 95%CI 1.4–4.7; P = 0.002). Cardiovascular hospital mortality was also higher with epinephrine (aOR 5.5; 95%CI 3.0–10.3; P &amp;amp;amp;lt; 0.001), as was the proportion of patients with CPC of 3–5 at hospital discharge. Sensitivity analyses produced consistent results. The analysis involving adjustment on a propensity score to control for confounders showed similar findings (aOR 2.1; 95%CI 1.1–4.0; P = 0.02). Conclusion: Among patients with post-resuscitation shock after out-of-hospital cardiac arrest, use of epinephrine was associated with higher all-cause and cardiovascular-specific mortality, compared with norepinephrine infusion. Until additional data become available, intensivists may want to choose norepinephrine rather than epinephrine for the treatment of post-resuscitation shock after OHCA.;,citation_author=Wulfran Bougouin;,citation_author=Kaci Slimani;,citation_author=Marie Renaudier;,citation_author=Yannick Binois;,citation_author=Marine Paul;,citation_author=Florence Dumas;,citation_author=Lionel Lamhaut;,citation_author=Thomas Loeb;,citation_author=Sofia Ortuno;,citation_author=Nicolas Deye;,citation_author=Sebastian Voicu;,citation_author=Frankie Beganton;,citation_author=Daniel Jost;,citation_author=Armand Mekontso-Dessap;,citation_author=Eloi Marijon;,citation_author=Xavier Jouven;,citation_author=Nadia Aissaoui;,citation_author=Alain Cariou;,citation_author=the Sudden Death Expertise Center Investigators;,citation_author=F. Adnet;,citation_author=J. M. Agostinucci;,citation_author=N. Aissaoui-Balanant;,citation_author=V. Algalarrondo;,citation_author=F. Alla;,citation_author=C. Alonso;,citation_author=W. Amara;,citation_author=D. Annane;,citation_author=C. Antoine;,citation_author=P. Aubry;,citation_author=E. Azoulay;,citation_author=F. Beganton;,citation_author=C. Billon;,citation_author=W. Bougouin;,citation_author=J. Boutet;,citation_author=C. Bruel;,citation_author=P. Bruneval;,citation_author=A. Cariou;,citation_author=P. Carli;,citation_author=E. Casalino;,citation_author=C. Cerf;,citation_author=A. Chaib;,citation_author=B. Cholley;,citation_author=Y. Cohen;,citation_author=A. Combes;,citation_author=J. M. Coulaud;,citation_author=M. Crahes;,citation_author=D. Da Silva;,citation_author=V. Das;,citation_author=A. Demoule;,citation_author=I Denjoy;,citation_author=N. Deye;,citation_author=J. L. Diehl;,citation_author=S. Dinanian;,citation_author=L. Domanski;,citation_author=D. Dreyfuss;,citation_author=D. Duboc;,citation_author=J. L. Dubois-Rande;,citation_author=F. Dumas;,citation_author=J. Duranteau;,citation_author=J. P. Empana;,citation_author=F. Extramiana;,citation_author=J. Y. Fagon;,citation_author=M. Fartoukh;,citation_author=F. Fieux;,citation_author=M. Gabbas;,citation_author=E. Gandjbakhch;,citation_author=G. Geri;,citation_author=B. Guidet;,citation_author=F. Halimi;,citation_author=P. Henry;,citation_author=F. Hidden Lucet;,citation_author=P. Jabre;,citation_author=L. Joseph;,citation_author=D. Jost;,citation_author=X. Jouven;,citation_author=N. Karam;,citation_author=H. Kassim;,citation_author=J. Lacotte;,citation_author=K. Lahlou-Laforet;,citation_author=L. Lamhaut;,citation_author=A. Lanceleur;,citation_author=O. Langeron;,citation_author=T. Lavergne;,citation_author=E. Lecarpentier;,citation_author=A. Leenhardt;,citation_author=N. Lellouche;,citation_author=V. Lemiale;,citation_author=F. Lemoine;,citation_author=F. Linval;,citation_author=T. Loeb;,citation_author=B. Ludes;,citation_author=C. E. Luyt;,citation_author=A. Maltret;,citation_author=N. Mansencal;,citation_author=N. Mansouri;,citation_author=E. Marijon;,citation_author=J. Marty;,citation_author=E. Maury;,citation_author=V. Maxime;,citation_author=B. Megarbane;,citation_author=A. Mekontso-Dessap;,citation_author=H. Mentec;,citation_author=J. P. Mira;,citation_author=X. Monnet;,citation_author=K. Narayanan;,citation_author=N. Ngoyi;,citation_author=M. C. Perier;,citation_author=O. Piot;,citation_author=R. Pirracchio;,citation_author=P. Plaisance;,citation_author=B. Plaud;,citation_author=I. Plu;,citation_author=J. H. Raphalen;,citation_author=M. Raux;,citation_author=F. Revaux;,citation_author=J. D. Ricard;,citation_author=C. Richard;,citation_author=B. Riou;,citation_author=F. Roussin;,citation_author=F. Santoli;,citation_author=F. Schortgen;,citation_author=A. Sharifzadehgan;,citation_author=T. Sharshar;,citation_author=G. Sideris;,citation_author=T. Similowski;,citation_author=C. Spaulding;,citation_author=J. L. Teboul;,citation_author=J. F. Timsit;,citation_author=J. P. Tourtier;,citation_author=P. Tuppin;,citation_author=C. Ursat;,citation_author=O. Varenne;,citation_author=A. Vieillard-Baron;,citation_author=S. Voicu;,citation_author=K. Wahbi;,citation_author=V. Waldman;,citation_publication_date=2022-03;,citation_cover_date=2022-03;,citation_year=2022;,citation_issue=3;,citation_doi=10.1007/s00134-021-06608-7;,citation_issn=0342-4642, 1432-1238;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=When Someone Should Do Something About This: How a Cryptococcal Clinical Trialist Became Involved With the Coronavirus Disease 2019 Pandemic;,citation_author=David R Boulware;,citation_publication_date=2023-11;,citation_cover_date=2023-11;,citation_year=2023;,citation_doi=10.1093/cid/ciad648;,citation_issn=1058-4838, 1537-6591;,citation_language=en-US;,citation_journal_title=Clinical Infectious Diseases;">
<meta name="citation_reference" content="citation_title=Efficacy and Safety of Early Administration of 4-Factor Prothrombin Complex Concentrate in Patients With Trauma at Risk of Massive Transfusion: The PROCOAG Randomized Clinical Trial;,citation_abstract=Optimal transfusion strategies in traumatic hemorrhage are unknown. Reports suggest a beneficial effect of 4-factor prothrombin complex concentrate (4F-PCC) on blood product consumption.To investigate the efficacy and safety of 4F-PCC administration in patients at risk of massive transfusion.Double-blind, randomized, placebo-controlled superiority trial in 12 French designated level I trauma centers from December 29, 2017, to August 31, 2021, involving consecutive patients with trauma at risk of massive transfusion. Follow-up was completed on August 31, 2021.Intravenous administration of 1 mL/kg of 4F-PCC (25 IU of factor IX/kg) vs 1 mL/kg of saline solution (placebo). Patients, investigators, and data analysts were blinded to treatment assignment. All patients received early ratio-based transfusion (packed red blood cells:fresh frozen plasma ratio of 1:1 to 2:1) and were treated according to European traumatic hemorrhage guidelines.The primary outcome was 24-hour all blood product consumption (efficacy); arterial or venous thromboembolic events were a secondary outcome (safety).Of 4313 patients with the highest trauma level activation, 350 were eligible for emergency inclusion, 327 were randomized, and 324 were analyzed (164 in the 4F-PCC group and 160 in the placebo group). The median (IQR) age of participants was 39 (27-56) years, Injury Severity Score was 36 (26-50 [major trauma]), and admission blood lactate level was 4.6 (2.8-7.4) mmol/L; prehospital arterial systolic blood pressure was less than 90 mm Hg in 179 of 324 patients (59%), 233 patients (73%) were men, and 226 (69%) required expedient hemorrhage control. There was no statistically or clinically significant between-group difference in median (IQR) total 24-hour blood product consumption (12 [5-19] U in the 4F-PCC group vs 11 [6-19] U in the placebo group; absolute difference, 0.2 U [95% CI, -2.99 to 3.33]; P = .72). In the 4F-PCC group, 56 patients (35%) presented with at least 1 thromboembolic event vs 37 patients (24%) in the placebo group (absolute difference, 11% [95% CI, 1%-21%]; relative risk, 1.48 [95% CI, 1.04-2.10]; P = .03).Among patients with trauma at risk of massive transfusion, there was no significant reduction of 24-hour blood product consumption after administration of 4F-PCC, but thromboembolic events were more common. These findings do not support systematic use of 4F-PCC in patients at risk of massive transfusion.ClinicalTrials.gov Identifier: NCT03218722;,citation_author=Pierre Bouzat;,citation_author=Jonathan Charbit;,citation_author=Paer-Selim Abback;,citation_author=Delphine Huet-Garrigue;,citation_author=Nathalie Delhaye;,citation_author=Marc Leone;,citation_author=Guillaume Marcotte;,citation_author=Jean-Stéphane David;,citation_author=Albrice Levrat;,citation_author=Karim Asehnoune;,citation_author=Julien Pottecher;,citation_author=Jacques Duranteau;,citation_author=Elie Courvalin;,citation_author=Anais Adolle;,citation_author=Dimitri Sourd;,citation_author=Jean-Luc Bosson;,citation_author=Bruno Riou;,citation_author=Tobias Gauss;,citation_author=Jean-François Payen;,citation_author=PROCOAG Study Group;,citation_publication_date=2023-03;,citation_cover_date=2023-03;,citation_year=2023;,citation_doi=10.1001/jama.2023.4080;,citation_issn=0098-7484;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=HIV-associated opportunistic CNS infections: Pathophysiology, diagnosis and treatment;,citation_abstract=Nearly 30 years after the advent of antiretroviral therapy (ART), CNS opportunistic infections remain a major cause of morbidity and mortality in HIV-positive individuals. Unknown HIV-positive disease status, antiretroviral drug resistance, poor drug compliance, and recreational drug abuse are factors that continue to influence the morbidity and mortality of infections. The clinical and radiographic pattern of CNS opportunistic infections is unique in the setting of HIV infection: opportunistic infections in HIV-positive patients often have characteristic clinical and radiological presentations that can differ from the presentation of opportunistic infections in immunocompetent patients and are often sufficient to establish the diagnosis. ART in the setting of these opportunistic infections can lead to a paradoxical worsening caused by an immune reconstitution inflammatory syndrome (IRIS). In this Review, we discuss several of the most common CNS opportunistic infections: cerebral toxoplasmosis, progressive multifocal leuko encephalopathy (PML), tuberculous meningitis, cryptococcal meningitis and cytomegalovirus infection, with an emphasis on clinical pearls, pathological findings, MRI findings and treatment. Moreover, we discuss the risk factors, pathophysiology and management of IRIS. We also summarize the challenges that remain in management of CNS opportunistic infections, which includes the lack of phase II and III clinical trials, absence of antimicrobials for infections such as PML, and controversy regarding the use of corticosteroids for treatment of IRIS.;,citation_author=Lauren N. Bowen;,citation_author=Bryan Smith;,citation_author=Daniel Reich;,citation_author=Martha Quezado;,citation_author=Avindra Nath;,citation_publication_date=2016-11;,citation_cover_date=2016-11;,citation_year=2016;,citation_issue=11;,citation_doi=10.1038/nrneurol.2016.149;,citation_issn=1759-4758, 1759-4766;,citation_volume=12;,citation_language=en-US;,citation_journal_title=Nature Reviews Neurology;">
<meta name="citation_reference" content="citation_title=Improving Traumatic Brain Injury Care and Research: A Report From the National Academies of Sciences, Engineering, and Medicine;,citation_author=Katherine Bowman;,citation_author=Chanel Matney;,citation_author=Donald M. Berwick;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_issue=5;,citation_doi=10.1001/jama.2022.0089;,citation_issn=0098-7484;,citation_volume=327;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Immediate versus Postponed Intervention for Infected Necrotizing Pancreatitis;,citation_abstract=BACKGROUND Infected necrotizing pancreatitis is a potentially lethal disease that is treated with the use of a step-up approach, with catheter drainage often delayed until the infected necrosis is encapsulated. Whether outcomes could be improved by earlier catheter drainage is unknown. METHODS We conducted a multicenter, randomized superiority trial involving patients with infected necrotizing pancreatitis, in which we compared immediate drainage within 24 hours after randomization once infected necrosis was diagnosed with drainage that was postponed until the stage of walled-off necrosis was reached. The primary end point was the score on the Comprehensive Complication Index, which incorporates all complications over the course of 6 months of follow-up. RESULTS A total of 104 patients were randomly assigned to immediate drainage (55 patients) or postponed drainage (49 patients). The mean score on the Comprehensive Complication Index (scores range from 0 to 100, with higher scores indicating more severe complications) was 57 in the immediate-drainage group and 58 in the postponed-drainage group (mean difference, -1; 95% confidence interval [CI], -12 to 10; P = 0.90). Mortality was 13% in the immediate-drainage group and 10% in the postponed-drainage group (relative risk, 1.25; 95% CI, 0.42 to 3.68). The mean number of interventions (catheter drainage and necrosectomy) was 4.4 in the immediate-drainage group and 2.6 in the postponed-drainage group (mean difference, 1.8; 95% CI, 0.6 to 3.0). In the postponed-drainage group, 19 patients (39%) were treated conservatively with antibiotics and did not require drainage; 17 of these patients survived. The incidence of adverse events was similar in the two groups. CONCLUSIONS This trial did not show the superiority of immediate drainage over postponed drainage with regard to complications in patients with infected necrotizing pancreatitis. Patients randomly assigned to the postponed-drainage strategy received fewer invasive interventions. (Funded by Fonds NutsOhra and Amsterdam UMC; POINTER ISRCTN Registry number, ISRCTN33682933.);,citation_author=Lotte Boxhoorn;,citation_author=Sven M. Dijk;,citation_author=Janneke Grinsven;,citation_author=Robert C. Verdonk;,citation_author=Marja A. Boermeester;,citation_author=Thomas L. Bollen;,citation_author=Stefan A. W. Bouwense;,citation_author=Marco J. Bruno;,citation_author=Vincent C. Cappendijk;,citation_author=Cornelis H. C. Dejong;,citation_author=Peter Duijvendijk;,citation_author=Casper H. J. Eijck;,citation_author=Paul Fockens;,citation_author=Michiel F. G. Francken;,citation_author=Harry Goor;,citation_author=Muhammed Hadithi;,citation_author=Nora D. L. Hallensleben;,citation_author=Jan Willem Haveman;,citation_author=Maarten A. J. M. Jacobs;,citation_author=Jeroen M. Jansen;,citation_author=Marnix P. M. Kop;,citation_author=Krijn P. Lienden;,citation_author=Eric R. Manusama;,citation_author=J. Sven D. Mieog;,citation_author=I. Quintus Molenaar;,citation_author=Vincent B. Nieuwenhuijs;,citation_author=Alexander C. Poen;,citation_author=Jan-Werner Poley;,citation_author=Marcel Poll;,citation_author=Rutger Quispel;,citation_author=Tessa E. H. Römkens;,citation_author=Matthijs P. Schwartz;,citation_author=Tom C. Seerden;,citation_author=Martijn W. J. Stommel;,citation_author=Jan Willem A. Straathof;,citation_author=Hester C. Timmerhuis;,citation_author=Niels G. Venneman;,citation_author=Rogier P. Voermans;,citation_author=Wim Vrie;,citation_author=Ben J. Witteman;,citation_author=Marcel G. W. Dijkgraaf;,citation_author=Hjalmar C. Santvoort;,citation_author=Marc G. Besselink;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=15;,citation_doi=10.1056/NEJMoa2100826;,citation_issn=0028-4793, 1533-4406;,citation_volume=385;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=The Fragility of Evidence in Critical Care Research: Is It Just a House of Cards?;,citation_author=Owen Boyd;,citation_publication_date=2016;,citation_cover_date=2016;,citation_year=2016;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Head-to-head comparison of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in advanced pancreatic cancer: A target trial emulation using real-world data;,citation_abstract=Purpose To emulate a hypothetical target trial assessing the effect of initiating 5-fluorouracil, folinic acid, irinotecan, and oxaliplatin (FOLFIRINOX) versus gemcitabine plus nab-paclitaxel (GN) within 8 weeks of diagnosis on overall survival. Methods An observational cohort study was conducted using population-level data from Alberta, Canada. Individuals diagnosed with advanced pancreatic cancer between April 2015 and December 2019 were identified through the provincial cancer registry and followed until March 2021. Records were linked to other administrative databases containing information on relevant variables. Individuals were excluded if they did not have adequate hemoglobin, platelet, white blood cell, and serum creatinine measures or if they received prior therapy. The observational analog of the per-protocol effect was estimated using inverse probability weighted Kaplan-Meier curves with bootstrapped 95% confidence intervals. Results Four hundred seven individuals were eligible. The weighted median overall survival was 8.3 months (95% CI, 5.7–11.9) for FOLFIRINOX and 5.1 months (95% CI: 4.3 to 5.8) for GN. The adjusted difference in median overall survival was 3.2 months (95% CI, 1.1–7.4) and the mortality hazard ratio was 0.78 (95% CI, 0.61–0.97). Conclusions Our estimates favored the initiation of FOLFIRINOX over GN with respect to overall survival.;,citation_author=Devon J. Boyne;,citation_author=Darren R. Brenner;,citation_author=Alind Gupta;,citation_author=Eric Mackay;,citation_author=Paul Arora;,citation_author=Radek Wasiak;,citation_author=Winson Y Cheung;,citation_author=Miguel A. Hernán;,citation_publication_date=2023-02;,citation_cover_date=2023-02;,citation_year=2023;,citation_doi=10.1016/j.annepidem.2022.12.005;,citation_issn=1047-2797;,citation_volume=78;,citation_language=en-US;,citation_journal_title=Annals of Epidemiology;">
<meta name="citation_reference" content="citation_title=Social Media and Mental Health;,citation_abstract=The diffusion of social media coincided with a worsening of mental health conditions among adolescents and young adults in the United States, giving rise to speculation that social media might be detrimental to mental health. In this paper, we provide the first quasi-experimental estimates of the impact of social media on mental health by leveraging a unique natural experiment: the staggered introduction of Facebook across U.S. colleges. Our analysis couples data on student mental health around the years of Facebook’s expansion with a generalized difference-in-differences empirical strategy. We find that the roll-out of Facebook at a college increased symptoms of poor mental health, especially depression, and led to increased utilization of mental healthcare services. We also find that, according to the students’ reports, the decline in mental health translated into worse academic performance. Additional evidence on mechanisms suggests the results are due to Facebook fostering unfavorable social comparisons.;,citation_author=Luca Braghieri;,citation_author=Ro’ee Levy;,citation_author=Alexey Makarin;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=EBM’s Six Dangerous Words;,citation_abstract=The six most dangerous words in evidence-based medicine (EBM) do not directly cause deaths or adverse events. They do not directly cause medical errors or diminutions in quality of care. However, they may indirectly cause these adverse consequences by leading to false inferences for decision making. Consider the following statements, each of which includes the six most dangerous words:\bullet There is no evidence to suggest that hospitalizing compared with not hospitalizing patients with acute shortness of breath reduces mortality.;,citation_author=R. Scott Braithwaite;,citation_publication_date=2020-05;,citation_cover_date=2020-05;,citation_year=2020;,citation_issue=17;,citation_doi=10.1001/jama.2020.2855;,citation_issn=0098-7484;,citation_volume=323;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19;,citation_author=Carolyn T. Bramante;,citation_author=Jared D. Huling;,citation_author=Christopher J. Tignanelli;,citation_author=John B. Buse;,citation_author=David M. Liebovitz;,citation_author=Jacinda M. Nicklas;,citation_author=Kenneth Cohen;,citation_author=Michael A. Puskarich;,citation_author=Hrishikesh K. Belani;,citation_author=Jennifer L. Proper;,citation_author=Lianne K. Siegel;,citation_author=Nichole R. Klatt;,citation_author=David J. Odde;,citation_author=Darlette G. Luke;,citation_author=Blake Anderson;,citation_author=Amy B. Karger;,citation_author=Nicholas E. Ingraham;,citation_author=Katrina M. Hartman;,citation_author=Via Rao;,citation_author=Aubrey A. Hagen;,citation_author=Barkha Patel;,citation_author=Sarah L. Fenno;,citation_author=Nandini Avula;,citation_author=Neha V. Reddy;,citation_author=Spencer M. Erickson;,citation_author=Sarah Lindberg;,citation_author=Regina Fricton;,citation_author=Samuel Lee;,citation_author=Adnin Zaman;,citation_author=Hanna G. Saveraid;,citation_author=Walker J. Tordsen;,citation_author=Matthew F. Pullen;,citation_author=Michelle Biros;,citation_author=Nancy E. Sherwood;,citation_author=Jennifer L. Thompson;,citation_author=David R. Boulware;,citation_author=Thomas A. Murray;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_issue=7;,citation_doi=10.1056/NEJMoa2201662;,citation_issn=0028-4793;,citation_volume=387;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Is High-Dose Vitamin C Beneficial for Patients With Sepsis?;,citation_author=Emily B. Brant;,citation_author=Derek C. Angus;,citation_publication_date=2019-10;,citation_cover_date=2019-10;,citation_year=2019;,citation_issue=13;,citation_doi=10.1001/jama.2019.11643;,citation_issn=1538-3598;,citation_pmid=31573621;,citation_volume=322;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Intracranial pressure pulse morphology: The missing link?;,citation_author=Sérgio Brasil;,citation_publication_date=2022-11;,citation_cover_date=2022-11;,citation_year=2022;,citation_issue=11;,citation_doi=10.1007/s00134-022-06855-2;,citation_issn=1432-1238;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Losing the dogmatic view of cerebral autoregulation;,citation_abstract=In 1959, Niels Lassen illustrated the cerebral autoregulation curve in the classic review article entitled Cerebral Blood Flow and Oxygen Consumption in Man. This concept suggested a relatively broad mean arterial pressure range (~60– mmHg) wherein cerebral blood flow remains constant. However, the assumption that this wide cerebral autoregulation plateau could be applied on a within-individual basis is incorrect and greatly variable between individuals. Indeed, each data point on the autoregulatory curve originated from independent samples of participants and patients and represented interindividual relationships between cerebral blood flow and mean arterial pressure. Nonetheless, this influential concept remains commonly cited and illustrated in various high-impact publications and medical textbooks, and is frequently taught in medical and science education without appropriate nuances and caveats.;,citation_author=Patrice Brassard;,citation_author=Lawrence Labrecque;,citation_author=Jonathan D. Smirl;,citation_author=Michael M. Tymko;,citation_author=Hannah G. Caldwell;,citation_author=Ryan L. Hoiland;,citation_author=Samuel J. E. Lucas;,citation_author=André Y. Denault;,citation_author=Etienne J. Couture;,citation_author=Philip N. Ainslie;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_issue=15;,citation_doi=10.14814/phy2.14982;,citation_issn=2051-817X, 2051-817X;,citation_volume=9;,citation_language=en-US;,citation_journal_title=Physiological Reports;">
<meta name="citation_reference" content="citation_title=Clinical impact of syndromic molecular point-of-care testing for gastrointestinal pathogens in adults hospitalised with suspected gastroenteritis (GastroPOC): A pragmatic, open-label, randomised controlled trial;,citation_abstract=Background Single-occupancy isolation rooms are a finite resource in UK hospitals but are crucial in preventing transmission of infection. Patients with suspected gastroenteritis are nursed in single-occupancy rooms, but delays in laboratory testing lead to non-infectious patients remaining isolated for prolonged periods unnecessarily. Rapid molecular test panels for gastrointestinal pathogens have a run time of around 1 h but their clinical impact is unknown. We aimed to evaluate the clinical impact of syndromic molecular point-of-care testing (mPOCT) for gastrointestinal pathogens in adult patients presenting to hospital with suspected gastroenteritis on single-occupancy room use and a range of other outcome measures.;,citation_author=Nathan J Brendish;,citation_author=Kate R Beard;,citation_author=Ahalya K Malachira;,citation_author=Alex R Tanner;,citation_author=Langizya Sanga-Nyirongo;,citation_author=Markus Gwiggner;,citation_author=J R Fraser Cummings;,citation_author=Helen E Moyses;,citation_author=Tristan W Clark;,citation_publication_date=2023-04;,citation_cover_date=2023-04;,citation_year=2023;,citation_doi=10.1016/S1473-3099(23)00066-X;,citation_issn=14733099;,citation_language=en-US;,citation_journal_title=The Lancet Infectious Diseases;">
<meta name="citation_reference" content="citation_title=Fusion designs and estimators for treatment effects;,citation_author=Alexander Breskin;,citation_author=Stephen R. Cole;,citation_author=Jessie K. Edwards;,citation_author=Ron Brookmeyer;,citation_author=Joseph J. Eron;,citation_author=Adimora A. Adimora;,citation_publication_date=2021-06;,citation_cover_date=2021-06;,citation_year=2021;,citation_issue=13;,citation_doi=10.1002/sim.8963;,citation_issn=0277-6715, 1097-0258;,citation_volume=40;,citation_language=en-US;,citation_journal_title=Statistics in Medicine;">
<meta name="citation_reference" content="citation_title=Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death;,citation_author=Michael Bretthauer;,citation_author=Magnus Løberg;,citation_author=Paulina Wieszczy;,citation_author=Mette Kalager;,citation_author=Louise Emilsson;,citation_author=Kjetil Garborg;,citation_author=Maciej Rupinski;,citation_author=Evelien Dekker;,citation_author=Manon Spaander;,citation_author=Marek Bugajski;,citation_author=Øyvind Holme;,citation_author=Ann G. Zauber;,citation_author=Nastazja D. Pilonis;,citation_author=Andrzej Mroz;,citation_author=Ernst J. Kuipers;,citation_author=Joy Shi;,citation_author=Miguel A. Hernán;,citation_author=Hans-Olov Adami;,citation_author=Jaroslaw Regula;,citation_author=Geir Hoff;,citation_author=Michal F. Kaminski;,citation_publication_date=2022-10;,citation_cover_date=2022-10;,citation_year=2022;,citation_issue=0;,citation_doi=10.1056/NEJMoa2208375;,citation_issn=0028-4793;,citation_volume=0;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Why Is a Cow? Curiosity, Tweetorials, and the Return to Why;,citation_author=Anthony C. Breu;,citation_publication_date=2019-09;,citation_cover_date=2019-09;,citation_year=2019;,citation_issue=12;,citation_doi=10.1056/NEJMp1906790;,citation_issn=0028-4793, 1533-4406;,citation_volume=381;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=The Substitute for p-Values;,citation_abstract=If it was not obvious before, after reading McShane and Gal, the conclusion is that p-values should be proscribed. There are no good uses for them; indeed, every use either violates frequentist theory, is fallacious, or is based on a misunderstanding. A replacement for p-values is suggested, based on predictive models.;,citation_author=William M. Briggs;,citation_publication_date=2017-07;,citation_cover_date=2017-07;,citation_year=2017;,citation_issue=519;,citation_doi=10.1080/01621459.2017.1311264;,citation_issn=0162-1459;,citation_volume=112;,citation_journal_title=Journal of the American Statistical Association;,citation_publisher=Taylor &amp;amp;amp; Francis;">
<meta name="citation_reference" content="citation_title=Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults;,citation_abstract=Purpose— The aim of this statement is to present current and comprehensive recommendations for the diagnosis and treatment of acute spontaneous intracerebral hemorrhage. Methods— A formal literature search of Medline was performed through the end date of August 2006. The results of this search were complemented by additional articles on related issues known to the writing committee. Data were synthesized with the use of evidence tables. The American Heart Association Stroke Council’s Levels of Evidence grading algorithm was used to grade each recommendation. Prerelease review of the draft guideline was performed by 5 expert peer reviewers and by the members of the Stroke Council Leadership Committee. It is intended that this guideline be fully updated in 3 years’ time. Results— Evidence-based guidelines are presented for the diagnosis of intracerebral hemorrhage, the management of increased arterial blood pressure and intracranial pressure, the treatment of medical complications of intracerebral hemorrhage, and the prevention of recurrent intracerebral hemorrhage. Recent trials of recombinant factor VII to slow initial bleeding are discussed. Recommendations for various surgical approaches for treatment of spontaneous intracerebral hemorrhage are presented. Finally, withdrawal-of-care and end-of-life issues in patients with intracerebral hemorrhage are examined. (Stroke. 2007;38:2001-2023.);,citation_author=Joseph Broderick;,citation_author=Sander Connolly;,citation_author=Edward Feldmann;,citation_author=Daniel Hanley;,citation_author=Carlos Kase;,citation_author=Derk Krieger;,citation_author=Marc Mayberg;,citation_author=Lewis Morgenstern;,citation_author=Christopher S. Ogilvy;,citation_author=Paul Vespa;,citation_author=Mario Zuccarello;,citation_publication_date=2007-06;,citation_cover_date=2007-06;,citation_year=2007;,citation_issue=6;,citation_doi=10.1161/STROKEAHA.107.183689;,citation_volume=38;,citation_journal_title=Stroke;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=Extracorporeal Membrane Oxygenation during Respiratory Pandemics: Past, Present, and Future;,citation_author=Daniel Brodie;,citation_author=Darryl Abrams;,citation_author=Graeme MacLaren;,citation_author=Crystal E. Brown;,citation_author=Laura Evans;,citation_author=Ryan P. Barbaro;,citation_author=Carolyn S. Calfee;,citation_author=Catherine L. Hough;,citation_author=Jo-anne Fowles;,citation_author=Christian Karagiannidis;,citation_author=Arthur S. Slutsky;,citation_author=Alain Combes;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_issue=12;,citation_doi=10.1164/rccm.202111-2661CP;,citation_issn=1073-449X, 1535-4970;,citation_volume=205;,citation_language=en-US;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Among Patients With Intracerebral Hemorrhage, Is Intensive Blood Pressure Decreasing Associated With Improved Outcome?;,citation_author=Zachary T. Brodrick;,citation_author=Rachael Freeze-Ramsey;,citation_author=Rawle A. Seupaul;,citation_publication_date=2018-11;,citation_cover_date=2018-11;,citation_year=2018;,citation_issue=5;,citation_doi=10.1016/j.annemergmed.2018.01.018;,citation_issn=01960644;,citation_volume=72;,citation_language=en-US;,citation_journal_title=Annals of Emergency Medicine;">
<meta name="citation_reference" content="citation_title=Data Organization in Spreadsheets;,citation_abstract=Spreadsheets are widely used software tools for data entry, storage, analysis, and visualization. Focusing on the data entry and storage aspects, this article offers practical recommendations for organizing spreadsheet data to reduce errors and ease later analyses. The basic principles are: be consistent, write dates like YYYYMM-DD, do not leave any cells empty, put just one thing in a cell, organize the data as a single rectangle (with subjects as rows and variables as columns, and with a single header row), create a data dictionary, do not include calculations in the raw data files, do not use font color or highlighting as data, choose good names for things, make backups, use data validation to avoid data entry errors, and save the data in plain text files.;,citation_author=Karl W. Broman;,citation_author=Kara H. Woo;,citation_publication_date=2018-01;,citation_cover_date=2018-01;,citation_year=2018;,citation_issue=1;,citation_doi=10.1080/00031305.2017.1375989;,citation_issn=0003-1305, 1537-2731;,citation_volume=72;,citation_language=en-US;,citation_journal_title=The American Statistician;">
<meta name="citation_reference" content="citation_title=Molnupiravir’s authorisation was premature;,citation_author=James M Brophy;,citation_publication_date=2022-03;,citation_cover_date=2022-03;,citation_year=2022;,citation_doi=10.1136/bmj.o443;,citation_issn=1756-1833;,citation_language=en-US;,citation_journal_title=BMJ;">
<meta name="citation_reference" content="citation_title=Asking Causal Questions of Observational Data: The Quest Continues;,citation_author=Samuel M. Brown;,citation_author=Robert Paine;,citation_publication_date=2019-08;,citation_cover_date=2019-08;,citation_year=2019;,citation_issue=8;,citation_doi=10.1513/AnnalsATS.201905-397ED;,citation_issn=2329-6933, 2325-6621;,citation_volume=16;,citation_language=en-US;,citation_journal_title=Annals of the American Thoracic Society;">
<meta name="citation_reference" content="citation_title=Association Between Serotonergic Antidepressant Use During Pregnancy and Autism Spectrum Disorder in Children;,citation_abstract=OBJECTIVE To evaluate the association between serotonergic antidepressant exposure during pregnancy and child autism spectrum disorder. DESIGN, SETTING, AND PARTICIPANTS Retrospective cohort study. Health administrative data sets were used to study children born to mothers who were receiving public prescription drug coverage during pregnancy in Ontario, Canada, from 2002-2010, reflecting 4.2% of births. Children were followed up until March 31, 2014. EXPOSURES Serotonergic antidepressant exposure was defined as 2 or more consecutive maternal prescriptions for a selective serotonin or serotonin-norepinephrine reuptake inhibitor between conception and delivery. MAIN OUTCOMES AND MEASURES Child autism spectrum disorder identified after the age of 2 years. Exposure group differences were addressed by inverse probability of treatment weighting based on derived high-dimensional propensity scores (computerized algorithm used to select a large number of potential confounders) and by comparing exposed children with unexposed siblings. RESULTS There were 35 906 singleton births at a mean gestational age of 38.7 weeks (50.4% were male, mean maternal age was 26.7 years, and mean duration of follow-up was 4.95 years). In the 2837 pregnancies (7.9%) exposed to antidepressants, 2.0% (95% CI, 1.6%-2.6%) of children were diagnosed with autism spectrum disorder. The incidence of autism spectrum disorder was 4.51 per 1000 person-years among children exposed to antidepressants vs 2.03 per 1000 person-years among unexposed children (between-group difference, 2.48 [95% CI, 2.33-2.62] per 1000 person-years; hazard ratio [HR], 2.16 [95% CI, 1.64-2.86]; adjusted HR, 1.59 [95% CI, 1.17-2.17]). After inverse probability of treatment weighting based on the high-dimensional propensity score, the association was not significant (HR, 1.61 [95% CI, 0.997-2.59]). The association was also not significant when exposed children were compared with unexposed siblings (incidence of autism spectrum disorder was 3.40 per 1000 person-years vs 2.05 per 1000 person-years, respectively; adjusted HR, 1.60 [95% CI, 0.69-3.74]). CONCLUSIONS AND RELEVANCE In children born to mothers receiving public drug coverage in Ontario, Canada, in utero serotonergic antidepressant exposure compared with no exposure was not associated with autism spectrum disorder in the child. Although a causal relationship cannot be ruled out, the previously observed association may be explained by other factors.;,citation_author=Hilary K. Brown;,citation_author=Joel G. Ray;,citation_author=Andrew S. Wilton;,citation_author=Yona Lunsky;,citation_author=Tara Gomes;,citation_author=Simone N. Vigod;,citation_publication_date=2017-04;,citation_cover_date=2017-04;,citation_year=2017;,citation_issue=15;,citation_doi=10.1001/jama.2017.3415;,citation_issn=0098-7484;,citation_volume=317;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=The number needed to mourn;,citation_author=Samuel M. Brown;,citation_publication_date=2019-08;,citation_cover_date=2019-08;,citation_year=2019;,citation_issue=8;,citation_doi=10.1007/s00134-019-05669-z;,citation_issn=0342-4642, 1432-1238;,citation_volume=45;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Stroke trials: A shift to shift analysis?;,citation_author=D. L. Brown;,citation_author=C. S. Coffey;,citation_publication_date=2009-04;,citation_cover_date=2009-04;,citation_year=2009;,citation_issue=15;,citation_doi=10.1212/WNL.0b013e3181a11417;,citation_issn=0028-3878, 1526-632X;,citation_volume=72;,citation_language=en-US;,citation_journal_title=Neurology;">
<meta name="citation_reference" content="citation_title=Understanding patient outcomes after acute respiratory distress syndrome: Identifying subtypes of physical, cognitive and mental health outcomes;,citation_abstract=Purpose With improving short-term mortality in acute respiratory distress syndrome (ARDS), understanding survivors’ posthospitalisation outcomes is increasingly important. However, little is known regarding associaFor numbered affiliations see end of article. tions among physical, cognitive and mental health outcomes. Identification of outcome subtypes may advance Correspondence to Dr Samuel M Brown, Shock Trauma Intensive Care Unit, 5121 South Cottonwood Street, understanding of post-ARDS morbidities. Methods We analysed baseline variables and 6-month health status for participants in the ARDS Network LongTerm Outcomes Study. After division into derivation and Murray, UT 84107, USA; samuel. validation datasets, we used weighted network analysis brown@imail.org to identify subtypes from predictors and outcomes in the Received 31 March 2017 Revised 23 June 2017 derivation dataset. We then used recursive partitioning to develop a subtype classification rule and assessed Accepted 10 July 2017 adequacy of the classification rule using a kappa statistic with the validation dataset. ResultsAmong 645 ARDS survivors, 430 were in the derivation and 215 in the validation datasets. Physical and mental health status, but not cognitive status, were closely associated. Four distinct subtypes were apparent (percentages in the derivation cohort): (1) mildly impaired physical and mental health (22% of patients), (2) moderately impaired physical and mental health (39%), (3) severely impaired physical health with moderately impaired mental health (15%) and (4) severely impaired physical and mental health (24%). The classification rule had high agreement (kappa=0.89 in validation dataset). Female Latino smokers had the poorest status, while male, non-Latino non-smokers had the best status. Conclusions We identified four post-ARDS outcome subtypes that were predicted by sex, ethnicity, preARDS smoking status and other baseline factors. These subtypes may help develop tailored rehabilitation strategies, including investigation of combined physical and mental health interventions, and distinct interventions to improve cognitive outcomes.;,citation_author=Samuel M Brown;,citation_author=Emily L Wilson;,citation_author=Angela P Presson;,citation_author=Victor D Dinglas;,citation_author=Tom Greene;,citation_author=Ramona O Hopkins;,citation_author=Dale M Needham;,citation_publication_date=2017-12;,citation_cover_date=2017-12;,citation_year=2017;,citation_issue=12;,citation_doi=10.1136/thoraxjnl-2017-210337;,citation_issn=0040-6376, 1468-3296;,citation_volume=72;,citation_language=en-US;,citation_journal_title=Thorax;">
<meta name="citation_reference" content="citation_title=Better understanding the downsides of low value healthcare could reduce harm;,citation_author=Shannon M Brownlee;,citation_author=Deborah Korenstein;,citation_publication_date=2021-03;,citation_cover_date=2021-03;,citation_year=2021;,citation_doi=10.1136/bmj.n117;,citation_issn=1756-1833;,citation_language=en-US;,citation_journal_title=BMJ;">
<meta name="citation_reference" content="citation_title=The Role of Expert Judgment in Statistical Inference and Evidence-Based Decision-Making;,citation_abstract=This article resulted from our participation in the session on the “role of expert opinion and judgment in statistical inference” at the October 2017 ASA Symposium on Statistical Inference. We present a strong, unified statement on roles of expert judgment in statistics with processes for obtaining input, whether from a Bayesian or frequentist perspective. Topics include the role of subjectivity in the cycle of scientific inference and decisions, followed by a clinical trial and a greenhouse gas emissions case study that illustrate the role of judgments and the importance of basing them on objective information and a comprehensive uncertainty assessment. We close with a call for increased proactivity and involvement of statisticians in study conceptualization, design, conduct, analysis, and communication.;,citation_author=Naomi C. Brownstein;,citation_author=Thomas A. Louis;,citation_author=Anthony O’Hagan;,citation_author=Jane Pendergast;,citation_publication_date=2019-03;,citation_cover_date=2019-03;,citation_year=2019;,citation_issue=sup1;,citation_doi=10.1080/00031305.2018.1529623;,citation_issn=0003-1305, 1537-2731;,citation_volume=73;,citation_language=en-US;,citation_journal_title=The American Statistician;">
<meta name="citation_reference" content="citation_title=Intensive Insulin Therapy and Pentastarch Resuscitation in Severe Sepsis;,citation_abstract=In a study by Van den Berghe et al. involving critically ill surgical patients, intensive insulin therapy to maintain euglycemia (glucose level, 80 to 110 mg per deciliter [4.4 to 6.1 mmol per liter]) lowered in-hospital mortality from 10.9% to 7.2%, mostly by reducing deaths from multiple organ failure with a proven septic focus.1 This beneficial effect occurred predominantly in cardiac surgical patients who received high glucose challenges immediately after surgery (8 to 12 g of glucose intravenously per hour) and was associated with an unusually high rate of death (5.1%) among controls. Furthermore, in a follow-up study by Van . . .;,citation_author=Frank M. Brunkhorst;,citation_author=Christoph Engel;,citation_author=Frank Bloos;,citation_author=Andreas Meier-Hellmann;,citation_author=Max Ragaller;,citation_author=Norbert Weiler;,citation_author=Onnen Moerer;,citation_author=Matthias Gruendling;,citation_author=Michael Oppert;,citation_author=Stefan Grond;,citation_author=Derk Olthoff;,citation_author=Ulrich Jaschinski;,citation_author=Stefan John;,citation_author=Rolf Rossaint;,citation_author=Tobias Welte;,citation_author=Martin Schaefer;,citation_author=Peter Kern;,citation_author=Evelyn Kuhnt;,citation_author=Michael Kiehntopf;,citation_author=Christiane Hartog;,citation_author=Charles Natanson;,citation_author=Markus Loeffler;,citation_author=Konrad Reinhart;,citation_publication_date=2008-01;,citation_cover_date=2008-01;,citation_year=2008;,citation_issue=2;,citation_doi=10.1056/NEJMoa070716;,citation_issn=0028-4793;,citation_pmid=18184958;,citation_volume=358;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=A survey on self-assessed well-being in a cohort of chronic locked-in syndrome patients: Happy majority, miserable minority;,citation_abstract=Objectives Locked-in syndrome (LIS) consists of anarthria and quadriplegia while consciousness is preserved. Classically, vertical eye movements or blinking allow coded communication. Given appropriate medical care, patients can survive for decades. We studied the self-reported quality of life in chronic LIS patients. Design 168 LIS members of the French Association for LIS were invited to answer a questionnaire on medical history, current status and end-of-life issues. They self-assessed their global subjective well-being with the Anamnestic Comparative Self-Assessment (ACSA) scale, whose +5 and -5 anchors were their memories of the best period in their life before LIS and their worst period ever, respectively. Results 91 patients (54%) responded and 26 were excluded because of missing data on quality of life. 47 patients professed happiness (median ACSA +3) and 18 unhappiness (median ACSA -4). Variables associated with unhappiness included anxiety and dissatisfaction with mobility in the community, recreational activities and recovery of speech production. A longer time in LIS was correlated with happiness. 58% declared they did not wish to be resuscitated in case of cardiac arrest and 7% expressed a wish for euthanasia. Conclusions Our data stress the need for extra palliative efforts directed at mobility and recreational activities in LIS and the importance of anxiolytic therapy. Recently affected LIS patients who wish to die should be assured that there is a high chance they will regain a happy meaningful life. End-of-life decisions, including euthanasia, should not be avoided, but a moratorium to allow a steady state to be reached should be proposed.;,citation_author=Marie-Aurélie Bruno;,citation_author=Jan L. Bernheim;,citation_author=Didier Ledoux;,citation_author=Frédéric Pellas;,citation_author=Athena Demertzi;,citation_author=Steven Laureys;,citation_publication_date=2011-01;,citation_cover_date=2011-01;,citation_year=2011;,citation_issue=1;,citation_doi=10.1136/bmjopen-2010-000039;,citation_issn=2044-6055, 2044-6055;,citation_pmid=22021735;,citation_volume=1;,citation_language=en-US;,citation_journal_title=BMJ Open;,citation_publisher=British Medical Journal Publishing Group;">
<meta name="citation_reference" content="citation_title=Effect of Teaching Bayesian Methods Using Learning by Concept vs Learning by Example on Medical Students’ Ability to Estimate Probability of a Diagnosis: A Randomized Clinical Trial;,citation_abstract=Clinicians use probability estimates to make a diagnosis. Teaching students to make more accurate probability estimates could improve the diagnostic process and, ultimately, the quality of medical care.To test whether novice clinicians can be taught to make more accurate bayesian revisions of diagnostic probabilities using teaching methods that apply either explicit conceptual instruction or repeated examples.A randomized clinical trial of 2 methods for teaching bayesian updating and diagnostic reasoning was performed. A web-based platform was used for consent, randomization, intervention, and testing of the effect of the intervention. Participants included 61 medical students at McMaster University and Eastern Virginia Medical School recruited from May 1 to September 30, 2018.Students were randomized to (1) receive explicit conceptual instruction regarding diagnostic testing and bayesian revision (concept group), (2) exposure to repeated examples of cases with feedback regarding posttest probability (experience group), or (3) a control condition with no conceptual instruction or repeated examples.Students in all 3 groups were tested on their ability to update the probability of a diagnosis based on either negative or positive test results. Their probability revisions were compared with posttest probability revisions that were calculated using the Bayes rule and known test sensitivity and specificity.Of the 61 participants, 22 were assigned to the concept group, 20 to the experience group, and 19 to the control group. Approximate age was 25 years. Two participants were first-year; 37, second-year; 12, third-year; and 10, fourth-year students. Mean (SE) probability estimates of students in the concept group were statistically significantly closer to calculated bayesian probability than the other 2 groups (concept, 0.4%; [0.7%]; experience, 3.5% [0.7%]; control, 4.3% [0.7%]; P &amp;amp;amp;lt; .001). Although statistically significant, the differences between groups were relatively modest, and students in all groups performed better than expected, based on prior reports in the literature.The study showed a modest advantage for students who received theoretical instruction on bayesian concepts. All participants’ probability estimates were, on average, close to the bayesian calculation. These findings have implications for how to teach diagnostic reasoning to novice clinicians.ClinicalTrials.gov identifier: NCT04130607;,citation_author=John E. Brush;,citation_author=Mark Lee;,citation_author=Jonathan Sherbino;,citation_author=Judith C. Taylor-Fishwick;,citation_author=Geoffrey Norman;,citation_publication_date=2019-12;,citation_cover_date=2019-12;,citation_year=2019;,citation_issue=12;,citation_doi=10.1001/jamanetworkopen.2019.18023;,citation_issn=2574-3805;,citation_volume=2;,citation_journal_title=JAMA Network Open;">
<meta name="citation_reference" content="citation_title=Accelerating Coronavirus Disease 2019 Therapeutic Interventions and Vaccines—Selecting Compounds for Clinical Evaluation in Coronavirus Disease 2019 Clinical Trials;,citation_abstract=Given the urgent need for coronavirus disease 2019 therapeutics, early in the pandemic the Accelerating Coronavirus Disease 2019 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership rapidly designed a unique therapeutic agent intake and assessment process for candidate treatments of coronavirus disease 2019. These treatments included antivirals, immune modulators, severe acute respiratory syndrome coronavirus 2 neutralizing antibodies, and organ-supportive treatments at both the preclinical and clinical stages of development. The ACTIV Therapeutics-Clinical Working Group Agent Prioritization subgroup established a uniform data collection process required to perform an assessment of any agent type using review criteria that were identified and differentially weighted for each agent class. The ACTIV Therapeutics-Clinical Working Group evaluated over 750 therapeutic agents with potential application for coronavirus disease 2019 and prioritized promising candidates for testing within the master protocols conducted by ACTIV. In addition, promising agents among preclinical candidates were selected by ACTIV to be matched with laboratories that could assist in executing rigorous preclinical studies. Between April 14, 2020, and May 31, 2021, the Agent Prioritization subgroup advanced 20 agents into the Accelerating Coronavirus Disease 2019 Therapeutic Interventions and Vaccines master protocols and matched 25 agents with laboratories to assist with preclinical testing.;,citation_author=Timothy G. Buchman;,citation_author=Ruxandra Draghia-Akli;,citation_author=Stacey J. Adam;,citation_author=Neil R. Aggarwal;,citation_author=Joshua P. Fessel;,citation_author=Elizabeth S. Higgs;,citation_author=Joseph P. Menetski;,citation_author=Sarah W. Read;,citation_author=Eric A. Hughes;,citation_publication_date=2021-11;,citation_cover_date=2021-11;,citation_year=2021;,citation_issue=11;,citation_doi=10.1097/CCM.0000000000005295;,citation_issn=0090-3493;,citation_volume=49;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Trends in COVID-19 therapeutic clinical trials;,citation_author=Kevin Bugin;,citation_author=Janet Woodcock;,citation_publication_date=2021-04;,citation_cover_date=2021-04;,citation_year=2021;,citation_issue=4;,citation_doi=10.1038/d41573-021-00037-3;,citation_issn=1474-1776, 1474-1784;,citation_volume=20;,citation_language=en-US;,citation_journal_title=Nature Reviews Drug Discovery;">
<meta name="citation_reference" content="citation_title=Multistate models as a framework for estimand specification in clinical trials of complex processes;,citation_abstract=Intensity-based multistate models provide a useful framework for characterizing disease processes, the introduction of interventions, loss to followup, and other complications arising in the conduct of randomized trials studying complex life history processes. Within this framework we discuss the issues involved in the specification of estimands and show the limiting values of common estimators of marginal process features based on cumulative incidence function regression models. When intercurrent events arise we stress the need to carefully define the target estimand and the importance of avoiding targets of inference that are not interpretable in the real world. This has implications for analyses, but also the design of clinical trials where protocols may help in the interpretation of estimands based on marginal features.;,citation_author=Alexandra Bühler;,citation_author=Richard J. Cook;,citation_author=Jerald F. Lawless;,citation_issue=n/a;,citation_doi=10.1002/sim.9675;,citation_issn=1097-0258;,citation_volume=n/a;,citation_language=en-US;,citation_journal_title=Statistics in Medicine;">
<meta name="citation_reference" content="citation_title=Causal inference in regression: Advice to authors;,citation_author=Joseph Bulbulia;,citation_author=Uffe Schjoedt;,citation_author=John H. Shaver;,citation_author=Richard Sosis;,citation_author=Wesley J. Wildman;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=4;,citation_doi=10.1080/2153599X.2021.2001259;,citation_issn=2153-599X;,citation_volume=11;,citation_journal_title=Religion, Brain &amp;amp;amp; Behavior;,citation_publisher=Routledge;">
<meta name="citation_reference" content="citation_title=A workflow for causal inference in cross-cultural psychology;,citation_author=Joseph A. Bulbulia;,citation_publication_date=2022-07;,citation_cover_date=2022-07;,citation_year=2022;,citation_issue=0;,citation_doi=10.1080/2153599X.2022.2070245;,citation_issn=2153-599X;,citation_volume=0;,citation_journal_title=Religion, Brain &amp;amp;amp; Behavior;,citation_publisher=Routledge;">
<meta name="citation_reference" content="citation_title=Studies of Medical Tests;,citation_author=Jennifer A. Bullen;,citation_publication_date=2020-07;,citation_cover_date=2020-07;,citation_year=2020;,citation_issue=1;,citation_doi=10.1016/j.chest.2020.03.006;,citation_issn=00123692;,citation_volume=158;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Studies of Medical Tests: Design and Analytical Considerations;,citation_author=Jennifer A Bullen;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Taking the Bait from the Prescription Opioid Industry: A Mea Culpa;,citation_author=Diana J. Burgess;,citation_author=Erin E. Krebs;,citation_author=Craig S. Roth;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_doi=10.1007/s11606-021-07381-5;,citation_issn=0884-8734, 1525-1497;,citation_language=en-US;,citation_journal_title=Journal of General Internal Medicine;">
<meta name="citation_reference" content="citation_title=Ordinal Regression Models in Psychology: A Tutorial;,citation_abstract=Ordinal variables, although extremely common in psychology, are almost exclusively analyzed with statistical models that falsely assume them to be metric. This practice can lead to distorted effect-size estimates, inflated error rates, and other problems. We argue for the application of ordinal models that make appropriate assumptions about the variables under study. In this Tutorial, we first explain the three major classes of ordinal models: the cumulative, sequential, and adjacent-category models. We then show how to fit ordinal models in a fully Bayesian framework with the R package brms, using data sets on opinions about stem-cell research and time courses of marriage. The appendices provide detailed mathematical derivations of the models and a discussion of censored ordinal models. Compared with metric models, ordinal models provide better theoretical interpretation and numerical inference from ordinal data, and we recommend their widespread adoption in psychology.;,citation_author=Paul-Christian Bürkner;,citation_author=Matti Vuorre;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Ventilator Weaning and Discontinuation Practices for Critically Ill Patients;,citation_abstract=OBJECTIVE To describe practice variation in IMV discontinuation internationally, associations between initial discontinuation events and outcomes, and factors associated with the use of select discontinuation strategies and failed initial spontaneous breathing trials (SBTs). DESIGN, SETTING, AND PARTICIPANTS Prospective, multinational, observational study of critically ill adults who received IMV for at least 24 hours from 142 intensive care units (ICUs) in 19 countries within 6 regions (27 in Canada, 23 in India, 22 in the UK, 26 in Europe, 21 in Australia/New Zealand, and 23 in the US). EXPOSURES Receiving IMV. MAIN OUTCOMES AND MEASURES Primary analyses characterized types of initial IMV discontinuation events (extubation, SBT, or tracheostomy) and associations with clinical outcomes (including duration of ventilation, ICU and hospital mortality, and ICU and hospital length of stay). Secondary analyses examined the associations between SBT outcome and SBT timing and clinical outcomes. RESULTS Among 1868 patients (median [interquartile range] age, 61.8 [48.9-73.1] years; 1173 [62.8%] men) 424 (22.7%) underwent direct extubation, 930 (49.8%) had an initial SBT (761 [81.8%] successful), 150 (8.0%) underwent direct tracheostomy, and 364 (19.5%) died before a weaning attempt. Across regions, there was variation in the use of written directives to guide care, daily screening, SBT techniques, ventilator modes, and the roles played by clinicians involved in weaning. Compared with initial direct extubation, patients who had an initial SBT had higher ICU mortality (20 [4.7%] vs 96 [10.3%]; absolute difference, 5.6% [95% CI, 2.6%-8.6%]), longer duration of ventilation (median of 2.9 vs 4.1 days; absolute difference, 1.2 days [95% CI, 0.7-1.6]), and longer ICU stay (median of 6.7 vs 8.1 days; absolute difference, 1.4 days [95% CI, 0.8-2.4]). Patients whose initial SBT failed (vs passed) had higher ICU mortality (29 [17.2%] vs 67 [8.8%]; absolute difference, 8.4% [95% CI, 2.0%-14.7%]), longer duration of ventilation (median of 6.1 vs 3.5 days; absolute difference, 2.6 days [95% CI, 1.6-3.6]), and longer ICU stay (median of 10.6 vs 7.7 days; absolute difference, 2.8 days [95% CI, 1.1-5.2]). Compared with patients who underwent early initial SBTs, patients who underwent late initial SBTs (&amp;amp;amp;gt;2.3 days after intubation) had longer duration of ventilation (median of 2.1 vs 6.1 days; absolute difference, 4.0 days [95% CI, 3.7-4.5]), longer ICU stay (median of 5.9 vs 10.8 days; absolute difference, 4.9 days [95% CI, 4.0-6.3]), and longer hospital stay (median of 14.3 vs 22.8 days; absolute difference, 8.5 days [95% CI, 6.0-11.0]). CONCLUSIONS AND RELEVANCE In this observational study of invasive mechanical ventilation discontinuation in 142 ICUs in Canada, India, the UK, Europe, Australia/New Zealand, and the US from 2013 to 2016, weaning practices varied internationally.;,citation_author=Karen E. A. Burns;,citation_author=Leena Rizvi;,citation_author=Deborah J. Cook;,citation_author=Gerald Lebovic;,citation_author=Peter Dodek;,citation_author=Jesús Villar;,citation_author=Arthur S. Slutsky;,citation_author=Andrew Jones;,citation_author=Farhad N. Kapadia;,citation_author=David J. Gattas;,citation_author=Scott K. Epstein;,citation_author=Paolo Pelosi;,citation_author=Kallirroi Kefala;,citation_author=Maureen O. Meade;,citation_author=Canadian Critical Care Trials Group;,citation_publication_date=2021-03;,citation_cover_date=2021-03;,citation_year=2021;,citation_issue=12;,citation_doi=10.1001/jama.2021.2384;,citation_issn=0098-7484;,citation_volume=325;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Rapid Translation of COVID-19 Preprint Data into Critical Care Practice;,citation_author=Aidan J. C. Burrell;,citation_author=Ary Serpa Neto;,citation_author=Tony Trapani;,citation_author=Tessa Broadley;,citation_author=Craig French;,citation_author=Andrew A. Udy;,citation_author=Adam Visser;,citation_author=Adrian Mattke;,citation_author=Adrian Regli;,citation_author=Alan Rashid;,citation_author=Alexis Tabah;,citation_author=Alison Walker;,citation_author=Allen Cheng;,citation_author=Amanda Corley;,citation_author=Andrew Udy;,citation_author=Anil Ramnani;,citation_author=(Isabel) Anne Leditschke;,citation_author=Anthony Eidan;,citation_author=Bart DeKeulenaer;,citation_author=Baumik Mevavala;,citation_author=Ben Mulholland;,citation_author=Benjamin Reddi;,citation_author=Brent Richards;,citation_author=Cameron Knott;,citation_author=Cara Moore;,citation_author=Carmel Delzoppo;,citation_author=Catherine Boschert;,citation_author=Catherine Tacon;,citation_author=Claire Corrigan;,citation_author=Craig French;,citation_author=Danielle Austin;,citation_author=David Brewster;,citation_author=David Cooper;,citation_author=David Crosbie;,citation_author=David Hawkins;,citation_author=Edda Jessen;,citation_author=Eduardo Martinez;,citation_author=Edward Fysh;,citation_author=Edward Litton;,citation_author=Felix Oberender;,citation_author=Forbes McGain;,citation_author=Gavin Salt;,citation_author=Glenn Eastwood;,citation_author=Gopal Taori;,citation_author=Hannah Thompson;,citation_author=Hayden White;,citation_author=Hergen Buscher;,citation_author=Ian Seppelt;,citation_author=Ifrah Khan;,citation_author=Janelle Young;,citation_author=Jayshree Lavana;,citation_author=Jeremy Cohen;,citation_author=Jessica Lugsdin;,citation_author=Jill Garlick;,citation_author=Jim Buttery;,citation_author=John Botha;,citation_author=John Santamaria;,citation_author=Jonathan Barrett;,citation_author=Kasha Singh;,citation_author=Kevin Laupland;,citation_author=Khaled El-Khawas;,citation_author=Kristine Estensen;,citation_author=Kush Deshpande;,citation_author=Kyle White;,citation_author=Leigh Fitzpatrick;,citation_author=Lewis Campbell;,citation_author=Mahesh Ramanan;,citation_author=Manoj Saxena;,citation_author=Marie Draper;,citation_author=Marion Kainer;,citation_author=Mark Kol;,citation_author=Mark Page;,citation_author=Mark Plummer;,citation_author=Martin Sterba;,citation_author=Matthew Anstey;,citation_author=Matthew Brain;,citation_author=Matthew Maiden;,citation_author=Myrene Kilminster;,citation_author=Naomi Hammond;,citation_author=Neeraj Bhadange;,citation_author=Nicole Humphreys;,citation_author=Paras Jain;,citation_author=Paul Azzi;,citation_author=Paul Secombe;,citation_author=Paula Lister;,citation_author=Peter Chan;,citation_author=Peter McCanny;,citation_author=Phillip Britton;,citation_author=Pierre Janin;,citation_author=Rashmi Runiyar;,citation_author=Ravi Krishnamurthy;,citation_author=Ravikiran Sonawane;,citation_author=Ravindranath Tiruvoipati;,citation_author=Rebecca Jessup;,citation_author=Richard Totaro;,citation_author=Rinaldo Bellomo;,citation_author=Ritesh Sanghavi;,citation_author=Samantha Bates;,citation_author=Sandra Peake;,citation_author=Shailesh Bihari;,citation_author=Shane George;,citation_author=Sharon Waterson;,citation_author=Simon Erickson;,citation_author=Steve Webb;,citation_author=Subhash Arora;,citation_author=Subodh Ganu;,citation_author=Thomas Rozen;,citation_author=Toni McKenna;,citation_author=Umesh Kadam;,citation_author=Vineet Nayyar;,citation_author=Wei Han Choy;,citation_author=Wisam Albassam;,citation_publication_date=2021-02;,citation_cover_date=2021-02;,citation_year=2021;,citation_issue=3;,citation_doi=10.1164/rccm.202009-3661LE;,citation_issn=1073-449X, 1535-4970;,citation_volume=203;,citation_language=en-US;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Melatonin in ICU delirium: Shining light on the hormone of darkness;,citation_author=Lisa Burry;,citation_author=Romain Sonneville;,citation_author=E. Wesley Ely;,citation_publication_date=2022-04;,citation_cover_date=2022-04;,citation_year=2022;,citation_issue=4;,citation_doi=10.1007/s00134-022-06656-7;,citation_issn=1432-1238;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Sex differences in quality of life after ischemic stroke;,citation_abstract=Objective: We aimed to compare quality of life (QOL) in women and men after ischemic stroke or TIA, and to determine the incremental impact of demographic, socioeconomic, clinical, and stroke-specific effects on longitudinal QOL. Methods: We assessed QOL in patients with ischemic stroke or TIA at 3 and 12 months postdischarge in the Adherence eValuation After Ischemic stroke–Longitudinal Registry using the European Quality of Life–5 Dimensions (EQ-5D) instrument. We generated multivariable linear regression models to evaluate the association between sex and EQ-5D while sequentially adjusting for sociodemographic, clinical, and stroke-related variables. We also used a proportional odds model to assess sex differences in the change in EQ-5D scores from 3 to 12 months. Correspondence to Dr. Bushnell: cbushnel@wakehealth.edu Results: A total of 1,370 patients were included, 53.7% male, median age 65 years (interquartile range 56–77 years). Women had significantly lower QOL at 3 months (unadjusted EQ-5D 0.81 in women vs 0.84 in men; p , 0.001) and 12 months (0.83 vs men 0.84; p , 0.001) poststroke. After multivariable adjustment for sociodemographic, clinical, and stroke-related factors, women continued to have lower QOL at 3 months (mean difference 20.036; p 5 0.003) and at 12 months (mean difference 20.022; p 5 0.046). Women fared worse in the dimensions of mobility, pain/ discomfort, and anxiety/depression at 3 and 12 months. There were no sex differences in change in EQ-5D score from 3 to 12 months. Conclusion: Women have worse QOL than men up to 12 months after stroke, even after adjusting for important sociodemographic variables, stroke severity, and disability. Neurology 2014;82:922–931;,citation_author=C. D. Bushnell;,citation_author=M. J. Reeves;,citation_author=X. Zhao;,citation_author=W. Pan;,citation_author=J. Prvu-Bettger;,citation_author=L. Zimmer;,citation_author=D. Olson;,citation_author=E. Peterson;,citation_publication_date=2014-03;,citation_cover_date=2014-03;,citation_year=2014;,citation_issue=11;,citation_doi=10.1212/WNL.0000000000000208;,citation_issn=0028-3878, 1526-632X;,citation_volume=82;,citation_language=en-US;,citation_journal_title=Neurology;">
<meta name="citation_reference" content="citation_title=Cerebral Embolic Protection and Outcomes of Transcatheter Aortic Valve Replacement: Results From the Transcatheter Valve Therapy Registry;,citation_abstract=Background: Stroke remains a devastating complication of transcatheter aortic valve replacement (TAVR), which has persisted despite refinements in technique and increased operator experience. While cerebral embolic protection devices (EPDs) have been developed to mitigate this risk, data regarding their impact on stroke and other outcomes after TAVR are limited. Methods: We performed an observational study using data from the Society for Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Patients were included if they underwent elective or urgent transfemoral TAVR between January 2018 and December 2019. The primary outcome was in-hospital stroke. To adjust for confounding, the association between EPD use and clinical outcomes was evaluated using instrumental variable analysis, a technique designed to support causal inference from observational data, with site-level preference for EPD use within the same quarter of the procedure as the instrument. We also performed a propensity score–based secondary analysis using overlap weights. Results: Our analytic sample included 123 186 patients from 599 sites. The use of EPD during TAVR increased over time, reaching 28% of sites and 13% of TAVR procedures by December 2019. There was wide variation in EPD use across hospitals, with 8% of sites performing &amp;amp;amp;gt;50% of TAVR procedures with an EPD and 72% performing no procedures with an EPD in the last quarter of 2019. In our primary analysis using the instrumental variable model, there was no association between EPD use and in-hospital stroke (adjusted relative risk, 0.90 [95% CI, 0.68–1.13]; absolute risk difference, -0.15% [95% CI, -0.49 to 0.20]). However, in our secondary analysis using the propensity score–based model, EPD use was associated with 18% lower odds of in-hospital stroke (adjusted odds ratio, 0.82 [95% CI, 0.69–0.97]; absolute risk difference, -0.28% [95% CI, -0.52 to -0.03]). Results were generally consistent across the secondary end points, as well as subgroup analyses. Conclusions: In this nationally representative observational study, we did not find an association between EPD use for TAVR and in-hospital stroke in our primary instrumental variable analysis, and found only a modestly lower risk of in-hospital stroke in our secondary propensity-weighted analysis. These findings provide a strong basis for large-scale randomized, controlled trials to test whether EPDs provide meaningful clinical benefit for patients undergoing TAVR.;,citation_author=Neel M. Butala;,citation_author=Raj Makkar;,citation_author=Eric A. Secemsky;,citation_author=Dianne Gallup;,citation_author=Guillaume Marquis-Gravel;,citation_author=Andrzej S. Kosinski;,citation_author=Sreekanth Vemulapalli;,citation_author=Javier A. Valle;,citation_author=Steven M. Bradley;,citation_author=Tarun Chakravarty;,citation_author=Robert W. Yeh;,citation_author=David J. Cohen;,citation_publication_date=2021-06;,citation_cover_date=2021-06;,citation_year=2021;,citation_issue=23;,citation_doi=10.1161/CIRCULATIONAHA.120.052874;,citation_volume=143;,citation_journal_title=Circulation;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial;,citation_abstract=BACKGROUND AND PURPOSE: Acute blood pressure (BP) reduction aimed at attenuation of intracerebral hemorrhage (ICH) expansion might also compromise cerebral blood flow (CBF). We tested the hypothesis that CBF in acute ICH patients is unaffected by BP reduction. METHODS: Patients with spontaneous ICH &amp;amp;amp;lt;24 hours after onset and systolic BP &amp;gt; 150 mm Hg were randomly assigned to an intravenous antihypertensive treatment protocol targeting a systolic BP of &amp;lt;150 mm Hg (n=39) or <180 mm Hg (n=36). Patients underwent computed tomography perfusion imaging 2 hours postrandomization. The primary end point was perihematoma relative (relative CBF). RESULTS: Treatment groups were balanced with respect to baseline systolic BP: 18220 mm Hg (<150 mm Hg target group) versus 18425 mm Hg (<180 mm Hg target group; P=0.60), and for hematoma volume: 25.630.8 versus 26.925.2 mL (P=0.66). Mean systolic BP 2 hours after randomization was significantly lower in the <150 mm Hg target group (14019 vs 16212 mm Hg; P<0.001). Perihematoma CBF (38.711.9 mL/100 g per minute) was lower than in contralateral homologous regions (44.111.1 mL/100 g per minute; P<0.001) in all patients. The primary end point of perihematoma relative CBF in the <150 mm Hg target group (0.860.12) was not significantly lower than that in the <180 mm Hg group (0.890.09; P=0.19; absolute difference, 0.03; 95% confidence interval -0.018 to 0.078). There was no relationship between the magnitude of BP change and perihematoma relative CBF in the <150 mm Hg (R=0.00005; 95% confidence interval, -0.001 to 0.001) or <180 mm Hg target groups (R=0.000; 95% confidence interval, -0.001 to 0.001). CONCLUSIONS: Rapid BP lowering after a moderate volume of ICH does not reduce perihematoma CBF. These physiological data indicate that acute BP reduction does not precipitate cerebral ischemia in ICH patients. Clinical Trial Registration Information- URL:http://clinicaltrials.gov. Unique Identifier: NCT00963976.;,citation_author=Kenneth S. Butcher;,citation_author=Thomas Jeerakathil;,citation_author=Michael Hill;,citation_author=Andrew M. Demchuk;,citation_author=Dariush Dowlatshahi;,citation_author=Shelagh B. Coutts;,citation_author=Bronwen Gould;,citation_author=Rebecca McCourt;,citation_author=Negar Asdaghi;,citation_author=J. Max Findlay;,citation_author=Derek Emery;,citation_author=Ashfaq Shuaib;,citation_author=ICH ADAPT Investigators;,citation_publication_date=2013-03;,citation_cover_date=2013-03;,citation_year=2013;,citation_issue=3;,citation_doi=10.1161/STROKEAHA.111.000188;,citation_issn=1524-4628;,citation_pmid=23391776;,citation_volume=44;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=Case 15-2022: A 57-Year-Old Man with Persistent Cough and Pulmonary Opacities;,citation_author=Rachel S. Knipe;,citation_author=George A. Alba;,citation_author=Jeanna M. Harvey Barnes;,citation_author=Lida P. Hariri;,citation_editor=Richard C. Cabot;,citation_editor=Eric S. Rosenberg;,citation_editor=David M. Dudzinski;,citation_editor=Meridale V. Baggett;,citation_editor=Kathy M. Tran;,citation_editor=Dennis C. Sgroi;,citation_editor=Jo-Anne O. Shepard;,citation_editor=Emily K. McDonald;,citation_editor=Tara Corpuz;,citation_publication_date=2022-05;,citation_cover_date=2022-05;,citation_year=2022;,citation_issue=20;,citation_doi=10.1056/NEJMcpc2201234;,citation_issn=0028-4793, 1533-4406;,citation_volume=386;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Reply to Mulla and Pathak: Sleep Apnea and Poor COVID-19 Outcomes: Beware of Causal Intermediates and Colliders;,citation_author=Brian E. Cade;,citation_author=Hassan S. Dashti;,citation_author=Syed M. Hassan;,citation_author=Susan Redline;,citation_author=Elizabeth W. Karlson;,citation_publication_date=2021-05;,citation_cover_date=2021-05;,citation_year=2021;,citation_issue=10;,citation_doi=10.1164/rccm.202101-0210LE;,citation_issn=1073-449X, 1535-4970;,citation_volume=203;,citation_language=en-US;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Association of Initial Illness Severity and Outcomes After Cardiac Arrest With Targeted Temperature Management at 36 ^\circC or 33 ^\circC;,citation_abstract=It is uncertain what the optimal target temperature is for targeted temperature management (TTM) in patients who are comatose following cardiac arrest.To examine whether illness severity is associated with changes in the association between target temperature and patient outcome.This cohort study compared outcomes for 1319 patients who were comatose after cardiac arrest at a single center in Pittsburgh, Pennsylvania, from January 2010 to December 2018. Initial illness severity was based on coma and organ failure scores, presence of severe cerebral edema, and presence of highly malignant electroencephalogram (EEG) after resuscitation.TTM at 36 ^\circC or 33 ^\circC.Primary outcome was survival to hospital discharge, and secondary outcomes were modified Rankin Scale and cerebral performance category.Among 1319 patients, 728 (55.2%) had TTM at 33 ^\circC (451 [62.0%] men; median [interquartile range] age, 61 [50-72] years) and 591 (44.8%) had TTM at 36 ^\circC (353 [59.7%] men; median [interquartile range] age, 59 [48-69] years). Overall, 184 of 187 patients (98.4%) with severe cerebral edema died and 234 of 243 patients (96.3%) with highly malignant EEG died regardless of TTM strategy. Comparing TTM at 33 ^\circC with TTM at 36 ^\circC in 911 patients (69.1%) with neither severe cerebral edema nor highly malignant EEG, survival was lower in patients with mild to moderate coma and no shock (risk difference, –13.8%; 95% CI, –24.4% to –3.2%) but higher in patients with mild to moderate coma and cardiopulmonary failure (risk difference, 21.8%; 95% CI, 5.4% to 38.2%) or with severe coma (risk difference, 9.7%; 95% CI, 4.0% to 15.3%). Interactions were similar for functional outcomes. Most deaths (633 of 968 [65.4%]) resulted after withdrawal of life-sustaining therapies.In this study, TTM at 33 ^\circC was associated with better survival than TTM at 36 ^\circC among patients with the most severe post–cardiac arrest illness but without severe cerebral edema or malignant EEG. However, TTM at 36 ^\circC was associated with better survival among patients with mild- to moderate-severity illness.;,citation_author=Clifton W. Callaway;,citation_author=Patrick J. Coppler;,citation_author=John Faro;,citation_author=Jacob S. Puyana;,citation_author=Pawan Solanki;,citation_author=Cameron Dezfulian;,citation_author=Ankur A. Doshi;,citation_author=Jonathan Elmer;,citation_author=Adam Frisch;,citation_author=Francis X. Guyette;,citation_author=Masashi Okubo;,citation_author=Jon C. Rittenberger;,citation_author=Alexandra Weissman;,citation_publication_date=2020-07;,citation_cover_date=2020-07;,citation_year=2020;,citation_issue=7;,citation_doi=10.1001/jamanetworkopen.2020.8215;,citation_issn=2574-3805;,citation_volume=3;,citation_journal_title=JAMA Network Open;">
<meta name="citation_reference" content="citation_title=Critical care archetypes;,citation_author=Paul A. Cameron;,citation_author=Wael Haddara;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=10;,citation_doi=10.1007/s12630-021-02062-7;,citation_issn=0832-610X, 1496-8975;,citation_volume=68;,citation_language=en-US;,citation_journal_title=Canadian Journal of Anesthesia/Journal canadien d’anesthésie;">
<meta name="citation_reference" content="citation_title=Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke: The EXTEND-IA TNK Part 2 Randomized Clinical Trial;,citation_abstract=Intravenous thrombolysis with tenecteplase improves reperfusion prior to endovascular thrombectomy for ischemic stroke compared with alteplase.To determine whether 0.40 mg/kg of tenecteplase safely improves reperfusion before endovascular thrombectomy vs 0.25 mg/kg of tenecteplase in patients with large vessel occlusion ischemic stroke.Randomized clinical trial at 27 hospitals in Australia and 1 in New Zealand using open-label treatment and blinded assessment of radiological and clinical outcomes. Patients were enrolled from December 2017 to July 2019 with follow-up until October 2019. Adult patients (N = 300) with ischemic stroke due to occlusion of the intracranial internal carotid, \basilar, or middle cerebral artery were included less than 4.5 hours after symptom onset using standard intravenous thrombolysis eligibility criteria.Open-label tenecteplase at 0.40 mg/kg (maximum, 40 mg; n = 150) or 0.25 mg/kg (maximum, 25 mg; n = 150) given as a bolus before endovascular thrombectomy.The primary outcome was reperfusion of greater than 50% of the involved ischemic territory prior to thrombectomy, assessed by consensus of 2 blinded neuroradiologists. Prespecified secondary outcomes were level of disability at day 90 (modified Rankin Scale [mRS] score; range, 0-6); mRS score of 0 to 1 (freedom from disability) or no change from baseline at 90 days; mRS score of 0 to 2 (functional independence) or no change from baseline at 90 days; substantial neurological improvement at 3 days; symptomatic intracranial hemorrhage within 36 hours; and all-cause death.All 300 patients who were randomized (mean age, 72.7 years; 141 [47%] women) completed the trial. The number of participants with greater than 50% reperfusion of the previously occluded vascular territory was 29 of 150 (19.3%) in the 0.40 mg/kg group vs 29 of 150 (19.3%) in the 0.25 mg/kg group (unadjusted risk difference, 0.0% [95% CI, -8.9% to -8.9%]; adjusted risk ratio, 1.03 [95% CI, 0.66-1.61]; P = .89). Among the 6 secondary outcomes, there were no significant differences in any of the 4 functional outcomes between the 0.40 mg/kg and 0.25 mg/kg groups nor in all-cause deaths (26 [17%] vs 22 [15%]; unadjusted risk difference, 2.7% [95% CI, -5.6% to 11.0%]) or symptomatic intracranial hemorrhage (7 [4.7%] vs 2 [1.3%]; unadjusted risk difference, 3.3% [95% CI, -0.5% to 7.2%]).Among patients with large vessel occlusion ischemic stroke, a dose of 0.40 mg/kg, compared with 0.25 mg/kg, of tenecteplase did not significantly improve cerebral reperfusion prior to endovascular thrombectomy. The findings suggest that the 0.40-mg/kg dose of tenecteplase does not confer an advantage over the 0.25-mg/kg dose in patients with large vessel occlusion ischemic stroke in whom endovascular thrombectomy is planned.ClinicalTrials.gov Identifier: NCT03340493;,citation_author=Bruce C. V. Campbell;,citation_author=Peter J. Mitchell;,citation_author=Leonid Churilov;,citation_author=Nawaf Yassi;,citation_author=Timothy J. Kleinig;,citation_author=Richard J. Dowling;,citation_author=Bernard Yan;,citation_author=Steven J. Bush;,citation_author=Vincent Thijs;,citation_author=Rebecca Scroop;,citation_author=Marion Simpson;,citation_author=Mark Brooks;,citation_author=Hamed Asadi;,citation_author=Teddy Y. Wu;,citation_author=Darshan G. Shah;,citation_author=Tissa Wijeratne;,citation_author=Henry Zhao;,citation_author=Fana Alemseged;,citation_author=Felix Ng;,citation_author=Peter Bailey;,citation_author=Henry Rice;,citation_author=Laetitia Villiers;,citation_author=Helen M. Dewey;,citation_author=Philip M. C. Choi;,citation_author=Helen Brown;,citation_author=Kendal Redmond;,citation_author=David Leggett;,citation_author=John N. Fink;,citation_author=Wayne Collecutt;,citation_author=Thomas Kraemer;,citation_author=Martin Krause;,citation_author=Dennis Cordato;,citation_author=Deborah Field;,citation_author=Henry Ma;,citation_author=Bill O’Brien;,citation_author=Benjamin Clissold;,citation_author=Ferdinand Miteff;,citation_author=Anna Clissold;,citation_author=Geoffrey C. Cloud;,citation_author=Leslie E. Bolitho;,citation_author=Luke Bonavia;,citation_author=Arup Bhattacharya;,citation_author=Alistair Wright;,citation_author=Abul Mamun;,citation_author=Fintan O’Rourke;,citation_author=John Worthington;,citation_author=Andrew A. Wong;,citation_author=Christopher R. Levi;,citation_author=Christopher F. Bladin;,citation_author=Gagan Sharma;,citation_author=Patricia M. Desmond;,citation_author=Mark W. Parsons;,citation_author=Geoffrey A. Donnan;,citation_author=Stephen M. Davis;,citation_author=EXTEND-IA TNK Part 2 investigators;,citation_publication_date=2020-04;,citation_cover_date=2020-04;,citation_year=2020;,citation_issue=13;,citation_doi=10.1001/jama.2020.1511;,citation_issn=0098-7484;,citation_volume=323;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Role of Intravenous Thrombolytics Prior to Endovascular Thrombectomy;,citation_abstract=Intravenous thrombolytics and endovascular thrombectomy for ischemic stroke have evolved in parallel. However, the best approach to combine these reperfusion therapies in patients eligible for both strategies remains uncertain. Initial randomized trials of endovascular thrombectomy included administration of intravenous thrombolytics to all eligible patients. However, whether that is of net benefit has been questioned and parallels drawn with treatment of ST-segment–elevation myocardial infarction, where intravenous thrombolytics are only given if first medical contact to percutaneous intervention is expected to be &amp;amp;amp;gt;90 minutes. Six randomized trials of a direct thrombectomy approach versus intravenous thrombolytics followed by endovascular thrombectomy have now reported their results. With exception of a minority of patients in one trial, the trials all used alteplase rather than potentially more effective tenecteplase. This review examines the current state of evidence and implications for clinical practice. Importantly, these trials only apply to patients who present to a hospital with immediate access to endovascular thrombectomy and are not relevant to patients who receive thrombolytic and are then transferred to an endovascular-capable hospital. Although 2 of the 6 randomized trials met their prespecified noninferiority margin, these margins were large compared with the absolute benefit of alteplase. Overall, functional outcome was similar, with slight trends favoring bridging thrombolytics and a significant increase in final reperfusion. Symptomatic hemorrhage was increased by \approx1.8% in the bridging group but death was nonsignificantly lower. The workflow in direct thrombectomy trials involved delaying thrombolytic administration until eligibility for thrombectomy and the trials was established and randomization completed. This reduced the time available for thrombolytics to occur prethrombectomy compared with standard practice. We conclude that, pending individual-patient data meta-analyses, intravenous thrombolytics retain an important role alongside endovascular thrombectomy. Further efforts to accelerate and enhance reperfusion with thrombolytics and perform individual patient-level pooled subgroup analyses are warranted.;,citation_author=Bruce C. V. Campbell;,citation_author=Manon Kappelhof;,citation_author=Urs Fischer;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_issue=6;,citation_doi=10.1161/STROKEAHA.122.036929;,citation_issn=0039-2499, 1524-4628;,citation_volume=53;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke;,citation_abstract=Tenecteplase vs. Alteplase for Thrombolysis in Stroke In a randomized trial involving patients with acute stroke, the incidence of revascularization was higher with tenecteplase than with alteplase for intravenous thrombolysis before endovascular thrombectomy. Cerebral hemorrhage occurred at the same rate in each group.;,citation_author=Bruce C. V. Campbell;,citation_author=Peter J. Mitchell;,citation_author=Leonid Churilov;,citation_author=Nawaf Yassi;,citation_author=Timothy J. Kleinig;,citation_author=Richard J. Dowling;,citation_author=Bernard Yan;,citation_author=Steven J. Bush;,citation_author=Helen M. Dewey;,citation_author=Vincent Thijs;,citation_author=Rebecca Scroop;,citation_author=Marion Simpson;,citation_author=Mark Brooks;,citation_author=Hamed Asadi;,citation_author=Teddy Y. Wu;,citation_author=Darshan G. Shah;,citation_author=Tissa Wijeratne;,citation_author=Timothy Ang;,citation_author=Ferdinand Miteff;,citation_author=Christopher R. Levi;,citation_author=Edrich Rodrigues;,citation_author=Henry Zhao;,citation_author=Patrick Salvaris;,citation_author=Carlos Garcia-Esperon;,citation_author=Peter Bailey;,citation_author=Henry Rice;,citation_author=Laetitia Villiers;,citation_author=Helen Brown;,citation_author=Kendal Redmond;,citation_author=David Leggett;,citation_author=John N. Fink;,citation_author=Wayne Collecutt;,citation_author=Andrew A. Wong;,citation_author=Claire Muller;,citation_author=Alan Coulthard;,citation_author=Ken Mitchell;,citation_author=John Clouston;,citation_author=Kate Mahady;,citation_author=Deborah Field;,citation_author=Henry Ma;,citation_author=Thanh G. Phan;,citation_author=Winston Chong;,citation_author=Ronil V. Chandra;,citation_author=Lee-Anne Slater;,citation_author=Martin Krause;,citation_author=Timothy J. Harrington;,citation_author=Kenneth C. Faulder;,citation_author=Brendan S. Steinfort;,citation_author=Christopher F. Bladin;,citation_author=Gagan Sharma;,citation_author=Patricia M. Desmond;,citation_author=Mark W. Parsons;,citation_author=Geoffrey A. Donnan;,citation_author=Stephen M. Davis;,citation_publication_date=2018-04;,citation_cover_date=2018-04;,citation_year=2018;,citation_issue=17;,citation_doi=10.1056/NEJMoa1716405;,citation_issn=0028-4793;,citation_pmid=29694815;,citation_volume=378;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults;,citation_abstract=BACKGROUND Safe and effective oral treatments are needed to improve clinical outcomes for nonhospitalized patients with Covid-19. Molnupiravir is an orally administered, small-molecule ribonucleoside prodrug shown to inhibit replication of severe acute respiratory syndrome coronavirus 2 in vitro and in animal models.;,citation_author=Yoseph Caraco;,citation_author=Gordon E. Crofoot;,citation_author=Pablo Andres Moncada;,citation_author=Anna Nikolaevna Galustyan;,citation_author=Dany Badibanga Musungaie;,citation_author=Brendan Payne;,citation_author=Evgeniy Kovalchuk;,citation_author=Antonio Gonzalez;,citation_author=Michelle L. Brown;,citation_author=Angela Williams-Diaz;,citation_author=Wei Gao;,citation_author=Julie M. Strizki;,citation_author=Jay Grobler;,citation_author=Jiejun Du;,citation_author=Christopher A. Assaid;,citation_author=Amanda Paschke;,citation_author=Joan R. Butterton;,citation_author=Matthew G. Johnson;,citation_author=Carisa De Anda;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=2;,citation_doi=10.1056/EVIDoa2100043;,citation_issn=2766-5526;,citation_volume=1;,citation_language=en-US;,citation_journal_title=NEJM Evidence;">
<meta name="citation_reference" content="citation_title=Causal Considerations Can Inform the Interpretation of Surprising Associations in Medical Registries;,citation_abstract=An exploratory analysis of registry data from 2437 patients with advanced gastric cancer revealed a surprising association between astrological birth signs and overall survival (OS) with p \frac{1}{4} 0.01. After dichotomizing or changing the reference sign, p-values &amp;amp;amp;lt;0.05 were observed for several birth signs following adjustments for multiple comparisons. Bayesian models with moderately skeptical priors still pointed to these associations. A more plausible causal model, justified by contextual knowledge, revealed that these associations arose from the astrological sign association with seasonality. This case study illustrates how causal considerations can guide analyses through what would otherwise be a hopeless maze of statistical possibilities.;,citation_author=Alberto Carmona-Bayonas;,citation_author=Paula Jiménez-Fonseca;,citation_author=Javier Gallego;,citation_author=Pavlos Msaouel;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=1;,citation_doi=10.1080/07357907.2021.1999971;,citation_issn=0735-7907, 1532-4192;,citation_volume=40;,citation_language=en-US;,citation_journal_title=Cancer Investigation;">
<meta name="citation_reference" content="citation_title=Prediction of quality of life in early breast cancer upon completion of adjuvant chemotherapy;,citation_abstract=Quality of life (QoL) is a complex, ordinal endpoint with multiple conditioning factors. A predictive model of QoL after adjuvant chemotherapy can support decision making or the communication of information about the range of treatment options available. Patients with localized breast cancer (n = 219) were prospectively recruited at 17 centers. Participants completed the EORTC QLQ-C30 questionnaire. The primary aim was to predict health status upon completion of adjuvant chemotherapy adjusted for multiple covariates. We developed a Bayesian model with six covariates (chemotherapy regimen, TNM stage, axillary lymph node dissection, perceived risk of recurrence, age, type of surgery, and baseline EORTC scores). This model allows both prediction and causal inference. The patients with mastectomy reported a discrete decline on all QoL scores. The effect of surgery depended on the interaction with age. Women with ages on either end of the range displayed worse scores, especially with mastectomy. The perceived risk of recurrence had a striking effect on health status. In conclusion, we have developed a predictive model of health status in patients with early breast cancer based on the individual’s profile.;,citation_author=Alberto Carmona-Bayonas;,citation_author=Caterina Calderón;,citation_author=Raquel Hernández;,citation_author=Ana Fernández Montes;,citation_author=Beatriz Castelo;,citation_author=Laura Ciria-Suarez;,citation_author=Mónica Antoñanzas;,citation_author=Jacobo Rogado;,citation_author=Vilma Pacheco-Barcia;,citation_author=Elena Asensio Martínez;,citation_author=Alejandra Ivars;,citation_author=Francisco Ayala de la Peña;,citation_author=Paula Jimenez-Fonseca;,citation_publication_date=2021-07;,citation_cover_date=2021-07;,citation_year=2021;,citation_issue=1;,citation_doi=10.1038/s41523-021-00296-8;,citation_issn=2374-4677;,citation_volume=7;,citation_language=en-US;,citation_journal_title=npj Breast Cancer;,citation_publisher=Nature Publishing Group;">
<meta name="citation_reference" content="citation_title=Missing data: A statistical framework for practice;,citation_abstract=Missing data are ubiquitous in medical research, yet there is still uncertainty over when restricting to the complete records is likely to be acceptable, when more complex methods (e.g. maximum likelihood, multiple imputation and Bayesian methods) should be used, how they relate to each other and the role of sensitivity analysis. This article seeks to address both applied practitioners and researchers interested in a more formal explanation of some of the results. For practitioners, the framework, illustrative examples and code should equip them with a practical approach to address the issues raised by missing data (particularly using multiple imputation), alongside an overview of how the various approaches in the literature relate. In particular, we describe how multiple imputation can be readily used for sensitivity analyses, which are still infrequently performed. For those interested in more formal derivations, we give outline arguments for key results, use simple examples to show how methods relate, and references for full details. The ideas are illustrated with a cohort study, a multi-centre case control study and a randomised clinical trial.;,citation_author=James R. Carpenter;,citation_author=Melanie Smuk;,citation_publication_date=2021-06;,citation_cover_date=2021-06;,citation_year=2021;,citation_issue=5;,citation_doi=10.1002/bimj.202000196;,citation_issn=0323-3847, 1521-4036;,citation_volume=63;,citation_language=en-US;,citation_journal_title=Biometrical Journal;">
<meta name="citation_reference" content="citation_title=Association of Dose of Intracranial Hypertension with Outcome in Subarachnoid Hemorrhage;,citation_abstract=In patients with aneurysmal subarachnoid hemorrhage (aSAH) the burden of intracranial pressure (ICP) and its contribution to outcomes remains unclear. In this multicenter study, the independent association between intensity and duration, or “dose,” of episodes of intracranial hypertension and 12-month neurological outcomes was investigated.;,citation_author=Giorgia Carra;,citation_author=Francesca Elli;,citation_author=Bogdan Ianosi;,citation_author=Marine Flechet;,citation_author=Lukas Huber;,citation_author=Verena Rass;,citation_author=Bart Depreitere;,citation_author=Fabian Güiza;,citation_author=Geert Meyfroidt;,citation_author=Giuseppe Citerio;,citation_author=Raimund Helbok;,citation_publication_date=2021-06;,citation_cover_date=2021-06;,citation_year=2021;,citation_issue=3;,citation_doi=10.1007/s12028-021-01221-4;,citation_issn=1556-0961;,citation_volume=34;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Improving GRADE evidence tables part 1: A randomized trial shows improved understanding of content in summary of findings tables with a new format;,citation_abstract=Objectives: The current format of summary of findings (SoFs) tables for presenting effect estimates and associated quality of evidence improve understanding and assist users finding key information in systematic reviews. Users of SoF tables have demanded alternative formats to express findings from systematic reviews. Study Design and Setting: We conducted a randomized controlled trial among systematic review users to compare the relative merits of a new format with the current formats of SoF tables regarding understanding, accessibility of information, satisfaction, and preference. Our primary goal was to show that the new format is not inferior to the current format. Results: Of 390 potentially eligible subjects, 290 were randomized. Of seven items testing understanding, three showed similar results, two showed small differences favoring the new format, and two (understanding risk difference and quality of the evidence associated with a treatment effect) showed large differences favoring the new format [63% (95% confidence interval {CI}: 55, 71) and 62% (95% CI: 52, 71) more correct answers, respectively]. Respondents rated information in the alternative format as more accessible overall and preferred the new format over the current format. Conclusions: While providing at least similar levels of understanding for some items and increased understanding for others, users prefer the new format of SoF tables. Ó 2016 Elsevier Inc. All rights reserved.;,citation_author=Alonso Carrasco-Labra;,citation_author=Romina Brignardello-Petersen;,citation_author=Nancy Santesso;,citation_author=Ignacio Neumann;,citation_author=Reem A. Mustafa;,citation_author=Lawrence Mbuagbaw;,citation_author=Itziar Etxeandia Ikobaltzeta;,citation_author=Catherine De Stio;,citation_author=Lauren J. McCullagh;,citation_author=Pablo Alonso-Coello;,citation_author=Joerg J. Meerpohl;,citation_author=Per Olav Vandvik;,citation_author=Jan L. Brozek;,citation_author=Elie A. Akl;,citation_author=Patrick Bossuyt;,citation_author=Rachel Churchill;,citation_author=Claire Glenton;,citation_author=Sarah Rosenbaum;,citation_author=Peter Tugwell;,citation_author=Vivian Welch;,citation_author=Paul Garner;,citation_author=Gordon Guyatt;,citation_author=Holger J. Schünemann;,citation_publication_date=2016-06;,citation_cover_date=2016-06;,citation_year=2016;,citation_doi=10.1016/j.jclinepi.2015.12.007;,citation_issn=08954356;,citation_volume=74;,citation_language=en-US;,citation_journal_title=Journal of Clinical Epidemiology;">
<meta name="citation_reference" content="citation_title=Restrictive or Liberal Transfusion Strategy in Myocardial Infarction and Anemia;,citation_author=Jeffrey L. Carson;,citation_author=Maria Mori Brooks;,citation_author=Paul C. Hébert;,citation_author=Shaun G. Goodman;,citation_author=Marnie Bertolet;,citation_author=Simone A. Glynn;,citation_author=Bernard R. Chaitman;,citation_author=Tabassome Simon;,citation_author=Renato D. Lopes;,citation_author=Andrew M. Goldsweig;,citation_author=Andrew P. DeFilippis;,citation_author=J. Dawn Abbott;,citation_author=Brian J. Potter;,citation_author=Francois Martin Carrier;,citation_author=Sunil V. Rao;,citation_author=Howard A. Cooper;,citation_author=Shahab Ghafghazi;,citation_author=Dean A. Fergusson;,citation_author=William J. Kostis;,citation_author=Helaine Noveck;,citation_author=Sarang Kim;,citation_author=Meechai Tessalee;,citation_author=Gregory Ducrocq;,citation_author=Pedro Gabriel Melo de Barros e Silva;,citation_author=Darrell J. Triulzi;,citation_author=Caroline Alsweiler;,citation_author=Mark A. Menegus;,citation_author=John D. Neary;,citation_author=Lynn Uhl;,citation_author=Jordan B. Strom;,citation_author=Christopher B. Fordyce;,citation_author=Emile Ferrari;,citation_author=Johanne Silvain;,citation_author=Frances O. Wood;,citation_author=Benoit Daneault;,citation_author=Tamar S. Polonsky;,citation_author=Manohara Senaratne;,citation_author=Etienne Puymirat;,citation_author=Claire Bouleti;,citation_author=Benoit Lattuca;,citation_author=Harvey D. White;,citation_author=Sheryl F. Kelsey;,citation_author=P. Gabriel Steg;,citation_author=John H. Alexander;,citation_publication_date=2023-11;,citation_cover_date=2023-11;,citation_year=2023;,citation_issue=0;,citation_doi=10.1056/NEJMoa2307983;,citation_issn=0028-4793;,citation_volume=0;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=The management of acute meningitis: An update;,citation_abstract=&amp;amp;amp;lt;h3&amp;gt;ABSTRACT&amp;lt;/h3&amp;gt; <p>Meningitis remains an important cause of mortality and morbidity. Clinicians should be alert to this diagnosis and have a low threshold for investigation and treatment of meningitis. This article provides an update of current evidence and existing guidelines for the management of suspected acute meningitis in adults in the UK.</p>;,citation_author=Emma Carter;,citation_author=Fiona McGill;,citation_publication_date=2022-09;,citation_cover_date=2022-09;,citation_year=2022;,citation_issue=5;,citation_doi=10.7861/clinmed.2022-cme-meningitis;,citation_issn=1470-2118, 1473-4893;,citation_volume=22;,citation_language=en-US;,citation_journal_title=Clinical Medicine;,citation_publisher=Royal College of Physicians;">
<meta name="citation_reference" content="citation_title=Causation: One Word, Many Things;,citation_abstract=We currently have on offer a variety of different theories of causation. Many are strikingly good, providing detailed and plausible treatments of exemplary cases; and all suffer from clear counterexamples. I argue that, contra Hume and Kant, this is because causation is not a single, monolithic concept. There are different kinds of causal relations imbedded in different kinds of systems, readily described using thick causal concepts. Our causal theories pick out important and useful structures that fit some familiar cases—cases we discover and ones we devise to fit.;,citation_author=Nancy Cartwright;,citation_publication_date=2004-12;,citation_cover_date=2004-12;,citation_year=2004;,citation_issue=5;,citation_doi=10.1086/426771;,citation_issn=0031-8248, 1539-767X;,citation_volume=71;,citation_language=en-US;,citation_journal_title=Philosophy of Science;,citation_publisher=Cambridge University Press;">
<meta name="citation_reference" content="citation_title=From Causation to Explanation and Back;,citation_author=Nancy Cartwright;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Use of pragmatic and explanatory trial designs in acute care research: Lessons from COVID-19;,citation_author=Jonathan D Casey;,citation_author=Laura M Beskow;,citation_author=Jeremy Brown;,citation_author=Samuel M Brown;,citation_author=Étienne Gayat;,citation_author=Michelle Ng Gong;,citation_author=Michael O Harhay;,citation_author=Samir Jaber;,citation_author=Jacob C Jentzer;,citation_author=Pierre-François Laterre;,citation_author=John C Marshall;,citation_author=Michael A Matthay;,citation_author=Todd W Rice;,citation_author=Yves Rosenberg;,citation_author=Alison E Turnbull;,citation_author=Lorraine B Ware;,citation_author=Wesley H Self;,citation_author=Alexandre Mebazaa;,citation_author=Sean P Collins;,citation_publication_date=2022-07;,citation_cover_date=2022-07;,citation_year=2022;,citation_issue=7;,citation_doi=10.1016/S2213-2600(22)00044-3;,citation_issn=22132600;,citation_volume=10;,citation_language=en-US;,citation_journal_title=The Lancet Respiratory Medicine;">
<meta name="citation_reference" content="citation_title=Lessons to be learned in intracerebral haemorrhage research;,citation_author=Valeria Caso;,citation_author=Maria Giulia Mosconi;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=10;,citation_doi=10.1016/S1474-4422(21)00296-9;,citation_issn=14744422;,citation_volume=20;,citation_language=en-US;,citation_journal_title=The Lancet Neurology;">
<meta name="citation_reference" content="citation_title=Rapid clinical expansion and the fate of the hospitalist educator;,citation_author=Julia B. Caton;,citation_author=Shannon K. Martin;,citation_author=Marisha Burden;,citation_author=Zaven Sargsyan;,citation_author=Michelle Brooks;,citation_author=Daniel N. Ricotta;,citation_issue=n/a;,citation_doi=10.1002/jhm.12984;,citation_issn=1553-5606;,citation_volume=n/a;,citation_language=en-US;,citation_journal_title=Journal of Hospital Medicine;">
<meta name="citation_reference" content="citation_title=Pharmacological Prevention of Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage;,citation_abstract=Causes of morbidity and mortality following aneurysmal subarachnoid hemorrhage (aSAH) include early brain injury and delayed neurologic deterioration, which may result from delayed cerebral ischemia (DCI). Complex pathophysiological mechanisms underlie DCI, which often includes angiographic vasospasm (aVSP) of cerebral arteries.;,citation_author=Meghan M. Caylor;,citation_author=R. Loch Macdonald;,citation_publication_date=2023-09;,citation_cover_date=2023-09;,citation_year=2023;,citation_doi=10.1007/s12028-023-01847-6;,citation_issn=1556-0961;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Surveillance Report of Traumatic Brain Injury-related Deaths by Age Group, Sex, and Mechanism of Injury—United States, 2018 and 2019;,citation_author=Centers for Disease Control and Prevention;,citation_publication_date=2022;,citation_cover_date=2022;,citation_year=2022;,citation_language=en-US;,citation_publisher=enters for Disease Control and Prevention;">
<meta name="citation_reference" content="citation_title=Recovery Focused Nutritional Therapy across the Continuum of Care: Learning from COVID-19;,citation_abstract=Targeted nutritional therapy should be started early in severe illness and sustained through to recovery if clinical and patient-centred outcomes are to be optimised. The coronavirus disease 2019 (COVID-19) pandemic has shone a light on this need. The literature on nutrition and COVID-19 mainly focuses on the importance of nutrition to preserve life and prevent clinical deterioration during the acute phase of illness. However, there is a lack of information guiding practice across the whole patient journey (e.g., hospital to home) with a focus on targeting recovery (e.g., long COVID). This review paper is of relevance to doctors and other healthcare professionals in acute care and primary care worldwide, since it addresses early, multi-modal individualised nutrition interventions across the continuum of care to improve COVID-19 patient outcomes. It is of relevance to nutrition experts and non-nutrition experts and can be used to promote inter-professional and inter-organisational knowledge transfer on the topic. The primary goal is to prevent complications and support recovery to enable COVID-19 patients to achieve the best possible nutritional, physical, functional and mental health status and to apply the learning to date from the COVID-19 pandemic to other patient groups experiencing acute severe illness.;,citation_author=Emanuele Cereda;,citation_author=Pere Clavé;,citation_author=Peter F. Collins;,citation_author=Anne Holdoway;,citation_author=Paul E. Wischmeyer;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_issue=9;,citation_doi=10.3390/nu13093293;,citation_issn=2072-6643;,citation_volume=13;,citation_language=en-US;,citation_journal_title=Nutrients;">
<meta name="citation_reference" content="citation_title=Cardiac Arrest Treatment Center Differences in Sedation and Analgesia Dosing During Targeted Temperature Management;,citation_abstract=Background: Sedation and analgesia are recommended during targeted temperature management (TTM) after cardiac arrest, but there are few data to provide guidance on dosing to bedside clinicians. We evaluated differences in patient-level sedation and analgesia dosing in an international multicenter TTM trial to better characterize current practice and clinically important outcomes. Methods: A total 950 patients in the international TTM trial were randomly assigned to a TTM of 33 ^\circC or 36 ^\circC after resuscitation from cardiac arrest in 36 intensive care units. We recorded cumulative doses of sedative and analgesic drugs at 12, 24, and 48 h and normalized to midazolam and fentanyl equivalents. We compared number of medications used, dosing, and titration among centers by using multivariable models, including common severity of illness factors. We also compared dosing with time to awakening, incidence of clinical seizures, and survival. Results: A total of 614 patients at 18 centers were analyzed. Propofol (70%) and fentanyl (51%) were most frequently used. The average dosages of midazolam and fentanyl equivalents were 0.13 (0.07, 0.22) mg/kg/h and 1.16 (0.49, 1.81) g/kg/h, respectively. There were significant differences in number of medications (p &amp;amp;amp;lt; 0.001), average dosages (p &amp;lt; 0.001), and titration at all time points between centers (p < 0.001), and the outcomes of patients in these centers were associated with all parameters described in the multivariate analysis, except for a difference in the titration of sedatives between 12 and 24 h (p = 0.40). There were associations between higher dosing at 48 h (p = 0.003, odds ratio [OR] 1.75) and increased titration of analgesics between 24 and 48 h (p = 0.005, OR 4.89) with awakening after 5 days, increased titration of sedatives between 24 and 48 h with awakening after 5 days (p < 0.001, OR &amp;gt; 100), and increased titration of sedatives between 24 and 48 h with a higher incidence of clinical seizures in the multivariate analysis (p = 0.04, OR 240). There were also significant associations between decreased titration of analgesics and survival at 6 months in the multivariate analysis (p = 0.048). Conclusions: There is significant variation in choice of drug, dosing, and titration when providing sedation and analgesics between centers. Sedation and analgesia dosing and titration were associated with delayed awakening, incidence of clinical seizures, and survival, but the causal relation of these findings cannot be proven.;,citation_author=Ameldina Ceric;,citation_author=Teresa L. May;,citation_author=Anna Lybeck;,citation_author=Tobias Cronberg;,citation_author=David B. Seder;,citation_author=Richard R. Riker;,citation_author=Christian Hassager;,citation_author=Jesper Kjaergaard;,citation_author=Zana Haxhija;,citation_author=Hans Friberg;,citation_author=Josef Dankiewicz;,citation_author=Niklas Nielsen;,citation_publication_date=2022-07;,citation_cover_date=2022-07;,citation_year=2022;,citation_doi=10.1007/s12028-022-01564-6;,citation_issn=1541-6933, 1556-0961;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Cost and Access Implications of Defining CAR-T Therapy as a Drug;,citation_author=Rohan Chalasani;,citation_author=Tina B. Hershey;,citation_author=Walid F. Gellad;,citation_publication_date=2020-07;,citation_cover_date=2020-07;,citation_year=2020;,citation_issue=7;,citation_doi=10.1001/jamahealthforum.2020.0868;,citation_issn=2689-0186;,citation_volume=1;,citation_language=en-US;,citation_journal_title=JAMA Health Forum;">
<meta name="citation_reference" content="citation_title=Development and Validation of a Postprocedural Model to Predict Outcome After Endovascular Treatment for Ischemic Stroke;,citation_abstract=Outcome prediction after endovascular treatment (EVT) for ischemic stroke is important to patients, family members, and physicians.To develop and validate a model based on preprocedural and postprocedural characteristics to predict functional outcome for individual patients after EVT.A prediction model was developed using individual patient data from 7 randomized clinical trials, performed between December 2010 and December 2014. The model was developed within the Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke Trials (HERMES) collaboration and external validation in data from the Dutch Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN) Registry of patients treated in clinical practice between March 2014 and November 2017. Participants included patients from multiple centers throughout different countries in Europe, North America, East Asia, and Oceania (derivation cohort), and multiple centers in the Netherlands (validation cohort). Included were adult patients with a history of ischemic stroke from an intracranial large vessel occlusion in the anterior circulation who underwent EVT within 12 hours of symptom onset or last seen well. Data were last analyzed in July 2022.A total of 19 variables were assessed by multivariable ordinal regression to predict functional outcome (modified Rankin Scale [mRS] score) 90 days after EVT. Variables were routinely available 1 day after EVT. Akaike information criterion (AIC) was used to optimize model fit vs model complexity. Probabilities for functional independence (mRS 0-2) and survival (mRS 0-5) were derived from the ordinal model. Model performance was expressed with discrimination (C statistic) and calibration.A total of 781 patients (median [IQR] age, 67 [57-76] years; 414 men [53%]) constituted the derivation cohort, and 3260 patients (median [IQR] age, 72 [61-80] years; 1684 men [52%]) composed the validation cohort. Nine variables were included in the model: age, baseline National Institutes of Health Stroke Scale (NIHSS) score, prestroke mRS score, history of diabetes, occlusion location, collateral score, reperfusion grade, NIHSS score at 24 hours, and symptomatic intracranial hemorrhage 24 hours after EVT. External validation in the MR CLEAN Registry showed excellent discriminative ability for functional independence (C statistic, 0.91; 95% CI, 0.90-0.92) and survival (0.89; 95% CI, 0.88-0.90). The proportion of functional independence in the MR CLEAN Registry was systematically higher than predicted by the model (41% vs 34%), whereas observed and predicted survival were similar (72% vs 75%). The model was updated and implemented for clinical use.The prognostic tool MR PREDICTS@24H can be applied 1 day after EVT to accurately predict functional outcome for individual patients at 90 days and to provide reliable outcome expectations and personalize follow-up and rehabilitation plans. It will need further validation and updating for contemporary patients.;,citation_author=Vicky Chalos;,citation_author=Esmee Venema;,citation_author=Maxim J. H. L. Mulder;,citation_author=Bob Roozenbeek;,citation_author=Ewout W. Steyerberg;,citation_author=Marieke J. H. Wermer;,citation_author=Geert J. Lycklama à Nijeholt;,citation_author=H. Bart Worp;,citation_author=Mayank Goyal;,citation_author=Bruce C. V. Campbell;,citation_author=Keith W. Muir;,citation_author=Francis Guillemin;,citation_author=Serge Bracard;,citation_author=Philip White;,citation_author=Antoni Dávalos;,citation_author=Tudor G. Jovin;,citation_author=Michael D. Hill;,citation_author=Peter J. Mitchell;,citation_author=Andrew M. Demchuk;,citation_author=Jeffrey L. Saver;,citation_author=Aad Lugt;,citation_author=Scott Brown;,citation_author=Diederik W. J. Dippel;,citation_author=Hester F. Lingsma;,citation_author=HERMES CollaboratorsMR CLEAN Registry Investigators;,citation_publication_date=2023-09;,citation_cover_date=2023-09;,citation_year=2023;,citation_issue=9;,citation_doi=10.1001/jamaneurol.2023.2392;,citation_issn=2168-6149;,citation_volume=80;,citation_journal_title=JAMA Neurology;">
<meta name="citation_reference" content="citation_title=FPIN’s Clinical Inquiries;,citation_author=Jennifer G Chang;,citation_author=Christopher P Paulson;,citation_author=Rita F Smith;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Propensity score methods for observational studies with clustered data: A review;,citation_abstract=Propensity score methods are a popular approach to mitigating confounding bias when estimating causal effects in observational studies. When study units are clustered (eg, patients nested within health systems), additional challenges arise such as accounting for unmeasured confounding at multiple levels and dependence between units within the same cluster. While clustered observational data are widely used to draw causal inferences in many fields, including medicine and healthcare, extensions of propensity score methods to clustered settings are still a relatively new area of research. This article presents a framework for estimating causal effects using propensity scores when study units are nested within clusters and are nonrandomly assigned to treatment conditions. We emphasize the need for investigators to examine the nature of the clustering, among other properties, of the observational data at hand in order to guide their choice of causal estimands and the corresponding propensity score approach.;,citation_author=Ting-Hsuan Chang;,citation_author=Elizabeth A. Stuart;,citation_publication_date=2022;,citation_cover_date=2022;,citation_year=2022;,citation_issue=18;,citation_doi=10.1002/sim.9437;,citation_issn=1097-0258;,citation_volume=41;,citation_language=en-US;,citation_journal_title=Statistics in Medicine;">
<meta name="citation_reference" content="citation_title=The Boston criteria version 2.0 for cerebral amyloid angiopathy: A multicentre, retrospective, MRI–neuropathology diagnostic accuracy study;,citation_abstract=Background Cerebral amyloid angiopathy (CAA) is an age-related small vessel disease, characterised pathologically by progressive deposition of amyloid \beta in the cerebrovascular wall. The Boston criteria are used worldwide for the in-vivo diagnosis of CAA but have not been updated since 2010, before the emergence of additional MRI markers. We report an international collaborative study aiming to update and externally validate the Boston diagnostic criteria across the full spectrum of clinical CAA presentations. Methods In this multicentre, hospital-based, retrospective, MRI and neuropathology diagnostic accuracy study, we did a retrospective analysis of clinical, radiological, and histopathological data available to sites participating in the International CAA Association to formulate updated Boston criteria and establish their diagnostic accuracy across different populations and clinical presentations. Ten North American and European academic medical centres identified patients aged 50 years and older with potential CAA-related clinical presentations (ie, spontaneous intracerebral haemorrhage, cognitive impairment, or transient focal neurological episodes), available brain MRI, and histopathological assessment for CAA diagnosis. MRI scans were centrally rated at Massachusetts General Hospital (Boston, MA, USA) for haemorrhagic and non-haemorrhagic CAA markers, and brain tissue samples were rated by neuropathologists at the contributing sites. We derived the Boston criteria version 2.0 (v2.0) by selecting MRI features to optimise diagnostic specificity and sensitivity in a prespecified derivation cohort (Boston cases 1994–2012, n=159), then externally validated the criteria in a prespecified temporal validation cohort (Boston cases 2012–18, n=59) and a geographical validation cohort (non-Boston cases 2004–18; n=123), comparing accuracy of the new criteria to the currently used modified Boston criteria with histopathological assessment of CAA as the diagnostic standard. We also assessed performance of the v2.0 criteria in patients across all cohorts who had the diagnostic gold standard of brain autopsy. Findings The study protocol was finalised on Jan 15, 2017, patient identification was completed on Dec 31, 2018, and imaging analyses were completed on Sept 30, 2019. Of 401 potentially eligible patients presenting to Massachusetts General Hospital, 218 were eligible to be included in the analysis; of 160 patient datasets from other centres, 123 were included. Using the derivation cohort, we derived provisional criteria for probable CAA requiring the presence of at least two strictly lobar haemorrhagic lesions (ie, intracerebral haemorrhages, cerebral microbleeds, or foci of cortical superficial siderosis) or at least one strictly lobar haemorrhagic lesion and at least one white matter characteristic (ie, severe visible perivascular spaces in centrum semiovale or white matter hyperintensities in a multispot pattern). The sensitivity and specificity of these criteria were 74\cdot8% (95% CI 65\cdot4–82\cdot7) and 84\cdot6% (71\cdot9–93\cdot1) in the derivation cohort, 92\cdot5% (79\cdot6–98\cdot4) and 89\cdot5% (66\cdot9–98\cdot7) in the temporal validation cohort, 80\cdot2% (70\cdot8–87\cdot6) and 81\cdot5% (61\cdot9–93\cdot7) in the geographical validation cohort, and 74\cdot5% (65\cdot4–82\cdot4) and 95\cdot0% (83\cdot1–99\cdot4) in all patients who had autopsy as the diagnostic standard. The area under the receiver operating characteristic curve (AUC) was 0\cdot797 (0\cdot732–0\cdot861) in the derivation cohort, 0\cdot910 (0\cdot828–0\cdot992) in the temporal validation cohort, 0\cdot808 (0\cdot724–0\cdot893) in the geographical validation cohort, and 0\cdot848 (0\cdot794–0\cdot901) in patients who had autopsy as the diagnostic standard. The v2.0 Boston criteria for probable CAA had superior accuracy to the current Boston criteria (sensitivity 64\cdot5% [54\cdot9–73\cdot4]; specificity 95\cdot0% [83\cdot1–99\cdot4]; AUC 0\cdot798 [0\cdot741–0854]; p=0\cdot0005 for comparison of AUC) across all individuals who had autopsy as the diagnostic standard. Interpretation The Boston criteria v2.0 incorporate emerging MRI markers of CAA to enhance sensitivity without compromising their specificity in our cohorts of patients aged 50 years and older presenting with spontaneous intracerebral haemorrhage, cognitive impairment, or transient focal neurological episodes. Future studies will be needed to determine generalisability of the v.2.0 criteria across the full range of patients and clinical presentations. Funding US National Institutes of Health (R01 AG26484).;,citation_author=Andreas Charidimou;,citation_author=Gregoire Boulouis;,citation_author=Matthew P Frosch;,citation_author=Jean-Claude Baron;,citation_author=Marco Pasi;,citation_author=Jean Francois Albucher;,citation_author=Gargi Banerjee;,citation_author=Carmen Barbato;,citation_author=Fabrice Bonneville;,citation_author=Sebastian Brandner;,citation_author=Lionel Calviere;,citation_author=François Caparros;,citation_author=Barbara Casolla;,citation_author=Charlotte Cordonnier;,citation_author=Marie-Bernadette Delisle;,citation_author=Vincent Deramecourt;,citation_author=Martin Dichgans;,citation_author=Elif Gokcal;,citation_author=Jochen Herms;,citation_author=Mar Hernandez-Guillamon;,citation_author=Hans Rolf Jäger;,citation_author=Zane Jaunmuktane;,citation_author=Jennifer Linn;,citation_author=Sergi Martinez-Ramirez;,citation_author=Elena Martínez-Sáez;,citation_author=Christian Mawrin;,citation_author=Joan Montaner;,citation_author=Solene Moulin;,citation_author=Jean-Marc Olivot;,citation_author=Fabrizio Piazza;,citation_author=Laurent Puy;,citation_author=Nicolas Raposo;,citation_author=Mark A Rodrigues;,citation_author=Sigrun Roeber;,citation_author=Jose Rafael Romero;,citation_author=Neshika Samarasekera;,citation_author=Julie A Schneider;,citation_author=Stefanie Schreiber;,citation_author=Frank Schreiber;,citation_author=Corentin Schwall;,citation_author=Colin Smith;,citation_author=Levente Szalardy;,citation_author=Pascale Varlet;,citation_author=Alain Viguier;,citation_author=Joanna M Wardlaw;,citation_author=Andrew Warren;,citation_author=Frank A Wollenweber;,citation_author=Marialuisa Zedde;,citation_author=Mark A Buchem;,citation_author=M Edip Gurol;,citation_author=Anand Viswanathan;,citation_author=Rustam Al-Shahi Salman;,citation_author=Eric E Smith;,citation_author=David J Werring;,citation_author=Steven M Greenberg;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_issue=8;,citation_doi=10.1016/S1474-4422(22)00208-3;,citation_issn=1474-4422;,citation_volume=21;,citation_language=en-US;,citation_journal_title=The Lancet Neurology;">
<meta name="citation_reference" content="citation_title=The Complexities of Mechanical Ventilation: Toppling the Tower of Babel;,citation_abstract=The exponential increase in the complexity of ventilator technology has created a growing knowledge gap that hinders education, research, and ultimately the quality of patient care. This gap is best addressed with a standardized approach to educating clinicians, just as education for basic and advanced life support classes is standardized. We have developed such a program, called Standardized Education for Ventilatory Assistance (SEVA), based on a formal taxonomy for modes of mechanical ventilation. The SEVA program is a progressive system of 6 sequential courses starting from an assumption of no prior knowledge and proceeding to full mastery of advanced techniques. The vision of the program is to provide a unique platform for standardizing training by unifying the concepts of physics, physiology, and technology of mechanical ventilation. The mission is to use both online and in-person simulation-based instruction that has both self-directed and instructor-led components to elevate the skills of health care providers to the mastery level. The first 3 levels of SEVA are free and open to the public. We are developing mechanisms to offer the other levels. Spinoffs of the SEVA program include a free smartphone app that classifies virtually all modes on all ventilators used in the United States (Ventilator Mode Map), a free biweekly online training sessions focusing on waveform interpretation (SEVA-VentRounds), and modifications to the electronic health care record system for entering and charting ventilator orders. The exponential increase in the complexity of ventilator technology has created a growing knowledge gap that hinders education, research, and ultimately the quality of patient care. This gap is best addressed with a standardized approach to educating clinicians, just as education for basic and advanced life support classes is standardized. We have developed such a program, called Standardized Education for Ventilatory Assistance (SEVA), based on a formal taxonomy for modes of mechanical ventilation. The SEVA program is a progressive system of 6 sequential courses starting from an assumption of no prior knowledge and proceeding to full mastery of advanced techniques. The vision of the program is to provide a unique platform for standardizing training by unifying the concepts of physics, physiology, and technology of mechanical ventilation. The mission is to use both online and in-person simulation-based instruction that has both self-directed and instructor-led components to elevate the skills of health care providers to the mastery level. The first 3 levels of SEVA are free and open to the public. We are developing mechanisms to offer the other levels. Spinoffs of the SEVA program include a free smartphone app that classifies virtually all modes on all ventilators used in the United States (Ventilator Mode Map), a free biweekly online training sessions focusing on waveform interpretation (SEVA-VentRounds), and modifications to the electronic health care record system for entering and charting ventilator orders.;,citation_author=Robert L. Chatburn;,citation_publication_date=2023-06;,citation_cover_date=2023-06;,citation_year=2023;,citation_issue=6;,citation_doi=10.4187/respcare.10828;,citation_issn=0020-1324, 1943-3654;,citation_pmid=37225651;,citation_volume=68;,citation_language=en-US;,citation_journal_title=Respiratory Care;,citation_publisher=Respiratory Care;">
<meta name="citation_reference" content="citation_title=The Causal Cookbook: Recipes for Propensity Scores, G-Computation, and Doubly Robust Standardization;,citation_abstract=Recent developments in the causal inference literature have renewed psychologists’ interest in how to improve causal conclusions based on observational data. A lot of the recent writing has focused on concerns of causal identification (under which conditions is it, in principle, possible to recover causal effects?); in this primer, we turn to causal estimation (how do we actually turn the data into an effect estimate?) and modern approaches to it that are commonly used in epidemiology. First, we explain how causal estimands can be defined rigorously with the help of the potential outcomes framework, and we highlight four crucial assumptions necessary for causal inference to succeed (exchangeability, positivity, consistency, and non-interference). Next, we present three types of approaches to causal estimation and compare their strengths and weaknesses: propensity score methods (in which the independent variable is modeled as a function of controls), g-computation methods (in which the dependent variable is modeled as a function of both controls and the independent variable), and doubly robust estimators (which combine models for both independent and dependent variables). A companion R Notebook can be found at github.com/ArthurChatton/CausalCookbook. We hope that this non-technical introduction not only helps psychologists and other social scientists expand their causal toolbox but also facilitates communication across disciplinary boundaries when it comes to causal inference, a research goal common to all fields of research.;,citation_author=Arthur Chatton;,citation_author=Julia M. Rohrer;,citation_publication_date=2023-09;,citation_cover_date=2023-09;,citation_year=2023;,citation_doi=10.31234/osf.io/k2gzp;,citation_language=en-US;,citation_technical_report_institution=PsyArXiv;">
<meta name="citation_reference" content="citation_title=Lowering Cholesterol and Intracerebral Hemorrhage: There Won’t Be Blood!;,citation_author=Seemant Chaturvedi;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_issue=2;,citation_doi=10.1161/STROKEAHA.121.037523;,citation_issn=0039-2499, 1524-4628;,citation_volume=53;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=Corticosteroids in COVID-19 and non-COVID-19 ARDS: A systematic review and meta-analysis;,citation_abstract=Purpose: Corticosteroids are now recommended for patients with severe COVID-19 including those with COVIDrelated ARDS. This has generated renewed interest regarding whether corticosteroids should be used in non-COVID ARDS as well. The objective of this study was to summarize all RCTs examining the use of corticosteroids in ARDS. Methods: The protocol of this study was pre-registered on PROSPERO (CRD42020200659). We searched online databases including MEDLINE, EMBASE, CDC library of COVID research, CINAHL, and COCHRANE. We included RCTs that compared the effect of corticosteroids to placebo or usual care in adult patients with ARDS, including patients with COVID-19. Three reviewers abstracted data independently and in duplicate using a pre-specified standardized form. We assessed individual study risk of bias using the revised Cochrane ROB-2 tool and rated certainty in outcomes using GRADE methodology. We pooled data using a random effects model. The main outcome for this review was 28-day-mortality. Results: We included 18 RCTs enrolling 2826 patients. The use of corticosteroids probably reduced mortality in patients with ARDS of any etiology (2740 patients in 16 trials, RR 0.82, 95% CI 0.72–0.95, ARR 8.0%, 95% CI 2.2–12.5%, moderate certainty). Patients who received a longer course of corticosteroids (over 7 days) had higher rates of survival compared to a shorter course. Conclusion: The use of corticosteroids probably reduces mortality in patients with ARDS. This effect was consistent between patients with COVID-19 and non-COVID-19 ARDS, corticosteroid types, and dosage.;,citation_author=Dipayan Chaudhuri;,citation_author=Kiyoka Sasaki;,citation_author=Aram Karkar;,citation_author=Sameer Sharif;,citation_author=Kimberly Lewis;,citation_author=Manoj J. Mammen;,citation_author=Paul Alexander;,citation_author=Zhikang Ye;,citation_author=Luis Enrique Colunga Lozano;,citation_author=Marie Warrer Munch;,citation_author=Anders Perner;,citation_author=Bin Du;,citation_author=Lawrence Mbuagbaw;,citation_author=Waleed Alhazzani;,citation_author=Stephen M. Pastores;,citation_author=John Marshall;,citation_author=François Lamontagne;,citation_author=Djillali Annane;,citation_author=Gianfranco Umberto Meduri;,citation_author=Bram Rochwerg;,citation_publication_date=2021-05;,citation_cover_date=2021-05;,citation_year=2021;,citation_issue=5;,citation_doi=10.1007/s00134-021-06394-2;,citation_issn=0342-4642, 1432-1238;,citation_volume=47;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Permissive azotemia during acute kidney injury enables more rapid renal recovery and less renal fibrosis: A hypothesis and clinical development plan;,citation_abstract=Preclinical models of acute kidney injury (AKI) consistently demonstrate that a uremic milieu enhances renal recovery and decreases kidney fibrosis. Similarly, significant decreases in monocyte/macrophage infiltration, complement levels, and other markers of inflammation in the injured kidney are observed across multiple studies and species. In essence, decreased renal clearance has the surprising and counterintuitive effect of being an effective treatment for AKI. In this Perspective, the author suggests a hypothesis describing why the uremic milieu is kidney protective and proposes a clinical trial of “permissive azotemia” to improve renal recovery and long-term renal outcomes in critically ill patients with severe AKI.;,citation_author=Lakhmir S. Chawla;,citation_publication_date=2022-12;,citation_cover_date=2022-12;,citation_year=2022;,citation_issue=1;,citation_doi=10.1186/s13054-022-03988-0;,citation_issn=1364-8535;,citation_volume=26;,citation_language=en-US;,citation_journal_title=Critical Care;">
<meta name="citation_reference" content="citation_title=Early Recanalization Among Patients Undergoing Bridging Therapy With Tenecteplase or Alteplase;,citation_abstract=BACKGROUND: Intravenous thrombolysis (IVT) with alteplase or tenecteplase before mechanical thrombectomy is the recommended treatment for large-vessel occlusion acute ischemic stroke. There are divergent data on whether these agents differ in terms of early recanalization (ER) rates before mechanical thrombectomy, and little data on their potential differences stratified by ER predictors such as IVT to ER evaluation (IVT-to-EReval) time, occlusion site and thrombus length. METHODS: We retrospectively compared the likelihood of ER after IVT with tenecteplase or alteplase in anterior circulation large-vessel occlusion acute ischemic stroke patients from the PREDICT-RECANAL (alteplase) and Tenecteplase Treatment in Ischemic Stroke (tenecteplase) French multicenter registries. ER was defined as a modified Thrombolysis in Cerebral Infarction score 2b-3 on the first angiographic run, or noninvasive vascular imaging in patients with early neurological improvement. Analyses were based on propensity score overlap weighting (leading to exact balance in patient history, stroke characteristics, and initial management between groups) and confirmed with adjusted logistic regression (sensitivity analysis). A stratified analysis based on pre-established ER predictors (IVT-to-EReval time, occlusion site, and thrombus length) was conducted. RESULTS: Overall, 1865 patients were included. ER occurred in 156/787 (19.8%) and 199/1078 (18.5%) patients treated with tenecteplase or alteplase, respectively (odds ratio, 1.09 [95% CI, 0.83–1.44]; P=0.52). A differential effect of tenecteplase versus alteplase on the probability of ER according to thrombus length was observed (Pinteraction=0.003), with tenecteplase being associated with higher odds of ER in thrombi &amp;amp;amp;gt;10 mm (odds ratio, 2.43 [95% CI, 1.02–5.81]; P=0.04). There was no differential effect of tenecteplase versus alteplase on the likelihood of ER according to the IVT-to-EReval time (Pinteraction=0.40) or occlusion site (Pinteraction=0.80). CONCLUSIONS: Both thrombolytics achieved ER in one-fifth of patients with large-vessel occlusion acute ischemic stroke without significant interaction with IVT-to-EReval time and occlusion site. Compared with alteplase, tenecteplase was associated with a 2-fold higher likelihood of ER in larger thrombi.;,citation_author=Thomas Checkouri;,citation_author=Gaspard Gerschenfeld;,citation_author=Pierre Seners;,citation_author=Marion Yger;,citation_author=Wagih Ben Hassen;,citation_author=Nicolas Chausson;,citation_author=Stéphane Olindo;,citation_author=Jildaz Caroff;,citation_author=Gaultier Marnat;,citation_author=Frédéric Clarençon;,citation_author=Jean-Claude Baron;,citation_author=Guillaume Turc;,citation_author=Sonia Alamowitch;,citation_author=Caroline Arquizan;,citation_author=Yves Berthezene;,citation_author=Grégoire Boulouis;,citation_author=Serge Bracard;,citation_author=Nicolas Bricout;,citation_author=Tae-Hee Cho;,citation_author=Arturo Consoli;,citation_author=Vincent Costalat;,citation_author=Jean-Philippe Cottier;,citation_author=Séverine Debiais;,citation_author=Benjamin Gory;,citation_author=Hilde Henon;,citation_author=Bertrand Lapergue;,citation_author=Michael Obadia;,citation_author=Catherine Oppenheim;,citation_author=Fernando Pico;,citation_author=Michel Piotin;,citation_author=Sébastien Richard;,citation_author=Mathieu Zuber;,citation_author=Clémence Blanc;,citation_author=David Calvet;,citation_author=Christian Denier;,citation_author=Sam Ghazanfari;,citation_author=Erwah Kalsoum;,citation_author=Yann L’Hermitte;,citation_author=Laurence Legrand;,citation_author=Jean-Sebastien Liegey;,citation_author=Malgorzata Milnerowicz;,citation_author=Olivier Naggara;,citation_author=Mathilde Poli;,citation_author=Kévin Premat;,citation_author=Igor Sibon;,citation_author=Candice Sabben;,citation_author=Eimad Shotar;,citation_author=Didier Smadja;,citation_author=Laurent Spelle;,citation_publication_date=2023-10;,citation_cover_date=2023-10;,citation_year=2023;,citation_issue=10;,citation_doi=10.1161/STROKEAHA.123.042691;,citation_issn=0039-2499, 1524-4628;,citation_volume=54;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=Effect of Remote Ischemic Conditioning vs Usual Care on Neurologic Function in Patients With Acute Moderate Ischemic Stroke: The RICAMIS Randomized Clinical Trial;,citation_abstract=Preclinical and clinical studies have suggested a neuroprotective effect of remote ischemic conditioning (RIC), which involves repeated occlusion/release cycles on bilateral upper limb arteries; however, robust evidence in patients with ischemic stroke is lacking.To assess the efficacy of RIC for acute moderate ischemic stroke.This multicenter, open-label, blinded–end point, randomized clinical trial including 1893 patients with acute moderate ischemic stroke was conducted at 55 hospitals in China from December 26, 2018, through January 19, 2021, and the date of final follow-up was April 19, 2021.Eligible patients were randomly assigned within 48 hours after symptom onset to receive treatment with RIC (using a pneumatic electronic device and consisting of 5 cycles of cuff inflation for 5 minutes and deflation for 5 minutes to the bilateral upper limbs to 200 mm Hg) for 10 to 14 days as an adjunct to guideline-based treatment (n = 922) or guideline-based treatment alone (n = 971).The primary end point was excellent functional outcome at 90 days, defined as a modified Rankin Scale score of 0 to 1. All end points had blinded assessment and were analyzed on a full analysis set.Among 1893 eligible patients with acute moderate ischemic stroke who were randomized (mean [SD] age, 65 [10.3] years; 606 women [34.1%]), 1776 (93.8%) completed the trial. The number with excellent functional outcome at 90 days was 582 (67.4%) in the RIC group and 566 (62.0%) in the control group (risk difference, 5.4% [95% CI, 1.0%-9.9%]; odds ratio, 1.27 [95% CI, 1.05-1.54]; P = .02). The proportion of patients with any adverse events was 6.8% (59/863) in the RIC group and 5.6% (51/913) in the control group.Among adults with acute moderate ischemic stroke, treatment with remote ischemic conditioning compared with usual care significantly increased the likelihood of excellent neurologic function at 90 days. However, these findings require replication in another trial before concluding efficacy for this intervention.ClinicalTrials.gov Identifier: NCT03740971;,citation_author=Hui-Sheng Chen;,citation_author=Yu Cui;,citation_author=Xiao-Qiu Li;,citation_author=Xin-Hong Wang;,citation_author=Yu-Tong Ma;,citation_author=Yong Zhao;,citation_author=Jing Han;,citation_author=Chang-Qing Deng;,citation_author=Mei Hong;,citation_author=Ying Bao;,citation_author=Li-Hong Zhao;,citation_author=Ting-Guang Yan;,citation_author=Ren-Lin Zou;,citation_author=Hui Wang;,citation_author=Zhuo Li;,citation_author=Li-Shu Wan;,citation_author=Li Zhang;,citation_author=Lian-Qiang Wang;,citation_author=Li-Yan Guo;,citation_author=Ming-Nan Li;,citation_author=Dong-Qing Wang;,citation_author=Qiang Zhang;,citation_author=Da-Wei Chang;,citation_author=Hong-Li Zhang;,citation_author=Jing Sun;,citation_author=Chong Meng;,citation_author=Zai-Hui Zhang;,citation_author=Li-Ying Shen;,citation_author=Li Ma;,citation_author=Gui-Chun Wang;,citation_author=Run-Hui Li;,citation_author=Ling Zhang;,citation_author=Cheng Bi;,citation_author=Li-Yun Wang;,citation_author=Duo-Lao Wang;,citation_author=RICAMIS Investigators;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_issue=7;,citation_doi=10.1001/jama.2022.13123;,citation_issn=0098-7484;,citation_volume=328;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Effect of Argatroban Plus Intravenous Alteplase vs Intravenous Alteplase Alone on Neurologic Function in Patients With Acute Ischemic Stroke: The ARAIS Randomized Clinical Trial;,citation_abstract=Previous studies suggested a benefit of argatroban plus alteplase (recombinant tissue-type plasminogen activator) in patients with acute ischemic stroke (AIS). However, robust evidence in trials with large sample sizes is lacking.To assess the efficacy of argatroban plus alteplase for AIS.This multicenter, open-label, blinded end point randomized clinical trial including 808 patients with AIS was conducted at 50 hospitals in China with enrollment from January 18, 2019, through October 30, 2021, and final follow-up on January 24, 2022.Eligible patients were randomly assigned within 4.5 hours of symptom onset to the argatroban plus alteplase group (n = 402), which received intravenous argatroban (100 \mug/kg bolus over 3-5 minutes followed by an infusion of 1.0 \mug/kg per minute for 48 hours) within 1 hour after alteplase (0.9 mg/kg; maximum dose, 90 mg; 10% administered as 1-minute bolus, remaining infused over 1 hour), or alteplase alone group (n = 415), which received intravenous alteplase alone. Both groups received guideline-based treatments.The primary end point was excellent functional outcome, defined as a modified Rankin Scale score (range, 0 [no symptoms] to 6 [death]) of 0 to 1 at 90 days. All end points had blinded assessment and were analyzed on a full analysis set.Among 817 eligible patients with AIS who were randomized (median [IQR] age, 65 [57-71] years; 238 [29.1%] women; median [IQR] National Institutes of Health Stroke Scale score, 9 [7-12]), 760 (93.0%) completed the trial. At 90 days, 210 of 329 participants (63.8%) in the argatroban plus alteplase group vs 238 of 367 (64.9%) in the alteplase alone group had an excellent functional outcome (risk difference, -1.0% [95% CI, -8.1% to 6.1%]; risk ratio, 0.98 [95% CI, 0.88-1.10]; P = .78). The percentages of participants with symptomatic intracranial hemorrhage, parenchymal hematoma type 2, and major systemic bleeding were 2.1% (8/383), 2.3% (9/383), and 0.3% (1/383), respectively, in the argatroban plus alteplase group and 1.8% (7/397), 2.5% (10/397), and 0.5% (2/397), respectively, in the alteplase alone group.Among patients with acute ischemic stroke, treatment with argatroban plus intravenous alteplase compared with alteplase alone did not result in a significantly greater likelihood of excellent functional outcome at 90 days.ClinicalTrials.gov Identifier: NCT03740958;,citation_author=Hui-Sheng Chen;,citation_author=Yu Cui;,citation_author=Zhong-He Zhou;,citation_author=Ying-Jie Dai;,citation_author=Gao-Hua Li;,citation_author=Zhao-Long Peng;,citation_author=Yi Zhang;,citation_author=Xiao-Dong Liu;,citation_author=Zhi-Mei Yuan;,citation_author=Chang-Hao Jiang;,citation_author=Qing-Cheng Yang;,citation_author=Ying-Jie Duan;,citation_author=Guang-Bin Ma;,citation_author=Li-Wei Zhao;,citation_author=Rui-Xian Wang;,citation_author=Yuan-Lin Sun;,citation_author=Lei Shen;,citation_author=Er-Qiang Wang;,citation_author=Li-Hua Wang;,citation_author=Ye-Fang Feng;,citation_author=Feng-Yun Wang;,citation_author=Ren-Lin Zou;,citation_author=He-Ping Yang;,citation_author=Kai Wang;,citation_author=Duo-Lao Wang;,citation_author=Yi-Long Wang;,citation_author=ARAIS Investigators;,citation_publication_date=2023-02;,citation_cover_date=2023-02;,citation_year=2023;,citation_issue=8;,citation_doi=10.1001/jama.2023.0550;,citation_issn=0098-7484;,citation_volume=329;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Impact of Altered Airway Pressure on Intracranial Pressure, Perfusion, and Oxygenation: A Narrative Review;,citation_author=Han Chen;,citation_author=David K. Menon;,citation_author=Brian P. Kavanagh;,citation_publication_date=2019-02;,citation_cover_date=2019-02;,citation_year=2019;,citation_issue=2;,citation_doi=10.1097/CCM.0000000000003558;,citation_issn=0090-3493;,citation_volume=47;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Raising awareness for time-limited trial discussion upon ICU triage and admission;,citation_author=Emmanuel Hei-Lok Cheung;,citation_author=Jonathan Chun-Hei Cheung;,citation_author=Yu-Yeung Yip;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_issue=2;,citation_doi=10.1007/s00134-021-06590-0;,citation_issn=0342-4642, 1432-1238;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Re-analysis on the statistical sampling biases of a mask promotion trial in Bangladesh: A statistical replication;,citation_abstract=A recent randomized trial evaluated the impact of mask promotion on COVID-19-related outcomes. We find that staff behavior in both unblinded and supposedly blinded steps caused large and statistically significant imbalances in population sizes. These denominator differences constitute the rate differences observed in the trial, complicating inferences of causality.;,citation_author=Maria Chikina;,citation_author=Wesley Pegden;,citation_author=Benjamin Recht;,citation_publication_date=2022-09;,citation_cover_date=2022-09;,citation_year=2022;,citation_issue=1;,citation_doi=10.1186/s13063-022-06704-z;,citation_issn=1745-6215;,citation_volume=23;,citation_journal_title=Trials;">
<meta name="citation_reference" content="citation_title=Traumatic brain injury advances since 2017: What has changed?;,citation_author=Patrick F Chinnery;,citation_publication_date=2022-09;,citation_cover_date=2022-09;,citation_year=2022;,citation_doi=10.1016/S1474-4422(22)00337-4;,citation_issn=1474-4422;,citation_language=en-US;,citation_journal_title=The Lancet Neurology;">
<meta name="citation_reference" content="citation_title=Assessing the Possible Direct Effect of Birth Weight on Childhood Blood Pressure: A Sensitivity Analysis;,citation_author=A. Chiolero;,citation_author=G. Paradis;,citation_author=J. S. Kaufman;,citation_publication_date=2014-01;,citation_cover_date=2014-01;,citation_year=2014;,citation_issue=1;,citation_doi=10.1093/aje/kwt228;,citation_issn=0002-9262, 1476-6256;,citation_volume=179;,citation_language=en-US;,citation_journal_title=American Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Estimating the effect of nutritional interventions using observational data: The American Heart Association’s 2020 Dietary Goals and mortality;,citation_abstract=Background: Because randomized trials of sustained dietary changes are sometimes impractical for long-term outcomes, the explicit emulation of a (hypothetical) target trial using observational data may be an important tool for nutritional epidemiology.;,citation_author=Yu-Han Chiu;,citation_author=Jorge E Chavarro;,citation_author=Barbra A Dickerman;,citation_author=JoAnn E Manson;,citation_author=Kenneth J Mukamal;,citation_author=Kathryn M Rexrode;,citation_author=Eric B Rimm;,citation_author=Miguel A Hernán;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_issue=2;,citation_doi=10.1093/ajcn/nqab100;,citation_issn=0002-9165, 1938-3207;,citation_volume=114;,citation_language=en-US;,citation_journal_title=The American Journal of Clinical Nutrition;">
<meta name="citation_reference" content="citation_title=Early Convalescent Plasma Therapy and Mortality Among US Veterans Hospitalized With Nonsevere COVID-19: An Observational Analysis Emulating a Target Trial;,citation_abstract=Background.\quad Early convalescent plasma transfusion may reduce mortality in patients with nonsevere coronavirus disease 2019 (COVID-19). Methods.\quad This study emulates a (hypothetical) target trial using observational data from a cohort of US veterans admitted to a Department of Veterans Affairs (VA) facility between 1 May and 17 November 2020 with nonsevere COVID-19. The intervention was convalescent plasma initiated within 2 days of eligibility. Thirty-day mortality was compared using cumulative incidence curves, risk differences, and hazard ratios estimated from pooled logistic models with inverse probability weighting to adjust for confounding. Results.\quad Of 11 269 eligible person-trials contributed by 4755 patients, 402 trials were assigned to the convalescent plasma group. Forty and 671 deaths occurred within the plasma and nonplasma groups, respectively. The estimated 30-day mortality risk was 6.5% (95% confidence interval [CI], 4.0%–9.7%) in the plasma group and 6.2% (95% CI, 5.6%–7.0%) in the nonplasma group. The associated risk difference was 0.30% (95% CI, -2.30% to 3.60%) and the hazard ratio was 1.04 (95% CI, .64–1.62). Conclusions.\quad Our target trial emulation estimated no meaningful differences in 30-day mortality between nonsevere COVID19 patients treated and untreated with convalescent plasma. Clinical Trials Registration. NCT04545047.;,citation_author=Kelly Cho;,citation_author=Sarah C Keithly;,citation_author=Katherine E Kurgansky;,citation_author=Arin L Madenci;,citation_author=Hanna Gerlovin;,citation_author=Helen Marucci-Wellman;,citation_author=Annie Doubleday;,citation_author=Eva R Thomas;,citation_author=Yojin Park;,citation_author=Yuk-Lam Ho;,citation_author=Jonathan D Sugimoto;,citation_author=Kathryn P Moore;,citation_author=Alexander C Peterson;,citation_author=Constance Hoag;,citation_author=Kalpana Gupta;,citation_author=Karen Jeans;,citation_author=Molly Klote;,citation_author=Rachel Ramoni;,citation_author=Grant D Huang;,citation_author=Juan P Casas;,citation_author=David R Gagnon;,citation_author=Miguel A Hernán;,citation_author=Nicholas L Smith;,citation_author=J Michael Gaziano;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_issue=6;,citation_doi=10.1093/infdis/jiab330;,citation_issn=0022-1899, 1537-6613;,citation_volume=224;,citation_language=en-US;,citation_journal_title=The Journal of Infectious Diseases;">
<meta name="citation_reference" content="citation_title=Enhancing Surveys of Health Care Professionals: A Meta-Analysis of Techniques to Improve Response;,citation_abstract=Surveys involving health care providers are characterized by low and declining response rates (RRs), and researchers have utilized various strategies to increase survey RRs among health professionals. Based on 48 studies with 156 subgroups of within-study conditions, a multilevel meta-regression analysis was conducted to summarize the effects of different strategies employed in surveys of health professionals. An estimated overall survey RR among health professionals was 0.53 with a significant downward trend during the last half century.;,citation_author=Young Ik Cho;,citation_author=Timothy P. Johnson;,citation_author=Jonathan B. VanGeest;,citation_publication_date=2013-09;,citation_cover_date=2013-09;,citation_year=2013;,citation_issue=3;,citation_doi=10.1177/0163278713496425;,citation_issn=0163-2787, 1552-3918;,citation_volume=36;,citation_language=en-US;,citation_journal_title=Evaluation &amp;amp;amp; the Health Professions;">
<meta name="citation_reference" content="citation_title=Ischemic and Hemorrhagic Stroke Among Critically Ill Patients With Coronavirus Disease 2019: An International Multicenter Coronavirus Disease 2019 Critical Care Consortium Study;,citation_abstract=OBJECTIVES: Stroke has been reported in observational series as a frequent complication of coronavirus disease 2019, but more information is needed regarding stroke prevalence and outcomes. We explored the prevalence and outcomes of acute stroke in an international cohort of patients with coronavirus disease 2019 who required ICU admission. DESIGN: Retrospective analysis of prospectively collected database. SETTING: A registry of coronavirus disease 2019 patients admitted to ICUs at over 370 international sites was reviewed for patients diagnosed with acute stroke during their stay. PATIENTS: Patients older than 18 years old with acute coronavirus disease 2019 infection in ICU. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Of 2,699 patients identified (median age 59 yr; male 65%), 59 (2.2%) experienced acute stroke: 0.7% ischemic, 1.0% hemorrhagic, and 0.5% unspecified type. Systemic anticoagulant use was not associated with any stroke type. The frequency of diabetes, hypertension, and smoking was higher in patients with ischemic stroke than in stroke-free and hemorrhagic stroke patients. Extracorporeal membrane oxygenation support was more common among patients with hemorrhagic (56%) and ischemic stroke (16%) than in those without stroke (10%). Extracorporeal membrane oxygenation patients had higher cumulative 90-day probabilities of hemorrhagic (relative risk = 10.5) and ischemic stroke (relative risk = 1.7) versus nonextracorporeal membrane oxygenation patients. Hemorrhagic stroke increased the hazard of death (hazard ratio = 2.74), but ischemic stroke did not—similar to the effects of these stroke types seen in noncoronavirus disease 2019 ICU patients. CONCLUSIONS: In an international registry of ICU patients with coronavirus disease 2019, stroke was infrequent. Hemorrhagic stroke, but not ischemic stroke, was associated with increased mortality. Further, both hemorrhagic stroke and ischemic stroke were associated with traditional vascular risk factors. Extracorporeal membrane oxygenation use was strongly associated with both stroke and death.;,citation_author=Sung-Min Cho;,citation_author=Lavienraj Premraj;,citation_author=Jonathon Fanning;,citation_author=Samuel Huth;,citation_author=Adrian Barnett;,citation_author=Glenn Whitman;,citation_author=Rakesh C. Arora;,citation_author=Denise Battaglini;,citation_author=Diego Bastos Porto;,citation_author=HuiMahn Choi;,citation_author=Jacky Suen;,citation_author=Gianluigi Li Bassi;,citation_author=John F. Fraser;,citation_author=Chiara Robba;,citation_author=Matthew Griffee;,citation_publication_date=2021-07;,citation_cover_date=2021-07;,citation_year=2021;,citation_doi=10.1097/CCM.0000000000005209;,citation_issn=0090-3493;,citation_volume=Publish Ahead of Print;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Neurocritical Care for Extracorporeal Membrane Oxygenation Patients:;,citation_author=Sung-Min Cho;,citation_author=Salia Farrokh;,citation_author=Glenn Whitman;,citation_author=Thomas P. Bleck;,citation_author=Romergryko G. Geocadin;,citation_publication_date=2019-12;,citation_cover_date=2019-12;,citation_year=2019;,citation_issue=12;,citation_doi=10.1097/CCM.0000000000004060;,citation_issn=0090-3493;,citation_volume=47;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Coronary Artery Calcium Scoring for Prevention of Cardiovascular Disease;,citation_author=Hiu Ying Joanna Choi;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Global Incidence of Neurological Manifestations Among Patients Hospitalized With COVID-19—A Report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium;,citation_abstract=IMPORTANCE The COVID-19 pandemic continues to affect millions of people globally, with increasing reports of neurological manifestations but limited data on their incidence and associations with outcome.;,citation_author=Sherry H.-Y. Chou;,citation_author=Ettore Beghi;,citation_author=Raimund Helbok;,citation_author=Elena Moro;,citation_author=Joshua Sampson;,citation_author=Valeria Altamirano;,citation_author=Shraddha Mainali;,citation_author=Claudio Bassetti;,citation_author=Jose I. Suarez;,citation_author=Molly McNett;,citation_author=GCS-NeuroCOVID Consortium and ENERGY Consortium;,citation_author=Lawrence Nolan;,citation_author=Kristi Temro;,citation_author=Anna M. Cervantes-Arslanian;,citation_author=Pria Anand;,citation_author=Shibani Mukerji;,citation_author=Haitham Alabasi;,citation_author=M. Brandon Westover;,citation_author=Tapan Kavi;,citation_author=Sayona John;,citation_author=Ivan Da Silva;,citation_author=Arif Shaik;,citation_author=Aarti Sarwal;,citation_author=Saef Izzy;,citation_author=Eric M. Liotta;,citation_author=Ayush Batra;,citation_author=Aimee Aysenne;,citation_author=Clio Rubinos;,citation_author=Ahmed Y. Azzam;,citation_author=Mohammed A. Azab;,citation_author=Justin Sandall;,citation_author=LeighAnn M. Persondek;,citation_author=Hanno Ulmer;,citation_author=Verena Rass;,citation_author=Bettina Pfausler;,citation_author=Christoph Müller;,citation_author=Simon Jung;,citation_author=Michael Crean;,citation_author=Sara Meoni;,citation_author=Daniel Bereczki;,citation_author=Tibor Kovács;,citation_author=Netta Agajany;,citation_author=Carmel Armon;,citation_author=Sharon Wolfson;,citation_author=Maria Sofia Cotelli;,citation_author=Elisa Bianchi;,citation_author=Anis Riahi;,citation_author=Serefnur Öztürk;,citation_author=Onur Ural;,citation_author=Gryb Viktoriia;,citation_author=Mariana Lesiv;,citation_author=Luis Maia;,citation_author=Vanessa Oliveira;,citation_author=Mafalda Seabra;,citation_author=Vanessa Carvalho;,citation_author=Paul Vespa;,citation_author=Javier Provencio;,citation_author=Daiwai Olson;,citation_author=Claude Hemphill;,citation_author=Chethan P Venkatasubba Rao;,citation_author=Nerissa Ko;,citation_author=Ericka Fink;,citation_author=Courtney Robertson;,citation_author=Michelle Schober;,citation_author=Ali Smith Scott;,citation_author=Michal Hammond;,citation_author=Nicole Paul;,citation_author=Aleksandra Safonova;,citation_author=Lauren Kaplan;,citation_author=Charith Ratnayake;,citation_author=Adytia D Sharma;,citation_author=Abigail Skeel;,citation_author=Carlos Villamizar Rosales;,citation_author=Dominika Dolak;,citation_author=Panayiotis Varelas;,citation_author=Lev Lotman;,citation_author=Lalit Kaltenbach;,citation_author=Menon David K.;,citation_publication_date=2021-05;,citation_cover_date=2021-05;,citation_year=2021;,citation_issue=5;,citation_doi=10.1001/jamanetworkopen.2021.12131;,citation_issn=2574-3805;,citation_volume=4;,citation_language=en-US;,citation_journal_title=JAMA Network Open;">
<meta name="citation_reference" content="citation_title=Less pharmacotherapy is more in delirium;,citation_author=Shinn-Te Chou;,citation_author=Melanie Pogach;,citation_author=Laura K. Rock;,citation_publication_date=2022-04;,citation_cover_date=2022-04;,citation_year=2022;,citation_doi=10.1007/s00134-022-06707-z;,citation_issn=0342-4642, 1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Subarachnoid Hemorrhage;,citation_abstract=cal trials and evidence to date, prognostic considerations, controversies, recent developments, and future directions in SAH. RECENT FINDINGS Historically, management of SAH focused on prevention and treatment of subsequent cerebral vasospasm, which was thought to be the primary cause of delayed cerebral ischemia. Clinical and translational studies over the past decade, including several therapeutic phase 3 randomized clinical trials, suggest that the pathophysiology of SAH-associated brain injury is multiphasic and multifactorial beyond large vessel cerebral vasospasm. The quest to reduce SAH-associated brain injury and improve outcomes is shifting away from large vessel cerebral vasospasm to a new paradigm targeting multiple brain injury mechanisms, including early brain injury, delayed cerebral ischemia, microcirculatory dysfunction, spreading cortical depolarization, inflammation, and the brain-body interaction in vascular brain injury with critical illness. Despite multiple negative randomized clinical trials in search of potential therapeutic agents ameliorating the downstream effects after SAH, the overall outcome of SAH has improved over recent decades, likely related to improvements in interventional options for ruptured cerebral aneurysms and in critical care management. Emerging clinical evidence also suggests potential harmful impact of historic empiric treatments for SAH-associated vasospasm, such as prophylactic induction of hypertension, hypervolemia, and hemodilution (triple H therapy). With decreasing mortality, long-term SAH survivorship and efforts to reduce chronic morbidity and to improve quality of life and patient-centered outcome are growing areas of unmet need. Despite existing guidelines, significant variabilities in local and regional practices and in scientific terminologies have historically limited advancement in SAH care and therapeutic development. Large global collaborative efforts developed harmonized SAH common data elements in 2019, and studies are under way to examine how existing variabilities in SAH care impact long-term SAH outcomes. SUMMARY Although the overall incidence and mortality of SAH is decreasing with advances in preventive and acute care, SAH remains a major cause of long-term morbidity in survivors. Significant variabilities in care settings and empiric treatment protocols and inconsistent scientific terminologies have limited advancement in patient care and therapeutic clinical studies. Large consensus efforts are under way to introduce clinical guidelines and common data elements to advance therapeutic approaches and improve patient outcome....;,citation_author=Sherry Hsiang-Yi Chou;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=5;,citation_doi=10.1212/CON.0000000000001052;,citation_issn=1080-2371;,citation_volume=27;,citation_language=en-US;,citation_journal_title=CONTINUUM: Lifelong Learning in Neurology;">
<meta name="citation_reference" content="citation_title=Diabetes insipidus;,citation_abstract=Diabetes insipidus (DI) is a disorder characterized by excretion of large amounts of hypotonic urine. Central DI results from a deficiency of the hormone arginine vasopressin (AVP) in the pituitary gland or the hypothalamus, whereas nephrogenic DI results from resistance to AVP in the kidneys. Central and nephrogenic DI are usually acquired, but genetic causes must be evaluated, especially if symptoms occur in early childhood. Central or nephrogenic DI must be differentiated from primary polydipsia, which involves excessive intake of large amounts of water despite normal AVP secretion and action. Primary polydipsia is most common in psychiatric patients and health enthusiasts but the polydipsia in a small subgroup of patients seems to be due to an abnormally low thirst threshold, a condition termed dipsogenic DI. Distinguishing between the different types of DI can be challenging and is done either by a water deprivation test or by hypertonic saline stimulation together with copeptin (or AVP) measurement. Furthermore, a detailed medical history\mkern1mu, physical examination and imaging studies are needed to ensure an accurate DI diagnosis. Treatment of DI or primary polydipsia depends on the underlying aetiology and differs in central DI, nephrogenic DI and primary polydipsia.;,citation_author=Mirjam Christ-Crain;,citation_author=Daniel G. Bichet;,citation_author=Wiebke K. Fenske;,citation_author=Morris B. Goldman;,citation_author=Soren Rittig;,citation_author=Joseph G. Verbalis;,citation_author=Alan S. Verkman;,citation_publication_date=2019-12;,citation_cover_date=2019-12;,citation_year=2019;,citation_issue=1;,citation_doi=10.1038/s41572-019-0103-2;,citation_issn=2056-676X;,citation_volume=5;,citation_language=en-US;,citation_journal_title=Nature Reviews Disease Primers;">
<meta name="citation_reference" content="citation_title=Number-Needed-to-Treat (NNT) – Needs Treatment with Care;,citation_abstract=Abstract: The “number-needed-to-treat” (NNT) was introduced about 15 years ago and has gained widespread use. It has been claimed to be “easy to understand” and gives “intuitive meaning”. When used to measure the effectiveness of interventions targeting chronic disease processes e.g. atherosclerosis and osteoporosis, NNT (as well as relative and absolute risk reduction) does not capture the crucial time component, a fact that has important consequences: NNT varies over time, it may not mean that adverse events (fractures, myocardial infarctions etc.) are avoided, but simply that they are postponed. Finally, empirical studies indicate that lay people and doctors misunderstand NNT. We recommend that NNT be used with considerable care. There is probably no single effect measure that is able to convey all necessary information.;,citation_author=Palle Mark Christensen;,citation_author=Ivar Sønbø Kristiansen;,citation_publication_date=2006;,citation_cover_date=2006;,citation_year=2006;,citation_issue=1;,citation_doi=10.1111/j.1742-7843.2006.pto_412.x;,citation_issn=1742-7843;,citation_volume=99;,citation_language=en-US;,citation_journal_title=Basic &amp;amp;amp; Clinical Pharmacology &amp; Toxicology;">
<meta name="citation_reference" content="citation_title=The self-fulfilling prophecy of post-hoc power calculations;,citation_author=Christos Christogiannis;,citation_author=Stavros Nikolakopoulos;,citation_author=Nikolaos Pandis;,citation_author=Dimitris Mavridis;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_issue=2;,citation_doi=10.1016/j.ajodo.2021.10.008;,citation_issn=08895406;,citation_volume=161;,citation_language=en-US;,citation_journal_title=American Journal of Orthodontics and Dentofacial Orthopedics;">
<meta name="citation_reference" content="citation_title=US Insurer Spending on Ivermectin Prescriptions for COVID-19;,citation_author=Kao-Ping Chua;,citation_author=Rena M. Conti;,citation_author=Nora V. Becker;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_issue=6;,citation_doi=10.1001/jama.2021.24352;,citation_issn=0098-7484;,citation_volume=327;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Peri-operative neurological monitoring with electroencephalography and cerebral oximetry: A narrative review;,citation_abstract=Surgery and anaesthesia subject the brain to considerable stress in the peri-operative period. This may be caused by potentially neurotoxic anaesthetic drugs, impaired cerebral perfusion and reperfusion injury related to surgery or thromboembolic events. Patient monitoring using electroencephalogram and cerebral oximetry can assist in optimising depth of anaesthesia and assessment of cerebral metabolic activity. However, research findings have been contradictory as to whether these monitors can help ameliorate peri-operative neurocognitive complications. In this narrative review, we will discuss recent evidence in the use of electroencephalography and cerebral oximetry and the underlying scientific principles. It is important to appreciate the raw electroencephalographic changes under anaesthesia and those associated with ageing, in order to interpret depth of anaesthesia indices correctly. Cerebral oximetry is useful not only for the detection of cerebral desaturation but also to identify those patients who are particularly vulnerable to injury, for better risk stratification. An algorithm-based approach may be most effective in managing the episodes of cerebral desaturation.;,citation_author=C. K. E. Chung;,citation_author=C. C. M. Poon;,citation_author=M. G. Irwin;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=S1;,citation_doi=10.1111/anae.15616;,citation_issn=0003-2409, 1365-2044;,citation_volume=77;,citation_language=en-US;,citation_journal_title=Anaesthesia;">
<meta name="citation_reference" content="citation_title=Hospital-Level Variation in Death for Critically Ill Patients with COVID-19;,citation_abstract=Rationale: Variation in hospital mortality has been described for coronavirus disease (COVID-19), but the factors that explain these differences remain unclear.;,citation_author=Matthew M. Churpek;,citation_author=Shruti Gupta;,citation_author=Alexandra B. Spicer;,citation_author=William F. Parker;,citation_author=John Fahrenbach;,citation_author=Samantha K. Brenner;,citation_author=David E. Leaf;,citation_author=Carl P. Walther;,citation_author=Samaya J. Anumudu;,citation_author=Justin Arunthamakun;,citation_author=Kathleen F. Kopecky;,citation_author=Gregory P. Milligan;,citation_author=Peter A. McCullough;,citation_author=Thuy-Duyen Nguyen;,citation_author=Shahzad Shaefi;,citation_author=Megan L. Krajewski;,citation_author=Sidharth Shankar;,citation_author=Ameeka Pannu;,citation_author=Juan D. Valencia;,citation_author=Sushrut S. Waikar;,citation_author=Zoe A. Kibbelaar;,citation_author=Ambarish M. Athavale;,citation_author=Peter Hart;,citation_author=Shristi Upadhyay;,citation_author=Ishaan Vohra;,citation_author=Adam Green;,citation_author=Jean-Sebastien Rachoin;,citation_author=Christa A. Schorr;,citation_author=Lisa Shea;,citation_author=Daniel L. Edmonston;,citation_author=Christopher L. Mosher;,citation_author=Alexandre M. Shehata;,citation_author=Zaza Cohen;,citation_author=Valerie Allusson;,citation_author=Gabriela Bambrick-Santoyo;,citation_author=Noor Bhatti;,citation_author=Bijal Mehta;,citation_author=Aquino Williams;,citation_author=Samantha K. Brenner;,citation_author=Patricia Walters;,citation_author=Ronaldo C. Go;,citation_author=Keith M. Rose;,citation_author=Miguel A. Hernán;,citation_author=Lili Chan;,citation_author=Kusum S. Mathews;,citation_author=Steven G. Coca;,citation_author=Deena R. Altman;,citation_author=Aparna Saha;,citation_author=Howard Soh;,citation_author=Huei Hsun Wen;,citation_author=Sonali Bose;,citation_author=Emily A. Leven;,citation_author=Jing G. Wang;,citation_author=Gohar Mosoyan;,citation_author=Girish N. Nadkarni;,citation_author=Pattharawin Pattharanitima;,citation_author=Emily J. Gallagher;,citation_author=Allon N. Friedman;,citation_author=John Guirguis;,citation_author=Rajat Kapoor;,citation_author=Christopher Meshberger;,citation_author=Katherine J. Kelly;,citation_author=Chirag R. Parikh;,citation_author=Brian T. Garibaldi;,citation_author=Celia P. Corona-Villalobos;,citation_author=Yumeng Wen;,citation_author=Steven Menez;,citation_author=Rubab F. Malik;,citation_author=Elena Cervantes;,citation_author=Samir Gautam;,citation_author=Mary C. Mallappallil;,citation_author=Jie Ouyang;,citation_author=Sabu John;,citation_author=Ernie Yap;,citation_author=Yohannes Melaku;,citation_author=Ibrahim Mohamed;,citation_author=Siddartha Bajracharya;,citation_author=Isha Puri;,citation_author=Mariah Thaxton;,citation_author=Jyotsna Bhattacharya;,citation_author=John Wagner;,citation_author=Leon Boudourakis;,citation_author=H. Bryant Nguyen;,citation_author=Afshin Ahoubim;,citation_author=Leslie F. Thomas;,citation_author=Dheeraj Reddy Sirganagari;,citation_author=Pramod K. Guru;,citation_author=Kianoush Kashani;,citation_author=Shahrzad Tehranian;,citation_author=Yan Zhou;,citation_author=Paul A. Bergl;,citation_author=Jesus Rodriguez;,citation_author=Jatan A. Shah;,citation_author=Mrigank S. Gupta;,citation_author=Princy N. Kumar;,citation_author=Deepa G. Lazarous;,citation_author=Seble G. Kassaye;,citation_author=Michal L. Melamed;,citation_author=Tanya S. Johns;,citation_author=Ryan Mocerino;,citation_author=Kalyan Prudhvi;,citation_author=Denzel Zhu;,citation_author=Rebecca V. Levy;,citation_author=Yorg Azzi;,citation_author=Molly Fisher;,citation_author=Milagros Yunes;,citation_author=Kaltrina Sedaliu;,citation_author=Ladan Golestaneh;,citation_author=Maureen Brogan;,citation_author=Neelja Kumar;,citation_author=Michael Chang;,citation_author=Jyotsana Thakkar;,citation_author=Ritesh Raichoudhury;,citation_author=Akshay Athreya;,citation_author=Mohamed Farag;,citation_author=Edward J. Schenck;,citation_author=Soo Jung Cho;,citation_author=Maria Plataki;,citation_author=Sergio L. Alvarez-Mulett;,citation_author=Luis G. Gomez-Escobar;,citation_author=Di Pan;,citation_author=Stefi Lee;,citation_author=Jamuna Krishnan;,citation_author=William Whalen;,citation_author=David Charytan;,citation_author=Ashley Macina;,citation_author=Sobaata Chaudhry;,citation_author=Benjamin Wu;,citation_author=Frank Modersitzki;,citation_author=Anand Srivastava;,citation_author=Alexander S. Leidner;,citation_author=Carlos Martinez;,citation_author=Jacqueline M. Kruser;,citation_author=Richard G. Wunderink;,citation_author=Alexander J. Hodakowski;,citation_author=Juan Carlos Q. Velez;,citation_author=Eboni G. Price-Haywood;,citation_author=Luis A. Matute-Trochez;,citation_author=Anna E. Hasty;,citation_author=Muner M. B. Mohamed;,citation_author=Rupali S. Avasare;,citation_author=David Zonies;,citation_author=Meghan E. Sise;,citation_author=Erik T. Newman;,citation_author=Samah Abu Omar;,citation_author=Kapil K. Pokharel;,citation_author=Shreyak Sharma;,citation_author=Harkarandeep Singh;,citation_author=Simon Correa;,citation_author=Tanveer Shaukat;,citation_author=Omer Kamal;,citation_author=Wei Wang;,citation_author=Heather Yang;,citation_author=Jeffery O. Boateng;,citation_author=Meghan Lee;,citation_author=Ian A. Strohbehn;,citation_author=Jiahua Li;,citation_author=Ariel L. Mueller;,citation_author=Roberta Redfern;,citation_author=Nicholas S. Cairl;,citation_author=Gabriel Naimy;,citation_author=Abeer Abu-Saif;,citation_author=Danyell Hall;,citation_author=Laura Bickley;,citation_author=Chris Rowan;,citation_author=Farah Madhai-Lovely;,citation_author=Vasil Peev;,citation_author=Jochen Reiser;,citation_author=John J. Byun;,citation_author=Andrew Vissing;,citation_author=Esha M. Kapania;,citation_author=Zoe Post;,citation_author=Nilam P. Patel;,citation_author=Joy-Marie Hermes;,citation_author=Anne K. Sutherland;,citation_author=Amee Patrawalla;,citation_author=Diana G. Finkel;,citation_author=Barbara A. Danek;,citation_author=Sowminya Arikapudi;,citation_author=Jeffrey M. Paer;,citation_author=Peter Cangialosi;,citation_author=Mark Liotta;,citation_author=Jared Radbel;,citation_author=Jag Sunderram;,citation_author=Sonika Puri;,citation_author=Jayanth S. Vatson;,citation_author=Matthew T. Scharf;,citation_author=Ayesha Ahmed;,citation_author=Ilya Berim;,citation_author=Shuchi Anand;,citation_author=Joseph E. Levitt;,citation_author=Pablo Garcia;,citation_author=Suzanne M. Boyle;,citation_author=Rui Song;,citation_author=Ali Arif;,citation_author=Jingjing Zhang;,citation_author=Sang Hoon Woo;,citation_author=Xiaoying Deng;,citation_author=Goni Katz-Greenberg;,citation_author=Katharine Senter;,citation_author=Moh’d A. Sharshir;,citation_author=Vadym V. Rusnak;,citation_author=Muhammad Imran Ali;,citation_author=Terri Peters;,citation_author=Kathy Hughes;,citation_author=Anip Bansal;,citation_author=Amber S. Podoll;,citation_author=Michel Chonchol;,citation_author=Sunita Sharma;,citation_author=Ellen L. Burnham;,citation_author=Arash Rashidi;,citation_author=Rana Hejal;,citation_author=Eric Judd;,citation_author=Laura Latta;,citation_author=Ashita Tolwani;,citation_author=Timothy E. Albertson;,citation_author=Jason Y. Adams;,citation_author=Steven Y. Chang;,citation_author=Rebecca M. Beutler;,citation_author=Santa Monica;,citation_author=Carl E. Schulze;,citation_author=Etienne Macedo;,citation_author=Harin Rhee;,citation_author=Kathleen D. Liu;,citation_author=Vasantha K. Jotwani;,citation_author=Jay L. Koyner;,citation_author=Chintan V. Shah;,citation_author=Vishal Jaikaransingh;,citation_author=Stephanie M. Toth-Manikowski;,citation_author=Min J. Joo;,citation_author=James P. Lash;,citation_author=Javier A. Neyra;,citation_author=Nourhan Chaaban;,citation_author=Alfredo Iardino;,citation_author=Elizabeth H. Au;,citation_author=Jill H. Sharma;,citation_author=Marie Anne Sosa;,citation_author=Sabrina Taldone;,citation_author=Gabriel Contreras;,citation_author=David De La Zerda;,citation_author=Alessia Fornoni;,citation_author=Hayley B. Gershengorn;,citation_author=Salim S. Hayek;,citation_author=Pennelope Blakely;,citation_author=Hanna Berlin;,citation_author=Tariq U. Azam;,citation_author=Husam Shadid;,citation_author=Michael Pan;,citation_author=Patrick O’Hayer;,citation_author=Chelsea Meloche;,citation_author=Rafey Feroze;,citation_author=Rayan Kaakati;,citation_author=Danny Perry;,citation_author=Abbas Bitar;,citation_author=Elizabeth Anderson;,citation_author=Kishan J. Padalia;,citation_author=Christopher Launius;,citation_author=John P. Donnelly;,citation_author=Andrew J. Admon;,citation_author=Jennifer E. Flythe;,citation_author=Matthew J. Tugman;,citation_author=Emily H. Chang;,citation_author=Brent R. Brown;,citation_author=Amanda K. Leonberg-Yoo;,citation_author=Ryan C. Spiardi;,citation_author=Todd A. Miano;,citation_author=Meaghan S. Roche;,citation_author=Charles R. Vasquez;,citation_author=Amar D. Bansal;,citation_author=Natalie C. Ernecoff;,citation_author=Sanjana Kapoor;,citation_author=Siddharth Verma;,citation_author=Huiwen Chen;,citation_author=Csaba P. Kovesdy;,citation_author=Miklos Z. Molnar;,citation_author=Ambreen Azhar;,citation_author=S. Susan Hedayati;,citation_author=Mridula V. Nadamuni;,citation_author=Shani Shastri;,citation_author=Duwayne L. Willett;,citation_author=Samuel A. P. Short;,citation_author=Amanda D. Renaghan;,citation_author=Kyle B. Enfield;,citation_author=Pavan K. Bhatraju;,citation_author=A. Bilal Malik;,citation_author=Matthew W. Semler;,citation_author=Anitha Vijayan;,citation_author=Christina Mariyam Joy;,citation_author=Tingting Li;,citation_author=Seth Goldberg;,citation_author=Patricia F. Kao;,citation_author=Greg L. Schumaker;,citation_author=Nitender Goyal;,citation_author=Anthony J. Faugno;,citation_author=Caroline M. Hsu;,citation_author=Asma Tariq;,citation_author=Leah Meyer;,citation_author=Ravi K. Kshirsagar;,citation_author=Daniel E. Weiner;,citation_author=Marta Christov;,citation_author=Jennifer Griffiths;,citation_author=Sanjeev Gupta;,citation_author=Aromma Kapoor;,citation_author=Perry Wilson;,citation_author=Tanima Arora;,citation_author=Ugochukwu Ugwuowo;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_issue=4;,citation_doi=10.1164/rccm.202012-4547OC;,citation_issn=1073-449X, 1535-4970;,citation_volume=204;,citation_language=en-US;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=A Crash Course in Good and Bad Controls;,citation_abstract=Many students of statistics and econometrics express frustration with the way a problem known as “bad control” is treated in the traditional literature. The issue arises when the addition of a variable to a regression equation produces an unintended discrepancy between the regression coefficient and the effect that the coefficient is expected to represent. Avoiding such discrepancies presents a challenge to all analysts in the data intensive sciences. This note describes graphical tools for understanding, visualizing, and resolving the problem through a series of illustrative examples. We have found that the cases presented here can serve as a powerful instructional device to supplement more extended and formal discussions of the problem. By making this “crash course” accessible to instructors and practitioners, we hope to avail these tools to a broader community of scientists concerned with the causal interpretation of regression models.;,citation_author=Carlos Cinelli;,citation_author=Andrew Forney;,citation_author=Judea Pearl;,citation_publication_date=2020;,citation_cover_date=2020;,citation_year=2020;,citation_doi=10.2139/ssrn.3689437;,citation_issn=1556-5068;,citation_language=en-US;,citation_journal_title=SSRN Electronic Journal;">
<meta name="citation_reference" content="citation_title=Extubation in neurocritical care patients: The ENIO international prospective study;,citation_abstract=Neurocritical care patients receive prolonged invasive mechanical ventilation (IMV), but there is poor specific information in this high-risk population about the liberation strategies of invasive mechanical ventilation.;,citation_author=Raphaël Cinotti;,citation_author=Julio Cesar Mijangos;,citation_author=Paolo Pelosi;,citation_author=Matthias Haenggi;,citation_author=Mohan Gurjar;,citation_author=Marcus J. Schultz;,citation_author=Callum Kaye;,citation_author=Daniel Agustin Godoy;,citation_author=Pablo Alvarez;,citation_author=Aikaterini Ioakeimidou;,citation_author=Yoshitoyo Ueno;,citation_author=Rafael Badenes;,citation_author=Abdurrahmaan Ali Suei Elbuzidi;,citation_author=Michaël Piagnerelli;,citation_author=Muhammed Elhadi;,citation_author=Syed Tariq Reza;,citation_author=Mohammed Atef Azab;,citation_author=Victoria McCredie;,citation_author=Robert D. Stevens;,citation_author=Jean Catherine Digitale;,citation_author=Nicholas Fong;,citation_author=Karim Asehnoune;,citation_author=Paër-sélim Abback;,citation_author=Anaı̈s Codorniu;,citation_author=Giuseppe Citerio;,citation_author=Vittoria Ludovica Sala;,citation_author=Marinella Astuto;,citation_author=Eleonora Tringali;,citation_author=Daniela Alampi;,citation_author=Monica Rocco;,citation_author=Jessica Giuseppina Maugeri;,citation_author=Agrippino Bellissima;,citation_author=Matteo Filippini;,citation_author=Nicoletta Lazzeri;,citation_author=Andrea Cortegiani;,citation_author=Mariachiara Ippolito;,citation_author=Chiara Robba;,citation_author=Denise Battaglini;,citation_author=Patrick Biston;,citation_author=Mohamed Fathi Al-Gharyani;,citation_author=Russell Chabanne;,citation_author=Léo Astier;,citation_author=Benjamin Soyer;,citation_author=Samuel Gaugain;,citation_author=Alice Zimmerli;,citation_author=Urs Pietsch;,citation_author=Miodrag Filipovic;,citation_author=Giovanna Brandi;,citation_author=Giulio Bicciato;,citation_author=Ainhoa Serrano;,citation_author=Berta Monleon;,citation_author=Peter Vliet;,citation_author=Benjamin Marcel Gerretsen;,citation_author=Iris Xochitl Ortiz-Macias;,citation_author=Jun Oto;,citation_author=Noriya Enomoto;,citation_author=Tomomichi Matsuda;,citation_author=Nobutaka Masui;,citation_author=Pierre Garçon;,citation_author=Jonathan Zarka;,citation_author=Wytze J. Vermeijden;,citation_author=Alexander Daniel Cornet;,citation_author=Sergio Reyes Inurrigarro;,citation_author=Rafael Cirino Lara Domínguez;,citation_author=Maria Mercedes Bellini;,citation_author=Maria Milagros Gomez Haedo;,citation_author=Laura Lamot;,citation_author=Jose Orquera;,citation_author=Matthieu Biais;,citation_author=Delphine Georges;,citation_author=Arvind Baronia;,citation_author=Roberto Carlos Miranda-Ackerman;,citation_author=Francisco José Barbosa-Camacho;,citation_author=John Porter;,citation_author=Miguel Lopez-Morales;,citation_author=Thomas Geeraerts;,citation_author=Baptiste Compagnon;,citation_author=David Pérez-Torres;,citation_author=Estefanía Prol-Silva;,citation_author=Hana Basheer Yahya;,citation_author=Ala Khaled;,citation_author=Mohamed Ghula;,citation_author=Cracchiolo Neville Andrea;,citation_author=Palma Maria Daniela;,citation_author=Cristian Deana;,citation_author=Luigi Vetrugno;,citation_author=Manuel J. Rivera Chavez;,citation_author=Rocio Mendoza Trujillo;,citation_author=Vincent Legros;,citation_author=Benjamin Brochet;,citation_author=Olivier Huet;,citation_author=Marie Geslain;,citation_author=Mathieu Jagt;,citation_author=Job Steenkiste;,citation_author=Hazem Ahmed;,citation_author=Alexander Edward Coombs;,citation_author=Jessie Welbourne;,citation_author=Ana Alicia Velarde Pineda;,citation_author=Víctor Hugo Nubert Castillo;,citation_author=Mohammed A. Azab;,citation_author=Ahmed Y. Azzam;,citation_author=David Michael Paul Meenen;,citation_author=Gilberto Adrian Gasca;,citation_author=Alfredo Arellano;,citation_author=Forttino Galicia-Espinosa;,citation_author=José Carlos García-Ramos;,citation_author=Ghanshyam Yadav;,citation_author=Amarendra Kumar Jha;,citation_author=Vincent Robert-Edan;,citation_author=Pierre-Andre Rodie-Talbere;,citation_author=Gaurav Jain;,citation_author=Sagarika Panda;,citation_author=Sonika Agarwal;,citation_author=Yashbir Deewan;,citation_author=Gilberto Adrian Gasca;,citation_author=Alfredo Arellano;,citation_author=Syed Tariq Reza;,citation_author=Md. Mozaffer Hossain;,citation_author=Christos Papadas;,citation_author=Vasiliki Chantziara;,citation_author=Chrysanthi Sklavou;,citation_author=Yannick Hourmant;,citation_author=Nicolas Grillot;,citation_author=Job Steenkiste;,citation_author=Mathieu Jagt;,citation_author=Romain Pirracchio;,citation_author=Abdelraouf Akkari;,citation_author=Mohamed Abdelaty;,citation_author=Ahmed Hashim;,citation_author=Yoann Launey;,citation_author=Elodie Masseret;,citation_author=Sigismond Lasocki;,citation_author=Soizic Gergaud;,citation_author=Nicolas Mouclier;,citation_author=Sulekha Saxena;,citation_author=Avinash Agrawal;,citation_author=Shakti Bedanta Mishra;,citation_author=Samir Samal;,citation_author=the Colegio Mexicano de Medicina Critica ENIO Study Group;,citation_publication_date=2022-11;,citation_cover_date=2022-11;,citation_year=2022;,citation_issue=11;,citation_doi=10.1007/s00134-022-06825-8;,citation_issn=1432-1238;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=What Is the Best Fluid for Volume Resuscitation in Critically Ill Adults With Sepsis? The Jury Is Still Out, but a Verdict Is Urgently Needed …*;,citation_abstract=An abstract is unavailable.;,citation_author=Tatiana C. Ciomartan;,citation_publication_date=2014-07;,citation_cover_date=2014-07;,citation_year=2014;,citation_issue=7;,citation_doi=10.1097/CCM.0000000000000375;,citation_issn=0090-3493;,citation_volume=42;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Marijuana Legislation and Electronic Cigarette– or Vaping–Associated Lung Injury: A Historical Perspective;,citation_abstract=In JAMA Network Open, Wing et al report an intriguing and insightful analysis of state-level incidences of electronic cigarette (e-cigarette)– or vaping–associated lung injury (EVALI), determined from case rates from the Centers for Disease Control and Prevention and Surveillance, Epidemiology, and End Results estimates of state populations. They found that the incidence of EVALI is lower in states that have legalized recreational marijuana and its active ingredient, tetrahydrocannabinol (THC), compared with states where it remains illegal or available only for medicinal uses. This finding withstood adjustment for variation in vaping rates among states. The cross-sectional nature of the analysis and inherent limitations of the available data mean that the ecological fallacy and other sources of confounding may be at play. In part because of its preliminary nature, interesting questions arise from the analysis, answers to which are likely to ultimately be found at the intersection of sociology, public health, and the law. It is illuminating to examine some of these questions through a wide historical lens.;,citation_author=Meghan M. Cirulis;,citation_author=Sean J. Callahan;,citation_author=Scott K. Aberegg;,citation_publication_date=2020-04;,citation_cover_date=2020-04;,citation_year=2020;,citation_issue=4;,citation_doi=10.1001/jamanetworkopen.2020.2238;,citation_issn=2574-3805;,citation_volume=3;,citation_journal_title=JAMA Network Open;">
<meta name="citation_reference" content="citation_title=Big Data and Artificial Intelligence for Precision Medicine in the Neuro-ICU: Bla, Bla, Bla;,citation_author=Giuseppe Citerio;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_doi=10.1007/s12028-021-01427-6;,citation_issn=1541-6933, 1556-0961;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Management of arterial partial pressure of carbon dioxide in the first week after traumatic brain injury: Results from the CENTER-TBI study;,citation_abstract=Purpose: To describe the management of arterial partial pressure of carbon dioxide (PaCO2) in severe traumatic brain-injured (TBI) patients, and the optimal target of PaCO2 in patients with high intracranial pressure (ICP). Methods: Secondary analysis of CENTER-TBI, a multicentre, prospective, observational, cohort study. The primary aim was to describe current practice in PaCO2 management during the first week of intensive care unit (ICU) after TBI, focusing on the lowest PaCO2 values. We also assessed PaCO2 management in patients with and without ICP monitoring (ICPm), and with and without intracranial hypertension. We evaluated the effect of profound hyperventilation (defined as PaCO2 &amp;amp;amp;lt; 30 mmHg) on long-term outcome. Results: We included 1100 patients, with a total of 11,791 measurements of PaCO2 (5931 lowest and 5860 highest daily values). The mean (  SD) PaCO2 was 38.9 ( 5.2) mmHg, and the mean minimum PaCO2 was 35.2 ( 5.3) mmHg. Mean daily minimum P aCO2 values were significantly lower in the ICPm group (34.5 vs 36.7 mmHg, p &amp;lt; 0.001). Daily PaCO2 nadir was lower in patients with intracranial hypertension (33.8 vs 35.7 mmHg, p < 0.001). Considerable heterogeneity was observed between centers. Management in a centre using profound hyperventilation (HV) more frequently was not associated with increased 6 months mortality (OR = 1.06, 95% CI = 0.77–1.45, p value = 0.7166), or unfavourable neurological outcome (OR 1.12, 95% CI = 0.90–1.38, p value = 0.3138). Conclusions: Ventilation is manipulated differently among centers and in response to intracranial dynamics. P aCO2 tends to be lower in patients with ICP monitoring, especially if ICP is increased. Being in a centre which more frequently uses profound hyperventilation does not affect patient outcomes.;,citation_author=Giuseppe Citerio;,citation_author=Chiara Robba;,citation_author=Paola Rebora;,citation_author=Matteo Petrosino;,citation_author=Eleonora Rossi;,citation_author=Letterio Malgeri;,citation_author=Nino Stocchetti;,citation_author=Stefania Galimberti;,citation_author=David K. Menon;,citation_author=on behalf of the Center-TBI participants and investigators;,citation_author=Cecilia Åkerlund;,citation_author=Krisztina Amrein;,citation_author=Nada Andelic;,citation_author=Lasse Andreassen;,citation_author=Audny Anke;,citation_author=Anna Antoni;,citation_author=Gérard Audibert;,citation_author=Philippe Azouvi;,citation_author=Maria Luisa Azzolini;,citation_author=Ronald Bartels;,citation_author=Pál Barzó;,citation_author=Romuald Beauvais;,citation_author=Ronny Beer;,citation_author=Bo-Michael Bellander;,citation_author=Antonio Belli;,citation_author=Habib Benali;,citation_author=Maurizio Berardino;,citation_author=Luigi Beretta;,citation_author=Morten Blaabjerg;,citation_author=Peter Bragge;,citation_author=Alexandra Brazinova;,citation_author=Vibeke Brinck;,citation_author=Joanne Brooker;,citation_author=Camilla Brorsson;,citation_author=Andras Buki;,citation_author=Monika Bullinger;,citation_author=Manuel Cabeleira;,citation_author=Alessio Caccioppola;,citation_author=Emiliana Calappi;,citation_author=Maria Rosa Calvi;,citation_author=Peter Cameron;,citation_author=Guillermo Carbayo Lozano;,citation_author=Marco Carbonara;,citation_author=Simona Cavallo;,citation_author=Giorgio Chevallard;,citation_author=Arturo Chieregato;,citation_author=Giuseppe Citerio;,citation_author=Hans Clusmann;,citation_author=Mark Coburn;,citation_author=Jonathan Coles;,citation_author=Jamie D. Cooper;,citation_author=Marta Correia;,citation_author=Amra Čović;,citation_author=Nicola Curry;,citation_author=Endre Czeiter;,citation_author=Marek Czosnyka;,citation_author=Claire Dahyot-Fizelier;,citation_author=Paul Dark;,citation_author=Helen Dawes;,citation_author=Véronique De Keyser;,citation_author=Vincent Degos;,citation_author=Francesco Della Corte;,citation_author=Hugo Boogert;,citation_author=Bart Depreitere;,citation_author=ula ilvesi;,citation_author=Abhishek Dixit;,citation_author=Emma Donoghue;,citation_author=Jens Dreier;,citation_author=Guy-Loup Dulière;,citation_author=Ari Ercole;,citation_author=Patrick Esser;,citation_author=Erzsébet Ezer;,citation_author=Martin Fabricius;,citation_author=Valery L. Feigin;,citation_author=Kelly Foks;,citation_author=Shirin Frisvold;,citation_author=Alex Furmanov;,citation_author=Pablo Gagliardo;,citation_author=Damien Galanaud;,citation_author=Dashiell Gantner;,citation_author=Guoyi Gao;,citation_author=Pradeep George;,citation_author=Alexandre Ghuysen;,citation_author=Lelde Giga;,citation_author=Ben Glocker;,citation_author=Jagoš Golubovic;,citation_author=Pedro A. Gomez;,citation_author=Johannes Gratz;,citation_author=Benjamin Gravesteijn;,citation_author=Francesca Grossi;,citation_author=Russell L. Gruen;,citation_author=Deepak Gupta;,citation_author=Juanita A. Haagsma;,citation_author=Iain Haitsma;,citation_author=Raimund Helbok;,citation_author=Eirik Helseth;,citation_author=Lindsay Horton;,citation_author=Jilske Huijben;,citation_author=Peter J. Hutchinson;,citation_author=Bram Jacobs;,citation_author=Stefan Jankowski;,citation_author=Mike Jarrett;,citation_author=Ji-yao Jiang;,citation_author=Faye Johnson;,citation_author=Kelly Jones;,citation_author=Mladen Karan;,citation_author=Angelos G. Kolias;,citation_author=Erwin Kompanje;,citation_author=Daniel Kondziella;,citation_author=Evgenios Kornaropoulos;,citation_author=Lars-Owe Koskinen;,citation_author=Noémi Kovács;,citation_author=Ana Kowark;,citation_author=Alfonso Lagares;,citation_author=Linda Lanyon;,citation_author=Steven Laureys;,citation_author=Fiona Lecky;,citation_author=Didier Ledoux;,citation_author=Rolf Lefering;,citation_author=Valerie Legrand;,citation_author=Aurelie Lejeune;,citation_author=Leon Levi;,citation_author=Roger Lightfoot;,citation_author=Hester Lingsma;,citation_author=Andrew I. R. Maas;,citation_author=Ana M. Castaño-León;,citation_author=Marc Maegele;,citation_author=Marek Majdan;,citation_author=Alex Manara;,citation_author=Geoffrey Manley;,citation_author=Costanza Martino;,citation_author=Hugues Maréchal;,citation_author=Julia Mattern;,citation_author=Catherine McMahon;,citation_author=Béla Melegh;,citation_author=David Menon;,citation_author=Tomas Menovsky;,citation_author=Ana Mikolic;,citation_author=Benoit Misset;,citation_author=Visakh Muraleedharan;,citation_author=Lynnette Murray;,citation_author=Ancuta Negru;,citation_author=David Nelson;,citation_author=Virginia Newcombe;,citation_author=Daan Nieboer;,citation_author=József Nyirádi;,citation_author=Otesile Olubukola;,citation_author=Matej Oresic;,citation_author=Fabrizio Ortolano;,citation_author=Aarno Palotie;,citation_author=Paul M. Parizel;,citation_author=Jean-François Payen;,citation_author=Natascha Perera;,citation_author=Vincent Perlbarg;,citation_author=Paolo Persona;,citation_author=Wilco Peul;,citation_author=Anna Piippo-Karjalainen;,citation_author=Matti Pirinen;,citation_author=Dana Pisica;,citation_author=Horia Ples;,citation_author=Suzanne Polinder;,citation_author=Inigo Pomposo;,citation_author=Jussi P. Posti;,citation_author=Louis Puybasset;,citation_author=Andreea Radoi;,citation_author=Arminas Ragauskas;,citation_author=Rahul Raj;,citation_author=Malinka Rambadagalla;,citation_author=Isabel Retel Helmrich;,citation_author=Jonathan Rhodes;,citation_author=Sylvia Richardson;,citation_author=Sophie Richter;,citation_author=Samuli Ripatti;,citation_author=Saulius Rocka;,citation_author=Cecilie Roe;,citation_author=Olav Roise;,citation_author=Jonathan Rosand;,citation_author=Jeffrey V. Rosenfeld;,citation_author=Christina Rosenlund;,citation_author=Guy Rosenthal;,citation_author=Rolf Rossaint;,citation_author=Sandra Rossi;,citation_author=Daniel Rueckert Martin Rusnák;,citation_author=Juan Sahuquillo;,citation_author=Oliver Sakowitz;,citation_author=Renan Sanchez-Porras;,citation_author=Janos Sandor;,citation_author=Nadine Schäfer;,citation_author=Silke Schmidt;,citation_author=Herbert Schoechl;,citation_author=Guus Schoonman;,citation_author=Rico Frederik Schou;,citation_author=Elisabeth Schwendenwein;,citation_author=Charlie Sewalt;,citation_author=Toril Skandsen;,citation_author=Peter Smielewski;,citation_author=Abayomi Sorinola;,citation_author=Emmanuel Stamatakis;,citation_author=Simon Stanworth;,citation_author=Robert Stevens;,citation_author=William Stewart;,citation_author=Ewout W. Steyerberg;,citation_author=Nino Stocchetti;,citation_author=Nina Sundström;,citation_author=Riikka Takala;,citation_author=Viktória Tamás;,citation_author=Tomas Tamosuitis;,citation_author=Mark Steven Taylor;,citation_author=Braden Te Ao;,citation_author=Olli Tenovuo;,citation_author=Alice Theadom;,citation_author=Matt Thomas;,citation_author=Dick Tibboel;,citation_author=Marjolein Timmers;,citation_author=Christos Tolias;,citation_author=Tony Trapani;,citation_author=Cristina Maria Tudora;,citation_author=Andreas Unterberg;,citation_author=Peter Vajkoczy;,citation_author=Shirley Vallance;,citation_author=Egils Valeinis;,citation_author=Zoltán Vámos;,citation_author=Mathieu Jagt;,citation_author=Gregory Van der Steen;,citation_author=Joukje Naalt;,citation_author=Jeroen T. J. M. Dijck;,citation_author=Thomas A. Essen;,citation_author=Wim Van Hecke;,citation_author=Caroline Heugten;,citation_author=Dominique Van Praag;,citation_author=Ernest Veen;,citation_author=Thijs Vande Vyvere;,citation_author=Roel P. J. Wijk;,citation_author=Alessia Vargiolu;,citation_author=Emmanuel Vega;,citation_author=Kimberley Velt;,citation_author=Jan Verheyden;,citation_author=Paul M. Vespa;,citation_author=Anne Vik;,citation_author=Rimantas Vilcinis;,citation_author=Victor Volovici;,citation_author=Nicole Steinbüchel;,citation_author=Daphne Voormolen;,citation_author=Petar Vulekovic;,citation_author=Kevin K. W. K. W. Wang;,citation_author=Eveline Wiegers;,citation_author=Guy Williams;,citation_author=Lindsay Wilson;,citation_author=Stefan Winzeck;,citation_author=Stefan Wolf;,citation_author=Zhihui Yang;,citation_author=Peter Ylén;,citation_author=Alexander Younsi;,citation_author=Frederick A. Zeiler;,citation_author=Veronika Zelinkova;,citation_author=Agate Ziverte;,citation_author=Tommaso Zoerle;,citation_publication_date=2021-07;,citation_cover_date=2021-07;,citation_year=2021;,citation_doi=10.1007/s00134-021-06470-7;,citation_issn=0342-4642, 1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Regulation of cerebral blood flow in humans: Physiology and clinical implications of autoregulation;,citation_abstract=Brain function critically depends on a close matching between metabolic demands, appropriate delivery of oxygen and nutrients, and removal of cellular waste. This matching requires continuous regulation of cerebral blood flow (CBF), which can be categorized into four broad topics: 1) autoregulation, which describes the response of the cerebrovasculature to changes in perfusion pressure; 2) vascular reactivity to vasoactive stimuli [including carbon dioxide (CO )]; 3) neurovascular coupling (NVC), i.e., the CBF response to local changes in neural activity (often stan2dardized cognitive stimuli in humans); and 4) endothelium-dependent responses. This review focuses primarily on autoregulation and its clinical implications. To place autoregulation in a more precise context, and to better understand integrated approaches in the cerebral circulation, we also briefly address reactivity to CO and NVC. In addition to our focus on effects of perfusion pressure (or blood pressure), we describe the i2mpact of select stimuli on regulation of CBF (i.e., arterial blood gases, cerebral metabolism, neural mechanisms, and specific vascular cells), the interrelationships between these stimuli, and implications for regulation of CBF at the level of large arteries and the microcirculation. We review clinical implications of autoregulation in aging, hypertension, stroke, mild cognitive impairment, anesthesia, and dementias. Finally, we discuss autoregulation in the context of common daily physiological challenges, including changes in posture (e.g., orthostatic hypotension, syncope) and physical activity.;,citation_author=Jurgen A. H. R. Claassen;,citation_author=Dick H. J. Thijssen;,citation_author=Ronney B. Panerai;,citation_author=Frank M. Faraci;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=4;,citation_doi=10.1152/physrev.00022.2020;,citation_issn=0031-9333, 1522-1210;,citation_volume=101;,citation_language=en-US;,citation_journal_title=Physiological Reviews;">
<meta name="citation_reference" content="citation_title=Spontaneous subarachnoid haemorrhage;,citation_abstract=Subarachnoid haemorrhage (SAH) is the third most common subtype of stroke. Incidence has decreased over past decades, possibly in part related to lifestyle changes such as smoking cessation and management of hypertension. Approximately a quarter of patients with SAH die before hospital admission; overall outcomes are improved in those admitted to hospital, but with elevated risk of long-term neuropsychiatric sequelae such as depression. The disease continues to have a major public health impact as the mean age of onset is in the mid-fifties, leading to many years of reduced quality of life. The clinical presentation varies, but severe, sudden onset of headache is the most common symptom, variably associated with meningismus, transient or prolonged unconsciousness, and focal neurological deficits including cranial nerve palsies and paresis. Diagnosis is made by CT scan of the head possibly followed by lumbar puncture. Aneurysms are commonly the underlying vascular cause of spontaneous SAH and are diagnosed by angiography. Emergent therapeutic interventions are focused on decreasing the risk of rebleeding (ie, preventing hypertension and correcting coagulopathies) and, most crucially, early aneurysm treatment using coil embolisation or clipping. Management of the disease is best delivered in specialised intensive care units and high-volume centres by a multidisciplinary team. Increasingly, early brain injury presenting as global cerebral oedema is recognised as a potential treatment target but, currently, disease management is largely focused on addressing secondary complications such as hydrocephalus, delayed cerebral ischaemia related to microvascular dysfunction and large vessel vasospasm, and medical complications such as stunned myocardium and hospital acquired infections.;,citation_author=Jan Claassen;,citation_author=Soojin Park;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_doi=10.1016/S0140-6736(22)00938-2;,citation_issn=0140-6736;,citation_language=en-US;,citation_journal_title=The Lancet;">
<meta name="citation_reference" content="citation_title=Quantifying Treatment Effects in Trials with Multiple Event-Time Outcomes;,citation_abstract=BACKGROUND Data on the occurrence times of multiple outcomes, reflecting the temporal profile of disease burden/progression, have been used to estimate treatment effects in various recent randomized trials. Most procedures for analyzing these data require specific model assumptions. When the assumptions are not met, the results may be misleading. Robust, model-free procedures for study design and analysis that enable clinically meaningful interpretations are warranted. METHODS For each treatment group, we constructed and summarized the estimated mean cumulative count of events over time by the area under the curve (AUC), which can be interpreted as the mean total event-free time lost from multiple undesirable outcomes. A higher curve, and resulting larger AUC, implies a worse treatment. The treatment effect is quantified by the ratio and/or difference of AUCs. The timing and occurrence of recurrent heart failure hospitalizations (HFHs) and cardiovascular (CV) death from Prospective Comparison of ARNI with ARB Global Outcomes in HF with Preserved Ejection Fraction (PARAGON-HF), comparing sacubitril/valsartan with valsartan, are presented for illustration. We also discuss the design of future studies on the basis of the proposed method. RESULTS With 48 months of follow-up, estimated AUCs, representing the total event-free time lost to HFHs and CV death, were 11.3 and 13.1 event-months for sacubitril/valsartan and valsartan, respectively. The ratio of these AUCs was 0.86 (95% confidence interval, 0.75 to 1.00; P=0.049), a 14% reduction of disease burden favoring combination therapy. A future study, similar to PARAGON-HF, designed using the new proposal would require fewer patients would than a conventional time-to-first-event analysis. CONCLUSIONS The proposed method is robust and model-free and provides a clinically interpretable, time-scale summary of the treatment effect. (Funded by National Institutes of Health.);,citation_author=Brian Lee Claggett;,citation_author=Zachary R. McCaw;,citation_author=Lu Tian;,citation_author=John J. V. McMurray;,citation_author=Pardeep S. Jhund;,citation_author=Hajime Uno;,citation_author=Marc A. Pfeffer;,citation_author=Scott D. Solomon;,citation_author=Lee-Jen Wei;,citation_publication_date=2022-09;,citation_cover_date=2022-09;,citation_year=2022;,citation_issue=10;,citation_doi=10.1056/EVIDoa2200047;,citation_volume=1;,citation_journal_title=NEJM Evidence;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Estimands: Bringing clarity and focus to research questions in clinical trials;,citation_abstract=Precise specification of the research question and associated treatment effect of interest is essential in clinical research, yet recent work shows that they are often incompletely specified. The ICH E9 (R1) Addendum on Estimands and Sensitivity Analysis in Clinical Trials introduces a framework that supports researchers in precisely and transparently specifying the treatment effect they aim to estimate in their clinical trial. In this paper, we present practical examples to demonstrate to all researchers involved in clinical trials how estimands can help them to specify the research question, lead to a better understanding of the treatment effect to be estimated and hence increase the probability of success of the trial.;,citation_author=Timothy Peter Clark;,citation_author=Brennan C. Kahan;,citation_author=Alan Phillips;,citation_author=Ian White;,citation_author=James R. Carpenter;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=1;,citation_doi=10.1136/bmjopen-2021-052953;,citation_issn=2044-6055, 2044-6055;,citation_pmid=34980616;,citation_volume=12;,citation_language=en-US;,citation_journal_title=BMJ Open;,citation_publisher=British Medical Journal Publishing Group;">
<meta name="citation_reference" content="citation_title=Quality of Life Following Stroke: Negotiating Disability, Identity, and Resources;,citation_abstract=Residual physical and cognitive impairments following a stroke can pose a significant threat to a survivor’s quality of life. Yet, there is not always a direct one-to-one correlation between functional disability and subjective quality of life. This research investigated the complexity of factors that influence quality of life after stroke, using qualitative interviews. Results indicate that a stroke has a significant impact on the quality of life of survivors, but some individuals find ways to adapt to their functional disabilities and report a high quality of life. Common elements of this process consist of reordering priorities to focus on those activities considered most salient to an individual’s identity; then drawing on existing resources, including health services and social supports, to maintain a customary activity, even in a modified form, retaining salient aspects of the individual’s identity and maintaining a sense of continuity in his or her life.;,citation_author=Philippa Clarke;,citation_author=Sandra E. Black;,citation_publication_date=2005-08;,citation_cover_date=2005-08;,citation_year=2005;,citation_issue=4;,citation_doi=10.1177/0733464805277976;,citation_issn=0733-4648, 1552-4523;,citation_volume=24;,citation_language=en-US;,citation_journal_title=Journal of Applied Gerontology;">
<meta name="citation_reference" content="citation_title=Liquefied Petroleum Gas or Biomass for Cooking and Effects on Birth Weight;,citation_author=Thomas F. Clasen;,citation_author=Howard H. Chang;,citation_author=Lisa M. Thompson;,citation_author=Miles A. Kirby;,citation_author=Kalpana Balakrishnan;,citation_author=Anaité Díaz-Artiga;,citation_author=John P. McCracken;,citation_author=Ghislaine Rosa;,citation_author=Kyle Steenland;,citation_author=Ashley Younger;,citation_author=Vigneswari Aravindalochanan;,citation_author=Dana B. Barr;,citation_author=Adly Castañaza;,citation_author=Yunyun Chen;,citation_author=Marilú Chiang;,citation_author=Maggie L. Clark;,citation_author=Sarada Garg;,citation_author=Stella Hartinger;,citation_author=Shirin Jabbarzadeh;,citation_author=Michael A. Johnson;,citation_author=Dong-Yun Kim;,citation_author=Amy E. Lovvorn;,citation_author=Eric D. McCollum;,citation_author=Libny Monroy;,citation_author=Lawrence H. Moulton;,citation_author=Alexie Mukeshimana;,citation_author=Krishnendu Mukhopadhyay;,citation_author=Luke P. Naeher;,citation_author=Florien Ndagijimana;,citation_author=Aris Papageorghiou;,citation_author=Ricardo Piedrahita;,citation_author=Ajay Pillarisetti;,citation_author=Naveen Puttaswamy;,citation_author=Ashlinn Quinn;,citation_author=Usha Ramakrishnan;,citation_author=Sankar Sambandam;,citation_author=Sheela S. Sinharoy;,citation_author=Gurusamy Thangavel;,citation_author=Lindsay J. Underhill;,citation_author=Lance A. Waller;,citation_author=Jiantong Wang;,citation_author=Kendra N. Williams;,citation_author=Joshua P. Rosenthal;,citation_author=William Checkley;,citation_author=Jennifer L. Peel;,citation_publication_date=2022-10;,citation_cover_date=2022-10;,citation_year=2022;,citation_issue=0;,citation_doi=10.1056/NEJMoa2206734;,citation_issn=0028-4793;,citation_volume=0;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Fluid thresholds and outcome from severe brain injury;,citation_abstract=OBJECTIVE: To determine, by retrospective analysis, critical thresholds for intracranial pressure, mean arterial pressure, cerebral perfusion pressure, and fluid balance associated with poor outcome in patients with severe brain injury. DESIGN: Retrospective review of patient data from the prospective, randomized, multicenter National Acute Brain Injury Study: Hypothermia, comparing outcome results at 6 months after injury with intracranial pressure, mean arterial pressure, cerebral perfusion pressure, and fluid balance measurements recorded during the 96-hr period after randomization. SETTING: Emergency departments and intensive care units in 11 metropolitan tertiary care university hospitals. PATIENTS: A total of 392 patients, aged 16-65 yrs, with severe, nonpenetrating brain injuries and a Glasgow Coma Scale score of 3-8 after resuscitation, who were enrolled in a study designed to determine the treatment effect of moderate hypothermia in patients with severe brain injury. INTERVENTION: Standard brain injury treatment for 193 randomly assigned patients and standard treatment plus hypothermia for 48 hrs for 199 patients. MEASUREMENTS AND MAIN RESULTS: Intracranial pressure levels of 20, 25, and 30 mm Hg, mean arterial pressure levels of 70 and 80 mm Hg, cerebral perfusion pressure levels of 50, 60, and 70 mm Hg, and fluid balance levels in quartiles were examined for their effect on outcome as measured by the Glasgow Outcome Scale at 6 months after injury. When considered separately, any of the following-intracranial pressure &amp;amp;amp;gt;25 mm Hg, mean arterial pressure &amp;lt;70 mm Hg, or cerebral perfusion pressure &amp;lt;60 mm Hg and fluid balance lower than -594 mL-was associated with an increased percentage of patients with poor outcome. When the variables were combined into a stepwise logistic regression model, Glasgow Coma Scale score at admission, age, mean arterial pressure <70 mm Hg, fluid balance lower than -594 mL, and intracranial pressure &amp;gt; 25 mm Hg, in that order, were the most powerful variables in determining outcome. CONCLUSIONS: Exceeding thresholds of intracranial pressure, mean arterial pressure, cerebral perfusion pressure, and fluid volume may be detrimental to severe brain injury outcome. Fluid balance lower than -594 mL was associated with an adverse effect on outcome, independent of its relationship to intracranial pressure, mean arterial pressure, or cerebral perfusion pressure.;,citation_author=Guy L. Clifton;,citation_author=Emmy R. Miller;,citation_author=Sung C. Choi;,citation_author=Harvey S. Levin;,citation_publication_date=2002-04;,citation_cover_date=2002-04;,citation_year=2002;,citation_issue=4;,citation_doi=10.1097/00003246-200204000-00003;,citation_issn=0090-3493;,citation_pmid=11940738;,citation_volume=30;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Low-Dose Aspirin and the Risk of Stroke and Intracerebral Bleeding in Healthy Older People: Secondary Analysis of a Randomized Clinical Trial;,citation_abstract=Low-dose aspirin has been widely used for primary and secondary prevention of stroke. The balance between potential reduction of ischemic stroke events and increased intracranial bleeding has not been established in older individuals.To establish the risks of ischemic stroke and intracranial bleeding among healthy older people receiving daily low-dose aspirin.This secondary analysis of the Aspirin in Reducing Events in the Elderly (ASPREE) randomized, double-blind, placebo-controlled trial of daily low-dose aspirin was conducted among community-dwelling people living in Australia or the US. Participants were older adults free of symptomatic cardiovascular disease. Recruitment took place between 2010 and 2014, and participants were followed up for a median (IQR) of 4.7 (3.6-5.7) years. This analysis was completed from August 2021 to March 2023.Daily 100-mg enteric-coated aspirin or matching placebo.Stroke and stroke etiology were predetermined secondary outcomes and are presented with a focus on prevention of initial stroke or intracranial bleeding event. Outcomes were assessed by review of medical records.Among 19 114 older adults (10 782 females [56.4%]; median [IQR] age, 74 [71.6-77.7] years), 9525 individuals received aspirin and 9589 individuals received placebo. Aspirin did not produce a statistically significant reduction in the incidence of ischemic stroke (hazard ratio [HR], 0.89; 95% CI, 0.71-1.11). However, a statistically significant increase in intracranial bleeding was observed among individuals assigned to aspirin (108 individuals [1.1%]) compared with those receiving placebo (79 individuals [0.8%]; HR, 1.38; 95% CI, 1.03-1.84). This occurred by an increase in a combination of subdural, extradural, and subarachnoid bleeding with aspirin compared with placebo (59 individuals [0.6%] vs 41 individuals [0.4%]; HR, 1.45; 95% CI, 0.98-2.16). Hemorrhagic stroke was recorded in 49 individuals (0.5%) assigned to aspirin compared with 37 individuals (0.4%) in the placebo group (HR, 1.33; 95% CI, 0.87-2.04).This study found a significant increase in intracranial bleeding with daily low-dose aspirin but no significant reduction of ischemic stroke. These findings may have particular relevance to older individuals prone to developing intracranial bleeding after head trauma.ISRCTN.org Identifier: ISRCTN83772183;,citation_author=Geoffrey C. Cloud;,citation_author=Jeff D. Williamson;,citation_author=Le Thi Phuong Thao;,citation_author=Cammie Tran;,citation_author=Charles B. Eaton;,citation_author=Rory Wolfe;,citation_author=Mark R. Nelson;,citation_author=Christopher M. Reid;,citation_author=Anne B. Newman;,citation_author=Jessica Lockery;,citation_author=Sharyn M. Fitzgerald;,citation_author=Anne M. Murray;,citation_author=Raj C. Shah;,citation_author=Robyn L. Woods;,citation_author=Geoffrey A. Donnan;,citation_author=John J. McNeil;,citation_publication_date=2023-07;,citation_cover_date=2023-07;,citation_year=2023;,citation_issue=7;,citation_doi=10.1001/jamanetworkopen.2023.25803;,citation_issn=2574-3805;,citation_volume=6;,citation_journal_title=JAMA Network Open;">
<meta name="citation_reference" content="citation_title=Adjusting for confounding by indication in observational studies: A case study in traumatic brain injury;,citation_abstract=Introduction: Observational studies of interventions are at risk for confounding by indication. The objective of the current study was to define the circumstances for the validity of methods to adjust for confounding by indication in observational studies. Patients and methods: We performed post hoc analyses of data prospectively collected from three European and North American traumatic brain injury studies including 1,725 patients. The effects of three interventions (intracranial pressure [ICP] monitoring, intracranial operation and primary referral) were estimated in a proportional odds regression model with the Glasgow Outcome Scale as ordinal outcome variable. Three analytical methods were compared: classical covariate adjustment, propensity score matching and instrumental variable (IV) analysis in which the percentage exposed to an intervention in each hospital was added as an independent variable, together with a random intercept for each hospital. In addition, a simulation study was performed in which the effect of a hypothetical beneficial intervention (OR 1.65) was simulated for scenarios with and without unmeasured confounders. Results: For all three interventions, covariate adjustment and propensity score matching resulted in negative estimates of the treatment effect (OR ranging from 0.80 to 0.92), whereas the IV approach indicated that both ICP monitoring and intracranial operation might be beneficial (OR per 10% change 1.17, 95% CI 1.01–1.42 and 1.42, 95% CI 0.95–1.97). In our simulation study, we found that covariate adjustment and propensity score matching resulted in an invalid estimate of the treatment effect in case of unmeasured confounders (OR ranging from 0.90 to 1.03). The IV approach provided an estimate in the similar direction as the simulated effect (OR per 10% change 1.04–1.05) but was statistically inefficient. Conclusion: The effect estimation of interventions in observational studies strongly depends on the analytical method used. When unobserved confounding and practice variation are expected in observational multicenter studies, IV analysis should be considered.;,citation_author=Maryse Cnossen;,citation_author=Thomas A Essen;,citation_author=Iris E Ceyisakar;,citation_author=Suzanne Polinder;,citation_author=Teuntje Andriessen;,citation_author=Joukje Naalt;,citation_author=Iain Haitsma;,citation_author=Janneke Horn;,citation_author=Gaby Franschman;,citation_author=Pieter Vos;,citation_author=Wilco Peul;,citation_author=David K Menon;,citation_author=Andrew Maas;,citation_author=Ewout Steyerberg;,citation_author=Hester Lingsma;,citation_publication_date=2018-07;,citation_cover_date=2018-07;,citation_year=2018;,citation_doi=10.2147/CLEP.S154500;,citation_issn=1179-1349;,citation_volume=Volume 10;,citation_language=en-US;,citation_journal_title=Clinical Epidemiology;">
<meta name="citation_reference" content="citation_title=Evaluating sources of bias in observational studies of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use during COVID-19: Beyond confounding;,citation_author=Jordana B. Cohen;,citation_author=Lucy D’Agostino McGowan;,citation_author=Elizabeth T. Jensen;,citation_author=Joseph Rigdon;,citation_author=Andrew M. South;,citation_publication_date=2021-04;,citation_cover_date=2021-04;,citation_year=2021;,citation_issue=4;,citation_doi=10.1097/HJH.0000000000002706;,citation_issn=0263-6352, 1473-5598;,citation_volume=39;,citation_language=en-US;,citation_journal_title=Journal of Hypertension;">
<meta name="citation_reference" content="citation_title=The Drug Price Controversy Nobody Notices: The Drug Price Controversy Nobody Notices;,citation_author=Jonathan Cohn;,citation_publication_date=2016-06;,citation_cover_date=2016-06;,citation_year=2016;,citation_issue=2;,citation_doi=10.1111/1468-0009.12193;,citation_issn=0887378X;,citation_volume=94;,citation_language=en-US;,citation_journal_title=The Milbank Quarterly;">
<meta name="citation_reference" content="citation_title=Generalizing Evidence From Randomized Clinical Trials to Target Populations: The ACTG 320 Trial;,citation_author=S. R. Cole;,citation_author=E. A. Stuart;,citation_publication_date=2010-07;,citation_cover_date=2010-07;,citation_year=2010;,citation_issue=1;,citation_doi=10.1093/aje/kwq084;,citation_issn=0002-9262, 1476-6256;,citation_volume=172;,citation_language=en-US;,citation_journal_title=American Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Balanced crystalloid solution versus saline in deceased donor kidney transplantation (BEST-Fluids): A pragmatic, double-blind, randomised, controlled trial;,citation_author=Michael G. Collins;,citation_author=Magid A. Fahim;,citation_author=Elaine M. Pascoe;,citation_author=Carmel M. Hawley;,citation_author=David W. Johnson;,citation_author=Julie Varghese;,citation_author=Laura E. Hickey;,citation_author=Philip A. Clayton;,citation_author=Kathryn B. Dansie;,citation_author=Rachael C. McConnochie;,citation_author=Liza A. Vergara;,citation_author=Charani Kiriwandeniya;,citation_author=Donna Reidlinger;,citation_author=Peter F. Mount;,citation_author=Laurence Weinberg;,citation_author=Colin J. McArthur;,citation_author=P. Toby Coates;,citation_author=Zoltan H. Endre;,citation_author=David Goodman;,citation_author=Kirsten Howard;,citation_author=Martin Howell;,citation_author=Jagadish S. Jamboti;,citation_author=John Kanellis;,citation_author=Jerome M. Laurence;,citation_author=Wai H. Lim;,citation_author=Steven J. McTaggart;,citation_author=Philip J. O’Connell;,citation_author=Helen L. Pilmore;,citation_author=Germaine Wong;,citation_author=Steven J. Chadban;,citation_author=Tracey Ying;,citation_author=David Gracey;,citation_author=Leyla Aouad;,citation_author=Kate Wyburn;,citation_author=Beatriz Habijanec;,citation_author=Hee-eun (Ellen) Yeo;,citation_author=Lin Lin;,citation_author=Brenda Rosales;,citation_author=Julia Hudaly;,citation_author=Vera Rodrigues;,citation_author=Germaine Wong;,citation_author=Philip O’Connell;,citation_author=Penelope Murie;,citation_author=Zoltan Endre;,citation_author=Zuzana Gray;,citation_author=Rebecca Spicer;,citation_author=Anne Durkan;,citation_author=Magid A. Fahim;,citation_author=Dev Jegatheesan;,citation_author=Diana Leary;,citation_author=Yujing (Sarah) Guo;,citation_author=Amanda Coburn;,citation_author=Rachael Irvine;,citation_author=Steven McTaggart;,citation_author=Aimee Crawford;,citation_author=P. Toby Coates;,citation_author=Bronwyn Hockley;,citation_author=Karen Fischer;,citation_author=Laurence Weinberg;,citation_author=Peter Mount;,citation_author=Sarah Baulch;,citation_author=Gayle Claxton;,citation_author=Saskia Harris;,citation_author=Sofia Sidiropoulos;,citation_author=Marieke Veenendal;,citation_author=John Kanellis;,citation_author=Rita Barbis;,citation_author=David Goodman;,citation_author=Anjalee Brahmbhatt;,citation_author=Amelia Le Page;,citation_author=Jagadish Jamboti;,citation_author=Anna Chiam;,citation_author=Anne Warger;,citation_author=Wai H. Lim;,citation_author=Michael Collins;,citation_author=Helen Pilmore;,citation_author=Ian Dittmer;,citation_author=Paul Manley;,citation_author=Jafar Ahmed;,citation_author=Rachael McConnochie;,citation_author=Lynette Newby;,citation_author=Yan Chen;,citation_author=Catherine Simmonds;,citation_author=John Irvine;,citation_author=Jenny Usher;,citation_author=Carolyn Clark;,citation_author=Claire Beckett;,citation_author=Chanel Prestidge;,citation_author=Robin Erickson;,citation_author=Miriam Rea;,citation_author=Claire Scherring;,citation_publication_date=2023-07;,citation_cover_date=2023-07;,citation_year=2023;,citation_issue=10396;,citation_doi=10.1016/S0140-6736(23)00642-6;,citation_issn=0140-6736, 1474-547X;,citation_pmid=37343576;,citation_volume=402;,citation_language=en-US;,citation_journal_title=The Lancet;,citation_publisher=Elsevier;">
<meta name="citation_reference" content="citation_title=The Magic of Randomization versus the Myth of Real-World Evidence;,citation_author=Rory Collins;,citation_author=Louise Bowman;,citation_author=Martin Landray;,citation_author=Richard Peto;,citation_publication_date=2020-02;,citation_cover_date=2020-02;,citation_year=2020;,citation_issue=7;,citation_doi=10.1056/NEJMsb1901642;,citation_issn=0028-4793, 1533-4406;,citation_volume=382;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Outcomes and long-term quality-of-life of patients supported by extracorporeal membrane oxygenation for refractory cardiogenic shock*;,citation_abstract=Objective:&nbsp; To assess the outcomes and long-term quality-of-life of patients supported by extracorporeal membrane oxygenation (ECMO) for refractory cardiogenic shock. Design, Setting, and Patients:&nbsp; Refractory cardiogenic shock is almost always lethal without emergency circulatory support, e.g., ECMO. ECMO-associated morbidity and mortality plead for identification of early predictors of its failure, and detailed analyses of short- and long-term outcomes to refine patient selection and improve results. Outcomes of 81 patients given ECMO support for medical (n = 55), postcardiotomy (n = 16), or posttransplantation (n = 10) cardiogenic shock were evaluated. Measurements and Main Results:&nbsp; Thirty-four (42%) patients survived to hospital discharge; 57% suffered \geq1 major ECMO-related complications. Independent predictors of intensive care unit death were: device insertion under cardiac massage (odds ratio [OR] = 20.68), 24 hr urine output &amp;amp;amp;lt;500 mL (OR = 6.52), prothrombin activity &amp;lt;50% (OR = 3.93), and female sex (OR = 3.89); myocarditides were associated with better outcomes (OR = .13). Sequelae and health-related quality-of-life were evaluated for 28 long-term survivors (median follow-up, 11 months), whose mean Short-Form 36 scores were significantly lower than matched healthy controls for physical role, general health, and social functioning, but higher than those reported for patients on chronic hemodialysis, with advanced heart failure, or after recovery from acute respiratory distress syndrome. Conclusions:&nbsp; ECMO support can rescue 40% of otherwise fatal cardiogenic shock patients but its initiation under cardiac massage or after renal or hepatic failure carried higher risks of intensive care unit death, while fulminant myocarditis had a better prognosis. Despite satisfactory mental health and vitality, long-term survivors’ persistent physical and social problems might benefit from tailored medical or psychosocial interventions.;,citation_author=Alain Combes;,citation_author=Pascal Leprince;,citation_author=Charles-Edouard Luyt;,citation_author=Nicolas Bonnet;,citation_author=Jean-Louis Trouillet;,citation_author=Philippe Léger;,citation_author=Alain Pavie;,citation_author=Jean Chastre;,citation_publication_date=2008-05;,citation_cover_date=2008-05;,citation_year=2008;,citation_issue=5;,citation_doi=10.1097/CCM.0b013e31816f7cf7;,citation_issn=0090-3493;,citation_volume=36;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association;,citation_abstract=Purpose—The aim of this guideline is to present current and comprehensive recommendations for the diagnosis and treatment of aneurysmal subarachnoid hemorrhage (aSAH). Methods—A formal literature search of MEDLINE (November 1, 2006, through May 1, 2010) was performed. Data were synthesized with the use of evidence tables. Writing group members met by teleconference to discuss data-derived recommendations. The American Heart Association Stroke Council’s Levels of Evidence grading algorithm was used to grade each recommendation. The guideline draft was reviewed by 7 expert peer reviewers and by the members of the Stroke Council Leadership and Manuscript Oversight Committees. It is intended that this guideline be fully updated every 3 years. Results—Evidence-based guidelines are presented for the care of patients presenting with aSAH. The focus of the guideline was subdivided into incidence, risk factors, prevention, natural history and outcome, diagnosis, prevention of rebleeding, surgical and endovascular repair of ruptured aneurysms, systems of care, anesthetic management during repair, management of vasospasm and delayed cerebral ischemia, management of hydrocephalus, management of seizures, and management of medical complications. Conclusions—aSAH is a serious medical condition in which outcome can be dramatically impacted by early, aggressive, expert care. The guidelines offer a framework for goal-directed treatment of the patient with aSAH. (Stroke. 2012;43:1711-1737.);,citation_author=E. Sander Connolly;,citation_author=Alejandro A. Rabinstein;,citation_author=J. Ricardo Carhuapoma;,citation_author=Colin P. Derdeyn;,citation_author=Jacques Dion;,citation_author=Randall T. Higashida;,citation_author=Brian L. Hoh;,citation_author=Catherine J. Kirkness;,citation_author=Andrew M. Naidech;,citation_author=Christopher S. Ogilvy;,citation_author=Aman B. Patel;,citation_author=B. Gregory Thompson;,citation_author=Paul Vespa;,citation_publication_date=2012-06;,citation_cover_date=2012-06;,citation_year=2012;,citation_issue=6;,citation_doi=10.1161/STR.0b013e3182587839;,citation_issn=0039-2499, 1524-4628;,citation_volume=43;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=Bayesian adaptive trials offer advantages in comparative effectiveness trials: An example in status epilepticus;,citation_abstract=Objective: We present a novel Bayesian adaptive comparative effectiveness trial comparing three treatments for status epilepticus that uses adaptive randomization with potential early stopping. Study Design and Setting: The trial will enroll 720 unique patients in emergency departments and uses a Bayesian adaptive design. Results: The trial design is compared to a trial without adaptive randomization and produces an efficient trial in which a higher proportion of patients are likely to be randomized to the most effective treatment arm while generally using fewer total patients and offers higher power than an analogous trial with fixed randomization when identifying a superior treatment. Conclusion: When one treatment is superior to the other two, the trial design provides better patient care, higher power, and a lower expected sample size. Ó 2013 Elsevier Inc. All rights reserved.;,citation_author=Jason T. Connor;,citation_author=Jordan J. Elm;,citation_author=Kristine R. Broglio;,citation_publication_date=2013-08;,citation_cover_date=2013-08;,citation_year=2013;,citation_issue=8;,citation_doi=10.1016/j.jclinepi.2013.02.015;,citation_issn=08954356;,citation_volume=66;,citation_language=en-US;,citation_journal_title=Journal of Clinical Epidemiology;">
<meta name="citation_reference" content="citation_title=Does Crystalloid Composition or Rate of Fluid Administration Make a Difference When Resuscitating Patients in the ICU?;,citation_abstract=Administration of intravenous fluids is among the most common interventions performed in intensive care units (ICUs). The first description of fluids for resuscitation of a critically ill patient occurred during the 1830s cholera outbreak in England. In the 200 years since, debates continue surrounding the volume, composition, and rate of fluid administration, with few definitive answers to guide clinicians.Previous studies have demonstrated that mortality is decreased when critically ill patients receive early fluid resuscitation during septic shock and hemorrhagic shock, although studies exploring the rate of fluid resuscitation have largely been absent. Although there is some intuitive appeal to rapid resuscitation in an underresuscitated patient, the potential benefits may be counterbalanced by concerns that overly rapid fluid administration may impair right ventricular function, worsen tissue edema, and decrease organ function.;,citation_author=Michael J. Connor;,citation_author=Craig M. Coopersmith;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_issue=9;,citation_doi=10.1001/jama.2021.11119;,citation_issn=0098-7484;,citation_volume=326;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Let the question determine the methods: Descriptive epidemiology done right;,citation_abstract=Summary What does it mean to control for confounding, and when do we actually need to do it? To answer this, we need a well-defined research question, driven by the goal of the study. For descriptive goals, we explain that confounding adjustment is often not just unnecessary but can be harmful.;,citation_author=Sara Conroy;,citation_author=Eleanor J. Murray;,citation_publication_date=2020-10;,citation_cover_date=2020-10;,citation_year=2020;,citation_issue=9;,citation_doi=10.1038/s41416-020-1019-z;,citation_issn=0007-0920, 1532-1827;,citation_volume=123;,citation_language=en-US;,citation_journal_title=British Journal of Cancer;">
<meta name="citation_reference" content="citation_title=Assessing methods to specify the target difference for a randomised controlled trial - DELTA (Difference ELicitation in TriAls) review;,citation_abstract=Background The randomised controlled trial (RCT) is widely considered to be the gold standard study for comparing the effectiveness of health interventions. Central to the design and validity of a RCT is a calculation of the number of participants needed (the sample size). The value used to determine the sample size can be considered the “target difference”. From both a scientific and an ethical standpoint, selecting an appropriate target difference is of crucial importance. Determination of the target difference, as opposed to statistical approaches to calculating the sample size, has been greatly neglected though a variety of approaches have been proposed the current state of the evidence is unclear. Objectives The aim was to provide an overview of the current evidence regarding specifying the target difference in a RCT sample size calculation. The specific objectives were to conduct a systematic review of methods for specifying a target difference; to evaluate current practice by surveying triallists; to develop guidance on specifying the target difference in a RCT; and to identify future research needs. Design The biomedical and social science databases searched were MEDLINE, MEDLINE In-Process &amp;amp;amp; Other Non-Indexed Citations, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Methodology Register, PsycINFO, Science Citation Index, EconLit, Education Resources Information Center (ERIC) and Scopus for in-press publications. All were searched from 1966 or the earliest date of the database coverage and searches were undertaken between November 2010 and January 2011. There were three interlinked components: (1) systematic review of methods for specifying a target difference for RCTs – a comprehensive search strategy involving an electronic literature search of biomedical and some non-biomedical databases and clinical trials textbooks was carried out; (2) identification of current trial practice using two surveys of triallists – members of the Society for Clinical Trials (SCT) were invited to complete an online survey and respondents were asked about their awareness and use of, and willingness to recommend, methods; one individual per triallist group [UK Clinical Research Collaboration (UKCRC)-registered Clinical Trials Units (CTUs), Medical Research Council (MRC) UK Hubs for Trials Methodology Research and National Institute for Health Research (NIHR) UK Research Design Services (RDS)] was invited to complete a survey; (3) production of a structured guidance document to aid the design of future trials – the draft guidance was developed utilising the results of the systematic review and surveys by the project steering and advisory groups. Setting Methodological review incorporating electronic searches, review of books and guidelines, two surveys of experts (membership of an international society and UK- and Ireland-based triallists) and development of guidance. Participants The two surveys were sent out to membership of the SCT and UK- and Ireland-based triallists. Interventions The review focused on methods for specifying the target difference in a RCT. It was not restricted to any type of intervention or condition. Main outcome measures Methods for specifying the target difference for a RCT were considered. Results The search identified 11,485 potentially relevant studies. In total, 1434 were selected for full-text assessment and 777 were included in the review. Seven methods to specify the target difference for a RCT were identified – anchor, distribution, health economic, opinion-seeking, pilot study, review of evidence base (RoEB) and standardised effect size (SES) – each having important variations in implementation. A total of 216 of the included studies used more than one method. A total of 180 (15%) responses to the SCT survey were received, representing 13 countries. Awareness of methods ranged from 38% (n = 69) for the health economic method to 90% (n = 162) for the pilot study. Of the 61 surveys sent out to UK triallist groups, 34 (56%) responses were received. Awareness ranged from 97% (n = 33) for the RoEB and pilot study methods to only 41% (n = 14) for the distribution method. Based on the most recent trial, all bar three groups (91%, n = 30) used a formal method. Guidance was developed on the use of each method and the reporting of the sample size calculation in a trial protocol and results paper. Conclusions There is a clear need for greater use of formal methods to determine the target difference and better reporting of its specification. Raising the standard of RCT sample size calculations and the corresponding reporting of them would aid health professionals, patients, researchers and funders in judging the strength of the evidence and ensuring better use of scarce resources. Funding The Medical Research Council UK and the National Institute for Health Research Joint Methodology Research programme.;,citation_author=Jonathan A. Cook;,citation_author=Jennifer Hislop;,citation_author=Temitope E. Adewuyi;,citation_author=Kirsten Harrild;,citation_author=Douglas G. Altman;,citation_author=Craig R. Ramsay;,citation_author=Cynthia Fraser;,citation_author=Brian Buckley;,citation_author=Peter Fayers;,citation_author=Ian Harvey;,citation_author=Andrew H. Briggs;,citation_author=John D. Norrie;,citation_author=Dean Fergusson;,citation_author=Ian Ford;,citation_author=Luke D. Vale;,citation_publication_date=2014-05;,citation_cover_date=2014-05;,citation_year=2014;,citation_issue=28;,citation_doi=10.3310/hta18280;,citation_issn=ISSN: 2046-4924, ISSN: 1366-5278;,citation_volume=18;,citation_language=en-US;,citation_journal_title=Health Technology Assessment;">
<meta name="citation_reference" content="citation_title=DELTA2 guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial;,citation_abstract=&amp;amp;amp;lt;p&amp;gt;Randomised controlled trials are considered to be the best method to assess comparative clinical efficacy and effectiveness, and can be a key source of data for estimating cost effectiveness. Central to the design of a randomised controlled trial is an a priori sample size calculation, which ensures that the study has a high probability of achieving its prespecified main objective. Beyond pure statistical or scientific concerns, it is ethically imperative that an appropriate number of study participants be recruited, to avoid imposing the burdens of a clinical trial on more patients than necessary. The scientific concern is satisfied and the ethical imperative is further addressed by the specification of a target difference between treatments that is considered realistic or important by one or more key stakeholder groups. The sample size calculation ensures that the trial will have the required statistical power to identify whether a difference of a particular magnitude exists. In this article, the key messages from the DELTA&amp;lt;sup&amp;gt;2</sup> guidance on determining the target difference and sample size calculation for a randomised controlled trial are presented. Recommendations for the subsequent reporting of the sample size calculation are also provided.</p>;,citation_author=Jonathan A. Cook;,citation_author=Steven A. Julious;,citation_author=William Sones;,citation_author=Lisa V. Hampson;,citation_author=Catherine Hewitt;,citation_author=Jesse A. Berlin;,citation_author=Deborah Ashby;,citation_author=Richard Emsley;,citation_author=Dean A. Fergusson;,citation_author=Stephen J. Walters;,citation_author=Edward C. F. Wilson;,citation_author=Graeme MacLennan;,citation_author=Nigel Stallard;,citation_author=Joanne C. Rothwell;,citation_author=Martin Bland;,citation_author=Louise Brown;,citation_author=Craig R. Ramsay;,citation_author=Andrew Cook;,citation_author=David Armstrong;,citation_author=Doug Altman;,citation_author=Luke D. Vale;,citation_publication_date=2018-11;,citation_cover_date=2018-11;,citation_year=2018;,citation_doi=10.1136/bmj.k3750;,citation_issn=0959-8138, 1756-1833;,citation_pmid=30560792;,citation_volume=363;,citation_language=en-US;,citation_journal_title=BMJ;,citation_publisher=British Medical Journal Publishing Group;">
<meta name="citation_reference" content="citation_title=Guidelines for the Acute Treatment of Cerebral Edema in Neurocritical Care Patients;,citation_abstract=Background: Acute treatment of cerebral edema and elevated intracranial pressure is a common issue in patients with neurological injury. Practical recommendations regarding selection and monitoring of therapies for initial management of cerebral edema for optimal efficacy and safety are generally lacking. This guideline evaluates the role of hyperosmolar agents (mannitol, HTS), corticosteroids, and selected non-pharmacologic therapies in the acute treatment of cerebral edema. Clinicians must be able to select appropriate therapies for initial cerebral edema management based on available evidence while balancing efficacy and safety. Methods: The Neurocritical Care Society recruited experts in neurocritical care, nursing, and pharmacy to create a panel in 2017. The group generated 16 clinical questions related to initial management of cerebral edema in various neurological insults using the PICO format. A research librarian executed a comprehensive literature search through July 2018. The panel screened the identified articles for inclusion related to each specific PICO question and abstracted necessary information for pertinent publications. The panel used GRADE methodology to categorize the quality of evidence as high, moderate, low, or very low based on their confidence that the findings of each publication approximate the true effect of the therapy. Results: The panel generated recommendations regarding initial management of cerebral edema in neurocritical care patients with subarachnoid hemorrhage, traumatic brain injury, acute ischemic stroke, intracerebral hemorrhage, bacterial meningitis, and hepatic encephalopathy. Conclusion: The available evidence suggests hyperosmolar therapy may be helpful in reducing ICP elevations or cerebral edema in patients with SAH, TBI, AIS, ICH, and HE, although neurological outcomes do not appear to be affected. Corticosteroids appear to be helpful in reducing cerebral edema in patients with bacterial meningitis, but not ICH.;,citation_author=Aaron M. Cook;,citation_author=G. Morgan Jones;,citation_author=Gregory W. J. Hawryluk;,citation_author=Patrick Mailloux;,citation_author=Diane McLaughlin;,citation_author=Alexander Papangelou;,citation_author=Sophie Samuel;,citation_author=Sheri Tokumaru;,citation_author=Chitra Venkatasubramanian;,citation_author=Christopher Zacko;,citation_author=Lara L. Zimmermann;,citation_author=Karen Hirsch;,citation_author=Lori Shutter;,citation_publication_date=2020-06;,citation_cover_date=2020-06;,citation_year=2020;,citation_issue=3;,citation_doi=10.1007/s12028-020-00959-7;,citation_issn=1541-6933, 1556-0961;,citation_volume=32;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=AI and Medical Education — A 21st-Century Pandora’s Box;,citation_author=Avraham Cooper;,citation_author=Adam Rodman;,citation_publication_date=2023-07;,citation_cover_date=2023-07;,citation_year=2023;,citation_issue=0;,citation_doi=10.1056/NEJMp2304993;,citation_issn=0028-4793;,citation_volume=0;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Albumin Resuscitation for Traumatic Brain Injury: Is Intracranial Hypertension the Cause of Increased Mortality?;,citation_abstract=Mortality is higher in patients with traumatic brain injury (TBI) resuscitated with albumin compared with saline, but the mechanism for increased mortality is unknown. In patients from the Saline vs. Albumin Fluid Evaluation (SAFE) study with TBI who underwent intracranial pressure (ICP) monitoring, interventional data were collected from randomization to day 14 to determine changes in ICP (primary outcome) and in therapies used to treat increased ICP. Pattern mixture modelling, designed to address informative dropouts, was used to compare temporal changes between the albumin and saline groups, and 321 patients were identified, of whom 164 (51.1%) received albumin and 157 (48.9%) received saline. There was a significant linear increase in mean ICP and significantly more deaths in the albumin group compared with saline when ICP monitoring was discontinued during the first week (1.300.33 vs. -0.370.36, p=0.0006; and 34.4% vs. 17.4%; p=0.006 respectively), but not when monitoring ceased during the second week (-0.080.44 vs. -0.230.38, p=0.79; and 18.6% vs. 12.1%; p=0.36 respectively). There were statistically significant differences in the mean total daily doses of morphine (-0.420.07 vs. -0.660.0, p=0.0009), propofol (-0.450.11 vs. -0.760.11; p=0.034) and norepinephrine (-0.500.07 vs. -0.740.07) and in temperature (0.030.03 vs. 0.160.03; p=0.0014) between the albumin and saline groups when ICP monitoring ceased during the first week. The use of albumin for resuscitation in patients with severe TBI is associated with increased ICP during the first week. This is the most likely mechanism of increased mortality in these patients.;,citation_author=D. James Cooper;,citation_author=John Myburgh;,citation_author=Stephane Heritier;,citation_author=Simon Finfer;,citation_author=Rinaldo Bellomo;,citation_author=Laurent Billot;,citation_author=Lynette Murray;,citation_author=Shirley Vallance;,citation_publication_date=2013-04;,citation_cover_date=2013-04;,citation_year=2013;,citation_issue=7;,citation_doi=10.1089/neu.2012.2573;,citation_issn=0897-7151;,citation_volume=30;,citation_journal_title=Journal of Neurotrauma;,citation_publisher=Mary Ann Liebert, Inc., publishers;">
<meta name="citation_reference" content="citation_title=Variability of Post-Cardiac Arrest Care Practices Among Cardiac Arrest Centers: United States and South Korean Dual Network Survey of Emergency Physician Research Principal Investigators;,citation_author=Patrick J. Coppler;,citation_author=Kelly N. Sawyer;,citation_author=Chun Song Youn;,citation_author=Seung Pill Choi;,citation_author=Kyu Nam Park;,citation_author=Young-Min Kim;,citation_author=Joshua C. Reynolds;,citation_author=David F. Gaieski;,citation_author=Byung Kook Lee;,citation_author=Joo Suk Oh;,citation_author=Won Young Kim;,citation_author=Hyung Jun Moon;,citation_author=Benjamin S. Abella;,citation_author=Jonathan Elmer;,citation_author=Clifton W. Callaway;,citation_author=Jon C. Rittenberger;,citation_author=on behalf of the Korean Hypothermia Network Investigators (KORHN) and the National Post-Arrest Research Consortium (NPARC);,citation_publication_date=2017-03;,citation_cover_date=2017-03;,citation_year=2017;,citation_issue=1;,citation_doi=10.1089/ther.2016.0017;,citation_issn=2153-7658, 2153-7933;,citation_volume=7;,citation_language=en-US;,citation_journal_title=Therapeutic Hypothermia and Temperature Management;">
<meta name="citation_reference" content="citation_title=Role of total lung stress on the progression of early COVID-19 pneumonia;,citation_abstract=Purpose: We investigated if the stress applied to the lung during non-invasive respiratory support may contribute to the coronavirus disease 2019 (COVID-19) progression. Methods: Single-center, prospective, cohort study of 140 consecutive COVID-19 pneumonia patients treated in high-dependency unit with continuous positive airway pressure (n = 131) or non-invasive ventilation (n = 9). We measured quantitative lung computed tomography, esophageal pressure swings and total lung stress. Results: Patients were divided in five subgroups based on their baseline PaO2/FiO2 (day 1): non-CARDS (median PaO2/FiO2 361 mmHg, IQR [323–379]), mild (224 mmHg [211–249]), mild-moderate (173 mmHg [164–185]), moderate-severe (126 mmHg [114–138]) and severe (88 mmHg [86–99], p &amp;amp;amp;lt; 0.001). Each subgroup had similar median lung weight: 1215 g [1083–1294], 1153 [888–1321], 968 [858–1253], 1060 [869–1269], and 1127 [937–1193] (p = 0.37). They also had similar non-aerated tissue fraction: 10.4% [5.9–13.7], 9.6 [7.1–15.8], 9.4 [5.8–16.7], 8.4 [6.7–12.3] and 9.4 [5.9–13.8], respectively (p = 0.85). Treatment failure of CPAP/NIV occurred in 34 patients (24.3%). Only three variables, at day one, distinguished patients with negative outcome: PaO2/FiO2 ratio (OR 0.99 [0.98–0.99], p = 0.02), esophageal pressure swing (OR 1.13 [1.01–1.27], p = 0.032) and total stress (OR 1.17 [1.06–1.31], p = 0.004). When these three variables were evaluated together in a multivariate logistic regression analysis, only the total stress was independently associated with negative outcome (OR 1.16 [1.01–1.33], p = 0.032). Conclusions: In early COVID-19 pneumonia, hypoxemia is not linked to computed tomography (CT) pathoanatomy, differently from typical ARDS. High lung stress was independently associated with the failure of non-invasive respiratory support.;,citation_author=Silvia Coppola;,citation_author=Davide Chiumello;,citation_author=Mattia Busana;,citation_author=Emanuele Giola;,citation_author=Paola Palermo;,citation_author=Tommaso Pozzi;,citation_author=Irene Steinberg;,citation_author=Stefano Roli;,citation_author=Federica Romitti;,citation_author=Stefano Lazzari;,citation_author=Simone Gattarello;,citation_author=Michela Palumbo;,citation_author=Peter Herrmann;,citation_author=Leif Saager;,citation_author=Michael Quintel;,citation_author=Konrad Meissner;,citation_author=Luigi Camporota;,citation_author=John J. Marini;,citation_author=Stefano Centanni;,citation_author=Luciano Gattinoni;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=10;,citation_doi=10.1007/s00134-021-06519-7;,citation_issn=0342-4642, 1432-1238;,citation_volume=47;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Mistie iii;,citation_author=Charlotte Cordonnier;,citation_author=Mike Tymianski;,citation_publication_date=2019-06;,citation_cover_date=2019-06;,citation_year=2019;,citation_issue=6;,citation_doi=10.1161/STROKEAHA.119.025443;,citation_volume=50;,citation_journal_title=Stroke;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=Positive End-Expiratory Pressure. When More May Not Be Better;,citation_author=Başak Çoruh;,citation_author=Andrew M. Luks;,citation_publication_date=2014-10;,citation_cover_date=2014-10;,citation_year=2014;,citation_issue=8;,citation_doi=10.1513/AnnalsATS.201404-151CC;,citation_issn=2329-6933, 2325-6621;,citation_volume=11;,citation_language=en-US;,citation_journal_title=Annals of the American Thoracic Society;">
<meta name="citation_reference" content="citation_title=Ventilatory Variables and Mechanical Power in Patients with Acute Respiratory Distress Syndrome;,citation_abstract=Rationale: Mortality in acute respiratory distress syndrome (ARDS) has decreased after the adoption of lung-protective strategies. Lower VT, lower driving pressure (DP), lower respiratory rates (RR), and higher end-expiratory pressure have all been suggested as key components of lung protection strategies. A unifying theoretical explanation has been proposed that attributes lung injury to the energy transfer rate (mechanical power) from the ventilator to the patient, calculated from a combination of several ventilator variables.;,citation_author=Eduardo L. V. Costa;,citation_author=Arthur S. Slutsky;,citation_author=Laurent J. Brochard;,citation_author=Roy Brower;,citation_author=Ary Serpa-Neto;,citation_author=Alexandre B. Cavalcanti;,citation_author=Alain Mercat;,citation_author=Maureen Meade;,citation_author=Caio C. A. Morais;,citation_author=Ewan Goligher;,citation_author=Carlos R. R. Carvalho;,citation_author=Marcelo B. P. Amato;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_issue=3;,citation_doi=10.1164/rccm.202009-3467OC;,citation_issn=1073-449X, 1535-4970;,citation_volume=204;,citation_language=en-US;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Tenecteplase for acute stroke: The thrombolysis puzzle;,citation_author=Shelagh B Coutts;,citation_author=Amy Y X Yu;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_issue=6;,citation_doi=10.1016/S1474-4422(22)00172-7;,citation_issn=14744422;,citation_volume=21;,citation_language=en-US;,citation_journal_title=The Lancet Neurology;">
<meta name="citation_reference" content="citation_title=Lifting Universal Masking in Schools — Covid-19 Incidence among Students and Staff;,citation_abstract=BACKGROUND In February 2022, Massachusetts rescinded a statewide universal masking policy in public schools, and many Massachusetts school districts lifted masking requirements during the subsequent weeks. In the greater Boston area, only two school districts — the Boston and neighboring Chelsea districts — sustained masking requirements through June 2022. The staggered lifting of masking requirements provided an opportunity to examine the effect of universal masking policies on the incidence of coronavirus disease 2019 (Covid-19) in schools. METHODS We used a difference-in-differences analysis for staggered policy implementation to compare the incidence of Covid-19 among students and staff in school districts in the greater Boston area that lifted masking requirements with the incidence in districts that sustained masking requirements during the 2021–2022 school year. Characteristics of the school districts were also compared. From the François–Xavier Bagnoud Center for Health and Human Rights, Harvard T.H. Chan School of Public Health (T.L.C., M.T.B., N.L.), the Boston Public Health Commission (T.L.C., E.J.M., J.C., B.O.O., S.M.S., K.T.H.), the Department of Epidemiology, School of Public Health, Boston University (E.J.M.), the Division of Infectious Diseases, Massachusetts General Hospital (B.O.O., S.M.S.), and Brigham and Women’s Hospital and Harvard Medical School (B.O.O., K.T.H.) —all in Boston. Dr. Cowger can be contacted at vcowger@hsph.harvard.edu or at the François–Xavier Bagnoud Center for Health and Human Rights, Harvard T.H. Chan School of Public Health, 651 Huntington Ave., Boston, MA 02115. RESULTS Before the statewide masking policy was rescinded, trends in the incidence of Covid-19 were similar across school districts. During the 15 weeks after the statewide masking policy was rescinded, the lifting of masking requirements was associated with an additional 44.9 cases per 1000 students and staff (95% confidence interval, 32.6 to 57.1), which corresponded to an estimated 11,901 cases and to 29.4% of the cases in all districts during that time. Districts that chose to sustain masking requirements longer tended to have school buildings that were older and in worse condition and to have more students per classroom than districts that chose to lift masking requirements earlier. In addition, these districts had higher percentages of low-income students, students with disabilities, and students who were English-language learners, as well as higher percentages of Black and Latinx students and staff. Our results support universal masking as an important strategy for reducing Covid-19 incidence in schools and loss of in-person school days. As such, we believe that universal masking may be especially useful for mitigating effects of structural racism in schools, including potential deepening of educational inequities. This article was published on November 9, 2022, at NEJM.org. DOI: 10.1056/NEJMoa2211029 Copyright © 2022 Massachusetts Medical Society. CONCLUSIONS Among school districts in the greater Boston area, the lifting of masking requirements was associated with an additional 44.9 Covid-19 cases per 1000 students and staff during the 15 weeks after the statewide masking policy was rescinded.;,citation_author=Tori L. Cowger;,citation_author=Eleanor J. Murray;,citation_author=Jaylen Clarke;,citation_author=Mary T. Bassett;,citation_author=Bisola O. Ojikutu;,citation_author=Sarimer M. Sánchez;,citation_author=Natalia Linos;,citation_author=Kathryn T. Hall;,citation_publication_date=2022-11;,citation_cover_date=2022-11;,citation_year=2022;,citation_doi=10.1056/NEJMoa2211029;,citation_issn=0028-4793, 1533-4406;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Critical Evaluation of Data Requires Rigorous but Broadly Based Statistical Inference;,citation_author=Nancy J. Cox;,citation_author=Jennifer E. Below;,citation_publication_date=2018-04;,citation_cover_date=2018-04;,citation_year=2018;,citation_issue=8;,citation_doi=10.1161/CIRCRESAHA.118.312530;,citation_issn=0009-7330, 1524-4571;,citation_volume=122;,citation_language=en-US;,citation_journal_title=Circulation Research;">
<meta name="citation_reference" content="citation_title=Minimal Clinically Important Difference for Safe and Simple Novel Acute Ischemic Stroke Therapies;,citation_abstract=Background and Purpose—Determining the minimal clinically important difference (MCID) is essential for evaluating novel therapies. For acute ischemic stroke, expert surveys have yielded MCIDs that are substantially higher than the MCIDs observed in actual expert behavior in guideline writing and clinical practice, potentially because of anchoring bias. Methods—We administered a structured, internet-based survey to a cross-section of academic stroke neurologists in the United States. Survey responses assessed demographic and clinical experience, and expert judgment of the MCID of the absolute increase needed in the proportion of patients achieving functional independence at 3 months to consider a novel, safe neuroprotective agent as clinically worthwhile. To mitigate anchoring bias, the survey response framework used a base 1000 rather than base 100 patient framework. Results—Survey responses were received from 122 of 333 academic stroke neurologists, there were 23% women, 72.8% had \geq6 years of practice experience, and neurovascular disease accounted for more than half of practice time in &amp;amp;amp;gt;70%. Responder–nonresponder and continuum of resistance tests indicated that responders were representative of the full expert population. Among respondents, the median MCID was 1.3% (interquartile range, 0.8% to &amp;gt;2%). Conclusions—Stroke expert responses to MCID surveys are affected by anchoring and centrality bias. When survey design takes these into account, the expert-derived MCID for a safe acute ischemic stroke treatment is 1.1% to 1.5%, in accord with actual physician behavior in guideline writing and clinical practice. This revised MCID value can guide clinical trial design and grant-funding and regulatory agency decisions. \mkern1mu(Stroke. 2017;48:2946-2951. DOI: 10.1161/ STROKEAHA.117.017496.);,citation_author=Jessica S. Cranston;,citation_author=Brett D. Kaplan;,citation_author=Jeffrey L. Saver;,citation_publication_date=2017-11;,citation_cover_date=2017-11;,citation_year=2017;,citation_issue=11;,citation_doi=10.1161/STROKEAHA.117.017496;,citation_issn=0039-2499, 1524-4628;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=Long-term mortality and health-related quality of life of lower versus higher oxygenation targets in ICU patients with severe hypoxaemia;,citation_abstract=We assessed outcomes after 1 year of lower versus higher oxygenation targets in intensive care unit (ICU) patients with severe hypoxaemia.;,citation_author=Elena Crescioli;,citation_author=Thomas Lass Klitgaard;,citation_author=Lone Musaeus Poulsen;,citation_author=Bjørn Anders Brand;,citation_author=Martin Siegemund;,citation_author=Thorbjørn Grøfte;,citation_author=Frederik Keus;,citation_author=Ulf Gøttrup Pedersen;,citation_author=Minna Bäcklund;,citation_author=Johanna Karttunen;,citation_author=Matthew Morgan;,citation_author=Andrei Ciubotariu;,citation_author=Anne-Marie Gellert Bunzel;,citation_author=Stine Rom Vestergaard;,citation_author=Nicolaj Munch Jensen;,citation_author=Thomas Steen Jensen;,citation_author=Maj-Brit Nørregaard Kjær;,citation_author=Aksel Karl Georg Jensen;,citation_author=Theis Lange;,citation_author=Jørn Wetterslev;,citation_author=Anders Perner;,citation_author=Olav Lilleholt Schjørring;,citation_author=Bodil Steen Rasmussen;,citation_publication_date=2022-04;,citation_cover_date=2022-04;,citation_year=2022;,citation_doi=10.1007/s00134-022-06695-0;,citation_issn=1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Is Endovascular Thrombectomy for the Very Elderly?;,citation_author=Claire J. Creutzfeldt;,citation_author=Michael R. Levitt;,citation_author=Thabele M. Leslie-Mazwi;,citation_publication_date=2022-07;,citation_cover_date=2022-07;,citation_year=2022;,citation_issue=7;,citation_doi=10.1161/STROKEAHA.122.039340;,citation_volume=53;,citation_journal_title=Stroke;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=Predicting decline and survival in severe acute brain injury: The fourth trajectory;,citation_abstract=&amp;amp;amp;lt;p&amp;gt;Illness trajectories depicting how function declines to death with certain diseases, such as cancer, can help with palliative care. &amp;lt;b&amp;gt;Creutzfeldt and colleagues</b> propose a fourth trajectory is needed for patients with severe acute brain injury to improve decision making and standards of care</p>;,citation_author=Claire J. Creutzfeldt;,citation_author=W. T. Longstreth;,citation_author=Robert G. Holloway;,citation_publication_date=2015-08;,citation_cover_date=2015-08;,citation_year=2015;,citation_doi=10.1136/bmj.h3904;,citation_issn=1756-1833;,citation_pmid=26251409;,citation_volume=351;,citation_language=en-US;,citation_journal_title=BMJ;,citation_publisher=British Medical Journal Publishing Group;">
<meta name="citation_reference" content="citation_title=Treatment Decisions for a Future Self: Ethical Obligations to Guide Truly Informed Choices;,citation_author=Claire J. Creutzfeldt;,citation_author=Robert G. Holloway;,citation_publication_date=2020-01;,citation_cover_date=2020-01;,citation_year=2020;,citation_doi=10.1001/jama.2019.19652;,citation_issn=0098-7484;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Preserving equipoise and performing randomised trials for COVID-19 social distancing interventions;,citation_abstract=In the coronavirus disease 2019 (COVID-19) pandemic, a large number of non-pharmaceutical measures that pertain to the wider group of social distancing interventions (e.g. public gathering bans, closures of schools, workplaces and all but essential business, mandatory stay-at-home policies, travel restrictions, border closures and others) have been deployed. Their urgent deployment was defended with modelling and observational data of spurious credibility. There is major debate on whether these measures are effective and there is also uncertainty about the magnitude of the harms that these measures might induce. Given that there is equipoise for how, when and if specific social distancing interventions for COVID-19 should be applied and removed/modified during reopening, we argue that informative randomised-controlled trials are needed. Only a few such randomised trials have already been conducted, but the ones done to-date demonstrate that a randomised trials agenda is feasible. We discuss here issues of study design choice, selection of comparators (intervention and controls), choice of outcomes and additional considerations for the conduct of such trials. We also discuss and refute common counter-arguments against the conduct of such trials.;,citation_author=Ioana Alina Cristea;,citation_author=Florian Naudet;,citation_author=John P. A. Ioannidis;,citation_publication_date=2020;,citation_cover_date=2020;,citation_year=2020;,citation_doi=10.1017/S2045796020000992;,citation_issn=2045-7960, 2045-7979;,citation_volume=29;,citation_language=en-US;,citation_journal_title=Epidemiology and Psychiatric Sciences;">
<meta name="citation_reference" content="citation_title=Evaluating how clear the questions being investigated in randomised trials are: Systematic review of estimands;,citation_abstract=Objectives To evaluate how often the precise research question being addressed about an intervention (the estimand) is stated or can be determined from reported methods, and to identify what types of questions are being investigated in phase 2-4 randomised trials. Design Systematic review of the clarity of research questions being investigated in randomised trials in 2020 in six leading general medical journals. Data source PubMed search in February 2021. Eligibility criteria for selecting studies Phase 2-4 randomised trials, with no restrictions on medical conditions or interventions. Cluster randomised, crossover, non-inferiority, and equivalence trials were excluded. Main outcome measures Number of trials that stated the precise primary question being addressed about an intervention (ie, the primary estimand), or for which the primary estimand could be determined unambiguously from the reported methods using statistical knowledge. Strategies used to handle post-randomisation events that affect the interpretation or existence of patient outcomes, such as intervention discontinuations or uses of additional drug treatments (known as intercurrent events), and the corresponding types of questions being investigated. Results 255 eligible randomised trials were identified. No trials clearly stated all the attributes of the estimand. In 117 (46%) of 255 trials, the primary estimand could be determined from the reported methods. Intercurrent events were reported in 242 (95%) of 255 trials; but the handling of these could only be determined in 125 (49%) of 255 trials. Most trials that provided this information considered the occurrence of intercurrent events as irrelevant in the calculation of the treatment effect and assessed the effect of the intervention regardless (96/125, 77%)—that is, they used a treatment policy strategy. Four (4%) of 99 trials with treatment non-adherence owing to adverse events estimated the treatment effect in a hypothetical setting (ie, the effect as if participants continued treatment despite adverse events), and 19 (79%) of 24 trials where some patients died estimated the treatment effect in a hypothetical setting (ie, the effect as if participants did not die). Conclusions The precise research question being investigated in most trials is unclear, mainly because of a lack of clarity on the approach to handling intercurrent events. Clear reporting of estimands is necessary in trial reports so that all stakeholders, including clinicians, patients and policy makers, can make fully informed decisions about medical interventions. Systematic review registration PROSPERO CRD42021238053.;,citation_author=Suzie Cro;,citation_author=Brennan C. Kahan;,citation_author=Sunita Rehal;,citation_author=Anca Chis Ster;,citation_author=James R. Carpenter;,citation_author=Ian R. White;,citation_author=Victoria R. Cornelius;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_doi=10.1136/bmj-2022-070146;,citation_issn=1756-1833;,citation_pmid=35998928;,citation_volume=378;,citation_language=en-US;,citation_journal_title=BMJ;,citation_publisher=British Medical Journal Publishing Group;">
<meta name="citation_reference" content="citation_title=Brain injury after cardiac arrest: From prognostication of comatose patients to rehabilitation;,citation_author=Tobias Cronberg;,citation_author=David M Greer;,citation_author=Gisela Lilja;,citation_author=Véronique Moulaert;,citation_author=Paul Swindell;,citation_author=Andrea O Rossetti;,citation_publication_date=2020-07;,citation_cover_date=2020-07;,citation_year=2020;,citation_issue=7;,citation_doi=10.1016/S1474-4422(20)30117-4;,citation_issn=14744422;,citation_volume=19;,citation_language=en-US;,citation_journal_title=The Lancet Neurology;">
<meta name="citation_reference" content="citation_title=The Rational Diagnostician and Achieving Diagnostic Excellence;,citation_author=Pat Croskerry;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=4;,citation_doi=10.1001/jama.2021.24988;,citation_issn=0098-7484;,citation_volume=327;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Concise Definitive Review for Reinitiation of Antidepressants, Antipsychotics, and Gabapentinoids in ICU Patients;,citation_author=Michaelia D. Cucci;,citation_author=Katleen W. Chester;,citation_author=Leslie A. Hamilton;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_doi=10.1097/CCM.0000000000005415;,citation_issn=0090-3493;,citation_volume=Publish Ahead of Print;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Inference by Eye: Confidence Intervals and How to Read Pictures of Data.;,citation_author=Geoff Cumming;,citation_author=Sue Finch;,citation_publication_date=2005;,citation_cover_date=2005;,citation_year=2005;,citation_issue=2;,citation_doi=10.1037/0003-066X.60.2.170;,citation_issn=1935-990X, 0003-066X;,citation_volume=60;,citation_language=en-US;,citation_journal_title=American Psychologist;">
<meta name="citation_reference" content="citation_title=The Missing Medians: Exclusion of Ordinal Data from Meta-Analyses;,citation_abstract=Background Meta-analyses are considered the gold standard of evidence-based health care, and are used to guide clinical decisions and health policy. A major limitation of current meta-analysis techniques is their inability to pool ordinal data. Our objectives were to determine the extent of this problem in the context of neurological rating scales and to provide a solution. Methods Using an existing database of clinical trials of oral neuroprotective therapies, we identified the 6 most commonly used clinical rating scales and recorded how data from these scales were reported and analysed. We then identified systematic reviews of studies that used these scales (via the Cochrane database) and recorded the meta-analytic techniques used. Finally, we identified a statistical technique for calculating a common language effect size measure for ordinal data. Results We identified 103 studies, with 128 instances of the 6 clinical scales being reported. The majority– 80%–reported means alone for central tendency, with only 13% reporting medians. In analysis, 40% of studies used parametric statistics alone, 34% of studies employed non-parametric analysis, and 26% did not include or specify analysis. Of the 60 systematic reviews identified that included meta-analysis, 88% used mean difference and 22% employed difference in proportions; none included rank-based analysis. We propose the use of a rank-based generalised odds ratio (WMW GenOR) as an assumptionfree effect size measure that is easy to compute and can be readily combined in metaanalysis. Conclusion There is wide scope for improvement in the reporting and analysis of ordinal data in the literature. We hope that adoption of the WMW GenOR will have the dual effect of improving the;,citation_author=Toby B. Cumming;,citation_author=Leonid Churilov;,citation_author=Emily S. Sena;,citation_editor=Jakob Pietschnig;,citation_publication_date=2015-12;,citation_cover_date=2015-12;,citation_year=2015;,citation_issue=12;,citation_doi=10.1371/journal.pone.0145580;,citation_issn=1932-6203;,citation_volume=10;,citation_language=en-US;,citation_journal_title=PLOS ONE;">
<meta name="citation_reference" content="citation_title=The Relative Merits of Risk Ratios and Odds Ratios;,citation_author=Peter Cummings;,citation_publication_date=2009-05;,citation_cover_date=2009-05;,citation_year=2009;,citation_issue=5;,citation_doi=10.1001/archpediatrics.2009.31;,citation_issn=1072-4710;,citation_volume=163;,citation_language=en-US;,citation_journal_title=Archives of Pediatrics &amp;amp;amp; Adolescent Medicine;">
<meta name="citation_reference" content="citation_title=Integrating palliative care into the ICU: A lasting and developing legacy;,citation_author=J. Randall Curtis;,citation_author=Irene J. Higginson;,citation_author=Douglas B. White;,citation_publication_date=2022-07;,citation_cover_date=2022-07;,citation_year=2022;,citation_issue=7;,citation_doi=10.1007/s00134-022-06729-7;,citation_issn=0342-4642, 1432-1238;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=The long-term outcomes of mechanical ventilation: What are they and how should they be used?;,citation_abstract=In the critical care setting, usually the most important outcome is survival. However, this is not the only important outcome of critical care. There are increasing data that the patient’s quality of life and functional status can be affected long after an intensive care unit stay, and some data suggest that mechanical ventilation strategies could influence those outcomes. Critical care clinicians’ decisions regarding mechanical ventilation and related treatments such as level of sedation might have more profound and far-reaching residual effects than has been previously recognized. To deliver effective, cost-effective, and patient-centered care, critical-care clinicians must consider outcomes other than survival. These outcomes include such diverse concepts as quality of life, functional status, and neuropsychological function. This review addresses theoretical and practical challenges to measuring and interpreting those other outcomes.;,citation_author=J. Randall Curtis;,citation_publication_date=2002-04;,citation_cover_date=2002-04;,citation_year=2002;,citation_issue=4;,citation_issn=0020-1324;,citation_pmid=11929620;,citation_volume=47;,citation_language=en-US;,citation_journal_title=Respiratory Care;">
<meta name="citation_reference" content="citation_title=Providing Compassionate Care in the ICU;,citation_author=J. Randall Curtis;,citation_author=Mitchell M. Levy;,citation_publication_date=2022-05;,citation_cover_date=2022-05;,citation_year=2022;,citation_issue=9;,citation_doi=10.1164/rccm.202112-2787ED;,citation_issn=1073-449X, 1535-4970;,citation_volume=205;,citation_language=en-US;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Resumption of Anticoagulation After Intracranial Hemorrhage;,citation_abstract=Anticoagulation is a vital therapy in a number of different disease processes, and is strongly recommended for the prevention of stroke in patients with atrial fibrillation and/or with mechanical prosthetic heart valves. Studies involving patients on oral anticoagulants (OACs) have revealed that ICH can occur eight times more frequently in this population, with an annual estimated incidence of 0.25 to 1.1%. The decision of whether and when to resume anticoagulation following intracranial hemorrhage is challenging and requires an assessment of associated risks and benefits. Clinical data, imaging, and risk factors for both ischemic and hemorrhagic complications may aid in decision-making. Baseline functional status, life expectancy, compliance with therapy, and family support also impact decision analyses. Currently available data suggest that anticoagulation could be safely restarted in select groups of OAC-ICH patients within 4&nbsp;weeks of intracranial hemorrhage; however, high-quality randomized, clinical trials are needed.;,citation_author=Ivan Rocha Ferreira Silva;,citation_author=Jennifer A. Frontera;,citation_publication_date=2017-09;,citation_cover_date=2017-09;,citation_year=2017;,citation_issue=11;,citation_doi=10.1007/s11940-017-0477-y;,citation_issn=1534-3138;,citation_volume=19;,citation_language=en-US;,citation_journal_title=Current Treatment Options in Neurology;">
<meta name="citation_reference" content="citation_title=Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group;,citation_abstract=In observational studies, investigators have no control over the treatment assignment. The treated and non-treated (that is, control) groups may have large differences on their observed covariates, and these differences can lead to biased estimates of treatment effects. Even traditional covariance analysis adjustments may be inadequate to eliminate this bias. The propensity score, defined as the conditional probability of being treated given the covariates, can be used to balance the covariates in the two groups, and therefore reduce this bias. In order to estimate the propensity score, one must model the distribution of the treatment indicator variable given the observed covariates. Once estimated the propensity score can be used to reduce bias through matching, stratification (subclassification), regression adjustment, or some combination of all three. In this tutorial we discuss the uses of propensity score methods for bias reduction, give references to the literature and illustrate the uses through applied examples. © 1998 John Wiley &amp;amp;amp; Sons, Ltd.;,citation_author=Ralph B. D’Agostino Jr.;,citation_publication_date=1998;,citation_cover_date=1998;,citation_year=1998;,citation_issue=19;,citation_doi=10.1002/(SICI)1097-0258(19981015)17:19&amp;amp;lt;2265::AID-SIM918&amp;gt;3.0.CO;2-B;,citation_issn=1097-0258;,citation_volume=17;,citation_language=en-US;,citation_journal_title=Statistics in Medicine;">
<meta name="citation_reference" content="citation_title=Causal Inference Is Not Just a Statistics Problem;,citation_abstract=This article introduces a collection of four datasets, similar to Anscombe’s quartet, that aim to highlight the challenges involved when estimating causal effects. Each of the four datasets is generated based on a distinct causal mechanism: the first involves a collider, the second involves a confounder, the third involves a mediator, and the fourth involves the induction of M-Bias by an included factor. The article includes a mathematical summary of each dataset, as well as directed acyclic graphs that depict the relationships between the variables. Despite the fact that the statistical summaries and visualizations for each dataset are identical, the true causal effect differs, and estimating it correctly requires knowledge of the data-generating mechanism. These example datasets can help practitioners gain a better understanding of the assumptions underlying causal inference methods and emphasize the importance of gathering more information beyond what can be obtained from statistical tools alone. The article also includes R code for reproducing all figures and provides access to the datasets themselves through an R package named “quartets.” Supplementary materials for this article are available online.;,citation_author=Lucy D’Agostino McGowan;,citation_author=Travis Gerke;,citation_author=Malcolm Barrett;,citation_publication_date=2023;,citation_cover_date=2023;,citation_year=2023;,citation_issue=0;,citation_doi=10.1080/26939169.2023.2276446;,citation_issn=null;,citation_volume=0;,citation_journal_title=Journal of Statistics and Data Science Education;,citation_publisher=Taylor &amp;amp;amp; Francis;">
<meta name="citation_reference" content="citation_title=Effect of oral chlorhexidine de-adoption and implementation of an oral care bundle on mortality for mechanically ventilated patients in the intensive care unit (CHORAL): A multi-center stepped wedge cluster-randomized controlled trial;,citation_abstract=Purpose: Oral chlorhexidine is used widely for mechanically ventilated patients to prevent pneumonia, but recent studies show an association with excess mortality. We examined whether de-adoption of chlorhexidine and parallel implementation of a standardized oral care bundle reduces intensive care unit (ICU) mortality in mechanically venti-lated patients. Methods: A stepped wedge cluster-randomized controlled trial with concurrent process evaluation in 6 ICUs in Toronto, Canada. Clusters were randomized to de-adopt chlorhexidine and implement a standardized oral care bun-dle at 2-month intervals. The primary outcome was ICU mortality. Secondary outcomes were time to infection-related ventilator-associated complications (IVACs), oral procedural pain and oral health dysfunction. An exploratory post hoc analysis examined time to extubation in survivors. Results: A total of 3260 patients were enrolled; 1560 control, 1700 intervention. ICU mortality for the intervention and control periods were 399 (23.5%) and 330 (21.2%), respectively (adjusted odds ratio [aOR], 1.13; 95% confidence interval [CI] 0.82 to 1.54; P = 0.46). Time to IVACs (adjusted hazard ratio [aHR], 1.06; 95% CI 0.44 to 2.57; P = 0.90), time to extubation (aHR 1.03; 95% CI 0.85 to 1.23; P = 0.79) (survivors) and oral procedural pain (aOR, 0.62; 95% CI 0.34 to 1.10; P = 0.10) were similar between control and intervention periods. However, oral health dysfunction scores (- 0.96; 95% CI - 1.75 to - 0.17; P = 0.02) improved in the intervention period. Conclusion: Among mechanically ventilated ICU patients, no benefit was observed for de-adoption of chlorhexidine and implementation of an oral care bundle on ICU mortality, IVACs, oral procedural pain, or time to extubation. The intervention may improve oral health.;,citation_author=Craig M. Dale;,citation_author=Louise Rose;,citation_author=Sarah Carbone;,citation_author=Ruxandra Pinto;,citation_author=Orla M. Smith;,citation_author=Lisa Burry;,citation_author=Eddy Fan;,citation_author=Andre Carlos Kajdacsy-Balla Amaral;,citation_author=Victoria A. McCredie;,citation_author=Damon C. Scales;,citation_author=Brian H. Cuthbertson;,citation_publication_date=2021-11;,citation_cover_date=2021-11;,citation_year=2021;,citation_issue=11;,citation_doi=10.1007/s00134-021-06475-2;,citation_issn=0342-4642, 1432-1238;,citation_volume=47;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Bias in Observational Studies of Prevalent Users: Lessons for Comparative Effectiveness Research From a Meta-Analysis of Statins;,citation_author=Goodarz Danaei;,citation_author=Mohammad Tavakkoli;,citation_author=Miguel A. Hernán;,citation_publication_date=2012-02;,citation_cover_date=2012-02;,citation_year=2012;,citation_issue=4;,citation_doi=10.1093/aje/kwr301;,citation_issn=1476-6256, 0002-9262;,citation_volume=175;,citation_language=en-US;,citation_journal_title=American Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Does the obesity paradox predict functional outcome in intracerebral hemorrhage?;,citation_abstract=OBJECTIVE Being overweight or mildly obese has been associated with a decreased risk of death or hospitalization in patients with cardiovascular disease. Similarly, overweight patients admitted to an intensive care unit (ICU) have improved survival up to 1 year after admission. These counterintuitive observations are examples of the “obesity paradox.” Does the obesity paradox exist in patients with intracerebral hemorrhage (ICH)? In this study the authors examined whether there was an association between obesity and functional outcome in patients with ICH. METHODS The authors analyzed 202 patients admitted to the neurological ICU (NICU) who were prospectively enrolled in the Columbia University ICH Outcomes Project between September 2009 and December 2012. Patients were categorized into 2 groups: overweight (body mass index [BMI] \geq 25 kg/m2) and not overweight (BMI &amp;amp;amp;lt; 25 kg/m2). The primary outcome was defined as survival with favorable outcome (modified Rankin Scale [mRS] score 0–3) versus death or severe disability (mRS score 4–6) at 3 months. RESULTS The mean age of the patients in the study was 61 years. The mean BMI was 28  6 kg/m2. The mean Glasgow Coma Scale score was 10  4 and the mean ICH score was 1.9  1.3. The overall 90-day mortality rate was 41%. Among patients with a BMI &amp;lt; 25 kg/m2, 24% (17/70) had a good outcome, compared with 39% (52/132) among those with a BMI \geq 25 kg/m2 (p = 0.03). After adjusting for ICH score, sex, do-not-resuscitate code status, and history of hypertension, being overweight or obese (BMI \geq 25 kg/m2) was associated with twice the odds of having a good outcome compared with patients with BMI < 25 kg/m2 (adjusted odds ratio 2.05, 95% confidence interval 1.03–4.06, p = 0.04). CONCLUSIONS In patients with ICH admitted to the NICU, being overweight or obese (BMI \geq 25 kg/m2) was associated with favorable outcome after adjustment for established predictors. The reason for this finding requires further study. https://thejns.org/doi/abs/10.3171/2017.5.JNS163266 KEY WORDS intracerebral hemorrhage; obesity; functional recovery; intensive care unit; vascular disorders;,citation_author=Neha S. Dangayach;,citation_author=Harpreet Singh Grewal;,citation_author=Gian Marco De Marchis;,citation_author=Roberta K. Sefcik;,citation_author=Rachel Bruce;,citation_author=Aarti Chhatlani;,citation_author=E. Sander Connolly;,citation_author=M. Cristina Falo;,citation_author=Sachin Agarwal;,citation_author=Jan Claassen;,citation_author=J. Michael Schmidt;,citation_author=Stephan A. Mayer;,citation_publication_date=2018-11;,citation_cover_date=2018-11;,citation_year=2018;,citation_issue=5;,citation_doi=10.3171/2017.5.JNS163266;,citation_issn=0022-3085, 1933-0693;,citation_volume=129;,citation_language=en-US;,citation_journal_title=Journal of Neurosurgery;">
<meta name="citation_reference" content="citation_title=A Pragmatic Randomized Trial Comparing Surgical Clipping and Endovascular Treatment of Unruptured Intracranial Aneurysms;,citation_abstract=BACKGROUND AND PURPOSE: Surgical clipping and endovascular treatment are commonly used in patients with unruptured intracranial aneurysms. We compared the safety and efficacy of the 2 treatments in a randomized trial. MATERIALS AND METHODS: Clipping or endovascular treatments were randomly allocated to patients with one or more 3- to 25-mm unruptured intracranial aneurysms judged treatable both ways by participating physicians. The study hypothesized that clipping would decrease the incidence of treatment failure from 13% to 4%, a composite primary outcome defined as failure of aneurysm occlusion, intracranial hemorrhage during follow-up, or residual aneurysms at 1 year, as adjudicated by a core lab. Safety outcomes included new neurologic deficits following treatment, hospitalization of &amp;amp;amp;gt;5 days, and overall morbidity and mortality (mRS &amp;gt; 2) at 1 year. There was no blinding. RESULTS: Two hundred ninety-one patients were enrolled from 2010 to 2020 in 7 centers. The 1-year primary outcome, ascertainable in 290/291 (99%) patients, was reached in 13/142 (9%; 95% CI, 5%–15%) patients allocated to surgery and in 28/148 (19%; 95% CI, 13%–26%) patients allocated to endovascular treatments (relative risk: 2.07; 95% CI, 1.12–3.83; P = .021). Morbidity and mortality (mRS >2) at 1 year occurred in 3/143 and 3/148 (2%; 95% CI, 1%–6%) patients allocated to surgery and endovascular treatments, respectively. Neurologic deficits (32/143, 22%; 95% CI, 16%–30% versus 19/148, 12%; 95% CI, 8%–19%; relative risk: 1.74; 95% CI, 1.04–2.92; P = .04) and hospitalizations beyond 5 days (69/143, 48%; 95% CI, 40%–56% versus 12/148, 8%; 95% CI, 5%–14%; relative risk: 0.18; 95% CI, 0.11–0.31; P &amp;lt; .001) were more frequent after surgery. CONCLUSIONS: Surgical clipping is more effective than endovascular treatment of unruptured intracranial aneurysms in terms of the frequency of the primary outcome of treatment failure. Results were mainly driven by angiographic results at 1 year.;,citation_author=T. E. Darsaut;,citation_author=J. M. Findlay;,citation_author=M. W. Bojanowski;,citation_author=C. Chalaala;,citation_author=D. Iancu;,citation_author=D. Roy;,citation_author=A. Weill;,citation_author=W. Boisseau;,citation_author=A. Diouf;,citation_author=E. Magro;,citation_author=M. Kotowski;,citation_author=M. B. Keough;,citation_author=L. Estrade;,citation_author=N. Bricout;,citation_author=J.-P. Lejeune;,citation_author=M. M. C. Chow;,citation_author=C. J. O’Kelly;,citation_author=J. L. Rempel;,citation_author=R. A. Ashforth;,citation_author=H. Lesiuk;,citation_author=J. Sinclair;,citation_author=U.-E. Erdenebold;,citation_author=J. H. Wong;,citation_author=F. Scholtes;,citation_author=D. Martin;,citation_author=B. Otto;,citation_author=A. Bilocq;,citation_author=E. Truffer;,citation_author=K. Butcher;,citation_author=A. J. Fox;,citation_author=A. S. Arthur;,citation_author=L. Létourneau-Guillon;,citation_author=F. Guilbert;,citation_author=M. Chagnon;,citation_author=J. Zehr;,citation_author=B. Farzin;,citation_author=G. Gevry;,citation_author=J. Raymond;,citation_publication_date=2023-05;,citation_cover_date=2023-05;,citation_year=2023;,citation_doi=10.3174/ajnr.A7865;,citation_issn=0195-6108, 1936-959X;,citation_pmid=37169541;,citation_language=en-US;,citation_journal_title=American Journal of Neuroradiology;,citation_publisher=American Journal of Neuroradiology;">
<meta name="citation_reference" content="citation_title=Systemic Thrombolysis by Alteplase for Acute Ischemic Stroke;,citation_abstract=Evidence was summarized to determine the effect of alteplase in adult stroke patients. There is substantial uncertainty concerning the evidence due to the risk of bias in the available studies and imprecision in how the magnitude of the treatment effects were estimated. The identified research suggests that alteplase administered within 3 hours of a stroke might result in: fewer deaths after 18 months and little-to-no difference in death after 7 days, 3 months, 6 months, or 3 years increased brain bleeds after 7 days but no difference after 36 hours or after 3 months improvements in functioning and independence after 7 days and after 6 months; at 3 months, some studies showed no difference in independence and another study showed higher functioning. The identified research suggests that alteplase administered between 3 hours and 4.5 hours after a stroke might result in: little-to-no difference in deaths after 3 months; at 7 days, some evidence showed little-to-no difference in death while other evidence suggested more deaths little-to-no differences in brain bleeds after 36 hours; at 7 days, some evidence showed no effect on brain bleeds, while other evidence showed more brain bleeds no differences in functioning and independence after 6 months; at 3 months, some evidence showed no effect on functioning, while other evidence reported improved functioning.;,citation_author=Nazia Darvesh;,citation_author=Robyn Butcher;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_issue=6;,citation_doi=10.51731/cjht.2022.351;,citation_issn=2563-6596;,citation_volume=2;,citation_language=en-US;,citation_journal_title=Canadian Journal of Health Technologies;">
<meta name="citation_reference" content="citation_title=What Are Terminally Ill Cancer Patients Told About Their Expected Deaths? A Study of Cancer Physicians’ Self-Reports of Prognosis Disclosure;,citation_abstract=Purpose Little is known about how physicians discuss prognosis with terminally ill cancer patients. Thus, we sought to obtain cancer physicians’ self-reports of their prognosis communication practices. Methods A survey seeking self-reports regarding prognosis communication with their terminally ill cancer patients was mailed to a systematic sample of medical oncologists in the United States. Results Of 1,137 physicians, 729 completed and returned surveys (64% response rate). Median age of respondents was 51 years (range, 33 to 80 years); 82% were men. Respondents had practiced cancer care for a median of 18 years (range, 1.5 to 50 years) and reported seeing a median of 60 patients per week (range, 0 to 250 patients per week). Although 98% said their usual practice is to tell terminally ill patients that they will die, 48% specifically described communicating terminal prognoses to patients only when specific preferences for prognosis information were expressed. Forty-three percent said they always or usually communicate a medical estimate of time as to when death is likely to occur, and 57% reported sometimes, rarely, or never giving a time frame. Seventy-three percent said prognosis communication education was either absent or inadequate during their training, and 96% believed it should be part of cancer care training. Conclusion Medical oncologists report routinely informing their terminally ill patients that they will die. However, they are divided in describing themselves as either always discussing a terminal prognosis or doing so if it is consistent with their patients’ preferences for prognostic information. Most medical oncologists say they do not routinely communicate an estimated survival time to their patients.;,citation_author=Christopher K. Daugherty;,citation_author=Fay J. Hlubocky;,citation_publication_date=2008-12;,citation_cover_date=2008-12;,citation_year=2008;,citation_issue=36;,citation_doi=10.1200/JCO.2008.17.2221;,citation_issn=0732-183X, 1527-7755;,citation_volume=26;,citation_language=en-US;,citation_journal_title=Journal of Clinical Oncology;">
<meta name="citation_reference" content="citation_title=Can the Future of ID Escape the Inertial Dogma of Its Past? : The Exemplars of Shorter Is Better and Oral Is the New IV;,citation_abstract=Like all fields of medicine, Infectious Diseases is rife with dogma that underpins much clinical practice. Here we discuss two specific examples of historical practice that have been overturned recently by numerous prospective studies: traditional durations of antimicrobial therapy and the necessity of intravenous (IV)-only therapy for specific infectious syndromes. These dogmas are based on uncontrolled case series from &amp;amp;amp;gt;50 years ago, amplified by the opinions of eminent experts. Conversely, more than 120 modern, randomized controlled trials have established that shorter durations of therapy are equally effective for many infections. Furthermore, 21 concordant randomized controlled trials have demonstrated that oral antibiotic therapy is at least as effective as IV-only therapy for osteomyelitis, bacteremia, and endocarditis. Nevertheless, practitioners in many clinical settings remain refractory to adopting these changes. It is time for Infectious Diseases to move beyond its history of eminent opinion-based medicine and truly into the era of evidenced-based medicine.;,citation_author=Kusha Davar;,citation_author=Devin Clark;,citation_author=Robert M Centor;,citation_author=Fernando Dominguez;,citation_author=Bassam Ghanem;,citation_author=Rachael Lee;,citation_author=Todd C Lee;,citation_author=Emily G McDonald;,citation_author=Matthew C Phillips;,citation_author=Parham Sendi;,citation_author=Brad Spellberg;,citation_publication_date=2022-12;,citation_cover_date=2022-12;,citation_year=2022;,citation_doi=10.1093/ofid/ofac706;,citation_issn=2328-8957;,citation_journal_title=Open Forum Infectious Diseases;">
<meta name="citation_reference" content="citation_title=Correlation without a cause: An epidemiological odyssey;,citation_abstract=Background: In the 1980s debate intensified over whether there was a protective effect of high-density lipoprotein cholesterol (HDL-C) or an adverse effect of triglycerides on coronary heart disease (CHD) risk. In a 1991 paper reprinted in the IJE we suggested that the high degree of correlation between the two, together with plausible levels of measurement error, made it unlikely that conventional epidemiological approaches could contribute to causal understanding. The consensus that HDL-C was protective, popularly reified in the notion of “good cholesterol”, strengthened over subsequent years. Reviewing the biostatistical and epidemiological literature from before and after 1991 we suggest that within the observational epidemiology pantheon only Mendelian randomization studies—that began to appear at the same time as the initial negative randomized controlled trials—made a meaningful contribution. It is sobering to realize that many issues that appear suitable targets for epidemiological investigation are simply refractory to conventional approaches. The discipline should surely revisit this and other highprofile cases of consequential epidemiological failure—such as that with respect to vitamin E supplementation and CHD risk—rather than pass them over in silence.;,citation_author=George Davey Smith;,citation_author=Andrew N Phillips;,citation_publication_date=2020-02;,citation_cover_date=2020-02;,citation_year=2020;,citation_issue=1;,citation_doi=10.1093/ije/dyaa016;,citation_issn=0300-5771, 1464-3685;,citation_volume=49;,citation_language=en-US;,citation_journal_title=International Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Reduced Quality of Life in Survivors of Acute Respiratory Distress Syndrome Compared With Critically Ill Control Patients;,citation_abstract=Objective To determine if there are differences in the HRQL of ARDS survivors and comparably ill or injured controls without ARDS. Design Prospective, matched, parallel cohort study. Setting A 411-bed municipal medical and regional level I trauma center. Patients Seventy-three pairs of ARDS survivors and severity-matched controls with the clinical risk factors for ARDS of sepsis and trauma admitted between January 1, 1994, and July 30, 1996. Main Outcome Measures The HRQL of ARDS survivors and controls, assessed by generic and pulmonary disease–specific HRQL instruments (Medical Outcomes Study 36-Item Short Form Health Survey, Standard Form [SF-36] and St George’s Respiratory Questionnaire [SGRQ], respectively). Results Clinically meaningful and statistically significant reductions in HRQL scores of ARDS survivors (n = 73) were seen in 7 of 8 SF-36 domains and 3 of 3 SGRQ domains compared with matched controls (PϽ.001 for all reductions). The largest decrements in the HRQL were seen in physical function and pulmonary symptoms and limitations. Analysis of trauma-matched pairs (n = 46) revealed significant reductions in 7 of 8 SF-36 domains (PՅ.02) and 3 of 3 SGRQ domains (PՅ.003). Analysis of sepsis-matched pairs (n = 27) revealed significant reductions in 6 of 8 SF-36 domains (PՅ.05) and 3 of 3 SGRQ domains (PՅ.002). Conclusions Survivors of ARDS have a clinically significant reduction in HRQL that appears to be caused exclusively by ARDS and its sequelae. Reductions were primarily noted in physical functioning and pulmonary disease–specific domains.;,citation_author=Timothy A Davidson;,citation_author=Ellen S Caldwell;,citation_author=J Randall Curtis;,citation_author=Leonard D Hudson;,citation_author=Kenneth P Steinberg;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Reshaping the review of consent so we might improve participant choice;,citation_abstract=Consent is one necessary foundation for ethical research and it’s one of the research ethics committee’s major roles to ensure that the consent process meets acceptable standards. Although on Oxford “A” REC (an NHS Research Ethics Committee based in the UK) we’ve been impressed by the thought and work put into this aspect of research ethics, we’ve continued to have concerns about the suitability and effectiveness of consent processes in supporting decision making, particularly for clinical trials. There’s poor understanding of what people want to help them decide; current processes don’t provide the best grounding for informed consent and there’s inadequate public involvement. We’ve also found a lack of proportionality with researchers failing to adapt consent procedures in proportion to the burdens and consequences of the study. As a result, people are often not best helped to make an informed choice when asked to join a research study. To address these concerns, we considered how we might improve this aspect of research ethics review. Recognising the central importance of the dialogue between the volunteer and researcher, we’ve drawn up a model or flowchart of what we deem good consent practice, proposing consent should be built around four simple steps: Step 1: Introducing the study and the choices: helping the potential participants get an overview of the proposal and introducing the key issues. Step 2: Explaining all the details of the study using the detailed Participant Information Sheet. Step 3: After a gap, if necessary, reviewing and checking understanding. Step 4: Reaching agreement and recording consent. These steps, we believe, could help all involved and this article lays out ways we might improve participant choice while complying with accepted principles and current regulations.;,citation_author=Hugh Davies;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_doi=10.1177/17470161211043703;,citation_issn=1747-0161, 2047-6094;,citation_language=en-US;,citation_journal_title=Research Ethics;">
<meta name="citation_reference" content="citation_title=Functional Disability, Cognitive Impairment, and Depression After Hospitalization for Pneumonia;,citation_abstract=OBJECTIVE: The study objective was to examine whether hospitalization for pneumonia is associated with functional decline, cognitive impairment, and depression, and to compare this impairment with that seen after known disabling conditions, such as myocardial infarction or stroke. METHODS: We used data from a prospective cohort of 1434 adults aged more than 50 years who survived 1711 hospitalizations for pneumonia, myocardial infarction, or stroke drawn from the Health and Retirement Study (1998-2010). Main outcome measures included the number of Activities and Instrumental Activities of Daily Living requiring assistance and the presence of cognitive impairment and substantial depressive symptoms. RESULTS: Hospitalization for pneumonia was associated with 1.01 new impairments in Activities and Instrumental Activities of Daily Living (95% confidence interval [CI], 0.71-1.32) among patients without baseline functional impairment and 0.99 new impairments in Activities and Instrumental Activities of Daily Living (95% CI, 0.57-1.41) among those with mild-to-moderate baseline limitations, as well as moderate-to-severe cognitive impairment (odds ratio, 2.46; 95% CI, 1.60-3.79) and substantial depressive symptoms (odds ratio, 1.63; 95% CI, 1.06-2.51). Patients without baseline functional impairment who survived pneumonia hospitalization had more subsequent impairments in Activities and Instrumental Activities of Daily Living than those who survived myocardial infarction hospitalization. There were no significant differences in subsequent moderate-to-severe cognitive impairment or substantial depressive symptoms between patients who survived myocardial infarction or stroke and those who survived pneumonia. CONCLUSIONS: Hospitalization for pneumonia in older adults is associated with subsequent functional and cognitive impairment. Improved pneumonia prevention and interventions to ameliorate adverse sequelae during and after hospitalization may improve outcomes.;,citation_author=Dimitry S. Davydow;,citation_author=Catherine L. Hough;,citation_author=Deborah A. Levine;,citation_author=Kenneth M. Langa;,citation_author=Theodore J. Iwashyna;,citation_publication_date=2013-07;,citation_cover_date=2013-07;,citation_year=2013;,citation_issue=7;,citation_doi=10.1016/j.amjmed.2012.12.006;,citation_issn=00029343;,citation_volume=126;,citation_language=en-US;,citation_journal_title=The American Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Vagus nerve stimulation paired with rehabilitation for upper limb motor function after ischaemic stroke (VNS-REHAB): A randomised, blinded, pivotal, device trial;,citation_abstract=Background Long-term loss of arm function after ischaemic stroke is common and might be improved by vagus nerve stimulation paired with rehabilitation. We aimed to determine whether this strategy is a safe and effective treatment for improving arm function after stroke.;,citation_author=Jesse Dawson;,citation_author=Charles Y Liu;,citation_author=Gerard E Francisco;,citation_author=Steven C Cramer;,citation_author=Steven L Wolf;,citation_author=Anand Dixit;,citation_author=Jen Alexander;,citation_author=Rushna Ali;,citation_author=Benjamin L Brown;,citation_author=Wuwei Feng;,citation_author=Louis DeMark;,citation_author=Leigh R Hochberg;,citation_author=Steven A Kautz;,citation_author=Arshad Majid;,citation_author=Michael W O’Dell;,citation_author=David Pierce;,citation_author=Cecília N Prudente;,citation_author=Jessica Redgrave;,citation_author=Duncan L Turner;,citation_author=Navzer D Engineer;,citation_author=Teresa J Kimberley;,citation_publication_date=2021-04;,citation_cover_date=2021-04;,citation_year=2021;,citation_issue=10284;,citation_doi=10.1016/S0140-6736(21)00475-X;,citation_issn=01406736;,citation_volume=397;,citation_language=en-US;,citation_journal_title=The Lancet;">
<meta name="citation_reference" content="citation_title=Prophylactic Therapies for Morbidity and Mortality After Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Network Meta-Analysis of Randomized Trials;,citation_abstract=BACKGROUND: Aneurysmal subarachnoid hemorrhage (aSAH) is associated with high mortality and morbidity. We aimed to determine the relative benefits of pharmacological prophylactic treatments in patients with aneurysmal subarachnoid hemorrhage by performing a network meta-analysis of randomized trials. METHODS: We searched Medline, Web of Science, Embase, Scopus, ProQuest, and Cochrane Central to February 2020. Pairs of reviewers independently identified eligible trials, extracted data, and assessed the risk of bias. Eligible trials compared the prophylactic effects of any oral or intravenous medications or intracranial drug-eluting implants to one another or placebo or standard of care in adult hospitalized patients with confirmed aneurysmal subarachnoid hemorrhage. We used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to assess the certainty of the evidence. RESULTS: We included 53 trials enrolling 10 415 patients. Nimodipine likely reduces all-cause mortality compared to placebo (odds ratio [OR],0.73 [95% CI, 0.53–1.00]; moderate certainty; absolute risk reduction (ARR), -3.35%). Nimodipine (OR, 1.46 [95% CI, 1.07–1.99]; high certainty; absolute risk increase, 8.25%) and cilostazol (OR, 3.73 [95% CI, 1.14–12.18]; moderate certainty; absolute risk increase, 23.15%) were the most effective treatments in improving disability at the longest follow-up. Compared to placebo, clazosentan (10 mg/kg; OR, 0.39 [95% CI, 0.22–0.68]; high certainty; ARR, -16.65%), nicardipine (OR, 0.48 [95% CI, 0.24–0.94]; moderate certainty; ARR, -13.70%), fasudil (OR, 0.55 [95% CI, 0.31–0.98]; moderate certainty; ARR, -11.54%), and magnesium (OR, 0.66 [95% CI, 0.46–0.94]; high certainty; ARR, -8.37%) proved most effective in reducing the likelihood of delayed cerebral ischemia. CONCLUSIONS: Nimodipine and cilostazol are likely the most effective treatments in preventing morbidity and mortality in patients with aneurysmal subarachnoid hemorrhage. Clazosentan, nicardipine, fasudil, and magnesium showed beneficial effects on delayed cerebral ischemia and vasospasm but they were not found to reduce mortality or disability. Future trials are warranted to elaborately investigate the prophylactic effects of medications that may improve mortality and long-term functional outcomes, such as cilostazol and clazosentan.;,citation_author=Mojtaba Dayyani;,citation_author=Behnam Sadeghirad;,citation_author=James C. Grotta;,citation_author=Samira Zabihyan;,citation_author=Saba Ahmadvand;,citation_author=Yuting Wang;,citation_author=Gordon H. Guyatt;,citation_author=Sepideh Amin-Hanjani;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_issue=6;,citation_doi=10.1161/STROKEAHA.121.035699;,citation_issn=0039-2499, 1524-4628;,citation_volume=53;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=How can assessing hemodynamics help to assess volume status?;,citation_abstract=In critically ill patients, fluid infusion is aimed at increasing cardiac output and tissue perfusion. However, it may contribute to fluid overload which may be harmful. Thus, volume status, risks and potential efficacy of fluid administration and/or removal should be carefully evaluated, and monitoring techniques help for this purpose. Central venous pressure is a marker of right ventricular preload. Very low values indicate hypovolemia, while extremely high values suggest fluid harmfulness. The pulmonary artery catheter enables a comprehensive assessment of the hemodynamic profile and is particularly useful for indicating the risk of pulmonary oedema through the pulmonary artery occlusion pressure. Besides cardiac output and preload, transpulmonary thermodilution measures extravascular lung water, which reflects the extent of lung flooding and assesses the risk of fluid infusion. Echocardiography estimates the volume status through intravascular volumes and pressures. Finally, lung ultrasound estimates lung edema. Guided by these variables, the decision to infuse fluid should first consider specific triggers, such as signs of tissue hypoperfusion. Second, benefits and risks of fluid infusion should be weighted. Thereafter, fluid responsiveness should be assessed. Monitoring techniques help for this purpose, especially by providing real time and precise measurements of cardiac output. When decided, fluid resuscitation should be performed through fluid challenges, the effects of which should be assessed through critical endpoints including cardiac output. This comprehensive evaluation of the risk, benefits and efficacy of fluid infusion helps to individualize fluid management, which should be preferred over a fixed restrictive or liberal strategy.;,citation_author=Daniel De Backer;,citation_author=Nadia Aissaoui;,citation_author=Maurizio Cecconi;,citation_author=Michelle S. Chew;,citation_author=André Denault;,citation_author=Ludhmila Hajjar;,citation_author=Glenn Hernandez;,citation_author=Antonio Messina;,citation_author=Sheila Nainan Myatra;,citation_author=Marlies Ostermann;,citation_author=Michael R. Pinsky;,citation_author=Jean-Louis Teboul;,citation_author=Philippe Vignon;,citation_author=Jean-Louis Vincent;,citation_author=Xavier Monnet;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_doi=10.1007/s00134-022-06808-9;,citation_issn=1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Vasoconstriction in septic shock;,citation_author=Daniel De Backer;,citation_author=Ludhmila Hajjar;,citation_author=Xavier Monnet;,citation_publication_date=2024-02;,citation_cover_date=2024-02;,citation_year=2024;,citation_doi=10.1007/s00134-024-07332-8;,citation_issn=1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Vitamin C for Sepsis and Acute Respiratory Failure;,citation_abstract=To the Editor As ever more critical care trials fail to demonstrate a mortality effect, we believe that randomized trials can be made more efficient and informative by the careful choice of a disease-oriented end point rather than mortality.The CITRIS-ALI trial used the Sequential Organ Failure Assessment (SOFA) score at 96 hours after randomization to compare high-dose vitamin C vs placebo for patients with sepsis-related acute respiratory failure. The SOFA score is one of the best validated disease-oriented end points available for critically ill patients and is correlated with mortality risk. Thus, the reported findings that vitamin C had no effect on the co–primary end point of 96-hour SOFA score while it significantly decreased the 96-hour and 28-day mortality rates were surprising.;,citation_author=Harm-Jan Grooth;,citation_author=Paul W. G. Elbers;,citation_author=Jean-Louis Vincent;,citation_publication_date=2020-02;,citation_cover_date=2020-02;,citation_year=2020;,citation_issue=8;,citation_doi=10.1001/jama.2019.21981;,citation_issn=0098-7484;,citation_volume=323;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=How to improve intubation in the intensive care unit. Update on knowledge and devices;,citation_abstract=Tracheal intubation in the critically ill is associated with serious complications, mainly cardiovascular collapse and severe hypoxemia. In this narrative review, we present an update of interventions aiming to decrease these complications. MACOCHA is a simple score that helps to identify patients at risk of difficult intubation in the intensive care unit (ICU). Preoxygenation combining the use of inspiratory support and positive end-expiratory pressure should remain the standard method for preoxygenation of hypoxemic patients. Apneic oxygenation using high-flow nasal oxygen may be supplemented, to prevent further hypoxemia during tracheal intubation. Face mask ventilation after rapid sequence induction may also be used to prevent hypoxemia, in selected patients without high-risk of aspiration. Hemodynamic optimization and management are essential before, during and after the intubation procedure. All these elements can be integrated in a bundle. An airway management algorithm should be adopted in each ICU and adapted to the needs, situation and expertise of each operator. Videolaryngoscopes should be used by experienced operators.;,citation_author=Audrey De Jong;,citation_author=Sheila Nainan Myatra;,citation_author=Oriol Roca;,citation_author=Samir Jaber;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_doi=10.1007/s00134-022-06849-0;,citation_issn=1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Imaging Patterns of Toxic and Metabolic Brain Disorders;,citation_author=Arthur M. Oliveira;,citation_author=Matheus V. Paulino;,citation_author=Ana P. F. Vieira;,citation_author=Alexander M. McKinney;,citation_author=Antonio J. Rocha;,citation_author=Germana T. Santos;,citation_author=Claudia da Costa Leite;,citation_author=Luis F. de Souza Godoy;,citation_author=Leandro T. Lucato;,citation_publication_date=2019-10;,citation_cover_date=2019-10;,citation_year=2019;,citation_issue=6;,citation_doi=10.1148/rg.2019190016;,citation_issn=0271-5333, 1527-1323;,citation_volume=39;,citation_language=en-US;,citation_journal_title=RadioGraphics;">
<meta name="citation_reference" content="citation_title=Aneurysmal subarachnoid haemorrhage from a neuroimaging perspective;,citation_author=Airton Leonardo Oliveira Manoel;,citation_author=Ann Mansur;,citation_author=Amanda Murphy;,citation_author=David Turkel-Parrella;,citation_author=Matt Macdonald;,citation_author=R Loch Macdonald;,citation_author=Walter Montanera;,citation_author=Thomas R Marotta;,citation_author=Aditya Bharatha;,citation_author=Khaled Effendi;,citation_author=Tom A Schweizer;,citation_publication_date=2014-12;,citation_cover_date=2014-12;,citation_year=2014;,citation_issue=6;,citation_doi=10.1186/s13054-014-0557-2;,citation_issn=1364-8535;,citation_volume=18;,citation_language=en-US;,citation_journal_title=Critical Care;">
<meta name="citation_reference" content="citation_title=The critical care management of poor-grade subarachnoid haemorrhage;,citation_author=Airton Leonardo Oliveira Manoel;,citation_author=Alberto Goffi;,citation_author=Tom R. Marotta;,citation_author=Tom A. Schweizer;,citation_author=Simon Abrahamson;,citation_author=R. Loch Macdonald;,citation_publication_date=2016-12;,citation_cover_date=2016-12;,citation_year=2016;,citation_issue=1;,citation_doi=10.1186/s13054-016-1193-9;,citation_issn=1364-8535;,citation_volume=20;,citation_language=en-US;,citation_journal_title=Critical Care;">
<meta name="citation_reference" content="citation_title=Antifungal stewardship in critically ill patients;,citation_author=Gennaro De Pascale;,citation_author=Ignacio Martin-Loeches;,citation_author=Saad Nseir;,citation_publication_date=2023-03;,citation_cover_date=2023-03;,citation_year=2023;,citation_doi=10.1007/s00134-023-07034-7;,citation_issn=1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Understanding and misunderstanding randomized controlled trials;,citation_abstract=Randomized Controlled Trials (RCTs) are increasingly popular in the social sciences, not only in medicine. We argue that the lay public, and sometimes researchers, put too much trust in RCTs over other methods of investigation. Contrary to frequent claims in the applied literature, randomization does not equalize everything other than the treatment in the treatment and control groups, it does not automatically deliver a precise estimate of the average treatment effect (ATE), and it does not relieve us of the need to think about (observed or unobserved) covariates. Finding out whether an estimate was generated by chance is more difficult than commonly believed. At best, an RCT yields an unbiased estimate, but this property is of limited practical value. Even then, estimates apply only to the sample selected for the trial, often no more than a convenience sample, and justification is required to extend the results to other groups, including any population to which the trial sample belongs, or to any individual, including an individual in the trial. Demanding “external validity” is unhelpful because it expects too much of an RCT while undervaluing its potential contribution. RCTs do indeed require minimal assumptions and can operate with little prior knowledge. This is an advantage when persuading distrustful audiences, but it is a disadvantage for cumulative scientific progress, where prior knowledge should be built upon, not discarded. RCTs can play a role in building scientific knowledge and useful predictions but they can only do so as part of a cumulative program, combining with other methods, including conceptual and theoretical development, to discover not “what works”, but “why things work”.;,citation_author=Angus Deaton;,citation_author=Nancy Cartwright;,citation_publication_date=2018-08;,citation_cover_date=2018-08;,citation_year=2018;,citation_doi=10.1016/j.socscimed.2017.12.005;,citation_issn=02779536;,citation_volume=210;,citation_language=en-US;,citation_journal_title=Social Science &amp;amp;amp; Medicine;">
<meta name="citation_reference" content="citation_title=Neuromuscular Blockade in the 21st Century Management of the Critically Ill Patient;,citation_author=Julian deBacker;,citation_author=Nicholas Hart;,citation_author=Eddy Fan;,citation_publication_date=2017-03;,citation_cover_date=2017-03;,citation_year=2017;,citation_issue=3;,citation_doi=10.1016/j.chest.2016.10.040;,citation_issn=00123692;,citation_volume=151;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=The obesity paradox in critically ill patients: A causal learning approach to a casual finding;,citation_abstract=Background: While obesity confers an increased risk of death in the general population, numerous studies have reported an association between obesity and improved survival among critically ill patients. This contrary finding has been referred to as the obesity paradox. In this retrospective study, two causal inference approaches were used to address whether the survival of non-obese critically ill patients would have been improved if they had been obese. Methods: The study cohort comprised 6557 adult critically ill patients hospitalized at the Intensive Care Unit of the Ghent University Hospital between 2015 and 2017. Obesity was defined as a body mass index of \geq 30 kg/m2. Two causal inference approaches were used to estimate the average effect of obesity in the non-obese (AON): a traditional approach that used regression adjustment for confounding and that assumed missingness completely at random and a robust approach that used machine learning within the targeted maximum likelihood estimation framework along with multiple imputation of missing values under the assumption of missingness at random. 1754 (26.8%) patients were discarded in the traditional approach because of at least one missing value for obesity status or confounders. Results: Obesity was present in 18.9% of patients. The in-hospital mortality was 14.6% in non-obese patients and 13.5% in obese patients. The raw marginal risk difference for in-hospital mortality between obese and non-obese patients was - 1.06% (95% confidence interval (CI) - 3.23 to 1.11%, P = 0.337). The traditional approach resulted in an AON of - 2.48% (95% CI - 4.80 to - 0.15%, P = 0.037), whereas the robust approach yielded an AON of - 0.59% (95% CI - 2.77 to 1.60%, P = 0.599). Conclusions: A causal inference approach that is robust to residual confounding bias due to model misspecification and selection bias due to missing (at random) data mitigates the obesity paradox observed in critically ill patients, whereas a traditional approach results in even more paradoxical findings. The robust approach does not provide evidence that the survival of non-obese critically ill patients would have been improved if they had been obese.;,citation_author=Alexander Decruyenaere;,citation_author=Johan Steen;,citation_author=Kirsten Colpaert;,citation_author=Dominique D. Benoit;,citation_author=Johan Decruyenaere;,citation_author=Stijn Vansteelandt;,citation_publication_date=2020-12;,citation_cover_date=2020-12;,citation_year=2020;,citation_issue=1;,citation_doi=10.1186/s13054-020-03199-5;,citation_issn=1364-8535;,citation_volume=24;,citation_language=en-US;,citation_journal_title=Critical Care;">
<meta name="citation_reference" content="citation_title=How to assess the external validity of therapeutic trials: A conceptual approach;,citation_abstract=Background External validity of study results is an important issue from a clinical point of view. From a methodological point of view, however, the concept of external validity is more complex than it seems to be at first glance. Methods Methodological review to address the concept of external validity. Results External validity refers to the question whether results are generalizable to persons other than the population in the original study. The only formal way to establish the external validity would be to repeat the study for that specific target population. We propose a three-way approach for assessing the external validity for specified target populations. (i) The study population might not be representative for the eligibility criteria that were intended. It should be addressed whether the study population differs from the intended source population with respect to characteristics that influence outcome. (ii) The target population will, by definition, differ from the study population with respect to geographical, temporal and ethnical conditions. Pondering external validity means asking the question whether these differences may influence study results. (iii) It should be assessed whether the study’s conclusions can be generalized to target populations that do not meet all the eligibility criteria. Conclusion Judging the external validity of study results cannot be done by;,citation_author=O M Dekkers;,citation_author=E Elm;,citation_author=A Algra;,citation_author=J A Romijn;,citation_author=J P Vandenbroucke;,citation_publication_date=2010-02;,citation_cover_date=2010-02;,citation_year=2010;,citation_issue=1;,citation_doi=10.1093/ije/dyp174;,citation_issn=0300-5771, 1464-3685;,citation_volume=39;,citation_language=en-US;,citation_journal_title=International Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Hydrocortisone in Severe Community-Acquired Pneumonia;,citation_abstract=BACKGROUND Whether the antiinflammatory and immunomodulatory effects of glucocorticoids may decrease mortality among patients with severe community-acquired pneumonia is unclear. METHODS In this phase 3, multicenter, double-blind, randomized, controlled trial, we assigned adults who had been admitted to the intensive care unit (ICU) for severe community-acquired pneumonia to receive intravenous hydrocortisone (200 mg daily for either 4 or 8 days as determined by clinical improvement, followed by tapering for a total of 8 or 14 days) or to receive placebo. All the patients received standard therapy, including antibiotics and supportive care. The primary outcome was death at 28 days. RESULTS A total of 800 patients had undergone randomization when the trial was stopped after the second planned interim analysis. Data from 795 patients were analyzed. By day 28, death had occurred in 25 of 400 patients (6.2%; 95% confidence interval [CI], 3.9 to 8.6) in the hydrocortisone group and in 47 of 395 patients (11.9%; 95% CI, 8.7 to 15.1) in the placebo group (absolute difference, -5.6 percentage points; 95% CI, -9.6 to -1.7; P = 0.006). Among the patients who were not undergoing mechanical ventilation at baseline, endotracheal intubation was performed in 40 of 222 (18.0%) in the hydrocortisone group and in 65 of 220 (29.5%) in the placebo group (hazard ratio, 0.59; 95% CI, 0.40 to 0.86). Among the patients who were not receiving vasopressors at baseline, such therapy was initiated by day 28 in 55 of 359 (15.3%) of the hydrocortisone group and in 86 of 344 (25.0%) in the placebo group (hazard ratio, 0.59; 95% CI, 0.43 to 0.82). The frequencies of hospital-acquired infections and gastrointestinal bleeding were similar in the two groups; patients in the hydrocortisone group received higher daily doses of insulin during the first week of treatment. The authors’ full names, academic degrees, and affiliations are listed in the Appendix. Dr. Dequin can be contacted at dequin@univ-tours.fr or at Service de Médecine Intensive–Réanimation, Hôpital Bretonneau, 37 044 Tours Cedex 9, France. *A list of the members of the CRICSTriGGERSep Network is provided in the Supplementary Appendix, available at NEJM.org. This article was published on March 21, 2023, at NEJM.org. DOI: 10.1056/NEJMoa2215145 Copyright © 2023 Massachusetts Medical Society. CONCLUSIONS Among patients with severe community-acquired pneumonia being treated in the ICU, those who received hydrocortisone had a lower risk of death by day 28 than those who received placebo. (Funded by the French Ministry of Health; CAPE COD ClinicalTrials.gov number, NCT02517489.);,citation_author=Pierre-François Dequin;,citation_author=Ferhat Meziani;,citation_author=Jean-Pierre Quenot;,citation_author=Toufik Kamel;,citation_author=Jean-Damien Ricard;,citation_author=Julio Badie;,citation_author=Jean Reignier;,citation_author=Nicholas Heming;,citation_author=Gaëtan Plantefève;,citation_author=Bertrand Souweine;,citation_author=Guillaume Voiriot;,citation_author=Gwenhaël Colin;,citation_author=Jean-Pierre Frat;,citation_author=Jean-Paul Mira;,citation_author=Nicolas Barbarot;,citation_author=Bruno François;,citation_author=Guillaume Louis;,citation_author=Sébastien Gibot;,citation_author=Christophe Guitton;,citation_author=Christophe Giacardi;,citation_author=Sami Hraiech;,citation_author=Sylvie Vimeux;,citation_author=Erwan L’Her;,citation_author=Henri Faure;,citation_author=Jean-Etienne Herbrecht;,citation_author=Camille Bouisse;,citation_author=Aurélie Joret;,citation_author=Nicolas Terzi;,citation_author=Arnaud Gacouin;,citation_author=Charlotte Quentin;,citation_author=Mercé Jourdain;,citation_author=Marie Leclerc;,citation_author=Carine Coffre;,citation_author=Hélène Bourgoin;,citation_author=Céline Lengellé;,citation_author=Caroline Caille-Fénérol;,citation_author=Bruno Giraudeau;,citation_author=Amélie Le Gouge;,citation_publication_date=2023-03;,citation_cover_date=2023-03;,citation_year=2023;,citation_doi=10.1056/NEJMoa2215145;,citation_issn=0028-4793, 1533-4406;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=The Causal Effects of Place on Health and Longevity;,citation_abstract=Life expectancy varies substantially across local regions within a country, raising conjectures that place of residence affects health. However, population sorting and other confounders make it difficult to disentangle the effects of place on health from other geographic differences in life expectancy. Recent studies have overcome such challenges to demonstrate that place of residence substantially influences health and mortality. Whether policies that encourage people to move to places that are better for their health or that improve areas that are detrimental to health are desirable depends on the mechanisms behind place effects, yet these mechanisms remain poorly understood.;,citation_author=Tatyana Deryugina;,citation_author=David Molitor;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_doi=10.3386/w29321;,citation_language=en-US;,citation_technical_report_institution=National Bureau of Economic Research;,citation_technical_report_number=w29321;">
<meta name="citation_reference" content="citation_title=Angiography after Out-of-Hospital Cardiac Arrest without ST-Segment Elevation;,citation_abstract=BACKGROUND Myocardial infarction is a frequent cause of out-of-hospital cardiac arrest. However, the benefits of early coronary angiography and revascularization in resuscitated patients without electrocardiographic evidence of ST-segment elevation are unclear. METHODS In this multicenter trial, we randomly assigned 554 patients with successfully resuscitated out-of-hospital cardiac arrest of possible coronary origin to undergo either immediate coronary angiography (immediate-angiography group) or initial intensive care assessment with delayed or selective angiography (delayed-angiography group). All the patients had no evidence of ST-segment elevation on postresuscitation electrocardiography. The primary end point was death from any cause at 30 days. Secondary end points included a composite of death from any cause or severe neurologic deficit at 30 days. RESULTS A total of 530 of 554 patients (95.7%) were included in the primary analysis. At 30 days, 143 of 265 patients (54.0%) in the immediate-angiography group and 122 of 265 patients (46.0%) in the delayed-angiography group had died (hazard ratio, 1.28; 95% confidence interval [CI], 1.00 to 1.63; P = 0.06). The composite of death or severe neurologic deficit occurred more frequently in the immediate-angiography group (in 164 of 255 patients [64.3%]) than in the delayed-angiography group (in 138 of 248 patients [55.6%]), for a relative risk of 1.16 (95% CI, 1.00 to 1.34). Values for peak troponin release and for the incidence of moderate or severe bleeding, stroke, and renal-replacement therapy were similar in the two groups. The authors’ full names, academic degrees, and affiliations are listed in the Appendix. Address reprint requests to Dr. Desch at the Department of Internal Medicine–Cardiology, Heart Center Leipzig at the University of Leipzig, Strümpellstr. 39, Leipzig 04289, Germany, or at steffen .desch@medizin.uni-leipzig.de. *A list of the investigators in the TOMAHAWK trial is provided in the Supplementary Appendix, available at NEJM.org. Drs. Desch and Freund contributed equally to this article. This article was published on August 29, 2021, at NEJM.org. DOI: 10.1056/NEJMoa2101909 Copyright © 2021 Massachusetts Medical Society. CONCLUSIONS Among patients with resuscitated out-of-hospital cardiac arrest without ST-segment elevation, a strategy of performing immediate angiography provided no benefit over a delayed or selective strategy with respect to the 30-day risk of death from any cause. (Funded by the German Center for Cardiovascular Research; TOMAHAWK ClinicalTrials.gov number, NCT02750462.);,citation_author=Steffen Desch;,citation_author=Anne Freund;,citation_author=Ibrahim Akin;,citation_author=Michael Behnes;,citation_author=Michael R. Preusch;,citation_author=Thomas A. Zelniker;,citation_author=Carsten Skurk;,citation_author=Ulf Landmesser;,citation_author=Tobias Graf;,citation_author=Ingo Eitel;,citation_author=Georg Fuernau;,citation_author=Hendrik Haake;,citation_author=Peter Nordbeck;,citation_author=Fabian Hammer;,citation_author=Stephan B. Felix;,citation_author=Christian Hassager;,citation_author=Thomas Engstrøm;,citation_author=Stephan Fichtlscherer;,citation_author=Jakob Ledwoch;,citation_author=Karsten Lenk;,citation_author=Michael Joner;,citation_author=Stephan Steiner;,citation_author=Christoph Liebetrau;,citation_author=Ingo Voigt;,citation_author=Uwe Zeymer;,citation_author=Michael Brand;,citation_author=Roland Schmitz;,citation_author=Jan Horstkotte;,citation_author=Claudius Jacobshagen;,citation_author=Janine Pöss;,citation_author=Mohamed Abdel-Wahab;,citation_author=Philipp Lurz;,citation_author=Alexander Jobs;,citation_author=Suzanne Waha-Thiele;,citation_author=Denise Olbrich;,citation_author=Frank Sandig;,citation_author=Inke R. König;,citation_author=Sabine Brett;,citation_author=Maren Vens;,citation_author=Kathrin Klinge;,citation_author=Holger Thiele;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_doi=10.1056/NEJMoa2101909;,citation_issn=0028-4793, 1533-4406;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Tranexamic Acid in Patients Undergoing Noncardiac Surgery;,citation_abstract=BACKGROUND Perioperative bleeding is common in patients undergoing noncardiac surgery. Tranexamic acid is an antifibrinolytic drug that may safely decrease such bleeding. METHODS We conducted a trial involving patients undergoing noncardiac surgery. Patients were randomly assigned to receive tranexamic acid (1-g intravenous bolus) or placebo at the start and end of surgery (reported here) and, with the use of a partial factorial design, a hypotension-avoidance or hypertension-avoidance strategy (not reported here). The primary efficacy outcome was life-threatening bleeding, major bleeding, or bleeding into a critical organ (composite bleeding outcome) at 30 days. The primary safety outcome was myocardial injury after noncardiac surgery, nonhemorrhagic stroke, peripheral arterial thrombosis, or symptomatic proximal venous thromboembolism (composite cardiovascular outcome) at 30 days. To establish the noninferiority of tranexamic acid to placebo for the composite cardiovascular outcome, the upper boundary of the one-sided 97.5% confidence interval for the hazard ratio had to be below 1.125, and the one-sided P value had to be less than 0.025. RESULTS A total of 9535 patients underwent randomization. A composite bleeding outcome event occurred in 433 of 4757 patients (9.1%) in the tranexamic acid group and in 561 of 4778 patients (11.7%) in the placebo group (hazard ratio, 0.76; 95% confidence interval [CI], 0.67 to 0.87; absolute difference, -2.6 percentage points; 95% CI, -3.8 to -1.4; two-sided P&amp;amp;amp;lt;0.001 for superiority). A composite cardiovascular outcome event occurred in 649 of 4581 patients (14.2%) in the tranexamic acid group and in 639 of 4601 patients (13.9%) in the placebo group (hazard ratio, 1.02; 95% CI, 0.92 to 1.14; upper boundary of the one-sided 97.5% CI, 1.14; absolute difference, 0.3 percentage points; 95% CI, -1.1 to 1.7; one-sided P = 0.04 for noninferiority). CONCLUSIONS Among patients undergoing noncardiac surgery, the incidence of the composite bleeding outcome was significantly lower with tranexamic acid than with placebo. Although the between-group difference in the composite cardiovascular outcome was small, the noninferiority of tranexamic acid was not established. (Funded by the Canadian Institutes of Health Research and others; POISE-3 ClinicalTrials.gov number, NCT03505723.) The authors’ full names, academic de-;,citation_author=P. J. Devereaux;,citation_author=Maura Marcucci;,citation_author=Thomas W. Painter;,citation_author=David Conen;,citation_author=Vladimir Lomivorotov;,citation_author=Daniel I. Sessler;,citation_author=Matthew T. V. Chan;,citation_author=Flavia K. Borges;,citation_author=María J. Martínez-Zapata;,citation_author=Chew Yin Wang;,citation_author=Denis Xavier;,citation_author=Sandra N. Ofori;,citation_author=Michael K. Wang;,citation_author=Sergey Efremov;,citation_author=Giovanni Landoni;,citation_author=Ydo V. Kleinlugtenbelt;,citation_author=Wojciech Szczeklik;,citation_author=Denis Schmartz;,citation_author=Amit X. Garg;,citation_author=Timothy G. Short;,citation_author=Maria Wittmann;,citation_author=Christian S. Meyhoff;,citation_author=Mohammed Amir;,citation_author=David Torres;,citation_author=Ameen Patel;,citation_author=Emmanuelle Duceppe;,citation_author=Kurt Ruetzler;,citation_author=Joel L. Parlow;,citation_author=Vikas Tandon;,citation_author=Edith Fleischmann;,citation_author=Carisi A. Polanczyk;,citation_author=Andre Lamy;,citation_author=Sergey V. Astrakov;,citation_author=Mangala Rao;,citation_author=William K. K. Wu;,citation_author=Keyur Bhatt;,citation_author=Miriam Nadal;,citation_author=Valery V. Likhvantsev;,citation_author=Pilar Paniagua;,citation_author=Hector J. Aguado;,citation_author=Richard P. Whitlock;,citation_author=Michael H. McGillion;,citation_author=Michael Prystajecky;,citation_author=Jessica Vincent;,citation_author=John Eikelboom;,citation_author=Ingrid Copland;,citation_author=Kumar Balasubramanian;,citation_author=Alparslan Turan;,citation_author=Shrikant I. Bangdiwala;,citation_author=David Stillo;,citation_author=Peter L. Gross;,citation_author=Teresa Cafaro;,citation_author=Pascal Alfonsi;,citation_author=Pavel S. Roshanov;,citation_author=Emilie P. Belley-Côté;,citation_author=Jessica Spence;,citation_author=Toby Richards;,citation_author=Tomas VanHelder;,citation_author=William McIntyre;,citation_author=Gordon Guyatt;,citation_author=Salim Yusuf;,citation_author=Kate Leslie;,citation_publication_date=2022-05;,citation_cover_date=2022-05;,citation_year=2022;,citation_issue=21;,citation_doi=10.1056/NEJMoa2201171;,citation_issn=0028-4793, 1533-4406;,citation_volume=386;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=A Practical Overview of Case-Control Studies in Clinical Practice;,citation_author=Tanujit Dey;,citation_author=Anish Mukherjee;,citation_author=Sounak Chakraborty;,citation_publication_date=2020-07;,citation_cover_date=2020-07;,citation_year=2020;,citation_issue=1;,citation_doi=10.1016/j.chest.2020.03.009;,citation_issn=00123692;,citation_volume=158;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=A Practical Overview and Reporting Strategies for Statistical Analysis of Survival Studies;,citation_author=Tanujit Dey;,citation_author=Anish Mukherjee;,citation_author=Sounak Chakraborty;,citation_publication_date=2020-07;,citation_cover_date=2020-07;,citation_year=2020;,citation_issue=1;,citation_doi=10.1016/j.chest.2020.03.015;,citation_issn=00123692;,citation_volume=158;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Racial Biology and Medical Misconceptions;,citation_author=Andrea Deyrup;,citation_author=Joseph L. Graves;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_issue=6;,citation_doi=10.1056/NEJMp2116224;,citation_issn=0028-4793, 1533-4406;,citation_volume=386;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Avoidable flaws in observational analyses: An application to statins and cancer;,citation_author=Barbra A. Dickerman;,citation_author=Xabier García-Albéniz;,citation_author=Roger W. Logan;,citation_author=Spiros Denaxas;,citation_author=Miguel A. Hernán;,citation_publication_date=2019-10;,citation_cover_date=2019-10;,citation_year=2019;,citation_issue=10;,citation_doi=10.1038/s41591-019-0597-x;,citation_issn=1078-8956, 1546-170X;,citation_volume=25;,citation_language=en-US;,citation_journal_title=Nature Medicine;">
<meta name="citation_reference" content="citation_title=Global, Regional, and National Burden of Ischemic Stroke, 1990–2019;,citation_abstract=Background and Objectives To the best of our knowledge, no comprehensive update of the descriptive epidemiology and trends of ischemic stroke has been released since Global Burden of Disease (GBD) 2017. Thus, our objective was to examine ischemic stroke burden at the global, regional, and national levels in terms of sex, age, and social development index (SDI).;,citation_author=Quanquan Ding;,citation_author=Shiwei Liu;,citation_author=Yindan Yao;,citation_author=Huina Liu;,citation_author=Ting Cai;,citation_author=Liyuan Han;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=3;,citation_doi=10.1212/WNL.0000000000013115;,citation_issn=0028-3878, 1526-632X;,citation_volume=98;,citation_language=en-US;,citation_journal_title=Neurology;">
<meta name="citation_reference" content="citation_title=Anaesthesia for mechanical thrombectomy: A narrative review;,citation_abstract=Stroke is a leading cause of death and disability, and is associated with a huge societal and economic burden. Interventions for the immediate treatment of ischaemic stroke due to large vessel occlusion are dependent on recanalisation of the occluded vessel. Trials have provided evidence supporting the efficacy of mechanical thrombectomy in ischaemic stroke due to large vessel occlusion. This has resulted in changes in management and organisation of stroke care worldwide. Major determinants of effectiveness of thrombectomy include: time between stroke onset and reperfusion; location of occlusion and local collateral perfusion; adequacy of reperfusion; patient age; and stroke severity. The role of anaesthetic technique on outcome remains controversial with published research showing conflicting results. As a result, choice of conscious sedation or general anaesthesia for mechanical thrombectomy is often dependent on individual operator choice or institutional preference. More recent randomised controlled trials have suggested that protocol-driven general anaesthesia is no worse than conscious sedation and may even be associated with better outcomes. These and other studies have highlighted the importance of optimal blood pressure management as a major determinant of patient outcome. Anaesthetic management should be tailored to the individual patient and circumstances. Acute ischaemic stroke is a neurological emergency; clinicians should focus on minimising door-to-groin puncture time and the provision of high-quality periprocedural care with a particular emphasis on the maintenance of an adequate blood pressure.;,citation_author=J. E. Dinsmore;,citation_author=A. Tan;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=S1;,citation_doi=10.1111/anae.15586;,citation_issn=0003-2409, 1365-2044;,citation_volume=77;,citation_language=en-US;,citation_journal_title=Anaesthesia;">
<meta name="citation_reference" content="citation_title=Clinical applications of point-of-care ultrasound in brain injury: A narrative review;,citation_abstract=The use of point-of-care ultrasound has increased considerably over the last two decades. It has become a readily available, non-invasive bed-side modality for the rapid diagnosis and management of patients in various settings. Point-of-care ultrasound for assessing the heart, lung, abdomen, airway and vascular systems is now well established. Transcranial Doppler ultrasound for assessing cerebral blood flow has been in use for many years. In recent years, brain ultrasonography has been shown to be a powerful tool in the rapid bed-side assessment of cerebral haemodynamics and structural pathology. Brain ultrasound has been shown to be useful in both the emergency department and neurocritical care setting for the non-invasive assessment of raised intracranial pressure, cerebral autoregulation and diagnosis of intracranial haematoma and other spaceoccupying lesions. Point-of-care ultrasound is an important alternative technique to routine imaging and invasive monitoring techniques, and results are comparable. Competence is easily attainable without formal radiology training. With technological advancement, applications for the use of brain ultrasound continue to grow. This review discusses the clinical use of point-of-care ultrasound in the diagnosis and management of brain injury.;,citation_author=M. Dinsmore;,citation_author=L. Venkatraghavan;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=S1;,citation_doi=10.1111/anae.15604;,citation_issn=0003-2409, 1365-2044;,citation_volume=77;,citation_language=en-US;,citation_journal_title=Anaesthesia;">
<meta name="citation_reference" content="citation_title=Evidence, values, and masks for control of COVID-19;,citation_author=Benjamin Djulbegovic;,citation_author=Iztok Hozo;,citation_author=Gordon Guyatt;,citation_publication_date=2021-03;,citation_cover_date=2021-03;,citation_year=2021;,citation_doi=10.1016/j.jclinepi.2020.11.020;,citation_issn=08954356;,citation_volume=131;,citation_language=en-US;,citation_journal_title=Journal of Clinical Epidemiology;">
<meta name="citation_reference" content="citation_title=Periprocedural antithrombotic management for lumbar puncture: Association of British Neurologists clinical guideline;,citation_abstract=Lumbar puncture (LP) is an important and frequently performed invasive procedure for the diagnosis and management of neurological conditions. There is little in the neurological literature on the topic of periprocedural management of antithrombotics in patients undergoing LP. Current practice is therefore largely extrapolated from guidelines produced by anaesthetic bodies on neuraxial anaesthesia, haematology groups advising on periprocedural management of antiplatelet agents and anticoagulants, and by neuroradiology on imaging-guided spinal procedures. This paper summarises the existing literature on the topic and offers recommendations to guide periprocedural antithrombotic management for LP, based on the consolidation of the best available evidence. ;,citation_author=Katherine Claire Dodd;,citation_author=Hedley C A Emsley;,citation_author=Michael J R Desborough;,citation_author=Suresh K Chhetri;,citation_publication_date=2018-12;,citation_cover_date=2018-12;,citation_year=2018;,citation_issue=6;,citation_doi=10.1136/practneurol-2017-001820;,citation_issn=1474-7758, 1474-7766;,citation_volume=18;,citation_language=en-US;,citation_journal_title=Practical Neurology;">
<meta name="citation_reference" content="citation_title=Controversy and Debate: Questionable utility of the relative risk in clinical research: Paper 1: A call for change to practice;,citation_abstract=Background and Objectives: In clinical trials, the relative risk or risk ratio (RR) is a mainstay of reporting of the effect magnitude for an intervention. The RR is the ratio of the probability of an outcome in an intervention group to its probability in a control group. Thus, the RR provides a measure of change in the likelihood of an event linked to a given intervention. This measure has been widely used because it is today considered a measure with “portability” across varying outcome prevalence, especially when the outcome is rare. It turns out, however, that there is a much more important problem with this ratio, and this paper aims to demonstrate this problem. Methods: We used mathematical derivation to determine if the RR is a measure of effect magnitude alone (i.e., a larger absolute value always indicating a stronger effect) or not. We also used the same derivation to determine its relationship to the prevalence of an outcome. We confirm the derivation results with a follow-up analysis of 140,620 trials scraped from the Cochrane. Results: We demonstrate that the RR varies for reasons other than the magnitude of the effect because it is a ratio of two posterior probabilities, both of which are dependent on baseline prevalence of an outcome. In addition, we demonstrate that the RR shifts toward its null value with increasing outcome prevalence. The shift toward the null happens regardless of the strength of the association between intervention and outcome. The odds ratio (OR), the other commonly used ratio, measures solely the effect magnitude and has no relationship to the prevalence of an outcome in a study nor does it overestimate the RR as is commonly thought. Conclusions: The results demonstrate the need to (1) end the primary use of the RR in clinical trials and meta-analyses as its direct interpretation is not meaningful, (2) replace the RR by the OR, and (3) only use the postintervention risk recalculated from the OR for any expected level of baseline risk in absolute terms for purposes of interpretation such as the number needed to treat. These results will have far-reaching implications such as reducing misleading results from clinical trials and meta-analyses and ushering in a new era in the reporting of such trials or meta-analyses in practice. Ó 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).;,citation_author=Suhail A. Doi;,citation_author=Luis Furuya-Kanamori;,citation_author=Chang Xu;,citation_author=Lifeng Lin;,citation_author=Tawanda Chivese;,citation_author=Lukman Thalib;,citation_publication_date=2020-11;,citation_cover_date=2020-11;,citation_year=2020;,citation_doi=10.1016/j.jclinepi.2020.08.019;,citation_issn=08954356;,citation_language=en-US;,citation_journal_title=Journal of Clinical Epidemiology;">
<meta name="citation_reference" content="citation_title=Death during life sustaining treatment must be considered a failure but can be acceptable if the treatment was proportional;,citation_author=Thomas M. Donaldson;,citation_publication_date=2022-03;,citation_cover_date=2022-03;,citation_year=2022;,citation_doi=10.1007/s00134-022-06657-6;,citation_issn=0342-4642, 1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Readmission and Death After Initial Hospital Discharge Among Patients With COVID-19 in a Large Multihospital System;,citation_author=John P. Donnelly;,citation_author=Xiao Qing Wang;,citation_author=Theodore J. Iwashyna;,citation_author=Hallie C. Prescott;,citation_publication_date=2021-01;,citation_cover_date=2021-01;,citation_year=2021;,citation_issue=3;,citation_doi=10.1001/jama.2020.21465;,citation_issn=0098-7484;,citation_volume=325;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19;,citation_abstract=BACKGROUND Patients with underlying medical conditions are at increased risk for severe coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, neutralizing monoclonal-antibody treatment provides immediate, passive immunity and may limit disease progression and complications. METHODS In this phase 3 trial, we randomly assigned, in a 1:1 ratio, a cohort of ambulatory patients with mild or moderate Covid-19 who were at high risk for progression to severe disease to receive a single intravenous infusion of either a neutralizing monoclonal-antibody combination agent (2800 mg of bamlanivimab and 2800 mg of etesevimab, administered together) or placebo within 3 days after a laboratory diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The primary outcome was the overall clinical status of the patients, defined as Covid-19–related hospitalization or death from any cause by day 29. RESULTS A total of 1035 patients underwent randomization and received an infusion of bamlanivimab–etesevimab or placebo. The mean (SD) age of the patients was 53.816.8 years, and 52.0% were adolescent girls or women. By day 29, a total of 11 of 518 patients (2.1%) in the bamlanivimab–etesevimab group had a Covid-19–related hospitalization or death from any cause, as compared with 36 of 517 patients (7.0%) in the placebo group (absolute risk difference, -4.8 percentage points; 95% confidence interval [CI], -7.4 to -2.3; relative risk difference, 70%; P&amp;amp;amp;lt;0.001). No deaths occurred in the bamlanivimab–etesevimab group; in the placebo group, 10 deaths occurred, 9 of which were designated by the trial investigators as Covid-19–related. At day 7, a greater reduction from baseline in the log viral load was observed among patients who received bamlanivimab plus etesevimab than among those who received placebo (difference from placebo in the change from baseline, -1.20; 95% CI, -1.46 to -0.94; P&amp;lt;0.001). CONCLUSIONS Among high-risk ambulatory patients, bamlanivimab plus etesevimab led to a lower incidence of Covid-19–related hospitalization and death than did placebo and accelerated the decline in the SARS-CoV-2 viral load. (Funded by Eli Lilly; BLAZE-1 ClinicalTrials.gov number, NCT04427501.);,citation_author=Michael Dougan;,citation_author=Ajay Nirula;,citation_author=Masoud Azizad;,citation_author=Bharat Mocherla;,citation_author=Robert L. Gottlieb;,citation_author=Peter Chen;,citation_author=Corey Hebert;,citation_author=Russell Perry;,citation_author=Joseph Boscia;,citation_author=Barry Heller;,citation_author=Jason Morris;,citation_author=Chad Crystal;,citation_author=Awawu Igbinadolor;,citation_author=Gregory Huhn;,citation_author=Jose Cardona;,citation_author=Imad Shawa;,citation_author=Princy Kumar;,citation_author=Andrew C. Adams;,citation_author=Jacob Van Naarden;,citation_author=Kenneth L. Custer;,citation_author=Michael Durante;,citation_author=Gerard Oakley;,citation_author=Andrew E. Schade;,citation_author=Timothy R. Holzer;,citation_author=Philip J. Ebert;,citation_author=Richard E. Higgs;,citation_author=Nicole L. Kallewaard;,citation_author=Janelle Sabo;,citation_author=Dipak R. Patel;,citation_author=Matan C. Dabora;,citation_author=Paul Klekotka;,citation_author=Lei Shen;,citation_author=Daniel M. Skovronsky;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=15;,citation_doi=10.1056/NEJMoa2102685;,citation_issn=0028-4793, 1533-4406;,citation_volume=385;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation;,citation_abstract=For patients with atrial fibrillation who are receiving warfarin and require an elective operation or other elective invasive procedure, the need for bridging anticoagulation during perioperative interruption of warfarin treatment has long been uncertain.1–3 Each year, this common clinical scenario affects approximately one in six warfarin-treated patients with atrial fibrillation.4,5 Warfarin treatment is typically stopped 5 days before an elective procedure to allow its anticoagulant effect to wane; it is resumed after the procedure, when hemostasis is secured, at which point 5 to 10 days of treatment is required to attain therapeutic anticoagulation.6,7 During the interruption of . . .;,citation_author=James D. Douketis;,citation_author=Alex C. Spyropoulos;,citation_author=Scott Kaatz;,citation_author=Richard C. Becker;,citation_author=Joseph A. Caprini;,citation_author=Andrew S. Dunn;,citation_author=David A. Garcia;,citation_author=Alan Jacobson;,citation_author=Amir K. Jaffer;,citation_author=David F. Kong;,citation_author=Sam Schulman;,citation_author=Alexander G. G. Turpie;,citation_author=Vic Hasselblad;,citation_author=Thomas L. Ortel;,citation_publication_date=2015-08;,citation_cover_date=2015-08;,citation_year=2015;,citation_issue=9;,citation_doi=10.1056/NEJMoa1501035;,citation_issn=0028-4793;,citation_pmid=26095867;,citation_volume=373;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Communicating About Time-Limited Trials;,citation_abstract=Conflict of Interest Statements: There are no conflicts of interest due to financial or other obligations among any of the listed authors.;,citation_author=Kendall Downer;,citation_author=Jillian Gustin;,citation_author=Taylor Lincoln;,citation_author=Lauren Goodman;,citation_author=Michael D. Barnett;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=1;,citation_doi=10.1016/j.chest.2021.08.071;,citation_issn=00123692;,citation_volume=161;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=The Primary Outcome Fails — What Next?;,citation_author=Stuart J. Pocock;,citation_author=Gregg W. Stone;,citation_editor=Jeffrey M. Drazen;,citation_editor=David P. Harrington;,citation_editor=John J. V. McMurray;,citation_editor=James H. Ware;,citation_editor=Janet Woodcock;,citation_publication_date=2016-09;,citation_cover_date=2016-09;,citation_year=2016;,citation_issue=9;,citation_doi=10.1056/NEJMra1510064;,citation_issn=0028-4793, 1533-4406;,citation_volume=375;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Quality of life in patients with intracranial tumors: Does tumor laterality matter?;,citation_abstract=OBJECTIVE Traditionally, the dominant (usually left) cerebral hemisphere is regarded as the more important one, and everyday clinical decisions are influenced by this view. However, reported results on the impact of lesion laterality are inconsistent in the scarce literature on quality of life (QOL) in patients with brain tumors. The authors aimed to study which cerebral hemisphere is the most important to patients with intracranial tumors with respect to health-related QOL (HRQOL). METHODS Two hundred forty-eight patients with unilateral, unifocal gliomas or meningiomas scheduled for primary surgery were included in this prospective cohort study. Generic HRQOL was measured using the EQ-5D-3L questionnaire preoperatively and after 4–6 weeks. Cross-sectional and longitudinal analyses of data were performed. RESULTS Tumor volumes were significantly larger in right-sided tumors at diagnosis, and language or speech problems were more common in left-sided lesions. Otherwise, no differences existed in baseline data. The median EQ-5D-3L index was 0.73 (range -0.24 to 1.00) in patients with right-sided tumors and 0.76 (range -0.48 to 1.00) in patients with left-sided tumors (p = 0.709). Due to the difference in tumor volumes at baseline, histopathology and tumor volumes were matched in 198 patients. EQ-5D-3L index scores in this 1:1 matched analysis were 0.74 (range -0.7 to 1.00) for patients with right-sided and 0.76 (range -0.48 to 1.00) for left-sided lesions (p = 0.342). In the analysis of longitudinal data, no association was found between tumor laterality and postoperative EQ-5D-3L index scores (p = 0.957) or clinically significant change in HRQOL following surgery (p = 0.793). CONCLUSIONS In an overall patient-reported QOL perspective, tumor laterality does not appear to be of significant importance for generic HRQOL in patients with intracranial tumors. This may imply that right-sided cerebral functions are underestimated by clinicians.;,citation_author=Christina Drewes;,citation_author=Lisa Millgård Sagberg;,citation_author=Asgeir Store Jakola;,citation_author=Ole Solheim;,citation_publication_date=2016-12;,citation_cover_date=2016-12;,citation_year=2016;,citation_issue=6;,citation_doi=10.3171/2015.12.JNS152252;,citation_issn=1933-0693, 0022-3085;,citation_volume=125;,citation_language=en-US;,citation_journal_title=Journal of Neurosurgery;,citation_publisher=American Association of Neurological Surgeons;">
<meta name="citation_reference" content="citation_title=Temperature Management in the ICU;,citation_author=Anne Drewry;,citation_author=Nicholas M. Mohr;,citation_publication_date=2022-04;,citation_cover_date=2022-04;,citation_year=2022;,citation_doi=10.1097/CCM.0000000000005556;,citation_issn=0090-3493;,citation_volume=Publish Ahead of Print;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Treatment strategies for new onset atrial fibrillation in patients treated on an intensive care unit: A systematic scoping review;,citation_abstract=New-onset atrial fibrillation (NOAF) in patients treated on an intensive care unit (ICU) is common and associated with significant morbidity and mortality. We undertook a systematic scoping review to summarise comparative evidence to inform NOAF management for patients admitted to ICU.;,citation_author=Laura Drikite;,citation_author=Jonathan P. Bedford;,citation_author=Liam O’Bryan;,citation_author=Tatjana Petrinic;,citation_author=Kim Rajappan;,citation_author=James Doidge;,citation_author=David A. Harrison;,citation_author=Kathryn M. Rowan;,citation_author=Paul R. Mouncey;,citation_author=Duncan Young;,citation_author=Peter J. Watkinson;,citation_author=Mark Corbett;,citation_publication_date=2021-07;,citation_cover_date=2021-07;,citation_year=2021;,citation_issue=1;,citation_doi=10.1186/s13054-021-03684-5;,citation_issn=1364-8535;,citation_volume=25;,citation_journal_title=Critical Care;">
<meta name="citation_reference" content="citation_title=Oral Immunotherapy for Peanut Allergy in Children 1 to Less Than 4 Years of Age;,citation_author=George Du Toit;,citation_author=Kari R. Brown;,citation_author=Andrea Vereda;,citation_author=Anne-Marie Irani;,citation_author=Stephen Tilles;,citation_author=Anoshie Ratnayake;,citation_author=Stacie M. Jones;,citation_author=Brian P. Vickery;,citation_author=POSEIDON Study Group;,citation_publication_date=2023-10;,citation_cover_date=2023-10;,citation_year=2023;,citation_issue=11;,citation_doi=10.1056/EVIDoa2300145;,citation_volume=2;,citation_journal_title=NEJM Evidence;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy;,citation_abstract=The prevalence of peanut allergy among children in Western countries has doubled in the past 10 years, reaching rates of 1.4 to 3.0%,1–3 and peanut allergy is becoming apparent in Africa and Asia.4,5 This allergy is the leading cause of anaphylaxis and death due to food allergy and imposes substantial psychosocial and economic burdens on patients and their families.6 Peanut allergy develops early in life and is rarely outgrown.7–9 Clinical practice guidelines from the United Kingdom in 19989 and from the United States in 200010 recommended the exclusion of allergenic foods from the diets of infants at . . .;,citation_author=George Du Toit;,citation_author=Graham Roberts;,citation_author=Peter H. Sayre;,citation_author=Henry T. Bahnson;,citation_author=Suzana Radulovic;,citation_author=Alexandra F. Santos;,citation_author=Helen A. Brough;,citation_author=Deborah Phippard;,citation_author=Monica Basting;,citation_author=Mary Feeney;,citation_author=Victor Turcanu;,citation_author=Michelle L. Sever;,citation_author=Margarita Gomez Lorenzo;,citation_author=Marshall Plaut;,citation_author=Gideon Lack;,citation_publication_date=2015-02;,citation_cover_date=2015-02;,citation_year=2015;,citation_issue=9;,citation_doi=10.1056/NEJMoa1414850;,citation_issn=0028-4793;,citation_pmid=25705822;,citation_volume=372;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Use of albumin in the intensive care unit;,citation_abstract=Recent publications have renewed interest in albumin use in the ICU. Meta-analyses have been published that demonstrate the safety of albumin administration and even potential benefits. Hypoalbuminemia, which has long been considered a marker of disease, has been causally linked to the development of complications. Finally, advances have been made in our knowledge of the unique and potentially beneficial properties of albumin.;,citation_author=Marc-Jacques Dubois;,citation_author=Jean-Louis Vincent;,citation_publication_date=2002-08;,citation_cover_date=2002-08;,citation_year=2002;,citation_issue=4;,citation_doi=10.1097/00075198-200208000-00005;,citation_issn=1070-5295;,citation_pmid=12386489;,citation_volume=8;,citation_language=en-US;,citation_journal_title=Current Opinion in Critical Care;">
<meta name="citation_reference" content="citation_title=Hypovolemia with peripheral edema: What is wrong?;,citation_abstract=Fluid normally exchanges freely between the plasma and interstitial space and is returned primarily via the lymphatic system. This balance can be disturbed by diseases and medications. In inflammatory disease states, such as sepsis, the return flow of fluid from the interstitial space to the plasma seems to be very slow, which promotes the well-known triad of hypovolemia, hypoalbuminemia, and peripheral edema. Similarly, general anesthesia, for example, even without mechanical ventilation, increases accumulation of infused crystalloid fluid in a slowly equilibrating fraction of the extravascular compartment. Herein, we have combined data from fluid kinetic trials with previously unconnected mechanisms of inflammation, interstitial fluid physiology and lymphatic pathology to synthesize a novel explanation for common and clinically relevant examples of circulatory dysregulation. Experimental studies suggest that two key mechanisms contribute to the combination of hypovolemia, hypoalbuminemia and edema; (1) acute lowering of the interstitial pressure by inflammatory mediators such as TNF\alpha, IL-1\beta, and IL-6 and, (2) nitric oxide-induced inhibition of intrinsic lymphatic pumping.;,citation_author=Randal O. Dull;,citation_author=Robert G. Hahn;,citation_publication_date=2023-12;,citation_cover_date=2023-12;,citation_year=2023;,citation_issue=1;,citation_doi=10.1186/s13054-023-04496-5;,citation_issn=1364-8535;,citation_volume=27;,citation_language=en-US;,citation_journal_title=Critical Care;,citation_publisher=BioMed Central;">
<meta name="citation_reference" content="citation_title=Ignac Semmelweis (1818-1865) of Budapest and the prevention of puerperal fever;,citation_author=P M Dunn;,citation_publication_date=2005-07;,citation_cover_date=2005-07;,citation_year=2005;,citation_issue=4;,citation_doi=10.1136/adc.2004.062901;,citation_issn=1359-2998, 1468-2052;,citation_volume=90;,citation_language=en-US;,citation_journal_title=Archives of Disease in Childhood - Fetal and Neonatal Edition;">
<meta name="citation_reference" content="citation_title=Science, Competing Values, and Trade-offs in Public Health — The Example of Covid-19 and Masking;,citation_author=Sarah C. Dupont;,citation_author=Sandro Galea;,citation_publication_date=2022-09;,citation_cover_date=2022-09;,citation_year=2022;,citation_issue=10;,citation_doi=10.1056/NEJMp2207670;,citation_issn=0028-4793, 1533-4406;,citation_volume=387;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Discordance Between Respiratory Drive and Sedation Depth in Critically Ill Patients Receiving Mechanical Ventilation;,citation_abstract=OBJECTIVES: In mechanically ventilated patients, deep sedation is often assumed to induce “respirolysis,” that is, lyse spontaneous respiratory effort, whereas light sedation is often assumed to preserve spontaneous effort. This study was conducted to determine validity of these common assumptions, evaluating the association of respiratory drive with sedation depth and ventilator-free days in acute respiratory failure. DESIGN: Prospective cohort study. SETTING: Patients were enrolled during 2 month-long periods in 2016–2017 from five ICUs representing medical, surgical, and cardiac specialties at a U.S. academic hospital. PATIENTS: Eligible patients were critically ill adults receiving invasive ventilation initiated no more than 36 hours before enrollment. Patients with neuromuscular disease compromising respiratory function or expiratory flow limitation were excluded. INTERVENTIONS: Respiratory drive was measured via P0.1, the change in airway pressure during a 0.1-second airway occlusion at initiation of patient inspiratory effort, every 12  3 hours for 3 days. Sedation depth was evaluated via the Richmond Agitation-Sedation Scale. Analyses evaluated the association of P0.1 with Richmond Agitation-Sedation Scale (primary outcome) and ventilator-free days. MEASUREMENTS AND MAIN RESULTS: Fifty-six patients undergoing 197 bedside evaluations across five ICUs were included. P0.1 ranged between 0 and 13.3 cm H2O (median [interquartile range], 0.1 cm H2O [0.0–1.3 cm H2O]). P0.1 was not significantly correlated with the Richmond Agitation-Sedation Scale (R , Spearman 0.02; 95% CI, –0.12 to 0.16; p = 0.80). Considering P0.1 terciles (range less than 0.2, 0.2–1.0, and greater than 1.0 cm H2O), patients in the middle tercile had significantly more ventilator-free days than the lowest tercile (incidence rate ratio, 0.78; 95% CI, 0.65–0.93; p &amp;amp;amp;lt; 0.01) or highest tercile (incidence rate ratio, 0.58; 95% CI, 0.48–0.70; p &amp;lt; 0.01). CONCLUSIONS: Sedation depth is not a reliable marker of respiratory drive during critical illness. Respiratory drive can be low, moderate, or high across the range of routinely targeted sedation depth.;,citation_author=Amy L. Dzierba;,citation_author=Anas M. Khalil;,citation_author=Katrina L. Derry;,citation_author=Purnema Madahar;,citation_author=Jeremy R. Beitler;,citation_publication_date=2021-06;,citation_cover_date=2021-06;,citation_year=2021;,citation_doi=10.1097/CCM.0000000000005113;,citation_issn=0090-3493;,citation_volume=Publish Ahead of Print;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Cognitive Impairment, Functional Outcome, and Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage;,citation_abstract=Background Measures such as modified Rankin Scale (mRS) may not reflect cognitive outcome following aneurysmal subarachnoid hemorrhage. The aim of this study was to assess the relationship between functional outcome, measured by mRS, and cognition, measured by mini-mental state examination (MMSE), after aSAH. A secondary analysis evaluated the impact of delayed cerebral ischemia (DCI) on the proportion of patients who had cognitive impairment. Methods We performed a post hoc analysis of the Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After Subarachnoid Hemorrhage (CONSCIOUS-1) trial data. MMSE and mRS scores were compared using Kruskal-Wallis equality-of-populations rank test with pairwise comparison post hoc analysis. Cognitive impairment was defined as MMSE score &amp;amp;amp;lt;27. A stepwise logistic regression model evaluated whether DCI was a predictor of cognitive impairment. Results CONSCIOUS-1 comprised 413 patients. Of these, 337 took an MMSE at their 12-week follow-up. Mean MMSE score was 27 with a median of 29 (range, 0–30; SD 5.4). There were no significant differences between MMSE scores of patients who had 12-week mRS scores of 0–2. On multivariate analysis, DCI was independently associated with cognitive impairment after aSAH. Conclusions Patients considered to have a good outcome on mRS had varying degrees of cognitive function on MMSE, whereas development of DCI was an independent predictor of cognitive impairment after aSAH. MMSE may not be sensitive enough to discern subtle defects in cognition, as the median score was 29 out of&nbsp;30.;,citation_author=Matthew E. Eagles;,citation_author=Michael K. Tso;,citation_author=R. Loch Macdonald;,citation_publication_date=2019-04;,citation_cover_date=2019-04;,citation_year=2019;,citation_doi=10.1016/j.wneu.2018.12.152;,citation_issn=1878-8750;,citation_volume=124;,citation_language=en-US;,citation_journal_title=World Neurosurgery;">
<meta name="citation_reference" content="citation_title=Heparin-Induced Thrombocytopenia in the Critically Ill Patient;,citation_author=James M. East;,citation_author=Christine M. Cserti-Gazdewich;,citation_author=John T. Granton;,citation_publication_date=2018-09;,citation_cover_date=2018-09;,citation_year=2018;,citation_issue=3;,citation_doi=10.1016/j.chest.2017.11.039;,citation_issn=00123692;,citation_volume=154;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Mild Hypercapnia or Normocapnia after Out-of-Hospital Cardiac Arrest;,citation_author=Glenn Eastwood;,citation_author=Alistair D. Nichol;,citation_author=Carol Hodgson;,citation_author=Rachael L. Parke;,citation_author=Shay McGuinness;,citation_author=Niklas Nielsen;,citation_author=Stephen Bernard;,citation_author=Markus B. Skrifvars;,citation_author=Dion Stub;,citation_author=Fabio S. Taccone;,citation_author=John Archer;,citation_author=Demetrios Kutsogiannis;,citation_author=Josef Dankiewicz;,citation_author=Gisela Lilja;,citation_author=Tobias Cronberg;,citation_author=Hans Kirkegaard;,citation_author=Gilles Capellier;,citation_author=Giovanni Landoni;,citation_author=Janneke Horn;,citation_author=Theresa Olasveengen;,citation_author=Yaseen Arabi;,citation_author=Yew Woon Chia;,citation_author=Andrej Markota;,citation_author=Matthias Hænggi;,citation_author=Matt P. Wise;,citation_author=Anders M. Grejs;,citation_author=Steffen Christensen;,citation_author=Heidi Munk-Andersen;,citation_author=Asger Granfeldt;,citation_author=Geir Ø. Andersen;,citation_author=Eirik Qvigstad;,citation_author=Arnljot Flaa;,citation_author=Matthew Thomas;,citation_author=Katie Sweet;,citation_author=Jeremy Bewley;,citation_author=Minna Bäcklund;,citation_author=Marjaana Tiainen;,citation_author=Manuela Iten;,citation_author=Anja Levis;,citation_author=Leah Peck;,citation_author=James Walsham;,citation_author=Adam Deane;,citation_author=Angajendra Ghosh;,citation_author=Filippo Annoni;,citation_author=Yan Chen;,citation_author=David Knight;,citation_author=Eden Lesona;,citation_author=Haytham Tlayjeh;,citation_author=Franc Svenšek;,citation_author=Peter J. McGuigan;,citation_author=Jade Cole;,citation_author=David Pogson;,citation_author=Matthias P. Hilty;,citation_author=Joachim P. Düring;,citation_author=Michael J. Bailey;,citation_author=Eldho Paul;,citation_author=Bridget Ady;,citation_author=Kate Ainscough;,citation_author=Anna Hunt;,citation_author=Sinéad Monahan;,citation_author=Tony Trapani;,citation_author=Ciara Fahey;,citation_author=Rinaldo Bellomo;,citation_publication_date=2023-06;,citation_cover_date=2023-06;,citation_year=2023;,citation_issue=0;,citation_doi=10.1056/NEJMoa2214552;,citation_issn=0028-4793;,citation_volume=0;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Commentary: Should we always deliberately be non-representative?;,citation_author=S. Ebrahim;,citation_author=G. Davey Smith;,citation_publication_date=2013-08;,citation_cover_date=2013-08;,citation_year=2013;,citation_issue=4;,citation_doi=10.1093/ije/dyt105;,citation_issn=0300-5771, 1464-3685;,citation_volume=42;,citation_language=en-US;,citation_journal_title=International Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Pathophysiology of chronic subdural haematoma: Inflammation, angiogenesis and implications for pharmacotherapy;,citation_abstract=Chronic subdural haematoma (CSDH) is an encapsulated collection of blood and fluid on the surface of the brain. Historically considered a result of head trauma, recent evidence suggests there are more complex processes involved. Trauma may be absent or very minor and does not explain the progressive, chronic course of the condition. This review focuses on several key processes involved in CSDH development: angiogenesis, fibrinolysis and inflammation. The characteristic membrane surrounding the CSDH has been identified as a source of fluid exudation and haemorrhage. Angiogenic stimuli lead to the creation of fragile blood vessels within membrane walls, whilst fibrinolytic processes prevent clot formation resulting in continued haemorrhage. An abundance of inflammatory cells and markers have been identified within the membranes and subdural fluid and are likely to contribute to propagating an inflammatory response which stimulates ongoing membrane growth and fluid accumulation. Currently, the mainstay of treatment for CSDH is surgical drainage, which has associated risks of recurrence requiring repeat surgery. Understanding of the underlying pathophysiological processes has been applied to developing potential drug treatments. Ongoing research is needed to identify if these therapies are successful in controlling the inflammatory and angiogenic disease processes leading to control and resolution of CSDH.;,citation_author=Ellie Edlmann;,citation_author=Susan Giorgi-Coll;,citation_author=Peter C. Whitfield;,citation_author=Keri L. H. Carpenter;,citation_author=Peter J. Hutchinson;,citation_publication_date=2017-12;,citation_cover_date=2017-12;,citation_year=2017;,citation_issue=1;,citation_doi=10.1186/s12974-017-0881-y;,citation_issn=1742-2094;,citation_volume=14;,citation_language=en-US;,citation_journal_title=Journal of Neuroinflammation;">
<meta name="citation_reference" content="citation_title=Early Rehabilitation for Patients with Disorders of Consciousness after Severe COVID-19;,citation_author=Brian L. Edlow;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_doi=10.1007/s12028-021-01361-7;,citation_issn=1541-6933, 1556-0961;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Measuring Consciousness in the Intensive Care Unit;,citation_abstract=Early reemergence of consciousness predicts long-term functional recovery for patients with severe brain injury. However, tools to reliably detect consciousness in the intensive care unit are lacking. Transcranial magnetic stimulation electroencephalography has the potential to detect consciousness in the intensive care unit, predict recovery, and prevent premature withdrawal of life-sustaining therapy.;,citation_author=Brian L. Edlow;,citation_author=Matteo Fecchio;,citation_author=Yelena G. Bodien;,citation_author=Angela Comanducci;,citation_author=Mario Rosanova;,citation_author=Silvia Casarotto;,citation_author=Michael J. Young;,citation_author=Jian Li;,citation_author=Darin D. Dougherty;,citation_author=Christof Koch;,citation_author=Giulio Tononi;,citation_author=Marcello Massimini;,citation_author=Melanie Boly;,citation_publication_date=2023-04;,citation_cover_date=2023-04;,citation_year=2023;,citation_doi=10.1007/s12028-023-01706-4;,citation_issn=1556-0961;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Recovery from disorders of consciousness: Mechanisms, prognosis and emerging therapies;,citation_abstract=Substantial progress has been made over the past two decades in detecting, predicting and promoting recovery of consciousness in patients with disorders of consciousness (DoC) caused by severe brain injuries. Advanced neuroimaging and electrophysiological techniques have revealed new insights into the biological mechanisms underlying recovery of consciousness and have enabled the identification of preserved brain networks in patients who seem unresponsive, thus raising hope for more accurate diagnosis and prognosis. Emerging evidence suggests that covert consciousness, or cognitive motor dissociation (CMD), is present in up to 15–20% of patients with DoC and that detection of CMD in the intensive care unit can predict functional recovery at 1 year post injury. Although fundamental questions remain about which patients with DoC have the potential for recovery, novel pharmacological and electrophysiological therapies have shown the potential to reactivate injured neural networks and promote re-emergence of consciousness. In this Review, we focus on mechanisms of recovery from DoC in the acute and subacute-to-chronic stages, and we discuss recent progress in detecting and predicting recovery of consciousness. We also describe the developments in pharmacological and electrophysiological therapies that are creating new opportunities to improve the lives of patients with DoC.;,citation_author=Brian L. Edlow;,citation_author=Jan Claassen;,citation_author=Nicholas D. Schiff;,citation_author=David M. Greer;,citation_publication_date=2021-03;,citation_cover_date=2021-03;,citation_year=2021;,citation_issue=3;,citation_doi=10.1038/s41582-020-00428-x;,citation_issn=1759-4758, 1759-4766;,citation_volume=17;,citation_language=en-US;,citation_journal_title=Nature Reviews Neurology;">
<meta name="citation_reference" content="citation_title=Therapies to Restore Consciousness in Patients with Severe Brain Injuries: A Gap Analysis and Future Directions;,citation_abstract=Background/Objective: For patients with disorders of consciousness (DoC) and their families, the search for new therapies has been a source of hope and frustration. Almost all clinical trials in patients with DoC have been limited by small sample sizes, lack of placebo groups, and use of heterogeneous outcome measures. As a result, few therapies have strong evidence to support their use; amantadine is the only therapy recommended by current clinical guidelines, specifically for patients with DoC caused by severe traumatic brain injury. To foster and advance development of consciousness-promoting therapies for patients with DoC, the Curing Coma Campaign convened a Coma Science Work Group to perform a gap analysis. Methods: We consider five classes of therapies: (1) pharmacologic; (2) electromagnetic; (3) mechanical; (4) sensory; and (5) regenerative. For each class of therapy, we summarize the state of the science, identify gaps in knowledge, and suggest future directions for therapy development. Results: Knowledge gaps in all five therapeutic classes can be attributed to the lack of: (1) a unifying conceptual framework for evaluating therapeutic mechanisms of action; (2) large-scale randomized controlled trials; and (3) pharmacodynamic biomarkers that measure subclinical therapeutic effects in early-phase trials. To address these gaps, we propose a precision medicine approach in which clinical trials selectively enroll patients based upon their physiological receptivity to targeted therapies, and therapeutic effects are measured by complementary behavioral, neuroimaging, and electrophysiologic endpoints. Conclusions: This personalized approach can be realized through rigorous clinical trial design and international collaboration, both of which will be essential for advancing the development of new therapies and ultimately improving the lives of patients with DoC.;,citation_author=Brian L. Edlow;,citation_author=Leandro R. D. Sanz;,citation_author=Len Polizzotto;,citation_author=Nader Pouratian;,citation_author=John D. Rolston;,citation_author=Samuel B. Snider;,citation_author=Aurore Thibaut;,citation_author=Robert D. Stevens;,citation_author=Olivia Gosseries;,citation_author=the Curing Coma Campaign and its contributing members;,citation_author=Yama Akbari;,citation_author=Thomas P. Bleck;,citation_author=Michael N. Diringer;,citation_author=Brandon Foreman;,citation_author=Jed A. Hartings;,citation_author=Raimund Helbok;,citation_author=J. Claude Hemphill;,citation_author=Geoffrey S. F. Ling;,citation_author=Stephan A. Mayer;,citation_author=Molly McNett;,citation_author=Martin M. Monti;,citation_author=DaiWai M. Olson;,citation_author=Adrian M. Owen;,citation_author=Soojin Park;,citation_author=J. Javier Provencio;,citation_author=Louis Puybasset;,citation_author=Paul Vespa;,citation_author=Amy Wagner;,citation_author=John Whyte;,citation_author=Wendy Ziai;,citation_publication_date=2021-07;,citation_cover_date=2021-07;,citation_year=2021;,citation_issue=S1;,citation_doi=10.1007/s12028-021-01227-y;,citation_issn=1541-6933, 1556-0961;,citation_volume=35;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Computer Age Statistical Inference;,citation_author=Bradley Efron;,citation_author=Trevor Hastie;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Why Isn’t Everyone a Bayesian?;,citation_author=B. Efron;,citation_publication_date=1986-02;,citation_cover_date=1986-02;,citation_year=1986;,citation_issue=1;,citation_doi=10.1080/00031305.1986.10475342;,citation_issn=0003-1305, 1537-2731;,citation_volume=40;,citation_language=en-US;,citation_journal_title=The American Statistician;">
<meta name="citation_reference" content="citation_title=Association Between Acute Care and Critical Illness Hospitalization and Cognitive Function in Older Adults;,citation_abstract=Objectives To determine whether decline in cognitive function was greater among older individuals who experienced acute care or critical illness hospitalizations relative to those not hospitalized and to determine whether the risk for incident dementia differed by these exposures. Design, Setting, and Participants Analysis of data from a prospective cohort study from 1994 through 2007 comprising 2929 individuals 65 years old and older without dementia at baseline residing in the community in the Seattle area and belonging to the Group Health Cooperative. Participants with 2 or more study visits were included, and those who had a hospitalization for a diagnosis of primary brain injury were censored at the time of hospitalization. Individuals were screened with the Cognitive Abilities Screening Instrument (CASI) (score range, 0-100) every 2 years at follow-up visits, and those with a score less than 86 underwent a clinical examination for dementia. Main Outcome Measures Score on the CASI at follow-up study visits and incident dementia diagnosed in study participants, adjusted for baseline cognitive scores, age, and other risk factors. Results During a mean (SD) follow-up of 6.1 (3.2) years, 1601 participants had no hospitalization, 1287 had 1 or more noncritical illness hospitalizations, and 41 had 1 or more critical illness hospitalizations. The CASI score was assessed more than 45 days after discharge for 94.3% of participants. Adjusted CASI scores averaged 1.01 points lower for visits following acute care illness hospitalization compared with follow-up visits not following any hospitalization (95% confidence interval [CI], -1.33 to -0.70; PϽ.001) and 2.14 points lower on average for visits following critical illness hospitalization (95% CI, -4.24 to -0.03; P=.047). There were 146 cases of dementia among those not hospitalized, 228 cases of dementia among those with 1 or more noncritical illness hospitalizations, and 5 cases of dementia among those with 1 or more critical illness hospitalizations. The adjusted hazard ratio for incident dementia was 1.4 following a noncritical illness hospitalization (95% CI, 1.1 to 1.7; P=.001) and 2.3 following a critical illness hospitalization (95% CI, 0.9 to 5.7; P=.09). Conclusions Among a cohort of older adults without dementia at baseline, those who experienced acute care hospitalization and critical illness hospitalization had a greater likelihood of cognitive decline compared with those who had no hospitalization. Noncritical illness hospitalization was significantly associated with the development of dementia.;,citation_author=William J Ehlenbach;,citation_author=Catherine L Hough;,citation_author=Paul K Crane;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Inhaled Amikacin to Prevent Ventilator-Associated Pneumonia;,citation_author=Stephan Ehrmann;,citation_author=François Barbier;,citation_author=Julien Demiselle;,citation_author=Jean-Pierre Quenot;,citation_author=Jean-Etienne Herbrecht;,citation_author=Damien Roux;,citation_author=Jean-Claude Lacherade;,citation_author=Mickaël Landais;,citation_author=Philippe Seguin;,citation_author=David Schnell;,citation_author=Anne Veinstein;,citation_author=Philippe Gouin;,citation_author=Sigismond Lasocki;,citation_author=Qin Lu;,citation_author=Gaëtan Beduneau;,citation_author=Martine Ferrandiere;,citation_author=Gaëtan Plantefève;,citation_author=Claire Dahyot-Fizelier;,citation_author=Nader Chebib;,citation_author=Emmanuelle Mercier;,citation_author=Nathalie Heuzé-Vourc’h;,citation_author=Renaud Respaud;,citation_author=Nicolas Gregoire;,citation_author=Denis Garot;,citation_author=Mai-Anh Nay;,citation_author=Ferhat Meziani;,citation_author=Pascal Andreu;,citation_author=Raphaël Clere-Jehl;,citation_author=Noémie Zucman;,citation_author=Marie-Ange Azaı̈s;,citation_author=Marjorie Saint-Martin;,citation_author=Charlotte Salmon Gandonnière;,citation_author=Dalila Benzekri;,citation_author=Hamid Merdji;,citation_author=Elsa Tavernier;,citation_publication_date=2023-10;,citation_cover_date=2023-10;,citation_year=2023;,citation_issue=0;,citation_doi=10.1056/NEJMoa2310307;,citation_issn=0028-4793;,citation_volume=0;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Principal Component Analyses (PCA)-based findings in population genetic studies are highly biased and must be reevaluated;,citation_abstract=Principal Component Analysis (PCA) is a multivariate analysis that reduces the complexity of datasets while preserving data covariance. The outcome can be visualized on colorful scatterplots, ideally with only a minimal loss of information. PCA applications, implemented in well-cited packages like EIGENSOFT and PLINK, are extensively used as the foremost analyses in population genetics and related fields (e.g., animal and plant or medical genetics). PCA outcomes are used to shape study design, identify, and characterize individuals and populations, and draw historical and ethnobiological conclusions on origins, evolution, dispersion, and relatedness. The replicability crisis in science has prompted us to evaluate whether PCA results are reliable, robust, and replicable. We analyzed twelve common test cases using an intuitive color-based model alongside human population data. We demonstrate that PCA results can be artifacts of the data and can be easily manipulated to generate desired outcomes. PCA adjustment also yielded unfavorable outcomes in association studies. PCA results may not be reliable, robust, or replicable as the field assumes. Our findings raise concerns about the validity of results reported in the population genetics literature and related fields that place a disproportionate reliance upon PCA outcomes and the insights derived from them. We conclude that PCA may have a biasing role in genetic investigations and that 32,000-216,000 genetic studies should be reevaluated. An alternative mixed-admixture population genetic model is discussed.;,citation_author=Eran Elhaik;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_issue=1;,citation_doi=10.1038/s41598-022-14395-4;,citation_issn=2045-2322;,citation_volume=12;,citation_language=en-US;,citation_journal_title=Scientific Reports;,citation_publisher=Nature Publishing Group;">
<meta name="citation_reference" content="citation_title=Statistical inference through estimation: Recommendations from the International Society of Physiotherapy Journal Editors;,citation_author=Mark R Elkins;,citation_author=Rafael Zambelli Pinto;,citation_author=Arianne Verhagen;,citation_author=Monika Grygorowicz;,citation_author=Anne Söderlund;,citation_author=Matthieu Guemann;,citation_author=Antonia Gómez-Conesa;,citation_author=Sarah Blanton;,citation_author=Jean-Michel Brismée;,citation_author=Clare Ardern;,citation_author=Shabnam Agarwal;,citation_author=Alan Jette;,citation_author=Sven Karstens;,citation_author=Michele Harms;,citation_author=Geert Verheyden;,citation_author=Umer Sheikh;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=1;,citation_doi=10.1016/j.jphys.2021.12.001;,citation_issn=18369553;,citation_volume=68;,citation_language=en-US;,citation_journal_title=Journal of Physiotherapy;">
<meta name="citation_reference" content="citation_title=Publish or Perish: The Research Arms Race in Residency Selection;,citation_abstract=“We need less research, better research, and research done for the right reasons.”1 So began a 1994 editorial in the British Medical Journal by statistician Douglas G. Altman. Noting that incentives for career advancement led many physicians to conduct research that was inappropriately designed, incorrectly analyzed, selectively interpreted, or outright fraudulent, Altman argued for abandoning the use of publication quantity as a measure of ability.One might hope that Altman’s words would have inspired systemic change in the nearly 3 decades following his eloquent editorial. Instead, it seems the publish-or-perish arms race has spread to medical trainees. The Figure shows the dramatic increase in PubMed-indexed research publications with medical student authors in the past 15 years. While these data are limited in their ability to represent all medical student research, they are a sample that alludes to an alarming trend.;,citation_author=Brian Elliott;,citation_author=J. Bryan Carmody;,citation_publication_date=2023-10;,citation_cover_date=2023-10;,citation_year=2023;,citation_issue=5;,citation_doi=10.4300/JGME-D-23-00262.1;,citation_issn=1949-8349;,citation_volume=15;,citation_journal_title=Journal of Graduate Medical Education;">
<meta name="citation_reference" content="citation_title=Commentary: On representativeness;,citation_author=J. M. Elwood;,citation_publication_date=2013-08;,citation_cover_date=2013-08;,citation_year=2013;,citation_issue=4;,citation_doi=10.1093/ije/dyt101;,citation_issn=0300-5771, 1464-3685;,citation_volume=42;,citation_language=en-US;,citation_journal_title=International Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: An exploratory, randomised, placebo-controlled trial;,citation_abstract=Background The oral, selective Janus kinase 1/2 inhibitor baricitinib has shown efficacy in studies of hospitalised adults with COVID-19. COV-BARRIER (NCT04421027) was a multinational, phase 3, randomised, double-blind, placebo-controlled trial of baricitinib in patients with confirmed SARS-CoV-2 infection. We aimed to evaluate the efficacy and safety of baricitinib plus standard of care in critically ill hospitalised adults with COVID-19 requiring invasive mechanical ventilation or extracorporeal membrane oxygenation.;,citation_author=E Wesley Ely;,citation_author=Athimalaipet V Ramanan;,citation_author=Cynthia E Kartman;,citation_author=Stephanie Bono;,citation_author=Ran Liao;,citation_author=Maria Lucia B Piruzeli;,citation_author=Jason D Goldman;,citation_author=José Francisco Kerr Saraiva;,citation_author=Sujatro Chakladar;,citation_author=Vincent C Marconi;,citation_author=Jorge Alatorre-Alexander;,citation_author=Javier David Altclas;,citation_author=Marcelo Casas;,citation_author=Valeria CevoliRecio;,citation_author=Todd Ellerin;,citation_author=Kleber Giovanni Luz;,citation_author=Jason D. Goldman;,citation_author=Maria Patelli Juliani Souza Lima;,citation_author=Akram Khan;,citation_author=Priscila Paulin;,citation_author=Ana Carolina Procopio Carvalho;,citation_author=Gustavo Rojas Velasco;,citation_author=Jose Francisco Kerr Saraiva;,citation_author=Imad Shawa;,citation_author=Jesus Simon Campos;,citation_author=Brian Tiffany;,citation_author=Adilson Westheimer Cavalcante;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_doi=10.1016/S2213-2600(22)00006-6;,citation_issn=22132600;,citation_language=en-US;,citation_journal_title=The Lancet Respiratory Medicine;">
<meta name="citation_reference" content="citation_title=Comparison of Propensity Score Methods and Covariate Adjustment;,citation_abstract=Propensity scores (PS) are an increasingly popular method to adjust for confounding in observational studies. Propensity score methods have theoretical advantages over conventional covariate adjustment, but their relative performance in real-word scenarios is poorly characterized. We used datasets from 4 large-scale cardiovascular observational studies (PROMETHEUS, ADAPT-DES [the Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents], THIN [The Health Improvement Network], and CHARM [Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity]) to compare the performance of conventional covariate adjustment with 4 common PS methods: matching, stratification, inverse probability weighting, and use of PS as a covariate. We found that stratification performed poorly with few outcome events, and inverse probability weighting gave imprecise estimates of treatment effect and undue influence to a small number of observations when substantial confounding was present. Covariate adjustment and matching performed well in all of our examples, although matching tended to give less precise estimates in some cases. PS methods are not necessarily superior to conventional covariate adjustment, and care should be taken to select the most suitable method.;,citation_author=Markus C. Elze;,citation_author=John Gregson;,citation_author=Usman Baber;,citation_author=Elizabeth Williamson;,citation_author=Samantha Sartori;,citation_author=Roxana Mehran;,citation_author=Melissa Nichols;,citation_author=Gregg W. Stone;,citation_author=Stuart J. Pocock;,citation_publication_date=2017-01;,citation_cover_date=2017-01;,citation_year=2017;,citation_issue=3;,citation_doi=10.1016/j.jacc.2016.10.060;,citation_issn=07351097;,citation_volume=69;,citation_language=en-US;,citation_journal_title=Journal of the American College of Cardiology;">
<meta name="citation_reference" content="citation_title=Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: A meta-analysis of individual patient data from randomised trials;,citation_author=Jonathan Emberson;,citation_author=Kennedy R. Lees;,citation_author=Patrick Lyden;,citation_author=Lisa Blackwell;,citation_author=Gregory Albers;,citation_author=Erich Bluhmki;,citation_author=Thomas Brott;,citation_author=Geoff Cohen;,citation_author=Stephen Davis;,citation_author=Geoffrey Donnan;,citation_author=James Grotta;,citation_author=George Howard;,citation_author=Markku Kaste;,citation_author=Masatoshi Koga;,citation_author=Ruediger Kummer;,citation_author=Maarten Lansberg;,citation_author=Richard I. Lindley;,citation_author=Gordon Murray;,citation_author=Jean Marc Olivot;,citation_author=Mark Parsons;,citation_author=Barbara Tilley;,citation_author=Danilo Toni;,citation_author=Kazunori Toyoda;,citation_author=Nils Wahlgren;,citation_author=Joanna Wardlaw;,citation_author=William Whiteley;,citation_author=Gregory J. Zoppo;,citation_author=Colin Baigent;,citation_author=Peter Sandercock;,citation_author=Werner Hacke;,citation_publication_date=2014-11;,citation_cover_date=2014-11;,citation_year=2014;,citation_issue=9958;,citation_doi=10.1016/S0140-6736(14)60584-5;,citation_issn=0140-6736, 1474-547X;,citation_pmid=25106063;,citation_volume=384;,citation_language=en-US;,citation_journal_title=The Lancet;,citation_publisher=Elsevier;">
<meta name="citation_reference" content="citation_title=Association of Statin Use With Overall and Cancer Survival—Reply;,citation_author=Louise Emilsson;,citation_author=Xabier García-Albéniz;,citation_author=Miguel A. Hernan;,citation_publication_date=2018-07;,citation_cover_date=2018-07;,citation_year=2018;,citation_issue=7;,citation_doi=10.1001/jamaoncol.2018.0736;,citation_issn=2374-2437;,citation_volume=4;,citation_language=en-US;,citation_journal_title=JAMA Oncology;">
<meta name="citation_reference" content="citation_title=Examining Bias in Studies of Statin Treatment and Survival in Patients With Cancer;,citation_abstract=OBJECTIVE To emulate a randomized trial of statin therapy initiation that is free of selection bias and immortal-time bias. DESIGN, SETTING, AND PARTICIPANTS We used observational data on 17 372 patients with cancer from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database (2007-2009) with complete follow-up until 2011. The SEER-Medicare database links 17 US cancer registries and claims files from Medicare and Medicaid in 12 US states. We included individuals with a new diagnosis of colorectal, breast, prostate, or bladder cancer who had not been prescribed statins for at least 6 months before the cancer diagnosis. Individuals were duplicated, and each replicate was assigned to either the strategy “statin therapy initiation within 6 months after diagnosis” or “no statin therapy initiation.” Replicates were censored when they stopped following their assigned strategy, and the potential selection bias was adjusted for via inverse-probability weighting. Hazard ratios (HRs), cumulative incidences, and risk differences were calculated for all-cause mortality and cancer-specific mortality. We then compared our estimates with those obtained using the same analytic approaches used in previous observational studies. EXPOSURES Statin therapy initiation within 6 months after cancer diagnosis. MAIN OUTCOMES AND MEASURES Cancer-specific and all-cause mortality using SEER-Medicare data and data from previous studies. Supplemental content RESULTS Of the 17 372 patients whose data were analyzed, 8440 (49%) were men, and 8932 (51%) were women (mean [SD] age, 76.4 [7.4] years; range, 66-115 years). The adjusted HR (95% CI) comparing statin therapy initiation vs no initiation was 1.00 (0.88-1.15) for cancer-specific mortality and 1.07 (0.93-1.21) for overall mortality. Cumulative incidence curves for both groups were almost overlapping (the risk difference never exceeded 0.8%). In contrast, the methods used by prior studies resulted in an inverse association between statin use and mortality (pooled hazard ratio 0.69). CONCLUSION AND RELEVANCE After using methods that are not susceptible to selection bias from prevalent users and to immortal time bias, we found that initiation of therapy with statins within 6 months after cancer diagnosis did not appear to improve 3-year cancer-specific or overall survival.;,citation_author=Louise Emilsson;,citation_author=Xabier García-Albéniz;,citation_author=Roger W. Logan;,citation_author=Ellen C. Caniglia;,citation_author=Mette Kalager;,citation_author=Miguel A. Hernán;,citation_publication_date=2018-01;,citation_cover_date=2018-01;,citation_year=2018;,citation_issue=1;,citation_doi=10.1001/jamaoncol.2017.2752;,citation_issn=2374-2437;,citation_volume=4;,citation_language=en-US;,citation_journal_title=JAMA Oncology;">
<meta name="citation_reference" content="citation_title=Effects of clazosentan on cerebral vasospasm–related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage: Two randomized phase 3 trials in Japanese patients;,citation_abstract=OBJECTIVE Clazosentan has been investigated globally for the prevention of cerebral vasospasm after aneurysmal subarachnoid hemorrhage (aSAH). The authors evaluated its effects on vasospasm-related morbidity and all-cause mortality following aSAH in Japanese patients. METHODS Two similar double-blind, placebo-controlled phase 3 studies were conducted in 57 Japanese centers in patients with aSAH, after aneurysms were secured by endovascular coiling in one study and surgical clipping in the other. In each study, patients were randomly administered intravenous clazosentan (10 mg/hr) or placebo (1:1) starting within 48 hours of aSAH and for up to 15 days after aSAH. Stratified randomization based on World Federation of Neurosurgical Societies grade was performed using a centralized interactive web response system. Vasospasm-related morbidity and all-cause mortality within 6 weeks post-aSAH, including new cerebral infarcts and delayed ischemic neurological deficits as well as all-cause mortality, were the first primary endpoint in each study. The second primary endpoint was all-cause morbidity (new cerebral infarct or delayed ischemic neurological deficit from any causes) and all-cause mortality (all-cause morbidity/mortality) within 6 weeks post-aSAH. The incidence of individual components of the primary morbidity/mortality endpoints within 6 weeks and patient outcome at 12 weeks post-aSAH (including the modified Rankin Scale scores) were also evaluated. The above analyses were also performed in the population pooled from both studies. RESULTS In each study, 221 patients were randomized and 220 were included in the full analysis set of the primary analysis (109 in each clazosentan group, 111 in each placebo group). Clazosentan significantly reduced the incidence of vasospasm-related morbidity and all-cause mortality after aneurysm coiling (from 28.8% to 13.6%; relative risk reduction 53%; 95% CI 17%–73%) and after clipping (from 39.6% to 16.2%; relative risk reduction 59%; 95% CI 33%–75%). All-cause morbidity/mortality and poor outcome (dichotomized modified Rankin Scale scores) were significantly reduced by clazosentan after preplanned study pooling. Treatment-emergent adverse events were similar to those reported previously. CONCLUSIONS Clazosentan significantly reduced the combined incidence of vasospasm-related morbidity and allcause mortality post-aSAH with no unexpected safety findings. Clinical trial registration nos.: JapicCTI-163368 and JapicCTI-163369 (https://www.clinicaltrials.jp) https://thejns.org/doi/abs/10.3171/2022.2.JNS212914;,citation_author=Hidenori Endo;,citation_author=Yasushi Hagihara;,citation_author=Naoto Kimura;,citation_author=Katsumi Takizawa;,citation_author=Kuniyasu Niizuma;,citation_author=Osamu Togo;,citation_author=Teiji Tominaga;,citation_publication_date=2022-04;,citation_cover_date=2022-04;,citation_year=2022;,citation_doi=10.3171/2022.2.JNS212914;,citation_issn=0022-3085, 1933-0693;,citation_language=en-US;,citation_journal_title=Journal of Neurosurgery;">
<meta name="citation_reference" content="citation_title=Hyperoxia and traumatic brain injury: Time to stop cooking the books?;,citation_author=Ari Ercole;,citation_publication_date=2022-12;,citation_cover_date=2022-12;,citation_year=2022;,citation_doi=10.1007/s00134-022-06938-0;,citation_issn=1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Fluid therapy in patients with brain injury: What does physiology tell us?;,citation_author=Christian Ertmer;,citation_author=Hugo Van Aken;,citation_publication_date=2014-03;,citation_cover_date=2014-03;,citation_year=2014;,citation_issue=2;,citation_doi=10.1186/cc13764;,citation_issn=1364-8535;,citation_volume=18;,citation_journal_title=Critical Care;">
<meta name="citation_reference" content="citation_title=Is the literature inconclusive about the harm from HES? Yes;,citation_author=Christian Ertmer;,citation_author=Djillali Annane;,citation_author=Philippe Van Der Linden;,citation_publication_date=2017-10;,citation_cover_date=2017-10;,citation_year=2017;,citation_issue=10;,citation_doi=10.1007/s00134-016-4278-7;,citation_issn=0342-4642, 1432-1238;,citation_volume=43;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Biomarkers of Coagulation and Inflammation in COVID-19–Associated Ischemic Stroke;,citation_abstract=BACKGROUND AND PURPOSE: We sought to determine if biomarkers of inflammation and coagulation can help define coronavirus disease 2019 (COVID-19)–associated ischemic stroke as a novel acute ischemic stroke (AIS) subtype. METHODS: We performed a machine learning cluster analysis of common biomarkers in patients admitted with severe acute respiratory syndrome coronavirus 2 to determine if any were associated with AIS. Findings were validated using aggregate data from 3 large healthcare systems. RESULTS: Clustering grouped 2908 unique patient encounters into 4 unique biomarker phenotypes based on levels of c-reactive protein, D-dimer, lactate dehydrogenase, white blood cell count, and partial thromboplastin time. The most severe cluster phenotype had the highest prevalence of AIS (3.6%, P&amp;amp;amp;lt;0.001), in-hospital AIS (53%, P&amp;lt;0.002), severe AIS (31%, P=0.004), and cryptogenic AIS (73%, P<0.001). D-dimer was the only biomarker independently associated with prevalent AIS with quartile 4 having an 8-fold higher risk of AIS compared to quartile 1 (P=0.005), a finding that was further corroborated in a separate cohort of 157 patients hospitalized with COVID-19 and AIS. CONCLUSIONS: COVID-19–associated ischemic stroke may be related to COVID-19 illness severity and associated coagulopathy as defined by increasing D-dimer burden.;,citation_author=Charles Esenwa;,citation_author=Natalie T. Cheng;,citation_author=Jorge Luna;,citation_author=Joshua Willey;,citation_author=Amelia K. Boehme;,citation_author=Kathryn Kirchoff-Torres;,citation_author=Daniel Labovitz;,citation_author=Ava L. Liberman;,citation_author=Peter Mabie;,citation_author=Khadean Moncrieffe;,citation_author=Ainie Soetanto;,citation_author=Andrea Lendaris;,citation_author=Johanna Seiden;,citation_author=Inessa Goldman;,citation_author=David Altschul;,citation_author=Ryan Holland;,citation_author=Joshua Benton;,citation_author=Joseph Dardick;,citation_author=Jenelys Fernandez-Torres;,citation_author=David Flomenbaum;,citation_author=Jenny Lu;,citation_author=Avinash Malaviya;,citation_author=Nikunj Patel;,citation_author=Aureliana Toma;,citation_author=Aaron Lord;,citation_author=Koto Ishida;,citation_author=Jose Torres;,citation_author=Thomas Snyder;,citation_author=Jennifer Frontera;,citation_author=Shadi Yaghi;,citation_publication_date=2021-11;,citation_cover_date=2021-11;,citation_year=2021;,citation_issue=11;,citation_doi=10.1161/STROKEAHA.121.035045;,citation_issn=0039-2499, 1524-4628;,citation_volume=52;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=Post-Transcriptional Genetic Silencing of &amp;amp;amp;lt;i&amp;gt;BCL11A&amp;lt;/i&amp;gt; to Treat Sickle Cell Disease;,citation_abstract=BACKGROUND Sickle cell disease is characterized by hemolytic anemia, pain, and progressive organ damage. A high level of erythrocyte fetal hemoglobin (HbF) comprising \alpha- and \gamma-globins may ameliorate these manifestations by mitigating sickle hemoglobin polymerization and erythrocyte sickling. BCL11A is a repressor of \gamma-globin expression and HbF production in adult erythrocytes. Its down-regulation is a promising therapeutic strategy for induction of HbF. METHODS We enrolled patients with sickle cell disease in a single-center, open-label pilot study. The investigational therapy involved infusion of autologous CD34+ cells transduced with the BCH-BB694 lentiviral vector, which encodes a short hairpin RNA (shRNA) targeting BCL11A mRNA embedded in a microRNA (shmiR), allowing erythroid lineage–specific knockdown. Patients were assessed for primary end points of engraftment and safety and for hematologic and clinical responses to treatment. RESULTS As of October 2020, six patients had been followed for at least 6 months after receiving BCH-BB694 gene therapy; median follow-up was 18 months (range, 7 to 29). All patients had engraftment, and adverse events were consistent with effects of the preparative chemotherapy. All the patients who could be fully evaluated achieved robust and stable HbF induction (percentage HbF/(F+S) at most recent follow-up, 20.4 to 41.3%), with HbF broadly distributed in red cells (F-cells 58.9 to 93.6% of untransfused red cells) and HbF per F-cell of 9.0 to 18.6 pg per cell. Clinical manifestations of sickle cell disease were reduced or absent during the follow-up period. From the Dana–Farber/Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School (E.B.E., L.E.L., A.B., C.B., M.F.C., B.M., K.B., S.-Y.P., W.B.L., C.D., M.M.H., D.A.W.), the Harvard Stem Cell Institute, Harvard Medical School (A.B., C.B.), the Gene Therapy Program, Dana–Farber/Boston Children’s Cancer and Blood Disorders Center (A.B., M.F.C., B.M., E.M., A.F., S.-Y.P., C.D., D.A.W.), the Division of Hematology, Brigham and Women’s Hospital, Harvard Medical School (M. Achebe), the Connell and O’Reilly Families Cell Manipulation Core Facility, Dana–Farber Cancer Institute (H.D., R.K., K.S., H.N., S.N., J.R.), the TransLab, Boston Children’s Hospital (D.A., M. Armant), and the Department of Laboratory Medicine, Boston Children’s Hospital, Harvard Medical School ( J.P.M.) — all in Boston; and Bluebird Bio, Cambridge, MA (O.N.). Address reprint requests to Dr. Williams at 300 Longwood Ave., Karp 08125.3, Boston, MA 02115, or at dawilliams@childrens.harvard.edu. This article was published on December 5, 2020, and updated on December 8, 2020, at NEJM.org. N Engl J Med 2021;384:205-15. DOI: 10.1056/NEJMoa2029392 Copyright © 2020 Massachusetts Medical Society. CONCLUSIONS This study validates BCL11A inhibition as an effective target for HbF induction and provides preliminary evidence that shmiR-based gene knockdown offers a favorable risk–benefit profile in sickle cell disease. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT03282656);,citation_author=Erica B. Esrick;,citation_author=Leslie E. Lehmann;,citation_author=Alessandra Biffi;,citation_author=Maureen Achebe;,citation_author=Christian Brendel;,citation_author=Marioara F. Ciuculescu;,citation_author=Heather Daley;,citation_author=Brenda MacKinnon;,citation_author=Emily Morris;,citation_author=Amy Federico;,citation_author=Daniela Abriss;,citation_author=Kari Boardman;,citation_author=Radia Khelladi;,citation_author=Kit Shaw;,citation_author=Helene Negre;,citation_author=Olivier Negre;,citation_author=Sarah Nikiforow;,citation_author=Jerome Ritz;,citation_author=Sung-Yun Pai;,citation_author=Wendy B. London;,citation_author=Colleen Dansereau;,citation_author=Matthew M. Heeney;,citation_author=Myriam Armant;,citation_author=John P Manis;,citation_author=David A. Williams;,citation_publication_date=2021-01;,citation_cover_date=2021-01;,citation_year=2021;,citation_issue=3;,citation_doi=10.1056/NEJMoa2029392;,citation_issn=0028-4793, 1533-4406;,citation_volume=384;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Using Causal Diagrams to Improve the Design and Interpretation of Medical Research;,citation_author=Mahyar Etminan;,citation_author=Gary S. Collins;,citation_author=Mohammad Ali Mansournia;,citation_publication_date=2020-07;,citation_cover_date=2020-07;,citation_year=2020;,citation_issue=1;,citation_doi=10.1016/j.chest.2020.03.011;,citation_issn=00123692;,citation_volume=158;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Independent Oversight of Clinical Trials through Data and Safety Monitoring Boards;,citation_author=Scott R. Evans;,citation_editor=Scott R. Evans;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=1;,citation_doi=10.1056/EVIDctw2100005;,citation_issn=2766-5526;,citation_volume=1;,citation_language=en-US;,citation_journal_title=NEJM Evidence;">
<meta name="citation_reference" content="citation_title=Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2021;,citation_author=Laura Evans;,citation_author=Andrew Rhodes;,citation_author=Waleed Alhazzani;,citation_author=Massimo Antonelli;,citation_author=Craig M. Coopersmith;,citation_author=Craig French;,citation_author=Flávia R. Machado;,citation_author=Lauralyn Mcintyre;,citation_author=Marlies Ostermann;,citation_author=Hallie C. Prescott;,citation_author=Christa Schorr;,citation_author=Steven Simpson;,citation_author=W. Joost Wiersinga;,citation_author=Fayez Alshamsi;,citation_author=Derek C. Angus;,citation_author=Yaseen Arabi;,citation_author=Luciano Azevedo;,citation_author=Richard Beale;,citation_author=Gregory Beilman;,citation_author=Emilie Belley-Cote;,citation_author=Lisa Burry;,citation_author=Maurizio Cecconi;,citation_author=John Centofanti;,citation_author=Angel Coz Yataco;,citation_author=Jan De Waele;,citation_author=R. Phillip Dellinger;,citation_author=Kent Doi;,citation_author=Bin Du;,citation_author=Elisa Estenssoro;,citation_author=Ricard Ferrer;,citation_author=Charles Gomersall;,citation_author=Carol Hodgson;,citation_author=Morten Hylander Møller;,citation_author=Theodore Iwashyna;,citation_author=Shevin Jacob;,citation_author=Ruth Kleinpell;,citation_author=Michael Klompas;,citation_author=Younsuck Koh;,citation_author=Anand Kumar;,citation_author=Arthur Kwizera;,citation_author=Suzana Lobo;,citation_author=Henry Masur;,citation_author=Steven McGloughlin;,citation_author=Sangeeta Mehta;,citation_author=Yatin Mehta;,citation_author=Mervyn Mer;,citation_author=Mark Nunnally;,citation_author=Simon Oczkowski;,citation_author=Tiffany Osborn;,citation_author=Elizabeth Papathanassoglou;,citation_author=Anders Perner;,citation_author=Michael Puskarich;,citation_author=Jason Roberts;,citation_author=William Schweickert;,citation_author=Maureen Seckel;,citation_author=Jonathan Sevransky;,citation_author=Charles L. Sprung;,citation_author=Tobias Welte;,citation_author=Janice Zimmerman;,citation_author=Mitchell Levy;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_doi=10.1007/s00134-021-06506-y;,citation_issn=0342-4642, 1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Acute peri-operative neurocognitive disorders: A narrative review;,citation_abstract=Peri-operative neurocognitive disorders are the most common complication experienced by older individuals undergoing anaesthesia and surgery. Peri-operative neurocognitive disorders, particularly postoperative delirium, result in long-term poor outcomes including: death; dementia; loss of independence; and poor cognitive and functional outcomes. Recent changes to the nomenclature of these disorders aims to align perioperative neurocognitive disorders with cognitive disorders in the community, with consistent definitions and clinical diagnosis. Possible mechanisms include: undiagnosed neurodegenerative disease; inflammation and resulting neuroinflammation; neuronal damage; and comorbid systemic disease. Pre-operative frailty represents a significant risk for poor postoperative outcomes; it is associated with an increase in the incidence of cognitive decline at 3 and 12 months postoperatively. In addition to cognitive decline, frailty is associated with poor functional outcomes following elective non-cardiac surgery. It was recently shown that 29% of frail patients died or experienced institutionalisation or new disability within 90 days of major elective surgery. Identification of vulnerable patients before undergoing surgery and anaesthesia is the key to preventing peri-operative neurocognitive disorders. Current approaches include: pre-operative delirium and cognitive screening; blood biomarker analysis; intra-operative management that may reduce the incidence of postoperative delirium such as lighter anaesthesia using processed electroencephalography devices; and introduction of guidelines which may reduce or prevent delirium and postoperative neurocognitive disorders. This review will address these issues and advocate for an approach to care for older peri-operative patients which starts in the community and continues throughout the pre-operative, intra-operative, postoperative and post-discharge phases of care management, involving multidisciplinary medical teams, as well as family and caregivers wherever possible.;,citation_author=L. Evered;,citation_author=K. Atkins;,citation_author=B. Silbert;,citation_author=D. A. Scott;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=S1;,citation_doi=10.1111/anae.15613;,citation_issn=0003-2409, 1365-2044;,citation_volume=77;,citation_language=en-US;,citation_journal_title=Anaesthesia;">
<meta name="citation_reference" content="citation_title=Does This Patient Need Blood Cultures? A Scoping Review of Indications for Blood Cultures in Adult Nonneutropenic Inpatients;,citation_abstract=Abstract Guidance regarding indications for initial or follow-up blood cultures is limited. We conducted a scoping review of articles published between January 2004 and June 2019 that reported the yield of blood cultures and/or their impact in the clinical management of fever and common infectious syndromes in nonneutropenic adult inpatients. A total of 2893 articles were screened; 50 were included. Based on the reported incidence of bacteremia, syndromes were categorized into low, moderate, and high pretest probability of bacteremia. Routine blood cultures are recommended in syndromes with a high likelihood of bacteremia (eg, endovascular infections) and those with moderate likelihood when cultures from the primary source of infection are unavailable or when prompt initiation of antibiotics is needed prior to obtaining primary source cultures. In syndromes where blood cultures are low-yield, blood cultures can be considered for patients at risk of adverse events if a bacteremia is missed (eg, patient with pacemaker and severe purulent cellulitis). If a patient has adequate source control and risk factors or concern for endovascular infection are not present, most streptococci or Enterobacterales bacteremias do not require routine follow-up blood cultures.;,citation_author=Valeria Fabre;,citation_author=Sima L Sharara;,citation_author=Alejandra B Salinas;,citation_author=Karen C Carroll;,citation_author=Sanjay Desai;,citation_author=Sara E Cosgrove;,citation_publication_date=2020-08;,citation_cover_date=2020-08;,citation_year=2020;,citation_issue=5;,citation_doi=10.1093/cid/ciaa039;,citation_issn=1058-4838, 1537-6591;,citation_volume=71;,citation_language=en-US;,citation_journal_title=Clinical Infectious Diseases;">
<meta name="citation_reference" content="citation_title=Artificial Intelligence and Statistics: Just the Old Wine in New Wineskins?;,citation_author=Livia Faes;,citation_author=Dawn A. Sim;,citation_author=Maarten Smeden;,citation_author=Ulrike Held;,citation_author=Patrick M. Bossuyt;,citation_author=Lucas M. Bachmann;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_doi=10.3389/fdgth.2022.833912;,citation_issn=2673-253X;,citation_volume=4;,citation_language=en-US;,citation_journal_title=Frontiers in Digital Health;">
<meta name="citation_reference" content="citation_title=Enough: The Failure of the Living Will;,citation_author=Angela Fagerlin;,citation_author=Carl E. Schneider;,citation_publication_date=2004-03;,citation_cover_date=2004-03;,citation_year=2004;,citation_fulltext_html_url=https://www.jstor.org/stable/3527683;,citation_issue=2;,citation_doi=10.2307/3527683;,citation_issn=00930334;,citation_volume=34;,citation_language=en-US;,citation_journal_title=The Hastings Center Report;">
<meta name="citation_reference" content="citation_title=Albumin in critical care: SAFE, but worth its salt?;,citation_abstract=Intravascular fluid therapy is a common critical care intervention. However, the optimal type of resuscitation fluid, crystalloid or colloid, remains controversial. Despite the many theoretical benefits of human albumin administration in critically ill patients, there has been little evidence to support its widespread clinical use. Previous systematic reviews have led to conflicting results regarding the safety and efficacy of albumin. The recently reported Saline versus Albumin Evaluation study has provided conclusive evidence that 4% albumin is as safe as saline for resuscitation, although no overall benefit of albumin use was seen. Subgroup analysis of the albumin-treated group revealed a trend towards decreased mortality in patients with septic shock, and a trend towards increased mortality in trauma patients, especially those with traumatic brain injury. The results of these subgroups, as well as the use of higher albumin concentrations and other synthetic colloids (dextrans, starches), require rigorous evaluation in clinical trials. Finally, the Saline versus Albumin Evaluation trial represents a methodological milestone in critical care medicine, due to its size, its efficient trial design, and its logistical coordination. Future studies are still required, however, to establish a therapeutic niche for albumin and other colloids.;,citation_author=Eddy Fan;,citation_author=Thomas E. Stewart;,citation_publication_date=2004-08;,citation_cover_date=2004-08;,citation_year=2004;,citation_issue=5;,citation_doi=10.1186/cc2943;,citation_issn=1364-8535;,citation_volume=8;,citation_journal_title=Critical Care;">
<meta name="citation_reference" content="citation_title=Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: A multicentre, double-blind, phase 3, randomised controlled study;,citation_abstract=Background Spread of SARS-CoV-2 led to a global pandemic, and there remains unmet medical needs in the treatment of Omicron infections. VV116, an oral antiviral agent that has potent activity against SARS-CoV-2, was compared with a placebo in this phase 3 study to investigate its efficacy and safety in patients with mild-to-moderate COVID-19.;,citation_author=Xiaohong Fan;,citation_author=Xiahong Dai;,citation_author=Yun Ling;,citation_author=Lihua Wu;,citation_author=Lingling Tang;,citation_author=Chunxian Peng;,citation_author=Chaolin Huang;,citation_author=Hongyan Liu;,citation_author=Hongzhou Lu;,citation_author=Xinghua Shen;,citation_author=Wei Zhang;,citation_author=Furong Wang;,citation_author=Guangming Li;,citation_author=Ming Li;,citation_author=Yanming Huang;,citation_author=Hongying Zhang;,citation_author=Minghui Li;,citation_author=Fei Ren;,citation_author=Yuanyuan Li;,citation_author=Chenfan Liu;,citation_author=Zhiguo Zhou;,citation_author=Wei Sun;,citation_author=Yongxiang Yi;,citation_author=Daming Zhou;,citation_author=Hainv Gao;,citation_author=Qi Pan;,citation_author=Hongde Liu;,citation_author=Jiang Zhao;,citation_author=Zhen Ding;,citation_author=Yingmin Ma;,citation_author=Wei Li;,citation_author=Quanhong Wang;,citation_author=Xicheng Wang;,citation_author=Yichun Bai;,citation_author=Xiangao Jiang;,citation_author=Juan Ma;,citation_author=Bingying Xie;,citation_author=Kui Zhang;,citation_author=Lanjuan Li;,citation_publication_date=2023-11;,citation_cover_date=2023-11;,citation_year=2023;,citation_doi=10.1016/S1473-3099(23)00577-7;,citation_issn=14733099;,citation_language=en-US;,citation_journal_title=The Lancet Infectious Diseases;">
<meta name="citation_reference" content="citation_title=Physical Complications in Acute Lung Injury Survivors: A Two-Year Longitudinal Prospective Study;,citation_abstract=Objective—Survivors of severe critical illness frequently develop substantial and persistent physical complications, including muscle weakness, impaired physical function, and decreased health-related quality of life (HRQOL). Our objective was to determine the longitudinal epidemiology of muscle weakness, physical function, and HRQOL, and their associations with critical illness and intensive care unit exposures.;,citation_author=Eddy Fan;,citation_author=David W. Dowdy;,citation_author=Elizabeth Colantuoni;,citation_author=Pedro A. Mendez-Tellez;,citation_author=Jonathan E. Sevransky;,citation_author=Carl Shanholtz;,citation_author=Cheryl R. Dennison Himmelfarb;,citation_author=Sanjay V. Desai;,citation_author=Nancy Ciesla;,citation_author=Margaret S. Herridge;,citation_author=Peter J. Pronovost;,citation_author=Dale M. Needham;,citation_publication_date=2014-04;,citation_cover_date=2014-04;,citation_year=2014;,citation_issue=4;,citation_doi=10.1097/CCM.0000000000000040;,citation_issn=0090-3493;,citation_volume=42;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Randomized Trials Versus Common Sense and Clinical Observation;,citation_abstract=Concerns about the external validity of traditional randomized clinical trials (RCTs), together with the widespread availability of real-world data and advanced data analytic tools, have led to claims that common sense and clinical observation, rather than RCTs, should be the preferred method to generate evidence to support clinical decision-making. However, over the past 4 decades, results from well-done RCTs have repeatedly contradicted practices supported by common sense and clinical observation. Common sense and clinical observation fail for several reasons: incomplete understanding of pathophysiology, biases and unmeasured confounding in observational research, and failure to understand risks and benefits of treatments within complex systems. Concerns about traditional RCT models are legitimate, but randomization remains a critical tool to understand the causal relationship between treatments and outcomes. Instead, development and promulgation of tools to apply randomization to real-world data are needed to build the best evidence base in cardiovascular medicine. (J Am Coll Cardiol 2020;76:580–9) © 2020 by the American College of Cardiology Foundation.;,citation_author=Alexander C. Fanaroff;,citation_author=Robert M. Califf;,citation_author=Robert A. Harrington;,citation_author=Christopher B. Granger;,citation_author=John J. V. McMurray;,citation_author=Manesh R. Patel;,citation_author=Deepak L. Bhatt;,citation_author=Stephan Windecker;,citation_author=Adrian F. Hernandez;,citation_author=C. Michael Gibson;,citation_author=John H. Alexander;,citation_author=Renato D. Lopes;,citation_publication_date=2020-08;,citation_cover_date=2020-08;,citation_year=2020;,citation_issue=5;,citation_doi=10.1016/j.jacc.2020.05.069;,citation_issn=07351097;,citation_volume=76;,citation_language=en-US;,citation_journal_title=Journal of the American College of Cardiology;">
<meta name="citation_reference" content="citation_title=Surgery or Endovascular Therapy for Chronic Limb-Threatening Ischemia;,citation_author=Alik Farber;,citation_author=Matthew T. Menard;,citation_author=Michael S. Conte;,citation_author=John A. Kaufman;,citation_author=Richard J. Powell;,citation_author=Niteesh K. Choudhry;,citation_author=Taye H. Hamza;,citation_author=Susan F. Assmann;,citation_author=Mark A. Creager;,citation_author=Mark J. Cziraky;,citation_author=Michael D. Dake;,citation_author=Michael R. Jaff;,citation_author=Diane Reid;,citation_author=Flora S. Siami;,citation_author=George Sopko;,citation_author=Christopher J. White;,citation_author=Max Over;,citation_author=Michael B. Strong;,citation_author=Maria F. Villarreal;,citation_author=Michelle McKean;,citation_author=Ezana Azene;,citation_author=Amir Azarbal;,citation_author=Andrew Barleben;,citation_author=David K. Chew;,citation_author=Leonardo C. Clavijo;,citation_author=Yvan Douville;,citation_author=Laura Findeiss;,citation_author=Nitin Garg;,citation_author=Warren Gasper;,citation_author=Kristina A. Giles;,citation_author=Philip P. Goodney;,citation_author=Beau M. Hawkins;,citation_author=Christine R. Herman;,citation_author=Jeffrey A. Kalish;,citation_author=Matthew C. Koopmann;,citation_author=Igor A. Laskowski;,citation_author=Carlos Mena-Hurtado;,citation_author=Raghu Motaganahalli;,citation_author=Vincent L. Rowe;,citation_author=Andres Schanzer;,citation_author=Peter A. Schneider;,citation_author=Jeffrey J. Siracuse;,citation_author=Maarit Venermo;,citation_author=Kenneth Rosenfield;,citation_publication_date=2022-11;,citation_cover_date=2022-11;,citation_year=2022;,citation_issue=0;,citation_doi=10.1056/NEJMoa2207899;,citation_issn=0028-4793;,citation_volume=0;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Mechanical thrombectomy decision making and prognostication: Stroke treatment Assessments prior to Thrombectomy In Neurointervention (SATIN) study;,citation_abstract=Background Mechanical thrombectomy (MT) is the standard-of-care treatment for stroke patients with emergent large vessel occlusions. Despite this, little is known about physician decision making regarding MT and prognostic accuracy. Methods A prospective multicenter cohort study of patients undergoing MT was performed at 11 comprehensive stroke centers. The attending neurointerventionalist completed a preprocedure survey prior to arterial access and identified key decision factors and the most likely radiographic and clinical outcome at 90 days. Post hoc review was subsequently performed to document hospital course and outcome. Results 299 patients were enrolled. Good clinical outcome (modified Rankin Scale (mRS) score of 0–2) was obtained in 38% of patients. The most frequently identified factors influencing the decision to proceed with thrombectomy were site of occlusion (81%), National Institutes of Health Stroke Scale score (74%), and perfusion imaging mismatch (43%). Premorbid mRS score determination in the hyperacute setting accurately matched retrospectively collected data from the hospital admission in only 140 patients (46.8%). Physicians correctly predicted the patient’s 90 day mRS tertile (0–2, 3–4, or 5–6) and final modified Thrombolysis in Ischemic Cerebral Infarction score preprocedure in only 44.2% and 44.3% of patients, respectively. Clinicians tended to overestimate the influence of occlusion site and perfusion imaging on outcomes, while underestimating the importance of pre-morbid mRS. Conclusions This is the first prospective study to evaluate neurointerventionalists’ ability to accurately predict clinical outcome after MT. Overall, neurointerventionalists performed poorly in prognosticating patient 90 day outcomes, raising ethical questions regarding whether MT should be withheld in patients with emergent large vessel occlusions thought to have a poor prognosis.;,citation_author=Kyle M. Fargen;,citation_author=Carol Kittel;,citation_author=Brian P. Curry;,citation_author=Connor W. Hile;,citation_author=Stacey Q. Wolfe;,citation_author=Patrick Brown;,citation_author=Maxim Mokin;,citation_author=Ansaar T. Rai;,citation_author=Michael Chen;,citation_author=Robert M. Starke;,citation_author=Felipe C. Albuquerque;,citation_author=Sameer A. Ansari;,citation_author=Peter Kan;,citation_author=Alejandro M. Spiotta;,citation_author=Guilherme Dabus;,citation_author=Thabele M. Leslie-Mazwi;,citation_author=Joshua A. Hirsch;,citation_publication_date=2023-01;,citation_cover_date=2023-01;,citation_year=2023;,citation_doi=10.1136/jnis-2022-019741;,citation_issn=1759-8478, 1759-8486;,citation_pmid=36609542;,citation_language=en-US;,citation_journal_title=Journal of NeuroInterventional Surgery;,citation_publisher=British Medical Journal Publishing Group;">
<meta name="citation_reference" content="citation_title=The Relationship between Serum Sodium, Serum Osmolality, and Intracranial Pressure in Patients with Traumatic Brain Injury Treated with Hyperosmolar Therapy;,citation_abstract=Background: Treatment of elevated intracranial pressure (ICP) in traumatic brain injury (TBI) is controversial. Hyperosmolar therapy is used to prevent cerebral edema in these patients. Many intensivists measure direct correlates of these agents—serum sodium and osmolality. We seek to provide context on the utility of using these measures to estimate ICP in TBI patients.;,citation_author=Paige Farley;,citation_author=Daniel Salisbury;,citation_author=John R Murfee;,citation_author=Colin T Buckley;,citation_author=Catherine N Taylor;,citation_author=Alissa Doll;,citation_author=Nathan M Polite;,citation_author=Maryann I Mbaka;,citation_author=Christopher M Kinnard;,citation_author=Charles Caleb Butts;,citation_author=Jon D Simmons;,citation_author=Yann-Leei L Lee;,citation_publication_date=2021-12;,citation_cover_date=2021-12;,citation_year=2021;,citation_doi=10.1177/00031348211058627;,citation_issn=0003-1348, 1555-9823;,citation_language=en-US;,citation_journal_title=The American Surgeon;">
<meta name="citation_reference" content="citation_title=The Hidden Side of Animal Cognition Research: Scientists’ Attitudes Toward Bias, Replicability and Scientific Practice;,citation_abstract=Animal cognition research aims to understand animal minds by using a diverse range of methods across an equally diverse range of species. Throughout its history, the field has sought to mitigate various biases that occur when studying animal minds, from experimenter effects to anthropomorphism. Recently, there has also been a focus on how common scientific practices might affect the reliability and validity of published research. Usually, these issues are discussed in the literature by a small group of scholars with a specific interest in the topics. This study aimed to survey a wider range of animal cognition researchers to ask about their attitudes towards classic and contemporary issues facing the field. Two-hundred and ten active animal cognition researchers completed our survey, and provided answers on questions relating to bias, replicability, statistics, publication, and belief in animal cognition. Collectively, researchers were wary of bias in the research field as a whole, but less so in their own work. Despite sometimes (39.7% of responses) or often (38.8% of responses) hoping for one result over another, researchers reported that they could often (45.8% of responses) or always (38.4% of responses) detach from any biases to perform objectively fair tests of animal cognition. Over 70% of researchers endorsed Morgan’s canon as a useful principle but many caveated this in their free-text responses, and researchers selfreported that a median of 80% of their studies had been published. Their free-text responses suggested a stronger publication bias against negative and inconclusive results, and results that questioned “preferred” theories. Researchers rarely reported having performed questionable research practices themselves — however they thought that other researchers sometimes (52.7% of responses) or often (27.9% of responses) perform them. Researchers near unanimously agreed that replication studies are important but too infrequently performed in animal cognition research, and 44.7% of researchers agreed that their own area (44.7% of responses), or other areas (73.0% of responses) of research could experience a “replication crisis” if replication studies were performed. Consistently, participants’ free-text responses provided a nuanced picture of the challenges animal cognition research faces, and highlighted many possible improvements. Overall, these data provide a picture of active researchers’ beliefs about the animal cognition research processes that can be used to inform debates on where and how the field can improve.;,citation_author=Benjamin Farrar;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Fluids and hyperosmolar agents in neurocritical care: An update;,citation_abstract=Purpose of review&nbsp; To discuss recent updates in fluid management and use of hyperosmolar therapy in neurocritical care. Recent findings&nbsp; Maintaining euvolemia with crystalloids seems to be the recommended fluid resuscitation for neurocritical care patients. Buffered crystalloids have been shown to reduce hyperchloremia in patients with subarachnoid hemorrhage without causing hyponatremia or hypo-osmolality. In addition, in patients with traumatic brain injury, buffered solutions reduce the incidence of hyperchloremic acidosis but are not associated with intracranial pressure (ICP) alteration. Both mannitol and hypertonic saline are established as effective hyperosmolar agents to control ICP. Both agents have been shown to control ICP, but their effects on neurologic outcomes are unclear. A recent surge in preference for using hypertonic saline as a hyperosmolar agent is based on few studies without strong evidence. Summary&nbsp; Fluid resuscitation with crystalloids seems to be reasonable in this setting although no recommendations can be made regarding type of crystalloids. Based on current evidence, elevated ICP can be effectively reduced by either hypertonic saline or mannitol.;,citation_author=Salia Farrokh;,citation_author=Sung-Min Cho;,citation_author=Jose I. Suarez;,citation_publication_date=2019-04;,citation_cover_date=2019-04;,citation_year=2019;,citation_issue=2;,citation_doi=10.1097/MCC.0000000000000585;,citation_issn=1070-5295;,citation_volume=25;,citation_language=en-US;,citation_journal_title=Current Opinion in Critical Care;">
<meta name="citation_reference" content="citation_title=Improved Prospects for Thrombectomy in Large Ischemic Stroke;,citation_abstract=Mechanical endovascular thrombectomy, when performed within 24 hours after the onset of symptoms in patients with small-to-moderate acute ischemic strokes that are due to proximal occlusion of a large cerebral vessel, has been shown to result in rates of recanalization of 70 to 80% and to significantly improve functional independence at 90 days.1,2 Thrombectomy represents one of the most effective treatments in medicine: the number needed to treat to prevent disability in one patient with stroke is 2.3. These results, however, do not apply to patients with large strokes, who have been mostly excluded from clinical trials of thrombectomy. Treatment . . .;,citation_author=Pierre Fayad;,citation_publication_date=2023-02;,citation_cover_date=2023-02;,citation_year=2023;,citation_issue=0;,citation_doi=10.1056/NEJMe2300193;,citation_issn=0028-4793;,citation_volume=0;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Evidence synthesis for constructing directed acyclic graphs (ESC-DAGs): A novel and systematic method for building directed acyclic graphs;,citation_abstract=Background: Directed acyclic graphs (DAGs) are popular tools for identifying appropriate adjustment strategies for epidemiological analysis. However, a lack of direction on how to build them is problematic. As a solution, we propose using a combination of evidence synthesis strategies and causal inference principles to integrate the DAG-building exercise within the review stages of research projects. We demonstrate this idea by introducing a novel protocol: “Evidence Synthesis for Constructing Directed Acyclic Graphs” (ESC-DAGs)’. Methods: ESC-DAGs operates on empirical studies identified by a literature search, ideally a novel systematic review or review of systematic reviews. It involves three key stages: (i) the conclusions of each study are “mapped” into a DAG; (ii) the causal structures in these DAGs are systematically assessed using several causal inference principles and are corrected accordingly; (iii) the resulting DAGs are then synthesised into one or more “integrated DAGs”. This demonstration article didactically applies ESC-DAGs to the literature on parental influences on offspring alcohol use during adolescence. Conclusions: ESC-DAGs is a practical, systematic and transparent approach for developing DAGs from background knowledge. These DAGs can then direct primary data analysis and DAG-based sensitivity analysis. ESC-DAGs has a modular design to allow researchers who are experienced DAG users to both use and improve upon the approach. It is also accessible to researchers with limited experience of DAGs or evidence synthesis.;,citation_author=Karl D Ferguson;,citation_author=Mark McCann;,citation_author=Srinivasa Vittal Katikireddi;,citation_author=Hilary Thomson;,citation_author=Michael J Green;,citation_author=Daniel J Smith;,citation_author=James D Lewsey;,citation_publication_date=2020-02;,citation_cover_date=2020-02;,citation_year=2020;,citation_issue=1;,citation_doi=10.1093/ije/dyz150;,citation_issn=0300-5771, 1464-3685;,citation_volume=49;,citation_language=en-US;,citation_journal_title=International Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Post-randomisation exclusions: The intention to treat principle and excluding patients from analysis;,citation_abstract=&amp;amp;amp;lt;p&amp;gt;&amp;lt;i&amp;gt;When is it legitimate to exclude randomised patients from the analysis of data in clinical trials? Basing their analysis on the desirability of minimising bias and random error, the authors consider the circumstances when it may be possible to exclude patients, even in an intention to treat trial</i></p>;,citation_author=Dean Fergusson;,citation_author=Shawn D. Aaron;,citation_author=Gordon Guyatt;,citation_author=Paul Hébert;,citation_publication_date=2002-09;,citation_cover_date=2002-09;,citation_year=2002;,citation_issue=7365;,citation_doi=10.1136/bmj.325.7365.652;,citation_issn=0959-8138, 1468-5833;,citation_pmid=12242181;,citation_volume=325;,citation_language=en-US;,citation_journal_title=BMJ;,citation_publisher=British Medical Journal Publishing Group;">
<meta name="citation_reference" content="citation_title=Surgery in Intracerebral Hemorrhage;,citation_abstract=Background and Purpose—Primary intracerebral hemorrhage (ICH) accounts for 10% to 20% of stroke but carries the highest rates of mortality and morbidity of all stroke subtypes. Current treatment, however, is varied and haphazard. The most recent Cochrane systematic review refers to 4 prospective, randomized controlled trials. We present a further meta-analysis to include 3 new trials. In addition, we review the trials of Chen et al and McKissock et al and discuss aspects of their quality that, we believe, prevent their inclusion in modern day meta-analysis. Methods—Literature databases and articles were searched from 1966 to October 1999. Using the end points of death and dependency, the results of the 7 identified randomized trials were expressed as odds ratios. All available data were then analyzed with meta-analysis techniques. Analysis of relevant subsets of trials was also carried out. Results—Meta-analysis of all 7 trials shows a trend toward a higher chance of death and dependency after surgery (OR 1.20; 95% CI 0.83 to 1.74). Meta-analysis was also carried out after exclusion of the Chen and McKissock trials for reasons discussed in the text. This meta-analysis suggests a benefit from surgery, with a reduction in the chances of death and dependency after surgical treatment by a factor of 0.63 (OR 0.63; 95% CI 0.35 to 1.14). Conclusions—When meta-analysis is restricted to modern-day, post-CT, well-constructed, balanced trials, a trend for surgery to reduce the chances of death and dependency is found. Perhaps, then, in the modern era of CT, good neuroanesthesia, intensive care, and the operating microscope, surgery has a role in the treatment of supratentorial intracerebral hemorrhage. The results of a large, multicenter, randomized controlled trial are urgently needed, and the ongoing International Surgical Trial of Intracerebral Hemorrhage should fulfill this objective.;,citation_author=H. M. Fernandes;,citation_author=B. Gregson;,citation_author=S. Siddique;,citation_author=A. D. Mendelow;,citation_publication_date=2000-10;,citation_cover_date=2000-10;,citation_year=2000;,citation_issue=10;,citation_doi=10.1161/01.STR.31.10.2511;,citation_volume=31;,citation_journal_title=Stroke;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=SER-109, an Oral Microbiome Therapy for Recurrent &amp;amp;amp;lt;i&amp;gt;Clostridioides&amp;lt;/i&amp;gt; <i>Difficile</i> Infection;,citation_abstract=BACKGROUND Current therapies for recurrent Clostridioides difficile infection do not address the disrupted microbiome, which supports C. difficile spore germination into toxinproducing bacteria. SER-109 is an investigational microbiome therapeutic composed of purified Firmicutes spores for the treatment of recurrent C. difficile infection. METHODS We conducted a phase 3, double-blind, randomized, placebo-controlled trial in which patients who had had three or more episodes of C. difficile infection (inclusive of the qualifying acute episode) received SER-109 or placebo (four capsules daily for 3 days) after standard-of-care antibiotic treatment. The primary efficacy objective was to show superiority of SER-109 as compared with placebo in reducing the risk of C. difficile infection recurrence up to 8 weeks after treatment. Diagnosis by toxin testing was performed at trial entry, and randomization was stratified according to age and antibiotic agent received. Analyses of safety, microbiome engraftment, and metabolites were also performed. RESULTS Among the 281 patients screened, 182 were enrolled. The percentage of patients with recurrence of C. difficile infection was 12% in the SER-109 group and 40% in the placebo group (relative risk, 0.32; 95% confidence interval [CI], 0.18 to 0.58; P&amp;amp;lt;0.001 for a relative risk of <1.0; P<0.001 for a relative risk of <0.833). SER-109 led to less frequent recurrence than placebo in analyses stratified according to age stratum (relative risk, 0.24 [95% CI, 0.07 to 0.78] for patients <65 years of age and 0.36 [95% CI, 0.18 to 0.72] for those \geq65 years) and antibiotic received (relative risk, 0.41 [95% CI, 0.22 to 0.79] with vancomycin and 0.09 [95% CI, 0.01 to 0.63] with fidaxomicin). Most adverse events were mild to moderate and were gastrointestinal in nature, with similar numbers in the two groups. SER-109 dose species were detected as early as week 1 and were associated with bile-acid profiles that are known to inhibit C. difficile spore germination. CONCLUSIONS In patients with symptom resolution of C. difficile infection after treatment with standard-of-care antibiotics, oral administration of SER-109 was superior to placebo in reducing the risk of recurrent infection. The observed safety profile of SER-109 was similar to that of placebo. (Funded by Seres Therapeutics; ECOSPOR III ClinicalTrials.gov number, NCT03183128.);,citation_author=Paul Feuerstadt;,citation_author=Thomas J. Louie;,citation_author=Bret Lashner;,citation_author=Elaine E. L. Wang;,citation_author=Liyang Diao;,citation_author=Jessica A. Bryant;,citation_author=Matthew Sims;,citation_author=Colleen S. Kraft;,citation_author=Stuart H. Cohen;,citation_author=Charles S. Berenson;,citation_author=Louis Y. Korman;,citation_author=Christopher B. Ford;,citation_author=Kevin D. Litcofsky;,citation_author=Mary-Jane Lombardo;,citation_author=Jennifer R. Wortman;,citation_author=Henry Wu;,citation_author=John G. Auniņš;,citation_author=Christopher W. J. McChalicher;,citation_author=Jonathan A. Winkler;,citation_author=Barbara H. McGovern;,citation_author=Michele Trucksis;,citation_author=Matthew R. Henn;,citation_author=Lisa Moltke;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=3;,citation_doi=10.1056/NEJMoa2106516;,citation_issn=0028-4793, 1533-4406;,citation_volume=386;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Against method;,citation_author=Paul Feyerabend;,citation_publication_date=1993;,citation_cover_date=1993;,citation_year=1993;,citation_isbn=978-0-86091-481-5 978-0-86091-646-8;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Beyond Low Tidal Volume Ventilation: Treatment Adjuncts for Severe Respiratory Failure in Acute Respiratory Distress Syndrome;,citation_author=Vikram Fielding-Singh;,citation_author=Michael A. Matthay;,citation_author=Carolyn S. Calfee;,citation_publication_date=2018-11;,citation_cover_date=2018-11;,citation_year=2018;,citation_issue=11;,citation_doi=10.1097/CCM.0000000000003406;,citation_issn=0090-3493;,citation_volume=46;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Community-Acquired Pneumonia;,citation_author=Thomas M. File;,citation_author=Julio A. Ramirez;,citation_publication_date=2023-08;,citation_cover_date=2023-08;,citation_year=2023;,citation_issue=7;,citation_doi=10.1056/NEJMcp2303286;,citation_issn=0028-4793;,citation_pmid=37585629;,citation_volume=389;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Balanced Multielectrolyte Solution versus Saline in Critically Ill Adults;,citation_abstract=BACKGROUND Whether the use of balanced multielectrolyte solution (BMES) in preference to 0.9% sodium chloride solution (saline) in critically ill patients reduces the risk of acute kidney injury or death is uncertain. METHODS In a double-blind, randomized, controlled trial, we assigned critically ill patients to receive BMES (Plasma-Lyte 148) or saline as fluid therapy in the intensive care unit (ICU) for 90 days. The primary outcome was death from any cause within 90 days after randomization. Secondary outcomes were receipt of new renal-replacement therapy and the maximum increase in the creatinine level during ICU stay. RESULTS A total of 5037 patients were recruited from 53 ICUs in Australia and New Zealand — 2515 patients were assigned to the BMES group and 2522 to the saline group. Death within 90 days after randomization occurred in 530 of 2433 patients (21.8%) in the BMES group and in 530 of 2413 patients (22.0%) in the saline group, for a difference of -0.15 percentage points (95% confidence interval [CI], -3.60 to 3.30; P = 0.90). New renal-replacement therapy was initiated in 306 of 2403 patients (12.7%) in the BMES group and in 310 of 2394 patients (12.9%) in the saline group, for a difference of -0.20 percentage points (95% CI, -2.96 to 2.56). The mean (SD) maximum increase in serum creatinine level was 0.411.06 mg per deciliter (36.694.0 \mumol per liter) in the BMES group and 0.411.02 mg per deciliter (36.190.0 \mumol per liter) in the saline group, for a difference of 0.01 mg per deciliter (95% CI, -0.05 to 0.06) (0.5 \mumol per liter [95% CI, -4.7 to 5.7]). The number of adverse and serious adverse events did not differ meaningfully between the groups. The authors’ affiliations are listed in the Appendix. Dr. Finfer can be contacted at sfinfer@georgeinstitute.org.au or at the George Institute for Global Health, 1 King St., Newtown, NSW 2042, Australia. *The Plasma-Lyte 148 versus Saline (PLUS) Study investigators are listed in the Supplementary Appendix, available at NEJM.org. This article was published on January 18, 2022, and updated on February 7, 2022, at NEJM.org. DOI: 10.1056/NEJMoa2114464 Copyright © 2022 Massachusetts Medical Society. CONCLUSIONS We found no evidence that the risk of death or acute kidney injury among critically ill adults in the ICU was lower with the use of BMES than with saline. (Funded by the National Health and Medical Research Council of Australia and the Health Research Council of New Zealand; PLUS ClinicalTrials.gov number, NCT02721654.);,citation_author=Simon Finfer;,citation_author=Sharon Micallef;,citation_author=Naomi Hammond;,citation_author=Leanlove Navarra;,citation_author=Rinaldo Bellomo;,citation_author=Laurent Billot;,citation_author=Anthony Delaney;,citation_author=Martin Gallagher;,citation_author=David Gattas;,citation_author=Qiang Li;,citation_author=Diane Mackle;,citation_author=Jayanthi Mysore;,citation_author=Manoj Saxena;,citation_author=Colman Taylor;,citation_author=Paul Young;,citation_author=John Myburgh;,citation_publication_date=2022-03;,citation_cover_date=2022-03;,citation_year=2022;,citation_issue=9;,citation_doi=10.1056/NEJMoa2114464;,citation_issn=0028-4793, 1533-4406;,citation_volume=386;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Clinical Research: From Case Reports to International Multicenter Clinical Trials;,citation_author=Simon Finfer;,citation_author=Deborah Cook;,citation_author=Flavia R. Machado;,citation_author=Anders Perner;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_doi=10.1097/CCM.0000000000005247;,citation_issn=0090-3493;,citation_volume=Publish Ahead of Print;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Crystalloid Composition and Rate of Fluid Administration When Resuscitating Patients in the Intensive Care Unit;,citation_abstract=To the Editor In their recent Editorial about the Balanced Solutions in Intensive Care Study (BaSICS), Drs Connor and Coopersmith speculate that the results from the BaSICS trial and the 0.9% Saline vs Plasma-Lyte 148 for ICU Fluid Therapy (SPLIT) trial may have been divergent from those of the Isotonic Solutions and Major Adverse Renal Events Trial (SMART) because the Plasma-Lyte 148 used in the BaSICS and SPLIT trials had a pH of 5.5, whereas the balanced fluid used in the SMART trial had a higher pH.However, the pH of Plasma-Lyte 148 solutions varies around the world. The pH of the Plasma-Lyte 148 solutions administered in both the BaSICS and SPLIT trials was 7.4, as was the pH of the Plasma-Lyte 148 administered in the recently completed Plasma-Lyte 148 v Saline (PLUS) study. Therefore, the concern that the pH of Plasma-Lyte 148 administered in these trials was responsible for the differences in the study outcomes is unfounded.;,citation_author=Simon Finfer;,citation_author=Fernando G. Zampieri;,citation_author=Paul J. Young;,citation_publication_date=2021-12;,citation_cover_date=2021-12;,citation_year=2021;,citation_issue=24;,citation_doi=10.1001/jama.2021.20279;,citation_issn=0098-7484;,citation_volume=326;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Resuscitation fluid use in critically ill adults: An international cross-sectional study in 391 intensive care units;,citation_abstract=Recent evidence suggests that choice of fluid used for resuscitation may influence mortality in critically ill patients.;,citation_author=Simon Finfer;,citation_author=Bette Liu;,citation_author=Colman Taylor;,citation_author=Rinaldo Bellomo;,citation_author=Laurent Billot;,citation_author=Deborah Cook;,citation_author=Bin Du;,citation_author=Colin McArthur;,citation_author=John Myburgh;,citation_author=SAFE TRIPS Investigators;,citation_publication_date=2010-10;,citation_cover_date=2010-10;,citation_year=2010;,citation_issue=5;,citation_doi=10.1186/cc9293;,citation_issn=1364-8535;,citation_volume=14;,citation_journal_title=Critical Care;">
<meta name="citation_reference" content="citation_title=Does hemispheric lateralization influence functional and cardiovascular outcomes after stroke?: An analysis of placebo-treated patients from prospective acute stroke trials;,citation_abstract=BACKGROUND AND PURPOSE: The influence of stroke lateralization on functional and cardiovascular outcome after stroke is not well established. We evaluated the influence of hemispheric lateralization among patients enrolled in prospective acute stroke trials. METHODS: We obtained data from the VISTA database for acute stroke trials which reported lateralization. Baseline data, cardiac adverse events, and 90-day outcomes were compared between right and left hemisphere stroke patients. A &amp;amp;amp;quot;hemisphere unbiased&amp;quot; subscore of the NIHSS which omitted items strongly associated with lateralized cognitive deficits was also compared for trials which reported individual NIHSS item scores. A multivariable analysis of outcome predictors was performed. RESULTS: Three acute stroke trials met the prespecified inclusion criteria. 1644 placebo-treated patients with documented hemispheric lateralization were included in the analysis. Baseline NIHSS was higher for left hemisphere patients (mean 16.2, versus 12.8 right, P&amp;lt;0.001); there was no difference in the &quot;hemisphere unbiased&quot; NIHSS subscore (10.88 left, 11.08 right, n=687, P=0.49). There was no difference between hemispheres in 90-day modified Rankin Score (3.43 left, 3.29 right, P=0.13), mortality (22.1% left, 19.5% right, P=0.20), or cardiac adverse events (P=0.71). Hemispheric lateralization was not an independent predictor of outcome in the multivariable analysis after controlling for the hemispheric bias intrinsic to the NIHSS. CONCLUSIONS: There is no difference in functional outcome between patients with right or left hemisphere stroke. Use of the baseline NIHSS score to predict stroke outcome must take hemispheric lateralization into account. Stroke lateralization is not an important predictor of cardiac adverse events or 90-day mortality.;,citation_author=John N. Fink;,citation_author=Christopher M. Frampton;,citation_author=Patrick Lyden;,citation_author=Kennedy R. Lees;,citation_author=Virtual International Stroke Trials Archive Investigators;,citation_publication_date=2008-12;,citation_cover_date=2008-12;,citation_year=2008;,citation_issue=12;,citation_doi=10.1161/STROKEAHA.108.523365;,citation_issn=1524-4628;,citation_pmid=18988910;,citation_volume=39;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=Mosquito Net Use in Early Childhood and Survival to Adulthood in Tanzania;,citation_abstract=BACKGROUND It has been hypothesized that in high-transmission settings, malaria control in early childhood (&amp;amp;amp;lt;5 years of age) might delay the acquisition of functional immunity and shift child deaths from younger to older ages. METHODS We used data from a 22-year prospective cohort study in rural southern Tanzania to estimate the association between early-life use of treated nets and survival to adulthood. All the children born between January 1, 1998, and August 30, 2000, in the study area were invited to enroll in a longitudinal study from 1998 through 2003. Adult survival outcomes were verified in 2019 through community outreach and mobile telephones. We used Cox proportional-hazards models to estimate the association between the use of treated nets in early childhood and survival to adulthood, adjusting for potential confounders. RESULTS A total of 6706 children were enrolled. In 2019, we verified information on the vital status of 5983 participants (89%). According to reports of early-life community outreach visits, approximately one quarter of children never slept under a treated net, one half slept under a treated net some of the time, and the remaining quarter always slept under a treated net. Participants who were reported to have used treated nets at half the early-life visits or more had a hazard ratio for death of 0.57 (95% confidence interval [CI], 0.45 to 0.72) as compared with those who were reported to have used treated nets at less than half the visits. The corresponding hazard ratio between 5 years of age and adulthood was 0.93 (95% CI, 0.58 to 1.49). CONCLUSIONS In this long-term study of early-life malaria control in a high-transmission setting, the survival benefit from early-life use of treated nets persisted to adulthood. (Funded by the Eckenstein-Geigy Professorship and others.);,citation_author=Günther Fink;,citation_author=Sigilbert Mrema;,citation_author=Salim Abdulla;,citation_author=S. Patrick Kachur;,citation_author=Rashid Khatib;,citation_author=Christian Lengeler;,citation_author=Honorati Masanja;,citation_author=Fredros Okumu;,citation_author=Joanna Schellenberg;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_issue=5;,citation_doi=10.1056/NEJMoa2112524;,citation_issn=0028-4793, 1533-4406;,citation_volume=386;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=The Clinician and Dataset Shift in Artificial Intelligence;,citation_author=Samuel G. Finlayson;,citation_author=Adarsh Subbaswamy;,citation_author=Karandeep Singh;,citation_author=John Bowers;,citation_author=Annabel Kupke;,citation_author=Jonathan Zittrain;,citation_author=Isaac S. Kohane;,citation_author=Suchi Saria;,citation_publication_date=2021-07;,citation_cover_date=2021-07;,citation_year=2021;,citation_issue=3;,citation_doi=10.1056/NEJMc2104626;,citation_issn=0028-4793, 1533-4406;,citation_volume=385;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=SpPin and SnNout Are Not Enough. It’s Time to Fully Embrace Likelihood Ratios and Probabilistic Reasoning to Achieve Diagnostic Excellence;,citation_author=Brett G. Fischer;,citation_author=Arthur T. Evans;,citation_publication_date=2023-04;,citation_cover_date=2023-04;,citation_year=2023;,citation_doi=10.1007/s11606-023-08177-5;,citation_issn=1525-1497;,citation_language=en-US;,citation_journal_title=Journal of General Internal Medicine;">
<meta name="citation_reference" content="citation_title=The Challenge of Designing a Treatment Trial for Warfarin-Associated Intracerebral Hemorrhage;,citation_abstract=Background and Purpose— Warfarin-associated intracerebral hemorrhage (WICH) became more frequent in the past 2 decades. Interest in potential WICH treatment trials has grown, but the practicality of such trials has received less attention. We determined the number of patients that would be eligible for enrollment in hypothetical treatment trials for WICH using a population-based study. Methods— We identified all patients aged 18 years or older from the Greater Cincinnati/Northern Kentucky region with nontraumatic intracerebral hemorrhage in 2005. Three hypothetical WICH treatment trial criteria sets were used to determine eligibility for enrollment, varying from relatively strict to broadly inclusive. For the hypothetical trials, we assumed the comparison of a standard therapy to an alternative therapy. Sample size calculations assumed different rates of poor outcome depending on the criteria set, various effect sizes, a 2-sided alpha of 0.05, and 80% power. Given 5 years of trial enrollment, the population base needed to enroll the required subjects was then calculated. Results— Warfarin-associated intracerebral hemorrhage accounted for 54 of 286 (19%) cases of intracerebral hemorrhage within the Greater Cincinnati/Northern Kentucky region in 2005. Eligibility rates ranged from 2 of 54 WICH patients (4% of cases, strictest set) to 11 of 54 WICH patients (20% of cases, most inclusive set). Given these rates, a population base of at least 67 million persons would be required to conduct a 5-year trial for WICH with a 10% effect size using a moderately strict criteria set. Conclusions— Any planned treatment trial for WICH should anticipate significant challenges in successfully enrolling adequate numbers of patients.;,citation_author=Matthew L. Flaherty;,citation_author=Opeolu Adeoye;,citation_author=Padmini Sekar;,citation_author=Mary Haverbusch;,citation_author=Charles J. Moomaw;,citation_author=Haiyang Tao;,citation_author=Joseph P. Broderick;,citation_author=Daniel Woo;,citation_publication_date=2009-05;,citation_cover_date=2009-05;,citation_year=2009;,citation_issue=5;,citation_doi=10.1161/STROKEAHA.108.538462;,citation_volume=40;,citation_journal_title=Stroke;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=In search of the perfect outcome in neuroanaesthesia and neurocritical care;,citation_author=A. M. Flexman;,citation_author=A. Tung;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=S1;,citation_doi=10.1111/anae.15637;,citation_issn=0003-2409, 1365-2044;,citation_volume=77;,citation_language=en-US;,citation_journal_title=Anaesthesia;">
<meta name="citation_reference" content="citation_title=Bayesian Approach to Bioequivalence Assessment: An Example;,citation_author=H. Fluehler;,citation_author=A. P. Grieve;,citation_author=D. Mandallaz;,citation_author=J. Mau;,citation_author=H. A. Moser;,citation_publication_date=1983-10;,citation_cover_date=1983-10;,citation_year=1983;,citation_issue=10;,citation_doi=10.1002/jps.2600721018;,citation_issn=00223549;,citation_volume=72;,citation_language=en-US;,citation_journal_title=Journal of Pharmaceutical Sciences;">
<meta name="citation_reference" content="citation_title=Stepwise Ventilator Waveform Assessment to Diagnose Pulmonary Pathophysiology;,citation_abstract=Electronically displayed ventilator waveforms provide a wealth of insight into the physiology of the respiratory system. Pressure and flow values can be independent variables that reflect control by the ventilator or dependent variables that demonstrate the respiratory system’s response to mechanical ventilation. Diagrams of time-based pressure and flow curves may reveal underlying pathophysiology beyond more commonly assessed parameters such as peak airway pressure, respiratory rate, and tidal volume. In this narrative review, we introduce a stepwise approach clinicians can take to diagnose pulmonary pathophysiology by using ventilator waveforms in patients receiving pressure control ventilation or volume control ventilation. Understanding a patient’s pathophysiology (i.e., increased airway resistance) does not distinguish pathology (i.e., kinked endotracheal tube or bronchospasm). A pathology such as pulmonary edema may have more than one pathophysiologic process (i.e., increased airway resistance and low respiratory compliance). To interpret ventilator waveforms, we assume a one-compartment lung model with a linear response to a range of tidal volumes.1 We do not discuss identification of ventilation mode or adaptive ventilation.2;,citation_author=Brigid C. Flynn;,citation_author=Haley G. Miranda;,citation_author=Aaron M. Mittel;,citation_author=Vivek K. Moitra;,citation_publication_date=2022-07;,citation_cover_date=2022-07;,citation_year=2022;,citation_issue=1;,citation_doi=10.1097/ALN.0000000000004220;,citation_issn=0003-3022;,citation_volume=137;,citation_journal_title=Anesthesiology;">
<meta name="citation_reference" content="citation_title=Eligibility for Randomized Trials of Treatments Specifically for Intracerebral Hemorrhage;,citation_abstract=Background and Purpose— Acute treatments specifically for intracerebral hemorrhage (ICH) are being sought in randomized controlled trials. The treatment effect sizes in ongoing and future trials are likely to be small, necessitating large sample sizes. Methods— We searched online trial registries for randomized controlled trials investigating an acute treatment for ICH. For the trials whose eligibility criteria could be assessed in a prospective, community-based ICH cohort study (2010–2011), we quantified the proportions of patients who were eligible and investigated influences on these proportions. Results— We applied the eligibility criteria of 17 trials to 166 adults with ICH, of whom between 0.6% (95% confidence interval, 0.1–3.3) to 40% (95% confidence interval, 33–48) were eligible for each trial. Fewer patients were eligible for trials restricted to patients randomized within 12 hours of ICH onset (versus trials with a longer time window; P=0.03) and trials restricting eligibility according to premorbid disability (versus trials without this restriction; P=0.046). Each additional eligibility criterion reduced the portion of eligible patients by 1.3% (95% confidence interval, 0.4–2.2; adjusted R2=0.47; P=0.004). Conclusions— Less than half of patients with ICH were eligible for current randomized controlled trials. Future trials could maximize enrollment by minimizing the number of eligibility criteria, maximizing the time window for recruiting patients after ICH onset, permitting premorbid disability, and using a simulator to assess the impact of other eligibility critiera (www.dcn.ed.ac.uk/ICHsimulator/).;,citation_author=Arthur F. Fonville;,citation_author=Neshika Samarasekera;,citation_author=Aidan Hutchison;,citation_author=David Perry;,citation_author=Yvo B. Roos;,citation_author=Rustam Al-Shahi Salman;,citation_publication_date=2013-10;,citation_cover_date=2013-10;,citation_year=2013;,citation_issue=10;,citation_doi=10.1161/STROKEAHA.113.001493;,citation_volume=44;,citation_journal_title=Stroke;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=The Pathophysiology of Delayed Cerebral Ischemia;,citation_abstract=Summary:&nbsp; Subarachnoid hemorrhage (SAH) affects 30,000 people in the Unites States alone each year. Delayed cerebral ischemia occurs days after subarachnoid hemorrhage and represents a potentially treatable cause of morbidity for approximately one-third of those who survive the initial hemorrhage. While vasospasm has been traditionally linked to the development of cerebral ischemia several days after subarachnoid hemorrhage, emerging evidence reveals that delayed cerebral ischemia is part of a much more complicated post–subarachnoid hemorrhage syndrome. The development of delayed cerebral ischemia involves early arteriolar vasospasm with microthrombosis, perfusion mismatch and neurovascular uncoupling, spreading depolarizations, and inflammatory responses that begin at the time of the hemorrhage and evolve over time, culminating in cortical infarction. Large-vessel vasospasm is likely a late contributor to ongoing injury, and effective treatment for delayed cerebral ischemia will require improved detection of critical early pathophysiologic changes as well as therapeutic options that target multiple related pathways.;,citation_author=Brandon Foreman;,citation_publication_date=2016-06;,citation_cover_date=2016-06;,citation_year=2016;,citation_issue=3;,citation_doi=10.1097/WNP.0000000000000273;,citation_issn=0736-0258;,citation_volume=33;,citation_language=en-US;,citation_journal_title=Journal of Clinical Neurophysiology;">
<meta name="citation_reference" content="citation_title=Diagnostic and therapeutic approach to fungal pneumonia in the critically ill patient;,citation_abstract=Aspergillus spp. is the fungus most frequently producing ventilator-associated pneumonia (VAP), constituting 8% of them. This risk is significantly increased in onco-hematological patients: solid organ transplant recipients, chronic obstructive pulmonary disease (COPD), corticotherapy, cirrhosis, solid cancer, or viral pneumonias. The European Organization for Research and Treatment of Cancer Mycoses (EORT/MSG criteria) developed for onco-hematological patients with angioinvasive forms of aspergillosis have important limitations for broncho-pulmonary forms, such as aspergillosis cases in the ICU. In recent years, new diagnostic criteria were developed to have a greater role in broncho-alveolar lavage, especially GM and lateral flow assay (LFA). Voriconazole and isavuconazole are the first treatment option. However, drug-drug interaction, level requirements, toxicity, and QT-interval modification are limitations that may favor isavuconazole or liposomal amphotercin B in the ICU.;,citation_author=Jesús Fortún;,citation_publication_date=2022-04;,citation_cover_date=2022-04;,citation_year=2022;,citation_issue=Suppl1;,citation_doi=10.37201/req/s01.21.2022;,citation_issn=02143429, 19889518;,citation_volume=35;,citation_language=en-US;,citation_journal_title=Revista Española de Quimioterapia;">
<meta name="citation_reference" content="citation_title=Effect of Deferoxamine on Trajectory of Recovery After Intracerebral Hemorrhage: A Post Hoc Analysis of the i-DEF Trial;,citation_abstract=Background: There are limited data on the trajectory of recovery and long-term functional outcomes after intracerebral hemorrhage (ICH). Most ICH trials have conventionally assessed outcomes at 3 months following the footsteps of ischemic stroke. The i-DEF trial (Intracerebral Hemorrhage Deferoxamine Trial) assessed modified Rankin Scale (mRS) longitudinally at prespecified time points from day 7 through the end of the 6-month follow-up period. We evaluated the trajectory of mRS among trial participants and examined the effect of deferoxamine on this trajectory. Methods: We performed a post hoc analysis of the i-DEF trial, a multicenter, randomized, placebo-controlled, double-blind, futility-design, phase 2 clinical trial, based on the actual treatment received. Favorable outcome was defined as mRS score of 0–2. A generalized linear mixed model was used to evaluate the outcome trajectory over time, as well as whether the trajectory was altered by deferoxamine, after adjustments for randomization variables, presence of intraventricular hemorrhage, and ICH location. Results: A total of 291 subjects were included in analysis (145 placebo and 146 deferoxamine). The proportion of patients with mRS score of 0–2 continually increased from day 7 to 180 in both groups (interaction P&amp;amp;amp;lt;0.0001 for time in main effects model), but treatment with deferoxamine favorably altered the trajectory (interaction P=0.0010). Between day 90 and 180, the deferoxamine group improved (P=0.0001), whereas there was not significant improvement in the placebo arm (P=0.3005). Conclusions: A large proportion of patients continue to improve up to 6 months after ICH. Future ICH trials should assess outcomes past 90 days for a minimum of 6 months. In i-DEF, treatment with deferoxamine seemed to accelerate and alter the trajectory of recovery as assessed by mRS. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02175225.;,citation_author=Lydia Foster;,citation_author=Laura Robinson;,citation_author=Sharon D. Yeatts;,citation_author=Robin A. Conwit;,citation_author=Amjad Shehadah;,citation_author=Vasileios Lioutas;,citation_author=Magdy Selim;,citation_author=null null;,citation_publication_date=2022-07;,citation_cover_date=2022-07;,citation_year=2022;,citation_issue=7;,citation_doi=10.1161/STROKEAHA.121.037298;,citation_volume=53;,citation_journal_title=Stroke;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial;,citation_abstract=Experimental data suggest that intravenous vitamin C may attenuate inflammation and vascular injury associated with sepsis and acute respiratory distress syndrome (ARDS).To determine the effect of intravenous vitamin C infusion on organ failure scores and biological markers of inflammation and vascular injury in patients with sepsis and ARDS.The CITRIS-ALI trial was a randomized, double-blind, placebo-controlled, multicenter trial conducted in 7 medical intensive care units in the United States, enrolling patients (N = 167) with sepsis and ARDS present for less than 24 hours. The study was conducted from September 2014 to November 2017, and final follow-up was January 2018.Patients were randomly assigned to receive intravenous infusion of vitamin C (50 mg/kg in dextrose 5% in water, n = 84) or placebo (dextrose 5% in water only, n = 83) every 6 hours for 96 hours.The primary outcomes were change in organ failure as assessed by a modified Sequential Organ Failure Assessment score (range, 0-20, with higher scores indicating more dysfunction) from baseline to 96 hours, and plasma biomarkers of inflammation (C-reactive protein levels) and vascular injury (thrombomodulin levels) measured at 0, 48, 96, and 168 hours.Among 167 randomized patients (mean [SD] age, 54.8 years [16.7]; 90 men [54%]), 103 (62%) completed the study to day 60. There were no significant differences between the vitamin C and placebo groups in the primary end points of change in mean modified Sequential Organ Failure Assessment score from baseline to 96 hours (from 9.8 to 6.8 in the vitamin C group [3 points] and from 10.3 to 6.8 in the placebo group [3.5 points]; difference, -0.10; 95% CI, -1.23 to 1.03; P = .86) or in C-reactive protein levels (54.1 vs 46.1 \mug/mL; difference, 7.94 \mug/mL; 95% CI, -8.2 to 24.11; P = .33) and thrombomodulin levels (14.5 vs 13.8 ng/mL; difference, 0.69 ng/mL; 95% CI, -2.8 to 4.2; P = .70) at 168 hours.In this preliminary study of patients with sepsis and ARDS, a 96-hour infusion of vitamin C compared with placebo did not significantly improve organ dysfunction scores or alter markers of inflammation and vascular injury. Further research is needed to evaluate the potential role of vitamin C for other outcomes in sepsis and ARDS.ClinicalTrials.gov Identifier: NCT02106975;,citation_author=Alpha A. Fowler;,citation_author=Jonathon D. Truwit;,citation_author=R. Duncan Hite;,citation_author=Peter E. Morris;,citation_author=Christine DeWilde;,citation_author=Anna Priday;,citation_author=Bernard Fisher;,citation_author=Leroy R. Thacker;,citation_author=Ramesh Natarajan;,citation_author=Donald F. Brophy;,citation_author=Robin Sculthorpe;,citation_author=Rahul Nanchal;,citation_author=Aamer Syed;,citation_author=Jamie Sturgill;,citation_author=Greg S. Martin;,citation_author=Jonathan Sevransky;,citation_author=Markos Kashiouris;,citation_author=Stella Hamman;,citation_author=Katherine F. Egan;,citation_author=Andrei Hastings;,citation_author=Wendy Spencer;,citation_author=Shawnda Tench;,citation_author=Omar Mehkri;,citation_author=James Bindas;,citation_author=Abhijit Duggal;,citation_author=Jeanette Graf;,citation_author=Stephanie Zellner;,citation_author=Lynda Yanny;,citation_author=Catherine McPolin;,citation_author=Tonya Hollrith;,citation_author=David Kramer;,citation_author=Charles Ojielo;,citation_author=Tessa Damm;,citation_author=Evan Cassity;,citation_author=Aleksandra Wieliczko;,citation_author=Matthew Halquist;,citation_publication_date=2019-10;,citation_cover_date=2019-10;,citation_year=2019;,citation_issue=13;,citation_doi=10.1001/jama.2019.11825;,citation_issn=0098-7484;,citation_volume=322;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Comparison of Lurasidone Versus Quetiapine for the Treatment of Delirium in Critically Ill Patients;,citation_abstract=Objective: To evaluate the efficacy and safety of lurasidone compared with quetiapine for treatment of delirium in critically ill patients. Design: Prospective, observational cohort study. Setting: Single-center community teaching hospital. Patients: Forty adult intensive care unit (ICU) patients with delirium (Confusion Assessment Method in the ICU positive), tolerating enteral nutrition, and without active alcohol withdrawal or prior use of atypical antipsychotics. Interventions: Patients were treated at the discretion of the prescriber with either lurasidone or quetiapine for delirium. Dose escalation and/or discontinuation were determined at the discretion of individual providers. Results: Baseline characteristics differed with a higher severity of illness in patients in the quetiapine group (n \frac{1}{4} 20) and a higher baseline QTc interval in the lurasidone group (n \frac{1}{4} 20). No significant difference was seen in the time to delirium resolution (3.2 vs 3.4 days), average daily haloperidol requirements (5.7 vs 6.9 mg), hospital length of stay (LOS; 23.6 vs 27.9 days), or ICU LOS (12.1 vs 14.2 days). Lurasidone was associated with fewer ventilator support days (4.0 [interquartile range, IQR: 2.3-6.8] days vs 7 [IQR: 4.0-9.8; P \frac{1}{4} .0295] days) but also a fewer number of deliriumfree days (0 [IQR: 0-1.0] days vs 2 [IQR: 0-3.0; P \frac{1}{4} .0231] days). Additionally, no difference was seen for ICU mortality (20% vs 20%), percentage of time oversedated (2.8% vs 2.7%), or incidence of QTc prolongation (10.0% vs 10.0%). Conclusions: Lurasidone for the treatment of delirium in critically ill patients did not differ in the time to delirium resolution when compared to quetiapine. Additionally, the incidence of QTc prolongation between agents does not appear to be different. Future randomized trials should evaluate dose escalation schemes and a larger proportion of patients to evaluate differences in mortality, efficacy, and life-threatening arrhythmias associated with atypical antipsychotic use.;,citation_author=Marlena A. Fox;,citation_author=Jessica L. Elefritz;,citation_author=Brandon M. Huang;,citation_author=Charles Hunley;,citation_publication_date=2020-04;,citation_cover_date=2020-04;,citation_year=2020;,citation_issue=4;,citation_doi=10.1177/0885066617754187;,citation_issn=0885-0666, 1525-1489;,citation_volume=35;,citation_language=en-US;,citation_journal_title=Journal of Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Illustrating How to Simulate Data From Directed Acyclic Graphs to Understand Epidemiologic Concepts;,citation_abstract=Abstract Simulation methods are a powerful set of tools that can allow researchers to better characterize phenomena from the real world. As such, the ability to simulate data represents a critical set of skills that epidemiologists should use to better understand epidemiologic concepts and ensure that they have the tools to continue to self-teach even when their formal instruction ends. Simulation methods are not always taught in epidemiology methods courses, whereas causal directed acyclic graphs (DAGs) often are. Therefore, this paper details an approach to building simulations from DAGs and provides examples and code for learning to perform simulations. We recommend using very simple DAGs to learn the procedures and code necessary to set up a simulation that builds on key concepts frequently of interest to epidemiologists (e.g., mediation, confounding bias, M bias). We believe that following this approach will allow epidemiologists to gain confidence with a critical skill set that may in turn have a positive impact on how they conduct future epidemiologic studies.;,citation_author=Matthew P Fox;,citation_author=Roch Nianogo;,citation_author=Jacqueline E Rudolph;,citation_author=Chanelle J Howe;,citation_publication_date=2022-03;,citation_cover_date=2022-03;,citation_year=2022;,citation_doi=10.1093/aje/kwac041;,citation_issn=0002-9262, 1476-6256;,citation_language=en-US;,citation_journal_title=American Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=On the Need to Revitalize Descriptive Epidemiology;,citation_abstract=Nearly every introductory epidemiology course begins with a focus on person, place, and time, the key components of descriptive epidemiology. And yet in our experience, introductory epidemiology courses were the last time we spent any significant amount of training time focused on descriptive epidemiology. This gave us the impression that descriptive epidemiology does not suffer from bias and is less impactful than causal epidemiology. Descriptive epidemiology may also suffer from a lack of prestige in academia and may be more difficult to fund. We believe this does a disservice to the field and slows progress towards goals of improving population health and ensuring equity in health. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak and subsequent coronavirus disease 2019 pandemic have highlighted the importance of descriptive epidemiology in responding to serious public health crises. In this commentary, we make the case for renewed focus on the importance of descriptive epidemiology in the epidemiology curriculum using SARS-CoV-2 as a motivating example. The framework for error we use in etiological research can be applied in descriptive research to focus on both systematic and random error. We use the current pandemic to illustrate differences between causal and descriptive epidemiology and areas where descriptive epidemiology can have an important impact.;,citation_author=Matthew P Fox;,citation_author=Eleanor J Murray;,citation_author=Catherine R Lesko;,citation_author=Shawnita Sealy-Jefferson;,citation_publication_date=2022-03;,citation_cover_date=2022-03;,citation_year=2022;,citation_issue=7;,citation_doi=10.1093/aje/kwac056;,citation_issn=0002-9262;,citation_pmid=35325036;,citation_volume=191;,citation_journal_title=American Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=The case for intervention Bias in the Practice of Medicine;,citation_author=Andrew J Foy;,citation_author=Edward J Filippone;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Imaging Predictors of Vasospasm and Delayed Cerebral Ischaemia After Subarachnoid Haemorrhage;,citation_abstract=Acute spontaneous subarachnoid haemorrhage (SAH) is a severe disease, frequently complicated by vasospasm and delayed cerebral ischaemia (DCI), which have a negative impact on prognosis. Imaging studies are essential in the diagnosis of SAH. In this article, we review the available imaging techniques for prediction, monitoring and diagnosis of these complications of SAH.;,citation_author=Isabel Fragata;,citation_author=Bruno Cunha;,citation_author=Patrícia Canhão;,citation_publication_date=2020-11;,citation_cover_date=2020-11;,citation_year=2020;,citation_issue=12;,citation_doi=10.1007/s11940-020-00653-1;,citation_issn=1534-3138;,citation_volume=22;,citation_language=en-US;,citation_journal_title=Current Treatment Options in Neurology;">
<meta name="citation_reference" content="citation_title=Acute Blood Pressure and Outcome After Intracerebral Hemorrhage: The VISTA-ICH Cohort;,citation_author=Charles L Francoeur;,citation_author=Stephan A Mayer;,citation_publication_date=2021-01;,citation_cover_date=2021-01;,citation_year=2021;,citation_issue=1;,citation_doi=10.1016/j.jstrokecerebrovasdis.2020.105456;,citation_issn=10523057;,citation_volume=30;,citation_language=en-US;,citation_journal_title=Journal of Stroke and Cerebrovascular Diseases;">
<meta name="citation_reference" content="citation_title=Management of delayed cerebral ischemia after subarachnoid hemorrhage;,citation_author=Charles L. Francoeur;,citation_author=Stephan A. Mayer;,citation_publication_date=2016-12;,citation_cover_date=2016-12;,citation_year=2016;,citation_issue=1;,citation_doi=10.1186/s13054-016-1447-6;,citation_issn=1364-8535;,citation_volume=20;,citation_language=en-US;,citation_journal_title=Critical Care;">
<meta name="citation_reference" content="citation_title=Prevention of Early Ventilator-Associated Pneumonia after Cardiac Arrest;,citation_author=Bruno François;,citation_author=Alain Cariou;,citation_author=Raphaël Clere-Jehl;,citation_author=Pierre-François Dequin;,citation_author=Françoise Renon-Carron;,citation_author=Thomas Daix;,citation_author=Christophe Guitton;,citation_author=Nicolas Deye;,citation_author=Stéphane Legriel;,citation_author=Gaëtan Plantefève;,citation_author=Jean-Pierre Quenot;,citation_author=Arnaud Desachy;,citation_author=Toufik Kamel;,citation_author=Sandrine Bedon-Carte;,citation_author=Jean-Luc Diehl;,citation_author=Nicolas Chudeau;,citation_author=Elias Karam;,citation_author=Isabelle Durand-Zaleski;,citation_author=Bruno Giraudeau;,citation_author=Philippe Vignon;,citation_author=Amélie Le Gouge;,citation_publication_date=2019-11;,citation_cover_date=2019-11;,citation_year=2019;,citation_issue=19;,citation_doi=10.1056/NEJMoa1812379;,citation_issn=0028-4793;,citation_volume=381;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative;,citation_abstract=Background: Regulators are evaluating the use of non-interventional real-world evidence (RWE) studies to assess the effectiveness of medical products. The RCT-DUPLICATE initiative uses a structured process to design RWE studies emulating randomized controlled trials (RCTs) and compare results. Here, we report findings of the first 10 trial emulations, evaluating cardiovascular outcomes of antidiabetic or antiplatelet medications. Methods: We selected 3 active-controlled and 7 placebo-controlled RCTs for replication. Using patient-level claims data from US commercial and Medicare payers, we implemented inclusion/exclusion criteria, selected primary endpoints, and comparator populations to emulate those of each corresponding RCT. Within the trial-mimicking populations, we conducted propensity score matching to control for &amp;amp;amp;gt;120 pre-exposure confounders. All study parameters were prospectively defined and protocols registered before hazard ratios (HRs) and 95% confidence intervals (CIs) were computed. Success criteria for the primary analysis were prespecified for each replication. Results: Despite attempts to emulate RCT design as closely as possible, differences between the RCT and corresponding RWE study populations remained. The regulatory conclusions were equivalent in 6 of 10. The RWE emulations achieved a HR estimate that was within the 95% CI from the corresponding RCT in 8 of 10 studies. In 9 of 10, either the regulatory or estimate agreement success criteria were fulfilled. The largest differences in effect estimates were found for RCTs where second-generation sulfonylureas were used as a proxy for placebo regarding cardiovascular effects. Nine of 10 replications had a standardized difference between effect estimates of &amp;lt;2, which suggests differences within expected random variation. Conclusions: Agreement between RCT and RWE findings varies depending on which agreement metric is used. Interim findings indicate that selection of active comparator therapies with similar indications and use patterns enhances the validity of RWE. Even in the context of active comparators, concordance between RCT and RWE findings is not guaranteed, partially because trials are not emulated exactly. More trial emulations are needed to understand how often and in what contexts RWE findings match RCTs. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifiers: NCT03936049, NCT04215523, NCT04215536, NCT03936010, NCT03936036, NCT03936062, NCT03936023, NCT03648424, NCT04237935, NCT04237922;,citation_author=Jessica M. Franklin;,citation_author=Elisabetta Patorno;,citation_author=Rishi J. Desai;,citation_author=Robert J. Glynn;,citation_author=David Martin;,citation_author=Kenneth Quinto;,citation_author=Ajinkya Pawar;,citation_author=Lily G. Bessette;,citation_author=Hemin Lee;,citation_author=Elizabeth M. Garry;,citation_author=Nileesa Gautam;,citation_author=Sebastian Schneeweiss;,citation_publication_date=2021-03;,citation_cover_date=2021-03;,citation_year=2021;,citation_issue=10;,citation_doi=10.1161/CIRCULATIONAHA.120.051718;,citation_issn=0009-7322, 1524-4539;,citation_volume=143;,citation_language=en-US;,citation_journal_title=Circulation;">
<meta name="citation_reference" content="citation_title=When Can Nonrandomized Studies Support Valid Inference Regarding Effectiveness or Safety of New Medical Treatments?;,citation_author=Jessica M. Franklin;,citation_author=Richard Platt;,citation_author=Nancy A. Dreyer;,citation_author=Alex John London;,citation_author=Gregory E. Simon;,citation_author=Jonathan H. Watanabe;,citation_author=Michael Horberg;,citation_author=Adrian Hernandez;,citation_author=Robert M. Califf;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=1;,citation_doi=10.1002/cpt.2255;,citation_issn=0009-9236, 1532-6535;,citation_volume=111;,citation_language=en-US;,citation_journal_title=Clinical Pharmacology &amp;amp;amp; Therapeutics;">
<meta name="citation_reference" content="citation_title=The &amp;amp;amp;lt;i&amp;gt;p&amp;lt;/i&amp;gt; -value Function and Statistical Inference;,citation_abstract=This article has two objectives. The first and narrower is to formalize the p-value function, which records all possible p-values, each corresponding to a value for whatever the scalar parameter of interest is for the problem at hand, and to show how this p-value function directly provides full inference information for any corresponding user or scientist. The p-value function provides familiar inference objects: significance levels, confidence intervals, critical values for fixed-level tests, and the power function at all values of the parameter of interest. It thus gives an immediate accurate and visual summary of inference information for the parameter of interest. We show that the p-value function of the key scalar interest parameter records the statistical position of the observed data relative to that parameter, and we then describe an accurate approximation to that p-value function which is readily constructed.;,citation_author=D. A. S. Fraser;,citation_publication_date=2019-03;,citation_cover_date=2019-03;,citation_year=2019;,citation_issue=sup1;,citation_doi=10.1080/00031305.2018.1556735;,citation_issn=0003-1305, 1537-2731;,citation_volume=73;,citation_language=en-US;,citation_journal_title=The American Statistician;">
<meta name="citation_reference" content="citation_title=Antithrombotic Therapy After Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation;,citation_abstract=BACKGROUND Pivotal trials of percutaneous left atrial appendage occlusion (LAAO) used specific postprocedure treatment protocols. OBJECTIVES This study sought to evaluate patterns of postprocedure care after LAAO with the Watchman device in clinical practice and compare the risk of adverse events for different discharge antithrombotic strategies. METHODS We evaluated patients in the LAAO Registry of the National Cardiovascular Data Registry who underwent LAAO with the Watchman device between 2016 and 2018. We assessed adherence to the full postprocedure trial protocol including standardized follow-up, imaging, and antithrombotic agents and then evaluated the most commonly used antithrombotic strategies and compared the rates and risk of adverse events at 45 days and 6 months by means of multivariable COX frailty regression. RESULTS Among 31,994 patients undergoing successful LAAO, only 12.2% received the full postprocedure treatment protocol studied in pivotal trials; the most common protocol deviations were with discharge antithrombotic medications. The most common discharge medication strategies were warfarin and aspirin (36.9%), direct oral anticoagulant (DOAC) and aspirin (20.8%), warfarin only (13.5%), DOAC only (12.3%), and dual antiplatelet therapy (5.0%). In multivariable Cox frailty regression, the adjusted risk of any adverse event through the 45-day follow-up visit were significantly lower for discharge on warfarin alone (HR: 0.692; 95% CI: 0.569-0.841) and DOAC alone (HR: 0.731; 95% CI: 0.574-0.930) compared with warfarin and aspirin. Warfarin alone retained lower risk at the 6-month follow-up. CONCLUSIONS In contemporary U.S. practice, practitioners rarely used the full U.S. Food and Drug Administration–approved postprocedure treatment protocols studied in pivotal trials of the Watchman device. Discharge after implantation on warfarin or DOAC without concomitant aspirin was associated with lower risk of adverse outcomes. (J Am Coll Cardiol 2022;79:1785–1798) © 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/ licenses/by-nc-nd/4.0/).;,citation_author=James V. Freeman;,citation_author=Angela Y. Higgins;,citation_author=Yongfei Wang;,citation_author=Chengan Du;,citation_author=Daniel J. Friedman;,citation_author=Usama A. Daimee;,citation_author=Karl E. Minges;,citation_author=Lucy Pereira;,citation_author=Andrew M. Goldsweig;,citation_author=Matthew J. Price;,citation_author=Vivek Y. Reddy;,citation_author=Douglas Gibson;,citation_author=Shephal K. Doshi;,citation_author=Paul D. Varosy;,citation_author=Frederick A. Masoudi;,citation_author=Jeptha P. Curtis;,citation_publication_date=2022-05;,citation_cover_date=2022-05;,citation_year=2022;,citation_issue=18;,citation_doi=10.1016/j.jacc.2022.02.047;,citation_issn=07351097;,citation_volume=79;,citation_language=en-US;,citation_journal_title=Journal of the American College of Cardiology;">
<meta name="citation_reference" content="citation_title=Making inferences on treatment effects from real world data: Propensity scores, confounding by indication, and other perils for the unwary in observational research;,citation_author=N. Freemantle;,citation_author=L. Marston;,citation_author=K. Walters;,citation_author=J. Wood;,citation_author=M. R. Reynolds;,citation_author=I. Petersen;,citation_publication_date=2013-11;,citation_cover_date=2013-11;,citation_year=2013;,citation_issue=nov11 3;,citation_doi=10.1136/bmj.f6409;,citation_issn=1756-1833;,citation_volume=347;,citation_language=en-US;,citation_journal_title=BMJ;">
<meta name="citation_reference" content="citation_title=Regression Models for Ordinal Outcomes;,citation_author=Benjamin French;,citation_author=Matthew S. Shotwell;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_issue=8;,citation_doi=10.1001/jama.2022.12104;,citation_issn=0098-7484;,citation_volume=328;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Video Laryngoscopy for Intubation — Time for a New Paradigm?;,citation_abstract=Endotracheal intubation — a potentially lifesaving procedure that is used for the care of many critically ill patients — demands precision, speed, and skill. It involves the placement of a tube into the trachea to protect the airways while ensuring adequate oxygenation and ventilation for patients who are in respiratory distress or are unable to breathe effectively on their own (or both). Historically, direct laryngoscopy has been the favored technique, in which practitioners use a laryngoscope blade to visualize the larynx directly through the mouth in order to correctly position the endotracheal tube for insertion. Video laryngoscopy has emerged as . . .;,citation_author=Yonathan Freund;,citation_author=Ben Bloom;,citation_publication_date=2023-08;,citation_cover_date=2023-08;,citation_year=2023;,citation_issue=5;,citation_doi=10.1056/NEJMe2305596;,citation_issn=0028-4793;,citation_pmid=37326314;,citation_volume=389;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes;,citation_author=Juan P. Frías;,citation_author=Melanie J. Davies;,citation_author=Julio Rosenstock;,citation_author=Federico C. Pérez Manghi;,citation_author=Laura Fernández Landó;,citation_author=Brandon K. Bergman;,citation_author=Bing Liu;,citation_author=Xuewei Cui;,citation_author=Katelyn Brown;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_issue=6;,citation_doi=10.1056/NEJMoa2107519;,citation_issn=0028-4793;,citation_pmid=34170647;,citation_volume=385;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Understanding the treatment preferences of seriously ill patients;,citation_abstract=BACKGROUND: The questions patients are asked about their preferences with regard to life-sustaining treatment usually focus on specific interventions, but the outcomes of treatment and their likelihood affect patients’ preferences. METHODS: We administered a questionnaire about treatment preferences to 226 persons who were 60 years of age or older and who had a limited life expectancy due to cancer, congestive heart failure, or chronic obstructive pulmonary disease. The study participants were asked whether they would want to receive a given treatment, first when the outcome was known with certainty and then with different likelihoods of an adverse outcome. The outcome without treatment was specified as death from the underlying disease. RESULTS: The burden of treatment (i.e., the length of the hospital stay, extent of testing, and invasiveness of interventions), the outcome, and the likelihood of the outcome all influenced treatment preferences. For a low-burden treatment with the restoration of current health, 98.7 percent of participants said they would choose to receive the treatment (rather than not receive it and die), but 11.2 percent of these participants would not choose the treatment if it had a high burden. If the outcome was survival but with severe functional impairment or cognitive impairment, 74.4 percent and 88.8 percent of these participants, respectively, would not choose treatment. The number of participants who said they would choose treatment declined as the likelihood of an adverse outcome increased, with fewer participants choosing treatment when the possible outcome was functional or cognitive impairment than when it was death. Preferences did not differ according to the primary diagnosis. CONCLUSIONS: Advance care planning should take into account patients’ attitudes toward the burden of treatment, the possible outcomes, and their likelihood. The likelihood of adverse functional and cognitive outcomes of treatment requires explicit consideration.;,citation_author=Terri R. Fried;,citation_author=Elizabeth H. Bradley;,citation_author=Virginia R. Towle;,citation_author=Heather Allore;,citation_publication_date=2002-04;,citation_cover_date=2002-04;,citation_year=2002;,citation_issue=14;,citation_doi=10.1056/NEJMsa012528;,citation_issn=1533-4406;,citation_pmid=11932474;,citation_volume=346;,citation_language=en-US;,citation_journal_title=The New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=In adults with acute ICH, intensive BP management did not reduce death or major disability;,citation_author=Rick Frieden;,citation_publication_date=2013-10;,citation_cover_date=2013-10;,citation_year=2013;,citation_issue=8;,citation_doi=10.7326/0003-4819-159-8-201310150-02006;,citation_issn=0003-4819;,citation_volume=159;,citation_language=en-US;,citation_journal_title=Annals of Internal Medicine;">
<meta name="citation_reference" content="citation_title=Risk literacy assessment of general practitioners and medical students using the Berlin Numeracy Test;,citation_abstract=Background: The responsibility for helping patients understand potential health benefits and risks, especially regarding screening tests, falls largely to general practitioners (GPs). The Berlin Numeracy Test (BNT) specifically measures risk literacy (i.e., the ability to understand different aspects of statistical numeracy associated with accurate interpretation of information about risks). This study explored the association between risk literacy levels and clinical experience in GPs vs. medical students. Additionally, the effect of GP risk literacy on evaluation of the predictive value of screening tests was examined. Methods: The participants were 84 GPs and 92 third-year medical students who completed the BNT (total score range 0–4 points). The GPs received an additional case scenario on mammography screening as a simple measure of performance in applying numeracy skills. Results: Despite having an average of 25.9 years of clinical experience, GPs scored no better than medical students on risk literacy (GPs: 2.33 points, 95% confidence interval [CI] 2.08–2.59; students: 2.34, 95% CI 2.07–2.61; P = .983). Of all GPs, 71.6% (n = 58) greatly overestimated the real predictive value. Conclusions: In this study, we found no difference in risk literacy between current students and current GPs. GPs lack risk literacy and consequently do not fully understand numeric estimates of probability in routine screening procedures.;,citation_author=Hendrik Friederichs;,citation_author=Roman Birkenstein;,citation_author=Jan C. Becker;,citation_author=Bernhard Marschall;,citation_author=Anne Weissenstein;,citation_publication_date=2020-12;,citation_cover_date=2020-12;,citation_year=2020;,citation_issue=1;,citation_doi=10.1186/s12875-020-01214-w;,citation_issn=1471-2296;,citation_volume=21;,citation_language=en-US;,citation_journal_title=BMC Family Practice;">
<meta name="citation_reference" content="citation_title=Mortality As a Measure of Treatment Effect in Clinical Trials Recruiting Critically Ill Patients*;,citation_author=Jan O. Friedrich;,citation_author=Michael O. Harhay;,citation_author=Derek C. Angus;,citation_author=Karen E. A. Burns;,citation_author=Deborah J. Cook;,citation_author=Dean A. Fergusson;,citation_author=Simon Finfer;,citation_author=Paul Hébert;,citation_author=Kathy Rowan;,citation_author=Gordon Rubenfeld;,citation_author=John C. Marshall;,citation_author=in collaboration with the International Forum for Acute Care Trialists (InFACT);,citation_publication_date=2023-02;,citation_cover_date=2023-02;,citation_year=2023;,citation_issue=2;,citation_doi=10.1097/CCM.0000000000005721;,citation_issn=0090-3493;,citation_volume=51;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Lung Microbiome in Critically Ill Patients;,citation_abstract=The historical hypothesis of sterility of the lungs was invalidated over a decade ago when studies demonstrated the existence of sparse but very diverse bacterial populations in the normal lung and the association between pulmonary dysbiosis and chronic respiratory diseases. Under mechanical ventilation, dysbiosis occurs rapidly with a gradual decline in diversity over time and the progressive predominance of a bacterial pathogen (mainly Proteobacteria) when lung infection occurs. During acute respiratory distress syndrome, an enrichment in bacteria of intestinal origin, mainly Enterobacteriaceae, is observed. However, the role of this dysbiosis in the pathogenesis of ventilator-associated pneumonia and acute respiratory distress syndrome is not yet fully understood. The lack of exploration of other microbial populations, viruses (eukaryotes and prokaryotes) and fungi is a key issue. Further analysis of the interaction between these microbial kingdoms and a better understanding of the host-microbiome interaction are necessary to fully elucidate the role of the microbiome in the pathogenicity of acute diseases. The validation of a consensual and robust methodology in order to make the comparison of the different studies relevant is also required. Filling these different gaps should help develop preventive and therapeutic strategies for both acute respiratory distress syndrome and ventilator-associated pneumonia.;,citation_author=Mélanie Fromentin;,citation_author=Jean-Damien Ricard;,citation_author=Damien Roux;,citation_publication_date=2021-12;,citation_cover_date=2021-12;,citation_year=2021;,citation_issue=1;,citation_doi=10.3390/life12010007;,citation_issn=2075-1729;,citation_volume=12;,citation_language=en-US;,citation_journal_title=Life;">
<meta name="citation_reference" content="citation_title=Borderline P-values in critical care trials: Time for a paradigm shift;,citation_author=Jakub Fronczek;,citation_author=Wojciech Szczeklik;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_doi=10.1016/j.bja.2022.07.042;,citation_issn=0007-0912;,citation_language=en-US;,citation_journal_title=British Journal of Anaesthesia;">
<meta name="citation_reference" content="citation_title=Integrating Palliative Care Into the Care of Neurocritically Ill Patients: A Report From the Improving Palliative Care in the ICU Project Advisory Board and the Center to Advance Palliative Care*;,citation_abstract=Objectives:&nbsp; To describe unique features of neurocritical illness that are relevant to provision of high-quality palliative care; to discuss key prognostic aids and their limitations for neurocritical illnesses; to review challenges and strategies for establishing realistic goals of care for patients in the neuro-ICU; and to describe elements of best practice concerning symptom management, limitation of life support, and organ donation for the neurocritically ill. Data Sources:&nbsp; A search of PubMed and MEDLINE was conducted from inception through January 2015 for all English-language articles using the term “palliative care,” “supportive care,” “end-of-life care,” “withdrawal of life-sustaining therapy,” “limitation of life support,” “prognosis,” or “goals of care” together with “neurocritical care,” “neurointensive care,” “neurological,” “stroke,” “subarachnoid hemorrhage,” “intracerebral hemorrhage,” or “brain injury.” Data Extraction and Synthesis:&nbsp; We reviewed the existing literature on delivery of palliative care in the neurointensive care unit setting, focusing on challenges and strategies for establishing realistic and appropriate goals of care, symptom management, organ donation, and other considerations related to use and limitation of life-sustaining therapies for neurocritically ill patients. Based on review of these articles and the experiences of our interdisciplinary/interprofessional expert advisory board, this report was prepared to guide critical care staff, palliative care specialists, and others who practice in this setting. Conclusions:&nbsp; Most neurocritically ill patients and their families face the sudden onset of devastating cognitive and functional changes that challenge clinicians to provide patient-centered palliative care within a complex and often uncertain prognostic environment. Application of palliative care principles concerning symptom relief, goal setting, and family emotional support will provide clinicians a framework to address decision making at a time of crisis that enhances patient/family autonomy and clinician professionalism.;,citation_author=Jennifer A. Frontera;,citation_author=J. Randall Curtis;,citation_author=Judith E. Nelson;,citation_author=Margaret Campbell;,citation_author=Michelle Gabriel;,citation_author=Anne C. Mosenthal;,citation_author=Colleen Mulkerin;,citation_author=Kathleen A. Puntillo;,citation_author=Daniel E. Ray;,citation_author=Rick Bassett;,citation_author=Renee D. Boss;,citation_author=Dana R. Lustbader;,citation_author=Karen J. Brasel;,citation_author=Stefanie P. Weiss;,citation_author=David E. Weissman;,citation_author=for the Improving Palliative Care in the ICU Project Advisory Board;,citation_publication_date=2015-09;,citation_cover_date=2015-09;,citation_year=2015;,citation_issue=9;,citation_doi=10.1097/CCM.0000000000001131;,citation_issn=0090-3493;,citation_volume=43;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=PREDICTION OF SYMPTOMATIC VASOSPASMAFTER SUBARACHNOID HEMORRHAGE: THE MODIFIED FISHER SCALE;,citation_abstract=OBJECTIVE&nbsp; We developed a modification of the Fisher computed tomographic (CT) rating scale and compared it to the original Fisher scale to determine which scale best predicts symptomatic vasospasm after subarachnoid hemorrhage (SAH). METHODS&nbsp; We analyzed data from 1355 SAH patients in the placebo-arm of four randomized, double-blind, placebo-controlled studies of tirilazad. Modified Fisher CT grades were calculated based the presence of cisternal blood and intraventricular hemorrhage. Crude odds ratios (OR) reflecting the risk of developing symptomatic vasospasm were calculated for each scale level, and adjusted ORs expressing the incremental risk were calculated after controlling for known predictors of vasospasm. RESULTS&nbsp; Of 1355 patients, 451 (33%) developed symptomatic vasospasm. For the modified Fisher scale, compared to Grade 0–1 patients, the crude OR for vasospasm was 1.6 (95% CI 1.0–2.5) for Grade 2, 1.6 (95% CI 1.1–2.2) for Grade 3, and 2.2 (95% CI 1.6–3.1) for Grade 4. For the original Fisher scale, referenced to Grade 1, the OR for vasospasm was 1.3 (95% CI 0.7–2.2) for Grade 2, 2.2 (95% CI 1.4–3.5) for Grade 3 and 1.7 (95% CI 1.0–3.0) for Grade 4. Early angiographic vasospasm, history of hypertension, neurological grade, and elevated admission mean arterial pressure were identified as risk factors for symptomatic vasospasm. After adjusting for these variables, the modified Fisher scale remained a significant predictor of vasospasm (adjusted OR 1.28, 95% CI 1.06–1.54) while the original Fisher scale was not. CONCLUSIONS&nbsp; The modified Fisher scale, which accounts for thick cisternal and ventricular blood, predicts symptomatic vasospasm after SAH more accurately than original Fisher scale.;,citation_author=Jennifer A. Frontera;,citation_author=Jan Claassen;,citation_author=J. Michael Schmidt;,citation_author=Katja E. Wartenberg;,citation_author=Richard Temes;,citation_author=E. Sander Connolly;,citation_author=R. Loch Macdonald;,citation_author=Stephan A. Mayer;,citation_publication_date=2006-07;,citation_cover_date=2006-07;,citation_year=2006;,citation_issue=1;,citation_doi=10.1227/01.neu.0000243277.86222.6c;,citation_issn=0148-396X;,citation_volume=59;,citation_language=en-US;,citation_journal_title=Neurosurgery;">
<meta name="citation_reference" content="citation_title=Toxic Metabolic Encephalopathy in Hospitalized Patients with COVID-19;,citation_abstract=Background: Toxic metabolic encephalopathy (TME) has been reported in 7–31% of hospitalized patients with coronavirus disease 2019 (COVID-19); however, some reports include sedation-related delirium and few data exist on the etiology of TME. We aimed to identify the prevalence, etiologies, and mortality rates associated with TME in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive patients. Methods: We conducted a retrospective, multicenter, observational cohort study among patients with reverse transcriptase–polymerase chain reaction-confirmed SARS-CoV-2 infection hospitalized at four New York City hospitals in the same health network between March 1, 2020, and May 20, 2020. TME was diagnosed in patients with altered mental status off sedation or after an adequate sedation washout. Patients with structural brain disease, seizures, or primary neurological diagnoses were excluded. The coprimary outcomes were the prevalence of TME stratified by etiology and in-hospital mortality (excluding comfort care only patients) assessed by using a multivariable time-dependent Cox proportional hazards models with adjustment for age, race, sex, intubation, intensive care unit requirement, Sequential Organ Failure Assessment scores, hospital location, and date of admission. Results: Among 4491 patients with COVID-19, 559 (12%) were diagnosed with TME, of whom 435 of 559 (78%) developed encephalopathy immediately prior to hospital admission. The most common etiologies were septic encephalopathy (n = 247 of 559 [62%]), hypoxic-ischemic encephalopathy (HIE) (n = 331 of 559 [59%]), and uremia (n = 156 of 559 [28%]). Multiple etiologies were present in 435 (78%) patients. Compared with those without TME (n = 3932), patients with TME were older (76 vs. 62 years), had dementia (27% vs. 3%) or psychiatric history (20% vs. 10%), were more often intubated (37% vs. 20%), had a longer hospital length of stay (7.9 vs. 6.0 days), and were less often discharged home (25% vs. 66% [all P &amp;amp;amp;lt; 0.001]). Excluding comfort care patients (n = 267 of 4491 [6%]) and after adjustment for confounders, TME remained associated with increased risk of in-hospital death (n = 128 of 425 [30%] patients with TME died, compared with n = 600 of 3799 [16%] patients without TME; adjusted hazard ratio [aHR] 1.24, 95% confidence interval [CI] 1.02–1.52, P = 0.031), and TME due to hypoxemia conferred the highest risk (n = 97 of 233 [42%] patients with HIE died, compared with n = 631 of 3991 [16%] patients without HIE; aHR 1.56, 95% CI 1.21–2.00, P = 0.001). Conclusions: TME occurred in one in eight hospitalized patients with COVID-19, was typically multifactorial, and was most often due to hypoxemia, sepsis, and uremia. After we adjustment for confounding factors, TME was associated with a 24% increased risk of in-hospital mortality.;,citation_author=Jennifer A. Frontera;,citation_author=Kara Melmed;,citation_author=Taolin Fang;,citation_author=Andre Granger;,citation_author=Jessica Lin;,citation_author=Shadi Yaghi;,citation_author=Ting Zhou;,citation_author=Ariane Lewis;,citation_author=Sebastian Kurz;,citation_author=D. Ethan Kahn;,citation_author=Adam Havenon;,citation_author=Joshua Huang;,citation_author=Barry M. Czeisler;,citation_author=Aaron Lord;,citation_author=Sharon B. Meropol;,citation_author=Andrea B. Troxel;,citation_author=Thomas Wisniewski;,citation_author=Laura Balcer;,citation_author=Steven Galetta;,citation_publication_date=2021-03;,citation_cover_date=2021-03;,citation_year=2021;,citation_doi=10.1007/s12028-021-01220-5;,citation_issn=1541-6933, 1556-0961;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Timing of dialysis initiation to reduce mortality and cardiovascular events in advanced chronic kidney disease: Nationwide cohort study;,citation_abstract=Abstract Objective To identify the optimal estimated glomerular filtration rate (eGFR) at which to initiate dialysis in people with advanced chronic kidney disease. Design Nationwide observational cohort study. Setting National Swedish Renal Registry of patients referred to nephrologists. Participants Patients had a baseline eGFR between 10 and 20 mL/min/1.73 m 2 and were included between 1 January 2007 and 31 December 2016, with follow-up until 1 June 2017. Main outcome measures The strict design criteria of a clinical trial were mimicked by using the cloning, censoring, and weighting method to eliminate immortal time bias, lead time bias, and survivor bias. A dynamic marginal structural model was used to estimate adjusted hazard ratios and absolute risks for five year all cause mortality and major adverse cardiovascular events (composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) for 15 dialysis initiation strategies with eGFR values between 4 and 19 mL/min/1.73 m 2 in increments of 1 mL/min/1.73 m 2 . An eGFR between 6 and 7 mL/min/1.73 m 2 (eGFR 6-7 ) was taken as the reference. Results Among 10 290 incident patients with advanced chronic kidney disease (median age 73 years; 3739 (36%) women; median eGFR 16.8 mL/min/1.73 m 2 ), 3822 started dialysis, 4160 died, and 2446 had a major adverse cardiovascular event. A parabolic relation was observed for mortality, with the lowest risk for eGFR 15-16 . Compared with dialysis initiation at eGFR 6-7 , initiation at eGFR 15-16 was associated with a 5.1% (95% confidence interval 2.5% to 6.9%) lower absolute five year mortality risk and 2.9% (0.2% to 5.5%) lower risk of a major adverse cardiovascular event, corresponding to hazard ratios of 0.89 (95% confidence interval 0.87 to 0.92) and 0.94 (0.91 to 0.98), respectively. This 5.1% absolute risk difference corresponded to a mean postponement of death of 1.6 months over five years of follow-up. However, dialysis would need to be started four years earlier. When emulating the intended strategies of the Initiating Dialysis Early and Late (IDEAL) trial (eGFR 10-14 v eGFR 5-7 ) and the achieved eGFRs in IDEAL (eGFR 7-10 v eGFR 5-7 ), hazard ratios for all cause mortality were 0.96 (0.94 to 0.99) and 0.97 (0.94 to 1.00), respectively, which are congruent with the findings of the randomised IDEAL trial. Conclusions Very early initiation of dialysis was associated with a modest reduction in mortality and cardiovascular events. For most patients, such a reduction may not outweigh the burden of a substantially longer period spent on dialysis.;,citation_author=Edouard L Fu;,citation_author=Marie Evans;,citation_author=Juan-Jesus Carrero;,citation_author=Hein Putter;,citation_author=Catherine M Clase;,citation_author=Fergus J Caskey;,citation_author=Maciej Szymczak;,citation_author=Claudia Torino;,citation_author=Nicholas C Chesnaye;,citation_author=Kitty J Jager;,citation_author=Christoph Wanner;,citation_author=Friedo W Dekker;,citation_author=Merel Diepen;,citation_publication_date=2021-11;,citation_cover_date=2021-11;,citation_year=2021;,citation_doi=10.1136/bmj-2021-066306;,citation_issn=1756-1833;,citation_language=en-US;,citation_journal_title=BMJ;">
<meta name="citation_reference" content="citation_title=Effect of Vitamin C, Hydrocortisone, and Thiamine vs Hydrocortisone Alone on Time Alive and Free of Vasopressor Support Among Patients With Septic Shock: The VITAMINS Randomized Clinical Trial;,citation_abstract=It is unclear whether vitamin C, hydrocortisone, and thiamine are more effective than hydrocortisone alone in expediting resolution of septic shock.To determine whether the combination of vitamin C, hydrocortisone, and thiamine, compared with hydrocortisone alone, improves the duration of time alive and free of vasopressor administration in patients with septic shock.Multicenter, open-label, randomized clinical trial conducted in 10 intensive care units in Australia, New Zealand, and Brazil that recruited 216 patients fulfilling the Sepsis-3 definition of septic shock. The first patient was enrolled on May 8, 2018, and the last on July 9, 2019. The final date of follow-up was October 6, 2019.Patients were randomized to the intervention group (n = 109), consisting of intravenous vitamin C (1.5 g every 6 hours), hydrocortisone (50 mg every 6 hours), and thiamine (200 mg every 12 hours), or to the control group (n = 107), consisting of intravenous hydrocortisone (50 mg every 6 hours) alone until shock resolution or up to 10 days.The primary trial outcome was duration of time alive and free of vasopressor administration up to day 7. Ten secondary outcomes were prespecified, including 90-day mortality.Among 216 patients who were randomized, 211 provided consent and completed the primary outcome measurement (mean age, 61.7 years [SD, 15.0]; 133 men [63%]). Time alive and vasopressor free up to day 7 was 122.1 hours (interquartile range [IQR], 76.3-145.4 hours) in the intervention group and 124.6 hours (IQR, 82.1-147.0 hours) in the control group; the median of all paired differences was –0.6 hours (95% CI, –8.3 to 7.2 hours; P = .83). Of 10 prespecified secondary outcomes, 9 showed no statistically significant difference. Ninety-day mortality was 30/105 (28.6%) in the intervention group and 25/102 (24.5%) in the control group (hazard ratio, 1.18; 95% CI, 0.69-2.00). No serious adverse events were reported.In patients with septic shock, treatment with intravenous vitamin C, hydrocortisone, and thiamine, compared with intravenous hydrocortisone alone, did not significantly improve the duration of time alive and free of vasopressor administration over 7 days. The finding suggests that treatment with intravenous vitamin C, hydrocortisone, and thiamine does not lead to a more rapid resolution of septic shock compared with intravenous hydrocortisone alone.ClinicalTrials.gov Identifier: NCT03333278;,citation_author=Tomoko Fujii;,citation_author=Nora Luethi;,citation_author=Paul J. Young;,citation_author=Daniel R. Frei;,citation_author=Glenn M. Eastwood;,citation_author=Craig J. French;,citation_author=Adam M. Deane;,citation_author=Yahya Shehabi;,citation_author=Ludhmila A. Hajjar;,citation_author=Gisele Oliveira;,citation_author=Andrew A. Udy;,citation_author=Neil Orford;,citation_author=Samantha J. Edney;,citation_author=Anna L. Hunt;,citation_author=Harriet L. Judd;,citation_author=Laurent Bitker;,citation_author=Luca Cioccari;,citation_author=Thummaporn Naorungroj;,citation_author=Fumitaka Yanase;,citation_author=Samantha Bates;,citation_author=Forbes McGain;,citation_author=Elizabeth P. Hudson;,citation_author=Wisam Al-Bassam;,citation_author=Dhiraj Bhatia Dwivedi;,citation_author=Chloe Peppin;,citation_author=Phoebe McCracken;,citation_author=Judit Orosz;,citation_author=Michael Bailey;,citation_author=Rinaldo Bellomo;,citation_author=for the VITAMINS Trial Investigators;,citation_publication_date=2020-02;,citation_cover_date=2020-02;,citation_year=2020;,citation_issue=5;,citation_doi=10.1001/jama.2019.22176;,citation_issn=0098-7484;,citation_volume=323;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Evaluating Effect Size in Psychological Research: Sense and Nonsense;,citation_abstract=Effect sizes are underappreciated and often misinterpreted—the most common mistakes being to describe them in ways that are uninformative (e.g., using arbitrary standards) or misleading (e.g., squaring effect-size rs). We propose that effect sizes can be usefully evaluated by comparing them with well-understood benchmarks or by considering them in terms of concrete consequences. In that light, we conclude that when reliably estimated (a critical consideration), an effect-size r of .05 indicates an effect that is very small for the explanation of single events but potentially consequential in the not-very-long run, an effect-size r of .10 indicates an effect that is still small at the level of single events but potentially more ultimately consequential, an effect-size r of .20 indicates a medium effect that is of some explanatory and practical use even in the short run and therefore even more important, and an effect-size r of .30 indicates a large effect that is potentially powerful in both the short and the long run. A very large effect size (r = .40 or greater) in the context of psychological research is likely to be a gross overestimate that will rarely be found in a large sample or in a replication. Our goal is to help advance the treatment of effect sizes so that rather than being numbers that are ignored, reported without interpretation, or interpreted superficially or incorrectly, they become aspects of research reports that can better inform the application and theoretical development of psychological research.;,citation_author=David C. Funder;,citation_author=Daniel J. Ozer;,citation_publication_date=2019-06;,citation_cover_date=2019-06;,citation_year=2019;,citation_issue=2;,citation_doi=10.1177/2515245919847202;,citation_issn=2515-2459;,citation_volume=2;,citation_language=en-US;,citation_journal_title=Advances in Methods and Practices in Psychological Science;,citation_publisher=SAGE Publications Inc;">
<meta name="citation_reference" content="citation_title=Effect of Hydroxyethyl Starch vs Saline for Volume Replacement Therapy on Death or Postoperative Complications Among High-Risk Patients Undergoing Major Abdominal Surgery: The FLASH Randomized Clinical Trial;,citation_abstract=OBJECTIVE To evaluate the effect of HES 130/0.4 compared with 0.9% saline for intravascular volume expansion on mortality and postoperative complications after major abdominal surgery. DESIGN, SETTING, AND PARTICIPANTS Multicenter, double-blind, parallel-group, randomized clinical trial of 775 adult patients at increased risk of postoperative kidney injury undergoing major abdominal surgery at 20 university hospitals in France from February 2016 to July 2018; final follow-up was in October 2018. INTERVENTIONS Patients were randomized to receive fluid containing either 6% HES 130/0.4 diluted in 0.9% saline (n = 389) or 0.9% saline alone (n = 386) in 250-mL boluses using an individualized hemodynamic algorithm during surgery and for up to 24 hours on the first postoperative day, defined as ending at 7:59 AM the following day. MAIN OUTCOMES AND MEASURES The primary outcome was a composite of death or major postoperative complications at 14 days after surgery. Secondary outcomes included predefined postoperative complications within 14 days after surgery, durations of intensive care unit and hospital stays, and all-cause mortality at postoperative days 28 and 90. RESULTS Among 826 patients enrolled (mean age, 68 [SD, 7] years; 91 women [12%]), 775 (94%) completed the trial. The primary outcome occurred in 139 of 389 patients (36%) in the HES group and 125 of 386 patients (32%) in the saline group (difference, 3.3% [95% CI, -3.3% to 10.0%]; relative risk, 1.10 [95% CI, 0.91-1.34]; P = .33). Among 12 prespecified secondary outcomes reported, 11 showed no significant difference, but a statistically significant difference was found in median volume of study fluid administered on day 1: 1250 mL (interquartile range, 750-2000 mL) in the HES group and 1500 mL (interquartile range, 750-2150 mL) in the saline group (median difference, 250 mL [95% CI, 83-417 mL]; P = .006). At 28 days after surgery, 4.1% and 2.3% of patients had died in the HES and saline groups, respectively (difference, 1.8% [95% CI, -0.7% to 4.3%]; relative risk, 1.76 [95% CI, 0.79-3.94]; P = .17). CONCLUSIONS AND RELEVANCE Among patients at risk of postoperative kidney injury undergoing major abdominal surgery, use of HES for volume replacement therapy compared with 0.9% saline resulted in no significant difference in a composite outcome of death or major postoperative complications within 14 days after surgery. These findings do not support the use of HES for volume replacement therapy in such patients.;,citation_author=Emmanuel Futier;,citation_author=Matthias Garot;,citation_author=Thomas Godet;,citation_author=Matthieu Biais;,citation_author=Daniel Verzilli;,citation_author=Alexandre Ouattara;,citation_author=Olivier Huet;,citation_author=Thomas Lescot;,citation_author=Gilles Lebuffe;,citation_author=Antoine Dewitte;,citation_author=Anna Cadic;,citation_author=Aymeric Restoux;,citation_author=Karim Asehnoune;,citation_author=Catherine Paugam-Burtz;,citation_author=Philippe Cuvillon;,citation_author=Marion Faucher;,citation_author=Camille Vaisse;,citation_author=Younes El Amine;,citation_author=Hélène Beloeil;,citation_author=Marc Leone;,citation_author=Eric Noll;,citation_author=Vincent Piriou;,citation_author=Sigismond Lasocki;,citation_author=Jean-Etienne Bazin;,citation_author=Bruno Pereira;,citation_author=Samir Jaber;,citation_author=for the FLASH Trial Group;,citation_publication_date=2020-01;,citation_cover_date=2020-01;,citation_year=2020;,citation_issue=3;,citation_doi=10.1001/jama.2019.20833;,citation_issn=0098-7484;,citation_volume=323;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Bayesianism and Causality, or, Why I am Only a Half-Bayesian;,citation_author=Judea Pearl;,citation_editor=Dov M. Gabbay;,citation_editor=Jon Barwise;,citation_editor=David Corfield;,citation_editor=Jon Williamson;,citation_publication_date=2001;,citation_cover_date=2001;,citation_year=2001;,citation_doi=10.1007/978-94-017-1586-7_2;,citation_isbn=978-90-481-5920-8 978-94-017-1586-7;,citation_volume=24;,citation_language=en-US;,citation_inbook_title=Foundations of Bayesianism;">
<meta name="citation_reference" content="citation_title=Visualization in Bayesian Workflow;,citation_abstract=Bayesian data analysis is about more than just computing a posterior distribution, and Bayesian visualization is about more than trace plots of Markov chains. Practical Bayesian data analysis, like all data analysis, is an iterative process of model building, inference, model checking and evaluation, and model expansion. Visualization is helpful in each of these stages of the Bayesian workflow and it is indispensable when drawing inferences from the types of modern, high dimensional models that are used by applied researchers.;,citation_author=Jonah Gabry;,citation_author=Daniel Simpson;,citation_author=Aki Vehtari;,citation_author=Michael Betancourt;,citation_author=Andrew Gelman;,citation_publication_date=2019-02;,citation_cover_date=2019-02;,citation_year=2019;,citation_issue=2;,citation_doi=10.1111/rssa.12378;,citation_issn=0964-1998;,citation_volume=182;,citation_journal_title=Journal of the Royal Statistical Society Series A: Statistics in Society;">
<meta name="citation_reference" content="citation_title=The Hand;,citation_author=Ognjen Gajic;,citation_publication_date=2011-06;,citation_cover_date=2011-06;,citation_year=2011;,citation_issue=12;,citation_doi=10.1164/rccm.201102-0191OE;,citation_issn=1073-449X, 1535-4970;,citation_volume=183;,citation_language=en-US;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Editors’ Note: Novel Score for Stratifying Risk of Critical Care Needs in Patients With Intracerebral Hemorrhage;,citation_author=James E. Siegler;,citation_author=Steven Galetta;,citation_editor=Steven Galetta;,citation_editor=Aravind Ganesh;,citation_editor=Ariane Lewis;,citation_editor=James E. Siegler;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=15;,citation_doi=10.1212/WNL.0000000000012678;,citation_issn=0028-3878, 1526-632X;,citation_volume=97;,citation_language=en-US;,citation_journal_title=Neurology;">
<meta name="citation_reference" content="citation_title=Association Between Availability of ECMO and Mortality in COVID-19 Patients Eligible for ECMO: A Natural Experiment;,citation_author=Whitney D. Gannon;,citation_author=John W. Stokes;,citation_author=Sean A. Francois;,citation_author=Yatrik J. Patel;,citation_author=Meredith E. Pugh;,citation_author=Clayne Benson;,citation_author=Todd W Rice;,citation_author=Matthew Bacchetta;,citation_author=Matthew W Semler;,citation_author=Jonathan D Casey;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_doi=10.1164/rccm.202110-2399LE;,citation_issn=1073-449X, 1535-4970;,citation_language=en-US;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Intravenous fluids in traumatic brain injury: What’s the solution?;,citation_abstract=Purpose of review&nbsp; Intravenous fluid is a fundamental component of trauma care and fluid management influences patient outcomes. This narrative review appraises recent clinical studies of fluid therapy in patients with traumatic brain injury (TBI), with respect to its use in volume resuscitation and prevention of secondary injury. Recent findings&nbsp; Despite the development of level 1 evidence in fluid resuscitation, in patients with TBI key questions concerning optimal composition and volume remain unanswered. In the absence of randomized trials demonstrating patient outcome differences, clinical practice is often based on physiological principles and surrogate endpoints. There is a physiological rationale why excessive fluid administration and positive fluid balance may increase brain swelling and intracranial pressure (ICP); in some patients, a lower cumulative fluid balance may improve outcomes, but limited human data exist. Resuscitation with 4% albumin in TBI patients in ICU worsens mortality, which may be mediated by increased ICP during the first week after injury. Hypertonic saline and mannitol decrease ICP, but may not improve survival or neurological outcomes. Sodium lactate may be a future therapy for treatment and prevention of secondary brain injury. Summary&nbsp; In patients with TBI, intravenous fluids are integral to management; they may be both a source of harm and a potential therapy to limit secondary brain injury. They should be prescribed in accordance with other pharmaceutical or therapeutic interventions. Refined usage may improve patient outcomes.;,citation_author=Dashiell Gantner;,citation_author=Elizabeth M. Moore;,citation_author=D. James Cooper;,citation_publication_date=2014-08;,citation_cover_date=2014-08;,citation_year=2014;,citation_issue=4;,citation_doi=10.1097/MCC.0000000000000114;,citation_issn=1070-5295;,citation_volume=20;,citation_language=en-US;,citation_journal_title=Current Opinion in Critical Care;">
<meta name="citation_reference" content="citation_title=Dual Antiplatelet Treatment up to 72 Hours after Ischemic Stroke;,citation_author=Ying Gao;,citation_author=Weiqi Chen;,citation_author=Yuesong Pan;,citation_author=Jing Jing;,citation_author=Chunjuan Wang;,citation_author=S. Claiborne Johnston;,citation_author=Pierre Amarenco;,citation_author=Philip M. Bath;,citation_author=Lingling Jiang;,citation_author=Yingying Yang;,citation_author=Tingting Wang;,citation_author=Shangrong Han;,citation_author=Xia Meng;,citation_author=Jinxi Lin;,citation_author=Xingquan Zhao;,citation_author=Liping Liu;,citation_author=Jinguo Zhao;,citation_author=Ying Li;,citation_author=Yingzhuo Zang;,citation_author=Shuo Zhang;,citation_author=Hongqin Yang;,citation_author=Jianbo Yang;,citation_author=Yuanwei Wang;,citation_author=Dali Li;,citation_author=Yanxia Wang;,citation_author=Dongqi Liu;,citation_author=Guangming Kang;,citation_author=Yongjun Wang;,citation_author=Yilong Wang;,citation_publication_date=2023-12;,citation_cover_date=2023-12;,citation_year=2023;,citation_issue=26;,citation_doi=10.1056/NEJMoa2309137;,citation_issn=0028-4793;,citation_volume=389;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Pneumonia Update for Emergency Clinicians;,citation_abstract=Purpose of Review Many new concepts in diagnosis, management, and risk stratification of patients with pneumonia have been described recently. The COVID pandemic made importance of viruses as dangerous pathogens of pneumonia quite clear while several non-invasive measures for patients with respiratory failure gained a more wide-spread usage.;,citation_author=Boris Garber;,citation_publication_date=2022-09;,citation_cover_date=2022-09;,citation_year=2022;,citation_issue=3;,citation_doi=10.1007/s40138-022-00246-z;,citation_issn=2167-4884;,citation_volume=10;,citation_language=en-US;,citation_journal_title=Current Emergency and Hospital Medicine Reports;">
<meta name="citation_reference" content="citation_title=Effectiveness of Screening Colonoscopy to Prevent Colorectal Cancer Among Medicare Beneficiaries Aged 70 to 79 Years: A Prospective Observational Study;,citation_abstract=BACKGROUND: No randomized, controlled trials of screening colonoscopy have been completed, and ongoing trials exclude persons aged 75 years or older. The Medicare program, however, reimburses screening colonoscopy without an upper age limit. OBJECTIVE: To evaluate the effectiveness and safety of screening colonoscopy to prevent colorectal cancer (CRC) in persons aged 70 to 74 and those aged 75 to 79 years. DESIGN: Large-scale, population-based, prospective study. The observational data were used to emulate a target trial with 2 groups: colonoscopy screening and no screening. SETTING: United States. PARTICIPANTS: 1&nbsp;355&nbsp;692 Medicare beneficiaries (2004 to 2012) aged 70 to 79 years at average risk for CRC who used Medicare preventive services and had no previous diagnostic or surveillance colonoscopies in the past 5 years. MEASUREMENTS: 8-year risk for CRC and 30-day risk for adverse events. RESULTS: In beneficiaries aged 70 to 74 years, the 8-year risk for CRC was 2.19% (95% CI, 2.00% to 2.37%) in the screening colonoscopy group and 2.62% (CI, 2.56% to 2.67%) in the no-screening group (absolute risk difference, -0.42% [CI, -0.24% to -0.63%]). Among those aged 75 to 79 years, the 8-year risk for CRC was 2.84% (CI, 2.54% to 3.13%) in the screening colonoscopy group and 2.97% (CI, 2.92% to 3.03%) in the no-screening group (risk difference, -0.14% [CI, -0.41 to 0.16]). The excess 30-day risk for any adverse event in the colonoscopy group was 5.6 events per 1000 individuals (CI, 4.4 to 6.8) in the 70- to 74-year age group and 10.3 per 1000 (CI, 8.6 to 11.1) in the 75- to 79-year age group. LIMITATION: CRC-specific mortality was not available, but CRC incidence and stage were studied at diagnosis. CONCLUSION: Screening colonoscopy may have had a modest benefit in preventing CRC in beneficiaries aged 70 to 74 years and a smaller benefit in older beneficiaries. The risk for adverse events was low but greater among older persons. PRIMARY FUNDING SOURCE: National Institutes of Health.;,citation_author=Xabier García-Albéniz;,citation_author=John Hsu;,citation_author=Michael Bretthauer;,citation_author=Miguel A. Hernán;,citation_publication_date=2017-01;,citation_cover_date=2017-01;,citation_year=2017;,citation_issue=1;,citation_doi=10.7326/M16-0758;,citation_issn=1539-3704;,citation_pmid=27669524;,citation_volume=166;,citation_language=en-US;,citation_journal_title=Annals of Internal Medicine;">
<meta name="citation_reference" content="citation_title=Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19;,citation_abstract=Background: Recruitment into randomized trials of hydroxychloroquine (HCQ) for prevention of COVID-19 has been adversely affected by a widespread conviction that HCQ is not effective for prevention. In the absence of an updated systematic review, we conducted a meta-analysis of randomized trials that study the effectiveness of HCQ to prevent COVID19.;,citation_author=Xabier García-Albéniz;,citation_author=Julia Amo;,citation_author=Rosa Polo;,citation_author=José Miguel Morales-Asencio;,citation_author=Miguel A Hernán;,citation_publication_date=2020-09;,citation_cover_date=2020-09;,citation_year=2020;,citation_doi=10.1101/2020.09.29.20203869;,citation_language=en-US;,citation_technical_report_institution=Epidemiology;">
<meta name="citation_reference" content="citation_title=Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19;,citation_abstract=Background Recruitment into randomized trials of hydroxychloroquine (HCQ) for prevention of COVID-19 has been adversely affected by a widespread conviction that HCQ is not effective for prevention. In the absence of an updated systematic review, we conducted a meta-analysis of randomized trials that study the effectiveness of HCQ to prevent COVID-19.;,citation_author=Xabier García-Albéniz;,citation_author=Julia Amo;,citation_author=Rosa Polo;,citation_author=José Miguel Morales-Asencio;,citation_author=Miguel A Hernán;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_issue=8;,citation_doi=10.1007/s10654-022-00891-4;,citation_issn=0393-2990, 1573-7284;,citation_volume=37;,citation_language=en-US;,citation_journal_title=European Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=The value of explicitly emulating a target trial when using real world evidence: An application to colorectal cancer screening;,citation_abstract=Observational analyses for causal inference often rely on real world data collected for purposes other than research. A frequent goal of these observational analyses is to use the data to emulate a hypothetical randomized experiment, i.e., the target trial, that mimics the design features of a true experiment, including a clear definition of time zero with synchronization of treatment assignment and determination of eligibility. We review a recent observational analysis that explicitly emulated a target trial of screening colonoscopy using insurance claims from U.S. Medicare. We then compare this explicit emulation with alternative, simpler observational analyses that do not synchronize treatment assignment and eligibility determination at time zero and/or do not allow for repeated eligibility. This empirical comparison suggests that lack of an explicit emulation of the target trial leads to biased estimates, and shows that allowing for repeated eligibility increases the statistical efficiency of the estimates.;,citation_author=Xabier García-Albéniz;,citation_author=John Hsu;,citation_author=Miguel A. Hernán;,citation_publication_date=2017-06;,citation_cover_date=2017-06;,citation_year=2017;,citation_issue=6;,citation_doi=10.1007/s10654-017-0287-2;,citation_issn=1573-7284;,citation_pmid=28748498;,citation_volume=32;,citation_language=en-US;,citation_journal_title=European Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Methodological survey of missing outcome data in an alteplase for ischemic stroke meta-analysis;,citation_abstract=Objective Recent national guidelines recommend alteplase treatment for ischemic stroke within 4.5 h of symptom-onset based on meta-analyses of randomized controlled clinical trials (RCT). A detailed description of missing outcome data (MOD) due to participant loss to follow-up has never been published. The objective of this study was to perform a methodlogical survey on missing outcome data in an alteplase for ischemic stroke meta-analysis. Materials and Methods A methodological survey was performed on a chosen meta-analysis of alteplase for ischemic stroke RCTs that most closely aligns with recent national guideline recommendations. Data were collected to assess the number of participants lost to follow-up; differential lost to follow-up between allocation groups; baseline characteristics of those lost to follow-up; and the imputation methods used by individual trials and the chosen meta-analysis. The number of participants lost to follow-up was compared with the fragility index; and repeated for individually positive RCTs in the meta-analysis. Results The methodological survey revealed a substantial degree of missing information regarding MOD in the chosen meta-analysis and in individual RCTs. Single imputation was exclusively used in all RCTs and in the meta-analysis. The number of participants lost to follow-up was greater than the fragility index in the chosen meta-analysis and individually positive component RCTs suggesting that MOD may impact the direction of the reported effect or effect size. Conclusion This methodological survey of an alteplase for ischemic stroke meta-analysis revealed MOD may be an important source of unrecognized bias. This survey highlights the need for sensitivity analyses using more robust methods of imputation.;,citation_author=Ravi Garg;,citation_publication_date=2022;,citation_cover_date=2022;,citation_year=2022;,citation_issue=3;,citation_doi=10.1111/ane.13656;,citation_issn=1600-0404;,citation_volume=146;,citation_language=en-US;,citation_journal_title=Acta Neurologica Scandinavica;">
<meta name="citation_reference" content="citation_title=Risk of selection bias assessment in the NINDS rt-PA stroke study;,citation_abstract=The NINDS rt-PA Stroke Study is frequently cited in support of alteplase for acute ischemic stroke within 3 h of symptom onset. Multiple post-hoc reanalyses of this trial have been published to adjust for a baseline imbalance in stroke severity. We performed a risk of selection bias assessment and reanalyzed trial data to determine if the etiology of this baseline imbalance was more likely due to random chance or randomization errors.;,citation_author=Ravi Garg;,citation_author=Steffen Mickenautsch;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_issue=1;,citation_doi=10.1186/s12874-022-01651-4;,citation_issn=1471-2288;,citation_volume=22;,citation_journal_title=BMC Medical Research Methodology;">
<meta name="citation_reference" content="citation_title=Addressing the Elephant in the Intensive Care Unit: The Role of Interprofessional Education;,citation_author=Phillip J. Gary;,citation_author=Yue Dong;,citation_author=Alexander S. Niven;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_issue=3;,citation_doi=10.34197/ats-scholar.2021-0100ED;,citation_issn=2690-7097;,citation_volume=2;,citation_language=en-US;,citation_journal_title=ATS Scholar;">
<meta name="citation_reference" content="citation_title=Reporting and interpretation of results from clinical trials that did not claim a treatment difference: Survey of four general medical journals;,citation_abstract=Objectives To describe and summarise how the results of randomised controlled trials (RCTs) that did not find a significant treatment effect are reported, and to estimate how commonly trial reports make unwarranted claims. Design We performed a retrospective survey of published RCTs, published in four high impact factor general medical journals between June 2016 and June 2017. Setting Trials conducted in all settings were included. Participants 94 reports of RCTs that did not find a difference in their main comparison or comparisons were included. Interventions All interventions. Primary and secondary outcomes We recorded the way the results of each trial for its primary outcome or outcomes were described in Results and Conclusions sections of the Abstract, using a 10-category classification. Other outcomes were whether confidence intervals (CIs) and p values were presented for the main treatment comparisons, and whether the results and conclusions referred to measures of uncertainty. We estimated the proportion of papers that made claims that were not justified by the results, or were open to multiple interpretations. Results 94 trial reports (120 treatment comparisons) were included. In Results sections, for 58/120 comparisons (48.3%) the results of the study were re-stated, without interpretation, and 38/120 (31.7%) stated that there was no statistically significant difference. In Conclusions, 65/120 treatment comparisons (54.2%) stated that there was no treatment benefit, 14/120 (11.7%) that there was no significant benefit and 16/120 (13.3%) that there was no significant difference. CIs and p values were both presented by 84% of studies (79/94), but only 3/94 studies referred to uncertainty when drawing conclusions. Conclusions The majority of trials (54.2%) inappropriately interpreted a result that was not statistically significant as indicating no treatment benefit. Very few studies interpreted the result as indicating a lack of evidence against the null hypothesis of zero difference between the trial arms.;,citation_author=Simon Gates;,citation_author=Elizabeth Ealing;,citation_publication_date=2019-09;,citation_cover_date=2019-09;,citation_year=2019;,citation_issue=9;,citation_doi=10.1136/bmjopen-2018-024785;,citation_issn=2044-6055, 2044-6055;,citation_pmid=31501094;,citation_volume=9;,citation_language=en-US;,citation_journal_title=BMJ Open;,citation_publisher=British Medical Journal Publishing Group;">
<meta name="citation_reference" content="citation_title=Statistical review of A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 by B. Cao et al;,citation_abstract=The following review has been prepared in collaboration with members of the MRC-NIHR Trials Methodology Research Partnership. The reviewers named above, and other, unnamed discussants of the paper, are all qualified statisticians with experience in clinical trials. Our objective is to provide a rapid review of publications, preprints and protocols from clinical trials of COVID-19 treatments, independent of journal specific review processes. We aim to provide timely, constructive, focused, clear advice aimed at improving both the research outputs under review, as well as future studies. Given our collective expertise (clinical trial statistics) our reviews focus on the designs of the trials and other statistical content (methods, presentation and accuracy of results, inferences). Here we review &amp;amp;amp;lt;em&amp;gt;A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19&amp;lt;/em&amp;gt;, by B.Cao <em>et al</em>, published in the New England Journal of Medicine on 18 March 2020. This was one of the first randomised controlled trials of treatments for COVID-19 to be published, and the first in a high-profile medical journal.;,citation_author=Simon Gates;,citation_author=Richard Emsley;,citation_author=Darren Dahly;,citation_publication_date=2020-04;,citation_cover_date=2020-04;,citation_year=2020;,citation_doi=10.5281/ZENODO.3746512;,citation_language=en-US;,citation_technical_report_institution=Zenodo;">
<meta name="citation_reference" content="citation_title=COVID-19 Does Not Lead to a “Typical” Acute Respiratory Distress Syndrome;,citation_author=Luciano Gattinoni;,citation_author=Silvia Coppola;,citation_author=Massimo Cressoni;,citation_author=Mattia Busana;,citation_author=Sandra Rossi;,citation_author=Davide Chiumello;,citation_publication_date=2020-05;,citation_cover_date=2020-05;,citation_year=2020;,citation_issue=10;,citation_doi=10.1164/rccm.202003-0817LE;,citation_issn=1073-449X, 1535-4970;,citation_volume=201;,citation_language=en-US;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=In search of the Holy Grail: Identifying the best PEEP in ventilated patients;,citation_author=Luciano Gattinoni;,citation_author=John J. Marini;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_issue=6;,citation_doi=10.1007/s00134-022-06698-x;,citation_issn=0342-4642, 1432-1238;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Selecting the “right” positive end-expiratory pressure level:;,citation_abstract=When compared, most of the methods give the same positive end-expiratory pressure values in patients with higher and lower recruitability. The positive end-expiratory pressure/inspiratory oxygen fraction tables are the only methods providing lower positive end-expiratory pressure in lower recruiters and higher positive end-expiratory pressure in higher recruiters.;,citation_author=Luciano Gattinoni;,citation_author=Eleonora Carlesso;,citation_author=Massimo Cressoni;,citation_publication_date=2015-02;,citation_cover_date=2015-02;,citation_year=2015;,citation_issue=1;,citation_doi=10.1097/MCC.0000000000000166;,citation_issn=1070-5295;,citation_volume=21;,citation_language=en-US;,citation_journal_title=Current Opinion in Critical Care;">
<meta name="citation_reference" content="citation_title=Variability of Prognostic Communication in Critically Ill Neurologic Patients: A Pilot Multicenter Mixed-Methods Study;,citation_abstract=OBJECTIVES: Primary: to demonstrate feasibility of audio-recording clinicianfamily meetings for CINPs at multiple centers and characterize how clinicians communicate prognosis during these meetings. Secondary: to explore associations of 1) clinician, family, or patient characteristics with clinicians’ prognostication approaches and 2) prognostication approach and WOLST. DESIGN, SETTING, AND PARTICIPANTS: Forty-three audio-recorded clinician-family meetings during which prognosis was discussed from seven U.S. centers for 39 CINPs with 88 family members and 27 clinicians. MAIN OUTCOMES AND MEASURES: Two investigators qualitatively coded transcripts using inductive methods (inter-rater reliability &amp;amp;amp;gt; 80%) to characterize how clinicians prognosticate. We then applied univariate and multivariable multinomial and binomial logistic regression. RESULTS: Clinicians used four distinct prognostication approaches: Authoritative (21%; recommending treatments without discussing values and preferences); Informational (23%; disclosing just the prognosis without further discussions); advisory (42%; disclosing prognosis followed by discussion of values and preferences); and responsive (14%; eliciting values and preferences, then disclosing prognosis). Before adjustment, prognostication approach was associated with center (p &amp;lt; 0.001), clinician specialty (neurointensivists vs non-neurointensivists; p = 0.001), patient age (p = 0.08), diagnosis (p = 0.059), and meeting length (p = 0.03). After adjustment, only clinician specialty independently predicted prognostication approach (p = 0.027). WOLST decisions occurred in 41% of patients and were most common under the advisory approach (56%). WOLST was more likely in older patients (p = 0.059) and with more experienced clinicians (p = 0.07). Prognostication approach was not independently associated with WOLST (p = 0.198). CONCLUSIONS AND RELEVANCE: It is feasible to audio-record sensitive clinician-family meetings about CINPs in multiple ICUs. We found that clinicians prognosticate with high variability. Our data suggest that larger studies are warranted in CINPs to examine the role of clinicians’ variable prognostication in WOLST decisions.;,citation_author=Connie Ge;,citation_author=Adeline L. Goss;,citation_author=Sybil Crawford;,citation_author=Kelsey Goostrey;,citation_author=Praewpannarai Buddadhumaruk;,citation_author=Anne-Marie Shields;,citation_author=Catherine L. Hough;,citation_author=Bernard Lo;,citation_author=Shannon S. Carson;,citation_author=Jay Steingrub;,citation_author=Douglas B. White;,citation_author=Susanne Muehlschlegel;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_issue=2;,citation_doi=10.1097/CCE.0000000000000640;,citation_issn=2639-8028;,citation_volume=4;,citation_language=en-US;,citation_journal_title=Critical Care Explorations;">
<meta name="citation_reference" content="citation_title=The Causal Foundations of Applied Probability and Statistics;,citation_abstract=Statistical science (as opposed to mathematical statistics) involves far more than probability theory, for it requires realistic causal models of data generators – even for purely descriptive goals. Statistical decision theory requires more causality: Rational decisions are actions taken to minimize costs while maximizing benefits, and thus require explication of causes of loss and gain. Competent statistical practice thus integrates logic, context, and probability into scientific inference and decision using narratives filled with causality. This reality was seen and accounted for intuitively by the founders of modern statistics, but was not well recognized in the ensuing statistical theory (which focused instead on the causally inert properties of probability measures). Nonetheless, both statistical foundations and basic statistics can and should be taught using formal causal models. The causal view of statistical science fits within a broader information-processing framework which illuminates and unifies frequentist, Bayesian, and related probability-based foundations of statistics. Causality theory can thus be seen as a key component connecting computation to contextual information, not “extrastatistical” but instead essential for sound statistical training and applications. Acknowledgements: I am grateful to Steve Cole, Joseph Halpern, Jay Kaufman, Blakeley McShane, and Sherrilyn Roush for their helpful comments on the drafts.;,citation_author=Sander Greenland;,citation_editor=Hector Geffner;,citation_editor=Rina Dechter;,citation_editor=Joseph Y. Halpern;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_doi=10.1145/3501714.3501747;,citation_isbn=978-1-4503-9586-1;,citation_language=en-US;,citation_inbook_title=Probabilistic and Causal Inference;">
<meta name="citation_reference" content="citation_title=Myocarditis after vaccination against covid-19;,citation_author=Walid F Gellad;,citation_publication_date=2021-12;,citation_cover_date=2021-12;,citation_year=2021;,citation_doi=10.1136/bmj.n3090;,citation_issn=1756-1833;,citation_language=en-US;,citation_journal_title=BMJ;">
<meta name="citation_reference" content="citation_title=Are confidence intervals better termed “uncertainty intervals”?;,citation_author=Andrew Gelman;,citation_author=Sander Greenland;,citation_publication_date=2019-09;,citation_cover_date=2019-09;,citation_year=2019;,citation_doi=10.1136/bmj.l5381;,citation_issn=0959-8138, 1756-1833;,citation_language=en-US;,citation_journal_title=BMJ;">
<meta name="citation_reference" content="citation_title=Attitudes toward amalgamating evidence in statistics;,citation_abstract=Weighing and amalgamating evidence is a central problem in statistics, giving rise to much debate on what methods are appropriate as well as exactly where, when and for what purposes they should be used. On the other hand, the weighing and amalgamating of evidence within a single isolated study (the multiple observations) in many default approaches in statistics is surprisingly often just automatic and implicit. Now vigorous debate on basic approaches in statistics likely comes as no surprise to statisticians and increasingly almost everyone else. Although there is much agreement on mathematical definitions of terms and procedures in statistics (what they are), as well as the discerning if particular instances meet these (is it this?), when it comes to the appropriate roles for these terms and procedures in facilitating scientific inquiry - their very purposes and what to make of them - it seems beyond agreement for the foreseeable future. The tools are largely agreed upon, their appropriate use, where and for what purposes, not at all. For instance, there is a fair amount of agreement on what probabilities are, but not on what they can be used for. Many frequentests ban any use of probability in representing (uncertain) knowledge of unknown parameters. On the other hand, although almost all Bayesians would use probabilities to represent knowledge (or lack of it), some Bayesians would ban any testing or empirically based assessment of these. In the case of a single study, some statisticians would be concerned about properties of procedures that can be discerned if the procedure would be repeatedly applied infinitely often under similar kinds of studies or even exactly the same study conditions. Others argue this is not even sensible.;,citation_author=Andrew Gelman;,citation_author=Keith O’Rourke;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Bayesian analysis of tests with unknown specificity and sensitivity;,citation_abstract=When testing for a rare disease, prevalence estimates can be highly sensitive to uncertainty in the specificity and sensitivity of the test. Bayesian inference is a natural way to propagate these uncertainties, with hierarchical modelling capturing variation in these parameters across experiments. Another concern is the people in the sample not being representative of the general population. Statistical adjustment cannot without strong assumptions correct for selection bias in an opt-in sample, but multilevel regression and post-stratification can at least adjust for known differences between the sample and the population. We demonstrate hierarchical regression and post-stratification models with code in Stan and discuss their application to a controversial recent study of SARS-CoV-2 antibodies in a sample of people from the Stanford University area. Wide posterior intervals make it impossible to evaluate the quantitative claims of that study regarding the number of unreported infections. For future studies, the methods described here should facilitate more accurate estimates of disease prevalence from imperfect tests performed on non-representative samples.;,citation_author=Andrew Gelman;,citation_author=Bob Carpenter;,citation_publication_date=2020;,citation_cover_date=2020;,citation_year=2020;,citation_issue=5;,citation_doi=10.1111/rssc.12435;,citation_issn=1467-9876;,citation_volume=69;,citation_language=en-US;,citation_journal_title=Journal of the Royal Statistical Society: Series C (Applied Statistics);">
<meta name="citation_reference" content="citation_title=Bayesian Workflow;,citation_abstract=The Bayesian approach to data analysis provides a powerful way to handle uncertainty in all observations, model parameters, and model structure using probability theory. Probabilistic programming languages make it easier to specify and fit Bayesian models, but this still leaves us with many options regarding constructing, evaluating, and using these models, along with many remaining challenges in computation. Using Bayesian inference to solve real-world problems requires not only statistical skills, subject matter knowledge, and programming, but also awareness of the decisions made in the process of data analysis. All of these aspects can be understood as part of a tangled workflow of applied Bayesian statistics. Beyond inference, the workflow also includes iterative model building, model checking, validation and troubleshooting of computational problems, model understanding, and model comparison. We review all these aspects of workflow in the context of several examples, keeping in mind that in practice we will be fitting many models for any given problem, even if only a subset of them will ultimately be relevant for our conclusions.;,citation_author=Andrew Gelman;,citation_author=Aki Vehtari;,citation_author=Daniel Simpson;,citation_author=Charles C. Margossian;,citation_author=Bob Carpenter;,citation_author=Yuling Yao;,citation_author=Lauren Kennedy;,citation_author=Jonah Gabry;,citation_author=Paul-Christian Bürkner;,citation_author=Martin Modrák;,citation_publication_date=2020;,citation_cover_date=2020;,citation_year=2020;,citation_doi=10.48550/ARXIV.2011.01808;,citation_publisher=arXiv;">
<meta name="citation_reference" content="citation_title=Beyond Power Calculations: Assessing Type S (Sign) and Type M (Magnitude) Errors;,citation_abstract=Statistical power analysis provides the conventional approach to assess error rates when designing a research study. However, power analysis is flawed in that a narrow emphasis on statistical significance is placed as the primary focus of study design. In noisy, small-sample settings, statistically significant results can often be misleading. To help researchers address this problem in the context of their own studies, we recommend design calculations in which (a) the probability of an estimate being in the wrong direction (Type S [sign] error) and (b) the factor by which the magnitude of an effect might be overestimated (Type M [magnitude] error or exaggeration ratio) are estimated. We illustrate with examples from recent published research and discuss the largest challenge in a design calculation: coming up with reasonable estimates of plausible effect sizes based on external information.;,citation_author=Andrew Gelman;,citation_author=John Carlin;,citation_publication_date=2014-11;,citation_cover_date=2014-11;,citation_year=2014;,citation_issue=6;,citation_doi=10.1177/1745691614551642;,citation_issn=1745-6916, 1745-6924;,citation_volume=9;,citation_language=en-US;,citation_journal_title=Perspectives on Psychological Science;">
<meta name="citation_reference" content="citation_title=The Boxer, the Wrestler, and the Coin Flip: A Paradox of Robust Bayesian Inference and Belief Functions;,citation_author=Andrew Gelman;,citation_publication_date=2006-05;,citation_cover_date=2006-05;,citation_year=2006;,citation_issue=2;,citation_doi=10.1198/000313006X106190;,citation_issn=0003-1305, 1537-2731;,citation_volume=60;,citation_language=en-US;,citation_journal_title=The American Statistician;">
<meta name="citation_reference" content="citation_title=Causal quartets: Different ways to attain the same average treatment effect*;,citation_abstract=The average causal effect can often be best understood in the context of its variation. We demonstrate with two sets of four graphs, all of which represent the same average effect but with much different patterns of heterogeneity. As with the famous correlation quartet of Anscombe (1973), these graphs dramatize the way in which real-world variation can be more complex than simple numerical summaries. The graphs also give insight into why the average effect is often much smaller than anticipated.;,citation_author=Andrew Gelman;,citation_author=Jessica Hullman;,citation_author=Lauren Kennedy;,citation_publication_date=2023-10;,citation_cover_date=2023-10;,citation_year=2023;,citation_doi=10.1080/00031305.2023.2267597;,citation_issn=0003-1305, 1537-2731;,citation_language=en-US;,citation_journal_title=The American Statistician;">
<meta name="citation_reference" content="citation_title=Ethics and Statistics: Honesty and Transparency Are Not Enough;,citation_author=Andrew Gelman;,citation_publication_date=2017-01;,citation_cover_date=2017-01;,citation_year=2017;,citation_issue=1;,citation_doi=10.1080/09332480.2017.1302720;,citation_issn=0933-2480, 1867-2280;,citation_volume=30;,citation_language=en-US;,citation_journal_title=CHANCE;">
<meta name="citation_reference" content="citation_title=The Failure of Null Hypothesis Significance Testing When Studying Incremental Changes, and What to Do About It;,citation_abstract=A standard mode of inference in social and behavioral science is to establish stylized facts using statistical significance in quantitative studies. However, in a world in which measurements are noisy and effects are small, this will not work: selection on statistical significance leads to effect sizes which are overestimated and often in the wrong direction. After a brief discussion of two examples, one in economics and one in social psychology, we consider the procedural solution of open post-publication review, the design solution of devoting more effort to accurate measurements and within-person comparisons, and the statistical analysis solution of multilevel modeling and reporting all results rather than selection on significance. We argue that the current replication crisis in science arises in part from the ill effects of null hypothesis significance testing being used to study small effects with noisy data. In such settings, apparent success comes easy but truly replicable results require a more serious connection between theory, measurement, and data.;,citation_author=Andrew Gelman;,citation_publication_date=2018-01;,citation_cover_date=2018-01;,citation_year=2018;,citation_issue=1;,citation_doi=10.1177/0146167217729162;,citation_issn=0146-1672, 1552-7433;,citation_volume=44;,citation_language=en-US;,citation_journal_title=Personality and Social Psychology Bulletin;">
<meta name="citation_reference" content="citation_title=The garden of forking paths: Why multiple comparisons can be a problem, even when there is no “fishing expedition” or “p-hacking” and the research hypothesis was posited ahead of time;,citation_abstract=Researcher degrees of freedom can lead to a multiple comparisons problem, even in settings where researchers perform only a single analysis on their data. The problem is there can be a large number of potential comparisons when the details of data analysis are highly contingent on data, without the researcher having to perform any conscious procedure of fishing or examining multiple p-values. We discuss in the context of several examples of published papers where data-analysis decisions were theoretically-motivated based on previous literature, but where the details of data selection and analysis were not pre-specified and, as a result, were contingent on data.;,citation_author=Andrew Gelman;,citation_author=Eric Loken;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Philosophy and the practice of Bayesian statistics: &amp;amp;amp;lt;i&amp;gt;Philosophy&amp;lt;/i&amp;gt; <i>and the Practice of</i> <i>Bayesian</i> <i>Statistics</i>;,citation_author=Andrew Gelman;,citation_author=Cosma Rohilla Shalizi;,citation_publication_date=2013-02;,citation_cover_date=2013-02;,citation_year=2013;,citation_issue=1;,citation_doi=10.1111/j.2044-8317.2011.02037.x;,citation_issn=00071102;,citation_volume=66;,citation_language=en-US;,citation_journal_title=British Journal of Mathematical and Statistical Psychology;">
<meta name="citation_reference" content="citation_title=The Problems With P-Values are not Just With P-Values;,citation_author=Andrew Gelman;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Posterior Reversible Encephalopathy Syndrome;,citation_author=Romergryko G. Geocadin;,citation_publication_date=2023-06;,citation_cover_date=2023-06;,citation_year=2023;,citation_issue=23;,citation_doi=10.1056/NEJMra2114482;,citation_issn=0028-4793;,citation_volume=388;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Functional Outcome, Recanalization, and Hemorrhage Rates After Large Vessel Occlusion Stroke Treated With Tenecteplase Before Thrombectomy;,citation_abstract=Background and Objectives To investigate in routine care the efficacy and safety of IV thrombolysis (IVT) with tenecteplase prior to mechanical thrombectomy (MT) in patients with large vessel occlusion acute ischemic strokes (LVO-AIS), either secondarily transferred after IVT or directly admitted to a comprehensive stroke center (CSC). Methods We retrospectively analyzed clinical and procedural data of patients treated with 0.25 mg/kg tenecteplase within 270 minutes of LVO-AIS who underwent brain angiography. The main outcome was 3-month functional independence (modified Rankin Scale score \leq2). Recanalization (revised Treatment in Cerebral Ischemia score 2b–3) was evaluated before (pre-MT) and after MT (final). Results We included 588 patients (median age 75 years [interquartile range (IQR) 61–84]; 315 women [54%]; median NIH Stroke Scale score 16 [IQR 10–20]), of whom 520 (88%) were secondarily transferred after IVT. Functional independence occurred in 47% (n = 269/570; 95% confidence interval [CI] 43.0–51.4) of patients. Pre-MT recanalization occurred in 120 patients (20.4%; 95% CI 17.2–23.9), at a similar rate across treatment paradigms (direct admission, n = 14/68 [20.6%]; secondary transfer, n = 106/520 [20.4%]; p &amp;amp;amp;gt; 0.99) despite a shorter median IVT to puncture time in directly admitted patients (38 [IQR 23–55] vs 86 [IQR 70–110] minutes; p &amp;lt; 0.001). Final recanalization was achieved in 492 patients (83.7%; 95%CI 80.4–86.6). Symptomatic intracerebral hemorrhage occurred in 2.5% of patients (n = 14/567; 95% CI 1.4–4.1). Discussions Tenecteplase before MT is safe, effective, and achieves a fast recanalization in everyday practice in patients secondarily transferred or directly admitted to a CSC, in line with published results. These findings should encourage its wider use in bridging therapy. Classification of Evidence This study provides Class IV evidence that tenecteplase within 270 minutes of LVO-AIS increases the probability of functional independence.;,citation_author=Gaspard Gerschenfeld;,citation_author=Didier Smadja;,citation_author=Guillaume Turc;,citation_author=Stephane Olindo;,citation_author=François-Xavier Laborne;,citation_author=Marion Yger;,citation_author=Jildaz Caroff;,citation_author=Bruno Gonçalves;,citation_author=Pierre Seners;,citation_author=Marie Cantier;,citation_author=Yann Hermitte;,citation_author=Manvel Aghasaryan;,citation_author=Cosmin Alecu;,citation_author=Gaultier Marnat;,citation_author=Wagih Ben Hassen;,citation_author=Erwah Kalsoum;,citation_author=Frédéric Clarençon;,citation_author=Michel Piotin;,citation_author=Laurent Spelle;,citation_author=Christian Denier;,citation_author=Igor Sibon;,citation_author=Sonia Alamowitch;,citation_author=Nicolas Chausson;,citation_author=on behalf of the TETRIS Study Group;,citation_publication_date=2021-11;,citation_cover_date=2021-11;,citation_year=2021;,citation_issue=22;,citation_doi=10.1212/WNL.0000000000012915;,citation_issn=0028-3878, 1526-632X;,citation_pmid=34635558;,citation_volume=97;,citation_language=en-US;,citation_journal_title=Neurology;,citation_publisher=Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology;">
<meta name="citation_reference" content="citation_title=Temporal Trends and Variability in Ketamine Use for Mechanically Ventilated Adults in the United States;,citation_abstract=Rationale: The epidemiology of continuous ketamine use in the management of critically ill adults receiving invasive mechanical ventilation (MV) in the United States is unknown. Objectives: To quantify temporal trends and variation across U.S. hospitals in continuous ketamine use. Methods: We performed a retrospective cohort study of adults (age \geq 18 yr) receiving MV who were discharged (alive or dead) from U.S. hospitals contributing data to the Premier Healthcare Database between January 2008 and September 2018. We used mixed-effects multivariable logistic regression modeling (fixed effects: patient and hospital characteristics; random effect: discharge hospital) to evaluate the associations of discharge quarter and discharge hospital with continuous ketamine use (defined as a charge for intravenous ketamine on \geq2 consecutive calendar days). Results: We identified 2,059,599 adults receiving MV across 842 hospitals; of these, 7,927 (0.4%) received continuous ketamine. Ketamine use increased over time from 0.07% of all patients in quarter 1 of 2008 to 1.1% of all patients in quarter 3 of 2018. After adjustment, the odds of receiving continuous ketamine were consistently increased starting in quarter 4 of 2011 (odds ratio, 1.83 [95% confidence interval, 1.09–3.06] vs. quarter 1 of 2008; P = 0.023), with more than 10-fold increased odds starting in quarter 2 of 2017. Among 842 hospitals, 486 (57.7%) used continuous ketamine on at least one cohort patient during the study period. Across these hospitals ever using ketamine, median use was 0.2% (interquartile range, 0.08–0.5%), with 5 hospitals using continuous ketamine in &amp;amp;amp;gt;5% of patients. The adjusted median odds ratio for discharge hospital was 3.72 (95% confidence interval, 3.37–4.13), which was higher than the odds ratio for any patient or hospital covariable other than discharge quarter. Conclusions: In U.S. hospitals, use of continuous infusion ketamine increased markedly over time in critically ill patients receiving MV, with substantial variability among hospitals. Given the unique properties of ketamine as a sedative, further research is needed to assess its safety and utility in critically ill populations.;,citation_author=Hayley B. Gershengorn;,citation_author=Hannah Wunsch;,citation_publication_date=2022-09;,citation_cover_date=2022-09;,citation_year=2022;,citation_issue=9;,citation_doi=10.1513/AnnalsATS.202112-1376OC;,citation_issn=2329-6933;,citation_volume=19;,citation_journal_title=Annals of the American Thoracic Society;,citation_publisher=American Thoracic Society - AJRCCM;">
<meta name="citation_reference" content="citation_title=Informing Healthcare Decisions with Observational Research Assessing Causal Effect. An Official American Thoracic Society Research Statement;,citation_author=Andrea S. Gershon;,citation_author=Peter K. Lindenauer;,citation_author=Kevin C. Wilson;,citation_author=Louise Rose;,citation_author=Allan J. Walkey;,citation_author=Mohsen Sadatsafavi;,citation_author=Kevin J. Anstrom;,citation_author=David H. Au;,citation_author=Bruce G. Bender;,citation_author=M. Alan Brookhart;,citation_author=Raed A. Dweik;,citation_author=MeiLan K. Han;,citation_author=Min J. Joo;,citation_author=Valery Lavergne;,citation_author=Anuj B. Mehta;,citation_author=Marc Miravitlles;,citation_author=Richard A. Mularski;,citation_author=Nicolas Roche;,citation_author=Eyal Oren;,citation_author=Kristin A. Riekert;,citation_author=Noah C. Schoenberg;,citation_author=Therese A. Stukel;,citation_author=Curtis H. Weiss;,citation_author=Hannah Wunsch;,citation_author=Joel J. Africk;,citation_author=Jerry A. Krishnan;,citation_publication_date=2021-01;,citation_cover_date=2021-01;,citation_year=2021;,citation_issue=1;,citation_doi=10.1164/rccm.202010-3943ST;,citation_issn=1073-449X, 1535-4970;,citation_volume=203;,citation_language=en-US;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Leveraging a Critical Care Database;,citation_abstract=Background: Observational studies have found an increased risk of adverse effects such as hemorrhage, stroke, and increased mortality in patients taking selective serotonin reuptake inhibitors (SSRIs). The impact of prior use of these medications on outcomes in critically ill patients has not been previously examined. We performed a retrospective study to determine if preadmission use of SSRIs or serotonin norepinephrine reuptake inhibitors (SNRIs) is associated with mortality differences in patients admitted to the ICU. Methods: The retrospective study used a modifiable data mining technique applied to the publicly available Multiparameter Intelligent Monitoring in Intensive Care (MIMIC) 2.6 database. A total of 14,709 patient records, consisting of 2,471 in the SSRI/SNRI group and 12,238 control subjects, were analyzed. The study outcome was in-hospital mortality. Results: After adjustment for age, Simplified Acute Physiology Score, vasopressor use, ventilator use, and combined Elixhauser score, SSRI/SNRI use was associated with significantly increased in-hospital mortality (OR, 1.19; 95% CI, 1.02-1.40; P 5 .026). Among patient subgroups, risk was highest in patients with acute coronary syndrome (OR, 1.95; 95% CI, 1.21-3.13; P 5 .006) and patients admitted to the cardiac surgery recovery unit (OR, 1.51; 95% CI, 1.11-2.04; P 5 .008). Mortality appeared to vary by specific SSRI, with higher mortalities associated with higher levels of serotonin inhibition. Conclusions: We found significant increases in hospital stay mortality among those patients in the ICU taking SSRI/SNRIs prior to admission as compared with control subjects. Mortality was higher in patients receiving SSRI/SNRI agents that produce greater degrees of serotonin reuptake inhibition. The study serves to demonstrate the potential for the future application of advanced data examination techniques upon detailed (and growing) clinical databases being made available by the digitization of medicine.;,citation_author=Marzyeh Ghassemi;,citation_author=John Marshall;,citation_author=Nakul Singh;,citation_author=David J. Stone;,citation_author=Leo Anthony Celi;,citation_publication_date=2014-04;,citation_cover_date=2014-04;,citation_year=2014;,citation_issue=4;,citation_doi=10.1378/chest.13-1722;,citation_issn=00123692;,citation_volume=145;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=D-dimer and bleeding during ECMO: The chicken and the egg?;,citation_author=Marco Giani;,citation_author=Mauro Panigada;,citation_publication_date=2023-12;,citation_cover_date=2023-12;,citation_year=2023;,citation_issue=12;,citation_doi=10.1007/s00134-023-07265-8;,citation_issn=0342-4642, 1432-1238;,citation_volume=49;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=The Role of &amp;amp;amp;lt;i&amp;gt;p&amp;lt;/i&amp;gt; -Values in Judging the Strength of Evidence and Realistic Replication Expectations;,citation_author=Eric W. Gibson;,citation_publication_date=2021-01;,citation_cover_date=2021-01;,citation_year=2021;,citation_issue=1;,citation_doi=10.1080/19466315.2020.1724560;,citation_issn=1946-6315;,citation_volume=13;,citation_language=en-US;,citation_journal_title=Statistics in Biopharmaceutical Research;">
<meta name="citation_reference" content="citation_title=Helping Doctors and Patients Make Sense of Health Statistics;,citation_abstract=Many doctors, patients, journalists, and politicians alike do not understand what health statistics mean or draw wrong conclusions without noticing. Collective statistical illiteracy refers to the widespread inability to understand the meaning of numbers. For instance, many citizens are unaware that higher survival rates with cancer screening do not imply longer life, or that the statement that mammography screening reduces the risk of dying from breast cancer by 25% in fact means that 1 less woman out of 1,000 will die of the disease. We provide evidence that statistical illiteracy (a) is common to patients, journalists, and physicians; (b) is created by nontransparent framing of information that is sometimes an unintentional result of lack of understanding but can also be a result of intentional efforts to manipulate or persuade people; and (c) can have serious consequences for health.;,citation_author=Gerd Gigerenzer;,citation_author=Wolfgang Gaissmaier;,citation_author=Elke Kurz-Milcke;,citation_author=Lisa M. Schwartz;,citation_author=Steven Woloshin;,citation_publication_date=2007-11;,citation_cover_date=2007-11;,citation_year=2007;,citation_issue=2;,citation_doi=10.1111/j.1539-6053.2008.00033.x;,citation_issn=1529-1006, 1539-6053;,citation_volume=8;,citation_language=en-US;,citation_journal_title=Psychological Science in the Public Interest;">
<meta name="citation_reference" content="citation_title=Heuristic Decision Making;,citation_abstract=As reflected in the amount of controversy, few areas in psychology have undergone such dramatic conceptual changes in the past decade as the emerging science of heuristics. Heuristics are efficient cognitive processes, conscious or unconscious, that ignore part of the information. Because using heuristics saves effort, the classical view has been that heuristic decisions imply greater errors than do “rational” decisions as defined by logic or statistical models. However, for many decisions, the assumptions of rational models are not met, and it is an empirical rather than an a priori issue how well cognitive heuristics function in an uncertain world. To answer both the descriptive question (“Which heuristics do people use in which situations?”) and the prescriptive question (“When should people rely on a given heuristic rather than a complex strategy to make better judgments?”), formal models are indispensable. We review research that tests formal models of heuristic inference, including in business organizations, health care, and legal institutions. This research indicates that (a) individuals and organizations often rely on simple heuristics in an adaptive way, and (b) ignoring part of the information can lead to more accurate judgments than weighting and adding all information, for instance for low predictability and small samples. The big future challenge is to develop a systematic theory of the building blocks of heuristics as well as the core capacities and environmental structures these exploit.;,citation_author=Gerd Gigerenzer;,citation_author=Wolfgang Gaissmaier;,citation_publication_date=2011-01;,citation_cover_date=2011-01;,citation_year=2011;,citation_issue=1;,citation_doi=10.1146/annurev-psych-120709-145346;,citation_issn=0066-4308, 1545-2085;,citation_volume=62;,citation_language=en-US;,citation_journal_title=Annual Review of Psychology;">
<meta name="citation_reference" content="citation_title=How to Improve Bayesian Reasoning Without Instruction: Frequency Formats;,citation_author=Gerd Gigerenzer;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Mindless statistics;,citation_abstract=Statistical rituals largely eliminate statistical thinking in the social sciences. Rituals are indispensable for identification with social groups, but they should be the subject rather than the procedure of science. What I call the “null ritual” consists of three steps: (1) set up a statistical null hypothesis, but do not specify your own hypothesis nor any alternative hypothesis, (2) use the 5% significance level for rejecting the null and accepting your hypothesis, and (3) always perform this procedure. I report evidence of the resulting collective confusion and fears about sanctions on the part of students and teachers, researchers and editors, as well as textbook writers.;,citation_author=Gerd Gigerenzer;,citation_publication_date=2004-11;,citation_cover_date=2004-11;,citation_year=2004;,citation_issue=5;,citation_doi=10.1016/j.socec.2004.09.033;,citation_issn=10535357;,citation_volume=33;,citation_language=en-US;,citation_journal_title=The Journal of Socio-Economics;">
<meta name="citation_reference" content="citation_title=Probabilistic Mental Models: A Brunswikian Theory of Confidence;,citation_author=Gerd Gigerenzer;,citation_author=Ulrich Hoffrage;,citation_author=Heinz Kleinbfilting;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Autoimmune-Associated Seizures;,citation_abstract=PURPOSE OF REVIEW: This article focuses on the seizure manifestations and presentations of autoimmune-associated epilepsy and acute symptomatic seizures in autoimmune encephalitis. It discusses the specificity of the various central nervous system autoantibodies and clarifies when their presence can be considered indicative of an immune etiology. Finally, current recommendations regarding patient selection for autoimmune antibody evaluation are reviewed, and an approach to immunotherapy is provided.;,citation_author=Lisa Gillinder;,citation_author=Jeffrey Britton;,citation_publication_date=2022-04;,citation_cover_date=2022-04;,citation_year=2022;,citation_issue=2;,citation_doi=10.1212/CON.0000000000001079;,citation_issn=1538-6899, 1080-2371;,citation_volume=28;,citation_language=en-US;,citation_journal_title=CONTINUUM: Lifelong Learning in Neurology;">
<meta name="citation_reference" content="citation_title=Effect of Conservative vs Conventional Oxygen Therapy on Mortality Among Patients in an Intensive Care Unit: The Oxygen-ICU Randomized Clinical Trial;,citation_abstract=OBJECTIVE To assess whether a conservative protocol for oxygen supplementation could improve outcomes in patients admitted to intensive care units (ICUs). DESIGN, SETTING, AND PATIENTS Oxygen-ICU was a single-center, open-label, randomized clinical trial conducted from March 2010 to October 2012 that included all adults admitted with an expected length of stay of 72 hours or longer to the medical-surgical ICU of Modena University Hospital, Italy. The originally planned sample size was 660 patients, but the study was stopped early due to difficulties in enrollment after inclusion of 480 patients. INTERVENTIONS Patients were randomly assigned to receive oxygen therapy to maintain PaO2 between 70 and 100 mm Hg or arterial oxyhemoglobin saturation (SpO2) between 94% and 98% (conservative group) or, according to standard ICU practice, to allow PaO2 values up to 150 mm Hg or SpO2 values between 97% and 100% (conventional control group). MAIN OUTCOMES AND MEASURES The primary outcome was ICU mortality. Secondary outcomes included occurrence of new organ failure and infection 48 hours or more after ICU admission. RESULTS A total of 434 patients (median age, 64 years; 188 [43.3%] women) received conventional (n = 218) or conservative (n = 216) oxygen therapy and were included in the modified intent-to-treat analysis. Daily time-weighted PaO2 averages during the ICU stay were significantly higher (P &amp;amp;amp;lt; .001) in the conventional group (median PaO2, 102 mm Hg [IQR, 88-116]) vs the conservative group (median PaO2, 87 mm Hg [IQR, 79-97]). Mortality was lower in the conservative oxygen therapy group. The conservative group had fewer episodes of shock, liver failure, and bacteremia. Primary outcome ICU mortality Secondary outcomes Shock Liver failure Bacteremia Oxygen Therapy, No. (%) Conservative Conventional (n = 216) (n = 218) Absolute Risk Reduction (95% CI) P Value 25 (11.6) 44 (20.2) 0.086 (0.017-0.150) .01 8 (3.7) 23 (10.6) 0.068 (0.020-0.120) .006 4 (1.9) 14 (6.4) 0.046 (0.008-0.088) .02 11 (5.1) 22 (10.1) 0.050 (0.000-0.090) .049 Editorial page 1553 Supplemental content CONCLUSIONS AND RELEVANCE Among critically ill patients with an ICU length of stay of 72 hours or longer, a conservative protocol for oxygen therapy vs conventional therapy resulted in lower ICU mortality. These preliminary findings were based on unplanned early termination of the trial, and a larger multicenter trial is needed to evaluate the potential benefit of this approach.;,citation_author=Massimo Girardis;,citation_author=Stefano Busani;,citation_author=Elisa Damiani;,citation_author=Abele Donati;,citation_author=Laura Rinaldi;,citation_author=Andrea Marudi;,citation_author=Andrea Morelli;,citation_author=Massimo Antonelli;,citation_author=Mervyn Singer;,citation_publication_date=2016-10;,citation_cover_date=2016-10;,citation_year=2016;,citation_issue=15;,citation_doi=10.1001/jama.2016.11993;,citation_issn=0098-7484;,citation_volume=316;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Causal Inference in Public Health;,citation_abstract=Causal inference has a central role in public health; the determination that an association is causal indicates the possibility for intervention. We review and comment on the long-used guidelines for interpreting evidence as supporting a causal association and contrast them with the potential outcomes framework that encourages thinking in terms of causes that are interventions. We argue that in public health this framework is more suitable, providing an estimate of an action’s consequences rather than the less precise notion of a risk factor’s causal effect. A variety of modern statistical methods adopt this approach. When an intervention cannot be specified, causal relations can still exist, but how to intervene to change the outcome will be unclear. In application, the often-complex structure of causal processes needs to be acknowledged and appropriate data collected to study them. These newer approaches need to be brought to bear on the increasingly complex public health challenges of our globalized world.;,citation_author=Thomas A. Glass;,citation_author=Steven N. Goodman;,citation_author=Miguel A. Hernán;,citation_author=Jonathan M. Samet;,citation_publication_date=2013-03;,citation_cover_date=2013-03;,citation_year=2013;,citation_issue=1;,citation_doi=10.1146/annurev-publhealth-031811-124606;,citation_issn=0163-7525, 1545-2093;,citation_volume=34;,citation_language=en-US;,citation_journal_title=Annual Review of Public Health;">
<meta name="citation_reference" content="citation_title=Unintended Consequences of Approving Unproven Treatments—Hope, Hype, or Harm?;,citation_author=Jonathan D. Glass;,citation_author=Christina N. Fournier;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_issue=2;,citation_doi=10.1001/jamaneurol.2021.4193;,citation_issn=2168-6149;,citation_volume=79;,citation_language=en-US;,citation_journal_title=JAMA Neurology;">
<meta name="citation_reference" content="citation_title=Changes in intravenous fluid use patterns in Australia and New Zealand: Evidence of research translating into practice;,citation_abstract=Objectives: To describe changes in the use of intravenous (IV) fluid by quantity and type in different regions of Australia and New Zealand. &amp;amp;amp;lt;br /&amp;gt;&amp;lt;br /&amp;gt; Design, setting and participants: We conducted a retrospective ecological study examining regional and temporal trends in IV fluid consumption across Australia and New Zealand over the periods 2012-2013 and 2013- 2014, using national proprietary sales data as a surrogate for consumption, and demographic data from the public domain. <br /><br /> Results: More than 13.3 million litres of IV fluid were consumed in Australia and New Zealand in 2012-2013, and more than 13.9 million litres in 2013-2014, with colloid solutions accounting for < 2%. There was marked regional variation in consumption of fluids, by volumes and proportions used, when standardised to overall Australian and New Zealand values. There was no significant change in the overall volume of crystalloid solutions consumed but there was a significant decrease (9%; P = 0.02) in the ratio of unbalanced to balanced crystalloid solutions consumed. Consumption of all forms of colloid solutions decreased, with a 12% reduction overall (P = 0.02), primarily driven by a 67% reduction in the consumption of hydroxyethyl starch (HES) solutions. <br /><br /> Conclusions: The amount and type of IV fluid use, as determined by fluid sales, is highly variable across Australia and New Zealand. However, overall use of balanced crystalloid solutions is increasing and the use of HES has decreased dramatically.;,citation_author=Neil J. Glassford;,citation_author=Craig J. French;,citation_author=Michael Bailey;,citation_author=Johan Martensson;,citation_author=Glenn M. Eastwood;,citation_author=Rinaldo Bellomo;,citation_issue=2;,citation_doi=10.3316/informit.278542731564428;,citation_volume=18;,citation_journal_title=Critical Care and Resuscitation;,citation_publisher=College of Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Covid heterodoxy in three layers;,citation_abstract=Lockdowns and related policies of behavioral and economic restriction introduced in response to the COVID-19 pandemic are criticized, drawing on three sets of ideas and arguments that are organized in accordance with the likely degree of controversy associated with their guiding assumptions. The first set of arguments makes use of cost–benefit reasoning within a broadly utilitarian framework, emphasizing uncertainty, the role of worst-case scenarios, and the need to consider at least the medium term as well as immediate effects. The second draws on assumptions about the political value of basic liberties. The third draws on ideas about the roles of different stages within human life.;,citation_author=Peter Godfrey-Smith;,citation_publication_date=2021-11;,citation_cover_date=2021-11;,citation_year=2021;,citation_doi=10.1007/s40592-021-00140-6;,citation_issn=1321-2753, 1836-6716;,citation_language=en-US;,citation_journal_title=Monash Bioethics Review;">
<meta name="citation_reference" content="citation_title=Acute Intracranial Hypertension During Pregnancy: Special Considerations and Management Adjustments;,citation_abstract=Pregnancy is associated with a number of pathophysiological changes (including modification of vascular resistance, increased vascular permeability, and coagulative disorders) that can lead to specific (eclampsia, preeclampsia) or not specific (intracranial hemorrhage) neurological complications. In addition to these disorders, pregnancy can affect numerous preexisting neurologic conditions, including epilepsy, brain tumors, and intracerebral bleeding from cerebral aneurysm or arteriovenous malformations. Intracranial complications related to pregnancy can expose patients to a high risk of intracranial hypertension (IHT). Unfortunately, at present, the therapeutic measures that are generally adopted for the control of elevated intracranial pressure (ICP) in the general population have not been examined in pregnant patients, and their efficacy and safety for the mother and the fetus is still unknown. In addition, no specific guidelines for the application of the staircase approach, including escalating treatments with increasing intensity of level, for the management of IHT exist for this population. Although some of basic measures can be considered safe even in pregnant patients (management of stable hemodynamic and respiratory function, optimization of systemic physiology), some other interventions, such as hyperventilation, osmotic therapy, hypothermia, barbiturates, and decompressive craniectomy, can lead to specific concerns for the safety of both mother and fetus. The aim of this review is to summarize the neurological pathophysiological changes occurring during pregnancy and explore the effects of the possible therapeutic interventions applied to the general population for the management of IHT during pregnancy, taking into consideration ethical and clinical concerns as well as the decision for the timing of treatment and delivery.;,citation_author=Daniel Agustin Godoy;,citation_author=Chiara Robba;,citation_author=Wellingson Silva Paiva;,citation_author=Alejandro A. Rabinstein;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_doi=10.1007/s12028-021-01333-x;,citation_issn=1541-6933, 1556-0961;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Acute Pulmonary Embolism: Part II: Risk Stratification, Treatment, and Prevention;,citation_author=Samuel Z. Goldhaber;,citation_author=C. Gregory Elliott;,citation_publication_date=2003-12;,citation_cover_date=2003-12;,citation_year=2003;,citation_issue=23;,citation_doi=10.1161/01.CIR.0000098427.74047.42;,citation_issn=0009-7322, 1524-4539;,citation_volume=108;,citation_language=en-US;,citation_journal_title=Circulation;">
<meta name="citation_reference" content="citation_title=Acute Pulmonary Embolism: Part I: Epidemiology, Pathophysiology, and Diagnosis;,citation_author=Samuel Z. Goldhaber;,citation_author=C. Gregory Elliott;,citation_publication_date=2003-12;,citation_cover_date=2003-12;,citation_year=2003;,citation_issue=22;,citation_doi=10.1161/01.CIR.0000097829.89204.0C;,citation_issn=0009-7322, 1524-4539;,citation_volume=108;,citation_language=en-US;,citation_journal_title=Circulation;">
<meta name="citation_reference" content="citation_title=Health Insurance and Mortality: Experimental Evidence from Taxpayer Outreach;,citation_abstract=We evaluate a randomized outreach study in which the IRS sent informational letters to 3.9 million households that paid a tax penalty for lacking health insurance coverage under the Affordable Care Act. Drawing on administrative data, we study the effect of this intervention on taxpayers’ subsequent health insurance enrollment and mortality. We find the intervention led to increased coverage during the subsequent two years and reduced mortality among middle-aged adults over the same time period. The results provide experimental evidence that health insurance coverage can reduce mortality in the United States.;,citation_author=Jacob Goldin;,citation_author=Ithai Z Lurie;,citation_author=Janet McCubbin;,citation_publication_date=2021-02;,citation_cover_date=2021-02;,citation_year=2021;,citation_issue=1;,citation_doi=10.1093/qje/qjaa029;,citation_issn=0033-5533;,citation_volume=136;,citation_journal_title=The Quarterly Journal of Economics;">
<meta name="citation_reference" content="citation_title=Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19;,citation_abstract=Randomized clinical trials (RCTs) of therapeutic-dose heparin in patients hospitalized with COVID-19 produced conflicting results, possibly due to heterogeneity of treatment effect (HTE) across individuals. Better understanding of HTE could facilitate individualized clinical decision-making.To evaluate HTE of therapeutic-dose heparin for patients hospitalized for COVID-19 and to compare approaches to assessing HTE.Exploratory analysis of a multiplatform adaptive RCT of therapeutic-dose heparin vs usual care pharmacologic thromboprophylaxis in 3320 patients hospitalized for COVID-19 enrolled in North America, South America, Europe, Asia, and Australia between April 2020 and January 2021. Heterogeneity of treatment effect was assessed 3 ways: using (1) conventional subgroup analyses of baseline characteristics, (2) a multivariable outcome prediction model (risk-based approach), and (3) a multivariable causal forest model (effect-based approach). Analyses primarily used bayesian statistics, consistent with the original trial.Participants were randomized to therapeutic-dose heparin or usual care pharmacologic thromboprophylaxis.Organ support–free days, assigning a value of -1 to those who died in the hospital and the number of days free of cardiovascular or respiratory organ support up to day 21 for those who survived to hospital discharge; and hospital survival.Baseline demographic characteristics were similar between patients randomized to therapeutic-dose heparin or usual care (median age, 60 years; 38% female; 32% known non-White race; 45% Hispanic). In the overall multiplatform RCT population, therapeutic-dose heparin was not associated with an increase in organ support–free days (median value for the posterior distribution of the OR, 1.05; 95% credible interval, 0.91-1.22). In conventional subgroup analyses, the effect of therapeutic-dose heparin on organ support–free days differed between patients requiring organ support at baseline or not (median OR, 0.85 vs 1.30; posterior probability of difference in OR, 99.8%), between females and males (median OR, 0.87 vs 1.16; posterior probability of difference in OR, 96.4%), and between patients with lower body mass index (BMI &amp;amp;amp;lt;30) vs higher BMI groups (BMI \geq30; posterior probability of difference in ORs &amp;gt;90% for all comparisons). In risk-based analysis, patients at lowest risk of poor outcome had the highest propensity for benefit from heparin (lowest risk decile: posterior probability of OR &amp;gt;1, 92%) while those at highest risk were most likely to be harmed (highest risk decile: posterior probability of OR &amp;lt;1, 87%). In effect-based analysis, a subset of patients identified at high risk of harm (P = .05 for difference in treatment effect) tended to have high BMI and were more likely to require organ support at baseline.Among patients hospitalized for COVID-19, the effect of therapeutic-dose heparin was heterogeneous. In all 3 approaches to assessing HTE, heparin was more likely to be beneficial in those who were less severely ill at presentation or had lower BMI and more likely to be harmful in sicker patients and those with higher BMI. The findings illustrate the importance of considering HTE in the design and analysis of RCTs.ClinicalTrials.gov Identifiers: NCT02735707, NCT04505774, NCT04359277, NCT04372589;,citation_author=Ewan C. Goligher;,citation_author=Patrick R. Lawler;,citation_author=Thomas P. Jensen;,citation_author=Victor Talisa;,citation_author=Lindsay R. Berry;,citation_author=Elizabeth Lorenzi;,citation_author=Bryan J. McVerry;,citation_author=Chung-Chou Ho Chang;,citation_author=Eric Leifer;,citation_author=Charlotte Bradbury;,citation_author=Jeffrey Berger;,citation_author=Beverly J. Hunt;,citation_author=Lana A. Castellucci;,citation_author=Lucy Z. Kornblith;,citation_author=Anthony C. Gordon;,citation_author=Colin McArthur;,citation_author=Steven Webb;,citation_author=Judith Hochman;,citation_author=Matthew D. Neal;,citation_author=Ryan Zarychanski;,citation_author=Scott Berry;,citation_author=Derek C. Angus;,citation_author=ATTACC REMAP-CAP;,citation_publication_date=2023-03;,citation_cover_date=2023-03;,citation_year=2023;,citation_doi=10.1001/jama.2023.3651;,citation_issn=0098-7484;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=A manifesto for the future of ICU trials;,citation_author=Ewan C. Goligher;,citation_author=Fernando Zampieri;,citation_author=Carolyn S. Calfee;,citation_author=Christopher W. Seymour;,citation_publication_date=2020-12;,citation_cover_date=2020-12;,citation_year=2020;,citation_issue=1;,citation_doi=10.1186/s13054-020-03393-5;,citation_issn=1364-8535;,citation_volume=24;,citation_language=en-US;,citation_journal_title=Critical Care;">
<meta name="citation_reference" content="citation_title=Meta-Analysis of Reversal Agents for Severe Bleeding Associated With Direct Oral Anticoagulants;,citation_abstract=BACKGROUND Direct oral anticoagulants (DOACs) have shown a positive benefit-risk balance in both clinical trials and real-world data, but approximately 2% to 3.5% of patients experience major bleeding annually. Many of these patients require hospitalization, and the administration of reversal agents may be required to control bleeding. OBJECTIVES The aim of this study was to investigate clinical outcomes associated with the use of 4-factor prothrombin complex concentrates, idarucizumab, or andexanet for reversal of severe DOAC-associated bleeding. METHODS The investigators systematically searched for studies of reversal agents for the treatment of severe bleeding associated with DOAC. Mortality rates, thromboembolic events, and hemostatic efficacy were meta-analyzed using a random effects model. RESULTS The investigators evaluated 60 studies in 4,735 patients with severe DOAC-related bleeding who were treated with 4-factor prothrombin complex concentrates (n \frac{1}{4} 2,688), idarucizumab (n \frac{1}{4} 1,111), or andexanet (n \frac{1}{4} 936). The mortality rate was 17.7% (95% confidence interval [CI]: 15.1% to 20.4%), and it was higher in patients with intracranial bleedings (20.2%) than in patients with extracranial hemorrhages (15.4%). The thromboembolism rate was 4.6% (95% CI: 3.3% to 6.0%), being particularly high with andexanet (10.7%; 95% CI: 6.5% to 15.7%). The effective hemostasis rate was 78.5% (95% CI: 75.1% to 81.8%) and was similar regardless of the reversal agent considered. The rebleeding rate was 13.2% (95% CI: 5.5% to 23.1%) and 78% of rebleeds occurred after resumption of anticoagulation. The risk of death was markedly and significantly associated with failure to achieve effective hemostasis (relative risk: 3.63; 95% CI: 2.56 to 5.16). The results were robust regardless of the type of study or the hemostatic scale used. CONCLUSIONS The risk of death after severe DOAC-related bleeding remains significant despite a high rate of effective hemostasis with reversal agents. Failure to achieve effective hemostasis strongly correlated with a fatal outcome. Thromboembolism rates are particularly high with andexanet. Comparative clinical trials are needed. (J Am Coll Cardiol 2021;77:2987–3001) © 2021 by the American College of Cardiology Foundation.;,citation_author=Antonio Gómez-Outes;,citation_author=Pau Alcubilla;,citation_author=Gonzalo Calvo-Rojas;,citation_author=Ana Isabel Terleira-Fernández;,citation_author=Ma Luisa Suárez-Gea;,citation_author=Ramón Lecumberri;,citation_author=Emilio Vargas-Castrillón;,citation_publication_date=2021-06;,citation_cover_date=2021-06;,citation_year=2021;,citation_issue=24;,citation_doi=10.1016/j.jacc.2021.04.061;,citation_issn=07351097;,citation_volume=77;,citation_language=en-US;,citation_journal_title=Journal of the American College of Cardiology;">
<meta name="citation_reference" content="citation_title=Ongoing Clinical Trials in Intracerebral Hemorrhage;,citation_author=Nicole R. Gonzales;,citation_publication_date=2013-06;,citation_cover_date=2013-06;,citation_year=2013;,citation_issue=6_suppl_1;,citation_doi=10.1161/STROKEAHA.111.000563;,citation_volume=44;,citation_journal_title=Stroke;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=A Dirty Dozen: Twelve P-Value Misconceptions;,citation_author=Steven Goodman;,citation_publication_date=2008-07;,citation_cover_date=2008-07;,citation_year=2008;,citation_issue=3;,citation_doi=10.1053/j.seminhematol.2008.04.003;,citation_issn=00371963;,citation_volume=45;,citation_language=en-US;,citation_journal_title=Seminars in Hematology;">
<meta name="citation_reference" content="citation_title=Vitamin C in Sepsis — No Longer a Benign Intervention?;,citation_author=Andrew J. Goodwin;,citation_author=Charles Terry;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_issue=9;,citation_doi=10.1056/EVIDe2200163;,citation_volume=1;,citation_journal_title=NEJM Evidence;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=The European clinical research response to optimise treatment of patients with COVID-19: Lessons learned, future perspective, and recommendations;,citation_author=Herman Goossens;,citation_author=Lennie Derde;,citation_author=Peter Horby;,citation_author=Marc Bonten;,citation_publication_date=2021-12;,citation_cover_date=2021-12;,citation_year=2021;,citation_doi=10.1016/S1473-3099(21)00705-2;,citation_issn=14733099;,citation_language=en-US;,citation_journal_title=The Lancet Infectious Diseases;">
<meta name="citation_reference" content="citation_title=Prognostication and shared decision making in neurocritical care;,citation_abstract=Prognostication is crucial in the neurological intensive care unit (neuroICU). Patients with severe acute brain injury (SABI) are unable to make their own decisions because of the insult itself or sedation needs. Surrogate decision makers, usually family members, must make decisions on the patient’s behalf. However, many are unprepared for their role as surrogates owing to the sudden and unexpected nature of SABI. Surrogates rely on clinicians in the neuroICU to provide them with an outlook (prognosis) with which to make substituted judgments and decide on treatments and goals of care on behalf of the patient. Therefore, how a prognostic estimate is derived, and then communicated, is extremely important. Prognostication in the neuroICU is highly variable between clinicians and institutions, and evidence based guidelines are lacking. Shared decision making (SDM), where surrogates and clinicians arrive together at an individualized decision based on patient values and preferences, has been proposed as an opportunity to improve clinician-family communication and ensure that patients receive treatments they would choose. This review outlines the importance and current challenges of prognostication in the neuroICU and how prognostication and SDM intersect, based on relevant research and expert opinion.;,citation_author=Kelsey Goostrey;,citation_author=Susanne Muehlschlegel;,citation_publication_date=2022-04;,citation_cover_date=2022-04;,citation_year=2022;,citation_doi=10.1136/bmj-2021-060154;,citation_issn=1756-1833;,citation_pmid=35696329;,citation_volume=377;,citation_language=en-US;,citation_journal_title=BMJ (Clinical research ed.);">
<meta name="citation_reference" content="citation_title=Vasopressor dose equivalence: A scoping review and suggested formula;,citation_abstract=Purpose: Calculating equipotent doses between vasopressor agents is necessary in clinical practice and research pertaining to the management of shock. This scoping review summarizes conversion ratios between vasopressors and provides a formula to incorporate into study designs. Materials and methods: Medline, Embase and Web of Science databases were searched from inception to 21st October 2020. Additional papers were obtained through bibliography searches of retrieved articles. Two investigators assessed articles for eligibility. Clinical trials comparing the potency of at least two intravenous vasopressors (norepinephrine, epinephrine, dopamine, phenylephrine, vasopressin, metaraminol or angiotensin II), with regard to an outcome of blood pressure, were selected. Results: Of 16,315 articles, 21 were included for synthesis. The range of conversion ratios equivalent to one unit of norepinephrine were: epinephrine (0.7-1.4), dopamine (75.2-144.4), metaraminol (8.3), phenylephrine (1.1-16.3), vasopressin (0.3-0.4) and angiotensin II (0.070.13). The following formula may be considered for the calculation of norepinephrine equivalents (NE) (all in mcg/kg/min, except vasopressin in units/min): NE = norepinephrine + epinephrine + phenylephrine/10 + dopamine/100 + metaraminol/8 + vasopressin*2.5 + angiotensin II*10. Conclusion: A summary of equipotent ratios for common vasopressors used in clinical practice has been provided. Our formula may be considered to calculate NE for studies in the intensive care unit.;,citation_author=Shruti Goradia;,citation_author=Arwa Abu Sardaneh;,citation_author=Sujita W. Narayan;,citation_author=Jonathan Penm;,citation_author=Asad E. Patanwala;,citation_publication_date=2021-02;,citation_cover_date=2021-02;,citation_year=2021;,citation_doi=10.1016/j.jcrc.2020.11.002;,citation_issn=08839441;,citation_volume=61;,citation_language=en-US;,citation_journal_title=Journal of Critical Care;">
<meta name="citation_reference" content="citation_title=Acute respiratory distress syndrome in adults: Diagnosis, outcomes, long-term sequelae, and management;,citation_author=Ellen A. Gorman;,citation_author=Cecilia M. O’Kane;,citation_author=Daniel F. McAuley;,citation_publication_date=2022-10;,citation_cover_date=2022-10;,citation_year=2022;,citation_issue=10358;,citation_doi=10.1016/S0140-6736(22)01439-8;,citation_issn=0140-6736, 1474-547X;,citation_pmid=36070788;,citation_volume=400;,citation_language=en-US;,citation_journal_title=The Lancet;,citation_publisher=Elsevier;">
<meta name="citation_reference" content="citation_title=Prognostication, Ethical Issues, and Palliative Care in Disorders of Consciousness;,citation_author=Adeline L. Goss;,citation_author=Claire J. Creutzfeldt;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_issue=1;,citation_doi=10.1016/j.ncl.2021.08.005;,citation_issn=07338619;,citation_volume=40;,citation_language=en-US;,citation_journal_title=Neurologic Clinics;">
<meta name="citation_reference" content="citation_title=Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients;,citation_abstract=BACKGROUND Remdesivir improves clinical outcomes in patients hospitalized with moderate-tosevere coronavirus disease 2019 (Covid-19). Whether the use of remdesivir in symptomatic, nonhospitalized patients with Covid-19 who are at high risk for disease progression prevents hospitalization is uncertain. METHODS We conducted a randomized, double-blind, placebo-controlled trial involving nonhospitalized patients with Covid-19 who had symptom onset within the previous 7 days and who had at least one risk factor for disease progression (age \geq60 years, obesity, or certain coexisting medical conditions). Patients were randomly assigned to receive intravenous remdesivir (200 mg on day 1 and 100 mg on days 2 and 3) or placebo. The primary efficacy end point was a composite of Covid-19–related hospitalization or death from any cause by day 28. The primary safety end point was any adverse event. A secondary end point was a composite of a Covid-19–related medically attended visit or death from any cause by day 28. RESULTS A total of 562 patients who underwent randomization and received at least one dose of remdesivir or placebo were included in the analyses: 279 patients in the remdesivir group and 283 in the placebo group. The mean age was 50 years, 47.9% of the patients were women, and 41.8% were Hispanic or Latinx. The most common coexisting conditions were diabetes mellitus (61.6%), obesity (55.2%), and hypertension (47.7%). Covid-19–related hospitalization or death from any cause occurred in 2 patients (0.7%) in the remdesivir group and in 15 (5.3%) in the placebo group (hazard ratio, 0.13; 95% confidence interval [CI], 0.03 to 0.59; P = 0.008). A total of 4 of 246 patients (1.6%) in the remdesivir group and 21 of 252 (8.3%) in the placebo group had a Covid-19–related medically attended visit by day 28 (hazard ratio, 0.19; 95% CI, 0.07 to 0.56). No patients had died by day 28. Adverse events occurred in 42.3% of the patients in the remdesivir group and in 46.3% of those in the placebo group. The authors’ full names, academic degrees, and affiliations are listed in the Appendix. Dr. Gottlieb can be contacted at robert.gottlieb@bswhealth.org or at Baylor University Medical Center, Center for Advanced Heart and Lung Disease, 3410 Worth St., Ste. 250, Dallas, TX 75246. *Deceased. A complete list of the GS-US-540-9012 (PINETREE) Investigators is provided in the Supplementary Appendix, available at NEJM.org. This article was published on December 22, 2021, at NEJM.org. N Engl J Med 2022;386:305-15. DOI: 10.1056/NEJMoa2116846 Copyright © 2021 Massachusetts Medical Society. CME at NEJM.org CONCLUSIONS Among nonhospitalized patients who were at high risk for Covid-19 progression, a 3-day course of remdesivir had an acceptable safety profile and resulted in an 87% lower risk of hospitalization or death than placebo. (Funded by Gilead Sciences; PINETREE ClinicalTrials.gov number, NCT04501952; EudraCT number, 2020--.);,citation_author=Robert L. Gottlieb;,citation_author=Carlos E. Vaca;,citation_author=Roger Paredes;,citation_author=Jorge Mera;,citation_author=Brandon J. Webb;,citation_author=Gilberto Perez;,citation_author=Godson Oguchi;,citation_author=Pablo Ryan;,citation_author=Bibi U. Nielsen;,citation_author=Michael Brown;,citation_author=Ausberto Hidalgo;,citation_author=Yessica Sachdeva;,citation_author=Shilpi Mittal;,citation_author=Olayemi Osiyemi;,citation_author=Jacek Skarbinski;,citation_author=Kavita Juneja;,citation_author=Robert H. Hyland;,citation_author=Anu Osinusi;,citation_author=Shuguang Chen;,citation_author=Gregory Camus;,citation_author=Mazin Abdelghany;,citation_author=Santosh Davies;,citation_author=Nicole Behenna-Renton;,citation_author=Frank Duff;,citation_author=Francisco M. Marty;,citation_author=Morgan J. Katz;,citation_author=Adit A. Ginde;,citation_author=Samuel M. Brown;,citation_author=Joshua T. Schiffer;,citation_author=Joshua A. Hill;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=4;,citation_doi=10.1056/NEJMoa2116846;,citation_issn=0028-4793, 1533-4406;,citation_volume=386;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=The Need for a US National Clinical Trial Infrastructure in a Public Health Crisis;,citation_author=Scott Gottlieb;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_issue=8;,citation_doi=10.1001/jamahealthforum.2021.3223;,citation_issn=2689-0186;,citation_volume=2;,citation_language=en-US;,citation_journal_title=JAMA Health Forum;">
<meta name="citation_reference" content="citation_title=Time course of outcome in poor grade subarachnoid hemorrhage patients: A longitudinal retrospective study;,citation_abstract=Background: Neurological outcome and mortality of patients suffering from poor grade subarachnoid hemorrhage (SAH) may have changed over time. Several factors, including patients’ characteristics, the presence of hydrocephalus and intraparenchymal hematoma, might also contribute to this effect. The aim of this study was to assess the temporal changes in mortality and neurologic outcome in SAH patients and identify their predictors. Methods: We performed a single center retrospective cohort study from 2004 to 2018. All non-traumatic SAH patients with poor grade on admission (WFNS score of 4 or 5) who remained at least 24 h in the hospital were included. Time course was analyzed into four groups according to the years of admission (2004–2007; 2008–2011; 2012–2015 and 2016–2018). Results: A total of 353 patients were included in this study: 202 patients died (57 %) and 260 (74 %) had unfavorable neurological outcome (UO) at 3 months. Mortality tended to decrease in in 2008–2011 and 2016–2018 periods (HR 0.55 [0.34–0.89] and HR 0.33 [0.20–0.53], respectively, when compared to 2004–2007). The proportion of patients with UO remained high and did not vary significantly over time. Patients with WFNS 5 had higher mortality (68 % vs. 34 %, p = 0.001) and more frequent UO (83 % vs. 54 %, p = 0.001) than those with WFNS 4. In the multivariable analysis, WFNS 5 was independently associated with mortality (HR 2.12 [1.43–3.14]) and UO (OR 3.23 [1.67–6.25]). The presence of hydrocephalus was associated with a lower risk of mortality (HR 0.60 [0.43–0.84]). Conclusions: Both hospital mortality and UO remained high in poor grade SAH patients. Patients with WFNS 5 on admission had worse prognosis than others; this should be taken into consideration for future clinical studies.;,citation_author=Elisa Gouvêa Bogossian;,citation_author=Daniela Diaferia;,citation_author=Andrea Minini;,citation_author=Narcisse Ndieugnou Djangang;,citation_author=Marco Menozzi;,citation_author=Lorenzo Peluso;,citation_author=Filippo Annoni;,citation_author=Jacques Creteur;,citation_author=Sophie Schuind;,citation_author=Olivier Dewitte;,citation_author=Fabio Silvio Taccone;,citation_publication_date=2021-12;,citation_cover_date=2021-12;,citation_year=2021;,citation_issue=1;,citation_doi=10.1186/s12883-021-02229-1;,citation_issn=1471-2377;,citation_volume=21;,citation_language=en-US;,citation_journal_title=BMC Neurology;">
<meta name="citation_reference" content="citation_title=Health-related quality of life before, 1 month after, and 9 months after intensive care in medical cardiovascular and pulmonary patients;,citation_abstract=OBJECTIVE: Assessment of health-related quality of life before, 1 month after, and 9 months after an intensive care unit stay using an established generic instrument, the Medical Outcome Survey Short Form-36 (SF-36). DESIGN: Prospective, observational study. SETTING: University hospital medical intensive care unit. PATIENTS: Two hundred forty-five patients with predominantly cardiovascular and pulmonary disorders. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Demographic data, Simplified Acute Physiology Score (SAPS) II, and Sepsis-Related Organ Failure Assessment (SOFA) were obtained. All adult survivors staying in the intensive care unit for &amp;amp;amp;gt;24 hrs were eligible. Pre-intensive care unit status was obtained for 245 patients (179 males, mean age 64 yrs, mean intensive care unit stay 3 days, SAPS II 26 +/- 10), and 153 patients completed all three questionnaires. In this cohort, none of the eight health dimensions of the SF-36 showed impaired functioning after 9 months compared with baseline values. Physical and emotional role deteriorated after 1 month but returned to baseline thereafter. Notably, the mental health summary scale did not change during the course of the study, whereas the physical health summary scale consistently improved over time. Patients older than the median of 66 yrs rated their physical functioning lower. No association with SAPS II or SOFA and SF-36 was found. CONCLUSION: Quality of life after intensive care unit is a dynamic process, with some functions improving shortly after intensive care unit discharge and others deteriorating but returning at least to baseline values later on. In this patient population, the SF-36 was independent from measures of severity of illness or morbidity. Health-related quality of life represents a feasible method to collect patients’ individual views in contrast to surrogate measures of outcome.;,citation_author=Jürgen Graf;,citation_author=Mechthild Koch;,citation_author=Robert Dujardin;,citation_author=Alexander Kersten;,citation_author=Uwe Janssens;,citation_publication_date=2003-08;,citation_cover_date=2003-08;,citation_year=2003;,citation_issue=8;,citation_doi=10.1097/01.CCM.0000079607.87009.3A;,citation_issn=0090-3493;,citation_pmid=12973175;,citation_volume=31;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Acute Respiratory Distress Syndrome;,citation_author=Alin Gragossian;,citation_author=Matthew T. Siuba;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_issue=3;,citation_doi=10.1016/j.emc.2022.05.002;,citation_issn=07338627;,citation_volume=40;,citation_language=en-US;,citation_journal_title=Emergency Medicine Clinics of North America;">
<meta name="citation_reference" content="citation_title=Adaptr: An R package for simulating and comparingadaptive clinical trials;,citation_abstract=The adaptr R package facilitates simulation and comparison of adaptive clinical trial designs using Bayesian statistical methods. The package supports a flexible number of arms, use of a common control arm, pre-specified and user-defined outcome- and posterior probability distribution-generating functions, fixed- and response-adaptive randomisation (RAR), various adaptation rules for arm dropping and stopping, calculation of trial design performance metrics, and visualisation of results. Simulations are relatively fast, can run in parallel, and can be reloaded from previous sessions.;,citation_author=Anders Granholm;,citation_author=Aksel Karl Georg Jensen;,citation_author=Theis Lange;,citation_author=Benjamin Skov Kaas-Hansen;,citation_publication_date=2022-04;,citation_cover_date=2022-04;,citation_year=2022;,citation_issue=72;,citation_doi=10.21105/joss.04284;,citation_issn=2475-9066;,citation_volume=7;,citation_language=en-US;,citation_journal_title=Journal of Open Source Software;">
<meta name="citation_reference" content="citation_title=Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: A pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial;,citation_abstract=Purpose: We compared dexamethasone 12 versus 6 mg daily for up to 10 days in patients with coronavirus disease 2019 (COVID-19) and severe hypoxaemia in the international, randomised, blinded COVID STEROID 2 trial. In the primary, conventional analyses, the predefined statistical significance thresholds were not reached. We conducted a pre-planned Bayesian analysis to facilitate probabilistic interpretation. Methods: We analysed outcome data within 90 days in the intention-to-treat population (data available in 967 to 982 patients) using Bayesian models with various sensitivity analyses. Results are presented as median posterior probabili-ties with 95% credible intervals (CrIs) and probabilities of different effect sizes with 12 mg dexamethasone. Results: The adjusted mean difference on days alive without life support at day 28 (primary outcome) was 1.3 days (95% CrI -0.3 to 2.9; 94.2% probability of benefit). Adjusted relative risks and probabilities of benefit on seri-ous adverse reactions was 0.85 (0.63 to 1.16; 84.1%) and on mortality 0.87 (0.73 to 1.03; 94.8%) at day 28 and 0.88 (0.75 to 1.02; 95.1%) at day 90. Probabilities of benefit on days alive without life support and days alive out of hospital at day 90 were 85 and 95.7%, respectively. Results were largely consistent across sensitivity analyses, with relatively low probabilities of clinically important harm with 12 mg on all outcomes in all analyses.;,citation_author=Anders Granholm;,citation_author=Marie Warrer Munch;,citation_author=Sheila Nainan Myatra;,citation_author=Bharath Kumar Tirupakuzhi Vijayaraghavan;,citation_author=Maria Cronhjort;,citation_author=Rebecka Rubenson Wahlin;,citation_author=Stephan M. Jakob;,citation_author=Luca Cioccari;,citation_author=Maj-Brit Nørregaard Kjær;,citation_author=Gitte Kingo Vesterlund;,citation_author=Tine Sylvest Meyhoff;,citation_author=Marie Helleberg;,citation_author=Morten Hylander Møller;,citation_author=Thomas Benfield;,citation_author=Balasubramanian Venkatesh;,citation_author=Naomi E. Hammond;,citation_author=Sharon Micallef;,citation_author=Abhinav Bassi;,citation_author=Oommen John;,citation_author=Vivekanand Jha;,citation_author=Klaus Tjelle Kristiansen;,citation_author=Charlotte Suppli Ulrik;,citation_author=Vibeke Lind Jørgensen;,citation_author=Margit Smitt;,citation_author=Morten H. Bestle;,citation_author=Anne Sofie Andreasen;,citation_author=Lone Musaeus Poulsen;,citation_author=Bodil Steen Rasmussen;,citation_author=Anne Craveiro Brøchner;,citation_author=Thomas Strøm;,citation_author=Anders Møller;,citation_author=Mohd Saif Khan;,citation_author=Ajay Padmanaban;,citation_author=Jigeeshu Vasishtha Divatia;,citation_author=Sanjith Saseedharan;,citation_author=Kapil Borawake;,citation_author=Farhad Kapadia;,citation_author=Subhal Dixit;,citation_author=Rajesh Chawla;,citation_author=Urvi Shukla;,citation_author=Pravin Amin;,citation_author=Michelle S. Chew;,citation_author=Christian Aage Wamberg;,citation_author=Christian Gluud;,citation_author=Theis Lange;,citation_author=Anders Perner;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=1;,citation_doi=10.1007/s00134-021-06573-1;,citation_issn=0342-4642, 1432-1238;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Higher vs Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia (COVID STEROID 2) trial: Protocol for a secondary Bayesian analysis;,citation_abstract=Background: Coronavirus disease 2019 (COVID-) can lead to severe hypoxic respiratory failure and death. Corticosteroids decrease mortality in severely or critically ill patients with COVID-. However, the optimal dose remains unresolved. The ongoing randomised COVID STEROID 2 trial investigates the effects of higher vs lower doses of dexamethasone (12 vs 6 mg intravenously daily for up to 10 days) in 1,000 adult patients with COVID- and severe hypoxia.;,citation_author=Anders Granholm;,citation_author=Marie Warrer Munch;,citation_author=Sheila Nainan Myatra;,citation_author=Bharath Kumar Tirupakuzhi Vijayaraghavan;,citation_author=Maria Cronhjort;,citation_author=Rebecka Rubenson Wahlin;,citation_author=Stephan M. Jakob;,citation_author=Luca Cioccari;,citation_author=Maj-Brit Nørregaard Kjær;,citation_author=Gitte Kingo Vesterlund;,citation_author=Tine Sylvest Meyhoff;,citation_author=Marie Helleberg;,citation_author=Morten Hylander Møller;,citation_author=Thomas Benfield;,citation_author=Balasubramanian Venkatesh;,citation_author=Naomi Hammond;,citation_author=Sharon Micallef;,citation_author=Abhinav Bassi;,citation_author=Oommen John;,citation_author=Vivekanand Jha;,citation_author=Klaus Tjelle Kristiansen;,citation_author=Charlotte Suppli Ulrik;,citation_author=Vibeke Lind Jørgensen;,citation_author=Margit Smitt;,citation_author=Morten H. Bestle;,citation_author=Anne Sofie Andreasen;,citation_author=Lone Musaeus Poulsen;,citation_author=Bodil Steen Rasmussen;,citation_author=Anne Craveiro Brøchner;,citation_author=Thomas Strøm;,citation_author=Anders Møller;,citation_author=Mohd Saif Khan;,citation_author=Ajay Padmanaban;,citation_author=Jigeeshu Vasishtha Divatia;,citation_author=Sanjith Saseedharan;,citation_author=Kapil Borawake;,citation_author=Farhad Kapadia;,citation_author=Subhal Dixit;,citation_author=Rajesh Chawla;,citation_author=Urvi Shukla;,citation_author=Pravin Amin;,citation_author=Michelle S. Chew;,citation_author=Christian Gluud;,citation_author=Theis Lange;,citation_author=Anders Perner;,citation_publication_date=2021-05;,citation_cover_date=2021-05;,citation_year=2021;,citation_issue=5;,citation_doi=10.1111/aas.13793;,citation_issn=0001-5172, 1399-6576;,citation_volume=65;,citation_language=en-US;,citation_journal_title=Acta Anaesthesiologica Scandinavica;">
<meta name="citation_reference" content="citation_title=Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia;,citation_abstract=Purpose: We assessed long-term outcomes of dexamethasone 12 mg versus 6 mg given daily for up to 10 days in patients with coronavirus disease 2019 (COVID-19) and severe hypoxaemia. Methods: We assessed 180-day mortality and health-related quality of life (HRQoL) using EuroQoL (EQ)-5D-5L index values and EQ visual analogue scale (VAS) in the international, stratified, blinded COVID STEROID 2 trial, which ran-domised 1000 adults with confirmed COVID-19 receiving at least 10 L/min of oxygen or mechanical ventilation in 26 hospitals in Europe and India. In the HRQoL analyses, higher values indicated better outcomes, and deceased patients were given a score of zero. Results: We obtained vital status at 180 days for 963 of 982 patients (98.1%) in the intention-to-treat population, EQ5D-5L index value data for 922 (93.9%) and EQ VAS data for 924 (94.1%). At 180 days, 164 of 486 patients (33.7%) had died in the 12 mg group versus 184 of 477 (38.6%) in the 6 mg group [adjusted risk difference - 4.3%; 99% confidence interval (CI) - 11.7–3.0; relative risk 0.89; 0.72–1.09; P = 0.13]. The adjusted mean differences between the 12 mg and the 6 mg groups in EQ-5D-5L index values were 0.06 (99% CI - 0.01 to 0.12; P = 0.10) and in EQ VAS scores 4 (- 3 to 10; P = 0.22).;,citation_author=Anders Granholm;,citation_author=Maj-Brit Nørregaard Kjær;,citation_author=Marie Warrer Munch;,citation_author=Sheila Nainan Myatra;,citation_author=Bharath Kumar Tirupakuzhi Vijayaraghavan;,citation_author=Maria Cronhjort;,citation_author=Rebecka Rubenson Wahlin;,citation_author=Stephan M. Jakob;,citation_author=Luca Cioccari;,citation_author=Gitte Kingo Vesterlund;,citation_author=Tine Sylvest Meyhoff;,citation_author=Marie Helleberg;,citation_author=Morten Hylander Møller;,citation_author=Thomas Benfield;,citation_author=Balasubramanian Venkatesh;,citation_author=Naomi E. Hammond;,citation_author=Sharon Micallef;,citation_author=Abhinav Bassi;,citation_author=Oommen John;,citation_author=Vivekanand Jha;,citation_author=Klaus Tjelle Kristiansen;,citation_author=Charlotte Suppli Ulrik;,citation_author=Vibeke Lind Jørgensen;,citation_author=Margit Smitt;,citation_author=Morten H. Bestle;,citation_author=Anne Sofie Andreasen;,citation_author=Lone Musaeus Poulsen;,citation_author=Bodil Steen Rasmussen;,citation_author=Anne Craveiro Brøchner;,citation_author=Thomas Strøm;,citation_author=Anders Møller;,citation_author=Mohd Saif Khan;,citation_author=Ajay Padmanaban;,citation_author=Jigeeshu Vasishtha Divatia;,citation_author=Sanjith Saseedharan;,citation_author=Kapil Borawake;,citation_author=Farhad Kapadia;,citation_author=Subhal Dixit;,citation_author=Rajesh Chawla;,citation_author=Urvi Shukla;,citation_author=Pravin Amin;,citation_author=Michelle S. Chew;,citation_author=Christian Aage Wamberg;,citation_author=Neeta Bose;,citation_author=Mehul S. Shah;,citation_author=Iben S. Darfelt;,citation_author=Christian Gluud;,citation_author=Theis Lange;,citation_author=Anders Perner;,citation_publication_date=2022-05;,citation_cover_date=2022-05;,citation_year=2022;,citation_issue=5;,citation_doi=10.1007/s00134-022-06677-2;,citation_issn=0342-4642, 1432-1238;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Patient-Important Outcomes Other Than Mortality in Contemporary ICU Trials: A Scoping Review;,citation_author=Anders Granholm;,citation_author=Carl T. Anthon;,citation_author=Maj-Brit N. Kjær;,citation_author=Mathias Maagaard;,citation_author=Benjamin S. Kaas-Hansen;,citation_author=Praleene Sivapalan;,citation_author=Olav L. Schjørring;,citation_author=Lars W. Andersen;,citation_author=Ole Mathiesen;,citation_author=Thomas Strøm;,citation_author=Aksel K. G. Jensen;,citation_author=Anders Perner;,citation_author=Morten H. Møller;,citation_publication_date=2022-10;,citation_cover_date=2022-10;,citation_year=2022;,citation_issue=10;,citation_doi=10.1097/CCM.0000000000005637;,citation_issn=0090-3493;,citation_volume=50;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Randomised clinical trials in critical care: Past, present and future;,citation_abstract=Randomised clinical trials (RCTs) are the gold standard for providing unbiased evidence of intervention effects. Here, we provide an overview of the history of RCTs and discuss the major challenges and limitations of current critical care RCTs, including overly optimistic effect sizes; unnuanced conclusions based on dichotomization of results; limited focus on patient-centred outcomes other than mortality; lack of flexibility and ability to adapt, increasing the risk of inconclusive results and limiting knowledge gains before trial completion; and inefficiency due to lack of re-use of trial infrastructure. We discuss recent developments in critical care RCTs and novel methods that may provide solutions to some of these challenges, including a research programme approach (consecutive, complementary studies of multiple types rather than individual, independent studies), and novel design and analysis methods. These include standardization of trial protocols; alternative outcome choices and use of core outcome sets; increased acceptance of uncertainty, probabilistic interpretations and use of Bayesian statistics; novel approaches to assessing heterogeneity of treatment effects; adaptation and platform trials; and increased integration between clinical trials and clinical practice. We outline the advantages and discuss the potential methodological and practical disadvantages with these approaches. With this review, we aim to inform clinicians and researchers about conventional and novel RCTs, including the rationale for choosing one or the other methodological approach based on a thorough discussion of pros and cons. Importantly, the most central feature remains the randomisation, which provides unparalleled restriction of confounding compared to non-randomised designs by reducing confounding to chance.;,citation_author=Anders Granholm;,citation_author=Waleed Alhazzani;,citation_author=Lennie P. G. Derde;,citation_author=Derek C. Angus;,citation_author=Fernando G. Zampieri;,citation_author=Naomi E. Hammond;,citation_author=Rob Mac Sweeney;,citation_author=Sheila N. Myatra;,citation_author=Elie Azoulay;,citation_author=Kathryn Rowan;,citation_author=Paul J. Young;,citation_author=Anders Perner;,citation_author=Morten Hylander Møller;,citation_publication_date=2021-12;,citation_cover_date=2021-12;,citation_year=2021;,citation_doi=10.1007/s00134-021-06587-9;,citation_issn=0342-4642, 1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Converting an odds ratio to a range of plausible relative risks for better communication of research findings;,citation_author=R. L. Grant;,citation_publication_date=2014-01;,citation_cover_date=2014-01;,citation_year=2014;,citation_issue=jan24 1;,citation_doi=10.1136/bmj.f7450;,citation_issn=1756-1833;,citation_volume=348;,citation_language=en-US;,citation_journal_title=BMJ;">
<meta name="citation_reference" content="citation_title=Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes;,citation_abstract=Objective The contemporary diagnosis of paraneoplastic neurologic syndromes (PNSs) requires an increasing understanding of their clinical, immunologic, and oncologic heterogeneity. The 2004 PNS criteria are partially outdated due to advances in PNS research in the last 16 years leading to the identification of new phenotypes and antibodies that have transformed the diagnostic approach to PNS. Here, we propose updated diagnostic criteria for PNS. Methods A panel of experts developed by consensus a modified set of diagnostic PNS criteria for clinical decision making and research purposes. The panel reappraised the 2004 criteria alongside new knowledge on PNS obtained from published and unpublished data generated by the different laboratories involved in the project. Results The panel proposed to substitute “classical syndromes” with the term “high-risk phenotypes” for cancer and introduce the concept of “intermediate-risk phenotypes.” The term “onconeural antibody” was replaced by “high risk” (&amp;amp;amp;gt;70% associated with cancer) and “intermediate risk” (30%–70% associated with cancer) antibodies. The panel classified 3 levels of evidence for PNS: definite, probable, and possible. Each level can be reached by using the PNS-Care Score, which combines clinical phenotype, antibody type, the presence or absence of cancer, and time of follow-up. With the exception of opsoclonus-myoclonus, the diagnosis of definite PNS requires the presence of high- or intermediate-risk antibodies. Specific recommendations for similar syndromes triggered by immune checkpoint inhibitors are also provided. Conclusions The proposed criteria and recommendations should be used to enhance the clinical care of patients with PNS and to encourage standardization of research initiatives addressing PNS.;,citation_author=Francesc Graus;,citation_author=Alberto Vogrig;,citation_author=Sergio Muñiz-Castrillo;,citation_author=Jean-Christophe G. Antoine;,citation_author=Virginie Desestret;,citation_author=Divyanshu Dubey;,citation_author=Bruno Giometto;,citation_author=Sarosh R. Irani;,citation_author=Bastien Joubert;,citation_author=Frank Leypoldt;,citation_author=Andrew McKeon;,citation_author=Harald Prüss;,citation_author=Dimitri Psimaras;,citation_author=Laure Thomas;,citation_author=Maarten J. Titulaer;,citation_author=Christian A. Vedeler;,citation_author=Jan J. Verschuuren;,citation_author=Josep Dalmau;,citation_author=Jerome Honnorat;,citation_publication_date=2021-07;,citation_cover_date=2021-07;,citation_year=2021;,citation_issue=4;,citation_doi=10.1212/NXI.0000000000001014;,citation_issn=2332-7812;,citation_volume=8;,citation_language=en-US;,citation_journal_title=Neurology - Neuroimmunology Neuroinflammation;">
<meta name="citation_reference" content="citation_title=Targeted temperature management after out-of-hospital cardiac arrest, no de-implementation required based on network meta analysis;,citation_author=Benjamin Yaël Gravesteijn;,citation_author=Charlie Aletta Sewalt;,citation_publication_date=2021-12;,citation_cover_date=2021-12;,citation_year=2021;,citation_issue=12;,citation_doi=10.1007/s00134-021-06520-0;,citation_issn=0342-4642, 1432-1238;,citation_volume=47;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Decline in Independent Activity as a Cause of Decline in Children’s Mental Well-being: Summary of the Evidence;,citation_author=Peter Gray;,citation_author=David F. Lancy;,citation_author=David F. Bjorklund;,citation_publication_date=2023-09;,citation_cover_date=2023-09;,citation_year=2023;,citation_doi=10.1016/j.jpeds.2023.02.004;,citation_issn=00223476;,citation_volume=260;,citation_language=en-US;,citation_journal_title=The Journal of Pediatrics;">
<meta name="citation_reference" content="citation_title=2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association;,citation_author=Steven M. Greenberg;,citation_author=Wendy C. Ziai;,citation_author=Charlotte Cordonnier;,citation_author=Dar Dowlatshahi;,citation_author=Brandon Francis;,citation_author=Joshua N. Goldstein;,citation_author=J. Claude Hemphill;,citation_author=Ronda Johnson;,citation_author=Kiffon M. Keigher;,citation_author=William J. Mack;,citation_author=J. Mocco;,citation_author=Eileena J. Newton;,citation_author=Ilana M. Ruff;,citation_author=Lauren H. Sansing;,citation_author=Sam Schulman;,citation_author=Magdy H. Selim;,citation_author=Kevin N. Sheth;,citation_author=Nikola Sprigg;,citation_author=Katharina S. Sunnerhagen;,citation_author=null null;,citation_publication_date=2022-07;,citation_cover_date=2022-07;,citation_year=2022;,citation_issue=7;,citation_doi=10.1161/STR.0000000000000407;,citation_volume=53;,citation_journal_title=Stroke;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=Should Evidence Come with an Expiration Date?;,citation_author=Palmer Greene;,citation_author=Vinay Prasad;,citation_author=Adam Cifu;,citation_publication_date=2019-07;,citation_cover_date=2019-07;,citation_year=2019;,citation_issue=7;,citation_doi=10.1007/s11606-019-05032-4;,citation_issn=0884-8734, 1525-1497;,citation_volume=34;,citation_language=en-US;,citation_journal_title=Journal of General Internal Medicine;">
<meta name="citation_reference" content="citation_title=Miasmas, mental models and preventive public health: Some philosophical reflections on science in the COVID-19 pandemic;,citation_abstract=When the history of the COVID-19 pandemic is written, it is likely to show that the mental models held by scientists sometimes facilitated their thinking, thereby leading to lives saved, and at other times constrained their thinking, thereby leading to lives lost. This paper explores some competing mental models of how infectious diseases spread and shows how these models influenced the scientific process and the kinds of facts that were generated, legitimized and used to support policy. A central theme in the paper is the relative weight given by dominant scientific voices to probabilistic arguments based on experimental measurements versus mechanistic arguments based on theory. Two examples are explored: the cholera epidemic in nineteenth century London—in which the story of John Snow and the Broad Street pump is retold—and the unfolding of the COVID-19 pandemic in 2020 and early 2021—in which the evidence-based medicine movement and its hierarchy of evidence features prominently. In each case, it is shown that prevailing mental models—which were assumed by some to transcend theory but were actually heavily theory-laden—powerfully shaped both science and policy, with fatal consequences for some.;,citation_author=Trisha Greenhalgh;,citation_publication_date=2021-12;,citation_cover_date=2021-12;,citation_year=2021;,citation_issue=6;,citation_doi=10.1098/rsfs.2021.0017;,citation_issn=2042-8901;,citation_volume=11;,citation_language=en-US;,citation_journal_title=Interface Focus;">
<meta name="citation_reference" content="citation_title=Causal Diagrams for Epidemiologic Research;,citation_author=Sander Greenland;,citation_author=Judea Pearl;,citation_author=James M. Robins;,citation_publication_date=1999;,citation_cover_date=1999;,citation_year=1999;,citation_fulltext_html_url=https://www.jstor.org/stable/3702180;,citation_issue=1;,citation_volume=10;,citation_language=en-US;,citation_journal_title=Epidemiology;">
<meta name="citation_reference" content="citation_title=Invited Commentary: The Need for Cognitive Science in Methodology;,citation_author=Sander Greenland;,citation_publication_date=2017-09;,citation_cover_date=2017-09;,citation_year=2017;,citation_issue=6;,citation_doi=10.1093/aje/kwx259;,citation_issn=0002-9262, 1476-6256;,citation_volume=186;,citation_language=en-US;,citation_journal_title=American Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Living with P Values: Resurrecting a Bayesian Perspective on Frequentist Statistics;,citation_abstract=In response to the widespread abuse and misinterpretation of significance tests of null hypotheses, some editors and authors have strongly discouraged P values. However, null P values still thrive in most journals and are routinely misinterpreted as probabilities of a “chance finding” or of the null, when they are no such thing. This misuse may be lessened by recognizing correct Bayesian interpretations. For example, under weak priors, 95% confidence intervals approximate 95% posterior probability intervals, one-sided P values approximate directional posterior probabilities, and point estimates approximate posterior medians. Furthermore, under certain conditions, a one-sided P value for a prior median provides an approximate lower bound on the posterior probability that the point estimate is on the wrong side of that median. More generally, P values can be incorporated into a modern analysis framework that emphasizes measurement of fit, distance, and posterior probability in place of “statistical significance” and accept/reject decisions.;,citation_author=Sander Greenland;,citation_author=Charles Poole;,citation_publication_date=2013-01;,citation_cover_date=2013-01;,citation_year=2013;,citation_issue=1;,citation_doi=10.1097/EDE.0b013e3182785741;,citation_issn=1044-3983;,citation_volume=24;,citation_language=en-US;,citation_journal_title=Epidemiology;">
<meta name="citation_reference" content="citation_title=Multiple comparisons controversies are about context and costs, not frequentism versus Bayesianism;,citation_author=Sander Greenland;,citation_author=Albert Hofman;,citation_publication_date=2019-09;,citation_cover_date=2019-09;,citation_year=2019;,citation_issue=9;,citation_doi=10.1007/s10654-019-00552-z;,citation_issn=0393-2990, 1573-7284;,citation_volume=34;,citation_language=en-US;,citation_journal_title=European Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Quantifying Biases in Causal Models: Classical Confounding vs Collider-Stratification Bias:;,citation_author=Sander Greenland;,citation_publication_date=2003-05;,citation_cover_date=2003-05;,citation_year=2003;,citation_issue=3;,citation_doi=10.1097/01.EDE.0000042804.12056.6C;,citation_issn=1044-3983;,citation_volume=14;,citation_language=en-US;,citation_journal_title=Epidemiology;">
<meta name="citation_reference" content="citation_title=Sparse data bias: A problem hiding in plain sight;,citation_author=Sander Greenland;,citation_author=Mohammad Ali Mansournia;,citation_author=Douglas G Altman;,citation_publication_date=2016-04;,citation_cover_date=2016-04;,citation_year=2016;,citation_doi=10.1136/bmj.i1981;,citation_issn=1756-1833;,citation_language=en-US;,citation_journal_title=BMJ;">
<meta name="citation_reference" content="citation_title=Statistical tests, P values, confidence intervals, and power: A guide to misinterpretations;,citation_author=Sander Greenland;,citation_author=Stephen J. Senn;,citation_author=Kenneth J. Rothman;,citation_author=John B. Carlin;,citation_author=Charles Poole;,citation_author=Steven N. Goodman;,citation_author=Douglas G. Altman;,citation_publication_date=2016-04;,citation_cover_date=2016-04;,citation_year=2016;,citation_issue=4;,citation_doi=10.1007/s10654-016-0149-3;,citation_issn=0393-2990, 1573-7284;,citation_volume=31;,citation_language=en-US;,citation_journal_title=European Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Valid &amp;amp;amp;lt;i&amp;gt;P&amp;lt;/i&amp;gt; -Values Behave Exactly as They Should: Some Misleading Criticisms of <i>P</i> -Values and Their Resolution With <i>S</i> -Values;,citation_author=Sander Greenland;,citation_publication_date=2019-03;,citation_cover_date=2019-03;,citation_year=2019;,citation_issue=sup1;,citation_doi=10.1080/00031305.2018.1529625;,citation_issn=0003-1305, 1537-2731;,citation_volume=73;,citation_language=en-US;,citation_journal_title=The American Statistician;">
<meta name="citation_reference" content="citation_title=Evaluation of Left Ventricular Diastolic Function by the Intensivist;,citation_author=Yonatan Y. Greenstein;,citation_author=Paul H. Mayo;,citation_publication_date=2018-03;,citation_cover_date=2018-03;,citation_year=2018;,citation_issue=3;,citation_doi=10.1016/j.chest.2017.10.032;,citation_issn=00123692;,citation_volume=153;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Pediatric and Adult Brain Death/Death by Neurologic Criteria Consensus Guideline: Report of the AAN Guidelines Subcommittee, AAP, CNS, and SCCM;,citation_abstract=Background and Objectives The purpose of this guideline is to update the 2010 American Academy of Neurology (AAN) brain death/death by neurologic criteria (BD/DNC) guideline for adults and the 2011 American Academy of Pediatrics, Child Neurology Society, and Society of Critical Care Medicine guideline for infants and children and to clarify the BD/DNC determination process by integrating guidance for adults and children into a single guideline. Updates in this guideline include guidance related to conducting the BD/DNC evaluation in the context of extracorporeal membrane oxygenation, targeted temperature management, and primary infratentorial injury.;,citation_author=David M. Greer;,citation_author=Matthew P. Kirschen;,citation_author=Ariane Lewis;,citation_author=Gary S. Gronseth;,citation_author=Alexander Rae-Grant;,citation_author=Stephen Ashwal;,citation_author=Maya A. Babu;,citation_author=David F. Bauer;,citation_author=Lori Billinghurst;,citation_author=Amanda Corey;,citation_author=Sonia Partap;,citation_author=Michael A. Rubin;,citation_author=Lori Shutter;,citation_author=Courtney Takahashi;,citation_author=Robert C. Tasker;,citation_author=Panayiotis Nicolaou Varelas;,citation_author=Eelco Wijdicks;,citation_author=Amy Bennett;,citation_author=Scott R. Wessels;,citation_author=John J. Halperin;,citation_publication_date=2023-10;,citation_cover_date=2023-10;,citation_year=2023;,citation_doi=10.1212/WNL.0000000000207740;,citation_issn=0028-3878, 1526-632X;,citation_language=en-US;,citation_journal_title=Neurology;">
<meta name="citation_reference" content="citation_title=Non-invasive ventilatory support and high-flow nasal oxygen as first-line treatment of acute hypoxemic respiratory failure and ARDS;,citation_abstract=The role of non-invasive respiratory support (high-flow nasal oxygen and noninvasive ventilation) in the manage-ment of acute hypoxemic respiratory failure and acute respiratory distress syndrome is debated. The oxygenation improvement coupled with lung and diaphragm protection produced by non-invasive support may help to avoid endotracheal intubation, which prevents the complications of sedation and invasive mechanical ventilation. However, spontaneous breathing in patients with lung injury carries the risk that vigorous inspiratory effort, combined or not with mechanical increases in inspiratory airway pressure, produces high transpulmonary pressure swings and local lung overstretch. This ultimately results in additional lung damage (patient self-inflicted lung injury), so that patients intubated after a trial of noninvasive support are burdened by increased mortality. Reducing inspiratory effort by high-flow nasal oxygen or delivery of sustained positive end-expiratory pressure through the helmet interface may reduce these risks. In this physiology-to-bedside review, we provide an updated overview about the role of nonin-vasive respiratory support strategies as early treatment of hypoxemic respiratory failure in the intensive care unit. Noninvasive strategies appear safe and effective in mild-to-moderate hypoxemia (PaO2/FiO2 &amp;amp;amp;gt; 150 mmHg), while they can yield delayed intubation with increased mortality in a significant proportion of moderate-to-severe (PaO2/ FiO2 \leq 150 mmHg) cases. High-flow nasal oxygen and helmet noninvasive ventilation represent the most promising techniques for first-line treatment of severe patients. However, no conclusive evidence allows to recommend a single approach over the others in case of moderate-to-severe hypoxemia. During any treatment, strict physiological moni-toring remains of paramount importance to promptly detect the need for endotracheal intubation and not delay protective ventilation.;,citation_author=Domenico Luca Grieco;,citation_author=Salvatore Maurizio Maggiore;,citation_author=Oriol Roca;,citation_author=Elena Spinelli;,citation_author=Bhakti K. Patel;,citation_author=Arnaud W. Thille;,citation_author=Carmen Sílvia V. Barbas;,citation_author=Marina Garcia Acilu;,citation_author=Salvatore Lucio Cutuli;,citation_author=Filippo Bongiovanni;,citation_author=Marcelo Amato;,citation_author=Jean-Pierre Frat;,citation_author=Tommaso Mauri;,citation_author=John P. Kress;,citation_author=Jordi Mancebo;,citation_author=Massimo Antonelli;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_issue=8;,citation_doi=10.1007/s00134-021-06459-2;,citation_issn=0342-4642, 1432-1238;,citation_volume=47;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Personalized noninvasive respiratory support for acute hypoxemic respiratory failure;,citation_author=Domenico Luca Grieco;,citation_author=Laveena Munshi;,citation_author=Lise Piquilloud;,citation_publication_date=2023-07;,citation_cover_date=2023-07;,citation_year=2023;,citation_issue=7;,citation_doi=10.1007/s00134-023-07048-1;,citation_issn=1432-1238;,citation_volume=49;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Collider bias undermines our understanding of COVID-19 disease risk and severity;,citation_abstract=Abstract Numerous observational studies have attempted to identify risk factors for infection with SARS-CoV-2 and COVID-19 disease outcomes. Studies have used datasets sampled from patients admitted to hospital, people tested for active infection, or people who volunteered to participate. Here, we highlight the challenge of interpreting observational evidence from such non-representative samples. Collider bias can induce associations between two or more variables which affect the likelihood of an individual being sampled, distorting associations between these variables in the sample. Analysing UK Biobank data, compared to the wider cohort the participants tested for COVID-19 were highly selected for a range of genetic, behavioural, cardiovascular, demographic, and anthropometric traits. We discuss the mechanisms inducing these problems, and approaches that could help mitigate them. While collider bias should be explored in existing studies, the optimal way to mitigate the problem is to use appropriate sampling strategies at the study design stage.;,citation_author=Gareth J. Griffith;,citation_author=Tim T. Morris;,citation_author=Matthew J. Tudball;,citation_author=Annie Herbert;,citation_author=Giulia Mancano;,citation_author=Lindsey Pike;,citation_author=Gemma C. Sharp;,citation_author=Jonathan Sterne;,citation_author=Tom M. Palmer;,citation_author=George Davey Smith;,citation_author=Kate Tilling;,citation_author=Luisa Zuccolo;,citation_author=Neil M. Davies;,citation_author=Gibran Hemani;,citation_publication_date=2020-12;,citation_cover_date=2020-12;,citation_year=2020;,citation_issue=1;,citation_doi=10.1038/s41467-020-19478-2;,citation_issn=2041-1723;,citation_volume=11;,citation_language=en-US;,citation_journal_title=Nature Communications;">
<meta name="citation_reference" content="citation_title=Epidemiology in the right direction: The importance of descriptive research;,citation_author=Diederick E. Grobbee;,citation_publication_date=2004;,citation_cover_date=2004;,citation_year=2004;,citation_issue=8;,citation_doi=10.1023/b:ejep.0000036614.48503.2c;,citation_issn=0393-2990;,citation_pmid=15469029;,citation_volume=19;,citation_language=en-US;,citation_journal_title=European Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Hematoma Enlargement as a Target for Treating Intracerebral Hemorrhage: A More Granular View;,citation_author=James C. Grotta;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_issue=8;,citation_doi=10.1212/WNL.0000000000012391;,citation_issn=0028-3878, 1526-632X;,citation_volume=97;,citation_language=en-US;,citation_journal_title=Neurology;">
<meta name="citation_reference" content="citation_title=Prospective, Multicenter, Controlled Trial of Mobile Stroke Units;,citation_abstract=BACKGROUND Mobile stroke units (MSUs) are ambulances with staff and a computed tomographic scanner that may enable faster treatment with tissue plasminogen activator (t-PA) than standard management by emergency medical services (EMS). Whether and how much MSUs alter outcomes has not been extensively studied. METHODS In an observational, prospective, multicenter, alternating-week trial, we assessed outcomes from MSU or EMS management within 4.5 hours after onset of acute stroke symptoms. The primary outcome was the score on the utility-weighted modified Rankin scale (range, 0 to 1, with higher scores indicating better outcomes according to a patient value system, derived from scores on the modified Rankin scale of 0 to 6, with higher scores indicating more disability). The main analysis involved dichotomized scores on the utility-weighted modified Rankin scale (\geq0.91 or &amp;amp;amp;lt;0.91, approximating scores on the modified Rankin scale of \leq1 or &amp;gt;1) at 90 days in patients eligible for t-PA. Analyses were also performed in all enrolled patients. The authors’ full names, academic degrees, and affiliations are listed in the Appendix. Address reprint requests to Dr. Grotta at the Mobile Stroke Unit, Memorial Hermann Hospital–Texas Medical Center, 6410 Fannin St., Suite 1423, Houston, TX 77030, or at james.c.grotta@u th.tmc.edu. Drs. Grotta and Yamal and Ms. Parker contributed equally to this article. N Engl J Med 2021;385:971-81. DOI: 10.1056/NEJMoa2103879 Copyright © 2021 Massachusetts Medical Society. CME at NEJM.org RESULTS We enrolled 1515 patients, of whom 1047 were eligible to receive t-PA; 617 received care by MSU and 430 by EMS. The median time from onset of stroke to administration of t-PA was 72 minutes in the MSU group and 108 minutes in the EMS group. Of patients eligible for t-PA, 97.1% in the MSU group received t-PA, as compared with 79.5% in the EMS group. The mean score on the utility-weighted modified Rankin scale at 90 days in patients eligible for t-PA was 0.72 in the MSU group and 0.66 in the EMS group (adjusted odds ratio for a score of \geq0.91, 2.43; 95% confidence interval [CI], 1.75 to 3.36; P&amp;lt;0.001). Among the patients eligible for t-PA, 55.0% in the MSU group and 44.4% in the EMS group had a score of 0 or 1 on the modified Rankin scale at 90 days. Among all enrolled patients, the mean score on the utility-weighted modified Rankin scale at discharge was 0.57 in the MSU group and 0.51 in the EMS group (adjusted odds ratio for a score of \geq0.91, 1.82; 95% CI, 1.39 to 2.37; P<0.001). Secondary clinical outcomes generally favored MSUs. Mortality at 90 days was 8.9% in the MSU group and 11.9% in the EMS group. CONCLUSIONS In patients with acute stroke who were eligible for t-PA, utility-weighted disability outcomes at 90 days were better with MSUs than with EMS. (Funded by the PatientCentered Outcomes Research Institute; BEST-MSU ClinicalTrials.gov number, NCT02190500.);,citation_author=James C. Grotta;,citation_author=Jose-Miguel Yamal;,citation_author=Stephanie A. Parker;,citation_author=Suja S. Rajan;,citation_author=Nicole R. Gonzales;,citation_author=William J. Jones;,citation_author=Anne W. Alexandrov;,citation_author=Babak B. Navi;,citation_author=May Nour;,citation_author=Ilana Spokoyny;,citation_author=Jason Mackey;,citation_author=David Persse;,citation_author=Asha P. Jacob;,citation_author=Mengxi Wang;,citation_author=Noopur Singh;,citation_author=Andrei V. Alexandrov;,citation_author=Matthew E. Fink;,citation_author=Jeffrey L. Saver;,citation_author=Joey English;,citation_author=Nobl Barazangi;,citation_author=Patti L. Bratina;,citation_author=Michael Gonzalez;,citation_author=Brandi D. Schimpf;,citation_author=Kim Ackerson;,citation_author=Carla Sherman;,citation_author=Mackenzie Lerario;,citation_author=Saad Mir;,citation_author=Jenny Im;,citation_author=Josh Z. Willey;,citation_author=David Chiu;,citation_author=Michael Eisshofer;,citation_author=Janice Miller;,citation_author=David Ornelas;,citation_author=James P. Rhudy;,citation_author=Kevin M. Brown;,citation_author=Bryan M. Villareal;,citation_author=Marianne Gausche-Hill;,citation_author=Nichole Bosson;,citation_author=Greg Gilbert;,citation_author=Sarah Q. Collins;,citation_author=Kelly Silnes;,citation_author=Jay Volpi;,citation_author=Vivek Misra;,citation_author=James McCarthy;,citation_author=Tom Flanagan;,citation_author=Chethan P. V. Rao;,citation_author=Joseph S. Kass;,citation_author=Laura Griffin;,citation_author=Nicole Rangel-Gutierrez;,citation_author=Edgar Lechuga;,citation_author=Jonathan Stephenson;,citation_author=Kenny Phan;,citation_author=Yvette Sanders;,citation_author=Elizabeth A. Noser;,citation_author=Ritvij Bowry;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_issue=11;,citation_doi=10.1056/NEJMoa2103879;,citation_issn=0028-4793, 1533-4406;,citation_volume=385;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Variability in the Use of Platelet Transfusion in Patients with Intracerebral Hemorrhage: Observations from the Ethnic/Racial Variations of Intracerebral Hemorrhage Study;,citation_author=Waldo R. Guerrero;,citation_author=Nicole R. Gonzales;,citation_author=Padmini Sekar;,citation_author=Jorge Kawano-Castillo;,citation_author=Charles J. Moomaw;,citation_author=Bradford B. Worrall;,citation_author=Carl D. Langefeld;,citation_author=Sharyl R. Martini;,citation_author=Matthew L. Flaherty;,citation_author=Kevin N. Sheth;,citation_author=Jennifer Osborne;,citation_author=Daniel Woo;,citation_publication_date=2017-09;,citation_cover_date=2017-09;,citation_year=2017;,citation_issue=9;,citation_doi=10.1016/j.jstrokecerebrovasdis.2017.06.014;,citation_issn=10523057;,citation_volume=26;,citation_language=en-US;,citation_journal_title=Journal of Stroke and Cerebrovascular Diseases;">
<meta name="citation_reference" content="citation_title=Aggressiveness of care following intracerebral hemorrhage in women and men;,citation_abstract=OBJECTIVE: To compare comorbidities and use of surgery and palliative care between men and women with intracerebral hemorrhage (ICH). METHODS: The Ethnic/Racial Variations of Intracerebral Hemorrhage (ERICH) study is a prospective, multicenter, case-control study of ICH risk factors and outcomes. We compared comorbidities, treatments, and use of do-not-resuscitate (DNR) orders in men vs women. Multivariate analysis was used to assess the likelihood of ICH surgery and palliative care after adjustment for variables that were p &amp;amp;amp;lt; 0.1 in univariate analyses and backward elimination to retain those that were significant (p &amp;lt; 0.05). RESULTS: Women were older on average (65.0 vs 59.9, p < 0.0001), and higher proportions of women had previous stroke (24.1% vs 19.3%, p = 0.002), had dementia (6.1% vs 3.4%, p = 0.0007), lived alone (23.1% vs 18.0%, p = 0.0005), and took anticoagulants (12.8% vs 10.1% p = 0.02), compared with men. Men had higher rates of alcohol and cocaine use. After adjusting for age, hematoma volume, and ICH location, there was no difference in rates of surgical treatment by sex (odds ratio [OR] 0.93 for men vs women, 95% confidence interval [CI] 0.68-1.28, p = 0.67), and there was no difference in DNR/comfort care decisions after adjustment for ICH score, prior stroke, and dementia (OR 0.96, CI 0.77-1.22, p = 0.76). CONCLUSIONS: After ICH, women do not receive less aggressive care than men after controlling for the substantial comorbidity differences. Future studies on sex bias should include the presence of comorbidities, prestroke disability, and other factors that may influence management.;,citation_author=Rahul Guha;,citation_author=Amelia Boehme;,citation_author=Stacie L. Demel;,citation_author=Janet J. Li;,citation_author=Xuemei Cai;,citation_author=Michael L. James;,citation_author=Sebastian Koch;,citation_author=Carl D. Langefeld;,citation_author=Charles J. Moomaw;,citation_author=Jennifer Osborne;,citation_author=Padmini Sekar;,citation_author=Kevin N. Sheth;,citation_author=E. Woodrich;,citation_author=Bradford B. Worrall;,citation_author=Daniel Woo;,citation_author=Seemant Chaturvedi;,citation_publication_date=2017-07;,citation_cover_date=2017-07;,citation_year=2017;,citation_issue=4;,citation_doi=10.1212/WNL.0000000000004143;,citation_issn=1526-632X;,citation_pmid=28659419;,citation_volume=89;,citation_language=en-US;,citation_journal_title=Neurology;">
<meta name="citation_reference" content="citation_title=A balanced view of balanced solutions;,citation_abstract=The present review of fluid therapy studies using balanced solutions versus isotonic saline fluids (both crystalloids and colloids) aims to address recent controversy in this topic. The change to the acid-base equilibrium based on fluid selection is described. Key terms such as dilutional-hyperchloraemic acidosis (correctly used instead of dilutional acidosis or hyperchloraemic metabolic acidosis to account for both the Henderson-Hasselbalch and Stewart equations), isotonic saline and balanced solutions are defined. The review concludes that dilutional-hyperchloraemic acidosis is a side effect, mainly observed after the administration of large volumes of isotonic saline as a crystalloid. Its effect is moderate and relatively transient, and is minimised by limiting crystalloid administration through the use of colloids (in any carrier). Convincing evidence for clinically relevant adverse effects of dilutional-hyperchloraemic acidosis on renal function, coagulation, blood loss, the need for transfusion, gastrointestinal function or mortality cannot be found. In view of the long-term use of isotonic saline either as a crystalloid or as a colloid carrier, the paucity of data documenting detrimental effects of dilutional-hyperchloraemic acidosis and the limited published information on the effects of balanced solutions on outcome, we cannot currently recommend changing fluid therapy to the use of a balanced colloid preparation.;,citation_author=Bertrand Guidet;,citation_author=Neil Soni;,citation_author=Giorgio Della Rocca;,citation_author=Sibylle Kozek;,citation_author=Benoı̂t Vallet;,citation_author=Djillali Annane;,citation_author=Mike James;,citation_publication_date=2010;,citation_cover_date=2010;,citation_year=2010;,citation_issue=5;,citation_doi=10.1186/cc9230;,citation_issn=1466-609X;,citation_pmid=21067552;,citation_volume=14;,citation_language=en-US;,citation_journal_title=Critical Care (London, England);">
<meta name="citation_reference" content="citation_title=Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia;,citation_abstract=BACKGROUND The efficacy and safety of tofacitinib, a Janus kinase inhibitor, in patients who are hospitalized with coronavirus disease 2019 (Covid-19) pneumonia are unclear. METHODS We randomly assigned, in a 1:1 ratio, hospitalized adults with Covid-19 pneumonia to receive either tofacitinib at a dose of 10 mg or placebo twice daily for up to 14 days or until hospital discharge. The primary outcome was the occurrence of death or respiratory failure through day 28 as assessed with the use of an eightlevel ordinal scale (with scores ranging from 1 to 8 and higher scores indicating a worse condition). All-cause mortality and safety were also assessed. RESULTS A total of 289 patients underwent randomization at 15 sites in Brazil. Overall, 89.3% of the patients received glucocorticoids during hospitalization. The cumulative incidence of death or respiratory failure through day 28 was 18.1% in the tofacitinib group and 29.0% in the placebo group (risk ratio, 0.63; 95% confidence interval [CI], 0.41 to 0.97; P = 0.04). Death from any cause through day 28 occurred in 2.8% of the patients in the tofacitinib group and in 5.5% of those in the placebo group (hazard ratio, 0.49; 95% CI, 0.15 to 1.63). The proportional odds of having a worse score on the eight-level ordinal scale with tofacitinib, as compared with placebo, was 0.60 (95% CI, 0.36 to 1.00) at day 14 and 0.54 (95% CI, 0.27 to 1.06) at day 28. Serious adverse events occurred in 20 patients (14.1%) in the tofacitinib group and in 17 (12.0%) in the placebo group. CONCLUSIONS Among patients hospitalized with Covid-19 pneumonia, tofacitinib led to a lower risk of death or respiratory failure through day 28 than placebo. (Funded by Pfizer; STOP-COVID ClinicalTrials.gov number, NCT04469114.);,citation_author=Patrícia O. Guimarães;,citation_author=Daniel Quirk;,citation_author=Remo H. Furtado;,citation_author=Lilia N. Maia;,citation_author=José F. Saraiva;,citation_author=Murillo O. Antunes;,citation_author=Roberto Kalil Filho;,citation_author=Vagner M. Junior;,citation_author=Alexandre M. Soeiro;,citation_author=Alexandre P. Tognon;,citation_author=Viviane C. Veiga;,citation_author=Priscilla A. Martins;,citation_author=Diogo D. F. Moia;,citation_author=Bruna S. Sampaio;,citation_author=Silvia R. L. Assis;,citation_author=Ronaldo V. P. Soares;,citation_author=Luciana P. A. Piano;,citation_author=Kleber Castilho;,citation_author=Roberta G. R. A. P. Momesso;,citation_author=Frederico Monfardini;,citation_author=Helio P. Guimarães;,citation_author=Dario Ponce de Leon;,citation_author=Majori Dulcine;,citation_author=Marcia R. T. Pinheiro;,citation_author=Levent M. Gunay;,citation_author=J. Jasper Deuring;,citation_author=Luiz V. Rizzo;,citation_author=Tamas Koncz;,citation_author=Otavio Berwanger;,citation_publication_date=2021-07;,citation_cover_date=2021-07;,citation_year=2021;,citation_issue=5;,citation_doi=10.1056/NEJMoa2101643;,citation_issn=0028-4793, 1533-4406;,citation_volume=385;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Host Receptor Targeting to Treat Covid-19;,citation_author=Jesper Damsgaard Gunst;,citation_author=Ole Schmeltz Søgaard;,citation_publication_date=2023-10;,citation_cover_date=2023-10;,citation_year=2023;,citation_issue=11;,citation_doi=10.1056/EVIDe2300222;,citation_volume=2;,citation_journal_title=NEJM Evidence;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Tight Blood-Glucose Control without Early Parenteral Nutrition in the ICU;,citation_author=Jan Gunst;,citation_author=Yves Debaveye;,citation_author=Fabian Güiza;,citation_author=Jasperina Dubois;,citation_author=Astrid De Bruyn;,citation_author=Dieter Dauwe;,citation_author=Erwin De Troy;,citation_author=Michael P. Casaer;,citation_author=Greet De Vlieger;,citation_author=Renata Haghedooren;,citation_author=Bart Jacobs;,citation_author=Geert Meyfroidt;,citation_author=Catherine Ingels;,citation_author=Jan Muller;,citation_author=Dirk Vlasselaers;,citation_author=Lars Desmet;,citation_author=Liese Mebis;,citation_author=Pieter J. Wouters;,citation_author=Björn Stessel;,citation_author=Laurien Geebelen;,citation_author=Jeroen Vandenbrande;,citation_author=Michiel Brands;,citation_author=Ine Gruyters;,citation_author=Ester Geerts;,citation_author=Ilse De Pauw;,citation_author=Joris Vermassen;,citation_author=Harlinde Peperstraete;,citation_author=Eric Hoste;,citation_author=Jan J. De Waele;,citation_author=Ingrid Herck;,citation_author=Pieter Depuydt;,citation_author=Alexander Wilmer;,citation_author=Greet Hermans;,citation_author=Dominique D. Benoit;,citation_author=Greet Van den Berghe;,citation_publication_date=2023-09;,citation_cover_date=2023-09;,citation_year=2023;,citation_issue=13;,citation_doi=10.1056/NEJMoa2304855;,citation_issn=0028-4793;,citation_pmid=37754283;,citation_volume=389;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Practice Patterns for Neurosurgical Utilization and Outcome in Acute Intracerebral Hemorrhage: Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trials 1 and 2 Studies;,citation_abstract=BACKGROUND: The prognosis in acute spontaneous intracerebral hemorrhage (ICH) is related to hematoma volume, where &amp;amp;amp;gt;30 mL is commonly used to define large ICH as a threshold for neurosurgical decompression but without clear supporting evidence. OBJECTIVES: To determine the factors associated with large ICH and neurosurgical intervention among participants of the Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trials (INTERACT). METHODS: We performed pooled analysis of the pilot INTERACT1 (n = 404) and main INTERACT2 (n = 2839) studies of ICH patients (&amp;lt;6 h of onset) with elevated systolic blood pressure (SBP, 150-220 mm Hg) who were randomized to intensive (target SBP &amp;lt; 140 mm Hg) or contemporaneous guideline-recommended (target SBP < 180 mm Hg) management. Neurosurgical intervention data were collected at 7 d postrandomization. Multivariable logistic regression was used to determine associations. RESULTS: There were 372 (13%) patients with large ICH volume (&amp;gt;30 mL), which was associated with nonresiding in China, nondiabetic status, severe neurological deficit (National Institutes of Health stroke scale [NIHSS] score \geq 15), lobar location, intraventricular hemorrhage extension, raised leucocyte count, and hyponatremia. Significant predictors of those patients who underwent surgery (226 of 3233 patients overall; 83 of 372 patients with large ICH) were younger age, severe neurological deficit (lower Glasgow coma scale score, and NIHSS score \geq 15), baseline ICH volume > 30 mL, and intraventricular hemorrhage. CONCLUSIONS: Early identification of severe ICH, based on age and clinical and imaging parameters, may facilitate neurosurgery and intensive monitoring of patients.;,citation_author=Rui Guo;,citation_author=David J. Blacker;,citation_author=Xia Wang;,citation_author=Hisatomi Arima;,citation_author=Pablo M. Lavados;,citation_author=Richard I. Lindley;,citation_author=John Chalmers;,citation_author=Craig S. Anderson;,citation_author=Thompson Robinson;,citation_author=INTERACT Investigators;,citation_publication_date=2017-12;,citation_cover_date=2017-12;,citation_year=2017;,citation_issue=6;,citation_doi=10.1093/neuros/nyx129;,citation_issn=1524-4040;,citation_pmid=28605557;,citation_volume=81;,citation_language=en-US;,citation_journal_title=Neurosurgery;">
<meta name="citation_reference" content="citation_title=Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19;,citation_abstract=OBJECTIVE To test whether tocilizumab decreases mortality in this population. DESIGN, SETTING, AND PARTICIPANTS The data for this study were derived from a multicenter cohort study of 4485 adults with COVID-19 admitted to participating intensive care units (ICUs) at 68 hospitals across the US from March 4 to May 10, 2020. Critically ill adults with COVID-19 were categorized according to whether they received or did not receive tocilizumab in the first 2 days of admission to the ICU. Data were collected retrospectively until June 12, 2020. A Cox regression model with inverse probability weighting was used to adjust for confounding. EXPOSURES Treatment with tocilizumab in the first 2 days of ICU admission. MAIN OUTCOMES AND MEASURES Time to death, compared via hazard ratios (HRs), and 30-day mortality, compared via risk differences. RESULTS Among the 3924 patients included in the analysis (2464 male [62.8%]; median age, 62 [interquartile range {IQR}, 52-71] years), 433 (11.0%) received tocilizumab in the first 2 days of ICU admission. Patients treated with tocilizumab were younger (median age, 58 [IQR, 48-65] vs 63 [IQR, 52-72] years) and had a higher prevalence of hypoxemia on ICU admission (205 of 433 [47.3%] vs 1322 of 3491 [37.9%] with mechanical ventilation and a ratio of partial pressure of arterial oxygen to fraction of inspired oxygen of &amp;amp;amp;lt;200 mm Hg) than patients not treated with tocilizumab. After applying inverse probability weighting, baseline and severity-of-illness characteristics were well balanced between groups. A total of 1544 patients (39.3%) died, including 125 (28.9%) treated with tocilizumab and 1419 (40.6%) not treated with tocilizumab. In the primary analysis, during a median follow-up of 27 (IQR, 14-37) days, patients treated with tocilizumab had a lower risk of death compared with those not treated with tocilizumab (HR, 0.71; 95% CI, 0.56-0.92). The estimated 30-day mortality was 27.5% (95% CI, 21.2%-33.8%) in the tocilizumab-treated patients and 37.1% (95% CI, 35.5%-38.7%) in the non-tocilizumab–treated patients (risk difference, 9.6%; 95% CI, 3.1%-16.0%). CONCLUSIONS AND RELEVANCE Among critically ill patients with COVID-19 in this cohort study, the risk of in-hospital mortality in this study was lower in patients treated with tocilizumab in the first 2 days of ICU admission compared with patients whose treatment did not include early use of tocilizumab. However, the findings may be susceptible to unmeasured confounding, and further research from randomized clinical trials is needed.;,citation_author=Shruti Gupta;,citation_author=Wei Wang;,citation_author=Salim S. Hayek;,citation_author=Lili Chan;,citation_author=Kusum S. Mathews;,citation_author=Michal L. Melamed;,citation_author=Samantha K. Brenner;,citation_author=Amanda Leonberg-Yoo;,citation_author=Edward J. Schenck;,citation_author=Jared Radbel;,citation_author=Jochen Reiser;,citation_author=Anip Bansal;,citation_author=Anand Srivastava;,citation_author=Yan Zhou;,citation_author=Diana Finkel;,citation_author=Adam Green;,citation_author=Mary Mallappallil;,citation_author=Anthony J. Faugno;,citation_author=Jingjing Zhang;,citation_author=Juan Carlos Q. Velez;,citation_author=Shahzad Shaefi;,citation_author=Chirag R. Parikh;,citation_author=David M. Charytan;,citation_author=Ambarish M. Athavale;,citation_author=Allon N. Friedman;,citation_author=Roberta E. Redfern;,citation_author=Samuel A. P. Short;,citation_author=Simon Correa;,citation_author=Kapil K. Pokharel;,citation_author=Andrew J. Admon;,citation_author=John P. Donnelly;,citation_author=Hayley B. Gershengorn;,citation_author=David J. Douin;,citation_author=Matthew W. Semler;,citation_author=Miguel A. Hernán;,citation_author=David E. Leaf;,citation_author=STOP-COVID Investigators;,citation_author=Carl P. Walther;,citation_author=Samaya J. Anumudu;,citation_author=Justin Arunthamakun;,citation_author=Kathleen F. Kopecky;,citation_author=Gregory P. Milligan;,citation_author=Peter A. McCullough;,citation_author=Thuy-Duyen Nguyen;,citation_author=Shahzad Shaefi;,citation_author=Megan L. Krajewski;,citation_author=Sidharth Shankar;,citation_author=Ameeka Pannu;,citation_author=Juan D. Valencia;,citation_author=Sushrut S. Waikar;,citation_author=Zoe A. Kibbelaar;,citation_author=Ambarish M. Athavale;,citation_author=Peter Hart;,citation_author=Shristi Upadhyay;,citation_author=Ishaan Vohra;,citation_author=Ajiboye Oyintayo;,citation_author=Adam Green;,citation_author=Jean-Sebastien Rachoin;,citation_author=Christa A. Schorr;,citation_author=Lisa Shea;,citation_author=Daniel L. Edmonston;,citation_author=Christopher L. Mosher;,citation_author=Alexandre M. Shehata;,citation_author=Zaza Cohen;,citation_author=Valerie Allusson;,citation_author=Gabriela Bambrick-Santoyo;,citation_author=Noor Bhatti;,citation_author=Bijal Mehta;,citation_author=Aquino Williams;,citation_author=Samantha K. Brenner;,citation_author=Patricia Walters;,citation_author=Ronaldo C. Go;,citation_author=Keith M. Rose;,citation_author=Miguel A. Hernán;,citation_author=Rebecca Lisk;,citation_author=Amy M. Zhou;,citation_author=Ethan C. Kim;,citation_author=Lili Chan;,citation_author=Kusum S. Mathews;,citation_author=Steven G. Coca;,citation_author=Deena R. Altman;,citation_author=Aparna Saha;,citation_author=Howard Soh;,citation_author=Huei Hsun Wen;,citation_author=Sonali Bose;,citation_author=Emily A. Leven;,citation_author=Jing G. Wang;,citation_author=Gohar Mosoyan;,citation_author=Girish N. Nadkarni;,citation_author=Pattharawin Pattharanitima;,citation_author=Emily J. Gallagher;,citation_author=Allon N. Friedman;,citation_author=John Guirguis;,citation_author=Rajat Kapoor;,citation_author=Christopher Meshberger;,citation_author=Katherine J. Kelly;,citation_author=Chirag R. Parikh;,citation_author=Brian T. Garibaldi;,citation_author=Celia P. Corona-Villalobos;,citation_author=Yumeng Wen;,citation_author=Steven Menez;,citation_author=Rubab F. Malik;,citation_author=Carmen Elena Cervantes;,citation_author=Samir C. Gautam;,citation_author=Mary C. Mallappallil;,citation_author=Jie Ouyang;,citation_author=Sabu John;,citation_author=Ernie Yap;,citation_author=Yohannes Melaku;,citation_author=Ibrahim Mohamed;,citation_author=Siddhartha Bajracharya;,citation_author=Isha Puri;,citation_author=Mariah Thaxton;,citation_author=Jyotsna Bhattacharya;,citation_author=John Wagner;,citation_author=Leon Boudourakis;,citation_author=H. Bryant Nguyen;,citation_author=Afshin Ahoubim;,citation_author=Kianoush Kashani;,citation_author=Shahrzad Tehranian;,citation_author=Leslie F. Thomas;,citation_author=Dheeraj Reddy Sirganagari;,citation_author=Pramod K. Guru;,citation_author=Yan Zhou;,citation_author=Paul A. Bergl;,citation_author=Jesus Rodriguez;,citation_author=Jatan A. Shah;,citation_author=Mrigank S. Gupta;,citation_author=Princy N. Kumar;,citation_author=Deepa G. Lazarous;,citation_author=Seble G. Kassaye;,citation_author=Michal L. Melamed;,citation_author=Tanya S. Johns;,citation_author=Ryan Mocerino;,citation_author=Kalyan Prudhvi;,citation_author=Denzel Zhu;,citation_author=Rebecca V. Levy;,citation_author=Yorg Azzi;,citation_author=Molly Fisher;,citation_author=Milagros Yunes;,citation_author=Kaltrina Sedaliu;,citation_author=Ladan Golestaneh;,citation_author=Maureen Brogan;,citation_author=Neelja Kumar;,citation_author=Michael Chang;,citation_author=Jyotsana Thakkar;,citation_author=Ritesh Raichoudhury;,citation_author=Akshay Athreya;,citation_author=Mohamed Farag;,citation_author=Edward J. Schenck;,citation_author=Soo Jung Cho;,citation_author=Maria Plataki;,citation_author=Sergio L. Alvarez-Mulett;,citation_author=Luis G. Gomez-Escobar;,citation_author=Di Pan;,citation_author=Stefi Lee;,citation_author=Jamuna Krishnan;,citation_author=William Whalen;,citation_author=David Charytan;,citation_author=Ashley Macina;,citation_author=Sobaata Chaudhry;,citation_author=Benjamin Wu;,citation_author=Frank Modersitzki;,citation_author=Anand Srivastava;,citation_author=Alexander S. Leidner;,citation_author=Carlos Martinez;,citation_author=Jacqueline M. Kruser;,citation_author=Richard G. Wunderink;,citation_author=Alexander J. Hodakowski;,citation_author=Juan Carlos Q. Velez;,citation_author=Eboni G. Price-Haywood;,citation_author=Luis A. Matute-Trochez;,citation_author=Anna E. Hasty;,citation_author=Muner MB. Mohamed;,citation_author=Rupali S. Avasare;,citation_author=David Zonies;,citation_author=David E. Leaf;,citation_author=Shruti Gupta;,citation_author=Meghan E. Sise;,citation_author=Erik T. Newman;,citation_author=Samah Abu Omar;,citation_author=Kapil K. Pokharel;,citation_author=Shreyak Sharma;,citation_author=Harkarandeep Singh;,citation_author=Simon Correa;,citation_author=Tanveer Shaukat;,citation_author=Omer Kamal;,citation_author=Wei Wang;,citation_author=Heather Yang;,citation_author=Jeffery O. Boateng;,citation_author=Meghan Lee;,citation_author=Ian A. Strohbehn;,citation_author=Jiahua Li;,citation_author=Ariel L. Mueller;,citation_author=Roberta E. Redfern;,citation_author=Nicholas S. Cairl;,citation_author=Gabriel Naimy;,citation_author=Abeer Abu-Saif;,citation_author=Danyell Hall;,citation_author=Laura Bickley;,citation_author=Chris Rowan;,citation_author=Farah Madhani-Lovely;,citation_author=Vasil Peev;,citation_author=Jochen Reiser;,citation_author=John J. Byun;,citation_author=Andrew Vissing;,citation_author=Esha M. Kapania;,citation_author=Zoe Post;,citation_author=Nilam P. Patel;,citation_author=Joy-Marie Hermes;,citation_author=Anne K. Sutherland;,citation_author=Amee Patrawalla;,citation_author=Diana G. Finkel;,citation_author=Barbara A. Danek;,citation_author=Sowminya Arikapudi;,citation_author=Jeffrey M. Paer;,citation_author=Peter Cangialosi;,citation_author=Mark Liotta;,citation_author=Jared Radbel;,citation_author=Sonika Puri;,citation_author=Jag Sunderram;,citation_author=Matthew T. Scharf;,citation_author=Ayesha Ahmed;,citation_author=Ilya Berim;,citation_author=Jayanth S. Vatson;,citation_author=Shuchi Anand;,citation_author=Joseph E. Levitt;,citation_author=Pablo Garcia;,citation_author=Suzanne M. Boyle;,citation_author=Rui Song;,citation_author=Ali Arif;,citation_author=Jingjing Zhang;,citation_author=Sang Hoon Woo;,citation_author=Xiaoying Deng;,citation_author=Goni Katz-Greenberg;,citation_author=Katharine Senter;,citation_author=Moh’d A. Sharshir;,citation_author=Vadym V. Rusnak;,citation_author=Muhammad Imran Ali;,citation_author=Terri Peters;,citation_author=Kathy Hughes;,citation_author=Anip Bansal;,citation_author=Amber S. Podoll;,citation_author=Michel Chonchol;,citation_author=Sunita Sharma;,citation_author=Ellen L. Burnham;,citation_author=David J. Douin;,citation_author=Arash Rashidi;,citation_author=Rana Hejal;,citation_author=Eric Judd;,citation_author=Laura Latta;,citation_author=Ashita Tolwani;,citation_author=Timothy E. Albertson;,citation_author=Jason Y. Adams;,citation_author=Steven Y. Chang;,citation_author=Rebecca M. Beutler;,citation_author=Carl E. Schulze;,citation_author=Etienne Macedo;,citation_author=Harin Rhee;,citation_author=Kathleen D. Liu;,citation_author=Vasantha K. Jotwani;,citation_author=Jay L. Koyner;,citation_author=Chintan V. Shah;,citation_author=Vishal Jaikaransingh;,citation_author=Stephanie M. Toth-Manikowski;,citation_author=Min J. Joo;,citation_author=James P. Lash;,citation_author=Javier A. Neyra;,citation_author=Nourhan Chaaban;,citation_author=Madona Elias;,citation_author=Yahya Ahmad;,citation_author=Alfredo Iardino;,citation_author=Elizabeth H. Au;,citation_author=Jill H. Sharma;,citation_author=Marie Anne Sosa;,citation_author=Sabrina Taldone;,citation_author=Gabriel Contreras;,citation_author=David De La Zerda;,citation_author=Alessia Fornoni;,citation_author=Hayley B. Gershengorn;,citation_author=Salim S. Hayek;,citation_author=Pennelope Blakely;,citation_author=Hanna Berlin;,citation_author=Tariq U. Azam;,citation_author=Husam Shadid;,citation_author=Michael Pan;,citation_author=Patrick O’ Hayer;,citation_author=Chelsea Meloche;,citation_author=Rafey Feroze;,citation_author=Kishan J. Padalia;,citation_author=Abbas Bitar;,citation_author=Jeff Leya;,citation_author=John P. Donnelly;,citation_author=Andrew J. Admon;,citation_author=Jennifer E. Flythe;,citation_author=Matthew J. Tugman;,citation_author=Emily H. Chang;,citation_author=Brent R. Brown;,citation_author=Amanda K. Leonberg-Yoo;,citation_author=Ryan C. Spiardi;,citation_author=Todd A. Miano;,citation_author=Meaghan S. Roche;,citation_author=Charles R. Vasquez;,citation_author=Amar D. Bansal;,citation_author=Natalie C. Ernecoff;,citation_author=Sanjana Kapoor;,citation_author=Siddharth Verma;,citation_author=Huiwen Chen;,citation_author=Csaba P. Kovesdy;,citation_author=Miklos Z. Molnar;,citation_author=Ambreen Azhar;,citation_author=S. Susan Hedayati;,citation_author=Mridula V. Nadamuni;,citation_author=Shani Shastri;,citation_author=Duwayne L. Willett;,citation_author=Samuel A. P. Short;,citation_author=Amanda D. Renaghan;,citation_author=Kyle B. Enfield;,citation_author=Pavan K. Bhatraju;,citation_author=A. Bilal Malik;,citation_author=Matthew W. Semler;,citation_author=Anitha Vijayan;,citation_author=Christina Mariyam Joy;,citation_author=Tingting Li;,citation_author=Seth Goldberg;,citation_author=Patricia F. Kao;,citation_author=Greg L. Schumaker;,citation_author=Nitender Goyal;,citation_author=Anthony J. Faugno;,citation_author=Caroline M. Hsu;,citation_author=Asma Tariq;,citation_author=Leah Meyer;,citation_author=Ravi K. Kshirsagar;,citation_author=Aju Jose;,citation_author=Daniel E. Weiner;,citation_author=Marta Christov;,citation_author=Jennifer Griffiths;,citation_author=Sanjeev Gupta;,citation_author=Aromma Kapoor;,citation_author=Perry Wilson;,citation_author=Tanima Arora;,citation_author=Ugochukwu Ugwuowo;,citation_publication_date=2021-01;,citation_cover_date=2021-01;,citation_year=2021;,citation_issue=1;,citation_doi=10.1001/jamainternmed.2020.6252;,citation_issn=2168-6106;,citation_volume=181;,citation_language=en-US;,citation_journal_title=JAMA Internal Medicine;">
<meta name="citation_reference" content="citation_title=Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: A prospective cohort study;,citation_abstract=Background Prognostic models to predict the risk of clinical deterioration in acute COVID-19 cases are urgently required to inform clinical management decisions.;,citation_author=Rishi K Gupta;,citation_author=Ewen M Harrison;,citation_author=Antonia Ho;,citation_author=Annemarie B Docherty;,citation_author=Stephen R Knight;,citation_author=Maarten Smeden;,citation_author=Ibrahim Abubakar;,citation_author=Marc Lipman;,citation_author=Matteo Quartagno;,citation_author=Riinu Pius;,citation_author=Iain Buchan;,citation_author=Gail Carson;,citation_author=Thomas M Drake;,citation_author=Jake Dunning;,citation_author=Cameron J Fairfield;,citation_author=Carrol Gamble;,citation_author=Christopher A Green;,citation_author=Sophie Halpin;,citation_author=Hayley E Hardwick;,citation_author=Karl A Holden;,citation_author=Peter W Horby;,citation_author=Clare Jackson;,citation_author=Kenneth A Mclean;,citation_author=Laura Merson;,citation_author=Jonathan S Nguyen-Van-Tam;,citation_author=Lisa Norman;,citation_author=Piero L Olliaro;,citation_author=Mark G Pritchard;,citation_author=Clark D Russell;,citation_author=James Scott-Brown;,citation_author=Catherine A Shaw;,citation_author=Aziz Sheikh;,citation_author=Tom Solomon;,citation_author=Cathie Sudlow;,citation_author=Olivia V Swann;,citation_author=Lance Turtle;,citation_author=Peter J M Openshaw;,citation_author=J Kenneth Baillie;,citation_author=Malcolm G Semple;,citation_author=Mahdad Noursadeghi;,citation_author=J Kenneth Baillie;,citation_author=Malcolm G Semple;,citation_author=Peter JM Openshaw;,citation_author=Gail Carson;,citation_author=Beatrice Alex;,citation_author=Benjamin Bach;,citation_author=Wendy S Barclay;,citation_author=Debby Bogaert;,citation_author=Meera Chand;,citation_author=Graham S Cooke;,citation_author=Annemarie B Docherty;,citation_author=Jake Dunning;,citation_author=Ana da Silva Filipe;,citation_author=Tom Fletcher;,citation_author=Christopher A Green;,citation_author=Ewen M Harrison;,citation_author=Julian A Hiscox;,citation_author=Antonia Ying Wai Ho;,citation_author=Peter W Horby;,citation_author=Samreen Ijaz;,citation_author=Saye Khoo;,citation_author=Paul Klenerman;,citation_author=Andrew Law;,citation_author=Wei Shen Lim;,citation_author=Alexander J Mentzer;,citation_author=Laura Merson;,citation_author=Alison M Meynert;,citation_author=Mahdad Noursadeghi;,citation_author=Shona C Moore;,citation_author=Massimo Palmarini;,citation_author=William A Paxton;,citation_author=Georgios Pollakis;,citation_author=Nicholas Price;,citation_author=Andrew Rambaut;,citation_author=David L Robertson;,citation_author=Clark D Russell;,citation_author=Vanessa Sancho-Shimizu;,citation_author=Janet T Scott;,citation_author=Thushan Silva;,citation_author=Louise Sigfrid;,citation_author=Tom Solomon;,citation_author=Shiranee Sriskandan;,citation_author=David Stuart;,citation_author=Charlotte Summers;,citation_author=Richard S Tedder;,citation_author=Emma C Thomson;,citation_author=AA Roger Thompson;,citation_author=Ryan S Thwaites;,citation_author=Lance CW Turtle;,citation_author=Maria Zambon;,citation_author=Hayley Hardwick;,citation_author=Chloe Donohue;,citation_author=Ruth Lyons;,citation_author=Fiona Griffiths;,citation_author=Wilna Oosthuyzen;,citation_author=Lisa Norman;,citation_author=Riinu Pius;,citation_author=Tom M Drake;,citation_author=Cameron J Fairfield;,citation_author=Stephen Knight;,citation_author=Kenneth A Mclean;,citation_author=Derek Murphy;,citation_author=Catherine A Shaw;,citation_author=Jo Dalton;,citation_author=James Lee;,citation_author=Daniel Plotkin;,citation_author=Michelle Girvan;,citation_author=Scott Mullaney;,citation_author=Claire Petersen;,citation_author=Egle Saviciute;,citation_author=Stephanie Roberts;,citation_author=Janet Harrison;,citation_author=Laura Marsh;,citation_author=Marie Connor;,citation_author=Sophie Halpin;,citation_author=Clare Jackson;,citation_author=Carrol Gamble;,citation_author=Gary Leeming;,citation_author=Andrew Law;,citation_author=Murray Wham;,citation_author=Sara Clohisey;,citation_author=Ross Hendry;,citation_author=James Scott-Brown;,citation_author=William Greenhalf;,citation_author=Victoria Shaw;,citation_author=Sarah McDonald;,citation_author=Seán Keating;,citation_author=Katie A. Ahmed;,citation_author=Jane A Armstrong;,citation_author=Milton Ashworth;,citation_author=Innocent G Asiimwe;,citation_author=Siddharth Bakshi;,citation_author=Samantha L Barlow;,citation_author=Laura Booth;,citation_author=Benjamin Brennan;,citation_author=Katie Bullock;,citation_author=Benjamin WA Catterall;,citation_author=Jordan J Clark;,citation_author=Emily A Clarke;,citation_author=Sarah Cole;,citation_author=Louise Cooper;,citation_author=Helen Cox;,citation_author=Christopher Davis;,citation_author=Oslem Dincarslan;,citation_author=Chris Dunn;,citation_author=Philip Dyer;,citation_author=Angela Elliott;,citation_author=Anthony Evans;,citation_author=Lorna Finch;,citation_author=Lewis WS Fisher;,citation_author=Terry Foster;,citation_author=Isabel Garcia-Dorival;,citation_author=Willliam Greenhalf;,citation_author=Philip Gunning;,citation_author=Catherine Hartley;,citation_author=Antonia Ho;,citation_author=Rebecca L Jensen;,citation_author=Christopher B Jones;,citation_author=Trevor R Jones;,citation_author=Shadia Khandaker;,citation_author=Katharine King;,citation_author=Robyn T. Kiy;,citation_author=Chrysa Koukorava;,citation_author=Annette Lake;,citation_author=Suzannah Lant;,citation_author=Diane Latawiec;,citation_author=L Lavelle-Langham;,citation_author=Daniella Lefteri;,citation_author=Lauren Lett;,citation_author=Lucia A Livoti;,citation_author=Maria Mancini;,citation_author=Sarah McDonald;,citation_author=Laurence McEvoy;,citation_author=John McLauchlan;,citation_author=Soeren Metelmann;,citation_author=Nahida S Miah;,citation_author=Joanna Middleton;,citation_author=Joyce Mitchell;,citation_author=Shona C Moore;,citation_author=Ellen G Murphy;,citation_author=Rebekah Penrice-Randal;,citation_author=Jack Pilgrim;,citation_author=Tessa Prince;,citation_author=Will Reynolds;,citation_author=P. Matthew Ridley;,citation_author=Debby Sales;,citation_author=Victoria E Shaw;,citation_author=Rebecca K Shears;,citation_author=Benjamin Small;,citation_author=Krishanthi S Subramaniam;,citation_author=Agnieska Szemiel;,citation_author=Aislynn Taggart;,citation_author=Jolanta Tanianis-Hughes;,citation_author=Jordan Thomas;,citation_author=Erwan Trochu;,citation_author=Libby Tonder;,citation_author=Eve Wilcock;,citation_author=J. Eunice Zhang;,citation_author=Kayode Adeniji;,citation_author=Daniel Agranoff;,citation_author=Ken Agwuh;,citation_author=Dhiraj Ail;,citation_author=Ana Alegria;,citation_author=Brian Angus;,citation_author=Abdul Ashish;,citation_author=Dougal Atkinson;,citation_author=Shahedal Bari;,citation_author=Gavin Barlow;,citation_author=Stella Barnass;,citation_author=Nicholas Barrett;,citation_author=Christopher Bassford;,citation_author=David Baxter;,citation_author=Michael Beadsworth;,citation_author=Jolanta Bernatoniene;,citation_author=John Berridge;,citation_author=Nicola Best;,citation_author=Pieter Bothma;,citation_author=David Brealey;,citation_author=Robin Brittain-Long;,citation_author=Naomi Bulteel;,citation_author=Tom Burden;,citation_author=Andrew Burtenshaw;,citation_author=Vikki Caruth;,citation_author=David Chadwick;,citation_author=Duncan Chambler;,citation_author=Nigel Chee;,citation_author=Jenny Child;,citation_author=Srikanth Chukkambotla;,citation_author=Tom Clark;,citation_author=Paul Collini;,citation_author=Catherine Cosgrove;,citation_author=Jason Cupitt;,citation_author=Maria-Teresa Cutino-Moguel;,citation_author=Paul Dark;,citation_author=Chris Dawson;,citation_author=Samir Dervisevic;,citation_author=Phil Donnison;,citation_author=Sam Douthwaite;,citation_author=Ingrid DuRand;,citation_author=Ahilanadan Dushianthan;,citation_author=Tristan Dyer;,citation_author=Cariad Evans;,citation_author=Chi Eziefula;,citation_author=Chrisopher Fegan;,citation_author=Adam Finn;,citation_author=Duncan Fullerton;,citation_author=Sanjeev Garg;,citation_author=Sanjeev Garg;,citation_author=Atul Garg;,citation_author=Effrossyni Gkrania-Klotsas;,citation_author=Jo Godden;,citation_author=Arthur Goldsmith;,citation_author=Clive Graham;,citation_author=Elaine Hardy;,citation_author=Stuart Hartshorn;,citation_author=Daniel Harvey;,citation_author=Peter Havalda;,citation_author=Daniel B Hawcutt;,citation_author=Maria Hobrok;,citation_author=Luke Hodgson;,citation_author=Anil Hormis;,citation_author=Michael Jacobs;,citation_author=Susan Jain;,citation_author=Paul Jennings;,citation_author=Agilan Kaliappan;,citation_author=Vidya Kasipandian;,citation_author=Stephen Kegg;,citation_author=Michael Kelsey;,citation_author=Jason Kendall;,citation_author=Caroline Kerrison;,citation_author=Ian Kerslake;,citation_author=Oliver Koch;,citation_author=Gouri Koduri;,citation_author=George Koshy;,citation_author=Shondipon Laha;,citation_author=Steven Laird;,citation_author=Susan Larkin;,citation_author=Tamas Leiner;,citation_author=Patrick Lillie;,citation_author=James Limb;,citation_author=Vanessa Linnett;,citation_author=Jeff Little;,citation_author=Michael MacMahon;,citation_author=Emily MacNaughton;,citation_author=Ravish Mankregod;,citation_author=Huw Masson;,citation_author=Elijah Matovu;,citation_author=Katherine McCullough;,citation_author=Ruth McEwen;,citation_author=Manjula Meda;,citation_author=Gary Mills;,citation_author=Jane Minton;,citation_author=Mariyam Mirfenderesky;,citation_author=Kavya Mohandas;,citation_author=Quen Mok;,citation_author=James Moon;,citation_author=Elinoor Moore;,citation_author=Patrick Morgan;,citation_author=Craig Morris;,citation_author=Katherine Mortimore;,citation_author=Samuel Moses;,citation_author=Mbiye Mpenge;,citation_author=Rohinton Mulla;,citation_author=Michael Murphy;,citation_author=Megan Nagel;,citation_author=Thapas Nagarajan;,citation_author=Mark Nelson;,citation_author=Igor Otahal;,citation_author=Mark Pais;,citation_author=Selva Panchatsharam;,citation_author=Hassan Paraiso;,citation_author=Brij Patel;,citation_author=Natalie Pattison;,citation_author=Justin Pepperell;,citation_author=Mark Peters;,citation_author=Mandeep Phull;,citation_author=Stefania Pintus;,citation_author=Jagtur Singh Pooni;,citation_author=Frank Post;,citation_author=David Price;,citation_author=Rachel Prout;,citation_author=Nikolas Rae;,citation_author=Henrik Reschreiter;,citation_author=Tim Reynolds;,citation_author=Neil Richardson;,citation_author=Mark Roberts;,citation_author=Devender Roberts;,citation_author=Alistair Rose;,citation_author=Guy Rousseau;,citation_author=Brendan Ryan;,citation_author=Taranprit Saluja;,citation_author=Aarti Shah;,citation_author=Prad Shanmuga;,citation_author=Anil Sharma;,citation_author=Anna Shawcross;,citation_author=Jeremy Sizer;,citation_author=Manu Shankar-Hari;,citation_author=Richard Smith;,citation_author=Catherine Snelson;,citation_author=Nick Spittle;,citation_author=Nikki Staines;,citation_author=Tom Stambach;,citation_author=Richard Stewart;,citation_author=Pradeep Subudhi;,citation_author=Tamas Szakmany;,citation_author=Kate Tatham;,citation_author=Jo Thomas;,citation_author=Chris Thompson;,citation_author=Robert Thompson;,citation_author=Ascanio Tridente;,citation_author=Darell Tupper-Carey;,citation_author=Mary Twagira;,citation_author=Andrew Ustianowski;,citation_author=Nick Vallotton;,citation_author=Lisa Vincent-Smith;,citation_author=Shico Visuvanathan;,citation_author=Alan Vuylsteke;,citation_author=Sam Waddy;,citation_author=Rachel Wake;,citation_author=Andrew Walden;,citation_author=Ingeborg Welters;,citation_author=Tony Whitehouse;,citation_author=Paul Whittaker;,citation_author=Ashley Whittington;,citation_author=Meme Wijesinghe;,citation_author=Martin Williams;,citation_author=Lawrence Wilson;,citation_author=Sarah Wilson;,citation_author=Stephen Winchester;,citation_author=Martin Wiselka;,citation_author=Adam Wolverson;,citation_author=Daniel G Wooton;,citation_author=Andrew Workman;,citation_author=Bryan Yates;,citation_author=Peter Young;,citation_publication_date=2021-04;,citation_cover_date=2021-04;,citation_year=2021;,citation_issue=4;,citation_doi=10.1016/S2213-2600(20)30559-2;,citation_issn=22132600;,citation_volume=9;,citation_language=en-US;,citation_journal_title=The Lancet Respiratory Medicine;">
<meta name="citation_reference" content="citation_title=Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab;,citation_abstract=BACKGROUND Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization or death in older patients and those with underlying conditions. Sotrovimab is a pan-sarbecovirus monoclonal antibody that was designed to prevent progression of Covid-19 in high-risk patients early in the course of disease. METHODS In this ongoing, multicenter, double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, nonhospitalized patients with symptomatic Covid-19 (\leq5 days after the onset of symptoms) and at least one risk factor for disease progression to receive a single infusion of sotrovimab at a dose of 500 mg or placebo. The primary efficacy outcome was hospitalization (for &amp;amp;amp;gt;24 hours) for any cause or death within 29 days after randomization. RESULTS In this prespecified interim analysis, which included an intention-to-treat population of 583 patients (291 in the sotrovimab group and 292 in the placebo group), 3 patients (1%) in the sotrovimab group, as compared with 21 patients (7%) in the placebo group, had disease progression leading to hospitalization or death (relative risk reduction, 85%; 97.24% confidence interval, 44 to 96; P = 0.002). In the placebo group, 5 patients were admitted to the intensive care unit, including 1 who died by day 29. Safety was assessed in 868 patients (430 in the sotrovimab group and 438 in the placebo group). Adverse events were reported by 17% of the patients in the sotrovimab group and 19% of those in the placebo group; serious adverse events were less common with sotrovimab than with placebo (in 2% and 6% of the patients, respectively). From the Albion Finch Medical Centre, William Osler Health Centre, Toronto (A.G.); Optimus U (Y.G.-R.) and Florida International Medical Research (E.J.), Miami, Pines Care Research Center, Pembroke Pines (J.M.), and Sarkis Clinical Trials, Gainesville (E.S.) — all in Florida; Álvaro Cunqueiro Hospital, IIS Galicia Sur, Vigo, Spain (M.C.C.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (D.R.F.); Centex Studies, McAllen (J. Solis), and Central Texas Clinical Research, Austin (C.B.) — both in Texas; Vir Biotechnology, San Francisco (H.Z., A.L.C., C.M.H., J. Sager, E.M., E.A., P.S.P., M.A.); Glaxo SmithKline, Stevenage, United Kingdom (N.S., C.T.); GlaxoSmithKline, Cambridge, MA (A.P.); Pinnacle Research Group, Anniston, AL (A.F.); and the Departments of Global Health and Medicine, University of Washington, and Fred Hutchinson Cancer Research Center, Seattle (A.E.S.). Dr. Shapiro can be contacted at a eshapir@ uw.edu or at the Fred Hutchinson Cancer Research Center, Mailstop E5-110, 1100 Fairview Ave. N., Seattle, WA 98109. *A list of the COMET-ICE investigators is provided in the Supplementary Appendix, available at NEJM.org. This article was published on October 27, 2021, at NEJM.org. CONCLUSIONS Among high-risk patients with mild-to-moderate Covid-19, sotrovimab reduced the risk of disease progression. No safety signals were identified. (Funded by Vir Biotechnology and GlaxoSmithKline; COMET-ICE ClinicalTrials.gov number, NCT04545060.);,citation_author=Anil Gupta;,citation_author=Yaneicy Gonzalez-Rojas;,citation_author=Erick Juarez;,citation_author=Manuel Crespo Casal;,citation_author=Jaynier Moya;,citation_author=Diego R. Falci;,citation_author=Elias Sarkis;,citation_author=Joel Solis;,citation_author=Hanzhe Zheng;,citation_author=Nicola Scott;,citation_author=Andrea L. Cathcart;,citation_author=Christy M. Hebner;,citation_author=Jennifer Sager;,citation_author=Erik Mogalian;,citation_author=Craig Tipple;,citation_author=Amanda Peppercorn;,citation_author=Elizabeth Alexander;,citation_author=Phillip S. Pang;,citation_author=Almena Free;,citation_author=Cynthia Brinson;,citation_author=Melissa Aldinger;,citation_author=Adrienne E. Shapiro;,citation_publication_date=2021-11;,citation_cover_date=2021-11;,citation_year=2021;,citation_issue=21;,citation_doi=10.1056/NEJMoa2107934;,citation_issn=0028-4793, 1533-4406;,citation_volume=385;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Early Neurorehabilitation and Recovery from Disorders of Consciousness After Severe COVID-19;,citation_abstract=Background: Early neurorehabilitation improves outcomes in patients with disorders of consciousness (DoC) after brain injury, but its applicability in COVID-19 is unknown. We describe our experience implementing an early neurorehabilitation protocol for patients with COVID-19-associated DoC in the intensive care unit (ICU) and evaluate factors associated with recovery. Methods: During the initial COVID-19 surge in New York City between March 10 and May 20, 2020, faced with a disproportionately high number of ICU patients with prolonged unresponsiveness, we developed and implemented an early neurorehabilitation protocol, applying standard practices from brain injury rehabilitation care to the ICU setting. Twenty-one patients with delayed recovery of consciousness after severe COVID-19 participated in a pilot early neurorehabilitation program that included serial Coma Recovery Scale-Revised (CRS-R) assessments, multimodal treatment, and access to clinicians specializing in brain injury medicine. We retrospectively compared clinical features of patients who did and did not recover to the minimally conscious state (MCS) or better, defined as a CRS-R total score (TS) \geq 8, before discharge. We additionally examined factors associated with best CRS-R TS, last CRS-R TS, hospital length of stay, and time on mechanical ventilation. Results: Patients underwent CRS-R assessments a median of six (interquartile range [IQR] 3–10) times before discharge, beginning a median of 48 days (IQR 40–55) from admission. Twelve (57%) patients recovered to MCS after a median of 8 days (IQR 2–14) off continuous sedation; they had lower body mass index (p = 0.009), lower peak serum C-reactive protein levels (p = 0.023), higher minimum arterial partial pressure of oxygen (p = 0.028), and earlier fentanyl discontinuation (p = 0.018). CRS-R scores fluctuated over time, and the best CRS-R TS was significantly higher than the last CRS-R TS (median 8 [IQR 5–23] vs. 5 [IQR 3–18], p = 0.002). Earlier fentanyl (p = 0.001) and neuromuscular blockade (p = 0.015) discontinuation correlated with a higher last CRS-R TS. Conclusions: More than half of our cohort of patients with prolonged unresponsiveness following severe COVID19 recovered to MCS or better before hospital discharge, achieving a clinical benchmark known to have relatively favorable long-term prognostic implications in DoC of other etiologies. Hypoxia, systemic inflammation, sedation, and;,citation_author=Lindsey Gurin;,citation_author=Megan Evangelist;,citation_author=Patricia Laverty;,citation_author=Kaitlin Hanley;,citation_author=John Corcoran;,citation_author=Jodi Herbsman;,citation_author=Brian Im;,citation_author=Jennifer Frontera;,citation_author=Steven Flanagan;,citation_author=Steven Galetta;,citation_author=Ariane Lewis;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_doi=10.1007/s12028-021-01359-1;,citation_issn=1541-6933, 1556-0961;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=GRADE guidelines: 12. Preparing Summary of Findings tables—binary outcomes;,citation_abstract=Summary of Findings (SoF) tables present, for each of the seven (or fewer) most important outcomes, the following: the number of studies and number of participants; the confidence in effect estimates (quality of evidence); and the best estimates of relative and absolute effects. Potentially challenging choices in preparing SoF table include using direct evidence (which may have very few events) or indirect evidence (from a surrogate) as the best evidence for a treatment effect. If a surrogate is chosen, it must be labeled as substituting for the corresponding patient-important outcome.;,citation_author=Gordon H. Guyatt;,citation_author=Andrew D. Oxman;,citation_author=Nancy Santesso;,citation_author=Mark Helfand;,citation_author=Gunn Vist;,citation_author=Regina Kunz;,citation_author=Jan Brozek;,citation_author=Susan Norris;,citation_author=Joerg Meerpohl;,citation_author=Ben Djulbegovic;,citation_author=Pablo Alonso-Coello;,citation_author=Piet N. Post;,citation_author=Jason W. Busse;,citation_author=Paul Glasziou;,citation_author=Robin Christensen;,citation_author=Holger J. Schünemann;,citation_publication_date=2013-02;,citation_cover_date=2013-02;,citation_year=2013;,citation_issue=2;,citation_doi=10.1016/j.jclinepi.2012.01.012;,citation_issn=08954356;,citation_volume=66;,citation_language=en-US;,citation_journal_title=Journal of Clinical Epidemiology;">
<meta name="citation_reference" content="citation_title=Preparing reports for publication and responding to reviewers’ comments;,citation_author=Gordon H. Guyatt;,citation_author=R. Brian Haynes;,citation_publication_date=2006-09;,citation_cover_date=2006-09;,citation_year=2006;,citation_issue=9;,citation_doi=10.1016/j.jclinepi.2006.05.004;,citation_issn=08954356;,citation_volume=59;,citation_language=en-US;,citation_journal_title=Journal of Clinical Epidemiology;">
<meta name="citation_reference" content="citation_title=Fulfilling the Mandate of the US Food and Drug Administration’s Accelerated Approval Pathway: The Need for Reforms;,citation_author=Bishal Gyawali;,citation_author=Joseph S. Ross;,citation_author=Aaron S. Kesselheim;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=10;,citation_doi=10.1001/jamainternmed.2021.4604;,citation_issn=2168-6106;,citation_volume=181;,citation_language=en-US;,citation_journal_title=JAMA Internal Medicine;">
<meta name="citation_reference" content="citation_title=Association of Severe Trauma With Work and Earnings in a National Cohort in Canada;,citation_abstract=OBJECTIVE To evaluate the association of severe traumatic injury with subsequent employment and earnings in long-term survivors. DESIGN, SETTING, AND PARTICIPANTS This is a retrospective, matched, national, population-based cohort study of adults who had employment and were hospitalized with severe traumatic injury in Canada between January 2008 and December 2010. All acute care hospitalizations for severe injury were included if they involved adults aged 30 to 61 years who were hospitalized with severe traumatic injury, working in the 2 years prior to injury, and alive through the third calendar year after their injury. Patients were matched with unexposed control participants based on age, sex, marital status, province of residence, rurality, baseline health characteristics, baseline earnings, self-employment status, union membership, and year of the index event. Data analysis occurred from March 2019 to December 2019. MAIN OUTCOMES AND MEASURES Changes in employment status and annual earnings, compared with unexposed control participants, were evaluated in the third calendar year after injury. Weighted multivariable probit regression was used to compare proportions of individuals working between those who survived trauma and control participants. The association of injury with mean yearly earnings was quantified using matched difference-in-difference, ordinary least-squares regression. RESULTS A total of 5167 adults (25.6% female; mean [SD] age, 47.3 [8.8] years) with severe injuries were matched with control participants who were unexposed (25.6% female; mean [SD] age, 47.3 [8.8] years). Three years after trauma, 79.3% of those who survived trauma were working, compared with 91.7% of control participants, a difference of -12.4 (95% CI, -13.5 to -11.4) percentage points. Three years after injury, patients with injuries experienced a mean loss of $9745 (95% CI, -$10 739 to -$8752) in earnings compared with control participants, representing a 19.0% difference in annual earnings. Those who remained employed 3 years after injury experienced a 10.8% loss of earnings compared with control participants (-$6043 [95% CI, -$7101 to -$4986]). Loss of work was proportionately higher in those with lower preinjury income (lowest tercile, -18.5% [95% CI, -20.8% to -16.2%]; middle tercile, -11.5% [95% CI, -13.2% to -9.9%]; highest tercile, -6.0% (95% CI, -7.8% to -4.3%]). CONCLUSIONS AND RELEVANCE In this study, severe traumatic injury had a significant association with employment and earnings of adults of working age. Those with lower preinjury earnings experienced the greatest relative loss of employment and earnings.;,citation_author=Barbara Haas;,citation_author=Sung-Hee Jeon;,citation_author=Michelle Rotermann;,citation_author=Michael Stepner;,citation_author=Randy Fransoo;,citation_author=Claudia Sanmartin;,citation_author=Hannah Wunsch;,citation_author=Damon C. Scales;,citation_author=Theodore J. Iwashyna;,citation_author=Allan Garland;,citation_publication_date=2020-10;,citation_cover_date=2020-10;,citation_year=2020;,citation_doi=10.1001/jamasurg.2020.4599;,citation_issn=2168-6254;,citation_language=en-US;,citation_journal_title=JAMA Surgery;">
<meta name="citation_reference" content="citation_title=Hydroxyethyl starch for resuscitation:;,citation_abstract=There is no evidence for an overall beneficial effect of HES in any subgroup of critically ill patients, but there are clear signs of harm. As safer alternatives exist, we recommend that HES is no longer used in critically ill patients.;,citation_author=Nicolai Haase;,citation_author=Anders Perner;,citation_publication_date=2013-08;,citation_cover_date=2013-08;,citation_year=2013;,citation_issue=4;,citation_doi=10.1097/MCC.0b013e3283632de6;,citation_issn=1070-5295;,citation_volume=19;,citation_language=en-US;,citation_journal_title=Current Opinion in Critical Care;">
<meta name="citation_reference" content="citation_title=Causal and Associational Language in Observational Health Research: A Systematic Evaluation;,citation_abstract=We estimated the degree to which language used in the high-profile medical/public health/epidemiology literature implied causality using language linking exposures to outcomes and action recommendations; examined disconnects between language and recommendations; identified the most common linking phrases; and estimated how strongly linking phrases imply causality. We searched for and screened 1,170 articles from 18 high-profile journals (65 per journal) published from 2010–2019. Based on written framing and systematic guidance, 3 reviewers rated the degree of causality implied in abstracts and full text for exposure/outcome linking language and action recommendations. Reviewers rated the causal implication of exposure/outcome linking language as none (no causal implication) in 13.8%, weak in 34.2%, moderate in 33.2%, and strong in 18.7% of abstracts. The implied causality of action recommendations was higher than the implied causality of linking sentences for 44.5% or commensurate for 40.3% of articles. The most common linking word in abstracts was “associate” (45.7%). Reviewers’ ratings of linking word roots were highly heterogeneous; over half of reviewers rated “association” as having at least some causal implication. This research undercuts the assumption that avoiding “causal” words leads to clarity of interpretation in medical research.;,citation_author=Noah A Haber;,citation_author=Sarah E Wieten;,citation_author=Julia M Rohrer;,citation_author=Onyebuchi A Arah;,citation_author=Peter W G Tennant;,citation_author=Elizabeth A Stuart;,citation_author=Eleanor J Murray;,citation_author=Sophie Pilleron;,citation_author=Sze Tung Lam;,citation_author=Emily Riederer;,citation_author=Sarah Jane Howcutt;,citation_author=Alison E Simmons;,citation_author=Clémence Leyrat;,citation_author=Philipp Schoenegger;,citation_author=Anna Booman;,citation_author=Mi-Suk Kang Dufour;,citation_author=Ashley L O’Donoghue;,citation_author=Rebekah Baglini;,citation_author=Stefanie Do;,citation_author=Mari De La Rosa Takashima;,citation_author=Thomas Rhys Evans;,citation_author=Daloha Rodriguez-Molina;,citation_author=Taym M Alsalti;,citation_author=Daniel J Dunleavy;,citation_author=Gideon Meyerowitz-Katz;,citation_author=Alberto Antonietti;,citation_author=Jose A Calvache;,citation_author=Mark J Kelson;,citation_author=Meg G Salvia;,citation_author=Camila Olarte Parra;,citation_author=Saman Khalatbari-Soltani;,citation_author=Taylor McLinden;,citation_author=Arthur Chatton;,citation_author=Jessie Seiler;,citation_author=Andreea Steriu;,citation_author=Talal S Alshihayb;,citation_author=Sarah E Twardowski;,citation_author=Julia Dabravolskaj;,citation_author=Eric Au;,citation_author=Rachel A Hoopsick;,citation_author=Shashank Suresh;,citation_author=Nicholas Judd;,citation_author=Sebastián Peña;,citation_author=Cathrine Axfors;,citation_author=Palwasha Khan;,citation_author=Ariadne E Rivera Aguirre;,citation_author=Nnaemeka U Odo;,citation_author=Ian Schmid;,citation_author=Matthew P Fox;,citation_publication_date=2022-11;,citation_cover_date=2022-11;,citation_year=2022;,citation_issue=12;,citation_doi=10.1093/aje/kwac137;,citation_issn=0002-9262;,citation_volume=191;,citation_journal_title=American Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Much ado about something: A response to &amp;amp;amp;quot;COVID-19: Underpowered randomised trials, or no randomised trials?&amp;quot;;,citation_abstract=Non-pharmaceutical interventions (NPI) for infectious diseases such as COVID-19 are particularly challenging given the complexities of what is both practical and ethical to randomize. We are often faced with the difficult decision between having weak trials or not having a trial at all. In a recent article, Dr. Atle Fretheim argues that statistically underpowered studies are still valuable, particularly in conjunction with other similar studies in meta-analysis in the context of the DANMASK-19 trial, asking &amp;amp;quot;Surely, some trial evidence must be better than no trial evidence?&quot; However, informative trials are not always feasible, and feasible trials are not always informative. In some cases, even a well-conducted but weakly designed and/or underpowered trial such as DANMASK-19 may be uninformative or worse, both individually and in a body of literature. Meta-analysis, for example, can only resolve issues of statistical power if there is a reasonable expectation of compatible well-designed trials. Uninformative designs may also invite misinformation. Here, we make the case that-when considering informativeness, ethics, and opportunity costs in addition to statistical power-&quot;nothing&quot; is often the better choice.;,citation_author=Noah A. Haber;,citation_author=Sarah E. Wieten;,citation_author=Emily R. Smith;,citation_author=David Nunan;,citation_publication_date=2021-11;,citation_cover_date=2021-11;,citation_year=2021;,citation_issue=1;,citation_doi=10.1186/s13063-021-05755-y;,citation_issn=1745-6215;,citation_pmid=34743755;,citation_volume=22;,citation_language=en-US;,citation_journal_title=Trials;">
<meta name="citation_reference" content="citation_title=Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: A randomized controlled trial;,citation_abstract=Purpose: Insufficient antimicrobial exposure is associated with worse outcomes in sepsis. We evaluated whether therapeutic drug monitoring (TDM)-guided antibiotic therapy improves outcomes. Methods: Randomized, multicenter, controlled trial from January 2017 to December 2019. Adult patients (n = 254) with sepsis or septic shock were randomly assigned 1:1 to receive continuous infusion of piperacillin/tazobactam with dosing guided by daily TDM of piperacillin or continuous infusion with a fixed dose (13.5 g/24 h if eGFR \geq 20 mL/min). Target plasma concentration was four times the minimal inhibitory concentration (range  20%) of the underlying pathogen, respectively, of Pseudomonas aeruginosa in empiric situation. Primary outcome was the mean of daily total Sequential Organ Failure Assessment (SOFA) score up to day 10. Results: Among 249 evaluable patients (66.3  13.7 years; female, 30.9%), there was no significant difference in mean SOFA score between patients with TDM (7.9 points; 95% CI 7.1–8.7) and without TDM (8.2 points; 95% CI 7.5–9.0) (p = 0.39). Patients with TDM-guided therapy showed a lower 28-day mortality (21.6% vs. 25.8%, RR 0.8, 95% CI 0.5–1.3, p = 0.44) and a higher rate of clinical (OR 1.9; 95% CI 0.5–6.2, p = 0.30) and microbiological cure (OR 2.4; 95% CI 0.7–7.4, p = 0.12), but these differences did not reach statistical significance. Attainment of target concentration was more common in patients with TDM (37.3% vs. 14.6%, OR 4.5, CI 95%, 2.9–6.9, p &amp;amp;amp;lt; 0.001).;,citation_author=Stefan Hagel;,citation_author=Friedhelm Bach;,citation_author=Thorsten Brenner;,citation_author=Hendrik Bracht;,citation_author=Alexander Brinkmann;,citation_author=Thorsten Annecke;,citation_author=Andreas Hohn;,citation_author=Markus Weigand;,citation_author=Guido Michels;,citation_author=Stefan Kluge;,citation_author=Axel Nierhaus;,citation_author=Dominik Jarczak;,citation_author=Christina König;,citation_author=Dirk Weismann;,citation_author=Otto Frey;,citation_author=Dominic Witzke;,citation_author=Carsten Müller;,citation_author=Michael Bauer;,citation_author=Michael Kiehntopf;,citation_author=Sophie Neugebauer;,citation_author=Thomas Lehmann;,citation_author=Jason A. Roberts;,citation_author=Mathias W. Pletz;,citation_author=the TARGET Trial Investigators;,citation_author=Anke Braune;,citation_author=Karsten Schmidt;,citation_author=Johann Motsch;,citation_author=Nadine Pinder;,citation_author=Daniel Richter;,citation_author=Peter Schlattmann;,citation_author=Andreas Ameln-Mayerhofer von;,citation_author=Markus Schappacher;,citation_author=Thomas Fuchs;,citation_author=Anka Röhr;,citation_author=Max Kurlbaum;,citation_author=Oliver Schreiner;,citation_author=Lars Hüter;,citation_author=Matthias Gründling;,citation_author=Stefan Angermair;,citation_author=Maria Deja;,citation_author=Frank Bloos;,citation_author=Sandra Fiedler;,citation_author=Hicham Chkirni;,citation_publication_date=2022-03;,citation_cover_date=2022-03;,citation_year=2022;,citation_issue=3;,citation_doi=10.1007/s00134-021-06609-6;,citation_issn=0342-4642, 1432-1238;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Orange You Wishing There Were Definitive Randomized Controlled Trials Already?*;,citation_author=David N. Hager;,citation_author=Ankita Agarwal;,citation_author=Bram Rochwerg;,citation_publication_date=2021-12;,citation_cover_date=2021-12;,citation_year=2021;,citation_issue=12;,citation_doi=10.1097/CCM.0000000000005319;,citation_issn=0090-3493;,citation_volume=49;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Fluid Therapy: Present Controversies;,citation_abstract=Critical illness is often associated with major disturbances of the fluid homeostasis of the body. Therefore, it seems essential that the fluid therapy and plasma volume support of the critically ill patient is in accordance with evidence-based, generally accepted recommendations. However, a debate on the optimal fluid regimens for critically ill patients has been going on for decades and is still as intense as ever before. Not only have the old crystalloid versus colloid discussions been reactivated [1–5] but also the choice of colloid, the use of albumin in particular, is a matter of considerable controversy [6–11]. The ongoing debate is somewhat confusing and there are presently no generally accepted intensive care unit (ICU) strategies or guidelines for fluid therapy of critically ill patients.;,citation_author=H. Haljamäe;,citation_author=S. Lindgren;,citation_editor=Jean-Louis Vincent;,citation_publication_date=2000;,citation_cover_date=2000;,citation_year=2000;,citation_doi=10.1007/978-3-662-13455-9_37;,citation_isbn=978-3-662-13455-9;,citation_language=en-US;,citation_conference_title=Yearbook of Intensive Care and Emergency Medicine 2000;,citation_conference=Springer;,citation_series_title=Yearbook of Intensive Care and Emergency Medicine;">
<meta name="citation_reference" content="citation_title=What the Cyclical Response of Advertising Reveals about Markups and other Macroeconomic Wedges;,citation_abstract=Theory suggests advertising should be remarkably sensitive to profit margins. Firms advertise to stimulate demand for their products. They advertise high-margin products aggressively and low-margin ones hardly at all. In modern macroeconomics, wedges are potent sources of fluctuations in employment. The profit margin or markup ratio is a leading example. In an important class of fluctuations models, profit margins rise in recessions and mediate the decline in employment. But a rise in profit margins should expand advertising by a lot. Really a lot. Advertising should be highly countercyclical. Instead, it is somewhat procyclical. The ratio of advertising spending to private GDP falls when the economy contracts. The behavior of advertising refutes the hypothesis that profit margins rise. But it is true that the labor share of income falls. Hence there must be another factor that lowers the labor share without raising profit margins. An influence that fits some of the facts is a rise in a product-market friction or wedge that has the same effect as an increase in sales taxes. The cyclical behavior of advertising should point macroeconomics in a somewhat different direction in explaining employment fluctuations.;,citation_author=Robert E Hall;,citation_author=Hoover Institution;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Building a National Public Health System in the United States;,citation_author=Margaret A. Hamburg;,citation_author=Mandy Cohen;,citation_author=Karen DeSalvo;,citation_author=Julie Gerberding;,citation_author=Joneigh Khaldun;,citation_author=David Lakey;,citation_author=Ellen MacKenzie;,citation_author=Herminia Palacio;,citation_author=Nirav R. Shah;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_issue=5;,citation_doi=10.1056/NEJMp2207374;,citation_issn=0028-4793, 1533-4406;,citation_volume=387;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer;,citation_author=Freddie C. Hamdy;,citation_author=Jenny L. Donovan;,citation_author=J. Athene Lane;,citation_author=Chris Metcalfe;,citation_author=Michael Davis;,citation_author=Emma L. Turner;,citation_author=Richard M. Martin;,citation_author=Grace J. Young;,citation_author=Eleanor I. Walsh;,citation_author=Richard J. Bryant;,citation_author=Prasad Bollina;,citation_author=Andrew Doble;,citation_author=Alan Doherty;,citation_author=David Gillatt;,citation_author=Vincent Gnanapragasam;,citation_author=Owen Hughes;,citation_author=Roger Kockelbergh;,citation_author=Howard Kynaston;,citation_author=Alan Paul;,citation_author=Edgar Paez;,citation_author=Philip Powell;,citation_author=Derek J. Rosario;,citation_author=Edward Rowe;,citation_author=Malcolm Mason;,citation_author=James W. F. Catto;,citation_author=Tim J. Peters;,citation_author=Jon Oxley;,citation_author=Naomi J. Williams;,citation_author=John Staffurth;,citation_author=David E. Neal;,citation_publication_date=2023-04;,citation_cover_date=2023-04;,citation_year=2023;,citation_issue=17;,citation_doi=10.1056/NEJMoa2214122;,citation_issn=0028-4793;,citation_pmid=36912538;,citation_volume=388;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Association Between Selective Decontamination of the Digestive Tract and In-Hospital Mortality in Intensive Care Unit Patients Receiving Mechanical Ventilation: A Systematic Review and Meta-analysis;,citation_abstract=The effectiveness of selective decontamination of the digestive tract (SDD) in critically ill adults receiving mechanical ventilation is uncertain.To determine whether SDD is associated with reduced risk of death in adults receiving mechanical ventilation in intensive care units (ICUs) compared with standard care.The primary search was conducted using MEDLINE, EMBASE, and CENTRAL databases until September 2022.Randomized clinical trials including adults receiving mechanical ventilation in the ICU comparing SDD vs standard care or placebo.Data extraction and risk of bias assessments were performed in duplicate. The primary analysis was conducted using a bayesian framework.The primary outcome was hospital mortality. Subgroups included SDD with an intravenous agent compared with SDD without an intravenous agent. There were 8 secondary outcomes including the incidence of ventilator-associated pneumonia, ICU-acquired bacteremia, and the incidence of positive cultures of antimicrobial-resistant organisms.There were 32 randomized clinical trials including 24 389 participants in the analysis. The median age of participants in the included studies was 54 years (IQR, 44-60), and the median proportion of female trial participants was 33% (IQR, 25%-38%). Data from 30 trials including 24 034 participants contributed to the primary outcome. The pooled estimated risk ratio (RR) for mortality for SDD compared with standard care was 0.91 (95% credible interval [CrI], 0.82-0.99; I2 = 33.9%; moderate certainty) with a 99.3% posterior probability that SDD reduced hospital mortality. The beneficial association of SDD was evident in trials with an intravenous agent (RR, 0.84 [95% CrI, 0.74-0.94]), but not in trials without an intravenous agent (RR, 1.01 [95% CrI, 0.91-1.11]) (P value for the interaction between subgroups = .02). SDD was associated with reduced risk of ventilator-associated pneumonia (RR, 0.44 [95% CrI, 0.36-0.54]) and ICU-acquired bacteremia (RR, 0.68 [95% CrI, 0.57-0.81]). Available data regarding the incidence of positive cultures of antimicrobial-resistant organisms were not amenable to pooling and were of very low certainty.Among adults in the ICU treated with mechanical ventilation, the use of SDD compared with standard care or placebo was associated with lower hospital mortality. Evidence regarding the effect of SDD on antimicrobial resistance was of very low certainty.;,citation_author=Naomi E. Hammond;,citation_author=John Myburgh;,citation_author=Ian Seppelt;,citation_author=Tessa Garside;,citation_author=Ruan Vlok;,citation_author=Sajeev Mahendran;,citation_author=Derick Adigbli;,citation_author=Simon Finfer;,citation_author=Ya Gao;,citation_author=Fiona Goodman;,citation_author=Gordon Guyatt;,citation_author=Joseph Alvin Santos;,citation_author=Balasubramanian Venkatesh;,citation_author=Liang Yao;,citation_author=Gian Luca Di Tanna;,citation_author=Anthony Delaney;,citation_publication_date=2022-11;,citation_cover_date=2022-11;,citation_year=2022;,citation_issue=19;,citation_doi=10.1001/jama.2022.19709;,citation_issn=0098-7484;,citation_volume=328;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Balanced Crystalloids versus Saline in Critically Ill Adults — A Systematic Review with Meta-Analysis;,citation_abstract=BACKGROUND The comparative efficacy and safety of balanced crystalloid solutions and saline for fluid therapy in critically ill adults remain uncertain. METHODS We systematically reviewed randomized clinical trials (RCTs) comparing the use of balanced crystalloids with saline in critically ill adults. The primary outcome was 90-day mortality after pooling data from low-risk-of-bias trials using a random-effects model. We also performed a Bayesian meta-analysis to describe the primary treatment effect in probability terms. Secondary outcomes included the incidence of acute kidney injury (AKI), new treatment with renal replacement therapy (RRT), and ventilator-free and vasopressor-free days to day 28. RESULTS We identified 13 RCTs, comprising 35,884 participants. From six trials (34,450 participants) with a low risk of bias, the risk ratio (RR) for 90-day mortality with balanced crystalloids versus saline was 0.96 (95% confidence interval [CI], 0.91 to 1.01; I2 5 12.1%); using vague priors, the posterior probability that balanced crystalloids reduce mortality was 89.5%. The RRs of developing AKI and of being treated with RRT with balanced crystalloids versus saline were 0.96 (95% CI, 0.89 to 1.02) and 0.95 (95% CI, 0.81 to 1.11), respectively. Ventilator-free days (mean difference, 0.18 days; 95% CI, 20.45 to 0.81) and vasopressor-free days (mean difference, 0.19 days; 95% CI, 20.14 to 0.51) were similar between groups. CONCLUSIONS The estimated effect of using balanced crystalloids versus saline in critically ill adults ranges from a 9% relative reduction to a 1% relative increase in the risk of death, with a high probability that the average effect of using balanced crystalloids is to reduce mortality. (PROSPERO number, CRD42021243399.);,citation_author=Naomi E. Hammond;,citation_author=Fernando G. Zampieri;,citation_author=Gian Luca Di Tanna;,citation_author=Tessa Garside;,citation_author=Derick Adigbli;,citation_author=Alexandre B. Cavalcanti;,citation_author=Flavia R. Machado;,citation_author=Sharon Micallef;,citation_author=John Myburgh;,citation_author=Mahesh Ramanan;,citation_author=Todd W. Rice;,citation_author=Matthew W. Semler;,citation_author=Paul J. Young;,citation_author=Balasubramanian Venkatesh;,citation_author=Simon Finfer;,citation_author=Anthony Delaney;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_doi=10.1056/EVIDoa2100010;,citation_issn=2766-5526;,citation_language=en-US;,citation_journal_title=NEJM Evidence;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Balanced Crystalloids Versus Saline in Critically Ill Adults: A Systematic Review and Meta-analysis;,citation_abstract=Background: The optimal resuscitative fluid remains controversial. Objective: To assess the association between crystalloid fluid and outcomes in critically ill adults. Methods: Cumulative Index to Nursing and Allied Health Literature, Scopus, PubMed, and Cochrane Central Register for Controlled Trials were searched from inception through July 2019. Cohort studies and randomized trials of critically ill adults provided predominantly nonperioperative fluid resuscitation with balanced crystalloids or 0.9% sodium chloride (saline) were included. Results: Thirteen studies (n = 30 950) were included. Balanced crystalloids demonstrated lower hospital or 28-/30-day mortality (risk ratio [RR] = 0.86; 95% CI = 0.750.99; I2 = 82%) overall, in observational studies (RR = 0.64; 95% CI = 0.41-0.99; I2 = 63%), and approached significance in randomized trials (RR = 0.94; 95% CI = 0.88-1.02; I2 = 0%). New acute kidney injury occurred less frequently with balanced crystalloids (RR = 0.91; 95% CI = 0.85-0.98; I2 = 0%), though progression to renal replacement therapy was similar (RR = 0.91; 95% CI = 0.79-1.04; I2 = 38%). In the sepsis cohort, odds of hospital or 28-/30-day mortality were similar, but the odds of major adverse kidney events occurring in the first 30 days were less with balanced crystalloids than saline (OR = 0.78; 95% CI = 0.66-0.91; I2 = 42%). Conclusion and Relevance: Resuscitation with balanced crystalloids demonstrated lower hospital or 28-/30-day mortality compared with saline in critically ill adults but not specifically those with sepsis. Balanced crystalloids should be provided preferentially to saline in most critically ill adult patients.;,citation_author=Drayton A Hammond;,citation_author=Simon W Lam;,citation_author=Megan A Rech;,citation_author=Melanie N Smith;,citation_author=Jennifer Westrick;,citation_language=en-US;,citation_journal_title=Annals of Pharmacotherapy;">
<meta name="citation_reference" content="citation_title=Can we design better ARDS trials?;,citation_abstract=It is not a novel observation that the clinical trial enterprise has largely been unsuccessful in finding new and effective treatments for the acute respiratory distress syndrome (ARDS).1 2 While a significant contributor to the absence of success may be the testing of ineffective treatments, other likely contributors include selecting the wrong population and having unrealistic expectations about the possible effect of the treatment on the outcomes, most often risk of death or duration of ventilatory support. In common with sepsis, ARDS is not a disease but rather a syndrome characterised by heterogeneity at many levels. This includes recognisable heterogeneity such as the precipitating insult and the trial participants’ phenotype (eg, age, baseline frailty and comorbidities) and less overt heterogeneity such as genotype and the biology of ARDS itself.3 Even when a trial intervention is beneficial in at least some patients with ARDS, confirming that beneficial effect in a randomised clinical trial (RCT) is critically dependent on selecting the correct participants. The likelihood of enrolling the “correct” participants is increased by appropriate use of enrichment strategies.2 Predictive enrichment refers to selectively enrolling a subpopulation of patients who have an increased likelihood of responding to the test treatment, an example of which might be selecting patients with ARDS with a hyperinflammatory phenotype in studying the effect of simvastatin.4 Prognostic …;,citation_author=Naomi E. Hammond;,citation_author=Simon Finfer;,citation_publication_date=2023-07;,citation_cover_date=2023-07;,citation_year=2023;,citation_doi=10.1136/thorax-2023-220446;,citation_issn=0040-6376, 1468-3296;,citation_pmid=37495366;,citation_language=en-US;,citation_journal_title=Thorax;,citation_publisher=BMJ Publishing Group Ltd;">
<meta name="citation_reference" content="citation_title=Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19;,citation_abstract=BACKGROUND Nirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (Mpro) inhibitor with potent pan–human-coronavirus activity in vitro. METHODS We conducted a phase 2–3 double-blind, randomized, controlled trial in which symptomatic, unvaccinated, nonhospitalized adults at high risk for progression to severe coronavirus disease 2019 (Covid-19) were assigned in a 1:1 ratio to receive either 300 mg of nirmatrelvir plus 100 mg of ritonavir (a pharmacokinetic enhancer) or placebo every 12 hours for 5 days. Covid-19–related hospitalization or death from any cause through day 28, viral load, and safety were evaluated. RESULTS A total of 2246 patients underwent randomization; 1120 patients received nirmatrelvir plus ritonavir (nirmatrelvir group) and 1126 received placebo (placebo group). In the planned interim analysis of patients treated within 3 days after symptom onset (modified intention-to treat population, comprising 774 of the 1361 patients in the full analysis population), the incidence of Covid-19–related hospitalization or death by day 28 was lower in the nirmatrelvir group than in the placebo group by 6.32 percentage points (95% confidence interval [CI], -9.04 to -3.59; P&amp;amp;amp;lt;0.001; relative risk reduction, 89.1%); the incidence was 0.77% (3 of 389 patients) in the nirmatrelvir group, with 0 deaths, as compared with 7.01% (27 of 385 patients) in the placebo group, with 7 deaths. Efficacy was maintained in the final analysis involving the 1379 patients in the modified intention-to-treat population, with a difference of -5.81 percentage points (95% CI, -7.78 to -3.84; P&amp;lt;0.001; relative risk reduction, 88.9%). All 13 deaths occurred in the placebo group. The viral load was lower with nirmaltrelvir plus ritonavir than with placebo at day 5 of treatment, with an adjusted mean difference of -0.868 log10 copies per milliliter when treatment was initiated within 3 days after the onset of symptoms. The incidence of adverse events that emerged during the treatment period was similar in the two groups (any adverse event, 22.6% with nirmatrelvir plus ritonavir vs. 23.9% with placebo; serious adverse events, 1.6% vs. 6.6%; and adverse events leading to discontinuation of the drugs or placebo, 2.1% vs. 4.2%). Dysgeusia (5.6% vs. 0.3%) and diarrhea (3.1% vs. 1.6%) occurred more frequently with nirmatrelvir plus ritonavir than with placebo. From Global Product Development, Pfizer, Collegeville, PA (J.H., H.L.-T.); Global Product Development (A.G.) and Early Clinical Development (M.L.B.), Pfizer, Cambridge, MA; Global Product Development, Pfizer, New York (P.A., W.B., B.D., R.P.); Global Product Development, Pfizer, Lake Forest, IL (W.W.); Medical and Safety, Pfizer, Sandwich, United Kingdom (V.M.H.); Köhler and Milstein Research, Mérida, Yucatan, Mexico (A.S.-C.); and Global Product Development, Pfizer, Tampa, FL (J.M.R.). Dr. Hammond can be contacted at jennifer .hammond@pfizer.com, or at Pfizer, 500 Arcola Rd., Collegeville, PA 19426. *A list of the EPIC-HR investigators is provided in the Supplementary Appendix. This article was published on February 16, 2022, at NEJM.org. DOI: 10.1056/NEJMoa2118542 Copyright © 2022 Massachusetts Medical Society. CONCLUSIONS Treatment of symptomatic Covid-19 with nirmatrelvir plus ritonavir resulted in a risk of progression to severe Covid-19 that was 89% lower than the risk with placebo, without evident safety concerns. (Supported by Pfizer; ClinicalTrials.gov number, NCT04960202.);,citation_author=Jennifer Hammond;,citation_author=Heidi Leister-Tebbe;,citation_author=Annie Gardner;,citation_author=Paula Abreu;,citation_author=Weihang Bao;,citation_author=Wayne Wisemandle;,citation_author=MaryLynn Baniecki;,citation_author=Victoria M. Hendrick;,citation_author=Bharat Damle;,citation_author=Abraham Simón-Campos;,citation_author=Rienk Pypstra;,citation_author=James M. Rusnak;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_doi=10.1056/NEJMoa2118542;,citation_issn=0028-4793, 1533-4406;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Patterns of intravenous fluid resuscitation use in adult intensive care patients between 2007 and 2014: An international cross-sectional study;,citation_abstract=Background In 2007, the Saline versus Albumin Fluid Evaluation—Translation of Research Into Practice Study (SAFE-TRIPS) reported that 0.9% sodium chloride (saline) and hydroxyethyl starch (HES) were the most commonly used resuscitation fluids in intensive care unit (ICU) patients. Evidence has emerged since 2007 that these fluids are associated with adverse patient-centred outcomes. Based on the published evidence since 2007, we sought to determine the current type of fluid resuscitation used in clinical practice and the predictors of fluid choice and determine whether these have changed between 2007 and 2014. Methods In 2014, an international, cross-sectional study was conducted (Fluid-TRIPS) to document current patterns of intravenous resuscitation fluid use and determine factors associated with fluid choice. We examined univariate and multivariate associations between patients and prescriber characteristics, geographical region and fluid type. Additionally, we report secular trends of resuscitation fluid use in a cohort of ICUs that participated in both the 2007 and 2014 studies. Regression analysis were conducted to determine changes in the administration of crystalloid or colloid between 2007 and 2014. Findings In 2014, a total of 426 ICUs in 27 countries participated. Over the 24 hour study day, 1456/6707 (21.7%) patients received resuscitation fluid during 2716 resuscitation episodes. Crystalloids were administered to 1227/1456 (84.3%) patients during 2208/2716 (81.3%) episodes and colloids to 394/1456 (27.1%) patients during 581/2716 (21.4%) episodes. In multivariate analyses, practice significantly varied between geographical regions. Additionally, patients with a traumatic brain injury were less likely to receive colloid when compared to patients with no trauma (adjusted OR 0.24; 95% CI 0.1 to 0.62; p = 0.003). Patients in the ICU for one or more days where more likely to receive colloid compared to patients in the ICU on their admission date (adjusted OR 1.75; 95% CI 1.27 to 2.41; p = &amp;amp;amp;lt;0.001). For secular trends in fluid resuscitation, 84 ICUs in 17 countries contributed data. In 2007, 527/1663 (31.7%) patients received fluid resuscitation during 1167 episodes compared to 491/1763 (27.9%) patients during 960 episodes in 2014. The use of crystalloids increased from 498/1167 (42.7%) in 2007 to 694/960 (72.3%) in 2014 (odds ratio (OR) 3.75, 95% confidence interval (CI) 2.95 to 4.77; p = &amp;lt;0.001), primarily due to a significant increase in the use of buffered salt solutions. The use of colloids decreased from 724/1167 (62.0%) in 2007 to 297/960 (30.9%) in 2014 (OR 0.29, 95% CI 0.19 to 0.43; p = <0.001), primarily due to a decrease in the use of HES, but an overall increase in the use of albumin. Conclusions Clinical practices of intravenous fluid resuscitation have changed between 2007 and 2014. Geographical location remains a strong predictor of the type of fluid administered for fluid resuscitation. Overall, there is a preferential use of crystalloids, specifically buffered salt solutions, over colloids. There is now an imperative to conduct a trial determining the safety and efficacy of these fluids on patient-centred outcomes. Trial registration Clinicaltrials.gov: Fluid-Translation of research into practice study (Fluid-TRIPS) NCT02002013;,citation_author=Naomi E. Hammond;,citation_author=Colman Taylor;,citation_author=Simon Finfer;,citation_author=Flavia R. Machado;,citation_author=YouZhong An;,citation_author=Laurent Billot;,citation_author=Frank Bloos;,citation_author=Fernando Bozza;,citation_author=Alexandre Biasi Cavalcanti;,citation_author=Maryam Correa;,citation_author=Bin Du;,citation_author=Peter B. Hjortrup;,citation_author=Yang Li;,citation_author=Lauralyn McIntryre;,citation_author=Manoj Saxena;,citation_author=Frédérique Schortgen;,citation_author=Nicola R. Watts;,citation_author=John Myburgh;,citation_author=for the Fluid-TRIPS and Fluidos Investigators;,citation_author=The ANZICS Clinical Trials Group The George Institute for Global Health;,citation_publication_date=2017-05;,citation_cover_date=2017-05;,citation_year=2017;,citation_issue=5;,citation_doi=10.1371/journal.pone.0176292;,citation_issn=1932-6203;,citation_volume=12;,citation_language=en-US;,citation_journal_title=PLOS ONE;,citation_publisher=Public Library of Science;">
<meta name="citation_reference" content="citation_title=Central venous pressure (CVP);,citation_author=Olfa Hamzaoui;,citation_author=Jean-Louis Teboul;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_doi=10.1007/s00134-022-06835-6;,citation_issn=1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Truth-telling in discussing prognosis in advanced life-limiting illnesses: A systematic review;,citation_abstract=Many health professionals (HPs) express discomfort at having to broach the topic of prognosis, including limited life expectancy, and may withhold information or not disclose prognosis. A systematic review was conducted of 46 studies relating to truth-telling in discussing prognosis with patients with progressive, advanced life-limiting illnesses and their caregivers. Relevant studies meeting the inclusion criteria were identified by searching computerized databases (MEDLINE, EMBASE, CINAHL, PsychINFO and Cochrane Register of Controlled Trials) up to November 2004, with handsearching of studies, as well as inclusion of studies satisfying selection criteria reported in 2005 by the authors. The reference lists of identified studies were hand-searched for further relevant studies. Inclusion criteria were studies of any design evaluating communication of prognostic information that included adult patients with an advanced, life-limiting illness; their caregivers; and qualified HPs. Results showed that although the majority of HPs believed that patients and caregivers should be told the truth about the prognosis, in practice, many either avoid discussing the topic or withhold information. Reasons include perceived lack of training, stress, no time to attend to the patient’s emotional needs, fear of a negative impact on the patient, uncertainty about prognostication, requests from family members to withhold information and a feeling of inadequacy or hopelessness regarding the unavailability of further curative treatment. Studies suggest that patients can discuss the topic without it having a negative impact on them. Differences and similarities in findings from different cultures are explored. Palliative Medicine 2007; 21: 507—517;,citation_author=Karen Hancock;,citation_author=Josephine M Clayton;,citation_author=Sharon M Parker;,citation_author=Sharon Wal der;,citation_author=Phyllis N Butow;,citation_author=Sue Carrick;,citation_author=David Currow;,citation_author=Davina Ghersi;,citation_author=Paul Glare;,citation_author=Rebecca Hagerty;,citation_author=Martin HN Tattersall;,citation_publication_date=2007-09;,citation_cover_date=2007-09;,citation_year=2007;,citation_issue=6;,citation_doi=10.1177/0269216307080823;,citation_issn=0269-2163, 1477-030X;,citation_volume=21;,citation_language=en-US;,citation_journal_title=Palliative Medicine;">
<meta name="citation_reference" content="citation_title=Cerebrospinal fluid and blood biomarkers of status epilepticus;,citation_abstract=Status epilepticus is a condition resulting either from the failure of the mechanisms responsible for seizure termination or from the initiation of mechanisms that lead to abnormally prolonged seizures and require urgent administration of antiepileptic drugs. Refractory status epilepticus requires anesthetics drugs and may lead to brain injury with molecular and cellular alterations (eg, inflammation, and neuronal and astroglial injury) that could induce neurologic sequels and further development of epilepsy. Outcome scores based on demographic, clinical, and electroencephalography (EEG) condition are available, allowing prediction of the risk of mortality, but the severity of brain injury in survivors is poorly evaluated. New biomarkers are needed to predict with higher accuracy the outcome of patients admitted with status in an intensive care unit. Here, we summarize the findings of studies from patients and animal models of status epilepticus. Specific protein markers can be detected in the cerebrospinal fluid and the blood. One of the first described markers of neuronal death is the neuron-specific enolase. Gliosis resulting from inflammatory responses after status can be detected through the increase of S100-beta, or some cytokines, like the High Mobility Group Box 1. Other proteins, like progranulin may reflect the neuroprotective mechanisms resulting from the brain adaptation to excitotoxicity. These new biomarkers aim to prospectively identify the severity and development of disability, and subsequent epilepsy of patients with status. We discuss the advantages and disadvantages of each biomarker, by evaluating their brain specificity, stability in the fluids, and sensitivity to external interferences, such as hemolysis. Finally, we emphasize the need for further development and validation of such biomarkers in order to better assess patients with severe status epilepticus.;,citation_author=Aurélie Hanin;,citation_author=Virginie Lambrecq;,citation_author=Jérôme Alexandre Denis;,citation_author=Françoise Imbert-Bismut;,citation_author=Benoı̂t Rucheton;,citation_author=Foudil Lamari;,citation_author=Dominique Bonnefont-Rousselot;,citation_author=Sophie Demeret;,citation_author=Vincent Navarro;,citation_publication_date=2020-01;,citation_cover_date=2020-01;,citation_year=2020;,citation_issue=1;,citation_doi=10.1111/epi.16405;,citation_issn=0013-9580, 1528-1167;,citation_volume=61;,citation_language=en-US;,citation_journal_title=Epilepsia;">
<meta name="citation_reference" content="citation_title=Secondary stroke prevention;,citation_abstract=Survivors of stroke and transient ischaemic attacks are at risk of a recurrent stroke, which is often more severe and disabling than the index event. Optimum secondary prevention of recurrent stroke needs rapid diagnosis and treatment and prompt identification of the underlying cardiovascular cause. Effective treatments include organised acute assessment and intervention with antithrombotic therapy, carotid revascularisation, and control of causal risk factors, as appropriate. However, effective treatments are not implemented optimally in clinical practice. Recurrent strokes continue to account for 25–30% of all strokes and represent unsuccessful secondary prevention. Immediate and sustained implementation of effective and appropriate secondary prevention strategies in patients with first-ever stroke or transient ischaemic attack has the potential to reduce the burden of stroke by up to a quarter.;,citation_author=Graeme J Hankey;,citation_publication_date=2014-02;,citation_cover_date=2014-02;,citation_year=2014;,citation_issue=2;,citation_doi=10.1016/S1474-4422(13)70255-2;,citation_issn=1474-4422;,citation_volume=13;,citation_language=en-US;,citation_journal_title=The Lancet Neurology;">
<meta name="citation_reference" content="citation_title=Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): A randomised, controlled, open-label, blinded endpoint phase 3 trial;,citation_abstract=Background Acute stroke due to supratentorial intracerebral haemorrhage is associated with high morbidity and mortality. Open craniotomy haematoma evacuation has not been found to have any benefit in large randomised trials. We assessed whether minimally invasive catheter evacuation followed by thrombolysis (MISTIE), with the aim of decreasing clot size to 15 mL or less, would improve functional outcome in patients with intracerebral haemorrhage. Methods MISTIE III was an open-label, blinded endpoint, phase 3 trial done at 78 hospitals in the USA, Canada, Europe, Australia, and Asia. We enrolled patients aged 18 years or older with spontaneous, non-traumatic, supratentorial intracerebral haemorrhage of 30 mL or more. We used a computer-generated number sequence with a block size of four or six to centrally randomise patients to image-guided MISTIE treatment (1\cdot0 mg alteplase every 8 h for up to nine doses) or standard medical care. Primary outcome was good functional outcome, defined as the proportion of patients who achieved a modified Rankin Scale (mRS) score of 0–3 at 365 days, adjusted for group differences in prespecified baseline covariates (stability intracerebral haemorrhage size, age, Glasgow Coma Scale, stability intraventricular haemorrhage size, and clot location). Analysis of the primary efficacy outcome was done in the modified intention-to-treat (mITT) population, which included all eligible, randomly assigned patients who were exposed to treatment. All randomly assigned patients were included in the safety analysis. This study is registered with ClinicalTrials.gov, number NCT01827046. Findings Between Dec 30, 2013, and Aug 15, 2017, 506 patients were randomly allocated: 255 (50%) to the MISTIE group and 251 (50%) to standard medical care. 499 patients (n=250 in the MISTIE group; n=249 in the standard medical care group) received treatment and were included in the mITT analysis set. The mITT primary adjusted efficacy analysis estimated that 45% of patients in the MISTIE group and 41% patients in the standard medical care group had achieved an mRS score of 0–3 at 365 days (adjusted risk difference 4% [95% CI -4 to 12]; p=0\cdot33). Sensitivity analyses of 365-day mRS using generalised ordered logistic regression models adjusted for baseline variables showed that the estimated odds ratios comparing MISTIE with standard medical care for mRS scores higher than 5 versus 5 or less, higher than 4 versus 4 or less, higher than 3 versus 3 or less, and higher than 2 versus 2 or less were 0\cdot60 (p=0\cdot03), 0\cdot84 (p=0\cdot42), 0\cdot87 (p=0\cdot49), and 0\cdot82 (p=0\cdot44), respectively. At 7 days, two (1%) of 255 patients in the MISTIE group and ten (4%) of 251 patients in the standard medical care group had died (p=0\cdot02) and at 30 days, 24 (9%) patients in the MISTIE group and 37 (15%) patients in the standard medical care group had died (p=0\cdot07). The number of patients with symptomatic bleeding and brain bacterial infections was similar between the MISTIE and standard medical care groups (six [2%] of 255 patients vs three [1%] of 251 patients; p=0\cdot33 for symptomatic bleeding; two [1%] of 255 patients vs 0 [0%] of 251 patients; p=0\cdot16 for brain bacterial infections). At 30 days, 76 (30%) of 255 patients in the MISTIE group and 84 (33%) of 251 patients in the standard medical care group had one or more serious adverse event, and the difference in number of serious adverse events between the groups was statistically significant (p=0\cdot012). Interpretation For moderate to large intracerebral haemorrhage, MISTIE did not improve the proportion of patients who achieved a good response 365 days after intracerebral haemorrhage. The procedure was safely adopted by our sample of surgeons. Funding National Institute of Neurological Disorders and Stroke and Genentech.;,citation_author=Daniel F Hanley;,citation_author=Richard E Thompson;,citation_author=Michael Rosenblum;,citation_author=Gayane Yenokyan;,citation_author=Karen Lane;,citation_author=Nichol McBee;,citation_author=Steven W Mayo;,citation_author=Amanda J Bistran-Hall;,citation_author=Dheeraj Gandhi;,citation_author=W Andrew Mould;,citation_author=Natalie Ullman;,citation_author=Hasan Ali;,citation_author=J Ricardo Carhuapoma;,citation_author=Carlos S Kase;,citation_author=Kennedy R Lees;,citation_author=Jesse Dawson;,citation_author=Alastair Wilson;,citation_author=Joshua F Betz;,citation_author=Elizabeth A Sugar;,citation_author=Yi Hao;,citation_author=Radhika Avadhani;,citation_author=Jean-Louis Caron;,citation_author=Mark R Harrigan;,citation_author=Andrew P Carlson;,citation_author=Diederik Bulters;,citation_author=David LeDoux;,citation_author=Judy Huang;,citation_author=Cully Cobb;,citation_author=Gaurav Gupta;,citation_author=Ryan Kitagawa;,citation_author=Michael R Chicoine;,citation_author=Hiren Patel;,citation_author=Robert Dodd;,citation_author=Paul J Camarata;,citation_author=Stacey Wolfe;,citation_author=Agnieszka Stadnik;,citation_author=P Lynn Money;,citation_author=Patrick Mitchell;,citation_author=Rosario Sarabia;,citation_author=Sagi Harnof;,citation_author=Pal Barzo;,citation_author=Andreas Unterberg;,citation_author=Jeanne S Teitelbaum;,citation_author=Weimin Wang;,citation_author=Craig S Anderson;,citation_author=A David Mendelow;,citation_author=Barbara Gregson;,citation_author=Scott Janis;,citation_author=Paul Vespa;,citation_author=Wendy Ziai;,citation_author=Mario Zuccarello;,citation_author=Issam A Awad;,citation_author=Azmil Abdul-Rahim;,citation_author=Amal Abou-Hamden;,citation_author=Michael Abraham;,citation_author=Azam Ahmed;,citation_author=Carlos Alarcon Alba;,citation_author=E. Francois Aldrich;,citation_author=David Altschul;,citation_author=Sepideh Amin-Hanjani;,citation_author=Doug Anderson;,citation_author=Safdar Ansari;,citation_author=David Antezana;,citation_author=Agnieszka Ardelt;,citation_author=Fuat Arikan;,citation_author=Marcelino Baguena;,citation_author=Alexandra Baker;,citation_author=Steven J. Barrer;,citation_author=Kyra J. Becker;,citation_author=Thomas Bergman;,citation_author=Azize Boström;,citation_author=Jamie Braun;,citation_author=Peter Brindley;,citation_author=William C. Broaddus;,citation_author=Robert Brown;,citation_author=Andras Buki;,citation_author=Bing Cao;,citation_author=Ying Cao;,citation_author=Julian Carrion-Penagos;,citation_author=Julio Chalela;,citation_author=Tiffany Chang;,citation_author=Indalecio Moran Chorro;,citation_author=Shakeel Chowdhry;,citation_author=Luisa Corral;,citation_author=Laszlo Csiba;,citation_author=Jason Davies;,citation_author=Alberto Torres Díaz;,citation_author=Colin P. Derdeyn;,citation_author=Michael Diringer;,citation_author=Rachel Dlugash;,citation_author=Robert Ecker;,citation_author=Tracey Economas;,citation_author=Pedro Enriquez;,citation_author=Erzsebet Ezer;,citation_author=Yuhua Fan;,citation_author=Hua Feng;,citation_author=Douglas Franz;,citation_author=W. David Freeman;,citation_author=Matthew Fusco;,citation_author=Walter Galicich;,citation_author=Mary Leigh Gelea;,citation_author=Joshua Goldstein;,citation_author=Alejandro Carrasco Gonzalez;,citation_author=Christina Grabarits;,citation_author=Steven Greenberg;,citation_author=Daryl Gress;,citation_author=Eugene Gu;,citation_author=Christiana Hall;,citation_author=Fernando Muñoz Hernandez;,citation_author=Robert Hoesch;,citation_author=Brian L. Hoh;,citation_author=Jennifer Houser;,citation_author=Rong Hu;,citation_author=Yi Huang;,citation_author=Mohammed Akbar Hussain;,citation_author=Salvatore Insinga;,citation_author=Ashutosh Jadhav;,citation_author=Jennifer Jaffe;,citation_author=Babak S. Jahromi;,citation_author=Jack Jallo;,citation_author=Michael James;,citation_author=Robert F. James;,citation_author=Brian Jankowitz;,citation_author=Esther Jeon;,citation_author=Draga Jichici;,citation_author=Karin Jonczak;,citation_author=Ben Jonker;,citation_author=Nicki Karlen;,citation_author=Naureen Keric;,citation_author=Thomas Kerz;,citation_author=Jared Knopman;,citation_author=Carolyn Koenig;,citation_author=Satish Krishnamurthy;,citation_author=Avinash Kumar;,citation_author=Inam Kureshi;,citation_author=John Laidlaw;,citation_author=Arun Lakhanpal;,citation_author=Julius Gene Latorre;,citation_author=Dana Leifer;,citation_author=James Leiphart;,citation_author=Sarah Lenington;,citation_author=Yunke Li;,citation_author=George Lopez;,citation_author=Darren Lovick;,citation_author=Christianto Lumenta;,citation_author=Jinbiao Luo;,citation_author=Matthew B. Maas;,citation_author=Joel MacDonald;,citation_author=Larami MacKenzie;,citation_author=Vikram Madan;,citation_author=Ryan Majkowski;,citation_author=Otto Major;,citation_author=Rishi Malhorta;,citation_author=Marc Malkoff;,citation_author=Halinder Mangat;,citation_author=Ahmed Maswadeh;,citation_author=Charles Matouk;,citation_author=Kate McArthur;,citation_author=Scott McCaul;,citation_author=Joshua Medow;,citation_author=Geza Mezey;,citation_author=Janet Mighty;,citation_author=David Miller;,citation_author=Krishna K. Mohan;,citation_author=Keith Muir;,citation_author=Lorenzo Muñoz;,citation_author=Peter Nakaji;,citation_author=Alex Nee;,citation_author=Saman Nekoovaght-Tak;,citation_author=Paul Nyquist;,citation_author=Roddy O’Kane;,citation_author=Mohamed Okasha;,citation_author=Cian O’Kelly;,citation_author=Noeleen Ostapkovich;,citation_author=Aditya Pandey;,citation_author=Adrian Parry-Jones;,citation_author=Krissia Rivera Perla;,citation_author=Ania Pollack;,citation_author=Sean Polster;,citation_author=Nader Pouratian;,citation_author=Terry Quinn;,citation_author=Ventatakrishna Rajajee;,citation_author=Kesava Reddy;,citation_author=Mohammed Rehman;,citation_author=Ronald Reimer;,citation_author=Fred Rincon;,citation_author=Igor Rybinnik;,citation_author=Baltasar Sanchez;,citation_author=Lauren Sansing;,citation_author=Michael Schneck;,citation_author=Ludwig Schuerer;,citation_author=David Schul;,citation_author=Jeffrey Schweitzer;,citation_author=David B. Seder;,citation_author=Donald Seyfried;,citation_author=Kevin Sheth;,citation_author=Alejandro Spiotta;,citation_author=Michael Stechison;,citation_author=Katalin Szabo;,citation_author=Gonzalo Tamayo;,citation_author=Krisztian Tanczos;,citation_author=Philipp Taussky;,citation_author=John Terry;,citation_author=Fernando Testai;,citation_author=Kathrine Thomas;,citation_author=Carol B. Thompson;,citation_author=Gregory Thompson;,citation_author=James C. Torner;,citation_author=Huy Tran;,citation_author=Kristi Tucker;,citation_author=Lior Ungar;,citation_author=Panos Varelas;,citation_author=Nataly Montano Vargas;,citation_author=Hartmut Vatter;,citation_author=Chitra Venkatasubramanian;,citation_author=Krista Vermillion;,citation_author=Dennis Vollmer;,citation_author=Yan Wang;,citation_author=Ying Wang;,citation_author=Jiajun Wen;,citation_author=Louis Tony Whitworth;,citation_author=Byron Willis;,citation_author=Myriha Wrencher;,citation_author=Shawn E. Wright;,citation_author=Yongge Xu;,citation_author=Lisa Yanase;,citation_author=Xuxia Yi;,citation_author=Zhiyuan Yu;,citation_author=Ali Zomorodi;,citation_publication_date=2019-03;,citation_cover_date=2019-03;,citation_year=2019;,citation_issue=10175;,citation_doi=10.1016/S0140-6736(19)30195-3;,citation_issn=0140-6736;,citation_volume=393;,citation_language=en-US;,citation_journal_title=The Lancet;">
<meta name="citation_reference" content="citation_title=Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: Results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial;,citation_abstract=BACKGROUND: Intraventricular haemorrhage is a subtype of intracerebral haemorrhage, with 50% mortality and serious disability for survivors. We aimed to test whether attempting to remove intraventricular haemorrhage with alteplase versus saline irrigation improved functional outcome. METHODS: In this randomised, double-blinded, placebo-controlled, multiregional trial (CLEAR III), participants with a routinely placed extraventricular drain, in the intensive care unit with stable, non-traumatic intracerebral haemorrhage volume less than 30 mL, intraventricular haemorrhage obstructing the 3rd or 4th ventricles, and no underlying pathology were adaptively randomly assigned (1:1), via a web-based system to receive up to 12 doses, 8 h apart of 1 mg of alteplase or 0\cdot9% saline via the extraventricular drain. The treating physician, clinical research staff, and participants were masked to treatment assignment. CT scans were obtained every 24 h throughout dosing. The primary efficacy outcome was good functional outcome, defined as a modified Rankin Scale score (mRS) of 3 or less at 180 days per central adjudication by blinded evaluators. This study is registered with ClinicalTrials.gov, NCT00784134. FINDINGS: Between Sept 18, 2009, and Jan 13, 2015, 500 patients were randomised: 249 to the alteplase group and 251 to the saline group. 180-day follow-up data were available for analysis from 246 of 249 participants in the alteplase group and 245 of 251 participants in the placebo group. The primary efficacy outcome was similar in each group (good outcome in alteplase group 48% vs saline 45%; risk ratio [RR] 1\cdot06 [95% CI 0\cdot88-1\cdot28; p=0\cdot554]). A difference of 3\cdot5% (RR 1\cdot08 [95% CI 0\cdot90-1\cdot29], p=0\cdot420) was found after adjustment for intraventricular haemorrhage size and thalamic intracerebral haemorrhage. At 180 days, the treatment group had lower case fatality (46 [18%] vs saline 73 [29%], hazard ratio 0\cdot60 [95% CI 0\cdot41-0\cdot86], p=0\cdot006), but a greater proportion with mRS 5 (42 [17%] vs 21 [9%]; RR 1\cdot99 [95% CI 1\cdot22-3\cdot26], p=0\cdot007). Ventriculitis (17 [7%] alteplase vs 31 [12%] saline; RR 0\cdot55 [95% CI 0\cdot31-0\cdot97], p=0\cdot048) and serious adverse events (114 [46%] alteplase vs 151 [60%] saline; RR 0\cdot76 [95% CI 0\cdot64-0\cdot90], p=0\cdot002) were less frequent with alteplase treatment. Symptomatic bleeding (six [2%] in the alteplase group vs five [2%] in the saline group; RR 1\cdot21 [95% CI 0\cdot37-3\cdot91], p=0\cdot771) was similar. INTERPRETATION: In patients with intraventricular haemorrhage and a routine extraventricular drain, irrigation with alteplase did not substantially improve functional outcomes at the mRS 3 cutoff compared with irrigation with saline. Protocol-based use of alteplase with extraventricular drain seems safe. Future investigation is needed to determine whether a greater frequency of complete intraventricular haemorrhage removal via alteplase produces gains in functional status. FUNDING: National Institute of Neurological Disorders and Stroke.;,citation_author=Daniel F. Hanley;,citation_author=Karen Lane;,citation_author=Nichol McBee;,citation_author=Wendy Ziai;,citation_author=Stanley Tuhrim;,citation_author=Kennedy R. Lees;,citation_author=Jesse Dawson;,citation_author=Dheeraj Gandhi;,citation_author=Natalie Ullman;,citation_author=W. Andrew Mould;,citation_author=Steven W. Mayo;,citation_author=A. David Mendelow;,citation_author=Barbara Gregson;,citation_author=Kenneth Butcher;,citation_author=Paul Vespa;,citation_author=David W. Wright;,citation_author=Carlos S. Kase;,citation_author=J. Ricardo Carhuapoma;,citation_author=Penelope M. Keyl;,citation_author=Marie Diener-West;,citation_author=John Muschelli;,citation_author=Joshua F. Betz;,citation_author=Carol B. Thompson;,citation_author=Elizabeth A. Sugar;,citation_author=Gayane Yenokyan;,citation_author=Scott Janis;,citation_author=Sayona John;,citation_author=Sagi Harnof;,citation_author=George A. Lopez;,citation_author=E. Francois Aldrich;,citation_author=Mark R. Harrigan;,citation_author=Safdar Ansari;,citation_author=Jack Jallo;,citation_author=Jean-Louis Caron;,citation_author=David LeDoux;,citation_author=Opeolu Adeoye;,citation_author=Mario Zuccarello;,citation_author=Harold P. Adams;,citation_author=Michael Rosenblum;,citation_author=Richard E. Thompson;,citation_author=Issam A. Awad;,citation_author=CLEAR III Investigators;,citation_publication_date=2017-02;,citation_cover_date=2017-02;,citation_year=2017;,citation_issue=10069;,citation_doi=10.1016/S0140-6736(16)32410-2;,citation_issn=1474-547X;,citation_pmid=28081952;,citation_volume=389;,citation_language=en-US;,citation_journal_title=Lancet (London, England);">
<meta name="citation_reference" content="citation_title=Pressin’ On: Effect of Vasopressin and Steroids on Achieving Return of Spontaneous Circulation During Inhospital Cardiac Arrest (The VAM-IHCA Trial);,citation_author=Eriny Hanna;,citation_author=Aaron Lacy;,citation_author=Tyler Barrett;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=1;,citation_doi=10.1016/j.annemergmed.2021.11.014;,citation_issn=01960644;,citation_volume=79;,citation_language=en-US;,citation_journal_title=Annals of Emergency Medicine;">
<meta name="citation_reference" content="citation_title=Applicability of Clinical Trials in an Unselected Cohort of Patients With Intracerebral Hemorrhage;,citation_abstract=Background and Purpose— Patient selection in clinical trials on intracerebral hemorrhage (ICH) affects overall applicability of results. We estimated eligibility for completed, ongoing, and planned clinical trials in an unselected cohort of patients with ICH. Methods— Large clinical ICH trials were identified using trial registration databases. Each trial’s inclusion criteria were applied to a consecutive group of patients with ICH from the prospective hospital-based Lund Stroke Register. Survival status was obtained from the National Census Office and 90-day poor functional outcome (modified Rankin Scale \geq4) from the Swedish Stroke Register or medical files. Results— Among 253 patients with ICH, estimated eligibility proportions ranged between 2% and 36% for the 11 identified clinical trials. Patients not eligible for any trial (n=96) had more intraventricular hemorrhage, lower baseline level of consciousness, higher rates of cerebellar ICH, and lower rates of lobar ICH (P\leq0.001). Thirty-day case fatality for noneligible patients was 54% versus 18% among patients eligible in \geq1 trial (95% confidence interval, 44%–64% versus 13%–25%; P&amp;amp;amp;lt;0.001). Noneligible ICH patients more frequently had poor functional outcome (75% versus 48%; 95% confidence interval, 65%–83% versus 40%–56%; P&amp;lt;0.001). Conclusions— There is large variation in proportions of patients with ICH eligible for inclusion in clinical trials and over a third of patients with ICH are not eligible for any trial.;,citation_author=Björn M. Hansen;,citation_author=Natalie Ullman;,citation_author=Bo Norrving;,citation_author=Daniel F. Hanley;,citation_author=Arne Lindgren;,citation_publication_date=2016-10;,citation_cover_date=2016-10;,citation_year=2016;,citation_issue=10;,citation_doi=10.1161/STROKEAHA.116.014203;,citation_volume=47;,citation_journal_title=Stroke;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=Development of the TrAnsparent ReportinG of observational studies Emulating a Target trial (TARGET) guideline;,citation_abstract=Background Observational studies are increasingly used to inform health decision-making when randomised trials are not feasible, ethical or timely. The target trial approach provides a framework to help minimise common biases in observational studies that aim to estimate the causal effect of interventions. Incomplete reporting of studies using the target trial framework limits the ability for clinicians, researchers, patients and other decision-makers to appraise, synthesise and interpret findings to inform clinical and public health practice and policy. This paper describes the methods that we will use to develop the TrAnsparent ReportinG of observational studies Emulating a Target trial (TARGET) reporting guideline. Methods/design The TARGET reporting guideline will be developed in five stages following recommended guidance. The first stage will identify target trial reporting practices by systematically reviewing published studies that explicitly emulated a target trial. The second stage will identify and refine items to be considered for inclusion in the TARGET guideline by consulting content experts using sequential online surveys. The third stage will prioritise and consolidate key items to be included in the TARGET guideline at an in-person consensus meeting of TARGET investigators. The fourth stage will produce and pilot-test both the TARGET guideline and explanation and elaboration document with relevant stakeholders. The fifth stage will disseminate the TARGET guideline and resources via journals, conferences and courses. Ethics and dissemination Ethical approval for the survey has been attained (HC220536). The TARGET guideline will be disseminated widely in partnership with stakeholders to maximise adoption and improve reporting of these studies.;,citation_author=Harrison J. Hansford;,citation_author=Aidan G. Cashin;,citation_author=Matthew D. Jones;,citation_author=Sonja A. Swanson;,citation_author=Nazrul Islam;,citation_author=Issa J. Dahabreh;,citation_author=Barbra A. Dickerman;,citation_author=Matthias Egger;,citation_author=Xavier Garcia-Albeniz;,citation_author=Robert M. Golub;,citation_author=Sara Lodi;,citation_author=Margarita Moreno-Betancur;,citation_author=Sallie-Anne Pearson;,citation_author=Sebastian Schneeweiss;,citation_author=Jonathan Sterne;,citation_author=Melissa K. Sharp;,citation_author=Elizabeth A. Stuart;,citation_author=Miguel A. Hernan;,citation_author=Hopin Lee;,citation_author=James H. McAuley;,citation_publication_date=2023-09;,citation_cover_date=2023-09;,citation_year=2023;,citation_issue=9;,citation_doi=10.1136/bmjopen-2023-074626;,citation_issn=2044-6055, 2044-6055;,citation_pmid=37699620;,citation_volume=13;,citation_language=en-US;,citation_journal_title=BMJ Open;,citation_publisher=British Medical Journal Publishing Group;">
<meta name="citation_reference" content="citation_title=Immune Modulation in Sepsis, ARDS, and Covid-19 — The Road Traveled and the Road Ahead;,citation_abstract=Leligdowicz et al. consider the history and future of immunomodulating therapies in sepsis and ARDS, including ARDS due to Covid-19, and remark on the larger challenge of clinical research on therapies for syndromes with profound clinical and biologic heterogeneity.;,citation_author=Aleksandra Leligdowicz;,citation_author=Michael O. Harhay;,citation_author=Carolyn S. Calfee;,citation_editor=C. Corey Hardin;,citation_publication_date=2022-10;,citation_cover_date=2022-10;,citation_year=2022;,citation_issue=11;,citation_doi=10.1056/EVIDra2200118;,citation_issn=2766-5526;,citation_volume=1;,citation_language=en-US;,citation_journal_title=NEJM Evidence;">
<meta name="citation_reference" content="citation_title=Improved Protocols for Ventilator Liberation;,citation_abstract=Like many critical care interventions, mechanical ventilation is lifesaving when indicated but is beset by potential complications as the duration of use increases. Early identification of patients who are ready to be liberated from ventilator support is therefore key to the management of respiratory failure. Because clinician judgment lacks both sensitivity and specificity for identifying such patients,1 this task is best accomplished by means of protocolized spontaneous-breathing trials,2,3 in which patients who meet a defined set of criteria undergo a test period of minimal or no ventilator support. Many, if not most, patients who meet the criteria for a spontaneous-breathing . . .;,citation_author=C. Corey Hardin;,citation_publication_date=2022-11;,citation_cover_date=2022-11;,citation_year=2022;,citation_issue=20;,citation_doi=10.1056/NEJMe2212594;,citation_issn=0028-4793;,citation_volume=387;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Contemporary strategies to improve clinical trial design for critical care research: Insights from the First Critical Care Clinical Trialists Workshop;,citation_abstract=Conducting research in critically-ill patient populations is challenging, and most randomized trials of critically-ill patients have not achieved pre-specified statistical thresholds to conclude that the intervention being investigated was beneficial.;,citation_author=Michael O. Harhay;,citation_author=Jonathan D. Casey;,citation_author=Marina Clement;,citation_author=Sean P. Collins;,citation_author=Étienne Gayat;,citation_author=Michelle Ng Gong;,citation_author=Samir Jaber;,citation_author=Pierre-François Laterre;,citation_author=John C. Marshall;,citation_author=Michael A. Matthay;,citation_author=Rhonda E. Monroe;,citation_author=Todd W. Rice;,citation_author=Eileen Rubin;,citation_author=Wesley H. Self;,citation_author=Alexandre Mebazaa;,citation_publication_date=2020-05;,citation_cover_date=2020-05;,citation_year=2020;,citation_issue=5;,citation_doi=10.1007/s00134-020-05934-6;,citation_issn=1432-1238;,citation_volume=46;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=eAppendix: Would Stronger Seat Belt Laws Reduce Motor Vehicle Crash Deaths? A Semi-Bayesian Analysis;,citation_author=Sam Harper;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Would Stronger Seat Belt Laws Reduce Motor Vehicle Crash Deaths?: A Semi-Bayesian Analysis;,citation_abstract=Background:&nbsp; For policy questions where substantial empirical background information exists, conventional frequentist policy analysis is hard to justify. Bayesian analysis quantitatively incorporates prior knowledge, but is not often used in applied policy analysis. Methods:&nbsp; We combined 2000–2016 data from the Fatal Analysis Reporting System with priors based on past empirical studies and policy documents to study the impact of mandatory seat belt laws on traffic fatalities. We used a Bayesian data augmentation approach to combine information from prior studies with difference-in-differences analyses of recent law changes to provide updated evidence on the impact that upgrading to primary enforcement of seat belt laws has on fatalities. Results:&nbsp; After incorporating the evidence from past studies, we find limited evidence to support the hypothesis that recent policy upgrades affect fatality rates. We estimate that upgrading to primary enforcement reduced fatality rates by 0.37 deaths per billion vehicle miles traveled (95% posterior interval -0.90, 0.16), or a rate ratio of 0.96 (95% posterior interval 0.91, 1.02), and increased the proportion of decedents reported as wearing seat belts by 7 percentage points (95% posterior interval 5, 8), or a risk ratio of 1.18 (95% posterior interval 1.13, 1.24). Conclusions:&nbsp; Bayesian methods can provide credible estimates of future policy impacts, especially for policy questions that occur in dynamic environments, such as traffic safety.;,citation_author=Sam Harper;,citation_publication_date=2019-05;,citation_cover_date=2019-05;,citation_year=2019;,citation_issue=3;,citation_doi=10.1097/EDE.0000000000000990;,citation_issn=1044-3983;,citation_volume=30;,citation_language=en-US;,citation_journal_title=Epidemiology;">
<meta name="citation_reference" content="citation_title=The evidence contained in the P-value is context dependent;,citation_author=Florian Hartig;,citation_author=Frédéric Barraquand;,citation_publication_date=2022-07;,citation_cover_date=2022-07;,citation_year=2022;,citation_issue=7;,citation_doi=10.1016/j.tree.2022.02.011;,citation_issn=01695347;,citation_volume=37;,citation_language=en-US;,citation_journal_title=Trends in Ecology &amp;amp;amp; Evolution;">
<meta name="citation_reference" content="citation_title=Duration of Device-Based Fever Prevention after Cardiac Arrest;,citation_author=Christian Hassager;,citation_author=Henrik Schmidt;,citation_author=Jacob E. Møller;,citation_author=Johannes Grand;,citation_author=Simon Mølstrøm;,citation_author=Rasmus P. Beske;,citation_author=Søren Boesgaard;,citation_author=Britt Borregaard;,citation_author=Ditte Bekker-Jensen;,citation_author=Jordi S. Dahl;,citation_author=Martin S. Frydland;,citation_author=Dan E. Høfsten;,citation_author=Yusuf A. Isse;,citation_author=Jakob Josiassen;,citation_author=Vibeke R. Lind Jørgensen;,citation_author=Daniel Kondziella;,citation_author=Matias G. Lindholm;,citation_author=Emil Moser;,citation_author=Benjamin C. Nyholm;,citation_author=Laust E. R. Obling;,citation_author=Laura Sarkisian;,citation_author=Frederik T. Søndergaard;,citation_author=Jakob H. Thomsen;,citation_author=Jens J. Thune;,citation_author=Søren Venø;,citation_author=Sebastian C. Wiberg;,citation_author=Matilde Winther-Jensen;,citation_author=Martin A. S. Meyer;,citation_author=Jesper Kjaergaard;,citation_publication_date=2022-11;,citation_cover_date=2022-11;,citation_year=2022;,citation_doi=10.1056/NEJMoa2212528;,citation_issn=0028-4793;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=The Origin of the Burst-Suppression Paradigm in Treatment of Status Epilepticus;,citation_abstract=After electroencephalography (EEG) was introduced in hospitals, early literature recognized burst-suppression pattern (BSP) as a distinctive EEG pattern characterized by intermittent high-power oscillations alternating with isoelectric periods in coma and epileptic encephalopathies of childhood or the pattern could be induced by general anesthesia and hypothermia. The term was introduced by Swank and Watson in 1949 but was initially described by Derbyshire et al. in 1936 in their study about the anesthetic effects of tribromoethanol. Once the EEG/BSP pattern emerged in the literature as therapeutic goal in refractory status epilepticus, researchers began exploring whether the depth of EEG suppression correlated with improved seizure control and clinical outcomes. We can conclude that, from a historical perspective, the evidence to suppress the brain to a BSP when treating status epilepticus is inconclusive.;,citation_author=Maximiliano A. Hawkes;,citation_author=Mouhanned Eliliwi;,citation_author=Eelco F. M. Wijdicks;,citation_publication_date=2023-11;,citation_cover_date=2023-11;,citation_year=2023;,citation_doi=10.1007/s12028-023-01877-0;,citation_issn=1556-0961;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Use of Confidence Intervals in Interpreting Nonstatistically Significant Results;,citation_author=Alexander T. Hawkins;,citation_author=Lauren R. Samuels;,citation_publication_date=2021-11;,citation_cover_date=2021-11;,citation_year=2021;,citation_issue=20;,citation_doi=10.1001/jama.2021.16172;,citation_issn=0098-7484;,citation_volume=326;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Intracranial pressure: Current perspectives on physiology and monitoring;,citation_abstract=Intracranial pressure (ICP) monitoring is now viewed as integral to the clinical care of many life-threatening brain insults, such as severe traumatic brain injury, subarachnoid hemorrhage, and malignant stroke. It serves to warn of expanding intracranial mass lesions, to prevent or treat herniation events as well as pressure elevation which impedes nutrient delivery to the brain. It facilitates the calculation of cerebral perfusion pressure (CPP) and the estimation of cerebrovascular autoregulatory status. Despite advancements in our knowledge emanating from a half century of experience with this technology, important controversies remain related even to fundamental aspects of ICP measurements, including indications for monitoring, ICP treatment thresholds, and management of intracranial hypertension. Here, we review the history of ICP monitoring, the underlying pathophysiology as well as current perspectives on why, when and how ICP monitoring is best used. ICP is typically assessed invasively but a number of emerging, non-invasive technologies with inherently lower risk are showing promise. In selected cases, additional neuromonitoring can be used to assist in the interpretation of ICP monitoring information and adapt directed treatment accordingly. Additional efforts to expand the evidence base relevant to ICP monitoring, related technologies and management remain a high priority in neurosurgery and neurocritical care.;,citation_author=Gregory W. J. Hawryluk;,citation_author=Giuseppe Citerio;,citation_author=Peter Hutchinson;,citation_author=Angelos Kolias;,citation_author=Geert Meyfroidt;,citation_author=Chiara Robba;,citation_author=Nino Stocchetti;,citation_author=Randall Chesnut;,citation_publication_date=2022-10;,citation_cover_date=2022-10;,citation_year=2022;,citation_issue=10;,citation_doi=10.1007/s00134-022-06786-y;,citation_issn=1432-1238;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Intracranial pressure pulse morphology: The missing link? Author’s reply;,citation_author=Gregory W. J. Hawryluk;,citation_author=Giuseppe Citerio;,citation_author=Chiara Robba;,citation_publication_date=2022-11;,citation_cover_date=2022-11;,citation_year=2022;,citation_issue=11;,citation_doi=10.1007/s00134-022-06863-2;,citation_issn=1432-1238;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Most medical practices are not parachutes: A citation analysis of practices felt by biomedical authors to be analogous to parachutes;,citation_abstract=Background: In a 2003 paper in BMJ, the authors made the tongue-in-cheek observation that there are no randomized controlled trials (RCTs) of parachutes. This paper has been widely read, cited and used to argue that RCTs are impractical or unnecessary for some medical practices. We performed a study to identify and evaluate claims that a medical practice is akin to a parachute.;,citation_author=Michael J. Hayes;,citation_author=Victoria Kaestner;,citation_author=Sham Mailankody;,citation_author=Vinay Prasad;,citation_publication_date=2018-01;,citation_cover_date=2018-01;,citation_year=2018;,citation_issue=1;,citation_doi=10.9778/cmajo.20170088;,citation_issn=2291-0026;,citation_volume=6;,citation_language=en-US;,citation_journal_title=CMAJ Open;">
<meta name="citation_reference" content="citation_title=Delirium in the Neuro Intensive Care Unit;,citation_abstract=This article reviews current literature regarding the neuro intensive care unit (ICU) and the ICU setting in general regarding delirium, pain, agitation, and evidence-based guidelines and assessment tools. Delirium in the ICU affects as many as 50% to 80% of patients. Delirium is associated with increased burden of illness, higher mortality, and increased suffering. Evidence-based guidelines recommend using validated and reliable assessment tools. We reviewed current national clinical guidelines, validated tools for assessing pain, agitation/sedation, and delirium. We also reviewed a delirium risk-assessment/prediction tool.;,citation_author=Joseph B. Haymore;,citation_author=Nikhil Patel;,citation_publication_date=2016-03;,citation_cover_date=2016-03;,citation_year=2016;,citation_issue=1;,citation_doi=10.1016/j.cnc.2015.11.001;,citation_issn=1558-3481;,citation_pmid=26873757;,citation_volume=28;,citation_language=en-US;,citation_journal_title=Critical Care Nursing Clinics of North America;">
<meta name="citation_reference" content="citation_title=How to keep up with the medical literature: I. Why try to keep up and how to get started;,citation_abstract=Patient care is often outmoded because physicians lack awareness about important advances in medical knowledge. According to physicians, reading journals is the most popular method for staying informed, but the great volume of journal literature precludes clinicians’ from reading all of it. In this first of six articles on keeping up with the medical literature, we describe three strategies to enhance the efficiency and effectiveness of journal reading. First, priority should be given to reading original articles concerning reports of planned investigations because only these articles provide sufficient details to assess the relevance, validity, and clinical application of new knowledge. Second, reading should be restricted to articles of direct pertinence to one’s clinical practice. Third, the methods section of articles should be quickly screened first to select studies that have used sufficiently high standards to warrant clinical action based on study results.;,citation_author=R. B. Haynes;,citation_author=K. A. McKibbon;,citation_author=D. Fitzgerald;,citation_author=G. H. Guyatt;,citation_author=C. J. Walker;,citation_author=D. L. Sackett;,citation_publication_date=1986-07;,citation_cover_date=1986-07;,citation_year=1986;,citation_issue=1;,citation_doi=10.7326/0003-4819-105-1-149;,citation_issn=0003-4819;,citation_pmid=3717805;,citation_volume=105;,citation_language=en-US;,citation_journal_title=Annals of Internal Medicine;">
<meta name="citation_reference" content="citation_title=Reporting Clinical Trial Results To Inform Providers, Payers, And Consumers;,citation_abstract=Results of randomized clinical trials are the preferred “evidence” for establishing the benefits and safety of medical treatments. We present evidence suggesting that the conventional approach to reporting clinical trials has fundamental flaws that can result in overlooking identifiable subgroups harmed by a treatment while underestimating benefits to others. A risk-stratified approach can dramatically reduce the chances of such errors. Since professional and economic incentives reward advocating treatments for as broad a patient population as possible, we suggest that payers and regulatory bodies might need to act to motivate prompt, routine adoption of risk-stratified assessments of medical treatments’ safety and benefits.;,citation_author=Rodney A. Hayward;,citation_author=David M. Kent;,citation_author=Sandeep Vijan;,citation_author=Timothy P. Hofer;,citation_publication_date=2005-11;,citation_cover_date=2005-11;,citation_year=2005;,citation_issue=6;,citation_doi=10.1377/hlthaff.24.6.1571;,citation_issn=0278-2715;,citation_volume=24;,citation_journal_title=Health Affairs;,citation_publisher=Health Affairs;">
<meta name="citation_reference" content="citation_title=Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation;,citation_author=Jeff S. Healey;,citation_author=Renato D. Lopes;,citation_author=Christopher B. Granger;,citation_author=Marco Alings;,citation_author=Lena Rivard;,citation_author=William F. McIntyre;,citation_author=Dan Atar;,citation_author=David H. Birnie;,citation_author=Giuseppe Boriani;,citation_author=A. John Camm;,citation_author=David Conen;,citation_author=Julia W. Erath;,citation_author=Michael R. Gold;,citation_author=Stefan H. Hohnloser;,citation_author=John Ip;,citation_author=Josef Kautzner;,citation_author=Valentina Kutyifa;,citation_author=Cecilia Linde;,citation_author=Philippe Mabo;,citation_author=Georges Mairesse;,citation_author=Juan Benezet Mazuecos;,citation_author=Jens Cosedis Nielsen;,citation_author=Francois Philippon;,citation_author=Marco Proietti;,citation_author=Christian Sticherling;,citation_author=Jorge A. Wong;,citation_author=David J. Wright;,citation_author=Ignatius G. Zarraga;,citation_author=Shelagh B. Coutts;,citation_author=Andrew Kaplan;,citation_author=Marta Pombo;,citation_author=Felix Ayala-Paredes;,citation_author=Lizhen Xu;,citation_author=Kim Simek;,citation_author=Sandra Nevills;,citation_author=Rajibul Mian;,citation_author=Stuart J. Connolly;,citation_publication_date=2023-11;,citation_cover_date=2023-11;,citation_year=2023;,citation_issue=0;,citation_doi=10.1056/NEJMoa2310234;,citation_issn=0028-4793;,citation_volume=0;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=The event-driven nature of online political hostility: How offline political events make online interactions more hostile;,citation_abstract=Hostile interactions permeate political debates on social media, but what is driving the long-term developments in online political hostility? Prior research focuses on individual-level factors such as the dispositions of users or network-level factors such as echo chambers. Moving beyond these accounts, we develop and test an event-oriented explanation and demonstrate that over the course of the 2020 election year in the United States, all major shifts in political hostility on the social media platform Twitter were driven by external offline events. Importantly, these events were magnified by Twitter users within the most politically hostile and most ideologically homogeneous networks. Further contributing to the individual and network-oriented accounts, we show that divisive offline events mobilized individual users not already disposed for hostility and may have helped facilitate the formation of echo chambers. The dynamics of online interactions—including their level of hostility—seem crucially dependent on developments in the offline world.;,citation_author=Stig Hebbelstrup Rye Rasmussen;,citation_author=Michael Bang Petersen;,citation_editor=Noshir Contractor;,citation_publication_date=2023-11;,citation_cover_date=2023-11;,citation_year=2023;,citation_issue=11;,citation_doi=10.1093/pnasnexus/pgad382;,citation_issn=2752-6542;,citation_volume=2;,citation_language=en-US;,citation_journal_title=PNAS Nexus;">
<meta name="citation_reference" content="citation_title=Mercury vs. Water: An Analysis of Multi-Institutional Survey Data Assessing Intracranial Pressure Unit of Measure Awareness;,citation_abstract=BACKGROUND: Intracranial pressure (ICP) reporting impacts neurosurgical care. Millimeters of mercury (mmHg) and centimeters of water (cmH2O) are both used to report ICP in clinical practice and the literature. In this study, we investigated ICP unit of measure awareness in the neurosurgical community. METHODS: A survey was conducted at four US academic neurosurgery departments asking the following questions: What is your threshold for a concerning ICP? How many minutes is that ICP sustained for you to be concerned? What unit are you implying when you state that ICP? What unit of measure is an ICP reported on the monitor when transduced? When setting an external ventricular drain Becker bag level, what unit of measure do you set it to? Do you ever manually check an ICP based on a column of cerebrospinal fluid? How many cmH2O is 20&nbsp;mmHg? RESULTS: An ICP of 20 and sustained for five minutes were the two most common answers. Some 71% of residents and 34% of attendings reported using cmH2O as the unit of measure; 18% of residents and 24% of attendings implied different units when discussing ICP than the unit they thought was transduced; and 53% of residents and 34% of attendings did not know the transduced ICP unit of measure reported in their intensive care unit. CONCLUSIONS: Variability and discrepancies regarding the ICP unit of measure exist in academic neurosurgery departments. Clinicians should familiarize themselves with their hospital’s practices. Institutions and all of medicine may consider standardizing the ICP unit of measure, using mmHg as a universal nomenclature.;,citation_author=Daniel M. Heiferman;,citation_author=Megan M. Jack;,citation_author=Kendrick D. Johnson;,citation_author=Gennadiy A. Katsevman;,citation_author=Vikram C. Prabhu;,citation_author=Anand V. Germanwala;,citation_author=Joseph C. Serrone;,citation_publication_date=2019-09;,citation_cover_date=2019-09;,citation_year=2019;,citation_doi=10.1016/j.wneu.2019.05.238;,citation_issn=1878-8769;,citation_pmid=31281108;,citation_volume=129;,citation_language=en-US;,citation_journal_title=World Neurosurgery;">
<meta name="citation_reference" content="citation_title=The Goldilocks Time for Remdesivir — Is Any Indication Just Right?;,citation_author=Emily L. Heil;,citation_author=Shyam Kottilil;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=4;,citation_doi=10.1056/NEJMe2118579;,citation_issn=0028-4793, 1533-4406;,citation_volume=386;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Causal Inference;,citation_author=Andrew Heiss;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Can Visualization Alleviate Dichotomous Thinking? Effects of Visual Representations on the Cliff Effect;,citation_abstract=Common reporting styles for statistical results in scientific articles, such as p-values and confidence intervals (CI), have been reported to be prone to dichotomous interpretations, especially with respect to the null hypothesis significance testing framework. For example when the p-value is small enough or the CIs of the mean effects of a studied drug and a placebo are not overlapping, scientists tend to claim significant differences while often disregarding the magnitudes and absolute differences in the effect sizes. This type of reasoning has been shown to be potentially harmful to science. Techniques relying on the visual estimation of the strength of evidence have been recommended to reduce such dichotomous interpretations but their effectiveness has also been challenged. We ran two experiments on researchers with expertise in statistical analysis to compare several alternative representations of confidence intervals and used Bayesian multilevel models to estimate the effects of the representation styles on differences in researchers’ subjective confidence in the results. We also asked the respondents’ opinions and preferences in representation styles. Our results suggest that adding visual information to classic CI representation can decrease the tendency towards dichotomous interpretations –measured as the “cliff effect”: the sudden drop in confidence around p-value 0.05 – compared with classic CI visualization and textual representation of the CI with p-values. All data and analyses are publicly available at https://github.com/helske/statvis.;,citation_author=Jouni Helske;,citation_author=Satu Helske;,citation_author=Matthew Cooper;,citation_author=Anders Ynnerman;,citation_author=Lonni Besancon;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_issue=8;,citation_doi=10.1109/TVCG.2021.3073466;,citation_issn=1077-2626, 1941-0506, 2160-9306;,citation_volume=27;,citation_language=en-US;,citation_journal_title=IEEE Transactions on Visualization and Computer Graphics;">
<meta name="citation_reference" content="citation_title=Routinely collected data and comparative effectiveness evidence: Promises and limitations;,citation_abstract=Routinely collected data (RCD) are increasingly used for biomedical research. Extensive resources have been invested in this field: they include the set-up of disease registries and clinical databases at regional, national or international levels; the promotion of the use of electronic health;,citation_author=Lars G. Hemkens;,citation_author=Despina G. Contopoulos-Ioannidis;,citation_author=John P. A. Ioannidis;,citation_publication_date=2016-05;,citation_cover_date=2016-05;,citation_year=2016;,citation_issue=8;,citation_doi=10.1503/cmaj.150653;,citation_issn=0820-3946, 1488-2329;,citation_pmid=26883316;,citation_volume=188;,citation_language=en-US;,citation_journal_title=CMAJ;,citation_publisher=CMAJ;">
<meta name="citation_reference" content="citation_title=A review of high impact journals found that misinterpretation of non-statistically significant results from randomised trials was common;,citation_author=Karla Hemming;,citation_author=Iqra Javid;,citation_author=Monica Taljaard;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_doi=10.1016/j.jclinepi.2022.01.014;,citation_issn=08954356;,citation_language=en-US;,citation_journal_title=Journal of Clinical Epidemiology;">
<meta name="citation_reference" content="citation_title=The ICH Score;,citation_abstract=Background and Purpose—Intracerebral hemorrhage (ICH) constitutes 10% to 15% of all strokes and remains without a treatment of proven benefit. Despite several existing outcome prediction models for ICH, there is no standard clinical grading scale for ICH analogous to those for traumatic brain injury, subarachnoid hemorrhage, or ischemic stroke. Methods—Records of all patients with acute ICH presenting to the University of California, San Francisco during 1997–1998 were reviewed. Independent predictors of 30-day mortality were identified by logistic regression. A risk stratification scale (the ICH Score) was developed with weighting of independent predictors based on strength of association. Results—Factors independently associated with 30-day mortality were Glasgow Coma Scale score (P&amp;amp;amp;lt;0.001), age \geq80 years (P=0.001), infratentorial origin of ICH (P=0.03), ICH volume (P=0.047), and presence of intraventricular hemorrhage (P=0.052). The ICH Score was the sum of individual points assigned as follows: GCS score 3 to 4 (=2 points), 5 to 12 (=1), 13 to 15 (=0); age \geq80 years yes (=1), no (=0); infratentorial origin yes (=1), no (=0); ICH volume \geq30 cm3 (=1), &amp;lt;30 cm3 (=0); and intraventricular hemorrhage yes (=1), no (=0). All 26 patients with an ICH Score of 0 survived, and all 6 patients with an ICH Score of 5 died. Thirty-day mortality increased steadily with ICH Score (P<0.005). Conclusions—The ICH Score is a simple clinical grading scale that allows risk stratification on presentation with ICH. The use of a scale such as the ICH Score could improve standardization of clinical treatment protocols and clinical research studies in ICH.;,citation_author=J. Claude Hemphill;,citation_author=David C. Bonovich;,citation_author=Lavrentios Besmertis;,citation_author=Geoffrey T. Manley;,citation_author=S. Claiborne Johnston;,citation_publication_date=2001-04;,citation_cover_date=2001-04;,citation_year=2001;,citation_issue=4;,citation_doi=10.1161/01.STR.32.4.891;,citation_volume=32;,citation_journal_title=Stroke;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=Tenecteplase versus alteplase before mechanical thrombectomy: Experience from a US healthcare system undergoing a system-wide transition of primary thrombolytic;,citation_abstract=Background Tenecteplase (TNK) is a genetically modified variant of alteplase (TPA) and has been established as a non-inferior alternative to TPA in acute ischemic stroke (AIS). Whether TNK exerts distinct benefits in large vessel occlusion (LVO) AIS is still being investigated. Objective To describe our first-year experience after a healthcare system-wide transition from TPA to TNK as the primary thrombolytic. Methods Patients with AIS who received intravenous thrombolytics between January 2020 and August 2022 were retrospectively reviewed. All patients with LVO considered for mechanical thrombectomy (MT) were included in this analysis. Spontaneous recanalization (SR) after TNK/TPA was a composite variable of reperfusion &amp;amp;amp;gt;50% of the target vessel territory on cerebral angiography or rapid, significant neurological recovery averting MT. Propensity score matching (PSM) was performed to compare SR rates between TNK and TPA. Results A total of 148 patients were identified; 51/148 (34.5%) received TNK and 97/148 (65.5%) TPA. The middle cerebral arteries M1 (60.8%) and M2 (29.7%) were the most frequent occlusion sites. Baseline demographics were comparable between TNK and TPA groups. Spontaneous recanalization was significantly more frequently observed in the TNK than in the TPA groups (unmatched: 23.5% vs 10.3%, P=0.032). PSM substantiated the observed SR rates (20% vs 10%). Symptomatic intracranial hemorrhage, 90-day mortality, and functional outcomes were similar. Conclusions The preliminary experience from a real- world setting demonstrates the effectiveness and safety of TNK before MT. The higher spontaneous recanalization rates with TNK are striking. Additional studies are required to investigate whether TNK is superior to TPA in LVO AIS.;,citation_author=Philipp Hendrix;,citation_author=Malie K Collins;,citation_author=Christoph J Griessenauer;,citation_author=Oded Goren;,citation_author=Itay Melamed;,citation_author=Gregory M Weiner;,citation_author=Shamsher S Dalal;,citation_author=Matthew J Kole;,citation_author=Anthony Noto;,citation_author=Clemens M Schirmer;,citation_publication_date=2022-11;,citation_cover_date=2022-11;,citation_year=2022;,citation_doi=10.1136/jnis-2022-019662;,citation_issn=1759-8478, 1759-8486;,citation_language=en-US;,citation_journal_title=Journal of NeuroInterventional Surgery;">
<meta name="citation_reference" content="citation_title=COUNTERPOINT: Should Corticosteroids Be Routine Treatment in Early ARDS? No;,citation_author=Matthew K. Hensley;,citation_author=Michael W. Sjoding;,citation_author=Hallie C. Prescott;,citation_publication_date=2021-01;,citation_cover_date=2021-01;,citation_year=2021;,citation_issue=1;,citation_doi=10.1016/j.chest.2020.07.059;,citation_issn=1931-3543;,citation_pmid=33422201;,citation_volume=159;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=The spectre of Berkson’s paradox: Collider bias in Covid-19 research;,citation_author=Annie Herbert;,citation_author=Gareth Griffith;,citation_author=Gibran Hemani;,citation_author=Luisa Zuccolo;,citation_publication_date=2020-08;,citation_cover_date=2020-08;,citation_year=2020;,citation_issue=4;,citation_doi=10.1111/1740-9713.01413;,citation_issn=1740-9705, 1740-9713;,citation_volume=17;,citation_language=en-US;,citation_journal_title=Significance;">
<meta name="citation_reference" content="citation_title=Hypothermia for Patients Requiring Evacuation of Subdural Hematoma: A Multicenter Randomized Clinical Trial;,citation_abstract=Background: Hypothermia is neuroprotective in some ischemia–reperfusion injuries. Ischemia–reperfusion injury may occur with traumatic subdural hematoma (SDH). This study aimed to determine whether early induction and maintenance of hypothermia in patients with acute SDH would lead to decreased ischemia–reperfusion injury and improve global neurologic outcome. Methods: This international, multicenter randomized controlled trial enrolled adult patients with SDH requiring evacuation of hematoma within 6 h of injury. The intervention was controlled temperature management of hypothermia to 35 ^\circC prior to dura opening followed by 33 ^\circC for 48 h compared with normothermia (37 ^\circC). Investigators randomly assigned patients at a 1:1 ratio between hypothermia and normothermia. Blinded evaluators assessed outcome using a 6-month Glasgow Outcome Scale Extended score. Investigators measured circulating glial fibrillary acidic protein and ubiquitin C-terminal hydrolase L1 levels. Results: Independent statisticians performed an interim analysis of 31 patients to assess the predictive probability of success and the Data and Safety Monitoring Board recommended the early termination of the study because of futility. Thirty-two patients, 16 per arm, were analyzed. Favorable 6-month Glasgow Outcome Scale Extended outcomes were not statistically significantly different between hypothermia vs. normothermia groups (6 of 16, 38% vs. 4 of 16, 25%; odds ratio 1.8 [95% confidence interval 0.39 to \infty], p = .35). Plasma levels of glial fibrillary acidic protein (p = .036), but not ubiquitin C-terminal hydrolase L1 (p = .26), were lower in the patients with favorable outcome compared with those with unfavorable outcome, but differences were not identified by temperature group. Adverse events were similar between groups.;,citation_author=Georgene W. Hergenroeder;,citation_author=Shoji Yokobori;,citation_author=Huimahn Alex Choi;,citation_author=Karl Schmitt;,citation_author=Michelle A. Detry;,citation_author=Lisa H. Schmitt;,citation_author=Anna McGlothlin;,citation_author=Ava M. Puccio;,citation_author=Jonathan Jagid;,citation_author=Yasuhiro Kuroda;,citation_author=Yukihiko Nakamura;,citation_author=Eiichi Suehiro;,citation_author=Faiz Ahmad;,citation_author=Kert Viele;,citation_author=Elisabeth A. Wilde;,citation_author=Stephen R. McCauley;,citation_author=Ryan S. Kitagawa;,citation_author=Nancy R. Temkin;,citation_author=Shelly D. Timmons;,citation_author=Michael N. Diringer;,citation_author=Pramod K. Dash;,citation_author=Ross Bullock;,citation_author=David O. Okonkwo;,citation_author=Donald A. Berry;,citation_author=Dong H. Kim;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_doi=10.1007/s12028-021-01334-w;,citation_issn=1541-6933, 1556-0961;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Consensus Statement on Continuous EEG in Critically Ill Adults and Children, Part I: Indications;,citation_abstract=ISSN: 0736-0258/15/3202-0087 indicated, evidence supporting use of CCEEG, utility of video and quantitative EEG trends, suggested timing and duration of CCEEG, and suggested frequency of review and interpretation. Conclusion: CCEEG has an important role in detection of secondary injuries such as seizures and ischemia in critically ill adults and children with altered mental status.;,citation_author=Susan T Herman;,citation_author=Nicholas S Abend;,citation_author=Thomas P Bleck;,citation_author=Kevin E Chapman;,citation_author=Frank W Drislane;,citation_author=Ronald G Emerson;,citation_author=Suzette M LaRoche;,citation_author=Marc R Nuwer;,citation_author=Liberty A Simmons;,citation_author=Tammy N Tsuchida;,citation_author=Lawrence J Hirsch;,citation_publication_date=2015;,citation_cover_date=2015;,citation_year=2015;,citation_issue=2;,citation_volume=32;,citation_language=en-US;,citation_journal_title=Journal of Clinical Neurophysiology;">
<meta name="citation_reference" content="citation_title=Five-year mortality and morbidity impact of prolonged versus brief ICU stay: A propensity score matched cohort study;,citation_abstract=Purpose Long-term outcomes of critical illness may be affected by duration of critical illness and intensive care. We aimed to investigate differences in mortality and morbidity after short (&amp;amp;amp;lt;8 days) and prolonged (\geq8 days) intensive care unit (ICU) stay. Methods Former EPaNIC-trial patients were included in this preplanned prospective cohort, 5-year followup study. Mortality was assessed in all. For morbidity analyses, all long-stay and—for feasibility—a random sample (30%) of short-stay survivors were contacted. Primary outcomes were total and post-28-day 5-year mortality. Secondary outcomes comprised handgrip strength (HGF, %pred), 6-minute-walking distance (6MWD, %pred) and SF-36 Physical Function score (PF SF-36). One-to-one propensity-score matching of shortstay and long-stay patients was performed for nutritional strategy, demographics, comorbidities, illness severity and admission diagnosis. Multivariable regression analyses were performed to explore ICU factors possibly explaining any post-ICU observed outcome differences. Results After matching, total and post-28-day 5-year mortality were higher for long-stayers (48.2% (95%CI: 43.9% to 52.6%) and 40.8% (95%CI: 36.4% to 45.1%)) versus short-stayers (36.2% (95%CI: 32.4% to 40.0%) and 29.7% (95%CI: 26.0% to 33.5%), p&amp;lt;0.001). ICU risk factors comprised hypoglycaemia, use of corticosteroids, neuromuscular blocking agents, benzodiazepines, mechanical ventilation, new dialysis and the occurrence of new infection, whereas clonidine could be protective. Among 276 long-stay and 398 short-stay 5-year survivors, HGF, 6MWD and PF SF-36 were significantly lower in long-stayers (matched subset HGF: 83% (95%CI: 60% to 100%) versus 87% (95%CI: 73% to 103%), p=0.020; 6MWD: 85% (95%CI: 69% to 101%) versus 94% (95%CI: 76% to 105%), p=0.005; PF SF-36: 65 (95%CI: 35 to 90) versus 75 (95%CI: 55 to 90), p=0.002). Conclusion Longer duration of intensive care is associated with excess 5-year mortality and morbidity, partially explained by potentially modifiable ICU factors. Trail registration number NCT00512122.;,citation_author=Greet Hermans;,citation_author=Nathalie Van Aerde;,citation_author=Philippe Meersseman;,citation_author=Helena Van Mechelen;,citation_author=Yves Debaveye;,citation_author=Alexander Wilmer;,citation_author=Jan Gunst;,citation_author=Michael Paul Casaer;,citation_author=Jasperina Dubois;,citation_author=Pieter Wouters;,citation_author=Rik Gosselink;,citation_author=Greet Van den Berghe;,citation_publication_date=2019-11;,citation_cover_date=2019-11;,citation_year=2019;,citation_issue=11;,citation_doi=10.1136/thoraxjnl-2018-213020;,citation_issn=0040-6376, 1468-3296;,citation_volume=74;,citation_language=en-US;,citation_journal_title=Thorax;">
<meta name="citation_reference" content="citation_title=Authors’ Response, Part I: Observational Studies Analyzed Like Randomized Experiments: Best of Both Worlds;,citation_author=Miguel A. Hernán;,citation_author=James M. Robins;,citation_publication_date=2008-11;,citation_cover_date=2008-11;,citation_year=2008;,citation_issue=6;,citation_doi=10.1097/EDE.0b013e318188e85f;,citation_issn=1044-3983;,citation_volume=19;,citation_language=en-US;,citation_journal_title=Epidemiology;">
<meta name="citation_reference" content="citation_title=The C-Word: Scientific Euphemisms Do Not Improve Causal Inference From Observational Data;,citation_author=Miguel A. Hernán;,citation_publication_date=2018-05;,citation_cover_date=2018-05;,citation_year=2018;,citation_issue=5;,citation_doi=10.2105/AJPH.2018.304337;,citation_issn=0090-0036, 1541-0048;,citation_volume=108;,citation_language=en-US;,citation_journal_title=American Journal of Public Health;">
<meta name="citation_reference" content="citation_title=The C-Word: The More We Discuss It, the Less Dirty It Sounds;,citation_author=Miguel Hernán;,citation_publication_date=2018-05;,citation_cover_date=2018-05;,citation_year=2018;,citation_issue=5;,citation_doi=10.2105/AJPH.2018.304392;,citation_issn=0090-0036, 1541-0048;,citation_volume=108;,citation_language=en-US;,citation_journal_title=American Journal of Public Health;">
<meta name="citation_reference" content="citation_title=Causal Knowledge as a Prerequisite for Confounding Evaluation: An Application to Birth Defects Epidemiology;,citation_author=M. A. Hernan;,citation_publication_date=2002-01;,citation_cover_date=2002-01;,citation_year=2002;,citation_issue=2;,citation_doi=10.1093/aje/155.2.176;,citation_issn=00029262;,citation_volume=155;,citation_language=en-US;,citation_journal_title=American Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Does water kill? A call for less casual causal inferences;,citation_abstract=Can this number be interpreted as a causal effect?” is a key question for scientists and decision makers. The potential outcomes approach, a quantitative counterfactual theory, describes conditions under which the question can be answered affirmatively. This article reviews one of those conditions, known as consistency, and its implications for real world decisions.;,citation_author=Miguel A. Hernán;,citation_publication_date=2016-10;,citation_cover_date=2016-10;,citation_year=2016;,citation_issue=10;,citation_doi=10.1016/j.annepidem.2016.08.016;,citation_issn=10472797;,citation_volume=26;,citation_language=en-US;,citation_journal_title=Annals of Epidemiology;">
<meta name="citation_reference" content="citation_title=The Hazards of Hazard Ratios;,citation_author=Miguel A. Hernán;,citation_publication_date=2010-01;,citation_cover_date=2010-01;,citation_year=2010;,citation_issue=1;,citation_doi=10.1097/EDE.0b013e3181c1ea43;,citation_issn=1044-3983;,citation_volume=21;,citation_language=en-US;,citation_journal_title=Epidemiology;">
<meta name="citation_reference" content="citation_title=How to estimate the effect of treatment duration on survival outcomes using observational data;,citation_author=Miguel A Hernán;,citation_publication_date=2018-02;,citation_cover_date=2018-02;,citation_year=2018;,citation_doi=10.1136/bmj.k182;,citation_issn=0959-8138, 1756-1833;,citation_pmid=29419381;,citation_language=en-US;,citation_journal_title=BMJ;,citation_publisher=British Medical Journal Publishing Group;">
<meta name="citation_reference" content="citation_title=Invited Commentary: Hypothetical Interventions to Define Causal Effects—Afterthought or Prerequisite?;,citation_author=Miguel A. Hernán;,citation_publication_date=2005-10;,citation_cover_date=2005-10;,citation_year=2005;,citation_issue=7;,citation_doi=10.1093/aje/kwi255;,citation_issn=1476-6256, 0002-9262;,citation_volume=162;,citation_language=en-US;,citation_journal_title=American Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Invited Commentary: Selection Bias Without Colliders;,citation_abstract=In causal analyses, conditioning on a collider generally results in selection bias. Conditioning on a prognostic factor that is independent of the exposure—and therefore is not a collider—can also result in selection bias when 1) the exposure has a non-null effect on the outcome and 2) the association between the noncollider and the outcome is heterogenous across levels of the exposure. This result was empirically demonstrated by Greenland in 1977 (Am J Epidemiol. 1977;106(3):184–187).;,citation_author=Miguel A. Hernán;,citation_publication_date=2017-06;,citation_cover_date=2017-06;,citation_year=2017;,citation_issue=11;,citation_doi=10.1093/aje/kwx077;,citation_issn=0002-9262;,citation_volume=185;,citation_journal_title=American Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Methods of Public Health Research — Strengthening Causal Inference from Observational Data;,citation_author=Miguel A. Hernán;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=15;,citation_doi=10.1056/NEJMp2113319;,citation_issn=0028-4793, 1533-4406;,citation_volume=385;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Observational Studies Analyzed Like Randomized Experiments: An Application to Postmenopausal Hormone Therapy and Coronary Heart Disease;,citation_author=Miguel A. Hernán;,citation_author=Alvaro Alonso;,citation_author=Roger Logan;,citation_author=Francine Grodstein;,citation_author=Karin B. Michels;,citation_author=Walter C. Willett;,citation_author=JoAnn E. Manson;,citation_author=James M. Robins;,citation_publication_date=2008-11;,citation_cover_date=2008-11;,citation_year=2008;,citation_issue=6;,citation_doi=10.1097/EDE.0b013e3181875e61;,citation_issn=1044-3983;,citation_volume=19;,citation_language=en-US;,citation_journal_title=Epidemiology;">
<meta name="citation_reference" content="citation_title=Per-Protocol Analyses of Pragmatic Trials;,citation_author=Miguel A. Hernán;,citation_author=James M. Robins;,citation_publication_date=2017-10;,citation_cover_date=2017-10;,citation_year=2017;,citation_issue=14;,citation_doi=10.1056/NEJMsm1605385;,citation_issn=0028-4793;,citation_volume=377;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Selection bias due to conditioning on a collider;,citation_abstract=&amp;amp;amp;lt;p&amp;gt;Effect estimates may be biased when the study design or the data analysis is conditional on a collider—a variable that is caused by two other variables. Causal directed acyclic graphs are a helpful tool to identify colliders that may introduce selection bias in observational research.&amp;lt;/p&amp;gt;;,citation_author=Miguel A. Hernán;,citation_author=Susana Monge;,citation_publication_date=2023-06;,citation_cover_date=2023-06;,citation_year=2023;,citation_doi=10.1136/bmj.p1135;,citation_issn=1756-1833;,citation_pmid=37286200;,citation_volume=381;,citation_language=en-US;,citation_journal_title=BMJ;,citation_publisher=British Medical Journal Publishing Group;">
<meta name="citation_reference" content="citation_title=Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses;,citation_abstract=Many analyses of observational data are attempts to emulate a target trial. The emulation of the target trial may fail when researchers deviate from simple principles that guide the design and analysis of randomized experiments. We review a framework to describe and prevent biases, including immortal time bias, that result from a failure to align start of follow-up, specification of eligibility, and treatment assignment. We review some analytic approaches to avoid these problems in comparative effectiveness or safety research.;,citation_author=Miguel A. Hernán;,citation_author=Brian C. Sauer;,citation_author=Sonia Hernández-Díaz;,citation_author=Robert Platt;,citation_author=Ian Shrier;,citation_publication_date=2016-11;,citation_cover_date=2016-11;,citation_year=2016;,citation_doi=10.1016/j.jclinepi.2016.04.014;,citation_issn=0895-4356;,citation_volume=79;,citation_language=en-US;,citation_journal_title=Journal of Clinical Epidemiology;">
<meta name="citation_reference" content="citation_title=A Structural Approach to Selection Bias:;,citation_abstract=The term “selection bias” encompasses various biases in epidemiology. We describe examples of selection bias in casecontrol studies (eg, inappropriate selection of controls) and cohort studies (eg, informative censoring). We argue that the causal structure underlying the bias in each example is essentially the same: conditioning on a common effect of 2 variables, one of which is either exposure or a cause of exposure and the other is either the outcome or a cause of the outcome. This structure is shared by other biases (eg, adjustment for variables affected by prior exposure). A structural classification of bias distinguishes between biases resulting from conditioning on common effects (“selection bias”) and those resulting from the existence of common causes of exposure and outcome (“confounding”). This classification also leads to a unified approach to adjust for selection bias.;,citation_author=Miguel A. Hernán;,citation_author=Sonia Hernández-Díaz;,citation_author=James M. Robins;,citation_publication_date=2004-09;,citation_cover_date=2004-09;,citation_year=2004;,citation_issue=5;,citation_doi=10.1097/01.ede.0000135174.63482.43;,citation_issn=1044-3983;,citation_volume=15;,citation_language=en-US;,citation_journal_title=Epidemiology;">
<meta name="citation_reference" content="citation_title=Target Trial Emulation: A Framework for Causal Inference From Observational Data;,citation_abstract=This Guide to Statistics and Methods describes the use of target trial emulation to design an observational study so it preserves the advantages of a randomized clinical trial, points out the limitations of the method, and provides an example of its use.;,citation_author=Miguel A. Hernán;,citation_author=Wei Wang;,citation_author=David E. Leaf;,citation_publication_date=2022-12;,citation_cover_date=2022-12;,citation_year=2022;,citation_issue=24;,citation_doi=10.1001/jama.2022.21383;,citation_issn=0098-7484;,citation_volume=328;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available;,citation_abstract=Ideally, questions about comparative effectiveness or safety would be answered using an appropriately designed and conducted randomized experiment. When we cannot conduct a randomized experiment, we analyze observational data. Causal inference from large observational databases (big data) can be viewed as an attempt to emulate a randomized experiment—the target experiment or target trial—that would answer the question of interest. When the goal is to guide decisions among several strategies, causal analyses of observational data need to be evaluated with respect to how well they emulate a particular target trial. We outline a framework for comparative effectiveness research using big data that makes the target trial explicit. This framework channels counterfactual theory for comparing the effects of sustained treatment strategies, organizes analytic approaches, provides a structured process for the criticism of observational studies, and helps avoid common methodologic pitfalls.;,citation_author=Miguel A. Hernán;,citation_author=James M. Robins;,citation_publication_date=2016-04;,citation_cover_date=2016-04;,citation_year=2016;,citation_issue=8;,citation_doi=10.1093/aje/kwv254;,citation_issn=0002-9262;,citation_volume=183;,citation_journal_title=American Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Meta-Analysis;,citation_author=Adrian V. Hernandez;,citation_author=Katherine M. Marti;,citation_author=Yuani M. Roman;,citation_publication_date=2020-07;,citation_cover_date=2020-07;,citation_year=2020;,citation_issue=1;,citation_doi=10.1016/j.chest.2020.03.003;,citation_issn=00123692;,citation_volume=158;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=The Birth Weight “Paradox” Uncovered?;,citation_abstract=Low birth weight (LBW) infants have lower infant mortality in groups in which LBW is most frequent. For example, in 1991, US infants born to smokers had higher risks of both LBW and infant mortality than infants born to nonsmokers. However, among LBW infants, infant mortality was lower for infants born to smokers (relative rate = 0.79). There are competing theories regarding this so-called “paradox.” One is that maternal smoking is beneficial for LBW infants. The authors use causal diagrams to show that, even in the absence of any beneficial effect of smoking, an inverse association due to stratification on birth weight can be found. This variable is affected by the exposure of interest and shares common causes with the outcome. That is, LBW infants born to smokers may have a lower risk of mortality than other LBW infants whose LBW is due to causes associated with high mortality (e.g., birth defects). Under realistic causal diagrams, adjustment for birth weight is unwarranted when the analytical goal is to estimate overall effects of prenatal variables on infant mortality. Even for estimating direct effects of prenatal variables, adjustment for birth weight may be invalid when there is an unmeasured common cause of LBW and mortality. An appropriate justification for conditioning on birth weight requires specifying 1) the causal question motivating this analytical approach and 2) the assumptions regarding the proposed underlying biologic mechanisms.;,citation_author=Sonia Hernández-Díaz;,citation_author=Enrique F. Schisterman;,citation_author=Miguel A. Hernán;,citation_publication_date=2006-12;,citation_cover_date=2006-12;,citation_year=2006;,citation_issue=11;,citation_doi=10.1093/aje/kwj275;,citation_issn=0002-9262;,citation_volume=164;,citation_journal_title=American Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Management of Acute Ischemic Stroke;,citation_author=Franziska Herpich;,citation_author=Fred Rincon;,citation_publication_date=2020-11;,citation_cover_date=2020-11;,citation_year=2020;,citation_issue=11;,citation_doi=10.1097/CCM.0000000000004597;,citation_issn=0090-3493;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=A comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals;,citation_abstract=The ability to identify medical reversals and other low-value medical practices is an essential prerequisite for efforts to reduce spending on such practices. Through an analysis of more than 3000 randomized controlled trials (RCTs) published in three leading medical journals (the Journal of the American Medical Association, the Lancet, and the New England Journal of Medicine), we have identified 396 medical reversals. Most of the studies (92%) were conducted on populations in highincome countries, cardiovascular disease was the most common medical category (20%), and medication was the most common type of intervention (33%).;,citation_author=Diana Herrera-Perez;,citation_author=Alyson Haslam;,citation_author=Tyler Crain;,citation_author=Jennifer Gill;,citation_author=Catherine Livingston;,citation_author=Victoria Kaestner;,citation_author=Michael Hayes;,citation_author=Dan Morgan;,citation_author=Adam S Cifu;,citation_author=Vinay Prasad;,citation_publication_date=2019-06;,citation_cover_date=2019-06;,citation_year=2019;,citation_doi=10.7554/eLife.45183;,citation_issn=2050-084X;,citation_volume=8;,citation_language=en-US;,citation_journal_title=eLife;">
<meta name="citation_reference" content="citation_title=Functional Disability 5 Years after Acute Respiratory Distress Syndrome;,citation_abstract=Background There have been few detailed, in-person interviews and examinations to obtain follow-up data on 5-year outcomes among survivors of the acute respiratory distress syndrome (ARDS). Methods We evaluated 109 survivors of ARDS at 3, 6, and 12 months and at 2, 3, 4, and 5 years after discharge from the intensive care unit. At each visit, patients were interviewed and examined; underwent pulmonary-function tests, the 6-minute walk test, resting and exercise oximetry, chest imaging, and a quality-of-life evaluation; and reported their use of health care services. Results At 5 years, the median 6-minute walk distance was 436 m (76% of predicted distance) and the Physical Component Score on the Medical Outcomes Study 36-Item ShortForm Health Survey was 41 (mean norm score matched for age and sex, 50). With respect to this score, younger patients had a greater rate of recovery than older patients, but neither group returned to normal predicted levels of physical function at 5 years. Pulmonary function was normal to near-normal. A constellation of other physical and psychological problems developed or persisted in patients and family caregivers for up to 5 years. Patients with more coexisting illnesses incurred greater 5-year costs. From the Department of Medicine, University Health Network (M.S.H., C.M.T., A.M., G.T., P.K., A.M.C.); the Interdepartmental Division of Critical Care (M.S.H., A.C., C.B.G., C.D.M., S.M., T.E.S., A.S.S.); the Department of Public Health Sciences (N.D.-G., A.M.C.); the Departments of Critical Care Medicine and Anesthesia, Sunnybrook Health Sciences Centre (A.C., C.B.G.); the Departments of Anesthesia (C.D.M.) and Medicine and Critical Care Medicine (A.S.S.) and the Keenan Research Center at the Li Ka Shing Knowledge Institute (C.D.M., A.S.S.), St. Michael’s Hospital; the Dalla Lana School of Public Health (G.T., N.D.-G., A.M.C.) and the Departments of Medicine (S.M., T.E.S.) and Anesthesia (T.E.S.), Mount Sinai Hospital — all at the University of Toronto, Toronto; and the Departments of Medicine and Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada (D.C.). Address reprint requests to Dr. Herridge at Toronto General Hospital, NCSB 11C-1180, 585 University Ave., Toronto, ON M5G 2N2, Canada, or at margaret.herridge@ uhn.on.ca. Conclusions Exercise limitation, physical and psychological sequelae, decreased physical quality of life, and increased costs and use of health care services are important legacies of severe lung injury.;,citation_author=Margaret S Herridge;,citation_author=Natalia Diaz-Granados;,citation_author=Andrew Cooper;,citation_author=Sangeeta Mehta;,citation_author=Arthur S Slutsky;,citation_publication_date=2011;,citation_cover_date=2011;,citation_year=2011;,citation_language=en-US;,citation_journal_title=n engl j med;">
<meta name="citation_reference" content="citation_title=One-Year Outcomes in Survivors of the Acute Respiratory Distress Syndrome;,citation_author=Margaret S Herridge;,citation_author=Andrea Matte-Martyn;,citation_author=Natalia Diaz-Granados;,citation_author=Fatma Al-Saidi;,citation_author=Cameron B Guest;,citation_author=Deborah Cook;,citation_publication_date=2003;,citation_cover_date=2003;,citation_year=2003;,citation_language=en-US;,citation_journal_title=The New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Outcomes after Critical Illness;,citation_author=Margaret S. Herridge;,citation_author=Élie Azoulay;,citation_publication_date=2023-03;,citation_cover_date=2023-03;,citation_year=2023;,citation_issue=10;,citation_doi=10.1056/NEJMra2104669;,citation_issn=0028-4793;,citation_pmid=36884324;,citation_volume=388;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Is the concept of clinical equipoise still relevant to research?;,citation_abstract=&amp;amp;amp;lt;p&amp;gt;&amp;lt;b&amp;gt;Spencer Hey</b>, <b>Alex John London</b>, and <b>Charles Weijer</b> argue that there is no better framework for justifying patient participation in research. But <b>Annette Rid</b> and <b>Franklin Miller</b> say that it is a mistake to require clinical research ethics to align with the norms of clinical practice</p>;,citation_author=Spencer Phillips Hey;,citation_author=Alex John London;,citation_author=Charles Weijer;,citation_author=Annette Rid;,citation_author=Franklin Miller;,citation_publication_date=2017-12;,citation_cover_date=2017-12;,citation_year=2017;,citation_doi=10.1136/bmj.j5787;,citation_issn=0959-8138, 1756-1833;,citation_pmid=29284666;,citation_volume=359;,citation_language=en-US;,citation_journal_title=BMJ;,citation_publisher=British Medical Journal Publishing Group;">
<meta name="citation_reference" content="citation_title=A practical approach for eliciting expert prior beliefs about cancer survival in phase III randomized trial;,citation_abstract=Objective To propose and compare practical approaches that allow eliciting and using expert opinions about the benefit effect on a censored endpoint, such as event-free survival (EFS), used in the planning of a clinical trial based on Bayesian methodology. Study Design and Setting Individual interviews of 37 experts. Bayesian normal models on the log hazard ratio (HR) of EFS were implemented. We illustrate our approach by using a trial of autologous stem cell transplantation (ASCT) vs. chemotherapy (CT) in chronic lymphocytic leukemia (CLL). We elicited experts’ prior beliefs about the difference in 3-year EFS between the two treatment arms, either roughly or throughout weights over the difference scale. Subsequently, a Bayesian synthesis of the information reported in the trial protocol with that in the experts’ prior was performed, using: (1) the postulated treatment effect based on null (skeptical) and alternative (enthusiastic) hypotheses with shared standard error; and (2) the expected difference derived from experts’ distributions. Results As compared with the priors based on the trial protocol data, expert priors agreed with some average from enthusiastic and skeptical information, with close standard errors. Conclusion This case study illustrates a rational approach to construct an expert-based prior. It should be considered as part of the design of future Bayesian trials.;,citation_author=Anne Hiance;,citation_author=Sylvie Chevret;,citation_author=Vincent Lévy;,citation_publication_date=2009-04;,citation_cover_date=2009-04;,citation_year=2009;,citation_issue=4;,citation_doi=10.1016/j.jclinepi.2008.04.009;,citation_issn=0895-4356;,citation_volume=62;,citation_language=en-US;,citation_journal_title=Journal of Clinical Epidemiology;">
<meta name="citation_reference" content="citation_title=Association Between Elevated Mean Arterial Blood Pressure and Neurologic Outcome After Resuscitation From Cardiac Arrest: Results From a Multicenter Prospective Cohort Study;,citation_author=David Hinckley;,citation_author=Jerrilyn Jones;,citation_publication_date=2019-07;,citation_cover_date=2019-07;,citation_year=2019;,citation_issue=1;,citation_doi=10.1016/j.jemermed.2019.05.052;,citation_issn=07364679;,citation_volume=57;,citation_language=en-US;,citation_journal_title=The Journal of Emergency Medicine;">
<meta name="citation_reference" content="citation_title=A Systematic Review and Meta-Analysis of Hypothermia in Experimental Traumatic Brain Injury: Why Have Promising Animal Studies Not Been Replicated in Pragmatic Clinical Trials?;,citation_author=Theodore C. Hirst;,citation_author=Max G. Klasen;,citation_author=Jonathan K. Rhodes;,citation_author=Malcolm R. Macleod;,citation_author=Peter J. D. Andrews;,citation_publication_date=2020-10;,citation_cover_date=2020-10;,citation_year=2020;,citation_issue=19;,citation_doi=10.1089/neu.2019.6923;,citation_issn=0897-7151, 1557-9042;,citation_volume=37;,citation_language=en-US;,citation_journal_title=Journal of Neurotrauma;">
<meta name="citation_reference" content="citation_title=Bias in Before–After Studies: Narrative Overview for Anesthesiologists;,citation_author=Anthony M. H. Ho;,citation_author=Rachel Phelan;,citation_author=Glenio B. Mizubuti;,citation_author=John A. C. Murdoch;,citation_author=Sarah Wickett;,citation_author=Adrienne K. Ho;,citation_author=Vidur Shyam;,citation_author=Ian Gilron;,citation_publication_date=2018-05;,citation_cover_date=2018-05;,citation_year=2018;,citation_issue=5;,citation_doi=10.1213/ANE.0000000000002705;,citation_issn=0003-2999;,citation_volume=126;,citation_language=en-US;,citation_journal_title=Anesthesia &amp;amp;amp; Analgesia;">
<meta name="citation_reference" content="citation_title=Oxygen Toxicity in Critically Ill Adults;,citation_author=Chad H. Hochberg;,citation_author=Matthew W. Semler;,citation_author=Roy G. Brower;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_issue=6;,citation_doi=10.1164/rccm.202102-0417CI;,citation_issn=1073-449X, 1535-4970;,citation_volume=204;,citation_language=en-US;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Incidence of death or disability at 6 months after extracorporeal membrane oxygenation in Australia: A prospective, multicentre, registry-embedded cohort study;,citation_abstract=Background Extracorporeal membrane oxygenation (ECMO) is an invasive procedure used to support critically ill patients with the most severe forms of cardiac or respiratory failure in the short term, but long-term effects on incidence of death and disability are unknown. We aimed to assess incidence of death or disability associated with ECMO up to 6 months (180 days) after treatment.;,citation_author=Carol L Hodgson;,citation_author=Alisa M Higgins;,citation_author=Michael J Bailey;,citation_author=Shannah Anderson;,citation_author=Stephen Bernard;,citation_author=Bentley J Fulcher;,citation_author=Denise Koe;,citation_author=Natalie J Linke;,citation_author=Jasmin V Board;,citation_author=Daniel Brodie;,citation_author=Heidi Buhr;,citation_author=Aidan J C Burrell;,citation_author=D James Cooper;,citation_author=Eddy Fan;,citation_author=John F Fraser;,citation_author=David J Gattas;,citation_author=Ingrid K Hopper;,citation_author=Sue Huckson;,citation_author=Edward Litton;,citation_author=Shay P McGuinness;,citation_author=Priya Nair;,citation_author=Neil Orford;,citation_author=Rachael L Parke;,citation_author=Vincent A Pellegrino;,citation_author=David V Pilcher;,citation_author=Jayne Sheldrake;,citation_author=Benjamin A J Reddi;,citation_author=Dion Stub;,citation_author=Tony V Trapani;,citation_author=Andrew A Udy;,citation_author=Ary Serpa Neto;,citation_author=Carol L Hodgson;,citation_author=Alisa M Higgins;,citation_author=Michael J Bailey;,citation_author=Shannah Anderson;,citation_author=Stephen Bernard;,citation_author=Bentley J Fulcher;,citation_author=Denise Koe;,citation_author=Natalie J Linke;,citation_author=Jasmin V Board;,citation_author=Daniel Brodie;,citation_author=Heidi Buhr;,citation_author=Aidan J C Burrell;,citation_author=D James Cooper;,citation_author=Eddy Fan;,citation_author=John F Fraser;,citation_author=David J Gattas;,citation_author=Ingrid K Hopper;,citation_author=Sue Huckson;,citation_author=Edward Litton;,citation_author=Shay McGuinness;,citation_author=Priya Nair;,citation_author=Neil Orford;,citation_author=Rachael L Parke;,citation_author=Vincent A Pellegrino;,citation_author=David V Pilcher;,citation_author=Jayne Sheldrake Sheldrake;,citation_author=Benjamin A J Reddi;,citation_author=Dion Stub;,citation_author=Tony V Trapani;,citation_author=Andrew A Udy;,citation_author=Ary Serpa Neto;,citation_publication_date=2022-11;,citation_cover_date=2022-11;,citation_year=2022;,citation_issue=11;,citation_doi=10.1016/S2213-2600(22)00248-X;,citation_issn=22132600;,citation_volume=10;,citation_language=en-US;,citation_journal_title=The Lancet Respiratory Medicine;">
<meta name="citation_reference" content="citation_title=Long-term quality of life in patients with acute respiratory distress syndrome requiring extracorporeal membrane oxygenation for refractory hypoxaemia;,citation_abstract=INTRODUCTION: The purpose of the study was to assess the long term outcome and quality of life of patients with acute respiratory distress syndrome (ARDS) receiving extracorporeal membrane oxygenation (ECMO) for refractory hypoxemia. METHODS: A retrospective observational study with prospective health related quality of life (HRQoL) assessment was conducted in ARDS patients who had ECMO as a rescue therapy for reversible refractory hypoxemia from January 2009 until April 2011 in a tertiary Australian centre. Survival and long-term quality of life assessment, using the Short-Form 36 (SF-36) and the EuroQol health related quality of life questionnaire (EQ5D) were assessed and compared to international data from other research groups. RESULTS: Twenty-one patients (mean age 36.3 years) with ARDS receiving ECMO for refractory hypoxemia were studied. Eighteen (86%) patients were retrieved from external intensive care units (ICUs) by a dedicated ECMO retrieval team. Eleven (55%) had H1N1 influenza A-associated pneumonitis. Eighteen (86%) patients survived to hospital discharge. Of the 18 survivors, ten (56%) were discharged to other hospitals and 8 (44%) were discharged directly home. Sequelae and health related quality of life were evaluated for 15 of the 18 (71%) long-term survivors (assessment at median 8 months). Mean SF-36 scores were significantly lower across all domains compared to age and sex matched Australian norms. Mean SF-36 scores were lower (minimum important difference at least 5 points) than previously described ARDS survivors in the domains of general health, mental health, vitality and social function. One patient had long-term disability as a result of ICU acquired weakness. Only 26% of survivors had returned to previous work levels at the time of follow-up. CONCLUSIONS: This ARDS cohort had a high survival rate (86%) after use of ECMO support for reversible refractory hypoxemia. Long term survivors had similar physical health but decreased mental health, general health, vitality and social function compared to other ARDS survivors and an unexpectedly poor return to work.;,citation_author=Carol L. Hodgson;,citation_author=Kate Hayes;,citation_author=Tori Everard;,citation_author=Alistair Nichol;,citation_author=Andrew R. Davies;,citation_author=Michael J. Bailey;,citation_author=David V. Tuxen;,citation_author=David J. Cooper;,citation_author=Vin Pellegrino;,citation_publication_date=2012-10;,citation_cover_date=2012-10;,citation_year=2012;,citation_issue=5;,citation_doi=10.1186/cc11811;,citation_issn=1466-609X;,citation_pmid=23082772;,citation_volume=16;,citation_language=en-US;,citation_journal_title=Critical Care (London, England);">
<meta name="citation_reference" content="citation_title=To mobilise or not to mobilise: Is that the right question?;,citation_author=Carol L. Hodgson;,citation_author=Michelle E. Kho;,citation_author=Vinicius Maldaner Da Silva;,citation_publication_date=2023-05;,citation_cover_date=2023-05;,citation_year=2023;,citation_doi=10.1007/s00134-023-07088-7;,citation_issn=0342-4642, 1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Comparison of a Target Trial Emulation Framework vs Cox Regression to Estimate the Association of Corticosteroids With COVID-19 Mortality;,citation_abstract=Communication and adoption of modern study design and analytical techniques is of high importance for the improvement of clinical research from observational data.To compare a modern method for statistical inference, including a target trial emulation framework and doubly robust estimation, with approaches common in the clinical literature, such as Cox proportional hazards models.This retrospective cohort study used longitudinal electronic health record data for outcomes at 28-days from time of hospitalization within a multicenter New York, New York, hospital system. Participants included adult patients hospitalized between March 1 and May 15, 2020, with COVID-19 and not receiving corticosteroids for chronic use. Data were analyzed from October 2021 to March 2022.Corticosteroid exposure was defined as more than 0.5 mg/kg methylprednisolone equivalent in a 24-hour period. For target trial emulation, exposures were corticosteroids for 6 days if and when a patient met criteria for severe hypoxia vs no corticosteroids. For approaches common in clinical literature, treatment definitions used for variables in Cox regression models varied by study design (no time frame, 1 day, and 5 days from time of severe hypoxia).The main outcome was 28-day mortality from time of hospitalization. The association of corticosteroids with mortality for patients with moderate to severe COVID-19 was assessed using the World Health Organization (WHO) meta-analysis of corticosteroid randomized clinical trials as a benchmark.A total of 3298 patients (median [IQR] age, 65 [53-77] years; 1970 [60%] men) were assessed, including 423 patients who received corticosteroids at any point during hospitalization and 699 patients who died within 28 days of hospitalization. Target trial emulation analysis found corticosteroids were associated with a reduced 28-day mortality rate, from 32.2%; (95% CI, 30.9%-33.5%) to 25.7% (95% CI, 24.5%-26.9%). This estimate is qualitatively identical to the WHO meta-analysis odds ratio of 0.66 (95% CI, 0.53-0.82). Hazard ratios using methods comparable with current corticosteroid research range in size and direction, from 0.50 (95% CI, 0.41-0.62) to 1.08 (95% CI, 0.80-1.47).These findings suggest that clinical research based on observational data can be used to estimate findings similar to those from randomized clinical trials; however, the correctness of these estimates requires designing the study and analyzing the data based on principles that are different from the current standard in clinical research.;,citation_author=Katherine L. Hoffman;,citation_author=Edward J. Schenck;,citation_author=Michael J. Satlin;,citation_author=William Whalen;,citation_author=Di Pan;,citation_author=Nicholas Williams;,citation_author=Iván Díaz;,citation_publication_date=2022-10;,citation_cover_date=2022-10;,citation_year=2022;,citation_issue=10;,citation_doi=10.1001/jamanetworkopen.2022.34425;,citation_issn=2574-3805;,citation_volume=5;,citation_journal_title=JAMA Network Open;">
<meta name="citation_reference" content="citation_title=Racial bias in pain assessment and treatment recommendations, and false beliefs about biological differences between blacks and whites;,citation_abstract=Black Americans are systematically undertreated for pain relative to white Americans. We examine whether this racial bias is related to false beliefs about biological differences between blacks and whites (e.g., “black people’s skin is thicker than white people’s skin”). Study 1 documented these beliefs among white laypersons and revealed that participants who more strongly endorsed false beliefs about biological differences reported lower pain ratings for a black (vs. white) target. Study 2 extended these findings to the medical context and found that half of a sample of white medical students and residents endorsed these beliefs. Moreover, participants who endorsed these beliefs rated the black (vs. white) patient’s pain as lower and made less accurate treatment recommendations. Participants who did not endorse these beliefs rated the black (vs. white) patient’s pain as higher, but showed no bias in treatment recommendations. These findings suggest that individuals with at least some medical training hold and may use false beliefs about biological differences between blacks and whites to inform medical judgments, which may contribute to racial disparities in pain assessment and treatment.;,citation_author=Kelly M. Hoffman;,citation_author=Sophie Trawalter;,citation_author=Jordan R. Axt;,citation_author=M. Norman Oliver;,citation_publication_date=2016-04;,citation_cover_date=2016-04;,citation_year=2016;,citation_issue=16;,citation_doi=10.1073/pnas.1516047113;,citation_issn=0027-8424, 1091-6490;,citation_volume=113;,citation_language=en-US;,citation_journal_title=Proceedings of the National Academy of Sciences;">
<meta name="citation_reference" content="citation_title=Basing Information on Comprehensive, Critically Appraised, and Up-to-Date Syntheses of the Scientific Evidence: An Update from the International Patient Decision Aid Standards;,citation_abstract=Background Patients and clinicians expect the information in patient decision aids to be based on the best available research evidence. The objectives of this International Patient Decision Aid Standards (IPDAS) review were to 1) check the currency of, and where needed, update evidence for the domain of “basing the information in decision aids on comprehensive, critically appraised, and up-to-date syntheses of the evidence”; 2) analyze the evidence characteristics of decision aids; and 3) propose updates to relevant IPDAS criteria. Methods We searched MEDLINE and PubMed to inform updates of this domain’s definitions, justifications, and components. We also searched 5 sources to identify all publicly available decision aids ( N = 471). Two assessors independently extracted each aid’s evidence characteristics. Results Minor updates to the definitions and theoretical justifications of this IPDAS domain are provided and changes to relevant IPDAS criteria proposed. Nearly all aids (97%) provided a year of creation/update, but most (81%) did not report an explicit update or expiration policy. No scientific references were cited in 33% of aids. Of the 314 that cited at least 1 reference, 39% cited at least 1 guideline, 44% cited at least 1 systematic review, and 23% cited at least 1 randomized trial. In 35%, it was unclear what statement in the aid the citations referred to. Only 14% reported any of the processes used to find and decide on evidence inclusion. Only 14% reported the evidence quality. Many emerging issues and future research areas were identified. Conclusions Although many emerging issues need to be addressed, this IPDAS domain is validated and criteria refined. High-quality patient decision aids should be based on comprehensive and up-to-date syntheses of critically appraised evidence.;,citation_author=Tammy C. Hoffmann;,citation_author=Mina Bakhit;,citation_author=Marie-Anne Durand;,citation_author=Lilisbeth Perestelo-Pérez;,citation_author=Catherine Saunders;,citation_author=Juan P. Brito;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=7;,citation_doi=10.1177/0272989X21996622;,citation_issn=0272-989X, 1552-681X;,citation_volume=41;,citation_language=en-US;,citation_journal_title=Medical Decision Making;">
<meta name="citation_reference" content="citation_title=The multiplicity of analysis strategies jeopardizes replicability: Lessons learned across disciplines;,citation_abstract=For a given research question, there are usually a large variety of possible analysis strategies acceptable according to the scientific standards of the field, and there are concerns that this multiplicity of analysis strategies plays an important role in the non-replicability of research findings. Here, we define a general framework on common sources of uncertainty arising in computational analyses that lead to this multiplicity, and apply this framework within an overview of approaches proposed across disciplines to address the issue. Armed with this framework, and a set of recommendations derived therefrom, researchers will be able to recognize strategies applicable to their field and use them to generate findings more likely to be replicated in future studies, ultimately improving the credibility of the scientific process.;,citation_author=Sabine Hoffmann;,citation_author=Felix Schönbrodt;,citation_author=Ralf Elsas;,citation_author=Rory Wilson;,citation_author=Ulrich Strasser;,citation_author=Anne-Laure Boulesteix;,citation_publication_date=2021-04;,citation_cover_date=2021-04;,citation_year=2021;,citation_issue=4;,citation_doi=10.1098/rsos.201925;,citation_issn=2054-5703;,citation_volume=8;,citation_language=en-US;,citation_journal_title=Royal Society Open Science;">
<meta name="citation_reference" content="citation_title=Challenging management dogma where evidence is non-existent, weak or outdated;,citation_abstract=Medical practice is dogged by dogma. A conclusive evidence base is lacking for many aspects of patient management. Clinicians, therefore, rely upon engrained treatment strategies as the dogma seems to work, or at least is assumed to do so. Evidence is often distorted, overlooked or misapplied in the re-telling. However, it is incorporated as fact in textbooks, policies, guidelines and protocols with resource and medicolegal implications. We provide here four examples of medical dogma that underline the above points: loop diuretic treatment for acute heart failure; the effectiveness of heparin thromboprophylaxis; the rate of sodium correction for hyponatraemia; and the mantra of “each hour counts” for treating meningitis. It is notable that the underpinning evidence is largely unsupportive of these doctrines. We do not necessarily advocate change, but rather encourage critical reflection on current practices and the need for prospective studies.;,citation_author=Daniel A. Hofmaenner;,citation_author=Mervyn Singer;,citation_publication_date=2022-03;,citation_cover_date=2022-03;,citation_year=2022;,citation_doi=10.1007/s00134-022-06659-4;,citation_issn=0342-4642, 1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Hypothermic versus Normothermic Temperature Control after Cardiac Arrest;,citation_abstract=BACKGROUND The evidence for temperature control for comatose survivors of cardiac arrest is inconclusive. Controversy exists as to whether the effects of hypothermia differ per the circumstances of the cardiac arrest or patient characteristics.;,citation_author=Johan Holgersson;,citation_author=Martin Abild Stengaard Meyer;,citation_author=Josef Dankiewicz;,citation_author=Gisela Lilja;,citation_author=Susann Ullén;,citation_author=Christian Hassager;,citation_author=Tobias Cronberg;,citation_author=Matt P. Wise;,citation_author=Jan Bělohlávek;,citation_author=Jan Hovdenes;,citation_author=Paolo Pelosi;,citation_author=David Erlinge;,citation_author=Claudia Schrag;,citation_author=Ondrej Smid;,citation_author=Iole Brunetti;,citation_author=Christian Rylander;,citation_author=Paul J. Young;,citation_author=Manoj Saxena;,citation_author=Anders Åneman;,citation_author=Alain Cariou;,citation_author=Clifton Callaway;,citation_author=Glenn M. Eastwood;,citation_author=Matthias Haenggi;,citation_author=Michael Joannidis;,citation_author=Thomas R. Keeble;,citation_author=Hans Kirkegaard;,citation_author=Christoph Leithner;,citation_author=Helena Levin;,citation_author=Alistair D. Nichol;,citation_author=Matt P. G. Morgan;,citation_author=Per Nordberg;,citation_author=Mauro Oddo;,citation_author=Christian Storm;,citation_author=Fabio Silvio Taccone;,citation_author=Matthew Thomas;,citation_author=John Bro-Jeppesen;,citation_author=Janneke Horn;,citation_author=Jesper Kjaergaard;,citation_author=Michael Kuiper;,citation_author=Tommaso Pellis;,citation_author=Pascal Stammet;,citation_author=Michael Jaeger Wanscher;,citation_author=Hans Friberg;,citation_author=Niklas Nielsen;,citation_author=Janus Christian Jakobsen;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_doi=10.1056/EVIDoa2200137;,citation_issn=2766-5526;,citation_language=en-US;,citation_journal_title=NEJM Evidence;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia;,citation_author=Thomas L. Holland;,citation_author=Sara E. Cosgrove;,citation_author=Sarah B. Doernberg;,citation_author=Timothy C. Jenkins;,citation_author=Nicholas A. Turner;,citation_author=Helen W. Boucher;,citation_author=Oleksander Pavlov;,citation_author=Ivan Titov;,citation_author=Serhii Kosulnykov;,citation_author=Boyko Atanasov;,citation_author=Ivan Poromanski;,citation_author=Manana Makhviladze;,citation_author=Anastasia Anderzhanova;,citation_author=Martin E. Stryjewski;,citation_author=Maziar Assadi Gehr;,citation_author=Marc Engelhardt;,citation_author=Kamal Hamed;,citation_author=Daniel Ionescu;,citation_author=Mark Jones;,citation_author=Mikael Saulay;,citation_author=Jennifer Smart;,citation_author=Harald Seifert;,citation_author=Vance G. Fowler;,citation_publication_date=2023-09;,citation_cover_date=2023-09;,citation_year=2023;,citation_issue=0;,citation_doi=10.1056/NEJMoa2300220;,citation_issn=0028-4793;,citation_volume=0;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Statistics and Causal Inference;,citation_author=Paul W. Holland;,citation_publication_date=1986-12;,citation_cover_date=1986-12;,citation_year=1986;,citation_issue=396;,citation_doi=10.1080/01621459.1986.10478354;,citation_issn=0162-1459, 1537-274X;,citation_volume=81;,citation_language=en-US;,citation_journal_title=Journal of the American Statistical Association;">
<meta name="citation_reference" content="citation_title=Prognosis and decision making in severe stroke;,citation_abstract=CONTEXT: An increasing number of deaths following severe stroke are due to terminal extubations. Variation in withdrawal-of-care practices suggests the possibility of unnecessary prolongation of suffering or of unwanted deaths. OBJECTIVES: To review the available evidence on prognosis in mechanically ventilated stroke patients and to provide an overall framework to optimize decision making for clinicians, patients, and families. DATA SOURCES: Search of MEDLINE from 1980 through March 2005 for English-language articles addressing prognosis in mechanically ventilated stroke patients. From 689 articles identified, we selected 17 for further review. We also identified factors that influence, and decision-making biases that may result, in overuse or underuse of life-sustaining therapies, with a particular emphasis on mechanical ventilation. EVIDENCE SYNTHESIS: Overall mortality among mechanically ventilated stroke patients is high, with a 30-day death rate approximating 58% (range in literature, 46%-75%). Although data are limited, among survivors as many as one third may have no or only slight disability, yet many others have severe disability. One can further refine prognosis according to knowledge of stroke syndromes, early patient characteristics, use of clinical prediction rules, and the need for continuing interventions. Factors influencing preferences for life-sustaining treatments include the severity and pattern of future clinical deficits, the probability of these deficits, and the burdens of treatments. Decision-making biases that may affect withdrawal-of-treatment decisions include erroneous prognostic estimates, inappropriate methods of communicating evidence, misunderstanding patient values and expectations, and failing to appreciate the extent to which patients can physically and psychologically adapt. CONCLUSIONS: Although prognosis among mechanically ventilated stroke patients is generally poor, a minority do survive without severe disability. Prognosis can be assessed according to clinical presentation and patient characteristics. There is an urgent need to better understand the marked variation in the care of these patients and to reliably measure and improve the patient-centeredness of such decisions.;,citation_author=Robert G. Holloway;,citation_author=Curtis G. Benesch;,citation_author=W. Scott Burgin;,citation_author=Justine B. Zentner;,citation_publication_date=2005-08;,citation_cover_date=2005-08;,citation_year=2005;,citation_issue=6;,citation_doi=10.1001/jama.294.6.725;,citation_issn=1538-3598;,citation_pmid=16091575;,citation_volume=294;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Collider Bias;,citation_abstract=Bias is a systematic, nonrandom error in the estimation of a treatment effect or the effect of an exposure or risk factor. Bias can lead to invalid results in observational studies and randomized clinical trials (RCTs). Bias is often broadly categorized into 3 groups: confounding, information (or measurement) bias, and selection bias. Selection bias is a general term describing bias that occurs when study participants are identified in a manner such that they are no longer representative of the target population. This can occur when an exposure and outcome each influence a common third variable—the collider—and that variable has been controlled for in the statistical analysis of the study data. Collider bias threatens the internal validity of a study and the accurate estimation of causal relationships.;,citation_author=Mathias J. Holmberg;,citation_author=Lars W. Andersen;,citation_publication_date=2022-04;,citation_cover_date=2022-04;,citation_year=2022;,citation_issue=13;,citation_doi=10.1001/jama.2022.1820;,citation_issn=0098-7484;,citation_volume=327;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Natural History of Cognitive Impairment in Critical Illness Survivors. A Systematic Review;,citation_author=Kimia Honarmand;,citation_author=Rajkamal S. Lalli;,citation_author=Fran Priestap;,citation_author=Jennifer L. Chen;,citation_author=Christopher W. McIntyre;,citation_author=Adrian M. Owen;,citation_author=Marat Slessarev;,citation_publication_date=2020-07;,citation_cover_date=2020-07;,citation_year=2020;,citation_issue=2;,citation_doi=10.1164/rccm.201904-0816CI;,citation_issn=1073-449X, 1535-4970;,citation_volume=202;,citation_language=en-US;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Decompressive craniectomy for severe traumatic brain injury: Is life worth living?;,citation_abstract=OBJECT: The object of this study was to assess the long-term outcome and quality of life of patients who have survived with severe disability following decompressive craniectomy for severe traumatic brain injury (TBI). METHODS: The authors assessed outcome beyond 3 years among a cohort of 39 patients who had been adjudged either severely disabled or in vegetative state 18 months after decompressive craniectomy for TBI. Assessments performed included the Extended Glasgow Outcome Scale, modified Barthel Index (mBI), Zarit Burden Interview, and 36-Item Short-Form Health Survey (SF-36). The issue of retrospective consent for surgery was also assessed. RESULTS: Of the 39 eligible patients, 7 died, 12 were lost to follow-up, and 20 patients or their next of kin consented to participate in the study. Among those 20 patients, 5 in a vegetative state at 18 months remained so beyond 3 years, and the other 15 patients remained severely disabled after a median follow-up of 5 years. The patients’ average daily activity per the mBI (Pearson correlation coefficient [r] = -0.661, p = 0.01) and SF-36 physical score (r = -0.543, p = 0.037) were inversely correlated with the severity of TBI. However, the SF-36 mental scores of the patients were reasonably high (median 46, interquartile range 37-52). The majority of patients and their next of kin believed that they would have provided consent for surgical decompression even if they had known the eventual outcome. CONCLUSIONS: Substantial physical recovery beyond 18 months after decompressive craniectomy for severe TBI was not observed; however, many patients appeared to have recalibrated their expectations regarding what they believed to be an acceptable quality of life.;,citation_author=Stephen Honeybul;,citation_author=Courtney Janzen;,citation_author=Kate Kruger;,citation_author=Kwok M. Ho;,citation_publication_date=2013-12;,citation_cover_date=2013-12;,citation_year=2013;,citation_issue=6;,citation_doi=10.3171/2013.8.JNS13857;,citation_issn=1933-0693;,citation_pmid=24116729;,citation_volume=119;,citation_language=en-US;,citation_journal_title=Journal of Neurosurgery;">
<meta name="citation_reference" content="citation_title=A tutorial on individualized treatment effect prediction from randomized trials with a binary endpoint;,citation_author=Jeroen Hoogland;,citation_author=Joanna IntHout;,citation_author=Michail Belias;,citation_author=Maroeska M. Rovers;,citation_author=Richard D. Riley;,citation_author=Frank E. Harrell Jr;,citation_author=Karel G. M. Moons;,citation_author=Thomas P. A. Debray;,citation_author=Johannes B. Reitsma;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_doi=10.1002/sim.9154;,citation_issn=0277-6715, 1097-0258;,citation_language=en-US;,citation_journal_title=Statistics in Medicine;">
<meta name="citation_reference" content="citation_title=Short- and Long-Term Cognitive Outcomes in Intensive Care Unit Survivors;,citation_author=Ramona O. Hopkins;,citation_author=James C. Jackson;,citation_publication_date=2009-03;,citation_cover_date=2009-03;,citation_year=2009;,citation_issue=1;,citation_doi=10.1016/j.ccm.2008.11.001;,citation_issn=02725231;,citation_volume=30;,citation_language=en-US;,citation_journal_title=Clinics in Chest Medicine;">
<meta name="citation_reference" content="citation_title=Two-Year Cognitive, Emotional, and Quality-of-Life Outcomes in Acute Respiratory Distress Syndrome;,citation_author=Ramona O. Hopkins;,citation_author=Lindell K. Weaver;,citation_author=Dave Collingridge;,citation_author=R. Bruce Parkinson;,citation_author=Karen J. Chan;,citation_author=James F. Orme;,citation_publication_date=2005-02;,citation_cover_date=2005-02;,citation_year=2005;,citation_issue=4;,citation_doi=10.1164/rccm.200406-763OC;,citation_issn=1073-449X, 1535-4970;,citation_volume=171;,citation_language=en-US;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Predictive Factors of Functional Outcome in World Federation of Neurosurgical Societies Grade V Subarachnoid Hemorrhage;,citation_abstract=Objective: Patients with World Federation of Neurosurgical Societies (WFNS) grade V subarachnoid hemorrhage (SAH) frequently have poor outcomes. The current understanding of the predictors of functional outcome only in WFNS grade V SAH is limited. Journal Pre-proof Methods: WFNS grade V SAH patients were retrospectively analyzed between April 2008 and August 2019. Surgical treatment is commonly delayed until clinical improvement is observed using a less aggressive approach. Clinical and radiological data on admission were assessed, and disease-related characteristics were compared between patients with favorable outcomes (modified Rankin Scale [mRS] 0-3) and those with unfavorable outcomes (mRS 4-6). Results: A total of 144 patients were included, and 22 patients (15.3%) achieved favorable outcomes, whereas 122 patients (84.7%) had unfavorable outcomes. Surgical aneurysm repair was performed in all patients with favorable outcomes and in 21.3% of those with unfavorable outcomes. Multivariate analysis demonstrated that GCS 3, high-grade Early Brain Edema Score (EBES), absence of bilaterally light reflex and neurological improvement, and hypertension were significantly associated with unfavorable outcomes (OR 9.54, P=0.03; OR 5.37, P=0.04; OR 11.80, P=0.009; OR 0.14, P=0.02 and OR 6.53, P=0.04, respectively). Conclusions: The final outcome of patients with WFNS grade V SAH was still poor and highly predicted by GCS score 3, high-grade EBES, absence of bilaterally light reflex and neurological improvement, and a history of hypertension. The efficacy of;,citation_author=Satoshi Hori;,citation_author=Daina Kashiwazaki;,citation_author=Naoki Akioka;,citation_author=Soshi Okamoto;,citation_author=Michiya Kubo;,citation_author=Yukio Horie;,citation_author=Naoya Kuwayama;,citation_author=Satoshi Kuroda;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_doi=10.1016/j.wneu.2022.05.135;,citation_issn=18788750;,citation_language=en-US;,citation_journal_title=World Neurosurgery;">
<meta name="citation_reference" content="citation_title=Offline: What is medicine’s 5 sigma?;,citation_author=Richard Horton;,citation_publication_date=2015-04;,citation_cover_date=2015-04;,citation_year=2015;,citation_issue=9976;,citation_doi=10.1016/S0140-6736(15)60696-1;,citation_issn=0140-6736, 1474-547X;,citation_volume=385;,citation_language=en-US;,citation_journal_title=The Lancet;,citation_publisher=Elsevier;">
<meta name="citation_reference" content="citation_title=A Simple, Assumption-Free, and Clinically Interpretable Approach for Analysis of Modified Rankin Outcomes;,citation_abstract=Background and Purpose— There is debate regarding the approach for analysis of modified Rankin scale scores, the most common functional outcome scale used in acute stroke trials. Methods— We propose to use tests to assess treatment differences addressing the metric, “if a patient is chosen at random from each treatment group and if they have different outcomes, what is the chance the patient who received the investigational treatment will have a better outcome than will the patient receiving the standard treatment?” This approach has an associated statement of treatment efficacy easily understood by patients and clinicians, and leads to statistical testing of treatment differences by tests closely related to the Mann-Whitney U test (Wilcoxon Rank-Sum test), which can be tested precisely by permutation tests (randomization tests). Results— We show that a permutation test is as powerful as are other approaches assessing ordinal outcomes of the modified Rankin scores, and we provide data from several examples contrasting alternative approaches. Discussion— Whereas many approaches to analysis of modified Rankin scores outcomes have generally similar statistical performance, this proposed approach: captures information from the ordinal scale, provides a powerful clinical interpretation understood by both patients and clinicians, has power at least equivalent to other ordinal approaches, avoids assumptions in the parameterization, and provides an interpretable parameter based on the same foundation as the calculation of the probability value.;,citation_author=George Howard;,citation_author=Jennifer L. Waller;,citation_author=Jenifer H. Voeks;,citation_author=Virginia J. Howard;,citation_author=Edward C. Jauch;,citation_author=Kennedy R. Lees;,citation_author=Fenwick T. Nichols;,citation_author=Volker W. Rahlfs;,citation_author=David C. Hess;,citation_publication_date=2012-03;,citation_cover_date=2012-03;,citation_year=2012;,citation_issue=3;,citation_doi=10.1161/STROKEAHA.111.632935;,citation_issn=0039-2499, 1524-4628;,citation_volume=43;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=Most healthcare interventions tested in Cochrane Reviews are not effective according to high quality evidence: A systematic review and meta-analysis;,citation_abstract=Objective To estimate the proportion of healthcare interventions tested within Cochrane Reviews that are effective according to high-quality evidence. Methods We selected a random sample of 2,428 (35%) of all Cochrane Reviews published between 1 January 2008 and 5 March 2021. We extracted data about interventions within these reviews that were compared with placebo, or no treatment, and whose outcome quality was rated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. We calculated the proportion of interventions whose benefits were based on high-quality evidence (defined as having high quality GRADE rating for at least one primary outcome, statistically significant positive results, and being judged by review authors as effective. We also calculated the proportion of interventions that suggested harm. Results Of 1,567 eligible interventions, 87 (5.6%) had high-quality evidence supporting their benefits. Harms were measured for 577 (36.8%) interventions. There was statistically significant evidence for harm in 127 (8.1%) of these. Our dependence on the reliability of Cochrane author assessments (including their GRADE assessments) was the main potential limitation of our study. Conclusion More than 9 in 10 healthcare interventions studied within recent Cochrane Reviews are not supported by high-quality evidence, and harms are under-reported.;,citation_author=Jeremy Howick;,citation_author=Despina Koletsi;,citation_author=John P. A. Ioannidis;,citation_author=Claire Madigan;,citation_author=Nikolaos Pandis;,citation_author=Martin Loef;,citation_author=Harald Walach;,citation_author=Sebastian Sauer;,citation_author=Jos Kleijnen;,citation_author=Jadbinder Seehra;,citation_author=Tess Johnson;,citation_author=Stefan Schmidt;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_doi=10.1016/j.jclinepi.2022.04.017;,citation_issn=0895-4356;,citation_volume=148;,citation_language=en-US;,citation_journal_title=Journal of Clinical Epidemiology;">
<meta name="citation_reference" content="citation_title=Studies for the Evaluation of Diagnostic Tests;,citation_abstract=Background: The accurate diagnosis of a disease is a prerequisite for its appropriate treatment. How well a medical test is able to correctly identify or rule out a target disease can be assessed by diagnostic accuracy studies. Methods: The main statistical parameters that are derived from diagnostic accuracy studies, and their proper interpretation, will be presented here in the light of publications retrieved by a selective literature search, supplemented by the authors’ own experience. Aspects of study planning and the analysis of complex studies on diagnostic tests will also be discussed. Results: In the usual case, the findings of a diagnostic accuracy study are presented in a 2  2 contingency table containing the number of true-positive, true-negative, false-positive, and true-positive test results. This information allows the calculation of various statistical parameters, of which the most important are the two pairs sensitivity/specificity and positive/negative predictive value. All of these parameters are quotients, with the number of true positive (resp. true negative) test results in the numerator; the denominator is, in the first pair, the total number of ill (resp. healthy) patients, and in the second pair, the total number of patients with a positive (resp. negative) test. The predictive values are the parameters of greatest interest to physicians and patients, but their main disadvantage is that they can easily be misinterpreted. We will also present the receiver operating characteristic (ROC) curve and the area under the curve (AUC) as additional important measures for the assessment of diagnostic tests. Further topics are discussed in the supplementary materials. Conclusion: The statistical parameters used to assess diagnostic tests are primarily based on 2  2 contingency tables. These parameters must be interpreted with care in order to draw correct conclusions for use in medical practice.;,citation_author=Annika Hoyer;,citation_author=Antonia Zapf;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_doi=10.3238/arztebl.m2021.0224;,citation_issn=1866-0452;,citation_language=en-US;,citation_journal_title=Deutsches Ärzteblatt international;">
<meta name="citation_reference" content="citation_title=Misleading communication of risk;,citation_author=Rodriguez Hp;,citation_author=Scoggins Jf;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Race, Genetic Ancestry, and Estimating Kidney Function in CKD;,citation_abstract=BACKGROUND The inclusion of race in equations to estimate the glomerular filtration rate (GFR) has become controversial. Alternative equations that can be used to achieve similar accuracy without the use of race are needed. METHODS In a large national study involving adults with chronic kidney disease, we conducted cross-sectional analyses of baseline data from 1248 participants for whom data, including the following, had been collected: race as reported by the participant, genetic ancestry markers, and the serum creatinine, serum cystatin C, and 24-hour urinary creatinine levels. RESULTS Using current formulations of GFR estimating equations, we found that in participants who identified as Black, a model that omitted race resulted in more underestimation of the GFR (median difference between measured and estimated GFR, 3.99 ml per minute per 1.73 m2 of body-surface area; 95% confidence interval [CI], 2.17 to 5.62) and lower accuracy (percent of estimated GFR within 10% of measured GFR [P10], 31%; 95% CI, 24 to 39) than models that included race (median difference, 1.11 ml per minute per 1.73 m2; 95% CI, -0.29 to 2.54; P10, 42%; 95% CI, 34 to 50). The incorporation of genetic ancestry data instead of race resulted in similar estimates of the GFR (median difference, 1.33 ml per minute per 1.73 m2; 95% CI, -0.12 to 2.33; P10, 42%; 95% CI, 34 to 50). The inclusion of non-GFR determinants of the serum creatinine level (e.g., body-composition metrics and urinary excretion of creatinine) that differed according to race reported by the participants and genetic ancestry did not eliminate the misclassification introduced by removing race (or ancestry) from serum creatinine–based GFR estimating equations. In contrast, the incorporation of race or ancestry was not necessary to achieve similarly statistically unbiased (median difference, 0.33 ml per minute per 1.73 m2; 95% CI, -1.43 to 1.92) and accurate (P10, 41%; 95% CI, 34 to 49) estimates in Black participants when GFR was estimated with the use of cystatin C. The authors’ full names, academic degrees, and affiliations are listed in the Appendix. Address reprint requests to Dr. Go at the Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA 94612, or at alan .s.go@k p.org. *A full list of the Chronic Renal Insufficiency Cohort (CRIC) Study Investigators is provided in the Supplementary Appendix, available at NEJM.org. Drs. Hsu, Yang, Feldman, and Go contributed equally to this article. This article was published on September 23, 2021, at NEJM.org. DOI: 10.1056/NEJMoa2103753 Copyright © 2021 Massachusetts Medical Society. CONCLUSIONS The use of the serum creatinine level to estimate the GFR without race (or genetic ancestry) introduced systematic misclassification that could not be eliminated even when numerous non-GFR determinants of the serum creatinine level were accounted for. The estimation of GFR with the use of cystatin C generated similar results while eliminating the negative consequences of the current race-based approaches. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others.);,citation_author=Chi-yuan Hsu;,citation_author=Wei Yang;,citation_author=Rishi V. Parikh;,citation_author=Amanda H. Anderson;,citation_author=Teresa K. Chen;,citation_author=Debbie L. Cohen;,citation_author=Jiang He;,citation_author=Madhumita J. Mohanty;,citation_author=James P. Lash;,citation_author=Katherine T. Mills;,citation_author=Anthony N. Muiru;,citation_author=Afshin Parsa;,citation_author=Milda R. Saunders;,citation_author=Tariq Shafi;,citation_author=Raymond R. Townsend;,citation_author=Sushrut S. Waikar;,citation_author=Jianqiao Wang;,citation_author=Myles Wolf;,citation_author=Thida C. Tan;,citation_author=Harold I. Feldman;,citation_author=Alan S. Go;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_doi=10.1056/NEJMoa2103753;,citation_issn=0028-4793, 1533-4406;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Pearls &amp;amp;amp; Oy-sters: Trigeminal Nerve Dysfunction as the Key Diagnostic Clue to Listeria Rhombencephalitis;,citation_author=Christopher Donald Hue;,citation_author=Maria Bres Bullrich;,citation_author=Amit Kumar Sharma;,citation_author=Asma Saba Syed;,citation_author=Sachin Kishore Pandey;,citation_author=Sarah Anne Morrow;,citation_author=Derek Brian Debicki;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=A Contemporary Conceptual Framework for Initial Data Analysis;,citation_abstract=Initial data analyses (IDA) are often performed as part of studies with primary-data collection, where data are obtained to address a predefined set of research questions, and with a clear plan of the intended statistical analyses. An informal or unstructured approach may have a large and non-transparent impact on results and conclusions presented in publications. Key principles for IDA are to avoid analyses that are part of the research question, and full documentation and transparency.;,citation_author=Marianne Huebner;,citation_author=Saskia Cessie;,citation_author=Carsten O. Schmidt;,citation_author=Werner Vach;,citation_publication_date=2018;,citation_cover_date=2018;,citation_year=2018;,citation_issue=1;,citation_doi=10.1353/obs.2018.0014;,citation_issn=2767-3324;,citation_volume=4;,citation_language=en-US;,citation_journal_title=Observational Studies;">
<meta name="citation_reference" content="citation_title=Is caviar a risk factor for being a millionaire?: Table 1;,citation_author=Anders Huitfeldt;,citation_publication_date=2016-12;,citation_cover_date=2016-12;,citation_year=2016;,citation_doi=10.1136/bmj.i6536;,citation_issn=1756-1833;,citation_language=en-US;,citation_journal_title=BMJ;">
<meta name="citation_reference" content="citation_title=The GRADE Working Group clarifies the construct of certainty of evidence;,citation_abstract=Objective: To clarify the grading of recommendations assessment, development and evaluation (GRADE) definition of certainty of evidence and suggest possible approaches to rating certainty of the evidence for systematic reviews, health technology assessments, and guidelines. Study Design and Setting: This work was carried out by a project group within the GRADE Working Group, through brainstorming and iterative refinement of ideas, using input from workshops, presentations, and discussions at GRADE Working Group meetings to produce this document, which constitutes official GRADE guidance.;,citation_author=Monica Hultcrantz;,citation_author=David Rind;,citation_author=Elie A. Akl;,citation_author=Shaun Treweek;,citation_author=Reem A. Mustafa;,citation_author=Alfonso Iorio;,citation_author=Brian S. Alper;,citation_author=Joerg J. Meerpohl;,citation_author=M Hassan Murad;,citation_author=Mohammed T. Ansari;,citation_author=Srinivasa Vittal Katikireddi;,citation_author=Pernilla Östlund;,citation_author=Sofia Tranæus;,citation_author=Robin Christensen;,citation_author=Gerald Gartlehner;,citation_author=Jan Brozek;,citation_author=Ariel Izcovich;,citation_author=Holger Schünemann;,citation_author=Gordon Guyatt;,citation_publication_date=2017-07;,citation_cover_date=2017-07;,citation_year=2017;,citation_doi=10.1016/j.jclinepi.2017.05.006;,citation_issn=08954356;,citation_volume=87;,citation_language=en-US;,citation_journal_title=Journal of Clinical Epidemiology;">
<meta name="citation_reference" content="citation_title=Causal Inference and Data Fusion in Econometrics;,citation_abstract=Learning about cause and effect is arguably the main goal in applied econometrics. In practice, the validity of these causal inferences is contingent on a number of critical assumptions regarding the type of data that has been collected and the substantive knowledge that is available. For instance, unobserved confounding factors threaten the internal validity of estimates, data availability is often limited to non-random, selection-biased samples, causal effects need to be learned from surrogate experiments with imperfect compliance, and causal knowledge has to be extrapolated across structurally heterogeneous populations. A powerful causal inference framework is required to tackle these challenges, which plague most data analysis to varying degrees. Building on the structural approach to causality introduced by Haavelmo (1943) and the graph-theoretic framework proposed by Pearl (1995), the artificial intelligence (AI) literature has developed a wide array of techniques for causal learning that allow to leverage information from various imperfect, heterogeneous, and biased data sources (Bareinboim and Pearl, 2016). In this paper, we discuss recent advances in this literature that have the potential to contribute to econometric methodology along three dimensions. First, they provide a unified and comprehensive framework for causal inference, in which the aforementioned problems can be addressed in full generality. Second, due to their origin in AI, they come together with sound, efficient, and complete algorithmic criteria for automatization of the corresponding identification task. And third, because of the nonparametric description of structural models that graph-theoretic approaches build on, they combine the strengths of both structural econometrics as well as the potential outcomes framework, and thus offer an effective middle ground between these two literature streams.;,citation_author=Paul Hünermund;,citation_author=Elias Bareinboim;,citation_publication_date=2021-03;,citation_cover_date=2021-03;,citation_year=2021;,citation_fulltext_html_url=https://arxiv.org/abs/1912.09104;,citation_doi=10.48550/arXiv.1912.09104;,citation_publisher=arXiv;">
<meta name="citation_reference" content="citation_title=Trial of Endovascular Therapy for Acute Ischemic Stroke with Large Infarct;,citation_author=Xiaochuan Huo;,citation_author=Gaoting Ma;,citation_author=Xu Tong;,citation_author=Xuelei Zhang;,citation_author=Yuesong Pan;,citation_author=Thanh N. Nguyen;,citation_author=Guangxiong Yuan;,citation_author=Hongxing Han;,citation_author=Wenhuo Chen;,citation_author=Ming Wei;,citation_author=Jiangang Zhang;,citation_author=Zhiming Zhou;,citation_author=Xiaoxi Yao;,citation_author=Guoqing Wang;,citation_author=Weigen Song;,citation_author=Xueli Cai;,citation_author=Guangxian Nan;,citation_author=Di Li;,citation_author=A. Yi-Chou Wang;,citation_author=Wentong Ling;,citation_author=Chuwei Cai;,citation_author=Changming Wen;,citation_author=En Wang;,citation_author=Liyong Zhang;,citation_author=Changchun Jiang;,citation_author=Yajie Liu;,citation_author=Geng Liao;,citation_author=Xiaohui Chen;,citation_author=Tianxiao Li;,citation_author=Shudong Liu;,citation_author=Jinglun Li;,citation_author=Feng Gao;,citation_author=Ning Ma;,citation_author=Dapeng Mo;,citation_author=Ligang Song;,citation_author=Xuan Sun;,citation_author=Xiaoqing Li;,citation_author=Yiming Deng;,citation_author=Gang Luo;,citation_author=Ming Lv;,citation_author=Hongwei He;,citation_author=Aihua Liu;,citation_author=Jingbo Zhang;,citation_author=Shiqing Mu;,citation_author=Lian Liu;,citation_author=Jing Jing;,citation_author=Ximing Nie;,citation_author=Zeyu Ding;,citation_author=Wanliang Du;,citation_author=Xingquan Zhao;,citation_author=Pengfei Yang;,citation_author=Liping Liu;,citation_author=Yilong Wang;,citation_author=David S. Liebeskind;,citation_author=Vitor M. Pereira;,citation_author=Zeguang Ren;,citation_author=Yongjun Wang;,citation_author=Zhongrong Miao;,citation_publication_date=2023-02;,citation_cover_date=2023-02;,citation_year=2023;,citation_issue=0;,citation_doi=10.1056/NEJMoa2213379;,citation_issn=0028-4793;,citation_volume=0;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=The Reemergence of Ketamine for Treatment in Critically Ill Adults;,citation_author=Kimberly P. Hurth;,citation_author=Anthony Jaworski;,citation_author=Kristen B. Thomas;,citation_author=William B. Kirsch;,citation_author=Michael A. Rudoni;,citation_author=Kevin M. Wohlfarth;,citation_publication_date=2020-06;,citation_cover_date=2020-06;,citation_year=2020;,citation_issue=6;,citation_doi=10.1097/CCM.0000000000004335;,citation_issn=0090-3493;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes;,citation_author=Mansoor Husain;,citation_author=Andreas L. Birkenfeld;,citation_author=Morten Donsmark;,citation_author=Kathleen Dungan;,citation_author=Freddy G. Eliaschewitz;,citation_author=Denise R. Franco;,citation_author=Ole K. Jeppesen;,citation_author=Ildiko Lingvay;,citation_author=Ofri Mosenzon;,citation_author=Sue D. Pedersen;,citation_author=Cees J. Tack;,citation_author=Mette Thomsen;,citation_author=Tina Vilsbøll;,citation_author=Mark L. Warren;,citation_author=Stephen C. Bain;,citation_publication_date=2019-08;,citation_cover_date=2019-08;,citation_year=2019;,citation_issue=9;,citation_doi=10.1056/NEJMoa1901118;,citation_issn=0028-4793;,citation_pmid=31185157;,citation_volume=381;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Decompressive Craniectomy versus Craniotomy for Acute Subdural Hematoma;,citation_author=Peter J. Hutchinson;,citation_author=Hadie Adams;,citation_author=Midhun Mohan;,citation_author=Bhagavatula I. Devi;,citation_author=Christopher Uff;,citation_author=Shumaila Hasan;,citation_author=Harry Mee;,citation_author=Mark H. Wilson;,citation_author=Deepak K. Gupta;,citation_author=Diederik Bulters;,citation_author=Ardalan Zolnourian;,citation_author=Catherine J. McMahon;,citation_author=Matthew G. Stovell;,citation_author=Yahia Z. Al-Tamimi;,citation_author=Manoj K. Tewari;,citation_author=Manjul Tripathi;,citation_author=Simon Thomson;,citation_author=Edoardo Viaroli;,citation_author=Antonio Belli;,citation_author=Andrew T. King;,citation_author=Adel E. Helmy;,citation_author=Ivan S. Timofeev;,citation_author=Sarah Pyne;,citation_author=Dhaval P. Shukla;,citation_author=Dhananjaya I. Bhat;,citation_author=Andrew R. Maas;,citation_author=Franco Servadei;,citation_author=Geoffrey T. Manley;,citation_author=Garry Barton;,citation_author=Carole Turner;,citation_author=David K. Menon;,citation_author=Barbara Gregson;,citation_author=Angelos G. Kolias;,citation_publication_date=2023-06;,citation_cover_date=2023-06;,citation_year=2023;,citation_issue=24;,citation_doi=10.1056/NEJMoa2214172;,citation_issn=0028-4793;,citation_pmid=37092792;,citation_volume=388;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor–Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care;,citation_abstract=BACKGROUND AND PURPOSE: It is unestablished whether andexanet alfa, compared with guideline-based usual care including prothrombin complex concentrates, is associated with reduced hematoma expansion (HE) and mortality in patients with factor-Xa inhibitor–related intracerebral hemorrhage (ICH). We compared the occurrence of HE and clinical outcomes in patients treated either with andexanet alfa or with usual care during the acute phase of factor-Xa inhibitor–related ICH. METHODS: Data were extracted from the multicenter, prospective, single-arm ANNEXA-4 trial (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors) and a multicenter observational cohort study, RETRACE-II (GermanWide Multicenter Analysis of Oral Anticoagulant-Associated Intracerebral Hemorrhage - Part Two). HE was based on computed tomography scans performed within 36 hours from baseline imaging. Inverse probability of treatment weighting was performed to adjust for baseline comorbidities and ICH severity. Patients presenting with atraumatic ICH while receiving apixaban or rivaroxaban within 18 hours of admission were included. Patients with secondary ICH or not fulfilling the inclusion criteria for the ANNEXA-4 trial were excluded. We compared ANNEXA-4 patients, who received andexanet alfa for hemostatic treatment, with RETRACE-II patients who were treated with usual care, primarily administration of prothrombin complex concentrates. Primary outcome was rate of HE defined as relative increase of \geq35%. Secondary outcomes comprised mean absolute change in hematoma volume, as well as in-hospital mortality and functional outcome. RESULTS: Overall, 182 patients with factor-Xa inhibitor–related ICH (85 receiving andexanet alfa versus 97 receiving usual care) were selected for analysis. There were no relevant differences regarding demographic or clinical characteristics between both groups. HE occurred in 11 of 80 (14%) andexanet alfa patients compared with 21 of 67 (36%) usual care patients (adjusted relative risk, 0.40 [95% CI, 0.20–0.78]; P=0.005), with a reduction in mean overall hematoma volume change of 7 mL. There were no statistically significant differences among in-hospital mortality or functional outcomes. Sensitivity analysis including only usual care patients receiving prothrombin complex concentrates demonstrated consistent results. CONCLUSIONS: As compared with usual care, andexanet alfa was associated with a lower rate of HE in atraumatic factor-Xa inhibitor–related ICH, however, without translating into significantly improved clinical outcomes. A comparative trial is needed to confirm the benefit on limiting HE and to explore clinical outcomes across patient subgroups and by time to treatment.;,citation_author=Hagen B. Huttner;,citation_author=Stefan T. Gerner;,citation_author=Joji B. Kuramatsu;,citation_author=Stuart J. Connolly;,citation_author=Jan Beyer-Westendorf;,citation_author=Andrew M. Demchuk;,citation_author=Saskia Middeldorp;,citation_author=Elena Zotova;,citation_author=Julia Altevers;,citation_author=Frank Andersohn;,citation_author=Mary J. Christoph;,citation_author=Patrick Yue;,citation_author=Leonhard Stross;,citation_author=Stefan Schwab;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_doi=10.1161/STROKEAHA.121.034572;,citation_issn=0039-2499, 1524-4628;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=Pre Versus Post Implementation of a Pharmacologic Antishivering Protocol During Targeted Temperature Management Following Cardiac Arrest;,citation_abstract=Background: Targeted temperature management (TTM) is endorsed by various guidelines to improve neurologic outcomes following cardiac arrest. Shivering, a consequence of hypothermia, can counteract the benefits of TTM. Despite its frequent occurrence, consensus guidelines provide minimal guidance on the management of shivering. The purpose of this study was to evaluate the impact of a pharmacologic antishivering protocol in patients undergoing TTM following cardiac arrest on the incidence of shivering. Methods: A retrospective observational cohort study at a large academic medical center of adult patients who underwent TTM targeting 33 ^\circC following out-of-hospital (OHCA) or in-hospital cardiac arrest (IHCA) was conducted between January 2013 and January 2019. Patients were included in the preprotocol group if they received TTM prior to the initiation of a pharmacologic antishivering protocol in 2015. The primary outcome was incidence of shivering between pre- and postprotocol patients. Secondary outcomes included time from arrest (IHCA) or admission to the hospital (OHCA) to goal body temperature, total time spent at goal body temperature, and percentage of patients alive at discharge. All pharmacologic agents listed as part of the antishivering protocol were recorded. Results: Fifty-one patients were included in the preprotocol group, and 80 patients were included in the postprotocol group. There were no significant differences in baseline characteristics between the groups, including percentage of patients experiencing OHCA (75% vs. 63%, p = 0.15) and time from arrest to return of spontaneous circulation (17.5 vs. 17.9 min, p = 0.96). Incidence of patients with shivering was significantly reduced in the postprotocol group (57% vs. 39%, p = 0.03). Time from arrest (IHCA) or admission to the hospital (OHCA) to goal body temperature was similar in both groups (5.1 vs. 5.3 h, p = 0.57), in addition to total time spent at goal body temperature (17.7 vs. 18 h, p = 0.93). The percentage of patients alive at discharge was significantly improved in the postprotocol group (35% vs. 55%, p = 0.02). Patients in the postprotocol group received significantly more buspirone (4% vs. 73%, p &amp;amp;amp;lt; 0.01), meperidine (8% vs. 34%, p &amp;lt; 0.01), and acetaminophen (12% vs. 65%, p < 0.01) as part of the pharmacologic antishivering protocol. Use of neuromuscular blockade significantly decreased post protocol (19% vs. 6%, p = 0.02). Conclusions: In patients undergoing TTM following cardiac arrest, the implementation of a pharmacologic antishivering protocol reduced the incidence of shivering and the use neuromuscular blocking agents. Prospective data are;,citation_author=Calvin Huynh;,citation_author=Jevons Lui;,citation_author=Vala Behbahani;,citation_author=Ashley Thompson Quan;,citation_author=Amanda Morris;,citation_author=Laura Baumgartner;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_doi=10.1007/s12028-021-01327-9;,citation_issn=1541-6933, 1556-0961;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Guidelines for Neuroprognostication in Critically Ill Adults with Intracerebral Hemorrhage;,citation_abstract=The objective of this document is to provide recommendations on the formal reliability of major clinical predictors often associated with intracerebral hemorrhage (ICH) neuroprognostication.;,citation_author=David Y. Hwang;,citation_author=Keri S. Kim;,citation_author=Susanne Muehlschlegel;,citation_author=Katja E. Wartenberg;,citation_author=Venkatakrishna Rajajee;,citation_author=Sheila A. Alexander;,citation_author=Katharina M. Busl;,citation_author=Claire J. Creutzfeldt;,citation_author=Gabriel V. Fontaine;,citation_author=Sara E. Hocker;,citation_author=Dominik Madzar;,citation_author=Dea Mahanes;,citation_author=Shraddha Mainali;,citation_author=Oliver W. Sakowitz;,citation_author=Panayiotis N. Varelas;,citation_author=Christian Weimar;,citation_author=Thomas Westermaier;,citation_author=Jürgen Meixensberger;,citation_publication_date=2023-11;,citation_cover_date=2023-11;,citation_year=2023;,citation_doi=10.1007/s12028-023-01854-7;,citation_issn=1556-0961;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease;,citation_author=Costantino Iadecola;,citation_publication_date=2017-09;,citation_cover_date=2017-09;,citation_year=2017;,citation_issue=1;,citation_doi=10.1016/j.neuron.2017.07.030;,citation_issn=08966273;,citation_volume=96;,citation_language=en-US;,citation_journal_title=Neuron;">
<meta name="citation_reference" content="citation_title=Use of Airway Pressure Release Ventilation in Patients With Acute Respiratory Failure Due to Coronavirus Disease 2019: Results of a Single-Center Randomized Controlled Trial;,citation_abstract=OBJECTIVES: Airway pressure release ventilation is a ventilatory mode characterized by a mandatory inverse inspiratory:expiratory ratio with a very short expiratory phase, aimed to avoid derecruitment and allow spontaneous breathing. Recent basic and clinical evidence suggests that this mode could be associated with improved outcomes in patients with acute respiratory distress syndrome. The aim of this study was to compare the outcomes between airway pressure release ventilation and traditional ventilation targeting low tidal volume, in patients with severe coronavirus disease 2019. DESIGN: Single-center randomized controlled trial. SETTING: ICU of a Mexican referral center dedicated to care of patients with confirmed diagnosis of coronavirus disease 2019. PATIENTS: Ninety adult intubated patients with acute respiratory distress syndrome associated with severe coronavirus disease 2019. INTERVENTIONS: Within 48 hours after intubation, patients were randomized to either receive ventilatory management with airway pressure release ventilation or continue low tidal volume ventilation. MEASUREMENTS AND MAIN RESULTS: Forty-five patients in airway pressure release ventilation group and 45 in the low tidal volume group were included. Ventilator-free days were 3.7 (0–15) and 5.2 (0–19) in the airway pressure release ventilation and low tidal volume groups, respectively (p = 0.28). During the first 7 days, patients in airway pressure release ventilation had a higher Pao2/Fio2 (mean difference, 26 [95%CI, 13–38]; p &amp;amp;amp;lt; 0.001) and static compliance (mean difference, 3.7 mL/cm H2O [95% CI, 0.2–7.2]; p = 0.03), higher mean airway pressure (mean difference, 3.1 cm H2O [95% CI, 2.1–4.1]; p &amp;lt; 0.001), and higher tidal volume (mean difference, 0.76 mL/kg/predicted body weight [95% CI, 0.5–1.0]; p < 0.001). More patients in airway pressure release ventilation had transient severe hypercapnia, defined as an elevation of Pco2 at greater than or equal to 55 along with a pH less than 7.15 (42% vs 15%; p = 0.009); other outcomes were similar. Overall mortality was 69%, with no difference between the groups (78% in airway pressure release ventilation vs 60% in low tidal volume; p = 0.07). CONCLUSIONS: In conclusion, when compared with low tidal volume, airway pressure release ventilation was not associated with more ventilator-free days or improvement in other relevant outcomes in patients with severe coronavirus disease 2019.;,citation_author=Miguel Á. Ibarra-Estrada;,citation_author=Yessica García-Salas;,citation_author=Eduardo Mireles-Cabodevila;,citation_author=José A. López-Pulgarín;,citation_author=Quetzalcóatl Chávez-Peña;,citation_author=Roxana García-Salcido;,citation_author=Julio C. Mijangos-Méndez;,citation_author=Guadalupe Aguirre-Avalos;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_doi=10.1097/CCM.0000000000005312;,citation_issn=0090-3493;,citation_volume=Publish Ahead of Print;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Statistical Significance, &amp;amp;amp;lt;i&amp;gt;p&amp;lt;/i&amp;gt; -Values, and the Reporting of Uncertainty;,citation_abstract=The use of statistical significance and p-values has become a matter of substantial controversy in various fields using statistical methods. This has gone as far as some journals banning the use of indicators for statistical significance, or even any reports of p-values, and, in one case, any mention of confidence intervals. I discuss three of the issues that have led to these often-heated debates. First, I argue that in many cases, p-values and indicators of statistical significance do not answer the questions of primary interest. Such questions typically involve making (recommendations on) decisions under uncertainty. In that case, point estimates and measures of uncertainty in the form of confidence intervals or even better, Bayesian intervals, are often more informative summary statistics. In fact, in that case, the presence or absence of statistical significance is essentially irrelevant, and including them in the discussion may confuse the matter at hand. Second, I argue that there are also cases where testing null hypotheses is a natural goal and where p-values are reasonable and appropriate summary statistics. I conclude that banning them in general is counterproductive. Third, I discuss that the overemphasis in empirical work on statistical significance has led to abuse of p-values in the form of p-hacking and publication bias. The use of pre-analysis plans and replication studies, in combination with lowering the emphasis on statistical significance may help address these problems.;,citation_author=Guido W. Imbens;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_issue=3;,citation_doi=10.1257/jep.35.3.157;,citation_issn=0895-3309;,citation_volume=35;,citation_language=en-US;,citation_journal_title=Journal of Economic Perspectives;">
<meta name="citation_reference" content="citation_title=Reflection on modern methods: Selection bias—a review of recent developments;,citation_abstract=Selection bias remains a more difficult bias to understand than confounding or measurement error. Past definitions have not always been illuminating and a simple method (such as the change-in-estimate method for confounding) has not been available to determine its presence and magnitude in the study sample. A better understanding of the nature of the bias has led to the definition of endogenous selection bias. It is the result of conditioning on a collider variable, itself caused by two other variables; the latter variables become spuriously associated. Conditioning on a variable in the analysis that is a collider or on an indicator of sample selection has the same effect. Note that selection bias is possible even in the absence of a collider, but in the presence of endogenous selection bias, the concern is whether it is possible to identify a causal effect in the sample. Conditions have been outlined to determine that. However, even if conditions are met to identify a causal effect in the study sample, its generalization to a defined target population is not a given.;,citation_author=Claire Infante-Rivard;,citation_author=Alexandre Cusson;,citation_publication_date=2018-10;,citation_cover_date=2018-10;,citation_year=2018;,citation_issue=5;,citation_doi=10.1093/ije/dyy138;,citation_issn=0300-5771, 1464-3685;,citation_volume=47;,citation_language=en-US;,citation_journal_title=International Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Liver Transplantation;,citation_author=Michael R. Lucey;,citation_author=Katryn N. Furuya;,citation_author=David P. Foley;,citation_editor=Julie R. Ingelfinger;,citation_publication_date=2023-11;,citation_cover_date=2023-11;,citation_year=2023;,citation_issue=20;,citation_doi=10.1056/NEJMra2200923;,citation_issn=0028-4793, 1533-4406;,citation_volume=389;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race;,citation_abstract=BACKGROUND Current equations for estimated glomerular filtration rate (eGFR) that use serum creatinine or cystatin C incorporate age, sex, and race to estimate measured GFR. However, race in eGFR equations is a social and not a biologic construct. METHODS We developed new eGFR equations without race using data from two development data sets: 10 studies (8254 participants, 31.5% Black) for serum creatinine and 13 studies (5352 participants, 39.7% Black) for both serum creatinine and cystatin C. In a validation data set of 12 studies (4050 participants, 14.3% Black), we compared the accuracy of new eGFR equations to measured GFR. We projected the prevalence of chronic kidney disease (CKD) and GFR stages in a sample of U.S. adults, using current and new equations. RESULTS In the validation data set, the current creatinine equation that uses age, sex, and race overestimated measured GFR in Blacks (median, 3.7 ml per minute per 1.73 m2 of body-surface area; 95% confidence interval [CI], 1.8 to 5.4) and to a lesser degree in non-Blacks (median, 0.5 ml per minute per 1.73 m2; 95% CI, 0.0 to 0.9). When the adjustment for Black race was omitted from the current eGFR equation, measured GFR in Blacks was underestimated (median, 7.1 ml per minute per 1.73 m2; 95% CI, 5.9 to 8.8). A new equation using age and sex and omitting race underestimated measured GFR in Blacks (median, 3.6 ml per minute per 1.73 m2; 95% CI, 1.8 to 5.5) and overestimated measured GFR in non-Blacks (median, 3.9 ml per minute per 1.73 m2; 95% CI, 3.4 to 4.4). For all equations, 85% or more of the eGFRs for Blacks and non-Blacks were within 30% of measured GFR. New creatinine–cystatin C equations without race were more accurate than new creatinine equations, with smaller differences between race groups. As compared with the current creatinine equation, the new creatinine equations, but not the new creatinine–cystatin C equations, increased population estimates of CKD prevalence among Blacks and yielded similar or lower prevalence among non-Blacks. The authors’ full names, academic degrees, and affiliations are listed in the Appendix. Address reprint requests to Dr. Inker at the Division of Nephrology, Tufts Medical Center, 800 Washington St., Box 391, Boston, MA 02111, or at linker@tuftsmedicalcenter.org. *The members of the Chronic Kidney Disease Epidemiology Collaboration are listed in the Supplementary Appendix, available at NEJM.org. This article was published on September 23, 2021, at NEJM.org. DOI: 10.1056/NEJMoa2102953 Copyright © 2021 Massachusetts Medical Society. CONCLUSIONS New eGFR equations that incorporate creatinine and cystatin C but omit race are more accurate and led to smaller differences between Black participants and nonBlack participants than new equations without race with either creatinine or cystatin C alone. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases.);,citation_author=Lesley A. Inker;,citation_author=Nwamaka D. Eneanya;,citation_author=Josef Coresh;,citation_author=Hocine Tighiouart;,citation_author=Dan Wang;,citation_author=Yingying Sang;,citation_author=Deidra C. Crews;,citation_author=Alessandro Doria;,citation_author=Michelle M. Estrella;,citation_author=Marc Froissart;,citation_author=Morgan E. Grams;,citation_author=Tom Greene;,citation_author=Anders Grubb;,citation_author=Vilmundur Gudnason;,citation_author=Orlando M. Gutiérrez;,citation_author=Roberto Kalil;,citation_author=Amy B. Karger;,citation_author=Michael Mauer;,citation_author=Gerjan Navis;,citation_author=Robert G. Nelson;,citation_author=Emilio D. Poggio;,citation_author=Roger Rodby;,citation_author=Peter Rossing;,citation_author=Andrew D. Rule;,citation_author=Elizabeth Selvin;,citation_author=Jesse C. Seegmiller;,citation_author=Michael G. Shlipak;,citation_author=Vicente E. Torres;,citation_author=Wei Yang;,citation_author=Shoshana H. Ballew;,citation_author=Sara J. Couture;,citation_author=Neil R. Powe;,citation_author=Andrew S. Levey;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_doi=10.1056/NEJMoa2102953;,citation_issn=0028-4793, 1533-4406;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=High-cited favorable studies for COVID-19 treatments ineffective in large trials;,citation_abstract=Objectives To evaluate for coronavirus disease 2019 treatments without benefits in subsequent large randomized controlled trials (RCTs) how many of their most-cited clinical studies had declared favorable results. Study Design and Setting Scopus searches (December 23, 2021) identified articles on lopinavir-ritonavir, hydroxychloroquine, azithromycin, remdesivir, convalescent plasma, colchicine, or interferon (index interventions) that represented clinical trials and had &amp;amp;amp;gt;150 citations. Their conclusions were correlated with study design features. The 10 most recent citations for the most-cited article on each index intervention were examined on whether they were critical to the highly cited study. Altmetric scores were also obtained. Results Forty eligible articles of clinical studies had received &amp;gt;150 citations. Twenty of forty (50%) had favorable conclusions and four were equivocal. Highly cited articles with favorable conclusions were rarely RCTs (3/20), although those without favorable conclusions were mostly RCTs (15/20, P&nbsp;=&nbsp;0.0003). Only one RCT with favorable conclusions had >160 patients. Citation counts correlated strongly with Altmetric scores, especially news items. Only nine (15%) of 60 recent citations to the most highly cited studies with favorable or equivocal conclusions were critical. Conclusion Many clinical studies with favorable conclusions for largely ineffective coronavirus disease 2019 treatments are uncritically heavily cited and disseminated. Early observational studies and small randomized trials may cause spurious claims of effectiveness that get perpetuated.;,citation_author=John P. A. Ioannidis;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_doi=10.1016/j.jclinepi.2022.04.001;,citation_issn=0895-4356;,citation_volume=148;,citation_language=en-US;,citation_journal_title=Journal of Clinical Epidemiology;">
<meta name="citation_reference" content="citation_title=The impact of high-risk patients on the results of clinical trials;,citation_author=John P. A. Ioannidis;,citation_author=Joseph Lau;,citation_publication_date=1997-10;,citation_cover_date=1997-10;,citation_year=1997;,citation_issue=10;,citation_doi=10.1016/S0895-4356(97)00149-2;,citation_issn=08954356;,citation_volume=50;,citation_language=en-US;,citation_journal_title=Journal of Clinical Epidemiology;">
<meta name="citation_reference" content="citation_title=The Importance of Potential Studies That Have Not Existed and Registration of Observational Data Sets;,citation_author=John P. A. Ioannidis;,citation_publication_date=2012-08;,citation_cover_date=2012-08;,citation_year=2012;,citation_issue=6;,citation_doi=10.1001/jama.2012.8144;,citation_issn=0098-7484;,citation_volume=308;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=The Importance of Predefined Rules and Prespecified Statistical Analyses: Do Not Abandon Significance;,citation_author=John P. A. Ioannidis;,citation_publication_date=2019-06;,citation_cover_date=2019-06;,citation_year=2019;,citation_issue=21;,citation_doi=10.1001/jama.2019.4582;,citation_issn=0098-7484;,citation_volume=321;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Meta-research: Evaluation and Improvement of Research Methods and Practices;,citation_abstract=As the scientific enterprise has grown in size and diversity, we need empirical evidence on the research process to test and apply interventions that make it more efficient and its results more reliable. Meta-research is an evolving scientific discipline that aims to evaluate and improve research practices. It includes thematic areas of methods, reporting, reproducibility, evaluation, and incentives (how to do, report, verify, correct, and reward science).;,citation_author=John P. A. Ioannidis;,citation_author=Daniele Fanelli;,citation_author=Debbie Drake Dunne;,citation_author=Steven N. Goodman;,citation_publication_date=2015-10;,citation_cover_date=2015-10;,citation_year=2015;,citation_issue=10;,citation_doi=10.1371/journal.pbio.1002264;,citation_issn=1545-7885;,citation_volume=13;,citation_language=en-US;,citation_journal_title=PLOS Biology;">
<meta name="citation_reference" content="citation_title=Meta-research: Why research on research matters;,citation_abstract=Meta-research is the study of research itself: its methods, reporting, reproducibility, evaluation, and incentives. Given that science is the key driver of human progress, improving the efficiency of scientific investigation and yielding more credible and more useful research results can translate to major benefits. The research enterprise grows very fast. Both new opportunities for knowledge and innovation and new threats to validity and scientific integrity emerge. Old biases abound, and new ones continuously appear as novel disciplines emerge with different standards and challenges. Meta-research uses an interdisciplinary approach to study, promote, and defend robust science. Major disruptions are likely to happen in the way we pursue scientific investigation, and it is important to ensure that these disruptions are evidence based.;,citation_author=John P. A. Ioannidis;,citation_publication_date=2018-03;,citation_cover_date=2018-03;,citation_year=2018;,citation_issue=3;,citation_doi=10.1371/journal.pbio.2005468;,citation_issn=1545-7885;,citation_volume=16;,citation_language=en-US;,citation_journal_title=PLOS Biology;">
<meta name="citation_reference" content="citation_title=The Proposal to Lower &amp;amp;amp;lt;i&amp;gt;P&amp;lt;/i&amp;gt; Value Thresholds to .005;,citation_author=John P. A. Ioannidis;,citation_publication_date=2018-04;,citation_cover_date=2018-04;,citation_year=2018;,citation_issue=14;,citation_doi=10.1001/jama.2018.1536;,citation_issn=0098-7484;,citation_volume=319;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=What Have We (Not) Learnt from Millions of Scientific Papers with &amp;amp;amp;lt;i&amp;gt;P&amp;lt;/i&amp;gt; Values?;,citation_abstract=P values linked to null hypothesis significance testing (NHST) is the most widely (mis)used method of statistical inference. Empirical data suggest that across the biomedical literature (1990–2015), when abstracts use P values 96% of them have P values of 0.05 or less. The same percentage (96%) applies for full-text articles. Among 100 articles in PubMed, 55 report P values, while only 4 present confidence intervals for all the reported effect sizes, none use Bayesian methods and none use false-discovery rate. Over 25 years (1990–2015), use of P values in abstracts has doubled for all PubMed, and tripled for meta-analyses, while for some types of designs such as randomized trials the majority of abstracts report P values. There is major selective reporting for P values. Abstracts tend to highlight most favorable P values and inferences use even further spin to reach exaggerated, unreliable conclusions. The availability of large-scale data on P values from many papers has allowed the development and applications of methods that try to detect and model selection biases, for example, p-hacking, that cause patterns of excess significance. Inferences need to be cautious as they depend on the assumptions made by these models and can be affected by the presence of other biases (e.g., confounding in observational studies). While much of the unreliability of past and present research is driven by small, underpowered studies, NHST with P values may be also particularly problematic in the era of overpowered big data. NHST and P values are optimal only in a minority of current research. Using a more stringent threshold, as in the recently proposed shift from P &amp;amp;lt; 0.05 to P < 0.005, is a temporizing measure to contain the flood and death-by-significance. NHST and P values may be replaced in many fields by other, more fit-for-purpose, inferential methods. However, curtailing selection biases requires additional measures, beyond changes in inferential methods, and in particular reproducible research practices.;,citation_author=John P. A. Ioannidis;,citation_publication_date=2019-03;,citation_cover_date=2019-03;,citation_year=2019;,citation_issue=sup1;,citation_doi=10.1080/00031305.2018.1447512;,citation_issn=0003-1305, 1537-2731;,citation_volume=73;,citation_language=en-US;,citation_journal_title=The American Statistician;">
<meta name="citation_reference" content="citation_title=Why Most Published Research Findings Are False;,citation_abstract=There is increasing concern that most current published research findings are false. The probability that a research claim is true may depend on study power and bias, the number of other studies on the same question, and, importantly, the ratio of true to no relationships among the relationships probed in each scientific field. In this framework, a research finding is less likely to be true when the studies conducted in a field are smaller; when effect sizes are smaller; when there is a greater number and lesser preselection of tested relationships; where there is greater flexibility in designs, definitions, outcomes, and analytical modes; when there is greater financial and other interest and prejudice; and when more teams are involved in a scientific field in chase of statistical significance. Simulations show that for most study designs and settings, it is more likely for a research claim to be false than true. Moreover, for many current scientific fields, claimed research findings may often be simply accurate measures of the prevailing bias. In this essay, I discuss the implications of these problems for the conduct and interpretation of research.;,citation_author=John P. A. Ioannidis;,citation_publication_date=2005-08;,citation_cover_date=2005-08;,citation_year=2005;,citation_issue=8;,citation_doi=10.1371/journal.pmed.0020124;,citation_issn=1549-1676;,citation_volume=2;,citation_language=en-US;,citation_journal_title=PLoS Medicine;">
<meta name="citation_reference" content="citation_title=Effectiveness of mRNA COVID-19 Vaccine Boosters Against Infection, Hospitalization, and Death: A Target Trial Emulation in the Omicron (B.1.1.529) Variant Era;,citation_abstract=BACKGROUND: The effectiveness of a third mRNA COVID-19 vaccine dose (booster dose) against the Omicron (B.1.1.529) variant is uncertain, especially in older, high-risk populations. OBJECTIVE: To determine mRNA booster vaccine effectiveness (VE) against SARS-CoV-2 infection, hospitalization, and death in the Omicron era by booster type, primary vaccine type, time since primary vaccination, age, and comorbidity burden. DESIGN: Retrospective matched cohort study designed to emulate a target trial of booster vaccination versus no booster, conducted from 1 December 2021 to 31 March 2022. SETTING: U.S. Department of Veterans Affairs health care system. PARTICIPANTS: Persons who had received 2 mRNA COVID-19 vaccine doses at least 5 months earlier. INTERVENTION: Booster monovalent mRNA vaccination (Pfizer-BioNTech’s BNT162b2 or Moderna’s mRNA-1273) versus no booster. MEASUREMENTS: Booster VE. RESULTS: Each group included 490&nbsp;838 well-matched persons, who were predominantly male (88%), had a mean age of 63.0 years (SD, 14.0), and were followed for up to 121 days (mean, 79.8 days). Booster VE more than 10 days after a booster dose was 42.3% (95% CI, 40.6% to 43.9%) against SARS-CoV-2 infection, 53.3% (CI, 48.1% to 58.0%) against SARS-CoV-2-related hospitalization, and 79.1% (CI, 71.2% to 84.9%) against SARS-CoV-2-related death. Booster VE was similar for different booster types (BNT162b2 or mRNA-1273), age groups, and primary vaccination regimens but was significantly higher with longer time since primary vaccination and higher comorbidity burden. LIMITATION: Predominantly male population. CONCLUSION: Booster mRNA vaccination was highly effective in preventing death and moderately effective in preventing infection and hospitalization for up to 4 months after administration in the Omicron era. Increased uptake of booster vaccination, which is currently suboptimal, should be pursued to limit the morbidity and mortality of SARS-CoV-2 infection, especially in persons with high comorbidity burden. PRIMARY FUNDING SOURCE: U.S. Department of Veterans Affairs.;,citation_author=George N. Ioannou;,citation_author=Amy S. B. Bohnert;,citation_author=Ann M. O’Hare;,citation_author=Edward J. Boyko;,citation_author=Matthew L. Maciejewski;,citation_author=Valerie A. Smith;,citation_author=C. Barrett Bowling;,citation_author=Elizabeth Viglianti;,citation_author=Theodore J. Iwashyna;,citation_author=Denise M. Hynes;,citation_author=Kristin Berry;,citation_author=COVID-19 Observational Research Collaboratory (CORC)*;,citation_publication_date=2022-10;,citation_cover_date=2022-10;,citation_year=2022;,citation_doi=10.7326/M22-1856;,citation_issn=1539-3704;,citation_pmid=36215715;,citation_language=en-US;,citation_journal_title=Annals of Internal Medicine;">
<meta name="citation_reference" content="citation_title=Equivalence Testing for Psychological Research: A Tutorial;,citation_abstract=Psychologists must be able to test both for the presence of an effect and for the absence of an effect. In addition to testing against zero, researchers can use the two one-sided tests (TOST) procedure to test for equivalence and reject the presence of a smallest effect size of interest (SESOI). The TOST procedure can be used to determine if an observed effect is surprisingly small, given that a true effect at least as extreme as the SESOI exists. We explain a range of approaches to determine the SESOI in psychological science and provide detailed examples of how equivalence tests should be performed and reported. Equivalence tests are an important extension of the statistical tools psychologists currently use and enable researchers to falsify predictions about the presence, and declare the absence, of meaningful effects.;,citation_author=Peder Isager;,citation_author=Anne Scheel;,citation_author=Daniel Lakens;,citation_publication_date=2019;,citation_cover_date=2019;,citation_year=2019;,citation_doi=10.17605/OSF.IO/QAMC6;,citation_language=en-US;,citation_publisher=Open Science Framework;">
<meta name="citation_reference" content="citation_title=The Burdens of Survivorship: An Approach to Thinking about Long-Term Outcomes after Critical Illness;,citation_author=Theodore Iwashyna;,citation_author=Giora Netzer;,citation_publication_date=2012-08;,citation_cover_date=2012-08;,citation_year=2012;,citation_issue=04;,citation_doi=10.1055/s-0032-1321982;,citation_issn=1069-3424, 1098-9048;,citation_volume=33;,citation_language=en-US;,citation_journal_title=Seminars in Respiratory and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Long-term Cognitive Impairment and Functional Disability Among Survivors of Severe Sepsis;,citation_abstract=Objective To determine the change in cognitive impairment and physical functioning among patients who survive severe sepsis, controlling for their presepsis functioning. Design, Setting, and Patients A prospective cohort involving 1194 patients with 1520 hospitalizations for severe sepsis drawn from the Health and Retirement Study, a nationally representative survey of US residents (1998-2006). A total of 9223 respondents had a baseline cognitive and functional assessment and had linked Medicare claims; 516 survived severe sepsis and 4517 survived a nonsepsis hospitalization to at least 1 follow-up survey and are included in the analysis. Main Outcome Measures Personal interviews were conducted with respondents or proxies using validated surveys to assess the presence of cognitive impairment and to determine the number of activities of daily living (ADLs) and instrumental ADLs (IADLs) for which patients needed assistance. Results Survivors’ mean age at hospitalization was 76.9 years. The prevalence of moderate to severe cognitive impairment increased 10.6 percentage points among patients who survived severe sepsis, an odds ratio (OR) of 3.34 (95% confidence interval [CI], 1.53-7.25) in multivariable regression. Likewise, a high rate of new functional limitations was seen following sepsis: in those with no limits before sepsis, a mean 1.57 new limitations (95% CI, 0.99-2.15); and for those with mild to moderate limitations before sepsis, a mean of 1.50 new limitations (95% CI, 0.87-2.12). In contrast, nonsepsis general hospitalizations were associated with no change in moderate to severe cognitive impairment (OR, 1.15; 95% CI, 0.80-1.67; P for difference vs sepsis=.01) and with the development of fewer new limitations (mean among those with no limits before hospitalization, 0.48; 95% CI, 0.39-0.57; P for difference vs sepsis Ͻ.001 and mean among those with mild to moderate limits, 0.43; 95% CI, 0.23-0.63; P for difference=.001). The declines in cognitive and physical function persisted for at least 8 years. Conclusions Severe sepsis in this older population was independently associated with substantial and persistent new cognitive impairment and functional disability among survivors. The magnitude of these new deficits was large, likely resulting in a pivotal downturn in patients’ ability to live independently.;,citation_author=Theodore J Iwashyna;,citation_author=E Wesley Ely;,citation_author=Dylan M Smith;,citation_author=Kenneth M Langa;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Population Burden of Long-Term Survivorship After Severe Sepsis in Older Americans;,citation_author=Theodore J. Iwashyna;,citation_author=Colin R. Cooke;,citation_author=Hannah Wunsch;,citation_author=Jeremy M. Kahn;,citation_publication_date=2012-06;,citation_cover_date=2012-06;,citation_year=2012;,citation_issue=6;,citation_doi=10.1111/j.1532-5415.2012.03989.x;,citation_issn=00028614;,citation_volume=60;,citation_language=en-US;,citation_journal_title=Journal of the American Geriatrics Society;">
<meta name="citation_reference" content="citation_title=Recognizing a Patient Is Acutely Dying;,citation_author=Theodore J. Iwashyna;,citation_publication_date=2020-10;,citation_cover_date=2020-10;,citation_year=2020;,citation_issue=10;,citation_doi=10.1513/AnnalsATS.202002-115IP;,citation_issn=2329-6933, 2325-6621;,citation_volume=17;,citation_language=en-US;,citation_journal_title=Annals of the American Thoracic Society;">
<meta name="citation_reference" content="citation_title=Timing of onset and burden of persistent critical illness in Australia and New Zealand: A retrospective, population-based, observational study;,citation_abstract=Background Critical care physicians recognise persistent critical illness as a specific syndrome, yet few data exist for the timing of the transition from acute to persistent critical illness. Defining the onset of persistent critical illness as the time at which diagnosis and illness severity at intensive care unit (ICU) arrival no longer predict outcome better than do simple pre-ICU patient characteristics, we measured the timing of this onset at a population level in Australia and New Zealand, and the variation therein, and assessed the characteristics, burden of care, and hospital outcomes of patients with persistent critical illness.;,citation_author=Theodore J Iwashyna;,citation_author=Carol L Hodgson;,citation_author=David Pilcher;,citation_author=Michael Bailey;,citation_author=Allison Lint;,citation_author=Shaila Chavan;,citation_author=Rinaldo Bellomo;,citation_publication_date=2016-07;,citation_cover_date=2016-07;,citation_year=2016;,citation_issue=7;,citation_doi=10.1016/S2213-2600(16)30098-4;,citation_issn=22132600;,citation_volume=4;,citation_language=en-US;,citation_journal_title=The Lancet Respiratory Medicine;">
<meta name="citation_reference" content="citation_title=Trajectories of Recovery and Dysfunction after Acute Illness, with Implications for Clinical Trial Design;,citation_author=Theodore J. Iwashyna;,citation_publication_date=2012-08;,citation_cover_date=2012-08;,citation_year=2012;,citation_issue=4;,citation_doi=10.1164/rccm.201206-1138ED;,citation_issn=1073-449X, 1535-4970;,citation_volume=186;,citation_language=en-US;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage and Traumatic Brain Injury;,citation_author=Saef Izzy;,citation_author=Susanne Muehlschlegel;,citation_publication_date=2014-01;,citation_cover_date=2014-01;,citation_year=2014;,citation_issue=1;,citation_doi=10.1007/s11940-013-0278-x;,citation_issn=1092-8480, 1534-3138;,citation_volume=16;,citation_language=en-US;,citation_journal_title=Current Treatment Options in Neurology;">
<meta name="citation_reference" content="citation_title=Six-month neuropsychological outcome of medical intensive care unit patients;,citation_abstract=OBJECTIVE: To examine neuropsychological function, depression, and quality of life 6 months after discharge in patients who received mechanical ventilation in the intensive care unit. DESIGN: Prospective cohort study. SETTING: Tertiary care, medical and coronary intensive care unit of a university-based medical center. STUDY POPULATION: A total of 275 consecutive, mechanically ventilated patients from a medical intensive care unit were prospectively followed. At 6 months, 157 were alive, of whom 41 (26%) returned for extensive follow-up testing. MEASUREMENT AND MAIN RESULTS: Neuropsychological testing and assessment of depression and quality of life were performed at 6-month follow-up. Seven of 41 patients were excluded from further analysis due to preexisting cognitive impairment determined via surrogate interviews using the Modified Blessed Dementia Rating Scale and a review of medical records. On the basis of strict criteria derived from normative data, we found that 11 of 34 patients (32%) were neuropsychologically impaired. Impairment was generally diffuse but occurred primarily in areas of psychomotor speed, visual and working memory, verbal fluency, and visuo-construction. The rate of neuropsychological deficits in the study population was markedly higher than population norms for mild dementia. Scores on the Geriatric Depression Scale-Short Form were significantly more abnormal in the neuropsychologically impaired group than in the nonimpaired group at hospital discharge (p =.04) and at 6-month follow-up (p =.02), and clinically significant depression was found in 27% of impaired subjects at hospital discharge and in 36% at 6-month follow-up. No differences were observed between groups in quality of life as measured with the Short Form Health Survey-12 at discharge or 6-month follow-up. CONCLUSIONS: Prolonged neuropsychological impairment is common among survivors of the medical intensive care unit and occurs with greater than anticipated frequency when compared with relevant normative data. Future investigations are warranted to elucidate the nature of the association between critical illness, neuropsychological impairment, depression, and decreased quality of life.;,citation_author=James C. Jackson;,citation_author=Robert P. Hart;,citation_author=Sharon M. Gordon;,citation_author=Ayumi Shintani;,citation_author=Brenda Truman;,citation_author=Lisa May;,citation_author=E. Wesley Ely;,citation_publication_date=2003-04;,citation_cover_date=2003-04;,citation_year=2003;,citation_issue=4;,citation_doi=10.1097/01.CCM.0000059996.30263.94;,citation_issn=0090-3493;,citation_pmid=12682497;,citation_volume=31;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Childhood Cardiovascular Risk Factors and Adult Cardiovascular Events;,citation_abstract=BACKGROUND Childhood cardiovascular risk factors predict subclinical adult cardiovascular disease, but links to clinical events are unclear. METHODS In a prospective cohort study involving participants in the International Childhood Cardiovascular Cohorts (i3C) Consortium, we evaluated whether childhood risk factors (at the ages of 3 to 19 years) were associated with cardiovascular events in adulthood after a mean follow-up of 35 years. Body-mass index, systolic blood pressure, total cholesterol level, triglyceride level, and youth smoking were analyzed with the use of i3C-derived age- and sex-specific z scores and with a combined-risk z score that was calculated as the unweighted mean of the five risk z scores. An algebraically comparable adult combined-risk z score (before any cardiovascular event) was analyzed jointly with the childhood risk factors. Study outcomes were fatal cardiovascular events and fatal or nonfatal cardiovascular events, and analyses were performed after multiple imputation with the use of proportional-hazards regression. The authors’ full names, academic degrees, and affiliations are listed in the Appendix. Dr. Woo can be contacted at jessica.woo@cchmc.org or at the Cincinnati Children’s Hospital Medical Center, 3333 Burnet Ave., MLC 5041, Cincinnati, OH 45229-3039. Drs. Jacobs, Woo, and Sinaiko and Drs. Bazzano, Burns, Prineas, Steinberger, Urbina, Venn, Raitakari, and Dwyer contributed equally to this article. This article was published on April 4, 2022, at NEJM.org. DOI: 10.1056/NEJMoa2109191 Copyright © 2022 Massachusetts Medical Society. RESULTS In the analysis of 319 fatal cardiovascular events that occurred among 38,589 participants (49.7% male and 15.0% Black; mean [SD] age at childhood visits, 11.83.1 years), the hazard ratios for a fatal cardiovascular event in adulthood ranged from 1.30 (95% confidence interval [CI], 1.14 to 1.47) per unit increase in the z score for total cholesterol level to 1.61 (95% CI, 1.21 to 2.13) for youth smoking (yes vs. no). The hazard ratio for a fatal cardiovascular event with respect to the combined-risk z score was 2.71 (95% CI, 2.23 to 3.29) per unit increase. The hazard ratios and their 95% confidence intervals in the analyses of fatal cardiovascular events were similar to those in the analyses of 779 fatal or nonfatal cardiovascular events that occurred among 20,656 participants who could be evaluated for this outcome. In the analysis of 115 fatal cardiovascular events that occurred in a subgroup of 13,401 participants (31.05.6 years of age at the adult measurement) who had data on adult risk factors, the adjusted hazard ratio with respect to the childhood combined-risk z score was 3.54 (95% CI, 2.57 to 4.87) per unit increase, and the mutually adjusted hazard ratio with respect to the change in the combined-risk z score from childhood to adulthood was 2.88 (95% CI, 2.06 to 4.05) per unit increase. The results were similar in the analysis of 524 fatal or nonfatal cardiovascular events. CONCLUSIONS In this prospective cohort study, childhood risk factors and the change in the combined-risk z score between childhood and adulthood were associated with cardiovascular events in midlife. (Funded by the National Institutes of Health.);,citation_author=David R. Jacobs;,citation_author=Jessica G. Woo;,citation_author=Alan R. Sinaiko;,citation_author=Stephen R. Daniels;,citation_author=Johanna Ikonen;,citation_author=Markus Juonala;,citation_author=Noora Kartiosuo;,citation_author=Terho Lehtimäki;,citation_author=Costan G. Magnussen;,citation_author=Jorma S. A. Viikari;,citation_author=Nanhua Zhang;,citation_author=Lydia A. Bazzano;,citation_author=Trudy L. Burns;,citation_author=Ronald J. Prineas;,citation_author=Julia Steinberger;,citation_author=Elaine M. Urbina;,citation_author=Alison J. Venn;,citation_author=Olli T. Raitakari;,citation_author=Terence Dwyer;,citation_publication_date=2022-05;,citation_cover_date=2022-05;,citation_year=2022;,citation_issue=20;,citation_doi=10.1056/NEJMoa2109191;,citation_issn=0028-4793, 1533-4406;,citation_volume=386;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Association Between Socioeconomic Disadvantage and Decline in Function, Cognition, and Mental Health After Critical Illness Among Older Adults: A Cohort Study;,citation_author=Snigdha Jain;,citation_author=Terrence E. Murphy;,citation_author=John R. O’Leary;,citation_author=Linda Leo-Summers;,citation_author=Lauren E. Ferrante;,citation_publication_date=2022-05;,citation_cover_date=2022-05;,citation_year=2022;,citation_issue=5;,citation_doi=10.7326/M21-3086;,citation_issn=0003-4819, 1539-3704;,citation_volume=175;,citation_language=en-US;,citation_journal_title=Annals of Internal Medicine;">
<meta name="citation_reference" content="citation_title=Novel Treatments in Neuroprotection for Aneurysmal Subarachnoid Hemorrhage;,citation_abstract=New neuroprotective treatments aimed at preventing or minimizing “delayed brain injury” are attractive areas of investigation and hold the potential to have substantial beneficial effects on aneurysmal subarachnoid hemorrhage (aSAH) survivors. The underlying mechanisms for this “delayed brain injury” are multi-factorial and not fully understood. The most ideal treatment strategies would have the potential for a pleotropic effect positively modulating multiple implicated pathophysiological mechanisms at once. My personal management (RFJ) of patients with aneurysmal subarachnoid hemorrhage closely follows those treatment recommendations contained in modern published guidelines. However, over the last 5&nbsp;years, I have also utilized a novel treatment strategy, originally developed at the University of Maryland, which consists of a 14-day continuous low-dose intravenous heparin infusion (LDIVH) beginning 12&nbsp;h after securing the ruptured aneurysm. In addition to its well-known anti-coagulant properties, unfractionated heparin has potent anti-inflammatory effects and through multiple mechanisms may favorably modulate the neurotoxic and neuroinflammatory processes prominent in aneurysmal subarachnoid hemorrhage. In my personal series of patients treated with LDIVH, I have found significant preservation of neurocognitive function as measured by the Montreal Cognitive Assessment (MoCA) compared to a control cohort of my patients treated without LDIVH (RFJ unpublished data presented at the 2015 AHA/ASA International Stroke Conference symposium on neuroinflammation in aSAH and in abstract format at the 2015 AANS/CNS Joint Cerebrovascular Section Annual Meeting). It is important for academic physicians involved in the management of these complex patients to continue to explore new treatment options that may be protective against the potentially devastating “delayed brain injury” following cerebral aneurysm rupture. Several of the treatment options included in this review show promise and could be carefully adopted as the level of evidence for each improves. Other proposed neuroprotective treatments like statins and magnesium sulfate were previously thought to be very promising and to varying degrees were adopted at numerous institutions based on somewhat limited human evidence. Recent clinical trials and meta-analysis have shown no benefit for these treatments, and I currently no longer utilize either treatment as prophylaxis in my practice.;,citation_author=Robert F. James;,citation_author=Daniel R. Kramer;,citation_author=Zaid S. Aljuboori;,citation_author=Gunjan Parikh;,citation_author=Shawn W. Adams;,citation_author=Jessica C. Eaton;,citation_author=Hussam Abou Al-Shaar;,citation_author=Neeraj Badjatia;,citation_author=William J. Mack;,citation_author=J. Marc Simard;,citation_publication_date=2016-06;,citation_cover_date=2016-06;,citation_year=2016;,citation_issue=8;,citation_doi=10.1007/s11940-016-0421-6;,citation_issn=1534-3138;,citation_volume=18;,citation_language=en-US;,citation_journal_title=Current Treatment Options in Neurology;">
<meta name="citation_reference" content="citation_title=Bayesian clinical trial designs: Another option for trauma trials?;,citation_abstract=Conducting clinical trials in trauma care is challenging. As new treatments become available, we are faced with the dilemma of how to confirm their effectiveness and strengthen the evidence base. Randomized controlled trials are the criterion standard, but target groups in trauma care are often small and specialized, making the classic approach to trial design difficult. Bayesian designs represent an innovative means of increasing trial efficiency and conducting trials with more realistic sample sizes. This article examines the design of such trials, using the UK-REBOA Trial as an example.;,citation_author=Jan O. Jansen;,citation_author=Philip Pallmann;,citation_author=Graeme MacLennan;,citation_author=Marion K. Campbell;,citation_author=the UK-REBOA Trial Investigators;,citation_publication_date=2017-10;,citation_cover_date=2017-10;,citation_year=2017;,citation_issue=4;,citation_doi=10.1097/TA.0000000000001638;,citation_issn=2163-0755;,citation_volume=83;,citation_language=en-US;,citation_journal_title=Journal of Trauma and Acute Care Surgery;">
<meta name="citation_reference" content="citation_title=Factors Associated with Inpatient Mortality after Intracerebral Hemorrhage: Updated Information from the United States Nationwide Inpatient Sample;,citation_author=Vijayakumar Javalkar;,citation_author=Okkes Kuybu;,citation_author=Debra Davis;,citation_author=Roger E. Kelley;,citation_publication_date=2020-03;,citation_cover_date=2020-03;,citation_year=2020;,citation_issue=3;,citation_doi=10.1016/j.jstrokecerebrovasdis.2019.104583;,citation_issn=10523057;,citation_volume=29;,citation_language=en-US;,citation_journal_title=Journal of Stroke and Cerebrovascular Diseases;">
<meta name="citation_reference" content="citation_title=Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients;,citation_abstract=BACKGROUND New treatments are needed to reduce the risk of progression of coronavirus disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is active against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). METHODS We conducted a phase 3, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of treatment with molnupiravir started within 5 days after the onset of signs or symptoms in nonhospitalized, unvaccinated adults with mild-to-moderate, laboratory-confirmed Covid-19 and at least one risk factor for severe Covid-19 illness. Participants in the trial were randomly assigned to receive 800 mg of molnupiravir or placebo twice daily for 5 days. The primary efficacy end point was the incidence hospitalization or death at day 29; the incidence of adverse events was the primary safety end point. A planned interim analysis was performed when 50% of 1550 participants (target enrollment) had been followed through day 29. The authors’ full names, academic degrees, and affiliations are listed in the Appendix. Dr. De Anda can be contacted at Merck, 309 Sumneytown Pike, North Wales, PA 19454. *The members of the MOVe-OUT study group are listed in the Supplementary Appendix, available at NEJM.org. This article was published on December 16, 2021, at NEJM.org. DOI: 10.1056/NEJMoa2116044 Copyright © 2021 Massachusetts Medical Society. RESULTS A total of 1433 participants underwent randomization; 716 were assigned to receive molnupiravir and 717 to receive placebo. With the exception of an imbalance in sex, baseline characteristics were similar in the two groups. The superiority of molnupiravir was demonstrated at the interim analysis; the risk of hospitalization for any cause or death through day 29 was lower with molnupiravir (28 of 385 participants [7.3%]) than with placebo (53 of 377 [14.1%]) (difference, -6.8 percentage points; 95% confidence interval, -11.3 to -2.4; P = 0.001). In the analysis of all participants who had undergone randomization, the percentage of participants who were hospitalized or died through day 29 was lower in the molnupiravir group than in the placebo group (6.8% [48 of 709] vs. 9.7% [68 of 699]; difference, -3.0 percentage points; 95% confidence interval, -5.9 to -0.1). Results of subgroup analyses were largely consistent with these overall results; in some subgroups, such as patients with evidence of previous SARS-CoV-2 infection, those with low baseline viral load, and those with diabetes, the point estimate for the difference favored placebo. One death was reported in the molnupiravir group and 9 were reported in the placebo group through day 29. Adverse events were reported in 216 of 710 participants (30.4%) in the molnupiravir group and 231 of 701 (33.0%) in the placebo group. CONCLUSIONS Early treatment with molnupiravir reduced the risk of hospitalization or death in at-risk, unvaccinated adults with Covid-19. (Funded by Merck Sharp and Dohme; MOVe-OUT ClinicalTrials.gov number, NCT04575597.);,citation_author=Angélica Jayk Bernal;,citation_author=Monica M. Gomes da Silva;,citation_author=Dany B. Musungaie;,citation_author=Evgeniy Kovalchuk;,citation_author=Antonio Gonzalez;,citation_author=Virginia Delos Reyes;,citation_author=Alejandro Martín-Quirós;,citation_author=Yoseph Caraco;,citation_author=Angela Williams-Diaz;,citation_author=Michelle L. Brown;,citation_author=Jiejun Du;,citation_author=Alison Pedley;,citation_author=Christopher Assaid;,citation_author=Julie Strizki;,citation_author=Jay A. Grobler;,citation_author=Hala H. Shamsuddin;,citation_author=Robert Tipping;,citation_author=Hong Wan;,citation_author=Amanda Paschke;,citation_author=Joan R. Butterton;,citation_author=Matthew G. Johnson;,citation_author=Carisa De Anda;,citation_publication_date=2021-12;,citation_cover_date=2021-12;,citation_year=2021;,citation_doi=10.1056/NEJMoa2116044;,citation_issn=0028-4793, 1533-4406;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Confounding in the Association of Proton Pump Inhibitor Use With Risk of Community-Acquired Pneumonia;,citation_abstract=BACKGROUND: Use of proton pump inhibitors (PPIs) is associated with community-acquired pneumonia (CAP), an association which may be confounded by unobserved patient and prescriber characteristics. OBJECTIVE: We assessed for confounding in the association between PPI use and CAP by using a “falsification approach,” which estimated whether PPI use is also implausibly associated with other common medical conditions for which no known pathophysiologic link exists. DESIGN: Retrospective claims-based cohort study. SETTING: Six private U.S. health plans. SUBJECTS: Individuals who filled at least one prescription for a PPI (N=26,436) and those who never did (N=28,054) over 11 years. INTERVENTIONS: Multivariate linear regression of the association between a filled prescription for a PPI and a diagnosis of CAP in each 3-month quarter. In falsification analyses, we tested for implausible associations between PPI use in each quarter and rates of osteoarthritis, chest pain, urinary tract infection (UTI), deep venous thrombosis (DVT), skin infection, and rheumatoid arthritis. Independent variables included an indicator for whether a prescription for a PPI was filled in a given quarter, and quarterly indicators for various co-morbidities, age, income, geographic location, and marital status. KEY RESULTS: Compared to nonusers, those ever using a PPI had higher adjusted rates of CAP in quarters in which no prescription was filled (68 vs. 61 cases per 10,000 persons, p&amp;amp;amp;lt;0.001). Similar associations were noted for all conditions (e.g. chest pain, 336 vs. 282 cases, p&amp;lt;0.001; UTI, 151 vs. 139 cases, p<0.001). Among those ever using a PPI, quarters in which a prescription was filled were associated with higher adjusted rates of CAP (111 vs. 68 cases per 10,000, p<0.001) and all other conditions (e.g. chest pain, 597 vs. 336 cases, p<0.001; UTI, 186 vs. 151 cases, p<0.001), compared to quarters in which no prescription was filled. CONCLUSION: PPI use is associated with CAP, but also implausibly associated with common medical conditions.;,citation_author=Anupam B. Jena;,citation_author=Eric Sun;,citation_author=Dana P. Goldman;,citation_publication_date=2013-02;,citation_cover_date=2013-02;,citation_year=2013;,citation_issue=2;,citation_doi=10.1007/s11606-012-2211-5;,citation_issn=0884-8734, 1525-1497;,citation_volume=28;,citation_language=en-US;,citation_journal_title=Journal of General Internal Medicine;">
<meta name="citation_reference" content="citation_title=Sexually Transmitted Diseases Among Users of Erectile Dysfunction Drugs: Analysis of Claims Data;,citation_author=Anupam B Jena;,citation_author=Dana P Goldman;,citation_author=Amee Kamdar;,citation_author=Darius N Lakdawalla;,citation_author=Yang Lu;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Continual updating and monitoring of clinical prediction models: Time for dynamic prediction systems?;,citation_abstract=Clinical prediction models (CPMs) have become fundamental for risk stratification across healthcare. The CPM pipeline (development, validation, deployment, and impact assessment) is commonly viewed as a one-time activity, with model updating rarely considered and done in a somewhat ad hoc manner. This fails to address the fact that the performance of a CPM worsens over time as natural changes in populations and care pathways occur. CPMs need constant surveillance to maintain adequate predictive performance. Rather than reactively updating a developed CPM once evidence of deteriorated performance accumulates, it is possible to proactively adapt CPMs whenever new data becomes available. Approaches for validation then need to be changed accordingly, making validation a continuous rather than a discrete effort. As such, “living” (dynamic) CPMs represent a paradigm shift, where the analytical methods dynamically generate updated versions of a model through time; one then needs to validate the system rather than each subsequent model revision.;,citation_author=David A. Jenkins;,citation_author=Glen P. Martin;,citation_author=Matthew Sperrin;,citation_author=Richard D. Riley;,citation_author=Thomas P. A. Debray;,citation_author=Gary S. Collins;,citation_author=Niels Peek;,citation_publication_date=2021-12;,citation_cover_date=2021-12;,citation_year=2021;,citation_issue=1;,citation_doi=10.1186/s41512-020-00090-3;,citation_issn=2397-7523;,citation_volume=5;,citation_language=en-US;,citation_journal_title=Diagnostic and Prognostic Research;">
<meta name="citation_reference" content="citation_title=Cholestatic Alterations in the Critically Ill;,citation_author=Marc Jenniskens;,citation_author=Lies Langouche;,citation_author=Greet Van den Berghe;,citation_publication_date=2018-03;,citation_cover_date=2018-03;,citation_year=2018;,citation_issue=3;,citation_doi=10.1016/j.chest.2017.08.018;,citation_issn=00123692;,citation_volume=153;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Management of Refractory Vasodilatory Shock;,citation_author=Jacob C. Jentzer;,citation_author=Saraschandra Vallabhajosyula;,citation_author=Ashish K. Khanna;,citation_author=Lakhmir S. Chawla;,citation_author=Laurence W. Busse;,citation_author=Kianoush B. Kashani;,citation_publication_date=2018-08;,citation_cover_date=2018-08;,citation_year=2018;,citation_issue=2;,citation_doi=10.1016/j.chest.2017.12.021;,citation_issn=00123692;,citation_volume=154;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Mammogram Trials;,citation_author=Saurabh Jha;,citation_author=Jeffrey B. Ware;,citation_publication_date=2015-08;,citation_cover_date=2015-08;,citation_year=2015;,citation_issue=8;,citation_doi=10.1016/j.acra.2015.05.003;,citation_issn=1076-6332, 1878-4046;,citation_volume=22;,citation_language=en-US;,citation_journal_title=Academic Radiology;,citation_publisher=Elsevier;">
<meta name="citation_reference" content="citation_title=COUNTERPOINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? No;,citation_author=David Jimenez;,citation_author=Parth Rali;,citation_author=Kevin Doerschug;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_issue=6;,citation_doi=10.1016/j.chest.2022.01.037;,citation_issn=00123692;,citation_volume=161;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Rebuttal From Dr David Jimenez et al;,citation_author=David Jimenez;,citation_author=Parth Rali;,citation_author=Kevin Doerschug;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_issue=6;,citation_doi=10.1016/j.chest.2022.01.038;,citation_issn=00123692;,citation_volume=161;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Ten myths about albumin;,citation_author=Michael Joannidis;,citation_author=Christian J. Wiedermann;,citation_author=Marlies Ostermann;,citation_publication_date=2022-05;,citation_cover_date=2022-05;,citation_year=2022;,citation_issue=5;,citation_doi=10.1007/s00134-022-06655-8;,citation_issn=0342-4642, 1432-1238;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Prostacyclin in Intubated Patients with COVID-19 and Severe Endotheliopathy: A Multicenter, Randomized Clinical Trial;,citation_abstract=Rationale: The mortality in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who require mechanical ventilation remains high, and endotheliopathy has been implicated.;,citation_author=Pär I. Johansson;,citation_author=Peter Søe-Jensen;,citation_author=Morten H. Bestle;,citation_author=Niels E. Clausen;,citation_author=Klaus T. Kristiansen;,citation_author=Theis Lange;,citation_author=Jakob Stensballe;,citation_author=Anders Perner;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_issue=3;,citation_doi=10.1164/rccm.202108-1855OC;,citation_issn=1073-449X, 1535-4970;,citation_volume=205;,citation_language=en-US;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Ventilator Management and Respiratory Care After Cardiac Arrest: Oxygenation, Ventilation, Infection, and Injury;,citation_abstract=Return of spontaneous circulation after cardiac arrest results in a systemic inflammatory state called the post-cardiac arrest syndrome, which is characterized by oxidative stress, coagulopathy, neuronal injury, and organ dysfunction. Perturbations in oxygenation and ventilation may exacerbate secondary injury after cardiac arrest and have been shown to be associated with poor outcome. Further, patients who experience cardiac arrest are at risk for a number of other pulmonary complications. Up to 70%&nbsp;of patients experience early infection after cardiac arrest, and the respiratory tract is the most common source. Vigilance for early-onset pneumonia, as well as aggressive diagnosis and early antimicrobial agent administration are important components of critical care in this population. Patients who experience cardiac arrest are at risk for the development of ARDS. Risk factors include aspiration, pulmonary contusions (from chest compressions), systemic inflammation, and reperfusion injury. Early evidence suggests that they may benefit from ventilation with low tidal volumes. Meticulous attention to&nbsp;mechanical ventilation, early assessment and optimization of respiratory gas exchange, and&nbsp;therapies targeted at potential pulmonary complications may improve outcomes after cardiac&nbsp;arrest.;,citation_author=Nicholas J. Johnson;,citation_author=David J. Carlbom;,citation_author=David F. Gaieski;,citation_publication_date=2018-06;,citation_cover_date=2018-06;,citation_year=2018;,citation_issue=6;,citation_doi=10.1016/j.chest.2017.11.012;,citation_issn=1931-3543;,citation_pmid=29175085;,citation_volume=153;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Lung recruitment;,citation_author=Annemijn H. Jonkman;,citation_author=V. Marco Ranieri;,citation_author=Laurent Brochard;,citation_publication_date=2022-07;,citation_cover_date=2022-07;,citation_year=2022;,citation_issue=7;,citation_doi=10.1007/s00134-022-06715-z;,citation_issn=0342-4642, 1432-1238;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Air Pollution and Mortality at the Intersection of Race and Social Class;,citation_author=Kevin P. Josey;,citation_author=Scott W. Delaney;,citation_author=Xiao Wu;,citation_author=Rachel C. Nethery;,citation_author=Priyanka DeSouza;,citation_author=Danielle Braun;,citation_author=Francesca Dominici;,citation_publication_date=2023-03;,citation_cover_date=2023-03;,citation_year=2023;,citation_issue=0;,citation_doi=10.1056/NEJMsa2300523;,citation_issn=0028-4793;,citation_volume=0;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Trial of Thrombectomy 6 to 24 Hours after Stroke Due to Basilar-Artery Occlusion;,citation_author=Tudor G. Jovin;,citation_author=Chuanhui Li;,citation_author=Longfei Wu;,citation_author=Chuanjie Wu;,citation_author=Jian Chen;,citation_author=Changchun Jiang;,citation_author=Zhonghua Shi;,citation_author=Zongen Gao;,citation_author=Cunfeng Song;,citation_author=Wenhuo Chen;,citation_author=Ya Peng;,citation_author=Chen Yao;,citation_author=Ming Wei;,citation_author=Tong Li;,citation_author=Liping Wei;,citation_author=Guodong Xiao;,citation_author=Hua Yang;,citation_author=Ming Ren;,citation_author=Jiangang Duan;,citation_author=Xinfeng Liu;,citation_author=Qingwu Yang;,citation_author=Yuxiu Liu;,citation_author=Qingfeng Zhu;,citation_author=Wanchao Shi;,citation_author=Qiyi Zhu;,citation_author=Xiaobo Li;,citation_author=Zaiyu Guo;,citation_author=Qi Yang;,citation_author=Chengbei Hou;,citation_author=Wenbo Zhao;,citation_author=Qingfeng Ma;,citation_author=Yunzhou Zhang;,citation_author=Liqun Jiao;,citation_author=Hongqi Zhang;,citation_author=David S. Liebeskind;,citation_author=Hui Liang;,citation_author=Ashutosh P. Jadhav;,citation_author=Changming Wen;,citation_author=Scott Brown;,citation_author=Liangfu Zhu;,citation_author=Huawei Ye;,citation_author=Marc Ribo;,citation_author=Mingze Chang;,citation_author=Haiqing Song;,citation_author=Jun Chen;,citation_author=Xunming Ji;,citation_publication_date=2022-10;,citation_cover_date=2022-10;,citation_year=2022;,citation_issue=15;,citation_doi=10.1056/NEJMoa2207576;,citation_issn=0028-4793;,citation_volume=387;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Protective ventilation;,citation_author=Nicole P. Juffermans;,citation_author=Patricia R. M. Rocco;,citation_author=John G. Laffey;,citation_publication_date=2022-11;,citation_cover_date=2022-11;,citation_year=2022;,citation_issue=11;,citation_doi=10.1007/s00134-022-06820-z;,citation_issn=1432-1238;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Frailty in intensive care medicine must be measured, interpreted and taken into account!;,citation_author=Christian Jung;,citation_author=Bertrand Guidet;,citation_author=Hans Flaatten;,citation_author=Jesper Fjølner;,citation_author=Raphael Romano Bruno;,citation_author=Malte Kelm;,citation_author=Michael Beil;,citation_author=Sviri Sigal;,citation_author=Wojciech Szczeklik;,citation_author=Susannah Leaver;,citation_author=Dylan W. De Lange;,citation_author=the VIP study group;,citation_publication_date=2022-10;,citation_cover_date=2022-10;,citation_year=2022;,citation_doi=10.1007/s00134-022-06887-8;,citation_issn=1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Expiratory Flow Limitation During Mechanical Ventilation;,citation_author=Detajin Junhasavasdikul;,citation_author=Irene Telias;,citation_author=Domenico Luca Grieco;,citation_author=Lu Chen;,citation_author=Cinta Millan Gutierrez;,citation_author=Thomas Piraino;,citation_author=Laurent Brochard;,citation_publication_date=2018-10;,citation_cover_date=2018-10;,citation_year=2018;,citation_issue=4;,citation_doi=10.1016/j.chest.2018.01.046;,citation_issn=00123692;,citation_volume=154;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Causal inference for planning randomised critical care trials: Protocol for a scoping review;,citation_abstract=Background: Randomised clinical trials in critical care are prone to inconclusiveness owing, in part, to undue optimism about effect sizes and suboptimal accounting for heterogeneous treatment effects. Planned predictive enrichment based on secondary critical care data (often very rich with respect to both data types and temporal granularity) and causal inference methods may help overcome these challenges, but no overview exists about their use to this end.;,citation_author=Benjamin Skov Kaas-Hansen;,citation_author=Anders Granholm;,citation_author=Carl Thomas Anthon;,citation_author=Maj-Brit Nørregaard Kjær;,citation_author=Praleene Sivapalan;,citation_author=Mathias Maagaard;,citation_author=Olav Lilleholt Schjørring;,citation_author=Steen Kåre Fagerberg;,citation_author=Karen Louise Ellekjær;,citation_author=Jesper Mølgaard;,citation_author=Claus Thorn Ekstrøm;,citation_author=Morten Hylander Møller;,citation_author=Anders Perner;,citation_publication_date=2022-09;,citation_cover_date=2022-09;,citation_year=2022;,citation_doi=10.1111/aas.14142;,citation_issn=0001-5172, 1399-6576;,citation_language=en-US;,citation_journal_title=Acta Anaesthesiologica Scandinavica;">
<meta name="citation_reference" content="citation_title=Eliminating ambiguous treatment effects using estimands;,citation_abstract=Most reported treatment effects in medical research studies are ambiguously defined, which can lead to misinterpretation of study results. This is because most studies do not attempt to describe what the treatment effect represents, and instead require readers to deduce this based on the reported statistical methods. However, this approach is fraught, as many methods provide counterintuitive results. For example, some methods include data from all patients, yet the resulting treatment effect applies only to a subset of patients, whereas other methods will exclude certain patients while results will apply to everyone. Additionally, some analyses provide estimates pertaining to hypothetical settings where patients never die or discontinue treatment. Herein we introduce estimands as a solution to the aforementioned problem. An estimand is a clear description of what the treatment effect represents, thus saving readers the necessity of trying to infer this from study methods and potentially getting it wrong. We provide examples of how estimands can remove ambiguity from reported treatment effects and describe their current use in practice. The crux of our argument is that readers should not have to infer what investigators are estimating; they should be told explicitly.;,citation_author=Brennan C Kahan;,citation_author=Suzie Cro;,citation_author=Fan Li;,citation_author=Michael O Harhay;,citation_publication_date=2023-02;,citation_cover_date=2023-02;,citation_year=2023;,citation_doi=10.1093/aje/kwad036;,citation_issn=0002-9262;,citation_journal_title=American Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Estimands in published protocols of randomised trials: Urgent improvement needed;,citation_abstract=Background: An estimand is a precise description of the treatment effect to be estimated from a trial (the question) and is distinct from the methods of statistical analysis (how the question is to be answered). The potential use of estimands to improve trial research and reporting has been underpinned by the recent publication of the ICH E9(R1) Addendum on the use of estimands in clinical trials in 2019. We set out to assess how well estimands are described in published trial protocols. Methods: We reviewed 50 trial protocols published in October 2020 in Trials and BMJ Open. For each protocol, we determined whether the estimand for the primary outcome was explicitly stated, not stated but inferable (i.e. could be constructed from the information given), or not inferable. Results: None of the 50 trials explicitly described the estimand for the primary outcome, and in 74% of trials, it was impossible to infer the estimand from the information included in the protocol. The population attribute of the estimand could not be inferred in 36% of trials, the treatment condition attribute in 20%, the population-level summary measure in 34%, and the handling of intercurrent events in 60% (the strategy for handling non-adherence was not inferable in 32% of protocols, and the strategy for handling mortality was not inferable in 80% of the protocols for which it was applicable). Conversely, the outcome attribute was stated for all trials. In 28% of trials, three or more of the five estimand attributes could not be inferred. Conclusions: The description of estimands in published trial protocols is poor, and in most trials, it is impossible to understand exactly what treatment effect is being estimated. Given the utility of estimands to improve clinical research and reporting, this urgently needs to change.;,citation_author=Brennan C. Kahan;,citation_author=Tim P. Morris;,citation_author=Ian R. White;,citation_author=James Carpenter;,citation_author=Suzie Cro;,citation_publication_date=2021-12;,citation_cover_date=2021-12;,citation_year=2021;,citation_issue=1;,citation_doi=10.1186/s13063-021-05644-4;,citation_issn=1745-6215;,citation_volume=22;,citation_language=en-US;,citation_journal_title=Trials;">
<meta name="citation_reference" content="citation_title=Estimands in cluster-randomized trials: Choosing analyses that answer the right question;,citation_abstract=Cluster-randomized trials (CRTs) involve randomizing groups of individuals (e.g. hospitals, schools or villages) to different interventions. Various approaches exist for analysing CRTs but there has been little discussion around the treatment effects (estimands) targeted by each.We describe the different estimands that can be addressed through CRTs and demonstrate how choices between different analytic approaches can impact the interpretation of results by fundamentally changing the question being asked, or, equivalently, the target estimand.CRTs can address either the participant-average treatment effect (the average treatment effect across participants) or the cluster-average treatment effect (the average treatment effect across clusters). These two estimands can differ when participant outcomes or the treatment effect depends on the cluster size (referred to as “informative cluster size”), which can occur for reasons such as differences in staffing levels or types of participants between small and large clusters. Furthermore, common estimators, such as mixed-effects models or generalized estimating equations with an exchangeable working correlation structure, can produce biased estimates for both the participant-average and cluster-average treatment effects when cluster size is informative. We describe alternative estimators (independence estimating equations and cluster-level analyses) that are unbiased for CRTs even when informative cluster size is present.We conclude that careful specification of the estimand at the outset can ensure that the study question being addressed is clear and relevant, and, in turn, that the selected estimator provides an unbiased estimate of the desired quantity.;,citation_author=Brennan C Kahan;,citation_author=Fan Li;,citation_author=Andrew J Copas;,citation_author=Michael O Harhay;,citation_publication_date=2022-07;,citation_cover_date=2022-07;,citation_year=2022;,citation_doi=10.1093/ije/dyac131;,citation_issn=0300-5771;,citation_journal_title=International Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=The risks and rewards of covariate adjustment in randomized trials: An assessment of 12 outcomes from 8 studies;,citation_abstract=Background: Adjustment for prognostic covariates can lead to increased power in the analysis of randomized trials. However, adjusted analyses are not often performed in practice. Methods: We used simulation to examine the impact of covariate adjustment on 12 outcomes from 8 studies across a range of therapeutic areas. We assessed (1) how large an increase in power can be expected in practice; and (2) the impact of adjustment for covariates that are not prognostic. Results: Adjustment for known prognostic covariates led to large increases in power for most outcomes. When power was set to 80% based on an unadjusted analysis, covariate adjustment led to a median increase in power to 92.6% across the 12 outcomes (range 80.6 to 99.4%). Power was increased to over 85% for 8 of 12 outcomes, and to over 95% for 5 of 12 outcomes. Conversely, the largest decrease in power from adjustment for covariates that were not prognostic was from 80% to 78.5%. Conclusions: Adjustment for known prognostic covariates can lead to substantial increases in power, and should be routinely incorporated into the analysis of randomized trials. The potential benefits of adjusting for a small number of possibly prognostic covariates in trials with moderate or large sample sizes far outweigh the risks of doing so, and so should also be considered.;,citation_author=Brennan C Kahan;,citation_author=Vipul Jairath;,citation_author=Caroline J Doré;,citation_author=Tim P Morris;,citation_publication_date=2014-12;,citation_cover_date=2014-12;,citation_year=2014;,citation_issue=1;,citation_doi=10.1186/1745-6215-15-139;,citation_issn=1745-6215;,citation_volume=15;,citation_language=en-US;,citation_journal_title=Trials;">
<meta name="citation_reference" content="citation_title=Long-term Acute Care Hospital Utilization After Critical Illness;,citation_abstract=Objective To examine temporal trends in long-term acute care hospital utilization after an episode of critical illness among fee-for-service Medicare beneficiaries aged 65 years or older. Design, Setting, and Patients Retrospective cohort study using the Medicare Provider Analysis and Review files from 1997 to 2006. We included all Medicare hospitalizations involving admission to an intensive care unit of an acute care, nonfederal hospital within the continental United States. Main Outcome Measures Overall long-term acute care utilization, associated costs, and survival following transfer. Results The number of long-term acute care hospitals in the United States increased at a mean rate of 8.8% per year, from 192 in 1997 to 408 in 2006. During that time, the annual number of long-term acute care admissions after critical illness increased from 13 732 to 40 353, with annual costs increasing from $484 million to $1.325 billion. The age-standardized population incidence of long-term acute care utilization after critical illness increased from 38.1 per 100 000 in 1997 to 99.7 per 100 000 in 2006, with greater use among male individuals and black individuals in all periods. Over time, transferred patients had higher numbers of comorbidities (5.0 in 19972000 vs 5.8 in 2004-2006, PϽ.001) and were more likely to receive mechanical ventilation at the long-term acute care hospital (16.4% in 1997-2000 vs 29.8% in 20042006, PϽ.001). One-year mortality after long-term acute care hospital admission was high throughout the study period: 50.7% in 1997-2000 and 52.2% in 2004-2006. Conclusions Long-term acute care hospital utilization after critical illness is common and increasing. Survival among Medicare beneficiaries transferred to long-term acute care after critical illness is poor.;,citation_author=Jeremy M. Kahn;,citation_publication_date=2010-06;,citation_cover_date=2010-06;,citation_year=2010;,citation_issue=22;,citation_doi=10.1001/jama.2010.761;,citation_issn=0098-7484;,citation_volume=303;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Noninferiority Trials: Is a New Treatment Almost as Effective as Another?;,citation_author=Amy H. Kaji;,citation_author=Roger J. Lewis;,citation_publication_date=2015-06;,citation_cover_date=2015-06;,citation_year=2015;,citation_issue=23;,citation_doi=10.1001/jama.2015.6645;,citation_issn=1538-3598;,citation_pmid=26080342;,citation_volume=313;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Statins in COPD;,citation_author=Or Kalchiem-Dekel;,citation_author=Robert M. Reed;,citation_publication_date=2017-09;,citation_cover_date=2017-09;,citation_year=2017;,citation_issue=3;,citation_doi=10.1016/j.chest.2017.04.156;,citation_issn=00123692;,citation_volume=152;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19;,citation_abstract=BACKGROUND Severe coronavirus disease 2019 (Covid-19) is associated with dysregulated inflammation. The effects of combination treatment with baricitinib, a Janus kinase inhibitor, plus remdesivir are not known. METHODS We conducted a double-blind, randomized, placebo-controlled trial evaluating baricitinib plus remdesivir in hospitalized adults with Covid-19. All the patients received remdesivir (\leq10 days) and either baricitinib (\leq14 days) or placebo (control). The primary outcome was the time to recovery. The key secondary outcome was clinical status at day 15. RESULTS A total of 1033 patients underwent randomization (with 515 assigned to combination treatment and 518 to control). Patients receiving baricitinib had a median time to recovery of 7 days (95% confidence interval [CI], 6 to 8), as compared with 8 days (95% CI, 7 to 9) with control (rate ratio for recovery, 1.16; 95% CI, 1.01 to 1.32; P = 0.03), and a 30% higher odds of improvement in clinical status at day 15 (odds ratio, 1.3; 95% CI, 1.0 to 1.6). Patients receiving high-flow oxygen or noninvasive ventilation at enrollment had a time to recovery of 10 days with combination treatment and 18 days with control (rate ratio for recovery, 1.51; 95% CI, 1.10 to 2.08). The 28-day mortality was 5.1% in the combination group and 7.8% in the control group (hazard ratio for death, 0.65; 95% CI, 0.39 to 1.09). Serious adverse events were less frequent in the combination group than in the control group (16.0% vs. 21.0%; difference, -5.0 percentage points; 95% CI, -9.8 to -0.3; P = 0.03), as were new infections (5.9% vs. 11.2%; difference, -5.3 percentage points; 95% CI, -8.7 to -1.9; P = 0.003). The authors’ full names, academic degrees, and affiliations are listed in the Appendix. Address reprint requests to Dr. Kalil at the University of Nebraska Medical Center, 985400 Nebraska Medicine, Omaha, NE 68198-5400, or at akalil@ unmc.edu. *A complete list of members of the ACTT-2 Study Group is provided in the Supplementary Appendix, available at NEJM.org. This article was published on December 11, 2020, and updated on January 5, 2021, at NEJM.org. N Engl J Med 2021;384:795-807. DOI: 10.1056/NEJMoa2031994 Copyright © 2020 Massachusetts Medical Society. CONCLUSIONS Baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation. The combination was associated with fewer serious adverse events. (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT04401579.);,citation_author=Andre C. Kalil;,citation_author=Thomas F. Patterson;,citation_author=Aneesh K. Mehta;,citation_author=Kay M. Tomashek;,citation_author=Cameron R. Wolfe;,citation_author=Varduhi Ghazaryan;,citation_author=Vincent C. Marconi;,citation_author=Guillermo M. Ruiz-Palacios;,citation_author=Lanny Hsieh;,citation_author=Susan Kline;,citation_author=Victor Tapson;,citation_author=Nicole M. Iovine;,citation_author=Mamta K. Jain;,citation_author=Daniel A. Sweeney;,citation_author=Hana M. El Sahly;,citation_author=Angela R. Branche;,citation_author=Justino Regalado Pineda;,citation_author=David C. Lye;,citation_author=Uriel Sandkovsky;,citation_author=Anne F. Luetkemeyer;,citation_author=Stuart H. Cohen;,citation_author=Robert W. Finberg;,citation_author=Patrick E. H. Jackson;,citation_author=Babafemi Taiwo;,citation_author=Catharine I. Paules;,citation_author=Henry Arguinchona;,citation_author=Nathaniel Erdmann;,citation_author=Neera Ahuja;,citation_author=Maria Frank;,citation_author=Myoung-don Oh;,citation_author=Eu-Suk Kim;,citation_author=Seow Y. Tan;,citation_author=Richard A. Mularski;,citation_author=Henrik Nielsen;,citation_author=Philip O. Ponce;,citation_author=Barbara S. Taylor;,citation_author=LuAnn Larson;,citation_author=Nadine G. Rouphael;,citation_author=Youssef Saklawi;,citation_author=Valeria D. Cantos;,citation_author=Emily R. Ko;,citation_author=John J. Engemann;,citation_author=Alpesh N. Amin;,citation_author=Miki Watanabe;,citation_author=Joanne Billings;,citation_author=Marie-Carmelle Elie;,citation_author=Richard T. Davey;,citation_author=Timothy H. Burgess;,citation_author=Jennifer Ferreira;,citation_author=Michelle Green;,citation_author=Mat Makowski;,citation_author=Anabela Cardoso;,citation_author=Stephanie Bono;,citation_author=Tyler Bonnett;,citation_author=Michael Proschan;,citation_author=Gregory A. Deye;,citation_author=Walla Dempsey;,citation_author=Seema U. Nayak;,citation_author=Lori E. Dodd;,citation_author=John H. Beigel;,citation_publication_date=2021-03;,citation_cover_date=2021-03;,citation_year=2021;,citation_issue=9;,citation_doi=10.1056/NEJMoa2031994;,citation_issn=0028-4793, 1533-4406;,citation_volume=384;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Bayesian Methodology for the Design and Interpretation of Clinical Trials in Critical Care Medicine: A Primer for Clinicians;,citation_author=Andre C. Kalil;,citation_author=Junfeng Sun;,citation_publication_date=2014-10;,citation_cover_date=2014-10;,citation_year=2014;,citation_issue=10;,citation_doi=10.1097/CCM.0000000000000576;,citation_issn=0090-3493;,citation_volume=42;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: A double-bind, randomised, placebo-controlled, phase 3 trial;,citation_abstract=Background Functional impairment of interferon, a natural antiviral component of the immune system, is associated with the pathogenesis and severity of COVID-19. We aimed to compare the efficacy of interferon beta-1a in combination with remdesivir compared with remdesivir alone in hospitalised patients with COVID-19.;,citation_author=Andre C Kalil;,citation_author=Aneesh K Mehta;,citation_author=Thomas F Patterson;,citation_author=Nathaniel Erdmann;,citation_author=Carlos A Gomez;,citation_author=Mamta K Jain;,citation_author=Cameron R Wolfe;,citation_author=Guillermo M Ruiz-Palacios;,citation_author=Susan Kline;,citation_author=Justino Regalado Pineda;,citation_author=Anne F Luetkemeyer;,citation_author=Michelle S Harkins;,citation_author=Patrick E H Jackson;,citation_author=Nicole M Iovine;,citation_author=Victor F Tapson;,citation_author=Myoung-don Oh;,citation_author=Jennifer A Whitaker;,citation_author=Richard A Mularski;,citation_author=Catharine I Paules;,citation_author=Dilek Ince;,citation_author=Jin Takasaki;,citation_author=Daniel A Sweeney;,citation_author=Uriel Sandkovsky;,citation_author=David L Wyles;,citation_author=Elizabeth Hohmann;,citation_author=Kevin A Grimes;,citation_author=Robert Grossberg;,citation_author=Maryrose Laguio-Vila;,citation_author=Allison A Lambert;,citation_author=Diego Lopez de Castilla;,citation_author=EuSuk Kim;,citation_author=LuAnn Larson;,citation_author=Claire R Wan;,citation_author=Jessica J Traenkner;,citation_author=Philip O Ponce;,citation_author=Jan E Patterson;,citation_author=Paul A Goepfert;,citation_author=Theresa A Sofarelli;,citation_author=Satish Mocherla;,citation_author=Emily R Ko;,citation_author=Alfredo Ponce de Leon;,citation_author=Sarah B Doernberg;,citation_author=Robert L Atmar;,citation_author=Ryan C Maves;,citation_author=Fernando Dangond;,citation_author=Jennifer Ferreira;,citation_author=Michelle Green;,citation_author=Mat Makowski;,citation_author=Tyler Bonnett;,citation_author=Tatiana Beresnev;,citation_author=Varduhi Ghazaryan;,citation_author=Walla Dempsey;,citation_author=Seema U Nayak;,citation_author=Lori Dodd;,citation_author=Kay M Tomashek;,citation_author=John H Beigel;,citation_author=Angela Hewlett;,citation_author=Barbara S Taylor;,citation_author=Jason E Bowling;,citation_author=Ruth C Serrano;,citation_author=Nadine G Rouphael;,citation_author=Zanthia Wiley;,citation_author=Varun K Phadke;,citation_author=Laura Certain;,citation_author=Hannah N Imlay;,citation_author=John J Engemann;,citation_author=Emmanuel B Walter;,citation_author=Jessica Meisner;,citation_author=Sandra Rajme;,citation_author=Joanne Billings;,citation_author=Hyun Kim;,citation_author=Jose A Martinez-Orozco;,citation_author=Nora Bautista Felix;,citation_author=Sammy T Elmor;,citation_author=Laurel R Bristow;,citation_author=Gregory Mertz;,citation_author=Nestor Sosa;,citation_author=Taison D Bell;,citation_author=Miranda J West;,citation_author=Marie-Carmelle Elie-Turenne;,citation_author=Jonathan Grein;,citation_author=Fayyaz Sutterwala;,citation_author=Pyoeng Gyun Choe;,citation_author=Chang Kyung Kang;,citation_author=Hana M El Sahly;,citation_author=Kevin S Rhie;,citation_author=Rezhan H Hussein;,citation_author=Patricia L Winokur;,citation_author=Ayako Mikami;,citation_author=Sho Saito;,citation_author=Constance A Benson;,citation_author=Kimberly McConnell;,citation_author=Mezgebe Berhe;,citation_author=Emma Dishner;,citation_author=Maria G Frank;,citation_author=Ellen Sarcone;,citation_author=Pierre-Cedric B Crouch;,citation_author=Hannah Jang;,citation_author=Nikolaus Jilg;,citation_author=Katherine Perez;,citation_author=Charles Janak;,citation_author=Valeria D Cantos;,citation_author=Paulina A Rebolledo;,citation_author=John Gharbin;,citation_author=Barry S Zingman;,citation_author=Paul F Riska;,citation_author=Ann R Falsey;,citation_author=Edward E Walsh;,citation_author=Angela R Branche;,citation_author=Henry Arguinchona;,citation_author=Christa Arguinchona;,citation_author=Jason W Van Winkle;,citation_author=Diego F Zea;,citation_author=Jongtak Jung;,citation_author=Kyoung-Ho Song;,citation_author=Hong Bin Kim;,citation_author=Jay Dwyer;,citation_author=Emma Bainbridge;,citation_author=David C Hostler;,citation_author=Jordanna M Hostler;,citation_author=Brian T Shahan;,citation_author=Lanny Hsieh;,citation_author=Alpesh N Amin;,citation_author=Miki Watanabe;,citation_author=William R Short;,citation_author=Pablo Tebas;,citation_author=Jillian T Baron;,citation_author=Neera Ahuja;,citation_author=Evelyn Ling;,citation_author=Minjoung Go;,citation_author=Otto O Yang;,citation_author=Jenny Ahn;,citation_author=Rubi Arias;,citation_author=Rekha R Rapaka;,citation_author=Fleesie A Hubbard;,citation_author=James D Campbell;,citation_author=Stuart H Cohen;,citation_author=George R Thompson;,citation_author=Melony Chakrabarty;,citation_author=Stephanie N Taylor;,citation_author=Najy Masri;,citation_author=Alisha Lacour;,citation_author=Tida Lee;,citation_author=Tahaniyat Lalani;,citation_author=David A Lindholm;,citation_author=Ana Elizabeth Markelz;,citation_author=Katrin Mende;,citation_author=Christopher J Colombo;,citation_author=Christina Schofield;,citation_author=Rhonda E Colombo;,citation_author=Faheem Guirgis;,citation_author=Mark Holodniy;,citation_author=Aarthi Chary;,citation_author=Mary Bessesen;,citation_author=Noreen A Hynes;,citation_author=Lauren M Sauer;,citation_author=Vincent C Marconi;,citation_author=Abeer Moanna;,citation_author=Telisha Harrison;,citation_author=David C Lye;,citation_author=Sean W X Ong;,citation_author=Po Ying Chia;,citation_author=Nikhil Huprikar;,citation_author=Anuradha Ganesan;,citation_author=Christian Madar;,citation_author=Richard M Novak;,citation_author=Andrea Wendrow;,citation_author=Scott A Borgetti;,citation_author=Sarah L George;,citation_author=Daniel F Hoft;,citation_author=James D Brien;,citation_author=Susan L F McLellan;,citation_author=Corri Levine;,citation_author=Joy Nock;,citation_author=Seow Yen Tan;,citation_author=Humaira Shafi;,citation_author=Jaime M F Chien;,citation_author=Keith Candiotti;,citation_author=Robert W Finberg;,citation_author=Jennifer P Wang;,citation_author=Mireya Wessolossky;,citation_author=Gregory C Utz;,citation_author=Susan E Chambers;,citation_author=David S Stephens;,citation_author=Timothy H Burgess;,citation_author=Julia Rozman;,citation_author=Yann Hyvert;,citation_author=Andrea Seitzinger;,citation_author=Anu Osinusi;,citation_author=Huyen Cao;,citation_author=Kevin K Chung;,citation_author=Tom M Conrad;,citation_author=Kaitlyn Cross;,citation_author=Jill A El-Khorazaty;,citation_author=Heather Hill;,citation_author=Stephanie Pettibone;,citation_author=Michael R Wierzbicki;,citation_author=Nikki Gettinger;,citation_author=Theresa Engel;,citation_author=Teri Lewis;,citation_author=Jing Wang;,citation_author=Gregory A Deye;,citation_author=Effie Nomicos;,citation_author=Rhonda Pikaart-Tautges;,citation_author=Mohamed Elsafy;,citation_author=Robert Jurao;,citation_author=Hyung Koo;,citation_author=Michael Proschan;,citation_author=Richard Davey;,citation_author=Tammy Yokum;,citation_author=Janice Arega;,citation_author=Ruth Florese;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_doi=10.1016/S2213-2600(21)00384-2;,citation_issn=22132600;,citation_language=en-US;,citation_journal_title=The Lancet Respiratory Medicine;">
<meta name="citation_reference" content="citation_title=Lack of Benefit of High-Dose Vitamin C, Thiamine, and Hydrocortisone Combination for Patients With Sepsis;,citation_abstract=The use of vitamin C for treatment of patients with sepsis has generated substantial interest and controversy. In 2017, a single-center observational study suggested that the combination of high-dose vitamin C, thiamine, and hydrocortisone in conjunction with usual care was associated with reduced mortality (8.5% for combination treatment vs 40.4% for control). Despite the small sample size (94 patients), lack of concurrent controls and randomization, and important baseline imbalances between study groups, the study garnered significant attention. There were reports that some physicians were keen to adopt the strategy as part of routine practice, even though this approach had not been tested in a rigorous clinical trial.;,citation_author=Andre C. Kalil;,citation_publication_date=2020-02;,citation_cover_date=2020-02;,citation_year=2020;,citation_issue=5;,citation_doi=10.1001/jama.2019.22438;,citation_issn=0098-7484;,citation_volume=323;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Remdesivir saves lives. Were 3 years needed to learn that?;,citation_author=Andre C Kalil;,citation_publication_date=2023-02;,citation_cover_date=2023-02;,citation_year=2023;,citation_doi=10.1016/S2213-2600(23)00036-X;,citation_issn=22132600;,citation_language=en-US;,citation_journal_title=The Lancet Respiratory Medicine;">
<meta name="citation_reference" content="citation_title=Vitamin C and Sepsis: Is Bayesian Reanalysis Useful to Translate the Results of Frequentist Randomized Trials?*;,citation_author=Andre C. Kalil;,citation_author=Steven Q. Simpson;,citation_publication_date=2023-08;,citation_cover_date=2023-08;,citation_year=2023;,citation_issue=8;,citation_doi=10.1097/CCM.0000000000005939;,citation_issn=0090-3493;,citation_volume=51;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Why are clinicians not embracing the results from pivotal clinical trials in severe sepsis? A bayesian analysis;,citation_abstract=BACKGROUND: Five pivotal clinical trials (Intensive Insulin Therapy; Recombinant Human Activated Protein C [rhAPC]; Low-Tidal Volume; Low-Dose Steroid; Early Goal-Directed Therapy [EGDT]) demonstrated mortality reduction in patients with severe sepsis and expert guidelines have recommended them to clinical practice. Yet, the adoption of these therapies remains low among clinicians. OBJECTIVES: We selected these five trials and asked: Question 1–What is the current probability that the new therapy is not better than the standard of care in my patient with severe sepsis? Question 2–What is the current probability of reducing the relative risk of death (RRR) of my patient with severe sepsis by meaningful clinical thresholds (RRR &amp;amp;amp;gt;15%; &amp;gt;20%; >25%)? METHODS: Bayesian methodologies were applied to this study. Odds ratio (OR) was considered for Question 1, and RRR was used for Question 2. We constructed prior distributions (enthusiastic; mild, moderate, and severe skeptic) based on various effective sample sizes of other relevant clinical trials (unfavorable evidence). Posterior distributions were calculated by combining the prior distributions and the data from pivotal trials (favorable evidence). MAIN FINDINGS: Answer 1–The analysis based on mild skeptic prior shows beneficial results with the Intensive Insulin, rhAPC, and Low-Tidal Volume trials, but not with the Low-Dose Steroid and EGDT trials. All trials’ results become unacceptable by the analyses using moderate or severe skeptic priors. Answer 2–If we aim for a RRR>15%, the mild skeptic analysis shows that the current probability of reducing death by this clinical threshold is 88% for the Intensive Insulin, 62-65% for the Low-Tidal Volume, rhAPC, EGDT trials, and 17% for the Low-Dose Steroid trial. The moderate and severe skeptic analyses show no clinically meaningful reduction in the risk of death for all trials. If we aim for a RRR >20% or >25%, all probabilities of benefits become lower independent of the degree of skepticism. CONCLUSIONS: Our clinical threshold analysis offers a new bedside tool to be directly applied to the care of patients with severe sepsis. Our results demonstrate that the strength of evidence (statistical and clinical) is weak for all trials, particularly for the Low-Dose Steroid and EGDT trials. It is essential to replicate the results of each of these five clinical trials in confirmatory studies if we want to provide patient care based on scientifically sound evidence.;,citation_author=Andre C. Kalil;,citation_author=Junfeng Sun;,citation_publication_date=2008-05;,citation_cover_date=2008-05;,citation_year=2008;,citation_issue=5;,citation_doi=10.1371/journal.pone.0002291;,citation_issn=1932-6203;,citation_pmid=18509455;,citation_volume=3;,citation_language=en-US;,citation_journal_title=PloS One;">
<meta name="citation_reference" content="citation_title=Association of Recent Use of Non–Vitamin K Antagonist Oral Anticoagulants With Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Treated With Alteplase;,citation_abstract=OBJECTIVE To evaluate the safety and functional outcomes of intravenous alteplase among patients who were taking NOACs prior to stroke and compare outcomes with patients who were not taking long-term anticoagulants. DESIGN, SETTING, AND PARTICIPANTS A retrospective cohort study of 163 038 patients with acute ischemic stroke either taking NOACs or not taking anticoagulants prior to stroke and treated with intravenous alteplase within 4.5 hours of symptom onset at 1752 US hospitals participating in the Get With The Guidelines–Stroke program between April 2015 and March 2020, with complementary data from the Addressing Real-world Anticoagulant Management Issues in Stroke registry. EXPOSURES Prestroke treatment with NOACs within 7 days prior to alteplase treatment. MAIN OUTCOMES AND MEASURES The primary outcome was symptomatic intracranial hemorrhage occurring within 36 hours after intravenous alteplase administration. There were 4 secondary safety outcomes, including inpatient mortality, and 7 secondary functional outcomes assessed at hospital discharge, including the proportion of patients discharged home. RESULTS Of 163 038 patients treated with intravenous alteplase (median age, 70 [IQR, 59 to 81] years; 49.1% women), 2207 (1.4%) were taking NOACs and 160 831 (98.6%) were not taking anticoagulants prior to their stroke. Patients taking NOACs were older (median age, 75 [IQR, 64 to 82] years vs 70 [IQR, 58 to 81] years for those not taking anticoagulants), had a higher prevalence of cardiovascular comorbidities, and experienced more severe strokes (median National Institutes of Health Stroke Scale score, 10 [IQR, 5 to 17] vs 7 [IQR, 4 to 14]) (all standardized differences &amp;amp;amp;gt;10). The unadjusted rate of symptomatic intracranial hemorrhage was 3.7% (95% CI, 2.9% to 4.5%) for patients taking NOACs vs 3.2% (95% CI, 3.1% to 3.3%) for patients not taking anticoagulants. After adjusting for baseline clinical factors, the risk of symptomatic intracranial hemorrhage was not significantly different between groups (adjusted odds ratio [OR], 0.88 [95% CI, 0.70 to 1.10]; adjusted risk difference [RD], -0.51% [95% CI, -1.36% to 0.34%]). There were no significant differences in the secondary safety outcomes, including inpatient mortality (6.3% for patients taking NOACs vs 4.9% for patients not taking anticoagulants; adjusted OR, 0.84 [95% CI, 0.69 to 1.01]; adjusted RD, -1.20% [95% CI, -2.39% to -0%]). Of the secondary functional outcomes, 4 of 7 showed significant differences in favor of the NOAC group after adjustment, including the proportion of patients discharged home (45.9% vs 53.6% for patients not taking anticoagulants; adjusted OR, 1.17 [95% CI, 1.06 to 1.29]; adjusted RD, 3.84% [95% CI, 1.46% to 6.22%]). CONCLUSIONS AND RELEVANCE Among patients with acute ischemic stroke treated with intravenous alteplase, use of NOACs within the preceding 7 days, compared with no use of anticoagulants, was not associated with a significantly increased risk of intracranial hemorrhage.;,citation_author=Wayneho Kam;,citation_author=DaJuanicia N. Holmes;,citation_author=Adrian F. Hernandez;,citation_author=Jeffrey L. Saver;,citation_author=Gregg C. Fonarow;,citation_author=Eric E. Smith;,citation_author=Deepak L. Bhatt;,citation_author=Lee H. Schwamm;,citation_author=Mathew J. Reeves;,citation_author=Roland A. Matsouaka;,citation_author=Yosef M. Khan;,citation_author=Martin Unverdorben;,citation_author=Mary C. Birmingham;,citation_author=Patrick D. Lyden;,citation_author=Andrew W. Asimos;,citation_author=Dorothea Altschul;,citation_author=Timothy L. Schoonover;,citation_author=Mouhammad A. Jumaa;,citation_author=Jason T. Nomura;,citation_author=Muhammad Fareed K. Suri;,citation_author=S. Arthur Moore;,citation_author=Eugene F. Lafranchise;,citation_author=DaiWai Olson;,citation_author=Eric D. Peterson;,citation_author=Ying Xian;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_issue=8;,citation_doi=10.1001/jama.2022.0948;,citation_issn=0098-7484;,citation_volume=327;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Atrial Fibrillation and Mechanisms of Stroke;,citation_author=Hooman Kamel;,citation_author=Peter M. Okin;,citation_author=Mitchell S. V. Elkind;,citation_author=Costantino Iadecola;,citation_publication_date=2016-03;,citation_cover_date=2016-03;,citation_year=2016;,citation_issue=3;,citation_doi=10.1161/STROKEAHA.115.012004;,citation_volume=47;,citation_journal_title=Stroke;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=Mediators of Atherosclerosis in South Asians Living in America (MASALA) Study: Objectives, Methods, and Cohort Description;,citation_abstract=Background South Asians (individuals from India, Pakistan, Bangladesh, Nepal, and Sri Lanka) have high rates of cardiovascular disease (CVD) that cannot be explained by traditional risk factors. There are few prospective cohort studies investigating antecedents of CVD in South Asians. Objectives The Mediators of Atherosclerosis in South Asians Living in America (MASALA) study is investigating the prevalence, correlates, and outcomes associated with subclinical CVD in a population-based sample of South Asian men and women age 40–79 years at 2 US clinical field centers. Population and Methodology This cohort is similar in methods and measures to the Multi-Ethnic Study of Atherosclerosis (MESA) to allow for efficient cross-ethnic comparisons. Measurements obtained at the baseline examination include sociodemographic information, lifestyle and psychosocial factors, standard CVD risk factors, oral glucose tolerance testing, electrocardiography, assessment of microalbuminuria, ankle and brachial blood pressures, carotid intima-media wall thickness using ultrasonography, coronary artery calcium measurement, and abdominal visceral fat measurement using computed tomography. Blood samples will be assayed for biochemical risk factors. Between October 2010 and March 2013, we enrolled 906 South Asians with mean age of 55  9 years (46% women; 98% immigrants who have lived 27  11 years in the United States). The sociodemographic characteristics of this cohort are representative of US South Asians. Participants are being followed with annual telephone calls for identification of CVD events including acute myocardial infarction and other coronary heart disease, stroke, peripheral vascular disease, congestive heart failure, therapeutic interventions for CVD, and mortality. Conclusions The MASALA study will provide novel data on the prevalence and associations of cardiovascular risk factors and subclinical atherosclerosis in South Asians living in the United States.;,citation_author=Alka M. Kanaya;,citation_author=Namratha Kandula;,citation_author=David Herrington;,citation_author=Matthew J. Budoff;,citation_author=Stephen Hulley;,citation_author=Eric Vittinghoff;,citation_author=Kiang Liu;,citation_publication_date=2013;,citation_cover_date=2013;,citation_year=2013;,citation_issue=12;,citation_doi=10.1002/clc.22219;,citation_issn=1932-8737;,citation_volume=36;,citation_language=en-US;,citation_journal_title=Clinical Cardiology;">
<meta name="citation_reference" content="citation_title=Nonaneurysmal Perimesencephalic Subarachnoid Hemorrhage: Diagnosis, Pathophysiology, Clinical Characteristics, and Long-Term Outcome;,citation_author=Anish Kapadia;,citation_author=Tom A. Schweizer;,citation_author=Julian Spears;,citation_author=Michael Cusimano;,citation_author=R. Loch Macdonald;,citation_publication_date=2014-12;,citation_cover_date=2014-12;,citation_year=2014;,citation_issue=6;,citation_doi=10.1016/j.wneu.2014.07.006;,citation_issn=18788750;,citation_volume=82;,citation_language=en-US;,citation_journal_title=World Neurosurgery;">
<meta name="citation_reference" content="citation_title=Diagnosis and Management of Acute Myelopathies;,citation_abstract=Background: Acute myelopathies represent a heterogeneous group of disorders with distinct etiologies, clinical and radiologic features, and prognoses. Transverse myelitis (TM) is a prototype member of this group in which an immune-mediated process causes neural injury to the spinal cord, resulting in varying degrees of weakness, sensory alterations, and autonomic dysfunction. TM may exist as part of a multifocal CNS disease (eg, MS), multisystemic disease (eg, systemic lupus erythematosus), or as an isolated, idiopathic entity. Review Summary: In this article, we summarize recent classification and diagnostic schemes, which provide a framework for the diagnosis and management of patients with acute myelopathy. Additionally, we review the state of current knowledge about the epidemiology, natural history, immunopathogenesis, and treatment strategies for patients with TM. Conclusions: Our understanding of the classification, diagnosis, pathogenesis, and treatment of TM has recently begun to expand dramatically. With more rigorous criteria applied to distinguish acute myelopathies and with an emerging understanding of immunopathogenic events that underlie TM, it may now be possible to effectively initiate treatments in many of these disorders. Through the investigation of TM, we are also gaining a broader appreciation of the mechanisms that lead to autoimmune neurologic diseases in general.;,citation_author=Adam I. Kaplin;,citation_author=Chitra Krishnan;,citation_author=Deepa M. Deshpande;,citation_author=Carlos A. Pardo;,citation_author=Douglas A. Kerr;,citation_publication_date=2005-01;,citation_cover_date=2005-01;,citation_year=2005;,citation_issue=1;,citation_doi=10.1097/01.nrl.0000149975.39201.0b;,citation_issn=1074-7931;,citation_volume=11;,citation_language=en-US;,citation_journal_title=The Neurologist;">
<meta name="citation_reference" content="citation_title=Coronavirus Disease 2019 as Cause of Viral Sepsis: A Systematic Review and Meta-Analysis;,citation_author=Eleni Karakike;,citation_author=Evangelos J. Giamarellos-Bourboulis;,citation_author=Miltiades Kyprianou;,citation_author=Carolin Fleischmann-Struzek;,citation_author=Mathias W. Pletz;,citation_author=Mihai G. Netea;,citation_author=Konrad Reinhart;,citation_author=Evdoxia Kyriazopoulou;,citation_publication_date=2021-07;,citation_cover_date=2021-07;,citation_year=2021;,citation_doi=10.1097/CCM.0000000000005195;,citation_issn=0090-3493;,citation_volume=Publish Ahead of Print;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Tracking excess mortality across countries during the COVID-19 pandemic with the World Mortality Dataset;,citation_abstract=Comparing the impact of the COVID-19 pandemic between countries or across time is difficult because the reported numbers of cases and deaths can be strongly affected by testing capacity and reporting policy. Excess mortality, defined as the increase in all-cause mortality relative to the expected mortality, is widely considered as a more objective indicator of the COVID-19 death toll. However, there has been no global, frequently updated repository of the all-cause mortality data across countries. To fill this gap, we have collected weekly, monthly, or quarterly all-cause mortality data from 103 countries and territories, openly available as the regularly updated World Mortality Dataset. We used this dataset to compute the excess mortality in each country during the COVID-19 pandemic. We found that in several worst-affected countries (Peru, Ecuador, Bolivia, Mexico) the excess mortality was above 50% of the expected annual mortality (Peru, Ecuador, Bolivia, Mexico) or above 400 excess deaths per 100,000 population (Peru, Bulgaria, North Macedonia, Serbia). At the same time, in several other countries (e.g. Australia and New Zealand) mortality during the pandemic was below the usual level, presumably due to social distancing measures decreasing the non-COVID infectious mortality. Furthermore, we found that while many countries have been reporting the COVID-19 deaths very accurately, some countries have been substantially underreporting their COVID-19 deaths (e.g. Nicaragua, Russia, Uzbekistan), by up to two orders of magnitude (Tajikistan). Our results highlight the importance of open and rapid all-cause mortality reporting for pandemic monitoring.;,citation_author=Ariel Karlinsky;,citation_author=Dmitry Kobak;,citation_editor=Miles P Davenport;,citation_editor=Marc Lipsitch;,citation_editor=Marc Lipsitch;,citation_editor=Lone Simonsen;,citation_editor=Ayesha Mahmud;,citation_publication_date=2021-06;,citation_cover_date=2021-06;,citation_year=2021;,citation_doi=10.7554/eLife.69336;,citation_issn=2050-084X;,citation_volume=10;,citation_journal_title=eLife;,citation_publisher=eLife Sciences Publications, Ltd;">
<meta name="citation_reference" content="citation_title=Blood Pressure Trajectories and Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke;,citation_abstract=BACKGROUND: Data on systolic blood pressure (SBP) trajectories in the first 24 hours after endovascular thrombectomy (EVT) in acute ischemic stroke are limited. We sought to identify these trajectories and their relationship to outcomes. METHODS: We combined individual-level data from 5 studies of patients with acute ischemic stroke who underwent EVT and had individual blood pressure values after the end of the procedure. We used group-based trajectory analysis to identify the number and shape of SBP trajectories post-EVT. We used mixed effects regression models to identify associations between trajectory groups and outcomes adjusting for potential confounders and reported the respective adjusted odds ratios (aORs) and common odds ratios. RESULTS: There were 2640 total patients with acute ischemic stroke included in the analysis. The most parsimonious model identified 4 distinct SBP trajectories, that is, general directional patterns after repeated SBP measurements: high, moderatehigh, moderate, and low. Patients in the higher blood pressure trajectory groups were older, had a higher prevalence of vascular risk factors, presented with more severe stroke syndromes, and were less likely to achieve successful recanalization after the EVT. In the adjusted analyses, only patients in the high-SBP trajectory were found to have significantly higher odds of early neurological deterioration (aOR, 1.84 [95% CI, 1.20–2.82]), intracranial hemorrhage (aOR, 1.84 [95% CI, 1.31–2.59]), mortality (aOR, 1.75 [95% CI, 1.21–2.53), death or disability (aOR, 1.63 [95% CI, 1.15–2.31]), and worse functional outcomes (adjusted common odds ratio,1.92 [95% CI, 1.47–2.50]). CONCLUSIONS: Patients follow distinct SBP trajectories in the first 24 hours after an EVT. Persistently elevated SBP after the procedure is associated with unfavorable short-term and long-term outcomes. (Hypertension. 2024;81:00–00. DOI: 10.1161/HYPERTENSIONAHA.123.22164.) \bullet Supplement Material.;,citation_author=Aristeidis H. Katsanos;,citation_author=Raed Joundi;,citation_author=Lina Palaiodimou;,citation_author=Niaz Ahmed;,citation_author=Joon-Tae Kim;,citation_author=Nitin Goyal;,citation_author=Ilko L. Maier;,citation_author=Adam De Havenon;,citation_author=Mohammad Anadani;,citation_author=Marius Matusevicius;,citation_author=Eva A. Mistry;,citation_author=Pooja Khatri;,citation_author=Adam S. Arthur;,citation_author=Amrou Sarraj;,citation_author=Shadi Yaghi;,citation_author=Ashkan Shoamanesh;,citation_author=Luciana Catanese;,citation_author=Marios-Nikos Psychogios;,citation_author=Konstantinos Tsioufis;,citation_author=Konark Malhotra;,citation_author=Alejandro M. Spiotta;,citation_author=Else Charlotte Sandset;,citation_author=Andrei V. Alexandrov;,citation_author=Nils Petersen;,citation_author=Georgios Tsivgoulis;,citation_publication_date=2024-01;,citation_cover_date=2024-01;,citation_year=2024;,citation_doi=10.1161/HYPERTENSIONAHA.123.22164;,citation_issn=0194-911X, 1524-4563;,citation_language=en-US;,citation_journal_title=Hypertension;">
<meta name="citation_reference" content="citation_title=A Framework for the Evaluation of Statistical Prediction Models;,citation_author=Michael W. Kattan;,citation_author=Thomas A. Gerds;,citation_publication_date=2020-07;,citation_cover_date=2020-07;,citation_year=2020;,citation_issue=1;,citation_doi=10.1016/j.chest.2020.03.005;,citation_issn=00123692;,citation_volume=158;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Statistical Analysis and Reporting Guidelines for CHEST;,citation_author=Michael W. Kattan;,citation_author=Andrew J. Vickers;,citation_publication_date=2020-07;,citation_cover_date=2020-07;,citation_year=2020;,citation_issue=1;,citation_doi=10.1016/j.chest.2019.10.064;,citation_issn=00123692;,citation_volume=158;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Good enough: A primer on the analysis and interpretation of noninferiority trials;,citation_abstract=Active-control noninferiority trials are being performed with increasing frequency when standard placebo-controlled trials are considered unethical. Three attributes are optimally required to establish noninferiority: 1) The treatment under consideration exhibits therapeutic noninferiority to the active control; 2) the treatment would exhibit therapeutic efficacy in a placebo-controlled trial if such a trial were to be performed; and 3) the treatment offers ancillary advantages in safety, tolerability, cost, or convenience. Trials designed to show noninferiority require an appropriate reference population, a proven active control and dose, a high level of adherence to treatment, and adequate statistical power. However, the formal analysis of such trials is founded on several assumptions that cannot be validated explicitly. These assumptions are evaluated in the context of 8 recently published noninferiority trials. The analyses in this paper confirm the establishment of noninferiority in only 4 of the 8 trials. The authors conclude that if noninferiority trials are to be applied to clinical and regulatory decisions about the marketing and use of new treatments, these assumptions must be made explicit and their influence on the resultant conclusions assessed rigorously.;,citation_author=Sanjay Kaul;,citation_author=George A. Diamond;,citation_publication_date=2006-07;,citation_cover_date=2006-07;,citation_year=2006;,citation_issue=1;,citation_doi=10.7326/0003-4819-145-1-200607040-00011;,citation_issn=1539-3704;,citation_pmid=16818930;,citation_volume=145;,citation_language=en-US;,citation_journal_title=Annals of Internal Medicine;">
<meta name="citation_reference" content="citation_title=Normalizing physiological variables in acute illness: Five reasons for caution;,citation_author=Brian P. Kavanagh;,citation_author=L. Joanne Meyer;,citation_publication_date=2005-09;,citation_cover_date=2005-09;,citation_year=2005;,citation_issue=9;,citation_doi=10.1007/s00134-005-2729-7;,citation_issn=0342-4642, 1432-1238;,citation_volume=31;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Low Versus High-Chloride Content Intravenous Solutions For Critically Ill And Perioperative Adult Patients: A Systematic Review And Meta-Analysis;,citation_abstract=Purpose: To assess whether use of low-chloride solutions in unselected critically ill or perioperative adult patients for maintenance or resuscitation could reduce mortality and use of renal replacement therapy (RRT) when compared to high-chloride fluids. Methods: Systematic review and meta-analysis with random-effects inverse variance model. PubMed, Cochrane library, EMBASE, LILACS and Web of Science were searched up until October 2016. Eligible studies included published and unpublished randomised controlled trials (RCTs) in any language that enrolled critically ill and/or perioperative adult patients and compared a low- to a high-chloride solution for volume maintenance or resuscitation. The primary outcomes were mortality and RRT use. We conducted trial sequential analyses (TSA) and assessed risk of bias of individual trials and the overall quality of evidence. Results: Fifteen trials with 4,067 patients, most at low risk of bias, were identified. Of those, only 11 and 10 trials had data on mortality and RRT use, respectively. In the majority of the studies, there was a low study fluid exposure, in the range of 2-3L. Volumes around 7L (or above) were administered only in 3.2% (131/4,067) of this meta-analysis population. No statistically significant impact on mortality (Odds Ratio (OR) 0.90; 95% confidence interval (CI) CI 0.69 – 1.17; p = 0.44; I2 = 0%) or RRT use (OR 1.12; 95%CI 0.80 – 1.58; p = 0.52; I2 = 0%) was found. Overall quality of evidence was moderate for both primary outcomes . TSA was performed for mortality and use of RRT. Neither the curve for mortality nor for RRT crossed the boundaries of superiority or inferiority. Available data was insufficient to calculate the futility boundary. Optimal sample size was estimated in 9,517 patients for mortality and 22,826 for RRT. Conclusions: The current evidence on low- versus high-chloride solutions for unselected critically ill or perioperative adult patients demonstrates no benefit but suffers from considerable imprecision. Results from well-conducted, adequately-powered RCTs examining sufficiently large fluid exposure are necessary.;,citation_author=L Kawano-Dourado;,citation_author=F G Zampieri;,citation_author=L C P Azevedo;,citation_author=T D Correa;,citation_author=M Figueiro;,citation_author=M W Semler;,citation_author=J Kellum;,citation_author=A B Cavalcanti;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Management of Peripheral Venoarterial Extracorporeal Membrane Oxygenation in Cardiogenic Shock:;,citation_author=Steven P. Keller;,citation_publication_date=2019-09;,citation_cover_date=2019-09;,citation_year=2019;,citation_issue=9;,citation_doi=10.1097/CCM.0000000000003879;,citation_issn=0090-3493;,citation_volume=47;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Surgical Evacuation of Intracerebral Hemorrhage: The Potential Importance of Timing;,citation_author=Christopher P. Kellner;,citation_author=Alexander J. Schupper;,citation_author=J Mocco;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=10;,citation_doi=10.1161/STROKEAHA.121.032238;,citation_issn=0039-2499, 1524-4628;,citation_volume=52;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=Abnormal saline and the history of intravenous fluids;,citation_author=John A. Kellum;,citation_publication_date=2018-06;,citation_cover_date=2018-06;,citation_year=2018;,citation_issue=6;,citation_doi=10.1038/s41581-018-0008-4;,citation_issn=1759-5061, 1759-507X;,citation_volume=14;,citation_language=en-US;,citation_journal_title=Nature Reviews Nephrology;">
<meta name="citation_reference" content="citation_title=Assessing Toxicity of Intravenous Crystalloids in Critically Ill Patients;,citation_abstract=Intravenous administration of a specific fluid may have very different effects compared with enteral administration of the same fluid. For example, pure water is well tolerated when given orally, but is highly injurious (leading to hemolysis) when administered intravenously. Intravenous fluids are the most common intervention prescribed for hospitalized patients and may be administered for multiple reasons, such as for rehydration (as an alternative to the enteral route), as a vehicle or carrier for medication delivery, and to produce direct physiologic effects on cardiac output and electrolyte concentrations (as drugs). There are important differences in the composition, volume, and rate of administration of fluids for these different uses.;,citation_author=John A. Kellum;,citation_author=Andrew D. Shaw;,citation_publication_date=2015-10;,citation_cover_date=2015-10;,citation_year=2015;,citation_issue=16;,citation_doi=10.1001/jama.2015.12390;,citation_issn=0098-7484;,citation_volume=314;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Surrogate endpoints in oncology: When are they acceptable for regulatory and clinical decisions, and are they currently overused?;,citation_abstract=Background: Surrogate outcomes are not intrinsically beneficial to patients, but are designed to be easier and faster to measure than clinically meaningful outcomes. The use of surrogates as an endpoint in clinical trials and basis for regulatory approval is common, and frequently exceeds the guidance given by regulatory bodies. Discussion: In this article, we demonstrate that the use of surrogates in oncology is widespread and increasing. At the same time, the strength of association between the surrogates used and clinically meaningful outcomes is often unknown or weak. Attempts to validate surrogates are rarely undertaken. When this is done, validation relies on only a fraction of available data, and often concludes that the surrogate is poor. Post-marketing studies, designed to ensure drugs have meaningful benefits, are often not performed. Alternatively, if a drug fails to improve quality of life or overall survival, market authorization is rarely revoked. We suggest this reliance on surrogates, and the imprecision surrounding their acceptable use, means that numerous drugs are now approved based on small yet statistically significant increases in surrogates of questionable reliability. In turn, this means the benefits of many approved drugs are uncertain. This is an unacceptable situation for patients and professionals, as prior experience has shown that such uncertainty can be associated with significant harm. Conclusion: The use of surrogate outcomes should be limited to situations where a surrogate has demonstrated robust ability to predict meaningful benefits, or where cases are dire, rare or with few treatment options. In both cases, surrogates must be used only when continuing studies examining hard endpoints have been fully recruited.;,citation_author=Robert Kemp;,citation_author=Vinay Prasad;,citation_publication_date=2017-12;,citation_cover_date=2017-12;,citation_year=2017;,citation_issue=1;,citation_doi=10.1186/s12916-017-0902-9;,citation_issn=1741-7015;,citation_volume=15;,citation_language=en-US;,citation_journal_title=BMC Medicine;">
<meta name="citation_reference" content="citation_title=Assessing and reporting heterogeneity in treatment effects in clinical trials: A proposal;,citation_abstract=Mounting evidence suggests that there is frequently considerable variation in the risk of the outcome of interest in clinical trial populations. These differences in risk will often cause clinically important heterogeneity in treatment effects (HTE) across the trial population, such that the balance between treatment risks and benefits may differ substantially between large identifiable patient subgroups; the &amp;amp;amp;quot;average&amp;quot; benefit observed in the summary result may even be non-representative of the treatment effect for a typical patient in the trial. Conventional subgroup analyses, which examine whether specific patient characteristics modify the effects of treatment, are usually unable to detect even large variations in treatment benefit (and harm) across risk groups because they do not account for the fact that patients have multiple characteristics simultaneously that affect the likelihood of treatment benefit. Based upon recent evidence on optimal statistical approaches to assessing HTE, we propose a framework that prioritizes the analysis and reporting of multivariate risk-based HTE and suggests that other subgroup analyses should be explicitly labeled either as primary subgroup analyses (well-motivated by prior evidence and intended to produce clinically actionable results) or secondary (exploratory) subgroup analyses (performed to inform future research). A standardized and transparent approach to HTE assessment and reporting could substantially improve clinical trial utility and interpretability.;,citation_author=David M. Kent;,citation_author=Peter M. Rothwell;,citation_author=John PA Ioannidis;,citation_author=Doug G. Altman;,citation_author=Rodney A. Hayward;,citation_publication_date=2010-12;,citation_cover_date=2010-12;,citation_year=2010;,citation_issue=1;,citation_doi=10.1186/1745-6215-11-85;,citation_issn=1745-6215;,citation_volume=11;,citation_language=en-US;,citation_journal_title=Trials;,citation_publisher=BioMed Central;">
<meta name="citation_reference" content="citation_title=Personalized evidence based medicine: Predictive approaches to heterogeneous treatment effects;,citation_abstract=The use of evidence from clinical trials to support decisions for individual patients is a form of “reference class forecasting”: implicit predictions for an individual are made on the basis of outcomes in a reference class of “similar” patients treated with alternative therapies. Evidence based medicine has generally emphasized the broad reference class of patients qualifying for a trial. Yet patients in a trial (and in clinical practice) differ from one another in many ways that can affect the outcome of interest and the potential for benefit. The central goal of personalized medicine, in its various forms, is to narrow the reference class to yield more patient specific effect estimates to support more individualized clinical decision making. This article will review fundamental conceptual problems with the prediction of outcome risk and heterogeneity of treatment effect (HTE), as well as the limitations of conventional (one-variable-at-a-time) subgroup analysis. It will also discuss several regression based approaches to “predictive” heterogeneity of treatment effect analysis, including analyses based on “risk modeling” (such as stratifying trial populations by their risk of the primary outcome or their risk of serious treatment-related harms) and analysis based on “effect modeling” (which incorporates modifiers of relative effect). It will illustrate these approaches with clinical examples and discuss their respective strengths and vulnerabilities.;,citation_author=David M Kent;,citation_author=Ewout Steyerberg;,citation_author=David Klaveren;,citation_publication_date=2018-12;,citation_cover_date=2018-12;,citation_year=2018;,citation_doi=10.1136/bmj.k4245;,citation_issn=0959-8138;,citation_pmid=30530757;,citation_volume=363;,citation_journal_title=The BMJ;">
<meta name="citation_reference" content="citation_title=The legacy of the interprofessional family meeting;,citation_author=Nancy Kentish-Barnes;,citation_author=Hanne Irene Jensen;,citation_author=J. Randall Curtis;,citation_publication_date=2022-07;,citation_cover_date=2022-07;,citation_year=2022;,citation_issue=7;,citation_doi=10.1007/s00134-022-06718-w;,citation_issn=0342-4642, 1432-1238;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Utilization of Rehabilitation Services in Stroke: A Study Utilizing the Health and Retirement Study With Linked Medicare Claims Data;,citation_abstract=Objectives: To describe Medicare fee-for-service beneficiaries who used poststroke rehabilitation services and identified the strongest predictors of utilization after the initial stroke care episode. Design: Pooled, cross-sectional design using data from 1998 to 2010 from the Health and Retirement Study (HRS) with linked Medicare claims data. Setting: NA. Participants: Stroke survivors who were Medicare fee-for-service beneficiaries and participated in the HRS were included (NZ515). Main Outcome Measure: Utilization of rehabilitation services up to 10 years poststroke was the primary outcome with logistic regression used to predict utilization. Covariates included demographic factors, baseline functional status, health conditions, personal lifestyle factors, and social support. Results: Rehabilitation service utilization was 21.6%, 6.8%, 15.8%, 16.5%, and &amp;amp;amp;lt;16% in years 2, 4, 6, 8, and 10, respectively. Age was the primary factor predicting use of rehabilitation in the first 10 years poststroke (odds ratio: 1.14; PZ.001). Recurrent stroke (odds ratio: 1.64; PZ.051) was also significantly associated with utilization, whereas unspecified incident stroke at incident trended toward significance (odds ratio: 2.17; PZ.077). None of the other factors was a significant predictor of participation in rehabilitation services in this period. Conclusion: A small number of Medicare fee-for-service beneficiaries who are stroke survivors utilize rehabilitation services in the first 10 years poststroke. Of those who do, age is the primary driver of utilization. We analyzed a multitude of factors that might influence utilization, but other factors not available in these data also need to be explored.;,citation_author=Karen M. Keptner;,citation_author=Kathleen Smyth;,citation_author=Siran Koroukian;,citation_author=Mark Schluchter;,citation_author=Anthony Furlan;,citation_publication_date=2019-12;,citation_cover_date=2019-12;,citation_year=2019;,citation_issue=12;,citation_doi=10.1016/j.apmr.2019.06.017;,citation_issn=00039993;,citation_volume=100;,citation_language=en-US;,citation_journal_title=Archives of Physical Medicine and Rehabilitation;">
<meta name="citation_reference" content="citation_title=Comparative Effectiveness of Carotid Endarterectomy vs Initial Medical Therapy in Patients With Asymptomatic Carotid Stenosis;,citation_abstract=Carotid endarterectomy (CEA) among asymptomatic patients involves a trade-off between a higher short-term perioperative risk in exchange for a lower long-term risk of stroke. The clinical benefit observed in randomized clinical trials (RCTs) may not extend to real-world practice.To examine whether early intervention (CEA) was superior to initial medical therapy in real-world practice in preventing fatal and nonfatal strokes among patients with asymptomatic carotid stenosis.This comparative effectiveness study was conducted from August 28, 2018, to March 2, 2020, using the Corporate Data Warehouse, Suicide Data Repository, and other databases of the US Department of Veterans Affairs. Data analyzed were those of veterans of the US Armed Forces aged 65 years or older who received carotid imaging between January 1, 2005, and December 31, 2009. Patients without a carotid imaging report, those with carotid stenosis of less than 50% or hemodynamically insignificant stenosis, and those with a history of stroke or transient ischemic attack in the 6 months before index imaging were excluded. A cohort of patients who received initial medical therapy and a cohort of similar patients who received CEA were constructed and followed up for 5 years. The target trial method was used to compute weighted Kaplan-Meier curves and estimate the risk of fatal and nonfatal strokes in each cohort in the pragmatic sample across 5 years of follow-up. This analysis was repeated after restricting the sample to patients who met RCT inclusion criteria. Cumulative incidence functions for fatal and nonfatal strokes were estimated, accounting for nonstroke deaths as competing risks in both the pragmatic and RCT-like samples.Receipt of CEA vs initial medical therapy.Fatal and nonfatal strokes.Of the total 5221 patients, 2712 (51.9%; mean [SD] age, 73.6 [6.0] years; 2678 men [98.8%]) received CEA and 2509 (48.1%; mean [SD] age, 73.6 [6.0] years; 2479 men [98.8%]) received initial medical therapy within 1 year after the index carotid imaging. The observed rate of stroke or death (perioperative complications) within 30 days in the CEA cohort was 2.5% (95% CI, 2.0%-3.1%). The 5-year risk of fatal and nonfatal strokes was lower among patients randomized to CEA compared with patients randomized to initial medical therapy (5.6% vs 7.8%; risk difference, -2.3%; 95% CI, -4.0% to -0.3%). In an analysis that incorporated the competing risk of death, the risk difference between the 2 cohorts was lower and not statistically significant (risk difference, -0.8%; 95% CI, -2.1% to 0.5%). Among patients who met RCT inclusion criteria, the 5-year risk of fatal and nonfatal strokes was 5.5% (95% CI, 4.5%-6.5%) among patients randomized to CEA and was 7.6% (95% CI, 5.7%-9.5%) among those randomized to initial medical therapy (risk difference, -2.1%; 95% CI, -4.4% to -0.2%). Accounting for competing risks resulted in a risk difference of -0.9% (95% CI, -2.9% to 0.7%) that was not statistically significant.This study found that the absolute reduction in the risk of fatal and nonfatal strokes associated with early CEA was less than half the risk difference in trials from 20 years ago and was no longer statistically significant when the competing risk of nonstroke deaths was accounted for in the analysis. Given the nonnegligible perioperative 30-day risks and the improvements in stroke prevention, medical therapy may be an acceptable therapeutic strategy.;,citation_author=Salomeh Keyhani;,citation_author=Eric M. Cheng;,citation_author=Katherine J. Hoggatt;,citation_author=Peter C. Austin;,citation_author=Erin Madden;,citation_author=Paul L. Hebert;,citation_author=Ethan A. Halm;,citation_author=Ayman Naseri;,citation_author=Jason M. Johanning;,citation_author=Danielle Mowery;,citation_author=Wendy W. Chapman;,citation_author=Dawn M. Bravata;,citation_publication_date=2020-09;,citation_cover_date=2020-09;,citation_year=2020;,citation_issue=9;,citation_doi=10.1001/jamaneurol.2020.1427;,citation_issn=2168-6149;,citation_volume=77;,citation_journal_title=JAMA Neurology;">
<meta name="citation_reference" content="citation_title=Application of the Reverse Fragility Index to Statistically Nonsignificant Randomized Clinical Trial Results;,citation_abstract=OBJECTIVE To use the concept of reverse fragility index (RFI) to provide a measure of confidence in the neutrality of RCT results when assessed from the clinical perspective. DESIGN, SETTING, AND PARTICIPANTS In this cross-sectional study, a MEDLINE search was conducted for RCTs published from January 1, 2013, to December 31, 2018, in JAMA, the New England Journal of Medicine (NEJM), and The Lancet. Eligible studies were phase 3 and 4 trials with 1:1 randomization and statistically nonsignificant binary primary end points. Data analysis was performed from August 1, 2019, to August 31, 2019. EXPOSURES Single vs multicenter enrollment, total number of events, private vs government funding, placebo vs active control, and time to event vs frequency data. MAIN OUTCOMES AND MEASURES The primary outcome was the median RFI with interquartile range (IQR) at the P = .05 threshold. Secondary outcomes were the number of RCTs in which the number of participants lost to follow-up was greater than the RFI; the median RFI with IQR at different P value thresholds; the median reverse fragility quotient with IQR; and the correlation between sample sizes, number of events, and P values of the RCT and RFI. RESULTS Of the 167 RCTs included, 76 (46%) were published in the NEJM, 50 (30%) in JAMA, and 41 (24%) in The Lancet. The median (IQR) sample size was 970 (470-3427) participants, and the median (IQR) number of events was 251 (105-570). The median (IQR) RFI at the P = .05 threshold was 8 (5-13). Fifty-seven RCTs (34%) had an RFI of 5 or lower, and in 68 RCTs (41%) the number of participants lost to follow-up was greater than the RFI. Trials with P values ranging from P = .06 to P = .10 had a median (IQR) RFI of 3 (2-4). When compared, median (IQR) RFIs were not statistically significant for single-center vs multicenter enrollment (5 [4-13] vs 8 [5-13]; P = .41), private vs government-funded studies (9 [5-13] vs 8 [5-13]; P = .34), and time-to-event primary end points vs frequency data (9 [5-14] vs 7 [4-13]; P = .43). The median (IQR) RFI at the P = .01 threshold was 12 (7-19) and at the P = .005 threshold was 14 (9-21). CONCLUSIONS AND RELEVANCE This cross-sectional study found that a relatively small number of events (median of 8) had to change to move the primary end point of an RCT from nonsignificant to statistically significant. These findings emphasize the nuance required when interpreting trial results that did not meet prespecified significance thresholds.;,citation_author=Muhammad Shahzeb Khan;,citation_author=Gregg C. Fonarow;,citation_author=Tim Friede;,citation_author=Noman Lateef;,citation_author=Safi U. Khan;,citation_author=Stefan D. Anker;,citation_author=Frank E. Harrell;,citation_author=Javed Butler;,citation_publication_date=2020-08;,citation_cover_date=2020-08;,citation_year=2020;,citation_issue=8;,citation_doi=10.1001/jamanetworkopen.2020.12469;,citation_issn=2574-3805;,citation_volume=3;,citation_language=en-US;,citation_journal_title=JAMA Network Open;">
<meta name="citation_reference" content="citation_title=Use of hypertonic saline in the treatment of severe refractory posttraumatic intracranial hypertension in pediatric traumatic brain injury:;,citation_author=Sandeep Khanna;,citation_author=Daniel Davis;,citation_author=Bradley Peterson;,citation_author=Brock Fisher;,citation_author=Howard Tung;,citation_author=John O’Quigley;,citation_author=Reena Deutsch;,citation_publication_date=2000-04;,citation_cover_date=2000-04;,citation_year=2000;,citation_issue=4;,citation_doi=10.1097/00003246-200004000-00038;,citation_issn=0090-3493;,citation_volume=28;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Effect of Intravenous Recombinant Tissue-Type Plasminogen Activator in Patients With Mild Stroke in the Third International Stroke Trial-3;,citation_abstract=Background and Purpose— Randomized trial evidence on the risk/benefit ratio of thrombolysis for mild stroke is limited. We sought to determine the efficacy of intravenous recombinant tissue-type plasminogen activator (IV r-tPA) in a subset of patients with mild deficit in the third International Stroke Trial (IST-3). Methods— IST-3 compared IV r-tPA with control within 6 hours of onset in patients for whom IV r-tPA was considered promising but unproven. Analysis was restricted to subjects randomized within 3 hours of onset with a baseline National Institutes of Health Stroke Scale \leq5, pretreatment blood pressure &amp;amp;amp;lt;185/110, and no other r-tPA exclusion criteria. We compared r-tPA and control arms for primary (Oxfordshire Handicap Score [OHS] 0–2) and secondary (ordinal OHS and OHS 0–1) outcomes at 6 months. Results— Among 3035 IST-3 subjects, 612 (20.2%) had an National Institutes of Health Stroke Scale \leq5; of these 106 (17.6%) met the restricted criteria. Allocation to r-tPA was associated with an increase in OHS 0 to 2 (84% r-tPA versus 65% control; adjusted odds ratio, 3.31; 95% confidence interval, 1.24–8.79) and a favorable shift in OHS distribution (adjusted odds ratio, 2.38; 95% confidence interval, 1.17–4.85). There was no significant effect of r-tPA on OHS 0 to 1 (60% versus 51%; adjusted odds ratio, 1.92; 95% confidence interval, 0.83–4.43). Conclusions— This post hoc analysis in a highly selected sample of IST-3 supports the rationale of A Study of the Efficacy and Safety of Activase (Alteplase) in Patients With Mild Stroke (PRISMS) trial—a randomized, phase IIIb study to evaluate IV r-tPA in mild ischemic stroke.;,citation_author=Pooja Khatri;,citation_author=Darren Tayama;,citation_author=Geoff Cohen;,citation_author=Richard I. Lindley;,citation_author=Joanna M. Wardlaw;,citation_author=Sharon D. Yeatts;,citation_author=Joseph P. Broderick;,citation_author=Peter Sandercock;,citation_publication_date=2015-08;,citation_cover_date=2015-08;,citation_year=2015;,citation_issue=8;,citation_doi=10.1161/STROKEAHA.115.009951;,citation_volume=46;,citation_journal_title=Stroke;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=Intra-arterial Thrombolysis to Target Occlusions in Distal Arteries and the Microcirculation;,citation_author=Pooja Khatri;,citation_publication_date=2022-03;,citation_cover_date=2022-03;,citation_year=2022;,citation_issue=9;,citation_doi=10.1001/jama.2021.25014;,citation_issn=0098-7484;,citation_volume=327;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Adherence to Methodological Standards in Research Using the National Inpatient Sample;,citation_abstract=Publicly available data sets hold much potential, but their unique design may require specific analytic approaches.To determine adherence to appropriate research practices for a frequently used large public database, the National Inpatient Sample (NIS) of the Agency for Healthcare Research and Quality (AHRQ).In this observational study of the 1082 studies published using the NIS from January 2015 through December 2016, a representative sample of 120 studies was systematically evaluated for adherence to practices required by AHRQ for the design and conduct of research using the NIS.None.All studies were evaluated on 7 required research practices based on AHRQ’s recommendations and compiled under 3 domains: (1) data interpretation (interpreting data as hospitalization records rather than unique patients); (2) research design (avoiding use in performing state-, hospital-, and physician-level assessments where inappropriate; not using nonspecific administrative secondary diagnosis codes to study in-hospital events); and (3) data analysis (accounting for complex survey design of the NIS and changes in data structure over time).Of 120 published studies, 85% (n = 102) did not adhere to 1 or more required practices and 62% (n = 74) did not adhere to 2 or more required practices. An estimated 925 (95% CI, 852-998) NIS publications did not adhere to 1 or more required practices and 696 (95% CI, 596-796) NIS publications did not adhere to 2 or more required practices. A total of 79 sampled studies (68.3% [95% CI, 59.3%-77.3%]) among the 1082 NIS studies screened for eligibility did not account for the effects of sampling error, clustering, and stratification; 62 (54.4% [95% CI, 44.7%-64.0%]) extrapolated nonspecific secondary diagnoses to infer in-hospital events; 45 (40.4% [95% CI, 30.9%-50.0%]) miscategorized hospitalizations as individual patients; 10 (7.1% [95% CI, 2.1%-12.1%]) performed state-level analyses; and 3 (2.9% [95% CI, 0.0%-6.2%]) reported physician-level volume estimates. Of 27 studies (weighted; 218 studies [95% CI, 134-303]) spanning periods of major changes in the data structure of the NIS, 21 (79.7% [95% CI, 62.5%-97.0%]) did not account for the changes. Among the 24 studies published in journals with an impact factor of 10 or greater, 16 (67%) did not adhere to 1 or more practices, and 9 (38%) did not adhere to 2 or more practices.In this study of 120 recent publications that used data from the NIS, the majority did not adhere to required practices. Further research is needed to identify strategies to improve the quality of research using the NIS and assess whether there are similar problems with use of other publicly available data sets.;,citation_author=Rohan Khera;,citation_author=Suveen Angraal;,citation_author=Tyler Couch;,citation_author=John W. Welsh;,citation_author=Brahmajee K. Nallamothu;,citation_author=Saket Girotra;,citation_author=Paul S. Chan;,citation_author=Harlan M. Krumholz;,citation_publication_date=2017-11;,citation_cover_date=2017-11;,citation_year=2017;,citation_issue=20;,citation_doi=10.1001/jama.2017.17653;,citation_issn=0098-7484;,citation_volume=318;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=A Framework for Understanding Medical Epistemologies;,citation_abstract=What clinicians, biomedical scientists, and other health care professionals know as individuals or as groups and how they come to know and use knowledge are central concerns of medical epistemology. Activities associated with knowledge production and use are called epistemic practices. Such practices are considered in biomedical and clinical literatures, social sciences of medicine, philosophy of science and philosophy of medicine, and also in other nonmedical literatures. A host of different kinds of knowledge claims have been identified, each with different uses and logics of justification. A general framework is needed to situate these diverse contributions in medical epistemology, so we can see how they fit together. But developing such a framework turns out to be quite tricky. In this survey, three possible frameworks are considered along with the difficulties associated with each of them. The essay concludes with a fourth framework, which considers any epistemology as part of a practice that is oriented toward overcoming errors that emerge in antecedently given practices where knowledge is developed and used. As medicine indirectly advances health by directly mitigating disease, so epistemology indirectly advances knowledge by directly mitigating error.;,citation_author=G. Khushf;,citation_publication_date=2013-10;,citation_cover_date=2013-10;,citation_year=2013;,citation_issue=5;,citation_doi=10.1093/jmp/jht044;,citation_issn=0360-5310, 1744-5019;,citation_volume=38;,citation_language=en-US;,citation_journal_title=Journal of Medicine and Philosophy;">
<meta name="citation_reference" content="citation_title=Assessment of Discordance Between Physicians and Family Members Regarding Prognosis in Patients With Severe Acute Brain Injury;,citation_abstract=IMPORTANCE Shared decision-making requires key stakeholders to align in perceptions of prognosis and likely treatment outcomes.;,citation_author=Whitney A. Kiker;,citation_author=Rachel Rutz Voumard;,citation_author=Leah I. B. Andrews;,citation_author=Robert G. Holloway;,citation_author=Lyndia C. Brumback;,citation_author=Ruth A. Engelberg;,citation_author=J. Randall Curtis;,citation_author=Claire J. Creutzfeldt;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=10;,citation_doi=10.1001/jamanetworkopen.2021.28991;,citation_issn=2574-3805;,citation_volume=4;,citation_language=en-US;,citation_journal_title=JAMA Network Open;">
<meta name="citation_reference" content="citation_title=Extending Dual Antiplatelet Therapy for TIA or Stroke;,citation_abstract=Although stroke is typically understood to be a medical emergency, the same pertains when cerebral ischemia produces seemingly mild or transient symptoms. For transient ischemic attack (TIA) and minor stroke, urgent evaluation and treatment are no less important than for larger strokes, given that the risk of recurrent stroke occurs early. Nearly half the 90-day stroke risk occurs within the first 48 hours after an event.1 The risk is modifiable with interventions such as aspirin2 or dual antiplatelet therapy with clopidogrel–aspirin3,4 or ticagrelor–aspirin5 if it is initiated within 24 hours. The trials that established the efficacy of short-term dual antiplatelet . . .;,citation_author=Anthony S. Kim;,citation_publication_date=2023-12;,citation_cover_date=2023-12;,citation_year=2023;,citation_issue=26;,citation_doi=10.1056/NEJMe2311961;,citation_issn=0028-4793;,citation_volume=389;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Focused Management of Patients With Severe Acute Brain Injury and ARDS;,citation_author=Jennifer A. Kim;,citation_author=Sarah Wahlster;,citation_author=Jamie Nicole LaBuzetta;,citation_author=Christa O’Hana S. Nobleza;,citation_author=Nicholas J. Johnson;,citation_author=Clio Rubinos;,citation_author=Deepa Malaiyandi;,citation_author=Kristine H. O’Phalen;,citation_author=Shraddha Mainali;,citation_author=Aarti Sarwal;,citation_author=Emily J. Gilmore;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_doi=10.1016/j.chest.2021.08.066;,citation_issn=00123692;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Practical “1-2-3-4-Day” Rule for Starting Direct Oral Anticoagulants After Ischemic Stroke With Atrial Fibrillation: Combined Hospital-Based Cohort Study;,citation_abstract=Background: The “1-3-6-12-day rule” for starting direct oral anticoagulants (DOACs) in patients with nonvalvular atrial fibrillation after acute ischemic stroke or transient ischemic attack recommends timings that may be later than used in clinical practice. We investigated more practical optimal timing of DOAC initiation according to stroke severity. Methods: The combined data of prospective registries in Japan, Stroke Acute Management with Urgent Risk-factor Assessment and Improvement-nonvalvular atrial fibrillation (September 2011 to March 2014) and RELAXED (February 2014 to April 2016) were used. Patients were divided into transient ischemic attack and 3 stroke subgroups by the National Institutes of Health Stroke Scale score: mild (0–7), moderate (8–15), and severe (\geq16). The early treatment group was defined as patients starting DOACs earlier than the median initiation day in each subgroup. Outcomes included a composite of recurrent stroke or systemic embolism, ischemic stroke, and severe bleeding within 90 days. Six European prospective registries were used for validation. Results: In the 1797 derivation cohort patients, DOACs were started at median 2 days after transient ischemic attack and 3, 4, and 5 days after mild, moderate, and severe strokes, respectively. Stroke or systemic embolism was less common in Early Group (n=785)—initiating DOACS within 1, 2, 3, and 4 days, respectively—than Late Group (n=1012) (1.9% versus 3.9%; adjusted hazard ratio, 0.50 [95% CI, 0.27–0.89]), as was ischemic stroke (1.7% versus 3.2%, 0.54 [0.27–0.999]). Major bleeding was similarly common in the 2 groups (0.8% versus 1.0%). On validation, both ischemic stroke (2.4% versus 2.2%) and intracranial hemorrhage (0.2% versus 0.6%) were similarly common in Early (n=547) and Late (n=1483) Groups defined using derivation data. Conclusions: In Japanese and European populations, early DOAC initiation within 1, 2, 3, or 4 days according to stroke severity seemed to be feasible to decrease the risk of recurrent stroke or systemic embolism and no increase in major bleeding. These findings support ongoing randomized trials to better establish the optimal timing of DOAC initiation.;,citation_author=Shunsuke Kimura;,citation_author=Kazunori Toyoda;,citation_author=Sohei Yoshimura;,citation_author=Kazuo Minematsu;,citation_author=Masahiro Yasaka;,citation_author=Maurizio Paciaroni;,citation_author=David J. Werring;,citation_author=Hiroshi Yamagami;,citation_author=Takehiko Nagao;,citation_author=Shinichi Yoshimura;,citation_author=Alexandros Polymeris;,citation_author=Annaelle Zietz;,citation_author=Stefan T. Engelter;,citation_author=Bernd Kallmünzer;,citation_author=Manuel Cappellari;,citation_author=Tetsuya Chiba;,citation_author=Takeshi Yoshimoto;,citation_author=Masayuki Shiozawa;,citation_author=Takanari Kitazono;,citation_author=Masatoshi Koga;,citation_author=Kenichi Todo;,citation_author=Kazumi Kimura;,citation_author=Yoshiki Yagita;,citation_author=Eisuke Furui;,citation_author=Ryo Itabashi;,citation_author=Tadashi Terasaki;,citation_author=Yoshiaki Shiokawa;,citation_author=Teruyuki Hirano;,citation_author=Kenji Kamiyama;,citation_author=Jyoji Nakagawara;,citation_author=Shunya Takizawa;,citation_author=Kazunari Homma;,citation_author=Satoshi Okuda;,citation_author=Yasushi Okada;,citation_author=Keisuke Tokunaga;,citation_author=Tomoaki Kameda;,citation_author=Kazuomi Kario;,citation_author=Yoshinari Nagakane;,citation_author=Yasuhiro Hasegawa;,citation_author=Hisanao Akiyama;,citation_author=Satoshi Shibuya;,citation_author=Hiroshi Mochizuki;,citation_author=Yasuhiro Ito;,citation_author=Takahiro Nakashima;,citation_author=Hideki Matsuoka;,citation_author=Kazuhiro Takamatsu;,citation_author=Kazutoshi Nishiyama;,citation_author=Shoichiro Sato;,citation_author=Shoji Arihiro;,citation_author=Manabu Inoue;,citation_author=Masahito Takagi;,citation_author=Kanta Tanaka;,citation_author=Kazuyuki Nagatsuka;,citation_author=Takenori Yamaguchi;,citation_author=Yasuhiro Hasegawa;,citation_author=Yoichiro Hashimoto;,citation_author=Kiyohiro Houkin;,citation_author=Kazumi Kimura;,citation_author=Kazuo Kitagawa;,citation_author=Masayasu Matsumoto;,citation_author=Yasushi Okada;,citation_author=Satoshi Okuda;,citation_author=Norio Tanahashi;,citation_author=Yasuo Terayama;,citation_author=Shinichiro Uchiyama;,citation_author=Etsuro Mori;,citation_author=Yutaka Furukawa;,citation_author=Takeshi Kimura;,citation_author=Yoshiaki Kumon;,citation_author=Ken Nagata;,citation_author=Shigeru Nogawa;,citation_author=Tomohiro Sakamoto;,citation_author=Teruyuki Hirano;,citation_author=Toshinori Hirai;,citation_author=Kohsuke Kudo;,citation_author=Makoto Sasaki;,citation_author=Shotai Kobayashi;,citation_author=Toshimitsu Hamasaki;,citation_author=Michela Giustozzi;,citation_author=Monica Acciarresi;,citation_author=Giancarlo Agnelli;,citation_author=Valeria Caso;,citation_author=Fabio Bandini;,citation_author=Georgios Tsivgoulis;,citation_author=Shadi Yaghi;,citation_author=Karen L. Furie;,citation_author=Prasanna Tadi;,citation_author=Cecilia Becattini;,citation_author=Marialuisa Zedde;,citation_author=Azmil H Abdul-Rahim;,citation_author=Kennedy R Lees;,citation_author=Andrea Alberti;,citation_author=Michele Venti;,citation_author=Cataldo D’Amore;,citation_author=Maria Giulia Mosconi;,citation_author=Ludovica Anna Cimini;,citation_author=Paolo Bovi;,citation_author=Monica Carletti;,citation_author=Alberto Rigatelli;,citation_author=Jukka Putaala;,citation_author=Liisa Tomppo;,citation_author=Turgut Tatlisumak;,citation_author=Simona Marcheselli;,citation_author=Alessandro Pezzini;,citation_author=Loris Poli;,citation_author=Alessandro Padovani;,citation_author=Vieri Vannucchi;,citation_author=Sung-Il Sohn;,citation_author=Gianni Lorenzini;,citation_author=Rossana Tassi;,citation_author=Francesca Guideri;,citation_author=Maurizio Acampa;,citation_author=Giuseppe Martini;,citation_author=George Ntaios;,citation_author=George Athanasakis;,citation_author=Konstantinos Makaritsis;,citation_author=Efstathia Karagkiozi;,citation_author=Konstantinos Vadikolias;,citation_author=Chrissoula Liantinioti;,citation_author=Maria Chondrogianni;,citation_author=Nicola Mumoli;,citation_author=Franco Galati;,citation_author=Simona Sacco;,citation_author=Cindy Tiseo;,citation_author=Francesco Corea;,citation_author=Walter Ageno;,citation_author=Marta Bellesini;,citation_author=Giovanna Colombo;,citation_author=Giorgio Silvestrelli;,citation_author=Alfonso Ciccone;,citation_author=Alessia Lanari;,citation_author=Umberto Scoditti;,citation_author=Licia Denti;,citation_author=Michelangelo Mancuso;,citation_author=Miriam Maccarrone;,citation_author=Leonardo Ulivi;,citation_author=Giovanni Orlandi;,citation_author=Nicola Giannini;,citation_author=Tiziana Tassinari;,citation_author=Maria Luisa De Lodovici;,citation_author=Christina Rueckert;,citation_author=Antonio Baldi;,citation_author=Danilo Toni;,citation_author=Federica Letteri;,citation_author=Martina Giuntini;,citation_author=Enrico Maria Lotti;,citation_author=Yuriy Flomin;,citation_author=Alessio Pieroni;,citation_author=Odysseas Kargiotis;,citation_author=Theodore Karapanayiotides;,citation_author=Serena Monaco;,citation_author=Mario Maimone Baronello;,citation_author=Laszló Csiba;,citation_author=Lilla Szabó;,citation_author=Alberto Chiti;,citation_author=Elisa Giorli;,citation_author=Massimo Del Sette;,citation_author=Davide Imberti;,citation_author=Dorjan Zabzuni;,citation_author=Boris Doronin;,citation_author=Vera Volodina;,citation_author=Patrik Michel;,citation_author=Peter Vanacker;,citation_author=Kristian Barlinn;,citation_author=Lars-Peder Pallesen;,citation_author=Jessica Barlinn;,citation_author=Dirk Deleu;,citation_author=Gayane Melikyan;,citation_author=Faisal Ibrahim;,citation_author=Naveed Akhtar;,citation_author=Vanessa Gourbali;,citation_author=Luca Masotti;,citation_author=Adrian Parry-Jones;,citation_author=Chris Patterson;,citation_author=Christopher Price;,citation_author=Abduelbaset Elmarimi;,citation_author=Anthea Parry;,citation_author=Arumug Nallasivam;,citation_author=Azlisham Mohd Nor;,citation_author=Bernard Esis;,citation_author=David Bruce;,citation_author=Christine Roffe;,citation_author=Clare Holmes;,citation_author=David Cohen;,citation_author=David Hargroves;,citation_author=David Mangion;,citation_author=Dinesh Chadha;,citation_author=Djamil Vahidassr;,citation_author=Dulka Manawadu;,citation_author=Elio Giallombardo;,citation_author=Elizabeth Warburton;,citation_author=Enrico Flossman;,citation_author=Gunaratam Gunathilagan;,citation_author=Harald Proschel;,citation_author=Hedley Emsley;,citation_author=Ijaz Anwar;,citation_author=James Okwera;,citation_author=Janet Putterill;,citation_author=Janice O’Connell;,citation_author=John Bamford;,citation_author=John Corrigan;,citation_author=Jon Scott;,citation_author=Jonathan Birns;,citation_author=Karen Kee;,citation_author=Kari Saastamoinen;,citation_author=Kath Pasco;,citation_author=Krishna Dani;,citation_author=Lakshmanan Sekaran;,citation_author=Lillian Choy;,citation_author=Liz Iveson;,citation_author=Maam Mamun;,citation_author=Mahmud Sajid;,citation_author=Martin Cooper;,citation_author=Matthew Burn;,citation_author=Matthew Smith;,citation_author=Michael Power;,citation_author=Michelle Davis;,citation_author=Nigel Smyth;,citation_author=Roland Veltkamp;,citation_author=Pankaj Sharma;,citation_author=Paul Guyler;,citation_author=Paul O’Mahony;,citation_author=Peter Wilkinson;,citation_author=Prabel Datta;,citation_author=Prasanna Aghoram;,citation_author=Rachel Marsh;,citation_author=Robert Luder;,citation_author=Sanjeevikumar Meenakishundaram;,citation_author=Santhosh Subramonian;,citation_author=Simon Leach;,citation_author=Sissi Ispoglou;,citation_author=Sreeman Andole;,citation_author=Timothy England;,citation_author=Aravindakshan Manoj;,citation_author=Frances Harrington;,citation_author=Habib Rehman;,citation_author=Jane Sword;,citation_author=Julie Staals;,citation_author=Karim Mahawish;,citation_author=Kirsty Harkness;,citation_author=Louise Shaw;,citation_author=Michael McCormich;,citation_author=Nikola Sprigg;,citation_author=Syed Mansoor;,citation_author=Vinodh Krishnamurthy;,citation_author=Philippe A Lyrer;,citation_author=Leo H Bonati;,citation_author=David J Seiffge;,citation_author=Christopher Traenka;,citation_author=Nils Peters;,citation_author=Gian Marco De Marchis;,citation_author=Sebastian Thilemann;,citation_author=Nikolaos S Avramiotis;,citation_author=Henrik Gensicke;,citation_author=Lisa Hert;,citation_author=Benjamin Wagner;,citation_author=Fabian Schaub;,citation_author=Louisa Meya;,citation_author=Joachim Fladt;,citation_author=Tolga Dittrich;,citation_author=Urs Fisch;,citation_author=Bruno Bonetti;,citation_author=Paolo Bovi;,citation_author=Giampaolo Tomelleri;,citation_author=Nicola Micheletti;,citation_author=Cecilia Zivelonghi;,citation_author=Andrea Emiliani;,citation_author=Kosmas Macha;,citation_author=Gabriela Siedler;,citation_author=Svenja Stoll;,citation_author=Ruihao Wang;,citation_author=Bastian Volbers;,citation_author=Stefan Schwab;,citation_author=David Haupenthal;,citation_author=Luise Gaßmann;,citation_publication_date=2022-05;,citation_cover_date=2022-05;,citation_year=2022;,citation_issue=5;,citation_doi=10.1161/STROKEAHA.121.036695;,citation_volume=53;,citation_journal_title=Stroke;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=Why Propensity Scores Should Not Be Used for Matching;,citation_abstract=We show that propensity score matching (PSM), an enormously popular method of preprocessing data for causal inference, often accomplishes the opposite of its intended goal—thus increasing imbalance, inefficiency, model dependence, and bias. The weakness of PSM comes from its attempts to approximate a completely randomized experiment, rather than, as with other matching methods, a more efficient fully blocked randomized experiment. PSM is thus uniquely blind to the often large portion of imbalance that can be eliminated by approximating full blocking with other matching methods. Moreover, in data balanced enough to approximate complete randomization, either to begin with or after pruning some observations, PSM approximates random matching which, we show, increases imbalance even relative to the original data. Although these results suggest researchers replace PSM with one of the other available matching methods, propensity scores have other productive uses.;,citation_author=Gary King;,citation_author=Richard Nielsen;,citation_publication_date=2019-10;,citation_cover_date=2019-10;,citation_year=2019;,citation_issue=4;,citation_doi=10.1017/pan.2019.11;,citation_issn=1047-1987, 1476-4989;,citation_volume=27;,citation_language=en-US;,citation_journal_title=Political Analysis;,citation_publisher=Cambridge University Press;">
<meta name="citation_reference" content="citation_title=Polysocial Risk Scores for Assessing Social Determinants of Health;,citation_author=Stuart A. Kinner;,citation_author=Rohan Borschmann;,citation_publication_date=2020-10;,citation_cover_date=2020-10;,citation_year=2020;,citation_issue=16;,citation_doi=10.1001/jama.2020.15699;,citation_issn=0098-7484;,citation_volume=324;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Seek and Ye Shall Find: COVID-19 and Bacterial Superinfection;,citation_author=Georgios D. Kitsios;,citation_author=Alison Morris;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=8;,citation_doi=10.1164/rccm.202107-1790ED;,citation_issn=1073-449X, 1535-4970;,citation_volume=204;,citation_language=en-US;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Ethnic and Racial Variation in Intracerebral Hemorrhage Risk Factors and Risk Factor Burden;,citation_abstract=Black and Hispanic individuals have an increased risk of intracerebral hemorrhage (ICH) compared with their White counterparts, but no large studies of ICH have been conducted in these disproportionately affected populations.To examine the prevalence, odds, and population attributable risk (PAR) percentage for established and novel risk factors for ICH, stratified by ICH location and racial/ethnic group.The Ethnic/Racial Variations of Intracerebral Hemorrhage Study was a case-control study of ICH among 3000 Black, Hispanic, and White individuals who experienced spontaneous ICH (1000 cases in each group). Recruitment was conducted between September 2009 and July 2016 at 19 US sites comprising 42 hospitals. Control participants were identified through random digit dialing and were matched to case participants by age (5 years), sex, race/ethnicity, and geographic area. Data analyses were conducted from January 2019 to May 2020.Case and control participants underwent a standardized interview, physical measurement for body mass index, and genotyping for the \varepsilon2 and \varepsilon4 alleles of APOE, the gene encoding apolipoprotein E. Prevalence, multivariable adjusted odds ratio (OR), and PAR percentage were calculated for each risk factor in the entire ICH population and stratified by racial/ethnic group and by lobar or nonlobar location.There were 1000 Black patients (median [interquartile range (IQR)] age, 57 [50-65] years, 425 [42.5%] women), 1000 Hispanic patients (median [IQR] age, 58 [49-69] years; 373 [37.3%] women), and 1000 White patients (median [IQR] age, 71 [59-80] years; 437 [43.7%] women). The mean (SD) age of patients with ICH was significantly lower among Black and Hispanic patients compared with White patients (eg, lobar ICH: Black, 62.2 [15.2] years; Hispanic, 62.5 [15.7] years; White, 71.0 [13.3] years). More than half of all ICH in Black and Hispanic patients was associated with treated or untreated hypertension (PAR for treated hypertension, Black patients: 53.6%; 95% CI, 46.4%-59.8%; Hispanic patients: 46.5%; 95% CI, 40.6%-51.8%; untreated hypertension, Black patients: 45.5%; 95% CI, 39.%-51.1%; Hispanic patients: 42.7%; 95% CI, 37.6%-47.3%). Lack of health insurance also had a disproportionate association with the PAR percentage for ICH in Black and Hispanic patients (Black patients: 21.7%; 95% CI, 17.5%-25.7%; Hispanic patients: 30.2%; 95% CI, 26.1%-34.1%; White patients: 5.8%; 95% CI, 3.3%-8.2%). A high sleep apnea risk score was associated with both lobar (OR, 1.68; 95% CI, 1.36-2.06) and nonlobar (OR, 1.62; 95% CI, 1.37-1.91) ICH, and high cholesterol was inversely associated only with nonlobar ICH (OR, 0.60; 95% CI, 0.52-0.70); both had no interactions with race and ethnicity. In contrast to the association between the \varepsilon2 and \varepsilon4 alleles of APOE and ICH in White individuals (eg, presence of APOE \varepsilon2 allele: OR, 1.84; 95% CI, 1.34-2.52), APOE alleles were not associated with lobar ICH among Black or Hispanic individuals.This study found sleep apnea as a novel risk factor for ICH. The results suggest a strong contribution from inadequately treated hypertension and lack of health insurance to the disproportionate burden and earlier onset of ICH in Black and Hispanic populations. These findings emphasize the importance of addressing modifiable risk factors and the social determinants of health to reduce health disparities.;,citation_author=Steven J. Kittner;,citation_author=Padmini Sekar;,citation_author=Mary E. Comeau;,citation_author=Christopher D. Anderson;,citation_author=Gunjan Y. Parikh;,citation_author=Tachira Tavarez;,citation_author=Matthew L. Flaherty;,citation_author=Fernando D. Testai;,citation_author=Michael R. Frankel;,citation_author=Michael L. James;,citation_author=Gene Sung;,citation_author=Mitchell S. V. Elkind;,citation_author=Bradford B. Worrall;,citation_author=Chelsea S. Kidwell;,citation_author=Nicole R. Gonzales;,citation_author=Sebastian Koch;,citation_author=Christiana E. Hall;,citation_author=Lee Birnbaum;,citation_author=Douglas Mayson;,citation_author=Bruce Coull;,citation_author=Marc D. Malkoff;,citation_author=Kevin N. Sheth;,citation_author=Jacob L. McCauley;,citation_author=Jennifer Osborne;,citation_author=Misty Morgan;,citation_author=Lee A. Gilkerson;,citation_author=Tyler P. Behymer;,citation_author=Stacie L. Demel;,citation_author=Charles J. Moomaw;,citation_author=Jonathan Rosand;,citation_author=Carl D. Langefeld;,citation_author=Daniel Woo;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_issue=8;,citation_doi=10.1001/jamanetworkopen.2021.21921;,citation_issn=2574-3805;,citation_volume=4;,citation_journal_title=JAMA Network Open;">
<meta name="citation_reference" content="citation_title=Physical Rehabilitation for Older Patients Hospitalized for Heart Failure;,citation_abstract=BACKGROUND Older patients who are hospitalized for acute decompensated heart failure have high rates of physical frailty, poor quality of life, delayed recovery, and frequent rehospitalizations. Interventions to address physical frailty in this population are not well established. METHODS We conducted a multicenter, randomized, controlled trial to evaluate a transitional, tailored, progressive rehabilitation intervention that included four physicalfunction domains (strength, balance, mobility, and endurance). The intervention was initiated during, or early after, hospitalization for heart failure and was continued after discharge for 36 outpatient sessions. The primary outcome was the score on the Short Physical Performance Battery (total scores range from 0 to 12, with lower scores indicating more severe physical dysfunction) at 3 months. The secondary outcome was the 6-month rate of rehospitalization for any cause. RESULTS A total of 349 patients underwent randomization; 175 were assigned to the rehabilitation intervention and 174 to usual care (control). At baseline, patients in each group had markedly impaired physical function, and 97% were frail or prefrail; the mean number of coexisting conditions was five in each group. Patient retention in the intervention group was 82%, and adherence to the intervention sessions was 67%. After adjustment for baseline Short Physical Performance Battery score and other baseline characteristics, the least-squares mean (SE) score on the Short Physical Performance Battery at 3 months was 8.30.2 in the intervention group and 6.90.2 in the control group (mean between-group difference, 1.5; 95% confidence interval [CI], 0.9 to 2.0; P&amp;amp;amp;lt;0.001). At 6 months, the rates of rehospitalization for any cause were 1.18 in the intervention group and 1.28 in the control group (rate ratio, 0.93; 95% CI, 0.66 to 1.19). There were 21 deaths (15 from cardiovascular causes) in the intervention group and 16 deaths (8 from cardiovascular causes) in the control group. The rates of death from any cause were 0.13 and 0.10, respectively (rate ratio, 1.17; 95% CI, 0.61 to 2.27). CONCLUSIONS In a diverse population of older patients who were hospitalized for acute decompensated heart failure, an early, transitional, tailored, progressive rehabilitation intervention that included multiple physical-function domains resulted in greater improvement in physical function than usual care. (Funded by the National Institutes of Health and others; REHAB-HF ClinicalTrials.gov number, NCT02196038.) n engl j med 385;3\quad nejm.org\quad July 15, 2021;,citation_author=Dalane W. Kitzman;,citation_author=David J. Whellan;,citation_author=Pamela Duncan;,citation_author=Amy M. Pastva;,citation_author=Robert J. Mentz;,citation_author=Gordon R. Reeves;,citation_author=M. Benjamin Nelson;,citation_author=Haiying Chen;,citation_author=Bharathi Upadhya;,citation_author=Shelby D. Reed;,citation_author=Mark A. Espeland;,citation_author=LeighAnn Hewston;,citation_author=Christopher M. O’Connor;,citation_publication_date=2021-07;,citation_cover_date=2021-07;,citation_year=2021;,citation_issue=3;,citation_doi=10.1056/NEJMoa2026141;,citation_issn=0028-4793, 1533-4406;,citation_volume=385;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Blood-Pressure Targets in Comatose Survivors of Cardiac Arrest;,citation_author=Jesper Kjaergaard;,citation_author=Jacob E. Møller;,citation_author=Henrik Schmidt;,citation_author=Johannes Grand;,citation_author=Simon Mølstrøm;,citation_author=Britt Borregaard;,citation_author=Søren Venø;,citation_author=Laura Sarkisian;,citation_author=Dmitry Mamaev;,citation_author=Lisette O. Jensen;,citation_author=Benjamin Nyholm;,citation_author=Dan E. Høfsten;,citation_author=Jakob Josiassen;,citation_author=Jakob H. Thomsen;,citation_author=Jens J. Thune;,citation_author=Laust E. R. Obling;,citation_author=Matias G. Lindholm;,citation_author=Martin Frydland;,citation_author=Martin A. S. Meyer;,citation_author=Matilde Winther-Jensen;,citation_author=Rasmus P. Beske;,citation_author=Ruth Frikke-Schmidt;,citation_author=Sebastian Wiberg;,citation_author=Søren Boesgaard;,citation_author=Søren A. Madsen;,citation_author=Vibeke L. Jørgensen;,citation_author=Christian Hassager;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_issue=0;,citation_doi=10.1056/NEJMoa2208687;,citation_issn=0028-4793;,citation_volume=0;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Trauma-induced coagulopathy;,citation_author=Derek J. B. Kleinveld;,citation_author=Sophie R. Hamada;,citation_author=Claudio Sandroni;,citation_publication_date=2022-11;,citation_cover_date=2022-11;,citation_year=2022;,citation_issue=11;,citation_doi=10.1007/s00134-022-06834-7;,citation_issn=1432-1238;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Lower versus higher oxygenation targets in critically ill patients with severe hypoxaemia: Secondary Bayesian analysis to explore heterogeneous treatment effects in the Handling Oxygenation Targets in the Intensive Care Unit (HOT-ICU) trial;,citation_abstract=Background: In the Handling Oxygenation Targets in the Intensive Care Unit (HOT-ICU) trial, a lower (8 kPa) vs a higher (12 kPa) PaO2 target did not affect mortality amongst critically ill adult patients. We used Bayesian statistics to evaluate any heterogeneity in the effect of oxygenation targets on mortality between different patient groups within the HOT-ICU trial. Methods: We analysed 90-day all-cause mortality using adjusted Bayesian logistic regression models, and assessed heterogeneous treatment effects according to four selected baseline variables using both hierarchical models of subgroups and models with interactions on the continuous scales. Results are presented as mortality probability (%) and relative risk (RR) with 95% credibility intervals (CrI). Results: All 2888 patients in the intention-to-treat cohort of the HOT-ICU trial were included. The adjusted 90-day mortality rates were 43.0% (CrI: 38.3e47.8%) and 42.3% (CrI: 37.7e47.1%) in the lower and higher oxygenation groups, respectively (RR 1.02 [CrI: 0.93e1.11]), with 36.5% probability of an RR &amp;amp;amp;lt;1.00. Analyses of heterogeneous treatment effects suggested a doseeresponse relationship between baseline norepinephrine dose and increased mortality with the lower oxygenation target, with 95% probability of increased mortality associated with the lower oxygenation target as norepinephrine doses increased. Conclusions: A lower oxygenation target was unlikely to affect overall mortality amongst critically ill adult patients with acute hypoxaemic respiratory failure. However, our results suggest an increasing mortality risk for patients with a lower oxygen target as the baseline norepinephrine dose increases. These findings warrant additional investigation.;,citation_author=Thomas L. Klitgaard;,citation_author=Olav L. Schjørring;,citation_author=Theis Lange;,citation_author=Morten H. Møller;,citation_author=Anders Perner;,citation_author=Bodil S. Rasmussen;,citation_author=Anders Granholm;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=1;,citation_doi=10.1016/j.bja.2021.09.010;,citation_issn=00070912;,citation_volume=128;,citation_language=en-US;,citation_journal_title=British Journal of Anaesthesia;">
<meta name="citation_reference" content="citation_title=Balanced solution versus saline in critically ill patients: A new piece to the puzzle!;,citation_author=Kada Klouche;,citation_author=Xavier Monnet;,citation_author=Alexander Zarbock;,citation_publication_date=2023-12;,citation_cover_date=2023-12;,citation_year=2023;,citation_doi=10.1007/s00134-023-07306-2;,citation_issn=1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Long-term health-related quality of life of adult patients treated with extracorporeal membrane oxygenation (ECMO): An integrative review;,citation_abstract=Background: Extracorporeal membrane oxygenation (ECMO), a rescue treatment for patients with severe pulmonary and/or cardiac dysfunction, is increasingly being used worldwide. A better understanding of long-term health-related quality of life (HRQOL) is needed. Objective: To synthesize research on long-term (at least 6 months post-ECMO) HRQOL of adults treated with ECMO. Methods: In this integrative review, we searched 3 electronic databases and did a hand search of relevant journals for articles published 2000–2019, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Results: Thirty-one studies, representing 913 patients treated with ECMO, were included. Long-term HRQOL was slightly better for patients treated with veno-venous ECMO than veno-arterial ECMO, and mental health outcomes tended to be better than physical ones. Survivors frequently experienced physical complications, functional limitations, anxiety, depression, and post-traumatic stress symptoms, although improvements were observed over time. Conclusions: Early identification and management of physical and mental health problems may improve HRQOL outcomes.;,citation_author=Krista A. Knudson;,citation_author=Carolina M. Gustafson;,citation_author=Lois S. Sadler;,citation_author=Robin Whittemore;,citation_author=Nancy S. Redeker;,citation_author=Laura K. Andrews;,citation_author=Abeel Mangi;,citation_author=Marjorie Funk;,citation_publication_date=2019-11;,citation_cover_date=2019-11;,citation_year=2019;,citation_issue=6;,citation_doi=10.1016/j.hrtlng.2019.08.016;,citation_issn=0147-9563;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Heart &amp;amp;amp; Lung;">
<meta name="citation_reference" content="citation_title=Outcome Following Hemorrhage From Cranial Dural Arteriovenous Fistulae: Analysis of the Multicenter International CONDOR Registry;,citation_abstract=BACKGROUND AND PURPOSE: Dural arteriovenous fistulae can present with hemorrhage, but there remains a paucity of data regarding subsequent outcomes. We sought to use the CONDOR (Consortium for Dural Arteriovenous Fistula Outcomes Research), a multi-institutional registry, to characterize the morbidity and mortality of dural arteriovenous fistula–related hemorrhage. METHODS: A retrospective review of patients in CONDOR who presented with dural arteriovenous fistula–related hemorrhage was performed. Patient characteristics, clinical follow-up, and radiographic details were analyzed for associations with poor outcome (defined as modified Rankin Scale score \geq3). RESULTS: The CONDOR dataset yielded 262 patients with incident hemorrhage, with median follow-up of 1.4 years. Poor outcome was observed in 17.0% (95% CI, 12.3%–21.7%) at follow-up, including a 3.6% (95% CI, 1.3%–6.0%) mortality. Age and anticoagulant use were associated with poor outcome on multivariable analysis (odds ratio, 1.04, odds ratio, 5.1 respectively). Subtype of hemorrhage and venous shunting pattern of the lesion did not affect outcome significantly. CONCLUSIONS: Within the CONDOR registry, dural arteriovenous fistula–related hemorrhage was associated with a relatively lower morbidity and mortality than published outcomes from other arterialized cerebrovascular lesions but still at clinically consequential rates.;,citation_author=Matthew J. Koch;,citation_author=Christopher J. Stapleton;,citation_author=Ridhima Guniganti;,citation_author=Giuseppe Lanzino;,citation_author=Jason Sheehan;,citation_author=Ali Alaraj;,citation_author=Diederik Bulters;,citation_author=Louis Kim;,citation_author=W. Christopher Fox;,citation_author=Bradley A. Gross;,citation_author=Minako Hayakawa;,citation_author=J. Marc C. DijK;,citation_author=Robert M. Starke;,citation_author=Junichiro Satomi;,citation_author=Adam J. Polifka;,citation_author=Gregory J. Zipfel;,citation_author=Sepideh Amin-Hanjani;,citation_author=for the CONDOR Consortium*;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=10;,citation_doi=10.1161/STROKEAHA.121.034707;,citation_issn=0039-2499, 1524-4628;,citation_volume=52;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=Evaluation of Outcomes Among Patients With Traumatic Intracranial Hypertension Treated With Decompressive Craniectomy vs Standard Medical Care at 24 Months: A Secondary Analysis of the RESCUEicp Randomized Clinical Trial;,citation_abstract=Trials often assess primary outcomes of traumatic brain injury at 6 months. Longer-term data are needed to assess outcomes for patients receiving surgical vs medical treatment for traumatic intracranial hypertension.To evaluate 24-month outcomes for patients with traumatic intracranial hypertension treated with decompressive craniectomy or standard medical care.Prespecified secondary analysis of the Randomized Evaluation of Surgery With Craniectomy for Uncontrollable Elevation of Intracranial Pressure (RESCUEicp) randomized clinical trial data was performed for patients with traumatic intracranial hypertension (&amp;amp;amp;gt;25 mm Hg) from 52 centers in 20 countries. Enrollment occurred between January 2004 and March 2014. Data were analyzed between 2018 and 2021. Eligibility criteria were age 10 to 65 years, traumatic brain injury (confirmed via computed tomography), intracranial pressure monitoring, and sustained and refractory elevated intracranial pressure for 1 to 12 hours despite pressure-controlling measures. Exclusion criteria were bilateral fixed and dilated pupils, bleeding diathesis, or unsurvivable injury.Patients were randomly assigned 1:1 to receive a decompressive craniectomy with standard care (surgical group) or to ongoing medical treatment with the option to add barbiturate infusion (medical group).The primary outcome was measured with the 8-point Extended Glasgow Outcome Scale (1 indicates death and 8 denotes upper good recovery), and the 6- to 24-month outcome trajectory was examined.This study enrolled 408 patients: 206 in the surgical group and 202 in the medical group. The mean (SD) age was 32.3 (13.2) and 34.8 (13.7) years, respectively, and the study population was predominantly male (165 [81.7%] and 156 [80.0%], respectively). At 24 months, patients in the surgical group had reduced mortality (61 [33.5%] vs 94 [54.0%]; absolute difference, -20.5 [95% CI, -30.8 to -10.2]) and higher rates of vegetative state (absolute difference, 4.3 [95% CI, 0.0 to 8.6]), lower or upper moderate disability (4.7 [-0.9 to 10.3] vs 2.8 [-4.2 to 9.8]), and lower or upper severe disability (2.2 [-5.4 to 9.8] vs 6.5 [1.8 to 11.2]; \chi27 = 24.20, P = .001). For every 100 individuals treated surgically, 21 additional patients survived at 24 months; 4 were in a vegetative state, 2 had lower and 7 had upper severe disability, and 5 had lower and 3 had upper moderate disability, respectively. Rates of lower and upper good recovery were similar for the surgical and medical groups (20 [11.0%] vs 19 [10.9%]), and significant differences in net improvement (\geq1 grade) were observed between 6 and 24 months (55 [30.0%] vs 25 [14.0%]; \chi22 = 13.27, P = .001).At 24 months, patients with surgically treated posttraumatic refractory intracranial hypertension had a sustained reduction in mortality and higher rates of vegetative state, severe disability, and moderate disability. Patients in the surgical group were more likely to improve over time vs patients in the medical group.ISRCTN Identifier: 66202560;,citation_author=Angelos G. Kolias;,citation_author=Hadie Adams;,citation_author=Ivan S. Timofeev;,citation_author=Elizabeth A. Corteen;,citation_author=Iftakher Hossain;,citation_author=Marek Czosnyka;,citation_author=Jake Timothy;,citation_author=Ian Anderson;,citation_author=Diederik O. Bulters;,citation_author=Antonio Belli;,citation_author=C. Andrew Eynon;,citation_author=John Wadley;,citation_author=A. David Mendelow;,citation_author=Patrick M. Mitchell;,citation_author=Mark H. Wilson;,citation_author=Giles Critchley;,citation_author=Juan Sahuquillo;,citation_author=Andreas Unterberg;,citation_author=Jussi P. Posti;,citation_author=Franco Servadei;,citation_author=Graham M. Teasdale;,citation_author=John D. Pickard;,citation_author=David K. Menon;,citation_author=Gordon D. Murray;,citation_author=Peter J. Kirkpatrick;,citation_author=Peter J. Hutchinson;,citation_author=RESCUEicp Trial Collaborators;,citation_publication_date=2022-07;,citation_cover_date=2022-07;,citation_year=2022;,citation_issue=7;,citation_doi=10.1001/jamaneurol.2022.1070;,citation_issn=2168-6149;,citation_volume=79;,citation_journal_title=JAMA Neurology;">
<meta name="citation_reference" content="citation_title=Timing of antibiotic therapy in the ICU;,citation_abstract=Severe or life threatening infections are common among patients in the intensive care unit (ICU). Most infections in the ICU are bacterial or fungal in origin and require antimicrobial therapy for clinical resolution. Antibiotics are the cornerstone of therapy for infected critically ill patients. However, antibiotics are often not optimally administered resulting in less favorable patient outcomes including greater mortality. The timing of antibiotics in patients with life threatening infections including sepsis and septic shock is now recognized as one of the most important deter-minants of survival for this population. Individuals who have a delay in the administration of antibiotic therapy for serious infections can have a doubling or more in their mortality. Additionally, the timing of an appropriate antibiotic regimen, one that is active against the offending pathogens based on in vitro susceptibility, also influences survival. Thus not only is early empiric antibiotic administration important but the selection of those agents is crucial as well. The duration of antibiotic infusions, especially for \beta-lactams, can also influence antibiotic efficacy by increasing antimicrobial drug exposure for the offending pathogen. However, due to mounting antibiotic resistance, aggres-sive antimicrobial de-escalation based on microbiology results is necessary to counterbalance the pressures of early broad-spectrum antibiotic therapy. In this review, we examine time related variables impacting antibiotic optimiza-tion as it relates to the treatment of life threatening infections in the ICU. In addition to highlighting the importance of antibiotic timing in the ICU we hope to provide an approach to antimicrobials that also minimizes the unneces-sary use of these agents. Such approaches will increasingly be linked to advances in molecular microbiology testing and artificial intelligence/machine learning. Such advances should help identify patients needing empiric antibiotic therapy at an earlier time point as well as the specific antibiotics required in order to avoid unnecessary administra-tion of broad-spectrum antibiotics.;,citation_author=Marin H. Kollef;,citation_author=Andrew F. Shorr;,citation_author=Matteo Bassetti;,citation_author=Jean-Francois Timsit;,citation_author=Scott T. Micek;,citation_author=Andrew P. Michelson;,citation_author=Jose Garnacho-Montero;,citation_publication_date=2021-12;,citation_cover_date=2021-12;,citation_year=2021;,citation_issue=1;,citation_doi=10.1186/s13054-021-03787-z;,citation_issn=1364-8535;,citation_volume=25;,citation_language=en-US;,citation_journal_title=Critical Care;">
<meta name="citation_reference" content="citation_title=Outcome after Hunt and Hess Grade V subarachnoid hemorrhage: A comparison of pre-coiling era (1980–1995) versus post-ISAT era (2005–2014);,citation_abstract=OBJECTIVE Outcome analysis of comatose patients (Hunt and Hess Grade V) after subarachnoid hemorrhage (SAH) is still lacking. The aims of this study were to analyze the outcome of Hunt and Hess Grade V SAH and to compare outcomes in the current period with those of the pre–International Subarachnoid Aneurysm Trial (ISAT) era as well as with published data from trials of decompressive craniectomy (DC) for middle cerebral artery (MCA) infarction. METHODS The authors analyzed cases of Hunt and Hess Grade V SAH from 1980–1995 (referred to in this study as the earlier period) and 2005–2014 (current period) and compared the results for the 2 periods. The outcomes of 257 cases were analyzed and stratified on the basis of modified Rankin Scale (mRS) scores obtained 6 months after SAH. Outcomes were dichotomized as favorable (mRS score of 0–2) or unfavorable (mRS score of 3–6). Data and number needed to treat (NNT) were also compared with the results of decompressive craniectomy (DC) trials for middle cerebral artery (MCA) infarctions. RESULTS Early aneurysm treatment within 72 hours occurred significantly more often in the current period (in 67% of cases vs 22% in earlier period). In the earlier period, patients had a significantly higher 30-day mortality rate (83% vs 39% in the current period) and 6-month mortality rate (94% vs 49%), and no patient (0%) had a favorable outcome, compared with 23% overall in the current period (p &amp;amp;amp;lt; 0.01, OR 32), or 29.5% of patients whose aneurysms were treated (p &amp;lt; 0.01, OR 219). Cerebral infarctions occurred in up to 65% of the treated patients in the current period. Comparison with data from DC MCA trials showed that the NNTs were significantly lower in the current period with 2 for survival and 3 for mRS score of 0–3 (vs 3 and 7, respectively, for the DC MCA trials). CONCLUSIONS Early and aggressive treatment resulted in a significant improvement in survival rate (NNT = 2) and favorable outcome (NNT = 3 for mRS score of 0–3) for comatose patients with Hunt and Hess Grade V SAH compared with the earlier period. Independent predictors for favorable outcome were younger age and bilateral intact corneal reflexes. Despite a high rate of cerebral infarction (65%) in the current period, 29.5% of the patients who received treatment for their aneurysms during the current era (2005–2014) had a favorable outcome. However, careful individual decision making is essential in these cases. https://thejns.org/doi/abs/10.3171/2016.8.JNS161075 KEY WORDS subarachnoid hemorrhage; Hunt and Hess Grade V; severe SAH; clinical outcome; prognostic factors; stroke trials; coma; vascular disorders;,citation_author=Juergen Konczalla;,citation_author=Volker Seifert;,citation_author=Juergen Beck;,citation_author=Erdem Güresir;,citation_author=Hartmut Vatter;,citation_author=Andreas Raabe;,citation_author=Gerhard Marquardt;,citation_publication_date=2018-01;,citation_cover_date=2018-01;,citation_year=2018;,citation_issue=1;,citation_doi=10.3171/2016.8.JNS161075;,citation_issn=0022-3085, 1933-0693;,citation_volume=128;,citation_language=en-US;,citation_journal_title=Journal of Neurosurgery;">
<meta name="citation_reference" content="citation_title=The Neurology of Death and the Dying Brain: A Pictorial Essay;,citation_abstract=As neurologists earn their living with the preservation and restoration of brain function, they are also well-positioned to address the science behind the transition from life to death. This essay in pictures highlights areas of neurological expertise needed for brain death determination; shows pitfalls to avoid during the clinical examination and interpretation of confirmatory laboratory tests in brain death protocols; illustrates the great variability of brain death legislations around the world; discusses arguments for the implementation of donation after circulatory death (DCD); points to unresolved questions related to DCD and the time between cardiac standstill and organ procurement (“hands-off period”); provides an overview of the epidemiology and semiology of near-death experiences, including their importance for religion, literature, and the visual arts; suggests biological mechanisms for near-death experiences such as dysfunction of temporoparietal cortex, N-methyl-D-aspartate receptor antagonism, migraine aura, and rapid eye movement sleep; hypothesizes that thanatosis (aka. death-feigning, a common behavioral trait in the animal kingdom) represents the evolutionary origin of neardeath experiences; and speculates about the future implications of recent attempts of brain resuscitation in an animal model. The aim is to provide the reader with a thorough understanding that the boundaries within the neurology of death and the dying brain are being pushed just like everywhere else in the clinical neurosciences.;,citation_author=Daniel Kondziella;,citation_publication_date=2020-07;,citation_cover_date=2020-07;,citation_year=2020;,citation_doi=10.3389/fneur.2020.00736;,citation_issn=1664-2295;,citation_volume=11;,citation_language=en-US;,citation_journal_title=Frontiers in Neurology;">
<meta name="citation_reference" content="citation_title=Diagnosis of Fluid Overload: From Conventional to Contemporary Concepts;,citation_abstract=Fluid overload has been associated with morbidity and mortality in various clinical scenarios including heart failure and critical illness. It exerts pathologic sequelae in almost all the organ systems. Proper management of patients with fluid overload requires knowledge of the underlying pathophysiology, objective evaluation of volume status, selection of appropriate therapeutic options, and maintenance and modulation of tissue perfusion. There are several methods to appraise volume status but none without limitations. In this review, we discuss the diagnostic utility, prognostic significance, and shortcomings of various bedside tools in the detection of fluid overload and evaluation of hemodynamic status. These include clinical examination, biomarkers, blood volume assessment, bioimpedance analysis, point-of-care ultrasound, and remote pulmonary pressure monitoring. In our opinion, clinicians must adopt a multiparametric approach offsetting the limitations of individual methods to formulate a management plan tailored to patients’ needs.;,citation_author=Abhilash Koratala;,citation_author=Claudio Ronco;,citation_author=Amir Kazory;,citation_publication_date=2022-09;,citation_cover_date=2022-09;,citation_year=2022;,citation_doi=10.1159/000526902;,citation_issn=1664-3828, 1664-5502;,citation_language=en-US;,citation_journal_title=Cardiorenal Medicine;">
<meta name="citation_reference" content="citation_title=POCUS for Nephrologists - Basic Principles and a General Approach;,citation_abstract=Point of care ultrasonography (POCUS) has evolved as a valuable adjunct to physical examination in the recent past and various medical specialties have embraced it. However, POCUS training and scope of practice remain relatively undefined in nephrology. The utility of diagnostic POCUS beyond kidney and vascular access is under-recognized. Assessment of fluid status is a frequent dilemma faced by nephrologists in day-to-day practice where multi-organ POCUS can enhance the sensitivity of conventional physical examination. POCUS also reduces fragmentation of care, facilitates timely diagnosis, and expedites management. While the need for further imaging studies is obviated in selected cases, POCUS is not meant to serve as an alternative to consultative imaging. In addition, utility of POCUS depends on the skills and experience of the operator, which in turn depends on the quality of training. In this review, we discuss the rationale behind nephrologists performing POCUS, discuss case examples to illustrate the basic principles of focused ultrasonography, and share our experience-based opinion about developing a POCUS training program at the institutional level.;,citation_author=Abhilash Koratala;,citation_author=Nathaniel Reisinger;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_doi=10.34067/KID.0002482021;,citation_issn=2641-7650, 2641-7650;,citation_language=en-US;,citation_journal_title=Kidney360;">
<meta name="citation_reference" content="citation_title=Early Convalescent Plasma for High-Risk Outpatients with Covid-19;,citation_abstract=BACKGROUND Early administration of convalescent plasma obtained from blood donors who have recovered from coronavirus disease 2019 (Covid-19) may prevent disease progression in acutely ill, high-risk patients with Covid-19. METHODS In this randomized, multicenter, single-blind trial, we assigned patients who were being treated in an emergency department for Covid-19 symptoms to receive either one unit of convalescent plasma with a high titer of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or placebo. All the patients were either 50 years of age or older or had one or more risk factors for disease progression. In addition, all the patients presented to the emergency department within 7 days after symptom onset and were in stable condition for outpatient management. The primary outcome was disease progression within 15 days after randomization, which was a composite of hospital admission for any reason, seeking emergency or urgent care, or death without hospitalization. Secondary outcomes included the worst severity of illness on an 8-category ordinal scale, hospital-free days within 30 days after randomization, and death from any cause. The authors’ full names, academic degrees, and affiliations are listed in the Appendix. Address reprint requests to Dr. Callaway at the University of Pittsburgh, 400A Iroquois, 3600 Forbes Ave., Pittsburgh, PA 15260, or at callawaycw@ upmc.edu. *A list of the SIREN-C3PO investigators is provided in the Supplementary Appendix, available at NEJM.org. This article was published on August 18, 2021, at NEJM.org. N Engl J Med 2021;385:1951-60. DOI: 10.1056/NEJMoa2103784 Copyright © 2021 Massachusetts Medical Society. RESULTS A total of 511 patients were enrolled in the trial (257 in the convalescent-plasma group and 254 in the placebo group). The median age of the patients was 54 years; the median symptom duration was 4 days. In the donor plasma samples, the median titer of SARS-CoV-2 neutralizing antibodies was 1:641. Disease progression occurred in 77 patients (30.0%) in the convalescent-plasma group and in 81 patients (31.9%) in the placebo group (risk difference, 1.9 percentage points; 95% credible interval, -6.0 to 9.8; posterior probability of superiority of convalescent plasma, 0.68). Five patients in the plasma group and 1 patient in the placebo group died. Outcomes regarding worst illness severity and hospital-free days were similar in the two groups. CONCLUSIONS The administration of Covid-19 convalescent plasma to high-risk outpatients within 1 week after the onset of symptoms of Covid-19 did not prevent disease progression. (SIREN-C3PO ClinicalTrials.gov number, NCT04355767.);,citation_author=Frederick K. Korley;,citation_author=Valerie Durkalski-Mauldin;,citation_author=Sharon D. Yeatts;,citation_author=Kevin Schulman;,citation_author=Robertson D. Davenport;,citation_author=Larry J. Dumont;,citation_author=Nahed El Kassar;,citation_author=Lydia D. Foster;,citation_author=Jennifer M. Hah;,citation_author=Siddartha Jaiswal;,citation_author=Alesia Kaplan;,citation_author=Ezekiel Lowell;,citation_author=John F. McDyer;,citation_author=James Quinn;,citation_author=Darrell J. Triulzi;,citation_author=Carol Van Huysen;,citation_author=Valerie L. W. Stevenson;,citation_author=Kabir Yadav;,citation_author=Christopher W. Jones;,citation_author=Bory Kea;,citation_author=Aaron Burnett;,citation_author=Joshua C. Reynolds;,citation_author=Colin F. Greineder;,citation_author=Nathan L. Haas;,citation_author=David G. Beiser;,citation_author=Robert Silbergleit;,citation_author=William Barsan;,citation_author=Clifton W. Callaway;,citation_publication_date=2021-11;,citation_cover_date=2021-11;,citation_year=2021;,citation_issue=21;,citation_doi=10.1056/NEJMoa2103784;,citation_issn=0028-4793, 1533-4406;,citation_volume=385;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Framework for advancing rigorous research;,citation_abstract=There is a pressing need to increase the rigor of research in the life and biomedical sciences. To address this issue, we propose that communities of ’rigor champions’ be established to campaign for reforms of the research culture that has led to shortcomings in rigor. These communities of rigor champions would also assist in the development and adoption of a comprehensive educational platform that would teach the principles of rigorous science to researchers at all career stages.;,citation_author=Walter J Koroshetz;,citation_author=Shannon Behrman;,citation_author=Cynthia J Brame;,citation_author=Janet L Branchaw;,citation_author=Emery N Brown;,citation_author=Erin A Clark;,citation_author=David Dockterman;,citation_author=Jordan J Elm;,citation_author=Pamela L Gay;,citation_author=Katelyn M Green;,citation_author=Sherry Hsi;,citation_author=Michael G Kaplitt;,citation_author=Benedict J Kolber;,citation_author=Alex L Kolodkin;,citation_author=Diane Lipscombe;,citation_author=Malcolm R MacLeod;,citation_author=Caleb C McKinney;,citation_author=Marcus R Munafò;,citation_author=Barbara Oakley;,citation_author=Jeffrey T Olimpo;,citation_author=Nathalie Percie du Sert;,citation_author=Indira M Raman;,citation_author=Ceri Riley;,citation_author=Amy L Shelton;,citation_author=Stephen Miles Uzzo;,citation_author=Devon C Crawford;,citation_author=Shai D Silberberg;,citation_publication_date=2020-03;,citation_cover_date=2020-03;,citation_year=2020;,citation_doi=10.7554/eLife.55915;,citation_issn=2050-084X;,citation_volume=9;,citation_language=en-US;,citation_journal_title=eLife;">
<meta name="citation_reference" content="citation_title=Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity;,citation_author=Mikhail N. Kosiborod;,citation_author=Steen Z. Abildstrøm;,citation_author=Barry A. Borlaug;,citation_author=Javed Butler;,citation_author=Søren Rasmussen;,citation_author=Melanie Davies;,citation_author=G. Kees Hovingh;,citation_author=Dalane W. Kitzman;,citation_author=Marie L. Lindegaard;,citation_author=Daniél V. Møller;,citation_author=Sanjiv J. Shah;,citation_author=Marianne B. Treppendahl;,citation_author=Subodh Verma;,citation_author=Walter Abhayaratna;,citation_author=Fozia Z. Ahmed;,citation_author=Vijay Chopra;,citation_author=Justin Ezekowitz;,citation_author=Michael Fu;,citation_author=Hiroshi Ito;,citation_author=Małgorzata Lelonek;,citation_author=Vojtech Melenovsky;,citation_author=Bela Merkely;,citation_author=Julio Núñez;,citation_author=Eduardo Perna;,citation_author=Morten Schou;,citation_author=Michele Senni;,citation_author=Kavita Sharma;,citation_author=Peter Van der Meer;,citation_author=Dirk Lewinski;,citation_author=Dennis Wolf;,citation_author=Mark C Petrie;,citation_publication_date=2023-09;,citation_cover_date=2023-09;,citation_year=2023;,citation_issue=12;,citation_doi=10.1056/NEJMoa2306963;,citation_issn=0028-4793;,citation_volume=389;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=What Is a Mentor?;,citation_author=Suzanne Koven;,citation_publication_date=2024-02;,citation_cover_date=2024-02;,citation_year=2024;,citation_issue=0;,citation_doi=10.1056/NEJMp2313304;,citation_issn=0028-4793;,citation_volume=0;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Spoke-Administered Thrombolysis Improves Large-Vessel Occlusion Early Recanalization: The Real-World Experience of a Large Academic Hub-and-Spoke Telestroke Network;,citation_abstract=Background Intravenous thrombolysis (IVT) before mechanical thrombectomy (MT) for large-vessel occlusion (LVO) stroke is increasingly controversial. Recent trials suggest MT without IVT is reasonable for patients presenting directly to MT-capable “hub” centers. However, bypassing IVT has not been evaluated for patients presenting to IVT-capable “spoke” hospitals that require hub transfer for MT. A perceived lack of efficacy of IVT to result in LVO early recanalization (ER) is often cited to support bypassing IVT, but data for IVT in patients who require interhospital transfer are limited. Here, we examined LVO ER rates after spoke-administered IVT in our hub-and-spoke stroke network. Methods Patients presenting to 25 spokes before hub transfer for MT consideration from 2018 to 2020 were retrospectively identified from a prospectively maintained database. Inclusion criteria were pretransfer computed tomography angiography–defined LVO, Alberta Stroke Program Early Computed Tomography Score \geq6, and posttransfer repeat vessel imaging. Results Of 167 patients, median age was 69, and 51% were women. Seventy-six received spoke IVT, and 91 did not. Alteplase was the only IVT used in this study. Comorbidities and National Institutes of Health Stroke Scale were similar between groups. ER frequency was increased 7.2-fold in patients who received spoke IVT (12/76 [15.8%] versus 2/91 [2.2%]; P&amp;amp;amp;lt;0.001]. Spoke-administered IVT was independently associated with ER (adjusted odds ratio, =11.5 [95% CI, 2.2–99.6; P&amp;lt;0.05) after adjusting for the timing of&nbsp;last known well, interhospital transfer, and repeat vessel imaging. Interval National Institutes of Health Stroke Scale score was improved in patients with ER (median -2 [interquartile range, -6.3 to -0.8] versus 0 [-2.5 to 1]; P<0.05). Conclusion Within our network, patients who received spoke IVT had a 7.2-fold increased ER relative likelihood. This real-world analysis supports IVT use in eligible patients with LVO at spoke hospitals before hub transfer for MT.;,citation_author=Andrew W. Kraft;,citation_author=Robert W. Regenhardt;,citation_author=Amine Awad;,citation_author=Joseph A. Rosenthal;,citation_author=Adam A. Dmytriw;,citation_author=Justin E. Vranic;,citation_author=Anna K. Bonkhoff;,citation_author=Martin Bretzner;,citation_author=Joshua A. Hirsch;,citation_author=James D. Rabinov;,citation_author=Christopher J. Stapleton;,citation_author=Lee H. Schwamm;,citation_author=Aneesh B. Singhal;,citation_author=Natalia S. Rost;,citation_author=Thabele M. Leslie-Mazwi;,citation_author=Aman B. Patel;,citation_publication_date=2023-01;,citation_cover_date=2023-01;,citation_year=2023;,citation_issue=1;,citation_doi=10.1161/SVIN.122.000427;,citation_volume=3;,citation_journal_title=Stroke: Vascular and Interventional Neurology;,citation_publisher=Wiley;">
<meta name="citation_reference" content="citation_title=Decoding the meaning of medical guidelines and their medicolegal implications;,citation_abstract=Medical practice guidelines (MPGs) are important in medicine to ensure well tolerated and effective healthcare. They provide evidence-based recommendations for healthcare professionals in daily clinical settings. MPGs help patients and practitioners make informed decisions, ensure quality of care, allocate healthcare resources effectively and reduce legal liability. MPGs have medicolegal implications, as they influence clinical decision-making and patient outcomes, which can impact liability and malpractice cases. They define the standard of care within the healthcare industry and provide best practice recommendations. MPGs are a cornerstone of the informed consent process, as they facilitate a shared decision support system and they provide valuable evidence-based recommendations on various treatments or medical options. Finally, MPGs are also relevant in medical claims; thus, adherence to MPGs is highly encouraged in order to assure the best medical care. Nonetheless, MPGs have limitations and we advocate for wise usage of MPGs combined with the expertise of trained physicians that allows for individualisation and evidence-based recommendations. In this review, we describe the potential legal implications that MPGs may represent for healthcare providers and the role that MPGs have in daily practice at different stages in the doctor–patient relationship.;,citation_author=Peter Kranke;,citation_author=Arash Afshari;,citation_author=Patrick Meybohm;,citation_author=Wolfgang Buhre;,citation_author=Stephanie Wiege;,citation_author=Carolina S. Romero;,citation_publication_date=2024-02;,citation_cover_date=2024-02;,citation_year=2024;,citation_issue=2;,citation_doi=10.1097/EJA.0000000000001917;,citation_issn=0265-0215, 1365-2346;,citation_volume=41;,citation_language=en-US;,citation_journal_title=European Journal of Anaesthesiology;">
<meta name="citation_reference" content="citation_title=Considerations in boosting COVID-19 vaccine immune responses;,citation_author=Philip R Krause;,citation_author=Thomas R Fleming;,citation_author=Richard Peto;,citation_author=Ira M Longini;,citation_author=J Peter Figueroa;,citation_author=Jonathan A C Sterne;,citation_author=Alejandro Cravioto;,citation_author=Helen Rees;,citation_author=Julian P T Higgins;,citation_author=Isabelle Boutron;,citation_author=Hongchao Pan;,citation_author=Marion F Gruber;,citation_author=Narendra Arora;,citation_author=Fatema Kazi;,citation_author=Rogerio Gaspar;,citation_author=Soumya Swaminathan;,citation_author=Michael J Ryan;,citation_author=Ana-Maria Henao-Restrepo;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=10308;,citation_doi=10.1016/S0140-6736(21)02046-8;,citation_issn=01406736;,citation_volume=398;,citation_language=en-US;,citation_journal_title=The Lancet;">
<meta name="citation_reference" content="citation_title=“How I Teach”: A Novel Guide to Teaching in Pulmonary, Critical Care, and Sleep Medicine;,citation_author=Patricia A. Kritek;,citation_author=Kristin M. Burkart;,citation_author=Nitin Seam;,citation_publication_date=2022-12;,citation_cover_date=2022-12;,citation_year=2022;,citation_issue=4;,citation_doi=10.34197/ats-scholar.2022-0122ED;,citation_volume=3;,citation_journal_title=ATS Scholar;,citation_publisher=American Thoracic Society - ATS Scholar;">
<meta name="citation_reference" content="citation_title=Bayesian data analysis;,citation_abstract=Abstract Bayesian methods have garnered huge interest in cognitive science as an approach to models of cognition and perception. On the other hand, Bayesian methods for data analysis have not yet made much headway in cognitive science against the institutionalized inertia of 20th century null hypothesis significance testing (NHST). Ironically, specific Bayesian models of cognition and perception may not long endure the ravages of empirical verification, but generic Bayesian methods for data analysis will eventually dominate. It is time that Bayesian data analysis became the norm for empirical methods in cognitive science. This article reviews a fatal flaw of NHST and introduces the reader to some benefits of Bayesian data analysis. The article presents illustrative examples of multiple comparisons in Bayesian analysis of variance and Bayesian approaches to statistical power. Copyright © 2010 John Wiley &amp;amp;amp; Sons, Ltd. This article is categorized under: Psychology &amp;gt; Theory and Methods;,citation_author=John K. Kruschke;,citation_publication_date=2010-09;,citation_cover_date=2010-09;,citation_year=2010;,citation_issue=5;,citation_doi=10.1002/wcs.72;,citation_issn=1939-5078, 1939-5086;,citation_volume=1;,citation_language=en-US;,citation_journal_title=WIREs Cognitive Science;">
<meta name="citation_reference" content="citation_title=Bayesian estimation supersedes the t test.;,citation_abstract=Bayesian estimation for 2 groups provides complete distributions of credible values for the effect size, group means and their difference, standard deviations and their difference, and the normality of the data. The method handles outliers. The decision rule can accept the null value (unlike traditional t tests) when certainty in the estimate is high (unlike Bayesian model comparison using Bayes factors). The method also yields precise estimates of statistical power for various research goals. The software and programs are free and run on Macintosh, Windows, and Linux platforms.;,citation_author=John K. Kruschke;,citation_publication_date=2013;,citation_cover_date=2013;,citation_year=2013;,citation_issue=2;,citation_doi=10.1037/a0029146;,citation_issn=1939-2222, 0096-3445;,citation_volume=142;,citation_language=en-US;,citation_journal_title=Journal of Experimental Psychology: General;">
<meta name="citation_reference" content="citation_title=The Bayesian New Statistics: Hypothesis testing, estimation, meta-analysis, and power analysis from a Bayesian perspective;,citation_abstract=In the practice of data analysis, there is a conceptual distinction between hypothesis testing, on the one hand, and estimation with quantified uncertainty on the other. Among frequentists in psychology, a shift of emphasis from hypothesis testing to estimation has been dubbed “the New Statistics” (Cumming, 2014). A second conceptual distinction is between frequentist methods and Bayesian methods. Our main goal in this article is to explain how Bayesian methods achieve the goals of the New Statistics better than frequentist methods. The article reviews frequentist and Bayesian approaches to hypothesis testing and to estimation with confidence or credible intervals. The article also describes Bayesian approaches to meta-analysis, randomized controlled trials, and power analysis.;,citation_author=John K. Kruschke;,citation_author=Torrin M. Liddell;,citation_publication_date=2018-02;,citation_cover_date=2018-02;,citation_year=2018;,citation_issue=1;,citation_doi=10.3758/s13423-016-1221-4;,citation_issn=1069-9384, 1531-5320;,citation_volume=25;,citation_language=en-US;,citation_journal_title=Psychonomic Bulletin &amp;amp;amp; Review;">
<meta name="citation_reference" content="citation_title=Bayesian data analysis for newcomers;,citation_abstract=This article explains the foundational concepts of Bayesian data analysis using virtually no mathematical notation. Bayesian ideas already match your intuitions from everyday reasoning and from traditional data analysis. Simple examples of Bayesian data analysis are presented that illustrate how the information delivered by a Bayesian analysis can be directly interpreted. Bayesian approaches to null-value assessment are discussed. The article clarifies misconceptions about Bayesian methods that newcomers might have acquired elsewhere. We discuss prior distributions and explain how they are not a liability but an important asset. We discuss the relation of Bayesian data analysis to Bayesian models of mind, and we briefly discuss what methodological problems Bayesian data analysis is not meant to solve. After you have read this article, you should have a clear sense of how Bayesian data analysis works and the sort of information it delivers, and why that information is so intuitive and useful for drawing conclusions from data.;,citation_author=John K. Kruschke;,citation_author=Torrin M. Liddell;,citation_publication_date=2018-02;,citation_cover_date=2018-02;,citation_year=2018;,citation_issue=1;,citation_doi=10.3758/s13423-017-1272-1;,citation_issn=1069-9384, 1531-5320;,citation_volume=25;,citation_language=en-US;,citation_journal_title=Psychonomic Bulletin &amp;amp;amp; Review;">
<meta name="citation_reference" content="citation_title=Bayesian Analysis Reporting Guidelines;,citation_abstract=Previous surveys of the literature have shown that reports of statistical analyses often lack important information, causing lack of transparency and failure of reproducibility. Editors and authors agree that guidelines for reporting should be encouraged. This Review presents a set of Bayesian analysis reporting guidelines (BARG). The BARG encompass the features of previous guidelines, while including many additional details for contemporary Bayesian analyses, with explanations. An extensive example of applying the BARG is presented. The BARG should be useful to researchers, authors, reviewers, editors, educators and students. Utilization, endorsement and promotion of the BARG may improve the quality, transparency and reproducibility of Bayesian analyses.;,citation_author=John K. Kruschke;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=10;,citation_doi=10.1038/s41562-021-01177-7;,citation_issn=2397-3374;,citation_volume=5;,citation_language=en-US;,citation_journal_title=Nature Human Behaviour;,citation_publisher=Nature Publishing Group;">
<meta name="citation_reference" content="citation_title=Defining the Time-Limited Trial for Patients with Critical Illness: An Official American Thoracic Society Workshop Report;,citation_abstract=In critical care, the specific, structured approach to patient care known as a “time-limited trial” has been promoted in the literature to help patients, surrogate decision makers, and clinicians navigate consequential decisions about life-sustaining therapy in the face of uncertainty. Despite promotion of the time-limited trial approach, a lack of consensus about its definition and essential elements prevents optimal clinical use and rigorous evaluation of its impact. The objectives of this American Thoracic Society Workshop Committee were to establish a consensus definition of a time-limited trial in critical care, identify the essential elements for conducting a time-limited trial, and prioritize directions for future work. We achieved these objectives through a structured search of the literature, a modified Delphi process with 100 interdisciplinary and interprofessional stakeholders, and iterative committee discussions. We conclude that a time-limited trial for patients with critical illness is a collaborative plan among clinicians and a patient and/or their surrogate decision maker(s) to use life-sustaining therapy for a defined duration, after which the patient’s response to therapy informs the decision to continue care directed towards recovery, transition to care focused exclusively on comfort, or extend the trial’s duration. The plan’s 16 essential elements follow four sequential phases: consider, plan, support, reassess. We acknowledge considerable gaps in evidence about the impact of timelimited trials and highlight a concern that, if inadequately implemented, time-limited trials may perpetuate unintended harm. Future work is needed to better implement this defined, specific approach to care in practice through a person-centered equity lens and to evaluate its impact on patients, surrogates, and clinicians.;,citation_author=Jacqueline M Kruser;,citation_author=Deepshikha C. Ashana;,citation_author=Katherine R Courtright;,citation_author=Erin K. Kross;,citation_author=Thanh H Neville;,citation_author=Eileen Rubin;,citation_author=Yael Schenker;,citation_author=Donald Sullivan;,citation_author=J. Daryl Thornton;,citation_author=Elizabeth M. Viglianti;,citation_author=Deena Kelly Costa;,citation_author=Claire J Creutzfeldt;,citation_author=Michael E. Detsky;,citation_author=Heidi Engel;,citation_author=Neera Grover;,citation_author=Aluko A Hope;,citation_author=Jason N Katz;,citation_author=Rachel Kohn;,citation_author=Andrew G Miller;,citation_author=Michael J. Nabozny;,citation_author=Judith E. Nelson;,citation_author=Hasan Shanawani;,citation_author=Jennifer P. Stevens;,citation_author=Alison E. Turnbull;,citation_author=Curtis H. Weiss;,citation_author=M. Jeanne Wirpsa;,citation_author=Christopher E Cox;,citation_publication_date=2023-12;,citation_cover_date=2023-12;,citation_year=2023;,citation_doi=10.1513/AnnalsATS.202310-925ST;,citation_issn=2329-6933, 2325-6621;,citation_language=en-US;,citation_journal_title=Annals of the American Thoracic Society;">
<meta name="citation_reference" content="citation_title=Mild therapeutic hypothermia or targeted temperature management for cardiac arrest survivors?;,citation_author=Jacek Kubica;,citation_author=Robert Gajda;,citation_author=Klaudiusz Nadolny;,citation_publication_date=2022-10;,citation_cover_date=2022-10;,citation_year=2022;,citation_doi=10.5603/CJ.a2022.0098;,citation_issn=1898-018X, 1897-5593;,citation_language=en-US;,citation_journal_title=Cardiology Journal;">
<meta name="citation_reference" content="citation_title=Early Deterioration, Hematoma Expansion, and Outcomes in Deep Versus Lobar Intracerebral Hemorrhage: The FAST Trial;,citation_abstract=BACKGROUND: In patients with intracerebral hemorrhage (ICH), it is unclear whether early neurological deterioration, hematoma expansion (HE), and outcome vary by supratentorial ICH location (deep versus lobar). Herein, we assessed these relationships in a clinical trial cohort that underwent brain imaging early after symptom onset. We hypothesized that HE would occur more frequently, and outcome would be worse in patients with deep ICH. METHODS: We performed a post hoc analysis of the FAST (Factor-VII-for-Acute-Hemorrhagic-Stroke-Treatment) trial including all patients with supratentorial hemorrhage. Enrolled patients underwent brain imaging within 3 hours of symptom onset and 24 hours after randomization. Multivariable regression was used to test the association between ICH location and 3 outcomes: HE (increase of \geq33% or 6mL), early neurological deterioration (decrease in Glasgow Coma Scale score \geq2 points or increase in National Institutes of Health Stroke Scale \geq4 points within 24 hours of admission), and 90-day outcome (modified Rankin Scale). RESULTS: Of 841 FAST trial patients, we included 728 (mean age 64 years, 38% women) with supratentorial hemorrhages (deep n=623, lobar n=105). HE (44 versus 27%, P=0.001) and early neurological deterioration (31 versus 17%, P=0.001) were more common in lobar hemorrhages. Deep hemorrhages were smaller than lobar hemorrhages at baseline (12 versus 35mL, P&amp;amp;amp;lt;0.001) and 24 hours (14 versus 38mL, P&amp;lt;0.001). Unadjusted 90-day outcome was worse in lobar compared with deep ICH (median modified Rankin Scale score 5 versus 4, P=0.03). However, when adjusting for variables included in the ICH score including ICH volume, deep location was associated with worse and lobar location with better outcome (odds ratio lobar location, 0.58 [95% CI, 0.38–0.89]; P=0.01). CONCLUSIONS: In this secondary analysis of randomized trial patients, lobar ICH location was associated with larger ICH volume, more HE and early neurological deterioration, and worse outcome than deep ICH. After adjustment for prognostic variables, however, deep ICH was associated with worse outcome, likely due to their proximity to eloquent brain structures.;,citation_author=Lindsey R. Kuohn;,citation_author=Jens Witsch;,citation_author=Thorsten Steiner;,citation_author=Kevin N. Sheth;,citation_author=Hooman Kamel;,citation_author=Babak B. Navi;,citation_author=Alexander E. Merkler;,citation_author=Santosh B. Murthy;,citation_author=Stephan A. Mayer;,citation_publication_date=2022-04;,citation_cover_date=2022-04;,citation_year=2022;,citation_doi=10.1161/STROKEAHA.121.037974;,citation_issn=0039-2499, 1524-4628;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=Association of Intraventricular Fibrinolysis With Clinical Outcomes in Intracerebral Hemorrhage: An Individual Participant Data Meta-Analysis;,citation_abstract=Background: In patients with intracerebral hemorrhage (ICH), the presence of intraventricular hemorrhage constitutes a promising therapeutic target. Intraventricular fibrinolysis (IVF) reduces mortality, yet impact on functional disability remains unclear. Thus, we aimed to determine the influence of IVF on functional outcomes. Methods: This individual participant data meta-analysis pooled 1501 patients from 2 randomized trials and 7 observational studies enrolled during 2004 to 2015. We compared IVF versus standard of care (including placebo) in patients treated with external ventricular drainage due to acute hydrocephalus caused by ICH with intraventricular hemorrhage. The primary outcome was functional disability evaluated by the modified Rankin Scale (mRS; range: 0–6, lower scores indicating less disability) at 6 months, dichotomized into mRS score: 0 to 3 versus mRS: 4 to 6. Secondary outcomes included ordinal-shift analysis, all-cause mortality, and intracranial adverse events. Confounding and bias were adjusted by random effects and doubly robust models to calculate odds ratios and absolute treatment effects (ATE). Results: Comparing treatment of 596 with IVF to 905 with standard of care resulted in an ATE to achieve the primary outcome of 9.3% (95% CI, 4.4–14.1). IVF treatment showed a significant shift towards improved outcome across the entire range of mRS estimates, common odds ratio, 1.75 (95% CI, 1.39–2.17), reduced mortality, odds ratio, 0.47 (95% CI, 0.35–0.64), without increased adverse events, absolute difference, 1.0% (95% CI, -2.7 to 4.8). Exploratory analyses provided that early IVF treatment (\leq48 hours) after symptom onset was associated with an ATE, 15.2% (95% CI, 8.6–21.8) to achieve the primary outcome. Conclusions: As compared to standard of care, the administration of IVF in patients with acute hydrocephalus caused by intracerebral and intraventricular hemorrhage was significantly associated with improved functional outcome at 6 months. The treatment effect was linked to an early time window &amp;amp;amp;lt;48 hours, specifying a target population for future trials.;,citation_author=Joji B. Kuramatsu;,citation_author=Stefan T. Gerner;,citation_author=Wendy Ziai;,citation_author=Jürgen Bardutzky;,citation_author=Jochen A. Sembill;,citation_author=Maximilian I. Sprügel;,citation_author=Anne Mrochen;,citation_author=Kathrin Kölbl;,citation_author=Malathi Ram;,citation_author=Radhika Avadhani;,citation_author=Guido J. Falcone;,citation_author=Magdy H. Selim;,citation_author=Vasileios-Arsenios Lioutas;,citation_author=Matthias Endres;,citation_author=Sarah Zweynert;,citation_author=Peter Vajkoczy;,citation_author=Peter A. Ringleb;,citation_author=Jan C. Purrucker;,citation_author=Jens Volkmann;,citation_author=Hermann Neugebauer;,citation_author=Frank Erbguth;,citation_author=Peter D. Schellinger;,citation_author=Ulrich J. Knappe;,citation_author=Gereon R. Fink;,citation_author=Christian Dohmen;,citation_author=Jens Minnerup;,citation_author=Heinz Reichmann;,citation_author=Hauke Schneider;,citation_author=Joachim Röther;,citation_author=Gernot Reimann;,citation_author=Michael Schwarz;,citation_author=Hansjörg Bäzner;,citation_author=Joseph Claßen;,citation_author=Dominik Michalski;,citation_author=Otto W. Witte;,citation_author=Albrecht Günther;,citation_author=Gerhard F. Hamann;,citation_author=Hannes Lücking;,citation_author=Arnd Dörfler;,citation_author=Muhammad Fawad Ishfaq;,citation_author=Jason J. Chang;,citation_author=Fernando D. Testai;,citation_author=Daniel Woo;,citation_author=Andrei V. Alexandrov;,citation_author=Dimitre Staykov;,citation_author=Nitin Goyal;,citation_author=Georgios Tsivgoulis;,citation_author=Kevin N. Sheth;,citation_author=Issam A. Awad;,citation_author=Stefan Schwab;,citation_author=Daniel F. Hanley;,citation_author=Hagen B. Huttner;,citation_author=Lauren Sansing;,citation_author=Charles C. Matouk;,citation_author=Audrey Leasure;,citation_author=Jan Sobesky;,citation_author=Miriam Bauer;,citation_author=Johannes Schurig;,citation_author=Timolaos Rizos;,citation_author=Karl Georg Haeusler;,citation_author=Wolfgang Müllges;,citation_author=Peter Kraft;,citation_author=Anna-Lena Schubert;,citation_author=Sebastian Stösser;,citation_author=Albert Christian Ludolph;,citation_author=Martin Nueckel;,citation_author=Jörg Glahn;,citation_author=Henning Stetefeld;,citation_author=Jan Rahmig;,citation_author=Anna Lena Fisse;,citation_author=Peter Michels;,citation_author=Henning Schwert;,citation_author=Georg Hagemann;,citation_author=Florian Rakers;,citation_author=Johannes C. Wöhrle;,citation_author=Fahid Alshammari;,citation_author=Markus Horn;,citation_author=Dirk Bahner;,citation_author=Christian Urbanek;,citation_author=Frederick Palm;,citation_author=Armin Grau;,citation_publication_date=2022-09;,citation_cover_date=2022-09;,citation_year=2022;,citation_issue=9;,citation_doi=10.1161/STROKEAHA.121.038455;,citation_issn=0039-2499, 1524-4628;,citation_volume=53;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): A phase 3, randomised, open-label, blinded endpoint, non-inferiority trial;,citation_abstract=Background Tenecteplase is a modified tissue plasminogen activator with pharmacological and practical advantages over alteplase—which is currently the only approved thrombolytic drug for ischaemic stroke. The NOR-TEST trial showed that 0\cdot4 mg/kg tenecteplase had an efficacy and safety profile similar to that of a standard dose (0\cdot9 mg/kg) of alteplase, albeit in a patient population with a high prevalence of minor stroke. The aim of NOR-TEST 2 was to establish the non-inferiority of tenecteplase 0\cdot4 mg/kg to alteplase 0\cdot9 mg/kg for patients with moderate or severe ischaemic stroke. Methods This phase 3, randomised, open-label, blinded endpoint, non-inferiority trial was performed at 11 hospitals with stroke units in Norway. Patients with suspected acute ischaemic stroke with a National Institutes of Health Stroke Scale score of 6 or more who were eligible for thrombolysis and admitted within 4\cdot5 h of symptom onset were consecutively included. Random assignment, done by a computer with a block size of 4 and with allocations placed into opaque envelopes to be opened consecutively, was 1:1 between intravenous tenecteplase (0\cdot4 mg/kg) or standard dose alteplase (0\cdot9 mg/kg). Doctors and nurses providing acute care were not masked to treatment, but primary outcome assessment at 3 months was masked. The primary outcome was favourable functional outcome defined as a modified Rankin Scale score of 0–1 at 3 months, assessed in the modified intention-to-treat analysis (excluding patients who did not qualify for thrombolysis after randomisation or who withdrew informed consent). The non-inferiority margin was 3%. This trial (NOR-TEST 2) is registered with EudraCT (number 2018–003090–95) and ClinicalTrials.gov (NCT03854500). The trial was stopped early for safety reasons and is designated part A for analysis. Part B is ongoing with a lower dose of tenecteplase (0\cdot25 mg/kg). Findings Between Oct 28, 2019, and Sept 26, 2021, 216 patients were enrolled. Patient enrolment was stopped after a per-protocol safety review showed an imbalance in the rates of symptomatic intracranial haemorrhage between the treatment groups, which surpassed the prespecified criteria for stopping the trial. Of 204 patients entering the modified intention-to-treat analysis, 100 were randomly allocated tenecteplase and 104 were allocated alteplase. All patients were followed up within 14 days of the end of the 3-months’ follow-up period. A favourable functional outcome was reported less frequently in patients receiving tenecteplase (31 [32%] of 96 patients) compared with alteplase (52 [51%] of 101 patients; unadjusted OR 0\cdot45 [95% CI 0\cdot25–0\cdot80]; p=0\cdot0064). Any intracranial haemorrhage was significantly more frequent with tenecteplase (21 [21%] of 100 patients) than with alteplase (seven [7%] of 104 patients; unadjusted OR 3\cdot68 [95% CI 1\cdot49–9\cdot11]; p=0\cdot0031). Mortality at 3 months was also significantly higher with tenecteplase (15 [16%] of 96 patients) than with alteplase (five [5%] of 101 patients; unadjusted OR 3\cdot56 [95% CI 1\cdot24–10\cdot21]; p=0\cdot013). Numerically more cases of symptomatic intracranial haemorrhage were reported with tenecteplase (six [6%] of 100 patients) than with alteplase (one [1%] of 104 patients; unadjusted OR 6\cdot57 [95% CI 0\cdot78–55\cdot62]; p=0\cdot061). Interpretation In this prematurely terminated study (terminated to fulfil the prespecified safety criteria), tenecteplase at a dose of 0\cdot4 mg/kg yielded worse safety and functional outcomes compared with alteplase. Our study consequently could not show that 0\cdot4 mg/kg tenecteplase is non-inferior to alteplase in moderate and severe ischaemic stroke. Future stroke trials should assess a lower dose of tenecteplase versus alteplase in patients with moderate or severe stroke. Funding The Norwegian National Programme for Clinical Therapy Research.;,citation_author=Christopher Elnan Kvistad;,citation_author=Halvor Næss;,citation_author=Bernt H Helleberg;,citation_author=Titto Idicula;,citation_author=Guri Hagberg;,citation_author=Linn Marie Nordby;,citation_author=Kristian N Jenssen;,citation_author=Håkon Tobro;,citation_author=Dag M Rörholt;,citation_author=Kamaljit Kaur;,citation_author=Agnethe Eltoft;,citation_author=Kristin Evensen;,citation_author=Judit Haasz;,citation_author=Guruparan Singaravel;,citation_author=Annette Fromm;,citation_author=Lars Thomassen;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_issue=6;,citation_doi=10.1016/S1474-4422(22)00124-7;,citation_issn=1474-4422;,citation_volume=21;,citation_language=en-US;,citation_journal_title=The Lancet Neurology;">
<meta name="citation_reference" content="citation_title=The intensity and variation of surgical care at the end of life: A retrospective cohort study;,citation_abstract=BACKGROUND: Although the extent of hospital and intensive-care use at the end of life is well known, patterns of surgical care during this period are poorly understood. We examined national patterns of surgical care in the USA among elderly fee-for-service Medicare beneficiaries in their last year of life. METHODS: We did a retrospective cohort study of elderly beneficiaries of fee-for-service Medicare in the USA, aged 65 years or older, who died in 2008. We identified claims for inpatient surgical procedures in the year before death and examined the relation between receipt of an inpatient procedure and both age and geographical region. We calculated an end-of-life surgical intensity (EOLSI) score for each hospital referral region defined as proportion of decedents who underwent a surgical procedure during the year before their death, adjusted for age, sex, race, and income. We compared patient characteristics with Rao-Scott \chi(2) tests, resource use with generalised estimating equations, regional differences with generalised estimating equations Wald tests, and end-of-life surgical intensity scores with Spearman’s partial-rank-order correlation coefficients. FINDINGS: Of 1,802,029 elderly beneficiaries of fee-for-service Medicare who died in 2008, 31\cdot9% (95% CI 31\cdot9-32\cdot0; 575,596 of 1,802,029) underwent an inpatient surgical procedure during the year before death, 18\cdot3% (18\cdot2-18\cdot4; 329,771 of 1,802,029) underwent a procedure in their last month of life, and 8\cdot0% (8\cdot0-8\cdot1; 144,162 of 1,802,029) underwent a procedure during their last week of life. Between the ages of 80 and 90 years, the percentage of decedents undergoing a surgical procedure in the last year of life decreased by 33% (35\cdot3% [95% CI 34\cdot7-35\cdot9; 8858 of 25,094] to 23\cdot6% [22\cdot9-24\cdot3; 3340 of 14,152]). EOLSI score in the highest intensity region (Munster, IN) was 34\cdot4 (95% CI 33\cdot7-35\cdot1) and in the lowest intensity region (Honolulu, HI) was 11\cdot5 (11\cdot3-11\cdot7). Regions with a high number of hospital beds per head had high end-of-life surgical intensity (r=0\cdot37, 95% CI 0\cdot27-0\cdot46; p&amp;amp;amp;lt;0\cdot0001), as did regions with high total Medicare spending (r=0\cdot50, 0\cdot41-0\cdot58; p&amp;lt;0\cdot0001). INTERPRETATION: Many elderly people in the USA undergo surgery in the year before their death. The rate at which they undergo surgery varies substantially with age and region and might suggest discretion in health-care providers’ decisions to intervene surgically at the end of life. FUNDING: None.;,citation_author=Alvin C. Kwok;,citation_author=Marcus E. Semel;,citation_author=Stuart R. Lipsitz;,citation_author=Angela M. Bader;,citation_author=Amber E. Barnato;,citation_author=Atul A. Gawande;,citation_author=Ashish K. Jha;,citation_publication_date=2011-10;,citation_cover_date=2011-10;,citation_year=2011;,citation_issue=9800;,citation_doi=10.1016/S0140-6736(11)61268-3;,citation_issn=1474-547X;,citation_pmid=21982520;,citation_volume=378;,citation_language=en-US;,citation_journal_title=Lancet (London, England);">
<meta name="citation_reference" content="citation_title=Corticosteroids in H1N1, non-viral, and COVID-19 ARDS;,citation_author=Kyoung-Eun Kwon;,citation_author=Sun-Young Jung;,citation_author=Moon Seong Baek;,citation_author=Won-Young Kim;,citation_publication_date=2022-09;,citation_cover_date=2022-09;,citation_year=2022;,citation_doi=10.1007/s00134-022-06891-y;,citation_issn=0342-4642, 1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Confounding by Indication in Clinical Research;,citation_author=Demetrios N. Kyriacou;,citation_author=Roger J. Lewis;,citation_publication_date=2016-11;,citation_cover_date=2016-11;,citation_year=2016;,citation_issue=17;,citation_doi=10.1001/jama.2016.16435;,citation_issn=0098-7484;,citation_volume=316;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=A lingua franca for guidelines—or a Tower of Babel?;,citation_author=Jon Henrik Laake;,citation_author=Morten Hylander Møller;,citation_publication_date=2023-08;,citation_cover_date=2023-08;,citation_year=2023;,citation_issue=7;,citation_doi=10.1111/aas.14242;,citation_issn=0001-5172, 1399-6576;,citation_volume=67;,citation_language=en-US;,citation_journal_title=Acta Anaesthesiologica Scandinavica;">
<meta name="citation_reference" content="citation_title=Early Apixaban Use Following Stroke in Patients With Atrial Fibrillation: Results of the AREST Trial;,citation_abstract=BACKGROUND AND PURPOSE: It is unknown when to start anticoagulation after acute ischemic stroke (AIS) from atrial fibrillation (AF). Early anticoagulation may prevent recurrent infarctions but may provoke hemorrhagic transformation as AF strokes are typically larger and hemorrhagic transformation-prone. Later anticoagulation may prevent hemorrhagic transformation but increases risk of secondary stroke in this time frame. Our aim was to compare early anticoagulation with apixaban in AF patients with stroke or transient ischemic attack (TIA) versus warfarin administration at later intervals. METHODS: AREST (Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation) was an open-label, randomized controlled trial comparing the safety of early use of apixaban at day 0 to 3 for TIA, day 3 to 5 for small-sized AIS (&amp;amp;amp;lt;1.5 cm), and day 7 to 9 for medium-sized AIS (\geq1.5 cm, excluding full cortical territory), to warfarin, in a 1:1 ratio at 1 week post-TIA, or 2 weeks post-AIS. RESULTS: Although AREST ended prematurely after a national guideline focused update recommended direct oral anticoagulants over warfarin for AF, it revealed that apixaban had statistically similar yet generally numerically lower rates of recurrent strokes/TIA (14.6% versus 19.2%, P=0.78), death (4.9% versus 8.5%, P=0.68), fatal strokes (2.4% versus 8.5%, P=0.37), symptomatic hemorrhages (0% versus 2.1%), and the primary composite outcome of fatal stroke, recurrent ischemic stroke, or TIA (17.1% versus 25.5%, P=0.44). One symptomatic intracerebral hemorrhage occurred on warfarin, none on apixaban. Five asymptomatic hemorrhagic transformation occurred in each arm. CONCLUSIONS: Early initiation of anticoagulation after TIA, small-, or medium-sized AIS from AF does not appear to compromise patient safety. Potential efficacy of early initiation of anticoagulation remains to be determined from larger pivotal trials.;,citation_author=Arthur J. Labovitz;,citation_author=David Z. Rose;,citation_author=Michael G. Fradley;,citation_author=John N. Meriwether;,citation_author=Swetha Renati;,citation_author=Ryan Martin;,citation_author=Thomas Kasprowicz;,citation_author=Ryan Murtagh;,citation_author=Kevin Kip;,citation_author=Theresa M. Beckie;,citation_author=Marcus Stoddard;,citation_author=Andrea C. Bozeman;,citation_author=Tara McTigue;,citation_author=Bonnie Kirby;,citation_author=Nhi Tran;,citation_author=W. Scott Burgin;,citation_author=M. Armanious;,citation_author=A. Beltagy;,citation_author=S. Chae;,citation_author=A. Chen;,citation_author=C. Cook;,citation_author=C. Edwards;,citation_author=C. L. Gooch;,citation_author=H. Glunk;,citation_author=W. Guerrero;,citation_author=D. Falcao;,citation_author=J. Fernandez;,citation_author=S. Gangadhara;,citation_author=R. Hermann;,citation_author=C. Lockwood;,citation_author=M. Mokin;,citation_author=G. Oliveira;,citation_author=A. Patel;,citation_author=A. Pendurthi;,citation_author=J. Pesquera;,citation_author=J. Ramos-Canseco;,citation_author=J. Shaw;,citation_author=N. Wick;,citation_author=R. Longaker;,citation_author=A. Webb;,citation_author=W. Liu;,citation_author=R. Korabathina;,citation_author=K. Delmontagne;,citation_author=T. Henderson;,citation_author=B Mehta;,citation_author=J. Ledesma;,citation_author=K. Berube;,citation_author=Brett Cucchiara;,citation_author=Greg Flaker;,citation_author=Shunichi Homma;,citation_author=Janice Zgibor;,citation_publication_date=2021-04;,citation_cover_date=2021-04;,citation_year=2021;,citation_issue=4;,citation_doi=10.1161/STROKEAHA.120.030042;,citation_issn=0039-2499, 1524-4628;,citation_volume=52;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=The incidence of deep and lobar intracerebral hemorrhage in whites, blacks, and Hispanics;,citation_abstract=BACKGROUND: Black and Hispanic Americans have a greater risk of primary intracerebral hemorrhage (ICH) than whites. Deep ICH is most often associated with hypertension, while lobar ICH is associated with cerebral amyloid angiopathy. The authors conducted a population-based incidence study to directly compare the incidence of deep vs lobar ICH in all three race-ethnic groups. METHODS: The authors used an active hospital and community surveillance program and autopsy reports to identify incident ICH cases among white, black, and Caribbean Hispanic adults in Northern Manhattan between July 1993 and June 1997. Incidence rates were adjusted for age and sex to the 1990 US Census. CIs for risk ratios (RR) were calculated with Byar’s chi2 approximation of the Poisson distribution. RESULTS: The authors identified 155 cases of ICH for an annual incidence of 30.9/100,000 (26.7 to 35.0). Men had a higher risk of ICH than women (RR 1.5, 95% CI 1.2 to 1.8), driven entirely by the incidence of deep ICH (RR 1.8) rather than lobar ICH (RR 1.0). Compared with whites, RR for blacks was all ICH 3.8 (2.2 to 8.9), deep 4.8 (2.3 to 21.1), lobar 2.8 (1.2 to 14.4); RR for Hispanics was all 2.6 (1.4 to 6.1), deep 3.7 (1.7 to 16.5), lobar 1.4 (0.4 to 7.4). CONCLUSIONS: ICH is a heterogeneous disease with deep and lobar subtypes distinguishable on an epidemiologic basis. The different patterns of these two subtypes in our race-ethnically diverse population lend credence to the notion that ICH should no longer be treated as a single entity.;,citation_author=D. L. Labovitz;,citation_author=A. Halim;,citation_author=B. Boden-Albala;,citation_author=W. A. Hauser;,citation_author=R. L. Sacco;,citation_publication_date=2005-08;,citation_cover_date=2005-08;,citation_year=2005;,citation_issue=4;,citation_doi=10.1212/01.wnl.0000172915.71933.00;,citation_issn=1526-632X;,citation_pmid=16116109;,citation_volume=65;,citation_language=en-US;,citation_journal_title=Neurology;">
<meta name="citation_reference" content="citation_title=Target trial emulation: Teaching epidemiology and beyond;,citation_author=Jeremy A. Labrecque;,citation_author=Sonja A. Swanson;,citation_publication_date=2017-06;,citation_cover_date=2017-06;,citation_year=2017;,citation_issue=6;,citation_doi=10.1007/s10654-017-0293-4;,citation_issn=0393-2990, 1573-7284;,citation_volume=32;,citation_language=en-US;,citation_journal_title=European Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Are We Still Withdrawing Too Soon?—Predictors of Late Awakening After Cardiac Arrest*;,citation_author=Brittany Bolduc Lachance;,citation_author=Niklas Nielsen;,citation_author=Xiaofeng Jia;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_issue=2;,citation_doi=10.1097/CCM.0000000000005379;,citation_issn=0090-3493;,citation_volume=50;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Negative trials in critical care: Why most research is probably wrong;,citation_author=John G. Laffey;,citation_author=Brian P. Kavanagh;,citation_publication_date=2018-09;,citation_cover_date=2018-09;,citation_year=2018;,citation_issue=9;,citation_doi=10.1016/S2213-2600(18)30279-0;,citation_issn=2213-2600, 2213-2619;,citation_pmid=30061048;,citation_volume=6;,citation_language=en-US;,citation_journal_title=The Lancet Respiratory Medicine;,citation_publisher=Elsevier;">
<meta name="citation_reference" content="citation_title=Clazosentan for Improvement of Time to Peak Perfusion in Patients with Angiographically Confirmed Severe Vasospasm;,citation_abstract=Background: Clazosentan, an endothelin-1 receptor antagonist, has been shown to prevent the development of large vessel angiographic vasospasm after aneurysmal subarachnoid hemorrhage. We hypothesized that clazosentan can improve cerebral perfusion for territories affected by angiographically confirmed vasospasm. Methods: The REVERSE study (REversal of Vasospasm with clazosEntan post-aneuRysmal Subarachnoid hEmorrhage) was a prospective multicenter open-label pilot study of adult patients with aneurysmal subarachnoid hemorrhage who received intravenous clazosentan after developing moderate to severe angiographic vasospasm. Using the radiographic data from the REVERSE study and additional retrospective radiographic data from our tertiary medical center, we compared the impact of intravenous clazosentan with intraarterial vasodilator therapy (medical standard of care) on vasospasm reversal using time to peak perfusion (TTPP; the time interval between the peak opacification of contrast dye in the main artery supplying an anatomically defined territory and the parenchymal phase when the dye is diffusely present in the brain parenchyma). Results: Both intravenous clazosentan (n = 7 vessels) and intraarterial vasodilator therapy (n = 11 vessels) resulted in a statistically significant improvement in TTPP at 24 h post intervention, when compared with the TTPP just prior to intervention for territories with angiographically confirmed severe vasospasm in the proximal arteries at baseline (linear mixed-effect model, p = 0.02). The clazosentan and intraarterial vasodilator therapy groups exhibited no statisti-cally significant interaction term [time x treatment group (medical standard of care vs. clazosentan)] in our model (p = 0.71), suggesting similar temporal course of two therapies. Conclusions: In our small pilot study, intravenous clazosentan administered for at least 24 h had an effect compara-ble with that of intraarterial vasodilator therapy in reversing angiographically confirmed severe vasospasm. Our results may indicate that clazosentan, in an appropriately selected patient cohort, could offer a noninvasive approach for alleviating vasospasm.;,citation_author=Austin Lai;,citation_author=Can Ozan Tan;,citation_author=Justin Vranic;,citation_author=Stefan Weidauer;,citation_author=Thabele Leslie-Mazwi;,citation_author=Joshua A. Hirsch;,citation_author=Rajiv Gupta;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_issue=1;,citation_doi=10.1007/s12028-021-01291-4;,citation_issn=1541-6933, 1556-0961;,citation_volume=36;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=The Impact of Insurance Status on the Outcomes after Aneurysmal Subarachnoid Hemorrhage;,citation_abstract=Investigation into the association of insurance status with the outcomes of patients undergoing neurosurgical intervention has been limited: this is the first nationwide study to analyze the impact of primary payer on the outcomes of patients with aneurysmal subarachnoid hemorrhage who underwent endovascular coiling or microsurgical clipping. The Nationwide Inpatient Sample (2001–2010) was utilized to identify patients; those with both an ICD-9 diagnosis codes for subarachnoid hemorrhage and a procedure code for aneurysm repair (either via an endovascular or surgical approach) were included. Hierarchical multivariate regression analyses were utilized to evaluate the impact of primary payer on in-hospital mortality, hospital discharge disposition, and length of hospital stay with hospital as the random effects variable. Models were adjusted for patient age, sex, race, comorbidities, socioeconomic status, hospital region, location (urban versus rural), and teaching status, procedural volume, year of admission, and the proportion of patients who underwent ventriculostomy. Subsequent models were also adjusted for time to aneurysm repair and time to ventriculostomy; subgroup analyses evaluated for those who underwent endovascular and surgical procedures separately. 15,557 hospitalizations were included. In the initial model, the adjusted odds of in-hospital mortality were higher for Medicare (OR 1.23, p,0.001), Medicaid (OR 1.23, p,0.001), and uninsured patients (OR 1.49, p,0.001) compared to those with private insurance. After also adjusting for timing of intervention, Medicaid and uninsured patients had a reduced odds of non-routine discharge (OR 0.75, p,0.001 and OR 0.42, p,0.001) despite longer hospital stays (by 8.35 days, p,0.001 and 2.45 days, p = 0.005). Variations in outcomes by primary payer–including in-hospital post-procedural mortality–were more pronounced for patients of all insurance types who underwent microsurgical clipping. The observed differences by primary payer are likely multifactorial, attributable to varied socioeconomic factors and the complexities of the American healthcare delivery system.;,citation_author=Pui Man Rosalind Lai;,citation_author=Hormuzdiyar Dasenbrock;,citation_author=Ning Lin;,citation_author=Rose Du;,citation_editor=Jorge I. F. Salluh;,citation_publication_date=2013-10;,citation_cover_date=2013-10;,citation_year=2013;,citation_issue=10;,citation_doi=10.1371/journal.pone.0078047;,citation_issn=1932-6203;,citation_volume=8;,citation_language=en-US;,citation_journal_title=PLoS ONE;">
<meta name="citation_reference" content="citation_title=Should Patients with Chronic Disease Be Told to Gain Weight? The Obesity Paradox and Selection Bias;,citation_author=Martín Lajous;,citation_author=Hailey R. Banack;,citation_author=Jay S. Kaufman;,citation_author=Miguel A. Hernán;,citation_publication_date=2015-04;,citation_cover_date=2015-04;,citation_year=2015;,citation_issue=4;,citation_doi=10.1016/j.amjmed.2014.10.043;,citation_issn=00029343;,citation_volume=128;,citation_language=en-US;,citation_journal_title=The American Journal of Medicine;">
<meta name="citation_reference" content="citation_title=The Practical Alternative to the p Value Is the Correctly Used p Value;,citation_abstract=Because of the strong overreliance on p values in the scientific literature, some researchers have argued that we need to move beyond p values and embrace practical alternatives. When proposing alternatives to p values statisticians often commit the “statistician’s fallacy,” whereby they declare which statistic researchers really “want to know.” Instead of telling researchers what they want to know, statisticians should teach researchers which questions they can ask. In some situations, the answer to the question they are most interested in will be the p value. As long as null-hypothesis tests have been criticized, researchers have suggested including minimum-effect tests and equivalence tests in our statistical toolbox, and these tests have the potential to greatly improve the questions researchers ask. If anyone believes p values affect the quality of scientific research, preventing the misinterpretation of p values by developing better evidence-based education and user-centered statistical software should be a top priority. Polarized discussions about which statistic scientists should use has distracted us from examining more important questions, such as asking researchers what they want to know when they conduct scientific research. Before we can improve our statistical inferences, we need to improve our statistical questions.;,citation_author=Daniël Lakens;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Intravenous Milrinone for Cerebral Vasospasm in Subarachnoid Hemorrhage: The MILRISPASM Controlled Before–After Study;,citation_abstract=Background: Intravenous (IV) milrinone, in combination with induced hypertension, has been proposed as a treat-ment option for cerebral vasospasm after aneurysmal subarachnoid hemorrhage (aSAH). However, data on its safety and efficacy are scarce. Methods: This was a controlled observational study conducted in an academic hospital with prospectively and retrospectively collected data. Consecutive patients with cerebral vasospasm following aSAH and treated with both IV milrinone (0.5 g/kg/min-1, as part of a strict protocol) and induced hypertension were compared with a historical control group receiving hypertension alone. Multivariable analyses aimed at minimizing potential biases. We assessed (1) 6-month functional disability (defined as a score between 2 and 6 on the modified Rankin Scale) and vasospasmrelated brain infarction, (2) the rate of first-line or rescue endovascular angioplasty for vasospasm, and (3) immediate tolerance to IV milrinone. Results: Ninety-four patients were included (41 and 53 in the IV milrinone and the control group, respectively). IV milrinone infusion was independently associated with a lower likelihood of 6-month functional disability (adjusted odds ratio [aOR] = 0.28, 95% confidence interval [CI] = 0.10–0.77]) and vasospasm-related brain infarction (aOR = 0.19, 95% CI 0.04–0.94). Endovascular angioplasty was less frequent in the IV milrinone group (6 [15%] vs. 28 [53%] patients, p = 0.0001, aOR = 0.12, 95% CI 0.04–0.38). IV milrinone (median duration of infusion, 5 [2–8] days) was prematurely discontinued owing to poor tolerance in 12 patients, mostly (n = 10) for “non/hardly-attained induced hypertension” (mean arterial blood pressure &amp;amp;amp;lt; 100 mmHg despite 1.5 g/kg/min-1 of norepinephrine). However, this event was simi-larly observed in IV milrinone and control patients (n = 10 [24%] vs. n = 11 [21%], respectively, p = 0.68). IV milrinone was associated with a higher incidence of polyuria (IV milrinone patients had creatinine clearance of 191 [153–238] ml/min-1) and hyponatremia or hypokalemia, whereas arrhythmia, myocardial ischemia, and thrombocytopenia were infrequent. Conclusions: Despite its premature discontinuation in 29% of patients as a result of its poor tolerance, IV milrinone was associated with a lower rate of endovascular angioplasty and a positive impact on long-term neurological and radiological outcomes. These preliminary findings encourage the conduction of confirmatory randomized trials.;,citation_author=Karim Lakhal;,citation_author=Antoine Hivert;,citation_author=Pierre-Louis Alexandre;,citation_author=Marion Fresco;,citation_author=Vincent Robert-Edan;,citation_author=Pierre-André Rodie-Talbere;,citation_author=Xavier Ambrosi;,citation_author=Romain Bourcier;,citation_author=Bertrand Rozec;,citation_author=Julien Cadiet;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_doi=10.1007/s12028-021-01331-z;,citation_issn=1541-6933, 1556-0961;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Noninvasive BP Monitoring in the Critically Ill;,citation_author=Karim Lakhal;,citation_author=Stephan Ehrmann;,citation_author=Thierry Boulain;,citation_publication_date=2018-04;,citation_cover_date=2018-04;,citation_year=2018;,citation_issue=4;,citation_doi=10.1016/j.chest.2017.10.030;,citation_issn=00123692;,citation_volume=153;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit;,citation_author=François Lamontagne;,citation_author=Marie-Hélène Masse;,citation_author=Julie Menard;,citation_author=Sheila Sprague;,citation_author=Ruxandra Pinto;,citation_author=Daren K. Heyland;,citation_author=Deborah J Cook;,citation_author=Marie-Claude Battista;,citation_author=Andrew G. Day;,citation_author=Gordon H. Guyatt;,citation_author=Salmaan Kanji;,citation_author=Rachael Parke;,citation_author=Shay P. McGuinness;,citation_author=Bharath-Kumar Tirupakuzhi Vijayaraghavan;,citation_author=Djillali Annane;,citation_author=Dian Cohen;,citation_author=Yaseen M. Arabi;,citation_author=Brigitte Bolduc;,citation_author=Nicole Marinoff;,citation_author=Bram Rochwerg;,citation_author=Tina Millen;,citation_author=Maureen O. Meade;,citation_author=Lori Hand;,citation_author=Irene Watpool;,citation_author=Rebecca Porteous;,citation_author=Paul J. Young;,citation_author=Frederick D’Aragon;,citation_author=Emilie P. Belley-Cote;,citation_author=Elaine Carbonneau;,citation_author=France Clarke;,citation_author=David M. Maslove;,citation_author=Miranda Hunt;,citation_author=Michaël Chassé;,citation_author=Martine Lebrasseur;,citation_author=François Lauzier;,citation_author=Sangeeta Mehta;,citation_author=Hector Quiroz-Martinez;,citation_author=Oleksa G. Rewa;,citation_author=Emmanuel Charbonney;,citation_author=Andrew J. E. Seely;,citation_author=Demetrios J. Kutsogiannis;,citation_author=Remi LeBlanc;,citation_author=Armand Mekontso-Dessap;,citation_author=Tina S. Mele;,citation_author=Alexis F. Turgeon;,citation_author=Gordon Wood;,citation_author=Sandeep S. Kohli;,citation_author=Jason Shahin;,citation_author=Pawel Twardowski;,citation_author=Neill K. J. Adhikari;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_issue=25;,citation_doi=10.1056/NEJMoa2200644;,citation_issn=0028-4793;,citation_volume=386;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Effect of specialist consultation on emergency department revisits among patients with uncomplicated recent-onset atrial fibrillation or flutter;,citation_abstract=Objectives To examine the association between specialist consultation and risk of 30-day ED revisit in emergency department (ED) patients with recent-onset uncomplicated atrial fibrillation or flutter (AF/AFL). Methods As a secondary analysis of a previously published trial, clinical experts identified predictors of consultation including age and sex, ED sinus conversion, thromboembolic risk, heart rate, rate control medication use, coronary artery disease and anti-platelet use, and chronic obstructive pulmonary disease. These were included in a propensity-matched hierarchical Bayesian model accounting for hospital site as a random effect, with 30-day ED revisit as the primary outcome. We also measured ED length of stay for consulted and non-consulted patients. Results We analyzed data from 11 sites for 829 ED patients with AF/AFL, of whom 364 (44%) had specialist consultation. A total of 128 patients (15.4%) had an ED revisit, 78 (16.8%) from the no consult group and 50 (13.7%) from the consult group. Consultation rates ranged from 8.8 to 71% between sites. Median length of stay was 591 min (interquartile range [IQR] 359–1024) for consulted patients and 300 min (IQR 212–409) for patients without consultation. After propensitymatching, consulted patients had a 0.6% (IQR - 4 to 3%) lower risk of 30-day revisits than non-consulted patients (probability of lower risk 55%). Conclusions In ED patients with uncomplicated AF/AFL, there was substantial between-site variation in specialist consultations; such consultation was unlikely to influence revisits within 30 days while ED length of stay was nearly double. ED specialist consultations may not be necessary for uncomplicated patients.;,citation_author=Daniel J. Lane;,citation_author=Frank X. Scheuermeyer;,citation_author=Marie-Joe Nemnom;,citation_author=Monica Taljaard;,citation_author=Ian Stiell;,citation_publication_date=2022-09;,citation_cover_date=2022-09;,citation_year=2022;,citation_doi=10.1007/s43678-022-00370-5;,citation_issn=1481-8035, 1481-8043;,citation_language=en-US;,citation_journal_title=Canadian Journal of Emergency Medicine;">
<meta name="citation_reference" content="citation_title=Understanding base excess (BE): Merits and pitfalls;,citation_author=Thomas Langer;,citation_author=Serena Brusatori;,citation_author=Luciano Gattinoni;,citation_publication_date=2022-05;,citation_cover_date=2022-05;,citation_year=2022;,citation_doi=10.1007/s00134-022-06748-4;,citation_issn=0342-4642, 1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Non-inferiority versus superiority trial design for new antibiotics in an era of high antimicrobial resistance: The case for post-marketing, adaptive randomised controlled trials;,citation_author=Simone Lanini;,citation_author=John P. A. Ioannidis;,citation_author=Francesco Vairo;,citation_author=Michel Pletschette;,citation_author=Gina Portella;,citation_author=Virginia Di Bari;,citation_author=Alessia Mammone;,citation_author=Raffaella Pisapia;,citation_author=Stefano Merler;,citation_author=Boniface Nguhuni;,citation_author=Martin Langer;,citation_author=Antonino Di Caro;,citation_author=Sarah J. L. Edwards;,citation_author=Nicola Petrosillo;,citation_author=Alimuddin Zumla;,citation_author=Giuseppe Ippolito;,citation_publication_date=2019-12;,citation_cover_date=2019-12;,citation_year=2019;,citation_issue=12;,citation_doi=10.1016/S1473-3099(19)30284-1;,citation_issn=1473-3099, 1474-4457;,citation_pmid=31451421;,citation_volume=19;,citation_language=en-US;,citation_journal_title=The Lancet Infectious Diseases;,citation_publisher=Elsevier;">
<meta name="citation_reference" content="citation_title=Corticosteroids as Adjunctive Therapy in the Treatment of Influenza: An Updated Cochrane Systematic Review and Meta-analysis;,citation_abstract=Objectives:&nbsp; Corticosteroids may be beneficial in sepsis, but uncertainty remains over their effects in severe influenza. This systematic review updates the current evidence regarding corticosteroids in the treatment of influenza and examines the effect of dose on outcome. Data Sources:&nbsp; Electronic databases (MEDLINE, EMBASE, CINAHL, LILACS, CENTRAL, and Web of Science) and trial registries were searched to October 2018 for randomized controlled trials, quasi-experimental designs, and observational cohort studies reporting corticosteroid versus no corticosteroid treatment in individuals with influenza. Study Selection and Data Extraction:&nbsp; Two researchers independently assessed studies for inclusion. Risk of bias was assessed using the Cochrane Risk of Bias tool (randomized controlled trials) or Newcastle-Ottawa Scale (observational studies). Where appropriate, we estimated the effect of corticosteroids by random-effects meta-analyses using the generic inverse variance method. Meta–regression analysis was used to assess the association of corticosteroid dose and mortality. Data Synthesis:&nbsp; We identified 30 eligible studies, all observational apart from one randomized controlled trial. Twenty-one observational studies were included in the meta-analysis of mortality, which suggested an adverse association with corticosteroid therapy (odds ratio, 3.90; 95% CI, 2.31–6.60; 15 studies; adjusted hazard ratio, 1.49; 95% CI, 1.09–2.02; six studies). Risk of bias assessment was consistent with potential confounding by indication. Pooled analysis of seven studies showed increased odds of hospital-acquired infection in people treated with corticosteroids (unadjusted odds ratio, 2.74; 95% CI, 1.51–4.95). Meta-regression of the effect of dose on mortality did not reveal an association, but reported doses of corticosteroids in included studies were high (mostly &amp;amp;amp;gt; 40 mg methylprednisolone [or equivalent] per day). Conclusions:&nbsp; Corticosteroid treatment in influenza is associated with increased mortality and hospital-acquired infection, but the evidence relates mainly to high corticosteroid doses and is of low quality with potential confounding by indication a major concern.;,citation_author=Louise E. Lansbury;,citation_author=Chamira Rodrigo;,citation_author=Jo Leonardi-Bee;,citation_author=Jonathan Nguyen-Van-Tam;,citation_author=Wei Shen Lim;,citation_publication_date=2020-02;,citation_cover_date=2020-02;,citation_year=2020;,citation_issue=2;,citation_doi=10.1097/CCM.0000000000004093;,citation_issn=0090-3493;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Considerations for Reporting and Reviewing Studies Including Health-Related Quality of Life;,citation_author=Brittany R. Lapin;,citation_publication_date=2020-07;,citation_cover_date=2020-07;,citation_year=2020;,citation_issue=1;,citation_doi=10.1016/j.chest.2020.03.007;,citation_issn=00123692;,citation_volume=158;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Association Between Antiseizure Drug Monotherapy and Mortality for Patients With Poststroke Epilepsy;,citation_abstract=OBJECTIVE To investigate whether mortality varies with specific ASMs among patients with poststroke epilepsy. DESIGN, SETTING, AND PARTICIPANTS A cohort study was conducted using individual-level data from linked registers on all adults in Sweden with acute stroke from July 1, 2005, to December 31, 2010, and subsequent onset of epilepsy before December 31, 2014. A total of 2577 patients receiving continuous ASM monotherapy were eligible for the study. Data were analyzed between May 27, 2019, and April 8, 2021. EXPOSURES The dispensed ASM (Anatomical Therapeutic Chemical code N03A) determined exposure status, and the first dispensation date marked the start of treatment. MAIN OUTCOMES AND MEASURES The primary outcome, all-cause death, was analyzed using Cox proportional hazards regression with carbamazepine as the reference. Cardiovascular death (International Statistical Classification of Diseases and Related Health Problems, Tenth Revision codes I0-I99 as the underlying cause) was assessed using Fine-Gray competing risk regression models. RESULTS A total of 2577 patients (1400 men [54%]; median age, 78 years [IQR, 69-85 years]) were included. The adjusted hazard ratio of all-cause death compared with carbamazepine was 0.72 (95% CI, 0.60-0.86) for lamotrigine, 0.96 (95% CI, 0.80-1.15) for levetiracetam, 1.40 (95% CI, 1.23-1.59) for valproic acid, 1.16 (95% CI, 0.88-1.51) for phenytoin, and 1.16 (95% CI, 0.81-1.66) for oxcarbazepine. The adjusted hazard ratio of cardiovascular death compared with carbamazepine was 0.76 (95% CI, 0.61-0.95) for lamotrigine, 0.77 (95% CI, 0.60-0.99) for levetiracetam, 1.40 (95% CI, 1.19-1.64) for valproic acid, 1.02 (95% CI, 0.71-1.47) for phenytoin, and 0.71 (95% CI, 0.42-1.18) for oxcarbazepine. CONCLUSIONS AND RELEVANCE This cohort study’s findings suggest differences in survival between patients treated with different ASMs for poststroke epilepsy. Patients receiving lamotrigine monotherapy had significantly lower mortality compared with those receiving carbamazepine. The opposite applied to patients prescribed valproic acid, who had a higher risk of cardiovascular and all-cause death. Levetiracetam was associated with a reduced risk of cardiovascular death compared with carbamazepine, but there was no significant difference in overall mortality.;,citation_author=David Larsson;,citation_author=Arton Baftiu;,citation_author=Cecilie Johannessen Landmark;,citation_author=Mia Euler;,citation_author=Eva Kumlien;,citation_author=Signild Åsberg;,citation_author=Johan Zelano;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_issue=2;,citation_doi=10.1001/jamaneurol.2021.4584;,citation_issn=2168-6149;,citation_volume=79;,citation_language=en-US;,citation_journal_title=JAMA Neurology;">
<meta name="citation_reference" content="citation_title=COVID-19-related ARDS: One disease, two trajectories, and several unanswered questions;,citation_author=Jean-Baptiste Lascarrou;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Insights from patients screened but not randomised in the HYPERION trial;,citation_abstract=Background: Few data are available about outcomes of patients screened for, but not enrolled in, randomised clini-cal trials. Methods: We retrospectively reviewed patients who had non-inclusion criteria for the HYPERION trial comparing 33 ^\circC to 37 ^\circC in patients comatose after cardiac arrest in non-shockable rhythm, due to any cause. A good neurologi-cal outcome was defined as a day-90 Cerebral Performance Category score of 1 or 2. Results: Of the 1144 patients with non-inclusion criteria, 1130 had day-90 information and, among these, 158 (14%) had good functional outcomes, compared to 7.9% overall in the HYPERION trial (10.2% with and 5.7% without hypothermia). Considerable centre-to-centre variability was found in the proportion of non-included patients who received hypothermia (0% to 83.8%) and who had good day-90 functional outcomes (0% to 31.3%). The proportion of patients with a good day-90 functional outcome was significantly higher with than without hypothermia (18.5% vs. 11.9%, P = 0.003). Conclusion: Our finding of better functional outcomes without than with inclusion in the HYPERION trial, despite most non-inclusion criteria being of adverse prognostic significance (e.g., long no-flow and low-flow times and haemodynamic instability), raises important questions about the choice of patient selection criteria and the applica-bility of trial results to everyday practice. At present, reserving hypothermia for patients without predictors of poor prognosis seems open to criticism.;,citation_author=J. B. Lascarrou;,citation_author=Gregoire Muller;,citation_author=Jean-Pierre Quenot;,citation_author=Nicolas Massart;,citation_author=Mickael Landais;,citation_author=Pierre Asfar;,citation_author=Jean-Pierre Frat;,citation_author=Jean-Charles Chakarian;,citation_author=Michel Sirodot;,citation_author=Bruno Francois;,citation_author=Guillaume Grillet;,citation_author=Sylvie Vimeux;,citation_author=Arnaud Delahaye;,citation_author=Stéphane Legriel;,citation_author=Didier Thevenin;,citation_author=Jean Reignier;,citation_author=Gwenhael Colin;,citation_author=for the AfterROSC Network;,citation_publication_date=2021-12;,citation_cover_date=2021-12;,citation_year=2021;,citation_issue=1;,citation_doi=10.1186/s13613-021-00947-w;,citation_issn=2110-5820;,citation_volume=11;,citation_language=en-US;,citation_journal_title=Annals of Intensive Care;">
<meta name="citation_reference" content="citation_title=Cost-effectiveness of remdesivir plus usual care versus usual care alone for hospitalized patients with COVID-19: An economic evaluation as part of the Canadian Treatments for COVID-19 (CATCO) randomized clinical trial;,citation_abstract=Background: The role of remdesivir in the treatment of hospitalized patients with COVID-19 remains ill-defined. We conducted a cost-effectiveness analysis alongside the Canadian Treatments for COVID-19 (CATCO) open-label, randomized clinical trial evaluating remdesivir.;,citation_author=Vincent I. Lau;,citation_author=Robert Fowler;,citation_author=Ruxandra Pinto;,citation_author=Alain Tremblay;,citation_author=Sergio Borgia;,citation_author=François M. Carrier;,citation_author=Matthew P. Cheng;,citation_author=John Conly;,citation_author=Cecilia T. Costiniuk;,citation_author=Peter Daley;,citation_author=Erick Duan;,citation_author=Madeleine Durand;,citation_author=Patricia S. Fontela;,citation_author=George Farjou;,citation_author=Mike Fralick;,citation_author=Anna Geagea;,citation_author=Jennifer Grant;,citation_author=Yoav Keynan;,citation_author=Kosar Khwaja;,citation_author=Nelson Lee;,citation_author=Todd C. Lee;,citation_author=Rachel Lim;,citation_author=Conar R. O’Neil;,citation_author=Jesse Papenburg;,citation_author=Makeda Semret;,citation_author=Michael Silverman;,citation_author=Wendy Sligl;,citation_author=Ranjani Somayaji;,citation_author=Darrell H. S. Tan;,citation_author=Jennifer L. Y. Tsang;,citation_author=Jason Weatherald;,citation_author=Cedric Philippe Yansouni;,citation_author=Ryan Zarychanski;,citation_author=Srinivas Murthy;,citation_publication_date=2022-07;,citation_cover_date=2022-07;,citation_year=2022;,citation_issue=3;,citation_doi=10.9778/cmajo.20220077;,citation_issn=2291-0026;,citation_volume=10;,citation_language=en-US;,citation_journal_title=CMAJ Open;">
<meta name="citation_reference" content="citation_title=The Randomized Registry Trial — The Next Disruptive Technology in Clinical Research?;,citation_author=Michael S. Lauer;,citation_author=Ralph B. D’Agostino;,citation_publication_date=2013-10;,citation_cover_date=2013-10;,citation_year=2013;,citation_issue=17;,citation_doi=10.1056/NEJMp1310102;,citation_issn=0028-4793, 1533-4406;,citation_volume=369;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Early Brain Injury After Subarachnoid Hemorrhage: Incidence and Mechanisms;,citation_abstract=Aneurysmal subarachnoid hemorrhage is a devastating condition causing significant morbidity and mortality. While outcomes from subarachnoid hemorrhage have improved in recent years, there continues to be significant interest in identifying therapeutic targets for this disease. In particular, there has been a shift in emphasis toward secondary brain injury that develops in the first 72 hours after subarachnoid hemorrhage. This time period of interest is referred to as the early brain injury period and comprises processes including microcirculatory dysfunction, blood-brain-barrier breakdown, neuroinflammation, cerebral edema, oxidative cascades, and neuronal death. Advances in our understanding of the mechanisms defining the early brain injury period have been accompanied by improved imaging and nonimaging biomarkers for identifying early brain injury, leading to the recognition of an elevated clinical incidence of early brain injury compared with prior estimates. With the frequency, impact, and mechanisms of early brain injury better defined, there is a need to review the literature in this area to guide preclinical and clinical study.;,citation_author=David C. Lauzier;,citation_author=Keshav Jayaraman;,citation_author=Jane Y. Yuan;,citation_author=Deepti Diwan;,citation_author=Ananth K. Vellimana;,citation_author=Joshua W. Osbun;,citation_author=Arindam R. Chatterjee;,citation_author=Umeshkumar Athiraman;,citation_author=Rajat Dhar;,citation_author=Gregory J. Zipfel;,citation_issue=0;,citation_doi=10.1161/STROKEAHA.122.040072;,citation_volume=0;,citation_journal_title=Stroke;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=Targeted temperature management in patients with intracerebral haemorrhage, subarachnoid haemorrhage, or acute ischaemic stroke: Updated consensus guideline recommendations by the Neuroprotective Therapy Consensus Review (NTCR) group;,citation_author=Andrea Lavinio;,citation_author=John Andrzejowski;,citation_author=Ileana Antonopoulou;,citation_author=Jonathan Coles;,citation_author=Pierce Geoghegan;,citation_author=Kyle Gibson;,citation_author=Sandeep Gudibande;,citation_author=Carmen Lopez-Soto;,citation_author=Randeep Mullhi;,citation_author=Priya Nair;,citation_author=Vijai P. Pauliah;,citation_author=Aoife Quinn;,citation_author=Frank Rasulo;,citation_author=Andrew Ratcliffe;,citation_author=Ugan Reddy;,citation_author=Jonathan Rhodes;,citation_author=Chiara Robba;,citation_author=Matthew Wiles;,citation_author=Ashleigh Williams;,citation_publication_date=2023-05;,citation_cover_date=2023-05;,citation_year=2023;,citation_issue=0;,citation_doi=10.1016/j.bja.2023.04.030;,citation_issn=0007-0912, 1471-6771;,citation_pmid=37225535;,citation_volume=0;,citation_language=en-US;,citation_journal_title=British Journal of Anaesthesia;,citation_publisher=Elsevier;">
<meta name="citation_reference" content="citation_title=Comparison of Heart Rate After Phenylephrine vs Norepinephrine Initiation in Patients With Septic Shock and Atrial Fibrillation;,citation_abstract=&amp;amp;amp;lt;h3&amp;gt;Background&amp;lt;/h3&amp;gt;<p>Atrial fibrillation (AF) is a common complication of sepsis. It is unclear whether norepinephrine, an \alpha- and \beta-agonist, and phenylephrine, an \alpha-agonist, are associated with different heart rates among patients with sepsis and AF.</p><h3>Research Question</h3><p>Among patients with sepsis and AF, what is the difference in heart rate after phenylephrine initiation vs norepinephrine initiation?</p><h3>Study Design and Methods</h3><p>With the use of an extensive database, we identified patients with sepsis and AF at the time of norepinephrine or phenylephrine initiation. We estimated the difference in heart rate between patients who received phenylephrine or norepinephrine 1 and 6 h after vasopressor initiation with the use of multivariable-adjusted linear regression, tested for effect modification by heart rate, and stratified by baseline heart rate \geq 110 or < 110 beats/min. Secondary outcomes included conversion to sinus rhythm, bradycardia, vasopressor duration, ICU and hospital length of stay, and hospital death. Exploratory analyses were adjusted for practices that occurred after vasopressor initiation; sensitivity analyses used interrupted time series to estimate the difference in average heart rate between patients who received phenylephrine or norepinephrine.</p><h3>Results</h3><p>Among 1847 patients with sepsis and AF, 946 patients (51%) received norepinephrine, and 901 patients (49%) received phenylephrine. After multivariable adjustment, phenylephrine was associated with a lower heart rate at 1 h (-4 beats/min; 95% CI, -6 to -1; <i>P</i> < .001) and 6 h (-4 beats/min; 95% CI, -6 to -1; <i>P</i> = .004). Higher heart rate before vasopressor administration was associated with larger heart rate reduction in patients who received phenylephrine compared with norepinephrine. There were no differences in secondary outcomes. Results were similar in exploratory and sensitivity analyses.</p><h3>Interpretation</h3><p>In patients with sepsis and AF, the initiation of phenylephrine was associated with modestly lower heart rate compared with norepinephrine. Heart rate at vasopressor initiation appeared to be an important effect modifier. Whether modest reductions in heart rate are associated with clinical outcomes requires further study.</p>;,citation_author=Anica C. Law;,citation_author=Nicholas A. Bosch;,citation_author=Daniel Peterson;,citation_author=Allan J. Walkey;,citation_publication_date=2022-05;,citation_cover_date=2022-05;,citation_year=2022;,citation_issue=0;,citation_doi=10.1016/j.chest.2022.04.147;,citation_issn=0012-3692;,citation_pmid=35526604;,citation_volume=0;,citation_language=en-US;,citation_journal_title=CHEST;,citation_publisher=Elsevier;">
<meta name="citation_reference" content="citation_title=Days Out of Institution Following Tracheostomy and Gastrostomy Placement in Critically Ill Older Adults;,citation_author=Anica C Law;,citation_author=Jennifer P. Stevens;,citation_author=Eunhee Choi;,citation_author=Changyu Shen;,citation_author=Anuj B Mehta;,citation_author=Robert W. Yeh;,citation_author=Allan J Walkey;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_doi=10.1513/AnnalsATS.202106-649OC;,citation_issn=2329-6933, 2325-6621;,citation_language=en-US;,citation_journal_title=Annals of the American Thoracic Society;">
<meta name="citation_reference" content="citation_title=Gastrostomy Tube Use in the Critically Ill, 1994–2014;,citation_abstract=Rationale: Although gastrostomy tubes have shown to be of limited benefit in patients with advanced dementia, they continue to be used to deliver nutritional support in critically ill patients. The epidemiology and short-term outcomes are unclear.;,citation_author=Anica C. Law;,citation_author=Jennifer P. Stevens;,citation_author=Allan J. Walkey;,citation_publication_date=2019-06;,citation_cover_date=2019-06;,citation_year=2019;,citation_issue=6;,citation_doi=10.1513/AnnalsATS.201809-638OC;,citation_issn=2329-6933, 2325-6621;,citation_volume=16;,citation_language=en-US;,citation_journal_title=Annals of the American Thoracic Society;">
<meta name="citation_reference" content="citation_title=Hemostatic Therapies For Acute Spontaneous Intracerebral Hemorrhage;,citation_author=Zhe Kang Law;,citation_author=Rustam Al-Shahi Salman;,citation_author=Philip M. Bath;,citation_author=Thorsten Steiner;,citation_author=Nikola Sprigg;,citation_publication_date=2018-08;,citation_cover_date=2018-08;,citation_year=2018;,citation_issue=8;,citation_doi=10.1161/STROKEAHA.118.022071;,citation_volume=49;,citation_journal_title=Stroke;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=Functional independence after major abdominal surgery in the elderly;,citation_abstract=BACKGROUND: Elders undergo approximately 40% of more than 1 million major abdominal operations annually. Yet evidence about recovery to preoperative levels of functional independence is limited. This study details course and predictors of functional recovery after elective major abdominal operations in the elderly. STUDY DESIGN: This was a prospective cohort of 372 consecutive patients, 60 years old or more, enrolled from surgeons in private practice and two university-affiliated hospitals, assessed preoperatively and postoperatively at 1, 3, and 6 weeks, 3 and 6 months, using self-report and performance-based measures (Activities of Daily Living [ADL], Instrumental Activities of Daily Living [IADL], Medical Outcomes Study Short Form-36 Physical Component and Mental Component Scales [PCS, MCS], Geriatric Depression Scale [GDS], Folstein Mini-Mental State Exam [MMSE], timed walk, functional reach, hand grip strength). RESULTS: Mean age was 69 +/- 6 years with 56% men, 47% nonHispanic Caucasian, and 42% Mexican American; hospital distribution was 49% private, 51% university-affiliated. Maximum functional declines (95% CI) occurred 1 week postoperatively: ADL, 2.8 points (2.4 to 3.2); IADL, 7.6 points (7 to 8.3); SF-36 PCS, 6.5 points (5.4 to 7.6); Mini-Mental State Exam, 0.5 points (0.2 to 0.7); timed walk, 6.8 seconds (5.2 to 8.4); functional reach, 1.7 inches (1.2 to 2.2); grip strength, 2 kilograms (1.3 to 2.7) (p &amp;amp;amp;lt; 0.001 for all). SF-36 mental component scale and Geriatric Depression Scale scores did not worsen. Mean recovery times were: Mini-Mental State Exam, 3 weeks; timed walk, 6 weeks; ADL, SF-36 PCS, and functional reach, 3 months; and IADL, 6 months. Mean grip strength did not return to preoperative status by 6 months. The incidence of persistent disability at 6 months, compared with preoperative status, was: ADL, 9%; IADL, 19%; PCS, 16%; mental component scale, 17%; timed walk, 39%; functional reach, 58%; and grip strength, 52%. Potentially modifiable independent predictors of ADL and IADL recovery were preoperative physical conditioning and depression plus serious postoperative complications. CONCLUSIONS: The clinical course of functional recovery varied across different measures. Protracted disability at 6 months after operation was substantial. Several potentially modifiable factors consistently predicted recovery.;,citation_author=Valerie A. Lawrence;,citation_author=Helen P. Hazuda;,citation_author=John E. Cornell;,citation_author=Thomas Pederson;,citation_author=Patrick T. Bradshaw;,citation_author=Cynthia D. Mulrow;,citation_author=Carey P. Page;,citation_publication_date=2004-11;,citation_cover_date=2004-11;,citation_year=2004;,citation_issue=5;,citation_doi=10.1016/j.jamcollsurg.2004.05.280;,citation_issn=1072-7515;,citation_pmid=15501119;,citation_volume=199;,citation_language=en-US;,citation_journal_title=Journal of the American College of Surgeons;">
<meta name="citation_reference" content="citation_title=The lesson of ivermectin: Meta-analyses based on summary data alone are inherently unreliable;,citation_author=Jack M. Lawrence;,citation_author=Gideon Meyerowitz-Katz;,citation_author=James A. J. Heathers;,citation_author=Nicholas J. L. Brown;,citation_author=Kyle A. Sheldrick;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_doi=10.1038/s41591-021-01535-y;,citation_issn=1078-8956, 1546-170X;,citation_language=en-US;,citation_journal_title=Nature Medicine;">
<meta name="citation_reference" content="citation_title=Attention Deficit–Hyperactivity Disorder and Month of School Enrollment;,citation_abstract=BACKGROUND Younger children in a school grade cohort may be more likely to receive a diagnosis of attention deficit–hyperactivity disorder (ADHD) than their older peers because of age-based variation in behavior that may be attributed to ADHD rather than to the younger age of the children. Most U.S. states have arbitrary age cutoffs for entry into public school. Therefore, within the same grade, children with birthdays close to the cutoff date can differ in age by nearly 1 year. METHODS We used data from 2007 through 2015 from a large insurance database to compare the rate of ADHD diagnosis among children born in August with that among children born in September in states with and states without the requirement that children be 5 years old by September 1 for enrollment in kindergarten. ADHD diagnosis was determined on the basis of diagnosis codes from the International Classification of Diseases, 9th Revision. We also used prescription records to compare ADHD treatment between children born in August and children born in September in states with and states without the cutoff date of September 1. RESULTS The study population included 407,846 children in all U.S. states who were born in the period from 2007 through 2009 and were followed through December 2015. The rate of claims-based ADHD diagnosis among children in states with a September 1 cutoff was 85.1 per 10,000 children (309 cases among 36,319 children; 95% confidence interval [CI], 75.6 to 94.2) among those born in August and 63.6 per 10,000 children (225 cases among 35,353 children; 95% CI, 55.4 to 71.9) among those born in September, an absolute difference of 21.5 per 10,000 children (95% CI, 8.8 to 34.0); the corresponding difference in states without the September 1 cutoff was 8.9 per 10,000 children (95% CI, -14.9 to 20.8). The rate of ADHD treatment was 52.9 per 10,000 children (192 of 36,319 children; 95% CI, 45.4 to 60.3) among those born in August and 40.4 per 10,000 children (143 of 35,353 children; 95% CI, 33.8 to 47.1) among those born in September, an absolute difference of 12.5 per 10,000 children (95% CI, 2.43 to 22.4). These differences were not observed for other month-to-month comparisons, nor were they observed in states with non-September cutoff dates for starting kindergarten. In addition, in states with a September 1 cutoff, no significant differences between August-born and September-born children were observed in rates of asthma, diabetes, or obesity. CONCLUSIONS Rates of diagnosis and treatment of ADHD are higher among children born in August than among children born in September in states with a September 1 cutoff for kindergarten entry. (Funded by the National Institutes of Health.);,citation_author=Timothy J. Layton;,citation_author=Michael L. Barnett;,citation_author=Tanner R. Hicks;,citation_author=Anupam B. Jena;,citation_publication_date=2018-11;,citation_cover_date=2018-11;,citation_year=2018;,citation_issue=22;,citation_doi=10.1056/NEJMoa1806828;,citation_issn=0028-4793, 1533-4406;,citation_volume=379;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Brain-Lung Conflicts and Patterns of Mechanical Ventilation*;,citation_author=Christos Lazaridis;,citation_publication_date=2021-07;,citation_cover_date=2021-07;,citation_year=2021;,citation_issue=7;,citation_doi=10.1097/CCM.0000000000004957;,citation_issn=0090-3493;,citation_volume=49;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Effect of Moderate vs Mild Therapeutic Hypothermia on Mortality and Neurologic Outcomes in Comatose Survivors of Out-of-Hospital Cardiac Arrest: The CAPITAL CHILL Randomized Clinical Trial;,citation_abstract=OBJECTIVE To determine whether moderate hypothermia (31 ^\circC), compared with mild hypothermia (34 ^\circC), improves clinical outcomes in comatose survivors of out-of-hospital cardiac arrest. DESIGN, SETTING, AND PARTICIPANTS Single-center, double-blind, randomized, clinical superiority trial carried out in a tertiary cardiac care center in eastern Ontario, Canada. A total of 389 patients with out-of-hospital cardiac arrest were enrolled between August 4, 2013, and March 20, 2020, with final follow-up on October 15, 2020. INTERVENTIONS Patients were randomly assigned to temperature management with a target body temperature of 31 ^\circC (n = 193) or 34 ^\circC (n = 196) for a period of 24 hours. MAIN OUTCOMES AND MEASURES The primary outcome was all-cause mortality or poor neurologic outcome at 180 days. Neurologic outcome was assessed using the Disability Rating Scale, with poor neurologic outcome defined as a score greater than 5 (range, 0-29, with 29 being the worst outcome [vegetative state]). There were 19 secondary outcomes, including mortality at 180 days and length of stay in the intensive care unit. RESULTS Among 367 patients included in the primary analysis (mean age, 61 years; 69 women [19%]), 366 (99.7%) completed the trial. The primary outcome occurred in 89 of 184 patients (48.4%) in the 31 ^\circC group and in 83 of 183 patients (45.4%) in the 34 ^\circC group (risk difference, 3.0% [95% CI, 7.2%-13.2%]; relative risk, 1.07 [95% CI, 0.86-1.33]; P = .56). Of the 19 secondary outcomes, 18 were not statistically significant. Mortality at 180 days was 43.5% and 41.0% in patients treated with a target temperature of 31 ^\circC and 34 ^\circC, respectively (P = .63). The median length of stay in the intensive care unit was longer in the 31 ^\circC group (10 vs 7 days; P = .004). Among adverse events in the 31 ^\circC group vs the 34 ^\circC group, deep vein thrombosis occurred in 11.4% vs 10.9% and thrombus in the inferior vena cava occurred in 3.8% and 7.7%, respectively. CONCLUSIONS AND RELEVANCE In comatose survivors of out-of-hospital cardiac arrest, a target temperature of 31 ^\circC did not significantly reduce the rate of death or poor neurologic outcome at 180 days compared with a target temperature of 34 ^\circC. However, the study may have been underpowered to detect a clinically important difference.;,citation_author=Michel Le May;,citation_author=Christina Osborne;,citation_author=Juan Russo;,citation_author=Derek So;,citation_author=Aun Yeong Chong;,citation_author=Alexander Dick;,citation_author=Michael Froeschl;,citation_author=Christopher Glover;,citation_author=Benjamin Hibbert;,citation_author=Jean-François Marquis;,citation_author=Sophie De Roock;,citation_author=Marino Labinaz;,citation_author=Jordan Bernick;,citation_author=Shawn Marshall;,citation_author=Ronnen Maze;,citation_author=George Wells;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=15;,citation_doi=10.1001/jama.2021.15703;,citation_issn=0098-7484;,citation_volume=326;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Predicting outcome in poor-grade patients with subarachnoid hemorrhage: A retrospective review of 159 aggressively managed cases;,citation_abstract= To determine what factors predict outcome, the authors retrospectively reviewed the management of all 159 poor-grade patients admitted to Harborview Medical Center at the University of Washington who suffered aneurysmal subarachnoid hemorrhage between 1983 and 1993. Favorable outcome (assessed by the Glasgow Outcome Scale) occurred in 53.9% of Hunt and Hess Grade IV, and 24.1% of Grade V patients. Outcome was largely determined by the initial hemorrhage and subsequent development of intractable intracranial hypertension or cerebral infarction. Using multivariate analysis, the authors developed three models to predict outcome. It was found that predicting outcome based only on clinical and diagnostic criteria present at admission may have resulted in withholding treatment from 30% of the patients who subsequently experienced favorable outcomes. It is concluded that aggressive management including surgical aneurysm obliteration can benefit patients with poor neurological grades and should not be denied solely on the basis of the neurological condition on admission.;,citation_author=Peter D. Le Roux;,citation_author=J. Paul Elliott;,citation_author=David W. Newell;,citation_author=M. Sean Grady;,citation_author=H. Richard Winn;,citation_publication_date=1996-07;,citation_cover_date=1996-07;,citation_year=1996;,citation_issue=1;,citation_doi=10.3171/jns.1996.85.1.0039;,citation_issn=0022-3085;,citation_volume=85;,citation_journal_title=Journal of Neurosurgery;">
<meta name="citation_reference" content="citation_title=Early prone positioning in acute respiratory distress syndrome related to COVID-19: A propensity score analysis from the multicentric cohort COVID-ICU network—the ProneCOVID study;,citation_abstract=Background: Delaying time to prone positioning (PP) may be associated with higher mortality in acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19). We evaluated the use and the impact of early PP on clinical outcomes in intubated patients hospitalized in intensive care units (ICUs) for COVID-19. Methods: All intubated patients with ARDS due to COVID-19 were involved in a secondary analysis from a prospective multicenter cohort study of COVID-ICU network including 149 ICUs across France, Belgium and Switzerland. Patients were followed-up until Day-90. The primary outcome was survival at Day-60. Analysis used a Cox proportional hazard model including a propensity score. Results: Among 2137 intubated patients, 1504 (70.4%) were placed in PP during their ICU stay and 491 (23%) during the first 24 h following ICU admission. One hundred and eighty-one patients (36.9%) of the early PP group had a PaO2/FiO2 ratio &amp;amp;amp;gt; 150 mmHg when prone positioning was initiated. Among non-early PP group patients, 1013 (47.4%) patients had finally been placed in PP within a median delay of 3 days after ICU admission. Day-60 mortality in nonearly PP group was 34.2% versus 39.3% in the early PP group (p = 0.038). Day-28 and Day-90 mortality as well as the need for adjunctive therapies was more important in patients with early PP. After propensity score adjustment, no significant difference in survival at Day-60 was found between the two study groups (HR 1.34 [0.96–1.68], p = 0.09 and HR 1.19 [0.998–1.412], p = 0.053 in complete case analysis or in multiple imputation analysis, respectively). Conclusions: In a large multicentric international cohort of intubated ICU patients with ARDS due to COVID-19, PP has been used frequently as a main treatment. In this study, our data failed to show a survival benefit associated with early PP started within 24 h after ICU admission compared to PP after day-1 for all COVID-19 patients requiring invasive mechanical ventilation regardless of their severity.;,citation_author=Christophe Le Terrier;,citation_author=Florian Sigaud;,citation_author=Said Lebbah;,citation_author=Luc Desmedt;,citation_author=David Hajage;,citation_author=Claude Guérin;,citation_author=Jérôme Pugin;,citation_author=Steve Primmaz;,citation_author=Nicolas Terzi;,citation_author=COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators;,citation_author=Alain Mercat;,citation_author=Pierre Asfar;,citation_author=François Beloncle;,citation_author=Julien Demiselle;,citation_author=Tài Pham;,citation_author=Arthur Pavot;,citation_author=Xavier Monnet;,citation_author=Christian Richard;,citation_author=Alexandre Demoule;,citation_author=Martin Dres;,citation_author=Julien Mayaux;,citation_author=Alexandra Beurton;,citation_author=Cédric Daubin;,citation_author=Richard Descamps;,citation_author=Aurélie Joret;,citation_author=Damien Du Cheyron;,citation_author=Frédéric Pene;,citation_author=Jean-Daniel Chiche;,citation_author=Mathieu Jozwiak;,citation_author=Paul Jaubert;,citation_author=Guillaume Voiriot;,citation_author=Muriel Fartoukh;,citation_author=Marion Teulier;,citation_author=Clarisse Blayau;,citation_author=Erwen L’Her;,citation_author=Cécile Aubron;,citation_author=Laetitia Bodenes;,citation_author=Nicolas Ferriere;,citation_author=Johann Auchabie;,citation_author=Anthony Le Meur;,citation_author=Sylvain Pignal;,citation_author=Thierry Mazzoni;,citation_author=Jean-Pierre Quenot;,citation_author=Pascal Andreu;,citation_author=Jean-Baptiste Roudau;,citation_author=Marie Labruyère;,citation_author=Saad Nseir;,citation_author=Sébastien Preau;,citation_author=Julien Poissy;,citation_author=Daniel Mathieu;,citation_author=Sarah Benhamida;,citation_author=Rémi Paulet;,citation_author=Nicolas Roucaud;,citation_author=Martial Thyrault;,citation_author=Florence Daviet;,citation_author=Sami Hraiech;,citation_author=Gabriel Parzy;,citation_author=Aude Sylvestre;,citation_author=Sébastien Jochmans;,citation_author=Anne-Laure Bouilland;,citation_author=Mehran Monchi;,citation_author=Marc Danguy Déserts;,citation_author=Quentin Mathais;,citation_author=Gwendoline Rager;,citation_author=Pierre Pasquier;,citation_author=Reignier Jean;,citation_author=Seguin Amélie;,citation_author=Garret Charlotte;,citation_author=Canet Emmanuel;,citation_author=Jean Dellamonica;,citation_author=Clément Saccheri;,citation_author=Romain Lombardi;,citation_author=Yanis Kouchit;,citation_author=Sophie Jacquier;,citation_author=Armelle Mathonnet;,citation_author=Mai-Ahn Nay;,citation_author=Isabelle Runge;,citation_author=Frédéric Martino;,citation_author=Laure Flurin;,citation_author=Amélie Rolle;,citation_author=Michel Carles;,citation_author=Rémi Coudroy;,citation_author=Arnaud W. Thille;,citation_author=Jean-Pierre Frat;,citation_author=Maeva Rodriguez;,citation_author=Pascal Beuret;,citation_author=Audrey Tientcheu;,citation_author=Arthur Vincent;,citation_author=Florian Michelin;,citation_author=Fabienne Tamion;,citation_author=Dorothée Carpentier;,citation_author=Déborah Boyer;,citation_author=Christophe Girault;,citation_author=Valérie Gissot;,citation_author=Stéphan Ehrmann;,citation_author=Charlotte Salmon Gandonniere;,citation_author=Djlali Elaroussi;,citation_author=Agathe Delbove;,citation_author=Yannick Fedun;,citation_author=Julien Huntzinger;,citation_author=Eddy Lebas;,citation_author=Grâce Kisoka;,citation_author=Céline Grégoire;,citation_author=Stella Marchetta;,citation_author=Bernard Lambermont;,citation_author=Laurent Argaud;,citation_author=Thomas Baudry;,citation_author=Pierre-Jean Bertrand;,citation_author=Auguste Dargent;,citation_author=Christophe Guitton;,citation_author=Nicolas Chudeau;,citation_author=Mickaël Landais;,citation_author=Cédric Darreau;,citation_author=Alexis Ferre;,citation_author=Antoine Gros;,citation_author=Guillaume Lacave;,citation_author=Fabrice Bruneel;,citation_author=Mathilde Neuville;,citation_author=Jérôme Devaquet;,citation_author=Guillaume Tachon;,citation_author=Richard Gallot;,citation_author=Riad Chelha;,citation_author=Arnaud Galbois;,citation_author=Anne Jallot;,citation_author=Ludivine Chalumeau Lemoine;,citation_author=Khaldoun Kuteifan;,citation_author=Valentin Pointurier;,citation_author=Louise-Marie Jandeaux;,citation_author=Joy Mootien;,citation_author=Charles Damoisel;,citation_author=Benjamin Sztrymf;,citation_author=Matthieu Schmidt;,citation_author=Alain Combes;,citation_author=Juliette Chommeloux;,citation_author=Charles Edouard Luyt;,citation_author=Frédérique Schortgen;,citation_author=Leon Rusel;,citation_author=Camille Jung;,citation_author=Florent Gobert;,citation_author=Damien Vimpere;,citation_author=Lionel Lamhaut;,citation_author=Bertrand Sauneuf;,citation_author=Liliane Charrrier;,citation_author=Julien Calus;,citation_author=Isabelle Desmeules;,citation_author=Benoı̂t Painvin;,citation_author=Jean-Marc Tadie;,citation_author=Vincent Castelain;,citation_author=Baptiste Michard;,citation_author=Jean-Etienne Herbrecht;,citation_author=Mathieu Baldacini;,citation_author=Nicolas Weiss;,citation_author=Sophie Demeret;,citation_author=Clémence Marois;,citation_author=Benjamin Rohaut;,citation_author=Pierre-Henri Moury;,citation_author=Anne-Charlotte Savida;,citation_author=Emmanuel Couadau;,citation_author=Mathieu Série;,citation_author=Nica Alexandru;,citation_author=Cédric Bruel;,citation_author=Candice Fontaine;,citation_author=Sonia Garrigou;,citation_author=Juliette Courtiade Mahler;,citation_author=Maxime Leclerc;,citation_author=Michel Ramakers;,citation_author=Pierre Garçon;,citation_author=Nicole Massou;,citation_author=Ly Van Vong;,citation_author=Juliane Sen;,citation_author=Nolwenn Lucas;,citation_author=Franck Chemouni;,citation_author=Annabelle Stoclin;,citation_author=Alexandre Avenel;,citation_author=Henri Faure;,citation_author=Angélie Gentilhomme;,citation_author=Sylvie Ricome;,citation_author=Paul Abraham;,citation_author=Céline Monard;,citation_author=Julien Textoris;,citation_author=Thomas Rimmele;,citation_author=Florent Montini;,citation_author=Gabriel Lejour;,citation_author=Thierry Lazard;,citation_author=Isabelle Etienney;,citation_author=Younes Kerroumi;,citation_author=Claire Dupuis;,citation_author=Marine Bereiziat;,citation_author=Elisabeth Coupez;,citation_author=François Thouy;,citation_author=Clément Hoffmann;,citation_author=Nicolas Donat;,citation_author=Anne Chrisment;,citation_author=Rose-Marie Blot;,citation_author=Antoine Kimmoun;,citation_author=Audrey Jacquot;,citation_author=Matthieu Mattei;,citation_author=Bruno Levy;,citation_author=Ramin Ravan;,citation_author=Loı̈c Dopeux;,citation_author=Jean-Mathias Liteaudon;,citation_author=Delphine Roux;,citation_author=Brice Rey;,citation_author=Radu Anghel;,citation_author=Deborah Schenesse;,citation_author=Vincent Gevrey;,citation_author=Jermy Castanera;,citation_author=Philippe Petua;,citation_author=Benjamin Madeux;,citation_author=Otto Hartman;,citation_author=Michael Piagnerelli;,citation_author=Anne Joosten;,citation_author=Cinderella Noel;,citation_author=Patrick Biston;,citation_author=Thibaut Noel;,citation_author=Gurvan L. E. Bouar;,citation_author=Messabi Boukhanza;,citation_author=Elsa Demarest;,citation_author=Marie-France Bajolet;,citation_author=Nathanaël Charrier;,citation_author=Audrey Quenet;,citation_author=Cécile Zylberfajn;,citation_author=Nicolas Dufour;,citation_author=Buno Mégarbane;,citation_author=Sqébastian Voicu;,citation_author=Nicolas Deye;,citation_author=Isabelle Malissin;,citation_author=François Legay;,citation_author=Matthieu Debarre;,citation_author=Nicolas Barbarot;,citation_author=Pierre Fillatre;,citation_author=Bertrand Delord;,citation_author=Thomas Laterrade;,citation_author=Tahar Saghi;,citation_author=Wilfried Pujol;,citation_author=Pierre Julien Cungi;,citation_author=Pierre Esnault;,citation_author=Mickael Cardinale;,citation_author=Vivien Hong Tuan Ha;,citation_author=Grégory Fleury;,citation_author=Marie-Ange Brou;,citation_author=Daniel Zafimahazo;,citation_author=David Tran-Van;,citation_author=Patrick Avargues;,citation_author=Lisa Carenco;,citation_author=Nicolas Robin;,citation_author=Alexandre Ouali;,citation_author=Lucie Houdou;,citation_author=Christophe Le Terrier;,citation_author=Noémie Suh;,citation_author=Steve Primmaz;,citation_author=Jérôme Pugin;,citation_author=Emmanuel Weiss;,citation_author=Tobias Gauss;,citation_author=Jean-Denis Moyer;,citation_author=Catherine Paugam Burtz;,citation_author=Béatrice La Combe;,citation_author=Rolland Smonig;,citation_author=Jade Violleau;,citation_author=Pauline Cailliez;,citation_author=Jonathan Chelly;,citation_author=Antoine Marchalot;,citation_author=Cécile Saladin;,citation_author=Christelle Bigot;,citation_author=Pierre-Marie Fayolle;,citation_author=Jules Fatséas;,citation_author=Amr Ibrahim;,citation_author=Dabor Resiere;,citation_author=Rabih Hage;,citation_author=Clémentine Cholet;,citation_author=Marie Cantier;,citation_author=Pierre Trouiler;,citation_author=Philippe Montravers;,citation_author=Brice Lortat-Jacob;,citation_author=Sebastien Tanaka;,citation_author=Alexy Tran Dinh;,citation_author=Jacques Duranteau;,citation_author=Anatole Harrois;,citation_author=Guillaume Dubreuil;,citation_author=Marie Werner;,citation_author=Anne Godier;,citation_author=Sophie Hamada;,citation_author=Diane Zlotnik;,citation_author=Hélène Nougue;,citation_author=Armand Mekontso-Dessap;,citation_author=Guillaume Carteaux;,citation_author=Keyvan Razazi;,citation_author=Nicolas De Prost;,citation_author=Nicolas Mongardon;,citation_author=Olivier Langeron;,citation_author=Eric Levesque;,citation_author=Arié Attias;,citation_author=Charles Roquetaillade;,citation_author=Benjamin G. Chousterman;,citation_author=Alexandre Mebazaa;,citation_author=Etienne Gayat;,citation_author=Marc Garnier;,citation_author=Emmanuel Pardo;,citation_author=Lea Satre-Buisson;,citation_author=Christophe Gutton;,citation_author=Elise Yvin;,citation_author=Clémence Marcault;,citation_author=Elie Azoulay;,citation_author=Michael Darmon;,citation_author=Hafid Ait Oufella;,citation_author=Geoffroy Hariri;,citation_author=Tomas Urbina;,citation_author=Sandie Mazerand;,citation_author=Nicholas Heming;,citation_author=Francesca Santi;,citation_author=Pierre Moine;,citation_author=Djillali Annane;,citation_author=Adrien Bouglé;,citation_author=Edris Omar;,citation_author=Aymeric Lancelot;,citation_author=Emmanuelle Begot;,citation_author=Gaétan Plantefeve;,citation_author=Damien Contou;,citation_author=Hervé Mentec;,citation_author=Olivier Pajot;,citation_author=Stanislas Faguer;,citation_author=Olivier Cointault;,citation_author=Laurence Lavayssiere;,citation_author=Marie-Béatrice Nogier;,citation_author=Matthieu Jamme;,citation_author=Claire Pichereau;,citation_author=Jan Hayon;,citation_author=Hervé Outin;,citation_author=François Dépret;,citation_author=Maxime Coutrot;,citation_author=Maité Chaussard;,citation_author=Lucie Guillemet;,citation_author=Pierre Goffin;,citation_author=Romain Thouny;,citation_author=Julien Guntz;,citation_author=Laurent Jadot;,citation_author=Romain Persichini;,citation_author=Vanessa Jean-Michel;,citation_author=Hugues Georges;,citation_author=Thomas Caulier;,citation_author=Gaël Pradel;,citation_author=Marie-Hélène Hausermann;,citation_author=Thi My Hue Nguyen-Valat;,citation_author=Michel Boudinaud;,citation_author=Emmanuel Vivier;,citation_author=Sylvène Rosseli;,citation_author=Gaël Bourdin;,citation_author=Christian Pommier;,citation_author=Marc Vinclair;,citation_author=Simon Poignant;,citation_author=Sandrine Mons;,citation_author=Wulfran Bougouin;,citation_author=Franklin Bruna;,citation_author=Quentin Maestraggi;,citation_author=Christian Roth;,citation_author=Laurent Bitker;,citation_author=François Dhelft;,citation_author=Justine Bonnet-Chateau;,citation_author=Mathilde Filippelli;,citation_author=Tristan Morichau-Beauchant;,citation_author=Stéphane Thierry;,citation_author=Charlotte Le Roy;,citation_author=Mélanie Saint Jouan;,citation_author=Bruno Goncalves;,citation_author=Aurélien Mazeraud;,citation_author=Matthieu Daniel;,citation_author=Tarek Sharshar;,citation_author=Cyril Cadoz;,citation_author=Rostane Gaci;,citation_author=Sébastien Gette;,citation_author=Guillaune Louis;,citation_author=Sophe-Caroline Sacleux;,citation_author=Marie-Amélie Ordan;,citation_author=Aurélie Cravoisy;,citation_author=Marie Conrad;,citation_author=Guilhem Courte;,citation_author=Sébastien Gibot;,citation_author=Younès Benzidi;,citation_author=Claudia Casella;,citation_author=Laurent Serpin;,citation_author=Jean-Lou Setti;,citation_author=Marie-Catherine Besse;,citation_author=Anna Bourreau;,citation_author=Jérôme Pillot;,citation_author=Caroline Rivera;,citation_author=Camille Vinclair;,citation_author=Marie-Aline Robaux;,citation_author=Chloé Achino;,citation_author=Marie-Charlotte Delignette;,citation_author=Tessa Mazard;,citation_author=Frédéric Aubrun;,citation_author=Bruno Bouchet;,citation_author=Aurélien Frérou;,citation_author=Laura Muller;,citation_author=Charlotte Quentin;,citation_author=Samuel Degoul;,citation_author=Xavier Stihle;,citation_author=Claude Sumian;,citation_author=Nicoletta Bergero;,citation_author=Bernard Lanaspre;,citation_author=Hervé Quintard;,citation_author=Eve Marie Maiziere;,citation_author=Pierre-Yves Egreteau;,citation_author=Guillaume Leloup;,citation_author=Florin Berteau;,citation_author=Marjolaine Cottrel;,citation_author=Marie Bouteloup;,citation_author=Matthieu Jeannot;,citation_author=Quentin Blanc;,citation_author=Julien Saison;,citation_author=Isabelle Geneau;,citation_author=Romaric Grenot;,citation_author=Abdel Ouchike;,citation_author=Pascal Hazera;,citation_author=Anne-Lyse Masse;,citation_author=Suela Demiri;,citation_author=Corinne Vezinet;,citation_author=Elodie Baron;,citation_author=Deborah Benchetrit;,citation_author=Antoine Monsel;,citation_author=Grégoire Trebbia;,citation_author=Emmanuelle Schaack;,citation_author=Raphaël Lepecq;,citation_author=Mathieu Bobet;,citation_author=Christophe Vinsonneau;,citation_author=Thibault Dekeyser;,citation_author=Quentin Delforge;,citation_author=Imen Rahmani;,citation_author=Bérengère Vivet;,citation_author=Jonathan Paillot;,citation_author=Lucie Hierle;,citation_author=Claire Chaignat;,citation_author=Sarah Valette;,citation_author=Benoı̈t Her;,citation_author=Jennifier Brunet;,citation_author=Mathieu Page;,citation_author=Fabienne Boiste;,citation_author=Anthony Collin;,citation_author=Florent Bavozet;,citation_author=Aude Garin;,citation_author=Mohamed Dlala;,citation_author=Kais Mhamdi;,citation_author=Bassem Beilouny;,citation_author=Alexandra Lavalard;,citation_author=Severine Perez;,citation_author=Benoit Veber;,citation_author=Pierre-Gildas Guitard;,citation_author=Philippe Gouin;,citation_author=Anna Lamacz;,citation_author=Fabienne Plouvier;,citation_author=Bertrand P. Delaborde;,citation_author=Aı̈ssa Kherchache;,citation_author=Amina Chaalal;,citation_author=Jean-Damien Ricard;,citation_author=Marc Amouretti;,citation_author=Santiago Freita-Ramos;,citation_author=Damien Roux;,citation_author=Jean-Michel Constantin;,citation_author=Mona Assefi;,citation_author=Marine Lecore;,citation_author=Agathe Selves;,citation_author=Florian Prevost;,citation_author=Christian Lamer;,citation_author=Ruiying Shi;,citation_author=Lyes Knani;,citation_author=Sébastien Pili Floury;,citation_author=Lucie Vettoretti;,citation_author=Michael Levy;,citation_author=Lucile Marsac;,citation_author=Stéphane Dauger;,citation_author=Sophie Guilmin-Crépon;,citation_author=Hadrien Winiszewski;,citation_author=Gael Piton;,citation_author=Thibaud Soumagne;,citation_author=Gilles Capellier;,citation_author=Jean-Baptiste Putegnat;,citation_author=Frédérique Bayle;,citation_author=Maya Perrou;,citation_author=Ghyslaine Thao;,citation_author=Guillaume Géri;,citation_author=Cyril Charron;,citation_author=Xavier Repessé;,citation_author=Antoine Vieillard-Baron;,citation_author=Mathieu Guilbart;,citation_author=Pierre-Alexandre Roger;,citation_author=Sébastien Hinard;,citation_author=Pierre-Yves Macq;,citation_author=Kevin Chaulier;,citation_author=Sylvie Goutte;,citation_author=Patrick Chillet;,citation_author=Anaı̈s Pitta;,citation_author=Barbara Darjent;,citation_author=Amandine Bruneau;,citation_author=Sigismond Lasocki;,citation_author=Maxime Leger;,citation_author=Soizic Gergaud;,citation_author=Pierre Lemarie;,citation_author=Nicolas Terzi;,citation_author=Carole Schwebel;,citation_author=Anaı̈s Dartevel;,citation_author=Louis-Marie Galerneau;,citation_author=Jean-Luc Diehl;,citation_author=Caroline Hauw-Berlemont;,citation_author=Nicolas Péron;,citation_author=Emmanuel Guérot;,citation_author=Abolfazl Mohebbi Amoli;,citation_author=Michel Benhamou;,citation_author=Jean-Pierre Deyme;,citation_author=Olivier Andremont;,citation_author=Diane Lena;,citation_author=Julien Cady;,citation_author=Arnaud Causeret;,citation_author=Arnaud De La Chapelle;,citation_author=Christophe Cracco;,citation_author=Stéphane Rouleau;,citation_author=David Schnell;,citation_author=Camille Foucault;,citation_author=Cécile Lory;,citation_author=Thibault Chapelle;,citation_author=Vincent Bruckert;,citation_author=Julie Garcia;,citation_author=Abdlazize Sahraoui;,citation_author=Nathalie Abbosh;,citation_author=Caroline Bornstain;,citation_author=Pierre Pernet;,citation_author=Florent Poirson;,citation_author=Ahmed Pasem;,citation_author=Philippe Karoubi;,citation_author=Virginie Poupinel;,citation_author=Caroline Gauthier;,citation_author=François Bouniol;,citation_author=Philippe Feuchere;,citation_author=Florent Bavozet;,citation_author=Anne Heron;,citation_author=Serge Carreira;,citation_author=Malo Emery;,citation_author=Anne Sophie Le Floch;,citation_author=Luana Giovannangeli;,citation_author=Nicolas Herzog;,citation_author=Christophe Giacardi;,citation_author=Thibaut Baudic;,citation_author=Chloé Thill;,citation_author=Said Lebbah;,citation_author=Jessica Palmyre;,citation_author=Florence Tubach;,citation_author=David Hajage;,citation_author=Nicolas Bonnet;,citation_author=Nathan Ebstein;,citation_author=Stéphane Gaudry;,citation_author=Yves Cohen;,citation_author=Julie Noublanche;,citation_author=Olivier Lesieur;,citation_author=Arnaud Sément;,citation_author=Isabel Roca-Cerezo;,citation_author=Michel Pascal;,citation_author=Nesrine Sma;,citation_author=Gwenhaël Colin;,citation_author=Jean-Claude Lacherade;,citation_author=Gauthier Bionz;,citation_author=Natacha Maquigneau;,citation_author=Pierre Bouzat;,citation_author=Michel Durand;,citation_author=Marie-Christine Hérault;,citation_author=Jean-Francois Payen;,citation_publication_date=2022-12;,citation_cover_date=2022-12;,citation_year=2022;,citation_issue=1;,citation_doi=10.1186/s13054-022-03949-7;,citation_issn=1364-8535;,citation_volume=26;,citation_language=en-US;,citation_journal_title=Critical Care;">
<meta name="citation_reference" content="citation_title=Treatment of Edema Associated With Intracerebral Hemorrhage;,citation_abstract=Cerebral edema (i.e., “brain swelling”) is a common complication following intracerebral hemorrhage (ICH) and is associated with worse clinical outcomes. Perihematomal edema (PHE) accumulates during the first 72&nbsp;h after hemorrhage, and during this period, patients are at risk of clinical deterioration due to the resulting tissue shifts and brain herniation. First-line medical therapies for patients symptomatic of PHE include osmotic agents, such as mannitol in low- or high-dose bolus form, or boluses of hypertonic saline (HTS) at varied concentrations with or without subsequent continuous infusion. Decompressive craniectomy may be required for symptomatic edema refractory to osmotherapy. Other strategies that reduce PHE such as hypothermia and minimally invasive surgery have shown promise in pilot studies and are currently being evaluated in larger clinical trials. Ongoing basic, translational, and clinical research seek to better elucidate the pathophysiology of PHE to identify novel strategies to prevent edema formation as a next major advance in the treatment of ICH.;,citation_author=Audrey Leasure;,citation_author=W. Taylor Kimberly;,citation_author=Lauren H. Sansing;,citation_author=Kristopher T. Kahle;,citation_author=Golo Kronenberg;,citation_author=Hagen Kunte;,citation_author=J. Marc Simard;,citation_author=Kevin N. Sheth;,citation_publication_date=2016-02;,citation_cover_date=2016-02;,citation_year=2016;,citation_issue=2;,citation_doi=10.1007/s11940-015-0392-z;,citation_issn=1534-3138;,citation_volume=18;,citation_language=en-US;,citation_journal_title=Current Treatment Options in Neurology;">
<meta name="citation_reference" content="citation_title=A Randomized Trial of Intravenous Alteplase before Endovascular Treatment for Stroke;,citation_abstract=BACKGROUND The value of administering intravenous alteplase before endovascular treatment (EVT) for acute ischemic stroke has not been studied extensively, particularly in non-Asian populations. METHODS We performed an open-label, multicenter, randomized trial in Europe involving patients with stroke who presented directly to a hospital that was capable of providing EVT and who were eligible for intravenous alteplase and EVT. Patients were randomly assigned in a 1:1 ratio to receive EVT alone or intravenous alteplase followed by EVT (the standard of care). The primary end point was functional outcome on the modified Rankin scale (range, 0 [no disability] to 6 [death]) at 90 days. We assessed the superiority of EVT alone over alteplase plus EVT, as well as noninferiority by a margin of 0.8 for the lower boundary of the 95% confidence interval for the odds ratio of the two trial groups. Death from any cause and symptomatic intracerebral hemorrhage were the main safety end points. The authors’ full names, academic degrees, and affiliations are listed in the Appendix. Dr. Roos can be contacted at y.b.roos@a msterdamumc.nl or at Amsterdam UMC, Location AMC, Department of Neurology, P.O. Box 22660, 1100 DD Amsterdam, the Netherlands. *A full list of the MR CLEAN–NO IV investigators is provided in the Supplementary Appendix, available at NEJM.org. Drs. LeCouffe, Kappelhof, and Treurniet and Drs. Majoie and Roos contributed equally to this article. N Engl J Med 2021;385:1833-44. DOI: 10.1056/NEJMoa2107727 Copyright © 2021 Massachusetts Medical Society. RESULTS The analysis included 539 patients. The median score on the modified Rankin scale at 90 days was 3 (interquartile range, 2 to 5) with EVT alone and 2 (interquartile range, 2 to 5) with alteplase plus EVT. The adjusted common odds ratio was 0.84 (95% confidence interval [CI], 0.62 to 1.15; P = 0.28), which showed neither superiority nor noninferiority of EVT alone. Mortality was 20.5% with EVT alone and 15.8% with alteplase plus EVT (adjusted odds ratio, 1.39; 95% CI, 0.84 to 2.30). Symptomatic intracerebral hemorrhage occurred in 5.9% and 5.3% of the patients in the respective groups (adjusted odds ratio, 1.30; 95% CI, 0.60 to 2.81). CONCLUSIONS In a randomized trial involving European patients, EVT alone was neither superior nor noninferior to intravenous alteplase followed by EVT with regard to disability outcome at 90 days after stroke. The incidence of symptomatic intracerebral hemorrhage was similar in the two groups. (Funded by the Collaboration for New Treatments of Acute Stroke consortium and others; MR CLEAN–NO IV ISRCTN number, ISRCTN80619088.);,citation_author=Natalie E. LeCouffe;,citation_author=Manon Kappelhof;,citation_author=Kilian M. Treurniet;,citation_author=Leon A. Rinkel;,citation_author=Agnetha E. Bruggeman;,citation_author=Olvert A. Berkhemer;,citation_author=Lennard Wolff;,citation_author=Henk Voorst;,citation_author=Manon L. Tolhuisen;,citation_author=Diederik W. J. Dippel;,citation_author=Aad Lugt;,citation_author=Adriaan C. G. M. Es;,citation_author=Jelis Boiten;,citation_author=Geert J. Lycklama à Nijeholt;,citation_author=Koos Keizer;,citation_author=Rob A. R. Gons;,citation_author=Lonneke S. F. Yo;,citation_author=Robert J. Oostenbrugge;,citation_author=Wim H. Zwam;,citation_author=Bob Roozenbeek;,citation_author=H. Bart Worp;,citation_author=Rob T. H. Lo;,citation_author=Ido R. Wijngaard;,citation_author=Inger R. Ridder;,citation_author=Vincent Costalat;,citation_author=Caroline Arquizan;,citation_author=Robin Lemmens;,citation_author=Jelle Demeestere;,citation_author=Jeannette Hofmeijer;,citation_author=Jasper M. Martens;,citation_author=Wouter J. Schonewille;,citation_author=Jan-Albert Vos;,citation_author=Maarten Uyttenboogaart;,citation_author=Reinoud P. H. Bokkers;,citation_author=Julia H. Tuijl;,citation_author=Hans Kortman;,citation_author=Floris H. B. M. Schreuder;,citation_author=Hieronymus D. Boogaarts;,citation_author=Karlijn F. Laat;,citation_author=Lukas C. Dijk;,citation_author=Heleen M. Hertog;,citation_author=Boudewijn A. A. M. Hasselt;,citation_author=Paul J. A. M. Brouwers;,citation_author=Tomas Bulut;,citation_author=Michel J. M. Remmers;,citation_author=Anouk Norden;,citation_author=Farshad Imani;,citation_author=Anouk D. Rozeman;,citation_author=Otto E. H. Elgersma;,citation_author=Philippe Desfontaines;,citation_author=Denis Brisbois;,citation_author=Yves Samson;,citation_author=Frédéric Clarençon;,citation_author=G. Menno Krietemeijer;,citation_author=Alida A. Postma;,citation_author=Pieter-Jan Doormaal;,citation_author=René Berg;,citation_author=Anouk Hoorn;,citation_author=Ludo F. M. Beenen;,citation_author=Daan Nieboer;,citation_author=Hester F. Lingsma;,citation_author=Bart J. Emmer;,citation_author=Jonathan M. Coutinho;,citation_author=Charles B. L. M. Majoie;,citation_author=Yvo B. W. E. M. Roos;,citation_publication_date=2021-11;,citation_cover_date=2021-11;,citation_year=2021;,citation_issue=20;,citation_doi=10.1056/NEJMoa2107727;,citation_issn=0028-4793, 1533-4406;,citation_volume=385;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals;,citation_author=David J. Lederer;,citation_author=Scott C. Bell;,citation_author=Richard D. Branson;,citation_author=James D. Chalmers;,citation_author=Rachel Marshall;,citation_author=David M. Maslove;,citation_author=David E. Ost;,citation_author=Naresh M. Punjabi;,citation_author=Michael Schatz;,citation_author=Alan R. Smyth;,citation_author=Paul W. Stewart;,citation_author=Samy Suissa;,citation_author=Alex A. Adjei;,citation_author=Cezmi A. Akdis;,citation_author=Élie Azoulay;,citation_author=Jan Bakker;,citation_author=Zuhair K. Ballas;,citation_author=Philip G. Bardin;,citation_author=Esther Barreiro;,citation_author=Rinaldo Bellomo;,citation_author=Jonathan A. Bernstein;,citation_author=Vito Brusasco;,citation_author=Timothy G. Buchman;,citation_author=Sudhansu Chokroverty;,citation_author=Nancy A. Collop;,citation_author=James D. Crapo;,citation_author=Dominic A. Fitzgerald;,citation_author=Lauren Hale;,citation_author=Nicholas Hart;,citation_author=Felix J. Herth;,citation_author=Theodore J. Iwashyna;,citation_author=Gisli Jenkins;,citation_author=Martin Kolb;,citation_author=Guy B. Marks;,citation_author=Peter Mazzone;,citation_author=J. Randall Moorman;,citation_author=Thomas M. Murphy;,citation_author=Terry L. Noah;,citation_author=Paul Reynolds;,citation_author=Dieter Riemann;,citation_author=Richard E. Russell;,citation_author=Aziz Sheikh;,citation_author=Giovanni Sotgiu;,citation_author=Erik R. Swenson;,citation_author=Rhonda Szczesniak;,citation_author=Ronald Szymusiak;,citation_author=Jean-Louis Teboul;,citation_author=Jean-Louis Vincent;,citation_publication_date=2019-01;,citation_cover_date=2019-01;,citation_year=2019;,citation_issue=1;,citation_doi=10.1513/AnnalsATS.201808-564PS;,citation_issn=2329-6933, 2325-6621;,citation_volume=16;,citation_language=en-US;,citation_journal_title=Annals of the American Thoracic Society;">
<meta name="citation_reference" content="citation_title=Anticoagulant Therapy for Venous Thromboembolism in Cancer;,citation_abstract=Direct oral anticoagulants were introduced for the treatment for acute venous thromboembolism just over a decade ago. Unlike warfarin, these drugs are given in fixed doses and do not require laboratory monitoring of the anticoagulant effect. Although direct oral anticoagulants are similar to warfarin in efficacy, they are more convenient to use and are associated with a lower risk of major bleeding, particularly intracranial hemorrhage. These factors prompted a change in practice guidelines to recommend the use of direct oral anticoagulants as the first-line therapy over warfarin and transformed outpatient treatment for the majority of patients with acute venous thromboembolism.1 . . .;,citation_author=Agnes Y. Y. Lee;,citation_publication_date=2020-04;,citation_cover_date=2020-04;,citation_year=2020;,citation_issue=17;,citation_doi=10.1056/NEJMe2004220;,citation_issn=0028-4793;,citation_pmid=32223115;,citation_volume=382;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Automated Insulin Delivery in Women with Pregnancy Complicated by Type 1 Diabetes;,citation_author=Tara T. M. Lee;,citation_author=Corinne Collett;,citation_author=Simon Bergford;,citation_author=Sara Hartnell;,citation_author=Eleanor M. Scott;,citation_author=Robert S. Lindsay;,citation_author=Katharine F. Hunt;,citation_author=David R. McCance;,citation_author=Katharine Barnard-Kelly;,citation_author=David Rankin;,citation_author=Julia Lawton;,citation_author=Rebecca M. Reynolds;,citation_author=Emma Flanagan;,citation_author=Matthew Hammond;,citation_author=Lee Shepstone;,citation_author=Malgorzata E. Wilinska;,citation_author=Judy Sibayan;,citation_author=Craig Kollman;,citation_author=Roy Beck;,citation_author=Roman Hovorka;,citation_author=Helen R. Murphy;,citation_publication_date=2023-10;,citation_cover_date=2023-10;,citation_year=2023;,citation_issue=17;,citation_doi=10.1056/NEJMoa2303911;,citation_issn=0028-4793;,citation_volume=389;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Late Awakening Is Common in Settings Without Withdrawal of Life-Sustaining Therapy in Out-of-Hospital Cardiac Arrest Survivors Who Undergo Targeted Temperature Management;,citation_abstract=OBJECTIVES: We investigated awakening time and characteristics of awakening compared nonawakening and factors contributing to poor neurologic outcomes in out-of-hospital cardiac arrest survivors in no withdrawal of life-sustaining therapy settings. DESIGN: Retrospective analysis of the Korean Hypothermia Network Pro registry. SETTING: Multicenter ICU. PATIENTS: Adult (\geq 18 yr) comatose out-of-hospital cardiac arrest survivors who underwent targeted temperature management at 33–36^\circC between October 2015 and December 2018. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: We measured the time from the end of rewarming to awakening, defined as a total Glasgow Coma Scale score greater than or equal to 9 or Glasgow Coma Scale motor score equals to 6. The primary outcome was awakening time. The secondary outcome was 6-month neurologic outcomes (poor outcome: Cerebral Performance Category 3–5). Among 1,145 out-of-hospital cardiac arrest survivors, 477 patients (41.7%) regained consciousness 30 hours (6–71 hr) later, and 116 patients (24.3%) awakened late (72 hr after the end of rewarming). Young age, witnessed arrest, shockable rhythm, cardiac etiology, shorter time to return of spontaneous circulation, lower serum lactate level, absence of seizures, and multisedative requirement were associated with awakening. Of the 477 who woke up, 74 (15.5%) had poor neurologic outcomes. Older age, liver cirrhosis, nonshockable rhythm, noncardiac etiology, a higher Sequential Organ Failure Assessment score, and higher serum lactate levels were associated with poor neurologic outcomes. Late awakeners were more common in the poor than in the good neurologic outcome group (38/74 [51.4%] vs 78/403 [19.4%]; p &amp;amp;amp;lt; 0.001). The awakening time (odds ratio, 1.005; 95% CIs, 1.003–1.008) and late awakening (odds ratio, 3.194; 95% CIs, 1.776–5.746) were independently associated with poor neurologic outcomes. CONCLUSIONS: Late awakening after out-of-hospital cardiac arrest was common in no withdrawal of life-sustaining therapy settings and the probability of awakening decreased over time.;,citation_author=Dong Hun Lee;,citation_author=Yong Soo Cho;,citation_author=Byung Kook Lee;,citation_author=Hyoung Youn Lee;,citation_author=Kyung Woon Jeung;,citation_author=Yong Hun Jung;,citation_author=Kyu Nam Park;,citation_author=Youn-Jung Kim;,citation_author=Minjung Kathy Chae;,citation_author=Dong-Woo Seo;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_doi=10.1097/CCM.0000000000005274;,citation_issn=0090-3493;,citation_volume=Publish Ahead of Print;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer;,citation_author=Agnes Y. Y. Lee;,citation_author=Mark N. Levine;,citation_author=Ross I. Baker;,citation_author=Chris Bowden;,citation_author=Ajay K. Kakkar;,citation_author=Martin Prins;,citation_author=Frederick R. Rickles;,citation_author=Jim A. Julian;,citation_author=Susan Haley;,citation_author=Michael J. Kovacs;,citation_author=Michael Gent;,citation_publication_date=2003-07;,citation_cover_date=2003-07;,citation_year=2003;,citation_issue=2;,citation_doi=10.1056/NEJMoa025313;,citation_issn=0028-4793;,citation_volume=349;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Remdesivir for the Treatment of COVID-19: An Updated Systematic Review and Meta-Analysis;,citation_abstract=Background: The benefits of remdesivir in the treatment of hospitalized patients with Covid-19 remain debated with the National Institutes of Health and the World Health Organization providing contradictory recommendations for and against use. Methods: We performed a systematic review of randomized controlled trials (RCTs) of remdesivir for the treatment of hospitalized patients with COVID-19. The primary outcome was mortality, stratified by oxygen use (none, supplemental oxygen without mechanical ventilation, and mechanical ventilation). We conducted a frequentist random effects meta-analysis on the risk ratio (RR) scale and, to better contextualize the probabilistic benefits, we also performed a bayesian random effects meta-analysis on the risk difference scale. Results: We identified 8 randomized trials, totaling 9157 participants. The RR for mortality comparing remdesivir versus control was 0.71 (95% confidence interval [CI] 0.42-1.22; I2=0.0%) in the patients who did not require supplemental oxygen; 0.83 (95%CI 0.73-0.95; I2=0.0%) for nonventilated patients requiring oxygen; and 1.19 (95%CI 0.98-1.44 I2=0.0%) in the setting of mechanical ventilation. Using neutral priors, the probabilities that remdesivir reduces mortality were 74.7%, 96.9% and 8.9%, respectively. The probability that remdesivir reduced mortality by more than 1% was 88.1% for nonventilated patients requiring oxygen. Conclusion: Based on this meta-analysis, there is a high probability that remdesivir reduces mortality for nonventilated patients with COVID-19 requiring supplemental oxygen therapy.;,citation_author=Todd C. Lee;,citation_author=Srinivas Murthy;,citation_author=Olivier Del Corpo;,citation_author=Julien Senécal;,citation_author=Guillaume Butler-Laporte;,citation_author=Zahra N Sohani;,citation_author=James M. Brophy;,citation_author=Emily G. McDonald;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_doi=10.1101/2022.01.22.22269545;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Tips for Success As an Academic Clinical Investigator;,citation_author=Stephanie J. Lee;,citation_publication_date=2013-02;,citation_cover_date=2013-02;,citation_year=2013;,citation_issue=6;,citation_doi=10.1200/JCO.2012.46.8751;,citation_issn=0732-183X, 1527-7755;,citation_volume=31;,citation_language=en-US;,citation_journal_title=Journal of Clinical Oncology;">
<meta name="citation_reference" content="citation_title=Epidemiology of intravenous immune globulin in septic shock: A retrospective cohort analysis of the Premier Healthcare Database;,citation_abstract=Methods We conducted a retrospective database study of adult patients with septic shock admitted to US hospitals in the Premier Healthcare Database (from July 2010 to June 2013). We described the proportion of patients with septic shock receiving IVIG, examined IVIG regimens across sites and employed random-effects multivariable regression techniques to identify predictors of IVIG use. Results Intravenous immune globulin was administered to 0.3% (n = 685) of patients with septic shock; with a median [interquartile range (IQR)] dose of 1 [0.5–1.8] gÁkg-1 for a median [IQR] of 1 [1–2] day. Receipt of IVIG was less likely for Black patients (odds ratio [OR], 0.54; 95% confidence interval [CI] 0.41 to 0.72) and patients without private insurance (Medicare OR, 0.73; 95% CI 0.59 to 0.90; Medicaid OR, 0.41; 95% CI 0.30 to 0.57) and more likely for patients with immunocompromise (OR, 6.83; 95% CI 5.47 to 8.53), necrotizing fasciitis (OR, 9.78; 95% CI 6.97 to 13.72), and toxic shock (OR, 56.9; 95% CI 38.7 to 83.7). Conclusions Intravenous immune globulin is used infrequently across the US in patients with septic shock. Regimens of IVIG in septic shock may be less intensive than those associated with a survival benefit in metaanalyses. Observed infrequent use supports apparent clinical equipoise, perhaps secondary to limitations of the primary literature. A clinical trial evaluating the role of IVIG in septic shock is needed.;,citation_author=Murdoch Leeies;,citation_author=Hayley B. Gershengorn;,citation_author=Emmanuel Charbonney;,citation_author=Anand Kumar;,citation_author=Dean A. Fergusson;,citation_author=Alexis F. Turgeon;,citation_author=Allan Garland;,citation_author=Donald S. Houston;,citation_author=Brett Houston;,citation_author=Emily Rimmer;,citation_author=Eric Jacobsohn;,citation_author=Srinivas Murthy;,citation_author=Rob Fowler;,citation_author=Robert Balshaw;,citation_author=Ryan Zarychanski;,citation_publication_date=2021-11;,citation_cover_date=2021-11;,citation_year=2021;,citation_issue=11;,citation_doi=10.1007/s12630-021-02081-4;,citation_issn=0832-610X, 1496-8975;,citation_volume=68;,citation_language=en-US;,citation_journal_title=Canadian Journal of Anesthesia/Journal canadien d’anesthésie;">
<meta name="citation_reference" content="citation_title=Neglecting the Difference;,citation_abstract=Background and Purpose— Patients with right hemispheric strokes (RHSs) present later to an emergency department, have a lower chance to receive intravenous recombinant tissue plasminogen activator (IV rt-PA), and have worse clinical outcomes than do patients with left hemispheric strokes (LHSs). We analyzed outcomes after IV rt-PA with respect to the side of the affected hemisphere. Methods— A prospective cohort of acute stroke patients was treated with IV rt-PA at the London Health Sciences Centre (December 1998 to March 2003). Differences between patients with RHS and LHS were identified by univariate analysis. Logistic-regression analysis was used to determine a subset of variables independently associated with major neurological improvement at 24 hours and good outcome at 3 months after treatment. Results— Of 219 stroke patients who received IV rt-PA, 165 had hemispheric strokes (68 RHSs and 97 LHSs). Patients with RHSs were less hypertensive (P=0.001) and had lower pretreatment National Institutes of Health Stroke Scale (NIHSS) scores (P=0.005). LHS (odds ratio [OR], 2.29; 95% CI, 1.14 to 4.59; P=0.019), age (OR, 0.96; 95% CI, 0.93 to 0.99; P=0.012), and pretreatment NIHSS (OR, 0.83; 95% CI, 0.78 to 0.89; P&amp;amp;amp;lt;0.0001) were independent predictors of 3-month outcome. Female sex (OR, 3; 95% CI, 1.53 to 5.90; P=0.001) and LHS (OR, 2.07; 95% CI, 1.05 to 4.08; P=0.03) were independent predictors of major neurological improvement at 24 hours after IV rt-PA. Conclusions— Despite higher pretreatment NIHSS, patients with LHSs have a 2-fold increased chance of a good outcome 3 months after rt-PA treatment compared with patients with RHSs. This gain can be clinically detected at 24 hours after treatment. These results need to be coupled with neuroimaging and hemodynamic characteristics known to influence stroke outcome.;,citation_author=Silvia Di Legge;,citation_author=Gustavo Saposnik;,citation_author=Yongchai Nilanont;,citation_author=Vladimir Hachinski;,citation_publication_date=2006-08;,citation_cover_date=2006-08;,citation_year=2006;,citation_issue=8;,citation_doi=10.1161/01.STR.0000229899.66019.62;,citation_volume=37;,citation_journal_title=Stroke;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=Burst Suppression as a Treatment Goal in Refractory Status Epilepticus;,citation_author=Stephane Legriel;,citation_publication_date=2023-11;,citation_cover_date=2023-11;,citation_year=2023;,citation_doi=10.1007/s12028-023-01880-5;,citation_issn=1556-0961;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Respiratory parameters and acute kidney injury in acute respiratory distress syndrome: A causal inference study;,citation_abstract=Background: Assess the respiratory-related parameters associated with subsequent severe acute kidney injury in mechanically ventilated patients with acute respiratory distress syndrome (ARDS). Methods: Retrospective cohort, analyzing a large public database—Multiparameter Intelligent Monitoring in Intensive Care-III. Adult patients with at least 48 h of mechanical ventilation (MV), under volume controlled ventilation and an oxygenation index less than 300 mmHg were included. Results: A total of 1,142 patients had complete data and were included in the final analyses. According to a causal directed acyclic graph (DAG) that included respiratory system compliance (Crs), tidal volume (Vt), driving pressure (\DeltaP), plateau pressure (PPlat), PEEP, PaO2 and PaCO2 as possible exposures related to severe AKI, only Crs and PEEP levels had significant causal association with severe acute kidney injury (AKI) (OR 0.90, 95% CI: 0.84–0.94 for each 5-mL/cmH2O reduction in Crs; OR, 1.05 95% CI: 1.03–1.10 for each 1-cmH2O increase of PEEP). Using mediation analysis, we examined whether any mechanical ventilation, blood gas or hemodynamic parameters could explain the effects of Csr on AKI. Only PEEP mediated the significant but small effect (less than 5%) of Csr on severe AKI. The effects of PEEP, in turn, were not mediated by any other evaluated parameter. Several sensitivity analyses with (I) need of renal replacement therapy (RRT) as an alternative outcome and (II) only patients with Vt &amp;amp;amp;lt;8 mL/kg, confirmed our main findings. In trying to validate our DAG assumptions, we confirmed that only \DeltaP was associated with mortality but not with severe AKI. Conclusions: Crs and PEEP are the only respiratory-related variables with a direct causal association in severe AKI. No mechanical ventilator or blood gas parameter mediated the effects of Crs. Approaches reducing Vt and/or \DeltaP in ARDS can have limited effect on renal protection.;,citation_author=Tacyano Tavares Leite;,citation_author=Cícero Abdon Malheiro Gomes;,citation_author=Juan Miguel Cosquillo Valdivia;,citation_author=Alexandre Braga Libório;,citation_publication_date=2019-12;,citation_cover_date=2019-12;,citation_year=2019;,citation_issue=23;,citation_doi=10.21037/atm.2019.11.92;,citation_issn=23055839, 23055847;,citation_volume=7;,citation_language=en-US;,citation_journal_title=Annals of Translational Medicine;">
<meta name="citation_reference" content="citation_title=The Obesity Paradox in Cancer: A Review;,citation_abstract=There is a common perception that excess adiposity, commonly approximated by body mass index (BMI), is associated with reduced cancer survival. A number of studies have emerged challenging this by demonstrating that overweight and early obese states are associated with improved survival. This finding is termed the Bobesity paradox^ and is well recognized in the cardio-metabolic literature but less so in oncology. Here, we summarize the epidemiological findings related to the obesity paradox in cancer. Our review highlights that many observations of the obesity paradox in cancer reflect methodological mechanisms including the crudeness of BMI as an obesity measure, confounding, detection bias, reverse causality, and a specific form of the selection bias, known as collider bias. It is imperative for the oncologist to interpret the observation of the obesity paradox against the above methodological framework and avoid the misinterpretation that being obese might be Bgood^ or Bprotective^ for cancer patients.;,citation_author=Hannah Lennon;,citation_author=Matthew Sperrin;,citation_author=Ellena Badrick;,citation_author=Andrew G. Renehan;,citation_publication_date=2016-09;,citation_cover_date=2016-09;,citation_year=2016;,citation_issue=9;,citation_doi=10.1007/s11912-016-0539-4;,citation_issn=1523-3790, 1534-6269;,citation_volume=18;,citation_language=en-US;,citation_journal_title=Current Oncology Reports;">
<meta name="citation_reference" content="citation_title=Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression;,citation_author=Eric J. Lenze;,citation_author=Benoit H. Mulsant;,citation_author=Steven P. Roose;,citation_author=Helen Lavretsky;,citation_author=Charles F. Reynolds;,citation_author=Daniel M. Blumberger;,citation_author=Patrick J. Brown;,citation_author=Pilar Cristancho;,citation_author=Alastair J. Flint;,citation_author=Marie A. Gebara;,citation_author=Torie R. Gettinger;,citation_author=Emily Lenard;,citation_author=J. Philip Miller;,citation_author=Ginger E. Nicol;,citation_author=Hanadi A. Oughli;,citation_author=Vy T. Pham;,citation_author=Bruce L. Rollman;,citation_author=Lei Yang;,citation_author=Jordan F. Karp;,citation_publication_date=2023-03;,citation_cover_date=2023-03;,citation_year=2023;,citation_issue=12;,citation_doi=10.1056/NEJMoa2204462;,citation_issn=0028-4793;,citation_volume=388;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Alteplase for stroke: Money and optimistic claims buttress the “brain attack” campaignCommentary: Who pays the guideline writers?Commentary: Thrombolysis in stroke: It works!;,citation_abstract=# Alteplase for stroke: money and optimistic claims buttress the “brain attack” campaign {#article-title-2} Both doctors and the public are becoming more alert to potential conflicts of interest, and an increasing number of journals now require competing interest statements from their authors and reviewers. In this article Jeanne Lenzer uses the example of guidelines produced by the American Heart Association to discuss some of the questions that can arise when interests conflict As doctors and the public become more aware of conflicts of interest involving study bias,1 publication bias,2 and industry gift giving3 they turn to credible non-profit organisations for sound medical recommendations. Unfortunately, many groups (and their individual panellists) that serve as arbiters of inconclusive data may also suffer from conflicts of interest. 4 5 One such conflict is self referencing bias. An example of this is in specialty guidelines for colon cancer screening, where radiologists recommend barium enemas while gastroenterologists recommend colonoscopy. A more important conflict arises when corporations with a financial stake in the recommendations issued by a non-profit making organisation provide financial support for that organisation. In this paper I examine an example of such a conflict, in which a treatment recommendation that could cost more lives than the disease itself was supported by statistics from only one randomised controlled study. Additionally, poor outcomes and dissenting opinion appear to have been obscured. This recommendation may have been made in a true spirit of unbiased scientific inquiry, but the appearance of dispassionate analysis was eroded by large donations from a drug company to the organisation making the recommendation and payments for research and lecture fees to its individual expert panellists. #### Summary points The American Heart Association rated the thrombolytic agent alteplase (tPA) as a class I (definitely recommended) intervention for stroke despite controversy about its safety and efficacy Most of the association’s stroke experts have ties to the manufacturers of … Correspondence to: Dr Starkman;,citation_author=Jeanne Lenzer;,citation_author=Charles Warlow;,citation_author=Jeffrey L. Saver;,citation_author=Chelsea S. Kidwell;,citation_author=Sidney Starkman;,citation_publication_date=2002-03;,citation_cover_date=2002-03;,citation_year=2002;,citation_issue=7339;,citation_doi=10.1136/bmj.324.7339.723;,citation_issn=0959-8138, 1468-5833;,citation_pmid=11909792;,citation_volume=324;,citation_language=en-US;,citation_journal_title=BMJ;,citation_publisher=British Medical Journal Publishing Group;">
<meta name="citation_reference" content="citation_title=Diagnosis and management of Guillain–Barré syndrome in ten steps;,citation_abstract=Guillain–Barré syndrome (GBS) is a rare, but potentially fatal, immune-m ediated disease of the peripheral nerves and nerve roots that is usually triggered by infections. The incidence of GBS can therefore increase during outbreaks of infectious diseases, as was seen during the Zika virus epidemics in 2013 in French Polynesia and 2015 in Latin America. Diagnosis and management of GBS can be complicated as its clinical presentation and disease course are heterogeneous, and no international clinical guidelines are currently available. To support clinicians, especially in the context of an outbreak\mkern1mu, we have developed a globally applicable guideline for the diagnosis and management of GBS. The guideline is based on current literature and expert consensus, and has a ten-step structure to facilitate its use in clinical practice. We first provide an introduction to the diagnostic criteria, clinical variants and differential diagnoses of GBS. The ten steps then cover early recognition and diagnosis of GBS, admission to the intensive care unit, treatment indication and selection, monitoring and treatment of disease progression, prediction of clinical course and outcome, and management of complications and sequelae.;,citation_author=Sonja E. Leonhard;,citation_author=Melissa R. Mandarakas;,citation_author=Francisco A. A. Gondim;,citation_author=Kathleen Bateman;,citation_author=Maria L. B. Ferreira;,citation_author=David R. Cornblath;,citation_author=Pieter A. Doorn;,citation_author=Mario E. Dourado;,citation_author=Richard A. C. Hughes;,citation_author=Badrul Islam;,citation_author=Susumu Kusunoki;,citation_author=Carlos A. Pardo;,citation_author=Ricardo Reisin;,citation_author=James J. Sejvar;,citation_author=Nortina Shahrizaila;,citation_author=Cristiane Soares;,citation_author=Thirugnanam Umapathi;,citation_author=Yuzhong Wang;,citation_author=Eppie M. Yiu;,citation_author=Hugh J. Willison;,citation_author=Bart C. Jacobs;,citation_publication_date=2019-11;,citation_cover_date=2019-11;,citation_year=2019;,citation_issue=11;,citation_doi=10.1038/s41582-019-0250-9;,citation_issn=1759-4758, 1759-4766;,citation_volume=15;,citation_language=en-US;,citation_journal_title=Nature Reviews Neurology;">
<meta name="citation_reference" content="citation_title=Routine Early ECLS in Infarct-Related Cardiogenic Shock?;,citation_abstract=The 30-day mortality among patients with an acute myocardial infarction complicated by cardiogenic shock who undergo coronary-artery revascularization procedures approaches 50% in contemporary clinical trials and registries.1 In patients with persistent hemodynamic compromise and organ hypoperfusion despite resuscitative measures, mechanical circulatory support may improve both systemic and myocardial perfusion, reduce ventricular workload, and provide periprocedural support for percutaneous coronary intervention (PCI).2 Among the available percutaneous devices, extracorporeal life support (ECLS) with venoarterial extracorporeal membrane oxygenation provides complete cardiopulmonary circulatory support and manages refractory respiratory failure. Despite its increasing use in patients with myocardial infarction and cardiogenic shock, data regarding the . . .;,citation_author=Jane A. Leopold;,citation_author=Darren B. Taichman;,citation_publication_date=2023-08;,citation_cover_date=2023-08;,citation_year=2023;,citation_issue=0;,citation_doi=10.1056/NEJMe2309395;,citation_issn=0028-4793;,citation_volume=0;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Enteral Nutrition Practices in Critically Ill Children Requiring Noninvasive Positive Pressure Ventilation*:;,citation_author=Matthew K. Leroue;,citation_author=Ryan J. Good;,citation_author=Heather E. Skillman;,citation_author=Angela S. Czaja;,citation_publication_date=2017-12;,citation_cover_date=2017-12;,citation_year=2017;,citation_issue=12;,citation_doi=10.1097/PCC.0000000000001302;,citation_issn=1529-7535;,citation_volume=18;,citation_language=en-US;,citation_journal_title=Pediatric Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Hospital Variation in Mortality and Ventilator Management among Mechanically Ventilated Patients with ARDS;,citation_abstract=Rationale Acute Respiratory Distress Syndrome (ARDS) is associated with significant mortality. Despite the mortality benefits of lung protective ventilation, adherence rates to evidence-based ventilator practice have remained low and ARDS mortality has remained high. Objective Determine variation in ARDS mortality and adherence to low tidal volume ventilation (LTV) across US hospitals. Materials and Methods We identified mechanically ventilated patients with ARDS using data from Philips eICU (2014-2015). We then used multi-variable hierarchical logistic regression models with hospital site as the random effect and patient and hospital level factors as fixed effects to assess the hospital risk adjusted mortality rate and median odds ratio for the association between mortality and hospital site. We then assessed associations between adherence to LTV (defined as 4-8mL/kg PBW) and hospital risk adjusted mortality rates using Spearman correlation. Results Among 4441 patients admitted at 110 hospitals with ARDS, the hospital risk-adjusted mortality rate ranged from 19% to 39%, and the MOR for hospital of admission was 1.33 (95% CI 1.25-1.41). Among 3070 patients at 72 hospitals with available ventilator data, 73% of patients had a median set Vt between 4 to 8mL/kg PBW; hospital adherence rates to LTV ranged from 13% to 95%. There was no association between hospital adherence to LTV and risk-adjusted mortality rate (spearman correlation coefficient -0.01, p = .93). Similarly, among 956 patients who started with a Vt &amp;amp;amp;gt; 8mL/kg PBW, there was no association between the percent of patients at each hospital whose Vt was decreased to \leq 8mL/kg PBW and risk adjusted mortality rate (spearman correlation coefficient .05, p = .73). Conclusion Risk adjusted mortality and use of LTV for patients with ARDS varied widely across hospitals. However, hospital adherence to LTV was not associated with ARDS mortality rates. Further evaluation of hospital practices associated with lower ARDS mortality are warranted.;,citation_author=Mallory N. LeSieur;,citation_author=Nicholas A. Bosch;,citation_author=Allan J. Walkey;,citation_publication_date=2022-07;,citation_cover_date=2022-07;,citation_year=2022;,citation_doi=10.1177/08850666221111748;,citation_issn=0885-0666, 1525-1489;,citation_language=en-US;,citation_journal_title=Journal of Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=A Framework for Descriptive Epidemiology;,citation_abstract=In this paper, we propose a framework for thinking through the design and conduct of descriptive epidemiologic studies. A well-defined descriptive question aims to quantify and characterize some feature of the health of a population and must clearly state: 1) the target population, characterized by person and place, and anchored in time; 2) the outcome, event, or health state or characteristic; and 3) the measure of occurrence that will be used to summarize the outcome (e.g., incidence, prevalence, average time to event, etc.). Additionally, 4) any auxiliary variables will be prespecified and their roles as stratification factors (to characterize the outcome distribution) or nuisance variables (to be standardized over) will be stated. We illustrate application of this framework to describe the prevalence of viral suppression on December 31, 2019, among people living with human immunodeficiency virus (HIV) who had been linked to HIV care in the United States. Application of this framework highlights biases that may arise from missing data, especially 1) differences between the target population and the analytical sample; 2) measurement error; 3) competing events, late entries, loss to follow-up, and inappropriate interpretation of the chosen measure of outcome occurrence; and 4) inappropriate adjustment.;,citation_author=Catherine R Lesko;,citation_author=Matthew P Fox;,citation_author=Jessie K Edwards;,citation_publication_date=2022-11;,citation_cover_date=2022-11;,citation_year=2022;,citation_issue=12;,citation_doi=10.1093/aje/kwac115;,citation_issn=0002-9262;,citation_volume=191;,citation_journal_title=American Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Teaching More About Less: Preparing Clinicians for Practice;,citation_author=Juan N. Lessing;,citation_author=Read G. Pierce;,citation_author=Gurpreet Dhaliwal;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_issue=6;,citation_doi=10.1016/j.amjmed.2022.01.060;,citation_issn=00029343;,citation_volume=135;,citation_language=en-US;,citation_journal_title=The American Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Let us not rush back to odds ratios without a recommendation to convert them to interpretable measures;,citation_author=Stefan Leucht;,citation_publication_date=2021-06;,citation_cover_date=2021-06;,citation_year=2021;,citation_doi=10.1016/j.jclinepi.2021.02.017;,citation_issn=08954356;,citation_volume=134;,citation_language=en-US;,citation_journal_title=Journal of Clinical Epidemiology;">
<meta name="citation_reference" content="citation_title=Effect of Moderate Hypothermia vs Normothermia on 30-Day Mortality in Patients With Cardiogenic Shock Receiving Venoarterial Extracorporeal Membrane Oxygenation: A Randomized Clinical Trial;,citation_abstract=OBJECTIVE To determine whether early use of moderate hypothermia (33-34 ^\circC) compared with strict normothermia (36-37 ^\circC) improves mortality in patients with cardiogenic shock receiving venoarterial ECMO. DESIGN, SETTING, AND PARTICIPANTS Randomized clinical trial of patients (who were eligible if they had been endotracheally intubated and were receiving venoarterial ECMO for cardiogenic shock for &amp;amp;amp;lt;6 hours) conducted in the intensive care units at 20 French cardiac shock care centers between October 2016 and July 2019. Of 786 eligible patients, 374 were randomized. Final follow-up occurred in November 2019. INTERVENTIONS Early moderate hypothermia (33-34 ^\circC; n = 168) for 24 hours or strict normothermia (36-37 ^\circC; n = 166). MAIN OUTCOMES AND MEASURES The primary outcome was mortality at 30 days. There were 31 secondary outcomes including mortality at days 7, 60, and 180; a composite outcome of death, heart transplant, escalation to left ventricular assist device implantation, or stroke at days 30, 60, and 180; and days without requiring a ventilator or kidney replacement therapy at days 30, 60, and 180. Adverse events included rates of severe bleeding, sepsis, and number of units of packed red blood cells transfused during venoarterial ECMO. RESULTS Among the 374 patients who were randomized, 334 completed the trial (mean age, 58 [SD, 12] years; 24% women) and were included in the primary analysis. At 30 days, 71 patients (42%) in the moderate hypothermia group had died vs 84 patients (51%) in the normothermia group (adjusted odds ratio, 0.71 [95% CI, 0.45 to 1.13], P = .15; risk difference, -8.3% [95% CI, -16.3% to -0.3%]). For the composite outcome of death, heart transplant, escalation to left ventricular assist device implantation, or stroke at day 30, the adjusted odds ratio was 0.61 (95% CI, 0.39 to 0.96; P = .03) for the moderate hypothermia group compared with the normothermia group and the risk difference was -11.5% (95% CI, -23.2% to 0.2%). Of the 31 secondary outcomes, 30 were inconclusive. The incidence of moderate or severe bleeding was 41% in the moderate hypothermia group vs 42% in the normothermia group. The incidence of infections was 52% in both groups. The incidence of bacteremia was 20% in the moderate hypothermia group vs 30% in the normothermia group. CONCLUSIONS AND RELEVANCE In this randomized clinical trial involving patients with refractory cardiogenic shock treated with venoarterial ECMO, early application of moderate hypothermia for 24 hours did not significantly increase survival compared with normothermia. However, because the 95% CI was wide and included a potentially important effect size, these findings should be considered inconclusive.;,citation_author=Bruno Levy;,citation_author=Nicolas Girerd;,citation_author=Julien Amour;,citation_author=Emmanuel Besnier;,citation_author=Nicolas Nesseler;,citation_author=Julie Helms;,citation_author=Clément Delmas;,citation_author=Romain Sonneville;,citation_author=Catherine Guidon;,citation_author=Bertrand Rozec;,citation_author=Helène David;,citation_author=David Bougon;,citation_author=Oussama Chaouch;,citation_author=Oulehri Walid;,citation_author=Dupont Hervé;,citation_author=Nicolas Belin;,citation_author=Lucie Gaide-Chevronnay;,citation_author=Patrick Rossignol;,citation_author=Antoine Kimmoun;,citation_author=Kevin Duarte;,citation_author=Arthur S. Slutsky;,citation_author=Daniel Brodie;,citation_author=Jean-Luc Fellahi;,citation_author=Alexandre Ouattara;,citation_author=Alain Combes;,citation_author=HYPO-ECMO Trial Group and the International ECMO Network (ECMONet);,citation_author=Mathieu Mattei;,citation_author=Carine Thivillier;,citation_author=Thomas Auchet;,citation_author=Pierrre Perez;,citation_author=Caroline Fritz;,citation_author=Pablo Maureira;,citation_author=Maxime Hubert;,citation_author=Yihua Liu;,citation_author=Ferhat Meziani;,citation_author=Hamid Merdji;,citation_author=Alexandra Monnier;,citation_author=Raphaël Clere-Jehl;,citation_author=Ania Nieszkowska;,citation_author=Marc Pineton;,citation_author=Juliette Chommeloux;,citation_author=Guillaume Hékimian;,citation_author=Guillaume Lebreton;,citation_author=Astrid Quessard;,citation_author=Julien Imbault;,citation_author=Alain Rémy;,citation_author=Mathieu Pernot;,citation_author=Pierre Joseph;,citation_author=Giovanni Scollo;,citation_author=Matteo Pozzi;,citation_author=Étienne Escudier;,citation_author=Michel Muller;,citation_author=Didier Dorez;,citation_author=Michel Sirodot;,citation_author=Fabien Doguet;,citation_author=Vincent Scherrer;,citation_author=Chadi Aludaat;,citation_author=Michael Bernasinski;,citation_author=Elie Zogheib;,citation_author=Thierry Caus;,citation_author=Philippe Bizouarn;,citation_author=Mickael Vourc’h;,citation_author=Jean-Christian Roussel;,citation_author=Thomas Senage;,citation_author=Erwan Flecher;,citation_author=Jean-Philippe Verhoye;,citation_author=Antoine Roisne;,citation_author=Sébastien Biedermann;,citation_author=Fanny Vardon-Bounes;,citation_author=Laure Crognier;,citation_author=Jean Porterie;,citation_author=Pascal Colson;,citation_author=Philippe Gaudard;,citation_author=Philippe Rouviere;,citation_author=Lila Bouadma;,citation_author=Fabrice Sinnah;,citation_author=Patrick Nataf;,citation_author=Marylou Para;,citation_author=Pauline Dureau;,citation_author=Nima Djavidi;,citation_author=Adrien Bouglé;,citation_author=Pascal Leprince;,citation_author=Géraldine Dessertaine;,citation_author=Michel Durand;,citation_author=Pierre Albaladejo;,citation_author=Cecile Martin;,citation_author=François Belon;,citation_author=Gael Piton;,citation_author=Hadrien Winiszewski;,citation_author=Andrea Perroti;,citation_author=David Tonon;,citation_author=Bernard Cholley;,citation_author=Diane Zlotnik;,citation_author=Paul Achouh;,citation_author=Hélène Nougue;,citation_author=Olivier Collange;,citation_author=Paul Michel Mertes;,citation_author=Michel Kindo;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_issue=5;,citation_doi=10.1001/jama.2021.24776;,citation_issn=0098-7484;,citation_volume=327;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Maintenance or Discontinuation of Antidepressants in Primary Care;,citation_abstract=BACKGROUND Patients with depression who are treated in primary care practices may receive antidepressants for prolonged periods. Data are limited on the effects of maintaining or discontinuing antidepressant therapy in this setting. METHODS We conducted a randomized, double-blind trial involving adults who were being treated in 150 general practices in the United Kingdom. All the patients had a history of at least two depressive episodes or had been taking antidepressants for 2 years or longer and felt well enough to consider stopping antidepressants. Patients who had received citalopram, fluoxetine, sertraline, or mirtazapine were randomly assigned in a 1:1 ratio to maintain their current antidepressant therapy (maintenance group) or to taper and discontinue such therapy with the use of matching placebo (discontinuation group). The primary outcome was the first relapse of depression during the 52-week trial period, as evaluated in a time-toevent analysis. Secondary outcomes were depressive and anxiety symptoms, physical and withdrawal symptoms, quality of life, time to stopping an antidepressant or placebo, and global mood ratings. RESULTS A total of 1466 patients underwent screening. Of these patients, 478 were enrolled in the trial (238 in the maintenance group and 240 in the discontinuation group). The average age of the patients was 54 years; 73% were women. Adherence to the trial assignment was 70% in the maintenance group and 52% in the discontinuation group. By 52 weeks, relapse occurred in 92 of 238 patients (39%) in the maintenance group and in 135 of 240 (56%) in the discontinuation group (hazard ratio, 2.06; 95% confidence interval, 1.56 to 2.70; P&amp;amp;amp;lt;0.001). Secondary outcomes were generally in the same direction as the primary outcome. Patients in the discontinuation group had more symptoms of depression, anxiety, and withdrawal than those in the maintenance group. From the Division of Psychiatry, Faculty of Brain Sciences (Gemma Lewis, L.D., M.K., P.L., F.B., M.B., Glyn Lewis), the Research Department of Primary Care and Population Health and Priment Clinical Trials Unit (L.M., R.H., I.N., C.S.C.), and the Institute of Clinical Trials and Methodology (N.F.), University College London, London, the Department of Health Sciences and Hull York Medical School, University of York, York (S.G., S.B., J.P.), Primary Care Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, Southampton (T.K., M.M., A.H.), and Population Health Sciences (D.K.) and the Centre for Academic Mental Health (N.W., A.B.), Bristol Medical School, University of Bristol, Bristol — all in the United Kingdom; and the Department of Family Medicine, McMaster University, Hamilton, ON, Canada (D.M.). Address reprint requests to Dr. Lewis at the Division of Psychiatry, University College London, 149 Tottenham Court Rd., 6th Floor, Maple House London, London W1T 7NF, United Kingdom, or at gemma.lewis@ucl.ac.uk. Drs. Gemma Lewis and Marston contributed equally to this article. N Engl J Med 2021;385:1257-67. DOI: 10.1056/NEJMoa2106356 Copyright © 2021 Massachusetts Medical Society. CME at NEJM.org CONCLUSIONS Among patients in primary care practices who felt well enough to discontinue antidepressant therapy, those who were assigned to stop their medication had a higher risk of relapse of depression by 52 weeks than those who were assigned to maintain their current therapy. (Funded by the National Institute for Health Research; ANTLER ISRCTN number, ISRCTN15969819.);,citation_author=Gemma Lewis;,citation_author=Louise Marston;,citation_author=Larisa Duffy;,citation_author=Nick Freemantle;,citation_author=Simon Gilbody;,citation_author=Rachael Hunter;,citation_author=Tony Kendrick;,citation_author=David Kessler;,citation_author=Dee Mangin;,citation_author=Michael King;,citation_author=Paul Lanham;,citation_author=Michael Moore;,citation_author=Irwin Nazareth;,citation_author=Nicola Wiles;,citation_author=Faye Bacon;,citation_author=Molly Bird;,citation_author=Sally Brabyn;,citation_author=Alison Burns;,citation_author=Caroline S. Clarke;,citation_author=Anna Hunt;,citation_author=Jodi Pervin;,citation_author=Glyn Lewis;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_issue=14;,citation_doi=10.1056/NEJMoa2106356;,citation_issn=0028-4793, 1533-4406;,citation_volume=385;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Awake prone positioning for non-intubated patients with COVID-19-related acute hypoxaemic respiratory failure: A systematic review and meta-analysis;,citation_author=Jie Li;,citation_author=Jian Luo;,citation_author=Ivan Pavlov;,citation_author=Yonatan Perez;,citation_author=Wei Tan;,citation_author=Oriol Roca;,citation_author=Elsa Tavernier;,citation_author=Aileen Kharat;,citation_author=Bairbre McNicholas;,citation_author=Miguel Ibarra-Estrada;,citation_author=David L. Vines;,citation_author=Nicholas A. Bosch;,citation_author=Garrett Rampon;,citation_author=Steven Q. Simpson;,citation_author=Allan J. Walkey;,citation_author=Michael Fralick;,citation_author=Amol Verma;,citation_author=Fahad Razak;,citation_author=Tim Harris;,citation_author=John G. Laffey;,citation_author=Claude Guerin;,citation_author=Stephan Ehrmann;,citation_author=Jie Li;,citation_author=Jian Luo;,citation_author=Ivan Pavlov;,citation_author=Yonatan Perez;,citation_author=Wei Tan;,citation_author=Oriol Roca;,citation_author=Elsa Tavernier;,citation_author=Aileen Kharat;,citation_author=Bairbre McNicholas;,citation_author=Miguel Ibarra-Estrada;,citation_author=David Vines;,citation_author=Nicholas A. Bosch;,citation_author=Garrett Rampon;,citation_author=Steven Q. Simpson;,citation_author=Allan J. Walkey;,citation_author=Michael Fralick;,citation_author=Amol Verma;,citation_author=Fahad Razak;,citation_author=Tim Harris;,citation_author=John G. Laffey;,citation_author=Claude Guerin;,citation_author=Stephan Ehrmann;,citation_author=Sara Mirza;,citation_author=Luzheng Xue;,citation_author=Ian D. Pavord;,citation_author=Patrice Plamondon;,citation_author=Dev Jayaraman;,citation_author=Jason Shahin;,citation_author=Joseph Dahine;,citation_author=Anne Kulenkamp;,citation_author=Andrés Pacheco;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_issue=6;,citation_doi=10.1016/S2213-2600(22)00043-1;,citation_issn=2213-2600, 2213-2619;,citation_pmid=35305308;,citation_volume=10;,citation_language=en-US;,citation_journal_title=The Lancet Respiratory Medicine;,citation_publisher=Elsevier;">
<meta name="citation_reference" content="citation_title=An introduction to multiplicity issues in clinical trials: The what, why, when and how;,citation_abstract=In clinical trials it is not uncommon to face a multiple testing problem which can have an impact on both type I and type II error rates, leading to inappropriate interpretation of trial results. Multiplicity issues may need to be considered at the design, analysis and interpretation stages of a trial. The proportion of trial reports not adequately correcting for multiple testing remains substantial. The purpose of this article is to provide an introduction to multiple testing issues in clinical trials, and to reduce confusion around the need for multiplicity adjustments. We use a tutorial, question-and-answer approach to address the key issues of why, when and how to consider multiplicity adjustments in trials. We summarize the relevant circumstances under which multiplicity adjustments ought to be considered, as well as options for carrying out multiplicity adjustments in terms of trial design factors including Population, Intervention/Comparison, Outcome, Time frame and Analysis (PICOTA). Results are presented in an easy-to-use table and flow diagrams. Confusion about multiplicity issues can be reduced or avoided by considering the potential impact of multiplicity on type I and II errors and, if necessary pre-specifying statistical approaches to either avoid or adjust for multiplicity in the trial protocol or analysis plan.;,citation_author=Guowei Li;,citation_author=Monica Taljaard;,citation_author=Edwin R Van den Heuvel;,citation_author=Mitchell AH Levine;,citation_author=Deborah J Cook;,citation_author=George A Wells;,citation_author=Philip J Devereaux;,citation_author=Lehana Thabane;,citation_publication_date=2017-04;,citation_cover_date=2017-04;,citation_year=2017;,citation_issue=2;,citation_doi=10.1093/ije/dyw320;,citation_issn=0300-5771;,citation_volume=46;,citation_journal_title=International Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Stroke Lateralization in Large Hemisphere Infarctions: Characteristics, Stroke-Related Complications, and Outcomes;,citation_abstract=Objectives: To assess the hemispheric differences in characteristics, stroke-related complications, and outcomes of patients with large hemisphere infarctions (LHI)., Methods: We enrolled consecutive patients admitted within 24 h after the diagnosis of LHI (defined as an ischemic stroke involving more than 50% of the territory of the middle cerebral artery in computed tomography and/or magnetic resonance imaging). Univariate and multivariate analysis were performed to explore the association between lateralization and stroke-related complications and clinical outcomes., Results: A total of 314 patients with LHI were enrolled, with 171 (54.5%) having right hemispheric involvement. Right-sided patients with LHI had lower baseline National Institutes of Health Stroke Scale (NIHSS) score (18 vs. 22, p &amp;amp;amp;lt; 0.001), higher frequency of atrial fibrillation (69.0 vs. 52.4%, p = 0.003), and higher proportion of cardio-embolism (73.1 vs. 56.6%, p = 0.013) than the left. Right-sided LHI had higher incidence rates of malignant brain edema (MBE) (48.5 vs. 30.8%, p = 0.001) and a composite of cardiovascular events (29.8 vs. 17.5%, p = 0.011) during hospitalization. The incidence rate of 1-month mortality (34.5 vs. 23.8%, p = 0.036) was higher in right-sided patients with LHI, but there were no hemispheric differences in the incidence rates of 3-month mortality and unfavorable outcome (both p &amp;gt; 0.05). Multivariate analyses suggested right hemisphere involvement was independently associated with increased risk of MBE (adjusted OR 2.37, 95% CI 1.26–4.43, p = 0.007) and composite of cardiovascular events (adjusted OR 2.04, 95% CI 1.12–3.72, p = 0.020). However, it was not independently associated with 1-month death, 3-month mortality, and 3-month unfavorable outcome (all p &amp;gt; 0.05)., Conclusions: Right-sided patients with LHI had higher frequency of atrial fibrillation and cardio-embolism than the left-sided patients. Right hemisphere involvement was independently associated with increased risk of MBE and composite of cardiovascular events during hospitalization, whereas stroke lateralization was not an independent predictor of mortality and unfavorable outcome in patients with LHI.;,citation_author=Jie Li;,citation_author=Ping Zhang;,citation_author=Yingying Liu;,citation_author=Wanli Chen;,citation_author=Xingyang Yi;,citation_author=Chun Wang;,citation_publication_date=2021-12;,citation_cover_date=2021-12;,citation_year=2021;,citation_doi=10.3389/fneur.2021.774247;,citation_issn=1664-2295;,citation_pmid=34956055;,citation_volume=12;,citation_journal_title=Frontiers in Neurology;">
<meta name="citation_reference" content="citation_title=Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV;,citation_abstract=OBJECTIVE: To compare the risk of coronavirus disease 2019 (COVID-19) outcomes by antiretroviral therapy (ART) regimens among men with HIV. DESIGN: We included men with HIV on ART in the Veterans Aging Cohort Study who, between February 2020 and October 2021, were 18\mkern1muyears or older and had adequate virological control, CD4 + cell count, and HIV viral load measured in the previous 12\mkern1mumonths, and no previous COVID-19 diagnosis or vaccination. METHODS: We compared the adjusted risks of documented severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, COVID-19-related hospitalization, and intensive care unit (ICU) admission by baseline ART regimen: tenofovir alafenamide (TAF)/emtricitabine (FTC), tenofovir disoproxil fumarate (TDF)/FTC, abacavir (ABC)/lamivudine (3TC), and other. We fit pooled logistic regressions to estimate the 18-month risks standardized by demographic and clinical factors. RESULTS: Among 20 494 eligible individuals, the baseline characteristics were similar across regimens, except that TDF/FTC and TAF/FTC had lower prevalences of chronic kidney disease and estimated glomerular filtration rate &amp;amp;amp;lt;60\mkern1muml/min. Compared with TAF/FTC, the estimated 18-month risk ratio (95% confidence interval) of documented SARS-CoV-2 infection was 0.65 (0.43, 0.89) for TDF/FTC, 1.00 (0.85, 1.18) for ABC/3TC, and 0.87 (0.70, 1.04) for others. The corresponding risk ratios for COVID-19 hospitalization were 0.43 (0.07, 0.87), 1.09 (0.79, 1.48), and 1.21 (0.88, 1.62). The risk of COVID-19 ICU admission was lowest for TDF/FTC, but the estimates were imprecise. CONCLUSION: Our study suggests that, in men living with HIV, TDF/FTC may protect against COVID-19-related events. Randomized trials are needed to investigate the effectiveness of TDF as prophylaxis for, and early treatment of, COVID-19 in the general population.;,citation_author=Guilin Li;,citation_author=Lesley S. Park;,citation_author=Sara Lodi;,citation_author=Roger W. Logan;,citation_author=Emily J. Cartwright;,citation_author=Lydia Aoun-Barakat;,citation_author=Juan P. Casas;,citation_author=Barbra A. Dickerman;,citation_author=Christopher T. Rentsch;,citation_author=Amy C. Justice;,citation_author=Miguel A. Hernán;,citation_publication_date=2022-10;,citation_cover_date=2022-10;,citation_year=2022;,citation_issue=12;,citation_doi=10.1097/QAD.0000000000003314;,citation_issn=1473-5571;,citation_pmid=35848570;,citation_volume=36;,citation_language=en-US;,citation_journal_title=AIDS (London, England);">
<meta name="citation_reference" content="citation_title=Analyzing ordinal data with metric models: What could possibly go wrong?;,citation_abstract=We surveyed all articles in the Journal of Personality and Social Psychology (JPSP), Psychological Science (PS), and the Journal of Experimental Psychology: General (JEP:G) that mentioned the term “Likert,” and found that 100% of the articles that analyzed ordinal data did so using a metric model. We present novel evidence that analyzing ordinal data as if they were metric can systematically lead to errors. We demonstrate false alarms (i.e., detecting an effect where none exists, Type I errors) and failures to detect effects (i.e., loss of power, Type II errors). We demonstrate systematic inversions of effects, for which treating ordinal data as metric indicates the opposite ordering of means than the true ordering of means. We show the same problems — false alarms, misses, and inversions — for interactions in factorial designs and for trend analyses in regression. We demonstrate that averaging across multiple ordinal measurements does not solve or even ameliorate these problems. A central contribution is a graphical explanation of how and when the misrepresentations occur. Moreover, we point out that there is no sure-fire way to detect these problems by treating the ordinal values as metric, and instead we advocate use of ordered-probit models (or similar) because they will better describe the data. Finally, although frequentist approaches to some ordered-probit models are available, we use Bayesian methods because of their flexibility in specifying models and their richness and accuracy in providing parameter estimates. An R script is provided for running an analysis that compares ordered-probit and metric models.;,citation_author=Torrin M. Liddell;,citation_author=John K. Kruschke;,citation_publication_date=2018-11;,citation_cover_date=2018-11;,citation_year=2018;,citation_doi=10.1016/j.jesp.2018.08.009;,citation_issn=00221031;,citation_volume=79;,citation_language=en-US;,citation_journal_title=Journal of Experimental Social Psychology;">
<meta name="citation_reference" content="citation_title=Bias from conditioning on live birth in pregnancy cohorts: An illustration based on neurodevelopment in children after prenatal exposure to organic pollutants;,citation_abstract=Only 60–70% of fertilized eggs may result in a live birth, and very early fetal loss mainly goes unnoticed. Outcomes that can only be ascertained in live-born children will be missing for those who do not survive till birth. In this article, we illustrate a common bias structure (leading to “live-birth bias”) that arises from studying the effects of prenatal exposure to environmental factors on long-term health outcomes among live births only in pregnancy cohorts. To illustrate this we used prenatal exposure to perfluoroalkyl substances (PFAS) and attention-deficit/hyperactivity disorder (ADHD) in school-aged children as an example. PFAS are persistent organic pollutants that may impact human fecundity and be toxic for neurodevelopment. We simulated several hypothetical scenarios based on characteristics from the Danish National Birth Cohort and found that a weak inverse association may appear even if PFAS do not cause ADHD but have a considerable effect on fetal survival. The magnitude of the negative bias was generally small, and adjusting for common causes of the outcome and fetal loss can reduce the bias. Our example highlights the need to identify the determinants of pregnancy loss and the importance of quantifying bias arising from conditioning on live birth in observational studies.;,citation_author=Zeyan Liew;,citation_author=Jørn Olsen;,citation_author=Xin Cui;,citation_author=Beate Ritz;,citation_author=Onyebuchi A Arah;,citation_publication_date=2015-02;,citation_cover_date=2015-02;,citation_year=2015;,citation_issue=1;,citation_doi=10.1093/ije/dyu249;,citation_issn=0300-5771;,citation_volume=44;,citation_journal_title=International Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Effects of Hypothermia vs Normothermia on Societal Participation and Cognitive Function at 6 Months in Survivors After Out-of-Hospital Cardiac Arrest: A Predefined Analysis of the TTM2 Randomized Clinical Trial;,citation_abstract=The Targeted Hypothermia vs Targeted Normothermia After Out-of-Hospital Cardiac Arrest (TTM2) trial reported no difference in mortality or poor functional outcome at 6 months after out-of-hospital cardiac arrest (OHCA). This predefined exploratory analysis provides more detailed estimation of brain dysfunction for the comparison of the 2 intervention regimens.To investigate the effects of targeted hypothermia vs targeted normothermia on functional outcome with focus on societal participation and cognitive function in survivors 6 months after OHCA.This study is a predefined analysis of an international multicenter, randomized clinical trial that took place from November 2017 to January 2020 and included participants at 61 hospitals in 14 countries. A structured follow-up for survivors performed at 6 months was by masked outcome assessors. The last follow-up took place in October 2020. Participants included 1861 adult (older than 18 years) patients with OHCA who were comatose at hospital admission. At 6 months, 939 of 1861 were alive and invited to a follow-up, of which 103 of 939 declined or were missing.Randomization 1:1 to temperature control with targeted hypothermia at 33 ^\circC or targeted normothermia and early treatment of fever (37.8 ^\circC or higher).Functional outcome focusing on societal participation assessed by the Glasgow Outcome Scale Extended ([GOSE] 1 to 8) and cognitive function assessed by the Montreal Cognitive Assessment ([MoCA] 0 to 30) and the Symbol Digit Modalities Test ([SDMT] z scores). Higher scores represent better outcomes.At 6 months, 836 of 939 survivors with a mean age of 60 (SD, 13) (range, 18 to 88) years (700 of 836 male [84%]) participated in the follow-up. There were no differences between the 2 intervention groups in functional outcome focusing on societal participation (GOSE score, odds ratio, 0.91; 95% CI, 0.71-1.17; P = .46) or in cognitive function by MoCA (mean difference, 0.36; 95% CI,-0.33 to 1.05; P = .37) and SDMT (mean difference, 0.06; 95% CI,-0.16 to 0.27; P = .62). Limitations in societal participation (GOSE score less than 7) were common regardless of intervention (hypothermia, 178 of 415 [43%]; normothermia, 168 of 419 [40%]). Cognitive impairment was identified in 353 of 599 survivors (59%).In this predefined analysis of comatose patients after OHCA, hypothermia did not lead to better functional outcome assessed with a focus on societal participation and cognitive function than management with normothermia. At 6 months, many survivors had not regained their pre-arrest activities and roles, and mild cognitive dysfunction was common.ClinicalTrials.gov Identifier: NCT02908308;,citation_author=Gisela Lilja;,citation_author=Susann Ullén;,citation_author=Josef Dankiewicz;,citation_author=Hans Friberg;,citation_author=Helena Levin;,citation_author=Erik Blennow Nordström;,citation_author=Katarina Heimburg;,citation_author=Janus Christian Jakobsen;,citation_author=Marita Ahlqvist;,citation_author=Frances Bass;,citation_author=Jan Belohlavek;,citation_author=Roy Bjørkholt Olsen;,citation_author=Alain Cariou;,citation_author=Glenn Eastwood;,citation_author=Hans Rune Fanebust;,citation_author=Anders M. Grejs;,citation_author=Lisa Grimmer;,citation_author=Naomi E. Hammond;,citation_author=Jan Hovdenes;,citation_author=Juraj Hrecko;,citation_author=Manuela Iten;,citation_author=Henriette Johansen;,citation_author=Thomas R. Keeble;,citation_author=Hans Kirkegaard;,citation_author=Jean-Baptiste Lascarrou;,citation_author=Christoph Leithner;,citation_author=Mildred Eden Lesona;,citation_author=Anja Levis;,citation_author=Marco Mion;,citation_author=Marion Moseby-Knappe;,citation_author=Leanlove Navarra;,citation_author=Per Nordberg;,citation_author=Paolo Pelosi;,citation_author=Rachael Quayle;,citation_author=Christian Rylander;,citation_author=Helena Sandberg;,citation_author=Manoj Saxena;,citation_author=Claudia Schrag;,citation_author=Michal Siranec;,citation_author=Cassina Tiziano;,citation_author=Philippe Vignon;,citation_author=Pedro David Wendel-Garcia;,citation_author=Matt P. Wise;,citation_author=Kim Wright;,citation_author=Niklas Nielsen;,citation_author=Tobias Cronberg;,citation_publication_date=2023-10;,citation_cover_date=2023-10;,citation_year=2023;,citation_issue=10;,citation_doi=10.1001/jamaneurol.2023.2536;,citation_issn=2168-6149;,citation_volume=80;,citation_journal_title=JAMA Neurology;">
<meta name="citation_reference" content="citation_title=Effect of Delays in Concordant Antibiotic Treatment on Mortality in Patients With Hospital-Acquired &amp;amp;amp;lt;i&amp;gt;Acinetobacter&amp;lt;/i&amp;gt; Species Bacteremia: Emulating a Target Randomized Trial With a 13-Year Retrospective Cohort;,citation_abstract=Abstract Delays in treating bacteremias with antibiotics to which the causative organism is susceptible are expected to adversely affect patient outcomes. Quantifying the impact of such delays to concordant treatment is important for decision-making about interventions to reduce the delays and for quantifying the burden of disease due to antimicrobial resistance. There are, however, potentially important biases to be addressed, including immortal time bias. We aimed to estimate the impact of delays in appropriate antibiotic treatment of patients with Acinetobacter species hospital-acquired bacteremia in Thailand on 30-day mortality by emulating a target trial using retrospective cohort data from Sunpasitthiprasong Hospital in 2003–2015. For each day, we defined treatment as concordant if the isolated organism was susceptible to at least 1 antibiotic given. Among 1,203 patients with Acinetobacter species hospital-acquired bacteremia, 682 had 1 or more days of delays to concordant treatment. Surprisingly, crude 30-day mortality was lower in patients with delays of \geq3 days compared with those who had 1–2 days of delays. Accounting for confounders and immortal time bias resolved this paradox. Emulating a target trial, we found that these delays were associated with an absolute increase in expected 30-day mortality of 6.6% (95% confidence interval: 0.2, 13.0), from 33.8% to 40.4%.;,citation_author=Cherry Lim;,citation_author=Yin Mo;,citation_author=Prapit Teparrukkul;,citation_author=Maliwan Hongsuwan;,citation_author=Nicholas P J Day;,citation_author=Direk Limmathurotsakul;,citation_author=Ben S Cooper;,citation_publication_date=2021-11;,citation_cover_date=2021-11;,citation_year=2021;,citation_issue=11;,citation_doi=10.1093/aje/kwab158;,citation_issn=0002-9262, 1476-6256;,citation_volume=190;,citation_language=en-US;,citation_journal_title=American Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Decompressive Hemicraniectomy for Large Hemispheric Strokes;,citation_abstract=Large hemispheric infarcts occur in up to 10% of all ischemic strokes and can cause devastating disability. Significant research and clinical efforts have been made in hopes of mitigating the morbidity and mortality of this disease. Areas of interest include identifying predictors of malignant edema, optimizing medical and surgical techniques, selecting the patient population that would benefit most from decompressive hemicraniectomy, and studying the impact on quality of life of those who survive. Decompressive surgery can be a life-saving measure, and here we discuss the most up-to-date literature and provide a review on the surgical management of large hemispheric ischemic strokes.;,citation_author=Jessica Lin;,citation_author=Jennifer A. Frontera;,citation_publication_date=2021-04;,citation_cover_date=2021-04;,citation_year=2021;,citation_issue=4;,citation_doi=10.1161/STROKEAHA.120.032359;,citation_volume=52;,citation_journal_title=Stroke;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina;,citation_abstract=BACKGROUND The duration of protection afforded by coronavirus disease 2019 (Covid-19) vaccines in the United States is unclear. Whether the increase in postvaccination infections during the summer of 2021 was caused by declining immunity over time, the emergence of the B.1.617.2 (delta) variant, or both is unknown. METHODS We extracted data regarding Covid-19–related vaccination and outcomes during a 9-month period (December 11, 2020, to September 8, 2021) for approximately 10.6 million North Carolina residents by linking data from the North Carolina Covid-19 Surveillance System and the Covid-19 Vaccine Management System. We used a Cox regression model to estimate the effectiveness of the BNT162b2 (Pfizer–BioNTech), mRNA-1273 (Moderna), and Ad26.COV2.S (Johnson &amp;amp;amp; Johnson–Janssen) vaccines in reducing the current risks of Covid-19, hospitalization, and death, as a function of time elapsed since vaccination. RESULTS For the two-dose regimens of messenger RNA (mRNA) vaccines BNT162b2 (30 \mug per dose) and mRNA-1273 (100 \mug per dose), vaccine effectiveness against Covid-19 was 94.5% (95% confidence interval [CI], 94.1 to 94.9) and 95.9% (95% CI, 95.5 to 96.2), respectively, at 2 months after the first dose and decreased to 66.6% (95% CI, 65.2 to 67.8) and 80.3% (95% CI, 79.3 to 81.2), respectively, at 7 months. Among early recipients of BNT162b2 and mRNA-1273, effectiveness decreased by approximately 15 and 10 percentage points, respectively, from mid-June to mid-July, when the delta variant became dominant. For the one-dose regimen of Ad26.COV2.S (5  1010 viral particles), effectiveness against Covid-19 was 74.8% (95% CI, 72.5 to 76.9) at 1 month and decreased to 59.4% (95% CI, 57.2 to 61.5) at 5 months. All three vaccines maintained better effectiveness in preventing hospitalization and death than in preventing infection over time, although the two mRNA vaccines provided higher levels of protection than Ad26.COV2.S. From the Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill (D.-Y.L., Y.G., D.Z.), and the North Carolina Department of Health and Human Services (B.W., H.Y., Z.M.), North Carolina State University (S.H.), and the CDC Foundation, North Carolina Department of Health and Human Services (S.-K.S.), Raleigh. Dr. Lin can be contacted at lin@ bios.unc.edu or at the Department of Biostatistics, University of North Carolina at Chapel Hill, 3101E McGavran-Greenberg Hall, Chapel Hill, NC 27599. This article was published on January 12, 2022, at NEJM.org. DOI: 10.1056/NEJMoa2117128 Copyright © 2022 Massachusetts Medical Society. CONCLUSIONS All three Covid-19 vaccines had durable effectiveness in reducing the risks of hospitalization and death. Waning protection against infection over time was due to both declining immunity and the emergence of the delta variant. (Funded by a Dennis Gillings Distinguished Professorship and the National Institutes of Health.);,citation_author=Dan-Yu Lin;,citation_author=Yu Gu;,citation_author=Bradford Wheeler;,citation_author=Hayley Young;,citation_author=Shannon Holloway;,citation_author=Shadia-Khan Sunny;,citation_author=Zack Moore;,citation_author=Donglin Zeng;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_doi=10.1056/NEJMoa2117128;,citation_issn=0028-4793, 1533-4406;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=A Fork in the Road: Mapping the Paths of Emergency Medicine and Critical Care Blogs and Podcasts (Preprint);,citation_abstract=Background: Free, open access meducation (FOAM) refers to open access, online learning resources in medicine. It includes all formats of digital products including blogs and podcasts. The number of FOAM blog and podcast sites in emergency medicine and critical care increased dramatically from 2002 to 2013, and physicians began to rely on the availability of these resources. The current landscape of these FOAM sites is unknown. Objective: This study aimed to (1) estimate the current number of active, open access blogs and podcasts in emergency medicine and critical care, and (2) describe observed and anticipated trends in the FOAM movement using Christensen’s Theory of Disruptive Innovation as a theoretical framework. Methods: The authors used multiple resources and sampling strategies to identify active, open-access blogs and podcasts between April 25-May 8, 2022, and classified these websites as blogs, podcasts, or blogs+podcasts. For each category, they reported the following outcome measures using descriptive statistics: age, funding, affiliations, and team composition. Based on these findings, the authors projected trends in the number of active sites using a positivist paradigm and Christensen’s Theory of Disruptive Innovation as a theoretical framework. Results: The authors identified 109 emergency medicine and critical care websites, comprised of 50 blogs, 25 podcasts, and 34 blogs+podcasts. Ages ranged from 0 to 18 years; 27.5% sold products, 18.3% used advertisements, 44% had institutional funding, and 27.5% had no affiliation or external funding sources. Team sizes ranged from 1 (23.9%) to ?5 (55%) individuals. Conclusions: There was a sharp decline in the number of emergency medicine and critical care blogs and podcasts in the last decade, dropping 40.4% since 2013. The initial growth of FOAM and its subsequent downturn align with principles in Christensen’s Theory of Disruptive Innovation. These findings have important implications for the field of medical education.;,citation_author=Michelle Lin;,citation_author=Mina Phipps;,citation_author=Michael A. Gisondi;,citation_author=Yusuf Yilmaz;,citation_author=Christopher Nash;,citation_author=Teresa M. Chan;,citation_publication_date=2022-05;,citation_cover_date=2022-05;,citation_year=2022;,citation_doi=10.2196/preprints.39946;,citation_language=en-US;,citation_technical_report_institution=JMIR Medical Education;">
<meta name="citation_reference" content="citation_title=Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes;,citation_author=A. Michael Lincoff;,citation_author=Kirstine Brown-Frandsen;,citation_author=Helen M. Colhoun;,citation_author=John Deanfield;,citation_author=Scott S. Emerson;,citation_author=Sille Esbjerg;,citation_author=Søren Hardt-Lindberg;,citation_author=G. Kees Hovingh;,citation_author=Steven E. Kahn;,citation_author=Robert F. Kushner;,citation_author=Ildiko Lingvay;,citation_author=Tugce K. Oral;,citation_author=Marie M. Michelsen;,citation_author=Jorge Plutzky;,citation_author=Christoffer W. Tornøe;,citation_author=Donna H. Ryan;,citation_publication_date=2023-11;,citation_cover_date=2023-11;,citation_year=2023;,citation_issue=0;,citation_doi=10.1056/NEJMoa2307563;,citation_issn=0028-4793;,citation_volume=0;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial;,citation_author=Jes S. Lindholt;,citation_author=Rikke Søgaard;,citation_author=Lars M. Rasmussen;,citation_author=Anne Mejldal;,citation_author=Jess Lambrechtsen;,citation_author=Flemming H. Steffensen;,citation_author=Lars Frost;,citation_author=Kenneth Egstrup;,citation_author=Grazina Urbonaviciene;,citation_author=Martin Busk;,citation_author=Axel Cosmus Pyndt Diederichsen;,citation_publication_date=2022-10;,citation_cover_date=2022-10;,citation_year=2022;,citation_issue=15;,citation_doi=10.1056/NEJMoa2208681;,citation_issn=0028-4793;,citation_volume=387;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=The Analysis of Experimental Data: The Appreciation of Tea and Wine;,citation_abstract=A classical experiment on the tasting of tea is used to show that many standard methods of analysis of the resulting data are unsatisfactory. A similar experiment with wine is used to show how a more sensible method may be developed.;,citation_author=Dennis V Lindley;,citation_publication_date=1993-03;,citation_cover_date=1993-03;,citation_year=1993;,citation_issue=1;,citation_doi=10.1111/j.1467-9639.1993.tb00252.x;,citation_issn=0141-982X, 1467-9639;,citation_volume=15;,citation_language=en-US;,citation_journal_title=Teaching Statistics;">
<meta name="citation_reference" content="citation_title=Long-Term Clinical Trajectory of Patients with Subarachnoid Hemorrhage: Linking Acute Care and Neurorehabilitation;,citation_abstract=Despite improvements in the critical care management of subarachnoid hemorrhage (SAH), a substantial number of patients still suffer from disabilities. In most areas of the world, longitudinal follow-up is not routinely performed, and the patient’s trajectory remains unknown.;,citation_author=Anna Lindner;,citation_author=Luca Brunelli;,citation_author=Verena Rass;,citation_author=Bogdan-Andrei Ianosi;,citation_author=Max Gaasch;,citation_author=Mario Kofler;,citation_author=Victoria Limmert;,citation_author=Alois J. Schiefecker;,citation_author=Bettina Pfausler;,citation_author=Ronny Beer;,citation_author=Elke Pucks-Faes;,citation_author=Raimund Helbok;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_doi=10.1007/s12028-022-01572-6;,citation_issn=1556-0961;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Negative Controls: A Tool for Detecting Confounding and Bias in Observational Studies;,citation_abstract=Noncausal associations between exposures and outcomes are a threat to validity of causal inference in observational studies. Many techniques have been developed for study design and analysis to identify and eliminate such errors. Such problems are not expected to compromise experimental studies, where careful standardization of conditions (for laboratory work) and randomization (for population studies) should, if applied properly, eliminate most such noncausal associations. We argue, however, that a routine precaution taken in the design of biologic laboratory experiments—the use of “negative controls”—is designed to detect both suspected and unsuspected sources of spurious causal inference. In epidemiology, analogous negative controls help to identify and resolve confounding as well as other sources of error, including recall bias or analytic flaws. We distinguish 2 types of negative controls (exposure controls and outcome controls), describe examples of each type from the epidemiologic literature, and identify the conditions for the use of such negative controls to detect confounding. We conclude that negative controls should be more commonly employed in observational studies, and that additional work is needed to specify the conditions under which negative controls will be sensitive detectors of other sources of error in observational studies.;,citation_author=Marc Lipsitch;,citation_author=Eric Tchetgen Tchetgen;,citation_author=Ted Cohen;,citation_publication_date=2010-05;,citation_cover_date=2010-05;,citation_year=2010;,citation_issue=3;,citation_doi=10.1097/EDE.0b013e3181d61eeb;,citation_issn=1044-3983;,citation_volume=21;,citation_language=en-US;,citation_journal_title=Epidemiology;">
<meta name="citation_reference" content="citation_title=Causal Directed Acyclic Graphs;,citation_author=Ari M Lipsky;,citation_author=Sander Greenland;,citation_publication_date=2022;,citation_cover_date=2022;,citation_year=2022;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Estimands, Estimators, and Estimates;,citation_abstract=The primary goal of most randomized clinical trials (RCTs) is to draw conclusions about the effect of a treatment in a specific population of patients. The true effect of the intervention, termed the estimand, is estimated with the data acquired in the trial, subject to limitations associated with variations in adherence to treatment, patients being lost to follow-up, and data quality.The choice of estimand and associated target population should reflect the goals of the trial, and can vary according to who designed or sponsored the study, who will use the results of the study, and the motivating scientific question. In the PIONEER 3 trial, investigators compared 3 doses of oral semaglutide with sitagliptin, added to background therapy, in adults with type 2 diabetes. The primary end point was the change in glycated hemoglobin (HbA1c). The trial design considered 2 estimands for summarizing treatment effect, termed the treatment policy estimand and the trial product estimand.;,citation_author=Roderick J. Little;,citation_author=Roger J. Lewis;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_issue=10;,citation_doi=10.1001/jama.2021.2886;,citation_issn=0098-7484;,citation_volume=326;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Overestimation of benefit when clinical trials stop early: A simulation study;,citation_abstract=Background: Stopping trials early because of a favourable interim analysis can exaggerate benefit. This study simulated trials typical of those stopping early for benefit in the real world and estimated the degree to which early stopping likely overestimates benefit. Methods: From 1 million simulated trials, we selected those trials that exceeded interim stopping criteria, and compared apparent benefit when stopped with the true benefit used to generate the data. Each simulation randomly assigned period of observation, number of subjects, and control event rate using normal distributions centred on the same parameters in a template trial typical of real-world “truncated” (i.e. stopped for benefit) trials. The intervention’s true relative risk reduction (RRR) was also randomized, and assumed 1% of drugs have a warfarin-like effect (60% RRR), 5% a statin-like effect (35% RRR), 39% an ASA-like effect (15% RRR), 50% no effect (0% RRR), and that 5% would cause harm (modelled as a 20% relative risk increase). Trials had a single interim analysis and a z-value for stopping of 2.782 (O’Brien-Fleming threshold). We also modelled (1) a large truncated trial based on the SPRINT blood pressure trial (using SPRINT’s parameters and stopping criteria) and (2) the same typical truncated trials if they instead went to completion as planned with no interim analysis. Results: For typical truncated trials, the true RRR was roughly 2/3 the observed RRR at the time of stopping. RRR was overestimated by an absolute 14.9% (median, IQR 6.4–24.6) in typical truncated trials, by 5.3% (IQR -0.1 to 11.4) in the same trials if instead carried to completion, and by 2.3% (IQR 0.98–1.09) in large SPRINT-like trials. For all models, to keep the absolute RRR overestimate below 5%, 250 events were required. Conclusion: Simulated trials typical of those stopping early for benefit overestimate the true relative risk reduction by roughly 50% (i.e. the true RRR was 2/3 of the observed value). Overestimation was much smaller, and likely unimportant, when simulating large SPRINT-like trials stopping early. Whether trials were large or small, stopped early or not, a minimum 250 events were needed to avoid overestimating relative risk reduction by an absolute 5% or more.;,citation_author=Sharon Liu;,citation_author=Scott R. Garrison;,citation_publication_date=2022-09;,citation_cover_date=2022-09;,citation_year=2022;,citation_issue=1;,citation_doi=10.1186/s13063-022-06689-9;,citation_issn=1745-6215;,citation_volume=23;,citation_language=en-US;,citation_journal_title=Trials;">
<meta name="citation_reference" content="citation_title=Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): A phase 3, randomised, open-label, blinded endpoint trial;,citation_abstract=Background Tenecteplase is a newer thrombolytic agent with some pharmacological advantages over alteplase. Previous phase 2 trials of tenecteplase in acute ischaemic stroke have shown promising results. We aimed to investigate the safety and efficacy of tenecteplase versus alteplase in patients with acute stroke who were eligible for intravenous thrombolysis. Methods This phase 3, randomised, open-label, blinded endpoint, superiority trial was done in 13 stroke units in Norway. We enrolled adults with suspected acute ischaemic stroke who were eligible for thrombolysis and admitted within 4\cdot5 h of symptom onset or within 4\cdot5 h of awakening with symptoms, or who were eligible for bridging therapy before thrombectomy. Patients were randomly assigned (1:1) to receive intravenous tenecteplase 0\cdot4 mg/kg (to a maximum of 40 mg) or alteplase 0\cdot9 mg/kg (to a maximum of 90 mg), via a block randomisation schedule stratified by centre of inclusion. Patients were not informed of treatment allocation; treating physicians were aware of treatment allocation but those assessing the primary and secondary endpoints were not. The primary outcome was excellent functional outcome defined as modified Rankin Scale (mRS) score 0–1 at 3 months. The primary analysis was an unadjusted and non-stratified intention-to-treat analysis with last observation carried forward for imputation of missing data. This study is registered with ClinicalTrials.gov, number NCT01949948. Findings Between Sept 1, 2012, and Sept 30, 2016, 1107 patients met the inclusion criteria and seven patients were excluded because informed consent was withdrawn or eligibility for thrombolytic treatment was reconsidered. 1100 patients were randomly assigned to the tenecteplase (n=549) or alteplase (n=551) groups. The median age of participants was 77 years (IQR 64–79) and the median National Institutes of Health Stroke Scale score at baseline was 4 points (IQR 2–8). A final diagnosis other than ischaemic stroke or transient ischaemic attack was found in 99 (18%) patients in the tenecteplase group and 91 (17%) patients in the alteplase group. The primary outcome was achieved by 354 (64%) patients in the tenecteplase group and 345 (63%) patients in the alteplase group (odds ratio 1\cdot08, 95% CI 0\cdot84–1\cdot38; p=0\cdot52). By 3 months, 29 (5%) patients had died in the tenecteplase group compared with 26 (5%) in the alteplase group. The frequency of serious adverse events was similar between groups (145 [26%] in the tenecteplase group vs 141 [26%] in the alteplase group; p=0\cdot74). Interpretation Tenecteplase was not superior to alteplase and showed a similar safety profile. Most patients enrolled in this study had mild stroke. Further trials are needed to establish the safety and efficacy in patients with severe stroke and whether tenecteplase is non-inferior to alteplase. Funding Research Council of Norway.;,citation_author=Nicola Logallo;,citation_author=Vojtech Novotny;,citation_author=Jörg Assmus;,citation_author=Christopher E Kvistad;,citation_author=Lars Alteheld;,citation_author=Ole Morten Rønning;,citation_author=Bente Thommessen;,citation_author=Karl-Friedrich Amthor;,citation_author=Hege Ihle-Hansen;,citation_author=Martin Kurz;,citation_author=Håkon Tobro;,citation_author=Kamaljit Kaur;,citation_author=Magdalena Stankiewicz;,citation_author=Maria Carlsson;,citation_author=Åse Morsund;,citation_author=Titto Idicula;,citation_author=Anne Hege Aamodt;,citation_author=Christian Lund;,citation_author=Halvor Næss;,citation_author=Ulrike Waje-Andreassen;,citation_author=Lars Thomassen;,citation_publication_date=2017-10;,citation_cover_date=2017-10;,citation_year=2017;,citation_issue=10;,citation_doi=10.1016/S1474-4422(17)30253-3;,citation_issn=1474-4422;,citation_volume=16;,citation_language=en-US;,citation_journal_title=The Lancet Neurology;">
<meta name="citation_reference" content="citation_title=Effect of desmopressin on hematoma expansion in antiplatelet-associated intracerebral hemorrhage: A systematic review and meta-analysis;,citation_abstract=The purpose of this study was to perform a systematic review and meta-analysis on the effect of desmopressin on hematoma expansion (HE) in antiplatelet-associated intracerebral hemorrhage (AA-ICH). Secondary outcomes examined were the rate of thrombotic complications and neurologic outcome.;,citation_author=Andrea Loggini;,citation_author=Faten El Ammar;,citation_author=Andrea J. Darzi;,citation_author=Ali Mansour;,citation_author=Christopher L. Kramer;,citation_author=Fernando D. Goldenberg;,citation_author=Christos Lazaridis;,citation_publication_date=2021-04;,citation_cover_date=2021-04;,citation_year=2021;,citation_doi=10.1016/j.jocn.2021.01.017;,citation_issn=09675868;,citation_volume=86;,citation_language=en-US;,citation_journal_title=Journal of Clinical Neuroscience;">
<meta name="citation_reference" content="citation_title=Measurement error and the replication crisis;,citation_author=Eric Loken;,citation_author=Andrew Gelman;,citation_publication_date=2017-02;,citation_cover_date=2017-02;,citation_year=2017;,citation_issue=6325;,citation_doi=10.1126/science.aal3618;,citation_issn=0036-8075, 1095-9203;,citation_volume=355;,citation_language=en-US;,citation_journal_title=Science;">
<meta name="citation_reference" content="citation_title=Balanced Crystalloid versus Saline in Adults with Traumatic Brain Injury: Secondary Analysis of a Clinical Trial;,citation_abstract=Balanced crystalloids may improve outcomes compared with saline for some critically ill adults. Lower tonicity of balanced crystalloids could worsen cerebral edema in patients with intracranial pathology. The effect of balanced crystalloids versus saline on clinical outcomes in patients with traumatic brain injury (TBI) requires further study. We planned an a priori subgroup analysis of TBI patients enrolled in the pragmatic, cluster-randomized, multiple-crossover Isotonic Solutions and Major Adverse Renal Events Trial (SMART) (ClinicalTrials.gov: NCT02444988, NCT02547779). Primary outcome was 30-day in-hospital mortality. Secondary outcomes included hospital discharge disposition (home, facility, death). Regression models adjusted for pre-specified baseline covariates compared outcomes. TBI patients assigned to balanced crystalloids (n = 588) and saline (n = 569) had similar baseline characteristics including Injury Severity Score 19 (10); mean maximum head/neck Abbreviated Injury Score, 3.4 (1.0). Isotonic crystalloid volume administered between intensive care unit admission and first of hospital discharge or 30 days was 2037 (3470) mL and 1723 (2923) mL in the balanced crystalloids and saline groups, respectively (p = 0.18). During the study period, 94 (16%) and 82 (14%) patients (16%) died in the balanced crystalloid and saline groups, respectively (adjusted odds ratio [aOR], 1.03; 95% confidence interval [CI], 0.60 to 1.75; p = 0.913). Patients in the balanced crystalloid group were more likely to die or be discharged to another medical facility (aOR 1.38 [1.02-1.86]; p = 0.04). Overall, balanced crystalloids were associated with worse discharge disposition in critically injured patients with TBI compared with saline. The confidence intervals cannot exclude a clinically relevant increase in mortality when balanced crystalloids are used for patients with TBI.;,citation_author=Sarah Lombardo;,citation_author=Michael C. Smith;,citation_author=Matthew W. Semler;,citation_author=Li Wang;,citation_author=Mary Lynn Dear;,citation_author=Christopher J. Lindsell;,citation_author=Robert E. Freundlich;,citation_author=Oscar D. Guillamondegui;,citation_author=Wesley H. Self;,citation_author=Todd W. Rice;,citation_author=Matthew W. Semler;,citation_author=Wesley H. Self;,citation_author=Jonathan P. Wanderer;,citation_author=Jesse M. Ehrenfeld;,citation_author=Li Wang;,citation_author=Daniel W. Byrne;,citation_author=Joanna L. Stollings;,citation_author=Avinash B. Kumar;,citation_author=Christopher G. Hughes;,citation_author=Antonio Hernandez;,citation_author=Oscar D. Guillamondegui;,citation_author=Addison K. May;,citation_author=Liza Weavind;,citation_author=Jonathan D. Casey;,citation_author=Edward D. Siew;,citation_author=Andrew D. Shaw;,citation_author=Gordon R. Bernard;,citation_author=Todd W. Rice;,citation_author=Ryan M. Brown;,citation_author=Michael J. Noto;,citation_author=Henry J. Domenico;,citation_author=William T. Costello;,citation_author=Jayme Gibson;,citation_author=Emily W. Holcombe;,citation_author=Mias Pretorius;,citation_author=Abraham S. McCall;,citation_author=Leanne Atchison;,citation_author=Debra F. Dunlap;,citation_author=Matthew Felbinger;,citation_author=Susan E. Hamblin;,citation_author=Molly Knostman;,citation_author=Kelli A. Rumbaugh;,citation_author=Mark Sullivan;,citation_author=Julie Y. Valenzuela;,citation_author=Jason B. Young;,citation_author=David P. Mulherin;,citation_author=Fred R. Hargrove;,citation_author=Gordon Bernard;,citation_author=Robert Dittus;,citation_author=Shon Dwyer;,citation_author=Robert Freundlich;,citation_author=Cheryl Gatto;,citation_author=Frank Harrell;,citation_author=Paul Harris;,citation_author=Tina Hartert;,citation_author=Jim Hayman;,citation_author=Catherine Ivory;,citation_author=Kevin Johnson;,citation_author=Ruth Kleinpell;,citation_author=Sunil Kripalani;,citation_author=Christopher Lindsell;,citation_author=Lee Ann Liska;,citation_author=Patrick Luther;,citation_author=Jay Morrison;,citation_author=Thomas Nantais;,citation_author=Mariann Piano;,citation_author=Jill Pulley;,citation_author=Kris Rehm;,citation_author=Todd Rice;,citation_author=Russell Rothman;,citation_author=Matthew Semler;,citation_author=Robin Steaban;,citation_author=Philip Walker;,citation_author=Consuelo Wilkins;,citation_author=Adam Wright;,citation_author=Autumn Zuckerman;,citation_publication_date=2022-09;,citation_cover_date=2022-09;,citation_year=2022;,citation_issue=17-18;,citation_doi=10.1089/neu.2021.0465;,citation_issn=0897-7151;,citation_volume=39;,citation_journal_title=Journal of Neurotrauma;,citation_publisher=Mary Ann Liebert, Inc., publishers;">
<meta name="citation_reference" content="citation_title=Against pandemic research exceptionalism;,citation_author=Alex John London;,citation_author=Jonathan Kimmelman;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Artificial intelligence in medicine: Overcoming or recapitulating structural challenges to improving patient care?;,citation_abstract=There is considerable enthusiasm about the prospect that artificial intelligence (AI) will help to improve the safety and efficacy of health services and the efficiency of health systems. To realize this potential, however, AI systems will have to overcome structural problems in the culture and practice of medicine and the organization of health systems that impact the data from which AI models are built, the environments into which they will be deployed, and the practices and incentives that structure their development. This perspective elaborates on some of these structural challenges and provides recommendations to address potential shortcomings.;,citation_author=Alex John London;,citation_publication_date=2022-05;,citation_cover_date=2022-05;,citation_year=2022;,citation_issue=5;,citation_doi=10.1016/j.xcrm.2022.100622;,citation_issn=26663791;,citation_volume=3;,citation_language=en-US;,citation_journal_title=Cell Reports Medicine;">
<meta name="citation_reference" content="citation_title=Equipoise in Research: Integrating Ethics and Science in Human Research;,citation_author=Alex John London;,citation_publication_date=2017-02;,citation_cover_date=2017-02;,citation_year=2017;,citation_issue=5;,citation_doi=10.1001/jama.2017.0016;,citation_issn=0098-7484;,citation_volume=317;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Vitamin C, Hydrocortisone, and Thiamine for Septic Shock;,citation_abstract=To the Editor The Vitamin C, Hydrocortisone, and Thiamine in Patients With Septic Shock (VITAMINS) trial found that vitamin C, hydrocortisone, and thiamine, compared with hydrocortisone alone, did not improve outcomes in patients with septic shock.In randomized trials in sepsis, time spent to select and stabilize patients by initiating early interventions such as antibiotics, fluids, and vasopressors must precede patient enrollment, randomization, and administration of study drug. The VITAMINS trial reflects this—although hydrocortisone use was standardized and presumptively administered quickly, thiamine and vitamin C were delayed.;,citation_author=Micah T. Long;,citation_author=Pierre Kory;,citation_author=Paul Marik;,citation_publication_date=2020-06;,citation_cover_date=2020-06;,citation_year=2020;,citation_issue=21;,citation_doi=10.1001/jama.2020.5844;,citation_issn=0098-7484;,citation_volume=323;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Things We Do for No Reason™: Pharmacological sleep aids for hospitalized patients with acute insomnia;,citation_author=August Longino;,citation_author=Odette Zero;,citation_author=Matthew L. Lorenz;,citation_issue=n/a;,citation_doi=10.1002/jhm.13182;,citation_issn=1553-5606;,citation_volume=n/a;,citation_language=en-US;,citation_journal_title=Journal of Hospital Medicine;">
<meta name="citation_reference" content="citation_title=Anticoagulation in COVID-19;,citation_author=Renato D. Lopes;,citation_author=Alexander C. Fanaroff;,citation_publication_date=2020-10;,citation_cover_date=2020-10;,citation_year=2020;,citation_issue=16;,citation_doi=10.1016/j.jacc.2020.09.008;,citation_issn=07351097;,citation_volume=76;,citation_language=en-US;,citation_journal_title=Journal of the American College of Cardiology;">
<meta name="citation_reference" content="citation_title=Taking a Chance to Recover: Families Look Back on the Decision to Pursue Tracheostomy After Severe Acute Brain Injury;,citation_abstract=Background: Tracheostomy represents one important and value-laden treatment decision after severe acute brain injury (SABI). Whether to pursue this life-sustaining treatment typically hinges on intense conversations between family and clinicians. The aim of this study was, among a cohort of patient who had undergone tracheostomy after SABI, to explore the long-term reflections of patients and their families as they look back on this decision. Methods: For this qualitative study, we reviewed the electronic medical records of patients with SABI who underwent tracheostomy. We included all patients who were admitted to our 30-bed neuro-intensive care unit with SABI and underwent tracheostomy between November 2017 and October 2019. Using purposive sampling, we invited survivors and family members to participate in telephone interviews greater than 3 months after SABI until thematic saturation was reached. Interviews were audiotaped, transcribed, and analyzed by using thematic analysis. Results: Overall, 38 patients with SABI in the neuro-intensive care unit underwent tracheostomy. The mean age of patients was 49 (range 18–81), with 19 of 38 patients diagnosed with traumatic brain injury and 19 of 38 with stroke. We interviewed 20 family members of 18 of 38 patients at a mean of 16 (SD 9) months after hospitalization. The mean patient age among those with an interview was 50 (range 18–76); the mean modified Rankin Scale score (mRS) was 4.7 (SD 0.8) at hospital discharge. At the time of the interview, ten patients lived at home and two in a skilled nursing facility and had a mean mRS of 2.6 (SD 0.9), and six had died. As families reflected on the decision to proceed with a tracheostomy, two themes emerged. First, families did not remember tracheostomy as a choice because the uncertain chance of recovery rendered the certain alternative of death unacceptable or because they valued survival above all and therefore could not perceive an alternative to life-sustaining treatment. Second, families identified a fundamental need to receive supportive, consistent communication centering around compassion, clarity, and hope. When this need was met, families were able to reflect on the tracheostomy decision with peace, regardless of their loved one’s eventual outcome. Conclusions: After SABI, prognostic uncertainty almost transcends the concept of choice. Families who proceeded with a tracheostomy saw it as the only option at the time. High-quality communication may mitigate the stress surrounding this high-stakes decision.;,citation_author=William Lou;,citation_author=Justin H. Granstein;,citation_author=Rafael Wabl;,citation_author=Amita Singh;,citation_author=Sarah Wahlster;,citation_author=Claire J. Creutzfeldt;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_doi=10.1007/s12028-021-01335-9;,citation_issn=1541-6933, 1556-0961;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Toward a Clearer Definition of Selection Bias When Estimating Causal Effects;,citation_abstract=Selection bias remains a subject of controversy. Existing definitions of selection bias are ambiguous. To improve communication and the conduct of epidemiologic research focused on estimating causal effects, we propose to unify the various existing definitions of selection bias in the literature by considering any bias away from the true causal effect in the referent population (the population before the selection process), due to selecting the sample from the referent population, as selection bias. Given this unified definition, selection bias can be further categorized into two broad types: type 1 selection bias owing to restricting to one or more level(s) of a collider (or a descendant of a collider) and type 2 selection bias owing to restricting to one or more level(s) of an effect measure modifier. To aid in explaining these two types—which can co-occur—we start by reviewing the concepts of the target population, the study sample, and the analytic sample. Then, we illustrate both types of selection bias using causal diagrams. In addition, we explore the differences between these two types of selection bias, and describe methods to minimize selection bias. Finally, we use an example of “M-bias” to demonstrate the advantage of classifying selection bias into these two types.;,citation_author=Haidong Lu;,citation_author=Stephen R. Cole;,citation_author=Chanelle J. Howe;,citation_author=Daniel Westreich;,citation_publication_date=2022-09;,citation_cover_date=2022-09;,citation_year=2022;,citation_issue=5;,citation_doi=10.1097/EDE.0000000000001516;,citation_issn=1044-3983;,citation_volume=33;,citation_language=en-US;,citation_journal_title=Epidemiology;">
<meta name="citation_reference" content="citation_title=What constitutes an &amp;amp;amp;quot;unmet medical need&amp;quot; in oncology? An empirical evaluation of author usage in the biomedical literature;,citation_abstract=The phrase &amp;amp;quot;unmet medical need&quot; has important regulatory implications, but there is no empirical analysis of its real world usage. We sought to determine the annual US incidence, 5-year survival, and number of National Comprehensive Cancer Network (NCCN)-recommended regimens for indications described in the literature as an &quot;unmet medical need.&quot; We queried Google Scholar to identify publications where authors used the phrase &quot;unmet medical need&quot; to refer to a specific cancer indication. For each indication, we investigated the annual US incidence, 5-year survival, and number of NCCN recommended regimens. We identified 237 cancer indications considered by authors an &quot;unmet medical need.&quot; The term was found most frequently appended to breast cancer indications comprising 30 of the 237 citations (12.7%). This was followed by lung 24/237 (10.1%), hepatocellular 18/237 (7.6%), and prostate cancer 13/237 (5.4%). In 55 of 237 (23.2%) instances where an indication was described by the authors as an unmet medical need, the incidence was 1,000 cases per year, there were five regimens recommended by NCCN, and there was a 50% or greater 5-year survival. Forty-three of 237 (18.1%) indications had at least an incidence of 10,000 cases a year, 10 recommended regimens, and a 50% 5-year survival. In conclusion, &quot;unmet medical need&quot; has been used to describe cancer indications that are rare, and have few options and poor survival outcomes. However, the term has also been used to describe indications that occur commonly, have many treatment alternatives, and are clinically indolent with more encouraging expectations for survival. Some standardization is needed.;,citation_author=Eric Lu;,citation_author=Joseph Shatzel;,citation_author=Florence Shin;,citation_author=Vinay Prasad;,citation_publication_date=2017-02;,citation_cover_date=2017-02;,citation_year=2017;,citation_issue=1;,citation_doi=10.1053/j.seminoncol.2017.02.009;,citation_issn=1532-8708;,citation_pmid=28395768;,citation_volume=44;,citation_language=en-US;,citation_journal_title=Seminars in Oncology;">
<meta name="citation_reference" content="citation_title=Can We Trust Knee Meniscus Studies? One-Way Crossover Confounds Intent-to-Treat Statistical Methods;,citation_author=James H. Lubowitz;,citation_author=Ralph B. D’Agostino;,citation_author=Matthew T. Provencher;,citation_author=Michael J. Rossi;,citation_author=Jefferson C. Brand;,citation_publication_date=2016-11;,citation_cover_date=2016-11;,citation_year=2016;,citation_issue=11;,citation_doi=10.1016/j.arthro.2016.09.009;,citation_issn=0749-8063, 1526-3231;,citation_pmid=27816090;,citation_volume=32;,citation_language=en-US;,citation_journal_title=Arthroscopy;,citation_publisher=Elsevier;">
<meta name="citation_reference" content="citation_title=Effects of Fluoxetine on Outcomes at 12 Months After Acute Stroke: Results From EFFECTS, a Randomized Controlled Trial;,citation_abstract=BACKGROUND AND PURPOSE: The EFFECTS (Efficacy of Fluoxetine—a Randomised Controlled Trial in Stroke) recently reported that 20 mg fluoxetine once daily for 6 months after acute stroke did not improve functional outcome but reduced depression and increased fractures and hyponatremia at 6 months. The purpose of this predefined secondary analysis was to identify if any effects of fluoxetine were maintained or delayed over 12 months. METHODS: EFFECTS was an investigator-led, randomized, placebo-controlled, double-blind, parallel group trial in Sweden that enrolled adult patients with stroke. Patients were randomized to 20 mg oral fluoxetine or matching placebo for 6 months and followed for another 6 months. The primary outcome was functional outcome (modified Rankin Scale), at 6 months. Predefined secondary outcomes for these analyses included the modified Rankin Scale, health status, quality of life, fatigue, mood, and depression at 12 months. RESULTS: One thousand five hundred patients were recruited from 35 centers in Sweden between 2014 and 2019; 750 were allocated fluoxetine and 750 placebo. At 12 months, modified Rankin Scale data were available in 715 (95%) patients allocated fluoxetine and 712 (95%) placebo. The distribution of modified Rankin Scale categories was similar in the 2 groups (adjusted common odds ratio, 0.92 [95% CI, 0.76–1.10]). Patients allocated fluoxetine scored worse on memory with a median value of 89 (interquartile range, 75–100) versus 93 (interquartile range, 82–100); P=0.0021 and communication 93 (interquartile range, 82–100) versus 96 (interquartile range, 86–100); P=0.024 domains of the Stroke Impact Scale compared with placebo. There were no other differences in secondary outcomes. CONCLUSIONS: Fluoxetine after acute stroke had no effect on functional outcome at 12 months. Patients allocated fluoxetine scored worse on memory and communication on the Stroke Impact Scale compared with placebo, but this is likely to be due to chance.;,citation_author=Erik Lundström;,citation_author=Eva Isaksson;,citation_author=Nina Greilert Norin;,citation_author=Per Näsman;,citation_author=Per Wester;,citation_author=Björn Mårtensson;,citation_author=Bo Norrving;,citation_author=Håkan Wallén;,citation_author=Jörgen Borg;,citation_author=Graeme J. Hankey;,citation_author=Maree L. Hackett;,citation_author=Gillian E. Mead;,citation_author=Martin S. Dennis;,citation_author=Katharina S. Sunnerhagen;,citation_author=on the behalf of the EFFECTS Writing Committee;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=10;,citation_doi=10.1161/STROKEAHA.121.034705;,citation_issn=0039-2499, 1524-4628;,citation_volume=52;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=Targeted Temperature Management in Postresuscitation Care After Incorporating Results of the TTM2 Trial;,citation_abstract=Cardiac arrest still accounts for a substantial proportion of cardiovascular related deaths and is associated with a tremendous risk of neurological injury and, among the few survivors, poor quality of life. Critical determinants of survival and long-term functional status after cardiac arrest are timely initiation of cardiopulmonary resuscitation and use of an external defibrillator for patients with a shockable rhythm. Outcomes are still far from satisfactory, despite ongoing efforts to improve cardiac arrest response systems, as well as elaborate postresuscitation algorithms. Targeted temperature management at the wide range between 32 ^\circC and 36 ^\circC has been one of the main therapeutic strategies to improve neurological outcome in postresuscitation care. This recommendation has been mainly based on 2 small randomized trials that were published 20 years ago. Most recent data derived from the TTM2 (Targeted Hypothermia Versus Targeted Normothermia After Out-of-Hospital Cardiac Arrest) trial, which included 1861 patients, challenge this strategy. It showed no benefit of targeted hypothermia at 33 ^\circC over normothermia at 36 ^\circC to 37.5 ^\circC with fever prevention. Because temperature management at lower temperatures also correlated with an increased risk of side effects without any benefit in the TTM2 trial, a modification of the guidelines with harmonizing temperature management to normothermia might be necessary.;,citation_author=Enzo Lüsebrink;,citation_author=Leonhard Binzenhöfer;,citation_author=Antonia Kellnar;,citation_author=Clemens Scherer;,citation_author=Johannes Schier;,citation_author=Jan Kleeberger;,citation_author=Thomas J. Stocker;,citation_author=Sven Peterss;,citation_author=Christian Hagl;,citation_author=Konstantin Stark;,citation_author=Tobias Petzold;,citation_author=Stephanie Fichtner;,citation_author=Daniel Braun;,citation_author=Stefan Kääb;,citation_author=Stefan Brunner;,citation_author=Hans Theiss;,citation_author=Jörg Hausleiter;,citation_author=Steffen Massberg;,citation_author=Martin Orban;,citation_publication_date=2022-11;,citation_cover_date=2022-11;,citation_year=2022;,citation_issue=21;,citation_doi=10.1161/JAHA.122.026539;,citation_volume=11;,citation_journal_title=Journal of the American Heart Association;">
<meta name="citation_reference" content="citation_title=The Effect of Insurance Status on Mortality and Procedural Use in Critically Ill Patients;,citation_abstract=Objectives: To determine whether uninsured critically ill patients had differences in 30-day mortality and critical care service use compared with those with private insurance and to determine if outcome variability could be attributed to patient-level or hospital-level effects. Methods: Retrospective cohort study using Pennsylvania hospital discharge data with detailed clinical risk adjustment, from fiscal years 2005 and 2006, consisting of 167 general acute care hospitals, with 138,720 critically ill adult patients 64 years of age or younger. Measurements and Main Results: Measurements were 30-day mortality and receipt of five critical care procedures. Uninsured patients had an absolute 30-day mortality of 5.7%, compared with 4.6% for those with private insurance and 6.4% for those with Medicaid. Increased 30-day mortality among uninsured patients persisted after adjustment for patient characteristics (odds ratio [OR], 1.25 for uninsured vs. insured; 95% confidence interval [CI], 1.04–1.50) and hospital-level effects (OR, 1.26; 95% CI, 1.05–1.51). Compared with insured patients, uninsured patients had decreased risk-adjusted odds of receiving a central venous catheter (OR, 0.84; 95% CI, 0.72–0.97), acute hemodialysis (OR, 0.59; 95% CI, 0.39–0.91), and tracheostomy (OR, 0.43; 95% CI, 0.29–0.64). Conclusions: Lack of health insurance is associated with increased 30-day mortality and decreased use of common procedures for the critically ill in Pennsylvania. Differences were not attributable to hospital-level effects, suggesting that the uninsured have a higher mortality and receive fewer procedures when compared with privately insured patients treated at the same hospitals.;,citation_author=Sarah M. Lyon;,citation_author=Nicole M. Benson;,citation_author=Colin R. Cooke;,citation_author=Theodore J. Iwashyna;,citation_author=Sarah J. Ratcliffe;,citation_author=Jeremy M. Kahn;,citation_publication_date=2011-10;,citation_cover_date=2011-10;,citation_year=2011;,citation_issue=7;,citation_doi=10.1164/rccm.201101-0089OC;,citation_issn=1073-449X, 1535-4970;,citation_volume=184;,citation_language=en-US;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Early administration of hydrocortisone, vitamin C, and thiamine in adult patients with septic shock: A randomized controlled clinical trial;,citation_abstract=The combination therapy of hydrocortisone, vitamin C, and thiamine has been proposed as a potential treatment in patients with sepsis and septic shock. However, subsequent trials have reported conflicting results in relation to survival outcomes. Hence, we performed this randomized controlled trial (RCT) to evaluate the efficacy and safety of early combination therapy among adult patients with septic shock.;,citation_author=Qing-Quan Lyu;,citation_author=Rui-Qiang Zheng;,citation_author=Qi-Hong Chen;,citation_author=Jiang-Quan Yu;,citation_author=Jun Shao;,citation_author=Xiao-Hua Gu;,citation_publication_date=2022-09;,citation_cover_date=2022-09;,citation_year=2022;,citation_issue=1;,citation_doi=10.1186/s13054-022-04175-x;,citation_issn=1364-8535;,citation_volume=26;,citation_journal_title=Critical Care;">
<meta name="citation_reference" content="citation_title=The third Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3): An international, stepped wedge cluster randomised controlled trial;,citation_author=Lu Ma;,citation_author=Xin Hu;,citation_author=Lili Song;,citation_author=Xiaoying Chen;,citation_author=Menglu Ouyang;,citation_author=Laurent Billot;,citation_author=Qiang Li;,citation_author=Alejandra Malavera;,citation_author=Xi Li;,citation_author=Paula Muñoz-Venturelli;,citation_author=Asita Silva;,citation_author=Nguyen Huy Thang;,citation_author=Kolawole W. Wahab;,citation_author=Jeyaraj D. Pandian;,citation_author=Mohammad Wasay;,citation_author=Octavio M. Pontes-Neto;,citation_author=Carlos Abanto;,citation_author=Antonio Arauz;,citation_author=Haiping Shi;,citation_author=Guanghai Tang;,citation_author=Sheng Zhu;,citation_author=Xiaochun She;,citation_author=Leibo Liu;,citation_author=Yuki Sakamoto;,citation_author=Shoujiang You;,citation_author=Qiao Han;,citation_author=Bernard Crutzen;,citation_author=Emily Cheung;,citation_author=Yunke Li;,citation_author=Xia Wang;,citation_author=Chen Chen;,citation_author=Feifeng Liu;,citation_author=Yang Zhao;,citation_author=Hao Li;,citation_author=Yi Liu;,citation_author=Yan Jiang;,citation_author=Lei Chen;,citation_author=Bo Wu;,citation_author=Ming Liu;,citation_author=Jianguo Xu;,citation_author=Chao You;,citation_author=Craig S. Anderson;,citation_author=Thompson Robinson;,citation_author=J. Jaime Miranda;,citation_author=Craig S. Anderson;,citation_author=Chao You;,citation_author=Lili Song;,citation_author=Adrian Parry-Jones;,citation_author=Nikola Sprigg;,citation_author=Sophie Durrans;,citation_author=Caroline Harris;,citation_author=Ann Bamford;,citation_author=Olivia Smith;,citation_author=Robert Herbert;,citation_author=Christopher Chen;,citation_author=William Whiteley;,citation_author=Rong Hu;,citation_author=Laurent Billot;,citation_author=Qiang Li;,citation_author=Jayanthi Mysore;,citation_author=Xin Hu;,citation_author=Yao Zhang;,citation_author=Feifeng Liu;,citation_author=Yuki Sakamoto;,citation_author=Shoujiang You;,citation_author=Qiao Han;,citation_author=Bernard Crutzen;,citation_author=Yunke Li;,citation_author=Emily Cheung;,citation_author=Stephen Jan;,citation_author=Hueiming Liu;,citation_author=Menglu Ouyang;,citation_author=Lingli Sun;,citation_author=Honglin Chu;,citation_author=Anila Anjum;,citation_author=Francisca Gonzalez Mc Cawley;,citation_author=Alejandra Del Rio;,citation_author=Bruna Rimoli;,citation_author=Rodrigo Cerantola;,citation_author=Thanushanthan Jeevarajah;,citation_author=Madhushani Kannangara;,citation_author=Andrene Joseph;,citation_author=Chamath Nanayakkara;,citation_author=Xiaoying Chen;,citation_author=Alejandra Malavera;,citation_author=Chunmiao Zhang;,citation_author=Zhao Yang;,citation_author=Brook Li;,citation_author=Zhuo Meng;,citation_author=Menglu Ouyang;,citation_author=Leibo Liu;,citation_author=Yi Ning;,citation_author=Le Dong;,citation_author=Manuela Armenis;,citation_author=Joyce Lim;,citation_author=Helen Monaghan;,citation_author=Lu Ma;,citation_author=Xin Hu;,citation_author=Xi Li;,citation_author=Rui Luo;,citation_author=Guojuan Cheng;,citation_author=Yilin Dong;,citation_author=Ziqin Liu;,citation_author=Shuihong Wang;,citation_author=Ying Zhang;,citation_author=Jipeng Cheng;,citation_author=Hui Shi;,citation_author=Wenjing Li;,citation_author=Langming Mou;,citation_author=Ping Yi;,citation_author=Chen Chen;,citation_author=Xue Chen;,citation_author=Shalomi Weerawardena;,citation_author=Poornima Ellawala;,citation_author=Enalee Ranasinghe;,citation_author=Chrishmi Rodrigo;,citation_author=Kolawala Wahab;,citation_author=Sunday Adeniyi;,citation_author=Jeyaraj Pandian;,citation_author=Megha Khanna;,citation_author=Paula Muñoz Venturelli;,citation_author=Francisca González;,citation_author=Francisca Urrutia Goldsack;,citation_author=Mohammad Wasay;,citation_author=Dilshad Begum;,citation_author=Anila Anjum;,citation_author=Octavio Pontes-Neto;,citation_author=Millene Camilo;,citation_author=Francisco Dias;,citation_author=Octavio Vincenzi;,citation_author=Rodrigo Cerantola;,citation_author=Carla Moro;,citation_author=Renata Santos;,citation_author=Nara Texeira;,citation_author=Alexandre Longo;,citation_author=Rafaela Liberato;,citation_author=Sheila Martins;,citation_author=Arthur Pille;,citation_author=Bruna Chwal;,citation_author=Isabel Silva;,citation_author=Natacha Titton;,citation_author=Gustavo Weiss;,citation_author=Daissy Mora;,citation_author=Magda Ouriques;,citation_author=Leonardo Carbonera;,citation_author=Rodrigo Bazan;,citation_author=Gabriel Modolo;,citation_author=Fernanda Winckler;,citation_author=Luana Miranda;,citation_author=Juli Souza;,citation_author=Alexis Rojo;,citation_author=Wilhelm Uslar;,citation_author=Lorena Medel;,citation_author=Javiera Lopez;,citation_author=Diego Herrero;,citation_author=Pablo Lavados;,citation_author=Barbara Vargas Latorre;,citation_author=Nathalie Conejan;,citation_author=Tomas Esparza;,citation_author=Patricio Sotomayor;,citation_author=Denisse Wenger;,citation_author=Juan Pablo Gigoux;,citation_author=Aldo Letelier;,citation_author=Lilian Acevedo;,citation_author=Vivianne Moya;,citation_author=Cristian Figueroa;,citation_author=Nicol Vallejos;,citation_author=Nathalie Conejan;,citation_author=Tomas Esparza;,citation_author=Patricio Sotomayor;,citation_author=Rodrigo Guerrero;,citation_author=Mauricio Velasquez;,citation_author=Jose Vallejos;,citation_author=Kimerly Pallauta;,citation_author=Tamara Santibanez;,citation_author=Angelo Queirolo;,citation_author=Andrea Lobos;,citation_author=Yongming Jiang;,citation_author=Weimin Li;,citation_author=Wei Huang;,citation_author=Ke Luo;,citation_author=Gangying Liu;,citation_author=Guanghai Tang;,citation_author=Guang Yang;,citation_author=Hongtao Jiang;,citation_author=Xu Zhang;,citation_author=Hongyan Jing;,citation_author=Sheng Zhu;,citation_author=Bo Pu;,citation_author=Dong Lv;,citation_author=Hui Kang;,citation_author=Qiuping Hu;,citation_author=Xiaochun She;,citation_author=Xiaoming Jiang;,citation_author=Yanli Chen;,citation_author=Shenghua Yang;,citation_author=Jianjun He;,citation_author=Zongping Li;,citation_author=Gang Cheng;,citation_author=Hailin Huang;,citation_author=Xiaoyi Wang;,citation_author=Jianqiong Lin;,citation_author=Minhui Chen;,citation_author=Chenghao Yang;,citation_author=Hao Ding;,citation_author=Yunliang Deng;,citation_author=Fei Luo;,citation_author=Rongjun Zhang;,citation_author=Xiaofeng Wang;,citation_author=Hongbing Zhang;,citation_author=Xiaoliang Yang;,citation_author=Yang Zhang;,citation_author=Chengyi Yang;,citation_author=Yu He;,citation_author=Feng Liu;,citation_author=Rongjie Wang;,citation_author=Yuhui Zhang;,citation_author=Xiaodong Xin;,citation_author=Bin Feng;,citation_author=Wanru Hao;,citation_author=Chang Song;,citation_author=Yun Guo;,citation_author=Dehua Jiang;,citation_author=Jie Chen;,citation_author=Changtong Tang;,citation_author=Hongliang Zhu;,citation_author=Xin Li;,citation_author=Jin Cui;,citation_author=Haidong Xu;,citation_author=Boyang Li;,citation_author=Fusheng Tang;,citation_author=Yuanbin Li;,citation_author=Min Gao;,citation_author=Bo Yang;,citation_author=Xuejun Xu;,citation_author=Bing Deng;,citation_author=Yi Zheng;,citation_author=Yuanhong Ge;,citation_author=Keyu Chen;,citation_author=Yang Liu;,citation_author=Xinshen Li;,citation_author=Tingting Zhong;,citation_author=Jianfeng Xu;,citation_author=Hai Zhang;,citation_author=Jiyue Wang;,citation_author=Jianxin Zhu;,citation_author=Hanyu Sun;,citation_author=Fuhua Yu;,citation_author=Xueguang Zhang;,citation_author=Chao You;,citation_author=Lu Ma;,citation_author=Xin Hu;,citation_author=Jianguo Xu;,citation_author=Xi Li;,citation_author=Mingsen Zhang;,citation_author=Bin Wang;,citation_author=Yiming Ma;,citation_author=Donglin Jiang;,citation_author=Jun Zhou;,citation_author=Cong Liu;,citation_author=Wenhong Nie;,citation_author=Mingguo Li;,citation_author=Tao Tian;,citation_author=Yong Li;,citation_author=Mingfang He;,citation_author=Xiaolong Tu;,citation_author=Zhengjun Wu;,citation_author=Hong Liu;,citation_author=Dongsheng Zhong;,citation_author=Rongcai Jiang;,citation_author=Jian Sun;,citation_author=Ye Tian;,citation_author=Yingsheng Wei;,citation_author=Shuo An;,citation_author=Pingbo Wei;,citation_author=Le Luo;,citation_author=Bin Lin;,citation_author=Gang Liu;,citation_author=Yan Wen;,citation_author=Qiang Cai;,citation_author=Qianxue Chen;,citation_author=Pan Lei;,citation_author=Zhiyang Li;,citation_author=Meifang Zhang;,citation_author=Jiaquan He;,citation_author=Yan Chen;,citation_author=Jun Liu;,citation_author=Xinghai Liu;,citation_author=Junyan Li;,citation_author=Min Chen;,citation_author=Jing Wang;,citation_author=Bingzhi Zhou;,citation_author=Baichun Ye;,citation_author=Jiancheng Zhang;,citation_author=Manyuan Zhang;,citation_author=Xuming Pan;,citation_author=Xiaoxiang Yu;,citation_author=Jian Xu;,citation_author=Qingbao Xiao;,citation_author=Yuefei Wang;,citation_author=Liang Tao;,citation_author=Lin Shi;,citation_author=Niandong Zheng;,citation_author=Guoliang You;,citation_author=Bo Lei;,citation_author=Shu Chen;,citation_author=Honggang Wu;,citation_author=Jin Hu;,citation_author=Jianlan Zhao;,citation_author=Jian Yu;,citation_author=Qiang Yuan;,citation_author=Zhuoying Du;,citation_author=Xielin Tang;,citation_author=Qianke Li;,citation_author=Shenghua Liu;,citation_author=Feilong Yang;,citation_author=Kui Xiao;,citation_author=Chao Luo;,citation_author=Guang Wang;,citation_author=Xudong Che;,citation_author=Zhipeng Teng;,citation_author=Wenwu Wan;,citation_author=Jun Li;,citation_author=Yu Liu;,citation_author=Mingbo Fan;,citation_author=Tao Zhang;,citation_author=Lun Cai;,citation_author=Yuan Ma;,citation_author=Zhifeng Ma;,citation_author=Bin Li;,citation_author=Linlin He;,citation_author=Jinghui Li;,citation_author=Weibing Zhang;,citation_author=Shuxin Zhang;,citation_author=Hongzhen Zhang;,citation_author=Yingguang Dai;,citation_author=Jun Lei;,citation_author=Lei Mao;,citation_author=Yiyang Huang;,citation_author=Zhi Zhou;,citation_author=Ping Chen;,citation_author=Fang Chen;,citation_author=Pan Wei;,citation_author=Tiangui Li;,citation_author=Honglin Chen;,citation_author=Mengfei Zeng;,citation_author=Kejie Mou;,citation_author=Jun Xue;,citation_author=Yong Jiang;,citation_author=Xiaoping Tang;,citation_author=Tao Chen;,citation_author=Yalan Zhang;,citation_author=Yanbing Xu;,citation_author=Yuchen Gu;,citation_author=Lei Chen;,citation_author=Yujun Zhao;,citation_author=Bin Yang;,citation_author=Peng Kuai;,citation_author=Xi Wang;,citation_author=Yuwang Yang;,citation_author=Xueling Hu;,citation_author=Huitian Zhang;,citation_author=Yintao Yang;,citation_author=Weifeng Wang;,citation_author=Junyi Zhang;,citation_author=Wei Cheng;,citation_author=Xiaoxue Zhang;,citation_author=Xiaowen Ma;,citation_author=Qin He;,citation_author=Li Zhang;,citation_author=Rong Gao;,citation_author=Huixiang Liu;,citation_author=Jingwei Ye;,citation_author=Ping Xu;,citation_author=Xin Wu;,citation_author=Yuan Yuan;,citation_author=Peng Zou;,citation_author=Zhen Zhang;,citation_author=Jiyong Cheng;,citation_author=Zhangming Zhou;,citation_author=Yijun Zeng;,citation_author=Zhang Liang;,citation_author=Deming Du;,citation_author=Shui Yu;,citation_author=Yongjun Cao;,citation_author=Shoujiang You;,citation_author=Jiaping Xu;,citation_author=Zhichao Huang;,citation_author=Dongqin Chen;,citation_author=Wenfeng Xiao;,citation_author=Li Zhu;,citation_author=Miao Yuan;,citation_author=Yuhai Wang;,citation_author=Dongliang Shi;,citation_author=Xu Hu;,citation_author=Dingchao Xiang;,citation_author=Like Shi;,citation_author=Hongqin Wang;,citation_author=Liu Yang;,citation_author=Wang Miao;,citation_author=Yiyi Hu;,citation_author=Yuchun Zhao;,citation_author=Xi Hu;,citation_author=Yang Liu;,citation_author=Weiduo Zhou;,citation_author=Chao Sun;,citation_author=Tao Chen;,citation_author=Dong Tang;,citation_author=Kun Yao;,citation_author=Jin You;,citation_author=Shishi Chen;,citation_author=Jianmin Yao;,citation_author=Huanmei Li;,citation_author=Jinmei Liu;,citation_author=Ailin Bai;,citation_author=Yong Yi;,citation_author=Qingshan Deng;,citation_author=Peng Luo;,citation_author=Han Wang;,citation_author=Jingcheng Jiang;,citation_author=Qingwei Yang;,citation_author=Shunpo He;,citation_author=Jun Wang;,citation_author=Yu Chen;,citation_author=Hua He;,citation_author=Yuyang Deng;,citation_author=Zhikai Cao;,citation_author=Xuxia Yi;,citation_author=Jinbiao Luo;,citation_author=Shuang Luo;,citation_author=Min Gong;,citation_author=Li Liu;,citation_author=Xuejun Gao;,citation_author=Jia Liu;,citation_author=Li’e Wu;,citation_author=Jia Zhang;,citation_author=Hongying Sun;,citation_author=Xinhui Li;,citation_author=Lu Jia;,citation_author=Jianbing Wu;,citation_author=Jie Zhang;,citation_author=Huajun Zhang;,citation_author=Chunfu Du;,citation_author=Shun Li;,citation_author=Xiaobin Yang;,citation_author=Jie He;,citation_author=Lei Liao;,citation_author=Gezhi Zhou;,citation_author=Wentao Dong;,citation_author=Yunxiang Chen;,citation_author=Xiaofeng Lin;,citation_author=Xujian Shui;,citation_author=Peng Zhang;,citation_author=Yuan Zhao;,citation_author=Hongli Yang;,citation_author=Wenbin Zhao;,citation_author=Xiaoyi Zhang;,citation_author=Jincao Chen;,citation_author=Qian Wu;,citation_author=Xuan Dai;,citation_author=Baogui Tang;,citation_author=Yinjuan Wang;,citation_author=Tao Liu;,citation_author=Haixia Zhang;,citation_author=Faliang Duan;,citation_author=Ming Luo;,citation_author=Qingfang Jiao;,citation_author=Guoliang Lei;,citation_author=Dong Wang;,citation_author=Chunwang Song;,citation_author=Haopeng Tan;,citation_author=Feng Ye;,citation_author=Xinghu Qin;,citation_author=Xiaolong Liang;,citation_author=Junling Liu;,citation_author=Lang Yang;,citation_author=Jie Yang;,citation_author=Yapeng Lin;,citation_author=Qian Yang;,citation_author=Xuntai Ma;,citation_author=Yinkuang Qi;,citation_author=Baogen Pan;,citation_author=Caixia Jiang;,citation_author=Zhanying Ye;,citation_author=Ce Dong;,citation_author=Xiongfei Yue;,citation_author=Xiaopeng Yang;,citation_author=Tuoheti Maimaitiyiming;,citation_author=Jun Dong;,citation_author=Yonggang Wu;,citation_author=Feng Gao;,citation_author=Deqiang Zhao;,citation_author=Xinghai Zhang;,citation_author=PengJun Wang;,citation_author=Hongbo Jiang;,citation_author=Jianping Li;,citation_author=Wei Zhang;,citation_author=Jing Chen;,citation_author=Haibo Tong;,citation_author=Yonghong Wang;,citation_author=Kaipeng Qiao;,citation_author=Fuyou Guo;,citation_author=Mingchu Zhang;,citation_author=Yan Hu;,citation_author=Mengzhao Feng;,citation_author=Dengpan Song;,citation_author=Yi Zuo;,citation_author=Shangjun Chen;,citation_author=Chao Qian;,citation_author=Baoming Li;,citation_author=Jingku Ma;,citation_author=Sunfu Zhang;,citation_author=Bin Kong;,citation_author=Xingyu Dong;,citation_author=Qiang Li;,citation_author=Sheng Fang;,citation_author=Bin Lu;,citation_author=Yang Li;,citation_author=Zhen Zhang;,citation_author=Yongling Yang;,citation_author=Hong Yu;,citation_author=Huaiyu Sun;,citation_author=Yue Wang;,citation_author=Weimin Wang;,citation_author=Tong Li;,citation_author=Shengli Li;,citation_author=Zhiming Xu;,citation_author=Yongyi Wang;,citation_author=Qiang Dong;,citation_author=Yuping Tang;,citation_author=Heling Chu;,citation_author=Ying Lu;,citation_author=Zhong Wang;,citation_author=Xiaoou Sun;,citation_author=Jianhua Zhao;,citation_author=Shuaifeng Yang;,citation_author=Xiying Qian;,citation_author=Aralikatte Onkarappa Saroja;,citation_author=Ravishankar Naik K;,citation_author=Sandip Chindhi;,citation_author=Nakul Pampaniya;,citation_author=Kurubara Amaresh;,citation_author=Thomas Iype;,citation_author=Dileep R;,citation_author=Reeja Rajan;,citation_author=Praveen Panicker;,citation_author=Rupjyoti Das;,citation_author=Nupur Choudhury;,citation_author=Pankaja Gohain;,citation_author=Jemin Webster;,citation_author=Biyol Pakma;,citation_author=Lalbiak Sangi;,citation_author=Ivy Sebastian;,citation_author=Gaurav Aggrawal;,citation_author=Komal Raj;,citation_author=Deepankshi Rajoura;,citation_author=Sulena Singh;,citation_author=Varun Aggrawal;,citation_author=Amit Narang;,citation_author=Antonio Arauz;,citation_author=Vanesa Cano-Nigenda;,citation_author=Diego López-Mena;,citation_author=Héctor Valdez-Ruvalcaba;,citation_author=Roberto Toledo-Treviño;,citation_author=Reginald Obiako;,citation_author=Sani Abubakar;,citation_author=Oguike Emeka;,citation_author=Balogun Olayemi;,citation_author=Melika Lois;,citation_author=Ibinaiye Philip;,citation_author=Olurishe Comfort O;,citation_author=Njideka Okubadejo;,citation_author=Osigwe Agabi;,citation_author=Oluwadamilola Ojo;,citation_author=Kolawole Wahab;,citation_author=Abiodun Bello;,citation_author=Oyinloye Ibukun;,citation_author=Olufemi Sanayaolu;,citation_author=Sunday Adeniyi;,citation_author=Abdulraheem Jimoh;,citation_author=Mohammad Wasay;,citation_author=Dilshad Begum;,citation_author=Anila Anjum;,citation_author=Shahid Waheed;,citation_author=Dr Ayeesha Kamal;,citation_author=Raja Farhat Shoaib;,citation_author=Fizza Orooj;,citation_author=Sadaf Majid;,citation_author=Taskeen Zehra;,citation_author=Abdus Salam Khan;,citation_author=Ravi Shanker;,citation_author=Nadir Ali Syed;,citation_author=Nashwa Ahmad;,citation_author=Carlos Abanto;,citation_author=Ana Valencia;,citation_author=Danny Barrientos;,citation_author=Jorge Ramirez;,citation_author=Pilar Calle;,citation_author=Dilum Palliyeguruge;,citation_author=Sumudu Muthucumarana;,citation_author=Shiroma Ratnayaka;,citation_author=Dilhara Ganihiarachchi;,citation_author=Arundathi Bandaranayake;,citation_author=S. D. B. Somaratne;,citation_author=Saumya Narayana;,citation_author=Sithara Gallage;,citation_author=Bimsara Senanayake;,citation_author=Udari Samarasiri;,citation_author=Dunya Luke;,citation_author=Mythily Sivapathasundaram;,citation_author=Vithoosan Sahadevan;,citation_author=Amani Rasmi;,citation_author=Yuran Deshaka;,citation_author=Nilukshi Fernando;,citation_author=Aruna Munasinghe;,citation_author=Kapilanga Rathnapriya;,citation_author=A. S. Nissanka;,citation_author=Kanchana Karunathilake;,citation_author=Isuru Gayan;,citation_author=Kaminda Wijenayake;,citation_author=Hasitha Gunasekara;,citation_author=Jagath Vidyarathne;,citation_author=Ajantha Keshavaraj;,citation_author=Kanagasabapathy Janarthanan;,citation_author=Arhivalaky Gerald Jeevathasan;,citation_author=Sivaram Sivamainthan;,citation_author=Mathyamuthan John Priyanth;,citation_author=Abirami John Priyanth;,citation_author=Thambippillai Rajendiran;,citation_author=Sanjeewa Alwis;,citation_author=Nushara Gunasekare;,citation_author=Vasundara Liyanarachchi;,citation_author=Athula Dissanayake;,citation_author=Wimalasiri Mewa Uluwattage;,citation_author=Gimhani Ratnayake;,citation_author=Charika Rajinee;,citation_author=Sakura Jayawardana;,citation_author=Janaka Peiris;,citation_author=Ranjith Wicramasinghe;,citation_author=Chamila Fernando;,citation_author=Jessie Abbas;,citation_author=Nethmini Withanage;,citation_author=Makaranda Bandara;,citation_author=Duy Ton Mai;,citation_author=Van Chi Nguyen;,citation_author=Viet Phuong Dao;,citation_author=Xuan Trung Vuong;,citation_author=Tien Dung Nguyen;,citation_author=Trung Hieu Dinh;,citation_author=Ha Quan Phan;,citation_author=Quoc Viet Bui;,citation_author=Dinh Tho Phung;,citation_author=Quang Tho Pham;,citation_author=Dinh Dai Pham;,citation_author=Duc Thuan Do;,citation_author=Phuc Duc Dang;,citation_author=Minh Duc Dang;,citation_author=Dang Hai Nguyen;,citation_author=Thi Phuong Nga Nguyen;,citation_author=Quoc Huy Nguyen;,citation_author=Quoc Dai Pham;,citation_author=Quoc Vinh Chau;,citation_author=Vinh Thy Van Tai;,citation_author=Tran Vinh Le;,citation_author=Cong Tri Le;,citation_author=Ha Mai Khuong Tran;,citation_author=Huu Khanh Nguyen;,citation_author=Hoang Minh Thao Ngyen;,citation_author=Duc Chien Vo;,citation_author=Thai My Phuong Nguyen;,citation_author=Trung Thanh Tran;,citation_author=Thi Hanh Vi Vo;,citation_author=Hao Nhien Cao;,citation_author=Ba Thang Nguyen;,citation_author=Thi Ngoc Suong Le;,citation_author=Thien Duc La;,citation_author=Chi Duc Pham;,citation_author=Huy Thai;,citation_publication_date=2023-05;,citation_cover_date=2023-05;,citation_year=2023;,citation_issue=0;,citation_doi=10.1016/S0140-6736(23)00806-1;,citation_issn=0140-6736, 1474-547X;,citation_volume=0;,citation_language=en-US;,citation_journal_title=The Lancet;,citation_publisher=Elsevier;">
<meta name="citation_reference" content="citation_title=Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: A randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2);,citation_abstract=Background Clazosentan, an endothelin receptor antagonist, significantly and dose-dependently reduced angiographic vasospasm after aneurysmal subarachnoid haemorrhage (aSAH). We investigated whether clazosentan reduced vasospasm-related morbidity and all-cause mortality. Methods In this randomised, double-blind, placebo-controlled, phase 3 study, we randomly assigned patients with aSAH secured by surgical clipping to clazosentan (5 mg/h, n=768) or placebo (n=389) for up to 14 days (27 countries, 102 sites, inpatient and outpatient settings) using an interactive web response system. The primary composite endpoint (week 6) included all-cause mortality, vasospasm-related new cerebral infarcts, delayed ischaemic neurological deficit due to vasospasm, and rescue therapy for vasospasm. The main secondary endpoint was dichotomised extended Glasgow outcome scale (GOSE; week 12). This trial is registered with ClinicalTrials.gov, number NCT00558311. Findings In the all-treated dataset, the primary endpoint was met in 161 (21%) of 764 clazosentan-treated patients and 97 (25%) of 383 placebo-treated patients (relative risk reduction 17%, 95% CI -4 to 33; p=0\cdot10). Poor functional outcome (GOSE score \leq4) occurred in 224 (29%) clazosentan-treated patients and 95 (25%) placebo-treated patients (-18%, -45 to 4; p=0\cdot10). Lung complications, anaemia, and hypotension were more common with clazosentan. Mortality (week 12) was 6% in both groups. Interpretation Clazosentan at 5 mg/h had no significant effect on mortality and vasospasm-related morbidity or functional outcome. Further investigation of patients undergoing endovascular coiling of ruptured aneurysms is needed to fully understand the potential usefulness of clazosentan in patients with aSAH. Funding Actelion Pharmaceuticals.;,citation_author=R Loch Macdonald;,citation_author=Randall T Higashida;,citation_author=Emanuela Keller;,citation_author=Stephan A Mayer;,citation_author=Andy Molyneux;,citation_author=Andreas Raabe;,citation_author=Peter Vajkoczy;,citation_author=Isabel Wanke;,citation_author=Doris Bach;,citation_author=Aline Frey;,citation_author=Angelina Marr;,citation_author=Sébastien Roux;,citation_author=Neal Kassell;,citation_publication_date=2011-07;,citation_cover_date=2011-07;,citation_year=2011;,citation_issue=7;,citation_doi=10.1016/S1474-4422(11)70108-9;,citation_issn=1474-4422;,citation_volume=10;,citation_language=en-US;,citation_journal_title=The Lancet Neurology;">
<meta name="citation_reference" content="citation_title=Delayed neurological deterioration after subarachnoid haemorrhage;,citation_author=R. Loch Macdonald;,citation_publication_date=2014-01;,citation_cover_date=2014-01;,citation_year=2014;,citation_issue=1;,citation_doi=10.1038/nrneurol.2013.246;,citation_issn=1759-4758, 1759-4766;,citation_volume=10;,citation_language=en-US;,citation_journal_title=Nature Reviews Neurology;">
<meta name="citation_reference" content="citation_title=The Importance of Making Assumptions in Bias Analysis;,citation_abstract=Quantitative bias analyses allow researchers to adjust for uncontrolled confounding, given specification of certain bias parameters. When researchers are concerned about unknown confounders, plausible values for these bias parameters will be difficult to specify. Ding and VanderWeele developed bounding factor and E-value approaches that require the user to specify only some of the bias parameters. We describe the mathematical meaning of bounding factors and E-values and the plausibility of these methods in an applied context. We encourage researchers to pay particular attention to the assumption made, when using E-values, that the prevalence of the uncontrolled confounder among the exposed is 100% (or, equivalently, the prevalence of the exposure among those without the confounder is 0%). We contrast methods that attempt to bound biases or effects and alternative approaches such as quantitative bias analysis. We provide an example where failure to make this distinction led to erroneous statements. If the primary concern in an analysis is with known but unmeasured potential confounders, then E-values are not needed and may be misleading. In cases where the concern is with unknown confounders, the E-value assumption of an extreme possible prevalence of the confounder limits its practical utility.;,citation_author=Richard F. MacLehose;,citation_author=Thomas P. Ahern;,citation_author=Timothy L. Lash;,citation_author=Charles Poole;,citation_author=Sander Greenland;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_issue=5;,citation_doi=10.1097/EDE.0000000000001381;,citation_issn=1044-3983;,citation_volume=32;,citation_language=en-US;,citation_journal_title=Epidemiology;">
<meta name="citation_reference" content="citation_title=Neurocritical Care Society Guidelines Update: Lessons from a Decade of GRADE Guidelines;,citation_author=Lori K. Madden;,citation_author=Venkatakrishna Rajajee;,citation_author=Theresa Human;,citation_author=Mark S. Wainwright;,citation_author=Mary Guanci;,citation_author=Shraddha Mainali;,citation_author=Shaun Rowe;,citation_author=Diane McLaughlin;,citation_author=John Lunde;,citation_author=Abhijit Lele;,citation_author=Herb Fried;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_issue=1;,citation_doi=10.1007/s12028-021-01375-1;,citation_issn=1541-6933, 1556-0961;,citation_volume=36;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Comparison of Mortality Risk With Different Surgeon and Hospital Operative Volumes Among Individuals Undergoing Pancreatectomy by Emulating Target Trials in US Medicare Beneficiaries;,citation_abstract=OBJECTIVE To specify how (hypothetical) target trials would be designed to estimate the association between postoperative mortality of patients undergoing operations and a range of surgeon and hospital volume conditions and then to emulate these trials by using observational data. DESIGN, SETTING, AND PARTICIPANTS This observational data analysis emulated 4 hypothetical target trials of increasing complexity, ranging from a poorly defined trial that would randomly assign participants only to surgeon volume to one that would randomly assign participants to surgeon volume, hospital volume, and specific surgeon and hospital. This population-based cohort study included 9136 Medicare beneficiaries with a first diagnosis of pancreatic malignant neoplasm who did not require neoadjuvant therapy and underwent pancreatectomy between January 1, 2012, and September 30, 2016. Data analysis was performed between September 1, 2019, and October 8, 2021. EXPOSURES Number of pancreatectomies performed by surgeon and hospital during the prior year. MAIN OUTCOMES AND MEASURES Ninety-day mortality. RESULTS The analyses included 9136 Medicare beneficiaries treated by 1358 surgeons at 697 hospitals; median age was 73.3 years (IQR, 69.1-78.1 years), and 4642 were men (51%). When trials with poorly defined interventions on surgeon volume were emulated, the estimated 90-day mortality was 7.9% (95% CI, 6.4%-9.4%) for lower-volume surgeons and 5.2% (95% CI, 2.7%-10.9%) for higher-volume surgeons. When trials with better-defined interventions were emulated, the difference was reduced: 7.8% (95% CI, 6.3%-9.3%) for lower-volume surgeons and 7.2% (95% CI, 6.0%-8.7%) for higher-volume surgeons. CONCLUSIONS AND RELEVANCE In this cohort study that emulated 4 different target trials with data from Medicare beneficiaries undergoing pancreatectomy, mortality differences across surgical volume levels were attenuated when the interventions were well defined. The application of the hypothetical target trial framework to this specific volume-outcomes scenario revealed the complexities of this research question and the unintentional biases introduced in prior studies, which emulated poorly defined trials whose results are therefore difficult to interpret. The target trial;,citation_author=Arin L. Madenci;,citation_author=Kerollos Nashat Wanis;,citation_author=Zara Cooper;,citation_author=S. V. Subramanian;,citation_author=Sebastien Haneuse;,citation_author=Albert Hofman;,citation_author=Miguel Hernán;,citation_publication_date=2022-03;,citation_cover_date=2022-03;,citation_year=2022;,citation_issue=3;,citation_doi=10.1001/jamanetworkopen.2022.1766;,citation_issn=2574-3805;,citation_volume=5;,citation_language=en-US;,citation_journal_title=JAMA Network Open;">
<meta name="citation_reference" content="citation_title=Fragility Part I: A guide to understanding statistical power;,citation_abstract=The aim of this paper is to close the knowledge-to-practice gap around statistical power. We demonstrate how four factors affect power: p value, effect size, sample size, and variance. This article further delves into the advantages and disadvantages of a priori versus post hoc power analyses, though we believe only understanding of the former is essential to addressing the present-day issue of reproducibility in research. Upon reading this paper, physician–scientists should have expanded their arsenal of statistical tools and have the necessary context to understand statistical fragility.;,citation_author=Sophia J. Madjarova;,citation_author=Ayoosh Pareek;,citation_author=Christina M. Eckhardt;,citation_author=Arjun Khorana;,citation_author=Kyle N. Kunze;,citation_author=Mattheu Ollivier;,citation_author=Jón Karlsson;,citation_author=Riley J. Williams;,citation_author=Benedict U. Nwachukwu;,citation_publication_date=2022-10;,citation_cover_date=2022-10;,citation_year=2022;,citation_doi=10.1007/s00167-022-07188-9;,citation_issn=1433-7347;,citation_language=en-US;,citation_journal_title=Knee Surgery, Sports Traumatology, Arthroscopy;">
<meta name="citation_reference" content="citation_title=Resolved versus confirmed ARDS after 24&nbsp;h: Insights from the LUNG SAFE study;,citation_abstract=To evaluate patients with resolved versus confirmed ARDS, identify subgroups with substantial mortality risk, and to determine the utility of day 2 ARDS reclassification.;,citation_author=Fabiana Madotto;,citation_author=Tài Pham;,citation_author=Giacomo Bellani;,citation_author=Lieuwe D. Bos;,citation_author=Fabienne D. Simonis;,citation_author=Eddy Fan;,citation_author=Antonio Artigas;,citation_author=Laurent Brochard;,citation_author=Marcus J. Schultz;,citation_author=John G. Laffey;,citation_author=Antonio Pesenti;,citation_author=Andres Esteban;,citation_author=Luciano Gattinoni;,citation_author=Frank Haren;,citation_author=Anders Larsson;,citation_author=Daniel F. McAuley;,citation_author=Marco Ranieri;,citation_author=Gordon Rubenfeld;,citation_author=B. Taylor Thompson;,citation_author=Hermann Wrigge;,citation_author=Arthur S. Slutsky;,citation_author=Fernando Rios;,citation_author=Frank Van Haren;,citation_author=T. Sottiaux;,citation_author=P. Depuydt;,citation_author=Fredy S. Lora;,citation_author=Luciano Cesar Azevedo;,citation_author=Eddy Fan;,citation_author=Guillermo Bugedo;,citation_author=Haibo Qiu;,citation_author=Marcos Gonzalez;,citation_author=Juan Silesky;,citation_author=Vladimir Cerny;,citation_author=Jonas Nielsen;,citation_author=Manuel Jibaja;,citation_author=Hermann Wrigge;,citation_author=Dimitrios Matamis;,citation_author=Jorge Luis Ranero;,citation_author=Pravin Amin;,citation_author=S. M. Hashemian;,citation_author=Kevin Clarkson;,citation_author=Kiyoyasu Kurahashi;,citation_author=Asisclo Villagomez;,citation_author=Amine Ali Zeggwagh;,citation_author=Leo M. Heunks;,citation_author=Jon Henrik Laake;,citation_author=Jose Emmanuel Palo;,citation_author=Antero Vale Fernandes;,citation_author=Dorel Sandesc;,citation_author=Yaasen Arabi;,citation_author=Vesna Bumbasierevic;,citation_author=Nicolas Nin;,citation_author=Jose A. Lorente;,citation_author=Anders Larsson;,citation_author=Lise Piquilloud;,citation_author=Fekri Abroug;,citation_author=Daniel F. McAuley;,citation_author=Lia McNamee;,citation_author=Javier Hurtado;,citation_author=Ed Bajwa;,citation_author=Gabriel Démpaire;,citation_author=Hektor Sula;,citation_author=Lordian Nunci;,citation_author=Alma Cani;,citation_author=Alan Zazu;,citation_author=Christian Dellera;,citation_author=Risso V. Alejandro;,citation_author=Julio Daldin;,citation_author=Mauricio Vinzio;,citation_author=Ruben O. Fernandez;,citation_author=Luis P. Cardonnet;,citation_author=Lisandro R. Bettini;,citation_author=Mariano Carboni Bisso;,citation_author=Emilio M. Osman;,citation_author=Mariano G. Setten;,citation_author=Pablo Lovazzano;,citation_author=Javier Alvarez;,citation_author=Veronica Villar;,citation_author=Norberto C. Pozo;,citation_author=Nicolas Grubissich;,citation_author=Gustavo A. Plotnikow;,citation_author=Daniela N. Vasquez;,citation_author=Santiago Ilutovich;,citation_author=Norberto Tiribelli;,citation_author=Ariel Chena;,citation_author=Carlos A. Pellegrini;,citation_author=María G. Saenz;,citation_author=Elisa Estenssoro;,citation_author=Matias Brizuela;,citation_author=Hernan Gianinetto;,citation_author=Pablo E. Gomez;,citation_author=Valeria I. Cerrato;,citation_author=Marco G. Bezzi;,citation_author=Silvina A. Borello;,citation_author=Flavia A. Loiacono;,citation_author=Adriana M. Fernandez;,citation_author=Serena Knowles;,citation_author=Claire Reynolds;,citation_author=Deborah M. Inskip;,citation_author=Jennene J. Miller;,citation_author=Jing Kong;,citation_author=Christina Whitehead;,citation_author=Shailesh Bihari;,citation_author=Aylin Seven;,citation_author=Amanda Krstevski;,citation_author=Helen J. Rodgers;,citation_author=Rebecca T. Millar;,citation_author=Toni E. Mckenna;,citation_author=Irene M. Bailey;,citation_author=Gabrielle C. Hanlon;,citation_author=Anders Aneman;,citation_author=Joan M. Lynch;,citation_author=Raman Azad;,citation_author=John Neal;,citation_author=Paul W. Woods;,citation_author=Brigit L. Roberts;,citation_author=Mark R. Kol;,citation_author=Helen S. Wong;,citation_author=Katharina C. Riss;,citation_author=Thomas Staudinger;,citation_author=Xavier Wittebole;,citation_author=Caroline Berghe;,citation_author=Pierre A. Bulpa;,citation_author=Alain M. Dive;,citation_author=Rik Verstraete;,citation_author=Herve Lebbinck;,citation_author=Pieter Depuydt;,citation_author=Joris Vermassen;,citation_author=Philippe Meersseman;,citation_author=Helga Ceunen;,citation_author=Jonas I. Rosa;,citation_author=Daniel O. Beraldo;,citation_author=Claudio Piras;,citation_author=Adenilton M. Rampinelli;,citation_author=Antonio P. Nassar;,citation_author=Sergio Mataloun;,citation_author=Marcelo Moock;,citation_author=Marlus M. Thompson;,citation_author=Claudio H. Gonçalves;,citation_author=Ana Carolina P. Antônio;,citation_author=Aline Ascoli;,citation_author=Rodrigo S. Biondi;,citation_author=Danielle C. Fontenele;,citation_author=Danielle Nobrega;,citation_author=Vanessa M. Sales;,citation_author=Suresh Shindhe;,citation_author=Dk Maizatul Aiman B. Pg Hj Ismail;,citation_author=John Laffey;,citation_author=Francois Beloncle;,citation_author=Kyle G. Davies;,citation_author=Rob Cirone;,citation_author=Venika Manoharan;,citation_author=Mehvish Ismail;,citation_author=Ewan C. Goligher;,citation_author=Mandeep Jassal;,citation_author=Erin Nishikawa;,citation_author=Areej Javeed;,citation_author=Gerard Curley;,citation_author=Nuttapol Rittayamai;,citation_author=Matteo Parotto;,citation_author=Niall D. Ferguson;,citation_author=Sangeeta Mehta;,citation_author=Jenny Knoll;,citation_author=Antoine Pronovost;,citation_author=Sergio Canestrini;,citation_author=Alejandro R. Bruhn;,citation_author=Patricio H. Garcia;,citation_author=Felipe A. Aliaga;,citation_author=Pamela A. Farías;,citation_author=Jacob S. Yumha;,citation_author=Claudia A. Ortiz;,citation_author=Javier E. Salas;,citation_author=Alejandro A. Saez;,citation_author=Luis D. Vega;,citation_author=Eduardo F. Labarca;,citation_author=Felipe T. Martinez;,citation_author=Nicolás G. Carreño;,citation_author=Pilar Lora;,citation_author=Haitao Liu;,citation_author=Haibo Qiu;,citation_author=Ling Liu;,citation_author=Rui Tang;,citation_author=Xiaoming Luo;,citation_author=Youzhong An;,citation_author=Huiying Zhao;,citation_author=Yan Gao;,citation_author=Zhe Zhai;,citation_author=Zheng L. Ye;,citation_author=Wei Wang;,citation_author=Wenwen Li;,citation_author=Qingdong Li;,citation_author=Ruiqiang Zheng;,citation_author=Wenkui Yu;,citation_author=Juanhong Shen;,citation_author=Xinyu Li;,citation_author=Tao Yu;,citation_author=Weihua Lu;,citation_author=Ya Q. Wu;,citation_author=Xiao B. Huang;,citation_author=Zhenyang He;,citation_author=Yuanhua Lu;,citation_author=Hui Han;,citation_author=Fan Zhang;,citation_author=Renhua Sun;,citation_author=Hua X. Wang;,citation_author=Shu H. Qin;,citation_author=Bao H. Zhu;,citation_author=Jun Zhao;,citation_author=Jian Liu;,citation_author=Bin Li;,citation_author=Jing L. Liu;,citation_author=Fa C. Zhou;,citation_author=Qiong J. Li;,citation_author=Xing Y. Zhang;,citation_author=Zhou Li-Xin;,citation_author=Qiang Xin-Hua;,citation_author=Liangyan Jiang;,citation_author=Yuan N. Gao;,citation_author=Xian Y. Zhao;,citation_author=Yuan Y. Li;,citation_author=Xiao L. Li;,citation_author=Chunting Wang;,citation_author=Qingchun Yao;,citation_author=Rongguo Yu;,citation_author=Kai Chen;,citation_author=Huanzhang Shao;,citation_author=Bingyu Qin;,citation_author=Qing Q. Huang;,citation_author=Wei H. Zhu;,citation_author=Ai Y. Hang;,citation_author=Ma X. Hua;,citation_author=Yimin Li;,citation_author=Yonghao Xu;,citation_author=Yu D. Di;,citation_author=Long L. Ling;,citation_author=Tie H. Qin;,citation_author=Shou H. Wang;,citation_author=Junping Qin;,citation_author=Yi Han;,citation_author=Suming Zhou;,citation_author=Monica P. Vargas;,citation_author=Juan I. Silesky Jimenez;,citation_author=Manuel A. González Rojas;,citation_author=Jaime E. Solis-Quesada;,citation_author=Christian M. Ramirez-Alfaro;,citation_author=Jan Máca;,citation_author=Peter Sklienka;,citation_author=Jakob Gjedsted;,citation_author=Aage Christiansen;,citation_author=Jonas Nielsen;,citation_author=Boris G. Villamagua;,citation_author=Miguel Llano;,citation_author=Philippe Burtin;,citation_author=Gautier Buzancais;,citation_author=Pascal Beuret;,citation_author=Nicolas Pelletier;,citation_author=Satar Mortaza;,citation_author=Alain Mercat;,citation_author=Jonathan Chelly;,citation_author=Sébastien Jochmans;,citation_author=Nicolas Terzi;,citation_author=Cédric Daubin;,citation_author=Guillaume Carteaux;,citation_author=Nicolas Prost;,citation_author=Jean-Daniel Chiche;,citation_author=Fabrice Daviaud;,citation_author=Tai Pham;,citation_author=Muriel Fartoukh;,citation_author=Guillaume Barberet;,citation_author=Jerome Biehler;,citation_author=Jean Dellamonica;,citation_author=Denis Doyen;,citation_author=Jean-Michel Arnal;,citation_author=Anais Briquet;,citation_author=Sami Hraiech;,citation_author=Laurent Papazian;,citation_author=Damien Roux;,citation_author=Jonathan Messika;,citation_author=Evangelos Kalaitzis;,citation_author=Laurence Dangers;,citation_author=Alain Combes;,citation_author=Siu-Ming Au;,citation_author=Gaetan Béduneau;,citation_author=Dorothée Carpentier;,citation_author=Elie H. Zogheib;,citation_author=Herve Dupont;,citation_author=Sylvie Ricome;,citation_author=Francesco L. Santoli;,citation_author=Sebastien L. Besset;,citation_author=Philippe Michel;,citation_author=Bruno Gelée;,citation_author=Pierre-Eric Danin;,citation_author=Bernard Goubaux;,citation_author=Philippe J. Crova;,citation_author=Nga T. Phan;,citation_author=Frantz Berkelmans;,citation_author=Julio C. Badie;,citation_author=Romain Tapponnier;,citation_author=Josette Gally;,citation_author=LUNG SAFE Investigators and the ESICM Trials Group;,citation_publication_date=2018-05;,citation_cover_date=2018-05;,citation_year=2018;,citation_issue=5;,citation_doi=10.1007/s00134-018-5152-6;,citation_issn=1432-1238;,citation_volume=44;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Right Atrial Pressure in the Critically Ill;,citation_author=Sheldon Magder;,citation_publication_date=2017-04;,citation_cover_date=2017-04;,citation_year=2017;,citation_issue=4;,citation_doi=10.1016/j.chest.2016.10.026;,citation_issn=00123692;,citation_volume=151;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting;,citation_abstract=BACKGROUND With large waves of infection driven by the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), alongside evidence of waning immunity after the booster dose of coronavirus disease 2019 (Covid-19) vaccine, several countries have begun giving at-risk persons a fourth vaccine dose. METHODS To evaluate the early effectiveness of a fourth dose of the BNT162b2 vaccine for the prevention of Covid-19–related outcomes, we analyzed data recorded by the largest health care organization in Israel from January 3 to February 18, 2022. We evaluated the relative effectiveness of a fourth vaccine dose as compared with that of a third dose given at least 4 months earlier among persons 60 years of age or older. We compared outcomes in persons who had received a fourth dose with those in persons who had not, individually matching persons from these two groups with respect to multiple sociodemographic and clinical variables. A sensitivity analysis was performed with the use of parametric Poisson regression. RESULTS The primary analysis included 182,122 matched pairs. Relative vaccine effectiveness in days 7 to 30 after the fourth dose was estimated to be 45% (95% confidence interval [CI], 44 to 47) against polymerase-chain-reaction–confirmed SARSCoV-2 infection, 55% (95% CI, 53 to 58) against symptomatic Covid-19, 68% (95% CI, 59 to 74) against Covid-19–related hospitalization, 62% (95% CI, 50 to 74) against severe Covid-19, and 74% (95% CI, 50 to 90) against Covid-19–related death. The corresponding estimates in days 14 to 30 after the fourth dose were 52% (95% CI, 49 to 54), 61% (95% CI, 58 to 64), 72% (95% CI, 63 to 79), 64% (95% CI, 48 to 77), and 76% (95% CI, 48 to 91). In days 7 to 30 after a fourth vaccine dose, the difference in the absolute risk (three doses vs. four doses) was 180.1 cases per 100,000 persons (95% CI, 142.8 to 211.9) for Covid-19–related hospitalization and 68.8 cases per 100,000 persons (95% CI, 48.5 to 91.9) for severe Covid-19. In sensitivity analyses, estimates of relative effectiveness against documented infection were similar to those in the primary analysis. From the Clalit Research Institute, Innovation Division (O.M., J.G.W., M.M.-A., R.D.B., N.D.), and the Tel-Aviv District, Community Division (R.V.), Clalit Health Services, and the Sackler Faculty of Medicine, Tel-Aviv University (D.D.), Tel Aviv, the Department of Internal Medicine D, Hasharon Hospital Rabin Medical Center, Petah Tikva (D.D.), and the School of Public Health, Faculty of Health Sciences (R.D.B.), and the Department of Software and Information Systems Engineering (N.D.), Ben Gurion University of the Negev, Be’er Sheva — all in Israel; and the Departments of Epidemiology and Biostatistics and CAUSALab (M.A.H.) and the Center for Communicable Disease Dynamics, Departments of Epidemiology and of Immunology and Infectious Diseases (M.L.), Harvard T.H. Chan School of Public Health, the Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School and Clalit Research Institute (B.Y.R., R.D.B., N.D.), the Predictive Medicine Group, Computational Health Informatics Program, Boston Children’s Hospital (B.Y.R.), and the Departments of Pediatrics (B.Y.R.) and Biomedical Informatics (B.Y.R., N.D.), Harvard Medical School — all in Boston. Dr. Dagan can be contacted at noada@clalit.org.il or at the Clalit Research Institute, Innovation Division, Clalit Health Services, 101 Arlozorov St., 6209804, Tel Aviv, Israel. Drs. Magen, Waxman, and Makov-Assif contributed equally to this article. This article was published on April 13, 2022, at NEJM.org. CONCLUSIONS A fourth dose of the BNT162b2 vaccine was effective in reducing the short-term risk of Covid-19–related outcomes among persons who had received a third dose at least 4 months earlier. (Funded by the Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School and Clalit Research Institute.);,citation_author=Ori Magen;,citation_author=Jacob G. Waxman;,citation_author=Maya Makov-Assif;,citation_author=Roni Vered;,citation_author=Dror Dicker;,citation_author=Miguel A. Hernán;,citation_author=Marc Lipsitch;,citation_author=Ben Y. Reis;,citation_author=Ran D. Balicer;,citation_author=Noa Dagan;,citation_publication_date=2022-04;,citation_cover_date=2022-04;,citation_year=2022;,citation_issue=17;,citation_doi=10.1056/NEJMoa2201688;,citation_issn=0028-4793, 1533-4406;,citation_volume=386;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Cerebral Hemorrhage: Pathophysiology, Treatment, and Future Directions;,citation_abstract=Intracerebral hemorrhage (ICH) is a devastating form of stroke with high morbidity and mortality. This review article focuses on the epidemiology, cause, mechanisms of injury, current treatment strategies, and future research directions of ICH. Incidence of hemorrhagic stroke has increased worldwide over the past 40 years, with shifts in the cause over time as hypertension management has improved and anticoagulant use has increased. Preclinical and clinical trials have elucidated the underlying ICH cause and mechanisms of injury from ICH including the complex interaction between edema, inflammation, iron-induced injury, and oxidative stress. Several trials have investigated optimal medical and surgical management of ICH without clear improvement in survival and functional outcomes. Ongoing research into novel approaches for ICH management provide hope for reducing the devastating effect of this disease in the future. Areas of promise in ICH therapy include prognostic biomarkers and primary prevention based on disease pathobiology, ultra-early hemostatic therapy, minimally invasive surgery, and perihematomal protection against inflammatory brain injury.;,citation_author=Jessica Magid-Bernstein;,citation_author=Romuald Girard;,citation_author=Sean Polster;,citation_author=Abhinav Srinath;,citation_author=Sharbel Romanos;,citation_author=Issam A. Awad;,citation_author=Lauren H. Sansing;,citation_publication_date=2022-04;,citation_cover_date=2022-04;,citation_year=2022;,citation_issue=8;,citation_doi=10.1161/CIRCRESAHA.121.319949;,citation_issn=0009-7330, 1524-4571;,citation_volume=130;,citation_language=en-US;,citation_journal_title=Circulation Research;">
<meta name="citation_reference" content="citation_title=Covid-19: Remdesivir has “small effect” against death or progression to ventilation, WHO trial finds;,citation_author=Elisabeth Mahase;,citation_publication_date=2022-05;,citation_cover_date=2022-05;,citation_year=2022;,citation_doi=10.1136/bmj.o1118;,citation_issn=1756-1833;,citation_language=en-US;,citation_journal_title=BMJ;">
<meta name="citation_reference" content="citation_title=Exploring mechanisms of excess mortality with early fluid resuscitation: Insights from the FEAST trial;,citation_abstract=BACKGROUND: Early rapid fluid resuscitation (boluses) in African children with severe febrile illnesses increases the 48-hour mortality by 3.3% compared with controls (no bolus). We explored the effect of boluses on 48-hour all-cause mortality by clinical presentation at enrolment, hemodynamic changes over the first hour, and on different modes of death, according to terminal clinical events. We hypothesize that boluses may cause excess deaths from neurological or respiratory events relating to fluid overload. METHODS: Pre-defined presentation syndromes (PS; severe acidosis or severe shock, respiratory, neurological) and predominant terminal clinical events (cardiovascular collapse, respiratory, neurological) were described by randomized arm (bolus versus control) in 3,141 severely ill febrile children with shock enrolled in the Fluid Expansion as Supportive Therapy (FEAST) trial. Landmark analyses were used to compare early mortality in treatment groups, conditional on changes in shock and hypoxia parameters. Competing risks methods were used to estimate cumulative incidence curves and sub-hazard ratios to compare treatment groups in terms of terminal clinical events. RESULTS: Of 2,396 out of 3,141 (76%) classifiable participants, 1,647 (69%) had a severe metabolic acidosis or severe shock PS, 625 (26%) had a respiratory PS and 976 (41%) had a neurological PS, either alone or in combination. Mortality was greatest among children fulfilling criteria for all three PS (28% bolus, 21% control) and lowest for lone respiratory (2% bolus, 5% control) or neurological (3% bolus, 0% control) presentations. Excess mortality in bolus arms versus control was apparent for all three PS, including all their component features. By one hour, shock had resolved (responders) more frequently in bolus versus control groups (43% versus 32%, P &amp;amp;amp;lt;0.001), but excess mortality with boluses was evident in responders (relative risk 1.98, 95% confidence interval 0.94 to 4.17, P = 0.06) and ’non-responders’ (relative risk 1.67, 95% confidence interval 1.23 to 2.28, P = 0.001), with no evidence of heterogeneity (P = 0.68). The major difference between bolus and control arms was the higher proportion of cardiogenic or shock terminal clinical events in bolus arms (n = 123; 4.6% versus 2.6%, P = 0.008) rather than respiratory (n = 61; 2.2% versus 1.3%, P = 0.09) or neurological (n = 63, 2.1% versus 1.8%, P = 0.6) terminal clinical events. CONCLUSIONS: Excess mortality from boluses occurred in all subgroups of children. Contrary to expectation, cardiovascular collapse rather than fluid overload appeared to contribute most to excess deaths with rapid fluid resuscitation. These results should prompt a re-evaluation of evidence on fluid resuscitation for shock and a re-appraisal of the rate, composition and volume of resuscitation fluids. TRIAL REGISTRATION: ISRCTN69856593.;,citation_author=Kathryn Maitland;,citation_author=Elizabeth C. George;,citation_author=Jennifer A. Evans;,citation_author=Sarah Kiguli;,citation_author=Peter Olupot-Olupot;,citation_author=Samuel O. Akech;,citation_author=Robert O. Opoka;,citation_author=Charles Engoru;,citation_author=Richard Nyeko;,citation_author=George Mtove;,citation_author=Hugh Reyburn;,citation_author=Bernadette Brent;,citation_author=Julius Nteziyaremye;,citation_author=Ayub Mpoya;,citation_author=Natalie Prevatt;,citation_author=Cornelius M. Dambisya;,citation_author=Daniel Semakula;,citation_author=Ahmed Ddungu;,citation_author=Vicent Okuuny;,citation_author=Ronald Wokulira;,citation_author=Molline Timbwa;,citation_author=Benedict Otii;,citation_author=Michael Levin;,citation_author=Jane Crawley;,citation_author=Abdel G. Babiker;,citation_author=Diana M. Gibb;,citation_author=FEAST trial group;,citation_publication_date=2013-03;,citation_cover_date=2013-03;,citation_year=2013;,citation_doi=10.1186/1741-7015-11-68;,citation_issn=1741-7015;,citation_pmid=23496872;,citation_volume=11;,citation_language=en-US;,citation_journal_title=BMC medicine;">
<meta name="citation_reference" content="citation_title=Value of intravenous thrombolysis in endovascular treatment for large-vessel anterior circulation stroke: Individual participant data meta-analysis of six randomised trials;,citation_abstract=Background Intravenous thrombolysis is recommended before endovascular treatment, but its value has been questioned in patients who are admitted directly to centres capable of endovascular treatment. Existing randomised controlled trials have indicated non-inferiority of endovascular treatment alone or have been statistically inconclusive. We formed the Improving Reperfusion Strategies in Acute Ischaemic Stroke collaboration to assess non-inferiority of endovascular treatment alone versus intravenous thrombolysis plus endovascular treatment. Methods We conducted a systematic review and individual participant data meta-analysis to establish non-inferiority of endovascular treatment alone versus intravenous thrombolysis plus endovascular treatment. We searched PubMed and MEDLINE with the terms “stroke”, “endovascular treatment”, “intravenous thrombolysis”, and synonyms for articles published from database inception to March 9, 2023. We included randomised controlled trials on the topic of interest, without language restrictions. Authors of the identified trials agreed to take part, and individual participant data were provided by the principal investigators of the respective trials and collated centrally by the collaborators. Our primary outcome was the 90-day modified Rankin Scale (mRS) score. Non-inferiority of endovascular treatment alone was assessed using a lower boundary of 0\cdot82 for the 95% CI around the adjusted common odds ratio (acOR) for shift towards improved outcome (analogous to 5% absolute difference in functional independence) with ordinal regression. We used mixed-effects models for all analyses. This study is registered with PROSPERO, CRD42023411986. Findings We identified 1081 studies, and six studies (n=2313; 1153 participants randomly assigned to receive endovascular treatment alone and 1160 randomly assigned to receive intravenous thrombolysis and endovascular treatment) were eligible for analysis. The risk of bias of the included studies was low to moderate. Variability between studies was small, and mainly related to the choice and dose of the thrombolytic drug and country of execution. The median mRS score at 90 days was 3 (IQR 1–5) for participants who received endovascular treatment alone and 2 (1–4) for participants who received intravenous thrombolysis plus endovascular treatment (acOR 0\cdot89, 95% CI 0\cdot76–1\cdot04). Any intracranial haemorrhage (0\cdot82, 0\cdot68–0\cdot99) occurred less frequently with endovascular treatment alone than with intravenous thrombolysis plus endovascular treatment. Symptomatic intracranial haemorrhage and mortality rates did not differ significantly. Interpretation We did not establish non-inferiority of endovascular treatment alone compared with intravenous thrombolysis plus endovascular treatment in patients presenting directly at endovascular treatment centres. Further research could focus on cost-effectiveness analysis and on individualised decisions when patient characteristics, medication shortages, or delays are expected to offset a potential benefit of administering intravenous thrombolysis before endovascular treatment. Funding Stryker and Amsterdam University Medical Centers, University of Amsterdam.;,citation_author=Charles B Majoie;,citation_author=Fabiano Cavalcante;,citation_author=Jan Gralla;,citation_author=Pengfei Yang;,citation_author=Johannes Kaesmacher;,citation_author=Kilian M Treurniet;,citation_author=Manon Kappelhof;,citation_author=Bernard Yan;,citation_author=Kentaro Suzuki;,citation_author=Yongwei Zhang;,citation_author=Fengli Li;,citation_author=Masafumi Morimoto;,citation_author=Lei Zhang;,citation_author=Zhongrong Miao;,citation_author=Leon A Rinkel;,citation_author=Jiacheng Huang;,citation_author=Toshiaki Otsuka;,citation_author=Shouchun Wang;,citation_author=Stephen Davis;,citation_author=Christophe Cognard;,citation_author=Bo Hong;,citation_author=Jonathan M Coutinho;,citation_author=Jiaxing Song;,citation_author=Wenhuo Chen;,citation_author=Bart J Emmer;,citation_author=Omer Eker;,citation_author=Liyong Zhang;,citation_author=Tomas Dobrocky;,citation_author=Huy-Thang Nguyen;,citation_author=Steven Bush;,citation_author=Ya Peng;,citation_author=Natalie E LeCouffe;,citation_author=Masataka Takeuchi;,citation_author=Hongxing Han;,citation_author=Yuji Matsumaru;,citation_author=Daniel Strbian;,citation_author=Hester F Lingsma;,citation_author=Daan Nieboer;,citation_author=Qingwu Yang;,citation_author=Thomas Meinel;,citation_author=Peter Mitchell;,citation_author=Kazumi Kimura;,citation_author=Wenjie Zi;,citation_author=Raul G Nogueira;,citation_author=Jianmin Liu;,citation_author=Yvo B Roos;,citation_author=Urs Fischer;,citation_author=Wenjie Zi;,citation_author=Raul Nogueira;,citation_author=Qingwu Yang;,citation_author=Jianmin Liu;,citation_author=Pengfei Yang;,citation_author=Yongwei Zhang;,citation_author=Bernard Yan;,citation_author=Peter Mitchell;,citation_author=Zhong Rong Miao;,citation_author=Charles B. Majoie;,citation_author=Yvo B. Roos;,citation_author=Kentaro Suzuki;,citation_author=Kazumi Kimura;,citation_author=Yuji Matsumaru;,citation_author=Urs Fischer;,citation_author=Jan Gralla;,citation_author=Fabiano W. Cavalcante;,citation_author=Manon Kappelhof;,citation_author=Kilian M. Treurniet;,citation_author=Johannes Kaesmacher;,citation_author=Lei Zhang;,citation_author=Steven Bush;,citation_author=Daan Nieboer;,citation_author=Hester F. Lingsma;,citation_author=Peter Rothwell;,citation_author=Jeffrey Saver;,citation_author=Jens Fiehler;,citation_author=Fengli Li;,citation_author=Jiacheng Huang;,citation_author=Jiaxing Song;,citation_author=Bo Hong;,citation_author=Wenhuo Chen;,citation_author=Ya Peng;,citation_author=Hongxing Han;,citation_author=Liyong Zhang;,citation_author=Zifu Li;,citation_author=Pengfei Xing;,citation_author=Hongjian Shen;,citation_author=Ping Zhang;,citation_author=Xiaoxi Zhang;,citation_author=Stephen Davis;,citation_author=Huy-Thang Nguyen;,citation_author=Geoffrey Donnan;,citation_author=Xiaochuan Huo;,citation_author=Guangxian Nan;,citation_author=Andrew Bivard;,citation_author=Henry Ma;,citation_author=Dang Lu Vu;,citation_author=Bruce Campbell;,citation_author=Leon A. Rinkel;,citation_author=Bart J. Emmer;,citation_author=Jonathan M. Coutinho;,citation_author=Natalie E. LeCouffe;,citation_author=Diederik W. Dippel;,citation_author=Aad Lugt;,citation_author=Wim H. Zwam;,citation_author=Robert J. Oostenbrugge;,citation_author=Maarten Uyttenboogaart;,citation_author=Vincent Costalat;,citation_author=Geert Lycklama;,citation_author=Jeannette Hofmeijer;,citation_author=Anouk Norden;,citation_author=Toshiaki Otsuka;,citation_author=Masataka Takeuchi;,citation_author=Masafumi Morimoto;,citation_author=Ryuzaburo Kanazawa;,citation_author=Yohei Takayama;,citation_author=Yuki Kamiya;,citation_author=Keigo Shigeta;,citation_author=Seiji Okubo;,citation_author=Mikito Hayakawa;,citation_author=Daniel Strbian;,citation_author=Omer Eker;,citation_author=Christophe Cognard;,citation_author=Thomas Meinel;,citation_author=Tomas Dobrocky;,citation_author=Simon Jung;,citation_author=Eike Piechowiak;,citation_author=Gaultier Marnat;,citation_author=Igor Sibon;,citation_author=Romain Bourcier;,citation_author=Solene Gaalon;,citation_author=Chrysanthi Papagiannaki;,citation_author=Margaux Lefebvre;,citation_publication_date=2023-08;,citation_cover_date=2023-08;,citation_year=2023;,citation_doi=10.1016/S0140-6736(23)01142-X;,citation_issn=0140-6736;,citation_journal_title=The Lancet;">
<meta name="citation_reference" content="citation_title=The Clinical Course after Long-Term Acute Care Hospital Admission among Older Medicare Beneficiaries;,citation_author=Anil N. Makam;,citation_author=Thu Tran;,citation_author=Michael E. Miller;,citation_author=Lei Xuan;,citation_author=Oanh Kieu Nguyen;,citation_author=Ethan A. Halm;,citation_publication_date=2019-11;,citation_cover_date=2019-11;,citation_year=2019;,citation_issue=11;,citation_doi=10.1111/jgs.16106;,citation_issn=0002-8614, 1532-5415;,citation_volume=67;,citation_language=en-US;,citation_journal_title=Journal of the American Geriatrics Society;">
<meta name="citation_reference" content="citation_title=Factors Associated With Variation in Long-term Acute Care Hospital vs Skilled Nursing Facility Use Among Hospitalized Older Adults;,citation_abstract=OBJECTIVE To examine factors associated with variation in LTAC vs SNF transfer among hospitalized older adults. Supplemental content DESIGN, SETTING, AND PARTICIPANTS We conducted this retrospective observational cohort study of hospitalized older adults (Ն65 years) transferred to an LTAC vs SNF during fiscal year 2012 using national 5% Medicare data. MAIN OUTCOMES AND MEASURES Predictors of LTAC transfer were assessed using a multilevel mixed-effects model adjusting for patient-, hospital-, and region-level factors. We estimated variation partition coefficients and adjusted hospital- and region-specific LTAC transfer rates using sequential models. RESULTS Among 65 525 hospitalized older adults (42 461 [64.8%] women; 39 908 [60.9%] Ն85 years) transferred to an LTAC or SNF, 3093 (4.7%) were transferred to an LTAC. We identified 29 patient-, 3 hospital-, and 5 region-level independent predictors. The strongest predictors of LTAC transfer were receiving a tracheostomy (adjusted odds ration [aOR], 23.8; 95% CI, 15.8-35.9) and being hospitalized in close proximity to an LTAC (0-2 vs &amp;amp;amp;gt;42 miles; aOR, 8.4, 95% CI, 6.1-11.5). After adjusting for case-mix, differences between patients explained 52.1% (95% CI, 47.7%-56.5%) of the variation in LTAC use. The remainder was attributable to hospital (15.0%; 95% CI, 12.3%-17.6%), and regional differences (32.9%; 95% CI, 27.6%-38.3%). Case-mix adjusted LTAC use was very high in the South (17%-37%) compared with the Pacific Northwest, North, and Northeast (&amp;lt;2.2%). From the full multilevel model, the median adjusted hospital LTAC transfer rate was 2.1% (10th-90th percentile, 0.24%-10.8%). Even within a region, adjusted hospital LTAC transfer rates varied substantially (intraclass correlation coefficient [ICC], 0.26; 95% CI, 0.23-0.30). CONCLUSIONS AND RELEVANCE Although many patient-level factors were associated with LTAC use, half of the variation in LTAC vs SNF transfer is independent of patients’ illness severity or clinical complexity, and is explained by where the patient was hospitalized and in what region, with far greater use in the South. Even among hospitals in regions with similar LTAC access, there was considerable variation in LTAC use. Given the higher expense associated with LTACs vs SNFs, greater attention is needed to define the optimal role of LTACs in the postacute care of older adults.;,citation_author=Anil N. Makam;,citation_author=Oanh Kieu Nguyen;,citation_author=Lei Xuan;,citation_author=Michael E. Miller;,citation_author=James S. Goodwin;,citation_author=Ethan A. Halm;,citation_publication_date=2018-03;,citation_cover_date=2018-03;,citation_year=2018;,citation_issue=3;,citation_doi=10.1001/jamainternmed.2017.8467;,citation_issn=2168-6106;,citation_volume=178;,citation_language=en-US;,citation_journal_title=JAMA Internal Medicine;">
<meta name="citation_reference" content="citation_title=Everything you need to know about deresuscitation;,citation_author=Manu L. N. G. Malbrain;,citation_author=Greg Martin;,citation_author=Marlies Ostermann;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_doi=10.1007/s00134-022-06761-7;,citation_issn=1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Patterns of care for ruptured aneurysms of the middle cerebral artery: Analysis of a Swiss national database (Swiss SOS);,citation_abstract=OBJECTIVE The objective of this study was to determine patterns of care and outcomes in ruptured intracranial aneurysms (IAs) of the middle cerebral artery (MCA) in a contemporary national cohort. METHODS The authors conducted a retrospective analysis of prospective data from a nationwide multicenter registry of all aneurysmal subarachnoid hemorrhage (aSAH) cases admitted to a tertiary care neurosurgical department in Switzerland in the years 2009–2015 (Swiss Study on Aneurysmal Subarachnoid Hemorrhage [Swiss SOS]). Patterns of care and outcomes at discharge and the 1-year follow-up in MCA aneurysm (MCAA) patients were analyzed and compared with those in a control group of patients with IAs in locations other than the MCA (non-MCAA patients). Independent predictors of a favorable outcome (modified Rankin Scale score \leq 3) were identified, and their effect size was determined. RESULTS Among 1866 consecutive aSAH patients, 413 (22.1%) harbored an MCAA. These MCAA patients presented with higher World Federation of Neurosurgical Societies grades (p = 0.007), showed a higher rate of concomitant intracerebral hemorrhage (ICH; 41.9% vs 16.7%, p &amp;amp;amp;lt; 0.001), and experienced delayed cerebral ischemia (DCI) more frequently (38.9% vs 29.4%, p = 0.001) than non-MCAA patients. After adjustment for confounders, patients with MCAA were as likely as non-MCAA patients to experience DCI (aOR 1.04, 95% CI 0.74–1.45, p = 0.830). Surgical treatment was the dominant treatment modality in MCAA patients and at a significantly higher rate than in non-MCAA patients (81.7% vs 36.7%, p &amp;lt; 0.001). An MCAA location was a strong independent predictor of surgical treatment (aOR 8.49, 95% CI 5.89–12.25, p < 0.001), despite statistical adjustment for variables traditionally associated with surgical treatment, such as (space-occupying) ICH (aOR 1.73, 95% CI 1.23–2.45, p = 0.002). Even though MCAA patients were less likely to die during the acute hospitalization (aOR 0.52, 0.30–0.91, p = 0.022), their rate of a favorable outcome was lower at discharge than that in non-MCAA patients (55.7% vs 63.7%, p = 0.003). At the 1-year follow-up, 68.5% and 69.6% of MCAA and non-MCAA patients, respectively, had a favorable outcome (p = 0.676). CONCLUSIONS Microsurgical occlusion remains the predominant treatment choice for about 80% of ruptured MCAAs in a European industrialized country. Although patients with MCAAs presented with worse admission grades and greater rates of concomitant ICH, in-hospital mortality was lower and long-term disability was comparable to those in patients with non-MCAA.;,citation_author=Nicolai Maldaner;,citation_author=Valentin K. Steinsiepe;,citation_author=Johannes Goldberg;,citation_author=Christian Fung;,citation_author=David Bervini;,citation_author=Adrien May;,citation_author=Philippe Bijlenga;,citation_author=Karl Schaller;,citation_author=Michel Roethlisberger;,citation_author=Daniel W. Zumofen;,citation_author=Donato D’Alonzo;,citation_author=Serge Marbacher;,citation_author=Javier Fandino;,citation_author=Rodolfo Maduri;,citation_author=Roy Thomas Daniel;,citation_author=Jan-Karl Burkhardt;,citation_author=Alessio Chiappini;,citation_author=Thomas Robert;,citation_author=Bawarjan Schatlo;,citation_author=Martin A. Seule;,citation_author=Astrid Weyerbrock;,citation_author=Luca Regli;,citation_author=Martin Nikolaus Stienen;,citation_author=_ _;,citation_publication_date=2020-12;,citation_cover_date=2020-12;,citation_year=2020;,citation_issue=6;,citation_doi=10.3171/2019.9.JNS192055;,citation_issn=0022-3085, 1933-0693;,citation_volume=133;,citation_language=en-US;,citation_journal_title=Journal of Neurosurgery;">
<meta name="citation_reference" content="citation_title=Outcomes of Cardiac Screening in Adolescent Soccer Players;,citation_abstract=BACKGROUND The authors’ affiliations are listed in the Reports on the incidence and causes of sudden cardiac death among young athAppendix. Address reprint requests to Dr. letes have relied largely on estimated rates of participation and varied methods of Sharma at the Cardiology Clinical Academic Group, St. George’s, University of reporting. We sought to investigate the incidence and causes of sudden cardiac London, Cranmer Terrace, London SW17 death among adolescent soccer players in the United Kingdom. 0RE, United Kingdom, or at s asharma@ sgul.ac.uk. METHODS A list of the authors who are members of the Cardiology Consensus Group of the English Football Association is provided in the Supplementary Appendix, available at NEJM.org. N Engl J Med 2018;379:524-34. DOI: 10.1056/NEJMoa1714719 From 1996 through 2016, we screened 11,168 adolescent athletes with a mean (SD) age of 16.41.2 years (95% of whom were male) in the English Football Association (FA) cardiac screening program, which consisted of a health questionnaire, physical examination, electrocardiography, and echocardiography. The FA registry was interrogated to identify sudden cardiac deaths, which were confirmed with autopsy reports. Copyright © 2018 Massachusetts Medical Society. RESULTS During screening, 42 athletes (0.38%) were found to have cardiac disorders that are associated with sudden cardiac death. A further 225 athletes (2%) with congenital or valvular abnormalities were identified. After screening, there were 23 deaths from any cause, of which 8 (35%) were sudden deaths attributed to cardiac disease. Cardiomyopathy accounted for 7 of 8 sudden cardiac deaths (88%). Six athletes (75%) with sudden cardiac death had had normal cardiac screening results. The mean time between screening and sudden cardiac death was 6.8 years. On the basis of a total of 118,351 person-years, the incidence of sudden cardiac death among previously screened adolescent soccer players was 1 per 14,794 person-years (6.8 per 100,000 athletes). CONCLUSIONS Diseases that are associated with sudden cardiac death were identified in 0.38% of adolescent soccer players in a cohort that underwent cardiovascular screening. The incidence of sudden cardiac death was 1 per 14,794 person-years, or 6.8 per 100,000 athletes; most of these deaths were due to cardiomyopathies that had not been detected on screening. (Funded by the English Football Association and others.);,citation_author=Aneil Malhotra;,citation_author=Harshil Dhutia;,citation_author=Gherardo Finocchiaro;,citation_author=Sabiha Gati;,citation_author=Ian Beasley;,citation_author=Paul Clift;,citation_author=Charlotte Cowie;,citation_author=Antoinette Kenny;,citation_author=Jamil Mayet;,citation_author=David Oxborough;,citation_author=Kiran Patel;,citation_author=Guido Pieles;,citation_author=Dhrubo Rakhit;,citation_author=David Ramsdale;,citation_author=Leonard Shapiro;,citation_author=John Somauroo;,citation_author=Graham Stuart;,citation_author=Amanda Varnava;,citation_author=John Walsh;,citation_author=Zaheer Yousef;,citation_author=Maite Tome;,citation_author=Michael Papadakis;,citation_author=Sanjay Sharma;,citation_publication_date=2018-08;,citation_cover_date=2018-08;,citation_year=2018;,citation_issue=6;,citation_doi=10.1056/NEJMoa1714719;,citation_issn=0028-4793, 1533-4406;,citation_volume=379;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Metric Myopia — Trading Away Our Clinical Judgment;,citation_author=Lisa Rosenbaum;,citation_editor=Debra Malina;,citation_publication_date=2022-05;,citation_cover_date=2022-05;,citation_year=2022;,citation_issue=18;,citation_doi=10.1056/NEJMms2200977;,citation_issn=0028-4793, 1533-4406;,citation_volume=386;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Reassessing Quality Assessment — The Flawed System for Fixing a Flawed System;,citation_author=Lisa Rosenbaum;,citation_editor=Debra Malina;,citation_publication_date=2022-04;,citation_cover_date=2022-04;,citation_year=2022;,citation_issue=17;,citation_doi=10.1056/NEJMms2200976;,citation_issn=0028-4793, 1533-4406;,citation_volume=386;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Understanding the null hypothesis (H0) in non-inferiority trials;,citation_author=Jihad Mallat;,citation_publication_date=2017-12;,citation_cover_date=2017-12;,citation_year=2017;,citation_issue=1;,citation_doi=10.1186/s13054-017-1685-2;,citation_issn=1364-8535;,citation_volume=21;,citation_language=en-US;,citation_journal_title=Critical Care;,citation_publisher=BioMed Central;">
<meta name="citation_reference" content="citation_title=What the Aducanumab Approval Reveals About Alzheimer Disease Research;,citation_author=Jennifer J. Manly;,citation_author=M. Maria Glymour;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_doi=10.1001/jamaneurol.2021.3404;,citation_issn=2168-6149;,citation_language=en-US;,citation_journal_title=JAMA Neurology;">
<meta name="citation_reference" content="citation_title=Handling time varying confounding in observational research;,citation_author=Mohammad Ali Mansournia;,citation_author=Mahyar Etminan;,citation_author=Goodarz Danaei;,citation_author=Jay S Kaufman;,citation_author=Gary Collins;,citation_publication_date=2017-10;,citation_cover_date=2017-10;,citation_year=2017;,citation_doi=10.1136/bmj.j4587;,citation_issn=0959-8138, 1756-1833;,citation_language=en-US;,citation_journal_title=BMJ;">
<meta name="citation_reference" content="citation_title=Matched designs and causal diagrams;,citation_author=Mohammad A Mansournia;,citation_author=Miguel A Hernán;,citation_author=Sander Greenland;,citation_publication_date=2013-06;,citation_cover_date=2013-06;,citation_year=2013;,citation_issue=3;,citation_doi=10.1093/ije/dyt083;,citation_issn=1464-3685, 0300-5771;,citation_volume=42;,citation_language=en-US;,citation_journal_title=International Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Acute Effects of Coffee Consumption on Health among Ambulatory Adults;,citation_author=Gregory M. Marcus;,citation_author=David G. Rosenthal;,citation_author=Gregory Nah;,citation_author=Eric Vittinghoff;,citation_author=Christina Fang;,citation_author=Kelsey Ogomori;,citation_author=Sean Joyce;,citation_author=Defne Yilmaz;,citation_author=Vivian Yang;,citation_author=Tara Kessedjian;,citation_author=Emily Wilson;,citation_author=Michelle Yang;,citation_author=Kathleen Chang;,citation_author=Grace Wall;,citation_author=Jeffrey E. Olgin;,citation_publication_date=2023-03;,citation_cover_date=2023-03;,citation_year=2023;,citation_issue=12;,citation_doi=10.1056/NEJMoa2204737;,citation_issn=0028-4793;,citation_volume=388;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=The compliment sandwich;,citation_abstract=What is the best way to ensure that scientific criticism is heard and understood?;,citation_author=Eve Marder;,citation_publication_date=2022-09;,citation_cover_date=2022-09;,citation_year=2022;,citation_doi=10.7554/eLife.82928;,citation_issn=2050-084X;,citation_volume=11;,citation_language=en-US;,citation_journal_title=eLife;">
<meta name="citation_reference" content="citation_title=Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock;,citation_abstract=BACKGROUND: The global burden of sepsis is estimated as 15 to 19 million cases annually, with a mortality rate approaching 60% in low-income countries. METHODS: In this retrospective before-after clinical study, we compared the outcome and clinical course of consecutive septic patients treated with intravenous vitamin C, hydrocortisone, and thiamine during a 7-month period (treatment group) with a control group treated in our ICU during the preceding 7 months. The primary outcome was hospital survival. A propensity score was generated to adjust the primary outcome. RESULTS: There were 47 patients in both treatment and control groups, with no significant differences in baseline characteristics between the two groups. The hospital mortality was 8.5% (4 of 47) in the treatment group compared with 40.4% (19 of 47) in the control group (P &amp;amp;amp;lt; .001). The propensity adjusted odds of mortality in the patients treated with the vitamin C protocol was 0.13 (95% CI, 0.04-0.48; P \frac{1}{4} .002). The Sepsis-Related Organ Failure Assessment score decreased in all patients in the treatment group, with none developing progressive organ failure. All patients in the treatment group were weaned off vasopressors, a mean of 18.3 Æ 9.8 h after starting treatment with the vitamin C protocol. The mean duration of vasopressor use was 54.9 Æ 28.4 h in the control group (P &amp;lt; .001). CONCLUSIONS: Our results suggest that the early use of intravenous vitamin C, together with corticosteroids and thiamine, are effective in preventing progressive organ dysfunction, including acute kidney injury, and in reducing the mortality of patients with severe sepsis and septic shock. Additional studies are required to confirm these preliminary findings.;,citation_author=Paul E. Marik;,citation_author=Vikramjit Khangoora;,citation_author=Racquel Rivera;,citation_author=Michael H. Hooper;,citation_author=John Catravas;,citation_publication_date=2017-06;,citation_cover_date=2017-06;,citation_year=2017;,citation_issue=6;,citation_doi=10.1016/j.chest.2016.11.036;,citation_issn=00123692;,citation_volume=151;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Reflection on modern methods: Trial emulation in the presence of immortal-time bias. Assessing the benefit of major surgery for elderly lung cancer patients using observational data;,citation_abstract=Acquiring real-world evidence is crucial to support health policy, but observational studies are prone to serious biases. An approach was recently proposed to overcome confounding and immortal-time biases within the emulated trial framework. This tutorial provides a step-by-step description of the design and analysis of emulated trials, as well as R and Stata code, to facilitate its use in practice. The steps consist in: (i) specifying the target trial and inclusion criteria; (ii) cloning patients; (iii) defining censoring and survival times; (iv) estimating the weights to account for informative censoring introduced by design; and (v) analysing these data. These steps are illustrated with observational data to assess the benefit of surgery among 70–89-year-old patients diagnosed with early-stage lung cancer. Because of the severe unbalance of the patient characteristics between treatment arms (surgery yes/no), a naı̈ve Kaplan-Meier survival analysis of the initial cohort severely overestimated the benefit of surgery on 1-year survival (22% difference), as did a survival analysis of the cloned dataset when informative censoring was ignored (17% difference). By contrast, the estimated weights adequately removed the covariate imbalance. The weighted analysis still showed evidence of a benefit, though smaller (11% difference), of surgery among older lung cancer patients on 1-year survival. Complementing the CERBOT tool, this tutorial explains how to proceed to conduct emulated trials using observational data in the presence of immortal-time bias. The strength of this approach is its transparency and its principles that are easily understandable by non-specialists.;,citation_author=Camille Maringe;,citation_author=Sara Benitez Majano;,citation_author=Aimilia Exarchakou;,citation_author=Matthew Smith;,citation_author=Bernard Rachet;,citation_author=Aurélien Belot;,citation_author=Clémence Leyrat;,citation_publication_date=2020-05;,citation_cover_date=2020-05;,citation_year=2020;,citation_issue=5;,citation_doi=10.1093/ije/dyaa057;,citation_issn=0300-5771;,citation_pmid=32386426;,citation_volume=49;,citation_journal_title=International Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Acute Lobar Atelectasis;,citation_author=John J. Marini;,citation_publication_date=2019-05;,citation_cover_date=2019-05;,citation_year=2019;,citation_issue=5;,citation_doi=10.1016/j.chest.2018.11.014;,citation_issn=00123692;,citation_volume=155;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Static and Dynamic Contributors to Ventilator-induced Lung Injury in Clinical Practice. Pressure, Energy, and Power;,citation_author=John J. Marini;,citation_author=Patricia R. M. Rocco;,citation_author=Luciano Gattinoni;,citation_publication_date=2020-04;,citation_cover_date=2020-04;,citation_year=2020;,citation_issue=7;,citation_doi=10.1164/rccm.201908-1545CI;,citation_issn=1073-449X, 1535-4970;,citation_volume=201;,citation_language=en-US;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=A review of progress in understanding the pathophysiology and treatment of brain edema;,citation_abstract=Object Brain edema resulting from traumatic brain injury (TBI) or ischemia if uncontrolled exhausts volume reserve and leads to raised intracranial pressure and brain herniation. The basic types of edema—vasogenic and cytotoxic—were classified 50 years ago, and their definitions remain intact. Methods In this paper the author provides a review of progress over the past several decades in understanding the pathophysiology of the edematous process and the success and failures of treatment. Recent progress focused on those manuscripts that were published within the past 5 years. Results Perhaps the most exciting new findings that speak to both the control of production and resolution of edema in both trauma and ischemia are the recent studies that have focused on the newly described “water channels” or aquaporins. Other important findings relate to the predominance of cellular edema in TBI. Conclusions Significant new findings have been made in understanding the pathophysiology of brain edema; however, less progress has been made in treatment. Aquaporin water channels offer hope for modulating and abating the devastating effects of fulminating brain edema in trauma and stroke.;,citation_author=Anthony Marmarou;,citation_publication_date=2007-05;,citation_cover_date=2007-05;,citation_year=2007;,citation_issue=5;,citation_doi=10.3171/foc.2007.22.5.2;,citation_issn=1092-0684;,citation_volume=22;,citation_language=en-US;,citation_journal_title=Neurosurgical Focus;,citation_publisher=American Association of Neurological Surgeons;">
<meta name="citation_reference" content="citation_title=Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m);,citation_abstract=Background The Anticoagulation Therapy in Selected Cancer Patients at Risk of Recurrence of Venous Thromboembolism (SELECT-D) trial demonstrated reduction in recurrent venous thromboembolism (VTE) but increased bleeding with rivaroxaban compared with dalteparin for treatment of acute VTE in cancer patients, at 6 months. Uncertainty remains around optimal duration of anticoagulation. Objectives To assess VTE recurrence and bleeding, with anticoagulation or not, beyond 6 months. Patients/Methods In SELECT-D, after 6 months of trial treatment for VTE, patients with active cancer and residual deep vein thrombosis (RDVT) or index pulmonary embolism (PE) were eligible for randomization to a further 6 months of rivaroxaban or placebo. Patients with no RDVT stopped anticoagulation. Primary outcome was VTE recurrence at 12 months. The second randomization closed prematurely because of low recruitment when 92 of the planned 300 patients were recruited. Results Ninety-two of 136 eligible patients were randomized to rivaroxaban or placebo. The cumulative VTE recurrence after 6 months from the second randomization was 14% with placebo and 4% with rivaroxaban (hazard ratio, 0.32; 95% confidence interval [CI], 0.06-1.58). The major and clinically relevant non-major bleeding rates were 0% and 0% with placebo; and 5% (95% CI, 1-18) and 4% (95% CI, 1-17) with rivaroxaban. In an exploratory analysis, 7 (15%) of 46 placebo patients with RDVT or an index PE experienced recurrent VTE compared to none in the 35 patients in the RDVT-negative cohort (P = .03). Conclusion The SELECT-D trial was underpowered to detect a statistically significant reduction in recurrent VTE with extended anticoagulation. The absence of RDVT and/or index PE, defined a population at low risk of recurrence.;,citation_author=Andrea Marshall;,citation_author=Mark Levine;,citation_author=Catherine Hill;,citation_author=Danielle Hale;,citation_author=Jenny Thirlwall;,citation_author=Veronica Wilkie;,citation_author=Karen French;,citation_author=Ajay Kakkar;,citation_author=Anand Lokare;,citation_author=Anthony Maraveyas;,citation_author=Oliver Chapman;,citation_author=Azra Arif;,citation_author=Stavros Petrou;,citation_author=Mandy Maredza;,citation_author=Richard Hobbs;,citation_author=Janet A. Dunn;,citation_author=Annie M. Young;,citation_publication_date=2020;,citation_cover_date=2020;,citation_year=2020;,citation_issue=4;,citation_doi=10.1111/jth.14752;,citation_issn=1538-7836;,citation_volume=18;,citation_language=en-US;,citation_journal_title=Journal of Thrombosis and Haemostasis;">
<meta name="citation_reference" content="citation_title=Impact of COVID-19 Infection on the Outcome of Patients With Ischemic Stroke;,citation_abstract=BACKGROUND AND PURPOSE: We evaluated whether stroke severity, functional outcome, and mortality are different in patients with ischemic stroke with or without coronavirus disease 2019 (COVID-19) infection. METHODS: A prospective, observational, multicentre cohort study in Catalonia, Spain. Recruitment was consecutive from midMarch to mid-May 2020. Patients had an acute ischemic stroke within 48 hours and a previous modified Rankin Scale (mRS) score of 0 to 3. We collected demographic data, vascular risk factors, prior mRS score, National Institutes of Health Stroke Scale score, rate of reperfusion therapies, logistics, and metrics. Primary end point was functional outcome at 3 months. Favourable outcome was defined depending on the previous mRS score. Secondary outcome was mortality at 3 months. We performed mRS shift and multivariable analyses. RESULTS: We evaluated 701 patients (mean age 72.313.3 years, 60.5% men) and 91 (13%) had COVID-19 infection. Median baseline National Institutes of Health Stroke Scale score was higher in patients with COVID-19 compared with patients without COVID-19 (8 [3–18] versus 6 [2–14], P=0.049). Proportion of patients with a favourable functional outcome was 33.7% in the COVID-19 and 47% in the non-COVID-19 group. However, after a multivariable logistic regression analysis, COVID-19 infection did not increase the probability of unfavourable functional outcome. Mortality rate was 39.3% among patients with COVID-19 and 16.1% in the non-COVID-19 group. In the multivariable logistic regression analysis, COVID-19 infection was a risk factor for mortality (hazard ratio, 3.14 [95% CI, 2.10–4.71]; P&amp;amp;amp;lt;0.001). CONCLUSIONS: Patients with ischemic stroke and COVID-19 infection have more severe strokes and a higher mortality than patients with stroke without COVID-19 infection. However, functional outcome is comparable in both groups.;,citation_author=Joan Martí-Fàbregas;,citation_author=Daniel Guisado-Alonso;,citation_author=Raquel Delgado-Mederos;,citation_author=Alejandro Martínez-Domeño;,citation_author=Luis Prats-Sánchez;,citation_author=Marina Guasch-Jiménez;,citation_author=Pere Cardona;,citation_author=Ana Núñez-Guillén;,citation_author=Manuel Requena;,citation_author=Marta Rubiera;,citation_author=Marta Olivé;,citation_author=Alejandro Bustamante;,citation_author=Meritxell Gomis;,citation_author=Sergio Amaro;,citation_author=Laura Llull;,citation_author=Xavier Ustrell;,citation_author=Gislaine Castilho de Oliveira;,citation_author=Laia Seró;,citation_author=Manuel Gomez-Choco;,citation_author=Luis Mena;,citation_author=Joaquín Serena;,citation_author=Saima Bashir Viturro;,citation_author=Francisco Purroy;,citation_author=Mikel Vicente;,citation_author=Ana Rodríguez-Campello;,citation_author=Angel Ois;,citation_author=Esther Catena;,citation_author=Maria Carmen Garcia-Carreira;,citation_author=Oriol Barrachina;,citation_author=Ernest Palomeras;,citation_author=Jerzky Krupinski;,citation_author=Marta Almeria;,citation_author=Josep Zaragoza;,citation_author=Patricia Esteve;,citation_author=Dolores Cocho;,citation_author=Antia Moreira;,citation_author=Cecile Eendenburg;,citation_author=Javier Emilio Codas;,citation_author=Natalia Pérez de la Ossa;,citation_author=Mercè Salvat;,citation_author=Pol Camps-Renom;,citation_author=for the COVICTUS Collaborators;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_doi=10.1161/STROKEAHA.121.034883;,citation_issn=0039-2499, 1524-4628;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=Deconditioned, disabled, or debilitated? Formalizing management of functional mobility impairments in the medical inpatient setting;,citation_author=Maylyn Martinez;,citation_author=Jason R. Falvey;,citation_author=Adam Cifu;,citation_publication_date=2022;,citation_cover_date=2022;,citation_year=2022;,citation_issue=10;,citation_doi=10.1002/jhm.12910;,citation_issn=1553-5606;,citation_volume=17;,citation_language=en-US;,citation_journal_title=Journal of Hospital Medicine;">
<meta name="citation_reference" content="citation_title=Prophylactic Melatonin for Delirium in Intensive Care (Pro-MEDIC): Study protocol for a randomised controlled trial;,citation_abstract=Background: Delirium is an acute state of brain dysfunction characterised by fluctuating inattention and cognitive disturbances, usually due to illness. It occurs commonly in the intensive care unit (ICU), and it is associated with greater morbidity and mortality. It is likely that disturbances of sleep and of the day-night cycle play a significant role. Melatonin is a naturally occurring, safe and cheap hormone that can be administered to improve sleep. The main aim of this trial will be to determine whether prophylactic melatonin administered to critically ill adults, when compared with placebo, decreases the rate of delirium. Methods: This trial will be a multi-centre, randomised, placebo-controlled study conducted in closed ICUs in Australia. Our aim is to enrol 850 adult patients with an expected ICU length of stay (LOS) of 72 h or more. Eligible patients for whom there is consent will be randomised to receive melatonin 4 mg enterally or placebo in a 1:1 ratio according to a computer-generated randomisation list, stratified by site. The study drug will be indistinguishable from placebo. Patients, doctors, nurses, investigators and statisticians will be blinded. Melatonin or placebo will be administered once per day at 21:00 until ICU discharge or 14 days after enrolment, whichever occurs first. Trained staff will assess patients twice daily to determine the presence or absence of delirium using the Confusion Assessment Method for the ICU score. Data will also be collected on demographics, the overall prevalence of delirium, duration and severity of delirium, sleep quality, participation in physiotherapy sessions, ICU and hospital LOS, morbidity and mortality, and healthcare costs. A subgroup of 100 patients will undergo polysomnographic testing to further evaluate the quality of sleep. Discussion: Delirium is a significant issue in ICU because of its frequency and associated poorer outcomes. This trial will be the largest evaluation of melatonin as a prophylactic agent to prevent delirium in the critically ill population. This study will also provide one of the largest series of polysomnographic testing done in ICU.;,citation_author=F. Eduardo Martinez;,citation_author=Matthew Anstey;,citation_author=Andrew Ford;,citation_author=Brigit Roberts;,citation_author=Miranda Hardie;,citation_author=Robert Palmer;,citation_author=Lynn Choo;,citation_author=David Hillman;,citation_author=Michael Hensley;,citation_author=Erin Kelty;,citation_author=Kevin Murray;,citation_author=Bhajan Singh;,citation_author=Bradley Wibrow;,citation_publication_date=2017-12;,citation_cover_date=2017-12;,citation_year=2017;,citation_issue=1;,citation_doi=10.1186/s13063-016-1751-0;,citation_issn=1745-6215;,citation_volume=18;,citation_language=en-US;,citation_journal_title=Trials;">
<meta name="citation_reference" content="citation_title=Drugs Associated With Ischemic Stroke: A Review for Clinicians;,citation_abstract=Certain drugs may increase the risk of ischemic stroke (IS). Our goal was to review associations between frequently used drugs and IS. We created an initial list of frequently used drugs to search Pubmed/MEDLINE from 1966 to 2020 and reviewed phase III and IV data, case series, and drug authorities’ safety warnings to assess a potential association with IS. Drugs were grouped according to the World Health Organization Anatomical Therapeutic Chemical Classification System. Predefined criteria were applied to establish a level of evidence for an association, from A (high level of evidence of association) to E (high level of evidence of absence of association). In addition, we assessed relative risks and reviewed potential mechanisms of IS facilitation. We assessed 81 drugs or drug classes from 11 World Health Organization Anatomical Therapeutic Chemical Groups. We identified a high level of association for erythropoietin, combined contraceptives, oral estrogen replacement therapy, bevacizumab, tamoxifen, and antipsychotics and a moderate level for ponatinib, nilotinib, darunavir, and gonadotropin-releasing hormone agonists. Drug dose and treatment duration may modify the risk. For a substantial number of drugs, we found no association, and for others, there were insufficient data to categorize risk. We identified a high level of association of IS with a limited number of drugs, a potential association with some, and a lack of data for others. The summarized information may help clinicians to estimate the contribution of a drug to an IS, to better assess drug benefit-risk ratios, and to support decisions about using specific drugs.;,citation_author=João Pedro Marto;,citation_author=Davide Strambo;,citation_author=Francoise Livio;,citation_author=Patrik Michel;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=10;,citation_doi=10.1161/STROKEAHA.120.033272;,citation_issn=0039-2499, 1524-4628;,citation_volume=52;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=Long-term cognitive outcomes following out-of-hospital cardiac arrest: A population-based study;,citation_abstract=Objective: To report the neurologic outcomes in long-term survivors of out-of-hospital cardiac arrest with ventricular fibrillation as the presenting rhythm (OHCA VF) at a population level. Methods: All adults who experienced OHCA VF in Olmsted County, MN, from 1990 to 2008, survived more than 6 months postarrest, and were alive at the time of study recruitment were invited to participate in structured neuropsychological testing and a neurologic examination. Cognitive test results were compared to the normal population using the Mayo’s Older Adults Normative Studies. Linear regression models were fit to evaluate each neuropsychological test result in relation to call-to-shock time, sex, age at cardiac arrest, time elapsed since event, witnessed vs unwitnessed arrest, and administration of bystander cardiopulmonary resuscitation. Results: Of 332 OHCA VF arrests, 140 people (42.2%, 95% confidence interval 36.9%–47.5%) survived to discharge. No patient entered a minimally conscious or permanent vegetative state. Long-term survivors (n ϭ 47, median survival 7.8 years postarrest) had lower scores on measures of long-term memory and learning efficiency (p ϭ 0.001) but higher than average scores on verbal IQ (p ϭ 0.001). Nearly all survivors were functionally independent and scored high on the MiniMental State Examination (MMSE) (median Barthel Index 100/100, median MMSE 29/30). Conclusions: Long-term survivors of OHCA VF have long-term memory deficits compared to the normal population at the same age and education level. These findings provide a baseline for cognitive outcomes studies of OHCA VF as new techniques are developed to improve survival. Neurology 2011;77:1438–1445;,citation_author=F. J. Mateen;,citation_author=K. A. Josephs;,citation_author=M. R. Trenerry;,citation_author=M. D. Felmlee-Devine;,citation_author=A. L. Weaver;,citation_author=M. Carone;,citation_author=R. D. White;,citation_publication_date=2011-10;,citation_cover_date=2011-10;,citation_year=2011;,citation_issue=15;,citation_doi=10.1212/WNL.0b013e318232ab33;,citation_issn=0028-3878, 1526-632X;,citation_volume=77;,citation_language=en-US;,citation_journal_title=Neurology;">
<meta name="citation_reference" content="citation_title=Brain-Lung Crosstalk: Management of Concomitant Severe Acute Brain Injury and Acute Respiratory Distress Syndrome;,citation_abstract=To summarize pathophysiology, key conflicts, and therapeutic approaches in managing concomitant severe acute brain injury (SABI) and acute respiratory distress syndrome (ARDS).;,citation_author=Nassim Matin;,citation_author=Kasra Sarhadi;,citation_author=C. Patrick Crooks;,citation_author=Abhijit V. Lele;,citation_author=Vasisht Srinivasan;,citation_author=Nicholas J. Johnson;,citation_author=Chiara Robba;,citation_author=James A. Town;,citation_author=Sarah Wahlster;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_doi=10.1007/s11940-022-00726-3;,citation_issn=1534-3138;,citation_language=en-US;,citation_journal_title=Current Treatment Options in Neurology;">
<meta name="citation_reference" content="citation_title=Alternative causal inference methods in population health research: Evaluating tradeoffs and triangulating evidence;,citation_abstract=Population health researchers from different fields often address similar substantive questions but rely on different study designs, reflecting their home disciplines. This is especially true in studies involving causal inference, for which semantic and substantive differences inhibit interdisciplinary dialogue and collaboration. In this paper, we group nonrandomized study designs into two categories: those that use confounder-control (such as regression adjustment or propensity score matching) and those that rely on an instrument (such as instru mental variables, regression discontinuity, or differences-in-differences approaches). Using the Shadish, Cook, and Campbell framework for evaluating threats to validity, we contrast the assumptions, strengths, and limi tations of these two approaches and illustrate differences with examples from the literature on education and health. Across disciplines, all methods to test a hypothesized causal relationship involve unverifiable assump tions, and rarely is there clear justification for exclusive reliance on one method. Each method entails trade-offs between statistical power, internal validity, measurement quality, and generalizability. The choice between confounder-control and instrument-based methods should be guided by these tradeoffs and consideration of the most important limitations of previous work in the area. Our goals are to foster common understanding of the methods available for causal inference in population health research and the tradeoffs between them; to encourage researchers to objectively evaluate what can be learned from methods outside one’s home discipline; and to facilitate the selection of methods that best answer the investigator’s scientific questions.;,citation_author=Ellicott C. Matthay;,citation_author=Erin Hagan;,citation_author=Laura M. Gottlieb;,citation_author=May Lynn Tan;,citation_author=David Vlahov;,citation_author=Nancy E. Adler;,citation_author=M. Maria Glymour;,citation_publication_date=2020-04;,citation_cover_date=2020-04;,citation_year=2020;,citation_doi=10.1016/j.ssmph.2019.100526;,citation_issn=23528273;,citation_volume=10;,citation_language=en-US;,citation_journal_title=SSM - Population Health;">
<meta name="citation_reference" content="citation_title=Clinical trials in acute respiratory distress syndrome: Challenges and opportunities;,citation_author=Michael A. Matthay;,citation_author=Daniel F. McAuley;,citation_author=Lorraine B. Ware;,citation_publication_date=2017-06;,citation_cover_date=2017-06;,citation_year=2017;,citation_issue=6;,citation_doi=10.1016/S2213-2600(17)30188-1;,citation_issn=2213-2600, 2213-2619;,citation_pmid=28664851;,citation_volume=5;,citation_language=en-US;,citation_journal_title=The Lancet Respiratory Medicine;,citation_publisher=Elsevier;">
<meta name="citation_reference" content="citation_title=A Graphical Catalog of Threats to Validity: Linking Social Science with Epidemiology;,citation_abstract=Directed acyclic graphs (DAGs), a prominent tool for expressing assumptions in epidemiologic research, are most useful when the hypothetical data generating structure is correctly encoded. Understanding a study’s data generating structure and translating that data structure into a DAG can be challenging, but these skills are often glossed over in training. Campbell and Stanley’s framework for causal inference has been extraordinarily influential in social science training programs but has received less attention in epidemiology. Their work, along with subsequent revisions and enhancements based on practical experience conducting empirical studies, presents a catalog of 37 threats to validity describing reasons empirical studies may fail to deliver causal effects. We interpret most of these threats to study validity as suggestions for common causal structures. Threats are organized into issues of statistical conclusion validity, internal validity, construct validity, or external validity. To assist epidemiologists in drawing the correct DAG for their application, we map the correspondence between threats to validity and epidemiologic concepts that can be represented with DAGs. Representing these threats as DAGs makes them amenable to formal analysis with d-separation rules and breaks down cross-disciplinary language barriers in communicating methodologic issues.;,citation_author=Ellicott C. Matthay;,citation_author=M. Maria Glymour;,citation_publication_date=2020-05;,citation_cover_date=2020-05;,citation_year=2020;,citation_issue=3;,citation_doi=10.1097/EDE.0000000000001161;,citation_issn=1044-3983;,citation_volume=31;,citation_language=en-US;,citation_journal_title=Epidemiology;">
<meta name="citation_reference" content="citation_title=Beyond “significance”: Principles and practice of the Analysis of Credibility;,citation_abstract=The inferential inadequacies of statistical significance testing are now widely recognized. There is, however, no consensus on how to move research into a “post p  &amp;amp;amp;lt; 0.05” era. We present a potential route forward via the Analysis of Credibility, a novel methodology that allows researchers to go beyond the simplistic dichotomy of significance testing and extract more insight from new findings. Using standard summary statistics, AnCred assesses the credibility of significant and non-significant findings on the basis of their evidential weight, and in the context of existing knowledge. The outcome is expressed in quantitative terms of direct relevance to the substantive research question, providing greater protection against misinterpretation. Worked examples are given to illustrate how AnCred extracts additional insight from the outcome of typical research study designs. Its ability to cast light on the use of p -values, the interpretation of non-significant findings and the so-called “replication crisis” is also discussed.;,citation_author=Robert A. J. Matthews;,citation_publication_date=2018-01;,citation_cover_date=2018-01;,citation_year=2018;,citation_issue=1;,citation_doi=10.1098/rsos.171047;,citation_issn=2054-5703;,citation_volume=5;,citation_language=en-US;,citation_journal_title=Royal Society Open Science;">
<meta name="citation_reference" content="citation_title=Methods for Assessing the Credibility of Clinical Trial Outcomes;,citation_author=Robert A. J. Matthews;,citation_publication_date=2001-10;,citation_cover_date=2001-10;,citation_year=2001;,citation_issue=4;,citation_doi=10.1177/009286150103500442;,citation_issn=0092-8615, 2164-9200;,citation_volume=35;,citation_language=en-US;,citation_journal_title=Drug Information Journal;">
<meta name="citation_reference" content="citation_title=Blood Pressure After Endovascular Thrombectomy: Modeling for Outcomes Based on Recanalization Status;,citation_abstract=Background and Purpose—The optimal level for blood pressure after endovascular thrombectomy in acute ischemic stroke is not well established. We sought to evaluate the association of post-endovascular thrombectomy systolic blood pressure (SBP) levels with clinical outcomes. Methods—We included endovascular thrombectomy–treated patients registered from 2014 to 2017 in the Safe Implementation of Treatments in Stroke International Thrombectomy Registry. The mean 24-hour SBP after endovascular thrombectomy treatment was analyzed both as a continuous variable and in intervals. The primary outcome was 3-month functional independence (modified Rankin Scale score of 0–2). The secondary outcomes were symptomatic intracerebral hemorrhage (SICH) and 3-month mortality. The SBP interval with the highest proportion of functional independence was chosen as reference. All analyses were performed for successful or unsuccessful recanalization (modified Treatment in Cerebral Ischemia score \geq2b or &amp;amp;amp;lt;2b, respectively). The results were adjusted for known confounders in logistic regression models. Results—In the multivariable analyses, a higher SBP value as a continuous variable was associated unfavorably with all outcomes in patients with successful recanalization (n=2920) and with more SICH in patients with unsuccessful recanalization (n=711). SBP interval \geq160 mm Hg was associated with less functional independence (adjusted odds ratio, 0.28 [95% CIs, 0.15–0.53]) and more SICH (adjusted odds ratio, 6.82 [95% CIs, 1.53–38.09]) compared with reference 100 to 119 mm Hg in patients with successful recanalization. SBP \geq160 mm Hg was associated with more SICH (adjusted odds ratio, 6.62 [95% CIs, 1.07–51.05]) compared with reference 120 to 139 mm Hg in patients with unsuccessful recanalization. Conclusions—Higher SBP values were associated with less functional independence at 3 months in patients with successful recanalization and with more SICH regardless of recanalization status. (\mkern1muStroke. 2020;51:519-525. DOI: 10.1161/ STROKEAHA.119.026914.);,citation_author=Marius Matusevicius;,citation_author=Charith Cooray;,citation_author=Matteo Bottai;,citation_author=Michael Mazya;,citation_author=Georgios Tsivgoulis;,citation_author=Ana Paiva Nunes;,citation_author=Tiago Moreira;,citation_author=Jyrki Ollikainen;,citation_author=Rosanna Tassi;,citation_author=Daniel Strbian;,citation_author=Danilo Toni;,citation_author=Staffan Holmin;,citation_author=Niaz Ahmed;,citation_publication_date=2020-02;,citation_cover_date=2020-02;,citation_year=2020;,citation_issue=2;,citation_doi=10.1161/STROKEAHA.119.026914;,citation_issn=0039-2499, 1524-4628;,citation_volume=51;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=Challenges in the Design and Interpretation of Noninferiority Trials;,citation_author=Laura Mauri;,citation_author=Ralph B. D’Agostino;,citation_publication_date=2017-10;,citation_cover_date=2017-10;,citation_year=2017;,citation_issue=14;,citation_doi=10.1056/NEJMra1510063;,citation_issn=0028-4793;,citation_pmid=28976859;,citation_volume=377;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Palliative Care Teams Reduce Hospital Mortality and Utilization: Causal Evidence from a &amp;amp;amp;lt;span style=&amp;quot;font-variant:small-caps;&amp;quot;&amp;gt;Quasi&amp;lt;/span&amp;gt;<span style=&quot;font-variant:small-caps;&quot;>-</span><span style=&quot;font-variant:small-caps;&quot;>Experimental</span> , Nationwide Evaluation in Ireland;,citation_author=Peter May;,citation_author=Soraya Matthews;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_issue=S2;,citation_doi=10.1111/1475-6773.13741;,citation_issn=0017-9124, 1475-6773;,citation_volume=56;,citation_language=en-US;,citation_journal_title=Health Services Research;">
<meta name="citation_reference" content="citation_title=Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage;,citation_abstract=Intracerebral hemorrhage is one of the most disabling forms of stroke. More than one third of patients with this disorder die within one month after the onset of symptoms, and only 20 percent regain functional independence.1 There is currently no effective treatment for intracerebral hemorrhage.2 The volume of the hematoma is a critical determinant of mortality and functional outcome after intracerebral hemorrhage,3,4 and early hematoma growth is an important cause of neurologic deterioration.5–8 An increase in volume of more than 33 percent is detectable on repeated computed tomography (CT) in 38 percent of patients initially scanned within three . . .;,citation_author=Stephan A. Mayer;,citation_author=Nikolai C. Brun;,citation_author=Kamilla Begtrup;,citation_author=Joseph Broderick;,citation_author=Stephen Davis;,citation_author=Michael N. Diringer;,citation_author=Brett E. Skolnick;,citation_author=Thorsten Steiner;,citation_publication_date=2005-02;,citation_cover_date=2005-02;,citation_year=2005;,citation_issue=8;,citation_doi=10.1056/NEJMoa042991;,citation_issn=0028-4793;,citation_pmid=15728810;,citation_volume=352;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Recommended Primary Outcomes for Clinical Trials Evaluating Hemostatic Agents in Patients With Intracranial Hemorrhage: A Consensus Statement;,citation_abstract=IMPORTANCE In patients with acute spontaneous or traumatic intracranial hemorrhage, early hemostasis is thought to be critical to minimize ongoing bleeding. However, research evaluating hemostatic therapies has been hampered by a lack of standardized clinical trial outcome measures.;,citation_author=Stephan A. Mayer;,citation_author=Jennifer A. Frontera;,citation_author=Brian Jankowitz;,citation_author=Christopher P. Kellner;,citation_author=Nathan Kuppermann;,citation_author=Bhiken I. Naik;,citation_author=Daniel K. Nishijima;,citation_author=Thorsten Steiner;,citation_author=Joshua N. Goldstein;,citation_author=CNS Bleeding/Neurosurgery Subgroup of the NHLBI Hemostasis Trials Outcomes Working Group;,citation_author=Simone Glynn;,citation_author=Andrei Kindzelski;,citation_author=Christopher Loftus;,citation_author=Yvo Roos;,citation_author=Jonathan Rosand;,citation_author=Juliana Tolles;,citation_author=Ronald Warren;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_issue=9;,citation_doi=10.1001/jamanetworkopen.2021.23629;,citation_issn=2574-3805;,citation_volume=4;,citation_language=en-US;,citation_journal_title=JAMA Network Open;">
<meta name="citation_reference" content="citation_title=Lessons in Public (Mis)communication about the Laboratory from the COVID-19 Pandemic;,citation_abstract=The coronavirus disease 2019 (COVID-19) pandemic has put the clinical laboratory in the spotlight. The news media is regularly seeking out interviews with microbiologists, infectious disease specialists, and pathologists. Increased public exposure offers opportunities to improve how laboratory professionals communicate our insights. We can emphasize what is new, unusual, or controversial about our knowledge; utilize social media effectively; and improve relationships with journalists by understanding their workflow and traditions. While public engagement has risks and must be considerate of institutional policies, it also validates our value to patients, policy makers, and employers.;,citation_author=Benjamin L. Mazer;,citation_editor=Alexander J. McAdam;,citation_publication_date=2021-03;,citation_cover_date=2021-03;,citation_year=2021;,citation_issue=4;,citation_doi=10.1128/JCM.02917-20;,citation_issn=0095-1137, 1098-660X;,citation_volume=59;,citation_language=en-US;,citation_journal_title=Journal of Clinical Microbiology;">
<meta name="citation_reference" content="citation_title=Medicine’s dangerous optimism: Lessons from Dr Pangloss;,citation_author=Benjamin L Mazer;,citation_publication_date=2020-07;,citation_cover_date=2020-07;,citation_year=2020;,citation_issue=7;,citation_doi=10.1177/0141076820907061;,citation_issn=0141-0768;,citation_volume=113;,citation_language=en-US;,citation_journal_title=Journal of the Royal Society of Medicine;,citation_publisher=SAGE Publications;">
<meta name="citation_reference" content="citation_title=Screening for pancreatic cancer has the potential to save lives, but is it practical?;,citation_author=Benjamin L. Mazer;,citation_author=Jae W. Lee;,citation_author=Nicholas J. Roberts;,citation_author=Linda C. Chu;,citation_author=Anne Marie Lennon;,citation_author=Alison P. Klein;,citation_author=James R. Eshleman;,citation_author=Elliot K. Fishman;,citation_author=Marcia Irene Canto;,citation_author=Michael G. Goggins;,citation_author=Ralph H. Hruban;,citation_publication_date=2023-06;,citation_cover_date=2023-06;,citation_year=2023;,citation_issue=6;,citation_doi=10.1080/17474124.2023.2217354;,citation_issn=1747-4124;,citation_volume=17;,citation_journal_title=Expert Review of Gastroenterology &amp;amp;amp; Hepatology;,citation_publisher=Taylor &amp;amp; Francis;">
<meta name="citation_reference" content="citation_title=Strengthening the Medical Error “Meme Pool”;,citation_author=Benjamin L. Mazer;,citation_author=Chadi Nabhan;,citation_publication_date=2019-10;,citation_cover_date=2019-10;,citation_year=2019;,citation_issue=10;,citation_doi=10.1007/s11606-019-05156-7;,citation_issn=0884-8734, 1525-1497;,citation_volume=34;,citation_language=en-US;,citation_journal_title=Journal of General Internal Medicine;">
<meta name="citation_reference" content="citation_title=Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TARGET): A multicentre, open-label, randomised controlled trial;,citation_author=Mikael Mazighi;,citation_author=Sebastien Richard;,citation_author=Bertrand Lapergue;,citation_author=Igor Sibon;,citation_author=Benjamin Gory;,citation_author=Jerome Berge;,citation_author=Arturo Consoli;,citation_author=Julien Labreuche;,citation_author=Jean-Marc Olivot;,citation_author=Joseph Broderick;,citation_author=Alain Duhamel;,citation_author=Emmanuel Touze;,citation_author=Adnan I. Qureshi;,citation_author=Amélie Yavchitz;,citation_author=Simon Escalard;,citation_author=Jean-Philippe Desilles;,citation_author=Hocine Redjem;,citation_author=Stanislas Smajda;,citation_author=Robert Fahed;,citation_author=Solène Hébert;,citation_author=Benjamin Maı̈er;,citation_author=François Delvoye;,citation_author=Perrine Boursin;,citation_author=Malek Ben Maacha;,citation_author=Michael Obadia;,citation_author=Candice Sabben;,citation_author=Raphael Blanc;,citation_author=Julien Savatovsky;,citation_author=Michel Piotin;,citation_author=Mikael Mazighi;,citation_author=Michel Piotin;,citation_author=Raphael Blanc;,citation_author=Hocine Redjem;,citation_author=Benjamin Maı̈er;,citation_author=Jean-Philippe Desilles;,citation_author=Simon Escalard;,citation_author=Stanislas Smajda;,citation_author=François Delvoye;,citation_author=Solène Hebert;,citation_author=Michael Obadia;,citation_author=Candice Sabben;,citation_author=Alexandre Obadia;,citation_author=Igor Raynouard;,citation_author=Erwan Morvan;,citation_author=Perrine Boursin;,citation_author=Malek Ben Maacha;,citation_author=Bertrand Lapergue;,citation_author=Arturo Consoli;,citation_author=Adrien Wang;,citation_author=Benjamin Gory;,citation_author=Sebastien Richard;,citation_author=Gioia Mione;,citation_author=Lisa Humbertjean;,citation_author=Matthieu Bonnerot;,citation_author=Jean-Christophe Lacour;,citation_author=René Anxionnat;,citation_author=Romain Tonnelet;,citation_author=Serge Bracard;,citation_author=Xavier Barreau;,citation_author=Gaultier Marnat;,citation_author=Jérôme Berge;,citation_author=Ludovic Lucas;,citation_author=Pauline Renou;,citation_author=Sabrina Debruxelles;,citation_author=Mathilde Poli;,citation_author=Sharmila Sagnier;,citation_publication_date=2021-04;,citation_cover_date=2021-04;,citation_year=2021;,citation_issue=4;,citation_doi=10.1016/S1474-4422(20)30483-X;,citation_issn=1474-4422, 1474-4465;,citation_pmid=33647246;,citation_volume=20;,citation_language=en-US;,citation_journal_title=The Lancet Neurology;,citation_publisher=Elsevier;">
<meta name="citation_reference" content="citation_title=Introduction;,citation_author=Peter J. Mazzone;,citation_author=Michael W. Kattan;,citation_publication_date=2020-07;,citation_cover_date=2020-07;,citation_year=2020;,citation_issue=1;,citation_doi=10.1016/j.chest.2020.03.002;,citation_issn=00123692;,citation_volume=158;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial;,citation_abstract=Background Low-molecular-weight heparin is the guideline-endorsed treatment for cancer-associated venous thromboembolism (VTE). While apixaban is approved for the treatment of acute VTE, limited data support its use in cancer patients. Objectives The primary outcome was major bleeding. Secondary outcomes included VTE recurrence and a composite of major plus clinically relevant non-major bleeding (CRNMB). Patients/Methods Patients with cancer-associated VTE were randomly assigned to receive either apixaban 10 mg twice daily for seven days followed by 5 mg twice daily for six months or subcutaneous dalteparin (200 IU/kg for one month followed by 150 IU/kg once daily). Results Of 300 patients randomized, 287 were included in the primary analysis. Metastatic disease was present in 66% of subjects; 74% were receiving concurrent chemotherapy. Major bleeding occurred in 0% of 145 patients receiving apixaban, compared with 1.4% of 142 patients receiving dalteparin [P = .138; hazard ratio (HR) not estimable because of 0 bleeding event in apixaban group]. Recurrent VTE occurred in 0.7% of apixaban, compared to 6.3% of dalteparin patients [HR 0.099, 95% confidence interval [CI], 0.013-0.780, P = .0281). Major bleeding or CRNMB rates were 6% for both groups. Conclusions Oral apixaban was associated with low major bleeding and VTE recurrence rates for the treatment of VTE in cancer patients.;,citation_author=Robert D. McBane II;,citation_author=Waldemar E. Wysokinski;,citation_author=Jennifer G. Le-Rademacher;,citation_author=Tyler Zemla;,citation_author=Aneel Ashrani;,citation_author=Alfonso Tafur;,citation_author=Usha Perepu;,citation_author=Daniel Anderson;,citation_author=Krishna Gundabolu;,citation_author=Charles Kuzma;,citation_author=Juliana Perez Botero;,citation_author=Roberto A. Leon Ferre;,citation_author=Stanislav Henkin;,citation_author=Charles J. Lenz;,citation_author=Damon E. Houghton;,citation_author=Prakash Vishnu;,citation_author=Charles L. Loprinzi;,citation_publication_date=2020;,citation_cover_date=2020;,citation_year=2020;,citation_issue=2;,citation_doi=10.1111/jth.14662;,citation_issn=1538-7836;,citation_volume=18;,citation_language=en-US;,citation_journal_title=Journal of Thrombosis and Haemostasis;">
<meta name="citation_reference" content="citation_title=Simulation-based mastery learning compared to standard education for discussing diagnostic uncertainty with patients in the emergency department: A randomized controlled trial;,citation_abstract=Background: Diagnostic uncertainty occurs frequently in emergency medical care, with more than one-third of patients leaving the emergency department (ED) without a clear diagnosis. Despite this frequency, ED providers are not adequately trained on how to discuss diagnostic uncertainty with these patients, who often leave the ED confused and concerned. To address this training need, we developed the Uncertainty Communication Education Module (UCEM) to teach physicians how to discuss diagnostic uncertainty. The purpose of the study is to evaluate the effectiveness of the UCEM in improving physician communications. Methods: The trial is a multicenter, two-arm randomized controlled trial designed to teach communication skills using simulation-based mastery learning (SBML). Resident emergency physicians from two training programs will be randomly assigned to immediate or delayed receipt of the two-part UCEM intervention after completing a baseline standardized patient encounter. The two UCEM components are: 1) a web-based interactive module, and 2) a smart-phone-based game. Both formats teach and reinforce communication skills for patient cases involving diagnostic uncertainty. Following baseline testing, participants in the immediate intervention arm will complete a remote deliberate practice session via a video platform and subsequently return for a second study visit to assess if they have achieved mastery. Participants in the delayed intervention arm will receive access to UCEM and remote deliberate practice after the second study visit. The primary outcome of interest is the proportion of residents in the immediate intervention arm who achieve mastery at the second study visit. Discussion: Patients’ understanding of the care they received has implications for care quality, safety, and patient satisfaction, especially when they are discharged without a definitive diagnosis. Developing a patient-centered diagnostic uncertainty communication strategy will improve safety of acute care discharges. Although use of SBML is a resource intensive educational approach, this trial has been deliberately designed to have a low-resource, scalable intervention that would allow for widespread dissemination and uptake. Trial registration: The trial was registered at clinicaltrials.gov (NCT04021771). Registration date: July 16, 2019.;,citation_author=Danielle M. McCarthy;,citation_author=Rhea E. Powell;,citation_author=Kenzie A. Cameron;,citation_author=David H. Salzman;,citation_author=Dimitrios Papanagnou;,citation_author=Amanda MB. Doty;,citation_author=Benjamin E. Leiby;,citation_author=Katherine Piserchia;,citation_author=Matthew R. Klein;,citation_author=Xiao C. Zhang;,citation_author=William C. McGaghie;,citation_author=Kristin L. Rising;,citation_publication_date=2020-12;,citation_cover_date=2020-12;,citation_year=2020;,citation_issue=1;,citation_doi=10.1186/s12909-020-1926-y;,citation_issn=1472-6920;,citation_volume=20;,citation_language=en-US;,citation_journal_title=BMC Medical Education;">
<meta name="citation_reference" content="citation_title=Medicine remains as conflicted as ever—we need a new world order;,citation_abstract=As I was saying: it’s hard to know what to do. When I gave up my weekly column in The BMJ some years ago, I did so with the intention of using my time to help solve (or at least, stop from becoming worse) a few of the problems that I kept writing about—especially how we manage conflicts of interest in medicine. The continual challenge for practitioners who want to call themselves evidence based is that these sorts of boring declarations are important, and we are by design disappointing. We are constantly charged with being the anti-glitter to the latest politician’s ideas for a glitzy NHS proposal rollout. The woes of the evidence based practitioner are inherent: forever pointing out uncertainties, flaws, and that …;,citation_author=Margaret McCartney;,citation_publication_date=2022-05;,citation_cover_date=2022-05;,citation_year=2022;,citation_doi=10.1136/bmj.o1344;,citation_issn=1756-1833;,citation_pmid=35623636;,citation_volume=377;,citation_language=en-US;,citation_journal_title=BMJ;,citation_publisher=British Medical Journal Publishing Group;">
<meta name="citation_reference" content="citation_title=Breaking the fast for procedural sedation: Changing risk or risking change?;,citation_author=G. C. McCracken;,citation_author=A. F. Smith;,citation_publication_date=2020;,citation_cover_date=2020;,citation_year=2020;,citation_issue=8;,citation_doi=10.1111/anae.15018;,citation_issn=1365-2044;,citation_volume=75;,citation_language=en-US;,citation_journal_title=Anaesthesia;">
<meta name="citation_reference" content="citation_title=Functional Outcomes Over the First Year After Moderate to Severe Traumatic Brain Injury in the Prospective, Longitudinal TRACK-TBI Study;,citation_abstract=OBJECTIVE To prospectively assess outcomes in major areas of life function at 2 weeks and 3, 6, and 12 months after msTBI. DESIGN, SETTING, AND PARTICIPANTS This cohort study, as part of the Transforming Research and Clinical Knowledge in TBI (TRACK-TBI) study, was conducted at 18 level 1 trauma centers in the US from February 2014 to August 2018 and prospectively assessed longitudinal outcomes, with follow-up to 12 months postinjury. Participants were patients with msTBI (Glasgow Coma Scale scores 3-12) extracted from a larger group of patients with mild, moderate, or severe TBI who were enrolled in TRACK-TBI. Data analysis took place from October 2019 to April 2021. EXPOSURES Moderate or severe TBI. MAIN OUTCOMES AND MEASURES The Glasgow Outcome Scale–Extended (GOSE) and Disability Rating Scale (DRS) were used to assess global functional status 2 weeks and 3, 6, and 12 months postinjury. Scores on the GOSE were dichotomized to determine favorable (scores 4-8) vs unfavorable (scores 1-3) outcomes. Neurocognitive testing and patient reported outcomes at 12 months postinjury were analyzed. RESULTS A total of 484 eligible patients were included from the 2679 individuals in the TRACK-TBI study. Participants with severe TBI (n = 362; 283 men [78.2%]; median [interquartile range] age, 35.5 [25-53] years) and moderate TBI (n = 122; 98 men [80.3%]; median [interquartile range] age, 38 [25-53] years) were comparable on demographic and premorbid variables. At 2 weeks postinjury, 36 of 290 participants with severe TBI (12.4%) and 38 of 93 participants with moderate TBI (41%) had favorable outcomes (GOSE scores 4-8); 301 of 322 in the severe TBI group (93.5%) and 81 of 103 in the moderate TBI group (78.6%) had moderate disability or worse on the DRS (total score Ն4). By 12 months postinjury, 142 of 271 with severe TBI (52.4%) and 54 of 72 with moderate TBI (75%) achieved favorable outcomes. Nearly 1 in 5 participants with severe TBI (52 of 270 [19.3%]) and 1 in 3 with moderate TBI (23 of 71 [32%]) reported no disability (DRS score 0) at 12 months. Among participants in a vegetative state at 2 weeks, 62 of 79 (78%) regained consciousness and 14 of 56 with available data (25%) regained orientation by 12 months. CONCLUSIONS AND RELEVANCE In this study, patients with msTBI frequently demonstrated major functional gains, including recovery of independence, between 2 weeks and 12 months postinjury. Severe impairment in the short term did not portend poor outcomes in a substantial minority of patients with msTBI. When discussing prognosis during the first 2 weeks after injury, clinicians should be particularly cautious about making early, definitive prognostic statements suggesting poor outcomes and withdrawal of life-sustaining treatment in patients with msTBI.;,citation_author=Michael A. McCrea;,citation_author=Joseph T. Giacino;,citation_author=Jason Barber;,citation_author=Nancy R. Temkin;,citation_author=Lindsay D. Nelson;,citation_author=Harvey S. Levin;,citation_author=Sureyya Dikmen;,citation_author=Murray Stein;,citation_author=Yelena G. Bodien;,citation_author=Kim Boase;,citation_author=Sabrina R. Taylor;,citation_author=Mary Vassar;,citation_author=Pratik Mukherjee;,citation_author=Claudia Robertson;,citation_author=Ramon Diaz-Arrastia;,citation_author=David O. Okonkwo;,citation_author=Amy J. Markowitz;,citation_author=Geoffrey T. Manley;,citation_author=TRACK-TBI Investigators;,citation_author=Opeolu Adeoye;,citation_author=Neeraj Badjatia;,citation_author=M. Ross Bullock;,citation_author=Randall Chesnut;,citation_author=John D. Corrigan;,citation_author=Karen Crawford;,citation_author=Ann-Christine Duhaime;,citation_author=Richard Ellenbogen;,citation_author=V. Ramana Feeser;,citation_author=Adam R. Ferguson;,citation_author=Brandon Foreman;,citation_author=Raquel Gardner;,citation_author=Etienne Gaudette;,citation_author=Dana Goldman;,citation_author=Luis Gonzalez;,citation_author=Shankar Gopinath;,citation_author=Rao Gullapalli;,citation_author=J. Claude Hemphill;,citation_author=Gillian Hotz;,citation_author=Sonia Jain;,citation_author=C. Dirk Keene;,citation_author=Frederick K. Korley;,citation_author=Joel Kramer;,citation_author=Natalie Kreitzer;,citation_author=Chris Lindsell;,citation_author=Joan Machamer;,citation_author=Christopher Madden;,citation_author=Alastair Martin;,citation_author=Thomas McAllister;,citation_author=Randall Merchant;,citation_author=Laura B. Ngwenya;,citation_author=Florence Noel;,citation_author=Amber Nolan;,citation_author=Eva Palacios;,citation_author=Daniel Perl;,citation_author=Ava Puccio;,citation_author=Miri Rabinowitz;,citation_author=Jonathan Rosand;,citation_author=Angelle Sander;,citation_author=Gabriella Satris;,citation_author=David Schnyer;,citation_author=Seth Seabury;,citation_author=Mark Sherer;,citation_author=Arthur Toga;,citation_author=Alex Valadka;,citation_author=Kevin Wang;,citation_author=John K. Yue;,citation_author=Esther Yuh;,citation_author=Ross Zafonte;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_issue=8;,citation_doi=10.1001/jamaneurol.2021.2043;,citation_issn=2168-6149;,citation_volume=78;,citation_language=en-US;,citation_journal_title=JAMA Neurology;">
<meta name="citation_reference" content="citation_title=Antibiotic Myths for the Infectious Diseases Clinician;,citation_abstract=Antimicrobials are commonly prescribed and often misunderstood. With over 50% of hospitalized patients receiving an antimicrobial agent at any point in time, judicious and optimal use of these drugs is paramount to advancing patient care. This narrative will focus on myths relevant to nuanced consultation from infectious diseases specialists, particularly surrounding specific considerations for a variety of antibiotics.;,citation_author=Erin K McCreary;,citation_author=Melissa D Johnson;,citation_author=Travis M Jones;,citation_author=S Shaefer Spires;,citation_author=Angelina E Davis;,citation_author=April P Dyer;,citation_author=Elizabeth Dodds Ashley;,citation_author=Jason C Gallagher;,citation_publication_date=2023-06;,citation_cover_date=2023-06;,citation_year=2023;,citation_doi=10.1093/cid/ciad357;,citation_issn=1058-4838;,citation_journal_title=Clinical Infectious Diseases;">
<meta name="citation_reference" content="citation_title=Design Principles for Data Analysis;,citation_abstract=The data revolution has led to an increased interest in the practice of data analysis. While much has been written about statistical thinking, a complementary form of thinking that appears in the practice of data analysis is design thinking—the problem-solving process to understand the people for whom a solution is being designed. For a given problem, there can be significant or subtle differences in how a data analyst (or producer of a data analysis) constructs, creates, or designs a data analysis, including differences in the choice of methods, tooling, and workflow. These choices can affect the data analysis products themselves and the experience of the consumer of the data analysis. Therefore, the role of a producer can be thought of as designing the data analysis with a set of design principles. Here, we introduce design principles for data analysis and describe how they can be mapped to data analyses in a quantitative and informative manner. We also provide data showing variation of principles within and between producers of data analyses. Our work suggests a formal mechanism to describe data analyses based on design principles. These results provide guidance for future work in characterizing the data analytic process. Supplementary materials for this article are available online.;,citation_author=Lucy D’Agostino McGowan;,citation_author=Roger D. Peng;,citation_author=Stephanie C. Hicks;,citation_publication_date=2022-09;,citation_cover_date=2022-09;,citation_year=2022;,citation_doi=10.1080/10618600.2022.2104290;,citation_issn=1061-8600, 1537-2715;,citation_language=en-US;,citation_journal_title=Journal of Computational and Graphical Statistics;">
<meta name="citation_reference" content="citation_title=Medicine is a data science, we should teach like it;,citation_abstract=Medicine has always been a data science. Collecting and interpreting data is a key component of every interaction between physicians and patients. Data can be anything from blood pressure measurements at a yearly exam to complex radiology images interpreted by experts or algorithms. Interpreting these uncertain data for accurate diagnosis, management, and care is a critical component of every physician’s daily life. The intimate relationship between data science and medicine is apparent in the pages of our most prominent medical journals. Using Pubmed, we pulled the abstracts of all papers published in The New England Journal of Medicine, JAMA, Nature Medicine, The Lancet, PLoS Medicine, and BMJ for the years 2010 - March 2019. We then searched for a list of statistical terms in the text of these abstracts. For these 12,281 abstracts a median of 50% (IQR 30%, 67%) of sentences contained a term that would require statistical training to understand.;,citation_author=Lucy D’Agostino McGowan;,citation_author=Jeffrey T Leek;,citation_publication_date=2020-03;,citation_cover_date=2020-03;,citation_year=2020;,citation_doi=10.31219/osf.io/e8tgp;,citation_language=en-US;,citation_technical_report_institution=Open Science Framework;">
<meta name="citation_reference" content="citation_title=Midline Shift Greater than 3 mm Independently Predicts Outcome After Ischemic Stroke;,citation_abstract=Background: Cerebral edema is associated with worse outcome after acute stroke; however, the minimum clinically relevant threshold remains unknown. This study aimed to identify the minimal degree of midline shift (MLS) that predicts outcome in a cohort encompassing a broad range of patients with acute stroke. Methods: Patient-level data from six acute stroke clinical trials were combined with endovascular thrombectomy registries from two academic referral centers, generating a combined cohort of 1977 patients. MLS was extracted from the original trial data or measured on computed tomography or magnetic resonance imaging that was obtained a median of 47.0 h (interquartile range 27.0–75.1 h) after stroke onset. Logistic regression was performed to identify predictors of poor outcome and the minimal clinically relevant MLS threshold. Results: The presence of MLS was a predictor of poor outcome, independent of baseline clinical and demographic factors (adjusted odds ratio 4.46, 95% confidence interval 3.56–5.59, p &amp;amp;amp;lt; 0.001). Examining the full range of MLS values identified, a value of greater than 3 mm was the critical threshold that significantly predicted poor outcome (adjusted odds ratio 3.20 [1.31–7.82], p = 0.011). Conclusions: These results show that the presence of MLS predicts poor outcome and, specifically, MLS value greater than 3 mm is an important threshold across a variety of clinical settings. These findings may have relevance for the design and interpretation of future trials for antiedema therapies.;,citation_author=Morgan E. McKeown;,citation_author=Ayush Prasad;,citation_author=Jessica Kobsa;,citation_author=Ilayda Top;,citation_author=Samuel B. Snider;,citation_author=Chelsea Kidwell;,citation_author=Bruce C. V. Campbell;,citation_author=Stephen M. Davis;,citation_author=Geoffrey A. Donnan;,citation_author=Michael Lev;,citation_author=Kevin N. Sheth;,citation_author=Nils Petersen;,citation_author=W. Taylor Kimberly;,citation_author=Matthew B. Bevers;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_issue=1;,citation_doi=10.1007/s12028-021-01341-x;,citation_issn=1541-6933, 1556-0961;,citation_volume=36;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Awake prone positioning;,citation_author=Bairbre A. McNicholas;,citation_author=Stephan Ehrmann;,citation_author=John G. Laffey;,citation_publication_date=2022-09;,citation_cover_date=2022-09;,citation_year=2022;,citation_doi=10.1007/s00134-022-06893-w;,citation_issn=0342-4642, 1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Return to Employment after Critical Illness and Its Association with Psychosocial Outcomes. A Systematic Review and Meta-Analysis;,citation_abstract=Background: Patients who survive critical illness have welldefined physical, cognitive, emotional, and familial problems. However, the impact of these problems on survivors’ ability to return to work and other financial outcomes is less clear.;,citation_author=Joanne McPeake;,citation_author=Mark E. Mikkelsen;,citation_author=Tara Quasim;,citation_author=Elizabeth Hibbert;,citation_author=Paul Cannon;,citation_author=Martin Shaw;,citation_author=Jane Ankori;,citation_author=Theodore J. Iwashyna;,citation_author=Kimberley J. Haines;,citation_publication_date=2019-10;,citation_cover_date=2019-10;,citation_year=2019;,citation_issue=10;,citation_doi=10.1513/AnnalsATS.201903-248OC;,citation_issn=2329-6933, 2325-6621;,citation_volume=16;,citation_language=en-US;,citation_journal_title=Annals of the American Thoracic Society;">
<meta name="citation_reference" content="citation_title=Abandon Statistical Significance;,citation_abstract=We discuss problems the null hypothesis significance testing (NHST) paradigm poses for replication and more broadly in the biomedical and social sciences as well as how these problems remain unresolved by proposals involving modified p-value thresholds, confidence intervals, and Bayes factors. We then discuss our own proposal, which is to abandon statistical significance. We recommend dropping the NHST paradigm—and the p-value thresholds intrinsic to it—as the default statistical paradigm for research, publication, and discovery in the biomedical and social sciences. Specifically, we propose that the p-value be demoted from its threshold screening role and instead, treated continuously, be considered along with currently subordinate factors (e.g., related prior evidence, plausibility of mechanism, study design and data quality, real world costs and benefits, novelty of finding, and other factors that vary by research domain) as just one among many pieces of evidence. We have no desire to “ban” p-values or other purely statistical measures. Rather, we believe that such measures should not be thresholded and that, thresholded or not, they should not take priority over the currently subordinate factors. We also argue that it seldom makes sense to calibrate evidence as a function of p-values or other purely statistical measures. We offer recommendations for how our proposal can be implemented in the scientific publication process as well as in statistical decision making more broadly.;,citation_author=Blakeley B. McShane;,citation_author=David Gal;,citation_author=Andrew Gelman;,citation_author=Christian Robert;,citation_author=Jennifer L. Tackett;,citation_publication_date=2019-03;,citation_cover_date=2019-03;,citation_year=2019;,citation_issue=sup1;,citation_doi=10.1080/00031305.2018.1527253;,citation_issn=0003-1305;,citation_volume=73;,citation_journal_title=The American Statistician;,citation_publisher=Taylor &amp;amp;amp; Francis;">
<meta name="citation_reference" content="citation_title=Statistical Significance and the Dichotomization of Evidence;,citation_abstract=In light of recent concerns about reproducibility and replicability, the ASA issued a Statement on Statistical Significance and p-values aimed at those who are not primarily statisticians. While the ASA Statement notes that statistical significance and p-values are “commonly misused and misinterpreted,” it does not discuss and document broader implications of these errors for the interpretation of evidence. In this article, we review research on how applied researchers who are not primarily statisticians misuse and misinterpret p-values in practice and how this can lead to errors in the interpretation of evidence. We also present new data showing, perhaps surprisingly, that researchers who are primarily statisticians are also prone to misuse and misinterpret p-values thus resulting in similar errors. In particular, we show that statisticians tend to interpret evidence dichotomously based on whether or not a p-value crosses the conventional 0.05 threshold for statistical significance. We discuss implications and offer recommendations.;,citation_author=Blakeley B. McShane;,citation_author=David Gal;,citation_publication_date=2017-07;,citation_cover_date=2017-07;,citation_year=2017;,citation_issue=519;,citation_doi=10.1080/01621459.2017.1289846;,citation_issn=0162-1459, 1537-274X;,citation_volume=112;,citation_language=en-US;,citation_journal_title=Journal of the American Statistical Association;">
<meta name="citation_reference" content="citation_title=POINT: Should Corticosteroids Be Routine Treatment in Early ARDS? Yes;,citation_author=Gianfranco Umberto Meduri;,citation_author=Bram Rochwerg;,citation_publication_date=2021-01;,citation_cover_date=2021-01;,citation_year=2021;,citation_issue=1;,citation_doi=10.1016/j.chest.2020.07.057;,citation_issn=1931-3543;,citation_pmid=33422200;,citation_volume=159;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Optimal Cerebral Perfusion Pressure and Brain Tissue Oxygen in Aneurysmal Subarachnoid Hemorrhage;,citation_abstract=BACKGROUND: Targeting a cerebral perfusion pressure optimal for cerebral autoregulation (CPPopt) has been gaining more attention to prevent secondary damage after acute neurological injury. Brain tissue oxygenation (PbtO2) can identify insufficient cerebral blood flow and secondary brain injury. Defining the relationship between CPPopt and PbtO2 after aneurysmal subarachnoid hemorrhage may result in (1) mechanistic insights into whether and how CPPopt-based strategies might be beneficial and (2) establishing support for the use of PbtO2 as an adjunctive monitor for adequate or optimal local perfusion. METHODS: We performed a retrospective analysis of a prospectively collected 2-center dataset of patients with aneurysmal subarachnoid hemorrhage with or without later diagnosis of delayed cerebral ischemia (DCI). CPPopt was calculated as the cerebral perfusion pressure (CPP) value corresponding to the lowest pressure reactivity index (moving correlation coefficient of mean arterial and intracranial pressure). The relationship of (hourly) deltaCPP (CPP-CPPopt) and PbtO2 was investigated using natural spline regression analysis. Data after DCI diagnosis were excluded. Brain tissue hypoxia was defined as PbtO2 &amp;amp;amp;lt;20 mmHg. RESULTS: One hundred thirty-one patients were included with a median of 44.0 (interquartile range, 20.8–78.3) hourly CPPopt/PbtO2 datapoints. The regression plot revealed a nonlinear relationship between PbtO2 and deltaCPP (P&amp;lt;0.001) with PbtO2 decrease with deltaCPP <0 mmHg and stable PbtO2 with deltaCPP \geq0mmHg, although there was substantial individual variation. Brain tissue hypoxia (34.6% of all measurements) was more frequent with deltaCPP <0 mmHg. These dynamics were similar in patients with or without DCI. CONCLUSIONS: We found a nonlinear relationship between PbtO2 and deviation of patients’ CPP from CPPopt in aneurysmal subarachnoid hemorrhage patients in the pre-DCI period. CPP values below calculated CPPopt were associated with lower PbtO2. Nevertheless, the nature of PbtO2 measurements is complex, and the variability is high. Combined multimodality monitoring with CPP/CPPopt and PbtO2 should be recommended to redefine individual pressure targets (CPP/CPPopt) and retain the option to detect local perfusion deficits during DCI (PbtO2), which cannot be fulfilled by both measurements interchangeably.;,citation_author=Murad Megjhani;,citation_author=Miriam Weiss;,citation_author=Jenna Ford;,citation_author=Kalijah Terilli;,citation_author=Nick Kastenholz;,citation_author=Daniel Nametz;,citation_author=Soon Bin Kwon;,citation_author=Angela Velazquez;,citation_author=Sachin Agarwal;,citation_author=David J. Roh;,citation_author=Catharina Conzen-Dilger;,citation_author=Walid Albanna;,citation_author=Michael Veldeman;,citation_author=E. Sander Connolly;,citation_author=Jan Claassen;,citation_author=Marcel Aries;,citation_author=Gerrit A. Schubert;,citation_author=Soojin Park;,citation_issue=0;,citation_doi=10.1161/STROKEAHA.122.040339;,citation_volume=0;,citation_journal_title=Stroke;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=The Modified Fisher Scale Lacks Interrater Reliability;,citation_abstract=Background: The modified Fisher scale (mFS) is a critical clinical and research tool for risk stratification of cerebral vasospasm. As such, the mFS is included as a common data element by the National Institute of Neurological Disorders and Stroke SAH Working Group. There are few studies assessing the interrater reliability of the mFS. Methods: We distributed a survey to a convenience sample with snowball sampling of practicing neurointensivists and through the research survey portion of the Neurocritical Care Society Web site. The survey consisted of 15 scrollable CT scans of patients with SAH for mFS grading, two questions regarding the definitions of the scale criteria and demographics of the responding physician. Kendall’s coefficient of concordance was used to determine the interrater reliability of mFS grading. Results: Forty-six participants (97.8% neurocritical care fellowship trained, 78% UCNS-certified in neurocritical care, median 5 years (IQR 3–6.3) in practice, treating median of 80 patients (IQR 50–100) with SAH annually from 32 institutions) completed the survey. By mFS criteria, 30% correctly identified that there is no clear measurement of thin versus thick blood, and 42% correctly identified that blood in any ventricle is scored as “intraventricular blood.”The overall interrater reliability by Kendall’s coefficient of concordance for the mFS was moderate (W = 0.586, p &amp;amp;amp;lt; 0.0005). Conclusions: Agreement among raters in grading the mFS is only moderate. Online training tools could be developed to improve mFS reliability and standardize research in SAH.;,citation_author=Christopher Melinosky;,citation_author=Hope Kincaid;,citation_author=Jan Claassen;,citation_author=Gunjan Parikh;,citation_author=Neeraj Badjatia;,citation_author=Nicholas A. Morris;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_issue=1;,citation_doi=10.1007/s12028-020-01142-8;,citation_issn=1541-6933, 1556-0961;,citation_volume=35;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): A randomised trial;,citation_author=A. David Mendelow;,citation_author=Barbara A. Gregson;,citation_author=Helen M. Fernandes;,citation_author=Gordon D. Murray;,citation_author=Graham M. Teasdale;,citation_author=D. Terence Hope;,citation_author=Abbas Karimi;,citation_author=M. Donald M. Shaw;,citation_author=David H. Barer;,citation_publication_date=2005-01;,citation_cover_date=2005-01;,citation_year=2005;,citation_issue=9457;,citation_doi=10.1016/S0140-6736(05)17826-X;,citation_issn=0140-6736, 1474-547X;,citation_pmid=15680453;,citation_volume=365;,citation_language=en-US;,citation_journal_title=The Lancet;,citation_publisher=Elsevier;">
<meta name="citation_reference" content="citation_title=Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): A randomised trial;,citation_abstract=BACKGROUND: The balance of risk and benefit from early neurosurgical intervention for conscious patients with superficial lobar intracerebral haemorrhage of 10-100 mL and no intraventricular haemorrhage admitted within 48 h of ictus is unclear. We therefore tested the hypothesis that early surgery compared with initial conservative treatment could improve outcome in these patients. METHODS: In this international, parallel-group trial undertaken in 78 centres in 27 countries, we compared early surgical haematoma evacuation within 12 h of randomisation plus medical treatment with initial medical treatment alone (later evacuation was allowed if judged necessary). An automatic telephone and internet-based randomisation service was used to assign patients to surgery and initial conservative treatment in a 1:1 ratio. The trial was not masked. The primary outcome was a prognosis-based dichotomised (favourable or unfavourable) outcome of the 8 point Extended Glasgow Outcome Scale (GOSE) obtained by questionnaires posted to patients at 6 months. Analysis was by intention to treat. This trial is registered, number ISRCTN22153967. FINDINGS: 307 of 601 patients were randomly assigned to early surgery and 294 to initial conservative treatment; 298 and 291 were followed up at 6 months, respectively; and 297 and 286 were included in the analysis, respectively. 174 (59%) of 297 patients in the early surgery group had an unfavourable outcome versus 178 (62%) of 286 patients in the initial conservative treatment group (absolute difference 3\cdot7% [95% CI -4\cdot3 to 11\cdot6], odds ratio 0\cdot86 [0\cdot62 to 1\cdot20]; p=0\cdot367). INTERPRETATION: The STICH II results confirm that early surgery does not increase the rate of death or disability at 6 months and might have a small but clinically relevant survival advantage for patients with spontaneous superficial intracerebral haemorrhage without intraventricular haemorrhage. FUNDING: UK Medical Research Council.;,citation_author=A. David Mendelow;,citation_author=Barbara A. Gregson;,citation_author=Elise N. Rowan;,citation_author=Gordon D. Murray;,citation_author=Anil Gholkar;,citation_author=Patrick M. Mitchell;,citation_author=STICH II Investigators;,citation_publication_date=2013-08;,citation_cover_date=2013-08;,citation_year=2013;,citation_issue=9890;,citation_doi=10.1016/S0140-6736(13)60986-1;,citation_issn=1474-547X;,citation_pmid=23726393;,citation_volume=382;,citation_language=en-US;,citation_journal_title=Lancet (London, England);">
<meta name="citation_reference" content="citation_title=Heterogeneity and Variability in Pressure Autoregulation of Organ Blood Flow: Lessons Learned Over 100+ Years;,citation_author=Lingzhong Meng;,citation_author=Yingwei Wang;,citation_author=Lina Zhang;,citation_author=David L. McDonagh;,citation_publication_date=2019-03;,citation_cover_date=2019-03;,citation_year=2019;,citation_issue=3;,citation_doi=10.1097/CCM.0000000000003569;,citation_issn=0090-3493;,citation_volume=47;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Association of Clinical, Imaging, and Thrombus Characteristics With Recanalization of Visible Intracranial Occlusion in Patients With Acute Ischemic Stroke;,citation_abstract=Recanalization of intracranial thrombus is associated with improved clinical outcome in patients with acute ischemic stroke. The association of intravenous alteplase treatment and thrombus characteristics with recanalization over time is important for stroke triage and future trial design.To examine recanalization over time across a range of intracranial thrombus occlusion sites and clinical and imaging characteristics in patients with ischemic stroke treated with intravenous alteplase or not treated with alteplase.Multicenter prospective cohort study of 575 patients from 12 centers (in Canada, Spain, South Korea, the Czech Republic, and Turkey) with acute ischemic stroke and intracranial arterial occlusion demonstrated on computed tomographic angiography (CTA).Demographics, clinical characteristics, time from alteplase to recanalization, and intracranial thrombus characteristics (location and permeability) defined on CTA.Recanalization on repeat CTA or on first angiographic acquisition of affected intracranial circulation obtained within 6 hours of baseline CTA, defined using the revised arterial occlusion scale (rAOL) (scores from 0 [primary occlusive lesion remains the same] to 3 [complete revascularization of primary occlusion]).Among 575 patients (median age, 72 years [IQR, 63-80]; 51.5% men; median time from patient last known well to baseline CTA of 114 minutes [IQR, 74-180]), 275 patients (47.8%) received intravenous alteplase only, 195 (33.9%) received intravenous alteplase plus endovascular thrombectomy, 48 (8.3%) received endovascular thrombectomy alone, and 57 (9.9%) received conservative treatment. Median time from baseline CTA to recanalization assessment was 158 minutes (IQR, 79-268); median time from intravenous alteplase start to recanalization assessment was 132.5 minutes (IQR, 62-238). Successful recanalization occurred at an unadjusted rate of 27.3% (157/575) overall, including in 30.4% (143/470) of patients who received intravenous alteplase and 13.3% (14/105) who did not (difference, 17.1% [95% CI, 10.2%-25.8%]). Among patients receiving alteplase, the following factors were associated with recanalization: time from treatment start to recanalization assessment (OR, 1.28 for every 30-minute increase in time [95% CI, 1.18-1.38]), more distal thrombus location, eg, distal M1 middle cerebral artery (39/84 [46.4%]) vs internal carotid artery (10/92 [10.9%]) (OR, 5.61 [95% CI, 2.38-13.26]), and higher residual flow (thrombus permeability) grade, eg, hairline streak (30/45 [66.7%]) vs none (91/377 [24.1%]) (OR, 7.03 [95% CI, 3.32-14.87]).In patients with acute ischemic stroke, more distal thrombus location, greater thrombus permeability, and longer time to recanalization assessment were associated with recanalization of arterial occlusion after administration of intravenous alteplase; among patients who did not receive alteplase, rates of arterial recanalization were low. These findings may help inform treatment and triage decisions in patients with acute ischemic stroke.;,citation_author=Bijoy K. Menon;,citation_author=Fahad S. Al-Ajlan;,citation_author=Mohamed Najm;,citation_author=Josep Puig;,citation_author=Mar Castellanos;,citation_author=Dar Dowlatshahi;,citation_author=Ana Calleja;,citation_author=Sung-Il Sohn;,citation_author=Seong H. Ahn;,citation_author=Alex Poppe;,citation_author=Robert Mikulik;,citation_author=Negar Asdaghi;,citation_author=Thalia S. Field;,citation_author=Albert Jin;,citation_author=Talip Asil;,citation_author=Jean-Martin Boulanger;,citation_author=Eric E. Smith;,citation_author=Shelagh B. Coutts;,citation_author=Phil A. Barber;,citation_author=Simerpreet Bal;,citation_author=Suresh Subramanian;,citation_author=Sachin Mishra;,citation_author=Anurag Trivedi;,citation_author=Sadanand Dey;,citation_author=Muneer Eesa;,citation_author=Tolulope Sajobi;,citation_author=Mayank Goyal;,citation_author=Michael D. Hill;,citation_author=Andrew M. Demchuk;,citation_author=for the INTERRSeCT Study Investigators;,citation_publication_date=2018-09;,citation_cover_date=2018-09;,citation_year=2018;,citation_issue=10;,citation_doi=10.1001/jama.2018.12498;,citation_issn=0098-7484;,citation_volume=320;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): A pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial;,citation_abstract=BACKGROUND: Intravenous thrombolysis with alteplase bolus followed by infusion is a global standard of care for patients with acute ischaemic stroke. We aimed to determine whether tenecteplase given as a single bolus might increase reperfusion compared with this standard of care. METHODS: In this multicentre, open-label, parallel-group, registry-linked, randomised, controlled trial (AcT), patients were enrolled from 22 primary and comprehensive stroke centres across Canada. Patients were eligible for inclusion if they were aged 18 years or older, with a diagnosis of ischaemic stroke causing disabling neurological deficit, presenting within 4\cdot5 h of symptom onset, and eligible for thrombolysis per Canadian guidelines. Eligible patients were randomly assigned (1:1), using a previously validated minimal sufficient balance algorithm to balance allocation by site and a secure real-time web-based server, to either intravenous tenecteplase (0\cdot25 mg/kg to a maximum of 25 mg) or alteplase (0\cdot9 mg/kg to a maximum of 90mg; 0\cdot09 mg/kg as a bolus and then a 60 min infusion of the remaining 0\cdot81 mg/kg). The primary outcome was the proportion of patients who had a modified Rankin Scale (mRS) score of 0-1 at 90-120 days after treatment, assessed via blinded review in the intention-to-treat (ITT) population (ie, all patients randomly assigned to treatment who did not withdraw consent). Non-inferiority was met if the lower 95% CI of the difference in the proportion of patients who met the primary outcome between the tenecteplase and alteplase groups was more than -5%. Safety was assessed in all patients who received any of either thrombolytic agent and who were reported as treated. The trial is registered with ClinicalTrials.gov, NCT03889249, and is closed to accrual. FINDINGS: Between Dec 10, 2019, and Jan 25, 2022, 1600 patients were enrolled and randomly assigned to tenecteplase (n=816) or alteplase (n=784), of whom 1577 were included in the ITT population (n=806 tenecteplase; n=771 alteplase). The median age was 74 years (IQR 63-83), 755 (47\cdot9%) of 1577 patients were female and 822 (52\cdot1%) were male. As of data cutoff (Jan 21, 2022), 296 (36\cdot9%) of 802 patients in the tenecteplase group and 266 (34\cdot8%) of 765 in the alteplase group had an mRS score of 0-1 at 90-120 days (unadjusted risk difference 2\cdot1% [95% CI - 2\cdot6 to 6\cdot9], meeting the prespecified non-inferiority threshold). In safety analyses, 27 (3\cdot4%) of 800 patients in the tenecteplase group and 24 (3\cdot2%) of 763 in the alteplase group had 24 h symptomatic intracerebral haemorrhage and 122 (15\cdot3%) of 796 and 117 (15\cdot4%) of 763 died within 90 days of starting treatment INTERPRETATION: Intravenous tenecteplase (0\cdot25 mg/kg) is a reasonable alternative to alteplase for all patients presenting with acute ischaemic stroke who meet standard criteria for thrombolysis. FUNDING: Canadian Institutes of Health Research, Alberta Strategy for Patient Oriented Research Support Unit.;,citation_author=Bijoy K. Menon;,citation_author=Brian H. Buck;,citation_author=Nishita Singh;,citation_author=Yan Deschaintre;,citation_author=Mohammed A. Almekhlafi;,citation_author=Shelagh B. Coutts;,citation_author=Sibi Thirunavukkarasu;,citation_author=Houman Khosravani;,citation_author=Ramana Appireddy;,citation_author=Francois Moreau;,citation_author=Gord Gubitz;,citation_author=Aleksander Tkach;,citation_author=Luciana Catanese;,citation_author=Dar Dowlatshahi;,citation_author=George Medvedev;,citation_author=Jennifer Mandzia;,citation_author=Aleksandra Pikula;,citation_author=Jai Shankar;,citation_author=Heather Williams;,citation_author=Thalia S. Field;,citation_author=Alejandro Manosalva;,citation_author=Muzaffar Siddiqui;,citation_author=Atif Zafar;,citation_author=Oje Imoukhuede;,citation_author=Gary Hunter;,citation_author=Andrew M. Demchuk;,citation_author=Sachin Mishra;,citation_author=Laura C. Gioia;,citation_author=Shirin Jalini;,citation_author=Caroline Cayer;,citation_author=Stephen Phillips;,citation_author=Elsadig Elamin;,citation_author=Ashkan Shoamanesh;,citation_author=Suresh Subramaniam;,citation_author=Mahesh Kate;,citation_author=Gregory Jacquin;,citation_author=Marie-Christine Camden;,citation_author=Faysal Benali;,citation_author=Ibrahim Alhabli;,citation_author=Fouzi Bala;,citation_author=MacKenzie Horn;,citation_author=Grant Stotts;,citation_author=Michael D. Hill;,citation_author=David J. Gladstone;,citation_author=Alexandre Poppe;,citation_author=Arshia Sehgal;,citation_author=Qiao Zhang;,citation_author=Brendan Cord Lethebe;,citation_author=Craig Doram;,citation_author=Ayoola Ademola;,citation_author=Michel Shamy;,citation_author=Carol Kenney;,citation_author=Tolulope T. Sajobi;,citation_author=Richard H. Swartz;,citation_author=AcT Trial Investigators;,citation_publication_date=2022-07;,citation_cover_date=2022-07;,citation_year=2022;,citation_issue=10347;,citation_doi=10.1016/S0140-6736(22)01054-6;,citation_issn=1474-547X;,citation_pmid=35779553;,citation_volume=400;,citation_language=en-US;,citation_journal_title=Lancet (London, England);">
<meta name="citation_reference" content="citation_title=Perimesencephalic Hemorrhage: A Review of Epidemiology, Risk Factors, Presumed Cause, Clinical Course, and Outcome;,citation_abstract=Background and Purpose— We systematically reviewed the literature on epidemiology, risk factors, presumed cause, clinical course, and outcome of perimesencephalic hemorrhage. Methods— PubMed, Embase, and the Cochrane Library were searched until March 2016. Quality assessment was done by 2 authors independently. Pooled prevalence ratios and pooled odds ratios with 95% confidence intervals were calculated for data extracted from case–control studies. Results— We included 208 papers. The incidence of perimesencephalic hemorrhage is \approx0.5 per 100.000 person-years, men are more often affected, and no risk factors were confirmed. Two decision analyses both found that a single, high-quality computed tomography angiography is the preferred diagnostic approach. Short-term complications, such as hydrocephalus or cranial nerve palsies, are rare, and usually transient, with the exception of acute symptomatic hydrocephalus necessitating treatment in 3% of patients. Lacunar infarcts in the brain stem were convincingly described in 4 patients only. Fatal rebleeding after installment of anticoagulation in the initial days after the hemorrhage was described in 1 patient. At long-term follow-up, death related to the hemorrhage has not been reported, disability is found in 0% to 6%, and neuropsychological sequelae are suggested. Conclusions— A single, high-quality computed tomography angiography is the preferred diagnostic strategy. Short-term complications are rare and often transient. Long-term outcome is excellent with respect to disability and death, but high-quality studies focused at neuropsychological sequelae are needed.;,citation_author=Liselore A. Mensing;,citation_author=Mervyn D. I. Vergouwen;,citation_author=Kamil G. Laban;,citation_author=Ynte M. Ruigrok;,citation_author=Birgitta K. Velthuis;,citation_author=Ale Algra;,citation_author=Gabriel J. E. Rinkel;,citation_publication_date=2018-06;,citation_cover_date=2018-06;,citation_year=2018;,citation_issue=6;,citation_doi=10.1161/STROKEAHA.117.019843;,citation_issn=0039-2499, 1524-4628;,citation_volume=49;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=Determining the Utility of Methicillin-Resistant Staphylococcus aureus Nares Screening in Antimicrobial Stewardship;,citation_abstract=Background.\quad Treatment of suspected methicillin-resistant Staphylococcus aureus (MRSA) is a cornerstone of many antibiotic regimens; however, there is associated toxicity. The Department of Veterans Affairs (VA) hospitals screen each patient for MRSA nares colonization on admission and transfer. The objective was to determine the negative predictive value (NPV) of MRSA screening in the determination of subsequent positive clinical culture for MRSA. High NPVs with MRSA nares screening may be used as a stewardship tool. Methods.\quad This was a retrospective cohort study across VA medical centers nationwide from 1 January 2007 to 1 January 2018. Data from patients with MRSA nares screening were obtained from the VA Corporate Data Warehouse. Subsequent clinical cultures within 7 days of the nares swab were evaluated for the presence of MRSA. Sensitivity, specificity, positive predictive values, and NPVs were calculated for the entire cohort as well as subgroups for specific culture sites. Results.\quad This cohort yielded 561 325 clinical cultures from a variety of anatomical sites. The sensitivity and specificity for positive MRSA clinical culture were 67.4% and 81.2%, respectively. The NPV of MRSA nares screening for ruling out MRSA infection was 96.5%. The NPV for bloodstream infections was 96.5%, for intraabdominal cultures it was 98.6%, for respiratory cultures it was 96.1%, for wound cultures it was 93.1%, and for cultures from the urinary system it was 99.2%. Conclusion.\quad Given the high NPVs, MRSA nares screening may be a powerful stewardship tool for deescalation and avoidance of empirical anti-MRSA therapy.;,citation_author=Kari A Mergenhagen;,citation_author=Kaitlyn E Starr;,citation_author=Bethany A Wattengel;,citation_author=Alan J Lesse;,citation_author=Zarchi Sumon;,citation_author=John A Sellick;,citation_publication_date=2020-08;,citation_cover_date=2020-08;,citation_year=2020;,citation_issue=5;,citation_doi=10.1093/cid/ciz974;,citation_issn=1058-4838, 1537-6591;,citation_volume=71;,citation_language=en-US;,citation_journal_title=Clinical Infectious Diseases;">
<meta name="citation_reference" content="citation_title=Normal saline versus balanced crystalloids: Is it all about sodium?;,citation_author=Anna S Messmer;,citation_author=Carmen A Pfortmueller;,citation_publication_date=2023-11;,citation_cover_date=2023-11;,citation_year=2023;,citation_doi=10.1016/S2213-2600(23)00416-2;,citation_issn=22132600;,citation_language=en-US;,citation_journal_title=The Lancet Respiratory Medicine;">
<meta name="citation_reference" content="citation_title=Time to Treat Severe Community-Acquired Pneumonia with Steroids?;,citation_abstract=Guidelines for the treatment of community-acquired pneumonia (CAP) focus primarily on the choice of antibiotic therapy. However, the 2019 guidelines of the American Thoracic Society and the Infectious Diseases Society of America for adult CAP was the first version to address the role of glucocorticoids as adjunct therapy. The guideline committee (which we cochaired) did not recommend the use of glucocorticoids for most patients with CAP,1 but it did endorse the use of glucocorticoids for adults with refractory septic shock that is resistant to fluid resuscitation and vasopressor support, consistent with the suggested use of these drugs in previously released . . .;,citation_author=Joshua P. Metlay;,citation_author=Grant W. Waterer;,citation_publication_date=2023-05;,citation_cover_date=2023-05;,citation_year=2023;,citation_issue=21;,citation_doi=10.1056/NEJMe2302544;,citation_issn=0028-4793;,citation_volume=388;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Interim Analyses During Group Sequential Clinical Trials;,citation_author=William J. Meurer;,citation_author=Juliana Tolles;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=15;,citation_doi=10.1001/jama.2021.10174;,citation_issn=0098-7484;,citation_volume=326;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Thrombectomy in Extensive Stroke May Not Be Beneficial and Is Associated With Increased Risk for Hemorrhage;,citation_abstract=BACKGROUND AND PURPOSE: This study evaluates the benefit of endovascular treatment (EVT) for patients with extensive baseline stroke compared with best medical treatment. METHODS: This retrospective, multicenter study compares EVT and best medical treatment for computed tomography (CT)–based selection of patients with extensive baseline infarcts (Alberta Stroke Program Early CT Score \leq5) attributed to anterior circulation stroke. Patients were selected from the German Stroke Registry and 3 tertiary stroke centers. Primary functional end points were rates of good (modified Rankin Scale score of \leq3) and very poor outcome (modified Rankin Scale score of \geq5) at 90 days. Secondary safety end point was the occurrence of symptomatic intracerebral hemorrhage. Angiographic outcome was evaluated with the modified Thrombolysis in Cerebral Infarction Scale. RESULTS: After 1:1 pair matching, a total of 248 patients were compared by treatment arm. Good functional outcome was observed in 27.4% in the EVT group, and in 25% in the best medical treatment group (P=0.665). Advanced age (adjusted odds ratio, 1.08 [95% CI, 1.05–1.10], P&amp;amp;amp;lt;0.001) and symptomatic intracerebral hemorrhage (adjusted odds ratio, 6.35 [95% CI, 2.08–19.35], P&amp;lt;0.001) were independently associated with very poor outcome. Mortality (43.5% versus 28.9%, P=0.025) and symptomatic intracerebral hemorrhage (16.1% versus 5.6%, P=0.008) were significantly higher in the EVT group. The lowest rates of good functional outcome (\approx15%) were observed in groups of failed and partial recanalization (modified Thrombolysis in Cerebral Infarction Scale score of 0/1–2a), whereas patients with complete recanalization (modified Thrombolysis in Cerebral Infarction Scale score of 3) with recanalization attempts \leq2 benefitted the most (modified Rankin Scale score of \leq3:42.3%, P=0.074) compared with best medical treatment. CONCLUSIONS: In daily clinical practice, EVT for CT–based selected patients with low Alberta Stroke Program Early CT Score anterior circulation stroke may not be beneficial and is associated with increased risk for hemorrhage and mortality, especially in the elderly. However, first- or second-pass complete recanalization seems to reveal a clinical benefit of EVT highlighting the vulnerability of the low Alberta Stroke Program Early CT Score subgroup.;,citation_author=Lukas Meyer;,citation_author=Matthias Bechstein;,citation_author=Maxim Bester;,citation_author=Uta Hanning;,citation_author=Caspar Brekenfeld;,citation_author=Fabian Flottmann;,citation_author=Helge Kniep;,citation_author=Noel Horn;,citation_author=Milani Deb-Chatterji;,citation_author=Götz Thomalla;,citation_author=Peter Sporns;,citation_author=Leonard Leong-Litt Yeo;,citation_author=Benjamin Yong-Qiang Tan;,citation_author=Anil Gopinathan;,citation_author=Andreas Kastrup;,citation_author=Maria Politi;,citation_author=Panagiotis Papanagiotou;,citation_author=André Kemmling;,citation_author=Jens Fiehler;,citation_author=Gabriel Broocks;,citation_author=for the German Stroke Registry–Endovascular Treatment (GSR-ET)*;,citation_author=Silke Wunderlich;,citation_author=Tobias Boeckh-Behrens;,citation_author=Arno Reich;,citation_author=Martin Wiesmann;,citation_author=Ulrike Ernemann;,citation_author=Till-Karsten Hauser;,citation_author=Eberhard Siebert;,citation_author=Christian Nolte;,citation_author=Sarah Zweynert;,citation_author=Georg Bohner;,citation_author=Alexander Ludolph;,citation_author=Karl-Heinz Henn;,citation_author=Waltraud Pfeilschifter;,citation_author=Marlis Wagner;,citation_author=Joachim Röther;,citation_author=Bernd Eckert;,citation_author=Jörg Berrouschot;,citation_author=Albrecht Bormann;,citation_author=Anna Alegiani;,citation_author=Elke Hattingen;,citation_author=Gabor Petzold;,citation_author=Sven Thonke;,citation_author=Christopher Bangard;,citation_author=Christoffer Kraemer;,citation_author=Martin Dichgans;,citation_author=Frank Wollenweber;,citation_author=Lars Kellert;,citation_author=Franziska Dorn;,citation_author=Moriz Herzberg;,citation_author=Marios Psychogios;,citation_author=Jan Liman;,citation_author=Martina Petersen;,citation_author=Florian Stögbauer;,citation_author=Peter Kraft;,citation_author=Mirko Pham;,citation_author=Michael Braun;,citation_author=Gerhard F. Hamann;,citation_author=Klaus Gröschel;,citation_author=Timo Uphaus;,citation_author=Volker Limmroth;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=10;,citation_doi=10.1161/STROKEAHA.120.033101;,citation_issn=0039-2499, 1524-4628;,citation_volume=52;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=Management of moderate to severe traumatic brain injury: An update for the intensivist;,citation_abstract=Traumatic brain injury (TBI) remains one of the most fatal and debilitating conditions in the world. Current clinical management in severe TBI patients is mainly concerned with reducing secondary insults and optimizing the balance between substrate delivery and consumption. Over the past decades, multimodality monitoring has become more widely available, and clinical management protocols have been published that recommend potential interventions to correct pathophysiological derangements. Even while evidence from randomized clinical trials is still lacking for many of the recommended interventions, these protocols and algorithms can be useful to define a clear standard of therapy where novel interventions can be added or be compared to. Over the past decade, more attention has been paid to holistic management, in which hemodynamic, respiratory, inflammatory or coagulation disturbances are detected and treated accordingly. Considerable variability with regards to the trajectories of recovery exists. Even while most of the recovery occurs in the first months after TBI, substantial changes may still occur in a later phase. Neuroprognostication is challenging in these patients, where a risk of self-fulfilling prophecies is a matter of concern. The present article provides a comprehensive and practical review of the current best practice in clinical management and long-term outcomes of moderate to severe TBI in adult patients admitted to the intensive care unit.;,citation_author=Geert Meyfroidt;,citation_author=Pierre Bouzat;,citation_author=Michael P. Casaer;,citation_author=Randall Chesnut;,citation_author=Sophie Rym Hamada;,citation_author=Raimund Helbok;,citation_author=Peter Hutchinson;,citation_author=Andrew I. R. Maas;,citation_author=Geoffrey Manley;,citation_author=David K. Menon;,citation_author=Virginia F. J. Newcombe;,citation_author=Mauro Oddo;,citation_author=Chiara Robba;,citation_author=Lori Shutter;,citation_author=Martin Smith;,citation_author=Ewout W. Steyerberg;,citation_author=Nino Stocchetti;,citation_author=Fabio Silvio Taccone;,citation_author=Lindsay Wilson;,citation_author=Elisa R. Zanier;,citation_author=Giuseppe Citerio;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_issue=6;,citation_doi=10.1007/s00134-022-06702-4;,citation_issn=0342-4642, 1432-1238;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Restriction of Intravenous Fluid in ICU Patients with Septic Shock;,citation_abstract=BACKGROUND Intravenous fluids are recommended for the treatment of patients who are in septic shock, but higher fluid volumes have been associated with harm in patients who are in the intensive care unit (ICU). METHODS In this international, randomized trial, we assigned patients with septic shock in the ICU who had received at least 1 liter of intravenous fluid to receive restricted intravenous fluid or standard intravenous fluid therapy; patients were included if the onset of shock had been within 12 hours before screening. The primary outcome was death from any cause within 90 days after randomization. RESULTS We enrolled 1554 patients; 770 were assigned to the restrictive-fluid group and 784 to the standard-fluid group. Primary outcome data were available for 1545 patients (99.4%). In the ICU, the restrictive-fluid group received a median of 1798 ml of intravenous fluid (interquartile range, 500 to 4366); the standard-fluid group received a median of 3811 ml (interquartile range, 1861 to 6762). At 90 days, death had occurred in 323 of 764 patients (42.3%) in the restrictive-fluid group, as compared with 329 of 781 patients (42.1%) in the standard-fluid group (adjusted absolute difference, 0.1 percentage points; 95% confidence interval [CI], -4.7 to 4.9; P = 0.96). In the ICU, serious adverse events occurred at least once in 221 of 751 patients (29.4%) in the restrictive-fluid group and in 238 of 772 patients (30.8%) in the standard-fluid group (adjusted absolute difference, -1.7 percentage points; 99% CI, -7.7 to 4.3). At 90 days after randomization, the numbers of days alive without life support and days alive and out of the hospital were similar in the two groups. The authors’ full names, academic degrees, and affiliations are listed in the Appendix. Dr. Perner can be contacted at anders.perner@regionh.dk or at the Department of Intensive Care, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. *A complete list of investigators in the Conservative versus Liberal Approach to Fluid Therapy in Septic Shock (CLASSIC) Trial Group is provided in the Supplementary Appendix, available at NEJM.org. This article was published on June 17, 2022, at NEJM.org. DOI: 10.1056/NEJMoa2202707 Copyright © 2022 Massachusetts Medical Society. CONCLUSIONS Among adult patients with septic shock in the ICU, intravenous fluid restriction did not result in fewer deaths at 90 days than standard intravenous fluid therapy. (Funded by the Novo Nordisk Foundation and others; CLASSIC ClinicalTrials.gov number, NCT03668236.);,citation_author=Tine S. Meyhoff;,citation_author=Peter B. Hjortrup;,citation_author=Jørn Wetterslev;,citation_author=Praleene Sivapalan;,citation_author=Jon H. Laake;,citation_author=Maria Cronhjort;,citation_author=Stephan M. Jakob;,citation_author=Maurizio Cecconi;,citation_author=Marek Nalos;,citation_author=Marlies Ostermann;,citation_author=Manu Malbrain;,citation_author=Ville Pettilä;,citation_author=Morten H. Møller;,citation_author=Maj-Brit N. Kjær;,citation_author=Theis Lange;,citation_author=Christian Overgaard-Steensen;,citation_author=Björn A. Brand;,citation_author=Marie Winther-Olesen;,citation_author=Jonathan O. White;,citation_author=Lars Quist;,citation_author=Bo Westergaard;,citation_author=Andreas B. Jonsson;,citation_author=Carl J. S. Hjortsø;,citation_author=Nick Meier;,citation_author=Thomas S. Jensen;,citation_author=Janus Engstrøm;,citation_author=Lars Nebrich;,citation_author=Nina C. Andersen-Ranberg;,citation_author=Jacob V. Jensen;,citation_author=Neeliya A. Joseph;,citation_author=Lone M. Poulsen;,citation_author=Louise S. Herløv;,citation_author=Christoffer G. Sølling;,citation_author=Susan K. Pedersen;,citation_author=Kurt K. Knudsen;,citation_author=Therese S. Straarup;,citation_author=Marianne L. Vang;,citation_author=Helle Bundgaard;,citation_author=Bodil S. Rasmussen;,citation_author=Søren R. Aagaard;,citation_author=Thomas Hildebrandt;,citation_author=Lene Russell;,citation_author=Morten H. Bestle;,citation_author=Martin Schønemann-Lund;,citation_author=Anne C. Brøchner;,citation_author=Claes F. Elvander;,citation_author=Søren K. L. Hoffmann;,citation_author=Michael L. Rasmussen;,citation_author=Yvonne K. Martin;,citation_author=Fredrik F. Friberg;,citation_author=Herman Seter;,citation_author=Tayyba N. Aslam;,citation_author=Sigrid Ådnøy;,citation_author=Philipp Seidel;,citation_author=Kristian Strand;,citation_author=Bror Johnstad;,citation_author=Eva Joelsson-Alm;,citation_author=Jens Christensen;,citation_author=Christian Ahlstedt;,citation_author=Carmen A. Pfortmueller;,citation_author=Martin Siegemund;,citation_author=Massimiliano Greco;,citation_author=Jaroslav Raděj;,citation_author=Miroslav Kříž;,citation_author=Doug W. Gould;,citation_author=Kathy M. Rowan;,citation_author=Paul R. Mouncey;,citation_author=Anders Perner;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_issue=26;,citation_doi=10.1056/NEJMoa2202707;,citation_issn=0028-4793, 1533-4406;,citation_volume=386;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Dexamethasone versus Surgery for Chronic Subdural Hematoma;,citation_author=Ishita P. Miah;,citation_author=Dana C. Holl;,citation_author=Jurre Blaauw;,citation_author=Hester F. Lingsma;,citation_author=Heleen M. Hertog;,citation_author=Bram Jacobs;,citation_author=Nyika D. Kruyt;,citation_author=Joukje Naalt;,citation_author=Suzanne Polinder;,citation_author=Rob J. M. Groen;,citation_author=Kuan H. Kho;,citation_author=Fop Kooten;,citation_author=Clemens M. F. Dirven;,citation_author=Wilco C. Peul;,citation_author=Korné Jellema;,citation_author=Ruben Dammers;,citation_author=Niels A. Gaag;,citation_publication_date=2023-06;,citation_cover_date=2023-06;,citation_year=2023;,citation_issue=24;,citation_doi=10.1056/NEJMoa2216767;,citation_issn=0028-4793;,citation_pmid=37314705;,citation_volume=388;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Haemolytic uraemic syndrome;,citation_author=Mini Michael;,citation_author=Arvind Bagga;,citation_author=Sarah E Sartain;,citation_author=Richard J H Smith;,citation_publication_date=2022-11;,citation_cover_date=2022-11;,citation_year=2022;,citation_issue=10364;,citation_doi=10.1016/S0140-6736(22)01202-8;,citation_issn=01406736;,citation_volume=400;,citation_language=en-US;,citation_journal_title=The Lancet;">
<meta name="citation_reference" content="citation_title=Understanding and extending the Starling principle;,citation_author=C. Charles Michel;,citation_author=Thomas E. Woodcock;,citation_author=Fitz-Roy E. Curry;,citation_publication_date=2020-09;,citation_cover_date=2020-09;,citation_year=2020;,citation_issue=8;,citation_doi=10.1111/aas.13603;,citation_issn=0001-5172, 1399-6576;,citation_volume=64;,citation_language=en-US;,citation_journal_title=Acta Anaesthesiologica Scandinavica;">
<meta name="citation_reference" content="citation_title=Letter to the Editor Regarding CADTH rapid review: Systemic Thrombolysis by Alteplase for Acute Ischemic Stroke;,citation_abstract=The Canadian Stroke Consortium read with interest the recent rapid review by CADTH on the evidence of alteplase for acute ischemic stroke. We felt it necessary to reply for several reasons: despite the 27-year history of alteplase since the NINDS publication, the rapid review limits the search to the last 6 years, which does not reflect the totality of the evidence, the process for inclusion of studies was questionable, leading to a strongly biased representation of the existing literature, and important concerns from the single expert reviewer were not adequately addressed prior to publication.;,citation_author=Andrew Micieli;,citation_author=Michal Krawczyk;,citation_author=Gary Hunter;,citation_author=Dylan Blacquiere;,citation_author=Andrew M. Demchuk;,citation_publication_date=2022-09;,citation_cover_date=2022-09;,citation_year=2022;,citation_issue=9;,citation_doi=10.51731/cjht.2022.443;,citation_issn=2563-6596;,citation_volume=2;,citation_language=en-US;,citation_journal_title=Canadian Journal of Health Technologies;">
<meta name="citation_reference" content="citation_title=Randomized controlled trials—a critical re-appraisal;,citation_abstract=Randomized controlled trials (RCTs) are considered to represent the gold standard of scientific studies and paved the way for evidencebased medicine (EBM). Besides the initial aim to improve the quality of patient care, EBM is used in the meanwhile for political and economic decision-making and legal issues as well. A review of the literature was performed, followed by a search using links and references of the detected articles. Additionally, homepages for German institutions of public health were screened. Substantial limitations of RCTs and EBM health care could be identified. Based on the selected literature, 80% of the medical treatments have low evidence. RCTs are expensive and are mainly performed by the industry nowadays. A publication bias for positive results exists. Some RCTs are of low external validity. Many studies have a low fragility index. Nonetheless, negative RCTs could be of benefit for the patients. The results of RCTs, gained in a distinct patient population, are partially generalized. RCTs should be analyzed critically before adopting the results to daily clinical routine. It is not really justified to use RCTs and EBM for political and economic decisionmaking and legal issues as seen today.;,citation_author=Dorothee Mielke;,citation_author=Veit Rohde;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_issue=4;,citation_doi=10.1007/s10143-020-01401-4;,citation_issn=0344-5607, 1437-2320;,citation_volume=44;,citation_language=en-US;,citation_journal_title=Neurosurgical Review;">
<meta name="citation_reference" content="citation_title=Management of status epilepticus: A narrative review;,citation_abstract=Status epilepticus causes prolonged or repetitive seizures that, if left untreated, can lead to neuronal injury, severe disability, coma and death in paediatric and adult populations. While convulsive status epilepticus can be diagnosed using clinical features alone, non-convulsive status epilepticus requires confirmation by electroencephalogram. Early seizure control remains key in preventing the complications of status epilepticus. This is especially true for convulsive status epilepticus, which has stronger evidence supporting the benefit of treatment on outcomes. When status epilepticus becomes refractory, often due to gamma-aminobutyric acid and N-methyl-D-aspartate receptor modulation, anaesthetic drugs are needed to suppress seizure activity, of which there is limited evidence regarding the selection, dose or duration of their use. Seizure monitoring with electroencephalogram is often needed when patients do not return to baseline or during anaesthetic wean; however, it is resource-intensive, costly, only available in highly specialised centres and has not been shown to improve functional outcomes. Thus, the treatment goals and aggressiveness of therapy remain under debate, especially for non-convulsive status epilepticus, where prolonged therapeutic coma can lead to severe complications. This review presents an evidence-based, clinically-oriented and comprehensive review of status epilepticus and its definitions, aetiologies, treatments, outcomes and prognosis at different stages of the patient’s journey.;,citation_author=I. Migdady;,citation_author=E. S. Rosenthal;,citation_author=H. R. Cock;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=S1;,citation_doi=10.1111/anae.15606;,citation_issn=0003-2409, 1365-2044;,citation_volume=77;,citation_language=en-US;,citation_journal_title=Anaesthesia;">
<meta name="citation_reference" content="citation_title=Prior knowledge elicitation: The past, present, and future;,citation_abstract=Specification of the prior distribution for a Bayesian model is a central part of the Bayesian workflow for data analysis, but it is often difficult even for statistical experts. In principle, prior elicitation transforms domain knowledge of various kinds into well-defined prior distributions, and offers a solution to the prior specification problem. In practice, however, we are still fairly far from having usable prior elicitation tools that could significantly influence the way we build probabilistic models in academia and industry. We lack elicitation methods that integrate well into the Bayesian workflow and perform elicitation efficiently in terms of costs of time and effort. We even lack a comprehensive theoretical framework for understanding different facets of the prior elicitation problem.;,citation_author=Petrus Mikkola;,citation_author=Osvaldo A. Martin;,citation_author=Suyog Chandramouli;,citation_author=Marcelo Hartmann;,citation_author=Oriol Abril Pla;,citation_author=Owen Thomas;,citation_author=Henri Pesonen;,citation_author=Jukka Corander;,citation_author=Aki Vehtari;,citation_author=Samuel Kaski;,citation_author=Paul-Christian Bürkner;,citation_author=Arto Klami;,citation_publication_date=2023-05;,citation_cover_date=2023-05;,citation_year=2023;,citation_fulltext_html_url=https://arxiv.org/abs/2112.01380;,citation_language=en-US;,citation_publisher=arXiv;">
<meta name="citation_reference" content="citation_title=Influences on physicians’ choices of intravenous colloids;,citation_abstract=Objectives. Controversy over the optimal intravenous fluid for volume resuscitation continues unabated. Our objectives were to characterize the demographics of physicians who prescribe intravenous colloids and determine factors that enter into their decision to choose a colloid.;,citation_author=Michael S. Miletin;,citation_author=Thomas E. Stewart;,citation_author=Peter G. Norton;,citation_publication_date=2002-07;,citation_cover_date=2002-07;,citation_year=2002;,citation_issue=7;,citation_doi=10.1007/s00134-002-1337-z;,citation_issn=1432-1238;,citation_volume=28;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Decolonization in Nursing Homes to Prevent Infection and Hospitalization;,citation_author=Loren G. Miller;,citation_author=James A. McKinnell;,citation_author=Raveena D. Singh;,citation_author=Gabrielle M. Gussin;,citation_author=Ken Kleinman;,citation_author=Raheeb Saavedra;,citation_author=Job Mendez;,citation_author=Tabitha D. Catuna;,citation_author=James Felix;,citation_author=Justin Chang;,citation_author=Lauren Heim;,citation_author=Ryan Franco;,citation_author=Thomas Tjoa;,citation_author=Nimalie D. Stone;,citation_author=Karl Steinberg;,citation_author=Nancy Beecham;,citation_author=Jocelyn Montgomery;,citation_author=DeAnn Walters;,citation_author=Steven Park;,citation_author=Steven Tam;,citation_author=Shruti K. Gohil;,citation_author=Philip A. Robinson;,citation_author=Marlene Estevez;,citation_author=Brian Lewis;,citation_author=Julie A. Shimabukuro;,citation_author=Gregory Tchakalian;,citation_author=Aaron Miner;,citation_author=Crystal Torres;,citation_author=Kaye D. Evans;,citation_author=Cassiana E. Bittencourt;,citation_author=Jiayi He;,citation_author=Eunjung Lee;,citation_author=Christine Nedelcu;,citation_author=Julia Lu;,citation_author=Shalini Agrawal;,citation_author=S. Gwynn Sturdevant;,citation_author=Ellena Peterson;,citation_author=Susan S. Huang;,citation_publication_date=2023-11;,citation_cover_date=2023-11;,citation_year=2023;,citation_issue=19;,citation_doi=10.1056/NEJMoa2215254;,citation_issn=0028-4793;,citation_pmid=37815935;,citation_volume=389;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Risk Assessment for Cardiovascular Disease with Nontraditional Risk Factors;,citation_abstract=Final/cardiovascular-disease-screening-using-nontraditional-risk-assessment. This series is coordinated by Kenny Lin, MD, MPH, Deputy Editor. A collection of Putting Prevention into Practice published in AFP is available at https://www.aafp.org/afp/ppip. CME This clinical content conforms to AAFP criteria for continuing medical education (CME). See CME Quiz on page 86. Author disclosure: No relevant financial affiliations.;,citation_author=Justin Mills;,citation_author=Alisha Thomas;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=CJEM Debate Series: #TPA should be the initial treatment in eligible patients presenting with an acute ischemic stroke;,citation_author=William Kenneth Milne;,citation_author=Eddy Lang;,citation_author=Daniel K. Ting;,citation_author=Paul Atkinson;,citation_publication_date=2020-03;,citation_cover_date=2020-03;,citation_year=2020;,citation_issue=2;,citation_doi=10.1017/cem.2020.3;,citation_issn=1481-8043;,citation_pmid=32209153;,citation_volume=22;,citation_language=en-US;,citation_journal_title=CJEM;">
<meta name="citation_reference" content="citation_title=Blood Pressure Management After Intracerebral and Subarachnoid Hemorrhage: The Knowns and Known Unknowns;,citation_abstract=Blood pressure (BP) elevations often complicate the management of intracerebral hemorrhage and aneurysmal subarachnoid hemorrhage, the most serious forms of acute stroke. Despite consensus on potential benefits of BP lowering in the acute phase of intracerebral hemorrhage, controversies persist over the timing, mechanisms, and approaches to treatment. BP control is even more complex for subarachnoid hemorrhage, where there are rationales for both BP lowering and elevation in reducing the risks of rebleeding and delayed cerebral ischemia, respectively. Efforts to disentangle the evidence has involved detailed exploration of individual patient data from clinical trials through meta-analysis to determine strength and direction of BP change in relation to key outcomes in intracerebral hemorrhage, and which likely also apply to subarachnoid hemorrhage. A wealth of hemodynamic data provides insights into pathophysiological interrelationships of BP and cerebral blood flow. This focused update provides an overview of current evidence, knowledge gaps, and emerging concepts on systemic hemodynamics, cerebral autoregulation and perfusion, to facilitate clinical practice recommendations and future research.;,citation_author=Jatinder S. Minhas;,citation_author=Tom J. Moullaali;,citation_author=Gabriel J. E. Rinkel;,citation_author=Craig S. Anderson;,citation_publication_date=2022-03;,citation_cover_date=2022-03;,citation_year=2022;,citation_doi=10.1161/STROKEAHA.121.036139;,citation_issn=0039-2499, 1524-4628;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=A Taxonomy for Patient-Ventilator Interactions and a Method to Read Ventilator Waveforms;,citation_author=Eduardo Mireles-Cabodevila;,citation_author=Matthew T Siuba;,citation_author=Robert L Chatburn;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=1;,citation_doi=10.4187/respcare.09316;,citation_issn=0020-1324, 1943-3654;,citation_volume=67;,citation_language=en-US;,citation_journal_title=Respiratory Care;">
<meta name="citation_reference" content="citation_title=Convalescent Plasma for Covid-19–Induced ARDS in Mechanically Ventilated Patients;,citation_author=Benoı̂t Misset;,citation_author=Michael Piagnerelli;,citation_author=Eric Hoste;,citation_author=Nadia Dardenne;,citation_author=David Grimaldi;,citation_author=Isabelle Michaux;,citation_author=Elisabeth De Waele;,citation_author=Alexander Dumoulin;,citation_author=Philippe G. Jorens;,citation_author=Emmanuel Hauwaert;,citation_author=Frédéric Vallot;,citation_author=Stoffel Lamote;,citation_author=Walter Swinnen;,citation_author=Nicolas De Schryver;,citation_author=Vincent Fraipont;,citation_author=Nathalie Mey;,citation_author=Nicolas Dauby;,citation_author=Nathalie Layios;,citation_author=Jean-Baptiste Mesland;,citation_author=Geert Meyfroidt;,citation_author=Michel Moutschen;,citation_author=Veerle Compernolle;,citation_author=André Gothot;,citation_author=Daniel Desmecht;,citation_author=Maria I. Taveira da Silva Pereira;,citation_author=Mutien Garigliany;,citation_author=Tome Najdovski;,citation_author=Axelle Bertrand;,citation_author=Anne-Françoise Donneau;,citation_author=Pierre-François Laterre;,citation_publication_date=2023-10;,citation_cover_date=2023-10;,citation_year=2023;,citation_issue=17;,citation_doi=10.1056/NEJMoa2209502;,citation_issn=0028-4793;,citation_volume=389;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Blood Pressure Management after Mechanical Thrombectomy for Acute Ischemic Stroke: A Survey of the StrokeNet Sites;,citation_abstract=BACKGROUND: It is unclear what factors providers take into account to determine the target blood pressure (BP) after mechanical thrombectomy (MT) in patients who had acute ischemic stroke. We aimed to understand practice patterns of post-MT BP management across institutions in the United States. METHODS: We surveyed StrokeNet institutions providing MT and post-MT care with an online questionnaire, designed to understand institutional post-MT BP management practices. RESULTS: Of 131 potential institutions, 58 completed the survey. The majority of institutions target systolic BP (SBP, n = 53, 91%) during the first 24 hours post-MT (n = 32, 55%) using nicardipine as a first-line agent (n = 43, 74%). At most institutions, BP management is determined by a team of physicians in a collaborative fashion (n = 30, 52%) and individualized on a case-by-case basis (n = 39, 67%) after taking the reperfusion status into account (n = 42, 72%). In patients with successful reperfusion, 36% (n = 21) of the institutions target SBP in the range of 120-139 mm&nbsp;Hg, 21% (n = 12) target 140-159 mm&nbsp;Hg, and 28% (n = 16) would accept any value less than or equal to 180 mm&nbsp;Hg. In patients with unsuccessful reperfusion, 43% (n = 25) would accept any SBP value less than or equal to 180 mm&nbsp;Hg and 10% (n = 6) would target SBP less than or equal to 220&nbsp;mm&nbsp;Hg. CONCLUSIONS: We found that majority of the institutions do not have a standardized protocol for post-MT BP management. There was interinstitutional heterogeneity in the preferred target of SBP post-MT and most institutions target values of SBP lower than 180 mm&nbsp;Hg in post-MT patients. Prospective data and randomized control trial are needed to identify the optimal target BP.;,citation_author=Eva A. Mistry;,citation_author=Stephan A. Mayer;,citation_author=Pooja Khatri;,citation_publication_date=2018-09;,citation_cover_date=2018-09;,citation_year=2018;,citation_issue=9;,citation_doi=10.1016/j.jstrokecerebrovasdis.2018.05.003;,citation_issn=1532-8511;,citation_pmid=29801812;,citation_volume=27;,citation_language=en-US;,citation_journal_title=Journal of Stroke and Cerebrovascular Diseases: The Official Journal of National Stroke Association;">
<meta name="citation_reference" content="citation_title=Blood Pressure Variability and Neurologic Outcome After Endovascular Thrombectomy;,citation_abstract=Background and Purpose— Although higher blood pressure variability (BPV) is associated with worse functional outcome after stroke, this association is not as well established in large vessel occlusion strokes treated with endovascular treatment (EVT). Methods— In this post hoc analysis of BEST (Blood Pressure after Endovascular Therapy for Ischemic Stroke), a prospective, multicenter cohort study of anterior circulation acute ischemic stroke patients undergoing EVT, we determined the association of BPV with poor outcome or death (90-day modified Rankin Scale, 3–6). We calculated BPV during the first 24 hours after EVT for systolic and diastolic BP using 5 methodologies, then divided BPV into tertiles and compared the highest to lowest tertile using logistic regression. Results— Of the 443 patients included in our analysis, 259 (58.5%) had a poor outcome, and 79 (17.8%) died. All measures of BPV were significantly higher in patients with poor outcome or death, but the difference was more pronounced for systolic than diastolic BPV. In the logistic regression, the highest tertile of systolic BPV consistently predicted poor outcome (odds ratio, 1.8–3.5, all P&amp;amp;amp;lt;0.05). The rate of death within 90 days was 10.1% in the tertile with the lowest systolic BPV versus 25.2% in the tertile with the highest BPV (P&amp;lt;0.001). Conclusions— In EVT-treated stroke patients, higher BPV in the first 24 hours is associated with worse 90-day outcome. This association was more robust for systolic BPV. The mechanism by which BPV may exert a negative influence on neurological outcome remains unknown, but the consistency of this association warrants further investigation and potentially intervention.;,citation_author=Eva A. Mistry;,citation_author=Tapan Mehta;,citation_author=Akshitkumar Mistry;,citation_author=Niraj Arora;,citation_author=Amy K. Starosciak;,citation_author=Felipe De Los Rios La Rosa;,citation_author=James Ernest Siegler;,citation_author=Rohan Chitale;,citation_author=Mohammad Anadani;,citation_author=Shadi Yaghi;,citation_author=Pooja Khatri;,citation_author=Adam Havenon;,citation_publication_date=2020-02;,citation_cover_date=2020-02;,citation_year=2020;,citation_issue=2;,citation_doi=10.1161/STROKEAHA.119.027549;,citation_volume=51;,citation_journal_title=Stroke;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=Blood pressure goals after mechanical thrombectomy: A moving target;,citation_author=Eva A. Mistry;,citation_author=Thanh N. Nguyen;,citation_publication_date=2022-11;,citation_cover_date=2022-11;,citation_year=2022;,citation_issue=10363;,citation_doi=10.1016/S0140-6736(22)01987-0;,citation_issn=0140-6736, 1474-547X;,citation_pmid=36341751;,citation_volume=400;,citation_language=en-US;,citation_journal_title=The Lancet;,citation_publisher=Elsevier;">
<meta name="citation_reference" content="citation_title=Blood Pressure Management After Endovascular Therapy for Acute Ischemic Stroke: The BEST-II Randomized Clinical Trial;,citation_abstract=OBJECTIVE To determine the futility of lower SBP targets after endovascular therapy (&amp;amp;amp;lt;140 mm Hg or 160 mm Hg) compared with a higher target (Յ180 mm Hg). DESIGN, SETTING, AND PARTICIPANTS Randomized, open-label, blinded end point, phase 2, futility clinical trial that enrolled 120 patients with acute ischemic stroke who had undergone successful endovascular therapy at 3 US comprehensive stroke centers from January 2020 to March 2022 (final follow-up, June 2022). INTERVENTION After undergoing endovascular therapy, participants were randomized to 1 of 3 SBP targets: 40 to less than 140 mm Hg, 40 to less than 160 mm Hg, and 40 to 180 mm Hg or less (guideline recommended) group, initiated within 60 minutes of recanalization and maintained for 24 hours. MAIN OUTCOMES AND MEASURES Prespecified multiple primary outcomes for the primary futility analysis were follow-up infarct volume measured at 36 (12) hours and utility-weighted modified Rankin Scale (mRS) score (range, 0 [worst] to 1 [best]) at 90 (14) days. Linear regression models were used to test the harm-futility boundaries of a 10-mL increase (slope of 0.5) in the follow-up infarct volume or a 0.10 decrease (slope of -0.005) in the utility-weighted mRS score with each 20-mm Hg SBP target reduction after endovascular therapy (1-sided \alpha = .05). Additional prespecified futility criterion was a less than 25% predicted probability of success for a future 2-group, superiority trial comparing SBP targets of the low- and mid-thresholds with the highthreshold (maximum sample size, 1500 with respect to the utility-weighted mRS score outcome). RESULTS Among 120 patients randomized (mean [SD] age, 69.6 [14.5] years; 69 females [58%]), 113 (94.2%) completed the trial. The mean follow-up infarct volume was 32.4 mL (95% CI, 18.0 to 46.7 mL) for the less than 140–mm Hg group, 50.7 mL (95% CI, 33.7 to 67.7 mL), for the less than 160–mm Hg group, and 46.4 mL (95% CI, 24.5 to 68.2 mL) for the 180–mm Hg or less group. The mean utility-weighted mRS score was 0.51 (95% CI, 0.38 to 0.63) for the less than 140–mm Hg group, 0.47 (95% CI, 0.35 to 0.60) for the less than 160–mm Hg group, and 0.58 (95% CI, 0.46 to 0.71) for the high-target group. The slope of the follow-up infarct volume for each mm Hg decrease in the SBP target, adjusted for the baseline Alberta Stroke Program Early CT score, was -0.29 (95% CI, -0.81 to \varrho; futility P = .99). The slope of the utility-weighted mRS score for each mm Hg decrease in the SBP target after endovascular therapy, adjusted for baseline utility-weighted mRS score, was -0.0019 (95% CI, -\varrho to 0.0017; futility P = .93). Comparing the high-target SBP group with the lower-target groups, the predicted probability of success for a future trial was 25% for the less than 140–mm Hg group and 14% for the 160–mm Hg group. CONCLUSIONS AND RELEVANCE Among patients with acute ischemic stroke, lower SBP targets less than either 140 mm Hg or 160 mm Hg after successful endovascular therapy did not meet prespecified criteria for futility compared with an SBP target of 180 mm Hg or less. However, the findings suggested a low probability of benefit from lower SBP targets after endovascular therapy if tested in a future larger trial.;,citation_author=Eva A. Mistry;,citation_author=Kimberly W. Hart;,citation_author=Larry T. Davis;,citation_author=Yue Gao;,citation_author=Charles J. Prestigiacomo;,citation_author=Shilpi Mittal;,citation_author=Tapan Mehta;,citation_author=Hayden LaFever;,citation_author=Pablo Harker;,citation_author=Hilary E. Wilson-Perez;,citation_author=Kalli A. Beasley;,citation_author=Neeharika Krothapalli;,citation_author=Emily Lippincott;,citation_author=Heather Stefek;,citation_author=Michael Froehler;,citation_author=Rohan Chitale;,citation_author=Matthew Fusco;,citation_author=Aaron Grossman;,citation_author=Peyman Shirani;,citation_author=Matthew Smith;,citation_author=Matthew N. Jaffa;,citation_author=Sharon D. Yeatts;,citation_author=Gregory W. Albers;,citation_author=Jonathan P. Wanderer;,citation_author=Juliana Tolles;,citation_author=Christopher J. Lindsell;,citation_author=Roger J. Lewis;,citation_author=Gordon R. Bernard;,citation_author=Pooja Khatri;,citation_publication_date=2023-09;,citation_cover_date=2023-09;,citation_year=2023;,citation_issue=9;,citation_doi=10.1001/jama.2023.14330;,citation_issn=0098-7484;,citation_volume=330;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Building Evidence on Safety of Thrombolysis for Patients Undergoing Direct Oral Anticoagulant Treatment;,citation_abstract=Nearly 20% of patients with acute ischemic stroke (AIS) are undergoing direct oral anticoagulant (DOAC) treatment at the time of their stroke. Common indications for DOACs among these patients include stroke prevention from atrial fibrillation, treatment of venous and pulmonary thrombosis, and coronary and peripheral atherosclerotic disease. Novel indications for DOAC use are expected to emerge and may increase the proportion of patients with AIS who are undergoing treatment with DOACs. Current US and European acute stroke treatment guidelines recommend withholding intravenous thrombolysis (thrombolysis), a morbidity- and mortality-saving AIS treatment for patients with recent a DOAC use. DOACs have emerged as preferred anticoagulants over vitamin K antagonists due to a favorable safety profile, particularly a lower risk of severe systemic and intracranial hemorrhage (ICH). However, if this translates into a lower risk of hemorrhagic complications of thrombolysis for AIS in the setting of DOAC treatment is yet to be definitively determined as data supporting this practice are limited and heterogenous. The present study by Meinel et al meaningfully advances the field by generating these critical data. Comparative analyses of different patient selection paradigms for thrombolysis in the presence of DOACs provide additional, timely relevance to the study.;,citation_author=Eva A. Mistry;,citation_publication_date=2023-01;,citation_cover_date=2023-01;,citation_year=2023;,citation_doi=10.1001/jamaneurol.2022.4765;,citation_issn=2168-6149;,citation_journal_title=JAMA Neurology;">
<meta name="citation_reference" content="citation_title=National Institutes of Health Stroke Scale as an Outcome in Stroke Research: Value of ANCOVA Over Analyzing Change From Baseline;,citation_abstract=National Institutes of Health Stroke Scale (NIHSS), measured a few hours to days after stroke onset, is an attractive outcome measure for stroke research. NIHSS at the time of presentation (baseline NIHSS) strongly predicts the follow-up NIHSS. Because of the need to account for the baseline NIHSS in the analysis of follow-up NIHSS as an outcome measure, a common and intuitive approach is to define study outcome as the change in NIHSS from baseline to follow-up (∆NIHSS). However, this approach has important limitations. Analyzing ∆NIHSS implies a very strong assumption about the relationship between baseline and follow-up NIHSS that is unlikely to be satisfied, drawing into question the validity of the resulting statistical analysis. This reduces the precision of the estimates of treatment effects and the power of clinical trials that use this approach to analysis. ANCOVA allows for the analysis of follow-up NIHSS as the dependent variable while adjusting for baseline NIHSS as a covariate in the model and addresses several challenges of using ∆NIHSS outcome using simple bivariate comparisons (eg, a t test, Wilcoxon rank-sum, linear regression without adjustment for baseline) for stroke research. In this article, we use clinical trial simulations to illustrate that variability in NIHSS outcome is less when follow-up NIHSS is adjusted for baseline compared to ∆NIHSS and how a reduction in this variability improves the power. We outline additional, important clinical and statistical arguments to support the superiority of ANCOVA using the final measurement of the NIHSS adjusted for baseline over, and caution against using, the simple bivariate comparison of absolute NIHSS change (ie, delta).;,citation_author=Eva A. Mistry;,citation_author=Sharon D. Yeatts;,citation_author=Pooja Khatri;,citation_author=Akshitkumar M. Mistry;,citation_author=Michelle Detry;,citation_author=Kert Viele;,citation_author=Frank E. Harrell;,citation_author=Roger J. Lewis;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_doi=10.1161/STROKEAHA.121.034859;,citation_issn=0039-2499, 1524-4628;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=Saline Versus Balanced Crystalloids for Adults With Aneurysmal Subarachnoid Hemorrhage: A Subgroup Analysis of the SMART Trial;,citation_abstract=Background Whether the composition of intravenous crystalloid solutions affects outcomes in adults with aneurysmal subarachnoid hemorrhage (aSAH) remains unknown. Therefore, we determined whether the use of saline is associated with a lower risk of disability and death in patients with aSAH compared with balanced crystalloids. Methods We conducted a post hoc subgroup analysis of SMART (Isotonic Solutions and Major Adverse Renal Events Trial), a pragmatic, unblinded, cluster-randomized, multiple-crossover clinical trial that enrolled 15&nbsp;802 adults between June 2015 and April 2017. We compared IV administration of saline to balanced crystalloids in consecutively enrolled patients with aSAH aged 18 years or older whose ruptured aneurysm was procedurally secured at a single academic center in the United States. The primary outcome was the score on the modified Rankin scale (range, 0 [no symptoms]–6 [death]) at 90&nbsp;days obtained from a prospective institutional stroke registry. Secondary outcome included death by 90&nbsp;days. Logistic or proportional odds regression models were used to test for between-group differences adjusted for age, hypertension, aSAH grade, and procedure type. Results Of the 79 patients with aSAH procedurally treated during the Isotonic Solutions and Major Adverse Renal Events Trial study period, 78 were enrolled (median age, 58 years; interquartile range, 49–64.5; 64% female), with 41 (53%) assigned to saline and 37 (47%) to balanced crystalloids. Plasma-Lyte was the primary balanced crystalloid used. Among 72 patients with 90-day modified Rankin scale assessment, the adjusted common odds ratio, for the modified Rankin scale was 0.68 (95% CI, 0.28–1.63; P=0.39), with values &amp;amp;amp;lt;1.0 favoring saline. By 90&nbsp;days, 2/39 patients (5%) in the saline group and 9/35 (26%) in the balanced-crystalloids group had died (adjusted common odds ratio, 0.06; 95% CI, 0.00–0.50; P=0.02). Conclusions Among procedurally treated patients with aSAH, the risk of disability or death at 90&nbsp;days did not significantly differ between saline and balanced crystalloids. Death occurred less frequently with saline than balanced crystalloids.;,citation_author=Akshitkumar M. Mistry;,citation_author=Jordan A. Magarik;,citation_author=Michael J. Feldman;,citation_author=Li Wang;,citation_author=Christopher J. Lindsell;,citation_author=Matthew R. Fusco;,citation_author=Rohan V. Chitale;,citation_author=Gordon R. Bernard;,citation_author=Wesley H. Self;,citation_author=Todd W. Rice;,citation_author=Christopher G. Hughes;,citation_author=Eva A. Mistry;,citation_author=Matthew W. Semler;,citation_publication_date=2022-07;,citation_cover_date=2022-07;,citation_year=2022;,citation_issue=4;,citation_doi=10.1161/SVIN.121.000128;,citation_volume=2;,citation_journal_title=Stroke: Vascular and Interventional Neurology;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=Race/ethnicity influences outcomes in young adults with supratentorial intracerebral hemorrhage;,citation_abstract=Objectives We investigated the predictors of functional outcome in young patients enrolled in a multiethnic study of intracerebral hemorrhage (ICH). Methods The Ethnic/Racial Variations in Intracerebral Hemorrhage (ERICH) study is a prospective multicenter study of ICH among adult (age \geq18 years) non-Hispanic white, non-Hispanic black, and Hispanic participants. The study recruited 1,000 participants per racial/ethnic group. The present study utilized the subset of ERICH participants aged &amp;amp;amp;lt;50 years with supratentorial ICH. Functional outcome was ascertained using the modified Rankin Scale (mRS) at 3 months. Logistic regression was used to identify factors associated with poor outcome (mRS 4–6), and analyses were compared by race/ethnicity to identify differences across these groups. Results Of the 3,000 patients with ICH enrolled in ERICH, 418 were studied (mean age 43 years, 69% male), of whom 48 (12%) were white, 173 (41%) were black, and 197 (47%) were Hispanic. For supratentorial ICH, black participants (odds ratio [OR], 0.42; p = 0.046) and Hispanic participants (OR, 0.34; p = 0.01) had better outcomes than white participants after adjustment for other factors associated with poor outcome: age, baseline disability, admission blood pressure, admission Glasgow Coma Scale score, ICH volume, deep ICH location, and intraventricular extension. Conclusions In young patients with supratentorial ICH, black and Hispanic race/ethnicity is associated with better functional outcomes, compared with white race. Additional studies are needed to identify the biological and social mediators of this association.;,citation_author=Laura C. Miyares;,citation_author=Guido J. Falcone;,citation_author=Audrey Leasure;,citation_author=Opeolu Adeoye;,citation_author=Fu-Dong Shi;,citation_author=Steven J. Kittner;,citation_author=Carl Langefeld;,citation_author=Achala Vagal;,citation_author=Kevin N. Sheth;,citation_author=Daniel Woo;,citation_publication_date=2020-03;,citation_cover_date=2020-03;,citation_year=2020;,citation_issue=12;,citation_doi=10.1212/WNL.0000000000008930;,citation_issn=0028-3878, 1526-632X;,citation_volume=94;,citation_language=en-US;,citation_journal_title=Neurology;">
<meta name="citation_reference" content="citation_title=CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials;,citation_abstract=Overwhelming evidence shows the quality of reporting of randomised controlled trials (RCTs) is not optimal. Without transparent reporting, readers cannot judge the reliability and validity of trial findings nor extract information for systematic reviews. Recent methodological analyses indicate that inadequate reporting and design are associated with biased estimates of treatment effects. Such systematic error is seriously damaging to RCTs, which are considered the gold standard for evaluating interventions because of their ability to minimise or avoid bias. A group of scientists and editors developed the CONSORT (Consolidated Standards of Reporting Trials) statement to improve the quality of reporting of RCTs. It was first published in 1996 and updated in 2001. The statement consists of a checklist and flow diagram that authors can use for reporting an RCT. Many leading medical journals and major international editorial groups have endorsed the CONSORT statement. The statement facilitates critical appraisal and interpretation of RCTs. During the 2001 CONSORT revision, it became clear that explanation and elaboration of the principles underlying the CONSORT statement would help investigators and others to write or appraise trial reports. A CONSORT explanation and elaboration article was published in 2001 alongside the 2001 version of the CONSORT statement. After an expert meeting in January 2007, the CONSORT statement has been further revised and is published as the CONSORT 2010 Statement. This update improves the wording and clarity of the previous checklist and incorporates recommendations related to topics that have only recently received recognition, such as selective outcome reporting bias. This explanatory and elaboration document—intended to enhance the use, understanding, and dissemination of the CONSORT statement—has also been extensively revised. It presents the meaning and rationale for each new and updated checklist item providing examples of good reporting and, where possible, references to relevant empirical studies. Several examples of flow diagrams are included. The CONSORT 2010 Statement, this revised explanatory and elaboration document, and the associated website (www. consort-statement.org) should be helpful resources to improve reporting of randomised trials.;,citation_author=D. Moher;,citation_author=S. Hopewell;,citation_author=K. F Schulz;,citation_author=V. Montori;,citation_author=P. C Gotzsche;,citation_author=P J Devereaux;,citation_author=D. Elbourne;,citation_author=M. Egger;,citation_author=D. G Altman;,citation_publication_date=2010-03;,citation_cover_date=2010-03;,citation_year=2010;,citation_issue=mar23 1;,citation_doi=10.1136/bmj.c869;,citation_issn=0959-8138, 1468-5833;,citation_volume=340;,citation_language=en-US;,citation_journal_title=BMJ;">
<meta name="citation_reference" content="citation_title=Effects of Hypothetical Interventions on Ischemic Stroke Using Parametric G-Formula;,citation_abstract=Background and Purpose—Standard analytic approaches (eg, logistic regression) fail to adequately control for timedependent confounding and, therefore, may yield biased estimates of the total effect of the exposure on the outcome. In the present study, we estimate the effect of body mass index, intentional physical activity, HDL (high-density lipoprotein) cholesterol, LDL (low-density lipoprotein) cholesterol, hypertension, and cigarette smoking on the 11-year risk of ischemic stroke by sex using the parametric g-formula to control time-dependent confounders. Methods—Using data from the MESA (Multi-Ethnic Study of Atherosclerosis), we followed 6809 men and women aged 45 to 84 years. We estimated the risk of stroke under 6 hypothetical interventions: maintaining body mass index &amp;amp;amp;lt;25 kg/ m2, maintaining normotension (systolic blood pressure &amp;lt;140 and diastolic <90 mm Hg), quitting smoking, maintaining HDL &amp;gt;1.55 mmol/L, maintaining LDL <3.11 mmol/L, and exercising at least 210 minutes per week. The effects of joint hypothetical interventions were also simulated. Results—In men, the 11-year risk of ischemic stroke would be reduced by 85% (95% CI, 66–96) for all 6 hypothetical interventions. In women, this same effect was estimated as 55% (95% CI, 6–82). Conclusions—The hypothetical interventions explored in our study resulted in risk reduction in both men and women. \mkern1mu(Stroke. 2019;50:3286-3288. DOI: 10.1161/STROKEAHA.119.025749.);,citation_author=Yaser Mokhayeri;,citation_author=Seyed Saeed Hashemi-Nazari;,citation_author=Soheila Khodakarim;,citation_author=Saeid Safiri;,citation_author=Nasrin Mansournia;,citation_author=Mohammad Ali Mansournia;,citation_author=Jay S. Kaufman;,citation_author=Ashley I. Naimi;,citation_publication_date=2019-11;,citation_cover_date=2019-11;,citation_year=2019;,citation_issue=11;,citation_doi=10.1161/STROKEAHA.119.025749;,citation_issn=0039-2499, 1524-4628;,citation_volume=50;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=New Modes of Learning Enabled by AI Chatbots: Three Methods and Assignments;,citation_abstract=Chatbots are able to produce high-quality, sophisticated text in natural language. The authors of this paper believe that AI can be used to overcome three barriers to learning in the classroom: improving transfer, breaking the illusion of explanatory depth, and training students to critically evaluate explanations. The paper provides background information and techniques on how AI can be used to overcome these barriers and includes prompts and assignments that teachers can incorporate into their teaching. The goal is to help teachers use the capabilities and drawbacks of AI to improve learning;,citation_author=Ethan R. Mollick;,citation_author=Lilach Mollick;,citation_publication_date=2022-12;,citation_cover_date=2022-12;,citation_year=2022;,citation_doi=10.2139/ssrn.4300783;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: A randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion;,citation_author=Andrew J Molyneux;,citation_author=Richard SC Kerr;,citation_author=Ly-Mee Yu;,citation_author=Mike Clarke;,citation_author=Mary Sneade;,citation_author=Julia A Yarnold;,citation_author=Peter Sandercock;,citation_publication_date=2005-09;,citation_cover_date=2005-09;,citation_year=2005;,citation_issue=9488;,citation_doi=10.1016/S0140-6736(05)67214-5;,citation_issn=01406736;,citation_volume=366;,citation_language=en-US;,citation_journal_title=The Lancet;">
<meta name="citation_reference" content="citation_title=How Conditioning on Posttreatment Variables Can Ruin Your Experiment and What to Do about It: STOP CONDITIONING ON POSTTREATMENT VARIABLES IN EXPERIMENTS;,citation_abstract=In principle, experiments offer a straightforward method for social scientists to accurately estimate causal effects. However, scholars often unwittingly distort treatment effect estimates by conditioning on variables that could be affected by their experimental manipulation. Typical examples include controlling for posttreatment variables in statistical models, eliminating observations based on posttreatment criteria, or subsetting the data based on posttreatment variables. Though these modeling choices are intended to address common problems encountered when conducting experiments, they can bias estimates of causal effects. Moreover, problems associated with conditioning on posttreatment variables remain largely unrecognized in the field, which we show frequently publishes experimental studies using these practices in our discipline’s most prestigious journals. We demonstrate the severity of experimental posttreatment bias analytically and document the magnitude of the potential distortions it induces using visualizations and reanalyses of real-world data. We conclude by providing applied researchers with recommendations for best practice.;,citation_author=Jacob M. Montgomery;,citation_author=Brendan Nyhan;,citation_author=Michelle Torres;,citation_publication_date=2018-07;,citation_cover_date=2018-07;,citation_year=2018;,citation_issue=3;,citation_doi=10.1111/ajps.12357;,citation_issn=00925853;,citation_volume=62;,citation_language=en-US;,citation_journal_title=American Journal of Political Science;">
<meta name="citation_reference" content="citation_title=Accuracy of Practitioner Estimates of Probability of Diagnosis Before and After Testing;,citation_abstract=OBJECTIVE To explore practitioner understanding of diagnostic reasoning. DESIGN, SETTING, AND PARTICIPANTS In this survey study, 723 practitioners at outpatient clinics in 8 US states were asked to estimate the probability of disease for 4 scenarios common in primary care (pneumonia, cardiac ischemia, breast cancer screening, and urinary tract infection) and the association of positive and negative test results with disease probability from June 1, 2018, to November 26, 2019. Of these practitioners, 585 responded to the survey, and 553 answered all of the questions. An expert panel developed the survey and determined correct responses based on literature review. RESULTS A total of 553 (290 resident physicians, 202 attending physicians, and 61 nurse practitioners and physician assistants) of 723 practitioners (76.5%) fully completed the survey (median age, 32 years; interquartile range, 29-44 years; 293 female [53.0%]; 296 [53.5%] White). Pretest probability was overestimated in all scenarios. Probabilities of disease after positive results were overestimated as follows: pneumonia after positive radiology results, 95% (evidence range, 46%-65%; comparison P &amp;amp;amp;lt; .001); breast cancer after positive mammography results, 50% (evidence range, 3%-9%; P &amp;lt; .001); cardiac ischemia after positive stress test result, 70% (evidence range, 2%-11%; P < .001); and urinary tract infection after positive urine culture result, 80% (evidence range, 0%-8.3%; P < .001). Overestimates of probability of disease with negative results were also observed as follows: pneumonia after negative radiography results, 50% (evidence range, 10%-19%; P < .001); breast cancer after negative mammography results, 5% (evidence range, <0.05%; P < .001); cardiac ischemia after negative stress test result, 5% (evidence range, 0.43%-2.5%; P < .001); and urinary tract infection after negative urine culture result, 5% (evidence range, 0%-0.11%; P < .001). Probability adjustments in response to test results varied from accurate to overestimates of risk by type of test (imputed median positive and negative likelihood ratios [LRs] for practitioners for chest radiography for pneumonia: positive LR, 4.8; evidence, 2.6; negative LR, 0.3; evidence, 0.3; mammography for breast cancer: positive LR, 44.3; evidence range, 13.0-33.0; negative LR, 1.0; evidence range, 0.05-0.24; exercise stress test for cardiac ischemia: positive LR, 21.0; evidence range, 2.0-2.7; negative LR, 0.6; evidence range, 0.5-0.6; urine culture for urinary tract infection: positive LR, 9.0; evidence, 9.0; negative LR, 0.1; evidence, 0.1). CONCLUSIONS AND RELEVANCE This survey study suggests that for common diseases and tests, practitioners overestimate the probability of disease before and after testing. Pretest probability was overestimated in all scenarios, whereas adjustment in probability after a positive or negative result varied by test. Widespread overestimates of the probability of disease likely contribute to overdiagnosis and overuse.;,citation_author=Daniel J. Morgan;,citation_author=Lisa Pineles;,citation_author=Jill Owczarzak;,citation_author=Larry Magder;,citation_author=Laura Scherer;,citation_author=Jessica P. Brown;,citation_author=Chris Pfeiffer;,citation_author=Chris Terndrup;,citation_author=Luci Leykum;,citation_author=David Feldstein;,citation_author=Andrew Foy;,citation_author=Deborah Stevens;,citation_author=Christina Koch;,citation_author=Max Masnick;,citation_author=Scott Weisenberg;,citation_author=Deborah Korenstein;,citation_publication_date=2021-06;,citation_cover_date=2021-06;,citation_year=2021;,citation_issue=6;,citation_doi=10.1001/jamainternmed.2021.0269;,citation_issn=2168-6106;,citation_volume=181;,citation_language=en-US;,citation_journal_title=JAMA Internal Medicine;">
<meta name="citation_reference" content="citation_title=Clinician Conceptualization of the Benefits of Treatments for Individual Patients;,citation_abstract=OBJECTIVE To explore clinicians’ conceptualizations of the chance that treatments will decrease the risk of disease outcomes. DESIGN, SETTING, AND PARTICIPANTS This survey study of attending and resident physicians, nurse practitioners, and physician assistants was conducted in outpatient clinical settings in 8 US states from June 2018 to November 2019. The survey was an in-person, paper, 26-item survey in which clinicians were asked to estimate the probability of adverse disease outcomes and expected effects of therapies for diseases common in primary care. MAIN OUTCOMES AND MEASURES Estimated chance that treatments would benefit an individual patient. RESULTS Of 723 clinicians, 585 (81%) responded, and 542 completed all the questions necessary for analysis, with a median (interquartile range [IQR]) age of 32 (29-44) years, 287 (53%) women, and 294 (54%) White participants. Clinicians consistently overestimated the chance that treatments would benefit an individual patient. The median (IQR) estimated chance that warfarin would prevent a stroke in the next year was 50% (5%-80%) compared with scientific evidence, which indicates an absolute risk reduction (ARR) of 0.2% to 1.0% based on a relative risk reduction (RRR) of 39% to 50%. The median (IQR) estimated chance that antihypertensive therapy would prevent a cardiovascular event within 5 years was 30% (10%-70%) vs evidence of an ARR of 0% to 3% based on an RRR of 0% to 28%. The median (IQR) estimated chance that bisphosphonate therapy would prevent a hip fracture in the next 5 years was 40% (10%-60%) vs evidence of ARR of 0.1% to 0.4% based on an RRR of 20% to 40%. The median (IQR) estimated chance that moderate-intensity statin therapy would prevent a cardiovascular event in the next 5 years was 20% (IQR 5%-50%) vs evidence of an ARR of 0.3% to 2% based on an RRR of 19% to 33%. Estimates of the chance that a treatment would prevent an adverse outcome exceeded estimates of the absolute chance of that outcome for 60% to 70% of clinicians. Clinicians whose overestimations were greater were more likely to report using that treatment for patients in their practice (eg, use of warfarin: correlation coefficient, 0.46; 95% CI, 0.40-0.53; P &amp;amp;amp;lt; .001). CONCLUSIONS AND RELEVANCE In this survey study, clinicians significantly overestimated the benefits of treatment to individual patients. Clinicians with greater overestimates were more likely to report using treatments in actual patients.;,citation_author=Daniel J. Morgan;,citation_author=Lisa Pineles;,citation_author=Jill Owczarzak;,citation_author=Larry Magder;,citation_author=Laura Scherer;,citation_author=Jessica P. Brown;,citation_author=Chris Pfeiffer;,citation_author=Chris Terndrup;,citation_author=Luci Leykum;,citation_author=David Feldstein;,citation_author=Andrew Foy;,citation_author=Deborah Stevens;,citation_author=Christina Koch;,citation_author=Max Masnick;,citation_author=Scott Weisenberg;,citation_author=Deborah Korenstein;,citation_publication_date=2021-07;,citation_cover_date=2021-07;,citation_year=2021;,citation_issue=7;,citation_doi=10.1001/jamanetworkopen.2021.19747;,citation_issn=2574-3805;,citation_volume=4;,citation_language=en-US;,citation_journal_title=JAMA Network Open;">
<meta name="citation_reference" content="citation_title=Handbook of Causal Analysis for Social Research;,citation_abstract=This chapter discusses the use of directed acyclic graphs (DAGs) for causal inference in the observational social sciences. It focuses on DAGs’ main uses, discusses central principles, and gives applied examples. DAGs are visual representations of qualitative causal assumptions: They encode researchers’ beliefs about how the world works. Straightforward rules map these causal assumptions onto the associations and independencies in observable data. The two primary uses of DAGs are (1) determining the identifiability of causal effects from observed data and (2) deriving the testable implications of a causal model. Concepts covered in this chapter include identification, d-separation, confounding, endogenous selection, and overcontrol. Illustrative applications then demonstrate that conditioning on variables at any stage in a causal process can induce as well as remove bias, that confounding is a fundamentally causal rather than an associational concept, that conventional approaches to causal mediation analysis are often biased, and that causal inference in social networks inherently faces endogenous selection bias. The chapter discusses several graphical criteria for the identification of causal effects of single, time-point treatments (including the famous backdoor criterion), as well identification criteria for multiple, time-varying treatments.;,citation_editor=Stephen L. Morgan;,citation_publication_date=2013;,citation_cover_date=2013;,citation_year=2013;,citation_doi=10.1007/978-94-007-6094-3;,citation_isbn=978-94-007-6093-6 978-94-007-6094-3;,citation_language=en-US;,citation_series_title=Handbooks of Sociology and Social Research;">
<meta name="citation_reference" content="citation_title=Guidelines for the Management of Spontaneous Intracerebral Hemorrhage;,citation_abstract=Purpose—The aim of this guideline is to present current and comprehensive recommendations for the diagnosis and treatment of acute spontaneous intracerebral hemorrhage. Methods—A formal literature search of MEDLINE was performed. Data were synthesized with the use of evidence tables. Writing committee members met by teleconference to discuss data-derived recommendations. The American Heart Association Stroke Council’s Levels of Evidence grading algorithm was used to grade each recommendation. Prerelease review of the draft guideline was performed by 6 expert peer reviewers and by the members of the Stroke Council Scientific Statements Oversight Committee and Stroke Council Leadership Committee. It is intended that this guideline be fully updated in 3 years’ time. Results—Evidence-based guidelines are presented for the care of patients presenting with intracerebral hemorrhage. The focus was subdivided into diagnosis, hemostasis, blood pressure management, inpatient and nursing management, preventing medical comorbidities, surgical treatment, outcome prediction, rehabilitation, prevention of recurrence, and future considerations. Conclusions—Intracerebral hemorrhage is a serious medical condition for which outcome can be impacted by early, aggressive care. The guidelines offer a framework for goal-directed treatment of the patient with intracerebral hemorrhage.;,citation_author=Lewis B. Morgenstern;,citation_author=J. Claude Hemphill;,citation_author=Craig Anderson;,citation_author=Kyra Becker;,citation_author=Joseph P. Broderick;,citation_author=E. Sander Connolly;,citation_author=Steven M. Greenberg;,citation_author=James N. Huang;,citation_author=R. Loch Macdonald;,citation_author=Steven R. Messé;,citation_author=Pamela H. Mitchell;,citation_author=Magdy Selim;,citation_author=Rafael J. Tamargo;,citation_publication_date=2010-09;,citation_cover_date=2010-09;,citation_year=2010;,citation_issue=9;,citation_doi=10.1161/STR.0b013e3181ec611b;,citation_volume=41;,citation_journal_title=Stroke;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=Intracerebral haemorrhage expansion: Definitions, predictors, and prevention;,citation_author=Andrea Morotti;,citation_author=Gregoire Boulouis;,citation_author=Dar Dowlatshahi;,citation_author=Qi Li;,citation_author=Michel Shamy;,citation_author=Rustam Al-Shahi Salman;,citation_author=Jonathan Rosand;,citation_author=Charlotte Cordonnier;,citation_author=Joshua N. Goldstein;,citation_author=Andreas Charidimou;,citation_publication_date=2022-10;,citation_cover_date=2022-10;,citation_year=2022;,citation_issue=0;,citation_doi=10.1016/S1474-4422(22)00338-6;,citation_issn=1474-4422, 1474-4465;,citation_pmid=36309041;,citation_volume=0;,citation_language=en-US;,citation_journal_title=The Lancet Neurology;,citation_publisher=Elsevier;">
<meta name="citation_reference" content="citation_title=White Matter Hyperintensities and Blood Pressure Lowering in Acute Intracerebral Hemorrhage: A Secondary Analysis of the ATACH-2 Trial;,citation_abstract=It is not clear whether subsets of patients with intracerebral hemorrhage (ICH) benefit from intensive blood pressure (BP) lowering. We evaluated whether white matter hyperintensities (WMH) burden influences response to this therapy.;,citation_author=Andrea Morotti;,citation_author=Ashkan Shoamanesh;,citation_author=Jamary Oliveira-Filho;,citation_author=Frieder Schlunk;,citation_author=Javier M. Romero;,citation_author=Michael Jessel;,citation_author=Alison Ayres;,citation_author=Anastasia Vashkevich;,citation_author=Kristin Schwab;,citation_author=Christy Cassarly;,citation_author=Renee’ Hebert Martin;,citation_author=Steven M. Greenberg;,citation_author=Adnan I. Qureshi;,citation_author=Jonathan Rosand;,citation_author=Joshua N. Goldstein;,citation_author=Antihypertensive Treatment of Acute Cerebral Hemorrhage 2 (ATACH-2) and the Neurological Emergencies Treatment Trials (NETT) Network Investigators;,citation_publication_date=2020-02;,citation_cover_date=2020-02;,citation_year=2020;,citation_issue=1;,citation_doi=10.1007/s12028-019-00761-0;,citation_issn=1556-0961;,citation_volume=32;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=The effect of platelet transfusion on functional independence and mortality after antiplatelet therapy associated spontaneous intracerebral hemorrhage: A systematic review and meta-analysis;,citation_abstract=INTRODUCTION: The practice of platelet transfusion to mitigate the deleterious effects of antiplatelet agents on spontaneous intracerebral hemorrhage (ICH) remains common. However, the effect of antiplatelet agents on patients with ICH is still controversial and transfusing platelets is not without risk. We performed a meta-analysis in order to determine the effect of platelet transfusion on antiplatelet agent associated ICH. METHODS: We queried PubMed, Embase, and Scopus databases to identify cohort studies, case-control studies, and randomized control trials. Study quality was graded by the Newcastle-Ottawa Scale and Cochrane Risk of Bias tool, as appropriate. Outcomes of interest included functional independence as measured by the modified Rankin Scale and mortality. We compared patients with antiplatelet agent associated ICH who received platelet transfusion to those that did not. RESULTS: We identified 625 articles. After reviewing 44 full text articles, 5 were deemed appropriate for meta-analysis, including 4 cohort studies and one randomized control trial. Considerable heterogeneity was present among the studies (I2&nbsp;&amp;amp;amp;gt;~81% for all analyses). We did not find a significant effect of platelet transfusions on functional independence (Odds Ratio [OR] 1.3, 95% CI.0.45-3.9) or mortality (OR 0.58, 95% Confidence Interval [CI] 0.12-2.6). CONCLUSION: We found no evidence for an effect of platelet transfusions on functional independence or mortality following antiplatelet associated ICH. More randomized trials are needed to evaluate platelet transfusion in patients with ICH and proven reduced platelet activity or those requiring neurosurgical intervention.;,citation_author=Nicholas A. Morris;,citation_author=Nikhil Patel;,citation_author=Samuel M. Galvagno;,citation_author=Emilie Ludeman;,citation_author=Gary T. Schwartzbauer;,citation_author=Ali Pourmand;,citation_author=Quincy K. Tran;,citation_publication_date=2020-10;,citation_cover_date=2020-10;,citation_year=2020;,citation_doi=10.1016/j.jns.2020.117075;,citation_issn=1878-5883;,citation_pmid=32763508;,citation_volume=417;,citation_language=en-US;,citation_journal_title=Journal of the Neurological Sciences;">
<meta name="citation_reference" content="citation_title=Using simulation studies to evaluate statistical methods;,citation_author=Tim P. Morris;,citation_author=Ian R. White;,citation_author=Michael J. Crowther;,citation_publication_date=2019-05;,citation_cover_date=2019-05;,citation_year=2019;,citation_issue=11;,citation_doi=10.1002/sim.8086;,citation_issn=0277-6715, 1097-0258;,citation_volume=38;,citation_language=en-US;,citation_journal_title=Statistics in Medicine;">
<meta name="citation_reference" content="citation_title=What’s Wrong With Advance Care Planning?;,citation_author=R. Sean Morrison;,citation_author=Diane E. Meier;,citation_author=Robert M. Arnold;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_doi=10.1001/jama.2021.16430;,citation_issn=0098-7484;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Neuroprosthesis for Decoding Speech in a Paralyzed Person with Anarthria;,citation_abstract=BACKGROUND Technology to restore the ability to communicate in paralyzed persons who cannot speak has the potential to improve autonomy and quality of life. An approach that decodes words and sentences directly from the cerebral cortical activity of such patients may represent an advancement over existing methods for assisted communication. METHODS We implanted a subdural, high-density, multielectrode array over the area of the sensorimotor cortex that controls speech in a person with anarthria (the loss of the ability to articulate speech) and spastic quadriparesis caused by a brain-stem stroke. Over the course of 48 sessions, we recorded 22 hours of cortical activity while the participant attempted to say individual words from a vocabulary set of 50 words. We used deep-learning algorithms to create computational models for the detection and classification of words from patterns in the recorded cortical activity. We applied these computational models, as well as a natural-language model that yielded next-word probabilities given the preceding words in a sequence, to decode full sentences as the participant attempted to say them. From the Department of Neurological Surgery (D.A.M., S.L.M., J.R.L., G.K.A., J.G.M., P.F.S., J.C., M.E.D., E.F.C.), the Weill Institute for Neuroscience (D.A.M., S.L.M., J.R.L., G.K.A., J.G.M., P.F.S., J.C., K.G., E.F.C.), and the Departments of Rehabilitation Services (P.M.L.) and Neurology (G.M.A., A.T.-C., K.G.), University of California, San Francisco (UCSF), San Francisco, and the Graduate Program in Bioengineering, University of California, Berkeley–UCSF, Berkeley (S.L.M., J.R.L., E.F.C.). Address reprint requests to Dr. Chang at edward.chang@ucsf.edu. Dr. Moses, Mr. Metzger, and Ms. Liu contributed equally to this article. N Engl J Med 2021;385:217-27. DOI: 10.1056/NEJMoa2027540 Copyright © 2021 Massachusetts Medical Society. RESULTS We decoded sentences from the participant’s cortical activity in real time at a median rate of 15.2 words per minute, with a median word error rate of 25.6%. In post hoc analyses, we detected 98% of the attempts by the participant to produce individual words, and we classified words with 47.1% accuracy using cortical signals that were stable throughout the 81-week study period. CONCLUSIONS In a person with anarthria and spastic quadriparesis caused by a brain-stem stroke, words and sentences were decoded directly from cortical activity during attempted speech with the use of deep-learning models and a natural-language model. (Funded by Facebook and others; ClinicalTrials.gov number, NCT03698149.);,citation_author=David A. Moses;,citation_author=Sean L. Metzger;,citation_author=Jessie R. Liu;,citation_author=Gopala K. Anumanchipalli;,citation_author=Joseph G. Makin;,citation_author=Pengfei F. Sun;,citation_author=Josh Chartier;,citation_author=Maximilian E. Dougherty;,citation_author=Patricia M. Liu;,citation_author=Gary M. Abrams;,citation_author=Adelyn Tu-Chan;,citation_author=Karunesh Ganguly;,citation_author=Edward F. Chang;,citation_publication_date=2021-07;,citation_cover_date=2021-07;,citation_year=2021;,citation_issue=3;,citation_doi=10.1056/NEJMoa2027540;,citation_issn=0028-4793, 1533-4406;,citation_volume=385;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Early Mobilization of Critical Care Patients — Still More to Learn;,citation_abstract=Each year, intensive care unit (ICU)–acquired weakness occurs in approximately 1 million critically ill patients who are undergoing mechanical ventilation worldwide.1 ICU-acquired weakness begins early in the course of critical illness and is related to multiple mechanisms, including deconditioning, myopathy, and neuropathy. Its development is associated with several deleterious outcomes, including increased mortality and diminished long-term quality of life.2 By improving muscle strength, endurance, and the performance of functional activities, early patient mobilization may be a treatment option for ICU-acquired weakness. However, previous studies examining early mobilization have shown conflicting results.3-7 As reported now in the Journal, the Treatment of . . .;,citation_author=Marc Moss;,citation_publication_date=2022-11;,citation_cover_date=2022-11;,citation_year=2022;,citation_issue=19;,citation_doi=10.1056/NEJMe2212360;,citation_issn=0028-4793;,citation_volume=387;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Decompressive Hemicraniectomy in the Modern Era of Mechanical Thrombectomy;,citation_author=Nikolaos Mouchtouris;,citation_author=Fadi Al Saiegh;,citation_author=Michael P. Baldassari;,citation_author=Lohit Velagapudi;,citation_author=Omaditya Khanna;,citation_author=Karim Hafazalla;,citation_author=David Nauheim;,citation_author=Ahmad Sweid;,citation_author=Victor Romo;,citation_author=M. Reid Gooch;,citation_author=Stavropoula I. Tjoumakaris;,citation_author=Pascal Jabbour;,citation_author=Robert H. Rosenwasser;,citation_author=Fred Rincon;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_doi=10.1016/j.wneu.2021.08.138;,citation_issn=18788750;,citation_language=en-US;,citation_journal_title=World Neurosurgery;">
<meta name="citation_reference" content="citation_title=Blood pressure control and clinical outcomes in acute intracerebral haemorrhage: A preplanned pooled analysis of individual participant data;,citation_abstract=BACKGROUND: Uncertainty persists over the effects of blood pressure lowering in acute intracerebral haemorrhage. We aimed to combine individual patient-level data from the two largest randomised controlled trials of blood pressure lowering strategies in patients with acute intracerebral haemorrhage to determine the strength of associations between key measures of systolic blood pressure control and safety and efficacy outcomes. METHODS: We did a preplanned pooled analysis of individual patient-level data acquired from the main phase of the Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT2) and the second Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH-II) trial. These trials included adult patients aged 19-99 years with spontaneous (non-traumatic) intracerebral haemorrhage and elevated systolic blood pressure, without a clear indication or contraindication to treatment. Patients were excluded if they had a structural cerebral cause for the intracerebral haemorrhage, had a low score (3-5) on the Glasgow Coma Scale, or required immediate neurosurgery. Our primary analysis assessed the independent associations between three post-randomisation systolic blood pressure summary measures-magnitude of reduction in 1 h, mean achieved systolic blood pressure, and variability in systolic blood pressure between 1 h and 24 h-and the primary outcome of functional status, as defined by the distribution of scores on the modified Rankin Scale at 90 days post-randomisation. We analysed the systolic blood pressure measures as continuous variables using generalised linear mixed models, adjusted for baseline covariables and trial. The primary and safety analyses were done in a modified intention-to-treat population, which only included patients with sufficient data on systolic blood pressure. FINDINGS: 3829 patients (mean age 63\cdot1 years [SD 12\cdot9], 1429 [37%] women, and 2490 [65%] Asian ethnicity) were randomly assigned in INTERACT2 and ATACH-II, with a median neurological impairment defined by scores on the National Institutes of Health Stroke Scale of 11 (IQR 6-16) and median time from the onset of symptoms of intracerebral haemorrhage to randomisation of 3\cdot6 h (2\cdot7-4\cdot4). We excluded 20 patients with insufficient or no systolic blood pressure data, and we imputed missing systolic blood pressure data in 23 (1%) of the remaining 3809 patients. Overall, the mean magnitude of early systolic blood pressure reduction was 29 mm Hg (SD 22), and subsequent mean systolic blood pressure achieved was 147 mm Hg (15) and variability in systolic blood pressure was 14 mm Hg (8). Achieved systolic blood pressure was continuously associated with functional status (improvement per 10 mm Hg increase adjusted odds ratio [OR] 0\cdot90 [95% CI 0\cdot87-0\cdot94], p&amp;amp;amp;lt;0\cdot0001). Symptomatic hypotension occurred in 28 (1%) patients, renal serious adverse events occurred in 26 (1%) patients, and cardiac serious adverse events occurred in 99 (3%) patients. INTERPRETATION: Our pooled analyses indicate that achieving early and stable systolic blood pressure seems to be safe and associated with favourable outcomes in patients with acute intracerebral haemorrhage of predominantly mild-to-moderate severity. FUNDING: None.;,citation_author=Tom J. Moullaali;,citation_author=Xia Wang;,citation_author=Reneé H. Martin;,citation_author=Virginia B. Shipes;,citation_author=Thompson G. Robinson;,citation_author=John Chalmers;,citation_author=Jose I. Suarez;,citation_author=Adnan I. Qureshi;,citation_author=Yuko Y. Palesch;,citation_author=Craig S. Anderson;,citation_publication_date=2019-09;,citation_cover_date=2019-09;,citation_year=2019;,citation_issue=9;,citation_doi=10.1016/S1474-4422(19)30196-6;,citation_issn=1474-4465;,citation_pmid=31397290;,citation_volume=18;,citation_language=en-US;,citation_journal_title=The Lancet. Neurology;">
<meta name="citation_reference" content="citation_title=Trial of Early, Goal-Directed Resuscitation for Septic Shock;,citation_abstract=The incidence of severe sepsis and septic shock in adults is estimated to range from 56 to 91 per 100,000 population per year.1 Affected patients have high rates of death, complications, and resource utilization.2–5 Since 2002, the Surviving Sepsis Campaign (SSC) has promoted best practice, including early recognition, source control, appropriate and timely antibiotic administration, and resuscitation with intravenous fluids and vasoactive drugs.6–8 Resuscitation guidance is largely based on a 2001 single-center, proof-of-concept study by Rivers et al., which indicated that protocolized delivery of 6 hours of early, goal-directed therapy (EGDT) to patients presenting to the emergency department . . .;,citation_author=Paul R. Mouncey;,citation_author=Tiffany M. Osborn;,citation_author=G. Sarah Power;,citation_author=David A. Harrison;,citation_author=M. Zia Sadique;,citation_author=Richard D. Grieve;,citation_author=Rahi Jahan;,citation_author=Sheila E. Harvey;,citation_author=Derek Bell;,citation_author=Julian F. Bion;,citation_author=Timothy J. Coats;,citation_author=Mervyn Singer;,citation_author=J. Duncan Young;,citation_author=Kathryn M. Rowan;,citation_publication_date=2015-04;,citation_cover_date=2015-04;,citation_year=2015;,citation_issue=14;,citation_doi=10.1056/NEJMoa1500896;,citation_issn=0028-4793;,citation_pmid=25776532;,citation_volume=372;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Comparative Effectiveness and Safety of Seizure Prophylaxis Among Adults After Acute Ischemic Stroke;,citation_abstract=Background: Older adults occasionally receive seizure prophylaxis in an acute ischemic stroke (AIS) setting, despite safety concerns. There are no trial data available about the net impact of early seizure prophylaxis on post-AIS survival. Methods: Using a stroke registry (American Heart Association’s Get With The Guidelines) individually linked to electronic health records, we examined the effect of initiating seizure prophylaxis (ie, epilepsy-specific antiseizure drugs) within 7 days of an AIS admission versus not initiating in patients \geq65 years admitted for a new, nonsevere AIS (National Institutes of Health Stroke Severity score \leq20) between 2014 and 2021 with no recorded use of epilepsy-specific antiseizure drugs in the previous 3 months. We addressed confounding by using inverse-probability weights. We performed standardization accounting for pertinent clinical and health care factors (eg, National Institutes of Health Stroke Severity scale, prescription counts, seizure-like events). Results: The study sample included 151 patients who received antiseizure drugs and 3020 who did not. The crude 30-day mortality risks were 219 deaths per 1000 patients among epilepsy-specific antiseizure drugs initiators and 120 deaths per 1000 among noninitiators. After standardization, the estimated mortality was 251 (95% CI, 190–307) deaths per 1000 among initiators and 120 (95% CI, 86–144) deaths per 1000 among noninitiators, corresponding to a risk difference of 131 (95% CI, 65–200) excess deaths per 1000 patients. In the prespecified subgroup analyses, the risk difference was 52 (95% CI, 11–72) among patients with minor AIS and 138 (95% CI, 52–222) among moderate-to-severe AIS patients. Similarly, the risk differences were 86 (95% CI, 18–118) and 157 (95% CI, 57–219) among patients aged 65 to 74 years and \geq75 years, respectively. Conclusions: There was a higher risk of 30-day mortality associated with initiating versus not initiating seizure prophylaxis within 7 days post-AIS. This study does not support the role of seizure prophylaxis in reducing 30-day poststroke mortality.;,citation_author=Lidia M. V. R. Moura;,citation_author=Maria A. Donahue;,citation_author=Zhiyu Yan;,citation_author=Louisa H. Smith;,citation_author=John Hsu;,citation_author=Joseph P. Newhouse;,citation_author=Lee H. Schwamm;,citation_author=Sebastien Haneuse;,citation_author=Sonia Hernandez-Diaz;,citation_author=Deborah Blacker;,citation_publication_date=2023-02;,citation_cover_date=2023-02;,citation_year=2023;,citation_issue=2;,citation_doi=10.1161/STROKEAHA.122.039946;,citation_volume=54;,citation_journal_title=Stroke;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=Liberation From the &amp;amp;amp;lt;i&amp;gt;P&amp;lt;/i&amp;gt; Value’s Tyranny;,citation_author=Lem Moyé;,citation_author=Michelle Cohen;,citation_publication_date=2018-04;,citation_cover_date=2018-04;,citation_year=2018;,citation_issue=8;,citation_doi=10.1161/CIRCRESAHA.117.312227;,citation_issn=0009-7330, 1524-4571;,citation_volume=122;,citation_language=en-US;,citation_journal_title=Circulation Research;">
<meta name="citation_reference" content="citation_title=The Big Data Paradox in Clinical Practice;,citation_abstract=The big data paradox is a real-world phenomenon whereby as the number of patients enrolled in a study increases, the probability that the confidence intervals from that study will include the truth decreases. This occurs in both observational and experimental studies, including randomized clinical trials, and should always be considered when clinicians are interpreting research data. Furthermore, as data quantity continues to increase in today’s era of big data, the paradox is becoming more pernicious. Herein, I consider three mechanisms that underlie this paradox, as well as three potential strategies to mitigate it: (1) improving data quality; (2) anticipating and modeling patient heterogeneity; (3) including the systematic error, not just the variance, in the estimation of error intervals.;,citation_author=Pavlos Msaouel;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_issue=7;,citation_doi=10.1080/07357907.2022.2084621;,citation_issn=0735-7907, 1532-4192;,citation_volume=40;,citation_language=en-US;,citation_journal_title=Cancer Investigation;">
<meta name="citation_reference" content="citation_title=Interpreting Randomized Controlled Trials;,citation_abstract=This article describes rationales and limitations for making inferences based on data from randomized controlled trials (RCTs). We argue that obtaining a representative random sample from a patient population is impossible for a clinical trial because patients are accrued sequentially over time and thus comprise a convenience sample, subject only to protocol entry criteria. Consequently, the trial’s sample is unlikely to represent a definable patient population. We use causal diagrams to illustrate the difference between random allocation of interventions within a clinical trial sample and true simple or stratified random sampling, as executed in surveys. We argue that group-specific statistics, such as a median survival time estimate for a treatment arm in an RCT, have limited meaning as estimates of larger patient population parameters. In contrast, random allocation between interventions facilitates comparative causal inferences about between-treatment effects, such as hazard ratios or differences between probabilities of response. Comparative inferences also require the assumption of transportability from a clinical trial’s convenience sample to a targeted patient population. We focus on the consequences and limitations of randomization procedures in order to clarify the distinctions between pairs of complementary concepts of fundamental importance to data science and RCT interpretation. These include internal and external validity, generalizability and transportability, uncertainty and variability, representativeness and inclusiveness, blocking and stratification, relevance and robustness, forward and reverse causal inference, intention to treat and per protocol analyses, and potential outcomes and counterfactuals.;,citation_author=Pavlos Msaouel;,citation_author=Juhee Lee;,citation_author=Peter F. Thall;,citation_publication_date=2023-01;,citation_cover_date=2023-01;,citation_year=2023;,citation_issue=19;,citation_doi=10.3390/cancers15194674;,citation_issn=2072-6694;,citation_volume=15;,citation_language=en-US;,citation_journal_title=Cancers;,citation_publisher=Multidisciplinary Digital Publishing Institute;">
<meta name="citation_reference" content="citation_title=Making Patient-Specific Treatment Decisions Using Prognostic Variables and Utilities of Clinical Outcomes;,citation_abstract=We argue that well-informed patient-specific decision-making may be carried out as three consecutive tasks: (1) estimating key parameters of a statistical model, (2) using prognostic information to convert these parameters into clinically interpretable values, and (3) specifying joint utility functions to quantify risk–benefit trade-offs between clinical outcomes. Using the management of metastatic clear cell renal cell carcinoma as our motivating example, we explain the role of prognostic covariates that characterize between-patient heterogeneity in clinical outcomes. We show that explicitly specifying the joint utility of clinical outcomes provides a coherent basis for patient-specific decision-making.;,citation_author=Pavlos Msaouel;,citation_author=Juhee Lee;,citation_author=Peter F. Thall;,citation_publication_date=2021-06;,citation_cover_date=2021-06;,citation_year=2021;,citation_issue=11;,citation_doi=10.3390/cancers13112741;,citation_issn=2072-6694;,citation_volume=13;,citation_language=en-US;,citation_journal_title=Cancers;">
<meta name="citation_reference" content="citation_title=Pilot Randomized Clinical Trial of a Goals-of-Care Decision Aid for Surrogates of Patients With Severe Acute Brain Injury;,citation_abstract=Background and Objectives Breakdowns in clinician-family communication in neurologic intensive care units (neuroICUs) are common, particularly for goals-of-care decisions to continue or withdraw life-sustaining treatments while considering long-term prognoses. Shared decision-making interventions (decision aids [DAs]) may prevent this problem and increase patient-centered care, yet none are currently available. We assessed the feasibility, acceptability, and perceived usefulness of a DA for goals-of-care communication with surrogate decision makers for critically ill patients with severe acute brain injury (SABI) after hemispheric acute ischemic stroke, intracerebral hemorrhage, or traumatic brain injury. Methods We conducted a parallel-arm, unblinded, patient-level randomized, controlled pilot trial at 2 tertiary care US neuroICUs and randomized surrogate participants 1:1 to a tailored paper-based DA provided to surrogates before clinician-family goals-of-care meetings or usual care (no intervention before clinician-family meetings). The primary outcomes were feasibility of deploying the DA (recruitment, participation, and retention), acceptability, and perceived usefulness of the DA among surrogates. Exploratory outcomes included outcome of surrogate goals-of-care decision, code status changes during admission, patients’ 3-month functional outcome, and surrogates’ 3-month validated psychological outcomes. Results We approached 83 surrogates of 58 patients and enrolled 66 surrogates of 41 patients (80% consent rate). Of 66 surrogates, 45 remained in the study at 3 months (68% retention). Of the 33 surrogates randomized to intervention, 27 were able to receive the DA, and 25 subsequently read the DA (93% participation). Eighty-two percent rated the DA’s acceptability as good or excellent (median acceptability score 2 [IQR 2–3]); 96% found it useful for goals-of-care decision making. In the DA group, there was a trend toward fewer comfort care decisions (27% vs 56%, p = 0.1) and fewer code status changes (no change, 73% vs 44%, p = 0.02). At 3 months, fewer patients in the DA group had died (33% vs 69%, p = 0.05; median Glasgow Outcome Scale 3 vs1, p = 0.05). Regardless of intervention, 3-month psychological outcomes were significantly worse among surrogates who had chosen continuation of care. Discussion A goals-of-care DA to support ICU shared decision making for patients with SABI is feasible to deploy and well perceived by surrogates. A larger trial is feasible to conduct, although surrogates who select continuation of care deserve additional psychosocial support. Clinical Trials Registration Clinicaltrials.gov NCT03833375. Classification of Evidence This study provides Class IV evidence that the use of a DA explaining the goals-of-care decision and the treatment options is acceptable and useful to surrogates of incapacitated critically ill patients with ischemic stroke, intracerebral hemorrhage, or traumatic brain injury.;,citation_author=Susanne Muehlschlegel;,citation_author=Kelsey Goostrey;,citation_author=Julie Flahive;,citation_author=Qiang Zhang;,citation_author=Jolanta J. Pach;,citation_author=David Y. Hwang;,citation_publication_date=2022-10;,citation_cover_date=2022-10;,citation_year=2022;,citation_issue=14;,citation_doi=10.1212/WNL.0000000000200937;,citation_issn=0028-3878, 1526-632X;,citation_volume=99;,citation_language=en-US;,citation_journal_title=Neurology;,citation_publisher=Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology;">
<meta name="citation_reference" content="citation_title=Subarachnoid Hemorrhage;,citation_abstract=the most common and potentially life-threatening neurologic and medical complications to promote their early recognition and prevent secondary brain injury. RECENT FINDINGS Over the past 30 years, the incidence of SAH has remained stable; yet, likely because of improved care in specialized neurocritical care units, discharge mortality has considerably decreased. Two consensus guidelines by the American Heart Association/American Stroke Association and the Neurocritical Care Society have outlined best practices for the management of patients with SAH. The most important recommendations include admission of patients to high-volume centers (defined as more than 35 SAH admissions per year) under the management of a multidisciplinary, specialized team; expeditious identification and treatment of the bleeding source with evaluation by a multidisciplinary team consisting of cerebrovascular neurosurgeons, neuroendovascular specialists, and neurointensivists; management of patients in a neurocritical care unit with enteral nimodipine, blood pressure control, euvolemia, and close monitoring for neurologic and medical complications; and treatment of symptomatic cerebral vasospasm/delayed cerebral ischemia with induced hypertension and endovascular therapies. This article also highlights new insights of SAH pathophysiology and provides updates in the management approach. SUMMARY SAH remains a neurologic emergency. Management of patients with SAH includes adherence to published guidelines, but some areas of SAH management remain understudied. Clinical trials are required to elucidate the role of these controversial management approaches in improving patient outcomes....;,citation_author=Susanne Muehlschlegel;,citation_publication_date=2018-12;,citation_cover_date=2018-12;,citation_year=2018;,citation_issue=6;,citation_doi=10.1212/CON.0000000000000679;,citation_issn=1080-2371;,citation_volume=24;,citation_language=en-US;,citation_journal_title=CONTINUUM: Lifelong Learning in Neurology;">
<meta name="citation_reference" content="citation_title=When Doctors and Families Disagree in the Neurologic Intensive Care Unit—Misunderstandings and Optimistic Beliefs;,citation_abstract=In JAMA Network Open, Kiker et al present their mixed-methods cross-sectional study on the prevalence and predictors of prognosis discordance between physicians and surrogate decision-makers in patients with severe acute brain injury. This study is both novel and significant in this special patient population. The findings deserve attention, as they provide data about a rarely studied yet very common bedside issue in the neurologic intensive care unit (ICU): prognosis discordance and misunderstandings between the physicians and family members. This study not only documents the high prevalence of prognosis discordance and misunderstandings but also attempts to identify associations and qualitatively explores the potential underlying reasons for optimistic belief differences.;,citation_author=Susanne Muehlschlegel;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=10;,citation_doi=10.1001/jamanetworkopen.2021.29079;,citation_issn=2574-3805;,citation_volume=4;,citation_journal_title=JAMA Network Open;">
<meta name="citation_reference" content="citation_title=Methods to systematically review and meta-analyse observational studies: A systematic scoping review of recommendations;,citation_abstract=Background: Systematic reviews and meta-analyses of observational studies are frequently performed, but no widely accepted guidance is available at present. We performed a systematic scoping review of published methodological recommendations on how to systematically review and meta-analyse observational studies. Methods: We searched online databases and websites and contacted experts in the field to locate potentially eligible articles. We included articles that provided any type of recommendation on how to conduct systematic reviews and meta-analyses of observational studies. We extracted and summarised recommendations on pre-defined key items: protocol development, research question, search strategy, study eligibility, data extraction, dealing with different study designs, risk of bias assessment, publication bias, heterogeneity, statistical analysis. We summarised recommendations by key item, identifying areas of agreement and disagreement as well as areas where recommendations were missing or scarce. Results: The searches identified 2461 articles of which 93 were eligible. Many recommendations for reviews and metaanalyses of observational studies were transferred from guidance developed for reviews and meta-analyses of RCTs. Although there was substantial agreement in some methodological areas there was also considerable disagreement on how evidence synthesis of observational studies should be conducted. Conflicting recommendations were seen on topics such as the inclusion of different study designs in systematic reviews and meta-analyses, the use of quality scales to assess the risk of bias, and the choice of model (e.g. fixed vs. random effects) for meta-analysis. Conclusion: There is a need for sound methodological guidance on how to conduct systematic reviews and metaanalyses of observational studies, which critically considers areas in which there are conflicting recommendations.;,citation_author=Monika Mueller;,citation_author=Maddalena D’Addario;,citation_author=Matthias Egger;,citation_author=Myriam Cevallos;,citation_author=Olaf Dekkers;,citation_author=Catrina Mugglin;,citation_author=Pippa Scott;,citation_publication_date=2018-12;,citation_cover_date=2018-12;,citation_year=2018;,citation_issue=1;,citation_doi=10.1186/s12874-018-0495-9;,citation_issn=1471-2288;,citation_volume=18;,citation_language=en-US;,citation_journal_title=BMC Medical Research Methodology;">
<meta name="citation_reference" content="citation_title=Rewriting results sections in the language of evidence;,citation_author=Stefanie Muff;,citation_author=Erlend B. Nilsen;,citation_author=Robert B. O’Hara;,citation_author=Chloé R. Nater;,citation_publication_date=2022-03;,citation_cover_date=2022-03;,citation_year=2022;,citation_issue=3;,citation_doi=10.1016/j.tree.2021.10.009;,citation_issn=01695347;,citation_volume=37;,citation_language=en-US;,citation_journal_title=Trends in Ecology &amp;amp;amp; Evolution;">
<meta name="citation_reference" content="citation_title=Should Tenecteplase Replace Alteplase for Acute Thrombolysis?;,citation_author=Keith W. Muir;,citation_publication_date=2021-03;,citation_cover_date=2021-03;,citation_year=2021;,citation_issue=3;,citation_doi=10.1161/STROKEAHA.120.033593;,citation_issn=0039-2499, 1524-4628;,citation_volume=52;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=Getting started with simulating data in R: Some helpful functions and how to use them;,citation_author=Ariel Muldoon;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Acetazolamide in Acute Decompensated Heart Failure with Volume Overload;,citation_author=Wilfried Mullens;,citation_author=Jeroen Dauw;,citation_author=Pieter Martens;,citation_author=Frederik H. Verbrugge;,citation_author=Petra Nijst;,citation_author=Evelyne Meekers;,citation_author=Katrien Tartaglia;,citation_author=Fabien Chenot;,citation_author=Samer Moubayed;,citation_author=Riet Dierckx;,citation_author=Philippe Blouard;,citation_author=Pierre Troisfontaines;,citation_author=David Derthoo;,citation_author=Walter Smolders;,citation_author=Liesbeth Bruckers;,citation_author=Walter Droogne;,citation_author=Jozine M. Ter Maaten;,citation_author=Kevin Damman;,citation_author=Johan Lassus;,citation_author=Alexandre Mebazaa;,citation_author=Gerasimos Filippatos;,citation_author=Frank Ruschitzka;,citation_author=Matthias Dupont;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_issue=0;,citation_doi=10.1056/NEJMoa2203094;,citation_issn=0028-4793;,citation_volume=0;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Fragility Index Meta-Analysis of Randomized Controlled Trials Shows Highly Robust Evidential Strength for Benefit of &amp;amp;amp;lt;3 Hour Intravenous Alteplase;,citation_abstract=Background: Cumulative fragility index (FI) analysis enables quantification of the evidential strength of intravenous alteplase’s core indication—treatment of disabling acute ischemic stroke within 3 hours of onset. Methods: Meta-analyses were performed (study level) or identified (individual participant level) for freedom-from-disability (modified Rankin Scale [mRS] score 0–1, primary efficacy), functional independence (mRS score 0–2, secondary efficacy), and mortality outcomes. Individual trial and cumulative FI analyses were serially conducted after each successive randomized controlled trial (RCT). FI scores were classified as follows: not robust (FI 0–4), somewhat robust (FI 5–12), robust (FI 13–33), and highly robust (FI &amp;amp;gt;33). Results: Nine randomized controlled trials were identified from 1995 to 2021 of within-3-hour intravenous alteplase for acute ischemic stroke. In study-level meta-analyses, alteplase increased freedom-from-disability outcome (mRS score 0–1), 31.0% versus 22.3%, relative risk, 1.39 (95% CI, 1.20–1.61); P&amp;lt;0.00001; increased functional independence (mRS score 0–2), 39.7% versus 31.2%, relative risk, 1.29 (95% CI, 1.14–1.45), P&amp;lt;0.000; and did not alter mortality, 24.1% versus 26.1%; P=0.23. Overall FIs for study-level meta-analyses were both highly robust at 42 and 40 for mRS score 0–1 and mRS score 0–2, respectively. Serial FI analyses showed robust evidential strength for intravenous alteplase superiority with publication of the 2 NINDS-tPA trials (National Institute of Neurological Disorders and Stroke–tissue-type plasminogen activator) in 1995, increased to highly robust in 2012, and remains highly robust in 2021. Conclusions: Within-3-hour intravenous alteplase for acute ischemic stroke is one of the most robustly proven therapies in medicine. The initial concurrent trials 25 years ago showed robust evidence for benefit and, after additional studies, advanced to highly robust.;,citation_author=Katherine T. Mun;,citation_author=Jordan B. Bonomo;,citation_author=David S. Liebeskind;,citation_author=Jeffrey L. Saver;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_issue=6;,citation_doi=10.1161/STROKEAHA.121.038153;,citation_volume=53;,citation_journal_title=Stroke;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=Collider scope: When selection bias can substantially influence observed associations;,citation_abstract=Large-scale cross-sectional and cohort studies have transformed our understanding of the genetic and environmental determinants of health outcomes. However, the representativeness of these samples may be limited–either through selection into studies, or by attrition from studies over time. Here we explore the potential impact of this selection bias on results obtained from these studies, from the perspective that this amounts to conditioning on a collider (i.e. a form of collider bias). Whereas it is acknowledged that selection bias will have a strong effect on representativeness and prevalence estimates, it is often assumed that it should not have a strong impact on estimates of associations. We argue that because selection can induce collider bias (which occurs when two variables independently influence a third variable, and that third variable is conditioned upon), selection can lead to substantially biased estimates of associations. In particular, selection related to phenotypes can bias associations with genetic variants associated with those phenotypes. In simulations, we show that even modest influences on selection into, or attrition from, a study can generate biased and potentially misleading estimates of both phenotypic and genotypic associations. Our results highlight the value of knowing which population your study sample is representative of. If the factors influencing selection and attrition are known, they can be adjusted for. For example, having DNA available on most participants in a birth cohort study offers the possibility of investigating the extent to which polygenic scores predict subsequent participation, which in turn would enable sensitivity analyses of the extent to which bias might distort estimates.;,citation_author=Marcus R Munafò;,citation_author=Kate Tilling;,citation_author=Amy E Taylor;,citation_author=David M Evans;,citation_author=George Davey Smith;,citation_publication_date=2018-02;,citation_cover_date=2018-02;,citation_year=2018;,citation_issue=1;,citation_doi=10.1093/ije/dyx206;,citation_issn=0300-5771, 1464-3685;,citation_volume=47;,citation_language=en-US;,citation_journal_title=International Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=The reproducibility debate is an opportunity, not a crisis;,citation_abstract=There are many factors that contribute to the reproducibility and replicability of scientific research. There is a need to understand the research ecosystem, and improvements will require combined efforts across all parts of this ecosystem. National structures can play an important role in coordinating these efforts, working collaboratively with researchers, institutions, funders, publishers, learned societies and other sectoral organisations, and providing a monitoring and reporting function. Whilst many new ways of working and emerging innovations hold a great deal of promise, it will be important to invest in meta-research activity to ensure that these approaches are evidence based, work as intended, and do not have unintended consequences. Addressing reproducibility will require working collaboratively across the research ecosystem to share best practice and to make the most effective use of resources. The UK Reproducibility Network (UKRN) brings together Local Networks of researchers, Institutions, and External Stakeholders (funders, publishers, learned societies and other sectoral organisations), to coordinate action on reproducibility and work to ensure the UK retains its place as a centre for world-leading research. This activity is coordinated by the UKRN Steering Group. We consider this structure as valuable, bringing together a range of voices at a range of levels to support the combined efforts required to enact change.;,citation_author=Marcus R. Munafò;,citation_author=Chris Chambers;,citation_author=Alexandra Collins;,citation_author=Laura Fortunato;,citation_author=Malcolm Macleod;,citation_publication_date=2022-12;,citation_cover_date=2022-12;,citation_year=2022;,citation_issue=1;,citation_doi=10.1186/s13104-022-05942-3;,citation_issn=1756-0500;,citation_volume=15;,citation_language=en-US;,citation_journal_title=BMC Research Notes;">
<meta name="citation_reference" content="citation_title=Robust research needs many lines of evidence;,citation_abstract=Replication is not enough. Marcus R. Munafò and George Davey Smith state the case for triangulation.;,citation_author=Marcus R. Munafò;,citation_author=George Davey Smith;,citation_publication_date=2018-01;,citation_cover_date=2018-01;,citation_year=2018;,citation_issue=7689;,citation_doi=10.1038/d41586-018-01023-3;,citation_volume=553;,citation_language=en-US;,citation_journal_title=Nature;,citation_publisher=Nature Publishing Group;">
<meta name="citation_reference" content="citation_title=In-person schooling is essential even during periods of high transmission of COVID-19;,citation_abstract=During the early phase of the pandemic, school closures were one of the non-pharmaceutical interventions (NPIs) implemented globally to reduce transmission. Given that SARS-CoV-2 will continue to circulate for years to come, school closures may be debated again. As familiar respiratory viruses have returned, their combined pressure alongside COVID-19 caused renewed discussion of closures in the UK and initiation of remote learning in areas of the USA in the winter of 2022.1 2 This suggests that debates around school closures will continue into the future. According to the Oxford COVID-19 policy tracker,3 school closures around the world were rapid and nearly uniform in March 2020. In contrast, the reopening process was much more variable, with different countries using different metrics and criteria to reopen. According to our analysis, the variability in duration of school closures between January 2020 and December 2021 was extreme. A handful of countries had zero days (including Burundi, Tajikistan and Turkmenistan), while Brazil, Panama, Peru and Ukraine required some level of closure for a total of 660 days, and Saudi Arabia for 663 days (figures 1 and 2). These differences highlight the lack of consensus about the efficacy of school closures on reducing COVID-19 deaths. Figure 1 Heatmap of the status of school closures from 1 January 2020 to 31 December 2021. Figure 2 Geographical representation of the number of days of required school closure (Oxford COVID-19 policy tracker score 2 or 3). At the start of the pandemic, the justifications of closing schools included a combination of “first principles” (anything reducing social contact is valuable) and drawing on previous evidence based on influenza outbreaks.4 Such interventions have their origins in complex historical precedent, social and medical circumstances. During the 1918 influenza pandemic, school closures were implemented and heavily debated, with experts arguing that harms of closing …;,citation_author=Alasdair Munro;,citation_author=Danilo Buonsenso;,citation_author=Sebastián González-Dambrauskas;,citation_author=Robert C. Hughes;,citation_author=Sunil S. Bhopal;,citation_author=Pablo Vásquez-Hoyos;,citation_author=Muge Cevik;,citation_author=Maria Lucia Mesa Rubio;,citation_author=Damian Roland;,citation_publication_date=2023-04;,citation_cover_date=2023-04;,citation_year=2023;,citation_doi=10.1136/bmjebm-2023-112277;,citation_issn=2515-446X, 2515-4478;,citation_pmid=37068921;,citation_language=en-US;,citation_journal_title=BMJ Evidence-Based Medicine;,citation_publisher=Royal Society of Medicine;">
<meta name="citation_reference" content="citation_title=Extracorporeal Support for Acute Respiratory Distress Syndrome in Adults;,citation_abstract=There is a subset of patients who develop severe ARDS for whom supportive care with mechanical ventilation is insufficient or possibly injurious. The use of ECMO as an adjunct to treat these patients is reviewed.;,citation_author=Laveena Munshi;,citation_author=Daniel Brodie;,citation_author=Eddy Fan;,citation_publication_date=2022-09;,citation_cover_date=2022-09;,citation_year=2022;,citation_issue=10;,citation_doi=10.1056/EVIDra2200128;,citation_volume=1;,citation_journal_title=NEJM Evidence;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=ACP provided 2 conditional recommendations on use of high-flow nasal oxygen in acute respiratory failure;,citation_author=Maitri Munsif;,citation_author=Christine F. McDonald;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_issue=9;,citation_doi=10.7326/ACPJ202109210-098;,citation_issn=0003-4819, 1539-3704;,citation_volume=174;,citation_language=en-US;,citation_journal_title=Annals of Internal Medicine;">
<meta name="citation_reference" content="citation_title=Evidence-based medicine has already adapted and is very much alive;,citation_author=Mohammad Hassan Murad;,citation_author=Samer Saadi;,citation_publication_date=2022-07;,citation_cover_date=2022-07;,citation_year=2022;,citation_doi=10.1136/bmjebm-2022-112046;,citation_issn=2515-446X, 2515-4478;,citation_language=en-US;,citation_journal_title=BMJ Evidence-Based Medicine;">
<meta name="citation_reference" content="citation_title=As the Wheel Turns: Causal Inference for Feedback Loops and Bidirectional Effects;,citation_abstract=Directed acyclic graphs (DAGs) are a visual tool used in causal inference to guide which variables to include in statistical models in research. A primary feature of DAGs is their acyclic nature, which for causal DAGs means variables cannot have direct or indirect effects on their own parent variables occurring before them in time. This is often taken to mean that DAGs cannot display “feedback loops” where two variables inform each other over time, and thus that the utility of DAGs for displaying complex biological relationship is limited. These “feedback loops,” hereafter referred to as bidirectional effects, are common in epidemiological, biological, and psychological research and do pose a major challenge for researchers aiming to incorporate DAGs into their research process. However, this challenge does not arise from a violation of the underlying temporality of causation but rather from a need to clearly specify how causal relationships evolve over time. In this article, we explain how to approach bidirectional relationships in DAGs and discuss considerations and strategies for using DAGs when bidirectional effects are present in research areas.;,citation_author=Eleanor J. Murray;,citation_author=Zach Kunicki;,citation_publication_date=2024-02;,citation_cover_date=2024-02;,citation_year=2024;,citation_doi=10.31219/osf.io/9em5q;,citation_language=en-US;,citation_publisher=OSF;">
<meta name="citation_reference" content="citation_title=Systematic review of the association between ABO blood type and COVID-19 incidence and mortality;,citation_author=Eleanor J Murray;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Antiplatelet Therapy After Spontaneous Intracerebral Hemorrhage and Functional Outcomes;,citation_abstract=Background and Purpose—Observational data suggest that antiplatelet therapy after intracerebral hemorrhage (ICH) alleviates thromboembolic risk without increasing the risk of recurrent ICH. Given the paucity of data on the relationship between antiplatelet therapy after ICH and functional outcomes, we aimed to study this association in a multicenter cohort. Methods—We meta-analyzed data from (1) the Massachusetts General Hospital ICH registry (n=1854), (2) the Virtual International Stroke Trials Archive database (n=762), and (3) the Yale stroke registry (n=185). Our exposure was antiplatelet therapy after ICH, which was modeled as a time-varying covariate. Our primary outcomes were all-cause mortality and a composite of major disability or death (modified Rankin Scale score 4–6). We used Cox proportional regression analyses to estimate the hazard ratio of death or poor functional outcome as a function of antiplatelet therapy and random-effects meta-analysis to pool the estimated HRs across studies. Additional analyses stratified by hematoma location (lobar and deep ICH) were performed. Results—We included a total of 2801 ICH patients, of whom 288 (10.3%) were started on antiplatelet medications after ICH. Median times to antiplatelet therapy ranged from 7 to 39 days. Antiplatelet therapy after ICH was not associated with mortality (hazard ratio, 0.85; 95% CI, 0.66–1.09), or death or major disability (hazard ratio, 0.83; 95% CI, 0.59–1.16) compared with patients not started on antiplatelet therapy. Similar results were obtained in additional analyses stratified by hematoma location. Conclusions—Antiplatelet therapy after ICH appeared safe and was not associated with all-cause mortality or functional outcome, regardless of hematoma location. Randomized clinical trials are needed to determine the effects and harms of antiplatelet therapy after ICH. \mkern1mu(Stroke. 2019;50:3057-3063. DOI: 10.1161/STROKEAHA.119.025972.);,citation_author=Santosh B. Murthy;,citation_author=Alessandro Biffi;,citation_author=Guido J. Falcone;,citation_author=Lauren H. Sansing;,citation_author=Victor Torres Lopez;,citation_author=Babak B. Navi;,citation_author=David J. Roh;,citation_author=Pitchaiah Mandava;,citation_author=Daniel F. Hanley;,citation_author=Wendy C. Ziai;,citation_author=Hooman Kamel;,citation_author=Jonathan Rosand;,citation_author=Kevin N. Sheth;,citation_author=on behalf of the VISTA-ICH Collaborators;,citation_author=K. Butcher;,citation_author=S. Davis;,citation_author=B. Gregson;,citation_author=K. R. Lees;,citation_author=P. Lyden;,citation_author=S. Mayer;,citation_author=K. Muir;,citation_author=T. Steiner;,citation_publication_date=2019-11;,citation_cover_date=2019-11;,citation_year=2019;,citation_issue=11;,citation_doi=10.1161/STROKEAHA.119.025972;,citation_issn=0039-2499, 1524-4628;,citation_volume=50;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=Prior antiplatelet therapy and haematoma expansion after primary intracerebral haemorrhage: An individual patient-level analysis of CLEAR III, MISTIE III and VISTA-ICH;,citation_abstract=Objective To evaluate the relationship between prior antiplatelet therapy (APT) and outcomes after primary intracerebral haemorrhage (ICH), and assess if it varies by haematoma location. Methods We pooled individual patient data from the Virtual International Stroke Trials Archive-ICH trials dataset, Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage III trial and the Minimally Invasive Surgery Plus Alteplase for Intracerebral Hemorrhage Evacuation Phase III trial. The exposure was APT preceding ICH diagnosis. The primary outcome was haematoma expansion at 72 hours. Secondary outcomes were admission haematoma volume, all-cause mortality, death or major disability (modified Rankin Scale (mRS) score \geq4) and shift in mRS distribution. Mixed-effects models were used to assess the relationship between APT and outcomes. Secondary analyses were stratified by ICH location and study cohort. Results Among 1420 patients with ICH, there were 782 (55.1%) lobar and 596 (42.0%) deep haemorrhages. APT was reported in 284 (20.0%) patients. In adjusted regression models, prior APT was not associated with haematoma expansion (OR, 0.97; 95% CI 0.60 to 1.57), major disability or death (OR, 1.05; 95% CI 0.61 to 1.63), all-cause mortality (OR, 0.89; 95% CI 0.47 to 1.85), admission haematoma volume (beta, -0.17; SE, 0.09; p=0.07) and shift in mRS (p=0.43). In secondary analyses, APT was associated with admission haematoma volume in lobar ICH (beta, 0.25; SE, 0.12; p=0.03), but there was no relationship with other ICH outcomes when stratified by haematoma location or study cohort. Conclusions In a large heterogeneous cohort of patients with ICH, prior APT was not associated with haematoma expansion or functional outcomes after ICH, regardless of haematoma location. APT was associated with admission haematoma volumes in lobar ICH.;,citation_author=Santosh Murthy;,citation_author=David J Roh;,citation_author=Abhinaba Chatterjee;,citation_author=Nichol McBee;,citation_author=Neal S Parikh;,citation_author=Alexander E Merkler;,citation_author=Babak B Navi;,citation_author=Guido J Falcone;,citation_author=Kevin N Sheth;,citation_author=Issam Awad;,citation_author=Daniel Hanley;,citation_author=Hooman Kamel;,citation_author=Wendy C Ziai;,citation_publication_date=2021-04;,citation_cover_date=2021-04;,citation_year=2021;,citation_issue=4;,citation_doi=10.1136/jnnp-2020-323458;,citation_issn=0022-3050, 1468-330X;,citation_volume=92;,citation_language=en-US;,citation_journal_title=Journal of Neurology, Neurosurgery &amp;amp;amp; Psychiatry;">
<meta name="citation_reference" content="citation_title=Resuscitation Fluids;,citation_abstract=Fluid resuscitation with colloid and crystalloid solutions is a ubiquitous intervention in acute medicine. The selection and use of resuscitation fluids is based on physiological principles, but clinical practice is determined largely by clinician preference, with marked regional variation. No ideal resuscitation fluid exists. There is emerging evidence that the type and dose of resuscitation fluid may affect patient-centered outcomes. Despite what may be inferred from physiological principles, colloid solutions do not offer substantive advantages over crystalloid solutions with respect to hemodynamic effects. Albumin is regarded as the reference colloid solution, but its cost is a limitation to its use. . . .;,citation_author=John A. Myburgh;,citation_author=Michael G. Mythen;,citation_publication_date=2013-09;,citation_cover_date=2013-09;,citation_year=2013;,citation_issue=13;,citation_doi=10.1056/NEJMra1208627;,citation_issn=0028-4793;,citation_pmid=24066745;,citation_volume=369;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Restrictive versus Liberal Fluid Therapy for Major Abdominal Surgery;,citation_author=Paul S. Myles;,citation_author=Rinaldo Bellomo;,citation_author=Tomas Corcoran;,citation_author=Andrew Forbes;,citation_author=Philip Peyton;,citation_author=David Story;,citation_author=Chris Christophi;,citation_author=Kate Leslie;,citation_author=Shay McGuinness;,citation_author=Rachael Parke;,citation_author=Jonathan Serpell;,citation_author=Matthew T. V. Chan;,citation_author=Thomas Painter;,citation_author=Stuart McCluskey;,citation_author=Gary Minto;,citation_author=Sophie Wallace;,citation_publication_date=2018-06;,citation_cover_date=2018-06;,citation_year=2018;,citation_issue=24;,citation_doi=10.1056/NEJMoa1801601;,citation_issn=0028-4793;,citation_pmid=29742967;,citation_volume=378;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Acute Kidney Injury in Patients with Cirrhosis;,citation_author=Mitra K. Nadim;,citation_author=Guadalupe Garcia-Tsao;,citation_publication_date=2023-02;,citation_cover_date=2023-02;,citation_year=2023;,citation_issue=8;,citation_doi=10.1056/NEJMra2215289;,citation_issn=0028-4793;,citation_volume=388;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19;,citation_abstract=BACKGROUND Thromboembolic disease is common in coronavirus disease-2019 (COVID-19). There is limited evidence on the association of in-hospital anticoagulation (AC) with outcomes and postmortem findings. OBJECTIVES The purpose of this study was to examine association of AC with in-hospital outcomes and describe thromboembolic findings on autopsies. METHODS This retrospective analysis examined the association of AC with mortality, intubation, and major bleeding. Subanalyses were also conducted on the association of therapeutic versus prophylactic AC initiated #48 h from admission. Thromboembolic disease was contextualized by premortem AC among consecutive autopsies. RESULTS Among 4,389 patients, median age was 65 years with 44% women. Compared with no AC (n \frac{1}{4} 1,530; 34.9%), therapeutic AC (n \frac{1}{4} 900; 20.5%) and prophylactic AC (n \frac{1}{4} 1,959; 44.6%) were associated with lower in-hospital mortality (adjusted hazard ratio [aHR]: 0.53; 95% confidence interval [CI]: 0.45 to 0.62 and aHR: 0.50; 95% CI: 0.45 to 0.57, respectively), and intubation (aHR: 0.69; 95% CI: 0.51 to 0.94 and aHR: 0.72; 95% CI: 0.58 to 0.89, respectively). When initiated #48 h from admission, there was no statistically significant difference between therapeutic (n \frac{1}{4} 766) versus prophylactic AC (n \frac{1}{4} 1,860) (aHR: 0.86; 95% CI: 0.73 to 1.02; p \frac{1}{4} 0.08). Overall, 89 patients (2%) had major bleeding adjudicated by clinician review, with 27 of 900 (3.0%) on therapeutic, 33 of 1,959 (1.7%) on prophylactic, and 29 of 1,530 (1.9%) on no AC. Of 26 autopsies, 11 (42%) had thromboembolic disease not clinically suspected and 3 of 11 (27%) were on therapeutic AC. CONCLUSIONS AC was associated with lower mortality and intubation among hospitalized COVID-19 patients. Compared with prophylactic AC, therapeutic AC was associated with lower mortality, although not statistically significant. Autopsies revealed frequent thromboembolic disease. These data may inform trials to determine optimal AC regimens. (J Am Coll Cardiol 2020;76:1815–26) © 2020 Published by Elsevier on behalf of the American College of Cardiology Foundation.;,citation_author=Girish N. Nadkarni;,citation_author=Anuradha Lala;,citation_author=Emilia Bagiella;,citation_author=Helena L. Chang;,citation_author=Pedro R. Moreno;,citation_author=Elisabet Pujadas;,citation_author=Varun Arvind;,citation_author=Sonali Bose;,citation_author=Alexander W. Charney;,citation_author=Martin D. Chen;,citation_author=Carlos Cordon-Cardo;,citation_author=Andrew S. Dunn;,citation_author=Michael E. Farkouh;,citation_author=Benjamin S. Glicksberg;,citation_author=Arash Kia;,citation_author=Roopa Kohli-Seth;,citation_author=Matthew A. Levin;,citation_author=Prem Timsina;,citation_author=Shan Zhao;,citation_author=Zahi A. Fayad;,citation_author=Valentin Fuster;,citation_publication_date=2020-10;,citation_cover_date=2020-10;,citation_year=2020;,citation_issue=16;,citation_doi=10.1016/j.jacc.2020.08.041;,citation_issn=07351097;,citation_volume=76;,citation_language=en-US;,citation_journal_title=Journal of the American College of Cardiology;">
<meta name="citation_reference" content="citation_title=Heart Failure After Right Ventricular Myocardial Infarction;,citation_abstract=Heart failure (HF) after right ventricular myocardial infarction (RVMI) is common and complicates its clinical course. This review aims to provide a current overview on the characteristic features of RV failure with focus on acute management.;,citation_author=Matthias P. Nägele;,citation_author=Andreas J. Flammer;,citation_publication_date=2022-10;,citation_cover_date=2022-10;,citation_year=2022;,citation_doi=10.1007/s11897-022-00577-8;,citation_issn=1546-9549;,citation_language=en-US;,citation_journal_title=Current Heart Failure Reports;">
<meta name="citation_reference" content="citation_title=Early Seizures Are Predictive of Worse Health-Related Quality of Life at Follow-Up After Intracerebral Hemorrhage;,citation_abstract=OBJECTIVES: Early seizures are a common complication of intracerebral hemorrhage, occurring in ~10% of patients. However, the independent effect of early seizures on patient outcomes, particularly health-related quality of life, is unclear. Without a potential benefit to patient outcomes, the widespread use (~40%) of prophylactic seizure medications has no reasonable chance of improving patient outcomes. We tested the hypothesis that health-related quality of life at follow-up is different between patients with and without early seizures (and secondarily, with nonconvulsive status epilepticus) after intracerebral hemorrhage. DESIGN: Patients with intracerebral hemorrhage were enrolled in an observational cohort study that prospectively collected clinical data and health-related quality of life at follow-up. SETTING: Academic medical center. PATIENTS: One-hundred thirty-three patients whose health-related quality of life was assessed 3 months after intracerebral hemorrhage onset. MEASUREMENTS AND MAIN RESULTS: Health-related quality of life was obtained at 3 months after intracerebral hemorrhage onset. T Scores of health-related quality of life were modeled with multivariable linear models accounting for severity with the intracerebral hemorrhage Score and hematoma location. Health-related quality of life was measured with National Institutes of Health Patient Reported Outcomes Measurement Information System/Neuroquality of life, expressed in T Scores (U.S. normal 50  10). The modified Rankin Scale (a global measure) was a secondary outcome. There were 12 patients (9%) with early seizures. T Scores of health-related quality of life at follow-up were lower (worse) in patients with early seizure compared with patients without an early seizure (44 [32.75–51.85] vs 30.25 [18.9–39.15]; p = 0.04); results for other domains of health-related quality of life were similar. The association persisted in multivariable models. There was no association between early seizures and prophylactic seizure medications (p = 0.4). Results for patients with nonconvulsive status epilepticus were similar. There was no association between early seizures and the modified Rankin Scale at 3 months. CONCLUSIONS: Early seizures and nonconvulsive status epilepticus were associated with lower health-related quality of life at follow-up in survivors of intracerebral hemorrhage.;,citation_author=Andrew M. Naidech;,citation_author=Bradley Weaver;,citation_author=Matthew Maas;,citation_author=Thomas P. Bleck;,citation_author=Stephen VanHaerents;,citation_author=Stephan U. Schuele;,citation_publication_date=2021-06;,citation_cover_date=2021-06;,citation_year=2021;,citation_issue=6;,citation_doi=10.1097/CCM.0000000000004936;,citation_issn=0090-3493;,citation_volume=49;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Magnesium Sulfate and Hematoma Expansion: An Ancillary Analysis of the FAST-MAG Randomized Trial;,citation_abstract=BACKGROUND: Intracerebral hemorrhage (ICH) is the deadliest form of stroke. In observational studies, lower serum magnesium has been linked to more hematoma expansion (HE) and intracranial hemorrhage, implying that supplemental magnesium sulfate is a potential acute treatment for patients with ICH and could reduce HE. FAST-MAG (Field Administration of Stroke Therapy - Magnesium) was a clinical trial of magnesium sulfate started prehospital in patients with acute stroke within 2 hours of last known well enrolled. CT was not required prior to enrollment, and several hundred patients with acute ICH were enrolled. In this ancillary analysis, we assessed the effect of magnesium sulfate treatment upon HE in patients with acute ICH. METHODS: We retrospectively analyzed data that were prospectively collected in the FAST-MAG study. Patients received intravenous magnesium sulfate or matched placebo within 2 hours of onset. We compared HE among patients allocated to intravenous magnesium sulfate or placebo with a Mann-Whitney U. We used the same method to compare neurological deficit severity (National Institutes of Health Stroke Scale) and global disability (modified Rankin Scale) at 3 months. RESULTS: Among 268 patients with ICH meeting study entry criteria, mean 65.413/4 years, 33% were female, and 211 (79%) had a history of hypertension. Initial deficit severities were median (interquartile range) of 4 (3–5) on the Los Angeles Motor Scale in the field and National Institutes of Health Stroke Scale score of 16 (9.5–25.5) early after hospital arrival. Follow-up brain imaging was performed a median of 17.1 (11.3–22.7) hours after first scan. The magnesium and placebo groups did not statistically differ in hematoma volume on arrival, 10.1 (5.6–28.7) versus 12.4 (5.6–28.7) mL (P=0.6), or HE, 2.0 (0.1–7.4) versus 1.5 (-0.2 to 8) mL (P=0.5). There was no difference in functional outcomes (modified Rankin Scale score of 3–6), 59% versus 50% (P=0.5). CONCLUSIONS: Magnesium sulfate did not reduce HE or improve functional outcomes at 90 days. A benefit for patients with initial hypomagnesemia was not addressed.;,citation_author=Andrew M. Naidech;,citation_author=Kristina Shkirkova;,citation_author=Juan Pablo Villablanca;,citation_author=Nerses Sanossian;,citation_author=David S. Liebeskind;,citation_author=Latisha Sharma;,citation_author=Mark Eckstein;,citation_author=Samuel Stratton;,citation_author=Robin Conwit;,citation_author=Scott Hamilton;,citation_author=Jeffrey L. Saver;,citation_author=for the FAST-MAG Investigators and Coordinators;,citation_publication_date=2022-05;,citation_cover_date=2022-05;,citation_year=2022;,citation_issue=5;,citation_doi=10.1161/STROKEAHA.121.037999;,citation_issn=0039-2499, 1524-4628;,citation_volume=53;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=Re: Confounding by Indication in Retrospective Studies of Intracerebral Hemorrhage: Antiepileptic Treatment and Mortality;,citation_author=Andrew M. Naidech;,citation_author=Matthew B. Maas;,citation_author=Eric M. Liotta;,citation_author=James C. Guth;,citation_author=Rebecca M. Bauer;,citation_author=Rajeev K. Garg;,citation_author=Stephan U. Schuele;,citation_author=Thomas P. Bleck;,citation_publication_date=2013-04;,citation_cover_date=2013-04;,citation_year=2013;,citation_issue=2;,citation_doi=10.1007/s12028-012-9811-0;,citation_issn=1541-6933, 1556-0961;,citation_volume=18;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Can Confidence Intervals Be Interpreted?;,citation_author=Ashley I Naimi;,citation_author=Brian W Whitcomb;,citation_publication_date=2020-07;,citation_cover_date=2020-07;,citation_year=2020;,citation_issue=7;,citation_doi=10.1093/aje/kwaa004;,citation_issn=0002-9262, 1476-6256;,citation_volume=189;,citation_language=en-US;,citation_journal_title=American Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Of Papers, PDFs, and Platforms;,citation_author=Brahmajee K. Nallamothu;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_issue=9;,citation_doi=10.1161/CIRCOUTCOMES.121.008466;,citation_issn=1941-7713, 1941-7705;,citation_volume=14;,citation_language=en-US;,citation_journal_title=Circulation: Cardiovascular Quality and Outcomes;">
<meta name="citation_reference" content="citation_title=Intensive vs Conventional Blood Pressure Lowering After Endovascular Thrombectomy in Acute Ischemic Stroke: The OPTIMAL-BP Randomized Clinical Trial;,citation_abstract=Optimal blood pressure (BP) control after successful reperfusion with endovascular thrombectomy (EVT) for patients with acute ischemic stroke is unclear.To determine whether intensive BP management during the first 24 hours after successful reperfusion leads to better clinical outcomes than conventional BP management in patients who underwent EVT.Multicenter, randomized, open-label trial with a blinded end-point evaluation, conducted across 19 stroke centers in South Korea from June 2020 to November 2022 (final follow-up, March 8, 2023). It included 306 patients with large vessel occlusion acute ischemic stroke treated with EVT and with a modified Thrombolysis in Cerebral Infarction score of 2b or greater (partial or complete reperfusion).Participants were randomly assigned to receive intensive BP management (systolic BP target &amp;amp;amp;lt;140 mm Hg; n = 155) or conventional management (systolic BP target 140-180 mm Hg; n = 150) for 24 hours after enrollment.The primary outcome was functional independence at 3 months (modified Rankin Scale score of 0-2). The primary safety outcomes were symptomatic intracerebral hemorrhage within 36 hours and death related to the index stroke within 3 months.The trial was terminated early based on the recommendation of the data and safety monitoring board, which noted safety concerns. Among 306 randomized patients, 305 were confirmed eligible and 302 (99.0%) completed the trial (mean age, 73.0 years; 122 women [40.4%]). The intensive management group had a lower proportion achieving functional independence (39.4%) than the conventional management group (54.4%), with a significant risk difference (-15.1% [95% CI, -26.2% to -3.9%]) and adjusted odds ratio (0.56 [95% CI, 0.33-0.96]; P = .03). Rates of symptomatic intracerebral hemorrhage were 9.0% in the intensive group and 8.1% in the conventional group (risk difference, 1.0% [95% CI, -5.3% to 7.3%]; adjusted odds ratio, 1.10 [95% CI, 0.48-2.53]; P = .82). Death related to the index stroke within 3 months occurred in 7.7% of the intensive group and 5.4% of the conventional group (risk difference, 2.3% [95% CI, -3.3% to 7.9%]; adjusted odds ratio, 1.73 [95% CI, 0.61-4.92]; P = .31).Among patients who achieved successful reperfusion with EVT for acute ischemic stroke with large vessel occlusion, intensive BP management for 24 hours led to a lower likelihood of functional independence at 3 months compared with conventional BP management. These results suggest that intensive BP management should be avoided after successful EVT in acute ischemic stroke.ClinicalTrials.gov Identifier: NCT04205305;,citation_author=Hyo Suk Nam;,citation_author=Young Dae Kim;,citation_author=JoonNyung Heo;,citation_author=Hyungwoo Lee;,citation_author=Jae Wook Jung;,citation_author=Jin Kyo Choi;,citation_author=Il Hyung Lee;,citation_author=In Hwan Lim;,citation_author=Soon-Ho Hong;,citation_author=Minyoul Baik;,citation_author=Byung Moon Kim;,citation_author=Dong Joon Kim;,citation_author=Na-Young Shin;,citation_author=Bang-Hoon Cho;,citation_author=Seong Hwan Ahn;,citation_author=Hyungjong Park;,citation_author=Sung-Il Sohn;,citation_author=Jeong-Ho Hong;,citation_author=Tae-Jin Song;,citation_author=Yoonkyung Chang;,citation_author=Gyu Sik Kim;,citation_author=Kwon-Duk Seo;,citation_author=Kijeong Lee;,citation_author=Jun Young Chang;,citation_author=Jung Hwa Seo;,citation_author=Sukyoon Lee;,citation_author=Jang-Hyun Baek;,citation_author=Han-Jin Cho;,citation_author=Dong Hoon Shin;,citation_author=Jinkwon Kim;,citation_author=Joonsang Yoo;,citation_author=Kyung-Yul Lee;,citation_author=Yo Han Jung;,citation_author=Yang-Ha Hwang;,citation_author=Chi Kyung Kim;,citation_author=Jae Guk Kim;,citation_author=Chan Joo Lee;,citation_author=Sungha Park;,citation_author=Hye Sun Lee;,citation_author=Sun U. Kwon;,citation_author=Oh Young Bang;,citation_author=Craig S. Anderson;,citation_author=Ji Hoe Heo;,citation_author=OPTIMAL-BP Trial Investigators;,citation_publication_date=2023-09;,citation_cover_date=2023-09;,citation_year=2023;,citation_issue=9;,citation_doi=10.1001/jama.2023.14590;,citation_issn=0098-7484;,citation_volume=330;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Assessing the odds—the women were right;,citation_author=Maryann Napoli;,citation_publication_date=1998-02;,citation_cover_date=1998-02;,citation_year=1998;,citation_issue=9100;,citation_doi=10.1016/S0140-6736(05)78410-5;,citation_issn=0140-6736;,citation_volume=351;,citation_language=en-US;,citation_journal_title=The Lancet;">
<meta name="citation_reference" content="citation_title=Update in Management of Severe Hypoxemic Respiratory Failure;,citation_author=Dharani Kumari Narendra;,citation_author=Dean R. Hess;,citation_author=Curtis N. Sessler;,citation_author=Habtamu M. Belete;,citation_author=Kalpalatha K. Guntupalli;,citation_author=Felix Khusid;,citation_author=Charles Mark Carpati;,citation_author=Mark Elton Astiz;,citation_author=Suhail Raoof;,citation_publication_date=2017-10;,citation_cover_date=2017-10;,citation_year=2017;,citation_issue=4;,citation_doi=10.1016/j.chest.2017.06.039;,citation_issn=00123692;,citation_volume=152;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Effect of Salt Substitution on Cardiovascular Events and Death;,citation_abstract=BACKGROUND Salt substitutes with reduced sodium levels and increased potassium levels have been shown to lower blood pressure, but their effects on cardiovascular and safety outcomes are uncertain. METHODS We conducted an open-label, cluster-randomized trial involving persons from 600 villages in rural China. The participants had a history of stroke or were 60 years of age or older and had high blood pressure. The villages were randomly assigned in a 1:1 ratio to the intervention group, in which the participants used a salt substitute (75% sodium chloride and 25% potassium chloride by mass), or to the control group, in which the participants continued to use regular salt (100% sodium chloride). The primary outcome was stroke, the secondary outcomes were major adverse cardiovascular events and death from any cause, and the safety outcome was clinical hyperkalemia. RESULTS A total of 20,995 persons were enrolled in the trial. The mean age of the participants was 65.4 years, and 49.5% were female, 72.6% had a history of stroke, and 88.4% a history of hypertension. The mean duration of follow-up was 4.74 years. The rate of stroke was lower with the salt substitute than with regular salt (29.14 events vs. 33.65 events per 1000 person-years; rate ratio, 0.86; 95% confidence interval [CI], 0.77 to 0.96; P = 0.006), as were the rates of major cardiovascular events (49.09 events vs. 56.29 events per 1000 person-years; rate ratio, 0.87; 95% CI, 0.80 to 0.94; P&amp;amp;amp;lt;0.001) and death (39.28 events vs. 44.61 events per 1000 person-years; rate ratio, 0.88; 95% CI, 0.82 to 0.95; P&amp;lt;0.001). The rate of serious adverse events attributed to hyperkalemia was not significantly higher with the salt substitute than with regular salt (3.35 events vs. 3.30 events per 1000 person-years; rate ratio, 1.04; 95% CI, 0.80 to 1.37; P = 0.76). The authors’ full names, academic degrees, and affiliations are listed in the Appendix. Address reprint requests to Dr. Wu at Peking University Clinical Research Center, Peking University, 38 Xueyuan Rd., Haidian District, Beijing, China, or at wuyf@bjmu.edu.cn, or to Dr. Tian at the George Institute for Global Health at Peking University Health Science Center, Rm. 052A, Unit 1, Tayuan Diplomatic Office Bldg., No. 14 Liangmahe Nan Lu, Chaoyang District, Beijing, China, or at mtian@georgeinstitute.org.cn. *Deceased. Drs. Neal and Wu contributed equally to this article. This article was published on August 29, 2021, at NEJM.org. DOI: 10.1056/NEJMoa2105675 Copyright © 2021 Massachusetts Medical Society. CONCLUSIONS Among persons who had a history of stroke or were 60 years of age or older and had high blood pressure, the rates of stroke, major cardiovascular events, and death from any cause were lower with the salt substitute than with regular salt. (Funded by the National Health and Medical Research Council of Australia; SSaSS ClinicalTrials.gov number, NCT02092090.);,citation_author=Bruce Neal;,citation_author=Yangfeng Wu;,citation_author=Xiangxian Feng;,citation_author=Ruijuan Zhang;,citation_author=Yuhong Zhang;,citation_author=Jingpu Shi;,citation_author=Jianxin Zhang;,citation_author=Maoyi Tian;,citation_author=Liping Huang;,citation_author=Zhifang Li;,citation_author=Yan Yu;,citation_author=Yi Zhao;,citation_author=Bo Zhou;,citation_author=Jixin Sun;,citation_author=Yishu Liu;,citation_author=Xuejun Yin;,citation_author=Zhixin Hao;,citation_author=Jie Yu;,citation_author=Ka-Chun Li;,citation_author=Xinyi Zhang;,citation_author=Peifen Duan;,citation_author=Faxuan Wang;,citation_author=Bing Ma;,citation_author=Weiwei Shi;,citation_author=Gian Luca Di Tanna;,citation_author=Sandrine Stepien;,citation_author=Sana Shan;,citation_author=Sallie-Anne Pearson;,citation_author=Nicole Li;,citation_author=Lijing L. Yan;,citation_author=Darwin Labarthe;,citation_author=Paul Elliott;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_issue=12;,citation_doi=10.1056/NEJMoa2105675;,citation_issn=0028-4793, 1533-4406;,citation_volume=385;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Andexanet Alfa or Prothrombin Complex Concentrate for Factor Xa Inhibitor Reversal in Acute Major Bleeding: A Systematic Review and Meta-Analysis;,citation_author=Charlie J. Nederpelt;,citation_author=Leon Naar;,citation_author=Pieta Krijnen;,citation_author=Saskia Cessie;,citation_author=Haytham M. A. Kaafarani;,citation_author=Menno V. Huisman;,citation_author=George C. Velmahos;,citation_author=Inger B. Schipper;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=10;,citation_doi=10.1097/CCM.0000000000005059;,citation_issn=0090-3493;,citation_volume=49;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Improving long-term outcomes after discharge from intensive care unit: Report from a stakeholders’ conference*;,citation_author=Dale M. Needham;,citation_author=Judy Davidson;,citation_author=Henry Cohen;,citation_author=Ramona O. Hopkins;,citation_author=Craig Weinert;,citation_author=Hannah Wunsch;,citation_author=Christine Zawistowski;,citation_author=Anita Bemis-Dougherty;,citation_author=Susan C. Berney;,citation_author=O. Joseph Bienvenu;,citation_author=Susan L. Brady;,citation_author=Martin B. Brodsky;,citation_author=Linda Denehy;,citation_author=Doug Elliott;,citation_author=Carl Flatley;,citation_author=Andrea L. Harabin;,citation_author=Christina Jones;,citation_author=Deborah Louis;,citation_author=Wendy Meltzer;,citation_author=Sean R. Muldoon;,citation_author=Jeffrey B. Palmer;,citation_author=Christiane Perme;,citation_author=Marla Robinson;,citation_author=David M. Schmidt;,citation_author=Elizabeth Scruth;,citation_author=Gayle R. Spill;,citation_author=C. Porter Storey;,citation_author=Marta Render;,citation_author=John Votto;,citation_author=Maurene A. Harvey;,citation_publication_date=2012-02;,citation_cover_date=2012-02;,citation_year=2012;,citation_issue=2;,citation_doi=10.1097/CCM.0b013e318232da75;,citation_issn=0090-3493;,citation_volume=40;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Status Epilepticus, Refractory Status Epilepticus, and Super-refractory Status Epilepticus:;,citation_abstract=PURPOSE OF REVIEW: Status epilepticus, refractory status epilepticus, and super-refractory status epilepticus can be life-threatening conditions. This article presents an overview of the three conditions and discusses their management and outcomes.;,citation_author=Sarah E. Nelson;,citation_author=Panayiotis N. Varelas;,citation_publication_date=2018-12;,citation_cover_date=2018-12;,citation_year=2018;,citation_issue=6;,citation_doi=10.1212/CON.0000000000000668;,citation_issn=1080-2371;,citation_volume=24;,citation_language=en-US;,citation_journal_title=CONTINUUM: Lifelong Learning in Neurology;">
<meta name="citation_reference" content="citation_title=Attitudes of Patients and Relatives Toward Disability and Treatment in Malignant MCA Infarction;,citation_abstract=Attitudes among patients and relatives toward the degree of acceptable disability and the importance of aphasia are critical in deciding on decompressive hemicraniectomy (DHC) in malignant middle cerebral artery infarction (MMI). However, most MMI patients are not able to communicate their will. Furthermore, attitudes of healthy individuals and relatives may not correspond to those of stroke patients.;,citation_author=Hermann Neugebauer;,citation_author=Matthias Schnabl;,citation_author=Dorothée Lulé;,citation_author=Peter U. Heuschmann;,citation_author=Eric Jüttler;,citation_author=for the IGNITE Study Group (Initiative of German NeuroIntensive Trial Engagement);,citation_publication_date=2017-04;,citation_cover_date=2017-04;,citation_year=2017;,citation_issue=2;,citation_doi=10.1007/s12028-016-0362-7;,citation_issn=1556-0961;,citation_volume=26;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=DESTINY-S: Attitudes of Physicians Toward Disability and Treatment in Malignant MCA Infarction;,citation_abstract=Decompressive hemicraniectomy (DHC) reduces mortality and improves outcome after malignant middle cerebral artery (MCA) infarction but leaves a high number of survivors severely disabled. Attitudes among physicians toward the degree of disability that is considered acceptable and the impact of aphasia may play a major role in treatment decisions.;,citation_author=Hermann Neugebauer;,citation_author=Claire J. Creutzfeldt;,citation_author=J. Claude Hemphill;,citation_author=Peter U. Heuschmann;,citation_author=Eric Jüttler;,citation_publication_date=2014-08;,citation_cover_date=2014-08;,citation_year=2014;,citation_issue=1;,citation_doi=10.1007/s12028-014-9956-0;,citation_issn=1556-0961;,citation_volume=21;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Palliative care in intensive care;,citation_author=Martin Neukirchen;,citation_author=Victoria Metaxa;,citation_author=Maximilian S. Schaefer;,citation_publication_date=2023-11;,citation_cover_date=2023-11;,citation_year=2023;,citation_doi=10.1007/s00134-023-07260-z;,citation_issn=1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis;,citation_author=Philip N. Newsome;,citation_author=Kristine Buchholtz;,citation_author=Kenneth Cusi;,citation_author=Martin Linder;,citation_author=Takeshi Okanoue;,citation_author=Vlad Ratziu;,citation_author=Arun J. Sanyal;,citation_author=Anne-Sophie Sejling;,citation_author=Stephen A. Harrison;,citation_publication_date=2021-03;,citation_cover_date=2021-03;,citation_year=2021;,citation_issue=12;,citation_doi=10.1056/NEJMoa2028395;,citation_issn=0028-4793;,citation_pmid=33185364;,citation_volume=384;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=How Twitter Gamifies Communication;,citation_abstract=In this chapter, C. Thi Nguyen argues that Twitter makes conversation into something like a game. It scores our communication, giving us vivid and quantified feedback, via Likes, Retweets, and Follower counts. But this gamification doesn’t just increase our motivation to communicate; it changes the very nature of the activity. Games are more satisfying than ordinary life precisely because game goals are simpler, cleaner, and easier to apply. Twitter is thrilling precisely because its goals have been artificially clarified and narrowed. When we buy into Twitter’s gamification, then our values shift from the complex and pluralistic values of communication to the narrower quest for popularity and virality. Twitter’s gamification bears some resemblance with the phenomena of echo chambers and moral outrage porn. In all these phenomena, we are instrumentalizing our ends for hedonistic reasons. We have shifted our aims in an activity, not because the new aims are more valuable, but in exchange for extra pleasure.;,citation_author=C. Thi Nguyen;,citation_publication_date=2021-05;,citation_cover_date=2021-05;,citation_year=2021;,citation_doi=10.1093/oso/9780198833659.003.0017;,citation_isbn=978-0-19-883365-9 978-0-19-187208-2;,citation_language=en-US;,citation_inbook_title=Applied Epistemology;">
<meta name="citation_reference" content="citation_title=Noncontrast Computed Tomography vs Computed Tomography Perfusion or Magnetic Resonance Imaging Selection in Late Presentation of Stroke With Large-Vessel Occlusion;,citation_abstract=OBJECTIVE To compare the clinical outcomes of patients selected for mechanical thrombectomy by noncontrast computed tomography (CT) vs those selected by computed tomography perfusion (CTP) or magnetic resonance imaging (MRI) in the extended time window. DESIGN, SETTING, AND PARTICIPANTS This multinational cohort study included consecutive patients with proximal anterior circulation occlusion stroke presenting within 6 to 24 hours of time last seen well from January 2014 to December 2020. This study was conducted at 15 sites across 5 countries in Europe and North America. The duration of follow-up was 90 days from stroke onset. EXPOSURES Computed tomography with Alberta Stroke Program Early CT Score, CTP, or MRI. MAIN OUTCOMES AND MEASURES The primary end point was the distribution of modified Rankin Scale (mRS) scores at 90 days (ordinal shift). Secondary outcomes included the rates of 90-day functional independence (mRS scores of 0-2), symptomatic intracranial hemorrhage, and 90-day mortality. RESULTS Of 2304 patients screened for eligibility, 1604 patients were included, with a median (IQR) age of 70 (59-80) years; 848 (52.9%) were women. A total of 534 patients were selected to undergo mechanical thrombectomy by CT, 752 by CTP, and 318 by MRI. After adjustment of confounders, there was no difference in 90-day ordinal mRS shift between patients selected by CT vs CTP (adjusted odds ratio [aOR], 0.95 [95% CI, 0.77-1.17]; P = .64) or CT vs MRI (aOR, 0.95 [95% CI, 0.8-1.13]; P = .55). The rates of 90-day functional independence (mRS scores 0-2 vs 3-6) were similar between patients selected by CT vs CTP (aOR, 0.90 [95% CI, 0.7-1.16]; P = .42) but lower in patients selected by MRI than CT (aOR, 0.79 [95% CI, 0.64-0.98]; P = .03). Successful reperfusion was more common in the CT and CTP groups compared with the MRI group (474 [88.9%] and 670 [89.5%] vs 250 [78.9%]; P &amp;amp;amp;lt; .001). No significant differences in symptomatic intracranial hemorrhage (CT, 42 [8.1%]; CTP, 43 [5.8%]; MRI, 15 [4.7%]; P = .11) or 90-day mortality (CT, 125 [23.4%]; CTP, 159 [21.1%]; MRI, 62 [19.5%]; P = .38) were observed. CONCLUSIONS AND RELEVANCE In patients undergoing proximal anterior circulation mechanical thrombectomy in the extended time window, there were no significant differences in the clinical outcomes of patients selected with noncontrast CT compared with those selected with CTP or MRI. These findings have the potential to widen the indication for treating patients in the extended window using a simpler and more widespread noncontrast CT–only paradigm.;,citation_author=Thanh N. Nguyen;,citation_author=Mohamad Abdalkader;,citation_author=Simon Nagel;,citation_author=Muhammad M. Qureshi;,citation_author=Marc Ribo;,citation_author=Francois Caparros;,citation_author=Diogo C. Haussen;,citation_author=Mahmoud H. Mohammaden;,citation_author=Sunil A. Sheth;,citation_author=Santiago Ortega-Gutierrez;,citation_author=James E. Siegler;,citation_author=Syed Zaidi;,citation_author=Marta Olive-Gadea;,citation_author=Hilde Henon;,citation_author=Markus A. Möhlenbruch;,citation_author=Alicia C. Castonguay;,citation_author=Stefania Nannoni;,citation_author=Johannes Kaesmacher;,citation_author=Ajit S. Puri;,citation_author=Fatih Seker;,citation_author=Mudassir Farooqui;,citation_author=Sergio Salazar-Marioni;,citation_author=Anna L. Kuhn;,citation_author=Artem Kaliaev;,citation_author=Behzad Farzin;,citation_author=William Boisseau;,citation_author=Hesham E. Masoud;,citation_author=Carlos Ynigo Lopez;,citation_author=Ameena Rana;,citation_author=Samer Abdul Kareem;,citation_author=Anvitha Sathya;,citation_author=Piers Klein;,citation_author=Mohammad W. Kassem;,citation_author=Peter A. Ringleb;,citation_author=Charlotte Cordonnier;,citation_author=Jan Gralla;,citation_author=Urs Fischer;,citation_author=Patrik Michel;,citation_author=Tudor G. Jovin;,citation_author=Jean Raymond;,citation_author=Osama O. Zaidat;,citation_author=Raul G. Nogueira;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=1;,citation_doi=10.1001/jamaneurol.2021.4082;,citation_issn=2168-6149;,citation_volume=79;,citation_language=en-US;,citation_journal_title=JAMA Neurology;">
<meta name="citation_reference" content="citation_title=Financial relationships with industry among guideline authors for the management of acute ischemic stroke;,citation_author=Joshua D. Niforatos;,citation_author=Richard M. Pescatore;,citation_publication_date=2019-05;,citation_cover_date=2019-05;,citation_year=2019;,citation_issue=5;,citation_doi=10.1016/j.ajem.2019.01.037;,citation_issn=0735-6757, 1532-8171;,citation_pmid=30704949;,citation_volume=37;,citation_language=en-US;,citation_journal_title=The American Journal of Emergency Medicine;,citation_publisher=Elsevier;">
<meta name="citation_reference" content="citation_title=Patient Relevance of the Modified Rankin Scale in Subarachnoid Hemorrhage Research: An International Cross-sectional Survey;,citation_abstract=Background and Objectives There is significant heterogeneity in the reporting of outcome measures in aneurysmal subarachnoid hemorrhage (aSAH) research. The modified Rankin scale (mRS) is the most commonly reported functional outcome measure. The mRS focuses on physical disability; however, many aSAH survivors experience sequalae in other domains, and the mRS may therefore not capture outcomes important to aSAH survivors. The objective of this study was to assess the clinical relevance of the mRS as a research outcome measure to people with lived aSAH experience. Methods We conducted an international cross-sectional survey of 355 aSAH survivors, family members, and caregivers to evaluate patient-perceived outcomes in relation to the mRS. The mRS was assessed using a previously validated web-based tool. Results Response rate was 60%; respondents from 7 continents were composed of 86% aSAH survivors and 14% family members/caregivers. Agreement between self-assessed outcome and the mRS was poor (Kappa 0.26 [CI 0.14–0.39]). Of the 172 respondents who self-assessed as having had a good aSAH outcome, 122 (71%) had a score of 0–2 on the mRS. Approximately 19% of respondents with a good outcome, based on a measured mRS score of 0–2, self-assessed as having had a poor aSAH outcome. When the mRS score was dichotomized as 0–3 corresponding to a good outcome, agreement between the score and self-assessed outcome remained poor with a Kappa score of 0.40 (CI 0.20–0.60). Approximately 30% of respondents believed that the mRS should not be used as an outcome measure in future aSAH trials. Discussion The findings suggest that there is poor agreement between aSAH survivors’ self-assessed outcome, their actual mRS score, and the dichotomization of the mRS score into good/poor outcomes. Patient-centered and patient-informed outcome measurement tools are needed to guide the aSAH research agenda.;,citation_author=Naomi Niznick;,citation_author=Victoria Saigle;,citation_author=Maria Luisa Marti;,citation_author=Josephine Laframboise;,citation_author=Xiaohui Zha;,citation_author=Chris Andersen;,citation_author=Justin Presseau;,citation_author=Michaël Chassé;,citation_author=Lauralyn McIntyre;,citation_author=Dean Fergusson;,citation_author=Alexis F. Turgeon;,citation_author=François Lauzier;,citation_author=Stephan A. Mayer;,citation_author=Shouri Lahiri;,citation_author=Tim Ramsay;,citation_author=Shane English;,citation_author=for the APOC Investigators and the Canadian Critical Care Trials Group;,citation_publication_date=2023-04;,citation_cover_date=2023-04;,citation_year=2023;,citation_issue=15;,citation_doi=10.1212/WNL.0000000000206879;,citation_issn=0028-3878, 1526-632X;,citation_pmid=36750387;,citation_volume=100;,citation_language=en-US;,citation_journal_title=Neurology;,citation_publisher=Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology;">
<meta name="citation_reference" content="citation_title=Advanced modelling strategies;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Attention Deficit–Hyperactivity Disorder and Month of School Enrollment;,citation_publication_date=2019-02;,citation_cover_date=2019-02;,citation_year=2019;,citation_issue=7;,citation_doi=10.1056/NEJMc1817539;,citation_issn=0028-4793, 1533-4406;,citation_volume=380;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Balanced Electrolyte Solution or Saline in the Critically Ill;,citation_abstract=To the Editor: In a multicenter trial, Finfer et al. (March 3 issue)1 addressed an important clinical issue: whether to use a multielectrolyte solution or saline in critically ill adults. In accordance with the protocol, patients in the intensive care unit (ICU) were assigned to receive balanced multielectrolyte solution (BMES) or saline during their entire stay in the ICU. The median duration of treatment with the assigned trial fluid was 6.0 days (interquartile range, 3.0 to 10.0) in both groups. We can thus assume that 75% of the patients remained in the ICU at the end of day 3 and . . .;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_issue=23;,citation_doi=10.1056/NEJMc2204390;,citation_issn=0028-4793;,citation_volume=386;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=The causal foundations of applied probability and statistics.pdf;">
<meta name="citation_reference" content="citation_title=Causal Inference with Observational Data;,citation_doi=10.1177/1536867X0800700403;,citation_language=en-US;,citation_publisher=https://journals.sagepub.com/doi/epdf/10.1177/1536867X0800700403;">
<meta name="citation_reference" content="citation_title=A Comparison of Albumin and Saline for Fluid Resuscitation in the Intensive Care Unit;,citation_abstract=The administration of intravenous fluids to maintain or increase intravascular volume is a common intervention in the intensive care unit (ICU), but there is uncertainty whether the choice of fluid significantly influences patients’ outcomes.1–7 In particular, no adequately powered randomized, controlled trials have examined the effect of fluid choice on the survival of patients in the ICU. In the absence of such trials, a number of meta-analyses have examined how the choice of crystalloid or colloid solution and of albumin-containing or albumin-free fluid affects survival in critically ill patients and in patients who are less severely ill.1–3, . . .;,citation_publication_date=2004-05;,citation_cover_date=2004-05;,citation_year=2004;,citation_issue=22;,citation_doi=10.1056/NEJMoa040232;,citation_issn=0028-4793;,citation_pmid=15163774;,citation_volume=350;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Détente: A Practical Understanding of P values and Bayesian Posterior Probabilities - Ruberg - 2021 - Clinical Pharmacology &amp;amp;amp; Therapeutics - Wiley Online Library;,citation_doi=10.1002/cpt.2004;">
<meta name="citation_reference" content="citation_title=Dicing with the unknown;,citation_doi=10.1111/j.1740-9713.2004.00050.x;">
<meta name="citation_reference" content="citation_title=Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome;,citation_publication_date=2019-05;,citation_cover_date=2019-05;,citation_year=2019;,citation_issue=21;,citation_doi=10.1056/NEJMoa1901686;,citation_issn=0028-4793;,citation_pmid=31112383;,citation_volume=380;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Early Active Mobilization during Mechanical Ventilation in the ICU;,citation_publication_date=2022-11;,citation_cover_date=2022-11;,citation_year=2022;,citation_issue=19;,citation_doi=10.1056/NEJMoa2209083;,citation_issn=0028-4793;,citation_volume=387;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Early Restrictive or Liberal Fluid Management for Sepsis-Induced Hypotension;,citation_publication_date=2023-02;,citation_cover_date=2023-02;,citation_year=2023;,citation_issue=6;,citation_doi=10.1056/NEJMoa2212663;,citation_issn=0028-4793;,citation_volume=388;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Early Active Mobilization during Mechanical Ventilation in the ICU;,citation_abstract=To the Editor: Previous investigations have shown that oversedation and immobilization of mechanically ventilated patients are associated with or result in greater length of hospital stay, decreased survival, and greater incidence of acquired dementia.1-3 The evidence-based ABCDEF (analgesia monitoring and management, breaks daily from both sedation and ventilator use, choice of sedation [avoiding benzodiazepines], delirium monitoring and management, early mobility, and family engagement) safety bundle helps us rehumanize care and establish higher adherence to key steps; E (for early mobility) yields dose–response results of earlier discharge and greater survival.4 The TEAM (Treatment of Mechanically Ventilated Adults with Early Activity and . . .;,citation_publication_date=2023-02;,citation_cover_date=2023-02;,citation_year=2023;,citation_issue=6;,citation_doi=10.1056/NEJMc2216086;,citation_issn=0028-4793;,citation_volume=388;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Effect of Fluid Bolus Administration on Cardiovascular Collapse Among Critically Ill Patients Undergoing Tracheal Intubation: A Randomized Clinical Trial;,citation_abstract=OBJECTIVE To determine the effect of fluid bolus administration on the incidence of severe hypotension, cardiac arrest, and death. DESIGN, SETTING, AND PARTICIPANTS This randomized clinical trial enrolled 1067 critically ill adults undergoing tracheal intubation with sedation and positive pressure ventilation at 11 intensive care units in the US between February 1, 2019, and May 24, 2021. The date of final follow-up was June 21, 2021. INTERVENTIONS Patients were randomly assigned to receive either a 500-mL intravenous fluid bolus (n = 538) or no fluid bolus (n = 527). MAIN OUTCOMES AND MEASURES The primary outcome was cardiovascular collapse (defined as new or increased receipt of vasopressors or a systolic blood pressure &amp;amp;amp;lt;65 mm Hg between induction of anesthesia and 2 minutes after tracheal intubation, or cardiac arrest or death between induction of anesthesia and 1 hour after tracheal intubation). The secondary outcome was the incidence of death prior to day 28, which was censored at hospital discharge. RESULTS Among 1067 patients randomized, 1065 (99.8%) completed the trial and were included in the primary analysis (median age, 62 years [IQR, 51-70 years]; 42.1% were women). Cardiovascular collapse occurred in 113 patients (21.0%) in the fluid bolus group and in 96 patients (18.2%) in the no fluid bolus group (absolute difference, 2.8% [95% CI, -2.2% to 7.7%]; P = .25). New or increased receipt of vasopressors occurred in 20.6% of patients in the fluid bolus group compared with 17.6% of patients in the no fluid bolus group, a systolic blood pressure of less than 65 mm Hg occurred in 3.9% vs 4.2%, respectively, cardiac arrest occurred in 1.7% vs 1.5%, and death occurred in 0.7% vs 0.6%. Death prior to day 28 (censored at hospital discharge) occurred in 218 patients (40.5%) in the fluid bolus group compared with 223 patients (42.3%) in the no fluid bolus group (absolute difference, -1.8% [95% CI, -7.9% to 4.3%]; P = .55). CONCLUSIONS AND RELEVANCE Among critically ill adults undergoing tracheal intubation, administration of an intravenous fluid bolus compared with no fluid bolus did not significantly decrease the incidence of cardiovascular collapse.;,citation_publication_date=2022;,citation_cover_date=2022;,citation_year=2022;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=End-of-Life Practices in European Intensive Care Units: The Ethicus Study;,citation_abstract=Objectives To determine the frequency and types of actual end-of-life practices in European intensive care units (ICUs) and to analyze the similarities and differences. Design and Setting A prospective, observational study of European ICUs. Participants Consecutive patients who died or had any limitation of therapy. Intervention Prospectively defined end-of-life practices in 37 ICUs in 17 European countries were studied from January 1, 1999, to June 30, 2000. Main Outcome Measures Comparison and analysis of the frequencies and patterns of end-of-life care by geographic regions and different patients and professionals. Results Of 31417 patients admitted to ICUs, 4248 patients (13.5%) died or had a limitation of life-sustaining therapy. Of these, 3086 patients (72.6%) had limitations of treatments (10% of admissions). Substantial intercountry variability was found in the limitations and the manner of dying: unsuccessful cardiopulmonary resuscitation in 20% (range, 5%-48%), brain death in 8% (range, 0%-15%), withholding therapy in 38% (range, 16%-70%), withdrawing therapy in 33% (range, 5%-69%), and active shortening of the dying process in 2% (range, 0%-19%). Shortening of the dying process was reported in 7 countries. Doses of opioids and benzodiazepines reported for shortening of the dying process were in the same range as those used for symptom relief in previous studies. Limitation of therapy vs continuation of life-sustaining therapy was associated with patient age, acute and chronic diagnoses, number of days in ICU, region, and religion (PϽ.001). Conclusion The limiting of life-sustaining treatment in European ICUs is common and variable. Limitations were associated with patient age, diagnoses, ICU stay, and geographic and religious factors. Although shortening of the dying process is rare, clarity between withdrawing therapies and shortening of the dying process and between therapies intended to relieve pain and suffering and those intended to shorten the dying process may be lacking.;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Evidence-based Colloid Use in the Critically Ill: American Thoracic Society Consensus Statement;,citation_publication_date=2004-12;,citation_cover_date=2004-12;,citation_year=2004;,citation_issue=11;,citation_doi=10.1164/rccm.200208-909ST;,citation_issn=1073-449X, 1535-4970;,citation_volume=170;,citation_language=en-US;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Hemicraniectomy for Massive Middle Cerebral Artery Territory Infarction;,citation_doi=10.1161/01.STR.0000109772.64650.18;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Home-Time as a Surrogate Marker for Functional Outcome After Aneurysmal Subarachnoid Hemorrhage;,citation_doi=10.1161/STROKEAHA.118.022808;,citation_language=en-US;,citation_publisher=https://www.ahajournals.org/doi/epub/10.1161/STROKEAHA.118.022808;">
<meta name="citation_reference" content="citation_title=Impact of community masking on COVID-19: A cluster-randomized trial in Bangladesh;,citation_doi=10.1126/science.abi9069;,citation_language=en-US;,citation_publisher=https://www.science.org/doi/10.1126/science.abi9069;">
<meta name="citation_reference" content="citation_title=Lawmakers v. The Scientific Realities of Human Reproduction;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_issue=0;,citation_doi=10.1056/NEJMe2208288;,citation_issn=0028-4793;,citation_volume=0;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock;,citation_abstract=BACKGROUND Cardiogenic shock is associated with substantial morbidity and mortality. Although inotropic support is a mainstay of medical therapy for cardiogenic shock, little evidence exists to guide the selection of inotropic agents in clinical practice. METHODS We randomly assigned patients with cardiogenic shock to receive milrinone or dobutamine in a double-blind fashion. The primary outcome was a composite of in-hospital death from any cause, resuscitated cardiac arrest, receipt of a cardiac transplant or mechanical circulatory support, nonfatal myocardial infarction, transient ischemic attack or stroke diagnosed by a neurologist, or initiation of renal replacement therapy. Secondary outcomes included the individual components of the primary composite outcome. RESULTS A total of 192 participants (96 in each group) were enrolled. The treatment groups did not differ significantly with respect to the primary outcome; a primary outcome event occurred in 47 participants (49%) in the milrinone group and in 52 participants (54%) in the dobutamine group (relative risk, 0.90; 95% confidence interval [CI], 0.69 to 1.19; P = 0.47). There were also no significant differences between the groups with respect to secondary outcomes, including in-hospital death (37% and 43% of the participants, respectively; relative risk, 0.85; 95% CI, 0.60 to 1.21), resuscitated cardiac arrest (7% and 9%; hazard ratio, 0.78; 95% CI, 0.29 to 2.07), receipt of mechanical circulatory support (12% and 15%; hazard ratio, 0.78; 95% CI, 0.36 to 1.71), or initiation of renal replacement therapy (22% and 17%; hazard ratio, 1.39; 95% CI, 0.73 to 2.67). CONCLUSIONS In patients with cardiogenic shock, no significant difference between milrinone and dobutamine was found with respect to the primary composite outcome or important secondary outcomes. (Funded by the Innovation Fund of the Alternative Funding Plan for the Academic Health Sciences Centres of Ontario; ClinicalTrials .gov number, NCT03207165.);,citation_publication_date=2021-11;,citation_cover_date=2021-11;,citation_year=2021;,citation_issue=22;,citation_doi=10.1056/NEJMc2114890;,citation_issn=0028-4793, 1533-4406;,citation_volume=385;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Minimal Clinically Important Difference: Defining What Really Matters to Patients;,citation_publication_date=2014;,citation_cover_date=2014;,citation_year=2014;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Morning Report  NEJM;,citation_doi=10.1056/NEJMp1701939;">
<meta name="citation_reference" content="citation_title=NEJM Notable Articles of 2022;,citation_publisher=https://downloads.ctfassets.net/otzakoj1abuh/5Plvb3b8YsdD3zlsJ5hlE2/f8c4abb7bba3ab39d9196a33d302d1d7/Notable_Articles_of_2022.pdf;">
<meta name="citation_reference" content="citation_title=Prehospital Tranexamic Acid for Severe Trauma;,citation_publication_date=2023-06;,citation_cover_date=2023-06;,citation_year=2023;,citation_issue=0;,citation_doi=10.1056/NEJMoa2215457;,citation_issn=0028-4793;,citation_volume=0;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Premier Healthcare Database White Paper: Data that informs and performs;,citation_language=en-US;,citation_publisher=https://offers.premierinc.com/Premier-Healthcare-Database-Whitepaper-LandingPage.html;">
<meta name="citation_reference" content="citation_title=Randomization versus Real-World Evidence;,citation_publication_date=2020-07;,citation_cover_date=2020-07;,citation_year=2020;,citation_issue=4;,citation_doi=10.1056/NEJMc2020020;,citation_issn=0028-4793, 1533-4406;,citation_volume=383;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=A Randomized Trial of Protocol-Based Care for Early Septic Shock;,citation_abstract=There are more than 750,000 cases of severe sepsis and septic shock in the United States each year.1 Most patients who present with sepsis receive initial care in the emergency department, and the short-term mortality is 20% or more.2,3 In 2001, Rivers et al. reported that among patients with severe sepsis or septic shock in a single urban emergency department, mortality was significantly lower among those who were treated according to a 6-hour protocol of early goal-directed therapy (EGDT) than among those who were given standard therapy (30.5% vs. 46.5%).4 On the basis of the premise that usual care . . .;,citation_publication_date=2014-05;,citation_cover_date=2014-05;,citation_year=2014;,citation_issue=18;,citation_doi=10.1056/NEJMoa1401602;,citation_issn=0028-4793;,citation_pmid=24635773;,citation_volume=370;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Randomized Controlled Trial of Early Rehabilitation After Intracerebral Hemorrhage Stroke  Stroke;,citation_publisher=https://www.ahajournals.org/doi/10.1161/STROKEAHA.114.005661;">
<meta name="citation_reference" content="citation_title=Remdesivir and three other drugs for hospitalised patients with COVID-19: Final results of the WHO Solidarity randomised trial and updated meta-analyses;,citation_abstract=Background The Solidarity trial among COVID-19 inpatients has previously reported interim mortality analyses for four repurposed antiviral drugs. Lopinavir, hydroxychloroquine, and interferon (IFN)-\beta1a were discontinued for futility but randomisation to remdesivir continued. Here, we report the final results of Solidarity and meta-analyses of mortality in all relevant trials to date.;,citation_publication_date=2022-05;,citation_cover_date=2022-05;,citation_year=2022;,citation_issue=10339;,citation_doi=10.1016/S0140-6736(22)00519-0;,citation_issn=01406736;,citation_volume=399;,citation_language=en-US;,citation_journal_title=The Lancet;">
<meta name="citation_reference" content="citation_title=Reporting of Noninferiority and Equivalence Randomized Trials: Extension of the CONSORT 2010 Statement;,citation_abstract=METHODS-OUTCOME: CLARIFY FOR ALL REPORTED OUTCOMES WHETHER NONINFERIORITY OR SUPERIORITY. “The primary objective was a noninferiority comparison between duloxetine and pregabalin on improvement in the weekly mean of the diary-based daily pain score (0- to 10-point scale) at end point. “ . . . adverse effects, nausea, insomnia, hyperhidrosis, and decreased appetite [were secondary outcomes to be assessed for superiority].” RESULTS-OUTCOME: FOR THE PRIMARY NONINFERIORITY OUTCOME, RESULTS IN RELATION TO NONINFERIORITY MARGIN. “The 97.5% lower confidence limit was a Ϫ0.05 difference in means, establishing noninferiority.” CONCLUSIONS: INTERPRETATION TAKING INTO ACCOUNT THE NONINFERIORITY HYPOTHESES AND ANY SUPERIORITY HYPOTHESES. “Duloxetine was noninferior to pregabalin for the treatment of pain in patients with diabetic peripheral neuropathy who had an inadequate pain response to gabapentin.” Explanation. Clear, transparent, and sufficiently detailed abstracts are important. Readers may only have access to the abstract, and many others skim it before deciding whether to read further. A well-written abstract also helps in retrieval of relevant reports from elec-;,citation_publication_date=2010;,citation_cover_date=2010;,citation_year=2010;,citation_doi=10.1001/jama.295.10.1152;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Risk Assessment for Cardiovascular Disease with Nontraditional Risk Factors: Recommendation Statement;,citation_publication_date=2019-01;,citation_cover_date=2019-01;,citation_year=2019;,citation_issue=2;,citation_issn=1532-0650;,citation_pmid=30633483;,citation_volume=99;,citation_language=en-US;,citation_journal_title=American Family Physician;">
<meta name="citation_reference" content="citation_title=Saline or Albumin for Fluid Resuscitation in Patients with Traumatic Brain Injury;,citation_abstract=In patients with traumatic brain injury, resuscitation fluids are fundamental components of the restoration and maintenance of the systemic and cerebral circulations.1,2 There is uncertainty about the best choice of fluids due to the lack of adequately powered randomized, controlled trials. Consequently, both crystalloid-based and colloid-based resuscitation strategies have been advocated.3,4 The Saline versus Albumin Fluid Evaluation (SAFE) study compared the effect of fluid resuscitation with albumin or saline on mortality in a heterogeneous population of patients in intensive care units (ICUs).5 Overall, the study showed no significant difference in the risk of death among patients who received . . .;,citation_publication_date=2007-08;,citation_cover_date=2007-08;,citation_year=2007;,citation_issue=9;,citation_doi=10.1056/NEJMoa067514;,citation_issn=0028-4793;,citation_pmid=17761591;,citation_volume=357;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Simvastatin in Critically Ill Patients with Covid-19;,citation_publication_date=2023-10;,citation_cover_date=2023-10;,citation_year=2023;,citation_issue=0;,citation_doi=10.1056/NEJMoa2309995;,citation_issn=0028-4793;,citation_volume=0;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Subarachnoid haemorrhage caused by a ruptured aneurysm: Diagnosis and management;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_issue=9;,citation_doi=10.1056/NEJMoa2105911;,citation_issn=0028-4793;,citation_pmid=34351721;,citation_volume=385;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Universal videolaryngoscopy: Take care when crossing the Rubicon;,citation_doi=10.1111/anae.15977;,citation_language=en-US;,citation_publisher=https://associationofanaesthetists.publications.onlinelibrary.wiley.com/doi/epdf/10.1111/anae.15977;">
<meta name="citation_reference" content="citation_title=The value of open-source clinical science in pandemic response: Lessons from ISARIC;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_doi=10.1016/S1473-3099(21)00565-X;,citation_issn=14733099;,citation_language=en-US;,citation_journal_title=The Lancet Infectious Diseases;">
<meta name="citation_reference" content="citation_title=Who Says There Is No “I” in Team? Achieving Individual Success in Collaborative Clinical Research in Critical Care  American Journal of Respiratory and Critical Care Medicine;,citation_doi=10.1164/rccm.201602-0405LE;">
<meta name="citation_reference" content="citation_title=Commentary: Epidemiologists have debated representativeness for more than 40 years–has the time come to move on?;,citation_author=E. A. Nohr;,citation_author=J. Olsen;,citation_publication_date=2013-08;,citation_cover_date=2013-08;,citation_year=2013;,citation_issue=4;,citation_doi=10.1093/ije/dyt102;,citation_issn=0300-5771, 1464-3685;,citation_volume=42;,citation_language=en-US;,citation_journal_title=International Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=I. Hydroxyethyl starch: Here today, gone tomorrow;,citation_author=J. P. Nolan;,citation_author=M. G. Mythen;,citation_publication_date=2013-09;,citation_cover_date=2013-09;,citation_year=2013;,citation_issue=3;,citation_doi=10.1093/bja/aet294;,citation_issn=00070912;,citation_volume=111;,citation_language=en-US;,citation_journal_title=British Journal of Anaesthesia;">
<meta name="citation_reference" content="citation_title=Unpacking the complexities of de-implementing inappropriate health interventions;,citation_abstract=De-implementing inappropriate health interventions is essential for minimizing patient harm, maximizing efficient use of resources, and improving population health. Research on de-implementation has expanded in recent years as it cuts across types of interventions, patient populations, health conditions, and delivery settings. This commentary explores unique aspects of de-implementing inappropriate interventions that differentiate it from implementing evidence-based interventions, including multi-level factors, types of action, strategies for de-implementation, outcomes, and unintended negative consequences. We highlight opportunities to continue to advance research on the deimplementation of inappropriate interventions in health care and public health.;,citation_author=Wynne E. Norton;,citation_author=David A. Chambers;,citation_publication_date=2020-12;,citation_cover_date=2020-12;,citation_year=2020;,citation_issue=1;,citation_doi=10.1186/s13012-019-0960-9;,citation_issn=1748-5908;,citation_volume=15;,citation_language=en-US;,citation_journal_title=Implementation Science;">
<meta name="citation_reference" content="citation_title=The preregistration revolution;,citation_abstract=Progress in science relies in part on generating hypotheses with existing observations and testing hypotheses with new observations. This distinction between postdiction and prediction is appreciated conceptually but is not respected in practice. Mistaking generation of postdictions with testing of predictions reduces the credibility of research findings. However, ordinary biases in human reasoning, such as hindsight bias, make it hard to avoid this mistake. An effective solution is to define the research questions and analysis plan before observing the research outcomes—a process called preregistration. Preregistration distinguishes analyses and outcomes that result from predictions from those that result from postdictions. A variety of practical strategies are available to make the best possible use of preregistration in circumstances that fall short of the ideal application, such as when the data are preexisting. Services are now available for preregistration across all disciplines, facilitating a rapid increase in the practice. Widespread adoption of preregistration will increase distinctiveness between hypothesis generation and hypothesis testing and will improve the credibility of research findings.;,citation_author=Brian A. Nosek;,citation_author=Charles R. Ebersole;,citation_author=Alexander C. DeHaven;,citation_author=David T. Mellor;,citation_publication_date=2018-03;,citation_cover_date=2018-03;,citation_year=2018;,citation_issue=11;,citation_doi=10.1073/pnas.1708274114;,citation_volume=115;,citation_journal_title=Proceedings of the National Academy of Sciences;,citation_publisher=Proceedings of the National Academy of Sciences;">
<meta name="citation_reference" content="citation_title=Priorities for Clinical Research in Intracerebral Hemorrhage;,citation_abstract=Background and Purpose— Spontaneous intracerebral hemorrhage (ICH) is one of the most lethal stroke types. In December 2003, a National Institute of Neurological Disorders and Stroke (NINDS) workshop was convened to develop a consensus for ICH research priorities. The focus was clinical research aimed at acute ICH in patients. Methods— Workshop participants were divided into 6 groups: (1) current state of ICH research; (2) basic science; and (3) imaging, (4) medical, (5) surgical, and (6) clinical methodology. Each group formulated research priorities before the workshop. At the workshop, these were discussed and refined. Results— Recent progress in management of hemorrhage growth, intraventricular hemorrhage, and limitations in the benefit of open craniotomy were noted. The workshop identified the importance of developing animal models to reflect human ICH, as well as the phenomena of rebleeding. More human ICH pathology is needed. Real-time, high-field magnets and 3-dimensional imaging, as well as high-resolution tissue probes, are ICH imaging priorities. Trials of acute blood pressure–lowering in ICH and coagulopathy reversal are medical priorities. The exact role of edema in human ICH pathology and its treatment requires intensive study. Trials of minimally invasive surgical techniques including mechanical and chemical surgical adjuncts are critically important. The methodologic challenges include establishing research networks and a multi-specialty approach. Waiver of consent issues and standardizing care in trials are important issues. Encouragement of young investigators from varied backgrounds to enter the ICH research field is critical. Conclusions— Increasing ICH research is crucial. A collaborative approach is likely to yield therapies for this devastating form of brain injury.;,citation_author=null null;,citation_publication_date=2005-03;,citation_cover_date=2005-03;,citation_year=2005;,citation_issue=3;,citation_doi=10.1161/01.STR.0000155685.77775.4c;,citation_volume=36;,citation_journal_title=Stroke;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=Education in evidence-based health care: Never a greater need;,citation_author=David Nunan;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=5;,citation_doi=10.1136/bmjebm-2021-111792;,citation_issn=2515-446X, 2515-4478;,citation_volume=26;,citation_language=en-US;,citation_journal_title=BMJ Evidence-Based Medicine;">
<meta name="citation_reference" content="citation_title=Ten papers for teachers of evidence-based medicine and health care: Sicily workshop 2019;,citation_author=David Nunan;,citation_author=Adrienne Lindblad;,citation_author=Indah S Widyahening;,citation_author=Wanderley M Bernardo;,citation_author=Ching-Chi Chi;,citation_author=Fiona Cowdell;,citation_author=Karen Becker;,citation_author=Shadia Constantine;,citation_author=Christine East;,citation_author=Hilde T Myrhaug;,citation_author=Susanne Grødem Johnson;,citation_author=Edmund Jack;,citation_author=Rachel Thompson;,citation_author=Haris Achilleos;,citation_author=Rigmor C Berg;,citation_author=Anne Kristin Snibsøer;,citation_author=Lucian Puscasiu;,citation_author=Marie-Louise EL Bartelink;,citation_author=Petra G Peet;,citation_author=Franco Berti;,citation_author=Julie Tilson;,citation_author=Kari AO Tikkinen;,citation_author=Loai Albarqouni;,citation_author=Peter Hoegen;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=5;,citation_doi=10.1136/bmjebm-2020-111479;,citation_issn=2515-446X, 2515-4478;,citation_volume=26;,citation_language=en-US;,citation_journal_title=BMJ Evidence-Based Medicine;">
<meta name="citation_reference" content="citation_title=Ten resources for understanding bias in health research: EBM live workshop 2022;,citation_abstract=Previous articles introduced resources for practising1 and teaching2 evidence-based medicine (EBM) and healthcare (EBHC). In an in-person workshop at the 2022 EBM live conference in Oxford, participants were invited to consider resources on bias in health research, contribute to a database of such studies and disseminate their learning. This paper shares insights from the workshop. ### Resource selection process The resource selection process is outlined in figure 1. Briefly, participants (n=25), in small groups, were given time to list and discuss resources they deemed useful for understanding bias in health research. Each resource was accompanied by its details and reasons for inclusion. The groups then selected their top three resources and finally, their top resource for this manuscript. Little information was provided before the workshop as to its nature so as to deliberately ensure the challenge of participants having to recall, find and discuss relevant articles, texts and examples. A real-time Google spreadsheet served as a database of resources. Due to time constraints, most groups could not provide a synopsis of their resources during the workshop; hence, it was done later. Figure 1 Resource selection process. While acknowledging the potential for exclusion of relevant articles, the consensus was that if, out of a group of 25 or so EBHC enthusiasts, a specific resource from one of the authors in the workshop was not mentioned then it …;,citation_author=David Nunan;,citation_author=Kainat Bashir;,citation_author=Krish Bilimoria;,citation_author=Jasminder Birdi;,citation_author=Fiona Campbell;,citation_author=Rachel Dean;,citation_author=Matthew B. Downer;,citation_author=Gabriel Gonçalves Costa;,citation_author=Melanie M. Golob;,citation_author=Angille Heintzman;,citation_author=Mark Steven Howe;,citation_author=Sathya Karunananthan;,citation_author=Karishma Krishna Kurup;,citation_author=Andrea Leinberger-Jabari;,citation_author=Yan Luo;,citation_author=Nonsikelelo Mathe;,citation_author=Red Thaddeus D. Miguel;,citation_author=Richard L. Morrow;,citation_author=Caroline Scobie;,citation_author=Victoria South;,citation_author=Jenny Stavisky;,citation_author=Uday Narayan Yadav;,citation_publication_date=2023-07;,citation_cover_date=2023-07;,citation_year=2023;,citation_doi=10.1136/bmjebm-2023-112344;,citation_issn=2515-446X, 2515-4478;,citation_pmid=37479244;,citation_language=en-US;,citation_journal_title=BMJ Evidence-Based Medicine;,citation_publisher=Royal Society of Medicine;">
<meta name="citation_reference" content="citation_title=Prehospital high-dose methylprednisolone in resuscitated out-of-hospital cardiac arrest patients (STEROHCA): A randomized clinical trial;,citation_abstract=Purpose: Patients who are successfully resuscitated following out-of-hospital cardiac arrest (OHCA) are still at a high risk of neurological damage and death. Inflammation and brain injury are components of the post-cardiac arrest syndrome, and can be assessed by systemic interleukin 6 (IL-6) and neuron-specific enolase (NSE). Anti-inflammatory treatment with methylprednisolone may dampen inflammation, thereby improving outcome. This study aimed to determine if prehospital high-dose methylprednisolone could reduce IL-6 and NSE in comatose OHCA patients. Methods: The STEROHCA trial was a randomized, blinded, placebo-controlled, phase II prehospital trial performed at two cardiac arrest centers in Denmark. Resuscitated comatose patients with suspected cardiac etiology were randomly assigned 1:1 to a single intravenous injection of 250 mg methylprednisolone or placebo. The co-primary outcome was reduction of IL-6 and NSE-blood levels measured daily for 72 h from admission. The main secondary outcome was survival at 180 days follow-up. Results: We randomized 137 patients to methylprednisolone (n = 68) or placebo (n = 69). We found reduced IL-6 levels (p &amp;amp;amp;lt; 0.0001) in the intervention group, with median (interquartile range, IQR) levels at 24 h of 2.1 pg/ml (1.0; 7.1) and 30.7 pg/ml (14.2; 59) in the placebo group. We observed no difference between groups in NSE levels (p = 0.22), with levels at 48 h of 18.8 ug/L (14.4; 24.6) and 14.8 ug/L (11.2; 19.4) in the intervention and placebo group, respec-tively. In the intervention group, 51 (75%) patients survived and 44 (64%) in the placebo group. Conclusion: Prehospital treatment with high-dose methylprednisolone to resuscitated comatose OHCA patients, resulted in reduced IL-6 levels after 24 h, but did not reduce NSE levels.;,citation_author=Laust E. R. Obling;,citation_author=Rasmus P. Beske;,citation_author=Martin A. S. Meyer;,citation_author=Johannes Grand;,citation_author=Sebastian Wiberg;,citation_author=Benjamin Nyholm;,citation_author=Jakob Josiassen;,citation_author=Frederik T. Søndergaard;,citation_author=Thomas Mohr;,citation_author=Anders Damm-Hejmdal;,citation_author=Mette Bjerre;,citation_author=Ruth Frikke-Schmidt;,citation_author=Fredrik Folke;,citation_author=Jacob E. Møller;,citation_author=Jesper Kjaergaard;,citation_author=Christian Hassager;,citation_publication_date=2023-12;,citation_cover_date=2023-12;,citation_year=2023;,citation_issue=12;,citation_doi=10.1007/s00134-023-07247-w;,citation_issn=0342-4642, 1432-1238;,citation_volume=49;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial;,citation_abstract=OBJECTIVE To evaluate the effect of combination subcutaneous casirivimab and imdevimab on progression from early asymptomatic SARS-CoV-2 infection to symptomatic COVID-19. DESIGN, SETTING, AND PARTICIPANTS Randomized, double-blind, placebo-controlled, phase 3 trial of close household contacts of a SARS-CoV-2–infected index case at 112 sites in the US, Romania, and Moldova enrolled July 13, 2020–January 28, 2021; follow-up ended March 11, 2021. Asymptomatic individuals (aged Ն12 years) were eligible if identified within 96 hours of index case positive test collection. Results from 314 individuals positive on SARS-CoV-2 reverse transcriptase–quantitative polymerase chain reaction (RT-qPCR) testing are reported. INTERVENTIONS Individuals were randomized 1:1 to receive 1 dose of subcutaneous casirivimab and imdevimab, 1200 mg (600 mg of each; n = 158), or placebo (n = 156). MAIN OUTCOMES AND MEASURES The primary end point was the proportion of seronegative participants who developed symptomatic COVID-19 during the 28-day efficacy assessment period. The key secondary efficacy end points were the number of weeks of symptomatic SARS-CoV-2 infection and the number of weeks of high viral load (&amp;amp;amp;gt;4 log10 copies/mL). RESULTS Among 314 randomized participants (mean age, 41.0 years; 51.6% women), 310 (99.7%) completed the efficacy assessment period; 204 were asymptomatic and seronegative at baseline and included in the primary efficacy analysis. Subcutaneous casirivimab and imdevimab, 1200 mg, significantly prevented progression to symptomatic disease (29/100 [29.0%] vs 44/104 [42.3%] with placebo; odds ratio, 0.54 [95% CI, 0.30-0.97]; P = .04; absolute risk difference, -13.3% [95% CI, -26.3% to -0.3%]). Casirivimab and imdevimab reduced the number of symptomatic weeks per 1000 participants (895.7 weeks vs 1637.4 weeks with placebo; P = .03), an approximately 5.6-day reduction in symptom duration per symptomatic participant. Treatment with casirivimab and imdevimab also reduced the number of high viral load weeks per 1000 participants (489.8 weeks vs 811.9 weeks with placebo; P = .001). The proportion of participants receiving casirivimab and imdevimab who had 1 or more treatment-emergent adverse event was 33.5% vs 48.1% for placebo, including events related (25.8% vs 39.7%) or not related (11.0% vs 16.0%) to COVID-19. CONCLUSIONS AND RELEVANCE Among asymptomatic SARS-CoV-2 RT-qPCR–positive individuals living with an infected household contact, treatment with subcutaneous casirivimab and imdevimab antibody combination vs placebo significantly reduced the incidence of symptomatic COVID-19 over 28 days.;,citation_author=Meagan P. O’Brien;,citation_author=Eduardo Forleo-Neto;,citation_author=Neena Sarkar;,citation_author=Flonza Isa;,citation_author=Peijie Hou;,citation_author=Kuo-Chen Chan;,citation_author=Bret J. Musser;,citation_author=Katharine J. Bar;,citation_author=Ruanne V. Barnabas;,citation_author=Dan H. Barouch;,citation_author=Myron S. Cohen;,citation_author=Christopher B. Hurt;,citation_author=Dale R. Burwen;,citation_author=Mary A. Marovich;,citation_author=Elizabeth R. Brown;,citation_author=Ingeborg Heirman;,citation_author=John D. Davis;,citation_author=Kenneth C. Turner;,citation_author=Divya Ramesh;,citation_author=Adnan Mahmood;,citation_author=Andrea T. Hooper;,citation_author=Jennifer D. Hamilton;,citation_author=Yunji Kim;,citation_author=Lisa A. Purcell;,citation_author=Alina Baum;,citation_author=Christos A. Kyratsous;,citation_author=James Krainson;,citation_author=Richard Perez-Perez;,citation_author=Rizwana Mohseni;,citation_author=Bari Kowal;,citation_author=A. Thomas DiCioccio;,citation_author=Gregory P. Geba;,citation_author=Neil Stahl;,citation_author=Leah Lipsich;,citation_author=Ned Braunstein;,citation_author=Gary Herman;,citation_author=George D. Yancopoulos;,citation_author=David M. Weinreich;,citation_author=COVID-19 Phase 3 Prevention Trial Team;,citation_author=Neal Warshoff;,citation_author=Liudmila Moreiras;,citation_author=Dario Altamirano;,citation_author=Dickson Ellington;,citation_author=Faisal Faikih;,citation_author=William Smith;,citation_author=Richard Gibson;,citation_author=Katie Buckner;,citation_author=Robert Rosen;,citation_author=Amy Sapp;,citation_author=Anita Kohli;,citation_author=Vicki McIntyre;,citation_author=Yessica Sachdeva;,citation_author=Amanda McFarland;,citation_author=Dina Gibson;,citation_author=Kenneth Kim;,citation_author=Jason Ahn;,citation_author=Lisa Neinchel;,citation_author=Nayna Paryani;,citation_author=Amber Mottola;,citation_author=Eva Day;,citation_author=Martha Navarro;,citation_author=Rafaelito Victoria;,citation_author=Xanthe Victoria;,citation_author=Rene Uong;,citation_author=Mindy Sampson;,citation_author=Christopher Polk;,citation_author=Michael Leonard;,citation_author=Lewis McCurdy;,citation_author=Leigh A. Medaris;,citation_author=Zainab Shahid;,citation_author=Lisa Davidson;,citation_author=Jawad Nazir;,citation_author=John Lee;,citation_author=Amy Elliott;,citation_author=Swami Sathyanaryan;,citation_author=Mansi Oberoi;,citation_author=Muhammad (Danial) Siddiqui;,citation_author=Muhammad Arsad;,citation_author=Kara Bruning;,citation_author=Sybil Hosek;,citation_author=Temitope Oyedele;,citation_author=Vanessa Sarda;,citation_author=Monica Mercon;,citation_author=Kathryn Stephenson;,citation_author=Boris Juelg;,citation_author=Chen Sabrina Tan;,citation_author=Rebecca Zash;,citation_author=Ai-ris Collier;,citation_author=Jessica Ansel;,citation_author=Kate Jaegle;,citation_author=Lilia Roque-Guerrero;,citation_author=Ana Gomez Ramirez;,citation_author=Javier Capote;,citation_author=Gisel Paz;,citation_author=Michael Paasche-Orlow;,citation_author=Julien Dedier;,citation_author=Sanjay Vadgama;,citation_author=Ramachandra Patak;,citation_author=Nicolas Chronos;,citation_author=Cary Hefty;,citation_author=Judith Borger;,citation_author=Ifeanyi Momodu;,citation_author=Lindsey Carswell;,citation_author=Benjamin King;,citation_author=Ryan Starr;,citation_author=Scott Syndergaard;,citation_author=Nancy Patel;,citation_author=Ravikumar Patel;,citation_author=Ryan Sattar;,citation_author=Jeffrey Unger;,citation_author=Sheila De Jesus-Maranan;,citation_author=Cecilia Casaclang;,citation_author=Michael Seep;,citation_author=Celeste Brown;,citation_author=Joshua Whatley;,citation_author=Dennis Levinson;,citation_author=Saad Alvi;,citation_author=Norman James;,citation_author=Azazuddin Ahmed;,citation_author=Robinson Koilpillai;,citation_author=Stephanie Cassady;,citation_author=Jennifer Cox;,citation_author=Eduardo Torres;,citation_author=Mark J. Rosenthal;,citation_author=Michael Winnie;,citation_author=Jerry Plemons;,citation_author=Omesh Verma;,citation_author=Richard Leggett;,citation_author=Ramon Reyes;,citation_author=Keith Beck;,citation_author=Brian Poliquin;,citation_author=Murtaza Mussaji;,citation_author=Jignesh Shah;,citation_author=David Sutton;,citation_author=Edward Pereira;,citation_author=Rodel Gloria;,citation_author=Stacey Kelly;,citation_author=Amy Dennis-Saltz;,citation_author=Mae Sheikh-Ali;,citation_author=Elias Saikali;,citation_author=James Magee;,citation_author=Rebecca Goldfaden;,citation_author=Haresh Boghara;,citation_author=Sunny Patel;,citation_author=Bari Eichelbaum;,citation_author=Duane Anderson;,citation_author=Sean Su;,citation_author=Alexander Akhavan;,citation_author=Diana Kirby;,citation_author=Joy Venglik;,citation_author=Kenneth Mayer;,citation_author=Taimur Khan;,citation_author=Marcy Gelman;,citation_author=Faisal A. Fakih;,citation_author=Faisal M. Fakih;,citation_author=Daniel Layish;,citation_author=Fernando Alvarado;,citation_author=Jose Diaz;,citation_author=Augusto Focil;,citation_author=Griselda Rosas;,citation_author=Stevan Correa;,citation_author=Michael Bogseth;,citation_author=Bhaktasharan Patel;,citation_author=Gary Tarshis;,citation_author=Katrina Grablin;,citation_author=Paul Simonelli;,citation_author=Stanley Martin;,citation_author=Alvin Sharma;,citation_author=Anna Chen;,citation_author=Pragya Dhaubhadel;,citation_author=Shaeesta Khan;,citation_author=Sreelatha Naik;,citation_author=Sudheer Penupolu;,citation_author=Thulashie Sivarajah;,citation_author=Tae-Sung Kwon;,citation_author=Lakshmi Saladi;,citation_author=Farbod Raiszadeh;,citation_author=Sharon Mannheimer;,citation_author=Raji Ayinla;,citation_author=Khaing Myint;,citation_author=Akari Kyawa;,citation_author=Donna Dowie;,citation_author=Robin O’Reilly;,citation_author=Hussein Assallum;,citation_author=Lovelyamma Varghese;,citation_author=Ellen Morrison;,citation_author=Julie Franks;,citation_author=Jun Avelino Loquere;,citation_author=Orlando Rosario;,citation_author=Andrea Low;,citation_author=Joan Villacrucis;,citation_author=Alan Skolnick;,citation_author=Harold Minkowitz;,citation_author=David Leiman;,citation_author=Todd Price;,citation_author=Anatoli Krasko;,citation_author=Idisoro Wiener;,citation_author=Larry Reed;,citation_author=Oscar Lin;,citation_author=Mayur Ramesh;,citation_author=George Alangaden;,citation_author=Suraj Saggar;,citation_author=Thomas Birch;,citation_author=Benjamin De La Rosa;,citation_author=Karyna Neyra;,citation_author=Erina Kunwar;,citation_author=Jeffrey Kingsley;,citation_author=April Pixler;,citation_author=Veronica McBride;,citation_author=Judith Aberg;,citation_author=Michelle Cespedes;,citation_author=Alexandra Abrams-Downey;,citation_author=Erna Kojic;,citation_author=Luz Lugo;,citation_author=Sean Liu;,citation_author=Nadim Salomon;,citation_author=David Perlman;,citation_author=Deena Altman;,citation_author=Farah Rahman;,citation_author=Georgina Osorio;,citation_author=Joseph Mathew;,citation_author=Sanjana Koshy;,citation_author=Dana Mazo;,citation_author=Francesca Cossarini;,citation_author=Sondra Middleton;,citation_author=Alina Jen;,citation_author=Erika Maria Reategui Schwarz;,citation_author=Miguel Trevino;,citation_author=Benjamin DeVries;,citation_author=Vidya Menon;,citation_author=Moiz Kasubhai;,citation_author=Usha Venugopal;,citation_author=Anjana Pillai;,citation_author=Franscene Oulds;,citation_author=Matthew Hong;,citation_author=Wayne Harper;,citation_author=Lynn Eckert;,citation_author=Douglas Wadeson;,citation_author=Lisa Cohen;,citation_author=Joel Chua;,citation_author=Shyam Kottilil;,citation_author=Jennifer Husson;,citation_author=John Baddley;,citation_author=R. Gentry Wilkerson;,citation_author=Shivakumar Narayanan;,citation_author=Uzoamaka Eke;,citation_author=Myint Noe;,citation_author=Melanie Malave Sanchez;,citation_author=Arthur Kim;,citation_author=Greg Robbins;,citation_author=Mark Siedner;,citation_author=Rajesh Gandhi;,citation_author=Kristen Hysell;,citation_author=Jacob Lazarus;,citation_author=Lael Yonker;,citation_author=Roberto Arduino;,citation_author=Karen J. Vigil;,citation_author=Carlos J. Bello;,citation_author=Esperanza Arce-Nunez;,citation_author=Jorge Acosta;,citation_author=Julio L. Arronte;,citation_author=Eric Meissner;,citation_author=Patrick Flume;,citation_author=Andrew Goodwin;,citation_author=Deeksha Jandhyala;,citation_author=Nandita Nadig;,citation_author=Robert Jeanfreau;,citation_author=Susan Jeanfreau;,citation_author=Susan Tortorich;,citation_author=Shiva Akula;,citation_author=Paul Matherne;,citation_author=Donald Gaddy;,citation_author=Magdy Mikhail;,citation_author=Rajasekaran Annamalai;,citation_author=Huy Nguyen;,citation_author=Nizar Nayani;,citation_author=Mahalakshmi Ramchandra;,citation_author=Priyesh Mehta;,citation_author=Jacqueline Horne;,citation_author=Grace Hassan;,citation_author=Godson Oguchi;,citation_author=Judepatricks Onyema;,citation_author=Moti Ramgopal;,citation_author=Brenda Jacobs;,citation_author=Lisa Cason;,citation_author=Angela Trodglen;,citation_author=Adrian Streinu;,citation_author=Daniela Manolache;,citation_author=Anca Streinu-Cercel;,citation_author=Oana Sandulescu;,citation_author=Ana Blanaru;,citation_author=Monica Stoica;,citation_author=Ana Maria Andone;,citation_author=Daniela Dospinoiu;,citation_author=Silviu Serban;,citation_author=Loredana Patru;,citation_author=Christina Buhuara;,citation_author=Ramona Dorobantu;,citation_author=Magdalena Motoi;,citation_author=Ioana Daramus;,citation_author=George Bihoi;,citation_author=Alexandra Ghita;,citation_author=Victor Miron;,citation_author=Gylda Spataru;,citation_author=Amesika Nyaku;,citation_author=Shobha Swaminathan;,citation_author=Terence Chang;,citation_author=Robbyn Traylor;,citation_author=Lenee Gordon;,citation_author=John McDivitt;,citation_author=Lizette Castro;,citation_author=Douglas Young;,citation_author=Gary Carson;,citation_author=Angelica Kottkamp;,citation_author=Mark J. Mulligan;,citation_author=Anna Bershteyn;,citation_author=Vanessa Raabe;,citation_author=Tamia Davis;,citation_author=Mary Olson;,citation_author=Seuli Brill;,citation_author=Carlos Malvestutto;,citation_author=Susan Koletar;,citation_author=Taru Saigal;,citation_author=Mahdee Sobhanie;,citation_author=Vignesh Doraiswamy;,citation_author=Mahrous Abo Hassan;,citation_author=Jeremy Young;,citation_author=Edwin DeJesus;,citation_author=Charlotte-Paige Rolle;,citation_author=Federico Hinestrosa;,citation_author=Dan Cruz;,citation_author=Terry Wilder;,citation_author=Jeffrey Garrett;,citation_author=Stephanie Skipper;,citation_author=Ramprasad Dandillaya;,citation_author=Kartik Ananth;,citation_author=Ian Frank;,citation_author=Helen Koenig;,citation_author=Eileen Donaghy;,citation_author=Debora Dunbar;,citation_author=Jennifer Killion;,citation_author=Rupal Amin;,citation_author=Shauna Basener;,citation_author=Timothy Lowry;,citation_author=Kevin Cannon;,citation_author=Mesha Chadwick;,citation_author=Oscar Galvez;,citation_author=Fausto Castillo;,citation_author=John Jefferies;,citation_author=Sandy Arnold;,citation_author=Amber Thacker;,citation_author=Edward Cordasco;,citation_author=Brian Zeno;,citation_author=Heather Holmes;,citation_author=Heather Lee;,citation_author=Natalia Gaibu;,citation_author=Victor Cojocaru;,citation_author=Aristia Seremet;,citation_author=Sergiu Iacob;,citation_author=Rodica Usatii;,citation_author=Nelea Ghicavii;,citation_author=Angela Coltuclu;,citation_author=Oxana Bujor;,citation_author=Eleftherios Mylonakis;,citation_author=Dimitrios Farmakiotis;,citation_author=Karen Tashima;,citation_author=Natasha Ryback;,citation_author=Peter Ruane;,citation_author=Peter Wolfe;,citation_author=Kenny Trinidad;,citation_author=James Moy;,citation_author=Raj Shah;,citation_author=Bandi Sindhura;,citation_author=Beverly Sha;,citation_author=Mark Savant;,citation_author=Francis Hsiao;,citation_author=Edna Yee;,citation_author=Manuel Gordillo;,citation_author=Rishi Bhattacharyya;,citation_author=Sudha Tallapragada;,citation_author=Annette Artau;,citation_author=Julie Larkin;,citation_author=Roberto Mercado;,citation_author=Michael Milam;,citation_author=Natan Kraitman;,citation_author=Michael Lowry;,citation_author=Sarah Temple;,citation_author=Lenka Offner;,citation_author=Rabih Loutfi;,citation_author=Kirk Voelker;,citation_author=Marshall Frank;,citation_author=Ashley Grant;,citation_author=James Sims;,citation_author=Manuel Vasquez;,citation_author=Kenneth Degazon;,citation_author=Katherine Asuncion;,citation_author=Jason Andrews;,citation_author=Aruna Subramanian;,citation_author=Upinder Singh;,citation_author=Yvonne Maldonado;,citation_author=Chaitan Khosla;,citation_author=Esteban Olivera;,citation_author=Mayra Abreu;,citation_author=Adil Fatakia;,citation_author=Marissa Miller;,citation_author=Kristen Clinton;,citation_author=Gary Reiss;,citation_author=Srilatha Edupuganti;,citation_author=Nadine Rouphael;,citation_author=Colleen Kelley;,citation_author=Varun Phadke;,citation_author=Cassie Grimsley Ackerley;,citation_author=Matthew Collins;,citation_author=Loren Miller;,citation_author=Timothy Hatlen;,citation_author=Michael Chung;,citation_author=Valeria Cantos Lucio;,citation_author=Carlos Rio;,citation_author=Jeffrey Lennox;,citation_author=Sheetal Kandiah;,citation_author=Caitlin Moran;,citation_author=Anandi Sheth;,citation_author=Paulina Rebolledo;,citation_author=Nithin Gopalsamy;,citation_author=Divya Bhamidipati;,citation_author=Olayemi Osiyemi;,citation_author=Jose A. Menajovsky-Chaves;,citation_author=Christina Campbell;,citation_author=Andrew Strand;,citation_author=Andreas Klein;,citation_author=Debra Poutsiaka;,citation_author=Roberto Viau Colindres;,citation_author=Brian Chow;,citation_author=Cheleste Thorpe;,citation_author=Mary Hopkins;,citation_author=Jenn Chow;,citation_author=Rakhi Kohli;,citation_author=Jose Caro;,citation_author=Jeffrey Griffiths;,citation_author=Helen Boucher;,citation_author=Whitney Perry;,citation_author=Laura Kogelman;,citation_author=Yoav Golan;,citation_author=Tine Vindenes;,citation_author=Carlos Mendoza;,citation_author=Saba Mostafavi;,citation_author=Christhian Alejandro Cano Guerra;,citation_author=Paula Dabenigno;,citation_author=Bipin Malla;,citation_author=Dahlene Fusco;,citation_author=Arnaud Drouin;,citation_author=Joshua Denson;,citation_author=Jerry Zifodya;,citation_author=Christine Bojanowski;,citation_author=Monika Dietrich;,citation_author=Stacy Drury;,citation_author=Jesica Herrick;,citation_author=Richard Novak;,citation_author=Mahesh Patel;,citation_author=Gerard Acloque;,citation_author=Agustin Martinez;,citation_author=Sanjay Sethi;,citation_author=Brian Clemency;,citation_author=Rajesh Kunadharaju;,citation_author=Sairam Parthasarathy;,citation_author=Franz Rischard;,citation_author=Stuart Cohen;,citation_author=George Thompson;,citation_author=Hien Nguyen;,citation_author=Scott Crabtree;,citation_author=Carl Fichtenbaum;,citation_author=Moises Huaman;,citation_author=Jaime Robertson;,citation_author=Eric A. F. Simões;,citation_author=Thomas Campbell;,citation_author=Poornima Ramanan;,citation_author=Hillary Dunlevy;,citation_author=Esther Benamu;,citation_author=Amiran Baduashvili;,citation_author=Martin Krsak;,citation_author=Steven Johnson;,citation_author=Lakshmi Chauhan;,citation_author=Erica Fredregil;,citation_author=Samantha Economos;,citation_author=Brian T. Montague;,citation_author=Rowena Crow;,citation_author=Gary Kleiner;,citation_author=Lilian Abbo;,citation_author=Bhavarth Shukla;,citation_author=Jennifer Gebbia;,citation_author=Maria Rodriguez;,citation_author=Anne-Marie Leuck;,citation_author=Mahsa Abassi;,citation_author=Matthew Pullen;,citation_author=Jose Lucar Lloveras;,citation_author=Leandro Mena;,citation_author=Luis Shimose Ciudad;,citation_author=Jessica Lin;,citation_author=David Wohl;,citation_author=William Fischer;,citation_author=Kathleen Tompkins;,citation_author=Kami Kim;,citation_author=Seetha Lakshmi;,citation_author=Charurut Somboonwit;,citation_author=Jason Wilson;,citation_author=Asa Oxner;,citation_author=Tiffany Vasey;,citation_author=Lucy Guerra;,citation_author=William Petri;,citation_author=Katie Dykstra;,citation_author=Marianne Morrissey;,citation_author=Lejla Cesko;,citation_author=Jae Shin;,citation_author=Cirle Warren;,citation_author=Jennifer Sasson;,citation_author=Chelsea Marie;,citation_author=Debbie-Ann Shirley;,citation_author=Rebecca Carpenter;,citation_author=Gregory Madden;,citation_author=Danielle Donigan;,citation_author=Michelle Sutton;,citation_author=Cynthia Edwards;,citation_author=Elizabeth Brooks;,citation_author=Rebecca Wade;,citation_author=Samantha Simmons;,citation_author=Jennifer Pinnata;,citation_author=Shelly Karuna;,citation_author=Ann C. Collier;,citation_author=Julie McElrath;,citation_author=Janine Maenza;,citation_author=Adrienne Shapiro;,citation_author=Helen Stankiewicz-Karita;,citation_author=Helen Chu;,citation_author=Chandler Church;,citation_author=William Hartman;,citation_author=Joseph Connor;,citation_author=Robert Striker;,citation_author=Julie Philley;,citation_author=Megan Devine;,citation_author=Richard Yates;,citation_author=Steven Hickerson;,citation_author=Spyros Kalams;,citation_author=Greg Wilson;,citation_author=Michael Donnenberg;,citation_author=Marjolein Wit;,citation_author=David Erb;,citation_author=Luis DeLaCruz;,citation_author=Supinder Channa;,citation_author=Sarah Henn;,citation_author=Megan Coleman;,citation_author=Lynsay MacLaren;,citation_author=Deborah Goldstein;,citation_author=Alice Eggleston;,citation_author=Carrington Koebele;,citation_author=Mark McKenzie;,citation_author=Teresa Deese;,citation_author=Benjamin Thomas;,citation_author=Laura Tsakiris;,citation_author=Stephen Blank;,citation_author=Ronald Mirenda;,citation_author=Anna Martin;,citation_author=Gargi Gharat;,citation_author=Candace Kokaram;,citation_author=Ket Wray;,citation_author=Clement Partap;,citation_author=Ulyana Arzamasova;,citation_author=Kristina Louissaint;,citation_author=Maria Fernandez;,citation_author=Achint Chani;,citation_author=Adebiyi Adepoju;,citation_author=Aisha Mortagy;,citation_author=Ajla Dupljak;,citation_author=Alison Brown;,citation_author=Amy Froment;,citation_author=Andrea Margiotta;,citation_author=Andrew Bombardier;,citation_author=Anita Islam;,citation_author=Anne Smith;,citation_author=Arvinder Dhillon;,citation_author=Audra McMillian;,citation_author=Aurora Breazna;,citation_author=Ayesha Aslam;,citation_author=Barabara Carpentino;,citation_author=Barry Siliverstein;,citation_author=Benjamin Horel;,citation_author=Bo Zhu;,citation_author=Brian Bush;,citation_author=Brian Head;,citation_author=Brian Snow;,citation_author=Bryan Zhu;,citation_author=Camille Debray;,citation_author=Careta Phillips;,citation_author=Carmella Simiele;,citation_author=Carol Lee;,citation_author=Carolyn Nienstedt;,citation_author=Caryn Trbovic;,citation_author=Catherine Elliott;,citation_author=Chad Fish;,citation_author=Charlie Ni;,citation_author=Christa Polidori;,citation_author=Christine Enciso;,citation_author=Christopher Caira;,citation_author=Christopher Powell;,citation_author=Cliff Baum;,citation_author=Colin McDonald;,citation_author=Cynthia Leigh;,citation_author=Cynthia Pan;,citation_author=Dana Wolken;,citation_author=Danielle Manganello;,citation_author=David Liu;,citation_author=David Stein;,citation_author=Dawlat Hassan;,citation_author=Daya Gulabani;,citation_author=Deborah Fix;,citation_author=Deborah Leonard;,citation_author=Deepshree Sarda;,citation_author=Denise Bonhomme;,citation_author=Denise Kennedy;,citation_author=Devin Darcy;,citation_author=Dhanalakshmi Barron;,citation_author=Diana Hughes;,citation_author=Diana Rofail;,citation_author=Dipinder Kaur;,citation_author=Dona Bianco;,citation_author=Donna Cohen;,citation_author=Edward Jean-Baptiste;,citation_author=Ehsan Bukhari;,citation_author=Eileen Doyle;,citation_author=Elizabeth Bucknam;,citation_author=Emily Labriola-Tomkins;,citation_author=Emily Nanna;,citation_author=Esther Huffman O’Keefe;,citation_author=Evelyn Gasparino;,citation_author=Evonne Fung;,citation_author=Fung-Yee To;,citation_author=Georgia Bellingham;,citation_author=Giane Sumner;,citation_author=Grainne Moggan;,citation_author=Grainne Power;,citation_author=Haixia Zeng;,citation_author=Hazel Mariveles;,citation_author=Heath Gonzalez;,citation_author=Helen Kang;,citation_author=Hibo Noor;,citation_author=Ian Minns;,citation_author=Izabella Peszek;,citation_author=James Donohue;,citation_author=Jamie Rusconi;,citation_author=Janice Austin;,citation_author=Janie Parrino;,citation_author=Jeannie Yo;,citation_author=Jenna McDonnell;,citation_author=Jessica Boarder;,citation_author=Jianguo Wei;,citation_author=Jingchun Yu;,citation_author=Joanne Malia;,citation_author=Joanne Tucciarone;,citation_author=Jodie Tyler-Gale;,citation_author=John Strein;,citation_author=Jonathan Cohen;,citation_author=Jonathan Meyer;,citation_author=Jordan Ursino;,citation_author=Joseph Im;,citation_author=Joseph Tramaglini;,citation_author=Joseph Wolken;,citation_author=Kaitlyn Potter;,citation_author=Kaitlyn Scacalossi;,citation_author=Kamala Naidu;,citation_author=Karen Browning;,citation_author=Karen Rutkowski;,citation_author=Karen Yau;,citation_author=Katherine Woloshin;,citation_author=Kelly Lewis-Amezcua;,citation_author=Kimberly Dornheim;,citation_author=Kit Chiu;,citation_author=Kosalai Mohan;,citation_author=Kristina McGuire;,citation_author=Kristy Macci;,citation_author=Kurt Ringleben;,citation_author=Kusha Mohammadi;,citation_author=Kyle Foster;,citation_author=Latora Knighton;,citation_author=Lindsay Darling;,citation_author=Lisa Boersma;,citation_author=Lisa Cowen;,citation_author=Lisa Hersh;,citation_author=Lisa Jackson;,citation_author=Lisa Sherpinsky;,citation_author=Livia Lai;,citation_author=Lori Faria;,citation_author=Lori Geissler;,citation_author=Louise Boppert;,citation_author=Lyra Fiske;,citation_author=Marc Dickens;,citation_author=Marco Mancini;,citation_author=Maria C. Leigh;,citation_author=Michael Batchelder;,citation_author=Michael Klinger;,citation_author=Michael Partridge;,citation_author=Michel Tarabocchia;,citation_author=Michelle Wong;,citation_author=Mivianisse Rodriguez;,citation_author=Moetaz Albizem;,citation_author=Muriel O’Byrne;,citation_author=Nicole Deitz;,citation_author=Nicole Memblatt;,citation_author=Nirav Shah;,citation_author=Nitin Kumar;,citation_author=Olga Herrera;,citation_author=Oluchi Adedoyin;,citation_author=Ori Yellin;,citation_author=Pamela Snodgrass;,citation_author=Patrick Floody;,citation_author=Paul D’Ambrosio;,citation_author=Paul (Xiaobang) Gao;,citation_author=Philippa Hearld;,citation_author=Qin Li;,citation_author=Rachel Kitchenoff;,citation_author=Rakiyya Ali;,citation_author=Ramya Iyer;,citation_author=Ravikanth Chava;,citation_author=Rinol Alaj;,citation_author=Rita Pedraza;,citation_author=Robert Hamlin;,citation_author=Romana Hosain;,citation_author=Ruchin Gorawala;,citation_author=Ryan White;,citation_author=Ryan Yu;,citation_author=Rylee Fogarty;,citation_author=S. Balachandra Dass;,citation_author=Sagarika Bollini;,citation_author=Samit Ganguly;,citation_author=Sandra DeCicco;,citation_author=Sanket Patel;,citation_author=Sarah Cassimaty;,citation_author=Selin Somersan-Karakaya;,citation_author=Shane McCarthy;,citation_author=Sharon Henkel;,citation_author=Shazia Ali;,citation_author=Shelley Geila Shapiro;,citation_author=Somang Kim;,citation_author=Soraya Nossoughi;,citation_author=Stephanie Bisulco;,citation_author=Steven Elkin;,citation_author=Steven Long;,citation_author=Sumathi Sivapalasingam;,citation_author=Susan Irvin;,citation_author=Susan Wilt;,citation_author=Tami Min;,citation_author=Tatiana Constant;,citation_author=Theresa Devins;,citation_author=Thomas Norton;,citation_author=Travis Bernardo;,citation_author=Tzu-Chien Chuang;,citation_author=Victor (Jianguo) Wei;,citation_author=Vinh Nuce;,citation_author=Vishnu Battini;,citation_author=Wilson Caldwell;,citation_author=Xiaobang Gao;,citation_author=Xin Chen;,citation_author=Yanmei Tian;,citation_author=Yasmin Khan;,citation_author=Yuming Zhao;,citation_author=Bonnie Dye;,citation_author=David Burns;,citation_author=Meredith Clement;,citation_author=Nirupama Sista;,citation_author=Sheryl Zwerski;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_issue=5;,citation_doi=10.1001/jama.2021.24939;,citation_issn=0098-7484;,citation_volume=327;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19;,citation_abstract=BACKGROUND The authors’ full names, academic de- REGEN-COV (previously known as REGN-COV2), a combination of the monoclonal grees, and affiliations are listed in the antibodies casirivimab and imdevimab, has been shown to markedly reduce the Appendix. Address reprint requests to Dr. O’Brien at Regeneron Pharmaceuticals, risk of hospitalization or death among high-risk persons with coronavirus disease 777 Old Saw Mill River Rd., Tarrytown, 2019 (Covid-19). Whether subcutaneous REGEN-COV prevents severe acute respiraNY 10591-6707, or at meagan.obrien@ tory syndrome coronavirus 2 (SARS-CoV-2) infection and subsequent Covid-19 in regeneron.com. persons at high risk for infection because of household exposure to a person with *The members of the Covid-19 Phase 3 SARS-CoV-2 infection is unknown. Prevention Trial Team are listed in the Supplementary Appendix, available at METHODS NEJM.org. We randomly assigned, in a 1:1 ratio, participants (\geq12 years of age) who were This article was published on August 4, enrolled within 96 hours after a household contact received a diagnosis of SARS2021, at NEJM.org. CoV-2 infection to receive a total dose of 1200 mg of REGEN-COV or matching N Engl J Med 2021;385:1184-95. DOI: 10.1056/NEJMoa2109682 placebo administered by means of subcutaneous injection. At the time of randomization, participants were stratified according to the results of the local diagnostic Copyright © 2021 Massachusetts Medical Society. assay for SARS-CoV-2 and according to age. The primary efficacy end point was the development of symptomatic SARS-CoV-2 infection through day 28 in participants who did not have SARS-CoV-2 infection (as measured by reverse-transcriptase–quantitative polymerase-chain-reaction assay) or previous immunity (seronegativity). RESULTS Symptomatic SARS-CoV-2 infection developed in 11 of 753 participants in the REGEN-COV group (1.5%) and in 59 of 752 participants in the placebo group (7.8%) (relative risk reduction [1 minus the relative risk], 81.4%; P&amp;amp;amp;lt;0.001). In weeks 2 to 4, a total of 2 of 753 participants in the REGEN-COV group (0.3%) and 27 of 752 participants in the placebo group (3.6%) had symptomatic SARS-CoV-2 infection (relative risk reduction, 92.6%). REGEN-COV also prevented symptomatic and asymptomatic infections overall (relative risk reduction, 66.4%). Among symptomatic infected participants, the median time to resolution of symptoms was 2 weeks shorter with REGEN-COV than with placebo (1.2 weeks and 3.2 weeks, respectively), and the duration of a high viral load (&amp;gt;104 copies per milliliter) was shorter (0.4 weeks and 1.3 weeks, respectively). No dose-limiting toxic effects of REGEN-COV were noted. CONCLUSIONS Subcutaneous REGEN-COV prevented symptomatic Covid-19 and asymptomatic SARS-CoV-2 infection in previously uninfected household contacts of infected persons. Among the participants who became infected, REGEN-COV reduced the duration of symptomatic disease and the duration of a high viral load. (Funded by Regeneron Pharmaceuticals and others; ClinicalTrials.gov number, NCT04452318.);,citation_author=Meagan P. O’Brien;,citation_author=Eduardo Forleo-Neto;,citation_author=Bret J. Musser;,citation_author=Flonza Isa;,citation_author=Kuo-Chen Chan;,citation_author=Neena Sarkar;,citation_author=Katharine J. Bar;,citation_author=Ruanne V. Barnabas;,citation_author=Dan H. Barouch;,citation_author=Myron S. Cohen;,citation_author=Christopher B. Hurt;,citation_author=Dale R. Burwen;,citation_author=Mary A. Marovich;,citation_author=Peijie Hou;,citation_author=Ingeborg Heirman;,citation_author=John D. Davis;,citation_author=Kenneth C. Turner;,citation_author=Divya Ramesh;,citation_author=Adnan Mahmood;,citation_author=Andrea T. Hooper;,citation_author=Jennifer D. Hamilton;,citation_author=Yunji Kim;,citation_author=Lisa A. Purcell;,citation_author=Alina Baum;,citation_author=Christos A. Kyratsous;,citation_author=James Krainson;,citation_author=Richard Perez-Perez;,citation_author=Rizwana Mohseni;,citation_author=Bari Kowal;,citation_author=A. Thomas DiCioccio;,citation_author=Neil Stahl;,citation_author=Leah Lipsich;,citation_author=Ned Braunstein;,citation_author=Gary Herman;,citation_author=George D. Yancopoulos;,citation_author=David M. Weinreich;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_issue=13;,citation_doi=10.1056/NEJMoa2109682;,citation_issn=0028-4793, 1533-4406;,citation_volume=385;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Fluid therapy in neurointensive care patients: ESICM consensus and clinical practice recommendations;,citation_abstract=OBJECTIVE: To report the ESICM consensus and clinical practice recommendations on fluid therapy in neurointensive care patients. DESIGN: A consensus committee comprising 22 international experts met in October 2016 during ESICM LIVES2016. Teleconferences and electronic-based discussions between the members of the committee subsequently served to discuss and develop the consensus process. METHODS: Population, intervention, comparison, and outcomes (PICO) questions were reviewed and updated as needed, and evidence profiles generated. The consensus focused on three main topics: (1) general fluid resuscitation and maintenance in neurointensive care patients, (2) hyperosmolar fluids for intracranial pressure control, (3) fluid management in delayed cerebral ischemia after subarachnoid haemorrhage. After an extensive literature search, the principles of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system were applied to assess the quality of evidence (from high to very low), to formulate treatment recommendations as strong or weak, and to issue best practice statements when applicable. A modified Delphi process based on the integration of evidence provided by the literature and expert opinions-using a sequential approach to avoid biases and misinterpretations-was used to generate the final consensus statement. RESULTS: The final consensus comprises a total of 32 statements, including 13 strong recommendations and 17 weak recommendations. No recommendations were provided for two statements. CONCLUSIONS: We present a consensus statement and clinical practice recommendations on fluid therapy for neurointensive care patients.;,citation_author=Mauro Oddo;,citation_author=Daniele Poole;,citation_author=Raimund Helbok;,citation_author=Geert Meyfroidt;,citation_author=Nino Stocchetti;,citation_author=Pierre Bouzat;,citation_author=Maurizio Cecconi;,citation_author=Thomas Geeraerts;,citation_author=Ignacio Martin-Loeches;,citation_author=Hervé Quintard;,citation_author=Fabio Silvio Taccone;,citation_author=Romergryko G. Geocadin;,citation_author=Claude Hemphill;,citation_author=Carole Ichai;,citation_author=David Menon;,citation_author=Jean-François Payen;,citation_author=Anders Perner;,citation_author=Martin Smith;,citation_author=José Suarez;,citation_author=Walter Videtta;,citation_author=Elisa R. Zanier;,citation_author=Giuseppe Citerio;,citation_publication_date=2018-04;,citation_cover_date=2018-04;,citation_year=2018;,citation_issue=4;,citation_doi=10.1007/s00134-018-5086-z;,citation_issn=1432-1238;,citation_pmid=29500701;,citation_volume=44;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Management of mechanical ventilation in acute severe asthma: Practical aspects;,citation_author=Mauro Oddo;,citation_author=François Feihl;,citation_author=Marie-Denise Schaller;,citation_author=Claude Perret;,citation_publication_date=2006-04;,citation_cover_date=2006-04;,citation_year=2006;,citation_issue=4;,citation_doi=10.1007/s00134-005-0045-x;,citation_issn=0342-4642, 1432-1238;,citation_volume=32;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=The Neurological Pupil index for outcome prognostication in people with acute brain injury (ORANGE): A prospective, observational, multicentre cohort study;,citation_abstract=Background Improving the prognostication of acute brain injury is a key element of critical care. Standard assessment includes pupillary light reactivity testing with a hand-held light source, but findings are interpreted subjectively; automated pupillometry might be more precise and reproducible. We aimed to assess the association of the Neurological Pupil index (NPi)—a quantitative measure of pupillary reactivity computed by automated pupillometry—with outcomes of patients with severe non-anoxic acute brain injury.;,citation_author=Mauro Oddo;,citation_author=Fabio S Taccone;,citation_author=Matteo Petrosino;,citation_author=Rafael Badenes;,citation_author=Aaron Blandino-Ortiz;,citation_author=Pierre Bouzat;,citation_author=Anselmo Caricato;,citation_author=Randall M Chesnut;,citation_author=Anders C Feyling;,citation_author=Nawfel Ben-Hamouda;,citation_author=J Claude Hemphill;,citation_author=Julia Koehn;,citation_author=Frank Rasulo;,citation_author=Jose I Suarez;,citation_author=Francesca Elli;,citation_author=Alessia Vargiolu;,citation_author=Paola Rebora;,citation_author=Stefania Galimberti;,citation_author=Giuseppe Citerio;,citation_author=Samia Abed-Maillard;,citation_author=Marco Anderloni;,citation_author=Alessandra Beretta;,citation_author=Sung-Min Cho;,citation_author=Silvia Del Bianco;,citation_author=Eva Favre;,citation_author=Madeline E. Greil;,citation_author=Angelo Guglielmi;,citation_author=Juan Higuera Lucas;,citation_author=Cosimo Iacca;,citation_author=Joji B. Kuramatsu;,citation_author=Linda Marie Lundberg;,citation_author=Federico Magni;,citation_author=Letterio Malgeri;,citation_author=Paolo Mangili;,citation_author=Isabella Melchionda;,citation_author=John-Paul Miroz;,citation_author=Berta Monleón;,citation_author=Dominica Randazzo;,citation_author=Samia Salah;,citation_author=Angela Scavone;,citation_author=Clothilde Schilte;,citation_author=Serena Silva;,citation_author=Kjetil Sunde;,citation_author=Ruihao Wang;,citation_publication_date=2023-10;,citation_cover_date=2023-10;,citation_year=2023;,citation_issue=10;,citation_doi=10.1016/S1474-4422(23)00271-5;,citation_issn=14744422;,citation_volume=22;,citation_language=en-US;,citation_journal_title=The Lancet Neurology;">
<meta name="citation_reference" content="citation_title=Causal Diagrams for Interference;,citation_abstract=The term “interference” has been used to describe any setting in which one subject’s exposure may affect another subject’s outcome. We use causal diagrams to distinguish among three causal mechanisms that give rise to interference. The first causal mechanism by which interference can operate is a direct causal effect of one individual’s treatment on another individual’s outcome; we call this direct interference. Interference by contagion is present when one individual’s outcome may affect the outcomes of other individuals with whom he comes into contact. Then giving treatment to the first individual could have an indirect effect on others through the treated individual’s outcome. The third pathway by which interference may operate is allocational interference. Treatment in this case allocates individuals to groups; through interactions within a group, individuals may affect one another’s outcomes in any number of ways. In many settings, more than one type of interference will be present simultaneously. The causal effects of interest differ according to which types of interference are present, as do the conditions under which causal effects are identifiable. Using causal diagrams for interference, we describe these differences, give criteria for the identification of important causal effects, and discuss applications to infectious diseases.;,citation_author=Elizabeth L. Ogburn;,citation_author=Tyler J. VanderWeele;,citation_publication_date=2014-11;,citation_cover_date=2014-11;,citation_year=2014;,citation_issue=4;,citation_doi=10.1214/14-STS501;,citation_issn=0883-4237;,citation_volume=29;,citation_language=en-US;,citation_journal_title=Statistical Science;">
<meta name="citation_reference" content="citation_title=Prevention of Central Line–Associated Bloodstream Infections;,citation_author=Naomi P. O’Grady;,citation_publication_date=2023-09;,citation_cover_date=2023-09;,citation_year=2023;,citation_issue=12;,citation_doi=10.1056/NEJMra2213296;,citation_issn=0028-4793;,citation_volume=389;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Early Versus Delayed Non–Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study;,citation_abstract=Background: There are no evidence-based recommendations on the optimal time point to initiate non–vitamin K antagonist oral anticoagulants (NOACs) after acute ischemic stroke in patients with atrial fibrillation. We aimed to investigate the efficacy and safety of early versus delayed initiation of NOAC in these patients. Methods: TIMING (Timing of Oral Anticoagulant Therapy in Acute Ischemic Stroke With Atrial Fibrillation) was a registry-based, randomized, noninferiority, open-label, blinded end-point study at 34 stroke units using the Swedish Stroke Register for enrollment and follow-up. Within 72 hours from stroke onset, patients were randomized to early (\leq4 days) or delayed (5–10 days) NOAC initiation, with choice of NOAC at the investigators’ discretion. The primary outcome was the composite of recurrent ischemic stroke, symptomatic intracerebral hemorrhage, or all-cause mortality at 90 days. The prespecified noninferiority margin was 3%. Secondary outcomes included the individual components of the primary outcome. Results: Between April 2, 2017, and December 30, 2020, 888 patients were randomized to either early (n=450) or delayed (n=438) initiation of NOAC. No patient was lost to 90-day follow-up. Mean age was 78.3 years (SD, 9.9 years); 46.2% were women; 49.1% had previously known atrial fibrillation; and 17.5% prior stroke. The primary outcome occurred in 31 patients (6.89%) assigned to early initiation and in 38 patients (8.68%) assigned to delayed NOAC initiation (absolute risk difference, -1.79% [95% CI, -5.31% to 1.74%]; Pnoninferiority=0.004). Ischemic stroke rates were 3.11% and 4.57% (risk difference, -1.46% [95% CI, -3.98% to 1.07%]) and all-cause mortality rates were 4.67% and 5.71% (risk difference, -1.04% [95% CI, -3.96% to 1.88%]) in the early and delayed groups, respectively. No patient in either group experienced symptomatic intracerebral hemorrhage. Conclusions: Early initiation was noninferior to delayed start of NOAC after acute ischemic stroke in patients with atrial fibrillation. Numerically lower rates of ischemic stroke and death and the absence of symptomatic intracerebral hemorrhages implied that the early start of NOAC was safe and should be considered for acute secondary stroke prevention in patients eligible for NOAC treatment. Registration: URL: http://www.clinicaltrials.gov; Unique identifier: NCT02961348.;,citation_author=Jonas Oldgren;,citation_author=Signild Åsberg;,citation_author=Ziad Hijazi;,citation_author=Per Wester;,citation_author=Maria Bertilsson;,citation_author=Bo Norrving;,citation_author=null null;,citation_publication_date=2022-10;,citation_cover_date=2022-10;,citation_year=2022;,citation_issue=14;,citation_doi=10.1161/CIRCULATIONAHA.122.060666;,citation_volume=146;,citation_journal_title=Circulation;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=The Next Generation of Sepsis Clinical Trial Designs: What Is Next After the Demise of Recombinant Human Activated Protein C?*;,citation_abstract=Objective:&nbsp; The developmental pipeline for novel therapeutics to treat sepsis has diminished to a trickle compared to previous years of sepsis research. While enormous strides have been made in understanding the basic molecular mechanisms that underlie the pathophysiology of sepsis, a long list of novel agents have now been tested in clinical trials without a single immunomodulating therapy showing consistent benefit. The only antisepsis agent to successfully complete a phase III clinical trial was human recumbent activated protein C. This drug was taken off the market after a follow-up placebo-controlled trial (human recombinant activated Protein C Worldwide Evaluation of Severe Sepsis and septic Shock [PROWESS SHOCK]) failed to replicate the favorable results of the initial registration trial performed ten years earlier. We must critically reevaluate our basic approach to the preclinical and clinical evaluation of new sepsis therapies. Data Sources:&nbsp; We selected the major clinical studies that investigated interventional trials with novel therapies to treat sepsis over the last 30 years. Study Selection:&nbsp; Phase II and phase III trials investigating new treatments for sepsis and editorials and critiques of these studies. Data Extraction:&nbsp; Selected manuscripts and clinical study reports were analyzed from sepsis trials. Specific shortcomings and potential pit falls in preclinical evaluation and clinical study design and analysis were reviewed and synthesized. Data Synthesis:&nbsp; After review and discussion, a series of 12 recommendations were generated with suggestions to guide future studies with new treatments for sepsis. Conclusions:&nbsp; We need to improve our ability to define appropriate molecular targets for preclinical development and develop better methods to determine the clinical value of novel sepsis agents. Clinical trials must have realistic sample sizes and meaningful endpoints. Biomarker-driven studies should be considered to categorize specific “at risk” populations most likely to benefit from a new treatment. Innovations in clinical trial design such as parallel crossover design, alternative endpoints, or adaptive trials should be pursued to improve the outlook for future interventional trials in sepsis.;,citation_author=Steven M. Opal;,citation_author=R. Phillip Dellinger;,citation_author=Jean-Louis Vincent;,citation_author=Henry Masur;,citation_author=Derek C. Angus;,citation_publication_date=2014-07;,citation_cover_date=2014-07;,citation_year=2014;,citation_issue=7;,citation_doi=10.1097/CCM.0000000000000325;,citation_issn=0090-3493;,citation_volume=42;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Sedatives in neurocritical care: An update on pharmacological agents and modes of sedation;,citation_abstract=Extrapolating the findings from studies in the general ICU population suggests to reserve deep continuous sedation in the neuro-ICU for specific indications. Although an improved understanding of cerebral physiological changes in patients with brain injury may be helpful to guide individualized sedation, we still lack the evidence base to make broad recommendations for specific patient groups.;,citation_author=Olivier Opdenakker;,citation_author=Anna Vanstraelen;,citation_author=Veerle De Sloovere;,citation_author=Geert Meyfroidt;,citation_publication_date=2019-04;,citation_cover_date=2019-04;,citation_year=2019;,citation_issue=2;,citation_doi=10.1097/MCC.0000000000000592;,citation_issn=1070-5295;,citation_volume=25;,citation_language=en-US;,citation_journal_title=Current Opinion in Critical Care;">
<meta name="citation_reference" content="citation_title=Estimating the reproducibility of psychological science;,citation_author=OPEN SCIENCE COLLABORATION;,citation_publication_date=2015-08;,citation_cover_date=2015-08;,citation_year=2015;,citation_issue=6251;,citation_doi=10.1126/science.aac4716;,citation_volume=349;,citation_journal_title=Science;,citation_publisher=American Association for the Advancement of Science;">
<meta name="citation_reference" content="citation_title=Academic clinician–scientists risk becoming an endangered species;,citation_abstract=Barriers to their training and retention threaten medical research;,citation_author=Stephen O’Rahilly;,citation_publication_date=2023-12;,citation_cover_date=2023-12;,citation_year=2023;,citation_issue=12;,citation_doi=10.1038/s41591-023-02626-8;,citation_issn=1546-170X;,citation_volume=29;,citation_language=en-US;,citation_journal_title=Nature Medicine;,citation_publisher=Nature Publishing Group;">
<meta name="citation_reference" content="citation_title=Current controversies in shock and resuscitation;,citation_abstract=Many controversies and uncertainties surround resuscitation of hemorrhagic shock caused by vascular trauma. Whereas the basic pathophysiology is better understood, much remains to be learned about the many immunologic cascades that lead to problems beyond those of initial fluid resuscitation or operative hemostasis. Fluid therapy is on the verge of significant advances with substitute oxygen carriers, yet surgeons are still beset with questions of how much and what type of initial fluid to provide. Finally, the parameters chosen to guide therapy and the methods used to monitor patients present other interesting issues.;,citation_author=M. Orlinsky;,citation_author=W. Shoemaker;,citation_author=E. D. Reis;,citation_author=M. D. Kerstein;,citation_publication_date=2001-12;,citation_cover_date=2001-12;,citation_year=2001;,citation_issue=6;,citation_doi=10.1016/s0039-6109(01)80006-2;,citation_issn=0039-6109;,citation_pmid=11766174;,citation_volume=81;,citation_language=en-US;,citation_journal_title=The Surgical Clinics of North America;">
<meta name="citation_reference" content="citation_title=Variation in cerebral palsy profile by socio-economic status;,citation_author=Maryam Oskoui;,citation_author=Carmen Messerlian;,citation_author=Alexandra Blair;,citation_author=Philippe Gamache;,citation_author=Michael Shevell;,citation_publication_date=2016-02;,citation_cover_date=2016-02;,citation_year=2016;,citation_issue=2;,citation_doi=10.1111/dmcn.12808;,citation_issn=00121622;,citation_volume=58;,citation_language=en-US;,citation_journal_title=Developmental Medicine &amp;amp;amp; Child Neurology;">
<meta name="citation_reference" content="citation_title=Acute kidney injury;,citation_author=Marlies Ostermann;,citation_author=Rajit K. Basu;,citation_author=Ravindra L. Mehta;,citation_publication_date=2023-01;,citation_cover_date=2023-01;,citation_year=2023;,citation_doi=10.1007/s00134-022-06946-0;,citation_issn=0342-4642, 1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Management of oliguria;,citation_author=Marlies Ostermann;,citation_author=Andrew D. Shaw;,citation_author=Michael Joannidis;,citation_publication_date=2022-10;,citation_cover_date=2022-10;,citation_year=2022;,citation_doi=10.1007/s00134-022-06909-5;,citation_issn=0342-4642, 1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Resuscitation Fluid Composition and Acute Kidney Injury in Critical Illness;,citation_abstract=Acute kidney injury often complicates critical illness and is associated with high morbidity, with patients not infrequently receiving renal replacement therapy, and with increased mortality.1 Patients with acute kidney injury have an elevated risk of chronic kidney disease, cardiovascular disease, and premature death, even when kidney function has recovered.2 Because acute kidney injury confers serious short- and long-term risks, therapy during the course of critical illness should avoid iatrogenic harm, including nephrotoxic effects.3 Fluid therapy to improve hemodynamic status and organ perfusion helps prevent acute kidney injury. Intravenous 0.9% sodium chloride solution (saline) has been a standard resuscitation fluid for . . .;,citation_author=Marlies Ostermann;,citation_author=Adrienne G. Randolph;,citation_publication_date=2022-03;,citation_cover_date=2022-03;,citation_year=2022;,citation_issue=9;,citation_doi=10.1056/NEJMe2200294;,citation_issn=0028-4793;,citation_pmid=35235731;,citation_volume=386;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Analysis of 567,758 randomized controlled trials published over 30 years reveals trends in phrases used to discuss results that do not reach statistical significance;,citation_abstract=The power of language to modify the reader’s perception of interpreting biomedical results cannot be underestimated. Misreporting and misinterpretation are pressing problems in randomized controlled trials (RCT) output. This may be partially related to the statistical significance paradigm used in clinical trials centered around a P value below 0.05 cutoff. Strict use of this P value may lead to strategies of clinical researchers to describe their clinical results with P values approaching but not reaching the threshold to be “almost significant.” The question is how phrases expressing nonsignificant results have been reported in RCTs over the past 30 years. To this end, we conducted a quantitative analysis of English full texts containing 567,758 RCTs recorded in PubMed between 1990 and 2020 (81.5% of all published RCTs in PubMed). We determined the exact presence of 505 predefined phrases denoting results that approach but do not cross the line of formal statistical significance ( P &amp;amp;amp;lt; 0.05). We modeled temporal trends in phrase data with Bayesian linear regression. Evidence for temporal change was obtained through Bayes factor (BF) analysis. In a randomly sampled subset, the associated P values were manually extracted. We identified 61,741 phrases in 49,134 RCTs indicating almost significant results (8.65%; 95% confidence interval (CI): 8.58% to 8.73%). The overall prevalence of these phrases remained stable over time, with the most prevalent phrases being “marginally significant” (in 7,735 RCTs), “all but significant” (7,015), “a nonsignificant trend” (3,442), “failed to reach statistical significance” (2,578), and “a strong trend” (1,700). The strongest evidence for an increased temporal prevalence was found for “a numerical trend,” “a positive trend,” “an increasing trend,” and “nominally significant.” In contrast, the phrases “all but significant,” “approaches statistical significance,” “did not quite reach statistical significance,” “difference was apparent,” “failed to reach statistical significance,” and “not quite significant” decreased over time. In a random sampled subset of 29,000 phrases, the manually identified and corresponding 11,926 P values, 68,1% ranged between 0.05 and 0.15 (CI: 67. to 69.0; median 0.06). Our results show that RCT reports regularly contain specific phrases describing marginally nonsignificant results to report P values close to but above the dominant 0.05 cutoff. The fact that the prevalence of the phrases remained stable over time indicates that this practice of broadly interpreting P values close to a predefined threshold remains prevalent. To enhance responsible and transparent interpretation of RCT results, researchers, clinicians, reviewers, and editors may reduce the focus on formal statistical significance thresholds and stimulate reporting of P values with corresponding effect sizes and CIs and focus on the clinical relevance of the statistical difference found in RCTs.;,citation_author=Willem M. Otte;,citation_author=Christiaan H. Vinkers;,citation_author=Philippe C. Habets;,citation_author=David G. P. IJzendoorn;,citation_author=Joeri K. Tijdink;,citation_editor=Isabelle Boutron;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_issue=2;,citation_doi=10.1371/journal.pbio.3001562;,citation_issn=1545-7885;,citation_volume=20;,citation_language=en-US;,citation_journal_title=PLOS Biology;">
<meta name="citation_reference" content="citation_title=Improving Bayesian Reasoning: The Effects of Phrasing, Visualization, and Spatial Ability;,citation_abstract=Decades of research have repeatedly shown that people perform poorly at estimating and understanding conditional probabilities that are inherent in Bayesian reasoning problems. Yet in the medical domain, both physicians and patients make daily, life-critical judgments based on conditional probability. Although there have been a number of attempts to develop more effective ways to facilitate Bayesian reasoning, reports of these findings tend to be inconsistent and sometimes even contradictory. For instance, the reported accuracies for individuals being able to correctly estimate conditional probability range from 6% to 62%. In this work, we show that problem representation can significantly affect accuracies. By controlling the amount of information presented to the user, we demonstrate how text and visualization designs can increase overall accuracies to as high as 77%. Additionally, we found that for users with high spatial ability, our designs can further improve their accuracies to as high as 100%. By and large, our findings provide explanations for the inconsistent reports on accuracy in Bayesian reasoning tasks and show a significant improvement over existing methods. We believe that these findings can have immediate impact on risk communication in health-related fields.;,citation_author=Alvitta Ottley;,citation_author=Evan M. Peck;,citation_author=Lane T. Harrison;,citation_author=Daniel Afergan;,citation_author=Caroline Ziemkiewicz;,citation_author=Holly A. Taylor;,citation_author=Paul K. J. Han;,citation_author=Remco Chang;,citation_publication_date=2016-01;,citation_cover_date=2016-01;,citation_year=2016;,citation_issue=1;,citation_doi=10.1109/TVCG.2015.2467758;,citation_issn=1077-2626, 1941-0506, 2160-9306;,citation_volume=22;,citation_language=en-US;,citation_journal_title=IEEE Transactions on Visualization and Computer Graphics;">
<meta name="citation_reference" content="citation_title=Rethinking the intention-to-treat principle: One size does not fit all;,citation_author=Katrien Oude Rengerink;,citation_author=Marian Mitroiu;,citation_author=Steven Teerenstra;,citation_author=Frank Pétavy;,citation_author=Kit Christian Bernardo Roes;,citation_publication_date=2020-09;,citation_cover_date=2020-09;,citation_year=2020;,citation_doi=10.1016/j.jclinepi.2020.04.023;,citation_issn=08954356;,citation_volume=125;,citation_language=en-US;,citation_journal_title=Journal of Clinical Epidemiology;">
<meta name="citation_reference" content="citation_title=Systematic Review of the “Pragmatism” of Pragmatic Critical Care Trials;,citation_author=Jessica A. Palakshappa;,citation_author=Kevin W. Gibbs;,citation_author=Margo T. Lannan;,citation_author=Anna R. Cranford;,citation_author=Stephanie P. Taylor;,citation_publication_date=2022-07;,citation_cover_date=2022-07;,citation_year=2022;,citation_issue=7;,citation_doi=10.1097/CCE.0000000000000738;,citation_issn=2639-8028;,citation_volume=4;,citation_language=en-US;,citation_journal_title=Critical Care Explorations;">
<meta name="citation_reference" content="citation_title=Triglyceride Levels and Their Relationship to Sedation Choice and Outcomes in Mechanically Ventilated Patients Receiving Propofol;,citation_author=Parth Pancholi;,citation_author=Jianwen Wu;,citation_author=Samantha Lessen;,citation_author=James Brogan;,citation_author=Nicholas J Quinn;,citation_author=Michelle Ng Gong;,citation_author=Ari Moskowitz;,citation_publication_date=2022-09;,citation_cover_date=2022-09;,citation_year=2022;,citation_doi=10.1513/AnnalsATS.202205-403OC;,citation_issn=2329-6933, 2325-6621;,citation_language=en-US;,citation_journal_title=Annals of the American Thoracic Society;">
<meta name="citation_reference" content="citation_title=Long-Term Cognitive Impairment after Critical Illness;,citation_abstract=BACKGROUND Survivors of critical illness often have a prolonged and disabling form of cognitive impairment that remains inadequately characterized. METHODS We enrolled adults with respiratory failure or shock in the medical or surgical intensive care unit (ICU), evaluated them for in-hospital delirium, and assessed global cognition and executive function 3 and 12 months after discharge with the use of the Repeatable Battery for the Assessment of Neuropsychological Status (population age-adjusted mean [SD] score, 10015, with lower values indicating worse global cognition) and the Trail Making Test, Part B (population age-, sex-, and education-adjusted mean score, 5010, with lower scores indicating worse executive function). Associations of the duration of delirium and the use of sedative or analgesic agents with the outcomes were assessed with the use of linear regression, with adjustment for potential confounders. RESULTS Of the 821 patients enrolled, 6% had cognitive impairment at baseline, and delirium developed in 74% during the hospital stay. At 3 months, 40% of the patients had global cognition scores that were 1.5 SD below the population means (similar to scores for patients with moderate traumatic brain injury), and 26% had scores 2 SD below the population means (similar to scores for patients with mild Alzheimer’s disease). Deficits occurred in both older and younger patients and persisted, with 34% and 24% of all patients with assessments at 12 months that were similar to scores for patients with moderate traumatic brain injury and scores for patients with mild Alzheimer’s disease, respectively. A longer duration of delirium was independently associated with worse global cognition at 3 and 12 months (P = 0.001 and P = 0.04, respectively) and worse executive function at 3 and 12 months (P = 0.004 and P = 0.007, respectively). Use of sedative or analgesic medications was not consistently associated with cognitive impairment at 3 and 12 months. CONCLUSIONS Patients in medical and surgical ICUs are at high risk for long-term cognitive impairment. A longer duration of delirium in the hospital was associated with worse global cognition and executive function scores at 3 and 12 months. (Funded by the National Institutes of Health and others; BRAIN-ICU ClinicalTrials.gov number, NCT00392795.);,citation_author=P. P. Pandharipande;,citation_author=T. D. Girard;,citation_author=J. C. Jackson;,citation_author=A. Morandi;,citation_author=J. L. Thompson;,citation_author=B. T. Pun;,citation_author=N. E. Brummel;,citation_author=C. G. Hughes;,citation_author=E. E. Vasilevskis;,citation_author=A. K. Shintani;,citation_author=K. G. Moons;,citation_author=S. K. Geevarghese;,citation_author=A. Canonico;,citation_author=R. O. Hopkins;,citation_author=G. R. Bernard;,citation_author=R. S. Dittus;,citation_author=E. W. Ely;,citation_publication_date=2013-10;,citation_cover_date=2013-10;,citation_year=2013;,citation_issue=14;,citation_doi=10.1056/NEJMoa1301372;,citation_issn=0028-4793, 1533-4406;,citation_volume=369;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Epidemiology and Costs of Sepsis in the United States—An Analysis Based on Timing of Diagnosis and Severity Level*:;,citation_author=Carly J. Paoli;,citation_author=Mark A. Reynolds;,citation_author=Meenal Sinha;,citation_author=Matthew Gitlin;,citation_author=Elliott Crouser;,citation_publication_date=2018-12;,citation_cover_date=2018-12;,citation_year=2018;,citation_issue=12;,citation_doi=10.1097/CCM.0000000000003342;,citation_issn=0090-3493;,citation_volume=46;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Evaluation of young men with organic erectile dysfunction;,citation_author=Dimitri Papagiannopoulos;,citation_author=Ajay Nehra;,citation_author=Narenda Khare;,citation_publication_date=2015;,citation_cover_date=2015;,citation_year=2015;,citation_issue=1;,citation_doi=10.4103/1008-682X.139253;,citation_issn=1008-682X;,citation_volume=17;,citation_language=en-US;,citation_journal_title=Asian Journal of Andrology;">
<meta name="citation_reference" content="citation_title=Inaugural State of the Union: Continuous Cerebral Autoregulation Monitoring in the Clinical Practice of Neurocritical Care and Anesthesia;,citation_author=Soojin Park;,citation_author=Erta Beqiri;,citation_author=Peter Smielewski;,citation_author=Marcel Aries;,citation_author=CLINICCA (CLINical use of Information on Continuous monitoring of Cerebral Autoregulation);,citation_author=Francisco Abecasis;,citation_author=Shruti Agrawal;,citation_author=Brian Appavu;,citation_author=Ramani Balu;,citation_author=Ken Brady;,citation_author=Celina Brunsch;,citation_author=Karol Budohoski;,citation_author=András Czigler;,citation_author=Bart Depreitere;,citation_author=Celeste Dias;,citation_author=Per Enblad;,citation_author=Ari Ercole;,citation_author=Anthony Figaji;,citation_author=Brandon Foreman;,citation_author=Shirin K. Frisvold;,citation_author=Clare Gallagher;,citation_author=Donald Griesdale;,citation_author=Raimund Helbok;,citation_author=Adel Helmy;,citation_author=Cornelia Hoedemaekers;,citation_author=Matthew Kirschen;,citation_author=Elisabeth Kooi;,citation_author=Andreas Kramer;,citation_author=Andrea Lavinio;,citation_author=Jennifer K. Lee;,citation_author=Victoria McCredie;,citation_author=David K. Menon;,citation_author=Geert Meyfroidt;,citation_author=David Nelson;,citation_author=Nils Petersen;,citation_author=Nicolas De Riva;,citation_author=Lucia Rivera-Lara;,citation_author=Chiara Robba;,citation_author=Gerrit Schubert;,citation_author=Martin U. Schuhmann;,citation_author=Mypinder S. Sekhon;,citation_author=Josef Skola;,citation_author=Luzius A. Steiner;,citation_author=Teodor Svedung Wettervik;,citation_author=Fabio S. Taccone;,citation_author=Peter J. Toth;,citation_author=Miriam Weiss;,citation_author=Stefan Wolf;,citation_author=Frederick Zeiler;,citation_author=Wendy Ziai;,citation_publication_date=2023-10;,citation_cover_date=2023-10;,citation_year=2023;,citation_doi=10.1007/s12028-023-01860-9;,citation_issn=1541-6933, 1556-0961;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Caring for the Unvaccinated;,citation_author=William F. Parker;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_issue=2;,citation_doi=10.1513/AnnalsATS.202109-1039IP;,citation_issn=2329-6933, 2325-6621;,citation_volume=19;,citation_language=en-US;,citation_journal_title=Annals of the American Thoracic Society;">
<meta name="citation_reference" content="citation_title=The Story of the Pulmonary Artery Catheter: Five Decades in Critical Care Medicine;,citation_abstract=An abstract is unavailable.;,citation_author=Margaret M. Parker;,citation_author=Michael R. Pinsky;,citation_author=Jukka Takala;,citation_author=Jean-Louis Vincent;,citation_publication_date=2023-02;,citation_cover_date=2023-02;,citation_year=2023;,citation_issue=2;,citation_doi=10.1097/CCM.0000000000005718;,citation_issn=0090-3493;,citation_volume=51;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Group sequential designs in pragmatic trials: Feasibility and assessment of utility using data from a number of recent surgical RCTs;,citation_abstract=Background: Assessing the long term effects of many surgical interventions tested in pragmatic RCTs may require extended periods of participant follow-up to assess effectiveness and use patient-reported outcomes that require large sample sizes. Consequently the RCTs are often perceived as being expensive and time-consuming, particularly if the results show the test intervention is not effective. Adaptive, and particularly group sequential, designs have great potential to improve the efficiency and cost of testing new and existing surgical interventions. As a means to assess the potential utility of group sequential designs, we re-analyse data from a number of recent high-profile RCTs and assess whether using such a design would have caused the trial to stop early. Methods: Many pragmatic RCTs monitor participants at a number of occasions (e.g. at 6, 12 and 24 months after surgery) during follow-up as a means to assess recovery and also to keep participants engaged with the trial process. Conventionally one of the outcomes is selected as the primary (final) outcome, for clinical reasons, with others designated as either early or late outcomes. In such settings, novel group sequential designs that use data from not only the final outcome but also from early outcomes at interim analyses can be used to inform stopping decisions.;,citation_author=Nick R. Parsons;,citation_author=Nigel Stallard;,citation_author=Helen Parsons;,citation_author=Aminul Haque;,citation_author=Martin Underwood;,citation_author=James Mason;,citation_author=Iftekhar Khan;,citation_author=Matthew L. Costa;,citation_author=Damian R. Griffin;,citation_author=James Griffin;,citation_author=David J. Beard;,citation_author=Jonathan A. Cook;,citation_author=Loretta Davies;,citation_author=Jemma Hudson;,citation_author=Andrew Metcalfe;,citation_publication_date=2022-10;,citation_cover_date=2022-10;,citation_year=2022;,citation_issue=1;,citation_doi=10.1186/s12874-022-01734-2;,citation_issn=1471-2288;,citation_volume=22;,citation_language=en-US;,citation_journal_title=BMC Medical Research Methodology;">
<meta name="citation_reference" content="citation_title=Battle of the Experts: The Strange Career of Meta-Expertise;,citation_abstract=Sociologists and philosophers have critically examined the interplay between democracy and expertise. This article develops a law and political economy approach to the topic, focusing on the challenge posed to traditional professions by “meta-experts” (who develop standardized algorithmic and quantitative methods to trans-substantively evaluate experts’ performance and value).The very concept of meta-expertise confounds traditional distinctions between elite and democratic power. On the one hand, the meta-expert seems to suffer from all the debilities of the traditional expert, only more so. Whereas a traditional expert at least has a bounded set of situations to claim to be knowledgeable about, the meta-expert asserts expansive intellectual authority. On the other hand, skeptics of professions (as well as professional skeptics) claim that experts’ authority must have some substantive (and not merely democratic and procedural) limits. These skeptics tend to see the meta-expert as a powerful “tribune of the people,” capable of vindicating both common sense and counterintuitive findings in the face of guildish lethargy and incuriosity.Law has three critical roles to play in adjudicating emerging conflicts between experts and meta-experts. First, whatever jurisdictional claims they make over some domain may be confirmed or contradicted by lawmakers. Therefore, law is critical to the practical establishment of practical epistemic authority. Second, administrative law has long addressed the balance between legal regularity, politics, and expertise in the proper functioning of agencies. And most specifically, antitrust law is a particularly potent way of unraveling some modes of professional self-organization and standards, while promoting others. This chapter explores the role of law and political economy in shaping “battles of the experts,” as economists and coders challenge the authority of other professionals.;,citation_author=Frank A. Pasquale;,citation_publication_date=2021-03;,citation_cover_date=2021-03;,citation_year=2021;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Andexanet Alfa for Factor Xa Inhibitor–Associated Intracerebral Hemorrhage: Does a Specific Reversal Agent Justify Its Cost?;,citation_author=Nikhil Patel;,citation_author=Nicholas A. Morris;,citation_publication_date=2021-11;,citation_cover_date=2021-11;,citation_year=2021;,citation_issue=21;,citation_doi=10.1212/WNL.0000000000012857;,citation_issn=0028-3878, 1526-632X;,citation_volume=97;,citation_language=en-US;,citation_journal_title=Neurology;">
<meta name="citation_reference" content="citation_title=Effect of early mobilisation on long-term cognitive impairment in critical illness in the USA: A randomised controlled trial;,citation_abstract=Background Patients who have received mechanical ventilation can have prolonged cognitive impairment for which there is no known treatment. We aimed to establish whether early mobilisation could reduce the rates of cognitive impairment and other aspects of disability 1 year after critical illness.;,citation_author=Bhakti K Patel;,citation_author=Krysta S Wolfe;,citation_author=Shruti B Patel;,citation_author=Karen C Dugan;,citation_author=Cheryl L Esbrook;,citation_author=Amy J Pawlik;,citation_author=Megan Stulberg;,citation_author=Crystal Kemple;,citation_author=Megan Teele;,citation_author=Erin Zeleny;,citation_author=Donald Hedeker;,citation_author=Anne S Pohlman;,citation_author=Vineet M Arora;,citation_author=Jesse B Hall;,citation_author=John P Kress;,citation_publication_date=2023-06;,citation_cover_date=2023-06;,citation_year=2023;,citation_issue=6;,citation_doi=10.1016/S2213-2600(22)00489-1;,citation_issn=22132600;,citation_volume=11;,citation_language=en-US;,citation_journal_title=The Lancet Respiratory Medicine;">
<meta name="citation_reference" content="citation_title=IV Vitamin C in Critically Ill Patients: A Systematic Review and Meta-Analysis;,citation_author=Jayshil J. Patel;,citation_author=Alfonso Ortiz-Reyes;,citation_author=Rupinder Dhaliwal;,citation_author=John Clarke;,citation_author=Aileen Hill;,citation_author=Christian Stoppe;,citation_author=Zheng-Yii Lee;,citation_author=Daren K. Heyland;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_doi=10.1097/CCM.0000000000005320;,citation_issn=0090-3493;,citation_volume=Publish Ahead of Print;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Mystery Case: A 23-year-old man with headaches, confusion, and lower extremity weakness;,citation_author=Nikhil M. Patel;,citation_author=Jay Bronder;,citation_author=Melissa Motta;,citation_author=Nicholas Morris;,citation_publication_date=2019-04;,citation_cover_date=2019-04;,citation_year=2019;,citation_issue=18;,citation_doi=10.1212/WNL.0000000000007405;,citation_issn=1526-632X;,citation_pmid=31036572;,citation_volume=92;,citation_language=en-US;,citation_journal_title=Neurology;">
<meta name="citation_reference" content="citation_title=Traumatic Brain Injury: Patient Characteristics, Hospital Costs and Trends Over Time;,citation_abstract=Background: Traumatic brain injury (TBI) is an increasingly diagnosed condition, but the trends in TBI visits and the cost of which have not been quantified from the hospital perspective. Objectives: To quantify the costs of TBI stratified by inpatient and outpatient visits and to examine trends in TBI incidence over time. Methods: This descriptive study utilized data for 2007-2012 from the Premier hospital database, which includes clinical and utilization information from hospitals across the United States. TBI was identified through International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes. Descriptive data were obtained to identify the TBI costs, visit costs, patient characteristics, and intertemporal trends in TBI rates. Results: TBI patients were treated on an outpatient basis 88% of the time. Nearly 45% (44.3%) of TBI patients requiring inpatient admissions were age 65 or over, and 20% of TBI patients treated as an outpatient were age 75 or over. Children aged 4 or younger accounted for nearly 14% of TBI cases treated on an outpatient basis. TBI patients treated in the inpatient setting incurred fairly long hospital visits (mean 4.8 days; median 3.0 days) and substantial hospital costs (mean $12,717; median $8,176). The rate of TBI visits have risen substantially over time, especially among children under age 18 years and patients in the Northeast US Census Region. Conclusion: TBI is a serious medical condition that appears to be on the rise. Large differences exist between the hospital costs associated with TBIs treated in the inpatient and outpatient settings. Further research to understand factors affecting the costs and clinical outcomes of TBI can help refine treatment strategies to enhance patient outcomes while providing cost effective care.;,citation_author=Pankaj A. Patel;,citation_author=Peter J. Mallow;,citation_author=Mary Vassar;,citation_author=John A. Rizzo;,citation_author=Bhavik J. Pandya;,citation_author=Denise T. Kruzikas;,citation_publication_date=2014-10;,citation_cover_date=2014-10;,citation_year=2014;,citation_issue=2;,citation_doi=10.36469/9893;,citation_issn=2327-2236;,citation_volume=2;,citation_language=en-US;,citation_journal_title=Journal of Health Economics and Outcomes Research;">
<meta name="citation_reference" content="citation_title=Triage of Patients with Intracerebral Hemorrhage to Comprehensive Versus Primary Stroke Centers;,citation_author=Nikhil M. Patel;,citation_author=Quincy K. Tran;,citation_author=Paul Capobianco;,citation_author=Timothy Traynor;,citation_author=Michael J. Armahizer;,citation_author=Melissa Motta;,citation_author=Gunjan Y. Parikh;,citation_author=Neeraj Badjatia;,citation_author=Wan-Tsu Chang;,citation_author=Nicholas A. Morris;,citation_publication_date=2021-05;,citation_cover_date=2021-05;,citation_year=2021;,citation_issue=5;,citation_doi=10.1016/j.jstrokecerebrovasdis.2021.105672;,citation_issn=10523057;,citation_volume=30;,citation_language=en-US;,citation_journal_title=Journal of Stroke and Cerebrovascular Diseases;">
<meta name="citation_reference" content="citation_title=Ultrasound for Pleural Disease. Beyond a Pocket of Pleural Fluid;,citation_author=Kinner M. Patel;,citation_author=Kazi Ullah;,citation_author=Hassan Patail;,citation_author=Sahar Ahmad;,citation_publication_date=2021-05;,citation_cover_date=2021-05;,citation_year=2021;,citation_issue=5;,citation_doi=10.1513/AnnalsATS.202008-948CME;,citation_issn=2329-6933, 2325-6621;,citation_volume=18;,citation_language=en-US;,citation_journal_title=Annals of the American Thoracic Society;">
<meta name="citation_reference" content="citation_title=A review of traumatic brain injury trauma center visits meeting physiologic criteria from The American College of Surgeons Committee on Trauma/Centers for Disease Control and Prevention Field Triage Guidelines;,citation_abstract=BACKGROUND: Traumatic brain injury (TBI) represents a serious subset of injuries among persons in the United States, and prehospital care of these injuries can mitigate both the morbidity and the mortality in patients who suffer from these injuries. Guidelines for triage of injured patients have been set forth by the American College of Surgeons Committee on Trauma (ACS-COT) in cooperation with the Centers for Disease Control and Prevention (CDC). These guidelines include physiologic criteria, such as the Glasgow Coma Scale (GCS) score, systolic blood pressure, and respiratory rate, which should be used in determining triage of an injured patient. OBJECTIVES: This study examined the numbers of visits at level I and II trauma centers by patients with a diagnosed TBI to determine the prevalence of those meeting physiologic criteria from the ACS-COT/CDC guidelines and to determine the extent of mortality among this patient population. METHODS: The data for this study were taken from the 2007 National Trauma Data Bank (NTDB) National Sample Program (NSP). This data set is a nationally representative sample of visits to level I and II trauma centers across the United States and is funded by the American College of Surgeons. Estimates of demographic characteristics, physiologic measures, and death were made for this study population using both chi-square analyses and adjusted logistic regression modeling. RESULTS: The analyses demonstrated that although many people who sustain a TBI and were taken to a level I or II trauma center did not meet the physiologic criteria, those who did meet the physiologic criteria had significantly higher odds of death than those who did not meet the criteria. After controlling for age, gender, race, Injury Severity Score (ISS), and length of stay in the hospital, persons who had a GCS score \leq13 were 17 times more likely to die than TBI patients who had a higher GCS score (odds ratio [OR] 17.4; 95% confidence interval [CI] 10.7-28.3). Other physiologic criteria also demonstrated significant odds of death. CONCLUSIONS: These findings support the validity of the ACS-COT/CDC physiologic criteria in this population and stress the importance of prehospital triage of patients with TBI in the hopes of reducing both the morbidity and the mortality resulting from this injury.;,citation_author=William S. Pearson;,citation_author=Fernando Ovalle;,citation_author=Mark Faul;,citation_author=Scott M. Sasser;,citation_issue=3;,citation_doi=10.3109/10903127.2012.682701;,citation_issn=1545-0066;,citation_pmid=22548387;,citation_volume=16;,citation_language=en-US;,citation_journal_title=Prehospital Emergency Care;">
<meta name="citation_reference" content="citation_title=Outcomes of CMS-mandated fluid administration among fluid-overloaded patients with sepsis: A systematic review and meta-analysis;,citation_abstract=Introduction: The outcomes of large-volume IVF administration to septic shock patients with comorbid congestive heart failure (CHF) and/or end-stage renal disease (ESRD) are uncertain and widely debated in the existing literature. Despite this uncertainty, CMS continues to recommend that 30 ml/kg of an intravenous crystalloid solution be administered to patients in septic shock starting within 3 h of presentation. We performed a systematic review and meta-analysis to assess the relationship between adherence to this guideline and outcomes among patients whose underlying comorbidities present a risk of fluid overload. Methods: Our search was conducted on PubMed and Scopus through November 5, 2021 to identify studies that evaluated clinical outcomes among septic patients with CHF/ESRD based on volume of fluid administered. The primary outcome measured was mortality at 30 days post-hospital discharge. Other outcomes included the rates of vasopressor requirements, invasive mechanical ventilation during hospitalization, as well as length of stay in the intensive care unit and/or hospital. We used random effects meta-analysis when two or more studies reported the same outcome. Results: We included five studies in the final meta-analysis, which comprised 5804 patients, 5260 (91%) of whom received non-aggressive fluid resuscitation, as defined by the studies’ authors. Random-effects meta-analysis for all-cause mortality showed that aggressive fluid resuscitation was associated with statistically non-significant increased odds of mortality (OR 1.42, 95% CI 0.88–2.3, P = 0.15, I2 = 35%). There was no statistical association between volume of IVF administration and other outcomes evaluated. Conclusion: Among septic shock patients with CHF and/or ESRD, administration of greater than or equal to 30 ml/ kg IVF was associated with a non-significant increase in odds of mortality. All other outcomes measured were found to be non-significant, although there was a trend toward better outcomes among patients in the restricted-volume compared to the standard-volume IVF groups. Since this meta-analysis only included five observational studies, more studies are needed to guide an optimal volume and rate of fluid administration in this patient population.;,citation_author=Madeline Pence;,citation_author=Quincy K Tran;,citation_author=Robert Shesser;,citation_author=Christopher Payette;,citation_author=Ali Pourmand;,citation_publication_date=2022-05;,citation_cover_date=2022-05;,citation_year=2022;,citation_doi=10.1016/j.ajem.2022.03.004;,citation_issn=07356757;,citation_volume=55;,citation_language=en-US;,citation_journal_title=The American Journal of Emergency Medicine;">
<meta name="citation_reference" content="citation_title=In Search of the Optimal Antithrombotic Regimen for Intracerebral Hemorrhage Survivors with Atrial Fibrillation;,citation_abstract=Spontaneous intracerebral hemorrhage (ICH) constitutes 10–15% of all strokes, and is a significant cause of mortality and morbidity. Survivors of ICH, especially those with atrial fibrillation (AF), are at risk for both recurrent hemorrhagic and ischemic cerebrovascular events. A conundrum in the field of vascular neurology, neurosurgery, and cardiology has been the decision to initiate or resume versus withhold anticoagulation in survivors of ICH with AF. To initiate anticoagulation would decrease the risk of ischemic stroke but may increase the risk of hemorrhage. To withhold anticoagulation maintains a lower risk of hemorrhage but does not decrease the risk of ischemic stroke. In this narrative review, we discuss the evidence for and against the use of antithrombotics in ICH survivors with AF, focusing on recently completed and ongoing clinical trials.;,citation_author=Teng J. Peng;,citation_author=Catherine Viscoli;,citation_author=Pooja Khatri;,citation_author=Stacey Q. Wolfe;,citation_author=Nirav R. Bhatt;,citation_author=Tarun Girotra;,citation_author=Hooman Kamel;,citation_author=Kevin N. Sheth;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_doi=10.1007/s40265-022-01729-9;,citation_issn=0012-6667, 1179-1950;,citation_language=en-US;,citation_journal_title=Drugs;">
<meta name="citation_reference" content="citation_title=Procalcitonin-Guided Antibiotic Discontinuation and Mortality in Critically Ill Adults;,citation_abstract=BACKGROUND: Procalcitonin (PCT)-guided antibiotic discontinuation appears to decrease antibiotic use in critically ill patients, but its impact on survival remains less certain. METHODS: We searched PubMed, Embase, Scopus, Web of Science, and CENTRAL for randomized controlled trials (RCTs) of PCT-guided antibiotic discontinuation in critically ill adults reporting survival or antibiotic duration. Searches were conducted without language restrictions from inception to July 23, 2018. Two reviewers independently conducted all review stages; another adjudicated differences. Data were pooled using random-effects metaanalysis. Study quality was assessed with the Cochrane risk of bias tool, and evidence was graded using GRADEpro. RESULTS: Among critically ill adults (5,158 randomized; 5,000 analyzed), PCT-guided antibiotic discontinuation was associated with decreased mortality (16 RCTs; risk ratio [RR], 0.89; 95% CI, 0.83-0.97; I2 \frac{1}{4} 0%; low certainty). Death was the primary outcome in only one study and a survival benefit was not observed in the subset specified as sepsis (10 RCTs; RR, 0.94; 95% CI, 0.85-1.03; I2 \frac{1}{4} 0%), those without industry sponsorship (nine RCTs; RR, 0.98; 95% CI, 0.87-1.10; I2 \frac{1}{4} 0%), high PCT-guided algorithm adherence (five RCTs; RR, 0.93; 95% CI, 0.711.22; I2 \frac{1}{4} 0%), and PCT-guided algorithms without C-reactive protein (eight RCTs; RR, 0.96; 95% CI, 0.87-1.06; I2 \frac{1}{4} 0%). PCT-guided antibiotic discontinuation decreased antibiotic duration (mean difference, 1.31 days; 95% CI, –2.27 to –0.35; I2 \frac{1}{4} 93%) (low certainty). CONCLUSIONS: Our findings of increased survival and decreased antibiotic utilization associated with PCT-guided antibiotic discontinuation represent low-certainty evidence with a high risk of bias. This relationship was primarily observed in studies without high protocol adherence and in studies with algorithms combining PCT and C-reactive protein. Properly designed studies with mortality as the primary outcome are needed to address this question. TRIAL REGISTRY: International Prospective Register of Systematic Reviews (PROSPERO); No.: CRD42016049715; URL: http://www.crd.york.ac.uk/PROSPERO_REBRANDING/display_ record.asp?ID\frac{1}{4}CRD42016049715;,citation_author=Dominique J. Pepper;,citation_author=Junfeng Sun;,citation_author=Chanu Rhee;,citation_author=Judith Welsh;,citation_author=John H. Powers;,citation_author=Robert L. Danner;,citation_author=Sameer S. Kadri;,citation_publication_date=2019-06;,citation_cover_date=2019-06;,citation_year=2019;,citation_issue=6;,citation_doi=10.1016/j.chest.2018.12.029;,citation_issn=00123692;,citation_volume=155;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=DDAVP Is Effective in Preventing and Reversing Inadvertent Overcorrection of Hyponatremia;,citation_abstract=Background and objectives: Adherence to therapeutic guidelines for the treatment of hyponatremia becomes difficult when water diuresis emerges during therapy. The objective of this study was to assess the effectiveness and safety of desmopressin acetate as a therapeutic agent to avoid overcorrection of hyponatremia and to lower the plasma sodium concentration again after inadvertent overcorrection. Design, setting, participants, &amp;amp;amp; measurements: Retrospective chart review was conducted of all patients who were given desmopressin acetate during the treatment of hyponatremia during 6 yr in a 528-bed community teaching hospital. Results: Six patients (group 1) were given desmopressin acetate after the 24-h limit of 12 mmol/L had already been reached or exceeded; correction was prevented from exceeding the 48-h limit of 18 mmol/L in five of the six. Fourteen patients (group 2) were given desmopressin acetate in anticipation of overcorrection after the plasma sodium concentration had increased by 1 to 12 mmol/L. In all 14 patients who were treated with desmopressin acetate as a preventive measure, correction was prevented from exceeding either the 24- or 48-h limits. After desmopressin acetate was administered, the plasma sodium concentration of 14 of the 20 patients fell by 2 to 9 mmol/L. In all six group 1 patients and in five of the group 2 patients, the plasma sodium concentration was actively lowered again by the concurrent administration of desmopressin acetate and 5% dextrose in water; no serious adverse consequences from this maneuver were observed. Conclusion: Desmopressin acetate is effective in preventing and reversing inadvertent overcorrection of hyponatremia. Clin J Am Soc Nephrol 3: 331-336, 2008. doi: 10.2215/CJN.03190807;,citation_author=Anjana Perianayagam;,citation_author=Richard H. Sterns;,citation_author=Stephen M. Silver;,citation_author=Marvin Grieff;,citation_author=Robert Mayo;,citation_author=John Hix;,citation_author=Ruth Kouides;,citation_publication_date=2008-03;,citation_cover_date=2008-03;,citation_year=2008;,citation_issue=2;,citation_doi=10.2215/CJN.03190807;,citation_issn=1555-9041, 1555-905X;,citation_volume=3;,citation_language=en-US;,citation_journal_title=Clinical Journal of the American Society of Nephrology;">
<meta name="citation_reference" content="citation_title=Brain injury after cardiac arrest;,citation_author=Gavin D Perkins;,citation_author=Clifton W Callaway;,citation_author=Kirstie Haywood;,citation_author=Robert W Neumar;,citation_author=Gisela Lilja;,citation_author=Matthew J Rowland;,citation_author=Kelly N Sawyer;,citation_author=Markus B Skrifvars;,citation_author=Jerry P Nolan;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=10307;,citation_doi=10.1016/S0140-6736(21)00953-3;,citation_issn=01406736;,citation_volume=398;,citation_language=en-US;,citation_journal_title=The Lancet;">
<meta name="citation_reference" content="citation_title=Do Covariates Change the Estimand?;,citation_abstract=Adjustment for covariates has been underused in trials intended to support approval of medical products. This underuse results partly from confusion about whether adjusting changes the thing being estimated or only the estimate of it, and partly from misplaced concerns about assumptions of the analysis. If the thing being estimated is carefully defined, it is seen that adjustments can be used with minimal assumptions. Thus, the benefit of increased efficiency can be realized with essentially no cost in robustness or interpretability.;,citation_author=Thomas Permutt;,citation_publication_date=2020-01;,citation_cover_date=2020-01;,citation_year=2020;,citation_issue=1;,citation_doi=10.1080/19466315.2019.1647874;,citation_issn=null;,citation_volume=12;,citation_journal_title=Statistics in Biopharmaceutical Research;,citation_publisher=Taylor &amp;amp;amp; Francis;">
<meta name="citation_reference" content="citation_title=Hydroxyethyl Starch 130/0.42 versus Ringer’s Acetate in Severe Sepsis;,citation_abstract=Intravenous fluids are the mainstay of treatment for patients with hypovolemia due to severe sepsis. Colloid solutions are used to obtain rapid and lasting circulatory stabilization, but there are limited data to support this practice.1 The Surviving Sepsis Campaign guidelines recommend the use of either colloids or crystalloids,2 but high-molecular-weight hydroxyethyl starch (HES) may cause acute kidney failure in patients with severe sepsis, as observed in two randomized trials.3,4 Those trials had substantial limitations, and participants received HES solutions with a molecular weight of 200 kD and a substitution ratio (the number of hydroxyethyl groups per glucose molecule) of . . .;,citation_author=Anders Perner;,citation_author=Nicolai Haase;,citation_author=Anne B. Guttormsen;,citation_author=Jyrki Tenhunen;,citation_author=Gudmundur Klemenzson;,citation_author=Anders Åneman;,citation_author=Kristian R. Madsen;,citation_author=Morten H. Møller;,citation_author=Jeanie M. Elkjær;,citation_author=Lone M. Poulsen;,citation_author=Asger Bendtsen;,citation_author=Robert Winding;,citation_author=Morten Steensen;,citation_author=Pawel Berezowicz;,citation_author=Peter Søe-Jensen;,citation_author=Morten Bestle;,citation_author=Kristian Strand;,citation_author=Jørgen Wiis;,citation_author=Jonathan O. White;,citation_author=Klaus J. Thornberg;,citation_author=Lars Quist;,citation_author=Jonas Nielsen;,citation_author=Lasse H. Andersen;,citation_author=Lars B. Holst;,citation_author=Katrin Thormar;,citation_author=Anne-Lene Kjældgaard;,citation_author=Maria L. Fabritius;,citation_author=Frederik Mondrup;,citation_author=Frank C. Pott;,citation_author=Thea P. Møller;,citation_author=Per Winkel;,citation_author=Jørn Wetterslev;,citation_publication_date=2012-07;,citation_cover_date=2012-07;,citation_year=2012;,citation_issue=2;,citation_doi=10.1056/NEJMoa1204242;,citation_issn=0028-4793;,citation_pmid=22738085;,citation_volume=367;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=A review of spline function procedures in R;,citation_abstract=Background: With progress on both the theoretical and the computational fronts the use of spline modelling has become an established tool in statistical regression analysis. An important issue in spline modelling is the availability of user friendly, well documented software packages. Following the idea of the STRengthening Analytical Thinking for Observational Studies initiative to provide users with guidance documents on the application of statistical methods in observational research, the aim of this article is to provide an overview of the most widely used spline-based techniques and their implementation in R. Methods: In this work, we focus on the R Language for Statistical Computing which has become a hugely popular statistics software. We identified a set of packages that include functions for spline modelling within a regression framework. Using simulated and real data we provide an introduction to spline modelling and an overview of the most popular spline functions. Results: We present a series of simple scenarios of univariate data, where different basis functions are used to identify the correct functional form of an independent variable. Even in simple data, using routines from different packages would lead to different results. Conclusions: This work illustrate challenges that an analyst faces when working with data. Most differences can be attributed to the choice of hyper-parameters rather than the basis used. In fact an experienced user will know how to obtain a reasonable outcome, regardless of the type of spline used. However, many analysts do not have sufficient knowledge to use these powerful tools adequately and will need more guidance.;,citation_author=Aris Perperoglou;,citation_author=Willi Sauerbrei;,citation_author=Michal Abrahamowicz;,citation_author=Matthias Schmid;,citation_publication_date=2019-12;,citation_cover_date=2019-12;,citation_year=2019;,citation_issue=1;,citation_doi=10.1186/s12874-019-0666-3;,citation_issn=1471-2288;,citation_volume=19;,citation_language=en-US;,citation_journal_title=BMC Medical Research Methodology;">
<meta name="citation_reference" content="citation_title=Validation of the Ottawa Subarachnoid Hemorrhage Rule in patients with acute headache;,citation_author=Jeffrey J. Perry;,citation_author=Marco L. A. Sivilotti;,citation_author=Jane Sutherland;,citation_author=Corinne M. Hohl;,citation_author=Marcel Émond;,citation_author=Lisa A. Calder;,citation_author=Christian Vaillancourt;,citation_author=Venkatesh Thirganasambandamoorthy;,citation_author=Howard Lesiuk;,citation_author=George A. Wells;,citation_author=Ian G. Stiell;,citation_publication_date=2017-11;,citation_cover_date=2017-11;,citation_year=2017;,citation_issue=45;,citation_doi=10.1503/cmaj.170072;,citation_issn=0820-3946, 1488-2329;,citation_volume=189;,citation_language=en-US;,citation_journal_title=Canadian Medical Association Journal;">
<meta name="citation_reference" content="citation_title=Making trials part of good clinical care: Lessons from the RECOVERY trial;,citation_author=Guilherme Pessoa-Amorim;,citation_author=Mark Campbell;,citation_author=Lucy Fletcher;,citation_author=Peter Horby;,citation_author=Martin Landray;,citation_author=Marion Mafham;,citation_author=Richard Haynes;,citation_publication_date=2021-07;,citation_cover_date=2021-07;,citation_year=2021;,citation_issue=2;,citation_doi=10.7861/fhj.2021-0083;,citation_issn=2514-6645, 2514-6653;,citation_volume=8;,citation_language=en-US;,citation_journal_title=Future Healthcare Journal;">
<meta name="citation_reference" content="citation_title=Does Interrupting Self-Induced Lung Injury and Respiratory Drive Expedite Early Spontaneous Breathing in the Setting of Early Severe Diffuse Acute Respiratory Distress Syndrome?;,citation_author=Fabrice Petitjeans;,citation_author=Sandrine Leroy;,citation_author=Cyrille Pichot;,citation_author=Marco Ghignone;,citation_author=Luc Quintin;,citation_author=Jean-Michel Constantin;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_doi=10.1097/CCM.0000000000005288;,citation_issn=0090-3493;,citation_volume=Publish Ahead of Print;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction;,citation_abstract=BACKGROUND In patients with symptomatic heart failure, sacubitril–valsartan has been found to reduce the risk of hospitalization and death from cardiovascular causes more effectively than an angiotensin-converting–enzyme inhibitor. Trials comparing the effects of these drugs in patients with acute myocardial infarction have been lacking. METHODS We randomly assigned patients with myocardial infarction complicated by a reduced left ventricular ejection fraction, pulmonary congestion, or both to receive either sacubitril–valsartan (97 mg of sacubitril and 103 mg of valsartan twice daily) or ramipril (5 mg twice daily) in addition to recommended therapy. The primary outcome was death from cardiovascular causes or incident heart failure (outpatient symptomatic heart failure or heart failure leading to hospitalization), whichever occurred first. RESULTS A total of 5661 patients underwent randomization; 2830 were assigned to receive sacubitril–valsartan and 2831 to receive ramipril. Over a median of 22 months, a primary-outcome event occurred in 338 patients (11.9%) in the sacubitril–valsartan group and in 373 patients (13.2%) in the ramipril group (hazard ratio, 0.90; 95% confidence interval [CI], 0.78 to 1.04; P = 0.17). Death from cardiovascular causes or hospitalization for heart failure occurred in 308 patients (10.9%) in the sacubitril–valsartan group and in 335 patients (11.8%) in the ramipril group (hazard ratio, 0.91; 95% CI, 0.78 to 1.07); death from cardiovascular causes in 168 (5.9%) and 191 (6.7%), respectively (hazard ratio, 0.87; 95% CI, 0.71 to 1.08); and death from any cause in 213 (7.5%) and 242 (8.5%), respectively (hazard ratio, 0.88; 95% CI, 0.73 to 1.05). Treatment was discontinued because of an adverse event in 357 patients (12.6%) in the sacubitril–valsartan group and 379 patients (13.4%) in the ramipril group. The authors’ full names, academic degrees, and affiliations are listed in the Appendix. Dr. Pfeffer can be contacted at mpfeffer@rics.bwh.harvard.edu or at the Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis St., Boston, MA 02115. *The PARADISE-MI investigators and committees are listed in the Supplementary Appendix, available at NEJM.org. This article was updated on November 11, 2021, at NEJM.org. N Engl J Med 2021;385:1845-55. DOI: 10.1056/NEJMoa2104508 Copyright © 2021 Massachusetts Medical Society. CME at NEJM.org CONCLUSIONS Sacubitril–valsartan was not associated with a significantly lower incidence of death from cardiovascular causes or incident heart failure than ramipril among patients with acute myocardial infarction. (Funded by Novartis; PARADISE-MI ClinicalTrials.gov number, NCT02924727.);,citation_author=Marc A. Pfeffer;,citation_author=Brian Claggett;,citation_author=Eldrin F. Lewis;,citation_author=Christopher B. Granger;,citation_author=Lars Køber;,citation_author=Aldo P. Maggioni;,citation_author=Douglas L. Mann;,citation_author=John J. V. McMurray;,citation_author=Jean-Lucien Rouleau;,citation_author=Scott D. Solomon;,citation_author=Philippe G. Steg;,citation_author=Otavio Berwanger;,citation_author=Maja Cikes;,citation_author=Carmine G. De Pasquale;,citation_author=Cara East;,citation_author=Alberto Fernandez;,citation_author=Karola Jering;,citation_author=Ulf Landmesser;,citation_author=Roxana Mehran;,citation_author=Béla Merkely;,citation_author=Freny Vaghaiwalla Mody;,citation_author=Mark C. Petrie;,citation_author=Ivo Petrov;,citation_author=Morten Schou;,citation_author=Michele Senni;,citation_author=David Sim;,citation_author=Peter Meer;,citation_author=Martin Lefkowitz;,citation_author=Yinong Zhou;,citation_author=Jianjian Gong;,citation_author=Eugene Braunwald;,citation_publication_date=2021-11;,citation_cover_date=2021-11;,citation_year=2021;,citation_issue=20;,citation_doi=10.1056/NEJMoa2104508;,citation_issn=0028-4793, 1533-4406;,citation_volume=385;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Behind the Scenes of TOPCAT — Bending to Inform;,citation_author=Marc A. Pfeffer;,citation_author=Brian Claggett;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=1;,citation_doi=10.1056/EVIDctcs2100007;,citation_issn=2766-5526;,citation_volume=1;,citation_language=en-US;,citation_journal_title=NEJM Evidence;">
<meta name="citation_reference" content="citation_title=Has Mortality from Acute Respiratory Distress Syndrome Decreased over Time?: A Systematic Review;,citation_abstract=Objectives: To systematically review the literature assessing ARDS mortality over time and to determine patient- and study-level factors independently associated with mortality. Methods: We searched multiple databases (MEDLINE, EMBASE, CINAHL, Cochrane CENTRAL) for prospective observational studies or randomized controlled trials (RCTs) published during the period 1984 to 2006 that enrolled 50 or more patients with ALI/ARDS and reported mortality. We pooled mortality estimates using randomeffects meta-analysis and examined mortality trends before and after 1994 (when a consensus definition of ALI/ARDS was published) and factors associated with mortality using meta-regression models. Measurements and Main Results: Of 4,966 studies, 89 met inclusion criteria (53 observational, 36 RCTs). There was a total of 18,900 patients (mean age 51.6 years; 39% female). Overall pooled weighted mortality was 44.3% (95% confidence interval [CI], 41.8–46.9). Mortality decreased with time in observational studies conducted before 1994; no temporal associations with mortality were demonstrated in RCTs (any time) or observational studies (after 1994). Pooled mortality from 1994 to 2006 was 44.0% (95% CI, 40.1–47.5) for observational studies, and 36.2% (95% CI, 32.1–40.5) for RCTs. Meta-regression identified study type (observational versus RCT, odds ratio, 1.36; 95% CI, 1.08–1.73) and patient age (odds ratio per additional 10 yr, 1.27; 95% CI, 1.07–1.50) as the only factors associated with mortality. Conclusions: A decrease in ARDS mortality was only seen in observational studies from 1984 to 1993. Mortality did not decrease between 1994 (when a consensus definition was published) and 2006, and is lower in RCTs than observational studies.;,citation_author=Jason Phua;,citation_author=Joan R. Badia;,citation_author=Neill K. J. Adhikari;,citation_author=Jan O. Friedrich;,citation_author=Robert A. Fowler;,citation_author=Jeff M. Singh;,citation_author=Damon C. Scales;,citation_author=David R. Stather;,citation_author=Amanda Li;,citation_author=Andrew Jones;,citation_author=David J. Gattas;,citation_author=David Hallett;,citation_author=George Tomlinson;,citation_author=Thomas E. Stewart;,citation_author=Niall D. Ferguson;,citation_publication_date=2009-02;,citation_cover_date=2009-02;,citation_year=2009;,citation_issue=3;,citation_doi=10.1164/rccm.200805-722OC;,citation_issn=1073-449X, 1535-4970;,citation_volume=179;,citation_language=en-US;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management;,citation_abstract=The increase in the rate of obesity, a chronic disease with serious health consequences, largely explains the recent tripling in the prevalence of type 2 diabetes.1,2 Weight loss of 5 to 10% has been shown to reduce complications related to obesity and improve quality of life3–7; however, weight loss is difficult to maintain with lifestyle intervention alone.8 Liraglutide, a glucagon-like peptide-1 analogue with 97% homology to human glucagon-like peptide-1, is approved for the treatment of type 2 diabetes at doses up to 1.8 mg once daily.9 Weight loss with liraglutide is dose-dependent up to 3.0 mg once . . .;,citation_author=Xavier Pi-Sunyer;,citation_author=Arne Astrup;,citation_author=Ken Fujioka;,citation_author=Frank Greenway;,citation_author=Alfredo Halpern;,citation_author=Michel Krempf;,citation_author=David C. W. Lau;,citation_author=Carel W. Roux;,citation_author=Rafael Violante Ortiz;,citation_author=Christine Bjørn Jensen;,citation_author=John P. H. Wilding;,citation_publication_date=2015-07;,citation_cover_date=2015-07;,citation_year=2015;,citation_issue=1;,citation_doi=10.1056/NEJMoa1411892;,citation_issn=0028-4793;,citation_pmid=26132939;,citation_volume=373;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Early management of patients with aneurysmal subarachnoid hemorrhage in a hospital without neurosurgical/neuroendovascular facilities: A consensus and clinical recommendations of the Italian Society of Anesthesia and Intensive Care (SIAARTI);,citation_abstract=Background: The immediate management of subarachnoid hemorrhage (SAH) patients in hospitals without neurosurgical/neurointerventional facilities and their transfer to a specialized center is challenging and not well covered in existing guidelines. To address these issues, we created a consensus of experts endorsed by the Italian Society of Anesthesia and Intensive Care (SIAARTI) to provide clinical guidance. Methods: A multidisciplinary consensus panel composed by 19 physicians selected for their established clinical and scientific expertise in the acute management of SAH patients with different specializations (anesthesia/intensive care, neurosurgery and interventional neuroradiology) was created. A modified Delphi approach was adopted. Results: A total of 14 statements have been discussed. Consensus was reached on 11 strong recommendations and 2 weak recommendations. In one case, where consensus could not be agreed upon, no recommendation could be provided. Conclusions: Management of SAH in a non-specialized setting and early transfer are difficult and may have a critical impact on outcome. Clinical advice, based on multidisciplinary consensus, might be helpful. Our recommendations cover most, but not all, topics of clinical relevance.;,citation_author=Edoardo Picetti;,citation_author=Maurizio Berardino;,citation_author=Alessandro Bertuccio;,citation_author=Rita Bertuetti;,citation_author=Edoardo Pietro Boccardi;,citation_author=Anselmo Caricato;,citation_author=Carlo Alberto Castioni;,citation_author=Marco Cenzato;,citation_author=Arturo Chieregato;,citation_author=Giuseppe Citerio;,citation_author=Paolo Gritti;,citation_author=Luca Longhi;,citation_author=Costanza Martino;,citation_author=Marina Munari;,citation_author=Sandra Rossi;,citation_author=Nino Stocchetti;,citation_author=Tommaso Zoerle;,citation_author=Frank Rasulo;,citation_author=Chiara Robba;,citation_publication_date=2021-12;,citation_cover_date=2021-12;,citation_year=2021;,citation_issue=1;,citation_doi=10.1186/s44158-021-00012-9;,citation_issn=2731-3786;,citation_volume=1;,citation_language=en-US;,citation_journal_title=Journal of Anesthesia, Analgesia and Critical Care;">
<meta name="citation_reference" content="citation_title=Bacterial Superinfection Pneumonia in Patients Mechanically Ventilated for COVID-19 Pneumonia;,citation_abstract=Rationale: Current guidelines recommend patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia receive empirical antibiotics for suspected bacterial superinfection on the basis of weak evidence. Rates of ventilatorassociated pneumonia (VAP) in clinical trials of patients with SARS-CoV-2 pneumonia are unexpectedly low.;,citation_author=Chiagozie O. Pickens;,citation_author=Catherine A. Gao;,citation_author=Michael J. Cuttica;,citation_author=Sean B. Smith;,citation_author=Lorenzo L. Pesce;,citation_author=Rogan A. Grant;,citation_author=Mengjia Kang;,citation_author=Luisa Morales-Nebreda;,citation_author=Avni A. Bavishi;,citation_author=Jason M. Arnold;,citation_author=Anna Pawlowski;,citation_author=Chao Qi;,citation_author=G. R. Scott Budinger;,citation_author=Benjamin D. Singer;,citation_author=Richard G. Wunderink;,citation_author=A. Christine Argento;,citation_author=Ajay A. Wagh;,citation_author=Alexander V. Misharin;,citation_author=Alexandra C. McQuattie-Pimentel;,citation_author=Alexis Rose Wolfe;,citation_author=Alvaro Donayre;,citation_author=Ankit Bharat;,citation_author=Anne R. Levenson;,citation_author=Anthony M. Joudi;,citation_author=Betty Tran;,citation_author=Chitaru Kurihara;,citation_author=Clara J Schroedl;,citation_author=Daniel Meza;,citation_author=Daniel Schneider;,citation_author=David A. Kidd;,citation_author=David D. Odell;,citation_author=David W. Kamp;,citation_author=Elizabeth S. Malsin;,citation_author=Emily M. Leibenguth;,citation_author=Eric P. Cantey;,citation_author=Gabrielle Y. Liu;,citation_author=Helen K. Donnelly;,citation_author=Isaac A. Goldberg;,citation_author=Jacob I. Sznajder;,citation_author=Jacqueline M. Kruser;,citation_author=James M. Walter;,citation_author=Jane E. Dematte;,citation_author=John Coleman;,citation_author=Joseph I. Bailey;,citation_author=Joseph S. Deters;,citation_author=Justin A. Fiala;,citation_author=Katharine Secunda;,citation_author=Kaitlyn Vitale;,citation_author=Khalilah L. Gates;,citation_author=Kristy Todd;,citation_author=Lindsey D. Gradone;,citation_author=Lindsey N. Textor;,citation_author=Lisa F. Wolfe;,citation_author=Madeline L. Rosenbaum;,citation_author=Manu Jain;,citation_author=Marc A. Sala;,citation_author=Mary Carns;,citation_author=Marysa V. Leya;,citation_author=Michael J. Alexander;,citation_author=Michelle Hinsch Prickett;,citation_author=Natalie Jensema;,citation_author=Nicole Borkowski;,citation_author=Nikolay S. Markov;,citation_author=Orlyn R. Rivas;,citation_author=Paul A. Reyfman;,citation_author=Peter H. S. Sporn;,citation_author=Prasanth Nannapaneni;,citation_author=Rachel B. Kadar;,citation_author=Rachel M. Kaplan;,citation_author=Rade Tomic;,citation_author=Radhika Patel;,citation_author=Rafael Garza-Castillon;,citation_author=Ravi Kalhan;,citation_author=Romy Lawrence;,citation_author=Ruben J. Mylvaganam;,citation_author=Samuel S. Kim;,citation_author=Sanket Thakkar;,citation_author=SeungHye Han;,citation_author=Sharon R. Rosenberg;,citation_author=Susan R. Russell;,citation_author=Sydney M. Hyder;,citation_author=Taylor A. Poor;,citation_author=Theresa A. Lombardo;,citation_author=Zasu M. Klug;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=8;,citation_doi=10.1164/rccm.202106-1354OC;,citation_issn=1073-449X, 1535-4970;,citation_volume=204;,citation_language=en-US;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Principles and Practice of Antibiotic Stewardship in the ICU;,citation_author=Chiagozie I. Pickens;,citation_author=Richard G. Wunderink;,citation_publication_date=2019-07;,citation_cover_date=2019-07;,citation_year=2019;,citation_issue=1;,citation_doi=10.1016/j.chest.2019.01.013;,citation_issn=00123692;,citation_volume=156;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Acute kidney injury in the critically ill: An updated review on pathophysiology and management;,citation_abstract=Acute kidney injury (AKI) is now recognized as a heterogeneous syndrome that not only affects acute morbidity and mortality, but also a patient’s long-term prognosis. In this narrative review, an update on various aspects of AKI in critically ill patients will be provided. Focus will be on prediction and early detection of AKI (e.g., the role of biomarkers to identify high-risk patients and the use of machine learning to predict AKI), aspects of pathophysiology and progress in the recognition of different phenotypes of AKI, as well as an update on nephrotoxicity and organ cross-talk. In addition, prevention of AKI (focusing on fluid management, kidney perfusion pressure, and the choice of vasopressor) and supportive treatment of AKI is discussed. Finally, post-AKI risk of long-term sequelae including incident or progression of chronic kidney disease, cardiovascular events and mortality, will be addressed.;,citation_author=Peter Pickkers;,citation_author=Michael Darmon;,citation_author=Eric Hoste;,citation_author=Michael Joannidis;,citation_author=Matthieu Legrand;,citation_author=Marlies Ostermann;,citation_author=John R. Prowle;,citation_author=Antoine Schneider;,citation_author=Miet Schetz;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_issue=8;,citation_doi=10.1007/s00134-021-06454-7;,citation_issn=0342-4642, 1432-1238;,citation_volume=47;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial;,citation_abstract=OBJECTIVE To investigate the efficacy and safety of rituximab compared with placebo as an add-on to standard of care for MG. DESIGN, SETTING, AND PARTICIPANTS This randomized, double-blind, placebo-controlled study took place throughout 48 weeks at 7 regional clinics in Sweden. Key inclusion criteria were age older than 18 years, onset of generalized symptoms within 12 months or less, and a Quantitative Myasthenia Gravis (QMG) score of 6 or more. Patients were screened from October 20, 2016, to March 2, 2020. Key exclusion criteria included pure ocular MG, suspected thymoma, previous thymectomy, and prior noncorticosteroid immunosuppressants or high doses of corticosteroids. INTERVENTIONS Participants were randomized 1:1 without stratification to a single intravenous infusion of 500 mg of rituximab or matching placebo. MAIN OUTCOMES AND MEASURES Minimal disease manifestations at 16 weeks defined as a QMG score of 4 or less with prednisolone, 10 mg or less daily, and no rescue treatment. RESULTS Of 87 potentially eligible patients, 25 were randomized to rituximab (mean [SD] age, 67.4 [13.4] years; 7 [28%] female) and 22 to placebo (mean [SD] age, 58 [18.6] years; 7 [32%] female). Compared with placebo, a greater proportion with rituximab met the primary end point; 71% (17 of 24) in the rituximab group vs 29% (6 of 21) in the placebo group (Fisher exact test P = .007; probability ratio, 2.48 [95% CI, 1.20-5.11]). Secondary end points, comparing changes in Myasthenia Gravis Activities of Daily Living and Myasthenia Gravis Quality of Life at 16 weeks with QMG at 24 weeks did not differ between groups with censoring for rescue treatment (per-protocol analysis) but were in favor of active treatment when rescue treatment was taken into account by worst rank imputation (post hoc analysis). Rescue treatments were also more frequent in the placebo arm (rituximab: 1 [4%]; placebo, 8 [36%]). One patient in the placebo arm had a myocardial infarction with cardiac arrest and 1 patient in the active arm experienced a fatal cardiac event. CONCLUSIONS AND RELEVANCE A single dose of 500 mg of rituximab was associated with greater probability of minimal MG manifestations and reduced need of rescue medications compared with placebo. Further studies are needed to address long-term benefit-risk balance with this treatment.;,citation_author=Fredrik Piehl;,citation_author=Ann Eriksson-Dufva;,citation_author=Anna Budzianowska;,citation_author=Amalia Feresiadou;,citation_author=William Hansson;,citation_author=Max Albert Hietala;,citation_author=Irene Håkansson;,citation_author=Rune Johansson;,citation_author=Daniel Jons;,citation_author=Ivan Kmezic;,citation_author=Christopher Lindberg;,citation_author=Jonas Lindh;,citation_author=Fredrik Lundin;,citation_author=Ingela Nygren;,citation_author=Anna Rostedt Punga;,citation_author=Rayomand Press;,citation_author=Kristin Samuelsson;,citation_author=Peter Sundström;,citation_author=Oskar Wickberg;,citation_author=Susanna Brauner;,citation_author=Thomas Frisell;,citation_publication_date=2022-11;,citation_cover_date=2022-11;,citation_year=2022;,citation_issue=11;,citation_doi=10.1001/jamaneurol.2022.2887;,citation_issn=2168-6149;,citation_volume=79;,citation_language=en-US;,citation_journal_title=JAMA Neurology;">
<meta name="citation_reference" content="citation_title=The right ventricle: Interaction with the pulmonary circulation;,citation_abstract=The primary role of the right ventricle (RV) is to deliver all the blood it receives per beat into the pulmonary circulation without causing right atrial pressure to rise. To the extent that it also does not impede left ventricular (LV) filling, cardiac output responsiveness to increased metabolic demand is optimized. Since cardiac output is a function of metabolic demand of the body, during stress and exercise states the flow to the RV can vary widely. Also, instantaneous venous return varies widely for a constant cardiac output as ventilatory efforts alter the dynamic pressure gradient for venous return. Normally, blood flow varies with minimal changes in pulmonary arterial pressure. Similarly, RV filling normally occurs with minimal increases in right atrial pressure. When pulmonary vascular reserve is compromised RV ejection may also be compromised, increasing right atrial pressure and limiting maximal cardiac output. Acute increases in RV outflow resistance, as may occur with acute pulmonary embolism, will cause acute RV dilation and, by ventricular interdependence, markedly decreased LV diastolic compliance, rapidly spiraling to acute cardiogenic shock and death. Treatments include reversing the causes of pulmonary hypertension and sustaining mean arterial pressure higher than pulmonary artery pressure to maximal RV coronary blood flow. Chronic pulmonary hypertension induces progressive RV hypertrophy to match RV contractility to the increased pulmonary arterial elastance. Once fully developed, RV hypertrophy is associated with a sustained increase in right atrial pressure, impaired LV filling, and decreased exercise tolerance. Treatment focuses on pharmacologic therapies to selectively reduce pulmonary vasomotor tone and diuretics to minimize excessive RV dilation. Owning to the irreversible nature of most forms of pulmonary hypertension, when the pulmonary arterial elastance greatly exceeds the adaptive increase in RV systolic elastance, due to RV dilation, progressive pulmonary vascular obliteration, or both, end stage cor pulmonale ensues. If associated with cardiogenic shock, it can effectively be treated only by artificial ventricular support or lung transplantation. Knowing how the RV adapts to these stresses, its sign posts, and treatment options will greatly improve the bedside clinician’s ability to diagnose and treat RV dysfunction.;,citation_author=Michael R. Pinsky;,citation_publication_date=2016-12;,citation_cover_date=2016-12;,citation_year=2016;,citation_issue=1;,citation_doi=10.1186/s13054-016-1440-0;,citation_issn=1364-8535;,citation_volume=20;,citation_language=en-US;,citation_journal_title=Critical Care;,citation_publisher=BioMed Central;">
<meta name="citation_reference" content="citation_title=Heart Failure with Preserved Ejection Fraction — A Metabolic Disease?;,citation_abstract=The classification of heart failure is based on its accompanying ejection fraction: when the ejection fraction is below 40%, it is categorized as heart failure with reduced ejection fraction, and when the ejection fraction is above 50%, it is classified as heart failure with preserved ejection fraction. Heart failure with an ejection fraction between 40% and 50% is considered to be midrange. Heart failure with reduced ejection fraction and heart failure with preserved ejection fraction share many signs and symptoms that are attributable to increased intracardiac pressures, a hallmark of both conditions. In contrast to the similarity of the presentations, . . .;,citation_author=Yigal M. Pinto;,citation_publication_date=2023-09;,citation_cover_date=2023-09;,citation_year=2023;,citation_issue=12;,citation_doi=10.1056/NEJMe2309294;,citation_issn=0028-4793;,citation_volume=389;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Patient-Level Meta-Analysis of Low-Dose Hydrocortisone in Adults with Septic Shock;,citation_author=Romain Pirracchio;,citation_author=Djillali Annane;,citation_author=Andre K. Waschka;,citation_author=François Lamontagne;,citation_author=Yaseen M. Arabi;,citation_author=Pierre-Edouard Bollaert;,citation_author=Laurent Billot;,citation_author=Bin Du;,citation_author=Josef Briegel;,citation_author=Jeremy Cohen;,citation_author=Simon Finfer;,citation_author=Anthony Gordon;,citation_author=Naomi Hammond;,citation_author=Herve Hyvernat;,citation_author=Didier Keh;,citation_author=Yi Li;,citation_author=Ling Liu;,citation_author=Gianfranco Umberto Meduri;,citation_author=Liliana Mirea;,citation_author=John A. Myburgh;,citation_author=Charles L. Sprung;,citation_author=Neijla Tilouche;,citation_author=Surat Tongyoo;,citation_author=Balasubramanian Venkatesh;,citation_author=Ruiqiang Zheng;,citation_author=Anthony Delaney;,citation_publication_date=2023-05;,citation_cover_date=2023-05;,citation_year=2023;,citation_issue=6;,citation_doi=10.1056/EVIDoa2300034;,citation_volume=2;,citation_journal_title=NEJM Evidence;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Factors associated with acute mesenteric ischemia among critically ill ventilated patients with shock: A post hoc analysis of the NUTRIREA2 trial;,citation_abstract=Acute mesenteric ischemia (AMI) is a rare, but life-threatening condition occurring among critically ill patients. Several factors have been associated with AMI, but the causal link is debated, most studies being retrospective. Among these factors, enteral nutrition (EN) could be associated with AMI, in particular among patients with shock. We aimed to study the factors independently associated with AMI in a post hoc analysis of the NUTRIREA-2 trial including 2410 critically ill ventilated patients with shock, randomly assigned to receive EN or parenteral nutrition (PN).;,citation_author=Gaël Piton;,citation_author=Amélie Le Gouge;,citation_author=Julie Boisramé-Helms;,citation_author=Nadia Anguel;,citation_author=Laurent Argaud;,citation_author=Pierre Asfar;,citation_author=Vlad Botoc;,citation_author=Anne Bretagnol;,citation_author=Laurent Brisard;,citation_author=Hoang-Nam Bui;,citation_author=Emmanuel Canet;,citation_author=Delphine Chatelier;,citation_author=Louis Chauvelot;,citation_author=Michael Darmon;,citation_author=Vincent Das;,citation_author=Jérôme Devaquet;,citation_author=Michel Djibré;,citation_author=Frédérique Ganster;,citation_author=Maité Garrouste-Orgeas;,citation_author=Stéphane Gaudry;,citation_author=Olivier Gontier;,citation_author=Samuel Groyer;,citation_author=Bertrand Guidet;,citation_author=Jean-Etienne Herbrecht;,citation_author=Yannick Hourmant;,citation_author=Jean-Claude Lacherade;,citation_author=Philippe Letocart;,citation_author=Frédéric Martino;,citation_author=Virginie Maxime;,citation_author=Emmanuelle Mercier;,citation_author=Jean-Paul Mira;,citation_author=Saad Nseir;,citation_author=Jean-Pierre Quenot;,citation_author=Jack Richecoeur;,citation_author=Jean-Philippe Rigaud;,citation_author=Damien Roux;,citation_author=David Schnell;,citation_author=Carole Schwebel;,citation_author=Daniel Silva;,citation_author=Michel Sirodot;,citation_author=Bertrand Souweine;,citation_author=Nathalie Thieulot-Rolin;,citation_author=François Tinturier;,citation_author=Patrice Tirot;,citation_author=Didier Thévenin;,citation_author=Guillaume Thiéry;,citation_author=Jean-Baptiste Lascarrou;,citation_author=Jean Reignier;,citation_author=the Clinical Research in Intensive Care and Sepsis (CRICS) group;,citation_publication_date=2022-04;,citation_cover_date=2022-04;,citation_year=2022;,citation_issue=4;,citation_doi=10.1007/s00134-022-06637-w;,citation_issn=1432-1238;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=US Food and Drug Administration Approval of Aducanumab—Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?;,citation_author=Vincent Planche;,citation_author=Nicolas Villain;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_doi=10.1001/jamaneurol.2021.3126;,citation_issn=2168-6149;,citation_language=en-US;,citation_journal_title=JAMA Neurology;">
<meta name="citation_reference" content="citation_title=Invited Commentary: The Importance of Descriptive Epidemiology;,citation_abstract=Lesko et al. (Am J Epidemiol. 2022;191(12):2063–2070) propose a framework for descriptive epidemiology. This framework helps lay out some of the key issues in producing a useful descriptive work. Lesko et al. help emphasize the importance and value of descriptive work in epidemiology and public health. In this commentary, related issues are discussed and open questions are raised.;,citation_author=Robert W Platt;,citation_publication_date=2022-11;,citation_cover_date=2022-11;,citation_year=2022;,citation_issue=12;,citation_doi=10.1093/aje/kwac153;,citation_issn=0002-9262;,citation_volume=191;,citation_journal_title=American Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Reporting Noninferiority Trials—Reply;,citation_abstract=In Reply: We appreciate the concerns expressed by Dr Aberegg but disagree with his argument. We do not think that noninferiority trials require symmetry in their interpretation. A noninferiority trial is conducted to see if a new treatment is as good as a reference treatment in the sense that a specific potential magnitude of inferiority (delta) is contradicted by the trial’s data.If the upper limit of a 2-sided 95% confidence interval for the treatment difference is below delta, then the authors can claim evidence of noninferiority. The strength of evidence can be expressed by the P value for noninferiority, which tests for departure from the null hypothesis that the true treatment difference is at least delta. The appropriate choice of delta during trial design is key, as was discussed in our article.;,citation_author=Stuart J. Pocock;,citation_author=Gilda Piaggio;,citation_author=Douglas G. Altman;,citation_author=for CONSORT Group;,citation_publication_date=2013-04;,citation_cover_date=2013-04;,citation_year=2013;,citation_issue=15;,citation_doi=10.1001/jama.2013.3095;,citation_issn=0098-7484;,citation_volume=309;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Estimands—a basic element for clinical trials. Part 29 of a series on evaluation of scientific publications;,citation_abstract=Background: Clinical trials are of central importance for the evaluation and comparison of treatments. The transparency and intelligibility of the treatment effect under investigation is an essential matter for physicians, patients, and health-care authorities. The estimand framework has been introduced because many trials are deficient in this respect. Methods: Introduction, definition, and application of the estimand framework on the basis of an example and a selective review of the literature. Results: The estimand framework provides a systematic approach to the definition of the treatment effect under investigation in a clinical trial. An estimand consists of five attributes: treatment, population, variable, population-level summary, and handling of intercurrent events. Each of these attributes is defined in an interdisciplinary discussion during the trial planning phase, based on the clinical question being asked. Special attention is given to the handling of intercurrent events (ICEs): these are events—e.g., discontinuation or modification of treatment or the use of emergency medication—that can occur once the treatment has begun and might affect the possibility of observing the endpoints or their interpretability. There are various strategies for the handling of ICEs; these can, for example, also reflect the existing intention-to-treat (ITT) principle. Per-protocol analyses, in contrast, are prone to bias and cannot be represented in a sensible manner by an estimand, although they may be performed as a supplementary analysis. The discussion of potential intercurrent events and how they should appropriately be handled in view of the aim of the trial must already take place in the planning phase. Conclusion: Use of the estimand framework should make it easier for both physicians and patients to understand what trials reveal about the efficacy of treatment, and to compare the results of different trials.;,citation_author=Moritz Pohl;,citation_author=Lukas Baumann;,citation_author=Rouven Behnisch;,citation_author=Marietta Kirchner;,citation_author=Johannes Krisam;,citation_author=Anja Sander;,citation_publication_date=2021-12;,citation_cover_date=2021-12;,citation_year=2021;,citation_doi=10.3238/arztebl.m2021.0373;,citation_issn=1866-0452;,citation_language=en-US;,citation_journal_title=Deutsches Ärzteblatt international;">
<meta name="citation_reference" content="citation_title=Tranexamic Acid for Intracerebral Hemorrhage in Patients on Non-Vitamin K Antagonist Oral Anticoagulants (TICH-NOAC): A Multicenter, Randomized, Placebo-Controlled, Phase 2 Trial;,citation_abstract=BACKGROUND: Evidence-based hemostatic treatment for intracerebral hemorrhage (ICH) associated with non–vitamin K antagonist oral anticoagulants (NOACs) is lacking. Tranexamic acid (TXA) is an antifibrinolytic drug potentially limiting hematoma expansion. We aimed to assess the efficacy and safety of TXA in NOAC-ICH. METHODS: We performed a double-blind, randomized, placebo-controlled trial at 6 Swiss stroke centers. Patients with NOAC-ICH within 12 hours of symptom onset and 48 hours of last NOAC intake were randomized (1:1) to receive either intravenous TXA (1 g over 10 minutes followed by 1 g over 8 hours) or matching placebo in addition to standard medical care via a centralized Web-based procedure with minimization on key prognostic factors. All participants and investigators were masked to treatment allocation. Primary outcome was hematoma expansion, defined as \geq33% relative or \geq6 mL absolute volume increase at 24 hours and analyzed using logistic regression adjusted for baseline hematoma volume on an intention-to-treat basis. RESULTS: Between December 12, 2016, and September 30, 2021, we randomized 63 patients (median age, 82 years [interquartile range, 76–86]; 40% women; median hematoma volume, 11.5 [4.8–27.4] mL) of the 109 intended sample size before premature trial discontinuation due to exhausted funding. The primary outcome did not differ between TXA (n=32) and placebo (n=31) arms (12 [38%] versus 14 [45%]; adjusted odds ratio, 0.63 [95% CI, 0.22–1.82]; P=0.40). There was a signal for interaction with onset-to-treatment time (Pinteraction=0.024), favoring TXA when administered within 6 hours of symptom onset. Between the TXA and placebo arms, the proportion of participants who died (15 [47%] versus 13 [42%]; adjusted odds ratio, 1.07 [0.37–3.04]; P=0.91) or had major thromboembolic complications within 90 days (4 [13%] versus 2 [6%]; odds ratio, 1.86 [0.37–9.50]; P=0.45) did not differ. All thromboembolic events occurred at least 2 weeks after study treatment, exclusively in participants not restarted on oral anticoagulation. CONCLUSIONS: In a smaller-than-intended NOAC-ICH patient sample, we found no evidence that TXA prevents hematoma expansion, but there were no major safety concerns. Larger trials on hemostatic treatments targeting an early treatment window are needed for NOAC-ICH. REGISTRATION: URL: https://clinicaltrials.gov; Unique identifier: NCT02866838.;,citation_author=Alexandros A. Polymeris;,citation_author=Grzegorz M. Karwacki;,citation_author=Bernhard M. Siepen;,citation_author=Sabine Schaedelin;,citation_author=Dimitrios A. Tsakiris;,citation_author=Christoph Stippich;,citation_author=Raphael Guzman;,citation_author=Christian H. Nickel;,citation_author=Nikola Sprigg;,citation_author=Georg Kägi;,citation_author=Jochen Vehoff;,citation_author=Filip Barinka;,citation_author=Sebastian Thilemann;,citation_author=Marina Maurer;,citation_author=Benjamin Wagner;,citation_author=Christopher Traenka;,citation_author=Henrik Gensicke;,citation_author=Gian Marco De Marchis;,citation_author=Leo H. Bonati;,citation_author=Urs Fischer;,citation_author=Werner J. Z’Graggen;,citation_author=Krassen Nedeltchev;,citation_author=Susanne Wegener;,citation_author=Philipp Baumgartner;,citation_author=Stefan T. Engelter;,citation_author=David J. Seiffge;,citation_author=Nils Peters;,citation_author=Philippe A. Lyrer;,citation_author=Sandra Clarke;,citation_author=Martina Falcao;,citation_author=Nikolaos S Avramiotis;,citation_author=Tolga Dittrich;,citation_author=Urs Fisch;,citation_author=Joachim Fladt;,citation_author=Lisa Hert;,citation_author=Iris Schneider;,citation_author=Martina Wiegert;,citation_author=Annaelle Zietz;,citation_author=Morin Beyeler;,citation_author=Martina Goeldlin;,citation_author=Marianne Kormann;,citation_author=Basel Maamari;,citation_author=Liselotte McEvoy;,citation_author=Thomas R Meinel;,citation_author=Madlaina Müller;,citation_author=Jan Vynckier;,citation_author=Elena Ardila;,citation_author=Ingrid Feuerstein;,citation_author=Claudine Gantenbein;,citation_author=Anna Müller;,citation_author=Vjosa Seljmani;,citation_author=Benedikt Wagner;,citation_author=Bettina Anders;,citation_author=Roland Backhaus;,citation_author=Asterios Paliantonis;,citation_author=Shadi Taheri;,citation_author=Dennis Thumm;,citation_author=Jannie Duinen;,citation_author=Lita Von Bieberstein;,citation_issue=0;,citation_doi=10.1161/STROKEAHA.123.042866;,citation_volume=0;,citation_journal_title=Stroke;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=Ultra-early tranexamic acid after subarachnoid haemorrhage (ULTRA): A randomised controlled trial;,citation_abstract=BACKGROUND: In patients with aneurysmal subarachnoid haemorrhage, short-term antifibrinolytic therapy with tranexamic acid has been shown to reduce the risk of rebleeding. However, whether this treatment improves clinical outcome is unclear. We investigated whether ultra-early, short-term treatment with tranexamic acid improves clinical outcome at 6 months. METHODS: In this multicentre prospective, randomised, controlled, open-label trial with masked outcome assessment, adult patients with spontaneous CT-proven subarachnoid haemorrhage in eight treatment centres and 16 referring hospitals in the Netherlands were randomly assigned to treatment with tranexamic acid in addition to care as usual (tranexamic acid group) or care as usual only (control group). Tranexamic acid was started immediately after diagnosis in the presenting hospital (1 g bolus, followed by continuous infusion of 1 g every 8 h, terminated immediately before aneurysm treatment, or 24 h after start of the medication, whichever came first). The primary endpoint was clinical outcome at 6 months, assessed by the modified Rankin Scale, dichotomised into a good (0-3) or poor (4-6) clinical outcome. Both primary and safety analyses were according to intention to treat. This trial is registered at ClinicalTrials.gov, NCT02684812. FINDINGS: Between July 24, 2013, and July 29, 2019, we enrolled 955 patients; 480 patients were randomly assigned to tranexamic acid and 475 patients to the control group. In the intention-to-treat analysis, good clinical outcome was observed in 287 (60%) of 475 patients in the tranexamic acid group, and 300 (64%) of 470 patients in the control group (treatment centre adjusted odds ratio 0\cdot86, 95% CI 0\cdot66-1\cdot12). Rebleeding after randomisation and before aneurysm treatment occurred in 49 (10%) patients in the tranexamic acid and in 66 (14%) patients in the control group (odds ratio 0\cdot71, 95% CI 0\cdot48-1\cdot04). Other serious adverse events were comparable between groups. INTERPRETATION: In patients with CT-proven subarachnoid haemorrhage, presumably caused by a ruptured aneurysm, ultra-early, short-term tranexamic acid treatment did not improve clinical outcome at 6 months, as measured by the modified Rankin Scale. FUNDING: Fonds NutsOhra.;,citation_author=René Post;,citation_author=Menno R. Germans;,citation_author=Maud A. Tjerkstra;,citation_author=Mervyn D. I. Vergouwen;,citation_author=Korné Jellema;,citation_author=Radboud W. Koot;,citation_author=Nyika D. Kruyt;,citation_author=Peter W. A. Willems;,citation_author=Jasper F. C. Wolfs;,citation_author=Frits C. Beer;,citation_author=Hans Kieft;,citation_author=Dharmin Nanda;,citation_author=Bram Pol;,citation_author=Gerwin Roks;,citation_author=Frank Beer;,citation_author=Patricia H. A. Halkes;,citation_author=Loes J. A. Reichman;,citation_author=Paul J. A. M. Brouwers;,citation_author=Renske M. Berg-Vos;,citation_author=Vincent I. H. Kwa;,citation_author=Taco C. Ree;,citation_author=Irene Bronner;,citation_author=Janneke Vlekkert;,citation_author=Henri P. Bienfait;,citation_author=Hieronymus D. Boogaarts;,citation_author=Catharina J. M. Klijn;,citation_author=René Berg;,citation_author=Bert A. Coert;,citation_author=Janneke Horn;,citation_author=Charles B. L. M. Majoie;,citation_author=Gabriël J. E. Rinkel;,citation_author=Yvo B. W. E. M. Roos;,citation_author=W. Peter Vandertop;,citation_author=Dagmar Verbaan;,citation_author=ULTRA Investigators;,citation_publication_date=2021-01;,citation_cover_date=2021-01;,citation_year=2021;,citation_issue=10269;,citation_doi=10.1016/S0140-6736(20)32518-6;,citation_issn=1474-547X;,citation_pmid=33357465;,citation_volume=397;,citation_language=en-US;,citation_journal_title=Lancet (London, England);">
<meta name="citation_reference" content="citation_title=What is the role of steroids in pneumonia therapy?;,citation_abstract=Purpose of review&nbsp; This review evaluates the potential benefits as well as adverse effects from adjunctive therapy with systemic steroids in patients with pneumonia: either mild-to-moderate or severe, community-acquired or hospital-acquired, of bacterial or of viral origin (in particular H1N1 viral infection). Recent findings&nbsp; Steroids potentially modulate the marked and persistent activation of the immune system in pneumonia. However, several recent randomized controlled trials and large prospective observational studies have repeatedly shown that steroids had no impact on survival, the clinical event of interest, but in severe pneumonia some studies pointed to potential harmful effect. In addition, adverse effects, namely hyperglycemia, superinfections, as well as increased length-of-stay, were frequent findings in the steroid-treated patients. Summary&nbsp; According to the current evidence, there are no data to support the well tolerated use of systemic steroids as a standard of care in pneumonia, neither in mild-to-moderate and severe, nor in bacterial and viral infection. Clinical and basic research should work together to improve trial designs to identify reliable surrogate markers of outcome, in particular of mortality. This may improve the patient selection and facilitate the identification of subgroups that can benefit from adjunctive steroid therapy.;,citation_author=Pedro Póvoa;,citation_author=Jorge I. F. Salluh;,citation_publication_date=2012-04;,citation_cover_date=2012-04;,citation_year=2012;,citation_issue=2;,citation_doi=10.1097/QCO.0b013e32834f44c7;,citation_issn=0951-7375;,citation_volume=25;,citation_language=en-US;,citation_journal_title=Current Opinion in Infectious Diseases;">
<meta name="citation_reference" content="citation_title=When should we use corticosteroids in severe community-acquired pneumonia?;,citation_abstract=Purpose of review&nbsp; This review aims to evaluate the evidence and recommendations for the prescription of corticosteroids as adjunctive therapy in patients with severe community-acquired pneumonia. Recent findings&nbsp; Corticosteroids have been prescribed with the objective to attenuate the marked and persistent activation of the immune system. However, some causes of community-acquired pneumonia, namely viral, are associated with unexpected low levels of cytokines and depressed cellular immunity. As a result, several recent randomized controlled trials and large prospective observational studies repeatedly showed that corticosteroids had no impact on survival, and in some types of pneumonia like influenza, its use was associated with potential harmful effects like invasive aspergillosis. Apart from this, adverse effects, namely hyperglycemia, superinfections and increased length-of-stay, were frequent findings in the corticosteroid-treated patients. Summary&nbsp; According to the current evidence, corticosteroids are recommended in Pneumocystis jiroveci pneumonia in HIV-infected patients and recommendations are against its use in influenza. In all other forms of severe community-acquired pneumonia, with the exclusion of SARS-CoV-2 pneumonia, the strength of the evidence does not support the safe and widespread use of corticosteroids as adjunctive therapy. Further studies are needed to identify subgroups of severe community-acquired pneumonia that can benefit or not from corticosteroids.;,citation_author=Pedro Póvoa;,citation_author=Luís Coelho;,citation_author=Jorge Salluh;,citation_publication_date=2021-04;,citation_cover_date=2021-04;,citation_year=2021;,citation_issue=2;,citation_doi=10.1097/QCO.0000000000000709;,citation_issn=0951-7375;,citation_volume=34;,citation_language=en-US;,citation_journal_title=Current Opinion in Infectious Diseases;">
<meta name="citation_reference" content="citation_title=Colorectal cancer screening at a younger age: Pitfalls in the model-based recommendation of the USPSTF;,citation_author=Kerrington Powell;,citation_author=Vinay Prasad;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_doi=10.1136/bmjebm-2021-111793;,citation_issn=2515-446X, 2515-4478;,citation_language=en-US;,citation_journal_title=BMJ Evidence-Based Medicine;">
<meta name="citation_reference" content="citation_title=Old-fashioned Intelligence Will Always Be Needed in Medicine;,citation_author=Kerrington Powell;,citation_author=Vinay Prasad;,citation_publication_date=2021-07;,citation_cover_date=2021-07;,citation_year=2021;,citation_issue=4;,citation_doi=10.1016/j.euf.2021.03.022;,citation_issn=24054569;,citation_volume=7;,citation_language=en-US;,citation_journal_title=European Urology Focus;">
<meta name="citation_reference" content="citation_title=Where are randomized trials necessary: Are smoking and parachutes good counterexamples?;,citation_author=Kerrington Powell;,citation_author=Vinay Prasad;,citation_publication_date=2021-12;,citation_cover_date=2021-12;,citation_year=2021;,citation_doi=10.1111/eci.13730;,citation_issn=0014-2972, 1365-2362;,citation_language=en-US;,citation_journal_title=European Journal of Clinical Investigation;">
<meta name="citation_reference" content="citation_title=COVID-19 vaccines: History of the pandemic’s great scientific success &amp;amp;amp; flawed policy implementation;,citation_abstract=The COVID-19 vaccine has been a miraculous, life-saving advance, offering staggering efficacy in adults, and developed with astonishing speed. The time from sequencing the virus to authorizing the first COVID-19 vaccine was so brisk even the optimists appear close-minded. Yet, simultaneously, United States’ COVID-19 vaccination roll-out and related policies have contained missed opportunities, blunders, run counter to evidence-based medicine, and revealed limitations in the judgment of public policymakers. Misplaced utilization, contradictory messaging, and poor deployment in those who would benefit most — the elderly and high-risk — alongside unrealistic messaging, exaggeration, and coercion in those who benefit least — young, healthy Americans — is at the heart. It is important to consider the history of COVID-19 vaccines to identify where we succeeded and where we failed, and the effects that these errors may have more broadly on vaccination hesitancy and routine childhood immunization programs in the decades to come.;,citation_author=Vinay Prasad;,citation_publication_date=2022-11;,citation_cover_date=2022-11;,citation_year=2022;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=How Should Research Be Funded? Difficulties With the Argument for Proportionality to Causes of Death or Years of Life Lost;,citation_author=Vinay Prasad;,citation_publication_date=2016-03;,citation_cover_date=2016-03;,citation_year=2016;,citation_issue=3;,citation_doi=10.6004/jnccn.2016.0039;,citation_issn=1540-1405, 1540-1413;,citation_volume=14;,citation_language=en-US;,citation_journal_title=Journal of the National Comprehensive Cancer Network;">
<meta name="citation_reference" content="citation_title=Non-Inferiority Trials in Medicine: Practice Changing or a Self-Fulfilling Prophecy?;,citation_author=Vinay Prasad;,citation_publication_date=2018-01;,citation_cover_date=2018-01;,citation_year=2018;,citation_issue=1;,citation_doi=10.1007/s11606-017-4191-y;,citation_issn=0884-8734, 1525-1497;,citation_volume=33;,citation_language=en-US;,citation_journal_title=Journal of General Internal Medicine;">
<meta name="citation_reference" content="citation_title=Prespecified Falsification End Points: Can They Validate True Observational Associations?;,citation_author=Vinay Prasad;,citation_author=Anupam B. Jena;,citation_publication_date=2013-01;,citation_cover_date=2013-01;,citation_year=2013;,citation_issue=3;,citation_doi=10.1001/jama.2012.96867;,citation_issn=0098-7484;,citation_volume=309;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Reliable, cheap, fast and few: What is the best study for assessing medical practices? Randomized controlled trials or synthetic control arms?;,citation_author=Vinay Prasad;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_issue=8;,citation_doi=10.1111/eci.13580;,citation_issn=0014-2972, 1365-2362;,citation_volume=51;,citation_language=en-US;,citation_journal_title=European Journal of Clinical Investigation;">
<meta name="citation_reference" content="citation_title=Tips for Teachers of Evidence-Based Medicine: Understanding Odds Ratios and Their Relationship to Risk Ratios;,citation_author=Kameshwar Prasad;,citation_author=Roman Jaeschke;,citation_author=Peter Wyer;,citation_author=Sheri Keitz;,citation_author=Gordon Guyatt;,citation_author=Evidence-Based Medicine Teaching Tips Working Group;,citation_publication_date=2008-05;,citation_cover_date=2008-05;,citation_year=2008;,citation_issue=5;,citation_doi=10.1007/s11606-007-0453-4;,citation_issn=0884-8734, 1525-1497;,citation_volume=23;,citation_language=en-US;,citation_journal_title=Journal of General Internal Medicine;">
<meta name="citation_reference" content="citation_title=Why Randomized Controlled Trials Are Needed to Accept New Practices: 2 Medical Worldviews;,citation_author=Vinay Prasad;,citation_publication_date=2013-10;,citation_cover_date=2013-10;,citation_year=2013;,citation_issue=10;,citation_doi=10.1016/j.mayocp.2013.04.026;,citation_issn=00256196;,citation_volume=88;,citation_language=en-US;,citation_journal_title=Mayo Clinic Proceedings;">
<meta name="citation_reference" content="citation_title=A Fate Worse Than Death: Prognostication of Devastating Brain Injury;,citation_abstract=Objectives:&nbsp; To describe the sources of uncertainty in prognosticating devastating brain injury, the role of the intensivist in prognostication, and ethical considerations in prognosticating devastating brain injury in the ICU. Data Sources:&nbsp; A PubMed literature review was performed. Study Selection:&nbsp; Articles relevant to prognosis in intracerebral hemorrhage, acute ischemic stroke, traumatic brain injury, subarachnoid hemorrhage, and postcardiac arrest anoxic encephalopathy were selected. Data Extraction:&nbsp; Data regarding definition and prognosis of devastating brain injury were extracted. Themes related to how clinicians perform prognostication and their accuracy were reviewed and extracted. Data Synthesis:&nbsp; Although there are differences in pathophysiology and therefore prognosis in the various etiologies of devastating brain injury, some common themes emerge. Physicians tend to have fairly good prognostic accuracy, especially in severe cases with poor prognosis. Full supportive care is recommended for at least 72 hours from initial presentation to maximize the potential for recovery and minimize secondary injury. However, physician approaches to the timing of and recommendations for withdrawal of life-sustaining therapy have a significant impact on mortality from devastating brain injury. Conclusions:&nbsp; Intensivists should consider the modern literature describing prognosis for devastating brain injury and provide appropriate time for patient recovery and for discussions with the patient’s surrogates. Surrogates wish to have a prognosis enumerated even when uncertainty exists. These discussions must be handled with care and include admission of uncertainty when it exists. Respect for patient autonomy remains paramount, although physicians are not required to provide inappropriate medical therapies.;,citation_author=Alexandra K. Pratt;,citation_author=Jason J. Chang;,citation_author=Nneka O. Sederstrom;,citation_publication_date=2019-04;,citation_cover_date=2019-04;,citation_year=2019;,citation_issue=4;,citation_doi=10.1097/CCM.0000000000003647;,citation_issn=0090-3493;,citation_volume=47;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Video versus Direct Laryngoscopy for Tracheal Intubation of Critically Ill Adults;,citation_author=Matthew E. Prekker;,citation_author=Brian E. Driver;,citation_author=Stacy A. Trent;,citation_author=Daniel Resnick-Ault;,citation_author=Kevin P. Seitz;,citation_author=Derek W. Russell;,citation_author=John P. Gaillard;,citation_author=Andrew J. Latimer;,citation_author=Shekhar A. Ghamande;,citation_author=Kevin W. Gibbs;,citation_author=Derek J. Vonderhaar;,citation_author=Micah R. Whitson;,citation_author=Christopher R. Barnes;,citation_author=Jeremy P. Walco;,citation_author=Ivor S. Douglas;,citation_author=Vijay Krishnamoorthy;,citation_author=Alon Dagan;,citation_author=Jill J. Bastman;,citation_author=Bradley D. Lloyd;,citation_author=Sheetal Gandotra;,citation_author=Jordan K. Goranson;,citation_author=Steven H. Mitchell;,citation_author=Heath D. White;,citation_author=Jessica A. Palakshappa;,citation_author=Alyssa Espinera;,citation_author=David B. Page;,citation_author=Aaron Joffe;,citation_author=Sydney J. Hansen;,citation_author=Christopher G. Hughes;,citation_author=Tobias George;,citation_author=J. Taylor Herbert;,citation_author=Nathan I. Shapiro;,citation_author=Steven G. Schauer;,citation_author=Brit J. Long;,citation_author=Brant Imhoff;,citation_author=Li Wang;,citation_author=Jillian P. Rhoads;,citation_author=Kelsey N. Womack;,citation_author=David R. Janz;,citation_author=Wesley H. Self;,citation_author=Todd W. Rice;,citation_author=Adit A. Ginde;,citation_author=Jonathan D. Casey;,citation_author=Matthew W. Semler;,citation_publication_date=2023-08;,citation_cover_date=2023-08;,citation_year=2023;,citation_issue=5;,citation_doi=10.1056/NEJMoa2301601;,citation_issn=0028-4793;,citation_pmid=37326325;,citation_volume=389;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Confidence Interval or P-Value? Part 4 of a Series on Evaluation of Scientific Publications;,citation_author=Jean-Baptist Prel;,citation_author=Gerhard Hommel;,citation_author=Bernd Röhrig;,citation_author=Maria Blettner;,citation_publication_date=2009-05;,citation_cover_date=2009-05;,citation_year=2009;,citation_doi=10.3238/arztebl.2009.0335;,citation_issn=1866-0452;,citation_language=en-US;,citation_journal_title=Deutsches Ärzteblatt international;">
<meta name="citation_reference" content="citation_title=Late mortality after acute hypoxic respiratory failure;,citation_abstract=BackgroundAcute hypoxic respiratory failure (AHRF) is associated with significant acute mortality. It is unclear whether later mortality is predominantly driven by preexisting comorbid disease, the acute inciting event or is the result of AHRF itself. Methods Observational cohort study of elderly US Health and Retirement Study (HRS) participants in fee-for-service Medicare (1998–2012). Patients hospitalised with AHRF were matched 1:1 to otherwise similar adults who were not currently hospitalised and separately to patients hospitalised with acute inciting events (pneumonia, non-pulmonary infection, aspiration, trauma, pancreatitis) that may result in AHRF, here termed at-risk hospitalisations. The primary outcome was late mortality—death in the 31 days to 2 years following hospital admission. ResultsAmong 15 075 HRS participants, we identified 1268 AHRF and 13 117 at-risk hospitalisations. AHRF hospitalisations were matched to 1157 non-hospitalised adults and 1017 at-risk hospitalisations. Among patients who survived at least 30 days, AHRF was associated with a 24.4% (95%CI 19.9% to 28.9%, p&amp;amp;amp;lt;0.001) absolute increase in late mortality relative to adults not currently hospitalised and a 6.7% (95%CI 1.7% to 11.7%, p=0.01) increase relative to adults hospitalised with acute inciting event(s) alone. At-risk hospitalisation explained 71.2% of the increased odds of late mortality, whereas the development of AHRF itself explained 28.8%. Risk for death was equivalent to at-risk hospitalisation beyond 90 days, but remained elevated for more than 1 year compared with non-hospitalised controls. ConclusionsIn this national sample of older Americans, approximately one in four survivors with AHRF had a late death not explained by pre-AHRF health status. More than 70% of this increased risk was associated with hospitalisation for acute inciting events, while 30% was associated with hypoxemic respiratory failure.;,citation_author=Hallie C Prescott;,citation_author=Michael W Sjoding;,citation_author=Kenneth M Langa;,citation_author=Theodore J Iwashyna;,citation_author=Daniel F McAuley;,citation_publication_date=2018-07;,citation_cover_date=2018-07;,citation_year=2018;,citation_issue=7;,citation_doi=10.1136/thoraxjnl-2017-210109;,citation_issn=0040-6376, 1468-3296;,citation_volume=73;,citation_language=en-US;,citation_journal_title=Thorax;">
<meta name="citation_reference" content="citation_title=Readmission Diagnoses After Hospitalization for Severe Sepsis and Other Acute Medical Conditions;,citation_author=Hallie C. Prescott;,citation_author=Kenneth M. Langa;,citation_author=Theodore J. Iwashyna;,citation_publication_date=2015-03;,citation_cover_date=2015-03;,citation_year=2015;,citation_issue=10;,citation_doi=10.1001/jama.2015.1410;,citation_issn=0098-7484;,citation_volume=313;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Obesity Paradox: Conditioning on Disease Enhances Biases in Estimating the Mortality Risks of Obesity;,citation_abstract=Background: Many studies have documented an obesity paradox—a survival advantage of being obese—in populations diagnosed with a medical condition. Whether obesity is causally associated with improved mortality in these conditions is unresolved. Methods: We develop the logic of collider bias as it pertains to the association between smoking and obesity in a diseased population. Data from the National Health and Nutrition Examination Survey (NHANES) are used to investigate this bias empirically among persons with diabetes and prediabetes (dysglycemia). We also use NHANES to investigate whether reverse causal pathways are more prominent among people with dysglycemia than in the source population. Cox regression analysis is used to examine the extent of the obesity paradox among those with dysglycemia. In the regression analysis, we explore interactions between obesity and smoking, and we implement a variety of data restrictions designed to reduce the extent of reverse causality. Results: We find an obesity paradox among persons with dysglycemia. In this population, the inverse association between obesity and smoking is much stronger than in the source population, and the extent of illness and weight loss is greater. The obesity paradox is absent among never-smokers. Among smokers, the paradox is eliminated through successive efforts to reduce the extent of reverse causality. Conclusion: Higher mortality among normal-weight people with dysglycemia is not causal but is rather a product of the closer inverse association between obesity and smoking in this subpopulation.;,citation_author=Samuel H. Preston;,citation_author=Andrew Stokes;,citation_publication_date=2014-05;,citation_cover_date=2014-05;,citation_year=2014;,citation_issue=3;,citation_doi=10.1097/EDE.0000000000000075;,citation_issn=1044-3983;,citation_volume=25;,citation_language=en-US;,citation_journal_title=Epidemiology;">
<meta name="citation_reference" content="citation_title=&amp;amp;amp;lt;i&amp;gt;Nature’s&amp;lt;/i&amp;gt; <i>Capacities</i> <i>and</i> <i>Their Measurement</i> . Nancy Cartwright;,citation_author=Huw Price;,citation_publication_date=1991-09;,citation_cover_date=1991-09;,citation_year=1991;,citation_issue=3;,citation_doi=10.1086/355915;,citation_issn=0021-1753, 1545-6994;,citation_volume=82;,citation_language=en-US;,citation_journal_title=Isis;">
<meta name="citation_reference" content="citation_title=Hospital Problems;,citation_author=Michael Putman;,citation_publication_date=2023-07;,citation_cover_date=2023-07;,citation_year=2023;,citation_issue=2;,citation_doi=10.1056/NEJMp2304828;,citation_issn=0028-4793;,citation_pmid=37428186;,citation_volume=389;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=An Update on Management of Adult Patients with Acute Respiratory Distress Syndrome: An Official American Thoracic Society Clinical Practice Guideline;,citation_abstract=Background: This document updates previously published Clinical Practice Guidelines for the management of patients with acute respiratory distress syndrome (ARDS), incorporating new evidence addressing the use of corticosteroids, venovenous extracorporeal membrane oxygenation, neuromuscular blocking agents, and positive end-expiratory pressure (PEEP). Methods: We summarized evidence addressing four “PICO questions” (patient, intervention, comparison, and outcome). A multidisciplinary panel with expertise in ARDS used the Grading of Recommendations, Assessment, Development, and Evaluation framework to develop clinical recommendations. Results: We suggest the use of: 1) corticosteroids for patients with ARDS (conditional recommendation, moderate certainty of evidence), 2) venovenous extracorporeal membrane oxygenation in selected patients with severe ARDS (conditional recommendation, low certainty of evidence), 3) neuromuscular blockers in patients with early severe ARDS (conditional recommendation, low certainty of evidence), and 4) higher PEEP without lung recruitment maneuvers as opposed to lower PEEP in patients with moderate to severe ARDS (conditional recommendation, low to moderate certainty), and 5) we recommend against using prolonged lung recruitment maneuvers in patients with moderate to severe ARDS (strong recommendation, moderate certainty). Conclusions: We provide updated evidence-based recommendations for the management of ARDS. Individual patient and illness characteristics should be factored into clinical decision making and implementation of these recommendations while additional evidence is generated from much-needed clinical trials.;,citation_author=Nida Qadir;,citation_author=Sarina Sahetya;,citation_author=Laveena Munshi;,citation_author=Charlotte Summers;,citation_author=Darryl Abrams;,citation_author=Jeremy Beitler;,citation_author=Giacomo Bellani;,citation_author=Roy G. Brower;,citation_author=Lisa Burry;,citation_author=Jen-Ting Chen;,citation_author=Carol Hodgson;,citation_author=Catherine L. Hough;,citation_author=Francois Lamontagne;,citation_author=Anica Law;,citation_author=Laurent Papazian;,citation_author=Tai Pham;,citation_author=Eileen Rubin;,citation_author=Matthew Siuba;,citation_author=Irene Telias;,citation_author=Setu Patolia;,citation_author=Dipayan Chaudhuri;,citation_author=Allan Walkey;,citation_author=Bram Rochwerg;,citation_author=Eddy Fan;,citation_publication_date=2024-01;,citation_cover_date=2024-01;,citation_year=2024;,citation_issue=1;,citation_doi=10.1164/rccm.202311-2011ST;,citation_issn=1073-449X;,citation_volume=209;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;,citation_publisher=American Thoracic Society - AJRCCM;">
<meta name="citation_reference" content="citation_title=Variation in Early Management Practices in Moderate-to-Severe ARDS in the United States;,citation_author=Nida Qadir;,citation_author=Raquel R. Bartz;,citation_author=Mary L. Cooter;,citation_author=Catherine L. Hough;,citation_author=Michael J. Lanspa;,citation_author=Valerie M. Banner-Goodspeed;,citation_author=Jen-Ting Chen;,citation_author=Shewit Giovanni;,citation_author=Dina Gomaa;,citation_author=Michael W. Sjoding;,citation_author=Negin Hajizadeh;,citation_author=Jordan Komisarow;,citation_author=Abhijit Duggal;,citation_author=Ashish K. Khanna;,citation_author=Rahul Kashyap;,citation_author=Akram Khan;,citation_author=Steven Y. Chang;,citation_author=Joseph E. Tonna;,citation_author=Harry L. Anderson;,citation_author=Janice M. Liebler;,citation_author=Jarrod M. Mosier;,citation_author=Peter E. Morris;,citation_author=Alissa Genthon;,citation_author=Irene K. Louh;,citation_author=Mark Tidswell;,citation_author=R. Scott Stephens;,citation_author=Annette M. Esper;,citation_author=David J. Dries;,citation_author=Anthony Martinez;,citation_author=Kraftin E. Schreyer;,citation_author=William Bender;,citation_author=Anupama Tiwari;,citation_author=Pramod K. Guru;,citation_author=Sinan Hanna;,citation_author=Michelle N. Gong;,citation_author=Pauline K. Park;,citation_author=Jay S. Steingrub;,citation_author=Mark Tidswell;,citation_author=Valerie M. Banner-Goodspeed;,citation_author=Kristin Brierley;,citation_author=Julia L. Larson;,citation_author=Ariel Mueller;,citation_author=Tereza Pinkhasova;,citation_author=Daniel Talmor;,citation_author=Imoigele Aisiku;,citation_author=Rebecca Baron;,citation_author=Lauren Fredenburgh;,citation_author=Alissa Genthon;,citation_author=Peter Hou;,citation_author=Anthony Massaro;,citation_author=Raghu Seethala;,citation_author=Abhijit Duggal;,citation_author=Duncan Hite;,citation_author=Ashish K. Khanna;,citation_author=Daniel Brodie;,citation_author=Irene K. Louh;,citation_author=Briana Short;,citation_author=Raquel Bartz;,citation_author=Mary L. Cooter;,citation_author=Jordan C. Komisarow;,citation_author=Anupama Tiwari;,citation_author=William Bender;,citation_author=James Blum;,citation_author=Annette Esper;,citation_author=Greg S. Martin;,citation_author=Eileen Bulger;,citation_author=Catherine L. Hough;,citation_author=Anna Ungar;,citation_author=Samuel M. Brown;,citation_author=Colin K. Grissom;,citation_author=Eliotte L. Hirshberg;,citation_author=Michael J. Lanspa;,citation_author=Ithan D. Peltan;,citation_author=Roy G. Brower;,citation_author=Sarina K. Sahetya;,citation_author=R Scott Stephens;,citation_author=Pramod K. Guru;,citation_author=John K. Bohman;,citation_author=Hongchuan Coville;,citation_author=Ognjen Gajic;,citation_author=Rahul Kashyap;,citation_author=John C. O’Horo;,citation_author=Jorge-Bleik Ataucuri-Vargas;,citation_author=Jen-Ting Chen;,citation_author=Michelle N. Gong;,citation_author=Fiore Mastroianni;,citation_author=Negin Hajizadeh;,citation_author=Jamie Hirsch;,citation_author=Michael Qui;,citation_author=Molly Stewart;,citation_author=Akram Khan;,citation_author=Ebaad Haq;,citation_author=Makrina Kamel;,citation_author=Olivia Krol;,citation_author=Kimberly Lerner;,citation_author=David J. Dries;,citation_author=John Marini;,citation_author=Valentina Chiara Bistolfi Amaral;,citation_author=Anthony Martinez;,citation_author=Harry L. Anderson;,citation_author=Jill Brown;,citation_author=Michael Brozik;,citation_author=Heidi Kemmer;,citation_author=Janet Obear;,citation_author=Nina Gentile;,citation_author=Kraftin E. Shreyer;,citation_author=Charles Cairns;,citation_author=Cameron Hypes;,citation_author=Josh Malo;,citation_author=Jarrod Mosier;,citation_author=Bhupinder Natt;,citation_author=Steven Y. Chang;,citation_author=Scott Hu;,citation_author=Ishan Mehta;,citation_author=Nida Qadir;,citation_author=Richard Branson;,citation_author=Dina Gomaa;,citation_author=Betty Tsuei;,citation_author=Sanjay Dhar;,citation_author=Ashley Montgomery-Yates;,citation_author=Peter Morris;,citation_author=Tina Chen;,citation_author=Sinan Hanna;,citation_author=Pauline K. Park;,citation_author=Michael W. Sjoding;,citation_author=Alfredo Lee Chang;,citation_author=Perren Cobb;,citation_author=Janice M. Liebler;,citation_author=Estelle Harris;,citation_author=Nate Hatton;,citation_author=Gia Lewis;,citation_author=Stephen McKellar;,citation_author=Sanjeev Raman;,citation_author=Joseph Tonna;,citation_author=Ellen Caldwell;,citation_author=Sarah Dean;,citation_author=Shewit Giovanni;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=4;,citation_doi=10.1016/j.chest.2021.05.047;,citation_issn=00123692;,citation_volume=160;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Assessment of Awake Prone Positioning in Hospitalized Adults With COVID-19: A Nonrandomized Controlled Trial;,citation_abstract=OBJECTIVE To determine whether the recommendation of awake prone positioning is associated with improved outcomes among patients with COVID-19–related hypoxemia who have not received mechanical ventilation. DESIGN, SETTING, AND PARTICIPANTS This pragmatic nonrandomized controlled trial was conducted at 2 academic medical centers (Vanderbilt University Medical Center and NorthShore University HealthSystem) during the COVID-19 pandemic. A total of 501 adult patients with COVID-19–associated hypoxemia who had not received mechanical ventilation were enrolled from May 13 to December 11, 2020. INTERVENTIONS Patients were assigned 1:1 to receive either the practitioner-recommended awake prone positioning intervention (intervention group) or usual care (usual care group). MAIN OUTCOMES AND MEASURES Primary outcome analyses were performed using a bayesian proportional odds model with covariate adjustment for clinical severity ranking based on the World Health Organization ordinal outcome scale, which was modified to highlight the worst level of hypoxemia on study day 5. RESULTS A total of 501 patients (mean [SD] age, 61.0 [15.3] years; 284 [56.7%] were male; and most [417 (83.2%)] were self-reported non-Hispanic or non-Latinx) were included. Baseline severity was comparable between the intervention vs usual care groups, with 170 patients (65.9%) vs 162 patients (66.7%) receiving oxygen via standard low-flow nasal cannula, 71 patients (27.5%) vs 62 patients (25.5%) receiving oxygen via high-flow nasal cannula, and 16 patients (6.2%) vs 19 patients (7.8%) receiving noninvasive positive-pressure ventilation. Nursing observations estimated that patients in the intervention group spent a median of 4.2 hours (IQR, 1.8-6.7 hours) in the prone position per day compared with 0 hours (IQR, 0-0.7 hours) per day in the usual care group. On study day 5, the bayesian posterior probability of the intervention group having worse outcomes than the usual care group on the modified World Health Organization ordinal outcome scale was 0.998 (posterior median adjusted odds ratio [aOR], 1.63; 95% credibility interval [CrI], 1.16-2.31). However, on study days 14 and 28, the posterior probabilities of harm were 0.874 (aOR, 1.29; 95% CrI, 0.84-1.99) and 0.673 (aOR, 1.12; 95% CrI, 0.67-1.86), respectively. Exploratory outcomes (progression to mechanical ventilation, length of stay, and 28-day mortality) did not differ between groups. CONCLUSIONS AND RELEVANCE In this nonrandomized controlled trial, prone positioning offered no observed clinical benefit among patients with COVID-19–associated hypoxemia who had not received mechanical ventilation. Moreover, there was substantial evidence of worsened clinical outcomes at study day 5 among patients recommended to receive the awake prone positioning intervention, suggesting potential harm.;,citation_author=Edward Tang Qian;,citation_author=Cheryl L. Gatto;,citation_author=Olga Amusina;,citation_author=Mary Lynn Dear;,citation_author=William Hiser;,citation_author=Reagan Buie;,citation_author=Sunil Kripalani;,citation_author=Frank E. Harrell;,citation_author=Robert E. Freundlich;,citation_author=Yue Gao;,citation_author=Wu Gong;,citation_author=Cassandra Hennessy;,citation_author=Jillann Grooms;,citation_author=Megan Mattingly;,citation_author=Shashi K. Bellam;,citation_author=Jessica Burke;,citation_author=Arwa Zakaria;,citation_author=Eduard E. Vasilevskis;,citation_author=Frederic T. Billings;,citation_author=Jill M. Pulley;,citation_author=Gordon R. Bernard;,citation_author=Christopher J. Lindsell;,citation_author=Todd W. Rice;,citation_author=Vanderbilt Learning Healthcare System Platform Investigators;,citation_author=Robert Dittus;,citation_author=Shon Dwyer;,citation_author=Paul Harris;,citation_author=Tina Hartert;,citation_author=Jim Hayman;,citation_author=Catherine Ivory;,citation_author=Kevin Johnson;,citation_author=Ruth Kleinpell;,citation_author=Lee Ann Liska;,citation_author=Patrick Luther;,citation_author=Jay Morrison;,citation_author=Thomas Nantais;,citation_author=Mariann Piano;,citation_author=Kris Rhem;,citation_author=Russell Rothman;,citation_author=Matt Semler;,citation_author=Robin Steaban;,citation_author=Philip Walker;,citation_author=Consuelo Wilkins;,citation_author=Adam Wright;,citation_author=Autumn Zuckerman;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_issue=6;,citation_doi=10.1001/jamainternmed.2022.1070;,citation_issn=2168-6106;,citation_volume=182;,citation_language=en-US;,citation_journal_title=JAMA Internal Medicine;">
<meta name="citation_reference" content="citation_title=Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial;,citation_abstract=OBJECTIVE To determine whether the choice between cefepime and piperacillin-tazobactam affects the risks of acute kidney injury or neurological dysfunction. DESIGN, SETTING, AND PARTICIPANTS The Antibiotic Choice on Renal Outcomes (ACORN) randomized clinical trial compared cefepime vs piperacillin-tazobactam in adults for whom a clinician initiated an order for antipseudomonal antibiotics within 12 hours of presentation to the hospital in the emergency department or medical intensive care unit at an academic medical center in the US between November 10, 2021, and October 7, 2022. The final date of follow-up was November 4, 2022. INTERVENTIONS Patients were randomized in a 1:1 ratio to cefepime or piperacillin-tazobactam. MAIN OUTCOMES AND MEASURES The primary outcome was the highest stage of acute kidney injury or death by day 14, measured on a 5-level ordinal scale ranging from no acute kidney injury to death. The 2 secondary outcomes were the incidence of major adverse kidney events at day 14 and the number of days alive and free of delirium and coma within 14 days. RESULTS There were 2511 patients included in the primary analysis (median age, 58 years [IQR, 43-69 years]; 42.7% were female; 16.3% were Non-Hispanic Black; 5.4% were Hispanic; 94.7% were enrolled in the emergency department; and 77.2% were receiving vancomycin at enrollment). The highest stage of acute kidney injury or death was not significantly different between the cefepime group and the piperacillin-tazobactam group; there were 85 patients (n = 1214; 7.0%) in the cefepime group with stage 3 acute kidney injury and 92 (7.6%) who died vs 97 patients (n = 1297; 7.5%) in the piperacillin-tazobactam group with stage 3 acute kidney injury and 78 (6.0%) who died (odds ratio, 0.95 [95% CI, 0.80 to 1.13], P = .56). The incidence of major adverse kidney events at day 14 did not differ between groups (124 patients [10.2%] in the cefepime group vs 114 patients [8.8%] in the piperacillintazobactam group; absolute difference, 1.4% [95% CI, -1.0% to 3.8%]). Patients in the cefepime group experienced fewer days alive and free of delirium and coma within 14 days (mean [SD], 11.9 [4.6] days vs 12.2 [4.3] days in the piperacillin-tazobactam group; odds ratio, 0.79 [95% CI, 0.65 to 0.95]). CONCLUSIONS AND RELEVANCE Among hospitalized adults in this randomized clinical trial, treatment with piperacillin-tazobactam did not increase the incidence of acute kidney injury or death. Treatment with cefepime resulted in more neurological dysfunction.;,citation_author=Edward T. Qian;,citation_author=Jonathan D. Casey;,citation_author=Adam Wright;,citation_author=Li Wang;,citation_author=Matthew S. Shotwell;,citation_author=Justin K. Siemann;,citation_author=Mary Lynn Dear;,citation_author=Joanna L. Stollings;,citation_author=Brad D. Lloyd;,citation_author=Tanya K. Marvi;,citation_author=Kevin P. Seitz;,citation_author=George E. Nelson;,citation_author=Patty W. Wright;,citation_author=Edward D. Siew;,citation_author=Bradley M. Dennis;,citation_author=Jesse O. Wrenn;,citation_author=Jonathan W. Andereck;,citation_author=Jin H. Han;,citation_author=Wesley H. Self;,citation_author=Matthew W. Semler;,citation_author=Todd W. Rice;,citation_author=Vanderbilt Center for Learning Healthcare and the Pragmatic Critical Care Research Group;,citation_author=Gordon R Bernard;,citation_author=Robert S Dittus;,citation_author=Shon Dwyer;,citation_author=Peter J Embi;,citation_author=Robert E Freundlich;,citation_author=Cheryl L Gatto;,citation_author=Frank E Harrell;,citation_author=Paul A Harris;,citation_author=Tina Hartert;,citation_author=Jim Hayman;,citation_author=Catherine H Ivory;,citation_author=Ruth Kleinpell;,citation_author=Sunil Kripalani;,citation_author=Christopher J Lindsell;,citation_author=Lee A Liska;,citation_author=Patrick Luther;,citation_author=Jay Morrison;,citation_author=Thomas Nantais;,citation_author=Jill M Pulley;,citation_author=Kris Rehm;,citation_author=Todd W Rice;,citation_author=Russel L Rotheman;,citation_author=Patti Runyan;,citation_author=Wesley H Self;,citation_author=Matthew W Semler;,citation_author=Robin Steaban;,citation_author=Cosby A Stone;,citation_author=Philip D Walker;,citation_author=Consuelo H Wilkens;,citation_author=Adam Wright;,citation_author=Autumn D Zukerman;,citation_author=Chad Fitzgerald;,citation_author=Jonathan D Casey;,citation_author=Kevin P Seitz;,citation_author=Jillian Rhoads;,citation_author=Kelsey Womack;,citation_author=Li Wang;,citation_author=Brant Imhoff;,citation_author=Matthew S Shotwell;,citation_publication_date=2023-10;,citation_cover_date=2023-10;,citation_year=2023;,citation_issue=16;,citation_doi=10.1001/jama.2023.20583;,citation_issn=0098-7484;,citation_volume=330;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=ICU scoring systems;,citation_author=Amanda Quintairos;,citation_author=David Pilcher;,citation_author=Jorge I. F. Salluh;,citation_publication_date=2022-10;,citation_cover_date=2022-10;,citation_year=2022;,citation_doi=10.1007/s00134-022-06914-8;,citation_issn=0342-4642, 1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Effect of Moderate and Severe Persistent Hyperglycemia on Outcomes in Patients With Intracerebral Hemorrhage;,citation_abstract=BACKGROUND: We evaluated the effect of persistent hyperglycemia on outcomes in 1000 patients with intracerebral hemorrhage enrolled within 4.5 hours of symptom onset. METHODS: We defined moderate and severe hyperglycemia based on serum glucose levels \geq140 mg/dL—&amp;amp;amp;lt;180 and \geq180 mg/dL, respectively, measured at baseline, 24, 48, and 72 hours. Persistent hyperglycemia was defined by 2 consecutive (24 hours apart) serum glucose levels. We evaluated the relationship between moderate and severe hyperglycemia and death or disability (defined by modified Rankin Scale score of 4–6) at 90 days in the overall cohort and in groups defined by preexisting diabetes. RESULTS: In the multivariate analysis, both moderate (odds ratio, 1.8 [95% CI, 1.1–2.8]) and severe (odds ratio, 1.8 [95% CI, 1.2–2.7]) hyperglycemia were associated with higher 90-day death or disability after adjusting for Glasgow Coma Scale score, hematoma volume, presence or absence of intraventricular hemorrhage, hyperlipidemia, cigarette smoking, and hypertension (no interaction between hyperglycemia and preexisting diabetes, P=0.996). Among the patients without preexisting diabetes, both moderate (odds ratio, 1.8 [95% CI, 1.0–3.2]) and severe (odds ratio, 2.0 [95% CI, 1.1–3.7]) hyperglycemia were associated with 90-day death or disability after adjusting for above mentioned potential confounders. Among the patients with preexisting diabetes, moderate and severe hyperglycemia were not associated with 90-day death or disability. CONCLUSIONS: Persistent hyperglycemia, either moderate or severe, increased the risk of death or disability in nondiabetic patients with intracerebral hemorrhage.;,citation_author=Adnan I. Qureshi;,citation_author=Wei Huang;,citation_author=Iryna Lobanova;,citation_author=Premkumar N. Chandrasekaran;,citation_author=Daniel F. Hanley;,citation_author=Chung Y. Hsu;,citation_author=Renee H. Martin;,citation_author=Thorsten Steiner;,citation_author=Jose I. Suarez;,citation_author=Haruko Yamamoto;,citation_author=Kazunori Toyoda;,citation_publication_date=2022-04;,citation_cover_date=2022-04;,citation_year=2022;,citation_issue=4;,citation_doi=10.1161/STROKEAHA.121.034928;,citation_issn=0039-2499, 1524-4628;,citation_volume=53;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage;,citation_abstract=BACKGROUND Limited data are available to guide the choice of a target for the systolic blood-pressure level when treating acute hypertensive response in patients with intracerebral hemorrhage. METHODS We randomly assigned eligible participants with intracerebral hemorrhage (volume, &amp;amp;amp;lt;60 cm3) and a Glasgow Coma Scale (GCS) score of 5 or more (on a scale from 3 to 15, with lower scores indicating worse condition) to a systolic blood-pressure target of 110 to 139 mm Hg (intensive treatment) or a target of 140 to 179 mm Hg (standard treatment) in order to test the superiority of intensive reduction of systolic blood pressure to standard reduction; intravenous nicardipine to lower blood pressure was administered within 4.5 hours after symptom onset. The primary outcome was death or disability (modified Rankin scale score of 4 to 6, on a scale ranging from 0 [no symptoms] to 6 [death]) at 3 months after randomization, as ascertained by an investigator who was unaware of the treatment assignments. RESULTS Among 1000 participants with a mean (SD) systolic blood pressure of 200.627.0 mm Hg at baseline, 500 were assigned to intensive treatment and 500 to standard treatment. The mean age of the patients was 61.9 years, and 56.2% were Asian. Enrollment was stopped because of futility after a prespecified interim analysis. The primary outcome of death or disability was observed in 38.7% of the participants (186 of 481) in the intensive-treatment group and in 37.7% (181 of 480) in the standard-treatment group (relative risk, 1.04; 95% confidence interval, 0.85 to 1.27; analysis was adjusted for age, initial GCS score, and presence or absence of intraventricular hemorrhage). Serious adverse events occurring within 72 hours after randomization that were considered by the site investigator to be related to treatment were reported in 1.6% of the patients in the intensive-treatment group and in 1.2% of those in the standard-treatment group. The rate of renal adverse events within 7 days after randomization was significantly higher in the intensive-treatment group than in the standard-treatment group (9.0% vs. 4.0%, P = 0.002). The authors’ affiliations are listed in the Appendix. Address reprint requests to Dr. Qureshi at the Zeenat Qureshi Stroke Research Center, University of Minnesota, 925 Delaware St. SE, Minneapolis, MN 55455, or at qureshai@gmail.com. *A complete list of the investigators and sites participating in the Antihypertensive Treatment of Acute Cerebral Hemorrhage II (ATACH-2) trial is provided in the Supplementary Appendix, available at NEJM.org. This article was published on June 8, 2016, at NEJM.org. N Engl J Med 2016;375:1033-43. DOI: 10.1056/NEJMoa1603460 Copyright © 2016 Massachusetts Medical Society. CONCLUSIONS The treatment of participants with intracerebral hemorrhage to achieve a target systolic blood pressure of 110 to 139 mm Hg did not result in a lower rate of death or disability than standard reduction to a target of 140 to 179 mm Hg. (Funded by the National Institute of Neurological Disorders and Stroke and the National Cerebral and Cardiovascular Center; ATACH-2 ClinicalTrials.gov number, NCT01176565.);,citation_author=Adnan I. Qureshi;,citation_author=Yuko Y. Palesch;,citation_author=William G. Barsan;,citation_author=Daniel F. Hanley;,citation_author=Chung Y. Hsu;,citation_author=Renee L. Martin;,citation_author=Claudia S. Moy;,citation_author=Robert Silbergleit;,citation_author=Thorsten Steiner;,citation_author=Jose I. Suarez;,citation_author=Kazunori Toyoda;,citation_author=Yongjun Wang;,citation_author=Haruko Yamamoto;,citation_author=Byung-Woo Yoon;,citation_publication_date=2016-09;,citation_cover_date=2016-09;,citation_year=2016;,citation_issue=11;,citation_doi=10.1056/NEJMoa1603460;,citation_issn=0028-4793, 1533-4406;,citation_volume=375;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Interpretation and Implementation of Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT II);,citation_author=Adnan I Qureshi;,citation_author=Yuko Y Palesch;,citation_author=Renee Martin;,citation_author=Kazunori Toyoda;,citation_author=Haruko Yamamoto;,citation_author=Yongjun Wang;,citation_author=Yilong Wang;,citation_author=Chung Y Hsu;,citation_author=Byung-Woo Yoon;,citation_author=Thorsten Steiner;,citation_author=Kenneth Butcher;,citation_author=Daniel F Hanley;,citation_author=Jose I Suarez;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Prognosis after ICH: A necessity despite uncertainties;,citation_author=Alejandro A. Rabinstein;,citation_publication_date=2016-05;,citation_cover_date=2016-05;,citation_year=2016;,citation_issue=20;,citation_doi=10.1212/WNL.0000000000002684;,citation_issn=1526-632X;,citation_pmid=27164668;,citation_volume=86;,citation_language=en-US;,citation_journal_title=Neurology;">
<meta name="citation_reference" content="citation_title=Secondary brain injury after aneurysmal subarachnoid haemorrhage: More than vasospasm;,citation_author=Alejandro A Rabinstein;,citation_publication_date=2011-07;,citation_cover_date=2011-07;,citation_year=2011;,citation_issue=7;,citation_doi=10.1016/S1474-4422(11)70122-3;,citation_issn=1474-4422;,citation_volume=10;,citation_language=en-US;,citation_journal_title=The Lancet Neurology;">
<meta name="citation_reference" content="citation_title=Renal Replacement Therapy in the ICU:;,citation_author=Jean-Sebastien Rachoin;,citation_author=Lawrence S. Weisberg;,citation_publication_date=2019-05;,citation_cover_date=2019-05;,citation_year=2019;,citation_issue=5;,citation_doi=10.1097/CCM.0000000000003701;,citation_issn=0090-3493;,citation_volume=47;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Low Tidal Volumes for Everyone?;,citation_author=Craig R. Rackley;,citation_author=Neil R. MacIntyre;,citation_publication_date=2019-10;,citation_cover_date=2019-10;,citation_year=2019;,citation_issue=4;,citation_doi=10.1016/j.chest.2019.06.007;,citation_issn=00123692;,citation_volume=156;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Semantic and cognitive tools to aid statistical science: Replace confidence and significance by compatibility and surprise;,citation_abstract=Background: Researchers often misinterpret and misrepresent statistical outputs. This abuse has led to a large literature on modification or replacement of testing thresholds and P-values with confidence intervals, Bayes factors, and other devices. Because the core problems appear cognitive rather than statistical, we review some simple methods to aid researchers in interpreting statistical outputs. These methods emphasize logical and information concepts over probability, and thus may be more robust to common misinterpretations than are traditional descriptions. Methods: We use the Shannon transform of the P-value p, also known as the binary surprisal or S-value s = -log2(p), to provide a measure of the information supplied by the testing procedure, and to help calibrate intuitions against simple physical experiments like coin tossing. We also use tables or graphs of test statistics for alternative hypotheses, and interval estimates for different percentile levels, to thwart fallacies arising from arbitrary dichotomies. Finally, we reinterpret P-values and interval estimates in unconditional terms, which describe compatibility of data with the entire set of analysis assumptions. We illustrate these methods with a reanalysis of data from an existing record-based cohort study. Conclusions: In line with other recent recommendations, we advise that teaching materials and research reports discuss P-values as measures of compatibility rather than significance, compute P-values for alternative hypotheses whenever they are computed for null hypotheses, and interpret interval estimates as showing values of high compatibility with data, rather than regions of confidence. Our recommendations emphasize cognitive devices for displaying the compatibility of the observed data with various hypotheses of interest, rather than focusing on single hypothesis tests or interval estimates. We believe these simple reforms are well worth the minor effort they require.;,citation_author=Zad Rafi;,citation_author=Sander Greenland;,citation_publication_date=2020-12;,citation_cover_date=2020-12;,citation_year=2020;,citation_issue=1;,citation_doi=10.1186/s12874-020-01105-9;,citation_issn=1471-2288;,citation_volume=20;,citation_language=en-US;,citation_journal_title=BMC Medical Research Methodology;">
<meta name="citation_reference" content="citation_title=Technical Issues in the Interpretation of S-values and Their Relation to Other Information Measures;,citation_abstract=An extended technical discussion of $S$-values and unconditional information can be found in Greenland, 2019. Here we briefly cover several technical topics mentioned in our main paper, Rafi &amp;amp;amp; Greenland, 2020: Different units for (scaling of) the $S$-value besides base-2 logs (bits); the importance of uniformity (validity) of the $P$-value for interpretation of the $S$-value; and the relation of the $S$-value to other measures of statistical information about a test hypothesis or model.;,citation_author=Zad Rafi;,citation_author=Sander Greenland;,citation_publication_date=2020-10;,citation_cover_date=2020-10;,citation_year=2020;,citation_fulltext_html_url=https://arxiv.org/abs/2008.12991;,citation_language=en-US;,citation_journal_title=arXiv:2008.12991 [stat];">
<meta name="citation_reference" content="citation_title=Association Between the Choice of IV Crystalloid and In-Hospital Mortality Among Critically Ill Adults With Sepsis*:;,citation_abstract=Objective: Isotonic saline is the most commonly used crystalloid in the ICU, but recent evidence suggests that balanced fluids like Lactated Ringer’s solution may be preferable. We examined the association between choice of crystalloids and in-hospital mortality during the resuscitation of critically ill adults with sepsis. Design: A retrospective cohort study of patients admitted with sepsis, not undergoing any surgical procedures, and treated in an ICU by hospital day 2. We used propensity score matching to control for confounding and compared the following outcomes after resuscitation with balanced versus with no-balanced fluids: in-hospital mortality, acute renal failure with and without dialysis, and hospital and ICU lengths of stay. We also estimated the dose-response relationship between receipt of increasing proportions of balanced fluids and in-hospital mortality. Setting: Three hundred sixty U.S. hospitals that were members of the Premier Healthcare alliance between November 2005 and December 2010. Patients: A total of 53,448 patients with sepsis, treated with vasopressors and crystalloids in an ICU by hospital day 2 including 3,396 (6.4%) that received balanced fluids. Interventions: None. Measurements and Main Results: Patients treated with balanced fluids were younger and less likely to have heart or chronic renal failure, but they were more likely to receive mechanical ventilation, invasive monitoring, colloids, steroids, and larger crystalloid volumes (median 7 vs 5 L). Among 6,730 patients in a p ropensity-matched cohort, receipt of balanced fluids was associated with lower inhospital mortality (19.6% vs 22.8%; relative risk, 0.86; 95% CI, 0.78, 0.94). Mortality was progressively lower among patients receiving larger proportions of balanced fluids. There were no significant differences in the prevalence of acute renal failure (with and without dialysis) or in-hospital and ICU lengths of stay. Conclusions: Among critically ill adults with sepsis, resuscitation with balanced fluids was associated with a lower risk of in-hospital mortality. If confirmed in randomized trials, this finding could have significant public health implications, as crystalloid resuscitation is nearly universal in sepsis. (Crit Care Med 2014; 42:1585–1591);,citation_author=Karthik Raghunathan;,citation_author=Andrew Shaw;,citation_author=Brian Nathanson;,citation_author=Til Stürmer;,citation_author=Alan Brookhart;,citation_author=Mihaela S. Stefan;,citation_author=Soko Setoguchi;,citation_author=Chris Beadles;,citation_author=Peter K. Lindenauer;,citation_publication_date=2014-07;,citation_cover_date=2014-07;,citation_year=2014;,citation_issue=7;,citation_doi=10.1097/CCM.0000000000000305;,citation_issn=0090-3493;,citation_volume=42;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Universal Masking Policies in Schools and Mitigating the Inequitable Costs of Covid-19;,citation_author=Julia Raifman;,citation_author=Tiffany Green;,citation_publication_date=2022-11;,citation_cover_date=2022-11;,citation_year=2022;,citation_doi=10.1056/NEJMe2213556;,citation_issn=0028-4793, 1533-4406;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Arguing for a Negligible Effect;,citation_abstract=Political scientists often theorize that an explanatory variable should have “no effect” and support this claim by demonstrating that its coefficient’s estimate is not statistically significant. This empirical argument is quite weak, but I introduce applied researchers to simple, powerful tools that can strengthen their arguments for this hypothesis. With several supporting examples, I illustrate that researchers can use 90% confidence intervals to argue against meaningful effects and provide persuasive evidence for their hypothesis.;,citation_author=Carlisle Rainey;,citation_publication_date=2014;,citation_cover_date=2014;,citation_year=2014;,citation_issue=4;,citation_doi=10.1111/ajps.12102;,citation_issn=1540-5907;,citation_volume=58;,citation_language=en-US;,citation_journal_title=American Journal of Political Science;">
<meta name="citation_reference" content="citation_title=Subarachnoid Hemorrhage Management Guidelines: Perspectives on Methodology and Clinical Guidance;,citation_author=Venkatakrishna Rajajee;,citation_author=Theresa Human;,citation_publication_date=2023-05;,citation_cover_date=2023-05;,citation_year=2023;,citation_doi=10.1007/s12028-023-01740-2;,citation_issn=1556-0961;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina;,citation_author=Christopher A. Rajkumar;,citation_author=Michael J. Foley;,citation_author=Fiyyaz Ahmed-Jushuf;,citation_author=Alexandra N. Nowbar;,citation_author=Florentina A. Simader;,citation_author=John R. Davies;,citation_author=Peter D. O’Kane;,citation_author=Peter Haworth;,citation_author=Helen Routledge;,citation_author=Tushar Kotecha;,citation_author=Reto Gamma;,citation_author=Gerald Clesham;,citation_author=Rupert Williams;,citation_author=Jehangir Din;,citation_author=Sukhjinder S. Nijjer;,citation_author=Nick Curzen;,citation_author=Neil Ruparelia;,citation_author=Manas Sinha;,citation_author=Jason N. Dungu;,citation_author=Sashiananthan Ganesananthan;,citation_author=Ramzi Khamis;,citation_author=Lal Mughal;,citation_author=Tim Kinnaird;,citation_author=Ricardo Petraco;,citation_author=James C. Spratt;,citation_author=Sayan Sen;,citation_author=Joban Sehmi;,citation_author=David J. Collier;,citation_author=Afzal Sohaib;,citation_author=Thomas R. Keeble;,citation_author=Graham D. Cole;,citation_author=James P. Howard;,citation_author=Darrel P. Francis;,citation_author=Matthew J. Shun-Shin;,citation_author=Rasha K. Al-Lamee;,citation_publication_date=2023-11;,citation_cover_date=2023-11;,citation_year=2023;,citation_issue=0;,citation_doi=10.1056/NEJMoa2310610;,citation_issn=0028-4793;,citation_volume=0;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Acute Kidney Injury at the Neurocritical Care Unit;,citation_abstract=Neurocritical care has advanced substantially in recent decades, allowing doctors to treat patients with more com-plicated conditions who require a multidisciplinary approach to achieve better clinical outcomes. In neurocritical patients, nonneurological complications such as acute kidney injury (AKI) are independent predictors of worse clinical outcomes. Different research groups have reported an AKI incidence of 11.6% and an incidence of stage 3 AKI, accord-ing to the Kidney Disease: Improving Global Outcomes, that requires dialysis of 3% to 12% in neurocritical patients. These patients tend to be younger, have less comorbidity, and have a different risk profile, given the diagnostic and therapeutic procedures they undergo. Trauma-induced AKI, sepsis, sympathetic overstimulation, tubular epitheliopa-thy, hyperchloremia, use of nephrotoxic drugs, and renal hypoperfusion are some of the causes of AKI in neurocritical patients. AKI is the result of a sum of events, although the mechanisms underlying many of them remain uncertain; however, two important causes that merit mention are direct alteration of the physiological brain–kidney connection and exposure to injury as a result of the specific medical management and well-established therapies that neurocriti-cal patients are subjected to. This review will focus on AKI in neurocritical care patients. Specifically, it will discuss its epidemiology, causes, associated mechanisms, and relationship to the brain–kidney axis. Additionally, the use and risks of extracorporeal therapies in this group of patients will be reviewed.;,citation_author=Gonzalo Ramírez-Guerrero;,citation_author=Romyna Baghetti-Hernández;,citation_author=Claudio Ronco;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_doi=10.1007/s12028-021-01345-7;,citation_issn=1541-6933, 1556-0961;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Prediction or causality? A scoping review of their conflation within current observational research;,citation_abstract=Etiological research aims to uncover causal effects, whilst prediction research aims to forecast an outcome with the best accuracy. Causal and prediction research usually require different methods, and yet their findings may get conflated when reported and interpreted. The aim of the current study is to quantify the frequency of conflation between etiological and prediction research, to discuss common underlying mistakes and provide recommendations on how to avoid these. Observational cohort studies published in January 2018 in the top-ranked journals of six distinct medical fields (Cardiology, Clinical Epidemiology, Clinical Neurology, General and Internal Medicine, Nephrology and Surgery) were included for the current scoping review. Data on conflation was extracted through signaling questions. In total, 180 studies were included. Overall, 26% (n = 46) contained conflation between etiology and prediction. The frequency of conflation varied across medical field and journal impact factor. From the causal studies 22% was conflated, mainly due to the selection of covariates based on their ability to predict without taking the causal structure into account. Within prediction studies 38% was conflated, the most frequent reason was a causal interpretation of covariates included in a prediction model. Conflation of etiology and prediction is a common methodological error in observational medical research and more frequent in prediction studies. As this may lead to biased estimations and erroneous conclusions, researchers must be careful when designing, interpreting and disseminating their research to ensure this conflation is avoided.;,citation_author=Chava L. Ramspek;,citation_author=Ewout W. Steyerberg;,citation_author=Richard D. Riley;,citation_author=Frits R. Rosendaal;,citation_author=Olaf M. Dekkers;,citation_author=Friedo W. Dekker;,citation_author=Merel Diepen;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_issue=9;,citation_doi=10.1007/s10654-021-00794-w;,citation_issn=0393-2990, 1573-7284;,citation_volume=36;,citation_language=en-US;,citation_journal_title=European Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Long-term mortality after critical care: What is the starting point?;,citation_abstract=Mortality is still the most assessed outcome in the critically ill patient and is routinely used as the primary end-point in intervention trials, cohort studies, and benchmarking analysis. Despite this, interest in patient-centered prognosis after ICU discharge is increasing, and several studies report quality of life and long-term outcomes after critical illness. In a recent issue of Critical Care, Cuthbertson and colleagues reported interesting results from a cohort of 439 patients with sepsis, who showed high ongoing long-term mortality rates after severe sepsis, reaching 61% at 5 years (from a starting point of ICU admission). Follow-up may start at ICU admission, after ICU discharge, or after hospital discharge. Using ICU admission as a starting point will include patients with a wide range of illness severities and reasons for ICU admission. As a result, important consequences of the ICU, such as rehabilitation and reduced quality of life, may be diluted in an unselected population. ICU discharge is another frequently used starting point. ICU discharge is a marker of better outcome and reduced risk for acute deterioration, making this an interesting starting point for studying long-term mortality, need for ICU readmission, and critical illness rehabilitation. Finally, using hospital discharge as the starting point will include patients with the minimal requirements to sustain an adequate condition in a non-monitored environment but will add a ?survivors bias?; that is, patients who survive critical illness are a special group among the critically ill. In this commentary, we discuss the heterogeneity in long-term mortality from recent studies in critical care medicine ? heterogeneity that may be a consequence simply of changing the follow-up starting point ? and propose a standardized follow-up starting point for future studies according to the outcome of interest.;,citation_author=Otavio T. Ranzani;,citation_author=Fernando G. Zampieri;,citation_author=Marcelo Park;,citation_author=Jorge IF Salluh;,citation_publication_date=2013-09;,citation_cover_date=2013-09;,citation_year=2013;,citation_issue=5;,citation_doi=10.1186/cc13024;,citation_issn=1364-8535;,citation_volume=17;,citation_language=en-US;,citation_journal_title=Critical Care;">
<meta name="citation_reference" content="citation_title=Ventilator-associated pneumonia;,citation_author=Otavio T. Ranzani;,citation_author=Michael S. Niederman;,citation_author=Antoni Torres;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_doi=10.1007/s00134-022-06773-3;,citation_issn=1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Effect of Rapid Respiratory Virus Testing on Antibiotic Prescribing Among Children Presenting to the Emergency Department With Acute Respiratory Illness: A Randomized Clinical Trial;,citation_abstract=There is high usage of antibiotics in the emergency department (ED) for children with acute respiratory illnesses. Studies have reported decreased antibiotic use among inpatients with rapid respiratory pathogen (RRP) testing.To determine whether RRP testing leads to decreased antibiotic use and health care use among children with influenzalike illness (ILI) in an ED.A randomized clinical trial among children aged 1 month to 18 years presenting to an ED with ILI from December 1, 2018, to November 30, 2019, was conducted. Data were analyzed March 23, 2020, to April 2, 2021. All children received a nasopharyngeal swab for RRP testing and were randomized 1:1 to the intervention group or control group (results not given, routine clinical care). Results were available in 45 minutes. Intention-to-treat analyses and modified intention-to-treat (clinician knows results) analyses were conducted using multivariable Poisson regression.Rapid respiratory pathogen test results given to clinicians.Antibiotic prescribing was the primary outcome; influenza antiviral prescribing, ED length of stay, hospital admission, and recurrent health care visits were the secondary outcomes.Among 931 ED visits (intervention group, 452 children group and control group, 456 children after exclusion of those not meeting criteria or protocol violations), a total of 795 RRP test results (85%) were positive. The median age of the children was 2.1 years (interquartile range, 0.9-5.6 years); 509 (56%) were boys. Most children (478 [53%]) were Hispanic, 688 children (76%) received government insurance, and 314 (35%) had a high-risk medical condition. In the intention-to-treat intervention group, children were more likely to receive antibiotics (relative risk [RR], 1.3; 95% CI, 1.0-1.7), with no significant differences in antiviral prescribing, medical visits, and hospitalization. In inverse propensity-weighted modified intention-to-treat analyses, children with test results known were more likely to receive antivirals (RR, 2.6; 95% CI, 1.6-4.5) and be hospitalized (RR, 1.8; 95% CI, 1.4-2.5); there was no significant difference in antibiotic prescribing (RR, 1.1; 95% CI, 0.9-1.4).The use of RRP testing in the ED for ILI did not decrease antibiotic prescribing in this randomized clinical trial. There is a limited role for RRP pathogen testing in children in this setting.ClinicalTrials.gov Identifier: NCT03756753;,citation_author=Suchitra Rao;,citation_author=Molly M. Lamb;,citation_author=Angela Moss;,citation_author=Rakesh D. Mistry;,citation_author=Kathleen Grice;,citation_author=Wasiu Ahmed;,citation_author=Daniela Santos-Cantu;,citation_author=Elizabeth Kitchen;,citation_author=Chandni Patel;,citation_author=Ilaria Ferrari;,citation_author=Samuel R. Dominguez;,citation_publication_date=2021-06;,citation_cover_date=2021-06;,citation_year=2021;,citation_issue=6;,citation_doi=10.1001/jamanetworkopen.2021.11836;,citation_issn=2574-3805;,citation_volume=4;,citation_journal_title=JAMA Network Open;">
<meta name="citation_reference" content="citation_title=Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism;,citation_abstract=Edoxaban for Cancer-Associated Venous Thromboembolism In a randomized trial, 1050 patients with cancer who had acute venous thromboembolism were assigned to receive either dalteparin or edoxaban for 6 to 12 months. Edoxaban was noninferior to dalteparin with respect to the outcome of recurrent venous thromboembolism or major bleeding.;,citation_author=Gary E. Raskob;,citation_author=Nick Es;,citation_author=Peter Verhamme;,citation_author=Marc Carrier;,citation_author=Marcello Di Nisio;,citation_author=David Garcia;,citation_author=Michael A. Grosso;,citation_author=Ajay K. Kakkar;,citation_author=Michael J. Kovacs;,citation_author=Michele F. Mercuri;,citation_author=Guy Meyer;,citation_author=Annelise Segers;,citation_author=Minggao Shi;,citation_author=Tzu-Fei Wang;,citation_author=Erik Yeo;,citation_author=George Zhang;,citation_author=Jeffrey I. Zwicker;,citation_author=Jeffrey I. Weitz;,citation_author=Harry R. Büller;,citation_publication_date=2018-02;,citation_cover_date=2018-02;,citation_year=2018;,citation_issue=7;,citation_doi=10.1056/NEJMoa1711948;,citation_issn=0028-4793;,citation_pmid=29231094;,citation_volume=378;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=A Contemporary Update on Targeted Temperature Management;,citation_author=Tyler P Rasmussen;,citation_author=Saket Girotra;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Effect of perioperative crystalloid or colloid fluid therapy on hemorrhage, coagulation competence, and outcome: A systematic review and stratified meta-analysis;,citation_abstract=Background: A meta-analysis concerning perioperative coagulation competence, hemorrhage, and outcome was conducted including the use of hydroxyethyl starches (HESs), dextran, or albumin versus administration of a crystalloid as control to assess the efficacy and safety of colloids and crystalloids for fluid administration during major elective surgery. Surgery was restricted to cardiovascular and noncardiovascular surgery, and HESs were stratified to HES 130/0.4 and HES 200/0.5. Methods: We searched Cochrane Central Register of Controlled Trials, MEDLINE, ISI Web of Science, EMBASE, conference proceedings, reference lists, and databases of ongoing trials. Results: Thirty one primary clinical randomized controlled trials included 2287 patients undergoing major surgery from January 2000 to August 2015. The perioperative changes in coagulation competence were measured by thromboelastography (TEG) maximum amplitude (MA) in 9 studies administering crystalloids versus HES and in 4 studies administering albumin versus HES. All studies but 1 disclosed increased reduction in TEG-MA following HES administration (P = 0.0001 and 0.0002). The total loss of blood was reported in 17 studies in which crystalloids were compared to HES and 12 studies reported increased blood loss after administration of HES (P &amp;amp;amp;lt; 0.003). When administering albumin versus HES, 6 studies reported reduced hemorrhage associated with albumin administration (P = 0.005). Reoperation was not significantly reduced by the use of crystalloids, but may be more frequent after HESs compared to albumin (P &amp;lt; 0.03). In this analysis, more patients admitted to administration of HESs were exposed to decrease coagulation competence, compared to perioperative crystalloids and albumin administration. Conclusion: This stratified meta-analysis showed that increased blood loss was found in noncardiovascular surgery among patients receiving HES compared with crystalloids, followed by a marked reduction in TEG-MA, and infusion of 3rd-generation HES products did not influence the results significantly.;,citation_author=Kirsten C. Rasmussen;,citation_author=Niels H. Secher;,citation_author=Tom Pedersen;,citation_publication_date=2016-08;,citation_cover_date=2016-08;,citation_year=2016;,citation_issue=31;,citation_doi=10.1097/MD.0000000000004498;,citation_issn=0025-7974;,citation_volume=95;,citation_language=en-US;,citation_journal_title=Medicine;">
<meta name="citation_reference" content="citation_title=Fluid Intake But Not Fluid Balance Is Associated With Poor Outcome in Nontraumatic Subarachnoid Hemorrhage Patients;,citation_abstract=Objectives:&nbsp; Optimal fluid management is important in patients with acute brain injury, including subarachnoid hemorrhage. We aimed to examine the relationship between daily fluid intake and fluid balance with hospital complications and functional outcome. Design:&nbsp; Retrospective observational cohort study. Setting:&nbsp; Neurocritical care unit at a tertiary academic medical center. Patients:&nbsp; Two-hundred thirty-seven consecutive nontraumatic subarachnoid hemorrhage patients admitted to the neurologic ICU between 2010 and 2016. Interventions:&nbsp; Total daily amount of fluids and fluid balance were calculated over 15 days. Using multivariate generalized estimating equation models the association of daily fluid intake and fluid balance with disease severity, hospital complications and poor functional outcome (3-mo modified Rankin Score \geq 3) was investigated. Additionally, we described the composition of fluids given. Measurements and Main Results:&nbsp; Patients presented with a median admission Hunt and Hess grade of 3 (interquartile range, 1–5) and were 57 years old (interquartile range, 47–67 yr old). A higher daily fluid intake was associated with higher admission Hunt and Hess grade (odds ratio, 1.61; 95% CI, 1.47–1.76; p &amp;amp;amp;lt; 0.001), increased pulmonary fluid accumulation (adjusted odds ratio, 1.11; 95% CI, 1.01–1.21; p = 0.033), prolonged mechanical ventilation (Wald statistic = 20.08; degrees of freedom = 1; p &amp;lt; 0.001), higher daily Subarachnoid hemorrhage Early Brain Edema Score (adjusted odds ratio, 1.11; 95% CI, 1.01–1.22; p = 0.034), occurrence of anemia (adjusted odds ratio, 1.36; 95% CI, 1.20–1.54; p < 0.001), delayed cerebral ischemia (adjusted odds ratio, 1.31; 95% CI, 1.14–1.51; p < 0.001), and poor functional outcome (adjusted odds ratio, 1.25; 95% CI, 1.10–1.41; p < 0.001). Daily fluid balance was associated with higher admission Hunt and Hess grade (odds ratio, 1.09; 95% CI, 1.05–1.13; p < 0.001) and anemia (adjusted odds ratio, 1.17; 95% CI, 1.03–1.33; p = 0.019). The main contributors to fluids were nutritional compounds (31%), IV drugs (30%), and volume substitution (17%). Conclusions:&nbsp; Our study demonstrates a significant association of fluid intake but not fluid balance with hospital complications and poor functional outcome in subarachnoid hemorrhage patients. A larger prospective study is needed to confirm our results.;,citation_author=Verena Rass;,citation_author=Max Gaasch;,citation_author=Mario Kofler;,citation_author=Alois Josef Schiefecker;,citation_author=Bogdan-Andrei Ianosi;,citation_author=Fabian Steinkohl;,citation_author=Ronny Beer;,citation_author=Bettina Pfausler;,citation_author=Elke R. Gizewski;,citation_author=Claudius Thomé;,citation_author=Erich Schmutzhard;,citation_author=Raimund Helbok;,citation_publication_date=2019-07;,citation_cover_date=2019-07;,citation_year=2019;,citation_issue=7;,citation_doi=10.1097/CCM.0000000000003775;,citation_issn=0090-3493;,citation_volume=47;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Erectile dysfunction in fit and healthy young men: Psychological or pathological?;,citation_abstract=Epidemiological studies consistently show that prevalence of erectile dysfunction (ED) increases with ageing. Nonetheless, complaints of ED even in younger men are becoming more and more frequent. Healthcare professionals working in Sexual Medicine but even those operating in different clinical contexts might be adequately prepared to answer this increasing requirement. ED in younger men is likely to be overlooked and dismissed without performing any medical assessment, even the most basic ones, such as collection of medical history and physical exam. This is due to the widespread assumption that ED in younger individuals is a self-limiting condition, which does not deserve any clinical evaluation or therapy and can be managed only with patient reassurance. However, evidence shows that, in younger subjects, organic, psychological and relational conditions can contribute to the pathogenesis of ED and all these conditions might be evaluated and treated, whenever necessary. Among the organic conditions contributing to the onset of ED, metabolic and cardiovascular (CV) risk factors are surprisingly of particular relevance in this age group. In fact, in younger men with ED, even more than in older ones, recognizing CV risk factors or conditions suggestive of cardio-metabolic derangements can help identifying men who, although at low absolute risk due to young age, carry a high relative risk for development of CV events. In this view, the assessment of a possible organic component of ED even in younger individuals acquires a pivotal importance, because it offers the unique opportunity to unearth the presence of CV risk factors, thus allowing effective and high quality preventive interventions.;,citation_author=Giulia Rastrelli;,citation_author=Mario Maggi;,citation_publication_date=2017-02;,citation_cover_date=2017-02;,citation_year=2017;,citation_issue=1;,citation_doi=10.21037/tau.2016.09.06;,citation_issn=22234683, 22234691;,citation_volume=6;,citation_language=en-US;,citation_journal_title=Translational Andrology and Urology;">
<meta name="citation_reference" content="citation_title=Hemicraniectomy for Dominant vs Nondominant Middle Cerebral Artery Infarction: A Systematic Review and Meta-Analysis;,citation_author=Silja Räty;,citation_author=Georgios Georgiopoulos;,citation_author=Karoliina Aarnio;,citation_author=Nicolas Martinez-Majander;,citation_author=Eberhard Uhl;,citation_author=George Ntaios;,citation_author=Daniel Strbian;,citation_publication_date=2021-11;,citation_cover_date=2021-11;,citation_year=2021;,citation_issue=11;,citation_doi=10.1016/j.jstrokecerebrovasdis.2021.106102;,citation_issn=10523057;,citation_pmid=34536811;,citation_volume=30;,citation_language=en-US;,citation_journal_title=Journal of Stroke and Cerebrovascular Diseases;">
<meta name="citation_reference" content="citation_title=The Impact of Statin Drug Use on All-Cause Mortality in Patients With COPD;,citation_abstract=Background: Patients with chronic obstructive disease (COPD) are often prescribed statins due to the increased prevalence of cardiovascular disease (CVD). There is considerable debate about the benefits conferred by statins in patients with COPD. This study evaluates the association of statin use with all-cause and pulmonary-related mortality in COPD patients. Methods: This study uses population-based administrative data for the province of British Columbia, Canada. A cohort of COPD patients was identified based on individual patients’ prescription records. Statin exposure was ascertained in the 1-year period after COPD “diagnosis”. The primary and secondary outcomes, all-cause and pulmonaryrelated mortality, respectively, were evaluated in the 1-year period thereafter using multivariate Cox proportional hazards models and several definitions of medication exposure.;,citation_author=Adam J. N. Raymakers;,citation_author=Mohsen Sadatsafavi;,citation_author=Don D. Sin;,citation_author=Mary A. De Vera;,citation_author=Larry D. Lynd;,citation_publication_date=2017-09;,citation_cover_date=2017-09;,citation_year=2017;,citation_issue=3;,citation_doi=10.1016/j.chest.2017.02.002;,citation_issn=00123692;,citation_volume=152;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial;,citation_abstract=Background Colchicine has been proposed as a treatment for COVID-19 based on its anti-inflammatory actions. We aimed to evaluate the efficacy and safety of colchicine in patients admitted to hospital with COVID-19.;,citation_author=RECOVERY Collaborative Group;,citation_author=Peter W Horby;,citation_author=Mark Campbell;,citation_author=Enti Spata;,citation_author=Jonathan R Emberson;,citation_author=Natalie Staplin;,citation_author=Guilherme Pessoa-Amorim;,citation_author=Leon Peto;,citation_author=Martin Wiselka;,citation_author=Laura Wiffen;,citation_author=Simon Tiberi;,citation_author=Ben Caplin;,citation_author=Caroline Wroe;,citation_author=Christopher Green;,citation_author=Paul Hine;,citation_author=Benjamin Prudon;,citation_author=Tina George;,citation_author=Andrew Wight;,citation_author=J Kenneth Baillie;,citation_author=Buddha Basnyat;,citation_author=Maya H Buch;,citation_author=Lucy C Chappell;,citation_author=Jeremy N Day;,citation_author=Saul N Faust;,citation_author=Raph L Hamers;,citation_author=Thomas Jaki;,citation_author=Edmund Juszczak;,citation_author=Katie Jeffery;,citation_author=Wei Shen Lim;,citation_author=Alan Montgomery;,citation_author=Andrew Mumford;,citation_author=Kathryn Rowan;,citation_author=Guy Thwaites;,citation_author=Marion Mafham;,citation_author=Richard Haynes;,citation_author=Martin J Landray;,citation_publication_date=2021-05;,citation_cover_date=2021-05;,citation_year=2021;,citation_doi=10.1101/2021.05.18.21257267;,citation_language=en-US;,citation_technical_report_institution=Infectious Diseases (except HIV/AIDS);">
<meta name="citation_reference" content="citation_title=Diffuse large B cell lymphoma secondary to JC virus in progressive multifocal leukoencephalopathy;,citation_abstract=We present the case of a 43-year-old-man with a past medical history of HIV with recently initiated HAART and existing PML that presented with altered mental status. The initial diagnosis was deemed to be PML-IRIS; however, neuroimaging brought into question this diagnosis. Flow cytometry performed from the cerebrospinal fluid revealed diffuse large B cell lymphoma. JC virus may act in an oncogenic role similarly to EBV and predispose to CNS lymphomas. Patients with PML caused by JC virus may develop secondary malignancies.;,citation_author=Ashwin Reddi;,citation_author=Nikhil Patel;,citation_author=Nicholas A. Morris;,citation_publication_date=2019-12;,citation_cover_date=2019-12;,citation_year=2019;,citation_issue=6;,citation_doi=10.1007/s13365-019-00760-z;,citation_issn=1538-2443;,citation_pmid=31140130;,citation_volume=25;,citation_language=en-US;,citation_journal_title=Journal of Neurovirology;">
<meta name="citation_reference" content="citation_title=Boosters appear effective, but are they always needed?;,citation_author=K Srinath Reddy;,citation_publication_date=2021-12;,citation_cover_date=2021-12;,citation_year=2021;,citation_issue=10316;,citation_doi=10.1016/S0140-6736(21)02388-6;,citation_issn=01406736;,citation_volume=398;,citation_language=en-US;,citation_journal_title=The Lancet;">
<meta name="citation_reference" content="citation_title=The Fallacy of a Single Diagnosis;,citation_abstract=BackgroundDiagnostic reasoning requires clinicians to think through complex uncertainties. We tested the possibility of a bias toward an available single diagnosis in uncertain cases.DesignWe developed 5 different surveys providing a succinct description of a hypothetical individual patient scenaric. Each scenario was formulated in 2 versions randomized to participants, with the versions differing only in whether an alternative diagnosis was present or absent. The 5 scenarios were designed as separate tests of robustness using diverse cases, including a cautious scenario, a risky scenario, a sophisticated scenario, a validation scenario, and a comparative scenario (each survey containing only 1 version of 1 scenario). Participants included community members (n = 1104) and health care professionals (n = 200) who judged the chances of COVID infection in an individual patient.ResultsThe first scenario described a cautious patient and found a 47% reduction in the estimated odds of COVID when a flu diagnosis was present compared with absent (odds ratio = 0.53, 95% confidence interval 0.30 to 0.94, P = 0.003). The second scenario described a less cautious patient and found a 70% reduction in the estimated odds of COVID in the presence of a flu diagnosis (odds ratio = 0.30, 95% confidence interval 0.13 to 0.70, P &amp;amp;amp;lt; 0.001). The third was a more sophisticated scenario presented to medical professionals and found a 73% reduction in the estimated odds of COVID in the presence of a mononucleosis diagnosis (odds ratio = 0.27, 95% confidence interval 0.10 to 0.75, P &amp;lt; 0.001). Two further scenarios?avoiding mention of population norms?replicated the results.LimitationsBrief hypothetical scenarios may overestimate the extent of bias in more complicated medical situations.ConclusionsThese results demonstrate that an available simple diagnosis can lead individuals toward premature closure and a failure to fully consider additional severe diseases.HighlightsOccum?s razor has been debated for centuries yet rarely subjected to experimental testing for evidence-based medicine.This article offers direct evidence that people favor an available simple diagnosis, thereby neglecting to consider additional serious diseases.The bias can lead individuals to mistakenly lower their judged likelihood of COVID or another disease when an alternate diagnosis is present.This misconception over the laws of probability appears in judgments by community members and by health care workers.The pitfall in reasoning extends to high-risk cases and is not easily attributed to information, incentives, or random chance.;,citation_author=Donald A. Redelmeier;,citation_author=Eldar Shafir;,citation_publication_date=2022-09;,citation_cover_date=2022-09;,citation_year=2022;,citation_doi=10.1177/0272989X221121343;,citation_issn=0272-989X;,citation_language=en-US;,citation_journal_title=Medical Decision Making;,citation_publisher=SAGE Publications Inc STM;">
<meta name="citation_reference" content="citation_title=Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression;,citation_author=Andreas Reif;,citation_author=Istvan Bitter;,citation_author=Jozefien Buyze;,citation_author=Kerstin Cebulla;,citation_author=Richard Frey;,citation_author=Dong-Jing Fu;,citation_author=Tetsuro Ito;,citation_author=Yerkebulan Kambarov;,citation_author=Pierre-Michel Llorca;,citation_author=Albino J. Oliveira-Maia;,citation_author=Thomas Messer;,citation_author=Siobhán Mulhern-Haughey;,citation_author=Benoı̂t Rive;,citation_author=Christian Holt;,citation_author=Allan H. Young;,citation_author=Yordan Godinov;,citation_publication_date=2023-10;,citation_cover_date=2023-10;,citation_year=2023;,citation_issue=14;,citation_doi=10.1056/NEJMoa2304145;,citation_issn=0028-4793;,citation_volume=389;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: The TOGETHER randomised, platform clinical trial;,citation_abstract=Background Recent evidence indicates a potential therapeutic role of fluvoxamine for COVID-19. In the TOGETHER trial for acutely symptomatic patients with COVID-19, we aimed to assess the efficacy of fluvoxamine versus placebo in preventing hospitalisation defined as either retention in a COVID-19 emergency setting or transfer to a tertiary hospital due to COVID-19.;,citation_author=Gilmar Reis;,citation_author=Eduardo Augusto Santos Moreira-Silva;,citation_author=Daniela Carla Medeiros Silva;,citation_author=Lehana Thabane;,citation_author=Aline Cruz Milagres;,citation_author=Thiago Santiago Ferreira;,citation_author=Castilho Vitor Quirino Santos;,citation_author=Vitoria Helena Souza Campos;,citation_author=Ana Maria Ribeiro Nogueira;,citation_author=Ana Paula Figueiredo Guimaraes Almeida;,citation_author=Eduardo Diniz Callegari;,citation_author=Adhemar Dias Figueiredo Neto;,citation_author=Leonardo Cançado Monteiro Savassi;,citation_author=Maria Izabel Campos Simplicio;,citation_author=Luciene Barra Ribeiro;,citation_author=Rosemary Oliveira;,citation_author=Ofir Harari;,citation_author=Jamie I Forrest;,citation_author=Hinda Ruton;,citation_author=Sheila Sprague;,citation_author=Paula McKay;,citation_author=Alla V Glushchenko;,citation_author=Craig R Rayner;,citation_author=Eric J Lenze;,citation_author=Angela M Reiersen;,citation_author=Gordon H Guyatt;,citation_author=Edward J Mills;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_doi=10.1016/S2214-109X(21)00448-4;,citation_issn=2214109X;,citation_language=en-US;,citation_journal_title=The Lancet Global Health;">
<meta name="citation_reference" content="citation_title=Effect of Early Treatment with Ivermectin among Patients with Covid-19;,citation_abstract=BACKGROUND The efficacy of ivermectin in preventing hospitalization or extended observation in an emergency setting among outpatients with acutely symptomatic coronavirus disease 2019 (Covid-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is unclear. METHODS We conducted a double-blind, randomized, placebo-controlled, adaptive platform trial involving symptomatic SARS-CoV-2–positive adults recruited from 12 public health clinics in Brazil. Patients who had had symptoms of Covid-19 for up to 7 days and had at least one risk factor for disease progression were randomly assigned to receive ivermectin (400 \mug per kilogram of body weight) once daily for 3 days or placebo. (The trial also involved other interventions that are not reported here.) The primary composite outcome was hospitalization due to Covid-19 within 28 days after randomization or an emergency department visit due to clinical worsening of Covid-19 (defined as the participant remaining under observation for &amp;amp;amp;gt;6 hours) within 28 days after randomization. The authors’ full names, academic degrees, and affiliations are listed in the Appendix. Dr. Reis can be contacted at thetogethertrial@gmail.com or at the Research Division, Cardresearch–Cardiologia Assistencial e de Pesquisa, Rua Domingos Vieira 300, Sala 606, Belo Horizonte 30150-242, Brazil. Dr. Rayner can be contacted at thetogethertrial@ gmail.com or at the Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, Melbourne, VIC 3052, Australia. *A list of the TOGETHER Investigators is provided in the Supplementary Appendix, available at NEJM.org. This article was published on March 30, 2022, and updated on April 5, 2022, at NEJM.org. RESULTS A total of 3515 patients were randomly assigned to receive ivermectin (679 patients), placebo (679), or another intervention (2157). Overall, 100 patients (14.7%) in the ivermectin group had a primary-outcome event, as compared with 111 (16.3%) in the placebo group (relative risk, 0.90; 95% Bayesian credible interval, 0.70 to 1.16). Of the 211 primary-outcome events, 171 (81.0%) were hospital admissions. Findings were similar to the primary analysis in a modified intention-to-treat analysis that included only patients who received at least one dose of ivermectin or placebo (relative risk, 0.89; 95% Bayesian credible interval, 0.69 to 1.15) and in a per-protocol analysis that included only patients who reported 100% adherence to the assigned regimen (relative risk, 0.94; 95% Bayesian credible interval, 0.67 to 1.35). There were no significant effects of ivermectin use on secondary outcomes or adverse events. DOI: 10.1056/NEJMoa2115869 Copyright © 2022 Massachusetts Medical Society. CONCLUSIONS Treatment with ivermectin did not result in a lower incidence of medical admission to a hospital due to progression of Covid-19 or of prolonged emergency department observation among outpatients with an early diagnosis of Covid-19. (Funded by FastGrants and the Rainwater Charitable Foundation; TOGETHER ClinicalTrials.gov number, NCT04727424.);,citation_author=Gilmar Reis;,citation_author=Eduardo A. S. M. Silva;,citation_author=Daniela C. M. Silva;,citation_author=Lehana Thabane;,citation_author=Aline C. Milagres;,citation_author=Thiago S. Ferreira;,citation_author=Castilho V. Q. Santos;,citation_author=Vitoria H. S. Campos;,citation_author=Ana M. R. Nogueira;,citation_author=Ana P. F. G. Almeida;,citation_author=Eduardo D. Callegari;,citation_author=Adhemar D. F. Neto;,citation_author=Leonardo C. M. Savassi;,citation_author=Maria I. C. Simplicio;,citation_author=Luciene B. Ribeiro;,citation_author=Rosemary Oliveira;,citation_author=Ofir Harari;,citation_author=Jamie I. Forrest;,citation_author=Hinda Ruton;,citation_author=Sheila Sprague;,citation_author=Paula McKay;,citation_author=Christina M. Guo;,citation_author=Karen Rowland-Yeo;,citation_author=Gordon H. Guyatt;,citation_author=David R. Boulware;,citation_author=Craig R. Rayner;,citation_author=Edward J. Mills;,citation_publication_date=2022-05;,citation_cover_date=2022-05;,citation_year=2022;,citation_issue=18;,citation_doi=10.1056/NEJMoa2115869;,citation_issn=0028-4793, 1533-4406;,citation_volume=386;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Quality of evidence supporting Surviving Sepsis Campaign Recommendations;,citation_abstract=Introduction: The Surviving Sepsis Campaign (SSC) guidelines, released in 2017, are a combination of expert opinion and evidence-based medicine, adopted by many institutions as a standard of practice. The aim was to analyse the quality of evidence supporting recommendations on the management of sepsis. Methods: The strength and quality of evidence (high, moderate, low-very low and best practice statements) of each recommendation were extracted. Randomised controlled trials were required to qualify as high-quality evidence. Results: A total of 96 recommendations were formulated, and 87 were included. Among thirty-one (43%) strong recommendations, only 15.2% were supported by high-quality evidence. Overall, thirty-seven (42.5%) recommendations were based on low-quality evidence, followed by 28 (32.2%) based on moderate-quality, 15 (17.2%) were best practice statements and only seven (8.0%) were supported by high-quality evidence. Randomised controlled trials supported 21.4%, 9.5% and 8.6% recommendations on mechanical ventilation, resuscitation, and management/adjuvant therapy, respectively. In contrast, none high-quality evidence recommendation supported antimicrobial/source control (82.4% were lowvery low evidence or best practice statements), and nutrition. Conclusions: In the SSC guidelines most recommendations were informed by indirect evidence and nonsystematic observations. While awaiting trials results, Delphi-like approaches or multi-criteria decision analyses should guide recommendations.;,citation_author=Jordi Rello;,citation_author=Sofia Tejada;,citation_author=Elena Xu;,citation_author=Candela Solé-Lleonart;,citation_author=Laura Campogiani;,citation_author=Despoina Koulenti;,citation_author=João Ferreira-Coimbra;,citation_author=Jeff Lipman;,citation_publication_date=2020-08;,citation_cover_date=2020-08;,citation_year=2020;,citation_issue=4;,citation_doi=10.1016/j.accpm.2020.06.015;,citation_issn=23525568;,citation_volume=39;,citation_language=en-US;,citation_journal_title=Anaesthesia Critical Care &amp;amp;amp; Pain Medicine;">
<meta name="citation_reference" content="citation_title=Effect of Intra-arterial Alteplase vs Placebo Following Successful Thrombectomy on Functional Outcomes in Patients With Large Vessel Occlusion Acute Ischemic Stroke: The CHOICE Randomized Clinical Trial;,citation_abstract=OBJECTIVE To investigate whether treatment with adjunct intra-arterial alteplase after thrombectomy improves outcomes following reperfusion. DESIGN, SETTING, AND PARTICIPANTS Phase 2b randomized, double-blind, placebo-controlled trial performed from December 2018 through May 2021 in 7 stroke centers in Catalonia, Spain. The study included 121 patients with large vessel occlusion acute ischemic stroke treated with thrombectomy within 24 hours after stroke onset and with an expanded Treatment in Cerebral Ischemia angiographic score of 2b50 to 3. INTERVENTIONS Participants were randomized to receive intra-arterial alteplase (0.225 mg/kg; maximum dose, 22.5 mg) infused over 15 to 30 minutes (n = 61) or placebo (n = 52). MAIN OUTCOMES AND MEASURES The primary outcome was the difference in proportion of patients achieving a score of 0 or 1 on the 90-day modified Rankin Scale (range, 0 [no symptoms] to 6 [death]) in all patients treated as randomized. Safety outcomes included rate of symptomatic intracranial hemorrhage and death. RESULTS The study was terminated early for inability to maintain placebo availability and enrollment rate because of the COVID-19 pandemic. Of 1825 patients with acute ischemic stroke treated with thrombectomy at the 7 study sites, 748 (41%) patients fulfilled the angiographic criteria, 121 (7%) patients were randomized (mean age, 70.6 [SD, 13.7] years; 57 women [47%]), and 113 (6%) were treated as randomized. The proportion of participants with a modified Rankin Scale score of 0 or 1 at 90 days was 59.0% (36/61) with alteplase and 40.4% (21/52) with placebo (adjusted risk difference, 18.4%; 95% CI, 0.3%-36.4%; P = .047). The proportion of patients with symptomatic intracranial hemorrhage within 24 hours was 0% with alteplase and 3.8% with placebo (risk difference, -3.8%; 95% CI, -13.2% to 2.5%). Ninety-day mortality was 8% with alteplase and 15% with placebo (risk difference, -7.2%; 95% CI, -19.2% to 4.8%). CONCLUSIONS AND RELEVANCE Among patients with large vessel occlusion acute ischemic stroke and successful reperfusion following thrombectomy, the use of adjunct intra-arterial alteplase compared with placebo resulted in a greater likelihood of excellent neurological outcome at 90 days. However, because of study limitations, these findings should be interpreted as preliminary and require replication.;,citation_author=Arturo Renú;,citation_author=Mónica Millán;,citation_author=Luis San Román;,citation_author=Jordi Blasco;,citation_author=Joan Martí-Fàbregas;,citation_author=Mikel Terceño;,citation_author=Sergio Amaro;,citation_author=Joaquín Serena;,citation_author=Xabier Urra;,citation_author=Carlos Laredo;,citation_author=Roger Barranco;,citation_author=Pol Camps-Renom;,citation_author=Federico Zarco;,citation_author=Laura Oleaga;,citation_author=Pere Cardona;,citation_author=Carlos Castaño;,citation_author=Juan Macho;,citation_author=Elisa Cuadrado-Godía;,citation_author=Elio Vivas;,citation_author=Antonio López-Rueda;,citation_author=Leopoldo Guimaraens;,citation_author=Anna Ramos-Pachón;,citation_author=Jaume Roquer;,citation_author=Marian Muchada;,citation_author=Alejandro Tomasello;,citation_author=Antonio Dávalos;,citation_author=Ferran Torres;,citation_author=Ángel Chamorro;,citation_author=CHOICE Investigators;,citation_author=Laura Llull;,citation_author=Martha Vargas;,citation_author=Victor Obach;,citation_author=Salvatore Rudilosso;,citation_author=Alejandro Rodríguez-Vázquez;,citation_author=Daniel Santana;,citation_author=Napoleón Macías;,citation_author=Elena Serrano;,citation_author=Javier Moreno;,citation_author=Natalia Pérez de la Ossa;,citation_author=Laura Dorado;,citation_author=Maria Hernández-Pérez;,citation_author=Meritxell Gomis;,citation_author=Lucia Muñoz;,citation_author=P. Rodríguez-Molinos;,citation_author=Martí Boix;,citation_author=Ernest Palomeras;,citation_author=F. Núñez;,citation_author=Sebastián Remollo;,citation_author=Mariano Werner;,citation_author=Victor Vera;,citation_author=Laura Paul;,citation_author=Laura Pardo;,citation_author=Montserrat Reina;,citation_author=Saima Bashir;,citation_author=Ursula Bojaryn;,citation_author=Yolanda Silva;,citation_author=Marina Guasch;,citation_author=Alan Murillo;,citation_author=Juan Rodríguez Álvarez-Cienfuegos;,citation_author=M. Comas;,citation_author=B. Martínez;,citation_author=E. Nogué;,citation_author=Oscar Chirife;,citation_author=Helena Quesada;,citation_author=Blanca Lara;,citation_author=Andres Paipa;,citation_author=Lucia Aja;,citation_author=Paloma Mora;,citation_author=Maria Angel Miquel;,citation_author=Sónia Aixut;,citation_author=Anna Maria Ferrer;,citation_author=R. Marín;,citation_author=Luis Prats-Sánchez;,citation_author=Raquel Delgado-Mederos;,citation_author=A Martínez-Domeño;,citation_author=Joan Branera;,citation_author=R. Guerrero;,citation_author=J Villalba;,citation_author=A Rodríguez;,citation_author=N. Berga;,citation_author=Elena Jiménez-Xarrié;,citation_author=G. Romeral;,citation_author=Ángel Ois;,citation_author=Jordi Jiménez;,citation_author=C. Avellaneda;,citation_author=N Cayuela;,citation_author=Ana Rodríguez;,citation_author=Eva Giralt;,citation_author=M Espona;,citation_author=J. Saldaña;,citation_author=David Hernández;,citation_author=Marc Ribó;,citation_author=Carlos Piñana;,citation_author=Noelia Rodríguez;,citation_author=Sandra Boned;,citation_author=Carlos Molina;,citation_author=Marta Rubiera;,citation_author=Jesús Juega;,citation_author=David Rodríguez-Luna;,citation_author=Juan Pagola;,citation_author=Alvaro Garcia-Tonel;,citation_author=Matias Deck;,citation_author=V Sala;,citation_author=Estela Sanjuan;,citation_author=K. Santana;,citation_author=C. Losada;,citation_author=P. Suñe;,citation_author=Tudor G. Jovin;,citation_author=Enrique Leira;,citation_author=José Rios;,citation_publication_date=2022-03;,citation_cover_date=2022-03;,citation_year=2022;,citation_issue=9;,citation_doi=10.1001/jama.2022.1645;,citation_issn=0098-7484;,citation_volume=327;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Direct to Angiography Suite Without Stopping for Computed Tomography Imaging for Patients With Acute Stroke: A Randomized Clinical Trial;,citation_abstract=OBJECTIVE To explore the effect of DTAS on clinical outcomes among patients with LVO stroke in a randomized clinical trial. DESIGN, SETTING, AND PARTICIPANTS The study was an investigator-initiated, single-center, evaluator-blinded randomized clinical trial. Of 466 consecutive patients with acute stroke screened, 174 with suspected LVO acute stroke within 6 hours of symptom onset were included. Enrollment took place from September 2018 to November 2020 and was stopped after a preplanned interim analysis. Final follow-up was in February 2021. INTERVENTIONS Patients were randomly assigned (1:1) to follow either DTAS (89 patients) or conventional workflow (85 patients received direct transfer to computed tomographic imaging, with usual imaging performed and EVT indication decided) to assess the indication of EVT. Patients were stratified according to their having been transferred from a primary center vs having a direct admission. MAIN OUTCOMES AND MEASURES The primary outcome was a shift analysis assessing the distribution of the 90-day 7-category (from 0 [no symptoms] to 6 [death]) modified Rankin Scale (mRS) score among patients with LVO whether or not they received EVT (modified intention-to-treat population) assessed by blinded external evaluators. Secondary outcomes included rate of EVT and door-to-arterial puncture time. Safety outcomes included 90-day mortality and rates of symptomatic intracranial hemorrhage. RESULTS In total, 174 patients were included, with a mean (SD) age of 73.4 (12.6) years (range, 19-95 years), and 78 patients (44.8%) were women. Their mean (SD) onset-to-door time was 228.0 (117.9) minutes, and their median admission National Institutes of Health Stroke Scale score was 18 (interquartile range [IQR], 14-21). In the modified intention-to-treat population, EVT was performed for all 74 patients in the DTAS group and for 64 patients (87.7%) in the conventional workflow group (P = .002). The DTAS protocol decreased the median door–to–arterial puncture time (18 minutes [IQR, 15-24 minutes] vs 42 minutes [IQR, 35-51 minutes]; P &amp;amp;amp;lt; .001) and door-to-reperfusion time (57 minutes [IQR, 43-77 minutes] vs 84 minutes [IQR, 63-117 minutes]; P &amp;lt; .001). The DTAS protocol decreased the severity of disability across the range of the mRS (adjusted common odds ratio, 2.2; 95% CI, 1.2-4.1; P = .009). Safety variables were comparable between groups. CONCLUSIONS AND RELEVANCE For patients with LVO admitted within 6 hours after symptom onset, this randomized clinical trial found that, compared with conventional workflow, the use of DTAS increased the odds of patients undergoing EVT, decreased hospital workflow time, and improved clinical outcome.;,citation_author=Manuel Requena;,citation_author=Marta Olivé-Gadea;,citation_author=Marian Muchada;,citation_author=David Hernández;,citation_author=Marta Rubiera;,citation_author=Sandra Boned;,citation_author=Carlos Piñana;,citation_author=Matías Deck;,citation_author=Álvaro García-Tornel;,citation_author=Humberto Díaz-Silva;,citation_author=Noelia Rodriguez-Villatoro;,citation_author=Jesús Juega;,citation_author=David Rodriguez-Luna;,citation_author=Jorge Pagola;,citation_author=Carlos Molina;,citation_author=Alejandro Tomasello;,citation_author=Marc Ribo;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_issue=9;,citation_doi=10.1001/jamaneurol.2021.2385;,citation_issn=2168-6149;,citation_volume=78;,citation_language=en-US;,citation_journal_title=JAMA Neurology;">
<meta name="citation_reference" content="citation_title=Erectile Dysfunction;,citation_author=Karl T Rew;,citation_author=Joel J Heidelbaugh;,citation_publication_date=2016;,citation_cover_date=2016;,citation_year=2016;,citation_issue=10;,citation_volume=94;,citation_language=en-US;,citation_journal_title=Erectile Dysfunction;">
<meta name="citation_reference" content="citation_title=Congratulations to Ochsner Medical Center for their 1st Randomization!;,citation_author=Richard Zweifler;,citation_author=Jessica Henry;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Commentary: Representativeness is usually not necessary and often should be avoided;,citation_author=Lorenzo Richiardi;,citation_author=Costanza Pizzi;,citation_author=Neil Pearce;,citation_publication_date=2013-08;,citation_cover_date=2013-08;,citation_year=2013;,citation_issue=4;,citation_doi=10.1093/ije/dyt103;,citation_issn=1464-3685, 0300-5771;,citation_volume=42;,citation_language=en-US;,citation_journal_title=International Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=The Fragility Index in Multicenter Randomized Controlled Critical Care Trials*:;,citation_author=Elliott E. Ridgeon;,citation_author=Paul J. Young;,citation_author=Rinaldo Bellomo;,citation_author=Marta Mucchetti;,citation_author=Rosalba Lembo;,citation_author=Giovanni Landoni;,citation_publication_date=2016-07;,citation_cover_date=2016-07;,citation_year=2016;,citation_issue=7;,citation_doi=10.1097/CCM.0000000000001670;,citation_issn=0090-3493;,citation_volume=44;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=On the 12th Day of Christmas, a Statistician Sent to Me . . .;,citation_author=Richard D Riley;,citation_author=Tim J Cole;,citation_author=Jon Deeks;,citation_author=Jamie J Kirkham;,citation_author=Julie Morris;,citation_author=Rafael Perera;,citation_author=Angie Wade;,citation_author=Gary S Collins;,citation_publication_date=2022-12;,citation_cover_date=2022-12;,citation_year=2022;,citation_doi=10.1136/bmj-2022-072883;,citation_issn=1756-1833;,citation_language=en-US;,citation_journal_title=BMJ;">
<meta name="citation_reference" content="citation_title=Clinical prediction models and the multiverse of madness;,citation_abstract=Each year, thousands of clinical prediction models are developed to make predictions (e.g. estimated risk) to inform individual diagnosis and prognosis in healthcare. However, most are not reliable for use in clinical practice. We discuss how the creation of a prediction model (e.g. using regression or machine learning methods) is dependent on the sample and size of data used to develop it—were a different sample of the same size used from the same overarching population, the developed model could be very different even when the same model development methods are used. In other words, for each model created, there exists a multiverse of other potential models for that sample size and, crucially, an individual’s predicted value (e.g. estimated risk) may vary greatly across this multiverse. The more an individual’s prediction varies across the multiverse, the greater the instability. We show how small development datasets lead to more different models in the multiverse, often with vastly unstable individual predictions, and explain how this can be exposed by using bootstrapping and presenting instability plots. We recommend healthcare researchers seek to use large model development datasets to reduce instability concerns. This is especially important to ensure reliability across subgroups and improve model fairness in practice. Instability is concerning as an individual’s predicted value is used to guide their counselling, resource prioritisation, and clinical decision making. If different samples lead to different models with very different predictions for the same individual, then this should cast doubt into using a particular model for that individual. Therefore, visualising, quantifying and reporting the instability in individual-level predictions is essential when proposing a new model.;,citation_author=Richard D. Riley;,citation_author=Alexander Pate;,citation_author=Paula Dhiman;,citation_author=Lucinda Archer;,citation_author=Glen P. Martin;,citation_author=Gary S. Collins;,citation_publication_date=2023-12;,citation_cover_date=2023-12;,citation_year=2023;,citation_issue=1;,citation_doi=10.1186/s12916-023-03212-y;,citation_issn=1741-7015;,citation_volume=21;,citation_language=en-US;,citation_journal_title=BMC Medicine;,citation_publisher=BioMed Central;">
<meta name="citation_reference" content="citation_title=The Epidemiology of Intracerebral Hemorrhage in the United States from 1979 to 2008;,citation_abstract=Intracerebral hemorrhage (ICH) causes 15&nbsp;% of strokes annually in the United States.;,citation_author=Fred Rincon;,citation_author=Stephan A. Mayer;,citation_publication_date=2013-08;,citation_cover_date=2013-08;,citation_year=2013;,citation_issue=1;,citation_doi=10.1007/s12028-012-9793-y;,citation_issn=1556-0961;,citation_volume=19;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Reporting Bayesian Results;,citation_abstract=Because of the different philosophy of Bayesian statistics, where parameters are random variables and data are considered fixed, the analysis and presentation of results will differ from that of frequentist statistics. Most importantly, the probabilities that a parameter is in certain regions of the parameter space are crucial quantities in Bayesian statistics that are not calculable (or considered important) in the frequentist approach that is the basis of much of traditional statistics. In this article, I discuss the implications of these differences for presentation of the results of Bayesian analyses. In doing so, I present more detailed guidelines than are usually provided and explain the rationale for my suggestions.;,citation_author=David Rindskopf;,citation_publication_date=2020-08;,citation_cover_date=2020-08;,citation_year=2020;,citation_issue=4;,citation_doi=10.1177/0193841X20977619;,citation_issn=0193-841X, 1552-3926;,citation_volume=44;,citation_language=en-US;,citation_journal_title=Evaluation Review;">
<meta name="citation_reference" content="citation_title=Noninvasive respiratory support in intensive care medicine;,citation_author=Nuttapol Rittayamai;,citation_author=Domenico L. Grieco;,citation_author=Laurent Brochard;,citation_publication_date=2022-09;,citation_cover_date=2022-09;,citation_year=2022;,citation_issue=9;,citation_doi=10.1007/s00134-022-06762-6;,citation_issn=0342-4642, 1432-1238;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Diagnosis, Treatment and Follow Up of Acute Pulmonary Embolism: Consensus Practice from the PERT Consortium;,citation_abstract=Pulmonary embolism (PE) is a life-threatening condition and a leading cause of morbidity and mortality. There have been many advances in the field of PE in the last few years, requiring a careful assessment of their impact on patient care. However, variations in recommendations by different clinical guidelines, as well as lack of robust clinical trials, make clinical decisions challenging. The Pulmonary Embolism Response Team Consortium is an international association created to advance the diagnosis, treatment, and outcomes of patients with PE. In this consensus practice document, we provide a comprehensive review of the diagnosis, treatment, and follow-up of acute PE, including both clinical data and consensus opinion to provide guidance for clinicians caring for these patients.;,citation_author=Belinda Rivera-Lebron;,citation_author=Michael McDaniel;,citation_author=Kamran Ahrar;,citation_author=Abdulah Alrifai;,citation_author=David M. Dudzinski;,citation_author=Christina Fanola;,citation_author=Danielle Blais;,citation_author=David Janicke;,citation_author=Roman Melamed;,citation_author=Kerry Mohrien;,citation_author=Elizabeth Rozycki;,citation_author=Charles B. Ross;,citation_author=Andrew J. Klein;,citation_author=Parth Rali;,citation_author=Nicholas R. Teman;,citation_author=Leoara Yarboro;,citation_author=Eugene Ichinose;,citation_author=Aditya M. Sharma;,citation_author=Jason A. Bartos;,citation_author=Mahir Elder;,citation_author=Brent Keeling;,citation_author=Harold Palevsky;,citation_author=Soophia Naydenov;,citation_author=Parijat Sen;,citation_author=Nancy Amoroso;,citation_author=Josanna M. Rodriguez-Lopez;,citation_author=George A. Davis;,citation_author=Rachel Rosovsky;,citation_author=Kenneth Rosenfield;,citation_author=Christopher Kabrhel;,citation_author=James Horowitz;,citation_author=Jay S. Giri;,citation_author=Victor Tapson;,citation_author=Richard Channick;,citation_author=PERT Consortium;,citation_doi=10.1177/1076029619853037;,citation_issn=1938-2723;,citation_pmid=31185730;,citation_volume=25;,citation_language=en-US;,citation_journal_title=Clinical and Applied Thrombosis/Hemostasis: Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis;">
<meta name="citation_reference" content="citation_title=Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): A multicentre, open-label, randomised controlled trial;,citation_author=Melinda B. Roaldsen;,citation_author=Agnethe Eltoft;,citation_author=Tom Wilsgaard;,citation_author=Hanne Christensen;,citation_author=Stefan T. Engelter;,citation_author=Bent Indredavik;,citation_author=Dalius Jatužis;,citation_author=Guntis Karelis;,citation_author=Janika Kõrv;,citation_author=Erik Lundström;,citation_author=Jesper Petersson;,citation_author=Jukka Putaala;,citation_author=Mary-Helen Søyland;,citation_author=Arnstein Tveiten;,citation_author=Andrew Bivard;,citation_author=Stein Harald Johnsen;,citation_author=Michael V. Mazya;,citation_author=David J. Werring;,citation_author=Teddy Y. Wu;,citation_author=Gian Marco De Marchis;,citation_author=Thompson G. Robinson;,citation_author=Ellisiv B. Mathiesen;,citation_author=M. Parson;,citation_author=M. Valente;,citation_author=A. Chen;,citation_author=A. Sharobeam;,citation_author=L. Edwards;,citation_author=C. Blair;,citation_author=L. Christensen;,citation_author=K. Ægidius;,citation_author=T. Pihl;,citation_author=C. Fassel-Larsen;,citation_author=L. Wassvik;,citation_author=M. Folke;,citation_author=S. Rosenbaum;,citation_author=S. S. Gharehbagh;,citation_author=A. Hansen;,citation_author=N. Preisler;,citation_author=K. Antsov;,citation_author=S. Mallene;,citation_author=M. Lill;,citation_author=M. Herodes;,citation_author=R. Vibo;,citation_author=A. Rakitin;,citation_author=J. Saarinen;,citation_author=M. Tiainen;,citation_author=O. Tumpula;,citation_author=T. Noppari;,citation_author=S. Raty;,citation_author=G. Sibolt;,citation_author=J. Nieminen;,citation_author=J. Niederhauser;,citation_author=I. Haritoncenko;,citation_author=J. Puustinen;,citation_author=T.-M. Haula;,citation_author=J. Sipilä;,citation_author=B. Viesulaite;,citation_author=S. Taroza;,citation_author=D. Rastenyte;,citation_author=V. Matijosaitis;,citation_author=A. Vilionskis;,citation_author=R. Masiliunas;,citation_author=A. Ekkert;,citation_author=P. Chmeliauskas;,citation_author=V. Lukosaitis;,citation_author=A. Reichenbach;,citation_author=T. T. Moss;,citation_author=H. Y. Nilsen;,citation_author=R. Hammer-Berntzen;,citation_author=L. M. Nordby;,citation_author=T. A. Weiby;,citation_author=K. Nordengen;,citation_author=H. Ihle-Hansen;,citation_author=M. Stankiewiecz;,citation_author=O. Grotle;,citation_author=M. Nes;,citation_author=K. Thiemann;,citation_author=I. M. Særvold;,citation_author=M. Fraas;,citation_author=S. Størdahl;,citation_author=J. W. Horn;,citation_author=H. Hildrum;,citation_author=C. Myrstad;,citation_author=H. Tobro;,citation_author=J.-A. Tunvold;,citation_author=O. Jacobsen;,citation_author=N. Aamodt;,citation_author=H. Baisa;,citation_author=V. N. Malmberg;,citation_author=G. Rohweder;,citation_author=H. Ellekjær;,citation_author=F. Ildstad;,citation_author=E. Egstad;,citation_author=B. H. Helleberg;,citation_author=H. H. Berg;,citation_author=J. Jørgensen;,citation_author=E. Tronvik;,citation_author=M. Shirzadi;,citation_author=R. Solhoff;,citation_author=R. Van Lessen;,citation_author=A. Vatne;,citation_author=K. Forselv;,citation_author=H. Frøyshov;,citation_author=M. S. Fjeldstad;,citation_author=L. Tangen;,citation_author=S. Matapour;,citation_author=K. Kindberg;,citation_author=C. Johannessen;,citation_author=M. Rist;,citation_author=I. Mathisen;,citation_author=T. Nyrnes;,citation_author=A. Haavik;,citation_author=G. Toverud;,citation_author=K. Aakvik;,citation_author=M. Larsson;,citation_author=K. Ytrehus;,citation_author=S. Ingebrigtsen;,citation_author=T. Stokmo;,citation_author=C. Helander;,citation_author=I. C. Larsen;,citation_author=T. O. Solberg;,citation_author=Y. M. Seljeseth;,citation_author=S. Maini;,citation_author=I. Bersås;,citation_author=J. Mathé;,citation_author=E. Rooth;,citation_author=A.-C. Laska;,citation_author=A.-S. Rudberg;,citation_author=M. Esbjörnsson;,citation_author=F. Andler;,citation_author=A. Ericsson;,citation_author=O. Wickberg;,citation_author=J.-E. Karlsson;,citation_author=P. Redfors;,citation_author=K. Jood;,citation_author=F. Buchwald;,citation_author=K. Mansson;,citation_author=O. Gråhamn;,citation_author=K. Sjölin;,citation_author=E. Lindvall;,citation_author=Å Cidh;,citation_author=A. Tolf;,citation_author=O. Fasth;,citation_author=B. Hedström;,citation_author=J. Fladt;,citation_author=T. D. Dittrich;,citation_author=L. Kriemler;,citation_author=N. Hannon;,citation_author=E. Amis;,citation_author=S. Finlay;,citation_author=J. Mitchell-Douglas;,citation_author=J. McGee;,citation_author=R. Davies;,citation_author=V. Johnson;,citation_author=A. Nair;,citation_author=M. Robinson;,citation_author=J. Greig;,citation_author=O. Halse;,citation_author=P. Wilding;,citation_author=S. Mashate;,citation_author=K. Chatterjee;,citation_author=M. Martin;,citation_author=S. Leason;,citation_author=J. Roberts;,citation_author=D. Dutta;,citation_author=D. Ward;,citation_author=R. Rayessa;,citation_author=E. Clarkson;,citation_author=J. Teo;,citation_author=C. Ho;,citation_author=S. Conway;,citation_author=M. Aissa;,citation_author=V. Papavasileiou;,citation_author=S. Fry;,citation_author=D. Waugh;,citation_author=J. Britton;,citation_author=A. Hassan;,citation_author=L. Manning;,citation_author=S. Khan;,citation_author=A. Asaipillai;,citation_author=C. Fornolles;,citation_author=M. L. Tate;,citation_author=S. Chenna;,citation_author=T. Anjum;,citation_author=D. Karunatilake;,citation_author=J. Foot;,citation_author=L. VanPelt;,citation_author=A. Shetty;,citation_author=G. Wilkes;,citation_author=A. Buck;,citation_author=B. Jackson;,citation_author=L. Fleming;,citation_author=M. Carpenter;,citation_author=L. Jackson;,citation_author=A. Needle;,citation_author=T. Zahoor;,citation_author=T. Duraisami;,citation_author=K. Northcott;,citation_author=J. Kubie;,citation_author=A. Bowring;,citation_author=S. Keenan;,citation_author=D. Mackle;,citation_author=T. England;,citation_author=B. Rushton;,citation_author=A. Hedstrom;,citation_author=S. Amlani;,citation_author=R. Evans;,citation_author=G. Muddegowda;,citation_author=A. Remegoso;,citation_author=P. Ferdinand;,citation_author=R. Varquez;,citation_author=M. Davis;,citation_author=E. Elkin;,citation_author=R. Seal;,citation_author=M. Fawcett;,citation_author=C. Gradwell;,citation_author=C. Travers;,citation_author=B. Atkinson;,citation_author=S. Woodward;,citation_author=L. Giraldo;,citation_author=J. Byers;,citation_author=B. Cheripelli;,citation_author=S. Lee;,citation_author=R. Marigold;,citation_author=S. Smith;,citation_author=L. Zhang;,citation_author=R. Ghatala;,citation_author=C. H. Sim;,citation_author=U. Ghani;,citation_author=K. Yates;,citation_author=S. Obarey;,citation_author=M. Willmot;,citation_author=K. Ahlquist;,citation_author=M. Bates;,citation_author=K. Rashed;,citation_author=S. Board;,citation_author=G. Andsberg;,citation_author=S. Sundayi;,citation_author=M. Garside;,citation_author=M.-J. Macleod;,citation_author=A. Manoj;,citation_author=O. Hopper;,citation_author=B. Cederin;,citation_author=T. Toomsoo;,citation_author=K. Gross-Paju;,citation_author=T. Tapiola;,citation_author=J. Kestutis;,citation_author=K.-F. Amthor;,citation_author=B. Heermann;,citation_author=V. Ottesen;,citation_author=T. A. Melum;,citation_author=M. Kurz;,citation_author=M. Parsons;,citation_author=M. Valente;,citation_author=A. Chen;,citation_author=A. Sharobeam;,citation_author=L. Edwards;,citation_author=C. Blair;,citation_publication_date=2022-12;,citation_cover_date=2022-12;,citation_year=2022;,citation_issue=0;,citation_doi=10.1016/S1474-4422(22)00484-7;,citation_issn=1474-4422, 1474-4465;,citation_pmid=36549308;,citation_volume=0;,citation_language=en-US;,citation_journal_title=The Lancet Neurology;,citation_publisher=Elsevier;">
<meta name="citation_reference" content="citation_title=Intracranial pressure monitoring in patients with acute brain injury in the intensive care unit (SYNAPSE-ICU): An international, prospective observational cohort study;,citation_author=Chiara Robba;,citation_author=Francesca Graziano;,citation_author=Paola Rebora;,citation_author=Francesca Elli;,citation_author=Carlo Giussani;,citation_author=Mauro Oddo;,citation_author=Geert Meyfroidt;,citation_author=Raimund Helbok;,citation_author=Fabio S. Taccone;,citation_author=Lara Prisco;,citation_author=Jean-Louis Vincent;,citation_author=Jose I. Suarez;,citation_author=Nino Stocchetti;,citation_author=Giuseppe Citerio;,citation_author=M. Abdelaty;,citation_author=S. Abed Maillard;,citation_author=H. Ahmed;,citation_author=L. Albrecht;,citation_author=A. Alsudani;,citation_author=E. D. Amundarain;,citation_author=S. Anand;,citation_author=J. B. Andersen;,citation_author=M. Anglada;,citation_author=Y. Arabi;,citation_author=I. Aragao;,citation_author=M. D. Arias Verdu;,citation_author=K. Asehnoune;,citation_author=F. Assunção;,citation_author=G. Audibert;,citation_author=R. Badenes;,citation_author=T. Bajracharya;,citation_author=P. Banco;,citation_author=D. Batista;,citation_author=E. Bertellini;,citation_author=H. Berty Gutiérrez;,citation_author=G. Besch;,citation_author=P. Biston;,citation_author=A. Blandino Ortiz;,citation_author=V. Blazquez;,citation_author=S. Bloria;,citation_author=C. Bonetti;,citation_author=P. Bresil;,citation_author=I. Brunetti;,citation_author=V. Buldini;,citation_author=A. Caillard;,citation_author=I. Calamai;,citation_author=M. Carbonara;,citation_author=A. Caricato;,citation_author=M. C. Casadio;,citation_author=M. Casanova;,citation_author=P. Cavaleiro;,citation_author=M. Celaya Lopez;,citation_author=C. Y. Chan;,citation_author=R. Chauhan;,citation_author=R. Cinotti;,citation_author=L. Corral;,citation_author=A. Cortegiani;,citation_author=A. Cotoia;,citation_author=I. A. Crippa;,citation_author=V. Davidovich;,citation_author=S. Del Bianco;,citation_author=C. Diakaki;,citation_author=J. Dibu;,citation_author=A. Dimoula;,citation_author=G. Domeniconi;,citation_author=L. J. Y. Dominguez;,citation_author=N. Dovbysh;,citation_author=P. Duque;,citation_author=H. S. Eddelien;,citation_author=A. Efthymiou;,citation_author=T. Egmose Larsen;,citation_author=M. Elhadi;,citation_author=E. Favre Eva;,citation_author=M. Fencl;,citation_author=P. Forjan;,citation_author=R. Freitas;,citation_author=K. Fuest;,citation_author=M. Fumale;,citation_author=C. Gakuba;,citation_author=L. Galarza;,citation_author=M. F. García;,citation_author=G. A. Gasca López;,citation_author=C. Gelormini;,citation_author=A. Gempeler;,citation_author=A. Giannopoulos;,citation_author=M. E. Giménez;,citation_author=A. Giugni;,citation_author=D. Glorieux;,citation_author=M. I. Gonzalez Perez;,citation_author=P. Gradisek;,citation_author=M. Grandis;,citation_author=D. Griesdale;,citation_author=A. Gritsan;,citation_author=S. Grotheer;,citation_author=D. Gupta;,citation_author=E. D. Hallt;,citation_author=C. Hawthorne;,citation_author=R. Helbok;,citation_author=M. O. Holm;,citation_author=C. Iasonidou;,citation_author=O. Idowu;,citation_author=E. Ioannoni;,citation_author=A. Izzi;,citation_author=M. Jibaja;,citation_author=P. Kafle;,citation_author=D. H. Kandamby;,citation_author=M. M. Khan;,citation_author=S. Khomiakov;,citation_author=B. Kilapong;,citation_author=J. Kletecka;,citation_author=K. Kojder;,citation_author=A. Kolias;,citation_author=E. Kontoudaki;,citation_author=G. Koukoulitsios;,citation_author=N. Kovac;,citation_author=S. Kozar;,citation_author=S. M. Krieg;,citation_author=P. Kurtz;,citation_author=G. Kyriazopoulos;,citation_author=M. Lamperti;,citation_author=P. Lavicka;,citation_author=L. Lencastre;,citation_author=M. Levin;,citation_author=R. Lightfoot;,citation_author=A. Lindner;,citation_author=P. López Ojeda;,citation_author=A. Lores;,citation_author=M. Lucca;,citation_author=A. Luthra;,citation_author=F. Magni;,citation_author=B. Majholm;,citation_author=D. Makris;,citation_author=F. Maldonado;,citation_author=A. Marudi;,citation_author=S. Maskey;,citation_author=L. Mebis;,citation_author=J. H. Mejia-Mantilla;,citation_author=R. Mendoza;,citation_author=N. Milivojevic;,citation_author=J. P. Miroz;,citation_author=B. Monleon;,citation_author=J. M. Montes;,citation_author=P. Morelli;,citation_author=A. Motta;,citation_author=E. Mouloudi;,citation_author=S. Muehlschlegel;,citation_author=S. A. Ñamendys Silva;,citation_author=G. Nardai;,citation_author=K. Nilam;,citation_author=D. Olson;,citation_author=A. Ozair;,citation_author=C. Pacheco;,citation_author=J. Padilla Juan;,citation_author=E. Palli;,citation_author=N. Panda;,citation_author=N. Pantelas;,citation_author=L. Pariente;,citation_author=D. Pearson;,citation_author=R. Pérez-Araos;,citation_author=E. Picetti;,citation_author=J. L. Pinedo Portilla;,citation_author=B. Pons;,citation_author=F. Pozzi;,citation_author=E. Provaznikova;,citation_author=M. C. Quartarone;,citation_author=H. Quintard;,citation_author=L. Rajbanshi;,citation_author=M. Reade;,citation_author=S. F. Ribaric;,citation_author=A. Rigamonti;,citation_author=L. L. Rivera;,citation_author=J. Roberts;,citation_author=Y. B. Roka;,citation_author=O. Sabelnikovs;,citation_author=H. Sapra;,citation_author=S. J. Schaller;,citation_author=M. Sekhon;,citation_author=W. Sellami;,citation_author=I. Seppelt;,citation_author=A. Serrano;,citation_author=K. Sharma;,citation_author=G. S. Shrestha;,citation_author=H. P. Shum;,citation_author=S. Silva;,citation_author=M. Simoes;,citation_author=S. Sivakumar;,citation_author=R. Siviter;,citation_author=J. Skola;,citation_author=M. Škoti;,citation_author=M. Smitt;,citation_author=R. Soley;,citation_author=R. Sonneville;,citation_author=A. Soragni;,citation_author=B. Soyer;,citation_author=V. Spatenkova;,citation_author=E. E. Stamou;,citation_author=E. Stival;,citation_author=Z. Olson;,citation_author=K. Tánczos;,citation_author=C. Thompson;,citation_author=J. Thomsen;,citation_author=S. Tsikriki;,citation_author=S. Van De Velde;,citation_author=W. Videtta;,citation_author=F. Villa;,citation_author=K. Vrbica;,citation_author=C. Vrettou;,citation_author=H. Westy Hoffmeyer;,citation_author=S. Wolf;,citation_author=S. Wolf;,citation_author=S. Yasin Wayhs;,citation_author=S. M. Zerbi;,citation_publication_date=2021-07;,citation_cover_date=2021-07;,citation_year=2021;,citation_issue=7;,citation_doi=10.1016/S1474-4422(21)00138-1;,citation_issn=1474-4422, 1474-4465;,citation_pmid=34146513;,citation_volume=20;,citation_language=en-US;,citation_journal_title=The Lancet Neurology;,citation_publisher=Elsevier;">
<meta name="citation_reference" content="citation_title=Mechanical ventilation in patients with acute brain injury: Recommendations of the European Society of Intensive Care Medicine consensus;,citation_abstract=To provide clinical practice recommendations and generate a research agenda on mechanical ventilation and respiratory support in patients with acute brain injury (ABI).;,citation_author=Chiara Robba;,citation_author=Daniele Poole;,citation_author=Molly McNett;,citation_author=Karim Asehnoune;,citation_author=Julian Bösel;,citation_author=Nicolas Bruder;,citation_author=Arturo Chieregato;,citation_author=Raphael Cinotti;,citation_author=Jacques Duranteau;,citation_author=Sharon Einav;,citation_author=Ari Ercole;,citation_author=Niall Ferguson;,citation_author=Claude Guerin;,citation_author=Ilias I. Siempos;,citation_author=Pedro Kurtz;,citation_author=Nicole P. Juffermans;,citation_author=Jordi Mancebo;,citation_author=Luciana Mascia;,citation_author=Victoria McCredie;,citation_author=Nicolas Nin;,citation_author=Mauro Oddo;,citation_author=Paolo Pelosi;,citation_author=Alejandro A. Rabinstein;,citation_author=Ary Serpa Neto;,citation_author=David B. Seder;,citation_author=Markus B. Skrifvars;,citation_author=Jose I. Suarez;,citation_author=Fabio Silvio Taccone;,citation_author=Mathieu Jagt;,citation_author=Giuseppe Citerio;,citation_author=Robert D. Stevens;,citation_publication_date=2020-12;,citation_cover_date=2020-12;,citation_year=2020;,citation_issue=12;,citation_doi=10.1007/s00134-020-06283-0;,citation_issn=1432-1238;,citation_volume=46;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Monitoring cerebral oxygenation in acute brain-injured patients;,citation_author=Chiara Robba;,citation_author=Fabio S. Taccone;,citation_author=Giuseppe Citerio;,citation_publication_date=2022-10;,citation_cover_date=2022-10;,citation_year=2022;,citation_issue=10;,citation_doi=10.1007/s00134-022-06788-w;,citation_issn=0342-4642, 1432-1238;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Oxygen targets and 6-month outcome after out of hospital cardiac arrest: A pre-planned sub-analysis of the targeted hypothermia versus targeted normothermia after Out-of-Hospital Cardiac Arrest (TTM2) trial;,citation_abstract=Abstract Background Optimal oxygen targets in patients resuscitated after cardiac arrest are uncertain. The primary aim of this study was to describe the values of partial pressure of oxygen values (PaO 2 ) and the episodes of hypoxemia and hyperoxemia occurring within the first 72&nbsp;h of mechanical ventilation in out of hospital cardiac arrest (OHCA) patients. The secondary aim was to evaluate the association of PaO 2 with patients’ outcome. Methods Preplanned secondary analysis of the targeted hypothermia versus targeted normothermia after OHCA (TTM2) trial. Arterial blood gases values were collected from randomization every 4&nbsp;h for the first 32&nbsp;h, and then, every 8&nbsp;h until day 3. Hypoxemia was defined as PaO 2  &amp;amp;amp;lt; 60&nbsp;mmHg and severe hyperoxemia as PaO 2  &amp;gt; 300&nbsp;mmHg. Mortality and poor neurological outcome (defined according to modified Rankin scale) were collected at 6&nbsp;months. Results 1418 patients were included in the analysis. The mean age was 64  14&nbsp;years, and 292 patients (20.6%) were female. 24.9% of patients had at least one episode of hypoxemia, and 7.6% of patients had at least one episode of severe hyperoxemia. Both hypoxemia and hyperoxemia were independently associated with 6-month mortality, but not with poor neurological outcome. The best cutoff point associated with 6-month mortality for hypoxemia was 69&nbsp;mmHg (Risk Ratio, RR = 1.009, 95% CI 0.93–1.09), and for hyperoxemia was 195&nbsp;mmHg (RR = 1.006, 95% CI 0.95–1.06). The time exposure, i.e., the area under the curve (PaO 2 -AUC), for hyperoxemia was significantly associated with mortality ( p  = 0.003). Conclusions In OHCA patients, both hypoxemia and hyperoxemia are associated with 6-months mortality, with an effect mediated by the timing exposure to high values of oxygen. Precise titration of oxygen levels should be considered in this group of patients. Trial registration : clinicaltrials.gov NCT02908308 , Registered September 20, 2016.;,citation_author=Chiara Robba;,citation_author=Rafael Badenes;,citation_author=Denise Battaglini;,citation_author=Lorenzo Ball;,citation_author=Filippo Sanfilippo;,citation_author=Iole Brunetti;,citation_author=Janus Christian Jakobsen;,citation_author=Gisela Lilja;,citation_author=Hans Friberg;,citation_author=Pedro David Wendel-Garcia;,citation_author=Paul J. Young;,citation_author=Glenn Eastwood;,citation_author=Michelle S. Chew;,citation_author=Johan Unden;,citation_author=Matthew Thomas;,citation_author=Michael Joannidis;,citation_author=Alistair Nichol;,citation_author=Andreas Lundin;,citation_author=Jacob Hollenberg;,citation_author=Naomi Hammond;,citation_author=Manoj Saxena;,citation_author=Annborn Martin;,citation_author=Miroslav Solar;,citation_author=Fabio Silvio Taccone;,citation_author=Josef Dankiewicz;,citation_author=Niklas Nielsen;,citation_author=Anders Morten Grejs;,citation_author=Florian Ebner;,citation_author=Paolo Pelosi;,citation_author=TTM2 Trial collaborators;,citation_author=Jan Bělohlávek;,citation_author=Clifton Callaway;,citation_author=Alain Cariou;,citation_author=Tobias Cronberg;,citation_author=David Erlinge;,citation_author=Jan Hovdenes;,citation_author=Hans Kirkegaard;,citation_author=Helena Levin;,citation_author=Matt P. G. Morgan;,citation_author=Per Nordberg;,citation_author=Mauro Oddo;,citation_author=Christian Rylander;,citation_author=Christian Storm;,citation_author=Susann Ullén;,citation_author=Matt P. Wise;,citation_author=Kathy Rowan;,citation_author=David Harrison;,citation_author=Paul Mouncey;,citation_author=Manu Shankar-Hari;,citation_author=Duncan Young;,citation_author=Theis Lange;,citation_author=Karolina Palmér;,citation_author=Ulla-Britt Karlsson;,citation_author=Simon Heissler;,citation_author=Frances Bass;,citation_author=John Myburgh;,citation_author=Colman Taylor;,citation_author=Adele Bellino;,citation_author=Marwa Abel-all;,citation_author=Ben Finfer;,citation_author=Carolyn Koch;,citation_author=Yang Li;,citation_author=Anne O’Connor;,citation_author=Julia Pilowsky;,citation_author=Tina Schneider;,citation_author=Anna Tippett;,citation_author=Bridget Ady;,citation_author=Tessa Broadley;,citation_author=Amanda Brown;,citation_author=Liz Melgaard;,citation_author=Mimi Morgan;,citation_author=Vanessa Singh;,citation_author=Rebecca Symons;,citation_author=Kathrin Becker;,citation_author=Nathalie Sante;,citation_author=Vendula Saleova;,citation_author=Silvie Zerzanova;,citation_author=Samia Sefir-Kribel;,citation_author=Ute Lübeck;,citation_author=Martina Carrara;,citation_author=Kathryn Fernando;,citation_author=Diane Mackle;,citation_author=Leanlove Navarra;,citation_author=Judith Riley;,citation_author=Elin Westerheim;,citation_author=Marianne Flatebø;,citation_author=Ameldina Ceric;,citation_author=Zana Haxhija;,citation_author=Lovisa Terling;,citation_author=Lena Bossmar;,citation_author=Liz Jergle;,citation_author=Helén Holm Månsson;,citation_author=Samia Abed Maillard;,citation_author=Andreja Vujicic Zagar;,citation_author=Christina Jodlauk;,citation_author=Jennifer Scrivens;,citation_author=Kate Ainscough;,citation_author=Ciara Fahey;,citation_author=Rinaldo Bellomo;,citation_author=Leah Peck;,citation_author=Helen Young;,citation_author=Winston Cheung;,citation_author=Rosalba Cross;,citation_author=Michael Hayes;,citation_author=Nitin Jain;,citation_author=Mark Kol;,citation_author=Asim Shah;,citation_author=Atul Wagh;,citation_author=Helen Wong;,citation_author=F. Eduardo Martinez;,citation_author=Gail Brinkerhoff;,citation_author=Dustin Bush;,citation_author=Antony Stewart;,citation_author=Anders Aneman;,citation_author=Lien Lombardo;,citation_author=Peter McCanny;,citation_author=James Penketh;,citation_author=Ian Seppelt;,citation_author=Rebecca Gresham;,citation_author=Julie Lowrey;,citation_author=Kristy Masters;,citation_author=Christina Whitehead;,citation_author=James Walsham;,citation_author=Meg Harward;,citation_author=Josephine Mackay;,citation_author=Jason Meyer;,citation_author=Emma Saylor;,citation_author=Ellen Venz;,citation_author=Krista Wetzig;,citation_author=Wade Stedman;,citation_author=Angela Ashelford;,citation_author=Sharon Mar;,citation_author=Miyuki Tokumitsu;,citation_author=Elizabeth Yarad;,citation_author=Hergen Buscher;,citation_author=Claire Reynolds;,citation_author=Andrew Udy;,citation_author=Aidan Burrell;,citation_author=Jasmin Collins;,citation_author=Dashiell Gantner;,citation_author=Victoria Emma-Leah Martin;,citation_author=Phoebe Mccracken;,citation_author=Vinodh Nanjayya;,citation_author=Alexander Sacha Richardson;,citation_author=Meredith Young;,citation_author=Angaj Ghosh;,citation_author=Simone Said;,citation_author=Ronny Beer;,citation_author=Frank Hartig;,citation_author=Raimund Helbok;,citation_author=Sebastian Klein;,citation_author=Andreas Peer;,citation_author=Jacques Creteur;,citation_author=Dominique Durand;,citation_author=Matthias Dupont;,citation_author=Sigrid Christiaens;,citation_author=Carola Claes;,citation_author=Sebastiaan Deckx;,citation_author=Bert Ferdinande;,citation_author=Sanne Lenaerts;,citation_author=Wilifred Mullens;,citation_author=Sarah Stroobants;,citation_author=Evi Theunissen;,citation_author=David Verhaert;,citation_author=Ondřej Šmíd;,citation_author=Marek Flaksa;,citation_author=David Kemlink;,citation_author=Jan Malík;,citation_author=Michal Otáhal;,citation_author=Jan Rulíšek;,citation_author=Michal Šíranec;,citation_author=Zdeněk Stach;,citation_author=Anna Valeriánová;,citation_author=Petra Zavadilova;,citation_author=Miroslav Solař;,citation_author=Róber Bánszky;,citation_author=Jana Červená;,citation_author=Renata Černá Pařízková;,citation_author=Libor Šimůnek;,citation_author=Filip Varhaník;,citation_author=Jiří Karásek;,citation_author=Matěj Strýček;,citation_author=Anders Grejs;,citation_author=Steffen Christensen;,citation_author=Peter Juhl-Olsen;,citation_author=Ida Katrine Thomsen;,citation_author=Lisa Gregersen Østergaard;,citation_author=Albert Cao;,citation_author=Pierre Dupland;,citation_author=Ariane Gavaud;,citation_author=Paul Jaubert;,citation_author=Mathieu Jozwiak;,citation_author=Nathalie Marin;,citation_author=Guillaume Savary;,citation_author=Nicolas Deye;,citation_author=Bruno Megarbane;,citation_author=Pierre Mora;,citation_author=Laetitia Sutterlin;,citation_author=Stephane Legriel;,citation_author=Hugo Bellut;,citation_author=Alexis Ferre;,citation_author=Guillaume Lacave;,citation_author=Marine Paul;,citation_author=Jean-Baptiste Lascarrou;,citation_author=Emmanuel Canet;,citation_author=Charlotte Garret;,citation_author=Arnaud Felix Miaihle;,citation_author=Jean Reignier;,citation_author=Philippe Vignon;,citation_author=Thomas Daix;,citation_author=Arnaud Desachy;,citation_author=Bruno Evrard;,citation_author=Bruno Francois;,citation_author=Anne-Laure Fedou;,citation_author=Marine Goudelin;,citation_author=Christoph Leithner;,citation_author=Jens Nee;,citation_author=Kaspar Josche Streitberger;,citation_author=Giulia Bonatti;,citation_author=Iacopo Firpo;,citation_author=Paolo Frisoni;,citation_author=Arianna Iachi;,citation_author=Simona Maiani;,citation_author=Maura Mandelli;,citation_author=Fabio Tarantino;,citation_author=Alberto Barbieri;,citation_author=Elisabetta Bertellini;,citation_author=Enrico Giuliani;,citation_author=Gabriele Melegari;,citation_author=Erik Roman-Pognuz;,citation_author=Giorgio Berlot;,citation_author=Umberto Lucangelo;,citation_author=Elisabetta Macchini;,citation_author=Vibeke Aune;,citation_author=Tomas Drægni;,citation_author=Simon Jacobsen;,citation_author=Søren Pieschke;,citation_author=Åse Rasmussen;,citation_author=Gro Ringstad Akselsen;,citation_author=Halvor Langeland;,citation_author=Daniel Bergum;,citation_author=Therese M Erbe;,citation_author=Pål Klepstad;,citation_author=Helle M Næss;,citation_author=Roy Bjørkholt Olsen;,citation_author=Lena Eriksen Skjelnes;,citation_author=Marius Holen;,citation_author=Joakim Iver Post;,citation_author=Rune Fanebust;,citation_author=Linda Hårteig Sørensen;,citation_author=Ken Åge Kårstad;,citation_author=CarstenFredrik Wickman;,citation_author=Colin Barnes;,citation_author=Ben Barry;,citation_author=Nina Beehre;,citation_author=Dick Dinsdale;,citation_author=Sam Edney;,citation_author=Anna Hunt;,citation_author=Harriet Judd;,citation_author=Charlotte Latimer-Bell;,citation_author=Cassie Lawrence;,citation_author=James Moore;,citation_author=Shaanti Olatunji;,citation_author=Alex Psirides;,citation_author=Chelsea Robinson;,citation_author=Kate Tietjens;,citation_author=Jason Wright;,citation_author=David Knight;,citation_author=Brandon Birker;,citation_author=David Bowie;,citation_author=Tara Burke;,citation_author=David Closey;,citation_author=Rosalind Crombie;,citation_author=Neil Davidson;,citation_author=Seton Henderson;,citation_author=Louise Hitchings;,citation_author=James McKay;,citation_author=Jan Mehrtens;,citation_author=Emmeline Minto;,citation_author=Stacey Morgan;,citation_author=Anna Morris;,citation_author=Jay Ritzemar-Carter;,citation_author=Jessica Roberts;,citation_author=Geoffrey Shaw;,citation_author=Katherine Townend;,citation_author=Kymbalee Vander Heyden;,citation_author=Marita Ahlqvist;,citation_author=Roman Desta Lindgren;,citation_author=Ingrid Eiving;,citation_author=Patrik Martner;,citation_author=Elisabeth Myhrman;,citation_author=Birgitta Ryding;,citation_author=Joachim Düring;,citation_author=Mattias Bergström;,citation_author=Mattias Bohm;,citation_author=Ingrid Didriksson;,citation_author=Petrea Frid;,citation_author=Katarina Heimburg;,citation_author=Marina Larsson;,citation_author=Oscar Lundberg;,citation_author=Stefan Olsson Hau;,citation_author=Simon Schmidbauer;,citation_author=Ola Borgquist;,citation_author=Anne Adolfsson;,citation_author=Anna Bjärnroos;,citation_author=Erik Blennow-Nordström;,citation_author=Irina Dragancea;,citation_author=Thomas Kander;,citation_author=Anna Lybeck;,citation_author=Gustav Mattiasson;,citation_author=Olof Persson;,citation_author=Malin Rundgren;,citation_author=Susann Schrey;,citation_author=Erik Westhall;,citation_author=Martin Annborn;,citation_author=Sara Andertun;,citation_author=Nerida Gustavsson;,citation_author=Lisa Hassel;,citation_author=Jesper Johnsson;,citation_author=Marie Nelderup;,citation_author=Heléne Petersson;,citation_author=Jörgen Petersson;,citation_author=Frideriki Stafilidou;,citation_author=Johan Undén;,citation_author=Frida Antonsson;,citation_author=Git Bergman;,citation_author=Jörgen Gamroth;,citation_author=Maria Meirik;,citation_author=Katarina Rudolfsson;,citation_author=Helena Sandberg;,citation_author=Martin Thorsson;,citation_author=Kristin Savolainen;,citation_author=Maria Hansbo;,citation_author=Malin Helliksson;,citation_author=Björne Nödtveidt;,citation_author=Johan Sanner;,citation_author=Victoria Sem;,citation_author=Camilla Sund Lindquist;,citation_author=Akil Awad;,citation_author=Anna-Sofia Börjesson;,citation_author=Malin Hedberg;,citation_author=Mia Henning;,citation_author=Per Petersen;,citation_author=Emelia Dahlberg;,citation_author=Johan Forshammar;,citation_author=Veronica Svensson;,citation_author=Michael Wanecek;,citation_author=Håkan Eskilsson;,citation_author=Daniel Rodriguez-Santos;,citation_author=Åsa Appelqvist;,citation_author=Henrietta Jidbratt;,citation_author=Elisabeth Johansson;,citation_author=Lars Kiszakiewicz;,citation_author=Åsa Nilsson;,citation_author=Sinnika Olsson;,citation_author=Anders Paulsson;,citation_author=Urszula Stempel;,citation_author=Andreas Thoren;,citation_author=Stefan Persson;,citation_author=Ida Berglund;,citation_author=Eric Bergström;,citation_author=Cathrine Törnqvist;,citation_author=Ingela Östman;,citation_author=Sten Rubertsson;,citation_author=Ing-Marie Larsson;,citation_author=Elin Söderman;,citation_author=Ewa Wallin;,citation_author=Joanna Wessbergh;,citation_author=Thomas Halliday;,citation_author=Filippa Engvall;,citation_author=Nawfel Ben-Hamouda;,citation_author=Adriano Bernini;,citation_author=Pierre-Nicolas Carron;,citation_author=Philippe Eckert;,citation_author=Eva Favre;,citation_author=John-Paul Miroz;,citation_author=Paola Morelli;,citation_author=Olivier Muller;,citation_author=Jan Novi;,citation_author=Andrea Rosseti;,citation_author=Madeleine Schnorf;,citation_author=Matthias Haenggi;,citation_author=Anja Levis;,citation_author=Sandra Nansoz;,citation_author=Marianne Roth &amp;amp; Team;,citation_author=Nicole Söll;,citation_author=Claudia Schrag;,citation_author=Mensur Alicajic;,citation_author=Philipp Baier;,citation_author=Joel Dütschler;,citation_author=Dominique Flügel;,citation_author=Edith Fässler;,citation_author=Ruth Gamio-Veis;,citation_author=Marc Güpfert;,citation_author=Yvonne Hilpertshauser;,citation_author=Stefan Hägele-Link;,citation_author=Gian-Reto Kleger;,citation_author=Peter Krähenmann;,citation_author=Maria Elisabeth Mair;,citation_author=Nadja Schai;,citation_author=Christoph Strohmaier;,citation_author=Peter Tangl;,citation_author=Dominik Zieglgänsberger;,citation_author=Marco Maggiorini;,citation_author=Gabriele Claus;,citation_author=Gabi Consani-Vogel;,citation_author=Lukas Imbach;,citation_author=Samira Kaiser;,citation_author=Eva-Maria Kleinert;,citation_author=Pedro David Wendel Garcia;,citation_author=Tiziano Cassina;,citation_author=Pamela Agazzi;,citation_author=Bruno Capelli;,citation_author=Gabriele Casso;,citation_author=Martino Regazzi;,citation_author=Hervé Schlotterbeck;,citation_author=Gabriele Via;,citation_author=Michele Villa;,citation_author=Jenny Brooks;,citation_author=Eve Cocks;,citation_author=Jade Cole;,citation_author=Jacqueline Curtin;,citation_author=Michelle Davies;,citation_author=Rhys Davies;,citation_author=Stephen Fernandez;,citation_author=Julie Highfield;,citation_author=Helen Hill;,citation_author=Lydia Pennant;,citation_author=Sofia Rose;,citation_author=Emma Thomas;,citation_author=Angharad Williams;,citation_author=Peter McGuigan;,citation_author=Stephen Haffey;,citation_author=Aisling O’Neill;,citation_author=Kathryn Ward;,citation_author=Jeremy Bewley;,citation_author=Anna Chillingworth;,citation_author=Julie Cloake;,citation_author=Libby Cole;,citation_author=Hilary Galvin;,citation_author=Zoe Garland;,citation_author=Lisa Grimmer;,citation_author=Bethany Gumbrill;,citation_author=Lucy Howie;,citation_author=Rebekah Johnson;,citation_author=Chloe Searles;,citation_author=Agnieszka Skorko;,citation_author=Katie Sweet;,citation_author=Victoria Taylor;,citation_author=Denise Webster;,citation_author=Thomas Keeble;,citation_author=Gill Adams;,citation_author=Rajesh K. Aggarwal;,citation_author=Jo-Anne Cartwright;,citation_author=Steven Church;,citation_author=Gerald J. Clesham;,citation_author=John R. Davies;,citation_author=Kelly Farrell;,citation_author=Reto Gamma;,citation_author=Jane Harding;,citation_author=Rohan Jagathesan;,citation_author=Alamgir Kabir;,citation_author=Paul A. Kelly;,citation_author=Lauren Kittridge;,citation_author=Maria Maccaroni;,citation_author=Gracie Maloney;,citation_author=Marco Mion;,citation_author=Naveen Nain;,citation_author=Raghunath Nalgirkar;,citation_author=Gyanesh Namjoshi;,citation_author=Stacey Pepper;,citation_author=Emily Redman;,citation_author=Jeremy Sayer;,citation_author=Amanda Solesbury;,citation_author=Kare H. Tang;,citation_author=Sali Urovi;,citation_author=Kunal Waghmare;,citation_author=Noel Watson;,citation_author=Teresa Webber;,citation_author=Peter Isherwood;,citation_author=Conor Bentley;,citation_author=Colin Bergin;,citation_author=Ronald Carrera;,citation_author=Amy Clark;,citation_author=Lauren Cooper;,citation_author=Liesl Despy;,citation_author=Natalie Dooley;,citation_author=Karen Ellis;,citation_author=Emma Fellows;,citation_author=Stephanie Goundry;,citation_author=Samantha Harkett;,citation_author=Christopher McGhee;,citation_author=Aoife Neal;,citation_author=Hazel Smith;,citation_author=Catherine Snelson;,citation_author=Elaine Spruce;,citation_author=Tony Whitehouse;,citation_author=Kamal Yakoub;,citation_author=Andrew Walden;,citation_author=Shauna Bartley;,citation_author=Parminder Bhuie;,citation_author=Matthew Frise;,citation_author=Nicola Jacques;,citation_author=Liza Keating;,citation_author=David Pogson;,citation_author=Zoe Daly;,citation_author=Steve Rose;,citation_author=Jonathan Bannard-Smith;,citation_author=Rachael Quayle;,citation_author=Nigel Chee;,citation_author=Nina Barratt;,citation_author=Katie Bowman;,citation_author=Debbie Branney;,citation_author=Elizabeth Howe;,citation_author=Maria Letts;,citation_author=Sally Pitts;,citation_author=Luke Vamplew;,citation_author=Clifton W. Callaway;,citation_author=Sara Difiore Sprouse;,citation_author=Ankur A. Doshi;,citation_author=Jennifer Fugate;,citation_author=Amy M. Headlee;,citation_author=Eelco F. M. Wijdicks;,citation_publication_date=2022-10;,citation_cover_date=2022-10;,citation_year=2022;,citation_issue=1;,citation_doi=10.1186/s13054-022-04186-8;,citation_issn=1364-8535;,citation_volume=26;,citation_language=en-US;,citation_journal_title=Critical Care;">
<meta name="citation_reference" content="citation_title=Data, Design, and Background Knowledge in Etiologic Inference:;,citation_author=James M. Robins;,citation_publication_date=2001-05;,citation_cover_date=2001-05;,citation_year=2001;,citation_issue=3;,citation_doi=10.1097/00001648-200105000-00011;,citation_issn=1044-3983;,citation_volume=12;,citation_language=en-US;,citation_journal_title=Epidemiology;">
<meta name="citation_reference" content="citation_title=Hospital Prices for Physician-Administered Drugs for Patients with Private Insurance;,citation_abstract=BACKGROUND Hospitals can leverage their position between the ultimate buyers and sellers of drugs to retain a substantial share of insurer pharmaceutical expenditures. METHODS In this study, we used 2020–2021 national Blue Cross Blue Shield claims data regarding patients in the United States who had drug-infusion visits for oncologic conditions, inflammatory conditions, or blood-cell deficiency disorders. Markups of the reimbursement prices were measured in terms of amounts paid by Blue Cross Blue Shield plans to hospitals and physician practices relative to the amounts paid by these providers to drug manufacturers. Acquisition-price reductions in hospital payments to drug manufacturers were measured in terms of discounts under the federal 340B Drug Pricing Program. We estimated the percentage of Blue Cross Blue Shield drug spending that was received by drug manufacturers and the percentage retained by provider organizations. RESULTS The study included 404,443 patients in the United States who had 4,727,189 druginfusion visits. The median price markup (defined as the ratio of the reimbursement price to the acquisition price) for hospitals eligible for 340B discounts was 3.08 (interquartile range, 1.87 to 6.38). After adjustment for drug, patient, and geographic factors, price markups at hospitals eligible for 340B discounts were 6.59 times (95% confidence interval [CI], 6.02 to 7.16) as high as those in independent physician practices, and price markups at noneligible hospitals were 4.34 times (95% CI, 3.77 to 4.90) as high as those in physician practices. Hospitals eligible for 340B discounts retained 64.3% of insurer drug expenditures, whereas hospitals not eligible for 340B discounts retained 44.8% and independent physician practices retained 19.1%. CONCLUSIONS This study showed that hospitals imposed large price markups and retained a substantial share of total insurer spending on physician-administered drugs for patients with private insurance. The effects were especially large for hospitals eligible for discounts under the federal 340B Drug Pricing Program on acquisition costs paid to manufacturers. (Funded by Arnold Ventures and the National Institute for Health Care Management.);,citation_author=James C. Robinson;,citation_author=Christopher Whaley;,citation_author=Sanket S. Dhruva;,citation_publication_date=2024-01;,citation_cover_date=2024-01;,citation_year=2024;,citation_issue=4;,citation_doi=10.1056/NEJMsa2306609;,citation_issn=0028-4793, 1533-4406;,citation_volume=390;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Reclaiming the review of systems: An opportunity for medical educators;,citation_author=Adam Rodman;,citation_author=Gurpreet Dhaliwal;,citation_issue=n/a;,citation_doi=10.1002/jhm.13144;,citation_issn=1553-5606;,citation_volume=n/a;,citation_language=en-US;,citation_journal_title=Journal of Hospital Medicine;">
<meta name="citation_reference" content="citation_title=Reflection on modern methods: Constructing directed acyclic graphs (DAGs) with domain experts for health services research;,citation_abstract=Directed acyclic graphs (DAGs) are a useful tool to represent, in a graphical format, researchers’ assumptions about the causal structure among variables while providing a rationale for the choice of confounding variables to adjust for. With origins in the field of probabilistic graphical modelling, DAGs are yet to be widely adopted in applied health research, where causal assumptions are frequently made for the purpose of evaluating health services initiatives. In this context, there is still limited practical guidance on how to construct and use DAGs. Some progress has recently been made in terms of building DAGs based on studies from the literature, but an area that has received less attention is how to create DAGs from information provided by domain experts, an approach of particular importance when there is limited published information about the intervention under study. This approach offers the opportunity for findings to be more robust and relevant to patients, carers and the public, and more likely to inform policy and clinical practice. This article draws lessons from a stakeholder workshop involving patients, health care professionals, researchers, commissioners and representatives from industry, whose objective was to draw DAGs for a complex intervention—online consultation, i.e. written exchange between the patient and health care professional using an online system—in the context of the English National Health Service. We provide some initial, practical guidance to those interested in engaging with domain experts to develop DAGs.;,citation_author=Daniela Rodrigues;,citation_author=Noemi Kreif;,citation_author=Anna Lawrence-Jones;,citation_author=Mauricio Barahona;,citation_author=Erik Mayer;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_doi=10.1093/ije/dyac135;,citation_issn=0300-5771;,citation_journal_title=International Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Effect modification in a clinical trial should be assessed through interaction terms, not prognostic modelling;,citation_author=Roberta M. L. Roepke;,citation_author=Pedro V. Mendes;,citation_author=Luis C. M. Cardozo Junior;,citation_author=Marcelo Park;,citation_author=Bruno A. M. P. Besen;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_issue=8;,citation_doi=10.1007/s00134-022-06741-x;,citation_issn=1432-1238;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Cluster randomised trials of prescribing policy: An ethical approach to generating drug safety evidence? A discussion of the ethical application of a new research method;,citation_abstract=For most chronic medical conditions, multiple medications are available and prescribers often have limited evidence about which therapy is likely to be the most effective and safe for an individual patient. As many patients are exposed every day to medicines that may be less effective than available alternatives, this is of public health importance. Cluster randomised trials of prescribing policy offer an opportunity to rapidly obtain evidence of comparative effectiveness and safety. These trials can pose a low risk to patients and cause minimal disruption to usual care. Despite the potential scientific value of this approach, there remain valid concerns about consent, medication switching and the use of routinely collected data in research. We discuss these concerns with reference to an ongoing pilot study (Evaluating Diuretics in Normal Care (EVIDENCE) - a cluster randomised evaluation of hypertension prescribing policy, ISRCTN 46635087, registered 11 August 2017).;,citation_author=Amy Rogers;,citation_author=Gillian Craig;,citation_author=Angela Flynn;,citation_author=Isla Mackenzie;,citation_author=Thomas MacDonald;,citation_author=Alexander Doney;,citation_publication_date=2020-12;,citation_cover_date=2020-12;,citation_year=2020;,citation_issue=1;,citation_doi=10.1186/s13063-020-04357-4;,citation_issn=1745-6215;,citation_volume=21;,citation_language=en-US;,citation_journal_title=Trials;">
<meta name="citation_reference" content="citation_title=Evaluating Diuretics in Normal Care (EVIDENCE): Protocol of a cluster randomised controlled equivalence trial of prescribing policy to compare the effectiveness of thiazide-type diuretics in hypertension;,citation_abstract=Introduction: Healthcare systems must use treatments that are effective and safe. Regulators licensed many currently used older medications before introducing the stringent evidential requirements imposed on modern treatments. Also, there has been little encouragement to carry out within-class, head-to-head comparisons of licensed medicines. For commonly prescribed drugs, even small differences in effectiveness or safety could have significant public health implications. However, conventional clinical trials that randomise individual subjects are costly and unwieldy. Such trials are also often criticised as having low external validity. We describe an approach to rapidly generate externally valid evidence of comparative safety and effectiveness using the example of two widely used diuretics for the management of hypertension.;,citation_author=Amy Rogers;,citation_author=Angela Flynn;,citation_author=Isla S. Mackenzie;,citation_author=Lewis McConnachie;,citation_author=Rebecca Barr;,citation_author=Robert W. V. Flynn;,citation_author=Steve Morant;,citation_author=Thomas M. MacDonald;,citation_author=Alexander Doney;,citation_publication_date=2021-12;,citation_cover_date=2021-12;,citation_year=2021;,citation_issue=1;,citation_doi=10.1186/s13063-021-05782-9;,citation_issn=1745-6215;,citation_volume=22;,citation_language=en-US;,citation_journal_title=Trials;">
<meta name="citation_reference" content="citation_title=Physicians’ attitudes towards disclosure of prognostic information;,citation_abstract=Objective: To investigate if attitudes towards disclosure of prognostic information vary by speciality, previous experience and demographic factors in a general physician population. Methods: A postal survey among a representative sample of Norwegian physicians across all specialities (N = 1605), using a translated questionnaire previously used to study attitudes towards disclosing prognostic information among US internists. Results: A response rate of 70% was obtained after one reminder. 85% of the responders agreed to the helpfulness of an optimistic attitude. A factor analysis revealed three meaningful factors: “Prognostic communication is stressful”, “Fearing loss of reputation” and “Reinforcement of positive prospects”. In multivariable models significantly more female than male physicians found aspects of prognostication straining (b = 0.143, p &amp;amp;amp;lt; 0.001). Those more experienced in communication of prognostic information towards end of life were less likely to support using reinforcement of positive prospects (b = 0.067, p = 0.001). Conclusion: After years of focusing on patient autonomy and open communication between patient and physician many Norwegian physicians display attitudes that might hide the true content of prognostic information from the patients.;,citation_author=Lotte Rogg;,citation_author=Jon Håvard Loge;,citation_author=Olaf Gjerløw Aasland;,citation_author=Peter Kjær Graugaard;,citation_publication_date=2009-11;,citation_cover_date=2009-11;,citation_year=2009;,citation_issue=2;,citation_doi=10.1016/j.pec.2009.03.007;,citation_issn=07383991;,citation_volume=77;,citation_language=en-US;,citation_journal_title=Patient Education and Counseling;">
<meta name="citation_reference" content="citation_title=That’s a lot to Process! Pitfalls of Popular Path Models;,citation_abstract=Path models to test claims about mediation and moderation are a staple of psychology. But applied researchers may sometimes not understand the underlying causal inference problems and thus endorse conclusions that rest on unrealistic assumptions. In this article, we aim to provide a clear explanation for the limited conditions under which standard procedures for mediation and moderation analysis can succeed. We discuss why reversing arrows or comparing model fit indices cannot tell us which model is the right one, and how tests of conditional independence can at least tell us where our model goes wrong. Causal modeling practices in psychology are far from optimal but may be kept alive by domain norms which demand that every article makes some novel claim about processes and boundary conditions. We end with a vision for a different research culture in which causal inference is pursued in a much slower, more deliberate, and collaborative manner.;,citation_author=Julia M. Rohrer;,citation_author=Paul Hünermund;,citation_author=Ruben C. Arslan;,citation_author=Malte Elson;,citation_publication_date=2021-02;,citation_cover_date=2021-02;,citation_year=2021;,citation_doi=10.31234/osf.io/paeb7;,citation_language=en-US;,citation_publisher=PsyArXiv;">
<meta name="citation_reference" content="citation_title=Thinking Clearly About Correlations and Causation: Graphical Causal Models for Observational Data;,citation_abstract=Correlation does not imply causation; but often, observational data are the only option, even though the research question at hand involves causality. This article discusses causal inference based on observational data, introducing readers to graphical causal models that can provide a powerful tool for thinking more clearly about the interrelations between variables. Topics covered include the rationale behind the statistical control of third variables, common procedures for statistical control, and what can go wrong during their implementation. Certain types of third variables—colliders and mediators—should not be controlled for because that can actually move the estimate of an association away from the value of the causal effect of interest. More subtle variations of such harmful control include using unrepresentative samples, which can undermine the validity of causal conclusions, and statistically controlling for mediators. Drawing valid causal inferences on the basis of observational data is not a mechanistic procedure but rather always depends on assumptions that require domain knowledge and that can be more or less plausible. However, this caveat holds not only for research based on observational data, but for all empirical research endeavors.;,citation_author=Julia M Rohrer;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Clinical applications of the venous excess ultrasound (VExUS) score: Conceptual review and case series;,citation_abstract=The importance of functional right ventricular failure and resultant splanchnic venous congestion has long been under-appreciated and is difficult to assess by traditional physical examination and standard diagnostic imaging. The recent development of the venous excess ultrasound score (VExUS) and growth of point-of-care ultrasound in the last decade has made for a potentially very useful clinical tool. We review the rationale for its use in several pathologies and illustrate with several clinical cases where VExUS was pivotal in clinical management.;,citation_author=Philippe Rola;,citation_author=Francisco Miralles-Aguiar;,citation_author=Eduardo Argaiz;,citation_author=William Beaubien-Souligny;,citation_author=Korbin Haycock;,citation_author=Timur Karimov;,citation_author=Vi Am Dinh;,citation_author=Rory Spiegel;,citation_publication_date=2021-12;,citation_cover_date=2021-12;,citation_year=2021;,citation_issue=1;,citation_doi=10.1186/s13089-021-00232-8;,citation_issn=2524-8987;,citation_volume=13;,citation_language=en-US;,citation_journal_title=The Ultrasound Journal;">
<meta name="citation_reference" content="citation_title=The added value of ordinal analysis in clinical trials: An example in traumatic brain injury;,citation_abstract=Introduction: In clinical trials, ordinal outcome measures are often dichotomized into two categories. In traumatic brain injury (TBI) the 5-point Glasgow outcome scale (GOS) is collapsed into unfavourable versus favourable outcome. Simulation studies have shown that exploiting the ordinal nature of the GOS increases chances of detecting treatment effects. The objective of this study is to quantify the benefits of ordinal analysis in the real-life situation of a large TBI trial. Methods: We used data from the CRASH trial that investigated the efficacy of corticosteroids in TBI patients (n = 9,554). We applied two techniques for ordinal analysis: proportional odds analysis and the sliding dichotomy approach, where the GOS is dichotomized at different cut-offs according to baseline prognostic risk. These approaches were compared to dichotomous analysis. The information density in each analysis was indicated by a Wald statistic. All analyses were adjusted for baseline characteristics. Results: Dichotomous analysis of the six-month GOS showed a non-significant treatment effect (OR = 1.09, 95% CI 0.98 to 1.21, P = 0.096). Ordinal analysis with proportional odds regression or sliding dichotomy showed highly statistically significant treatment effects (OR 1.15, 95% CI 1.06 to 1.25, P = 0.0007 and 1.19, 95% CI 1.08 to 1.30, P = 0.0002), with 2.05-fold and 2.56-fold higher information density compared to the dichotomous approach respectively. Conclusions: Analysis of the CRASH trial data confirmed that ordinal analysis of outcome substantially increases statistical power. We expect these results to hold for other fields of critical care medicine that use ordinal outcome measures and recommend that future trials adopt ordinal analyses. This will permit detection of smaller treatment effects.;,citation_author=Bob Roozenbeek;,citation_author=Hester F Lingsma;,citation_author=Pablo Perel;,citation_author=Phil Edwards;,citation_author=Ian Roberts;,citation_author=Gordon D Murray;,citation_author=Andrew IR Maas;,citation_author=Ewout W Steyerberg;,citation_author=the IMPACT (International Mission on Prognosis and Clinical Trial Design in Traumatic Brain Injury) Study Group and the CRASH (Corticosteroid Randomisation After Significant Head Injury) Trial Collaborators;,citation_publication_date=2011;,citation_cover_date=2011;,citation_year=2011;,citation_issue=3;,citation_doi=10.1186/cc10240;,citation_issn=1364-8535;,citation_volume=15;,citation_language=en-US;,citation_journal_title=Critical Care;">
<meta name="citation_reference" content="citation_title=Effect of Continuous Infusion of Hypertonic Saline vs Standard Care on 6-Month Neurological Outcomes in Patients With Traumatic Brain Injury: The COBI Randomized Clinical Trial;,citation_abstract=Fluid therapy is an important component of care for patients with traumatic brain injury, but whether it modulates clinical outcomes remains unclear.To determine whether continuous infusion of hypertonic saline solution improves neurological outcome at 6 months in patients with traumatic brain injury.Multicenter randomized clinical trial conducted in 9 intensive care units in France, including 370 patients with moderate to severe traumatic brain injury who were recruited from October 2017 to August 2019. Follow-up was completed in February 2020.Adult patients with moderate to severe traumatic brain injury were randomly assigned to receive continuous infusion of 20% hypertonic saline solution plus standard care (n = 185) or standard care alone (controls; n = 185). The 20% hypertonic saline solution was administered for 48 hours or longer if patients remained at risk of intracranial hypertension.The primary outcome was Extended Glasgow Outcome Scale (GOS-E) score (range, 1-8, with lower scores indicating worse functional outcome) at 6 months, obtained centrally by blinded assessors and analyzed with ordinal logistic regression adjusted for prespecified prognostic factors (with a common odds ratio [OR] &amp;amp;amp;gt;1.0 favoring intervention). There were 12 secondary outcomes measured at multiple time points, including development of intracranial hypertension and 6-month mortality.Among 370 patients who were randomized (median age, 44 [interquartile range, 27-59] years; 77 [20.2%] women), 359 (97%) completed the trial. The adjusted common OR for the GOS-E score at 6 months was 1.02 (95% CI, 0.71-1.47; P = .92). Of the 12 secondary outcomes, 10 were not significantly different. Intracranial hypertension developed in 62 (33.7%) patients in the intervention group and 66 (36.3%) patients in the control group (absolute difference, -2.6% [95% CI, -12.3% to 7.2%]; OR, 0.80 [95% CI, 0.51-1.26]). There was no significant difference in 6-month mortality (29 [15.9%] in the intervention group vs 37 [20.8%] in the control group; absolute difference, -4.9% [95% CI, -12.8% to 3.1%]; hazard ratio, 0.79 [95% CI, 0.48-1.28]).Among patients with moderate to severe traumatic brain injury, treatment with continuous infusion of 20% hypertonic saline compared with standard care did not result in a significantly better neurological status at 6 months. However, confidence intervals for the findings were wide, and the study may have had limited power to detect a clinically important difference.ClinicalTrials.gov Identifier: NCT03143751;,citation_author=Antoine Roquilly;,citation_author=Jean Denis Moyer;,citation_author=Olivier Huet;,citation_author=Sigismond Lasocki;,citation_author=Benjamin Cohen;,citation_author=Claire Dahyot-Fizelier;,citation_author=Kevin Chalard;,citation_author=Philippe Seguin;,citation_author=Caroline Jeantrelle;,citation_author=Véronique Vermeersch;,citation_author=Thomas Gaillard;,citation_author=Raphael Cinotti;,citation_author=Dominique Demeure dit Latte;,citation_author=Pierre Joachim Mahe;,citation_author=Mickael Vourc’h;,citation_author=Florian Pierre Martin;,citation_author=Alice Chopin;,citation_author=Celine Lerebourg;,citation_author=Laurent Flet;,citation_author=Anne Chiffoleau;,citation_author=Fanny Feuillet;,citation_author=Karim Asehnoune;,citation_author=Atlanrea Study Group and the Société Française d’Anesthésie Réanimation (SFAR) Research Network;,citation_publication_date=2021-05;,citation_cover_date=2021-05;,citation_year=2021;,citation_issue=20;,citation_doi=10.1001/jama.2021.5561;,citation_issn=0098-7484;,citation_volume=325;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Advance Care Planning in Serious Illness: A Narrative Review;,citation_abstract=Objective. To delineate ACP’s potential benefits and missed opportunities and identify an evidence-informed, clinically relevant path ahead for ACP in serious illness. Methods. We conducted a narrative review merging the best available ACP empirical data, grey literature, and emergent scholarly discourse using a snowball search of PubMed, Medline, and Google Scholar (2000-2022). Findings were informed by our team’s interprofessional clinical and research expertise in serious illness care. Results. Early ACP practices were largely tied to mandated document completion, potentially failing to capture the holistic preferences of patients and surrogates. ACP models focused on serious illness communication rather than documentation show promising patient and clinician results. Ideally, ACP would lead to goal-concordant care even amid the unpredictability of serious illness trajectories. But ACP might also provide a false sense of security that patients’ wishes will be honored and revisited at end-of-life. An iterative, “building block” framework to integrate ACP throughout serious illness is provided alongside clinical practice, research, and policy recommendations. Conclusions. We advocate a balanced approach to ACP, recognizing empirical deficits while acknowledging potential benefits and ethical imperatives (e.g., fostering clinician-patient trust and shared decision-making). We support prioritizing patient/surrogate-centered outcomes with more robust measures to account for interpersonal clinician-patient variables that likely inform ACP efficacy and may better evaluate information gleaned during serious illness encounters. J Pain Symptom Manage 2023;65:e63-e78. © 2022 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.;,citation_author=William E. Rosa;,citation_author=Shigeko Izumi;,citation_author=Donald R. Sullivan;,citation_author=Joshua Lakin;,citation_author=Abby R. Rosenberg;,citation_author=Claire J. Creutzfeldt;,citation_author=Debbie Lafond;,citation_author=Jennifer Tjia;,citation_author=Valerie Cotter;,citation_author=Cara Wallace;,citation_author=Danetta E. Sloan;,citation_author=Dulce Maria Cruz-Oliver;,citation_author=Susan DeSanto-Madeya;,citation_author=Rachelle Bernacki;,citation_author=Thomas W. Leblanc;,citation_author=Andrew S. Epstein;,citation_publication_date=2023-01;,citation_cover_date=2023-01;,citation_year=2023;,citation_issue=1;,citation_doi=10.1016/j.jpainsymman.2022.08.012;,citation_issn=08853924;,citation_volume=65;,citation_language=en-US;,citation_journal_title=Journal of Pain and Symptom Management;">
<meta name="citation_reference" content="citation_title=Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: A randomized clinical trial;,citation_abstract=Purpose: Trials of tocilizumab in patients with severe COVID-19 pneumonia have demonstrated mixed results, and the role of tocilizumab in combination with other treatments is uncertain. Here we evaluated whether tocilizumab plus remdesivir provides greater benefit than remdesivir alone in patients with severe COVID-19 pneumonia. Methods: This randomized, double-blind, placebo-controlled, multicenter trial included patients hospitalized with severe COVID-19 pneumonia requiring &amp;amp;amp;gt; 6 L/min supplemental oxygen. Patients were randomly assigned (2:1 ratio) to receive tocilizumab 8 mg/kg or placebo intravenously plus \leq 10 days of remdesivir. The primary outcome was time from randomization to hospital discharge or “ready for discharge” (defined as category 1, assessed by the investigator on a 7-category ordinal scale of clinical status) to day 28. Patients were followed for 60 days. Results: Among 649 enrolled patients, 434 were randomly assigned to tocilizumab plus remdesivir and 215 to pla-cebo plus remdesivir. 566 patients (88.2%) received corticosteroids during the trial to day 28. Median time from rand-omization to hospital discharge or “ready for discharge” was 14 (95% CI 12–15) days with tocilizumab plus remdesivir and 14 (95% CI 11–16) days with placebo plus remdesivir [log-rank P = 0.74; Cox proportional hazards ratio 0.97 (95% CI 0.78–1.19)]. Serious adverse events occurred in 128 (29.8%) tocilizumab plus remdesivir and 72 (33.8%) placebo plus remdesivir patients; 78 (18.2%) and 42 (19.7%) patients, respectively, died by day 28. Conclusions: Tocilizumab plus remdesivir did not shorten time to hospital discharge or “ready for discharge” to day 28 compared with placebo plus remdesivir in patients with severe COVID-19 pneumonia.;,citation_author=Ivan O. Rosas;,citation_author=George Diaz;,citation_author=Robert L. Gottlieb;,citation_author=Suzana M. Lobo;,citation_author=Philip Robinson;,citation_author=Bradley D. Hunter;,citation_author=Adilson W. Cavalcante;,citation_author=J. Scott Overcash;,citation_author=Nicola A. Hanania;,citation_author=Alan Skarbnik;,citation_author=Julia Garcia-Diaz;,citation_author=Ivan Gordeev;,citation_author=Jordi Carratalà;,citation_author=Oliver Gordon;,citation_author=Emily Graham;,citation_author=Nicholas Lewin-Koh;,citation_author=Larry Tsai;,citation_author=Katie Tuckwell;,citation_author=Huyen Cao;,citation_author=Diana Brainard;,citation_author=Julie K. Olsson;,citation_publication_date=2021-11;,citation_cover_date=2021-11;,citation_year=2021;,citation_issue=11;,citation_doi=10.1007/s00134-021-06507-x;,citation_issn=0342-4642, 1432-1238;,citation_volume=47;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Prevalence, risk factors, and outcomes associated with physical restraint use in mechanically ventilated adults;,citation_abstract=Purpose: The purpose was to describe characteristics and outcomes of restrained and nonrestrained patients enrolled in a randomized trial of protocolized sedation compared with protocolized sedation plus daily sedation interruption and to identify patient and treatment factors associated with physical restraint.;,citation_author=Louise Rose;,citation_author=Lisa Burry;,citation_author=Ranjeeta Mallick;,citation_author=Elena Luk;,citation_author=Deborah Cook;,citation_author=Dean Fergusson;,citation_author=Peter Dodek;,citation_author=Karen Burns;,citation_author=John Granton;,citation_author=Niall Ferguson;,citation_author=John W. Devlin;,citation_author=Marilyn Steinberg;,citation_author=Sean Keenan;,citation_author=Stephen Reynolds;,citation_author=Maged Tanios;,citation_author=Robert A. Fowler;,citation_author=Michael Jacka;,citation_author=Kendiss Olafson;,citation_author=Yoanna Skrobik;,citation_author=Sangeeta Mehta;,citation_publication_date=2016-02;,citation_cover_date=2016-02;,citation_year=2016;,citation_issue=1;,citation_doi=10.1016/j.jcrc.2015.09.011;,citation_issn=08839441;,citation_volume=31;,citation_language=en-US;,citation_journal_title=Journal of Critical Care;">
<meta name="citation_reference" content="citation_title=Subarachnoid Hemorrhage Grading Scales: A Systematic Review;,citation_author=David S. Rosen;,citation_author=R. Loch Macdonald;,citation_publication_date=2005;,citation_cover_date=2005;,citation_year=2005;,citation_issue=2;,citation_doi=10.1385/NCC:2:2:110;,citation_issn=1541-6933;,citation_volume=2;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Prolonged Duration ECMO for ARDS: Futility, Native Lung Recovery, or Transplantation?;,citation_author=Andrew A. Rosenberg;,citation_author=Jonathan W. Haft;,citation_author=Robert Bartlett;,citation_author=Theodore J. Iwashyna;,citation_author=Steven K. Huang;,citation_author=William R. Lynch;,citation_author=Lena M. Napolitano;,citation_publication_date=2013-11;,citation_cover_date=2013-11;,citation_year=2013;,citation_issue=6;,citation_doi=10.1097/MAT.0b013e3182a9e341;,citation_issn=1058-2916;,citation_volume=59;,citation_language=en-US;,citation_journal_title=ASAIO Journal;">
<meta name="citation_reference" content="citation_title=The Counternull Value of an Effect Size: A New Statistic;,citation_author=Robert Rosenthal;,citation_author=Donald B. Rubin;,citation_publication_date=1994;,citation_cover_date=1994;,citation_year=1994;,citation_fulltext_html_url=https://www.jstor.org/stable/40063131;,citation_issue=6;,citation_volume=5;,citation_language=en-US;,citation_journal_title=Psychological Science;">
<meta name="citation_reference" content="citation_title=Seizures, Status Epilepticus, and Continuous EEG in the Intensive Care Unit;,citation_abstract=PURPOSE OF REVIEW: This article discusses the evolving definitions of seizures and status epilepticus in the critical care environment and the role of critical care EEG in both diagnosing seizure activity and serving as a predictive biomarker of clinical trajectory.;,citation_author=Eric S. Rosenthal;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=5;,citation_doi=10.1212/CON.0000000000001012;,citation_issn=1538-6899, 1080-2371;,citation_volume=27;,citation_language=en-US;,citation_journal_title=CONTINUUM: Lifelong Learning in Neurology;">
<meta name="citation_reference" content="citation_title=Data Sharing — A New Era for Research Funded by the U.S. Government;,citation_author=Joseph S. Ross;,citation_author=Joanne Waldstreicher;,citation_author=Harlan M. Krumholz;,citation_publication_date=2023-12;,citation_cover_date=2023-12;,citation_year=2023;,citation_issue=26;,citation_doi=10.1056/NEJMp2308792;,citation_issn=0028-4793, 1533-4406;,citation_volume=389;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Status epilepticus in the ICU;,citation_abstract=Status epilepticus (SE) is a common medical emergency associated with significant morbidity and mortality. Management that follows published guidelines is best suited to improve outcomes, with the most severe cases frequently being managed in the intensive care unit (ICU). Diagnosis of convulsive SE can be made without electroencephalography (EEG), but EEG is required to reliably diagnose nonconvulsive SE. Rapidly narrowing down underlying causes for SE is crucial, as this may guide additional management steps. Causes may range from underlying epilepsy to acute brain injuries such as trauma, cardiac arrest, stroke, and infections. Initial management consists of rapid administration of benzodiazepines and one of the following non-sedating intravenous antiseizure medications (ASM): (fos-)phenytoin, levetiracetam, or valproate; other ASM are increasingly used, such as lacosamide or brivaracetam. SE that continues despite these medications is called refractory, and most commonly treated with continuous infusions of midazolam or propofol. Alternatives include further non-sedating ASM and non-pharmacologic approaches. SE that reemerges after weaning or continues despite management with propofol or midazolam is labeled super-refractory SE. At this step, management may include non-sedating or sedating compounds including ketamine and barbiturates. Continuous video EEG is necessary for the management of refractory and super-refractory SE, as these are almost always nonconvulsive. If possible, management of the underlying cause of seizures is crucial particularly for patients with autoimmune encephalitis. Short-term mortality ranges from 10 to 15% after SE and is primarily related to increasing age, underlying etiology, and medical comorbidities. Refractoriness of treatment is clearly related to outcome with mortality rising from 10% in responsive cases, to 25% in refractory, and nearly 40% in super-refractory SE.;,citation_author=Andrea O. Rossetti;,citation_author=Jan Claassen;,citation_author=Nicolas Gaspard;,citation_publication_date=2023-12;,citation_cover_date=2023-12;,citation_year=2023;,citation_doi=10.1007/s00134-023-07263-w;,citation_issn=1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Overuse of Cardiac Testing;,citation_author=Alan R Roth;,citation_author=Andy Lazris;,citation_author=Sarju Ganatra;,citation_author=Lahey Hospital;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Planning Study Size Based on Precision Rather Than Power:;,citation_abstract=Study size has typically been planned based on statistical power and therefore has been heavily influenced by the philosophy of statistical hypothesis testing. A worthwhile alternative is to plan study size based on precision, for example by aiming to obtain a desired width of a confidence interval for the targeted effect. This article presents formulas for planning the size of an epidemiologic study based on the desired precision of the basic epidemiologic effect measures.;,citation_author=Kenneth J. Rothman;,citation_author=Sander Greenland;,citation_publication_date=2018-09;,citation_cover_date=2018-09;,citation_year=2018;,citation_issue=5;,citation_doi=10.1097/EDE.0000000000000876;,citation_issn=1044-3983;,citation_volume=29;,citation_language=en-US;,citation_journal_title=Epidemiology;">
<meta name="citation_reference" content="citation_title=Rebuttal: When it comes to scientific inference, sometimes a cigar is just a cigar;,citation_author=K. J. Rothman;,citation_author=J. E. Gallacher;,citation_author=E. E. Hatch;,citation_publication_date=2013-08;,citation_cover_date=2013-08;,citation_year=2013;,citation_issue=4;,citation_doi=10.1093/ije/dyt124;,citation_issn=0300-5771, 1464-3685;,citation_volume=42;,citation_language=en-US;,citation_journal_title=International Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Why representativeness should be avoided;,citation_author=K. J. Rothman;,citation_author=J. E. Gallacher;,citation_author=E. E. Hatch;,citation_publication_date=2013-08;,citation_cover_date=2013-08;,citation_year=2013;,citation_issue=4;,citation_doi=10.1093/ije/dys223;,citation_issn=0300-5771, 1464-3685;,citation_volume=42;,citation_language=en-US;,citation_journal_title=International Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Confronting the Frustrations of Negative Clinical Trials in Acute Respiratory Distress Syndrome;,citation_author=Gordon D. Rubenfeld;,citation_publication_date=2015-03;,citation_cover_date=2015-03;,citation_year=2015;,citation_issue=Supplement 1;,citation_doi=10.1513/AnnalsATS.201409-414MG;,citation_issn=2329-6933, 2325-6621;,citation_volume=12;,citation_language=en-US;,citation_journal_title=Annals of the American Thoracic Society;">
<meta name="citation_reference" content="citation_title=Autoimmune Encephalitis in Critical Care: Optimizing Immunosuppression;,citation_abstract=&amp;amp;amp;lt;p&amp;gt;Autoimmune diseases affecting the nervous systems are a common cause of admission to the intensive care unit (ICU). Although there exist several well-described clinical syndromes, patients more commonly present with progressive neurologic dysfunction and laboratory and radiographic evidence of central nervous system (CNS) inflammation. In the critical care setting, the urgency to intervene to prevent permanent damage to the nervous system and secondary injury from the systemic manifestations of these syndromes often conflicts with diagnostic uncertainty. Furthermore, treatment is limited by current therapeutic agents that remain non-specific for individual diseases, especially for those whose pathophysiology remains unclear. Primary autoimmune, paraneoplastic, parainfectious, and iatrogenic neurologic disorders all share the common underlying pathophysiology of an adaptive immune response directed against an antigen within the nervous system. Several different mechanisms of immune dysfunction are responsible for pathogenesis within each of these categories of disease, and it is at this level of pathophysiology that the most effective and appropriate therapeutic decisions are made. In this review, we outline the basic diagnostic and therapeutic principles in the management of autoimmune diseases of the nervous system in the ICU. We approach these disorders not as lists of distinct clinical syndromes or molecular targets of autoimmunity but rather as clusters of syndromes based on these common underlying mechanisms of immune dysfunction. This approach emphasizes early intervention over precise diagnosis. As our understanding of the immune system continues to grow, this framework will allow for a more sophisticated approach to the management of patients with these complex, often devastating but frequently reversible, neurologic illnesses.&amp;lt;/p&amp;gt;;,citation_author=Daniel B. Rubin;,citation_author=Ayush Batra;,citation_author=Ivana Vodopivec;,citation_author=Henrikas Vaitkevicius;,citation_publication_date=2017-12;,citation_cover_date=2017-12;,citation_year=2017;,citation_issue=06;,citation_doi=10.1055/s-0037-1608771;,citation_issn=1069-3424, 1098-9048;,citation_volume=38;,citation_language=en-US;,citation_journal_title=Seminars in Respiratory and Critical Care Medicine;,citation_publisher=Thieme Medical Publishers;">
<meta name="citation_reference" content="citation_title=When to adjust alpha during multiple testing: A consideration of disjunction, conjunction, and individual testing;,citation_abstract=Scientists often adjust their significance threshold (alpha level) during null hypothesis significance testing in order to take into account multiple testing and multiple comparisons. This alpha adjustment has become particularly relevant in the context of the replication crisis in science. The present article considers the conditions in which this alpha adjustment is appropriate and the conditions in which it is inappropriate. A distinction is drawn between three types of multiple testing: disjunction testing, conjunction testing, and individual testing. It is argued that alpha adjustment is only appropriate in the case of disjunction testing, in which at least one test result must be significant in order to reject the associated joint null hypothesis. Alpha adjustment is inappropriate in the case of conjunction testing, in which all relevant results must be significant in order to reject the joint null hypothesis. Alpha adjustment is also inappropriate in the case of individual testing, in which each individual result must be significant in order to reject each associated individual null hypothesis. The conditions under which each of these three types of multiple testing is warranted are examined. It is concluded that researchers should not automatically (mindlessly) assume that alpha adjustment is necessary during multiple testing. Illustrations are provided in relation to joint studywise hypotheses and joint multiway ANOVAwise hypotheses.;,citation_author=Mark Rubin;,citation_publication_date=2021-12;,citation_cover_date=2021-12;,citation_year=2021;,citation_issue=3;,citation_doi=10.1007/s11229-021-03276-4;,citation_issn=1573-0964;,citation_volume=199;,citation_language=en-US;,citation_journal_title=Synthese;">
<meta name="citation_reference" content="citation_title=Association of Long-term Statin Use With the Risk of Intracerebral Hemorrhage: A Danish Nationwide Case-Control Study;,citation_abstract=Background and Objectives A causal relationship between long-term statin use and the risk of intracerebral hemorrhage (ICH) remains uncertain. We investigated the association with statin use before hospital admission for ICH in a Danish population–based, nationwide case-control study.;,citation_author=Daniel Albjerg Rudolph;,citation_author=Stine Munk Hald;,citation_author=Luis Alberto García Rodríguez;,citation_author=Sören Möller;,citation_author=Jesper Hallas;,citation_author=Larry B. Goldstein;,citation_author=David Gaist;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_issue=7;,citation_doi=10.1212/WNL.0000000000200713;,citation_issn=0028-3878, 1526-632X;,citation_volume=99;,citation_language=en-US;,citation_journal_title=Neurology;">
<meta name="citation_reference" content="citation_title=Middle Meningeal Artery Embolization to Treat Chronic Subdural Hematoma;,citation_abstract=Background Chronic subdural hematoma is associated with high rates of perioperative complications and recurrence. Methods The classic treatments are observation or surgical evacuation. Middle meningeal artery embolization is a recently emerging procedure that has evolved as the neuroendovascular community has gained collective experience. This review summarizes the pathophysiology of chronic subdural hematoma, reviews the classic treatment strategies, discusses the advent and use of middle meningeal artery embolization, and describes the contemporary technical approach to middle meningeal artery embolization. Results Embolization has the advantages of targeting the vascular supply of the neomembranes implicated in chronic subdural hematoma pathophysiology and avoiding surgical or bedside drainage in a population associated with significant comorbidities. Conclusions Middle meningeal artery embolization is increasingly used both as an adjunct treatment to surgical evacuation and as a stand-alone method for managing this challenging entity.;,citation_author=Robert F. Rudy;,citation_author=Joshua S. Catapano;,citation_author=Ashutosh P. Jadhav;,citation_author=Felipe C. Albuquerque;,citation_author=Andrew F. Ducruet;,citation_publication_date=2023-01;,citation_cover_date=2023-01;,citation_year=2023;,citation_issue=1;,citation_doi=10.1161/SVIN.122.000490;,citation_volume=3;,citation_journal_title=Stroke: Vascular and Interventional Neurology;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=Evaluation of the antihypertensive effect of nocturnal administration of acetylsalicylic acid: A cross-over randomized clinical trial;,citation_abstract=Objective: Several studies have shown that evening intake of aspirin has antihypertensive effect in healthy adults, which has not been proven in patients with cardiovascular disease, who mostly take aspirin in the morning. We have evaluated the antihypertensive effect of bedtime administration of aspirin in patients with cardiovascular disease already treated for hypertension. Methods: This is a multicenter randomized triple-blind placebo-controlled crossover trial, with hypertensive patients treated with aspirin for secondary prevention. There was a baseline-randomized assignment to 2-month periods of bedtime aspirin (100 mg) first and morning-time aspirin later, or inversely, both periods separated by an open label 2–4 weeks period of morning-time aspirin. At the start and end of each treatment period, a 24-h ambulatory blood pressure monitoring was performed. The main outcome measure was mean 24-h blood pressure. The analyses were performed according to the intentionto-treat principle. Results: Overall, 225 patients were randomized. No significant differences were observed in ambulatory blood pressure by time of intake of usual low doses of aspirin. The mean SBP/DBP was 123.2/69.9 (95% CI 121.58–124.9/68.86–76.86) with bedtime administration and 122.4/68.8 (95% CI 120.76–124.01/67.85–69.83) with daytime administration (P \frac{1}{4} 0.3 and P \frac{1}{4} 0.23 for SBP and DBP, respectively). Conclusion: Administering aspirin at bedtime rather than in the morning does not modify the 24-h ambulatory blood pressure in hypertensive patients in secondary cardiovascular prevention. The trial was registered with ClinicalTrials.gov (number NCT01741922).;,citation_author=Maria Victoria Ruiz Arzalluz;,citation_author=Natalia Burgos-Alonso;,citation_author=Arturo Garcia-Alvarez;,citation_author=Maria Cruz Gomez Fernandez;,citation_author=Ernest Vinyoles;,citation_author=Gonzalo Grandes;,citation_publication_date=2019-02;,citation_cover_date=2019-02;,citation_year=2019;,citation_issue=2;,citation_doi=10.1097/HJH.0000000000001887;,citation_issn=0263-6352;,citation_volume=37;,citation_language=en-US;,citation_journal_title=Journal of Hypertension;">
<meta name="citation_reference" content="citation_title=Use of Mendelian randomization to better understand and treat sepsis;,citation_author=James A. Russell;,citation_author=Nuala J. Meyer;,citation_author=Keith R. Walley;,citation_publication_date=2022-11;,citation_cover_date=2022-11;,citation_year=2022;,citation_issue=11;,citation_doi=10.1007/s00134-022-06778-y;,citation_issn=1432-1238;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Vasopressor therapy in critically ill patients with shock;,citation_abstract=Background: Vasopressors are administered to critically ill patients with vasodilatory shock not responsive to volume resuscitation, and less often in cardiogenic shock, and hypovolemic shock. Objectives: The objectives are to review safety and efficacy of vasopressors, pathophysiology, agents that decrease vasopressor dose, predictive biomarkers, \beta1-blockers, and directions for research. Methods: The quality of evidence was evaluated using Grading of Recommendations Assessment, Development, and Evaluation (GRADE). Results: Vasopressors bind adrenergic: \alpha1, \alpha2, \beta1, \beta2; vasopressin: AVPR1a, AVPR1B, AVPR2; angiotensin II: AG1, AG2; and dopamine: DA1, DA2 receptors inducing vasoconstriction. Vasopressor choice and dose vary because of patients and physician practice. Adverse effects include excessive vasoconstriction, organ ischemia, hyperglycemia, hyperlactatemia, tachycardia, and tachyarrhythmias. No randomized controlled trials of vasopressors showed a significant difference in 28-day mortality rate. Norepinephrine is the first-choice vasopressor in vasodilatory shock after adequate volume resuscitation. Some strategies that decrease norepinephrine dose (vasopressin, angiotensin II) have not decreased 28-day mortality while corticosteroids have decreased 28-day mortality significantly in some (two large trials) but not all trials. In norepinephrine-refractory patients, vasopressin or epinephrine may be added. A new vasopressor, angiotensin II, may be useful in profoundly hypotensive patients. Dobutamine may be added because vasopressors may decrease ventricular contractility. Dopamine is recommended only in bradycardic patients. There are potent vasopressors with limited evidence (e.g. methylene blue, metaraminol) and novel vasopressors in development (selepressin). Conclusions: Norepinephrine is first choice followed by vasopressin or epinephrine. Angiotensin II and dopamine have limited indications. In future, predictive biomarkers may guide vasopressor selection and novel vasopressors may emerge.;,citation_author=James A. Russell;,citation_publication_date=2019-11;,citation_cover_date=2019-11;,citation_year=2019;,citation_issue=11;,citation_doi=10.1007/s00134-019-05801-z;,citation_issn=0342-4642, 1432-1238;,citation_volume=45;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Adapting to a New Normal After Severe Acute Brain Injury: An Observational Cohort Using a Sequential Explanatory Design;,citation_abstract=OBJECTIVES:&nbsp; Treatment decisions following severe acute brain injury need to consider patients’ goals-of-care and long-term outcomes. Using family members as respondents, we aimed to assess patients’ goals-of-care in the ICU and explore the impact of adaptation on survivors who did not reach the level of recovery initially considered acceptable. DESIGN:&nbsp; Prospective, observational, mixed-methods cohort study. SETTING:&nbsp; Comprehensive stroke and level 1 trauma center in Pacific Northwest United States. PARTICIPANTS:&nbsp; Family members of patients with severe acute brain injury in an ICU for greater than 2 days and Glasgow Coma Scale score less than 12. MEASUREMENTS AND MAIN RESULTS:&nbsp; At enrollment, we asked what level of physical and cognitive recovery the patient would find acceptable. At 6 months, we assessed level of recovery through family surveys and chart review. Families of patients whose outcome was below that considered acceptable were invited for semistructured interviews, examined with content analysis. RESULTS:&nbsp; For 184 patients, most family members set patients’ minimally acceptable cognitive recovery at “able to think and communicate” or better (82%) and physical recovery at independence or better (66%). Among 170 patients with known 6-month outcome, 40% had died in hospital. Of 102 survivors, 33% were able to think and communicate, 13% were independent, and 10% died after discharge. Among survivors whose family member had set minimally acceptable cognitive function at “able to think and communicate,” 64% survived below that level; for those with minimally acceptable physical function at independence, 80% survived below that. Qualitative analysis revealed two key themes: families struggled to adapt to a new, yet uncertain, normal and asked for support and guidance with ongoing treatment decisions. CONCLUSIONS AND RELEVANCE:&nbsp; Six months after severe acute brain injury, most patients survived to a state their families initially thought would not be acceptable. Survivors and their families need more support and guidance as they adapt to a new normal and struggle with persistent uncertainty.;,citation_author=Rachel Rutz Voumard;,citation_author=Whitney A. Kiker;,citation_author=Kaley M. Dugger;,citation_author=Ruth A. Engelberg;,citation_author=Gian Domenico Borasio;,citation_author=J. Randall Curtis;,citation_author=Ralf J. Jox;,citation_author=Claire J. Creutzfeldt;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_issue=8;,citation_doi=10.1097/CCM.0000000000004947;,citation_issn=0090-3493;,citation_volume=49;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Perioperative haemodynamic therapy for major gastrointestinal surgery: The effect of a Bayesian approach to interpreting the findings of a randomised controlled trial;,citation_abstract=Objective The traditional approach of null hypothesis testing dominates the design and analysis of randomised controlled trials. This study aimed to demonstrate how a simple Bayesian analysis could have been used to analyse the Optimisation of Perioperative Cardiovascular Management to Improve Surgical Outcome (OPTIMISE) trial to obtain more clinically interpretable results. Design, setting, participants and interventionsThe OPTIMISE trial was a pragmatic, multicentre, observerblinded, randomised controlled trial of 734 high-risk patients undergoing major gastrointestinal surgery in 17 acute care hospitals in the UK. Patients were randomly allocated to a cardiac output-guided haemodynamic therapy algorithm for intravenous fluid and inotropic drug administration during and in the 6 hours following surgery (n=368) or to standard care (n=366). The primary outcome was a binary outcome consisting of a composite of predefined 30-day moderate or major complications and mortality. Methods We repeated the primary outcome analysis of the OPTIMISE trial using Bayesian statistical methods to calculate the probability that the intervention was superior, and the probability that a clinically relevant difference existed. We explored the impact of a flat prior and an evidence-based prior on our analyses. Results Although OPTIMISE was not powered to detect a statistically significant difference between the treatment arms for the observed effect size (relative risk=0.84, 95% CI 0.70 to 1.01; p=0.07), by using Bayesian analyses we were able to demonstrate that there was a 96.9% (flat prior) to 99.5% (evidence-based prior) probability that the intervention was superior to the control. Conclusions The use of a Bayesian analytical approach provided a different interpretation of the findings of the OPTIMISE trial (compared with the original frequentist analysis), and suggested patient benefit from the intervention. Incorporation of information from previous studies provided further evidence of a benefit from the intervention. Bayesian analyses can produce results that are more easily interpretable and relevant to clinicians and policy-makers. Trial registration number ISRCTN04386758; Postresults.;,citation_author=Elizabeth G Ryan;,citation_author=Ewen M Harrison;,citation_author=Rupert M Pearse;,citation_author=Simon Gates;,citation_publication_date=2019-03;,citation_cover_date=2019-03;,citation_year=2019;,citation_issue=3;,citation_doi=10.1136/bmjopen-2018-024256;,citation_issn=2044-6055, 2044-6055;,citation_volume=9;,citation_language=en-US;,citation_journal_title=BMJ Open;">
<meta name="citation_reference" content="citation_title=Incidence and 10-year survival of intracerebral hemorrhage in a population-based registry;,citation_abstract=BACKGROUND AND PURPOSE: The purpose of this study was to evaluate the incidence and prognosis of intracerebral hemorrhage. METHODS: We analyzed data referring to our prospective population-based registry, including patients with a first-ever stroke followed up to 10 years. RESULTS: In a 5-year period, we included 549 patients (247 men and 302 women; mean age+/-SD, 73.6+/-12.5 years) with an intracerebral hemorrhage. The crude annual incidence rate was 36.9 per 100000 (95% CI, 33.8 to 40.0), 32.9 per 100000 when standardized to the 2006 European population, and 15.9 per 100000 when standardized to the world population. The case-fatality rate was 34.6% (95% CI, 30.6 to 38.6) at 7 days; it increased to 50.3% (95% CI, 46.1 to 54.5) at 30 days and to 59.0% (95% CI, 54.9 to 63.1) at 1 year. Diabetes mellitus and posterior fossa hemorrhage were associated with an increased risk of 7- and 30-day mortality, whereas older age was associated with an increased risk of 30-day mortality only. At the Kaplan-Meier analysis, the 10-year survival rate was 24.1% (95% CI, 20.1 to 28.1). CONCLUSIONS: Intracerebral hemorrhage is characterized by a severe prognosis, mostly in the short term. Because of the high proportion of fatal events that occurs early after the stroke, it is mandatory to identify and apply specific therapeutic strategies for patients with intracerebral hemorrhage.;,citation_author=Simona Sacco;,citation_author=Carmine Marini;,citation_author=Danilo Toni;,citation_author=Luigi Olivieri;,citation_author=Antonio Carolei;,citation_publication_date=2009-02;,citation_cover_date=2009-02;,citation_year=2009;,citation_issue=2;,citation_doi=10.1161/STROKEAHA.108.523209;,citation_issn=1524-4628;,citation_pmid=19038914;,citation_volume=40;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=Association Between Vasopressin Rebranding and Utilization in Patients With Septic Shock;,citation_abstract=OBJECTIVES: Vasopressin is suggested as an adjunct to norepinephrine in patients with septic shock. However, after vasopressin was rebranded in November 2014, its cost exponentially increased. Utilization patterns of vasopressin after its rebranding are unclear. The objective of this study was to determine if there is an association between the rebranding of vasopressin in November 2014 and its utilization in vasopressor-dependent patients with severe sepsis or septic shock. DESIGN: Retrospective, multicenter, database study between January 2010 and March 2017. SETTING: Premier Healthcare Database hospitals. PATIENTS: Adult patients admitted to an ICU with severe sepsis or septic shock, who received at least one vasoactive agent for two or more calendar days were included. INTERVENTIONS: The proportion of patients who received vasopressin and vasopressin cost was assessed before and after rebranding, and evaluated with segmented regression. MEASUREMENTS AND MAIN RESULTS: Among 294,733 patients (mean age, 66  15 yr), 27.8% received vasopressin, and ICU mortality was 26.5%. The proportion of patients receiving vasopressin was higher after rebranding (31.2% postrebranding vs 25.8% prerebranding). Before vasopressin rebranding, the quarterly proportion of patients who received vasopressin had an increasing slope (prerebranding slope 0.41% [95% CI, 0.35–0.46%]), with no difference in slope detected after vasopressin rebranding (postrebranding slope, 0.47% [95% CI, 0.29–0.64%]). After vasopressin rebranding, mean vasopressin cost per patient was higher ($527  1,130 vs $77  160), and the quarterly slope of vasopressin cost was higher (change in slope $77.18 [95% CI, $75.73–78.61]). Total vasopressin billed cost postrebranding continually increased by ~$294,276 per quarter from less than $500,000 in Q4 2014 to over $3,000,000 in Q1 2017. CONCLUSIONS: After vasopressin rebranding, utilization continued to increase quarterly despite a significant increase in vasopressin cost. Vasopressin appeared to have price inelastic demand in septic shock.;,citation_author=Gretchen L. Sacha;,citation_author=Tyree H. Kiser;,citation_author=Garth C. Wright;,citation_author=R. William Vandivier;,citation_author=Marc Moss;,citation_author=Ellen L. Burnham;,citation_author=P. Michael Ho;,citation_author=Paul M. Reynolds;,citation_author=Seth R. Bauer;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_doi=10.1097/CCM.0000000000005305;,citation_issn=0090-3493;,citation_volume=Publish Ahead of Print;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Association of Catecholamine Dose, Lactate, and Shock Duration at Vasopressin Initiation With Mortality in Patients With Septic Shock;,citation_abstract=OBJECTIVES: To determine the association of catecholamine dose, lactate concentration, and timing from shock onset at vasopressin initiation with in-hospital mortality. DESIGN: Retrospective, observational study using segmented and multivariable logistic regression to evaluate the associations of catecholamine dose, lactate concentration, and timing from shock onset at vasopressin initiation with in-hospital mortality. SETTING: Multiple hospitals within the Cleveland Clinic Health System. PATIENTS: Adult patients who met criteria for septic shock based on the U.S. Centers for Disease Control and Prevention Adult Sepsis Event definition. INTERVENTIONS: All patients received continuous infusion vasopressin as an adjunct to catecholamine vasopressors. MEASUREMENTS AND MAIN RESULTS: In total, 1,610 patients were included with a mean Acute Physiology and Chronic Health Evaluation III 109.0  35.1 and Sequential Organ Failure Assessment 14.0  3.5; 41% of patients survived the hospital admission. At the time of vasopressin initiation, patients had median (interquartile range) lactate concentration 3.9 mmol/L (2.3–7.2 mmol/L), norepinephrine-equivalent dose 25 g/min (18–40 g/min), and 5.3 hours (2.1–12.2 hr) elapsed since shock onset. The odds of in-hospital mortality increased 20.7% for every 10 g/min increase in norepinephrine-equivalent dose up to 60 g/min at the time of vasopressin initiation (adjusted odds ratio, 1.21 [95% CI, 1.09–1.34]), but no association was detected when the norepinephrine-equivalent dose exceeded 60 g/min (adjusted odds ratio, 0.96 [95% CI, 0.84–1.10]). There was a significant interaction between timing of vasopressin initiation and lactate concentration (p = 0.02) for the association with in-hospital mortality. A linear association between increasing in-hospital mortality was detected for increasing lactate concentration at the time of vasopressin initiation, but no association was detected for time elapsed from shock onset. CONCLUSIONS: Higher norepinephrine-equivalent dose at vasopressin initiation and higher lactate concentration at vasopressin initiation were each associated higher in-hospital mortality in patients with septic shock who received vasopressin.;,citation_author=Gretchen L. Sacha;,citation_author=Simon W. Lam;,citation_author=Lu Wang;,citation_author=Abhijit Duggal;,citation_author=Anita J. Reddy;,citation_author=Seth R. Bauer;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_doi=10.1097/CCM.0000000000005317;,citation_issn=0090-3493;,citation_volume=Publish Ahead of Print;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Accelerated Approval — Taking the FDA’s Concerns Seriously;,citation_author=Rachel E. Sachs;,citation_author=Julie M. Donohue;,citation_author=Stacie B. Dusetzina;,citation_publication_date=2022-07;,citation_cover_date=2022-07;,citation_year=2022;,citation_issue=3;,citation_doi=10.1056/NEJMp2204487;,citation_issn=0028-4793, 1533-4406;,citation_volume=387;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=The arrogance of preventive medicine;,citation_abstract=Preventive medicine displays all 3 elements of arrogance. First, it is aggressively assertive , pursuing symptomless individuals and telling them what they must do to remain healthy. Occasionally invoking the force of law (immunizations, seat belts), it prescribes and proscribes for both individual;,citation_author=David L. Sackett;,citation_publication_date=2002-08;,citation_cover_date=2002-08;,citation_year=2002;,citation_issue=4;,citation_issn=0820-3946, 1488-2329;,citation_pmid=12197692;,citation_volume=167;,citation_language=en-US;,citation_journal_title=CMAJ;,citation_publisher=CMAJ;">
<meta name="citation_reference" content="citation_title=Why did I become a clinician-trialist?;,citation_author=David Sackett;,citation_publication_date=2015-08;,citation_cover_date=2015-08;,citation_year=2015;,citation_issue=8;,citation_doi=10.1177/0141076815596690;,citation_issn=0141-0768;,citation_volume=108;,citation_language=en-US;,citation_journal_title=Journal of the Royal Society of Medicine;,citation_publisher=SAGE Publications;">
<meta name="citation_reference" content="citation_title=Estimating the attributable fraction of mortality from acute respiratory distress syndrome to inform enrichment in future randomised clinical trials;,citation_abstract=Background Efficiency of randomised clinical trials of acute respiratory distress syndrome (ARDS) depends on the fraction of deaths attributable to ARDS (AFARDS) to which interventions are targeted. Estimates of AFARDS in subpopulations of ARDS could improve design of ARDS trials. Methods We performed a matched case-control study using the Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE cohort. Primary outcome was intensive care unit mortality. We used nearest neighbour propensity score matching without replacement to match ARDS to non-ARDS populations. We derived two separate AFARDS estimates by matching patients with ARDS to patients with non-acute hypoxaemic respiratory failure (non-AHRF) and to patients with AHRF with unilateral infiltrates only (AHRF-UL). We also estimated AFARDS in subgroups based on severity of hypoxaemia, number of lung quadrants involved and hyperinflammatory versus hypoinflammatory phenotypes. Additionally, we derived AFAHRF estimates by matching patients with AHRF to non-AHRF controls, and AFAHRF-UL estimates by matching patients with AHRF-UL to non-AHRF controls. Results Estimated AFARDS was 20.9% (95% CI 10.5% to 31.4%) when compared with AHRF-UL controls and 38.0% (95% CI 34.4% to 41.6%) compared with non-AHRF controls. Within subgroups, estimates for AFARDS compared with AHRF-UL controls were highest in patients with severe hypoxaemia (41.1% (95% CI 25.2% to 57.1%)), in those with four quadrant involvement on chest radiography (28.9% (95% CI 13.4% to 44.3%)) and in the hyperinflammatory subphenotype (26.8% (95% CI 6.9% to 46.7%)). Estimated AFAHRF was 33.8% (95% CI 30.5% to 37.1%) compared with non-AHRF controls. Estimated AFAHRF-UL was 21.3% (95% CI 312.8% to 29.7%) compared with non-AHRF controls. Conclusions Overall AFARDS mean values were between 20.9% and 38.0%, with higher AFARDS seen with severe hypoxaemia, four quadrant involvement on chest radiography and hyperinflammatory ARDS.;,citation_author=Rohit Saha;,citation_author=Tài Pham;,citation_author=Pratik Sinha;,citation_author=Manoj V. Maddali;,citation_author=Giacomo Bellani;,citation_author=Eddy Fan;,citation_author=Charlotte Summers;,citation_author=Abdel Douiri;,citation_author=Gordon D. Rubenfeld;,citation_author=Carolyn S. Calfee;,citation_author=John Gerard Laffey;,citation_author=Daniel Francis McAuley;,citation_author=Manu Shankar-Hari;,citation_publication_date=2023-07;,citation_cover_date=2023-07;,citation_year=2023;,citation_doi=10.1136/thorax-2023-220262;,citation_issn=0040-6376, 1468-3296;,citation_pmid=37495364;,citation_language=en-US;,citation_journal_title=Thorax;,citation_publisher=BMJ Publishing Group Ltd;">
<meta name="citation_reference" content="citation_title=The impact of sample size mis-estimations on the interpretation of acute respiratory distress syndrome trials: Systematic review and meta-analysis;,citation_author=Rohit Saha;,citation_author=Benjamin Assouline;,citation_author=Georgina Mason;,citation_author=Abdel Douiri;,citation_author=Charlotte Summers;,citation_author=Manu Shankar-Har;,citation_publication_date=2022-05;,citation_cover_date=2022-05;,citation_year=2022;,citation_doi=10.1016/j.chest.2022.05.018;,citation_issn=00123692;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Confounding by Indication: An Example of Variation in the Use of Epidemiologic Terminology;,citation_author=M. Salas;,citation_author=A. Hotman;,citation_author=B. H. Stricker;,citation_publication_date=1999-06;,citation_cover_date=1999-06;,citation_year=1999;,citation_issue=11;,citation_doi=10.1093/oxfordjournals.aje.a009758;,citation_issn=0002-9262, 1476-6256;,citation_volume=149;,citation_language=en-US;,citation_journal_title=American Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Effect of Corticosteroids on Mortality and Clinical Cure in Community-Acquired Pneumonia: A Systematic Review, Meta-analysis, and Meta-regression of Randomized Control Trials;,citation_abstract=Background Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality. Corticosteroids may be a beneficial adjunct in the treatment of bacterial pneumonia. Research Question Is there any benefit of corticosteroid therapy in the management of bacterial CAP among patients requiring hospitalization? Study Design and Methods PubMed, Cochrane Library, and Embase were searched to identify randomized controlled trials assessing the use of systemic corticosteroids compared with standard care in the management of CAP. A systematic review, meta-analysis, and Trial Sequential Analysis (TSA) were performed. The primary outcome was all-cause mortality. Secondary outcomes included ICU admission, mechanical ventilation, treatment failure, readmission, and adverse events. Data are presented as risk ratio (RR) with 95%&nbsp;CI, P value, heterogeneity (I2), and TSA-adjusted CIs. Results Sixteen trials met the eligibility criteria. All-cause mortality (16 studies [3,842 patients]; RR, 0.85 [95%&nbsp;CI, 0.67-1.07]; P&nbsp;= .17; I2&nbsp;= 14%; TSA-adjusted CI, 0.61-1.09), ICU admission (six studies [2,619 patients]; RR, 0.66 [95%&nbsp;CI, 0.45-0.97]; P&nbsp;= .04; I2&nbsp;= 0%; TSA-adjusted CI, 0.37-1.12), treatment failure (six studies [2,093 patients]; RR, 0.78 [95%&nbsp;CI, 0.37-1.67]; P&nbsp;= .52; I2&nbsp;= 68%; TSA-adjusted CI, 0.02-25.5), and the incidence of adverse events (six studies [2,487 patients]; RR, 1.10 [95%&nbsp;CI, 0.97-1.25]; P&nbsp;= .14; I2&nbsp;= 53%; TSA-adjusted CI, 0.82-2.41) were similar between patients receiving corticosteroids and patients assigned to the control group. The need for mechanical ventilation (eight studies [1,457 patients]; RR, 0.51 [95%&nbsp;CI, 0.33-0.77]; P&nbsp;= .001; I2&nbsp;= 0%; TSA-adjusted CI, 0.20-0.85) was lower among patients receiving corticosteroids compared with those receiving standard care. However, corticosteroid use may be associated with higher rates of hospital readmission (five studies [2,853 patients]; RR, 1.20 [95%&nbsp;CI, 1.05-1.38]; P&nbsp;= .008; I2&nbsp;= 0%; TSA-adjusted CI, 0.89-1.98). Interpretation Corticosteroid therapy is associated with a lower incidence of progression to requiring mechanical ventilation among patients hospitalized with CAP. No association was found between corticosteroid therapy and mortality, treatment failure, or adverse events. Trial Registry PROSPERO; No.: CRD42021279359; URL: https://www.crd.york.ac.uk/prospero/;,citation_author=Naveed Saleem;,citation_author=Adarsh Kulkarni;,citation_author=Timothy Arthur Chandos Snow;,citation_author=Gareth Ambler;,citation_author=Mervyn Singer;,citation_author=Nishkantha Arulkumaran;,citation_publication_date=2023-03;,citation_cover_date=2023-03;,citation_year=2023;,citation_issue=3;,citation_doi=10.1016/j.chest.2022.08.2229;,citation_issn=0012-3692;,citation_volume=163;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Patterns of ischemic posterior circulation strokes: A clinical, anatomical, and radiological review;,citation_abstract=Background: Posterior circulation and anterior circulation strokes share many clinical, pathogenetic and radiological features, although some clinical signs are highly specific to posterior circulation strokes. Arterial stenosis and occlusions occur in significant numbers in both acute posterior circulation and anterior circulation strokes, making them good candidates for endovascular treatment. Among posterior circulation strokes, basilar artery occlusions stand out because of the diagnostic and acute treatment challenges. Methods: We reviewed the literature on clinical stroke syndromes and neuroimaging findings and systematically describe for each anatomical site of stroke the detailed clinical and radiological information (anatomical representation, diffusion weighted imaging and angiographic sequences). The principles of neuroimaging of posterior circulation strokes and the prognosis for each stroke localization are also discussed. Review summary: Stroke syndromes in the territories of the vertebral, basilar, cerebellar, and posterior cerebral arteries are presented. Features typical of posterior circulation strokes are highlighted, including patterns of basilar artery occlusions. Clinical severity and prognosis of posterior circulation strokes are highly variable, and given that they are more difficult to detect on CT-based neuroimaging, magnetic resonance imaging is the technique of choice in suspected posterior circulation strokes. Rapid identification of arterial occlusion patterns may provide prognostic information and support acute revascularization decisions. Conclusions: Posterior circulation stroke syndromes tightly reflect lesion localization and arterial occlusion patterns. Although many clinical and pathogenetic features are similar to anterior circulation strokes, notable differences exist in terms of clinical presentation, stroke mechanism, prognosis, and response to acute recanalization.;,citation_author=Alexander Salerno;,citation_author=Davide Strambo;,citation_author=Stefania Nannoni;,citation_author=Vincent Dunet;,citation_author=Patrik Michel;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_doi=10.1177/17474930211046758;,citation_issn=1747-4930, 1747-4949;,citation_language=en-US;,citation_journal_title=International Journal of Stroke;">
<meta name="citation_reference" content="citation_title=Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): Prospective, individual participant data meta-analysis of randomised trials;,citation_author=Rustam Al-Shahi Salman;,citation_author=Jacqueline Stephen;,citation_author=Jayne F. Tierney;,citation_author=Steff C. Lewis;,citation_author=David E. Newby;,citation_author=Adrian R. Parry-Jones;,citation_author=Philip M. White;,citation_author=Stuart J. Connolly;,citation_author=Oscar R. Benavente;,citation_author=Dar Dowlatshahi;,citation_author=Charlotte Cordonnier;,citation_author=Catherine M. Viscoli;,citation_author=Kevin N. Sheth;,citation_author=Hooman Kamel;,citation_author=Roland Veltkamp;,citation_author=Kristin T. Larsen;,citation_author=Jeannette Hofmeijer;,citation_author=Henk Kerkhoff;,citation_author=Floris H. B. M. Schreuder;,citation_author=Ashkan Shoamanesh;,citation_author=Catharina J. M. Klijn;,citation_author=H. Bart Worp;,citation_author=Didier Klug;,citation_author=Barbara Casolla;,citation_author=Laurent Puy;,citation_author=Morgane Coffee;,citation_author=Grégory Kuchcinski;,citation_author=Julien Labreuche;,citation_author=Koen M. Nieuwenhuizen;,citation_author=Ale Algra;,citation_author=Isabelle C. Gelder;,citation_author=L. Jaap Kappelle;,citation_author=Gabriel J. E. Rinkel;,citation_author=Roger E. G. Schutgens;,citation_author=Pooja Khatri;,citation_author=Robin Conwit;,citation_author=Guido Falcone;,citation_author=Jordan Elm;,citation_author=Craig S. Anderson;,citation_author=Lili Song;,citation_author=Jeyaraj Pandian;,citation_author=Robert G. Hart;,citation_author=Mukul Sharma;,citation_author=Hany Aref;,citation_author=Wadea Tarhuni;,citation_author=Joan Marti Fabregas;,citation_author=Hans-Christoph Diener;,citation_author=Matthias Endres;,citation_author=Robin Lemmens;,citation_author=Sun U. Kwon;,citation_author=Byung-Chul Lee;,citation_author=Sebastian Ameriso;,citation_author=Truman J. Milling;,citation_author=Scott E. Kasner;,citation_author=Robert Mikulik;,citation_author=Denis Xavier;,citation_author=Ronny Beer;,citation_author=Danilo Toni;,citation_author=Jens Eckstein;,citation_author=David Seiffge;,citation_author=Jose M. Ferro;,citation_author=Georgios Tsivgoulis;,citation_author=Sanjib K. Sharma;,citation_author=Chia Wei-Liou;,citation_author=Stefan H. Hohnloser;,citation_author=Aristeidis Katsanos;,citation_author=Jackie Bosch;,citation_author=Jeff Healey;,citation_author=John Eikelboom;,citation_author=Alexander Khaw;,citation_author=David Gladstone;,citation_author=Aleksandra Pikula;,citation_author=Shelagh Coutts;,citation_author=Eric E. Smith;,citation_author=Ken Butcher;,citation_author=Thalia Field;,citation_author=Laura Gioia;,citation_author=Christian Stapf;,citation_author=Omid Halse;,citation_author=Peter Ringleb;,citation_author=Christian Enzinger;,citation_author=Igor Sibon;,citation_author=Joan Montaner;,citation_author=Valeria Caso;,citation_author=Peter Heuschmann;,citation_author=Gregory Y. H. Lip;,citation_author=Walter Haefeli;,citation_author=Stefanie Debette;,citation_author=Martin S. Dennis;,citation_author=Torgeir Bruun Wyller;,citation_author=Ole M. Rønning;,citation_author=Helle Eilertsen;,citation_author=Hege Ihle-Hansen;,citation_author=Else Charlotte Sandset;,citation_author=Johanna Pennlert;,citation_author=Eva-Lotta Glader;,citation_author=Christina Kruuse;,citation_author=Per Wester;,citation_author=Maria Carlsson;,citation_author=Elisabeth Forfang;,citation_publication_date=2023-10;,citation_cover_date=2023-10;,citation_year=2023;,citation_issue=0;,citation_doi=10.1016/S1474-4422(23)00315-0;,citation_issn=1474-4422, 1474-4465;,citation_pmid=37839434;,citation_volume=0;,citation_language=en-US;,citation_journal_title=The Lancet Neurology;">
<meta name="citation_reference" content="citation_title=Prolonged higher dose methylprednisolone vs. Conventional dexamethasone in COVID-19 pneumonia: A randomised controlled trial (MEDEAS);,citation_abstract=Introduction Dysregulated systemic inflammation is the primary driver of mortality in severe COVID-19 pneumonia. Current guidelines favor a 7–10-day course of any glucocorticoid equivalent to dexamethasone 6 mg\cdotday-1. A comparative RCT with a higher dose and a longer duration of intervention was lacking. Methods We conducted a multi-center, open-label RCT to investigate methylprednisolone 80 mg as a continuous daily infusion for 8 days followed by slow tapering versus dexamethasone 6 mg daily for up to 10 days in adult patients with COVID-19 pneumonia requiring oxygen or noninvasive respiratory support. Primary outcome: reduction in 28-day mortality. Secondary outcomes: mechanical ventilation-free days at 28 days, need for ICU referral, length of hospitalisation, need for tracheostomy, changes in PaO2:FiO2 ratio, C-reactive protein levels and WHO clinical progression scale at days 3, 7, and 14. Results 677 randomised patients were included. Findings are reported as methylprednisolone (n=337) versus dexamethasone (n=340). By day 28, there were no significant differences in mortality (35[10.4%] versus 41[12.1%]; p=0.49), nor in the median mechanical ventilation-free days (23[14] versus 24[16]; p=0.49). ICU referral was necessary in 41[12.2%] versus 45[13.2%]; p=0.68 and tracheostomy in 8[2.4%] versus 9[2.6%]; p=0.82. Survivors in the methylprednisolone group required a longer median hospitalisation (15[11] versus 14[11] days; p=0.005) and experienced an improvement in C-reactive protein levels, but not in PaO2:FiO2 ratio, at days 7 and 14. There were no differences in disease progression at the prespecified timepoints. Conclusion Prolonged, higher dose methylprednisolone did not reduce mortality at 28 days compared to conventional dexamethasone in COVID-19 pneumonia.;,citation_author=Francesco Salton;,citation_author=Paola Confalonieri;,citation_author=Stefano Centanni;,citation_author=Michele Mondoni;,citation_author=Nicola Petrosillo;,citation_author=Paolo Bonfanti;,citation_author=Giuseppe Lapadula;,citation_author=Donato Lacedonia;,citation_author=Antonio Voza;,citation_author=Nicoletta Carpenè;,citation_author=Marcella Montico;,citation_author=Nicolò Reccardini;,citation_author=Gianfranco Umberto Meduri;,citation_author=Barbara Ruaro;,citation_author=MEDEAS Group;,citation_author=Marco Confalonieri;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_doi=10.1183/13993003.01514-2022;,citation_issn=0903-1936, 1399-3003;,citation_pmid=36356972;,citation_language=en-US;,citation_journal_title=European Respiratory Journal;,citation_publisher=European Respiratory Society;">
<meta name="citation_reference" content="citation_title=Blood Pressure in the First 6 Hours Following Endovascular Treatment for Ischemic Stroke Is Associated With Outcome;,citation_abstract=BACKGROUND AND PURPOSE: Optimal blood pressure (BP) management in the acute phase of ischemic stroke remains an unresolved issue. It is uncertain whether guidelines for BP management during and after intravenous alteplase can be extrapolated to endovascular treatment (EVT) for stroke due to large artery occlusion in the anterior circulation. We evaluated the associations between systolic BP (SBP) in the first 6 hours following EVT and functional outcome as well as symptomatic intracranial hemorrhage. METHODS: Patients of 8 MR CLEAN (Multicenter Randomized Controlled Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands) Registry centers, with available data on SBP in the 6 hours following EVT, were analyzed. We evaluated maximum, minimum, and mean SBP. Study outcomes were functional outcome (modified Rankin Scale) at 90 days and symptomatic intracranial hemorrhage. We used multivariable ordinal and binary regression analysis to adjust for important prognostic factors and studied possible effect modification by successful reperfusion. RESULTS: Post-EVT SBP data were available for 1161/1796 patients. Higher maximum SBP (per 10 mm Hg increments) was associated with worse functional outcome (adjusted common odds ratio, 0.93 [95% CI, 0.88–0.98]) and a higher rate of symptomatic intracranial hemorrhage (adjusted odds ratio, 1.17 [95% CI, 1.02–1.36]). The association between minimum SBP and functional outcome was nonlinear with an inflection point at 124 mm Hg. Minimum SBP lower and higher than the inflection point were associated with worse functional outcomes (adjusted common odds ratio, 0.85 per 10 mm Hg decrements [95% CI, 0.76–0.95] and adjusted common odds ratio, 0.81 per 10 mm Hg increments [95% CI, 0.71–0.92]). No association between mean SBP and functional outcome was observed. Successful reperfusion did not modify the relation of SBP with any of the outcomes. CONCLUSIONS: Maximum SBP in the first 6 hours following EVT is positively associated with worse functional outcome and an increased risk of symptomatic intracranial hemorrhage. Both lower and higher minimum SBP are associated with worse outcomes. A randomized trial to evaluate whether modifying post-intervention SBP results in better outcomes after EVT for ischemic stroke seems justified.;,citation_author=Noor Samuels;,citation_author=Rob A. Graaf;,citation_author=Carlijn A. L. Berg;,citation_author=Simone M. Uniken Venema;,citation_author=Kujtesa Bala;,citation_author=Pieter Jan Doormaal;,citation_author=Wouter Steen;,citation_author=Elbert Witvoet;,citation_author=Jelis Boiten;,citation_author=Heleen Hertog;,citation_author=Wouter J. Schonewille;,citation_author=Jeannette Hofmeijer;,citation_author=Floris Schreuder;,citation_author=Tobien A. H. C. M. L. Schreuder;,citation_author=H. Bart Worp;,citation_author=Yvo B. W. E. M. Roos;,citation_author=Charles B. L. M. Majoie;,citation_author=James F. Burke;,citation_author=Adriaan C. G. M. Es;,citation_author=Aad Lugt;,citation_author=Bob Roozenbeek;,citation_author=Hester F. Lingsma;,citation_author=Diederik W. J. Dippel;,citation_author=Robert J. Oostenbrugge;,citation_author=Wim H. Zwam;,citation_author=Jan Albert Vos;,citation_author=Ivo G. H. Jansen;,citation_author=Maxim J. H. L. Mulder;,citation_author=Robert- Jan B. Goldhoorn;,citation_author=Kars C. J. Compagne;,citation_author=Manon Kappelhof;,citation_author=Josje Brouwer;,citation_author=Sanne J. Hartog;,citation_author=Wouter H. Hinsenveld;,citation_author=Bart J. Emmer;,citation_author=Jonathan M. Coutinho;,citation_author=Jan Albert Vos;,citation_author=Marieke J. H. Wermer;,citation_author=Marianne A. A. Walderveen;,citation_author=Julie Staals;,citation_author=Robert J. Oostenbrugge;,citation_author=Wim H. Zwam;,citation_author=Jasper M. Martens;,citation_author=Geert J. Lycklama à Nijeholt;,citation_author=Sebastiaan F. Bruijn;,citation_author=Lukas C. Dijk;,citation_author=Rob H. Lo;,citation_author=Ewoud J. Dijk;,citation_author=Hieronymus D. Boogaarts;,citation_author=J. Vries;,citation_author=Paul L. M. Kort;,citation_author=Julia Tuijl;,citation_author=Jo P. Peluso;,citation_author=Puck Fransen;,citation_author=Jan S. P. Berg;,citation_author=Boudewijn A. A. M. Hasselt;,citation_author=Leo A. M. Aerden;,citation_author=J. Dallinga René;,citation_author=Maarten Uyttenboogaart;,citation_author=Omid Eschgi;,citation_author=Reinoud P. H. Bokkers;,citation_author=Roel J. J. Heijboer;,citation_author=Koos Keizer;,citation_author=Lonneke S. F. Yo;,citation_author=Emiel J. C. Sturm;,citation_author=Paul J. A. M. Brouwers;,citation_author=Wim H. Zwam;,citation_author=Geert J. Lycklama à Nijeholt;,citation_author=Marianne A. A. Walderveen;,citation_author=Marieke E. S. Sprengers;,citation_author=Sjoerd F. M. Jenniskens;,citation_author=René Berg;,citation_author=Albert J. Yoo;,citation_author=Ludo F. M. Beenen;,citation_author=Alida A. Postma;,citation_author=Stefan D. Roosendaal;,citation_author=Bas F. W. Kallen;,citation_author=Ido R. Wijngaard;,citation_author=Bart J. Emmer;,citation_author=Jasper M. Martens;,citation_author=Lonneke S. F. Yo;,citation_author=Jan Albert Vos;,citation_author=Joost Bot;,citation_author=Anton Meijer;,citation_author=Elyas Ghariq;,citation_author=Reinoud P. H. Bokkers;,citation_author=Marc P. Proosdij;,citation_author=G. Menno Krietemeijer;,citation_author=Jo P. Peluso;,citation_author=Hieronymus D. Boogaarts;,citation_author=Rob Lo;,citation_author=Dick Gerrits;,citation_author=Wouter Dinkelaar;,citation_author=Auke P. A. Appelman;,citation_author=Bas Hammer;,citation_author=Sjoert Pegge;,citation_author=Anouk Hoorn;,citation_author=Saman Vinke;,citation_author=Robert J. Oostenbrugge;,citation_author=Wim H. Zwam;,citation_author=Geert J. Lycklama à Nijeholt;,citation_author=Jan Albert Vos;,citation_author=Jasper M. Martens;,citation_author=Rob H. Lo;,citation_author=Robert J. Oostenbrugge;,citation_author=H. Zwenneke Flach;,citation_author=Naziha Ghannouti;,citation_author=Martin Sterrenberg;,citation_author=Corina Puppels;,citation_author=Wilma Pellikaan;,citation_author=Rita Sprengers;,citation_author=Marjan Elfrink;,citation_author=Michelle Simons;,citation_author=Marjolein Vossers;,citation_author=Joke Meris;,citation_author=Tamara Vermeulen;,citation_author=Annet Geerlings;,citation_author=Gina Vemde;,citation_author=Tiny Simons;,citation_author=Cathelijn Rijswijk;,citation_author=Gert Messchendorp;,citation_author=Nynke Nicolaij;,citation_author=Hester Bongenaar;,citation_author=Karin Bodde;,citation_author=Sandra Kleijn;,citation_author=Jasmijn Lodico;,citation_author=Hanneke Droste;,citation_author=Maureen Wollaert;,citation_author=Sabrina Verheesen;,citation_author=D. Jeurrissen;,citation_author=Erna Bos;,citation_author=Yvonne Drabbe;,citation_author=Michelle Sandiman;,citation_author=Nicoline Aaldering;,citation_author=Berber Zweedijk;,citation_author=Mostafa Khalilzada;,citation_author=Jocova Vervoort;,citation_author=Eva Ponjee;,citation_author=Sharon Romviel;,citation_author=Karin Kanselaar;,citation_author=Denn Barning;,citation_author=Esmee Venema;,citation_author=Vicky Chalos;,citation_author=Ralph R. Geuskens;,citation_author=Tim Straaten;,citation_author=Saliha Ergezen;,citation_author=Roger R. M. Harmsma;,citation_author=Daan Muijres;,citation_author=Anouk Jong;,citation_author=Olvert A. Berkhemer;,citation_author=Anna M. M. Boers;,citation_author=J. Huguet;,citation_author=P. F. C. Groot;,citation_author=Marieke A. Mens;,citation_author=Katinka R. Kranendonk;,citation_author=Kilian M. Treurniet;,citation_author=Manon L. Tolhuisen;,citation_author=Heitor Alves;,citation_author=Annick J. Weterings;,citation_author=Eleonora L. F. Kirkels;,citation_author=Eva J. H. F. Voogd;,citation_author=Lieve M. Schupp;,citation_author=Sabine Collette;,citation_author=Adrien E. D. Groot;,citation_author=Natalie E. LeCouffe;,citation_author=Praneeta R. Konduri;,citation_author=Haryadi Prasetya;,citation_author=Nerea Arrarte-Terrero;,citation_author=Lucas A. Ramos;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_doi=10.1161/STROKEAHA.120.033657;,citation_issn=0039-2499, 1524-4628;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=The Brain–Heart Connection;,citation_author=Martin A. Samuels;,citation_publication_date=2007-07;,citation_cover_date=2007-07;,citation_year=2007;,citation_issue=1;,citation_doi=10.1161/CIRCULATIONAHA.106.678995;,citation_volume=116;,citation_journal_title=Circulation;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=Cerebral Venous Thrombosis: A Clinical Overview;,citation_abstract=Cerebral venous thrombosis (CVT) is a less common cause of stroke that is an often under recognized entity in clinical practice. The goal of this chapter will be to provide clinicians with the knowledge to succinctly recognize the various presentations of CVT, emphasizing rapid diagnosis and the potential treatments necessary to produce optimal clinical outcomes. Detailed descriptions of the relevant anatomy and associated clinical syndromes will be discussed. Detailed sections regarding CVT epidemiology, pathophysiology, etiology, diagnosis and treatment will be provided. Prognosis and long-term follow-up will also be discussed. Relevant literature will be cited and clinical trials across the spectrum of CVT will be highlighted.;,citation_author=Christopher A. Stack;,citation_author=John W. Cole;,citation_editor=Pratap Sanchetee;,citation_publication_date=2018-10;,citation_cover_date=2018-10;,citation_year=2018;,citation_doi=10.5772/intechopen.79049;,citation_isbn=978-1-78984-219-7 978-1-78984-220-3;,citation_language=en-US;,citation_inbook_title=Ischemic Stroke of Brain;">
<meta name="citation_reference" content="citation_title=Transient Focal Neurological Events in Cerebral Amyloid Angiopathy and the Long-term Risk of Intracerebral Hemorrhage and Death: A Systematic Review and Meta-analysis;,citation_abstract=OBJECTIVE To perform a systematic review and meta-analysis to examine the factors associated with incident lobar intracerebral hemorrhage (ICH) and death in patients with CAA presenting with TFNEs. DATA SOURCES A systematic review and individual participant meta-analysis including (1) a hospital-based cohort and (2) the results obtained from a systematic search performed in MEDLINE and Embase completed in December 2019. STUDY SELECTION Included studies were observational reports of TFNEs. Patient-level clinical, imaging, and prognostic data were required for inclusion. For aggregate data studies, patient-level data were requested. Disagreements were resolved by consensus. DATA EXTRACTION AND SYNTHESIS Data were extracted following Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines by 4 independent reviewers. The quality of reports was determined based on the modified Pearson Case Report Quality Scale. MAIN OUTCOMES AND MEASURES The clinical characteristics of TFNEs, neuroimaging features, and use of antithrombotics during follow-up were considered exposures. The predefined main outcomes were lobar ICH and risk of death during follow-up. RESULTS Forty-two studies and 222 CAA-associated TFNE cases were included from the initial 1612 records produced by the systematic search; 26 additional patients (11 men [42.3%]; mean [SD] age, 77 [8] years) were provided by the hospital-based cohort. A total of 108 TFNEs (43.5%) consisted of motor symptoms. Convexity subarachnoid hemorrhage and cortical superficial siderosis were detected in 193 individuals (77.8%) and 156 individuals (62.9%) in the systematic search and hospital-based cohort, respectively. Follow-up duration could be obtained in 185 patients (median duration, 1 year [IQR, 0.8-2.5 years]). During follow-up, symptomatic lobar ICH occurred in 76 patients (39.4%). Motor symptoms (odds ratio, 2.08 [95% CI, 1.16-3.70]) at baseline and antithrombotic use during follow-up (odds ratio, 3.61 [95% CI, 1.67-7.84]) were associated with an increase in risk of lobar ICH. A total of 31 patients (16.5%) died during follow-up; lobar ICH during follow-up and cortical superficial siderosis were the main risk factors for death (odds ratio, 3.01 [95% CI, 1.36-6.69]; odds ratio, 3.20 [95% CI, 1.16-8.91], respectively). CONCLUSIONS AND RELEVANCE Patients presenting with CAA-associated TFNEs are at high risk of lobar ICH and death. Motor TFNEs and use of antithrombotics after a TFNE, in many cases because of misdiagnosis, are risk factors for ICH, and therefore accurate diagnosis and distinguishing this condition from transient ischemic attacks is critical.;,citation_author=Juan María Sanchez-Caro;,citation_author=Iñigo Lorenzo Martínez de Ubago;,citation_author=Elena Celis Ruiz;,citation_author=Ainara Barguilla Arribas;,citation_author=Lionel Calviere;,citation_author=Nicolas Raposo;,citation_author=Rafael Galiano Blancart;,citation_author=Blanca Fuentes;,citation_author=Exuperio Diez-Tejedor;,citation_author=Jorge Rodriguez-Pardo;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=1;,citation_doi=10.1001/jamaneurol.2021.3989;,citation_issn=2168-6149;,citation_volume=79;,citation_language=en-US;,citation_journal_title=JAMA Neurology;">
<meta name="citation_reference" content="citation_title=Clinical Documentation for Intensivists: The Impact of Diagnosis Documentation;,citation_author=Amy L. Sanderson;,citation_author=Jeffrey P. Burns;,citation_publication_date=2020-04;,citation_cover_date=2020-04;,citation_year=2020;,citation_issue=4;,citation_doi=10.1097/CCM.0000000000004200;,citation_issn=0090-3493;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Brain injury after cardiac arrest: Pathophysiology, treatment, and prognosis;,citation_abstract=Post-cardiac arrest brain injury (PCABI) is caused by initial ischaemia and subsequent reperfusion of the brain following resuscitation. In those who are admitted to intensive care unit after cardiac arrest, PCABI manifests as coma, and is the main cause of mortality and long-term disability. This review describes the mechanisms of PCABI, its treatment options, its outcomes, and the suggested strategies for outcome prediction.;,citation_author=Claudio Sandroni;,citation_author=Tobias Cronberg;,citation_author=Mypinder Sekhon;,citation_publication_date=2021-12;,citation_cover_date=2021-12;,citation_year=2021;,citation_issue=12;,citation_doi=10.1007/s00134-021-06548-2;,citation_issn=0342-4642, 1432-1238;,citation_volume=47;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=EEG monitoring after cardiac arrest;,citation_author=Claudio Sandroni;,citation_author=Tobias Cronberg;,citation_author=Jeannette Hofmeijer;,citation_publication_date=2022-04;,citation_cover_date=2022-04;,citation_year=2022;,citation_doi=10.1007/s00134-022-06697-y;,citation_issn=0342-4642, 1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=ERC-ESICM guidelines on temperature control after cardiac arrest in adults;,citation_abstract=The aim of these guidelines is to provide evidence-based guidance for temperature control in adults who are coma-tose after resuscitation from either in-hospital or out-of-hospital cardiac arrest, regardless of the underlying cardiac rhythm. These guidelines replace the recommendations on temperature management after cardiac arrest included in the 2021 post-resuscitation care guidelines co-issued by the European Resuscitation Council (ERC) and the Euro-pean Society of Intensive Care Medicine (ESICM). The guideline panel included thirteen international clinical experts who authored the 2021 ERC-ESICM guidelines and two methodologists who participated in the evidence review completed on behalf of the International Liaison Committee on Resuscitation (ILCOR) of whom ERC is a member society. We followed the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to assess the certainty of evidence and grade recommendations. The panel provided suggestions on guideline implementation and identified priorities for future research. The certainty of evidence ranged from moderate to low. In patients who remain comatose after cardiac arrest, we recommend continuous monitoring of core temperature and actively preventing fever (defined as a temperature &amp;amp;amp;gt; 37.7 ^\circC) for at least 72 h. There was insufficient evidence to recommend for or against temperature control at 32–36 ^\circC or early cooling after cardiac arrest. We recommend not actively rewarming comatose patients with mild hypothermia after return of spontaneous circulation (ROSC) to achieve normothermia. We recommend not using prehospital cooling with rapid infusion of large volumes of cold intravenous fluids immediately after ROSC.;,citation_author=Claudio Sandroni;,citation_author=Jerry P. Nolan;,citation_author=Lars W. Andersen;,citation_author=Bernd W. Böttiger;,citation_author=Alain Cariou;,citation_author=Tobias Cronberg;,citation_author=Hans Friberg;,citation_author=Cornelia Genbrugge;,citation_author=Gisela Lilja;,citation_author=Peter T. Morley;,citation_author=Nikolaos Nikolaou;,citation_author=Theresa M. Olasveengen;,citation_author=Markus B. Skrifvars;,citation_author=Fabio S. Taccone;,citation_author=Jasmeet Soar;,citation_publication_date=2022-03;,citation_cover_date=2022-03;,citation_year=2022;,citation_issue=3;,citation_doi=10.1007/s00134-022-06620-5;,citation_issn=0342-4642, 1432-1238;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Prediction of good neurological outcome in comatose survivors of cardiac arrest: A systematic review;,citation_abstract=Purpose: To assess the ability of clinical examination, blood biomarkers, electrophysiology or neuroimaging assessed within 7 days from return of spontaneous circulation (ROSC) to predict good neurological outcome, defined as no, mild, or moderate disability (CPC 1–2 or mRS 0–3) at discharge from intensive care unit or later, in comatose adult survivors from cardiac arrest (CA). Methods: PubMed, EMBASE, Web of Science and the Cochrane Database of Systematic Reviews were searched. Sensitivity and specificity for good outcome were calculated for each predictor. The risk of bias was assessed using the QUIPS tool. Results: A total of 37 studies were included. Due to heterogeneities in recording times, predictor thresholds, and definition of some predictors, meta-analysis was not performed. A withdrawal or localisation motor response to pain immediately or at 72–96 h after ROSC, normal blood values of neuron-specific enolase (NSE) at 24 h-72 h after ROSC, a short-latency somatosensory evoked potentials (SSEPs) N20 wave amplitude &amp;amp;amp;gt; 4 V or a continuous background without discharges on electroencephalogram (EEG) within 72 h from ROSC, and absent diffusion restriction in the cortex or deep grey matter on MRI on days 2–7 after ROSC predicted good neurological outcome with more than 80% specificity and a sensitivity above 40% in most studies. Most studies had moderate or high risk of bias. Conclusions: In comatose cardiac arrest survivors, clinical, biomarker, electrophysiology, and imaging studies identified patients destined to a good neurological outcome with high specificity within the first week after cardiac arrest (CA).;,citation_author=Claudio Sandroni;,citation_author=Sonia D’Arrigo;,citation_author=Sofia Cacciola;,citation_author=Cornelia W. E. Hoedemaekers;,citation_author=Erik Westhall;,citation_author=Marlijn J. A. Kamps;,citation_author=Fabio S. Taccone;,citation_author=Daniele Poole;,citation_author=Frederick J. A. Meijer;,citation_author=Massimo Antonelli;,citation_author=Karen G. Hirsch;,citation_author=Jasmeet Soar;,citation_author=Jerry P. Nolan;,citation_author=Tobias Cronberg;,citation_publication_date=2022-04;,citation_cover_date=2022-04;,citation_year=2022;,citation_issue=4;,citation_doi=10.1007/s00134-022-06618-z;,citation_issn=0342-4642, 1432-1238;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Management of Increased Intracranial Pressure;,citation_abstract=After brain injury, neurologic intensive care focuses on the detection and treatment of secondary brain insults that may compound the initial injury. Increased intracranial pressure (ICP) contributes to secondary brain injury by causing brain ischemia, hypoxia, and metabolic dysfunction. Because ICP is easily measured at the bedside, it is the target of numerous pharmacologic and surgical interventions in efforts to improve brain physiology and limit secondary injury. However, ICP may not adequately reflect the metabolic health of the underlying brain tissue, particularly in cases of focal brain injury. As a result, ICP control alone may be insufficient to impact patients’ long-term recovery. Further studies are needed to better understand the combination of cerebral, hemodynamic, and metabolic markers that are best utilized to ensure optimal brain and systemic recovery and overall patient outcome after brain injury.;,citation_author=Danielle K. Sandsmark;,citation_author=Kevin N. Sheth;,citation_publication_date=2014-01;,citation_cover_date=2014-01;,citation_year=2014;,citation_issue=2;,citation_doi=10.1007/s11940-013-0272-3;,citation_issn=1534-3138;,citation_volume=16;,citation_language=en-US;,citation_journal_title=Current Treatment Options in Neurology;">
<meta name="citation_reference" content="citation_title=Will the Real Bicarbonate Please Stand Up?;,citation_author=Sarah F. Sanghavi;,citation_author=Tyler J. Albert;,citation_author=Erik R. Swenson;,citation_publication_date=2022-07;,citation_cover_date=2022-07;,citation_year=2022;,citation_issue=7;,citation_doi=10.1513/AnnalsATS.202111-1286CC;,citation_issn=2329-6933, 2325-6621;,citation_volume=19;,citation_language=en-US;,citation_journal_title=Annals of the American Thoracic Society;">
<meta name="citation_reference" content="citation_title=Which Multicenter Randomized Controlled Trials in Critical Care Medicine Have Shown Reduced Mortality? A Systematic Review;,citation_abstract=OBJECTIVES: To determine which multicenter randomized controlled trials in critically ill patients have shown that the study intervention was associated with a statistically significant reduction in mortality. Our analysis provides an update to a report published 10 years ago. DATA SOURCES: MEDLINE database and PubMed interface from inception until April 30, 2019. STUDY SELECTION: All adult multicenter randomized controlled trials that evaluated the effects of any intervention or monitoring system in critically ill patients and reported mortality as a primary or secondary outcome were included. DATA EXTRACTION: Numbers of centers and patients, type of intervention, reported mortality outcome, and rate and level of significance were extracted into predefined tables. Included randomized controlled trials were classified as reporting reduced, increased, or no effect of the intervention on mortality. Methodologic quality of trials was evaluated using the updated Consolidated Standards of Reporting Trials statement. DATA SYNTHESIS: A total of 212 trials met the inclusion criteria: 27 (13%) reported a significant reduction in mortality, 16 (7%) an increase in mortality, and 170 (80%) no difference in mortality (one study was reported in 2 groups). Of the 27 trials reporting reduced mortality, six had assessed interventions likely to decrease ventilator-induced lung injury, including low tidal volume, prone position, and neuromuscular blockers, demonstrating the negative effects of mechanical ventilation strategies or improved process of care rather than positive effects of new therapies. Seven of the 27 trials reported beneficial effects of noninvasive ventilation. Results from some positive randomized controlled trials, for example, studies of recombinant activated protein C, talactoferrin, interleukin-1 receptor antagonist in sepsis, and muscle relaxants in severe acute respiratory distress syndrome were not replicated in subsequent randomized controlled trials. Other interventions, for example, gastric tonometry, have been abandoned. CONCLUSIONS: A systematic literature search provided no conclusive evidence of any pharmacologic intervention that has consistently reduced mortality in critically ill patients. Strategies associated with improved or noninvasive mechanical ventilation were associated with reduced mortality.;,citation_author=Carlos A. Santacruz;,citation_author=Adriano J. Pereira;,citation_author=Edgar Celis;,citation_author=Jean-Louis Vincent;,citation_publication_date=2019-12;,citation_cover_date=2019-12;,citation_year=2019;,citation_issue=12;,citation_doi=10.1097/CCM.0000000000004000;,citation_issn=1530-0293;,citation_pmid=31567349;,citation_volume=47;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=GRADE guidelines 26: Informative statements to communicate the findings of systematic reviews of interventions;,citation_abstract=Objectives Clear communication of systematic review findings will help readers and decision makers. We built on previous work to develop an approach that improves the clarity of statements to convey findings and that draws on Grading of Recommendations Assessment, Development and Evaluation (GRADE). Study Design and Setting We conducted workshops including 80 attendants and a survey of 110 producers and users of systematic reviews. We calculated acceptability of statements and revised the wording of those that were unacceptable to \geq40% of participants. Results Most participants agreed statements should be based on size of effect and certainty of evidence. Statements for low, moderate and high certainty evidence were acceptable to &amp;amp;amp;gt;60%. Key guidance, for example, includes statements for high, moderate and low certainty for a large effect on intervention x as: x results in a large reduction…; x likely results in a large reduction…; x may result in a large reduction…, respectively. Conclusions Producers and users of systematic reviews found statements to communicate findings combining size and certainty of an effect acceptable. This article provides GRADE guidance and a wording template to formulate statements in systematic reviews and other decision tools.;,citation_author=Nancy Santesso;,citation_author=Claire Glenton;,citation_author=Philipp Dahm;,citation_author=Paul Garner;,citation_author=Elie A. Akl;,citation_author=Brian Alper;,citation_author=Romina Brignardello-Petersen;,citation_author=Alonso Carrasco-Labra;,citation_author=Hans De Beer;,citation_author=Monica Hultcrantz;,citation_author=Ton Kuijpers;,citation_author=Joerg Meerpohl;,citation_author=Rebecca Morgan;,citation_author=Reem Mustafa;,citation_author=Nicole Skoetz;,citation_author=Shahnaz Sultan;,citation_author=Charles Wiysonge;,citation_author=Gordon Guyatt;,citation_author=Holger J. Schünemann;,citation_publication_date=2020-03;,citation_cover_date=2020-03;,citation_year=2020;,citation_doi=10.1016/j.jclinepi.2019.10.014;,citation_issn=0895-4356;,citation_volume=119;,citation_language=en-US;,citation_journal_title=Journal of Clinical Epidemiology;">
<meta name="citation_reference" content="citation_title=Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease;,citation_abstract=BACKGROUND The prognoses with respect to mortality and hepatic and nonhepatic outcomes across the histologic spectrum of nonalcoholic fatty liver disease (NAFLD) are not well defined. METHODS We prospectively followed a multicenter patient population that included the full histologic spectrum of NAFLD. The incidences of death and other outcomes were compared across baseline histologic characteristics. RESULTS A total of 1773 adults with NAFLD were followed for a median of 4 years. All-cause mortality increased with increasing fibrosis stages (0.32 deaths per 100 personyears for stage F0 to F2 [no, mild, or moderate fibrosis], 0.89 deaths per 100 persons-years for stage F3 [bridging fibrosis], and 1.76 deaths per 100 personyears for stage F4 [cirrhosis]). The incidence of liver-related complications per 100 person-years increased with fibrosis stage (F0 to F2 vs. F3 vs. F4) as follows: variceal hemorrhage (0.00 vs. 0.06 vs. 0.70), ascites (0.04 vs. 0.52 vs. 1.20), encephalopathy (0.02 vs. 0.75 vs. 2.39), and hepatocellular cancer (0.04 vs. 0.34 vs. 0.14). As compared with patients with stage F0 to F2 fibrosis, patients with stage F4 fibrosis also had a higher incidence of type 2 diabetes (7.53 vs. 4.45 events per 100 person-years) and a decrease of more than 40% in the estimated glomerular filtration rate (2.98 vs. 0.97 events per 100 person-years). The incidence of cardiac events and nonhepatic cancers were similar across fibrosis stages. After adjustment for age, sex, race, diabetes status, and baseline histologic severity, the incidence of any hepatic decompensation event (variceal hemorrhage, ascites, or encephalopathy) was associated with increased all-cause mortality (adjusted hazard ratio, 6.8; 95% confidence interval, 2.2 to 21.3). From the Virginia Commonwealth University School of Medicine, Richmond (A.J.S.); the Bloomberg School of Public Health, Johns Hopkins University, Baltimore (M.L.V.N., J.C., L.A.W., K.P.Y., P.B., M.L., J.T.), and the Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda (D.E.K.) — both in Maryland; Saint Louis University, St. Louis (B.A.N.-T.); Duke Univer sity, Durham, NC (A.M.D.); Cleveland Clinic, Cleveland (S.D.); the University of California, San Diego, School of Medicine, La Jolla (R.L., C.B.), and the University of California, San Francisco, School of Medicine, San Francisco (B.H.); Indiana University School of Medicine, Indianapolis (N.C.); and the Liver Institute Northwest, Seattle (K.K.). Dr. Sanyal can be contacted at arun.sanyal@vcuhealth .org or at Virginia Commonwealth University School of Medicine, Department of Internal Medicine, 1220 E. Broad St., Richmond, VA 23298-0565. *A full list of the investigators in the NASH CRN is provided in the Supplementary Appendix, available at NEJM.org. N Engl J Med 2021;385:1559-69. DOI: 10.1056/NEJMoa2029349 Copyright © 2021 Massachusetts Medical Society. CONCLUSIONS In this prospective study involving patients with NAFLD, fibrosis stages F3 and F4 were associated with increased risks of liver-related complications and death. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; NAFLD DB2 ClinicalTrials.gov number, NCT01030484.);,citation_author=Arun J. Sanyal;,citation_author=Mark L. Van Natta;,citation_author=Jeanne Clark;,citation_author=Brent A. Neuschwander-Tetri;,citation_author=AnnaMae Diehl;,citation_author=Srinivasan Dasarathy;,citation_author=Rohit Loomba;,citation_author=Naga Chalasani;,citation_author=Kris Kowdley;,citation_author=Bilal Hameed;,citation_author=Laura A. Wilson;,citation_author=Katherine P. Yates;,citation_author=Patricia Belt;,citation_author=Mariana Lazo;,citation_author=David E. Kleiner;,citation_author=Cynthia Behling;,citation_author=James Tonascia;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=17;,citation_doi=10.1056/NEJMoa2029349;,citation_issn=0028-4793, 1533-4406;,citation_volume=385;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Prognostication and Withdrawal of Care Decisions in Severe Traumatic Brain Injury: A Survey of The Seattle International Severe Traumatic Brain Injury Consensus Conference (SIBICC) Working Group;,citation_abstract=Best practice guidelines have advanced severe traumatic brain injury (TBI) care, however, little currently informs goals of care decisions and processes despite their importance and frequency. Panelists from the Seattle International severe traumatic Brain Injury Consensus Conference (SIBICC) participated in a survey consisting of 24 questions. Questions queried use of prognostic calculators, variability in and responsibility for goals of care decisions, acceptability of neurological outcomes as well as putative means of improving decisions which may limit care. 97.6% of the 42 SIBICC panelists completed the survey. Responses were highly variable to most questions. Overall panelists reported infrequent use of prognostic calculators and observing variability in patient prognostication and goals of care decisions. They felt that it would be beneficial for physicians to improve consensus on what constitutes an acceptable neurological outcome as well as what chance of achieving that outcome is acceptable. Panelists felt that the public should help to define what constitutes a good outcome and expressed some support for a “nihilism guard”. Over 50% of panelists felt that if it was certain to be enduring, a vegetative state or lower severe disability would justify a withdrawal of care decision while 15% felt that upper severe disability justified such a decision. Whether conceptualizing an ideal or existing prognostic calculator to predict death or an unacceptable outcome, a 64-69% chance of a poor outcome on average was felt to justify treatment withdrawal. These results demonstrate important variability in goals of care decision making and a desire to reduce this variability. Our panel of recognized TBI experts opined on the neurological outcomes and chances of those outcomes which might prompt consideration of care withdrawal, however imprecision of prognostication and existing prognostication tools is a significant impediment to standardizing the approach to care limiting decisions. Keywords: nihilism, withdrawal of care, survey, SIBICC, brain injury, prognosis;,citation_author=Buse Sarigul;,citation_author=Randy S Bell;,citation_author=Randall M. Chesnut;,citation_author=Sergio Aguilera;,citation_author=Andras Buki;,citation_author=Giuseppe Citerio;,citation_author=D. James Cooper;,citation_author=Ramon R. Diaz-Arrastia;,citation_author=Michael Diringer;,citation_author=Anthony Figaji;,citation_author=Guoyi Gao;,citation_author=Romer Geocadin;,citation_author=Jamshid Ghajar;,citation_author=Odette A Harris;,citation_author=Alan Hoffer;,citation_author=Peter John Hutchinson;,citation_author=Matthew Joseph;,citation_author=Ryan Seiji Kitagawa;,citation_author=Geoffrey T Manley;,citation_author=Stephan Mayer;,citation_author=David Menon;,citation_author=Geert Meyfroidt;,citation_author=Daniel Michael;,citation_author=Mauro Oddo;,citation_author=David O Okonkwo;,citation_author=Mayur B. Patel;,citation_author=Claudia S Robertson;,citation_author=Jeffrey V Rosenfeld;,citation_author=Andres M. Rubiano;,citation_author=Juan Sahuquillo;,citation_author=Franco Servadei;,citation_author=Lori Shutter;,citation_author=Deborah Stein;,citation_author=Nino Stocchetti;,citation_author=Fabio Taccone;,citation_author=Shelly Timmons;,citation_author=Eve Tsai;,citation_author=Jamie S. Ullman;,citation_author=Paul M. Vespa;,citation_author=Walter Videtta;,citation_author=David Wright;,citation_author=Christopher Zammit;,citation_author=Gregory Hawryluk;,citation_publication_date=2023-03;,citation_cover_date=2023-03;,citation_year=2023;,citation_doi=10.1089/neu.2022.0414;,citation_issn=0897-7151;,citation_journal_title=Journal of Neurotrauma;,citation_publisher=Mary Ann Liebert, Inc., publishers;">
<meta name="citation_reference" content="citation_title=Trial of Endovascular Thrombectomy for Large Ischemic Strokes;,citation_author=Amrou Sarraj;,citation_author=Ameer E. Hassan;,citation_author=Michael G. Abraham;,citation_author=Santiago Ortega-Gutierrez;,citation_author=Scott E. Kasner;,citation_author=M. Shazam Hussain;,citation_author=Michael Chen;,citation_author=Spiros Blackburn;,citation_author=Clark W. Sitton;,citation_author=Leonid Churilov;,citation_author=Sophia Sundararajan;,citation_author=Yin C. Hu;,citation_author=Nabeel A. Herial;,citation_author=Pascal Jabbour;,citation_author=Daniel Gibson;,citation_author=Adam N. Wallace;,citation_author=Juan F. Arenillas;,citation_author=Jenny P. Tsai;,citation_author=Ronald F. Budzik;,citation_author=William J. Hicks;,citation_author=Osman Kozak;,citation_author=Bernard Yan;,citation_author=Dennis J. Cordato;,citation_author=Nathan W. Manning;,citation_author=Mark W. Parsons;,citation_author=Ricardo A. Hanel;,citation_author=Amin N. Aghaebrahim;,citation_author=Teddy Y. Wu;,citation_author=Pere Cardona-Portela;,citation_author=Natalia Pérez de la Ossa;,citation_author=Joanna D. Schaafsma;,citation_author=Jordi Blasco;,citation_author=Navdeep Sangha;,citation_author=Steven Warach;,citation_author=Chirag D. Gandhi;,citation_author=Timothy J. Kleinig;,citation_author=Daniel Sahlein;,citation_author=Lucas Elijovich;,citation_author=Wondwossen Tekle;,citation_author=Edgar A. Samaniego;,citation_author=Laith Maali;,citation_author=M. Ammar Abdulrazzak;,citation_author=Marios N. Psychogios;,citation_author=Ashfaq Shuaib;,citation_author=Deep K. Pujara;,citation_author=Faris Shaker;,citation_author=Hannah Johns;,citation_author=Gagan Sharma;,citation_author=Vignan Yogendrakumar;,citation_author=Felix C. Ng;,citation_author=Mohammad H. Rahbar;,citation_author=Chunyan Cai;,citation_author=Philip Lavori;,citation_author=Scott Hamilton;,citation_author=Thanh Nguyen;,citation_author=Johanna T. Fifi;,citation_author=Stephen Davis;,citation_author=Lawrence Wechsler;,citation_author=Vitor M. Pereira;,citation_author=Maarten G. Lansberg;,citation_author=Michael D. Hill;,citation_author=James C. Grotta;,citation_author=Marc Ribo;,citation_author=Bruce C. Campbell;,citation_author=Gregory W. Albers;,citation_publication_date=2023-02;,citation_cover_date=2023-02;,citation_year=2023;,citation_issue=0;,citation_doi=10.1056/NEJMoa2214403;,citation_issn=0028-4793;,citation_volume=0;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Assessment of Magnetic Resonance Imaging Changes and Functional Outcomes Among Adults With Severe Herpes Simplex Encephalitis;,citation_abstract=OBJECTIVE To investigate the association between early brain MRI data and functional outcomes of patients with HSE at 90 days after intensive care unit (ICU) admission. DESIGN, SETTING, AND PARTICIPANTS This multicenter cohort study was conducted in 34 ICUs in France from 2007 to 2019 and recruited all patients who received a clinical diagnosis of encephalitis and exhibited cerebrospinal fluid positivity for herpes simplex virus DNA in the polymerase chain reaction analysis. Data analysis was performed from January to April 2020. EXPOSURES All patients underwent a standard brain MRI during the first 30 days after ICU admission. MAIN OUTCOMES AND MEASURES MRI acquisitions were analyzed by radiologists blinded to patients’ outcomes, using a predefined score. Multivariable logistic regression and supervised hierarchical classifiers methods were used to identify factors associated with poor outcome at 90 days, defined by a score of 3 to 6 (indicating moderate-to-severe disability or death) on the Modified Rankin Scale. RESULTS Overall, 138 patients (median [interquartile range {IQR}] age, 62.6 [54.0-72.0] years; 75 men [54.3%]) with an admission median (IQR) Glasgow Coma Scale score of 9 (6-12) were studied. The median (IQR) delay between ICU admission and MRI was 1 (1-7) days. At 90 days, 95 patients (68.8%) had a poor outcome, including 16 deaths (11.6%). The presence of fluid-attenuated inversion recovery MRI signal abnormalities in more than 3 brain lobes (odds ratio [OR], 25.71; 95% CI, 1.21-554.42), age older than 60 years (OR, 7.62; 95% CI, 2.02-28.91), and the presence of diffusionweighted MRI signal abnormalities in the left thalamus (OR, 6.90; 95% CI, 1.12-43.00) were independently associated with poor outcome. Machine learning models identified bilateral diffusion abnormalities as an additional factor associated with poor outcome (34 of 39 patients [87.2%] with bilateral abnormalities had poor outcomes) and confirmed the functional burden of left thalamic lesions, particularly in older patients (all 11 patients aged &amp;amp;amp;gt;60 years had left thalamic lesions). CONCLUSIONS AND RELEVANCE These findings suggest that in adult patients with HSE requiring ICU admission, extensive MRI changes in the brain are independently associated with poor functional;,citation_author=Benjamine Sarton;,citation_author=Pierre Jaquet;,citation_author=Djida Belkacemi;,citation_author=Etienne Montmollin;,citation_author=Fabrice Bonneville;,citation_author=Charline Sazio;,citation_author=Aurelien Frérou;,citation_author=Marie Conrad;,citation_author=Delphine Daubin;,citation_author=Russell Chabanne;,citation_author=Laurent Argaud;,citation_author=Frédéric Dailler;,citation_author=Noëlle Brulé;,citation_author=Nicolas Lerolle;,citation_author=Quentin Maestraggi;,citation_author=Julien Marechal;,citation_author=Pierre Bailly;,citation_author=Keyvan Razazi;,citation_author=Francois Mateos;,citation_author=Bertrand Guidet;,citation_author=Albrice Levrat;,citation_author=Vincent Susset;,citation_author=Alexandre Lautrette;,citation_author=Jean-Paul Mira;,citation_author=Ahmed El Kalioubie;,citation_author=Alexandre Robert;,citation_author=Alexandre Massri;,citation_author=Jean François Albucher;,citation_author=Jean Marc Olivot;,citation_author=Jean Marie Conil;,citation_author=Lila Boudma;,citation_author=Jean-François Timsit;,citation_author=Romain Sonneville;,citation_author=Stein Silva;,citation_author=ENCEPHALITICA Consortium;,citation_author=Pierre Jaquet;,citation_author=Etienne Montmollin;,citation_author=Claire Dupuis;,citation_author=Mikael Alves;,citation_author=Laurent Argaud;,citation_author=Pierre Bailly;,citation_author=François Barbier;,citation_author=Lila Bouadma;,citation_author=Noelle Brulé;,citation_author=Fabrice Brunel;,citation_author=Russell Chabanne;,citation_author=Marie Conrad;,citation_author=Daniel Da Silva;,citation_author=Frederic Dailler;,citation_author=Delphine Daubin;,citation_author=Sophie Demeret;,citation_author=Nicolas Lerolle;,citation_author=Julien Marechal;,citation_author=Bruno Mourvillier;,citation_author=Ahmed El Kalioubi;,citation_author=Benjamine Sarton;,citation_author=Stein Silva;,citation_author=Romain Sonneville;,citation_author=Vincent Susset;,citation_author=Jean Marc Tadié;,citation_author=Jean-Françoit Timsit;,citation_author=Michel Wolff;,citation_author=Alexandre Lautrette;,citation_author=Emmanuel Novy;,citation_author=Bertrand Guidet;,citation_author=François Mateos;,citation_author=Clément Brault;,citation_author=Quentin Maestraggi;,citation_author=Keyvan Razazi;,citation_author=Jean-Pierre Quenot;,citation_author=Aurélie Joret;,citation_author=Albrice Levrat;,citation_author=Alexandre Massri;,citation_author=Alexandre Robert;,citation_author=Damien Contou;,citation_author=Jean-Paul Mira;,citation_author=Stephane Gaudry;,citation_author=Guillaume Voiriot;,citation_author=Asael Berger;,citation_author=Vincent Das;,citation_author=Nicolas Engrand;,citation_author=Martin Murgier;,citation_author=Shidasp Siami;,citation_author=Sami Hraiech;,citation_author=Eric Mariotte;,citation_author=Claire Ragot;,citation_author=Annabelle Stoclin;,citation_author=Pierre Trouiller;,citation_author=Mathieu Schmidt;,citation_author=Charline Sazio;,citation_publication_date=2021-07;,citation_cover_date=2021-07;,citation_year=2021;,citation_issue=7;,citation_doi=10.1001/jamanetworkopen.2021.14328;,citation_issn=2574-3805;,citation_volume=4;,citation_language=en-US;,citation_journal_title=JAMA Network Open;">
<meta name="citation_reference" content="citation_title=Are We Ready for Clinical Therapy based on Cerebral Autoregulation? A Pro-con Debate;,citation_abstract=Cerebral autoregulation (CA) is a physiological mechanism that maintains constant cerebral blood flow regardless of changes in cerebral perfusion pressure and prevents brain damage caused by hypoperfusion or hyperperfusion. In recent decades, researchers have investigated the range of systemic blood pressures and clinical management strategies over which cerebral vasculature modifies intracranial hemodynamics to maintain cerebral perfusion. However, proposed clinical interventions to optimize autoregulation status have not demonstrated clear clinical benefit. As future trials are designed, it is crucial to comprehend the underlying cause of our inability to produce robust clinical evidence supporting the concept of CA-targeted management. This article examines the technological advances in monitoring techniques and the accuracy of continuous assessment of autoregulation techniques used in intraoperative and intensive care settings today. It also examines how increasing knowledge of CA from recent clinical trials contributes to a greater understanding of secondary brain injury in many disease processes, despite the fact that the lack of robust evidence influencing outcomes has prevented the translation of CA-guided algorithms into clinical practice.;,citation_author=Aarti Sarwal;,citation_author=Chiara Robba;,citation_author=Carla Venegas;,citation_author=Wendy Ziai;,citation_author=Marek Czosnyka;,citation_author=Deepak Sharma;,citation_publication_date=2023-05;,citation_cover_date=2023-05;,citation_year=2023;,citation_doi=10.1007/s12028-023-01741-1;,citation_issn=1556-0961;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Should a Reduction in All-Cause Mortality Be the Goal When Assessing Preventive Medical Therapies?;,citation_author=Peter D. Sasieni;,citation_author=Nicholas J. Wald;,citation_publication_date=2017-05;,citation_cover_date=2017-05;,citation_year=2017;,citation_issue=21;,citation_doi=10.1161/CIRCULATIONAHA.116.023359;,citation_volume=135;,citation_journal_title=Circulation;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=Blood Pressure Management After Intracerebral Hemorrhage;,citation_abstract=Elevated blood pressure (BP), which presents in approximately 80&nbsp;% of patients with acute intracerebral hemorrhage (ICH), is associated with increased risk of poor outcome. The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT2) study, a multinational, multicenter, randomized controlled trial published in 2013, demonstrated better functional outcomes with no harm for patients with acute spontaneous ICH within 6&nbsp;h of onset who received target-driven, early intensive BP lowering (systolic BP target &amp;amp;amp;lt;140&nbsp;mmHg within 1&nbsp;h, continued for 7&nbsp;days) and suggested that greater and faster reduction in BP might enhance the treatment effect by limiting hematoma growth. The trial resulted in revisions of guidelines for acute management of ICH, in which intensive BP lowering in patients with acute ICH is recommended as safe and effective treatment for improving functional outcome. BP lowering is also the only intervention that is proven to reduce the risk of recurrent ICH. Current evidences from several randomized trials, including PROGRESS and SPS3, indicate that long-term strict BP control in patients with ICH is safe and could offer additional benefits in major reduction in risk of recurrent ICH. The latest American Heart Association/American Stroke Association (AHA/ASA) guidelines recommended a target BP of &amp;lt;130/80&nbsp;mmHg after ICH, but supporting evidence is limited. Randomized controlled trials are needed that focus on strict BP control, initiated early after onset of the disease and continued long-term, to demonstrate effective prevention of recurrent stroke and other major vascular events without additional harms in the ICH population.;,citation_author=Shoichiro Sato;,citation_author=Cheryl Carcel;,citation_author=Craig S. Anderson;,citation_publication_date=2015-10;,citation_cover_date=2015-10;,citation_year=2015;,citation_issue=12;,citation_doi=10.1007/s11940-015-0382-1;,citation_issn=1534-3138;,citation_volume=17;,citation_language=en-US;,citation_journal_title=Current Treatment Options in Neurology;">
<meta name="citation_reference" content="citation_title=Effect of IV High-Dose Vitamin C on Mortality in Patients With Sepsis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials;,citation_abstract=OBJECTIVES: The aim of this study was to conduct a systematic review and meta-analysis of randomized controlled trials to investigate whether IV high-dose vitamin C improves the short-term mortality of patients with sepsis. DESIGN: This study is a systematic review and meta-analysis of randomized controlled trials. We searched EMBASE, the Cochrane Central Register of Controlled Trials, and MEDLINE for randomized controlled trials that met inclusion criteria. The protocol was registered at the University hospital Medical Information Network Clinical Trials Registry (UMIN000040528). All analyses were presented with the use of random-effects models. The primary outcome was short-term mortality defined as 28-day, 30-day, or in-hospital mortality. PATIENTS: Two authors independently evaluated the following eligibility criteria: 1) randomized controlled trial, 2) patients with sepsis aged \geq18 years, and 3) received intravenous high-dose vitamin C in addition to standard of care, or standard of care alone. Then, two authors independently extracted the selected patient and study characteristics and outcomes from studies that met above eligibility criteria. MEASUREMENTS AND MAIN RESULTS: Eleven randomized controlled trials (n = 1,737 patients) were included in this meta-analysis. High-dose IV vitamin C was not associated with a significantly lower short-term mortality (risk ratio, 0.88; 95% CI, 0.73–1.06; p = 0.18; I2 = 29%) but was associated with a significantly shorter duration of vasopressor use (standardized mean difference, –0.35; 95% CI, –0.63 to –0.07; p &amp;amp;amp;lt; 0.01; I2 = 80%) and a significantly greater decline in the Sequential Organ Failure Assessment score at 72–96 hours (standardized mean difference, –0.20; 95% CI, –0.32 to –0.08; p &amp;lt; 0.01; I2 = 16%). One study reported significant association with hypernatremia, but adverse effects were rare, and high-dose vitamin C is deemed relatively safe. CONCLUSIONS: In this meta-analysis, the use of IV high-dose vitamin C in patients with sepsis was not associated with lower short-term mortality although it was associated with significantly shorter duration of vasopressor use and greater decline in the Sequential Organ Failure Assessment score at 72–96 hours.;,citation_author=Ryota Sato;,citation_author=Daisuke Hasegawa;,citation_author=Narut Prasitlumkum;,citation_author=Miki Ueoka;,citation_author=Kazuki Nishida;,citation_author=Kunihiko Takahashi;,citation_author=Michitaka Nasu;,citation_author=Siddharth Dugar;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_doi=10.1097/CCM.0000000000005263;,citation_issn=0090-3493;,citation_volume=Publish Ahead of Print;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Higher mortality in patients with right hemispheric intracerebral haemorrhage: INTERACT1 and 2;,citation_abstract=Background and purpose Controversy exists over the prognostic significance of the affected hemisphere in stroke. We aimed to determine the relationship between laterality of acute intracerebral haemorrhage (ICH) and poor clinical outcomes. Methods A subsidiary analysis of the INTERACT Pilot and INTERACT2 studies—randomised controlled trials of patients with spontaneous acute ICH with elevated systolic blood pressure (BP), randomly assigned to intensive (target systolic BP &amp;amp;amp;lt;140 mm Hg) or guideline-based (&amp;lt;180 mm Hg) BP management. Outcomes were the combined and separate end points of death and major disability (modified Rankin scale (mRS) scores of 3–6, 6 and 3–5, respectively) at 90 days. Results A total of 2708 patients had supratentorial/hemispheric ICH and information on mRS at 90 days. Patients with right hemispheric ICH (1327, 49%) had a higher risk of death at 90 days compared to those with left hemispheric ICH after adjustment for potential confounding variables (OR, 1.77 (95% CI 1.33 to 2.37)). There were no differences between patients with right and left hemispheric ICH regarding the combined end point of death or major disability or major disability in the multivariable-adjusted models (1.07 (0.89 to 1.29) and 0.85 (0.72 to 1.01), respectively). Conclusions Right hemispheric lesion was associated with increased risk of death in patients with acute ICH. The laterality of the ICH does not appear to affect the level of disability in survivors. Trial registration number URL: http://www.clinicaltrials.gov. Unique identifier: NCT00226096 and NCT00716079.;,citation_author=Shoichiro Sato;,citation_author=Emma Heeley;,citation_author=Hisatomi Arima;,citation_author=Candice Delcourt;,citation_author=Yoichiro Hirakawa;,citation_author=Vijaya Pamidimukkala;,citation_author=Zhendong Li;,citation_author=Qingling Tao;,citation_author=Yuehong Xu;,citation_author=Michael G. Hennerici;,citation_author=Thompson Robinson;,citation_author=Christophe Tzourio;,citation_author=Richard I. Lindley;,citation_author=John Chalmers;,citation_author=Craig S. Anderson;,citation_publication_date=2015-12;,citation_cover_date=2015-12;,citation_year=2015;,citation_issue=12;,citation_doi=10.1136/jnnp-2014-309870;,citation_issn=0022-3050, 1468-330X;,citation_pmid=25589782;,citation_volume=86;,citation_language=en-US;,citation_journal_title=Journal of Neurology, Neurosurgery &amp;amp; Psychiatry;,citation_publisher=BMJ Publishing Group Ltd;">
<meta name="citation_reference" content="citation_title=Systematic Review and Comparison of Publicly Available ICU Data Sets—A Decision Guide for Clinicians and Data Scientists;,citation_author=Christopher M. Sauer;,citation_author=Tariq A. Dam;,citation_author=Leo A. Celi;,citation_author=Martin Faltys;,citation_author=Miguel A. A. Hoz;,citation_author=Lasith Adhikari;,citation_author=Kirsten A. Ziesemer;,citation_author=Armand Girbes;,citation_author=Patrick J. Thoral;,citation_author=Paul Elbers;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_issue=6;,citation_doi=10.1097/CCM.0000000000005517;,citation_issn=0090-3493;,citation_volume=50;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Incidence and Outcome of Aneurysmal Subarachnoid Hemorrhage: The Swiss Study on Subarachnoid Hemorrhage (Swiss SOS);,citation_abstract=BACKGROUND AND PURPOSE: The purpose of this study was to assess nationwide incidence and outcomes of aneurysmal subarachnoid hemorrhage (aSAH). The Swiss SOS (Swiss Study on Subarachnoid Hemorrhage) was established in 2008 and offers the unique opportunity to provide this data from the point of care on a nationwide level. METHODS: All patients with confirmed aneurysmal subarachnoid hemorrhage admitted between January 1, 2009 and December 31, 2014, within Switzerland were recorded in a prospective registry. Incidence rates were calculated based on time-matched population data. Admission parameters and outcomes at discharge and at 1 year were recorded. RESULTS: We recorded data of 1787 consecutive patients. The incidence of aneurysmal subarachnoid hemorrhage in Switzerland was 3.7 per 100 000 persons/y. The number of female patients was 1170 (65.5%). With a follow-up rate of 91.3% at 1 year, 1042 patients (58.8%) led an independent life according to the modified Rankin Scale (0–2). About 1 in 10 patients survived in a dependent state (modified Rankin Scale, 3–5; n=185; 10.4%). Case fatality was 20.1% (n=356) at discharge and 22.1% (n=391) after 1 year. CONCLUSIONS: The current incidence of aneurysmal subarachnoid hemorrhage in Switzerland is lower than expected and an indication of a global trend toward decreasing admissions for ruptured intracranial aneurysms.;,citation_author=Bawarjan Schatlo;,citation_author=Christian Fung;,citation_author=Martin N. Stienen;,citation_author=Ali R. Fathi;,citation_author=Javier Fandino;,citation_author=Nicolas R. Smoll;,citation_author=Daniel Zumofen;,citation_author=Roy Thomas Daniel;,citation_author=Jan-Karl Burkhardt;,citation_author=David Bervini;,citation_author=Serge Marbacher;,citation_author=Michael Reinert;,citation_author=Donato DAlonzo;,citation_author=Peter Ahlborn;,citation_author=Vitor Mendes Pereira;,citation_author=Michel Roethlisberger;,citation_author=Martin Seule;,citation_author=Hassen Kerkeni;,citation_author=Luca Remonda;,citation_author=Astrid Weyerbrock;,citation_author=Kerstin Woernle;,citation_author=Alice Venier;,citation_author=Fabienne Perren;,citation_author=Martin Sailer;,citation_author=Thomas Robert;,citation_author=Veit Rohde;,citation_author=Daniel Schöni;,citation_author=Johannes Goldberg;,citation_author=Edin Nevzati;,citation_author=Michael Diepers;,citation_author=Jan Gralla;,citation_author=Werner Z’Graggen;,citation_author=Daniele Starnoni;,citation_author=Christoph Woernle;,citation_author=Nicolai Maldaner;,citation_author=Zsolt Kulcsar;,citation_author=Khaled Mostaguir;,citation_author=Rodolfo Maduri;,citation_author=Christian Eisenring;,citation_author=René Bernays;,citation_author=Andrea Ferrari;,citation_author=Hiroki Dan-Ura;,citation_author=Sina Finkenstädt;,citation_author=Yvan Gasche;,citation_author=Asita Sarrafzadeh;,citation_author=Stephan M. Jakob;,citation_author=Marco Corniola;,citation_author=Fabian Baumann;,citation_author=Luca Regli;,citation_author=Marc Levivier;,citation_author=Gerhard Hildebrandt;,citation_author=Hans Landolt;,citation_author=Luigi Mariani;,citation_author=Raphael Guzman;,citation_author=Jürgen Beck;,citation_author=Andreas Raabe;,citation_author=Emanuela Keller;,citation_author=Philippe Bijlenga;,citation_author=Karl Schaller;,citation_publication_date=2021-01;,citation_cover_date=2021-01;,citation_year=2021;,citation_issue=1;,citation_doi=10.1161/STROKEAHA.120.029538;,citation_issn=0039-2499, 1524-4628;,citation_volume=52;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=Danger Signals in the ICU:;,citation_abstract=DAMPs are integral in the early coordination of the innate immune system in a variety of acute illnesses. Specifically, they convey danger to other cells, trigger inflammation, and activate the innate immune system to stop further damage. DAMPs also organize tissue healing and participate in communication to inform the appropriate adaptive immune response (14, 54). The knowledge the immune system responds similarly to traumatic, ischemic, and pathogen-associated threats offers great insight into the clinical characteristics of the patients seen under our care. This is indeed an attractive theory that both share the same pathway. It is also clear that controlled release and activation of the immune system is needed to appropriately respond to danger. These responses are designed to clear damaged cells and to stop potential invasion of pathogens through lost barrier integrity (5, 14, 53). The overwhelming, exuberant, and dysregulated response could be modified for clinical benefit (97). However, even with our rudimentary understanding of DAMP release and immune activation the task is daunting. Multiple DAMPs are released with cell death and in turn activate many receptors with redundant pathways leading to immune coordination. Several trials that have blocked the best studied PAMP/TLR interaction (lipopolysaccharide and TLR4) have been unsuccessful in modifying further cytokine release or improving patient-centered outcomes (98, 99). Under normal conditions, most molecules that can act as DAMPs exist in the organism and are essential for its continued survival. Therefore, a key aspect of futures studies will be targeting these molecules specifically in their role as DAMPs but without hindering their normal role in the body. In the near term, it is not clear who could benefit from modulation of these responses in the acute setting. Indiscriminant blocking of the immune response with our current understanding of the basic science is unlikely to help patients (100, 101).;,citation_author=Edward J. Schenck;,citation_author=Kevin C. Ma;,citation_author=Santosh B. Murthy;,citation_author=Augustine M. K. Choi;,citation_publication_date=2018-05;,citation_cover_date=2018-05;,citation_year=2018;,citation_issue=5;,citation_doi=10.1097/CCM.0000000000003007;,citation_issn=0090-3493;,citation_volume=46;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Rapidly Improving ARDS in Therapeutic Randomized Controlled Trials;,citation_abstract=BACKGROUND: Observational studies suggest that some patients meeting criteria for ARDS no longer fulfill the oxygenation criterion early in the course of their illness. This subphenotype of rapidly improving ARDS has not been well characterized. We attempted to assess the prevalence, characteristics, and outcomes of rapidly improving ARDS and to identify which variables are useful to predict it. METHODS: A secondary analysis was performed of patient level data from six ARDS Network&nbsp;randomized controlled trials. We defined rapidly improving ARDS, contrasted with ARDS &amp;amp;amp;gt; 1&nbsp;day, as extubation or a Pao2 to Fio2 ratio (Pao2:Fio2) &amp;gt; 300 on the first study day following enrollment. RESULTS: The prevalence of rapidly improving ARDS was 10.5%&nbsp;(458 of 4,361 patients) and increased over time. Of the 1,909 patients enrolled in the three most recently published trials, 197 (10.3%) were extubated on the first study day, and 265 (13.9%) in total had rapidly improving ARDS. Patients with rapidly improving ARDS had lower baseline severity of&nbsp;illness and lower 60-day mortality (10.2%&nbsp;vs&nbsp;26.3%; P&nbsp;&amp;lt; .0001) than ARDS >~1&nbsp;day. Pao2:Fio2 at screening, change in Pao2:Fio2 from screening to enrollment, use of vasopressor agents, Fio2 at enrollment, and serum bilirubin levels were useful predictive variables. CONCLUSIONS: Rapidly improving ARDS, mostly defined by early extubation, is an increasingly prevalent and distinct subphenotype, associated with better outcomes than ARDS > 1&nbsp;day. Enrollment of patients with rapidly improving ARDS may negatively affect the prognostic enrichment and contribute to the failure of therapeutic trials.;,citation_author=Edward J. Schenck;,citation_author=Clara Oromendia;,citation_author=Lisa K. Torres;,citation_author=David A. Berlin;,citation_author=Augustine M. K. Choi;,citation_author=Ilias I. Siempos;,citation_publication_date=2019-03;,citation_cover_date=2019-03;,citation_year=2019;,citation_issue=3;,citation_doi=10.1016/j.chest.2018.09.031;,citation_issn=1931-3543;,citation_pmid=30359616;,citation_volume=155;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Is the literature inconclusive about the harm of HES? We are not sure;,citation_author=Miet Schetz;,citation_author=Andrew D. Shaw;,citation_author=Jean-Louis Vincent;,citation_publication_date=2017-10;,citation_cover_date=2017-10;,citation_year=2017;,citation_issue=10;,citation_doi=10.1007/s00134-016-4329-0;,citation_issn=0342-4642, 1432-1238;,citation_volume=43;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Lower or Higher Oxygenation Targets for Acute Hypoxemic Respiratory Failure;,citation_abstract=BACKGROUND: Patients with acute hypoxemic respiratory failure in the intensive care unit (ICU) are treated with supplemental oxygen, but the benefits and harms of different oxygenation targets are unclear. We hypothesized that using a lower target for partial pressure of arterial oxygen (Pao2) would result in lower mortality than using a higher target. METHODS: In this multicenter trial, we randomly assigned 2928 adult patients who had recently been admitted to the ICU (\leq12 hours before randomization) and who were receiving at least 10 liters of oxygen per minute in an open system or had a fraction of inspired oxygen of at least 0.50 in a closed system to receive oxygen therapy targeting a Pao2 of either 60 mm Hg (lower-oxygenation group) or 90 mm Hg (higher-oxygenation group) for a maximum of 90 days. The primary outcome was death within 90 days. RESULTS: At 90 days, 618 of 1441 patients (42.9%) in the lower-oxygenation group and 613 of 1447 patients (42.4%) in the higher-oxygenation group had died (adjusted risk ratio, 1.02; 95% confidence interval, 0.94 to 1.11; P = 0.64). At 90 days, there was no significant between-group difference in the percentage of days that patients were alive without life support or in the percentage of days they were alive after hospital discharge. The percentages of patients who had new episodes of shock, myocardial ischemia, ischemic stroke, or intestinal ischemia were similar in the two groups (P = 0.24). CONCLUSIONS: Among adult patients with acute hypoxemic respiratory failure in the ICU, a lower oxygenation target did not result in lower mortality than a higher target at 90 days. (Funded by the Innovation Fund Denmark and others; HOT-ICU ClinicalTrials.gov number, NCT03174002.).;,citation_author=Olav L. Schjørring;,citation_author=Thomas L. Klitgaard;,citation_author=Anders Perner;,citation_author=Jørn Wetterslev;,citation_author=Theis Lange;,citation_author=Martin Siegemund;,citation_author=Minna Bäcklund;,citation_author=Frederik Keus;,citation_author=Jon H. Laake;,citation_author=Matthew Morgan;,citation_author=Katrin M. Thormar;,citation_author=Søren A. Rosborg;,citation_author=Jannie Bisgaard;,citation_author=Annette E. S. Erntgaard;,citation_author=Anne-Sofie H. Lynnerup;,citation_author=Rasmus L. Pedersen;,citation_author=Elena Crescioli;,citation_author=Theis C. Gielstrup;,citation_author=Meike T. Behzadi;,citation_author=Lone M. Poulsen;,citation_author=Stine Estrup;,citation_author=Jens P. Laigaard;,citation_author=Cheme Andersen;,citation_author=Camilla B. Mortensen;,citation_author=Björn A. Brand;,citation_author=Jonathan White;,citation_author=Inge-Lise Jarnvig;,citation_author=Morten H. Møller;,citation_author=Lars Quist;,citation_author=Morten H. Bestle;,citation_author=Martin Schønemann-Lund;,citation_author=Maj K. Kamper;,citation_author=Mathias Hindborg;,citation_author=Alexa Hollinger;,citation_author=Caroline E. Gebhard;,citation_author=Núria Zellweger;,citation_author=Christian S. Meyhoff;,citation_author=Mathias Hjort;,citation_author=Laura K. Bech;,citation_author=Thorbjørn Grøfte;,citation_author=Helle Bundgaard;,citation_author=Lars H. M. Østergaard;,citation_author=Maria A. Thyø;,citation_author=Thomas Hildebrandt;,citation_author=Bülent Uslu;,citation_author=Christoffer G. Sølling;,citation_author=Nette Møller-Nielsen;,citation_author=Anne C. Brøchner;,citation_author=Morten Borup;,citation_author=Marjatta Okkonen;,citation_author=Willem Dieperink;,citation_author=Ulf G. Pedersen;,citation_author=Anne S. Andreasen;,citation_author=Lone Buus;,citation_author=Tayyba N. Aslam;,citation_author=Robert R. Winding;,citation_author=Joerg C. Schefold;,citation_author=Stine B. Thorup;,citation_author=Susanne A. Iversen;,citation_author=Janus Engstrøm;,citation_author=Maj-Brit N. Kjær;,citation_author=Bodil S. Rasmussen;,citation_author=HOT-ICU Investigators;,citation_publication_date=2021-04;,citation_cover_date=2021-04;,citation_year=2021;,citation_issue=14;,citation_doi=10.1056/NEJMoa2032510;,citation_issn=1533-4406;,citation_pmid=33471452;,citation_volume=384;,citation_language=en-US;,citation_journal_title=The New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Oxygen Targets in Comatose Survivors of Cardiac Arrest;,citation_author=Henrik Schmidt;,citation_author=Jesper Kjaergaard;,citation_author=Christian Hassager;,citation_author=Simon Mølstrøm;,citation_author=Johannes Grand;,citation_author=Britt Borregaard;,citation_author=Laust E. Roelsgaard Obling;,citation_author=Søren Venø;,citation_author=Laura Sarkisian;,citation_author=Dmitry Mamaev;,citation_author=Lisette O. Jensen;,citation_author=Benjamin Nyholm;,citation_author=Dan E. Høfsten;,citation_author=Jakob Josiassen;,citation_author=Jakob H. Thomsen;,citation_author=Jens J. Thune;,citation_author=Matias G. Lindholm;,citation_author=Martin A. Stengaard Meyer;,citation_author=Matilde Winther-Jensen;,citation_author=Marc Sørensen;,citation_author=Martin Frydland;,citation_author=Rasmus P. Beske;,citation_author=Ruth Frikke-Schmidt;,citation_author=Sebastian Wiberg;,citation_author=Søren Boesgaard;,citation_author=Vibeke Lind Jørgensen;,citation_author=Jacob E. Møller;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_issue=0;,citation_doi=10.1056/NEJMoa2208686;,citation_issn=0028-4793;,citation_volume=0;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Prone Positioning During Extracorporeal Membrane Oxygenation in Patients With Severe ARDS: The PRONECMO Randomized Clinical Trial;,citation_abstract=OBJECTIVE To test whether prone positioning vs supine positioning decreases the time to successful ECMO weaning in patients with severe ARDS supported by VV-ECMO. DESIGN, SETTING, AND PARTICIPANTS Randomized clinical trial of patients with severe ARDS undergoing VV-ECMO for less than 48 hours at 14 intensive care units (ICUs) in France between March 3, 2021, and December 7, 2021. INTERVENTIONS Patients were randomized 1:1 to prone positioning (at least 4 sessions of 16 hours) (n = 86) or to supine positioning (n = 84). MAIN OUTCOMES AND MEASURES The primary outcome was time to successful ECMO weaning within 60 days following randomization. Secondary outcomes included ECMO and mechanical ventilation–free days, ICU and hospital length of stay, skin pressure injury, serious adverse events, and all-cause mortality at 90-day follow-up. RESULTS Among 170 randomized patients (median age, 51 [IQR, 43-59] years; n = 60 women [35%]), median respiratory system compliance was 15.0 (IQR, 10.7-20.6) mL/cm H2O; 159 patients (94%) had COVID-19–related ARDS; and 164 (96%) were in prone position before ECMO initiation. Within 60 days of enrollment, 38 of 86 patients (44%) had successful ECMO weaning in the prone ECMO group compared with 37 of 84 (44%) in the supine ECMO group (risk difference, 0.1% [95% CI, -14.9% to 15.2%]; subdistribution hazard ratio, 1.11 [95% CI, 0.71-1.75]; P = .64). Within 90 days, no significant difference was observed in ECMO duration (28 vs 32 days; difference, -4.9 [95% CI, -11.2 to 1.5] days; P = .13), ICU length of stay, or 90-day mortality (51% vs 48%; risk difference, 2.4% [95% CI, -13.9% to 18.6%]; P = .62). No serious adverse events were reported during the prone position procedure. CONCLUSIONS AND RELEVANCE Among patients with severe ARDS supported by VV-ECMO, prone positioning compared with supine positioning did not significantly reduce time to successful weaning of ECMO.;,citation_author=Matthieu Schmidt;,citation_author=David Hajage;,citation_author=Guillaume Lebreton;,citation_author=Martin Dres;,citation_author=Christophe Guervilly;,citation_author=Jean Christophe Richard;,citation_author=Romain Sonneville;,citation_author=Hadrien Winiszewski;,citation_author=Gregoire Muller;,citation_author=Gaëtan Beduneau;,citation_author=Emmanuelle Mercier;,citation_author=Hadrien Roze;,citation_author=Mathieu Lesouhaitier;,citation_author=Nicolas Terzi;,citation_author=Arnaud W. Thille;,citation_author=Isaura Laurent;,citation_author=Antoine Kimmoun;,citation_author=Alain Combes;,citation_author=PRONECMO Investigators, the REVA Network, and the International ECMO Network (ECMONet);,citation_author=Charles Edouard Luyt;,citation_author=Guillaume Hekimian;,citation_author=Nicolas Brechot;,citation_author=Juliette Chommeloux;,citation_author=Marc Pineton De Chambrun;,citation_author=Ouriel Saura;,citation_author=David Levy;,citation_author=Lucie Lefevre;,citation_author=Benjamin Assouline;,citation_author=Petra Bahroum;,citation_author=Melchior Gautier;,citation_author=Pascal Leprince;,citation_author=Charles Juvin;,citation_author=Pierre Demondion;,citation_author=Elodie Bergue;,citation_author=Pichoy Danial;,citation_author=Hamed Al-kabani;,citation_author=Karl Bounader;,citation_author=Thibaut Schoell;,citation_author=Cosimo D’Allesandro;,citation_author=Côme Bureau;,citation_author=Julien Le Marec;,citation_author=Julien Mayaux;,citation_author=Maxens Decavèle;,citation_author=Alexandre Demoule;,citation_author=Robin Deleris;,citation_author=Safaa Nemlaghi;,citation_author=Marie Lecronier;,citation_author=Gilles Capellier;,citation_author=Gael Piton;,citation_author=Francois Belon;,citation_author=Thibault Vieille;,citation_author=Valentin Lafay;,citation_author=Camille Manfait;,citation_author=Romain Tapponnier;,citation_author=Nicolas Belin;,citation_author=Arnaud Gacouin;,citation_author=Jean-Marc Tadié;,citation_author=Laurent Papazian;,citation_author=Sami Hraiech;,citation_author=Jean-Marie Forel;,citation_author=Antoine Roch;,citation_author=Mélanie Adda;,citation_author=Florence Daviet;,citation_author=Ines Gragueb-Chatti;,citation_author=Laura Textoris;,citation_author=Jean-François Timsit;,citation_author=Lila Bouadma;,citation_author=Etienne De Montmollin;,citation_author=Fariza Lamara;,citation_author=Véronique Deiler;,citation_author=Marylou Para;,citation_author=Patrick Nataf;,citation_author=Sylia Zmihi;,citation_author=Paul Henri Wicky;,citation_author=Juliette Patrier;,citation_author=Pierre Jaquet;,citation_author=Bruno Levy;,citation_author=Pierre Perez;,citation_author=Carine Thivilier;,citation_author=Mathieu Mattei;,citation_author=Clément Haddadi;,citation_author=Matthieu Kozutski;,citation_author=Pablo Maureira;,citation_author=Hodane Yonis;,citation_author=Medhi Mezidi;,citation_author=Louis Chauvelot;,citation_author=William Danjou;,citation_author=Francois Dhelft;,citation_author=Laurent Bitker;,citation_author=Clotilde Bettinger;,citation_author=Pauline Bernon;,citation_author=Grégoire Jolly;,citation_author=Dorothée Carpentier;,citation_author=Mai-Anh Nay;,citation_author=Thierry Boulain;,citation_author=Toukif Kamel;,citation_author=Francois Barbier;,citation_author=Anne Bretagnol;,citation_author=Armelle Mathonnet;,citation_author=Maxime Desgrouas;,citation_author=Marie Skarzynski;,citation_author=Benjamin Repusseau;,citation_author=Florian Sigaud;,citation_author=Guillaume Rigault;,citation_author=Louis-Marie Galerneau;,citation_author=Carole Schwebel;,citation_author=Clara Candille;,citation_author=Anaı̈s Dartevel;,citation_author=Joanna Bougnaud;,citation_author=Emanuele Turbil;,citation_author=Stephan Ehrmann;,citation_author=Denis Garot;,citation_author=Charlotte Salmon;,citation_author=Sylvain Le Pape;,citation_author=Francois Arrivé;,citation_publication_date=2023-12;,citation_cover_date=2023-12;,citation_year=2023;,citation_issue=24;,citation_doi=10.1001/jama.2023.24491;,citation_issn=0098-7484;,citation_volume=330;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Treatment of ARDS With Prone Positioning;,citation_author=Eric L. Scholten;,citation_author=Jeremy R. Beitler;,citation_author=G. Kim Prisk;,citation_author=Atul Malhotra;,citation_publication_date=2017-01;,citation_cover_date=2017-01;,citation_year=2017;,citation_issue=1;,citation_doi=10.1016/j.chest.2016.06.032;,citation_issn=00123692;,citation_volume=151;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=“Selection Bias by Death” and Other Ways Collider Bias May Cause the Obesity Paradox:;,citation_author=C. Mary Schooling;,citation_author=Shiu Lun Au Yeung;,citation_publication_date=2017-03;,citation_cover_date=2017-03;,citation_year=2017;,citation_issue=2;,citation_doi=10.1097/EDE.0000000000000591;,citation_issn=1044-3983;,citation_volume=28;,citation_language=en-US;,citation_journal_title=Epidemiology;">
<meta name="citation_reference" content="citation_title=Transplantation Outcomes with Donor Hearts after Circulatory Death;,citation_author=Jacob N. Schroder;,citation_author=Chetan B. Patel;,citation_author=Adam D. DeVore;,citation_author=Benjamin S. Bryner;,citation_author=Sarah Casalinova;,citation_author=Ashish Shah;,citation_author=Jason W. Smith;,citation_author=Amy G. Fiedler;,citation_author=Mani Daneshmand;,citation_author=Scott Silvestry;,citation_author=Arnar Geirsson;,citation_author=Victor Pretorius;,citation_author=David L. Joyce;,citation_author=John Y. Um;,citation_author=Fardad Esmailian;,citation_author=Koji Takeda;,citation_author=Karol Mudy;,citation_author=Yasuhiro Shudo;,citation_author=Christopher T. Salerno;,citation_author=Si M. Pham;,citation_author=Daniel J. Goldstein;,citation_author=Jonathan Philpott;,citation_author=John Dunning;,citation_author=Lucian Lozonschi;,citation_author=Gregory S. Couper;,citation_author=Hari Reddy Mallidi;,citation_author=Michael M. Givertz;,citation_author=Duc Thinh Pham;,citation_author=Andrew W. Shaffer;,citation_author=Masashi Kai;,citation_author=Mohammed A. Quader;,citation_author=Tarek Absi;,citation_author=Tamer S. Attia;,citation_author=Bassam Shukrallah;,citation_author=Ben C. Sun;,citation_author=Maryjane Farr;,citation_author=Mandeep R. Mehra;,citation_author=Joren C. Madsen;,citation_author=Carmelo A. Milano;,citation_author=David A. D’Alessandro;,citation_publication_date=2023-06;,citation_cover_date=2023-06;,citation_year=2023;,citation_issue=23;,citation_doi=10.1056/NEJMoa2212438;,citation_issn=0028-4793;,citation_volume=388;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Graphical Causal Models for Survey Inference;,citation_abstract=Directed acyclic graphs (DAGs) are now a popular tool to inform causal inferences. We discuss how DAGs can also be used to encode theoretical assumptions about nonprobability samples and survey nonresponse and to determine whether population quantities including conditional distributions and regressions can be identified. We describe sources of bias and assumptions for eliminating it in various selection scenarios. We then introduce and analyze graphical representations of multiple selection stages in the data collection process, and highlight the strong assumptions implicit in using only design weights. Furthermore, we show that the common practice of selecting adjustment variables based on correlations with sample selection and outcome variables of interest is ill-justified and that nonresponse weighting when the interest is in causal inference may come at severe costs. Finally, we identify further areas for survey methodology research that can benefit from advances in causal graph theory.;,citation_author=Julian Schuessler;,citation_author=Peter Selb;,citation_publication_date=2019-11;,citation_cover_date=2019-11;,citation_year=2019;,citation_doi=10.31235/osf.io/hbg3m;,citation_language=en-US;,citation_publisher=SocArXiv;">
<meta name="citation_reference" content="citation_title=The Impact of Acute Organ Dysfunction on Long-Term Survival in Sepsis*:;,citation_abstract=Objective—To estimate the impact of each of six types of acute organ dysfunction (hepatic, renal, coagulation, neurologic, cardiac, and respiratory) on long-term mortality after surviving sepsis hospitalization.;,citation_author=Alejandro Schuler;,citation_author=David A. Wulf;,citation_author=Yun Lu;,citation_author=Theodore J. Iwashyna;,citation_author=Gabriel J. Escobar;,citation_author=Nigam H. Shah;,citation_author=Vincent X. Liu;,citation_publication_date=2018-06;,citation_cover_date=2018-06;,citation_year=2018;,citation_issue=6;,citation_doi=10.1097/CCM.0000000000003023;,citation_issn=0090-3493;,citation_volume=46;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Is There Hope? Is She There? How Families and Clinicians Experience Severe Acute Brain Injury;,citation_abstract=Background: Patients with severe acute brain injury (SABI) raise important palliative care considerations associated with sudden devastating injury and uncertain prognosis. Objective: The goal of this study was to explore how family members, nurses, and physicians experience the palliative and supportive care needs of patients with SABI receiving care in the neuroscience intensive care unit (neuro-ICU). Design: Semistructured interviews were audiotaped, transcribed, and analyzed using thematic analysis. Setting/Subjects: Thirty-bed neuro-ICU in a regional comprehensive stroke and level-one trauma center in the United States. We completed 47 interviews regarding 15 patients with family members (n = 16), nurses (n = 15), and physicians (n = 16). Results: Two themes were identified: (1) hope and (2) personhood. (1) Families linked prognostic uncertainty to a need for hope and expressed a desire for physicians to acknowledge this relationship. The language of hope varied depending on the participant: clinicians used hope as an object that can be given or taken away, generally in the process of conveying prognosis, while families expressed hope as an action that supported coping with their loved one’s acute illness and its prognostic uncertainty. (2) Participants described the loss of personhood through brain injury, the need to recognize and treat the brain-injured patient as a person, and the importance of relatedness and connection, including personal support of families by clinicians. Conclusions: Support for hope and preservation of personhood challenge care in the neuro-ICU as identified by families and clinicians of patients with SABI. Specific practical approaches can address these challenges and improve the palliative care provided to patients and families in the neuro-ICU.;,citation_author=Rachael E. C. Schutz;,citation_author=Heather L. Coats;,citation_author=Ruth A. Engelberg;,citation_author=J. Randall Curtis;,citation_author=Claire J. Creutzfeldt;,citation_publication_date=2017-02;,citation_cover_date=2017-02;,citation_year=2017;,citation_issue=2;,citation_doi=10.1089/jpm.2016.0286;,citation_issn=1096-6218;,citation_volume=20;,citation_journal_title=Journal of Palliative Medicine;,citation_publisher=Mary Ann Liebert, Inc., publishers;">
<meta name="citation_reference" content="citation_title=Ten simple rules for good research practice;,citation_author=Simon Schwab;,citation_author=Perrine Janiaud;,citation_author=Michael Dayan;,citation_author=Valentin Amrhein;,citation_author=Radoslaw Panczak;,citation_author=Patricia M. Palagi;,citation_author=Lars G. Hemkens;,citation_author=Meike Ramon;,citation_author=Nicolas Rothen;,citation_author=Stephen Senn;,citation_author=Eva Furrer;,citation_author=Leonhard Held;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_issue=6;,citation_doi=10.1371/journal.pcbi.1010139;,citation_issn=1553-7358;,citation_volume=18;,citation_language=en-US;,citation_journal_title=PLOS Computational Biology;,citation_publisher=Public Library of Science;">
<meta name="citation_reference" content="citation_title=Ten Guidelines for Better Tables;,citation_abstract=Tables are a unique form of visualizing data because, unlike many charts, they are not usually intended to give a quick, visual representation of data. Instead, tables are useful when you want to show the exact values of your data or estimates. They are not the best solution if you want to show a lot of data or if you want to show the data in a compact space, but a well-designed table can help your reader find specific numbers and discover patterns and outliers. In this article, I present 10 guidelines for creating better, more effective tables; I then model these lessons by redesigning six tables from articles previously published in the Journal of Benefit-Cost Analysis.;,citation_author=Jonathan A. Schwabish;,citation_issue=2;,citation_doi=10.1017/bca.2020.11;,citation_issn=2194-5888, 2152-2812;,citation_volume=11;,citation_language=en-US;,citation_journal_title=Journal of Benefit-Cost Analysis;,citation_publisher=Cambridge University Press;">
<meta name="citation_reference" content="citation_title=The importance of stupidity in scientific research;,citation_author=Martin A. Schwartz;,citation_publication_date=2008-06;,citation_cover_date=2008-06;,citation_year=2008;,citation_doi=10.1242/jcs.033340;,citation_journal_title=Journal of Cell Science;">
<meta name="citation_reference" content="citation_title=Early physical and occupational therapy in mechanically ventilated, critically ill patients: A randomised controlled trial;,citation_author=William D. Schweickert;,citation_author=Mark C. Pohlman;,citation_author=Anne S. Pohlman;,citation_author=Celerina Nigos;,citation_author=Amy J. Pawlik;,citation_author=Cheryl L. Esbrook;,citation_author=Linda Spears;,citation_author=Megan Miller;,citation_author=Mietka Franczyk;,citation_author=Deanna Deprizio;,citation_author=Gregory A. Schmidt;,citation_author=Amy Bowman;,citation_author=Rhonda Barr;,citation_author=Kathryn E. McCallister;,citation_author=Jesse B. Hall;,citation_author=John P. Kress;,citation_publication_date=2009-05;,citation_cover_date=2009-05;,citation_year=2009;,citation_issue=9678;,citation_doi=10.1016/S0140-6736(09)60658-9;,citation_issn=0140-6736, 1474-547X;,citation_pmid=19446324;,citation_volume=373;,citation_language=en-US;,citation_journal_title=The Lancet;,citation_publisher=Elsevier;">
<meta name="citation_reference" content="citation_title=Timing of early mobilization to optimize outcomes in mechanically ventilated ICU patients;,citation_author=William D. Schweickert;,citation_author=Bhakti K. Patel;,citation_author=John P. Kress;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_doi=10.1007/s00134-022-06819-6;,citation_issn=1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Covid-19 vaccination: Evidence of waning immunity is overstated;,citation_author=Jake Scott;,citation_author=Aaron Richterman;,citation_author=Muge Cevik;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_doi=10.1136/bmj.n2320;,citation_issn=1756-1833;,citation_language=en-US;,citation_journal_title=BMJ;">
<meta name="citation_reference" content="citation_title=Extracorporeal cardiopulmonary resuscitation for out-of-hospital cardiac arrest: A systematic review and meta-analysis of randomized and propensity score-matched studies;,citation_abstract=Background: In selected patients with refractory out-of-hospital cardiac arrest, extracorporeal cardiopulmonary resuscitation represents a promising approach when conventional cardiopulmonary resuscitation fails to achieve return of spontaneous circulation. This systematic review and meta-a nalysis aimed to compare extracorporeal cardiopulmonary resuscitation to conventional cardiopulmonary resuscitation. Methods: We searched PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials up to November 28, 2021, for randomized trials and observational studies reporting propensity score-matched data and comparing adults with out-o f-h ospital cardiac arrest treated with extracorporeal cardiopulmonary resuscitation with those treated with conventional cardiopulmonary resuscitation. The primary outcome was survival with favorable neurological outcome at the longest follow-u p available. Secondary outcomes were survival at the longest follow-u p available and survival at hospital discharge/30 days. Results: We included six studies, two randomized and four propensity score- matched studies. Patients treated with extracorporeal cardiopulmonary resuscitation had higher rates of survival with favorable neurological outcome (81/584 [14%] vs. 46/593 [7.8%]; OR = 2.11; 95% CI, 1.41–3 .15; p &amp;amp;amp;lt; 0.001, number needed to treat 16) and of survival (131/584 [22%] vs. 102/593 [17%]; OR = 1.40; 95% CI, 1.05–; p = 0.02) at the longest follow-up available compared with conventional cardiopulmonary resuscitation. Survival at hospital discharge/30 days was similar between the two groups (142/584 [24%] vs. 122/593 [21%]; OR = 1.26; 95% CI, 0.95–; p = 0.10). Conclusions: Evidence from randomized trials and propensity score-m atched studies suggests increased survival and favorable neurological outcome in patients with refractory out-of-hospital cardiac arrest treated with extracorporeal;,citation_author=Tommaso Scquizzato;,citation_author=Alessandra Bonaccorso;,citation_author=Michela Consonni;,citation_author=Anna Mara Scandroglio;,citation_author=Justyna Swol;,citation_author=Giovanni Landoni;,citation_author=Alberto Zangrillo;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_doi=10.1111/aor.14205;,citation_issn=0160-564X, 1525-1594;,citation_language=en-US;,citation_journal_title=Artificial Organs;">
<meta name="citation_reference" content="citation_title=Incidence, characteristics, and outcome of out-of-hospital cardiac arrest in Italy: A systematic review and meta-analysis;,citation_abstract=Introduction Data on out-of-hospital cardiac arrest (OHCA) is limited in Italy, and there has never been a comprehensive systematic appraisal of the available evidence. Therefore, this review aims to explore the incidence, characteristics, and outcome of OHCA in Italy. Methods We systematically searched PubMed, Embase, Google Scholar, ResearchGate, and conference proceedings up to September 23, 2022. Studies investigating OHCA in Italy and reporting at least one outcome related to cardiac arrest were considered eligible. The primary outcome was survival at the longest follow-up available. Risk of bias was assessed using the Joanna Briggs Institute critical appraisal tool. A random-effects model proportion meta-analysis was performed to calculate the pooled outcomes with 95% confidence interval (CI). Results We included 42 studies (43,042 patients) from 13 of the 20 Italian regions published between 1995 and 2022. Only five studies were deemed to be at low risk of bias. The overall average incidences of OHCA attended by emergency medical services and with resuscitation attempted were 86 (range: 10–190) and 55 (range: 6–108) per 100,000 populations per year, respectively. Survival at the longest follow-up available was 9.0% (95% CI, 6.7–12%; 30 studies and 15,195 patients) in the overall population, 25% (95% CI, 21–30%; 16 studies and 2,863 patients) among patients with shockable rhythms, 28% (95% CI, 20–37%; 8 studies and 1,292 patients) among the Utstein comparator group. Favourable neurological outcome was 5.0% (95% CI, 3.6–6.6%; 16 studies and 9,675 patients). Return of spontaneous circulation was achieved in 19% (95% CI, 16–23%; 40 studies and 30,875 patients) of cases. Bystanders initiated cardiopulmonary resuscitation in 26% (95% CI, 21–32%; 33 studies and 23,491 patients) of cases but only in 3.2% (95% CI, 1.9–4.9%; 9 studies and 8,508 patients) with an automated external defibrillator. The mean response time was 10.2 (95% CI, 8.9–11.4; 25 studies and 23,997 patients) minutes. Conclusions Survival after OHCA in Italy occurred in one of every ten patients. Bystanders initiated cardiopulmonary resuscitation in only one-third of cases, rarely with a defibrillator. Different areas of the country collected data, but an essential part of the population was not included. There was high heterogeneity and large variation in outcomes results and reporting, limiting the confidence in the estimates of incidence and outcome. Creating and maintaining a nationwide registry is a priority.;,citation_author=Tommaso Scquizzato;,citation_author=Lorenzo Gamberini;,citation_author=Sonia D’Arrigo;,citation_author=Alessandro Galazzi;,citation_author=Giovanni Babini;,citation_author=Rosario Losiggio;,citation_author=Guglielmo Imbriaco;,citation_author=Francesca Fumagalli;,citation_author=Alberto Cucino;,citation_author=Giovanni Landoni;,citation_author=Andrea Scapigliati;,citation_author=Giuseppe Ristagno;,citation_author=Federico Semeraro;,citation_author=Francesco Bertoncello;,citation_author=Alberto Canalini;,citation_author=Stefano Colelli;,citation_author=Giuseppe Conti;,citation_author=Maurizio Giacometti;,citation_author=Giovanni Giuliani;,citation_author=Alessandro Graziano;,citation_author=Andrea Mina;,citation_author=Silvia Orazio;,citation_author=Andrea Paoli;,citation_author=Alberto Peratoner;,citation_author=Carlo Pegani;,citation_author=Andrea Roncarati;,citation_author=Cesare Sabetta;,citation_author=Simone Savastano;,citation_author=Federica Stella;,citation_author=Rosanna Varutti;,citation_author=Francesca Verginella;,citation_author=Michele Zuliani;,citation_publication_date=2022-12;,citation_cover_date=2022-12;,citation_year=2022;,citation_doi=10.1016/j.resplu.2022.100329;,citation_issn=2666-5204;,citation_volume=12;,citation_language=en-US;,citation_journal_title=Resuscitation Plus;">
<meta name="citation_reference" content="citation_title=Randomised trials of temperature management in cardiac arrest: Are we observing the Zeno’s paradox of the Tortoise and Achilles?;,citation_author=Tommaso Scquizzato;,citation_author=Paul J. Young;,citation_author=Giovanni Landoni;,citation_author=Luisa Zaraca;,citation_author=Alberto Zangrillo;,citation_publication_date=2021-12;,citation_cover_date=2021-12;,citation_year=2021;,citation_issue=1;,citation_doi=10.1186/s13054-021-03826-9;,citation_issn=1364-8535;,citation_volume=25;,citation_language=en-US;,citation_journal_title=Critical Care;">
<meta name="citation_reference" content="citation_title=Advance Directives/Care Planning: Clear, Simple, and Wrong;,citation_author=R. Sean Morrison;,citation_publication_date=2020-07;,citation_cover_date=2020-07;,citation_year=2020;,citation_issue=7;,citation_doi=10.1089/jpm.2020.0272;,citation_issn=1096-6218, 1557-7740;,citation_volume=23;,citation_language=en-US;,citation_journal_title=Journal of Palliative Medicine;">
<meta name="citation_reference" content="citation_title=Severe Hyponatremia Correction, Mortality, and Central Pontine Myelinolysis;,citation_author=Harish Seethapathy;,citation_author=Sophia Zhao;,citation_author=Tianqi Ouyang;,citation_author=Christie Passos;,citation_author=Adviti Sarang;,citation_author=Pui W. Cheung;,citation_author=Sushrut S. Waikar;,citation_author=David J. R. Steele;,citation_author=Sahir Kalim;,citation_author=Andrew S. Allegretti;,citation_author=Juan Carlos Ayus;,citation_author=Sagar U. Nigwekar;,citation_publication_date=2023-09;,citation_cover_date=2023-09;,citation_year=2023;,citation_issue=10;,citation_doi=10.1056/EVIDoa2300107;,citation_volume=2;,citation_journal_title=NEJM Evidence;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Factors Associated With Overuse of Health Care Within US Health Systems: A Cross-sectional Analysis of Medicare Beneficiaries From 2016 to 2018;,citation_abstract=OBJECTIVE To measure low-value health care use within health systems in the US and explore features of the health systems associated with low-value care delivery. DESIGN, SETTING, AND PARTICIPANTS In this cross-sectional analysis, we identified occurrences of 17 low-value services in 3745 hospitals and affiliated outpatient sites. Hospitals were linked to 676 health systems in the US using the Agency for Healthcare Research and Quality (AHRQ) Compendium of Health Systems. The participants were 100% of Medicare beneficiaries with claims from 2016 to 2018. EXPOSURES We identified occurrences of 17 low-value services in 3839 hospitals and affiliated outpatient sites. MAIN OUTCOMES AND MEASURES Hospitals were linked to health systems using AHRQ’s Compendium of Health Systems. Between March and August 2021, we modeled overuse occurrences with a negative binomial regression model including the year-quarter, procedure indicator, and a health system indicator. The model included random effects for hospital and beneficiary age, sex, and comorbidity count specific to each indicator, hospital, and quarter. The beta coefficients associated with the health system term, normalized, reflect the tendency of that system to use low-value services relative to all other systems. With ordinary least squares regression, we explored health system characteristics associated with the Overuse Index (OI), expressed as a standard deviation where the mean across all health systems is 0. RESULTS There were 676 unique health systems assessed in our study that included from 1 to 163 hospitals (median of 2). The mean age of eligible beneficiaries was 75.5 years and 76% were women. Relative to the lowest tertile, health systems in the upper tertile of medical groups count and bed count had an OI that was higher by 0.38 standard deviations (SD) and 0.44 SD, respectively. Health systems that were primarily investor owned had an OI that was 0.56 SD higher than those that were not investor owned. Relative to the lowest tertile, health systems in the upper tertile of primary care physicians, upper tertile of teaching intensity, and upper quartile of uncompensated care had an OI that was lower by 0.59 SD, 0.45 SD, and 0.47 SD, respectively. CONCLUSIONS AND RELEVANCE In this cross-sectional study of US health systems, higher amounts of overuse among health systems were associated with investor ownership and fewer primary care physicians. The OI is a valuable tool for identifying potentially modifiable drivers of overuse and is adaptable to other levels of investigation, such as the state or region, which might be affected by local policies affecting payment or system consolidation.;,citation_author=Jodi B. Segal;,citation_author=Aditi P. Sen;,citation_author=Eliana Glanzberg-Krainin;,citation_author=Susan Hutfless;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=1;,citation_doi=10.1001/jamahealthforum.2021.4543;,citation_issn=2689-0186;,citation_volume=3;,citation_language=en-US;,citation_journal_title=JAMA Health Forum;">
<meta name="citation_reference" content="citation_title=Intravenous Thrombolytic Therapy for Treatment of Acute Ischemic Stroke in Patients Taking Non–Vitamin K Antagonist Oral Anticoagulants;,citation_author=David J. Seiffge;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_issue=8;,citation_doi=10.1001/jama.2022.0068;,citation_issn=0098-7484;,citation_volume=327;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial;,citation_abstract=OBJECTIVE To determine whether hydroxychloroquine is an efficacious treatment for adults hospitalized with COVID-19. DESIGN, SETTING, AND PARTICIPANTS This was a multicenter, blinded, placebo-controlled randomized trial conducted at 34 hospitals in the US. Adults hospitalized with respiratory symptoms from severe acute respiratory syndrome coronavirus 2 infection were enrolled between April 2 and June 19, 2020, with the last outcome assessment on July 17, 2020. The planned sample size was 510 patients, with interim analyses planned after every 102 patients were enrolled. The trial was stopped at the fourth interim analysis for futility with a sample size of 479 patients. INTERVENTIONS Patients were randomly assigned to hydroxychloroquine (400 mg twice daily for 2 doses, then 200 mg twice daily for 8 doses) (n = 242) or placebo (n = 237). MAIN OUTCOMES AND MEASURES The primary outcome was clinical status 14 days after randomization as assessed with a 7-category ordinal scale ranging from 1 (death) to 7 (discharged from the hospital and able to perform normal activities). The primary outcome was analyzed with a multivariable proportional odds model, with an adjusted odds ratio (aOR) greater than 1.0 indicating more favorable outcomes with hydroxychloroquine than placebo. The trial included 12 secondary outcomes, including 28-day mortality. RESULTS Among 479 patients who were randomized (median age, 57 years; 44.3% female; 37.2% Hispanic/Latinx; 23.4% Black; 20.1% in the intensive care unit; 46.8% receiving supplemental oxygen without positive pressure; 11.5% receiving noninvasive ventilation or nasal high-flow oxygen; and 6.7% receiving invasive mechanical ventilation or extracorporeal membrane oxygenation), 433 (90.4%) completed the primary outcome assessment at 14 days and the remainder had clinical status imputed. The median duration of symptoms prior to randomization was 5 days (interquartile range [IQR], 3 to 7 days). Clinical status on the ordinal outcome scale at 14 days did not significantly differ between the hydroxychloroquine and placebo groups (median [IQR] score, 6 [4-7] vs 6 [4-7]; aOR, 1.02 [95% CI, 0.73 to 1.42]). None of the 12 secondary outcomes were significantly different between groups. At 28 days after randomization, 25 of 241 patients (10.4%) in the hydroxychloroquine group and 25 of 236 (10.6%) in the placebo group had died (absolute difference, -0.2% [95% CI, -5.7% to 5.3%]; aOR, 1.07 [95% CI, 0.54 to 2.09]). CONCLUSIONS AND RELEVANCE Among adults hospitalized with respiratory illness from COVID-19, treatment with hydroxychloroquine, compared with placebo, did not significantly improve clinical status at day 14. These findings do not support the use of hydroxychloroquine for treatment of COVID-19 among hospitalized adults.;,citation_author=Wesley H. Self;,citation_author=Matthew W. Semler;,citation_author=Lindsay M. Leither;,citation_author=Jonathan D. Casey;,citation_author=Derek C. Angus;,citation_author=Roy G. Brower;,citation_author=Steven Y. Chang;,citation_author=Sean P. Collins;,citation_author=John C. Eppensteiner;,citation_author=Michael R. Filbin;,citation_author=D. Clark Files;,citation_author=Kevin W. Gibbs;,citation_author=Adit A. Ginde;,citation_author=Michelle N. Gong;,citation_author=Frank E. Harrell;,citation_author=Douglas L. Hayden;,citation_author=Catherine L. Hough;,citation_author=Nicholas J. Johnson;,citation_author=Akram Khan;,citation_author=Christopher J. Lindsell;,citation_author=Michael A. Matthay;,citation_author=Marc Moss;,citation_author=Pauline K. Park;,citation_author=Todd W. Rice;,citation_author=Bryce R. H. Robinson;,citation_author=David A. Schoenfeld;,citation_author=Nathan I. Shapiro;,citation_author=Jay S. Steingrub;,citation_author=Christine A. Ulysse;,citation_author=Alexandra Weissman;,citation_author=Donald M. Yealy;,citation_author=B. Taylor Thompson;,citation_author=Samuel M. Brown;,citation_author=National Heart, Lung, and Blood Institute PETAL Clinical Trials Network;,citation_publication_date=2020-12;,citation_cover_date=2020-12;,citation_year=2020;,citation_issue=21;,citation_doi=10.1001/jama.2020.22240;,citation_issn=0098-7484;,citation_volume=324;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized With COVID-19;,citation_author=Wesley H. Self;,citation_author=Allison P. Wheeler;,citation_author=Thomas G. Stewart;,citation_author=Harry Schrager;,citation_author=Jason Mallada;,citation_author=Christopher B. Thomas;,citation_author=Vince D. Cataldo;,citation_author=Hollis R. O’Neal;,citation_author=Nathan I. Shapiro;,citation_author=Conor Higgins;,citation_author=Adit A. Ginde;,citation_author=Lakshmi Chauhan;,citation_author=Nicholas J. Johnson;,citation_author=Daniel J. Henning;,citation_author=Stuti J. Jaiswal;,citation_author=Manoj J. Mammen;,citation_author=Estelle S. Harris;,citation_author=Sonal R. Pannu;,citation_author=Maryrose Laguio-Vila;,citation_author=Wissam El Atrouni;,citation_author=Marjolein Wit;,citation_author=Daanish Hoda;,citation_author=Claudia S. Cohn;,citation_author=Carla McWilliams;,citation_author=Carl Shanholtz;,citation_author=Alan E. Jones;,citation_author=Jay S. Raval;,citation_author=Simon Mucha;,citation_author=Tina S. Ipe;,citation_author=Xian Qiao;,citation_author=Stephen J. Schrantz;,citation_author=Aarthi Shenoy;,citation_author=Richard D. Fremont;,citation_author=Eric J. Brady;,citation_author=Robert H. Carnahan;,citation_author=James D. Chappell;,citation_author=James E. Crowe;,citation_author=Mark R. Denison;,citation_author=Pavlo Gilchuk;,citation_author=Laura J. Stevens;,citation_author=Rachel E. Sutton;,citation_author=Isaac Thomsen;,citation_author=Sandra M. Yoder;,citation_author=Amanda J. Bistran-Hall;,citation_author=Jonathan D. Casey;,citation_author=Christopher J. Lindsell;,citation_author=Li Wang;,citation_author=Jill M. Pulley;,citation_author=Jillian P. Rhoads;,citation_author=Gordon R. Bernard;,citation_author=Todd W. Rice;,citation_publication_date=2022-11;,citation_cover_date=2022-11;,citation_year=2022;,citation_issue=5;,citation_doi=10.1016/j.chest.2022.06.029;,citation_issn=00123692;,citation_volume=162;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Chest wall loading in the ICU: Pushes, weights, and positions;,citation_abstract=Clinicians monitor mechanical ventilatory support using airway pressures—primarily the plateau and driving pressure, which are considered by many to determine the safety of the applied tidal volume. These airway pressures are influenced not only by the ventilator prescription, but also by the mechanical properties of the respiratory system, which consists of the series-coupled lung and chest wall. Actively limiting chest wall expansion through external compression of the rib cage or abdomen is seldom performed in the ICU. Recent literature describing the respiratory mechanics of patients with late-stage, unresolving, ARDS, however, has raised awareness of the potential diagnostic (and perhaps therapeutic) value of this unfamiliar and somewhat counterintuitive practice. In these patients, interventions that reduce resting lung volume, such as loading the chest wall through application of external weights or manual pressure, or placing the torso in a more horizontal position, have unexpectedly improved tidal compliance of the lung and integrated respiratory system by reducing previously undetected end-tidal hyperinflation. In this interpretive review, we first describe underappreciated lung and chest wall interactions that are clinically relevant to both normal individuals and to the acutely ill who receive ventilatory support. We then apply these physiologic principles, in addition to published clinical observation, to illustrate the utility of chest wall modification for the purposes of detecting end-tidal hyperinflation in everyday practice.;,citation_author=John Selickman;,citation_author=John J. Marini;,citation_publication_date=2022-11;,citation_cover_date=2022-11;,citation_year=2022;,citation_issue=1;,citation_doi=10.1186/s13613-022-01076-8;,citation_issn=2110-5820;,citation_volume=12;,citation_journal_title=Annals of Intensive Care;">
<meta name="citation_reference" content="citation_title=Balanced Crystalloids versus Saline in Critically Ill Adults;,citation_abstract=BACKGROUND Both balanced crystalloids and saline are used for intravenous fluid administration in critically ill adults, but it is not known which results in better clinical outcomes. METHODS In a pragmatic, cluster-randomized, multiple-crossover trial conducted in five intensive care units at an academic center, we assigned 15,802 adults to receive saline (0.9% sodium chloride) or balanced crystalloids (lactated Ringer’s solution or Plasma-Lyte A) according to the randomization of the unit to which they were admitted. The primary outcome was a major adverse kidney event within 30 days — a composite of death from any cause, new renal-replacement therapy, or persistent renal dysfunction (defined as an elevation of the creatinine level to \geq200% of baseline) — all censored at hospital discharge or 30 days, whichever occurred first. RESULTS Among the 7942 patients in the balanced-crystalloids group, 1139 (14.3%) had a major adverse kidney event, as compared with 1211 of 7860 patients (15.4%) in the saline group (marginal odds ratio, 0.91; 95% confidence interval [CI], 0.84 to 0.99; conditional odds ratio, 0.90; 95% CI, 0.82 to 0.99; P = 0.04). In-hospital mortality at 30 days was 10.3% in the balanced-crystalloids group and 11.1% in the saline group (P = 0.06). The incidence of new renal-replacement therapy was 2.5% and 2.9%, respectively (P = 0.08), and the incidence of persistent renal dysfunction was 6.4% and 6.6%, respectively (P = 0.60). From the Department of Medicine, Division of Allergy, Pulmonary, and Critical Care Medicine (M.W.S., J.D.C., G.R.B., T.W.R.), the Departments of Emergency Medicine (W.H.S.), Anesthesiology (J.P.W., J.M.E., A.B.K., C.G.H., A.H., L. Weavind, A.D.S.), Biomedical Informatics (J.P.W., J.M.E.), Surgery (J.M.E., O.D.G., A.K.M.), Health Policy (J.M.E.), Biostatistics (L. Wang, D.W.B.), and Pharmaceutical Services (J.L.S.), and the Division of Nephrology and Hypertension, Vanderbilt Center for Kidney Disease and Integrated Program for Acute Kidney Disease (E.D.S.) — all at Vanderbilt University Medical Center, Nashville. Address reprint requests to Dr. Rice at the Department of Medicine, Vanderbilt University Medical Center, T-1218 MCN, 1161 21st Ave. S., Nashville, TN 37232, or at todd.rice@v anderbilt.edu. *A complete list of the SMART Investigators is provided in the Supplementary Appendix, available at NEJM.org. N Engl J Med 2018;378:829-39. DOI: 10.1056/NEJMoa1711584 Copyright © 2018 Massachusetts Medical Society. CONCLUSIONS Among critically ill adults, the use of balanced crystalloids for intravenous fluid administration resulted in a lower rate of the composite outcome of death from any cause, new renal-replacement therapy, or persistent renal dysfunction than the use of saline. (Funded by the Vanderbilt Institute for Clinical and Translational Research and others; SMART-MED and SMART-SURG ClinicalTrials.gov numbers, NCT02444988 and NCT02547779.);,citation_author=Matthew W. Semler;,citation_author=Wesley H. Self;,citation_author=Jonathan P. Wanderer;,citation_author=Jesse M. Ehrenfeld;,citation_author=Li Wang;,citation_author=Daniel W. Byrne;,citation_author=Joanna L. Stollings;,citation_author=Avinash B. Kumar;,citation_author=Christopher G. Hughes;,citation_author=Antonio Hernandez;,citation_author=Oscar D. Guillamondegui;,citation_author=Addison K. May;,citation_author=Liza Weavind;,citation_author=Jonathan D. Casey;,citation_author=Edward D. Siew;,citation_author=Andrew D. Shaw;,citation_author=Gordon R. Bernard;,citation_author=Todd W. Rice;,citation_publication_date=2018-03;,citation_cover_date=2018-03;,citation_year=2018;,citation_issue=9;,citation_doi=10.1056/NEJMoa1711584;,citation_issn=0028-4793, 1533-4406;,citation_pmid=29485925;,citation_volume=378;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Balanced Crystalloid Solutions;,citation_abstract=Intravenous fluid therapy is the most common intervention received by acutely ill patients. Historically, saline (0.9% sodium chloride) has been the most frequently administered intravenous fluid, especially in North America. Balanced crystalloid solutions (e.g., lactated Ringer’s, Plasma-Lyte) are an increasingly used alternative to saline. Balanced crystalloids have a sodium, potassium, and chloride content closer to that of extracellular fluid and, when given intravenously, have fewer adverse effects on acid–base balance. Preclinical research has demonstrated that saline may cause hyperchloremic metabolic acidosis, inflammation, hypotension, acute kidney injury, and death. Studies of patients and healthy human volunteers suggest that even relatively small volumes of saline may exert physiological effects. Randomized trials in the operating room have demonstrated that using balanced crystalloids rather than saline prevents the development of hyperchloremic metabolic acidosis and may reduce the need for vasopressors. Observational studies among critically ill adults have associated receipt of balanced crystalloids with lower rates of complications, including acute kidney injury and death. Most recently, large randomized trials among critically ill adults have examined whether balanced crystalloids result in less death or severe renal dysfunction than saline. Although some of these trials are still ongoing, a growing body of evidence raises fundamental concerns regarding saline as the primary intravenous crystalloid for critically ill adults and highlights fundamental unanswered questions for future research about fluid therapy in critical illness.;,citation_author=Matthew W. Semler;,citation_author=John A. Kellum;,citation_publication_date=2019-04;,citation_cover_date=2019-04;,citation_year=2019;,citation_issue=8;,citation_doi=10.1164/rccm.201809-1677CI;,citation_issn=1073-449X;,citation_volume=199;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;,citation_publisher=American Thoracic Society - AJRCCM;">
<meta name="citation_reference" content="citation_title=Identification of Major Adverse Kidney Events Within the Electronic Health Record;,citation_abstract=Acute kidney injury is common among critically ill adults and is associated with increased mortality and morbidity. The Major Adverse Kidney Events by 30&nbsp;days (MAKE30) composite of death, new renal replacement therapy, or persistent renal dysfunction is recommended as a patient-centered outcome for pragmatic trials involving acute kidney injury. Accurate electronic detection of the MAKE30 endpoint using data within the electronic health record (EHR) could facilitate the use of the EHR in large-scale kidney injury research. In an observational study using prospectively collected data from 200 admissions to a single medical intensive care unit, we tested the performance of electronically-extracted data in identifying the MAKE30 composite compared to the reference standard of two-physician manual chart review. The incidence of MAKE30 on manual-review was 16&nbsp;%, which included 8.5&nbsp;% for in-hospital mortality, 3.5&nbsp;% for new renal replacement therapy, and 8.5&nbsp;% for persistent renal dysfunction. There was strong agreement between the electronic and manual assessment of MAKE30 (98.5&nbsp;% agreement [95&nbsp;% CI 96.5-100.0&nbsp;%]; kappa 0.95 [95&nbsp;% CI 0.87-1.00]; P &amp;amp;amp;lt; 0.001), with only three patients misclassified by electronic assessment. Performance of the electronic MAKE30 assessment was similar among patients with and without CKD and with and without a measured serum creatinine in the 12&nbsp;months prior to hospital admission. In summary, accurately identifying the MAKE30 composite outcome using EHR data collected as a part of routine care appears feasible.;,citation_author=Matthew W. Semler;,citation_author=Todd W. Rice;,citation_author=Andrew D. Shaw;,citation_author=Edward D. Siew;,citation_author=Wesley H. Self;,citation_author=Avinash B. Kumar;,citation_author=Daniel W. Byrne;,citation_author=Jesse M. Ehrenfeld;,citation_author=Jonathan P. Wanderer;,citation_publication_date=2016-07;,citation_cover_date=2016-07;,citation_year=2016;,citation_issue=7;,citation_doi=10.1007/s10916-016-0528-z;,citation_issn=1573-689X;,citation_pmid=27234478;,citation_volume=40;,citation_language=en-US;,citation_journal_title=Journal of Medical Systems;">
<meta name="citation_reference" content="citation_title=Identifying Clinical Research Priorities in Adult Pulmonary and Critical Care. NHLBI Working Group Report;,citation_author=Matthew W. Semler;,citation_author=Gordon R. Bernard;,citation_author=Shawn D. Aaron;,citation_author=Derek C. Angus;,citation_author=Michelle H. Biros;,citation_author=Roy G. Brower;,citation_author=Carolyn S. Calfee;,citation_author=Elizabeth A. Colantuoni;,citation_author=Niall D. Ferguson;,citation_author=Michelle N. Gong;,citation_author=Ramona O. Hopkins;,citation_author=Catherine L. Hough;,citation_author=Theodore J. Iwashyna;,citation_author=Bruce D. Levy;,citation_author=Thomas R. Martin;,citation_author=Michael A. Matthay;,citation_author=Joseph P. Mizgerd;,citation_author=Marc Moss;,citation_author=Dale M. Needham;,citation_author=Wesley H. Self;,citation_author=Christopher W. Seymour;,citation_author=Renee D. Stapleton;,citation_author=B. Taylor Thompson;,citation_author=Richard G. Wunderink;,citation_author=Neil R. Aggarwal;,citation_author=Lora A. Reineck;,citation_publication_date=2020-08;,citation_cover_date=2020-08;,citation_year=2020;,citation_issue=4;,citation_doi=10.1164/rccm.201908-1595WS;,citation_issn=1073-449X, 1535-4970;,citation_volume=202;,citation_language=en-US;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Intravenous Fluids—A Test Case for Learning Health Systems;,citation_abstract=Bledsoe and colleagues present the results of the I USE LR study. This before-and-after study evaluated the outcomes associated with an implementation intervention promoting use of lactated Ringer solution rather than saline solution among nearly 150 000 patients across 22 hospitals. The intervention used education and changes to the electronic order entry system to affect which fluid patients received beginning immediately at hospital presentation. The proportion of intravenous fluid administered that was lactated Ringer increased (from approximately 25% to 75%) and the use of saline decreased (from approximately 75% to 25%). In interrupted time series analysis, implementation of lactated Ringer was associated with a 2% absolute risk reduction in death, new receipt of kidney replacement therapy, or persistent kidney dysfunction. This effect size was greater for patients with sepsis and patients who received more fluid. This study raises important questions about the choice between lactated Ringer and saline and, more broadly, how we should make evidence-based choices between widely available, commonly used treatment alternatives in acute care.;,citation_author=Matthew W. Semler;,citation_publication_date=2022-05;,citation_cover_date=2022-05;,citation_year=2022;,citation_issue=5;,citation_doi=10.1001/jamanetworkopen.2022.10054;,citation_issn=2574-3805;,citation_volume=5;,citation_journal_title=JAMA Network Open;">
<meta name="citation_reference" content="citation_title=Reply to Vincent and De Backer: We Do Not Appreciate SALT;,citation_author=Matthew W. Semler;,citation_author=Wesley H. Self;,citation_author=Li Wang;,citation_author=Gordon R. Bernard;,citation_author=Todd W. Rice;,citation_publication_date=2018-05;,citation_cover_date=2018-05;,citation_year=2018;,citation_issue=10;,citation_doi=10.1164/rccm.201803-0392LE;,citation_issn=1073-449X, 1535-4970;,citation_volume=197;,citation_language=en-US;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Contribution to the discussion of ’&amp;amp;amp;quot;A critical evaluation of the current p-value controversy&amp;quot;’;,citation_abstract=I pick up a very few points of minor disagreement with Stefan Wellek’s comprehensive review of P-values in this journal. I conclude that P-values have a limited function in statistical inference but can nevertheless have their uses.;,citation_author=Stephen Senn;,citation_publication_date=2017-09;,citation_cover_date=2017-09;,citation_year=2017;,citation_issue=5;,citation_doi=10.1002/bimj.201700032;,citation_issn=1521-4036;,citation_pmid=28452192;,citation_volume=59;,citation_language=en-US;,citation_journal_title=Biometrical Journal. Biometrische Zeitschrift;">
<meta name="citation_reference" content="citation_title=Invalid inversion;,citation_abstract=Stephen Senn warns us that some things work backwards, but others do not.;,citation_author=Stephen Senn;,citation_publication_date=2013;,citation_cover_date=2013;,citation_year=2013;,citation_issue=2;,citation_doi=10.1111/j.1740-9713.2013.00652.x;,citation_issn=1740-9713;,citation_volume=10;,citation_language=en-US;,citation_journal_title=Significance;">
<meta name="citation_reference" content="citation_title=Mastering variation: Variance components and personalised medicine;,citation_abstract=Various sources of variation in observed response in clinical trials and clinical practice are considered, and ways in which the corresponding components of variation might be estimated are discussed. Although the issues have been generally well-covered in the statistical literature, they seem to be poorly understood in the medical literature and even the statistical literature occasionally shows some confusion. To increase understanding and communication, some simple graphical approaches to illustrating issues are proposed. It is also suggested that reducing variation in medical practice might make as big a contribution to improving health outcome as personalising its delivery according to the patient. It is concluded that the common belief that there is a strong personal element in response to treatment is not based on sound statistical evidence. © 2015 The Authors. Statistics in Medicine published by John Wiley &amp;amp;amp; Sons Ltd.;,citation_author=Stephen Senn;,citation_publication_date=2016;,citation_cover_date=2016;,citation_year=2016;,citation_issue=7;,citation_doi=10.1002/sim.6739;,citation_issn=1097-0258;,citation_volume=35;,citation_language=en-US;,citation_journal_title=Statistics in Medicine;">
<meta name="citation_reference" content="citation_title=A note regarding meta-analysis of sequential trials with stopping for efficacy;,citation_abstract=It is shown that fixed-effect meta-analyses of naı̈ve treatment estimates from sequentially run trials with the possibility of stopping for efficacy based on a single interim look are unbiassed (or at the very least consistent, depending on the point of view) provided that the trials are weighted by information provided. A simple proof of this is given. An argument is given suggesting that this also applies in the case of multiple looks. The implications for this are discussed. Copyright © 2014 John Wiley &amp;amp;amp; Sons, Ltd.;,citation_author=Stephen Senn;,citation_publication_date=2014;,citation_cover_date=2014;,citation_year=2014;,citation_issue=6;,citation_doi=10.1002/pst.1639;,citation_issn=1539-1612;,citation_volume=13;,citation_language=en-US;,citation_journal_title=Pharmaceutical Statistics;">
<meta name="citation_reference" content="citation_title=Seven myths of randomisation in clinical trials;,citation_author=Stephen Senn;,citation_publication_date=2013-04;,citation_cover_date=2013-04;,citation_year=2013;,citation_issue=9;,citation_doi=10.1002/sim.5713;,citation_issn=02776715;,citation_volume=32;,citation_language=en-US;,citation_journal_title=Statistics in Medicine;">
<meta name="citation_reference" content="citation_title=Treatment Effects in Multicenter Randomized Clinical Trials;,citation_author=Stephen J. Senn;,citation_author=Roger J. Lewis;,citation_publication_date=2019-03;,citation_cover_date=2019-03;,citation_year=2019;,citation_issue=12;,citation_doi=10.1001/jama.2019.1480;,citation_issn=0098-7484;,citation_volume=321;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=You May Believe You Are a Bayesian But You Are Probably Wrong;,citation_abstract=An elementary sketch of some issues in statistical inference and in particular of the central role of likelihood is given. This is followed by brief outlines of what George Barnard considered were the four great systems of statistical inferences. These can be thought of terms of the four combinations of two factors at two levels. The first is fundamental purpose (decision or inference) and the second probability argument (direct or inverse). Of these four systems the “fully Bayesian” approach of decision-making using inverse probability particularly associated with the Ramsay, De Finetti, Savage and Lindley has some claims to be the most impressive. It is claimed, however, and illustrated by example, that this approach seems to be impossible to follow. It is speculated that there may be some advantage to the practising statistician to follow George Barnard’s advice of being familiar with all four systems.;,citation_author=Stephen Senn;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Current knowledge and management of portal vein thrombosis in cirrhosis;,citation_abstract=Portal vein thrombosis (PVT) is an increasingly recognised complication of cirrhosis whose incidence increases in parallel with the severity of cirrhosis. Several risk factors have been associated with the occurrence and progression of PVT. Although the negative effect of complete PVT on the surgical outcome of liver transplant recipients is clear, its impact on cirrhosis progression remains uncertain. Treatment options include anticoagulants and interventional thrombolytic therapies, which are chosen almost on a case-by-case basis depending on the characteristics of the patient and the thrombus. In this manuscript, we review current knowledge regarding the epidemiology, risk factors, diagnosis and classification, natural history, clinical consequences and treatment of non-neoplastic PVT in cirrhosis.;,citation_author=Marco Senzolo;,citation_author=Guadalupe Garcia-Tsao;,citation_author=Juan Carlos García-Pagán;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_issue=2;,citation_doi=10.1016/j.jhep.2021.04.029;,citation_issn=01688278;,citation_volume=75;,citation_language=en-US;,citation_journal_title=Journal of Hepatology;">
<meta name="citation_reference" content="citation_title=Sodium Rising: Deciphering the Code*;,citation_author=Nicolás Serrano;,citation_publication_date=2021-12;,citation_cover_date=2021-12;,citation_year=2021;,citation_issue=12;,citation_doi=10.1097/CCM.0000000000005222;,citation_issn=0090-3493;,citation_volume=49;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=SCAI Position Statement on Best Practices for Percutaneous Axillary Arterial Access and Training;,citation_abstract=Axillary artery access has become increasingly widespread as an alternative to the femoral route for large-bore transcatheter aortic valve replacement (TAVR), endovascular aortic repair (EVAR), and mechanical circulatory support (MCS) procedures. Advantages of percutaneous access include avoidance of a surgical incision, general anesthesia, and conduit graft infection. This statement aims to review the anatomic considerations and risks for percutaneous axillary artery access, suggest best practices for access techniques, hemostasis/closure strategies, and complication management, and recommend options for training and privileging.;,citation_author=Arnold H. Seto;,citation_author=Jerry D. Estep;,citation_author=Rajiv Tayal;,citation_author=Shirling Tsai;,citation_author=John C. Messenger;,citation_author=M. Chadi Alraies;,citation_author=Darren B. Schneider;,citation_author=Andrew J. Klein;,citation_author=Yazan Duwayri;,citation_author=James M. McCabe;,citation_author=Suzanne J. Baron;,citation_author=Venu Vadlamudi;,citation_author=Timothy D. Smith;,citation_author=David A. Baran;,citation_publication_date=2022-05;,citation_cover_date=2022-05;,citation_year=2022;,citation_issue=3;,citation_doi=10.1016/j.jscai.2022.100041;,citation_issn=27729303;,citation_volume=1;,citation_language=en-US;,citation_journal_title=Journal of the Society for Cardiovascular Angiography &amp;amp;amp; Interventions;">
<meta name="citation_reference" content="citation_title=Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor-Free Days in Patients With Sepsis: The VICTAS Randomized Clinical Trial;,citation_abstract=Sepsis is a common syndrome with substantial morbidity and mortality. A combination of vitamin C, thiamine, and corticosteroids has been proposed as a potential treatment for patients with sepsis.To determine whether a combination of vitamin C, thiamine, and hydrocortisone every 6 hours increases ventilator- and vasopressor-free days compared with placebo in patients with sepsis.Multicenter, randomized, double-blind, adaptive-sample-size, placebo-controlled trial conducted in adult patients with sepsis-induced respiratory and/or cardiovascular dysfunction. Participants were enrolled in the emergency departments or intensive care units at 43 hospitals in the United States between August 2018 and July 2019. After enrollment of 501 participants, funding was withheld, leading to an administrative termination of the trial. All study-related follow-up was completed by January 2020.Participants were randomized to receive intravenous vitamin C (1.5 g), thiamine (100 mg), and hydrocortisone (50 mg) every 6 hours (n = 252) or matching placebo (n = 249) for 96 hours or until discharge from the intensive care unit or death. Participants could be treated with open-label corticosteroids by the clinical team, with study hydrocortisone or matching placebo withheld if the total daily dose was greater or equal to the equivalent of 200 mg of hydrocortisone.The primary outcome was the number of consecutive ventilator- and vasopressor-free days in the first 30 days following the day of randomization. The key secondary outcome was 30-day mortality.Among 501 participants randomized (median age, 62 [interquartile range {IQR}, 50-70] years; 46% female; 30% Black; median Acute Physiology and Chronic Health Evaluation II score, 27 [IQR, 20.8-33.0]; median Sequential Organ Failure Assessment score, 9 [IQR, 7-12]), all completed the trial. Open-label corticosteroids were prescribed to 33% and 32% of the intervention and control groups, respectively. Ventilator- and vasopressor-free days were a median of 25 days (IQR, 0-29 days) in the intervention group and 26 days (IQR, 0-28 days) in the placebo group, with a median difference of -1 day (95% CI, -4 to 2 days; P = .85). Thirty-day mortality was 22% in the intervention group and 24% in the placebo group.Among critically ill patients with sepsis, treatment with vitamin C, thiamine, and hydrocortisone, compared with placebo, did not significantly increase ventilator- and vasopressor-free days within 30 days. However, the trial was terminated early for administrative reasons and may have been underpowered to detect a clinically important difference.ClinicalTrials.gov Identifier: NCT03509350;,citation_author=Jonathan E. Sevransky;,citation_author=Richard E. Rothman;,citation_author=David N. Hager;,citation_author=Gordon R. Bernard;,citation_author=Samuel M. Brown;,citation_author=Timothy G. Buchman;,citation_author=Laurence W. Busse;,citation_author=Craig M. Coopersmith;,citation_author=Christine DeWilde;,citation_author=E. Wesley Ely;,citation_author=Lindsay M. Eyzaguirre;,citation_author=Alpha A. Fowler;,citation_author=David F. Gaieski;,citation_author=Michelle N. Gong;,citation_author=Alex Hall;,citation_author=Jeremiah S. Hinson;,citation_author=Michael H. Hooper;,citation_author=Gabor D. Kelen;,citation_author=Akram Khan;,citation_author=Mark A. Levine;,citation_author=Roger J. Lewis;,citation_author=Chris J. Lindsell;,citation_author=Jessica S. Marlin;,citation_author=Anna McGlothlin;,citation_author=Brooks L. Moore;,citation_author=Katherine L. Nugent;,citation_author=Samuel Nwosu;,citation_author=Carmen C. Polito;,citation_author=Todd W. Rice;,citation_author=Erin P. Ricketts;,citation_author=Caroline C. Rudolph;,citation_author=Fred Sanfilippo;,citation_author=Kert Viele;,citation_author=Greg S. Martin;,citation_author=David W. Wright;,citation_author=VICTAS Investigators;,citation_publication_date=2021-02;,citation_cover_date=2021-02;,citation_year=2021;,citation_issue=8;,citation_doi=10.1001/jama.2020.24505;,citation_issn=0098-7484;,citation_volume=325;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=One-Year Outcome Trajectories and Factors Associated with Functional Recovery Among Survivors of Intracerebral and Intraventricular Hemorrhage With Initial Severe Disability;,citation_abstract=OBJECTIVE To describe 1-year recovery trajectories among ICH and IVH survivors with initial severe disability and assess the association of hospital events with long-term recovery. DESIGN, SETTING, AND PARTICIPANTS This post hoc analysis pooled all individual patient data from the Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage phase 3 trial (CLEAR-III) and the Minimally Invasive Surgery Plus Alteplase for Intracerebral Hemorrhage Evacuation (MISTIE-III) phase 3 trial in multiple centers across the US, Canada, Europe, and Asia. Patients were enrolled from August 1, 2010, to September 30, 2018, with a follow-up duration of 1 year. Of 999 enrolled patients, 724 survived with a day 30 modified Rankin Scale score (mRS) of 4 to 5 after excluding 13 participants with missing day 30 mRS. An additional 9 patients were excluded because of missing 1-year mRS. The final pooled cohort included 715 patients (71.6%) with day 30 mRS 4 to 5. Data were analyzed from July 2019 to January 2022. EXPOSURES CLEAR-III participants randomized to intraventricular alteplase vs placebo. MISTIE-III participants randomized to stereotactic thrombolysis of hematoma vs standard medical care. MAIN OUTCOMES AND MEASURES Primary outcome was 1-year mRS. Patients were dichotomized into good outcome at 1 year (mRS 0 to 3) vs poor outcome at 1 year (mRS 4 to 6). Multivariable logistic regression models assessed associations between prospectively adjudicated hospital events and 1-year good outcome after adjusting for demographic characteristics, ICH and IVH severity, and trial cohort. RESULTS Of 715 survivors, 417 (58%) were male, and the overall mean (SD) age was 60.3 (11.7) years. Overall, 174 participants (24.3%) were Black, 491 (68.6%) were White, and 49 (6.9%) were of other races (including Asian, Native American, and Pacific Islander, consolidated owing to small numbers); 98 (13.7%) were of Hispanic ethnicity. By 1 year, 129 participants (18%) had died and 308 (43%) had achieved mRS 0 to 3. In adjusted models for the combined cohort, diabetes (adjusted odds ratio [aOR], 0.50; 95% CI, 0.26-0.96), National Institutes of Health Stroke Scale (aOR, 0.93; 95% CI, 0.90-0.96), severe leukoaraiosis (aOR, 0.30; 95% CI, 0.16-0.54), pineal gland shift (aOR, 0.87; 95% CI, 0.76-0.99]), acute ischemic stroke (aOR, 0.44; 95% CI, 0.21-0.94), gastrostomy (aOR, 0.30; 95% CI, 0.17-0.50), and persistent hydrocephalus by day 30 (aOR, 0.37; 95% CI, 0.14-0.98) were associated with lack of recovery. Resolution of ICH (aOR, 1.82; 95% CI, 1.08-3.04) and IVH (aOR, 2.19; 95% CI, 1.02-4.68) by day 30 were associated with recovery to good outcome. In the CLEAR-III model, cerebral perfusion pressure less than 60 mm Hg (aOR, 0.30; 95% CI, 0.13-0.71), sepsis (aOR, 0.05; 95% CI, 0.00-0.80), and prolonged mechanical ventilation (aOR, 0.96; 95% CI, 0.92-1.00 per day), and in MISTIE-III, need for intracranial pressure monitoring (aOR, 0.35; 95% CI, 0.12-0.98), were additional factors associated with poor outcome. Thirty-day event-based models strongly predicted 1-year outcome (area under the receiver operating characteristic curve [AUC], 0.87; 95% CI, 0.83–0.90), with significantly improved discrimination over models using baseline severity factors alone (AUC, 0.76; 95% CI, 0.71-0.80; P &amp;amp;amp;lt; .001). CONCLUSIONS AND RELEVANCE Among survivors of severe ICH and IVH with initial poor functional outcome, more than 40% recovered to good outcome by 1 year. Hospital events were strongly associated with long-term functional recovery and may be potential targets for intervention. Avoiding early pessimistic prognostication and delaying prognostication until after treatment may improve ability to predict future recovery.;,citation_author=Vishank A. Shah;,citation_author=Richard E. Thompson;,citation_author=Gayane Yenokyan;,citation_author=Julian N. Acosta;,citation_author=Radhika Avadhani;,citation_author=Rachel Dlugash;,citation_author=Nichol McBee;,citation_author=Yunke Li;,citation_author=Bjorn M. Hansen;,citation_author=Natalie Ullman;,citation_author=Guido Falcone;,citation_author=Issam A. Awad;,citation_author=Daniel F. Hanley;,citation_author=Wendy C. Ziai;,citation_publication_date=2022-09;,citation_cover_date=2022-09;,citation_year=2022;,citation_issue=9;,citation_doi=10.1001/jamaneurol.2022.1991;,citation_issn=2168-6149;,citation_volume=79;,citation_language=en-US;,citation_journal_title=JAMA Neurology;">
<meta name="citation_reference" content="citation_title=Taking a day off;,citation_author=Samir S. Shah;,citation_publication_date=2023-11;,citation_cover_date=2023-11;,citation_year=2023;,citation_doi=10.1002/jhm.13235;,citation_issn=1553-5592, 1553-5606;,citation_language=en-US;,citation_journal_title=Journal of Hospital Medicine;">
<meta name="citation_reference" content="citation_title=Therapies for Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage;,citation_abstract=Delayed cerebral ischemia (DCI) is one of the most important complications of subarachnoid hemorrhage. Despite lack of prospective evidence, medical rescue interventions for DCI include hemodynamic augmentation using vasopressors or inotropes, with limited guidance on specific blood pressure and hemodynamic parameters. For DCI refractory to medical interventions, endovascular rescue therapies (ERTs), including intraarterial (IA) vasodilators and percutaneous transluminal balloon angioplasty, are the cornerstone of management. Although there are no randomized controlled trials assessing the efficacy of ERTs for DCI and their impact on subarachnoid hemorrhage outcomes, survey studies suggest that they are widely used in clinical practice with significant variability worldwide. IA vasodilators are first line ERTs, with better safety profiles and access to distal vasculature. The most commonly used IA vasodilators include calcium channel blockers, with milrinone gaining popularity in more recent publications. Balloon angioplasty achieves better vasodilation compared with IA vasodilators but is associated with higher risk of life-threatening vascular complications and is reserved for proximal severe refractory vasospasm. The existing literature on DCI rescue therapies is limited by small sample sizes, significant variability in patient populations, lack of standardized methodology, variable definitions of DCI, poorly reported outcomes, lack of long-term functional, cognitive, and patient-centered outcomes, and lack of control groups. Therefore, our current ability to interpret clinical results and make reliable recommendations regarding the use of rescue therapies is limited. This review summarizes existing literature on rescue therapies for DCI, provides practical guidance, and identifies future research needs.;,citation_author=Vishank A. Shah;,citation_author=L. Fernando Gonzalez;,citation_author=Jose I. Suarez;,citation_publication_date=2023-05;,citation_cover_date=2023-05;,citation_year=2023;,citation_doi=10.1007/s12028-023-01747-9;,citation_issn=1556-0961;,citation_language=en-US;,citation_journal_title=Neurocritical Care;,citation_publisher=Springer US;">
<meta name="citation_reference" content="citation_title=Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): An international, randomised, double-blind, placebo-controlled trial;,citation_author=Haleema Shakur;,citation_author=Ian Roberts;,citation_author=Bukola Fawole;,citation_author=Rizwana Chaudhri;,citation_author=Mohamed El-Sheikh;,citation_author=Adesina Akintan;,citation_author=Zahida Qureshi;,citation_author=Hussein Kidanto;,citation_author=Bellington Vwalika;,citation_author=Abdulfetah Abdulkadir;,citation_author=Saturday Etuk;,citation_author=Shehla Noor;,citation_author=Etienne Asonganyi;,citation_author=Zarko Alfirevic;,citation_author=Danielle Beaumont;,citation_author=Carine Ronsmans;,citation_author=Sabaratnam Arulkumaran;,citation_author=Adrian Grant;,citation_author=Kaosar Afsana;,citation_author=Metin Gülmezoglu;,citation_author=Beverley Hunt;,citation_author=Oladapo Olayemi;,citation_author=Ian Roberts;,citation_author=Iain Chalmers;,citation_author=Pisake Lumbiganon;,citation_author=Gilda Piaggio;,citation_author=Tony Brady;,citation_author=Haleema Shakur;,citation_author=Ian Roberts;,citation_author=Zarko Alfirevic;,citation_author=Diana Elbourne;,citation_author=Metin Gülmezoglu;,citation_author=Carine Ronsmans;,citation_author=Eni Balogun;,citation_author=Tracey Pepple;,citation_author=Danielle Prowse;,citation_author=Nigel Quashi;,citation_author=Lin Barneston;,citation_author=Collette Barrow;,citation_author=Danielle Beaumont;,citation_author=Lisa Cook;,citation_author=Lauren Frimley;,citation_author=Daniel Gilbert;,citation_author=Catherine Gilliam;,citation_author=Rob Jackson;,citation_author=Taemi Kawahara;,citation_author=Hakim Miah;,citation_author=Sergey Kostrov;,citation_author=Maria Ramos;,citation_author=Ian Roberts;,citation_author=Haleema Shakur;,citation_author=Phil Edwards;,citation_author=Tom Godec;,citation_author=Sumaya Huque;,citation_author=Bukola Fawole;,citation_author=Olujide Okunade;,citation_author=Olusade Adetayo;,citation_author=Rizwana Chaudhri;,citation_author=Aasia Kayani;,citation_author=Kiran Javaid;,citation_author=Bukola Fawole;,citation_author=Rizwana Chaudhri;,citation_author=Chrstine Biryabarema;,citation_author=Zahida Qureshi;,citation_author=Robert Tchounzou;,citation_author=Mohamed El-Sheikh;,citation_author=Hussein Kidanto;,citation_author=Mohan Regmi;,citation_author=Bellington Vwalika;,citation_author=Kastriot Dallaku;,citation_author=Mateus Sahani;,citation_author=Sayeba Akhter;,citation_author=Abdulfetah Abdulkadir;,citation_author=Nicolas Meda;,citation_author=Anthony Kwame Dah;,citation_author=Adesina Akintan;,citation_author=Olufemi Odekunle;,citation_author=Oluwabusola Monehin;,citation_author=Austin Ojo;,citation_author=Grace Akinbinu;,citation_author=Ifeoma Offiah;,citation_author=Saturday Etuk;,citation_author=Ubong Akpan;,citation_author=Uduak Udofia;,citation_author=Useneno Okon;,citation_author=Ezukwa Omoronyia;,citation_author=Okpe James;,citation_author=Oladapo Olayemi;,citation_author=Nike Bello;,citation_author=Blessed Adeyemi;,citation_author=Chris Aimakhu;,citation_author=Olufemi Akinsanya;,citation_author=Bamidele Adeleye;,citation_author=Oluwaseun Adeyemi;,citation_author=Kayode Oluwatosin;,citation_author=Abiodun Aboyeji;,citation_author=Abiodun Adeniran;,citation_author=Adebayo Adewale;,citation_author=Noah Olaomo;,citation_author=Lawrence Omo-Aghoja;,citation_author=Emmanuel Okpako;,citation_author=Lucky Oyeye;,citation_author=Francis Alu;,citation_author=John Ogudu;,citation_author=Ezekiel Ladan;,citation_author=Ibrahim Habib;,citation_author=Babasola Okusanya;,citation_author=Olatunde Onafowokan;,citation_author=David Isah;,citation_author=Abalaka Aye;,citation_author=Felix Okogbo;,citation_author=Egbaname Aigere;,citation_author=Mark Ogbiti;,citation_author=Temitope Onile;,citation_author=Olaide Salau;,citation_author=Yinka Amode;,citation_author=Kamil Shoretire;,citation_author=Adebola Owodunni;,citation_author=Kehinde Ologunde;,citation_author=Akintunde Ayinde;,citation_author=Moses Alao;,citation_author=Olalekan Awonuga;,citation_author=Babatunde Awolaja;,citation_author=Omololu Adegbola;,citation_author=Fatimah Habeebu-Adeyemi;,citation_author=Adeyemi Okunowo;,citation_author=Hadiza Idris;,citation_author=Ola Okike;,citation_author=Nneka Madueke;,citation_author=Josiah Mutihir;,citation_author=Nankat Joseph;,citation_author=Babatunde Adebudo;,citation_author=Adeniyi Fasanu;,citation_author=Olugbenga Akintunde;,citation_author=Olufemi Abidoye;,citation_author=Owigho Opreh;,citation_author=Sophia Udonwa;,citation_author=Gladys Dibia;,citation_author=Simeon Bazuaye;,citation_author=Arafat Ifemeje;,citation_author=Aniefiok Umoiyoho;,citation_author=Emmanuel Inyang-Etoh;,citation_author=Sununu Yusuf;,citation_author=Kayode Olayinka;,citation_author=Babalola Adeyemi;,citation_author=Olusegun Ajenifuja;,citation_author=Umar Ibrahim;,citation_author=Yusuf Baffah Adamu;,citation_author=Oluwarotimi Akinola;,citation_author=Grace Adekola-Oni;,citation_author=Paul Kua;,citation_author=Roseline Iheagwam;,citation_author=Audu Idrisa;,citation_author=Ado Geidam;,citation_author=Andrea Jogo;,citation_author=Joseph Agulebe;,citation_author=Joseph Ikechebelu;,citation_author=Onyebuchi Udegbunam;,citation_author=Jacob Awoleke;,citation_author=Oluseyi Adelekan;,citation_author=Hajaratu Sulayman;,citation_author=Nkeiruka Ameh;,citation_author=Nurudeen Onaolapo;,citation_author=Affiss Adelodun;,citation_author=William Golit;,citation_author=Dachollom Audu;,citation_author=Adetunji Adeniji;,citation_author=Folasade Oyelade;,citation_author=Lamaran Dattijo;,citation_author=Palmer Henry;,citation_author=Babalola Adeyemi;,citation_author=Olabisi Loto;,citation_author=Odidika Umeora;,citation_author=Abraham Onwe;,citation_author=Emily Nzeribe;,citation_author=Bartthy Okorochukwu;,citation_author=Augustine Adeniyi;,citation_author=Emmanuel Gbejegbe;,citation_author=Akpojaro Ikpen;,citation_author=Ikemefuna Nwosu;,citation_author=Abdulrasaq Sambo;,citation_author=Olubunmi Ladipo;,citation_author=Sola Abubakar;,citation_author=Ola Nene Okike;,citation_author=Enyinnaya Chikwendu Nduka;,citation_author=Eziamaka Pauline Ezenkwele;,citation_author=Daniel Onwusulu;,citation_author=Theresa Azonima Irinyenikan;,citation_author=Swati Singh;,citation_author=Amaitari Bariweni;,citation_author=Hadiza Galadanci;,citation_author=Peter Achara;,citation_author=Osagie Osayande;,citation_author=Mohammed Gana;,citation_author=Rizwana Chaudhri;,citation_author=Kiran Jabeen;,citation_author=Ayesha Mobeen;,citation_author=Sadaf Mufti;,citation_author=Maliha Zafar;,citation_author=Shehla Noor;,citation_author=Basharat Ahmad;,citation_author=Maimoona Munawar;,citation_author=Jeharat Gul;,citation_author=Naseema Usman;,citation_author=Fehmida Shaheen;,citation_author=Mariam Tariq;,citation_author=Nadia Sadiq;,citation_author=Rabia Batool;,citation_author=Habiba Sharaf Ali;,citation_author=Manahil Jaffer;,citation_author=Asma Baloch;,citation_author=Noonari Mukhtiar;,citation_author=Tasneem Ashraf;,citation_author=Raheela Asmat;,citation_author=Salma Khudaidad;,citation_author=Ghazala Taj;,citation_author=Roshan Qazi;,citation_author=Saira Dars;,citation_author=Faryal Sardar;,citation_author=Sanobar Ashfaq;,citation_author=Saeeda Majeed;,citation_author=Sadaqat Jabeen;,citation_author=Rukhsana Karim;,citation_author=Farzana Burki;,citation_author=Syeda Rabia Bukhari;,citation_author=Fouzia Gul;,citation_author=Musarrat Jabeen;,citation_author=Akhtar Sherin;,citation_author=Qurratul Ain;,citation_author=Shahid Rao;,citation_author=Uzma Shaheen;,citation_author=Samina Manzoor;,citation_author=Shabween Masood;,citation_author=Shabana Rizvi;,citation_author=Anita Ali;,citation_author=Abida Sajid;,citation_author=Aisha Iftikhar;,citation_author=Shazia Batool;,citation_author=Lubna Dar;,citation_author=Shahenzad Sohail;,citation_author=Shazia Rasul;,citation_author=Shamsa Humayun;,citation_author=Rashida Sultana;,citation_author=Sofia Manzoor;,citation_author=Syeda Mazhar;,citation_author=Afshan Batool;,citation_author=Asia Nazir;,citation_author=Nasira Tasnim;,citation_author=Hajira Masood;,citation_author=Razia Khero;,citation_author=Neelam Surhio;,citation_author=Samana Aleem;,citation_author=Naila Israr;,citation_author=Saba Javed;,citation_author=Lubna Bashir;,citation_author=Samina Iqbal;,citation_author=Faiza Aleem;,citation_author=Rubina Sohail;,citation_author=Saima Iqbal;,citation_author=Samina Dojki;,citation_author=Alia Bano;,citation_author=Naseem Saba;,citation_author=Maimoona Hafeez;,citation_author=Nishat Akram;,citation_author=Naila Israr;,citation_author=Riffat Shaheen;,citation_author=Haleema Hashmi;,citation_author=Sharmeen Arshad;,citation_author=Rubina Hussain;,citation_author=Sadia Khan;,citation_author=Nighat Shaheen;,citation_author=Safia Khalil;,citation_author=Pushpa Sachdev;,citation_author=Gulfareen Arain;,citation_author=Amtullah Zarreen;,citation_author=Sara Saeed;,citation_author=Shamayela Hanif;,citation_author=Nabia Tariq;,citation_author=Mahwish Jamil;,citation_author=Shama Chaudhry;,citation_author=Hina Rajani;,citation_author=Tayyiba Wasim;,citation_author=Summera Aslam;,citation_author=Nilofar Mustafa;,citation_author=Huma Quddusi;,citation_author=Sajila Karim;,citation_author=Shazia Sultana;,citation_author=Misbah Harim;,citation_author=Mohd Chohan;,citation_author=Nabila Salman;,citation_author=Fareesa Waqar;,citation_author=Shamsunnisa Sadia;,citation_author=Lubna Kahloon;,citation_author=Shehla Manzoor;,citation_author=Samar Amin;,citation_author=Umbreen Akram;,citation_author=Ambreen Ikram;,citation_author=Samina Kausar;,citation_author=Tahira Batool;,citation_author=Brigadier Naila;,citation_author=Tahir Kyani;,citation_author=Christine Biryabarema;,citation_author=Ruth Bulime;,citation_author=Regina Akello;,citation_author=Bernadette Nakawooya Lwasa;,citation_author=Joselyn Ayikoru;,citation_author=Christine Namulwasira;,citation_author=Patrick Komagum;,citation_author=Isabirye Rebecca;,citation_author=Nayiga Annet;,citation_author=Nakirigya Nuulu;,citation_author=Elizabeth Nionzima;,citation_author=Rose Bwotya;,citation_author=Margret Nankya;,citation_author=Sarah Babirye;,citation_author=Joseph Ngonzi;,citation_author=Cesar Sanchez;,citation_author=Nkonwa Innocent;,citation_author=Kusasira Anitah;,citation_author=Ayiko Jackson;,citation_author=Elizabeth Ndagire;,citation_author=Christine Nanyongo;,citation_author=Dominic Drametu;,citation_author=Grace Meregurwa;,citation_author=Francis Banya;,citation_author=Rita Atim;,citation_author=Emmanuel Byaruhanga;,citation_author=Lema Felix;,citation_author=Hussein Iman;,citation_author=Vincent Oyiengo;,citation_author=Peninah Waigi;,citation_author=Rose Wangui;,citation_author=Faiza Nassir;,citation_author=Musimbi Soita;,citation_author=Rophina Msengeti;,citation_author=Zeinab Zubier;,citation_author=Hillary Mabeya;,citation_author=Antony Wanjala;,citation_author=Henry Mwangi;,citation_author=Brian Liyayi;,citation_author=Evelyn Muthoka;,citation_author=Alfred Osoti;,citation_author=Amos Otara;,citation_author=Veronicah Ongwae;,citation_author=Zahida Qureshi;,citation_author=Victor Wanjohi;,citation_author=Bonface Musila;,citation_author=Kubasu Wekesa;,citation_author=Alex Nyakundi Bosire;,citation_author=Etienne Asonganyi;,citation_author=Alice Ntem;,citation_author=Angeline Njoache;,citation_author=Alice Ashu;,citation_author=André Simo;,citation_author=Robert Tchounzou;,citation_author=Dorothy Keka;,citation_author=Kenfack Bruno;,citation_author=Amadou Ndouoya;,citation_author=Martin Saadio;,citation_author=Mesack Tchana;,citation_author=Odel Gwan;,citation_author=Pauline Assomo;,citation_author=Venantius Mutsu;,citation_author=Nji Eric;,citation_author=Pascal Foumane;,citation_author=Philemon Nsem;,citation_author=Jeanne Fouedjio;,citation_author=Ymele Fouelifack;,citation_author=Pierre Marie Tebeu;,citation_author=Georges Nko’ayissi;,citation_author=Eta Ngole Mbong;,citation_author=Wisal Nabag;,citation_author=Riham Desougi;,citation_author=Hadia Mustafa;,citation_author=Huida Eltaib;,citation_author=Taha Umbeli;,citation_author=Khalid Elfadl;,citation_author=Murwan Ibrahim;,citation_author=Abdalla Mohammed;,citation_author=Awadia Ali;,citation_author=Somia Abdelrahiem;,citation_author=Mohammed Musa;,citation_author=Khidir Awadalla;,citation_author=Samirra Ahmed;,citation_author=Mahdi Bushra;,citation_author=Omer Babiker;,citation_author=Hala Abdullahi;,citation_author=Mohamed Ahmed;,citation_author=Elhassan Safa;,citation_author=Huida Almardi;,citation_author=Duria Rayis;,citation_author=Saeed Abdelrahman Abdelgabar;,citation_author=Zarko Alfirevic;,citation_author=Gillian Houghton;,citation_author=Andrew Sharpe;,citation_author=Jim Thornton;,citation_author=Nick Grace;,citation_author=Carys Smith;,citation_author=Kim Hinshaw;,citation_author=Dawn Edmundson;,citation_author=Paul Ayuk;,citation_author=Alison Bates;,citation_author=George Bugg;,citation_author=Joanne Wilkins;,citation_author=Clare Tower;,citation_author=Alysha Allibone;,citation_author=Eugene Oteng-Ntim;,citation_author=Hussein Kidanto;,citation_author=Ahmad Kazumari;,citation_author=Anna Danford;,citation_author=Matilda Ngarina;,citation_author=Muzdalifat Abeid;,citation_author=Khadija Mayumba;,citation_author=Magreth Zacharia;,citation_author=George Mtove;,citation_author=Leonard Madame;,citation_author=Anthony Massinde;,citation_author=Berno Mwambe;,citation_author=Rwakyendela Onesmo;,citation_author=Sebastian Kitengile Ganyaka;,citation_author=Mohan Regmi;,citation_author=Shyam Gupta;,citation_author=Rabindra Bhatt;,citation_author=Ajay Agrawal;,citation_author=Pramila Pradhan;,citation_author=Nikita Dhakal;,citation_author=Punita Yadav;,citation_author=Gyanendra Karki;,citation_author=Bhola Ram Shrestha;,citation_author=Bellington Vwalika;,citation_author=Mwansa Lubeya;,citation_author=Jane Mumba;,citation_author=Willies Silwimba;,citation_author=Isaiah Hansingo;,citation_author=Noojiri Bopili;,citation_author=Ziche Makukula;,citation_author=Alexander Kawimbe;,citation_author=Mwansa Ketty Lubeya;,citation_author=Willard Mtambo;,citation_author=Mathew Ng’ambi;,citation_author=Kastriot Dallaku;,citation_author=Saimir Cenameri;,citation_author=Ilir Tasha;,citation_author=Aferdita Kruja;,citation_author=Besnik Brahimaj;,citation_author=Armida Tola;,citation_author=Leon Kaza;,citation_author=Mateus Sahani;,citation_author=Desire Tshombe;,citation_author=Elizabeth Buligho;,citation_author=Roger Paluku-Hamuli;,citation_author=Charles Kacha;,citation_author=Kato Faida;,citation_author=Badibanga Musau;,citation_author=Herman Kalyana;,citation_author=Phanny Simisi;,citation_author=Serge Mulyumba;,citation_author=Nzanzu Kikuhe Jason;,citation_author=Jean Robert Lubamba;,citation_author=Willis Missumba;,citation_author=Ferdousi Islam;,citation_author=Nazneen Begum;,citation_author=Sayeba Akhter;,citation_author=Ferdousi Chowdhury;,citation_author=Rokeya Begum;,citation_author=Farjana Basher;,citation_author=Nazlima Nargis;,citation_author=Abu Kholdun;,citation_author=Shahela Jesmin;,citation_author=Shrodha Paul;,citation_author=Hailemariam Segni;,citation_author=Getachew Ayana;,citation_author=William Haleke;,citation_author=Abdulfetah Abdulkadir;,citation_author=Hassen Hussien;,citation_author=Fikre Geremew;,citation_author=Moussa Bambara;,citation_author=Adolphe Somé;,citation_author=Amadou Ly;,citation_author=Roamba Pabakba;,citation_author=Horace Fletcher;,citation_author=Leslie Samuels;,citation_author=Henry Opare-Addo;,citation_author=Roderick Larsen-Reindorf;,citation_author=Kwadwo Nyarko-Jectey;,citation_author=Glen Mola;,citation_author=Malts Wai;,citation_author=Magdy El Rahman;,citation_author=Wafaa Basta;,citation_author=Hussein Khamis;,citation_author=Maria Fernanda Escobar;,citation_author=Liliana Vallecilla;,citation_author=Gabriel Essetchi Faye;,citation_publication_date=2017-05;,citation_cover_date=2017-05;,citation_year=2017;,citation_issue=10084;,citation_doi=10.1016/S0140-6736(17)30638-4;,citation_issn=0140-6736, 1474-547X;,citation_pmid=28456509;,citation_volume=389;,citation_language=en-US;,citation_journal_title=The Lancet;,citation_publisher=Elsevier;">
<meta name="citation_reference" content="citation_title=Can we learn individual-level treatment policies from clinical data?;,citation_abstract=One of the great promises of applying machine learning to clinical data is the possibility of learning optimal per-patient treatment rules. The goal is to use data collected in clinical settings such as a patient’s hospital record, or data collected in clinical trials, to learn an individualized treatment rule that will have greater benefit than existing treatment policies if applied to the entire population. Concretely, we use this running example: choosing the best blood pressure-lowering medication “A” or “B” for a patient with hypertension, measured in terms of lower 6-week prospective blood pressure. We note that hypertension is a condition with substantial variation in how patients are actually treated (Hripsak and others, 2016). Learning such individualized treatment rules involves at least two distinct challenges—a statistical one and a causal one.;,citation_author=Uri Shalit;,citation_publication_date=2020-04;,citation_cover_date=2020-04;,citation_year=2020;,citation_issue=2;,citation_doi=10.1093/biostatistics/kxz043;,citation_issn=1465-4644;,citation_volume=21;,citation_journal_title=Biostatistics;">
<meta name="citation_reference" content="citation_title=Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia;,citation_abstract=BACKGROUND Data regarding the efficacy of treatment with ibrutinib–rituximab, as compared with standard chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab, in patients with previously untreated chronic lymphocytic leukemia (CLL) have been limited. METHODS In a phase 3 trial, we randomly assigned (in a 2:1 ratio) patients 70 years of age or younger with previously untreated CLL to receive either ibrutinib and rituximab for six cycles (after a single cycle of ibrutinib alone), followed by ibrutinib until disease progression, or six cycles of chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab. The primary end point was progression-free survival, and overall survival was a secondary end point. We report the results of a planned interim analysis. RESULTS A total of 529 patients underwent randomization (354 patients to the ibrutinib–rituximab group, and 175 to the chemoimmunotherapy group). At a median follow-up of 33.6 months, the results of the analysis of progression-free survival favored ibrutinib–rituximab over chemo immunotherapy (89.4% vs. 72.9% at 3 years; hazard ratio for progression or death, 0.35; 95% confidence interval [CI], 0.22 to 0.56; P&amp;amp;amp;lt;0.001), and the results met the protocol-defined efficacy threshold for the interim analysis. The results of the analysis of overall survival also favored ibrutinib–rituximab over chemoimmunotherapy (98.8% vs. 91.5% at 3 years; hazard ratio for death, 0.17; 95% CI, 0.05 to 0.54; P&amp;lt;0.001). In a subgroup analysis involving patients without immunoglobulin heavy-chain variable region (IGHV) mutation, ibrutinib–rituximab resulted in better progression-free survival than chemoimmunotherapy (90.7% vs. 62.5% at 3 years; hazard ratio for progression or death, 0.26; 95% CI, 0.14 to 0.50). The 3-year progression-free survival among patients with IGHV mutation was 87.7% in the ibrutinib–rituxi mab group and 88.0% in the chemoimmunotherapy group (hazard ratio for progression or death, 0.44; 95% CI, 0.14 to 1.36). The incidence of adverse events of grade 3 or higher (regardless of attribution) was similar in the two groups (in 282 of 352 patients [80.1%] who received ibrutinib–rituximab and in 126 of 158 [79.7%] who received chemoimmunotherapy), whereas infectious complications of grade 3 or higher were less common with ibrutinib–rituximab than with chemoimmunotherapy (in 37 patients [10.5%] vs. 32 [20.3%], P<0.001). CONCLUSIONS The ibrutinib–rituximab regimen resulted in progression-free survival and overall survival that were superior to those with a standard chemoimmunotherapy regimen among patients 70 years of age or younger with previously untreated CLL. (Funded by the National Cancer Institute and Pharmacyclics; E1912 ClinicalTrials.gov number, NCT02048813.);,citation_author=Tait D. Shanafelt;,citation_author=Xin V. Wang;,citation_author=Neil E. Kay;,citation_author=Curtis A. Hanson;,citation_author=Susan O’Brien;,citation_author=Jacqueline Barrientos;,citation_author=Diane F. Jelinek;,citation_author=Esteban Braggio;,citation_author=Jose F. Leis;,citation_author=Cong C. Zhang;,citation_author=Steven E. Coutre;,citation_author=Paul M. Barr;,citation_author=Amanda F. Cashen;,citation_author=Anthony R. Mato;,citation_author=Avina K. Singh;,citation_author=Michael P. Mullane;,citation_author=Richard F. Little;,citation_author=Harry Erba;,citation_author=Richard M. Stone;,citation_author=Mark Litzow;,citation_author=Martin Tallman;,citation_publication_date=2019-08;,citation_cover_date=2019-08;,citation_year=2019;,citation_issue=5;,citation_doi=10.1056/NEJMoa1817073;,citation_issn=0028-4793, 1533-4406;,citation_volume=381;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Reflections on Critical Care’s Past, Present, and Future;,citation_author=Manu Shankar-Hari;,citation_author=Hannah Wunsch;,citation_author=Kathy Rowan;,citation_author=Mervyn Singer;,citation_author=Gordon D. Rubenfeld;,citation_author=Derek C. Angus;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_doi=10.1097/CCM.0000000000005246;,citation_issn=0090-3493;,citation_volume=Publish Ahead of Print;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=A Mathematical Theory of Communication;,citation_author=C E Shannon;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Causal Diagram Techniques for Urologic Oncology Research;,citation_abstract=Large quantities of data are now available to medical researchers; however, observational studies are plagued by bias and confounding. Additionally, much of this research only speculates on variable associations, leaving prospective randomized clinical trials as the sole purveyors of claims about causal relations between variables. There has been a growing movement of causal inference that uses new techniques to investigate causality using observational data. These techniques include the implementation of directed acyclic graphs, which allow researchers to explicitly and reproducibly define the causal relationships between study variables, thus making statistical analysis more robust. Directed acyclic graphs further allow researchers to identify confounding and other sources of bias and to discover causal effects among complex networks of variables. This review aims to introduce these techniques to the general urology and urologic oncology research communities in order to provide a basic understanding of causal inference and analysis and call for integration of these practices more generally in research methodology.;,citation_author=Daniel D. Shapiro;,citation_author=Pavlos Msaouel;,citation_publication_date=2021-06;,citation_cover_date=2021-06;,citation_year=2021;,citation_issue=3;,citation_doi=10.1016/j.clgc.2020.08.003;,citation_issn=15587673;,citation_volume=19;,citation_language=en-US;,citation_journal_title=Clinical Genitourinary Cancer;">
<meta name="citation_reference" content="citation_title=Neuroanatomy of the middle cerebral artery: Implications for thrombectomy;,citation_abstract=Our perspective on anatomy frequently depends on how this anatomy is utilized in clinical practice, and by which methods knowledge is acquired. The thrombectomy revolution, of which the middle cerebral artery (MCA) is the most common target, is an example of a clinical paradigm shift with a unique perspective on cerebrovascular anatomy. This article reviews important features of MCA anatomy in the context of thrombectomy. Recognizing that variation, frequently explained by evolutionary concepts, is the rule when it comes to branching pattern, vessel morphology, territory, or collateral potential is key to successful thrombectomy strategy.;,citation_author=Maksim Shapiro;,citation_author=Eytan Raz;,citation_author=Erez Nossek;,citation_author=Breehan Chancellor;,citation_author=Koto Ishida;,citation_author=Peter Kim Nelson;,citation_publication_date=2020-08;,citation_cover_date=2020-08;,citation_year=2020;,citation_issue=8;,citation_doi=10.1136/neurintsurg-2019-015782;,citation_issn=1759-8478, 1759-8486;,citation_volume=12;,citation_language=en-US;,citation_journal_title=Journal of NeuroInterventional Surgery;">
<meta name="citation_reference" content="citation_title=Major Complications, Mortality, and Resource Utilization After Open Abdominal Surgery: 0.9% Saline Compared to Plasma-Lyte;,citation_abstract=Objective:&nbsp; To assess the association of 0.9% saline use versus a calcium-free physiologically balanced crystalloid solution with major morbidity and clinical resource use after abdominal surgery. Background:&nbsp; 0.9% saline, which results in a hyperchloremic acidosis after infusion, is frequently used to replace volume losses after major surgery. Methods:&nbsp; An observational study using the Premier Perspective Comparative Database was performed to evaluate adult patients undergoing major open abdominal surgery who received either 0.9% saline (30,994 patients) or a balanced crystalloid solution (926 patients) on the day of surgery. The primary outcome was major morbidity and secondary outcomes included minor complications and acidosis-related interventions. Outcomes were evaluated using multivariable logistic regression and propensity scoring models. Results:&nbsp; For the entire cohort, the in-hospital mortality was 5.6% in the saline group and 2.9% in the balanced group (P &amp;amp;amp;lt; 0.001). One or more major complications occurred in 33.7% of the saline group and 23% of the balanced group (P &amp;lt; 0.001). In the 3:1 propensity-matched sample, treatment with balanced fluid was associated with fewer complications (odds ratio 0.79; 95% confidence interval 0.66–0.97). Postoperative infection (P = 0.006), renal failure requiring dialysis (P < 0.001), blood transfusion (P < 0.001), electrolyte disturbance (P = 0.046), acidosis investigation (P < 0.001), and intervention (P = 0.02) were all more frequent in patients receiving 0.9% saline. Conclusions:&nbsp; Among hospitals in the Premier Perspective Database, the use of a calcium-free balanced crystalloid for replacement of fluid losses on the day of major surgery was associated with less postoperative morbidity than 0.9% saline.;,citation_author=Andrew D. Shaw;,citation_author=Sean M. Bagshaw;,citation_author=Stuart L. Goldstein;,citation_author=Lynette A. Scherer;,citation_author=Michael Duan;,citation_author=Carol R. Schermer;,citation_author=John A. Kellum;,citation_publication_date=2012-05;,citation_cover_date=2012-05;,citation_year=2012;,citation_issue=5;,citation_doi=10.1097/SLA.0b013e31825074f5;,citation_issn=0003-4932;,citation_volume=255;,citation_language=en-US;,citation_journal_title=Annals of Surgery;">
<meta name="citation_reference" content="citation_title=Timing of Onset, Burden, and Postdischarge Mortality of Persistent Critical Illness in Scotland, 2005–2014: A Retrospective, Population-Based, Observational Study;,citation_author=Martin Shaw;,citation_author=Elizabeth M. Viglianti;,citation_author=Joanne McPeake;,citation_author=Sean M. Bagshaw;,citation_author=David Pilcher;,citation_author=Rinaldo Bellomo;,citation_author=Theodore J. Iwashyna;,citation_author=Tara Quasim;,citation_publication_date=2020-04;,citation_cover_date=2020-04;,citation_year=2020;,citation_issue=4;,citation_doi=10.1097/CCE.0000000000000102;,citation_issn=2639-8028;,citation_volume=2;,citation_language=en-US;,citation_journal_title=Critical Care Explorations;">
<meta name="citation_reference" content="citation_title=A review of inferior vena cava filters;,citation_abstract=The care of patients with venous thromboembolism (VTE) is delivered via a multidisciplinary team. The primary treatment for VTE is anticoagulation; however, placement of filter devices in the inferior vena cava (IVC) to prevent embolisation of deep venous thrombosis (DVT) is a well-established secondary treatment option. Many controversies remain regarding utilisation and management of filters.;,citation_author=Kevin P. Sheahan;,citation_author=Emma Tong;,citation_author=Michael J. Lee;,citation_publication_date=2023-01;,citation_cover_date=2023-01;,citation_year=2023;,citation_issue=1141;,citation_doi=10.1259/bjr.20211125;,citation_issn=0007-1285;,citation_volume=96;,citation_journal_title=The British Journal of Radiology;,citation_publisher=The British Institute of Radiology;">
<meta name="citation_reference" content="citation_title=To ventilate, oscillate, or cannulate?;,citation_abstract=Ventilatory management of acute respiratory distress syndrome has evolved significantly in the last few decades. The aims have shifted from optimal gas transfer without concern for iatrogenic risks to adequate gas transfer while minimizing lung injury. This change in focus, along with improved ventilator and multiorgan system management, has resulted in a significant improvement in patient outcomes. Despite this, a number of patients develop hypoxemic respiratory failure refractory to lung-protective ventilation (LPV). The intensivist then faces the dilemma of either persisting with LPV using adjuncts (neuromuscular blocking agents, prone positioning, recruitment maneuvers, inhaled nitric oxide, inhaled prostacyclin, steroids, and surfactant) or making a transition to rescue therapies such as high-frequency oscillatory ventilation (HFOV) and/or extracorporeal membrane oxygenation (ECMO) when both these modalities are at their disposal. The lack of quality evidence and potential harm reported in recent studies question the use of HFOV as a routine rescue option. Based on current literature, the role for venovenous (VV) ECMO is probably sequential as a salvage therapy to ensure ultraprotective ventilation in selected young patients with potentially reversible respiratory failure who fail LPV despite neuromuscular paralysis and prone ventilation. Given the risk profile and the economic impact, future research should identify the patients who benefit most from VV ECMO. These choices may be further influenced by the emerging novel extracorporeal carbon dioxide removal devices that can compliment LPV. Given the heterogeneity of acute respiratory distress syndrome, each of these modalities may play a role in an individual patient. Future studies comparing LPV, HFOV, and VV ECMO should not only focus on defining the patients who benefit most from each of these therapies but also consider long-term functional outcomes.;,citation_author=Kiran Shekar;,citation_author=Andrew R. Davies;,citation_author=Daniel V. Mullany;,citation_author=Ravindranath Tiruvoipati;,citation_author=John F. Fraser;,citation_publication_date=2013-10;,citation_cover_date=2013-10;,citation_year=2013;,citation_issue=5;,citation_doi=10.1016/j.jcrc.2013.04.009;,citation_issn=1557-8615;,citation_pmid=23827735;,citation_volume=28;,citation_language=en-US;,citation_journal_title=Journal of Critical Care;">
<meta name="citation_reference" content="citation_title=Spontaneous Intracerebral Hemorrhage;,citation_author=Kevin N. Sheth;,citation_publication_date=2022-10;,citation_cover_date=2022-10;,citation_year=2022;,citation_issue=17;,citation_doi=10.1056/NEJMra2201449;,citation_issn=0028-4793;,citation_volume=387;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Analysis of Functional Recovery in Older Adults Discharged to Skilled Nursing Facilities and Then Home;,citation_abstract=Although many older adults are discharged to skilled nursing facilities (SNFs) after hospitalization, rates of patients recovery afterward are unknown.To examine postacute functional recovery among older adults.This cohort study was conducted among older adults treated in SNFs, then at home with home health care (HHC). Participants were a 5% random sample of Medicare fee-for-service beneficiaries discharged to community HHC after SNF stay from 2014 to 2016 with continuous part A and B enrollment in the prior 6 months. Medicare claims data from 2014 to 2016 were used, including inpatient, SNF, hospice, HHC, outpatient, carrier, and durable medical equipment data and Minimum Data Set (MDS) and Outcome Assessment Information Set (OASIS) for SNF and HHC assessments, respectively. Data were analyzed from July 20, 2020, to June 5, 2022.Frailty was measured with a validated claims–based frailty index (CFI) (range, 0-1; higher scores indicate worse frailty) and categorized into not frail (&amp;amp;amp;lt;0.20), mildly frail (0.20-0.29), and moderately to severely frail (\geq0.30).The primary outcome was functional recovery, defined by discharge from HHC with stable or improved ability to perform activities of daily living (ADL). Recovery status was examined at 15, 30, 45, 60, 75, and 90 days after discharge to HHC using OASIS. Covariates were obtained from the MDS admission file at SNF admission, including age, race and ethnicity, cognitive status, functional status, and geographic region.Among 105 232 beneficiaries (mean [SD] age, 79.1 [10.6] years; 68 637 [65.2%] women; 8951 Black [8.5%], 3109 Hispanic [3.0%], and 88 583 White [84.2%] individuals), 65 796 individuals (62.5%) were discharged from HHC services with improved function over 90 days of follow-up. Among 39 436 beneficiaries not recovered, 19 612 individuals (49.7%) had mild frailty and 15 818 individuals (40.1%) had moderate to severe frailty. While 10 492 of 17 576 beneficiaries who were not frail recovered by 45 days (59.7%), 10 755 of 32 212 individuals with moderate to severe frailty had recovered (33.4%). Overall, frailty was negatively associated with functional recovery after adjustment for demographic characteristics, geographic census regions, and health-related variables, with a hazard ratio for moderate to severe frailty of 0.62 (95% CI, 0.60-0.63) compared with nonfrailty.This study found that recovery after posthospitalization SNF stay was particularly prolonged for individuals with frailty. Functional dependence in activities of daily living remained common among individuals with frailty long after discharge home.;,citation_author=Sandra Shi;,citation_author=Brianne Olivieri-Mui;,citation_author=Gahee Oh;,citation_author=Ellen McCarthy;,citation_author=Dae Hyun Kim;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_issue=8;,citation_doi=10.1001/jamanetworkopen.2022.25452;,citation_issn=2574-3805;,citation_volume=5;,citation_journal_title=JAMA Network Open;">
<meta name="citation_reference" content="citation_title=Confounding, effect modification, and the odds ratio: Common misinterpretations;,citation_author=Ian Shrier;,citation_author=Menglan Pang;,citation_publication_date=2015-04;,citation_cover_date=2015-04;,citation_year=2015;,citation_issue=4;,citation_doi=10.1016/j.jclinepi.2014.12.012;,citation_issn=08954356;,citation_volume=68;,citation_language=en-US;,citation_journal_title=Journal of Clinical Epidemiology;">
<meta name="citation_reference" content="citation_title=Reducing bias through directed acyclic graphs;,citation_abstract=The objective of most biomedical research is to determine an unbiased estimate of effect for an exposure on an outcome, i.e. to make causal inferences about the exposure. Recent developments in epidemiology have shown that traditional methods of identifying confounding and adjusting for confounding may be inadequate.;,citation_author=Ian Shrier;,citation_author=Robert W. Platt;,citation_publication_date=2008-10;,citation_cover_date=2008-10;,citation_year=2008;,citation_issue=1;,citation_doi=10.1186/1471-2288-8-70;,citation_issn=1471-2288;,citation_volume=8;,citation_journal_title=BMC Medical Research Methodology;">
<meta name="citation_reference" content="citation_title=Prior Ground: Selection of Prior Distributions When Analyzing Clinical Trial Data Using Bayesian Methods;,citation_author=Juned Siddique;,citation_author=Zeynab Aghabazaz;,citation_publication_date=2023-10;,citation_cover_date=2023-10;,citation_year=2023;,citation_issue=11;,citation_doi=10.1056/EVIDe2300250;,citation_volume=2;,citation_journal_title=NEJM Evidence;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Interpreting frequentist hypothesis tests: Insights from Bayesian inference;,citation_abstract=Randomized controlled trials are one of the best ways of quantifying the effectiveness of medical interventions. Therefore, when the authors of a randomized&nbsp;superiority trial report that differences in the primary outcome between the intervention group and the control group are “significant” (i.e., P \leq 0.05), we might assume that the intervention has an effect on the outcome. Similarly, when differences between the groups are “not significant,” we might assume that the intervention does not have an effect on the outcome. Nevertheless, both assumptions are frequently incorrect.;,citation_author=David Sidebotham;,citation_author=C. Jake Barlow;,citation_author=Janet Martin;,citation_author=Philip M. Jones;,citation_publication_date=2023-10;,citation_cover_date=2023-10;,citation_year=2023;,citation_doi=10.1007/s12630-023-02557-5;,citation_issn=1496-8975;,citation_language=en-US;,citation_journal_title=Canadian Journal of Anesthesia/Journal canadien d’anesthésie;">
<meta name="citation_reference" content="citation_title=The Attributable Risk of Nonstenotic Cervical Carotid Plaque in Cryptogenic Embolic Stroke;,citation_abstract=Nonstenotic plaque (NSP) of a cervical artery feeding the territory of acute cerebral infarction is increasingly recognized as a cause of cryptogenic stroke. While these atherosclerotic lesions are not associated with significant luminal stenosis (&amp;amp;amp;lt;50%), the probability of finding such plaque exceeds chance and is more common in parent vessels rather than vessels supplying brain regions remote from infarction. More than 20%–30% of patients with unilateral hemispheric embolic stroke of undetermined source may be attributable to cervical internal or common carotid NSP. For these patients, randomized clinical trials have not shown a significant benefit of revascularization (endarterectomy or stenting), and optimal secondary prevention strategies rely on risk factor modification and antiplatelet therapy. Heightened awareness of this subtle finding may inform second-tier diagnostic testing recommendations for occult stroke mechanisms (eg, monitoring for paroxysmal atrial fibrillation or hypercoagulability testing). Furthermore, recognition of NSP as a culprit lesion may lead to more targeted pharmacologic strategies aimed at stabilizing plaque. Recent guidelines have also incorporated evidence of plaque vulnerability (eg, intraplaque hemorrhage or lipid-rich necrotic core) in decision making regarding revascularization approaches. In this review, the epidemiology and management of NSP in patients with cryptogenic embolic infarction is summarized, with an emphasis on recognition of NSP such that future clinical trials can be designed to test novel interventional strategies against current medical management of embolic stroke of undetermined source.;,citation_author=James E. Siegler;,citation_issue=0;,citation_doi=10.1161/SVIN.122.000727;,citation_volume=0;,citation_journal_title=Stroke: Vascular and Interventional Neurology;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=Cerebral Vein Thrombosis With Vaccine-Induced Immune Thrombotic Thrombocytopenia;,citation_abstract=In the spring of 2021, reports of rare and unusual venous thrombosis in association with the ChAdOx1 and Ad26. COV2.S adenovirus-based coronavirus vaccines led to a brief suspension of their use by several countries. Thromboses in the cerebral and splanchnic veins among patients vaccinated in the preceding 4 weeks were described in 17 patients out of 7.98 million recipients of the Ad26.COV2.S vaccine (with 3 fatalities related to cerebral vein thrombosis) and 169 cases of cerebral vein thrombosis among 35 million ChAdOx1 recipients. Events were associated with thrombocytopenia and anti-PF4 (antibodies directed against platelet factor 4), leading to the designation vaccine-induced immune thrombotic thrombocytopenia. Unlike the related heparin-induced thrombotic thrombocytopenia, with an estimated incidence of &amp;amp;amp;lt;1:1000 patients treated with heparin, and a mortality rate of 25%, vaccine-induced immune thrombotic thrombocytopenia has been reported in 1:150 000 ChAdOx1 recipients and 1:470 000 Ad26.COV.2 recipients, with a reported mortality rate of 20% to 30%. Early recognition of this complication should prompt testing for anti-PF4 antibodies and acute treatment targeting the autoimmune and prothrombotic processes. Intravenous immunoglobulin (1 g/kg for 2 days), consideration of plasma exchange, and nonheparin anticoagulation (argatroban, fondaparinux) are recommended. In cases of cerebral vein thrombosis, one should monitor for and treat the known complications of venous congestion as they would in patients without vaccine-induced immune thrombotic thrombocytopenia. Now that the Ad26.COV2.S has been reapproved for use in several countries, it remains a critical component of our pharmacological armamentarium in stopping the spread of the human coronavirus and should be strongly recommended to patients. At this time, the patient and community-level benefits of these two adenoviral vaccines vastly outweigh the rare but serious risks of vaccination. Due to the relatively low risk of severe coronavirus disease 2019 (COVID-19) in young women (&amp;lt;50 years), it is reasonable to recommend an alternative vaccine if one is available. Ongoing postmarketing observational studies are important for tracking new vaccine-induced immune thrombotic thrombocytopenia cases and other rare side effects of these emergent interventions.;,citation_author=James E. Siegler;,citation_author=Piers Klein;,citation_author=Shadi Yaghi;,citation_author=Nicholas Vigilante;,citation_author=Mohamad Abdalkader;,citation_author=Jonathan M. Coutinho;,citation_author=Feras Abdul Khalek;,citation_author=Thanh N. Nguyen;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_issue=9;,citation_doi=10.1161/STROKEAHA.121.035613;,citation_issn=0039-2499, 1524-4628;,citation_volume=52;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=Risk Of Bias In Non-randomized Studies - of Exposure (ROBINS-E). Launch version, 1 June 2022;,citation_author=Raquel Silva;,citation_author=Courtney Lemeris;,citation_author=Elie Akl;,citation_author=Whitney Arroyave;,citation_author=Tom Bateson;,citation_author=Nancy Berkman;,citation_author=Paul Demers;,citation_author=Francesco Forastiere;,citation_author=Barbara Glenn;,citation_author=Asbjørn Hróbjartsson;,citation_author=Ellen Kirrane;,citation_author=Judy LaKind;,citation_author=Ruth Lunn;,citation_author=Alexandra McAleenan;,citation_author=Luke McGuinness;,citation_author=Joerg Meerpohl;,citation_author=Suril Mehta;,citation_author=Julie Obbagy;,citation_author=Annette O’Connor;,citation_author=Beth Radke;,citation_author=Jelena Savovi;,citation_author=Holger Schunemann;,citation_author=Bev Shea;,citation_author=Kyle Steenland;,citation_author=Trish Stewart;,citation_author=Kurt Straif;,citation_author=Kate Tilling;,citation_author=Roel Vermeulen;,citation_author=Meera Viswanathan;,citation_author=Shelia Zahm;,citation_author=Jonathan Sterne;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Outcomes in High-Risk Pulmonary Embolism Patients Undergoing FlowTriever Mechanical Thrombectomy or Other Contemporary Therapies: Results From the FLAME Study;,citation_abstract=Background: Hemodynamically unstable high-risk, or massive, pulmonary embolism (PE) has a reported in-hospital mortality of over 25%. Systemic thrombolysis is the guideline-recommended treatment despite limited evidence. The FLAME study (FlowTriever for Acute Massive PE) was designed to generate evidence for interventional treatments in high-risk PE. Methods: The FLAME study was a prospective, multicenter, nonrandomized, parallel group, observational study of high-risk PE. Eligible patients were treated with FlowTriever mechanical thrombectomy (FlowTriever Arm) or with other contemporary therapies (Context Arm). The primary end point was an in-hospital composite of all-cause mortality, bailout to an alternate thrombus removal strategy, clinical deterioration, and major bleeding. This was compared in the FlowTriever Arm to a prespecified performance goal derived from a contemporary systematic review and meta-analysis. Results: A total of 53 patients were enrolled in the FlowTriever Arm and 61 in the Context Arm. Context Arm patients were primarily treated with systemic thrombolysis (68.9%) or anticoagulation alone (23.0%). The primary end point was reached in 9/53 (17.0%) FlowTriever Arm patients, significantly lower than the 32.0% performance goal (P&amp;amp;amp;lt;0.01). The primary end point was reached in 39/61 (63.9%) Context Arm patients. In-hospital mortality occurred in 1/53 (1.9%) patients in the FlowTriever Arm and in 18/61 (29.5%) patients in the Context Arm. Conclusions: Among patients selected for mechanical thrombectomy with the FlowTriever System, a significantly lower associated rate of in-hospital adverse clinical outcomes was observed compared with a prespecified performance goal, primarily driven by low all-cause mortality of 1.9%. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04795167.;,citation_author=Mitchell J. Silver;,citation_author=C. Michael Gibson;,citation_author=Jay Giri;,citation_author=Sameer Khandhar;,citation_author=Wissam Jaber;,citation_author=Catalin Toma;,citation_author=Bushra Mina;,citation_author=Terry Bowers;,citation_author=Lee Greenspon;,citation_author=Herman Kado;,citation_author=David M. Zlotnick;,citation_author=Mithun Chakravarthy;,citation_author=Aaron R. DuCoffe;,citation_author=Paul Butros;,citation_author=James M. Horowitz;,citation_publication_date=2023-10;,citation_cover_date=2023-10;,citation_year=2023;,citation_issue=10;,citation_doi=10.1161/CIRCINTERVENTIONS.123.013406;,citation_volume=16;,citation_journal_title=Circulation: Cardiovascular Interventions;">
<meta name="citation_reference" content="citation_title=A critical review and update on autoimmune encephalitis: Understanding the alphabet soup;,citation_abstract=Autoimmune encephalitis (AE) comprises a group of diseases mediated by antibodies against neuronal cell surface or synaptic antigens, such as ion channels or neurotransmitter receptors. New clinical syndromes and their associated antibodies were and are still being characterized over the last two decades. The fact that their main clinical features are interdisciplinary, – encompassing neuropsychiatric symptoms, cognitive dysfunction, epileptic seizures, movement and sleep disorders – has led to a surge of interest in this field. Some of these diseases present with a well-defined syndrome, being recognizable on clinical grounds. Correct diagnosis is important since AE are potentially treatable diseases, despite their severity. On the other hand, an increasing number of neuronal antibodies being described casts doubt upon the way we should utilize antibody testing and interpret results. In this article we review, summarize and update the current knowledge on antibody mediated encephalitis.;,citation_author=Mateus Mistieri Simabukuro;,citation_author=Guilherme Diogo Silva;,citation_author=Luiz Henrique Martins Castro;,citation_author=Leandro Tavares Lucato;,citation_publication_date=2022-05;,citation_cover_date=2022-05;,citation_year=2022;,citation_issue=5 suppl 1;,citation_doi=10.1590/0004-282x-anp-2022-s122;,citation_issn=1678-4227, 0004-282X;,citation_volume=80;,citation_language=en-US;,citation_journal_title=Arquivos de Neuro-Psiquiatria;">
<meta name="citation_reference" content="citation_title=Low-dose intravenous heparin infusion in patients with aneurysmal subarachnoid hemorrhage: A preliminary assessment: Clinical article;,citation_abstract=Methods. The authors performed a retrospective analysis in 86 consecutive patients with Fisher Grade 3 aSAH due to rupture of a supratentorial aneurysm who presented within 36 hours and were treated by surgical clipping within 48 hours of their ictus. Forty-three patients were managed postoperatively with a low-dose intravenous heparin infusion (Maryland low-dose intravenous heparin infusion protocol: 8 U/kg/hr progressing over 36 hours to 10 U/kg/hr) beginning 12 hours after surgery and continuing until Day 14 after the ictus. Forty-three control patients received conventional subcutaneous heparin twice daily as deep vein thrombosis prophylaxis. Results. Patients in the 2 groups were balanced in terms of baseline characteristics. In the heparin group, activated partial thromboplastin times were normal to mildly elevated; no clinically significant hemorrhages or instances of heparin-induced thrombocytopenia or deep vein thrombosis were encountered. In the control group, the incidence of clinical vasospasm requiring rescue therapy (induced hypertension, selective intraarterial verapamil, and angioplasty) was 20 (47%) of 43 patients, and 9 (21%) of 43 patients experienced a delayed infarct on CT scanning. In the heparin group, the incidence of clinical vasospasm requiring rescue therapy was 9% (4 of 43, p = 0.0002), and no patient suffered a delayed infarct (p = 0.003). Conclusions. In patients with Fisher Grade 3 aSAH whose aneurysm is secured, postprocedure use of a low-dose intravenous heparin infusion may be safe and beneficial. (http://thejns.org/doi/abs/10.3171/2013.8.JNS1337);,citation_author=J. Marc Simard;,citation_author=E. Francois Aldrich;,citation_author=David Schreibman;,citation_author=Robert F. James;,citation_author=Adam Polifka;,citation_author=Narlin Beaty;,citation_publication_date=2013-12;,citation_cover_date=2013-12;,citation_year=2013;,citation_issue=6;,citation_doi=10.3171/2013.8.JNS1337;,citation_issn=0022-3085, 1933-0693;,citation_volume=119;,citation_language=en-US;,citation_journal_title=Journal of Neurosurgery;">
<meta name="citation_reference" content="citation_title=Understanding Academic Medical Centers: Simone’s Maxims;,citation_author=Joseph V Simone;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Secondary Hematoma Evacuation and Outcome After Initial Conservative Approach for Patients with Cerebellar Hematoma Larger than 3 cm;,citation_abstract=Background: In patients with spontaneous cerebellar intracerebral hemorrhage (ICH) guidelines advocate evacuation when the hematoma diameter is &amp;amp;amp;gt; 3 cm. We studied outcome in patients with cerebellar ICH &amp;gt; 3 cm who did not undergo immediate hematoma evacuation. Methods: We included consecutive patients with cerebellar ICH > 3 cm at two academic hospitals between 2008 and 2017. Patients who died &amp;lt; 24 h (h) were excluded because of probable confounding by indication. We determined patient characteristics, hematoma volumes, EVD placement, secondary hematoma evacuation, in-hospital and 3-month case-fatality, and functional outcome. Results: Of 130 patients with cerebellar ICH, 98 (77%) had a hematoma > 3 cm of whom 22 (23%) died &amp;lt; 24 h and 28 (29%) underwent hematoma evacuation < 24 h. Thus, 48 patients were initially treated conservatively (mean age 70  13, 24 (50%) female). Of these 48 patients, 7 (15%) underwent secondary hematoma evacuation > 24 h, of whom 1 (14%) had received an EVD < 24 h. Five others also received an EVD < 24 h without subsequent hematoma evacuation. Of the 41 patients without secondary hematoma evacuation, 11 (28%) died and 20 (51%) had a favorable outcome (mRS of 0–3) at 3 months. The 7 patients who underwent secondary hematoma evacuation had a decrease in GCS score of at least two points prior to surgery; two (29%) had deceased at 3 months; and 5 (71%) had a good functional outcome (mRS 0–3). Conclusions: While cerebellar ICH > 3 cm is often considered an indication for immediate hematoma evacuation, there may be a subgroup of patients in whom surgery can be safely deferred. Further data are needed to assess the optimal timing and indications of surgical treatment in these patients.;,citation_author=Sanjula D. Singh;,citation_author=Floris H. B. M. Schreuder;,citation_author=Koen M. Nieuwenhuizen;,citation_author=Wilmar M. Jolink;,citation_author=Jasper R. Senff;,citation_author=Joshua N. Goldstein;,citation_author=Jeroen Boogaarts;,citation_author=Catharina J. M. Klijn;,citation_author=Gabriel J. E. Rinkel;,citation_author=H. Bart Brouwers;,citation_publication_date=2021-12;,citation_cover_date=2021-12;,citation_year=2021;,citation_issue=3;,citation_doi=10.1007/s12028-021-01203-6;,citation_issn=1541-6933, 1556-0961;,citation_volume=35;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Evidence of the Different Associations of Prognostic Factors With Censoring Across Treatment Groups and Impact on Censoring Weight Model Specification: The Example of Anticoagulation in Atrial Fibrillation;,citation_abstract=Abstract Inverse probability of censoring weights (IPCWs) may reduce selection bias due to informative censoring in longitudinal studies. However, in studies with an active comparator, the associations between predictors and censoring may differ across treatment groups. We used the clinical example of anticoagulation treatment with warfarin or a direct oral anticoagulant (DOAC) in atrial fibrillation to illustrate this. The cohort of individuals initiating an oral anticoagulant during 2010–2016 was identified from the Régie de l’assurance maladie du Québec (RAMQ) databases. The parameter of interest was the hazard ratio (HR) of the composite of stroke, major bleeding, myocardial infarction, or death associated with continuous use of warfarin versus DOACs. Two strategies for the specification of the model for estimation of censoring weights were explored: exposure-unstratified and exposure-stratified. The HR associated with continuous treatment with warfarin versus DOACs adjusted with exposure-stratified IPCWs was 1.26 (95% confidence interval: 1.20, 1.33). Using exposure-unstratified IPCWs, the HR differed by 15% in favor of DOACs (1.41, 95% confidence interval: 1.34, 1.48). Not accounting for the different associations between the predictors and informative censoring across exposure groups may lead to misspecification of censoring weights and biased estimate on comparative effectiveness and safety.;,citation_author=Liliya Sinyavskaya;,citation_author=Mireille Schnitzer;,citation_author=Christel Renoux;,citation_author=Jason R Guertin;,citation_author=Denis Talbot;,citation_author=Madeleine Durand;,citation_publication_date=2021-12;,citation_cover_date=2021-12;,citation_year=2021;,citation_issue=12;,citation_doi=10.1093/aje/kwab186;,citation_issn=0002-9262, 1476-6256;,citation_volume=190;,citation_language=en-US;,citation_journal_title=American Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Comparing Clinical Features and Outcomes in Mechanically Ventilated Patients with COVID-19 and Acute Respiratory Distress Syndrome;,citation_abstract=Rationale: Patients with severe coronavirus disease (COVID-19) meet clinical criteria for the acute respiratory distress syndrome (ARDS), yet early reports suggested they differ physiologically and clinically from patients with non–COVID-19 ARDS, prompting treatment recommendations that deviate from standard evidencebased practices for ARDS.;,citation_author=Michael W. Sjoding;,citation_author=Andrew J. Admon;,citation_author=Anjan K. Saha;,citation_author=Stephen G. Kay;,citation_author=Christopher A. Brown;,citation_author=Ivan Co;,citation_author=Dru Claar;,citation_author=Jakob I. McSparron;,citation_author=Robert P. Dickson;,citation_publication_date=2021-11;,citation_cover_date=2021-11;,citation_year=2021;,citation_issue=11;,citation_doi=10.1513/AnnalsATS.202008-1076OC;,citation_issn=2329-6933, 2325-6621;,citation_volume=18;,citation_language=en-US;,citation_journal_title=Annals of the American Thoracic Society;">
<meta name="citation_reference" content="citation_title=Interobserver Reliability of the Berlin ARDS Definition and Strategies to Improve the Reliability of ARDS Diagnosis;,citation_abstract=Background Failure to reliably diagnose ARDS may be a major driver of negative clinical trials and underrecognition and treatment in clinical practice. We sought to examine the interobserver reliability of the Berlin ARDS definition and examine strategies for improving the reliability of ARDS diagnosis. Methods Two hundred five patients with hypoxic respiratory failure from four ICUs were reviewed independently by three clinicians, who evaluated whether patients had ARDS, the diagnostic confidence of the reviewers, whether patients met individual ARDS criteria, and the time when criteria were met. Results Interobserver reliability of an ARDS diagnosis was “moderate” (kappa&nbsp;= 0.50; 95%&nbsp;CI, 0.40-0.59). Sixty-seven percent of diagnostic disagreements between clinicians reviewing the same patient was explained by differences in how chest imaging studies were interpreted, with other ARDS criteria contributing less (identification of ARDS risk factor, 15%; cardiac edema/volume overload exclusion, 7%). Combining the independent reviews of three clinicians can increase reliability to “substantial” (kappa&nbsp;= 0.75; 95%&nbsp;CI, 0.68-0.80). When a clinician diagnosed ARDS with “high confidence,” all other clinicians agreed with the diagnosis in 72%&nbsp;of reviews. There was close agreement between clinicians about the time when a patient met&nbsp;all ARDS criteria if ARDS developed within the first 48 hours of hospitalization (median difference, 5 hours). Conclusions The reliability of the Berlin ARDS definition is moderate, driven primarily by differences in chest imaging interpretation. Combining independent reviews by multiple clinicians or improving methods to identify bilateral infiltrates on chest imaging are important strategies for improving the reliability of ARDS diagnosis.;,citation_author=Michael W. Sjoding;,citation_author=Timothy P. Hofer;,citation_author=Ivan Co;,citation_author=Anthony Courey;,citation_author=Colin R. Cooke;,citation_author=Theodore J. Iwashyna;,citation_publication_date=2018-02;,citation_cover_date=2018-02;,citation_year=2018;,citation_issue=2;,citation_doi=10.1016/j.chest.2017.11.037;,citation_issn=0012-3692;,citation_volume=153;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Power Calculations to Select Instruments for Clinical Trial Secondary Endpoints. A Case Study of Instrument Selection for Post-Traumatic Stress Symptoms in Subjects with Acute Respiratory Distress Syndrome;,citation_abstract=Rationale: After the sample size of a randomized clinical trial (RCT) is set by the power requirement of its primary endpoint, investigators select secondary endpoints while unable to further adjust sample size. How the sensitivity and specificity of an instrument used to measure these outcomes, together with their expected underlying event rates, affect an RCT’s power to measure significant differences in these outcomes is poorly understood.;,citation_author=Michael W. Sjoding;,citation_author=David A. Schoenfeld;,citation_author=Samuel M. Brown;,citation_author=Catherine L. Hough;,citation_author=Donald M. Yealy;,citation_author=Marc Moss;,citation_author=Derek C. Angus;,citation_author=Theodore J. Iwashyna;,citation_publication_date=2017-01;,citation_cover_date=2017-01;,citation_year=2017;,citation_issue=1;,citation_doi=10.1513/AnnalsATS.201608-585OC;,citation_issn=2329-6933, 2325-6621;,citation_volume=14;,citation_language=en-US;,citation_journal_title=Annals of the American Thoracic Society;">
<meta name="citation_reference" content="citation_title=Are E-values too optimistic or too pessimistic? Both and neither!;,citation_author=Arvid Sjölander;,citation_author=Sander Greenland;,citation_publication_date=2022-03;,citation_cover_date=2022-03;,citation_year=2022;,citation_doi=10.1093/ije/dyac018;,citation_issn=0300-5771, 1464-3685;,citation_language=en-US;,citation_journal_title=International Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=High-Frequency Oscillatory Ventilation in Adults With ARDS;,citation_author=Michael C. Sklar;,citation_author=Eddy Fan;,citation_author=Ewan C. Goligher;,citation_publication_date=2017-12;,citation_cover_date=2017-12;,citation_year=2017;,citation_issue=6;,citation_doi=10.1016/j.chest.2017.06.025;,citation_issn=00123692;,citation_volume=152;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Low-Dose Nocturnal Dexmedetomidine Prevents ICU Delirium. A Randomized, Placebo-controlled Trial;,citation_abstract=Rationale: Dexmedetomidine is associated with less delirium than benzodiazepines and better sleep architecture than either benzodiazepines or propofol; its effect on delirium and sleep when administered at night to patients requiring sedation remains unclear.;,citation_author=Yoanna Skrobik;,citation_author=Matthew S. Duprey;,citation_author=Nicholas S. Hill;,citation_author=John W. Devlin;,citation_publication_date=2018-05;,citation_cover_date=2018-05;,citation_year=2018;,citation_issue=9;,citation_doi=10.1164/rccm.201710-1995OC;,citation_issn=1073-449X, 1535-4970;,citation_volume=197;,citation_language=en-US;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Debate: Subgroup analyses in clinical trials: Fun to look at - but don’t believe them!;,citation_abstract=Analysis of subgroup results in a clinical trial is surprisingly unreliable, even in a large trial. This is the result of a combination of reduced statistical power, increased variance and the play of chance. Reliance on such analyses is likely to be more erroneous, and hence harmful, than application of the overall proportional (or relative) result in the whole trial to the estimate of absolute risk in that subgroup. Plausible explanations can usually be found for effects that are, in reality, simply due to the play of chance. When clinicians believe such subgroup analyses, there is a real danger of harm to the individual patient.;,citation_author=Peter Sleight;,citation_publication_date=2000-04;,citation_cover_date=2000-04;,citation_year=2000;,citation_issue=1;,citation_doi=10.1186/cvm-1-1-025;,citation_issn=1745-6215;,citation_volume=1;,citation_language=en-US;,citation_journal_title=Trials;,citation_publisher=BioMed Central;">
<meta name="citation_reference" content="citation_title=The natural selection of bad science;,citation_abstract=Poor research design and data analysis encourage false-positive findings. Such poor methods persist despite perennial calls for improvement, suggesting that they result from something more than just misunderstanding. The persistence of poor methods results partly from incentives that favour them, leading to the natural selection of bad science. This dynamic requires no conscious strategizing—no deliberate cheating nor loafing—by scientists, only that publication is a principal factor for career advancement. Some normative methods of analysis have almost certainly been selected to further publication instead of discovery. In order to improve the culture of science, a shift must be made away from correcting misunderstandings and towards rewarding understanding. We support this argument with empirical evidence and computational modelling. We first present a 60-year meta-analysis of statistical power in the behavioural sciences and show that power has not improved despite repeated demonstrations of the necessity of increasing power. To demonstrate the logical consequences of structural incentives, we then present a dynamic model of scientific communities in which competing laboratories investigate novel or previously published hypotheses using culturally transmitted research methods. As in the real world, successful labs produce more “progeny,” such that their methods are more often copied and their students are more likely to start labs of their own. Selection for high output leads to poorer methods and increasingly high false discovery rates. We additionally show that replication slows but does not stop the process of methodological deterioration. Improving the quality of research requires change at the institutional level.;,citation_author=Paul E. Smaldino;,citation_author=Richard McElreath;,citation_publication_date=2016-09;,citation_cover_date=2016-09;,citation_year=2016;,citation_issue=9;,citation_doi=10.1098/rsos.160384;,citation_issn=2054-5703;,citation_volume=3;,citation_language=en-US;,citation_journal_title=Royal Society Open Science;">
<meta name="citation_reference" content="citation_title=Novel diabetes subgroups;,citation_author=Maarten Smeden;,citation_author=Frank E. Harrell;,citation_author=Darren L. Dahly;,citation_publication_date=2018-06;,citation_cover_date=2018-06;,citation_year=2018;,citation_issue=6;,citation_doi=10.1016/S2213-8587(18)30124-4;,citation_issn=2213-8587, 2213-8595;,citation_pmid=29803262;,citation_volume=6;,citation_language=en-US;,citation_journal_title=The Lancet Diabetes &amp;amp;amp; Endocrinology;,citation_publisher=Elsevier;">
<meta name="citation_reference" content="citation_title=2022 Society of Critical Care Medicine Clinical Practice Guidelines on Prevention and Management of Pain, Agitation, Neuromuscular Blockade, and Delirium in Critically Ill Pediatric Patients With Consideration of the ICU Environment and Early Mobility;,citation_author=Heidi A. B. Smith;,citation_author=James B. Besunder;,citation_author=Kristina A. Betters;,citation_author=Peter N. Johnson;,citation_author=Vijay Srinivasan;,citation_author=Anne Stormorken;,citation_author=Elizabeth Farrington;,citation_author=Brenda Golianu;,citation_author=Aaron J. Godshall;,citation_author=Larkin Acinelli;,citation_author=Christina Almgren;,citation_author=Christine H. Bailey;,citation_author=Jenny M. Boyd;,citation_author=Michael J. Cisco;,citation_author=Mihaela Damian;,citation_author=Mary L. deAlmeida;,citation_author=James Fehr;,citation_author=Kimberly E. Fenton;,citation_author=Frances Gilliland;,citation_author=Mary Jo C. Grant;,citation_author=Joy Howell;,citation_author=Cassandra A. Ruggles;,citation_author=Shari Simone;,citation_author=Felice Su;,citation_author=Janice E. Sullivan;,citation_author=Ken Tegtmeyer;,citation_author=Chani Traube;,citation_author=Stacey Williams;,citation_author=John W. Berkenbosch;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_issue=2;,citation_doi=10.1097/PCC.0000000000002873;,citation_issn=1529-7535;,citation_volume=23;,citation_language=en-US;,citation_journal_title=Pediatric Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Declaring independence: Why we should be cautious.;,citation_author=G D Smith;,citation_author=A Phillips;,citation_publication_date=1990-12;,citation_cover_date=1990-12;,citation_year=1990;,citation_issue=4;,citation_doi=10.1136/jech.44.4.257;,citation_issn=0143-005X;,citation_volume=44;,citation_language=en-US;,citation_journal_title=Journal of Epidemiology &amp;amp;amp; Community Health;">
<meta name="citation_reference" content="citation_title=Step away from stepwise;,citation_abstract=Stepwise regression is a popular data-mining tool that uses statistical significance to select the explanatory variables to be used in a multiple-regression model.;,citation_author=Gary Smith;,citation_publication_date=2018-09;,citation_cover_date=2018-09;,citation_year=2018;,citation_issue=1;,citation_doi=10.1186/s40537-018-0143-6;,citation_issn=2196-1115;,citation_volume=5;,citation_journal_title=Journal of Big Data;">
<meta name="citation_reference" content="citation_title=Treatment of Intermediate-Risk Pulmonary Embolism;,citation_author=Robert Smyth;,citation_author=Christopher Kabrhel;,citation_author=Timothy Morris;,citation_publication_date=2023-07;,citation_cover_date=2023-07;,citation_year=2023;,citation_issue=2;,citation_doi=10.1056/NEJMclde2301330;,citation_issn=0028-4793;,citation_pmid=37437150;,citation_volume=389;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss;,citation_abstract=This database study examines the association between glucagon-like peptide 1 agonists (eg, semaglutide, liraglutide) used for weight loss and reports of gastrointestinal adverse events.;,citation_author=Mohit Sodhi;,citation_author=Ramin Rezaeianzadeh;,citation_author=Abbas Kezouh;,citation_author=Mahyar Etminan;,citation_publication_date=2023-11;,citation_cover_date=2023-11;,citation_year=2023;,citation_issue=18;,citation_doi=10.1001/jama.2023.19574;,citation_issn=0098-7484;,citation_volume=330;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Patient preferences for stroke outcomes.;,citation_abstract=In clinical trials stroke is reported as a major morbid outcome, but the impact of stroke on patients is not directly assessed. This study examines patient preferences for different outcomes of stroke, including death. We presented patients with written case scenarios of stroke outcomes. The scenarios represented four categories of stroke severity (mild, moderate, severe, and fatal), and for nonfatal strokes the scenarios described motor, language, and cognitive deficits. Patients reported values for each of the 10 stroke scenarios using a rank-and-scale method over a 100-point range, with 100 representing perfect health and 0 corresponding to the worst possible health state. One hundred seventeen of 209 consecutive patients at risk for stroke participated in this study. Severe strokes were uniformly rated as having low preference weights (mean +/- SD [median]: 3 +/- 4 [1] for disabling hemiplegia, 8 +/- 9 [5] for confusion, and 15 +/- 14 [10] for global aphasia), and severe motor impairment (a disabling hemiplegia) was rated as significantly worse than death. Even mild deficits resulted in substantial loss to patients (54 +/- 21 [55] for dysarthria and 53 +/- 21 [50] for mild anomia). Strokes may result in a wide variety of post-stroke consequences for patients. Severe strokes may be viewed by patients as tantamount to or worse than death. Even mild strokes may cause significant declines in patient preferences for health states. These data are useful in interpreting studies that report stroke and death, in designing new studies that measure stroke in at-risk populations, and in helping patients reach treatment decisions about therapies designed to prevent strokes.;,citation_author=N A Solomon;,citation_author=H A Glick;,citation_author=C J Russo;,citation_author=J Lee;,citation_author=K A Schulman;,citation_publication_date=1994-09;,citation_cover_date=1994-09;,citation_year=1994;,citation_issue=9;,citation_doi=10.1161/01.STR.25.9.1721;,citation_volume=25;,citation_journal_title=Stroke;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=One-Year Outcomes in Patients With Acute Stroke Requiring Mechanical Ventilation;,citation_abstract=Background: Long-term outcomes of patients with severe stroke remain poorly documented. We aimed to characterize one-year outcomes of patients with stroke requiring mechanical ventilation in the intensive care unit (ICU). Methods: We conducted a prospective multicenter cohort study in 33 ICUs in France (2017–2019) on patients with consecutive strokes requiring mechanical ventilation for at least 24 hours. Outcomes were collected via telephone interviews by an independent research assistant. The primary end point was poor functional outcome, defined by a modified Rankin Scale score of 4 to 6 at 1 year. Multivariable mixed models investigated variables associated with the primary end point. Secondary end points included quality of life, activities of daily living, and anxiety and depression in 1-year survivors. Results: Among the 364 patients included, 244 patients (66.5% [95% CI, 61.7%–71.3%]) had a poor functional outcome, including 190 deaths (52.2%). After adjustment for non-neurological organ failure, age \geq70 years (odds ratio [OR], 2.38 [95% CI, 1.26–4.49]), Charlson comorbidity index \geq2 (OR, 2.01 [95% CI, 1.16–3.49]), a score on the Glasgow Coma Scale &amp;amp;amp;lt;8 at ICU admission (OR, 3.43 [95% CI, 1.98–5.96]), stroke subtype (intracerebral hemorrhage: OR, 2.44 [95% CI, 1.29–4.63] versus ischemic stroke: OR, 2.06 [95% CI, 1.06–4.00] versus subarachnoid hemorrhage: reference) remained independently associated with poor functional outcome. In contrast, a time between stroke diagnosis and initiation of mechanical ventilation &amp;gt;1 day was protective (OR, 0.56 [95% CI, 0.33–0.94]). A sensitivity analysis conducted after exclusion of patients with early decisions of withholding/withdrawal of care yielded similar results. We observed persistent physical and psychological problems at 1 year in &amp;gt;50% of survivors. Conclusions: In patients with severe stroke requiring mechanical ventilation, several ICU admission variables may inform caregivers, patients, and their families on post-ICU trajectories and functional outcomes. The burden of persistent sequelae at 1 year reinforces the need for a personalized, multi-disciplinary, prolonged follow-up of these patients after ICU discharge. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03335995;,citation_author=Romain Sonneville;,citation_author=Mikael Mazighi;,citation_author=Magalie Collet;,citation_author=Etienne Gayat;,citation_author=Vincent Degos;,citation_author=Jacques Duranteau;,citation_author=Charles Grégoire;,citation_author=Tarek Sharshar;,citation_author=Giulia Naim;,citation_author=David Cortier;,citation_author=Paul-Henri Jost;,citation_author=Arnaud Foucrier;,citation_author=François Bagate;,citation_author=Etienne Montmollin;,citation_author=Gregory Papin;,citation_author=Eric Magalhaes;,citation_author=Bertrand Guidet;,citation_author=Omar Ben Hadj Salem;,citation_author=Sarah Benghanem;,citation_author=Loı̈c Guennec;,citation_author=Eric Delpierre;,citation_author=Stephane Legriel;,citation_author=Bruno Megarbane;,citation_author=Karim Toumert;,citation_author=Marc Tran;,citation_author=Guillaume Geri;,citation_author=Mehran Monchi;,citation_author=Eric Bodiguel;,citation_author=Eric Mariotte;,citation_author=Alexandre Demoule;,citation_author=Jonathan Zarka;,citation_author=Jean-Luc Diehl;,citation_author=Damien Roux;,citation_author=Eric Barré;,citation_author=Sebastien Tanaka;,citation_author=David Osman;,citation_author=Pierre Pasquier;,citation_author=Fariza Lamara;,citation_author=Isabelle Crassard;,citation_author=Perrine Boursin;,citation_author=Stéphane Ruckly;,citation_author=Quentin Staiquly;,citation_author=Jean-François Timsit;,citation_author=France Woimant;,citation_author=Tiare Ader;,citation_author=Hélène Bout;,citation_author=Damien Bresson;,citation_author=Alain Combes;,citation_author=Anne Chrisment;,citation_author=Sophie Crozier;,citation_author=Daniel Silva;,citation_author=Maxens Decavele;,citation_author=Martin Dres;,citation_author=Frédéric Faugeras;,citation_author=Marie-Céline Fournier;,citation_author=Tobias Gauss;,citation_author=Coralie Gernez;,citation_author=Dominique Hurel;,citation_author=Matthieu Jamme;,citation_author=Laurence Josse;,citation_author=Igor Jurcisin;,citation_author=Lionel Kerhuel;,citation_author=Catherine Lamy;,citation_author=Aymeric Lancelot;,citation_author=Bertrand Lapergue;,citation_author=Christophe Lenclud;,citation_author=Mathilde Lermuzeaux;,citation_author=Isabelle Malissin;,citation_author=Alain Maldjian;,citation_author=Nathalie Marin;,citation_author=Jérôme Martin;,citation_author=Thibault Martinez;,citation_author=Armand Mekontso Dessap;,citation_author=Hervé Outin;,citation_author=Claire Pichereau;,citation_author=Matthieu Pissot;,citation_author=Keyvan Razazi;,citation_author=Danielle Reuter;,citation_author=Christian Richard;,citation_author=Caroline Schimpf;,citation_author=Jérôme Servan;,citation_author=Laurie-Anne Thion;,citation_author=Widad Traki;,citation_author=Philippe Vassel;,citation_author=Bernard Vigué;,citation_author=Daniel Zafimahazo;,citation_issue=0;,citation_doi=10.1161/STROKEAHA.123.042910;,citation_volume=0;,citation_journal_title=Stroke;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=Applying a Clinical Decision Rule for CAD in Primary Care to Select a Diagnostic Test and Interpret the Results;,citation_abstract=Using the INTERCHEST chest pain decision rule to decide next steps when a patient presents to a primary care physician with chest pain.;,citation_author=Harold C. Sox;,citation_author=Marc Aerts;,citation_author=Jörg Haasenriter;,citation_publication_date=2019-05;,citation_cover_date=2019-05;,citation_year=2019;,citation_issue=9;,citation_volume=99;,citation_language=en-US;,citation_journal_title=American Family Physician;">
<meta name="citation_reference" content="citation_title=Association of Out-of-Hospital Hypotension Depth and Duration With Traumatic Brain Injury Mortality;,citation_abstract=STUDY OBJECTIVE: Out-of-hospital hypotension has been associated with increased mortality in traumatic brain injury. The association of traumatic brain injury mortality with the depth or duration of out-of-hospital hypotension is unknown. We evaluated the relationship between the depth and duration of out-of-hospital hypotension and mortality in major traumatic brain injury. METHODS: We evaluated adults and older children with moderate or severe traumatic brain injury in the preimplementation cohort of Arizona’s statewide Excellence in Prehospital Injury Care study. We used logistic regression to determine the association between the depth-duration dose of hypotension (depth of systolic blood pressure &amp;amp;amp;lt;90 mm Hg integrated over duration [minutes] of hypotension) and odds of inhospital death, controlling for significant confounders. RESULTS: There were 7,521 traumatic brain injury cases included (70.6% male patients; median age 40 years [interquartile range 24 to 58]). Mortality was 7.8% (95% confidence interval [CI] 7.2% to 8.5%) among the 6,982 patients without hypotension (systolic blood pressure \geq90 mm Hg) and 33.4% (95% CI 29.4% to 37.6%) among the 539 hypotensive patients (systolic blood pressure &amp;lt;90 mm Hg). Mortality was higher with increased hypotension dose: 0.01 to 14.99 mm Hg-minutes 16.3%; 15 to 49.99 mm Hg-minutes 28.1%; 50 to 141.99 mm Hg-minutes 38.8%; and greater than or equal to 142 mm Hg-minutes 50.4%. Log2 (the logarithm in base 2) of hypotension dose was associated with traumatic brain injury mortality (adjusted odds ratio 1.19 [95% CI 1.14 to 1.25] per 2-fold increase of dose). CONCLUSION: In this study, the depth and duration of out-of-hospital hypotension were associated with increased traumatic brain injury mortality. Assessments linking out-of-hospital blood pressure with traumatic brain injury outcomes should consider both depth and duration of hypotension.;,citation_author=Daniel W. Spaite;,citation_author=Chengcheng Hu;,citation_author=Bentley J. Bobrow;,citation_author=Vatsal Chikani;,citation_author=Bruce Barnhart;,citation_author=Joshua B. Gaither;,citation_author=Kurt R. Denninghoff;,citation_author=P. David Adelson;,citation_author=Samuel M. Keim;,citation_author=Chad Viscusi;,citation_author=Terry Mullins;,citation_author=Amber D. Rice;,citation_author=Duane Sherrill;,citation_publication_date=2017-10;,citation_cover_date=2017-10;,citation_year=2017;,citation_issue=4;,citation_doi=10.1016/j.annemergmed.2017.03.027;,citation_issn=1097-6760;,citation_pmid=28559036;,citation_volume=70;,citation_language=en-US;,citation_journal_title=Annals of Emergency Medicine;">
<meta name="citation_reference" content="citation_title=The Effect of Combined Out-of-Hospital Hypotension and Hypoxia on Mortality in Major Traumatic Brain Injury;,citation_abstract=Study objective Survival is significantly reduced by either hypotension or hypoxia during the out-of-hospital management of major traumatic brain injury. However, only a handful of small studies have investigated the influence of the combination of both hypotension and hypoxia occurring together. In patients with major traumatic brain injury, we evaluate the associations between mortality and out-of-hospital hypotension and hypoxia separately and in combination. Methods All moderate or severe traumatic brain injury cases in the preimplementation cohort of the Excellence in Prehospital Injury Care study (a statewide, before/after, controlled study of the effect of implementing the out-of-hospital traumatic brain injury treatment guidelines) from January 1, 2007, to March 31, 2014, were evaluated (exclusions: &amp;amp;amp;lt;10 years, out-of-hospital oxygen saturation \leq10%, and out-of-hospital systolic blood pressure &amp;lt;40 or &amp;gt;200 mm Hg). The relationship between mortality and hypotension (systolic blood pressure <90 mm Hg) or hypoxia (saturation <90%) was assessed with multivariable logistic regression, controlling for Injury Severity Score, head region severity, injury type (blunt versus penetrating), age, sex, race, ethnicity, payer, interhospital transfer, and trauma center. Results Among the 13,151 patients who met inclusion criteria (median age 45 years; 68.6% men), 11,545 (87.8%) had neither hypotension nor hypoxia, 604 (4.6%) had hypotension only, 790 (6.0%) had hypoxia only, and 212 (1.6%) had both hypotension and hypoxia. Mortality for the 4 study cohorts was 5.6%, 20.7%, 28.1%, and 43.9%, respectively. The crude and adjusted odds ratios for death within the cohorts, using the patients with neither hypotension nor hypoxia as the reference, were 4.4 and 2.5, 6.6 and 3.0, and 13.2 and 6.1, respectively. Evaluation for an interaction between hypotension and hypoxia revealed that the effects were additive on the log odds of death. Conclusion In this statewide analysis of major traumatic brain injury, combined out-of-hospital hypotension and hypoxia were associated with significantly increased mortality. This effect on survival persisted even after controlling for multiple potential confounders. In fact, the adjusted odds of death for patients with both hypotension and hypoxia were more than 2 times greater than for those with either hypotension or hypoxia alone. These findings seem supportive of the emphasis on aggressive prevention and treatment of hypotension and hypoxia reflected in the current emergency medical services traumatic brain injury treatment guidelines but clearly reveal the need for further study to determine their influence on outcome.;,citation_author=Daniel W. Spaite;,citation_author=Chengcheng Hu;,citation_author=Bentley J. Bobrow;,citation_author=Vatsal Chikani;,citation_author=Bruce Barnhart;,citation_author=Joshua B. Gaither;,citation_author=Kurt R. Denninghoff;,citation_author=P. David Adelson;,citation_author=Samuel M. Keim;,citation_author=Chad Viscusi;,citation_author=Terry Mullins;,citation_author=Duane Sherrill;,citation_publication_date=2017-01;,citation_cover_date=2017-01;,citation_year=2017;,citation_issue=1;,citation_doi=10.1016/j.annemergmed.2016.08.007;,citation_issn=0196-0644;,citation_volume=69;,citation_language=en-US;,citation_journal_title=Annals of Emergency Medicine;">
<meta name="citation_reference" content="citation_title=Clinician attitudes and concordance with self-assessed and actual intravenous fluid prescribing patterns: A single-institution evaluation of survey and electronic prescribing data;,citation_abstract=Background Recent studies suggest that balanced fluids improve inpatient outcomes compared to normal saline. The objective of this study was to obtain insights into clinicians’ knowledge, attitudes and perceived prescribing practices concerning IV isotonic fluids and to analyze perceived prescribing in the context of actual prescribing. Methods This study, conducted at a single center (Medical University of South Carolina), included 1) a cross-sectional survey of physicians and advanced practice providers (APPs) (7/2019-8/2019) and 2) review electronic health record (EHR) claims data (2/2018-1/2019) to quantify the prescribing patterns of isotonic fluids. Results Clinicians perceived ordering equivalent amounts of normal saline and balanced fluids although normal saline ordering predominated (59.7%). There was significant variation in perceived and actual ordering across specialties, with internal medicine/subspecialty and emergency medicine clinicians reporting preferential use of normal saline and surgical/subspecialty and anesthesia clinicians reporting preferential use of balanced fluids (p &amp;amp;amp;lt; 0.0001). Clinicians who self-reported providing care in an intensive care unit (ICU) reported more frequent use of balanced fluids than non-ICU clinicians (p&nbsp;=&nbsp;0.03). Actual prescribing data mirrored these differences. Clinicians’ self-reported use of continuous infusions (p&nbsp;=&nbsp;0.0006) and beliefs regarding the volume of fluid required to cause harm (p&nbsp;=&nbsp;0.003) were also associated with self-reported differences in fluid prescribing. Clinician experience, most clinical considerations (e.g., indications, contraindications, barriers to using a specific fluid), and fluid cost were not associated with differential prescribing. Conclusions Persistent normal saline utilization is associated with certain specialties, care locations, and the rate and volume of fluid administered, but not with other clinical considerations or cost. These findings can guide interventions to improve evidence-based fluid prescribing.;,citation_author=Michelle C. Spiegel;,citation_author=Annie N. Simpson;,citation_author=Nandita R. Nadig;,citation_author=Dee W. Ford;,citation_author=Andrew J. Goodwin;,citation_publication_date=2022-07;,citation_cover_date=2022-07;,citation_year=2022;,citation_issue=1;,citation_doi=10.1016/j.amjms.2022.03.010;,citation_issn=0002-9629;,citation_volume=364;,citation_language=en-US;,citation_journal_title=The American Journal of the Medical Sciences;">
<meta name="citation_reference" content="citation_title=Bayesian Approaches to Randomized Trials;,citation_abstract=Statisticailssuesinconductingrandomizedtrialsincludethechoiceofa samplesize,whether to stopa trialearlyand theappropriateanalysisand interpretatioonf thetrialresults.At each of thesestages,evidenceexternalto thetrialis useful,but generallysuch evidence is introducedinan unstructureadnd informaml anner.We arguethata Bayesianapproach allows a formalbasis forusingexternalevidenceand in additionprovidesa rationalway for dealing withissues such as the ethicsof randomization,trialsto show treatment equivalence,themonitoringof accumulatingdata and thepredictionof theconsequences of continuinga study.The motivationforusingthismethodologyis practicalratherthan ideological.;,citation_author=David J. Spiegelhalter;,citation_author=Laurence S. Freedman;,citation_author=Mahesh K. B. Parmar;,citation_publication_date=1994;,citation_cover_date=1994;,citation_year=1994;,citation_fulltext_html_url=https://www.jstor.org/stable/10.2307/2983527;,citation_issue=3;,citation_doi=10.2307/2983527;,citation_issn=09641998;,citation_volume=157;,citation_language=en-US;,citation_journal_title=Journal of the Royal Statistical Society. Series A (Statistics in Society);">
<meta name="citation_reference" content="citation_title=Beyond Mortality: Future Clinical Research in Acute Lung Injury;,citation_author=Roger G. Spragg;,citation_author=Gordon R. Bernard;,citation_author=William Checkley;,citation_author=J. Randall Curtis;,citation_author=Ognjen Gajic;,citation_author=Gordon Guyatt;,citation_author=Jesse Hall;,citation_author=Elliott Israel;,citation_author=Manu Jain;,citation_author=Dale M. Needham;,citation_author=Adrienne G. Randolph;,citation_author=Gordon D. Rubenfeld;,citation_author=David Schoenfeld;,citation_author=B. Taylor Thompson;,citation_author=Lorraine B. Ware;,citation_author=Duncan Young;,citation_author=Andrea L. Harabin;,citation_publication_date=2010-05;,citation_cover_date=2010-05;,citation_year=2010;,citation_issue=10;,citation_doi=10.1164/rccm.201001-0024WS;,citation_issn=1073-449X, 1535-4970;,citation_volume=181;,citation_language=en-US;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): An international randomised, placebo-controlled, phase 3 superiority trial;,citation_author=Nikola Sprigg;,citation_author=Katie Flaherty;,citation_author=Jason P. Appleton;,citation_author=Rustam Al-Shahi Salman;,citation_author=Daniel Bereczki;,citation_author=Maia Beridze;,citation_author=Hanne Christensen;,citation_author=Alfonso Ciccone;,citation_author=Ronan Collins;,citation_author=Anna Czlonkowska;,citation_author=Robert A. Dineen;,citation_author=Lelia Duley;,citation_author=Juan Jose Egea-Guerrero;,citation_author=Timothy J. England;,citation_author=Kailash Krishnan;,citation_author=Ann Charlotte Laska;,citation_author=Zhe Kang Law;,citation_author=Serefnur Ozturk;,citation_author=Stuart J. Pocock;,citation_author=Ian Roberts;,citation_author=Thompson G. Robinson;,citation_author=Christine Roffe;,citation_author=David Seiffge;,citation_author=Polly Scutt;,citation_author=Jegan Thanabalan;,citation_author=David Werring;,citation_author=David Whynes;,citation_author=Philip M. Bath;,citation_publication_date=2018-05;,citation_cover_date=2018-05;,citation_year=2018;,citation_issue=10135;,citation_doi=10.1016/S0140-6736(18)31033-X;,citation_issn=0140-6736, 1474-547X;,citation_pmid=29778325;,citation_volume=391;,citation_language=en-US;,citation_journal_title=The Lancet;,citation_publisher=Elsevier;">
<meta name="citation_reference" content="citation_title=Reconsidering Vasopressors for Cardiogenic Shock;,citation_author=Pierre Squara;,citation_author=Steven Hollenberg;,citation_author=Didier Payen;,citation_publication_date=2019-08;,citation_cover_date=2019-08;,citation_year=2019;,citation_issue=2;,citation_doi=10.1016/j.chest.2019.03.020;,citation_issn=00123692;,citation_volume=156;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Intracerebral Hemorrhage Location and Functional Outcomes of Patients: A Systematic Literature Review and Meta-Analysis;,citation_abstract=Intracerebral hemorrhage (ICH) has the highest mortality rate among all strokes. While ICH location, lobar versus non-lobar, has been established as a predictor of mortality, less is known regarding the relationship between more specific ICH locations and functional outcome. This review summarizes current work studying how ICH location affects outcome, with an emphasis on how studies designate regions of interest.;,citation_author=Anirudh Sreekrishnan;,citation_author=Jennifer L. Dearborn;,citation_author=David M. Greer;,citation_author=Fu-Dong Shi;,citation_author=David Y. Hwang;,citation_author=Audrey C. Leasure;,citation_author=Sonya E. Zhou;,citation_author=Emily J. Gilmore;,citation_author=Charles C. Matouk;,citation_author=Nils H. Petersen;,citation_author=Lauren H. Sansing;,citation_author=Kevin N. Sheth;,citation_publication_date=2016-12;,citation_cover_date=2016-12;,citation_year=2016;,citation_issue=3;,citation_doi=10.1007/s12028-016-0276-4;,citation_issn=1556-0961;,citation_volume=25;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=The researcher and the consultant: A dialogue on null hypothesis significance testing;,citation_abstract=Since its introduction, null hypothesis significance testing (NHST) has caused much debate. Many publications on common misunderstandings have appeared. Despite the many cautions, NHST remains one of the most prevalent, misused and abused statistical procedures in the biomedical literature. This article is directed at practicing researchers with limited statistical background who are driven by subject matter questions and have empirical data to be analyzed. We use a dialogue as in ancient Greek literature for didactic purposes. We illustrate several, though only a few, irritations that can come up when a researcher with minimal statistical background but a good sense of what she wants her study to do, and of what she wants to do with her study, asks for consultation by a statistician. We provide insights into the meaning of several concepts including null and alternative hypothesis, one- and two-sided null hypotheses, statistical models, test statistic, rejection and acceptance regions, type I and II error, p value, and the frequentist’ concept of endless study repetitions.;,citation_author=Andreas Stang;,citation_author=Charles Poole;,citation_publication_date=2013-12;,citation_cover_date=2013-12;,citation_year=2013;,citation_issue=12;,citation_doi=10.1007/s10654-013-9861-4;,citation_issn=0393-2990, 1573-7284;,citation_volume=28;,citation_language=en-US;,citation_journal_title=European Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Pay No Attention to the Model Behind the Curtain;,citation_abstract=Many widely used models amount to an elaborate means of making up numbers—but once a number has been produced, it tends to be taken seriously and its source (the model) is rarely examined carefully. Many widely used models have little connection to the real-world phenomena they purport to explain. Common steps in modeling to support policy decisions, such as putting disparate things on the same scale, may conflict with reality. Not all costs and benefits can be put on the same scale, not all uncertainties can be expressed as probabilities, and not all model parameters measure what they purport to measure. These ideas are illustrated with examples from seismology, wind-turbine bird deaths, soccer penalty cards, gender bias in academia, and climate policy.;,citation_author=Philip B. Stark;,citation_publication_date=2022-11;,citation_cover_date=2022-11;,citation_year=2022;,citation_issue=11;,citation_doi=10.1007/s00024-022-03137-2;,citation_issn=0033-4553, 1420-9136;,citation_volume=179;,citation_language=en-US;,citation_journal_title=Pure and Applied Geophysics;">
<meta name="citation_reference" content="citation_title=A Randomized Clinical Trial of Aggressive Blood Pressure Control in Patients With Acute Cerebral Hemorrhage:;,citation_author=Robert M. Starke;,citation_author=Eric C. Peterson;,citation_author=Ricardo J. Komotar;,citation_author=E. Sander Connolly;,citation_publication_date=2016-12;,citation_cover_date=2016-12;,citation_year=2016;,citation_issue=6;,citation_doi=10.1227/01.neu.0000508604.61565.ba;,citation_issn=0148-396X;,citation_volume=79;,citation_language=en-US;,citation_journal_title=Neurosurgery;">
<meta name="citation_reference" content="citation_title=Attributable Mortality of Ventilator-associated Pneumonia. Replicating Findings, Revisiting Methods;,citation_abstract=Rationale: Estimating the impact of ventilator-associated pneumonia (VAP) from routinely collected intensive care unit (ICU) data is methodologically challenging.;,citation_author=Johan Steen;,citation_author=Stijn Vansteelandt;,citation_author=Liesbet De Bus;,citation_author=Pieter Depuydt;,citation_author=Bram Gadeyne;,citation_author=Dominique D. Benoit;,citation_author=Johan Decruyenaere;,citation_publication_date=2021-05;,citation_cover_date=2021-05;,citation_year=2021;,citation_issue=5;,citation_doi=10.1513/AnnalsATS.202004-385OC;,citation_issn=2329-6933, 2325-6621;,citation_volume=18;,citation_language=en-US;,citation_journal_title=Annals of the American Thoracic Society;">
<meta name="citation_reference" content="citation_title=Factors considered important at the end of life by patients, family, physicians, and other care providers;,citation_abstract=CONTEXT: A clear understanding of what patients, families, and health care practitioners view as important at the end of life is integral to the success of improving care of dying patients. Empirical evidence defining such factors, however, is lacking. OBJECTIVE: To determine the factors considered important at the end of life by patients, their families, physicians, and other care providers. DESIGN AND SETTING: Cross-sectional, stratified random national survey conducted in March-August 1999. PARTICIPANTS: Seriously ill patients (n = 340), recently bereaved family (n = 332), physicians (n = 361), and other care providers (nurses, social workers, chaplains, and hospice volunteers; n = 429). MAIN OUTCOME MEASURES: Importance of 44 attributes of quality at the end of life (5-point scale) and rankings of 9 major attributes, compared in the 4 groups. RESULTS: Twenty-six items consistently were rated as being important (&amp;amp;amp;gt;70% responding that item is important) across all 4 groups, including pain and symptom management, preparation for death, achieving a sense of completion, decisions about treatment preferences, and being treated as a &amp;quot;whole person.&amp;quot; Eight items received strong importance ratings from patients but less from physicians (P&amp;lt;.001), including being mentally aware, having funeral arrangements planned, not being a burden, helping others, and coming to peace with God. Ten items had broad variation within as well as among the 4 groups, including decisions about life-sustaining treatments, dying at home, and talking about the meaning of death. Participants ranked freedom from pain most important and dying at home least important among 9 major attributes. CONCLUSIONS: Although pain and symptom management, communication with one’s physician, preparation for death, and the opportunity to achieve a sense of completion are important to most, other factors important to quality at the end of life differ by role and by individual. Efforts to evaluate and improve patients’ and families’ experiences at the end of life must account for diverse perceptions of quality. JAMA. 2000;284:2476-2482.;,citation_author=K. E. Steinhauser;,citation_author=N. A. Christakis;,citation_author=E. C. Clipp;,citation_author=M. McNeilly;,citation_author=L. McIntyre;,citation_author=J. A. Tulsky;,citation_publication_date=2000-11;,citation_cover_date=2000-11;,citation_year=2000;,citation_issue=19;,citation_doi=10.1001/jama.284.19.2476;,citation_issn=0098-7484;,citation_pmid=11074777;,citation_volume=284;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=A Guide to Performance Evaluation for the Intensivist: Ongoing Professional Practice Evaluation and Focused Professional Practice Evaluation in the ICU;,citation_author=Michael Sterling;,citation_author=Sara Gregg;,citation_author=Vishal Bakshi;,citation_author=Vanessa Moll;,citation_publication_date=2020-10;,citation_cover_date=2020-10;,citation_year=2020;,citation_issue=10;,citation_doi=10.1097/CCM.0000000000004441;,citation_issn=0090-3493;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions;,citation_abstract=&amp;amp;amp;lt;p&amp;gt;Non-randomised studies of the effects of interventions are critical to many areas of healthcare evaluation, but their results may be biased. It is therefore important to understand and appraise their strengths and weaknesses. We developed ROBINS-I (“Risk Of Bias In Non-randomised Studies - of Interventions”), a new tool for evaluating risk of bias in estimates of the comparative effectiveness (harm or benefit) of interventions from studies that did not use randomisation to allocate units (individuals or clusters of individuals) to comparison groups. The tool will be particularly useful to those undertaking systematic reviews that include non-randomised studies.&amp;lt;/p&amp;gt;;,citation_author=Jonathan AC Sterne;,citation_author=Miguel A. Hernán;,citation_author=Barnaby C. Reeves;,citation_author=Jelena Savović;,citation_author=Nancy D. Berkman;,citation_author=Meera Viswanathan;,citation_author=David Henry;,citation_author=Douglas G. Altman;,citation_author=Mohammed T. Ansari;,citation_author=Isabelle Boutron;,citation_author=James R. Carpenter;,citation_author=An-Wen Chan;,citation_author=Rachel Churchill;,citation_author=Jonathan J. Deeks;,citation_author=Asbjørn Hróbjartsson;,citation_author=Jamie Kirkham;,citation_author=Peter Jüni;,citation_author=Yoon K. Loke;,citation_author=Theresa D. Pigott;,citation_author=Craig R. Ramsay;,citation_author=Deborah Regidor;,citation_author=Hannah R. Rothstein;,citation_author=Lakhbir Sandhu;,citation_author=Pasqualina L. Santaguida;,citation_author=Holger J. Schünemann;,citation_author=Beverly Shea;,citation_author=Ian Shrier;,citation_author=Peter Tugwell;,citation_author=Lucy Turner;,citation_author=Jeffrey C. Valentine;,citation_author=Hugh Waddington;,citation_author=Elizabeth Waters;,citation_author=George A. Wells;,citation_author=Penny F. Whiting;,citation_author=Julian PT Higgins;,citation_publication_date=2016-10;,citation_cover_date=2016-10;,citation_year=2016;,citation_doi=10.1136/bmj.i4919;,citation_issn=1756-1833;,citation_pmid=27733354;,citation_volume=355;,citation_language=en-US;,citation_journal_title=BMJ;,citation_publisher=British Medical Journal Publishing Group;">
<meta name="citation_reference" content="citation_title=Sifting the evidence—what’s wrong with significance tests?;,citation_author=Jonathan A C Sterne;,citation_author=George Davey Smith;,citation_publication_date=2001-08;,citation_cover_date=2001-08;,citation_year=2001;,citation_issue=8;,citation_doi=10.1093/ptj/81.8.1464;,citation_issn=0031-9023, 1538-6724;,citation_volume=81;,citation_language=en-US;,citation_journal_title=Physical Therapy;">
<meta name="citation_reference" content="citation_title=Medical Student and Trainee Notes in the Electronic Health Record Era;,citation_author=Lindsay A. Stevens;,citation_author=Natalie M. Pageler;,citation_author=Christopher A. Longhurst;,citation_publication_date=2022-12;,citation_cover_date=2022-12;,citation_year=2022;,citation_issue=6;,citation_doi=10.1016/j.chest.2022.08.2208;,citation_issn=0012-3692;,citation_volume=162;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Death by Patient Portal;,citation_abstract=Entering the third year of the coronavirus pandemic, I finally broke. I was a relentless optimist during “COVID Times”—treating and soothing the ill and the anxious, but by the spring of ’23, I just burned out. “It’s like that final scene in The Perfect Storm,” I would tell friends. “Weathering catastrophe only to be upended by a rogue wave.”Burnout is not necessarily reducible. One cannot often identify a single cause. Nevertheless, I sought a culprit. My marriage was tight, my friends were supportive, my Pomeranian Finch remained the cutest creature on the planet. The world was returning to normal. But there was that patient portal! Like most physicians, I was getting many more messages than I had before the pandemic and was spending multiple hours a day answering them. I told my husband that I could fill my entire day just responding to patient messages and never actually examine anyone.;,citation_author=Michael Stillman;,citation_publication_date=2023-07;,citation_cover_date=2023-07;,citation_year=2023;,citation_issue=3;,citation_doi=10.1001/jama.2023.11629;,citation_issn=0098-7484;,citation_volume=330;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Delirium in critical illness: Clinical manifestations, outcomes, and management;,citation_abstract=Delirium is the most common manifestation of brain dysfunction in critically ill patients. In the intensive care unit (ICU), duration of delirium is independently predictive of excess death, length of stay, cost of care, and acquired dementia. There are numerous neurotransmitter/functional and/or injury-causing hypotheses rather than a unifying mechanism for delirium. Without using a validated delirium instrument, delirium can be misdiagnosed (under, but also overdiagnosed and trivialized), supporting the recommendation to use a monitoring instrument routinely. The best-validated ICU bedside instruments are CAM-ICU and ICDSC, both of which also detect subsyndromal delirium. Both tools have some inherent limitations in the neurologically injured patients, yet still provide valuable information about delirium once the sequelae of the primary injury settle into a new post-injury baseline. Now it is known that antipsychotics and other psychoactive medications do not reliably improve brain function in critically ill delirious patients. ICU teams should systematically screen for predisposing and precipitating factors. These include exacerbations of cardiac/respiratory failure or sepsis, metabolic disturbances (hypoglycemia, dysnatremia, uremia and ammonemia) receipt of psychoactive medications, and sensory deprivation through prolonged immobilization, uncorrected vision and hearing deficits, poor sleep hygiene, and isolation from loved ones so common during COVID19 pandemic. The ABCDEF (A2F) bundle is a means to facilitate implementation of the 2018 Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU (PADIS) Guidelines. In over 25,000 patients across nearly 100 institutions, the A2F bundle has been shown in a dose–response fashion (i.e., greater bundle compliance) to yield improved survival, length of stay, coma and delirium duration, cost, and less ICU bounce-backs and discharge to nursing homes.;,citation_author=Joanna L. Stollings;,citation_author=Katarzyna Kotfis;,citation_author=Gerald Chanques;,citation_author=Brenda T. Pun;,citation_author=Pratik P. Pandharipande;,citation_author=E. Wesley Ely;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=10;,citation_doi=10.1007/s00134-021-06503-1;,citation_issn=0342-4642, 1432-1238;,citation_volume=47;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Evolution of sedation management in the intensive care unit (ICU);,citation_author=Joanna L. Stollings;,citation_author=Michelle C. Balas;,citation_author=Gerald Chanques;,citation_publication_date=2022-07;,citation_cover_date=2022-07;,citation_year=2022;,citation_doi=10.1007/s00134-022-06806-x;,citation_issn=1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Stewart Acid-Base: A Simplified Bedside Approach;,citation_author=David A. Story;,citation_publication_date=2016-08;,citation_cover_date=2016-08;,citation_year=2016;,citation_issue=2;,citation_doi=10.1213/ANE.0000000000001261;,citation_issn=0003-2999;,citation_volume=123;,citation_language=en-US;,citation_journal_title=Anesthesia &amp;amp;amp; Analgesia;">
<meta name="citation_reference" content="citation_title=Causal inference for clinicians;,citation_abstract=Evidence-based medicine (EBM) calls on clinicians to incorporate the “best available evidence” into clinical decision-making. For decisions regarding treatment, the best evidence is that which determines the causal effect of treatments on the clinical outcomes of interest. Unfortunately, research often provides evidence where associations are not due to cause-and-effect, but rather due to non-causal reasons. These non-causal associations may provide valid evidence for diagnosis or prognosis, but biased evidence for treatment effects. Causal inference aims to determine when we can infer that associations are or are not due to causal effects. Since recommending treatments that do not have beneficial causal effects will not improve health, causal inference can advance the practice of EBM. The purpose of this article is to familiarise clinicians with some of the concepts and terminology that are being used in the field of causal inference, including graphical diagrams known as “causal directed acyclic graphs”. In order to demonstrate some of the links between causal inference methods and clinical treatment decisionmaking, we use a clinical vignette of assessing treatments to lower cardiovascular risk. As the field of causal inference advances, clinicians familiar with the methods and terminology will be able to improve their adherence to the principles of EBM by distinguishing causal effects of treatment from results due to non-causal associations that may be a source of bias.;,citation_author=Steven D Stovitz;,citation_author=Ian Shrier;,citation_publication_date=2019-06;,citation_cover_date=2019-06;,citation_year=2019;,citation_issue=3;,citation_doi=10.1136/bmjebm-2018-111069;,citation_issn=2515-446X, 2515-4478;,citation_volume=24;,citation_language=en-US;,citation_journal_title=BMJ Evidence-Based Medicine;">
<meta name="citation_reference" content="citation_title=Paediatric obesity appears to lower the risk of diabetes if selection bias is ignored;,citation_abstract=BACKGROUND: Frustrated with the onslaught of articles reporting fascination with results that appear paradoxical but are merely due to selection bias, we studied the apparent effect of obesity on diabetes risk in youth who had a test for diabetes. We hypothesised that obese subjects would have lower rates of diabetes than non-obese subjects due to selection bias, and consequently, obesity would appear to lower the risk of diabetes. METHODS: Retrospective cohort study of children (4-9 years), pre-teens (10-12 years) and teenagers (13-19 years). Participation was restricted to those who had a test of haemoglobin A1C along with measured height and weight. Body mass index percentile via the Centers for Disease Control and Prevention age and sex standards was calculated and categorised. The main outcome was A1C%, subsequently categorised at the level for diagnosis of diabetes mellitus (\geq6.5%). RESULTS: The sample consisted of 134 (2%) underweight, 1718 (30%) healthy weight, 660 (12%) overweight and 3190 (56%) obese individuals. 16% (n=936) had an A1C\geq6.5%. Overall, healthy weight children had 8.2 times the risk of A1C\geq6.5% (95% CI 5.3 to 12.7) compared with those in the obese category. The relative risk was 13 in pre-teens (95% CI 8.5 to 20.0) and 3.9 in teenagers (95% CI 3.3 to 4.7). CONCLUSIONS: Healthy weight was associated with a 4-13 times higher relative risk of diabetes mellitus compared with being obese. While apparently shocking, the study’s fatal flaw (selection bias) explains the ’paradoxical’ finding. Ignoring selection bias can delay advances in medical science.;,citation_author=Steven D. Stovitz;,citation_author=Hailey R. Banack;,citation_author=Jay S. Kaufman;,citation_publication_date=2018-04;,citation_cover_date=2018-04;,citation_year=2018;,citation_issue=4;,citation_doi=10.1136/jech-2017-209985;,citation_issn=1470-2738;,citation_pmid=29374028;,citation_volume=72;,citation_language=en-US;,citation_journal_title=Journal of Epidemiology and Community Health;">
<meta name="citation_reference" content="citation_title=Evidence-based medicine: A commentary on common criticisms;,citation_author=Sharon E Straus;,citation_author=Finlay A McAlister;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=The Pros and Cons of Propensity Scores;,citation_author=David L Streiner;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Assessment of the Validity of the 2HELPS2B Score for Inpatient Seizure Risk Prediction;,citation_abstract=OBJECTIVE To use an independent cohort to validate the 2HELPS2B score and develop a practical guide for its use. DESIGN, SETTING, AND PARTICIPANTS This multicenter retrospective medical record review analyzed clinical and EEG data from patients 18 years or older with a clinical indication for cEEG and an EEG duration of 12 hours or longer who were receiving consecutive cEEG at 6 centers from January 2012 to January 2019. 2HELPS2B was evaluated with the validation cohort using the mean calibration error (CAL), a measure of the difference between prediction and actual results. A Kaplan-Meier survival analysis was used to determine the duration of EEG monitoring to achieve a seizure risk of less than 5% based on the 2HELPS2B score calculated on first- hour (screening) EEG. Participants undergoing elective epilepsy monitoring and those who had experienced cardiac arrest were excluded. No participants who met the inclusion criteria were excluded. MAIN OUTCOMES AND MEASURES The main outcome was a CAL error of less than 5% in the validation cohort. RESULTS The study included 2111 participants (median age, 51 years; 1113 men [52.7%]; median EEG duration, 48 hours) and the primary outcome was met with a validation cohort CAL error of 4.0% compared with a CAL of 2.7% in the foundational cohort (P = .13). For the 2HELPS2B score calculated on only the first hour of EEG in those without seizures during that hour, the CAL error remained at less than 5.0% at 4.2% and allowed for stratifying patients into low(2HELPS2B = 0; &amp;amp;amp;lt;5% risk of seizures), medium- (2HELPS2B = 1; 12% risk of seizures), and high-risk (2HELPS2B, Ն2; risk of seizures, &amp;gt;25%) groups. Each of the categories had an associated minimum recommended duration of EEG monitoring to achieve at least a less than 5% risk of seizures, a 2HELPS2B score of 0 at 1-hour screening EEG, a 2HELPS2B score of 1 at 12 hours, and a 2HELPS2B score of 2 or greater at 24 hours. CONCLUSIONS AND RELEVANCE In this study, 2HELPS2B was validated as a clinical tool to aid in seizure detection, clinical communication, and cEEG use in hospitalized patients. In patients without prior clinical seizures, a screening 1-hour EEG that showed no epileptiform findings was an adequate screen. In patients with any highly epileptiform EEG patterns during the first hour of EEG (ie, a 2HELPS2B score of Ն2), at least 24 hours of recording is recommended.;,citation_author=Aaron F. Struck;,citation_author=Mohammad Tabaeizadeh;,citation_author=Sarah E. Schmitt;,citation_author=Andres Rodriguez Ruiz;,citation_author=Christa B. Swisher;,citation_author=Thanujaa Subramaniam;,citation_author=Christian Hernandez;,citation_author=Safa Kaleem;,citation_author=Hiba A. Haider;,citation_author=Abbas Fodé Cissé;,citation_author=Monica B. Dhakar;,citation_author=Lawrence J. Hirsch;,citation_author=Eric S. Rosenthal;,citation_author=Sahar F. Zafar;,citation_author=Nicholas Gaspard;,citation_author=M. Brandon Westover;,citation_publication_date=2020-04;,citation_cover_date=2020-04;,citation_year=2020;,citation_issue=4;,citation_doi=10.1001/jamaneurol.2019.4656;,citation_issn=2168-6149;,citation_volume=77;,citation_language=en-US;,citation_journal_title=JAMA Neurology;">
<meta name="citation_reference" content="citation_title=Association of an Electroencephalography-Based Risk Score With Seizure Probability in Hospitalized Patients;,citation_abstract=OBJECTIVE To use seizure risk factors from EEG and clinical history to create a simple scoring system associated with the probability of seizures in patients with acute illness. DESIGN, SETTING, AND PARTICIPANTS We used a prospective multicenter (Emory University Hospital, Brigham and Women’s Hospital, and Yale University Hospital) database containing clinical and electrographic variables on 5427 continuous EEG sessions from eligible patients if they had continuous EEG for clinical indications, excluding epilepsy monitoring unit admissions. We created a scoring system model to estimate seizure risk in acutely ill patients undergoing continuous EEG. The model was built using a new machine learning method (RiskSLIM) that is designed to produce accurate, risk-calibrated scoring systems with a limited number of variables and small integer weights. We validated the accuracy and risk calibration of our model using cross-validation and compared its performance with models built with state-of-the-art logistic regression methods. The database was developed by the Critical Care EEG Research Consortium and used data collected over 3 years. The EEG variables were interpreted using standardized terminology by certified reviewers. EXPOSURES All patients had more than 6 hours of uninterrupted EEG recordings. MAIN OUTCOMES AND MEASURES The main outcome was the average risk calibration error. RESULTS There were 5427 continuous EEGs performed on 4772 participants (2868 men, 49.9%; median age, 61 years) performed at 3 institutions, without further demographic stratification. Our final model, 2HELPS2B, had an area under the curve of 0.819 and average calibration error of 2.7% (95% CI, 2.0%-3.6%). It included 6 variables with the following point assignments: (1) brief (ictal) rhythmic discharges (B[I]RDs) (2 points); (2) presence of lateralized periodic discharges, lateralized rhythmic delta activity, or bilateral independent periodic discharges (1 point); (3) prior seizure (1 point); (4) sporadic epileptiform discharges (1 point); (5) frequency greater than 2.0 Hz for any periodic or rhythmic pattern (1 point); and (6) presence of “plus” features (superimposed, rhythmic, sharp, or fast activity) (1 point). The probable seizure risk of each score was 5% for a score of 0, 12% for a score of 1, 27% for a score of 2, 50% for a score of 3, 73% for a score of 4, 88% for a score of 5, and greater than 95% for a score of 6 or 7. Editorial page 1395 CME Quiz at jamanetwork.com/learning CONCLUSIONS AND RELEVANCE The 2HELPS2B model is a quick accurate tool to aid clinical judgment of the risk of seizures in critically ill patients.;,citation_author=Aaron F. Struck;,citation_author=Berk Ustun;,citation_author=Andres Rodriguez Ruiz;,citation_author=Jong Woo Lee;,citation_author=Suzette M. LaRoche;,citation_author=Lawrence J. Hirsch;,citation_author=Emily J. Gilmore;,citation_author=Jan Vlachy;,citation_author=Hiba Arif Haider;,citation_author=Cynthia Rudin;,citation_author=M. Brandon Westover;,citation_publication_date=2017-12;,citation_cover_date=2017-12;,citation_year=2017;,citation_issue=12;,citation_doi=10.1001/jamaneurol.2017.2459;,citation_issn=2168-6149;,citation_volume=74;,citation_language=en-US;,citation_journal_title=JAMA Neurology;">
<meta name="citation_reference" content="citation_title=Chronic subdural haematoma: The role of peri-operative medicine in a common form of reversible brain injury;,citation_abstract=Epidemiological studies project a significant rise in cases of chronic subdural haematoma over the next 20 years. Patients with this condition are frequently older and medically complex, with baseline characteristics that may increase peri-operative risk. The intra-operative period is only a small portion of a patient’s total hospital stay, with a majority of patients in the United Kingdom transferred between institutions for their surgical and rehabilitative care. Definitive management remains surgical, but peri-operative challenges exist which resonate with other surgical cohorts where multidisciplinary working has become the gold standard. These include shared decision-making, medical optimisation, the management of peri-operative anticoagulation and the identification of key points of equipoise for examination in the future trials. In this narrative review, we use a stereotyped patient journey to provide context to the recent literature, highlighting where multidisciplinary expertise may be required to optimise patient care and maximise the benefits of surgical management. We discuss the triage, pre-operative optimisation, intra-operative management and immediate postoperative care of patients undergoing surgery for a chronic subdural haematoma. We also discuss where adjunctive medical management may be indicated. In so doing, we present the current and emerging evidence base for the role of an integrated peri-operative medicine team in the care of patients with a chronic subdural haematoma.;,citation_author=D. J. Stubbs;,citation_author=B. M. Davies;,citation_author=D. K. Menon;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=S1;,citation_doi=10.1111/anae.15583;,citation_issn=0003-2409, 1365-2044;,citation_volume=77;,citation_language=en-US;,citation_journal_title=Anaesthesia;">
<meta name="citation_reference" content="citation_title=Lessons about Confounding and Selection Bias Taught by the New User Design;,citation_author=Til Stürmer;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Publication of noninferiority clinical trials: Changes over a 20-year interval;,citation_abstract=STUDY OBJECTIVES: The primary objective was to evaluate the change in publication rate of noninferiority trials over a 20-year interval (1989-2009). Secondary objectives were to analyze the frequency of noninferiority trials by therapeutic category, the frequency of noninferiority trial publication by journal, the impact factors of the publishing journals, any potential special advantages of the study drug over the control, the funding sources of the trials, pharmaceutical industry affiliation of the authors, and the use of ghostwriters in the creation of manuscripts. DESIGN: Retrospective literature review of 583 articles. DATA SOURCES: PubMed (January 1989-December 2009) and EMBASE (first quarter 1989-fourth quarter 2009) databases. MEASUREMENTS AND MAIN RESULTS: A total of 583 articles of the results of randomized controlled clinical trials with a noninferiority study design that evaluated drug therapies, published in English, between 1989 and 2009, were included in the analysis. A consistent increase was noted in their yearly publication rates, with no trials published in 1989 versus 133 in 2009. One hundred twenty-six articles (21.6%) were in the therapeutic category of infectious diseases, followed by 78 (13.4%) in cardiology. Among the journals identified, The New England Journal of Medicine had the highest publication rate of trials with a noninferiority design, with 29 (5.0%) of the identified trials published in this journal. The median impact factor of the journals publishing noninferiority trials was 4.807 (interquartile range 3.064-7.5). The most common advantage of the study drug over the control was reduced duration of treatment or reduced pill burden (80 studies [22.9%]). A total of 425 trials (72.9%) listed the pharmaceutical industry as the only funding source. Among 369 trials with authors employed by the pharmaceutical industry, 101 (17.3%) disclosed an acknowledgment to an individual, other than those listed as authors, who contributed to writing the manuscript and who was affiliated with a medical information company and/or a pharmaceutical company (i.e., potential ghostwriters). CONCLUSION: The publication of noninferiority trials increased during the 20 years from 1989 until 2009, particularly in the therapeutic areas of infectious diseases and cardiology. Because of this growth, clinicians and researchers need to be familiar with the caveats of the noninferiority study design to appropriately interpret and design these clinical studies.;,citation_author=Katie J. Suda;,citation_author=Anne M. Hurley;,citation_author=Trevor McKibbin;,citation_author=Susannah E. Motl Moroney;,citation_publication_date=2011-09;,citation_cover_date=2011-09;,citation_year=2011;,citation_issue=9;,citation_doi=10.1592/phco.31.9.833;,citation_issn=1875-9114;,citation_pmid=21923583;,citation_volume=31;,citation_language=en-US;,citation_journal_title=Pharmacotherapy;">
<meta name="citation_reference" content="citation_title=Immortal Time Bias in Pharmacoepidemiology;,citation_author=S. Suissa;,citation_publication_date=2008-01;,citation_cover_date=2008-01;,citation_year=2008;,citation_issue=4;,citation_doi=10.1093/aje/kwm324;,citation_issn=0002-9262, 1476-6256;,citation_volume=167;,citation_language=en-US;,citation_journal_title=American Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Alberta Stroke Program Early Computed Tomography Score, Infarct Core Volume, and Endovascular Therapy Outcomes in Patients With Large Infarct: A Secondary Analysis of the ANGEL-ASPECT Trial;,citation_abstract=OBJECTIVE To compare outcomes of EVT vs medical management across different strata of the Alberta Stroke Program Early Computed Tomography Score (ASPECTS) and infarct core volume in patients with large infarct. DESIGN, SETTING, AND PARTICIPANTS This prespecified secondary analysis of subgroups of the Endovascular Therapy in Acute Anterior Circulation Large Vessel Occlusive Patients With a Large Infarct Core (ANGEL-ASPECT) RCT included patients from 46 stroke centers across China between October 2, 2020, and May 18, 2022. Participants were enrolled within 24 hours of symptom onset and had ASPECTS of 3 to 5 or 0 to 2 and infarct core volume of 70 to 100 mL. Patients were divided into 3 groups: ASPECTS of 3 to 5 with infarct core volume less than 70 mL, ASPECTS of 3 to 5 with infarct core volume of 70 mL or greater, and ASPECTS of 0 to 2. INTERVENTIONS Endovascular therapy or medical management. MAIN OUTCOMES AND MEASURES The primary outcome was the ordinal 90-day modified Rankin Scale (mRS) score. RESULTS There were 455 patients in the trial; median age was 68 years (IQR, 60-73 years), and 279 (61.3%) were male. The treatment effect did not vary significantly across the 3 baseline imaging subgroups (P = .95 for interaction). The generalized odds ratio for the shift in the 90-day mRS distribution toward better outcomes with EVT vs medical management was 1.40 (95% CI, 1.06-1.85; P = .01) in patients with ASPECTS of 3 to 5 and infarct core volume less than 70 mL, 1.22 (95% CI, 0.81-1.83; P = .23) in patients with ASPECTS of 3 to 5 and infarct core volume of 70 mL or greater, and 1.59 (95% CI, 0.89-2.86; P = .09) in patients with ASPECTS of 0 to 2. CONCLUSIONS AND RELEVANCE In this study, no significant interaction was found between baseline imaging status and the benefit of EVT compared with medical management in patients with large infarct core volume. However, estimates within subgroups were underpowered. A pooled analysis of large core trials stratified by ASPECTS and infarct core volume strata is warranted.;,citation_author=Dapeng Sun;,citation_author=Xu Guo;,citation_author=Thanh N. Nguyen;,citation_author=Yuesong Pan;,citation_author=Gaoting Ma;,citation_author=Xu Tong;,citation_author=Raynald;,citation_author=Mengxing Wang;,citation_author=Ning Ma;,citation_author=Feng Gao;,citation_author=Dapeng Mo;,citation_author=Xiaochuan Huo;,citation_author=Zhongrong Miao;,citation_author=ANGEL-ASPECT Study Group;,citation_author=Guangxiong Yuan;,citation_author=Hongxing Han;,citation_author=Wenhuo Chen;,citation_author=Ming Wei;,citation_author=Jiangang Zhang;,citation_author=Zhimin Zhou;,citation_author=Xiaoxi Yao;,citation_author=Guoqing Wang;,citation_author=Weigen Song;,citation_author=Xueli Cai;,citation_author=Guangxian Nan;,citation_author=Di Li;,citation_author=Alvin Yi-Chou Wang;,citation_author=Wentong Ling;,citation_author=Chuwei Cai;,citation_author=Changming Wen;,citation_author=En Wang;,citation_author=Liyong Zhang;,citation_author=Changchun Jiang;,citation_author=Yajie Liu;,citation_author=Geng Liao;,citation_author=Xiaohui Chen;,citation_author=Tianxiao Li;,citation_author=Shudong Liu;,citation_author=Jinglun Li;,citation_author=Yaxuan Sun;,citation_author=Na Xu;,citation_author=Zong’en Gao;,citation_author=Dongsheng Ju;,citation_author=Cunfeng Song;,citation_author=Jinggang Xuan;,citation_author=Feng Zhou;,citation_author=Qing Shi;,citation_author=Jun Luo;,citation_author=Yan Liu;,citation_author=Zaiyu Guo;,citation_author=Tong Li;,citation_author=Hongbo Zheng;,citation_author=Linzhi Dai;,citation_author=Junfeng Zhao;,citation_author=Liqiang Gui;,citation_author=Xiaokun Geng;,citation_author=Yufeng Tang;,citation_author=Congguo Yin;,citation_author=Hua Yang;,citation_author=Yongjun Wang;,citation_author=Yilong Wang;,citation_author=Liping Liu;,citation_author=David Liebeskind;,citation_author=Zeguang Ren;,citation_author=Vitor Pereira;,citation_author=Xunming Ji;,citation_author=Qiang Dong;,citation_author=Anding Xu;,citation_author=Xinfeng Liu;,citation_author=Qingwu Yang;,citation_author=Jing Jing;,citation_author=Zhe Zhang;,citation_author=Yingkui Zhang;,citation_author=Wei Wu;,citation_author=Zhongqi Qi;,citation_author=Shuo Li;,citation_author=Zequan Yu;,citation_author=Jingyu Zhang;,citation_author=Fangguang Chen;,citation_author=Kangyue Li;,citation_author=Kai Zhang;,citation_author=Mingkai Hu;,citation_author=Jianmin Liu;,citation_author=Chen Yao;,citation_author=Kangning Chen;,citation_author=Kun Fang;,citation_author=Bo Song;,citation_author=Yi Dong;,citation_author=Ruiyang An;,citation_author=Yuying Sun;,citation_author=Yanan Wu;,citation_author=Chunlai Yu;,citation_author=Shuangcheng Zheng;,citation_author=Aoming Jin;,citation_author=Xianglong Xiang;,citation_author=Hongyi Yan;,citation_author=Yuanling He;,citation_author=Chunyang Li;,citation_author=Weixia Kong;,citation_author=Yuhuan Chen;,citation_author=Chenhao Guo;,citation_author=Fengjie Ji;,citation_author=Pengshan Ji;,citation_author=Lei Liu;,citation_author=Xinghua Lu;,citation_author=Guangkuo Luo;,citation_author=Nanjing Wang;,citation_author=Yu Zhang;,citation_author=Bo Liu;,citation_author=Jian Yang;,citation_author=Jingjing Deng;,citation_author=Juan Wang;,citation_author=Wanru Wang;,citation_author=Hang Yu;,citation_author=Le Cui;,citation_author=Wenwen Liu;,citation_author=Ziyong Wang;,citation_author=Xia Zhao;,citation_author=Zhou Zhou;,citation_publication_date=2023-11;,citation_cover_date=2023-11;,citation_year=2023;,citation_doi=10.1001/jamaneurol.2023.4430;,citation_issn=2168-6149;,citation_language=en-US;,citation_journal_title=JAMA Neurology;">
<meta name="citation_reference" content="citation_title=Sex-based differences in ED management of critically ill patients with sepsis: A nationwide cohort study;,citation_abstract=Purpose: To compare management and outcomes for critically ill women and men with sepsis in the emergency medical services (EMS), the emergency department (ED) and the ICU. Methods: We used two prospectively compiled Swedish national quality registers, the National Quality Sepsis Regis-try and the Swedish Intensive Care Registry to identify a nationwide cohort of 2720 adults admitted to an ICU within 24 h of arrival to any of 32 EDs, with a diagnosis of severe sepsis or septic shock between 2008 and 2015. Results: Patients were 44.5% female. In the EMS, a higher fraction of men had all vital signs recorded—54.4 vs 49.9% (p = 0.02) and received IV fluids and oxygen—40.0 vs 34.8% (p = 0.02). In the ED, men had completed 1-h sepsis bun-dles in 41.5% of cases compared to 30.0% in women (p &amp;amp;amp;lt; 0.001), and shorter time to antibiotics—65 (IQR 30–136) vs 87 min (IQR 39–172) (p = 0.0001). There was no significant difference between men and women regarding ICU nurs-ing workload, mechanical ventilation or ICU length of stay. In severity-adjusted multivariable analysis, OR for women achieving a completed sepsis bundle, compared to men was 0.64 (CI 0.51–0.81). Thirty-day mortality was 25.0% for women and 23.1% for men (p = 0.24). Adjusted OR for female death was 1.28 (CI 1.00–1.64), but the increased mortal-ity was not mediated by differential bundle completion. Conclusions: Women and men with severe sepsis or septic shock received differential care in the ED, but this did not explain higher odds of death in women.;,citation_author=Jonas Sunden-Cullberg;,citation_author=Anton Nilsson;,citation_author=Malin Inghammar;,citation_publication_date=2020-04;,citation_cover_date=2020-04;,citation_year=2020;,citation_issue=4;,citation_doi=10.1007/s00134-019-05910-9;,citation_issn=0342-4642, 1432-1238;,citation_volume=46;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Diaphragm Dysfunction in Critical Illness;,citation_author=Gerald S. Supinski;,citation_author=Peter E. Morris;,citation_author=Sanjay Dhar;,citation_author=Leigh Ann Callahan;,citation_publication_date=2018-04;,citation_cover_date=2018-04;,citation_year=2018;,citation_issue=4;,citation_doi=10.1016/j.chest.2017.08.1157;,citation_issn=00123692;,citation_volume=153;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=An IV for the RCT: Using instrumental variables to adjust for treatment contamination in randomised controlled trials;,citation_abstract=Although the randomised controlled trial is the &amp;amp;amp;quot;gold standard&amp;quot; for studying the efficacy and safety of medical treatments, it is not necessarily free from bias. When patients do not follow the protocol for their assigned treatment, the resultant &quot;treatment contamination&quot; can produce misleading findings. The methods used historically to deal with this problem, the &quot;as treated&quot; and &quot;per protocol&quot; analysis techniques, are flawed and inaccurate. Intention to treat analysis is the solution most often used to analyse randomised controlled trials, but this approach ignores this issue of treatment contamination. Intention to treat analysis estimates the effect of recommending a treatment to study participants, not the effect of the treatment on those study participants who actually received it. In this article, we describe a simple yet rarely used analytical technique, the &quot;contamination adjusted intention to treat analysis,&quot; which complements the intention to treat approach by producing a better estimate of the benefits and harms of receiving a treatment. This method uses the statistical technique of instrumental variable analysis to address contamination. We discuss the strengths and limitations of the current methods of addressing treatment contamination and the contamination adjusted intention to treat technique, provide examples of effective uses, and discuss how using estimates generated by contamination adjusted intention to treat analysis can improve clinical decision making and patient care.;,citation_author=Jeremy B. Sussman;,citation_author=Rodney A. Hayward;,citation_publication_date=2010-05;,citation_cover_date=2010-05;,citation_year=2010;,citation_doi=10.1136/bmj.c2073;,citation_issn=1756-1833;,citation_pmid=20442226;,citation_volume=340;,citation_language=en-US;,citation_journal_title=BMJ (Clinical research ed.);">
<meta name="citation_reference" content="citation_title=Graphical presentation of confounding in directed acyclic graphs;,citation_abstract=Since confounding obscures the real effect of the exposure, it is important to adequately address confounding for making valid causal inferences from observational data. Directed acyclic graphs (DAGs) are visual representations of causal assumptions that are increasingly used in modern epidemiology. They can help to identify the presence of confounding for the causal question at hand. This structured approach serves as a visual aid in the scientific discussion by making underlying relations explicit. This article explains the basic concepts of DAGs and provides examples in the field of nephrology with and without presence of confounding. Ultimately, these examples will show that DAGs can be preferable to the traditional methods to identify sources of confounding, especially in complex research questions.;,citation_author=Marit M. Suttorp;,citation_author=Bob Siegerink;,citation_author=Kitty J. Jager;,citation_author=Carmine Zoccali;,citation_author=Friedo W. Dekker;,citation_publication_date=2015-09;,citation_cover_date=2015-09;,citation_year=2015;,citation_issue=9;,citation_doi=10.1093/ndt/gfu325;,citation_issn=0931-0509, 1460-2385;,citation_volume=30;,citation_language=en-US;,citation_journal_title=Nephrology Dialysis Transplantation;">
<meta name="citation_reference" content="citation_title=Causal Diagrams: Pitfalls and Tips;,citation_abstract=Graphical models are useful tools in causal inference, and causal directed acyclic graphs (DAGs) are used extensively to determine the variables for which it is sufficient to control for confounding to estimate causal effects. We discuss the following ten pitfalls and tips that are easily overlooked when using DAGs: 1) Each node on DAGs corresponds to a random variable and not its realized values; 2) The presence or absence of arrows in DAGs corresponds to the presence or absence of individual causal effect in the population; 3) “Non-manipulable” variables and their arrows should be drawn with care; 4) It is preferable to draw DAGs for the total population, rather than for the exposed or unexposed groups; 5) DAGs are primarily useful to examine the presence of confounding in distribution in the notion of confounding in expectation; 6) Although DAGs provide qualitative differences of causal structures, they cannot describe details of how to adjust for confounding; 7) DAGs can be used to illustrate the consequences of matching and the appropriate handling of matched variables in cohort and case-control studies; 8) When explicitly accounting for temporal order in DAGs, it is necessary to use separate nodes for each timing; 9) In certain cases, DAGs with signed edges can be used in drawing conclusions about the direction of bias; and 10) DAGs can be (and should be) used to describe not only confounding bias but also other forms of bias. We also discuss recent developments of graphical models and their future directions.;,citation_author=Etsuji Suzuki;,citation_author=Tomohiro Shinozaki;,citation_author=Eiji Yamamoto;,citation_publication_date=2020-04;,citation_cover_date=2020-04;,citation_year=2020;,citation_issue=4;,citation_doi=10.2188/jea.JE20190192;,citation_issn=0917-5040, 1349-9092;,citation_volume=30;,citation_language=en-US;,citation_journal_title=Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Form follows function: The endothelial glycocalyx;,citation_author=Akio Suzuki;,citation_author=Hiroyuki Tomita;,citation_author=Hideshi Okada;,citation_publication_date=2022-04;,citation_cover_date=2022-04;,citation_year=2022;,citation_doi=10.1016/j.trsl.2022.03.014;,citation_issn=19315244;,citation_language=en-US;,citation_journal_title=Translational Research;">
<meta name="citation_reference" content="citation_title=Selecting on Treatment: A Pervasive Form of Bias in Instrumental Variable Analyses;,citation_author=Sonja A. Swanson;,citation_author=James M. Robins;,citation_author=Matthew Miller;,citation_author=Miguel A. Hernán;,citation_publication_date=2015-02;,citation_cover_date=2015-02;,citation_year=2015;,citation_issue=3;,citation_doi=10.1093/aje/kwu284;,citation_issn=0002-9262, 1476-6256;,citation_volume=181;,citation_language=en-US;,citation_journal_title=American Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Evidence-based strategies to reduce the incidence of postoperative delirium: A narrative review;,citation_abstract=Delirium is one of the most commonly occurring postoperative complications in older adults. It occurs due to the vulnerability of cerebral functioning to pathophysiological stressors. Identification of those at increased risk of developing delirium early in the surgical pathway provides an opportunity for modification of predisposing and precipitating risk factors and effective shared decision-making. No single delirium prediction tool is used widely in surgical settings. Multi-component interventions to prevent delirium involve structured risk factor modification supported by geriatrician input; these are clinically efficacious and cost effective. Barriers to the widespread implementation of such complex interventions exist, resulting in an “implementation gap”. There is a lack of evidence for pharmacological prophylaxis for the prevention of delirium. Current evidence suggests that avoidance of peri-operative benzodiazepines, careful titration of anaesthetic depth guided by processed electroencephalogram monitoring and treatment of pain are the most effective strategies to minimise the risk of delirium. Addressing postoperative delirium requires a collaborative, whole pathway approach, beginning with the early identification of those patients who are at risk. The research agenda should continue to examine the potential for pharmacological prophylaxis to prevent delirium while also addressing how successful models of delirium prevention can be translated from one setting to another, underpinned by implementation science methodology.;,citation_author=C. J. Swarbrick;,citation_author=J. S. L. Partridge;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=S1;,citation_doi=10.1111/anae.15607;,citation_issn=0003-2409, 1365-2044;,citation_volume=77;,citation_language=en-US;,citation_journal_title=Anaesthesia;">
<meta name="citation_reference" content="citation_title=From Syphilis to Sepsis: Pilot Studies and the Importance of Staying Grounded*;,citation_author=Daniel A. Sweeney;,citation_author=Andre C. Kalil;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_issue=6;,citation_doi=10.1097/CCM.0000000000005539;,citation_issn=0090-3493;,citation_volume=50;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Clinical characteristics and outcomes of methamphetamine-associated intracerebral hemorrhage;,citation_abstract=Objective To compare the clinical characteristics and outcomes of primary intracerebral hemorrhage (ICH) with and without methamphetamine exposure. Methods We performed a retrospective analysis of patients diagnosed with spontaneous, nontraumatic ICH over a 3-year period between January 2013 and December 2016. Demographics, clinical measures, and outcomes were compared between ICH patients with positive methamphetamine toxicology tests vs those with negative methamphetamine toxicology tests. Results Methamphetamine-positive ICH patients were younger than methamphetamine-negative ICH patients (52 vs 67 years, p &amp;amp;amp;lt; 0.001). Patients with methamphetamine-positive ICH had higher diastolic blood pressure (115 vs 101, p = 0.003), higher mean arterial pressure (144 vs 129, p = 0.01), longer lengths of hospital (18 vs 8 days, p &amp;lt; 0.001) and intensive care unit (ICU) stay (10 vs 5 days, p < 0.001), required more days of IV antihypertensive medications (5 vs 3 days, p = 0.02), and had more subcortical hemorrhages (63% vs 46%, p = 0.05). The methamphetaminepositive group had better premorbid modified Rankin Scale (mRS) scores (p < 0.001) and a greater change in functional ability as measured by mRS at the time of hospital discharge (p = 0.001). In multivariate analyses, methamphetamine use predicted both hospital length of stay (risk ratio [RR] 1.54, confidence interval [CI] 1.39–1.70, p < 0.001) and ICU length of stay (RR 1.36, CI 1.18–1.56, p < 0.001), but did not predict poor outcome (mRS 4–6). Conclusions Methamphetamine use is associated with earlier age at onset of ICH, longer hospital stays, and greater change in functional ability, but did not predict outcome.;,citation_author=Dionne E. Swor;,citation_author=Matthew B. Maas;,citation_author=Sandeep S. Walia;,citation_author=David P. Bissig;,citation_author=Eric M. Liotta;,citation_author=Andrew M. Naidech;,citation_author=Kwan L. Ng;,citation_publication_date=2019-07;,citation_cover_date=2019-07;,citation_year=2019;,citation_issue=1;,citation_doi=10.1212/WNL.0000000000007666;,citation_issn=0028-3878, 1526-632X;,citation_volume=93;,citation_language=en-US;,citation_journal_title=Neurology;">
<meta name="citation_reference" content="citation_title=Association of intracranial pressure with outcome in comatose patients with intracerebral hemorrhage;,citation_abstract=Background Therapeutic targets for intracranial pressure (ICP) in patients with severe intracerebral hemorrhage (ICH) are approximated from data of traumatic brain injury. However, specific data for ICH are lacking. Here, we aimed to investigate the association between ICP, mortality and functional outcome following severe ICH. Methods We analyzed consecutive comatose patients with ICH in whom ICP monitoring was applied. Outcome at 3months was assessed using the modified Rankin scale (mRS). Multivariate logistic regression including pre-defined predictors was used in order to identify the effects of ICP on outcome. Results 121 patients with ICH and ICP monitoring were analyzed. Mean ICP (OR 1.2, CI 1.08–1.45, p=0.003), ICP variability (OR 1.3, CI 1.03–1.73, p=0.03) and relative frequency of ICP values &amp;amp;amp;gt;20mmHg (OR 1.1, CI 1.02– 1.15, p=0.008) were independently associated with mortality at 3months. Relative frequency of ICP values &amp;gt;20mmHg (OR 1.1, CI 1.001–1.3, p=0.04) was associated also with poor functional outcome at 3months. Conclusions Our data suggest that in the context of other predictors as age, admission clinical status, hemorrhage volume and intraventricular hemorrhage, average ICP, ICP variability and the frequency of ICP values >20mmHg are independently associated with mortality and poor outcome after ICH. Further studies and prospective validations of ICP thresholds for ICH patients are highly warranted.;,citation_author=Marek Sykora;,citation_author=Sahra Steinmacher;,citation_author=Thorsten Steiner;,citation_author=Sven Poli;,citation_author=Jennifer Diedler;,citation_publication_date=2014-07;,citation_cover_date=2014-07;,citation_year=2014;,citation_issue=1;,citation_doi=10.1016/j.jns.2014.05.012;,citation_issn=0022-510X;,citation_volume=342;,citation_language=en-US;,citation_journal_title=Journal of the Neurological Sciences;">
<meta name="citation_reference" content="citation_title=Long-term neurocognitive outcome is not worsened by of the use of venovenous ECMO in severe ARDS patients;,citation_abstract=Venovenous extracorporeal membrane oxygenation (VV-ECMO) is associated with a significant morbidity. There is the need to investigate long-term cognitive outcome among ARDS survivors treated with VV-ECMO. We aimed to compare the prevalence of long-term cognitive dysfunction and neuropsychological impairment using a highly specific test in severe ARDS survivors treated or not treated with VV-ECMO.;,citation_author=Aude Sylvestre;,citation_author=Mélanie Adda;,citation_author=François Maltese;,citation_author=Ariane Lannelongue;,citation_author=Florence Daviet;,citation_author=Gabriel Parzy;,citation_author=Benjamin Coiffard;,citation_author=Antoine Roch;,citation_author=Anderson Loundou;,citation_author=Karine Baumstarck;,citation_author=Laurent Papazian;,citation_publication_date=2019-07;,citation_cover_date=2019-07;,citation_year=2019;,citation_issue=1;,citation_doi=10.1186/s13613-019-0556-1;,citation_issn=2110-5820;,citation_volume=9;,citation_language=en-US;,citation_journal_title=Annals of Intensive Care;">
<meta name="citation_reference" content="citation_title=Manipulating temperature: Devices for targeted temperature management (TTM) in brain injury;,citation_author=Fabio S. Taccone;,citation_author=Katia Donadello;,citation_author=Stephan A. Mayer;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_doi=10.1007/s00134-022-06858-z;,citation_issn=1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Should Combined Hormonal Contraception Be Stopped in the Perioperative Period?;,citation_author=Katherine Takvorian;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=1;,citation_doi=10.1056/EVIDtt2100050;,citation_issn=2766-5526;,citation_volume=1;,citation_language=en-US;,citation_journal_title=NEJM Evidence;">
<meta name="citation_reference" content="citation_title=Gymnopédie: Music in the ICU;,citation_author=Mark Z. Y. Tan;,citation_publication_date=2022-11;,citation_cover_date=2022-11;,citation_year=2022;,citation_doi=10.1007/s00134-022-06935-3;,citation_issn=0342-4642, 1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Continuous Renal Replacement Therapy;,citation_author=Srijan Tandukar;,citation_author=Paul M. Palevsky;,citation_publication_date=2019-03;,citation_cover_date=2019-03;,citation_year=2019;,citation_issue=3;,citation_doi=10.1016/j.chest.2018.09.004;,citation_issn=00123692;,citation_volume=155;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Trial of Endovascular Treatment of Acute Basilar-Artery Occlusion;,citation_author=Chunrong Tao;,citation_author=Raul G. Nogueira;,citation_author=Yuyou Zhu;,citation_author=Jun Sun;,citation_author=Hongxing Han;,citation_author=Guangxiong Yuan;,citation_author=Changming Wen;,citation_author=Peiyang Zhou;,citation_author=Wenhuo Chen;,citation_author=Guoyong Zeng;,citation_author=Yuwen Li;,citation_author=Zhengfei Ma;,citation_author=Chuanqing Yu;,citation_author=Junfeng Su;,citation_author=Zhiming Zhou;,citation_author=Zhongjun Chen;,citation_author=Geng Liao;,citation_author=Yaxuan Sun;,citation_author=Youquan Ren;,citation_author=Hui Zhang;,citation_author=Jie Chen;,citation_author=Xincan Yue;,citation_author=Guodong Xiao;,citation_author=Li Wang;,citation_author=Rui Liu;,citation_author=Wenhua Liu;,citation_author=Yong Liu;,citation_author=Li Wang;,citation_author=Chao Zhang;,citation_author=Tianlong Liu;,citation_author=Jianlong Song;,citation_author=Rui Li;,citation_author=Pengfei Xu;,citation_author=Yamei Yin;,citation_author=Guoping Wang;,citation_author=Blaise Baxter;,citation_author=Adnan I. Qureshi;,citation_author=Xinfeng Liu;,citation_author=Wei Hu;,citation_publication_date=2022-10;,citation_cover_date=2022-10;,citation_year=2022;,citation_issue=15;,citation_doi=10.1056/NEJMoa2206317;,citation_issn=0028-4793;,citation_volume=387;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Association of Days Alive and at Home at Day 90 After Intensive Care Unit Admission With Long-term Survival and Functional Status Among Mechanically Ventilated Patients;,citation_abstract=IMPORTANCE Many conventional end points in randomized clinical trials of interventions for critically ill patients do not account for patient-centered concerns such as time at home, physical function, and quality of life after critical illness.;,citation_author=Shaurya Taran;,citation_author=Benjamin Coiffard;,citation_author=Ella Huszti;,citation_author=Qixuan Li;,citation_author=Leslie Chu;,citation_author=Claire Thomas;,citation_author=Stacey Burns;,citation_author=Priscila Robles;,citation_author=Margaret S. Herridge;,citation_author=Ewan C. Goligher;,citation_publication_date=2023-03;,citation_cover_date=2023-03;,citation_year=2023;,citation_issue=3;,citation_doi=10.1001/jamanetworkopen.2023.3265;,citation_issn=2574-3805;,citation_volume=6;,citation_language=en-US;,citation_journal_title=JAMA Network Open;">
<meta name="citation_reference" content="citation_title=Discordances Between Factors Associated With Withholding Extubation and Extubation Failure After a Successful Spontaneous Breathing Trial;,citation_abstract=OBJECTIVES: To identify whether factors associated with withholding extubation in the ICU also predict the risk of extubation failure. DESIGN: Retrospective cohort study. SETTING: Eight medical-surgical ICUs in Toronto. PATIENTS: Adult patients receiving invasive mechanical ventilation, with a first successful spontaneous breathing trial within 28 days of initial ICU admission. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The primary end point had three mutually exclusive levels, including: 1) withholding extubation after a successful spontaneous breathing trial, 2) extubation failure within 48 hours, and 3) successful extubation. Among 9,910 patients, 38% of patients were not extubated within 24 hours of their first successful spontaneous breathing trial. A total of 12.9% of patients who were promptly extubated failed within the next 48 hours. Several discrepancies were evident in the association of factors with risk of withholding extubation and extubation failure. Specifically, both age and female sex were associated with withholding extubation (odds ratio, 1.07; 95% CI, 1.03–1.11; and odds ratio, 1.13; 95% CI, 1.02–1.26, respectively) but not a higher risk of failed extubation (odds ratio, 0.99; 95% CI, 0.93–1.05; and odds ratio, 0.93; 95% CI, 0.77–1.11, respectively). Conversely, both acute cardiovascular conditions and intubation for hypoxemic respiratory failure were associated with a higher risk of failed extubation (odds ratio, 1.32; 95% CI, 1.06–1.66; and odds ratio, 1.46; 95% CI, 1.16–1.82, respectively) but not a higher odds of a withheld extubation attempt (odds ratio, 0.79; 95% CI, 0.68–0.91; and odds ratio, 1.07; 95% CI, 0.93–1.23, respectively). CONCLUSIONS: Several factors showed discordance between the decision to withhold extubation and the risk of extubation failure. This discordance may lead to longer duration of mechanical ventilation or higher reintubation rates. Improving the decision-making behind extubation may help to reduce both exposure to invasive mechanical ventilation and extubation failure.;,citation_author=Shaurya Taran;,citation_author=Federico Angriman;,citation_author=Ruxandra Pinto;,citation_author=Bruno L. Ferreyro;,citation_author=Andre Carlos Kajdacsy-Balla Amaral;,citation_publication_date=2021-07;,citation_cover_date=2021-07;,citation_year=2021;,citation_doi=10.1097/CCM.0000000000005107;,citation_issn=0090-3493;,citation_volume=Publish Ahead of Print;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Falsifiability in medicine: What clinicians can learn from Karl Popper;,citation_author=Shaurya Taran;,citation_author=Neill K. J. Adhikari;,citation_author=Eddy Fan;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_issue=9;,citation_doi=10.1007/s00134-021-06432-z;,citation_issn=0342-4642, 1432-1238;,citation_volume=47;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Decision-making process during limitation life-sustaining support meetings in French intensive care units;,citation_author=Terry Tarcy;,citation_author=Hatem Kallel;,citation_author=Mathilde Giffard;,citation_author=Guillaume Besch;,citation_author=Régis Aubry;,citation_author=Régis Aubry;,citation_author=Guillaume Besch;,citation_author=Laurent Carteron;,citation_author=Mathilde Giffard;,citation_author=Hatem Kallel;,citation_author=Séverine Matheus;,citation_author=Gael Piton;,citation_author=Jean Marc Pujo;,citation_author=Jean-Pierre Quenot;,citation_author=Terry Tarcy;,citation_author=Hadrien Winiszewski;,citation_author=REUREA Study Group;,citation_publication_date=2022-11;,citation_cover_date=2022-11;,citation_year=2022;,citation_issue=11;,citation_doi=10.1007/s00134-022-06839-2;,citation_issn=1432-1238;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Trial of Pimavanserin in Dementia-Related Psychosis;,citation_abstract=BACKGROUND Patients with dementia due to neurodegenerative disease can have dementia-related psychosis. The effects of the oral 5-HT2A inverse agonist and antagonist pimavanserin on psychosis related to various causes of dementia are not clear. METHODS We conducted a phase 3, double-blind, randomized, placebo-controlled discontinuation trial involving patients with psychosis related to Alzheimer’s disease, Parkinson’s disease dementia, dementia with Lewy bodies, frontotemporal dementia, or vascular dementia. Patients received open-label pimavanserin for 12 weeks. Those who had a reduction from baseline of at least 30% in the score on the Scale for the Assessment of Positive Symptoms–Hallucinations and Delusions (SAPS–H+D, with higher scores indicating greater psychosis) and a Clinical Global Impression–Improvement (CGI-I) score of 1 (very much improved) or 2 (much improved) at weeks 8 and 12 were randomly assigned in a 1:1 ratio to continue receiving pimavanserin or to receive placebo for up to 26 weeks. The primary end point, assessed in a time-to-event analysis, was a relapse of psychosis as defined by any of the following: an increase of at least 30% in the SAPS–H+D score and a CGI-I score of 6 (much worse) or 7 (very much worse), hospitalization for dementia-related psychosis, stopping of the trial regimen or withdrawal from the trial for lack of efficacy, or use of antipsychotic agents for dementia-related psychosis. RESULTS Of the 392 patients in the open-label phase, 41 were withdrawn for administrative reasons because the trial was stopped for efficacy; of the remaining 351 patients, 217 (61.8%) had a sustained response, of whom 105 were assigned to receive pimavanserin and 112 to receive placebo. A relapse occurred in 12 of 95 patients (13%) in the pimavanserin group and in 28 of 99 (28%) in the placebo group (hazard ratio, 0.35; 95% confidence interval, 0.17 to 0.73; P = 0.005). During the double-blind phase, adverse events occurred in 43 of 105 patients (41.0%) in the pimavanserin group and in 41 of 112 (36.6%) in the placebo group. Headache, constipation, urinary tract infection, and asymptomatic QT prolongation occurred with pimavanserin. CONCLUSIONS In a trial that was stopped early for efficacy, patients with dementia-related psychosis who had a response to pimavanserin had a lower risk of relapse with continuation of the drug than with discontinuation. Longer and larger trials are required to determine the effects of pimavanserin in dementia-related psychosis. (Funded by Acadia Pharmaceuticals; HARMONY ClinicalTrials.gov number, NCT03325556.);,citation_author=Pierre N. Tariot;,citation_author=Jeffrey L. Cummings;,citation_author=Maria E. Soto-Martin;,citation_author=Clive Ballard;,citation_author=Deniz Erten-Lyons;,citation_author=David L. Sultzer;,citation_author=Davangere P. Devanand;,citation_author=Daniel Weintraub;,citation_author=Bradley McEvoy;,citation_author=James M. Youakim;,citation_author=Srdjan Stankovic;,citation_author=Erin P. Foff;,citation_publication_date=2021-07;,citation_cover_date=2021-07;,citation_year=2021;,citation_issue=4;,citation_doi=10.1056/NEJMoa2034634;,citation_issn=0028-4793, 1533-4406;,citation_volume=385;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Targeting Autoregulation-Guided Cerebral Perfusion Pressure after Traumatic Brain Injury (COGiTATE): A Feasibility Randomized Controlled Clinical Trial;,citation_abstract=Managing traumatic brain injury (TBI) patients with a cerebral perfusion pressure (CPP) near to the cerebral autoregulation (CA)-guided “optimal” CPP (CPPopt) value is associated with improved outcome and might be useful to individualize care, but has never been prospectively evaluated. This study evaluated the feasibility and safety of CA-guided CPP management in TBI patients requiring intracranial pressure monitoring and therapy (TBIicp patients). The CPPopt Guided Therapy: Assessment of Target Effectiveness (COGiTATE) parallel two-arm feasibility trial took place in four tertiary centers. TBIicp patients were randomized to either the Brain Trauma Foundation (BTF) guideline CPP target range (control group) or to the individualized CA-guided CPP targets (intervention group). CPP targets were guided by six times daily software-based alerts for up to 5 days. The primary feasibility end-point was the percentage of time with CPP concordant (–5 mm Hg) with the set CPP targets. The main secondary safety endpoint was an increase in therapeutic intensity level (TIL) between the control and intervention group. Twenty-eight patients were randomized to the control and 32 patients to the intervention group. CPP in the intervention group was in the target range for 46.5% (interquartile range, 41.2–58) of the monitored time, significantly higher than the feasibility target specified in the published protocol (36%; p &amp;amp;amp;lt; 0.001). There were no significant differences between groups for TIL or for other safety end-points. Conclusively, targeting an individual and dynamic CA-guided CPP is feasible and safe in TBIicp patients. This encourages a prospective trial powered for clinical outcomes.;,citation_author=Jeanette Tas;,citation_author=Erta Beqiri;,citation_author=Ruud C. Kaam;,citation_author=Marek Czosnyka;,citation_author=Joseph Donnelly;,citation_author=Roel H. Haeren;,citation_author=Iwan C. C. Horst;,citation_author=Peter J. Hutchinson;,citation_author=Sander M. J. Kuijk;,citation_author=Analisa L. Liberti;,citation_author=David K. Menon;,citation_author=Cornelia W. E. Hoedemaekers;,citation_author=Bart Depreitere;,citation_author=Peter Smielewski;,citation_author=Geert Meyfroidt;,citation_author=Ari Ercole;,citation_author=Marcel J. H. Aries;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_doi=10.1089/neu.2021.0197;,citation_issn=0897-7151, 1557-9042;,citation_language=en-US;,citation_journal_title=Journal of Neurotrauma;">
<meta name="citation_reference" content="citation_title=The REMDACTA trial: Do interleukin receptor antagonists provide additional benefit in COVID-19?;,citation_author=Kate C. Tatham;,citation_author=Manu Shankar-Hari;,citation_author=Yaseen M. Arabi;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_doi=10.1007/s00134-021-06540-w;,citation_issn=0342-4642, 1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Assessing and addressing collider bias in addiction research: The curious case of smoking and COVID-19;,citation_author=Harry Tattan-Birch;,citation_author=John Marsden;,citation_author=Robert West;,citation_author=Suzanne H. Gage;,citation_publication_date=2021-05;,citation_cover_date=2021-05;,citation_year=2021;,citation_issue=5;,citation_doi=10.1111/add.15348;,citation_issn=0965-2140, 1360-0443;,citation_volume=116;,citation_language=en-US;,citation_journal_title=Addiction;">
<meta name="citation_reference" content="citation_title=Knowledge from the Noise: A Regression Discontinuity Design to Inform Optimal Transfusion Thresholds for Critically Ill Patients;,citation_author=Stephanie P. Taylor;,citation_author=Andrew J. Admon;,citation_publication_date=2022-07;,citation_cover_date=2022-07;,citation_year=2022;,citation_issue=7;,citation_doi=10.1513/AnnalsATS.202203-259ED;,citation_issn=2329-6933;,citation_volume=19;,citation_journal_title=Annals of the American Thoracic Society;,citation_publisher=American Thoracic Society - AJRCCM;">
<meta name="citation_reference" content="citation_title=My Experience as a SPRINT Clinical Trial Participant;,citation_author=Moses Taylor;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=1;,citation_doi=10.1056/EVIDpp2100029;,citation_issn=2766-5526;,citation_volume=1;,citation_language=en-US;,citation_journal_title=NEJM Evidence;">
<meta name="citation_reference" content="citation_title=A Quantitative Study of Decision Thresholds for Initiation of Antibiotics in Suspected Sepsis;,citation_abstract=BackgroundClinicians? decision thresholds for initiating antibiotics in patients with suspected sepsis have not been quantified. We aimed to define an average threshold of infection likelihood at which clinicians initiate antibiotics when treating a patient with suspected infection and to evaluate the influence of severity of illness and clinician-related factors on the threshold.DesignThis was a prospective survey of 153 clinicians responding to 8 clinical vignettes constructed from real-world data from 3 health care systems in the United States. We treated each hour in the vignette as a decision to treat or not treat with antibiotics and assigned an infection probability to each hour using a previously developed infection prediction model. We then estimated decision thresholds using regression models based on the timing of antibiotic initiation. We compared thresholds across categories of severity of illness and clinician-related factors.ResultsOverall, the treatment threshold occurred at a 69% probability of infection, but the threshold varied significantly across severity of illness categories?when patients had high severity of illness, the treatment threshold occurred at a 55% probability of infection; when patients had intermediate severity, the threshold for antibiotic initiation occurred at an infection probability of 69%, and the threshold was 84% when patients had low severity of illness (P &amp;amp;amp;lt; 0.001 for group differences). Thresholds differed significantly across specialty, highest among infectious disease and lowest among emergency medicine clinicians and across years of experience, decreasing with increasing years of experience.ConclusionsThe threshold infection probability above which physicians choose to initiate antibiotics in suspected sepsis depends on illness severity as well as clinician factors.ImplicationsIncorporating these context-dependent thresholds into discriminating and well-calibrated models will inform the development of future sepsis clinical decision support systems. Clinician-related differences in treatment thresholds suggests potential unwarranted variation and opportunities for performance improvement.HighlightsDecision making about antibiotic initiation in suspected sepsis occurs under uncertainty, and little is known about clinicians? thresholds for treatment.In this prospective study, 153 clinicians from 3 health care systems reviewed 8 real-world clinical vignettes representing patients with sepsis and indicated the time that they would initiate antibiotics.Using a model-based approach, we estimated decision thresholds and found that thresholds differed significantly across illness severity categories and by clinician specialty and years of experience.;,citation_author=Stephanie Parks Taylor;,citation_author=Gary E. Weissman;,citation_author=Marc Kowalkowski;,citation_author=Andrew J. Admon;,citation_author=Sable Skewes;,citation_author=Yunfei Xia;,citation_author=Shih-Hsuing Chou;,citation_publication_date=2022-09;,citation_cover_date=2022-09;,citation_year=2022;,citation_doi=10.1177/0272989X221121279;,citation_issn=0272-989X;,citation_language=en-US;,citation_journal_title=Medical Decision Making;,citation_publisher=SAGE Publications Inc STM;">
<meta name="citation_reference" content="citation_title=Timing Is Everything. The Importance of Alignment of Time Anchors for Observational Causal Inference Research;,citation_author=Stephanie Parks Taylor;,citation_author=Marc A. Kowalkowski;,citation_author=Andrew J. Admon;,citation_publication_date=2021-05;,citation_cover_date=2021-05;,citation_year=2021;,citation_issue=5;,citation_doi=10.1513/AnnalsATS.202009-1163VP;,citation_issn=2329-6933, 2325-6621;,citation_volume=18;,citation_language=en-US;,citation_journal_title=Annals of the American Thoracic Society;">
<meta name="citation_reference" content="citation_title=Evolution Over Time of Ventilatory Management and Outcome of Patients With Neurologic Disease;,citation_abstract=OBJECTIVES: To describe the changes in ventilator management over time in patients with neurologic disease at ICU admission and to estimate factors associated with 28-day hospital mortality. DESIGN: Secondary analysis of three prospective, observational, multicenter studies. SETTING: Cohort studies conducted in 2004, 2010, and 2016. PATIENTS: Adult patients who received mechanical ventilation for more than 12 hours. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Among the 20,929 patients enrolled, we included 4,152 (20%) mechanically ventilated patients due to different neurologic diseases. Hemorrhagic stroke and brain trauma were the most common pathologies associated with the need for mechanical ventilation. Although volume-cycled ventilation remained the preferred ventilation mode, there was a significant (p &amp;amp;amp;lt; 0.001) increment in the use of pressure support ventilation. The proportion of patients receiving a protective lung ventilation strategy was increased over time: 47% in 2004, 63% in 2010, and 65% in 2016 (p &amp;lt; 0.001), as well as the duration of protective ventilation strategies: 406 days per 1,000 mechanical ventilation days in 2004, 523 days per 1,000 mechanical ventilation days in 2010, and 585 days per 1,000 mechanical ventilation days in 2016 (p < 0.001). There were no differences in the length of stay in the ICU, mortality in the ICU, and mortality in hospital from 2004 to 2016. Independent risk factors for 28-day mortality were age greater than 75 years, Simplified Acute Physiology Score II greater than 50, the occurrence of organ dysfunction within first 48 hours after brain injury, and specific neurologic diseases such as hemorrhagic stroke, ischemic stroke, and brain trauma. CONCLUSIONS: More lung-protective ventilatory strategies have been implemented over years in neurologic patients with no effect on pulmonary complications or on survival. We found several prognostic factors on mortality such as advanced age, the severity of the disease, organ dysfunctions, and the etiology of neurologic disease.;,citation_author=Eva E. Tejerina;,citation_author=Paolo Pelosi;,citation_author=Chiara Robba;,citation_author=Oscar Peñuelas;,citation_author=Alfonso Muriel;,citation_author=Deisy Barrios;,citation_author=Fernando Frutos-Vivar;,citation_author=Konstantinos Raymondos;,citation_author=Bin Du;,citation_author=Arnaud W. Thille;,citation_author=Fernando Ríos;,citation_author=Marco González;,citation_author=Lorenzo Sorbo;,citation_author=Maria del Carmen Marín;,citation_author=Bruno Valle Pinheiro;,citation_author=Marco Antonio Soares;,citation_author=Nicolas Nin;,citation_author=Salvatore M. Maggiore;,citation_author=Andrew Bersten;,citation_author=Pravin Amin;,citation_author=Nahit Cakar;,citation_author=Gee Young Suh;,citation_author=Fekri Abroug;,citation_author=Manuel Jibaja;,citation_author=Dimitros Matamis;,citation_author=Amine Ali Zeggwagh;,citation_author=Yuda Sutherasan;,citation_author=Antonio Anzueto;,citation_author=Andrés Esteban;,citation_publication_date=2021-02;,citation_cover_date=2021-02;,citation_year=2021;,citation_doi=10.1097/CCM.0000000000004921;,citation_issn=0090-3493;,citation_volume=Publish Ahead of Print;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=The physiological underpinnings of life-saving respiratory support;,citation_abstract=Treatment of respiratory failure has improved dramatically since the polio epidemic in the 1950s with the use of invasive techniques for respiratory support: mechanical ventilation and extracorporeal respiratory support. However, respiratory support is only a supportive therapy, designed to “buy time” while the disease causing respiratory failure abates. It ensures viable gas exchange and prevents cardiorespiratory collapse in the context of excessive loads. Because the use of invasive modalities of respiratory support is also associated with substantial harm, it remains the responsibility of the clinician to minimize such hazards. Direct iatrogenic consequences of mechanical ventilation include the risk to the lung (ventilator-induced lung injury) and the diaphragm (ventilator-induced diaphragm dysfunction and other forms of myotrauma). Adverse consequences on hemodynamics can also be significant. Indirect consequences (e.g., immobilization, sleep disruption) can have devastating long-term effects. Increasing awareness and understanding of these mechanisms of injury has led to a change in the philosophy of care with a shift from aiming to normalize gases toward minimizing harm. Lung (and more recently also diaphragm) protective ventilation strategies include the use of extracorporeal respiratory support when the risk of ventilation becomes excessive. This review provides an overview of the historical background of respiratory support, pathophysiology of respiratory failure and rationale for respiratory support, iatrogenic consequences from mechanical ventilation, specifics of the implementation of mechanical ventilation, and role of extracorporeal respiratory support. It highlights the need for appropriate monitoring to estimate risks and to individualize ventilation and sedation to provide safe respiratory support to each patient.;,citation_author=Irene Telias;,citation_author=Laurent J. Brochard;,citation_author=Simone Gattarello;,citation_author=Hannah Wunsch;,citation_author=Detajin Junhasavasdikul;,citation_author=Karen J. Bosma;,citation_author=Luigi Camporota;,citation_author=Daniel Brodie;,citation_author=John J. Marini;,citation_author=Arthur S. Slutsky;,citation_author=Luciano Gattinoni;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_doi=10.1007/s00134-022-06749-3;,citation_issn=1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity;,citation_abstract=OBJECTIVE To evaluate the association between vaccination with mRNA COVID-19 vaccines—mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech)—and COVID-19 hospitalization, and, among patients hospitalized with COVID-19, the association with progression to critical disease. DESIGN, SETTING, AND PARTICIPANTS A US 21-site case-control analysis of 4513 adults hospitalized between March 11 and August 15, 2021, with 28-day outcome data on death and mechanical ventilation available for patients enrolled through July 14, 2021. Date of final follow-up was August 8, 2021. EXPOSURES COVID-19 vaccination. MAIN OUTCOMES AND MEASURES Associations were evaluated between prior vaccination and (1) hospitalization for COVID-19, in which case patients were those hospitalized for COVID-19 and control patients were those hospitalized for an alternative diagnosis; and (2) disease progression among patients hospitalized for COVID-19, in which cases and controls were COVID-19 patients with and without progression to death or mechanical ventilation, respectively. Associations were measured with multivariable logistic regression. RESULTS Among 4513 patients (median age, 59 years [IQR, 45-69]; 2202 [48.8%] women; 23.0% non-Hispanic Black individuals, 15.9% Hispanic individuals, and 20.1% with an immunocompromising condition), 1983 were case patients with COVID-19 and 2530 were controls without COVID-19. Unvaccinated patients accounted for 84.2% (1669/1983) of COVID-19 hospitalizations. Hospitalization for COVID-19 was significantly associated with decreased likelihood of vaccination (cases, 15.8%; controls, 54.8%; adjusted OR, 0.15; 95% CI, 0.13-0.18), including for sequenced SARS-CoV-2 Alpha (8.7% vs 51.7%; aOR, 0.10; 95% CI, 0.06-0.16) and Delta variants (21.9% vs 61.8%; aOR, 0.14; 95% CI, 0.10-0.21). This association was stronger for immunocompetent patients (11.2% vs 53.5%; aOR, 0.10; 95% CI, 0.09-0.13) than immunocompromisedpatients(40.1%vs58.8%;aOR,0.49;95%CI,0.35-0.69)(P &amp;amp;amp;lt; .001)andweaker at more than 120 days since vaccination with BNT162b2 (5.8% vs 11.5%; aOR, 0.36; 95% CI, 0.270.49) than with mRNA-1273 (1.9% vs 8.3%; aOR, 0.15; 95% CI, 0.09-0.23) (P &amp;lt; .001). Among 1197 patients hospitalized with COVID-19, death or invasive mechanical ventilation by day 28 was associated with decreased likelihood of vaccination (12.0% vs 24.7%; aOR, 0.33; 95% CI, 0.19-0.58). CONCLUSIONS AND RELEVANCE Vaccination with an mRNA COVID-19 vaccine was significantly less likely among patients with COVID-19 hospitalization and disease progression to death or mechanical ventilation. These findings are consistent with risk reduction among vaccine breakthrough infections compared with absence of vaccination.;,citation_author=Mark W. Tenforde;,citation_author=Wesley H. Self;,citation_author=Katherine Adams;,citation_author=Manjusha Gaglani;,citation_author=Adit A. Ginde;,citation_author=Tresa McNeal;,citation_author=Shekhar Ghamande;,citation_author=David J. Douin;,citation_author=H. Keipp Talbot;,citation_author=Jonathan D. Casey;,citation_author=Nicholas M. Mohr;,citation_author=Anne Zepeski;,citation_author=Nathan I. Shapiro;,citation_author=Kevin W. Gibbs;,citation_author=D. Clark Files;,citation_author=David N. Hager;,citation_author=Arber Shehu;,citation_author=Matthew E. Prekker;,citation_author=Heidi L. Erickson;,citation_author=Matthew C. Exline;,citation_author=Michelle N. Gong;,citation_author=Amira Mohamed;,citation_author=Daniel J. Henning;,citation_author=Jay S. Steingrub;,citation_author=Ithan D. Peltan;,citation_author=Samuel M. Brown;,citation_author=Emily T. Martin;,citation_author=Arnold S. Monto;,citation_author=Akram Khan;,citation_author=Catherine L. Hough;,citation_author=Laurence W. Busse;,citation_author=Caitlin C. Lohuis;,citation_author=Abhijit Duggal;,citation_author=Jennifer G. Wilson;,citation_author=Alexandra June Gordon;,citation_author=Nida Qadir;,citation_author=Steven Y. Chang;,citation_author=Christopher Mallow;,citation_author=Carolina Rivas;,citation_author=Hilary M. Babcock;,citation_author=Jennie H. Kwon;,citation_author=Natasha Halasa;,citation_author=James D. Chappell;,citation_author=Adam S. Lauring;,citation_author=Carlos G. Grijalva;,citation_author=Todd W. Rice;,citation_author=Ian D. Jones;,citation_author=William B. Stubblefield;,citation_author=Adrienne Baughman;,citation_author=Kelsey N. Womack;,citation_author=Jillian P. Rhoads;,citation_author=Christopher J. Lindsell;,citation_author=Kimberly W. Hart;,citation_author=Yuwei Zhu;,citation_author=Samantha M. Olson;,citation_author=Miwako Kobayashi;,citation_author=Jennifer R. Verani;,citation_author=Manish M. Patel;,citation_author=Influenza and Other Viruses in the Acutely Ill (IVY) Network;,citation_publication_date=2021-11;,citation_cover_date=2021-11;,citation_year=2021;,citation_issue=20;,citation_doi=10.1001/jama.2021.19499;,citation_issn=0098-7484;,citation_volume=326;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Use of directed acyclic graphs (DAGs) to identify confounders in applied health research: Review and recommendations;,citation_abstract=Directed acyclic graphs (DAGs) are an increasingly popular approach for identifying confounding variables that require conditioning when estimating causal effects. This review examined the use of DAGs in applied health research to inform recommendations for improving their transparency and utility in future research.Original health research articles published during 1999–2017 mentioning “directed acyclic graphs” (or similar) or citing DAGitty were identified from Scopus, Web of Science, Medline and Embase. Data were extracted on the reporting of: estimands, DAGs and adjustment sets, alongside the characteristics of each article’s largest DAG.A total of 234 articles were identified that reported using DAGs. A fifth (n = 48, 21%) reported their target estimand(s) and half (n = 115, 48%) reported the adjustment set(s) implied by their DAG(s). Two-thirds of the articles (n = 144, 62%) made at least one DAG available. DAGs varied in size but averaged 12 nodes [interquartile range (IQR): 9–16, range: 3–28] and 29 arcs (IQR: 19–42, range: 3–99). The median saturation (i.e. percentage of total possible arcs) was 46% (IQR: 31–67, range: 12–100). 37% (n = 53) of the DAGs included unobserved variables, 17% (n = 25) included “super-nodes” (i.e. nodes containing more than one variable) and 34% (n = 49) were visually arranged so that the constituent arcs flowed in the same direction (e.g. top-to-bottom).There is substantial variation in the use and reporting of DAGs in applied health research. Although this partly reflects their flexibility, it also highlights some potential areas for improvement. This review hence offers several recommendations to improve the reporting and use of DAGs in future research.;,citation_author=Peter W G Tennant;,citation_author=Eleanor J Murray;,citation_author=Kellyn F Arnold;,citation_author=Laurie Berrie;,citation_author=Matthew P Fox;,citation_author=Sarah C Gadd;,citation_author=Wendy J Harrison;,citation_author=Claire Keeble;,citation_author=Lynsie R Ranker;,citation_author=Johannes Textor;,citation_author=Georgia D Tomova;,citation_author=Mark S Gilthorpe;,citation_author=George T H Ellison;,citation_publication_date=2021-04;,citation_cover_date=2021-04;,citation_year=2021;,citation_issue=2;,citation_doi=10.1093/ije/dyaa213;,citation_issn=0300-5771;,citation_volume=50;,citation_journal_title=International Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Promoting Multifaceted Interventions for Care of the Seriously Ill and Dying;,citation_author=Joan M. Teno;,citation_publication_date=2022-04;,citation_cover_date=2022-04;,citation_year=2022;,citation_issue=4;,citation_doi=10.1001/jamahealthforum.2022.1113;,citation_issn=2689-0186;,citation_volume=3;,citation_language=en-US;,citation_journal_title=JAMA Health Forum;">
<meta name="citation_reference" content="citation_title=Early recanalization in large-vessel occlusion stroke patients transferred for endovascular treatment;,citation_abstract=Background We performed an exploratory analysis to identify patient and thrombus characteristics associated with early recanalization in large-vessel occlusion (LVO) stroke patients transferred for endovascular treatment (EVT) from a primary (PSC) to a comprehensive stroke center (CSC). Methods We included patients with an LVO stroke of the anterior circulation who were transferred to our hospital for EVT and underwent repeated imaging between January 2016 and June 2019. We compared patient characteristics, workflow time metrics, functional outcome (modified Rankin Scale at 90 days), and baseline thrombus imaging characteristics, which included: occlusion location, thrombus length, attenuation, perviousness, distance from terminus of intracranial carotid artery to the thrombus (DT), and clot burden score (CBS), between early-recanalized LVO (ER-LVO), and non-early-recanalized LVO (NER-LVO) patients. Results One hundred and forty-nine patients were included in the analysis. Early recanalization occurred in 32% of patients. ER-LVO patients less often had a medical history of hypertension (31% vs 49%, P=0.04), and more often had clinical improvement between PSC and CSC (\DeltaNIHSS -5 vs 3, P&amp;amp;amp;lt;0.01), compared with NER-LVO patients. Thrombolysis administration was similar in both groups (88% vs 78%, P=0.18). ER-LVO patients had no ICA occlusions (0% vs 27%, P&amp;lt;0.01), more often an M2 occlusion (35% vs 17%, P=0.01), longer DT (27 mm vs 12 mm, P<0.01), shorter thrombi (17 mm vs 27 mm, P<0.01), and higher CBS (8 vs 6, P<0.01) at baseline imaging. ER-LVO patients had lower mRS scores (1 vs 3, P=0.02). Conclusions Early recanalization is associated with clinical improvement between PSC and CSC admission, more distal occlusions and shorter thrombi at baseline imaging, and better functional outcome.;,citation_author=Nerea Arrarte Terreros;,citation_author=Agnetha A. E. Bruggeman;,citation_author=Isabella S. J. Swijnenburg;,citation_author=Laura C. C. Meenen;,citation_author=Adrien E. Groot;,citation_author=Jonathan M. Coutinho;,citation_author=Yvo B. W. E. M. Roos;,citation_author=Bart J. Emmer;,citation_author=Ludo F. M. Beenen;,citation_author=Ed Bavel;,citation_author=Henk A. Marquering;,citation_author=Charles B. L. M. Majoie;,citation_publication_date=2022-05;,citation_cover_date=2022-05;,citation_year=2022;,citation_issue=5;,citation_doi=10.1136/neurintsurg-2021-017441;,citation_issn=1759-8478, 1759-8486;,citation_pmid=33986112;,citation_volume=14;,citation_language=en-US;,citation_journal_title=Journal of NeuroInterventional Surgery;,citation_publisher=British Medical Journal Publishing Group;">
<meta name="citation_reference" content="citation_title=Statistical Remedies for Medical Researchers;,citation_author=Peter F. Thall;,citation_publication_date=2020;,citation_cover_date=2020;,citation_year=2020;,citation_doi=10.1007/978-3-030-43714-5;,citation_isbn=978-3-030-43713-8 978-3-030-43714-5;,citation_language=en-US;,citation_series_title=Springer Series in Pharmaceutical Statistics;">
<meta name="citation_reference" content="citation_title=Goal-Directed Resuscitation for Patients with Early Septic Shock;,citation_abstract=Background Early goal-directed therapy (EGDT) has been endorsed in the guidelines of the Surviving Sepsis Campaign as a key strategy to decrease mortality among patients presenting to the emergency department with septic shock. However, its effectiveness is uncertain. Methods In this trial conducted at 51 centers (mostly in Australia or New Zealand), we randomly assigned patients presenting to the emergency department with early septic shock to receive either EGDT or usual care. The primary outcome was all-cause mortality within 90 days after randomization. Results Of the 1600 enrolled patients, 796 were assigned to the EGDT group and 804 to the usual-care group. Primary outcome data were available for more than 99% of the patients. Patients in the EGDT group received a larger mean (SD) volume of intravenous fluids in the first 6 hours after randomization than did those in the usualcare group (19641415 ml vs. 17131401 ml) and were more likely to receive vasopressor infusions (66.6% vs. 57.8%), red-cell transfusions (13.6% vs. 7.0%), and dobutamine (15.4% vs. 2.6%) (P&amp;amp;amp;lt;0.001 for all comparisons). At 90 days after randomization, 147 deaths had occurred in the EGDT group and 150 had occurred in the usual-care group, for rates of death of 18.6% and 18.8%, respectively (absolute risk difference with EGDT vs. usual care, -0.3 percentage points; 95% confidence interval, -4.1 to 3.6; P = 0.90). There was no significant difference in survival time, in-hospital mortality, duration of organ support, or length of hospital stay. Conclusions In critically ill patients presenting to the emergency department with early septic shock, EGDT did not reduce all-cause mortality at 90 days. (Funded by the National Health and Medical Research Council of Australia and the Alfred Foundation; ARISE ClinicalTrials.gov number, NCT00975793.);,citation_author=The ARISE Investigators and the ANZICS Clinical Trials Group;,citation_publication_date=2014-10;,citation_cover_date=2014-10;,citation_year=2014;,citation_issue=16;,citation_doi=10.1056/NEJMoa1404380;,citation_issn=0028-4793, 1533-4406;,citation_volume=371;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial;,citation_abstract=OBJECTIVE To assess the effects of 12 mg/d vs 6 mg/d of dexamethasone in patients with COVID-19 and severe hypoxemia. DESIGN, SETTING, AND PARTICIPANTS A multicenter, randomized clinical trial was conducted between August 2020 and May 2021 at 26 hospitals in Europe and India and included 1000 adults with confirmed COVID-19 requiring at least 10 L/min of oxygen or mechanical ventilation. End of 90-day follow-up was on August 19, 2021. INTERVENTIONS Patients were randomized 1:1 to 12 mg/d of intravenous dexamethasone (n = 503) or 6 mg/d of intravenous dexamethasone (n = 497) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was the number of days alive without life support (invasive mechanical ventilation, circulatory support, or kidney replacement therapy) at 28 days and was adjusted for stratification variables. Of the 8 prespecified secondary outcomes, 5 are included in this analysis (the number of days alive without life support at 90 days, the number of days alive out of the hospital at 90 days, mortality at 28 days and at 90 days, and Ն1 serious adverse reactions at 28 days). RESULTS Of the 1000 randomized patients, 982 were included (median age, 65 [IQR, 55-73] years; 305 [31%] women) and primary outcome data were available for 971 (491 in the 12 mg of dexamethasone group and 480 in the 6 mg of dexamethasone group). The median number of days alive without life support was 22.0 days (IQR, 6.0-28.0 days) in the 12 mg of dexamethasone group and 20.5 days (IQR, 4.0-28.0 days) in the 6 mg of dexamethasone group (adjusted mean difference, 1.3 days [95% CI, 0-2.6 days]; P = .07). Mortality at 28 days was 27.1% in the 12 mg of dexamethasone group vs 32.3% in the 6 mg of dexamethasone group (adjusted relative risk, 0.86 [99% CI, 0.68-1.08]). Mortality at 90 days was 32.0% in the 12 mg of dexamethasone group vs 37.7% in the 6 mg of dexamethasone group (adjusted relative risk, 0.87 [99% CI, 0.70-1.07]). Serious adverse reactions, including septic shock and invasive fungal infections, occurred in 11.3% in the 12 mg of dexamethasone group vs 13.4% in the 6 mg of dexamethasone group (adjusted relative risk, 0.83 [99% CI, 0.54-1.29]). CONCLUSIONS AND RELEVANCE Among patients with COVID-19 and severe hypoxemia, 12 mg/d of dexamethasone compared with 6 mg/d of dexamethasone did not result in statistically significantly more days alive without life support at 28 days. However, the trial may have been underpowered to identify a significant difference.;,citation_author=The COVID STEROID 2 Trial Group;,citation_author=Lene Russell;,citation_author=Kis Rønn Uhre;,citation_author=Ann Louise Syraach Lindgaard;,citation_author=Jette Fredlund Degn;,citation_author=Mik Wetterslev;,citation_author=Praleene Sivapalan;,citation_author=Carl Thomas Anthon;,citation_author=Vibe Sommer Mikkelsen;,citation_author=Louise Colette Porta;,citation_author=Thomas Steen Jensen;,citation_author=Charlotte Kastberg Levin;,citation_author=Gitte Kronborg;,citation_author=Rikke Krogh-Madsen;,citation_author=Ronni Thermann Reitz Plovsing;,citation_author=Helene Brix;,citation_author=Martin Schønemann-Lund;,citation_author=Lone Valbjørn;,citation_author=Sanne Lauritzen;,citation_author=Ellen Bjerre Koch;,citation_author=Valdemar Oskar Ingemann Sørensen;,citation_author=Hans Eric Sebastian Seitz-Rasmussen;,citation_author=Frederik Heiberg Bestle;,citation_author=Nina Christine Andersen-Ranberg;,citation_author=Camilla Bekker Mortensen;,citation_author=Cecilie Bauer Derby;,citation_author=Emma Ritsmer Stormholt;,citation_author=Yifei Cao;,citation_author=Thomas Steen Strøm;,citation_author=Eva Lærkner;,citation_author=Christine Gilberg;,citation_author=Michella Poulsen;,citation_author=Hanne Tanghus Olsen;,citation_author=Charlotte Rosenkilde;,citation_author=Trine Haberlandt;,citation_author=Lars Peter Kloster Andersen;,citation_author=Diana Bertelsen Jensen;,citation_author=Mia Charlotte Krogh Hansen;,citation_author=Søren Rosborg Aagaard;,citation_author=Stine Rom Vestergaard;,citation_author=Anne-Marie Gellert Bunzel;,citation_author=Rine Moulvad Siegumfeldt;,citation_author=Thomas Lass Klitgaard;,citation_author=Kirsten Uldal Krejberg;,citation_author=Henrik Nielsen;,citation_author=Evangeline Elvira;,citation_author=Hilda Nirmala Kumari;,citation_author=Jayanthi Swaminathan;,citation_author=K Arun Chander;,citation_author=N Ganesh Rajan;,citation_author=Sona Thomas;,citation_author=Ann Thomas;,citation_author=Vishnu Odankadummai;,citation_author=Anu M Antony;,citation_author=Atul P Kulkarni;,citation_author=Nishanth Baliga;,citation_author=Nirmalyo Lodh;,citation_author=Swapna C Vijayakumaran;,citation_author=Kushal Kalvit;,citation_author=Tarun Sahu;,citation_author=Vijaya P Patil;,citation_author=Amol T Kothekar;,citation_author=Shilpushp J Bhosale;,citation_author=Manoj Gorade;,citation_author=Anjana M Shrivastava;,citation_author=Jare Jagannath Uddhavrao;,citation_author=Ritika Sharma;,citation_author=Jyotsna Mali;,citation_author=H R Niranjan;,citation_author=Celine Lobo;,citation_author=Vaishali Neve;,citation_author=Deepika Maurya;,citation_author=Mahesh Salunke;,citation_author=Santiswaroop Pattanaik;,citation_author=Akhliesh Agrawal;,citation_author=Ashit Hegde;,citation_author=Rishi Kumar Badgurjar;,citation_author=Binit N Jhaveri;,citation_author=Digamber B Sarje;,citation_author=H. J Ananda;,citation_author=Bitan Sen;,citation_author=C. M Ambily;,citation_author=Emilin P Jose;,citation_author=Vaijayanti Kadam;,citation_author=Annapurna Chiluka;,citation_author=Rohit Kuril;,citation_author=Elizabeth Mathew;,citation_author=Survana Shirsekar;,citation_author=Sudha Kansal;,citation_author=Rinku Dahiya;,citation_author=Vijaya Kumar Thakur;,citation_author=Rajni Tewatia;,citation_author=Savita Rawat;,citation_author=Harsh Tyagi;,citation_author=Meenakshi Bhakare;,citation_author=Chinmayee Bhise;,citation_author=Amit Girme;,citation_author=Lini T Kunjumon;,citation_author=Merlin Jose;,citation_author=Nikunj Sharma;,citation_author=Amol Bali;,citation_author=Mayr Patel;,citation_author=Nirankar Bhutaka;,citation_author=Edwin Pathrose;,citation_author=Gopal Goyal;,citation_author=Riya Baby;,citation_author=Roshini Fernandez;,citation_author=Pradip K Bhattacharya;,citation_author=Srishti Kindo;,citation_author=A. Aaditya;,citation_author=Kritiaka Raj;,citation_author=Aastha Poddar;,citation_author=Aftab Ansari;,citation_author=Mustaque Alam;,citation_author=Vijay Khandagale;,citation_author=Satish Sarode;,citation_author=Sanesh Garde;,citation_author=Sushant Shinde;,citation_author=Narndev Jagtap;,citation_author=Chagan Khartode;,citation_author=Amit Palange;,citation_author=Aishwarya Pawar;,citation_author=Mayuri Mulay;,citation_author=Simrah Pirzade;,citation_author=Mohini Jagtap;,citation_author=Balbhim Rathod;,citation_author=Dhara Tanna;,citation_author=Kinjal Chaudhary;,citation_author=Shubhangi Deshpande;,citation_author=Rikin Raj;,citation_author=Sourab Ambapkar;,citation_author=Shobhana Ambapkar;,citation_author=Mukund Penurkar;,citation_author=Amit Sambare;,citation_author=Ravindra Joshi;,citation_author=Bhushan Kinolkar;,citation_author=Tarannum Aslam Shaikh;,citation_author=Helen Didriksson;,citation_author=Carina Jönsson;,citation_author=Gunilla Gagnö;,citation_author=David Zacharias;,citation_author=Margaret Lynn Jong;,citation_author=Marianne Roth;,citation_author=Rachelle Mader;,citation_author=Laureta Fazlija;,citation_author=Manuela Akaltan;,citation_author=Anjana Eichenberger;,citation_author=Gion Rüegg;,citation_author=Tatjana Dill;,citation_author=Bruno Schoenmaekers;,citation_author=Ashwani Kumar;,citation_author=Dorrilyn Rajbhandari;,citation_author=Sumaiya Arfin;,citation_author=Nikita Bathla;,citation_author=Rajesh Joshi;,citation_author=Mallikarjuna Kunigari;,citation_author=Marie W. Munch;,citation_author=Sheila N. Myatra;,citation_author=Bharath Kumar Tirupakuzhi Vijayaraghavan;,citation_author=Sanjith Saseedharan;,citation_author=Thomas Benfield;,citation_author=Rebecka R. Wahlin;,citation_author=Bodil S. Rasmussen;,citation_author=Anne Sofie Andreasen;,citation_author=Lone M. Poulsen;,citation_author=Luca Cioccari;,citation_author=Mohd S. Khan;,citation_author=Farhad Kapadia;,citation_author=Jigeeshu V. Divatia;,citation_author=Anne C. Brøchner;,citation_author=Morten H. Bestle;,citation_author=Marie Helleberg;,citation_author=Jens Michelsen;,citation_author=Ajay Padmanaban;,citation_author=Neeta Bose;,citation_author=Anders Møller;,citation_author=Kapil Borawake;,citation_author=Klaus T. Kristiansen;,citation_author=Urvi Shukla;,citation_author=Michelle S. Chew;,citation_author=Subhal Dixit;,citation_author=Charlotte S. Ulrik;,citation_author=Pravin R. Amin;,citation_author=Rajesh Chawla;,citation_author=Christian A. Wamberg;,citation_author=Mehul S. Shah;,citation_author=Iben S. Darfelt;,citation_author=Vibeke L. Jørgensen;,citation_author=Margit Smitt;,citation_author=Anders Granholm;,citation_author=Maj-Brit N. Kjær;,citation_author=Morten H. Møller;,citation_author=Tine S. Meyhoff;,citation_author=Gitte K. Vesterlund;,citation_author=Naomi E. Hammond;,citation_author=Sharon Micallef;,citation_author=Abhinav Bassi;,citation_author=Oommen John;,citation_author=Anubhuti Jha;,citation_author=Maria Cronhjort;,citation_author=Stephan M. Jakob;,citation_author=Christian Gluud;,citation_author=Theis Lange;,citation_author=Vaijayanti Kadam;,citation_author=Klaus V. Marcussen;,citation_author=Jacob Hollenberg;,citation_author=Anders Hedman;,citation_author=Henrik Nielsen;,citation_author=Olav L. Schjørring;,citation_author=Marie Q. Jensen;,citation_author=Jens W. Leistner;,citation_author=Trine B. Jonassen;,citation_author=Camilla M. Kristensen;,citation_author=Esben C. Clapp;,citation_author=Carl J. S. Hjortsø;,citation_author=Thomas S. Jensen;,citation_author=Liv S. Halstad;,citation_author=Emilie R. B. Bak;,citation_author=Reem Zaabalawi;,citation_author=Matias Metcalf-Clausen;,citation_author=Suhayb Abdi;,citation_author=Emma V. Hatley;,citation_author=Tobias S. Aksnes;,citation_author=Emil Gleipner-Andersen;,citation_author=Arif F. Alarcón;,citation_author=Gabriel Yamin;,citation_author=Adam Heymowski;,citation_author=Anton Berggren;,citation_author=Kirstine La Cour;,citation_author=Sarah Weihe;,citation_author=Alison H. Pind;,citation_author=Janus Engstrøm;,citation_author=Vivekanand Jha;,citation_author=Balasubramanian Venkatesh;,citation_author=Anders Perner;,citation_publication_date=2021-11;,citation_cover_date=2021-11;,citation_year=2021;,citation_issue=18;,citation_doi=10.1001/jama.2021.18295;,citation_issn=0098-7484;,citation_volume=326;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Conservative Oxygen Therapy during Mechanical Ventilation in the ICU;,citation_abstract=BACKGROUND Patients who are undergoing mechanical ventilation in the intensive care unit (ICU) often receive a high fraction of inspired oxygen (Fio2) and have a high arterial oxygen tension. The conservative use of oxygen may reduce oxygen exposure, diminish lung and systemic oxidative injury, and thereby increase the number of ventilator-free days (days alive and free from mechanical ventilation). METHODS We randomly assigned 1000 adult patients who were anticipated to require mechanical ventilation beyond the day after recruitment in the ICU to receive conservative or usual oxygen therapy. In the two groups, the default lower limit for oxygen saturation as measured by pulse oximetry (Spo2) was 90%. In the conservativeoxygen group, the upper limit of the Spo2 alarm was set to sound when the level reached 97%, and the Fio2 was decreased to 0.21 if the Spo2 was above the acceptable lower limit. In the usual-oxygen group, there were no specific measures limiting the Fio2 or the Spo2. The primary outcome was the number of ventilatorfree days from randomization until day 28. RESULTS The number of ventilator-free days did not differ significantly between the conservative-oxygen group and the usual-oxygen group, with a median duration of 21.3 days (interquartile range, 0 to 26.3) and 22.1 days (interquartile range, 0 to 26.2), respectively, for an absolute difference of -0.3 days (95% confidence interval [CI], -2.1 to 1.6; P = 0.80). The conservative-oxygen group spent more time in the ICU with an Fio2 of 0.21 than the usual-oxygen group, with a median duration of 29 hours (interquartile range, 5 to 78) and 1 hour (interquartile range, 0 to 17), respectively (absolute difference, 28 hours; 95% CI, 22 to 34); the conservative-oxygen group spent less time with an Spo2 exceeding 96%, with a duration of 27 hours (interquartile range, 11 to 63.5) and 49 hours (interquartile range, 22 to 112), respectively (absolute difference, 22 hours; 95% CI, 14 to 30). At 180 days, mortality was 35.7% in the conservative-oxygen group and 34.5% in the usual-oxygen group, for an unadjusted odds ratio of 1.05 (95% CI, 0.81 to 1.37). The members of the writing committee (Diane Mackle, M.N., Rinaldo Bellomo, M.D., Michael Bailey, Ph.D., Richard Beasley, M.D., D. Sc., Adam Deane, M.D., Ph.D., Glenn Eastwood, R.N., Ph.D., Simon Finfer, M.D., Ross Freebairn, M.D., Victoria King, R.N., Natalie Linke, R.N., Edward Litton, M.D., Ph.D., Colin McArthur, M.D., Shay McGuinness, M.D., Rakshit Panwar, M.D., and Paul Young, M.D., Ph.D.) assume responsibility for the overall content and integrity of this article. The affiliations of the members of the writing committee are listed in the Appendix. Address reprint requests to Dr. Young at the Intensive Care Unit, Wellington Regional Hospital, Private Bag 7902, Wellington South, New Zealand, or at paul.young@ccdhb.org.nz. *A complete list of investigators in the ICU-ROX trial is provided in the Supplementary Appendix, available at NEJM.org. This article was published on October 14, 2019, at NEJM.org. N Engl J Med 2020;382:989-98. DOI: 10.1056/NEJMoa1903297 Copyright © 2019 Massachusetts Medical Society. CONCLUSIONS In adults undergoing mechanical ventilation in the ICU, the use of conservative oxygen therapy, as compared with usual oxygen therapy, did not significantly affect the number of ventilator-free days. (Funded by the New Zealand Health Research Council; ICU-ROX Australian and New Zealand Clinical Trials Registry number, ACTRN12615000957594.);,citation_author=The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group;,citation_publication_date=2020-03;,citation_cover_date=2020-03;,citation_year=2020;,citation_issue=11;,citation_doi=10.1056/NEJMoa1903297;,citation_issn=0028-4793, 1533-4406;,citation_pmid=31613432;,citation_volume=382;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Why hybrid immunity is so triggering;,citation_author=The Lancet Infectious Diseases;,citation_publication_date=2022-12;,citation_cover_date=2022-12;,citation_year=2022;,citation_issue=12;,citation_doi=10.1016/S1473-3099(22)00746-0;,citation_issn=14733099;,citation_volume=22;,citation_language=en-US;,citation_journal_title=The Lancet Infectious Diseases;">
<meta name="citation_reference" content="citation_title=Intravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials;,citation_abstract=OBJECTIVE To determine whether vitamin C improves outcomes for patients with COVID-19. DESIGN, SETTING, AND PARTICIPANTS Two prospectively harmonized randomized clinical trials enrolled critically ill patients receiving organ support in intensive care units (90 sites) and patients who were not critically ill (40 sites) between July 23, 2020, and July 15, 2022, on 4 continents. INTERVENTIONS Patients were randomized to receive vitamin C administered intravenously or control (placebo or no vitamin C) every 6 hours for 96 hours (maximum of 16 doses). MAIN OUTCOMES AND MEASURES The primary outcome was a composite of organ support–free days defined as days alive and free of respiratory and cardiovascular organ support in the intensive care unit up to day 21 and survival to hospital discharge. Values ranged from –1 organ support–free days for patients experiencing in-hospital death to 22 organ support–free days for those who survived without needing organ support. The primary analysis used a bayesian cumulative logistic model. An odds ratio (OR) greater than 1 represented efficacy (improved survival, more organ support–free days, or both), an OR less than 1 represented harm, and an OR less than 1.2 represented futility. RESULTS Enrollment was terminated after statistical triggers for harm and futility were met. The trials had primary outcome data for 1568 critically ill patients (1037 in the vitamin C group and 531 in the control group; median age, 60 years [IQR, 50-70 years]; 35.9% were female) and 1022 patients who were not critically ill (456 in the vitamin C group and 566 in the control group; median age, 62 years [IQR, 51-72 years]; 39.6% were female). Among critically ill patients, the median number of organ support–free days was 7 (IQR, -1 to 17 days) for the vitamin C group vs 10 (IQR, -1 to 17 days) for the control group (adjusted proportional OR, 0.88 [95% credible interval {CrI}, 0.73 to 1.06]) and the posterior probabilities were 8.6% (efficacy), 91.4% (harm), and 99.9% (futility). Among patients who were not critically ill, the median number of organ support–free days was 22 (IQR, 18 to 22 days) for the vitamin C group vs 22 (IQR, 21 to 22 days) for the control group (adjusted proportional OR, 0.80 [95% CrI, 0.60 to 1.01]) and the posterior probabilities were 2.9% (efficacy), 97.1% (harm), and greater than 99.9% (futility). Among critically ill patients, survival to hospital discharge was 61.9% (642/1037) for the vitamin C group vs 64.6% (343/531) for the control group (adjusted OR, 0.92 [95% CrI, 0.73 to 1.17]) and the posterior probability was 24.0% for efficacy. Among patients who were not critically ill, survival to hospital discharge was 85.1% (388/456) for the vitamin C group vs 86.6% (490/566) for the control group (adjusted OR, 0.86 [95% CrI, 0.61 to 1.17]) and the posterior probability was 17.8% for efficacy. CONCLUSIONS AND RELEVANCE In hospitalized patients with COVID-19, vitamin C had low probability of improving the primary composite outcome of organ support–free days and hospital survival.;,citation_author=The LOVIT-COVID Investigators, on behalf of the Canadian Critical Care Trials Group, and the REMAP-CAP Investigators;,citation_author=Simin Florescu;,citation_author=Delia Stanciu;,citation_author=Mihaela Zaharia;,citation_author=Alma Kosa;,citation_author=Daniel Codreanu;,citation_author=Komal Fareed;,citation_author=Aneela Kidwai;,citation_author=Callum Kaye;,citation_author=Amanda Coutts;,citation_author=Lynn MacKay;,citation_author=Charlotte Summers;,citation_author=Petra Polgarova;,citation_author=Neda Farahi;,citation_author=Eleonore Fox;,citation_author=David Sapsford;,citation_author=Katherine Bongaerts;,citation_author=Peter Featherstone;,citation_author=Anthony Ng;,citation_author=Stephen McWilliam;,citation_author=Daniel Hawcutt;,citation_author=Laura Rad;,citation_author=Laura O’Malley;,citation_author=Jennifer Whitbread;,citation_author=Dawn Jones;,citation_author=Rachael Dore;,citation_author=Paula Saunderson;,citation_author=Olivia Kelsall;,citation_author=Nicholas Cowley;,citation_author=Laura Wild;,citation_author=Jessica Thrush;,citation_author=Hannah Wood;,citation_author=Karen Austin;,citation_author=Adrian Donnelly;,citation_author=Martin Kelly;,citation_author=Naoise Smyth;,citation_author=Sinéad O’Kane;,citation_author=Declan McClintock;,citation_author=Majella Warnock;,citation_author=Ryan Campbell;,citation_author=Edmund McCallion;,citation_author=Amine Azaiz;,citation_author=Cyril Charron;,citation_author=Mathieu Godement;,citation_author=Guillaume Geri;,citation_author=Antoine Vieillard-Baron;,citation_author=Paul Johnson;,citation_author=Shirley McKenna;,citation_author=Joanne Hanley;,citation_author=Andrew Currie;,citation_author=Barbara Allen;,citation_author=Clare McGoldrick;,citation_author=Moyra McMaster;,citation_author=Ashwin Mani;,citation_author=Meghena Mathew;,citation_author=Revathi Kandeepan;,citation_author=Chandrashekar Vignesh;,citation_author=Nagarajan Ramakrishnan;,citation_author=Augustian James;,citation_author=Evangeline Elvira;,citation_author=Ramachandran Pratheema;,citation_author=Suresh Babu;,citation_author=Rabindrarajan Ebenezer;,citation_author=S Krishnamoorthy;,citation_author=Lakshmi Ranganathan;,citation_author=Manisha Ganesan;,citation_author=Madhu Shree;,citation_author=Simone Piva;,citation_author=Emanuele Focà;,citation_author=Damiano Rizzoni;,citation_author=Gianluca Boari;,citation_author=Mattia Marchesi;,citation_author=Magdalena Butler;,citation_author=Keri-Anne Cowdrey;,citation_author=Brittany Mason;,citation_author=Melissa Woolett;,citation_author=Eamon Duffy;,citation_author=Yan Chen;,citation_author=Hiromi Nakamuro;,citation_author=Caroline O’Connor;,citation_author=Lauren West;,citation_author=Khaled El-Khawas;,citation_author=Angus Richardson;,citation_author=Dianne Hill;,citation_author=Robert Commons;,citation_author=Hussam Abdelkharim;,citation_author=Manoj Saxena;,citation_author=Margaret Muteithia;,citation_author=Kelsey Dobell-Brown;,citation_author=Rajeev Jha;,citation_author=Michael Kalogirou;,citation_author=Christine Ellis;,citation_author=Vinodh Krishnamurthy;,citation_author=Aibhilin O’Connor;,citation_author=Saranya Thurairatnam;,citation_author=Dipak Mukherjee;,citation_author=Agilan Kaliappan;,citation_author=Mark Vertue;,citation_author=Anne Nicholson;,citation_author=Joanne Riches;,citation_author=Gracie Maloney;,citation_author=Lauren Kittridge;,citation_author=Amanda Solesbury;,citation_author=Angelo Ramos;,citation_author=Daniel Collins;,citation_author=Kathy Brickell;,citation_author=Liadain Reid;,citation_author=Michelle Smyth;,citation_author=Patrick Breen;,citation_author=Sandra Spain;,citation_author=Gerard Curley;,citation_author=Natalie McEvoy;,citation_author=Pierce Geoghegan;,citation_author=Jennifer Clarke;,citation_author=Jon Silversides;,citation_author=Peter McGuigan;,citation_author=Kathryn Ward;,citation_author=Aisling O’Neill;,citation_author=Stephanie Finn;,citation_author=Chris Wright;,citation_author=Jackie Green;,citation_author=Érin Collins;,citation_author=Emmet Major;,citation_author=Julie McAuley;,citation_author=Angus Carter;,citation_author=Julie Smith;,citation_author=Catherine Boschert;,citation_author=Kitty Slieker;,citation_author=Esther Ewalds;,citation_author=Arnate Sanders;,citation_author=Wendy Wittenberg;,citation_author=Heidi Geurts;,citation_author=Latesh Poojara;,citation_author=Treena Sara;,citation_author=Kiran Nand;,citation_author=Brenda Reeve;,citation_author=William Dechert;,citation_author=Barbara Phillips;,citation_author=Laura Oritz-Ruiz de&nbsp;Gordoa;,citation_author=Marion Campbell;,citation_author=Filipa Dos Santos;,citation_author=Dan Hansen;,citation_author=Dee Mullan;,citation_author=Julia Affleck;,citation_author=Arif Shaikh;,citation_author=Andrew Murray;,citation_author=Mahesh Ramanan;,citation_author=Thuy Frakking;,citation_author=Jez Pinnell;,citation_author=Matt Robinson;,citation_author=Lisa Gledhill;,citation_author=Tracy Wood;,citation_author=Ritesh Sanghavi;,citation_author=Deepak Bhonagiri;,citation_author=Megan Ford;,citation_author=Harshel G. Parikh;,citation_author=Bronwyn Avard;,citation_author=Mary Nourse;,citation_author=Bree McDonald;,citation_author=Natasha Edmunds;,citation_author=Oscar Hoiting;,citation_author=Marco Peters;,citation_author=Els Rengers;,citation_author=Manon Bindels;,citation_author=Mirjam Evers;,citation_author=Anton Prinssen;,citation_author=Matt Morgan;,citation_author=Jade Cole;,citation_author=Helen Hill;,citation_author=Michelle Davies;,citation_author=Angharad Williams;,citation_author=Emma Thomas;,citation_author=Rhys Davies;,citation_author=Matt Wise;,citation_author=Daniel Law;,citation_author=Patrick Grimm;,citation_author=Jens Soukup;,citation_author=Richard Wetzold;,citation_author=Madlen Löbel;,citation_author=Lisa Starke;,citation_author=Francois Lellouche;,citation_author=Patricia Lizotte;,citation_author=Adrien Auvet;,citation_author=Celine Ravry;,citation_author=Vanessa Creange;,citation_author=Anne-Helene Boivin;,citation_author=Amélie Barreau;,citation_author=Sophie Vandewoestyne;,citation_author=Pierre-Louis Declercq;,citation_author=Antoine Marchalot;,citation_author=Cecile Saladin;,citation_author=Stephanie Gelinotte;,citation_author=Jean-Pierre Eraldi;,citation_author=François Bourgerol;,citation_author=Marion Beuzelin;,citation_author=Rigaud Jean-Philippe;,citation_author=Franck Pourcine;,citation_author=Mehran Monchi;,citation_author=Gael Pradel;,citation_author=Marie-Helene Hausermann;,citation_author=Michel Boudineau;,citation_author=Thi-My-Hue Nguyen-Valat;,citation_author=Christophe Guitton;,citation_author=Remy Marnai;,citation_author=Marie-Helene Leroyer;,citation_author=Michaël Landais;,citation_author=Cedric Darreau;,citation_author=Marjorie Saint Martin;,citation_author=Patrice Tirot;,citation_author=Nicolas Chudeau;,citation_author=Aurélie Brasselet;,citation_author=Lev Volkov;,citation_author=Jean-Christophe Callahan;,citation_author=Juliette Meunier;,citation_author=Thomas Douillard;,citation_author=Elliot Le Basnier;,citation_author=Marion Veillard;,citation_author=Dominique Vivier;,citation_author=David Luis;,citation_author=Romain Mercier;,citation_author=Anne Sagnier;,citation_author=Nathalie Verrier;,citation_author=Cecile Caplin;,citation_author=Jack Richecoeu;,citation_author=Daniele Combaux;,citation_author=Shidasp Siami;,citation_author=Christelle Aparicio;,citation_author=Sarah Vautier;,citation_author=Asma Jeblaoui;,citation_author=Delphine Lemaire-Brunel;,citation_author=Frédérick D’Aragon;,citation_author=Dominique Bérard;,citation_author=Brian Grondin-Beaudoin;,citation_author=Marc-André Leclair;,citation_author=Olivier Lesur;,citation_author=Michaël Mayette;,citation_author=Yannick Poulin;,citation_author=Hector Quiroz-Martinez;,citation_author=Charles St-Arnaud;,citation_author=Elaine Carbonneau;,citation_author=Brigitte Bolduc;,citation_author=Julie Bélisle;,citation_author=Marie-Pier Bouchard;,citation_author=Line Côté;,citation_author=Joannie Martineau;,citation_author=Alexandra Naisby;,citation_author=Louise Robert-Petit;,citation_author=Marie-Ève Thibault;,citation_author=Julie Leblond;,citation_author=Gaetan Plantefeve;,citation_author=Cécile Leparco;,citation_author=Damien Contou;,citation_author=Muriel Fartoukh;,citation_author=Laura Courtin;,citation_author=Vincent Labbe;,citation_author=Guillaume Voiriot;,citation_author=Sara Salhi;,citation_author=Michaël Chassé;,citation_author=Aslanian Pierre;,citation_author=Sylvain Bélisle;,citation_author=François Martin Carrier;,citation_author=Emmanuel Charbonney;,citation_author=Martin Girard;,citation_author=Jean-Gilles Guimond;,citation_author=Antoine Halwagi;,citation_author=Christophe Kolan;,citation_author=Nicholas Robillard;,citation_author=Dounia Boumahni;,citation_author=Fatna Benettaib;,citation_author=Marie-Ève Cantin;,citation_author=Katherine Coutu-Beaudry;,citation_author=Ali Ghamraoui;,citation_author=Francesca Lamothe;,citation_author=Martine Lebrasseur;,citation_author=Cindy Prie;,citation_author=Maya Salamé;,citation_author=Patrick Archambault;,citation_author=Émilie Côté;,citation_author=Rosalie Beaudoin;,citation_author=Monia Noel-Hunter;,citation_author=Mireille Boutin;,citation_author=Laurie Couture;,citation_author=Arnaud Sement;,citation_author=Alexandre Gachet;,citation_author=Alexis Hanisch;,citation_author=Abdelmagid Haffiane;,citation_author=Anne-Hélène Boivin;,citation_author=Amelie Barreau;,citation_author=Elodie Guerineau;,citation_author=Séverine Poupblanc;,citation_author=Pierre Yes Egreteau;,citation_author=Montaine Lefevre;,citation_author=Simon Bocher;,citation_author=Guillaume Le Loup;,citation_author=Lenaı̈g Le Guen;,citation_author=Vanessa Carn;,citation_author=Melanie Bertel;,citation_author=David Antcliffe;,citation_author=Maie Templeton;,citation_author=Roceld Rojo;,citation_author=Phoebe Coghlan;,citation_author=Joanna Smee;,citation_author=Gareth Barker;,citation_author=André Finn;,citation_author=Gabriele Kreß;,citation_author=Uwe Hoff;,citation_author=Carl Hinrichs;,citation_author=Jens Nee;,citation_author=Euan Mackay;,citation_author=Jon Cort;,citation_author=Amanda Whileman;,citation_author=Thomas Spencer;,citation_author=Nick Spittle;,citation_author=Sarah Beavis;,citation_author=Anand Padmakumar;,citation_author=Katie Dale;,citation_author=Joanne Hawes;,citation_author=Emma Moakes;,citation_author=Rachel Gascoyne;,citation_author=Kelly Pritchard;,citation_author=Lesley Stevenson;,citation_author=Justin Cooke;,citation_author=Karolina Nemeth-Roszpopa;,citation_author=Sheetal Adhikari;,citation_author=Basanta Gauli;,citation_author=Puja Kunwar;,citation_author=Grégoire Muller;,citation_author=Mai-Anh Nay;,citation_author=Toufik Kamel;,citation_author=Dalila Benzekri;,citation_author=Sophie Jacquier;,citation_author=Isabelle Runge;,citation_author=Armelle Mathonnet;,citation_author=François Barbier;,citation_author=Anne Bretagnol;,citation_author=Jay Carter;,citation_author=Kymbalee Van Der Heyden;,citation_author=Jan Mehrtens;,citation_author=Anna Morris;,citation_author=Stacey Morgan;,citation_author=Tara Burke;,citation_author=Emmanuelle Mercier;,citation_author=Delphine Chartier;,citation_author=Charlotte Salmon;,citation_author=Pierre-François Dequin;,citation_author=Denis Garot;,citation_author=Jean Pierre Quenot;,citation_author=Ludivine Garrier;,citation_author=Solenne Villot;,citation_author=Mathilde Audry;,citation_author=Eric Brassard;,citation_author=Charles Francoeur;,citation_author=François Lauzier;,citation_author=Guillaume Leblanc;,citation_author=Maude St-Onge;,citation_author=David Bellemare;,citation_author=Ève Cloutier;,citation_author=Rana Daher;,citation_author=Olivier Costerousse;,citation_author=Marie-Claude Boulanger;,citation_author=Émilie Couillard-Chénard;,citation_author=Louis-Charles Mallard;,citation_author=Frédérique Thibeault;,citation_author=Antoine Tremblay;,citation_author=Bruno Francois;,citation_author=Alexandra Gay;,citation_author=Fedou Anne-Laure;,citation_author=Mohamed Ramali;,citation_author=Ooi Hc;,citation_author=Alison Ghosh;,citation_author=Rawlings Osagie;,citation_author=Malka Arachchige;,citation_author=Melissa Hartley;,citation_author=Jennifer Shu Ki Lok;,citation_author=Bethany Plummer;,citation_author=Lok Hin Lui;,citation_author=Jack Bloomfield;,citation_author=Sam Balls-Burgess;,citation_author=Patick Seigne;,citation_author=Annlin Philip;,citation_author=Joanne Cleary;,citation_author=Lorraine O’Neill;,citation_author=Niamh Kelly;,citation_author=Peter Bamford;,citation_author=Andrew Reid;,citation_author=Kathryn Cawley;,citation_author=Maria Faulkner;,citation_author=Charlotte Pickering;,citation_author=Ashok Raj;,citation_author=Georgios Tsinaslanidis;,citation_author=Reena Khade;,citation_author=Gloria Agha;,citation_author=Rose Sekiwala;,citation_author=Tim Smith;,citation_author=Chris Brewer;,citation_author=Jane Gregory;,citation_author=James Limb;,citation_author=Amanda Cowton;,citation_author=Julie O’Brien;,citation_author=Kelly Postlethwaite;,citation_author=Salim Malakouti;,citation_author=Edvin Music;,citation_author=Dan Ricketts;,citation_author=Andrew King;,citation_author=Gilles Clermont;,citation_author=Robert Bart;,citation_author=Florian Mayr;,citation_author=Andrew Schoenling;,citation_author=Mark Andreae;,citation_author=Varun Shetty;,citation_author=Emily Brant;,citation_author=Brian Malley;,citation_author=Chenell Donadee;,citation_author=Christopher Horvat;,citation_author=Timothy Girard;,citation_author=Rachel Sackrowitz;,citation_author=Alexandra Weissman;,citation_author=Donald Yealy;,citation_author=David Barton;,citation_author=Nadine Talia;,citation_author=Nikitas Nikitas;,citation_author=Colin Wells;,citation_author=Helen McMillan;,citation_author=Bethan Stowe;,citation_author=Kayleigh Spencer;,citation_author=Liana Stapleton;,citation_author=Huub Van Den Oever;,citation_author=Arriette Kruisdijk-Gerritsen;,citation_author=Ghady Haidar;,citation_author=William Bain;,citation_author=Ian Barbash;,citation_author=Meghan Fitzpatrick;,citation_author=Georgios Kitsios;,citation_author=Kaveh Moghbeli;,citation_author=Brian Rosborough;,citation_author=Faraaz Shah;,citation_author=Tomeka Suber;,citation_author=Timothy Stanley;,citation_author=James Castle;,citation_author=Zoe Carr;,citation_author=Ana Alegria;,citation_author=Salah Turki;,citation_author=Tarek Elsefi;,citation_author=Nikki Crisp;,citation_author=Louise Allen;,citation_author=Nicholas Truman;,citation_author=Matthew Smith;,citation_author=Sri Chukkambotla;,citation_author=Wendy Goddard;,citation_author=Stephen Duberley;,citation_author=Meherunnisa Khan;,citation_author=Aayesha Kazi;,citation_author=Joanna Simpson;,citation_author=Graeme Duke;,citation_author=Peter Chan;,citation_author=Brittney Carter;,citation_author=Stephanie Hunter;,citation_author=Ingo Voigt;,citation_author=Robert Schueler;,citation_author=Elisabeth Blank;,citation_author=Vanessa Hüning;,citation_author=Melanie Steffen;,citation_author=Patricia Goralski;,citation_author=Adrian Regli;,citation_author=Susan Pellicano;,citation_author=Annamaria Palermo;,citation_author=Ege Eroglu;,citation_author=Shailesh Bihari;,citation_author=Russell D. Laver;,citation_author=Tapaswi Shrestha;,citation_author=Xia Jin;,citation_author=Joanne McIntyre;,citation_author=Iain McCullagh;,citation_author=Tom Cairns;,citation_author=Helen Hanson;,citation_author=Bijal Patel;,citation_author=Ian Clement;,citation_author=George Evetts;,citation_author=Omar Touma;,citation_author=Susan Holland;,citation_author=Christopher Hodge;,citation_author=Holly Taylor;,citation_author=Meera Alderman;,citation_author=Nicky Barnes;,citation_author=Joana Da Rocha;,citation_author=Catherine Smith;,citation_author=Nicole Brooks;,citation_author=Thanuja Weerasinghe;,citation_author=Julie-Ann Sinclair;,citation_author=Yousuf Abusamra;,citation_author=Ronan Doherty;,citation_author=Joanna Cudlipp;,citation_author=Rajeev Singh;,citation_author=Haili Yu;,citation_author=Admad Daebis;,citation_author=Christopher Ng;,citation_author=Sara Kendrick;,citation_author=Anita Saran;,citation_author=Ahmed Makky;,citation_author=Danni Greener;,citation_author=Louise Rowe-Leete;,citation_author=Alexandra Edwards;,citation_author=Yvonne Bland;,citation_author=Rozzie Dolman;,citation_author=Tracy Foster;,citation_author=Robert Conway;,citation_author=Peter Csabi;,citation_author=Piotr Szawarski;,citation_author=Bence Hajdu;,citation_author=Tina Tamm;,citation_author=Emma Bryden;,citation_author=Loukia Glynou;,citation_author=Jaroslaw Graniewski;,citation_author=Yuriy Kuybida;,citation_author=Samantha Jones;,citation_author=Lisa Kavanagh;,citation_author=Karen Singler;,citation_author=John Laffey;,citation_author=Bairbre McNicholas;,citation_author=Michael Scully;,citation_author=Siobhan Casey;,citation_author=Maeve Kernan;,citation_author=Aoife Brennan;,citation_author=Ritika Rangan;,citation_author=Riona Tully;,citation_author=Sarah Corbett;,citation_author=Aine McCarthy;,citation_author=Oscar Duffy;,citation_author=David Burke;,citation_author=Vanessa Linnett;,citation_author=Amanda Sanderson;,citation_author=Jenny Ritzema;,citation_author=Helen Wild;,citation_author=Rachael Lucas;,citation_author=Yvonne Marriott;,citation_author=Divya Khare;,citation_author=Meredith Pinder;,citation_author=Amitha Gopinath;,citation_author=Thogulava Kannan;,citation_author=Steven Dean;,citation_author=Piyush Vanmali;,citation_author=Pieter Depuydt;,citation_author=Jan De Waele;,citation_author=Liesbet De Bus;,citation_author=Jan Fierens;,citation_author=Stephanie Bracke;,citation_author=Joris Vermassen;,citation_author=Daisy Vermeiren;,citation_author=Jolien Van Hecke;,citation_author=Anouska De Smeytere;,citation_author=Richard Pugh;,citation_author=Richard Lean;,citation_author=Xinyi Qiu;,citation_author=Jeremy Scanlan;,citation_author=Andrew Evans;,citation_author=Gwyneth Davies;,citation_author=Joanne Lewis;,citation_author=Stephanie Rees;,citation_author=Callum MacKay;,citation_author=Richard Craddock;,citation_author=Jennifer Davies;,citation_author=Hannah Williams;,citation_author=Rachel Manley;,citation_author=Esther Garrod;,citation_author=Ameilia Tee;,citation_author=Yvonna Plesnikova;,citation_author=Ahmed Khoud;,citation_author=Samantha Coetzee;,citation_author=Kathryn Puxty;,citation_author=Susanne Cathcart;,citation_author=Dominic Rimmer;,citation_author=Catherine Bagot;,citation_author=Kathryn Scott;,citation_author=Laila Martin;,citation_author=Pamela MacTavish;,citation_author=Ryan Murphy;,citation_author=Samantha Carmichael;,citation_author=Jennifer Tait;,citation_author=Maria Nygren;,citation_author=Hakeem Yusuff;,citation_author=Graziella Isgro;,citation_author=Chris Brightling;,citation_author=Michelle Bourne;,citation_author=Michelle Craner;,citation_author=Rebecca Boyles;,citation_author=Brian Alexander;,citation_author=Tracey Roberts;,citation_author=Apoorva Nelli;,citation_author=Rachel Rosenstein-Sisson;,citation_author=Rebecca Speyer;,citation_author=Yadira Pech;,citation_author=James McCullough;,citation_author=Mandy Tallott;,citation_author=Gloria Vazquez-Grande;,citation_author=Nicole Marten;,citation_author=Theresa Liu;,citation_author=Atif Siddiqui;,citation_author=Sushil Khanal;,citation_author=Sameena Amatya;,citation_author=Sabita Shrestha;,citation_author=Shreya Pathak;,citation_author=Sharmila Mali;,citation_author=Bina Bhattarai;,citation_author=Tamas Szakmany;,citation_author=Shiney Cherian;,citation_author=Gemma Williams;,citation_author=Christie James;,citation_author=Abby Waters;,citation_author=Natalie Duric;,citation_author=Hasham Almeshhedani;,citation_author=Robert Jesty;,citation_author=Catriona Spiers;,citation_author=Rachel Prout;,citation_author=Roger Stedman;,citation_author=Louisa Davies;,citation_author=Suzannah Pegler;,citation_author=Lynsey Kyeremeh;,citation_author=Louise Moorhouse;,citation_author=Malcolm Watters;,citation_author=Gill Arbane;,citation_author=Aneta Bociek;,citation_author=Marlies Ostermann;,citation_author=Fabiola D’Amato;,citation_author=Neus GrauNovellas;,citation_author=Moncy Mathew;,citation_author=Rosario Lim;,citation_author=Kees Van Nieuwkoop;,citation_author=Thomas Ottens;,citation_author=Yorik Visser;,citation_author=Lettie Van Den Berg;,citation_author=Annemarie Van Der Kraan-Donker;,citation_author=Maureen Meade;,citation_author=Émilie Belley-Côté;,citation_author=Lori Hand;,citation_author=Stephen Brett;,citation_author=Sonia Arias;,citation_author=Rebecca Hall;,citation_author=Hem Paneru;,citation_author=Sabin Koirala;,citation_author=Pratibha Paudel;,citation_author=Roshni Shakya;,citation_author=Srijana Kayastha;,citation_author=Rakshya Karki;,citation_author=Maggie Wilson;,citation_author=Suvi Vaara;,citation_author=Leena Pettilä;,citation_author=Jonna Heinonen;,citation_author=Ville Pettilä;,citation_author=Susan Jain;,citation_author=Abhinav Gupta;,citation_author=Catherine Holbrook;,citation_author=Pierre Antoine;,citation_author=Ferhat Meziani;,citation_author=Hayat Allam;,citation_author=Jessy Cattelan;,citation_author=Raphael Clere-Jehl;,citation_author=Julie Helms;,citation_author=Christine Kummerlen;,citation_author=Hamid Merdji;,citation_author=Alexandra Monnier;,citation_author=Hassene Rahmani;,citation_author=Studer Antoine;,citation_author=Francis Schneider;,citation_author=Vincent Castelain;,citation_author=Guillaume Morel;,citation_author=Sylvie L’Hotellier;,citation_author=Evelina Ochin;,citation_author=Christian Vanjak;,citation_author=Patrick Rouge;,citation_author=Lynda Bendjemar;,citation_author=Martin Albert;,citation_author=Karim Serri;,citation_author=Alexandros Cavayas;,citation_author=Mathilde Duplaix;,citation_author=Virginie Williams;,citation_author=Nuno José Teodoro Amaro Dos Santos Catorze;,citation_author=Tiago Nuno Alfaro Lima Pereira;,citation_author=Ricardo Manuel Castro Ferreira;,citation_author=Joana Margarida Pereira Sousa Bastos;,citation_author=Teresa Margarida Oliveira Batista;,citation_author=Julio Badie;,citation_author=Fernando Berdaguer;,citation_author=Sylvain Malfroy;,citation_author=Chaouki Mezher;,citation_author=Charlotte Bourgoin;,citation_author=Guy Moneger;,citation_author=Elodie Bouvier;,citation_author=Rosana Muñoz-Bermúdez;,citation_author=Judith Marin-Corral;,citation_author=Anna Degracia;,citation_author=Francisco Gómez;,citation_author=Maria López;,citation_author=Purificación Pérez-Terán;,citation_author=Clara Vilá;,citation_author=Judit Bigas;,citation_author=Ferran Roche-Campo;,citation_author=Diego Franch-LLasat;,citation_author=Pablo Concha;,citation_author=Joana Domingo-Marco;,citation_author=Silvia Reverté-Villarroya;,citation_author=Esther Sauras-Colón;,citation_author=Gaspar Masdeu-Eixarch;,citation_author=Romina Aceto;,citation_author=Alessio Aghemo;,citation_author=Salvatore Badalamenti;,citation_author=Enrico Brunetta;,citation_author=Michele Ciccarelli;,citation_author=Elena Constantini;,citation_author=Massimiliano Greco;,citation_author=Marco Folci;,citation_author=Carlo Selmi;,citation_author=Antonio Voza;,citation_author=Giovanna Occhipinti;,citation_author=Claudia Constantino-Occhipinti;,citation_author=Raffaele Cuffaro;,citation_author=Giovanna Ruselli;,citation_author=Gennaro Martucci;,citation_author=Giovanni Landoni;,citation_author=Matteo Aldo Bonizzoni;,citation_author=Carola Galbiati;,citation_author=Cristina Nakhnoukh;,citation_author=Rosalba Lembo;,citation_author=Glenda Mascherpa;,citation_author=Giuseppe Giardina;,citation_author=Allesandro Belletti;,citation_author=Marco Ripa;,citation_author=Patrizia Rovere-Querini;,citation_author=Giuseppe Di Lucca;,citation_author=Allesandra Bonaccorso;,citation_author=Gianmarco Alessandro Carà;,citation_author=Giada Russo;,citation_author=Stefano Salvati;,citation_author=Enrico Tomasi;,citation_author=Jeremy Henning;,citation_author=Stephen Bonner;,citation_author=Keith Hugill;,citation_author=Emanuel Cirstea;,citation_author=Dean Wilkinson;,citation_author=Jessica Jones;,citation_author=Mohammed Altomy;,citation_author=Evie Headlam;,citation_author=Michal Karlikowski;,citation_author=Helen Sutherland;,citation_author=Elva Wilhelmsen;,citation_author=Jane Woods;,citation_author=Julie North;,citation_author=Andreas Brodbeck;,citation_author=Katherine Mackintosh;,citation_author=James Garvey;,citation_author=Pieter Bothma;,citation_author=Daryl Tupper-Carey;,citation_author=Ikhuemose Ikhena;,citation_author=Jason Osborne;,citation_author=Victoria Waugh;,citation_author=Mathias Pletz;,citation_author=Stefan Hagel;,citation_author=Juliane Ankert;,citation_author=Steffi Kolanos;,citation_author=Frank Bloos;,citation_author=Koen Simons;,citation_author=Tamara Van Zuylen;,citation_author=Angela Bouman;,citation_author=Nikhil Kumar;,citation_author=Rakshit Panwar;,citation_author=Amber-Louise Poulter;,citation_author=Krishna Sunkara;,citation_author=Bram Rochwerg;,citation_author=Tim Karachi;,citation_author=Simon Oczkowski;,citation_author=John Centofanti;,citation_author=Tina Millen;,citation_author=Mercedes Camargo;,citation_author=Alia Khaled;,citation_author=Dhinesh Sundaran;,citation_author=Laszlo Hollos;,citation_author=Anna Williams;,citation_author=Margaret Turns;,citation_author=Joanne Walsh;,citation_author=Eman Al Qasim;,citation_author=Lolowa Alswaidan;,citation_author=Mohamed Hegazy;,citation_author=Hatim Arishi;,citation_author=Ali Al Amri;,citation_author=Samah AlQahtani;,citation_author=Brintha Naidu;,citation_author=Haytham Tlayjeh;,citation_author=Sajid Hussain;,citation_author=Farhan Al Enezi;,citation_author=Sheryl Ann Abdukahil;,citation_author=Phil Hopkins;,citation_author=John Smith;,citation_author=Harriet Noble;,citation_author=Kevin O’Reilly;,citation_author=Reena Mehta;,citation_author=Onyee Wong;,citation_author=Esther Makanju;,citation_author=Deepak Rao;,citation_author=Nyma Sikondari;,citation_author=Sian Saha;,citation_author=Ele Corcoran;,citation_author=Evita Pappa;,citation_author=Maeve Cockrell;,citation_author=Clare Donegan;,citation_author=Morteza Balaie;,citation_author=Maria Depante;,citation_author=Daniela Nickoleit-Bitzenberger;,citation_author=Bernhard Schaaf;,citation_author=Werner Meermeier;,citation_author=Katharina Prebeg;,citation_author=Harun Azzaui;,citation_author=Martin Hower;,citation_author=Klaus-Gerd Brieger;,citation_author=Corinna Elender;,citation_author=Timo Sabelhaus;,citation_author=Ansgar Riepe;,citation_author=Ceren Akamp;,citation_author=Julius Kremling;,citation_author=Daniela Klein;,citation_author=Elke Landsiedel-Mechenbier;,citation_author=Shondipon Laha;,citation_author=Mark Verlander;,citation_author=Alexandra Williams;,citation_author=Avinash Jha;,citation_author=Bruno Megarbane;,citation_author=Sebastian Voicu;,citation_author=Nicolas Deye;,citation_author=Isabelle Malissin;,citation_author=Laetitia Sutterlin;,citation_author=Aymen Mrad;,citation_author=Adrien Lehalleur;,citation_author=Giulia Naim;,citation_author=Philippe Nguyen;,citation_author=Jean-Michel Ekhérian;,citation_author=Yvonnick Boué;,citation_author=Georgios Sidéris;,citation_author=Dominique Vodovar;,citation_author=Emmanuelle Guérin;,citation_author=Caroline Grant;,citation_author=Matthew Brain;,citation_author=Laurie Mckeon;,citation_author=Lixian Chen;,citation_author=Tarnya Tresize;,citation_author=Maria Unwin;,citation_author=Fabian Laugs;,citation_author=Ragnar Lunde;,citation_author=Wendy Blanck;,citation_author=Elankumaran Paramasivam;,citation_author=Elizabeth Wilby;,citation_author=Bethan Ogg;,citation_author=Clare Howcroft;,citation_author=Angelique Aspinwall;,citation_author=Sam Charlton;,citation_author=Richard Gould;,citation_author=Deena Mistry;,citation_author=Sidra Awan;,citation_author=Caroline Bedford;,citation_author=Joanne Carr-Wilkinson;,citation_author=Andrew Hall;,citation_author=Jill Cooke;,citation_author=Caroline Gardiner-Hill;,citation_author=Carolyn Maloney;,citation_author=Nigel Brunskill;,citation_author=Olivia Watchorn;,citation_author=Chloe Hardy;,citation_author=Hafiz Qureshi;,citation_author=Neil Flint;,citation_author=Sarah Nicholson;,citation_author=Sara Southin;,citation_author=Andrew Nicholson;,citation_author=Amardeep Ghattaoraya;,citation_author=Daniel Harding;,citation_author=Sinead O’Halloran;,citation_author=Amy Collins;,citation_author=Emma Smith;,citation_author=Estefania Trues;,citation_author=Barbara Borgatta;,citation_author=Ian Turner-Bone;,citation_author=Amie Reddy;,citation_author=Laura Wilding;,citation_author=Craig Wilson;,citation_author=Zuhra Surti;,citation_author=Anders Aneman;,citation_author=Christopher Dugan;,citation_author=Edison Chin;,citation_author=Jennene Miller;,citation_author=Hayden White;,citation_author=Kristen Estensen;,citation_author=Lynette Morrison;,citation_author=Joanne Sutton;,citation_author=Melanie Cooper;,citation_author=Loku Warnapura;,citation_author=Ronan Agno;,citation_author=Prasannakumari Sathianathan;,citation_author=Deborah Shaw;,citation_author=Nazia Ijaz;,citation_author=Adam Spong;,citation_author=Suganya Sabaretnam;,citation_author=Dean Burns;,citation_author=Eva Lang;,citation_author=Margaret Tate;,citation_author=Roy Fischer;,citation_author=Vishwanath Biradar;,citation_author=Natalie Soar;,citation_author=David Golden;,citation_author=Miriam Davey;,citation_author=Rebecca Seaman;,citation_author=Alexander Osborne;,citation_author=Jonathan Bannard-Smith;,citation_author=Richard Clark;,citation_author=Kathrine Birchall;,citation_author=Joanne Henry;,citation_author=Fiona Pomeroy;,citation_author=Rachael Quayle;,citation_author=Katharine Wylie;,citation_author=Anila Sukuraman;,citation_author=Maya John;,citation_author=Sindhu Sibin;,citation_author=Anne Leditschke;,citation_author=Mackenzie Finnis;,citation_author=Katherine Jongebloed;,citation_author=Rudy Roumen;,citation_author=Klaas De Groot;,citation_author=Kosar Khwaja;,citation_author=Josie Campisi;,citation_author=Marit Vonderen;,citation_author=Riejanne Stienstra;,citation_author=Linda Kampschreur;,citation_author=Mario Pietersma;,citation_author=Laura Van Gulik;,citation_author=Arystarch Makowski;,citation_author=Beata Misztal;,citation_author=Syeda Haider;,citation_author=Angela Liao;,citation_author=Rebecca Squires;,citation_author=Aneta Oborska;,citation_author=Abdul Kayani;,citation_author=Selver Kalchko-Veyssal;,citation_author=Rajalakshmi Prabakaran;,citation_author=Bernard Hadebe;,citation_author=Tony Williams;,citation_author=Rima Song;,citation_author=Dinuraj Girijadevi;,citation_author=Vivian Lai;,citation_author=Susan Morpeth;,citation_author=Tina Mwembani;,citation_author=Richard Stewart;,citation_author=Esther Mwaura;,citation_author=Louise Mew;,citation_author=Lynn Wren;,citation_author=Felicity Willams;,citation_author=Sara-Beth Sutherland;,citation_author=Rashmi Rebello;,citation_author=Atique Rehman;,citation_author=Kiranjit Bharaj;,citation_author=Yahya Shehabi;,citation_author=Wisam Al-Bassam;,citation_author=Amanda Hulley;,citation_author=Umesh Kadam;,citation_author=Kushaharan Sathianathan;,citation_author=Richard Burgess;,citation_author=Patricia Doble;,citation_author=Libby Graham;,citation_author=Charmaine Shovelton;,citation_author=Tessa Dean;,citation_author=Rebecca Purnell;,citation_author=Ashly Thomas;,citation_author=Sobia Masood;,citation_author=Nawal Salahuddin;,citation_author=Kishor Khanal;,citation_author=Krishan Dheke;,citation_author=Namrata Rai;,citation_author=Mili Maharjan;,citation_author=Diptesh Aryal;,citation_author=Kanchan Koirala;,citation_author=Subekshya Luitel;,citation_author=Ian Seppelt;,citation_author=Christina Whitehead;,citation_author=Julie Lowrey;,citation_author=Rebecca Gresham;,citation_author=Kristy Masters;,citation_author=Vincent Hamlyn;,citation_author=Nancy Hawkins;,citation_author=Anna Roynon-Reed;,citation_author=Sean Cutler;,citation_author=Sarah Lewis;,citation_author=Juan Martin-Lazarro;,citation_author=Tabitha Newman;,citation_author=Ausra Zdanavidiene;,citation_author=Karen Smallshaw;,citation_author=James Hand;,citation_author=Latha Aravindan;,citation_author=Adeeba Asghar;,citation_author=Jazz Bartholomew;,citation_author=Madeleine Bayne;,citation_author=Seonaid Beddows;,citation_author=Catherine Birch;,citation_author=Morwenna Brend;,citation_author=Rahim Byrne;,citation_author=Debbie Campbell;,citation_author=Hilary Campbell;,citation_author=Emma Chambers;,citation_author=Alison Clinton;,citation_author=Joanne Collins;,citation_author=Sarah Crawshaw;,citation_author=Laura Ann Dawson;,citation_author=Kate Donaldson;,citation_author=Chelsea Drake;,citation_author=Sarah Dyas;,citation_author=Yvette Ellis;,citation_author=Kate Gilmour;,citation_author=Jayne Goodwin;,citation_author=Sandra Halden;,citation_author=Alistair S Hall;,citation_author=Jane Hanson;,citation_author=Heather Harper;,citation_author=Susan Harrison;,citation_author=Amber Hayes;,citation_author=Helen Hodgson;,citation_author=Sally-Anne Hurford;,citation_author=Shane Jackson;,citation_author=Chris Levett;,citation_author=Stephen Lock;,citation_author=Teresa Lockett;,citation_author=Meg Logan;,citation_author=Kaatje Lomme;,citation_author=Ji Luo;,citation_author=Emma Marsh;,citation_author=Sonia McKenna;,citation_author=Nhlanhla Mguni;,citation_author=Holly Monaghan;,citation_author=Sheenagh Murphy;,citation_author=Natasha Muzengi;,citation_author=Mobeena Naz;,citation_author=Eleanor O’Kell;,citation_author=Anne Oliver;,citation_author=Joanna O’Reilly;,citation_author=Karen Pearson;,citation_author=David Porter;,citation_author=Alison Potter;,citation_author=Clare Rook;,citation_author=Charles Rounds;,citation_author=Jonathan Sheffield;,citation_author=Kim Shirley;,citation_author=Chris Siewerski;,citation_author=Tabitha Skinner;,citation_author=Holly Speight;,citation_author=Mihaela Sutu;,citation_author=Adam Unsworth;,citation_author=William Van’t Hoff;,citation_author=Susan Walker;,citation_author=Penny Williams;,citation_author=Dawn Williamson;,citation_author=James D Williamson;,citation_author=Jennifer Tsang;,citation_author=Erick Duan;,citation_author=Karim Ali;,citation_author=George Farjou;,citation_author=Han-Oh Chung;,citation_author=Lorraine Jensen;,citation_author=Lisa Patterson;,citation_author=Diane Nielsen-Smith;,citation_author=Julia Becevel;,citation_author=Christine Cavers;,citation_author=Josephine Ding;,citation_author=Jamie Irish;,citation_author=Jane Jomy;,citation_author=Pauline Austin;,citation_author=Susan Chapman;,citation_author=Louise Cabrelli;,citation_author=Simon Fletcher;,citation_author=Jurgens Nortje;,citation_author=Deirdre Fottrell-Gould;,citation_author=Georgina Randell;,citation_author=Katie Stammers;,citation_author=Gail Healey;,citation_author=Marta Pinto;,citation_author=Robert Woodward;,citation_author=Martyn Oliver;,citation_author=James Harvey;,citation_author=Karen Convery;,citation_author=Zarah Brown;,citation_author=Sian Taylor;,citation_author=Catherine Fraser;,citation_author=Georgina Glister;,citation_author=Grace Hindle;,citation_author=Kate O Rourke;,citation_author=Zoe Borrill;,citation_author=Tracy Duncan;,citation_author=Andrew Ustianowski;,citation_author=Alison Uriel;,citation_author=Ayaa Eltayeb;,citation_author=Jordan Alfonso;,citation_author=Samuel Hey;,citation_author=Joanne Shaw;,citation_author=Claire Fox;,citation_author=Gabriella Lindergard;,citation_author=Bethan Charles;,citation_author=Bethany Blackledge;,citation_author=Karen Connolly;,citation_author=Jade Harris;,citation_author=Jeronimo Cuesta;,citation_author=Kugan Xavier;,citation_author=Dharam Purohit;,citation_author=Munzir Elhassan;,citation_author=Anne Haldeos;,citation_author=Rachel Vincent;,citation_author=Marwa Abdelrazik;,citation_author=Samuel Jenkins;,citation_author=Arunkumar Ganesan;,citation_author=Rohit Kumar;,citation_author=David Carter;,citation_author=Dhanalakshmi Bakthavatsalam;,citation_author=Alasdair Frater;,citation_author=Malik Saleem;,citation_author=Daanyaal Madarbukus;,citation_author=Robert Everitt;,citation_author=Sarah Bridges;,citation_author=Hina Karim;,citation_author=Mohsin Zaman;,citation_author=Einas Elmahi;,citation_author=Andrea Jones;,citation_author=Kathryn Hall;,citation_author=Matt Phillips;,citation_author=Lenae Terrill;,citation_author=Gary Mills;,citation_author=Ajay Raithatha;,citation_author=Kris Bauchmuller;,citation_author=Kim Ryalls;,citation_author=Kate Harrington;,citation_author=Helen Bowler;,citation_author=Jas Sall;,citation_author=Richard Bourne;,citation_author=Alice Howell;,citation_author=Alison Lye;,citation_author=Rosemary Kirk;,citation_author=Claire Jarman;,citation_author=Bryan Yates;,citation_author=Mari Kilner;,citation_author=Charlotte Bomken;,citation_author=Jessica Reynolds;,citation_author=Jamie Gross;,citation_author=Natalie Massey;,citation_author=Olumide Adebambo;,citation_author=Matilda Long;,citation_author=Kiran Tony;,citation_author=Sonny Kohli;,citation_author=Fulan Cui;,citation_author=Vikas Khera;,citation_author=Sachdeep Rehsia;,citation_author=Adic Perez;,citation_author=Dalisha Bharti;,citation_author=Surbhi Handa;,citation_author=Fiona Shields;,citation_author=Alice Henschke;,citation_author=Nicole Juffermans;,citation_author=Matty Koopmans;,citation_author=Matthew Rowland;,citation_author=Paula Hutton;,citation_author=Archana Bashyal;,citation_author=Neil Davidson;,citation_author=Clare Hird;,citation_author=Sally Beer;,citation_author=Jean Wilson;,citation_author=Grace Polley;,citation_author=Manish Chhablani;,citation_author=Gunjan Phalod;,citation_author=Amy Kirkby;,citation_author=Simon Archer;,citation_author=Kimberley Netherton;,citation_author=Henrik Reschreiter;,citation_author=Julie Camsooksai;,citation_author=Sarah Patch;,citation_author=Sarah Jenkins;,citation_author=Charlotte Humphrey;,citation_author=Emma Langridge;,citation_author=Gordon Flynn;,citation_author=Claire Harrington;,citation_author=Peter Kruger;,citation_author=James Walsham;,citation_author=Jason Meyer;,citation_author=Meg Harward;,citation_author=Josephine Mackay;,citation_author=Cassie Jones;,citation_author=Sonia Sathe;,citation_author=Lisa Roche;,citation_author=Ellie Davies;,citation_author=Denise Skinner;,citation_author=Jane Gaylard;,citation_author=Julie Newman;,citation_author=David Pogson;,citation_author=Steve Rose;,citation_author=Zoe Daly;,citation_author=Lutece Brimfield;,citation_author=Angie Nown;,citation_author=Dhruv Parekh;,citation_author=Colin Bergin;,citation_author=Michelle Bates;,citation_author=Christopher McGhee;,citation_author=Daniella Lynch;,citation_author=Khushpreet Bhandal;,citation_author=Kyriaki Tsakiridou;,citation_author=Amy Bamford;,citation_author=Lauren Cooper;,citation_author=Tony Whitehouse;,citation_author=Tonny Veenith;,citation_author=Elliot Forster;,citation_author=Martin O’Connell;,citation_author=Shannon Page;,citation_author=Nafeesah Haider;,citation_author=Nick Adams;,citation_author=Malcolm Sim;,citation_author=Sophie Hay;,citation_author=Steven Henderson;,citation_author=Eliza Valentine;,citation_author=Maximillian Ralston;,citation_author=Gordan McCreath;,citation_author=Andrew Arnott;,citation_author=Izabela Orlikowska;,citation_author=Natasha Parker;,citation_author=Amro Katary;,citation_author=Gillian Bell;,citation_author=Louise Wilcox;,citation_author=Michail Mataliotakis;,citation_author=Paul Smith;,citation_author=Murtaza Ali;,citation_author=Agah Isguzar;,citation_author=Mandeep-Kaur Phull;,citation_author=Abbas Zaidi;,citation_author=Tatiana Pogreban;,citation_author=Lace Rosaroso;,citation_author=Neale O’Brien;,citation_author=Elisa Visentin;,citation_author=Daniel Harvey;,citation_author=Benjamin Lowe;,citation_author=Megan Meredith;,citation_author=Lucy Ryan;,citation_author=Amy Clark;,citation_author=Cecilia Peters;,citation_author=Catherine Walton;,citation_author=Treesa Joseph;,citation_author=Alexandra Gibbins;,citation_author=Julia Sampson;,citation_author=Lucy Morris;,citation_author=Martin Dent;,citation_author=Theerata Haghi;,citation_author=Jeroen Schouten;,citation_author=Peter Pickkers;,citation_author=Noortje Roovers;,citation_author=Margreet Klop-Riehl;,citation_author=Hetty Van Der Eng;,citation_author=Frank Van De Veerdonk;,citation_author=Sonja Sloots-Cuppen;,citation_author=Lieke Preijers;,citation_author=Margot Polfliet;,citation_author=Nicholas Heming;,citation_author=Pierre Moine;,citation_author=Virginie Maxime;,citation_author=Isabelle Bossard;,citation_author=Tiphaine Nicholier;,citation_author=Bernard Clair;,citation_author=David Orlikowski;,citation_author=Rania Bounab;,citation_author=Lilia Abdeladim;,citation_author=Stuart Baker;,citation_author=Alexis Tabah;,citation_author=Maree Duroux;,citation_author=Megan Ratcliffe;,citation_author=Eric Sy;,citation_author=Jonathan Mailman;,citation_author=Stephen Lee;,citation_author=Sandy Kassir;,citation_author=Jenna England;,citation_author=Rafael López;,citation_author=Jorge Rodríguez-Gómez;,citation_author=Sheila Cárcel;,citation_author=Rosario Carmona;,citation_author=Carmen Fuente;,citation_author=Marina Rodriguez;,citation_author=Julian De La Torre Cisneros;,citation_author=Robert Jan Hassing;,citation_author=Frances Greven;,citation_author=Danique Huijbens;,citation_author=Harald Roebers;,citation_author=L Robers;,citation_author=Helen Miles;,citation_author=Antony Attokaran;,citation_author=Ulrike Buehner;,citation_author=Erin Williams;,citation_author=Mark Plummer;,citation_author=Stephanie O’Connor;,citation_author=Kathleen Glasby;,citation_author=Justine Rivett;,citation_author=Nerissa Brown;,citation_author=Demetrios Kutsogiannis;,citation_author=Raiyan Chowdhury;,citation_author=Jon Davidow;,citation_author=Curtis Johnston;,citation_author=Michael Kim;,citation_author=Kimberley Macala;,citation_author=Darren Markland;,citation_author=Doug Matheson;,citation_author=Arabesque Parker;,citation_author=Damian Paton-Gay;,citation_author=Andrea Robinson;,citation_author=Patricia Thompson;,citation_author=Tayne Hewer;,citation_author=Kevin Rooney;,citation_author=Natalie Rodden;,citation_author=Nicola Thomson;,citation_author=Deborah McGlynn;,citation_author=Lynn Abel;,citation_author=Lisa Gemmell;,citation_author=Radha Sundaram;,citation_author=James Hornsby;,citation_author=Andrew Walden;,citation_author=Liza Keating;,citation_author=Matthew Frise;,citation_author=Sabi Rai;,citation_author=Shauna Bartley;,citation_author=Martin Schuster-Bruce;,citation_author=Sally Pitts;,citation_author=Rebecca Miln;,citation_author=Laura Purandare;,citation_author=Luke Vamplew;,citation_author=Brijesh Patel;,citation_author=Debra Dempster;,citation_author=Mahitha Gummadi;,citation_author=Natalie Dormand;,citation_author=Shu Wang;,citation_author=Michael Spivey;,citation_author=Sarah Bean;,citation_author=Karen Burt;,citation_author=Lorraine Moore;,citation_author=Fiona Hammonds;,citation_author=Carol Richards;,citation_author=Rachel Chapman;,citation_author=Thomas Cornell;,citation_author=Lewis Campbell;,citation_author=Kirsty Smyth;,citation_author=Elizabeth Ross;,citation_author=Brittney Mackenzie;,citation_author=Christopher Day;,citation_author=Letizia Zitter;,citation_author=Sarah Benyon;,citation_author=Jayaprakash Singh;,citation_author=Ceri Lynch;,citation_author=Justyna Mikusek;,citation_author=Bethan Deacon;,citation_author=Keri Turner;,citation_author=Evelyn Baker;,citation_author=John Hickey;,citation_author=Shreekant Champanerkar;,citation_author=Lindianne Aitken;,citation_author=Lorraine LewisProsser;,citation_author=Norfaizan Ahmad;,citation_author=Matt Wiles;,citation_author=Jayne Willson;,citation_author=Irina Grecu;,citation_author=Jane Martin;,citation_author=Caroline Wrey Brown;,citation_author=Ana-Marie Arias;,citation_author=Emily Bevan;,citation_author=Samantha Westlake;,citation_author=Thomas Craven;,citation_author=David Hope;,citation_author=Jo Singleton;,citation_author=Sarah Clark;,citation_author=Corrienne McCulloch;,citation_author=Simon Biddie;,citation_author=Lucy Marshall;,citation_author=Sophie Birch;,citation_author=Kate Britton;,citation_author=Ingeborg Welters;,citation_author=David Hamilton;,citation_author=Karen Williams;,citation_author=David Shaw;,citation_author=Suleman Mulla;,citation_author=Alicia Waite;,citation_author=Jaime Roman;,citation_author=Maria Martinez;,citation_author=Brian Johnston;,citation_author=Laura Medhurst;,citation_author=Stephanie Beresford;,citation_author=Robert Ayee;,citation_author=Zudin Puthucheary;,citation_author=Timothy Martin;,citation_author=Filipa Santos;,citation_author=Ruzena Uddin;,citation_author=Maria Fernandez;,citation_author=Fatima Seidu;,citation_author=Alastair Somerville;,citation_author=Mari-Liis Pakats;,citation_author=Salma Begum;,citation_author=Tasnin Shahid;,citation_author=Priya Dias;,citation_author=Jeffrey Presneill;,citation_author=Deborah Barge;,citation_author=Kathleen Byrne;,citation_author=Alain Vuylsteke;,citation_author=Charles Chan;,citation_author=Saji Victor;,citation_author=Sharon Waterson;,citation_author=Robert McNamara;,citation_author=Melanie Boardman;,citation_author=David Gattas;,citation_author=Heidi Buhr;,citation_author=Jennifer Coles;,citation_author=Ramprasad Matsa;,citation_author=Minerva Gellamucho;,citation_author=Elisa Sernicola;,citation_author=Lucy Bailey;,citation_author=Ben Creagh-Brown;,citation_author=Cheryl Marriot;,citation_author=Armorel Salberg;,citation_author=Louisa Zouita;,citation_author=Sarah Stone;,citation_author=Natalia Michalak-Glinska;,citation_author=Sinead Donlon;,citation_author=Shelia Mtuwa;,citation_author=Irving Mayangao;,citation_author=Jerik Verula;,citation_author=Dorota Burda;,citation_author=Celia Harris;,citation_author=Emily Jones;,citation_author=Paul Bradley;,citation_author=Esther Tarr;,citation_author=Lesley Harden;,citation_author=Charlie Piercy;,citation_author=Eleanor Smith;,citation_author=Jerry Nolan;,citation_author=Ian Kerslake;,citation_author=Tim Cook;,citation_author=Tom Simpson;,citation_author=James Dalton;,citation_author=Carrie Demetriou;,citation_author=Sarah Mitchard;,citation_author=Lidia Ramos;,citation_author=Katie White;,citation_author=Toby Johnson;,citation_author=William Headdon;,citation_author=Stephen Spencer;,citation_author=Alison White;,citation_author=Lucy Howie;,citation_author=Natalie Smith;,citation_author=Phillip Riddell;,citation_author=Sarah Hierons;,citation_author=Gabrielle Evans;,citation_author=Giulio Didiodato;,citation_author=Ana Igric;,citation_author=Kelly Cruise;,citation_author=Ian Ding;,citation_author=Victoria Shelep;,citation_author=Debra Pietersen;,citation_author=Sujata Pokhrel;,citation_author=Michael Reay;,citation_author=Steve Jenkins;,citation_author=Angela Watts;,citation_author=Eleanor Traverse;,citation_author=Stacey Jennings;,citation_author=Vikram Anumakonda;,citation_author=Caroline Tuckwell;,citation_author=Kath Harrow;,citation_author=Julie Matthews;,citation_author=Karen McGarry;,citation_author=Vanessa Moore;,citation_author=Lucie Smith;,citation_author=Anna Summerfield;,citation_author=Paul Dark;,citation_author=Alice Harvey;,citation_author=Reece Doonan;,citation_author=Liam McMorrow;,citation_author=Karen Knowles;,citation_author=Jessica Pendlebury;,citation_author=Stephanie Lee;,citation_author=Jane Perez;,citation_author=Tracy Marsden;,citation_author=Melanie Taylor;,citation_author=Angiy Michael;,citation_author=Matthew Collis;,citation_author=Andrew Claxton;,citation_author=Wadih Habeichi;,citation_author=Dan Horner;,citation_author=Melanie Slaughter;,citation_author=Vicky Thomas;,citation_author=Nicola Proudfoot;,citation_author=Claire Keatley;,citation_author=Danielle Mclaughlan;,citation_author=Phil Donnison;,citation_author=Ruth Casey;,citation_author=Ben Irving;,citation_author=Wadzanai Matimba-Mupaya;,citation_author=Catherine Reed;,citation_author=Alpha Anthony;,citation_author=Fiona Trim;,citation_author=Lenka Cambalova;,citation_author=Debra Robertson;,citation_author=Anna Wilson;,citation_author=Beena Eapen;,citation_author=Jonathan Hulme;,citation_author=Santhana Kannan;,citation_author=Fiona Kinney;,citation_author=Ho Senya;,citation_author=Anne Hayes;,citation_author=Kristina Diridis;,citation_author=Balaji Ramamurthi;,citation_author=John Bleasdale;,citation_author=Nabih Mokhtar;,citation_author=David Newbould;,citation_author=Anand Arora;,citation_author=Rupali Saluja;,citation_author=Deepak Sharma;,citation_author=Khalid Haiba;,citation_author=Kieran Donnelly;,citation_author=Nick Sherwood;,citation_author=Sibet Joseph;,citation_author=Sarah Potter;,citation_author=Lavinia Henry;,citation_author=Valli Ratnam;,citation_author=Mandy Gill;,citation_author=Jill Kirk;,citation_author=Sarah Shelton;,citation_author=Sacha Schweikert;,citation_author=Bradley Wibrow;,citation_author=Bhaumik Mevavala;,citation_author=Namra Asif;,citation_author=Muhamad Nasir Khoso;,citation_author=Huda Taqdees;,citation_author=Christian Frey;,citation_author=Riccardo Scano;,citation_author=Madeleine McKee;,citation_author=Peter Murphy;,citation_author=Matt Thomas;,citation_author=Ruth Worner;,citation_author=Beverley Faulkner;,citation_author=Emma Gendall;,citation_author=Kati Hayes;,citation_author=Hayley Blakemore;,citation_author=Borislava Borislavova;,citation_author=Kerry Smith;,citation_author=Deanna Stephens;,citation_author=Kush Deshpande;,citation_author=Frank Van Haren;,citation_author=Pam Konecny;,citation_author=Deborah Inskip;,citation_author=Raymond Tung;,citation_author=Leanne Hayes;,citation_author=Lorna Murphy;,citation_author=Andy Neill;,citation_author=Bryan Reidy;,citation_author=Michael O’Dwyer;,citation_author=Donal Ryan;,citation_author=Kate Ainscough;,citation_author=Colin Hamilton-Davies;,citation_author=Carmen Chan;,citation_author=Celina Mfuko;,citation_author=Hakam Abbass;,citation_author=Vineela Mandadapu;,citation_author=Susannah Leaver;,citation_author=Kamal Patel;,citation_author=Sarah Farnell-Ward;,citation_author=Romina Saluzzio;,citation_author=Sam Rawlins;,citation_author=Christine Sicat;,citation_author=Edna Fernandes;,citation_author=Bart De Keulenaer;,citation_author=Janet Ferrier;,citation_author=Ed Fysh;,citation_author=Ashlish Davda;,citation_author=Waleed Al-Hazzani;,citation_author=Tania Ligori;,citation_author=Mark Soth;,citation_author=France Clarke;,citation_author=Karlo Matic;,citation_author=Mary Copland;,citation_author=Neala Hoad;,citation_author=Ashley Sawyer;,citation_author=Dorota Banach;,citation_author=Ziortza Fernández De Pinedo Artaraz;,citation_author=Leilani Cabreros;,citation_author=Victoria Latham;,citation_author=Jenny Wong;,citation_author=Anita Gurung;,citation_author=Amal Mohammed;,citation_author=Eleanor Jepson;,citation_author=Rebecca Kruisselbrink;,citation_author=Laurent Brochard;,citation_author=Karen Burns;,citation_author=Gyan Sandhu;,citation_author=Imrana Khalid;,citation_author=Ian White;,citation_author=Maria Croft;,citation_author=Nicky Holland;,citation_author=Rita Pereira;,citation_author=Victoria Frost;,citation_author=Karen Wells;,citation_author=Teri Chin;,citation_author=Maia Aquino;,citation_author=Priya Nair;,citation_author=Hergen Buscher;,citation_author=Claire Reynolds;,citation_author=Alexandra Campion;,citation_author=Amelia Hall;,citation_author=John Santamaria;,citation_author=Tim Haydon;,citation_author=Jennifer Homes;,citation_author=Ahmed Zaki;,citation_author=David Johnson;,citation_author=Hywel Garrard;,citation_author=Vera Juhaz;,citation_author=Louise Brown;,citation_author=Abigail Pemberton;,citation_author=Alistair Roy;,citation_author=Anthony Rostron;,citation_author=Lindsey Woods;,citation_author=Sarah Cornell;,citation_author=Andre Amaral;,citation_author=Federico Angriman;,citation_author=Brian Cuthbertson;,citation_author=Rob Fowler;,citation_author=Dominique Piquette;,citation_author=Damon Scales;,citation_author=Bourke Tillman;,citation_author=Nicole Marinoff;,citation_author=Navjot Kaur;,citation_author=Zoya Adeel;,citation_author=Maneesha Kamra;,citation_author=Hamzah Khan;,citation_author=Deeptha Murali;,citation_author=Pinto Ruxandra;,citation_author=Thivya Sabananthan;,citation_author=Thuva Sugumaran;,citation_author=Peter Garrett;,citation_author=Lauren Murray;,citation_author=Jane Brailsford;,citation_author=Suresh Pillai;,citation_author=Rachel Harford;,citation_author=Helen Ivatt;,citation_author=Debra Evans;,citation_author=Suzanne Richards;,citation_author=Eilir Roberts;,citation_author=James Bowen;,citation_author=James Ainsworth;,citation_author=Marie Williams;,citation_author=Anne Kuitunen;,citation_author=Sari Karlsson;,citation_author=Annukka Vahtera;,citation_author=Heikki Kiiski;,citation_author=Sanna Ristimäki;,citation_author=Jonathan Albrett;,citation_author=Carolyn Jackson;,citation_author=Simon Kirkham;,citation_author=Kadri Tamme;,citation_author=Veronika Reinhard;,citation_author=Anneli Ellervee;,citation_author=Liisi Põldots;,citation_author=Pille Rennit;,citation_author=Nikolai Svitškar;,citation_author=Jonathan Chen;,citation_author=Amanda Miller;,citation_author=Phoebe McCracken;,citation_author=Meredith Young;,citation_author=Jasmin Board;,citation_author=Emma Martin;,citation_author=Vidya Kasipandian;,citation_author=Amit Patel;,citation_author=Suzanne Allibone;,citation_author=Roman Mary-Genetu;,citation_author=Shane English;,citation_author=Andrew Seely;,citation_author=Lauralyn McIntyre;,citation_author=Irene Watpool;,citation_author=Rebecca Porteous;,citation_author=Sydney Miezitis;,citation_author=Jessica Haines;,citation_author=Kara Brady;,citation_author=Cassandra Vale;,citation_author=Kiran Shekar;,citation_author=Jayshree Lavana;,citation_author=Dinesh Parmar;,citation_author=Sandra Peake;,citation_author=Patricia Williams;,citation_author=Catherine Kurenda;,citation_author=Gayathri Wijewardena;,citation_author=Anil Hormis;,citation_author=Rachel Walker;,citation_author=Dawn Collier;,citation_author=Sarah Kimpton;,citation_author=Susan Oakley;,citation_author=Cheryl Graham;,citation_author=Victoria Maynard;,citation_author=Sanjay Bhagani;,citation_author=Mark De Neef;,citation_author=Sara Garcia;,citation_author=Amitaa Maharajh;,citation_author=Aarti Nandani;,citation_author=Jade Dobson;,citation_author=Gloria Fernando;,citation_author=Christine Eastgate;,citation_author=Keith Gomez;,citation_author=Zakee Abdi;,citation_author=Glykeria Pakou;,citation_author=Kate Tatham;,citation_author=Shaman Jhanji;,citation_author=Ethel Black;,citation_author=Arnold Dela Rosa;,citation_author=Ryan Howle;,citation_author=Ravishankar Baikady;,citation_author=Redmond Tully;,citation_author=Andrew Drummond;,citation_author=Joy Dearden;,citation_author=Jennifer Philbin;,citation_author=Sheila Munt;,citation_author=Shameer Gopal;,citation_author=Jagtar-Singh Pooni;,citation_author=Saibal Ganguly;,citation_author=Andrew Smallwood;,citation_author=Stella Metherell;,citation_author=Anas Naeem;,citation_author=Laura Fagan;,citation_author=Elizabeth Turner;,citation_author=Vasanth Mariappa;,citation_author=Judith Smith;,citation_author=Angela Foulds;,citation_author=Adam Revill;,citation_author=Binita Bhattarai;,citation_author=Sabi Maharjan;,citation_author=Radhika Maharjan;,citation_author=Aarti Phuyal;,citation_author=Namrata Shrestha;,citation_author=Karina Meijer;,citation_author=Douwe Postma;,citation_author=Karen Thedinga;,citation_author=Evert De Jonge;,citation_author=Jeanette Wigbers;,citation_author=Michael Prado;,citation_author=Olaf Cremer;,citation_author=Jelle Mulier;,citation_author=Emma Rademaker;,citation_author=Anna Peters;,citation_author=Birgit Romberg;,citation_author=Helen Leavis;,citation_author=Roger Schutgens;,citation_author=Darren Troeman;,citation_author=Marjolein Opdorp;,citation_author=Henny Besten;,citation_author=Karen Brakké;,citation_author=Russell Barber;,citation_author=Anette Hilldrith;,citation_author=Andrew Sloan;,citation_author=Maryanne Okubanjo;,citation_author=Olesya Francis;,citation_author=Stephanie Barker;,citation_author=Susan Butler;,citation_author=Claire Hewitt;,citation_author=Kelvin Lee;,citation_author=Silvia Tavares;,citation_author=Stefan Kluge;,citation_author=Axel Nierhaus;,citation_author=Dominik Jarczak;,citation_author=Kevin Roedl;,citation_author=Matthias Kochanek;,citation_author=Giusi Rueß-Paterno;,citation_author=Josette Mc-Kenzie;,citation_author=Dennis Eichenauer;,citation_author=Alexander Shimabukuro-Vornhagen;,citation_author=Siri Göpel;,citation_author=Simone Eisenbeis;,citation_author=Reimer Rissen;,citation_author=Nadine Conzelmann;,citation_author=Elizabeth Wilcox;,citation_author=Lorenzo Del Sorbo;,citation_author=Hesham Abdelhady;,citation_author=Tina Romagnuolo;,citation_author=Scott Simpson;,citation_author=Matthew Maiden;,citation_author=Michelle Horton;,citation_author=Jemma Trickey;,citation_author=Farooq Brohi;,citation_author=Vijay Jagannathan;,citation_author=Michele Clark;,citation_author=Sarah Purvis;,citation_author=Bill Wetherill;,citation_author=Ahilanandan Dushianthan;,citation_author=Rebecca Cusack;,citation_author=Kim De Courcy-Golder;,citation_author=Karen Salmon;,citation_author=Rachel Burnish;,citation_author=Simon Smith;,citation_author=Susan Jackson;,citation_author=Winningtom Ruiz;,citation_author=Zoe Duke;,citation_author=Magaret Johns;,citation_author=Michelle Male;,citation_author=Kirsty Gladas;,citation_author=Satwinder Virdee;,citation_author=Jacqueline Swabe;,citation_author=Helen Tomlinson;,citation_author=Alice Baker;,citation_author=Michael Carter;,citation_author=Belinda Roberts;,citation_author=Emma Greene;,citation_author=Gernot Rohde;,citation_author=Achim Grünewaldt;,citation_author=Jörg Bojunga;,citation_author=Sirak Petros;,citation_author=Bastian Pasieka;,citation_author=Kevin Kunz;,citation_author=Svenja Laudi;,citation_author=Antje Seidel;,citation_author=Hannah Ullmann;,citation_author=Christian Schlegel;,citation_author=Dirk Weismann;,citation_author=Anna Frey;,citation_author=Maria Drayss;,citation_author=M. E. Goebeler;,citation_author=Thomas Flor;,citation_author=Gertrud Fragner;,citation_author=Nadine Wahl;,citation_author=Juliane Totzke;,citation_author=Cyrus Sayehli;,citation_author=Jeremy Bewley;,citation_author=Katie Sweet;,citation_author=Lisa Grimmer;,citation_author=Rebekah Johnson;,citation_author=Rachel Wyatt;,citation_author=Karen Morgan;,citation_author=Siby Varghese;,citation_author=Joanna Willis;,citation_author=Emma Stratton;,citation_author=Laura Kyle;,citation_author=Daniel Putensen;,citation_author=Kay Drury;,citation_author=Agnieszka Skorko;,citation_author=Abbie Dell;,citation_author=Kim Wright;,citation_author=Denise Webster;,citation_author=Kathleen Corcoran;,citation_author=Angeliki Kolovou;,citation_author=Georgia Efford;,citation_author=Liz McCullagh;,citation_author=Pamela Bremmer;,citation_author=Geraldine Ward;,citation_author=Christopher Bassford;,citation_author=Wendy Sligl;,citation_author=Nadia Baig;,citation_author=Oleksa Rewa;,citation_author=Sean Bagshaw;,citation_author=Andrej Markota;,citation_author=Žiga Kalamar;,citation_author=Franc Svenšek;,citation_author=Martin Marinšek;,citation_author=Jure Fluher;,citation_author=Katja Jerenec;,citation_author=Barbara Kit;,citation_author=Iris Živko;,citation_author=Kelsey Linstrum;,citation_author=Kim Basile;,citation_author=Dara Stavor;,citation_author=Dylan Burbee;,citation_author=Amanda McNamara;,citation_author=Renee Wunderley;,citation_author=Nicole Bensen;,citation_author=Aaron Richardson;,citation_author=Peter Adams;,citation_author=Tina Vita;,citation_author=Megan Buhay;,citation_author=Denise Scholl;,citation_author=Matthew Gilliam;,citation_author=James Winters;,citation_author=Kaleigh Doherty;,citation_author=Emily Berryman;,citation_author=Mehrdad Ghaffari;,citation_author=Oscar Marroquin;,citation_author=Kevin Quinn;,citation_author=William Garrard;,citation_author=Kyle Kalchthaler;,citation_author=Gregory Beard;,citation_author=Aimee Skrtich;,citation_author=Kavitha Bagavathy;,citation_author=Debra Drapola;,citation_author=Alan Wells;,citation_author=Kayla Bryan-Morris;,citation_author=John Arnold;,citation_author=Bob Reynolds;,citation_author=Mahwish Hussain;,citation_author=Janice Dunsavage;,citation_author=Salim Saiyed;,citation_author=Erik Hernandez;,citation_author=John Goldman;,citation_author=Cynthia Brown;,citation_author=Susan Comp;,citation_author=James Raczek;,citation_author=Jenny Morris;,citation_author=Jesus Vargas Jr.;,citation_author=Daniel Weiss;,citation_author=Joseph Hensley;,citation_author=Erik Kochert;,citation_author=Chris Wnuk;,citation_author=Christopher Nemeth;,citation_author=Brent Mowery;,citation_author=Christina Hutchinson;,citation_author=Lauren Winters;,citation_author=David McAdams;,citation_author=Gena Walker;,citation_author=Tami Minnier;,citation_author=Mary Wisniewski;,citation_author=Katelyn Mayak;,citation_author=Erin McCreary;,citation_author=Elise Martin;,citation_author=Ryan Bariola;,citation_author=Alex Viehman;,citation_author=Jessica Daley;,citation_author=Alyssa Lopus;,citation_author=Mark Schmidhofer;,citation_author=Richard Ambrosino;,citation_author=Sherbrina Keen;,citation_author=Sue Toffalo;,citation_author=Martha Stambaugh;,citation_author=Ken Trimmer;,citation_author=Reno Perri;,citation_author=Sherry Casali;,citation_author=Rebecca Medva;,citation_author=Brent Massar;,citation_author=Ashley Beyerl;,citation_author=Jason Burkey;,citation_author=Sheryl Keeler;,citation_author=Maryalyce Lowery;,citation_author=Lynne Oncea;,citation_author=Jason Daugherty;,citation_author=Chanthou Sevilla;,citation_author=Amy Woelke;,citation_author=Julie Dice;,citation_author=Lisa Weber;,citation_author=Jason Roth;,citation_author=Cindy Ferringer;,citation_author=Deborah Beer;,citation_author=Jessica Fesz;,citation_author=Lillian Carpio;,citation_author=Gwenhael Colin;,citation_author=Vanessa Zinzoni;,citation_author=Natacha Maquigneau;,citation_author=Matthieu Henri-Lagarrigue;,citation_author=Caroline Pouplet;,citation_author=Lorenz Reill;,citation_author=Michael Distler;,citation_author=Astrid Maselli;,citation_author=Robert Martynoga;,citation_author=Kara Trask;,citation_author=Amelia Butler;,citation_author=Jessica Newlands;,citation_author=Kelly Henderson;,citation_author=Ben Attwood;,citation_author=Penny Parsons;,citation_author=Bridget Campbell;,citation_author=Alex Smith;,citation_author=Sheeba Hakak;,citation_author=Aisling Murphy;,citation_author=Kirsten Joyce;,citation_author=Valerie Page;,citation_author=Xiao Zhao;,citation_author=Deepali Oza;,citation_author=Gail Abrahamson;,citation_author=Ben Sheath;,citation_author=Chiara Ellis;,citation_author=Mark Guanco;,citation_author=Elvira Hoxha;,citation_author=Ahmed Hegazy;,citation_author=Nazril Nordin;,citation_author=Lynn Denham;,citation_author=Paul Young;,citation_author=Eden Lesona;,citation_author=Leanlove Navarra;,citation_author=Kirsha Delaney;,citation_author=Joy Marmol;,citation_author=Reece Latino;,citation_author=Shan Qiu;,citation_author=Maree Monaghan;,citation_author=Jonathan Rhodes;,citation_author=Thomas Anderson;,citation_author=Sheila Morris;,citation_author=Yasser Madani;,citation_author=Vineet Nayyar;,citation_author=David Bowen;,citation_author=Jing Kong;,citation_author=Angelica Monzon;,citation_author=Ralph Fuchs;,citation_author=Bridget Lambert;,citation_author=Charlotte Tai;,citation_author=Amy Thomas;,citation_author=Alexandra Keen;,citation_author=Carey Tierney;,citation_author=Nimca Omer;,citation_author=Gina Bacon;,citation_author=Amy Evans;,citation_author=Alexandra Binnie;,citation_author=Elizabeth Powell;,citation_author=Alexandra McMillan;,citation_author=Tracy Luk;,citation_author=Noah Aref;,citation_author=Craig Denmade;,citation_author=Girendra Sadera;,citation_author=Reni Jacob;,citation_author=Cathy Jones;,citation_author=Debbie Hughes;,citation_author=Ahmad Elgendy;,citation_author=Wenli Geng;,citation_author=Stephen Digby;,citation_author=David Southern;,citation_author=Harsha Reddy;,citation_author=Sarah Hulse;,citation_author=Andrew Campbell;,citation_author=Mark Garton;,citation_author=Claire Watkins;,citation_author=Sara Smuts;,citation_author=Stephanie The;,citation_author=Oliver Smith;,citation_author=John Harris;,citation_author=Alison Quinn;,citation_author=Benjamin Simpson;,citation_author=Catherine McMillan;,citation_author=Cheryl Finch;,citation_author=Claire Hill;,citation_author=Josh Cooper;,citation_author=Michael Brittain;,citation_author=Hoon Teo;,citation_author=Natalia Waddington;,citation_author=Joanna Budd;,citation_author=Charlotte Small;,citation_author=Ryan O’Leary;,citation_author=Janine Birch;,citation_author=Emma Collins;,citation_author=Andrew Holland;,citation_author=Peter Alexander;,citation_author=Tim Felton;,citation_author=Susan Ferguson;,citation_author=Katharine Sellers;,citation_author=Luke Ward;,citation_author=Andrew Bentley;,citation_author=Sofia Fiouni;,citation_author=David Yates;,citation_author=Isobel Birkinshaw;,citation_author=Kay Kell;,citation_author=Zoe Scott;,citation_author=Harriet Pearson;,citation_author=Bastiaan Wittekamp;,citation_author=Bart Grady;,citation_author=Ellen Platenkamp;,citation_author=Madiha Hashmi;,citation_author=Maryam Ali;,citation_author=Noor Hassan;,citation_author=Ashok Panjwani;,citation_author=Zulfiqar Umrani;,citation_author=Mohiuddin Shaikh;,citation_author=Ayesha Siddiqui;,citation_author=Quratul Ain;,citation_author=Darakhshan Kanwal;,citation_author=Sjoerd Van Bree;,citation_author=Marianne Bouw-Ruiter;,citation_author=Margreet Osinga;,citation_author=Arthur Van Zanten;,citation_author=Neill Kj Adhikari;,citation_author=Djillali Annane;,citation_author=Marie-Claude Battista;,citation_author=Dian Cohen;,citation_author=Deborah Cook;,citation_author=Andrew Day;,citation_author=Gordon Guyatt;,citation_author=Daren Heyland;,citation_author=Salmaan Kanji;,citation_author=Bharath Kumar Tirupakuzhi Vijayaraghavan;,citation_author=Francois Lamontagne;,citation_author=Marie-Helene Masse;,citation_author=Shay McGuinness;,citation_author=Julie Menard;,citation_author=Rachael Parke;,citation_author=Ruxandra Pinto;,citation_author=Sheila Sprague;,citation_author=Lucie Bouffard;,citation_author=Ari Gritsas;,citation_author=Lisa Buckingham;,citation_author=Amélie Têtu;,citation_author=Francis Malenfant;,citation_author=Pierre Turcotte;,citation_author=Farah Al-Beidh;,citation_author=Derek Angus;,citation_author=Djillai Annane;,citation_author=Yaseen Arabi;,citation_author=Abigail Beane;,citation_author=Scott Berry;,citation_author=Zahra Bhimani;,citation_author=Marc Bonten;,citation_author=Charlotte Bradbury;,citation_author=Franck Brunkhorst;,citation_author=Aidan Burrell;,citation_author=Meredith Buxton;,citation_author=Maurizio Cecconi;,citation_author=Allen Cheng;,citation_author=Matthew Cove;,citation_author=Lennie Derde;,citation_author=Lise Escourt;,citation_author=Herman Goossens;,citation_author=Anthony Gordon;,citation_author=Camron Green;,citation_author=Rashan Haniffa;,citation_author=Thomas Hill;,citation_author=David Huang;,citation_author=Nao Ichihara;,citation_author=Patrick Lawler;,citation_author=John Marshall;,citation_author=Colin McArthur;,citation_author=Daniel McAuley;,citation_author=Zoe McGQuilten;,citation_author=Bryan McVerry;,citation_author=Paul Mouncey;,citation_author=Srinivas Murthy;,citation_author=Alistair Nichol;,citation_author=Jane Parker;,citation_author=Luis Felipe Reyes;,citation_author=Kathryn Rowan;,citation_author=Hiroki Saito;,citation_author=Marlene Santos;,citation_author=Christopher Seymour;,citation_author=Manu Shankar-Hari;,citation_author=Alexis Turgeon;,citation_author=Anne Turner;,citation_author=Steve Webb;,citation_author=Ryan Zarychanski;,citation_author=Rebecca McEldrew;,citation_author=Shirish Kc;,citation_author=Timo Tolppa;,citation_author=Sumayyah Rashan;,citation_author=Vanessa Singh;,citation_author=Wilma Van Bentum-Puijk;,citation_author=Curt Brugman;,citation_author=Erika Groeneveld;,citation_author=Mina Jafarzadeh;,citation_author=Irene Jongenelen;,citation_author=Nicole Keijzer-Timmers;,citation_author=Esmee Kester;,citation_author=Maaike Koelink;,citation_author=Clementina Okundaye;,citation_author=Lorraine Parker;,citation_author=Sonal Patil;,citation_author=Svenja Peters;,citation_author=Ilse Rietveld;,citation_author=Sarah Sayada;,citation_author=Albertine Smit;,citation_author=Roosmarijn Van Amerongen;,citation_author=Janine Vermont - Van Der Staaij;,citation_author=Peter Doran;,citation_author=Aisha Anjum;,citation_author=Carly Au;,citation_author=Janis-Best Lane;,citation_author=Elizabeth Fagboden;,citation_author=Frances Barton;,citation_author=Walton Charles;,citation_author=Lorna Miller;,citation_author=Karen Parry-Billings;,citation_author=Sam Peters;,citation_author=Alvin Richards-Belle;,citation_author=Michelle Saull;,citation_author=Stefan Sprinckmoller;,citation_author=Daisy Wiley;,citation_author=Robert Darnell;,citation_author=Lucy Stronach;,citation_author=Asako Wada;,citation_author=Besa Beqaj;,citation_author=Andrew Forbes;,citation_author=Cameron Green;,citation_author=Stephane Heritier;,citation_author=Thomas Hills;,citation_author=Bec McEldrew;,citation_author=Zoe McQuilten;,citation_author=Tony Trapani;,citation_author=Venika Manoharan;,citation_author=Arjen M Dondrop;,citation_author=Mohd Shahnaz Bin Hasan;,citation_author=Devachandran Jayakumar;,citation_author=Ismail Kalla;,citation_author=Lyle Murray;,citation_author=Wangari Siika;,citation_author=Frank Brunkhorst;,citation_author=Stephan Ehrmann;,citation_author=Pedro Povoa;,citation_author=Chrisptopher Horvat;,citation_author=Yohei Doi;,citation_author=Shigeki Fujitani;,citation_author=Hitoshi Honda;,citation_author=Kazuaki Jindai;,citation_author=Kazuhiro Kamata;,citation_author=Hideaki Kato;,citation_author=Hiroyuki Kunishima;,citation_author=Kenichi Nakazono;,citation_author=Ayumi Shintani;,citation_author=Yoshiaki Yamagishi;,citation_author=Chizuru Yamashita;,citation_author=Richard Beasley;,citation_author=Nick Daneman;,citation_author=Robert Fowler;,citation_author=Steve McGloughlin;,citation_author=David Paterson;,citation_author=Sebastiaan Hullegie;,citation_author=Edward Litton;,citation_author=Srinivas Murphy;,citation_author=Bala Venkatesh;,citation_author=Menno De Jong;,citation_author=Tim Uyeki;,citation_author=Kenneth Baillie;,citation_author=Mihai Netea;,citation_author=Katrina Orr;,citation_author=Asad Patanwala;,citation_author=Steve Tong;,citation_author=Nichola Cooper;,citation_author=James Galea;,citation_author=Kayode Ogungbenro;,citation_author=Asad Patawala;,citation_author=Steven Tong;,citation_author=Taryn Youngstein;,citation_author=Marc Carrier;,citation_author=Dean Fergusson;,citation_author=Ewan Goligher;,citation_author=Beverley Hunt;,citation_author=Anand Kumar;,citation_author=Mike Laffan;,citation_author=Sylvain Lother;,citation_author=Saskia Middledorp;,citation_author=Matthew Neal;,citation_author=Simon Stanworth;,citation_author=Matthew Anstey;,citation_author=Angelique De Man;,citation_author=Andrew Udy;,citation_author=Jacinta Abraham;,citation_author=Donald Arnold;,citation_author=Phillipe Begin;,citation_author=Richard Charlewood;,citation_author=Michael Chasse;,citation_author=Jamie Cooper;,citation_author=Mark Coyne;,citation_author=James Daly;,citation_author=Lise Estcourt;,citation_author=Iain Gosbell;,citation_author=Heli Harvala-Simmonds;,citation_author=Tom Hills;,citation_author=Sheila MacLennan;,citation_author=John McDyer;,citation_author=David Menon;,citation_author=Nicole Pridee;,citation_author=David Roberts;,citation_author=Helen Thomas;,citation_author=Alan Tinmouth;,citation_author=Darrell Triulzi;,citation_author=Tim Walsh;,citation_author=Erica Wood;,citation_author=Carolyn Calfee;,citation_author=Cecilia O’Kane;,citation_author=Murali Shyamsundar;,citation_author=Pratik Sinha;,citation_author=Taylor Thompson;,citation_author=Ian Young;,citation_author=Niall Ferguson;,citation_author=Carol Hodgson;,citation_author=Ary Neto;,citation_author=Neil Orford;,citation_author=Jason Phua;,citation_author=Rebecca Baron;,citation_author=Slava Epelman;,citation_author=Justin Ezekowitz;,citation_author=Claudia Frankfurter;,citation_author=Frank Gommans;,citation_author=Yvonne Kwan;,citation_author=Edy Kim;,citation_author=David Leaf;,citation_author=David Owen;,citation_author=Katrina Pollock;,citation_author=Michael Puskarich;,citation_author=Muthiah Vaduganathan;,citation_author=Roland Kimmenade;,citation_author=David Harrison;,citation_author=Alisa Higgins;,citation_author=Lamprini Lampro;,citation_author=Alexina Mason;,citation_author=Gema Mila De La Fuente;,citation_author=Evelien Leffelaar;,citation_author=Joost Schotsman;,citation_author=Craig Boyd;,citation_author=Cain Harland;,citation_author=Audrey Shearer;,citation_author=Jess Wren;,citation_author=Giles Clermont;,citation_author=Daniel Ricketts;,citation_author=Fathima Fazla;,citation_author=Himasha Muvindi;,citation_author=Pramodya Ishani;,citation_author=Aasiyah Rashan;,citation_author=Ishara Udayanga;,citation_author=Michelle Detry;,citation_author=Mark Fitzgerald;,citation_author=Roger Lewis;,citation_author=Anna McGlothlin;,citation_author=Christina Saunders;,citation_author=Lindsay Berry;,citation_author=Elizabeth Lorenzi;,citation_author=Neill K. J. Adhikari;,citation_author=Madiha Hashmi;,citation_author=Bharath Kumar Tirupakuzhi Vijayaraghavan;,citation_author=Rashan Haniffa;,citation_author=Abi Beane;,citation_author=Steve A. Webb;,citation_author=Derek C. Angus;,citation_author=Anthony C. Gordon;,citation_author=Deborah J. Cook;,citation_author=Gordon H. Guyatt;,citation_author=Lindsay R. Berry;,citation_author=Elizabeth Lorenzi;,citation_author=Paul R. Mouncey;,citation_author=Carly Au;,citation_author=Ruxandra Pinto;,citation_author=Julie Ménard;,citation_author=Sheila Sprague;,citation_author=Marie-Hélène Masse;,citation_author=David T. Huang;,citation_author=Daren K. Heyland;,citation_author=Alistair D. Nichol;,citation_author=Colin J. McArthur;,citation_author=Angelique De Man;,citation_author=Farah Al-Beidh;,citation_author=Djillali Annane;,citation_author=Matthew Anstey;,citation_author=Yaseen M. Arabi;,citation_author=Marie-Claude Battista;,citation_author=Scott Berry;,citation_author=Zahra Bhimani;,citation_author=Marc J. M. Bonten;,citation_author=Charlotte A. Bradbury;,citation_author=Emily B. Brant;,citation_author=Frank M. Brunkhorst;,citation_author=Aidan Burrell;,citation_author=Meredith Buxton;,citation_author=Maurizio Cecconi;,citation_author=Allen C. Cheng;,citation_author=Dian Cohen;,citation_author=Matthew E. Cove;,citation_author=Andrew G. Day;,citation_author=Lennie P. G. Derde;,citation_author=Michelle A. Detry;,citation_author=Lise J. Estcourt;,citation_author=Elizabeth O. Fagbodun;,citation_author=Mark Fitzgerald;,citation_author=Herman Goossens;,citation_author=Cameron Green;,citation_author=Alisa M. Higgins;,citation_author=Thomas E. Hills;,citation_author=Nao Ichihara;,citation_author=Devachandran Jayakumar;,citation_author=Salmaan Kanji;,citation_author=Muhammad Nasir Khoso;,citation_author=Patrick R. Lawler;,citation_author=Roger J. Lewis;,citation_author=Edward Litton;,citation_author=John C. Marshall;,citation_author=Daniel F. McAuley;,citation_author=Anna McGlothlin;,citation_author=Shay P. McGuinness;,citation_author=Zoe K. McQuilten;,citation_author=Bryan J. McVerry;,citation_author=Srinivas Murthy;,citation_author=Rachael L. Parke;,citation_author=Jane C. Parker;,citation_author=Luis Felipe Reyes;,citation_author=Kathryn M. Rowan;,citation_author=Hiroki Saito;,citation_author=Nawal Salahuddin;,citation_author=Marlene S. Santos;,citation_author=Christina T. Saunders;,citation_author=Christopher W. Seymour;,citation_author=Manu Shankar-Hari;,citation_author=Timo Tolppa;,citation_author=Tony Trapani;,citation_author=Alexis F. Turgeon;,citation_author=Anne M. Turner;,citation_author=Andrew A. Udy;,citation_author=Frank L. Van De Veerdonk;,citation_author=Ryan Zarychanski;,citation_author=François Lamontagne;,citation_publication_date=2023-10;,citation_cover_date=2023-10;,citation_year=2023;,citation_doi=10.1001/jama.2023.21407;,citation_issn=0098-7484;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Early High-Dose Vitamin D &amp;amp;amp;lt;sub&amp;gt;3&amp;lt;/sub&amp;gt; for Critically Ill, Vitamin D–Deficient Patients;,citation_abstract=BACKGROUND Vitamin D deficiency is a common, potentially reversible contributor to morbidity and mortality among critically ill patients. The potential benefits of vitamin D supplementation in acute critical illness require further study. METHODS We conducted a randomized, double-blind, placebo-controlled, phase 3 trial of early vitamin D3 supplementation in critically ill, vitamin D–deficient patients who were at high risk for death. Randomization occurred within 12 hours after the decision to admit the patient to an intensive care unit. Eligible patients received a single enteral dose of 540,000 IU of vitamin D3 or matched placebo. The primary end point was 90-day all-cause, all-location mortality. RESULTS A total of 1360 patients were found to be vitamin D–deficient during point-of-care screening and underwent randomization. Of these patients, 1078 had baseline vitamin D deficiency (25-hydroxyvitamin D level, &amp;amp;lt;20 ng per milliliter [50 nmol per liter]) confirmed by subsequent testing and were included in the primary analysis population. The mean day 3 level of 25-hydroxyvitamin D was 46.923.2 ng per milliliter (11758 nmol per liter) in the vitamin D group and 11.45.6 ng per milli liter (2814 nmol per liter) in the placebo group (difference, 35.5 ng per milliliter; 95% confidence interval [CI], 31.5 to 39.6). The 90-day mortality was 23.5% in the vitamin D group (125 of 531 patients) and 20.6% in the placebo group (109 of 528 patients) (difference, 2.9 percentage points; 95% CI, -2.1 to 7.9; P = 0.26). There were no clinically important differences between the groups with respect to secondary clinical, physiological, or safety end points. The severity of vitamin D deficiency at baseline did not affect the association between the treatment assignment and mortality. CONCLUSIONS Early administration of high-dose enteral vitamin D3 did not provide an advantage over placebo with respect to 90-day mortality or other, nonfatal outcomes among critically ill, vitamin D–deficient patients. (Funded by the National Heart, Lung, and Blood Institute; VIOLET ClinicalTrials.gov number, NCT03096314.);,citation_author=The National Heart, Lung, and Blood Institute PETAL Clinical Trials Network;,citation_publication_date=2019-12;,citation_cover_date=2019-12;,citation_year=2019;,citation_issue=26;,citation_doi=10.1056/NEJMoa1911124;,citation_issn=0028-4793, 1533-4406;,citation_volume=381;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19;,citation_abstract=BACKGROUND Thrombosis and inflammation may contribute to morbidity and mortality among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation would improve outcomes in critically ill patients with Covid-19. METHODS In an open-label, adaptive, multiplatform, randomized clinical trial, critically ill patients with severe Covid-19 were randomly assigned to a pragmatically defined regimen of either therapeutic-dose anticoagulation with heparin or pharmacologic thromboprophylaxis in accordance with local usual care. The primary outcome was organ support–free days, evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and the number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge. The members of the executive writing committee and the block writing committee assume responsibility for the overall content and integrity of this article. The full names, academic degrees, and affiliations of the members of the executive writing committee and the block writing committee are listed in the Appendix. Address reprint requests to Dr. Zarychanski at the Sections of Hematology/Oncology and Critical Care, University of Manitoba, Winnipeg, MB, Canada R3E 0V9, or at rzarychanski@c ancercare .mb.ca. *The full list of investigators and collaborators is provided in the Supplementary Appendix, available at NEJM.org. RESULTS The trial was stopped when the prespecified criterion for futility was met for therapeutic-dose anticoagulation. Data on the primary outcome were available for 1098 patients (534 assigned to therapeutic-dose anticoagulation and 564 assigned to usual-care thromboprophylaxis). The median value for organ support–free days was 1 (interquartile range, -1 to 16) among the patients assigned to therapeuticdose anticoagulation and was 4 (interquartile range, -1 to 16) among the patients assigned to usual-care thromboprophylaxis (adjusted proportional odds ratio, 0.83; 95% credible interval, 0.67 to 1.03; posterior probability of futility [defined as an odds ratio &amp;amp;amp;lt;1.2], 99.9%). The percentage of patients who survived to hospital discharge was similar in the two groups (62.7% and 64.5%, respectively; adjusted odds ratio, 0.84; 95% credible interval, 0.64 to 1.11). Major bleeding occurred in 3.8% of the patients assigned to therapeutic-dose anticoagulation and in 2.3% of those assigned to usual-care pharmacologic thromboprophylaxis. Drs. Goligher, Bradbury, McVerry, Lawler, Berger, and Gong and Drs. Berry, McArthur, Neal, Hochman, Webb, and Zarychanski contributed equally to this article. This article was published on August 4, 2021, at NEJM.org. N Engl J Med 2021;385:777-89. DOI: 10.1056/NEJMoa2103417 Copyright © 2021 Massachusetts Medical Society. CONCLUSIONS In critically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin did not result in a greater probability of survival to hospital discharge or a greater number of days free of cardiovascular or respiratory organ support than did usual-care pharmacologic thromboprophylaxis. (REMAP-CAP, ACTIV-4a, and ATTACC ClinicalTrials.gov numbers, NCT02735707, NCT04505774, NCT04359277, and NCT04372589.);,citation_author=The REMAP-CAP, ACTIV-4a, and ATTACC Investigators;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_issue=9;,citation_doi=10.1056/NEJMoa2103417;,citation_issn=0028-4793, 1533-4406;,citation_volume=385;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Extracorporeal membrane oxygenation in patients with severe respiratory failure from COVID-19;,citation_abstract=Purpose: Limited data are available on venovenous extracorporeal membrane oxygenation (ECMO) in patients with severe hypoxemic respiratory failure from coronavirus disease 2019 (COVID-19). Methods: We examined the clinical features and outcomes of 190 patients treated with ECMO within 14 days of ICU admission, using data from a multicenter cohort study of 5122 critically ill adults with COVID-19 admitted to 68 hospi-tals across the United States. To estimate the effect of ECMO on mortality, we emulated a target trial of ECMO receipt versus no ECMO receipt within 7 days of ICU admission among mechanically ventilated patients with severe hypox-emia (PaO2/FiO2 &amp;amp;amp;lt; 100). Patients were followed until hospital discharge, death, or a minimum of 60 days. We adjusted for confounding using a multivariable Cox model. Results: Among the 190 patients treated with ECMO, the median age was 49 years (IQR 41–58), 137 (72.1%) were men, and the median P aO2/FiO2 prior to ECMO initiation was 72 (IQR 61–90). At 60 days, 63 patients (33.2%) had died, 94 (49.5%) were discharged, and 33 (17.4%) remained hospitalized. Among the 1297 patients eligible for the target trial emulation, 45 of the 130 (34.6%) who received ECMO died, and 553 of the 1167 (47.4%) who did not receive ECMO died. In the primary analysis, patients who received ECMO had lower mortality than those who did not (HR 0.55; 95% CI 0.41–0.74). Results were similar in a secondary analysis limited to patients with PaO2/FiO2 &amp;lt; 80 (HR 0.55; 95% CI 0.40–0.77). Conclusion: In select patients with severe respiratory failure from COVID-19, ECMO may reduce mortality.;,citation_author=the STOP-COVID Investigators;,citation_author=Shahzad Shaefi;,citation_author=Samantha K. Brenner;,citation_author=Shruti Gupta;,citation_author=Brian P. O’Gara;,citation_author=Megan L. Krajewski;,citation_author=David M. Charytan;,citation_author=Sobaata Chaudhry;,citation_author=Sara H. Mirza;,citation_author=Vasil Peev;,citation_author=Mark Anderson;,citation_author=Anip Bansal;,citation_author=Salim S. Hayek;,citation_author=Anand Srivastava;,citation_author=Kusum S. Mathews;,citation_author=Tanya S. Johns;,citation_author=Amanda Leonberg-Yoo;,citation_author=Adam Green;,citation_author=Justin Arunthamakun;,citation_author=Keith M. Wille;,citation_author=Tanveer Shaukat;,citation_author=Harkarandeep Singh;,citation_author=Andrew J. Admon;,citation_author=Matthew W. Semler;,citation_author=Miguel A. Hernán;,citation_author=Ariel L. Mueller;,citation_author=Wei Wang;,citation_author=David E. Leaf;,citation_publication_date=2021-02;,citation_cover_date=2021-02;,citation_year=2021;,citation_issue=2;,citation_doi=10.1007/s00134-020-06331-9;,citation_issn=0342-4642, 1432-1238;,citation_volume=47;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Common Data Elements for Subarachnoid Hemorrhage and Unruptured Intracranial Aneurysms: Recommendations from the Working Group on Subject Characteristics;,citation_abstract=Background: The National Institute of Neurological Disorders and Stroke (NINDS) Common Data Elements (CDEs) have been generated to standardize and define terms used by the scientific community. The widespread use of these CDEs promotes harmonized data collection in clinical research. The aim of the NINDS Unruptured Intracranial Aneurysms (UIA) and Subarachnoid Hemorrhage (SAH), and Subject Characteristics working group (WG) was to identify, define, and classify CDEs describing the characteristics of patients diagnosed with an UIA and SAH. Thus, “Participant/ Subject characteristics” is a set of factors defining a population of selected individuals and allowing comparisons with a reference population and overtime. Methods: Based on standard terms defined by the United States’ Census Bureau, CDEs previously defined by several (Stroke, Epilepsy and Traumatic Brain Injury) NINDS CDE working groups literature and expert opinion of the WG, the “Participant/Subject characteristics” domain has been defined. Results: A set of 192 CDEs divided in 7 subsections: demographics (8 CDEs), social status (8 CDEs), behavioral status (22 CDEs), family and medical history (144 CDEs), pregnancy and perinatal history (8 CDEs), history data source reliability (3 CDEs), and prior functional status (3 CDEs) was defined. SAH is characterized by 6 core elements, all classified in the “Participant/Subject characteristics” domain. Four exploratory elements out of the 39 for SAH overall are in the “Participant/Subject characteristics” domain, and all remaining 182 CDEs in the “Participant/Subject characteristics” domain are classified as Supplemental-Highly Recommended elements. Conclusions: These CDEs would allow the development of best practice guidelines to standardize the assessment and reporting of observations concerning UIA and SAH.;,citation_author=the Unruptured Cerebral Aneurysms and SAH CDE Project Investigators;,citation_author=Philippe Bijlenga;,citation_author=Akio Morita;,citation_author=Nerissa U. Ko;,citation_author=J. Mocco;,citation_author=Sandrine Morel;,citation_author=Yuichi Murayama;,citation_author=Marieke J. H. Wermer;,citation_author=Robert D. Brown;,citation_publication_date=2019-06;,citation_cover_date=2019-06;,citation_year=2019;,citation_issue=S1;,citation_doi=10.1007/s12028-019-00724-5;,citation_issn=1541-6933, 1556-0961;,citation_volume=30;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Prioritization and Timing of Outcomes and Endpoints After Aneurysmal Subarachnoid Hemorrhage in Clinical Trials and Observational Studies: Proposal of a Multidisciplinary Research Group;,citation_abstract=Introduction: In studies on aneurysmal subarachnoid hemorrhage (SAH), substantial variability exists in the use and timing of outcomes and endpoints, which complicates interpretation and comparison of results between studies. The aim of the National Institute of Health/National Institute of Neurological Disorders and Stroke/National Library of Medicine Unruptured Intracranial Aneurysm (UIA) and SAH common data elements (CDE) Project was to provide a common structure for future UIA and SAH research. Methods: This article summarizes the recommendations of the UIA and SAH CDE Outcomes and Endpoints sub-group, which consisted of an international and multidisciplinary ad hoc panel of experts in clinical outcomes after SAH. Consensus recommendations were developed by review of previously published CDEs for other neurological diseases and the SAH literature. Recommendations for CDEs were classified by priority into “Core,”“Supplemental—Highly Recommended,”“Supplemental,” and “Exploratory.” Results: The subgroup identified over 50 outcomes measures and template case report forms (CRFs) to be included as part of the UIA and SAH CDE recommendations. None was classified as “Core”. The modified Rankin Scale score and Montreal Cognitive Assessment were considered the preferred outcomes and classified as Supplemental—Highly Recommended. Death, Glasgow Outcome Scale score, and Glasgow Outcome Scale-extended were classified as Supplemental. All other outcome measures were categorized as “Exploratory”. We propose outcome assessment at 3 months and at 12 months for studies interested in long-term outcomes. We give recommendations for standardized dichotomization.;,citation_author=the Unruptured Intracranial Aneurysms and SAH CDE Project Investigators;,citation_author=Martin N. Stienen;,citation_author=Johanna M. Visser-Meily;,citation_author=Tom A. Schweizer;,citation_author=Daniel Hänggi;,citation_author=R. Loch Macdonald;,citation_author=Mervyn D. I. Vergouwen;,citation_publication_date=2019-06;,citation_cover_date=2019-06;,citation_year=2019;,citation_issue=S1;,citation_doi=10.1007/s12028-019-00737-0;,citation_issn=1541-6933, 1556-0961;,citation_volume=30;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Extracorporeal Life Support in Infarct-Related Cardiogenic Shock;,citation_abstract=BACKGROUND Extracorporeal life support (ECLS) is increasingly used in the treatment of infarctrelated cardiogenic shock despite a lack of evidence regarding its effect on mortality. METHODS In this multicenter trial, patients with acute myocardial infarction complicated by cardiogenic shock for whom early revascularization was planned were randomly assigned to receive early ECLS plus usual medical treatment (ECLS group) or usual medical treatment alone (control group). The primary outcome was death from any cause at 30 days. Safety outcomes included bleeding, stroke, and peripheral vascular complications warranting interventional or surgical therapy. RESULTS A total of 420 patients underwent randomization, and 417 patients were included in final analyses. At 30 days, death from any cause had occurred in 100 of 209 patients (47.8%) in the ECLS group and in 102 of 208 patients (49.0%) in the control group (relative risk, 0.98; 95% confidence interval [CI], 0.80 to 1.19; P = 0.81). The median duration of mechanical ventilation was 7 days (interquartile range, 4 to 12) in the ECLS group and 5 days (interquartile range, 3 to 9) in the control group (median difference, 1 day; 95% CI, 0 to 2). The safety outcome consisting of moderate or severe bleeding occurred in 23.4% of the patients in the ECLS group and in 9.6% of those in the control group (relative risk, 2.44; 95% CI, 1.50 to 3.95); peripheral vascular complications warranting intervention occurred in 11.0% and 3.8%, respectively (relative risk, 2.86; 95% CI, 1.31 to 6.25). The authors’ full names, academic degrees, and affiliations are listed in the Appendix. Dr. Thiele can be contacted at holger.thiele@medizin.uni-leipzig.de or at Heart Center Leipzig, Department of Internal Medicine and Cardiology, University of Leipzig, Strümpellstr. 39, 04289 Leipzig, Germany. *Investigators in the ECLS-SHOCK trial are listed in the Supplementary Appendix, available at NEJM.org. Drs. Thiele and Zeymer and Drs. Desch and Freund contributed equally to this article. This article was published on August 26, 2023, at NEJM.org. DOI: 10.1056/NEJMoa2307227 Copyright © 2023 Massachusetts Medical Society. CONCLUSIONS In patients with acute myocardial infarction complicated by cardiogenic shock with planned early revascularization, the risk of death from any cause at the 30-day follow-up was not lower among the patients who received ECLS therapy than among those who received medical therapy alone. (Funded by the Else Kröner Fresenius Foundation and others; ECLS-SHOCK ClinicalTrials.gov number, NCT03637205.);,citation_author=Holger Thiele;,citation_author=Uwe Zeymer;,citation_author=Ibrahim Akin;,citation_author=Michael Behnes;,citation_author=Tienush Rassaf;,citation_author=Amir Abbas Mahabadi;,citation_author=Ralf Lehmann;,citation_author=Ingo Eitel;,citation_author=Tobias Graf;,citation_author=Tim Seidler;,citation_author=Andreas Schuster;,citation_author=Carsten Skurk;,citation_author=Daniel Duerschmied;,citation_author=Peter Clemmensen;,citation_author=Marcus Hennersdorf;,citation_author=Stephan Fichtlscherer;,citation_author=Ingo Voigt;,citation_author=Melchior Seyfarth;,citation_author=Stefan John;,citation_author=Sebastian Ewen;,citation_author=Axel Linke;,citation_author=Eike Tigges;,citation_author=Peter Nordbeck;,citation_author=Leonhard Bruch;,citation_author=Christian Jung;,citation_author=Jutta Franz;,citation_author=Philipp Lauten;,citation_author=Tomaz Goslar;,citation_author=Hans-Josef Feistritzer;,citation_author=Janine Pöss;,citation_author=Eva Kirchhof;,citation_author=Taoufik Ouarrak;,citation_author=Steffen Schneider;,citation_author=Steffen Desch;,citation_author=Anne Freund;,citation_publication_date=2023-08;,citation_cover_date=2023-08;,citation_year=2023;,citation_doi=10.1056/NEJMoa2307227;,citation_issn=0028-4793, 1533-4406;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Usual Care as the Control Group in Clinical Trials of Nonpharmacologic Interventions;,citation_author=B. T. Thompson;,citation_author=D. Schoenfeld;,citation_publication_date=2007-10;,citation_cover_date=2007-10;,citation_year=2007;,citation_issue=7;,citation_doi=10.1513/pats.200706-072JK;,citation_issn=1546-3222;,citation_volume=4;,citation_language=en-US;,citation_journal_title=Proceedings of the American Thoracic Society;">
<meta name="citation_reference" content="citation_title=Understanding of research results, evidence summaries and their applicability—not critical appraisal—are core skills of medical curriculum;,citation_author=Kari A O Tikkinen;,citation_author=Gordon H Guyatt;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=5;,citation_doi=10.1136/bmjebm-2020-111542;,citation_issn=2515-446X, 2515-4478;,citation_volume=26;,citation_language=en-US;,citation_journal_title=BMJ Evidence-Based Medicine;">
<meta name="citation_reference" content="citation_title=Large practice variations in diagnosis and treatment of delayed cerebral ischemia after subarachnoid hemorrhage;,citation_author=Maud A. Tjerkstra;,citation_author=Dagmar Verbaan;,citation_author=Bert A. Coert;,citation_author=Rene Post;,citation_author=René Berg;,citation_author=Jonathan M. Coutinho;,citation_author=Janneke Horn;,citation_author=W. Peter Vandertop;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_doi=10.1016/j.wneu.2022.01.033;,citation_issn=18788750;,citation_language=en-US;,citation_journal_title=World Neurosurgery;">
<meta name="citation_reference" content="citation_title=Overlooked Shortcomings of Observational Studies of Interventions in Coronavirus Disease 2019: An Illustrated Review for the Clinician;,citation_abstract=Abstract The rapid spread of severe acute respiratory syndrome coronavirus 2 infection across the globe triggered an unprecedented increase in research activities that resulted in an astronomical publication output of observational studies. However, most studies failed to apply fully the necessary methodological techniques that systematically deal with different biases and confounding, which not only limits their scientific merit but may result in harm through misleading information. In this article, we address a few important biases that can seriously threaten the validity of observational studies of coronavirus disease 2019 (COVID-19). We focus on treatment selection bias due to patients’ preference on goals of care, medical futility and disability bias, survivor bias, competing risks, and the misuse of propensity score analysis. We attempt to raise awareness and to help readers assess shortcomings of observational studies of interventions in COVID-19.;,citation_author=Imad M Tleyjeh;,citation_author=Tarek Kashour;,citation_author=Jay Mandrekar;,citation_author=Diana B Petitti;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_issue=8;,citation_doi=10.1093/ofid/ofab317;,citation_issn=2328-8957;,citation_volume=8;,citation_language=en-US;,citation_journal_title=Open Forum Infectious Diseases;">
<meta name="citation_reference" content="citation_title=What would the trial be? Emulating randomized dietary intervention trials to estimate causal effects with observational data;,citation_author=Deirdre K Tobias;,citation_author=Martín Lajous;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_issue=2;,citation_doi=10.1093/ajcn/nqab169;,citation_issn=0002-9165, 1938-3207;,citation_volume=114;,citation_language=en-US;,citation_journal_title=The American Journal of Clinical Nutrition;">
<meta name="citation_reference" content="citation_title=ARDS: Hidden perils of an overburdened diagnosis;,citation_abstract=A diagnosis of ARDS serves as a pretext for several perilous clinical practices. Clinical trials demonstrated that tidal volume 12 ml/kg increases patient mortality, but 6 ml/kg has not proven superior to 11 ml/kg or anything in between. Present guidelines recommend 4 ml/kg, which foments severe air hunger, leading to prescription of hazardous (yet ineffective) sedatives, narcotics and paralytic agents. Inappropriate lowering of tidal volume also fosters double triggering, which promotes alveolar overdistention and lung injury. Successive panels have devoted considerable energy to developing a more precise definition of ARDS to homogenize the recruitment of patients into clinical trials. Each of three pillars of the prevailing Berlin definition is extremely flimsy and the source of confusion and unscientific practices. For doctors at the bedside, none of the revisions have enhanced patient care over that using the original 1967 description of Ashbaugh and colleagues. Bedside doctors are better advised to diagnose ARDS on the basis of pattern recognition and instead concentrate their vigilance on resolving the numerous hidden dangers that follow inevitably once a diagnosis has been made.;,citation_author=Martin J. Tobin;,citation_publication_date=2022-12;,citation_cover_date=2022-12;,citation_year=2022;,citation_issue=1;,citation_doi=10.1186/s13054-022-04271-y;,citation_issn=1364-8535;,citation_volume=26;,citation_language=en-US;,citation_journal_title=Critical Care;">
<meta name="citation_reference" content="citation_title=Basing Respiratory Management of COVID-19 on Physiological Principles;,citation_author=Martin J. Tobin;,citation_publication_date=2020-06;,citation_cover_date=2020-06;,citation_year=2020;,citation_issue=11;,citation_doi=10.1164/rccm.202004-1076ED;,citation_issn=1073-449X, 1535-4970;,citation_volume=201;,citation_language=en-US;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Using ClinicalTrials.gov to Understand the State of Clinical Research in Pulmonary, Critical Care, and Sleep Medicine;,citation_abstract=Rationale: ClinicalTrials.gov is the largest trial registry in the world. Strengthened registration requirements, including federal mandates in 2007, have increased study representation. A systematic evaluation of all registered studies has been limited by the absence of an aggregate data set and specialty-specific search terms.;,citation_author=Jamie L. Todd;,citation_author=Kyle R. White;,citation_author=Karen Chiswell;,citation_author=Asba Tasneem;,citation_author=Scott M. Palmer;,citation_publication_date=2013-10;,citation_cover_date=2013-10;,citation_year=2013;,citation_issue=5;,citation_doi=10.1513/AnnalsATS.201305-111OC;,citation_issn=2329-6933, 2325-6621;,citation_volume=10;,citation_language=en-US;,citation_journal_title=Annals of the American Thoracic Society;">
<meta name="citation_reference" content="citation_title=Theory and performance of substitution models for estimating relative causal effects in nutritional epidemiology;,citation_abstract=Estimating relative causal effects (i.e., “substitution effects”) is a common aim of nutritional research. In observational data, this is usually attempted using 1 of 2 statistical modeling approaches: the leave-one-out model and the energy partition model. Despite their widespread use, there are concerns that neither approach is well understood in practice.We aimed to explore and illustrate the theory and performance of the leave-one-out and energy partition models for estimating substitution effects in nutritional epidemiology.Monte Carlo data simulations were used to illustrate the theory and performance of both the leave-one-out model and energy partition model, by considering 3 broad types of causal effect estimands: 1) direct substitutions of the exposure with a single component, 2) inadvertent substitutions of the exposure with several components, and 3) average relative causal effects of the exposure instead of all other dietary sources. Models containing macronutrients, foods measured in calories, and foods measured in grams were all examined.The leave-one-out and energy partition models both performed equally well when the target estimand involved substituting a single exposure with a single component, provided all variables were measured in the same units. Bias occurred when the substitution involved &amp;amp;amp;gt;1 substituting component. Leave-one-out models that examined foods in mass while adjusting for total energy intake evaluated obscure estimands.Regardless of the approach, substitution models need to be constructed from clearly defined causal effect estimands. Estimands involving a single exposure and a single substituting component are typically estimated more accurately than estimands involving more complex substitutions. The practice of examining foods measured in grams or portions while adjusting for total energy intake is likely to deliver obscure relative effect estimands with unclear interpretations.;,citation_author=Georgia D Tomova;,citation_author=Mark S Gilthorpe;,citation_author=Peter W G Tennant;,citation_publication_date=2022-10;,citation_cover_date=2022-10;,citation_year=2022;,citation_doi=10.1093/ajcn/nqac188;,citation_issn=0002-9165;,citation_journal_title=The American Journal of Clinical Nutrition;">
<meta name="citation_reference" content="citation_title=Acute Kidney Injury With Empirical Antibiotics for Sepsis;,citation_author=Steven Y. C. Tong;,citation_author=Balasubramanian Venkatesh;,citation_author=Erin K. McCreary;,citation_publication_date=2023-10;,citation_cover_date=2023-10;,citation_year=2023;,citation_issue=16;,citation_doi=10.1001/jama.2023.18591;,citation_issn=0098-7484;,citation_volume=330;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Collider bias in observational studies: Consequences for medical research. Part 30 of a series on evaluation of scientific publications;,citation_abstract=Background: The findings of observational studies can be distorted by a number of factors. So-called confounders are well known, but distortion by collider bias (CB) has received little attention in medical research to date. The goal of this article is to present the principle of CB, and measures that can be taken to avoid it, by way of a few illustrative examples. Methods: The findings of a selective review of the literature on CB are explained with illustrative examples. Results: The simplest case of a collider variable is one that is caused by at least two other variables. An example of CB is the observation that, among persons with diabetes, obesity is associated with lower mortality, even though it is associated with higher mortality in the general population. The false protective association between obesity and mortality arises from the restriction of the study population to persons with diabetes. Conclusion: CB is a distortion that arises through restriction on or stratification by a collider variable, or through statistical adjustment for a collider variable in a regression model. CB can arise in many ways. The graphic representation of causal structures helps to identify potential sources of CB. It is important to distinguish confounders from colliders, as methods that serve to correct for confounding can themselves cause bias when applied to colliders. There is no generally applicable method for correcting CB. German Center for Diabetes Research, Partner Düsseldorf, MünchenNeuherberg: Dr. med. Sabine Kahl Cite this as;,citation_author=Thaddäus Tönnies;,citation_author=Sabine Kahl;,citation_author=Oliver Kuss;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_doi=10.3238/arztebl.m2022.0076;,citation_issn=1866-0452;,citation_language=en-US;,citation_journal_title=Deutsches Ärzteblatt international;">
<meta name="citation_reference" content="citation_title=Early Vasopressor Utilization Strategies and Outcomes in Critically Ill Patients With Severe Traumatic Brain Injury;,citation_abstract=BACKGROUND: Early hypotension after severe traumatic brain injury (sTBI) is associated with increased mortality and poor long-term outcomes. Current guidelines suggest the use of intravenous vasopressors, commonly norepinephrine and phenylephrine, to support blood pressure after TBI. However, guidelines do not specify vasopressor type, resulting in variation in clinical practice. We describe early vasopressor utilization patterns in critically ill patients with TBI and examine the association between utilization of norepinephrine, compared to phenylephrine, with hospital mortality after sTBI. METHODS: We conducted a retrospective cohort study of US hospitals participating in the Premier Healthcare Database between 2009 and 2018. We examined adult patients (&amp;amp;amp;gt;17 years of age) with a primary diagnosis of sTBI who were treated in an intensive care unit (ICU) after injury. The primary exposure was vasopressor choice (phenylephrine versus norepinephrine) within the first 2 days of hospital admission. The primary outcome was in-hospital mortality. Secondary outcomes examined included hospital length of stay (LOS) and ICU LOS. We conducted a post hoc subgroup analysis in all patients with intracranial pressure (ICP) monitor placement. Regression analysis was used to assess differences in outcomes between patients exposed to phenylephrine versus norepinephrine, with propensity matching to address selection bias due to the nonrandom allocation of treatment groups. RESULTS: From 2009 to 2018, 24,718 (37.1%) of 66,610 sTBI patients received vasopressors within the first 2 days of hospitalization. Among these patients, 60.6% (n = 14,991) received only phenylephrine, 10.8% (n = 2668) received only norepinephrine, 3.5% (n = 877) received other vasopressors, and 25.0% (n = 6182) received multiple vasopressors. In that time period, the use of all vasopressors after sTBI increased. A moderate degree of variation in vasopressor choice was explained at the individual hospital level (23.1%). In propensity-matched analysis, the use of norepinephrine compared to phenylephrine was associated with an increased risk of in-hospital mortality (OR, 1.65; CI, 1.46–1.86; P &amp;lt; .0001). CONCLUSIONS: Early vasopressor utilization among critically ill patients with sTBI is common, increasing over the last decade, and varies across hospitals caring for TBI patients. Compared to phenylephrine, norepinephrine was associated with increased risk of in-hospital mortality in propensity-matched analysis. Given the wide variation in vasopressor utilization and possible differences in efficacy, our analysis suggests the need for randomized controlled trials to better inform vasopressor choice for patients with sTBI. (Anesth Analg 2022;00:00–00);,citation_author=Camilo Toro;,citation_author=Tetsu Ohnuma;,citation_author=Jordan Komisarow;,citation_author=Monica S. Vavilala;,citation_author=Daniel T. Laskowitz;,citation_author=Michael L. James;,citation_author=Joseph P. Mathew;,citation_author=Adrian F. Hernandez;,citation_author=Ben A. Goldstein;,citation_author=John H. Sampson;,citation_author=Vijay Krishnamoorthy;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_doi=10.1213/ANE.0000000000005949;,citation_issn=0003-2999;,citation_volume=Publish Ahead of Print;,citation_language=en-US;,citation_journal_title=Anesthesia &amp;amp; Analgesia;">
<meta name="citation_reference" content="citation_title=Twenty-Year Change in Severity and Outcome of Ischemic and Hemorrhagic Strokes;,citation_abstract=OBJECTIVE To determine secular changes in initial neurological severity and short-term functional outcomes of patients with acute stroke by sex using a large population. DESIGN, SETTING, AND PARTICIPANTS This nationwide, hospital-based, multicenter, prospective registry cohort study used the Japan Stroke Data Bank and included patients who developed acute stroke from January 2000 through December 2019. Patients with stroke, including ischemic and hemorrhagic strokes, who registered within 7 days after symptom onset were studied. Modified Rankin Scale scores were assessed at hospital discharge for all patients. EXPOSURE Time. MAIN OUTCOMES AND MEASURES Initial severity was assessed by the National Institutes of Health Stroke Scale for ischemic stroke and intracerebral hemorrhage and by the World Federation of Neurological Surgeons grading for subarachnoid hemorrhage. Outcomes were judged as favorable if the modified Rankin Scale score was 0 to 2 and unfavorable if 5 to 6. RESULTS Of 183 080 patients, 135 266 (53 800 women [39.8%]; median [IQR] age, 74 [66-82] years) developed ischemic stroke, 36 014 (15 365 women [42.7%]; median [IQR] age, 70 [59-79] years) developed intracerebral hemorrhage, and 11 800 (7924 women [67.2%]; median [IQR] age, 64 [53-75] years) developed subarachnoid hemorrhage. In all 3 stroke types, median ages at onset increased, and the National Institutes of Health Stroke Scale and World Federation of Neurological Surgeons scores decreased throughout the 20-year period on multivariable analysis. In ischemic stroke, the proportion of favorable outcomes showed an increase over time after age adjustment (odds ratio [OR], 1.020; 95% CI, 1.015-1.024 for women vs OR, 1.015; 95% CI, 1.011-1.018 for men) but then stagnated, or even decreased in men, on multivariate adjustment including reperfusion therapy (OR, 0.997; 95% CI, 0.991-1.003 for women vs OR, 0.990; 95% CI, 0.985-0.994 for men). Unfavorable outcomes and in-hospital deaths decreased in both sexes. In intracerebral hemorrhage, favorable outcomes decreased in both sexes, and unfavorable outcomes and deaths decreased only in women. In subarachnoid hemorrhage, the proportion of favorable outcomes was unchanged, and that of unfavorable outcomes and deaths decreased in both sexes. CONCLUSIONS AND RELEVANCE In this study, functional outcomes improved in patients with ischemic stroke during the past 20 years in both sexes presumably partly owing to the development of acute reperfusion therapy. The outcomes of patients with hemorrhagic stroke did not clearly improve in the same period.;,citation_author=Kazunori Toyoda;,citation_author=Sohei Yoshimura;,citation_author=Michikazu Nakai;,citation_author=Masatoshi Koga;,citation_author=Yusuke Sasahara;,citation_author=Kazutaka Sonoda;,citation_author=Kenji Kamiyama;,citation_author=Yukako Yazawa;,citation_author=Sanami Kawada;,citation_author=Masahiro Sasaki;,citation_author=Tadashi Terasaki;,citation_author=Kaori Miwa;,citation_author=Junpei Koge;,citation_author=Akiko Ishigami;,citation_author=Shinichi Wada;,citation_author=Yoshitaka Iwanaga;,citation_author=Yoshihiro Miyamoto;,citation_author=Kazuo Minematsu;,citation_author=Shotai Kobayashi;,citation_author=Japan Stroke Data Bank Investigators;,citation_author=Koji Iihara;,citation_author=Ryo Itabashi;,citation_author=Takanari Kitazono;,citation_author=Kuniaki Ogasawara;,citation_author=Shigeru Nogawa;,citation_author=Masaaki Uno;,citation_author=Fusao Ikawa;,citation_author=Shuhei Yamaguchi;,citation_author=Ai Ito;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=1;,citation_doi=10.1001/jamaneurol.2021.4346;,citation_issn=2168-6149;,citation_volume=79;,citation_language=en-US;,citation_journal_title=JAMA Neurology;">
<meta name="citation_reference" content="citation_title=Causal foundations of bias, disparity and fairness;,citation_abstract=The study of biases, such as gender or racial biases, is an important topic in the social and behavioural sciences. However, the literature does not always clearly define the concept. Definitions of bias are often ambiguous or not provided at all. To study biases in a precise manner, it is important to have a well-defined concept of bias. We propose to define bias as a direct causal effect that is unjustified. We propose to define the closely related concept of disparity as a direct or indirect causal effect that includes a bias. Our proposed definitions can be used to study biases and disparities in a more rigorous and systematic way. We compare our definitions of bias and disparity with various criteria of fairness introduced in the artificial intelligence literature. We also illustrate our definitions in two case studies, focusing on gender bias in science and racial bias in police shootings. Our proposed definitions aim to contribute to a better appreciation of the causal intricacies of studies of biases and disparities. We hope that this will also promote an improved understanding of the policy implications of such studies.;,citation_author=V. A. Traag;,citation_author=L. Waltman;,citation_publication_date=2022-12;,citation_cover_date=2022-12;,citation_year=2022;,citation_fulltext_html_url=https://arxiv.org/abs/2207.13665;,citation_doi=10.48550/arXiv.2207.13665;,citation_publisher=arXiv;">
<meta name="citation_reference" content="citation_title=Guidelines for the Neurocritical Care Management of Aneurysmal Subarachnoid Hemorrhage;,citation_abstract=The neurointensive care management of patients with aneurysmal subarachnoid hemorrhage (aSAH) is one of the most critical components contributing to short-term and long-term patient outcomes. Previous recommendations for the medical management of aSAH comprehensively summarized the evidence based on consensus conference held in 2011. In this report, we provide updated recommendations based on appraisal of the literature using the Grading of Recommendations Assessment, Development, and Evaluation methodology.;,citation_author=Miriam M. Treggiari;,citation_author=Alejandro A. Rabinstein;,citation_author=Katharina M. Busl;,citation_author=Meghan M. Caylor;,citation_author=Giuseppe Citerio;,citation_author=Steven Deem;,citation_author=Michael Diringer;,citation_author=Elizabeth Fox;,citation_author=Sarah Livesay;,citation_author=Kevin N. Sheth;,citation_author=Jose I. Suarez;,citation_author=Stavropoula Tjoumakaris;,citation_publication_date=2023-05;,citation_cover_date=2023-05;,citation_year=2023;,citation_doi=10.1007/s12028-023-01713-5;,citation_issn=1556-0961;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Role of intracranial pressure values and patterns in predicting outcome in traumatic brain injury: A systematic review;,citation_abstract=Introduction Raised intracranial pressure (ICP) has been consistently associated with poor neurological outcome. Our purpose was to systematically review the literature to estimate the association between ICP values and patterns and short- and long-term vital and neurological outcome.;,citation_author=Miriam M. Treggiari;,citation_author=Nicolas Schutz;,citation_author=N. David Yanez;,citation_author=Jacques-Andre Romand;,citation_publication_date=2007-04;,citation_cover_date=2007-04;,citation_year=2007;,citation_issue=2;,citation_doi=10.1007/s12028-007-0012-1;,citation_issn=1541-6933, 1556-0961;,citation_volume=6;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Current Challenges When Using Numbers in Patient Decision Aids: Advanced Concepts;,citation_abstract=Background Decision aid developers have to convey complex task-specific numeric information in a way that minimizes bias and promotes understanding of the options available within a particular decision. Whereas our companion paper summarizes fundamental issues, this article focuses on more complex, task-specific aspects of presenting numeric information in patient decision aids. Methods As part of the International Patient Decision Aids Standards third evidence update, we gathered an expert panel of 9 international experts who revised and expanded the topics covered in the 2013 review working in groups of 2 to 3 to update the evidence, based on their expertise and targeted searches of the literature. The full panel then reviewed and provided additional revisions, reaching consensus on the final version. Results Five of the 10 topics addressed more complex task-specific issues. We found strong evidence for using independent event rates and/or incremental absolute risk differences for the effect size of test and screening outcomes. Simple visual formats can help to reduce common judgment biases and enhance comprehension but can be misleading if not well designed. Graph literacy can moderate the effectiveness of visual formats and hence should be considered in tool design. There is less evidence supporting the inclusion of personalized and interactive risk estimates. Discussion More complex numeric information. such as the size of the benefits and harms for decision options, can be better understood by using incremental absolute risk differences alongside well-designed visual formats that consider the graph literacy of the intended audience. More research is needed into when and how to use personalized and/or interactive risk estimates because their complexity and accessibility may affect their feasibility in clinical practice.;,citation_author=Lyndal J. Trevena;,citation_author=Carissa Bonner;,citation_author=Yasmina Okan;,citation_author=Ellen Peters;,citation_author=Wolfgang Gaissmaier;,citation_author=Paul K. J. Han;,citation_author=Elissa Ozanne;,citation_author=Danielle Timmermans;,citation_author=Brian J. Zikmund-Fisher;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=7;,citation_doi=10.1177/0272989X21996342;,citation_issn=0272-989X, 1552-681X;,citation_volume=41;,citation_language=en-US;,citation_journal_title=Medical Decision Making;">
<meta name="citation_reference" content="citation_title=Effectiveness of Bedaquiline Use Beyond Six Months in Patients with Multidrug-Resistant Tuberculosis;,citation_abstract=Objectives: We emulated a target trial to estimate the effect of three bedaquiline duration treatment strategies (6 months, 7-11 months, \geq 12 months) on the probability of successful treatment among patients receiving a longer individualized regimen for multidrug-resistant tuberculosis. Methods: To estimate the probability of successful treatment, we implemented a three-step approach comprising cloning, censoring, and inverse-probability weighting. Main Results: The 1,468 eligible individuals received a median of four (IQR: 4-5) likely effective drugs. In 87.1% and 77.7% of participants, this included linezolid and clofazimine, respectively. The adjusted probability of successful treatment (95% CI) was 0.85 (0.81, 0.88) for 6 months of BDQ, 0.77 (0.73, 0.81) for 7-11 months, and 0.86 (0.83, 0.88) for &amp;amp;amp;gt; 12 months. Compared with 6 months of bedaquiline, the ratio of treatment success (95% CI) was 0.91 (0.85, 0.96) for 7-11 months and 1.01 (0.96, 1.06) for &amp;gt; 12 months. Naı̈ve analyses that did not account for bias found a higher probability of successful treatment with > 12 months: ratio 1.09 (1.05, 1.14). Conclusions: Bedaquiline use beyond six months did not increase the probability of successful treatment among patients receiving longer regimens that commonly included new and repurposed drugs. When not properly accounted for, immortal person-time can bias estimate of effects of treatment duration. Future analyses should explore the effect of duration of bedaquiline and other drugs in subgroups with advanced disease and/or receiving less potent regimens.;,citation_author=Letizia Trevisi;,citation_author=Miguel A. Hernán;,citation_author=Carole D Mitnick;,citation_author=Uzma Khan;,citation_author=Kwonjune J Seung;,citation_author=Michael L. Rich;,citation_author=Mathieu Bastard;,citation_author=Helena Huerga;,citation_author=Nara Melikyan;,citation_author=Sidney Atwood;,citation_author=Zaza Avaliani;,citation_author=Felix Llanos;,citation_author=Mohammed Manzur-ul-Alam;,citation_author=Khin Zarli;,citation_author=Amsalu Bekele Binedgie;,citation_author=Sana Adnan;,citation_author=Arusyak Melikyan;,citation_author=Alain Gelin;,citation_author=Afshan K Isani;,citation_author=Dmitry Vetushko;,citation_author=Zhenisgul Daugarina;,citation_author=Patrick Nkundanyirazo;,citation_author=Fauziah Asnely Putri;,citation_author=Charles Vilbrun;,citation_author=Munira Khan;,citation_author=Catherine Hewison;,citation_author=Palwasha Y Khan;,citation_author=Molly F Franke;,citation_publication_date=2023-02;,citation_cover_date=2023-02;,citation_year=2023;,citation_doi=10.1164/rccm.202211-2125OC;,citation_issn=1073-449X, 1535-4970;,citation_language=en-US;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Flexible approaches to clinical trials;,citation_author=Andrea C. Tricco;,citation_author=David Tovey;,citation_publication_date=2023-02;,citation_cover_date=2023-02;,citation_year=2023;,citation_doi=10.1016/j.jclinepi.2023.02.004;,citation_issn=0895-4356, 1878-5921;,citation_pmid=36933905;,citation_volume=154;,citation_language=en-US;,citation_journal_title=Journal of Clinical Epidemiology;,citation_publisher=Elsevier;">
<meta name="citation_reference" content="citation_title=Management of Status Epilepticus, Refractory Status Epilepticus, and Super-refractory Status Epilepticus;,citation_abstract=PURPOSE OF REVIEW: Status epilepticus is a serious condition caused by disorders and diseases that affect the central nervous system. In status epilepticus, hypersynchronous epileptic activity lasts longer than the usual duration of isolated self-limited seizures (time t1), which causes neuronal damage or alteration of neuronal networks at a certain time point (time t2), depending on the type of and duration of status epilepticus. The successful management of status epilepticus includes both the early termination of seizure activity and the earliest possible identification of a causative etiology, which may require independent acute treatment. In nonconvulsive status epilepticus, patients present only with subtle clinical signs or even without any visible clinical manifestations. In these cases, EEG allows for the assessment of cerebral function and identification of patterns in need of urgent treatment.;,citation_author=Eugen Trinka;,citation_author=Markus Leitinger;,citation_publication_date=2022-04;,citation_cover_date=2022-04;,citation_year=2022;,citation_issue=2;,citation_doi=10.1212/CON.0000000000001103;,citation_issn=1538-6899, 1080-2371;,citation_volume=28;,citation_language=en-US;,citation_journal_title=CONTINUUM: Lifelong Learning in Neurology;">
<meta name="citation_reference" content="citation_title=POINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? Yes;,citation_author=Tobias Tritschler;,citation_author=Grégoire Le Gal;,citation_author=Shari Brosnahan;,citation_author=Marc Carrier;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_issue=6;,citation_doi=10.1016/j.chest.2022.01.036;,citation_issn=00123692;,citation_volume=161;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Rebuttal From Dr Tritschler et al;,citation_author=Tobias Tritschler;,citation_author=Grégoire Le Gal;,citation_author=Shari Brosnahan;,citation_author=Marc Carrier;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_issue=6;,citation_doi=10.1016/j.chest.2022.01.039;,citation_issn=00123692;,citation_volume=161;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Infographics and Visual Abstracts;,citation_author=Shreya P. Trivedi;,citation_author=Alvin Chin;,citation_author=Andrew Ibrahim;,citation_author=Amy Ou;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_issue=4;,citation_doi=10.4300/JGME-D-21-00590;,citation_issn=1949-8357, 1949-8349;,citation_volume=13;,citation_language=en-US;,citation_journal_title=Journal of Graduate Medical Education;">
<meta name="citation_reference" content="citation_title=Is It Always Wrong to Perform Futile CPR?;,citation_abstract=Although there is currently much debate about the types of care to which patients are entitled, one thing on which everyone can agree is that nonbeneficial care should be eliminated. Although such care can be hard to define, in some circumstances experienced clinicians can be virtually certain that attempts at resuscitation will fail. In these cases, many argue that hospitals should adopt policies that allow physicians to refuse when families demand futile cardiopulmonary resuscitation (CPR). Several years ago, I cared for a 2-year-old boy who had been born with a large frontal encephalocele. He survived surgical excision but was left . . .;,citation_author=Robert D. Truog;,citation_publication_date=2010-02;,citation_cover_date=2010-02;,citation_year=2010;,citation_issue=6;,citation_doi=10.1056/NEJMp0908464;,citation_issn=0028-4793;,citation_pmid=20147712;,citation_volume=362;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Should We Prolong the Observation Period for Neurological Recovery After Cardiac Arrest?;,citation_abstract=OBJECTIVES: To evaluate whether the recommended observation period of 7 days for cardiac arrest survivors is sufficient for conscious recovery and to identify the variables associated with eventual neurologic recovery among patients with delayed awakening. DESIGN: A retrospective cohort study. SETTING: A single tertiary medical center. PATIENTS: Five-hundred twenty-nine nontraumatic adult cardiac arrest survivors with prearrest favorable neurologic function (Cerebral Performance Category 1–2) who survived to hospital discharge during 2011–2019. INTERVENTIONS: The enrolled patients were classified into favorable (Cerebral Performance Category 1–2) and poor (Cerebral Performance Category 3–4) neurologic recovery according to their neurologic function at hospital discharge. Among patients with favorable neurologic recovery, those who recovered within 7 days were assigned to the early recovery group or after 7 days as the late recovery group. MEASUREMENTS AND MAIN RESULTS: There were 395 patients exhibiting favorable neurologic recovery (n = 357 in the early group, n = 38 in late group) and 134 patients exhibiting poor neurologic recovery (poor recovery group). Among patients who remained unconscious on day 7, delayed awakening was associated with male sex (odds ratio [OR], 3.905; 95% CI, 1.153–13.221), prehospital return of spontaneous circulation (OR, 7.628; 95% CI, 2.084–27.922), therapeutic hypothermia (OR, 4.320; 95% CI, 1.624–11.488), and extracorporeal cardiopulmonary resuscitation (OR, 4.508; 95% CI, 1.414–14.371). Being transferred from another hospital, however, was less likely to be associated with delayed awakening (OR, 0.061; 95% CI, 0.009–0.431). The median duration for patients to regain clear consciousness in the late recovery group was 12.12 days. No patient who recovered consciousness had an unfavorable electroencephalography pattern, however, in patients with poor recovery, the 7-day electroencephalography showed 45 patients with generalized suppression (33.6%), two with burst suppression (1.5%), 14 with seizure/epileptic discharge (10.5%), and one with status epilepticus (0.7%). CONCLUSIONS: Up to 9.6% of cardiac arrest patients with favorable outcomes recover consciousness after the recommended 7 days of observation, indicating the observation time of 7 days seems justified but longer duration may be needed. The results of the culturally and clinically isolated population may limit the application to other population.;,citation_author=Min-Shan Tsai;,citation_author=Wen-Jone Chen;,citation_author=Wei-Ting Chen;,citation_author=Yu-Tzu Tien;,citation_author=Wei-Tien Chang;,citation_author=Hooi-Nee Ong;,citation_author=Chien-Hua Huang;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_doi=10.1097/CCM.0000000000005264;,citation_issn=0090-3493;,citation_volume=Publish Ahead of Print;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association;,citation_abstract=Background: The American Heart Association, in conjunction with the National Institutes of Health, annually reports the most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors, including core health behaviors (smoking, physical activity, diet, and weight) and health factors (cholesterol, blood pressure, and glucose control) that contribute to cardiovascular health. The Statistical Update presents the latest data on a range of major clinical heart and circulatory disease conditions (including stroke, congenital heart disease, rhythm disorders, subclinical atherosclerosis, coronary heart disease, heart failure, valvular disease, venous disease, and peripheral artery disease) and the associated outcomes (including quality of care, procedures, and economic costs). Methods: The American Heart Association, through its Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States to provide the most current information available in the annual Statistical Update. The 2022 Statistical Update is the product of a full year’s worth of effort by dedicated volunteer clinicians and scientists, committed government professionals, and American Heart Association staff members. This year’s edition includes data on the monitoring and benefits of cardiovascular health in the population and an enhanced focus on social determinants of health, adverse pregnancy outcomes, vascular contributions to brain health, and the global burden of cardiovascular disease and healthy life expectancy. Results: Each of the chapters in the Statistical Update focuses on a different topic related to heart disease and stroke statistics. Conclusions: The Statistical Update represents a critical resource for the lay public, policymakers, media professionals, clinicians, health care administrators, researchers, health advocates, and others seeking the best available data on these factors and conditions.;,citation_author=Connie W. Tsao;,citation_author=Aaron W. Aday;,citation_author=Zaid I. Almarzooq;,citation_author=Alvaro Alonso;,citation_author=Andrea Z. Beaton;,citation_author=Marcio S. Bittencourt;,citation_author=Amelia K. Boehme;,citation_author=Alfred E. Buxton;,citation_author=April P. Carson;,citation_author=Yvonne Commodore-Mensah;,citation_author=Mitchell S. V. Elkind;,citation_author=Kelly R. Evenson;,citation_author=Chete Eze-Nliam;,citation_author=Jane F. Ferguson;,citation_author=Giuliano Generoso;,citation_author=Jennifer E. Ho;,citation_author=Rizwan Kalani;,citation_author=Sadiya S. Khan;,citation_author=Brett M. Kissela;,citation_author=Kristen L. Knutson;,citation_author=Deborah A. Levine;,citation_author=Tené T. Lewis;,citation_author=Junxiu Liu;,citation_author=Matthew Shane Loop;,citation_author=Jun Ma;,citation_author=Michael E. Mussolino;,citation_author=Sankar D. Navaneethan;,citation_author=Amanda Marma Perak;,citation_author=Remy Poudel;,citation_author=Mary Rezk-Hanna;,citation_author=Gregory A. Roth;,citation_author=Emily B. Schroeder;,citation_author=Svati H. Shah;,citation_author=Evan L. Thacker;,citation_author=Lisa B. VanWagner;,citation_author=Salim S. Virani;,citation_author=Jenifer H. Voecks;,citation_author=Nae-Yuh Wang;,citation_author=Kristine Yaffe;,citation_author=Seth S. Martin;,citation_author=null null;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_issue=8;,citation_doi=10.1161/CIR.0000000000001052;,citation_volume=145;,citation_journal_title=Circulation;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=Lowering Nighttime Blood Pressure With Bedtime Dosing of Antihypertensive Medications: Controversies in Hypertension - Con Side of the Argument;,citation_author=Ricky D. Turgeon;,citation_author=Andrew D. Althouse;,citation_author=Jordana B. Cohen;,citation_author=Bogdan Enache;,citation_author=John B. Hogenesch;,citation_author=Michael E. Johansen;,citation_author=Raj Mehta;,citation_author=Gideon Meyerowitz-Katz;,citation_author=Boback Ziaeian;,citation_author=Swapnil Hiremath;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_issue=3;,citation_doi=10.1161/HYPERTENSIONAHA.121.16501;,citation_issn=0194-911X, 1524-4563;,citation_volume=78;,citation_language=en-US;,citation_journal_title=Hypertension;">
<meta name="citation_reference" content="citation_title=Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy;,citation_abstract=BACKGROUND Evidence-based medicine is valuable to the extent that the evidence base is complete and unbiased. Selective publication of clinical trials — and the outcomes within those trials — can lead to unrealistic estimates of drug effectiveness and alter the apparent risk–benefit ratio. METHODS We obtained reviews from the Food and Drug Administration (FDA) for studies of 12 antidepressant agents involving 12,564 patients. We conducted a systematic literature search to identify matching publications. For trials that were reported in the literature, we compared the published outcomes with the FDA outcomes. We also compared the effect size derived from the published reports with the effect size derived from the entire FDA data set. N Engl J Med 2008;358:252-60. Copyright © 2008 Massachusetts Medical Society. RESULTS Among 74 FDA-registered studies, 31%, accounting for 3449 study participants, were not published. Whether and how the studies were published were associated with the study outcome. A total of 37 studies viewed by the FDA as having positive results were published; 1 study viewed as positive was not published. Studies viewed by the FDA as having negative or questionable results were, with 3 exceptions, either not published (22 studies) or published in a way that, in our opinion, conveyed a positive outcome (11 studies). According to the published literature, it appeared that 94% of the trials conducted were positive. By contrast, the FDA analysis showed that 51% were positive. Separate meta-analyses of the FDA and journal data sets showed that the increase in effect size ranged from 11 to 69% for individual drugs and was 32% overall. CONCLUSIONS We cannot determine whether the bias observed resulted from a failure to submit manuscripts on the part of authors and sponsors, from decisions by journal editors and reviewers not to publish, or both. Selective reporting of clinical trial results may have adverse consequences for researchers, study participants, health care professionals, and patients.;,citation_author=Erick H Turner;,citation_author=Robert A Tell;,citation_publication_date=2008;,citation_cover_date=2008;,citation_year=2008;,citation_language=en-US;,citation_journal_title=n engl j med;">
<meta name="citation_reference" content="citation_title=Less in-person social interaction with peers among U.S. Adolescents in the 21st century and links to loneliness;,citation_abstract=In nationally representative samples of U.S. adolescents (age: 13–18) and entering college students, 1976–2017 (N = 8.2 million), iGen adolescents in the 2010s (vs. previous generations) spent less time on in-person (face-to-face) social interaction with peers, including getting together or socializing with friends, going to parties, going out, dating, going to movies, and riding in cars for fun. College-bound high school seniors in 2016 (vs. the late 1980s) spent an hour less a day engaging in in-person social interaction, despite declines in paid work and little change in homework or extracurricular activity time. The results suggest that time displacement occurs at the cohort level, with in-person social interaction declining as digital media use increased, but not at the individual level, where in-person social interaction and social media use are positively correlated. Adolescents’ feelings of loneliness increased sharply after 2011. Adolescents low in in-person social interaction and high in social media use reported the most loneliness.;,citation_author=Jean M. Twenge;,citation_author=Brian H. Spitzberg;,citation_author=W. Keith Campbell;,citation_publication_date=2019-06;,citation_cover_date=2019-06;,citation_year=2019;,citation_issue=6;,citation_doi=10.1177/0265407519836170;,citation_issn=0265-4075;,citation_volume=36;,citation_language=en-US;,citation_journal_title=Journal of Social and Personal Relationships;,citation_publisher=SAGE Publications Ltd;">
<meta name="citation_reference" content="citation_title=Economic Evaluation Studies;,citation_author=Belinda L. Udeh;,citation_publication_date=2020-07;,citation_cover_date=2020-07;,citation_year=2020;,citation_issue=1;,citation_doi=10.1016/j.chest.2020.03.008;,citation_issn=00123692;,citation_volume=158;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Glucose Control in the ICU;,citation_abstract=Randomized, controlled trials aiming for near-normal glycemic targets (80 to 110 mg per deciliter [4.4 to 6.1 mmol per liter]) in critically ill patients have shown conflicting data regarding the benefits of intensive glycemic control (Table 1). In 2001, Van den Berghe et al. reported a dramatic 42% lower mortality among patients in the surgical intensive care unit (ICU) in whom the blood glucose level had been adjusted to 80 to 110 mg per deciliter than among those who had received conventional treatment that was initiated when glucose levels exceeded 215 mg per deciliter (11.9 mmol per liter), with a . . .;,citation_author=Guillermo E. Umpierrez;,citation_publication_date=2023-09;,citation_cover_date=2023-09;,citation_year=2023;,citation_issue=13;,citation_doi=10.1056/NEJMe2309442;,citation_issn=0028-4793;,citation_pmid=37754290;,citation_volume=389;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Helicobacter pylori, Homologous-Recombination Genes, and Gastric Cancer;,citation_author=Yoshiaki Usui;,citation_author=Yukari Taniyama;,citation_author=Mikiko Endo;,citation_author=Yuriko N. Koyanagi;,citation_author=Yumiko Kasugai;,citation_author=Isao Oze;,citation_author=Hidemi Ito;,citation_author=Issei Imoto;,citation_author=Tsutomu Tanaka;,citation_author=Masahiro Tajika;,citation_author=Yasumasa Niwa;,citation_author=Yusuke Iwasaki;,citation_author=Tomomi Aoi;,citation_author=Nozomi Hakozaki;,citation_author=Sadaaki Takata;,citation_author=Kunihiko Suzuki;,citation_author=Chikashi Terao;,citation_author=Masanori Hatakeyama;,citation_author=Makoto Hirata;,citation_author=Kokichi Sugano;,citation_author=Teruhiko Yoshida;,citation_author=Yoichiro Kamatani;,citation_author=Hidewaki Nakagawa;,citation_author=Koichi Matsuda;,citation_author=Yoshinori Murakami;,citation_author=Amanda B. Spurdle;,citation_author=Keitaro Matsuo;,citation_author=Yukihide Momozawa;,citation_publication_date=2023-03;,citation_cover_date=2023-03;,citation_year=2023;,citation_issue=13;,citation_doi=10.1056/NEJMoa2211807;,citation_issn=0028-4793;,citation_pmid=36988593;,citation_volume=388;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=The Epistemic and Pragmatic Function of Dichotomous Claims Based on Statistical Hypothesis Tests;,citation_abstract=Researchers commonly make dichotomous claims based on continuous test statistics. Many have branded the practice as misuse of statistics, and criticize scientists for suffering from “dichotomania”. However, the role dichotomous claims play in science is not primarily a statistical one, but an epistemological and pragmatic one. The epistemological function of dichotomous claims consists in transforming data into factual statements that can falsify a universal statement. This transformation requires pre-specified methodological decision procedures such as statistical hypothesis testing (e.g., Neyman-Pearson tests). From the perspective of methodological falsificationism these decision procedures are necessary, as probabilistic statements (e.g. continuous test statistics) cannot function as falsifiers of substantive hypotheses. However, they are not sufficient since for dichotomous claims to have any implication regarding theoretical claims about phenomena, there should be a valid derivation chain linking theoretical, experimental and data models. The pragmatic function of dichotomous claims is facilitating scrutiny and criticism among peers by generating contestable statements, a process referred to by Popper as ’conjectures and refutations’, through which we can determine which theories withstand scrutiny the best. Abandoning dichotomous claims to combat the misuse of statistics would not improve scientific inferences but will sacrifice these crucial epistemic and pragmatic functions.;,citation_author=Duygu Uygun Tunç;,citation_author=Mehmet Necip Tunç;,citation_author=Daniel Lakens;,citation_publication_date=2021-02;,citation_cover_date=2021-02;,citation_year=2021;,citation_doi=10.31234/osf.io/af9by;,citation_language=en-US;,citation_technical_report_institution=PsyArXiv;">
<meta name="citation_reference" content="citation_title=Automated CT perfusion imaging for acute ischemic stroke: Pearls and pitfalls for real-world use;,citation_abstract=Recent positive trials have thrust acute cerebral perfusion imaging into the routine evaluation of acute ischemic stroke. Updated guidelines state that in patients with anterior circulation large vessel occlusions presenting beyond 6 hours from time last known well, advanced imaging selection including perfusion-based selection is necessary. Centers that receive patients with acute stroke must now have the capability to perform and interpret CT or magnetic resonance perfusion imaging or provide rapid transfer to centers with the capability of selecting patients for a highly impactful endovascular therapy, particularly in delayed time windows. Many stroke centers are quickly incorporating the use of automated perfusion processing software to interpret perfusion raw data. As CT perfusion (CTP) is being assimilated in real-world clinical practice, it is essential to understand the basics of perfusion acquisition, quantification, and interpretation. It is equally important to recognize the common technical and clinical diagnostic challenges of automated CTP including ischemic core and penumbral misclassifications that could result in underestimation or overestimation of the core and penumbra volumes. This review highlights the pitfalls of automated CTP along with practical pearls to address the common challenges. This is particularly tailored to aid the acute stroke clinician who must interpret automated perfusion studies in an emergency setting to make time-dependent treatment decisions for patients with acute ischemic stroke.;,citation_author=Achala Vagal;,citation_author=Max Wintermark;,citation_author=Kambiz Nael;,citation_author=Andrew Bivard;,citation_author=Mark Parsons;,citation_author=Aaron W. Grossman;,citation_author=Pooja Khatri;,citation_publication_date=2019-10;,citation_cover_date=2019-10;,citation_year=2019;,citation_doi=10.1212/WNL.0000000000008481;,citation_issn=0028-3878, 1526-632X;,citation_language=en-US;,citation_journal_title=Neurology;">
<meta name="citation_reference" content="citation_title=Early decompressive surgery in malignant infarction of the middle cerebral artery: A pooled analysis of three randomised controlled trials;,citation_abstract=Background Malignant infarction of the middle cerebral artery (MCA) is associated with an 80% mortality rate. Non-randomised studies have suggested that decompressive surgery reduces this mortality without increasing the number of severely disabled survivors. To obtain sufficient data as soon as possible to reliably estimate the effects of decompressive surgery, results from three European randomised controlled trials (DECIMAL, DESTINY, HAMLET) were pooled. The trials were ongoing when the pooled analysis was planned. Methods Individual data for patients aged between 18 years and 60 years, with space-occupying MCA infarction, included in one of the three trials, and treated within 48 h after stroke onset were pooled for analysis. The protocol was designed prospectively when the trials were still recruiting patients and outcomes were defined without knowledge of the results of the individual trials. The primary outcome measure was the score on the modified Rankin scale (mRS) at 1 year dichotomised between favourable (0–4) and unfavourable (5 and death) outcome. Secondary outcome measures included case fatality rate at 1 year and a dichotomisation of the mRS between 0–3 and 4 to death. Data analysis was done by an independent data monitoring committee. Findings 93 patients were included in the pooled analysis. More patients in the decompressive-surgery group than in the control group had an mRS\leq4 (75% vs 24%; pooled absolute risk reduction 51% [95% CI 34–69]), an mRS\leq3 (43% vs 21%; 23% [5–41]), and survived (78% vs 29%; 50% [33–67]), indicating numbers needed to treat of two for survival with mRS\leq4, four for survival with mRS\leq3, and two for survival irrespective of functional outcome. The effect of surgery was highly consistent across the three trials. Interpretation In patients with malignant MCA infarction, decompressive surgery undertaken within 48 h of stroke onset reduces mortality and increases the number of patients with a favourable functional outcome. The decision to perform decompressive surgery should, however, be made on an individual basis in every patient.;,citation_author=Katayoun Vahedi;,citation_author=Jeannette Hofmeijer;,citation_author=Eric Juettler;,citation_author=Eric Vicaut;,citation_author=Bernard George;,citation_author=Ale Algra;,citation_author=G Johan Amelink;,citation_author=Peter Schmiedeck;,citation_author=Stefan Schwab;,citation_author=Peter M Rothwell;,citation_author=Marie-Germaine Bousser;,citation_author=H Bart Worp;,citation_author=Werner Hacke;,citation_publication_date=2007-03;,citation_cover_date=2007-03;,citation_year=2007;,citation_issue=3;,citation_doi=10.1016/S1474-4422(07)70036-4;,citation_issn=1474-4422;,citation_volume=6;,citation_language=en-US;,citation_journal_title=The Lancet Neurology;">
<meta name="citation_reference" content="citation_title=Attention to Immortal Time Bias in Critical Care Research;,citation_author=Emily A. Vail;,citation_author=Hayley B. Gershengorn;,citation_author=Hannah Wunsch;,citation_author=Allan J. Walkey;,citation_publication_date=2021-05;,citation_cover_date=2021-05;,citation_year=2021;,citation_issue=10;,citation_doi=10.1164/rccm.202008-3238CP;,citation_issn=1073-449X, 1535-4970;,citation_volume=203;,citation_language=en-US;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;,citation_publisher=American Thoracic Society;">
<meta name="citation_reference" content="citation_title=Trials with “non-significant” results are not insignificant trials: A common significance threshold distorts reporting and interpretation of trial results;,citation_abstract=We discuss a newly published study examining how phrases are used in clinical trials to describe results when the estimated P-value is close to (slightly above or slightly below) 0.05, which has been arbitrarily designated by convention as the boundary for “statistical significance”. Terms such as “marginally significant”, “trending towards significant”, and “nominally significant” are well represented in biomedical literature, but are not actually scientifically meaningful. Acknowledging that “statistical significance” remains a major determinant of publication, we propose that scientific journals de-emphasise the use of P-values for null hypothesis significance testing, a purpose for which they were never intended, and avoid the use of these ambiguous and confusing terms in scientific articles. Instead, investigators could simply report their findings: effect sizes, P-values, and confidence intervals (or their Bayesian equivalents), and leave it to the discerning reader to infer the clinical applicability and importance. Our goal should be to move away from describing studies (or trials) as positive or negative based on an arbitrary P-value threshold, and rather to judge whether the scientific evidence provided is informative or uninformative.;,citation_author=Emily A. Vail;,citation_author=Michael S. Avidan;,citation_publication_date=2022-11;,citation_cover_date=2022-11;,citation_year=2022;,citation_issue=5;,citation_doi=10.1016/j.bja.2022.06.023;,citation_issn=0007-0912;,citation_volume=129;,citation_language=en-US;,citation_journal_title=British Journal of Anaesthesia;">
<meta name="citation_reference" content="citation_title=Use of Hydrocortisone, Ascorbic Acid, and Thiamine in Adults with Septic Shock;,citation_abstract=Rationale: In December 2016, a single-center study describing significant improvements in mortality among a small group of patients with severe sepsis and septic shock treated with hydrocortisone, high-dose ascorbic acid, and thiamine (HAT therapy) was published online. Objectives: This study aims to describe the administration of HAT therapy among U.S. adults with septic shock before and after study publication and to compare outcomes between patients who received and did not receive HAT therapy. Methods: We performed a retrospective cohort study of 379 acute care hospitals in the Premier Healthcare Database including patients discharged from October 1, 2015, to September 30, 2018. Exposure was quarter year of hospital discharge; postpublication was defined as January 2017 onward (July 2017 for effectiveness analyses). The primary outcome was receipt of HAT at least once during hospitalization. We conducted unadjusted segmented regression analyses to examine temporal trends in HAT administration. In patients with early septic shock, we compared the association of early HAT therapy (within 2 d of hospitalization) with hospital mortality using multivariable modeling and propensity score matching. Measurements and Main Results: Among 338,597 patients, 3,574 (1.1%) received HAT therapy, 98.7% in the postpublication period. HAT administration increased from 0.03% of patients (95% confidence interval [CI], 0.02–0.04) before publication to 2.65% (95% CI, 2.46–2.83) in the last quarter, with a significant step up in use after December 2016 (P &amp;amp;amp;lt; 0.001). Receipt of early HAT was associated with higher hospital mortality (28.2% vs. 19.7%; P &amp;lt; 0.001; adjusted odds ratio, 1.17 [95% CI, 1.02–1.33]; primary propensity-matched model adjusted odds ratio, 1.19 [95% CI, 1.02–1.40]). Conclusions: Publication of a single-center retrospective study was associated with significantly increased administration of HAT. Among patients with early septic shock, receipt of HAT was not associated with mortality benefit.;,citation_author=Emily A. Vail;,citation_author=Hannah Wunsch;,citation_author=Ruxandra Pinto;,citation_author=Nicholas A. Bosch;,citation_author=Allan J. Walkey;,citation_author=Peter K. Lindenauer;,citation_author=Hayley B. Gershengorn;,citation_publication_date=2020-12;,citation_cover_date=2020-12;,citation_year=2020;,citation_issue=11;,citation_doi=10.1164/rccm.202005-1829OC;,citation_issn=1073-449X;,citation_volume=202;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;,citation_publisher=American Thoracic Society - AJRCCM;">
<meta name="citation_reference" content="citation_title=Fooled by Randomness. The Misleading Effect of Treatment Crossover in Randomized Trials of Therapies with Marginal Treatment Benefit;,citation_abstract=Crossover can bias clinical outcomes of randomized clinical trials by increasing the risk of both type I (false positive) and type II (false negative) errors. To show how crossover can increase type I error, we provide computer simulation and review herein illustrative examples (iniparib, olaratumab) of recently reported RCTs that demonstrated false-positive treatment efficacy signals due to crossover. The ethical issues associated with crossover are also discussed.;,citation_author=Vicente Valentí;,citation_author=Paula Jiménez-Fonseca;,citation_author=Pavlos Msaouel;,citation_author=Ramón Salazar;,citation_author=Alberto Carmona-Bayonas;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_issue=2;,citation_doi=10.1080/07357907.2021.2020281;,citation_issn=0735-7907, 1532-4192;,citation_volume=40;,citation_language=en-US;,citation_journal_title=Cancer Investigation;">
<meta name="citation_reference" content="citation_title=Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk;,citation_abstract=BACKGROUND The appropriate duration of dual antiplatelet therapy in patients at high risk for bleeding after the implantation of a drug-eluting coronary stent remains unclear. METHODS One month after they had undergone implantation of a biodegradable-polymer sirolimus-eluting coronary stent, we randomly assigned patients at high bleeding risk to discontinue dual antiplatelet therapy immediately (abbreviated therapy) or to continue it for at least 2 additional months (standard therapy). The three ranked primary outcomes were net adverse clinical events (a composite of death from any cause, myocardial infarction, stroke, or major bleeding), major adverse cardiac or cerebral events (a composite of death from any cause, myocardial infarction, or stroke), and major or clinically relevant nonmajor bleeding; cumulative incidences were assessed at 335 days. The first two outcomes were assessed for noninferiority in the per-protocol population, and the third outcome for superiority in the intention-to-treat population. RESULTS Among the 4434 patients in the per-protocol population, net adverse clinical events occurred in 165 patients (7.5%) in the abbreviated-therapy group and in 172 (7.7%) in the standard-therapy group (difference, -0.23 percentage points; 95% confidence interval [CI], -1.80 to 1.33; P&amp;amp;amp;lt;0.001 for noninferiority). A total of 133 patients (6.1%) in the abbreviated-therapy group and 132 patients (5.9%) in the standard-therapy group had a major adverse cardiac or cerebral event (difference, 0.11 percentage points; 95% CI, -1.29 to 1.51; P = 0.001 for noninferiority). Among the 4579 patients in the intention-to-treat population, major or clinically relevant nonmajor bleeding occurred in 148 patients (6.5%) in the abbreviated-therapy group and in 211 (9.4%) in the standard-therapy group (difference, -2.82 percentage points; 95% CI, -4.40 to -1.24; P&amp;lt;0.001 for superiority). The authors’ full names, academic degrees, and affiliations are listed in the Appendix. Address reprint requests to Dr. Valgimigli at Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Università della Svizzera Italiana, Via Tesserete 48, 6900 CH, Lugano, Switzerland, or at marco.valgimigli@eoc.ch. *A complete list of the MASTER DAPT investigators is provided in the Supplementary Appendix, available at NEJM.org. This article was published on August 28, 2021, at NEJM.org. N Engl J Med 2021;385:1643-55. DOI: 10.1056/NEJMoa2108749 Copyright © 2021 Massachusetts Medical Society. CME at NEJM.org CONCLUSIONS One month of dual antiplatelet therapy was noninferior to the continuation of therapy for at least 2 additional months with regard to the occurrence of net adverse clinical events and major adverse cardiac or cerebral events; abbreviated therapy also resulted in a lower incidence of major or clinically relevant nonmajor bleeding. (Funded by Terumo; MASTER DAPT ClinicalTrials.gov number, NCT03023020.);,citation_author=Marco Valgimigli;,citation_author=Enrico Frigoli;,citation_author=Dik Heg;,citation_author=Jan Tijssen;,citation_author=Peter Jüni;,citation_author=Pascal Vranckx;,citation_author=Yukio Ozaki;,citation_author=Marie-Claude Morice;,citation_author=Bernard Chevalier;,citation_author=Yoshinobu Onuma;,citation_author=Stephan Windecker;,citation_author=Pim A. L. Tonino;,citation_author=Marco Roffi;,citation_author=Maciej Lesiak;,citation_author=Felix Mahfoud;,citation_author=Jozef Bartunek;,citation_author=David Hildick-Smith;,citation_author=Antonio Colombo;,citation_author=Goran Stanković;,citation_author=Andrés Iñiguez;,citation_author=Carl Schultz;,citation_author=Ran Kornowski;,citation_author=Paul J. L. Ong;,citation_author=Mirvat Alasnag;,citation_author=Alfredo E. Rodriguez;,citation_author=Aris Moschovitis;,citation_author=Peep Laanmets;,citation_author=Michael Donahue;,citation_author=Sergio Leonardi;,citation_author=Pieter C. Smits;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=18;,citation_doi=10.1056/NEJMoa2108749;,citation_issn=0028-4793, 1533-4406;,citation_volume=385;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Association of Intensive Care Unit Admission With Mortality Among Older Patients With Pneumonia;,citation_abstract=OBJECTIVE To estimate the relationship between ICU admission and outcomes for elderly patients with pneumonia. DESIGN, SETTING, AND PATIENTS Retrospective cohort study of Medicare beneficiaries (aged &amp;amp;amp;gt;64 years) admitted to 2988 acute care hospitals in the United States with pneumonia from 2010 to 2012. EXPOSURES ICU admission vs general ward admission. MAIN OUTCOMES AND MEASURES Primary outcome was 30-day all-cause mortality. Secondary outcomes included Medicare spending and hospital costs. Patient and hospital characteristics were adjusted to account for differences between patients with and without ICU admission. To account for unmeasured confounding, an instrumental variable was used—the differential distance to a hospital with high ICU admission (defined as any hospital in the upper 2 quintiles of ICU use). RESULTS Among 1 112 394 Medicare beneficiaries with pneumonia, 328 404 (30%) were admitted to the ICU. In unadjusted analyses, patients admitted to the ICU had significantly higher 30-day mortality, Medicare spending, and hospital costs than patients admitted to a general hospital ward. Patients (n = 553 597) living closer than the median differential distance (&amp;lt;3.3 miles) to a hospital with high ICU admission were significantly more likely to be admitted to the ICU than patients living farther away (n = 558 797) (36% for patients living closer vs 23% for patients living farther, P &amp;lt; .001). In adjusted analyses, for the 13% of patients whose ICU admission decision appeared to be discretionary (dependent only on distance), ICU admission was associated with a significantly lower adjusted 30-day mortality (14.8% for ICU admission vs 20.5% for general ward admission, P = .02; absolute decrease, -5.7% [95% CI, -10.6%, -0.9%]), yet there were no significant differences in Medicare spending or hospital costs for the hospitalization. CONCLUSIONS AND RELEVANCE Among Medicare beneficiaries hospitalized with pneumonia, ICU admission of patients for whom the decision appeared to be discretionary was associated with improved survival and no significant difference in costs. A randomized trial may be warranted to assess whether more liberal ICU admission policies improve mortality for patients with pneumonia.;,citation_author=Thomas S. Valley;,citation_author=Michael W. Sjoding;,citation_author=Andrew M. Ryan;,citation_author=Theodore J. Iwashyna;,citation_author=Colin R. Cooke;,citation_publication_date=2015-09;,citation_cover_date=2015-09;,citation_year=2015;,citation_issue=12;,citation_doi=10.1001/jama.2015.11068;,citation_issn=0098-7484;,citation_volume=314;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Mapping the Oxford Shoulder Score onto the EQ-5D utility index;,citation_abstract=Purpose In order to enable cost-utility analysis of shoulder pain conditions and treatments, this study aimed to develop and evaluate mapping algorithms to estimate the EQ-5D health index from the Oxford Shoulder Score (OSS) when health outcomes are only assessed with the OSS. Methods 5437 paired OSS and EQ-5D questionnaire responses from four national multicentre randomised controlled trials investigating different shoulder pathologies and treatments were split into training and testing samples. Separate EQ-5D-3L and EQ-5D-5L analyses were undertaken. Transfer to utility (TTU) regression (univariate linear, polynomial, spline, multivariable linear, two-part logistic-linear, tobit and adjusted limited dependent variable mixture models) and response mapping (ordered logistic regression and seemingly unrelated regression (SUR)) models were developed on the training sample. These were internally validated, and their performance evaluated on the testing sample. Model performance was evaluated over 100-fold repeated training–testing sample splits. Results For the EQ-5D-3L analysis, the multivariable linear and splines models had the lowest mean square error (MSE) of 0.0415. The SUR model had the lowest mean absolute error (MAE) of 0.136. Model performance was greatest in the midrange and best health states, and lowest in poor health states. For the EQ-5D-5L analyses, the multivariable linear and splines models had the lowest MSE (0.0241–0.0278) while the SUR models had the lowest MAE (0.105–0.113). Conclusion The developed models now allow accurate estimation of the EQ-5D health index when only the OSS responses are available as a measure of patient-reported health outcome.;,citation_author=Epaminondas M. Valsamis;,citation_author=David Beard;,citation_author=Andrew Carr;,citation_author=Gary S. Collins;,citation_author=Stephen Brealey;,citation_author=Amar Rangan;,citation_author=Rita Santos;,citation_author=Belen Corbacho;,citation_author=Jonathan L. Rees;,citation_author=Rafael Pinedo-Villanueva;,citation_publication_date=2022-09;,citation_cover_date=2022-09;,citation_year=2022;,citation_doi=10.1007/s11136-022-03262-4;,citation_issn=0962-9343, 1573-2649;,citation_language=en-US;,citation_journal_title=Quality of Life Research;">
<meta name="citation_reference" content="citation_title=Platelet Transfusion before CVC Placement in Patients with Thrombocytopenia;,citation_author=Floor L. F. Baarle;,citation_author=Emma K. Weerdt;,citation_author=Walter J. F. M. Velden;,citation_author=Roelof A. Ruiterkamp;,citation_author=Pieter R. Tuinman;,citation_author=Paula F. Ypma;,citation_author=Walter M. Bergh;,citation_author=Astrid M. P. Demandt;,citation_author=Emile D. Kerver;,citation_author=A. J. Gerard Jansen;,citation_author=Peter E. Westerweel;,citation_author=Sesmu M. Arbous;,citation_author=Rogier M. Determann;,citation_author=Walther N. K. A. Mook;,citation_author=Mirelle Koeman;,citation_author=Anja B. U. Mäkelburg;,citation_author=Krijn P. Lienden;,citation_author=Jan M. Binnekade;,citation_author=Bart J. Biemond;,citation_author=Alexander P. J. Vlaar;,citation_publication_date=2023-05;,citation_cover_date=2023-05;,citation_year=2023;,citation_issue=21;,citation_doi=10.1056/NEJMoa2214322;,citation_issn=0028-4793;,citation_pmid=37224197;,citation_volume=388;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Consequences of relying on statistical significance: Some illustrations;,citation_abstract=Background: Despite regular criticisms of null hypothesis significance testing (NHST), a focus on testing persists, sometimes in the belief to get published and sometimes encouraged by journal reviewers. This paper aims to demonstrate known key limitations of NHST using simple nontechnical illustrations. Design: The first illustration is based on simulated data of 20 000 studies that compare two groups for an outcome event. The true effect size (difference in event rates) and sample size (20-100 per group) were varied. The second illustration used real data from a meta-analysis on alpha-blockers for the treatment of ureteric stones. Results: The simulations demonstrated the large between-study variability in Pvalues (range between &amp;amp;amp;lt;.0001 and 1 for most simulation conditions). A focus on statistically significant effects (P &amp;lt; .05), notably in small to moderate samples, led to strongly overestimated effect sizes (up to 240%) and many false-positive conclusions, that is statistically significant effects that were, in fact, true null effects. Effect sizes also exerted strong between-study variability, but confidence intervals accounted for this: the interval width decreased with larger sample size, and the percentage of intervals that contained the true effect size was accurate across simulation conditions. Reducing alpha level, as recently suggested, reduced false-positive conclusions but strongly increased the overestimation of significant effects (up to 320%). Conclusions: Researchers and journals should abandon statistical significance as a pivotal element in most scientific publications. Confidence intervals around effect sizes are more informative, but should not merely be reported to comply with journal requirements.;,citation_author=Ben Van Calster;,citation_author=Ewout W. Steyerberg;,citation_author=Gary S. Collins;,citation_author=Tim Smits;,citation_publication_date=2018-05;,citation_cover_date=2018-05;,citation_year=2018;,citation_issue=5;,citation_doi=10.1111/eci.12912;,citation_issn=00142972;,citation_volume=48;,citation_language=en-US;,citation_journal_title=European Journal of Clinical Investigation;">
<meta name="citation_reference" content="citation_title=Methodology over metrics: Current scientific standards are a disservice to patients and society;,citation_abstract=Covid-19 research made it painfully clear that the scandal of poor medical research, as denounced by Altman in 1994, persists today. The overall quality of medical research remains poor, despite longstanding criticisms. The problems are well known, but the research community fails to properly address them. We suggest that most problems stem from an underlying paradox: although methodology is undeniably the backbone of high-quality and responsible research, science consistently undervalues methodology. The focus remains more on the destination (research claims and metrics) than on the journey. Notwithstanding, research should serve society more than the reputation of those involved. While we notice that many initiatives are being established to improve components of the research cycle, these initiatives are too disjointed. The overall system is monolithic and slow to adapt. We assert that top-down action is needed from journals, universities, funders and governments to break the cycle and put methodology first. These actions should involve the widespread adoption of registered reports, balanced research funding between innovative, incremental and methodological research projects, full recognition and demystification of peer review, improved methodological review of reports, adherence to reporting guidelines, and investment in methodological education and research. Currently, the scientific enterprise is doing a major disservice to patients and society.;,citation_author=Ben Van Calster;,citation_author=Laure Wynants;,citation_author=Richard D Riley;,citation_author=Maarten Smeden;,citation_author=Gary S Collins;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_doi=10.1016/j.jclinepi.2021.05.018;,citation_issn=0895-4356;,citation_volume=138;,citation_language=en-US;,citation_journal_title=Journal of Clinical Epidemiology;">
<meta name="citation_reference" content="citation_title=There is no such thing as a validated prediction model;,citation_abstract=Clinical prediction models should be validated before implementation in clinical practice. But is favorable performance at internal validation or one external validation sufficient to claim that a prediction model works well in the intended clinical context?;,citation_author=Ben Van Calster;,citation_author=Ewout W. Steyerberg;,citation_author=Laure Wynants;,citation_author=Maarten Smeden;,citation_publication_date=2023-02;,citation_cover_date=2023-02;,citation_year=2023;,citation_issue=1;,citation_doi=10.1186/s12916-023-02779-w;,citation_issn=1741-7015;,citation_volume=21;,citation_journal_title=BMC Medicine;">
<meta name="citation_reference" content="citation_title=Prehospital transdermal glyceryl trinitrate in patients with presumed acute stroke (MR ASAP): An ambulance-based, multicentre, randomised, open-label, blinded endpoint, phase 3 trial;,citation_abstract=Background Pooled analyses of previous randomised studies have suggested that very early treatment with glyceryl trinitrate (also known as nitroglycerin) improves functional outcome in patients with acute ischaemic stroke or intracerebral haemorrhage, but this finding was not confirmed in a more recent trial (RIGHT-2). We aimed to assess whether patients with presumed acute stroke benefit from glyceryl tr initrate started within 3 h after symptom onset.;,citation_author=Sophie A Berg;,citation_author=Simone M Uniken Venema;,citation_author=Hendrik Reinink;,citation_author=Jeannette Hofmeijer;,citation_author=Wouter J Schonewille;,citation_author=Irene Miedema;,citation_author=Puck S S Fransen;,citation_author=D Martijn O Pruissen;,citation_author=Theodora W M Raaijmakers;,citation_author=Gert W Dijk;,citation_author=Frank-Erik Leeuw;,citation_author=Jorine A Vliet;,citation_author=Vincent I H Kwa;,citation_author=Henk Kerkhoff;,citation_author=Alex Net;,citation_author=Rene Boomars;,citation_author=Arjen Siegers;,citation_author=Tycho Lok;,citation_author=Klaartje Caminada;,citation_author=Laura M Esteve Cuevas;,citation_author=Marieke C Visser;,citation_author=Casper P Zwetsloot;,citation_author=Jooske M F Boomsma;,citation_author=Mirjam H Schipper;,citation_author=Roeland P J Eijkelenburg;,citation_author=Olvert A Berkhemer;,citation_author=Daan Nieboer;,citation_author=Hester F Lingsma;,citation_author=Bart J Emmer;,citation_author=Robert J Oostenbrugge;,citation_author=Aad Lugt;,citation_author=Yvo B W E M Roos;,citation_author=Charles B L M Majoie;,citation_author=Diederik W J Dippel;,citation_author=Paul J Nederkoorn;,citation_author=H Bart Worp;,citation_author=Ayla Ahee;,citation_author=Frank Visseren;,citation_author=Patricia Halkes;,citation_author=Ruben Eijk;,citation_author=Michelle Simons;,citation_author=Wilma Pellikaan;,citation_author=Wilma Van Wijngaarden;,citation_author=Eva Ponjee;,citation_author=Petra Geijtenbeek;,citation_author=Ton Arts;,citation_author=Elles Zock;,citation_author=Wilma Oudshoorn;,citation_author=Frans Steenwinkel;,citation_author=Hamdia Samim;,citation_author=Mark Zandwijk;,citation_author=Lisette Vrielink;,citation_author=Peter Jan Mulder;,citation_author=Aico Gerritsen;,citation_author=Jim Ijzermans;,citation_author=Marjan Kooijman;,citation_author=Oscar Francissen;,citation_author=Rick Nuland;,citation_author=Wim Zwam;,citation_author=Linda Jacobi;,citation_author=Rene Berg;,citation_author=Ludo Beenen;,citation_author=Adriaan Es;,citation_author=Pieter-Jan Doormaal;,citation_author=Geert Lycklama a Nijeholt;,citation_author=Ido Wijngaard;,citation_author=Albert Yoo;,citation_author=Lonneke Yo;,citation_author=Jasper Martens;,citation_author=Bas Hammer;,citation_author=Stefan Roosendaal;,citation_author=Anton Meijer;,citation_author=Menno Krietemeijer;,citation_author=Reinoud Bokkers;,citation_author=Anouk Hoorn;,citation_author=Dick Gerrits;,citation_author=Jonathan Coutinho;,citation_author=Ben Jansen;,citation_author=Sanne Manschot;,citation_author=Peter Koudstaal;,citation_author=Koos Keizer;,citation_author=Vicky Chalos;,citation_author=Adriaan Versteeg;,citation_author=Lennard Wolff;,citation_author=Henk Voorst;,citation_author=Matthijs Sluijs;,citation_author=Arnolt-Jan Hoving;,citation_author=Kilian Treurniet;,citation_author=Natalie LeCouffe;,citation_author=Rob Graaf;,citation_author=Robert-Jan Goldhoorn;,citation_author=Wouter Hinseveld;,citation_author=Anne Pirson;,citation_author=Lotte Sondag;,citation_author=Manon Kappelhof;,citation_author=Manon Tolhuisen;,citation_author=Josje Brouwer;,citation_author=Wouter Steen;,citation_author=Leon Rinkel;,citation_author=Agnetha Bruggeman;,citation_author=Rita Sprengers;,citation_author=Martin Sterrenberg;,citation_author=Sabrina Verheesen;,citation_author=Leontien Heiligers;,citation_author=Yvonne Martens;,citation_author=Naziha El Ghannouti;,citation_author=Miranda Slotboom;,citation_publication_date=2022-11;,citation_cover_date=2022-11;,citation_year=2022;,citation_issue=11;,citation_doi=10.1016/S1474-4422(22)00333-7;,citation_issn=14744422;,citation_volume=21;,citation_language=en-US;,citation_journal_title=The Lancet Neurology;">
<meta name="citation_reference" content="citation_title=Fluid management of the neurological patient: A concise review;,citation_abstract=Maintenance fluids in critically ill brain-injured patients are part of routine critical care. Both the amounts of fluid volumes infused and the type and tonicity of maintenance fluids are relevant in understanding the impact of fluids on the pathophysiology of secondary brain injuries in these patients. In this narrative review, current evidence on routine fluid management of critically ill brain-injured patients and use of haemodynamic monitoring is summarized. Pertinent guidelines and consensus statements on fluid management for brain-injured patients are highlighted. In general, existing guidelines indicate that fluid management in these neurocritical care patients should be targeted at euvolemia using isotonic fluids. A critical appraisal is made of the available literature regarding the appropriate amount of fluids, haemodynamic monitoring and which types of fluids should be administered or avoided and a practical approach to fluid management is elaborated. Although hypovolemia is bound to contribute to secondary brain injury, some more recent data have emerged indicating the potential risks of fluid overload. However, it is acknowledged that many factors govern the relationship between fluid management and cerebral blood flow and oxygenation and more research seems warranted to optimise fluid management and improve outcomes.;,citation_author=Mathieu Jagt;,citation_publication_date=2016-05;,citation_cover_date=2016-05;,citation_year=2016;,citation_issue=1;,citation_doi=10.1186/s13054-016-1309-2;,citation_issn=1364-8535;,citation_volume=20;,citation_language=en-US;,citation_journal_title=Critical Care;">
<meta name="citation_reference" content="citation_title=Safety and efficacy of aspirin, unfractionated heparin, both, or neither during endovascular stroke treatment (MR CLEAN-MED): An open-label, multicentre, randomised controlled trial;,citation_abstract=Background Aspirin and unfractionated heparin are often used during endovascular stroke treatment to improve reperfusion and outcomes. However, the effects and risks of anti-thrombotics for this indication are unknown. We therefore aimed to assess the safety and efficacy of intravenous aspirin, unfractionated heparin, both, or neither started during endovascular treatment in patients with ischaemic stroke.;,citation_author=Wouter Steen;,citation_author=Rob A Graaf;,citation_author=Vicky Chalos;,citation_author=Hester F Lingsma;,citation_author=Pieter Jan Doormaal;,citation_author=Jonathan M Coutinho;,citation_author=Bart J Emmer;,citation_author=Inger Ridder;,citation_author=Wim Zwam;,citation_author=H Bart Worp;,citation_author=Irene Schaaf;,citation_author=Rob A R Gons;,citation_author=Lonneke S F Yo;,citation_author=Jelis Boiten;,citation_author=Ido Wijngaard;,citation_author=Jeannette Hofmeijer;,citation_author=Jasper Martens;,citation_author=Wouter Schonewille;,citation_author=Jan Albert Vos;,citation_author=Anil Man Tuladhar;,citation_author=Karlijn F Laat;,citation_author=Boudewijn Hasselt;,citation_author=Michel Remmers;,citation_author=Douwe Vos;,citation_author=Anouk Rozeman;,citation_author=Otto Elgersma;,citation_author=Maarten Uyttenboogaart;,citation_author=Reinoud P H Bokkers;,citation_author=Julia Tuijl;,citation_author=Issam Boukrab;,citation_author=René Berg;,citation_author=Ludo F M Beenen;,citation_author=Stefan D Roosendaal;,citation_author=Alida Annechien Postma;,citation_author=Menno Krietemeijer;,citation_author=Geert Lycklama;,citation_author=Frederick J A Meijer;,citation_author=Sebastiaan Hammer;,citation_author=Anouk Hoorn;,citation_author=Albert J Yoo;,citation_author=Dick Gerrits;,citation_author=Martine T B Truijman;,citation_author=Sanne Zinkstok;,citation_author=Peter J Koudstaal;,citation_author=Sanne Manschot;,citation_author=Henk Kerkhoff;,citation_author=Daan Nieboer;,citation_author=Olvert Berkhemer;,citation_author=Lennard Wolff;,citation_author=P Matthijs Sluijs;,citation_author=Henk Voorst;,citation_author=Manon Tolhuisen;,citation_author=Yvo B W E M Roos;,citation_author=Charles B L M Majoie;,citation_author=Julie Staals;,citation_author=Robert J Oostenbrugge;,citation_author=Sjoerd F M Jenniskens;,citation_author=Lukas C Dijk;,citation_author=Heleen M Hertog;,citation_author=Adriaan C G M Es;,citation_author=Aad Lugt;,citation_author=Diederik W J Dippel;,citation_author=Bob Roozenbeek;,citation_publication_date=2022-03;,citation_cover_date=2022-03;,citation_year=2022;,citation_issue=10329;,citation_doi=10.1016/S0140-6736(22)00014-9;,citation_issn=01406736;,citation_volume=399;,citation_language=en-US;,citation_journal_title=The Lancet;">
<meta name="citation_reference" content="citation_title=Comparing methods to combine functional loss and mortality in clinical trials for amyotrophic lateral sclerosis;,citation_abstract=Objective: Amyotrophic lateral sclerosis (ALS) clinical trials based on single end points only partially capture the full treatment effect when both function and mortality are affected, and may falsely dismiss efficacious drugs as futile. We aimed to investigate the statistical properties of several strategies for the simultaneous analysis of function and mortality in ALS clinical trials. Methods: Based on the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database, we simulated longitudinal patterns of functional decline, defined by the revised amyotrophic lateral sclerosis functional rating scale (ALSFRS-R) and conditional survival time. Different treatment scenarios with varying effect sizes were simulated with follow-up ranging from 12 to 18 months. We considered the following analytical strategies: 1) Cox model; 2) linear mixed effects (LME) model; 3) omnibus test based on Cox and LME models; 4) composite time-to-6-point decrease or death; 5) combined assessment of function and survival (CAFS); and 6) test based on joint modeling framework. For each analytical strategy, we calculated the empirical power and sample size. Results: Both Cox and LME models have increased false-negative rates when treatment exclusively affects either function or survival. The joint model has superior power compared to other strategies. The composite end point increases false-negative rates among all treatment scenarios. To detect a 15% reduction in ALSFRS-R decline and 34% decline in hazard with 80% power after 18 months, the Cox model requires 524 patients, the LME model 794 patients, the omnibus test 526 patients, the composite end point 1,274 patients, the CAFS 576 patients and the joint model 464 patients. Conclusion: Joint models have superior statistical power to analyze simultaneous effects on survival and function and may circumvent pitfalls encountered by other end points. Optimizing trial end points is essential, as selecting suboptimal outcomes may disguise important treatment clues.;,citation_author=Ruben P. A. Eijk;,citation_author=Marinus J. C. Eijkemans;,citation_author=Dimitris Rizopoulos;,citation_author=Leonard H. Berg;,citation_author=Stavros Nikolakopoulos;,citation_publication_date=2018-03;,citation_cover_date=2018-03;,citation_year=2018;,citation_doi=10.2147/CLEP.S153196;,citation_issn=1179-1349;,citation_volume=Volume 10;,citation_language=en-US;,citation_journal_title=Clinical Epidemiology;">
<meta name="citation_reference" content="citation_title=Maintenance fluid therapy and fluid creep impose more significant fluid, sodium, and chloride burdens than resuscitation fluids in critically ill patients: A retrospective study in a tertiary mixed ICU population;,citation_abstract=PURPOSE: Research on intravenous fluid therapy and its side effects, volume, sodium, and chloride overload, has focused almost exclusively on the resuscitation setting. We aimed to quantify all fluid sources in the ICU and assess fluid creep, the hidden and unintentional volume administered as a vehicle for medication or electrolytes. METHODS: We precisely recorded the volume, sodium, and chloride burdens imposed by every fluid source administered to 14,654 patients during the cumulative 103,098&nbsp;days they resided in our 45-bed tertiary ICU and simulated the impact of important strategic fluid choices on patients’ chloride burdens. In septic patients, we assessed the impact of the different fluid sources on cumulative fluid balance, an established marker of morbidity. RESULTS: Maintenance and replacement fluids accounted for 24.7% of the mean daily total fluid volume, thereby far exceeding resuscitation fluids (6.5%) and were the most important sources of sodium and chloride. Fluid creep represented a striking 32.6% of the mean daily total fluid volume [median 645&nbsp;mL (IQR 308-1039&nbsp;mL)]. Chloride levels can be more effectively reduced by adopting a hypotonic maintenance strategy [a daily difference in chloride burden of 30.8&nbsp;mmol (95% CI 30.5-31.1)] than a balanced resuscitation strategy [daily difference 3.0&nbsp;mmol (95% CI 2.9-3.1)]. In septic patients, non-resuscitation fluids had a larger absolute impact on cumulative fluid balance than did resuscitation fluids. CONCLUSIONS: Inadvertent daily volume, sodium, and chloride loading should be avoided when prescribing maintenance fluids in view of the vast amounts of fluid creep. This is especially important when adopting an isotonic maintenance strategy.;,citation_author=Niels Van Regenmortel;,citation_author=Walter Verbrugghe;,citation_author=Ella Roelant;,citation_author=Tim Van den Wyngaert;,citation_author=Philippe G. Jorens;,citation_publication_date=2018-04;,citation_cover_date=2018-04;,citation_year=2018;,citation_issue=4;,citation_doi=10.1007/s00134-018-5147-3;,citation_issn=1432-1238;,citation_pmid=29589054;,citation_volume=44;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Reflection on modern methods: Five myths about measurement error in epidemiological research;,citation_abstract=Epidemiologists are often confronted with datasets to analyse which contain measurement error due to, for instance, mistaken data entries, inaccurate recordings and measurement instrument or procedural errors. If the effect of measurement error is misjudged, the data analyses are hampered and the validity of the study’s inferences may be affected. In this paper, we describe five myths that contribute to misjudgments about measurement error, regarding expected structure, impact and solutions to mitigate the problems resulting from mismeasurements. The aim is to clarify these measurement error misconceptions. We show that the influence of measurement error in an epidemiological data analysis can play out in ways that go beyond simple heuristics, such as heuristics about whether or not to expect attenuation of the effect estimates. Whereas we encourage epidemiologists to deliberate about the structure and potential impact of measurement error in their analyses, we also recommend exercising restraint when making claims about the magnitude or even direction of effect of measurement error if not accompanied by statistical measurement error corrections or quantitative bias analysis. Suggestions for alleviating the problems or investigating the structure and magnitude of measurement error are given.;,citation_author=Maarten Smeden;,citation_author=Timothy L Lash;,citation_author=Rolf H H Groenwold;,citation_publication_date=2020-02;,citation_cover_date=2020-02;,citation_year=2020;,citation_issue=1;,citation_doi=10.1093/ije/dyz251;,citation_issn=0300-5771, 1464-3685;,citation_volume=49;,citation_language=en-US;,citation_journal_title=International Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=A Very Short List of Common Pitfalls in Research Design, Data Analysis, and Reporting;,citation_author=Maarten Smeden;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Occurrence and timing of withdrawal of life-sustaining measures in traumatic brain injury patients: A CENTER-TBI study;,citation_abstract=Background: In patients with severe brain injury, withdrawal of life-sustaining measures (WLSM) is common in intensive care units (ICU). WLSM constitutes a dilemma: instituting WLSM too early could result in death despite the possibility of an acceptable functional outcome, whereas delaying WLSM could unnecessarily burden patients, families, clinicians, and hospital resources. We aimed to describe the occurrence and timing of WLSM, and factors associated with timing of WLSM in European ICUs in patients with traumatic brain injury (TBI). Methods: The CENTER-TBI Study is a prospective multi-center cohort study. For the current study, patients with traumatic brain injury (TBI) admitted to the ICU and aged 16 or older were included. Occurrence and timing of WLSM were documented. For the analyses, we dichotomized timing of WLSM in early (&amp;amp;amp;lt; 72 h after injury) versus later (\geq 72 h after injury) based on recent guideline recommendations. We assessed factors associated with initiating WLSM early versus later, including geographic region, center, patient, injury, and treatment characteristics with univariable and multivariable (mixed effects) logistic regression. Results: A total of 2022 patients aged 16 or older were admitted to the ICU. ICU mortality was 13% (n = 267). Of these, 229 (86%) patients died after WLSM, and were included in the analyses. The occurrence of WLSM varied between regions ranging from 0% in Eastern Europe to 96% in Northern Europe. In 51% of the patients, WLSM was early. Patients in the early WLSM group had a lower maximum therapy intensity level (TIL) score than patients in the later WLSM group (median of 5 versus 10) The strongest independent variables associated with early WLSM were one unreactive pupil (odds ratio (OR) 4.0, 95% confidence interval (CI) 1.3–12.4) or two unreactive pupils (OR 5.8, CI 2.6–13.1) compared to two reactive pupils, and an Injury Severity Score (ISS) if over 41 (OR per point above 41 = 1.1, CI 1.0–1.1). Timing of WLSM was not significantly associated with region or center. Conclusion: WLSM occurs early in half of the patients, mostly in patients with severe TBI affecting brainstem reflexes who were severely injured. We found no regional or center influences in timing of WLSM. Whether WLSM is always appropriate or may contribute to a self-fulfilling prophecy requires further research and argues for reluctance to institute WLSM early in case of any doubt on prognosis.;,citation_author=Ernest Veen;,citation_author=Mathieu Jagt;,citation_author=Giuseppe Citerio;,citation_author=Nino Stocchetti;,citation_author=Diederik Gommers;,citation_author=Alex Burdorf;,citation_author=David K. Menon;,citation_author=Andrew I. R. Maas;,citation_author=Erwin J. O. Kompanje;,citation_author=Hester F. Lingsma;,citation_author=the CENTER-TBI investigators and participants;,citation_author=Cecilia Åkerlund;,citation_author=Krisztina Amrein;,citation_author=Nada Andelic;,citation_author=Lasse Andreassen;,citation_author=Audny Anke;,citation_author=Anna Antoni;,citation_author=Gérard Audibert;,citation_author=Philippe Azouvi;,citation_author=Maria Luisa Azzolini;,citation_author=Ronald Bartels;,citation_author=Pál Barzó;,citation_author=Romuald Beauvais;,citation_author=Ronny Beer;,citation_author=Bo-Michael Bellander;,citation_author=Antonio Belli;,citation_author=Habib Benali;,citation_author=Maurizio Berardino;,citation_author=Luigi Beretta;,citation_author=Morten Blaabjerg;,citation_author=Peter Bragge;,citation_author=Alexandra Brazinova;,citation_author=Vibeke Brinck;,citation_author=Joanne Brooker;,citation_author=Camilla Brorsson;,citation_author=Andras Buki;,citation_author=Monika Bullinger;,citation_author=Manuel Cabeleira;,citation_author=Alessio Caccioppola;,citation_author=Emiliana Calappi;,citation_author=Maria Rosa Calvi;,citation_author=Peter Cameron;,citation_author=Guillermo Carbayo Lozano;,citation_author=Marco Carbonara;,citation_author=Simona Cavallo;,citation_author=Giorgio Chevallard;,citation_author=Arturo Chieregato;,citation_author=Giuseppe Citerio;,citation_author=Hans Clusmann;,citation_author=Mark Coburn;,citation_author=Jonathan Coles;,citation_author=Jamie D. Cooper;,citation_author=Marta Correia;,citation_author=Amra Čović;,citation_author=Nicola Curry;,citation_author=Endre Czeiter;,citation_author=Marek Czosnyka;,citation_author=Claire Dahyot Fizelier;,citation_author=Paul Dark;,citation_author=Helen Dawes;,citation_author=Véronique De Keyser;,citation_author=Vincent Degos;,citation_author=Francesco Della Corte;,citation_author=Hugo Boogert;,citation_author=Bart Depreitere;,citation_author=ula ilvesi;,citation_author=Abhishek Dixit;,citation_author=Emma Donoghue;,citation_author=Jens Dreier;,citation_author=Guy Loup Dulière;,citation_author=Ari Ercole;,citation_author=Patrick Esser;,citation_author=Erzsébet Ezer;,citation_author=Martin Fabricius;,citation_author=Valery L. Feigin;,citation_author=Kelly Foks;,citation_author=Shirin Frisvold;,citation_author=Alex Furmanov;,citation_author=Pablo Gagliardo;,citation_author=Damien Galanaud;,citation_author=Dashiell Gantner;,citation_author=Guoyi Gao;,citation_author=Pradeep George;,citation_author=Alexandre Ghuysen;,citation_author=Lelde Giga;,citation_author=Ben Glocker;,citation_author=Jagoš Golubovic;,citation_author=Pedro A. Gomez;,citation_author=Johannes Gratz;,citation_author=Benjamin Gravesteijn;,citation_author=Francesca Grossi;,citation_author=Russell L. Gruen;,citation_author=Deepak Gupta;,citation_author=Juanita A. Haagsma;,citation_author=Iain Haitsma;,citation_author=Raimund Helbok;,citation_author=Eirik Helseth;,citation_author=Lindsay Horton;,citation_author=Jilske Huijben;,citation_author=Peter J. Hutchinson;,citation_author=Bram Jacobs;,citation_author=Stefan Jankowski;,citation_author=Mike Jarrett;,citation_author=Ji Jiang;,citation_author=Faye Johnson;,citation_author=Kelly Jones;,citation_author=Mladen Karan;,citation_author=Angelos G. Kolias;,citation_author=Erwin Kompanje;,citation_author=Daniel Kondziella;,citation_author=Evgenios Kornaropoulos;,citation_author=Lars Owe Koskinen;,citation_author=Noémi Kovács;,citation_author=Ana Kowark;,citation_author=Alfonso Lagares;,citation_author=Linda Lanyon;,citation_author=Steven Laureys;,citation_author=Fiona Lecky;,citation_author=Didier Ledoux;,citation_author=Rolf Lefering;,citation_author=Valerie Legrand;,citation_author=Aurelie Lejeune;,citation_author=Leon Levi;,citation_author=Roger Lightfoot;,citation_author=Hester Lingsma;,citation_author=Andrew I. R. Maas;,citation_author=Ana M. León Castaño;,citation_author=Marc Maegele;,citation_author=Marek Majdan;,citation_author=Alex Manara;,citation_author=Geoffrey Manley;,citation_author=Costanza Martino;,citation_author=Hugues Maréchal;,citation_author=Julia Mattern;,citation_author=Catherine McMahon;,citation_author=Béla Melegh;,citation_author=David Menon;,citation_author=Tomas Menovsky;,citation_author=Ana Mikolic;,citation_author=Benoit Misset;,citation_author=Visakh Muraleedharan;,citation_author=Lynnette Murray;,citation_author=Ancuta Negru;,citation_author=David Nelson;,citation_author=Virginia Newcombe;,citation_author=Daan Nieboer;,citation_author=József Nyirádi;,citation_author=Otesile Olubukola;,citation_author=Matej Oresic;,citation_author=Fabrizio Ortolano;,citation_author=Aarno Palotie;,citation_author=Paul M. Parizel;,citation_author=Jean François Payen;,citation_author=Natascha Perera;,citation_author=Vincent Perlbarg;,citation_author=Paolo Persona;,citation_author=Wilco Peul;,citation_author=Anna Piippo-Karjalainen;,citation_author=Matti Pirinen;,citation_author=Dana Pisica;,citation_author=Horia Ples;,citation_author=Suzanne Polinder;,citation_author=Inigo Pomposo;,citation_author=Jussi P. Posti;,citation_author=Louis Puybasset;,citation_author=Andreea Radoi;,citation_author=Arminas Ragauskas;,citation_author=Rahul Raj;,citation_author=Malinka Rambadagalla;,citation_author=Isabel Retel Helmrich;,citation_author=Jonathan Rhodes;,citation_author=Sylvia Richardson;,citation_author=Sophie Richter;,citation_author=Samuli Ripatti;,citation_author=Saulius Rocka;,citation_author=Cecilie Roe;,citation_author=Olav Roise;,citation_author=Jonathan Rosand;,citation_author=Jeffrey V. Rosenfeld;,citation_author=Christina Rosenlund;,citation_author=Guy Rosenthal;,citation_author=Rolf Rossaint;,citation_author=Sandra Rossi;,citation_author=Daniel Rueckert;,citation_author=Martin Rusnák;,citation_author=Juan Sahuquillo;,citation_author=Oliver Sakowitz;,citation_author=Renan Sanchez Porras;,citation_author=Janos Sandor;,citation_author=Nadine Schäfer;,citation_author=Silke Schmidt;,citation_author=Herbert Schoechl;,citation_author=Guus Schoonman;,citation_author=Rico Frederik Schou;,citation_author=Elisabeth Schwendenwein;,citation_author=Charlie Sewalt;,citation_author=Toril Skandsen;,citation_author=Peter Smielewski;,citation_author=Abayomi Sorinola;,citation_author=Emmanuel Stamatakis;,citation_author=Simon Stanworth;,citation_author=Robert Stevens;,citation_author=William Stewart;,citation_author=Ewout W. Steyerberg;,citation_author=Nino Stocchetti;,citation_author=Nina Sundström;,citation_author=Riikka Takala;,citation_author=Viktória Tamás;,citation_author=Tomas Tamosuitis;,citation_author=Mark Steven Taylo;,citation_author=Braden Te Ao;,citation_author=Olli Tenovuo;,citation_author=Alice Theadom;,citation_author=Matt Thomas;,citation_author=Dick Tibboel;,citation_author=Marjolein Timmers;,citation_author=Christos Tolias;,citation_author=Tony Trapani;,citation_author=Cristina Maria Tudora;,citation_author=Andreas Unterberg;,citation_author=Peter Vajkoczy;,citation_author=Shirley Vallance;,citation_author=Egils Valeinis;,citation_author=Zoltán Vámos;,citation_author=Mathieu Jagt;,citation_author=Gregory Van der Steen;,citation_author=Joukje Naalt;,citation_author=Jeroen T. J. M. Dijck;,citation_author=Thomas A. Essen;,citation_author=Wim Van Hecke;,citation_author=Caroline Heugten;,citation_author=Dominique Van Praag;,citation_author=Ernest Veen;,citation_author=Thijs Vande Vyvere;,citation_author=Roel P. J. Wijk;,citation_author=Alessia Vargiolu;,citation_author=Emmanuel Vega;,citation_author=Kimberley Velt;,citation_author=Jan Verheyden;,citation_author=Paul M. Vespa;,citation_author=Anne Vik;,citation_author=Rimantas Vilcinis;,citation_author=Victor Volovici;,citation_author=Nicole Steinbüchel;,citation_author=Daphne Voormolen;,citation_author=Petar Vulekovic;,citation_author=Kevin K. W. Wang;,citation_author=Eveline Wiegers;,citation_author=Guy Williams;,citation_author=Lindsay Wilson;,citation_author=Stefan Winzeck;,citation_author=Stefan Wolf;,citation_author=Zhihui Yang;,citation_author=Peter Ylén;,citation_author=Alexander Younsi;,citation_author=Frederick A. Zeiler;,citation_author=Veronika Zelinkova;,citation_author=Agate Ziverte;,citation_author=Tommaso Zoerle;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=10;,citation_doi=10.1007/s00134-021-06484-1;,citation_issn=0342-4642, 1432-1238;,citation_volume=47;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Addressing exaggeration of effects from single RCTs;,citation_abstract=Randomised controlled trials are often presented as the gold standard for testing new medical treatments. In the early stages of research, however, reports from single trials are likely to show exaggerated effect estimates. Erik van Zwet, Simon Schwab and Sander Greenland explain why – and propose a remedy;,citation_author=Erik Zwet;,citation_author=Simon Schwab;,citation_author=Sander Greenland;,citation_publication_date=2021;,citation_cover_date=2021;,citation_year=2021;,citation_issue=6;,citation_doi=10.1111/1740-9713.01587;,citation_issn=1740-9713;,citation_volume=18;,citation_language=en-US;,citation_journal_title=Significance;">
<meta name="citation_reference" content="citation_title=The significance filter, the winner’s curse and the need to shrink;,citation_abstract=The “significance filter” refers to focusing exclusively on statistically significant results. Since frequentist properties such as unbiasedness and coverage are valid only before the data have been observed, there are no guarantees if we condition on significance. In fact, the significance filter leads to overestimation of the magnitude of the parameter, which has been called the “winner’s curse.” It can also lead to undercoverage of the confidence interval. Moreover, these problems become more severe if the power is low. These issues clearly deserve our attention. They have been studied mostly through empirical observation and simulation, while there are relatively few mathematical results. Here we study them both from the frequentist and the Bayesian perspective. We prove that the relative bias of the magnitude is a decreasing function of the power and that the usual confidence interval undercovers when the power is less than 50%. We conclude that it is important to apply the appropriate amount of shrinkage to counter the winner’s curse.;,citation_author=Erik W. Zwet;,citation_author=Eric A. Cator;,citation_publication_date=2021;,citation_cover_date=2021;,citation_year=2021;,citation_issue=4;,citation_doi=10.1111/stan.12241;,citation_issn=1467-9574;,citation_volume=75;,citation_language=en-US;,citation_journal_title=Statistica Neerlandica;">
<meta name="citation_reference" content="citation_title=Avoiding overadjustment bias in social epidemiology through appropriate covariate selection: A primer;,citation_abstract=Obtaining accurate estimates of the causal effects of socioeconomic position (SEP) on health is important for public health interventions. To do this, researchers must identify and adjust for all potential confounding variables, while avoiding inappropriate adjustment for mediator variables on a causal pathway between the exposure and outcome. Unfortunately, “overadjustment bias” remains a common and under-recognized problem in social epidemiology. This paper offers an introduction on selecting appropriate variables for adjustment when examining effects of SEP on health, with a focus on overadjustment bias. We discuss the challenges of estimating different causal effects including overadjustment bias, provide guidance on overcoming them, and consider specific issues including the timing of variables across the life-course, mutual adjustment for socioeconomic indicators, and conducting systematic reviews. We recommend three key steps to select the most appropriate variables for adjustment. First, researchers should be clear about their research question and causal effect of interest. Second, using expert knowledge and theory, researchers should draw causal diagrams representing their assumptions about the interrelationships between their variables of interest. Third, based on their causal diagram(s) and causal effect(s) of interest, researchers should select the most appropriate set of variables, which maximizes adjustment for confounding while minimizing adjustment for mediators.;,citation_author=Anita Zwieten;,citation_author=Peter W. G. Tennant;,citation_author=Michelle Kelly-Irving;,citation_author=Fiona M. Blyth;,citation_author=Armando Teixeira-Pinto;,citation_author=Saman Khalatbari-Soltani;,citation_publication_date=2022-09;,citation_cover_date=2022-09;,citation_year=2022;,citation_doi=10.1016/j.jclinepi.2022.05.021;,citation_issn=0895-4356;,citation_volume=149;,citation_language=en-US;,citation_journal_title=Journal of Clinical Epidemiology;">
<meta name="citation_reference" content="citation_title=Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration;,citation_abstract=Much medical research is observational. The reporting of observational studies is often of insufficient quality. Poor reporting hampers the assessment of the strengths and weaknesses of a study and the generalisability of its results. Taking into account empirical evidence and theoretical considerations, a group of methodologists, researchers, and editors developed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) recommendations to improve the quality of reporting of observational studies. The STROBE Statement consists of a checklist of 22 items, which relate to the title, abstract, introduction, methods, results and discussion sections of articles. Eighteen items are common to cohort studies, casecontrol studies and cross-sectional studies and four are specific to each of the three study designs. The STROBE Statement provides guidance to authors about how to improve the reporting of observational studies and facilitates critical appraisal and interpretation of studies by reviewers, journal editors and readers. This explanatory and elaboration document is intended to enhance the use, understanding, and dissemination of the STROBE Statement. The meaning and rationale for each checklist item are presented. For each item, one or several published examples and, where possible, references to relevant empirical studies and methodological literature are provided. Examples of useful flow diagrams are also included. The STROBE Statement, this document, and the associated Web site (http://www. strobe-statement.org/) should be helpful resources to improve reporting of observational research.;,citation_author=Jan P Vandenbroucke;,citation_author=Charles Poole;,citation_author=James J Schlesselman;,citation_author=Matthias Egger;,citation_publication_date=2007;,citation_cover_date=2007;,citation_year=2007;,citation_issue=10;,citation_volume=4;,citation_language=en-US;,citation_journal_title=PLoS Medicine;">
<meta name="citation_reference" content="citation_title=Causal Directed Acyclic Graphs and the Direction of Unmeasured Confounding Bias;,citation_abstract=We present results that allow the researcher in certain cases to determine the direction of the bias that arises when control for confounding is inadequate. The results are given within the context of the directed acyclic graph causal framework and are stated in terms of signed edges. Rigorous definitions for signed edges are provided. We describe cases in which intuition concerning signed edges fails and we characterize the directed acyclic graphs that researchers can use to draw conclusions about the sign of the bias of unmeasured confounding. If there is only one unmeasured confounding variable on the graph, then nonincreasing or nondecreasing average causal effects suffice to draw conclusions about the direction of the bias. When there are more than one unmeasured confounding variable, nonincreasing and nondecreasing average causal effects can be used to draw conclusions only if the various unmeasured confounding variables are independent of one another conditional on the measured covariates. When this conditional independence property does not hold, stronger notions of monotonicity are needed to draw conclusions about the direction of the bias.;,citation_author=Tyler J. VanderWeele;,citation_author=Miguel A. Hernán;,citation_author=James M. Robins;,citation_publication_date=2008-09;,citation_cover_date=2008-09;,citation_year=2008;,citation_issue=5;,citation_doi=10.1097/EDE.0b013e3181810e29;,citation_issn=1044-3983;,citation_volume=19;,citation_language=en-US;,citation_journal_title=Epidemiology;">
<meta name="citation_reference" content="citation_title=Causal diagrams for empirical legal research: A methodology for identifying causation, avoiding bias and interpreting results;,citation_author=T. J. Vanderweele;,citation_author=N. Staudt;,citation_publication_date=2011-12;,citation_cover_date=2011-12;,citation_year=2011;,citation_issue=4;,citation_doi=10.1093/lpr/mgr019;,citation_issn=1470-8396, 1470-840X;,citation_volume=10;,citation_language=en-US;,citation_journal_title=Law, Probability and Risk;">
<meta name="citation_reference" content="citation_title=Directed Acyclic Graphs, Sufficient Causes, and the Properties of Conditioning on a Common Effect;,citation_author=Tyler J. VanderWeele;,citation_author=James M. Robins;,citation_publication_date=2007-11;,citation_cover_date=2007-11;,citation_year=2007;,citation_issue=9;,citation_doi=10.1093/aje/kwm179;,citation_issn=1476-6256, 0002-9262;,citation_volume=166;,citation_language=en-US;,citation_journal_title=American Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Sensitivity Analysis in Observational Research: Introducing the E-Value;,citation_author=Tyler J. VanderWeele;,citation_author=Peng Ding;,citation_publication_date=2017-08;,citation_cover_date=2017-08;,citation_year=2017;,citation_issue=4;,citation_doi=10.7326/M16-2607;,citation_issn=0003-4819;,citation_volume=167;,citation_language=en-US;,citation_journal_title=Annals of Internal Medicine;">
<meta name="citation_reference" content="citation_title=Surveying Clinicians: An Introduction to the Special Issue;,citation_author=Jonathan B. VanGeest;,citation_author=Timothy P. Johnson;,citation_publication_date=2013-09;,citation_cover_date=2013-09;,citation_year=2013;,citation_issue=3;,citation_doi=10.1177/0163278713498006;,citation_issn=0163-2787, 1552-3918;,citation_volume=36;,citation_language=en-US;,citation_journal_title=Evaluation &amp;amp;amp; the Health Professions;">
<meta name="citation_reference" content="citation_title=Invasive Multimodal Neuromonitoring in Aneurysmal Subarachnoid Hemorrhage: A Systematic Review;,citation_abstract=BACKGROUND AND PURPOSE: Aneurysmal subarachnoid hemorrhage is a devastating disease leaving surviving patients often severely disabled. Delayed cerebral ischemia (DCI) has been identified as one of the main contributors to poor clinical outcome after subarachnoid hemorrhage. The objective of this review is to summarize existing clinical evidence assessing the diagnostic value of invasive neuromonitoring (INM) in detecting DCI and provide an update of evidence since the 2014 consensus statement on multimodality monitoring in neurocritical care. METHODS: Three invasive monitoring techniques were targeted in the data collection process: brain tissue oxygen tension (ptiO2), cerebral microdialysis, and electrocorticography. Prospective and retrospective studies as well as case series (\geq10 patients) were included as long as monitoring was used to detect DCI or guide DCI treatment. RESULTS: Forty-seven studies reporting INM in the context of DCI were included (ptiO2: N=21; cerebral microdialysis: N=22; electrocorticography: N=4). Changes in brain oxygen tension are associated with angiographic vasospasm or reduction in regional cerebral blood flow. Metabolic monitoring with trend analysis of the lactate to pyruvate ratio using cerebral microdialysis, identifies patients at risk for DCI. Clusters of cortical spreading depolarizations are associated with clinical neurological worsening and cerebral infarction in selected patients receiving electrocorticography monitoring. CONCLUSIONS: Data supports the use of INM for the detection of DCI in selected patients. Generalizability to all subarachnoid hemorrhage patients is limited by design bias of available studies and lack of randomized trials. Continuous data recording with trend analysis and the combination of INM modalities can provide tailored treatment support in patients at high risk for DCI. Future trials should test interventions triggered by INM in relation to cerebral infarctions.;,citation_author=Michael Veldeman;,citation_author=Walid Albanna;,citation_author=Miriam Weiss;,citation_author=Soojin Park;,citation_author=Anke Hoellig;,citation_author=Hans Clusmann;,citation_author=Raimund Helbok;,citation_author=Yasin Temel;,citation_author=Gerrit Alexander Schubert;,citation_publication_date=2021-11;,citation_cover_date=2021-11;,citation_year=2021;,citation_issue=11;,citation_doi=10.1161/STROKEAHA.121.034633;,citation_issn=0039-2499, 1524-4628;,citation_volume=52;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=Acute encephalitis in immunocompetent adults;,citation_author=Arun Venkatesan;,citation_author=Benedict D Michael;,citation_author=John C Probasco;,citation_author=Romergryko G Geocadin;,citation_author=Tom Solomon;,citation_publication_date=2019-02;,citation_cover_date=2019-02;,citation_year=2019;,citation_issue=10172;,citation_doi=10.1016/S0140-6736(18)32526-1;,citation_issn=01406736;,citation_volume=393;,citation_language=en-US;,citation_journal_title=The Lancet;">
<meta name="citation_reference" content="citation_title=Nonconvulsive seizures after traumatic brain injury are associated with hippocampal atrophy;,citation_abstract=Objective: To determine if posttraumatic nonconvulsive electrographic seizures result in longterm brain atrophy. Methods: Prospective continuous EEG (cEEG) monitoring was done in 140 patients with moderate to severe traumatic brain injury (TBI) and in-depth study of 16 selected patients was done using serial volumetric MRI acutely and at 6 months after TBI. Fluorodeoxyglucose PET was done in the acute stage in 14/16 patients. These data were retrospectively analyzed after collection of data for 7 years. Results: cEEG detected seizures in 32/140 (23%) of the entire cohort. In the selected imaging subgroup, 6 patients with seizures were compared with a cohort of 10 age- and GCS-matched patients with TBI without seizures. In this subgroup, the seizures were repetitive and constituted status epilepticus in 4/6 patients. Patients with seizures had greater hippocampal atrophy as compared to those without seizures (21 Ϯ 9 vs 12 Ϯ 6%, p ϭ 0.017). Hippocampi ipsilateral to the electrographic seizure focus demonstrated a greater degree of volumetric atrophy as compared with nonseizure hippocampi (28 Ϯ 5 vs 13 Ϯ 9%, p ϭ 0.007). A single patient had an ictal PET scan which demonstrated increased hippocampal glucose uptake. Conclusion: Acute posttraumatic nonconvulsive seizures occur frequently after TBI and, in a selected subgroup, appear to be associated with disproportionate long-term hippocampal atrophy. These data suggest anatomic damage is potentially elicited by nonconvulsive seizures in the acute postinjury setting. Neurology 2010;75:792–798;,citation_author=P. M. Vespa;,citation_author=D. L. McArthur;,citation_author=Y. Xu;,citation_author=M. Eliseo;,citation_author=M. Etchepare;,citation_author=I. Dinov;,citation_author=J. Alger;,citation_author=T. P. Glenn;,citation_author=D. Hovda;,citation_publication_date=2010-08;,citation_cover_date=2010-08;,citation_year=2010;,citation_issue=9;,citation_doi=10.1212/WNL.0b013e3181f07334;,citation_issn=0028-3878, 1526-632X;,citation_volume=75;,citation_language=en-US;,citation_journal_title=Neurology;">
<meta name="citation_reference" content="citation_title=Surgical Trials in Intracerebral Hemorrhage;,citation_author=Paul M. Vespa;,citation_author=Neil Martin;,citation_author=Mario Zuccarello;,citation_author=Issam Awad;,citation_author=Daniel F. Hanley;,citation_publication_date=2013-06;,citation_cover_date=2013-06;,citation_year=2013;,citation_issue=6_suppl_1;,citation_doi=10.1161/STROKEAHA.113.001494;,citation_volume=44;,citation_journal_title=Stroke;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=Statistics Notes: Analysing controlled trials with baseline and follow up measurements;,citation_author=A. J Vickers;,citation_author=D. G Altman;,citation_publication_date=2001-11;,citation_cover_date=2001-11;,citation_year=2001;,citation_issue=7321;,citation_doi=10.1136/bmj.323.7321.1123;,citation_issn=0959-8138, 1468-5833;,citation_volume=323;,citation_language=en-US;,citation_journal_title=BMJ;">
<meta name="citation_reference" content="citation_title=A Cluster-Randomized Trial of Blood-Pressure Reduction in Black Barbershops;,citation_abstract=Blood-Pressure Reduction in Black Barbershops In this trial involving black male barbershop patrons with uncontrolled hypertension, health promotion by barbers resulted in larger blood-pressure reduction when coupled with medication management in barbershops by specialty-trained pharmacists.;,citation_author=Ronald G. Victor;,citation_author=Kathleen Lynch;,citation_author=Ning Li;,citation_author=Ciantel Blyler;,citation_author=Eric Muhammad;,citation_author=Joel Handler;,citation_author=Jeffrey Brettler;,citation_author=Mohamad Rashid;,citation_author=Brent Hsu;,citation_author=Davontae Foxx-Drew;,citation_author=Norma Moy;,citation_author=Anthony E. Reid;,citation_author=Robert M. Elashoff;,citation_publication_date=2018-04;,citation_cover_date=2018-04;,citation_year=2018;,citation_issue=14;,citation_doi=10.1056/NEJMoa1717250;,citation_issn=0028-4793;,citation_pmid=29527973;,citation_volume=378;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Use of historical control data for assessing treatment effects in clinical trials;,citation_author=Kert Viele;,citation_author=Scott Berry;,citation_author=Beat Neuenschwander;,citation_author=Billy Amzal;,citation_author=Fang Chen;,citation_author=Nathan Enas;,citation_author=Brian Hobbs;,citation_author=Joseph G. Ibrahim;,citation_author=Nelson Kinnersley;,citation_author=Stacy Lindborg;,citation_author=Sandrine Micallef;,citation_author=Satrajit Roychoudhury;,citation_author=Laura Thompson;,citation_publication_date=2014-01;,citation_cover_date=2014-01;,citation_year=2014;,citation_issue=1;,citation_doi=10.1002/pst.1589;,citation_issn=15391604;,citation_volume=13;,citation_language=en-US;,citation_journal_title=Pharmaceutical Statistics;">
<meta name="citation_reference" content="citation_title=The heterogeneity of prolonged ICU hospitalisations;,citation_author=Elizabeth Marie Viglianti;,citation_author=Jacqueline M Kruser;,citation_author=Theodore Iwashyna;,citation_publication_date=2019-11;,citation_cover_date=2019-11;,citation_year=2019;,citation_issue=11;,citation_doi=10.1136/thoraxjnl-2019-213779;,citation_issn=0040-6376, 1468-3296;,citation_volume=74;,citation_language=en-US;,citation_journal_title=Thorax;">
<meta name="citation_reference" content="citation_title=Individual and health system variation in rehospitalizations the year after pneumonia;,citation_abstract=Little is known about variation in patterns of recovery among patients discharged alive from hospitalizations for pneumonia. The aim of the is observational cohort study was to characterize the variation in patterns of hospital readmission and survival in the year after discharge for pneumonia in 3 different health systems. The 3 cohorts consisted of (1) the Health and Retirement Study participants enrolled in Fee-for-service Medicare (FFS), (2) Veterans Administration (VA) Healthcare system, and (3) Kaiser Permanente of Northern California (KPNC). The 365-day survival and rehospitalizations were determined for each cohort. Multinomial logistic regression was used to identify potential contributors to the different patterns.;,citation_author=Elizabeth M. Viglianti;,citation_author=Hallie C. Prescott;,citation_author=Vincent Liu;,citation_author=Gabriel J. Escobar;,citation_author=Theodore J. Iwashyna;,citation_publication_date=2017-08;,citation_cover_date=2017-08;,citation_year=2017;,citation_issue=31;,citation_doi=10.1097/MD.0000000000007695;,citation_issn=0025-7974;,citation_volume=96;,citation_language=en-US;,citation_journal_title=Medicine;">
<meta name="citation_reference" content="citation_title=Publishing a Clinical Research Manuscript;,citation_abstract=Methods Results Discussion Conclusion;,citation_author=Elizabeth M. Viglianti;,citation_author=Andrew J. Admon;,citation_author=Erin F. Carlton;,citation_author=Matthew K. Hensley;,citation_author=Hallie C. Prescott;,citation_author=Theodore J. Iwashyna;,citation_author=Jakob I. McSparron;,citation_publication_date=2019-12;,citation_cover_date=2019-12;,citation_year=2019;,citation_issue=6;,citation_doi=10.1016/j.chest.2019.06.014;,citation_issn=00123692;,citation_volume=156;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Annual Update in Intensive Care and Emergency Medicine 2022;,citation_editor=Jean-Louis Vincent;,citation_publication_date=2022;,citation_cover_date=2022;,citation_year=2022;,citation_doi=10.1007/978-3-030-93433-0;,citation_isbn=978-3-030-93432-3 978-3-030-93433-0;,citation_language=en-US;,citation_series_title=Annual Update in Intensive Care and Emergency Medicine;">
<meta name="citation_reference" content="citation_title=The End of “One Size Fits All” Sepsis Therapies: Toward an Individualized Approach;,citation_abstract=Sepsis, defined as life-threatening organ dysfunction caused by a dysregulated host response to an infection, remains a major challenge for clinicians and trialists. Despite decades of research and multiple randomized clinical trials, a specific therapeutic for sepsis is not available. The evaluation of therapeutics targeting components of host response anomalies in patients with sepsis has been complicated by the inability to identify those in this very heterogeneous population who are more likely to benefit from a specific intervention. Additionally, multiple and diverse host response aberrations often co-exist in sepsis, and knowledge of which dysregulated biological organ system or pathway drives sepsis-induced pathology in an individual patient is limited, further complicating the development of effective therapies. Here, we discuss the drawbacks of previous attempts to develop sepsis therapeutics and delineate a future wherein interventions will be based on the host response profile of a patient.;,citation_author=Jean-Louis Vincent;,citation_author=Tom Poll;,citation_author=John C. Marshall;,citation_publication_date=2022-09;,citation_cover_date=2022-09;,citation_year=2022;,citation_issue=9;,citation_doi=10.3390/biomedicines10092260;,citation_issn=2227-9059;,citation_volume=10;,citation_language=en-US;,citation_journal_title=Biomedicines;">
<meta name="citation_reference" content="citation_title=Hemodynamic Monitoring and Support;,citation_author=Jean-Louis Vincent;,citation_author=Alexandre Joosten;,citation_author=Bernd Saugel;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=10;,citation_doi=10.1097/CCM.0000000000005213;,citation_issn=0090-3493;,citation_volume=49;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Management of Intraoperative Hypotension: Prediction, Prevention and Personalization;,citation_author=T. W. L. Scheeren;,citation_author=B. Saugel;,citation_editor=Jean-Louis Vincent;,citation_publication_date=2018;,citation_cover_date=2018;,citation_year=2018;,citation_doi=10.1007/978-3-319-73670-9_8;,citation_isbn=978-3-319-73669-3 978-3-319-73670-9;,citation_language=en-US;,citation_inbook_title=Annual Update in Intensive Care and Emergency Medicine 2018;">
<meta name="citation_reference" content="citation_title=We should abandon randomized controlled trials in the intensive care unit:;,citation_author=Jean-Louis Vincent;,citation_publication_date=2010-10;,citation_cover_date=2010-10;,citation_year=2010;,citation_doi=10.1097/CCM.0b013e3181f208ac;,citation_issn=0090-3493;,citation_volume=38;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Yearbook of Intensive Care and Emergency Medicine 2000;,citation_editor=Jean-Louis Vincent;,citation_editor=Jean-Louis Vincent;,citation_publication_date=2000;,citation_cover_date=2000;,citation_year=2000;,citation_doi=10.1007/978-3-662-13455-9;,citation_isbn=978-3-540-66830-5 978-3-662-13455-9;,citation_volume=2000;,citation_language=en-US;,citation_series_title=Yearbook of Intensive Care and Emergency Medicine;">
<meta name="citation_reference" content="citation_title=Acute pancreatitis: The increasing role of medical management of a traditionally surgically managed disease;,citation_author=Kittane Vishnupriya;,citation_author=Arjun Chanmugam;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_doi=10.1016/j.amjmed.2021.08.021;,citation_issn=00029343;,citation_language=en-US;,citation_journal_title=The American Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Blood transfusion: The search for the sweet spot;,citation_author=Alexander P. J. Vlaar;,citation_publication_date=2022-09;,citation_cover_date=2022-09;,citation_year=2022;,citation_issue=9;,citation_doi=10.1007/s00134-022-06799-7;,citation_issn=0342-4642, 1432-1238;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=TRAUMATIC BRAIN INJURY;,citation_author=Victor Volovici;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Factors Associated with Early Withdrawal of Life-Sustaining Treatments After Out-of-Hospital Cardiac Arrest: A Subanalysis of a Randomized Trial of Prehospital Therapeutic Hypothermia;,citation_abstract=The objective of this study is to describe incidence and factors associated with early withdrawal of life-sustaining therapies based on presumed poor neurologic prognosis (WLST-N) and practices around multimodal prognostication after out-of-hospital cardiac arrest (OHCA).;,citation_author=Sarah Wahlster;,citation_author=Kyle Danielson;,citation_author=Lindy Craft;,citation_author=Nassim Matin;,citation_author=James A. Town;,citation_author=Vasisht Srinivasan;,citation_author=Glenn Schubert;,citation_author=David Carlbom;,citation_author=Francis Kim;,citation_author=Nicholas J. Johnson;,citation_author=David Tirschwell;,citation_publication_date=2022-11;,citation_cover_date=2022-11;,citation_year=2022;,citation_doi=10.1007/s12028-022-01636-7;,citation_issn=1556-0961;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Outcomes After Tracheostomy in Patients with Severe Acute Brain Injury: A Systematic Review and Meta-Analysis;,citation_abstract=To synthesize reported long-term outcomes in patients undergoing tracheostomy after severe acute brain injury (SABI).;,citation_author=Sarah Wahlster;,citation_author=Monisha Sharma;,citation_author=Frances Chu;,citation_author=Justin H. Granstein;,citation_author=Nicholas J. Johnson;,citation_author=W. T. Longstreth;,citation_author=Claire J. Creutzfeldt;,citation_publication_date=2021-06;,citation_cover_date=2021-06;,citation_year=2021;,citation_issue=3;,citation_doi=10.1007/s12028-020-01109-9;,citation_issn=1556-0961;,citation_volume=34;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Prognostic Accuracy of Presepsis and Intrasepsis Characteristics for Prediction of Cardiovascular Events After a Sepsis Hospitalization;,citation_abstract=OBJECTIVES: Sepsis survivors face increased risk for cardiovascular complications; however, the contribution of intrasepsis events to cardiovascular risk profiles is unclear. SETTING: Kaiser Permanente Northern California (KPNC) and Intermountain Healthcare (IH) integrated healthcare delivery systems. SUBJECTS: Sepsis survivors (2011–2017 [KPNC] and 2018–2020 [IH]) greater than or equal to 40 years old without prior cardiovascular disease. DESIGN: Data across KPNC and IH were harmonized and grouped into presepsis (demographics, atherosclerotic cardiovascular disease scores, comorbidities) or intrasepsis factors (e.g., laboratory values, vital signs, organ support, infection source) with random split for training/internal validation datasets (75%/25%) within KPNC and IH. Models were bidirectionally, externally validated between healthcare systems. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Changes to predictive accuracy (C-statistic) of cause-specific proportional hazards models predicting 1-year cardiovascular outcomes (atherosclerotic cardiovascular disease, heart failure, and atrial fibrillation events) were compared between models that did and did not contain intrasepsis factors. Among 39,590 KPNC and 16,388 IH sepsis survivors, 3,503 (8.8%) at Kaiser Permanente (KP) and 600 (3.7%) at IH experienced a cardiovascular event within 1-year after hospital discharge, including 996 (2.5%) at KP and 192 (1.2%) IH with an atherosclerotic event first, 564 (1.4%) at KP and 117 (0.7%) IH with a heart failure event, 2,310 (5.8%) at KP and 371 (2.3%) with an atrial fibrillation event. Death within 1 year after sepsis occurred for 7,948 (20%) KP and 2,085 (12.7%) IH patients. Combined models with presepsis and intrasepsis factors had better discrimination for cardiovascular events (KPNC C-statistic 0.783 [95% CI, 0.766–0.799]; IH 0.763 [0.726–0.801]) as compared with presepsis cardiovascular risk alone (KPNC: 0.666 [0.648–0.683], IH 0.660 [0.619–0.702]) during internal validation. External validation of models across healthcare systems showed similar performance (KPNC model within IH data C-statistic: 0.734 [0.725–0.744]; IH model within KPNC data: 0.787 [0.768–0.805]). CONCLUSIONS: Across two large healthcare systems, intrasepsis factors improved postsepsis cardiovascular risk prediction as compared with presepsis cardiovascular risk profiles. Further exploration of sepsis factors that contribute to postsepsis cardiovascular events is warranted for improved mechanistic and predictive models.;,citation_author=Allan J. Walkey;,citation_author=Daniel B. Knox;,citation_author=Laura C. Myers;,citation_author=Khanh K. Thai;,citation_author=Jason R. Jacobs;,citation_author=Patricia Kipnis;,citation_author=Manisha Desai;,citation_author=Alan S. Go;,citation_author=Yun Lu;,citation_author=Samuel M. Brown;,citation_author=Adriana Martinez;,citation_author=Heather Clancy;,citation_author=Ycar Devis;,citation_author=Vincent X. Liu;,citation_publication_date=2022-04;,citation_cover_date=2022-04;,citation_year=2022;,citation_issue=4;,citation_doi=10.1097/CCE.0000000000000674;,citation_issn=2639-8028;,citation_volume=4;,citation_language=en-US;,citation_journal_title=Critical Care Explorations;">
<meta name="citation_reference" content="citation_title=Evaluation of Evidence of Statistical Support and Corroboration of Subgroup Claims in Randomized Clinical Trials;,citation_abstract=OBJECTIVE To evaluate how often subgroup claims reported in the abstracts of RCTs are actually supported by statistical evidence (P &amp;amp;amp;lt; .05 from an interaction test) and corroborated by subsequent RCTs and meta-analyses. DATA SOURCES This meta-epidemiological survey examines data sets of trials with at least 1 subgroup claim, including Subgroup Analysis of Trials Is Rarely Easy (SATIRE) articles and Discontinuation of Randomized Trials (DISCO) articles. We used Scopus (updated July 2016) to search for English-language articles citing each of the eligible index articles with at least 1 subgroup finding in the abstract. STUDY SELECTION Articles with a subgroup claim in the abstract with or without evidence of statistical heterogeneity (P &amp;lt; .05 from an interaction test) in the text and articles attempting to corroborate the subgroup findings. DATA EXTRACTION AND SYNTHESIS Study characteristics of trials with at least 1 subgroup claim in the abstract were recorded. Two reviewers extracted the data necessary to calculate subgroup-level effect sizes, standard errors, and the P values for interaction. For individual RCTs and meta-analyses that attempted to corroborate the subgroup findings from the index articles, trial characteristics were extracted. Cochran Q test was used to reevaluate heterogeneity with the data from all available trials. MAIN OUTCOMES AND MEASURES The number of subgroup claims in the abstracts of RCTs, the number of subgroup claims in the abstracts of RCTs with statistical support (subgroup findings), and the number of subgroup findings corroborated by subsequent RCTs and meta-analyses. RESULTS Sixty-four eligible RCTs made a total of 117 subgroup claims in their abstracts. Of these 117 claims, only 46 (39.3%) in 33 articles had evidence of statistically significant heterogeneity from a test for interaction. In addition, out of these 46 subgroup findings, only 16 (34.8%) ensured balance between randomization groups within the subgroups (eg, through stratified randomization), 13 (28.3%) entailed a prespecified subgroup analysis, and 1 (2.2%) was adjusted for multiple testing. Only 5 (10.9%) of the 46 subgroup findings had at least 1 subsequent pure corroboration attempt by a meta-analysis or an RCT. In all 5 cases, the corroboration attempts found no evidence of a statistically significant subgroup effect. In addition, all effect sizes from meta-analyses were attenuated toward the null. CONCLUSIONS AND RELEVANCE A minority of subgroup claims made in the abstracts of RCTs are supported by their own data (ie, a significant interaction effect). For those that have statistical support (P < .05 from an interaction test), most fail to meet other best practices for subgroup tests, including prespecification, stratified randomization, and adjustment for multiple testing. Attempts to corroborate statistically significant subgroup differences are rare; when done, the initially observed subgroup differences are not reproduced.;,citation_author=Joshua D. Wallach;,citation_author=Patrick G. Sullivan;,citation_author=John F. Trepanowski;,citation_author=Kristin L. Sainani;,citation_author=Ewout W. Steyerberg;,citation_author=John P. A. Ioannidis;,citation_publication_date=2017-04;,citation_cover_date=2017-04;,citation_year=2017;,citation_issue=4;,citation_doi=10.1001/jamainternmed.2016.9125;,citation_issn=2168-6106;,citation_volume=177;,citation_language=en-US;,citation_journal_title=JAMA Internal Medicine;">
<meta name="citation_reference" content="citation_title=The statistical significance of randomized controlled trial results is frequently fragile: A case for a Fragility Index;,citation_abstract=Objectives: A P-value !0.05 is one metric used to evaluate the results of a randomized controlled trial (RCT). We wondered how often statistically significant results in RCTs may be lost with small changes in the numbers of outcomes. Study Design and Setting: A review of RCTs in high-impact medical journals that reported a statistically significant result for at least one dichotomous or time-to-event outcome in the abstract. In the group with the smallest number of events, we changed the status of patients without an event to an event until the P-value exceeded 0.05. We labeled this number the Fragility Index; smaller numbers indicated a more fragile result. Results: The 399 eligible trials had a median sample size of 682 patients (range: 15e112,604) and a median of 112 events (range: 8e5,142); 53% reported a P-value !0.01. The median Fragility Index was 8 (range: 0e109); 25% had a Fragility Index of 3 or less. In 53% of trials, the Fragility Index was less than the number of patients lost to follow-up. Conclusion: The statistically significant results of many RCTs hinge on small numbers of events. The Fragility Index complements the P-value and helps identify less robust results. Ó 2014 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.;,citation_author=Michael Walsh;,citation_author=Sadeesh K. Srinathan;,citation_author=Daniel F. McAuley;,citation_author=Marko Mrkobrada;,citation_author=Oren Levine;,citation_author=Christine Ribic;,citation_author=Amber O. Molnar;,citation_author=Neil D. Dattani;,citation_author=Andrew Burke;,citation_author=Gordon Guyatt;,citation_author=Lehana Thabane;,citation_author=Stephen D. Walter;,citation_author=Janice Pogue;,citation_author=P. J. Devereaux;,citation_publication_date=2014-06;,citation_cover_date=2014-06;,citation_year=2014;,citation_issue=6;,citation_doi=10.1016/j.jclinepi.2013.10.019;,citation_issn=08954356;,citation_volume=67;,citation_language=en-US;,citation_journal_title=Journal of Clinical Epidemiology;">
<meta name="citation_reference" content="citation_title=Untreated Hypertension: A Powerful Risk Factor for Lobar and Nonlobar Intracerebral Hemorrhage in Whites, Blacks, and Hispanics;,citation_abstract=BACKGROUND: Hypertension is a significant risk factor for intracerebral hemorrhage (ICH). Although ethnic/racial disparities related to hypertension and ICH have been reported, these previous studies were limited by a lack of Hispanics and inadequate power to analyze by ICH location. In the current study, while overcoming these prior limitations, we investigated whether there was variation by ethnicity/race of treated and untreated hypertension as risk factors for ICH. METHODS: The ERICH study (Ethnic/Racial Variations of Intracerebral Hemorrhage) is a prospective, multicenter, case-control study of ICH among whites, blacks, and Hispanics. Cases were enrolled from 42 recruitment sites. Controls matched to cases 1:1 by age (5 years), sex, ethnicity/race, and metropolitan area were identified by random-digit dialing. Subjects were interviewed to determine history of hypertension and use of antihypertensive medications. Cases and controls within ethnic groups were compared by using conditional logistic regression. Multivariable conditional logistic regression models were computed for ICH as an overall group and separately for the location subcategories deep, lobar, and infratentorial (brainstem/cerebellar). RESULTS: Nine hundred fifty-eight white, 880 black, and 766 Hispanic ICH patients were enrolled. For ICH cases, untreated hypertension was higher in blacks (43.6%, P&amp;amp;amp;lt;0.0001) and Hispanics (46.9%, P&amp;lt;0.0001) versus whites (32.7%). In multivariable analyses adjusted for alcohol use, anticoagulation, hypercholesterolemia, education, and medical insurance status, treated hypertension was a significant risk factor across all locations of ICH in whites (odds ratio [OR], 1.57; 95% confidence interval [CI], 1.24–1.98; P<0.0001), blacks (OR, 3.02; 95% CI, 2.16–4.22; P<0.0001), and Hispanics (OR, 2.50; 95% CI, 1.73–3.62; P<0.0001). Untreated hypertension was a substantially greater risk factor for all 3 racial/ethnic groups across all locations of ICH: whites (OR, 8.79; 95% CI, 5.66–13.66; P<0.0001), blacks (OR, 12.46; 95% CI, 8.08–19.20; P<0.0001), and Hispanics (OR, 10.95; 95% CI, 6.58–18.23; P<0.0001). There was an interaction between race/ethnicity and ICH risk (P<0.0001). CONCLUSIONS: Untreated hypertension confers a greater ICH risk in blacks and Hispanics relative to whites across all anatomic locations of ICH. Accelerated research efforts are needed to improve overall hypertension treatment rates and to monitor the impact of such efforts on racial/ethnic disparities in stroke.;,citation_author=Kyle B. Walsh;,citation_author=Daniel Woo;,citation_author=Padmini Sekar;,citation_author=Jennifer Osborne;,citation_author=Charles J. Moomaw;,citation_author=Carl D. Langefeld;,citation_author=Opeolu Adeoye;,citation_publication_date=2016-11;,citation_cover_date=2016-11;,citation_year=2016;,citation_issue=19;,citation_doi=10.1161/CIRCULATIONAHA.116.024073;,citation_issn=0009-7322, 1524-4539;,citation_volume=134;,citation_language=en-US;,citation_journal_title=Circulation;">
<meta name="citation_reference" content="citation_title=Cohort Studies;,citation_author=Xiaofeng Wang;,citation_author=Michael W. Kattan;,citation_publication_date=2020-07;,citation_cover_date=2020-07;,citation_year=2020;,citation_issue=1;,citation_doi=10.1016/j.chest.2020.03.014;,citation_issn=00123692;,citation_volume=158;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Cross-Sectional Studies;,citation_author=Xiaofeng Wang;,citation_author=Zhenshun Cheng;,citation_publication_date=2020-07;,citation_cover_date=2020-07;,citation_year=2020;,citation_issue=1;,citation_doi=10.1016/j.chest.2020.03.012;,citation_issn=00123692;,citation_volume=158;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Emulation of Randomized Clinical Trials With Nonrandomized Database Analyses: Results of 32 Clinical Trials;,citation_abstract=Nonrandomized studies using insurance claims databases can be analyzed to produce real-world evidence on the effectiveness of medical products. Given the lack of baseline randomization and measurement issues, concerns exist about whether such studies produce unbiased treatment effect estimates.To emulate the design of 30 completed and 2 ongoing randomized clinical trials (RCTs) of medications with database studies using observational analogues of the RCT design parameters (population, intervention, comparator, outcome, time [PICOT]) and to quantify agreement in RCT-database study pairs.New-user cohort studies with propensity score matching using 3 US claims databases (Optum Clinformatics, MarketScan, and Medicare). Inclusion-exclusion criteria for each database study were prespecified to emulate the corresponding RCT. RCTs were explicitly selected based on feasibility, including power, key confounders, and end points more likely to be emulated with real-world data. All 32 protocols were registered on ClinicalTrials.gov before conducting analyses. Emulations were conducted from 2017 through 2022.Therapies for multiple clinical conditions were included.Database study emulations focused on the primary outcome of the corresponding RCT. Findings of database studies were compared with RCTs using predefined metrics, including Pearson correlation coefficients and binary metrics based on statistical significance agreement, estimate agreement, and standardized difference.In these highly selected RCTs, the overall observed agreement between the RCT and the database emulation results was a Pearson correlation of 0.82 (95% CI, 0.64-0.91), with 75% meeting statistical significance, 66% estimate agreement, and 75% standardized difference agreement. In a post hoc analysis limited to 16 RCTs with closer emulation of trial design and measurements, concordance was higher (Pearson r, 0.93; 95% CI, 0.79-0.97; 94% meeting statistical significance, 88% estimate agreement, 88% standardized difference agreement). Weaker concordance occurred among 16 RCTs for which close emulation of certain design elements that define the research question (PICOT) with data from insurance claims was not possible (Pearson r, 0.53; 95% CI, 0.00-0.83; 56% meeting statistical significance, 50% estimate agreement, 69% standardized difference agreement).Real-world evidence studies can reach similar conclusions as RCTs when design and measurements can be closely emulated, but this may be difficult to achieve. Concordance in results varied depending on the agreement metric. Emulation differences, chance, and residual confounding can contribute to divergence in results and are difficult to disentangle.;,citation_author=Shirley V. Wang;,citation_author=Sebastian Schneeweiss;,citation_author=RCT-DUPLICATE Initiative;,citation_publication_date=2023-04;,citation_cover_date=2023-04;,citation_year=2023;,citation_issue=16;,citation_doi=10.1001/jama.2023.4221;,citation_issn=0098-7484;,citation_volume=329;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Sample Size Estimation in Clinical Research;,citation_author=Xiaofeng Wang;,citation_author=Xinge Ji;,citation_publication_date=2020-07;,citation_cover_date=2020-07;,citation_year=2020;,citation_issue=1;,citation_doi=10.1016/j.chest.2020.03.010;,citation_issn=00123692;,citation_volume=158;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Ticagrelor versus Clopidogrel in &amp;amp;amp;lt;i&amp;gt;CYP2C19&amp;lt;/i&amp;gt; Loss-of-Function Carriers with Stroke or TIA;,citation_abstract=BACKGROUND Comparisons between ticagrelor and clopidogrel for the secondary prevention of stroke in CYP2C19 loss-of-function carriers have not been extensively performed. METHODS We conducted a randomized, double-blind, placebo-controlled trial at 202 centers in China involving patients with a minor ischemic stroke or transient ischemic attack (TIA) who carried CYP2C19 loss-of-function alleles. Patients were assigned within 24 hours after symptom onset, in a 1:1 ratio, to receive ticagrelor (180 mg on day 1 followed by 90 mg twice daily on days 2 through 90) and placebo clopidogrel or to receive clopidogrel (300 mg on day 1 followed by 75 mg once daily on days 2 through 90) and placebo ticagrelor; both groups received aspirin for 21 days. The primary efficacy outcome was new stroke, and the primary safety outcome was severe or moderate bleeding, both within 90 days. RESULTS A total of 11,255 patients were screened and 6412 patients were enrolled, with 3205 assigned to the ticagrelor group and 3207 to the clopidogrel group. The median age of the patients was 64.8 years, and 33.8% were women; 98.0% belonged to the Han Chinese ethnic group. Stroke occurred within 90 days in 191 patients (6.0%) in the ticagrelor group and 243 patients (7.6%) in the clopidogrel group (hazard ratio, 0.77; 95% confidence interval, 0.64 to 0.94; P = 0.008). Secondary outcomes were generally in the same direction as the primary outcome. Severe or moderate bleeding occurred in 9 patients (0.3%) in the ticagrelor group and in 11 patients (0.3%) in the clopidogrel group; any bleeding occurred in 170 patients (5.3%) and 80 patients (2.5%), respectively. CONCLUSIONS Among Chinese patients with minor ischemic stroke or TIA who were carriers of CYP2C19 loss-of-function alleles, the risk of stroke at 90 days was modestly lower with ticagrelor than with clopidogrel. The risk of severe or moderate bleeding did not differ between the two treatment groups, but ticagrelor was associated with more total bleeding events than clopidogrel. (Funded by the Ministry of Science and Technology of the People’s Republic of China and others; CHANCE-2 ClinicalTrials .gov number, NCT04078737.);,citation_author=Yongjun Wang;,citation_author=Xia Meng;,citation_author=Anxin Wang;,citation_author=Xuewei Xie;,citation_author=Yuesong Pan;,citation_author=S. Claiborne Johnston;,citation_author=Hao Li;,citation_author=Philip M. Bath;,citation_author=Qiang Dong;,citation_author=Anding Xu;,citation_author=Jing Jing;,citation_author=Jinxi Lin;,citation_author=Siying Niu;,citation_author=Yilong Wang;,citation_author=Xingquan Zhao;,citation_author=Zixiao Li;,citation_author=Yong Jiang;,citation_author=Wei Li;,citation_author=Liping Liu;,citation_author=Jie Xu;,citation_author=Liguo Chang;,citation_author=Lihua Wang;,citation_author=Xianbo Zhuang;,citation_author=Jinguo Zhao;,citation_author=Yefang Feng;,citation_author=Honghao Man;,citation_author=Guozhong Li;,citation_author=Baojun Wang;,citation_publication_date=2021-12;,citation_cover_date=2021-12;,citation_year=2021;,citation_issue=27;,citation_doi=10.1056/NEJMoa2111749;,citation_issn=0028-4793, 1533-4406;,citation_volume=385;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Tenecteplase Thrombolysis for Acute Ischemic Stroke;,citation_abstract=Tenecteplase is a fibrinolytic drug with higher fibrin specificity and longer half-life than the standard stroke thrombolytic, alteplase, permitting the convenience of single bolus administration. Tenecteplase, at 0.5 mg/kg, has regulatory approval to treat ST-segment–elevation myocardial infarction, for which it has equivalent 30-day mortality and fewer systemic hemorrhages. Investigated as a thrombolytic for ischemic stroke over the past 15 years, tenecteplase is currently being studied in several phase 3 trials. Based on a systematic literature search, we provide a qualitative synthesis of published stroke clinical trials of tenecteplase that (1) performed randomized comparisons with alteplase, (2) compared different doses of tenecteplase, or (3) provided unique quantitative meta-analyses. Four phase 2 and one phase 3 study performed randomized comparisons with alteplase. These and other phase 2 studies compared different tenecteplase doses and effects on early outcomes of recanalization, reperfusion, and substantial neurological improvement, as well as symptomatic intracranial hemorrhage and 3-month disability on the modified Rankin Scale. Although no single trial prospectively demonstrated superiority or noninferiority of tenecteplase on clinical outcome, meta-analyses of these trials (1585 patients randomized) point to tenecteplase superiority in recanalization of large vessel occlusions and noninferiority in disability-free 3-month outcome, without increases in symptomatic intracranial hemorrhage or mortality. Doses of 0.25 and 0.4 mg/kg have been tested, but no advantage of the higher dose has been suggested by the results. Current clinical practice guidelines for stroke include intravenous tenecteplase at either dose as a second-tier option, with the 0.25 mg/kg dose recommended for large vessel occlusions, based on a phase 2 trial that demonstrated superior recanalization and improved 3-month outcome relative to alteplase. Ongoing randomized phase 3 trials may better define the comparative risks and benefits of tenecteplase and alteplase for stroke thrombolysis and answer questions of tenecteplase efficacy in the &amp;amp;amp;gt;4.5-hour time window, in wakeup stroke, and in combination with endovascular thrombectomy.;,citation_author=Steven J. Warach;,citation_author=Adrienne N. Dula;,citation_author=Truman J. Milling;,citation_publication_date=2020-11;,citation_cover_date=2020-11;,citation_year=2020;,citation_issue=11;,citation_doi=10.1161/STROKEAHA.120.029749;,citation_issn=0039-2499, 1524-4628;,citation_volume=51;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=The videolaryngoscopy vs. Direct laryngoscopy debate: A wider-angled view;,citation_author=P. A. Ward;,citation_publication_date=2023;,citation_cover_date=2023;,citation_year=2023;,citation_issue=8;,citation_doi=10.1111/anae.16046;,citation_issn=1365-2044;,citation_volume=78;,citation_language=en-US;,citation_journal_title=Anaesthesia;">
<meta name="citation_reference" content="citation_title=Evaluation of Lowering the &amp;amp;amp;lt;i&amp;gt;P&amp;lt;/i&amp;gt; Value Threshold for Statistical Significance From .05 to .005 in Previously Published Randomized Clinical Trials in Major Medical Journals;,citation_author=Cole Wayant;,citation_author=Jared Scott;,citation_author=Matt Vassar;,citation_publication_date=2018-11;,citation_cover_date=2018-11;,citation_year=2018;,citation_issue=17;,citation_doi=10.1001/jama.2018.12288;,citation_issn=0098-7484;,citation_volume=320;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Glucocorticoid Dose in COVID-19: Lessons for Clinical Trials During a Pandemic;,citation_author=Steven A. Webb;,citation_author=Alisa M. Higgins;,citation_author=Colin J. McArthur;,citation_publication_date=2021-11;,citation_cover_date=2021-11;,citation_year=2021;,citation_issue=18;,citation_doi=10.1001/jama.2021.16438;,citation_issn=0098-7484;,citation_volume=326;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Why Can Only 24% Solve Bayesian Reasoning Problems in Natural Frequencies: Frequency Phobia in Spite of Probability Blindness;,citation_abstract=For more than 20 years, research has proven the beneficial effect of natural frequencies when it comes to solving Bayesian reasoning tasks (Gigerenzer and Hoffrage, 1995). In a recent meta-analysis, McDowell and Jacobs (2017) showed that presenting a task in natural frequency format increases performance rates to 24% compared to only 4% when the same task is presented in probability format. Nevertheless, on average three quarters of participants in their meta-analysis failed to obtain the correct solution for such a task in frequency format. In this paper, we present an empirical study on what participants typically do wrong when confronted with natural frequencies. We found that many of them did not actually use natural frequencies for their calculations, but translated them back into complicated probabilities instead. This switch from the intuitive presentation format to a less intuitive calculation format will be discussed within the framework of psychological theories (e.g., the Einstellung effect).;,citation_author=Patrick Weber;,citation_author=Karin Binder;,citation_author=Stefan Krauss;,citation_publication_date=2018-10;,citation_cover_date=2018-10;,citation_year=2018;,citation_doi=10.3389/fpsyg.2018.01833;,citation_issn=1664-1078;,citation_volume=9;,citation_language=en-US;,citation_journal_title=Frontiers in Psychology;">
<meta name="citation_reference" content="citation_title=Once-Weekly Semaglutide in Adolescents with Obesity;,citation_author=Daniel Weghuber;,citation_author=Timothy Barrett;,citation_author=Margarita Barrientos-Pérez;,citation_author=Inge Gies;,citation_author=Dan Hesse;,citation_author=Ole K. Jeppesen;,citation_author=Aaron S. Kelly;,citation_author=Lucy D. Mastrandrea;,citation_author=Rasmus Sørrig;,citation_author=Silva Arslanian;,citation_publication_date=2022-12;,citation_cover_date=2022-12;,citation_year=2022;,citation_issue=24;,citation_doi=10.1056/NEJMoa2208601;,citation_issn=0028-4793;,citation_pmid=36322838;,citation_volume=387;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Effect of Deferoxamine on Outcome According to Baseline Hematoma Volume: A Post Hoc Analysis of the i-DEF Trial;,citation_abstract=BACKGROUND: Hematoma volume (HV) is a powerful determinant of outcome after intracerebral hemorrhage. We examined whether the effect of the iron chelator, deferoxamine, on functional outcome varied depending on HV in the i-DEF trial (Intracerebral Hemorrhage Deferoxamine). METHODS: A post hoc analysis of the i-DEF trial; participants were classified according to baseline HV (small &amp;amp;amp;lt;10 mL, moderate 10–30 mL, and large &amp;gt;30 mL). Favorable outcome was defined as a modified Rankin Scale score of 0–2 at day180; secondarily at day-90. Logistic regression was used to evaluate the differential treatment effect according to HV. RESULTS: Two hundred ninety-one subjects were included in the as-treated analysis; 121 with small, 114 moderate, and 56 large HV. Day-180 modified Rankin Scale scores were available for 270/291 subjects (111 with small, 105 moderate, and 54 large HV). There was a differential effect of treatment according to HV on day-180 outcomes (P-for-interaction =0.0077); 50% (27/54) of deferoxamine-treated patients with moderate HV had favorable outcome compared with 25.5% (13/51) of placebo-treated subjects (adjusted odds ratio, 2.7 [95% CI, 1.13–6.27]; P=0.0258). Treatment effect was not significant for small (adjusted odds ratio, 1.37 [95% CI, 0.62–3.02]) or large (adjusted odds ratio, 0.12 [95% CI, 0.01–1.05]) HV. Results for day-90 outcomes were comparable (P-for-interaction =0.0617). Sensitivity analyses yielded similar results. CONCLUSIONS: Among patients with moderate HV, a greater proportion of deferoxamine- than placebo-treated patients achieved modified Rankin Scale score 0–2. The treatment effect was not significant for small or large HVs. These findings have important trial design and therapeutic implications.;,citation_author=Chenchen Wei;,citation_author=Jeffrey Wang;,citation_author=Lydia D. Foster;,citation_author=Sharon D. Yeatts;,citation_author=Claudia Moy;,citation_author=J Mocco;,citation_author=Magdy Selim;,citation_author=Yuko Palesch;,citation_author=Jessica Griffin;,citation_author=Aaron Perlmutter;,citation_author=Casey Norton;,citation_author=Catherine Dillon;,citation_author=Andre Thornhill;,citation_author=Steven Greenberg;,citation_author=Lewis Morgenstern;,citation_author=Daniel Hanley;,citation_author=Guohua Xi;,citation_author=Thomas P Bleck;,citation_author=Robert Balk;,citation_author=Yuko Palesch;,citation_author=Jessica Griffin;,citation_author=Andre Thornhill;,citation_author=Aaron Perlmutter;,citation_author=Catherine Dillon;,citation_author=Wenle Zhao;,citation_author=Jaemyung Kim;,citation_author=Sandeep Kumar;,citation_author=Casey Norton;,citation_author=Megan Farinella;,citation_author=Erica Siwila-Sackman;,citation_author=Caroline Feigert;,citation_author=Gottfried Schlaug;,citation_author=Jasmine Wang;,citation_author=Clinton Wright;,citation_author=Scott Janis;,citation_author=Peter Gilbert;,citation_author=Carlos S Kase;,citation_author=Shannon Carson;,citation_author=Matthew Flaherty;,citation_author=Craig M Kessler;,citation_author=Leslie A McClure;,citation_author=Donna Bannon;,citation_author=Joseph Broderick;,citation_author=Amy Dill;,citation_publication_date=2022-04;,citation_cover_date=2022-04;,citation_year=2022;,citation_issue=4;,citation_doi=10.1161/STROKEAHA.121.035421;,citation_issn=0039-2499, 1524-4628;,citation_volume=53;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=Patient-Reported Outcome Measures in Clinical Research;,citation_abstract=Health conditions may cause patients to feel ill and have impaired functioning in their daily lives. Thus, it is important to assess how patients are feeling and functioning when evaluating the effects of interventions to prevent or treat health conditions. Aspects of health that patients can report on directly, such as the severity of pain or limitations in physical functioning, are patient-reported outcomes.The recommended quantitative approach to measure these aspects of health status is to ask patients directly using a standardized questionnaire. Patient-reported outcome measures are reports of “the status of a patient’s health condition that comes directly from the patient without interpretation of the patient’s response by a clinician or anyone else.” An example of a patient-reported outcome measure, the Short Form 36 (SF-36), was used in a randomized clinical trial conducted by Ghogawala et al to compare 2 surgical approaches (ventral or dorsal) for the treatment of cervical spondylotic myelopathy, which is a condition that can cause significant impairments in physical functioning.;,citation_author=Kevin P. Weinfurt;,citation_author=Bryce B. Reeve;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_issue=5;,citation_doi=10.1001/jama.2022.11238;,citation_issn=0098-7484;,citation_volume=328;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19;,citation_abstract=BACKGROUND In the phase 1–2 portion of an adaptive trial, REGEN-COV, a combination of the monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of medical visits in patients with coronavirus disease 2019 (Covid-19). REGEN-COV has activity in vitro against current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern. METHODS In the phase 3 portion of an adaptive trial, we randomly assigned outpatients with Covid-19 and risk factors for severe disease to receive various doses of intravenous REGEN-COV or placebo. Patients were followed through day 29. A prespecified hierarchical analysis was used to assess the end points of hospitalization or death and the time to resolution of symptoms. Safety was also evaluated. RESULTS Covid-19–related hospitalization or death from any cause occurred in 18 of 1355 patients in the REGEN-COV 2400-mg group (1.3%) and in 62 of 1341 patients in the placebo group who underwent randomization concurrently (4.6%) (relative risk reduction [1 minus the relative risk], 71.3%; P&amp;amp;amp;lt;0.001); these outcomes occurred in 7 of 736 patients in the REGEN-COV 1200-mg group (1.0%) and in 24 of 748 patients in the placebo group who underwent randomization concurrently (3.2%) (relative risk reduction, 70.4%; P = 0.002). The median time to resolution of symptoms was 4 days shorter with each REGEN-COV dose than with placebo (10 days vs. 14 days; P&amp;lt;0.001 for both comparisons). REGEN-COV was efficacious across various subgroups, including patients who were SARS-CoV-2 serum antibody–positive at baseline. Both REGEN-COV doses reduced viral load faster than placebo; the least-squares mean difference in viral load from baseline through day 7 was -0.71 log10 copies per milliliter (95% confidence interval [CI], -0.90 to -0.53) in the 1200-mg group and -0.86 log10 copies per milliliter (95% CI, -1.00 to -0.72) in the 2400-mg group. Serious adverse events occurred more frequently in the placebo group (4.0%) than in the 1200-mg group (1.1%) and the 2400-mg group (1.3%); infusion-related reactions of grade 2 or higher occurred in less than 0.3% of the patients in all groups. CONCLUSIONS REGEN-COV reduced the risk of Covid-19–related hospitalization or death from any cause, and it resolved symptoms and reduced the SARS-CoV-2 viral load more rapidly than placebo. (Funded by Regeneron Pharmaceuticals and others; ClinicalTrials .gov number, NCT04425629.);,citation_author=David M. Weinreich;,citation_author=Sumathi Sivapalasingam;,citation_author=Thomas Norton;,citation_author=Shazia Ali;,citation_author=Haitao Gao;,citation_author=Rafia Bhore;,citation_author=Jing Xiao;,citation_author=Andrea T. Hooper;,citation_author=Jennifer D. Hamilton;,citation_author=Bret J. Musser;,citation_author=Diana Rofail;,citation_author=Mohamed Hussein;,citation_author=Joseph Im;,citation_author=Dominique Y. Atmodjo;,citation_author=Christina Perry;,citation_author=Cynthia Pan;,citation_author=Adnan Mahmood;,citation_author=Romana Hosain;,citation_author=John D. Davis;,citation_author=Kenneth C. Turner;,citation_author=Alina Baum;,citation_author=Christos A. Kyratsous;,citation_author=Yunji Kim;,citation_author=Amanda Cook;,citation_author=Wendy Kampman;,citation_author=Lilia Roque-Guerrero;,citation_author=Gerard Acloque;,citation_author=Hessam Aazami;,citation_author=Kevin Cannon;,citation_author=J. Abraham Simón-Campos;,citation_author=Joseph A. Bocchini;,citation_author=Bari Kowal;,citation_author=A. Thomas DiCioccio;,citation_author=Yuhwen Soo;,citation_author=Gregory P. Geba;,citation_author=Neil Stahl;,citation_author=Leah Lipsich;,citation_author=Ned Braunstein;,citation_author=Gary Herman;,citation_author=George D. Yancopoulos;,citation_publication_date=2021-12;,citation_cover_date=2021-12;,citation_year=2021;,citation_issue=23;,citation_doi=10.1056/NEJMoa2108163;,citation_issn=0028-4793, 1533-4406;,citation_volume=385;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Optimal Cerebral Perfusion Pressure During Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage;,citation_abstract=OBJECTIVES: The recommendation of induced hypertension for delayed cerebral ischemia treatment after aneurysmal subarachnoid hemorrhage has been challenged recently and ideal pressure targets are missing. A new concept advocates an individual cerebral perfusion pressure where cerebral autoregulation functions best to ensure optimal global perfusion. We characterized optimal cerebral perfusion pressure at time of delayed cerebral ischemia and tested the conformity of induced hypertension with this target value. DESIGN: Retrospective analysis of prospectively collected data. SETTING: University hospital neurocritical care unit. PATIENTS: Thirty-nine aneurysmal subarachnoid hemorrhage patients with invasive neuromonitoring (20 with delayed cerebral ischemia, 19 without delayed cerebral ischemia). INTERVENTIONS: Induced hypertension greater than 180 mm Hg systolic blood pressure. MEASUREMENTS AND MAIN RESULTS: Changepoint analysis was used to calculate significant changes in cerebral perfusion pressure, optimal cerebral perfusion pressure, and the difference of cerebral perfusion pressure and optimal cerebral perfusion pressure 48 hours before delayed cerebral ischemia diagnosis. Optimal cerebral perfusion pressure increased 30 hours before the onset of delayed cerebral ischemia from 82.8  12.5 to 86.3  11.4 mm Hg (p &amp;amp;amp;lt; 0.05). Three hours before delayed cerebral ischemia, a changepoint was also found in the difference of cerebral perfusion pressure and optimal cerebral perfusion pressure (decrease from –0.2  11.2 to –7.7  7.6 mm Hg; p &amp;lt; 0.05) with a corresponding increase in pressure reactivity index (0.09  0.33 to 0.19  0.37; p < 0.05). Cerebral perfusion pressure at time of delayed cerebral ischemia was lower than in patients without delayed cerebral ischemia in a comparable time frame (cerebral perfusion pressure delayed cerebral ischemia 81.4  8.3 mm Hg, no delayed cerebral ischemia 90.4  10.5 mm Hg; p < 0.05). Inducing hypertension resulted in a cerebral perfusion pressure above optimal cerebral perfusion pressure (+12.4  8.3 mm Hg; p < 0.0001). Treatment response (improvement of delayed cerebral ischemia: induced hypertension+ [n = 15] or progression of delayed cerebral ischemia: induced hypertension– [n = 5]) did not correlate to either absolute values of cerebral perfusion pressure or optimal cerebral perfusion pressure, nor the resulting difference (cerebral perfusion pressure [p = 0.69]; optimal cerebral perfusion pressure [p = 0.97]; and the difference of cerebral perfusion pressure and optimal cerebral perfusion pressure [p = 0.51]). CONCLUSIONS: At the time of delayed cerebral ischemia occurrence, there is a significant discrepancy between cerebral perfusion pressure and optimal cerebral perfusion pressure with worsening of autoregulation, implying inadequate but identifiable individual perfusion. Standardized induction of hypertension resulted in cerebral perfusion pressures that exceeded individual optimal cerebral perfusion pressure in delayed cerebral ischemia patients. The potential benefit of individual Miriam Weiss, MD1;,citation_author=Miriam Weiss;,citation_author=Walid Albanna;,citation_author=Catharina Conzen;,citation_author=Murad Megjhani;,citation_author=Jeanette Tas;,citation_author=Katharina Seyfried;,citation_author=Nick Kastenholz;,citation_author=Michael Veldeman;,citation_author=Tobias Philip Schmidt;,citation_author=Henna Schulze-Steinen;,citation_author=Martin Wiesmann;,citation_author=Hans Clusmann;,citation_author=Soojin Park;,citation_author=Marcel Aries;,citation_author=Gerrit Alexander Schubert;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_issue=2;,citation_doi=10.1097/CCM.0000000000005396;,citation_issn=0090-3493;,citation_volume=50;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Reveal, Don’t Conceal: Transforming Data Visualization to Improve Transparency;,citation_abstract=Reports highlighting the problems with the standard practice of using bar graphs to show continuous data have prompted many journals to adopt new visualization policies. These policies encourage authors to avoid bar graphs and use graphics that show the data distribution; however, they provide little guidance on how to effectively display data. We conducted a systematic review of studies published in top peripheral vascular disease journals to determine what types of figures are used, and to assess the prevalence of suboptimal data visualization practices. Among papers with data figures, 47.7% of papers used bar graphs to present continuous data. This primer provides a detailed overview of strategies for addressing this issue by (1) outlining strategies for selecting the correct type of figure depending on the study design, sample size, and the type of variable; (2) examining techniques for making effective dot plots, box plots, and violin plots; and (3) illustrating how to avoid sending mixed messages by aligning the figure structure with the study design and statistical analysis. We also present solutions to other common problems identified in the systematic review. Resources include a list of free tools and templates that authors can use to create more informative figures and an online simulator that illustrates why summary statistics are meaningful only when there are enough data to summarize. Last, we consider steps that investigators can take to improve figures in the scientific literature.;,citation_author=Tracey L. Weissgerber;,citation_author=Stacey J. Winham;,citation_author=Ethan P. Heinzen;,citation_author=Jelena S. Milin-Lazovic;,citation_author=Oscar Garcia-Valencia;,citation_author=Zoran Bukumiric;,citation_author=Marko D. Savic;,citation_author=Vesna D. Garovic;,citation_author=Natasa M. Milic;,citation_publication_date=2019-10;,citation_cover_date=2019-10;,citation_year=2019;,citation_issue=18;,citation_doi=10.1161/CIRCULATIONAHA.118.037777;,citation_issn=0009-7322, 1524-4539;,citation_volume=140;,citation_language=en-US;,citation_journal_title=Circulation;">
<meta name="citation_reference" content="citation_title=Futility in Clinical Trials;,citation_abstract=This JAMA Guide to Statistics and Methods discusses the early stopping of clinical trials for futility due to lack of evidence supporting the desired benefit, evidence of harm, or practical issues that make successful completion unlikely.;,citation_author=Barbara Wendelberger;,citation_author=Roger J. Lewis;,citation_publication_date=2023-08;,citation_cover_date=2023-08;,citation_year=2023;,citation_issue=8;,citation_doi=10.1001/jama.2023.14111;,citation_issn=0098-7484;,citation_volume=330;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=External Validations of Cardiovascular Clinical Prediction Models: A Large-Scale Review of the Literature;,citation_abstract=Background: There are many clinical prediction models (CPMs) available to inform treatment decisions for patients with cardiovascular disease. However, the extent to which they have been externally tested, and how well they generally perform has not been broadly evaluated. Methods: A SCOPUS citation search was run on March 22, 2017 to identify external validations of cardiovascular CPMs in the Tufts Predictive Analytics and Comparative Effectiveness CPM Registry. We assessed the extent of external validation, performance heterogeneity across databases, and explored factors associated with model performance, including a global assessment of the clinical relatedness between the derivation and validation data. Results: We identified 2030 external validations of 1382 CPMs. Eight hundred seven (58%) of the CPMs in the Registry have never been externally validated. On average, there were 1.5 validations per CPM (range, 0–94). The median external validation area under the receiver operating characteristic curve was 0.73 (25th–75th percentile [interquartile range (IQR)], 0.66–0.79), representing a median percent decrease in discrimination of -11.1% (IQR, -32.4% to +2.7%) compared with performance on derivation data. 81% (n=1333) of validations reporting area under the receiver operating characteristic curve showed discrimination below that reported in the derivation dataset. 53% (n=983) of the validations report some measure of CPM calibration. For CPMs evaluated more than once, there was typically a large range of performance. Of 1702 validations classified by relatedness, the percent change in discrimination was -3.7% (IQR, -13.2 to 3.1) for closely related validations (n=123), -9.0 (IQR, -27.6 to 3.9) for related validations (n=862), and -17.2% (IQR, -42.3 to 0) for distantly related validations (n=717; P&amp;amp;amp;lt;0.001). Conclusions: Many published cardiovascular CPMs have never been externally validated, and for those that have, apparent performance during development is often overly optimistic. A single external validation appears insufficient to broadly understand the performance heterogeneity across different settings.;,citation_author=Benjamin S. Wessler;,citation_author=Jason Nelson;,citation_author=Jinny G. Park;,citation_author=Hannah McGinnes;,citation_author=Gaurav Gulati;,citation_author=Riley Brazil;,citation_author=Ben Van Calster;,citation_author=David Klaveren;,citation_author=Esmee Venema;,citation_author=Ewout Steyerberg;,citation_author=Jessica K. Paulus;,citation_author=David M. Kent;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_issue=8;,citation_doi=10.1161/CIRCOUTCOMES.121.007858;,citation_volume=14;,citation_journal_title=Circulation: Cardiovascular Quality and Outcomes;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=The Table 2 Fallacy: Presenting and Interpreting Confounder and Modifier Coefficients;,citation_author=D. Westreich;,citation_author=S. Greenland;,citation_publication_date=2013-02;,citation_cover_date=2013-02;,citation_year=2013;,citation_issue=4;,citation_doi=10.1093/aje/kws412;,citation_issn=0002-9262, 1476-6256;,citation_volume=177;,citation_language=en-US;,citation_journal_title=American Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Target Validity and the Hierarchy of Study Designs;,citation_abstract=In recent years, increasing attention has been paid to problems of external validity, specifically to methodological approaches for both quantitative generalizability and transportability of study results. However, most approaches to these issues have considered external validity separately from internal validity. Here we argue that considering either internal or external validity in isolation may be problematic. Further, we argue that a joint measure of the validity of an effect estimate with respect to a specific population of interest may be more useful: We call this proposed measure target validity. In this work, we introduce and formally define target bias as the total difference between the true causal effect in the target population and the estimated causal effect in the study sample, and target validity as target bias = 0. We illustrate this measure with a series of examples and show how this measure may help us to think more clearly about comparisons between experimental and nonexperimental research results. Specifically, we show that even perfect internal validity does not ensure that a causal effect will be unbiased in a specific target population.;,citation_author=Daniel Westreich;,citation_author=Jessie K. Edwards;,citation_author=Catherine R. Lesko;,citation_author=Stephen R. Cole;,citation_author=Elizabeth A. Stuart;,citation_publication_date=2019-02;,citation_cover_date=2019-02;,citation_year=2019;,citation_issue=2;,citation_doi=10.1093/aje/kwy228;,citation_issn=1476-6256;,citation_pmid=30299451;,citation_volume=188;,citation_language=en-US;,citation_journal_title=American Journal of Epidemiology;">
<meta name="citation_reference" content="citation_title=Management of supraventricular arrhythmias in the intensive care unit: A step in the right direction;,citation_author=Mik Wetterslev;,citation_author=Romain Pirracchio;,citation_author=Christian Jung;,citation_publication_date=2023-10;,citation_cover_date=2023-10;,citation_year=2023;,citation_doi=10.1007/s00134-023-07236-z;,citation_issn=0342-4642, 1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity;,citation_author=Sean Wharton;,citation_author=Thomas Blevins;,citation_author=Lisa Connery;,citation_author=Julio Rosenstock;,citation_author=Sohini Raha;,citation_author=Rong Liu;,citation_author=Xiaosu Ma;,citation_author=Kieren J. Mather;,citation_author=Axel Haupt;,citation_author=Deborah Robins;,citation_author=Edward Pratt;,citation_author=Christof Kazda;,citation_author=Manige Konig;,citation_publication_date=2023-09;,citation_cover_date=2023-09;,citation_year=2023;,citation_issue=10;,citation_doi=10.1056/NEJMoa2302392;,citation_issn=0028-4793;,citation_pmid=37351564;,citation_volume=389;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=AGAINST INFERENTIAL STATISTICS: HOW AND WHY CURRENT STATISTICS TEACHING GETS IT WRONG;,citation_author=Patrick White;,citation_author=Stephen Gorard;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Delirium and COVID-19: A narrative review of emerging evidence;,citation_abstract=Delirium is a common condition affecting hospital inpatients, including those having surgery and on the intensive care unit. Delirium is also common in patients with COVID-19 in hospital settings, and the occurrence is higher than expected for similar infections. The short-term outcomes of those with COVID-19 delirium are similar to that of classical delirium and include increased length of stay and increased mortality. Management of delirium in COVID-19 in the context of a global pandemic is limited by the severity of the syndrome and compounded by the environmental constraints. Practical management includes effective screening, early identification and appropriate treatment aimed at minimising complications and timely escalation decisions. The pandemic has played out on the national stage and the effect of delirium on patients, relatives and healthcare workers remains unknown but evidence from the previous SARS outbreak suggests there may be long-lasting psychological damage.;,citation_author=L. White;,citation_author=T. Jackson;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=S1;,citation_doi=10.1111/anae.15627;,citation_issn=0003-2409, 1365-2044;,citation_volume=77;,citation_language=en-US;,citation_journal_title=Anaesthesia;">
<meta name="citation_reference" content="citation_title=The Language of Prognostication in Intensive Care Units;,citation_abstract=Rationale. Although misunderstandings about prognosis are common in intensive care units (ICUs), little is known about how physicians actually communicate prognostic information. Objectives. The authors sought to 1) develop a framework to describe the language physicians use to disclose prognosis, 2) determine whether physicians frame prognostic statements as estimates for populations or estimates for individual patients, and 3) determine whether physicians use the recommended “ask-tell-ask” approach when discussing prognosis. Methods. The authors conducted a multicenter, cross-sectional study of 51 audiotaped physician-family conferences about life support decisions in ICUs. They identified each prognostic statement and used grounded theory methods to develop a framework to understand the language physicians use to communicate prognosis. Main Results. Physicians prognosticated in 50 of 51 conferences. When discussing prognosis, physicians used qualitative probability statements in 72% (36/50) of conferences, numeric statements in 20% (10/50), absolute statements in 13% (4/32), and nonprobabilistic statements in 40% (20/50). Physicians exclusively used population-based language in 10% (5/50) of conferences, single-event probability statements in 62% (31/50), and both in 28% (14/ 50). In only 2% (1/50) of conferences did physicians ask whether the family wished to hear prognostic information prior to discussing it, and in only 14% of conferences (7/50) did physicians check to verify that families understood the prognostic information. Conclusions. There is considerable variability in the language used by physicians to disclose prognosis, with only 20% of physicians using quantitative terms. Very few physicians checked whether families understood prognostic information. These findings may provide potential targets for interventions to improve communication about prognosis in ICUs.;,citation_author=Douglas B. White;,citation_author=Ruth A. Engelberg;,citation_author=Marjorie D. Wenrich;,citation_author=Bernard Lo;,citation_author=J. Randall Curtis;,citation_publication_date=2010-01;,citation_cover_date=2010-01;,citation_year=2010;,citation_issue=1;,citation_doi=10.1177/0272989X08317012;,citation_issn=0272-989X;,citation_volume=30;,citation_language=en-US;,citation_journal_title=Medical Decision Making;,citation_publisher=SAGE Publications Inc STM;">
<meta name="citation_reference" content="citation_title=Landiolol and Organ Failure in Patients With Septic Shock: The STRESS-L Randomized Clinical Trial;,citation_abstract=OBJECTIVES To assess the efficacy and safety of landiolol in patients with tachycardia and established septic shock requiring prolonged (&amp;amp;amp;gt;24 hours) vasopressor support. DESIGN, SETTING, AND PARTICIPANTS An open-label, multicenter, randomized trial involving 126 adults (Ն18 years) with tachycardia (heart rate Ն95/min) and established septic shock treated for at least 24 hours with continuous norepinephrine (Ն0.1 \mug/kg/min) in 40 UK National Health Service intensive care units. The trial ran from April 2018 to December 2021, with early termination in December 2021 due to a signal of possible harm. INTERVENTION Sixty-three patients were randomized to receive standard care and 63 to receive landiolol infusion. MAIN OUTCOMES AND MEASURES The primary outcome was the mean Sequential Organ Failure Assessment (SOFA) score from randomization through 14 days. Secondary outcomes included mortality at days 28 and 90 and the number of adverse events in each group. RESULTS The trial was stopped prematurely on the advice of the independent data monitoring committee because it was unlikely to demonstrate benefit and because of possible harm. Of a planned 340 participants, 126 (37%) were enrolled (mean age, 55.6 years [95% CI, 52.7 to 58.5 years]; 58.7% male). The mean (SD) SOFA score in the landiolol group was 8.8 (3.9) compared with 8.1 (3.2) in the standard care group (mean difference [MD], 0.75 [95% CI, -0.49 to 2.0]; P = .24). Mortality at day 28 after randomization in the landiolol group was 37.1% (23 of 62) and 25.4% (16 of 63) in the standard care group (absolute difference, 11.7% [95% CI, -4.4% to 27.8%]; P = .16). Mortality at day 90 after randomization was 43.5% (27 of 62) in the landiolol group and 28.6% (18 of 63) in the standard care group (absolute difference, 15% [95% CI, -1.7% to 31.6%]; P = .08). There were no differences in the number of patients having at least one adverse event. CONCLUSION AND RELEVANCE Among patients with septic shock with tachycardia and treated with norepinephrine for more than 24 hours, an infusion of landiolol did not reduce organ failure measured by the SOFA score over 14 days from randomization. These results do not support the use of landiolol for managing tachycardia among patients treated with norepinephrine for established septic shock.;,citation_author=Tony Whitehouse;,citation_author=Anower Hossain;,citation_author=Gavin D. Perkins;,citation_author=Anthony C. Gordon;,citation_author=Julian Bion;,citation_author=Duncan Young;,citation_author=Danny McAuley;,citation_author=Mervyn Singer;,citation_author=Janet Lord;,citation_author=Simon Gates;,citation_author=Tonny Veenith;,citation_author=Niall S. MacCallum;,citation_author=Joyce Yeung;,citation_author=Richard Innes;,citation_author=Ingeborg Welters;,citation_author=Nafisa Boota;,citation_author=Emma Skilton;,citation_author=Belinder Ghuman;,citation_author=Maddy Hill;,citation_author=Scott E. Regan;,citation_author=Dipesh Mistry;,citation_author=Ranjit Lall;,citation_author=STRESS-L Collaborators;,citation_author=Tonny Veenith;,citation_author=Jaimin Patel;,citation_author=Nick Murphy;,citation_author=Mansoor Bangash;,citation_author=Tomasz Torlinski;,citation_author=Nicholas Talbot;,citation_author=Catherine Snelson;,citation_author=Dhruv Parekh;,citation_author=Amisha Desai;,citation_author=Mary Kotada;,citation_author=Yin May Chin;,citation_author=Sophie Holden;,citation_author=Aoife Neal;,citation_author=Maximina Ventura;,citation_author=Martin Pope;,citation_author=Samantha Harkett;,citation_author=Christopher McGhee;,citation_author=Emma Fellows;,citation_author=Amy Bamford;,citation_author=Ronald Carrera;,citation_author=Karen Ellis;,citation_author=Elaine Spruce;,citation_author=Liesl Despy;,citation_author=Stephanie Porter;,citation_author=Colin Bergin;,citation_author=Stephanie Gouny;,citation_author=Hazel Smith;,citation_author=Tracy Mason;,citation_author=Natalie Dooley;,citation_author=Amy Clark;,citation_author=Joyce Yeung;,citation_author=Jo Gresty;,citation_author=Teresa Melody;,citation_author=Ellie Reeves;,citation_author=Rachel Smith;,citation_author=Julia Sampson;,citation_author=Accp Team Bhh Critical Care Unit;,citation_author=Chris Nutt;,citation_author=James Mcnamee;,citation_author=Danny Mcauley;,citation_author=Anen Boyle;,citation_author=Loren McGinley;,citation_author=Chris Wright;,citation_author=Kathryn Ward;,citation_author=Lauren Macartney;,citation_author=Justine Mccann;,citation_author=Brian Wells;,citation_author=Janette Mills;,citation_author=Leona Bannon;,citation_author=Aisling O’Neill;,citation_author=Stephanie Finn;,citation_author=Anthony Gordon;,citation_author=David Antcliffe;,citation_author=Stephen Brett;,citation_author=Dorota Banach;,citation_author=Leilani Cabreros;,citation_author=Laura Curran;,citation_author=Sonia Sousa Arias;,citation_author=Roceld Rojo;,citation_author=Ziortza Fernandez De Pinedo Artaraz;,citation_author=Phoebe Coghlan;,citation_author=Maie Templeton;,citation_author=Ahmed ElHaddad;,citation_author=Zohonon Sabine Loko;,citation_author=Gareth Barker;,citation_author=Niall MacCallum;,citation_author=David Brealey;,citation_author=Mervyn Singer;,citation_author=Kristian Warnes;,citation_author=Nina Bason;,citation_author=Dorota Filipowicz;,citation_author=Georgia Bercades;,citation_author=Ingrid Hass;,citation_author=Jung Ryu;,citation_author=Deborah Smyth;,citation_author=Dorothy Ilano;,citation_author=Dan Harvey;,citation_author=Louise Conner;,citation_author=Lucy Ryan;,citation_author=Cecilia Peters;,citation_author=Megan Meredith;,citation_author=Megan Mcaulay;,citation_author=Zoe Whitman;,citation_author=Lucy Morris;,citation_author=Claudia Woodford;,citation_author=Sally Hodgkinson;,citation_author=Sonya Finucane;,citation_author=Luigi Camporota;,citation_author=Manu Shankar-Hari;,citation_author=Marlies Ostermann;,citation_author=Aneta Bociek;,citation_author=Rosario Lim;,citation_author=Neus GrauNovellas;,citation_author=Natalie Palmer;,citation_author=Angela Cape;,citation_author=Anea Kelly;,citation_author=Gill Arbane;,citation_author=Sarah Campos;,citation_author=Michael Singh;,citation_author=Jinny Yoo;,citation_author=Richard Innes;,citation_author=Fiona Dempsey;,citation_author=Patricia Doble;,citation_author=Rebecca Purnell;,citation_author=Moira Tait;,citation_author=Jo Hutter;,citation_author=Corinne Pawley;,citation_author=Joy Rowe;,citation_author=Catherine Wane;,citation_author=Richard Burgess;,citation_author=Ashly Thomas;,citation_author=Pulak Paul;,citation_author=Brenda White;,citation_author=Wayne Lovegrove;,citation_author=Mandy Gill;,citation_author=Lynne Wade;,citation_author=Tracy Brear;,citation_author=Vishal Dhokia;,citation_author=Debbie Jackson;,citation_author=Sarah Shelton;,citation_author=Jill Kirk;,citation_author=Anew Boulton;,citation_author=Alistair Roy;,citation_author=Anthony Rostron;,citation_author=Zeynep Elcioglu;,citation_author=Lindsey Woods;,citation_author=Sarah Cornell;,citation_author=Rebecca Betts;,citation_author=Jill Holden;,citation_author=Stephen Laybourne;,citation_author=Kimberley Rogerson;,citation_author=Jeremy Bewley;,citation_author=Rebekah Johnson;,citation_author=Anna Chillingworth;,citation_author=Bethany Gumbrill;,citation_author=Hilary Galvin;,citation_author=Kim Wright;,citation_author=Georgia Efford;,citation_author=Kathleen Corcoran;,citation_author=Libby Cole;,citation_author=Katie Sweet;,citation_author=Denise Webster;,citation_author=Lisa Grimmer;,citation_author=Gemma Paris;,citation_author=Chloe Searles;,citation_author=Zoe Garland;,citation_author=Charly Gibson;,citation_author=Melanie Hutchings;,citation_author=Fiona Walters;,citation_author=Sinead Kelly;,citation_author=Lorraine Scaife;,citation_author=Kelly Littlewood;,citation_author=James Leavy;,citation_author=Shirley Todd;,citation_author=Elizabeth Gordon;,citation_author=Sadie Heddon;,citation_author=Victor Mariano;,citation_author=Karin Gupwell;,citation_author=Rebecca Appelboam;,citation_author=Samantha Keenan;,citation_author=Cassie Brady;,citation_author=Ian Mew;,citation_author=Duncan Chambler;,citation_author=Sarah Williams;,citation_author=Pauline Ashcroft;,citation_author=Patricia Williams;,citation_author=James Rees;,citation_author=Sophie Wiseman;,citation_author=Sarah Horton;,citation_author=Mark Shortland;,citation_author=Stephanie Dukes;,citation_author=Andy Ball;,citation_author=Michael Spivey;,citation_author=Jennie Stephens;,citation_author=Sarah Bean;,citation_author=Karen Burt;,citation_author=Rachel Chapman;,citation_author=Carol Richards;,citation_author=Lorraine Moore;,citation_author=Linda Allsop;,citation_author=Amber Wynn;,citation_author=Louise Latty;,citation_author=Sam Waddy;,citation_author=Kayleigh Spencer;,citation_author=Bethan Stowe;,citation_author=Georgina Cox;,citation_author=Helen McMillan;,citation_author=Liana Lankester;,citation_author=Colin Wells;,citation_author=Rosalyn Squire;,citation_author=Mike Marner;,citation_author=Robert Jackson;,citation_author=Nikitas Nikitas;,citation_author=Stuart Dickson;,citation_author=Henrik Reschreiter;,citation_author=James Bromilow;,citation_author=James Keegan;,citation_author=Chris Loew;,citation_author=Ken Power;,citation_author=Spike Briggs;,citation_author=Julie Camsooksai;,citation_author=Sarah Patch;,citation_author=Sarah Jenkins;,citation_author=Sharon Power;,citation_author=Elizabeth Woodward;,citation_author=David Pogson;,citation_author=Zoe Daly;,citation_author=Steve Rose;,citation_author=Aimi Collins;,citation_author=Amy Phelps;,citation_author=Helen Claridge;,citation_author=Christine Minnis;,citation_author=Sarah Inglis;,citation_author=Lutece Brimfield;,citation_author=Charlotte Wong;,citation_author=Ingeborg Welters;,citation_author=Karen Williams;,citation_author=Victoria Waugh;,citation_author=Julie Patrick-Heselton;,citation_author=Emily Johnson;,citation_author=David Shaw;,citation_author=Brian Johnston;,citation_author=Maryam Crews;,citation_author=Alicia Waite;,citation_author=Vinoth Sankar;,citation_author=Jonathan Walker;,citation_author=Peter Turton;,citation_author=Richard Wenstone;,citation_author=Jaime Fernandez Roman;,citation_author=Alison Hall;,citation_author=Maria Lopez Martinez;,citation_author=David Oliver Hamilton;,citation_author=David Coey;,citation_author=Philip Shelley;,citation_author=Martin Goulding;,citation_author=Karen Kavanagh;,citation_author=Ann Marron;,citation_author=Hannah Allsop;,citation_author=Phil Hopkins;,citation_author=John Smith;,citation_author=Harriet Noble;,citation_author=Evita Pappa;,citation_author=Clare Finney;,citation_author=Sinead Heyler;,citation_author=Emma Clarey;,citation_author=Maeve Cockrell;,citation_author=Maria Therese Depante;,citation_author=Kevin O’Reilly;,citation_author=Christopher Waterhouse;,citation_author=Vicky Chu;,citation_author=Joanne Gordon;,citation_author=Greg Marchant;,citation_author=Stuart Chandler;,citation_author=Senait Haile;,citation_author=Joanna Flanagan;,citation_author=Gaynor Notcheva;,citation_author=Dom Jimenez;,citation_author=Dilbagh Gill;,citation_author=Sunil Jamadarkhana;,citation_author=Sunita Gohil;,citation_author=Sura Dabbagh;,citation_author=Katy-Jane Chick;,citation_author=Carina Cruz;,citation_author=Vikram Anumakonda;,citation_author=Vanessa Moore;,citation_author=Lisa Stanton;,citation_author=Sharon Westwood;,citation_author=Jacqueline Smith;,citation_author=Karen Reid;,citation_author=Ranjit Gidda;,citation_author=Elena Anastasescu;,citation_author=Karim Salem;,citation_author=Mohamed Mooradun;,citation_author=Michael Reay;,citation_author=Nasirul Ekbal;,citation_author=Margaret McNeil;,citation_author=Helder Filipe;,citation_author=Aarti Nandani;,citation_author=Glykeria Pakou;,citation_author=Mark De Neef;,citation_author=Sara Mingo;,citation_author=Amitaa Maharajh;,citation_author=Prashanth Nandhabalan;,citation_author=Thomas Billyard;,citation_author=Laura Wild;,citation_author=Pamela Bremmer;,citation_author=Geraldine Ward;,citation_author=Fiona McGurk;,citation_author=Rajbinder Deol;,citation_author=Catherine Morgan;,citation_author=Kirandeep Pachoo;,citation_author=Barbara Phillips;,citation_author=Owen Boyd;,citation_author=Claire Phillips;,citation_author=Rakhee Hindocha;,citation_author=Stephen Age;,citation_author=John Porter;,citation_author=Alex Harrison;,citation_author=Lynn Evans;,citation_author=Louise Ortiz-Ruiz De Gordoa;,citation_author=Dominika Wlazly;,citation_author=Tomas Anews;,citation_author=Jess West;,citation_author=Ben Attwood;,citation_author=Paul Jefferson;,citation_author=Penny Parsons;,citation_author=Sophie Mason;,citation_author=Bridget Campbell;,citation_author=Julia Jones;,citation_author=Kathryn Webb;,citation_author=Karen Spicer;,citation_author=Angela Day;,citation_author=Camilla Stagg;,citation_author=Noor Ayesha Shah;,citation_author=Ian Purcell;,citation_author=Lucy Shafiq;,citation_author=Coralie Carle;,citation_author=Rebecca Chilvers;,citation_author=Heather MacColl;,citation_author=Alan Pope;,citation_author=Anew Holder;,citation_author=Nicola Butterworth-Cowin;,citation_author=Matthew Davies;,citation_author=Louise Wilmer;,citation_author=Nadeem Ismail;,citation_author=Sneha Gurung;,citation_author=Piers Murphy;,citation_author=Toby Elkington;,citation_author=Matthew Camilleri;,citation_author=Rob Charnock;,citation_author=Claire Shevlin;,citation_author=Emma McGregor;,citation_author=Chris Clarke;,citation_author=Judith Hinds;,citation_author=Sophie Hughes;,citation_author=Raymond McKee;,citation_author=Denise McFarland;,citation_author=Roisin McNulty;,citation_author=Andy Breen;,citation_author=Elizabeth Wilby;,citation_author=Nora Youngs;,citation_author=Richard French;,citation_author=Suzie Colquhoun;,citation_author=Claire Posnett;,citation_author=Clare Howcroft;,citation_author=Anew Taylor;,citation_author=Simon Whiteley;,citation_author=Bethan Ogg;,citation_author=Kate Long;,citation_author=Alicia Tomkinson;,citation_author=Ian Clement;,citation_author=Tara Shrestha;,citation_author=Leigh Dunn;,citation_author=Verity Calder;,citation_author=Maite Babio-Galan;,citation_author=Kimberley Zwiggelaar;,citation_author=Anne Mitchell;,citation_author=Julie Stephenson;,citation_author=Lesley Rigden;,citation_author=Jude Davison;,citation_author=Joseph Carter;,citation_author=Kate Howard;,citation_author=Hazel Cahill;,citation_author=Lia Grainger;,citation_author=Poppy Cottrell-Howe;,citation_author=Abigail Rowbotham;,citation_author=Laura Jeffery;,citation_author=Emily Waterman;,citation_author=Arran Fletcher;,citation_author=Zoe Guy;,citation_author=Isabel Birkinshaw;,citation_author=Jo Ingham;,citation_author=Zoe Scott;,citation_author=Samantha Stead;,citation_author=Raha West;,citation_author=Pradeep Shanmugasundaram;,citation_author=Judith Abrams;,citation_author=Geraldine Hambrook;,citation_author=Katarina Manso;,citation_author=Sally Scott;,citation_author=Iram Husain;,citation_author=Evelyn Chan;,citation_author=Siobhan Gettings;,citation_author=Anil Hormis;,citation_author=Rachel Walker;,citation_author=Dawn Collier;,citation_author=Cheryl Graham;,citation_author=Victoria Murray;,citation_author=Katy Curtis;,citation_author=Charlotte Widdop;,citation_author=Sarah Kimpton;,citation_author=Susan Oakley;,citation_author=Zirlish Afzal;,citation_author=James Varley;,citation_author=Petra Polgarova;,citation_author=Andrew Johnston;,citation_author=Lynne Whitehead;,citation_author=Andrew Conway Morris;,citation_author=Razeen Mahroof;,citation_author=Sofia Teixeira;,citation_author=Nazrudeen Ali;,citation_author=Jonny Wilkinson;,citation_author=Alex Lyon;,citation_author=Charlotte Mills;,citation_author=Kathryn Hall;,citation_author=Gayna Grantham;,citation_author=Lorraine Campey;,citation_author=Helen Cronshaw;,citation_author=Livia Malanjum;,citation_author=Lucy Dudgeon;,citation_author=Clare Hinchley;,citation_author=Stephen Langhon;,citation_author=Jane Hosea;,citation_author=Anea Hillyer;,citation_author=Rachel Kontogonis;,citation_author=Oninye Ndefo;,citation_author=Laura Robinson;,citation_author=Callum Kaye;,citation_author=Kevin Sim;,citation_author=Ian Scott;,citation_author=Teresa Scott;,citation_author=Felicity Anderson;,citation_author=Wendy Mitchell;,citation_author=Patricia Cooper;,citation_author=James MacBrayne;,citation_author=Fiona Willox;,citation_author=Kate Richmond;,citation_author=Rebecca Colleron;,citation_author=Erin Trumper;,citation_author=Bartosz Was;,citation_author=Michael Christie;,citation_author=Amber Johnson;,citation_author=Gillian Price;,citation_author=Malcolm Sim;,citation_author=Robert Docking;,citation_author=Scott McQueen;,citation_author=Sophie Kennedy-Kay;,citation_author=Lynn Abel;,citation_author=Steven Henderson;,citation_author=Kirsty McLeash;,citation_author=Anew Gratrix;,citation_author=Victoria Martinson;,citation_author=Louise Foster;,citation_author=Elizabeth Stones;,citation_author=Vicki Lowthorpe;,citation_author=Daniel Crawley;,citation_author=Susannah Leaver;,citation_author=Sarah Farnell Ward;,citation_author=Romina Pepermans Saluzzio;,citation_author=Frances Robinson;,citation_author=Carlos Delgado;,citation_author=Geraldine Gray;,citation_author=Rebecca Kanu;,citation_author=Robert Oakley;,citation_author=Karen M. Keates;,citation_author=Tim Walsh;,citation_publication_date=2023-10;,citation_cover_date=2023-10;,citation_year=2023;,citation_doi=10.1001/jama.2023.20134;,citation_issn=0098-7484;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Prophylactic melatonin for delirium in intensive care (Pro-MEDIC): A randomized controlled trial;,citation_abstract=Purpose: Delirium is common in the critically ill, highly distressing to patients and families and associated with increased morbidity and mortality. Results of studies on preventative use of melatonin in various patient groups have produced mixed results. The aim of this study was to determine whether administration of melatonin decreases the prevalence of delirium in critically ill patients. Methods: Multicentre, randomized, placebo-controlled, double-blind trial across 12 Australian ICUs recruiting patients from July 2016 to September 2019. Patients of at least 18 years requiring ICU admission with an expected length of stay (LOS) greater than 72 h; enrolled within 48 h of ICU admission. Indistinguishable liquid melatonin (4 mg; n = 419) or placebo (n = 422) was administered enterally at 21:00 h for 14 consecutive nights or until ICU discharge. The primary outcome was the proportion of delirium-free assessments, as a marker of delirium prevalence, within 14 days or before ICU discharge. Delirium was assessed twice daily using the Confusion Assessment Method for ICU (CAM-ICU) score. Secondary outcomes included sleep quality and quantity, hospital and ICU LOS, and hospital and 90-day mortality. Results: A total of 847 patients were randomized into the study with 841 included in data analysis. Baseline characteristics of the participants were similar. There was no significant difference in the average proportion of delirium-free assessments per patient between the melatonin and placebo groups (79.2 vs 80% respectively, p = 0.547). There was no significant difference in any secondary outcomes including ICU LOS (median: 5 vs 5 days, p = 0.135), hospital LOS (median: 14 vs 12 days, p = 0816), mortality at any time point including at 90 days (15.5 vs 15.6% p = 0.948), nor in the quantity or quality of sleep. There were no serious adverse events reported in either group. Conclusion: Enteral melatonin initiated within 48 h of ICU admission did not reduce the prevalence of delirium compared to placebo. These findings do not support the routine early use of melatonin in the critically ill.;,citation_author=Bradley Wibrow;,citation_author=F. Eduardo Martinez;,citation_author=Erina Myers;,citation_author=Andrew Chapman;,citation_author=Edward Litton;,citation_author=Kwok. M. Ho;,citation_author=Adrian Regli;,citation_author=David Hawkins;,citation_author=Andrew Ford;,citation_author=Frank M. P. Haren;,citation_author=Simon Wyer;,citation_author=Joe McCaffrey;,citation_author=Alan Rashid;,citation_author=Erin Kelty;,citation_author=Kevin Murray;,citation_author=Matthew Anstey;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_doi=10.1007/s00134-022-06638-9;,citation_issn=0342-4642, 1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=A perspective on the fluids and catheters treatment trial (FACTT). Fluid restriction is superior in acute lung injury and ARDS.;,citation_author=H. P Wiedemann;,citation_publication_date=2008-01;,citation_cover_date=2008-01;,citation_year=2008;,citation_issue=1;,citation_doi=10.3949/ccjm.75.1.42;,citation_issn=0891-1150, 1939-2869;,citation_volume=75;,citation_language=en-US;,citation_journal_title=Cleveland Clinic Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Is the literature inconclusive about the harm from HES? No;,citation_author=Christian J. Wiedermann;,citation_author=Rinaldo Bellomo;,citation_author=Anders Perner;,citation_publication_date=2017-10;,citation_cover_date=2017-10;,citation_year=2017;,citation_issue=10;,citation_doi=10.1007/s00134-016-4275-x;,citation_issn=0342-4642, 1432-1238;,citation_volume=43;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Predicting Coma Trajectories: The Impact of Bias and Noise on Shared Decisions;,citation_abstract=Coma trajectories are characterized by quick awakening or protracted awakening. Outcome is bookended by restored functionality or permanent cognitively and physically debilitated states. Given the stakes, prognostication cannot be easily questioned as a judgment call, and a scientific underpinning is elemental. Conventional wisdom in determining coma-outcome trajectories posits that (1) predictive models are better than personal experiences, (2) self-fulfilling prophesy is unchecked and driven by nihilism, with little regard for prior probability outcomes, and (3) recovery is impacted by patients’ prior wishes and preexisting medical conditions—but also by what families are told about the patient’s state and anticipated clinical course. Moreover, a predicted good outcome can be offset by a major subsequent complication, or a predicted poor outcome can be offset by aggressive care. This article examines some of these concepts, including how we decide on aggressiveness of care, how we judge quality of life, and the impact on outcome. Most patients who awaken quickly do well and can resume their pretrauma injury lives. In worse off, slowto-awaken patients, outcomes are a mixed bag of limited innate resilience, depleted cognitive and physical reserves, and adjusted quality of life. Bias and noise are factors not easily measured in outcome prediction, but their influence on recovery trajectories raises some troubling issues.;,citation_author=Eelco F. M. Wijdicks;,citation_author=David Y. Hwang;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_doi=10.1007/s12028-021-01324-y;,citation_issn=1541-6933, 1556-0961;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Breastfeeding Insufficiencies: Common and Preventable Harm to Neonates;,citation_abstract=Insufficient milk intake in breastfed neonates is common, frequently missed, and causes preventable hospitalizations for jaundice/hyperbilirubinemia, hypernatremia/dehydration, and hypoglycemia - accounting for most U.S. neonatal readmissions. These and other consequences of neonatal starvation and deprivation may substantially contribute to fully preventable morbidity and mortality in previously healthy neonates worldwide. Previous advanced civilizations recognized this problem of breastfeeding insufficiencies and had an infrastructure to solve it: Wetnursing, shared nursing, and prelacteal feeding traditions used to be well-organized and widespread. Modern societies accidentally destroyed that infrastructure. Then, modern reformers missing a few generations of direct knowledge transmission about safe breastfeeding invented a new, historically anomalous conception of breastfeeding defined in terms of exclusivity. As that new intervention has become increasingly widespread, so too have researchers widely reported associated possible harms of the longer neonatal starvation/deprivation and later infant under-nutrition periods that it creates when breastfeeding is insufficient. Early insufficient nutrition/hydration has possible long-term effects including neurodevelopmental consequences such as attention deficit hyperactivity disorder, autism, cerebral palsy, cognitive and developmental delay, epilepsy, hearing impairment, kernicterus, language disorder, mood disorders, lower IQ, and specific learning disorder. Current early infant feeding guidelines conflict with the available evidence. Recent reform efforts have tended to focus on using more technology and measurement to harm fewer neonates instead of proposing the indicated paradigm shift in early infant feeding to prevent more harm. The scientific evidence is already sufficient to mandate application of the precautionary principle to feed neonates early, adequate, and often milk before mothers’ milk comes in and whenever signs of hunger persist, mitigating possible risks including death or disability. In most contexts, the formula is the best supplementary milk for infants at risk from breastfeeding insufficiencies. National-level reviews of scientific evidence, health policy, and research methods and ethics are needed to initiate the early infant feeding paradigm shift that the data already support. Policy experiments and related legislative initiatives might also contribute to the shift, as insurers might decline or be required by law to decline reimbursing hospitals for costs of this type of preventable hospitalization, which otherwise generates profit.;,citation_author=Vera K. Wilde;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=10;,citation_doi=10.7759/cureus.18478;,citation_issn=2168-8184;,citation_pmid=34659917;,citation_volume=13;,citation_language=en-US;,citation_journal_title=Cureus;">
<meta name="citation_reference" content="citation_title=Once-Weekly Semaglutide in Adults with Overweight or Obesity;,citation_author=John P. H. Wilding;,citation_author=Rachel L. Batterham;,citation_author=Salvatore Calanna;,citation_author=Melanie Davies;,citation_author=Luc F. Van Gaal;,citation_author=Ildiko Lingvay;,citation_author=Barbara M. McGowan;,citation_author=Julio Rosenstock;,citation_author=Marie T. D. Tran;,citation_author=Thomas A. Wadden;,citation_author=Sean Wharton;,citation_author=Koutaro Yokote;,citation_author=Niels Zeuthen;,citation_author=Robert F. Kushner;,citation_publication_date=2021-03;,citation_cover_date=2021-03;,citation_year=2021;,citation_issue=11;,citation_doi=10.1056/NEJMoa2032183;,citation_issn=0028-4793;,citation_pmid=33567185;,citation_volume=384;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Management of traumatic brain injury: A narrative review of current evidence;,citation_abstract=Globally, approximately 70 million people sustain traumatic brain injury each year and this can have significant physical, psychosocial and economic consequences for patients, their families and society. The aim of this review is to provide clinicians with a summary of recent studies of direct relevance to the management of traumatic brain injury in order to promote best clinical practice. The use of tranexamic acid in the management of traumatic brain injury has been the focus of several studies, with one large randomised controlled trial suggesting a reduction in all-cause mortality within 24 h of injury. The use of therapeutic hypothermia does not improve neurological outcomes and maintenance of normothermia remains the optimal management strategy. For seizure management, levetiracetam appears to be as effective as phenytoin, but the optimal dose remains unclear. There has been a lack of clear outcome benefit for any individual osmotherapy agent, with no difference in mortality or neurological recovery. Early tracheostomy (&amp;amp;amp;lt; 7 days from injury) for patients with traumatic brain injury is associated with a reduction in the incidence of ventilator-associated pneumonia and duration of mechanical ventilation, critical care and hospital stay. Further research is needed in order to determine the optimal package of care and interventions. There is a need for research studies to focus on patient-centred outcome measures such as long-term neurological recovery and quality of life.;,citation_author=M. D. Wiles;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=S1;,citation_doi=10.1111/anae.15608;,citation_issn=0003-2409, 1365-2044;,citation_volume=77;,citation_language=en-US;,citation_journal_title=Anaesthesia;">
<meta name="citation_reference" content="citation_title=Directed acyclic graphs for the study of effects of occupation on risk of COVID-19- related outcomes.;,citation_author=Jack Wilkinson;,citation_author=Sarah Beale;,citation_author=Mark Cherrie;,citation_author=Rhiannon Edge;,citation_author=David Fishwick;,citation_author=Matt Gittins;,citation_author=Srinivasa Vittal Katikireddi;,citation_author=Damien McElvenny;,citation_author=Vahé Nafilyan;,citation_author=Neil Pearce;,citation_author=Sarah Rhodes;,citation_author=Martie Tongeren;,citation_language=en-US;">
<meta name="citation_reference" content="citation_title=Research Focus: Protas;,citation_author=Emma Wilkinson;,citation_publication_date=2022-04;,citation_cover_date=2022-04;,citation_year=2022;,citation_issue=10335;,citation_doi=10.1016/S0140-6736(22)00728-0;,citation_issn=01406736;,citation_volume=399;,citation_language=en-US;,citation_journal_title=The Lancet;">
<meta name="citation_reference" content="citation_title=Introduction to causal diagrams for confounder selection: Causal diagrams;,citation_author=Elizabeth J. Williamson;,citation_author=Zoe Aitken;,citation_author=Jock Lawrie;,citation_author=Shyamali C. Dharmage;,citation_author=John A. Burgess;,citation_author=Andrew B. Forbes;,citation_publication_date=2014-04;,citation_cover_date=2014-04;,citation_year=2014;,citation_issue=3;,citation_doi=10.1111/resp.12238;,citation_issn=13237799;,citation_volume=19;,citation_language=en-US;,citation_journal_title=Respirology;">
<meta name="citation_reference" content="citation_title=Integrative regulation of human brain blood flow: Integrative regulation of human brain blood flow;,citation_abstract=Herein, we review mechanisms regulating cerebral blood flow (CBF), with specific focus on humans. We revisit important concepts from the older literature and describe the interaction of various mechanisms of cerebrovascular control. We amalgamate this broad scope of information into a brief review, rather than detailing any one mechanism or area of research. The relationship between regulatory mechanisms is emphasized, but the following three broad categories of control are explicated: (1) the effect of blood gases and neuronal metabolism on CBF; (2) buffering of CBF with changes in blood pressure, termed cerebral autoregulation; and (3) the role of the autonomic nervous system in CBF regulation. With respect to these control mechanisms, we provide evidence against several canonized paradigms of CBF control. Specifically, we corroborate the following four key theses: (1) that cerebral autoregulation does not maintain constant perfusion through a mean arterial pressure range of 60–150 mmHg; (2) that there is important stimulatory synergism and regulatory interdependence of arterial blood gases and blood pressure on CBF regulation; (3) that cerebral autoregulation and cerebrovascular sensitivity to changes in arterial blood gases are not modulated solely at the pial arterioles; and (4) that neurogenic control of the cerebral vasculature is an important player in autoregulatory function and, crucially, acts to buffer surges in perfusion pressure. Finally, we summarize the state of our knowledge with respect to these areas, outline important gaps in the literature and suggest avenues for future research.;,citation_author=Christopher K. Willie;,citation_author=Yu-Chieh Tzeng;,citation_author=Joseph A. Fisher;,citation_author=Philip N. Ainslie;,citation_publication_date=2014-03;,citation_cover_date=2014-03;,citation_year=2014;,citation_issue=5;,citation_doi=10.1113/jphysiol.2013.268953;,citation_issn=00223751;,citation_volume=592;,citation_language=en-US;,citation_journal_title=The Journal of Physiology;">
<meta name="citation_reference" content="citation_title=A Manual for the Glasgow Outcome Scale-Extended Interview;,citation_abstract=The Glasgow Outcome Scale-Extended (GOSE) has become one of the most widely used outcome instruments to assess global disability and recovery after traumatic brain injury. Achieving consistency in the application of the assessment remains a challenge, particularly in multi-center studies involving many assessors. We present a manual for the GOSE interview that is designed to support both single- and multi-center studies and promote inter-rater agreement. Many patients fall clearly into a particular category; however, patients may have outcomes that are on the borderline between adjacent categories, and cases can present other challenges for assessment. The Manual includes the general principles of assessment, advice on administering each section of the GOSE interview, and guidance on “borderline” and “difficult” cases. Finally, we discuss the properties of the GOSE, including strengths and limitations, and outline recommendations for assessor training, accreditation, and monitoring.;,citation_author=Lindsay Wilson;,citation_author=Kim Boase;,citation_author=Lindsay D. Nelson;,citation_author=Nancy R. Temkin;,citation_author=Joseph T. Giacino;,citation_author=Amy J. Markowitz;,citation_author=Andrew Maas;,citation_author=David K. Menon;,citation_author=Graham Teasdale;,citation_author=Geoffrey T. Manley;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_issue=17;,citation_doi=10.1089/neu.2020.7527;,citation_issn=0897-7151, 1557-9042;,citation_volume=38;,citation_language=en-US;,citation_journal_title=Journal of Neurotrauma;">
<meta name="citation_reference" content="citation_title=Prevalence of Disagreement About Appropriateness of Treatment Between ICU Patients/Surrogates and Clinicians;,citation_abstract=BACKGROUND: ICU patients/surrogates may experience adverse outcomes related to perceived inappropriate treatment. The objective was to determine the prevalence of patient/surrogatereported perceived inappropriate treatment, its impact on adverse outcomes, and discordance with clinicians. METHODS: We conducted a multicenter, prospective, observational study of adult ICU patients. RESULTS: For 151 patients, 1,332 patient, surrogate, nurse, and physician surveys were collected. Disagreement between patients/surrogates and clinicians regarding “too much” treatment being administered occurred in 26% of patients. Disagreement regarding “too little” treatment occurred in 10% of patients. Disagreement about perceived inappropriate treatment was associated with prognostic discordance (P \frac{1}{4} .02) and lower patient/surrogate satisfaction (Likert scale 1-5 of 4 vs 5; P \frac{1}{4} .02). Patient/surrogate respondents reported “too much” treatment in 8% of patients and “too little” treatment in 6% of patients. Perceived inappropriate treatment was associated with moderate or high respondent distress for 55% of patient/surrogate respondents and 35% of physician/nurse respondents (P \frac{1}{4} .30). Patient/surrogate perception of inappropriate treatment was associated with lower satisfaction (Family Satisfaction in the ICU Questionnaire-24, 69.9 vs 86.6; P \frac{1}{4} .002) and lower trust in the clinical team (Likert scale 1-5 of 4 vs 5; P \frac{1}{4} .007), but no statistically significant differences in depression (Patient Health Questionnaire-2 of 2 vs 1; P \frac{1}{4} .06) or anxiety (Generalized Anxiety Disorder-7 Scale of 7 vs 4; P \frac{1}{4} .18). CONCLUSIONS: For approximately one-third of ICU patients, there is disagreement between clinicians and patients/surrogates about the appropriateness of treatment. Disagreement about appropriateness of treatment was associated with prognostic discordance and lower patient/surrogate satisfaction. Patients/surrogates who reported inappropriate treatment also reported lower satisfaction and trust in the ICU team. CHEST 2019; 155(6):1140-1147;,citation_author=Michael E. Wilson;,citation_author=Claudia C. Dobler;,citation_author=Laszlo Zubek;,citation_author=Ognjen Gajic;,citation_author=Daniel Talmor;,citation_author=J. Randall Curtis;,citation_author=Richard F. Hinds;,citation_author=Valerie M. Banner-Goodspeed;,citation_author=Ariel Mueller;,citation_author=Dee M. Rickett;,citation_author=Gabor Elo;,citation_author=Mario Filipe;,citation_author=Orsolya Szucs;,citation_author=Paul J. Novotny;,citation_author=Ruth D. Piers;,citation_author=Dominique D. Benoit;,citation_publication_date=2019-06;,citation_cover_date=2019-06;,citation_year=2019;,citation_issue=6;,citation_doi=10.1016/j.chest.2019.02.404;,citation_issn=00123692;,citation_volume=155;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Long-term mortality and quality of life in sepsis: A systematic review*:;,citation_author=Bradford D. Winters;,citation_author=Michael Eberlein;,citation_author=Janice Leung;,citation_author=Dale M. Needham;,citation_author=Peter J. Pronovost;,citation_author=Jonathan E. Sevransky;,citation_publication_date=2010-05;,citation_cover_date=2010-05;,citation_year=2010;,citation_issue=5;,citation_doi=10.1097/CCM.0b013e3181d8cc1d;,citation_issn=0090-3493;,citation_volume=38;,citation_language=en-US;,citation_journal_title=Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Evaluation of First Seizure and Newly Diagnosed Epilepsy;,citation_abstract=PURPOSE OF REVIEW: This article focuses on the evaluation of children and adults who present with new-onset seizures, with an emphasis on differential diagnosis, classification, evaluation, and management.;,citation_author=Elaine Wirrell;,citation_publication_date=2022-04;,citation_cover_date=2022-04;,citation_year=2022;,citation_issue=2;,citation_doi=10.1212/CON.0000000000001074;,citation_issn=1538-6899, 1080-2371;,citation_volume=28;,citation_language=en-US;,citation_journal_title=CONTINUUM: Lifelong Learning in Neurology;">
<meta name="citation_reference" content="citation_title=Systematic Development of Patient Decision Aids: An Update from the IPDAS Collaboration;,citation_abstract=Background The 2013 update of the evidence informing the quality dimensions behind the International Patient Decision Aid Standards (IPDAS) offered a model process for developers of patient decision aids. Objective To summarize and update the evidence used to inform the systematic development of patient decision aids from the IPDAS Collaboration. Methods To provide further details about design and development methods, we summarized findings from a subgroup ( n = 283 patient decision aid projects) in a recent systematic review of user involvement by Vaisson et al. Using a new measure of user-centeredness (UCD-11), we then rated the degree of user-centeredness reported in 66 articles describing patient decision aid development and citing the 2013 IPDAS update on systematic development. We contacted the 66 articles’ authors to request their self-reports of UCD-11 items. Results The 283 development processes varied substantially from minimal iteration cycles to more complex processes, with multiple iterations, needs assessments, and extensive involvement of end users. We summarized minimal, medium, and maximal processes from the data. Authors of 54 of 66 articles (82%) provided self-reported UCD-11 ratings. Self-reported scores were significantly higher than reviewer ratings (reviewers: mean [SD] = 6.45 [3.10]; authors: mean [SD] = 9.62 [1.16], P &amp;amp;amp;lt; 0.001). Conclusions Decision aid developers have embraced principles of user-centered design in the development of patient decision aids while also underreporting aspects of user involvement in publications about their tools. Templates may reduce the need for extensive development, and new approaches for rapid development of aids have been proposed when a more detailed approach is not feasible. We provide empirically derived benchmark processes and a reporting checklist to support developers in more fully describing their development processes. [Box: see text];,citation_author=Holly O. Witteman;,citation_author=Kristin G. Maki;,citation_author=Gratianne Vaisson;,citation_author=Jeanette Finderup;,citation_author=Krystina B. Lewis;,citation_author=Karina Dahl Steffensen;,citation_author=Caroline Beaudoin;,citation_author=Sandrine Comeau;,citation_author=Robert J. Volk;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=7;,citation_doi=10.1177/0272989X211014163;,citation_issn=0272-989X, 1552-681X;,citation_volume=41;,citation_language=en-US;,citation_journal_title=Medical Decision Making;">
<meta name="citation_reference" content="citation_title=Ensuring quality in medical laboratories;,citation_author=R. Wolber;,citation_author=D. Chercover;,citation_publication_date=2008-09;,citation_cover_date=2008-09;,citation_year=2008;,citation_issue=8;,citation_doi=10.1503/cmaj.1080094;,citation_issn=0820-3946, 1488-2329;,citation_volume=179;,citation_language=en-US;,citation_journal_title=Canadian Medical Association Journal;">
<meta name="citation_reference" content="citation_title=Effectiveness of Lumbar Cerebrospinal Fluid Drain Among Patients With Aneurysmal Subarachnoid Hemorrhage: A Randomized Clinical Trial;,citation_abstract=OBJECTIVE To determine the effectiveness of early lumbar cerebrospinal fluid drainage added to standard of care in patients after aneurysmal subarachnoid hemorrhage. DESIGN, SETTING, AND PARTICIPANTS The EARLYDRAIN trial was a pragmatic, multicenter, parallel-group, open-label randomized clinical trial with blinded end point evaluation conducted at 19 centers in Germany, Switzerland, and Canada. The first patient entered January 31, 2011, and the last on January 24, 2016, after 307 randomizations. Follow-up was completed July 2016. Query and retrieval of data on missing items in the case report forms was completed in September 2020. A total of 20 randomizations were invalid, the main reason being lack of informed consent. No participants meeting all inclusion and exclusion criteria were excluded from the intention-to-treat analysis. Exclusion of patients was only performed in per-protocol sensitivity analysis. A total of 287 adult patients with acute aneurysmal subarachnoid hemorrhage of all clinical grades were analyzable. Aneurysm treatment with clipping or coiling was performed within 48 hours. INTERVENTION A total of 144 patients were randomized to receive an additional lumbar drain after aneurysm treatment and 143 patients to standard of care only. Early lumbar drainage with 5 mL per hour was started within 72 hours of the subarachnoid hemorrhage. MAIN OUTCOMES AND MEASURES Primary outcome was the rate of unfavorable outcome, defined as modified Rankin Scale score of 3 to 6 (range, 0 to 6), obtained by masked assessors 6 months after hemorrhage. RESULTS Of 287 included patients, 197 (68.6%) were female, and the median (IQR) age was 55 (48-63) years. Lumbar drainage started at a median (IQR) of day 2 (1-2) after aneurysmal subarachnoid hemorrhage. At 6 months, 47 patients (32.6%) in the lumbar drain group and 64 patients (44.8%) in the standard of care group had an unfavorable neurological outcome (risk ratio, 0.73; 95% CI, 0.52 to 0.98; absolute risk difference, -0.12; 95% CI, -0.23 to -0.01; P = .04). Patients treated with a lumbar drain had fewer secondary infarctions at discharge (41 patients [28.5%] vs 57 patients [39.9%]; risk ratio, 0.71; 95% CI, 0.49 to 0.99; absolute risk difference, -0.11; 95% CI, -0.22 to 0; P = .04). CONCLUSION AND RELEVANCE In this trial, prophylactic lumbar drainage after aneurysmal subarachnoid hemorrhage lessened the burden of secondary infarction and decreased the rate of unfavorable outcome at 6 months. These findings support the use of lumbar drains after aneurysmal subarachnoid hemorrhage.;,citation_author=Stefan Wolf;,citation_author=Dorothee Mielke;,citation_author=Christoph Barner;,citation_author=Vesna Malinova;,citation_author=Thomas Kerz;,citation_author=Maria Wostrack;,citation_author=Patrick Czorlich;,citation_author=Farid Salih;,citation_author=Doortje C. Engel;,citation_author=Angelika Ehlert;,citation_author=Dimitre Staykov;,citation_author=Abdulrahman Y. Alturki;,citation_author=Ulrich Sure;,citation_author=Jürgen Bardutzky;,citation_author=Henry W. S. Schroeder;,citation_author=Ludwig Schürer;,citation_author=Jürgen Beck;,citation_author=Tareq A. Juratli;,citation_author=Michael Fritsch;,citation_author=Johannes Lemcke;,citation_author=Anne Pohrt;,citation_author=Bernhard Meyer;,citation_author=Stefan Schwab;,citation_author=Veit Rohde;,citation_author=Peter Vajkoczy;,citation_author=EARLYDRAIN Study Group;,citation_author=Norbert Baro;,citation_author=Miriam Bauer;,citation_author=Nora F. Dengler;,citation_author=Falk Von Dincklage;,citation_author=Tobias Finger;,citation_author=Roland Francis;,citation_author=Benjamin Hotter;,citation_author=Oliver Hunsicker;,citation_author=Daniel Jussen;,citation_author=Eric Jüttler;,citation_author=Andreas Schaumann;,citation_author=Jens Witsch;,citation_author=Christoph Nagel;,citation_author=Ullrich Meier;,citation_author=Dino Podlesik;,citation_author=Gabriele Schackert;,citation_author=Hagen Huttner;,citation_author=Sabine Hagedorn;,citation_author=Daniela Müller;,citation_author=Oliver Müller;,citation_author=Robert Sarge;,citation_author=Wolf-Dirk Niesen;,citation_author=Katharina Lange;,citation_author=Dennis Päsler;,citation_author=Stephanie Reinhardt;,citation_author=Jan Regelsberger;,citation_author=Thomas Sauvigny;,citation_author=Manfred Westphal;,citation_author=Rudolf Gremmer;,citation_author=Christian Beyer;,citation_author=Desiree Beyer;,citation_author=Alexandra Huthmann;,citation_author=Julia Landscheidt;,citation_author=David B. Schul;,citation_author=Yu-Mi Ryang;,citation_author=Elisabeth Toeroek;,citation_author=Wasim Arouk;,citation_author=Hosam Al-Jehani;,citation_author=David B. Sinclair;,citation_author=Christian Fung;,citation_author=Nicole Soell;,citation_author=Gerhard Hildebrandt;,citation_author=Karen Huscher;,citation_author=Heidrun Lange;,citation_author=Peter Hutchinson;,citation_author=Ming-Yuan Tseng;,citation_publication_date=2023-08;,citation_cover_date=2023-08;,citation_year=2023;,citation_issue=8;,citation_doi=10.1001/jamaneurol.2023.1792;,citation_issn=2168-6149;,citation_volume=80;,citation_language=en-US;,citation_journal_title=JAMA Neurology;">
<meta name="citation_reference" content="citation_title=Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): A randomised, double-blind, double placebo-controlled trial;,citation_abstract=Background Baricitinib and dexamethasone have randomised trials supporting their use for the treatment of patients with COVID-19. We assessed the combination of baricitinib plus remdesivir versus dexamethasone plus remdesivir in preventing progression to mechanical ventilation or death in hospitalised patients with COVID-19.;,citation_author=Cameron R Wolfe;,citation_author=Kay M Tomashek;,citation_author=Thomas F Patterson;,citation_author=Carlos A Gomez;,citation_author=Vincent C Marconi;,citation_author=Mamta K Jain;,citation_author=Otto O Yang;,citation_author=Catharine I Paules;,citation_author=Guillermo M Ruiz Palacios;,citation_author=Robert Grossberg;,citation_author=Michelle S Harkins;,citation_author=Richard A Mularski;,citation_author=Nathaniel Erdmann;,citation_author=Uriel Sandkovsky;,citation_author=Eyad Almasri;,citation_author=Justino Regalado Pineda;,citation_author=Alexandra W Dretler;,citation_author=Diego Lopez Castilla;,citation_author=Angela R Branche;,citation_author=Pauline K Park;,citation_author=Aneesh K Mehta;,citation_author=William R Short;,citation_author=Susan L F McLellan;,citation_author=Susan Kline;,citation_author=Nicole M Iovine;,citation_author=Hana M El Sahly;,citation_author=Sarah B Doernberg;,citation_author=Myoung-don Oh;,citation_author=Nikhil Huprikar;,citation_author=Elizabeth Hohmann;,citation_author=Colleen F Kelley;,citation_author=Mark Holodniy;,citation_author=Eu Suk Kim;,citation_author=Daniel A Sweeney;,citation_author=Robert W Finberg;,citation_author=Kevin A Grimes;,citation_author=Ryan C Maves;,citation_author=Emily R Ko;,citation_author=John J Engemann;,citation_author=Barbara S Taylor;,citation_author=Philip O Ponce;,citation_author=LuAnn Larson;,citation_author=Dante Paolo Melendez;,citation_author=Allan M Seibert;,citation_author=Nadine G Rouphael;,citation_author=Joslyn Strebe;,citation_author=Jesse L Clark;,citation_author=Kathleen G Julian;,citation_author=Alfredo Ponce Leon;,citation_author=Anabela Cardoso;,citation_author=Stephanie Bono;,citation_author=Robert L Atmar;,citation_author=Anuradha Ganesan;,citation_author=Jennifer L Ferreira;,citation_author=Michelle Green;,citation_author=Mat Makowski;,citation_author=Tyler Bonnett;,citation_author=Tatiana Beresnev;,citation_author=Varduhi Ghazaryan;,citation_author=Walla Dempsey;,citation_author=Seema U Nayak;,citation_author=Lori E Dodd;,citation_author=John H Beigel;,citation_author=Andre C Kalil;,citation_author=Lana Wahid;,citation_author=Emmanuel B. Walter;,citation_author=Akhila G. Belur;,citation_author=Grace Dreyer;,citation_author=Jan E. Patterson;,citation_author=Jason E. Bowling;,citation_author=Danielle O. Dixon;,citation_author=Angela Hewlett;,citation_author=Robert Odrobina;,citation_author=Jakrapun Pupaibool;,citation_author=Satish Mocherla;,citation_author=Suzana Lazarte;,citation_author=Meilani Cayabyab;,citation_author=Rezhan H. Hussein;,citation_author=Reshma R. Golamari;,citation_author=Kaleigh L. Krill;,citation_author=Sandra Rajme;,citation_author=Paul F. Riska;,citation_author=Barry S. Zingman;,citation_author=Gregory Mertz;,citation_author=Nestor Sosa;,citation_author=Paul A. Goepfert;,citation_author=Mezgebe Berhe;,citation_author=Emma Dishner;,citation_author=Mohamed Fayed;,citation_author=Kinsley Hubel;,citation_author=José Arturo Martinez-Orozco;,citation_author=Nora Bautista Felix;,citation_author=Sammy T. Elmor;,citation_author=Amer Ryan Bechnak;,citation_author=Youssef Saklawi;,citation_author=Jason W. Van Winkle;,citation_author=Diego F. Zea;,citation_author=Maryrose Laguio-Vila;,citation_author=Edward E. Walsh;,citation_author=Ann R. Falsey;,citation_author=Karen Carvajal;,citation_author=Robert C. Hyzy;,citation_author=Sinan Hanna;,citation_author=Norman Olbrich;,citation_author=Jessica J. Traenkner;,citation_author=Colleen S. Kraft;,citation_author=Pablo Tebas;,citation_author=Jillian T Baron;,citation_author=Corri Levine;,citation_author=Joy Nock;,citation_author=Joanne Billings;,citation_author=Hyun Kim;,citation_author=Marie-Carmelle Elie-Turenne;,citation_author=Jennifer A. Whitaker;,citation_author=Anne F. Luetkemeyer;,citation_author=Jay Dwyer;,citation_author=Emma Bainbridge;,citation_author=Pyoeng Gyun Choe;,citation_author=Chang Kyung Kang;,citation_author=Nikolaus Jilg;,citation_author=Valeria D Cantos;,citation_author=Divya R. Bhamidipati;,citation_author=Srinivasa Nithin Gopalsamy;,citation_author=Aarthi Chary;,citation_author=Jongtak Jung;,citation_author=Kyoung-Ho Song;,citation_author=Hong Bin Kim;,citation_author=Constance A. Benson;,citation_author=Kimberly McConnell;,citation_author=Jennifer P. Wang;,citation_author=Mireya Wessolossky;,citation_author=Katherine Perez;,citation_author=Taryn A Eubank;,citation_author=Catherine Berjohn;,citation_author=Gregory C. Utz;,citation_author=Patrick E. H. Jackson;,citation_author=Taison D. Bell;,citation_author=Heather M. Haughey;,citation_author=Abeer Moanna;,citation_author=Sushma Cribbs;,citation_author=Telisha Harrison;,citation_author=Christopher J. Colombo;,citation_author=Christina Schofield;,citation_author=Rhonda E. Colombo;,citation_author=Victor F. Tapson;,citation_author=Jonathan Grein;,citation_author=Fayyaz Sutterwala;,citation_author=Dilek Ince;,citation_author=Patricia L. Winokur;,citation_author=Monica Fung;,citation_author=Hannah Jang;,citation_author=David Wyles;,citation_author=Maria G. Frank;,citation_author=Ellen Sarcone;,citation_author=Henry Neumann;,citation_author=Anand Viswanathan;,citation_author=Sarah Hochman;,citation_author=Mark Mulligan;,citation_author=Benjamin Eckhardt;,citation_author=Ellie Carmody;,citation_author=Neera Ahuja;,citation_author=Kari Nadeau;,citation_author=David Svec;,citation_author=Jeffrey C. Macaraeg;,citation_author=Lee Morrow;,citation_author=Dave Quimby;,citation_author=Mary Bessesen;,citation_author=Lindsay Nicholson;,citation_author=Jill Adams;,citation_author=Princy Kumar;,citation_author=Allison A. Lambert;,citation_author=Henry Arguinchona;,citation_author=Radica Z. Alicic;,citation_author=Sho Saito;,citation_author=Norio Ohmagari;,citation_author=Ayako Mikami;,citation_author=David Chien Lye;,citation_author=Tau Hong Lee;,citation_author=Po Ying Chia;,citation_author=Lanny Hsieh;,citation_author=Alpesh N. Amin;,citation_author=Miki Watanabe;,citation_author=Keith A. Candiotti;,citation_author=Jose G. Castro;,citation_author=Maria A. Antor;,citation_author=Tida Lee;,citation_author=Tahaniyat Lalani;,citation_author=Richard M. Novak;,citation_author=Andrea Wendrow;,citation_author=Scott A. Borgetti;,citation_author=Sarah L. George;,citation_author=Daniel F. Hoft;,citation_author=James D. Brien;,citation_author=Stuart H. Cohen;,citation_author=George R. Thompson;,citation_author=Melony Chakrabarty;,citation_author=Faheem Guirgis;,citation_author=Richard T. Davey;,citation_author=Jocelyn Voell;,citation_author=Jeffrey R. Strich;,citation_author=David A. Lindholm;,citation_author=Katrin Mende;,citation_author=Trevor R. Wellington;,citation_author=Rekha R. Rapaka;,citation_author=Jennifer S. Husson;,citation_author=Andrea R. Levine;,citation_author=Seow Yen Tan;,citation_author=Humaira Shafi;,citation_author=Jaime M F Chien;,citation_author=David C. Hostler;,citation_author=Jordanna M. Hostler;,citation_author=Brian T. Shahan;,citation_author=David H. Adams;,citation_author=Anu Osinusi;,citation_author=Huyen Cao;,citation_author=Timothy H. Burgess;,citation_author=Julia Rozman;,citation_author=Kevin K. Chung;,citation_author=Christina Nieuwoudt;,citation_author=Jill A. El-Khorazaty;,citation_author=Heather Hill;,citation_author=Stephanie Pettibone;,citation_author=Nikki Gettinger;,citation_author=Theresa Engel;,citation_author=Teri Lewis;,citation_author=Jing Wang;,citation_author=Gregory A. Deye;,citation_author=Effie Nomicos;,citation_author=Rhonda Pikaart-Tautges;,citation_author=Mohamed Elsafy;,citation_author=Robert Jurao;,citation_author=Hyung Koo;,citation_author=Michael Proschan;,citation_author=Tammy Yokum;,citation_author=Janice Arega;,citation_author=Ruth Florese;,citation_publication_date=2022-05;,citation_cover_date=2022-05;,citation_year=2022;,citation_doi=10.1016/S2213-2600(22)00088-1;,citation_issn=22132600;,citation_language=en-US;,citation_journal_title=The Lancet Respiratory Medicine;">
<meta name="citation_reference" content="citation_title=Temperature Control After In-Hospital Cardiac Arrest: A Randomized Clinical Trial;,citation_abstract=BACKGROUND: This study was conducted to determine the effect of hypothermic temperature control after in-hospital cardiac arrest (IHCA) on mortality and functional outcome as compared with normothermia. METHODS: An investigator initiated, open-label, blinded-outcome-assessor, multicenter, randomized controlled trial comparing hypothermic temperature control (32-34^\circC) for 24 h with normothermia after IHCA in 11 hospitals in Germany. The primary endpoint was all-cause mortality after 180 days. Secondary end points included in-hospital mortality and favorable functional outcome using the Cerebral Performance Category scale after 180 days. A Cerebral Performance Category score of 1 or 2 was defined as a favorable functional outcome. RESULTS: A total of 1055 patients were screened for eligibility and 249 patients were randomized: 126 were assigned to hypothermic temperature control and 123 to normothermia. The mean age of the cohort was 72.610.4 years, 64% (152 of 236) were male, 73% (166 of 227) of cardiac arrests were witnessed, 25% (57 of 231) had an initial shockable rhythm, and time to return of spontaneous circulation was 16.410.5 minutes. Target temperature was reached within 4.1 hours after IHCA in the hypothermic group and temperature was controlled for 48 hours at 37.0^\circ\pm0.9^\circC in the normothermia group. Mortality by day 180 was 72.5% (87 of 120) in hypothermic temperature control arm, compared with 71.2% (84 of 118) in the normothermia group (relative risk, 1.03 [95% CI, 0.79–1.40]; P=0.822). In-hospital mortality was 62.5% (75 of 120) in the hypothermic temperature control as compared with 57.6% (68 of 118) in the normothermia group (relative risk, 1.11 [95% CI, 0.86–1.46, P=0.443). Favorable functional outcome (Cerebral Performance Category 1 or 2) by day 180 was 22.5% (27 of 120) in the hypothermic temperature control, compared with 23.7% (28 of 118) in the normothermia group (relative risk, 1.04 [95% CI, 0.78–1.44]; P=0.822). The study was prematurely terminated because of futility. CONCLUSIONS: Hypothermic temperature control as compared with normothermia did not improve survival nor functional outcome at day 180 in patients presenting with coma after IHCA. The HACA-IHCA (Hypothermia After In-Hospital Cardiac Arrest) trial was underpowered and may have failed to detect clinically important differences between hypothermic temperature control and normothermia. REGISTRATION: URL: ClinicalTrials.gov; Unique Identifier: NCT00457431;,citation_author=Sebastian Wolfrum;,citation_author=Kevin Roedl;,citation_author=Alexia Hanebutte;,citation_author=Rüdiger Pfeifer;,citation_author=Volkhard Kurowski;,citation_author=Reimer Riessen;,citation_author=Anne Daubmann;,citation_author=Stephan Braune;,citation_author=Gerold Söffker;,citation_author=Eric Bibiza-Freiwald;,citation_author=Karl Wegscheider;,citation_author=Heribert Schunkert;,citation_author=Holger Thiele;,citation_author=Stefan Kluge;,citation_author=null null;,citation_issue=0;,citation_doi=10.1161/CIRCULATIONAHA.122.060106;,citation_volume=0;,citation_journal_title=Circulation;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=Recommendations for core critical care ultrasound competencies as a part of specialist training in multidisciplinary intensive care: A framework proposed by the European Society of Intensive Care Medicine (ESICM);,citation_abstract=Background/aim: Critical care ultrasound (CCUS) is an essential component of intensive care practice. The purpose of this consensus document is to determine those CCUS competencies that should be a mandatory part of training in multidisciplinary intensive care. Methods: A three-round Delphi method followed by face-to-face meeting among 32 CCUS experts nominated by the European Society of Intensive Care Medicine. Agreement of at least 90% of experts was needed in order to enlist a competency as mandatory. Results: The final list of competencies includes 15 echocardiographic, 5 thoracic, 4 abdominal, deep vein thrombosis diagnosis and central venous access aid. Conclusion: The resulting recommendations offer the most contemporary and evolved set of core CCUS competencies for an intensive care clinician yet described.;,citation_author=Adrian Wong;,citation_author=Laura Galarza;,citation_author=Lui Forni;,citation_author=Daniel De Backer;,citation_author=Michael Slama;,citation_author=Bernard Cholley;,citation_author=Paul Mayo;,citation_author=Anthony McLean;,citation_author=Antoine Vieillard-Baron;,citation_author=Daniel Lichtenstein;,citation_author=Giovanni Volpicelli;,citation_author=Robert Arntfield;,citation_author=Ignacio Martin-Loeches;,citation_author=Gizella Melania Istrate;,citation_author=František Duška;,citation_author=on behalf of ESICM Critical Care Ultrasound Group;,citation_author=Adrian Wong;,citation_author=Laura Galarza;,citation_author=Lui Forni;,citation_author=Daniel De Backer;,citation_author=Michael Slama;,citation_author=Bernard Cholley;,citation_author=Paul Mayo;,citation_author=Anthony McLean;,citation_author=Antoine Vieillard-Baron;,citation_author=Daniel Lichtenstein;,citation_author=Giovanni Volpicelli;,citation_author=Robert Arntfield;,citation_author=Ignacio Martin-Loeches;,citation_author=Gizella Melania Istrate;,citation_author=František Duška;,citation_publication_date=2020-12;,citation_cover_date=2020-12;,citation_year=2020;,citation_issue=1;,citation_doi=10.1186/s13054-020-03099-8;,citation_issn=1364-8535;,citation_volume=24;,citation_language=en-US;,citation_journal_title=Critical Care;">
<meta name="citation_reference" content="citation_title=Rhetoric and Reality in the American Revolution;,citation_author=Gordon S. Wood;,citation_publication_date=1966-01;,citation_cover_date=1966-01;,citation_year=1966;,citation_fulltext_html_url=https://www.jstor.org/stable/2936154;,citation_issue=1;,citation_doi=10.2307/2936154;,citation_issn=00435597;,citation_volume=23;,citation_language=en-US;,citation_journal_title=The William and Mary Quarterly;">
<meta name="citation_reference" content="citation_title=Advances in the Starling Principle and Microvascular Fluid Exchange; Consequences and Implications for Fluid Therapy;,citation_abstract=Ernest Starling first presented a hypothesis about the absorption of tissue fluid to the plasma within tissue capillaries in 1896. In this Chapter we trace the evolution of Starling’s hypothesis to a principle and an equation, and then look in more detail at the extension of the Starling principle in recent years. In 2012 Thomas Woodcock and his son proposed that experience and experimental observations surrounding clinical practices involving the administration of intravenous fluids were better explained by the revised Starling principle. In particular, the revised or extended Starling principle can explain why crystalloid resuscitation from the abrupt physiologic insult of hypovolaemia is much more effective than the pre-revision Starling principle had led clinicians to expect. The authors of this chapter have since combined their science and clinical expertise to offer clinicians a better basis for their practice of rational fluid therapy.;,citation_author=Thomas E. Woodcock;,citation_author=C. Charles Michel;,citation_publication_date=2021-04;,citation_cover_date=2021-04;,citation_year=2021;,citation_doi=10.3389/fvets.2021.623671;,citation_issn=2297-1769;,citation_volume=8;,citation_language=en-US;,citation_journal_title=Frontiers in Veterinary Science;">
<meta name="citation_reference" content="citation_title=Fluid Therapy – the Basics, Reappraised;,citation_author=Thomas Woodcock;,citation_publication_date=2012-07;,citation_cover_date=2012-07;,citation_year=2012;,citation_issue=3;,citation_doi=10.1177/175114371201300302;,citation_issn=1751-1437;,citation_volume=13;,citation_language=en-US;,citation_journal_title=Journal of the Intensive Care Society;">
<meta name="citation_reference" content="citation_title=Plasma volume, tissue oedema, and the steady-state Starling principle;,citation_author=Te Woodcock;,citation_publication_date=2017-02;,citation_cover_date=2017-02;,citation_year=2017;,citation_issue=2;,citation_doi=10.1093/bjaed/mkw035;,citation_issn=20585349;,citation_volume=17;,citation_language=en-US;,citation_journal_title=BJA Education;">
<meta name="citation_reference" content="citation_title=Revised Starling equation and the glycocalyx model of transvascular fluid exchange: An improved paradigm for prescribing intravenous fluid therapy;,citation_abstract=I.V. fluid therapy does not result in the extracellular volume distribution expected from Starling’s original model of semi-permeable capillaries subject to hydrostatic and oncotic pressure gradients within the extracellular fluid. Fluid therapy to support the circulation relies on applying a physiological paradigm that better explains clinical and research observations. The revised Starling equation based on recent research considers the contributions of the endothelial glycocalyx layer (EGL), the endothelial basement membrane, and the extracellular matrix. The characteristics of capillaries in various tissues are reviewed and some clinical corollaries considered. The oncotic pressure difference across the EGL opposes, but does not reverse, the filtration rate (the “no absorption” rule) and is an important feature of the revised paradigm and highlights the limitations of attempting to prevent or treat oedema by transfusing colloids. Filtered fluid returns to the circulation as lymph. The EGL excludes larger molecules and occupies a substantial volume of the intravascular space and therefore requires a new interpretation of dilution studies of blood volume and the speculation that protection or restoration of the EGL might be an important therapeutic goal. An explanation for the phenomenon of context sensitivity of fluid volume kinetics is offered, and the proposal that crystalloid resuscitation from low capillary pressures is rational. Any potential advantage of plasma or plasma substitutes over crystalloids for volume expansion only manifests itself at higher capillary pressures.;,citation_author=T. E. Woodcock;,citation_author=T. M. Woodcock;,citation_publication_date=2012-03;,citation_cover_date=2012-03;,citation_year=2012;,citation_issue=3;,citation_doi=10.1093/bja/aer515;,citation_issn=00070912;,citation_volume=108;,citation_language=en-US;,citation_journal_title=British Journal of Anaesthesia;">
<meta name="citation_reference" content="citation_title=Product Hopping in the Drug Industry — Lessons from Albuterol;,citation_author=Olivier J. Wouters;,citation_author=William B. Feldman;,citation_author=S. Sean Tu;,citation_publication_date=2022-09;,citation_cover_date=2022-09;,citation_year=2022;,citation_issue=0;,citation_doi=10.1056/NEJMp2208613;,citation_issn=0028-4793;,citation_volume=0;,citation_journal_title=New England Journal of Medicine;,citation_publisher=Massachusetts Medical Society;">
<meta name="citation_reference" content="citation_title=Association of Social Determinants of Health and Their Cumulative Impact on Hospitalization Among a National Sample of Community-Dwelling US Adults;,citation_abstract=Abstract Importance While the association between Social Determinants of Health (SDOH) and health outcomes is well known, few studies have explored the impact of SDOH on hospitalization. Objective Examine the independent association and cumulative effect of six SDOH domains on hospitalization. Design Using cross-sectional data from the 2016–2018 National Health Interview Surveys (NHIS), we used multivariable logistical regression models controlling for sociodemographics and comorbid conditions to assess the association of each SDOH and SDOH burden (i.e., cumulative number of SDOH) with hospitalization. Setting National survey of community-dwelling individuals in the US Participants Adults \geq18 years who responded to the NHIS survey Exposure Six SDOH domains (economic instability, lack of community, educational deficits, food insecurity, social isolation, and inadequate access to medical care) Measures Hospitalization within 1 year Results Among all 55,186 respondents, most were \leq50 years old (54.2%), female (51.7%, 95% CI 51.1–52.3), non-Hispanic (83.9%, 95% CI 82.4–84.5), identified as White (77.9%, 95% CI 76.8–79.1), and had health insurance (90%, 95% CI 88.9–91.9). Hospitalized individuals ( n =5506; 8.7%) were more likely to be \geq50 years old (61.2%), female (60.7%, 95% CI 58.9–62.4), non-Hispanic (87%, 95% CI 86.2–88.4), and identify as White (78.5%, 95% CI 76.7–80.3), compared to those who were not hospitalized. Hospitalized individuals described poorer overall health, reporting higher incidence of having \geq5 comorbid conditions (38.9%, 95% CI 37.1–40.1) compared to those who did not report a hospitalization (15.9%, 95% CI 15.4–16.5). Hospitalized respondents reported higher rates of economic instability (33%), lack of community (14%), educational deficits (67%), food insecurity (14%), social isolation (34%), and less access to health care (6%) compared to non-hospitalized individuals. In adjusted analysis, food insecurity (OR: 1.36, 95% CI 1.22–1.52), social isolation (OR: 1.17, 95% CI 1.08–1.26), and lower educational attainment (OR: 1.12, 95% CI 1.02–1.25) were associated with hospitalization, while a higher SDOH burden was associated with increased odds of hospitalization (3–4 SDOH [OR: 1.25, 95% CI 1.06–1.49] and \geq5 SDOH [OR: 1.72, 95% CI 1.40–2.06]) compared to those who reported no SDOH. Conclusions Among community-dwelling US adults, three SDOH domains: food insecurity, social isolation, and low educational attainment increase an individual’s risk of hospitalization. Additionally, risk of hospitalization increases as SDOH burden increases.;,citation_author=Charlie M. Wray;,citation_author=Janet Tang;,citation_author=Lenny López;,citation_author=Katherine Hoggatt;,citation_author=Salomeh Keyhani;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_doi=10.1007/s11606-021-07067-y;,citation_issn=0884-8734, 1525-1497;,citation_language=en-US;,citation_journal_title=Journal of General Internal Medicine;">
<meta name="citation_reference" content="citation_title=Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support–Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial;,citation_abstract=Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19.To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19.In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022).Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days.The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes.On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively).In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes.ClinicalTrials.gov Identifier: NCT02735707;,citation_author=Writing Committee for the REMAP-CAP Investigators;,citation_publication_date=2023-04;,citation_cover_date=2023-04;,citation_year=2023;,citation_issue=14;,citation_doi=10.1001/jama.2023.4480;,citation_issn=0098-7484;,citation_volume=329;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial;,citation_abstract=OBJECTIVE To determine the effect of multiple interventions for critically ill adults with COVID-19 on longer-term outcomes. DESIGN, SETTING, AND PARTICIPANTS Prespecified secondary analysis of an ongoing adaptive platform trial (REMAP-CAP) testing interventions within multiple therapeutic domains in which 4869 critically ill adult patients with COVID-19 were enrolled between March 9, 2020, and June 22, 2021, from 197 sites in 14 countries. The final 180-day follow-up was completed on March 2, 2022. INTERVENTIONS Patients were randomized to receive 1 or more interventions within 6 treatment domains: immune modulators (n = 2274), convalescent plasma (n = 2011), antiplatelet therapy (n = 1557), anticoagulation (n = 1033), antivirals (n = 726), and corticosteroids (n = 401). MAIN OUTCOMES AND MEASURES The main outcome was survival through day 180, analyzed using a bayesian piecewise exponential model. A hazard ratio (HR) less than 1 represented improved survival (superiority), while an HR greater than 1 represented worsened survival (harm); futility was represented by a relative improvement less than 20% in outcome, shown by an HR greater than 0.83. RESULTS Among 4869 randomized patients (mean age, 59.3 years; 1537 [32.1%] women), 4107 (84.3%) had known vital status and 2590 (63.1%) were alive at day 180. IL-6 receptor antagonists had a greater than 99.9% probability of improving 6-month survival (adjusted HR, 0.74 [95% credible interval {CrI}, 0.61-0.90]) and antiplatelet agents had a 95% probability of improving 6-month survival (adjusted HR, 0.85 [95% CrI, 0.71-1.03]) compared with the control, while the probability of trial-defined statistical futility (HR &amp;amp;amp;gt;0.83) was high for therapeutic anticoagulation (99.9%; HR, 1.13 [95% CrI, 0.93-1.42]), convalescent plasma (99.2%; HR, 0.99 [95% CrI, 0.86-1.14]), and lopinavir-ritonavir (96.6%; HR, 1.06 [95% CrI, 0.82-1.38]) and the probabilities of harm from hydroxychloroquine (96.9%; HR, 1.51 [95% CrI, 0.98-2.29]) and the combination of lopinavir-ritonavir and hydroxychloroquine (96.8%; HR, 1.61 [95% CrI, 0.97-2.67]) were high. The corticosteroid domain was stopped early prior to reaching a predefined statistical trigger; there was a 57.1% to 61.6% probability of improving 6-month survival across varying hydrocortisone dosing strategies. CONCLUSIONS AND RELEVANCE Among critically ill patients with COVID-19 randomized to receive 1 or more therapeutic interventions, treatment with an IL-6 receptor antagonist had a greater than 99.9% probability of improved 180-day mortality compared with patients randomized to the control, and treatment with an antiplatelet had a 95.0% probability of improved 180-day mortality compared with patients randomized to the control. Overall, when considered with previously reported short-term results, the findings indicate that initial in-hospital treatment effects were consistent for most therapies through 6 months.;,citation_author=Writing Committee for the REMAP-CAP Investigators;,citation_author=Simin Florescu;,citation_author=Delia Stanciu;,citation_author=Mihaela Zaharia;,citation_author=Alma Kosa;,citation_author=Daniel Codreanu;,citation_author=Aneela Kidwai;,citation_author=Sobia Masood;,citation_author=Callum Kaye;,citation_author=Amanda Coutts;,citation_author=Lynn MacKay;,citation_author=Charlotte Summers;,citation_author=Petra Polgarova;,citation_author=Neda Farahi;,citation_author=Eleonore Fox;,citation_author=Stephen McWilliam;,citation_author=Daniel Hawcutt;,citation_author=Laura Rad;,citation_author=Laura O’Malley;,citation_author=Jennifer Whitbread;,citation_author=Dawn Jones;,citation_author=Rachael Dore;,citation_author=Paula Saunderson;,citation_author=Olivia Kelsall;,citation_author=Nicholas Cowley;,citation_author=Laura Wild;,citation_author=Jessica Thrush;,citation_author=Hannah Wood;,citation_author=Karen Austin;,citation_author=János Bélteczki;,citation_author=István Magyar;,citation_author=Ágnes Fazekas;,citation_author=Sándor Kovács;,citation_author=Viktória Szőke;,citation_author=Adrian Donnelly;,citation_author=Martin Kelly;,citation_author=Naoise Smyth;,citation_author=Sinéad O’Kane;,citation_author=Declan McClintock;,citation_author=Majella Warnock;,citation_author=Ryan Campbell;,citation_author=Edmund McCallion;,citation_author=Amine Azaiz;,citation_author=Cyril Charron;,citation_author=Mathieu Godement;,citation_author=Guillaume Geri;,citation_author=Antoine Vieillard-Baron;,citation_author=Paul Johnson;,citation_author=Shirley McKenna;,citation_author=Joanne Hanley;,citation_author=Andrew Currie;,citation_author=Barbara Allen;,citation_author=Clare McGoldrick;,citation_author=Moyra McMaster;,citation_author=Ashwin Mani;,citation_author=Meghena Mathew;,citation_author=Revathi Kandeepan;,citation_author=C Vignesh;,citation_author=Bharath Tv;,citation_author=N Ramakrishnan;,citation_author=Augustian James;,citation_author=Evangeline Elvira;,citation_author=Devachandran Jayakumar;,citation_author=Ramachandran Pratheema;,citation_author=Suresh Babu;,citation_author=R Ebenezer;,citation_author=S Krishnaoorthy;,citation_author=Lakshmi Ranganathan;,citation_author=Manisha Ganesan;,citation_author=Madhu Shree;,citation_author=Eileen Guilder;,citation_author=Magdalena Butler;,citation_author=Keri-Anne Cowdrey;,citation_author=Melissa Robertson;,citation_author=Farisha Ali;,citation_author=Ellie McMahon;,citation_author=Eamon Duffy;,citation_author=Yan Chen;,citation_author=Catherine Simmonds;,citation_author=Rachael McConnochie;,citation_author=Caroline O’Connor;,citation_author=Khaled El-Khawas;,citation_author=Angus Richardson;,citation_author=Dianne Hill;,citation_author=Robert Commons;,citation_author=Hussam Abdelkharim;,citation_author=Manoj Saxena;,citation_author=Margaret Muteithia;,citation_author=Kelsey Dobell-Brown;,citation_author=Rajeev Jha;,citation_author=Michael Kalogirou;,citation_author=Christine Ellis;,citation_author=Vinodh Krishnamurthy;,citation_author=Aibhilin O’Connor;,citation_author=Saranya Thurairatnam;,citation_author=Dipak Mukherjee;,citation_author=Agilan Kaliappan;,citation_author=Mark Vertue;,citation_author=Anne Nicholson;,citation_author=Joanne Riches;,citation_author=Gracie Maloney;,citation_author=Lauren Kittridge;,citation_author=Amanda Solesbury;,citation_author=Angelo Ramos;,citation_author=Daniel Collins;,citation_author=Kathy Brickell;,citation_author=Liadain Reid;,citation_author=Michelle Smyth;,citation_author=Patrick Breen;,citation_author=Sandra Spain;,citation_author=Gerard Curley;,citation_author=Natalie McEvoy;,citation_author=Pierce Geoghegan;,citation_author=Jennifer Clarke;,citation_author=Jon Silversides;,citation_author=Peter McGuigan;,citation_author=Kathryn Ward;,citation_author=Aisling O’Neill;,citation_author=Stephanie Finn;,citation_author=Chris Wright;,citation_author=Jackie Green;,citation_author=Érin Collins;,citation_author=Cameron Knott;,citation_author=Julie Smith;,citation_author=Catherine Boschert;,citation_author=Kitty Slieker;,citation_author=Esther Ewalds;,citation_author=Arnate Sanders;,citation_author=Wendy Wittenberg;,citation_author=Heidi Geurts;,citation_author=Latesh Poojara;,citation_author=Treena Sara;,citation_author=Kiran Nand;,citation_author=Brenda Reeve;,citation_author=William Dechert;,citation_author=Barbara Phillips;,citation_author=Laura Oritz-Ruiz de&nbsp;Gordoa;,citation_author=Julia Affleck;,citation_author=Arif Shaikh;,citation_author=Andrew Murray;,citation_author=Mahesh Ramanan;,citation_author=Thuy Frakking;,citation_author=Jez Pinnell;,citation_author=Matt Robinson;,citation_author=Lisa Gledhill;,citation_author=Tracy Wood;,citation_author=Ritesh Sanghavi;,citation_author=Deepak Bhonagiri;,citation_author=Megan Ford;,citation_author=Harshel G. Parikh;,citation_author=Bronwyn Avard;,citation_author=Mary Nourse;,citation_author=Bree McDonald;,citation_author=Natasha Edmunds;,citation_author=Oscar Hoiting;,citation_author=Marco Peters;,citation_author=Els Rengers;,citation_author=Mirjam Evers;,citation_author=Anton Prinssen;,citation_author=Matt Morgan;,citation_author=Jade Cole;,citation_author=Helen Hill;,citation_author=Michelle Davies;,citation_author=Angharad Williams;,citation_author=Emma Thomas;,citation_author=Rhys Davies;,citation_author=Matt Wise;,citation_author=Patrick Grimm;,citation_author=Jens Soukup;,citation_author=Richard Wetzold;,citation_author=Madlen Löbel;,citation_author=Lisa Starke;,citation_author=Francois Lellouche;,citation_author=Patricia Lizotte;,citation_author=Pierre Declerq;,citation_author=Marchalot Antoine;,citation_author=Gelinotte Stephanie;,citation_author=Eraldi Jean-Pierre;,citation_author=Bourgerol François;,citation_author=Beuzelin Marion;,citation_author=Rigaud Philippe;,citation_author=Franck Pourcine;,citation_author=Mehran Monchi;,citation_author=David Luis;,citation_author=Romain Mercier;,citation_author=Anne Sagnier;,citation_author=Nathalie Verrier;,citation_author=Cecile Caplin;,citation_author=Jack Richecoeu;,citation_author=Daniele Combaux;,citation_author=Shidasp Siami;,citation_author=Christelle Aparicio;,citation_author=Sarah Vautier;,citation_author=Asma Jeblaoui;,citation_author=Delphine Lemaire-Brunel;,citation_author=Frédérick D’Aragon;,citation_author=Elaine Carbonneau;,citation_author=Julie Leblond;,citation_author=Gaetan Plantefeve;,citation_author=Cécile Leparco;,citation_author=Damien Contou;,citation_author=Muriel Fartoukh;,citation_author=Laura Courtin;,citation_author=Vincent Labbe;,citation_author=Guillaume Voiriot;,citation_author=Sara Salhi;,citation_author=Michaël Chassé;,citation_author=François Carrier;,citation_author=Dounia Boumahni;,citation_author=Fatna Benettaib;,citation_author=Ali Ghamraoui;,citation_author=Arnaud Sement;,citation_author=Alexandre Gachet;,citation_author=Alexis Hanisch;,citation_author=Abdelmagid Haffiane;,citation_author=Anne-Hélène Boivin;,citation_author=Amelie Barreau;,citation_author=Elodie Guerineau;,citation_author=Séverine Poupblanc;,citation_author=Pierre Egreteau;,citation_author=Montaine Lefevre;,citation_author=Simon Bocher;,citation_author=Guillaume Le Loup;,citation_author=Lenaı̈g Le Guen;,citation_author=Vanessa Carn;,citation_author=Melanie Bertel;,citation_author=David Antcliffe;,citation_author=Maie Templeton;,citation_author=Roceld Rojo;,citation_author=Phoebe Coghlan;,citation_author=Joanna Smee;,citation_author=Gareth Barker;,citation_author=André Finn;,citation_author=Gabriele Kreb;,citation_author=Uwe Hoff;,citation_author=Carl Hinrichs;,citation_author=Jens Nee;,citation_author=Euan Mackay;,citation_author=Jon Cort;,citation_author=Amanda Whileman;,citation_author=Thomas Spencer;,citation_author=Nick Spittle;,citation_author=Sarah Beavis;,citation_author=Anand Padmakumar;,citation_author=Katie Dale;,citation_author=Joanne Hawes;,citation_author=Emma Moakes;,citation_author=Rachel Gascoyne;,citation_author=Kelly Pritchard;,citation_author=Lesley Stevenson;,citation_author=Justin Cooke;,citation_author=Karolina Nemeth-Roszpopa;,citation_author=Basanta Gauli;,citation_author=Sirjana Bastola;,citation_author=Grégoire Muller;,citation_author=Mai-Anh Nay;,citation_author=Toufik Kamel;,citation_author=Dalila Benzekri;,citation_author=Sophie Jacquier;,citation_author=Isabelle Runge;,citation_author=Armelle Mathonnet;,citation_author=François Barbier;,citation_author=Anne Bretagnol;,citation_author=Jay Carter;,citation_author=Kymbalee Van Der Heyden;,citation_author=Jan Mehrtens;,citation_author=Anna Morris;,citation_author=Stacey Morgan;,citation_author=Tara Burke;,citation_author=Emmanuelle Mercier;,citation_author=Delphine Chartier;,citation_author=Charlotte Salmon;,citation_author=Pierre-François Dequin;,citation_author=Denis Garot;,citation_author=David Bellemare;,citation_author=Ève Cloutier;,citation_author=Rana Daher;,citation_author=Olivier Costerousse;,citation_author=Marie-Claude Boulanger;,citation_author=Émilie Couillard-Chénard;,citation_author=François Lauzier;,citation_author=Charles Francoeur;,citation_author=Bruno Francois;,citation_author=Alexandra Gay;,citation_author=Fedou Anne-Laure;,citation_author=Mohamed Ramali;,citation_author=Ooi Hc;,citation_author=Alison Ghosh;,citation_author=Rawlings Osagie;,citation_author=Malka Arachchige;,citation_author=Melissa Hartley;,citation_author=Winston Cheung;,citation_author=Helen Wong;,citation_author=Patrick Seigne;,citation_author=Joe Eustace;,citation_author=Ann-Marie O’Callaghan;,citation_author=Fionnuala O’Brien;,citation_author=Peter Bamford;,citation_author=Andrew Reid;,citation_author=Kathryn Cawley;,citation_author=Maria Faulkner;,citation_author=Charlotte Pickering;,citation_author=Ashok Raj;,citation_author=Georgios Tsinaslanidis;,citation_author=Reena Khade;,citation_author=Gloria Agha;,citation_author=Rose Sekiwala;,citation_author=Tim Smith;,citation_author=Chris Brewer;,citation_author=Jane Gregory;,citation_author=James Limb;,citation_author=Amanda Cowton;,citation_author=Julie O’Brien;,citation_author=Kelly Postlethwaite;,citation_author=Salim Malakouti;,citation_author=Edvin Music;,citation_author=Dan Ricketts;,citation_author=Andrew King;,citation_author=Gilles Clermont;,citation_author=Robert Bart;,citation_author=Florian Mayr;,citation_author=Andrew Schoenling;,citation_author=Mark Andreae;,citation_author=Varun Shetty;,citation_author=Emily Brant;,citation_author=Brian Malley;,citation_author=Chenell Donadee;,citation_author=Rachel Sackrowitz;,citation_author=Alexandra Weissman;,citation_author=Donald Yealy;,citation_author=David Barton;,citation_author=Nadine Talia;,citation_author=Nikitas Nikitas;,citation_author=Colin Wells;,citation_author=Liana Lankester;,citation_author=Helen McMillan;,citation_author=Huub Oever;,citation_author=Arriette Kruisdijk-Gerritsen;,citation_author=Ghady Haidar;,citation_author=William Bain;,citation_author=Ian Barbash;,citation_author=Meghan Fitzpatrick;,citation_author=Christopher Franz;,citation_author=Georgios Kitsios;,citation_author=Kaveh Moghbeli;,citation_author=Brian Rosborough;,citation_author=Faraaz Shah;,citation_author=Tomeka Suber;,citation_author=Mark Pulletz;,citation_author=Patricia Williams;,citation_author=Jenny Birch;,citation_author=Sophie Wiseman;,citation_author=Sarah Horton;,citation_author=Ana Alegria;,citation_author=Salah Turki;,citation_author=Tarek Elsefi;,citation_author=Nikki Crisp;,citation_author=Louise Allen;,citation_author=Nicholas Truman;,citation_author=Matthew Smith;,citation_author=Sri Chukkambotla;,citation_author=Wendy Goddard;,citation_author=Stephen Duberley;,citation_author=Meherunnisa Khan;,citation_author=Aayesha Kazi;,citation_author=Joanna Simpson;,citation_author=Graeme Duke;,citation_author=Peter Chan;,citation_author=Brittney Carter;,citation_author=Stephanie Hunter;,citation_author=Ingo Voigt;,citation_author=Robert Schueler;,citation_author=Elisabeth Blank;,citation_author=Vanessa Hüning;,citation_author=Melanie Steffen;,citation_author=Patricia Goralski;,citation_author=Ed Litton;,citation_author=Adrian Regli;,citation_author=Susan Pellicano;,citation_author=Annamaria Palermo;,citation_author=Ege Eroglu;,citation_author=Shailesh Bihari;,citation_author=Russell D. Laver;,citation_author=Xia Jin;,citation_author=Julia Brown;,citation_author=Joanne McIntyre;,citation_author=Craig French;,citation_author=Samantha Bates;,citation_author=Miriam Towns;,citation_author=Yang Yang;,citation_author=Forbes McGain;,citation_author=Iain McCullagh;,citation_author=Tom Cairns;,citation_author=Helen Hanson;,citation_author=Bijal Patel;,citation_author=Ian Clement;,citation_author=George Evetts;,citation_author=Omar Touma;,citation_author=Susan Holland;,citation_author=Christopher Hodge;,citation_author=Holly Taylor;,citation_author=Meera Alderman;,citation_author=Nicky Barnes;,citation_author=Joana Da Rocha;,citation_author=Catherine Smith;,citation_author=Nicole Brooks;,citation_author=Thanuja Weerasinghe;,citation_author=Julie-Ann Sinclair;,citation_author=Yousuf Abusamra;,citation_author=Ronan Doherty;,citation_author=Joanna Cudlipp;,citation_author=Rajeev Singh;,citation_author=Haili Yu;,citation_author=Admad Daebis;,citation_author=Christopher Ng;,citation_author=Sara Kendrick;,citation_author=Anita Saran;,citation_author=Ahmed Makky;,citation_author=Danni Greener;,citation_author=Louise Rowe-Leete;,citation_author=Alexandra Edwards;,citation_author=Yvonne Bland;,citation_author=Rozzie Dolman;,citation_author=Tracy Foster;,citation_author=John Laffey;,citation_author=Bairbre McNicholas;,citation_author=Michael Scully;,citation_author=Siobhan Casey;,citation_author=Maeve Kernan;,citation_author=Aoife Brennan;,citation_author=Ritika Rangan;,citation_author=Riona Tully;,citation_author=Sarah Corbett;,citation_author=Aine McCarthy;,citation_author=Oscar Duffy;,citation_author=David Burke;,citation_author=Vanessa Linnett;,citation_author=Amanda Sanderson;,citation_author=Jenny Ritzema;,citation_author=Helen Wild;,citation_author=Rachael Lucas;,citation_author=Yvonne Marriott;,citation_author=Zdravko Andric;,citation_author=Sabina Cviljevic;,citation_author=Renata Br;,citation_author=Marija Zapalac;,citation_author=Gordan Mirković;,citation_author=Divya Khare;,citation_author=Meredith Pinder;,citation_author=Amitha Gopinath;,citation_author=Thogulava Kannan;,citation_author=Steven Dean;,citation_author=Piyush Vanmali;,citation_author=Pieter Depuydt;,citation_author=Jan De Waele;,citation_author=Liesbet De Bus;,citation_author=Jan Fierens;,citation_author=Stephanie Bracke;,citation_author=Joris Vermassen;,citation_author=Daisy Vermeiren;,citation_author=Richard Pugh;,citation_author=Richard Lean;,citation_author=Xinyi Qiu;,citation_author=Jeremy Scanlan;,citation_author=Andrew Evans;,citation_author=Gwyneth Davies;,citation_author=Joanne Lewis;,citation_author=Yvonna Plesnikova;,citation_author=Ahmed Khoud;,citation_author=Samantha Coetzee;,citation_author=Kathryn Puxty;,citation_author=Susanne Cathcart;,citation_author=Dominic Rimmer;,citation_author=Catherine Bagot;,citation_author=Kathryn Scott;,citation_author=Laila Martin;,citation_author=Hakeem Yusuff;,citation_author=Graziella Isgro;,citation_author=Chris Brightling;,citation_author=Michelle Bourne;,citation_author=Michelle Craner;,citation_author=Rebecca Boyles;,citation_author=Brian Alexander;,citation_author=Tracey Roberts;,citation_author=Apoorva Nelli;,citation_author=Rachel Rosenstein-Sisson;,citation_author=Rebecca Speyer;,citation_author=Yadira Pech;,citation_author=James McCullough;,citation_author=Mandy Tallott;,citation_author=Gloria Vazquez-Grande;,citation_author=Nicole Marten;,citation_author=Theresa Liu;,citation_author=Atif Siddiqui;,citation_author=Sushil Khanal;,citation_author=Sameena Amatya;,citation_author=Tamas Szakmany;,citation_author=Shiney Cherian;,citation_author=Gemma Williams;,citation_author=Christie James;,citation_author=Abby Waters;,citation_author=Rachel Prout;,citation_author=Roger Stedman;,citation_author=Louisa Davies;,citation_author=Suzannah Pegler;,citation_author=Lynsey Kyeremeh;,citation_author=Louise Moorhouse;,citation_author=Gill Arbane;,citation_author=Marina Marotti;,citation_author=Aneta Bociek;,citation_author=Sara Campos;,citation_author=Kees Nieuwkoop;,citation_author=Thomas Ottens;,citation_author=Yorik Visser;,citation_author=Lettie Berg;,citation_author=Annemarie Kraan-Donker;,citation_author=Stephen Brett;,citation_author=Sonia Arias;,citation_author=Rebecca Hall;,citation_author=Hem Paneru;,citation_author=Sabin Koirala;,citation_author=Pratibha Paudel;,citation_author=Maggie Wilson;,citation_author=Suvi Vaara;,citation_author=Leena Pettilä;,citation_author=Jonna Heinonen;,citation_author=Ville Pettilä;,citation_author=Susan Jain;,citation_author=Abhinav Gupta;,citation_author=Catherine Holbrook;,citation_author=Pierre Antoine;,citation_author=Ferhat Meziani;,citation_author=Hayat Allam;,citation_author=Jessy Cattelan;,citation_author=Raphael Clere-Jehl;,citation_author=Julie Helms;,citation_author=Christine Kummerlen;,citation_author=Hamid Merdji;,citation_author=Alexandra Monnier;,citation_author=Hassene Rahmani;,citation_author=Antoine Studer;,citation_author=Francis Schneider;,citation_author=Vincent Castelain;,citation_author=Guillaume Morel;,citation_author=Sylvie L’Hotellier;,citation_author=Evelina Ochin;,citation_author=Christian Vanjak;,citation_author=Patrick Rouge;,citation_author=Lynda Bendjemar;,citation_author=Martin Albert;,citation_author=Karim Serri;,citation_author=Alexandros Cavayas;,citation_author=Mathilde Duplaix;,citation_author=Virginie Williams;,citation_author=Nuno José Teodoro Amaro dos Santos Catorze;,citation_author=Tiago Nuno Alfaro Lima Pereira;,citation_author=Ricardo Manuel Castro Ferreira;,citation_author=Joana Margarida Pereira Sousa Bastos;,citation_author=Teresa Margarida Oliveira Batista;,citation_author=Julio Badie;,citation_author=Fernando Berdaguer;,citation_author=Sylvain Malfroy;,citation_author=Chaouki Mezher;,citation_author=Charlotte Bourgoin;,citation_author=Guy Moneger;,citation_author=Elodie Bouvier;,citation_author=Rosana Muñoz-Bermúdez;,citation_author=Judith Marin-Corral;,citation_author=Anna Degracia;,citation_author=Francisco Gómez;,citation_author=Maria López;,citation_author=Romina Aceto;,citation_author=Alessio Aghemo;,citation_author=Salvatore Badalamenti;,citation_author=Enrico Brunetta;,citation_author=Maurizio Cecconi;,citation_author=Michele Ciccarelli;,citation_author=Elena Constantini;,citation_author=Massimiliano Greco;,citation_author=Marco Folci;,citation_author=Carlo Selmi;,citation_author=Antonio Voza;,citation_author=Jeremy Henning;,citation_author=Stephen Bonner;,citation_author=Keith Hugill;,citation_author=Emanuel Cirstea;,citation_author=Dean Wilkinson;,citation_author=Jessica Jones;,citation_author=Mohammed Altomy;,citation_author=Michal Karlikowski;,citation_author=Helen Sutherland;,citation_author=Elva Wilhelmsen;,citation_author=Jane Woods;,citation_author=Julie North;,citation_author=Mathias Pletz;,citation_author=Stefan Hagel;,citation_author=Juliane Ankert;,citation_author=Steffi Kolanos;,citation_author=Frank Bloos;,citation_author=Koen Simons;,citation_author=Tamara Zuylen;,citation_author=Angela Bouman;,citation_author=Nikhil Kumar;,citation_author=Rakshit Panwar;,citation_author=Amber-Louise Poulter;,citation_author=Krishna Sunkara;,citation_author=Gábor Szigligeti;,citation_author=János Leszkoven;,citation_author=Bram Rochwerg;,citation_author=Tim Karachi;,citation_author=Simon Oczkowski;,citation_author=John Centofanti;,citation_author=Tina Millen;,citation_author=Dhinesh Sundaran;,citation_author=Laszlo Hollos;,citation_author=Anna Williams;,citation_author=Margaret Turns;,citation_author=Joanne Walsh;,citation_author=Eman Al Qasim;,citation_author=Lolowa Alswaidan;,citation_author=Mohamed Hegazy;,citation_author=Hatim Arishi;,citation_author=Ali Al Amri;,citation_author=Samah AlQahtani;,citation_author=Brintha Naidu;,citation_author=Haytham Tlayjeh;,citation_author=Sajid Hussain;,citation_author=Farhan Al Enezi;,citation_author=Sheryl Ann Abdukahil;,citation_author=Phil Hopkins;,citation_author=John Smith;,citation_author=Harriet Noble;,citation_author=Kevin O’Reilly;,citation_author=Reena Mehta;,citation_author=Onyee Wong;,citation_author=Esther Makanju;,citation_author=Deepak Rao;,citation_author=Nyma Sikondari;,citation_author=Sian Saha;,citation_author=Ele Corcoran;,citation_author=Evita Pappa;,citation_author=Maeve Cockrell;,citation_author=Clare Donegan;,citation_author=Morteza Balaie;,citation_author=Daniela Nickoleit-Bitzenberger;,citation_author=Bernhard Schaaf;,citation_author=Werner Meermeier;,citation_author=Katharina Prebeg;,citation_author=Harun Azzaui;,citation_author=Martin Hower;,citation_author=Klaus-Gerd Brieger;,citation_author=Corinna Elender;,citation_author=Timo Sabelhaus;,citation_author=Ansgar Riepe;,citation_author=Ceren Akamp;,citation_author=Julius Kremling;,citation_author=Daniela Klein;,citation_author=Elke Landsiedel-Mechenbier;,citation_author=Shondipon Laha;,citation_author=Mark Verlander;,citation_author=Alexandra Williams;,citation_author=Avinash Jha;,citation_author=Bruno Megarbane;,citation_author=Sebastian Voicu;,citation_author=Nicolas Deye;,citation_author=Isabelle Malissin;,citation_author=Laetitia Sutterlin;,citation_author=Aymen Mrad;,citation_author=Adrien Lehalleur;,citation_author=Giulia Naim;,citation_author=Philippe Nguyen;,citation_author=Jean-Michel Ekhérian;,citation_author=Yvonnick Boué;,citation_author=Georgios Sidéris;,citation_author=Dominique Vodovar;,citation_author=Emmanuelle Guérin;,citation_author=Caroline Grant;,citation_author=Matthew Brain;,citation_author=Sarah Mineall;,citation_author=Elankumaran Paramasivam;,citation_author=Elizabeth Wilby;,citation_author=Bethan Ogg;,citation_author=Clare Howcroft;,citation_author=Angelique Aspinwall;,citation_author=Sam Charlton;,citation_author=Richard Gould;,citation_author=Deena Mistry;,citation_author=Sidra Awan;,citation_author=Caroline Bedford;,citation_author=Joanne Carr-Wilkinson;,citation_author=Andrew Hall;,citation_author=Jill Cooke;,citation_author=Caroline Gardiner-Hill;,citation_author=Carolyn Maloney;,citation_author=Nigel Brunskill;,citation_author=Olivia Watchorn;,citation_author=Chloe Hardy;,citation_author=Hafiz Qureshi;,citation_author=Neil Flint;,citation_author=Sarah Nicholson;,citation_author=Sara Southin;,citation_author=Andrew Nicholson;,citation_author=Amardeep Ghattaoraya;,citation_author=Daniel Harding;,citation_author=Sinead O’Halloran;,citation_author=Amy Collins;,citation_author=Emma Smith;,citation_author=Estefania Trues;,citation_author=Barbara Borgatta;,citation_author=Ian Turner-Bone;,citation_author=Amie Reddy;,citation_author=Laura Wilding;,citation_author=Craig Wilson;,citation_author=Zuhra Surti;,citation_author=Anders Aneman;,citation_author=Jennene Miller;,citation_author=Hayden White;,citation_author=Kristen Estensen;,citation_author=Lynette Morrison;,citation_author=Joanne Sutton;,citation_author=Melanie Cooper;,citation_author=Loku Warnapura;,citation_author=Ronan Agno;,citation_author=Prasannakumari Sathianathan;,citation_author=Deborah Shaw;,citation_author=Nazia Ijaz;,citation_author=Adam Spong;,citation_author=Suganya Sabaretnam;,citation_author=Dean Burns;,citation_author=Eva Lang;,citation_author=Margaret Tate;,citation_author=Roy Fischer;,citation_author=Vishwanath Biradar;,citation_author=Natalie Soar;,citation_author=David Golden;,citation_author=Miriam Davey;,citation_author=Rebecca Seaman;,citation_author=Alexander Osborne;,citation_author=Jonathan Bannard-Smith;,citation_author=Richard Clark;,citation_author=Kathrine Birchall;,citation_author=Joanne Henry;,citation_author=Fiona Pomeroy;,citation_author=Rachael Quayle;,citation_author=Katharine Wylie;,citation_author=Anila Sukuraman;,citation_author=Maya John;,citation_author=Sindhu Sibin;,citation_author=Anne Leditschke;,citation_author=Mackenzie Finnis;,citation_author=Katherine Jongebloed;,citation_author=Kosar Khwaja;,citation_author=Josie Campisi;,citation_author=Marit Vonderen;,citation_author=Mario Pietersma;,citation_author=Loes Vrolijk;,citation_author=Linda Kampschreur;,citation_author=Laura Gulik;,citation_author=Arystarch Makowski;,citation_author=Beata Misztal;,citation_author=Syeda Haider;,citation_author=Angela Liao;,citation_author=Rebecca Squires;,citation_author=Aneta Oborska;,citation_author=Abdul Kayani;,citation_author=Selver Kalchko-Veyssal;,citation_author=Rajalakshmi Prabakaran;,citation_author=Bernard Hadebe;,citation_author=Selver KalchkoVeyssal;,citation_author=Tony Williams;,citation_author=Rima Song;,citation_author=Susan Morpeth;,citation_author=Vivian Lai;,citation_author=Hannah Habraken;,citation_author=Richard Stewart;,citation_author=Esther Mwaura;,citation_author=Louise Mew;,citation_author=Lynn Wren;,citation_author=Felicity Willams;,citation_author=Sara-Beth Sutherland;,citation_author=Rashmi Rebello;,citation_author=Yahya Shehabi;,citation_author=Wisam Al-Bassam;,citation_author=Amanda Hulley;,citation_author=Umesh Kadam;,citation_author=Kushaharan Sathianathan;,citation_author=Richard Innes;,citation_author=Patricia Doble;,citation_author=Libby Graham;,citation_author=Charmaine Shovelton;,citation_author=Tessa Dean;,citation_author=Nawal Salahuddin;,citation_author=Diptesh Aryal;,citation_author=Kanchan Koirala;,citation_author=Namrata Rai;,citation_author=Subekshya Luitel;,citation_author=Ian Seppelt;,citation_author=Christina Whitehead;,citation_author=Julie Lowrey;,citation_author=Rebecca Gresham;,citation_author=Kristy Masters;,citation_author=Vincent Hamlyn;,citation_author=Nancy Hawkins;,citation_author=Anna Roynon-Reed;,citation_author=Sean Cutler;,citation_author=Sarah Lewis;,citation_author=Juan Lazaro;,citation_author=Tabitha Newman;,citation_author=Latha Aravindan;,citation_author=Adeeba Asghar;,citation_author=Jazz Bartholomew;,citation_author=Madeleine Bayne;,citation_author=Seonaid Beddows;,citation_author=Catherine Birch;,citation_author=Morwenna Brend;,citation_author=Rahim Byrne;,citation_author=Debbie Campbell;,citation_author=Hilary Campbell;,citation_author=Emma Chambers;,citation_author=Alison Clinton;,citation_author=Joanne Collins;,citation_author=Sarah Crawshaw;,citation_author=Laura Ann Dawson;,citation_author=Kate Donaldson;,citation_author=Chelsea Drake;,citation_author=Sarah Dyas;,citation_author=Yvette Ellis;,citation_author=Kate Gilmour;,citation_author=Jayne Goodwin;,citation_author=Sandra Halden;,citation_author=Alistair S Hall;,citation_author=Jane Hanson;,citation_author=Heather Harper;,citation_author=Susan Harrison;,citation_author=Amber Hayes;,citation_author=Helen Hodgson;,citation_author=Sally-Anne Hurford;,citation_author=Shane Jackson;,citation_author=Chris Levett;,citation_author=Stephen Lock;,citation_author=Teresa Lockett;,citation_author=Meg Logan;,citation_author=Kaatje Lomme;,citation_author=Ji Luo;,citation_author=Emma Marsh;,citation_author=Sonia McKenna;,citation_author=Nhlanhla Mguni;,citation_author=Holly Monaghan;,citation_author=Sheenagh Murphy;,citation_author=Natasha Muzengi;,citation_author=Mobeena Naz;,citation_author=Eleanor O’Kell;,citation_author=Anne Oliver;,citation_author=Joanna O’Reilly;,citation_author=Karen Pearson;,citation_author=David Porter;,citation_author=Alison Potter;,citation_author=Clare Rook;,citation_author=Charles Rounds;,citation_author=Jonathan Sheffield;,citation_author=Kim Shirley;,citation_author=Chris Siewersk;,citation_author=Tabitha Skinner;,citation_author=Holly Speight;,citation_author=Mihaela Sutu;,citation_author=Adam Unsworth;,citation_author=William Van’t Hoff;,citation_author=Susan Walker;,citation_author=Hannah Williams;,citation_author=Penny Williams;,citation_author=Dawn Williamson;,citation_author=James D Williamson;,citation_author=Erick Duan;,citation_author=Jennifer Tsang;,citation_author=Lisa Patterson;,citation_author=Pauline Austin;,citation_author=Susan Chapman;,citation_author=Louise Cabrelli;,citation_author=Simon Fletcher;,citation_author=Jurgens Nortje;,citation_author=Deirdre Fottrell-Gould;,citation_author=Georgina Randell;,citation_author=Katie Stammers;,citation_author=Gail Healey;,citation_author=Marta Pinto;,citation_author=Zoe Borrill;,citation_author=Tracy Duncan;,citation_author=Andrew Ustianowski;,citation_author=Alison Uriel;,citation_author=Ayaa Eltayeb;,citation_author=Jordan Alfonso;,citation_author=Samuel Hey;,citation_author=Joanne Shaw;,citation_author=Claire Fox;,citation_author=Gabriella Lindergard;,citation_author=Bethan Charles;,citation_author=Bethany Blackledge;,citation_author=Karen Connolly;,citation_author=Jade Harris;,citation_author=Jeronimo Cuesta;,citation_author=Kugan Xavier;,citation_author=Dharam Purohit;,citation_author=Munzir Elhassan;,citation_author=Anne Haldeos;,citation_author=Rachel Vincent;,citation_author=Marwa Abdelrazik;,citation_author=Samuel Jenkins;,citation_author=Arunkumar Ganesan;,citation_author=Rohit Kumar;,citation_author=David Carter;,citation_author=Dhanalakshmi Bakthavatsalam;,citation_author=Alasdair Frater;,citation_author=Malik Saleem;,citation_author=Robert Everitt;,citation_author=Danielle Hacking;,citation_author=Mohsin Zaman;,citation_author=Einas Elmahi;,citation_author=Andrea Jones;,citation_author=Kathryn Hall;,citation_author=Matt Phillips;,citation_author=Lenae Terrill;,citation_author=Gary Mills;,citation_author=Ajay Raithatha;,citation_author=Kris Bauchmuller;,citation_author=Kim Ryalls;,citation_author=Kate Harrington;,citation_author=Helen Bowler;,citation_author=Jas Sall;,citation_author=Richard Bourne;,citation_author=Jamie Gross;,citation_author=Natalie Massey;,citation_author=Olumide Adebambo;,citation_author=Matilda Long;,citation_author=Kiran Tony;,citation_author=Nicole Juffermans;,citation_author=Matty Koopmans;,citation_author=Romein Dujardin;,citation_author=Bashar Alderink;,citation_author=Matthew Rowland;,citation_author=Paula Hutton;,citation_author=Archana Bashyal;,citation_author=Neil Davidson;,citation_author=Clare Hird;,citation_author=Manish Chhablani;,citation_author=Gunjan Phalod;,citation_author=Amy Kirkby;,citation_author=Simon Archer;,citation_author=Kimberley Netherton;,citation_author=Henrik Reschreiter;,citation_author=Julie Camsooksai;,citation_author=Sarah Patch;,citation_author=Sarah Jenkins;,citation_author=Charlotte Humphrey;,citation_author=Gordon Flynn;,citation_author=Claire Harrington;,citation_author=Peter Kruger;,citation_author=James Walsham;,citation_author=Jason Meyer;,citation_author=Meg Harward;,citation_author=Cassie Jones;,citation_author=Sonia Sathe;,citation_author=Lisa Roche;,citation_author=Ellie Davies;,citation_author=Denise Skinner;,citation_author=Jane Gaylard;,citation_author=Julie Newman;,citation_author=David Pogson;,citation_author=Steve Rose;,citation_author=Zoe Daly;,citation_author=Lutece Brimfield;,citation_author=Angie Nown;,citation_author=Dhruv Parekh;,citation_author=Colin Bergin;,citation_author=Michelle Bates;,citation_author=Christopher McGhee;,citation_author=Daniella Lynch;,citation_author=Khushpreet Bhandal;,citation_author=Kyriaki Tsakiridou;,citation_author=Amy Bamford;,citation_author=Lauren Cooper;,citation_author=Tony Whitehouse;,citation_author=Tonny Veenith;,citation_author=Elliot Forster;,citation_author=Martin O’Connell;,citation_author=Malcolm Sim;,citation_author=Sophie Hay;,citation_author=Steven Henderson;,citation_author=Maria Nygren;,citation_author=Eliza Valentine;,citation_author=Amro Katary;,citation_author=Gillian Bell;,citation_author=Louise Wilcox;,citation_author=Michail Mataliotakis;,citation_author=Paul Smith;,citation_author=Murtaza Ali;,citation_author=Agah Isguzar;,citation_author=Mandeep-Kaur Phull;,citation_author=Abbas Zaidi;,citation_author=Tatiana Pogreban;,citation_author=Lace Rosaroso;,citation_author=Daniel Harvey;,citation_author=Benjamin Lowe;,citation_author=Megan Meredith;,citation_author=Lucy Ryan;,citation_author=Jeroen Schouten;,citation_author=Peter Pickkers;,citation_author=Noortje Roovers;,citation_author=Margreet Klop-Riehl;,citation_author=Hetty Eng;,citation_author=Sonja Sloots-Cuppen;,citation_author=Lieke Preijers;,citation_author=Nienke Oosten;,citation_author=Pierre Moine;,citation_author=Nicholas Heming;,citation_author=Virginie Maxime;,citation_author=Isabelle Bossard;,citation_author=Tiphaine Nicholier;,citation_author=Bernard Clair;,citation_author=David Orlikowski;,citation_author=Rania Bounab;,citation_author=Lilia Abdeladim;,citation_author=Stuart Baker;,citation_author=Maree Duroux;,citation_author=Megan Ratcliffe;,citation_author=Eric Sy;,citation_author=Jonathan Mailman;,citation_author=Stephen Lee;,citation_author=Chiraag Gupta;,citation_author=Sandy Kassir;,citation_author=Rafael López;,citation_author=Jorge Rodríguez-Gómez;,citation_author=Sheila Cárcel;,citation_author=Rosario Carmona;,citation_author=Carmen Fuente;,citation_author=Marina Rodriguez;,citation_author=Robert Jan Hassing;,citation_author=Frances Greven;,citation_author=Danique Huijbens;,citation_author=L Roebers;,citation_author=Harald Verheij;,citation_author=Helen Miles;,citation_author=Antony Attokaran;,citation_author=Ulrike Buehner;,citation_author=Erin Williams;,citation_author=Marianne Chapman;,citation_author=Stephanie O’Connor;,citation_author=Kathleen Glasby;,citation_author=Justine Rivett;,citation_author=Nerissa Brown;,citation_author=Demetrios Kutsogiannis;,citation_author=Patricia Thompson;,citation_author=Kevin Rooney;,citation_author=Natalie Rodden;,citation_author=Nicola Thomson;,citation_author=Deborah McGlynn;,citation_author=Lynn Abel;,citation_author=Lisa Gemmell;,citation_author=Radha Sundaram;,citation_author=James Hornsby;,citation_author=Andrew Walden;,citation_author=Liza Keating;,citation_author=Matthew Frise;,citation_author=Sabi Rai;,citation_author=Shauna Bartley;,citation_author=Martin Schuster-Bruce;,citation_author=Sally Pitts;,citation_author=Rebecca Miln;,citation_author=Laura Purandare;,citation_author=Luke Vamplew;,citation_author=Brijesh Patel;,citation_author=Debra Dempster;,citation_author=Mahitha Gummadi;,citation_author=Natalie Dormand;,citation_author=Shu Wang;,citation_author=Michael Spivey;,citation_author=Sarah Bean;,citation_author=Karen Burt;,citation_author=Lorraine Moore;,citation_author=Fiona Hammonds;,citation_author=Carol Richards;,citation_author=Lewis Campbell;,citation_author=Kirsty Smyth;,citation_author=Christopher Day;,citation_author=Letizia Zitter;,citation_author=Sarah Benyon;,citation_author=Jayaprakash Singh;,citation_author=Ceri Lynch;,citation_author=Justyna Mikusek;,citation_author=Bethan Deacon;,citation_author=Keri Turner;,citation_author=Evelyn Baker;,citation_author=John Hickey;,citation_author=Shreekant Champanerkar;,citation_author=Lindianne Aitken;,citation_author=Lorraine LewisProsser;,citation_author=Norfaizan Ahmad;,citation_author=Matt Wiles;,citation_author=Jayne Willson;,citation_author=Irina Grecu;,citation_author=Jane Martin;,citation_author=Caroline Wrey Brown;,citation_author=Ana-Marie Arias;,citation_author=Emily Bevan;,citation_author=Samantha Westlake;,citation_author=Thomas Craven;,citation_author=David Hope;,citation_author=Jo Singleton;,citation_author=Sarah Clark;,citation_author=Corrienne McCulloch;,citation_author=Simon Biddie;,citation_author=Ingeborg Welters;,citation_author=David Hamilton;,citation_author=Karen Williams;,citation_author=Victoria Waugh;,citation_author=David Shaw;,citation_author=Suleman Mulla;,citation_author=Alicia Waite;,citation_author=Jaime Roman;,citation_author=Maria Martinez;,citation_author=Brian Johnston;,citation_author=Zudin Puthucheary;,citation_author=Timothy Martin;,citation_author=Filipa Santos;,citation_author=Ruzena Uddin;,citation_author=Maria Fernandez;,citation_author=Fatima Seidu;,citation_author=Alastair Somerville;,citation_author=Mari-Liis Pakats;,citation_author=Salma Begum;,citation_author=Tasnin Shahid;,citation_author=Jeffrey Presneill;,citation_author=Deborah Barge;,citation_author=Kathleen Byrne;,citation_author=Pierre Janin;,citation_author=Elizabeth Yarad;,citation_author=Frances Bass;,citation_author=Naomi Hammond;,citation_author=Anne O’Connor;,citation_author=Alain Vuylsteke;,citation_author=Charles Chan;,citation_author=Saji Victor;,citation_author=Sharon Waterson;,citation_author=Robert McNamara;,citation_author=Melanie Boardman;,citation_author=David Gattas;,citation_author=Heidi Buhr;,citation_author=Jennifer Coles;,citation_author=Ramprasad Matsa;,citation_author=Minerva Gellamucho;,citation_author=Ben Creagh-Brown;,citation_author=Cheryl Marriot;,citation_author=Armorel Salberg;,citation_author=Louisa Zouita;,citation_author=Sarah Stone;,citation_author=Natalia Michalak;,citation_author=Sinead Donlon;,citation_author=Shelia Mtuwa;,citation_author=Irving Mayangao;,citation_author=Jerik Verula;,citation_author=Dorota Burda;,citation_author=Celia Harris;,citation_author=Emily Jones;,citation_author=Paul Bradley;,citation_author=Esther Tarr;,citation_author=Lesley Harden;,citation_author=Charlie Piercy;,citation_author=Jerry Nolan;,citation_author=Ian Kerslake;,citation_author=Tim Cook;,citation_author=Tom Simpson;,citation_author=James Dalton;,citation_author=Carrie Demetriou;,citation_author=Sarah Mitchard;,citation_author=Lidia Ramos;,citation_author=Katie White;,citation_author=Toby Johnson;,citation_author=William Headdon;,citation_author=Stephen Spencer;,citation_author=Alison White;,citation_author=Lucy Howie;,citation_author=Michael Reay;,citation_author=Steve Jenkins;,citation_author=Angela Watts;,citation_author=Eleanor Traverse;,citation_author=Stacey Jennings;,citation_author=Vikram Anumakonda;,citation_author=Caroline Tuckwell;,citation_author=Kath Harrow;,citation_author=Julie Matthews;,citation_author=Karen McGarry;,citation_author=Vanessa Moore;,citation_author=Lucie Smith;,citation_author=Anna Summerfield;,citation_author=Paul Dark;,citation_author=Alice Harvey;,citation_author=Reece Doonan;,citation_author=Liam McMorrow;,citation_author=Karen Knowles;,citation_author=Jessica Pendlebury;,citation_author=Stephanie Lee;,citation_author=Jane Perez;,citation_author=Tracy Marsden;,citation_author=Melanie Taylor;,citation_author=Angiy Michael;,citation_author=Matthew Collis;,citation_author=Andrew Claxton;,citation_author=Wadih Habeichi;,citation_author=Dan Horner;,citation_author=Melanie Slaughter;,citation_author=Vicky Thomas;,citation_author=Nicola Proudfoot;,citation_author=Claire Keatley;,citation_author=Phil Donnison;,citation_author=Ruth Casey;,citation_author=Ben Irving;,citation_author=Wadzanai Matimba-Mupaya;,citation_author=Catherine Reed;,citation_author=Alpha Anthony;,citation_author=Fiona Trim;,citation_author=Lenka Cambalova;,citation_author=Debra Robertson;,citation_author=Anna Wilson;,citation_author=Jonathan Hulme;,citation_author=Santhana Kannan;,citation_author=Fiona Kinney;,citation_author=Ho Senya;,citation_author=Anne Hayes;,citation_author=Valli Ratnam;,citation_author=Mandy Gill;,citation_author=Jill Kirk;,citation_author=Sarah Shelton;,citation_author=Sacha Schweikert;,citation_author=Bradley Wibrow;,citation_author=Matthew Anstey;,citation_author=Rashmi Rauniyar;,citation_author=Nasir Khoso;,citation_author=Namra Asif;,citation_author=Huda Taqdees;,citation_author=Christian Frey;,citation_author=Riccardo Scano;,citation_author=Madeleine McKee;,citation_author=Peter Murphy;,citation_author=Matt Thomas;,citation_author=Ruth Worner;,citation_author=Beverley Faulkner;,citation_author=Emma Gendall;,citation_author=Kati Hayes;,citation_author=Hayley Blakemore;,citation_author=Borislava Borislavova;,citation_author=Kush Deshpande;,citation_author=Frank Haren;,citation_author=Pam Konecny;,citation_author=Deborah Inskip;,citation_author=Raymond Tung;,citation_author=Leanne Hayes;,citation_author=Lorna Murphy;,citation_author=Andy Neill;,citation_author=Bryan Reidy;,citation_author=Michael O’Dwyer;,citation_author=Donal Ryan;,citation_author=Kate Ainscough;,citation_author=Colin Hamilton-Davies;,citation_author=Carmen Chan;,citation_author=Celina Mfuko;,citation_author=Hakam Abbass;,citation_author=Vineela Mandadapu;,citation_author=Susannah Leaver;,citation_author=Kamal Patel;,citation_author=Sarah Farnell-Ward;,citation_author=Romina Saluzzio;,citation_author=Sam Rawlins;,citation_author=Christine Sicat;,citation_author=Bart De Keulenaer;,citation_author=Janet Ferrier;,citation_author=Ed Fysh;,citation_author=Ashish Davda;,citation_author=Bhaumik Mevavala;,citation_author=Deborah Cook;,citation_author=Frances Clarke;,citation_author=Dorota Banach;,citation_author=Ziortza Fernández de Pinedo&nbsp;Artaraz;,citation_author=Leilani Cabreros;,citation_author=Victoria Latham;,citation_author=Rebecca Kruisselbrink;,citation_author=Laurent Brochard;,citation_author=Karen Burns;,citation_author=Gyan Sandhu;,citation_author=Imrana Khalid;,citation_author=Ian White;,citation_author=Maria Croft;,citation_author=Nicky Holland;,citation_author=Rita Pereira;,citation_author=Priya Nair;,citation_author=Hergen Buscher;,citation_author=Claire Reynolds;,citation_author=Sally Newman;,citation_author=John Santamaria;,citation_author=Leanne Barbazza;,citation_author=Jennifer Homes;,citation_author=Roger Smith;,citation_author=Ahmed Zaki;,citation_author=David Johnson;,citation_author=Hywel Garrard;,citation_author=Vera Juhaz;,citation_author=Louise Brown;,citation_author=Abigail Pemberton;,citation_author=Alistair Roy;,citation_author=Anthony Rostron;,citation_author=Lindsey Woods;,citation_author=Sarah Cornell;,citation_author=Rob Fowler;,citation_author=Neill Adhikari;,citation_author=Maneesha Kamra;,citation_author=Nicole Marinoff;,citation_author=Peter Garrett;,citation_author=Lauren Murray;,citation_author=Jane Brailsford;,citation_author=Gerard Fennessy;,citation_author=John Mulder;,citation_author=Rebecca Morgan;,citation_author=Suresh Pillai;,citation_author=Rachel Harford;,citation_author=Helen Ivatt;,citation_author=Debra Evans;,citation_author=Suzanne Richards;,citation_author=Eilir Roberts;,citation_author=James Bowen;,citation_author=James Ainsworth;,citation_author=Anne Kuitunen;,citation_author=Sari Karlsson;,citation_author=Annukka Vahtera;,citation_author=Heikki Kiiski;,citation_author=Sanna Ristimäki;,citation_author=Jonathan Albrett;,citation_author=Carolyn Jackson;,citation_author=Simon Kirkham;,citation_author=Kadri Tamme;,citation_author=Veronika Reinhard;,citation_author=Anneli Ellervee;,citation_author=Liisi Põldots;,citation_author=Pille Rennit;,citation_author=Nikolai Svitškar;,citation_author=Troy Browne;,citation_author=Kate Grimwade;,citation_author=Jennifer Goodson;,citation_author=Owen Keet;,citation_author=Owen Callender;,citation_author=Andrew Udy;,citation_author=Phoebe McCracken;,citation_author=Meredith Young;,citation_author=Jasmin Board;,citation_author=Emma Martin;,citation_author=Vidya Kasipandian;,citation_author=Amit Patel;,citation_author=Suzanne Allibone;,citation_author=Roman Mary-Genetu;,citation_author=Shane English;,citation_author=Irene Watpool;,citation_author=Rebecca Porteous;,citation_author=Sydney Miezitis;,citation_author=Lauralyn McIntyre;,citation_author=Kara Brady;,citation_author=Cassandra Vale;,citation_author=Kiran Shekar;,citation_author=Jayshree Lavana;,citation_author=Dinesh Parmar;,citation_author=Sandra Peake;,citation_author=Catherine Kurenda;,citation_author=Anil Hormis;,citation_author=Rachel Walker;,citation_author=Dawn Collier;,citation_author=Sarah Kimpton;,citation_author=Susan Oakley;,citation_author=Sanjay Bhagani;,citation_author=Mark De Neef;,citation_author=Sara Garcia;,citation_author=Amitaa Maharajh;,citation_author=Aarti Nandani;,citation_author=Jade Dobson;,citation_author=Gloria Fernando;,citation_author=Christine Eastgate;,citation_author=Keith Gomez;,citation_author=Zakee Abdi;,citation_author=Kate Tatham;,citation_author=Shaman Jhanji;,citation_author=Ethel Black;,citation_author=Arnold Dela Rosa;,citation_author=Ryan Howle;,citation_author=Ravishankar Baikady;,citation_author=Redmond Tully;,citation_author=Andrew Drummond;,citation_author=Joy Dearden;,citation_author=Jennifer Philbin;,citation_author=Sheila Munt;,citation_author=Shameer Gopal;,citation_author=Jagtar- Singh Pooni;,citation_author=Saibal Ganguly;,citation_author=Andrew Smallwood;,citation_author=Stella Metherell;,citation_author=Anas Naeem;,citation_author=Laura Fagan;,citation_author=Emily Ryan;,citation_author=Vasanth Mariappa;,citation_author=Judith Smith;,citation_author=Angela Foulds;,citation_author=Adam Revill;,citation_author=Binita Bhattarai;,citation_author=Evert Jonge;,citation_author=Jeanette Wigbers;,citation_author=Michael Prado;,citation_author=Olaf Cremer;,citation_author=Jelle Mulier;,citation_author=Anna Peters;,citation_author=Birgit Romberg;,citation_author=Roger Schutgens;,citation_author=Darren Troeman;,citation_author=Marjolein Opdorp;,citation_author=Henny Besten;,citation_author=Karen Brakké;,citation_author=Russell Barber;,citation_author=Anette Hilldrith;,citation_author=Stefan Kluge;,citation_author=Axel Nierhaus;,citation_author=Dominik Jarczak;,citation_author=Kevin Roedl;,citation_author=Matthias Kochanek;,citation_author=Giusi Rueß-Paterno;,citation_author=Josette Mc-Kenzie;,citation_author=Dennis Eichenauer;,citation_author=Alexander Shimabukuro-Vornhagen;,citation_author=Elizabeth Wilcox;,citation_author=Lorenzo Sorbo;,citation_author=Hesham Abdelhady;,citation_author=Tina Romagnuolo;,citation_author=Scott Simpson;,citation_author=Matthew Maiden;,citation_author=Michelle Horton;,citation_author=Jemma Trickey;,citation_author=Vladimir Krajinovic;,citation_author=Marko Kutleša;,citation_author=Viktor Kotarski;,citation_author=Farooq Brohi;,citation_author=Vijay Jagannathan;,citation_author=Michele Clark;,citation_author=Sarah Purvis;,citation_author=Bill Wetherill;,citation_author=Ana Brajković;,citation_author=Jakša Babel;,citation_author=Helena Sever;,citation_author=Lidija Dragija;,citation_author=Ira Kušan;,citation_author=Ahilanandan Dushianthan;,citation_author=Rebecca Cusack;,citation_author=Kim Courcy-Golder;,citation_author=Karen Salmon;,citation_author=Rachel Burnish;,citation_author=Simon Smith;,citation_author=Susan Jackson;,citation_author=Winningtom Ruiz;,citation_author=Zoe Duke;,citation_author=Magaret Johns;,citation_author=Michelle Male;,citation_author=Kirsty Gladas;,citation_author=Satwinder Virdee;,citation_author=Jacqueline Swabe;,citation_author=Helen Tomlinson;,citation_author=Gernot Rohde;,citation_author=Achim Grünewaldt;,citation_author=Jörg Bojunga;,citation_author=Sirak Petros;,citation_author=Kevin Kunz;,citation_author=Bianka Schütze;,citation_author=Dirk Weismann;,citation_author=Anna Frey;,citation_author=Maria Drayss;,citation_author=M. E. Goebeler;,citation_author=Thomas Flor;,citation_author=Gertrud Fragner;,citation_author=Nadine Wahl;,citation_author=Juliane Totzke;,citation_author=Cyrus Sayehli;,citation_author=Sheeba Hakak;,citation_author=Wahid Altaf;,citation_author=Mike O’Sullivan;,citation_author=Aisling Murphy;,citation_author=Leo Walsh;,citation_author=Antonio Rega La Valle;,citation_author=Jeremy Bewley;,citation_author=Katie Sweet;,citation_author=Lisa Grimmer;,citation_author=Rebekah Johnson;,citation_author=Rachel Wyatt;,citation_author=Karen Morgan;,citation_author=Siby Varghese;,citation_author=Joanna Willis;,citation_author=Emma Stratton;,citation_author=Laura Kyle;,citation_author=Daniel Putensen;,citation_author=Kay Drury;,citation_author=Agnieszka Skorko;,citation_author=Pamela Bremmer;,citation_author=Geraldine Ward;,citation_author=Christopher Bassford;,citation_author=Wendy Sligl;,citation_author=Nadia Baig;,citation_author=Oleksa Rewa;,citation_author=Sean Bagshaw;,citation_author=Kim Basile;,citation_author=Dara Stavor;,citation_author=Dylan Burbee;,citation_author=Amanda McNamara;,citation_author=Renee Wunderley;,citation_author=Nicole Bensen;,citation_author=Aaron Richardson;,citation_author=Peter Adams;,citation_author=Tina Vita;,citation_author=Megan Buhay;,citation_author=Denise Scholl;,citation_author=Matthew Gilliam;,citation_author=James Winters;,citation_author=Kaleigh Doherty;,citation_author=Emily Berryman;,citation_author=Mehrdad Ghaffari;,citation_author=Oscar Marroquin;,citation_author=Kevin Quinn;,citation_author=William Garrard;,citation_author=Kyle Kalchthaler;,citation_author=Gregory Beard;,citation_author=Aimee Skrtich;,citation_author=Kavitha Bagavathy;,citation_author=Debra Drapola;,citation_author=Kayla Bryan-Morris;,citation_author=John Arnold;,citation_author=Bob Reynolds;,citation_author=Mahwish Hussain;,citation_author=Janice Dunsavage;,citation_author=Salim Saiyed;,citation_author=Erik Hernandez;,citation_author=John Goldman;,citation_author=Cynthia Brown;,citation_author=Susan Comp;,citation_author=James Raczek;,citation_author=Jenny Morris;,citation_author=Jesus Vargas Jr.;,citation_author=Daniel Weiss;,citation_author=Joseph Hensley;,citation_author=Erik Kochert;,citation_author=Chris Wnuk;,citation_author=Christopher Nemeth;,citation_author=Brent Mowery;,citation_author=Christina Hutchinson;,citation_author=Lauren Winters;,citation_author=David McAdams;,citation_author=Gena Walker;,citation_author=Tami Minnier;,citation_author=Mary Wisniewski;,citation_author=Katelyn Mayak;,citation_author=Erin McCreary;,citation_author=Elise Martin;,citation_author=Ryan Bariola;,citation_author=Alex Viehman;,citation_author=Jessica Daley;,citation_author=Alyssa Lopus;,citation_author=Mark Schmidhofer;,citation_author=Richard Ambrosino;,citation_author=Sherbrina Keen;,citation_author=Sue Toffalo;,citation_author=Martha Stambaugh;,citation_author=Ken Trimmer;,citation_author=Reno Perri;,citation_author=Sherry Casali;,citation_author=Rebecca Medva;,citation_author=Brent Massar;,citation_author=Ashley Beyerl;,citation_author=Jason Burkey;,citation_author=Sheryl Keeler;,citation_author=Maryalyce Lowery;,citation_author=Lynne Oncea;,citation_author=Jason Daugherty;,citation_author=Chanthou Sevilla;,citation_author=Amy Woelke;,citation_author=Julie Dice;,citation_author=Lisa Weber;,citation_author=Jason Roth;,citation_author=Cindy Ferringer;,citation_author=Deborah Beer;,citation_author=Jessica Fesz;,citation_author=Lillian Carpio;,citation_author=Gwenhael Colin;,citation_author=Vanessa Zinzoni;,citation_author=Natacha Maquigneau;,citation_author=Matthieu Henri-Lagarrigue;,citation_author=Caroline Pouplet;,citation_author=Lorenz Reill;,citation_author=Michael Distler;,citation_author=Astrid Maselli;,citation_author=Robert Martynoga;,citation_author=Kara Trask;,citation_author=Amelia Butler;,citation_author=Ben Attwood;,citation_author=Penny Parsons;,citation_author=Bridget Campbell;,citation_author=Alex Smith;,citation_author=Valerie Page;,citation_author=Xiao Zhao;,citation_author=Deepali Oza;,citation_author=Gail Abrahamson;,citation_author=Ben Sheath;,citation_author=Chiara Ellis;,citation_author=Paul Young;,citation_author=Chelsea Young;,citation_author=Eden Lesona;,citation_author=Leanlove Navarra;,citation_author=Raulle Cruz;,citation_author=Kirsha Delaney;,citation_author=Rhoze Cruz;,citation_author=April Aguilar-Dano;,citation_author=Marlene Gojanovic;,citation_author=Jonathan Rhodes;,citation_author=Thomas Anderson;,citation_author=Sheila Morris;,citation_author=Vineet Nayyar;,citation_author=David Bowen;,citation_author=Jing Kong;,citation_author=Jenyfer Joy;,citation_author=Ralph Fuchs;,citation_author=Bridget Lambert;,citation_author=Charlotte Tai;,citation_author=Amy Thomas;,citation_author=Alexandra Keen;,citation_author=Carey Tierney;,citation_author=Nimca Omer;,citation_author=Gina Bacon;,citation_author=Ascanio Tridente;,citation_author=Karen Shuker;,citation_author=Jeanette Anders;,citation_author=Sandra Greer;,citation_author=Paula Scott;,citation_author=Amy Millington;,citation_author=Philip Buchanan;,citation_author=Jodie Kirk;,citation_author=Alexandra Binnie;,citation_author=Elizabeth Powell;,citation_author=Alexandra McMillan;,citation_author=Tracy Luk;,citation_author=Noah Aref;,citation_author=Craig Denmade;,citation_author=Girendra Sadera;,citation_author=Reni Jacob;,citation_author=Cathy Jones;,citation_author=Debbie Hughes;,citation_author=Martin Sterba;,citation_author=Wenli Geng;,citation_author=Stephen Digby;,citation_author=David Southern;,citation_author=Harsha Reddy;,citation_author=Sarah Hulse;,citation_author=Andrew Campbell;,citation_author=Mark Garton;,citation_author=Claire Watkins;,citation_author=Sara Smuts;,citation_author=Alison Quinn;,citation_author=Benjamin Simpson;,citation_author=Catherine McMillan;,citation_author=Cheryl Finch;,citation_author=Claire Hill;,citation_author=Josh Cooper;,citation_author=Joanna Budd;,citation_author=Charlotte Small;,citation_author=Ryan O’Leary;,citation_author=Janine Birch;,citation_author=Emma Collins;,citation_author=Andrew Holland;,citation_author=Peter Alexander;,citation_author=Tim Felton;,citation_author=Susan Ferguson;,citation_author=Katharine Sellers;,citation_author=Luke Ward;,citation_author=David Yates;,citation_author=Isobel Birkinshaw;,citation_author=Kay Kell;,citation_author=Zoe Scott;,citation_author=Harriet Pearson;,citation_author=Madiha Hashmi;,citation_author=Maryam Ali;,citation_author=Noor Hassan;,citation_author=Ashok Panjwani;,citation_author=Zulfiqar Umrani;,citation_author=Mohiuddin Shaikh;,citation_author=Ayesha Siddiqui;,citation_author=Quratul Ain;,citation_author=Darakhshan Kanwal;,citation_author=Sjoerd Bree;,citation_author=Marianne Bouw-Ruiter;,citation_author=Margreet Osinga;,citation_author=Arthur Zanten;,citation_author=Rebecca McEldrew;,citation_author=Sumayyah Rashan;,citation_author=Vanessa Singh;,citation_author=Nora Azergui;,citation_author=Sara Bari;,citation_author=Mercedes Beltran;,citation_author=Curt Brugman;,citation_author=Erika Groeneveld;,citation_author=Mina Jafarzadeh;,citation_author=Nicole Keijzer-Timmers;,citation_author=Esmee Kester;,citation_author=Maaike Koelink;,citation_author=Marion Kwakkenbos-Craanen;,citation_author=Clementina Okundaye;,citation_author=Lorraine Parker;,citation_author=Svenja Peters;,citation_author=Sophie Post;,citation_author=Ilse Rietveld;,citation_author=Irma Scheepstra-Beukers;,citation_author=Gerwin Schreuder;,citation_author=Albertine Smit;,citation_author=Nicole Brillinger;,citation_author=René Markgraf;,citation_author=Fred Eichinger;,citation_author=Peter Doran;,citation_author=Aisha Anjum;,citation_author=Janis Best-Lane;,citation_author=Frances Barton;,citation_author=Lorna Miller;,citation_author=Sam Peters;,citation_author=Alvin Richards-Belle;,citation_author=Michelle Saull;,citation_author=Stefan Sprinckmoller;,citation_author=Daisy Wiley;,citation_author=Robert Darnell;,citation_author=Carly Au;,citation_author=Kelsey Lindstrum;,citation_author=Allen Cheng;,citation_author=Andrew Forbes;,citation_author=Stephane Heritier;,citation_author=Tony Trapani;,citation_author=Brian Cuthbertson;,citation_author=Venika Manoharan;,citation_author=Arjen Dondrop;,citation_author=Deva Jayakumar;,citation_author=Timo Tolppa;,citation_author=Stephan Ehrmann;,citation_author=Sebastiaan Hullegie;,citation_author=Pedro Povoa;,citation_author=Richard Beasley;,citation_author=Nick Daneman;,citation_author=Robert Fowler;,citation_author=Steve McGloughlin;,citation_author=David Paterson;,citation_author=Bala Venkatesh;,citation_author=Menno Jong;,citation_author=Tim Uyeki;,citation_author=Kenneth Baillie;,citation_author=Madhia Hashmi;,citation_author=Mihai Netea;,citation_author=Katrina Orr;,citation_author=Asad Patanwala;,citation_author=Steve Tong;,citation_author=Nichola Cooper;,citation_author=James Galea;,citation_author=Helen Leavis;,citation_author=Kayode Ogungbenro;,citation_author=Asad Patawala;,citation_author=Emma Rademaker;,citation_author=Steven Tong;,citation_author=Taryn Youngstein;,citation_author=Marc Carrier;,citation_author=Dean Fergusson;,citation_author=Beverley Hunt;,citation_author=Anand Kumar;,citation_author=Mike Laffan;,citation_author=Sylvain Lother;,citation_author=Saskia Middeldorp;,citation_author=Simon Stanworth;,citation_author=Angelique Man;,citation_author=Marie-Helene Masse;,citation_author=Jacinta Abraham;,citation_author=Donald Arnold;,citation_author=Phillipe Begin;,citation_author=Richard Charlewood;,citation_author=Michael Chasse;,citation_author=Jamie Cooper;,citation_author=Mark Coyne;,citation_author=James Daly;,citation_author=Iain Gosbell;,citation_author=Heli Harvala-Simmonds;,citation_author=Sheila MacLennan;,citation_author=John McDyer;,citation_author=David Menon;,citation_author=Nicole Pridee;,citation_author=David Roberts;,citation_author=Helen Thomas;,citation_author=Alan Tinmouth;,citation_author=Darrell Triulzi;,citation_author=Tim Walsh;,citation_author=Erica Wood;,citation_author=Carolyn Calfee;,citation_author=Cecilia O’Kane;,citation_author=Murali Shyamsundar;,citation_author=Pratik Sinha;,citation_author=Taylor Thompson;,citation_author=Ian Young;,citation_author=Aidan Burrell;,citation_author=Niall Ferguson;,citation_author=Carol Hodgson;,citation_author=Neil Orford;,citation_author=Jason Phua;,citation_author=Rebecca Baron;,citation_author=Slava Epelman;,citation_author=Claudia Frankfurter;,citation_author=Frank Gommans;,citation_author=Edy Kim;,citation_author=David Leaf;,citation_author=Muthiah Vaduganathan;,citation_author=Roland Kimmenade;,citation_author=Ashish Sanil;,citation_author=Marloes Beurden;,citation_author=Evelien Effelaar;,citation_author=Joost Schotsman;,citation_author=Craig Boyd;,citation_author=Cain Harland;,citation_author=Audrey Shearer;,citation_author=Jess Wren;,citation_author=Giles Clermont;,citation_author=Daniel Ricketts;,citation_author=Udara Attanayaka;,citation_author=Sri Darshana;,citation_author=Pramodya Ishani;,citation_author=Ishara Udayanga;,citation_author=Alisa M. Higgins;,citation_author=Lindsay R. Berry;,citation_author=Elizabeth Lorenzi;,citation_author=Srinivas Murthy;,citation_author=Zoe McQuilten;,citation_author=Paul R. Mouncey;,citation_author=Farah Al-Beidh;,citation_author=Djillali Annane;,citation_author=Yaseen M. Arabi;,citation_author=Abi Beane;,citation_author=Wilma Bentum-Puijk;,citation_author=Zahra Bhimani;,citation_author=Marc J. M. Bonten;,citation_author=Charlotte A. Bradbury;,citation_author=Frank M. Brunkhorst;,citation_author=Aiden Burrell;,citation_author=Adrian Buzgau;,citation_author=Meredith Buxton;,citation_author=Walton N. Charles;,citation_author=Matthew Cove;,citation_author=Michelle A. Detry;,citation_author=Lise J. Estcourt;,citation_author=Elizabeth O. Fagbodun;,citation_author=Mark Fitzgerald;,citation_author=Timothy D. Girard;,citation_author=Ewan C. Goligher;,citation_author=Herman Goossens;,citation_author=Rashan Haniffa;,citation_author=Thomas Hills;,citation_author=Christopher M. Horvat;,citation_author=David T. Huang;,citation_author=Nao Ichihara;,citation_author=Francois Lamontagne;,citation_author=John C. Marshall;,citation_author=Daniel F. McAuley;,citation_author=Anna McGlothlin;,citation_author=Shay P. McGuinness;,citation_author=Bryan J. McVerry;,citation_author=Matthew D. Neal;,citation_author=Alistair D. Nichol;,citation_author=Rachael L. Parke;,citation_author=Jane C. Parker;,citation_author=Karen Parry-Billings;,citation_author=Sam E. C. Peters;,citation_author=Luis F. Reyes;,citation_author=Kathryn M. Rowan;,citation_author=Hiroki Saito;,citation_author=Marlene S. Santos;,citation_author=Christina T. Saunders;,citation_author=Ary Serpa-Neto;,citation_author=Christopher W. Seymour;,citation_author=Manu Shankar-Hari;,citation_author=Lucy M. Stronach;,citation_author=Alexis F. Turgeon;,citation_author=Anne M. Turner;,citation_author=Frank L. Veerdonk;,citation_author=Ryan Zarychanski;,citation_author=Cameron Green;,citation_author=Roger J. Lewis;,citation_author=Derek C. Angus;,citation_author=Colin J. McArthur;,citation_author=Scott Berry;,citation_author=Lennie P. G. Derde;,citation_author=Anthony C. Gordon;,citation_author=Steve A. Webb;,citation_author=Patrick R. Lawler;,citation_publication_date=2022-12;,citation_cover_date=2022-12;,citation_year=2022;,citation_doi=10.1001/jama.2022.23257;,citation_issn=0098-7484;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Exploring Ketamine Analgosedation Use and Its Effect on Incident Delirium in Critically Ill Adults;,citation_abstract=OBJECTIVES: Ketamine is increasingly being used for analgosedation, but its effect on delirium remains unclear. We compared delirium risk variables and ketamine analgosedation use between adults who developed incident delirium and those who did not, evaluated whether ketamine analgosedation increases delirium risk, and compared ICU delirium characteristics, treatments, and outcomes between ketamine and nonketamine patients with delirium. DESIGN: Secondary, subgroup analysis of a cohort study. SETTING: Single, 36-bed mixed medical-surgical ICU in the Netherlands from July 2016 to February 2020. PATIENTS: Consecutive adults were included. Patients admitted after elective surgery, not expected to survive greater than or equal to 48 hours, admitted with delirium, or where delirium occurred prior to ketamine use were excluded. INTERVENTION: None. MEASUREMENTS AND MAIN RESULTS: Trained ICU nurses evaluated patients without coma (Richmond Agitation Sedation Scale. –4/–5) every 8 hours with the Confusion Assessment Method ICU; a delirium day was defined by greater than or equal to1 + Confusion Assessment Method ICU and/or scheduled antipsychotic use. Among 11 variables compared between the delirium and nondelirium groups (Baseline: age, Charlson Comorbidity score, cognitive impairment, admission type, and Acute Physiology and Chronic Health Evaluation-IV score, daily ICU [until delirium occurrence or discharge]: Sequential Organ Failure Assessment score, coma, benzodiazepine, opioid, and ketamine use) and total ICU days, 7 (age, Charlson score, Sequential Organ Failure Assessment score, coma, benzodiazepine, opioid, and ketamine use) were significantly different and were entered, along with delirium occurrence, in a logistic regression model. A total of 332 of 925 of patients (36%) developed delirium. Ketamine use was greater in patients with delirium (54 [16%] vs 4 [0.7%]; p &amp;amp;amp;lt; 0.01). Ketamine use (adjusted odds ratio, 5.60; 95% CI, 1.09–29.15), age (adjusted odds ratio, 1.03; 95% CI, 1.01–1.06), coma (adjusted odds ratio, 2.10; 95% CI, 1.15–3.78), opioid use (adjusted odds ratio, 171.17; 95% CI, 66.45–553.68), and benzodiazepine use (adjusted odds ratio, 34.07; 95% CI, 8.12–235.34) were each independently and significantly associated with increased delirium. Delirium duration, motoric subtype, delirium treatments, and outcomes were not different between the ketamine and nonketamine groups. CONCLUSIONS: Ketamine analgosedation may contribute to increased ICU delirium. The characteristics of ketamine and nonketamine delirium are similar. Further prospective research is required to evaluate the magnitude of risk for delirium with ketamine use.;,citation_author=Ting Ting Wu;,citation_author=Sally Ko;,citation_author=Rens Kooken;,citation_author=Mark Boogaard;,citation_author=John W. Devlin;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_issue=10;,citation_doi=10.1097/CCE.0000000000000544;,citation_issn=2639-8028;,citation_volume=3;,citation_language=en-US;,citation_journal_title=Critical Care Explorations;">
<meta name="citation_reference" content="citation_title=Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study;,citation_abstract=Background: A small randomized controlled trial suggested that dabigatran may be as effective as warfarin in the treatment of cerebral venous thrombosis (CVT). We aimed to compare direct oral anticoagulants (DOACs) to warfarin in a real-world CVT cohort. Methods: This multicenter international retrospective study (United States, Europe, New Zealand) included consecutive patients with CVT treated with oral anticoagulation from January 2015 to December 2020. We abstracted demographics and CVT risk factors, hypercoagulable labs, baseline imaging data, and clinical and radiological outcomes from medical records. We used adjusted inverse probability of treatment weighted Cox-regression models to compare recurrent cerebral or systemic venous thrombosis, death, and major hemorrhage in patients treated with warfarin versus DOACs. We performed adjusted inverse probability of treatment weighted logistic regression to compare recanalization rates on follow-up imaging across the 2 treatments groups. Results: Among 1025 CVT patients across 27 centers, 845 patients met our inclusion criteria. Mean age was 44.8 years, 64.7% were women; 33.0% received DOAC only, 51.8% received warfarin only, and 15.1% received both treatments at different times. During a median follow-up of 345 (interquartile range, 140–720) days, there were 5.68 recurrent venous thrombosis, 3.77 major hemorrhages, and 1.84 deaths per 100 patient-years. Among 525 patients who met recanalization analysis inclusion criteria, 36.6% had complete, 48.2% had partial, and 15.2% had no recanalization. When compared with warfarin, DOAC treatment was associated with similar risk of recurrent venous thrombosis (aHR, 0.94 [95% CI, 0.51–1.73]; P =0.84), death (aHR, 0.78 [95% CI, 0.22–2.76]; P =0.70), and rate of partial/complete recanalization (aOR, 0.92 [95% CI, 0.48–1.73]; P =0.79), but a lower risk of major hemorrhage (aHR, 0.35 [95% CI, 0.15–0.82]; P =0.02). Conclusions: In patients with CVT, treatment with DOACs was associated with similar clinical and radiographic outcomes and favorable safety profile when compared with warfarin treatment. Our findings need confirmation by large prospective or randomized studies.;,citation_author=Shadi Yaghi;,citation_author=Liqi Shu;,citation_author=Ekaterina Bakradze;,citation_author=Setareh Salehi Omran;,citation_author=James A. Giles;,citation_author=Jordan Y. Amar;,citation_author=Nils Henninger;,citation_author=Marwa Elnazeir;,citation_author=Ava L. Liberman;,citation_author=Khadean Moncrieffe;,citation_author=Jenny Lu;,citation_author=Richa Sharma;,citation_author=Yee Cheng;,citation_author=Adeel S. Zubair;,citation_author=Alexis N. Simpkins;,citation_author=Grace T. Li;,citation_author=Justin Chi Kung;,citation_author=Dezaray Perez;,citation_author=Mirjam Heldner;,citation_author=Adrian Scutelnic;,citation_author=David Seiffge;,citation_author=Bernhard Siepen;,citation_author=Aaron Rothstein;,citation_author=Ossama Khazaal;,citation_author=David Do;,citation_author=Sami Al Kasab;,citation_author=Line Abdul Rahman;,citation_author=Eva A. Mistry;,citation_author=Deborah Kerrigan;,citation_author=Hayden Lafever;,citation_author=Thanh N. Nguyen;,citation_author=Piers Klein;,citation_author=Hugo Aparicio;,citation_author=Jennifer Frontera;,citation_author=Lindsey Kuohn;,citation_author=Shashank Agarwal;,citation_author=Christoph Stretz;,citation_author=Narendra Kala;,citation_author=Sleiman El Jamal;,citation_author=Alison Chang;,citation_author=Shawna Cutting;,citation_author=Han Xiao;,citation_author=Adam Havenon;,citation_author=Varsha Muddasani;,citation_author=Teddy Wu;,citation_author=Duncan Wilson;,citation_author=Amre Nouh;,citation_author=Syed Daniyal Asad;,citation_author=Abid Qureshi;,citation_author=Justin Moore;,citation_author=Pooja Khatri;,citation_author=Yasmin Aziz;,citation_author=Bryce Casteigne;,citation_author=Muhib Khan;,citation_author=Yao Cheng;,citation_author=Brian Mac Grory;,citation_author=Martin Weiss;,citation_author=Dylan Ryan;,citation_author=Maria Cristina Vedovati;,citation_author=Maurizio Paciaroni;,citation_author=James E. Siegler;,citation_author=Scott Kamen;,citation_author=Siyuan Yu;,citation_author=Christopher R. Leon Guerrero;,citation_author=Eugenie Atallah;,citation_author=Gian Marco De Marchis;,citation_author=Alex Brehm;,citation_author=Tolga Dittrich;,citation_author=Marios Psychogios;,citation_author=Ronald Alvarado-Dyer;,citation_author=Tareq Kass-Hout;,citation_author=Shyam Prabhakaran;,citation_author=Tristan Honda;,citation_author=David S. Liebeskind;,citation_author=Karen Furie;,citation_publication_date=2022-03;,citation_cover_date=2022-03;,citation_year=2022;,citation_issue=3;,citation_doi=10.1161/STROKEAHA.121.037541;,citation_issn=0039-2499, 1524-4628;,citation_volume=53;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=Analysis of Epinephrine Dose, Targeted Temperature Management, and Neurologic and Survival Outcomes Among Adults With Out-of-Hospital Cardiac Arrest;,citation_abstract=OBJECTIVE To examine whether targeted temperature management (TTM) modifies the adverse association between increasing prehospital epinephrine dose and neurologically favorable survival. DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study assessed 14 612 adults from Seattle and King County, Washington, with nontraumatic OHCA between January 1, 2008, and December 31, 2018, and included those who achieved return of spontaneous circulation and were unconscious at hospital admission. Data analysis was performed from April 2021 to May 2022. EXPOSURES Epinephrine dose and TTM during prehospital resuscitation. MAIN OUTCOMES AND MEASURES Favorable neurologic survival (Cerebral Performance Category [CPC] 1 or 2) and survival to hospital discharge. RESULTS Of the 14 612 assessed adults, 5253 (median age, 63 years; IQR, 51-74 years; 3460 [65.8%] male) were eligible for the study. The median epinephrine dose was 2.0 mg (IQR, 1.0-3.0 mg); 3052 patients (58.1%) received TTM. In all, 1889 patients (36.0%) survived with CPC 1 to 2, and 2177 (41.4%) survived to discharge. Increasing doses of epinephrine were associated with a decreasing likelihood of CPC 1 to 2 (odds ratio [OR], 0.46; 95% CI 0.42-0.50 for each additional milligram of epinephrine) and survival (OR, 0.47; 95% CI, 0.43-0.51). The dose-dependent epinephrine association was modified by TTM. After adjusting for Utstein covariates, TTM was associated with a relative stepwise improvement in odds of CPC 1 to 2 (interaction OR, 1.36; 95% CI, 1.22-1.51) and survival (interaction OR, 1.37; 95% CI, 1.24-1.51). A significant interaction was also observed when the analysis was stratified according to initial rhythm among shockable OHCA and nonshockable OHCA (shockable interaction OR, 1.20; 95% CI, 1.04-1.39; and nonshockable interaction OR, 1.24, 95% CI, 1.07-1.45). CONCLUSIONS AND RELEVANCE This cohort study found an interaction between TTM and epinephrine dose such that the beneficial association of TTM increased with increasing epinephrine dose, suggesting that TTM may attenuate the adverse effects of higher-dose epinephrine.;,citation_author=Betty Y. Yang;,citation_author=Natalie Bulger;,citation_author=Richard Chocron;,citation_author=Catherine R. Counts;,citation_author=Chris Drucker;,citation_author=Lihua Yin;,citation_author=Megin Parayil;,citation_author=Nicholas J. Johnson;,citation_author=Nona Sotoodehenia;,citation_author=Peter J. Kudenchuk;,citation_author=Michael R. Sayre;,citation_author=Thomas D. Rea;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_issue=8;,citation_doi=10.1001/jamanetworkopen.2022.26191;,citation_issn=2574-3805;,citation_volume=5;,citation_language=en-US;,citation_journal_title=JAMA Network Open;">
<meta name="citation_reference" content="citation_title=Corticosteroids for the treatment of human infection with influenza virus: A systematic review and meta-analysis;,citation_abstract=Administration of corticosteroids to patients affected by influenza virus, especially pandemic avian influenza virus, although relatively common, remains controversial. A systematic review and meta-analysis was performed to assess the impact of corticosteroid treatment on outcomes of patients with influenza virus infection. The PubMed, EMBASE, Web of Science and Cochrane Library databases were searched up to February, 2015. Studies comparing corticosteroid treatment with no corticosteroid treatment in patients with influenza virus infection were included. The primary outcomes assessed were the association of mortality and nosocomial infection with corticosteroid treatment. Two authors independently extracted the data. ORs and weighted mean differences (WMDs) were used to describe dichotomous data and continuous data, respectively. Nineteen studies with 4916 patients were included in this meta-analysis. The results showed that corticosteroid treatment was significantly associated with mortality (OR 1.98, 95% CI 1.62-2.43, p &amp;amp;amp;lt; 0.00001) and nosocomial infection (OR 3.16, 95% CI 2.09-4.78, p &amp;lt; 0.00001). The durations of mechanical ventilation (WMD 3.82, 95% CI 1.49-6.15, p 0.001) and intensive-care unit stay (WMD 4.78, 95% CI 2.27-7.29, p 0.0002) were both markedly longer in the corticosteroid treatment group than in the control group. These findings suggest that routine steroid use may not be ideal for influenza virus infection. However, these results are derived from observational studies, with some important biases. They should be examined in future sufficiently powered randomized trials.;,citation_author=J.-W. Yang;,citation_author=L.-C. Fan;,citation_author=X.-Y. Miao;,citation_author=B. Mao;,citation_author=M.-H. Li;,citation_author=H.-W. Lu;,citation_author=S. Liang;,citation_author=J.-F. Xu;,citation_publication_date=2015-10;,citation_cover_date=2015-10;,citation_year=2015;,citation_issue=10;,citation_doi=10.1016/j.cmi.2015.06.022;,citation_issn=1469-0691;,citation_pmid=26123860;,citation_volume=21;,citation_language=en-US;,citation_journal_title=Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases;">
<meta name="citation_reference" content="citation_title=Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): A multicentre, open-label, blinded-endpoint, randomised controlled trial;,citation_abstract=Background The optimum systolic blood pressure after endovascular thrombectomy for acute ischaemic stroke is uncertain. We aimed to compare the safety and efficacy of blood pressure lowering treatment according to more intensive versus less intensive treatment targets in patients with elevated blood pressure after reperfusion with endovascular treatment. Methods We conducted an open-label, blinded-endpoint, randomised controlled trial at 44 tertiary-level hospitals in China. Eligible patients (aged \geq18 years) had persistently elevated systolic blood pressure (\geq140 mm Hg for &amp;amp;amp;gt;10 min) following successful reperfusion with endovascular thrombectomy for acute ischaemic stroke from any intracranial large-vessel occlusion. Patients were randomly assigned (1:1, by a central, web-based program with a minimisation algorithm) to more intensive treatment (systolic blood pressure target &amp;lt;120 mm Hg) or less intensive treatment (target 140–180 mm Hg) to be achieved within 1 h and sustained for 72 h. The primary efficacy outcome was functional recovery, assessed according to the distribution in scores on the modified Rankin scale (range 0 [no symptoms] to 6 [death]) at 90 days. Analyses were done according to the modified intention-to-treat principle. Efficacy analyses were performed with proportional odds logistic regression with adjustment for treatment allocation as a fixed effect, site as a random effect, and baseline prognostic factors, and included all randomly assigned patients who provided consent and had available data for the primary outcome. The safety analysis included all randomly assigned patients. The treatment effects were expressed as odds ratios (ORs). This trial is registered at ClinicalTrials.gov, NCT04140110, and the Chinese Clinical Trial Registry, 1900027785; recruitment has stopped at all participating centres. Findings Between July 20, 2020, and March 7, 2022, 821 patients were randomly assigned. The trial was stopped after review of the outcome data on June 22, 2022, due to persistent efficacy and safety concerns. 407 participants were assigned to the more intensive treatment group and 409 to the less intensive treatment group, of whom 404 patients in the more intensive treatment group and 406 patients in the less intensive treatment group had primary outcome data available. The likelihood of poor functional outcome was greater in the more intensive treatment group than the less intensive treatment group (common OR 1\cdot37 [95% CI 1\cdot07–1\cdot76]). Compared with the less intensive treatment group, the more intensive treatment group had more early neurological deterioration (common OR 1\cdot53 [95% 1\cdot18–1\cdot97]) and major disability at 90 days (OR 2\cdot07 [95% CI 1\cdot47–2\cdot93]) but there were no significant differences in symptomatic intracerebral haemorrhage. There were no significant differences in serious adverse events or mortality between groups. Interpretation Intensive control of systolic blood pressure to lower than 120 mm Hg should be avoided to prevent compromising the functional recovery of patients who have received endovascular thrombectomy for acute ischaemic stroke due to intracranial large-vessel occlusion. Funding The Shanghai Hospital Development Center; National Health and Medical Research Council of Australia; Medical Research Futures Fund of Australia; China Stroke Prevention; Shanghai Changhai Hospital, Science and Technology Commission of Shanghai Municipality; Takeda China; Hasten Biopharmaceutic; Genesis Medtech; Penumbra.;,citation_author=Pengfei Yang;,citation_author=Lili Song;,citation_author=Yongwei Zhang;,citation_author=Xiaoxi Zhang;,citation_author=Xiaoying Chen;,citation_author=Yunke Li;,citation_author=Lingli Sun;,citation_author=Yingfeng Wan;,citation_author=Laurent Billot;,citation_author=Qiang Li;,citation_author=Xinwen Ren;,citation_author=Hongjian Shen;,citation_author=Lei Zhang;,citation_author=Zifu Li;,citation_author=Pengfei Xing;,citation_author=Yongxin Zhang;,citation_author=Ping Zhang;,citation_author=Weilong Hua;,citation_author=Fang Shen;,citation_author=Yihan Zhou;,citation_author=Bing Tian;,citation_author=Wenhuo Chen;,citation_author=Hongxing Han;,citation_author=Liyong Zhang;,citation_author=Chenghua Xu;,citation_author=Tong Li;,citation_author=Ya Peng;,citation_author=Xincan Yue;,citation_author=Shengli Chen;,citation_author=Changming Wen;,citation_author=Shu Wan;,citation_author=Congguo Yin;,citation_author=Ming Wei;,citation_author=Hansheng Shu;,citation_author=Guangxian Nan;,citation_author=Sheng Liu;,citation_author=Wenhua Liu;,citation_author=Yiling Cai;,citation_author=Yi Sui;,citation_author=Maohua Chen;,citation_author=Yu Zhou;,citation_author=Qiao Zuo;,citation_author=Dongwei Dai;,citation_author=Rui Zhao;,citation_author=Qiang Li;,citation_author=Qinghai Huang;,citation_author=Yi Xu;,citation_author=Benqiang Deng;,citation_author=Tao Wu;,citation_author=Jianping Lu;,citation_author=Xia Wang;,citation_author=Mark W Parsons;,citation_author=Ken Butcher;,citation_author=Bruce Campbell;,citation_author=Thompson G Robinson;,citation_author=Mayank Goyal;,citation_author=Diederik Dippel;,citation_author=Yvo Roos;,citation_author=Charles Majoie;,citation_author=Longde Wang;,citation_author=Yongjun Wang;,citation_author=Jianmin Liu;,citation_author=Craig S Anderson;,citation_publication_date=2022-11;,citation_cover_date=2022-11;,citation_year=2022;,citation_issue=10363;,citation_doi=10.1016/S0140-6736(22)01882-7;,citation_issn=0140-6736;,citation_volume=400;,citation_language=en-US;,citation_journal_title=The Lancet;">
<meta name="citation_reference" content="citation_title=The need for reporting guidelines for early phase dose-finding trials: Dose-Finding CONSORT Extension;,citation_author=Christina Yap;,citation_author=Alun Bedding;,citation_author=Johann Bono;,citation_author=Munyaradzi Dimairo;,citation_author=Aude Espinasse;,citation_author=Jeffry Evans;,citation_author=Sally Hopewell;,citation_author=Thomas Jaki;,citation_author=Andrew Kightley;,citation_author=Shing Lee;,citation_author=Rong Liu;,citation_author=Adrian Mander;,citation_author=Olga Solovyeva;,citation_author=Christopher J. Weir;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=1;,citation_doi=10.1038/s41591-021-01594-1;,citation_issn=1078-8956, 1546-170X;,citation_volume=28;,citation_language=en-US;,citation_journal_title=Nature Medicine;">
<meta name="citation_reference" content="citation_title=Bayesian Analysis in Critical Care Medicine;,citation_author=Christopher J. Yarnell;,citation_author=John T. Granton;,citation_author=George Tomlinson;,citation_publication_date=2020-02;,citation_cover_date=2020-02;,citation_year=2020;,citation_issue=4;,citation_doi=10.1164/rccm.201910-2019ED;,citation_issn=1073-449X, 1535-4970;,citation_volume=201;,citation_language=en-US;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Clinical trials in critical care: Can a Bayesian approach enhance clinical and scientific decision making?;,citation_author=Christopher J Yarnell;,citation_author=Darryl Abrams;,citation_author=Matthew R Baldwin;,citation_author=Daniel Brodie;,citation_author=Eddy Fan;,citation_author=Niall D Ferguson;,citation_author=May Hua;,citation_author=Purnema Madahar;,citation_author=Danny F McAuley;,citation_author=Laveena Munshi;,citation_author=Gavin D Perkins;,citation_author=Gordon Rubenfeld;,citation_author=Arthur S Slutsky;,citation_author=Hannah Wunsch;,citation_author=Robert A Fowler;,citation_author=George Tomlinson;,citation_author=Jeremy R Beitler;,citation_author=Ewan C Goligher;,citation_publication_date=2021-02;,citation_cover_date=2021-02;,citation_year=2021;,citation_issue=2;,citation_doi=10.1016/S2213-2600(20)30471-9;,citation_issn=22132600;,citation_volume=9;,citation_language=en-US;,citation_journal_title=The Lancet Respiratory Medicine;">
<meta name="citation_reference" content="citation_title=Interpreting posterior probabilities in Bayesian analyses of clinical trials;,citation_author=Christopher J Yarnell;,citation_author=Ewan C Goligher;,citation_publication_date=2023-11;,citation_cover_date=2023-11;,citation_year=2023;,citation_doi=10.1016/S2213-2600(23)00459-9;,citation_issn=22132600;,citation_language=en-US;,citation_journal_title=The Lancet Respiratory Medicine;">
<meta name="citation_reference" content="citation_title=Effects of Influenza Vaccine on Mortality and Cardiovascular Outcomes in Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis;,citation_abstract=BACKGROUND: Influenza infection causes considerable morbidity and mortality in patients with cardiovascular disease. We assessed the effects of the influenza vaccine on mortality and cardiovascular outcomes in patients with cardiovascular disease. METHODS AND RESULTS: We searched PubMed, Embase, and the Cochrane Library through January 2020 for randomized controlled trials and observational studies assessing the effects of influenza vaccine on mortality and cardiovascular outcomes in patients with cardiovascular disease. Estimates were reported as random effects risk ratios (RRs) with 95% CIs. Analyses were stratified by study design into randomized controlled trials and observational studies. A total of 16 studies (n=237 058), including 4 randomized controlled trials (n=1667) and 12 observational studies (n=235 391), were identified. Participants’ mean age was 69.27.01 years, 36.6% were women, 65.1% had hypertension, 31.1% had diabetes mellitus, and 23.4% were smokers. At a median follow-up duration of 19.5 months, influenza vaccine was associated with a lower risk of all-cause mortality (RR, 0.75; 95% CI, 0.60– [P=0.01]), cardiovascular mortality (RR, 0.82; 95% CI, 0.80– [P&amp;amp;amp;lt;0.001]), and major adverse cardiovascular events (RR, 0.87; 95% CI, 0.80– [P&amp;lt;0.001]) compared with control. The use of the influenza vaccine was not associated with a statistically significant reduction of myocardial infarction (RR, 0.73; 95% CI, 0.49– [P=0.12]) compared with control. CONCLUSIONS: Data from both randomized controlled trials and observational studies support the use of the influenza vaccine in adults with cardiovascular disease to reduce mortality and cardiovascular events, as currently supported by clinical guidelines. Clinicians and health systems should continue to promote the influenza vaccine as part of comprehensive secondary prevention.;,citation_author=Siva H. Yedlapati;,citation_author=Safi U. Khan;,citation_author=Swapna Talluri;,citation_author=Ahmed N. Lone;,citation_author=Muhammad Zia Khan;,citation_author=Muhammad Shahzeb Khan;,citation_author=Ann M. Navar;,citation_author=Martha Gulati;,citation_author=Heather Johnson;,citation_author=Seth Baum;,citation_author=Erin D. Michos;,citation_publication_date=2021-03;,citation_cover_date=2021-03;,citation_year=2021;,citation_issue=6;,citation_doi=10.1161/JAHA.120.019636;,citation_issn=2047-9980;,citation_volume=10;,citation_language=en-US;,citation_journal_title=Journal of the American Heart Association;">
<meta name="citation_reference" content="citation_title=Bringing the Credibility Revolution to Observational Research in Cardiology;,citation_author=Robert W. Yeh;,citation_publication_date=2023-08;,citation_cover_date=2023-08;,citation_year=2023;,citation_issue=6;,citation_doi=10.1161/CIRCULATIONAHA.123.064645;,citation_volume=148;,citation_journal_title=Circulation;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=Parachute use to prevent death and major trauma when jumping from aircraft: Randomized controlled trial;,citation_abstract=Objective To determine if using a parachute prevents death or major traumatic injury when jumping from an aircraft. Design Randomized controlled trial. Setting Private or commercial aircraft between September 2017 and August 2018. Participants 92 aircraft passengers aged 18 and over were screened for participation. 23 agreed to be enrolled and were randomized. Intervention Jumping from an aircraft (airplane or helicopter) with a parachute versus an empty backpack (unblinded). Main outcome measures Composite of death or major traumatic injury (defined by an Injury Severity Score over 15) upon impact with the ground measured immediately after landing. Results Parachute use did not significantly reduce death or major injury (0% for parachute v 0% for control; P&amp;amp;amp;gt;0.9). This finding was consistent across multiple subgroups. Compared with individuals screened but not enrolled, participants included in the study were on aircraft at significantly lower altitude (mean of 0.6 m for participants v mean of 9146 m for non-participants; P&amp;lt;0.001) and lower velocity (mean of 0 km/h v mean of 800 km/h; P&amp;lt;0.001). Conclusions Parachute use did not reduce death or major traumatic injury when jumping from aircraft in the first randomized evaluation of this intervention. However, the trial was only able to enroll participants on small stationary aircraft on the ground, suggesting cautious extrapolation to high altitude jumps. When beliefs regarding the effectiveness of an intervention exist in the community, randomized trials might selectively enroll individuals with a lower perceived likelihood of benefit, thus diminishing the applicability of the results to clinical practice.;,citation_author=Robert W. Yeh;,citation_author=Linda R. Valsdottir;,citation_author=Michael W. Yeh;,citation_author=Changyu Shen;,citation_author=Daniel B. Kramer;,citation_author=Jordan B. Strom;,citation_author=Eric A. Secemsky;,citation_author=Joanne L. Healy;,citation_author=Robert M. Domeier;,citation_author=Dhruv S. Kazi;,citation_author=Brahmajee K. Nallamothu;,citation_publication_date=2018-12;,citation_cover_date=2018-12;,citation_year=2018;,citation_doi=10.1136/bmj.k5094;,citation_issn=0959-8138, 1756-1833;,citation_pmid=30545967;,citation_volume=363;,citation_language=en-US;,citation_journal_title=BMJ;,citation_publisher=British Medical Journal Publishing Group;">
<meta name="citation_reference" content="citation_title=Peri-operative management of patients with Parkinson’s disease;,citation_abstract=Patients with Parkinson’s disease are at higher risk of peri-operative medical and surgical complications. Multidisciplinary management, early recognition of potential complications, specialised care of medications and intra-operative protection of the vulnerable brain are all important aspects of the peri-operative management of patients with Parkinson’s disease. Advances in continuous dopaminergic treatment, development of a peri-operative Parkinson’s disease pathway and application of telemedicine are starting to play a role in improving peri-operative care. Management of patients with advanced Parkinson’s disease is also evolving, with potential for incorporation of integrated care and changes in the anaesthetic management for deep brain stimulation surgery. There are new methods for localisation of target nuclei and increasing insight on the effects of anaesthetic drugs on microelectrode recordings and clinical outcomes. Parkinson’s disease is a progressive disease, but management is improving with better perioperative care for patients.;,citation_author=R. L. H. Yim;,citation_author=K. M. M. Leung;,citation_author=C. C. M. Poon;,citation_author=M. G. Irwin;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=S1;,citation_doi=10.1111/anae.15617;,citation_issn=0003-2409, 1365-2044;,citation_volume=77;,citation_language=en-US;,citation_journal_title=Anaesthesia;">
<meta name="citation_reference" content="citation_title=Hematoma Expansion Shift Analysis to Assess Acute Intracerebral Hemorrhage Treatments;,citation_abstract=Objective Hematoma expansion (HE) is commonly analyzed as a dichotomous outcome in intracerebral hemorrhage (ICH) trials. In this proof-of-concept study, we propose an HE shift analysis model as a method to improve the evaluation of candidate ICH therapies. Methods Using data from the Antihypertensive Treatment of Acute Cerebral Hemorrhage II (ATACH2) trial, we performed HE shift analysis in response to intensive blood pressure lowering by generating polychotomous strata based on previously established HE definitions, percentile/ absolute quartiles of hematoma volume change, and quartiles of 24-hour follow-up hematoma volumes. The relationship between blood pressure treatment and HE shift was explored with proportional odds models. Results The primary analysis population included 863 patients. In both treatment groups, approximately one-third of patients exhibited no HE. With the use of a trichotomous HE stratification, the highest strata of \geq33% revealed a 5.8% reduction in hematoma growth for those randomized to intensive therapy (adjusted odds ratio [aOR] 0.77, 95% confidence interval [CI] 0.60–0.99). Using percentile quartiles of hematoma volume change, we observed a favorable shift to reduce growth in patients treated with intensive therapy (aOR 0.73, 95% CI 0.57–0.93). Similarly, in a tetrachotomous analysis of 24-hour follow-up hematoma volumes, shifts in the highest stratum (&amp;amp;amp;gt;21.9 mL) were most notable. Conclusions Our findings suggest that intensive blood pressure reduction may preferentially mitigate growth in patients at risk of high volume HE. A shift analysis model of HE provides additional insights into the biological effects of a given therapy and may be an additional way to assess hemostatic agents in future studies.;,citation_author=Vignan Yogendrakumar;,citation_author=Tim Ramsay;,citation_author=Bijoy K. Menon;,citation_author=Adnan I. Qureshi;,citation_author=Jeffrey L. Saver;,citation_author=Dar Dowlatshahi;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_issue=8;,citation_doi=10.1212/WNL.0000000000012393;,citation_issn=0028-3878, 1526-632X;,citation_volume=97;,citation_language=en-US;,citation_journal_title=Neurology;">
<meta name="citation_reference" content="citation_title=Tenecteplase Improves Reperfusion across Time in Large Vessel Stroke;,citation_abstract=Objective Tenecteplase improves reperfusion compared to alteplase in patients with large vessel occlusions. To determine whether this improvement varies across the spectrum of thrombolytic agent to reperfusion assessment times, we performed a comparative analysis of tenecteplase and alteplase reperfusion rates. Methods Patients with large vessel occlusion and treatment with thrombolysis were pooled from the Melbourne Stroke Registry, and the EXTEND-IA and EXTEND-IA TNK trials. The primary outcome, thrombolytic-induced reperfusion, was defined as the absence of retrievable thrombus or &amp;amp;amp;gt;50% reperfusion at imaging reassessment. We compared the treatment effect of tenecteplase and alteplase, accounting for thrombolytic to assessment exposure times, via Poisson modeling. We compared 90-day outcomes of patients who achieved reperfusion with a thrombolytic to patients who achieved reperfusion via endovascular therapy using ordinal logistic regression. Results Among 893 patients included in the primary analysis, thrombolytic-induced reperfusion was observed in 184 (21%) patients. Tenecteplase was associated with higher rates of reperfusion (adjusted incidence rate ratio [aIRR] = 1.50, 95% confidence interval [CI] = 1.09–2.07, p = 0.01). Findings were consistent in patient subgroups with first segment (aIRR = 1.41, 95% CI = 0.93–2.14) and second segment (aIRR = 2.07, 95% CI = 0.98–4.37) middle cerebral artery occlusions. Increased thrombolytic to reperfusion assessment times were associated with reperfusion (tenecteplase: adjusted risk ratio [aRR] = 1.08 per 15 minutes, 95% CI = 1.04–1.13 vs alteplase: aRR = 1.06 per 15 minutes, 95% CI = 1.00–1.13). No significant treatment-by-time interaction was observed (p = 0.87). Reperfusion via thrombolysis was associated with improved 90-day modified Rankin Scale scores (adjusted common odds ratio = 2.15, 95% CI = 1.54–3.01) compared to patients who achieved reperfusion following endovascular therapy. Interpretation Tenecteplase, compared to alteplase, increases prethrombectomy reperfusion, regardless of the time from administration to reperfusion assessment. Prethrombectomy reperfusion is associated with better clinical outcomes. ANN NEUROL 2023;93:489–499;,citation_author=Vignan Yogendrakumar;,citation_author=James Beharry;,citation_author=Leonid Churilov;,citation_author=Khairunnisa Alidin;,citation_author=Melissa Ugalde;,citation_author=Lauren Pesavento;,citation_author=Louise Weir;,citation_author=Peter J. Mitchell;,citation_author=Timothy J. Kleinig;,citation_author=Nawaf Yassi;,citation_author=Vincent Thijs;,citation_author=Teddy Y. Wu;,citation_author=Darshan G. Shah;,citation_author=Helen M. Dewey;,citation_author=Tissa Wijeratne;,citation_author=Bernard Yan;,citation_author=Patricia M. Desmond;,citation_author=Gagan Sharma;,citation_author=Mark W. Parsons;,citation_author=Geoffrey A. Donnan;,citation_author=Stephen M. Davis;,citation_author=Bruce C. V. Campbell;,citation_author=for the Royal Melbourne Stroke Registry and EXTEND-IA TNK Collaborators;,citation_publication_date=2023;,citation_cover_date=2023;,citation_year=2023;,citation_issue=3;,citation_doi=10.1002/ana.26547;,citation_issn=1531-8249;,citation_volume=93;,citation_language=en-US;,citation_journal_title=Annals of Neurology;">
<meta name="citation_reference" content="citation_title=Tenecteplase Treatment and Thrombus Characteristics Associated With Early Reperfusion: An EXTEND-IA TNK Trials Analysis;,citation_abstract=Background: Intracranial occlusion site, contrast permeability, and clot burden are thrombus characteristics that influence alteplase-associated reperfusion. In this study, we assessed the reperfusion efficacy of tenecteplase and alteplase in subgroups based on these characteristics in a pooled analysis of the EXTEND-IA TNK trial (Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke). Methods: Patients with large vessel occlusion were randomized to treatment with tenecteplase (0.25 or 0.4 mg/kg) or alteplase before thrombectomy in hospitals across Australia and New Zealand (2015–2019). The primary outcome, early reperfusion, was defined as the absence of retrievable thrombus or &amp;amp;amp;gt;50% reperfusion on first-pass angiogram. We compared the effect of tenecteplase versus alteplase overall, and in subgroups, based on the following measured with computed tomography angiography: intracranial occlusion site, contrast permeability (measured via residual flow grades), and clot burden (measured via clot burden scores). We adjusted for covariates using mixed effects logistic regression models. Results: Tenecteplase was associated with higher odds of early reperfusion (75/369 [20%] versus alteplase: 9/96 [9%], adjusted odds ratio [aOR], 2.18 [95% CI, 1.03–4.63]). The difference between thrombolytics was notable in occlusions with low clot burden (tenecteplase: 66/261 [25%] versus alteplase: 5/67 [7%], aOR, 3.93 [95% CI, 1.50–10.33]) when compared to high clot burden lesions (tenecteplase: 9/108 [8%] versus alteplase: 4/29 [14%], aOR, 0.58 [95% CI, 0.16–2.06]; Pinteraction=0.01). We did not observe an association between contrast permeability and tenecteplase treatment effect (permeability present: aOR, 2.83 [95% CI, 1.00–8.05] versus absent: aOR, 1.98 [95% CI, 0.65–6.03]; Pinteraction=0.62). Tenecteplase treatment effect was superior with distal M1 or M2 occlusions (53/176 [30%] versus alteplase: 4/42 [10%], aOR, 3.73 [95% CI, 1.25–11.11]), but both thrombolytics had limited efficacy with internal carotid artery occlusions (tenecteplase 1/73 [1%] versus alteplase 1/19 [5%], aOR, 0.22 [95% CI, 0.01–3.83]; Pinteraction=0.16). Conclusions: Tenecteplase demonstrates superior early reperfusion versus alteplase in lesions with low clot burden. Reperfusion efficacy remains limited in internal carotid artery occlusions and lesions with high clot burden. Further innovation in thrombolytic therapies are required.;,citation_author=Vignan Yogendrakumar;,citation_author=Leonid Churilov;,citation_author=Prodipta Guha;,citation_author=James Beharry;,citation_author=Peter J. Mitchell;,citation_author=Timothy J. Kleinig;,citation_author=Nawaf Yassi;,citation_author=Vincent Thijs;,citation_author=Teddy Y. Wu;,citation_author=Helen Brown;,citation_author=Helen M. Dewey;,citation_author=Tissa Wijeratne;,citation_author=Bernard Yan;,citation_author=Gagan Sharma;,citation_author=Patricia M. Desmond;,citation_author=Mark W. Parsons;,citation_author=Geoffrey A. Donnan;,citation_author=Stephen M. Davis;,citation_author=Bruce C. V. Campbell;,citation_author=Richard Dowling;,citation_author=Steven Bush;,citation_author=Rebecca Scroop;,citation_author=Mark Brooks;,citation_author=Hamed Asadi;,citation_author=Timothy Ang;,citation_author=Ferdinand Miteff;,citation_author=Christopher Levi;,citation_author=Henry Zhao;,citation_author=Felix Ng;,citation_author=Fana Alemseged;,citation_author=Henry Rice;,citation_author=Laetitia Villiers;,citation_author=Kendal Redmond;,citation_author=David Leggett;,citation_publication_date=2023-03;,citation_cover_date=2023-03;,citation_year=2023;,citation_issue=3;,citation_doi=10.1161/STROKEAHA.122.041061;,citation_volume=54;,citation_journal_title=Stroke;,citation_publisher=American Heart Association;">
<meta name="citation_reference" content="citation_title=Eastern Association for the Surgery of Trauma Multicenter Trial: Comparison of pre-injury antithrombotic use and reversal strategies among severe traumatic brain injury patients;,citation_abstract=BACKGROUND: Trauma teams are often faced with patients on antithrombotic (AT) drugs, which is challenging when bleeding occurs. We sought to compare the effects of different AT medications on head injury severity and hypothesized that AT reversal would not improve mortality in severe traumatic brain injury (TBI) patients. METHODS: An Eastern Association for the Surgery of Trauma–sponsored prospective, multicentered, observational study of 15 trauma centers was performed. Patient demographics, injury burden, comorbidities, AT agents, and reversal attempts were collected. Outcomes of interest were head injury severity and in-hospital mortality. RESULTS: Analysis was performed on 2,793 patients. The majority of patients were on aspirin (acetylsalicylic acid [ASA], 46.1%). Patients on a platelet chemoreceptor blocker (P2Y12) had the highest mean Injury Severity Score (9.1  8.1). Patients taking P2Y12 inhibitors  ASA, and ASA-warfarin had the highest head Abbreviated Injury Scale (AIS) mean (1.2  1.6). On risk-adjusted analysis, warfarin-ASA was associated with a higher head AIS (odds ratio [OR], 2.43; 95% confidence interval [CI], 1.34–4.42) after controlling for Injury Severity Score, Charlson Comorbidity Index, initial Glasgow Coma Scale score, and initial systolic blood pressure. Among patients with severe TBI (head AIS score, \geq3) on antiplatelet therapy, reversal with desmopressin (DDAVP) and/or platelet transfusion did not improve survival (82.9% reversal vs. 90.4% none, p = 0.30). In severe TBI patients taking Xa inhibitors who received prothrombin complex concentrate, survival was not improved (84.6% reversal vs. 84.6% none, p = 0.68). With risk adjustment as described previously, mortality was not improved with reversal attempts (antiplatelet agents: OR 0.83; 85% CI, 0.12–5.9 [p = 0.85]; Xa inhibitors: OR, 0.76; 95% CI, 0.12–4.64; p = 0.77). CONCLUSION:;,citation_author=Brian K. Yorkgitis;,citation_author=Danielle M. Tatum;,citation_author=Sharven Taghavi;,citation_author=Thomas J. Schroeppel;,citation_author=Matthew R. Noorbakhsh;,citation_author=Frances Hite Philps;,citation_author=Nikolay Bugaev;,citation_author=Kaushik Mukherjee;,citation_author=Mellody Bellora;,citation_author=Adrian W. Ong;,citation_author=Asanthi Ratnasekera;,citation_author=Kristen D. Nordham;,citation_author=Matthew M. Carrick;,citation_author=James M. Haan;,citation_author=Kelly L. Lightwine;,citation_author=Lawrence Lottenberg;,citation_author=Robert Borrego;,citation_author=Daniel C. Cullinane;,citation_author=John D. Berne;,citation_author=Dalier Rodriguez Mederos;,citation_author=Thomas Z. Hayward;,citation_author=Andy J. Kerwin;,citation_author=Marie Crandall;,citation_publication_date=2022-01;,citation_cover_date=2022-01;,citation_year=2022;,citation_issue=1;,citation_doi=10.1097/TA.0000000000003421;,citation_issn=2163-0763, 2163-0755;,citation_volume=92;,citation_language=en-US;,citation_journal_title=Journal of Trauma and Acute Care Surgery;">
<meta name="citation_reference" content="citation_title=Endovascular Therapy for Acute Stroke with a Large Ischemic Region;,citation_abstract=BACKGROUND Endovascular therapy for acute ischemic stroke is generally avoided when the infarction is large, but the effect of endovascular therapy with medical care as compared with medical care alone for large strokes has not been well studied. METHODS We conducted a multicenter, open-label, randomized clinical trial in Japan involving patients with occlusion of large cerebral vessels and sizable strokes on imaging, as indicated by an Alberta Stroke Program Early Computed Tomographic Score (ASPECTS) value of 3 to 5 (on a scale from 0 to 10, with lower values indicating larger infarction). Patients were randomly assigned in a 1:1 ratio to receive endovascular therapy with medical care or medical care alone within 6 hours after they were last known to be well or within 24 hours if there was no early change on fluid-attenuated inversion recovery images. Alteplase (0.6 mg per kilogram of body weight) was used when appropriate in both groups. The primary outcome was a modified Rankin scale score of 0 to 3 (on a scale from 0 to 6, with higher scores indicating greater disability) at 90 days. Secondary outcomes included a shift across the range of modified Rankin scale scores toward a better outcome at 90 days and an improvement of at least 8 points in the National Institutes of Health Stroke Scale (NIHSS) score (range, 0 to 42, with higher scores indicating greater deficit) at 48 hours. The authors’ full names, academic degrees, and affiliations are listed in the Appendix. Dr. Morimoto can be contacted at t-morimoto@umin.net or at the Department of Clinical Epidemiology, Hyogo College of Medicine, 1-1 Mukogawa, Nishinomiya, Hyogo 663-8501, Japan. This article was published on February 9, 2022, at NEJM.org. DOI: 10.1056/NEJMoa2118191 Copyright © 2022 Massachusetts Medical Society. RESULTS A total of 203 patients underwent randomization; 101 patients were assigned to the endovascular-therapy group and 102 to the medical-care group. Approximately 27% of patients in each group received alteplase. The percentage of patients with a modified Rankin scale score of 0 to 3 at 90 days was 31.0% in the endovasculartherapy group and 12.7% in the medical-care group (relative risk, 2.43; 95% confidence interval [CI], 1.35 to 4.37; P = 0.002). The ordinal shift across the range of modified Rankin scale scores generally favored endovascular therapy. An improvement of at least 8 points on the NIHSS score at 48 hours was observed in 31.0% of the patients in the endovascular-therapy group and 8.8% of those in the medical-care group (relative risk, 3.51; 95% CI, 1.76 to 7.00), and any intracranial hemorrhage occurred in 58.0% and 31.4%, respectively (P&amp;amp;amp;lt;0.001). CONCLUSIONS In a trial conducted in Japan, patients with large cerebral infarctions had better functional outcomes with endovascular therapy than with medical care alone but had more intracranial hemorrhages. (Funded by Mihara Cerebrovascular Disorder Research Promotion Fund and the Japanese Society for Neuroendovascular Therapy; RESCUE-Japan LIMIT ClinicalTrials.gov number, NCT03702413.);,citation_author=Shinichi Yoshimura;,citation_author=Nobuyuki Sakai;,citation_author=Hiroshi Yamagami;,citation_author=Kazutaka Uchida;,citation_author=Mikiya Beppu;,citation_author=Kazunori Toyoda;,citation_author=Yuji Matsumaru;,citation_author=Yasushi Matsumoto;,citation_author=Kazumi Kimura;,citation_author=Masataka Takeuchi;,citation_author=Yukako Yazawa;,citation_author=Naoto Kimura;,citation_author=Keigo Shigeta;,citation_author=Hirotoshi Imamura;,citation_author=Ichiro Suzuki;,citation_author=Yukiko Enomoto;,citation_author=So Tokunaga;,citation_author=Kenichi Morita;,citation_author=Fumihiro Sakakibara;,citation_author=Norito Kinjo;,citation_author=Takuya Saito;,citation_author=Reiichi Ishikura;,citation_author=Manabu Inoue;,citation_author=Takeshi Morimoto;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_doi=10.1056/NEJMoa2118191;,citation_issn=0028-4793, 1533-4406;,citation_language=en-US;,citation_journal_title=New England Journal of Medicine;">
<meta name="citation_reference" content="citation_title=Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D);,citation_abstract=Purpose Venous thromboembolism (VTE) is common in patients with cancer. Long-term daily subcutaneous low molecular weight heparin has been standard treatment for such patients. The purpose of this study was to assess if an oral factor Xa inhibitor, rivaroxaban, would offer an alternative treatment for VTE in patients with cancer. Patient and Methods In this multicenter, randomized, open-label, pilot trial in the United Kingdom, patients with active cancer who had symptomatic pulmonary embolism (PE), incidental PE, or symptomatic lower-extremity proximal deep vein thrombosis (DVT) were recruited. Allocation was to dalteparin (200 IU/kg daily during month 1, then 150 IU/kg daily for months 2-6) or rivaroxaban (15 mg twice daily for 3 weeks, then 20 mg once daily for a total of 6 months). The primary outcome was VTE recurrence over 6 months. Safety was assessed by major bleeding and clinically relevant nonmajor bleeding (CRNMB). A sample size of 400 patients would provide estimates of VTE recurrence to within  4.5%, assuming a VTE recurrence rate at 6 months of 10%. Results A total of 203 patients were randomly assigned to each group, 58% of whom had metastases. Twenty-six patients experienced recurrent VTE (dalteparin, n = 18; rivaroxaban, n = 8). The 6-month cumulative VTE recurrence rate was 11% (95% CI, 7% to 16%) with dalteparin and 4% (95% CI, 2% to 9%) with rivaroxaban (hazard ratio [HR], 0.43; 95% CI, 0.19 to 0.99). The 6-month cumulative rate of major bleeding was 4% (95% CI, 2% to 8%) for dalteparin and 6% (95% CI, 3% to 11%) for rivaroxaban (HR, 1.83; 95% CI, 0.68 to 4.96). Corresponding rates of CRNMB were 4% (95% CI, 2% to 9%) and 13% (95% CI, 9% to 19%), respectively (HR, 3.76; 95% CI, 1.63 to 8.69). Conclusion Rivaroxaban was associated with relatively low VTE recurrence but higher CRNMB compared with dalteparin.;,citation_author=Annie M. Young;,citation_author=Andrea Marshall;,citation_author=Jenny Thirlwall;,citation_author=Oliver Chapman;,citation_author=Anand Lokare;,citation_author=Catherine Hill;,citation_author=Danielle Hale;,citation_author=Janet A. Dunn;,citation_author=Gary H. Lyman;,citation_author=Charles Hutchinson;,citation_author=Peter MacCallum;,citation_author=Ajay Kakkar;,citation_author=F. D. Richard Hobbs;,citation_author=Stavros Petrou;,citation_author=Jeremy Dale;,citation_author=Christopher J. Poole;,citation_author=Anthony Maraveyas;,citation_author=Mark Levine;,citation_publication_date=2018-07;,citation_cover_date=2018-07;,citation_year=2018;,citation_issue=20;,citation_doi=10.1200/JCO.2018.78.8034;,citation_issn=0732-183X;,citation_volume=36;,citation_journal_title=Journal of Clinical Oncology;,citation_publisher=Wolters Kluwer;">
<meta name="citation_reference" content="citation_title=Conservative or liberal oxygen therapy for mechanically ventilated adults with acute brain pathologies: A post-hoc subgroup analysis;,citation_author=Paul J. Young;,citation_author=Diane Mackle;,citation_author=Carol Hodgson;,citation_author=Rinaldo Bellomo;,citation_author=Michael Bailey;,citation_author=Richard Beasley;,citation_author=Adam M. Deane;,citation_author=Glenn Eastwood;,citation_author=Simon Finfer;,citation_author=Ross Freebairn;,citation_author=Victoria King;,citation_author=Natalie Linke;,citation_author=Edward Litton;,citation_author=Colin McArthur;,citation_author=Shay McGuinness;,citation_author=Rakshit Panwar;,citation_publication_date=2022-10;,citation_cover_date=2022-10;,citation_year=2022;,citation_doi=10.1016/j.jcrc.2022.154079;,citation_issn=08839441;,citation_volume=71;,citation_language=en-US;,citation_journal_title=Journal of Critical Care;">
<meta name="citation_reference" content="citation_title=Effect of a Buffered Crystalloid Solution vs Saline on Acute Kidney Injury Among Patients in the Intensive Care Unit: The SPLIT Randomized Clinical Trial;,citation_abstract=Saline (0.9% sodium chloride) is the most commonly administered intravenous fluid; however, its use may be associated with acute kidney injury (AKI) and increased mortality.To determine the effect of a buffered crystalloid compared with saline on renal complications in patients admitted to the intensive care unit (ICU).Double-blind, cluster randomized, double-crossover trial conducted in 4 ICUs in New Zealand from April 2014 through October 2014. Three ICUs were general medical and surgical ICUs; 1 ICU had a predominance of cardiothoracic and vascular surgical patients.All patients admitted to the ICU requiring crystalloid fluid therapy were eligible for inclusion. Patients with established AKI requiring renal replacement therapy (RRT) were excluded. All 2278 eligible patients were enrolled; 1152 of 1162 patients (99.1%) receiving buffered crystalloid and 1110 of 1116 patients (99.5%) receiving saline were analyzed.Participating ICUs were assigned a masked study fluid, either saline or a buffered crystalloid, for alternating 7-week treatment blocks. Two ICUs commenced using 1 fluid and the other 2 commenced using the alternative fluid. Two crossovers occurred so that each ICU used each fluid twice over the 28 weeks of the study. The treating clinician determined the rate and frequency of fluid administration.The primary outcome was proportion of patients with AKI (defined as a rise in serum creatinine level of at least 2-fold or a serum creatinine level of \geq3.96 mg/dL with an increase of \geq0.5 mg/dL); main secondary outcomes were incidence of RRT use and in-hospital mortality.In the buffered crystalloid group, 102 of 1067 patients (9.6%) developed AKI within 90 days after enrollment compared with 94 of 1025 patients (9.2%) in the saline group (absolute difference, 0.4% [95% CI, -2.1% to 2.9%]; relative risk [RR], 1.04 [95% CI, 0.80 to 1.36]; P = .77). In the buffered crystalloid group, RRT was used in 38 of 1152 patients (3.3%) compared with 38 of 1110 patients (3.4%) in the saline group (absolute difference, -0.1% [95% CI, -1.6% to 1.4%]; RR, 0.96 [95% CI, 0.62 to 1.50]; P = .91). Overall, 87 of 1152 patients (7.6%) in the buffered crystalloid group and 95 of 1110 patients (8.6%) in the saline group died in the hospital (absolute difference, -1.0% [95% CI, -3.3% to 1.2%]; RR, 0.88 [95% CI, 0.67 to 1.17]; P = .40).Among patients receiving crystalloid fluid therapy in the ICU, use of a buffered crystalloid compared with saline did not reduce the risk of AKI. Further large randomized clinical trials are needed to assess efficacy in higher-risk populations and to measure clinical outcomes such as mortality.clinicaltrials.gov Identifier: ACTRN12613001370796;,citation_author=Paul Young;,citation_author=Michael Bailey;,citation_author=Richard Beasley;,citation_author=Seton Henderson;,citation_author=Diane Mackle;,citation_author=Colin McArthur;,citation_author=Shay McGuinness;,citation_author=Jan Mehrtens;,citation_author=John Myburgh;,citation_author=Alex Psirides;,citation_author=Sumeet Reddy;,citation_author=Rinaldo Bellomo;,citation_author=for the SPLIT Investigators and the ANZICS CTG;,citation_publication_date=2015-10;,citation_cover_date=2015-10;,citation_year=2015;,citation_issue=16;,citation_doi=10.1001/jama.2015.12334;,citation_issn=0098-7484;,citation_volume=314;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Evaluating Non–Statistically Significant Results From Trials in Practice—Reply;,citation_abstract=In Reply We submit that clinicians have a responsibility to evaluate major clinical trials and, at times, to implement their findings in advance of clinical guidelines being produced by scientific societies and government agencies. In our Viewpoint, we sought to provide a framework for them to do this in situations in which actionable findings might be hidden behind a non–statistically significant primary outcome. We agree with Dr Piovani and colleagues that when deciding whether to implement clinical trial findings, outcomes that matter to patients are the most important. However, because data pertaining to all potentially important outcomes are often not available, clinicians must make decisions about evidence under conditions of uncertainty. We consider that they should do so based on an assessment of the probability that a particular treatment will result in a net benefit for a patient, focusing first on outcomes that are likely to matter to patients.;,citation_author=Paul J. Young;,citation_author=Christopher P. Nickson;,citation_author=Anders Perner;,citation_publication_date=2020-10;,citation_cover_date=2020-10;,citation_year=2020;,citation_issue=16;,citation_doi=10.1001/jama.2020.15657;,citation_issn=0098-7484;,citation_volume=324;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Learning Healthcare Systems Will Protect Patients from Unscientific Practice Variation;,citation_author=Paul J. Young;,citation_publication_date=2018-02;,citation_cover_date=2018-02;,citation_year=2018;,citation_issue=2;,citation_doi=10.1513/AnnalsATS.201709-717IP;,citation_issn=2329-6933, 2325-6621;,citation_volume=15;,citation_language=en-US;,citation_journal_title=Annals of the American Thoracic Society;">
<meta name="citation_reference" content="citation_title=The neuroethics of disorders of consciousness: A brief history of evolving ideas;,citation_abstract=Abstract Neuroethical questions raised by recent advances in the diagnosis and treatment of disorders of consciousness are rapidly expanding, increasingly relevant, and yet underexplored. The aim of this thematic review is to provide a clinically applicable framework for understanding the current taxonomy of disorders of consciousness and to propose an approach to identifying and critically evaluating actionable neuroethical issues that are frequently encountered in research and clinical care for this vulnerable population. Increased awareness of these issues and clarity about opportunities for optimizing ethically-responsible care in this domain are especially timely given recent surges in critically ill patients with unusually prolonged disorders of consciousness associated with coronavirus disease 2019 (COVID-19) around the world. We begin with an overview of the field of neuroethics: what it is, its history and evolution in the context of biomedical ethics at large. We then explore nomenclature used in disorders of consciousness, covering categories proposed by the American Academy of Neurology, the American Congress of Rehabilitation Medicine, and the National Institute on Disability, Independent Living, and Rehabilitation Research, including definitions of terms such as coma, the vegetative state, unresponsive wakefulness syndrome, minimally conscious state, covert consciousness, and the confusional state. We discuss why these definitions matter, and why there has been such evolution in this nosology over the years, from Jennett and Plum in 1972 to the Multi-Society Task Force in 1994, the Aspen Working Group in 2002 and up until the 2018 American and 2020 European Disorders of Consciousness guidelines. We then move to a discussion of clinical aspects of disorders of consciousness, the natural history of recovery, and ethical issues that arise within the context of caring for persons with disorders of consciousness. We conclude with a discussion of key challenges associated with assessing residual consciousness in disorders of consciousness, potential solutions and future directions, including integration of crucial disability rights perspectives.;,citation_author=Michael J Young;,citation_author=Yelena G Bodien;,citation_author=Joseph T Giacino;,citation_author=Joseph J Fins;,citation_author=Robert D Truog;,citation_author=Leigh R Hochberg;,citation_author=Brian L Edlow;,citation_publication_date=2021-08;,citation_cover_date=2021-08;,citation_year=2021;,citation_doi=10.1093/brain/awab290;,citation_issn=0006-8950, 1460-2156;,citation_language=en-US;,citation_journal_title=Brain;">
<meta name="citation_reference" content="citation_title=Oxygen therapy for critically Ill and post-operative patients;,citation_abstract=Nearly all patients receiving treatment in a peri-operative or intensive care setting receive supplemental oxygen therapy. It is biologically plausible that the dose of oxygen used might affect important patient outcomes. Most peri-operative research has focussed on oxygen regimens that target higher than normal blood oxygen levels. Whereas, intensive care research has mostly focussed on conservative oxygen regimens which assiduously avoid exposure to higher than normal blood oxygen levels. While such conservative oxygen therapy is preferred for spontaneously breathing patients with chronic obstructive pulmonary disease, the optimal oxygen regimen in other patient groups is not clear. Some data suggest that conservative oxygen therapy might be preferred for patients with hypoxic ischaemic encephalopathy. However, unless oxygen supplies are constrained, routinely aggressively down-titrating oxygen in either the peri-operative or intensive care setting is not necessary based on available data. Targeting higher than normal levels of oxygen might reduce surgical site infections in the perioperative setting and/or improve outcomes for intensive care patients with sepsis but further research is required and available data are not sufficiently strong to warrant routine implementation of such oxygen strategies.;,citation_author=Paul J. Young;,citation_author=Daniel Frei;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_doi=10.1007/s00540-021-02996-8;,citation_issn=0913-8668, 1438-8359;,citation_language=en-US;,citation_journal_title=Journal of Anesthesia;">
<meta name="citation_reference" content="citation_title=Oxygen targets;,citation_author=Paul J. Young;,citation_author=Carol L. Hodgson;,citation_author=Bodil S. Rasmussen;,citation_publication_date=2022-06;,citation_cover_date=2022-06;,citation_year=2022;,citation_issue=6;,citation_doi=10.1007/s00134-022-06714-0;,citation_issn=0342-4642, 1432-1238;,citation_volume=48;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Selective digestive tract decontamination in critically ill adults with acute brain injuries: A Post-Hoc analysis of a Randomized Clinical Trial.;,citation_abstract=Purpose: To determine whether Selective Decontamination of the Digestive Tract (SDD) reduces inhospital mortality in mechanically ventilated critically ill adults admitted to the Intensive Care Unit (ICU) with acute brain injuries or conditions. Methods: A post-hoc analysis from a crossover, cluster-randomized clinical trial. ICUs were randomly assigned to adopt or not to adopt a SDD strategy for two alternating 12-month periods, separated by a 3month inter-period gap. Patients in the SDD group (n=2791; 968 admitted to the ICU with an acute brain injury) received a 6-hourly application of an oral paste and administration of a gastric suspension containing colistin, tobramycin, and nystatin for the duration of mechanical ventilation, plus a 4-day course of an intravenous antibiotic with a suitable antimicrobial spectrum. Patients in the control group (n=3191; 1093 admitted to the ICU with an acute brain injury) received standard care. The primary outcome was in-hospital mortality within 90 days. There were four secondary clinical outcomes: death in ICU, ventilator-, ICU- and hospital-free days to day 90. Results Of 2061 patients with acute brain injuries (mean age, 55.8 years; 36.4% women), all completed the trial. In patients with acute brain injuries, there were 313/968 (32.3%) and 415/1093 (38.0%) inhospital deaths in the SDD and standard care groups (unadjusted odds ratio [OR], 0.76, 95% confidence interval [CI] 0.63 to 0.92; p = 0.004). The use of SDD was associated with statistically significant improvements in the four clinical secondary outcomes compared to standard care. There was no statistical difference in the heterogeneity of treatment effect between patients with and without acute brain injuries (interaction p=0.22). Conclusions: In this post-hoc analysis of a randomized clinical trial in critically ill patients with acute brain injuries receiving mechanical ventilation, the use of SDD significantly reduced in-hospital mortality in patients compared to standard care without SDD. These findings require confirmation.;,citation_author=Paul Young;,citation_author=Anthony Devaux;,citation_author=Qiang Li;,citation_author=Laurent Billot;,citation_author=Joshua Davis;,citation_author=Anthony Delaney;,citation_author=Simon Finfer;,citation_author=Naomi Hammond;,citation_author=Sharon Micallef;,citation_author=Ian Seppelt;,citation_author=Balasubramanian Venkatesh;,citation_author=John A Myburgh;,citation_publication_date=2023-10;,citation_cover_date=2023-10;,citation_year=2023;,citation_doi=10.21203/rs.3.rs-3412001/v1;,citation_language=en-US;,citation_technical_report_institution=In Review;">
<meta name="citation_reference" content="citation_title=Vitamin C in sepsis;,citation_author=Paul J. Young;,citation_author=François Lamontagne;,citation_author=Tomoko Fujii;,citation_publication_date=2022-08;,citation_cover_date=2022-08;,citation_year=2022;,citation_doi=10.1007/s00134-022-06822-x;,citation_issn=1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=When Should Clinicians Act on Non–Statistically Significant Results From Clinical Trials?;,citation_abstract=Understanding whether the results of a randomized clinical trial (RCT) are clinically actionable is challenging. Reporting standards adopted by JAMA and other leading journals lead to relative uniformity of presentation of RCT findings that help simplify critical appraisal. Such uniform reporting also means that the conclusion of the trial may be dichotomized as “positive” or “no difference” based on the statistical significance of the primary outcome. Dichotomization based on the statistical significance of the primary outcome variable reflects the correct, albeit narrow, interpretation of the experiment that the RCT represents. It also reflects decisions made by the investigators in the design of the study and highlights findings in relation to prespecified assumptions. However, there are situations in which a broader appreciation of the results may suggest that non–statistically significant results in the primary outcome of a clinical trial could influence and perhaps change practice. This includes consideration of the outcome in terms of effect size and accompanying CIs, placing the findings from the trial in the context of the totality of the existing relevant evidence.;,citation_author=Paul J. Young;,citation_author=Christopher P. Nickson;,citation_author=Anders Perner;,citation_publication_date=2020-06;,citation_cover_date=2020-06;,citation_year=2020;,citation_issue=22;,citation_doi=10.1001/jama.2020.3508;,citation_issn=0098-7484;,citation_volume=323;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Association of Neighborhood-Level Material Deprivation With Health Care Costs and Outcome After Stroke;,citation_abstract=Background and Objectives To determine the association between material deprivation and direct health care costs and clinical outcomes following stroke in the context of a publicly funded universal health care system.;,citation_author=Amy Y. X. Yu;,citation_author=Eric E. Smith;,citation_author=Murray Krahn;,citation_author=Peter C. Austin;,citation_author=Mohammed Rashid;,citation_author=Jiming Fang;,citation_author=Joan Porter;,citation_author=Manav V. Vyas;,citation_author=Susan E. Bronskill;,citation_author=Richard H. Swartz;,citation_author=Moira K. Kapral;,citation_publication_date=2021-10;,citation_cover_date=2021-10;,citation_year=2021;,citation_issue=15;,citation_doi=10.1212/WNL.0000000000012676;,citation_issn=0028-3878, 1526-632X;,citation_volume=97;,citation_language=en-US;,citation_journal_title=Neurology;">
<meta name="citation_reference" content="citation_title=Pathological Computed Tomography Features Associated With Adverse Outcomes After Mild Traumatic Brain Injury: A TRACK-TBI Study With External Validation in CENTER-TBI;,citation_abstract=OBJECTIVE To identify pathological CT features associated with adverse outcomes after mTBI. DESIGN, SETTING, AND PARTICIPANTS The longitudinal, observational Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) study enrolled patients with TBI, including those 17 years and older with GCS scores of 13 to 15 who presented to emergency departments at 18 US level 1 trauma centers between February 26, 2014, and August 8, 2018, and underwent head CT imaging within 24 hours of TBI. Evaluations of CT imaging used TBI Common Data Elements. Glasgow Outcome Scale–Extended (GOSE) scores were assessed at 2 weeks and 3, 6, and 12 months postinjury. External validation of results was performed via the Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) study. Data analyses were completed from February 2020 to February 2021. EXPOSURES Acute nonpenetrating head trauma. MAIN OUTCOMES AND MEASURES Frequency, co-occurrence, and clustering of CT features; incomplete recovery (GOSE scores &amp;amp;amp;lt;8 vs 8); and an unfavorable outcome (GOSE scores &amp;lt;5 vs Ն5) at 2 weeks and 3, 6, and 12 months. RESULTS In 1935 patients with mTBI (mean [SD] age, 41.5 [17.6] years; 1286 men [66.5%]) in the TRACK-TBI cohort and 2594 patients with mTBI (mean [SD] age, 51.8 [20.3] years; 1658 men [63.9%]) in an external validation cohort, hierarchical cluster analysis identified 3 major clusters of CT features: contusion, subarachnoid hemorrhage, and/or subdural hematoma; intraventricular and/or petechial hemorrhage; and epidural hematoma. Contusion, subarachnoid hemorrhage, and/or subdural hematoma features were associated with incomplete recovery (odds ratios [ORs] for GOSE scores <8 at 1 year: TRACK-TBI, 1.80 [95% CI, 1.39-2.33]; CENTER-TBI, 2.73 [95% CI, 2.18-3.41]) and greater degrees of unfavorable outcomes (ORs for GOSE scores <5 at 1 year: TRACK-TBI, 3.23 [95% CI, 1.59-6.58]; CENTER-TBI, 1.68 [95% CI, 1.13-2.49]) out to 12 months after injury, but epidural hematoma was not. Intraventricular and/or petechial hemorrhage was associated with greater degrees of unfavorable outcomes up to 12 months after injury (eg, OR for GOSE scores <5 at 1 year in TRACK-TBI: 3.47 [95% CI, 1.66-7.26]). Some CT features were more strongly associated with outcomes than previously validated variables (eg, ORs for GOSE scores <5 at 1 year in TRACK-TBI: neuropsychiatric history, 1.43 [95% CI .98-2.10] vs contusion, subarachnoid hemorrhage, and/or subdural hematoma, 3.23 [95% CI 1.59-6.58]). Findings were externally validated in 2594 patients with mTBI enrolled in the CENTER-TBI study. CONCLUSIONS AND RELEVANCE In this study, pathological CT features carried different prognostic implications after mTBI to 1 year postinjury. Some patterns of injury were associated with worse outcomes than others. These results support that patients with mTBI and these CT features need TBI-specific education and systematic follow-up.;,citation_author=Esther L. Yuh;,citation_author=Sonia Jain;,citation_author=Xiaoying Sun;,citation_author=Dana Pisică;,citation_author=Mark H. Harris;,citation_author=Sabrina R. Taylor;,citation_author=Amy J. Markowitz;,citation_author=Pratik Mukherjee;,citation_author=Jan Verheyden;,citation_author=Joseph T. Giacino;,citation_author=Harvey S. Levin;,citation_author=Michael McCrea;,citation_author=Murray B. Stein;,citation_author=Nancy R. Temkin;,citation_author=Ramon Diaz-Arrastia;,citation_author=Claudia S. Robertson;,citation_author=Hester F. Lingsma;,citation_author=David O. Okonkwo;,citation_author=Andrew I. R. Maas;,citation_author=Geoffrey T. Manley;,citation_author=TRACK-TBI Investigators for the CENTER-TBI Investigators;,citation_author=Krisztina Amrein;,citation_author=Nada Andelic;,citation_author=Lasse Andreassen;,citation_author=Audny Anke;,citation_author=Anna Antoni;,citation_author=Gérard Audibert;,citation_author=Philippe Azouvi;,citation_author=Maria Luisa Azzolini;,citation_author=Ronald Bartels;,citation_author=Pál Barzó;,citation_author=Romuald Beauvais;,citation_author=Ronny Beer;,citation_author=Bo-Michael Bellander;,citation_author=Antonio Belli;,citation_author=Habib Benal;,citation_author=Maurizio Berardino;,citation_author=Luigi Beretta;,citation_author=Morten Blaabjerg;,citation_author=Peter Bragge;,citation_author=Alexandra Brazinova;,citation_author=Vibeke Brinck;,citation_author=Joanne Brooker;,citation_author=Camilla Brorsson;,citation_author=Andras Buki;,citation_author=Monika Bullinger;,citation_author=Manuel Cabeleira;,citation_author=Alessio Caccioppola;,citation_author=Emiliana Calappi;,citation_author=Maria Rosa Calvi;,citation_author=Peter Cameron;,citation_author=Guillermo Carbayo Lozano;,citation_author=Marco Carbonara;,citation_author=Ana M. Castaño-León;,citation_author=Simona Cavallo;,citation_author=Giorgio Chevallard;,citation_author=Arturo Chieregato;,citation_author=Giuseppe Citerio;,citation_author=Hans Clusmann;,citation_author=Mark Coburn;,citation_author=Jonathan Coles;,citation_author=Jamie D. Cooper;,citation_author=Marta Correia;,citation_author=Amra Čović;,citation_author=Nicola Curry;,citation_author=Endre Czeiter;,citation_author=Marek Czosnyka;,citation_author=Claire Dahyot-Fizelier;,citation_author=Paul Dark;,citation_author=Helen Dawes;,citation_author=Véronique De Keyser;,citation_author=Vincent Degos;,citation_author=Francesco Della Corte;,citation_author=Hugo Boogert;,citation_author=Bart Depreitere;,citation_author=ula ilvesi;,citation_author=Abhishek Dixit;,citation_author=Emma Donoghue;,citation_author=Jens Dreier;,citation_author=Guy-Loup Dulière;,citation_author=Ari Ercole;,citation_author=Patrick Esser;,citation_author=Erzsébet Ezer;,citation_author=Martin Fabricius;,citation_author=Valery L. Feigin;,citation_author=Kelly Foks;,citation_author=Shirin Frisvold;,citation_author=Alex Furmanov;,citation_author=Pablo Gagliardo;,citation_author=Damien Galanaud;,citation_author=Dashiell Gantner;,citation_author=Guoyi Gao;,citation_author=Pradeep George;,citation_author=Alexandre Ghuysen;,citation_author=Lelde Giga;,citation_author=Ben Glocker;,citation_author=Jagoš Golubovic;,citation_author=Pedro A. Gomez;,citation_author=Johannes Gratz;,citation_author=Benjamin Gravesteijn;,citation_author=Francesca Grossi;,citation_author=Russell L. Gruen;,citation_author=Deepak Gupta;,citation_author=Juanita A. Haagsma;,citation_author=Iain Haitsma;,citation_author=Raimund Helbok;,citation_author=Eirik Helseth;,citation_author=Lindsay Horton;,citation_author=Jilske Huijben;,citation_author=Peter J. Hutchinson;,citation_author=Bram Jacobs;,citation_author=Stefan Jankowski;,citation_author=Mike Jarrett;,citation_author=Ji-yao Jiang;,citation_author=Faye Johnson;,citation_author=Kelly Jones;,citation_author=Mladen Karan;,citation_author=Cecilia Kerlund;,citation_author=Angelos G. Kolias;,citation_author=Erwin Kompanje;,citation_author=Daniel Kondziella;,citation_author=Evgenios Kornaropoulos;,citation_author=Lars-Owe Koskinen;,citation_author=Noémi Kovács;,citation_author=Ana Kowark;,citation_author=Alfonso Lagares;,citation_author=Linda Lanyon;,citation_author=Steven Laureys;,citation_author=Fiona Lecky;,citation_author=Didier Ledoux;,citation_author=Rolf Lefering;,citation_author=Valerie Legrand;,citation_author=Aurelie Lejeune;,citation_author=Leon Levi;,citation_author=Roger Lightfoot;,citation_author=Marc Maegele;,citation_author=Marek Majdan;,citation_author=Alex Manara;,citation_author=Costanza Martino;,citation_author=Hugues Maréchal;,citation_author=Julia Mattern;,citation_author=Catherine McMahon;,citation_author=Béla Melegh;,citation_author=David Menon;,citation_author=Tomas Menovsky;,citation_author=Ana Mikolic;,citation_author=Benoit Misset;,citation_author=Visakh Muraleedharan;,citation_author=Lynnette Murray;,citation_author=Ancuta Negru;,citation_author=David Nelson;,citation_author=Virginia Newcombe;,citation_author=Daan Nieboer;,citation_author=József Nyirádi;,citation_author=Otesile Olubukola;,citation_author=Matej Oresic;,citation_author=Fabrizio Ortolano;,citation_author=Aarno Palotie;,citation_author=Paul M. Parizel;,citation_author=Jean-François Payen;,citation_author=Natascha Perera;,citation_author=Vincent Perlbarg;,citation_author=Paolo Persona;,citation_author=Wilco Peul;,citation_author=Anna Piippo-Karjalainen;,citation_author=Matti Pirinen;,citation_author=Horia Ples;,citation_author=Suzanne Polinder;,citation_author=Inigo Pomposo;,citation_author=Jussi P. Posti;,citation_author=Louis Puybasset;,citation_author=Andreea Radoi;,citation_author=Arminas Ragauskas;,citation_author=Rahul Raj;,citation_author=Malinka Rambadagalla;,citation_author=Jonathan Rhode;,citation_author=Sylvia Richardson;,citation_author=Sophie Richter;,citation_author=Samuli Ripatti;,citation_author=Saulius Rocka;,citation_author=Cecilie Roe;,citation_author=Olav Roise;,citation_author=Jeffrey V. Rosenfeld;,citation_author=Christina Rosenlund;,citation_author=Guy Rosenthal;,citation_author=Rolf Rossaint;,citation_author=Sandra Rossi;,citation_author=Daniel Rueckert;,citation_author=Martin Rusnák;,citation_author=Juan Sahuquillo;,citation_author=Oliver Sakowitz;,citation_author=Renan Sanchez-Porras;,citation_author=Janos Sandor;,citation_author=Nadine Schäfer;,citation_author=Silke Schmidt;,citation_author=Herbert Schoechl;,citation_author=Guus Schoonman;,citation_author=Rico Frederik Schou;,citation_author=Elisabeth Schwendenwein;,citation_author=Charlie Sewalt;,citation_author=Toril Skandsen;,citation_author=Peter Smielewski;,citation_author=Abayomi Sorinola;,citation_author=Emmanuel Stamatakis;,citation_author=Simon Stanworth;,citation_author=Robert Stevens;,citation_author=William Stewart;,citation_author=Ewout W. Steyerberg;,citation_author=Nino Stocchetti;,citation_author=Nina Sundström;,citation_author=Riikka Takala;,citation_author=Viktória Tamás;,citation_author=Tomas Tamosuitis;,citation_author=Mark Steven Taylor;,citation_author=Braden Te Ao;,citation_author=Olli Tenovuo;,citation_author=Alice Theadom;,citation_author=Matt Thomas;,citation_author=Dick Tibboel;,citation_author=Marjolein Timmers;,citation_author=Christos Tolias;,citation_author=Tony Trapani;,citation_author=Cristina Maria Tudora;,citation_author=Andreas Unterberg;,citation_author=Peter Vajkoczy;,citation_author=Shirley Vallance;,citation_author=Egils Valeinis;,citation_author=Zoltán Vámos;,citation_author=Luc Hauwe;,citation_author=Mathieu Jagt;,citation_author=Joukje Naalt;,citation_author=Gregory Van der Steen;,citation_author=Jeroen T. J. M. Dijck;,citation_author=Thomas A. Essen;,citation_author=Wim Van Hecke;,citation_author=Caroline Heugten;,citation_author=Dominique Van Praag;,citation_author=Thijs Vande Vyvere;,citation_author=Roel P. J. Wijk;,citation_author=Alessia Vargiolu Wijk;,citation_author=Emmanuel Vega;,citation_author=Kimberley Velt;,citation_author=Anne Vik;,citation_author=Rimantas Vilcinis;,citation_author=Victor Volovici;,citation_author=Nicole Steinbüchel;,citation_author=Daphne Voormolen;,citation_author=Petar Vulekovic;,citation_author=Kevin K. W. Wang;,citation_author=Eveline Wiegers;,citation_author=Guy Williams;,citation_author=Lindsay Wilson;,citation_author=Stefan Winzeck;,citation_author=Stefan Wolf;,citation_author=Zhihui Yang;,citation_author=Peter Ylén;,citation_author=Alexander Younsi;,citation_author=Frederick A. Zeiler;,citation_author=Veronika Zelinkova;,citation_author=Agate Ziverte;,citation_author=Tommaso Zoerle;,citation_author=Opeolu Adeoye;,citation_author=Neeraj Badjatia;,citation_author=Kim Boase;,citation_author=Yelena Bodien;,citation_author=John D. Corrigan;,citation_author=Karen Crawford;,citation_author=Sureyya Dikmen;,citation_author=Ann-Christine Duhaime;,citation_author=Richard Ellenbogen;,citation_author=V. Ramana Feeser;,citation_author=Adam R. Ferguson;,citation_author=Brandon Foreman;,citation_author=Raquel Gardner;,citation_author=Etienne Gaudette;,citation_author=Luis Gonzalez;,citation_author=Shankar Gopinath;,citation_author=Rao Gullapalli;,citation_author=J. Claude Hemphill;,citation_author=Gillian Hotz;,citation_author=C. Dirk Keene;,citation_author=Joel Kramer;,citation_author=Natalie Kreitzer;,citation_author=Chris Lindsell;,citation_author=Joan Machamer;,citation_author=Christopher Madden;,citation_author=Alastair Martin;,citation_author=Thomas McAllister;,citation_author=Randall Merchant;,citation_author=Lindsay Nelson;,citation_author=Laura B. Ngwenya;,citation_author=Florence Noel;,citation_author=Amber Nolan;,citation_author=Eva Palacios;,citation_author=Daniel Perl;,citation_author=Miri Rabinowitz;,citation_author=Jonathan Rosand;,citation_author=Angelle Sander;,citation_author=Gabriella Satris;,citation_author=David Schnyer;,citation_author=Seth Seabury;,citation_author=Arthur Toga;,citation_author=Alex Valadka;,citation_author=Mary Vassar;,citation_author=Ross Zafonte;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_issue=9;,citation_doi=10.1001/jamaneurol.2021.2120;,citation_issn=2168-6149;,citation_volume=78;,citation_language=en-US;,citation_journal_title=JAMA Neurology;">
<meta name="citation_reference" content="citation_title=Association Between a Chloride-Liberal vs Chloride-Restrictive Intravenous Fluid Administration Strategy and Kidney Injury in Critically Ill Adults;,citation_abstract=Administration of traditional chloride-liberal intravenous fluids may precipitate acute kidney injury (AKI).To assess the association of a chloride-restrictive (vs chloride-liberal) intravenous fluid strategy with AKI in critically ill patients.Prospective, open-label, sequential period pilot study of 760 patients admitted consecutively to the intensive care unit (ICU) during the control period (February 18 to August 17, 2008) compared with 773 patients admitted consecutively during the intervention period (February 18 to August 17, 2009) at a university-affiliated hospital in Melbourne, Australia.During the control period, patients received standard intravenous fluids. After a 6-month phase-out period (August 18, 2008, to February 17, 2009), any use of chloride-rich intravenous fluids (0.9% saline, 4% succinylated gelatin solution, or 4% albumin solution) was restricted to attending specialist approval only during the intervention period; patients instead received a lactated solution (Hartmann solution), a balanced solution (Plasma-Lyte 148), and chloride-poor 20% albumin.The primary outcomes included increase from baseline to peak creatinine level in the ICU and incidence of AKI according to the risk, injury, failure, loss, end-stage (RIFLE) classification. Secondary post hoc analysis outcomes included the need for renal replacement therapy (RRT), length of stay in ICU and hospital, and survival.Chloride administration decreased by 144&nbsp;504 mmol (from 694 to 496 mmol/patient) from the control period to the intervention period. Comparing the control period with the intervention period, the mean serum creatinine level increase while in the ICU was 22.6 \mumol/L (95% CI, 17.5-27.7 \mumol/L) vs 14.8 \mumol/L (95% CI, 9.8-19.9 \mumol/L) (P&nbsp;=&nbsp;.03), the incidence of injury and failure class of RIFLE-defined AKI was 14% (95% CI, 11%-16%; n&nbsp;=&nbsp;105) vs 8.4% (95% CI, 6.4%-10%; n&nbsp;=&nbsp;65) (P &amp;amp;amp;lt;.001), and the use of RRT was 10% (95% CI, 8.1%-12%; n&nbsp;=&nbsp;78) vs 6.3% (95% CI, 4.6%-8.1%; n&nbsp;=&nbsp;49) (P&nbsp;=&nbsp;.005). After adjustment for covariates, this association remained for incidence of injury and failure class of RIFLE-defined AKI (odds ratio, 0.52 [95% CI, 0.37-0.75]; P &amp;lt;.001) and use of RRT (odds ratio, 0.52 [95% CI, 0.33-0.81]; P&nbsp;=&nbsp;.004). There were no differences in hospital mortality, hospital or ICU length of stay, or need for RRT after hospital discharge.The implementation of a chloride-restrictive strategy in a tertiary ICU was associated with a significant decrease in the incidence of AKI and use of RRT.clinicaltrials.gov Identifier: NCT00885404;,citation_author=Nor’azim Mohd Yunos;,citation_author=Rinaldo Bellomo;,citation_author=Colin Hegarty;,citation_author=David Story;,citation_author=Lisa Ho;,citation_author=Michael Bailey;,citation_publication_date=2012-10;,citation_cover_date=2012-10;,citation_year=2012;,citation_issue=15;,citation_doi=10.1001/jama.2012.13356;,citation_issn=0098-7484;,citation_volume=308;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Why do we need some large, simple randomized trials?;,citation_author=Salim Yusuf;,citation_author=Rory Collins;,citation_author=Richard Peto;,citation_publication_date=1984-10;,citation_cover_date=1984-10;,citation_year=1984;,citation_issue=4;,citation_doi=10.1002/sim.4780030421;,citation_issn=02776715, 10970258;,citation_volume=3;,citation_language=en-US;,citation_journal_title=Statistics in Medicine;">
<meta name="citation_reference" content="citation_title=Randomized Controlled Trials;,citation_author=Emily C. Zabor;,citation_author=Alexander M. Kaizer;,citation_author=Brian P. Hobbs;,citation_publication_date=2020-07;,citation_cover_date=2020-07;,citation_year=2020;,citation_issue=1;,citation_doi=10.1016/j.chest.2020.03.013;,citation_issn=00123692;,citation_volume=158;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Antiseizure Medication Treatment and Outcomes in Patients with Subarachnoid Hemorrhage Undergoing Continuous EEG Monitoring;,citation_abstract=Background: Patients with aneurysmal subarachnoid hemorrhage (aSAH) with electroencephalographic epileptiform activity (seizures, periodic and rhythmic patterns, and sporadic discharges) are frequently treated with antiseizure medications (ASMs). However, the safety and effectiveness of ASM treatment for epileptiform activity has not been established. We used observational data to investigate the effectiveness of ASM treatment in patients with aSAH undergoing continuous electroencephalography (cEEG) to develop a causal hypothesis for testing in prospective trials. Methods: This was a retrospective single-center cohort study of patients with aSAH admitted between 2011 and 2016. Patients underwent \geq 24 h of cEEG within 4 days of admission. All patients received primary ASM prophylaxis until aneurysm treatment (typically within 24 h of admission). Treatment exposure was defined as reinitiation of ASMs after aneurysm treatment and cEEG initiation. We excluded patients with non-cEEG indications for ASMs (e.g., epilepsy, acute symptomatic seizures). Outcomes measures were 90-day mortality and good functional outcome (modified Rankin Scale scores 0–3). Propensity scores were used to adjust for baseline covariates and disease severity. Results: Ninety-four patients were eligible (40 continued ASM treatment; 54 received prophylaxis only). ASM continuation was not significantly associated with higher 90-day mortality (propensity-adjusted hazard ratio [HR] = 2.01 [95% confidence interval (CI) 0.57–7.02]). ASM continuation was associated with lower likelihood for 90-day good functional outcome (propensity-adjusted HR = 0.39 [95% CI 0.18–0.81]). In a secondary analysis, low-intensity treatment (low-dose single ASM) was not significantly associated with mortality (propensity-adjusted HR = 0.60 [95% CI 0.10–3.59]), although it was associated with a lower likelihood of good outcome (propensity-adjusted HR = 0.37 [95% CI 0.15–0.91]), compared with prophylaxis. High-intensity treatment (high-dose single ASM, multiple ASMs, or anesthetics) was associated with higher mortality (propensity-adjusted HR = 6.80 [95% CI 1.67–27.65]) and lower likelihood for good outcomes (propensity-adjusted HR = 0.30 [95% CI 0.10–0.94]) compared with prophylaxis only.;,citation_author=Sahar F. Zafar;,citation_author=Eric S. Rosenthal;,citation_author=Eva N. Postma;,citation_author=Paula Sanches;,citation_author=Muhammad Abubakar Ayub;,citation_author=Subapriya Rajan;,citation_author=Jennifer A. Kim;,citation_author=Daniel B. Rubin;,citation_author=Hang Lee;,citation_author=Aman B. Patel;,citation_author=John Hsu;,citation_author=Elisabetta Patorno;,citation_author=M. Brandon Westover;,citation_publication_date=2021-11;,citation_cover_date=2021-11;,citation_year=2021;,citation_doi=10.1007/s12028-021-01387-x;,citation_issn=1541-6933, 1556-0961;,citation_language=en-US;,citation_journal_title=Neurocritical Care;">
<meta name="citation_reference" content="citation_title=Variability in physician prognosis and recommendations after intracerebral hemorrhage;,citation_abstract=OBJECTIVE: To assess physician prognosis and treatment recommendations for intracerebral hemorrhage (ICH) and to determine the effect of providing physicians a validated prognostic score. METHODS: A written survey with 2 ICH scenarios was completed by practicing neurologists and neurosurgeons. Selected factors were randomly varied (patient older vs middle age, Glasgow Coma Scale [GCS] score 7T vs 11, and presence vs absence of a validated prognostic score). Outcomes included predicted 30-day mortality and recommendations for initial treatment intensity (6-point scale ranging from 1 = comfort only to 6 = full treatment). RESULTS: A total of 742 physicians were included (mean age 52, 32% neurosurgeons, 17% female). Physician predictions of 30-day mortality varied widely (mean [range] for the 4 possible combinations of age and GCS were 23% [0%-80%], 35% [0%-100%], 48% [0%-100%], and 58% [5%-100%]). Treatment recommendations also varied widely, with responses encompassing the full range of response options for each case. No physician demographic or personality characteristics were associated with treatment recommendations. Providing a prognostic score changed treatment recommendations, and the effect differed across cases. When the prognostic score suggested 0% chance of functional independence (76-year-old with GCS 7T), the likelihood of treatment limitations was increased (odds ratio [OR] 1.61, 95% confidence interval [CI] 1.12-2.33) compared to no prognostic score. Conversely, if the score suggested a 66% chance of independence (63-year-old with GCS 11), treatment limitations were less likely (OR 0.62, 95% CI 0.43-0.88). CONCLUSIONS: Physicians vary substantially in ICH prognostic estimates and treatment recommendations. This variability could have a profound effect on life and death decision-making and treatment for ICH.;,citation_author=Darin B. Zahuranec;,citation_author=Angela Fagerlin;,citation_author=Brisa N. Sánchez;,citation_author=Meghan E. Roney;,citation_author=Bradford B. Thompson;,citation_author=Andrea Fuhrel-Forbis;,citation_author=Lewis B. Morgenstern;,citation_publication_date=2016-05;,citation_cover_date=2016-05;,citation_year=2016;,citation_issue=20;,citation_doi=10.1212/WNL.0000000000002676;,citation_issn=1526-632X;,citation_pmid=27164665;,citation_volume=86;,citation_language=en-US;,citation_journal_title=Neurology;">
<meta name="citation_reference" content="citation_title=Association Between Type of Fluid Received Prior to Enrollment, Type of Admission, and Effect of Balanced Crystalloid in Critically Ill Adults: A Secondary Exploratory Analysis of the Balanced Solutions in Intensive Care (BaSICS) Study;,citation_abstract=Objectives: To assess whether results of a randomized controlled trial could be affected by fluid use before enrollment and admission type. Methods: Secondary post-hoc analysis of the Balanced Solution in Intensive Care (BaSICS) trial, which compared a balanced solution (Plasma-Lyte 148) to 0.9% saline in intensive care unit. Patients were categorized according to fluid use in the 24 hours before enrollment in four groups: balanced solutions only; 0.9% saline only; mix of both, and no fluid before enrollment, and according to admission type (planned, unplanned with sepsis and unplanned without sepsis). The association between 90-day mortality and the randomization group was assessed using an hierarchical logistic Bayesian model. Measurements and Main Results: 10,520 patients were included. There was a low probability that the balanced solution was associated with improved 90-day mortality in the whole trial population (odds ratio, 0.95; 89% credible intervals [CrI], 0.66-1.51; probability of benefit, 0.58); however, probability of benefit was high for patients that received only balanced solutions before enrollment (regardless of admission type, odds ratio, 0.78, 89% CrI, 0.56,1.03; probability of benefit, 0.92), mostly due to a benefit in unplanned admissions due to sepsis (odd ratio, 0.70; 89% CrI, 0.50-0.97; probability of benefit, 0.96) and planned admissions (odds ratio, 0.79; 89% CrI, 0.65-0.97; 0.97 probability of benefit, 0.97). Conclusion: There is a high probability that balanced solution use in the ICU reduces 90-day mortality in patients that exclusively received balanced fluids before trial enrollment.;,citation_author=Fernando G Zampieri;,citation_author=Flávia R Machado;,citation_author=Rodrigo S. Biondi;,citation_author=Flávio G. R. Freitas;,citation_author=Viviane C Veiga;,citation_author=Rodrigo C. Figueiredo;,citation_author=Wilson J Lovato;,citation_author=Cristina P. Amêndola;,citation_author=Ary Serpa-Neto;,citation_author=Jorge L. R. Paranhos;,citation_author=Eraldo A. Lúcio;,citation_author=Lúcio C. Oliveira-Júnior;,citation_author=Thiago C. Lisboa;,citation_author=Fábio H Lacerda;,citation_author=Israel S. Maia;,citation_author=Cintia M. C. Grion;,citation_author=Murillo S. C. Assunção;,citation_author=Airton L. O. Manoel;,citation_author=Thiago D Corrêa;,citation_author=Marco Antonio VA Guedes;,citation_author=Luciano C. P. Azevedo;,citation_author=Tamiris A. Miranda;,citation_author=Lucas P Damiani;,citation_author=Nilton Brandão da Silva;,citation_author=Alexandre B. Cavalcanti;,citation_author=for the BaSICS investigators and the BRICNet;,citation_publication_date=2022-03;,citation_cover_date=2022-03;,citation_year=2022;,citation_doi=10.1164/rccm.202111-2484OC;,citation_issn=1073-449X, 1535-4970;,citation_language=en-US;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Balanced crystalloids versus saline for critically ill patients (BEST-Living): A systematic review and individual patient data meta-analysis;,citation_abstract=Background The effect of balanced crystalloids compared with that of saline in critically ill patients overall and in specific subgroups is unclear. We aimed to assess whether use of balanced solutions, compared with 0\cdot9% sodium chloride (saline), decreased in-hospital mortality in adult patients in intensive care units (ICUs).;,citation_author=Fernando G Zampieri;,citation_author=Alexandre B Cavalcanti;,citation_author=Gian Luca Di Tanna;,citation_author=Lucas P Damiani;,citation_author=Naomi E Hammond;,citation_author=Flavia R Machado;,citation_author=Sharon Micallef;,citation_author=John Myburgh;,citation_author=Mahesh Ramanan;,citation_author=Balasubramanian Venkatesh;,citation_author=Todd W Rice;,citation_author=Matthew W Semler;,citation_author=Paul J Young;,citation_author=Simon Finfer;,citation_publication_date=2023-11;,citation_cover_date=2023-11;,citation_year=2023;,citation_doi=10.1016/S2213-2600(23)00417-4;,citation_issn=22132600;,citation_language=en-US;,citation_journal_title=The Lancet Respiratory Medicine;">
<meta name="citation_reference" content="citation_title=A Bayesian reanalysis of the Standard versus Accelerated Initiation of Renal-Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial;,citation_abstract=Timing of initiation of kidney-replacement therapy (KRT) in critically ill patients remains controversial. The Standard versus Accelerated Initiation of Renal-Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial compared two strategies of KRT initiation (accelerated versus standard) in critically ill patients with acute kidney injury and found neutral results for 90-day all-cause mortality. Probabilistic exploration of the trial endpoints may enable greater understanding of the trial findings. We aimed to perform a reanalysis using a Bayesian framework. We performed a secondary analysis of all 2927 patients randomized in multi-national STARRT-AKI trial, performed at 168 centers in 15 countries. The primary endpoint, 90-day all-cause mortality, was evaluated using hierarchical Bayesian logistic regression. A spectrum of priors includes optimistic, neutral, and pessimistic priors, along with priors informed from earlier clinical trials. Secondary endpoints (KRT-free days and hospital-free days) were assessed using zero–one inflated beta regression. The posterior probability of benefit comparing an accelerated versus a standard KRT initiation strategy for the primary endpoint suggested no important difference, regardless of the prior used (absolute difference of 0.13% [95% credible interval [CrI] - 3.30%; 3.40%], - 0.39% [95% CrI - 3.46%; 3.00%], and 0.64% [95% CrI - 2.53%; 3.88%] for neutral, optimistic, and pessimistic priors, respectively). There was a very low probability that the effect size was equal or larger than a consensus-defined minimal clinically important difference. Patients allocated to the accelerated strategy had a lower number of KRT-free days (median absolute difference of - 3.55 days [95% CrI - 6.38; - 0.48]), with a probability that the accelerated strategy was associated with more KRT-free days of 0.008. Hospital-free days were similar between strategies, with the accelerated strategy having a median absolute difference of 0.48 more hospital-free days (95% CrI - 1.87; 2.72) compared with the standard strategy and the probability that the accelerated strategy had more hospital-free days was 0.66. In a Bayesian reanalysis of the STARRT-AKI trial, we found very low probability that an accelerated strategy has clinically important benefits compared with the standard strategy. Patients receiving the accelerated strategy probably have fewer days alive and KRT-free. These findings do not support the adoption of an accelerated strategy of KRT initiation.;,citation_author=Fernando G. Zampieri;,citation_author=Bruno R. Costa;,citation_author=Suvi T. Vaara;,citation_author=François Lamontagne;,citation_author=Bram Rochwerg;,citation_author=Alistair D. Nichol;,citation_author=Shay McGuinness;,citation_author=Danny F. McAuley;,citation_author=Marlies Ostermann;,citation_author=Ron Wald;,citation_author=Sean M. Bagshaw;,citation_publication_date=2022-12;,citation_cover_date=2022-12;,citation_year=2022;,citation_issue=1;,citation_doi=10.1186/s13054-022-04120-y;,citation_issn=1364-8535;,citation_volume=26;,citation_language=en-US;,citation_journal_title=Critical Care;,citation_publisher=BioMed Central;">
<meta name="citation_reference" content="citation_title=Defining Optimal Respiratory Support for Patients With COVID-19;,citation_author=Fernando G. Zampieri;,citation_author=Juliana C. Ferreira;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_issue=6;,citation_doi=10.1001/jama.2022.0067;,citation_issn=0098-7484;,citation_volume=327;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Deploying Randomized Controlled Trials during the COVID-19 Pandemic: Reason and Bayesian Designs;,citation_author=Fernando G. Zampieri;,citation_publication_date=2020-08;,citation_cover_date=2020-08;,citation_year=2020;,citation_issue=8;,citation_doi=10.1513/AnnalsATS.202005-463ED;,citation_issn=2329-6933, 2325-6621;,citation_volume=17;,citation_language=en-US;,citation_journal_title=Annals of the American Thoracic Society;">
<meta name="citation_reference" content="citation_title=Determinants of fluid use and the association between volume of fluid used and effect of balanced solutions on mortality in critically ill patients: A secondary analysis of the BaSICS trial;,citation_abstract=Fluid use could modulate the effect of balanced solutions (BS) on outcome of intensive care unit (ICU) patients. It is uncertain whether fluid use practices are driven more by patient features or local practices. It is also unclear whether a “dose–response” for the potential benefits of balanced solutions exists.;,citation_author=Fernando G. Zampieri;,citation_author=Flavia R. Machado;,citation_author=Vivivane C. Veiga;,citation_author=Luciano C. P. Azevedo;,citation_author=Sean M. Bagshaw;,citation_author=Lucas P. Damiani;,citation_author=Alexandre B. Cavalcanti;,citation_publication_date=2023-11;,citation_cover_date=2023-11;,citation_year=2023;,citation_doi=10.1007/s00134-023-07264-9;,citation_issn=1432-1238;,citation_language=en-US;,citation_journal_title=Intensive Care Medicine;">
<meta name="citation_reference" content="citation_title=Effect of Intravenous Fluid Treatment With a Balanced Solution vs 0.9% Saline Solution on Mortality in Critically Ill Patients: The BaSICS Randomized Clinical Trial;,citation_abstract=Intravenous fluids are used for almost all intensive care unit (ICU) patients. Clinical and laboratory studies have questioned whether specific fluid types result in improved outcomes, including mortality and acute kidney injury.To determine the effect of a balanced solution vs saline solution (0.9% sodium chloride) on 90-day survival in critically ill patients.Double-blind, factorial, randomized clinical trial conducted at 75 ICUs in Brazil. Patients who were admitted to the ICU with at least 1 risk factor for worse outcomes, who required at least 1 fluid expansion, and who were expected to remain in the ICU for more than 24 hours were randomized between May 29, 2017, and March 2, 2020; follow-up concluded on October 29, 2020. Patients were randomized to 2 different fluid types (a balanced solution vs saline solution reported in this article) and 2 different infusion rates (reported separately).Patients were randomly assigned 1:1 to receive either a balanced solution (n = 5522) or 0.9% saline solution (n = 5530) for all intravenous fluids.The primary outcome was 90-day survival.Among 11 052 patients who were randomized, 10 520 (95.2%) were available for the analysis (mean age, 61.1 [SD, 17] years; 44.2% were women). There was no significant interaction between the 2 interventions (fluid type and infusion speed; P = .98). Planned surgical admissions represented 48.4% of all patients. Of all the patients, 60.6% had hypotension or vasopressor use and 44.3% required mechanical ventilation at enrollment. Patients in both groups received a median of 1.5 L of fluid during the first day after enrollment. By day 90, 1381 of 5230 patients (26.4%) assigned to a balanced solution died vs 1439 of 5290 patients (27.2%) assigned to saline solution (adjusted hazard ratio, 0.97 [95% CI, 0.90-1.05]; P = .47). There were no unexpected treatment-related severe adverse events in either group.Among critically ill patients requiring fluid challenges, use of a balanced solution compared with 0.9% saline solution did not significantly reduce 90-day mortality. The findings do not support the use of this balanced solution.ClinicalTrials.gov Identifier: NCT02875873;,citation_author=Fernando G. Zampieri;,citation_author=Flávia R. Machado;,citation_author=Rodrigo S. Biondi;,citation_author=Flávio G. R. Freitas;,citation_author=Viviane C. Veiga;,citation_author=Rodrigo C. Figueiredo;,citation_author=Wilson J. Lovato;,citation_author=Cristina P. Amêndola;,citation_author=Ary Serpa-Neto;,citation_author=Jorge L. R. Paranhos;,citation_author=Marco A. V. Guedes;,citation_author=Eraldo A. Lúcio;,citation_author=Lúcio C. Oliveira-Júnior;,citation_author=Thiago C. Lisboa;,citation_author=Fábio H. Lacerda;,citation_author=Israel S. Maia;,citation_author=Cintia M. C. Grion;,citation_author=Murillo S. C. Assunção;,citation_author=Airton L. O. Manoel;,citation_author=João M. Silva-Junior;,citation_author=Péricles Duarte;,citation_author=Rafael M. Soares;,citation_author=Tamiris A. Miranda;,citation_author=Lucas M. Lima;,citation_author=Rodrigo M. Gurgel;,citation_author=Denise M. Paisani;,citation_author=Thiago D. Corrêa;,citation_author=Luciano C. P. Azevedo;,citation_author=John A. Kellum;,citation_author=Lucas P. Damiani;,citation_author=Nilton Brandão da Silva;,citation_author=Alexandre B. Cavalcanti;,citation_author=BaSICS investigators and the BRICNet members;,citation_publication_date=2021-09;,citation_cover_date=2021-09;,citation_year=2021;,citation_issue=9;,citation_doi=10.1001/jama.2021.11684;,citation_issn=0098-7484;,citation_volume=326;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Effects of a Resuscitation Strategy Targeting Peripheral Perfusion Status versus Serum Lactate Levels among Patients with Septic Shock. A Bayesian Reanalysis of the ANDROMEDA-SHOCK Trial;,citation_abstract=Rationale: A recent randomized controlled trial showed that a peripheral perfusion–guided resuscitation strategy was associated with lower mortality and less organ dysfunction when compared with lactate-guided resuscitation strategy in patients with septic shock, but the difference in the primary outcome, 28-day mortality, did not reach the proposed statistical significance threshold (P = 0.06). We tested different analytic methods to aid in the interpretation of these results.;,citation_author=Fernando G. Zampieri;,citation_author=Lucas P. Damiani;,citation_author=Jan Bakker;,citation_author=Gustavo A. Ospina-Tascón;,citation_author=Ricardo Castro;,citation_author=Alexandre B. Cavalcanti;,citation_author=Glenn Hernandez;,citation_publication_date=2020-02;,citation_cover_date=2020-02;,citation_year=2020;,citation_issue=4;,citation_doi=10.1164/rccm.201905-0968OC;,citation_issn=1073-449X, 1535-4970;,citation_volume=201;,citation_language=en-US;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Hydroxyethyl Starch for Fluid Replacement Therapy in High-Risk Surgical Patients: Context and Caution;,citation_author=Fernando G. Zampieri;,citation_author=Alexandre B. Cavalcanti;,citation_publication_date=2020-01;,citation_cover_date=2020-01;,citation_year=2020;,citation_issue=3;,citation_doi=10.1001/jama.2019.20141;,citation_issn=0098-7484;,citation_volume=323;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=Reductio ad absurdum in critical care trials;,citation_author=Fernando G. Zampieri;,citation_publication_date=2021-02;,citation_cover_date=2021-02;,citation_year=2021;,citation_doi=10.1016/j.jcrc.2020.10.001;,citation_issn=08839441;,citation_volume=61;,citation_language=en-US;,citation_journal_title=Journal of Critical Care;">
<meta name="citation_reference" content="citation_title=Statistical Analysis Plan for Balanced versus Saline trialists living systematic review individual patient and aggregated data meta-analysis of randomized controlled trials (BEST-Living Study);,citation_abstract=Purpose: The Balanced versus Saline Trialists (BEST) -Living Study is an ongoing living systematic review with aggregated and individual patient data meta-analysis (IPDMA) from eligible trials that assessed the effects of using balanced solutions compared with saline in critically ill adults. We herein present the search strategies for the BEST-Living Study and provide details for future analysis and presentation. Methods: The report will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) and Preferred Reporting Items for Systematic Reviews and Meta-Analyses of Individual Participant Data (PRISMA-IPD) recommendations. Search was performed in Pubmed, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL). The primary endpoint will be hospital mortality, which will be analyzed using a Bayesian hierarchical model. Secondary endpoints include nurvival until longest follow-up available, use of kidney replacement therapy, and intensive care unit and hospital length-of-stay. Details on the analysis plan are provided in this statistical analysis plan. Conclusion: The study will provide the most up-to-date and comprehensive assessment using the best evidence available for the use of balanced solutions in critically ill patients.;,citation_author=Fernando G Zampieri;,citation_author=Alexandre B Cavalcanti;,citation_author=Gian Luca Di Tanna;,citation_author=Lucas P Damiani;,citation_author=Naomi E Hammond;,citation_author=Flavia R Machado;,citation_author=Sharon Micallef;,citation_author=John Myburgh;,citation_author=Mahesh Ramanan;,citation_author=Todd W Rice;,citation_author=Matthew W Semler;,citation_author=Paul J Young;,citation_author=Simon Finfer;,citation_publication_date=2022-09;,citation_cover_date=2022-09;,citation_year=2022;,citation_doi=10.1101/2022.09.06.22279363;,citation_language=en-US;,citation_technical_report_institution=Intensive Care and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Using Bayesian Methods to Augment the Interpretation of Critical Care Trials. An Overview of Theory and Example Reanalysis of the Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial;,citation_author=Fernando G. Zampieri;,citation_author=Jonathan D. Casey;,citation_author=Manu Shankar-Hari;,citation_author=Frank E. Harrell;,citation_author=Michael O. Harhay;,citation_publication_date=2021-03;,citation_cover_date=2021-03;,citation_year=2021;,citation_issue=5;,citation_doi=10.1164/rccm.202006-2381CP;,citation_issn=1073-449X, 1535-4970;,citation_volume=203;,citation_language=en-US;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=Liberation from Invasive Mechanical Ventilation with Continued Receipt of Vasopressor Infusions;,citation_abstract=Rationale: Weaning protocols for discontinuation of invasive mechanical ventilation often mandate resolution of shock. Whether extubation while receiving vasopressors is associated with harm is uncertain.;,citation_author=Baharan Zarrabian;,citation_author=Hannah Wunsch;,citation_author=Henry T. Stelfox;,citation_author=Theodore J. Iwashyna;,citation_author=Hayley B. Gershengorn;,citation_publication_date=2022-05;,citation_cover_date=2022-05;,citation_year=2022;,citation_issue=9;,citation_doi=10.1164/rccm.202108-2004OC;,citation_issn=1073-449X, 1535-4970;,citation_volume=205;,citation_language=en-US;,citation_journal_title=American Journal of Respiratory and Critical Care Medicine;">
<meta name="citation_reference" content="citation_title=There are no equal opportunity infectors: Epidemiological modelers must rethink our approach to inequality in infection risk;,citation_abstract=AMUath: ePmleastieccaolnmfiromdtehlastahlalhveeacdoinmgleevtoelpsalareyraepkreeysernotleedcinorgrleocbtlayl:pandemic preparedness and outbreak response: helping to plan for disease burden, hospital capacity, and inform nonpharmaceutical interventions. Such models have played a pivotal role in the COVID-19 pandemic, with transmission models—and, by consequence, modelers—guiding global, national, and local responses to SARS-CoV-2. However, these models have largely not accounted for the social and structural factors, which lead to socioeconomic, racial, and geographic health disparities. In this piece, we raise and attempt to clarify several questions relating to this important gap in the research and practice of infectious disease modeling: Why do epidemiologic models of emerging infections typically ignore known structural drivers of disparate health outcomes? What have been the consequences of a framework focused primarily on aggregate outcomes on infection equity? What should be done to develop a more holistic approach to modeling-based decision-making during pandemics? In this review, we evaluate potential historical and political explanations for the exclusion of drivers of disparity in infectious disease models for emerging infections, which have often been characterized as “equal opportunity infectors” despite ample evidence to the contrary. We look to examples from other disease systems (HIV, STIs) and successes in including social inequity in models of acute infection transmission as a blueprint for how social connections, environmental, and structural factors can be integrated into a coherent, rigorous, and interpretable modeling framework. We conclude by outlining principles to guide modeling of emerging infections in ways that represent the causes of inequity in infection as central rather than peripheral mechanisms.;,citation_author=Jon Zelner;,citation_author=Nina B. Masters;,citation_author=Ramya Naraharisetti;,citation_author=Sanyu A. Mojola;,citation_author=Merlin Chowkwanyun;,citation_author=Ryan Malosh;,citation_editor=Jason A. Papin;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_issue=2;,citation_doi=10.1371/journal.pcbi.1009795;,citation_issn=1553-7358;,citation_volume=18;,citation_language=en-US;,citation_journal_title=PLOS Computational Biology;">
<meta name="citation_reference" content="citation_title=Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: A clinical practice guideline;,citation_abstract=CLINICAL QUESTIONS What is the role of plasma exchange and what is the optimal dose of glucocorticoids in the first 6 months of therapy of patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)? This guideline was triggered by the publication of a new randomised controlled trial. CURRENT PRACTICE Existing guideline recommendations vary regarding the use of plasma exchange in AAV and lack explicit recommendations regarding the tapering regimen of glucocorticoids during induction therapy.;,citation_author=Linan Zeng;,citation_author=Michael Walsh;,citation_author=Gordon H Guyatt;,citation_author=Reed A C Siemieniuk;,citation_author=David Collister;,citation_author=Michelle Booth;,citation_author=Paul Brown;,citation_author=Lesha Farrar;,citation_author=Mark Farrar;,citation_author=Tracy Firth;,citation_author=Lynn A Fussner;,citation_author=Karin Kilian;,citation_author=Mark A Little;,citation_author=Thomas A Mavrakanas;,citation_author=Reem A Mustafa;,citation_author=Maryam Piram;,citation_author=Lisa K Stamp;,citation_author=Yingqi Xiao;,citation_author=Lyubov Lytvyn;,citation_author=Thomas Agoritsas;,citation_author=Per O Vandvik;,citation_author=Alfred Mahr;,citation_publication_date=2022-02;,citation_cover_date=2022-02;,citation_year=2022;,citation_doi=10.1136/bmj-2021-064597;,citation_issn=1756-1833;,citation_language=en-US;,citation_journal_title=BMJ;">
<meta name="citation_reference" content="citation_title=Intracerebral Hemorrhage Among Blood Donors and Their Transfusion Recipients;,citation_abstract=OBJECTIVE To determine whether spontaneous ICH in blood donors after blood donation is associated with development of spontaneous ICH in transfusion recipients. DESIGN, SETTING, AND PARTICIPANTS Exploratory retrospective cohort study using nationwide blood bank and health register data from Sweden (main cohort) and Denmark (validation cohort) and including all 1 089 370 patients aged 5 to 80 years recorded to have received a red blood cell transfusion from January 1, 1970 (Sweden), or January 1, 1980 (Denmark), until December 31, 2017. EXPOSURES Receipt of red blood cell transfusions from blood donors who subsequently developed (1) a single spontaneous ICH, (2) multiple spontaneous ICHs, or (3) no spontaneous ICH. MAIN OUTCOMES AND MEASURES Spontaneous ICH in transfusion recipients; ischemic stroke was a negative control outcome. RESULTS A total of 759 858 patients from Sweden (median age, 65 [IQR, 48-73] years; 59% female) and 329 512 from Denmark (median age, 64 [IQR, 50-73] years; 58% female) were included, with a median follow-up of 5.8 (IQR, 1.4-12.5) years and 6.1 (IQR, 1.5-11.6) years, respectively. Patients who underwent transfusion with red blood cell units from donors who developed multiple spontaneous ICHs had a significantly higher risk of a single spontaneous ICH themselves, compared with patients receiving transfusions from donors who did not develop spontaneous ICH, in both the Swedish cohort (unadjusted incidence rate [IR], 3.16 vs 1.12 per 1000 person-years; adjusted hazard ratio [HR], 2.73; 95% CI, 1.72-4.35; P &amp;amp;amp;lt; .001) and the Danish cohort (unadjusted IR, 2.82 vs 1.09 per 1000 person-years; adjusted HR, 2.32; 95% CI, 1.04-5.19; P = .04). No significant difference was found for patients receiving transfusions from donors who developed a single spontaneous ICH in the Swedish cohort (unadjusted IR, 1.35 vs 1.12 per 1000 person-years; adjusted HR, 1.06; 95% CI, 0.84-1.36; P = .62) nor the Danish cohort (unadjusted IR, 1.36 vs 1.09 per 1000 person-years; adjusted HR, 1.06; 95% CI, 0.70-1.60; P = .73), nor for ischemic stroke as a negative control outcome. CONCLUSIONS AND RELEVANCE In an exploratory analysis of patients who received red blood cell transfusions, patients who underwent transfusion with red blood cells from donors who later developed multiple spontaneous ICHs were at significantly increased risk of spontaneous ICH themselves. This may suggest a transfusion-transmissible agent associated with some types of spontaneous ICH, although the findings may be susceptible to selection bias and residual confounding, and further research is needed to investigate if transfusion transmission of cerebral amyloid angiopathy might explain this association.;,citation_author=Jingcheng Zhao;,citation_author=Klaus Rostgaard;,citation_author=Elsa Lauwers;,citation_author=Torsten Dahlén;,citation_author=Sisse Rye Ostrowski;,citation_author=Christian Erikstrup;,citation_author=Ole Birger Pedersen;,citation_author=Bart De Strooper;,citation_author=Robin Lemmens;,citation_author=Henrik Hjalgrim;,citation_author=Gustaf Edgren;,citation_publication_date=2023-09;,citation_cover_date=2023-09;,citation_year=2023;,citation_issue=10;,citation_doi=10.1001/jama.2023.14445;,citation_issn=0098-7484;,citation_volume=330;,citation_language=en-US;,citation_journal_title=JAMA;">
<meta name="citation_reference" content="citation_title=The Right Ventricle in ARDS;,citation_author=Vasileios Zochios;,citation_author=Ken Parhar;,citation_author=William Tunnicliffe;,citation_author=Andrew Roscoe;,citation_author=Fang Gao;,citation_publication_date=2017-07;,citation_cover_date=2017-07;,citation_year=2017;,citation_issue=1;,citation_doi=10.1016/j.chest.2017.02.019;,citation_issn=00123692;,citation_volume=152;,citation_language=en-US;,citation_journal_title=Chest;">
<meta name="citation_reference" content="citation_title=Association Between Beta-Blocker or Statin Drug Use and the Risk of Hemorrhage From Cerebral Cavernous Malformations;,citation_abstract=BACKGROUND: We aimed to determine the association between beta-blocker or statin drug use and the future risk of symptomatic intracranial hemorrhage or persistent/progressive focal neurological deficit from cerebral cavernous malformations (CCM). METHODS: The population-based Scottish Audit of Intracranial Vascular Malformations prospectively identified adults resident in Scotland first diagnosed with CCM during 1999 to 2003 or 2006 to 2010. We compared the association between beta-blocker or statin drug use after first presentation and the occurrence of new intracranial hemorrhage or persistent/progressive focal neurological deficit due to CCM for up to 15 years of prospective follow-up. We confirmed proportional hazards and used survival analysis with multivariable adjustment for age, intracranial hemorrhage at CCM presentation, and brain stem CCM location. RESULTS: Sixty-three (21%) of 300 adults used beta-blockers (27/63 [43%] used propranolol), and 73 (24%) used statin drugs over 3634 person-years of follow-up. At baseline, the only statistically significant imbalances in prespecified potential confounders were age by statin use and intracranial hemorrhage at presentation by beta-blocker use. Beta-blocker use was associated with a lower risk of new intracranial hemorrhage or persistent/progressive focal neurological deficit (adjusted hazard ratio, 0.09 [95% CI, 0.01–0.66]; P=0.018). Statin use was associated with a nonsignificant lower risk of intracranial hemorrhage or persistent/progressive focal neurological deficit (adjusted hazard ratio, 0.37 [95% CI, 0.01–1.07]; P=0.067). CONCLUSIONS: Beta-blocker, but not statin, use was associated with a lower risk of intracranial hemorrhage or persistent/ progressive focal neurological deficit in patients with CCM.;,citation_author=Susanna M. Zuurbier;,citation_author=Charlotte R. Hickman;,citation_author=Leon A. Rinkel;,citation_author=Rebecca Berg;,citation_author=Ulrich Sure;,citation_author=Rustam Al-Shahi Salman;,citation_author=for the Scottish Audit of Intracranial Vascular Malformations Steering Committee and Collaborators;,citation_publication_date=2022-04;,citation_cover_date=2022-04;,citation_year=2022;,citation_doi=10.1161/STROKEAHA.121.037009;,citation_issn=0039-2499, 1524-4628;,citation_language=en-US;,citation_journal_title=Stroke;">
<meta name="citation_reference" content="citation_title=How large should the next study be? Predictive power and sample size requirements for replication studies;,citation_abstract=We use information derived from over 40K trials in the Cochrane Collaboration database of systematic reviews (CDSR) to compute the replication probability, or predictive power of an experiment given its observed (two-sided) P-value. We find that an exact replication of a marginally significant result with P = .05 has less than 30% chance of again reaching significance. Moreover, the replication of a result with P = .005 still has only 50% chance of significance. We also compute the probability that the direction (sign) of the estimated effect is correct, which is closely related to the type S error of Gelman and Tuerlinckx. We find that if an estimated effect has P = .05, there is a 93% probability that its sign is correct. If P = .005, then that probability is 99%. Finally, we compute the required sample size for a replication study to achieve some specified power conditional on the p-value of the original study. We find that the replication of a result with P = .05 requires a sample size more than 16 times larger than the original study to achieve 80% power, while P = .005 requires at least 3.5 times larger sample size. These findings confirm that failure to replicate the statistical significance of a trial does not necessarily indicate that the original result was a fluke.;,citation_author=Erik W. Zwet;,citation_author=Steven N. Goodman;,citation_publication_date=2022-04;,citation_cover_date=2022-04;,citation_year=2022;,citation_doi=10.1002/sim.9406;,citation_issn=0277-6715, 1097-0258;,citation_language=en-US;,citation_journal_title=Statistics in Medicine;">
</head>

<body>

<header id="title-block-header" class="quarto-title-block default toc-left page-columns page-full">
  <div class="quarto-title-banner page-columns page-full">
    <div class="quarto-title column-body">
      <h1 class="title">Differences in care for patients with left vs.&nbsp;right hemisphere intracerebral hemorrhage</h1>
          </div>

    
    <div class="quarto-title-meta-container">
      <div class="quarto-title-meta-column-start">
            <div class="quarto-title-meta-author">
          <div class="quarto-title-meta-heading">Authors</div>
          <div class="quarto-title-meta-heading">Affiliation</div>
          
                <div class="quarto-title-meta-contents">
            <p class="author">Nikhil Patel <a href="mailto:nikhil.patel@atriumhealth.org" class="quarto-title-author-email"><i class="bi bi-envelope"></i></a> <a href="https://orcid.org/0000-0002-3193-8590" class="quarto-title-author-orcid"> <img src="data:image/png;base64,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"></a></p>
          </div>
                <div class="quarto-title-meta-contents">
                    <p class="affiliation">
                        Department of Neurology, Wake Forest School of Medicine
                      </p>
                  </div>
                      <div class="quarto-title-meta-contents">
            <p class="author">Rahul Karamchandani </p>
          </div>
                <div class="quarto-title-meta-contents">
                    <p class="affiliation">
                        Department of Neurology, Wake Forest School of Medicine
                      </p>
                  </div>
                    </div>
        
        <div class="quarto-title-meta">

                      
          
                
              </div>
      </div>
      <div class="quarto-title-meta-column-end quarto-other-formats-target">
      </div>
    </div>



    <div class="quarto-other-links-text-target">
    </div>  </div>
</header><div id="quarto-content" class="page-columns page-rows-contents page-layout-article toc-left">
<div id="quarto-sidebar-toc-left" class="sidebar toc-left">
  <nav id="TOC" role="doc-toc" class="toc-active">
    <h2 id="toc-title">Table of contents</h2>
   
  <ul>
  <li><a href="#section" id="toc-section" class="nav-link active" data-scroll-target="#section">Section</a></li>
  </ul>
</nav>
</div>
<div id="quarto-margin-sidebar" class="sidebar margin-sidebar zindex-bottom">
</div>
<main class="content quarto-banner-title-block" id="quarto-document-content">



  


<section id="section" class="level2">
<h2 class="anchored" data-anchor-id="section">Section</h2>
<p>This is a simple placeholder for the manuscript’s main document <span class="citation" data-cites="audetat_diagnosis_2017-1">(<a href="#ref-audetat_diagnosis_2017-1" role="doc-biblioref">Audétat et al. 2017</a>)</span>.</p>

</section>

<div id="quarto-appendix" class="default"><section class="quarto-appendix-contents" role="doc-bibliography" id="quarto-bibliography"><h2 class="anchored quarto-appendix-heading">References</h2><div id="refs" class="references csl-bib-body hanging-indent" data-entry-spacing="0" role="list">
<div id="ref-audetat_diagnosis_2017-1" class="csl-entry" role="listitem">
Audétat, Marie-Claude, Suzanne Laurin, Valérie Dory, Bernard Charlin, and Mathieu R. Nendaz. 2017. <span>“Diagnosis and Management of Clinical Reasoning Difficulties: <span>Part I</span>. <span>Clinical</span> Reasoning Supervision and Educational Diagnosis.”</span> <em>Medical Teacher</em> 39 (8): 792–96. <a href="https://doi.org/10.1080/0142159X.2017.1331033">https://doi.org/10.1080/0142159X.2017.1331033</a>.
</div>
</div></section></div></main>
<!-- /main column -->
<script id="quarto-html-after-body" type="application/javascript">
window.document.addEventListener("DOMContentLoaded", function (event) {
  const toggleBodyColorMode = (bsSheetEl) => {
    const mode = bsSheetEl.getAttribute("data-mode");
    const bodyEl = window.document.querySelector("body");
    if (mode === "dark") {
      bodyEl.classList.add("quarto-dark");
      bodyEl.classList.remove("quarto-light");
    } else {
      bodyEl.classList.add("quarto-light");
      bodyEl.classList.remove("quarto-dark");
    }
  }
  const toggleBodyColorPrimary = () => {
    const bsSheetEl = window.document.querySelector("link#quarto-bootstrap");
    if (bsSheetEl) {
      toggleBodyColorMode(bsSheetEl);
    }
  }
  toggleBodyColorPrimary();  
  const icon = "";
  const anchorJS = new window.AnchorJS();
  anchorJS.options = {
    placement: 'right',
    icon: icon
  };
  anchorJS.add('.anchored');
  const isCodeAnnotation = (el) => {
    for (const clz of el.classList) {
      if (clz.startsWith('code-annotation-')) {                     
        return true;
      }
    }
    return false;
  }
  const clipboard = new window.ClipboardJS('.code-copy-button', {
    text: function(trigger) {
      const codeEl = trigger.previousElementSibling.cloneNode(true);
      for (const childEl of codeEl.children) {
        if (isCodeAnnotation(childEl)) {
          childEl.remove();
        }
      }
      return codeEl.innerText;
    }
  });
  clipboard.on('success', function(e) {
    // button target
    const button = e.trigger;
    // don't keep focus
    button.blur();
    // flash "checked"
    button.classList.add('code-copy-button-checked');
    var currentTitle = button.getAttribute("title");
    button.setAttribute("title", "Copied!");
    let tooltip;
    if (window.bootstrap) {
      button.setAttribute("data-bs-toggle", "tooltip");
      button.setAttribute("data-bs-placement", "left");
      button.setAttribute("data-bs-title", "Copied!");
      tooltip = new bootstrap.Tooltip(button, 
        { trigger: "manual", 
          customClass: "code-copy-button-tooltip",
          offset: [0, -8]});
      tooltip.show();    
    }
    setTimeout(function() {
      if (tooltip) {
        tooltip.hide();
        button.removeAttribute("data-bs-title");
        button.removeAttribute("data-bs-toggle");
        button.removeAttribute("data-bs-placement");
      }
      button.setAttribute("title", currentTitle);
      button.classList.remove('code-copy-button-checked');
    }, 1000);
    // clear code selection
    e.clearSelection();
  });
  function tippyHover(el, contentFn, onTriggerFn, onUntriggerFn) {
    const config = {
      allowHTML: true,
      maxWidth: 500,
      delay: 100,
      arrow: false,
      appendTo: function(el) {
          return el.parentElement;
      },
      interactive: true,
      interactiveBorder: 10,
      theme: 'quarto',
      placement: 'bottom-start',
    };
    if (contentFn) {
      config.content = contentFn;
    }
    if (onTriggerFn) {
      config.onTrigger = onTriggerFn;
    }
    if (onUntriggerFn) {
      config.onUntrigger = onUntriggerFn;
    }
    window.tippy(el, config); 
  }
  const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
  for (var i=0; i<noterefs.length; i++) {
    const ref = noterefs[i];
    tippyHover(ref, function() {
      // use id or data attribute instead here
      let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
      try { href = new URL(href).hash; } catch {}
      const id = href.replace(/^#\/?/, "");
      const note = window.document.getElementById(id);
      return note.innerHTML;
    });
  }
  const xrefs = window.document.querySelectorAll('a.quarto-xref');
  const processXRef = (id, note) => {
    // Strip column container classes
    const stripColumnClz = (el) => {
      el.classList.remove("page-full", "page-columns");
      if (el.children) {
        for (const child of el.children) {
          stripColumnClz(child);
        }
      }
    }
    stripColumnClz(note)
    if (id === null || id.startsWith('sec-')) {
      // Special case sections, only their first couple elements
      const container = document.createElement("div");
      if (note.children && note.children.length > 2) {
        container.appendChild(note.children[0].cloneNode(true));
        for (let i = 1; i < note.children.length; i++) {
          const child = note.children[i];
          if (child.tagName === "P" && child.innerText === "") {
            continue;
          } else {
            container.appendChild(child.cloneNode(true));
            break;
          }
        }
        if (window.Quarto?.typesetMath) {
          window.Quarto.typesetMath(container);
        }
        return container.innerHTML
      } else {
        if (window.Quarto?.typesetMath) {
          window.Quarto.typesetMath(note);
        }
        return note.innerHTML;
      }
    } else {
      // Remove any anchor links if they are present
      const anchorLink = note.querySelector('a.anchorjs-link');
      if (anchorLink) {
        anchorLink.remove();
      }
      if (window.Quarto?.typesetMath) {
        window.Quarto.typesetMath(note);
      }
      // TODO in 1.5, we should make sure this works without a callout special case
      if (note.classList.contains("callout")) {
        return note.outerHTML;
      } else {
        return note.innerHTML;
      }
    }
  }
  for (var i=0; i<xrefs.length; i++) {
    const xref = xrefs[i];
    tippyHover(xref, undefined, function(instance) {
      instance.disable();
      let url = xref.getAttribute('href');
      let hash = undefined; 
      if (url.startsWith('#')) {
        hash = url;
      } else {
        try { hash = new URL(url).hash; } catch {}
      }
      if (hash) {
        const id = hash.replace(/^#\/?/, "");
        const note = window.document.getElementById(id);
        if (note !== null) {
          try {
            const html = processXRef(id, note.cloneNode(true));
            instance.setContent(html);
          } finally {
            instance.enable();
            instance.show();
          }
        } else {
          // See if we can fetch this
          fetch(url.split('#')[0])
          .then(res => res.text())
          .then(html => {
            const parser = new DOMParser();
            const htmlDoc = parser.parseFromString(html, "text/html");
            const note = htmlDoc.getElementById(id);
            if (note !== null) {
              const html = processXRef(id, note);
              instance.setContent(html);
            } 
          }).finally(() => {
            instance.enable();
            instance.show();
          });
        }
      } else {
        // See if we can fetch a full url (with no hash to target)
        // This is a special case and we should probably do some content thinning / targeting
        fetch(url)
        .then(res => res.text())
        .then(html => {
          const parser = new DOMParser();
          const htmlDoc = parser.parseFromString(html, "text/html");
          const note = htmlDoc.querySelector('main.content');
          if (note !== null) {
            // This should only happen for chapter cross references
            // (since there is no id in the URL)
            // remove the first header
            if (note.children.length > 0 && note.children[0].tagName === "HEADER") {
              note.children[0].remove();
            }
            const html = processXRef(null, note);
            instance.setContent(html);
          } 
        }).finally(() => {
          instance.enable();
          instance.show();
        });
      }
    }, function(instance) {
    });
  }
      let selectedAnnoteEl;
      const selectorForAnnotation = ( cell, annotation) => {
        let cellAttr = 'data-code-cell="' + cell + '"';
        let lineAttr = 'data-code-annotation="' +  annotation + '"';
        const selector = 'span[' + cellAttr + '][' + lineAttr + ']';
        return selector;
      }
      const selectCodeLines = (annoteEl) => {
        const doc = window.document;
        const targetCell = annoteEl.getAttribute("data-target-cell");
        const targetAnnotation = annoteEl.getAttribute("data-target-annotation");
        const annoteSpan = window.document.querySelector(selectorForAnnotation(targetCell, targetAnnotation));
        const lines = annoteSpan.getAttribute("data-code-lines").split(",");
        const lineIds = lines.map((line) => {
          return targetCell + "-" + line;
        })
        let top = null;
        let height = null;
        let parent = null;
        if (lineIds.length > 0) {
            //compute the position of the single el (top and bottom and make a div)
            const el = window.document.getElementById(lineIds[0]);
            top = el.offsetTop;
            height = el.offsetHeight;
            parent = el.parentElement.parentElement;
          if (lineIds.length > 1) {
            const lastEl = window.document.getElementById(lineIds[lineIds.length - 1]);
            const bottom = lastEl.offsetTop + lastEl.offsetHeight;
            height = bottom - top;
          }
          if (top !== null && height !== null && parent !== null) {
            // cook up a div (if necessary) and position it 
            let div = window.document.getElementById("code-annotation-line-highlight");
            if (div === null) {
              div = window.document.createElement("div");
              div.setAttribute("id", "code-annotation-line-highlight");
              div.style.position = 'absolute';
              parent.appendChild(div);
            }
            div.style.top = top - 2 + "px";
            div.style.height = height + 4 + "px";
            div.style.left = 0;
            let gutterDiv = window.document.getElementById("code-annotation-line-highlight-gutter");
            if (gutterDiv === null) {
              gutterDiv = window.document.createElement("div");
              gutterDiv.setAttribute("id", "code-annotation-line-highlight-gutter");
              gutterDiv.style.position = 'absolute';
              const codeCell = window.document.getElementById(targetCell);
              const gutter = codeCell.querySelector('.code-annotation-gutter');
              gutter.appendChild(gutterDiv);
            }
            gutterDiv.style.top = top - 2 + "px";
            gutterDiv.style.height = height + 4 + "px";
          }
          selectedAnnoteEl = annoteEl;
        }
      };
      const unselectCodeLines = () => {
        const elementsIds = ["code-annotation-line-highlight", "code-annotation-line-highlight-gutter"];
        elementsIds.forEach((elId) => {
          const div = window.document.getElementById(elId);
          if (div) {
            div.remove();
          }
        });
        selectedAnnoteEl = undefined;
      };
        // Handle positioning of the toggle
    window.addEventListener(
      "resize",
      throttle(() => {
        elRect = undefined;
        if (selectedAnnoteEl) {
          selectCodeLines(selectedAnnoteEl);
        }
      }, 10)
    );
    function throttle(fn, ms) {
    let throttle = false;
    let timer;
      return (...args) => {
        if(!throttle) { // first call gets through
            fn.apply(this, args);
            throttle = true;
        } else { // all the others get throttled
            if(timer) clearTimeout(timer); // cancel #2
            timer = setTimeout(() => {
              fn.apply(this, args);
              timer = throttle = false;
            }, ms);
        }
      };
    }
      // Attach click handler to the DT
      const annoteDls = window.document.querySelectorAll('dt[data-target-cell]');
      for (const annoteDlNode of annoteDls) {
        annoteDlNode.addEventListener('click', (event) => {
          const clickedEl = event.target;
          if (clickedEl !== selectedAnnoteEl) {
            unselectCodeLines();
            const activeEl = window.document.querySelector('dt[data-target-cell].code-annotation-active');
            if (activeEl) {
              activeEl.classList.remove('code-annotation-active');
            }
            selectCodeLines(clickedEl);
            clickedEl.classList.add('code-annotation-active');
          } else {
            // Unselect the line
            unselectCodeLines();
            clickedEl.classList.remove('code-annotation-active');
          }
        });
      }
  const findCites = (el) => {
    const parentEl = el.parentElement;
    if (parentEl) {
      const cites = parentEl.dataset.cites;
      if (cites) {
        return {
          el,
          cites: cites.split(' ')
        };
      } else {
        return findCites(el.parentElement)
      }
    } else {
      return undefined;
    }
  };
  var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
  for (var i=0; i<bibliorefs.length; i++) {
    const ref = bibliorefs[i];
    const citeInfo = findCites(ref);
    if (citeInfo) {
      tippyHover(citeInfo.el, function() {
        var popup = window.document.createElement('div');
        citeInfo.cites.forEach(function(cite) {
          var citeDiv = window.document.createElement('div');
          citeDiv.classList.add('hanging-indent');
          citeDiv.classList.add('csl-entry');
          var biblioDiv = window.document.getElementById('ref-' + cite);
          if (biblioDiv) {
            citeDiv.innerHTML = biblioDiv.innerHTML;
          }
          popup.appendChild(citeDiv);
        });
        return popup.innerHTML;
      });
    }
  }
});
</script>
</div> <!-- /content -->




</body></html>